Naloxone	B-Chemical
reverses	O
the	O
antihypertensive	B-Drug
effect	O
of	O
clonidine	B-Chemical
.	O

In	O
unanesthetized	O
,	O
spontaneously	O
hypertensive	B-Disease
rats	O
the	O
decrease	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
produced	O
by	O
intravenous	O
clonidine	B-Chemical
,	O
5	O
to	O
20	O
micrograms/kg	O
,	O
was	O
inhibited	O
or	O
reversed	O
by	O
nalozone	B-Chemical
,	O
0.2	O
to	O
2	O
mg/kg	O
.	O

The	O
hypotensive	B-Disease
effect	O
of	O
100	O
mg/kg	O
alpha-methyldopa	B-Chemical
was	O
also	O
partially	O
reversed	O
by	O
naloxone	B-Chemical
.	O

Naloxone	B-Chemical
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

In	O
brain	O
membranes	O
from	O
spontaneously	O
hypertensive	B-Disease
rats	O
clonidine	B-Chemical
,	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-5	O
)	O
M	O
,	O
did	O
not	O
influence	O
stereoselective	O
binding	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-naloxone	I-Chemical
(	O
8	O
nM	O
)	O
,	O
and	O
naloxone	B-Chemical
,	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-4	O
)	O
M	O
,	O
did	O
not	O
influence	O
clonidine-suppressible	B-Chemical
binding	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-dihydroergocryptine	I-Chemical
(	O
1	O
nM	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
the	O
effects	O
of	O
central	O
alpha-adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	O
receptors	O
.	O

As	O
naloxone	B-Chemical
and	O
clonidine	B-Chemical
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	O
site	O
,	O
the	O
observed	O
functional	O
antagonism	O
suggests	O
the	O
release	O
of	O
an	O
endogenous	O
opiate	O
by	O
clonidine	B-Chemical
or	O
alpha-methyldopa	B-Chemical
and	O
the	O
possible	O
role	O
of	O
the	O
opiate	O
in	O
the	O
central	O
control	O
of	O
sympathetic	O
tone	O
.	O

Lidocaine-induced	B-Chemical
cardiac	B-Disease
asystole	I-Disease
.	O

Intravenous	O
administration	O
of	O
a	O
single	O
50-mg	O
bolus	O
of	O
lidocaine	B-Chemical
in	O
a	O
67-year-old	O
man	O
resulted	O
in	O
profound	O
depression	B-Disease
of	O
the	O
activity	O
of	O
the	O
sinoatrial	O
and	O
atrioventricular	O
nodal	O
pacemakers	O
.	O

The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	B-Disease
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	B-Chemical
.	O

Suxamethonium	B-Chemical
infusion	O
rate	O
and	O
observed	O
fasciculations	B-Disease
.	O

A	O
dose-response	O
study	O
.	O

Suxamethonium	B-Chemical
chloride	I-Chemical
(	O
Sch	B-Chemical
)	O
was	O
administered	O
i.v	O
.	O

to	O
36	O
adult	O
males	O
at	O
six	O
rates	O
:	O
0.25	O
mg	O
s-1	O
to	O
20	O
mg	O
s-1	O
.	O

The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	B-Disease
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	B-Chemical
120	O
mg	O
was	O
exceeded	O
.	O

Six	O
additional	O
patients	O
received	O
a	O
30-mg	O
i.v	O
.	O

bolus	O
dose	O
.	O

Fasciculations	B-Disease
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	B-Disease
score	O
.	O

The	O
times	O
to	O
first	O
fasciculation	B-Disease
,	O
twitch	B-Disease
suppression	O
and	O
tetanus	B-Disease
suppression	O
were	O
inversely	O
related	O
to	O
the	O
infusion	O
rates	O
.	O

Fasciculations	B-Disease
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	B-Disease
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion	O
.	O

Total	O
fasciculation	B-Disease
scores	O
in	O
the	O
30-mg	O
bolus	O
group	O
and	O
the	O
5-mg	O
s-1	O
and	O
20-mg	O
s-1	O
infusion	O
groups	O
were	O
not	O
significantly	O
different	O
.	O

Galanthamine	B-Chemical
hydrobromide	I-Chemical
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug	B-Drug
,	O
in	O
the	O
treatment	O
of	O
the	O
central	O
effects	O
of	O
scopolamine	B-Chemical
(	O
Hyoscine	B-Chemical
)	O
.	O

Galanthamine	B-Chemical
hydrobromide	I-Chemical
,	O
an	O
anticholinesterase	O
drug	B-Drug
capable	O
of	O
penetrating	O
the	O
blood-brain	O
barrier	O
,	O
was	O
used	O
in	O
a	O
patient	O
demonstrating	O
central	O
effects	O
of	O
scopolamine	B-Chemical
(	O
hyoscine	B-Chemical
)	O
overdosage	B-Disease
.	O

It	O
is	O
longer	O
acting	O
than	O
physostigmine	B-Chemical
and	O
is	O
used	O
in	O
anaesthesia	O
to	O
reverse	O
the	O
non-depolarizing	O
neuromuscular	O
block	O
.	O

However	O
,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	B-Chemical
intoxication	O
are	O
indicated	O
.	O

Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium-induced	B-Chemical
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	O
rats	O
.	O

Rats	O
with	O
lithium-induced	B-Chemical
nephropathy	B-Disease
were	O
subjected	O
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	B-Disease
failure	I-Disease
.	O

Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium-containing	B-Chemical
diet	O
(	O
50	O
mmol/kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet	O
,	O
HP	O
diet	O
(	O
40	O
vs.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP+NX	O
for	O
another	O
8	O
weeks	O
.	O

Corresponding	O
non-lithium	B-Chemical
pretreated	O
groups	O
were	O
generated	O
.	O

When	O
comparing	O
all	O
lithium	B-Chemical
treated	O
versus	O
non-lithium-treated	B-Chemical
groups	O
,	O
lithium	B-Chemical
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	O
lithium	B-Chemical
clearance	O
.	O

Consequently	O
,	O
lithium	B-Chemical
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	B-Chemical
excretion	O
.	O

Lithium	B-Chemical
also	O
caused	O
proteinuria	B-Disease
and	O
systolic	O
hypertension	B-Disease
in	O
absence	O
of	O
glomerulosclerosis	B-Disease
.	O

HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	B-Disease
failure	I-Disease
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	O
plasma	O
creatinine	B-Chemical
levels	O
in	O
lithium	B-Chemical
pretreated	O
rats	O
.	O

NX	O
caused	O
an	O
additive	O
deterioration	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
ameliorated	O
by	O
HP	O
.	O

NX+HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
pressure	O
in	O
Li-pretreated	B-Chemical
rats	O
.	O

The	O
results	O
indicate	O
that	O
Li-induced	B-Chemical
nephropathy	B-Disease
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	O
with	O
proteinuria	B-Disease
and	O
arterial	O
systolic	O
hypertension	B-Disease
.	O

In	O
this	O
model	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
the	O
decline	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effective	O
renal	O
plasma	O
flow	O
,	O
which	O
may	O
be	O
the	O
functional	O
expression	O
of	O
the	O
formation	O
of	O
nonfiltrating	O
atubular	O
glomeruli	O
.	O

The	O
fractional	O
reabsorption	O
of	O
tubular	O
fluid	O
by	O
the	O
proximal	O
tubules	O
is	O
reduced	O
,	O
leaving	O
the	O
distal	O
delivery	O
unchanged	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Treatment	O
of	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
with	O
fusidic	B-Chemical
acid	I-Chemical
:	O
an	O
antibiotic	O
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	B-Chemical
.	O

Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T-cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	B-Chemical
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
in	O
chronic	O
active	O
,	O
therapy-resistant	O
patients	O
.	O

Eight	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
patients	O
were	O
included	O
.	O

Fusidic	B-Chemical
acid	I-Chemical
was	O
administered	O
orally	O
in	O
a	O
dose	O
of	O
500	O
mg	O
t.d.s	O
.	O

and	O
the	O
treatment	O
was	O
planned	O
to	O
last	O
8	O
weeks	O
.	O

The	O
disease	O
activity	O
was	O
primarily	O
measured	O
by	O
a	O
modified	O
individual	O
grading	O
score	O
.	O

Five	O
of	O
8	O
patients	O
(	O
63	O
%	O
)	O
improved	O
during	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O

There	O
were	O
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	B-Disease
.	O

Biochemically	O
,	O
an	O
increase	O
in	O
alkaline	O
phosphatases	O
was	O
noted	O
in	O
5	O
of	O
8	O
cases	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
increases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elevated	O
levels	O
prior	O
to	O
treatment	O
.	O

All	O
reversed	O
to	O
pre-treatment	O
levels	O
after	O
cessation	O
of	O
treatment	O
.	O

The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
fusidic	B-Chemical
acid	I-Chemical
may	O
be	O
of	O
benefit	O
in	O
selected	O
chronic	O
active	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
patients	O
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective	O
.	O

Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	O
of	O
fusidic	B-Chemical
acid	I-Chemical
at	O
the	O
cytokine	O
level	O
in	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatment	O
should	O
be	O
further	O
investigated	O
.	O

Electrocardiographic	O
evidence	O
of	O
myocardial	B-Disease
injury	I-Disease
in	O
psychiatrically	O
hospitalized	O
cocaine	B-Chemical
abusers	O
.	O

The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine-abusing	B-Chemical
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-Disease
controls	O
.	O

Eleven	O
of	O
the	O
cocaine	B-Chemical
abusers	O
and	O
none	O
of	O
the	O
controls	O
had	O
ECG	O
evidence	O
of	O
significant	O
myocardial	B-Disease
injury	I-Disease
defined	O
as	O
myocardial	B-Disease
infarction	I-Disease
,	O
ischemia	B-Disease
,	O
and	O
bundle	B-Disease
branch	I-Disease
block	I-Disease
.	O

Sulpiride-induced	B-Chemical
tardive	B-Disease
dystonia	I-Disease
.	O

Sulpiride	B-Chemical
is	O
a	O
selective	O
D2-receptor	O
antagonist	O
with	O
antipsychotic	O
and	O
antidepressant	B-Chemical
properties	O
.	O

Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidal	O
side	O
effects	O
,	O
sulpiride-induced	B-Chemical
tardive	B-Disease
dyskinesia	I-Disease
and	O
parkinsonism	B-Disease
have	O
been	O
reported	O
occasionally	O
.	O

We	O
studied	O
a	O
37-year-old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	B-Disease
within	O
2	O
months	O
after	O
starting	O
sulpiride	B-Chemical
therapy	O
.	O

We	O
could	O
not	O
find	O
any	O
previous	O
reports	O
of	O
sulpiride-induced	B-Chemical
tardive	B-Disease
dystonia	I-Disease
.	O

Ocular	B-Disease
and	I-Disease
auditory	I-Disease
toxicity	I-Disease
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	O
.	O

During	O
an	O
18-month	O
period	O
of	O
study	O
41	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-Chemical
(	O
10-40	O
mg/kg	O
BW/3	O
times	O
weekly	O
)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	O
of	O
audiovisual	B-Disease
toxicity	I-Disease
.	O

6	O
patients	O
presented	O
clinical	O
symptoms	O
of	O
visual	B-Disease
or	I-Disease
auditory	I-Disease
toxicity	I-Disease
.	O

Moreover	O
,	O
detailed	O
ophthalmologic	O
and	O
audiologic	O
studies	O
disclosed	O
abnormalities	O
in	O
7	O
more	O
asymptomatic	O
patients	O
.	O

Visual	O
toxicity	I-Chemical
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan-type	O
dyschromatopsy	O
,	O
sometimes	O
associated	O
with	O
a	O
loss	O
of	O
visual	B-Chemical
acuity	O
and	O
pigmentary	O
retinal	O
deposits	O
.	O

Auditory	O
toxicity	I-Chemical
was	O
characterized	O
by	O
a	O
mid-	O
to	O
high-frequency	O
neurosensorial	O
hearing	O
loss	O
and	O
the	O
lesion	O
was	O
of	O
the	O
cochlear	O
type	O
.	O

Desferrioxamine	O
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	O
loss	O
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3	O
.	O

This	O
toxicity	I-Chemical
appeared	O
in	O
patients	O
receiving	O
the	O
higher	O
doses	O
of	O
desferrioxamine	O
or	O
coincided	O
with	O
the	O
normalization	O
of	O
ferritin	O
or	O
aluminium	O
serum	O
levels	O
.	O

The	O
data	O
indicate	O
that	O
audiovisual	O
toxicity	I-Disease
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	O
.	O

Periodical	O
audiovisual	O
monitoring	O
should	O
be	O
performed	O
on	O
hemodialyzed	O
patients	O
receiving	O
the	O
drug	B-Drug
in	O
order	O
to	O
detect	O
adverse	O
effects	O
as	O
early	O
as	O
possible	O
.	O

Myasthenia	B-Disease
gravis	I-Disease
presenting	O
as	O
weakness	O
after	O
magnesium	B-Chemical
administration	O
.	O

We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	B-Disease
disease	I-Disease
who	O
became	O
virtually	O
quadriplegic	B-Disease
after	O
parenteral	O
magnesium	B-Chemical
administration	O
for	O
preeclampsia	B-Disease
.	O

The	O
serum	O
magnesium	B-Chemical
concentration	O
was	O
3.0	O
mEq/L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	O
.	O

The	O
magnesium	B-Chemical
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days	O
.	O

While	O
she	O
was	O
weak	O
,	O
2-Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise	O
,	O
suggesting	O
postsynaptic	B-Disease
neuromuscular	I-Disease
blockade	I-Disease
.	O

After	O
her	O
strength	O
returned	O
,	O
repetitive	O
stimulation	O
was	O
normal	O
,	O
but	O
single	O
fiber	O
EMG	O
revealed	O
increased	O
jitter	O
and	O
blocking	O
.	O

Her	O
acetylcholine	B-Chemical
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated	O
.	O

Although	O
paralysis	B-Disease
after	O
magnesium	B-Chemical
administration	O
has	O
been	O
described	O
in	O
patients	O
with	O
known	O
myasthenia	B-Disease
gravis	I-Disease
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestation	O
of	O
the	O
disease	O
.	O

Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	B-Chemical
should	O
be	O
suspected	O
of	I-Disease
having	O
an	O
underlying	O
disorder	B-Disease
of	I-Disease
neuromuscular	I-Disease
transmission	O
.	O

Chloroacetaldehyde	B-Chemical
and	O
its	O
contribution	O
to	O
urotoxicity	O
during	O
treatment	O
with	O
cyclophosphamide	B-Chemical
or	O
ifosfamide	B-Chemical
.	O

An	O
experimental	O
study/short	O
communication	O
.	O

Based	O
on	O
clinical	O
data	O
,	O
indicating	O
that	O
chloroacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
an	O
important	O
metabolite	O
of	O
oxazaphosphorine	O
cytostatics	O
,	O
an	O
experimental	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	B-Chemical
in	O
the	O
development	O
of	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

The	O
data	O
demonstrate	O
that	O
CAA	O
after	O
i.v	O
.	O

administration	O
does	O
not	O
contribute	O
to	O
bladder	O
damage	O
.	O

When	O
instilled	O
directly	O
into	O
the	O
bladder	O
,	O
CAA	O
exerts	O
urotoxic	O
effects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	O
.	O

Source	O
of	O
pain	B-Disease
and	O
primitive	O
dysfunction	O
in	O
migraine	B-Disease
:	O
an	O
identical	O
site	O
?	O
Twenty	O
common	O
migraine	B-Disease
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	B-Chemical
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	O
study	O
.	O

Early	O
onset	O
migraine	B-Disease
attacks	O
were	O
induced	O
by	O
nitroglycerin	B-Chemical
in	O
seven	O
out	O
of	O
10	O
patients	O
versus	O
no	O
patient	O
in	O
the	O
placebo	O
group	O
.	O

Subsequently	O
20	O
migraine	B-Disease
patients	O
,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	B-Chemical
,	O
received	O
the	O
drug	B-Drug
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas	O
.	O

No	O
early	O
onset	O
migraine	B-Disease
was	O
observed	O
.	O

Thus	O
the	O
migraine-inducing	B-Disease
effect	O
of	O
nitroglycerin	B-Chemical
seems	O
to	O
depend	O
on	O
direct	O
stimulation	O
of	O
the	O
habitual	O
site	O
of	O
pain	B-Disease
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
development	O
of	O
a	O
migraine	B-Disease
crisis	O
.	O

This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
origin	O
of	O
migraine	B-Disease
attack	O
.	O

Clotiazepam-induced	B-Chemical
acute	O
hepatitis	B-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
acute	O
hepatitis	B-Disease
with	O
extensive	B-Disease
hepatocellular	I-Disease
necrosis	I-Disease
,	O
7	O
months	O
after	O
the	O
onset	O
of	O
administration	O
of	O
clotiazepam	B-Chemical
,	O
a	O
thienodiazepine	B-Chemical
derivative	O
.	O

Clotiazepam	B-Chemical
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery	O
.	O

The	O
administration	O
of	O
several	O
benzodiazepines	B-Chemical
,	O
chemically	O
related	O
to	O
clotiazepam	B-Chemical
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	B-Disease
.	O

This	O
observation	O
shows	O
that	O
clotiazepam	B-Chemical
can	O
induce	O
acute	O
hepatitis	B-Disease
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	O
hepatotoxicity	B-Disease
between	O
clotiazepam	B-Chemical
and	O
several	O
benzodiazepines	B-Chemical
.	O

Arterial	O
hypertension	B-Disease
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	B-Chemical
treatment	O
.	O

Two	O
of	O
14	O
patients	O
with	O
Cushing	B-Disease
's	I-Disease
syndrome	I-Disease
treated	O
on	O
a	O
long-term	O
basis	O
with	O
ketoconazole	B-Chemical
developed	O
sustained	O
hypertension	B-Disease
.	O

In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	B-Chemical
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	B-Chemical
therapy	O
,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	B-Disease
31	O
(	O
patient	O
1	O
)	O
and	O
52	O
weeks	O
(	O
patient	O
2	O
)	O
after	O
treatment	O
.	O

In	O
patient	O
1	O
,	O
plasma	O
levels	O
of	O
deoxycorticosterone	B-Chemical
and	O
11-deoxycortisol	B-Chemical
were	O
elevated	O
.	O

In	O
patient	O
2	O
,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	B-Chemical
and	O
11-deoxycortisol	B-Chemical
levels	O
,	O
plasma	O
aldosterone	B-Chemical
values	O
were	O
raised	O
,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels	O
.	O

Our	O
findings	O
show	O
that	O
long-term	O
treatment	O
with	O
high	O
doses	O
of	O
ketoconazole	B-Chemical
may	O
induce	O
enzyme	O
blockade	O
leading	O
to	O
mineralocorticoid-related	O
hypertension	B-Disease
.	O

Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
Captopril	B-Chemical
)	O
on	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
due	O
to	O
intravascular	O
coagulation	O
in	O
the	O
rat	O
.	O

Induction	O
of	O
intravascular	B-Disease
coagulation	I-Disease
and	O
inhibition	O
of	O
fibrinolysis	O
by	O
injection	O
of	O
thrombin	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
AMCA	B-Chemical
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulmonary	B-Disease
and	I-Disease
renal	I-Disease
insufficiency	I-Disease
resembling	O
that	O
occurring	O
after	O
trauma	O
or	O
sepsis	O
in	O
man	O
.	O

Injection	O
of	O
Captopril	B-Drug
(	O
1	O
mg/kg	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	B-Drug
converting	O
enzyme	O
(	O
ACE	O
)	O
,	O
reduced	O
both	O
pulmonary	B-Chemical
and	O
renal	O
insufficiency	I-Chemical
in	O
this	O
rat	O
model	O
.	O

The	O
lung	O
weights	O
were	O
lower	O
and	O
PaO2	O
was	O
improved	O
in	O
rats	O
given	O
this	O
enzyme-blocking	O
agent	O
.	O

The	O
contents	O
of	O
albumin	O
in	O
the	O
lungs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopril	B-Drug
did	O
not	O
influence	O
the	O
extravasation	O
of	O
protein	O
.	O

Renal	O
damage	O
as	O
reflected	O
by	O
an	O
increase	O
in	O
serum	O
urea	O
and	O
in	O
kidney	O
weight	O
was	O
prevented	O
by	O
Captopril	B-Drug
.	O

The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	O
alone	O
.	O

It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	B-Drug
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	O
II	O
and	O
an	O
increase	O
in	O
prostacyclin	O
(	O
secondary	O
to	O
an	O
increase	O
in	O
bradykinin	O
)	O
.	O

Captopril	B-Drug
may	O
,	O
by	O
the	O
same	O
mechanism	O
,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin	O
,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	O
damage	O
will	O
be	O
produced	O
.	O

A	O
randomized	O
comparison	O
of	O
labetalol	B-Chemical
and	O
nitroprusside	B-Chemical
for	O
induced	O
hypotension	B-Disease
.	O

In	O
a	O
randomized	O
study	O
,	O
labetalol-induced	B-Chemical
hypotension	B-Disease
and	O
nitroprusside-induced	B-Chemical
hypotension	B-Disease
were	O
compared	O
in	I-Disease
20	O
patients	O
(	O
10	O
in	I-Disease
each	O
group	O
)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures	O
.	O

Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	B-Drug
protocol	O
and	O
similar	O
drug-induced	O
reductions	B-Disease
in	I-Disease
mean	I-Disease
arterial	I-Disease
blood	O
pressure	O
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O

Nitroprusside	B-Drug
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0.05	O
)	O
increase	B-Disease
in	B-Disease
heart	I-Disease
rate	I-Disease
and	I-Disease
cardiac	I-Disease
output	I-Disease
;	O
rebound	O
hypertension	B-Disease
was	O
observed	O
in	O
three	O
patients	O
after	O
discontinuation	O
of	O
nitroprusside	B-Chemical
.	O

Labetalol	B-Chemical
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings	O
.	O

Arterial	O
PO2	B-Chemical
decreased	O
in	O
both	O
groups	O
.	O

It	O
was	O
concluded	O
that	O
labetalol	B-Chemical
offers	O
advantages	O
over	O
nitroprusside	B-Chemical
.	O

Chronic	O
carbamazepine	B-Chemical
treatment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxicity	B-Disease
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	B-Chemical
concentrations	O
.	O

Folate	B-Chemical
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	B-Drug
(	O
AED	O
)	O
therapy	O
.	O

Carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
clinical	O
studies	O
.	O

A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	B-Chemical
treatment	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
.	O

In	O
the	O
course	O
of	O
developing	O
this	O
model	O
,	O
a	O
common	O
vehicle	O
,	O
propylene	B-Chemical
glycol	I-Chemical
,	O
by	O
itself	O
in	O
high	O
doses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
properties	O
against	O
induced	O
seizures	B-Disease
and	O
inhibited	O
weight	B-Disease
gain	I-Disease
.	O

Seizures	B-Disease
induced	O
by	O
hexafluorodiethyl	B-Chemical
ether	I-Chemical
(	O
HFDE	B-Chemical
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	B-Chemical
than	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
.	O

Oral	O
administration	O
of	O
CBZ	B-Chemical
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg/kg	O
was	O
continuously	O
protective	O
against	O
HFDE-induced	B-Chemical
seizures	B-Disease
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B-Disease
gain	I-Disease
over	O
8	O
weeks	O
of	O
treatment	O
.	O

The	O
CBZ	B-Chemical
levels	O
measured	O
in	O
plasma	O
and	O
brain	O
of	O
these	O
animals	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O

This	O
treatment	O
with	O
CBZ	B-Chemical
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	B-Chemical
concentrations	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	B-Chemical
concentration	O
increased	O
in	O
liver	O
after	O
6	O
weeks	O
of	O
treatment	O
and	O
in	O
plasma	O
at	O
8	O
weeks	O
of	O
treatment	O
.	O

Inhibition	O
of	O
sympathoadrenal	O
activity	O
by	O
atrial	O
natriuretic	O
factor	O
in	O
dogs	O
.	O

In	O
six	O
conscious	O
,	O
trained	O
dogs	O
,	O
maintained	O
on	O
a	O
normal	O
sodium	B-Chemical
intake	O
of	O
2	O
to	O
4	O
mEq/kg/day	O
,	O
sympathetic	O
activity	O
was	O
assessed	O
as	O
the	O
release	O
rate	O
of	O
norepinephrine	B-Chemical
and	O
epinephrine	B-Chemical
during	O
15-minute	O
i.v	O
.	O

infusions	O
of	O
human	O
alpha-atrial	O
natriuretic	O
factor	O
.	O

Mean	O
arterial	O
pressure	O
(	O
as	O
a	O
percentage	O
of	O
control	O
+/-	O
SEM	O
)	O
during	O
randomized	O
infusions	O
of	O
0.03	O
,	O
0.1	O
,	O
0.3	O
,	O
or	O
1.0	O
microgram/kg/min	O
was	O
99	O
+/-	O
1	O
,	O
95	O
+/-	O
1	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
93	O
+/-	O
1	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
or	O
79	O
+/-	O
6	O
%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardia	B-Disease
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	B-Chemical
release	O
rate	O
(	O
up	O
to	O
0.3	O
microgram/kg/min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	B-Disease
induced	O
by	O
hydralazine	B-Chemical
or	O
nitroglycerin	B-Chemical
.	O

The	O
release	O
rate	O
of	O
epinephrine	B-Chemical
(	O
control	O
,	O
6.7	O
+/-	O
0.6	O
ng/kg/min	O
)	O
declined	O
immediately	O
during	O
infusions	O
of	O
atrial	O
natriuretic	O
factor	O
to	O
a	O
minimum	O
of	O
49	O
+/-	O
5	O
%	O
of	O
control	O
(	O
p	O
less	O
than	O
0.001	O
)	O
during	O
0.1	O
microgram/kg/min	O
and	O
to	O
63	O
+/-	O
5	O
%	O
(	O
0.1	O
greater	O
than	O
p	O
greater	O
than	O
0.05	O
)	O
or	O
95	O
+/-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0.3	O
or	O
1.0	O
microgram/kg/min	O
.	O

Steady	O
state	O
arterial	O
plasma	O
concentrations	O
of	O
atrial	O
natriuretic	O
factor	O
were	O
39	O
+/-	O
10	O
pg/ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infusions	O
of	O
saline	O
and	O
284	O
+/-	O
24	O
pg/ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+/-	O
300	O
pg/ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0.03	O
and	O
0.1	O
microgram/kg/min	O
infusions	O
of	O
the	O
factor	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Death	B-Disease
from	O
chemotherapy	O
in	O
gestational	B-Disease
trophoblastic	I-Disease
disease	I-Disease
.	O

Multiple	O
cytotoxic	O
drug	B-Drug
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high-risk	O
stage	O
of	O
choriocarcinoma	B-Disease
.	O

Based	O
on	O
this	O
principle	O
a	O
27-year	O
old	O
woman	O
,	O
classified	O
as	O
being	O
in	O
the	O
high-risk	O
group	O
(	O
Goldstein	O
and	O
Berkowitz	O
score	O
:	O
11	O
)	O
,	O
was	O
treated	O
with	O
multiple	O
cytotoxic	O
drugs	B-Drug
.	O

The	O
multiple	O
drug	B-Drug
schema	O
consisted	O
of	O
:	O
Etoposide	B-Chemical
16.213	O
,	O
Methotrexate	B-Chemical
,	O
Cyclophosphamide	B-Chemical
,	O
Actomycin-D	B-Chemical
,	O
and	O
Cisplatin	B-Chemical
.	O

On	O
the	O
first	O
day	O
of	O
the	O
schedule	O
,	O
moderate	O
high	O
doses	O
of	O
Methotrexate	B-Chemical
,	O
Etoposide	B-Chemical
and	O
Cyclophosphamide	B-Chemical
were	O
administered	O
.	O

Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	B-Disease
obstruction	I-Disease
due	O
to	O
choriocarcinomic	O
tissue	O
plugs	O
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O

Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	B-Disease
necrosis	B-Disease
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	B-Disease
plugs	O
to	O
the	O
vascular	O
spaces	O
;	O
decrease	O
in	O
tumor	B-Disease
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	B-Disease
emboli	O
.	O

In	O
view	O
of	O
the	O
close	O
time	O
association	O
between	O
the	O
start	O
of	O
chemotherapy	O
and	O
the	O
acute	O
onset	O
of	O
massive	O
embolism	B-Disease
other	O
explanations	O
,	O
such	O
as	O
spontaneous	O
necrosis	B-Disease
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O

Patients	O
with	O
large	O
pelvic	B-Disease
tumor	I-Disease
loads	O
are	O
,	O
according	O
to	O
existing	O
classifications	O
,	O
at	O
high	O
risk	O
to	O
die	O
and	O
to	O
develop	O
drug	B-Drug
resistance	O
.	O

Notwithstanding	O
these	O
facts	O
our	O
findings	O
suggest	O
that	O
these	O
patients	O
might	O
benefit	O
from	O
relatively	O
mild	O
initial	O
treatment	O
,	O
especially	O
true	O
for	O
patients	O
not	O
previously	O
exposed	O
to	O
this	O
drug	B-Drug
.	O

Close	O
observation	O
of	O
the	O
response	O
status	O
both	O
clinically	O
and	O
with	O
beta-hCG	O
values	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agressive	O
combination	O
chemotherapy	O
should	O
be	O
started	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Sexual	B-Disease
dysfunction	I-Disease
among	O
patients	O
with	O
arthritis	B-Disease
.	O

The	O
relationship	O
of	O
arthritis	B-Disease
and	O
sexual	B-Disease
dysfunction	I-Disease
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
,	O
osteoarthritis	B-Disease
and	O
spondyloarthropathy	B-Disease
,	O
130	O
of	O
whom	O
were	O
pair-matched	O
to	O
controls	O
.	O

Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	B-Disease
mood	I-Disease
were	O
also	O
made	O
using	O
the	O
CES-D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	O
(	O
AMHS	O
)	O
.	O

Sexual	B-Disease
dysfunctions	I-Disease
were	O
found	O
to	O
be	O
common	O
among	O
patients	O
and	O
controls	O
,	O
the	O
majority	O
in	O
both	O
groups	O
reporting	O
one	O
or	O
more	O
dysfunctions	O
.	O

Impotence	B-Disease
was	O
more	O
common	O
among	O
male	O
patients	O
than	O
controls	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co-morbidity	O
and	O
the	O
taking	O
of	O
methotrexate	B-Chemical
.	O

Depressed	B-Disease
mood	I-Disease
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	B-Disease
.	O

Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	B-Disease
but	O
was	O
associated	O
with	O
sexual	B-Disease
dysfunction	I-Disease
,	O
sexual	O
dissatisfaction	O
and	O
being	O
female	O
.	O

Does	O
paracetamol	B-Chemical
cause	O
urothelial	B-Disease
cancer	I-Disease
or	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
?	O
The	O
risk	O
of	O
developing	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
or	I-Disease
cancer	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
,	I-Disease
ureter	I-Disease
or	I-Disease
bladder	O
associated	O
with	O
consumption	O
of	I-Chemical
either	O
phenacetin	O
or	O
paracetamol	O
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O

The	O
risk	O
of	I-Chemical
renal	I-Chemical
papillary	O
necrosis	O
was	O
increased	O
nearly	O
20-fold	O
by	O
consumption	O
of	I-Chemical
phenacetin	O
,	O
which	O
also	O
increased	O
the	I-Chemical
risk	O
for	O
cancer	B-Chemical
of	I-Chemical
the	I-Chemical
renal	O
pelvis	O
and	O
bladder	O
but	O
not	O
for	O
ureteric	O
cancer	B-Chemical
.	O

By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	O
consumption	O
for	O
renal	O
papillary	O
necrosis	O
or	O
any	O
of	I-Disease
these	O
cancers	B-Disease
although	O
there	O
was	O
a	O
suggestion	O
of	I-Disease
an	O
association	O
with	O
cancer	B-Disease
of	O
the	O
ureter	O
.	O

Dapsone-associated	B-Chemical
Heinz	O
body	O
hemolytic	B-Disease
anemia	I-Disease
in	O
a	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
.	O

A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	B-Disease
developed	O
a	O
Heinz	O
body	O
hemolytic	B-Disease
anemia	I-Disease
while	O
taking	O
a	O
dose	O
of	O
dapsone	B-Chemical
(	O
50	O
mg/day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	B-Disease
.	O

Her	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
decreased	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
,	O
and	O
decreased	O
GSH	B-Chemical
stability	O
.	O

The	O
pentose	B-Chemical
phosphate	I-Chemical
shunt	O
activity	O
of	O
the	O
dapsone-exposed	B-Chemical
AE	O
RBCs	O
was	O
increased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	B-Chemical
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
the	O
GSH	B-Chemical
content	O
and	O
GSH	B-Chemical
stability	O
were	O
normal	O
.	O

The	O
pentose	B-Chemical
phosphate	I-Chemical
shunt	O
activity	O
of	O
the	O
non-dapsone-exposed	B-Chemical
AE	O
RBCs	O
was	O
decreased	O
compared	O
to	O
normal	O
RBCs	O
.	O

Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsone	B-Chemical
does	O
not	O
cause	O
hemolytic	B-Disease
anemia	I-Disease
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals	O
.	O

Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	O
,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infection	B-Disease
is	O
present	O
,	O
in	O
individuals	O
of	O
ethnic	O
backgrounds	O
that	O
have	O
an	O
increased	O
prevalence	O
of	O
hemoglobin	O
E	O
.	O

Severe	O
complications	O
of	O
antianginal	O
drug	B-Drug
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	B-Chemical
,	O
propafenone	B-Chemical
,	O
diltiazem	B-Chemical
,	O
and	O
sparteine	B-Chemical
.	O

A	O
47-year-old	O
patient	O
suffering	O
from	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
was	O
admitted	O
to	O
the	O
CCU	O
in	O
shock	B-Disease
with	O
III	O
.	O

AV	B-Disease
block	I-Disease
,	O
severe	O
hypotension	B-Disease
,	O
and	O
impairment	B-Disease
of	I-Disease
ventricular	I-Disease
function	I-Disease
.	O

One	O
week	O
prior	O
to	O
admission	O
a	O
therapy	O
with	O
standard	O
doses	O
of	O
metoprolol	B-Chemical
(	O
100	O
mg	O
t.i.d	O
.	O

and	O
then	O
100	O
mg	O
b.i.d	O
.	O

)	O
had	O
been	O
initiated	O
.	O

Two	O
days	O
before	O
admission	O
diltiazem	B-Chemical
(	O
60	O
mg	O
b.i.d	O
.	O

)	O
was	O
prescribed	O
in	O
addition	O
.	O

Analyses	O
of	O
a	O
blood	O
sample	O
revealed	O
unusually	O
high	O
plasma	O
concentrations	O
of	O
metoprolol	B-Chemical
(	O
greater	O
than	O
3000	O
ng/ml	O
)	O
and	O
diltiazem	B-Chemical
(	O
526	O
ng/ml	O
)	O
.	O

The	O
patient	O
recovered	O
within	O
1	O
week	O
following	O
discontinuation	O
of	O
antianginal	O
therapy	O
.	O

Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	B-Chemical
,	O
diltiazem	B-Chemical
,	O
propafenone	B-Chemical
(	O
since	O
he	O
had	O
received	O
this	O
drug	B-Drug
in	O
the	O
past	O
)	O
,	O
and	O
sparteine	B-Chemical
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine/sparteine	B-Chemical
type	O
polymorphism	O
of	O
oxidative	O
drug	B-Drug
metabolism	O
)	O
.	O

It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metabolizer	O
of	O
all	O
four	O
drugs	B-Drug
,	O
indicating	O
that	O
their	O
metabolism	O
is	O
under	O
the	O
same	O
genetic	O
control	O
.	O

Therefore	O
,	O
patients	O
belonging	O
to	O
the	O
poor-metabolizer	O
phenotype	O
of	O
sparteine/debrisoquine	B-Chemical
polymorphism	O
in	O
drug	B-Drug
metabolism	O
,	O
which	O
constitutes	O
6.4	O
%	O
of	O
the	O
German	O
population	O
,	O
may	O
experience	O
adverse	O
drug	B-Drug
reactions	O
when	O
treated	O
with	O
standard	O
doses	O
of	O
one	O
of	O
these	O
drugs	B-Drug
alone	O
.	O

Moreover	O
,	O
the	O
coadministration	O
of	O
these	O
frequently	O
used	O
drugs	B-Drug
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O

Triazolam-induced	B-Chemical
brief	O
episodes	O
of	O
secondary	O
mania	B-Disease
in	O
a	O
depressed	B-Disease
patient	O
.	O

Large	O
doses	O
of	O
triazolam	B-Chemical
repeatedly	O
induced	O
brief	O
episodes	O
of	O
mania	B-Disease
in	O
a	O
depressed	B-Disease
elderly	O
woman	O
.	O

Features	O
of	O
organic	B-Disease
mental	I-Disease
disorder	I-Disease
(	O
delirium	B-Disease
)	O
were	O
not	O
present	O
.	O

Manic	B-Disease
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	B-Chemical
.	O

The	O
possible	O
contribution	O
of	O
the	O
triazolo	B-Chemical
group	O
to	O
changes	O
in	O
affective	O
status	O
is	O
discussed	O
.	O

On	O
the	O
mechanisms	O
of	O
the	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Disease
rigidity	I-Disease
produced	O
by	O
morphine	B-Chemical
in	O
rats	O
.	O

The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	B-Disease
rigidity	I-Disease
produced	O
by	O
morphine	B-Chemical
was	O
studied	O
in	O
rats	O
.	O

Saline-pretreated	O
controls	O
given	O
a	O
test	O
dose	O
of	O
morphine	B-Chemical
(	O
20	O
mg/kg	O
i.p	O
.	O

)	O
showed	O
a	O
pronounced	O
rigidity	B-Disease
recorded	O
as	O
tonic	O
activity	O
in	O
the	O
electromyogram	O
.	O

Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	B-Chemical
and	O
withdrawn	O
for	O
36-40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance	O
:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	B-Disease
after	O
the	O
test	O
dose	O
of	O
morphine	B-Chemical
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	B-Disease
(	O
A	O
group	O
)	O
.	O

The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	B-Disease
and	O
the	O
occurrence	O
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and/or	O
gnawing	O
in	O
presence	O
of	O
akinetic	B-Disease
or	O
hyperkinetic	B-Disease
(	O
K	O
)	O
behaviour	O
(	O
AS/KS	O
group	O
)	O
,	O
suggesting	O
signs	O
of	O
dopaminergic	B-Drug
activation	O
.	O

The	O
rigidity	B-Disease
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days	O
'	O
treatment	O
.	O

In	O
a	O
further	O
series	O
of	O
experiments	O
,	O
haloperidol	B-Chemical
(	O
0.2	O
mg/kg	O
i.p	O
.	O

)	O
was	O
used	O
in	O
order	O
to	O
block	O
the	O
dopaminergic	B-Drug
activation	O
and	O
to	O
estimate	O
the	O
real	O
degree	O
of	O
the	O
tolerance	O
to	O
the	O
rigidity	B-Disease
without	O
any	O
dopaminergic	B-Drug
interference	O
.	O

Haloperidol	B-Chemical
enhanced	O
the	O
rigidity	B-Disease
in	O
the	O
A	O
group	O
.	O

However	O
,	O
the	O
level	O
in	O
the	O
AS/KS	O
group	O
remained	O
considerably	O
lower	O
than	O
in	O
the	O
A	O
group	O
.	O

The	O
results	O
suggest	O
that	O
rigidity	B-Disease
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	O
of	O
morphine	B-Chemical
in	O
the	O
striatum	O
,	O
can	O
be	O
antagonized	O
by	O
another	O
process	O
leading	O
to	O
dopaminergic	B-Drug
activation	O
in	O
the	O
striatum	O
.	O

Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
tolerance	O
to	O
this	O
effect	O
.	O

The	O
rapid	O
alternations	O
of	O
rigidity	B-Disease
and	O
the	O
signs	O
of	O
dopaminergic	B-Drug
activation	O
observed	O
in	O
the	O
animals	O
of	O
the	O
AS/KS	O
group	O
might	O
be	O
due	O
to	O
rapid	O
shifts	O
in	O
the	O
predominance	O
of	O
various	O
DA-innervated	O
structures	O
.	O

Compression	B-Disease
neuropathy	I-Disease
of	I-Disease
the	I-Disease
radial	I-Disease
nerve	I-Disease
due	O
to	O
pentazocine-induced	O
fibrous	O
myopathy	O
.	O

Fibrous	B-Disease
myopathy	I-Disease
is	O
a	O
common	O
,	O
well-known	O
side	O
effect	O
of	O
repeated	O
pentazocine	B-Chemical
injection	O
.	O

However	O
,	O
compression	B-Disease
neuropathy	I-Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine-induced	B-Chemical
myopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
a	O
37-year-old	O
woman	O
with	O
documented	O
pentazocine-induced	B-Chemical
fibrous	B-Disease
myopathy	I-Disease
of	O
triceps	O
and	O
deltoid	O
muscles	O
bilaterally	O
and	O
a	O
three-week	O
history	O
of	O
right	O
wrist	O
drop	O
,	O
electrodiagnostic	O
examination	O
showed	O
a	O
severe	O
but	O
partial	O
lesion	O
of	O
the	O
right	O
radial	O
nerve	O
distal	O
to	O
the	O
branches	O
to	O
the	O
triceps	O
,	O
in	O
addition	O
to	O
the	O
fibrous	B-Disease
myopathy	I-Disease
.	O

Surgery	O
revealed	O
the	O
right	O
radial	O
nerve	O
to	O
be	O
severely	O
compressed	O
by	O
the	O
densely	O
fibrotic	O
lateral	O
head	O
of	O
the	O
triceps	O
.	O

Decompression	O
and	O
neurolysis	O
were	O
performed	O
with	O
good	O
subsequent	O
recovery	O
of	O
function	O
.	O

Recurrent	O
reversible	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
from	O
amphotericin	B-Chemical
.	O

A	O
patient	O
with	O
cryptogenic	O
cirrhosis	B-Disease
and	O
disseminated	O
sporotrichosis	B-Disease
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
immediately	O
following	O
the	O
administration	O
of	O
amphotericin	B-Chemical
B	I-Chemical
on	O
four	O
separate	O
occasions	O
.	O

The	O
abruptness	O
of	O
the	O
renal	B-Disease
failure	I-Disease
and	O
its	O
reversibility	O
within	O
days	O
suggests	O
that	O
there	O
was	O
a	O
functional	O
component	O
to	O
the	O
renal	B-Disease
dysfunction	I-Disease
.	O

We	O
propose	O
that	O
amphotericin	B-Chemical
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume	O
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Pneumonitis	O
with	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusion	I-Disease
and	O
neuropathy	O
during	O
amiodarone	B-Drug
therapy	O
.	O

A	O
patient	O
with	O
sinuatrial	B-Disease
disease	I-Disease
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	B-Chemical
(	O
maximum	O
dose	O
1000	O
mg	O
,	O
maintenance	O
dose	O
800	O
mg	O
daily	O
)	O
for	O
10	O
months	O
,	O
for	O
control	O
of	O
supraventricular	B-Disease
tachyarrhythmias	I-Disease
.	O

He	O
developed	O
pneumonitis	B-Disease
,	O
pleural	B-Disease
and	I-Disease
pericardial	I-Disease
effusions	I-Disease
,	O
and	O
a	O
predominantly	O
proximal	O
motor	O
neuropathy	O
.	O

Immediate	O
but	O
gradual	O
improvement	O
followed	O
withdrawal	O
of	O
amiodarone	B-Drug
and	O
treatment	O
with	O
prednisolone	B-Drug
.	O

Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	B-Drug
pneumonitis	O
,	O
immediate	O
withdrawal	O
of	O
amiodarone	B-Drug
,	O
and	O
prompt	O
but	O
continued	O
steroid	O
therapy	O
to	O
ensure	O
full	O
recovery	O
.	O

Indomethacin-induced	B-Chemical
renal	B-Disease
insufficiency	I-Disease
:	O
recurrence	O
on	O
rechallenge	O
.	O

We	O
have	O
reported	O
a	O
case	O
of	O
acute	O
oliguric	O
renal	B-Disease
failure	I-Disease
with	O
hyperkalemia	B-Disease
in	O
a	O
patient	O
with	O
cirrhosis	B-Disease
,	O
ascites	B-Disease
,	O
and	O
cor	B-Disease
pulmonale	I-Disease
after	O
indomethacin	B-Chemical
therapy	O
.	O

Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	B-Drug
withdrawal	O
,	O
while	O
re-exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	B-Chemical
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	B-Disease
.	O

Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	B-Chemical
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	I-Disease
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O

Since	O
nonsteroidal	O
anti-inflammatory	O
agents	O
interfere	O
with	O
this	O
compensatory	O
mechanism	O
and	O
may	O
cause	O
acute	B-Disease
renal	I-Disease
failure	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
patients	O
.	O

Comparison	O
of	O
the	O
subjective	O
effects	O
and	O
plasma	O
concentrations	O
following	O
oral	O
and	O
i.m	O
.	O

administration	O
of	O
flunitrazepam	B-Chemical
in	O
volunteers	O
.	O

Flunitrazepam	B-Chemical
0.5	O
,	O
1.0	O
or	O
2.0	O
mg	O
was	O
given	O
by	O
the	O
oral	O
or	O
i.m	O
.	O

routes	O
to	O
groups	O
of	O
volunteers	O
and	O
its	O
effects	O
compared	O
.	O

Plasma	O
concentrations	O
of	O
the	O
drug	B-Drug
were	O
estimated	O
by	O
gas-liquid	O
chromatography	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
subjects	O
.	O

The	O
most	O
striking	O
effect	O
was	O
sedation	O
which	O
increased	O
with	O
the	O
dose	O
,	O
2	O
mg	O
producing	O
deep	O
sleep	O
although	O
the	O
subjects	O
could	O
still	O
be	O
aroused	O
.	O

The	O
effects	O
of	O
i.m	O
.	O

administration	O
were	O
apparent	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
oral	O
administration	O
.	O

Dizziness	B-Disease
was	O
less	O
marked	O
than	O
sedation	O
,	O
but	O
increased	O
with	O
the	O
dose	O
.	O

There	O
was	O
pain	B-Disease
on	O
i.m	O
.	O

injection	O
of	O
flunitrazepam	B-Chemical
significantly	O
more	O
often	O
than	O
with	O
isotonic	O
saline	O
.	O

Plasma	O
concentrations	O
varied	O
with	O
dose	O
and	O
route	O
and	O
corresponded	O
qualitatively	O
with	O
the	O
subjective	O
effects	O
.	O

The	O
drug	B-Drug
was	O
still	O
present	O
in	O
measurable	O
quantities	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dose	O
.	O

Changes	O
in	O
heart	O
size	O
during	O
long-term	O
timolol	B-Chemical
treatment	O
after	O
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
effect	O
of	O
long-term	O
timolol	B-Chemical
treatment	O
on	O
heart	O
size	O
after	O
myocardial	B-Disease
infarction	I-Disease
was	O
evaluated	O
by	O
X-ray	O
in	O
a	O
double-blind	O
study	O
including	O
241	O
patients	O
(	O
placebo	O
126	O
,	O
timolol	B-Chemical
115	O
)	O
.	O

The	O
follow-up	O
period	O
was	O
12	O
months	O
.	O

The	O
timolol-treated	B-Chemical
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
timolol-induced	B-Chemical
bradycardia	B-Disease
and	O
a	O
compensatory	O
increase	O
in	O
end-diastolic	O
volume	O
.	O

The	O
timolol-related	B-Chemical
increase	O
in	O
heart	O
size	O
was	O
observed	O
only	O
in	O
patients	O
with	O
normal	O
and	O
borderline	O
heart	O
size	O
.	O

In	O
patients	O
with	O
cardiomegaly	B-Disease
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups	O
.	O

After	O
re-infarction	B-Disease
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	B-Chemical
group	O
.	O

Vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
in	O
dairy	O
cows	O
.	O

Large	O
parenteral	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
(	O
15	O
to	O
17.5	O
x	O
10	O
(	O
6	O
)	O
IU	O
vitamin	B-Chemical
D3	I-Chemical
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	B-Disease
,	O
hyperphosphatemia	B-Disease
,	O
and	O
large	O
increases	O
of	O
vitamin	B-Chemical
D3	I-Chemical
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows	O
.	O

Calcium	B-Chemical
concentrations	O
1	O
day	O
postpartum	O
were	O
higher	O
in	O
cows	O
treated	O
with	O
vitamin	B-Chemical
D3	I-Chemical
about	O
32	O
days	O
prepartum	O
(	O
8.8	O
mg/100	O
ml	O
)	O
than	O
in	O
control	O
cows	O
(	O
5.5	O
mg/100	O
ml	O
)	O
.	O

None	O
of	O
the	O
cows	O
treated	O
with	O
vitamin	B-Chemical
D3	I-Chemical
showed	O
signs	O
of	O
milk	B-Disease
fever	I-Disease
during	O
the	O
peripartal	O
period	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
control	O
cows	O
developed	O
clinical	O
signs	O
of	O
milk	B-Disease
fever	I-Disease
during	O
this	O
period	O
.	O

Signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	O
;	O
however	O
,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	B-Chemical
D3	I-Chemical
toxicity	B-Disease
and	O
10	O
of	O
17	O
cows	O
died	O
.	O

There	O
was	O
widespread	O
metastatic	O
calcification	O
in	O
the	O
cows	O
that	O
died	O
.	O

Because	O
of	O
the	O
extreme	O
toxicity	B-Disease
of	O
vitamin	B-Chemical
D3	I-Chemical
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	B-Chemical
D3	I-Chemical
that	O
prevent	O
milk	B-Disease
fever	I-Disease
and	O
doses	O
that	O
induce	O
milk	B-Disease
fever	I-Disease
,	O
we	O
concluded	O
that	O
vitamin	B-Chemical
D3	I-Chemical
can	O
not	O
be	O
used	O
practically	O
to	O
prevent	O
milk	B-Disease
fever	I-Disease
when	O
injected	O
several	O
weeks	O
prepartum	O
.	O

Diseases	B-Disease
of	I-Disease
peripheral	I-Disease
nerves	I-Disease
as	O
seen	O
in	O
the	O
Nigerian	O
African	O
.	O

The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	B-Disease
nerve	I-Disease
disease	I-Disease
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders	O
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	O
.	O

There	O
is	O
a	O
male	O
preponderance	O
and	O
the	O
peak	O
incidence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O

Sensori-motor	B-Disease
neuropathy	I-Disease
was	O
the	O
commonest	O
presentation	O
(	O
50	O
%	O
)	O
.	O

Guillain-Barr	B-Disease
syndrome	I-Disease
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15.6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	B-Disease
neuropathy	I-Disease
.	O

Peripheral	B-Disease
neuropathy	I-Disease
due	O
to	O
nutritional	B-Disease
deficiency	I-Disease
of	O
thiamine	B-Chemical
and	O
riboflavin	B-Chemical
was	O
common	O
(	O
10.1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sensory	O
and	O
sensori-motor	B-Disease
neuropathy	I-Disease
.	O

Diabetes	B-Disease
mellitus	I-Disease
was	O
the	O
major	O
cause	O
of	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

Isoniazid	B-Chemical
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug-induced	O
neuropathy	B-Disease
.	O

Migraine	B-Disease
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	B-Disease
neuropathy	I-Disease
although	O
malignancies	B-Disease
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	O
of	O
the	O
head	O
and	O
neck	O
were	O
more	O
frequent	O
(	O
26	O
%	O
)	O
.	O

In	O
26.5	O
%	O
of	O
all	O
the	O
cases	O
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	B-Disease
was	O
undetermined	O
.	O

Heredofamilial	O
and	O
connective	B-Disease
tissue	I-Disease
disorders	I-Disease
were	O
rare	O
.	O

Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	B-Disease
are	O
briefly	O
discussed	O
.	O

A	O
double-blind	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	B-Chemical
hydrochloride	I-Chemical
in	O
the	O
treatment	O
of	O
major	O
depressive	B-Disease
disorder	I-Disease
.	O

In	O
a	O
6-week	O
double-blind	O
parallel	O
treatment	O
study	O
,	O
dothiepin	B-Chemical
and	O
amitriptyline	B-Chemical
were	O
compared	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
33	O
depressed	B-Disease
outpatients	O
.	O

Dothiepin	B-Chemical
and	O
amitriptyline	B-Chemical
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	B-Disease
illness	I-Disease
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo	O
.	O

The	O
overall	O
incidence	O
of	O
side	O
effects	O
and	O
the	O
frequency	O
and	O
severity	O
of	O
blurred	B-Disease
vision	I-Disease
,	O
dry	B-Disease
mouth	I-Disease
,	O
and	O
drowsiness	O
were	O
significantly	O
less	O
with	O
dothiepin	B-Chemical
than	O
with	O
amitriptyline	B-Chemical
.	O

Dothiepin	B-Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O

There	O
were	O
no	O
clinically	O
important	O
changes	O
in	O
laboratory	O
parameters	O
.	O

Dothiepin	B-Chemical
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	B-Chemical
drug	B-Drug
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	B-Chemical
in	O
the	O
treatment	O
of	O
depressed	B-Disease
outpatients	O
.	O

Behavioral	O
effects	O
of	O
diazepam	B-Chemical
and	O
propranolol	B-Chemical
in	O
patients	O
with	O
panic	B-Disease
disorder	I-Disease
and	O
agoraphobia	B-Disease
.	O

The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	B-Chemical
(	O
single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg/day	O
for	O
2	O
weeks	O
)	O
and	O
propranolol	B-Chemical
(	O
single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg/day	O
for	O
2	O
weeks	O
)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	B-Disease
disorders	I-Disease
and	O
agoraphobia	B-Disease
were	O
investigated	O
in	O
a	O
double-blind	O
,	O
randomized	O
and	O
crossover	O
design	O
.	O

Both	O
drugs	B-Drug
impaired	B-Disease
immediate	I-Disease
free	I-Disease
recall	I-Disease
but	O
the	O
decrease	O
was	O
greater	O
for	O
diazepam	B-Chemical
than	O
propranolol	B-Chemical
.	O

Delayed	B-Disease
free	I-Disease
recall	I-Disease
was	I-Disease
also	I-Disease
impaired	I-Disease
but	O
the	O
two	O
drugs	B-Drug
did	O
not	O
differ	O
.	O

Patients	O
tapped	O
faster	O
after	O
propranolol	B-Chemical
than	O
diazepam	B-Chemical
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	B-Chemical
than	O
propranolol	B-Chemical
.	O

After	O
2	O
weeks	O
of	O
treatment	O
,	O
patients	O
tested	O
5-8	O
h	O
after	O
the	O
last	O
dose	O
of	O
medication	O
did	O
not	O
show	O
any	O
decrement	O
of	O
performance	O
.	O

These	O
results	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healthy	O
subjects	O
.	O

Accumulation	O
of	O
drugs	B-Drug
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	B-Disease
impairment	I-Disease
.	O

Effect	O
of	O
aspirin	B-Chemical
on	O
N-	B-Chemical
[	I-Chemical
4-	I-Chemical
(	I-Chemical
5-nitro-2-furyl	I-Chemical
)	I-Chemical
-2-thiazolyl	I-Chemical
]	I-Chemical
-formamide-induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat	O
.	O

The	O
co-administration	O
of	O
aspirin	B-Chemical
with	O
N-	B-Chemical
[	I-Chemical
4-	I-Chemical
(	I-Chemical
5-nitro-2-furyl	I-Chemical
)	I-Chemical
-2-thiazolyl	I-Chemical
]	I-Chemical
-formamide	I-Chemical
(	O
FANFT	B-Chemical
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT-induced	B-Chemical
bladder	B-Disease
carcinomas	I-Disease
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	B-Disease
tumors	I-Disease
.	O

An	O
autoradiographic	O
study	O
was	O
performed	O
on	O
male	O
F-344	O
rats	O
fed	O
diet	O
containing	O
FANFT	B-Chemical
at	O
a	O
level	O
of	O
0.2	O
%	O
and/or	O
aspirin	B-Chemical
at	O
a	O
level	O
of	O
0.5	O
%	O
to	O
evaluate	O
the	O
effect	O
of	O
aspirin	B-Chemical
on	O
the	O
increased	O
cell	O
proliferation	O
induced	O
by	O
FANFT	B-Chemical
in	O
the	O
forestomach	O
and	O
bladder	O
.	O

FANFT-induced	B-Chemical
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	B-Chemical
co-administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks	O
.	O

In	O
the	O
forestomach	O
,	O
and	O
also	O
in	O
the	O
liver	O
,	O
aspirin	B-Chemical
did	O
not	O
affect	O
the	O
FANFT-induced	B-Chemical
increase	O
in	O
labeling	O
index	O
.	O

The	O
present	O
results	O
are	O
consistent	O
with	O
the	O
carcinogenicity	O
experiment	O
suggesting	O
that	O
different	O
mechanisms	O
are	O
involved	O
in	O
FANFT	B-Chemical
carcinogenesis	B-Disease
in	O
the	O
bladder	O
and	O
forestomach	O
,	O
and	O
that	O
aspirin	B-Chemical
's	O
effect	O
on	O
FANFT	B-Chemical
in	O
the	O
forestomach	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O

Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	B-Chemical
.	O

Provocation	O
of	O
postural	O
hypotension	B-Disease
by	O
nitroglycerin	B-Chemical
in	O
diabetic	B-Disease
autonomic	I-Disease
neuropathy	I-Disease
?	O
The	O
effect	O
of	O
nitroglycerin	B-Chemical
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects	O
,	O
12	O
diabetic	B-Disease
subjects	O
without	O
autonomic	B-Disease
neuropathy	I-Disease
,	O
and	O
5	O
diabetic	B-Disease
subjects	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

The	O
magnitude	O
and	O
time	O
course	O
of	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
the	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
after	O
nitroglycerin	B-Chemical
were	O
similar	O
in	O
the	O
normal	O
and	O
diabetic	B-Disease
subjects	O
without	O
autonomic	B-Disease
neuropathy	I-Disease
,	O
whereas	O
a	O
lesser	O
increase	O
in	O
heart	O
rate	O
and	O
a	O
greater	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
occurred	O
in	O
the	O
diabetic	B-Disease
subjects	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
vasodilator	O
drugs	B-Drug
in	O
diabetic	B-Disease
patients	O
,	O
particularly	O
those	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O

Characterization	O
of	O
estrogen-induced	B-Chemical
adenohypophyseal	B-Disease
tumors	I-Disease
in	O
the	O
Fischer	O
344	O
rat	O
.	O

Pituitary	B-Disease
tumors	I-Disease
were	O
induced	O
in	O
F344	O
female	O
rats	O
by	O
chronic	O
treatment	O
with	O
diethylstilbestrol	B-Chemical
(	O
DES	B-Chemical
,	O
8-10	O
mg	O
)	O
implanted	O
subcutaneously	O
in	O
silastic	O
capsules	O
.	O

Over	O
a	O
range	O
of	O
1-150	O
days	O
of	O
DES	B-Chemical
treatment	O
,	O
pairs	O
of	O
control	O
and	O
DES-treated	B-Chemical
rats	O
were	O
sacrificed	O
,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single-cell	O
preparations	O
.	O

The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight	O
,	O
intracellular	O
prolactin	O
(	O
PRL	O
)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture	O
,	O
immunocytochemical	O
PRL	O
staining	O
,	O
density	O
and/or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll-Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation	O
,	O
and	O
cell	O
cycle	O
analysis	O
,	O
after	O
acriflavine	B-Chemical
DNA	O
staining	O
,	O
by	O
laser	O
flow	O
cytometry	O
.	O

Total	O
cell	O
yields	O
from	O
DES-treated	B-Chemical
pituitaries	O
increased	O
from	O
1.3	O
times	O
control	O
yields	O
at	O
8	O
days	O
of	O
treatment	O
to	O
58.9	O
times	O
control	O
values	O
by	O
day	O
150	O
.	O

Intracellular	O
PRL	O
content	O
ranged	O
from	O
1.9	O
to	O
9.4	O
times	O
control	O
levels	O
,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls	O
,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
.	O

Beyond	O
8	O
days	O
of	O
DES	B-Chemical
exposure	O
,	O
the	O
immunochemically	O
PRL-positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O

Increased	O
density	O
and/or	O
size	O
and	O
PRL	O
content	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
cell	O
population	O
in	O
both	O
types	O
of	O
separation	O
protocols	O
.	O

All	O
these	O
effects	O
of	O
DES	B-Chemical
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals	O
.	O

The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES-induced	B-Chemical
tumor	B-Disease
as	O
a	O
model	O
for	O
study	O
of	O
PRL	O
cellular	O
control	O
mechanisms	O
.	O

Triamterene	B-Chemical
nephrolithiasis	B-Disease
complicating	O
dyazide	B-Chemical
therapy	O
.	O

A	O
case	O
of	O
triamterene	B-Chemical
nephrolithiasis	B-Disease
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide-triamterene	B-Chemical
therapy	O
for	O
hypertension	B-Disease
.	O

The	O
stone	O
passed	O
spontaneously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	B-Chemical
metabolite	O
admixed	O
with	O
uric	B-Chemical
acid	I-Chemical
salts	I-Chemical
.	O

Factors	O
affecting	O
triamterene	B-Chemical
nephrolithiasis	B-Disease
are	O
discussed	O
and	O
2	O
previously	O
reported	O
cases	O
are	O
reviewed	O
.	O

Metabolic	O
involvement	O
in	O
adriamycin	B-Chemical
cardiotoxicity	B-Disease
.	O

The	O
cardiotoxic	B-Disease
effects	O
of	O
adriamycin	B-Chemical
were	O
studied	O
in	O
mammalian	O
myocardial	O
cells	O
in	O
culture	O
as	O
a	O
model	O
system	O
.	O

Adriamycin	B-Chemical
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture	O
.	O

A	O
possible	O
involvement	O
of	O
energy	O
metabolism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
study	O
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	B-Chemical
mole	O
fraction	O
were	O
determined	O
in	O
the	O
adriamycin-treated	B-Chemical
cells	O
.	O

The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	B-Chemical
mole	O
fraction	O
was	O
unchanged	O
.	O

Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	B-Chemical
phosphokinase	O
.	O

The	O
addition	O
of	O
1	O
mM	O
adenosine	B-Chemical
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	B-Chemical
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	B-Chemical
pool	O
.	O

In	O
the	O
adriamycin-treated	B-Chemical
cells	O
,	O
the	O
addition	O
of	O
adenosine	B-Chemical
increased	O
the	O
adenylate	O
charge	O
and	O
,	O
concomitant	O
with	O
this	O
inrcease	O
,	O
the	O
cells	O
'	O
functional	O
integrity	O
,	O
in	O
terms	O
of	O
percentage	O
of	O
beating	O
cells	O
and	O
rate	O
of	O
contractions	O
,	O
was	O
maintained	O
.	O

Age-dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	B-Disease
effects	O
of	O
streptomycin	B-Chemical
.	O

Streptomycin	B-Chemical
sulfate	O
(	O
300	O
mg/kg	O
s.c.	O
)	O
was	O
injected	O
for	O
various	O
periods	O
into	O
preweanling	O
rats	O
and	O
for	O
3	O
weeks	O
into	O
weanling	O
rats	O
.	O

Beginning	O
at	O
8	O
days	O
of	O
age	O
,	O
body	O
movement	O
and	O
hearing	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
weeks	O
,	O
respectively	O
.	O

Abnormal	B-Disease
movements	I-Disease
and	O
deafness	B-Disease
occurred	O
only	O
in	O
rats	O
treated	O
during	O
the	O
preweaning	O
period	O
;	O
within	O
this	O
period	O
the	O
greatest	O
sensitivities	O
for	O
these	O
abnormalities	O
occurred	O
from	O
2	O
to	O
11-17	O
and	O
5	O
to	O
11	O
days	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	O
to	O
streptomycin	B-Chemical
than	O
the	O
site	O
(	O
vestibular	O
or	O
central	O
)	O
responsible	O
for	O
the	O
dyskinesias	B-Disease
.	O

Crescentic	O
fibrillary	O
glomerulonephritis	B-Disease
associated	O
with	O
intermittent	O
rifampin	B-Chemical
therapy	O
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
.	O

This	O
case	O
study	O
reveals	O
an	O
unusual	O
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-Chemical
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disease	O
.	O

This	O
patient	O
underwent	O
a	O
10-month	O
regimen	O
of	O
rifampin	B-Chemical
and	O
isoniazid	B-Chemical
for	O
pulmonary	B-Disease
tuberculosis	I-Disease
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	B-Disease
failure	I-Disease
five	O
weeks	O
after	O
completion	O
of	O
therapy	O
.	O

Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	B-Disease
with	O
crescents	O
,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate	O
.	O

Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
were	O
investigated	O
and	O
ruled	O
out	O
.	O

This	O
report	O
documents	O
the	O
unusual	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-Chemical
.	O

Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	B-Chemical
aminonucleoside-induced	O
nephropathy	O
.	O

Reactive	O
oxygen	B-Chemical
species	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-induced	O
nephropathy	B-Disease
,	O
with	O
antioxidants	O
significantly	O
reducing	O
the	O
proteinuria	B-Disease
.	O

The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	B-Disease
was	O
examined	O
in	O
this	O
study	O
.	O

Rats	O
were	O
treated	O
with	O
a	O
single	O
IV	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
,	O
(	O
PAN	B-Chemical
,	O
7.5	O
mg/kg	O
)	O
and	O
24	O
hour	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
sacrifice	O
on	O
days	O
3,5,7,10,17,27,41	O
(	O
N	O
=	O
5-10	O
per	O
group	O
)	O
.	O

The	O
kidneys	O
were	O
removed	O
,	O
flushed	O
with	O
ice	O
cold	O
TRIS	O
buffer	O
.	O

Kidney	O
cortices	O
from	O
each	O
animal	O
were	O
used	O
to	O
prepare	O
homogenates	O
.	O

Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	O
substances	O
.	O

Proteinuria	B-Disease
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O

Lipid	O
peroxidation	O
in	O
homogenates	O
was	O
maximal	O
at	O
day	O
3	O
and	O
declined	O
rapidly	O
to	O
control	O
levels	O
by	O
day	O
17	O
.	O

This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	B-Disease
injury	I-Disease
in	O
PAN	B-Chemical
nephropathy	B-Disease
.	O

Clomipramine-induced	B-Chemical
sleep	B-Disease
disturbance	I-Disease
does	O
not	O
impair	O
its	O
prolactin-releasing	O
action	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	B-Disease
disturbance	I-Disease
,	O
induced	O
by	O
clomipramine	B-Chemical
administration	O
,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
drug	B-Drug
effect	O
.	O

Two	O
groups	O
of	O
supine	O
subjects	O
were	O
studied	O
under	O
placebo-controlled	O
conditions	O
,	O
one	O
during	O
the	O
night	O
,	O
when	O
sleeping	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
daytime	O
,	O
when	O
awake	O
(	O
n	O
=	O
6	O
)	O
.	O

Each	O
subject	O
received	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomipramine	B-Chemical
given	O
orally	O
2	O
hours	O
before	O
blood	O
collection	O
.	O

Plasma	O
PRL	O
concentrations	O
were	O
analysed	O
at	O
10	O
min	O
intervals	O
and	O
underlying	O
secretory	O
rates	O
calculated	O
by	O
a	O
deconvolution	O
procedure	O
.	O

For	O
both	O
experiments	O
the	O
drug	B-Drug
intake	O
led	O
to	O
significant	O
increases	O
in	O
PRL	O
secretion	O
,	O
acting	O
preferentially	O
on	O
tonic	O
secretion	O
as	O
pulse	O
amplitude	O
and	O
frequency	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
control	O
values	O
.	O

During	O
the	O
night	O
clomipramine	B-Chemical
ingestion	O
altered	O
the	O
complete	O
sleep	B-Disease
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	B-Disease
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness	O
.	O

As	O
the	O
relative	O
increase	O
in	O
PRL	O
secretion	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
night	O
and	O
day	O
time	O
studies	O
(	O
46	O
+/-	O
19	O
%	O
vs	O
34	O
+/-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	O
disturbance	O
did	O
not	O
interfere	O
with	O
the	O
drug	B-Drug
action	O
per	O
se	O
.	O

The	O
presence	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factor	O
either	O
for	O
secretory	O
pulse	O
amplitude	O
and	O
frequency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnal	O
values	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomipramine	B-Chemical
ingestion	O
.	O

Angioedema	B-Disease
following	O
the	O
intravenous	O
administration	O
of	O
metoprolol	B-Chemical
.	O

A	O
72-year-old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
``	O
flash	O
''	O
pulmonary	B-Disease
edema	I-Disease
,	O
preceded	O
by	O
chest	B-Disease
pain	I-Disease
,	O
requiring	O
intubation	O
.	O

Her	O
medical	O
history	O
included	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
with	O
previous	O
myocardial	B-Disease
infarctions	I-Disease
,	O
hypertension	B-Disease
,	O
and	O
diabetes	B-Disease
mellitus	I-Disease
.	O

A	O
history	O
of	O
angioedema	B-Disease
secondary	O
to	O
lisinopril	B-Chemical
therapy	O
was	O
elicited	O
.	O

Current	O
medications	O
did	O
not	O
include	O
angiotensin-converting	B-Chemical
enzyme	O
inhibitors	O
or	O
beta-blockers	O
.	O

She	O
had	O
no	O
previous	O
beta-blocking	B-Drug
drug	B-Drug
exposure	O
.	O

During	O
the	O
first	O
day	O
of	O
hospitalization	O
(	O
while	O
intubated	O
)	O
,	O
intravenous	O
metoprolol	B-Chemical
was	O
given	O
,	O
resulting	O
in	O
severe	O
angioedema	B-Disease
.	O

The	O
angioedema	B-Disease
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	B-Chemical
and	O
diphenhydramine	B-Chemical
hydrochloride	O
.	O

Effect	O
of	O
coniine	B-Chemical
on	O
the	O
developing	O
chick	O
embryo	O
.	O

Coniine	B-Chemical
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O

The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	B-Disease
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade	O
.	O

However	O
,	O
coniine	B-Chemical
has	O
failed	O
to	O
produce	O
arthrogryposis	B-Disease
in	O
rats	O
or	O
mice	O
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
in	O
the	O
developing	O
chick	O
.	O

Concentrations	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
0.015	O
%	O
,	O
0.03	O
%	O
,	O
0.075	O
%	O
,	O
0.15	O
%	O
,	O
0.75	O
%	O
,	O
1.5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O

Both	O
compounds	O
caused	O
deformations	B-Disease
and	O
lethality	O
in	O
a	O
dose-dependent	O
manner	O
.	O

All	O
concentrations	O
of	O
nicotine	B-Chemical
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	B-Chemical
lethality	O
was	O
0.75	O
%	O
.	O

The	O
deformations	B-Disease
caused	O
by	O
both	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
were	O
excessive	B-Disease
flexion	I-Disease
or	I-Disease
extension	I-Disease
of	I-Disease
one	I-Disease
or	I-Disease
more	I-Disease
toes	I-Disease
.	O

No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B-Disease
hemorrhage	I-Disease
occurred	O
in	O
all	O
nicotine	B-Chemical
sulfate-treated	O
chicks	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
decrease	O
in	O
movement	O
in	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound	O
.	O

Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33.67	O
%	O
of	O
the	O
time	O
,	O
while	O
coniine-treated	B-Chemical
chicks	O
were	O
only	O
moving	O
8.95	O
%	O
of	O
a	O
5-min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
.	O

In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine-induced	B-Chemical
arthrogryposis	B-Disease
.	O

Data	O
from	O
this	O
model	O
support	O
a	O
mechanism	O
involving	O
nicotinic	O
receptor	O
blockade	O
with	O
subsequent	O
decreased	O
fetal	O
movement	O
.	O

Epidural	O
blood	O
flow	O
during	O
prostaglandin	B-Chemical
E1	I-Chemical
or	O
trimethaphan	B-Chemical
induced	O
hypotension	B-Disease
.	O

To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
or	O
trimethaphan	B-Chemical
(	O
TMP	B-Chemical
)	O
induced	O
hypotension	B-Disease
on	O
epidural	O
blood	O
flow	O
(	O
EBF	O
)	O
during	O
spinal	O
surgery	O
,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero-lateral	O
interbody	O
fusion	O
under	O
isoflurane	B-Chemical
anaesthesia	O
.	O

An	O
initial	O
dose	O
of	O
0.1	O
microgram.kg-1.min-1	O
of	O
PGE1	B-Chemical
(	O
15	O
patients	O
)	O
,	O
or	O
10	O
micrograms.kg-1.min-1	O
of	O
TMP	B-Chemical
(	O
15	O
patients	O
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O

The	O
hypotensive	B-Disease
drug	B-Drug
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	O
procedure	O
.	O

After	O
starting	O
PGE1	B-Chemical
or	O
TMP	B-Chemical
,	O
MAP	O
and	O
rate	O
pressure	O
product	O
(	O
RPP	O
)	O
decreased	O
significantly	O
compared	O
with	O
preinfusion	O
values	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
degree	O
of	O
hypotension	B-Disease
due	O
to	O
PGE1	B-Chemical
remained	O
constant	O
until	O
60	O
min	O
after	O
its	O
discontinuation	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
group	O
.	O

EBFF	O
did	O
not	O
change	O
during	O
PGE1	B-Chemical
infusion	O
whereas	O
in	O
the	O
TMP	B-Chemical
group	O
,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	B-Chemical
(	O
preinfusion	O
:	O
45.9	O
+/-	O
13.9	O
ml/100g/min	O
.	O

30	O
min	O
:	O
32.3	O
+/-	O
9.9	O
ml/100	O
g/min	O
(	O
P	O
<	O
0.05	O
)	O
.	O

60	O
min	O
:	O
30	O
+/-	O
7.5	O
ml/100	O
g/min	O
(	O
P	O
<	O
0.05	O
)	O
)	O
.	O

These	O
results	O
suggest	O
that	O
PGE1	B-Chemical
may	O
be	O
preferable	O
to	O
TMP	B-Chemical
for	O
hypotensive	B-Disease
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	B-Chemical
decreased	O
EBF	O
.	O

Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	B-Disease
damage	I-Disease
in	O
experimental	O
focal	O
lesions	O
in	O
rat	O
.	O

Immunohistochemistry	O
with	O
monoclonal	O
antibodies	O
against	O
neurofilament	O
(	O
NF	O
)	O
proteins	O
of	O
middle	O
and	O
high	O
molecular	O
weight	O
class	O
,	O
NF-M	O
and	O
NF-H	O
,	O
was	O
used	O
to	O
study	O
axonal	B-Disease
injury	I-Disease
in	B-Disease
the	I-Disease
borderzone	O
of	O
focal	O
lesions	O
in	B-Disease
rats	O
.	O

Focal	O
injury	B-Disease
in	O
the	O
cortex	O
was	O
produced	O
by	O
infusion	O
of	O
lactate	B-Chemical
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion	O
.	O

Infarcts	B-Disease
in	I-Disease
substantia	I-Disease
nigra	I-Disease
pars	I-Disease
reticulata	I-Disease
were	O
evoked	O
by	O
prolonged	O
pilocarpine-induced	B-Chemical
status	B-Disease
epilepticus	I-Disease
.	O

Immunohistochemical	O
staining	O
for	O
NFs	O
showed	O
characteristic	O
terminal	O
clubs	O
of	O
axons	O
in	O
the	O
borderzone	O
of	O
lesions	O
.	O

Differences	O
in	O
the	O
labelling	O
pattern	O
occurred	O
with	O
different	O
antibodies	O
which	O
apparently	O
depended	O
on	O
molecular	O
weight	O
class	O
of	O
NFs	O
and	O
phosphorylation	O
state	O
.	O

These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	B-Disease
damage	I-Disease
in	O
various	O
experimental	O
traumatic	B-Disease
or	O
ischemic	O
lesions	O
.	O

Increase	O
of	O
Parkinson	B-Disease
disability	I-Disease
after	O
fluoxetine	B-Chemical
medication	O
.	O

Depression	B-Disease
is	O
a	O
major	O
clinical	O
feature	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

We	O
report	O
the	O
increased	O
amount	O
of	O
motor	B-Disease
disability	I-Disease
in	O
four	O
patients	O
with	O
idiopathic	B-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
after	O
exposure	O
to	O
the	O
antidepressant	B-Chemical
fluoxetine	B-Chemical
.	O

The	O
possibility	O
of	O
a	O
clinically	O
relevant	O
dopamine-antagonistic	B-Chemical
capacity	O
of	O
fluoxetine	B-Chemical
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
patients	O
must	O
be	O
considered	O
.	O

Acetaminophen-induced	B-Chemical
hypotension	B-Disease
.	O

Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O

The	O
potential	O
for	O
acetaminophen	B-Chemical
to	O
produce	O
cardiovascular	B-Disease
toxicities	I-Disease
is	O
very	O
low	O
.	O

However	O
,	O
acetaminophen	B-Chemical
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	B-Disease
,	O
including	O
hypotension	B-Disease
,	O
in	O
sensitive	O
individuals	O
.	O

This	O
article	O
describes	O
two	O
critically	B-Disease
ill	I-Disease
patients	O
in	O
whom	O
transient	O
episodes	O
of	O
hypotension	B-Disease
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	B-Chemical
.	O

Other	O
symptoms	O
of	O
allergic	B-Disease
reactions	I-Disease
were	O
not	O
clinically	O
detectable	O
.	O

The	O
hypotensive	B-Disease
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O

The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	B-Chemical
in	O
patients	O
with	O
hypotension	B-Disease
of	O
unknown	O
origin	O
.	O

Acute	O
hepatitis	B-Disease
,	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
erythroblastocytopenia	B-Disease
induced	O
by	O
ceftriaxone	B-Chemical
.	O

An	O
80-yr-old	O
man	O
developed	O
acute	O
hepatitis	B-Disease
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	B-Chemical
.	O

Although	O
the	O
transaminases	O
gradually	O
returned	O
to	O
baseline	O
after	O
withholding	O
the	O
beta	B-Chemical
lactam	I-Chemical
antibiotic	O
,	O
there	O
was	O
a	O
gradual	O
increase	O
in	O
serum	O
bilirubin	B-Chemical
and	O
a	O
decrease	O
in	O
hemoglobin	O
concentration	O
caused	O
by	O
an	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
and	O
erythroblastocytopenia	B-Disease
.	O

These	O
responded	O
to	O
systemic	O
steroids	B-Chemical
and	O
immunoglobulins	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
agents	O
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
beta	B-Chemical
lactam	I-Chemical
antibiotics	B-Drug
.	O

Adverse	O
effects	O
of	O
the	O
atypical	O
antipsychotics	O
.	O

Collaborative	O
Working	O
Group	O
on	O
Clinical	O
Trial	O
Evaluations	O
.	O

Adverse	O
effects	O
of	O
antipsychotics	O
often	O
lead	B-Drug
to	O
noncompliance	O
.	O

Thus	O
,	O
clinicians	O
should	O
address	O
patients	O
'	O
concerns	O
about	O
adverse	O
effects	O
and	O
attempt	O
to	O
choose	O
medications	O
that	O
will	O
improve	O
their	O
patients	O
'	O
quality	O
of	O
life	O
as	O
well	O
as	O
overall	O
health	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
the	O
atypical	O
antipsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventional	O
neuroleptics	O
.	O

Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects	O
,	O
including	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
,	O
tardive	B-Disease
dyskinesia	I-Disease
,	O
sedation	O
,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures	O
,	O
as	O
well	O
as	O
cardiac	O
effects	O
,	O
orthostatic	B-Disease
hypotension	I-Disease
,	O
hepatic	O
changes	O
,	O
anticholinergic	B-Drug
side	O
effects	O
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
and	O
weight	B-Disease
gain	I-Disease
.	O

The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	B-Disease
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation	O
,	O
cardiovascular	O
effects	O
,	O
anticholinergic	B-Drug
effects	O
,	O
weight	B-Disease
gain	I-Disease
,	O
sexual	B-Disease
dysfunction	I-Disease
,	O
hepatic	O
effects	O
,	O
lowered	O
seizure	B-Disease
threshold	O
(	O
primarily	O
clozapine	B-Chemical
)	O
,	O
and	O
agranulocytosis	B-Disease
(	O
clozapine	B-Chemical
only	O
)	O
.	O

Since	O
the	O
incidence	O
and	O
severity	O
of	O
specific	O
adverse	O
effects	O
differ	O
among	O
the	O
various	O
atypicals	O
,	O
the	O
clinician	O
should	O
carefully	O
consider	O
which	O
side	O
effects	O
are	O
most	O
likely	O
to	O
lead	B-Drug
to	O
the	O
individual	O
's	O
dissatisfaction	O
and	O
noncompliance	O
before	O
choosing	O
an	O
antipsychotic	O
for	O
a	O
particular	O
patient	O
.	O

Effects	O
of	O
tetrandrine	B-Chemical
and	O
fangchinoline	B-Chemical
on	O
experimental	O
thrombosis	B-Disease
in	O
mice	O
and	O
human	O
platelet	B-Disease
aggregation	I-Disease
.	O

Tetrandrine	B-Chemical
(	O
TET	B-Chemical
)	O
and	O
fangchinoline	B-Chemical
(	O
FAN	B-Chemical
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	B-Chemical
structure	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
on	O
the	O
experimental	O
thrombosis	B-Disease
induced	O
by	O
collagen	O
plus	O
epinephrine	B-Chemical
(	O
EP	B-Chemical
)	O
in	O
mice	O
,	O
and	O
platelet	B-Disease
aggregation	I-Disease
and	O
blood	B-Disease
coagulation	I-Disease
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	O
(	O
50	O
mg/kg	O
,	O
i.p	O
.	O

)	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	B-Disease
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	B-Chemical
acid	I-Chemical
(	O
ASA	B-Chemical
,	O
50	O
mg/kg	O
,	O
i.p	O
.	O

)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O

In	O
the	O
vitro	O
human	O
platelet	B-Disease
aggregations	I-Disease
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	B-Chemical
and	O
FAN	B-Chemical
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
addition	O
,	O
neither	O
TET	B-Chemical
nor	O
FAN	B-Chemical
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human-citrated	O
plasma	O
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

Gemcitabine	B-Chemical
plus	O
vinorelbine	B-Chemical
in	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
can	O
not	O
receive	O
cisplatin	B-Chemical
.	O

Oncopaz	O
Cooperative	O
Group	O
.	O

BACKGROUND	O
:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	B-Disease
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	B-Disease
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
or	O
gemcitabine	B-Chemical
(	O
GEM	B-Chemical
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20-30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-Disease
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	B-Disease
of	O
the	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
were	O
assessed	O
.	O

METHODS	O
:	O
Forty-nine	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
.	O

All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	B-Disease
.	O

Treatment	O
was	O
comprised	O
of	O
VNB	B-Chemical
,	O
25	O
mg/m	O
(	O
2	O
)	O
,	O
plus	O
GEM	B-Chemical
,	O
1000	O
mg/m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O

Patients	O
received	O
a	O
minimum	O
of	O
three	O
courses	O
unless	O
progressive	O
disease	O
was	O
detected	O
.	O

RESULTS	O
:	O
One	O
hundred	O
sixty-five	O
courses	O
were	O
administered	O
,	O
with	O
a	O
median	O
of	O
3	O
.	O

6	O
courses	O
per	O
patient	O
.	O

The	O
overall	O
response	O
rate	O
was	O
26	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
15-41	O
%	O
)	O
.	O

Two	O
patients	O
attained	O
a	O
complete	O
response	O
(	O
4	O
%	O
)	O
and	O
11	O
patients	O
(	O
22	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
improved	O
in	O
35	O
%	O
of	O
those	O
patients	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
relief	O
of	O
at	O
least	O
1	O
symptom	O
without	O
worsening	O
of	O
other	O
symptoms	O
was	O
noted	O
in	O
27	O
patients	O
(	O
55	O
%	O
)	O
.	O

The	O
median	O
time	O
to	O
progression	O
was	O
16	O
weeks	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
33	O
%	O
.	O

Toxicity	B-Disease
was	O
mild	O
.	O

Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3-4	O
neutropenia	B-Disease
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3-4	O
thrombocytopenia	B-Disease
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	B-Disease
.	O

Three	O
patients	O
with	O
severe	O
neutropenia	B-Disease
(	O
6	O
%	O
)	O
died	O
of	O
sepsis	B-Disease
.	O

The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3-4	O
neutropenia	B-Disease
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs.	O
72	O
years	O
;	O
P	O
=	O
0.047	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/=	O
75	O
years	O
.	O

This	O
age	O
group	O
had	O
an	O
increased	O
risk	O
of	O
myelosuppression	B-Disease
.	O

Therefore	O
the	O
prophylactic	O
use	O
of	O
granulocyte-colony	O
stimulating	O
factor	O
should	O
be	O
considered	O
with	O
this	O
treatment	O
.	O

New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	B-Disease
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
.	O

Warfarin-induced	B-Chemical
artery	B-Disease
calcification	I-Disease
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
treatment	O
enhance	O
the	O
extent	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	B-Chemical
to	O
inhibit	O
gamma-carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B-Disease
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	B-Disease
wall	O
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	B-Disease
calcification	O
in	O
Warfarin-treated	B-Chemical
rats	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	B-Chemical
caused	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20-day-old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B-Disease
in	O
42-day-old	O
rats	O
.	O

In	O
contrast	O
,	O
no	O
artery	B-Disease
calcification	I-Disease
could	O
be	O
detected	O
in	O
10-month-old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	B-Chemical
treatment	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin-induced	B-Chemical
artery	B-Disease
calcification	I-Disease
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20-day-old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6-g/d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	B-Chemical
produced	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
the	O
ad	O
libitum-fed	O
rats	O
but	O
no	O
detectable	O
artery	B-Disease
calcification	I-Disease
in	O
the	O
restricted-diet	O
,	O
growth-inhibited	O
group	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B-Disease
calcification	I-Disease
and	O
growth	O
status	O
can	O
not	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	B-Chemical
and	O
susceptibility	O
to	O
artery	B-Disease
calcification	I-Disease
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	B-Chemical
in	O
young	O
,	O
ad	O
libitum-fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin-induced	B-Chemical
artery	B-Disease
calcification	I-Disease
,	O
ie	O
,	O
the	O
10-month-old	O
rats	O
and	O
the	O
restricted-diet	O
,	O
growth-inhibited	O
young	O
rats	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin-induced	B-Chemical
artery	B-Disease
calcification	I-Disease
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	B-Chemical
levels	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	B-Chemical
D	I-Chemical
and	O
Warfarin	B-Chemical
in	O
artery	B-Disease
calcification	I-Disease
.	O

High	O
doses	O
of	O
vitamin	B-Chemical
D	I-Chemical
are	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

High	O
doses	O
of	O
the	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
Warfarin	B-Chemical
are	O
also	O
known	O
to	O
cause	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	B-Chemical
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	B-Disease
in	O
the	O
media	O
of	O
vitamin	B-Chemical
D-treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	B-Drug
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	B-Disease
calcification	I-Disease
through	O
its	O
effect	O
on	O
serum	O
calcium	B-Drug
.	O

Because	O
Warfarin	B-Drug
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	B-Drug
produced	O
by	O
vitamin	B-Chemical
D	I-Chemical
,	O
the	O
synergy	O
between	O
Warfarin	B-Drug
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	B-Drug
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	O
treated	O
with	O
vitamin	O
D	O
plus	O
Warfarin	B-Drug
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma-carboxylated	O
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma-carboxyglutamate	O
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	O
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	O
sites	O
.	O

Antidepressant-induced	B-Chemical
mania	B-Disease
in	O
bipolar	B-Disease
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	B-Disease
associated	O
with	O
antidepressants	B-Chemical
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	B-Disease
depression	I-Disease
.	O

METHOD	O
:	O
The	O
response	O
of	O
44	O
patients	O
meeting	O
DSM-IV	O
criteria	O
for	O
bipolar	B-Disease
disorder	I-Disease
to	O
naturalistic	O
treatment	O
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery-Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech-Rafaelson	O
Mania	O
Rating	O
Scale	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	B-Disease
or	O
hypomanic	B-Disease
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM-IV	B-Disease
bipolar	I-Disease
I	B-Disease
vs.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
,	O
type	O
of	O
antidepressant	B-Chemical
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs.	O
antidepressant	B-Chemical
drugs	B-Drug
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	B-Chemical
reuptake	I-Chemical
inhibitors	I-Chemical
[	O
SSRIs	B-Chemical
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	B-Chemical
vs.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi-structured	O
Affective	O
Temperament	O
Interview	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	B-Disease
or	O
mania	B-Disease
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	B-Chemical
[	O
8/33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	B-Disease
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	B-Disease
episodes	O
.	O

Sex	O
,	O
age	O
,	O
diagnosis	O
(	O
bipolar	B-Disease
I	I-Disease
vs.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

The	O
incidence	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patients	O
receiving	O
an	O
anticonvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stabilizer	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	B-Chemical
(	O
15	O
%	O
,	O
4/26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	B-Chemical
(	O
44	O
%	O
,	O
8/18	O
;	O
p	O
=	O
.04	O
)	O
.	O

The	O
number	O
of	O
previous	O
manic	B-Disease
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.008	O
)	O
.	O

CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	B-Chemical
therapy	O
may	O
be	O
reduced	O
by	O
lithium	B-Chemical
treatment	O
.	O

Particular	O
attention	O
should	O
be	O
paid	O
to	O
patients	O
with	O
a	O
hyperthymic	O
temperament	O
,	O
who	O
have	O
a	O
greater	O
risk	O
of	O
mood	O
switches	O
.	O

Caffeine-induced	B-Chemical
cardiac	B-Disease
arrhythmia	I-Disease
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O

We	O
describe	O
a	O
25-year-old	O
woman	O
with	O
pre-existing	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
who	O
developed	O
intractable	O
ventricular	B-Disease
fibrillation	I-Disease
after	O
consuming	O
a	O
``	O
natural	O
energy	O
''	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	B-Chemical
.	O

This	O
case	O
highlights	O
the	O
need	O
for	O
adequate	O
labelling	O
and	O
regulation	O
of	O
such	O
products	O
.	O

Bladder	O
retention	B-Disease
of	I-Disease
urine	I-Disease
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	B-Chemical
:	O
2	O
case	O
reports	O
.	O

Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	O
the	O
stress	O
and	O
pain	B-Disease
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O

Fentanyl	B-Chemical
,	O
an	O
opioid	O
analgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	B-Chemical
administration	O
include	O
chest	B-Disease
wall	I-Disease
rigidity	I-Disease
,	O
hypotension	B-Disease
,	O
respiratory	B-Disease
depression	I-Disease
,	O
and	O
bradycardia	B-Disease
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	B-Disease
bladder	I-Disease
retention	I-Disease
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	B-Disease
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	B-Chemical
are	O
reported	O
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B-Disease
and	O
elevates	O
plasma	O
lactate	B-Chemical
in	O
transgenic	O
AIDS	B-Disease
mice	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	B-Disease
(	O
CM	B-Disease
)	O
and	O
in	O
elevated	O
plasma	O
lactate	B-Chemical
(	O
LA	B-Chemical
)	O
in	O
AIDS	B-Disease
through	O
mechanisms	O
of	O
mitochondrial	B-Disease
dysfunction	I-Disease
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8-week-old	O
hemizygous	O
transgenic	O
AIDS	B-Disease
mice	O
(	O
NL4-3Delta	O
gag/pol	O
;	O
TG	O
)	O
and	O
wild-type	O
FVB/n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	B-Chemical
,	O
lamivudine	B-Chemical
,	O
and	O
indinavir	B-Chemical
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	B-Disease
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	B-Chemical
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	B-Chemical
.	O

Myocardial	O
histologic	O
features	O
were	O
analyzed	O
semiquantitatively	O
and	O
results	O
were	O
confirmed	O
by	O
transmission	O
electron	O
microscopy	O
.	O

After	O
35	O
days	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
,	O
left	O
ventricular	O
mass	O
increased	O
160	O
%	O
by	O
echocardiography	O
.	O

Molecularly	O
,	O
ANF	O
mRNA	O
increased	O
250	O
%	O
and	O
SERCA2	O
mRNA	O
decreased	O
57	O
%	O
.	O

Biochemically	O
,	O
LA	B-Chemical
was	O
elevated	O
(	O
8.5	O
+/-	O
2.0	O
mM	O
)	O
.	O

Pathologically	O
,	O
granular	O
cytoplasmic	O
changes	O
were	O
found	O
in	O
cardiac	O
myocytes	O
,	O
indicating	O
enlarged	O
,	O
damaged	O
mitochondria	O
.	O

Findings	O
were	O
confirmed	O
ultrastructurally	O
.	O

No	O
changes	O
were	O
found	O
in	O
other	O
cohorts	O
.	O

After	O
10	O
days	O
,	O
only	O
ANF	O
was	O
elevated	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
.	O

Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	B-Disease
with	O
elevated	O
LA	B-Chemical
in	O
AIDS	B-Disease
transgenic	O
mice	O
.	O

Oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
.	O

BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	B-Chemical
included	O
in	O
third-generation	O
(	O
i.e.	O
,	O
desogestrel	B-Chemical
or	O
gestodene	B-Chemical
)	O
and	O
second-generation	O
(	O
i.e.	O
,	O
levonorgestrel	B-Chemical
)	O
oral	B-Chemical
contraceptives	I-Chemical
,	O
the	O
dose	O
of	O
estrogen	B-Chemical
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population-based	O
,	O
case-control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	B-Disease
infarction	I-Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	B-Disease
infarction	I-Disease
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

Subjects	O
supplied	O
information	O
on	O
oral-contraceptive	B-Chemical
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	O
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	B-Disease
infarction	I-Disease
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	B-Chemical
contraceptive	I-Chemical
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2.0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
2.8	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
was	O
2.5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
4.1	O
)	O
among	O
women	O
who	O
used	O
second-generation	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
1.3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.7	O
to	O
2.5	O
)	O
among	O
those	O
who	O
used	O
third-generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

Among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
,	O
the	O
odds	O
ratio	O
was	O
2.1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
3.0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1.9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.6	O
to	O
5.5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
increased	O
among	O
women	O
who	O
used	O
second-generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third-generation	O
oral	B-Chemical
contraceptives	I-Chemical
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second-generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O

Effects	O
of	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine-induced	B-Chemical
locomotor	B-Disease
hyperactivity	I-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B-Disease
hyperactivity	I-Disease
induced	O
by	O
cocaine	B-Chemical
in	O
rats	O
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
an	O
antagonist	O
of	O
5-HT1B	O
receptors	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
an	O
agonist	O
of	O
5-HT1B	O
receptors	O
)	O
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0.1-10	O
microg/side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0.1-10	O
microg/side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Systemic	O
cocaine	B-Chemical
(	O
10	O
mg/kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats	O
.	O

GR	B-Chemical
55562	I-Chemical
(	O
0.1-10	O
microg/side	O
)	O
,	O
administered	O
intra-accumbens	O
shell	O
prior	O
to	O
cocaine	B-Chemical
,	O
dose-dependently	O
attenuated	O
the	O
psychostimulant-induced	O
locomotor	B-Disease
hyperactivity	I-Disease
.	O

Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	O
with	O
GR	B-Chemical
55562	I-Chemical
into	O
the	O
accumbens	O
core	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	B-Chemical
,	O
CP	B-Chemical
93129	I-Chemical
(	O
0.1-10	O
microg/side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	B-Chemical
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg/side	O
of	O
the	O
agonist	O
.	O

The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra-accumbens	O
shell	O
treatment	O
with	O
GR	B-Chemical
55562	I-Chemical
(	O
1	O
microg/side	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	B-Chemical
induced	O
hyperlocomotion	B-Disease
is	O
modified	O
by	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5-HT1B	O
receptor	O
antagonist	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agonist	O
(	O
CP	B-Chemical
93129	I-Chemical
)	O
,	O
respectively	O
.	O

In	O
other	O
words	O
,	O
the	O
present	O
results	O
suggest	O
that	O
the	O
accumbal	O
shell	O
5-HT1B	O
receptors	O
play	O
a	O
permissive	O
role	O
in	O
the	O
behavioural	O
response	O
to	O
the	O
psychostimulant	O
.	O

Ticlopidine-induced	B-Chemical
cholestatic	B-Disease
hepatitis	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine-induced	B-Chemical
cholestatic	B-Disease
hepatitis	I-Disease
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	B-Chemical
hepatitis	B-Chemical
after	O
receiving	O
ticlopidine	B-Drug
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow-up	O
period	O
.	O

T-cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	B-Drug
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O

DISCUSSION	O
:	O
Cholestatic	O
hepatitis	I-Disease
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	B-Drug
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

Our	O
patients	O
developed	O
jaundice	O
following	O
treatment	O
with	O
ticlopidine	B-Drug
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B-Disease
hepatitis	O
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	B-Drug
.	O

Hepatitis	O
may	O
develop	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	B-Drug
and	O
may	O
run	O
a	O
prolonged	O
course	O
,	O
but	O
complete	O
remission	O
was	O
observed	O
in	O
all	O
reported	O
cases	O
.	O

An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	B-Drug
event	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	B-Drug
.	O

The	O
mechanisms	O
of	O
this	O
ticlopidine-induced	O
cholestasis	O
are	O
unclear	O
.	O

Immune	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
drug	B-Drug
's	O
hepatotoxicity	O
,	O
as	O
suggested	O
by	O
the	O
T-cell	O
stimulation	O
study	O
reported	O
here	O
.	O

CONCLUSIONS	O
:	O
Cholestatic	O
hepatitis	O
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ticlopidine	B-Drug
that	O
may	O
be	O
immune	O
mediated	O
.	O

Patients	O
receiving	O
the	O
drug	B-Drug
should	O
be	O
monitored	O
with	O
liver	O
function	O
tests	O
along	O
with	O
complete	O
blood	O
cell	O
counts	O
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-Drug
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	O
.	O

Epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	B-Chemical
aminonucleoside-induced	O
nephrotic	O
syndrome	O
.	O

In	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
urinary	O
sodium	B-Chemical
excretion	O
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
leading	O
to	O
salt	O
retention	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O

The	O
rate-limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	B-Chemical
transport	O
is	O
the	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

The	O
time	O
courses	O
of	O
urinary	O
sodium	B-Chemical
excretion	O
,	O
plasma	O
aldosterone	B-Chemical
concentration	O
and	O
proteinuria	B-Disease
were	O
studied	O
in	O
male	O
Sprague-Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	B-Chemical
or	O
vehicle	O
.	O

The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNAs	O
were	O
determined	O
in	O
kidneys	O
from	O
these	O
rats	O
by	O
real-time	O
quantitative	O
TaqMan	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
proteins	O
by	O
Western	O
blot	O
.	O

The	O
kinetics	O
of	O
urinary	O
sodium	B-Chemical
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	B-Disease
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

Sodium	B-Chemical
retention	O
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	B-Chemical
injection	O
.	O

A	O
significant	O
up-regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	B-Chemical
retention	O
on	O
days	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down-regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	B-Chemical
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	B-Chemical
excretion	O
to	O
control	O
values	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN-induced	B-Chemical
sodium	B-Chemical
retention	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN-induced	B-Chemical
nephrotic	B-Disease
syndrome	I-Disease
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	B-Chemical
after	O
day	O
3	O
.	O

NO-induced	B-Chemical
migraine	B-Disease
attack	O
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	B-Chemical
gene-related	I-Chemical
peptide	I-Chemical
(	O
CGRP	B-Chemical
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	B-Chemical
release	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	B-Chemical
gene-related	I-Chemical
peptide	I-Chemical
(	O
CGRP	B-Chemical
)	O
concentration	O
and	O
platelet	O
serotonin	B-Chemical
(	O
5-hydroxytriptamine	B-Chemical
,	O
5-HT	B-Chemical
)	O
content	O
during	O
the	O
immediate	O
headache	B-Disease
and	O
the	O
delayed	O
genuine	O
migraine	B-Disease
attack	O
provoked	O
by	O
nitroglycerin	B-Chemical
.	O

Fifteen	O
female	O
migraineurs	B-Disease
(	I-Disease
without	I-Disease
aura	I-Disease
)	I-Disease
and	O
eight	O
controls	O
participated	O
in	O
the	O
study	O
.	O

Sublingual	O
nitroglycerin	B-Chemical
(	O
0.5	O
mg	O
)	O
was	O
administered	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	B-Chemical
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	B-Disease
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
)	O
.	O

In	O
those	O
subjects	O
who	O
had	O
no	O
migraine	B-Disease
attack	O
(	O
11	O
subjects	O
)	O
a	O
similar	O
time	O
schedule	O
was	O
used	O
.	O

Plasma	O
CGRP	B-Chemical
concentration	O
increased	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
during	O
the	O
migraine	B-Disease
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	B-Disease
.	O

In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positive	O
correlations	O
with	O
migraine	B-Disease
headache	B-Disease
intensity	O
(	O
P	O
<	O
0.001	O
)	O
.	O

However	O
,	O
plasma	O
CGRP	B-Chemical
concentrations	O
failed	O
to	O
change	O
during	O
immediate	O
headache	B-Disease
and	O
in	O
the	O
subjects	O
with	O
no	O
migraine	B-Disease
attack	O
.	O

Basal	O
CGRP	B-Chemical
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5-HT	B-Chemical
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	B-Disease
attack	O
.	O

Platelet	O
serotonin	B-Chemical
content	O
decreased	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
after	O
nitroglycerin	B-Chemical
in	O
subjects	O
with	O
no	O
migraine	B-Disease
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	B-Disease
attack	O
.	O

In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	B-Chemical
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	B-Disease
headache	B-Disease
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	B-Chemical
and	O
migraine	B-Disease
.	O

In	O
contrast	O
,	O
serotonin	B-Chemical
release	O
from	O
platelets	O
does	O
not	O
provoke	O
migraine	B-Disease
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	B-Disease
and	O
the	O
concomitant	O
CGRP	B-Chemical
release	O
in	O
this	O
model	O
.	O

Coronary	B-Disease
aneurysm	I-Disease
after	O
implantation	O
of	O
a	O
paclitaxel-eluting	B-Chemical
stent	O
.	O

Formation	O
of	O
coronary	B-Disease
aneurysm	I-Disease
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug-eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	B-Disease
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	B-Disease
or	O
vessel	B-Disease
rupture	I-Disease
.	O

We	O
present	O
a	O
43-year-old	O
man	O
who	O
developed	O
a	O
coronary	B-Disease
aneurysm	I-Disease
in	O
the	O
right	O
coronary	O
artery	O
6	O
months	O
after	O
receiving	O
a	O
paclitaxel-eluting	B-Chemical
stent	O
.	O

The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	B-Disease
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O

Angiography	O
and	O
intracoronary	O
ultrasound	O
demonstrated	O
lack	O
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	O
in	O
a	O
15-mm	O
long	O
segment	O
with	O
maximal	O
aneurysm	B-Disease
diameter	O
of	O
6.0	O
mm	O
.	O

The	O
patient	O
was	O
successfully	O
treated	O
with	O
a	O
graft	O
stent	O
.	O

Behavioral	O
effects	O
of	O
urotensin-II	B-Chemical
centrally	O
administered	O
in	O
mice	O
.	O

Urotensin-II	B-Chemical
(	O
U-II	B-Chemical
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Intracerebroventricular	O
(	O
i.c.v	O
.	O

)	O
injection	O
of	O
U-II	B-Chemical
causes	O
hypertension	B-Disease
and	O
bradycardia	B-Disease
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion	O
.	O

However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U-II	B-Chemical
have	O
received	O
little	O
attention	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
i.c.v	O
.	O

injections	O
of	O
U-II	B-Chemical
on	O
behavioral	O
,	O
metabolic	O
,	O
and	O
endocrine	O
responses	O
in	O
mice	O
.	O

Administration	O
of	O
graded	O
doses	O
of	O
U-II	B-Chemical
(	O
1-10,000	O
ng/mouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose-dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole-board	O
test	O
;	O
(	O
2	O
)	O
a	O
dose-dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black-and-white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus-maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose-dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced-swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O

Intracerebroventricular	O
injection	O
of	O
U-II	B-Chemical
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1,000	O
ng/mouse	O
,	O
water	O
intake	O
at	O
doses	O
of	O
100-10,000	O
ng/mouse	O
,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10,000	O
ng/mouse	O
.	O

Whatever	O
was	O
the	O
dose	O
,	O
the	O
central	O
administration	O
of	O
U-II	B-Chemical
had	O
no	O
effect	O
on	O
body	O
temperature	O
,	O
nociception	O
,	O
apomorphine-induced	B-Chemical
penile	B-Disease
erection	I-Disease
and	O
climbing	O
behavior	O
,	O
and	O
stress-induced	O
plasma	O
corticosterone	B-Chemical
level	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U-II	B-Chemical
at	O
doses	O
of	O
1-10,000	O
ng/mouse	O
induces	O
anxiogenic-	O
and	O
depressant-like	O
effects	O
in	O
mouse	O
.	O

These	O
data	O
suggest	O
that	O
U-II	B-Chemical
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-Disease
disorders	I-Disease
.	O

Recurrent	O
dysphonia	B-Disease
and	O
acitretin	B-Chemical
.	O

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	B-Disease
while	O
she	O
was	O
treated	O
by	O
acitretin	B-Chemical
.	O

Her	O
symptoms	O
totally	O
regressed	O
after	O
drug	B-Drug
withdrawal	O
and	O
reappeared	O
when	O
acitretin	B-Chemical
was	O
reintroduced	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
acitretin-induced	B-Chemical
dysphonia	B-Disease
.	O

This	O
effect	O
may	O
be	O
related	O
to	O
the	O
pharmacological	O
effect	O
of	O
this	O
drug	B-Drug
on	O
mucous	O
membranes	O
.	O

Pharmacological	O
modulation	O
of	O
pain-related	B-Disease
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans	O
.	O

Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
central	O
sensitization	O
)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	B-Disease
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	B-Disease
injury	I-Disease
(	O
secondary	B-Disease
hyperalgesia	I-Disease
)	O
.	O

Secondary	B-Disease
hyperalgesia	I-Disease
shares	O
clinical	O
characteristics	O
with	O
neurogenic	B-Disease
hyperalgesia	I-Disease
in	O
patients	O
with	O
neuropathic	B-Disease
pain	I-Disease
.	O

Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	B-Disease
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	B-Chemical
,	O
a	O
drug	B-Drug
effective	O
in	O
neuropathic	B-Disease
pain	I-Disease
patients	O
,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states	O
.	O

Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	O
,	O
we	O
studied	O
the	O
gabapentin-induced	B-Chemical
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin-induced	B-Chemical
secondary	B-Disease
hyperalgesia	I-Disease
.	O

The	O
dose	O
of	O
gabapentin	B-Chemical
was	O
1,800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administration	O
.	O

We	O
found	O
that	O
(	O
i	O
)	O
gabapentin	B-Chemical
reduced	O
the	O
activations	O
in	O
the	O
bilateral	O
operculoinsular	O
cortex	O
,	O
independently	O
of	O
the	O
presence	O
of	O
central	O
sensitization	O
;	O
(	O
ii	O
)	O
gabapentin	B-Chemical
reduced	O
the	O
activation	O
in	O
the	O
brainstem	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
(	O
iii	O
)	O
gabapentin	B-Chemical
suppressed	O
stimulus-induced	O
deactivations	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
this	O
effect	O
was	O
more	O
robust	O
than	O
the	O
effect	O
on	O
brain	O
activation	O
.	O

The	O
observed	O
drug-induced	O
effects	O
were	O
not	O
due	O
to	O
changes	O
in	O
the	O
baseline	O
fMRI	O
signal	O
.	O

These	O
findings	O
indicate	O
that	O
gabapentin	B-Chemical
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	B-Chemical
is	O
more	O
effective	O
in	O
modulating	O
nociceptive	O
transmission	O
when	O
central	O
sensitization	O
is	O
present	O
.	O

MDMA	B-Chemical
polydrug	O
users	O
show	O
process-specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-Disease
social	I-Disease
and	I-Disease
emotional	I-Disease
judgement	I-Disease
processes	I-Disease
.	O

In	O
recent	O
years	O
working	O
memory	B-Disease
deficits	I-Disease
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	B-Chemical
(	O
3,4-methylenedioxymethamphetamine	B-Chemical
,	O
ecstasy	B-Chemical
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	B-Chemical
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
``	O
prefrontal	O
''	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

Fifteen	O
polydrug	O
ecstasy	B-Chemical
users	O
and	O
15	O
polydrug	O
non-ecstasy	B-Chemical
user	O
controls	O
completed	O
a	O
general	O
drug	B-Drug
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O

Compared	O
with	O
MDMA-free	B-Chemical
polydrug	O
controls	O
,	O
MDMA	B-Chemical
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	B-Drug
use	O
.	O

These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-Chemical
use	O
.	O

Severe	O
citrate	B-Chemical
toxicity	B-Disease
complicating	O
volunteer	O
apheresis	O
platelet	O
donation	O
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
citrate	B-Chemical
toxicity	B-Disease
during	O
volunteer	O
donor	O
apheresis	O
platelet	O
collection	O
.	O

The	O
donor	O
was	O
a	O
40-year-old	O
female	O
,	O
first-time	O
apheresis	O
platelet	O
donor	O
.	O

Past	O
medical	O
history	O
was	O
remarkable	O
for	O
hypertension	B-Disease
,	O
hyperlipidemia	B-Disease
,	O
and	O
depression	B-Disease
.	O

Reported	O
medications	O
included	O
bumetanide	B-Chemical
,	O
pravastatin	B-Chemical
,	O
and	O
paroxetine	B-Chemical
.	O

Thirty	O
minutes	O
from	O
the	O
start	O
of	O
the	O
procedure	O
,	O
the	O
donor	O
noted	O
tingling	O
around	O
the	O
mouth	O
,	O
hands	O
,	O
and	O
feet	O
.	O

She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	B-Disease
.	O

Empirical	O
treatment	O
with	O
intravenous	O
calcium	B-Chemical
gluconate	I-Chemical
was	O
initiated	O
,	O
and	O
muscle	B-Disease
contractions	I-Disease
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes	O
.	O

The	O
events	O
are	O
consistent	O
with	O
a	O
severe	O
reaction	O
to	O
calcium	B-Chemical
chelation	O
by	O
sodium	B-Chemical
citrate	I-Chemical
anticoagulant	B-Drug
resulting	O
in	O
symptomatic	O
systemic	O
hypocalcemia	B-Disease
.	O

Upon	O
additional	O
retrospective	O
analysis	O
,	O
it	O
was	O
noted	O
that	O
bumetanide	B-Chemical
is	O
a	O
loop	B-Chemical
diuretic	I-Chemical
that	O
may	O
cause	O
significant	O
hypocalcemia	B-Disease
.	O

We	O
conclude	O
that	O
careful	O
screening	O
for	O
medications	O
and	O
underlying	O
conditions	O
predisposing	O
to	O
hypocalcemia	B-Disease
is	O
recommended	O
to	O
help	O
prevent	O
severe	O
reactions	O
due	O
to	O
citrate	B-Chemical
toxicity	B-Disease
.	O

Laboratory	O
measurement	O
of	O
pre-procedure	O
serum	O
calcium	B-Chemical
levels	O
in	O
selected	O
donors	O
may	O
identify	O
cases	O
requiring	O
heightened	O
vigilance	O
.	O

The	O
case	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
preparedness	O
for	O
managing	O
rare	O
but	O
serious	O
reactions	O
in	O
volunteer	O
apheresis	O
blood	O
donors	O
.	O

Proteinuria	B-Disease
after	O
conversion	O
to	O
sirolimus	B-Chemical
in	O
renal	O
transplant	O
recipients	O
.	O

Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppressive	O
agent	O
.	O

More	O
recently	O
,	O
proteinuria	B-Disease
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolimus	B-Chemical
therapy	O
,	O
although	O
the	O
mechanism	O
has	O
remained	O
unclear	O
.	O

We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients	O
,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	B-Disease
after	O
SRL	B-Chemical
conversion	O
.	O

The	O
patient	O
cohort	O
(	O
14	O
men	O
,	O
11	O
women	O
)	O
was	O
treated	O
with	O
SRL	B-Chemical
as	O
conversion	O
therapy	O
,	O
due	O
to	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
(	O
CAN	B-Disease
)	O
(	O
n	O
=	O
15	O
)	O
neoplasia	B-Disease
(	O
n	O
=	O
8	O
)	O
;	O
Kaposi	B-Disease
's	I-Disease
sarcoma	I-Disease
,	O
Four	O
skin	B-Disease
cancers	I-Disease
,	O
One	O
intestinal	B-Disease
tumors	I-Disease
,	O
One	O
renal	B-Disease
cell	I-Disease
carsinom	I-Disease
)	O
or	O
BK	O
virus	O
nephropathy	B-Disease
(	O
n	O
=	O
2	O
)	O
.	O

SRL	B-Chemical
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+/-	O
42	O
(	O
15	O
to	O
163	O
)	O
months	O
after	O
transplantation	O
.	O

Mean	O
follow-up	O
on	O
SRL	B-Chemical
therapy	O
was	O
20	O
+/-	O
12	O
(	O
6	O
to	O
43	O
)	O
months	O
.	O

Proteinuria	B-Disease
increased	O
from	O
0.445	O
(	O
0	O
to	O
1.5	O
)	O
g/d	O
before	O
conversion	O
to	O
3.2	O
g/dL	O
(	O
0.2	O
to	O
12	O
)	O
after	O
conversion	O
(	O
P	O
=	O
0.001	O
)	O
.	O

Before	O
conversion	O
8	O
(	O
32	O
%	O
)	O
patients	O
had	O
no	O
proteinuria	B-Disease
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	B-Disease
.	O

In	O
28	O
%	O
of	O
patients	O
proteinuria	B-Disease
remained	O
unchanged	O
,	O
whereas	O
it	O
increased	O
in	O
68	O
%	O
of	O
patients	O
.	O

In	O
40	O
%	O
it	O
increased	O
by	O
more	O
than	O
100	O
%	O
.	O

Twenty-eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	B-Disease
to	O
the	O
nephrotic	B-Disease
range	O
.	O

Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes	O
:	O
One	O
membranoproliferative	B-Disease
glomerulopathy	I-Disease
and	O
interstitial	B-Disease
nephritis	I-Disease
.	O

These	O
patients	O
showed	O
persistently	O
good	O
graft	O
function	O
.	O

Serum	O
creatinine	B-Chemical
values	O
did	O
not	O
change	O
significantly	O
:	O
1.98	O
+/-	O
0.8	O
mg/dL	O
before	O
SRL	B-Chemical
therapy	O
and	O
2.53	O
+/-	O
1.9	O
mg/dL	O
at	O
last	O
follow-up	O
(	O
P	O
=	O
.14	O
)	O
.	O

Five	O
grafts	O
were	O
lost	O
and	O
the	O
patients	O
returned	O
to	O
dialysis	O
.	O

Five	O
patients	O
displayed	O
CAN	B-Disease
and	O
Kaposi	B-Disease
's	I-Disease
sarcoma	I-Disease
.	O

Mean	O
urinary	O
protein	O
of	O
patients	O
who	O
returned	O
to	O
dialysis	O
was	O
1.26	O
(	O
0.5	O
to	O
3.5	O
)	O
g/d	O
before	O
and	O
4.7	O
(	O
3	O
to	O
12	O
)	O
g/d	O
after	O
conversion	O
(	O
P	O
=	O
.01	O
)	O
.	O

Mean	O
serum	O
creatinine	B-Chemical
level	O
before	O
conversion	O
was	O
2.21	O
mg/dL	O
and	O
thereafter	O
,	O
4.93	O
mg/dL	O
(	O
P	O
=	O
.02	O
)	O
.	O

Heavy	O
proteinuria	B-Disease
was	O
common	O
after	O
the	O
use	O
of	O
SRL	B-Chemical
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation	O
.	O

Therefore	O
,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	B-Disease
and	O
proteinuria	B-Disease
.	O

The	O
possibility	O
of	O
de	O
novo	O
glomerular	O
pathology	O
under	O
SRL	B-Chemical
treatment	O
requires	O
further	O
investigation	O
by	O
renal	O
biopsy	O
.	O

In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide-induced	B-Chemical
cystitis	B-Disease
in	O
the	O
rat	O
.	O

In	O
cyclophosphamide-induced	B-Chemical
cystitis	B-Disease
in	O
the	O
rat	O
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O

Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B-Disease
was	O
presently	O
investigated	O
.	O

Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide-pretreated	B-Chemical
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	O
,	O
adrenergic	O
and	O
purinergic	O
receptor	O
antagonists	O
.	O

Generally	O
,	O
atropine	B-Chemical
reduced	O
contractions	O
,	I-Chemical
but	O
in	O
contrast	O
to	O
controls	O
,	I-Chemical
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1-5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O

In	O
both	O
types	O
,	I-Chemical
purinoceptor	O
desensitization	O
with	O
alpha	B-Chemical
,	I-Chemical
beta-methylene	O
adenosine-5'-triphosphate	O
(	O
alpha	B-Chemical
,	I-Chemical
beta-meATP	O
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O

The	O
muscarinic	O
receptor	O
antagonists	O
atropine	B-Chemical
,	O
4-diphenylacetoxy-N-methylpiperidine	B-Chemical
(	O
4-DAMP	B-Chemical
)	O
(	O
'M	O
(	O
1	O
)	O
/M	O
(	O
3	O
)	O
/M	O
(	O
5	O
)	O
-selective	O
'	O
)	O
,	O
methoctramine	B-Chemical
(	O
'M	O
(	O
2	O
)	O
-selective	O
'	O
)	O
and	O
pirenzepine	B-Chemical
(	O
'M	O
(	O
1	O
)	O
-selective	O
'	O
)	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation-evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O

4-DAMP	B-Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	B-Chemical
and	O
pirenzepine	B-Chemical
.	O

In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	O
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation-evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	B-Chemical
and	O
4-DAMP	B-Chemical
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O

In	O
contrast	O
to	O
controls	O
,	O
methoctramine	B-Chemical
increased	O
--	O
instead	O
of	O
decreased	O
--	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O

While	O
contractions	O
to	O
carbachol	B-Chemical
and	O
ATP	B-Chemical
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	B-Chemical
response	O
,	O
isoprenaline-induced	B-Chemical
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O

Thus	O
,	O
in	O
cystitis	B-Disease
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O

While	O
postjunctional	O
beta-adrenoceptor-mediated	O
relaxations	O
are	O
reduced	O
,	O
effects	O
by	O
prejunctional	O
inhibitory	O
muscarinic	O
receptors	O
may	O
be	O
increased	O
.	O

Associations	O
between	O
use	O
of	O
benzodiazepines	B-Chemical
or	O
related	O
drugs	B-Drug
and	O
health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
:	O
a	O
non-randomised	O
clinical	O
study	O
in	O
the	O
elderly	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
associations	O
between	O
the	O
use	O
of	O
benzodiazepines	B-Chemical
or	O
related	O
drugs	B-Drug
(	O
BZDs/RDs	B-Chemical
)	O
and	O
health	O
,	O
functional	O
abilities	O
and	O
cognitive	O
function	O
in	O
the	O
elderly	O
.	O

METHODS	O
:	O
A	O
non-randomised	O
clinical	O
study	O
of	O
patients	O
aged	O
>	O
or	O
=65	O
years	O
admitted	O
to	O
acute	O
hospital	O
wards	O
during	O
1	O
month	O
.	O

164	O
patients	O
(	O
mean	O
age	O
+/-	O
standard	O
deviation	O
[	O
SD	O
]	O
81.6	O
+/-	O
6.8	O
years	O
)	O
were	O
admitted	O
.	O

Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs/RDs	B-Chemical
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non-users	O
.	O

Cognitive	O
ability	O
was	O
assessed	O
by	O
the	O
Mini-Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
.	O

Patients	O
scoring	O
>	O
or	O
=20	O
MMSE	O
sum	O
points	O
were	O
interviewed	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
symptoms	O
and	O
functional	O
abilities	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

Data	O
on	O
use	O
of	O
BZDs/RDs	B-Chemical
before	O
admission	O
,	O
current	O
medications	O
and	O
discharge	O
diagnoses	O
were	O
collected	O
from	O
medical	O
records	O
.	O

Health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
were	O
compared	O
between	O
BZD/RD	O
users	O
and	O
non-users	O
,	O
and	O
adjustments	O
were	O
made	O
for	O
confounding	O
variables	O
.	O

The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	B-Chemical
,	O
temazepam	B-Chemical
and	O
zopiclone	B-Chemical
were	O
analysed	O
.	O

RESULTS	O
:	O
The	O
mean	O
+/-	O
SD	O
duration	O
of	O
BZD/RD	O
use	O
was	O
7	O
+/-	O
7	O
years	O
(	O
range	O
1-31	O
)	O
.	O

Two	O
or	O
three	O
BZDs/RDs	B-Chemical
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
users	O
(	O
n	O
=	O
20	O
)	O
.	O

Long-term	O
use	O
of	O
these	O
drugs	B-Drug
was	O
associated	O
with	O
female	O
sex	O
and	O
use	O
of	O
a	O
higher	O
number	O
of	O
drugs	B-Drug
with	O
effects	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	O
dementia	B-Disease
.	O

After	O
adjustment	O
for	O
these	O
variables	O
as	O
confounders	O
,	O
use	O
of	O
BZDs/RDs	B-Chemical
was	O
not	O
associated	O
with	O
cognitive	O
function	O
as	O
measured	O
by	O
the	O
MMSE	O
.	O

However	O
,	O
use	O
of	O
BZDs/RDs	B-Chemical
was	O
associated	O
with	O
dizziness	B-Disease
,	O
inability	B-Disease
to	I-Disease
sleep	I-Disease
after	O
awaking	O
at	O
night	O
and	O
tiredness	B-Disease
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	B-Disease
symptoms	I-Disease
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O

Use	O
of	O
BZDs/RDs	B-Chemical
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night-time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O

A	O
higher	O
residual	O
serum	O
concentration	O
of	O
temazepam	B-Chemical
correlated	O
with	O
a	O
lower	O
MMSE	O
sum	O
score	O
after	O
adjustment	O
for	O
confounding	O
variables	O
.	O

CONCLUSIONS	O
:	O
Long-term	O
use	O
and	O
concomitant	O
use	O
of	O
more	O
than	O
one	O
BZD/RD	O
were	O
common	O
in	O
elderly	O
patients	O
hospitalised	O
because	O
of	O
acute	O
illnesses	O
.	O

Long-term	O
use	O
was	O
associated	O
with	O
daytime	O
and	O
night-time	O
symptoms	O
indicative	O
of	O
poorer	O
health	O
and	O
potentially	O
caused	O
by	O
the	O
adverse	O
effects	O
of	O
these	O
drugs	B-Drug
.	O

Acute	O
vocal	B-Disease
fold	I-Disease
palsy	I-Disease
after	O
acute	O
disulfiram	B-Chemical
intoxication	O
.	O

Acute	O
peripheral	B-Disease
neuropathy	I-Disease
caused	O
by	O
a	O
disulfiram	B-Chemical
overdose	B-Disease
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	B-Disease
fold	I-Disease
palsy	I-Disease
.	O

A	O
49-year-old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	B-Disease
,	O
lancinating	O
pain	B-Disease
,	O
sensory	B-Disease
loss	I-Disease
,	O
and	O
paresthesia	B-Disease
of	O
the	O
distal	O
limbs	O
.	O

One	O
month	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	B-Chemical
(	O
130	O
tablets	O
of	O
ALCOHOL	B-Chemical
STOP	O
TAB	O
,	O
Shin-Poong	O
Pharm	O
.	O

Co.	O
,	O
Ansan	O
,	O
Korea	O
)	O
in	O
a	O
suicide	O
attempt	O
.	O

She	O
was	O
not	O
an	O
alcoholic	O
.	O

For	O
the	O
first	O
few	O
days	O
after	O
ingestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mild	O
to	O
moderate	O
ataxia	B-Disease
and	O
giddiness	B-Disease
.	O

She	O
noticed	O
hoarseness	B-Disease
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state	O
.	O

A	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
severe	O
sensorimotor	O
axonal	O
polyneuropathy	B-Disease
.	O

Laryngeal	O
electromyography	O
(	O
thyroarytenoid	O
muscle	O
)	O
showed	O
ample	O
denervation	O
potentials	O
.	O

Laryngoscopy	O
revealed	O
asymmetric	O
vocal	O
fold	O
movements	O
during	O
phonation	O
.	O

Her	O
vocal	O
change	O
and	O
weakness	O
began	O
to	O
improve	O
spontaneously	O
about	O
3	O
weeks	O
after	O
transfer	O
.	O

This	O
was	O
a	O
case	O
of	O
acute	O
palsy	B-Disease
of	O
the	O
recurrent	O
laryngeal	O
nerve	O
and	O
superimposed	O
severe	O
acute	O
sensorimotor	O
axonal	O
polyneuropathy	B-Disease
caused	O
by	O
high-dose	O
disulfiram	B-Chemical
intoxication	O
.	O

Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	B-Disease
in	O
patients	O
with	O
heparin-induced	B-Chemical
thrombocytopenia	B-Disease
.	O

OBJECTIVES	O
:	O
To	O
correlate	O
optical	O
density	O
and	O
percent	O
inhibition	O
of	O
a	O
two-step	O
heparin-induced	B-Chemical
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
antigen	O
assay	O
with	O
thrombosis	B-Disease
;	O
the	O
assay	O
utilizes	O
reaction	O
inhibition	O
characteristics	O
of	O
a	O
high	O
heparin	B-Chemical
concentration	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
more	O
than	O
50	O
%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	B-Disease
(	O
<	O
150	O
x	O
10	O
(	O
9	O
)	O
/L	O
)	O
after	O
exposure	O
to	O
heparin	B-Chemical
,	O
who	O
had	O
a	O
positive	O
two-step	O
antigen	O
assay	O
[	O
optical	O
density	O
(	O
OD	O
)	O
>	O
0.4	O
and	O
>	O
50	O
inhibition	O
with	O
high	O
concentration	O
of	O
heparin	B-Chemical
]	O
were	O
included	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	B-Disease
patients	O
had	O
thrombosis	B-Disease
at	O
diagnosis	O
;	O
54/94	O
had	O
isolated-HIT	B-Disease
without	O
thrombosis	B-Disease
.	O

Eight	O
of	O
the	O
isolated-HIT	B-Disease
patients	O
developed	O
thrombosis	B-Disease
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	B-Disease
at	O
day	O
30	O
.	O

At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	B-Disease
patients	O
with	O
thrombosis	B-Disease
and	O
those	O
with	O
isolated-HIT	B-Disease
.	O

However	O
,	O
OD	O
was	O
significantly	O
higher	O
in	O
all	O
patients	O
with	O
thrombosis	B-Disease
(	O
n	O
=	O
48	O
,	O
1.34	O
+/-	O
0.89	O
)	O
,	O
including	O
isolated-HIT	B-Disease
patients	O
who	O
later	O
developed	O
thrombosis	B-Disease
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1.84	O
+/-	O
0.64	O
)	O
as	O
compared	O
to	O
isolated-HIT	B-Disease
patients	O
who	O
did	O
not	O
develop	O
thrombosis	B-Disease
(	O
0.96	O
+/-	O
0.75	O
;	O
P	O
=	O
0.011	O
and	O
P	O
=	O
0.008	O
)	O
.	O

The	O
Receiver	O
Operative	O
Characteristic	O
Curve	O
showed	O
that	O
OD	O
>	O
1.27	O
in	O
the	O
isolated-HIT	B-Disease
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	B-Disease
by	O
day	O
30	O
.	O

None	O
of	O
these	O
groups	O
showed	O
significant	O
difference	O
in	O
percent	O
inhibition	O
.	O

Multivariate	O
analysis	O
showed	O
a	O
2.8-fold	O
increased	O
risk	O
of	O
thrombosis	B-Disease
in	O
females	O
.	O

Similarly	O
,	O
thrombotic	B-Disease
risk	O
increased	O
with	O
age	O
and	O
OD	O
values	O
.	O

CONCLUSION	O
:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
risk	O
of	O
subsequent	O
thrombosis	B-Disease
in	O
patients	O
with	O
isolated-HIT	B-Disease
;	O
percent	O
inhibition	O
,	O
however	O
,	O
was	O
not	O
predictive	O
.	O

Central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
clomiphene-induced	B-Chemical
ovulation	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
clomiphene	B-Chemical
citrate	I-Chemical
(	O
CC	B-Chemical
)	O
.	O

DESIGN	O
:	O
Case	O
study	O
.	O

SETTING	O
:	O
Ophthalmology	O
clinic	O
of	O
an	O
academic	O
hospital	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
A	O
36-year-old	O
woman	O
referred	O
from	O
the	O
infertility	B-Disease
clinic	O
for	O
blurred	B-Disease
vision	I-Disease
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Ophthalmic	O
examination	O
after	O
CC	B-Chemical
therapy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
ovulation	O
induction	O
with	O
CC	B-Chemical
.	O

RESULT	O
(	O
S	O
)	O
:	O
A	O
36-year-old	O
Chinese	O
woman	O
developed	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
eight	O
courses	O
of	O
CC	B-Chemical
.	O

A	O
search	O
of	O
the	O
literature	O
on	O
the	O
thromboembolic	B-Disease
complications	O
of	O
CC	B-Chemical
does	O
not	O
include	O
this	O
severe	O
ophthalmic	O
complication	O
,	O
although	O
mild	O
visual	B-Disease
disturbance	I-Disease
after	O
CC	B-Chemical
intake	O
is	O
not	O
uncommon	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
after	O
treatment	O
with	O
CC	B-Chemical
.	O

Extra	O
caution	O
is	O
warranted	O
in	O
treating	O
infertility	B-Disease
patients	O
with	O
CC	B-Chemical
,	O
and	O
patients	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effect	O
before	O
commencement	O
of	O
therapy	O
.	O

Nicotine-induced	B-Chemical
nystagmus	B-Disease
correlates	O
with	O
midpontine	O
activation	O
.	O

The	O
pathomechanism	O
of	O
nicotine-induced	B-Chemical
nystagmus	B-Disease
(	O
NIN	B-Disease
)	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
brain	O
structures	O
that	O
are	O
involved	O
in	O
NIN	B-Disease
generation	O
.	O

Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	B-Chemical
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video-oculography	O
.	O

NIN	B-Disease
correlated	O
with	O
blood	O
oxygen	B-Chemical
level-dependent	O
(	O
BOLD	O
)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis	O
.	O

NIN-induced	B-Disease
midpontine	O
activation	O
may	O
correspond	O
to	O
activation	O
of	O
the	O
dorsomedial	O
pontine	O
nuclei	O
and	O
the	O
nucleus	O
reticularis	O
tegmenti	O
pontis	O
,	O
structures	O
known	O
to	O
participate	O
in	O
the	O
generation	O
of	O
multidirectional	O
saccades	O
and	O
smooth	O
pursuit	O
eye	O
movements	O
.	O

Protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcers	B-Disease
in	O
severe	O
atherosclerotic	B-Disease
rats	O
.	O

Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	B-Disease
rats	O
are	O
lacking	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back-diffusion	O
,	O
mast	O
cell	O
histamine	B-Chemical
release	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
ulcer	B-Disease
in	O
rats	O
with	O
atherosclerosis	B-Disease
induced	O
by	O
coadministration	O
of	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
.	O

Additionally	O
,	O
the	O
protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
this	O
ulcer	B-Disease
model	O
was	O
evaluated	O
.	O

Male	O
Wistar	O
rats	O
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1.0	O
ml/kg	O
of	O
corn	O
oil	O
containing	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
to	O
induce	O
atherosclerosis	B-Disease
.	O

Control	O
rats	O
received	O
corn	O
oil	O
only	O
.	O

After	O
gastric	O
surgery	O
,	O
rat	O
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	O
juice	O
or	O
normal	O
saline	O
.	O

Gastric	O
acid	O
back-diffusion	O
,	O
mucosal	O
LPO	O
generation	O
,	O
histamine	B-Chemical
concentration	O
,	O
microvascular	O
permeability	O
,	O
luminal	B-Chemical
hemoglobin	O
content	O
and	O
ulcer	B-Disease
areas	O
were	O
determined	O
.	O

Elevated	O
atherosclerotic	B-Disease
parameters	O
,	O
such	O
as	O
serum	O
calcium	B-Chemical
,	O
total	O
cholesterol	B-Chemical
and	O
low-density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B-Disease
rats	O
.	O

Severe	O
gastric	O
ulcers	B-Disease
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
,	O
including	O
gastric	O
acid	O
back-diffusion	O
,	O
histamine	B-Chemical
release	O
,	O
LPO	O
generation	O
and	O
luminal	B-Chemical
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats	O
.	O

Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	B-Chemical
to	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
to	O
ulcer	B-Disease
was	O
found	O
in	O
those	O
atherosclerotic	B-Disease
rats	O
.	O

This	O
hemorrhagic	B-Disease
ulcer	B-Disease
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose-dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	B-Chemical
.	O

Atherosclerosis	B-Disease
could	O
produce	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcer	B-Disease
via	O
aggravation	O
of	O
gastric	O
acid	O
back-diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	B-Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-Chemical
in	O
rats	O
.	O

Adriamycin-induced	B-Chemical
autophagic	O
cardiomyocyte	O
death	B-Disease
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	O
model	O
of	O
heart	B-Disease
failure	I-Disease
.	O

BACKGROUND	O
:	O
The	O
mechanisms	O
underlying	O
heart	B-Disease
failure	I-Disease
induced	O
by	O
adriamycin	B-Chemical
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
autophagy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Disease
failure	I-Disease
induced	O
by	O
adriamycin	B-Chemical
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatment	O
strategy	O
for	O
heart	B-Disease
failure	I-Disease
.	O

METHODS	O
:	O
3-methyladenine	B-Chemical
(	O
3MA	B-Chemical
)	O
,	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B-Disease
failure	I-Disease
model	O
of	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O

Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague-Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls	O
,	O
an	O
adriamycin-treated	B-Chemical
group	O
,	O
and	O
a	O
3MA	B-Chemical
plus	O
adriamycin-treated	B-Chemical
group	O
.	O

We	O
then	O
examined	O
the	O
morphology	O
,	O
expression	O
of	O
beclin	O
1	O
gene	O
,	O
mitochondrial	O
permeability	O
transition	O
(	O
MPT	O
)	O
,	O
and	O
Na+-K+	B-Chemical
ATPase	O
activity	O
in	O
vivo	O
.	O

We	O
also	O
assessed	O
cell	O
viability	O
,	O
mitochondrial	O
membrane	O
potential	O
changes	O
and	O
counted	O
autophagic	O
vacuoles	O
in	O
cultured	O
cardiomyocytes	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
autophagy	O
associated	O
gene	O
,	O
beclin	O
1	O
using	O
RT-PCR	O
and	O
Western	O
blotting	O
in	O
an	O
animal	O
model	O
.	O

RESULTS	O
:	O
3MA	B-Chemical
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury	O
.	O

Furthermore	O
,	O
adriamycin	B-Chemical
induced	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
,	O
and	O
3MA	B-Chemical
strongly	O
downregulated	O
the	O
expression	O
of	O
beclin	O
1	O
in	O
adriamycin-induced	B-Chemical
failing	O
heart	O
and	O
inhibited	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
.	O

CONCLUSION	O
:	O
Autophagic	O
cardiomyocyte	O
death	B-Disease
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	B-Disease
failure	I-Disease
in	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O

Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-Disease
failure	I-Disease
caused	O
by	O
adriamycin	B-Chemical
via	O
the	O
autophagy	O
pathway	O
.	O

Confusion	B-Disease
,	O
a	O
rather	O
serious	O
adverse	O
drug	B-Drug
reaction	O
with	O
valproic	B-Chemical
acid	I-Chemical
:	O
a	O
review	O
of	O
the	O
French	O
Pharmacovigilance	O
database	O
.	O

INTRODUCTION	O
:	O
Confusion	B-Disease
is	O
an	O
adverse	O
drug	B-Drug
reaction	O
frequently	O
observed	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O

Some	O
case	O
reports	O
are	O
published	O
in	O
the	O
literature	O
but	O
no	O
systematic	O
study	O
from	O
a	O
sample	O
of	O
patients	O
has	O
been	O
published	O
.	O

We	O
performed	O
this	O
study	O
in	O
order	O
to	O
describe	O
the	O
main	O
characteristics	O
of	O
this	O
adverse	O
drug	B-Drug
reaction	O
.	O

METHODS	O
:	O
Using	O
the	O
French	O
Pharmacovigilance	O
database	O
,	O
we	O
selected	O
the	O
cases	O
of	O
confusion	B-Disease
reported	O
since	O
1985	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O

RESULTS	O
:	O
272	O
cases	O
of	O
confusion	B-Disease
were	O
reported	O
with	O
valproic	B-Chemical
acid	I-Chemical
:	O
153	O
women	O
and	O
119	O
men	O
.	O

Confusion	B-Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	B-Chemical
acid	I-Chemical
exposure	O
(	O
39.7	O
%	O
)	O
.	O

It	O
was	O
``	O
serious	O
''	O
for	O
almost	O
2/3	O
of	O
the	O
patients	O
(	O
62.5	O
%	O
)	O
and	O
its	O
outcome	O
favourable	O
in	O
most	O
of	O
the	O
cases	O
(	O
82	O
%	O
)	O
.	O

The	O
occurrence	O
of	O
this	O
ADR	O
was	O
more	O
frequent	O
in	O
patients	O
aged	O
between	O
61	O
and	O
80	O
years	O
.	O

CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
confusion	B-Disease
with	O
valproic	B-Chemical
acid	I-Chemical
is	O
a	O
serious	O
,	O
rather	O
frequent	O
but	O
reversible	O
adverse	O
drug	B-Drug
reaction	O
.	O

It	O
occurs	O
especially	O
in	O
older	O
patients	O
and	O
during	O
the	O
first	O
two	O
weeks	O
of	O
treatment	O
.	O

Learning	B-Disease
and	I-Disease
memory	I-Disease
deficits	I-Disease
in	O
ecstasy	O
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face-learning	O
task	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-Chemical
users	O
display	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
performance	O
.	O

In	O
addition	O
,	O
working	O
memory	O
processing	O
in	I-Chemical
ecstasy	O
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	I-Chemical
hippocampal	O
and/or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O

Using	O
functional	O
imaging	O
and	O
a	O
face-learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face-name	O
associations	O
in	I-Chemical
20	O
recreational	O
drug	B-Drug
users	O
whose	O
predominant	O
drug	B-Drug
use	O
was	O
ecstasy	O
and	O
20	O
controls	O
.	O

To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	O
use	O
of	O
the	O
ecstasy	O
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	O
users	O
(	O
Nestor	O
,	O
L.	O
,	O
Roberts	O
,	O
G.	O
,	O
Garavan	O
,	O
H.	O
,	O
Hester	O
,	O
R.	O
,	O
2008	O
.	O

Deficits	O
in	I-Chemical
learning	O
and	O
memory	I-Chemical
:	O
parahippocampal	O
hyperactivity	O
and	O
frontocortical	O
hypoactivity	O
in	I-Chemical
cannabis	O
users	O
.	O

Neuroimage	O
40	O
,	O
1328-1339	O
)	O
.	O

Ecstasy	O
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	O
users	O
.	O

A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy-specific	B-Disease
hyperactivity	O
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O

Ecstasy-specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O

In	O
both	O
ecstasy	B-Chemical
and	O
cannabis	B-Chemical
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O

These	O
results	O
elucidated	O
ecstasy-related	B-Chemical
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	B-Chemical
use	O
.	O

These	O
ecstasy-specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	I-Chemical
allocortical	O
regions	O
to	O
the	O
neurotoxic	O
effects	O
of	O
ecstasy	O
.	O

Prolonged	O
elevation	O
of	O
plasma	O
argatroban	B-Chemical
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin-induced	B-Chemical
thrombocytopenia	B-Disease
with	O
thrombosis	B-Disease
.	O

BACKGROUND	O
:	O
Direct	O
thrombin	O
inhibitors	O
(	O
DTIs	O
)	O
provide	O
an	O
alternative	O
method	O
of	O
anticoagulation	O
for	O
patients	O
with	O
a	O
history	O
of	O
heparin-induced	B-Chemical
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
or	O
HIT	B-Disease
with	O
thrombosis	B-Disease
(	O
HITT	B-Disease
)	O
undergoing	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
.	O

In	O
the	O
following	O
report	O
,	O
a	O
65-year-old	O
critically	B-Disease
ill	I-Disease
patient	O
with	O
a	O
suspected	O
history	O
of	O
HITT	B-Disease
was	O
administered	O
argatroban	B-Chemical
for	O
anticoagulation	O
on	O
bypass	O
during	O
heart	O
transplantation	O
.	O

The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
cells	O
,	O
42	O
units	O
of	O
fresh-frozen	O
plasma	O
,	O
40	O
units	O
of	O
cryoprecipitate	O
,	O
40	O
units	O
of	O
platelets	O
,	O
and	I-Disease
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa	O
)	O
for	O
severe	O
intraoperative	B-Disease
and	I-Disease
postoperative	I-Disease
bleeding	I-Chemical
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	B-Drug
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	O
.	O

RESULTS	O
:	O
Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	B-Drug
were	O
measured	O
in	O
these	O
samples	O
(	O
range	O
,	O
0-32	O
microg/mL	O
)	O
,	O
and	O
a	O
prolonged	O
plasma	O
argatroban	B-Drug
half	O
life	O
(	O
t	O
(	O
1/2	O
)	O
)	O
of	O
514	O
minutes	O
was	O
observed	O
(	O
published	O
elimination	O
t	O
(	O
1/2	O
)	O
is	O
39-51	O
minutes	O
[	O
<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	O
impairment	O
]	O
)	O
.	O

CONCLUSIONS	O
:	O
Correlation	O
of	O
plasma	O
argatroban	B-Drug
concentration	O
versus	O
the	O
patient	O
's	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	B-Drug
may	O
have	O
contributed	O
to	O
the	O
patient	O
's	O
extended	O
coagulopathy	O
.	O

Because	O
DTIs	O
do	O
not	O
have	O
reversal	O
agents	O
,	O
surgical	O
teams	O
and	O
transfusion	O
services	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
transfusion	O
events	O
during	O
anticoagulation	O
with	O
these	O
agents	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
measure	O
plasma	O
argatroban	B-Drug
concentration	O
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	O
coagulopathy	O
.	O

Antituberculosis	B-Chemical
therapy-induced	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
:	O
magnitude	O
,	O
profile	O
,	O
prognosis	O
,	O
and	O
predictors	O
of	O
outcome	O
.	O

Antituberculosis	B-Chemical
therapy	O
(	O
ATT	O
)	O
-associated	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
ATT-ALF	B-Disease
)	O
is	O
the	O
commonest	O
drug-induced	O
ALF	B-Disease
in	O
South	O
Asia	O
.	O

Prospective	O
studies	O
on	O
ATT-ALF	B-Disease
are	O
lacking	O
.	O

The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude	O
,	O
clinical	O
course	O
,	O
outcome	O
,	O
and	O
prognostic	O
factors	O
in	O
ATT-ALF	B-Disease
.	O

From	O
January	O
1986	O
to	O
January	O
2009	O
,	O
1223	O
consecutive	O
ALF	B-Disease
patients	O
were	O
evaluated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5.7	O
%	O
)	O
patients	O
.	O

Another	O
15	O
(	O
1.2	O
%	O
)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	B-Disease
virus	I-Disease
infection	I-Disease
.	O

In	O
44	O
(	O
62.8	O
%	O
)	O
patients	O
,	O
ATT	O
was	O
prescribed	O
empirically	O
without	O
definitive	O
evidence	O
of	O
tuberculosis	B-Disease
.	O

ATT-ALF	B-Disease
patients	O
were	O
younger	O
(	O
32.87	O
[	O
+/-15.8	O
]	O
years	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
women	O
.	O

Most	O
had	O
hyperacute	O
presentation	O
;	O
the	O
median	O
icterus	B-Disease
encephalopathy	B-Disease
interval	O
was	O
4.5	O
(	O
0-30	O
)	O
days	O
.	O

The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	B-Disease
was	O
30	O
(	O
7-350	O
)	O
days	O
.	O

At	O
presentation	O
,	O
advanced	O
encephalopathy	B-Disease
and	O
cerebral	B-Disease
edema	I-Disease
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41.4	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

Gastrointestinal	B-Disease
bleed	I-Disease
,	O
seizures	B-Disease
,	O
infection	B-Disease
,	O
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
were	O
documented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7.1	O
%	O
)	O
,	O
26	O
(	O
37.1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
patients	O
,	O
respectively	O
.	O

Compared	O
with	O
hepatitis	B-Disease
E	I-Disease
virus	O
(	O
HEV	O
)	O
and	O
non-A	O
non-E-induced	O
ALF	B-Disease
,	O
ATT-ALF	B-Disease
patients	O
had	O
nearly	O
similar	O
presentations	O
except	O
for	O
older	O
age	O
and	O
less	O
elevation	O
of	O
liver	O
enzymes	O
.	O

The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT-ALF	B-Disease
was	O
high	O
(	O
67.1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32.9	O
%	O
)	O
patients	O
recovered	O
with	O
medical	O
treatment	O
.	O

In	O
multivariate	O
analysis	O
,	O
three	O
factors	O
independently	O
predicted	O
mortality	O
:	O
serum	O
bilirubin	B-Chemical
(	O
>	O
or=10.8	O
mg/dL	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
prolongation	O
(	O
>	O
or=26	O
seconds	O
)	O
,	O
and	O
grade	O
III/IV	O
encephalopathy	B-Disease
at	O
presentation	O
.	O

CONCLUSION	O
:	O
ATT-ALF	B-Disease
constituted	O
5.7	O
%	O
of	O
ALF	B-Disease
at	O
our	O
center	O
and	O
had	O
a	O
high	O
mortality	O
rate	O
.	O

Because	O
the	O
mortality	O
rate	O
is	O
so	O
high	O
,	O
determining	O
which	O
factors	O
are	O
predictors	O
is	O
less	O
important	O
.	O

A	O
high	O
proportion	O
of	O
patients	O
had	O
consumed	O
ATT	O
empirically	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O

Central	B-Disease
nervous	I-Disease
system	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
in	O
a	O
single	O
pediatric	O
institution	O
.	O

Central	B-Disease
nervous	I-Disease
system	I-Disease
(	I-Disease
CNS	I-Disease
)	I-Disease
complications	I-Disease
during	O
treatment	O
of	O
childhood	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
remain	O
a	O
challenging	O
clinical	O
problem	O
.	O

Outcome	O
improvement	O
with	O
more	O
intensive	O
chemotherapy	O
has	O
significantly	O
increased	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
events	O
.	O

This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	B-Disease
complications	I-Disease
during	O
ALL	B-Disease
treatment	O
in	O
a	O
single	O
pediatric	O
institution	O
,	O
focusing	O
on	O
clinical	O
,	O
radiological	O
,	O
and	O
electrophysiological	O
findings	O
.	O

Exclusion	O
criteria	O
included	O
CNS	O
leukemic	B-Disease
infiltration	I-Disease
at	O
diagnosis	O
,	O
therapy-related	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
late-onset	O
encephalopathy	B-Disease
,	O
or	O
long-term	O
neurocognitive	B-Disease
defects	I-Disease
.	O

During	O
a	O
9-year	O
period	O
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
patients	O
,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	B-Disease
front-line	O
protocol	O
.	O

CNS	O
complications	O
included	O
posterior	O
reversible	O
leukoencephalopathy	B-Disease
syndrome	O
(	O
n	O
=	O
10	O
)	O
,	O
stroke	B-Disease
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
(	O
n	O
=	O
2	O
)	O
,	O
high-dose	O
methotrexate	B-Chemical
toxicity	B-Disease
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	O
of	O
inappropriate	B-Disease
antidiuretic	I-Disease
hormone	I-Disease
secretion	I-Disease
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
CNS	O
complications	O
are	O
frequent	O
events	O
during	O
ALL	B-Disease
therapy	O
,	O
and	O
require	O
rapid	O
detection	O
and	O
prompt	O
treatment	O
to	O
limit	O
permanent	O
damage	O
.	O

Safety	O
of	O
capecitabine	B-Chemical
:	O
a	O
review	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	B-Chemical
,	O
in	O
particular	O
5-fluorouracil	B-Chemical
(	O
5-FU	B-Chemical
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B-Disease
,	I-Disease
including	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Chemical
,	O
for	O
>	O
40	O
years	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	B-Drug
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	B-Drug
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
,	O
renal	O
and	O
kidney	O
disease	O
.	O

We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	B-Drug
administration	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	B-Drug
is	O
an	O
oral	O
prodrug	O
of	O
5-FU	B-Drug
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety/efficacy	O
profile	O
.	O

It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B-Chemical
,	O
breast	B-Chemical
,	O
pancreaticobiliary	O
,	O
gastric	O
,	O
renal	O
cell	O
and	O
head	O
and	O
neck	O
cancers	I-Chemical
.	O

The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	B-Drug
are	O
diarrhea	O
,	O
nausea	O
,	O
vomiting	O
,	O
stomatitis	O
and	I-Disease
hand-foot	O
syndrome	O
.	O

Capecitabine	B-Drug
has	O
a	O
well-established	O
safety	O
profile	O
and	I-Disease
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	O
and	I-Disease
renal	O
dysfunctions	O
.	O

Effects	O
of	O
pallidal	O
neurotensin	B-Chemical
on	O
haloperidol-induced	B-Chemical
parkinsonian	B-Disease
catalepsy	I-Disease
:	O
behavioral	O
and	O
electrophysiological	O
studies	O
.	O

OBJECTIVE	O
:	O
The	O
globus	O
pallidus	O
plays	O
a	O
critical	O
role	O
in	O
movement	O
regulation	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	O
pallidus	O
receives	O
neurotensinergic	B-Chemical
innervation	O
from	O
the	O
striatum	O
,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	B-Chemical
analog	O
could	O
produce	O
antiparkinsonian	O
effects	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	B-Drug
on	O
haloperidol-induced	B-Chemical
parkinsonian	B-Disease
symptoms	I-Disease
.	O

METHODS	O
:	O
Behavioral	O
experiments	O
and	O
electrophysiological	O
recordings	O
were	O
performed	O
in	O
the	O
present	O
study	O
.	O

RESULTS	O
:	O
Bilateral	O
infusions	O
of	O
neurotensin	B-Chemical
into	O
the	O
globus	O
pallidus	O
reversed	O
haloperidol-induced	B-Chemical
parkinsonian	B-Disease
catalepsy	I-Disease
in	O
rats	O
.	O

Electrophysiological	O
recordings	O
showed	O
that	O
microinjection	O
of	O
neurotensin	B-Chemical
induced	O
excitation	O
of	O
pallidal	O
neurons	O
in	O
the	O
presence	O
of	O
systemic	O
haloperidol	B-Chemical
administration	O
.	O

The	O
neurotensin	B-Chemical
type-1	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
SR48692	B-Chemical
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	B-Chemical
.	O

CONCLUSION	O
:	O
Activation	O
of	O
pallidal	O
neurotensin	B-Chemical
receptors	O
may	O
be	O
involved	O
in	O
neurotensin-induced	B-Chemical
antiparkinsonian	O
effects	O
.	O

Antihypertensive	B-Drug
drugs	B-Drug
and	O
depression	B-Disease
:	O
a	O
reappraisal	O
.	O

Eighty-nine	O
new	O
referral	O
hypertensive	B-Disease
out-patients	O
and	O
46	O
new	O
referral	O
non-hypertensive	B-Disease
chronically	O
physically	O
ill	O
out-patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year	O
.	O

The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	B-Disease
in	O
both	O
groups	O
of	O
patients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	B-Disease
group	O
.	O

Hypertensive	B-Disease
patients	O
with	O
psychiatric	B-Disease
histories	O
had	O
a	O
higher	O
prevalence	O
of	O
depression	B-Disease
than	O
the	O
comparison	O
patients	O
.	O

This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	B-Disease
occurring	O
in	O
methyl	B-Chemical
dopa	I-Chemical
treated	O
patients	O
with	O
psychiatric	B-Disease
histories	O
.	O

Pulmonary	O
shunt	O
and	O
cardiovascular	O
responses	O
to	O
CPAP	O
during	O
nitroprusside-induced	B-Chemical
hypotension	B-Disease
.	O

The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS/QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	B-Chemical
nitroprusside	I-Chemical
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40-50	O
per	O
cent	O
.	O

Before	O
nitroprusside	B-Chemical
infusion	O
,	O
5	O
cm	O
H2O	B-Chemical
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.05	O
,	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
systemic	O
vascular	O
resistance	O
,	O
or	O
QS/QT	O
.	O

Ten	O
cm	O
H2O	B-Chemical
CPAP	O
before	O
nitroprusside	B-Chemical
infusion	O
produced	O
a	O
further	O
decrease	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	B-Disease
cardiac	I-Disease
output	I-Disease
and	O
QS/QT	O
.	O

Nitroprusside	B-Chemical
caused	O
significant	O
decreases	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS/QT	O
.	O

Five	O
cm	O
H2O	B-Chemical
CPAP	O
during	O
nitroprusside	B-Chemical
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above-mentioned	O
variables	O
.	O

However	O
,	O
10	O
cm	O
H2O	B-Chemical
CPAP	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
and	O
QS/QT	O
.	O

These	O
data	O
indicate	O
that	O
nitroprusside	B-Chemical
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40-50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS/QT	O
.	O

During	O
nitroprusside	B-Chemical
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics	O
,	O
but	O
high	O
levels	O
of	O
CPAP	O
(	O
10	O
cm	O
H2O	B-Chemical
)	O
,	O
while	O
decreasing	O
QS/QT	O
,	O
produce	O
marked	O
decreases	B-Disease
in	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
and	I-Disease
cardiac	I-Disease
output	I-Disease
.	O

Mediation	O
of	O
enhanced	O
reflex	O
vagal	O
bradycardia	B-Disease
by	O
L-dopa	B-Chemical
via	O
central	O
dopamine	B-Chemical
formation	O
in	O
dogs	O
.	O

L-Dopa	B-Chemical
(	O
5	O
mg/kg	O
i.v	O
.	O

)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK-486	B-Chemical
(	O
25	O
mg/kg	O
i.v	O
.	O

)	O
in	O
anesthetize	O
MAO-inhibited	B-Chemical
dogs	O
.	O

In	O
addition	O
,	O
reflex	O
bradycardia	B-Disease
caused	O
by	O
injected	O
norepinephrine	B-Chemical
was	O
significantly	O
enhanced	O
by	O
L-dopa	B-Chemical
,	O
DL-Threo-dihydroxyphenylserine	B-Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-Chemical
.	O

FLA-63	B-Chemical
,	O
a	O
dopamine-beta-oxidase	B-Chemical
inhibitor	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hypotension	B-Disease
,	O
bradycardia	B-Disease
or	O
reflex-enhancing	O
effect	O
of	O
L-dopa	B-Chemical
.	O

Pimozide	B-Chemical
did	O
not	O
affect	O
the	O
actions	O
of	O
L-dopa	B-Chemical
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes	O
.	O

Removal	O
of	O
the	O
carotid	O
sinuses	O
caused	O
an	O
elevation	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
abolished	O
the	O
negative	O
chronotropic	O
effect	O
of	O
norepinephrine	B-Chemical
.	O

However	O
,	O
L-dopa	B-Chemical
restored	O
the	O
bradycardia	B-Disease
caused	O
by	O
norepinephrine	B-Chemical
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

5-HTP	B-Chemical
(	O
5	O
mg/kg	O
i.v	O
.	O

)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
decreased	O
the	O
reflex	O
bradycardia	B-Disease
to	O
norepinephrine	B-Chemical
.	O

It	O
is	O
concluded	O
that	O
L-dopa	B-Chemical
enhances	O
reflex	O
bradycardia	B-Disease
through	O
central	O
alpha-receptor	O
stimulation	O
.	O

Furthermore	O
,	O
the	O
effects	O
are	O
mediated	O
through	O
dopamine	B-Chemical
rather	O
than	O
norepinephrine	B-Chemical
and	O
do	O
not	O
require	O
the	O
carotid	O
sinus	O
baroreceptors	O
.	O

Cocaine-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
:	O
clinical	O
observations	O
and	O
pathogenetic	O
considerations	O
.	O

Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	B-Chemical
may	O
result	O
in	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

In	O
individuals	O
with	O
preexisting	O
,	O
high-grade	O
coronary	O
arterial	O
narrowing	O
,	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
may	O
result	O
from	O
an	O
increase	O
in	O
myocardial	O
oxygen	B-Chemical
demand	O
associated	O
with	O
cocaine-induced	B-Chemical
increase	O
in	O
rate-pressure	O
product	O
.	O

In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	B-Disease
obstruction	I-Disease
,	O
coronary	B-Disease
occlusion	I-Disease
may	O
be	O
due	O
to	O
spasm	B-Disease
,	O
thrombus	B-Disease
,	O
or	O
both	O
.	O

With	O
regard	O
to	O
spasm	B-Disease
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine-induced	B-Chemical
vasoconstriction	O
remains	O
speculative	O
.	O

Although	O
certain	O
clinical	O
and	O
experimental	O
findings	O
support	O
the	O
hypothesis	O
that	O
spasm	B-Disease
involves	O
the	O
epicardial	O
,	O
medium-size	O
vessels	O
,	O
other	O
data	O
suggest	O
intramural	O
vasoconstriction	O
.	O

Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental	O
,	O
discrete	O
infarction	B-Disease
.	O

Whereas	O
certain	O
in	O
vivo	O
data	O
suggest	O
that	O
these	O
effects	O
are	O
alpha-mediated	O
,	O
other	O
in	O
vitro	O
data	O
suggest	O
the	O
opposite	O
.	O

The	O
finding	O
of	O
cocaine-induced	B-Chemical
vasoconstriction	O
in	O
segments	O
of	O
(	O
noninnervated	O
)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha-mediated	O
effects	O
.	O

Finally	O
,	O
the	O
contribution	O
of	O
a	O
primary	O
,	O
thrombotic	B-Disease
effect	O
of	O
cocaine	B-Chemical
has	O
not	O
been	O
excluded	O
.	O

Rabbit	B-Disease
syndrome	I-Disease
,	O
antidepressant	B-Chemical
use	O
,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings	O
.	O

The	O
rabbit	B-Disease
syndrome	I-Disease
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	B-Drug
therapy	O
.	O

Its	O
occurrence	O
in	O
a	O
patient	O
being	O
treated	O
with	O
imipramine	B-Chemical
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
case	O
of	O
this	O
syndrome	O
in	O
conjunction	O
with	O
antidepressants	B-Chemical
.	O

Repeated	O
cerebral	O
perfusion	I-Disease
SPECT	O
scans	O
revealed	O
decreased	B-Disease
basal	I-Disease
ganglia	I-Disease
perfusion	O
while	O
the	O
movement	B-Disease
disorder	I-Disease
was	O
present	O
,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	B-Disease
syndrome	I-Disease
resolved	O
.	O

Acute	O
bronchodilating	O
effects	O
of	O
ipratropium	B-Chemical
bromide	I-Chemical
and	O
theophylline	B-Chemical
in	O
chronic	B-Disease
obstructive	I-Disease
pulmonary	I-Disease
disease	I-Disease
.	O

The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	B-Chemical
bromide	I-Chemical
aerosol	O
(	O
36	O
micrograms	O
)	O
and	O
short-acting	O
theophylline	B-Chemical
tablets	O
(	O
dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10-20	O
micrograms/mL	O
)	O
were	O
compared	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable	O
,	O
chronic	B-Disease
obstructive	I-Disease
pulmonary	I-Disease
disease	I-Disease
.	O

Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
increase	O
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratropium	B-Chemical
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophylline	B-Chemical
.	O

The	O
average	O
FEV1	O
increases	O
during	O
the	O
6-hour	O
observation	O
period	O
were	O
18	O
%	O
for	O
ipratropium	B-Chemical
and	O
8	O
%	O
for	O
theophylline	B-Chemical
.	O

The	O
mean	O
duration	O
of	O
action	O
was	O
3.8	O
hours	O
with	O
ipratropium	B-Chemical
and	O
2.4	O
hours	O
with	O
theophylline	B-Chemical
.	O

While	O
side	O
effects	O
were	O
rare	O
,	O
those	O
experienced	O
after	O
theophylline	B-Chemical
use	O
did	O
involve	O
the	O
cardiovascular	B-Disease
and	I-Disease
gastrointestinal	I-Disease
systems	I-Disease
.	O

These	O
results	O
show	O
that	O
ipratropium	O
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	B-Drug
in	O
patients	O
with	O
chronic	O
airflow	O
obstruction	O
.	O

Irreversible	O
damage	O
to	O
the	O
medullary	O
interstitium	O
in	O
experimental	O
analgesic	O
nephropathy	B-Disease
in	O
F344	O
rats	O
.	O

Renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
(	O
RPN	B-Disease
)	O
and	O
a	O
decreased	O
urinary	O
concentrating	O
ability	O
developed	O
during	O
continuous	O
long-term	O
treatment	O
with	O
aspirin	B-Chemical
and	O
paracetamol	B-Chemical
in	O
female	O
Fischer	O
344	O
rats	O
.	O

Renal	O
structure	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
recovery	O
period	O
of	O
up	O
to	O
18	O
weeks	O
,	O
when	O
no	O
analgesics	O
were	O
given	O
,	O
to	O
investigate	O
whether	O
the	O
analgesic-induced	O
changes	O
were	O
reversible	O
.	O

There	O
was	O
no	O
evidence	O
of	O
repair	O
to	O
the	O
damaged	O
medullary	O
interstitial	O
matrix	O
,	O
or	O
proliferation	O
of	O
remaining	O
undamaged	O
type	O
1	O
medullary	O
interstitial	O
cells	O
after	O
the	O
recovery	O
period	O
following	O
analgesic	O
treatment	O
.	O

The	O
recovery	O
of	O
urinary	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
length	O
of	O
analgesic	O
treatment	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
inner	O
medullary	O
structural	O
damage	O
.	O

During	O
the	O
early	O
stages	O
of	O
analgesic	O
treatment	O
,	O
the	O
changes	O
in	O
urinary	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
prolonged	O
analgesic	O
treatment	O
,	O
maximum	O
urinary	O
concentrating	O
ability	O
failed	O
to	O
recover	O
.	O

This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	B-Disease
.	O

The	O
associated	O
urinary	O
concentrating	O
defect	O
is	O
reversible	O
only	O
during	O
the	O
early	O
stages	O
of	O
structural	O
damage	O
to	O
the	O
inner	O
medulla	O
.	O

Less	O
frequent	O
lithium	B-Chemical
administration	O
and	O
lower	O
urine	O
volume	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
maintained	O
on	O
a	O
regimen	O
of	O
lithium	B-Chemical
on	O
a	O
once-per-day	O
schedule	O
have	O
lower	O
urine	O
volumes	O
than	O
do	O
patients	O
receiving	O
multiple	O
doses	O
per	O
day	O
.	O

METHOD	O
:	O
This	O
was	O
a	O
cross-sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	B-Chemical
clinic	O
who	O
received	O
different	O
dose	O
schedules	O
.	O

Patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
measurement	O
of	O
lithium	B-Chemical
level	O
,	O
creatinine	B-Chemical
clearance	O
,	O
urine	O
volume	O
,	O
and	O
maximum	O
osmolality	O
.	O

RESULTS	O
:	O
Multiple	O
daily	O
doses	O
of	O
lithium	B-Chemical
were	O
associated	O
with	O
higher	O
urine	O
volumes	O
.	O

The	O
dosing	O
schedule	O
,	O
duration	O
of	O
lithium	B-Chemical
treatment	O
,	O
and	O
daily	O
dose	O
of	O
lithium	B-Chemical
did	O
not	O
affect	O
maximum	O
osmolality	O
or	O
creatinine	B-Chemical
clearance	O
.	O

CONCLUSIONS	O
:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	B-Chemical
once	O
daily	O
and/or	O
by	O
lowering	O
the	O
total	O
daily	O
dose	O
.	O

Lithium-induced	B-Chemical
polyuria	B-Disease
seems	O
to	O
be	O
related	O
to	O
extrarenal	O
as	O
well	O
as	O
to	O
renal	O
effects	O
.	O

Effect	O
of	O
adriamycin	B-Chemical
combined	O
with	O
whole	O
body	O
hyperthermia	B-Disease
on	O
tumor	B-Disease
and	O
normal	O
tissues	O
.	O

Thermal	O
enhancement	O
of	O
Adriamycin-mediated	B-Chemical
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	B-Disease
by	O
whole	O
body	O
hyperthermia	B-Disease
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O

Antitumor	B-Disease
activity	O
was	O
studied	O
using	O
a	O
tumor	O
growth	O
delay	O
assay	O
.	O

Acute	O
normal	O
tissue	O
toxicities	B-Disease
(	O
i.e.	O
,	O
leukopenia	B-Disease
and	O
thrombocytopenia	B-Disease
)	O
and	O
late	O
normal	O
tissue	O
toxicities	B-Disease
(	O
i.e.	O
,	O
myocardial	B-Disease
and	I-Disease
kidney	I-Disease
injury	I-Disease
)	O
were	O
evaluated	O
by	O
functional/physiological	O
assays	O
and	O
by	O
morphological	O
techniques	O
.	O

Whole	O
body	O
hyperthermia	O
(	O
120	O
min	O
at	O
41.5	O
degrees	O
C	O
)	O
enhanced	O
both	O
Adriamycin-mediated	O
antitumor	O
activity	O
and	O
toxic	O
side	O
effects	O
.	O

The	O
thermal	O
enhancement	O
ratio	O
calculated	O
for	O
antitumor	O
activity	O
was	O
1.6	O
.	O

Thermal	O
enhancement	O
ratios	O
estimated	O
for	O
``	O
acute	O
''	O
hematological	O
changes	O
were	O
1.3	O
,	O
whereas	O
those	O
estimated	O
for	O
``	O
late	O
''	O
damage	O
(	O
based	O
on	O
morphological	O
cardiac	O
and	O
renal	O
lesions	O
)	O
varied	O
between	O
2.4	O
and	O
4.3	O
.	O

Thus	O
,	O
while	O
whole	O
body	O
hyperthermia	O
enhances	O
Adriamycin-mediated	O
antitumor	O
effect	O
,	O
normal	O
tissue	O
toxicity	O
is	O
also	O
increased	O
,	O
and	O
the	O
potential	O
therapeutic	O
gain	O
of	O
the	O
combined	O
modality	O
treatment	O
is	O
eroded	O
.	O

Prazosin-induced	B-Chemical
stress	B-Disease
incontinence	I-Disease
.	O

A	O
case	O
of	O
genuine	O
stress	B-Disease
incontinence	I-Disease
due	O
to	O
prazosin	B-Chemical
,	O
a	O
common	O
antihypertensive	B-Drug
drug	B-Drug
,	O
is	O
presented	O
.	O

Prazosin	B-Chemical
exerts	O
its	O
antihypertensive	B-Drug
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha-1	O
adrenergic	O
receptors	O
.	O

As	O
an	O
alpha-blocker	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
relaxant	O
effect	O
on	O
the	O
bladder	O
neck	O
and	O
urethra	O
.	O

The	O
patient	O
's	O
clinical	O
course	O
is	O
described	O
and	O
correlated	O
with	O
initial	O
urodynamic	O
studies	O
while	O
on	O
prazosin	B-Chemical
and	O
subsequent	O
studies	O
while	O
taking	O
verapamil	B-Chemical
.	O

Her	O
incontinence	B-Disease
resolved	O
with	O
the	O
change	O
of	O
medication	O
.	O

The	O
restoration	O
of	O
continence	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maximum	O
urethral	O
pressure	O
,	O
maximum	O
urethral	O
closure	O
pressure	O
,	O
and	O
functional	O
urethral	O
length	O
.	O

Patients	O
who	O
present	O
with	O
stress	B-Disease
incontinence	I-Disease
while	O
taking	O
prazosin	B-Chemical
should	O
change	O
their	O
antihypertensive	B-Drug
medication	O
before	O
considering	O
surgery	O
,	O
because	O
their	O
incontinence	B-Disease
may	O
resolve	O
spontaneously	O
with	O
a	O
change	O
in	O
drug	B-Drug
therapy	O
.	O

Myocardial	B-Disease
infarction	I-Disease
following	O
sublingual	O
administration	O
of	O
isosorbide	B-Chemical
dinitrate	I-Chemical
.	O

A	O
78-year-old	O
with	O
healed	O
septal	O
necrosis	B-Disease
suffered	O
a	O
recurrent	O
myocardial	B-Disease
infarction	I-Disease
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	B-Chemical
dinitrate	I-Chemical
5	O
mg	O
sublingually	O
.	O

After	O
detailing	O
the	O
course	O
of	O
events	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	O
spasm	B-Disease
and	O
hypotension-mediated	B-Disease
myocardial	B-Disease
ischemia	I-Disease
occurring	O
downstream	O
to	O
significant	O
coronary	B-Disease
arterial	I-Disease
stenosis	I-Disease
in	O
the	O
pathophysiology	O
of	O
acute	B-Disease
coronary	I-Disease
insufficiency	I-Disease
.	O

Fluoxetine-induced	B-Chemical
akathisia	B-Disease
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O

Five	O
patients	O
receiving	O
fluoxetine	B-Chemical
for	O
the	O
treatment	O
of	O
obsessive	B-Disease
compulsive	I-Disease
disorder	I-Disease
or	O
major	B-Disease
depression	I-Disease
developed	O
akathisia	B-Disease
.	O

The	O
typical	O
fluoxetine-induced	B-Chemical
symptoms	O
of	O
restlessness	O
,	O
constant	O
pacing	O
,	O
purposeless	O
movements	O
of	O
the	O
feet	O
and	O
legs	O
,	O
and	O
marked	O
anxiety	B-Disease
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic-induced	O
akathisia	B-Disease
.	O

Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic-induced	O
akathisia	B-Disease
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine-induced	B-Chemical
akathisia	B-Disease
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O

Akathisia	B-Disease
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	B-Chemical
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta-adrenergic	O
antagonist	O
propranolol	B-Chemical
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O

The	O
authors	O
suggest	O
that	O
fluoxetine-induced	B-Chemical
akathisia	B-Disease
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	B-Drug
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine-induced	B-Chemical
akathisia	B-Disease
and	O
tricyclic	O
antidepressant-induced	B-Chemical
``	O
jitteriness	O
''	O
may	O
be	O
identical	O
.	O

Chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
associated	O
with	O
diclofenac	B-Chemical
sodium	I-Chemical
therapy	O
.	O

Diclofenac	B-Chemical
sodium	I-Chemical
(	O
Voltarol	B-Chemical
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non-steroidal	O
anti-inflammatory	O
derivative	O
of	O
phenylacetic	B-Chemical
acid	I-Chemical
.	O

Although	O
generally	O
well-tolerated	O
,	O
asymptomatic	O
abnormalities	B-Disease
of	I-Disease
liver	I-Disease
function	I-Disease
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severe	O
hepatitis	B-Disease
induced	O
by	O
diclofenac	B-Chemical
.	O

The	O
patient	O
described	O
developed	O
chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
after	O
six	O
months	O
therapy	O
with	O
diclofenac	B-Chemical
sodium	I-Chemical
which	O
progressed	O
despite	O
the	O
withdrawal	O
of	O
the	O
drug	B-Drug
,	O
a	O
finding	O
not	O
previously	O
reported	O
.	O

Stroke	B-Disease
associated	O
with	O
cocaine	B-Chemical
use	O
.	O

We	O
describe	O
eight	O
patients	O
in	O
whom	O
cocaine	B-Chemical
use	O
was	O
related	O
to	O
stroke	B-Disease
and	O
review	O
39	O
cases	O
from	O
the	O
literature	O
.	O

Among	O
these	O
47	O
patients	O
the	O
mean	O
(	O
+/-	O
SD	O
)	O
age	O
was	O
32.5	O
+/-	O
12.1	O
years	O
;	O
76	O
%	O
(	O
34/45	O
)	O
were	O
men	O
.	O

Stroke	B-Disease
followed	O
cocaine	B-Chemical
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	O
,	O
and	O
intramuscular	O
routes	O
.	O

Intracranial	B-Disease
aneurysms	I-Disease
or	O
arteriovenous	B-Disease
malformations	I-Disease
were	O
present	O
in	O
17	O
of	O
32	O
patients	O
studied	O
angiographically	O
or	O
at	O
autopsy	O
;	O
cerebral	B-Disease
vasculitis	I-Disease
was	O
present	O
in	O
two	O
patients	O
.	O

Cerebral	B-Disease
infarction	I-Disease
occurred	O
in	O
10	O
patients	O
(	O
22	O
%	O
)	O
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subarachnoid	B-Disease
hemorrhage	I-Disease
in	O
13	O
(	O
29	O
%	O
)	O
.	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apparent	O
incidence	O
of	O
stroke	B-Disease
related	O
to	O
cocaine	B-Chemical
use	O
is	O
increasing	O
;	O
(	O
2	O
)	O
cocaine-associated	B-Chemical
stroke	B-Disease
occurs	O
primarily	O
in	O
young	O
adults	O
;	O
(	O
3	O
)	O
stroke	B-Disease
may	O
follow	O
any	O
route	O
of	O
cocaine	B-Chemical
administration	O
;	O
(	O
4	O
)	O
stroke	B-Disease
after	O
cocaine	B-Chemical
use	O
is	O
frequently	O
associated	O
with	O
intracranial	B-Disease
aneurysms	I-Disease
and	O
arteriovenous	B-Disease
malformations	I-Disease
;	O
and	O
(	O
5	O
)	O
in	O
cocaine-associated	B-Chemical
stroke	B-Disease
,	O
the	O
frequency	O
of	O
intracranial	B-Disease
hemorrhage	I-Disease
exceeds	O
that	O
of	O
cerebral	B-Disease
infarction	I-Disease
.	O

Glyburide-induced	B-Chemical
hepatitis	B-Disease
.	O

Drug-induced	O
hepatotoxicity	B-Disease
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylureas	B-Chemical
.	O

For	O
glyburide	B-Chemical
,	O
a	O
second-generation	O
sulfonylurea	B-Chemical
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	B-Disease
exist	O
.	O

Two	O
patients	O
with	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
mellitus	I-Disease
developed	O
an	O
acute	B-Disease
hepatitis-like	I-Disease
syndrome	I-Disease
soon	O
after	O
initiation	O
of	O
glyburide	B-Chemical
therapy	O
.	O

There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	B-Disease
infection	I-Disease
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug-induced	B-Disease
hepatitis	I-Disease
.	O

Both	O
patients	O
recovered	O
quickly	O
after	O
stopping	O
glyburide	B-Chemical
therapy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow-up	O
period	O
of	O
1	O
year	O
.	O

Glyburide	B-Chemical
can	O
produce	O
an	O
acute	B-Disease
hepatitis-like	I-Disease
illness	I-Disease
in	O
some	O
persons	O
.	O

Systolic	O
pressure	O
variation	O
is	O
greater	O
during	O
hemorrhage	B-Disease
than	O
during	O
sodium	B-Chemical
nitroprusside-induced	O
hypotension	O
in	O
ventilated	O
dogs	O
.	O

The	O
systolic	O
pressure	O
variation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
maximal	O
and	O
minimal	O
values	O
of	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
after	O
one	O
positive-pressure	O
breath	O
,	O
was	O
studied	O
in	O
ventilated	O
dogs	O
subjected	O
to	O
hypotension	B-Disease
.	O

Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	B-Disease
(	O
HEM	B-Disease
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
,	O
n	O
=	O
7	O
)	O
.	O

During	O
HEM-induced	B-Disease
hypotension	B-Disease
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	B-Chemical
group	O
.	O

The	O
systemic	O
,	O
central	O
venous	O
,	O
pulmonary	O
capillary	O
wedge	O
pressures	O
,	O
and	O
heart	O
rates	O
,	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Analysis	O
of	O
the	O
respiratory	O
changes	O
in	O
the	O
arterial	O
pressure	O
waveform	O
enabled	O
differentiation	O
between	O
the	O
two	O
groups	O
.	O

The	O
SPV	O
during	O
hypotension	B-Disease
was	O
15.7	O
+/-	O
6.7	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
group	O
,	O
compared	O
with	O
9.1	O
+/-	O
2.0	O
mm	O
Hg	O
in	O
the	O
SNP	B-Chemical
group	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
delta	O
down	O
,	O
which	O
is	O
the	O
measure	O
of	O
decrease	O
of	O
SBP	O
after	O
a	O
mechanical	O
breath	O
,	O
was	O
20.3	O
+/-	O
8.4	O
and	O
10.1	O
+/-	O
3.8	O
mm	O
Hg	O
in	O
the	O
HEM	B-Disease
and	O
SNP	B-Chemical
groups	O
,	O
respectively	O
,	O
during	O
hypotension	B-Disease
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	B-Disease
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload	O
.	O

They	O
are	O
thus	O
more	O
important	O
during	O
absolute	O
hypovolemia	B-Disease
than	O
during	O
deliberate	O
hypotension	B-Disease
.	O

Drug-induced	O
arterial	O
spasm	B-Disease
relieved	O
by	O
lidocaine	B-Chemical
.	O

Case	O
report	O
.	O

Following	O
major	O
intracranial	O
surgery	O
in	O
a	O
35-year-old	O
man	O
,	O
sodium	B-Chemical
pentothal	I-Chemical
was	O
intravenously	O
infused	O
to	O
minimize	O
cerebral	B-Disease
ischaemia	I-Disease
.	O

Intense	O
vasospasm	B-Disease
with	O
threatened	O
gangrene	B-Disease
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O

Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	B-Chemical
was	O
given	O
intra-arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	B-Disease
.	O

The	O
treatment	O
was	O
rapidly	O
successful	O
.	O

Cerebral	O
blood	O
flow	O
and	O
metabolism	O
during	O
isoflurane-induced	B-Chemical
hypotension	B-Disease
in	O
patients	O
subjected	O
to	O
surgery	O
for	O
cerebral	B-Disease
aneurysms	I-Disease
.	O

Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	B-Chemical
were	O
measured	O
during	O
isoflurane-induced	B-Chemical
hypotension	B-Disease
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B-Disease
aneurysm	I-Disease
.	O

Flow	O
and	O
metabolism	O
were	O
measured	O
5-13	O
days	O
after	O
the	O
subarachnoid	B-Disease
haemorrhage	I-Disease
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety-Schmidt	O
technique	O
using	O
xenon-133	B-Chemical
i.v	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	B-Chemical
concentration	O
of	O
0.75	O
%	O
(	O
plus	O
67	O
%	O
nitrous	B-Chemical
oxide	I-Chemical
in	O
oxygen	B-Chemical
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34.3	O
+/-	O
2.1	O
ml/100	O
g	O
min-1	O
and	O
2.32	O
+/-	O
0.16	O
ml/100	O
g	O
min-1	O
at	O
PaCO2	O
4.1	O
+/-	O
0.1	O
kPa	O
(	O
mean	O
+/-	O
SEM	O
)	O
.	O

Controlled	O
hypotension	B-Disease
to	O
an	O
average	O
MAP	O
of	O
50-55	O
mm	O
Hg	B-Chemical
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	B-Chemical
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2.2	O
+/-	O
0.2	O
%	O
.	O

This	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
CMRO2	O
(	O
to	O
1.73	O
+/-	O
0.16	O
ml/100	O
g	O
min-1	O
)	O
,	O
while	O
CBF	O
was	O
unchanged	O
.	O

After	O
the	O
clipping	O
of	O
the	O
aneurysm	B-Disease
the	O
isoflurane	B-Chemical
concentration	O
was	O
reduced	O
to	O
0.75	O
%	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchanged	O
,	O
compared	O
with	O
pre-hypotensive	B-Disease
values	O
.	O

These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	B-Disease
.	O

Allergic	B-Disease
reaction	I-Disease
to	O
5-fluorouracil	B-Chemical
infusion	O
.	O

An	O
allergic	B-Disease
reaction	I-Disease
consisting	O
of	O
angioneurotic	B-Disease
edema	I-Disease
secondary	O
to	O
continuous	O
infusion	O
5-fluorouracil	B-Chemical
occurred	O
in	O
a	O
patient	O
with	O
recurrent	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
oral	I-Disease
cavity	I-Disease
,	O
cirrhosis	B-Disease
,	O
and	O
cisplatin-induced	B-Chemical
impaired	B-Disease
renal	I-Disease
function	I-Disease
.	O

This	O
reaction	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
courses	O
of	O
infusional	O
chemotherapy	O
.	O

Oral	O
diphenhydramine	B-Chemical
and	O
prednisone	B-Chemical
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	O
of	O
the	O
allergic	B-Disease
reaction	I-Disease
.	O

Discontinuance	O
of	O
effective	O
chemotherapy	O
in	O
this	O
patient	O
during	O
partial	O
remission	O
resulted	O
in	O
fatal	O
disease	O
progression	O
.	O

Amiodarone-induced	B-Chemical
sinoatrial	B-Disease
block	I-Disease
.	O

We	O
observed	O
sinoatrial	B-Disease
block	I-Disease
due	O
to	O
chronic	O
amiodarone	B-Chemical
administration	O
in	O
a	O
5-year-old	O
boy	O
with	O
primary	B-Disease
cardiomyopathy	I-Disease
,	O
Wolff-Parkinson-White	B-Disease
syndrome	I-Disease
and	O
supraventricular	B-Disease
tachycardia	I-Disease
.	O

Reduction	O
in	O
the	O
dosage	O
of	O
amiodarone	B-Chemical
resulted	O
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	B-Disease
block	I-Disease
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	B-Disease
bradycardia	I-Disease
.	O

Possible	O
teratogenicity	O
of	O
sulphasalazine	B-Chemical
.	O

Three	O
infants	O
,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
who	O
received	O
treatment	O
with	O
sulphasalazine	B-Chemical
throughout	O
pregnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenital	B-Disease
anomalies	I-Disease
.	O

In	O
the	O
singleton	O
pregnancy	O
,	O
the	O
mother	O
had	O
ulcerative	B-Disease
colitis	I-Disease
,	O
and	O
the	I-Disease
infant	O
,	O
a	O
male	O
,	O
had	O
coarctation	B-Disease
of	I-Disease
the	I-Disease
aorta	O
and	O
a	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
.	O

In	O
the	O
twin	O
pregnancy	O
,	O
the	O
mother	O
had	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
.	O

The	O
first	O
twin	O
,	O
a	O
female	O
,	O
had	O
a	O
left	O
Potter-type	B-Disease
IIa	I-Disease
polycystic	I-Disease
kidney	I-Disease
and	O
a	O
rudimentary	B-Disease
left	I-Disease
uterine	I-Disease
cornu	I-Disease
.	O

The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter	B-Disease
's	I-Disease
facies	I-Disease
,	O
hypoplastic	B-Disease
lungs	I-Disease
,	O
absent	B-Disease
kidneys	I-Disease
and	I-Disease
ureters	I-Disease
,	O
and	O
talipes	B-Disease
equinovarus	I-Disease
.	O

Despite	O
reports	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	B-Chemical
may	O
be	O
teratogenic	O
.	O

Veno-occlusive	B-Disease
liver	I-Disease
disease	I-Disease
after	O
dacarbazine	B-Chemical
therapy	O
(	O
DTIC	B-Chemical
)	O
for	O
melanoma	B-Disease
.	O

A	O
case	O
of	I-Disease
veno-occlusive	B-Disease
disease	I-Disease
of	I-Disease
the	I-Disease
liver	O
with	O
fatal	O
outcome	O
after	O
dacarbazine	B-Chemical
(	O
DTIC	B-Chemical
)	O
therapy	O
for	O
melanoma	B-Disease
is	O
reported	O
.	O

There	O
was	O
a	O
fulminant	O
clinical	O
course	O
from	O
start	O
of	O
symptoms	O
until	O
death	B-Disease
.	O

At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	B-Disease
congestion	I-Disease
.	O

Small-	O
and	O
medium-sized	O
hepatic	O
veins	O
were	O
blocked	O
by	O
thrombosis	B-Disease
.	O

Eosinophilic	O
infiltrations	O
were	O
found	O
around	O
the	O
vessels	O
.	O

Published	O
cases	O
from	O
the	O
literature	O
are	O
reviewed	O
and	O
pertinent	O
features	O
discussed	O
.	O

A	O
case	O
of	O
tardive	B-Disease
dyskinesia	I-Disease
caused	O
by	O
metoclopramide	B-Chemical
.	O

Abnormal	B-Disease
involuntary	I-Disease
movements	I-Disease
appeared	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
neck	O
and	O
abdomen	O
of	O
a	O
64-year-old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	B-Chemical
for	O
gastrointestinal	B-Disease
disorder	I-Disease
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days	O
.	O

The	O
symptoms	O
exacerbated	O
to	O
a	O
maximum	O
in	O
a	O
month	O
.	O

When	O
the	O
metoclopramide	B-Chemical
administration	O
was	O
discontinued	O
,	O
the	O
abnormal	B-Disease
movements	I-Disease
gradually	O
improved	O
to	O
a	O
considerable	O
extent	O
.	O

Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	B-Disease
dyskinesia	I-Disease
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
drug	B-Drug
.	O

Further	O
observations	O
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	O
amiodarone	B-Chemical
therapy	O
.	O

A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra-Hisian	B-Disease
block	I-Disease
occurring	O
under	O
amiodarone	B-Chemical
treatment	O
for	O
atrial	B-Disease
tachycardia	I-Disease
in	O
a	O
patient	O
without	O
clear	O
intraventricular	B-Disease
conduction	I-Disease
abnormalities	I-Disease
.	O

His	O
bundle	O
recordings	O
showed	O
an	O
atrial	B-Disease
tachycardia	I-Disease
with	O
intermittent	O
exit	O
block	O
and	O
greatly	O
prolonged	O
BH	O
and	O
HV	O
intervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O

Thirty	O
days	O
after	O
amiodarone	B-Chemical
discontinuation	O
,	O
His	O
bundle	O
electrograms	O
showed	O
atrial	B-Disease
flutter	I-Disease
without	O
intra-Hisian	O
or	O
infra-Hisian	O
delay	O
.	O

Amiodarone	B-Chemical
should	O
be	O
used	O
with	O
caution	O
during	O
long-term	O
oral	O
therapy	O
in	O
patients	O
with	O
or	O
without	O
clear	O
intraventricular	O
conduction	O
defects	O
.	O

Busulfan-induced	B-Chemical
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

A	O
case	O
of	O
a	O
busulfan-induced	B-Chemical
hemorrhage	B-Disease
cystitis	I-Disease
is	O
reported	O
.	O

Spontaneous	O
resolution	O
occurred	O
following	O
cessation	O
of	O
the	O
drug	B-Drug
.	O

The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	B-Drug
cystitis	O
and	O
both	O
radiation	O
and	O
cyclophosphamide-induced	O
cystitis	O
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed	O
.	O

In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfan	B-Drug
to	O
induce	O
cellular	O
atypia	O
and	O
carcinoma	O
in	O
other	O
sites	O
,	O
periodic	O
urinary	O
cytology	O
is	O
suggested	O
in	O
patients	O
on	O
long-term	O
therapy	O
.	O

Rebound	O
hypertensive	B-Disease
after	O
sodium	B-Chemical
nitroprusside	I-Chemical
prevented	O
by	O
saralasin	B-Chemical
in	O
rats	O
.	O

The	O
role	O
of	O
the	O
renin	O
--	O
angiotensin	B-Chemical
system	O
in	O
the	O
maintenance	O
of	O
blood	O
pressure	O
during	O
halothane	B-Chemical
anesthesia	B-Drug
and	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
-induced	O
hypotension	B-Disease
was	O
evaluated	O
.	O

Control	O
rats	O
received	O
halothane	B-Chemical
anesthesia	B-Drug
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	B-Chemical
infusion	O
,	O
40	O
microgram/kg/min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30-min	O
recovery	O
period	O
.	O

A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusion	O
of	O
saralasin	B-Chemical
(	O
a	O
competitive	O
inhibitor	O
of	O
angiotensin	B-Chemical
II	I-Chemical
)	O
throughout	O
the	O
experimental	O
period	O
.	O

In	O
each	O
group	O
,	O
SNP	B-Chemical
infusion	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
blood	O
pressure	O
from	O
86	O
torr	O
and	O
83	O
torr	O
,	O
respectively	O
,	O
to	O
48	O
torr	O
.	O

During	O
the	O
SNP	B-Chemical
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	B-Disease
in	B-Disease
blood	I-Disease
pressure	I-Disease
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin-treated	B-Chemical
animals	O
showed	O
no	O
change	O
.	O

Following	O
discontinuation	O
of	O
SNP	B-Chemical
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin-treated	B-Chemical
rats	O
.	O

This	O
study	O
indicates	O
that	O
with	O
stable	O
halothane	B-Chemical
anesthesia	B-Drug
,	O
the	O
partial	O
recovery	O
of	O
blood	O
pressure	O
during	O
SNP	B-Chemical
infusion	O
and	O
the	O
post-SNP	B-Chemical
rebound	O
of	O
blood	O
pressure	O
can	O
be	O
completely	O
blocked	O
by	O
saralasin	B-Chemical
.	O

This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin	O
--	O
angiotensin	B-Chemical
system	O
in	O
antagonizing	O
the	O
combined	O
hypotensive	B-Disease
effects	O
of	O
halothane	B-Chemical
and	O
SNP	B-Chemical
.	O

Toxic	B-Disease
hepatitis	I-Disease
induced	O
by	O
antithyroid	O
drugs	B-Drug
:	O
four	O
cases	O
including	O
one	O
with	O
cross-reactivity	O
between	O
carbimazole	B-Chemical
and	O
benzylthiouracil	B-Chemical
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepatic	B-Disease
adverse	I-Disease
effects	I-Disease
encountered	O
with	O
antithyroid	O
drugs	B-Drug
.	O

METHODS	O
:	O
Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	B-Disease
admitted	O
in	O
our	O
department	O
(	O
in-	O
or	O
out-patients	O
)	O
from	O
1986	O
to	O
1992	O
.	O

RESULTS	O
:	O
Four	O
patients	O
(	O
1.7	O
%	O
)	O
were	O
identified	O
with	O
toxic	B-Disease
hepatitis	I-Disease
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithyroid	O
agent	O
.	O

Two	O
patients	O
had	O
a	O
cholestatic	B-Disease
hepatitis	I-Disease
induced	O
by	O
carbimazole	B-Drug
(	O
N	O
omercazole	O
)	O
.	O

Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestatic	B-Chemical
and	O
cytolytic	O
)	O
hepatitis	B-Chemical
following	O
carbimazole	B-Disease
.	O

One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	O
which	O
appeared	O
after	O
Benzylthiouracil	O
(	O
Basd	O
ne	O
)	O
had	O
replaced	O
carbimazole	B-Drug
.	O

Biological	O
features	O
of	O
hepatitis	O
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug	B-Drug
,	O
while	O
biliary	O
,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative	O
.	O

Only	O
2	O
patients	O
of	O
our	O
retrospective	O
study	O
experienced	O
a	O
mild	O
or	O
severe	O
neutropenia	O
.	O

CONCLUSION	B-Chemical
:	O
Toxic	O
hepatitis	O
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	O
drugs	B-Drug
which	O
warrants	O
,	O
as	O
for	O
haematological	O
disturbances	O
,	O
a	O
pre-therapeutic	O
determination	O
and	O
a	O
careful	O
follow-up	O
of	O
relevant	O
biological	O
markers	O
.	O

Moreover	O
,	O
hepatotoxicity	O
may	O
not	O
be	O
restricted	O
to	O
one	O
class	O
of	O
antithyroid	O
agents	O
.	O

Study	O
of	O
the	O
role	O
of	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
in	O
preventing	O
hematologic	O
toxicity	B-Disease
of	O
zidovudine	B-Chemical
.	O

A	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
in	O
preventing	O
zidovudine	B-Chemical
(	O
ZDV	B-Chemical
)	O
-induced	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O

Seventy-five	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
-infected	I-Disease
patients	O
with	O
CD4+	O
cell	O
counts	O
<	O
500/mm3	O
were	O
randomized	O
to	O
receive	O
either	O
ZDV	B-Chemical
(	O
500	O
mg	O
daily	O
)	O
alone	O
(	O
group	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combination	O
with	O
folinic	B-Chemical
acid	I-Chemical
(	O
15	O
mg	O
daily	O
)	O
and	O
intramascular	O
vitamin	B-Chemical
B12	I-Chemical
(	O
1000	O
micrograms	O
monthly	O
)	O
(	O
group	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O

Finally	O
,	O
15	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
(	O
noncompliance	O
14	O
,	O
death	B-Disease
1	O
)	O
;	O
thus	O
,	O
60	O
patients	O
(	O
31	O
in	O
group	O
I	O
and	O
29	O
in	O
group	O
II	O
)	O
were	O
eligible	O
for	O
analysis	O
.	O

No	O
significant	O
differences	O
between	O
groups	O
were	O
found	O
at	O
enrollment	O
.	O

During	O
the	O
study	O
,	O
vitamin	B-Chemical
B12	I-Chemical
and	O
folate	B-Chemical
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients	O
;	O
however	O
,	O
no	O
differences	O
in	O
hemoglobin	O
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
white-cell	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
.	O

Severe	O
hematologic	O
toxicity	B-Disease
(	O
neutrophil	O
count	O
<	O
1000/mm3	O
and/or	O
hemoglobin	O
<	O
8	O
g/dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

There	O
was	O
no	O
correlation	O
between	O
vitamin	B-Chemical
B12	I-Chemical
or	O
folate	B-Chemical
levels	O
and	O
development	O
of	O
myelosuppression	B-Disease
.	O

Vitamin	B-Chemical
B12	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
supplementation	O
of	O
ZDV	B-Chemical
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	O
ZDV-induced	B-Chemical
myelotoxicity	B-Disease
in	O
the	O
overall	O
treated	O
population	O
,	O
although	O
a	O
beneficial	O
effect	O
in	O
certain	O
subgroups	O
of	O
patients	O
can	O
not	O
be	O
excluded	O
.	O

Acute	O
confusion	B-Disease
induced	O
by	O
a	O
high-dose	O
infusion	O
of	O
5-fluorouracil	B-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
.	O

A	O
61-year-old	O
man	O
was	O
treated	O
with	O
combination	O
chemotherapy	O
incorporating	O
cisplatinum	B-Chemical
,	O
etoposide	B-Chemical
,	O
high-dose	O
5-fluorouracil	B-Chemical
(	O
2,250	O
mg/m2/24	O
hours	O
)	O
and	O
folinic	B-Chemical
acid	I-Chemical
for	O
an	O
inoperable	O
gastric	B-Disease
adenocarcinoma	I-Disease
.	O

He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	B-Disease
,	O
disorientation	B-Disease
and	O
irritability	B-Disease
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	B-Disease
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(	O
day	O
2	O
)	O
of	O
5-fluorouracil	B-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
infusion	O
.	O

This	O
complication	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	O
of	O
5-fluorouracil	B-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
,	O
which	O
were	O
then	O
the	O
only	O
drugs	B-Drug
given	O
.	O

Because	O
folinic	B-Chemical
acid	I-Chemical
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition	O
,	O
neurotoxicity	B-Disease
due	O
to	O
high-dose	O
5-fluorouracil	B-Chemical
was	O
highly	O
suspected	O
.	O

The	O
pathogenesis	O
of	O
5-fluorouracil	B-Chemical
neurotoxicity	B-Disease
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	B-Chemical
and	O
fluorocitrate	B-Chemical
,	O
thiamine	B-Chemical
deficiency	O
,	O
or	O
dihydrouracil	B-Chemical
dehydrogenase	O
deficiency	O
.	O

High-dose	O
5-fluorouracil/folinic	B-Chemical
acid	I-Chemical
infusion	O
therapy	O
has	O
recently	O
become	O
a	O
popular	O
regimen	O
for	O
various	O
cancers	O
.	O

It	O
is	O
necessary	O
that	O
both	O
oncologists	O
and	O
neurologists	O
be	O
fully	O
aware	O
of	O
this	O
unusual	O
complication	O
.	O

Effect	O
of	O
switching	O
carbamazepine	B-Chemical
to	O
oxcarbazepine	B-Chemical
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics	O
.	O

A	O
case	O
report	O
.	O

Carbamazepine	B-Chemical
was	O
switched	O
to	O
its	O
10-keto	O
analogue	O
oxcarbazepine	B-Chemical
among	O
six	O
difficult-to-treat	O
schizophrenic	B-Disease
or	O
organic	B-Disease
psychotic	I-Disease
patients	O
using	O
concomitantly	O
haloperidol	B-Chemical
,	O
chlorpromazine	B-Chemical
or	O
clozapine	B-Chemical
.	O

This	O
change	O
resulted	O
within	O
2-4	O
weeks	O
in	O
the	O
50-200	O
%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	O
and	O
the	O
appearance	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O

None	O
of	O
the	O
patients	O
showed	O
any	O
clinical	O
deteriotation	O
during	O
the	O
following	O
3-6	O
months	O
.	O

The	O
results	O
of	O
this	O
case	O
report	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbamazepine	B-Chemical
oxcarbazepine	B-Chemical
does	O
not	O
induce	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
regulating	O
the	O
inactivation	O
of	O
antipsychotic	O
drugs	B-Drug
.	O

Erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
erythema	B-Disease
multiforme	I-Disease
and	O
hypersensitivity	B-Disease
myocarditis	I-Disease
caused	O
by	O
ampicillin	B-Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
13-year-old	O
boy	O
was	O
treated	O
with	O
ampicillin	B-Chemical
and	O
gentamicin	B-Chemical
because	O
of	O
suspected	O
septicemia	B-Disease
.	O

Medications	O
were	O
discontinued	O
when	O
erythema	B-Disease
multiforme	I-Disease
and	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
caused	O
by	O
myocarditis	B-Disease
occurred	O
.	O

The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	B-Chemical
and	O
gradually	O
improved	O
.	O

Macrophage-migration	O
inhibition	O
(	O
MIF	O
)	O
test	O
with	O
ampicillin	B-Chemical
was	O
positive	O
.	O

DISCUSSION	O
:	O
After	O
most	O
infections	B-Disease
causing	O
erythema	B-Disease
multiforme	I-Disease
and	O
myocarditis	B-Disease
were	O
ruled	O
out	O
,	O
a	O
drug-induced	B-Disease
allergic	I-Disease
reaction	I-Disease
was	O
suspected	O
.	O

Positive	O
MIF	O
test	O
for	O
ampicillin	B-Chemical
showed	O
sensitization	O
of	O
the	O
patient	O
's	O
lymphocytes	O
to	O
ampicillin	B-Chemical
.	O

CONCLUSIONS	O
:	O
Hypersensitivity	B-Disease
myocarditis	I-Disease
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	B-Disease
to	O
penicillins	B-Chemical
.	O

Immediate	O
allergic	B-Disease
reactions	I-Disease
to	O
amoxicillin	B-Chemical
.	O

A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	B-Disease
reactions	I-Disease
to	O
beta-lactam	B-Chemical
antibiotics	B-Drug
was	O
evaluated	O
.	O

A	O
detailed	O
clinical	O
history	O
,	O
together	O
with	O
skin	O
tests	O
,	O
RAST	O
(	O
radioallergosorbent	O
test	O
)	O
,	O
and	O
controlled	O
challenge	O
tests	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patients	O
allergic	B-Disease
to	O
beta-lactam	B-Chemical
antibiotics	B-Drug
had	O
selective	O
immediate	O
allergic	B-Disease
responses	O
to	O
amoxicillin	B-Chemical
(	O
AX	B-Chemical
)	O
or	O
were	O
cross-reacting	O
with	O
other	O
penicillin	B-Chemical
derivatives	O
.	O

Skin	O
tests	O
were	O
performed	O
with	O
benzylpenicilloyl-poly-L-lysine	B-Chemical
(	O
BPO-PLL	B-Chemical
)	O
,	O
benzylpenicilloate	B-Chemical
,	O
benzylpenicillin	B-Chemical
(	O
PG	B-Chemical
)	O
,	O
ampicillin	B-Chemical
(	O
AMP	B-Chemical
)	O
,	O
and	O
AX	B-Chemical
.	O

RAST	O
for	O
BPO-PLL	B-Chemical
and	O
AX-PLL	B-Chemical
was	O
done	O
.	O

When	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
BPO	B-Chemical
were	O
negative	O
,	O
single-blind	O
,	O
placebo-controlled	O
challenge	O
tests	O
were	O
done	O
to	O
ensure	O
tolerance	O
of	O
PG	B-Chemical
or	O
sensitivity	O
to	O
AX	B-Chemical
.	O

A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	B-Disease
to	O
beta-lactam	B-Chemical
antibiotics	B-Drug
.	O

We	O
selected	O
the	O
54	O
(	O
30.5	O
%	O
)	O
cases	O
of	O
immediate	O
AX	B-Chemical
allergy	B-Disease
with	O
good	O
tolerance	O
of	O
PG	B-Chemical
.	O

Anaphylaxis	B-Disease
was	O
seen	O
in	O
37	O
patients	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
urticaria	B-Disease
and/or	O
angioedema	B-Disease
.	O

All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	B-Chemical
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negative	O
to	O
MDM	B-Disease
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	B-Chemical
.	O

Skin	O
tests	O
with	O
AX	B-Chemical
were	O
positive	O
in	O
34	O
(	O
63	O
%	O
)	O
patients	O
.	O

RAST	O
was	O
positive	O
for	O
AX	B-Chemical
in	O
22	O
patients	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	B-Chemical
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O

None	O
of	O
the	O
sera	O
with	O
negative	O
RAST	O
for	O
AX	B-Chemical
were	O
positive	O
to	O
BPO	B-Chemical
.	O

Challenge	O
tests	O
with	O
AX	B-Chemical
were	O
performed	O
in	O
23	O
subjects	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	B-Disease
reaction	I-Disease
to	O
AX	B-Chemical
,	O
and	O
in	O
15	O
cases	O
(	O
28	O
%	O
)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	B-Chemical
were	O
negative	O
.	O

PG	B-Chemical
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients	O
.	O

We	O
describe	O
the	O
largest	O
group	O
of	O
AX-allergic	B-Chemical
patients	O
who	O
have	O
tolerated	O
PG	O
reported	O
so	O
far	O
.	O

Diagnosis	O
of	O
these	O
patients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX-related	O
reagents	O
are	O
employed	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
problem	O
and	O
to	O
improve	O
the	O
efficacy	O
of	O
diagnostic	O
methods	O
.	O

Persistent	O
paralysis	B-Disease
after	O
prolonged	O
use	O
of	O
atracurium	B-Chemical
in	O
the	O
absence	O
of	O
corticosteroids	O
.	O

Neuromuscular	O
blocking	O
agents	O
(	O
NMBAs	O
)	O
are	O
often	O
used	O
for	O
patients	O
requiring	O
prolonged	O
mechanical	O
ventilation	O
.	O

Reports	O
of	O
persistent	O
paralysis	B-Disease
after	O
the	O
discontinuance	O
of	O
these	O
drugs	B-Drug
have	O
most	O
often	O
involved	O
aminosteroid-based	O
NMBAs	O
such	O
as	O
vecuronium	B-Chemical
bromide	I-Chemical
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids	O
.	O

Atracurium	B-Chemical
besylate	I-Chemical
,	O
a	O
short-acting	O
benzylisoquinolinium	B-Chemical
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	O
or	O
hepatic	O
function	O
,	O
has	O
also	O
been	O
associated	O
with	O
persistent	O
paralysis	B-Disease
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids	O
.	O

We	O
report	O
a	O
case	O
of	O
atracurium-related	B-Chemical
paralysis	B-Disease
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patient	O
who	O
was	O
not	O
treated	O
with	O
corticosteroids	O
.	O

Habitual	O
use	O
of	O
acetaminophen	B-Chemical
as	O
a	O
risk	O
factor	O
for	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
:	O
a	O
comparison	O
with	O
phenacetin	B-Chemical
.	O

Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	B-Chemical
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
end-stage	B-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O

As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies	O
,	O
phenacetin	B-Chemical
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O

However	O
,	O
three	O
case	O
control	O
studies	O
,	O
one	O
each	O
in	O
North	O
Carolina	O
,	O
northern	O
Maryland	O
,	O
and	O
West	O
Berlin	O
,	O
Germany	O
,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
is	O
also	O
associated	O
with	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
ESRD	B-Disease
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O

These	O
studies	O
suggest	O
that	O
both	O
phenacetin	B-Chemical
and	O
acetaminophen	B-Chemical
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	B-Disease
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

This	O
apparent	O
difference	O
in	O
risk	O
may	O
not	O
be	O
due	O
to	O
differences	O
in	O
nephrotoxic	B-Disease
potential	O
of	O
the	O
drugs	B-Drug
themselves	O
.	O

A	O
lower	O
relative	O
risk	O
would	O
be	O
expected	O
for	O
acetaminophen	B-Chemical
if	O
the	O
risk	O
of	O
both	O
drugs	B-Drug
in	O
combination	O
with	O
other	O
analgesics	O
was	O
higher	O
than	O
the	O
risk	O
of	O
either	O
agent	O
alone	O
.	O

Thus	O
,	O
acetaminophen	B-Chemical
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics	O
,	O
whereas	O
phenacetin	B-Chemical
was	O
available	O
only	O
in	O
combinations	O
.	O

The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-Chemical
alone	O
increases	O
the	O
risk	O
of	O
ESRD	B-Disease
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
can	O
not	O
be	O
dismissed	O
.	O

Reduction	O
of	O
heparan	B-Chemical
sulphate-associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin-induced	O
diabetic	O
nephropathy	O
.	O

Heparan	B-Chemical
sulphate-associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
were	O
studied	O
in	O
rats	O
8	O
months	O
after	O
induction	O
of	O
diabetes	O
by	O
streptozotocin	O
and	O
in	O
age-	O
adn	O
sex-matched	O
control	O
rats	O
,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	O
blue	O
.	O

Morphometric	O
analysis	O
at	O
the	O
ultrastructural	O
level	O
was	O
performed	O
using	O
a	O
computerized	O
image	O
processor	O
.	O

The	O
heparan	O
sulphate	I-Chemical
specificity	O
of	O
the	O
cuprolinic	O
blue	O
staining	O
was	O
demonstrated	O
by	O
glycosaminoglycan-degrading	O
enzymes	O
,	O
showing	O
that	O
pretreatment	O
of	O
the	O
sections	O
with	O
heparitinase	O
abolished	O
all	O
staining	O
,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect	O
.	O

The	O
majority	O
of	O
anionic	O
sites	O
(	O
74	O
%	O
in	O
diabetic	O
and	O
81	O
%	O
in	O
control	O
rats	O
)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

A	O
minority	O
of	O
anionic	O
sites	O
were	O
scattered	O
throughout	O
the	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
p	O
<	O
0.001	O
and	O
p	O
<	O
0.01	O
for	O
diabetic	O
and	O
control	O
rats	O
,	O
respectively	O
)	O
.	O

Diabetic	O
rats	O
progressively	O
developed	O
albuminuria	O
reaching	O
40.3	O
(	O
32.2-62.0	O
)	O
mg/24	O
h	O
after	O
8	O
months	O
in	O
contrast	O
to	O
the	O
control	O
animals	O
(	O
0.8	O
(	O
0.2-0.9	O
)	O
mg/24	O
h	O
,	O
p	O
<	O
0.002	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	O
sulphate	O
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19	O
%	O
(	O
p	O
<	O
0.021	O
)	O
and	O
by	O
26	O
%	O
(	O
p	O
<	O
0.02	O
)	O
,	O
respectively	O
.	O

Number	O
and	O
total	O
anionic	O
site	O
surface	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
)	O
were	O
not	O
significantly	O
changed	O
.	O

We	O
conclude	O
that	O
in	O
streptozotocin-diabetic	O
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion	O
,	O
a	O
reduced	O
heparan	O
sulphate	O
charge	O
barrier/density	O
is	O
found	O
at	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

Effect	O
of	O
some	O
anticancer	O
drugs	B-Drug
and	O
combined	O
chemotherapy	O
on	O
renal	B-Disease
toxicity	I-Disease
.	O

The	O
nephrotoxic	B-Disease
action	O
of	O
anticancer	O
drugs	B-Drug
such	O
as	O
nitrogranulogen	B-Chemical
(	O
NG	B-Chemical
)	O
,	O
methotrexate	B-Chemical
(	O
MTX	B-Chemical
)	O
,	O
5-fluorouracil	B-Chemical
(	O
5-FU	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CY	B-Chemical
)	O
administered	O
alone	O
or	O
in	O
combination	O
[	O
MTX	B-Chemical
+	O
5-FU	B-Chemical
+	O
CY	B-Chemical
(	O
CMF	O
)	O
]	O
was	O
evaluated	O
in	O
experiments	O
on	O
Wistar	O
rats	O
.	O

After	O
drug	B-Drug
administration	O
,	O
creatinine	B-Chemical
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinine	B-Chemical
clearance	O
.	O

Histopathologic	O
evaluation	O
of	O
the	O
kidneys	O
was	O
also	O
performed	O
.	O

After	O
MTX	B-Chemical
administration	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0.0228	O
)	O
in	O
the	O
plasma	O
creatinine	B-Chemical
concentration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0.0001	O
)	O
decrease	O
in	O
creatinine	B-Chemical
clearance	O
was	O
noted	O
compared	O
to	O
controls	O
.	O

After	O
the	O
administration	O
of	O
NG	B-Chemical
,	O
5-FU	B-Chemical
and	O
CY	B-Chemical
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	B-Chemical
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	B-Chemical
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics	O
.	O

Following	O
polytherapy	O
according	O
to	O
the	O
CMF	O
regimen	O
,	O
a	O
statistically	O
significant	O
decrease	O
(	O
p	O
=	O
0.0343	O
)	O
in	O
creatinine	B-Chemical
clearance	O
was	O
found	O
,	O
but	O
creatinine	B-Chemical
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls	O
.	O

CY	B-Chemical
caused	O
hemorrhagic	B-Disease
cystitis	I-Disease
in	O
40	O
%	O
of	O
rats	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5-FU	B-Drug
and	O
MTX	B-Drug
.	O

Histologic	O
changes	O
were	O
found	O
in	O
rat	O
kidneys	O
after	O
administration	O
of	O
MTX	B-Drug
,	O
CY	O
and	O
NG	O
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5-FU	B-Drug
and	O
joint	O
administration	O
of	O
MTX	B-Drug
+	O
5-FU	B-Drug
+	O
CY	O
compared	O
to	O
controls	O
.	O

Our	O
studies	O
indicate	O
that	O
nephrotoxicity	O
of	O
MTX	B-Drug
+	O
5-FU	B-Drug
+	O
CY	O
administered	O
jointly	O
is	O
lower	O
than	O
in	O
monotherapy	O
.	O

Lithium-associated	B-Chemical
cognitive	B-Disease
and	I-Disease
functional	I-Disease
deficits	I-Disease
reduced	O
by	O
a	O
switch	O
to	O
divalproex	B-Chemical
sodium	I-Chemical
:	O
a	O
case	O
series	O
.	O

BACKGROUND	O
:	O
Lithium	B-Chemical
remains	O
a	O
first-line	O
treatment	O
for	O
the	O
acute	O
and	O
maintenance	O
treatment	O
of	O
bipolar	B-Disease
disorder	I-Disease
.	O

Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	B-Chemical
,	O
such	O
as	O
polyuria	B-Disease
and	O
tremor	B-Disease
,	O
more	O
subtle	O
lithium	B-Chemical
side	O
effects	O
such	O
as	O
cognitive	B-Disease
deficits	I-Disease
,	O
loss	B-Disease
of	I-Disease
creativity	I-Disease
,	O
and	O
functional	B-Disease
impairments	I-Disease
remain	O
understudied	O
.	O

This	O
report	O
summarizes	O
our	O
experience	O
in	O
switching	O
bipolar	B-Disease
patients	O
from	O
lithium	B-Chemical
to	O
divalproex	B-Chemical
sodium	I-Chemical
to	O
alleviate	O
such	O
cognitive	B-Disease
and	I-Disease
functional	I-Disease
impairments	I-Disease
.	O

METHOD	O
:	O
Open	O
,	O
case	O
series	O
design	O
.	O

RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	B-Chemical
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B-Disease
,	I-Disease
motivational	I-Disease
,	I-Disease
or	I-Disease
creative	I-Disease
deficits	I-Disease
attributed	O
to	O
lithium	B-Chemical
in	O
our	O
bipolar	B-Disease
patients	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
report	O
,	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
a	O
superior	O
alternative	O
to	O
lithium	B-Chemical
in	O
bipolar	B-Disease
patients	O
experiencing	O
cognitive	B-Disease
deficits	I-Disease
,	O
loss	B-Disease
of	I-Disease
creativity	I-Disease
,	O
and	O
functional	B-Disease
impairments	I-Disease
.	O

Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	B-Disease
cancer	I-Disease
by	O
mitoxantrone	B-Chemical
and	O
48-hour	O
continuous	O
infusion	O
of	O
high-dose	O
5-FU	B-Chemical
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
)	O
:	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment-related	O
toxicity	B-Disease
.	O

For	O
previously	O
treated	O
advanced	O
breast	B-Disease
cancer	I-Disease
,	O
there	O
is	O
no	O
standard	O
second-line	O
therapy	O
.	O

Combination	O
chemotherapy	O
with	O
mitoxantrone	B-Chemical
,	O
high-dose	O
5-fluorouracil	B-Chemical
(	O
5-FU	B-Chemical
)	O
and	O
leucovorin	B-Chemical
(	O
MFL	B-Chemical
regimen	I-Chemical
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen	O
.	O

From	O
October	O
1993	O
to	O
November	O
1995	O
,	O
we	O
treated	O
13	O
patients	O
with	O
previously	O
chemotherapy-treated	O
metastatic	O
breast	B-Disease
cancer	I-Disease
by	O
mitoxantrone	B-Chemical
,	O
12	O
mg/m2	O
,	O
on	O
day	O
1	O
and	O
continuous	O
infusion	O
of	O
5-FU	B-Chemical
,	O
3000	O
mg/m2	O
,	O
together	O
with	O
leucovorin	B-Chemical
,	O
300	O
mg/m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O

Each	O
course	O
of	O
chemotherapy	O
was	O
given	O
every	O
4	O
weeks	O
.	O

Most	O
of	O
these	O
patients	O
had	O
more	O
than	O
two	O
metastatic	O
sites	O
,	O
with	O
lung	O
metastasis	O
predominant	O
.	O

Seven	O
patients	O
had	O
been	O
treated	O
with	O
anthracycline	B-Chemical
.	O

Seven	O
patients	O
had	O
previously	O
received	O
radiotherapy	O
and	O
seven	O
had	O
received	O
hormone	O
therapy	O
.	O

Median	O
number	O
of	O
courses	O
of	O
MFL	B-Chemical
regimen	I-Chemical
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	B-Chemical
was	O
68.35	O
mg/m2	O
.	O

One	O
patient	O
had	O
complete	O
response	O
,	O
seven	O
had	O
stable	O
disease	O
,	O
none	O
had	O
partial	O
response	O
and	O
five	O
had	O
progressive	O
disease	O
.	O

The	O
overall	O
objective	O
response	O
rate	O
was	O
7.6	O
%	O
.	O

The	O
median	O
follow-up	O
period	O
was	O
14	O
months	O
.	O

Median	O
survival	O
was	O
16	O
months	O
.	O

Median	O
progression-free	O
survival	O
was	O
5	O
months	O
.	O

A	O
complete	O
responder	O
had	O
relapse-free	O
survival	O
up	O
to	O
17	O
months	O
.	O

Major	O
toxicities	B-Disease
were	O
cardiotoxicity	B-Disease
and	O
leukopenia	B-Disease
.	O

Eight	O
patients	O
were	O
dead	O
in	O
the	O
last	O
follow-up	O
;	O
two	O
of	O
them	O
died	O
of	O
treatment-related	O
toxicity	B-Disease
.	O

The	O
MFL	B-Chemical
regimen	I-Chemical
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	B-Disease
at	O
a	O
fairly	O
high	O
rate	O
.	O

Administration	O
of	O
this	O
regimen	O
to	O
breast	B-Disease
cancer	I-Disease
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	B-Disease
heart	I-Disease
function	I-Disease
requires	O
careful	O
attention	O
.	O

Upregulation	O
of	O
the	O
expression	O
of	O
vasopressin	B-Chemical
gene	O
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	O
of	O
the	O
lithium-induced	B-Chemical
diabetes	B-Disease
insipidus	I-Disease
rat	O
.	O

The	O
expression	O
of	O
arginine	B-Chemical
vasopressin	I-Chemical
(	O
AVP	B-Chemical
)	O
gene	O
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	B-Chemical
(	O
Li	B-Chemical
)	O
-induced	O
polyuria	B-Disease
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O

The	O
male	O
Wistar	O
rats	O
consuming	O
a	O
diet	O
that	O
contained	O
LiCl	B-Chemical
(	O
60	O
mmol/kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
polyuria	B-Disease
.	O

The	O
Li-treated	B-Chemical
rats	O
produced	O
a	O
large	O
volume	O
of	O
hypotonic	O
urine	O
with	O
low	O
ionic	O
concentrations	O
.	O

Plasma	O
sodium	B-Chemical
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li-treated	B-Chemical
rats	O
compared	O
with	O
those	O
in	O
controls	O
.	O

Plasma	O
concentration	O
of	O
AVP	B-Chemical
and	O
transcripts	O
of	O
AVP	B-Chemical
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li-treated	B-Chemical
rats	O
compared	O
with	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
dehydration	B-Disease
and/or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	B-Chemical
and	O
the	O
upregulation	O
of	O
AVP	B-Chemical
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li-induced	B-Chemical
diabetes	B-Disease
insipidus	I-Disease
rat	O
.	O

Suxamethonium-induced	B-Chemical
cardiac	B-Disease
arrest	I-Disease
and	O
death	B-Disease
following	O
5	O
days	O
of	O
immobilization	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
cardiac	B-Disease
arrest	I-Disease
and	O
subsequent	O
death	B-Disease
as	O
a	O
result	O
of	O
hyperkalaemia	B-Disease
following	O
the	O
use	O
of	O
suxamethonium	B-Chemical
in	O
a	O
23-year-old	O
Malawian	O
woman	O
.	O

Five	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
of	O
meningitis	B-Disease
,	O
the	O
patient	O
aspirated	O
stomach	O
contents	O
and	O
needed	O
endotracheal	O
intubation	O
.	O

Forty	O
seconds	O
after	O
injection	O
of	O
suxamethonium	B-Chemical
,	O
bradycardia	B-Disease
and	O
cardiac	B-Disease
arrest	I-Disease
occurred	O
.	O

Attempts	O
to	O
resuscitate	O
the	O
patient	O
were	O
not	O
successful	O
.	O

The	O
serum	O
level	O
of	O
potassium	B-Chemical
was	O
observed	O
to	O
be	O
8.4	O
mequiv	O
L-1	O
.	O

Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient	O
's	O
level	O
of	O
consciousness	O
,	O
there	O
were	O
no	O
signs	O
of	O
motor	O
neurone	O
damage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	B-Disease
following	O
the	O
administration	O
of	O
suxamethonium	B-Chemical
.	O

It	O
is	O
postulated	O
that	O
her	O
death	B-Disease
was	O
caused	O
by	O
hypersensitivity	B-Disease
to	O
suxamethonium	B-Chemical
,	O
associated	O
with	O
her	O
5-day	O
immobilization	O
.	O

An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	B-Chemical
with	O
adrenaline	B-Chemical
.	O

An	O
increase	B-Disease
in	B-Disease
blood	I-Disease
pressure	I-Disease
,	O
accompanied	O
by	O
atrial	B-Disease
fibrillation	I-Disease
,	O
agitation	B-Disease
,	O
incomprehensible	B-Disease
shouts	I-Disease
and	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
,	O
was	O
observed	O
in	O
an	O
elderly	O
,	O
ASA	B-Drug
classification	O
group	O
II	O
,	O
cardiovascularly	O
medicated	O
male	O
,	O
12	O
min	O
after	O
performance	O
of	O
axillary	O
block	O
with	O
mepivacaine	B-Chemical
850	O
mg	O
containing	O
adrenaline	B-Chemical
0.225	O
mg	O
,	O
for	O
correction	O
of	O
Dupuytren	B-Disease
's	I-Disease
contracture	I-Disease
.	O

After	O
intravenous	O
administration	O
of	O
labetalol	B-Chemical
,	O
metoprolol	B-Chemical
and	O
midazolam	B-Chemical
the	O
patient	O
's	O
condition	O
improved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O

The	O
block	O
was	O
successful	O
and	O
surgery	O
was	O
conducted	O
as	O
scheduled	O
despite	O
persisting	O
atrial	B-Disease
fibrillation	I-Disease
.	O

Postoperatively	O
,	O
the	O
patient	O
refused	O
DC	O
cardioversion	O
and	O
was	O
treated	O
medically	O
.	O

Both	O
the	O
temporal	O
relationship	O
of	O
events	O
and	O
the	O
response	O
to	O
treatment	O
suggest	O
that	O
a	O
rapid	O
systemic	O
absorption	O
of	O
mepivacaine	B-Chemical
with	O
adrenaline	B-Chemical
and/or	O
interaction	O
of	O
these	O
drugs	B-Drug
with	O
the	O
patient	O
's	O
cardiovascular	O
medications	O
were	O
responsible	O
for	O
the	O
perioperative	O
complications	O
.	O

Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
at	O
least	O
one	O
year	O
.	O

BACKGROUND	O
:	O
We	O
clinically	O
and	O
pathologically	O
analyzed	O
renal	O
allografts	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
treated	O
with	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
for	O
more	O
than	O
1	O
year	O
.	O

METHODS	O
:	O
Twenty-six	O
renal	O
allograft	O
biopsy	O
specimens	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
who	O
underwent	O
transplantations	O
between	O
1991	O
and	O
1993	O
were	O
evaluated	O
.	O

Thirteen	O
biopsies	O
were	O
performed	O
from	O
stable	O
functioning	O
renal	O
allografts	O
with	O
informed	O
consent	O
(	O
nonepisode	O
biopsy	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctional	O
renal	O
allografts	O
with	O
a	O
clinical	O
indication	O
for	O
biopsy	O
(	O
episode	O
biopsy	O
)	O
.	O

RESULTS	O
:	O
The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n=5	O
)	O
,	O
AR+CR	O
(	O
n	O
=4	O
)	O
,	O
recurrent	O
IgA	B-Disease
nephropathy	I-Disease
(	O
n	O
=5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=2	O
)	O
,	O
minimal-type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild-type	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
11	O
)	O
.	O

Of	O
the	O
nonepisode	O
biopsies	O
,	O
7	O
and	O
4	O
biopsies	O
showed	O
minimal-type	O
and	O
mild-type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
,	O
respectively	O
.	O

Chronic	O
FK506	B-Chemical
nephropathy	B-Disease
consisted	O
of	O
rough	O
and	O
foamy	O
tubular	O
vacuolization	O
(	O
5	O
biopsies	O
)	O
,	O
arteriolopathy	O
(	O
angiodegeneration	O
of	O
the	O
arteriolar	O
wall	O
;	O
20	O
biopsies	O
)	O
,	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
(	O
4	O
biopsies	O
)	O
and	O
the	O
striped	O
form	O
of	O
interstitial	B-Disease
fibrosis	I-Disease
(	O
11	O
biopsies	O
)	O
.	O

The	O
serum	O
creatinine	B-Chemical
levels	O
of	O
patients	O
in	O
the	O
mild-type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
group	O
,	O
which	O
included	O
7	O
episode	O
biopsies	O
,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum-type	O
chronic	O
FK506-nephropathy	B-Chemical
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
chronic	O
FK506	O
nephropathy	B-Disease
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall	O
,	O
and	O
suggests	O
that	O
mild-type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
is	O
a	O
condition	O
which	O
may	O
lead	B-Drug
to	O
deterioration	O
of	O
renal	O
allograft	O
function	O
.	O

Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	B-Chemical
releaser	O
PG-9	B-Chemical
.	O

The	O
effects	O
of	O
PG-9	B-Chemical
(	I-Chemical
3alpha-tropyl	B-Chemical
2-	I-Chemical
(	I-Chemical
p-bromophenyl	I-Chemical
)	I-Chemical
propionate	O
)	O
,	O
the	O
acetylcholine	B-Chemical
releaser	O
,	O
on	O
memory	O
processes	O
and	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
synthesis	O
were	O
evaluated	O
.	O

In	O
the	O
mouse	O
passive-avoidance	O
test	O
,	O
PG-9	B-Chemical
(	O
10-30	O
mg/kg	O
,	O
i.p	O
.	O

)	O
,	O
administered	O
20	O
min	O
before	O
the	O
training	O
session	O
,	O
prevented	O
amnesia	B-Disease
induced	O
by	O
both	O
the	O
non	O
selective	O
antimuscarinic	O
drug	B-Drug
scopolamine	B-Chemical
and	O
the	O
M1-selective	O
antagonist	O
S-	B-Chemical
(	I-Chemical
-	B-Chemical
)	I-Chemical
-ET-126	I-Chemical
.	O

In	O
the	O
same	O
experimental	O
conditions	O
,	O
PG-9	B-Chemical
(	O
5-20	O
microg	O
per	O
mouse	O
,	O
i.c.v	O
.	O

)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine-induced	O
amnesia	B-Disease
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity	O
.	O

At	O
the	O
highest	O
effective	O
doses	O
,	O
PG-9	B-Chemical
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity	O
,	O
as	O
revealed	O
by	O
the	O
hole-board	O
test	O
.	O

PG-9	B-Chemical
was	O
also	O
able	O
to	O
increase	O
the	O
amount	O
of	O
NGF	O
secreted	O
in	O
vitro	O
by	O
astrocytes	O
in	O
a	O
dose-dependent	O
manner	O
.	O

The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG-9	B-Chemical
were	O
17.6-fold	O
of	O
the	O
control	O
value	O
.	O

During	O
culture	O
,	O
no	O
morphological	O
changes	O
were	O
found	O
at	O
effective	O
concentrations	O
of	O
PG-9	B-Chemical
.	O

The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG-9	B-Chemical
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells	O
.	O

Therefore	O
,	O
PG-9	B-Chemical
could	O
represent	O
a	O
potential	O
useful	O
drug	B-Drug
able	O
to	O
improve	O
the	O
function	O
of	O
impaired	O
cognitive	O
processes	O
.	O

Angioedema	B-Disease
due	O
to	O
ACE	B-Chemical
inhibitors	I-Chemical
:	O
common	O
and	O
inadequately	O
diagnosed	O
.	O

The	O
estimated	O
incidence	O
of	O
angioedema	B-Disease
during	O
angiotensin-converting	B-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitor	I-Chemical
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O

This	O
potentially	O
serious	O
adverse	O
effect	O
is	O
often	O
preceded	O
by	O
minor	O
manifestations	O
that	O
may	O
serve	O
as	O
a	O
warning	O
.	O

Recurarization	O
in	O
the	O
recovery	O
room	O
.	O

A	O
case	O
of	O
recurarization	O
in	O
the	O
recovery	O
room	O
is	O
reported	O
.	O

Accumulation	O
of	O
atracurium	B-Chemical
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O

A	O
respiratory	B-Disease
arrest	I-Disease
with	O
severe	O
desaturation	B-Disease
and	O
bradycardia	B-Disease
occurred	O
.	O

Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	B-Disease
blockade	I-Disease
to	O
occur	O
,	O
following	O
the	O
administration	O
of	O
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O

Recurrent	O
use	O
of	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
associated	O
with	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	B-Chemical
use	O
,	O
namely	O
first-time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

Data	O
from	O
a	O
Transnational	O
case-control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
VTE	B-Disease
for	O
the	O
latter	O
patterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O

Over	O
the	O
period	O
1993-1996	O
,	O
551	O
cases	O
of	O
VTE	B-Disease
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O

Totals	O
of	O
128	O
cases	O
and	O
650	O
controls	O
were	O
analysed	O
for	O
repeat	O
use	O
and	O
135	O
cases	O
and	O
622	O
controls	O
for	O
switching	O
patterns	O
.	O

The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	B-Disease
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	B-Chemical
was	O
0.6	O
(	O
95	O
%	O
CI:0.3-1.2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1.3	O
(	O
95	O
%	O
CI:0.7-2.4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	O
of	O
VTE	B-Disease
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O

These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	O
for	O
the	O
newer	O
OC	B-Chemical
in	O
other	O
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O

Development	O
of	O
apomorphine-induced	B-Chemical
aggressive	B-Disease
behavior	I-Disease
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

The	O
development	O
of	O
apomorphine-induced	B-Chemical
(	O
1.0	O
mg/kg	O
s.c.	O
once	O
daily	O
)	O
aggressive	B-Disease
behavior	I-Disease
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	B-Chemical
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	B-Disease
behavior	I-Disease
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	B-Disease
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
female	O
rats	O
,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	B-Disease
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine-induced	B-Chemical
aggressive	B-Disease
behavior	I-Disease
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

Serotonergic	B-Chemical
antidepressants	I-Chemical
and	O
urinary	B-Disease
incontinence	I-Disease
.	O

Many	O
new	O
serotonergic	B-Chemical
antidepressants	I-Chemical
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O

Although	O
urinary	B-Disease
incontinence	I-Disease
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	B-Drug
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O

This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	B-Disease
while	O
taking	O
venlafaxine	B-Chemical
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B-Disease
secondary	O
to	O
the	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
paroxetine	B-Chemical
and	O
sertraline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-Chemical
.	O

In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	B-Chemical
carbonate	I-Chemical
and	O
beta-blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B-Disease
.	O

Animal	O
studies	O
suggest	O
that	O
incontinence	B-Disease
secondary	O
to	O
serotonergic	B-Chemical
antidepressants	I-Chemical
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O

Further	O
research	O
is	O
needed	O
to	O
delineate	O
the	O
frequency	O
of	O
this	O
troubling	O
side	O
effect	O
and	O
how	O
best	O
to	O
treat	O
it	O
.	O

Hypotension	B-Disease
following	O
the	O
initiation	O
of	O
tizanidine	B-Chemical
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	B-Disease
.	O

Centrally	O
acting	O
alpha-2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	B-Disease
related	O
to	O
disorders	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
.	O

In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	B-Disease
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O

Adults	O
chronically	O
treated	O
with	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	B-Disease
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O

The	O
authors	O
present	O
a	O
10-year-old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	B-Chemical
,	O
an	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	B-Disease
who	O
developed	O
hypotension	B-Disease
following	O
the	O
addition	O
of	O
tizanidine	B-Chemical
,	O
an	O
alpha-2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	B-Disease
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	B-Chemical
and	O
other	O
antihypertensive	B-Drug
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	B-Disease
or	O
spasticity	B-Disease
in	O
such	O
patients	O
.	O

Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	B-Disease
disease	I-Disease
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B-Disease
glomerulopathy	I-Disease
(	O
TG	B-Disease
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

Although	O
such	O
an	O
association	O
is	O
of	O
practical	O
and	O
theoretical	O
importance	O
,	O
only	O
one	O
prospective	O
study	O
has	O
tried	O
to	O
confirm	O
it	O
.	O

METHODS	O
:	O
We	O
examined	O
278	O
consecutive	O
renal	O
specimens	O
(	O
from	O
135	O
transplants	O
and	O
143	O
native	O
kidneys	O
)	O
for	O
ultrastructural	O
evidence	O
of	O
PTCR	O
.	O

In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	B-Disease
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	B-Disease
,	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
and	O
stable	O
grafts	O
(	O
``	O
protocol	O
biopsies	O
''	O
)	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	B-Disease
as	O
well	O
as	O
cases	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
malignant	B-Disease
hypertension	I-Disease
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
,	O
and	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O

RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	B-Disease
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	B-Disease
hypertension	I-Disease
,	O
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
lupus	B-Disease
nephritis	I-Disease
,	O
Henoch-Schonlein	B-Disease
nephritis	I-Disease
,	O
crescentic	O
glomerulonephritis	B-Disease
,	O
and	O
cocaine-related	B-Chemical
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	B-Disease
did	O
not	O
predict	O
renal	B-Disease
failure	I-Disease
or	O
significant	O
proteinuria	B-Disease
after	O
follow-up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well-developed	O
PTCR	O
and	O
TG	B-Disease
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	B-Disease
is	O
unclear	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	B-Disease
diseases	I-Disease
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	B-Disease
.	O

We	O
suggest	O
that	O
repeated	O
endothelial	B-Disease
injury	I-Disease
,	O
including	O
immunologic	B-Disease
injury	I-Disease
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	B-Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
targeting	O
sigma1	O
receptors	O
produce	O
anti-cocaine	B-Chemical
effects	O
in	O
mice	O
.	O

Cocaine	B-Chemical
's	O
ability	O
to	O
interact	O
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	B-Chemical
(	I-Chemical
3S-1-	B-Chemical
[	I-Chemical
2-	I-Chemical
(	I-Chemical
3,4-dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-1,4-diazabicyclo	I-Chemical
[	I-Chemical
4.3.0	I-Chemical
]	I-Chemical
nonane	O
)	O
,	O
BD1063	B-Chemical
(	I-Chemical
1-	B-Chemical
[	I-Chemical
2-	I-Chemical
(	I-Chemical
3,4-dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-4-methylpiperazine	O
)	O
,	O
and	O
LR132	B-Chemical
(	O
1R,2S-	O
(	O
+	O
)	O
-cis-N-	O
[	O
2-	O
(	O
3,4-dichlorophenyl	O
)	O
ethyl	O
]	O
-2-	O
(	O
1-pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Competition	O
binding	O
assays	O
demonstrated	O
that	O
all	O
three	O
compounds	O
have	O
high	O
affinities	O
for	O
sigma1	O
receptors	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	B-Chemical
,	O
opioid	O
,	O
GABA	B-Chemical
(	O
A	O
)	O
and	O
NMDA	B-Chemical
receptors	O
.	O

In	O
behavioral	O
studies	O
,	O
pre-treatment	O
of	O
mice	O
with	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
,	O
or	O
LR132	B-Chemical
significantly	O
attenuated	O
cocaine-induced	B-Chemical
convulsions	B-Disease
and	O
lethality	O
.	O

Moreover	O
,	O
post-treatment	O
with	O
LR132	B-Chemical
prevented	O
cocaine-induced	B-Chemical
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well-characterized	O
sigma	O
receptor	O
agonist	O
di-o-tolylguanidine	B-Chemical
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	B-Chemical
(	I-Chemical
3R-1-	B-Chemical
[	I-Chemical
2-	I-Chemical
(	I-Chemical
3,4-dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-1,4-diazabicyclo	I-Chemical
[	I-Chemical
4.3.0	I-Chemical
]	I-Chemical
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	B-Disease
of	O
cocaine	B-Chemical
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
and	O
LR132	B-Chemical
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-Chemical
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti-cocaine	B-Chemical
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	B-Disease
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-Chemical
.	O

Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine-induced	B-Chemical
behaviors	O
.	O

Pharmacokinetic/pharmacodynamic	O
assessment	O
of	O
the	O
effects	O
of	O
E4031	B-Chemical
,	O
cisapride	B-Chemical
,	O
terfenadine	B-Chemical
and	O
terodiline	B-Chemical
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O

1	O
.	O

Torsades	B-Disease
de	B-Disease
pointes	I-Disease
(	O
TDP	B-Disease
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	B-Disease
tachycardia	I-Disease
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

TDP	B-Disease
is	O
a	O
side-effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	B-Drug
from	O
the	O
market	O
(	O
e.g	O
.	O

terfenadine	B-Chemical
and	O
terodiline	B-Chemical
)	O
.	O

2	O
.	O

The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	B-Disease
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	B-Disease
were	O
investigated	O
:	O
terfenadine	B-Chemical
,	O
terodiline	B-Chemical
,	O
cisapride	B-Chemical
and	O
E4031	B-Chemical
.	O

On	O
the	O
basis	O
that	O
only	O
free	O
drug	B-Drug
in	O
the	O
systemic	O
circulation	O
will	O
elicit	O
a	O
pharmacological	O
response	O
target	O
,	O
free	O
concentrations	O
in	O
plasma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
drug	B-Drug
exposures	O
in	O
man	O
.	O

Infusion	O
regimens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
target-free	O
concentrations	O
of	O
these	O
drugs	B-Drug
in	O
plasma	O
and	O
data	O
on	O
the	O
relationship	O
between	O
free	O
concentration	O
and	O
changes	O
in	O
MAPD	O
were	O
obtained	O
for	O
these	O
compounds	O
.	O

3	O
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	B-Chemical
(	O
1.9	O
nM	O
)	O
,	O
terodiline	B-Chemical
(	O
76	O
nM	O
)	O
,	O
cisapride	B-Chemical
(	O
11	O
nM	O
)	O
and	O
E4031	B-Chemical
(	O
1.9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

For	O
compounds	O
that	O
have	O
shown	O
TDP	B-Disease
in	O
the	O
clinic	O
(	O
terfenadine	B-Chemical
,	O
terodiline	B-Chemical
,	O
cisapride	B-Chemical
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10-fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	O
ratio	O
with	O
respect	O
to	O
TDP	B-Disease
in	O
potential	O
development	O
candidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
drug	B-Drug
concentrations	O
in	O
pharmacokinetic/pharmacodynamic	O
studies	O
.	O

Fatal	O
myeloencephalopathy	B-Disease
due	O
to	O
accidental	O
intrathecal	O
vincristin	B-Chemical
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	B-Chemical
instillation	O
in	O
a	O
5-year	O
old	O
girl	O
with	O
recurrent	O
acute	B-Disease
lymphoblastic	I-Disease
leucemia	I-Disease
and	O
a	O
57-year	O
old	O
man	O
with	O
lymphoblastic	B-Disease
lymphoma	I-Disease
.	O

The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	B-Chemical
.	O

Clinically	O
,	I-Disease
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	B-Disease
,	I-Disease
sensory	I-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Chemical
and	O
ascending	O
paralysis	O
.	O

Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE-LFB	O
,	O
CD-68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	O
of	O
myelin	O
and	O
axons	O
as	O
well	O
as	O
pseudocystic	O
transformation	O
in	O
areas	O
exposed	O
to	O
vincristine	B-Drug
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

The	O
clinical	O
course	O
and	O
histopathological	O
results	O
of	O
the	O
two	O
cases	O
are	O
presented	O
.	O

A	O
review	O
of	O
all	O
reported	O
cases	O
in	O
the	O
literature	O
is	O
given	O
.	O

A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	B-Drug
and	O
intrathecal	O
chemotherapy	O
is	O
recommended	O
.	O

Intravenous	O
administration	O
of	O
prochlorperazine	B-Chemical
by	O
15-minute	O
infusion	O
versus	O
2-minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	B-Disease
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	B-Disease
after	O
administration	O
of	O
intravenous	O
prochlorperazine	B-Chemical
as	O
a	O
2-minute	O
bolus	O
or	O
15-minute	O
infusion	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
in	O
the	O
emergency	O
department	O
of	O
a	O
central-city	O
teaching	O
hospital	O
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	B-Chemical
for	O
headache	B-Disease
,	O
nausea	B-Disease
,	O
or	O
vomiting	B-Disease
were	O
eligible	O
for	O
inclusion	O
.	O

Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	B-Chemical
administered	O
intravenously	O
by	O
means	O
of	O
2-minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15-minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O

The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	O
akathisia	B-Disease
within	O
60	O
minutes	O
of	O
administration	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	B-Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient-reported	O
akathisia	B-Disease
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator-observed	O
akathisia	B-Disease
rating	O
scale	O
.	O

The	O
intensity	O
of	O
headache	B-Disease
and	O
nausea	B-Disease
was	O
measured	O
with	O
a	O
100-mm	O
visual	O
analog	O
scale	O
.	O

RESULTS	O
:	O
One	O
hundred	O
patients	O
were	O
enrolled	O
.	O

One	O
study	O
participant	O
was	O
excluded	O
after	O
protocol	O
violation	O
.	O

Seventy-three	O
percent	O
(	O
73/99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	B-Disease
and	O
70	O
%	O
(	O
70/99	O
)	O
for	O
nausea	B-Disease
.	O

In	O
the	O
bolus	O
group	O
,	O
26.0	O
%	O
(	O
13/50	O
)	O
had	O
akathisia	B-Disease
compared	O
with	O
32.7	O
%	O
(	O
16/49	O
)	O
in	O
the	O
infusion	O
group	O
(	O
Delta=-6.7	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-24.6	O
%	O
to	O
11.2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50	O
%	O
reduction	O
in	O
their	O
headache	B-Disease
intensity	O
within	O
30	O
minutes	O
was	O
11.8	O
%	O
(	O
95	O
%	O
CI	O
-9.6	O
%	O
to	O
33.3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50	O
%	O
reduction	O
in	O
their	O
nausea	B-Disease
was	O
12.6	O
%	O
(	O
95	O
%	O
CI	O
-4.6	O
%	O
to	O
29.8	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	B-Disease
when	O
prochlorperazine	B-Chemical
was	O
administered	O
by	O
means	O
of	O
15-minute	O
intravenous	O
infusion	O
versus	O
a	O
2-minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

The	O
efficacy	O
of	O
prochlorperazine	B-Chemical
in	O
the	O
treatment	O
of	O
headache	B-Disease
and	O
nausea	B-Disease
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

Antithymocyte	B-Chemical
globulin	I-Chemical
in	O
the	O
treatment	O
of	O
D-penicillamine-induced	B-Chemical
aplastic	B-Disease
anemia	I-Disease
.	O

A	O
patient	O
who	O
received	O
antithymocyte	B-Chemical
globulin	I-Chemical
therapy	O
for	O
aplastic	B-Disease
anemia	I-Disease
due	O
to	O
D-penicillamine	B-Chemical
therapy	O
is	O
described	O
.	O

Bone	O
marrow	O
recovery	O
and	O
peripheral	O
blood	O
recovery	O
were	O
complete	O
1	O
month	O
and	O
3	O
months	O
,	O
respectively	O
,	O
after	O
treatment	O
,	O
and	O
blood	O
transfusion	O
or	O
other	O
therapies	O
were	O
not	O
necessary	O
in	O
a	O
follow-up	O
period	O
of	O
more	O
than	O
2	O
years	O
.	O

Use	O
of	O
antithymocyte	B-Chemical
globulin	I-Chemical
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D-penicillamine-induced	B-Chemical
aplastic	B-Disease
anemia	I-Disease
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	B-Chemical
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure-prone	B-Disease
and	O
withdrawal	O
seizure-resistant	B-Disease
selected	O
mouse	O
lines	O
.	O

BACKGROUND	O
:	O
The	O
septo-hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	B-Chemical
withdrawal	O
severity	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	B-Chemical
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	B-Chemical
withdrawal	O
severity	O
.	O

METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol-na	B-Chemical
ve	O
Withdrawal	O
Seizure-Prone	B-Disease
(	O
WSP	O
)	O
and-Resistant	O
(	O
WSR	O
)	O
mice	O
.	O

Animals	O
were	O
administered	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
or	O
neostigmine	B-Chemical
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	B-Disease
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium-stimulated	B-Chemical
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

Potassium	B-Chemical
was	O
applied	O
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O

Hippocampal	O
ACh	B-Chemical
also	O
was	O
measured	O
during	O
testing	O
for	O
handling-induced	O
convulsions	B-Disease
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	B-Disease
endpoints	O
induced	O
by	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
and	O
neostigmine	B-Chemical
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	B-Chemical
,	O
and	O
50	O
mM	O
KCl	B-Chemical
increased	O
ACh	B-Chemical
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	B-Chemical
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	B-Chemical
was	O
2-fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

When	O
hippocampal	O
ACh	B-Chemical
was	O
measured	O
during	O
testing	O
for	O
handling-induced	O
convulsions	B-Disease
,	O
extracellular	O
ACh	B-Chemical
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
may	O
be	O
associated	O
with	O
ethanol	B-Chemical
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	B-Chemical
withdrawal	O
.	O

Specifically	O
,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-Disease
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O

Prenatal	O
dexamethasone	B-Chemical
programs	O
hypertension	B-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
the	O
rat	O
.	O

Dexamethasone	B-Drug
is	O
frequently	O
administered	O
to	O
the	O
developing	O
fetus	O
to	O
accelerate	O
pulmonary	O
development	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	B-Chemical
programmed	O
a	O
progressive	O
increase	B-Disease
in	B-Disease
blood	I-Disease
pressure	I-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
rats	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-Chemical
(	O
0.2	O
mg/kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offspring	O
of	O
rats	O
administered	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20	O
%	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527+/-509	O
versus	O
28	O
050+/-561	O
,	O
P	O
<	O
0.05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Six-	O
to	O
9-month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17	O
%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380+/-587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	B-Disease
blood	I-Disease
pressures	I-Disease
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
.	O

Adult	O
rats	O
given	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	B-Disease
than	O
control	O
rats	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	B-Chemical
in	I-Disease
rats	O
results	O
in	I-Disease
a	O
reduction	B-Disease
in	I-Disease
glomerular	O
number	O
,	O
glomerulosclerosis	B-Disease
,	O
and	O
hypertension	B-Disease
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

Hypertension	B-Disease
was	O
observed	O
in	I-Disease
animals	O
that	O
had	O
a	O
reduction	B-Disease
in	I-Disease
glomeruli	O
as	O
well	O
as	O
in	I-Disease
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
suggesting	O
that	O
a	O
reduction	O
in	O
glomerular	O
number	O
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	B-Disease
.	O

The	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
prescribed	O
cyproterone	B-Chemical
acetate	I-Chemical
in	O
combination	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case-control	O
study	O
.	O

BACKGROUND	O
:	O
Cyproterone	B-Chemical
acetate	I-Chemical
combined	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
CPA/EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
CPA/EE	B-Chemical
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

We	O
believe	O
the	O
results	O
of	O
those	O
studies	O
may	O
have	O
been	O
affected	O
by	O
residual	O
confounding	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case-control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	B-Disease
,	O
hirsutism	B-Disease
or	O
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	O
with	O
CPA/EE	O
.	O

RESULTS	O
:	O
The	O
age-adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA/EE	O
versus	O
conventional	O
COCs	O
was	O
2.20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.35-3.58	O
]	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case-control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7.44	O
(	O
95	O
%	O
CI	O
3.67-15.08	O
)	O
for	O
CPA/EE	O
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2.58	O
(	O
95	O
%	O
CI	O
1.60-4.18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA/EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
can	O
not	O
be	O
excluded	O
.	O

Pseudoacromegaly	B-Disease
induced	O
by	O
the	O
long-term	O
use	O
of	O
minoxidil	B-Chemical
.	O

Acromegaly	B-Disease
is	O
an	O
endocrine	B-Disease
disorder	I-Disease
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	O
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	B-Disease
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	B-Disease
verticis	I-Disease
gyrata	I-Disease
.	O

Pseudoacromegaly	B-Disease
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presence	O
of	O
similar	O
acromegaloid	O
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin-like	O
growth	O
factor	O
levels	O
.	O

We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	B-Disease
that	O
resulted	O
from	O
the	O
long-term	O
use	O
of	O
minoxidil	B-Chemical
at	O
an	O
unusually	O
high	O
dose	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	B-Disease
as	O
a	O
side	O
effect	O
of	O
minoxidil	B-Chemical
use	O
.	O

Combined	O
androgen	O
blockade-induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB	O
)	O
-induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty-two	O
patients	O
with	O
biopsy-proven	O
prostatic	B-Disease
adenocarcinoma	I-Disease
[	O
26	O
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
study	O
.	O

All	O
patients	O
received	O
CAB	O
[	O
leuprolide	B-Chemical
acetate	I-Chemical
(	O
LHRH-A	B-Chemical
)	O
3.75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	B-Chemical
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	B-Disease
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post-CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testosterone	B-Chemical
measurements	O
were	O
recorded	O
.	O

Patients	O
with	O
stage	O
D2-3	O
disease	O
,	O
abnormal	O
hemoglobin	O
level	O
or	O
renal	O
and	O
liver	O
function	O
tests	O
that	O
were	O
higher	O
than	O
the	O
upper	O
limits	O
were	O
excluded	O
from	O
the	O
study	O
.	O

The	O
duration	O
of	O
the	O
study	O
was	O
six	O
months	O
.	O

RESULTS	O
:	O
The	O
mean	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
were	O
significantly	O
declined	O
in	O
all	O
patients	O
from	O
baseline	O
of	O
14.2	O
g/dl	O
to	O
14.0	O
g/dl	O
,	O
13.5	O
g/dl	O
,	O
13.2	O
g/dl	O
and	O
12.7	O
g/dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post-CAB	O
,	O
respectively	O
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	B-Disease
of	O
Hb	O
<	O
11	O
g/dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14.3	O
%	O
)	O
.	O

This	O
CAB-induced	O
anemia	B-Disease
was	O
normochromic	O
and	O
normocytic	O
.	O

At	O
six	O
months	O
post-CAB	O
,	O
patients	O
with	O
severe	O
anemia	B-Disease
had	O
a	O
Hb	O
mean	O
value	O
of	O
10.2	O
+/-	O
0.1	O
g/dl	O
(	O
X	O
+/-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	B-Disease
with	O
Hb	O
mean	O
value	O
of	O
13.2	O
+/-	O
0.17	O
(	O
X	O
+/-	O
SE	O
)	O
.	O

The	O
development	O
of	O
severe	O
anemia	B-Disease
at	O
6	O
months	O
post-CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2.5	O
g/dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0.01	O
)	O
.	O

The	O
development	O
of	O
severe	O
CAB-induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng/ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng/ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O

Severe	O
and	O
clinically	O
evident	O
anemia	B-Disease
was	O
easily	O
corrected	O
by	O
subcutaneous	O
injections	O
(	O
3	O
times/week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO-beta	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO-beta	O
correctable	O
CAB-induced	O
anemia	B-Disease
occurs	O
in	O
14.3	O
%	O
of	O
prostate	B-Disease
cancer	I-Disease
patients	O
after	O
6	O
months	O
of	O
therapy	O
.	O

Reversible	O
dilated	B-Disease
cardiomyopathy	I-Disease
related	O
to	O
amphotericin	B-Chemical
B	I-Chemical
therapy	O
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	B-Disease
cardiomyopathy	I-Disease
and	O
clinical	O
congestive	O
heart	B-Disease
failure	I-Disease
after	O
2	O
months	O
of	O
therapy	O
with	O
amphotericin	B-Chemical
B	I-Chemical
(	O
AmB	B-Chemical
)	O
for	O
disseminated	O
coccidioidomycosis	B-Disease
.	O

His	O
echocardiographic	O
abnormalities	O
and	O
heart	B-Disease
failure	I-Disease
resolved	O
after	O
posaconazole	B-Chemical
was	O
substituted	O
for	O
AmB	B-Chemical
.	O

It	O
is	O
important	O
to	O
recognize	O
the	O
rare	O
and	O
potentially	O
reversible	O
toxicity	B-Disease
of	O
AmB	B-Chemical
.	O

Risks	O
of	O
the	O
consumption	O
of	O
beverages	O
containing	O
quinine	B-Chemical
.	O

Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	B-Drug
Administration	O
banned	O
its	O
use	O
for	O
nocturnal	B-Disease
leg	I-Disease
cramps	I-Disease
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy	O
,	O
quinine	B-Chemical
is	O
widely	O
available	O
in	O
beverages	O
including	O
tonic	O
water	O
and	O
bitter	O
lemon	O
.	O

Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	B-Chemical
may	O
produce	O
neurological	B-Disease
complications	I-Disease
,	O
including	O
confusion	B-Disease
,	O
altered	O
mental	O
status	O
,	O
seizures	B-Disease
,	O
and	O
coma	B-Disease
,	O
particularly	O
in	O
older	O
women	O
.	O

Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine-containing	B-Chemical
beverages	O
as	O
part	O
of	O
an	O
evaluation	O
process	O
.	O

Organophosphate-induced	B-Chemical
convulsions	B-Disease
and	O
prevention	O
of	O
neuropathological	B-Disease
damages	I-Disease
.	O

Such	O
organophosphorus	B-Chemical
(	O
OP	B-Chemical
)	O
compounds	O
as	O
diisopropylfluorophosphate	B-Chemical
(	O
DFP	B-Chemical
)	O
,	O
sarin	B-Chemical
and	O
soman	B-Chemical
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O

The	O
acute	O
toxicity	B-Disease
of	O
OPs	B-Chemical
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
levels	O
.	O

The	O
protective	O
action	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	B-Chemical
(	O
2.0	O
mg/kg	O
BW	O
)	O
intoxication	O
was	O
studied	O
in	O
9-10-weeks-old	O
Han-Wistar	O
male	O
rats	O
.	O

The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime-2-chloride	B-Chemical
(	O
2PAM	B-Chemical
)	O
(	O
30.0	O
mg/kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	B-Chemical
(	O
2.0	O
mg/kg	O
BW	O
)	O
,	O
A	O
(	O
1	O
)	O
-adenosine	B-Chemical
receptor	O
agonist	O
N	B-Chemical
(	I-Chemical
6	I-Chemical
)	I-Chemical
-cyclopentyl	I-Chemical
adenosine	I-Chemical
(	O
CPA	B-Chemical
)	O
(	O
2.0	O
mg/kg	O
BW	O
)	O
,	O
NMDA-receptor	B-Chemical
antagonist	O
dizocilpine	B-Chemical
maleate	I-Chemical
(	O
+-MK801	O
hydrogen	O
maleate	O
)	O
(	O
2.0	O
mg/kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	B-Drug
atropine	B-Chemical
sulfate	I-Chemical
(	O
50.0	O
mg/kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	B-Chemical
.	O

The	O
control	O
rats	O
received	O
atropine	B-Chemical
sulfate	I-Chemical
,	O
but	O
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	B-Chemical
,	O
respectively	O
.	O

All	O
rats	O
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	B-Chemical
injection	O
.	O

The	O
rats	O
treated	O
with	O
DFP-atropine	B-Chemical
showed	O
severe	O
typical	O
OP-induced	O
toxicity	O
signs	O
.	O

When	O
CPA	B-Drug
,	O
diazepam	B-Drug
or	O
2PAM	O
was	O
given	O
immediately	O
after	O
DFP-atropine	B-Chemical
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
.	O

Atropine-MK801	O
did	O
not	O
offer	O
any	O
additional	O
protection	O
against	O
DFP	O
toxicity	O
.	O

In	O
conclusion	O
,	O
CPA	B-Drug
,	O
diazepam	B-Drug
and	O
2PAM	O
in	O
combination	O
with	O
atropine	B-Drug
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	O
and	O
thus	O
reduced	O
the	O
toxicity	O
of	O
DFP	O
in	O
rat	O
.	O

Differential	O
modulation	O
by	O
estrogen	B-Chemical
of	O
alpha2-adrenergic	O
and	O
I1-imidazoline	B-Chemical
receptor-mediated	O
hypotension	B-Disease
in	O
female	O
rats	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogen	B-Chemical
negatively	O
modulates	O
the	O
hypotensive	B-Disease
effect	O
of	O
clonidine	B-Chemical
(	O
mixed	O
alpha2-/I1-receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O

The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	B-Chemical
involves	O
interaction	O
with	O
alpha2-	O
and/or	O
I1-receptors	O
.	O

Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	B-Chemical
(	O
600	O
microg/kg	O
)	O
or	O
alpha-methyldopa	B-Chemical
(	O
100	O
mg/kg	O
)	O
,	O
selective	O
I1-	O
and	O
alpha2-receptor	O
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham-operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague-Dawley	O
female	O
rats	O
with	O
or	O
without	O
12-wk	O
estrogen	B-Chemical
replacement	O
.	O

Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	O
variability	O
were	O
employed	O
:	O
the	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
as	O
a	O
measure	O
of	O
blood	O
pressure	O
variability	O
and	O
the	O
standard	O
deviation	O
of	O
beat-to-beat	O
intervals	O
(	O
SDRR	O
)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
in	O
R-wave-to-R-wave	O
intervals	O
as	O
measures	O
of	O
heart	O
rate	O
variability	O
.	O

In	O
sham-operated	O
rats	O
,	O
rilmenidine	B-Chemical
or	O
alpha-methyldopa	B-Chemical
elicited	O
similar	O
hypotension	B-Disease
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O

SDRR	O
was	O
reduced	O
only	O
by	O
alpha-methyldopa	B-Chemical
.	O

Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	B-Disease
response	O
to	O
alpha-methyldopa	B-Chemical
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	B-Chemical
hypotension	B-Disease
.	O

The	O
enhanced	O
alpha-methyldopa	B-Chemical
hypotension	B-Disease
in	O
Ovx	O
rats	B-Disease
was	B-Disease
paralleled	B-Disease
with	O
further	O
reduction	O
in	O
SDRR	O
and	B-Disease
a	O
reduced	O
locomotor	O
activity	O
.	O

Estrogen	O
replacement	O
(	O
17beta-estradiol	B-Chemical
subcutaneous	O
pellet	O
,	O
14.2	O
microg/day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha-methyldopa	B-Chemical
to	O
sham-operated	O
levels	O
.	O

These	O
findings	O
suggest	O
that	O
estrogen	B-Chemical
downregulates	O
alpha2-	O
but	O
not	O
I1-receptor-mediated	O
hypotension	B-Disease
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha-methyldopa-estrogen	B-Chemical
interaction	O
.	O

Cardioprotective	O
effect	O
of	I-Chemical
tincture	B-Chemical
of	I-Chemical
Crataegus	O
on	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Tincture	B-Chemical
of	I-Chemical
Crataegus	I-Chemical
(	O
TCR	B-Chemical
)	O
,	O
an	O
alcoholic	B-Chemical
extract	I-Chemical
of	I-Chemical
the	I-Chemical
berries	I-Chemical
of	I-Chemical
hawthorn	I-Chemical
(	O
Crataegus	B-Chemical
oxycantha	I-Chemical
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	B-Chemical
on	O
experimentally	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Pretreatment	O
of	O
TCR	B-Chemical
,	O
at	O
a	O
dose	O
of	O
0.5	O
mL/100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol-induced	B-Chemical
rats	O
(	O
85	O
mg	O
kg	O
(	O
-1	O
)	O
s.	O
c.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O

TCR	B-Chemical
prevented	O
the	O
isoproterenol-induced	B-Chemical
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP-stimulated	B-Chemical
oxygen	B-Chemical
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	B-Chemical
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	B-Chemical
in	O
rat	O
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	B-Chemical
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	B-Chemical
in	O
rat	O
heart	O
.	O

Safety	O
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	B-Chemical
:	O
multiple	O
outcomes	O
of	O
raloxifene	B-Chemical
evaluation	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	B-Chemical
on	O
major	O
adverse	O
events	O
that	O
occur	O
with	O
postmenopausal	O
estrogen	B-Chemical
therapy	O
or	O
tamoxifen	B-Chemical
.	O

METHODS	O
:	O
The	O
Multiple	O
Outcomes	O
of	O
Raloxifene	B-Chemical
Evaluation	O
,	O
a	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
trial	O
,	O
enrolled	O
7,705	O
postmenopausal	O
women	O
with	O
osteoporosis	B-Disease
.	O

Women	O
were	O
randomly	O
assigned	O
to	O
raloxifene	B-Chemical
60	O
mg/d	O
or	O
120	O
mg/d	O
or	O
placebo	O
.	O

Outcomes	O
included	O
venous	B-Disease
thromboembolism	I-Disease
,	O
cataracts	B-Disease
,	O
gallbladder	B-Disease
disease	I-Disease
,	O
and	O
endometrial	B-Disease
hyperplasia	I-Disease
or	I-Disease
cancer	I-Disease
.	O

RESULTS	O
:	O
During	O
a	O
mean	O
follow-up	O
of	O
3.3	O
years	O
,	O
raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	O
thromboembolism	O
(	O
relative	O
risk	O
[	O
RR	B-Drug
]	O
2.1	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.2-3.8	O
)	O
.	O

The	O
excess	O
event	O
rate	O
was	O
1.8	O
per	O
1,000	O
woman-years	O
(	O
95	O
%	O
CI	O
-0.5-4.1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
treat	O
to	O
cause	O
1	O
event	O
was	O
170	O
(	O
95	O
%	O
CI	O
100-582	O
)	O
over	O
3.3	O
years	O
.	O

Risk	O
in	O
the	O
raloxifene	O
group	O
was	O
higher	O
than	O
in	O
the	O
placebo	O
group	O
for	O
the	O
first	O
2	O
years	O
,	O
but	O
decreased	O
to	O
about	O
the	O
same	O
rate	O
as	O
in	O
the	O
placebo	O
group	O
thereafter	O
.	O

Raloxifene	O
did	O
not	O
increase	O
risk	O
for	O
cataracts	O
(	O
RR	B-Drug
0.9	O
;	O
95	O
%	O
CI	O
0.8-1.1	O
)	O
,	O
gallbladder	O
disease	O
(	O
RR	B-Drug
1.0	O
;	O
95	O
%	O
CI	O
0.7-1.3	O
)	O
,	O
endometrial	B-Chemical
hyperplasia	I-Chemical
(	O
RR	B-Drug
1.3	O
;	O
95	O
%	O
CI	O
0.4-5.1	O
)	O
,	O
or	O
endometrial	B-Chemical
cancer	I-Chemical
(	O
RR	B-Drug
0.9	O
;	O
95	O
%	O
CI	O
0.3-2.7	O
)	O
.	O

CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	O
thromboembolism	O
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	O
,	O
gallbladder	O
disease	O
,	O
endometrial	O
hyperplasia	O
,	O
or	O
endometrial	O
cancer	O
.	O

LEVEL	O
OF	O
EVIDENCE	O
:	O
I	O
Ceftriaxone-associated	B-Chemical
biliary	B-Disease
pseudolithiasis	I-Disease
in	O
paediatric	O
surgical	O
patients	O
.	O

It	O
is	O
well	O
known	O
that	O
ceftriaxone	B-Chemical
leads	O
to	O
pseudolithiasis	B-Disease
in	O
some	O
patients	O
.	O

Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	O
causing	O
gallbladder	B-Disease
dysfunction	I-Disease
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	O
of	O
pseudolithiasis	B-Disease
.	O

In	O
this	O
study	O
,	O
we	O
prospectively	O
evaluated	O
the	O
incidence	O
and	O
clinical	O
importance	O
of	O
pseudolithiasis	B-Disease
in	O
paediatric	O
surgical	O
patients	O
receiving	O
ceftriaxone	B-Chemical
treatment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post-operative	O
period	O
.	O

Fifty	O
children	O
who	O
were	O
given	O
ceftriaxone	B-Chemical
were	O
evaluated	O
by	O
serial	O
abdominal	O
sonograms	O
.	O

Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
biliary	O
pathology	O
.	O

Comparison	O
of	O
the	O
patients	O
with	O
or	O
without	O
pseudolithiasis	B-Disease
revealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
duration	O
of	O
the	O
treatment	O
and	O
starvation	O
variables	O
.	O

After	O
cessation	O
of	O
the	O
treatment	O
,	O
pseudolithiasis	B-Disease
resolved	O
spontaneously	O
within	O
a	O
short	O
period	O
.	O

The	O
incidence	O
of	O
pseudolithiasis	B-Disease
is	O
not	O
affected	O
by	O
fasting	O
.	O

Evaluation	O
of	O
the	O
anticocaine	O
monoclonal	O
antibody	O
GNC92H2	B-Chemical
as	O
an	O
immunotherapy	O
for	O
cocaine	B-Disease
overdose	I-Disease
.	O

The	O
illicit	O
use	O
of	O
cocaine	B-Chemical
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	O
for	O
cocaine	B-Disease
overdose	I-Disease
remains	O
elusive	O
.	O

Current	O
protein-based	O
technology	O
offers	O
a	O
new	O
therapeutic	O
venue	O
by	O
which	O
antibodies	O
bind	O
the	O
drug	B-Drug
in	O
the	O
blood	O
stream	O
,	O
inactivating	O
its	O
toxic	O
effects	O
.	O

The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	B-Chemical
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	B-Disease
overdose	I-Disease
.	O

Swiss	O
albino	O
mice	O
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	O
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg/kg	O
(	O
LD50	O
)	O
of	O
cocaine	B-Chemical
and	O
GNC92H2	B-Chemical
infusions	O
ranging	O
from	O
30	O
to	O
190	O
mg/kg	O
.	O

GNC92H2	B-Chemical
was	O
delivered	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaine	B-Chemical
treatment	O
.	O

Significant	O
blockade	O
of	O
cocaine	B-Chemical
toxicity	B-Disease
was	O
observed	O
with	O
the	O
higher	O
dose	O
of	O
GNC92H2	B-Chemical
(	O
190	O
mg/kg	O
)	O
,	O
where	O
premorbid	O
behaviors	O
were	O
reduced	O
up	O
to	O
40	O
%	O
,	O
seizures	B-Disease
up	O
to	O
77	O
%	O
and	O
death	B-Disease
by	O
72	O
%	O
.	O

Importantly	O
,	O
GNC92H2	B-Chemical
prevented	O
death	B-Disease
even	O
post-cocaine	B-Chemical
injection	O
.	O

The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	B-Chemical
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	B-Disease
overdose	I-Disease
.	O

The	O
effects	O
of	O
short-term	O
raloxifene	B-Chemical
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI-1	O
.	O

BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin-activatable	O
fibrinolysis	O
inhibitor	O
(	O
TAFI	O
)	O
,	O
tissue-type	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
,	O
and	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short-term	O
effects	O
of	O
raloxifene	B-Chemical
administration	O
in	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
Thirty-nine	O
postmenopausal	O
women	O
with	O
osteopenia	B-Disease
or	O
osteoporosis	B-Disease
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O

Twenty-five	O
women	O
were	O
given	O
raloxifene	B-Chemical
hydrochloride	I-Chemical
(	O
60	O
mg/day	O
)	O
plus	O
calcium	B-Chemical
(	O
500	O
mg/day	O
)	O
.	O

Age-matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-Chemical
.	O

Plasma	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI-1	O
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O

Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
's	O
test	O
.	O

Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O

RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	B-Chemical
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0.01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0.05	O
)	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	B-Disease
(	O
P	O
<	O
0.05	O
;	O
r	O
=	O
0.33	O
)	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
due	O
to	O
raloxifene	B-Chemical
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	O
levels	O
,	O
but	O
not	O
TAFI	O
levels	O
.	O

Ketoconazole	B-Chemical
induced	O
torsades	B-Disease
de	B-Disease
pointes	I-Disease
without	O
concomitant	O
use	O
of	O
QT	O
interval-prolonging	O
drug	B-Drug
.	O

Ketoconazole	B-Chemical
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	O
use	O
of	O
QT	O
interval-prolonging	O
drugs	B-Drug
.	O

We	O
report	O
a	O
woman	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
who	O
developed	O
a	O
markedly	O
prolonged	B-Disease
QT	I-Disease
interval	I-Disease
and	O
torsades	B-Disease
de	B-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
after	O
taking	O
ketoconazole	B-Chemical
for	O
treatment	O
of	O
fungal	B-Disease
infection	I-Disease
.	O

Her	O
QT	O
interval	O
returned	O
to	O
normal	O
upon	O
withdrawal	O
of	O
ketoconazole	B-Chemical
.	O

Genetic	O
study	O
did	O
not	O
find	O
any	O
mutation	O
in	O
her	O
genes	O
that	O
encode	O
cardiac	O
IKr	O
channel	O
proteins	O
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr	O
,	O
ketoconazole	B-Chemical
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP	B-Disease
.	O

This	O
calls	O
for	O
attention	O
when	O
ketoconazole	B-Chemical
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
.	O

Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	B-Chemical
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O

The	O
ethanolic	O
extract	B-Chemical
of	I-Chemical
Daucus	I-Chemical
carota	I-Chemical
seeds	I-Chemical
(	O
DCE	B-Chemical
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg/kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	O
.	O

Elevated	O
plus	O
maze	O
and	O
passive	O
avoidance	O
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	O
models	O
for	O
testing	O
memory	O
.	O

Diazepam-	B-Chemical
,	O
scopolamine-	B-Chemical
and	O
ageing-induced	O
amnesia	B-Disease
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O

DCE	B-Chemical
(	O
200	O
,	O
400	O
mg/kg	O
,	O
p.o	O
.	O

)	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	B-Chemical
was	O
23	O
%	O
at	O
the	O
dose	O
of	O
200	O
mg/kg	O
and	O
35	O
%	O
at	O
the	O
dose	O
of	O
400	O
mg/kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze	O
.	O

Similarly	O
,	O
significant	O
improvements	O
in	O
memory	O
scores	O
were	O
observed	O
using	O
passive	O
avoidance	O
apparatus	O
and	O
aged	O
mice	O
.	O

Furthermore	O
,	O
DCE	B-Chemical
reversed	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
0.4	O
mg/kg	O
,	O
i.p	O
.	O

)	O
and	O
diazepam	B-Chemical
(	O
1	O
mg/kg	O
,	O
i.p.	O
)	O
.	O

Daucus	B-Chemical
carota	I-Chemical
extract	I-Chemical
(	O
200	O
,	O
400	O
mg/kg	O
,	O
p.o	O
.	O

)	O
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	B-Chemical
levels	O
in	O
young	O
and	O
aged	O
mice	O
.	O

The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	B-Chemical
at	O
the	O
dose	O
of	O
400	O
mg/kg	O
was	O
22	O
%	O
in	O
young	O
and	O
19	O
%	O
in	O
aged	O
mice	O
.	O

There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	B-Chemical
level	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
young	O
and	O
21	O
%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	B-Chemical
.	O

Therefore	O
,	O
DCE	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
,	O
memory	O
improving	O
property	O
,	O
cholesterol	B-Chemical
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O

Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
after	O
epidural	O
steroid	B-Chemical
injection	O
:	O
a	O
case	O
report	O
.	O

OBJECTIVE	O
:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	B-Disease
are	O
physical	O
therapy	O
,	O
epidural	O
steroid	B-Chemical
injections	O
,	O
oral	O
medications	O
,	O
and	O
spinal	O
manipulative	O
therapy	O
.	O

Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	B-Drug
.	O

The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	B-Chemical
and	O
bupivacaine	B-Chemical
.	O

CLINICAL	O
FEATURES	O
:	O
A	O
50-year-old	O
woman	O
with	O
low	B-Disease
back	I-Disease
and	I-Disease
right	I-Disease
leg	I-Disease
pain	I-Disease
was	O
scheduled	O
for	O
epidural	O
steroid	O
injection	O
.	O

INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18-gauge	O
Touhy	O
needle	O
was	O
inserted	O
until	O
loss	O
of	O
resistance	O
occurred	O
at	O
the	O
L4-5	O
level	O
.	O

Spread	O
of	O
the	O
contrast	O
medium	O
within	O
the	O
epidural	O
space	O
was	O
determined	O
by	O
radiographic	O
imaging	O
.	O

After	O
verifying	O
the	O
epidural	O
space	O
,	O
bupivacaine	O
and	O
triamcinolone	O
diacetate	O
were	O
injected	O
.	O

After	O
the	O
injection	O
,	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms	O
.	O

Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	O
and	O
lower	B-Chemical
extremity	O
weakness	O
.	O

The	O
neurologic	O
evaluation	O
revealed	O
loss	O
of	O
sensation	O
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O

There	O
was	O
a	O
decrease	O
in	O
the	O
perception	O
of	O
pinprick	O
test	O
.	O

Deep-tendon	O
reflexes	O
were	O
decreased	O
especially	O
in	O
the	O
right	O
leg	O
.	O

She	O
was	O
unable	O
to	O
urinate	O
.	O

The	O
patient	O
's	O
symptoms	O
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O

She	O
had	O
a	O
gradual	O
return	O
of	O
motor	O
function	O
and	O
ability	O
of	O
feeling	O
Foley	O
catheter	O
.	O

All	O
of	O
the	O
symptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O

CONCLUSION	O
:	O
Complications	O
associated	O
with	O
epidural	O
steroid	O
injections	O
are	O
rare	O
.	O

Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	O
deterioration	O
after	O
epidural	O
steroid	O
injections	O
is	O
important	O
.	O

High-dose	O
testosterone	B-Chemical
is	O
associated	O
with	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
.	O

OBJECTIVES	O
:	O
To	O
study	O
the	O
long-term	O
effects	O
of	O
androgen	O
treatment	O
on	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
.	O

METHODS	O
:	O
In	O
a	O
population-based	O
study	O
in	O
513	O
naturally	O
postmenopausal	O
women	O
aged	O
54-67	O
years	O
,	O
we	O
studied	O
the	O
association	O
between	O
self-reported	O
intramuscularly	O
administered	O
high-dose	O
estrogen-testosterone	B-Chemical
therapy	O
(	O
estradiol-	O
and	O
testosterone	B-Chemical
esters	I-Chemical
)	O
and	I-Chemical
aortic	O
atherosclerosis	O
.	O

Aortic	O
atherosclerosis	O
was	O
diagnosed	O
by	O
radiographic	O
detection	O
of	O
calcified	O
deposits	O
in	O
the	O
abdominal	O
aorta	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
intima	O
atherosclerosis	O
.	O

Hormone	O
therapy	O
users	O
were	O
compared	O
with	O
never	O
users	O
.	O

RESULTS	O
:	O
Intramuscular	O
hormone	O
therapy	O
use	O
for	O
1	O
year	O
or	O
longer	O
was	O
reported	O
by	O
25	O
women	O
.	O

In	O
almost	O
half	O
of	O
these	O
women	O
severe	O
atherosclerosis	O
of	O
the	O
aorta	O
was	O
present	O
(	O
n=11	O
)	O
,	O
while	O
in	O
women	O
without	O
hormone	O
use	O
severe	O
atherosclerosis	O
of	O
the	O
aorta	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3.1	O
;	O
95	O
%	O
CI	O
,	O
1.1-8.5	O
,	O
adjusted	O
for	O
age	O
,	O
years	O
since	O
menopause	O
,	O
smoking	O
,	O
and	I-Chemical
body	O
mass	O
index	O
)	O
.	O

The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	O
,	O
cholesterol	O
level	O
,	O
systolic	O
blood	O
pressure	O
,	O
or	O
alcohol	B-Drug
use	O
.	O

No	O
association	O
was	O
found	O
for	O
hormone	O
use	O
less	O
than	O
1	O
year	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
high-dose	O
testosterone	I-Chemical
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
and	O
indicate	O
that	O
androgen	O
replacement	O
in	O
these	O
women	O
may	O
not	O
be	O
harmless	O
.	O

Sirolimus-associated	B-Chemical
proteinuria	B-Disease
and	O
renal	B-Disease
dysfunction	I-Disease
.	O

Sirolimus	B-Chemical
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor-containing	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
protein	O
kinase	O
.	O

Sirolimus	B-Chemical
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	O
allograft	O
nephropathy	B-Disease
.	O

Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	B-Disease
,	O
autoimmunity	B-Disease
,	O
cystic	B-Disease
renal	I-Disease
diseases	I-Disease
and	O
renal	B-Disease
cancer	I-Disease
is	O
under	O
investigation	O
.	O

Because	O
sirolimus	B-Chemical
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	O
inhibitors	O
,	O
it	O
has	O
been	O
designated	O
a	O
'non-nephrotoxic	B-Disease
drug	B-Drug
'	O
.	O

However	O
,	O
clinical	O
reports	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolimus	B-Chemical
is	O
associated	O
with	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
dysfunction	I-Disease
.	O

A	O
common	O
risk	O
factor	O
appears	O
to	O
be	O
presence	O
of	O
pre-existing	O
chronic	B-Disease
renal	I-Disease
damage	I-Disease
.	O

The	O
mechanisms	O
of	O
sirolimus-associated	B-Chemical
proteinuria	B-Disease
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
glomerular	O
capillary	O
pressure	O
following	O
calcineurin	O
inhibitor	O
withdrawal	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	B-Chemical
directly	O
causes	O
increased	O
glomerular	O
permeability/injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O

The	O
acute	B-Disease
renal	I-Disease
dysfunction	I-Disease
associated	O
with	O
sirolimus	B-Chemical
(	O
such	O
as	O
in	O
delayed	O
graft	O
function	O
)	O
may	O
be	O
due	O
to	O
suppression	O
of	O
compensatory	O
renal	O
cell	O
proliferation	O
and	O
survival/repair	O
processes	O
.	O

Although	O
these	O
adverse	O
effects	O
occur	O
in	O
some	O
patients	O
,	O
their	O
occurrence	O
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	O
effects	O
of	O
sirolimus	B-Chemical
on	O
the	O
kidney	O
,	O
the	O
use	O
of	O
sirolimus	B-Chemical
in	O
appropriate	O
patient	O
populations	O
,	O
close	O
monitoring	O
of	O
proteinuria	B-Disease
and	O
renal	O
function	O
,	O
use	O
of	O
angiotensin-converting	B-Chemical
enzyme	O
inhibitors	O
or	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
blockers	O
if	O
proteinuria	B-Disease
occurs	O
and	O
withdrawal	O
if	O
needed	O
.	O

Further	O
long-term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	B-Chemical
as	O
de	O
novo	O
immunosuppression	O
along	O
with	O
clinical	O
and	O
laboratory	O
studies	O
will	O
refine	O
these	O
issues	O
in	O
the	O
future	O
.	O

Progressive	O
myopathy	B-Disease
with	O
up-regulation	O
of	O
MHC-I	O
associated	O
with	O
statin	B-Chemical
therapy	O
.	O

Statins	B-Chemical
can	O
cause	O
a	O
necrotizing	O
myopathy	B-Disease
and	O
hyperCKaemia	B-Disease
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug	B-Drug
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	B-Chemical
may	O
induce	O
a	O
myopathy	B-Disease
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	B-Drug
.	O

We	O
investigated	O
the	O
muscle	O
pathology	O
in	O
8	O
such	O
cases	O
.	O

All	O
had	O
myofibre	O
necrosis	B-Disease
but	O
only	O
3	O
had	O
an	O
inflammatory	O
infiltrate	O
.	O

In	O
all	O
cases	O
there	O
was	O
diffuse	O
or	O
multifocal	O
up-regulation	O
of	O
MHC-I	O
expression	O
even	O
in	O
non-necrotic	B-Disease
fibres	O
.	O

Progressive	O
improvement	O
occurred	O
in	O
7	O
cases	O
after	O
commencement	O
of	O
prednisolone	B-Chemical
and	O
methotrexate	B-Chemical
,	O
and	O
in	O
one	O
case	O
spontaneously	O
.	O

These	O
observations	O
suggest	O
that	O
statins	B-Chemical
may	O
initiate	O
an	O
immune-mediated	O
myopathy	B-Disease
that	O
persists	O
after	O
withdrawal	O
of	O
the	O
drug	B-Drug
and	O
responds	O
to	O
immunosuppressive	O
therapy	O
.	O

The	O
mechanism	O
of	O
this	O
myopathy	B-Disease
is	O
uncertain	O
but	O
may	O
involve	O
the	O
induction	O
by	O
statins	B-Chemical
of	O
an	O
endoplasmic	O
reticulum	O
stress	O
response	O
with	O
associated	O
up-regulation	O
of	O
MHC-I	O
expression	O
and	O
antigen	O
presentation	O
by	O
muscle	O
fibres	O
.	O

Direct	O
inhibition	O
of	O
cardiac	O
hyperpolarization-activated	O
cyclic	B-Chemical
nucleotide-gated	O
pacemaker	O
channels	O
by	O
clonidine	B-Drug
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
cardiac	O
sympathetic	O
tone	O
represents	O
an	O
important	O
strategy	O
for	O
treatment	O
of	O
cardiovascular	B-Disease
disease	I-Disease
,	O
including	O
arrhythmia	B-Disease
,	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
,	O
and	O
chronic	O
heart	B-Disease
failure	I-Disease
.	O

Activation	O
of	O
presynaptic	O
alpha2-adrenoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanism	O
of	O
action	O
of	O
the	O
antisympathetic	O
drug	B-Drug
clonidine	B-Chemical
;	O
however	O
,	O
other	O
target	O
proteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actions	O
of	O
clonidine	B-Chemical
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
whether	O
clonidine	B-Chemical
elicits	O
pharmacological	O
effects	O
independent	O
of	O
alpha2-adrenoceptors	O
,	O
we	O
have	O
generated	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
all	O
3	O
alpha2-adrenoceptor	O
subtypes	O
(	O
alpha2ABC-/-	O
)	O
.	O

Alpha2ABC-/-	O
mice	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	O
and	O
hypnotic	O
effects	O
of	O
clonidine	B-Chemical
;	O
however	O
,	O
clonidine	B-Chemical
significantly	O
lowered	O
heart	O
rate	O
in	O
alpha2ABC-/-	O
mice	O
by	O
up	O
to	O
150	O
bpm	O
.	O

Clonidine-induced	B-Chemical
bradycardia	B-Disease
in	O
conscious	O
alpha2ABC-/-	O
mice	O
was	O
32.3	O
%	O
(	O
10	O
microg/kg	O
)	O
and	O
26.6	O
%	O
(	O
100	O
microg/kg	O
)	O
of	O
the	O
effect	O
in	O
wild-type	O
mice	O
.	O

A	O
similar	O
bradycardic	O
effect	O
of	O
clonidine	B-Chemical
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC-knockout	O
and	O
wild-type	O
mice	O
.	O

Clonidine	B-Chemical
inhibited	O
the	O
native	O
pacemaker	O
current	O
(	O
I	O
(	O
f	O
)	O
)	O
in	O
isolated	O
sinoatrial	O
node	O
pacemaker	O
cells	O
and	O
the	O
I	O
(	O
f	O
)	O
-generating	O
hyperpolarization-activated	O
cyclic	B-Chemical
nucleotide-gated	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channels	O
in	O
transfected	O
HEK293	O
cells	O
.	O

As	O
a	O
consequence	O
of	O
blocking	O
I	O
(	O
f	O
)	O
,	O
clonidine	B-Drug
reduced	O
the	O
slope	O
of	O
the	O
diastolic	O
depolarization	O
and	O
the	O
frequency	O
of	O
pacemaker	O
potentials	O
in	O
sinoatrial	O
node	O
cells	O
from	O
wild-type	O
and	O
alpha2ABC-knockout	O
mice	O
.	O

CONCLUSIONS	O
:	O
Direct	O
inhibition	O
of	O
cardiac	O
HCN	O
pacemaker	O
channels	O
contributes	O
to	O
the	O
bradycardic	O
effects	O
of	O
clonidine	B-Drug
gene-targeted	O
mice	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonidine-like	O
drugs	B-Drug
represent	O
novel	O
structures	O
for	O
future	O
HCN	O
channel	O
inhibitors	O
.	O

Influence	O
of	O
smoking	B-Chemical
on	O
developing	O
cochlea	O
.	O

Does	O
smoking	B-Chemical
during	O
pregnancy	O
affect	O
the	O
amplitudes	O
of	O
transient	O
evoked	O
otoacoustic	O
emissions	O
in	O
newborns	O
?	O
OBJECTIVE	O
:	O
Maternal	O
tobacco	O
smoking	B-Chemical
has	O
negative	O
effects	O
on	O
fetal	O
growth	O
.	O

The	O
influence	O
of	O
smoking	B-Chemical
during	O
pregnancy	O
on	O
the	O
developing	O
cochlea	O
has	O
not	O
been	O
estimated	O
,	O
although	O
smoking	B-Chemical
has	O
been	O
positively	O
associated	O
with	O
hearing	B-Disease
loss	I-Disease
in	O
adults	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	B-Chemical
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	O
neonates	O
.	O

METHODS	O
:	O
This	O
study	O
was	O
undertaken	O
as	O
part	O
of	O
neonatal	O
screening	O
for	O
hearing	B-Disease
impairment	I-Disease
and	O
involved	O
both	O
ears	O
of	O
200	O
newborns	O
.	O

Newborns	O
whose	O
mothers	O
reported	O
smoking	B-Chemical
during	O
pregnancy	O
(	O
n=200	O
ears	O
)	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	I-Disease
newborns	O
(	O
n=200	O
ears	O
)	O
,	O
whose	O
mothers	O
were	O
non-smokers	O
.	O

Exposure	O
to	O
tobacco	O
was	O
characterized	O
as	O
low	O
(	O
<	O
5	O
cigarettes	O
per	O
day	O
,	O
n=88	O
ears	O
)	O
,	O
moderate	O
(	O
5	O
<	O
or	O
=cigarettes	O
per	O
day	O
<	O
10	O
,	O
n=76	O
)	O
or	O
high	O
(	O
>	O
or	O
=10	O
cigarettes	O
per	O
day	O
,	O
n=36	O
)	O
.	O

RESULTS	O
:	O
In	O
exposed	O
neonates	O
,	O
TEOAEs	I-Disease
mean	O
response	O
(	O
across	O
frequency	O
)	O
and	O
mean	O
amplitude	O
at	O
4000Hz	O
was	O
significantly	O
lower	O
than	O
in	O
non-exposed	O
neonates	O
.	O

Comparisons	O
between	O
exposed	O
newborns	O
'	O
subgroups	O
revealed	O
no	O
significant	O
differences	O
.	O

However	O
,	O
by	O
comparing	O
each	O
subgroup	O
to	O
control	O
group	O
,	O
we	O
found	O
statistically	O
significant	O
decreases	B-Disease
of	I-Disease
TEOAEs	O
amplitudes	O
at	O
4000Hz	O
for	O
all	O
three	O
groups	O
.	O

Mean	O
TEOAEs	O
responses	O
of	O
highly	O
exposed	O
newborns	O
were	O
also	O
significantly	O
lower	O
in	O
comparison	O
to	O
our	O
control	O
group	O
.	O

CONCLUSION	O
:	O
In	O
utero	O
,	O
exposure	O
to	O
tobacco	O
smoking	B-Chemical
seems	O
to	O
have	O
a	O
small	O
impact	O
on	O
outer	O
hair	O
cells	O
.	O

These	O
effects	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
exposed	O
newborns	O
,	O
regardless	O
of	O
the	O
degree	O
of	O
exposure	O
.	O

Further	O
studies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potential	O
negative	O
effect	O
of	O
maternal	O
smoking	B-Chemical
on	O
the	O
neonate	O
's	O
hearing	O
acuity	O
.	O

Neuroinflammation	B-Disease
and	O
behavioral	B-Disease
abnormalities	I-Disease
after	O
neonatal	O
terbutaline	B-Chemical
treatment	O
in	O
rats	O
:	O
implications	O
for	O
autism	B-Disease
.	O

Autism	B-Disease
is	O
a	O
neurodevelopmental	B-Disease
disorder	I-Disease
presenting	O
before	O
3	O
years	O
of	O
age	O
with	O
deficits	B-Disease
in	I-Disease
communication	I-Disease
and	I-Disease
social	I-Disease
skills	I-Disease
and	O
repetitive	B-Disease
behaviors	I-Disease
.	O

In	O
addition	O
to	O
genetic	O
influences	O
,	O
recent	O
studies	O
suggest	O
that	O
prenatal	O
drug	B-Drug
or	O
chemical	O
exposures	O
are	O
risk	O
factors	O
for	O
autism	B-Disease
.	O

Terbutaline	B-Chemical
,	O
a	O
beta2-adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	B-Disease
labor	I-Disease
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	B-Disease
in	O
dizygotic	O
twins	O
.	O

We	O
studied	O
the	O
effects	O
of	O
terbutaline	B-Chemical
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats	O
.	O

Newborn	O
rats	O
were	O
given	O
terbutaline	B-Chemical
(	O
10	O
mg/kg	O
)	O
daily	O
on	O
postnatal	O
days	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dose	O
and	O
at	O
PN	O
30	O
.	O

Immunohistochemical	O
studies	O
showed	O
that	O
administration	O
of	O
terbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robust	O
increase	O
in	O
microglial	O
activation	O
on	O
PN	O
30	O
in	O
the	O
cerebral	O
cortex	O
,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocortical	O
white	O
matter	O
.	O

None	O
of	O
these	O
effects	O
occurred	O
in	O
animals	O
given	O
terbutaline	B-Chemical
on	O
PN	O
11	O
to	O
14	O
.	O

In	O
behavioral	O
tests	O
,	O
animals	O
treated	O
with	O
terbutaline	B-Chemical
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper-reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test	O
.	O

Our	O
findings	O
indicate	O
that	O
beta2-adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	B-Disease
abnormalities	I-Disease
,	O
similar	O
to	O
those	O
described	O
in	O
autism	B-Disease
.	O

This	O
study	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
understanding	O
the	O
neuropathological	O
processes	O
underlying	O
autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
.	O

Acute	O
myocarditis	B-Disease
associated	O
with	O
clozapine	B-Chemical
.	O

OBJECTIVE	O
:	O
A	O
case	O
of	O
acute	O
myocarditis	B-Disease
associated	O
with	O
the	O
commencement	O
of	O
clozapine	B-Chemical
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
course	O
and	O
possible	O
contributing	O
factors	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	O
complication	O
of	O
clozapine	B-Chemical
use	O
.	O

RESULTS	O
:	O
A	O
20-year-old	O
male	O
with	O
schizophrenia	B-Disease
developed	O
a	O
sudden	O
onset	O
of	O
myocarditis	B-Disease
after	O
commencement	O
of	O
clozapine	B-Chemical
.	O

The	O
patient	O
recovered	O
with	O
intensive	O
medical	O
support	O
.	O

The	O
symptoms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozapine	B-Chemical
in	O
an	O
inpatient	O
setting	O
.	O

Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	B-Chemical
use	O
and	O
unaccustomed	O
physical	O
activity	O
.	O

CONCLUSIONS	O
:	O
Myocarditis	B-Disease
is	O
an	O
increasingly	O
recognized	O
complication	O
associated	O
with	O
the	O
use	O
of	O
clozapine	B-Chemical
.	O

It	O
can	O
be	O
fatal	O
if	O
not	O
recognized	O
and	O
treated	O
early	O
.	O

Considering	O
that	O
clozapine	B-Chemical
remains	O
the	O
gold	B-Drug
standard	O
in	O
treatment	O
of	O
resistant	O
psychosis	B-Disease
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O

There	O
are	O
also	O
implications	O
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	B-Chemical
.	O

Encephalopathy	B-Disease
induced	O
by	O
levetiracetam	B-Chemical
added	O
to	O
valproate	B-Chemical
.	O

BACKGROUND	O
:	O
We	O
report	O
on	O
the	O
manifestation	O
of	O
a	O
levetiracetam	B-Chemical
(	O
LEV	B-Chemical
)	O
-induced	O
encephalopathy	B-Disease
.	O

FINDINGS	O
:	O
A	O
28-year-old	O
man	O
suffering	O
from	O
idiopathic	B-Disease
epilepsy	I-Disease
with	O
generalized	O
seizures	B-Disease
was	O
treated	O
with	O
LEV	B-Chemical
(	O
3000	O
mg	O
)	O
added	O
to	O
valproate	B-Chemical
(	O
VPA	B-Chemical
)	O
(	O
2000	O
mg	O
)	O
.	O

Frequency	O
of	O
generalized	O
tonic-clonic	B-Disease
seizures	I-Disease
increased	O
from	O
one	O
per	O
6	O
months	O
to	O
two	O
per	O
month	O
.	O

Neuropsychological	O
testing	O
showed	O
impaired	B-Disease
word	I-Disease
fluency	I-Disease
,	I-Disease
psychomotor	I-Disease
speed	I-Disease
and	I-Disease
working	I-Disease
memory	I-Disease
.	O

The	O
interictal	O
electroencephalogram	O
(	O
EEG	O
)	O
showed	O
a	O
generalized	O
slowing	O
to	O
5	O
per	O
second	O
theta	O
rhythms	O
with	O
bilateral	O
generalized	O
high-amplitude	O
discharges	O
.	O

OUTCOME	O
:	O
Following	O
discontinuation	O
of	O
LEV	B-Chemical
,	O
EEG	O
and	O
neuropsychological	O
findings	O
improved	O
and	O
seizure	B-Disease
frequency	O
decreased	O
.	O

Norepinephrine	B-Chemical
signaling	O
through	O
beta-adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine-induced	B-Chemical
anxiety	B-Disease
.	O

BACKGROUND	O
:	O
Cocaine	B-Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O

While	O
the	O
mechanisms	O
underlying	O
cocaine	B-Chemical
's	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	B-Chemical
,	O
such	O
as	O
anxiety	B-Disease
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	B-Chemical
beta-hydroxylase	O
knockout	O
(	O
Dbh	O
-/-	O
)	O
mice	O
,	O
which	O
lack	O
norepinephrine	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine-induced	B-Chemical
anxiety	B-Disease
.	O

RESULTS	O
:	O
We	O
found	O
that	O
cocaine	B-Chemical
dose-dependently	O
increased	O
anxiety-like	B-Disease
behavior	O
in	O
control	O
(	O
Dbh	O
+/-	O
)	O
mice	O
,	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration	O
.	O

The	O
Dbh	O
-/-	O
mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	B-Chemical
.	O

Cocaine-induced	B-Chemical
anxiety	B-Disease
was	O
also	O
attenuated	O
in	O
Dbh	O
+/-	O
mice	O
following	O
administration	O
of	O
disulfiram	B-Chemical
,	O
a	O
dopamine	B-Chemical
beta-hydroxylase	O
(	O
DBH	O
)	O
inhibitor	O
.	O

In	O
experiments	O
using	O
specific	O
adrenergic	O
antagonists	O
,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta-adrenergic	O
receptor	O
antagonist	O
propranolol	B-Chemical
blocked	O
cocaine-induced	B-Chemical
anxiety-like	B-Disease
behavior	O
in	O
Dbh	O
+/-	O
and	O
wild-type	O
C57BL6/J	O
mice	O
,	O
while	O
the	O
alpha	O
(	O
1	O
)	O
antagonist	O
prazosin	B-Chemical
and	O
the	O
alpha	O
(	O
2	O
)	O
antagonist	O
yohimbine	B-Chemical
had	O
no	O
effect	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta-adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine-induced	B-Chemical
anxiety	B-Disease
in	O
mice	O
.	O

Clonidine	B-Chemical
for	O
attention-deficit/hyperactivity	B-Disease
disorder	I-Disease
:	O
II	O
.	O

ECG	O
changes	O
and	O
adverse	O
events	O
analysis	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	B-Chemical
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
in	O
children	O
with	O
attention-deficit/hyperactivity	B-Disease
disorder	I-Disease
(	O
ADHD	B-Disease
)	O
.	O

METHOD	O
:	O
In	O
a	O
16-week	O
multicenter	O
,	O
double-blind	O
trial	O
,	O
122	O
children	O
with	O
ADHD	B-Disease
were	O
randomly	O
assigned	O
to	O
clonidine	B-Chemical
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidate	B-Chemical
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
30	O
)	O
.	O

Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0.6	O
mg/day	O
for	O
clonidine	B-Chemical
and	O
60	O
mg/day	O
for	O
methylphenidate	B-Chemical
(	O
both	O
with	O
divided	O
dosing	O
)	O
.	O

Groups	O
were	O
compared	O
regarding	O
adverse	O
events	O
and	O
changes	O
from	O
baseline	O
to	O
week	O
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs	O
.	O

RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-Disease
in	O
subjects	O
treated	O
with	O
clonidine	B-Chemical
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-Chemical
(	O
17.5	O
%	O
versus	O
3.4	O
%	O
;	O
p	O
=.02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O

There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
regarding	O
cardiovascular	O
outcomes	O
.	O

Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	B-Chemical
(	O
79.4	O
%	O
versus	O
49.2	O
%	O
;	O
p	O
=.0006	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O

Drowsiness	B-Disease
was	O
common	O
on	O
clonidine	B-Chemical
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O

CONCLUSIONS	O
:	O
Clonidine	B-Chemical
,	O
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	B-Disease
.	O

Physicians	O
prescribing	O
clonidine	B-Chemical
should	O
monitor	O
for	O
bradycardia	B-Disease
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	B-Disease
.	O

Thalidomide	B-Chemical
has	O
limited	O
single-agent	O
activity	O
in	O
relapsed	O
or	O
refractory	O
indolent	O
non-Hodgkin	B-Disease
lymphomas	I-Disease
:	O
a	O
phase	O
II	O
trial	O
of	O
the	O
Cancer	B-Disease
and	O
Leukemia	B-Disease
Group	O
B	O
.	O

Thalidomide	B-Chemical
is	O
an	O
immunomodulatory	O
agent	O
with	O
demonstrated	O
activity	O
in	O
multiple	B-Disease
myeloma	I-Disease
,	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
and	O
lymphoplasmacytic	B-Disease
lymphoma	I-Disease
.	O

Its	O
activity	O
is	O
believed	O
to	O
be	O
due	O
modulation	O
of	O
the	O
tumour	B-Disease
milieu	O
,	O
including	O
downregulation	O
of	O
angiogenesis	O
and	O
inflammatory	O
cytokines	O
.	O

Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patients	O
with	O
relapsed/refractory	O
indolent	O
lymphomas	B-Disease
received	O
thalidomide	B-Chemical
200	O
mg	O
daily	O
with	O
escalation	O
by	O
100	O
mg	O
daily	O
every	O
1-2	O
weeks	O
as	O
tolerated	O
,	O
up	O
to	O
a	O
maximum	O
of	O
800	O
mg	O
daily	O
.	O

Patients	O
had	O
received	O
a	O
median	O
of	O
2	O
(	O
range	O
,	O
1-4	O
)	O
prior	O
regimens	O
.	O

Of	O
24	O
evaluable	O
patients	O
,	O
two	O
achieved	O
a	O
complete	O
remission	O
and	O
one	O
achieved	O
a	O
partial	O
remission	O
for	O
an	O
overall	O
response	O
rate	O
of	O
12.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
2.6-32.4	O
%	O
)	O
.	O

Eleven	O
patients	O
progressed	O
during	O
therapy	O
.	O

Grade	O
3-4	O
adverse	O
effects	O
included	O
myelosuppression	B-Disease
,	O
fatigue	B-Disease
,	O
somnolence/depressed	B-Disease
mood	I-Disease
,	O
neuropathy	O
and	O
dyspnea	O
.	O

Of	O
concern	O
was	O
the	O
occurrence	O
of	O
four	O
thromboembolic	O
events	O
.	O

Our	O
results	O
failed	O
to	O
demonstrate	O
an	O
important	O
response	O
rate	O
to	O
single	O
agent	O
thalidomide	B-Drug
in	O
indolent	O
lymphomas	O
and	O
contrast	O
with	O
the	O
higher	O
activity	O
level	O
reported	O
with	O
the	O
second	O
generation	O
immunomodulatory	O
agent	O
,	O
lenalidomide	B-Drug
.	O

Intracavernous	O
epinephrine	B-Chemical
:	O
a	O
minimally	O
invasive	O
treatment	O
for	O
priapism	B-Disease
in	O
the	O
emergency	O
department	O
.	O

Priapism	B-Disease
is	O
the	O
prolonged	O
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	O
arousal	O
.	O

A	O
45-year-old	O
man	O
,	O
an	O
admitted	O
frequent	O
cocaine	B-Chemical
user	O
,	O
presented	O
to	O
the	O
Emergency	O
Department	O
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	B-Disease
after	O
cocaine	B-Chemical
use	O
.	O

The	O
management	O
options	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
individual	O
case	O
reports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	O
method	O
of	O
intracorporal	O
epinephrine	B-Chemical
instillation	O
,	O
are	O
discussed	O
.	O

Effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
combination	O
in	O
isoproterenol	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
on	O
heart	O
weight	O
,	O
body	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
endogenous	O
antioxidants	O
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
-induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Adult	O
male	O
albino	O
rats	O
,	O
treated	O
with	O
ISO	B-Chemical
(	O
200	O
mg/kg	O
,	O
s.c.	O
)	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
elevation	O
of	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
and	O
Ca+2	B-Chemical
ATPase	O
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
decrease	O
in	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na+/	B-Chemical
K+	B-Chemical
ATPase	O
and	O
Mg+2	B-Chemical
ATPase	O
levels	O
.	O

Administration	O
of	O
green	B-Chemical
tea	I-Chemical
(	O
100	O
mg/kg/day	O
,	O
p.o	O
.	O

)	O
and	O
vitamin	B-Chemical
E	I-Chemical
(	O
100	O
mg/kg/day	O
,	O
p.o	O
.	O

)	O
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	B-Chemical
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
decrease	O
in	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
Ca+2	B-Chemical
ATPase	O
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight	O
,	O
endogenous	O
antioxidants	O
,	O
Na+/K+	B-Chemical
ATPase	O
and	O
Mg+2	O
ATPase	O
when	O
compared	O
with	O
ISO	O
treated	O
group	O
and	O
green	O
tea	O
or	O
vitamin	O
E	O
alone	O
treated	O
groups	O
.	O

These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	O
tea	O
and	O
vitamin	O
E	O
during	O
ISO	O
induced	O
myocardial	O
infarction	O
in	O
rats	O
.	O

Development	O
of	O
ocular	B-Disease
myasthenia	I-Disease
during	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
ribavirin	B-Chemical
treatment	O
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
.	O

A	O
63-year-old	O
male	O
experienced	O
sudden	O
diplopia	B-Disease
after	O
9	O
weeks	O
of	O
administration	O
of	O
pegylated	B-Chemical
interferon	I-Chemical
(	I-Chemical
IFN	I-Chemical
)	I-Chemical
alpha-2b	I-Chemical
and	O
ribavirin	B-Chemical
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
(	O
CHC	B-Disease
)	O
.	O

Ophthalmologic	O
examinations	O
showed	O
ptosis	B-Disease
on	I-Disease
the	I-Disease
right	I-Disease
upper	I-Disease
lid	I-Disease
and	O
restricted	B-Disease
right	I-Disease
eye	I-Disease
movement	I-Disease
without	O
any	O
other	O
neurological	O
signs	O
.	O

A	O
brain	O
imaging	O
study	O
and	O
repetitive	O
nerve	O
stimulation	O
test	O
indicated	O
no	O
abnormality	O
.	O

The	O
acetylcholine	B-Chemical
receptor	O
antibody	O
titer	O
and	O
response	O
to	O
acetylcholinesterase	O
inhibitors	O
were	O
negative	O
,	O
and	O
the	O
results	O
of	O
thyroid	B-Drug
function	O
tests	O
were	O
normal	O
.	O

The	O
patient	O
's	O
ophthalmological	O
symptoms	O
improved	O
rapidly	O
3	O
weeks	O
after	O
discontinuation	O
of	O
pegylated	B-Chemical
IFN	I-Chemical
alpha-2b	I-Chemical
and	O
ribavirin	B-Chemical
.	O

The	O
ocular	B-Disease
myasthenia	I-Disease
associated	O
with	O
combination	O
therapy	O
of	O
pegylated	B-Chemical
IFN	I-Chemical
alpha-2b	I-Chemical
and	O
ribavirin	B-Chemical
for	O
CHC	B-Disease
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
case	O
with	O
a	O
review	O
of	O
the	O
various	O
eye	O
complications	O
of	O
IFN	B-Chemical
therapy	O
.	O

The	O
glycine	B-Chemical
transporter-1	O
inhibitor	O
SSR103800	B-Chemical
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic-like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O

Schizophrenia	B-Disease
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	B-Chemical
neurotransmission	O
.	O

However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	B-Chemical
N-methyl-D-aspartate	B-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
produce	O
schizophrenic-like	B-Disease
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	B-Chemical
receptor	O
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	B-Chemical
receptor	O
.	O

Among	O
them	O
are	O
glycine	B-Chemical
transporter-1	O
(	O
GlyT1	O
)	O
inhibitors	O
such	O
as	O
SSR103800	B-Chemical
,	O
which	O
indirectly	O
enhance	O
NMDA	B-Chemical
receptor	O
function	O
by	O
increasing	O
the	O
glycine	B-Chemical
(	O
a	O
co-agonist	O
for	O
the	O
NMDA	B-Chemical
receptor	O
)	O
levels	O
in	O
the	O
synapse	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic-like	O
properties	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-Disease
,	O
involving	O
either	O
drug	B-Drug
challenge	O
(	O
ie	O
,	O
amphetamine	B-Chemical
and	O
MK-801	B-Chemical
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	B-Chemical
Nr1	O
(	O
neo-/-	O
)	O
and	O
DAT	O
(	O
-/-	O
)	O
)	O
.	O

Results	O
showed	O
that	O
SSR103800	B-Chemical
(	O
10-30	O
mg/kg	O
p.o	O
.	O

)	O
blocked	O
hyperactivity	B-Disease
induced	O
by	O
the	O
non-competitive	O
NMDA	B-Chemical
receptor	O
antagonist	O
,	O
MK-801	B-Chemical
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	B-Disease
of	O
NMDA	B-Chemical
Nr1	O
(	O
neo-/-	O
)	O
mice	O
.	O

In	O
contrast	O
,	O
SSR103800	B-Chemical
failed	O
to	O
affect	O
hyperactivity	B-Disease
induced	O
by	O
amphetamine	B-Chemical
or	O
naturally	O
observed	O
in	O
dopamine	B-Chemical
transporter	O
(	O
DAT	O
(	O
-/-	O
)	O
)	O
knockout	O
mice	O
(	O
10-30	O
mg/kg	O
p.o.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	B-Chemical
)	O
and	O
atypical	O
(	O
olanzapine	B-Chemical
,	O
clozapine	B-Chemical
and	O
aripiprazole	B-Chemical
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	B-Disease
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	B-Chemical
did	O
not	O
produce	O
catalepsy	B-Disease
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg/kg	O
p.o	O
.	O

Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor	O
,	O
SSR103800	B-Chemical
,	O
produces	O
antipsychotic-like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	B-Drug
system	O
,	O
and	O
has	O
a	O
reduced	O
side-effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	B-Drug
.	O

Phenylephrine	B-Chemical
but	O
not	O
ephedrine	B-Chemical
reduces	B-Disease
frontal	I-Disease
lobe	I-Disease
oxygenation	I-Disease
following	O
anesthesia-induced	O
hypotension	B-Disease
.	O

BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia-induced	O
hypotension	B-Disease
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephrine	B-Chemical
and	O
ephedrine	B-Chemical
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthesia-induced	O
hypotension	B-Disease
.	O

METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	B-Drug
by	O
fentanyl	B-Chemical
(	O
0.15	O
mg	O
kg	O
(	O
-1	O
)	O
)	O
and	O
propofol	B-Chemical
(	O
2.0	O
mg	O
kg	O
(	O
-1	O
)	O
)	O
,	O
13	O
patients	O
received	O
phenylephrine	B-Chemical
(	O
0.1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	B-Chemical
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
stroke	B-Disease
volume	O
(	O
SV	I-Disease
)	O
,	I-Disease
cardiac	B-Disease
output	O
(	O
CO	I-Disease
)	O
,	I-Disease
and	B-Disease
frontal	B-Disease
lobe	O
oxygenation	B-Disease
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registered	O
.	O

RESULTS	O
:	O
Induction	O
of	O
anesthesia	B-Disease
was	B-Disease
followed	O
by	O
a	B-Disease
decrease	B-Chemical
in	I-Chemical
MAP	I-Chemical
,	O
HR	O
,	O
SV	O
,	O
and	B-Chemical
CO	I-Chemical
concomitant	B-Chemical
with	O
an	B-Chemical
elevation	B-Chemical
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
administration	O
of	O
phenylephrine	B-Disease
,	O
MAP	O
increased	O
(	O
51	O
+/-	O
12	O
to	O
81	O
+/-	O
13	O
mmHg	O
;	O
P	O
<	O
0.001	O
;	O
mean	O
+/-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+/-	O
8	O
%	O
to	O
60	O
+/-	O
7	O
%	O
)	O
reduction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0.05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	B-Drug
(	O
3.7	O
+/-	O
1.1	O
to	O
3.4	O
+/-	O
0.9	O
l	O
min	O
(	O
-1	O
)	O
)	O
.	O

The	O
administration	O
of	O
ephedrine	B-Chemical
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+/-	O
9	O
to	O
79	O
+/-	O
8	O
mmHg	O
;	O
P	O
<	O
0.001	O
)	O
,	O
restored	O
CO	B-Drug
(	O
3.2	O
+/-	O
1.2	O
to	O
5.0	O
+/-	O
1.3	O
l	O
min	O
(	O
-1	O
)	O
)	O
,	O
and	O
preserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	B-Chemical
to	O
correct	O
hypotension	B-Chemical
induced	O
by	O
anesthesia	B-Drug
has	O
a	O
negative	O
impact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrine	B-Chemical
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	B-Drug
.	O

A	O
novel	O
,	O
multiple	O
symptom	O
model	O
of	O
obsessive-compulsive-like	B-Disease
behaviors	I-Disease
in	O
animals	O
.	O

BACKGROUND	O
:	O
Current	O
animal	O
models	O
of	O
obsessive-compulsive	B-Disease
disorder	I-Disease
(	O
OCD	B-Disease
)	O
typically	O
involve	O
acute	O
,	O
drug-induced	O
symptom	O
provocation	O
or	O
a	O
genetic	O
association	O
with	O
stereotypies	O
or	O
anxiety	B-Disease
.	O

None	O
of	O
these	O
current	O
models	O
demonstrate	O
multiple	O
OCD-like	B-Disease
behaviors	O
.	O

METHODS	O
:	O
Neonatal	O
rats	O
were	O
treated	O
with	O
the	O
tricyclic	O
antidepressant	B-Chemical
clomipramine	B-Chemical
or	O
vehicle	O
between	O
days	O
9	O
and	O
16	O
twice	O
daily	O
and	O
behaviorally	O
tested	O
in	O
adulthood	O
.	O

RESULTS	O
:	O
Clomipramine	B-Chemical
exposure	O
in	O
immature	O
rats	O
produced	O
significant	O
behavioral	O
and	O
biochemical	O
changes	O
that	O
include	O
enhanced	O
anxiety	B-Disease
(	O
elevated	O
plus	O
maze	O
and	O
marble	O
burying	O
)	O
,	O
behavioral	B-Disease
inflexibility	I-Disease
(	O
perseveration	O
in	O
the	O
spontaneous	O
alternation	O
task	O
and	O
impaired	O
reversal	O
learning	O
)	O
,	O
working	O
memory	B-Disease
impairment	I-Disease
(	O
e.g.	O
,	O
win-shift	O
paradigm	O
)	O
,	O
hoarding	B-Disease
,	O
and	O
corticostriatal	B-Disease
dysfunction	I-Disease
.	O

Dopamine	B-Chemical
D2	O
receptors	O
were	O
elevated	O
in	O
the	O
striatum	O
,	O
whereas	O
serotonin	B-Chemical
2C	O
,	O
but	O
not	O
serotonin	B-Chemical
1A	O
,	O
receptors	O
were	O
elevated	O
in	O
the	O
orbital	O
frontal	O
cortex	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	O
symptoms	O
consistent	O
with	O
an	O
OCD-like	B-Disease
profile	O
in	O
animals	O
.	O

Moreover	O
,	O
these	O
behaviors	O
are	O
accompanied	O
by	O
biochemical	O
changes	O
in	O
brain	O
regions	O
previously	O
identified	O
as	O
relevant	O
to	O
OCD	B-Disease
.	O

This	O
novel	O
model	O
of	O
OCD	B-Disease
demonstrates	O
that	O
drug	B-Drug
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease-like	O
systems	O
permanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	B-Disease
disorders	I-Disease
.	O

Late	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
woman	O
with	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O

A	O
case	O
is	O
reported	O
of	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
(	O
HUS	B-Disease
)	O
in	O
a	O
woman	O
taking	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

She	O
was	O
treated	O
with	O
heparin	B-Chemical
,	O
dipyridamole	B-Chemical
and	O
hemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
months	O
,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	B-Disease
,	O
dialysis	O
treatment	O
was	O
stopped	O
.	O

This	O
case	O
emphasizes	O
the	O
possibility	O
that	O
HUS	B-Disease
in	O
adults	O
is	O
not	O
invariably	O
irreversible	O
and	O
that	O
,	O
despite	O
prolonged	O
oliguria	B-Disease
,	O
recovery	O
of	O
renal	O
function	O
can	O
be	O
obtained	O
.	O

Therefore	O
,	O
in	O
adult	O
patients	O
affected	O
by	O
HUS	B-Disease
,	O
dialysis	O
should	O
not	O
be	O
discontinued	O
prematurely	O
;	O
moreover	O
,	O
bilateral	O
nephrectomy	O
,	O
for	O
treatment	O
of	O
severe	O
hypertension	B-Disease
and	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Effects	O
of	O
acetylsalicylic	B-Chemical
acid	I-Chemical
,	O
dipyridamole	B-Chemical
,	O
and	O
hydrocortisone	B-Chemical
on	O
epinephrine-induced	B-Chemical
myocardial	B-Disease
injury	I-Disease
in	O
dogs	O
.	O

A	O
reproducible	O
model	O
for	O
producing	O
diffuse	O
myocardial	B-Disease
injury	I-Disease
(	O
epinephrine	B-Chemical
infusion	O
)	O
has	O
been	O
developed	O
to	O
study	O
the	O
cardioprotective	O
effects	O
of	O
agents	O
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

Infusions	O
of	O
epinephrine	B-Chemical
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
increased	O
radiocalcium	B-Chemical
uptakes	O
into	O
intact	O
myocardium	O
and	O
each	O
of	O
its	O
subcellular	O
components	O
with	O
the	O
mitochondrial	O
fraction	O
showing	O
the	O
most	O
consistent	O
changes	O
when	O
compared	O
to	O
saline-infused	O
control	O
animals	O
(	O
4,957	O
vs.	O
827	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
tissue	O
or	O
fraction	O
)	O
.	O

Myocardial	O
concentrations	O
of	O
calcium	B-Chemical
also	O
increased	O
significantly	O
(	O
12.0	O
vs.	O
5.0	O
mg.per	O
100	O
Gm	O
.	O

of	O
fat-free	O
dry	O
weight	O
)	O
.	O

Infusions	O
of	O
calcium	B-Chemical
chloride	I-Chemical
sufficient	O
to	O
raise	O
serum	O
calcium	B-Chemical
concentrations	O
2	O
mEq	O
.	O

per	O
liter	O
failed	O
to	O
increase	O
calcium	B-Chemical
influx	O
into	O
the	O
myocardial	O
cell	O
.	O

Mitochondrial	O
radiocalcium	B-Chemical
uptakes	O
were	O
significantly	O
decreased	O
in	O
animals	O
pretreated	O
with	O
acetylsalicylic	B-Chemical
acid	I-Chemical
or	O
dipyridamole	B-Chemical
or	O
when	O
hydrocortisone	B-Chemical
was	O
added	O
to	O
the	O
epinephrine	B-Chemical
infusion	O
(	O
2,682,2,803	O
,	O
and	O
3,424	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
fraction	O
,	O
respectively	O
)	O
.	O

Myocardial	O
calcium	B-Chemical
concentrations	O
also	O
were	O
decreased	O
(	O
11.2	O
,	O
8.3	O
,	O
and	O
8.9	O
mg.	O
per	O
100	O
Gm	O
.	O

of	O
fat-free	O
dry	O
weight	O
,	O
respectively	O
)	O
in	O
the	O
three	O
treatment	O
groups	O
,	O
being	O
significantly	O
decreased	O
only	O
in	O
the	O
last	O
two	O
.	O

Evidence	O
of	O
microscopic	O
damage	O
was	O
graded	O
as	O
less	O
severe	O
in	O
the	O
three	O
treatment	O
groups	O
.	O

Acetylsalicylic	B-Chemical
acid	I-Chemical
,	O
dipyridamole	B-Chemical
,	O
and	O
hydrocortisone	B-Chemical
all	O
appear	O
to	O
have	O
cardioprotective	O
effects	O
when	O
tested	O
in	O
this	O
model	O
.	O

Changes	O
in	O
depressive	B-Disease
status	O
associated	O
with	O
topical	O
beta-blockers	O
.	O

Depression	B-Disease
and	O
sexual	B-Disease
dysfunction	I-Disease
have	O
been	O
related	O
to	O
side	O
effects	O
of	O
topical	O
beta-blockers	O
.	O

We	O
performed	O
a	O
preliminary	O
study	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
beta-blocker	O
(	O
timolol	B-Chemical
)	O
and	O
a	O
selective	O
beta-blocker	O
(	O
betaxolol	B-Chemical
)	O
regarding	O
CNS	O
side	O
effects	O
.	O

Eight	O
glaucomatous	B-Disease
patients	O
chronically	O
treated	O
with	O
timolol	B-Chemical
0.5	O
%	O
/12h	O
,	O
suffering	O
from	O
depression	B-Disease
diagnosed	O
through	O
DMS-III-R	O
criteria	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

During	O
the	O
six-month	O
follow	O
up	O
,	O
depression	B-Disease
was	O
quantified	O
through	O
the	O
Beck	O
and	O
Zung-Conde	O
scales	O
every	O
two	O
months	O
.	O

In	O
a	O
double	O
blind	O
cross-over	O
study	O
with	O
control	O
group	O
,	O
the	O
patients	O
under	O
timolol	B-Chemical
treatment	O
presented	O
higher	O
depression	B-Disease
values	O
measured	O
through	O
the	O
Beck	O
and	O
the	O
Zung-Conde	O
scales	O
(	O
p	O
<	O
0.001	O
vs	O
control	O
)	O
.	O

These	O
results	O
suggest	O
that	O
betaxolol	B-Chemical
could	O
be	O
less	O
of	O
a	O
depression-inducer	B-Disease
than	O
timolol	B-Chemical
in	O
predisposed	O
patients	O
.	O

Long-term	O
follow-up	O
of	O
ifosfamide	B-Chemical
renal	B-Disease
toxicity	I-Disease
in	O
children	O
treated	O
for	O
malignant	B-Disease
mesenchymal	I-Disease
tumors	I-Disease
:	O
an	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
report	O
.	O

The	O
renal	O
function	O
of	O
74	O
children	O
with	O
malignant	B-Disease
mesenchymal	I-Disease
tumors	I-Disease
in	O
complete	O
remission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	B-Chemical
chemotherapy	O
protocol	O
(	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
Malignant	B-Disease
Mesenchymal	I-Disease
Tumor	I-Disease
Study	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment	O
.	O

Total	O
cumulative	O
doses	O
were	O
36	O
or	O
60	O
g/m2	O
of	O
ifosfamide	B-Chemical
(	O
six	O
or	O
10	O
cycles	O
of	O
ifosfamide	B-Chemical
,	I-Chemical
vincristine	I-Chemical
,	I-Chemical
and	I-Chemical
dactinomycin	I-Chemical
[	O
IVA	B-Chemical
]	O
)	O
.	O

None	O
of	O
them	O
had	O
received	O
cisplatin	B-Chemical
chemotherapy	O
.	O

Ages	O
ranged	O
from	O
4	O
months	O
to	O
17	O
years	O
;	O
58	O
patients	O
were	O
males	O
and	O
42	O
females	O
.	O

The	O
most	O
common	O
primary	O
tumor	B-Disease
site	O
was	O
the	O
head	O
and	O
neck	O
.	O

Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes	O
,	O
glucosuria	B-Disease
,	O
proteinuria	B-Disease
,	O
aminoaciduria	B-Disease
,	O
urinary	O
pH	O
,	O
osmolarity	O
,	O
creatinine	B-Chemical
clearance	O
,	O
phosphate	B-Chemical
tubular	O
reabsorption	O
,	O
beta	O
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O

Fifty-eight	O
patients	O
(	O
78	O
%	O
)	O
had	O
normal	O
renal	B-Disease
tests	O
,	O
whereas	O
16	O
patients	O
(	O
22	O
%	O
)	O
had	O
renal	B-Disease
abnormalities	O
.	O

Two	O
subsets	O
of	O
patients	O
were	O
identified	O
from	O
this	O
latter	O
group	O
:	O
the	O
first	O
included	O
four	O
patients	O
(	O
5	O
%	O
of	O
the	O
total	O
population	O
)	O
who	O
developed	O
major	O
toxicity	B-Disease
resulting	O
in	O
Fanconi	B-Disease
's	I-Disease
syndrome	I-Disease
(	O
TDFS	B-Disease
)	O
;	O
and	O
the	O
second	O
group	O
included	O
five	O
patients	O
with	O
elevated	O
beta	O
2	O
microglobulinuria	O
and	O
low	O
phosphate	B-Chemical
reabsorption	O
.	O

The	O
remaining	O
seven	O
patients	O
had	O
isolated	O
beta	O
2	O
microglobulinuria	O
.	O

Severe	O
toxicity	B-Disease
was	O
correlated	O
with	O
the	O
higher	O
cumulative	O
dose	O
of	O
60	O
g/m2	O
of	O
ifosfamide	B-Chemical
,	O
a	O
younger	O
age	O
(	O
less	O
than	O
2	O
1/2	O
years	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	B-Disease
involvement	O
.	O

This	O
low	O
percentage	O
(	O
5	O
%	O
)	O
of	O
TDFS	O
must	O
be	O
evaluated	O
with	O
respect	O
to	O
the	O
efficacy	O
of	O
ifosfamide	B-Chemical
in	O
the	O
treatment	O
of	O
mesenchymal	B-Disease
tumors	I-Disease
in	O
children	O
.	O

Evidence	O
for	O
an	O
involvement	O
of	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptors	O
in	O
mediating	O
nicotine-induced	B-Chemical
hyperactivity	B-Disease
in	O
rats	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
repeated	O
exposure	O
of	O
rats	O
to	O
the	O
drug	B-Drug
or	O
to	O
the	O
experimental	O
environment	O
is	O
necessary	O
to	O
observe	O
nicotine-induced	B-Chemical
locomotor	O
stimulation	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	O
environment	O
on	O
the	O
stimulant	O
effect	O
of	O
nicotine	B-Chemical
in	O
rats	O
was	O
examined	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
dopamine	B-Chemical
receptors	O
in	O
mediating	O
nicotine-induced	B-Chemical
locomotor	O
stimulation	O
was	O
investigated	O
by	O
examining	O
the	O
effects	O
of	O
selective	O
D1	O
and	O
D2	O
dopamine	B-Chemical
receptor	O
antagonists	O
on	O
activity	O
induced	O
by	O
nicotine	B-Chemical
.	O

Locomotor	O
activity	O
was	O
assessed	O
in	O
male	O
Sprague-Dawley	O
rats	O
tested	O
in	O
photocell	O
cages	O
.	O

Nicotine	B-Chemical
(	O
1.0	O
mg/kg	O
)	O
caused	O
a	O
significant	O
increase	B-Disease
in	B-Disease
locomotor	I-Disease
activity	I-Disease
in	O
rats	O
that	O
were	O
habituated	O
to	O
the	O
test	O
environment	O
,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	O
stimulant	O
action	O
in	O
rats	O
that	O
were	O
unfamiliar	O
with	O
the	O
test	O
environment	O
.	O

The	O
stimulant	O
action	O
of	O
nicotine	B-Chemical
was	O
blocked	O
by	O
the	O
central	O
nicotinic	O
antagonist	O
mecamylamine	B-Chemical
but	O
not	O
by	O
the	O
peripheral	O
nicotinic	O
blocker	O
hexamethonium	B-Chemical
,	O
indicating	O
that	O
the	O
response	O
is	O
probably	O
mediated	O
by	O
central	O
nicotinic	O
receptors	O
.	O

Nicotine-induced	B-Chemical
hyperactivity	B-Disease
was	O
blocked	O
by	O
the	O
selective	O
D1	O
antagonist	O
SCH	B-Chemical
23390	I-Chemical
,	O
the	O
selective	O
D2	O
antagonist	O
raclopride	B-Chemical
and	O
the	O
D1/D2	O
antagonist	O
fluphenazine	B-Chemical
.	O

Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	B-Chemical
enhanced	O
nicotine-induced	B-Chemical
hyperactivity	B-Disease
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	B-Chemical
38393	I-Chemical
had	O
no	O
effect	O
.	O

The	O
results	O
indicate	O
that	O
acute	O
nicotine	B-Chemical
injection	O
induces	O
a	O
pronounced	O
hyperactivity	B-Disease
in	O
rats	O
habituated	O
to	O
the	O
test	O
environment	O
.	O

The	O
effect	O
appears	O
to	O
be	O
mediated	O
by	O
central	O
nicotine	B-Chemical
receptors	O
,	O
possibly	O
located	O
on	O
dopaminergic	B-Chemical
neurons	O
,	O
and	O
also	O
requires	O
the	O
activation	O
of	O
both	O
D1	O
and	O
D2	O
dopamine	B-Drug
receptors	O
.	O

Neuropsychiatric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	B-Chemical
.	O

This	O
study	O
describes	O
neuropsychiatric	O
side	O
effects	O
in	O
patients	O
after	O
treatment	O
with	O
mefloquine	B-Chemical
.	O

Reactions	O
consisted	O
mainly	O
of	O
seizures	B-Disease
,	O
acute	O
psychoses	B-Disease
,	O
anxiety	B-Disease
neurosis	I-Disease
,	O
and	O
major	O
disturbances	B-Disease
of	I-Disease
sleep-wake	I-Disease
rhythm	I-Disease
.	O

Side	O
effects	O
occurred	O
after	O
both	O
therapeutic	O
and	O
prophylactic	O
intake	O
and	O
were	O
graded	O
from	O
moderate	O
to	O
severe	O
.	O

In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8,000	O
mefloquine	B-Chemical
users	O
suffers	O
from	O
such	O
reactions	O
.	O

The	O
incidence	O
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	O
users	O
had	O
reactions	O
,	O
compared	O
with	O
one	O
of	O
13,000	O
in	O
the	O
prophylaxis	O
group	O
,	O
making	O
the	O
risk	O
of	O
neuropsychiatric	O
reactions	O
after	O
mefloquine	B-Chemical
treatment	O
60	O
times	O
higher	O
than	O
after	O
prophylaxis	O
.	O

Therefore	O
,	O
certain	O
limitations	O
for	O
malaria	B-Disease
prophylaxis	O
and	O
treatment	O
with	O
mefloquine	B-Chemical
are	O
recommended	O
.	O

Reduction	O
in	O
injection	O
pain	B-Disease
using	O
buffered	O
lidocaine	B-Chemical
as	O
a	O
local	O
anesthetic	B-Drug
before	O
cardiac	O
catheterization	O
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
pain	B-Disease
associated	O
with	O
the	O
injection	O
of	O
lidocaine	B-Chemical
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	B-Chemical
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	B-Disease
during	O
injection	O
,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization	O
.	O

Twenty	O
patients	O
were	O
asked	O
to	O
quantify	O
the	O
severity	O
of	O
pain	B-Disease
after	O
receiving	O
standard	O
lidocaine	B-Chemical
in	O
one	O
femoral	O
area	O
and	O
buffered	O
lidocaine	B-Chemical
in	O
the	O
opposite	O
femoral	O
area	O
.	O

The	O
mean	O
pain	B-Disease
score	O
for	O
buffered	O
lidocaine	B-Chemical
was	O
significantly	O
lower	O
than	O
the	O
mean	O
score	O
for	O
standard	O
lidocaine	B-Chemical
(	O
2.7	O
+/-	O
1.9	O
vs.	O
3.8	O
+/-	O
2.2	O
,	O
P	O
=	O
0.03	O
)	O
.	O

The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	B-Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	B-Disease
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O

Randomized	O
,	O
double-blind	O
trial	O
of	O
mazindol	B-Chemical
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

There	O
is	O
evidence	O
that	O
growth	O
hormone	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weakness	B-Disease
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

We	O
conducted	O
a	O
12-month	O
controlled	O
trial	O
of	O
mazindol	B-Chemical
,	O
a	O
putative	O
growth	O
hormone	O
secretion	O
inhibitor	O
,	O
in	O
83	O
boys	O
with	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

Muscle	O
strength	O
,	O
contractures	O
,	O
functional	O
ability	O
and	O
pulmonary	O
function	O
were	O
tested	O
at	O
baseline	O
,	O
and	O
6	O
and	O
12	O
months	O
after	O
treatment	O
with	O
mazindol	B-Chemical
(	O
3	O
mg/d	O
)	O
or	O
placebo	O
.	O

The	O
study	O
was	O
designed	O
to	O
have	O
a	O
power	O
of	O
greater	O
than	O
0.90	O
to	O
detect	O
a	O
slowing	O
to	O
25	O
%	O
of	O
the	O
expected	O
rate	O
of	O
progression	O
of	O
weakness	B-Disease
at	O
P	O
less	O
than	O
0.05	O
.	O

Mazindol	B-Chemical
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study	O
.	O

Side	O
effects	O
attributable	O
to	O
mazindol	B-Chemical
included	O
decreased	B-Disease
appetite	I-Disease
(	O
36	O
%	O
)	O
,	O
dry	B-Disease
mouth	I-Disease
(	O
10	O
%	O
)	O
,	O
behavioral	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastrointestinal	B-Disease
symptoms	I-Disease
(	O
18	O
%	O
)	O
;	O
mazindol	B-Chemical
dosage	O
was	O
reduced	O
in	O
43	O
%	O
of	O
patients	O
.	O

The	O
effect	O
of	O
mazindol	B-Chemical
on	O
GH	O
secretion	O
was	O
estimated	O
indirectly	O
by	O
comparing	O
the	O
postabsorptive	O
IGF-I	O
levels	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
in	O
the	O
mazindol	B-Chemical
treated	O
to	O
those	O
in	O
the	O
placebo	O
groups	O
.	O

Although	O
mazindol-treated	B-Chemical
patients	O
gained	O
less	O
weight	O
and	O
height	O
than	O
placebo-treated	O
patients	O
,	O
no	O
significant	O
effect	O
on	O
IGF-I	O
levels	O
was	O
observed	O
.	O

Mazindol	B-Chemical
doses	O
not	O
slow	O
the	O
progression	O
of	O
weakness	B-Disease
in	O
Duchenne	B-Disease
dystrophy	I-Disease
.	O

Pentoxifylline	B-Chemical
(	O
Trental	B-Chemical
)	O
does	O
not	O
inhibit	O
dipyridamole-induced	B-Chemical
coronary	O
hyperemia	B-Disease
:	O
implications	O
for	O
dipyridamole-thallium-201	B-Chemical
myocardial	O
imaging	O
.	O

Dipyridamole-thallium-201	B-Chemical
imaging	O
is	O
often	O
performed	O
in	O
patients	O
unable	O
to	O
exercise	O
because	O
of	O
peripheral	O
vascular	O
disease	O
.	O

Many	O
of	O
these	O
patients	O
are	O
taking	O
pentoxifylline	B-Drug
(	O
Trental	O
)	O
,	O
a	O
methylxanthine	O
derivative	O
which	O
may	O
improve	O
intermittent	O
claudication	O
.	O

Whether	O
pentoxifylline	B-Drug
inhibits	O
dipyridamole-induced	O
coronary	O
hyperemia	O
like	O
other	O
methylxanthines	O
such	O
as	O
theophylline	B-Drug
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamole-thallium-201	B-Chemical
imaging	O
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
hyperemic	O
response	O
to	O
dipyridamole	B-Drug
in	O
seven	O
open-chest	O
anesthetized	O
dogs	O
after	O
pretreatment	O
with	O
either	O
pentoxifylline	B-Drug
(	O
0	O
,	O
7.5	O
,	O
or	O
15	O
mg/kg	O
i.v	O
.	O

)	O
or	O
theophylline	B-Drug
(	O
3	O
mg/kg	O
i.v.	O
)	O
.	O

Baseline	O
circumflex	O
coronary	O
blood	O
flows	O
did	O
not	O
differ	O
significantly	O
among	O
treatment	O
groups	O
.	O

Dipyridamole	B-Drug
significantly	O
increased	O
coronary	O
blood	O
flow	O
before	O
and	O
after	O
7.5	O
or	O
15	O
mm/kg	O
i.v	O
.	O

pentoxifylline	B-Drug
(	O
p	O
less	O
than	O
0.002	O
)	O
.	O

Neither	O
dose	O
of	O
pentoxifylline	B-Drug
significantly	O
decreased	O
the	O
dipyridamole-induced	O
hyperemia	O
,	O
while	O
peak	O
coronary	O
blood	O
flow	O
was	O
significantly	O
lower	O
after	O
theophylline	B-Drug
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

We	O
conclude	O
that	O
pentoxyifylline	O
does	O
not	O
inhibit	O
dipyridamole-induced	O
coronary	O
hyperemia	O
even	O
at	O
high	O
doses	O
.	O

Cause	O
of	O
death	B-Disease
among	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
:	O
a	O
rare	O
mortality	O
due	O
to	O
cerebral	B-Disease
haemorrhage	I-Disease
.	O

Causes	O
of	O
death	B-Disease
,	O
with	O
special	O
reference	O
to	O
cerebral	B-Disease
haemorrhage	I-Disease
,	O
among	O
240	O
patients	O
with	O
pathologically	O
verified	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
were	O
investigated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathological	O
Autopsy	O
Cases	O
in	O
Japan	O
from	O
1981	O
to	O
1985	O
.	O

The	O
leading	O
causes	O
of	O
death	B-Disease
were	O
pneumonia	B-Disease
and	O
bronchitis	B-Disease
(	O
44.1	O
%	O
)	O
,	O
malignant	O
neoplasms	B-Disease
(	O
11.6	O
%	O
)	O
,	O
heart	B-Disease
diseases	I-Disease
(	O
4.1	O
%	O
)	O
,	O
cerebral	B-Disease
infarction	I-Disease
(	O
3.7	O
%	O
)	O
and	O
septicaemia	B-Disease
(	O
3.3	O
%	O
)	O
.	O

Cerebral	B-Disease
haemorrhage	I-Disease
was	O
the	O
11th	O
most	O
frequent	O
cause	O
of	O
death	B-Disease
,	O
accounting	O
for	O
only	O
0.8	O
%	O
of	O
deaths	B-Disease
among	O
the	O
patients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
death	B-Disease
among	O
the	O
Japanese	O
general	O
population	O
in	O
1985	O
.	O

The	O
low	O
incidence	O
of	O
cerebral	B-Disease
haemorrhage	I-Disease
as	O
a	O
cause	O
of	O
death	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
may	O
reflect	O
the	O
hypotensive	B-Disease
effect	O
of	O
levodopa	B-Chemical
and	O
a	O
hypotensive	B-Disease
mechanism	O
due	O
to	O
reduced	O
noradrenaline	B-Chemical
levels	O
in	O
the	O
parkinsonian	B-Disease
brain	O
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-Chemical
in	O
patients	O
with	O
Argentine	B-Disease
hemorrhagic	I-Disease
fever	I-Disease
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-Chemical
was	O
studied	O
in	O
6	O
patients	O
with	O
Argentine	B-Disease
hemorrhagic	I-Disease
fever	I-Disease
(	O
AHF	B-Disease
)	O
of	O
more	O
than	O
8	O
days	O
of	O
evolution	O
.	O

Administration	O
of	O
ribavirin	B-Chemical
resulted	O
in	O
a	O
neutralization	O
of	O
viremia	B-Disease
and	O
a	O
drop	O
of	O
endogenous	O
interferon	O
titers	O
.	O

The	O
average	O
time	O
of	O
death	B-Disease
was	O
delayed	O
.	O

A	O
reversible	O
anemia	B-Disease
was	O
the	O
only	O
adverse	O
effect	O
observed	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
ribavirin	B-Chemical
has	O
an	O
antiviral	O
effect	O
in	O
advanced	O
cases	O
of	O
AHF	B-Disease
,	O
and	O
that	O
anemia	B-Disease
,	O
the	O
only	O
secondary	O
reaction	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O

The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	B-Chemical
during	O
the	O
initial	O
days	O
of	O
AHF	B-Disease
is	O
discussed	O
.	O

Dipyridamole-induced	B-Chemical
myocardial	B-Disease
ischemia	I-Disease
.	O

Angina	B-Disease
and	O
ischemic	O
electrocardiographic	O
changes	O
occurred	O
after	O
administration	O
of	O
oral	O
dipyridamole	B-Chemical
in	O
four	O
patients	O
awaiting	O
urgent	O
myocardial	O
revascularization	O
procedures	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effect	O
of	O
preoperative	O
dipyridamole	B-Chemical
therapy	O
,	O
although	O
dipyridamole-induced	B-Chemical
myocardial	B-Disease
ischemia	I-Disease
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	O
and	O
humans	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O

Epicardial	O
coronary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
patients	O
;	O
a	O
coronary	O
``	O
steal	O
''	O
phenomenon	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
dipyridamole-induced	B-Chemical
ischemia	B-Disease
observed	O
.	O

Inhibition	O
of	O
immunoreactive	O
corticotropin-releasing	O
factor	O
secretion	O
into	O
the	O
hypophysial-portal	O
circulation	O
by	O
delayed	O
glucocorticoid	O
feedback	O
.	O

Nitroprusside-induced	B-Chemical
hypotension	B-Disease
evokes	O
ACTH	B-Drug
secretion	O
which	O
is	O
primarily	O
mediated	O
by	O
enhanced	O
secretion	O
of	O
immunoreactive	O
corticotropin-releasing	O
factor	O
(	O
irCRF	O
)	O
into	O
the	O
hypophysial-portal	O
circulation	O
.	O

Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-Chemical
vasopressin	I-Chemical
nor	O
oxytocin	B-Chemical
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O

Application	O
of	O
a	O
delayed	O
feedback	O
signal	O
,	O
in	O
the	O
form	O
of	O
a	O
2-h	O
systemic	O
corticosterone	B-Chemical
infusion	O
in	O
urethane-anesthetized	B-Chemical
rats	O
with	O
pharmacological	O
blockade	O
of	O
glucocorticoid	O
synthesis	O
,	O
is	O
without	O
effect	O
on	O
the	O
resting	O
secretion	O
of	O
arginine	B-Chemical
vasopressin	I-Chemical
and	O
oxytocin	B-Chemical
at	O
any	O
corticosterone	B-Chemical
feedback	O
dose	O
tested	O
.	O

Resting	O
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	O
corticosterone	B-Chemical
infusion	O
rate	O
,	O
which	O
resulted	O
in	O
systemic	O
corticosterone	B-Chemical
levels	O
of	O
40	O
micrograms/dl	O
.	O

Suppression	O
of	O
irCRF	O
secretion	O
in	O
response	O
to	O
nitroprusside-induced	B-Chemical
hypotension	B-Disease
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	O
corticosterone	B-Chemical
level	O
between	O
8-12	O
micrograms/dl	O
.	O

These	O
studies	O
provide	O
further	O
evidence	O
for	O
a	O
strong	O
central	O
component	O
of	O
the	O
delayed	O
feedback	O
process	O
which	O
is	O
mediated	O
by	O
modulation	O
of	O
irCRF	O
release	O
.	O

Noradrenergic	O
involvement	O
in	O
catalepsy	B-Disease
induced	O
by	O
delta	B-Chemical
9-tetrahydrocannabinol	I-Chemical
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	B-Chemical
9-tetrahydrocannabinol	I-Chemical
(	O
THC	B-Chemical
)	O
,	O
the	O
effect	O
of	O
pretreatment	O
with	O
6-hydroxydopamine	B-Chemical
(	O
6-OHDA	B-Chemical
)	O
or	O
with	O
desipramine	B-Chemical
and	O
6-OHDA	B-Chemical
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
THC	B-Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
6-OHDA	B-Chemical
and	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	O
treated	O
with	O
desipramine	B-Chemical
and	O
6-OHDA	B-Chemical
,	O
as	O
compared	O
with	O
control	O
rats	O
.	O

On	O
the	O
contrary	O
,	O
the	O
cataleptogenic	O
effect	O
of	O
haloperidol	B-Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
desipramine	B-Chemical
and	O
6-OHDA	B-Chemical
but	O
not	O
in	O
rats	O
treated	O
with	O
6-OHDA	B-Chemical
or	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
.	O

These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	B-Disease
induced	O
by	O
THC	B-Chemical
,	O
whereas	O
dopaminergic	B-Drug
neurons	O
are	O
important	O
in	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
.	O

Intracranial	O
pressure	O
increases	O
during	O
alfentanil-induced	B-Chemical
rigidity	B-Disease
.	O

Intracranial	O
pressure	O
(	O
ICP	O
)	O
was	O
measured	O
during	O
alfentanil-induced	B-Chemical
rigidity	B-Disease
in	O
rats	O
.	O

Ten	O
rats	O
had	O
arterial	O
,	O
central	O
venous	O
(	O
CVP	O
)	O
,	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	B-Chemical
anesthesia	B-Drug
.	O

The	O
animals	O
were	O
mechanically	O
ventilated	O
to	O
achieve	O
normocarbia	O
(	O
PCO2	O
=	O
42	O
+/-	O
1	O
mmHg	O
,	O
mean	O
+/-	O
SE	O
)	O
.	O

Following	O
instrumentation	O
,	O
halothane	B-Chemical
was	O
discontinued	O
and	O
alfentanil	B-Chemical
(	O
125	O
mu/kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	B-Chemical
anesthesia	B-Drug
.	O

In	O
the	O
five	O
rats	O
that	O
developed	O
somatic	B-Disease
rigidity	I-Disease
,	O
ICP	O
and	O
CVP	O
increased	O
significantly	O
above	O
baseline	O
(	O
delta	O
ICP	O
7.5	O
+/-	O
1.0	O
mmHg	O
,	O
delta	O
CVP	O
5.9	O
+/-	O
1.3	O
mmHg	O
)	O
.	O

These	O
variables	O
returned	O
to	O
baseline	O
when	O
rigidity	B-Disease
was	O
abolished	O
with	O
metocurine	B-Chemical
.	O

In	O
five	O
rats	O
that	O
did	O
not	O
become	O
rigid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentanil	B-Chemical
.	O

These	O
observations	O
suggest	O
that	O
rigidity	B-Disease
should	O
be	O
prevented	O
when	O
alfentanil	B-Chemical
,	O
and	O
,	O
presumably	O
,	O
other	O
opiates	O
,	O
are	O
used	O
in	O
the	O
anesthetic	B-Drug
management	O
of	O
patients	O
with	O
ICP	O
problems	O
.	O

Adverse	O
cardiac	O
effects	O
during	O
induction	O
chemotherapy	O
treatment	O
with	O
cis-platin	B-Chemical
and	O
5-fluorouracil	B-Chemical
.	O

Survival	O
for	O
patients	O
with	O
advanced	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinoma	I-Disease
and	O
esophageal	B-Disease
carcinoma	I-Disease
is	O
poor	O
with	O
radiotherapy	O
and/or	O
surgery	O
.	O

Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effective	O
chemotherapy	O
.	O

In	O
the	O
present	O
study	O
,	O
cis-platin	B-Chemical
(	O
80-120	O
mg/m2BSA	O
)	O
and	O
5-FU	B-Chemical
(	O
1000	O
mg/m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days	O
)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
clarify	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
cardiac	O
effects	O
to	O
this	O
treatment	O
.	O

Before	O
treatment	O
all	O
patients	O
had	O
a	O
cardiac	O
evaluation	O
and	O
during	O
treatment	O
serial	O
ECG	O
recordings	O
were	O
performed	O
.	O

In	O
the	O
pre-treatment	O
evaluation	O
,	O
signs	O
of	O
cardiovascular	B-Disease
disease	I-Disease
were	O
found	O
in	O
33	O
patients	O
(	O
43	O
%	O
)	O
.	O

During	O
treatment	O
,	O
adverse	O
cardiac	O
effects	O
were	O
observed	O
in	O
14	O
patients	O
(	O
18	O
%	O
)	O
.	O

The	O
mean	O
age	O
of	O
these	O
patients	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
group	O
,	O
64	O
years	O
.	O

The	O
incidence	O
of	O
cardiotoxicity	B-Disease
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	B-Disease
disease	I-Disease
than	O
in	O
those	O
without	O
in	O
the	O
pre-treatment	O
evaluation	O
.	O

The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	B-Disease
were	O
chest	B-Disease
pain	I-Disease
,	O
ST-T	O
wave	O
changes	O
and	O
atrial	B-Disease
fibrillation	I-Disease
.	O

This	O
was	O
followed	O
by	O
ventricular	B-Disease
fibrillation	I-Disease
in	O
one	O
patient	O
and	O
sudden	B-Disease
death	I-Disease
in	O
another	O
.	O

It	O
is	O
concluded	O
that	O
patients	O
on	O
5-FU	B-Chemical
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	B-Disease
pain	I-Disease
or	O
tachyarrhythmia	B-Disease
is	O
observed	O
.	O

Verapamil-induced	B-Chemical
carbamazepine	B-Chemical
neurotoxicity	B-Disease
.	O

A	O
report	O
of	O
two	O
cases	O
.	O

Two	O
patients	O
with	O
signs	O
of	O
carbamazepine	B-Chemical
neurotoxicity	B-Disease
after	O
combined	O
treatment	O
with	O
verapamil	B-Chemical
showed	O
complete	O
recovery	O
after	O
discontinuation	O
of	O
the	O
calcium	B-Chemical
entry	O
blocker	O
.	O

Use	O
of	O
verapamil	B-Chemical
in	O
combination	O
with	O
carbamazepine	B-Chemical
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
by	O
one	O
half	O
)	O
.	O

Serial	O
studies	O
of	O
auditory	B-Disease
neurotoxicity	I-Disease
in	O
patients	O
receiving	O
deferoxamine	B-Chemical
therapy	O
.	O

Visual	B-Disease
and	I-Disease
auditory	I-Disease
neurotoxicity	I-Disease
was	O
previously	O
documented	O
in	O
42	O
of	O
89	O
patients	O
with	O
transfusion-dependent	O
anemia	O
who	O
were	O
receiving	O
iron	B-Drug
chelation	O
therapy	O
with	O
daily	O
subcutaneous	O
deferoxamine	O
.	O

Twenty-two	O
patients	O
in	O
the	O
affected	O
group	O
had	O
abnormal	O
audiograms	O
with	O
deficits	O
mostly	O
in	O
the	O
high	O
frequency	O
range	O
of	O
4,000	O
to	O
8,000	O
Hz	O
and	O
in	O
the	O
hearing	O
threshold	O
levels	O
of	O
30	O
to	O
100	O
decibels	O
.	O

When	O
deferoxamine	O
therapy	O
was	O
discontinued	O
and	O
serial	O
studies	O
were	O
performed	O
,	O
audiograms	O
in	O
seven	O
cases	O
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
patients	O
with	O
symptoms	O
became	O
asymptomatic	O
.	O

Audiograms	O
from	O
15	O
patients	O
remained	O
abnormal	O
and	O
four	O
patients	O
required	O
hearing	O
aids	O
because	O
of	O
permanent	O
disability	O
.	O

Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	O
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg/kg	O
per	O
dose	O
,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses	O
,	O
usually	O
50	O
mg/kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	O
abnormality	O
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	O
was	O
demonstrated	O
.	O

Auditory	O
deterioration	O
and	O
improvement	O
,	O
demonstrated	O
serially	O
in	O
individual	O
patients	O
receiving	O
and	O
not	O
receiving	O
deferoxamine	O
,	O
respectively	O
,	O
provided	O
convincing	O
evidence	O
for	O
a	O
cause-and-effect	O
relation	O
between	O
deferoxamine	O
administration	O
and	O
ototoxicity	O
.	O

Based	O
on	O
these	O
data	O
,	O
a	O
plan	O
of	O
management	O
was	O
developed	O
that	O
allows	O
effective	O
yet	O
safe	O
administration	O
of	O
deferoxamine	O
.	O

A	O
dose	O
of	O
50	O
mg/kg	O
is	O
recommended	O
in	O
those	O
without	O
audiogram	O
abnormalities	O
.	O

With	O
mild	O
toxicity	O
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg/kg	O
per	O
dose	O
should	O
result	O
in	O
a	O
reversal	O
of	O
the	O
abnormal	O
results	O
to	O
normal	O
within	O
four	O
weeks	O
.	O

Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	O
to	O
25	O
mg/kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O

In	O
those	O
with	O
symptoms	O
of	O
hearing	O
loss	O
,	O
the	O
drug	B-Drug
should	O
be	O
stopped	O
for	O
four	O
weeks	O
,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	O
or	O
improved	O
,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg/kg	O
per	O
dose	O
.	O

Serial	O
audiograms	O
should	O
be	O
performed	O
every	O
six	O
months	O
in	O
those	O
without	O
problems	O
and	O
more	O
frequently	O
in	O
young	O
patients	O
with	O
normal	O
serum	O
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	O
dysfunction	O
.	O

Flurbiprofen	B-Chemical
in	O
the	O
treatment	O
of	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
.	O

Thirty-four	O
patients	O
with	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	B-Chemical
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg/kg/day	O
,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	B-Disease
indices	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O

Improvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tender	B-Disease
joints	I-Disease
,	O
the	O
severity	O
of	O
swelling	B-Disease
and	O
tenderness	B-Disease
,	O
the	O
time	O
of	O
walk	O
50	O
feet	O
,	O
the	O
duration	O
of	O
morning	B-Disease
stiffness	I-Disease
and	O
the	O
circumference	O
of	O
the	O
left	O
knee	O
.	O

The	O
most	O
frequently	O
observed	O
side	O
effect	O
was	O
fecal	B-Disease
occult	I-Disease
blood	I-Disease
(	I-Disease
25	O
%	O
of	O
patients	O
)	I-Disease
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidence	O
of	O
gastrointestinal	B-Disease
(	I-Disease
GI	I-Disease
)	O
bleeding	O
in	O
these	O
patients	O
.	O

One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	B-Disease
and	O
abdominal	B-Disease
pain	I-Disease
.	O

Most	O
side	O
effects	O
were	O
mild	O
and	O
related	O
to	O
the	O
GI	O
tract	O
.	O

The	O
correlation	O
between	O
neurotoxic	B-Disease
esterase	O
inhibition	O
and	O
mipafox-induced	B-Chemical
neuropathic	B-Disease
damage	I-Disease
in	O
rats	O
.	O

The	O
correlation	O
between	O
neuropathic	B-Disease
damage	I-Disease
and	O
inhibition	O
of	O
neurotoxic	B-Disease
esterase	O
or	O
neuropathy	B-Disease
target	O
enzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	B-Chemical
(	O
N	B-Chemical
,	I-Chemical
N'-diisopropylphosphorodiamidofluoridate	B-Chemical
)	O
,	O
a	O
neurotoxic	B-Disease
organophosphate	B-Chemical
.	O

Brain	O
and	O
spinal	O
cord	O
NTE	O
activities	O
were	O
measured	O
in	O
Long-Evans	O
male	O
rats	O
1	O
hr	O
post-exposure	O
to	O
various	O
dosages	O
of	O
Mipafox	B-Chemical
(	O
ip	O
,	O
1-15	O
mg/kg	O
)	O
.	O

These	O
data	O
were	O
correlated	O
with	O
histologically	O
scored	O
cervical	O
cord	B-Disease
damage	I-Disease
in	O
a	O
separate	O
group	O
of	O
similarly	O
dosed	O
rats	O
sampled	O
14-21	O
days	O
post-exposure	O
.	O

Those	O
dosages	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
mg/kg	O
)	O
that	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
the	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
73	O
%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
67	O
%	O
of	O
control	O
values	O
produced	O
severe	O
(	O
greater	O
than	O
or	O
equal	O
to	O
3	O
)	O
cervical	O
cord	O
pathology	O
in	O
85	O
%	O
of	O
the	O
rats	O
.	O

In	O
contrast	O
,	O
dosages	O
of	O
Mipafox	B-Chemical
(	O
less	O
than	O
or	O
equal	O
to	O
5	O
mg/kg	O
)	O
which	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
spinal	O
cord	B-Disease
less	O
than	O
or	O
equal	O
to	O
61	O
%	O
and	O
brain	O
less	O
than	O
or	O
equal	O
to	O
60	O
%	O
produced	O
this	O
degree	O
of	O
cord	B-Disease
damage	O
in	O
only	O
9	O
%	O
of	O
the	O
animals	O
.	O

These	O
data	O
indicate	O
that	O
a	O
critical	O
percentage	O
of	O
NTE	O
inhibition	O
in	O
brain	O
and	O
spinal	O
cord	O
sampled	O
shortly	O
after	O
Mipafox	B-Chemical
exposure	O
can	O
predict	O
neuropathic	B-Disease
damage	I-Disease
in	O
rats	O
several	O
weeks	O
later	O
.	O

Cerebral	B-Disease
infarction	I-Disease
with	O
a	O
single	O
oral	O
dose	O
of	O
phenylpropanolamine	B-Chemical
.	O

Phenylpropanolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
,	O
a	O
synthetic	O
sympathomimetic	B-Drug
that	O
is	O
structurally	O
similar	O
to	O
amphetamine	B-Chemical
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics	O
,	O
nasal	O
congestants	O
,	O
and	O
cold	O
preparations	O
.	O

Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	B-Disease
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
,	O
neuropsychiatric	B-Disease
symptoms	I-Disease
,	O
and	O
nonhemorrhagic	O
cerebral	B-Disease
infarction	I-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
who	O
suffered	O
a	O
cerebral	B-Disease
infarction	I-Disease
after	O
taking	O
a	O
single	O
oral	O
dose	O
of	O
PPA	B-Chemical
.	O

Treatment	O
of	O
psoriasis	B-Disease
with	O
azathioprine	B-Chemical
.	O

Azathioprine	B-Chemical
treatment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
patients	O
suffering	O
from	O
severe	O
psoriasis	B-Disease
.	O

Haematological	O
complications	O
were	O
not	O
troublesome	O
and	O
results	O
of	O
biochemical	O
liver	O
function	O
tests	O
remained	O
normal	O
.	O

Minimal	O
cholestasis	B-Disease
was	O
seen	O
in	O
two	O
cases	O
and	O
portal	O
fibrosis	B-Disease
of	O
a	O
reversible	O
degree	O
in	O
eight	O
.	O

Liver	O
biopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
intervals	O
if	O
azathioprine	B-Chemical
therapy	O
is	O
continued	O
so	O
that	O
structural	O
liver	B-Disease
damage	I-Disease
may	O
be	O
detected	O
at	O
an	O
early	O
and	O
reversible	O
stage	O
.	O

Maternal	O
lithium	B-Chemical
and	O
neonatal	O
Ebstein	B-Disease
's	I-Disease
anomaly	I-Disease
:	O
evaluation	O
with	O
cross-sectional	O
echocardiography	O
.	O

Cross-sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	B-Chemical
during	O
pregnancy	O
.	O

In	O
one	O
infant	O
,	O
Ebstein	B-Disease
's	I-Disease
anomaly	I-Disease
of	O
the	O
tricuspid	O
valve	O
was	O
identified	O
.	O

In	O
the	O
other	O
infant	O
cross-sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein	B-Disease
's	I-Disease
anomaly	I-Disease
.	O

Cross-sectional	O
echocardiographic	O
screening	O
of	O
newborns	O
exposed	O
to	O
lithium	B-Chemical
during	O
gestation	O
can	O
provide	O
highly	O
accurate	O
,	O
noninvasive	O
assessment	O
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium-induced	B-Chemical
cardiac	B-Disease
malformations	I-Disease
.	O

Effects	O
of	O
training	O
on	O
the	O
extent	O
of	O
experimental	O
myocardial	B-Disease
infarction	I-Disease
in	O
aging	O
rats	O
.	O

The	O
effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
were	O
studied	O
in	O
female	O
albino	O
rats	O
of	O
20,40,60	O
and	O
80	O
weeks	O
of	O
age	O
.	O

The	O
rats	O
were	O
trained	O
to	O
swim	O
for	O
a	O
specific	O
duration	O
and	O
for	O
a	O
particular	O
period	O
.	O

The	O
occurrence	O
of	O
infarcts	B-Disease
were	O
confirmed	O
by	O
histological	O
methods	O
.	O

Elevations	O
in	O
the	O
serum	O
GOT	O
and	O
GPT	O
were	O
maximum	O
in	O
the	O
sedentary-isoproterenols	B-Chemical
and	O
minimum	O
in	O
the	O
exercise-controls	O
.	O

These	O
changes	O
in	O
the	O
serum	O
transaminases	O
were	O
associated	O
with	O
corresponding	O
depletions	O
in	O
the	O
cardiac	O
GOT	O
and	O
GPT	O
.	O

However	O
,	O
age	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
responses	O
exhibited	O
by	O
the	O
young	O
and	O
old	O
rats	O
.	O

Studies	O
dealing	O
with	O
myocardial	B-Disease
infarction	I-Disease
are	O
more	O
informative	O
when	O
dealt	O
with	O
age	O
.	O

Effect	O
of	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
on	O
adriamycin	B-Chemical
toxicity	B-Disease
in	O
mice	O
.	O

The	O
effect	O
of	O
a	O
widely	O
used	O
organic	O
solvent	O
,	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
(	O
PEG	B-Chemical
400	I-Chemical
)	O
,	O
on	O
the	O
toxic	O
action	O
of	O
an	O
acute	O
or	O
chronic	O
treatment	O
with	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
was	O
evaluated	O
in	O
mice	O
.	O

PEG	B-Chemical
400	I-Chemical
impressively	O
decreased	O
both	O
acute	O
high-dose	O
and	O
chronic	O
low-dose-ADR-associated	B-Chemical
lethality	O
.	O

Light	O
microscopic	O
analysis	O
showed	O
a	O
significant	O
protection	O
against	O
ADR-induced	B-Chemical
cardiac	B-Disease
morphological	I-Disease
alterations	I-Disease
.	O

Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	B-Chemical
antitumor	O
activity	O
in	O
L1210	B-Disease
leukemia	I-Disease
and	O
in	O
Ehrlich	B-Disease
ascites	I-Disease
tumor	I-Disease
.	O

Intra-arterial	O
BCNU	B-Chemical
chemotherapy	O
for	O
treatment	O
of	O
malignant	B-Disease
gliomas	I-Disease
of	O
the	O
central	O
nervous	O
system	O
.	O

Because	O
of	O
the	O
rapid	O
systemic	O
clearance	O
of	O
BCNU	B-Chemical
(	I-Chemical
1,3-bis-	B-Chemical
(	I-Chemical
2-chloroethyl	I-Chemical
)	I-Chemical
-1-nitrosourea	O
)	O
,	O
intra-arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	O
administration	O
for	O
the	O
treatment	O
of	O
malignant	B-Disease
gliomas	I-Disease
.	O

Thirty-six	O
patients	O
were	O
treated	O
with	O
BCNU	B-Chemical
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	B-Drug
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg/sq	O
m	O
body	O
surface	O
area	O
.	O

Twelve	O
patients	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomas	B-Disease
were	O
treated	O
after	O
partial	O
resection	O
of	O
the	O
tumor	B-Disease
without	O
prior	O
radiation	O
therapy	O
.	O

After	O
two	O
to	O
seven	O
cycles	O
of	O
chemotherapy	O
,	O
nine	O
patients	O
showed	O
a	O
decrease	O
in	O
tumor	B-Disease
size	O
and	O
surrounding	O
edema	B-Disease
on	O
contrast-enhanced	O
computerized	O
tomography	O
scans	O
.	O

In	O
the	O
nine	O
responders	O
,	O
median	O
duration	O
of	O
chemotherapy	O
response	O
from	O
the	O
time	O
of	O
operation	O
was	O
25	O
weeks	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
weeks	O
)	O
.	O

The	O
median	O
duration	O
of	O
survival	O
in	O
the	O
12	O
patients	O
was	O
54	O
weeks	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
weeks	O
)	O
,	O
with	O
an	O
18-month	O
survival	O
rate	O
of	O
42	O
%	O
.	O

Twenty-four	O
patients	O
with	O
recurrent	O
Grade	O
I	O
to	O
IV	O
astrocytomas	B-Disease
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
courses	O
of	O
intra-arterial	O
BCNU	B-Chemical
therapy	O
.	O

Seventeen	O
of	O
these	O
had	O
a	O
response	O
or	O
were	O
stable	O
for	O
a	O
median	O
of	O
20	O
weeks	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
weeks	O
)	O
.	O

The	O
catheterization	O
procedure	O
is	O
safe	O
,	O
with	O
no	O
immediate	O
complication	O
in	O
111	O
infusions	O
of	O
BCNU	B-Chemical
.	O

A	O
delayed	O
complication	O
in	O
nine	O
patients	O
has	O
been	O
unilateral	O
loss	B-Disease
of	I-Disease
vision	I-Disease
secondary	O
to	O
a	O
retinal	B-Disease
vasculitis	I-Disease
.	O

The	O
frequency	O
of	O
visual	B-Disease
loss	I-Disease
decreased	O
after	O
the	O
concentration	O
of	O
the	O
ethanol	B-Chemical
diluent	O
was	O
lowered	O
.	O

Blood	O
pressure	O
response	O
to	O
chronic	O
low-dose	O
intrarenal	O
noradrenaline	B-Chemical
infusion	O
in	O
conscious	O
rats	O
.	O

Sodium	B-Chemical
chloride	I-Chemical
solution	O
(	O
0.9	O
%	O
)	O
or	O
noradrenaline	B-Chemical
in	O
doses	O
of	O
4	O
,	O
12	O
and	O
36	O
micrograms	O
h-1	O
kg-1	O
was	O
infused	O
for	O
five	O
consecutive	O
days	O
,	O
either	O
intrarenally	O
(	O
by	O
a	O
new	O
technique	O
)	O
or	O
intravenously	O
into	O
rats	O
with	O
one	O
kidney	O
removed	O
.	O

Intrarenal	O
infusion	O
of	O
noradrenaline	B-Chemical
caused	O
hypertension	B-Disease
at	O
doses	O
which	O
did	O
not	O
do	O
so	O
when	O
infused	O
intravenously	O
.	O

Intrarenal	O
compared	O
with	O
intravenous	O
infusion	O
of	O
noradrenaline	B-Chemical
caused	O
higher	O
plasma	O
noradrenaline	B-Chemical
concentrations	O
and	O
a	O
shift	O
of	O
the	O
plasma	O
noradrenaline	B-Chemical
concentration-blood	O
pressure	O
effect	O
curve	O
towards	O
lower	O
plasma	O
noradrenaline	B-Chemical
levels	O
.	O

These	O
results	O
suggest	O
that	O
hypertension	B-Disease
after	O
chronic	O
intrarenal	O
noradrenaline	B-Chemical
infusion	O
is	O
produced	O
by	O
relatively	O
higher	O
levels	O
of	O
circulating	O
noradrenaline	B-Chemical
and	O
by	O
triggering	O
of	O
an	O
additional	O
intrarenal	O
pressor	O
mechanism	O
.	O

Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	B-Chemical
.	O

In	O
35	O
patients	O
(	O
ages	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidine	B-Chemical
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	B-Chemical
by	O
high-pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	B-Chemical
.	O

Cimetidine	B-Chemical
clearance	O
decreased	O
with	O
age	O
.	O

The	O
extrapolated	O
6-hr	O
serum	O
concentration	O
of	O
cimetidine	B-Chemical
per	O
unit	O
dose	O
,	O
after	O
intravenous	O
cimetidine	B-Chemical
,	O
increased	O
with	O
age	O
of	O
the	O
patients	O
.	O

The	O
ratio	O
of	O
cimetidine	B-Chemical
clearance	O
to	O
creatinine	B-Chemical
clearance	O
(	O
Rc	O
)	O
averaged	O
4.8	O
+/-	O
2.0	O
,	O
indicating	O
net	O
tubular	O
secretion	O
for	O
cimetidine	B-Chemical
.	O

Rc	O
seemed	O
to	O
be	O
independent	O
of	O
age	O
and	O
decreased	O
with	O
increasing	O
serum	O
concentration	O
of	O
cimetidine	B-Chemical
,	O
suggesting	O
that	O
secretion	O
of	O
cimetidine	B-Chemical
is	O
a	O
saturable	O
process	O
.	O

There	O
was	O
only	O
one	O
case	O
of	O
dementia	B-Disease
possibly	O
due	O
to	O
cimetidine	B-Chemical
(	O
with	O
a	O
drug	B-Drug
level	O
of	O
1.9	O
microgram/ml	O
6	O
hr	O
after	O
a	O
dose	O
)	O
in	O
a	O
group	O
of	O
13	O
patients	O
without	O
liver	B-Disease
or	I-Disease
kidney	I-Disease
disease	I-Disease
who	O
had	O
cimetidine	B-Drug
levels	O
above	O
1.25	O
microgram/ml	O
.	O

Thus	O
,	O
high	O
cimetidine	B-Drug
levels	O
alone	O
do	O
not	O
always	O
induce	O
dementia	O
.	O

Development	O
of	O
clear	B-Disease
cell	I-Disease
adenocarcinoma	I-Disease
in	O
DES-exposed	B-Chemical
offspring	O
under	O
observation	O
.	O

Two	O
cases	O
of	I-Disease
clear	B-Disease
cell	I-Disease
adenocarcinoma	I-Disease
of	I-Disease
the	I-Disease
vagina	O
detected	O
at	O
follow-up	O
in	O
young	O
women	O
exposed	O
in	O
utero	O
to	O
diethylstilbestrol	B-Drug
are	O
reported	O
.	O

One	O
patient	O
,	O
aged	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
years	O
before	O
carcinoma	O
was	O
diagnosed	O
;	O
the	O
second	O
patient	O
,	O
aged	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
years	O
,	O
8	O
months	O
.	O

In	O
both	O
instances	O
,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	O
was	O
aroused	O
by	O
the	O
palpation	O
of	O
a	O
small	O
nodule	O
in	O
the	O
vaginal	O
fornix	O
.	O

Hysterosalpingography	O
was	O
performed	O
on	O
both	O
patients	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abnormal	O
x-ray	O
film	O
was	O
reflected	O
by	O
the	O
gross	O
appearance	O
of	O
the	O
uterine	O
cavity	O
found	O
in	O
the	O
surgical	O
specimen	O
.	O

Phenobarbitone-induced	B-Chemical
enlargement	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
in	O
the	O
rat	O
:	O
its	O
relationship	O
to	O
carbon	B-Chemical
tetrachloride-induced	O
cirrhosis	O
.	O

The	O
yield	O
of	I-Disease
severe	O
cirrhosis	B-Disease
of	I-Disease
the	I-Disease
liver	O
(	O
defined	O
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	O
with	O
micronodular	O
histology	O
,	O
ascites	B-Disease
greater	O
than	O
30	O
ml	O
,	O
plasma	O
albumin	O
less	O
than	O
2.2	O
g/dl	O
,	O
splenomegaly	B-Disease
2-3	O
times	O
normal	O
,	O
and	O
testicular	O
atrophy	B-Disease
approximately	O
half	O
normal	O
weight	O
)	O
after	O
12	O
doses	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
given	O
intragastrically	O
in	O
the	O
phenobarbitone-primed	B-Chemical
rat	O
was	O
increased	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
``	O
calibrating	O
''	O
dose	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
at	O
the	O
peak	O
of	O
the	O
phenobarbitone-induced	B-Chemical
enlargement	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
.	O

At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochrome	O
P450/CCl4	B-Chemical
toxic	O
state	O
was	O
both	O
maximal	O
and	O
stable	O
.	O

The	O
optimal	O
rat	O
size	O
to	O
begin	O
phenobarbitone	B-Chemical
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
size	O
as	O
a	O
group	O
had	O
a	O
mean	O
maximum	O
relative	O
liver	O
weight	O
increase	O
47	O
%	O
greater	O
than	O
normal	O
rats	O
of	O
the	O
same	O
body	O
weight	O
.	O

The	O
optimal	O
time	O
for	O
the	O
initial	O
dose	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
was	O
after	O
14	O
days	O
on	O
phenobarbitone	B-Chemical
.	O

Attenuation	O
of	O
the	O
lithium-induced	B-Chemical
diabetes-insipidus-like	B-Disease
syndrome	I-Disease
by	O
amiloride	B-Chemical
in	O
rats	O
.	O

The	O
effect	O
of	O
amiloride	B-Chemical
on	O
lithium-induced	B-Chemical
polydipsia	B-Disease
and	O
polyuria	B-Disease
and	O
on	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
kidney	O
,	O
thyroid	B-Drug
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats	O
,	O
chronically	O
treated	O
with	O
LiCl	B-Chemical
.	O

Amiloride	B-Chemical
reduced	O
the	O
drinking	O
and	O
urine	O
volume	O
of	O
rats	O
in	O
an	O
acute	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacute	O
(	O
3	O
days	O
)	O
experiment	O
.	O

6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	B-Chemical
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	B-Chemical
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O

At	O
12	O
h	O
,	O
all	O
the	O
tissues	O
showed	O
a	O
slight	O
increase	O
in	O
lithium	B-Chemical
levels	O
.	O

After	O
3	O
days	O
of	O
combined	O
treatment	O
,	O
a	O
marked	O
elevation	O
in	O
plasma	O
and	O
tissue	O
lithium	B-Chemical
levels	O
accompanied	O
a	O
reduction	O
in	O
water	O
intake	O
.	O

In	O
all	O
the	O
experiments	O
,	O
the	O
attenuation	O
of	O
the	O
lithium-induced	B-Chemical
diabetes-insipidus-like	B-Disease
syndrome	I-Disease
by	O
amiloride	B-Chemical
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	B-Chemical
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	B-Chemical
level	O
.	O

It	O
is	O
concluded	O
that	O
acute	O
amiloride	B-Chemical
administration	O
to	O
lithium-treated	B-Chemical
patients	O
suffering	O
from	O
polydipsia	B-Disease
and	O
polyuria	B-Disease
might	O
relieve	O
these	O
patients	O
but	O
prolonged	O
amiloride	B-Chemical
supplementation	O
would	O
result	O
in	O
elevated	O
lithium	B-Chemical
levels	O
and	O
might	O
be	O
hazardous	O
.	O

Safety	O
and	O
side-effects	O
of	O
alprazolam	B-Chemical
.	O

Controlled	O
study	O
in	O
agoraphobia	B-Disease
with	O
panic	B-Disease
disorder	I-Disease
.	O

BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodiazepines	B-Chemical
has	O
led	O
to	O
increasing	O
recognition	O
of	O
their	O
unwanted	O
effects	O
.	O

The	O
efficacy	O
of	O
alprazolam	B-Chemical
and	O
placebo	O
in	O
panic	B-Disease
disorder	I-Disease
with	O
agoraphobia	B-Disease
,	O
and	O
the	O
side-effect	O
and	O
adverse	O
effect	O
profiles	O
of	O
both	O
drug	B-Drug
groups	O
were	O
measured	O
.	O

METHOD	O
:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM-III	O
criteria	O
for	O
panic	B-Disease
disorder	I-Disease
with	O
agoraphobia	B-Disease
were	O
randomised	O
to	O
alprazolam	B-Chemical
or	O
placebo	O
.	O

Subjects	O
in	O
each	O
drug	B-Drug
group	O
also	O
received	O
either	O
exposure	O
or	O
relaxation	O
.	O

Treatment	O
was	O
from	O
weeks	O
0	O
to	O
8	O
and	O
was	O
then	O
tapered	O
from	O
weeks	O
8	O
to	O
16	O
.	O

RESULTS	O
:	O
Mean	O
alprazolam	B-Chemical
dose	O
was	O
5	O
mg	O
daily	O
.	O

Compared	O
with	O
placebo	O
subjects	O
,	O
alprazolam	B-Chemical
patients	O
developed	O
more	O
adverse	O
reactions	O
(	O
21	O
%	O
v.	O
0	O
%	O
)	O
of	O
depression	B-Disease
,	O
enuresis	B-Disease
,	O
disinhibition	O
and	O
aggression	B-Disease
;	O
and	O
more	O
side-effects	O
,	O
particularly	O
sedation	O
,	O
irritability	B-Disease
,	O
impaired	B-Disease
memory	I-Disease
,	O
weight	B-Disease
loss	I-Disease
and	O
ataxia	B-Disease
.	O

Side-effects	O
tended	O
to	O
diminish	O
during	O
treatment	O
but	O
remained	O
significant	O
at	O
week	O
8	O
.	O

Despite	O
this	O
,	O
the	O
drop-out	O
rate	O
was	O
low	O
.	O

CONCLUSIONS	O
:	O
Alprazolam	B-Chemical
caused	O
side-effects	O
and	O
adverse	O
effects	O
during	O
treatment	O
but	O
many	O
patients	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Dup	B-Chemical
753	I-Chemical
prevents	O
the	O
development	O
of	O
puromycin	B-Chemical
aminonucleoside-induced	O
nephrosis	O
.	O

The	O
appearance	O
of	O
nephrotic	B-Disease
syndromes	I-Disease
such	O
as	O
proteinuria	B-Disease
,	O
hypoalbuminemia	B-Disease
,	O
hypercholesterolemia	B-Disease
and	O
increase	O
in	O
blood	B-Chemical
nitrogen	I-Chemical
urea	I-Chemical
,	O
induced	O
in	O
rats	O
by	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
was	O
markedly	O
inhibited	O
by	O
oral	O
administration	O
of	O
Dup	B-Chemical
753	I-Chemical
(	O
losartan	B-Chemical
)	O
,	O
a	O
novel	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
antagonist	O
,	O
at	O
a	O
dose	O
of	O
1	O
or	O
2	O
mg/kg	O
per	O
day	O
.	O

The	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
the	O
renin-angiotensin	B-Chemical
system	O
in	O
the	O
development	O
of	O
puromycin	B-Chemical
aminonucleoside-induced	O
nephrosis	O
.	O

Sodium	B-Chemical
bicarbonate	I-Chemical
alleviates	O
penile	B-Disease
pain	I-Disease
induced	O
by	O
intracavernous	O
injections	O
for	O
erectile	B-Disease
dysfunction	I-Disease
.	O

In	O
an	O
attempt	O
to	O
determine	O
whether	O
penile	B-Disease
pain	I-Disease
associated	O
with	O
intracorporeal	O
injections	O
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
we	O
performed	O
a	O
randomized	O
study	O
comparing	O
the	O
incidence	O
of	O
penile	B-Disease
pain	I-Disease
following	O
intracorporeal	O
injections	O
with	O
or	O
without	O
the	O
addition	O
of	O
sodium	B-Chemical
bicarbonate	I-Chemical
to	O
the	O
intracorporeal	O
medications	O
.	O

A	O
total	O
of	O
38	O
consecutive	O
patients	O
who	O
presented	O
to	O
our	O
clinic	O
with	O
impotence	B-Disease
received	O
0.2	O
ml	O
.	O

of	O
a	O
combination	O
of	O
3	O
drugs	B-Drug
:	O
6	O
mg.	O
papaverine	B-Chemical
,	O
100	O
micrograms	O
.	O

phentolamine	B-Chemical
and	O
10	O
micrograms	O
.	O

prostaglandin	B-Chemical
E1	I-Chemical
with	O
(	O
pH	O
7.05	O
)	O
or	O
without	O
(	O
pH	O
4.17	O
)	O
the	O
addition	O
of	O
sodium	B-Chemical
bicarbonate	I-Chemical
(	O
0.03	O
mEq.	O
)	O
.	O

Of	O
the	O
19	O
patients	O
without	O
sodium	B-Chemical
bicarbonate	I-Chemical
added	O
to	O
the	O
medication	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
penile	B-Disease
pain	I-Disease
due	O
to	O
the	O
medication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5	O
%	O
)	O
who	O
received	O
sodium	B-Chemical
bicarbonate	I-Chemical
complained	O
of	O
penile	B-Disease
pain	I-Disease
.	O

From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
penile	B-Disease
pain	I-Disease
following	O
intracorporeal	O
injections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevating	O
the	O
pH	O
to	O
a	O
neutral	O
level	O
.	O

Prospective	O
study	O
of	O
the	O
long-term	O
effects	O
of	O
somatostatin	B-Drug
analog	O
(	O
octreotide	B-Chemical
)	O
on	O
gallbladder	O
function	O
and	O
gallstone	B-Disease
formation	O
in	O
Chinese	O
acromegalic	B-Disease
patients	O
.	O

This	O
article	O
reports	O
the	O
changes	O
in	O
gallbladder	O
function	O
examined	O
by	O
ultrasonography	O
in	O
20	O
Chinese	O
patients	O
with	O
active	O
acromegaly	B-Disease
treated	O
with	O
sc	O
injection	O
of	O
the	O
somatostatin	B-Drug
analog	O
octreotide	B-Chemical
in	O
dosages	O
of	O
300-1500	O
micrograms/day	O
for	O
a	O
mean	O
of	O
24.2	O
+/-	O
13.9	O
months	O
.	O

During	O
treatment	O
with	O
octreotide	B-Chemical
,	O
17	O
patients	O
developed	O
sludge	O
,	O
10	O
had	O
gallstones	B-Disease
,	O
and	O
1	O
developed	O
acute	B-Disease
cholecystitis	I-Disease
requiring	O
surgery	O
.	O

In	O
all	O
of	O
7	O
patients	O
examined	O
acutely	O
,	O
gallbladder	O
contractility	O
was	O
inhibited	O
after	O
a	O
single	O
100-micrograms	O
injection	O
.	O

In	O
8	O
patients	O
followed	O
for	O
24	O
weeks	O
,	O
gallbladder	O
contractility	O
remained	O
depressed	B-Disease
throughout	O
therapy	O
.	O

After	O
withdrawal	O
of	O
octreotide	B-Chemical
in	O
10	O
patients	O
without	O
gallstones	B-Disease
,	O
8	O
patients	O
assessed	O
had	O
return	O
of	O
normal	O
gallbladder	O
contractility	O
within	O
1	O
month	O
.	O

In	O
8	O
of	O
the	O
remaining	O
10	O
patients	O
who	O
developed	O
gallstones	B-Disease
during	O
treatment	O
,	O
gallbladder	O
contractility	O
normalized	O
in	O
5	O
patients	O
(	O
3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	O
within	O
3	O
weeks	O
)	O
,	O
and	O
remained	O
depressed	B-Disease
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stones	O
present	O
at	O
6	O
months	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
gallbladder	O
contractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	O
of	O
bile	O
sludge	O
,	O
gallstones	B-Disease
,	O
and	O
cholecystitis	B-Disease
during	O
octreotide	B-Chemical
therapy	O
in	O
Chinese	O
acromegalic	B-Disease
patients	O
.	O

It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
changes	O
of	O
gallbladder	O
function	O
during	O
long-term	O
octreotide	B-Chemical
therapy	O
of	O
acromegalic	B-Disease
patients	O
.	O

Improvement	O
of	O
levodopa-induced	B-Chemical
dyskinesia	B-Disease
by	O
propranolol	B-Chemical
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

Seven	O
patients	O
suffering	O
from	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
with	O
severely	O
disabling	O
dyskinesia	B-Disease
received	O
low-dose	O
propranolol	B-Chemical
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	O
treatment	O
.	O

There	O
was	O
a	O
significant	O
40	O
%	O
improvement	O
in	O
the	O
dyskinesia	B-Disease
score	O
without	O
increase	O
of	O
parkinsonian	B-Disease
motor	B-Disease
disability	I-Disease
.	O

Ballistic	O
and	O
choreic	O
dyskinesia	B-Disease
were	O
markedly	O
ameliorated	O
,	O
whereas	O
dystonia	B-Disease
was	O
not	O
.	O

This	O
study	O
suggests	O
that	O
administration	O
of	O
low	O
doses	O
of	O
beta-blockers	O
may	O
improve	O
levodopa-induced	B-Chemical
ballistic	O
and	O
choreic	O
dyskinesia	B-Disease
in	O
PD	B-Disease
.	O

Morphological	O
features	O
of	O
encephalopathy	B-Disease
after	O
chronic	O
administration	O
of	O
the	O
antiepileptic	O
drug	B-Drug
valproate	B-Chemical
to	O
rats	O
.	O

A	O
transmission	O
electron	O
microscopic	O
study	O
of	O
capillaries	O
in	O
the	O
cerebellar	O
cortex	O
.	O

Long-term	O
intragastric	O
application	O
of	O
the	O
antiepileptic	O
drug	B-Drug
sodium	B-Chemical
valproate	I-Chemical
(	O
Vupral	O
``	O
Polfa	O
''	O
)	O
at	O
the	O
effective	O
dose	O
of	O
200	O
mg/kg	O
b.	O
w.	O
once	O
daily	O
to	O
rats	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
revealed	O
neurological	B-Disease
disorders	I-Disease
indicating	O
cerebellum	B-Disease
damage	I-Disease
(	O
``	O
valproate	B-Chemical
encephalopathy	B-Disease
''	O
)	O
.	O

The	O
first	O
ultrastructural	O
changes	O
in	O
structural	O
elements	O
of	O
the	O
blood-brain-barrier	O
(	O
BBB	O
)	O
in	O
the	O
cerebellar	O
cortex	O
were	O
detectable	O
after	O
3	O
months	O
of	O
the	O
experiment	O
.	O

They	O
became	O
more	O
severe	O
in	O
the	O
later	O
months	O
of	O
the	O
experiment	O
,	O
and	O
were	O
most	O
severe	O
after	O
12	O
months	O
,	O
located	O
mainly	O
in	O
the	O
molecular	O
layer	O
of	O
the	O
cerebellar	O
cortex	O
.	O

Lesions	O
of	O
the	O
capillary	O
included	O
necrosis	B-Disease
of	O
endothelial	O
cells	O
.	O

Organelles	O
of	O
these	O
cells	O
,	O
in	O
particular	O
the	O
mitochondria	O
(	O
increased	O
number	O
and	O
size	O
,	O
distinct	O
degeneration	O
of	O
their	O
matrix	O
and	O
cristae	O
)	O
and	O
Golgi	O
apparatus	O
were	O
altered	O
.	O

Reduced	O
size	O
of	O
capillary	O
lumen	O
and	O
occlusion	O
were	O
caused	O
by	O
swollen	O
endothelial	O
cells	O
which	O
had	O
luminal	B-Chemical
protrusions	O
and	O
swollen	O
microvilli	O
.	O

Pressure	O
on	O
the	O
vessel	O
wall	O
was	O
produced	O
by	O
enlarged	O
perivascular	O
astrocytic	O
processes	O
.	O

Fragments	O
of	O
necrotic	B-Disease
endothelial	O
cells	O
were	O
in	O
the	O
vascular	O
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	O
junctions	O
.	O

Damage	O
to	O
the	O
vascular	O
basement	O
lamina	O
was	O
also	O
observed	O
.	O

Damage	O
to	O
the	O
capillary	O
was	O
accompanied	O
by	O
marked	O
damage	O
to	O
neuroglial	O
cells	O
,	O
mainly	O
to	O
perivascular	O
processes	O
of	O
astrocytes	O
.	O

The	O
proliferation	O
of	O
astrocytes	O
(	O
Bergmann	O
's	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oligodendrocytes	O
was	O
found	O
.	O

Alterations	O
in	O
the	O
structural	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
lesions	O
of	O
neurons	O
of	O
the	O
cerebellum	O
(	O
Purkinje	O
cells	O
are	O
earliest	O
)	O
.	O

In	O
electron	O
micrographs	O
both	O
luminal	B-Chemical
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	O
of	O
the	O
cerebellar	O
cortex	O
had	O
similar	O
lesions	O
.	O

The	O
possible	O
influence	O
of	O
the	O
hepatic	B-Disease
damage	I-Disease
,	O
mainly	O
hyperammonemia	B-Disease
,	O
upon	O
the	O
development	O
of	O
valproate	B-Chemical
encephalopathy	B-Disease
is	O
discussed	O
.	O

Macula	O
toxicity	B-Disease
after	O
intravitreal	O
amikacin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
intravitreal	O
aminoglycosides	B-Chemical
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	B-Disease
,	O
macular	O
infarction	B-Disease
may	O
impair	O
full	O
visual	O
recovery	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
case	O
of	O
presumed	O
amikacin	B-Chemical
retinal	B-Disease
toxicity	I-Disease
following	O
treatment	O
with	O
amikacin	B-Chemical
and	O
vancomycin	B-Chemical
for	O
alpha-haemolytic	O
streptococcal	B-Disease
endophthalmitis	I-Disease
.	O

RESULTS	O
:	O
Endophthalmitis	B-Disease
resolved	O
with	O
improvement	O
in	O
visual	O
acuity	O
to	O
6/24	O
at	O
three	O
months	O
.	O

Fundus	O
fluorescein	B-Chemical
angiography	O
confirmed	O
macular	O
capillary	O
closure	O
and	O
telangiectasis	B-Disease
.	O

CONCLUSIONS	O
:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	O
regimens	O
may	O
cause	O
retinal	B-Disease
toxicity	I-Disease
and	O
macular	O
ischaemia	B-Disease
.	O

Treatment	O
strategies	O
aimed	O
at	O
avoiding	O
retinal	B-Disease
toxicity	I-Disease
are	O
discussed	O
.	O

Iatrogenically	O
induced	O
intractable	O
atrioventricular	B-Disease
reentrant	I-Disease
tachycardia	I-Disease
after	O
verapamil	B-Chemical
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff-Parkinson-White	B-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
.	O

In	O
a	O
patient	O
with	O
WPW	B-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
,	O
intractable	O
atrioventricular	B-Disease
reentrant	I-Disease
tachycardia	I-Disease
(	O
AVRT	B-Disease
)	O
was	O
iatrogenically	O
induced	O
.	O

QRS	O
without	O
preexcitation	O
,	O
caused	O
by	O
junctional	O
escape	O
beats	O
after	O
verapamil	B-Chemical
or	O
unidirectional	O
antegrade	O
block	O
of	O
accessory	O
pathway	O
after	O
catheter	O
ablation	O
,	O
established	O
frequent	O
AVRT	B-Disease
attack	O
.	O

Epidemic	O
of	O
liver	B-Disease
disease	I-Disease
caused	O
by	O
hydrochlorofluorocarbons	B-Chemical
used	O
as	O
ozone-sparing	B-Chemical
substitutes	O
of	O
chlorofluorocarbons	B-Chemical
.	O

BACKGROUND	O
:	O
Hydrochlorofluorocarbons	B-Chemical
(	O
HCFCs	B-Chemical
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone-depleting	B-Chemical
chlorofluorocarbons	B-Chemical
(	O
CFCs	B-Chemical
)	O
.	O

Limited	O
studies	O
in	O
animals	O
indicate	O
potential	O
hepatotoxicity	B-Disease
of	O
some	O
of	O
these	O
compounds	O
.	O

We	O
investigated	O
an	O
epidemic	O
of	O
liver	B-Disease
disease	I-Disease
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	O
accidental	O
exposure	O
to	O
a	O
mixture	O
of	O
1,1-dichloro-2,2,2-trifluoroethane	B-Chemical
(	O
HCFC	B-Chemical
123	I-Chemical
)	O
and	O
1-chloro-1,2,2,2-tetrafluoroethane	B-Chemical
(	O
HCFC	B-Chemical
124	I-Chemical
)	O
.	O

All	O
nine	O
exposed	O
workers	O
were	O
affected	O
to	O
various	O
degrees	O
.	O

Both	O
compounds	O
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1-bromo-1-chloro-2,2,2-trifluoroethane	B-Chemical
(	O
halothane	B-Chemical
)	O
to	O
form	O
reactive	O
trifluoroacetyl	B-Chemical
halide	O
intermediates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicity	B-Disease
of	O
halothane	B-Chemical
.	O

We	O
aimed	O
to	O
test	O
whether	O
HCFCs	B-Chemical
123	I-Chemical
and	I-Chemical
124	I-Chemical
can	O
result	O
in	O
serious	O
liver	O
disease	O
.	O

METHODS	O
:	O
For	O
one	O
severely	O
affected	O
worker	O
liver	O
biopsy	O
and	O
immunohistochemical	O
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	O
protein	O
adducts	O
were	O
done	O
.	O

The	O
serum	O
of	O
six	O
affected	O
workers	O
and	O
five	O
controls	O
was	O
tested	O
for	O
autoantibodies	O
that	O
react	O
with	O
human	O
liver	O
cytochrome-P450	O
2E1	O
(	O
P450	O
2E1	O
)	O
and	O
P58	O
protein	O
disulphide	O
isomerase	O
isoform	O
(	O
P58	O
)	O
.	O

FINDINGS	O
:	O
The	O
liver	O
biopsy	O
sample	O
showed	O
hepatocellular	O
necrosis	O
which	O
was	O
prominent	O
in	O
perivenular	O
zone	O
three	O
and	O
extended	O
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	O
(	O
bridging	O
necrosis	O
)	O
.	O

Trifluoroacetyl-adducted	O
proteins	O
were	O
detected	O
in	O
surviving	O
hepatocytes	O
.	O

Autoantibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
halothane	B-Drug
hepatitis	O
,	O
were	O
detected	O
in	O
the	O
serum	O
of	O
five	O
affected	O
workers	O
.	O

INTERPRETATION	O
:	O
Repeated	O
exposure	O
of	O
human	O
beings	O
to	O
HCFCs	B-Chemical
123	I-Chemical
and	O
124	I-Chemical
can	O
result	O
in	O
serious	O
liver	O
injury	O
in	O
a	O
large	O
proportion	O
of	O
the	O
exposed	O
population	O
.	O

Although	O
the	O
exact	O
mechanism	O
of	O
hepatotoxicity	O
of	O
these	O
agents	O
is	O
not	O
known	O
,	O
the	O
results	O
suggest	O
that	O
trifluoroacetyl-altered	O
liver	O
proteins	O
are	O
involved	O
.	O

In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
compounds	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
alternatives	O
.	O

The	O
effect	O
of	O
different	O
anaesthetic	O
agents	O
in	O
hearing	B-Disease
loss	I-Disease
following	O
spinal	O
anaesthesia	O
.	O

The	O
cause	O
of	O
hearing	B-Disease
loss	I-Disease
after	O
spinal	O
anaesthesia	O
is	O
unknown	O
.	O

Up	O
until	O
now	O
,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post-operative	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
this	O
hearing	B-Disease
loss	I-Disease
and	O
to	O
investigate	O
other	O
factors	O
influencing	O
the	O
degree	O
of	O
hearing	B-Disease
loss	I-Disease
.	O

Two	O
groups	O
of	O
22	O
similar	O
patients	O
were	O
studied	O
:	O
one	O
group	O
received	O
6	O
mL	O
prilocaine	B-Chemical
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	B-Chemical
0.5	O
%	O
.	O

Patients	O
given	O
prilocaine	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
hearing	B-Disease
loss	I-Disease
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaine	B-Chemical
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
average	O
hearing	B-Disease
loss	I-Disease
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	B-Chemical
and	O
15	O
dB	O
after	O
bupivacaine	B-Chemical
.	O

None	O
of	O
the	O
patients	O
complained	O
of	O
subjective	O
hearing	B-Disease
loss	I-Disease
.	O

Long-term	O
follow-up	O
of	O
the	O
patients	O
was	O
not	O
possible	O
.	O

A	O
transient	O
neurological	B-Disease
deficit	I-Disease
following	O
intrathecal	O
injection	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
for	O
unilateral	O
spinal	O
anaesthesia	O
.	O

We	O
describe	O
a	O
case	O
of	O
transient	O
neurological	B-Disease
deficit	I-Disease
that	O
occurred	O
after	O
unilateral	O
spinal	O
anaesthesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
slowly	O
injected	O
through	O
a	O
25-gauge	O
pencil-point	O
spinal	O
needle	O
.	O

The	O
surgery	O
and	O
anaesthesia	O
were	O
uneventful	O
,	O
but	O
3	O
days	O
after	O
surgery	O
,	O
the	O
patient	O
reported	O
an	O
area	O
of	I-Disease
hypoaesthesia	O
over	O
L3-L4	O
dermatomes	O
of	I-Disease
the	O
leg	O
which	O
had	O
been	O
operated	O
on	O
(	O
loss	B-Disease
of	I-Disease
pinprick	O
sensation	O
)	O
without	O
reduction	O
in	O
muscular	O
strength	O
.	O

Sensation	O
in	O
this	O
area	O
returned	O
to	O
normal	O
over	O
the	O
following	O
2	O
weeks	O
.	O

Prospective	O
multicentre	O
studies	O
with	O
a	O
large	O
population	O
and	O
a	O
long	O
follow-up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
this	O
unusual	O
side	O
effect	O
.	O

However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
solution	O
concentration	O
should	O
be	O
preferred	O
for	O
unilateral	O
spinal	O
anaesthesia	O
with	O
a	O
hyperbaric	O
anaesthetic	O
solution	O
(	O
if	O
pencil-point	O
needle	O
and	O
slow	O
injection	O
rate	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
a	O
localized	O
high	O
peak	O
anaesthetic	O
concentration	O
,	O
which	O
might	O
lead	B-Drug
to	O
a	O
transient	O
neurological	B-Disease
deficit	I-Disease
.	O

Pethidine-associated	B-Chemical
seizure	B-Disease
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	B-Chemical
for	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O

A	O
healthy	O
17-year-old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	B-Chemical
via	O
a	O
patient-controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B-Disease
pain	I-Disease
control	O
.	O

Twenty-three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self-limited	O
seizure	B-Disease
.	O

Both	O
plasma	O
pethidine	B-Chemical
and	O
norpethidine	B-Chemical
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	B-Disease
were	O
identified	O
.	O

This	O
method	O
allowed	O
frequent	O
self-dosing	O
of	O
pethidine	B-Chemical
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	B-Chemical
and	O
norpethidine	B-Chemical
.	O

The	O
routine	O
use	O
of	O
pethidine	B-Chemical
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	O
analgesia	O
should	O
be	O
reconsidered	O
.	O

Drug-associated	O
acute-onset	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
and	O
Stevens-Johnson	B-Disease
syndromes	I-Disease
in	O
a	O
child	O
.	O

Acute	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	O
is	O
a	O
rare	O
but	O
established	O
cause	O
of	O
progressive	O
cholestasis	B-Disease
in	O
adults	O
,	O
is	O
most	O
often	O
drug	B-Drug
or	O
toxin	B-Drug
related	O
,	O
and	O
is	O
of	O
unknown	O
pathogenesis	O
.	O

It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
children	O
.	O

Stevens-Johnson	B-Disease
syndrome	I-Disease
is	O
a	O
well-recognized	O
immune	O
complex-mediated	O
hypersensitivity	B-Disease
reaction	O
that	O
affects	O
all	O
age	O
groups	O
,	O
is	O
drug	B-Drug
or	O
infection	B-Disease
induced	O
,	O
and	O
has	O
classic	O
systemic	O
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	O
.	O

A	O
previously	O
healthy	O
child	O
who	O
developed	O
acute	O
,	O
severe	O
,	O
rapidly	O
progressive	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
shortly	O
after	O
Stevens-Johnson	B-Disease
syndrome	I-Disease
is	O
described	O
;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	B-Chemical
use	O
.	O

Despite	O
therapy	O
with	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
,	O
prednisone	B-Chemical
,	O
and	O
then	O
tacrolimus	B-Chemical
,	O
her	O
cholestatic	B-Disease
disease	I-Disease
was	O
unrelenting	O
,	O
with	O
cirrhosis	B-Disease
shown	O
by	O
biopsy	O
6	O
months	O
after	O
presentation	O
.	O

This	O
case	O
documents	O
acute	O
drug-related	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
in	O
the	O
pediatric	O
age	O
group	O
and	O
suggests	O
shared	O
immune	O
mechanisms	O
in	O
the	O
pathogenesis	O
of	O
both	O
Stevens-Johnson	B-Disease
syndrome	I-Disease
and	O
vanishing	B-Disease
bile	I-Disease
duct	I-Disease
syndrome	I-Disease
.	O

High	O
incidence	O
of	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
associated	O
with	O
appetite	B-Chemical
suppressants	I-Chemical
in	O
Belgium	O
.	O

Primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
is	O
a	O
rare	O
,	O
progressive	O
and	O
incurable	O
disease	O
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	B-Chemical
suppressant	I-Chemical
drugs	B-Drug
.	O

The	O
importance	O
of	O
this	O
association	O
was	O
evaluated	O
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
.	O

Thirty-five	O
patients	O
with	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(	O
1992-1994	O
)	O
in	O
Belgium	O
.	O

Exposure	O
to	O
appetite-suppressants	B-Chemical
was	O
assessed	O
on	O
the	O
basis	O
of	O
hospital	O
records	O
and	O
standardized	O
interview	O
.	O

Twenty-three	O
of	O
the	O
patients	O
had	O
previously	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
,	O
mainly	O
fenfluramines	B-Chemical
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	O
(	O
66	O
versus	O
6	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Five	O
patients	O
died	O
before	O
the	O
interview	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
.	O

In	O
8	O
patients	O
the	O
diagnosis	O
of	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetite	B-Chemical
suppressants	I-Chemical
.	O

The	O
patients	O
who	O
had	O
been	O
exposed	O
to	O
appetite	B-Chemical
suppressants	I-Chemical
tended	O
to	O
be	O
on	O
average	O
more	O
severely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shorter	O
median	O
delay	O
between	O
onset	O
of	O
symptoms	O
and	O
diagnosis	O
.	O

A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
may	O
lead	B-Drug
to	O
a	O
high	O
incidence	O
of	O
associated	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
.	O

Intake	O
of	O
appetite	B-Chemical
suppressants	I-Chemical
may	O
accelerate	O
the	O
progression	O
of	O
the	O
disease	O
.	O

Choreoathetoid	B-Disease
movements	I-Disease
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	B-Chemical
.	O

Choreatiform	B-Disease
hyperkinesias	I-Disease
are	O
known	O
to	O
be	O
occasional	O
movement	O
abnormalities	O
during	O
intoxications	O
with	O
cocaine	B-Drug
but	O
not	O
opiates	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
euphoria	O
and	O
choreoathetoid	O
movements	O
both	O
transiently	O
induced	O
by	O
rapid	O
adjustment	O
to	O
the	O
selective	O
mu-opioid	O
receptor	O
agonist	O
methadone	B-Drug
in	O
an	O
inpatient	O
previously	O
abusing	O
heroine	O
and	O
cocaine	B-Drug
.	O

In	O
addition	O
,	O
minor	O
EEG	O
abnormalities	O
occurred	O
.	O

Possible	O
underlying	O
neurobiological	O
phenomena	O
are	O
discussed	O
.	O

Cocaine-induced	B-Chemical
mood	B-Disease
disorder	I-Disease
:	O
prevalence	O
rates	O
and	O
psychiatric	B-Disease
symptoms	O
in	O
an	O
outpatient	O
cocaine-dependent	B-Chemical
sample	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	O
substance-induced	O
and	O
other	O
mood	B-Disease
disorders	I-Disease
.	O

243	O
cocaine-dependent	B-Chemical
outpatients	O
with	O
cocaine-induced	B-Chemical
mood	B-Disease
disorder	I-Disease
(	O
CIMD	B-Disease
)	O
,	O
other	O
mood	B-Disease
disorders	I-Disease
,	O
or	O
no	O
mood	B-Disease
disorder	I-Disease
were	O
compared	O
on	O
measures	O
of	O
psychiatric	B-Disease
symptoms	O
.	O

The	O
prevalence	O
rate	O
for	O
CIMD	B-Disease
was	O
12	O
%	O
at	O
baseline	O
.	O

Introduction	O
of	O
the	O
DSM-IV	O
diagnosis	O
of	O
CIMD	B-Disease
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	B-Disease
disorders	I-Disease
.	O

Patients	O
with	O
CIMD	B-Disease
had	O
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	B-Disease
disorder	I-Disease
.	O

These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM-IV	O
diagnosis	O
of	O
CIMD	B-Disease
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O

Hemolysis	B-Disease
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-Chemical
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Tamoxifen	B-Chemical
(	O
TAM	B-Chemical
)	O
,	O
the	O
antiestrogenic	O
drug	B-Drug
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	B-Disease
anemia	I-Disease
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	B-Chemical
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM-induced	B-Chemical
hemolytic	B-Disease
anemia	I-Disease
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

TAM	B-Chemical
induces	O
hemolysis	B-Disease
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration	O
.	O

The	O
extension	O
of	O
hemolysis	B-Disease
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12.5	O
microM	O
TAM	B-Chemical
induces	O
total	O
hemolysis	B-Disease
of	O
all	O
tested	O
suspensions	O
.	O

Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis	O
,	O
TAM	B-Chemical
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes	O
.	O

The	O
hemolytic	B-Disease
effect	O
of	O
TAM	B-Chemical
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha-tocopherol	B-Chemical
(	O
alpha-T	B-Chemical
)	O
and	O
alpha-tocopherol	B-Chemical
acetate	I-Chemical
(	O
alpha-TAc	B-Chemical
)	O
(	O
inactivated	O
functional	O
hydroxyl	B-Chemical
)	O
indicating	O
that	O
TAM-induced	B-Chemical
hemolysis	B-Disease
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	B-Chemical
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM-induced	B-Chemical
hemolysis	B-Disease
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	B-Chemical
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	B-Chemical
,	O
thus	O
ruling	O
out	O
TAM-induced	B-Chemical
cell	O
oxidative	O
stress	O
.	O

Hemolysis	B-Disease
caused	O
by	O
TAM	B-Chemical
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	B-Chemical
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid-osmotic	O
type	O
mechanism	O
of	O
hemolysis	B-Disease
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

However	O
,	O
TAM	B-Chemical
induces	O
release	O
of	O
peripheral	O
proteins	O
of	O
membrane-cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O

Either	O
alpha-T	B-Chemical
or	O
alpha-TAc	B-Chemical
increases	O
membrane	O
packing	O
and	O
prevents	O
TAM	B-Chemical
partition	O
into	O
model	O
membranes	O
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	B-Disease
by	O
tocopherols	B-Chemical
is	O
related	O
to	O
a	O
decreased	O
TAM	B-Chemical
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM-induced	B-Chemical
hemolysis	B-Disease
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	B-Chemical
,	O
resulting	O
in	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	O
,	O
the	O
disruption	O
of	O
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	O
TAM	B-Chemical
may	O
contribute	O
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O

Changes	O
of	O
sodium	B-Chemical
and	O
ATP	B-Chemical
affinities	O
of	O
the	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-ATPase	O
during	O
and	O
after	O
nitric	B-Chemical
oxide	I-Chemical
deficient	O
hypertension	B-Disease
.	O

In	O
the	O
cardiovascular	O
system	O
,	O
NO	B-Chemical
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
functions	O
.	O

Inhibition	O
of	O
NO	B-Chemical
synthesis	O
induces	O
sustained	O
hypertension	B-Disease
.	O

In	O
several	O
models	O
of	O
hypertension	B-Disease
,	O
elevation	O
of	O
intracellular	O
sodium	B-Chemical
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na+	B-Chemical
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-ATPase	O
to	O
NO-deficient	B-Chemical
hypertension	B-Disease
induced	O
in	O
rats	O
by	O
NO-synthase	B-Chemical
inhibition	O
with	O
40	O
mg/kg/day	O
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-nitro-L-arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L-NAME	B-Chemical
)	O
for	O
4	O
four	O
weeks	O
.	O

After	O
4-week	O
administration	O
of	O
L-NAME	B-Chemical
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	O
by	O
36	O
%	O
.	O

Two	O
weeks	O
after	O
terminating	O
the	O
treatment	O
,	O
the	O
SBP	O
recovered	O
to	O
control	O
value	O
.	O

When	O
activating	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-ATPase	B-Chemical
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO-deficient	B-Chemical
rats	O
.	O

During	O
activation	O
with	O
Na+	B-Chemical
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	B-Chemical
(	O
Na	B-Chemical
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na+-binding	B-Chemical
site	O
in	O
NO-deficient	B-Chemical
rats	O
.	O

After	O
recovery	O
from	O
hypertension	B-Disease
,	O
the	O
activity	O
of	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-ATPase	B-Chemical
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP-binding	B-Chemical
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	B-Chemical
value	O
for	O
ATP	O
.	O

The	O
K	O
(	O
Na	B-Chemical
)	O
value	O
for	O
Na+	B-Chemical
returned	O
to	O
control	O
value	O
.	O

Inhibition	O
of	O
NO-synthase	B-Chemical
induced	O
a	O
reversible	O
hypertension	B-Disease
accompanied	O
by	O
depressed	B-Disease
Na+-extrusion	B-Chemical
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na+-binding	B-Chemical
properties	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-ATPase	O
.	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na+	B-Chemical
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	B-Chemical
,	O
K	B-Chemical
)	O
-ATPase	O
activity	O
.	O

Effects	O
of	O
long-term	O
pretreatment	O
with	O
isoproterenol	B-Chemical
on	O
bromocriptine-induced	B-Chemical
tachycardia	B-Disease
in	O
conscious	O
rats	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine-induced	B-Chemical
tachycardia	B-Disease
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	B-Chemical
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5-day	O
isoproterenol	B-Chemical
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	B-Chemical
could	O
abolish	O
bromocriptine-induced	B-Chemical
tachycardia	B-Disease
in	O
conscious	O
rats	O
.	O

Isoproterenol	B-Chemical
pretreatment	O
for	O
15	O
days	O
caused	O
cardiac	B-Disease
hypertrophy	I-Disease
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	B-Chemical
(	O
150	O
microg/kg	O
)	O
induced	O
significant	O
hypotension	B-Disease
and	O
tachycardia	B-Disease
.	O

Bromocriptine-induced	B-Chemical
hypotension	B-Disease
was	O
unaffected	O
by	O
isoproterenol	B-Chemical
pretreatment	O
,	O
while	O
tachycardia	B-Disease
was	O
reversed	O
to	O
significant	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i.v	O
.	O

domperidone	B-Chemical
(	O
0.5	O
mg/kg	O
)	O
.	O

Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	O
by	O
isoproterenol	B-Chemical
pretreatment	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol-pretreated	B-Chemical
rats	O
,	O
the	O
isoproterenol-induced	B-Chemical
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline-pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol-induced	B-Chemical
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22-fold	O
)	O
.	O

These	O
results	O
show	O
that	O
15-day	O
isoproterenol	B-Chemical
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine-induced	B-Chemical
tachycardia	B-Disease
to	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta-adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	B-Disease
of	O
bromocriptine	B-Chemical
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	B-Disease
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	B-Chemical
D2	O
receptors	O
.	O

A	O
developmental	O
analysis	O
of	O
clonidine	B-Chemical
's	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats	O
.	O

Under	O
controlled	O
conditions	O
,	O
infant	O
rats	O
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	O
of	O
the	O
alpha	O
(	O
2	O
)	O
adrenoceptor	O
agonist	O
,	O
clonidine	B-Chemical
.	O

Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	O
response	O
to	O
clonidine	B-Chemical
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd-week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	B-Chemical
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	B-Disease
,	O
we	O
hypothesized	O
that	O
clonidine	B-Chemical
's	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
experiment	O
,	O
the	O
effects	O
of	O
clonidine	B-Chemical
administration	O
(	O
0.5	O
mg/kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2-	O
,	O
8-	O
,	O
15-	O
,	O
and	O
20-day-old	O
rats	O
.	O

Age-related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine-induced	B-Chemical
bradycardia	B-Disease
.	O

This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by-product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	O
for	O
clonidine	B-Chemical
's	O
detrimental	O
effects	O
on	O
cardiovascular	O
function	O
.	O

Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	B-Disease
induced	O
by	O
intradermal	O
capsaicin	B-Chemical
in	O
humans	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
brush-evoked	O
(	O
dynamic	O
)	O
pain	B-Disease
and	O
punctate-evoked	O
(	O
static	O
)	O
hyperalgesia	B-Disease
induced	O
by	O
capsaicin	B-Chemical
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
,	O
we	O
studied	O
12	O
volunteers	O
in	O
three	O
experiments	O
.	O

Capsaicin	B-Chemical
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i.v	O
.	O

infusion	O
of	O
ketamine	B-Chemical
(	O
bolus	O
0.1	O
mg	O
kg-1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg-1	O
min-1	O
)	O
,	O
lidocaine	B-Chemical
5	O
mg	O
kg-1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Infusion	O
started	O
15	O
min	O
after	O
injection	O
of	O
capsaicin	B-Chemical
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	B-Disease
,	O
pain	B-Disease
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush-evoked	O
and	O
punctate-evoked	O
hyperalgesia	B-Disease
.	O

Ketamine	B-Chemical
reduced	O
both	O
the	O
area	O
of	O
brush-evoked	O
and	O
punctate-evoked	O
hyperalgesia	B-Disease
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush-evoked	O
pain	B-Disease
.	O

Lidocaine	B-Chemical
reduced	O
the	O
area	O
of	O
punctate-evoked	O
hyperalgesia	B-Disease
significantly	O
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	B-Disease
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	B-Disease
.	O

The	O
differential	O
effects	O
of	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
static	O
and	O
dynamic	O
hyperalgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	B-Disease
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

Cyclosporine	B-Chemical
and	O
tacrolimus-associated	B-Chemical
thrombotic	B-Disease
microangiopathy	I-Disease
.	O

The	O
development	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
TMA	B-Disease
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	B-Chemical
has	O
been	O
well	O
documented	O
.	O

Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	B-Chemical
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O

However	O
,	O
for	O
recipients	O
of	O
organ	O
transplantation	O
,	O
removing	O
the	O
inciting	O
agent	O
is	O
not	O
without	O
the	O
attendant	O
risk	O
of	O
precipitating	O
acute	O
rejection	O
and	O
graft	O
loss	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	B-Chemical
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	B-Chemical
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	B-Chemical
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine-induced	B-Chemical
TMA	B-Disease
.	O

With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	B-Chemical
in	O
organ	O
transplantation	O
,	O
tacrolimus-associated	B-Chemical
TMA	B-Disease
has	O
also	O
been	O
recognized	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	B-Disease
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
is	O
limited	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine-induced	B-Chemical
TMA	B-Disease
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	B-Chemical
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

Introduction	O
of	O
tacrolimus	B-Chemical
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	O
of	O
TMA	B-Disease
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O

Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	B-Chemical
to	O
tacrolimus	B-Chemical
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	B-Disease
.	O

Repeated	O
transient	O
anuria	B-Disease
following	O
losartan	B-Chemical
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70-year-old	O
hypertensive	B-Disease
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	B-Disease
renal	I-Disease
insufficiency	I-Disease
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	B-Disease
after	O
losartan	B-Chemical
administration	O
.	O

He	O
was	O
hospitalized	O
for	O
a	O
myocardial	B-Disease
infarction	I-Disease
with	O
pulmonary	B-Disease
edema	I-Disease
,	O
treated	O
with	O
high-dose	O
diuretics	B-Drug
.	O

Due	O
to	O
severe	O
systolic	B-Disease
dysfunction	I-Disease
losartan	B-Chemical
was	O
prescribed	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	B-Chemical
resulted	O
in	O
a	O
sudden	O
anuria	B-Disease
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high-dose	O
furosemide	B-Chemical
and	O
amine	B-Chemical
infusion	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	B-Chemical
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	B-Disease
lasting	O
10	O
hours	O
.	O

During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	B-Disease
was	O
noted	O
.	O

Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70-80	O
%	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
.	O

In	O
this	O
patient	O
,	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
combined	O
with	O
heart	B-Disease
failure	I-Disease
and	O
diuretic	B-Drug
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	O
of	O
the	O
renin-angiotensin	B-Chemical
system	O
(	O
RAS	O
)	O
.	O

Under	O
such	O
conditions	O
,	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
blockade	O
by	O
losartan	B-Chemical
probably	O
induced	O
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
antagonist	O
losartan	B-Chemical
can	O
cause	O
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	B-Disease
disease	I-Disease
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	B-Disease
cell	O
deaths	O
during	O
acetaminophen-induced	B-Chemical
nephrotoxicity	B-Disease
,	O
amiodarone-induced	B-Chemical
lung	B-Disease
toxicity	I-Disease
and	O
doxorubicin-induced	B-Chemical
cardiotoxicity	B-Disease
by	O
a	O
novel	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
.	O

Grape	B-Chemical
seed	I-Chemical
extract	I-Chemical
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	B-Chemical
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide-range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
(	O
GSPE	B-Chemical
)	O
to	O
prevent	O
acetaminophen	B-Chemical
(	O
AAP	B-Chemical
)	O
-induced	O
nephrotoxicity	B-Disease
,	O
amiodarone	B-Chemical
(	O
AMI	B-Chemical
)	O
-induced	O
lung	B-Disease
toxicity	I-Disease
,	O
and	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-induced	O
cardiotoxicity	B-Disease
in	O
mice	O
.	O

Experimental	O
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	B-Chemical
alone	O
,	O
drug	B-Drug
alone	O
and	O
GSPE+drug	B-Chemical
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg/Kg	O
GSPE	B-Chemical
for	O
7-10	O
days	O
followed	O
by	O
i.p	O
.	O

injections	O
of	O
organ	O
specific	O
three	O
drugs	B-Drug
(	O
AAP	B-Chemical
:	O
500	O
mg/Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg/Kg/day	O
for	O
four	O
days	O
;	O
DOX	B-Chemical
:	O
20	O
mg/Kg	O
for	O
48	O
h	O
)	O
.	O

Parameters	O
of	O
study	O
included	O
analysis	O
of	O
serum	O
chemistry	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fragmentation	O
of	O
genomic	O
DNA	O
(	O
both	O
endonuclease-dependent	O
and	O
independent	O
)	O
in	O
addition	O
to	O
microscopic	O
evaluation	O
of	O
damage	O
and/or	O
protection	O
in	O
corresponding	O
PAS	O
stained	O
tissues	O
.	O

Results	O
indicate	O
that	O
GSPE	B-Chemical
preexposure	O
prior	O
to	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	B-Disease
damage	I-Disease
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	B-Drug
in	O
the	O
absence	O
of	O
GSPE	B-Chemical
preexposure	O
than	O
in	O
its	O
presence	O
.	O

GSPE+drug	B-Chemical
exposed	O
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O
.	O

Additionally	O
,	O
histopathological	O
alterations	O
mirrored	O
both	O
serum	O
chemistry	O
changes	O
and	O
the	O
pattern	O
of	O
DNA	O
fragmentation	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	B-Drug
,	O
such	O
as	O
,	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	B-Disease
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	B-Chemical
.	O

Since	O
AAP	B-Chemical
,	O
AMI	B-Chemical
and	O
DOX	B-Chemical
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	B-Chemical
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and/or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
repair	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemoprevention	O
process	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI-induced	B-Chemical
apoptotic	O
death	O
in	O
the	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	B-Chemical
's	O
abundant	O
bioavailability	O
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O

Palpebral	B-Disease
twitching	I-Disease
in	O
a	O
depressed	B-Disease
adolescent	O
on	O
citalopram	B-Chemical
.	O

Current	O
estimates	O
suggest	O
that	O
between	O
0.4	O
%	O
and	O
8.3	O
%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	B-Disease
depression	I-Disease
.	O

We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	B-Chemical
by	O
a	O
15-year-old	O
boy	O
with	O
major	B-Disease
depression	I-Disease
who	O
exhibited	O
palpebral	B-Disease
twitching	I-Disease
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	B-Chemical
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	O
.	O

Metamizol	B-Chemical
potentiates	O
morphine	B-Chemical
antinociception	O
but	O
not	O
constipation	B-Disease
after	O
chronic	O
treatment	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	B-Disease
effects	O
of	O
the	O
combination	O
of	O
3.2	O
mg/kg	O
s.c.	O
morphine	B-Chemical
with	O
177.8	O
mg/kg	O
s.c.	O
metamizol	B-Chemical
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain-induced	B-Disease
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	B-Chemical
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

Simultaneous	O
administration	O
of	O
morphine	B-Chemical
with	O
metamizol	B-Chemical
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298+/-7	O
vs.	O
139+/-36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
repeated	O
administration	O
(	O
280+/-17	O
vs.	O
131+/-22	O
ua	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Antinociceptive	O
effect	O
of	O
morphine	B-Chemical
was	O
reduced	O
in	O
chronically	O
treated	O
rats	O
(	O
39+/-10	O
vs.	O
18+/-5	O
au	O
)	O
while	O
the	O
combination-induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298+/-7	O
vs.	O
280+/-17	O
au	O
)	O
.	O

Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3.2	O
mg/kg	O
naloxone	B-Chemical
s.c.	O
(	O
P	O
<	O
0.05	O
)	O
,	O
suggesting	O
the	O
partial	O
involvement	O
of	O
the	O
opioidergic	O
system	O
in	O
the	O
synergism	O
observed	O
.	O

In	O
independent	O
groups	O
,	O
morphine	B-Chemical
inhibited	O
the	O
intestinal	O
transit	O
in	O
48+/-4	O
%	O
and	O
38+/-4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	B-Disease
effects	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	B-Chemical
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	B-Chemical
did	O
not	O
potentiate	O
morphine-induced	B-Chemical
constipation	B-Disease
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	B-Chemical
and	O
metamizol	B-Chemical
in	O
chronically	B-Disease
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	B-Disease
pain	O
.	O

Ifosfamide	B-Chemical
encephalopathy	B-Disease
presenting	O
with	O
asterixis	B-Disease
.	O

CNS	O
toxic	O
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	B-Chemical
(	O
IFX	B-Chemical
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	B-Drug
use	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51-year-old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	B-Disease
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	B-Chemical
for	O
plasmacytoma	B-Disease
.	O

He	O
was	O
awake	O
,	O
revealed	O
no	O
changes	O
of	I-Disease
mental	O
status	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
motor	O
symptoms	O
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	B-Disease
lesions	I-Disease
of	I-Disease
the	I-Disease
brain	O
and	O
metabolic	B-Disease
abnormalities	I-Disease
.	O

An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	O
encephalopathy	B-Disease
.	O

The	O
administration	O
of	O
ifosfamide	B-Chemical
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	B-Disease
resolved	O
completely	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	B-Disease
during	O
infusion	O
of	O
ifosfamide	B-Chemical
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	B-Drug
suggest	O
that	O
negative	O
myoclonus	B-Disease
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	B-Chemical
.	O

Sub-chronic	O
low	O
dose	O
gamma-vinyl	B-Chemical
GABA	I-Chemical
(	O
vigabatrin	B-Chemical
)	O
inhibits	O
cocaine-induced	B-Chemical
increases	O
in	O
nucleus	O
accumbens	O
dopamine	B-Chemical
.	O

RATIONALE	O
:	O
gamma-Vinyl	B-Chemical
GABA	I-Chemical
(	O
GVG	B-Chemical
)	O
irreversibly	O
inhibits	O
GABA-transaminase	B-Chemical
.	O

This	O
non-receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	O
of	O
functional	O
GABA	B-Chemical
catabolism	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	B-Disease
abuse	I-Disease
and	O
the	O
increased	O
risk	O
of	O
visual	B-Disease
field	I-Disease
defects	I-Disease
(	O
VFD	B-Disease
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub-chronic	O
low	O
dose	O
GVG	B-Chemical
on	O
cocaine-induced	B-Chemical
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
.	O

METHODS	O
:	O
Using	O
in	O
vivo	O
microdialysis	O
,	O
we	O
compared	O
acute	O
exposure	O
(	O
450	O
mg/kg	O
)	O
to	O
an	O
identical	O
sub-chronic	O
exposure	O
(	O
150	O
mg/kg	O
per	O
day	O
for	O
3	O
days	O
)	O
,	O
followed	O
by	O
1-	O
or	O
3-day	O
washout	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
low	O
dose	O
of	O
150	O
mg/kg	O
(	O
50	O
mg/kg	O
per	O
day	O
)	O
using	O
a	O
similar	O
washout	O
period	O
.	O

RESULTS	O
:	O
Sub-chronic	O
GVG	B-Chemical
exposure	O
inhibited	O
the	O
effect	O
of	O
cocaine	B-Chemical
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

CONCLUSIONS	O
:	O
Sub-chronic	O
low	O
dose	O
GVG	B-Chemical
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine-induced	B-Chemical
increases	O
in	O
dopamine	B-Chemical
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

Amount	O
of	O
bleeding	B-Disease
and	O
hematoma	B-Disease
size	O
in	O
the	O
collagenase-induced	O
intracerebral	B-Disease
hemorrhage	I-Disease
rat	O
model	O
.	O

The	O
aggravated	O
risk	O
on	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)	O
with	O
drugs	B-Drug
used	O
for	O
stroke	B-Disease
patients	O
should	O
be	O
estimated	O
carefully	O
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	B-Disease
model	O
for	O
detection	O
of	O
ICH	B-Disease
deterioration	O
.	O

In	O
ICH	B-Disease
intrastriatally	O
induced	O
by	O
0.014-unit	O
,	O
0.070-unit	O
,	O
and	O
0.350-unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	B-Disease
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	B-Disease
volume	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	B-Disease
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	B-Disease
induced	O
by	O
0.014-unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	B-Disease
deterioration	O
.	O

In	O
ICH	B-Disease
induction	O
using	O
0.014-unit	O
collagenase	O
,	O
heparin	B-Chemical
enhanced	O
the	O
hematoma	B-Disease
volume	O
3.4-fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	B-Disease
animals	O
and	O
the	O
bleeding	B-Disease
7.6-fold	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	B-Disease
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	B-Disease
induced	O
with	O
a	O
low-dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	B-Drug
that	O
may	O
affect	O
ICH	B-Disease
.	O

Estradiol	B-Chemical
reduces	O
seizure-induced	B-Disease
hippocampal	B-Disease
injury	I-Disease
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	B-Disease
injury	I-Disease
induced	O
by	O
kainic	B-Chemical
acid-induced	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta-estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium-pilocarpine-induced	O
SE	O
.	O

Rats	O
received	O
subcutaneous	O
injections	O
of	O
17beta-estradiol	O
(	O
2	O
microg/rat	O
)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days	O
.	O

SE	O
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later	O
.	O

The	O
extent	O
of	O
silver-stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	O
.	O

17beta-Estradiol	O
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males	O
.	O

17beta-Estradiol	O
reduced	O
the	O
argyrophilic	O
neurons	O
in	O
the	O
CA1	O
and	O
CA3-C	O
sectors	O
of	O
ovariectomized	O
rats	O
.	O

In	O
males	O
,	O
estradiol	B-Drug
increased	O
the	O
total	O
damage	O
score	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	B-Drug
on	O
seizure	O
threshold	O
and	O
damage	O
may	O
be	O
altered	O
by	O
sex-related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

Delirium	B-Disease
during	O
clozapine	B-Chemical
treatment	O
:	O
incidence	O
and	O
associated	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	B-Disease
during	O
clozapine	B-Chemical
treatment	O
require	O
further	O
clarification	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	B-Disease
inpatients	O
treated	O
with	O
clozapine	B-Chemical
(	O
1995-96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	B-Disease
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

RESULTS	O
:	O
Subjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	O
and	O
67	O
men	O
,	O
aged	O
40.8	O
+/-	O
12.1	O
years	O
,	O
hospitalized	O
for	O
24.9	O
+/-	O
23.3	O
days	O
,	O
and	O
given	O
clozapine	B-Chemical
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+/-	O
203	O
mg	O
(	O
3.45	O
+/-	O
2.45	O
mg/kg	O
)	O
for	O
18.9	O
+/-	O
16.4	O
days	O
.	O

Delirium	B-Disease
was	O
diagnosed	O
in	O
14	O
(	O
10.1	O
%	O
incidence	O
,	O
or	O
1.48	O
cases/person-years	O
of	O
exposure	O
)	O
;	O
71.4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O

Associated	O
factors	O
were	O
co-treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17.5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co-morbidity	O
,	O
and	O
daily	O
clozapine	B-Chemical
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

CONCLUSIONS	O
:	O
Delirium	B-Disease
was	O
found	O
in	O
10	O
%	O
of	O
clozapine-treated	B-Chemical
inpatients	O
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O

Delirium	B-Disease
was	O
inconsistently	O
recognized	O
clinically	O
in	O
milder	O
cases	O
and	O
was	O
associated	O
with	O
increased	O
length-of-stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O

Ketoconazole-induced	B-Chemical
neurologic	B-Disease
sequelae	I-Disease
.	O

A	O
77-y-old	O
patient	O
developed	O
weakness	B-Disease
of	I-Disease
extremities	I-Disease
,	O
legs	B-Disease
paralysis	I-Disease
,	O
dysarthria	B-Disease
and	O
tremor	B-Disease
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	B-Chemical
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O

All	O
complaints	O
faded	O
away	O
within	O
24	O
h.	O
Few	O
days	O
later	O
,	O
the	O
patient	O
used	O
another	O
200	O
mg	O
ketoconazole	B-Chemical
tablet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinical	O
picture	O
,	O
which	O
resolved	O
again	O
spontaneously	O
within	O
hours	O
.	O

Laboratory	O
evaluations	O
,	O
including	O
head	O
CT	O
scan	O
,	O
were	O
normal	O
.	O

This	O
case	O
illustrates	O
the	O
need	O
for	O
close	O
vigilance	O
in	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
,	O
particularly	O
in	O
the	O
elderly	O
.	O

Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino-parasympathetic	O
reflex	O
--	O
an	O
experimental	O
model	O
for	O
vascular	B-Disease
dysfunctions	I-Disease
in	O
cluster	B-Disease
headache	I-Disease
.	O

Cluster	B-Disease
headache	I-Disease
is	O
characterized	O
by	O
typical	O
autonomic	O
dysfunctions	O
including	O
facial	O
and	O
intracranial	B-Disease
vascular	I-Disease
disturbances	I-Disease
.	O

Both	O
the	O
trigeminal	O
and	O
the	O
cranial	O
parasympathetic	O
systems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfunctions	O
.	O

An	O
experimental	O
model	O
was	O
developed	O
in	O
the	O
rat	O
to	O
measure	O
changes	O
in	O
lacrimation	O
and	O
intracranial	O
blood	O
flow	O
following	O
noxious	O
chemical	O
stimulation	O
of	O
facial	O
mucosa	O
.	O

Blood	O
flow	O
was	O
monitored	O
in	O
arteries	O
of	O
the	O
exposed	O
cranial	O
dura	O
mater	O
and	O
the	O
parietal	O
cortex	O
using	O
laser	O
Doppler	O
flowmetry	O
.	O

Capsaicin	B-Chemical
(	O
0.01-1	O
mm	O
)	O
applied	O
to	O
oral	O
or	O
nasal	O
mucosa	O
induced	O
increases	B-Disease
in	B-Disease
dural	I-Disease
and	I-Disease
cortical	I-Disease
blood	I-Disease
flow	I-Disease
and	O
provoked	O
lacrimation	O
.	O

These	O
responses	O
were	O
blocked	O
by	O
systemic	O
pre-administration	O
of	O
hexamethonium	B-Chemical
chloride	I-Chemical
(	O
20	O
mg/kg	O
)	O
.	O

The	O
evoked	O
increases	B-Disease
in	B-Disease
dural	I-Disease
blood	I-Disease
flow	I-Disease
were	O
also	O
abolished	O
by	O
topical	O
pre-administration	O
of	O
atropine	B-Chemical
(	O
1	O
mm	O
)	O
and	O
[	O
Lys1	O
,	O
Pro2,5	O
,	O
Arg3,4	O
,	O
Tyr6	O
]	O
-VIP	O
(	O
0.1	O
mm	O
)	O
,	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
antagonist	O
,	O
onto	O
the	O
exposed	O
dura	O
mater	O
.	O

We	O
conclude	O
that	O
noxious	O
stimulation	O
of	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
and	O
lacrimation	O
via	O
a	O
trigemino-parasympathetic	O
reflex	O
.	O

The	O
blood	O
flow	O
responses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
release	O
of	O
acetylcholine	B-Chemical
and	O
VIP	O
within	O
the	O
meninges	O
.	O

Similar	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cluster	B-Disease
headache	I-Disease
.	O

Recurrent	O
excitation	O
in	O
the	O
dentate	O
gyrus	O
of	O
a	O
murine	O
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

Similar	O
to	O
rats	O
,	O
systemic	O
pilocarpine	B-Chemical
injection	O
causes	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
and	O
the	O
eventual	O
development	O
of	O
spontaneous	O
seizures	B-Disease
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL/6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O

Population	O
responses	O
in	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
examined	O
in	O
transverse	O
slices	O
of	O
the	O
ventral	O
hippocampus	O
from	O
pilocarpine-treated	B-Chemical
and	O
untreated	O
mice	O
.	O

In	O
Mg	B-Chemical
(	O
2+	O
)	O
-free	O
bathing	O
medium	O
containing	O
bicuculline	B-Chemical
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine-treated	B-Chemical
mice	O
that	O
did	O
not	O
experience	O
SE	B-Disease
.	O

In	O
SE	B-Disease
survivors	O
,	O
similar	O
stimulation	O
resulted	O
in	O
a	O
population	O
spike	O
followed	O
,	O
at	O
a	O
variable	O
latency	O
,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3-60	O
s	O
duration	O
,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	B-Chemical
receptor	O
antagonists	O
.	O

Focal	O
glutamate	B-Chemical
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1-30	O
s	O
duration	O
in	O
slices	O
from	O
SE	B-Disease
survivors	O
but	O
not	O
other	O
groups	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE-induced	B-Disease
mossy	O
fiber	O
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	B-Disease
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	B-Chemical
receptor	O
subunits	O
are	O
necessary	O
for	O
nicotine-induced	B-Chemical
seizures	B-Disease
and	O
hypolocomotion	B-Disease
in	O
mice	O
.	O

Binding	O
of	O
nicotine	B-Chemical
to	O
nicotinic	O
acetylcholine	B-Chemical
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose-dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	O
,	O
sedation	O
,	O
and	O
tremors	B-Disease
,	O
to	O
seizures	B-Disease
and	O
death	B-Disease
.	O

nAChRs	O
are	O
pentameric	O
ion	O
channels	O
usually	O
composed	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

A	O
gene	O
cluster	O
comprises	O
the	O
alpha3	O
,	O
alpha5	O
and	O
beta4	O
subunits	O
,	O
which	O
coassemble	O
to	O
form	O
functional	O
receptors	O
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
beta4	O
subunits	O
in	O
nicotine-induced	B-Chemical
seizures	B-Disease
and	O
hypolocomotion	B-Disease
in	O
beta4	O
homozygous	O
null	O
(	O
beta4	O
-/-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+/-	O
)	O
mice	O
.	O

beta4	O
-/-	O
mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	B-Chemical
both	O
at	O
low	O
doses	O
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	O
as	O
sensitivity	O
to	O
nicotine-induced	B-Chemical
seizures	B-Disease
.	O

Using	O
in	O
situ	O
hybridization	O
probes	O
for	O
the	O
alpha3	O
and	O
alpha5	O
subunits	O
,	O
we	O
showed	O
that	O
alpha5	O
mRNA	O
levels	O
are	O
unchanged	O
,	O
whereas	O
alpha3	O
mRNA	O
levels	O
are	O
selectively	O
decreased	O
in	O
the	O
mitral	O
cell	O
layer	O
of	O
the	O
olfactory	O
bulb	O
,	O
and	O
the	O
inferior	O
and	O
the	O
superior	O
colliculus	O
of	O
beta4	O
-/-	O
brains	O
.	O

alpha3	O
+/-	O
mice	O
were	O
partially	O
resistant	O
to	O
nicotine-induced	B-Chemical
seizures	B-Disease
when	O
compared	O
to	O
wild-type	O
littermates	O
.	O

mRNA	O
levels	O
for	O
the	O
alpha5	O
and	O
the	O
beta4	O
subunits	O
were	O
unchanged	O
in	O
alpha3	O
+/-	O
brains	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	O
of	O
nicotine-induced	B-Chemical
seizures	B-Disease
and	O
hypolocomotion	B-Disease
.	O

Recurrent	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
induced	O
by	O
azithromycin	B-Chemical
.	O

A	O
14-year-old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin-induced	B-Chemical
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
.	O

The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	B-Drug
therapy	O
,	O
renal	O
function	O
remained	O
impaired	O
.	O

Although	O
most	O
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
are	O
benign	O
and	O
self-limited	O
,	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	B-Disease
injury	I-Disease
.	O

Valproate-induced	B-Chemical
encephalopathy	B-Disease
.	O

Valproate-induced	B-Chemical
encephalopathy	B-Disease
is	O
a	O
rare	O
syndrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	B-Disease
individuals	O
.	O

It	O
may	O
even	O
present	O
in	O
patients	O
who	O
have	O
tolerated	O
this	O
medicine	O
well	O
in	O
the	O
past	O
.	O

It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	B-Disease
.	O

The	O
EEG	O
shows	O
characteristic	O
triphasic	O
waves	O
in	O
most	O
patients	O
with	O
this	O
complication	O
.	O

A	O
case	O
of	O
valproate-induced	B-Chemical
encephalopathy	B-Disease
is	O
presented	O
.	O

The	O
problems	O
in	O
diagnosing	O
this	O
condition	O
are	O
subsequently	O
discussed	O
.	O

Nitro-L-arginine	B-Chemical
methyl	I-Chemical
ester	I-Chemical
:	O
a	O
potential	O
protector	O
against	O
gentamicin	B-Chemical
ototoxicity	B-Disease
.	O

The	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
inhibitor	O
nitro-L-arginine	B-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L-NAME	B-Chemical
)	O
may	O
act	O
as	O
an	O
otoprotectant	O
against	O
high-frequency	B-Disease
hearing	I-Disease
loss	I-Disease
caused	O
by	O
gentamicin	B-Chemical
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
confirm	O
this.Aminoglycoside	B-Chemical
antibiotics	B-Drug
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficacy	O
and	O
low	O
cost	O
.	O

Their	O
ototoxicity	B-Disease
is	O
a	O
serious	O
health	O
problem	O
and	O
,	O
as	O
their	O
ototoxic	B-Disease
mechanism	O
involves	O
the	O
production	O
of	O
NO	B-Chemical
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	B-Chemical
inhibitors	O
for	O
the	O
prevention	O
of	O
aminoglycoside-induced	B-Chemical
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

In	O
this	O
experimental	O
study	O
we	O
used	O
30	O
Sprague-Dawley	O
rats	O
,	O
27	O
of	O
which	O
had	O
gentamicin	B-Chemical
instilled	O
into	O
the	O
middle	O
ear	O
.	O

The	O
otoprotectant	O
L-NAME	B-Chemical
was	O
administered	O
topically	O
to	O
12/27	O
animals	O
.	O

Its	O
effect	O
was	O
determined	O
in	O
terms	O
of	O
attenuation	O
of	O
hearing	B-Disease
loss	I-Disease
,	O
measured	O
by	O
shifts	O
in	O
the	O
auditory	O
brainstem	O
response	O
threshold	O
.	O

L-NAME	B-Chemical
reduced	O
gentamicin-induced	B-Chemical
hearing	B-Disease
loss	I-Disease
in	O
the	O
high-frequency	O
range	O
,	O
but	O
gave	O
no	O
protection	O
in	O
the	O
middle	O
or	O
low	O
frequencies	O
.	O

Cerebral	B-Disease
vasculitis	I-Disease
following	O
oral	O
methylphenidate	B-Chemical
intake	O
in	O
an	O
adult	O
:	O
a	O
case	O
report	O
.	O

Methylphenidate	B-Chemical
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamine	B-Chemical
.	O

Cerebral	B-Disease
vasculitis	I-Disease
associated	O
with	O
amphetamine	B-Disease
abuse	I-Disease
is	O
well	O
documented	O
,	O
and	O
in	O
rare	O
cases	O
ischaemic	B-Disease
stroke	I-Disease
has	O
been	O
reported	O
after	O
methylphenidate	B-Chemical
intake	O
in	O
children	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
63-year-old	O
female	O
who	O
was	O
treated	O
with	O
methylphenidate	B-Chemical
due	O
to	O
hyperactivity	B-Disease
and	O
suffered	O
from	O
multiple	O
ischaemic	B-Disease
strokes	I-Disease
.	O

We	O
consider	O
drug-induced	O
cerebral	B-Disease
vasculitis	I-Disease
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	O
ischaemic	B-Disease
strokes	I-Disease
in	O
the	O
absence	O
of	O
any	O
pathological	O
findings	O
during	O
the	O
diagnostic	O
work-up	O
.	O

We	O
conclude	O
that	O
methylphenidate	B-Chemical
mediated	O
vasculitis	B-Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	B-Chemical
therapy	O
.	O

This	O
potential	O
side-effect	O
,	O
though	O
very	O
rare	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	B-Chemical
.	O

Cerebral	B-Disease
haemorrhage	I-Disease
induced	O
by	O
warfarin	B-Chemical
-	O
the	O
influence	O
of	O
drug-drug	O
interactions	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
frequency	O
,	O
severity	O
and	O
preventability	O
of	O
warfarin-induced	B-Chemical
cerebral	B-Disease
haemorrhages	I-Disease
due	O
to	O
warfarin	B-Chemical
and	O
warfarin-drug	B-Chemical
interactions	O
in	O
patients	O
living	O
in	O
the	O
county	O
of	O
Osterg	O
tland	O
,	O
Sweden	O
.	O

METHODS	O
:	O
All	O
patients	O
with	O
a	O
diagnosed	O
cerebral	B-Disease
haemorrhage	I-Disease
at	O
three	O
hospitals	O
during	O
the	O
period	O
2000-2002	O
were	O
identified	O
.	O

Medical	O
records	O
were	O
studied	O
retrospectively	O
to	O
evaluate	O
whether	O
warfarin	B-Chemical
and	O
warfarin-drug	B-Chemical
interactions	O
could	O
have	O
caused	O
the	O
cerebral	B-Disease
haemorrhage	I-Disease
.	O

The	O
proportion	O
of	O
possibly	O
avoidable	O
cases	O
due	O
to	O
drug	B-Drug
interactions	O
was	O
estimated	O
.	O

RESULTS	O
:	O
Among	O
593	O
patients	O
with	O
cerebral	B-Disease
haemorrhage	I-Disease
,	O
59	O
(	O
10	O
%	O
)	O
were	O
assessed	O
as	O
related	O
to	O
warfarin	B-Chemical
treatment	O
.	O

This	O
imply	O
an	O
incidence	O
of	O
1.7/100,000	O
treatment	O
years	O
.	O

Of	O
the	O
59	O
cases	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fatal	O
outcome	O
,	O
compared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non-warfarin	B-Chemical
patients	O
(	O
p	O
<	O
0.01	O
)	O
.	O

A	O
warfarin-drug	B-Chemical
interaction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhage	B-Disease
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warfarin	B-Chemical
patients	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bleeding	B-Disease
complication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O

CONCLUSIONS	O
:	O
Warfarin-induced	B-Chemical
cerebral	B-Disease
haemorrhages	I-Disease
are	O
a	O
major	O
clinical	O
problem	O
with	O
a	O
high	O
fatality	O
rate	O
.	O

Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin-drug	B-Chemical
interaction	O
.	O

A	O
significant	O
proportion	O
of	O
warfarin-related	B-Chemical
cerebral	B-Disease
haemorrhages	I-Disease
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	B-Drug
known	O
to	O
interact	O
with	O
warfarin	B-Chemical
.	O

Side	O
effects	O
of	O
postoperative	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
into	O
the	O
posterior	O
sub-Tenon	O
's	O
space	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
incidence	O
of	O
postoperative	O
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
into	O
the	O
posterior	O
sub-Tenon	O
's	O
space	O
at	O
the	O
end	O
of	O
routine	O
cataract	B-Disease
surgery	O
.	O

SETTING	O
:	O
St.	O
Luke	O
's	O
Hospital	O
,	O
Gwardamangia	O
,	O
Malta	O
.	O

METHODS	O
:	O
A	O
double-blind	O
double-armed	O
prospective	O
study	O
comprised	O
40	O
patients	O
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub-Tenon	O
's	O
local	O
infiltration	O
of	O
3	O
mL	O
of	O
plain	O
lignocaine	B-Chemical
.	O

At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
Group	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg/0.5	O
mL	O
of	O
methylprednisolone	B-Chemical
and	O
10	O
mg/0.5	O
mL	O
of	O
gentamicin	B-Chemical
injected	O
into	O
the	O
posterior	O
sub-Tenon	O
's	O
space	O
and	O
Group	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
combination	O
injected	O
into	O
the	O
anterior	O
sub-Tenon	O
's	O
space	O
.	O

Postoperatively	O
,	I-Disease
all	O
patients	O
were	O
assessed	O
for	O
symptoms	O
of	O
nausea	B-Disease
,	I-Disease
vomiting	O
,	O
and	O
headache	B-Disease
.	O

A	O
chi-square	O
test	O
was	O
used	O
to	O
assess	O
the	O
statistical	O
significance	O
of	O
results	O
.	O

RESULTS	O
:	O
Sixty	O
percent	O
in	O
Group	O
A	O
developed	O
postoperative	B-Disease
emetic	I-Disease
symptoms	I-Disease
,	O
headache	B-Disease
,	O
or	O
both	O
;	O
1	O
patient	O
in	O
Group	O
B	O
developed	O
symptoms	O
.	O

CONCLUSIONS	O
:	O
The	O
administration	O
of	O
methylprednisolone	B-Chemical
and	O
gentamicin	B-Chemical
in	O
the	O
posterior	O
sub-Tenon	O
's	O
space	O
was	O
related	O
to	O
a	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
nausea	B-Disease
,	I-Disease
vomiting	I-Disease
,	O
and	O
headache	B-Disease
.	O

All	O
adverse	O
effects	O
were	O
self-limiting	O
.	O

Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(	O
CARE	O
)	O
study	O
:	O
a	O
randomized	O
double-blind	O
trial	O
of	O
contrast-induced	O
nephropathy	B-Disease
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
.	O

BACKGROUND	O
:	O
No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low-osmolality	O
contrast	B-Chemical
medium	I-Chemical
iopamidol	B-Chemical
with	O
that	O
of	O
the	O
iso-osmolality	O
contrast	B-Chemical
medium	I-Chemical
iodixanol	B-Chemical
in	O
high-risk	O
patients	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
comparison	O
of	O
iopamidol	B-Chemical
and	O
iodixanol	B-Chemical
in	O
patients	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
(	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
20	O
to	O
59	O
mL/min	O
)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions	O
.	O

Serum	O
creatinine	B-Chemical
(	O
SCr	O
)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications	O
.	O

The	O
primary	O
outcome	O
was	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
0.5	O
mg/dL	O
(	O
44.2	O
micromol/L	O
)	O
over	O
baseline	O
.	O

Secondary	O
outcomes	O
were	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
postdose	O
estimated	O
glomerular	O
filtration	O
rate	O
decrease	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O

In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B-Disease
mellitus	I-Disease
,	O
use	O
of	O
N-acetylcysteine	B-Chemical
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O

SCr	O
increases	O
>	O
or	O
=	O
0.5	O
mg/dL	O
occurred	O
in	O
4.4	O
%	O
(	O
9	O
of	O
204	O
patients	O
)	O
after	O
iopamidol	B-Chemical
and	O
6.7	O
%	O
(	O
14	O
of	O
210	O
patients	O
)	O
after	O
iodixanol	B-Chemical
(	O
P=0.39	O
)	O
,	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
9.8	O
%	O
and	O
12.4	O
%	O
,	O
respectively	O
(	O
P=0.44	O
)	O
.	O

In	O
patients	O
with	O
diabetes	B-Disease
,	O
SCr	O
increases	O
>	O
or	O
=	O
0.5	O
mg/dL	O
were	O
5.1	O
%	O
(	O
4	O
of	O
78	O
patients	O
)	O
with	O
iopamidol	B-Chemical
and	O
13.0	O
%	O
(	O
12	O
of	O
92	O
patients	O
)	O
with	O
iodixanol	B-Chemical
(	O
P=0.11	O
)	O
,	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
10.3	O
%	O
and	O
15.2	O
%	O
,	O
respectively	O
(	O
P=0.37	O
)	O
.	O

Mean	O
post-SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	B-Chemical
(	O
all	O
patients	O
:	O
0.07	O
versus	O
0.12	O
mg/dL	O
,	O
6.2	O
versus	O
10.6	O
micromol/L	O
,	O
P=0.03	O
;	O
patients	O
with	O
diabetes	B-Disease
:	O
0.07	O
versus	O
0.16	O
mg/dL	O
,	O
6.2	O
versus	O
14.1	O
micromol/L	O
,	O
P=0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rate	O
of	O
contrast-induced	O
nephropathy	B-Disease
,	O
defined	O
by	O
multiple	O
end	O
points	O
,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	B-Chemical
or	O
iodixanol	B-Chemical
to	O
high-risk	O
patients	O
,	O
with	O
or	O
without	O
diabetes	B-Disease
mellitus	I-Disease
.	O

Any	O
true	O
difference	O
between	O
the	O
agents	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O

A	O
novel	O
compound	O
,	O
maltolyl	B-Chemical
p-coumarate	I-Chemical
,	O
attenuates	O
cognitive	B-Disease
deficits	I-Disease
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B-Disease
models	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	B-Drug
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	B-Chemical
p-coumarate	I-Chemical
by	O
the	O
esterification	O
of	O
maltol	B-Chemical
and	O
p-coumaric	B-Chemical
acid	I-Chemical
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	B-Chemical
p-coumarate	I-Chemical
could	O
improve	O
cognitive	B-Disease
decline	I-Disease
in	O
scopolamine-injected	B-Chemical
rats	O
and	O
in	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1-42	I-Chemical
)	I-Chemical
-infused	O
rats	O
.	O

Maltolyl	B-Chemical
p-coumarate	I-Chemical
was	O
found	O
to	O
attenuate	O
cognitive	B-Disease
deficits	I-Disease
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1-42	I-Chemical
)	I-Chemical
-infused	O
rats	O
.	O

We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-Chemical
p-coumarate	I-Chemical
in	O
vitro	O
using	O
SH-SY5Y	O
cells	O
.	O

Cells	O
were	O
pretreated	O
with	O
maltolyl	B-Chemical
p-coumarate	I-Chemical
,	O
before	O
exposed	O
to	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1-42	I-Chemical
)	I-Chemical
,	O
glutamate	B-Chemical
or	O
H2O2	B-Chemical
.	O

We	O
found	O
that	O
maltolyl	B-Chemical
p-coumarate	I-Chemical
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	O
oxygen	O
species	O
,	O
cytochrome	O
c	O
release	O
,	O
and	O
caspase	O
3	O
activation	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	B-Chemical
p-coumarate	I-Chemical
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B-Disease
death	I-Disease
and	O
progressive	O
decline	B-Disease
of	I-Disease
cognitive	I-Disease
function	I-Disease
.	O

Interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
:	O
case	O
series	O
.	O

Warfarin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	B-Drug
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O

Levofloxacin	B-Chemical
,	O
a	O
fluoroquinolone	B-Chemical
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	B-Drug
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram-positive	O
,	O
Gram-negative	O
,	O
and	O
atypical	O
bacteria	O
.	O

While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug-drug	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	B-Chemical
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	B-Chemical
.	O

We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	B-Disease
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
.	O

Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	B-Chemical
to	O
patients	O
taking	O
warfarin	B-Chemical
.	O

Mutations	O
associated	O
with	O
lamivudine-resistance	B-Chemical
in	O
therapy-na	B-Chemical
ve	O
hepatitis	B-Disease
B	I-Disease
virus	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infected	I-Disease
patients	O
with	O
and	O
without	O
HIV	B-Disease
co-infection	I-Disease
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-Disease
and	I-Disease
HIV	I-Disease
co-infected	I-Disease
South	O
African	O
patients	O
.	O

This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine-resistant	B-Chemical
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
strains	O
in	O
selected	O
lamivudine-na	B-Chemical
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
co-infection	O
in	O
South	O
African	O
patients	O
.	O

Thirty-five	O
lamivudine-na	B-Chemical
ve	O
HBV	O
infected	O
patients	O
with	O
or	O
without	O
HIV	I-Disease
co-infection	I-Disease
were	O
studied	O
:	O
15	O
chronic	O
HBV	O
mono-infected	O
patients	O
and	O
20	O
HBV-HIV	O
co-infected	O
patients	O
.	O

The	O
latter	O
group	O
was	O
further	O
sub-divided	O
into	O
13	O
occult	O
HBV	O
(	I-Disease
HBsAg-negative	O
)	I-Disease
and	O
7	O
overt	O
HBV	O
(	I-Disease
HBsAg-	O
positive	O
)	I-Disease
patients	O
.	O

HBsAg	O
,	O
anti-HBs	O
,	O
anti-HBc	O
,	O
and	O
anti-HIV	O
1/2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	I-Disease
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine-methionine-aspartate-aspartate	O
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme	O
.	O

HBV	O
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	O
Monitor	O
test	O
v2.0	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O

HBV	O
lamivudine-resistant	B-Chemical
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono-infected	O
chronic	O
hepatitis	O
B	O
patients	O
and	O
10	O
of	O
20	O
HBV-HIV	O
co-infected	O
patients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine-resistant	O
strains	O
in	O
therapy-na	B-Chemical
ve	O
HBV-HIV	B-Disease
co-infected	O
patients	O
.	O

The	O
HBV	B-Disease
viral	O
loads	O
for	O
mono-infected	O
and	O
co-infected	O
patients	O
ranged	O
from	O
3.32	O
x	O
10	O
(	O
2	O
)	O
to	O
3.82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4.40	O
x	O
10	O
(	O
3	O
)	O
copies/ml	O
,	O
respectively	O
.	O

It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre-existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine-containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV-HIV	B-Disease
co-infected	O
patients	O
.	O

Sex	O
differences	O
in	O
NMDA	B-Chemical
antagonist	O
enhancement	O
of	O
morphine	B-Chemical
antihyperalgesia	O
in	O
a	O
capsaicin	B-Chemical
model	O
of	O
persistent	O
pain	B-Disease
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	B-Disease
pain	I-Disease
.	O

In	O
acute	B-Disease
pain	I-Disease
models	O
,	O
N-methyl-D-aspartate	B-Chemical
(	O
NMDA	B-Chemical
)	O
antagonists	O
enhance	O
the	O
antinociceptive	O
effects	O
of	O
morphine	B-Chemical
to	O
a	O
greater	O
extent	O
in	O
males	O
than	O
females	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
extend	O
these	O
findings	O
to	O
a	O
persistent	O
pain	B-Disease
model	O
which	O
could	O
be	O
distinguished	O
from	O
acute	B-Disease
pain	I-Disease
models	O
on	O
the	O
basis	O
of	O
the	O
nociceptive	O
fibers	O
activated	O
,	O
neurochemical	O
substrates	O
,	O
and	O
duration	O
of	O
the	O
nociceptive	O
stimulus	O
.	O

To	O
this	O
end	O
,	O
persistent	O
hyperalgesia	B-Disease
was	O
induced	O
by	O
administration	O
of	O
capsaicin	B-Chemical
in	O
the	O
tail	O
of	O
gonadally	O
intact	O
F344	O
rats	O
,	O
following	O
which	O
the	O
tail	O
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus	O
,	O
and	O
tail-withdrawal	O
latencies	O
measured	O
.	O

For	O
comparison	O
,	O
tests	O
were	O
conducted	O
in	O
two	O
acute	B-Disease
pain	I-Disease
models	O
,	O
the	O
hotplate	O
and	O
warm	O
water	O
tail-withdrawal	O
procedures	O
.	O

In	O
males	O
,	O
the	O
non-competitive	O
NMDA	B-Chemical
antagonist	O
dextromethorphan	B-Chemical
enhanced	O
the	O
antihyperalgesic	O
effect	O
of	O
low	O
to	O
moderate	O
doses	O
of	O
morphine	B-Chemical
in	O
a	O
dose-and	O
time-dependent	O
manner	O
.	O

Across	O
the	O
doses	O
and	O
pretreatment	O
times	O
examined	O
,	O
enhancement	O
was	O
not	O
observed	O
in	O
females	O
.	O

Enhancement	O
of	O
morphine	B-Chemical
antinociception	O
by	O
dextromethorphan	B-Chemical
was	O
seen	O
in	O
both	O
males	O
and	O
females	O
in	O
the	O
acute	B-Disease
pain	I-Disease
models	O
,	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
males	O
.	O

These	O
findings	O
demonstrate	O
a	O
sexually-dimorphic	O
interaction	O
between	O
NMDA	B-Chemical
antagonists	O
and	O
morphine	B-Chemical
in	O
a	O
persistent	O
pain	B-Disease
model	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	B-Disease
pain	I-Disease
models	O
.	O

Development	O
of	O
proteinuria	B-Disease
after	O
switch	O
to	O
sirolimus-based	B-Chemical
immunosuppression	O
in	O
long-term	O
cardiac	O
transplant	O
patients	O
.	O

Calcineurin-inhibitor	O
therapy	O
can	O
lead	B-Drug
to	O
renal	B-Disease
dysfunction	I-Disease
in	O
heart	O
transplantation	O
patients	O
.	O

The	O
novel	O
immunosuppressive	O
(	O
IS	O
)	O
drug	B-Drug
sirolmus	B-Chemical
(	O
Srl	B-Chemical
)	O
lacks	O
nephrotoxic	B-Disease
effects	O
;	O
however	O
,	O
proteinuria	B-Disease
associated	O
with	O
Srl	B-Chemical
has	O
been	O
reported	O
following	O
renal	O
transplantation	O
.	O

In	O
cardiac	O
transplantation	O
,	O
the	O
incidence	O
of	O
proteinuria	B-Disease
associated	O
with	O
Srl	B-Chemical
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
long-term	O
cardiac	O
transplant	O
patients	O
were	O
switched	O
from	O
cyclosporine	B-Chemical
to	O
Srl-based	B-Chemical
IS	O
.	O

Concomitant	O
IS	O
consisted	O
of	O
mycophenolate	B-Chemical
mofetil	I-Chemical
+/-	O
steroids	B-Chemical
.	O

Proteinuria	O
increased	O
significantly	O
from	O
a	O
median	O
of	O
0.13	O
g/day	O
(	O
range	O
0-5.7	O
)	O
preswitch	O
to	O
0.23	O
g/day	O
(	O
0-9.88	O
)	O
at	O
24	O
months	O
postswitch	O
(	O
p	O
=	O
0.0024	O
)	O
.	O

Before	O
the	O
switch	O
,	O
11.5	O
%	O
of	O
patients	O
had	O
high-grade	O
proteinuria	B-Disease
(	O
>	O
1.0	O
g/day	O
)	O
;	O
this	O
increased	O
to	O
22.9	O
%	O
postswitch	O
(	O
p	O
=	O
0.006	O
)	O
.	O

ACE	B-Chemical
inhibitor	I-Chemical
and	O
angiotensin-releasing	B-Chemical
blocker	I-Chemical
(	O
ARB	B-Chemical
)	O
therapy	O
reduced	O
proteinuria	B-Disease
development	O
.	O

Patients	O
without	O
proteinuria	B-Disease
had	O
increased	O
renal	O
function	O
(	O
median	O
42.5	O
vs.	O
64.1	O
,	O
p	O
=	O
0.25	O
)	O
,	O
whereas	O
patients	O
who	O
developed	O
high-grade	O
proteinuria	B-Disease
showed	O
decreased	O
renal	O
function	O
at	O
the	O
end	O
of	O
follow-up	O
(	O
median	O
39.6	O
vs.	O
29.2	O
,	O
p	O
=	O
0.125	O
)	O
.	O

Thus	O
,	O
proteinuria	B-Disease
may	O
develop	O
in	O
cardiac	O
transplant	O
patients	O
after	O
switch	O
to	O
Srl	B-Chemical
,	O
which	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
renal	O
function	O
in	O
these	O
patients	O
.	O

Srl	B-Chemical
should	O
be	O
used	O
with	O
ACEi/ARB	B-Chemical
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	O
and	O
increased	O
renal	O
dysfunction	O
.	O

Synthesis	O
of	O
N-pyrimidinyl-2-phenoxyacetamides	B-Chemical
as	O
adenosine	B-Chemical
A2A	O
receptor	O
antagonists	O
.	O

A	O
series	O
of	O
N-pyrimidinyl-2-phenoxyacetamide	B-Chemical
adenosine	B-Chemical
A	O
(	O
2A	O
)	O
antagonists	O
is	O
described	O
.	O

SAR	O
studies	O
led	O
to	O
compound	O
14	O
with	O
excellent	O
potency	O
(	O
K	O
(	O
i	O
)	O
=	O
0.4	O
nM	O
)	O
,	O
selectivity	O
(	O
A	O
(	O
1	O
)	O
/A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficacy	O
(	O
MED	O
10	O
mg/kg	O
p.o	O
.	O

)	O
in	O
the	O
rat	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
model	O
for	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

Methamphetamine-induced	B-Chemical
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling	O
.	O

Methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
damages	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O

Cardona	O
et	O
al	O
.	O

[	O
Nat	O
.	O

Neurosci	O
.	O

9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identified	O
the	O
microglial-specific	O
fractalkine	O
receptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP-induced	B-Chemical
neurodegeneration	B-Disease
of	O
DA	B-Chemical
neurons	O
.	O

Because	O
the	O
CNS	B-Disease
damage	I-Disease
caused	O
by	O
METH	B-Chemical
and	O
MPTP	B-Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	B-Chemical
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	B-Disease
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH-induced	B-Chemical
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
.	O

Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
were	O
treated	O
with	O
METH	B-Chemical
and	O
examined	O
for	O
striatal	O
neurotoxicity	B-Disease
.	O

METH	B-Chemical
depleted	O
DA	B-Chemical
,	O
caused	O
microglial	O
activation	O
,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild-type	O
controls	O
.	O

The	O
effects	O
of	O
METH	B-Chemical
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender-dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O

Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	B-Chemical
that	O
are	O
characteristic	O
of	O
activation	O
.	O

This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP-microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	B-Chemical
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	B-Chemical
neurotoxicity	B-Disease
or	O
microglial	O
activation	O
.	O

Furthermore	O
,	O
it	O
appears	O
that	O
striatal-resident	O
microglia	O
respond	O
to	O
METH	B-Chemical
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O

Recovery	O
of	O
tacrolimus-associated	B-Chemical
brachial	B-Disease
neuritis	I-Disease
after	O
conversion	O
to	O
everolimus	B-Chemical
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
--	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

TAC	B-Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O

Neurotoxicity	B-Disease
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O

It	O
is	O
characterized	O
by	O
encephalopathy	B-Disease
,	O
headaches	B-Disease
,	O
seizures	B-Disease
,	O
or	O
neurological	B-Disease
deficits	I-Disease
.	O

Here	O
,	O
we	O
describe	O
an	O
eight-and-a-half-yr-old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN	O
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B-Disease
and	O
right	O
brachial	B-Disease
plexitis	I-Disease
.	O

Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	B-Chemical
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	B-Chemical
pulse	O
therapy	O
.	O

Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	B-Chemical
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	B-Chemical
.	O

Valvular	B-Disease
heart	I-Disease
disease	I-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
treated	O
with	O
pergolide	B-Chemical
.	O

Course	O
following	O
treatment	O
modifications	O
.	O

Valvular	B-Disease
heart	I-Disease
abnormalities	I-Disease
have	O
been	O
reported	O
in	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
treated	O
with	O
pergolide	B-Chemical
.	O

However	O
,	O
the	O
incidence	O
and	O
severity	O
of	O
these	O
abnormalities	O
vary	O
from	O
study	O
to	O
study	O
and	O
their	O
course	O
after	O
drug	B-Drug
withdrawal	O
has	O
not	O
been	O
systematically	O
assessed	O
.	O

OBJECTIVES	O
:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	B-Disease
heart	I-Disease
abnormality	I-Disease
and	O
its	O
possible	O
reversibility	O
after	O
drug	B-Drug
withdrawal	O
in	O
a	O
case-control	O
study	O
.	O

METHODS	O
:	O
All	O
PD	B-Disease
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	B-Chemical
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography	O
.	O

Thirty	O
PD	B-Disease
patients	O
participated	O
in	O
the	O
study	O
.	O

A	O
second	O
echocardiography	O
was	O
performed	O
(	O
median	O
interval	O
:	O
13	O
months	O
)	O
after	O
pergolide	B-Chemical
withdrawal	O
(	O
n=10	O
patients	O
)	O
.	O

Controls	O
were	O
age-	O
and	O
sex-matched	O
non-PD	B-Disease
patients	O
referred	O
to	O
the	O
cardiology	O
department	O
.	O

RESULTS	O
:	O
Compared	O
to	O
controls	O
,	O
aortic	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
3.1	O
;	O
95	O
%	O
IC	O
:	O
1.1-8.8	O
)	O
and	O
mitral	B-Disease
regurgitation	I-Disease
(	O
OR	O
:	O
10.7	O
;	O
95	O
%	O
IC	O
:	O
2.1-53	O
)	O
were	O
more	O
frequent	O
in	O
PD	B-Disease
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O

The	O
number	O
of	O
affected	O
valves	O
(	O
n=2.4+/-0.7	O
)	O
and	O
the	O
sum	O
of	O
regurgitation	O
grades	O
(	O
n=2.8+/-1.09	O
)	O
were	O
higher	O
(	O
p=0.008	O
and	O
p=0.006	O
,	O
respectively	O
)	O
in	O
the	O
pergolide	B-Chemical
group	O
.	O

Severity	O
of	O
regurgitation	O
was	O
not	O
correlated	O
with	O
pergolide	B-Chemical
cumulative	O
dose	O
.	O

A	O
restrictive	O
pattern	O
of	O
valvular	B-Disease
regurgitation	I-Disease
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergolide	B-Chemical
,	O
was	O
observed	O
in	O
12/30	O
(	O
40	O
%	O
)	O
patients	O
including	O
two	O
with	O
heart	B-Disease
failure	I-Disease
.	O

Pergolide	B-Chemical
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(	O
p=0.01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	B-Disease
failure	I-Disease
returned	O
to	O
nearly	O
normal	O
clinical	O
examination	O
.	O

This	O
study	O
supports	O
the	O
high	O
frequency	O
of	O
restrictive	O
valve	B-Disease
regurgitation	I-Disease
in	O
PD	B-Disease
patients	O
treated	O
with	O
pergolide	B-Chemical
and	O
reveals	O
that	O
a	O
significant	O
improvement	O
is	O
usual	O
when	O
the	O
treatment	O
is	O
converted	O
to	O
non-ergot	O
dopamine	B-Chemical
agonists	O
.	O

Adverse	O
effects	O
of	O
topical	O
papaverine	B-Chemical
on	O
auditory	O
nerve	O
function	O
.	O

BACKGROUND	O
:	O
Papaverine	B-Chemical
hydrochloride	I-Chemical
is	O
a	O
direct-acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	B-Disease
during	O
various	O
neurosurgical	O
operations	O
.	O

Transient	O
cranial	B-Disease
nerve	I-Disease
dysfunction	I-Disease
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	B-Chemical
.	O

This	O
study	O
supports	O
previous	O
reports	O
and	O
provides	O
neurophysiological	O
evidence	O
of	O
an	O
adverse	O
effect	O
on	O
the	O
auditory	O
nerve	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	B-Chemical
for	O
vasospasm	B-Disease
.	O

Topical	O
papaverine	B-Chemical
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	B-Disease
in	O
a	O
total	O
of	O
11	O
patients	O
.	O

The	O
timing	O
of	O
papaverine	B-Chemical
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O

Brainstem	O
auditory	O
evoked	O
potentials	O
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
cochlear	O
nerve	O
function	O
during	O
these	O
operations	O
.	O

FINDINGS	O
:	O
A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	B-Chemical
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss	O
.	O

The	O
average	O
temporal	O
delay	O
between	O
papaverine	B-Chemical
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min	O
.	O

In	O
10	O
of	O
11	O
patients	O
,	O
BAEP	O
waves	O
II/III-V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	B-Chemical
.	O

Eight	O
of	O
these	O
10	O
patients	O
had	O
complete	O
loss	I-Disease
of	O
BAEP	O
waveforms	O
within	O
10	O
min	O
.	O

One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	B-Disease
hearing	I-Disease
loss	O
.	O

The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre-papaverine	B-Chemical
baseline	O
values	O
was	O
39	O
min	O
.	O

CONCLUSIONS	O
:	O
Topical	O
papaverine	B-Chemical
for	O
the	O
treatment	O
of	O
vasospasm	B-Disease
was	O
associated	O
with	O
the	I-Disease
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	I-Disease
ascending	O
auditory	O
brainstem	O
pathway	O
.	O

The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	B-Disease
effect	I-Disease
on	I-Disease
the	I-Disease
proximal	I-Disease
eighth	O
nerve	I-Disease
.	O

Recommendations	O
to	O
avoid	O
potential	O
cranial	B-Disease
nerve	I-Disease
deficits	O
from	O
papaverine	B-Chemical
are	O
provided	O
.	O

Massive	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
.	O

A	O
61-year-old	O
Japanese	O
man	O
with	O
nephrotic	B-Disease
syndrome	I-Disease
due	O
to	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
was	O
initially	O
responding	O
well	O
to	O
steroid	B-Chemical
therapy	O
.	O

The	O
amount	O
of	O
daily	O
urinary	O
protein	O
decreased	O
from	O
15.6	O
to	O
2.8	O
g.	O
Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
sodium	I-Chemical
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12.8	O
g	O
with	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

After	O
discontinuing	O
the	O
oral	O
alendronate	B-Chemical
,	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O

Urinary	O
volume	O
and	O
serum	O
creatinine	B-Chemical
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O

This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
,	O
but	O
also	O
oral	O
bisphosphonates	B-Chemical
can	O
aggravate	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Serum-	O
and	O
glucocorticoid-inducible	O
kinase	O
1	O
in	O
doxorubicin-induced	B-Chemical
nephrotic	B-Disease
syndrome	I-Disease
.	O

Doxorubicin-induced	B-Chemical
nephropathy	B-Disease
leads	O
to	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
-dependent	O
volume	B-Disease
retention	I-Disease
and	O
renal	O
fibrosis	B-Disease
.	O

The	O
aldosterone-sensitive	B-Chemical
serum-	O
and	O
glucocorticoid-inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	O
fibrosis	B-Disease
following	O
mineralocorticoid	O
and	O
salt	O
excess	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	B-Disease
retention	I-Disease
and	O
fibrosis	B-Disease
during	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

To	O
this	O
end	O
,	O
doxorubicin	B-Chemical
(	O
15	O
mug/g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene-targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1	O
(	O
-/-	O
)	O
)	O
and	O
their	O
wild-type	O
littermates	O
(	O
sgk1	O
(	O
+/+	O
)	O
)	O
.	O

Doxorubicin	B-Chemical
treatment	O
resulted	O
in	O
heavy	O
proteinuria	B-Disease
(	O
>	O
100	O
mg	O
protein/mg	O
crea	O
)	O
in	O
15/44	O
of	O
sgk1	O
(	O
+/+	O
)	O
and	O
15/44	O
of	O
sgk1	O
(	O
-/-	O
)	O
mice	O
leading	O
to	O
severe	O
nephrotic	B-Disease
syndrome	I-Disease
with	O
ascites	B-Disease
,	O
lipidemia	B-Disease
,	O
and	O
hypoalbuminemia	B-Disease
in	O
both	O
genotypes	O
.	O

Plasma	O
aldosterone	B-Chemical
levels	O
increased	O
in	O
nephrotic	B-Disease
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1	O
(	O
+/+	O
)	O
mice	O
.	O

Urinary	O
sodium	B-Chemical
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1	O
(	O
+/+	O
)	O
mice	O
(	O
15	O
+/-	O
5	O
mumol/mg	O
crea	O
)	O
than	O
in	O
sgk1	O
(	O
-/-	O
)	O
mice	O
(	O
35	O
+/-	O
5	O
mumol/mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	B-Disease
gain	I-Disease
in	O
sgk1	O
(	O
+/+	O
)	O
compared	O
with	O
sgk1	O
(	O
-/-	O
)	O
mice	O
(	O
+6.6	O
+/-	O
0.7	O
vs.	O
+4.1	O
+/-	O
0.8	O
g	O
)	O
.	O

During	O
the	O
course	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
serum	O
urea	B-Chemical
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1	O
(	O
-/-	O
)	O
mice	O
than	O
in	O
sgk1	O
(	O
+/+	O
)	O
mice	O
leading	O
to	O
uremia	B-Disease
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1	O
(	O
-/-	O
)	O
mice	O
(	O
29	O
vs.	O
40	O
days	O
in	O
sgk1	O
(	O
+/+	O
)	O
mice	O
)	O
.	O

In	O
conclusion	O
,	O
gene-targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	B-Disease
retention	I-Disease
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	O
fibrosis	B-Disease
during	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

Severe	O
and	O
long	O
lasting	O
cholestasis	B-Disease
after	O
high-dose	O
co-trimoxazole	B-Chemical
treatment	O
for	O
Pneumocystis	B-Disease
pneumonia	I-Disease
in	O
HIV-infected	B-Disease
patients	O
--	O
a	O
report	O
of	O
two	O
cases	O
.	O

Pneumocystis	B-Disease
pneumonia	I-Disease
(	O
PCP	B-Disease
)	O
,	O
a	O
common	O
opportunistic	B-Disease
infection	I-Disease
in	O
HIV-infected	B-Disease
individuals	O
,	O
is	O
generally	O
treated	O
with	O
high	O
doses	O
of	O
co-trimoxazole	B-Chemical
.	O

However	O
,	O
treatment	O
is	O
often	O
limited	O
by	O
adverse	O
effects	O
.	O

Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV-infected	B-Disease
patients	O
who	O
developed	O
severe	O
intrahepatic	B-Disease
cholestasis	I-Disease
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B-Disease
abscess	I-Disease
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co-trimoxazole	B-Chemical
treatment	O
for	O
PCP	B-Disease
.	O

Whereas	O
patient	O
1	O
showed	O
lesions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
detectable	O
on	O
magnetic	O
resonance	O
imaging	O
under	O
prolonged	O
co-trimoxazole	B-Chemical
treatment	O
,	O
therapy	O
of	O
patient	O
2	O
was	O
switched	O
early	O
.	O

Clinically	O
significant	O
proteinuria	B-Disease
following	O
the	O
administration	O
of	O
sirolimus	B-Chemical
to	O
renal	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection	O
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	B-Disease
than	O
calcineurin	O
inhibitor	O
(	O
CNI	O
)	O
-based	O
regimens	O
.	O

To	O
date	O
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	O
significant	O
proteinuria	B-Disease
linked	O
with	O
the	O
use	O
of	O
sirolimus	B-Chemical
.	O

We	O
have	O
encountered	O
several	O
patients	O
who	O
developed	O
substantial	O
proteinuria	B-Disease
associated	O
with	O
sirolimus	B-Chemical
use	O
.	O

In	O
each	O
patient	O
,	O
the	O
close	O
temporal	O
association	O
between	O
the	O
commencement	O
of	O
sirolimus	B-Chemical
therapy	O
and	O
proteinuria	B-Disease
implicated	O
sirolimus	B-Chemical
as	O
the	O
most	O
likely	O
etiology	O
of	O
the	O
proteinuria	B-Disease
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
clinical	O
and	O
laboratory	O
information	O
available	O
for	O
all	O
119	O
patients	O
transplanted	O
at	O
the	O
Washington	O
Hospital	O
Center	O
between	O
1999-2003	O
for	O
whom	O
sirolimus	B-Chemical
was	O
a	O
component	O
of	O
their	O
immunosuppressant	O
regimen	O
.	O

In	O
these	O
patients	O
,	O
the	O
magnitude	O
of	O
proteinuria	B-Disease
was	O
assessed	O
on	O
morning	O
urine	O
samples	O
by	O
turbidometric	O
measurement	O
or	O
random	O
urine	O
protein	O
:	O
creatinine	B-Chemical
ratios	O
,	O
an	O
estimate	O
of	O
grams	O
of	O
proteinuria/day	B-Disease
.	O

Laboratory	O
results	O
were	O
compared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolimus	B-Chemical
use	O
.	O

RESULTS	O
:	O
Twenty-eight	O
patients	O
(	O
24	O
%	O
)	O
developed	O
increased	O
proteinuria	B-Disease
from	O
baseline	O
during	O
their	O
post-transplantation	O
course	O
.	O

In	O
21	O
patients	O
an	O
alternative	O
cause	O
of	O
proteinuria	B-Disease
was	O
either	O
obvious	O
or	O
insufficient	O
data	O
was	O
available	O
to	O
be	O
conclusive	O
.	O

In	O
7	O
of	O
the	O
28	O
patients	O
there	O
was	O
a	O
striking	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
sirolimus	B-Chemical
and	O
the	O
development	O
of	O
nephrotic-range	B-Disease
proteinuria	B-Disease
.	O

Proteinuria	B-Disease
correlated	O
most	O
strongly	O
with	O
sirolimus	B-Chemical
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	O
variables	O
.	O

In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	B-Chemical
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	B-Disease
.	O

CONCLUSIONS	O
:	O
Sirolimus	B-Chemical
induces	O
or	O
aggravates	O
pre-existing	O
proteinuria	B-Disease
in	O
an	O
unpredictable	O
subset	O
of	O
renal	O
allograft	O
recipients	O
.	O

Proteinuria	B-Disease
may	O
improve	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolimus	B-Chemical
is	O
withdrawn	O
.	O

Comparative	O
cognitive	O
and	O
subjective	O
side	O
effects	O
of	O
immediate-release	O
oxycodone	B-Chemical
in	O
healthy	O
middle-aged	O
and	O
older	O
adults	O
.	O

This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10-mg	O
dose	O
of	O
immediate-release	O
oxycodone	B-Chemical
in	O
healthy	O
,	O
older	O
(	O
>	O
65	O
years	O
)	O
,	O
and	O
middle-aged	O
(	O
35	O
to	O
55	O
years	O
)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	B-Disease
.	O

Seventy-one	O
participants	O
completed	O
2	O
separate	O
study	O
days	O
and	O
were	O
blind	O
to	O
medication	O
condition	O
(	O
placebo	O
,	O
10-mg	O
oxycodone	B-Chemical
)	O
.	O

Plasma	O
oxycodone	B-Chemical
concentration	O
peaked	O
between	O
60	O
and	I-Disease
90	O
minutes	O
postdose	O
(	O
P	O
<	O
.01	O
)	O
and	I-Disease
pupil	O
size	O
,	I-Disease
an	O
indication	O
of	O
physiological	O
effects	O
of	O
the	O
medication	O
,	I-Disease
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutes	O
postdose	O
(	O
P	O
<	O
.01	O
)	O
.	O

Significant	O
declines	B-Disease
in	B-Disease
simple	I-Disease
and	I-Disease
sustained	I-Disease
attention	I-Disease
,	I-Disease
working	I-Disease
memory	I-Disease
,	O
and	I-Chemical
verbal	O
memory	O
were	O
observed	O
at	O
1	O
hour	O
postdose	O
compared	O
to	O
baseline	O
for	O
both	O
age	O
groups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseline	O
by	O
5	O
hours	O
postdose	O
.	O

For	O
almost	O
all	O
cognitive	O
measures	O
,	O
there	O
were	O
no	O
medication	O
by	O
age-interaction	O
effects	O
,	O
which	O
indicates	O
that	O
the	O
2	O
age	O
groups	O
exhibited	O
similar	O
responses	O
to	O
the	O
medication	O
challenge	O
.	O

This	O
study	O
suggests	O
that	O
for	O
healthy	O
older	O
adults	O
who	O
are	O
not	O
suffering	O
from	O
chronic	O
pain	O
,	O
neurocognitive	O
and	I-Chemical
pharmacodynamic	O
changes	O
in	B-Chemical
response	O
to	O
a	O
10-mg	O
dose	O
of	O
immediate-release	O
oxycodone	B-Drug
are	O
similar	O
to	O
those	O
observed	O
for	O
middle-aged	O
adults	O
.	O

PERSPECTIVE	O
:	O
Study	O
findings	O
indicate	O
that	O
the	O
metabolism	O
,	O
neurocognitive	O
effects	O
,	O
and	I-Chemical
physical	O
side	O
effects	O
of	O
oral	O
oxycodone	B-Drug
are	O
similar	O
for	O
healthy	O
middle-aged	O
and	I-Chemical
older	O
adults	O
.	O

Therefore	O
,	O
clinicians	O
should	O
not	O
avoid	O
prescribing	O
oral	O
opioids	O
to	O
older	O
adults	O
based	O
on	O
the	O
belief	O
that	O
older	O
adults	O
are	O
at	O
higher	O
risk	O
for	O
side	O
effects	O
than	O
younger	O
adults	O
.	O

Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning-dosed	O
modafinil	B-Chemical
on	O
sleep	O
and	O
daytime	B-Disease
sleepiness	I-Disease
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O

METHOD	O
:	O
Twenty	O
cocaine-dependent	B-Chemical
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	B-Chemical
,	O
400	O
mg	O
(	O
N=10	O
)	O
,	O
or	O
placebo	O
(	O
N=10	O
)	O
every	O
morning	O
at	O
7:30	O
a.m.	O
for	O
16	O
days	O
in	O
an	O
inpatient	O
,	O
double-blind	O
randomized	O
trial	O
.	O

Participants	O
underwent	O
polysomnographic	O
sleep	O
recordings	O
on	O
days	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeks	O
of	O
abstinence	O
)	O
.	O

The	O
Multiple	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11:30	O
a.m.	O
,	O
2:00	O
p.m.	O
,	O
and	O
4:30	O
p.m.	O
on	O
days	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O

For	O
comparison	O
of	O
sleep	O
architecture	O
variables	O
,	O
12	O
healthy	O
comparison	O
participants	O
underwent	O
a	O
single	O
night	O
of	O
experimental	O
polysomnography	O
that	O
followed	O
1	O
night	O
of	O
accommodation	O
polysomnography	O
.	O

RESULTS	O
:	O
Progressive	O
abstinence	O
from	O
cocaine	B-Chemical
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O

Compared	O
with	O
placebo	O
,	O
modafinil	B-Chemical
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow-wave	O
sleep	O
time	O
in	O
cocaine-dependent	B-Chemical
participants	O
.	O

The	O
effect	O
of	O
modafinil	B-Chemical
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O

Comparison	O
of	O
slow-wave	O
sleep	O
time	O
,	O
total	O
sleep	O
time	O
,	O
and	O
sleep	O
latency	O
in	O
cocaine-dependent	B-Chemical
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	B-Chemical
in	O
cocaine-dependent	B-Chemical
participants	O
.	O

Modafinil	B-Chemical
was	O
associated	O
with	O
increased	O
daytime	B-Disease
sleep	O
latency	O
,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B-Disease
sleepiness	O
.	O

CONCLUSIONS	O
:	O
Morning-dosed	O
modafinil	B-Chemical
promotes	O
nocturnal	O
sleep	O
,	O
normalizes	O
sleep	O
architecture	O
,	O
and	O
decreases	O
daytime	B-Disease
sleepiness	I-Disease
in	O
abstinent	O
cocaine	B-Chemical
users	O
.	O

These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	B-Chemical
dependence	O
.	O

Efficacy	O
and	O
safety	O
of	O
asenapine	B-Chemical
in	O
a	O
placebo-	O
and	O
haloperidol-controlled	B-Chemical
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	B-Disease
.	O

Asenapine	B-Chemical
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	B-Drug
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	B-Disease
or	O
of	O
manic	B-Disease
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B-Disease
I	I-Disease
disorder	I-Disease
with	O
or	O
without	O
psychotic	B-Disease
features	O
.	O

In	O
a	O
double-blind	O
6-week	O
trial	O
,	O
458	O
patients	O
with	O
acute	O
schizophrenia	B-Disease
were	O
randomly	O
assigned	O
to	O
fixed-dose	O
treatment	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	B-Chemical
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O

With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
(	O
-16.2	O
)	O
and	O
haloperidol	B-Chemical
(	O
-15.4	O
)	O
than	O
placebo	O
(	O
-10.7	O
;	O
both	O
P	O
<	O
0.05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-21.3	O
and	O
-19.4	O
,	O
respectively	O
)	O
and	O
haloperidol	B-Chemical
(	O
-20.0	O
)	O
than	O
placebo	O
(	O
-14.6	O
;	O
all	O
P	O
<	O
0.05	O
)	O
.	O

On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale	O
,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O

Treatment-related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Extrapyramidal	B-Disease
symptoms	I-Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Across	O
all	O
groups	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patients	O
had	O
clinically	O
significant	O
weight	O
change	O
.	O

Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	B-Chemical
and	O
haloperidol	B-Chemical
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O

Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
.	O

BACKGROUND/AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-Disease
starts	O
.	O

Using	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
(	O
PAN	O
)	O
rats	O
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte-associated	O
molecules	O
nephrin	O
,	O
a-actinin	O
,	O
dendrin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O

METHODS	O
:	O
Using	O
immune	O
stainings	O
,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O

Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O

Possible	O
effects	O
of	O
ACE	O
inhibition	O
were	O
tested	O
.	O

RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B-Disease
,	O
appeared	O
.	O

The	O
amount	O
of	O
nephrin	O
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O

The	O
other	O
proteins	O
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O

By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B-Disease
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O

Nephrin	O
decreased	O
further	O
,	O
while	O
dendrin	O
and	O
plekhh2	O
also	O
decreased	O
but	O
a-actinin	O
remained	O
unchanged	O
.	O

ACE	O
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O

CONCLUSIONS	O
:	O
PAN	O
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	B-Disease
.	O

This	O
was	O
preceded	O
by	O
altered	O
nephrin	O
expression	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O

The	O
novel	O
proteins	O
dendrin	O
and	O
plekhh2	O
were	O
both	O
reduced	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a-actinin	O
was	O
unchanged	O
.	O

Twin	O
preterm	O
neonates	O
with	O
cardiac	B-Disease
toxicity	I-Disease
related	O
to	O
lopinavir/ritonavir	B-Chemical
therapy	O
.	O

We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
infection	I-Disease
.	O

One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	B-Disease
block	I-Disease
and	O
dilated	B-Disease
cardiomyopathy	I-Disease
related	O
to	O
lopinavir/ritonavir	B-Chemical
therapy	O
,	O
a	O
boosted	O
protease-inhibitor	O
agent	O
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	B-Disease
.	O

We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopinavir/ritonavir	B-Chemical
in	O
the	O
immediate	O
neonatal	O
period	O
.	O

Learning	O
of	O
rats	O
under	O
amnesia	B-Disease
caused	O
by	O
pentobarbital	B-Chemical
.	O

Dissociated	O
learning	O
of	O
rats	O
in	O
the	O
normal	O
state	O
and	O
the	O
state	O
of	O
amnesia	B-Disease
produced	O
by	O
pentobarbital	B-Chemical
(	O
15	O
mg/kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O

Rats	O
were	O
trained	O
to	O
approach	O
a	O
shelf	O
where	O
they	O
received	O
food	O
reinforcement	O
.	O

In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	B-Chemical
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	O
.	O

In	O
Group	O
2	O
the	O
rats	O
were	O
trained	O
to	O
approach	O
different	O
shelves	O
in	O
different	O
drug	B-Drug
states	O
.	O

It	O
was	O
shown	O
that	O
memory	B-Disease
dissociation	I-Disease
occurred	O
in	O
both	O
groups	O
.	O

Differences	O
in	O
the	O
parameters	O
of	O
training	O
under	O
the	O
influence	O
of	O
pentobarbital	B-Chemical
between	O
Groups	O
1	O
and	O
2	O
were	O
revealed	O
.	O

These	O
findings	O
show	O
that	O
the	O
brain-dissociated	O
state	O
induced	O
by	O
pentobarbital	B-Chemical
is	O
formed	O
with	O
the	O
participation	O
of	O
the	O
mechanisms	O
of	O
information	O
perception	O
.	O

Angiosarcoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
associated	O
with	O
diethylstilbestrol	B-Drug
.	O

Angiosarcoma	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
occurred	O
in	O
a	O
76-year-old	O
man	O
who	O
had	O
been	O
treated	O
for	O
a	O
well-differentiated	O
adenocarcinoma	O
of	O
the	O
liver	O
with	O
diethylstilbestrol	B-Drug
for	O
13	O
years	O
.	O

Angiosarcoma	B-Chemical
was	O
also	O
present	O
within	O
pulmonary	O
and	O
renal	O
arteries	O
.	O

The	O
possibility	O
that	O
the	I-Chemical
intraarterial	O
lesions	O
might	O
represent	O
independent	O
primary	O
tumors	O
is	O
considered	O
.	O

Role	O
of	O
xanthine	B-Chemical
oxidase	O
in	O
dexamethasone-induced	B-Chemical
hypertension	B-Disease
in	O
rats	O
.	O

1	O
.	O

Glucocorticoid-induced	O
hypertension	B-Disease
(	O
GC-HT	B-Disease
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	B-Chemical
oxide-redox	O
imbalance	O
.	O

2	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthine	O
oxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
in	O
dexamethasone-induced	O
hypertension	O
(	O
dex-HT	O
)	O
.	O

3	O
.	O

Thirty	O
male	O
Sprague-Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
,	O
dexamethasone	B-Drug
(	O
dex	O
)	O
,	O
allopurinol	B-Drug
plus	O
saline	O
,	O
and	O
allopurinol	B-Drug
plus	O
dex	O
.	O

4	O
.	O

Systolic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
,	O
and	O
serum	O
urate	O
to	O
assess	O
XO	O
inhibition	O
.	O

5	O
.	O

Dex	O
increased	O
SBP	O
(	O
110	O
+/-	O
2-126	O
+/-	O
3	O
mmHg	O
;	O
P	O
<	O
0.001	O
)	O
and	O
decreased	O
thymus	O
(	O
P	O
<	O
0.001	O
)	O
and	O
bodyweights	O
(	O
P	O
''	O
<	O
0.01	O
)	O
.	O

Allopurinol	B-Drug
decreased	O
serum	O
urate	O
from	O
76	O
+/-	O
5	O
to	O
30	O
+/-	O
3	O
micromol/L	O
(	O
P	O
<	O
0.001	O
)	O
in	O
saline	O
and	O
from	O
84	O
+/-	O
13	O
to	O
28	O
+/-	O
2	O
micromol/L	O
in	O
dex-treated	O
(	O
P	O
<	O
0.01	O
)	O
groups	O
.	O

6	O
.	O

Allopurinol	B-Drug
did	O
not	O
prevent	O
dex-HT	O
.	O

This	O
,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	B-Drug
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	O
,	O
suggests	O
that	O
XO	O
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC-HT	O
in	O
the	O
rat	O
.	O

Extrapyramidal	O
side	O
effects	O
with	O
risperidone	B-Chemical
and	O
haloperidol	B-Chemical
at	O
comparable	O
D2	O
receptor	O
occupancy	O
levels	O
.	O

Risperidone	B-Chemical
is	O
an	O
antipsychotic	O
drug	B-Drug
with	O
high	O
affinity	O
at	O
dopamine	B-Chemical
D2	O
and	O
serotonin	B-Chemical
5-HT2	I-Chemical
receptors	O
.	O

Previous	O
clinical	O
studies	O
have	O
proposed	O
that	O
risperidone	B-Chemical
's	O
pharmacologic	O
profile	O
may	O
produce	O
improved	O
efficacy	O
for	O
negative	O
psychotic	B-Disease
symptoms	I-Disease
and	O
decreased	O
propensity	O
for	O
extrapyramidal	O
side	O
effects	O
;	O
features	O
shared	O
by	O
so-called	O
'atypical	O
'	O
neuroleptics	O
.	O

To	O
determine	O
if	O
routine	O
risperidone	B-Chemical
treatment	O
is	O
associated	O
with	O
a	O
unique	O
degree	O
of	O
D2	O
receptor	O
occupancy	O
and	O
pattern	O
of	O
clinical	O
effects	O
,	O
we	O
used	O
[	O
123I	O
]	O
IBZM	O
SPECT	O
to	O
determine	O
D2	O
occupancy	O
in	O
subjects	O
treated	O
with	O
routine	O
clinical	O
doses	O
of	O
risperidone	B-Chemical
(	O
n	O
=	O
12	O
)	O
or	O
haloperidol	B-Chemical
(	O
n	O
=	O
7	O
)	O
.	O

Both	O
risperidone	B-Chemical
and	O
haloperidol	B-Chemical
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standard	O
clinical	O
doses	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
occupancy	O
levels	O
obtained	O
with	O
haloperidol	B-Chemical
or	O
risperidone	B-Chemical
.	O

Drug-induced	B-Disease
parkinsonism	I-Disease
was	O
observed	O
in	O
subjects	O
treated	O
with	O
risperidone	B-Chemical
(	O
42	O
%	O
)	O
and	O
haloperidol	B-Chemical
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60	O
%	O
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
concluded	O
that	O
5-HT2	O
blockade	O
obtained	O
with	O
risperidone	B-Chemical
at	O
D2	O
occupancy	O
rates	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
risk	O
for	O
extrapyramidal	O
side	O
effects	O
.	O

Simvastatin-ezetimibe-induced	B-Chemical
hepatic	B-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
.	O

Abstract	O
Serum	O
aminotransferase	O
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3-hydroxy-3-methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitor	O
(	O
statin	B-Chemical
)	O
therapy	O
.	O

However	O
,	O
hepatotoxic	B-Disease
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	B-Chemical
or	O
the	O
combination	O
agent	O
simvastatin-ezetimibe	B-Chemical
.	O

We	O
describe	O
a	O
70-year-old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	B-Chemical
40	I-Chemical
mg/day	O
to	O
simvastatin	B-Chemical
10	I-Chemical
mg-ezetimibe	I-Chemical
40	I-Chemical
mg/day	O
.	O

The	O
patient	O
's	O
lipid	O
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	B-Chemical
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	B-Disease
.	O

A	O
routine	O
laboratory	O
work-up	O
10	O
weeks	O
after	O
conversion	O
revealed	O
elevated	O
serum	O
aminotransferase	O
levels	O
.	O

Simvastatinezetimibe	B-Chemical
and	O
escitalopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B-Disease
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	B-Disease
were	O
excluded	O
.	O

A	O
repeat	O
work-up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	O
levels	O
,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate-to-severe	O
drug	B-Disease
toxicity	I-Disease
.	O

She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course	O
.	O

Her	O
aminotransferase	O
levels	O
returned	O
to	O
normal	O
by	O
postoperative	O
day	O
23	O
,	O
and	O
her	O
2-year	O
follow-up	O
showed	O
no	O
adverse	O
events	O
.	O

Ezetimibe	B-Chemical
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	B-Chemical
diphosphate	I-Chemical
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-Chemical
hydroxy	I-Chemical
acid	I-Chemical
,	O
resulting	O
in	O
increased	O
simvastatin	B-Chemical
exposure	O
and	O
subsequent	O
hepatotoxicity	B-Disease
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin-ezetimibe-induced	B-Chemical
liver	B-Disease
failure	I-Disease
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O

We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe-induced	B-Chemical
hepatotoxicity	B-Disease
is	O
the	O
increased	O
simvastatin	B-Chemical
exposure	O
by	O
ezetimibe	B-Chemical
inhibition	O
of	O
UGT	O
enzymes	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	B-Disease
with	O
simvastatin-ezetimibe	B-Chemical
especially	O
in	O
elderly	O
patients	O
and	O
should	O
carefully	O
monitor	O
serum	O
aminotransferase	O
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O

Oral	O
manifestations	O
of	O
``	O
meth	B-Disease
mouth	I-Disease
''	O
:	O
a	O
case	O
report	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
``	O
meth	B-Disease
mouth	I-Disease
''	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O

BACKGROUND	O
:	O
Methamphetamine	B-Chemical
is	O
a	O
very	O
addictive	O
,	O
powerful	O
stimulant	O
that	O
increases	O
wakefulness	O
and	O
physical	O
activity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cardiac	B-Disease
dysrhythmias	I-Disease
,	O
hypertension	B-Disease
,	O
hallucinations	B-Disease
,	O
and	O
violent	B-Disease
behavior	I-Disease
.	O

Dental	O
patients	O
abusing	O
methamphetamine	B-Chemical
can	O
present	O
with	O
poor	O
oral	O
hygiene	O
,	O
xerostomia	B-Disease
,	O
rampant	O
caries	B-Disease
(	O
``	O
meth	B-Disease
mouth	I-Disease
''	O
)	O
,	O
and	O
excessive	O
tooth	B-Disease
wear	I-Disease
.	O

Oral	O
rehabilitation	O
of	O
patients	O
using	O
methamphetamine	B-Chemical
can	O
be	O
challenging	O
.	O

CASE	O
DESCRIPTION	O
:	O
A	O
30-year-old	O
Caucasian	O
woman	O
presented	O
with	O
dental	O
pain	B-Disease
,	O
bad	B-Disease
breath	I-Disease
,	O
and	O
self-reported	O
poor	O
esthetics	O
.	O

A	O
comprehensive	O
examination	O
including	O
her	O
medical	O
history	O
,	O
panoramic	O
radiograph	O
,	O
and	O
intraoral	O
examination	O
revealed	O
19	O
carious	B-Disease
lesions	I-Disease
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healthy	O
adult	O
.	O

She	O
reported	O
her	O
use	O
of	O
methamphetamine	B-Chemical
for	O
five	O
years	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carious	B-Disease
episodes	I-Disease
before	O
she	O
started	O
using	O
the	O
drug	B-Drug
.	O

SUMMARY	O
:	O
The	O
patient	O
's	O
medical	O
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	O
findings	O
lead	B-Drug
to	O
a	O
diagnosis	O
of	O
``	O
meth	B-Disease
mouth	I-Disease
.	O

''	O
Although	O
three	O
different	O
dental	O
treatment	O
modalities	O
(	O
either	O
conventional	O
or	O
implant-supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patient	O
since	O
August	O
2007	O
,	O
the	O
patient	O
has	O
yet	O
to	O
initiate	O
any	O
treatment	O
.	O

CLINICAL	O
SIGNIFICANCE	O
:	O
This	O
clinical	O
case	O
showing	O
oral	O
manifestations	O
of	O
meth	B-Disease
mouth	I-Disease
was	O
presented	O
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	O
who	O
may	O
be	O
abusing	O
methamphetamines	B-Chemical
.	O

Dental	O
practitioners	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliability	O
of	O
appointment	O
keeping	O
by	O
these	O
patients	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appointments	O
without	O
reasonable	O
justification	O
.	O

Thyroxine	B-Chemical
abuse	O
:	O
an	O
unusual	O
case	O
of	O
thyrotoxicosis	B-Disease
in	O
pregnancy	O
.	O

Eating	B-Disease
disorders	I-Disease
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	B-Disease
abuse	I-Disease
are	O
uncommon	O
in	O
pregnancy	O
.	O

When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
denial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
risk	O
to	O
both	O
the	O
mother	O
and	O
her	O
fetus	O
.	O

This	O
case	O
illustrates	O
a	O
number	O
of	O
problems	O
that	O
may	O
be	O
encountered	O
in	O
women	O
with	O
eating	B-Disease
disorders	I-Disease
in	O
pregnancy	O
,	O
including	O
prolonged	O
and	O
recurrent	O
metabolic	O
disturbances	O
and	O
diuretic	B-Drug
abuse	O
.	O

In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	B-Drug
function	O
seen	O
in	O
pregnant	O
women	O
with	O
eating	B-Disease
disorders	I-Disease
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	B-Disease
remains	O
obscure	O
,	O
thyroxine	B-Chemical
abuse	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Attenuation	O
of	O
methamphetamine-induced	B-Chemical
nigrostriatal	O
dopaminergic	B-Drug
neurotoxicity	B-Disease
in	O
mice	O
by	O
lipopolysaccharide	B-Chemical
pretreatment	O
.	O

Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine-induced	B-Chemical
dopaminergic	B-Disease
terminal	I-Disease
damage	I-Disease
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	B-Chemical
,	O
a	O
pro-inflammatory	O
and	O
inflammatory	O
factor	O
,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine-induced	B-Chemical
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O

Lipopolysaccharide	B-Chemical
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine-elicited	B-Chemical
hyperthermia	B-Disease
three	O
days	O
later	O
.	O

Such	O
systemic	O
lipopolysaccharide	B-Chemical
treatment	O
mitigated	O
methamphetamine-induced	B-Chemical
striatal	O
dopamine	B-Chemical
and	O
3,4-dihydroxyphenylacetic	B-Chemical
acid	I-Chemical
depletions	O
in	O
a	O
dose-dependent	O
manner	O
.	O

As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg/kg	O
)	O
of	O
lipopolysaccharide	B-Chemical
was	O
administered	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	B-Chemical
dosing	O
regimen	O
,	O
methamphetamine-induced	B-Chemical
striatal	O
dopamine	B-Chemical
and	O
3,4-dihydroxyphenylacetic	B-Chemical
acid	I-Chemical
depletions	O
remained	O
unaltered	O
.	O

Moreover	O
,	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
(	O
1	O
mg/kg	O
)	O
attenuated	O
local	O
methamphetamine	B-Chemical
infusion-produced	O
dopamine	B-Chemical
and	O
3,4-dihydroxyphenylacetic	B-Chemical
acid	I-Chemical
depletions	O
in	O
the	O
striatum	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	B-Chemical
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	B-Chemical
.	O

We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine-induced	B-Chemical
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O

Effect	O
of	O
converting	O
enzyme	O
inhibition	O
on	O
the	O
course	O
of	O
adriamycin-induced	B-Chemical
nephropathy	B-Disease
.	O

The	O
effect	O
of	O
the	O
converting	O
enzyme	O
inhibitor	O
(	O
CEI	O
)	O
enalapril	B-Chemical
was	O
assessed	O
in	O
Munich-Wistar	O
rats	O
with	O
established	O
adriamycin	B-Chemical
nephrosis	B-Disease
.	O

Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	B-Chemical
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	B-Disease
,	O
blood	O
pressure	O
,	O
and	O
plasma	O
albumin	O
concentration	O
.	O

Groups	O
1	O
and	O
3	O
remained	O
untreated	O
while	O
groups	O
2	O
and	O
4	O
received	O
enalapril	B-Chemical
.	O

Groups	O
1	O
and	O
2	O
underwent	O
micropuncture	O
studies	O
after	O
10	O
days	O
.	O

These	O
short-term	O
studies	O
showed	O
that	O
enalapril	B-Chemical
reduced	O
arterial	O
blood	O
pressure	O
(	O
101	O
+/-	O
2	O
vs.	O
124	O
+/-	O
3	O
mm	O
Hg	O
,	O
group	O
2	O
vs.	O
1	O
,	O
P	O
less	O
than	O
0.05	O
)	O
and	O
glomerular	O
capillary	O
pressure	O
(	O
54	O
+/-	O
1	O
vs.	O
61	O
+/-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0.05	O
)	O
without	O
reducing	O
albuminuria	B-Disease
(	O
617	O
+/-	O
50	O
vs.	O
570	O
+/-	O
47	O
mg/day	O
)	O
or	O
GFR	O
(	O
1.03	O
+/-	O
0.04	O
vs.	O
1.04	O
+/-	O
0.11	O
ml/min	O
)	O
.	O

Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	O
to	O
assess	O
the	O
effect	O
of	O
enalapril	B-Chemical
on	O
progression	O
of	O
renal	B-Disease
injury	I-Disease
in	O
adriamycin	B-Chemical
nephrosis	B-Disease
.	O

Chronic	O
enalapril	B-Chemical
treatment	O
reduced	O
blood	O
pressure	O
without	O
reducing	O
albuminuria	B-Disease
in	O
group	O
4	O
.	O

Untreated	O
group	O
3	O
rats	O
exhibited	O
a	O
progressive	O
reduction	O
in	O
GFR	O
(	O
0.35	O
+/-	O
0.08	O
ml/min	O
at	O
4	O
months	O
,	O
0.27	O
+/-	O
0.07	O
ml/min	O
at	O
6	O
months	O
)	O
.	O

Enalapril	B-Chemical
treatment	O
blunted	O
but	O
did	O
not	O
prevent	O
reduction	O
in	O
GFR	O
in	O
group	O
4	O
(	O
0.86	O
+/-	O
0.15	O
ml/min	O
at	O
4	O
months	O
,	O
0.69	O
+/-	O
0.13	O
ml/min	O
at	O
6	O
months	O
,	O
both	O
P	O
less	O
than	O
0.05	O
vs.	O
group	O
3	O
)	O
.	O

Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
both	O
treated	O
and	O
untreated	O
rats	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Butyrylcholinesterase	O
gene	O
mutations	O
in	O
patients	O
with	O
prolonged	O
apnea	B-Disease
after	O
succinylcholine	B-Chemical
for	O
electroconvulsive	O
therapy	O
.	O

BACKGROUND	O
:	O
patients	O
undergoing	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcholine	B-Chemical
as	O
part	O
of	O
the	O
anesthetic	B-Drug
procedure	O
.	O

The	O
duration	O
of	O
action	O
may	O
be	O
prolonged	O
in	O
patients	O
with	O
genetic	O
variants	O
of	O
the	O
butyrylcholinesterase	O
enzyme	O
(	O
BChE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K-	O
and	O
the	O
A-variants	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	O
gene	O
(	O
BCHE	O
)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
after	O
ECT	O
.	O

METHODS	O
:	O
a	O
total	O
of	O
13	O
patients	O
were	O
referred	O
to	O
the	O
Danish	O
Cholinesterase	O
Research	O
Unit	O
after	O
ECT	O
during	O
38	O
months	O
.	O

We	O
determined	O
the	O
BChE	O
activity	O
and	O
the	O
BCHE	O
genotype	O
using	O
molecular	O
genetic	O
methods	O
,	O
the	O
duration	O
of	O
apnea	B-Disease
,	O
time	O
to	O
sufficient	O
spontaneous	O
ventilation	O
and	O
whether	O
neuromuscular	O
monitoring	O
was	O
used	O
.	O

The	O
duration	O
of	O
apnea	B-Disease
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects	O
.	O

RESULTS	O
:	O
in	O
11	O
patients	O
,	O
mutations	O
were	O
found	O
in	O
the	O
BCHE	O
gene	O
,	O
the	O
K-variant	O
being	O
the	O
most	O
frequent	O
.	O

The	O
duration	O
of	O
apnea	B-Disease
was	O
5-15	O
min	O
compared	O
with	O
3-5.3	O
min	O
from	O
the	O
literature	O
.	O

Severe	O
distress	O
was	O
noted	O
in	O
the	O
recovery	O
phase	O
in	O
two	O
patients	O
.	O

Neuromuscular	O
monitoring	O
was	O
used	O
in	O
two	O
patients	O
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
had	O
mutations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	B-Disease
.	O

We	O
recommend	O
objective	O
neuromuscular	O
monitoring	O
during	O
the	O
first	O
ECT	O
.	O

Ketamine	B-Chemical
sedation	O
for	O
the	O
reduction	O
of	O
children	O
's	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	O

BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	B-Chemical
,	O
a	O
unique	O
anesthetic	B-Drug
,	O
for	O
emergency-department	O
procedures	O
requiring	O
sedation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	B-Chemical
for	O
sedation	O
in	O
the	O
treatment	O
of	O
children	O
's	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5.3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	B-Disease
or	O
dislocation	B-Disease
in	O
the	O
emergency	O
department	O
at	O
a	O
level-I	O
trauma	B-Disease
center	O
were	O
prospectively	O
evaluated	O
.	O

Ketamine	B-Chemical
hydrochloride	I-Chemical
was	O
administered	O
intravenously	O
(	O
at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
ninety-nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

A	O
board-certified	O
emergency	O
physician	O
skilled	O
in	O
airway	O
management	O
supervised	O
administration	O
of	O
the	O
anesthetic	B-Drug
,	O
and	O
the	O
patients	O
were	O
monitored	O
by	O
a	O
registered	O
nurse	O
.	O

Any	O
pain	B-Disease
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	O
(	O
CHEOPS	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	B-Chemical
to	O
manipulation	O
of	O
the	O
fracture	B-Disease
or	O
dislocation	B-Disease
was	O
one	O
minute	O
and	O
thirty-six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty-two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	O
was	O
6.4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	B-Disease
during	O
fracture	B-Disease
reduction	O
.	O

Adequate	O
fracture	B-Disease
reduction	O
was	O
obtained	O
in	O
111	O
of	O
the	O
children	O
.	O

Ninety-nine	O
percent	O
(	O
sixty-eight	O
)	O
of	O
the	O
sixty-nine	O
parents	O
present	O
during	O
the	O
reduction	O
were	O
pleased	O
with	O
the	O
sedation	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O

Patency	O
of	O
the	O
airway	O
and	O
independent	O
respiration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
patients	O
.	O

Blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
stable	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	B-Disease
(	O
thirteen	O
patients	O
)	O
,	O
emesis	B-Disease
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	B-Disease
)	O
,	O
clumsiness	B-Disease
(	O
evident	O
as	O
ataxic	B-Disease
movements	I-Disease
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-Disease
reaction	I-Disease
(	O
one	O
patient	O
)	O
.	O

No	O
long-term	O
sequelae	O
were	O
noted	O
,	O
and	O
no	O
patients	O
had	O
hallucinations	B-Disease
or	O
nightmares	O
.	O

CONCLUSIONS	O
:	O
Ketamine	B-Chemical
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	O
of	O
children	O
's	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O

Ketamine	B-Chemical
should	O
only	O
be	O
used	O
in	O
an	O
environment	O
such	O
as	O
the	O
emergency	O
department	O
,	O
where	O
proper	O
one-on-one	O
monitoring	O
is	O
used	O
and	O
board-certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	O
in	O
the	O
care	O
of	O
the	O
patient	O
.	O

Prophylactic	O
use	O
of	O
lamivudine	B-Chemical
with	O
chronic	O
immunosuppressive	O
therapy	O
for	O
rheumatologic	B-Disease
disorders	I-Disease
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
report	O
our	O
experience	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylactic	O
administration	O
of	O
lamivudine	B-Chemical
in	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBs	B-Chemical
Ag	I-Chemical
)	O
positive	O
patients	O
with	O
rheumatologic	B-Disease
disease	I-Disease
.	O

From	O
June	O
2004	O
to	O
October	O
2006	O
,	O
11	O
HBs	B-Chemical
Ag	I-Chemical
positive	O
patients	O
with	O
rheumatologic	B-Disease
diseases	I-Disease
,	O
who	O
were	O
on	O
both	O
immunosuppressive	O
and	O
prophylactic	O
lamivudine	B-Chemical
therapies	O
,	O
were	O
retrospectively	O
assessed	O
.	O

Liver	O
function	O
tests	O
,	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
serologic	O
markers	O
,	O
and	O
HBV	O
DNA	O
levels	O
of	O
the	O
patients	O
during	O
follow-up	O
were	O
obtained	O
from	O
hospital	O
file	O
records	O
.	O

Eleven	O
patients	O
(	O
six	O
male	O
)	O
with	O
median	O
age	O
47	O
years	O
(	O
range	O
27-73	O
)	O
,	O
median	O
disease	O
duration	O
50	O
months	O
(	O
range	O
9-178	O
)	O
and	O
median	O
follow-up	O
period	O
of	O
patients	O
13.8	O
months	O
(	O
range	O
5-27	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Lamivudine	B-Chemical
therapy	O
was	O
started	O
3-7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients	O
.	O

Baseline	O
,	O
liver	I-Disease
function	I-Disease
tests	O
were	O
elevated	O
in	O
two	O
patients	O
(	O
fourth	O
patient	O
:	O
ALT:122	O
IU/l	O
,	O
AST:111	O
IU/l	O
,	O
tenth	O
patient	O
:	O
ALT:294	O
IU/l	O
,	O
AST:274	O
IU/l	O
,	O
with	O
minimal	O
changes	O
in	O
the	O
liver	I-Disease
biopsy	O
in	O
both	O
)	O
.	O

Shortly	O
after	O
treatment	O
their	O
tests	O
normalized	O
and	O
during	O
follow-up	O
period	O
none	O
of	O
the	O
patients	O
had	O
abnormal	O
liver	O
function	O
tests	O
.	O

In	O
four	O
patients	O
HBV	O
DNA	O
levels	O
were	O
higher	O
than	O
normal	O
at	O
baseline	O
.	O

Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
increased	O
later	O
.	O

In	O
three	O
additional	O
patients	O
,	O
HBV	O
DNA	O
levels	O
were	O
increased	O
during	O
follow-up	O
.	O

None	O
of	O
the	O
patients	O
had	O
significant	O
clinical	O
sings	O
of	O
HBV	O
activation	O
.	O

Lamivudine	B-Chemical
was	O
well	O
tolerated	O
and	O
was	O
continued	O
in	O
all	O
patients	O
.	O

Prophylactic	O
administration	O
of	O
lamivudine	B-Chemical
in	O
patients	O
who	O
required	O
immunosuppressive	O
therapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolerated	O
and	O
effective	O
in	O
preventing	O
HBV	O
reactivation	O
.	O

Safety	O
of	O
transesophageal	O
echocardiography	O
in	O
adults	O
:	O
study	O
in	O
a	O
multidisciplinary	O
hospital	O
.	O

BACKGROUND	O
:	O
TEE	O
is	O
a	O
semi-invasive	O
tool	O
broadly	O
used	O
and	O
its	O
utilization	O
associated	O
to	O
sedatives	O
drugs	B-Drug
might	O
to	O
affect	O
the	O
procedure	O
safety	O
.	O

OBJECTIVE	O
:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	O
associated	O
to	O
the	O
use	O
of	O
Midazolan	B-Chemical
(	O
MZ	B-Chemical
)	O
and	O
Flumazenil	B-Chemical
(	O
FL	B-Chemical
)	O
and	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
on	O
the	O
event	O
rate	O
.	O

METHOD	O
:	O
prospective	O
study	O
with	O
137	O
patients	O
that	O
underwent	O
TEE	O
with	O
MZ	B-Chemical
associated	O
to	O
moderate	O
sedation	O
.	O

We	O
analyzed	O
the	O
following	O
events	O
:	O
complications	O
related	O
with	O
the	O
topical	O
anesthesia	B-Drug
,	O
with	O
MZ	B-Chemical
use	O
and	O
with	O
the	O
procedure	O
.	O

Uni-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
:	O
age	O
,	O
sex	O
,	O
stroke	B-Disease
,	O
myocardiopathy	B-Disease
(	O
MP	B-Disease
)	O
,	O
duration	O
of	O
the	O
test	O
,	O
mitral	B-Disease
regurgitation	I-Disease
(	O
MR	B-Disease
)	O
and	O
the	O
MZ	B-Chemical
dose	O
.	O

RESULTS	O
:	O
All	O
patients	O
(	O
65+/-16	O
yrs	O
;	O
58	O
%	O
males	O
)	O
finished	O
the	O
examination	O
.	O

The	O
mean	O
doses	O
of	O
MZ	B-Chemical
and	O
FL	B-Chemical
were	O
4.3+/-1.9	O
mg	O
and	O
0.28+/-0.2	O
mg	O
,	O
respectively	O
.	O

The	O
duration	O
of	O
the	O
examination	O
and	O
the	O
mean	O
ejection	O
fraction	O
(	O
EF	O
)	O
were	O
16.4+/-6.1	O
minutes	O
and	O
60+/-9	O
%	O
,	O
respectively	O
.	O

Mild	O
hypoxia	B-Disease
(	O
SO2	O
<	O
90	O
%	O
)	O
was	O
the	O
most	O
common	O
event	O
(	O
11	O
patients	O
)	O
;	O
3	O
patients	O
(	O
2	O
%	O
)	O
presented	O
transient	O
hypoxia	B-Disease
due	O
to	O
upper	O
airway	B-Disease
obstruction	I-Disease
by	O
probe	O
introduction	O
and	O
8	O
(	O
5.8	O
%	O
)	O
due	O
to	O
hypoxia	B-Disease
caused	O
by	O
MZ	B-Chemical
use	O
.	O

Transient	O
hypotension	B-Disease
(	O
SAP	O
<	O
90mmHg	O
)	O
occurred	O
in	O
1	O
patient	O
(	O
0.7	O
%	O
)	O
.	O

The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	B-Disease
,	O
MP	B-Disease
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
doses	O
of	O
MZ	B-Chemical
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
events	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
group	O
with	O
MP	B-Disease
and	O
44	O
%	O
in	O
the	O
group	O
with	O
severe	O
MR	B-Disease
and	O
it	O
can	O
be	O
a	O
factor	O
associated	O
with	O
clinical	O
events	O
in	O
the	O
last	O
group	O
.	O

CONCLUSION	O
:	O
TEE	O
with	O
sedation	O
presents	O
a	O
low	O
rate	O
of	O
events	O
.	O

There	O
were	O
no	O
severe	O
events	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
examinations	O
.	O

Effects	O
of	O
calcium	B-Chemical
channel	O
blockers	O
on	O
bupivacaine-induced	B-Chemical
toxicity	B-Disease
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
calcium	B-Chemical
channel	O
blockers	O
on	O
bupivacaine-induced	B-Chemical
acute	O
toxicity	B-Disease
.	O

For	O
each	O
of	O
the	O
three	O
tested	O
calcium	B-Chemical
channel	O
blockers	O
(	O
diltiazem	B-Chemical
,	O
verapamil	B-Chemical
and	O
bepridil	B-Chemical
)	O
6	O
groups	O
of	O
mice	O
were	O
treated	O
by	O
two	O
different	O
doses	O
,	O
i.e	O
.	O

2	O
and	O
10	O
mg/kg/i.p.	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
for	O
the	O
control	O
group	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutes	O
later	O
,	O
all	O
the	O
animals	O
were	O
injected	O
with	O
a	O
single	O
50	O
mg/kg/i.p	O
.	O

dose	O
of	O
bupivacaine	B-Chemical
.	O

The	O
convulsant	O
activity	O
,	O
the	O
time	O
of	O
latency	O
to	O
convulse	O
and	O
the	O
mortality	O
rate	O
were	O
assessed	O
in	O
each	O
group	O
.	O

The	O
local	O
anesthetic-induced	O
mortality	O
was	O
significantly	O
increased	O
by	O
the	O
three	O
different	O
calcium	B-Chemical
channel	O
blockers	O
.	O

The	O
convulsant	O
activity	O
of	O
bupivacaine	B-Chemical
was	O
not	O
significantly	O
modified	O
but	O
calcium	B-Chemical
channel	O
blockers	O
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine-induced	B-Chemical
convulsions	B-Disease
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	B-Chemical
.	O

Selegiline-induced	B-Chemical
postural	B-Disease
hypotension	I-Disease
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	B-Drug
withdrawal	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B-Disease
's	I-Disease
Disease	I-Disease
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	B-Chemical
per	O
day	O
and	O
L-dopa	B-Chemical
compared	O
with	O
those	O
taking	O
L-dopa	B-Chemical
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	B-Chemical
and	O
L-dopa	B-Chemical
was	O
associated	O
with	O
selective	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	B-Chemical
.	O

This	O
unwanted	O
effect	O
on	O
postural	O
blood	O
pressure	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonomic	O
failure	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	B-Chemical
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	B-Drug
causes	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head-up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	B-Disease
patients	O
receiving	O
selegiline	B-Chemical
and	O
as	O
the	O
drug	B-Drug
was	O
withdrawn	O
.	O

RESULTS	O
:	O
Head-up	O
tilt	O
caused	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B-Disease
patients	O
on	O
selegiline	B-Chemical
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

A	O
lesser	O
degree	O
of	O
orthostatic	B-Disease
hypotension	I-Disease
occurred	O
with	O
standing	O
.	O

Orthostatic	B-Disease
hypotension	I-Disease
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	B-Chemical
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	B-Drug
.	O

Stopping	O
selegiline	B-Chemical
also	O
significantly	O
reduced	B-Disease
the	I-Disease
supine	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
blood	I-Disease
pressures	I-Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	B-Chemical
in	O
combination	O
with	O
L-dopa	B-Chemical
is	O
associated	O
with	O
selective	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non-selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	B-Chemical
and	O
metamphetamine	B-Chemical
are	O
discussed	O
.	O

Explicit	O
episodic	O
memory	O
for	O
sensory-discriminative	O
components	O
of	O
capsaicin-induced	B-Chemical
pain	B-Disease
:	O
immediate	O
and	O
delayed	O
ratings	O
.	O

Pain	B-Disease
memory	O
is	O
thought	O
to	O
affect	O
future	O
pain	B-Disease
sensitivity	O
and	O
thus	O
contribute	O
to	O
clinical	O
pain	B-Disease
conditions	O
.	O

Systematic	O
investigations	O
of	O
the	O
human	O
capacity	O
to	O
remember	O
sensory	O
features	O
of	O
experimental	O
pain	B-Disease
are	O
sparse	O
.	O

In	O
order	O
to	O
address	O
long-term	O
pain	B-Disease
memory	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
intradermal	O
injections	O
of	O
three	O
doses	O
of	O
capsaicin	B-Chemical
(	O
0.05	O
,	O
1	O
and	O
20	O
microg	O
,	O
separated	O
by	O
15	O
min	O
breaks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanced	O
design	O
across	O
three	O
sessions	O
at	O
one	O
week	O
intervals	O
.	O

Pain	B-Disease
rating	O
was	O
performed	O
using	O
a	O
computerized	O
visual	O
analogue	O
scale	O
(	O
0-100	O
)	O
digitized	O
at	O
1/s	O
,	O
either	O
immediately	O
online	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injection	O
.	O

Subjects	O
also	O
recalled	O
their	O
pains	B-Disease
one	O
week	O
later	O
.	O

Capsaicin	B-Chemical
injection	O
reliably	O
induced	O
a	O
dose-dependent	O
flare	O
(	O
p	O
<	O
0.001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O

The	O
strong	O
burning	O
pain	B-Disease
decayed	O
exponentially	O
within	O
a	O
few	O
minutes	O
.	O

Subjects	O
were	O
able	O
to	O
reliably	O
discriminate	O
pain	B-Disease
magnitude	O
and	O
duration	O
across	O
capsaicin	B-Chemical
doses	O
(	O
both	O
p	O
<	O
0.001	O
)	O
,	O
regardless	O
of	O
whether	O
first-time	O
ratings	O
were	O
requested	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O

Pain	B-Disease
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magnitude	O
:	O
p	O
<	O
0.01	O
,	O
duration	O
:	O
p	O
<	O
0.05	O
)	O
.	O

Correlation	O
with	O
rating	O
recall	O
after	O
one	O
week	O
was	O
best	O
when	O
first-time	O
ratings	O
were	O
requested	O
as	O
late	O
as	O
one	O
day	O
after	O
injection	O
(	O
R	O
(	O
2	O
)	O
=0.79	O
)	O
indicating	O
that	O
both	O
rating	O
retrievals	O
utilized	O
similar	O
memory	O
traces	O
.	O

These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	B-Disease
.	O

The	O
data	O
further	O
suggest	O
that	O
the	O
consolidation	O
of	O
this	O
memory	O
is	O
an	O
important	O
interim	O
stage	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
day	O
.	O

Reversibility	O
of	O
captopril-induced	B-Chemical
renal	B-Disease
insufficiency	I-Disease
after	O
prolonged	O
use	O
in	O
an	O
unusual	O
case	O
of	O
renovascular	B-Disease
hypertension	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
severe	O
hypertension	B-Disease
with	O
an	O
occluded	O
renal	I-Disease
artery	O
to	O
a	O
solitary	O
kidney	O
,	O
who	O
developed	O
sudden	B-Disease
deterioration	I-Disease
of	I-Disease
renal	I-Disease
function	O
following	O
treatment	O
with	O
captopril	B-Chemical
.	O

His	O
renal	O
function	O
remained	O
impaired	O
but	O
stable	O
during	O
2	O
years	O
'	O
treatment	O
with	O
captopril	B-Chemical
but	O
returned	O
to	O
pre-treatment	O
levels	O
soon	O
after	O
cessation	O
of	O
the	O
drug	B-Drug
.	O

This	O
indicates	O
reversibility	O
in	O
captopril-induced	B-Chemical
renal	B-Disease
failure	I-Disease
even	O
after	O
its	O
prolonged	O
use	O
and	O
suggests	O
that	O
no	O
organic	O
damage	O
occurs	O
to	O
glomerular	O
arterioles	O
following	O
chronic	O
ACE	O
inhibition	O
.	O

Liver	B-Disease
disease	I-Disease
caused	O
by	O
propylthiouracil	B-Chemical
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	B-Disease
active	I-Disease
(	I-Disease
aggressive	I-Disease
)	I-Disease
hepatitis	I-Disease
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	B-Chemical
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	B-Drug
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
.	O

Capsaicin-induced	B-Chemical
muscle	B-Disease
pain	I-Disease
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw-stretch	O
reflex	O
.	O

The	O
pathophysiology	O
of	O
painful	O
temporomandibular	B-Disease
disorders	I-Disease
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	B-Disease
pain	I-Disease
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
activation	O
of	O
nociceptive	B-Disease
muscle	I-Disease
afferent	O
fibers	O
would	O
be	O
linked	O
to	O
an	O
increased	O
excitability	O
of	O
the	O
human	O
jaw-stretch	O
reflex	O
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	O
to	O
length	O
and	O
velocity	O
of	O
the	O
stretch	O
.	O

Capsaicin	B-Chemical
(	O
10	O
micro	O
g	O
)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	B-Disease
in	O
11	O
healthy	O
volunteers	O
.	O

Short-latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pain	B-Disease
.	O

The	O
normalized	O
reflex	O
amplitude	O
increased	O
with	O
an	O
increase	O
in	O
velocity	O
at	O
a	O
given	O
displacement	O
,	O
but	O
remained	O
constant	O
with	O
different	O
displacements	O
at	O
a	O
given	O
velocity	O
.	O

The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	B-Disease
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	B-Disease
muscle	I-Disease
.	O

Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	O
muscle	B-Disease
pain	I-Disease
could	O
be	O
one	O
likely	O
mechanism	O
to	O
explain	O
the	O
findings	O
.	O

Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

In	O
a	O
placebo-controlled	O
,	O
single-blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
``	O
real	O
''	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
``	O
sham	O
''	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
.	O

Ten	O
patients	O
with	O
PD	B-Disease
and	O
prominent	O
dyskinesias	B-Disease
had	O
rTMS	O
(	O
1,800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O

Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician-assessed	O
dyskinesia	B-Disease
severity	O
.	O

However	O
,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	B-Disease
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O

The	O
major	O
effect	O
was	O
on	O
dystonia	B-Disease
subscore	O
.	O

Similarly	O
,	O
in	O
patient	O
diaries	O
,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	B-Disease
scores	O
during	O
the	O
days	O
of	O
intervention	O
,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O

Following	O
rTMS	O
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	B-Disease
symptoms	O
were	O
noted	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low-frequency	O
rTMS	O
on	O
dyskinesias	B-Disease
in	O
PD	B-Disease
.	O

The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
potential	O
therapeutic	O
uses	O
.	O

Disulfiram-like	B-Chemical
syndrome	O
after	O
hydrogen	B-Chemical
cyanamide	I-Chemical
professional	O
skin	O
exposure	O
:	O
two	O
case	O
reports	O
in	O
France	O
.	O

Hydrogen	B-Chemical
cyanamide	I-Chemical
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees	O
.	O

Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	B-Chemical
dehydrogenase	O
and	O
can	O
induce	O
acetaldehyde	B-Chemical
syndrome	O
in	O
case	O
of	O
alcohol	B-Chemical
use	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
two	O
cases	O
of	O
a	O
disulfiram-like	B-Chemical
syndrome	O
following	O
occupational	O
exposure	O
to	O
hydrogen	B-Chemical
cyanamide	I-Chemical
.	O

The	O
first	O
case	O
involved	O
a	O
59-year-old	O
man	O
who	O
used	O
Dormex	B-Chemical
,	O
which	O
contains	O
hydrogen	B-Chemical
cyanamide	I-Chemical
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	B-Chemical
during	O
a	O
meal	O
.	O

In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestion	O
of	O
alcohol	B-Chemical
,	O
he	O
developed	O
malaise	O
with	O
flushing	B-Disease
of	I-Disease
the	I-Disease
face	I-Disease
,	O
tachycardia	B-Disease
,	O
and	O
dyspnea	B-Disease
.	O

Manifestations	O
regressed	O
spontaneously	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O

The	O
second	O
case	O
occurred	O
in	O
a	O
55-year-old	O
farmer	O
following	O
cutaneous	O
contact	O
with	O
Dormex	B-Chemical
.	O

Five	O
hours	O
after	O
exposure	O
,	O
he	O
developed	O
disulfiram-like	B-Chemical
syndrome	O
with	O
flushing	B-Disease
,	O
tachycardia	B-Disease
,	O
and	O
arterial	B-Disease
hypotension	I-Disease
after	O
consuming	O
three	O
glasses	O
of	O
wine	O
.	O

The	O
patient	O
recovered	O
spontaneously	O
in	O
3	O
hours	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O

These	O
cases	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcohol	B-Chemical
consumption	O
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	B-Chemical
and	O
of	O
preventing	O
cutaneous	O
contact	O
during	O
use	O
.	O

Repeated	O
trimipramine	B-Chemical
induces	O
dopamine	B-Chemical
D2/D3	O
and	O
alpha1-adrenergic	O
up-regulation	O
.	O

Trimipramine	B-Chemical
(	O
TRI	B-Chemical
)	O
,	O
which	O
shows	O
a	O
clinical	O
antidepressant	B-Chemical
activity	O
,	O
is	O
chemically	O
related	O
to	O
imipramine	B-Chemical
but	O
does	O
not	O
inhibit	O
the	O
reuptake	O
of	O
noradrenaline	B-Chemical
and	O
5-hydroxytryptamine	B-Chemical
,	O
nor	O
does	O
it	O
induce	O
beta-adrenergic	O
down-regulation	O
.	O

The	O
mechanism	O
of	O
its	O
antidepressant	B-Chemical
activity	O
is	O
still	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
TRI	B-Chemical
given	O
repeatedly	O
was	O
able	O
to	O
induce	O
adaptive	O
changes	O
in	O
the	O
dopaminergic	B-Drug
and	O
alpha1-adrenergic	O
systems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antidepressants	B-Chemical
.	O

TRI	B-Chemical
was	O
given	O
to	O
male	O
Wistar	O
rats	O
and	O
male	O
Albino	O
Swiss	O
mice	O
perorally	O
twice	O
daily	O
for	O
14	O
days	O
.	O

In	O
the	O
acute	O
experiment	O
TRI	B-Chemical
(	O
given	O
i.p	O
.	O

)	O
does	O
not	O
antagonize	O
the	O
reserpine	B-Chemical
hypothermia	B-Disease
in	O
mice	O
and	O
does	O
not	O
potentiate	O
the	O
5-hydroxytryptophan	B-Chemical
head	O
twitches	O
in	O
rats	O
.	O

TRI	B-Chemical
given	O
repeatedly	O
to	O
rats	O
increases	O
the	O
locomotor	O
hyperactivity	B-Disease
induced	O
by	O
d-amphetamine	B-Chemical
,	O
quinpirole	B-Chemical
and	O
(	O
+	O
)	O
-7-hydroxy-dipropyloaminotetralin	O
(	O
dopamine	B-Chemical
D2	O
and	O
D3	O
effects	O
)	O
.	O

The	O
stereotypies	O
induced	O
by	O
d-amphetamine	B-Chemical
or	O
apomorphine	B-Chemical
are	O
not	O
potentiated	O
by	O
TRI	B-Chemical
.	O

It	O
increases	O
the	O
behaviour	O
stimulation	O
evoked	O
by	O
phenylephrine	B-Chemical
(	O
given	O
intraventricularly	O
)	O
in	O
rats	O
,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
as	O
well	O
as	O
the	O
aggressiveness	B-Disease
evoked	O
by	O
clonidine	B-Chemical
in	O
mice	O
,	O
both	O
these	O
effects	O
being	O
mediated	O
by	O
an	O
alpha1-adrenergic	O
receptor	O
.	O

It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyclic	O
antidepressants	B-Chemical
studied	O
previously	O
,	O
TRI	B-Chemical
given	O
repeatedly	O
increases	O
the	O
responsiveness	O
of	O
brain	O
dopamine	B-Chemical
D2	O
and	O
D3	O
(	O
locomotor	O
activity	O
but	O
not	O
stereotypy	O
)	O
as	O
well	O
as	O
alpha1-adrenergic	O
receptors	O
to	O
their	O
agonists	O
.	O

A	O
question	O
arises	O
whether	O
the	O
reuptake	O
inhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	O
antidepressants	B-Chemical
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressant	B-Chemical
activity	O
.	O

Ranitidine-induced	B-Chemical
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O

Ranitidine	B-Chemical
frequently	O
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	O
transplantation	O
.	O

This	O
drug	B-Drug
occasionally	O
has	O
been	O
associated	O
with	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
native	O
kidneys	O
.	O

There	O
are	O
no	O
similar	O
reports	O
with	O
renal	O
transplantation	O
.	O

We	O
report	O
a	O
case	O
of	O
ranitidine-induced	B-Chemical
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	B-Drug
.	O

The	O
biopsy	O
specimen	O
showed	O
pathognomonic	O
features	O
,	O
including	O
eosinophilic	O
infiltration	O
of	O
the	O
interstitial	O
compartment	O
.	O

Allograft	O
function	O
improved	O
rapidly	O
and	O
returned	O
to	O
baseline	O
after	O
stopping	O
the	O
drug	B-Drug
.	O

Late	O
,	O
late	O
doxorubicin	B-Chemical
cardiotoxicity	B-Disease
.	O

Cardiac	B-Disease
toxicity	I-Disease
is	O
a	O
major	O
complication	O
which	O
limits	O
the	O
use	O
of	O
adriamycin	B-Chemical
as	O
a	O
chemotherapeutic	O
agent	O
.	O

Cardiomyopathy	B-Disease
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg/m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O

A	O
patient	O
is	O
reported	O
who	O
developed	O
progressive	O
cardiomyopathy	B-Disease
two	O
and	O
one-half	O
years	O
after	O
receiving	O
580	O
mg/m2	O
which	O
apparently	O
represents	O
late	O
,	O
late	O
cardiotoxicity	B-Disease
.	O

Acetazolamide-induced	B-Chemical
nephrolithiasis	B-Disease
:	O
implications	O
for	O
treatment	O
of	O
neuromuscular	B-Disease
disorders	I-Disease
.	O

Carbonic	O
anhydrase	O
inhibitors	O
can	O
cause	O
nephrolithiasis	B-Disease
.	O

We	O
studied	O
20	O
patients	O
receiving	O
long-term	O
carbonic	O
anhydrase	O
inhibitor	O
treatment	O
for	O
periodic	O
paralysis	B-Disease
and	O
myotonia	B-Disease
.	O

Three	O
patients	O
on	O
acetazolamide	B-Chemical
(	O
15	O
%	O
)	O
developed	O
renal	B-Disease
calculi	I-Disease
.	O

Extracorporeal	O
lithotripsy	O
successfully	O
removed	O
a	O
renal	B-Disease
calculus	I-Disease
in	O
one	O
patient	O
and	O
surgery	O
removed	O
a	O
staghorn	O
calculus	B-Disease
in	O
another	O
,	O
permitting	O
continued	O
treatment	O
.	O

Renal	O
function	O
remained	O
normal	O
in	O
all	O
patients	O
.	O

Nephrolithiasis	B-Disease
is	O
a	O
complication	O
of	O
acetazolamide	B-Chemical
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Is	O
the	O
treatment	O
of	O
scabies	B-Disease
hazardous	O
?	O
Treatment	O
for	O
scabies	B-Disease
is	O
usually	O
initiated	O
by	O
general	O
practitioners	O
;	O
most	O
consider	O
lindane	B-Chemical
(	O
gamma	B-Chemical
benzene	I-Chemical
hexachloride	I-Chemical
)	O
the	O
treatment	O
of	O
choice	O
.	O

Lindane	B-Chemical
is	O
also	O
widely	O
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide	O
,	O
and	O
as	O
a	O
result	O
the	O
toxic	O
profile	O
of	O
this	O
insecticide	O
is	O
well	O
understood	O
.	O

Evidence	O
is	O
accumulating	O
that	O
lindane	B-Chemical
can	O
be	O
toxic	B-Disease
to	B-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
and	O
may	O
be	O
associated	O
with	O
aplastic	B-Disease
anaemia	I-Disease
.	O

Preparations	O
containing	O
lindane	B-Chemical
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients	O
.	O

This	O
literature	O
review	O
suggests	O
that	O
general	O
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	O
caution	O
for	O
certain	O
at-risk	O
groups	O
,	O
and	O
give	O
adequate	O
warnings	O
regarding	O
potential	O
toxicity	B-Disease
.	O

Anaesthetists	O
'	O
nightmare	O
:	O
masseter	B-Disease
spasm	I-Disease
after	O
induction	O
in	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Disease
congenita	I-Disease
.	O

We	O
report	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-Disease
congenita	I-Disease
in	O
a	O
24-year-old	O
previously	O
healthy	O
primigravida	O
,	O
who	O
developed	O
life	O
threatening	O
masseter	B-Disease
spasm	I-Disease
following	O
a	O
standard	O
dose	O
of	O
intravenous	O
suxamethonium	B-Chemical
for	O
induction	O
of	O
anaesthesia	O
.	O

Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
was	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O

Toxicity	B-Disease
in	O
rhesus	O
monkeys	O
following	O
administration	O
of	O
the	O
8-aminoquinoline	B-Chemical
8-	B-Chemical
[	I-Chemical
(	I-Chemical
4-amino-l-methylbutyl	I-Chemical
)	I-Chemical
amino	I-Chemical
]	I-Chemical
-	B-Chemical
5-	I-Chemical
(	I-Chemical
l-hexyloxy	I-Chemical
)	I-Chemical
-6-methoxy-4-methylquinoline	I-Chemical
(	O
WR242511	B-Chemical
)	O
.	O

INTRODUCTION	O
:	O
Many	O
substances	O
that	O
form	O
methemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyanide	O
(	O
CN	O
)	O
toxicity	B-Disease
.	O

Although	O
MHb	O
formers	O
are	O
generally	O
applied	O
as	O
treatments	O
for	O
CN	O
poisoning	B-Disease
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stable	O
,	O
long-acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatment	O
.	O

Using	O
this	O
rationale	O
,	O
the	O
8-aminoquinoline	B-Chemical
WR242511	B-Chemical
,	O
a	O
potent	O
long-lasting	O
MHb	O
former	O
in	O
rodents	O
and	O
beagle	O
dogs	O
,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	O
development	O
as	O
a	O
potential	O
CN	O
pretreatment	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
WR242511	B-Chemical
was	O
administered	O
intravenously	O
(	O
IV	O
)	O
in	O
2	O
female	O
and	O
4	O
male	O
rhesus	O
monkeys	O
in	O
doses	O
of	O
3.5	O
and/or	O
7.0	O
mg/kg	O
;	O
a	O
single	O
male	O
also	O
received	O
WR242511	B-Chemical
orally	O
(	O
PO	O
)	O
at	O
7.0	O
mg/kg	O
.	O

Health	O
status	O
and	O
MHb	O
levels	O
were	O
monitored	O
following	O
exposure	O
.	O

RESULTS	O
:	O
The	O
selected	O
doses	O
of	O
WR242511	B-Chemical
,	O
which	O
produced	O
significant	O
methemoglobinemia	B-Disease
in	O
beagle	O
dogs	O
in	O
earlier	O
studies	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2.0	O
%	O
)	O
in	O
the	O
rhesus	O
monkey	O
.	O

Furthermore	O
,	O
transient	O
hemoglobinuria	B-Disease
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	B-Chemical
(	O
3.5	O
or	O
7.0	O
mg/kg	O
)	O
,	O
and	O
2	O
lethalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7.0	O
mg/kg	O
dose	O
.	O

Myoglobinuria	B-Disease
was	O
also	O
observed	O
following	O
the	O
7.0	O
mg/kg	O
dose	O
.	O

Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	B-Disease
and	I-Disease
kidney	I-Disease
toxicity	I-Disease
,	O
with	O
greater	O
severity	O
in	O
the	O
orally-treated	O
animal	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
direct	O
and/or	O
indirect	O
drug-induced	O
toxicity	I-Chemical
.	O

It	O
is	O
concluded	O
that	O
WR242511	O
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	O
for	O
CN	O
poisoning	O
unless	O
the	O
anti-CN	O
characteristics	O
of	O
this	O
compound	O
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	I-Chemical
.	O

Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O

Tonotopic	O
organization	O
is	O
an	O
essential	O
feature	O
of	O
the	O
primary	O
auditory	O
area	O
(	O
A1	O
)	O
of	O
primate	O
cortex	O
.	O

In	O
A1	O
of	O
macaque	O
monkeys	O
,	O
low	O
frequencies	O
are	O
represented	O
rostrolaterally	O
and	O
high	O
frequencies	O
are	O
represented	O
caudomedially	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	O
following	O
cochlear	O
hearing	B-Disease
loss	I-Disease
.	O

Under	O
anesthesia	B-Drug
,	O
the	O
superior	O
temporal	O
gyrus	O
of	O
adult	O
macaque	O
monkeys	O
was	O
exposed	O
,	O
and	O
the	O
tonotopic	O
organization	O
of	O
A1	O
was	O
mapped	O
using	O
conventional	O
microelectrode	O
recording	O
techniques	O
.	O

Following	O
recovery	O
,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	B-Chemical
and	O
furosemide	B-Chemical
.	O

The	O
actual	O
frequencies	O
deafened	O
were	O
determined	O
by	O
the	O
loss	I-Disease
of	O
tone-burst	O
elicited	O
auditory	O
brainstem	O
responses	O
.	O

Three	O
months	O
after	O
deafening	O
,	O
A1	O
was	O
remapped	O
.	O

Postmortem	O
cytoarchitectural	O
features	O
identifying	O
A1	O
were	O
correlated	O
with	O
the	O
electrophysiologic	O
data	O
.	O

The	O
results	O
indicate	O
that	O
the	O
deprived	O
area	O
of	O
A1	O
undergoes	O
extensive	O
reorganization	O
and	O
becomes	O
responsive	O
to	O
intact	O
cochlear	O
frequencies	O
.	O

The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	B-Disease
loss	O
.	O

The	O
site	O
of	O
common	O
side	O
effects	O
of	O
sumatriptan	B-Chemical
.	O

Atypical	B-Disease
sensations	I-Disease
following	O
the	O
use	O
of	O
subcutaneous	O
sumatriptan	B-Chemical
are	O
common	O
,	O
but	O
of	O
uncertain	O
origin	O
.	O

They	O
are	O
almost	O
always	O
benign	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adverse	O
event	O
by	O
the	O
patient	O
.	O

Two	O
patients	O
are	O
presented	O
with	O
tingling	B-Disease
or	I-Disease
burning	I-Disease
sensations	I-Disease
limited	O
to	O
areas	O
of	O
heat	O
exposure	O
or	O
sunburn	B-Disease
.	O

In	O
these	O
individuals	O
,	O
side	O
effects	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
skin	O
.	O

Tremor	B-Disease
side	O
effects	O
of	O
salbutamol	B-Chemical
,	O
quantified	O
by	O
a	O
laser	O
pointer	O
technique	O
.	O

OBJECTIVE	O
:	O
To	O
study	O
tremor	B-Disease
side	O
effects	O
of	O
salbutamol	B-Chemical
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low-priced	O
method	O
is	O
needed	O
.	O

A	O
new	O
method	O
using	O
a	O
commercially	O
available	O
,	O
pen-shaped	O
laser	O
pointer	O
was	O
developed	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
sensitivity	O
,	O
reproducibility	O
,	O
reference	O
values	O
and	O
the	O
agreement	O
with	O
a	O
questionnaire	O
.	O

METHODS	O
:	O
Tremor	B-Disease
was	O
measured	O
using	O
a	O
laser	O
pointer	O
technique	O
.	O

To	O
determine	O
sensitivity	O
we	O
assessed	O
tremor	B-Disease
in	O
44	O
patients	O
with	O
obstructive	B-Disease
lung	I-Disease
disease	I-Disease
after	O
administration	O
of	O
cumulative	O
doses	O
of	O
salbutamol	B-Chemical
.	O

Subjects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
centre	O
of	O
a	O
target	O
,	O
subdivided	O
in	O
concentric	O
circles	O
,	O
from	O
5	O
m	O
distance	O
.	O

The	O
circle	O
in	O
which	O
the	O
participant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
millimetres	O
radius	O
.	O

In	O
another	O
series	O
of	O
measurements	O
,	O
reproducibility	O
and	O
reference	O
values	O
of	O
the	O
tremor	B-Disease
was	O
assessed	O
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions	O
,	O
at	O
9	O
a.m.	O
,	O
4	O
p.m.	O
and	O
9	O
a.m.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O

Postural	O
tremor	B-Disease
was	O
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	B-Disease
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	O
and	O
finally	O
tremor	B-Disease
was	O
measured	O
after	O
holding	O
a	O
2-kg	O
weight	O
until	O
exhaustion	O
.	O

Inter-observer	O
variability	O
was	O
measured	O
in	O
a	O
series	O
of	O
10	O
healthy	O
subjects	O
.	O

Tremor	B-Disease
was	O
measured	O
simultaneously	O
by	O
two	O
independent	O
observers	O
.	O

RESULTS	O
:	O
Salbutamol	B-Chemical
significantly	O
increased	O
tremor	B-Disease
severity	O
in	O
patients	O
in	O
a	O
dose-dependent	O
way	O
.	O

Within	O
healthy	O
adults	O
no	O
age-dependency	O
could	O
be	O
found	O
(	O
b	O
=	O
0.262	O
mm/year	O
;	O
P	O
=	O
0.72	O
)	O
.	O

There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	O
and	O
tremor	B-Disease
severity	O
(	O
r	O
=	O
0.093	O
;	O
P	O
=	O
0.53	O
)	O
.	O

Postural	O
tremor	B-Disease
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
session	O
(	O
P	O
=	O
0.07	O
)	O
.	O

Support	O
of	O
the	O
arm	O
decreased	O
tremor	B-Disease
severity	O
,	O
exhaustion	O
increased	O
tremor	B-Disease
severity	O
significantly	O
.	O

A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
independent	O
observers	O
(	O
interclass	O
correlation	O
coefficient	O
0.72	O
)	O
.	O

DISCUSSION	O
:	O
Quantifying	O
tremor	B-Disease
by	O
using	O
an	O
inexpensive	O
laser	O
pointer	O
is	O
,	O
with	O
the	O
exception	O
of	O
children	O
(	O
<	O
12	O
years	O
)	O
a	O
sensitive	O
and	O
reproducible	O
method	O
.	O

Increased	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
with	O
the	O
combination	O
of	O
docetaxel	B-Chemical
and	O
thalidomide	B-Chemical
in	O
patients	O
with	O
metastatic	O
androgen-independent	O
prostate	B-Disease
cancer	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
in	O
patients	O
with	O
advanced	O
androgen-independent	O
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	O
with	O
docetaxel	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	B-Chemical
.	O

DESIGN	O
:	O
Retrospective	O
analysis	O
of	O
a	O
randomized	O
phase	O
II	O
trial	O
.	O

SETTING	O
:	O
National	O
Institutes	O
of	O
Health	O
clinical	O
research	O
center	O
.	O

PATIENTS	O
:	O
Seventy	O
men	O
,	O
aged	O
50-80	O
years	O
,	O
with	O
advanced	O
androgen-independent	O
prostate	B-Disease
cancer	I-Disease
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	B-Chemical
30	O
mg/m2/week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	B-Chemical
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	B-Chemical
regimen	O
.	O

This	O
4-week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	O
toxicity	B-Disease
or	O
disease	O
progression	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	B-Chemical
alone	O
developed	O
VTE	B-Disease
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	B-Chemical
plus	O
thalidomide	B-Chemical
developed	O
VTE	B-Disease
(	O
p=0.025	O
)	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	B-Chemical
to	O
docetaxel	B-Chemical
in	O
the	O
treatment	O
of	O
prostate	B-Disease
cancer	I-Disease
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	B-Disease
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	B-Chemical
to	O
chemotherapeutic	O
regimens	O
.	O

Sublingual	O
absorption	O
of	O
the	O
quaternary	B-Chemical
ammonium	I-Chemical
antiarrhythmic	B-Drug
agent	O
,	O
UM-272	B-Chemical
.	O

UM-272	B-Chemical
(	O
N	B-Chemical
,	I-Chemical
N-dimethylpropranolol	B-Chemical
)	O
,	O
a	O
quaternary	O
antiarrhythmic	B-Drug
agent	O
,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain-induced	B-Chemical
ventricular	B-Disease
tachycardias	I-Disease
.	O

Both	O
anti-arrhythmic	B-Drug
efficacy	O
and	O
bioavailability	O
were	O
compared	O
to	O
oral	O
drug	B-Drug
.	O

Sublingual	O
UM-272	B-Chemical
converted	O
ventricular	B-Disease
tachycardia	I-Disease
to	O
sinus	O
rhythm	O
in	O
all	O
5	O
dogs	O
.	O

The	O
area	O
under	O
the	O
plasma	O
concentration	O
time	O
curve	O
at	O
90	O
min	O
was	O
4-12	O
times	O
greater	O
than	O
for	O
oral	O
drug	B-Drug
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorption-limiting	O
process	O
in	O
the	O
intestine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
administration	O
for	O
quaternary	O
drugs	B-Drug
.	O

Severe	O
thrombocytopenia	B-Disease
and	O
haemolytic	B-Disease
anaemia	I-Disease
associated	O
with	O
ciprofloxacin	B-Chemical
:	O
a	O
case	O
report	O
with	O
fatal	O
outcome	O
.	O

Haematological	O
adverse	O
reactions	O
associated	O
with	O
fatal	O
outcome	O
are	O
rare	O
during	O
treatment	O
with	O
ciprofloxacin	B-Chemical
.	O

A	O
30-year	O
old	O
Caucasian	O
man	O
reported	O
with	O
abdominal	B-Disease
pain	I-Disease
and	O
jaundice	B-Disease
after	O
3-day	O
administration	O
of	O
oral	O
ciprofloxacin	B-Chemical
for	O
a	O
suspect	O
of	O
urinary	B-Disease
tract	I-Disease
infection	I-Disease
.	O

Clinical	O
evaluations	O
suggested	O
an	O
initial	O
diagnosis	O
of	O
severe	O
thrombocytopenia	B-Disease
and	O
haemolysis	B-Disease
.	O

The	O
patient	O
progressively	O
developed	O
petechiae	B-Disease
and	O
purpura	B-Disease
on	O
thorax	O
and	O
lower	O
limbs	O
.	O

Despite	O
pharmacological	O
and	O
supportive	O
interventions	O
,	O
laboratory	O
parameters	O
worsened	O
and	O
the	O
patient	O
died	O
17	O
hours	O
after	O
admission	O
.	O

An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	O
haemorrhages	B-Disease
.	O

No	O
signs	O
of	O
bone	B-Disease
marrow	I-Disease
depression	I-Disease
were	O
found	O
.	O

No	O
thrombi	B-Disease
or	O
signs	O
of	O
microangiopathies	B-Disease
were	O
observed	O
in	O
arterial	O
vessels	O
.	O

Blood	O
and	O
urine	O
cultures	O
did	O
not	O
show	O
any	O
bacterial	O
growth	O
.	O

This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	B-Chemical
may	O
precipitate	O
life-threatening	O
thrombocytopenia	B-Disease
and	O
haemolytic	B-Disease
anaemia	I-Disease
,	O
even	O
in	O
the	O
early	O
phases	O
of	O
treatment	O
and	O
without	O
apparent	O
previous	O
exposures	O
.	O

Simvastatin-induced	B-Chemical
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
associated	O
with	O
hypothyroidism	B-Disease
.	O

A	O
54-year-old	O
hypothyroid	B-Disease
male	O
taking	O
thyroxine	B-Chemical
and	O
simvastatin	B-Chemical
presented	O
with	O
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
.	O

Urgent	O
fasciotomies	O
were	O
performed	O
and	O
the	O
patient	O
made	O
an	O
uneventful	O
recovery	O
with	O
the	O
withdrawal	O
of	O
simvastatin	B-Chemical
.	O

It	O
is	O
likely	O
that	O
this	O
complication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	O
worldwide	O
use	O
of	O
this	O
drug	B-Drug
and	O
its	O
approval	O
for	O
all	O
arteriopathic	B-Disease
patients	O
.	O

Bile	B-Disease
duct	I-Disease
hamartoma	I-Disease
occurring	O
in	O
association	O
with	O
long-term	O
treatment	O
with	O
danazol	B-Drug
.	O

We	O
report	O
a	O
case	O
of	O
bile	B-Disease
duct	I-Disease
hamartoma	I-Disease
which	O
developed	O
in	O
a	O
patient	O
who	O
had	O
been	O
on	O
long-term	O
danazol	B-Drug
treatment	O
.	O

Such	O
patients	O
should	O
be	O
under	O
close	O
follow-up	O
,	O
preferably	O
with	O
periodic	O
ultrasound	O
examination	O
of	O
the	O
liver	O
.	O

If	O
the	O
patient	O
develops	O
a	O
liver	O
mass	O
,	O
because	O
of	O
non-specific	O
clinical	O
features	O
and	O
imaging	O
appearances	O
,	O
biopsy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
definitive	O
diagnosis	O
.	O

Granulomatous	B-Disease
hepatitis	I-Disease
due	O
to	O
combination	O
of	O
amoxicillin	B-Drug
and	O
clavulanic	O
acid	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
amoxicillin-clavulanic	B-Chemical
acid-induced	O
hepatitis	O
with	O
histologic	O
multiple	O
granulomas	O
.	O

This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	O
injury	O
due	O
to	O
this	O
drug	B-Drug
combination	O
,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	O
syndrome	O
.	O

The	O
association	O
of	O
granulomas	O
and	O
eosinophilia	O
favor	O
an	O
immunoallergic	O
mechanism	O
.	O

As	O
penicillin	B-Drug
derivatives	O
and	O
amoxicillin	B-Drug
alone	O
are	O
known	O
to	O
induce	O
such	O
types	O
of	O
lesions	O
,	O
the	O
amoxicillin	B-Drug
component	O
,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	O
of	O
clavulanic	O
acid	I-Chemical
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Intracranial	B-Disease
aneurysms	I-Disease
and	O
cocaine	B-Disease
abuse	I-Disease
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O

OBJECTIVE	O
:	O
The	O
outcome	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
associated	O
with	O
cocaine	B-Disease
abuse	I-Disease
is	O
reportedly	O
poor	O
.	O

However	O
,	O
no	O
study	O
in	O
the	O
literature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statistical	O
model	O
to	O
analyze	O
the	O
variables	O
that	O
influence	O
outcome	O
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6-year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine-related	B-Chemical
aneurysms	B-Disease
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	B-Disease
aneurysms	I-Disease
and	O
no	O
history	O
of	O
cocaine	B-Disease
abuse	I-Disease
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
,	O
size	O
of	O
the	O
aneurysm	B-Disease
,	O
location	O
of	O
the	O
aneurysm	B-Disease
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

RESULTS	O
:	O
The	O
patients	O
in	O
the	O
study	O
group	O
were	O
significantly	O
younger	O
than	O
the	O
patients	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.002	O
)	O
.	O

In	O
patients	O
in	O
the	O
study	O
group	O
,	O
all	O
aneurysms	B-Disease
were	O
located	O
in	O
the	O
anterior	O
circulation	O
.	O

The	O
majority	O
of	O
these	O
aneurysms	B-Disease
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+/-	O
6.08	O
mm	O
versus	O
11	O
+/-	O
5.4	O
mm	O
;	O
P	O
=	O
0.05	O
)	O
.	O

The	O
differences	O
in	O
mortality	O
and	O
morbidity	O
between	O
the	O
two	O
groups	O
were	O
not	O
significant	O
.	O

Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0.005	O
)	O
and	O
age	O
(	O
P	O
<	O
0.007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine-related	B-Chemical
aneurysms	B-Disease
.	O

CONCLUSION	O
:	O
Cocaine	B-Chemical
use	O
predisposed	O
aneurysmal	B-Disease
rupture	I-Disease
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	B-Disease
.	O

Contrary	O
to	O
the	O
published	O
literature	O
,	O
this	O
group	O
did	O
reasonably	O
well	O
with	O
aggressive	O
management	O
.	O

Anti-epileptic	B-Disease
drugs-induced	O
de	O
novo	O
absence	B-Disease
seizures	I-Disease
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	B-Disease
epilepsy	I-Disease
after	O
administration	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
.	O

Despite	O
the	O
underlying	O
diseases	O
,	O
the	O
prognosis	O
for	O
drug-induced	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	B-Drug
.	O

The	O
gamma-aminobutyric	B-Chemical
acid-transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	O
epilepsy	O
.	O

Because	O
drug-induced	O
de	O
novo	O
absence	O
seizure	O
is	O
rare	O
,	O
pro-absence	O
drugs	B-Drug
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O

The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	B-Drug
is	O
required	O
to	O
trigger	O
the	O
de	O
novo	O
absence	O
seizure	O
.	O

The	O
possibility	O
of	O
drug-induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	O
frequency	O
and/or	O
new	O
seizure	O
types	O
appear	O
following	O
a	O
change	O
in	O
drug	B-Drug
treatment	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	O
epilepsy	O
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	O
and	O
prevent	O
drug-induced	O
absence	O
seizures	O
.	O

Procainamide-induced	B-Chemical
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

Seven	O
cases	O
of	O
procainamide-induced	B-Chemical
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
are	O
presented	O
.	O

In	O
four	O
patients	O
,	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
appeared	O
after	O
intravenous	O
administration	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainamide	B-Chemical
for	O
the	O
treatment	O
of	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

In	O
the	O
remaining	O
three	O
patients	O
,	O
procainamide	B-Chemical
was	O
administered	O
orally	O
for	O
treatment	O
of	O
chronic	O
premature	B-Disease
ventricular	I-Disease
contractions	I-Disease
or	O
atrial	B-Disease
flutter	I-Disease
.	O

These	O
patients	O
had	O
Q-T	B-Disease
prolongation	I-Disease
and	O
recurrent	O
syncope	B-Disease
due	O
to	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

In	O
four	O
patients	O
,	O
the	O
arrhythmia	B-Disease
was	O
rapidly	O
diagnosed	O
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	O
of	O
the	O
arrhythmia	B-Disease
.	O

In	O
two	O
patients	O
,	O
the	O
arrhythmia	B-Disease
degenerated	O
into	O
irreversible	O
ventricular	B-Disease
fibrillation	I-Disease
and	O
both	O
patients	O
died	O
.	O

In	O
the	O
seventh	O
patient	O
,	O
a	O
permanent	O
ventricular	O
pacemaker	O
was	O
inserted	O
and	O
,	O
despite	O
continuation	O
of	O
procainamide	B-Chemical
therapy	O
,	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
did	O
not	O
reoccur	O
.	O

These	O
seven	O
cases	O
demonstrate	O
that	O
procainamide	B-Chemical
can	O
produce	O
an	O
acquired	O
prolonged	B-Disease
Q-T	I-Disease
syndrome	I-Disease
with	O
polymorphous	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

Role	O
of	O
activation	O
of	O
bradykinin	B-Chemical
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
.	O

Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
are	O
not	O
clear	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthesis/release	O
of	O
bradykinin	B-Chemical
to	O
activate	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
.	O

Permeability	O
of	O
the	O
blood-brain	O
barrier	O
was	O
quantitated	O
by	O
clearance	O
of	O
fluorescent-labeled	O
dextran	B-Chemical
before	O
and	O
during	O
phenylephrine-induced	B-Chemical
acute	O
hypertension	B-Disease
in	O
rats	O
treated	O
with	O
vehicle	O
and	O
Hoe-140	B-Chemical
(	O
0.1	O
microM	O
)	O
.	O

Phenylephrine	B-Chemical
infusion	O
increased	O
arterial	O
pressure	O
,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	B-Chemical
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups	O
.	O

These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	B-Disease
is	O
not	O
related	O
to	O
the	O
synthesis/release	O
of	O
bradykinin	B-Chemical
to	O
activate	O
B2	O
receptors	O
.	O

5-azacytidine	B-Chemical
potentiates	O
initiation	B-Disease
induced	I-Disease
by	I-Disease
carcinogens	I-Disease
in	O
rat	O
liver	O
.	O

To	O
test	O
the	O
validity	O
of	I-Disease
the	O
hypothesis	O
that	O
hypomethylation	O
of	I-Disease
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	B-Disease
of	I-Disease
carcinogenic	O
process	O
,	O
5-azacytidine	B-Chemical
(	O
5-AzC	B-Chemical
)	O
(	O
10	O
mg/kg	O
)	O
,	O
an	O
inhibitor	O
of	O
DNA	O
methylation	O
,	O
was	O
given	O
to	O
rats	O
during	O
the	O
phase	O
of	O
repair	O
synthesis	O
induced	O
by	O
the	O
three	O
carcinogens	O
,	O
benzo	B-Chemical
[	I-Chemical
a	I-Chemical
]	I-Chemical
-pyrene	I-Chemical
(	O
200	O
mg/kg	O
)	O
,	O
N-methyl-N-nitrosourea	B-Chemical
(	O
60	O
mg/kg	O
)	O
and	O
1,2-dimethylhydrazine	B-Chemical
(	O
1,2-DMH	B-Chemical
)	O
(	O
100	O
mg/kg	O
)	O
.	O

The	O
initiated	O
hepatocytes	O
in	O
the	O
liver	O
were	O
assayed	O
as	O
the	O
gamma-glutamyltransferase	O
(	O
gamma-GT	O
)	O
positive	O
foci	O
formed	O
following	O
a	O
2-week	O
selection	O
regimen	O
consisting	O
of	O
dietary	O
0.02	O
%	O
2-acetylaminofluorene	B-Chemical
coupled	O
with	O
a	O
necrogenic	O
dose	O
of	O
CCl4	B-Chemical
.	O

The	O
results	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcinogens	O
,	O
administration	O
of	O
5-AzC	B-Chemical
during	O
repair	O
synthesis	O
increased	O
the	O
incidence	O
of	O
initiated	O
hepatocytes	O
,	O
for	O
example	O
10-20	O
foci/cm2	O
in	O
5-AzC	B-Chemical
and	O
carcinogen-treated	O
rats	O
compared	O
with	O
3-5	O
foci/cm2	O
in	O
rats	O
treated	O
with	O
carcinogen	O
only	O
.	O

Administration	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-5-azadeoxycytidine	I-Chemical
during	O
the	O
repair	O
synthesis	O
induced	O
by	O
1,2-DMH	B-Chemical
further	O
showed	O
that	O
0.019	O
mol	O
%	O
of	O
cytosine	B-Chemical
residues	O
in	O
DNA	O
were	O
substituted	O
by	O
the	O
analogue	O
,	O
indicating	O
that	O
incorporation	O
of	O
5-AzC	B-Chemical
occurs	O
during	O
repair	O
synthesis	O
.	O

In	O
the	O
absence	O
of	O
the	O
carcinogen	O
,	O
5-AzC	B-Chemical
given	O
after	O
a	O
two	O
thirds	O
partial	O
hepatectomy	O
,	O
when	O
its	O
incorporation	O
should	O
be	O
maximum	O
,	O
failed	O
to	O
induce	O
any	O
gamma-GT	O
positive	O
foci	O
.	O

The	O
results	O
suggest	O
that	O
hypomethylation	O
of	O
DNA	O
per	O
se	O
may	O
not	O
be	O
sufficient	O
for	O
initiation	O
.	O

Perhaps	O
two	O
events	O
might	O
be	O
necessary	O
for	O
initiation	O
,	O
the	O
first	O
caused	O
by	O
the	O
carcinogen	O
and	O
a	O
second	O
involving	O
hypomethylation	O
of	O
DNA	O
.	O

Withdrawal-emergent	B-Disease
rabbit	I-Disease
syndrome	I-Disease
during	O
dose	O
reduction	O
of	O
risperidone	B-Drug
.	O

Rabbit	B-Disease
syndrome	I-Disease
(	O
RS	B-Disease
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	B-Drug
medication	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal-emergent	B-Disease
RS	I-Disease
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

The	O
patient	O
developed	O
RS	I-Chemical
during	O
dose	O
reduction	O
of	O
risperidone	B-Drug
.	O

The	O
symptom	O
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	B-Drug
anticholinergic	B-Drug
therapy	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal-emergent	B-Chemical
RS	I-Chemical
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	B-Drug
,	O
a	O
serotonin-dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	I-Chemical
.	O

Verapamil	B-Chemical
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	B-Disease
infarction	I-Disease
in	O
a	O
hypertensive	B-Disease
woman	O
with	O
a	O
normal	O
coronary	O
angiogram	O
.	O

Verapamil	B-Chemical
is	O
an	O
effective	O
and	O
relatively-safe	O
antihypertensive	B-Drug
drug	B-Drug
.	O

Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	B-Disease
of	O
cardiac	O
contractility	O
and	O
conduction	O
,	O
especially	O
when	O
the	O
drug	B-Drug
is	O
combined	O
with	O
beta-blocking	B-Drug
agents	O
.	O

We	O
report	O
a	O
case	O
in	O
which	O
myocardial	B-Disease
infarction	I-Disease
coincided	O
with	O
the	O
introduction	O
of	O
captopril	B-Chemical
and	O
the	O
withdrawal	O
of	O
verapamil	B-Chemical
in	O
a	O
previously	O
asymptomatic	O
woman	O
with	O
severe	O
hypertension	B-Disease
.	O

Possible	O
mechanisms	O
that	O
involve	O
a	O
verapamil-related	B-Chemical
increase	O
in	O
platelet	O
and/or	O
vascular	O
alpha	O
2-adrenoreceptor	O
affinity	O
for	O
catecholamines	B-Chemical
are	O
discussed	O
.	O

Remission	O
induction	O
of	O
meningeal	B-Disease
leukemia	I-Disease
with	O
high-dose	O
intravenous	O
methotrexate	B-Chemical
.	O

Twenty	O
children	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
who	O
developed	O
meningeal	B-Disease
disease	I-Disease
were	O
treated	O
with	O
a	O
high-dose	O
intravenous	O
methotrexate	B-Chemical
regimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrexate	B-Chemical
concentrations	O
of	O
10	O
(	O
-5	O
)	O
mol/L	O
without	O
the	O
need	O
for	O
concomitant	O
intrathecal	O
dosing	O
.	O

The	O
methotrexate	B-Chemical
was	O
administered	O
as	O
a	O
loading	O
dose	O
of	O
6,000	O
mg/m2	O
for	O
a	O
period	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infusion	O
of	O
1,200	O
mg/m2/h	O
for	O
23	O
hours	O
.	O

Leucovorin	B-Chemical
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusion	O
with	O
a	O
loading	O
dose	O
of	O
200	O
mg/m2	O
followed	O
by	O
12	O
mg/m2	O
every	O
three	O
hours	O
for	O
six	O
doses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plasma	O
methotrexate	B-Chemical
level	O
decreased	O
to	O
less	O
than	O
1	O
X	O
10	O
(	O
-7	O
)	O
mol/L	O
.	O

The	O
mean	O
steady-state	O
plasma	O
and	O
CSF	O
methotrexate	B-Chemical
concentrations	O
achieved	O
were	O
1.1	O
X	O
10	O
(	O
-3	O
)	O
mol/L	O
and	O
3.6	O
X	O
10	O
(	O
-5	O
)	O
mol/L	O
,	O
respectively	O
.	O

All	O
20	O
patients	O
responded	O
to	O
this	O
regimen	O
,	O
16/20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
remission	O
,	O
and	O
20	O
%	O
obtained	O
a	O
partial	O
remission	O
.	O

The	O
most	O
common	O
toxicities	B-Disease
encountered	O
were	O
transient	O
serum	O
transaminase	O
and	O
bilirubin	B-Chemical
elevations	O
,	O
neutropenia	B-Disease
,	O
and	O
mucositis	B-Disease
.	O

One	O
patient	O
had	O
focal	O
seizures	B-Disease
and	O
transient	B-Disease
hemiparesis	I-Disease
but	O
recovered	O
completely	O
.	O

High-dose	O
intravenous	O
methotrexate	B-Chemical
is	O
an	O
effective	O
treatment	O
for	O
the	O
induction	O
of	O
remission	O
after	O
meningeal	O
relapse	O
in	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O

Hypersensitivity	B-Disease
to	O
carbamazepine	B-Chemical
presenting	O
with	O
a	O
leukemoid	B-Disease
reaction	I-Disease
,	O
eosinophilia	B-Disease
,	O
erythroderma	B-Disease
,	O
and	O
renal	B-Disease
failure	I-Disease
.	O

We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	B-Disease
to	O
carbamazepine	B-Chemical
presented	O
with	O
generalized	O
erythroderma	B-Disease
,	O
a	O
severe	O
leukemoid	B-Disease
reaction	I-Disease
,	O
eosinophilia	B-Disease
,	O
hyponatremia	B-Disease
,	O
and	O
renal	B-Disease
failure	I-Disease
.	O

This	O
is	O
the	O
first	O
report	O
of	O
such	O
an	O
unusual	O
reaction	O
to	O
carbamazepine	B-Chemical
.	O

The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	B-Chemical
's	O
effects	O
on	O
free-field	O
activity	O
.	O

Partial	O
lesions	O
were	O
made	O
with	O
kainic	B-Chemical
acid	I-Chemical
in	O
the	O
interpeduncular	O
nucleus	O
of	O
the	O
ventral	O
midbrain	O
of	O
the	O
rat	O
.	O

Compared	O
with	O
sham-operated	O
controls	O
,	O
lesions	O
significantly	O
(	O
p	O
<	O
0.25	O
)	O
blunted	O
the	O
early	O
(	O
<	O
60	O
min	O
)	O
free-field	O
locomotor	B-Disease
hypoactivity	I-Disease
caused	O
by	O
nicotine	B-Chemical
(	O
0.5	O
mg	O
kg	O
(	O
-1	O
)	O
,	O
i.m	O
.	O

)	O
,	O
enhanced	O
the	O
later	O
(	O
60-120	O
min	O
)	O
nicotine-induced	B-Chemical
hyperactivity	B-Disease
,	O
and	O
raised	O
spontaneous	O
nocturnal	O
activity	O
.	O

Lesions	O
reduced	O
the	O
extent	O
of	O
immunohistological	O
staining	O
for	O
choline	B-Chemical
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	O
(	O
p	O
<	O
0.025	O
)	O
,	O
but	O
not	O
for	O
tyrosine	B-Chemical
hydroxylase	O
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region	O
.	O

We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	O
mediates	O
nicotinic	O
depression	B-Disease
of	O
locomotor	O
activity	O
and	O
dampens	O
nicotinic	O
arousal	O
mechanisms	O
located	O
elsewhere	O
in	O
the	O
brain	O
.	O

Assessment	O
of	O
a	O
new	O
non-invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine-induced	B-Chemical
myocardial	B-Disease
ischemia	I-Disease
.	O

BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine-induced	B-Chemical
myocardial	B-Disease
ischemia	I-Disease
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP/dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12-lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine-induced	B-Chemical
myocardial	B-Disease
ischemia	I-Disease
,	O
using	O
Tc99m-Sestamibi	B-Chemical
single-photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	B-Drug
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-Disease
.	O

METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi-SPECT/dobutamine	B-Chemical
stress	O
test	O
.	O

Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP/dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	B-Chemical
level	O
.	O

In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	O
were	O
detected	O
on	O
SPECT	O
.	O

The	O
increase	O
in	O
dP/dtejc	O
during	O
infusion	O
of	O
dobutamine	B-Chemical
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non-ischemic	O
group	O
.	O

dP/dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results	O
,	O
giving	O
an	O
ECG-enhanced	O
value	O
,	O
and	O
compared	O
to	O
ECG	O
alone	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
positive	O
predictive	O
value	O
increased	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negative	O
predictive	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
specificity	O
decreased	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP/dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost-savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	O
ischemia	B-Disease
,	O
especially	O
in	O
patients	O
unable	O
to	O
exercise	O
.	O

Acute	B-Disease
liver	I-Disease
failure	I-Disease
in	O
two	O
patients	O
with	O
regular	O
alcohol	B-Chemical
consumption	O
ingesting	O
paracetamol	B-Chemical
at	O
therapeutic	O
dosage	O
.	O

BACKGROUND	O
:	O
The	O
possible	O
role	O
of	O
alcohol	B-Chemical
in	O
the	O
development	O
of	O
hepatotoxicity	B-Disease
associated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-Chemical
(	O
acetaminophen	B-Chemical
)	O
is	O
currently	O
debated	O
.	O

CASE	O
REPORT	O
:	O
We	O
describe	O
2	O
patients	O
who	O
were	O
regular	O
consumers	O
of	O
alcohol	B-Chemical
and	O
who	O
developed	O
liver	B-Disease
failure	I-Disease
within	O
3-5	O
days	O
after	O
hospitalization	O
and	O
stopping	O
alcohol	B-Chemical
consumption	O
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol/day	B-Chemical
.	O

A	O
paracetamol	B-Chemical
serum	O
level	O
obtained	O
in	O
one	O
of	O
these	O
patients	O
was	O
not	O
in	O
the	O
toxic	O
range	O
.	O

Possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hepatotoxicity	B-Disease
in	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-Chemical
are	O
discussed	O
.	O

CONCLUSION	O
:	O
In	O
patients	O
with	O
risk	O
factors	O
,	O
e.g	O
.	O

regular	O
consumption	O
of	O
alcohol	B-Chemical
,	O
liver	B-Disease
failure	I-Disease
is	O
possible	O
when	O
therapeutic	O
doses	O
are	O
ingested	O
.	O

We	O
propose	O
that	O
the	O
paracetamol	B-Chemical
dose	O
should	O
not	O
exceed	O
2	O
g/day	O
in	O
such	O
patients	O
and	O
that	O
their	O
liver	O
function	O
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	B-Chemical
.	O

Cocaine	B-Chemical
related	O
chest	B-Disease
pain	I-Disease
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O
The	O
recreational	O
use	O
of	O
cocaine	B-Chemical
is	O
on	O
the	O
increase	O
.	O

The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
cocaine	B-Chemical
use	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	B-Chemical
to	O
produce	O
chest	B-Disease
pain	I-Disease
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	B-Disease
pain	I-Disease
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

The	O
mechanism	O
of	O
chest	B-Disease
pain	I-Disease
related	O
to	O
cocaine	B-Chemical
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O

Finally	O
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	O
of	O
potential	O
cocaine	B-Chemical
users	O
will	O
be	O
addressed	O
.	O

Severe	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
resulting	O
in	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

BACKGROUND	O
:	O
A	O
72-year-old	O
white	O
man	O
with	O
underlying	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
,	O
atrial	B-Disease
fibrillation	I-Disease
,	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
and	O
hyperlipidemia	B-Disease
presented	O
with	O
generalized	O
pain	B-Disease
,	O
fatigue	B-Disease
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O

The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	B-Chemical
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
)	O
;	O
amiodarone	B-Chemical
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
,	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanavir	B-Chemical
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
)	O
.	O

Laboratory	O
evaluation	O
revealed	O
66,680	O
U/L	O
creatine	B-Chemical
kinase	O
,	O
93	O
mg/dL	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
,	O
4.6	O
mg/dL	O
creatinine	B-Chemical
,	O
1579	O
U/L	O
aspartate	B-Chemical
aminotransferase	O
,	O
and	O
738	O
U/L	O
alanine	B-Chemical
aminotransferase	O
.	O

Simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
the	O
patient	O
's	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O

Nine	O
days	O
later	O
the	O
patient	O
's	O
creatine	B-Chemical
kinase	O
had	O
dropped	O
to	O
1695	O
U/L	O
and	O
creatinine	B-Chemical
was	O
3.3	O
mg/dL	O
.	O

The	O
patient	O
was	O
discharged	O
and	O
continued	O
outpatient	O
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered	O
.	O

DISCUSSION	O
:	O
The	O
risk	O
of	O
rhabdomyolysis	B-Disease
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	B-Drug
that	O
inhibit	O
simvastatin	B-Chemical
metabolism	O
.	O

Simvastatin	B-Chemical
is	O
metabolized	O
by	O
CYP3A4	B-Drug
.	O

Amiodarone	B-Chemical
and	O
atazanavir	B-Chemical
are	O
recognized	O
CYP3A4	B-Drug
inhibitors	O
.	O

CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	B-Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	B-Drug
interactions	O
.	O

In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	B-Chemical
and	O
CYP3A4	B-Drug
inhibitors	O
,	O
pravastatin	B-Chemical
,	O
fluvastatin	B-Chemical
,	O
and	O
rosuvastatin	B-Chemical
carry	O
the	O
lowest	O
risk	O
of	O
drug	B-Drug
interactions	O
;	O
atorvastatin	B-Chemical
carries	O
moderate	O
risk	O
,	O
whereas	O
simvastatin	B-Chemical
and	O
lovastatin	B-Chemical
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
taking	O
concomitant	O
CYP3A4	B-Drug
inhibitors	O
.	O

Phase	O
II	O
trial	O
of	O
vinorelbine	B-Chemical
in	O
metastatic	O
squamous	B-Disease
cell	I-Disease
esophageal	I-Disease
carcinoma	I-Disease
.	O

European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	B-Disease
Gastrointestinal	O
Treat	O
Cancer	B-Disease
Cooperative	O
Group	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	B-Chemical
(	O
VNB	B-Chemical
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	B-Disease
cell	I-Disease
esophageal	I-Disease
carcinoma	I-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty-six	O
eligible	O
patients	O
with	O
measurable	O
lesions	O
were	O
included	O
and	O
were	O
stratified	O
according	O
to	O
previous	O
chemotherapy	O
.	O

Thirty	O
patients	O
without	O
prior	O
chemotherapy	O
and	O
16	O
pretreated	O
with	O
cisplatin-based	B-Chemical
chemotherapy	O
were	O
assessable	O
for	O
toxicity	B-Disease
and	O
response	O
.	O

VNB	B-Chemical
was	O
administered	O
weekly	O
as	O
a	O
25-mg/m2	O
short	O
intravenous	O
(	O
i.v	O
.	O

)	O
infusion	O
.	O

RESULTS	O
:	O
Six	O
of	O
30	O
patients	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotherapy	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O

The	O
median	O
duration	O
of	O
response	O
was	O
21	O
weeks	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O

One	O
of	O
16	O
patients	O
(	O
6	O
%	O
)	O
with	O
prior	O
chemotherapy	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
of	O
31	O
weeks	O
'	O
duration	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O

The	O
overall	O
response	O
rate	O
(	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
criteria	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O

The	O
median	O
dose-intensity	O
(	O
DI	O
)	O
was	O
20	O
mg/m2/wk	O
.	O

VNB	B-Chemical
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	B-Disease
occurred	O
.	O

At	O
least	O
one	O
episode	O
of	O
grade	O
3	O
or	O
4	O
granulocytopenia	B-Disease
was	O
seen	O
in	O
59	O
%	O
of	O
patients	O
.	O

A	O
grade	O
2	O
or	O
3	O
infection	B-Disease
occurred	O
in	O
16	O
%	O
of	O
patients	O
,	O
but	O
no	O
toxic	O
deaths	B-Disease
occurred	O
.	O

Other	O
side	O
effects	O
were	O
rare	O
,	O
and	O
peripheral	B-Disease
neurotoxicity	I-Disease
has	O
been	O
minor	O
(	O
26	O
%	O
grade	O
1	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
VNB	B-Chemical
is	O
an	O
active	O
agent	O
in	O
metastatic	O
esophageal	B-Disease
squamous	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Given	O
its	O
excellent	O
tolerance	O
profile	O
and	O
low	O
toxicity	B-Disease
,	O
further	O
evaluation	O
of	O
VNB	B-Chemical
in	O
combination	O
therapy	O
is	O
warranted	O
.	O

Paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
.	O

BACKGROUND	O
:	O
Cisplatin-based	B-Chemical
chemotherapy	O
combinations	O
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	B-Disease
)	O
.	O

The	O
emergence	O
of	O
new	O
active	O
drugs	B-Drug
might	O
translate	O
into	O
more	O
effective	O
regimens	O
for	O
the	O
treatment	O
of	O
this	O
disease	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	B-Disease
of	O
a	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
combination	O
to	O
treat	O
metastatic	O
NSCLC	B-Disease
.	O

Thirty-five	O
consecutive	O
chemotherapy-naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	B-Disease
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0-2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	B-Chemical
(	O
135	O
mg/m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	B-Chemical
(	O
120	O
mg/m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	B-Chemical
(	O
800	O
mg/m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second-line	O
chemotherapy	O
after	O
disease	O
progression	O
,	O
the	O
response	O
and	O
toxicity	B-Disease
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	O
were	O
examined	O
for	O
toxicity	B-Disease
;	O
34	O
were	O
examinable	O
for	O
response	O
.	O

An	O
objective	O
response	O
was	O
observed	O
in	O
73.5	O
%	O
of	O
the	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
55.6-87.1	O
%	O
)	O
,	O
including	O
4	O
complete	O
responses	O
(	O
11.7	O
%	O
)	O
.	O

According	O
to	O
intention-to-treat	O
,	O
the	O
overall	O
response	O
rate	O
was	O
71.4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O

7-85.4	O
%	O
)	O
.	O

After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg/m	O
(	O
2	O
)	O
for	O
paclitaxel	B-Chemical
(	O
97.3	O
%	O
)	O
,	O
117	O
mg/m	O
(	O
2	O
)	O
for	O
cisplatin	B-Chemical
(	O
97.3	O
%	O
)	O
,	O
and	O
1378	O
mg/m	O
(	O
2	O
)	O
for	O
gemcitabine	B-Chemical
(	O
86.2	O
%	O
)	O
.	O

World	O
Health	O
Organization	O
Grade	O
3-4	O
neutropenia	B-Disease
and	O
thrombocytopenia	B-Disease
occurred	O
in	O
39.9	O
%	O
and	O
11.4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

There	O
was	O
one	O
treatment-related	O
death	B-Disease
.	O

Nonhematologic	O
toxicities	B-Disease
were	O
mild	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
22	O
months	O
,	O
the	O
median	O
progression	O
free	O
survival	O
rate	O
was	O
7	O
months	O
,	O
and	O
the	O
median	O
survival	O
time	O
was	O
16	O
months	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	B-Disease
.	O

This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin-based	B-Chemical
regimens	O
.	O

Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	B-Chemical
hydrochloride	I-Chemical
ophthalmic	O
solution	O
.	O

We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	B-Chemical
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1	O
%	O
apraclonidine	B-Chemical
in	O
their	O
right	O
eyes	O
.	O

Examinations	O
,	O
including	O
blood	O
pressure	O
,	O
pulse	O
rate	O
,	O
conjunctiva	O
and	O
cornea	O
,	O
intraocular	B-Disease
pressure	O
(	O
IOP	O
)	O
,	O
pupil	O
diameter	O
,	O
basal	O
tear	O
secretion	O
and	O
margin	O
reflex	O
distance	O
of	O
both	O
upper	O
and	O
lower	O
eyelids	O
,	O
were	O
performed	O
prior	O
to	O
entry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
instillation	O
.	O

The	O
ocular	B-Disease
hypotensive	O
effects	O
were	O
statistically	O
significant	O
for	O
apraclonidine-treated	B-Chemical
eyes	O
throughout	O
the	O
study	O
and	O
also	O
statistically	O
significant	O
for	O
contralateral	O
eyes	O
from	O
three	O
hours	O
after	O
topical	O
administration	O
of	O
1	O
%	O
apraclonidine	B-Chemical
.	O

Decreases	B-Disease
in	I-Disease
systolic	I-Disease
blood	I-Disease
pressure	I-Disease
were	O
statistically	O
,	O
but	O
not	O
clinically	O
,	O
significant	O
.	O

No	O
significant	O
changes	O
in	O
diastolic	O
blood	O
pressure	O
,	O
pulse	O
rate	O
and	O
basal	O
tear	O
secretion	O
were	O
noted	O
.	O

Conjunctival	B-Disease
blanching	I-Disease
and	O
mydriasis	B-Disease
were	O
commonly	O
found	O
.	O

Upper	O
lid	O
retraction	O
was	O
frequently	O
noted	O
.	O

While	O
the	O
elevations	O
of	O
the	O
upper	O
lid	O
margin	O
in	O
most	O
subjects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appearance	O
,	O
one	O
subject	O
suffered	O
from	O
mechanical	O
entropion	B-Disease
and	O
marked	O
corneal	B-Disease
abrasion	I-Disease
3	O
hours	O
after	O
instillation	O
of	O
the	O
medication	O
.	O

This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
finding	O
in	O
Asian	O
people	O
.	O

Carmofur-induced	B-Chemical
organic	B-Disease
mental	I-Disease
disorders	I-Disease
.	O

Organic	B-Disease
mental	I-Disease
disorder	I-Disease
was	O
observed	O
in	O
a	O
29-year-old	O
female	O
in	O
the	O
prognostic	O
period	O
after	O
the	O
onset	O
of	O
carmofur-induced	B-Chemical
leukoencephalopathy	B-Disease
.	O

Symptoms	O
such	O
as	O
euphoria	O
,	O
emotional	O
lability	O
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	B-Disease
personality	I-Disease
syndrome	I-Disease
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM-III-R	O
.	O

It	O
is	O
referred	O
to	O
as	O
a	O
frontal	B-Disease
lobe	I-Disease
syndrome	I-Disease
.	O

Brain	O
CT	O
revealed	O
a	O
periventricular	O
low	O
density	O
area	O
in	O
the	O
frontal	O
white	O
matter	O
and	O
moderate	O
dilatation	O
of	O
the	O
lateral	O
ventricles	O
especially	O
at	O
the	O
bilateral	O
anterior	O
horns	O
.	O

Consequently	O
,	O
carmofur-induced	B-Chemical
leukoencephalopathy	B-Disease
may	O
uncommonly	O
result	O
in	O
organic	B-Disease
personality	I-Disease
syndrome	I-Disease
in	O
the	I-Disease
residual	O
state	O
.	O

It	O
may	O
be	O
attributed	O
to	I-Disease
the	I-Disease
structural	B-Disease
damage	I-Disease
to	I-Disease
the	O
frontal	O
lobe	O
.	O

International	O
mexiletine	B-Chemical
and	O
placebo	O
antiarrhythmic	B-Drug
coronary	O
trial	O
:	O
I	O
.	O

Report	O
on	O
arrhythmia	B-Disease
and	O
other	O
findings	O
.	O

Impact	O
Research	O
Group	O
.	O

The	O
antiarrhythmic	B-Drug
effects	O
of	O
the	O
sustained	O
release	O
form	O
of	O
mexiletine	B-Chemical
(	O
Mexitil-Perlongets	B-Chemical
)	O
were	O
evaluated	O
in	O
a	O
double-blind	O
placebo	O
trial	O
in	O
630	O
patients	O
with	O
recent	O
documented	O
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
primary	O
response	O
variable	O
was	O
based	O
on	O
central	O
reading	O
of	O
24	O
hour	O
ambulatory	O
electrocardiographic	O
recordings	O
and	O
was	O
defined	O
as	O
the	O
occurrence	O
of	O
30	O
or	O
more	O
single	O
premature	O
ventricular	O
complexes	O
in	O
any	O
two	O
consecutive	O
30	O
minute	O
blocks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
premature	O
ventricular	O
complexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocardiographic	O
recording	O
.	O

Large	O
differences	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexiletine	B-Chemical
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12	O
.	O

These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
serum	O
mexiletine	B-Chemical
levels	O
obtained	O
in	O
this	O
study	O
were	O
generally	O
lower	O
than	O
those	O
observed	O
in	O
studies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
drug	B-Drug
.	O

There	O
were	O
more	O
deaths	B-Disease
in	O
the	O
mexiletine	B-Chemical
group	O
(	O
7.6	O
%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
4.8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

The	O
incidence	O
of	O
coronary	O
events	O
was	O
similar	O
in	O
both	O
groups	O
.	O

Previously	O
recognized	O
side	O
effects	O
,	O
particularly	O
tremor	B-Disease
and	O
gastrointestinal	B-Disease
problems	I-Disease
,	O
were	O
more	O
frequent	O
in	O
the	O
mexiletine	B-Chemical
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine-induced	B-Chemical
hyperactivity	B-Disease
by	O
intracerebral	O
calcitonin	B-Chemical
injections	O
.	O

Calcitonin	B-Chemical
receptors	O
are	O
found	O
in	O
the	O
brain	O
,	O
and	O
intracerebral	O
infusions	O
of	O
calcitonin	B-Chemical
can	O
produce	O
behavioral	O
effects	O
.	O

Among	O
these	O
behavioral	O
effects	O
are	O
decreases	O
in	O
food	O
intake	O
and	O
decreases	O
in	O
amphetamine-induced	B-Chemical
locomotor	O
activity	O
.	O

In	O
previous	O
experiments	O
we	O
found	O
that	O
decreases	O
in	O
food	O
intake	O
were	O
induced	O
by	O
local	O
administration	O
of	O
calcitonin	B-Chemical
into	O
several	O
hypothalamic	O
sites	O
and	O
into	O
the	O
nucleus	O
accumbens	O
.	O

In	O
the	O
present	O
experiment	O
calcitonin	B-Chemical
decreased	O
locomotor	O
activity	O
when	O
locally	O
injected	O
into	O
the	O
same	O
sites	O
where	O
it	O
decreases	O
food	O
intake	O
.	O

The	O
areas	O
where	O
calcitonin	B-Chemical
is	O
most	O
effective	O
in	O
decreasing	O
locomotor	O
activity	O
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	O
accumbens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sites	O
of	O
action	O
of	O
calcitonin	B-Chemical
in	O
inhibiting	O
amphetamine-induced	B-Chemical
locomotor	O
activity	O
.	O

Fatal	O
intracranial	B-Disease
bleeding	I-Disease
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	B-Chemical
.	O

We	O
present	O
a	O
case	O
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	O
of	O
allergic	B-Disease
reaction	I-Disease
in	O
a	O
case	O
of	O
pulmonary	B-Disease
edema	I-Disease
with	O
wheezing	B-Disease
.	O

The	O
sudden	O
onset	O
of	O
respiratory	B-Disease
distress	I-Disease
,	O
rash	B-Disease
,	O
and	O
a	O
history	O
of	O
a	O
new	O
medicine	O
led	O
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	O
epinephrine	B-Chemical
.	O

Subsequently	O
,	O
acute	O
cardiac	B-Disease
arrest	I-Disease
and	O
fatal	O
subarachnoid	B-Disease
hemorrhage	I-Disease
occurred	O
.	O

Epinephrine	B-Chemical
has	O
a	O
proven	O
role	O
in	O
cardiac	B-Disease
arrest	I-Disease
in	O
prehospital	O
care	O
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	B-Disease
reaction	I-Disease
and	O
severe	O
hypertension	B-Disease
should	O
be	O
viewed	O
with	O
caution	O
.	O

A	O
case	O
of	O
massive	O
rhabdomyolysis	B-Disease
following	O
molindone	B-Chemical
administration	O
.	O

Rhabdomyolysis	B-Disease
is	O
a	O
potentially	O
lethal	O
syndrome	O
that	O
psychiatric	B-Disease
patients	O
seem	O
predisposed	O
to	O
develop	O
.	O

The	O
clinical	O
signs	O
and	O
symptoms	O
,	O
typical	O
laboratory	O
features	O
,	O
and	O
complications	O
of	O
rhabdomyolysis	B-Disease
are	O
presented	O
.	O

The	O
case	O
of	O
a	O
schizophrenic	B-Disease
patient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysis	B-Disease
and	O
subsequent	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
molindone	B-Chemical
administration	O
.	O

Physicians	O
who	O
prescribe	O
molindone	B-Chemical
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O

Cardiovascular	B-Disease
alterations	I-Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
calcium	B-Chemical
channel	O
blockers	O
.	O

Preclinical	O
toxicologic	O
investigation	O
suggested	O
that	O
a	O
new	O
calcium	B-Chemical
channel	O
blocker	O
,	O
Ro	B-Chemical
40-5967	I-Chemical
,	O
induced	O
cardiovascular	B-Disease
alterations	I-Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
this	O
agent	O
during	O
organogenesis	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	B-Chemical
channel	O
blockers	O
in	O
general	O
induce	O
cardiovascular	B-Disease
malformations	I-Disease
indicating	O
a	O
pharmacologic	O
class	O
effect	O
.	O

We	O
studied	O
three	O
calcium	B-Chemical
channel	O
blockers	O
of	O
different	O
structure	O
,	O
nifedipine	B-Chemical
,	O
diltiazem	B-Chemical
,	O
and	O
verapamil	B-Chemical
,	O
along	O
with	O
the	O
new	O
agent	O
.	O

Pregnant	O
rats	O
were	O
administered	O
one	O
of	O
these	O
calcium	B-Chemical
channel	O
blockers	O
during	O
the	O
period	O
of	O
cardiac	O
morphogenesis	O
and	O
the	O
offspring	O
examined	O
on	O
day	O
20	O
of	O
gestation	O
for	O
cardiovascular	B-Disease
malformations	I-Disease
.	O

A	O
low	O
incidence	O
of	O
cardiovascular	B-Disease
malformations	I-Disease
was	O
observed	O
after	O
exposure	O
to	O
each	O
of	O
the	O
four	O
calcium	B-Chemical
channel	O
blockers	O
,	O
but	O
this	O
incidence	O
was	O
statistically	O
significant	O
only	O
for	O
verapamil	B-Chemical
and	O
nifedipine	B-Chemical
.	O

All	O
four	O
agents	O
were	O
associated	O
with	O
aortic	O
arch	O
branching	O
variants	O
,	O
although	O
significantly	O
increased	O
only	O
for	O
Ro	B-Chemical
40-5967	I-Chemical
and	O
verapamil	B-Chemical
.	O

Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine-resistant	B-Chemical
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
e	B-Chemical
antigen-positive	O
and	O
-negative	O
strains	O
.	O

Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	O
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O

Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O

We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	B-Drug
susceptibility	O
of	O
common	O
treatment-associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-Chemical
(	O
LAM	B-Chemical
)	O
and/or	O
HBeAg	B-Chemical
negativity	O
.	O

Replication-competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	B-Chemical
resistance	O
(	O
rtM204I	O
or	O
rtL180M/rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg-positive	B-Chemical
and	O
an	O
HBeAg-negative	B-Chemical
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	B-Drug
(	O
BCP	O
)	O
mutants	O
.	O

The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	B-Chemical
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM-resistant	B-Chemical
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild-type	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O

Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	B-Chemical
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM-resistant	B-Chemical
clones	O
.	O

However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	B-Chemical
negativity	O
(	O
PC/BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	B-Chemical
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild-type	O
HBV	O
.	O

In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	B-Chemical
resistance	O
mutations	O
,	O
the	O
nucleotide	B-Chemical
analogues	O
adefovir	B-Chemical
and	O
tenofovir	B-Chemical
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O

These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	B-Drug
susceptibility	O
of	O
complex	O
HBV	O
mutants	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O

The	O
effects	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine-induced	B-Chemical
convulsions	B-Disease
.	O

The	O
influence	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine-induced	B-Chemical
convulsions	B-Disease
was	O
studied	O
in	O
cats	O
.	O

The	O
convulsive	B-Disease
threshold	O
(	O
mean	O
+/-	O
SD	O
)	O
was	O
41.4	O
+/-	O
6.5	O
mg.	O
l	O
(	O
-1	O
)	O
with	O
lidocaine	B-Chemical
infusion	O
(	O
6	O
mg.kg	O
(	O
-1	O
)	O
.min	O
(	O
-1	O
)	O
)	O
,	O
increasing	O
significantly	O
to	O
66.6	O
+/-	O
10.9	O
mg.	O
l	O
(	O
-1	O
)	O
when	O
the	O
end-tidal	O
concentration	O
of	O
sevoflurane	B-Chemical
was	O
0.8	O
%	O
.	O

However	O
,	O
the	O
threshold	O
(	O
61.6	O
+/-	O
8.7	O
mg.	O
l	O
(	O
-1	O
)	O
)	O
during	O
1.6	O
%	O
sevoflurane	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0.8	O
%	O
sevoflurane	B-Chemical
,	O
indicating	O
a	O
celling	O
effect	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	B-Disease
threshold	O
between	O
sevoflurane	B-Chemical
and	O
enflurane	B-Chemical
.	O

The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	B-Chemical
or	O
enflurane	B-Chemical
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	B-Disease
decreased	O
significantly	O
in	O
1.6	O
%	O
sevoflurane	B-Chemical
,	O
and	O
in	O
0.8	O
%	O
and	O
1.6	O
%	O
enflurane	B-Chemical
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	B-Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O

Apamin	B-Chemical
,	O
a	O
selective	O
blocker	O
of	O
calcium-dependent	B-Chemical
potassium	B-Chemical
channels	O
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0.8	O
%	O
sevoflurane	B-Chemical
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O

Apamin	B-Chemical
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	B-Disease
threshold	O
(	O
21.6	O
+/-	O
2.2	O
to	O
19.9	O
+/-	O
2.5	O
mg.	O
l	O
(	O
-1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O

It	O
is	O
suggested	O
that	O
sevoflurane	B-Chemical
reduces	O
the	O
convulsive	B-Disease
effect	O
of	O
lidocaine	B-Chemical
toxicity	B-Disease
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	B-Disease
.	O

Anti-oxidant	O
effects	O
of	O
atorvastatin	B-Chemical
in	O
dexamethasone-induced	B-Chemical
hypertension	B-Disease
in	O
the	O
rat	O
.	O

1	O
.	O

Dexamethasone	B-Chemical
(	O
Dex	B-Chemical
)	O
-induced	O
hypertension	B-Disease
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
and	O
increased	O
superoxide	B-Chemical
(	O
O2-	B-Chemical
)	O
production	O
.	O

Atorvastatin	B-Chemical
(	O
Ato	B-Chemical
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	B-Chemical
and	O
reduced	O
O2-	B-Chemical
production	O
in	O
various	O
forms	O
of	O
hypertension	B-Disease
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
50	O
mg/kg	O
per	O
day	O
,	O
p.o.	O
,	O
Ato	B-Chemical
could	O
prevent	O
endothelial	O
NO	B-Chemical
synthase	O
(	O
eNOS	O
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2-	B-Chemical
in	O
Sprague-Dawley	O
(	O
SD	O
)	O
rats	O
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O

2	O
.	O

Male	O
SD	O
rats	O
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	B-Chemical
(	O
50	O
mg/kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dexamethasone	B-Chemical
(	O
10	O
microg/kg	O
per	O
day	O
,	O
s.c.	O
)	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato-treated	B-Chemical
and	O
non-treated	O
rats	O
and	O
continued	O
for	O
11-13	O
days	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
on	O
alternate	O
days	O
using	O
the	O
tail-cuff	O
method	O
.	O

Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine-induced	B-Chemical
vasorelaxation	O
and	O
phenylephrine-induced	B-Chemical
vasoconstriction	O
in	O
aortic	O
segments	O
.	O

Vascular	O
eNOS	O
mRNA	O
was	O
assessed	O
by	O
semi-quantitative	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
.	O

3	O
.	O

In	O
rats	O
treated	O
with	O
Dex	B-Chemical
alone	O
,	O
SBP	O
was	O
increased	O
from	O
109	O
+/-	O
2	O
to	O
133	O
+/-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
the	O
Ato	B-Chemical
+	O
Dex	B-Chemical
group	O
,	O
SBP	O
was	O
increased	O
from	O
113	O
+/-	O
2	O
to	O
119	O
+/-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
,	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Endothelial-dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
than	O
in	O
the	O
Dex	B-Chemical
only	O
group	O
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

Aortic	O
superoxide	B-Chemical
production	O
was	O
lower	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

4	O
.	O

Treatment	O
with	O
Ato	B-Chemical
improved	O
endothelial	O
function	O
,	O
reduced	O
superoxide	B-Chemical
production	O
and	O
reduced	O
SBP	O
in	O
Dex-treated	B-Chemical
SD	O
rats	O
.	O

99mTc-glucarate	B-Chemical
for	O
detection	O
of	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Infarct-avid	B-Disease
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	B-Disease
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	B-Chemical
.	O

A	O
new	O
infarct-avid	B-Disease
radiopharmaceutical	O
based	O
on	O
glucaric	B-Chemical
acid	I-Chemical
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

99mTc-glucarate	B-Chemical
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol-induced	B-Chemical
acute	O
myocardial	B-Disease
infarction	I-Disease
.	O

Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	B-Disease
18	O
h	O
after	O
isoproterenol	B-Chemical
administration	O
.	O

The	O
rat	O
biodistribution	O
studies	O
showed	O
a	O
rapid	O
blood	O
clearance	O
via	O
the	O
kidneys	O
.	O

Thirty	O
minutes	O
after	O
99mTc-glucarate	B-Chemical
administration	O
the	O
standardised	O
heart	O
uptake	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4.7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O

ROIs	O
drawn	O
over	O
the	O
gamma	O
camera	O
images	O
showed	O
a	O
ratio	O
of	O
4.4	O
.	O

The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	O
detect	O
,	O
in	O
patients	O
,	O
early	O
cardiac	B-Disease
infarction	I-Disease
.	O

A	O
randomized	O
,	O
placebo-controlled	O
dose-comparison	O
trial	O
of	O
haloperidol	B-Chemical
for	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
two	O
doses	O
of	O
haloperidol	B-Chemical
and	O
placebo	O
in	O
the	O
treatment	O
of	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
in	O
patients	O
with	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

METHOD	O
:	O
In	O
a	O
6-week	O
random-assignment	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
(	O
phase	O
A	O
)	O
,	O
haloperidol	B-Chemical
,	O
2-3	O
mg/day	O
(	O
standard	O
dose	O
)	O
,	O
and	O
haloperidol	B-Chemical
,	O
0.50-0.75	O
mg/day	O
(	O
low	O
dose	O
)	O
,	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

For	O
the	O
subsequent	O
6-week	O
double-blind	O
crossover	O
phase	O
(	O
phase	O
B	O
)	O
,	O
patients	O
taking	O
standard-	O
or	O
low-dose	O
haloperidol	B-Chemical
were	O
switched	O
to	O
placebo	O
,	O
and	O
patients	O
taking	O
placebo	O
were	O
randomly	O
assigned	O
to	O
standard-	O
or	O
low-dose	O
haloperidol	B-Chemical
.	O

RESULTS	O
:	O
For	O
the	O
60	O
patients	O
who	O
completed	O
phase	O
A	O
,	O
standard-dose	O
haloperidol	B-Chemical
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low-dose	O
haloperidol	B-Chemical
and	O
placebo	O
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
psychosis	B-Disease
factor	O
and	O
on	O
psychomotor	B-Disease
agitation	I-Disease
.	O

Response	O
rates	O
according	O
to	O
three	O
sets	O
of	O
criteria	O
were	O
greater	O
with	O
the	O
standard	O
dose	O
(	O
55	O
%	O
-60	O
%	O
)	O
than	O
the	O
low	O
dose	O
(	O
25	O
%	O
-35	O
%	O
)	O
and	O
placebo	O
(	O
25	O
%	O
-30	O
%	O
)	O
.	O

The	O
advantage	O
of	O
standard	O
dose	O
over	O
low	O
dose	O
was	O
replicated	O
in	O
phase	O
B	O
.	O

In	O
phase	O
A	O
,	O
extrapyramidal	B-Disease
signs	I-Disease
tended	O
to	O
be	O
greater	O
with	O
the	O
standard	O
dose	O
than	O
in	O
the	O
other	O
two	O
conditions	O
,	O
primarily	O
because	O
of	O
a	O
subgroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
moderate	O
to	O
severe	O
signs	O
.	O

Low-dose	O
haloperidol	B-Chemical
did	O
not	O
differ	O
from	O
placebo	O
on	O
any	O
measure	O
of	O
efficacy	O
or	O
side	O
effects	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
indicated	O
a	O
favorable	O
therapeutic	O
profile	O
for	O
haloperidol	B-Chemical
in	O
doses	O
of	O
2-3	O
mg/day	O
,	O
although	O
a	O
subgroup	O
developed	O
moderate	O
to	O
severe	O
extrapyramidal	B-Disease
signs	I-Disease
.	O

A	O
starting	O
dose	O
of	O
1	O
mg/day	O
with	O
gradual	O
,	O
upward	O
dose	O
titration	O
is	O
recommended	O
.	O

The	O
narrow	O
therapeutic	O
window	O
observed	O
with	O
haloperidol	B-Chemical
may	O
also	O
apply	O
to	O
other	O
neuroleptics	O
used	O
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
patients	O
with	O
psychosis	B-Disease
and	O
disruptive	B-Disease
behaviors	I-Disease
.	O

Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	O
susceptibility	O
to	O
adriamycin-induced	B-Chemical
renal	B-Disease
damage	I-Disease
.	O

BACKGROUND	O
:	O
In	O
man	O
,	O
differences	O
in	O
angiotensin-converting	B-Chemical
enzyme	O
(	O
ACE	O
)	O
levels	O
,	O
related	O
to	O
ACE	O
(	O
I/D	O
)	O
genotype	O
,	O
are	O
associated	O
with	O
renal	B-Disease
prognosis	O
.	O

This	O
raises	O
the	O
hypothesis	O
that	O
individual	O
differences	O
in	O
renal	B-Disease
ACE	O
activity	O
are	O
involved	O
in	O
renal	O
susceptibility	O
to	O
inflicted	O
damage	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
predictive	O
effect	O
of	O
renal	O
ACE	O
activity	O
for	O
the	O
severity	O
of	O
renal	O
damage	O
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	B-Chemical
in	O
rats	O
.	O

METHODS	O
:	O
Renal	O
ACE	O
activity	O
(	O
Hip-His-Leu	B-Chemical
cleavage	O
by	O
cortical	O
homogenates	O
)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats	O
.	O

After	O
1	O
week	O
of	O
recovery	O
,	O
proteinuria	B-Disease
was	O
induced	O
by	O
adriamycin	B-Chemical
[	O
1.5	O
mg/kg	O
intravenously	O
(	O
i.v	O
.	O

)	O
n	O
=	O
18	O
;	O
controls	O
,	O
saline	O
i.v	O
.	O

n	O
=	O
9	O
]	O
.	O

Proteinuria	B-Disease
was	O
measured	O
every	O
2	O
weeks	O
.	O

After	O
12	O
weeks	O
,	O
rats	O
were	O
sacrificed	O
and	O
their	O
kidneys	O
harvested	O
.	O

RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycin	B-Chemical
elicited	O
nephrotic	B-Disease
range	O
proteinuria	B-Disease
,	O
renal	B-Disease
interstitial	I-Disease
damage	I-Disease
and	O
mild	O
focal	B-Disease
glomerulosclerosis	I-Disease
.	O

Baseline	O
renal	O
ACE	O
positively	O
correlated	O
with	O
the	O
relative	O
rise	O
in	O
proteinuria	B-Disease
after	O
adriamycin	B-Chemical
(	O
r	O
=	O
0.62	O
,	O
P	O
<	O
0.01	O
)	O
,	O
renal	O
interstitial	O
alpha-smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0.49	O
,	O
P	O
<	O
0.05	O
)	O
,	O
interstitial	O
macrophage	O
influx	O
(	O
r	O
=	O
0.56	O
,	O
P	O
<	O
0.05	O
)	O
,	O
interstitial	O
collagen	O
III	O
(	O
r	O
=	O
0.53	O
,	O
P	O
<	O
0.05	O
)	O
,	O
glomerular	O
alpha-smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0.74	O
,	O
P	O
<	O
0.01	O
)	O
and	O
glomerular	O
desmin	O
(	O
r	O
=	O
0.48	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Baseline	O
renal	O
ACE	O
did	O
not	O
correlate	O
with	O
focal	B-Disease
glomerulosclerosis	I-Disease
(	O
r	O
=	O
0.22	O
,	O
NS	O
)	O
.	O

In	O
controls	O
,	O
no	O
predictive	O
values	O
for	O
renal	O
parameters	O
were	O
observed	O
.	O

CONCLUSION	O
:	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	O
the	O
severity	O
of	O
adriamycin-induced	B-Chemical
renal	B-Disease
damage	I-Disease
in	O
this	O
outbred	O
rat	O
strain	O
.	O

This	O
supports	O
the	O
assumption	O
that	O
differences	O
in	O
renal	B-Disease
ACE	O
activity	O
predispose	O
to	O
a	O
less	O
favourable	O
course	O
of	O
renal	B-Disease
damage	O
.	O

Clinical	O
nephrotoxicity	B-Disease
of	O
tobramycin	B-Chemical
and	O
gentamicin	B-Chemical
.	O

A	O
prospective	O
study	O
.	O

Nearly	O
3.2	O
million	O
people	O
in	O
this	O
country	O
receive	O
aminoglycoside	B-Chemical
antibiotics	B-Drug
annually	O
.	O

Gentamicin	B-Chemical
sulfate	I-Chemical
and	O
tobramycin	B-Chemical
sulfate	I-Chemical
continue	O
to	O
demonstrate	O
ototoxicity	B-Disease
and	O
nephrotoxicity	B-Disease
in	O
both	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
study	O
,	O
62	O
patients	O
with	O
confirmed	O
initial	O
normal	O
renal	O
function	O
and	O
treated	O
with	O
2	O
to	O
5	O
mg/kg/day	O
of	O
gentamicin	B-Chemical
sulfate	I-Chemical
or	O
tobramycin	B-Chemical
sulfate	I-Chemical
for	O
a	O
minimum	O
of	O
seven	O
days	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	O
of	O
aminoglycoside-related	B-Chemical
renal	B-Disease
failure	I-Disease
,	O
defined	O
as	O
at	O
least	O
a	O
one-third	O
reduction	O
in	O
renal	B-Disease
function	O
.	O

In	O
these	O
62	O
patients	O
,	O
no	O
other	O
causes	O
for	O
renal	B-Disease
failure	O
could	O
be	O
identified	O
.	O

Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramycin-treated	B-Chemical
patients	O
and	O
16	O
of	O
29	O
(	O
55.2	O
%	O
)	O
of	O
the	O
gentamicin-treated	B-Chemical
patients	O
had	O
renal	B-Disease
failure	I-Disease
.	O

Thus	O
,	O
gentamicin	B-Chemical
was	O
associated	O
with	O
renal	B-Disease
failure	I-Disease
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramycin	B-Chemical
.	O

Neuroprotective	O
action	O
of	O
MPEP	B-Chemical
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine-induced	B-Chemical
dopaminergic	B-Drug
neurotoxicity	B-Disease
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	B-Chemical
outflow	O
and	O
inhibition	O
of	O
hyperthermia	B-Disease
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	B-Chemical
receptor	O
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	B-Chemical
on	O
dopaminergic	B-Drug
neurones	O
in	O
rats	O
.	O

Methamphetamine	B-Chemical
(	O
10	O
mg/kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	O
the	O
levels	O
of	O
dopamine	B-Chemical
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2-methyl-6-	B-Chemical
(	I-Chemical
phenylethynyl	I-Chemical
)	I-Chemical
pyridine	I-Chemical
(	O
MPEP	B-Chemical
;	O
5	O
mg/kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	B-Chemical
injection	O
reversed	O
the	O
above-mentioned	O
methamphetamine	B-Chemical
effects	O
.	O

A	O
single	O
MPEP	B-Chemical
(	O
5	O
mg/kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	B-Chemical
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	B-Chemical
release	O
stimulated	O
either	O
by	O
methamphetamine	B-Chemical
(	O
10	O
mg/kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	B-Chemical
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	B-Chemical
(	O
10	O
mg/kg	O
sc	O
)	O
-induced	O
hyperthermia	B-Disease
and	O
reduced	O
basal	O
body	O
temperature	O
.	O

MPEP	B-Chemical
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	O
extracellular	O
dopamine	B-Chemical
levels	O
,	O
while	O
lower	O
concentrations	O
(	O
50-100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	B-Chemical
may	O
protect	O
dopaminergic	B-Drug
neurones	O
against	O
methamphetamine-induced	B-Chemical
toxicity	B-Disease
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	B-Chemical
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine-induced	B-Chemical
dopamine	B-Chemical
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	B-Disease
.	O

Pharmacokinetics	O
of	O
desipramine	B-Chemical
HCl	I-Chemical
when	O
administered	O
with	O
cinacalcet	B-Chemical
HCl	I-Chemical
.	O

OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	B-Chemical
on	O
CYP2D6	B-Drug
activity	O
,	O
using	O
desipramine	B-Chemical
as	O
a	O
probe	O
substrate	O
,	O
in	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	B-Drug
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open-label	O
,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	B-Chemical
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
,	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	B-Chemical
(	O
90	O
mg	O
for	O
7	O
days	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
predose	O
and	O
up	O
to	O
72	O
h	O
postdose	O
.	O

RESULTS	O
:	O
Fourteen	O
subjects	O
completed	O
both	O
treatment	O
arms	O
.	O

Relative	O
to	O
desipramine	B-Chemical
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desipramine	B-Chemical
increased	O
3.6-	O
and	O
1.8-fold	O
when	O
coadministered	O
with	O
cinacalcet	B-Chemical
.	O

The	O
t	O
(	O
1/2	O
,	O
z	O
)	O
of	O
desipramine	B-Chemical
was	O
longer	O
when	O
desipramine	B-Chemical
was	O
coadministered	O
with	O
cinacalcet	B-Chemical
(	O
21.0	O
versus	O
43.3	O
hs	O
)	O
.	O

The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimens	O
.	O

Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	B-Chemical
alone	O
than	O
when	O
receiving	O
desipramine	B-Chemical
with	O
cinacalcet	B-Chemical
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	B-Disease
and	O
headache	B-Disease
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	B-Chemical
or	O
cinacalcet	B-Chemical
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	B-Drug
.	O

These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	B-Chemical
,	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	B-Drug
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	B-Drug
.	O

Proteomic	O
analysis	O
of	O
striatal	O
proteins	O
in	O
the	O
rat	O
model	O
of	O
L-DOPA-induced	B-Chemical
dyskinesia	B-Disease
.	O

L-DOPA-induced	B-Chemical
dyskinesia	B-Disease
(	O
LID	B-Disease
)	O
is	O
among	O
the	O
motor	O
complications	O
that	O
arise	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
patients	O
after	O
a	O
prolonged	O
treatment	O
with	O
L-DOPA	B-Chemical
.	O

To	O
this	O
day	O
,	O
transcriptome	O
analysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
model	O
of	O
LID	B-Disease
[	O
Neurobiol	O
.	O

Dis.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
information	O
regarding	O
the	O
proteome	O
is	O
still	O
lacking	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
occurring	O
at	O
the	O
protein	O
level	O
in	O
striatal	O
samples	O
obtained	O
from	O
the	O
unilaterally	O
6-hydroxydopamine-lesion	B-Chemical
rat	O
model	O
of	O
PD	B-Disease
treated	O
with	O
saline	O
,	O
L-DOPA	B-Chemical
or	O
bromocriptine	B-Chemical
using	O
two-dimensional	O
difference	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
(	O
MS	O
)	O
.	O

Rats	O
treated	O
with	O
L-DOPA	B-Chemical
were	O
allocated	O
to	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	B-Disease
.	O

Among	O
the	O
2000	O
spots	O
compared	O
for	O
statistical	O
difference	O
,	O
67	O
spots	O
were	O
significantly	O
changed	O
in	O
abundance	O
and	O
identified	O
using	O
matrix-assisted	O
laser	O
desorption/ionization	O
time-of-flight	O
MS	O
,	O
atmospheric	O
pressure	O
matrix-assisted	O
laser	O
desorption/ionization	O
and	O
HPLC	O
coupled	O
tandem	O
MS	O
(	O
LC/MS/MS	O
)	O
.	O

Out	O
of	O
these	O
67	O
proteins	O
,	O
LID	B-Disease
significantly	O
changed	O
the	O
expression	O
level	O
of	O
five	O
proteins	O
:	O
alphabeta-crystalin	O
,	O
gamma-enolase	O
,	O
guanidoacetate	O
methyltransferase	O
,	O
vinculin	O
,	O
and	O
proteasome	O
alpha-2	O
subunit	O
.	O

Complementary	O
techniques	O
such	O
as	O
western	O
immunoblotting	O
and	O
immunohistochemistry	O
were	O
performed	O
to	O
investigate	O
the	O
validity	O
of	O
the	O
data	O
obtained	O
using	O
the	O
proteomic	O
approach	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
provides	O
new	O
insights	O
into	O
the	O
protein	O
changes	O
occurring	O
in	O
LID	B-Disease
.	O

Pseudo-allergic	B-Disease
reactions	I-Disease
to	O
corticosteroids	B-Chemical
:	O
diagnosis	O
and	O
alternatives	O
.	O

Two	O
patients	O
treated	O
with	O
parenteral	O
paramethasone	B-Chemical
(	O
Triniol	O
)	O
and	O
dexamethasone	B-Chemical
(	O
Sedionbel	O
)	O
are	O
described	O
.	O

A	O
few	O
minutes	O
after	O
administration	O
of	O
the	O
drugs	B-Drug
,	O
they	O
presented	O
urticaria	B-Disease
(	O
patients	O
1	O
and	O
2	O
)	O
and	O
conjunctivitis	B-Disease
(	O
patient	O
1	O
)	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patients	O
'	O
reactions	O
,	O
the	O
immunological	O
mechanisms	O
involved	O
and	O
whether	O
these	O
patients	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticoid	O
.	O

Clinical	O
examinations	O
and	O
skin	O
,	O
oral	O
and	O
parenteral	O
challenges	O
with	O
different	O
corticosteroids	B-Chemical
and	O
ELISA	O
tests	O
were	O
performed	O
.	O

In	O
the	O
two	O
patients	O
,	O
skin	O
and	O
ELISA	O
tests	O
with	O
paramethasone	B-Chemical
were	O
negative	O
,	O
as	O
was	O
the	O
prick	O
test	O
with	O
each	O
of	O
its	O
excipients	O
.	O

A	O
single-blind	O
parenteral	O
challenge	O
with	O
Triniol	O
was	O
positive	O
in	O
both	O
patients	O
after	O
the	O
administration	O
of	O
1	O
ml	O
of	O
the	O
drug	B-Drug
,	O
and	O
negative	O
with	O
its	O
excipients	O
.	O

We	O
also	O
carried	O
out	O
oral	O
and	O
parenteral	O
challenges	O
with	O
other	O
corticosteroids	B-Chemical
and	O
found	O
intolerance	O
to	O
some	O
of	O
them	O
.	O

These	O
results	O
suggest	O
that	O
paramethasone	B-Chemical
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients	O
.	O

Corticosteroids	O
different	O
from	O
paramethasone	B-Chemical
also	O
produced	O
hypersensitivity	B-Disease
reactions	O
in	O
these	O
patients	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolerated	O
.	O

The	O
basic	O
mechanisms	O
of	O
those	O
reactions	O
are	O
not	O
yet	O
fully	O
understood	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
pseudo-allergy	B-Disease
caused	O
by	O
paramethasone	B-Chemical
.	O

Valproic	B-Chemical
acid	I-Chemical
induced	O
encephalopathy	B-Disease
--	O
19	O
new	O
cases	O
in	O
Germany	O
from	O
1994	O
to	O
2003	O
--	O
a	O
side	O
effect	O
associated	O
to	O
VPA-therapy	B-Chemical
not	O
only	O
in	O
young	O
children	O
.	O

Valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
a	O
broad-spectrum	O
antiepileptic	O
drug	B-Drug
and	O
is	O
usually	O
well-tolerated	O
.	O

Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	B-Disease
,	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
,	O
VPA-induced	B-Chemical
hepatotoxicity	B-Disease
and	O
VPA-induced	B-Chemical
encephalopathy	B-Disease
.	O

The	O
typical	O
signs	O
of	O
VPA-induced	B-Chemical
encephalopathy	B-Disease
are	O
impaired	B-Disease
consciousness	I-Disease
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing	O
,	O
increased	O
seizure	B-Disease
frequency	O
,	O
with	O
or	O
without	O
hyperammonemia	B-Disease
.	O

There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	O
of	O
VPA	B-Chemical
in	O
patients	O
with	O
encephalopathy	B-Disease
,	O
but	O
only	O
of	O
an	O
association	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O

We	O
report	O
19	O
patients	O
with	O
VPA-associated	B-Chemical
encephalopathy	B-Disease
in	O
Germany	O
from	O
the	O
years	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
published	O
previously	O
.	O

Haemolytic-uraemic	B-Disease
syndrome	I-Disease
after	O
treatment	O
with	O
metronidazole	B-Chemical
.	O

This	O
paper	O
describes	O
the	O
clinical	O
features	O
of	O
six	O
children	O
who	O
developed	O
the	O
haemolytic-uraemic	B-Disease
syndrome	I-Disease
after	O
treatment	O
with	O
metronidazole	B-Chemical
.	O

These	O
children	O
were	O
older	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bowel	O
surgery	O
than	O
are	O
other	O
children	O
with	O
this	O
condition	O
.	O

While	O
the	O
involvement	O
of	O
metronidazole	B-Chemical
in	O
the	O
aetiology	O
of	O
the	O
haemolytic-uraemic	B-Disease
syndrome	I-Disease
is	O
not	O
established	O
firmly	O
,	O
the	O
action	O
of	O
this	O
drug	B-Drug
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic-uraemic	B-Disease
syndrome	I-Disease
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	B-Chemical
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic-uraemic	B-Disease
syndrome	I-Disease
.	O

Risk	O
factors	O
of	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
in	O
preterm	O
infants	O
.	O

Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991	O
,	O
8	O
children	O
(	O
1.46	O
%	O
)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O

Perinatal	O
risk	O
factors	O
of	O
infants	O
with	O
hearing	B-Disease
loss	I-Disease
were	O
compared	O
with	O
those	O
of	O
two	O
control	O
groups	O
matched	O
for	O
gestation	O
and	O
birth	O
weight	O
and	O
for	O
perinatal	O
complications	O
.	O

Our	O
observations	O
demonstrated	O
an	O
association	O
of	O
hearing	B-Disease
loss	I-Disease
with	O
a	O
higher	O
incidence	O
of	O
perinatal	O
complications	O
.	O

Ototoxicity	B-Disease
appeared	O
closely	O
related	O
to	O
a	O
prolonged	O
administration	O
and	O
higher	O
total	O
dose	O
of	O
ototoxic	B-Disease
drugs	B-Drug
,	O
particularly	O
aminoglycosides	B-Chemical
and	O
furosemide	B-Chemical
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	B-Disease
loss	I-Disease
is	O
of	O
delayed	O
onset	O
and	O
in	O
most	O
cases	O
bilateral	O
and	O
severe	O
.	O

Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine-associated	B-Chemical
mental	O
confusion	B-Disease
.	O

15	O
cases	O
of	O
cimetidine-associated	B-Chemical
mental	O
confusion	B-Disease
have	O
been	O
reported	O
.	O

In	O
order	O
that	O
this	O
syndrome	O
might	O
be	O
investigated	O
changes	O
in	O
mental	O
status	O
(	O
M.S	O
.	O

)	O
were	O
correlated	O
with	O
serum	O
concentrations	O
and	O
renal	O
and	O
hepatic	O
function	O
in	O
36	O
patients	O
,	O
30	O
patients	O
had	O
no	O
M.S	O
.	O

change	O
on	O
cimetidine	B-Chemical
and	I-Disease
6	O
had	O
moderate	O
to	O
severe	O
changes	O
.	O

These	O
6	O
patients	O
had	O
both	O
renal	B-Disease
and	I-Disease
liver	I-Disease
dysfunction	I-Chemical
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
as	O
well	O
as	O
cimetidine	B-Drug
trough-concentrations	O
of	O
more	O
than	O
1.25	O
microgram/ml	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
M.S	O
.	O

changes	O
increased	O
as	O
trough-concentrations	O
rose	O
,	O
5	O
patients	O
had	O
lumbar	O
puncture	O
.	O

The	O
cerebrospinal	O
fluid	O
:	O
serum	O
ratio	O
of	O
cimetidine	B-Drug
concentrations	O
was	O
0.24:1	O
and	O
indicates	O
that	O
cimetidine	B-Drug
passes	O
the	O
blood-brain	O
barrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M.S	O
.	O

changes	O
are	O
due	O
to	O
blockade	O
of	O
histamine	B-Drug
H2-receptors	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough-concentrations	O
and	O
mental	O
confusion	O
are	O
those	O
with	O
both	O
severe	O
renal	B-Chemical
and	O
hepatic	O
dysfunction	I-Chemical
.	O

They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	O
doses	O
of	O
cimetidine	B-Drug
.	O

Different	O
lobular	O
distributions	O
of	O
altered	O
hepatocyte	O
tight	O
junctions	O
in	O
rat	O
models	O
of	O
intrahepatic	B-Disease
and	I-Disease
extrahepatic	I-Disease
cholestasis	I-Disease
.	O

Hepatocyte	O
tight	O
junctions	O
(	O
TJs	O
)	O
,	O
the	O
only	O
intercellular	O
barrier	O
between	O
the	O
sinusoidal	O
and	O
the	O
canalicular	O
spaces	O
,	O
play	O
a	O
key	O
role	O
in	O
bile	O
formation	O
.	O

Although	O
hepatocyte	O
TJs	O
are	O
impaired	O
in	O
cholestasis	B-Disease
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	O
of	O
hepatocyte	O
TJ	O
damage	O
by	O
freeze-fracture	O
electron	O
microscopy	O
have	O
produced	O
limited	O
information	O
.	O

Recently	O
,	O
several	O
TJ-associated	O
proteins	O
like	O
ZO-1	O
and	O
7H6	O
have	O
been	O
identified	O
and	O
characterized	O
.	O

Immunolocalization	O
of	O
7H6	O
appears	O
to	O
closely	O
correlate	O
with	O
paracellular	O
permeability	O
.	O

We	O
used	O
rat	O
models	O
of	O
intrahepatic	B-Disease
cholestasis	I-Disease
by	O
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
EE	B-Chemical
)	O
treatment	O
and	O
extrahepatic	B-Disease
cholestasis	I-Disease
by	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
site	O
of	O
TJ	O
damage	O
.	O

Alterations	O
in	O
hepatocyte	O
TJs	O
were	O
assessed	O
by	O
double-immunolabeling	O
for	O
7H6	O
and	O
ZO-1	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
.	O

In	O
control	O
rats	O
,	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
colocalized	O
to	O
outline	O
bile	O
canaliculi	O
in	O
a	O
continuous	O
fashion	O
.	O

In	O
contrast	O
,	O
7H6	O
and	O
ZO-1	O
immunostaining	O
was	O
more	O
discontinuous	O
,	O
outlining	O
the	O
bile	O
canaliculi	O
after	O
BDL	O
.	O

Immunostaining	O
for	O
7H6	O
,	O
not	O
ZO-1	O
,	O
decreased	O
and	O
predominantly	O
appeared	O
as	O
discrete	O
signals	O
in	O
the	O
submembranous	O
cytoplasm	O
of	O
periportal	O
hepatocytes	O
after	O
BDL	O
.	O

After	O
EE	B-Chemical
treatment	O
,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-Chemical
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O

Long	O
term	O
audiological	O
evaluation	O
of	O
beta-thalassemic	B-Disease
patients	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	O
the	O
progression	O
of	O
hearing	B-Disease
loss	I-Disease
in	O
children	O
and	O
young	O
adults	O
with	O
beta-thalassemia	B-Disease
major	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patients	O
aged	O
6-35	O
years	O
(	O
mean	O
17,2	O
years	O
)	O
participated	O
in	O
the	O
study	O
.	O

All	O
patients	O
were	O
on	O
a	O
regular	O
transfusion-chelation	O
program	O
maintaining	O
a	O
mean	O
hemoglobin	O
level	O
of	O
9.5	O
gr/dl	O
.	O

Subjects	O
were	O
receiving	O
desferrioxamine	B-Chemical
(	O
DFO	B-Chemical
)	O
chelation	O
treatment	O
with	O
a	O
mean	O
daily	O
dose	O
of	O
50-60	O
mg/kg	O
,	O
5-6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study	O
,	O
which	O
was	O
then	O
reduced	O
to	O
40-50	O
mg/kg	O
for	O
the	O
following	O
eight	O
years	O
.	O

Patients	O
were	O
followed	O
for	O
8-14	O
years	O
.	O

RESULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patients	O
(	O
20.2	O
%	O
)	O
presented	O
with	O
high	O
frequency	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
(	O
SNHL	B-Disease
)	O
,	O
either	O
unilateral	O
or	O
bilateral	O
.	O

No	O
ototoxic	B-Disease
factor	O
,	O
other	O
than	O
DFO	B-Chemical
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O

Patients	O
with	O
SNHL	B-Disease
presented	O
with	O
relatively	O
lower	O
serum	O
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing	O
,	O
however	O
,	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
.	O

Subjects	O
with	O
SNHL	B-Disease
were	O
submitted	O
to	O
DFO	B-Chemical
reduction	O
or	O
temporary	O
withdrawal	O
.	O

Following	O
intervention	O
,	O
7	O
out	O
of	O
21	O
affected	O
patients	O
recovered	O
,	O
10	O
remained	O
stable	O
and	O
4	O
demonstrated	O
aggravation	O
.	O

CONCLUSION	O
:	O
The	O
findings	O
are	O
indicative	O
of	O
DFO	B-Chemical
's	O
contributing	O
role	O
in	O
the	O
development	O
of	O
hearing	B-Disease
impairment	I-Disease
.	O

Regular	O
audiologic	O
evaluation	O
is	O
imperative	O
in	O
all	O
thalassemic	B-Disease
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevent	O
or	O
reverse	O
hearing	B-Disease
impairment	I-Disease
.	O

Design	O
and	O
analysis	O
of	O
the	O
HYPREN-trial	O
:	O
safety	O
of	O
enalapril	B-Chemical
and	O
prazosin	B-Chemical
in	O
the	O
initial	O
treatment	O
phase	O
of	O
patients	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O

Since	O
the	O
introduction	O
of	O
angiotensin	B-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitors	I-Chemical
into	O
the	O
adjunctive	O
treatment	O
of	O
patients	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
cases	O
of	O
severe	O
hypotension	B-Disease
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O

To	O
assess	O
the	O
safety	O
of	O
the	O
ACE	B-Chemical
inhibitor	I-Chemical
enalapril	B-Chemical
a	O
multicenter	O
,	O
randomized	O
,	O
prazosin-controlled	B-Chemical
trial	O
was	O
designed	O
that	O
compared	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	B-Disease
on	O
the	O
first	O
day	O
of	O
treatment	O
.	O

Trial	O
medication	O
was	O
2.5	O
mg	O
enalapril	B-Chemical
or	O
0.5	O
prazosin	B-Chemical
.	O

Subjects	O
were	O
1210	O
inpatients	O
with	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
functional	O
class	O
II	O
and	O
III	O
.	O

Patients	O
who	O
received	O
enalapril	B-Chemical
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	B-Disease
(	O
5.2	O
%	O
)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	B-Chemical
(	O
12.9	O
%	O
)	O
.	O

All	O
patients	O
recovered	O
.	O

It	O
was	O
concluded	O
that	O
treatment	O
with	O
enalapril	B-Chemical
was	O
well	O
tolerated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	O
of	O
treatment	O
with	O
enalapril	B-Chemical
to	O
inpatients	O
.	O

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine-induced	B-Chemical
anemia	B-Disease
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O

Azidothymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
-induced	O
anemia	B-Disease
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF-IL-3	O
(	O
fusion	O
protein	O
of	O
insulin-like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Although	O
interleukin	O
3	O
(	O
IL-3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	O
of	O
IGF-IL-3	O
and	O
EPO	O
in	O
AZT-treated	B-Chemical
mice	O
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF-IL-3	O
or	O
EPO	O
alone	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
the	O
antagonistic	O
effect	O
of	O
IL-3	O
and	O
EPO	O
on	O
erythroid	O
cells	O
may	O
be	O
mediated	O
by	O
endothelial	O
cells	O
.	O

Bovine	O
liver	O
erythroid	O
cells	O
were	O
cultured	O
on	O
monolayers	O
of	O
human	O
bone	O
marrow	O
endothelial	O
cells	O
previously	O
treated	O
with	O
EPO	O
and	O
IGF-IL-3	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
thymidine	B-Chemical
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre-treated	O
with	O
IGF-IL-3	O
and	O
EPO	O
.	O

Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL-3	O
significantly	O
reduced	O
thymidine	B-Chemical
incorporation	O
into	O
erythroid	O
cells	O
as	O
compared	O
to	O
identical	O
fractions	O
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	O
with	O
EPO	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
endothelial	O
cells	O
treated	O
simultaneously	O
with	O
EPO	O
and	O
IL-3	O
have	O
a	O
negative	O
effect	O
on	O
erythroid	O
cell	O
production	O
.	O

Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
on	O
rat	O
atrial	O
spontaneous	O
frequency	O
.	O

The	O
effects	O
of	O
varying	O
the	O
extracellular	O
concentrations	O
of	O
Na	B-Chemical
and	O
Ca	B-Chemical
(	O
[	O
Na	B-Chemical
]	O
o	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
)	O
on	O
both	O
,	O
the	O
spontaneous	O
beating	O
and	O
the	O
negative	O
chronotropic	O
action	O
of	O
verapamil	B-Chemical
,	O
were	O
studied	O
in	O
the	O
isolated	O
rat	O
atria	O
.	O

Basal	O
frequency	O
(	O
BF	O
)	O
evaluated	O
by	O
surface	O
electrogram	O
was	O
223	O
+/-	O
4	O
beats/min	O
.	O

in	O
control	O
Krebs-Ringer	O
containing	O
137	O
mM	O
Na	B-Chemical
and	O
1.35	O
mM	O
Ca	B-Chemical
(	O
N	O
)	O
.	O

It	O
decreased	O
by	O
16	O
+/-	O
3	O
%	O
by	O
lowering	O
[	O
Na	B-Chemical
]	O
o	O
to	O
78	O
mM	O
(	O
LNa	B-Chemical
)	O
,	O
23	O
+/-	O
2	O
%	O
by	O
lowering	O
simultaneously	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
and	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
0.675	O
mM	O
(	O
LNa+LCa	B-Chemical
)	O
and	O
31	O
+/-	O
5	O
%	O
by	O
lowering	O
[	O
Na	O
]	O
o	O
to	O
78	O
mM	O
plus	O
increasing	O
[	O
Ca	B-Chemical
]	O
o	O
to	O
3.6	O
mM	O
(	O
LNa+HCa	B-Chemical
)	O
.	O

At	O
normal	O
[	O
Na	O
]	O
o	O
,	O
decrease	O
(	O
0.675	O
mM	O
)	O
or	O
increase	O
(	O
3.6	O
mM	O
)	O
of	O
[	O
Ca	B-Chemical
]	O
o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduction	O
of	O
ten	O
times	O
(	O
0.135	O
mM	O
of	O
normal	O
[	O
Ca	B-Chemical
]	O
o	O
was	O
effective	O
to	O
reduce	O
BF	O
by	O
40	O
+/-	O
13	O
%	O
.	O

All	O
negative	O
chronotropic	O
effects	O
were	O
BF-dependent	O
.	O

Dose-dependent	O
bradycardia	B-Disease
induced	O
by	O
verapamil	B-Chemical
was	O
potentiated	O
by	O
LNa	B-Chemical
,	O
LCa	B-Chemical
,	O
and	O
HCa	O
.	O

Independent	O
but	O
not	O
additive	O
effects	O
of	O
Na	O
and	O
Ca	O
are	O
shown	O
by	O
decreases	O
in	O
the	O
values	O
of	O
[	O
verapamil	B-Chemical
]	O
o	O
needed	O
to	O
reduce	O
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhibitory	O
potency	O
:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa+HCa	O
similar	O
to	O
LNa	O
.	O

The	O
[	O
verapamil	B-Chemical
]	O
o	O
that	O
arrested	O
atrial	O
beating	O
(	O
AC	O
)	O
was	O
also	O
potentiated	O
with	O
the	O
order	O
LNa	B-Chemical
=	O
LNa+LCa	B-Chemical
=	O
LNa+HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N.	O
The	O
results	O
indicate	O
that	O
rat	O
atrial	O
spontaneous	O
beating	O
is	O
more	O
dependent	O
on	O
[	O
Na	O
]	O
o	O
than	O
on	O
[	O
Ca	O
]	O
o	O
in	O
a	O
range	O
of	O
+/-	O
50	O
%	O
of	O
their	O
normal	O
concentration	O
.	O

Also	O
the	O
enhancement	O
of	O
verapamil	B-Chemical
effects	O
on	O
atrial	O
beating	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Sodium	B-Chemical
status	O
influences	O
chronic	O
amphotericin	B-Chemical
B	I-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
.	O

The	O
nephrotoxic	B-Disease
potential	O
of	O
amphotericin	B-Chemical
B	I-Chemical
(	O
5	O
mg/kg	O
per	O
day	O
intraperitoneally	O
for	O
3	O
weeks	O
)	O
has	O
been	O
investigated	O
in	O
salt-depleted	O
,	O
normal-salt	O
,	O
and	O
salt-loaded	O
rats	O
.	O

In	O
salt-depleted	O
rats	O
,	O
amphotericin	B-Chemical
B	I-Chemical
decreased	O
creatinine	B-Chemical
clearance	O
linearly	O
with	O
time	O
,	O
with	O
an	O
85	O
%	O
reduction	O
by	O
week	O
3	O
.	O

In	O
contrast	O
,	O
in	O
normal-salt	O
rats	O
creatinine	B-Chemical
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
salt-loaded	O
rats	O
creatinine	B-Chemical
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O

All	O
rats	O
in	O
the	O
sodium-depleted	B-Chemical
group	O
had	O
histopathological	O
evidence	O
of	O
patchy	O
tubular	O
cytoplasmic	O
degeneration	O
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal-salt	O
or	O
salt-loaded	O
rat	O
.	O

Concentrations	O
of	O
amphotericin	B-Chemical
B	I-Chemical
in	O
plasma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
at	O
any	O
time	O
during	O
the	O
study	O
.	O

However	O
,	O
at	O
the	O
end	O
of	O
3	O
weeks	O
,	O
amphotericin	B-Chemical
B	I-Chemical
levels	O
in	O
the	O
kidneys	O
and	O
liver	O
were	O
significantly	O
higher	O
in	O
salt-depleted	O
and	O
normal-salt	O
rats	O
than	O
those	O
in	O
salt-loaded	O
rats	O
,	O
with	O
plasma/kidney	O
ratios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salt-depleted	O
,	O
normal-salt	O
,	O
and	O
salt-loaded	O
rats	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
reductions	O
in	O
creatinine	B-Chemical
clearance	O
and	O
renal	O
amphotericin	B-Chemical
B	I-Chemical
accumulation	O
after	O
chronic	O
amphotericin	B-Chemical
B	I-Chemical
administration	O
were	O
enhanced	O
by	O
salt	O
depletion	O
and	O
attenuated	O
by	O
sodium	B-Chemical
loading	O
in	O
rats	O
.	O

Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesion	I-Disease
in	O
metronidazole-induced	B-Chemical
encephalopathy	B-Disease
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion-weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O

OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
in	O
metronidazole-induced	B-Chemical
encephalopathy	B-Disease
,	O
to	O
focus	O
on	O
the	O
diffusion-weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	O
(	O
5	O
men	O
and	O
3	O
women	O
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole-induced	B-Chemical
encephalopathy	B-Disease
(	O
age	O
range	O
;	O
43-78	O
years	O
)	O
.	O

They	O
had	O
been	O
taking	O
metronidazole	B-Chemical
(	O
total	O
dosage	O
,	O
45-120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B-Disease
in	O
various	O
organs	O
.	O

Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalization	O
,	O
including	O
DWI	O
(	O
8/8	O
)	O
,	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4/8	O
)	O
,	O
FLAIR	O
(	O
7/8	O
)	O
,	O
and	O
T2-weighted	O
image	O
(	O
8/8	O
)	O
.	O

Follow-up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	B-Chemical
administration	O
.	O

Findings	O
of	O
initial	O
and	O
follow-up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus	O
,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities	O
,	O
their	O
locations	O
,	O
and	O
signal	O
changes	O
on	O
follow-up	O
images	O
.	O

RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2-weighted	O
image	O
)	O
at	O
the	O
dentate	O
nucleus	O
(	O
8/8	O
)	O
,	O
inferior	O
colliculus	O
(	O
6/8	O
)	O
,	O
corpus	O
callosum	O
(	O
2/8	O
)	O
,	O
pons	O
(	O
2/8	O
)	O
,	O
medulla	O
(	O
1/8	O
)	O
,	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(	O
1/8	O
)	O
.	O

High-signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(	O
3/4	O
)	O
,	O
but	O
in	O
one	O
patient	O
,	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O

All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow-up	O
MRIs	O
in	O
5	O
patients	O
,	O
but	O
in	O
1	O
patient	O
of	O
them	O
,	O
corpus	O
callosal	B-Disease
lesion	I-Disease
persisted	O
.	O

CONCLUSIONS	O
:	O
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole-induced	B-Chemical
encephalopathy	B-Disease
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O

Comparison	O
of	O
the	O
respiratory	O
effects	O
of	O
i.v	O
.	O

infusions	O
of	O
morphine	B-Chemical
and	O
regional	O
analgesia	O
by	O
extradural	O
block	O
.	O

The	O
incidence	O
of	O
postoperative	O
respiratory	O
apnoea	B-Disease
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i.v	O
.	O

infusion	O
of	O
morphine	B-Chemical
(	O
mean	O
73.6	O
mg	O
)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0.25	O
%	O
bupivacaine	B-Chemical
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24-h	O
period	O
following	O
upper	O
abdominal	O
surgery	O
.	O

Monitoring	O
consisted	O
of	O
airflow	O
detection	O
by	O
a	O
carbon	B-Chemical
dioxide	I-Chemical
analyser	O
,	O
chest	O
wall	O
movement	O
detected	O
by	O
pneumatic	O
capsules	O
,	O
and	I-Disease
continuous	O
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	O
monitor	O
.	O

Both	O
obstructive	B-Disease
(	I-Disease
P	I-Disease
less	I-Disease
than	I-Disease
0.05	I-Disease
)	I-Disease
and	I-Disease
central	I-Disease
apnoea	I-Chemical
(	I-Chemical
P	I-Chemical
less	I-Chemical
than	I-Chemical
0.05	I-Chemical
)	I-Chemical
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
had	O
a	O
morphine	B-Drug
infusion	O
.	O

There	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
tachyarrhythmias	O
(	I-Chemical
P	O
less	O
than	O
0.05	O
)	O
and	O
ventricular	O
ectopic	O
beats	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
the	O
morphine	B-Drug
infusion	O
group	O
.	O

Magnetic	O
resonance	O
volumetry	O
of	O
the	O
cerebellum	O
in	O
epileptic	B-Disease
patients	O
after	O
phenytoin	B-Chemical
overdosages	B-Disease
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	B-Chemical
medication	O
and	O
cerebellar	B-Disease
atrophy	I-Disease
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication	O
.	O

Five	O
females	O
and	O
6	O
males	O
,	O
21-59	O
years	O
of	O
age	O
,	O
were	O
examined	O
with	O
a	O
1.5-T	O
whole-body	O
system	O
using	O
a	O
circular	O
polarized	O
head	O
coil	O
.	O

Conventional	O
spin	O
echo	O
images	O
were	O
acquired	O
in	O
the	O
sagittal	O
and	O
transverse	O
orientation	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
high-resolution	O
3D	O
gradient	O
echo	O
,	O
T1-weighted	O
sequences	O
at	O
a	O
1-mm	O
slice	O
thickness	O
.	O

The	O
images	O
were	O
subsequently	O
processed	O
to	O
obtain	O
volumetric	O
data	O
for	O
the	O
cerebellum	O
.	O

Cerebellar	O
volume	O
for	O
the	O
patient	O
group	O
ranged	O
between	O
67.66	O
and	O
131.08	O
ml	O
(	O
mean	O
108.9	O
ml	O
)	O
.	O

In	O
addition	O
3D	O
gradient	O
echo	O
data	O
sets	O
from	O
10	O
healthy	O
male	O
and	O
10	O
healthy	O
female	O
age-matched	O
volunteers	O
were	O
used	O
to	O
compare	O
cerebellar	O
volumes	O
.	O

Using	O
linear	O
regression	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seizure	B-Disease
duration	O
,	O
elevation	O
of	O
phenytoin	B-Chemical
serum	O
levels	O
and	O
cerebellar	O
volume	O
.	O

However	O
,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage	O
,	O
duration	O
of	O
phenytoin	B-Chemical
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters	O
.	O

We	O
conclude	O
that	O
phenytoin	B-Chemical
overdosage	B-Disease
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	B-Disease
atrophy	I-Disease
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	B-Chemical
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B-Disease
atrophy	I-Disease
in	O
the	O
remaining	O
patients	O
.	O

Quantitative	O
morphometric	O
studies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	O
of	O
cerebellar	B-Disease
disorders	I-Disease
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
doxorubicin-induced	B-Chemical
cardiomyopathy	B-Disease
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

BACKGROUND	O
:	O
Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
markers	O
of	O
myocardial	B-Disease
cell	I-Disease
injury	I-Disease
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
a	O
rat	O
model	O
of	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-induced	O
cardiomyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	B-Disease
disorders	I-Disease
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

METHODS	O
:	O
Thirty-five	O
Wistar	O
rats	O
were	O
given	O
1.5	O
mg/kg	O
DOX	B-Chemical
,	O
i.v.	O
,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg/kg	O
BW	O
.	O

Ten	O
rats	O
received	O
saline	O
as	O
a	O
control	O
group	O
.	O

cTnI	O
was	O
measured	O
with	O
Access	O
(	O
R	O
)	O
(	O
ng/ml	O
)	O
and	O
a	O
research	O
immunoassay	O
(	O
pg/ml	O
)	O
,	O
and	O
compared	O
with	O
cTnT	O
,	O
CK-MB	O
mass	O
and	O
CK	O
.	O

By	O
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	O
measured	O
in	O
all	O
rats	O
before	O
DOX	B-Chemical
or	O
saline	O
,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O

Histology	O
was	O
performed	O
in	O
DOX-rats	B-Chemical
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	B-Chemical
dose	O
and	O
in	O
all	O
controls	O
.	O

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	B-Chemical
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	B-Disease
during	O
the	O
9-week	O
period	O
.	O

End-diastolic	O
(	O
ED	O
)	O
and	O
end-systolic	O
(	O
ES	O
)	O
LV	O
diameters/BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	B-Chemical
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

These	O
parameters	O
remained	O
unchanged	O
in	O
controls	O
.	O

Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	B-Chemical
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	B-Disease
.	O

In	O
7	O
of	O
the	O
18	O
rats	O
,	O
degeneration	O
and	O
myocyte	O
vacuolisation	O
were	O
found	O
.	O

Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	O
fibrosis	B-Disease
.	O

A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	B-Chemical
rats	O
after	O
cumulative	O
doses	O
of	O
7.5	O
and	O
12	O
mg/kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p	O
<	O
0.05	O
)	O
.	O

cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg/kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7.5	O
mg/kg	O
DOX	B-Chemical
.	O

Maximal	O
cTnI	O
(	O
pg/ml	O
)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	O
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
(	O
p=0.006	O
,	O
0.007	O
)	O
.	O

cTnI	O
(	O
ng/ml	O
)	O
,	O
CK-MB	O
mass	O
and	O
CK	O
remained	O
unchanged	O
in	O
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
.	O

All	O
markers	O
remained	O
stable	O
in	O
controls	O
.	O

Analysis	O
of	O
data	O
revealed	O
a	O
significant	O
correlation	O
between	O
maximal	O
cTnT	O
and	O
ED	O
and	O
ES	O
LV	O
diameters/BW	O
(	O
r=0.81	O
and	O
0.65	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

A	O
significant	O
relationship	O
was	O
observed	O
between	O
maximal	O
cTnT	O
and	O
the	O
extent	O
of	O
myocardial	O
morphological	O
changes	O
,	O
and	O
between	O
LV	O
diameters/BW	O
and	O
histological	O
findings	O
.	O

CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	B-Disease
injury	I-Disease
after	O
DOX	B-Chemical
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	B-Disease
damage	I-Disease
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	B-Chemical
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross-reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	B-Chemical
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	B-Disease
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Calcineurin-inhibitor	O
induced	O
pain	B-Disease
syndrome	O
(	O
CIPS	B-Disease
)	O
:	O
a	O
severe	O
disabling	O
complication	O
after	O
organ	O
transplantation	O
.	O

Bone	O
pain	B-Disease
after	O
transplantation	O
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseases	O
.	O

Treatment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnosis	O
of	O
the	O
pain	B-Disease
.	O

Nine	O
patients	O
with	O
severe	O
pain	B-Disease
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	O
,	O
were	O
investigated	O
.	O

Bone	O
scans	O
showed	O
an	O
increased	O
tracer	O
uptake	O
of	O
the	O
foot	O
bones	B-Disease
.	O

Magnetic	O
resonance	O
imaging	O
demonstrated	O
bone	B-Disease
marrow	I-Disease
oedema	O
in	O
the	O
painful	O
bones	B-Chemical
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
's	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

The	O
reduction	O
of	O
cyclosporine-	O
or	O
tacrolimus	B-Drug
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	B-Drug
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	O
.	O

The	O
Calcineurin-inhibitor	O
Induced	O
Pain	O
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	B-Drug
or	O
tacrolimus	B-Drug
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	B-Chemical
scans	O
.	O

Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	B-Drug
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	O
from	O
CIPS	O
.	O

The	O
haemodynamic	O
effects	O
of	O
propofol	B-Chemical
in	O
combination	O
with	O
ephedrine	B-Chemical
in	O
elderly	O
patients	O
(	O
ASA	B-Drug
groups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	O
of	O
propofol	B-Chemical
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	B-Chemical
to	O
propofol	B-Chemical
in	O
order	O
to	O
obtund	O
the	O
hypotensive	B-Disease
response	O
.	O

The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	B-Chemical
to	O
200	O
mg	O
of	O
propofol	B-Chemical
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	B-Drug
3/4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito-urinary	O
surgery	O
.	O

The	O
addition	O
of	O
ephedrine	B-Chemical
to	O
propofol	B-Chemical
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	B-Disease
response	O
to	O
propofol	B-Chemical
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

However	O
,	O
marked	O
tachycardia	B-Disease
associated	O
with	O
the	O
use	O
of	O
ephedrine	B-Chemical
in	O
combination	O
with	O
propofol	B-Chemical
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	B-Disease
inducing	O
myocardial	B-Disease
ischemia	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine/propofol/mixtures	B-Chemical
studied	O
.	O

Neurotoxicity	B-Disease
of	O
halogenated	B-Chemical
hydroxyquinolines	I-Chemical
:	O
clinical	O
analysis	O
of	O
cases	O
reported	O
outside	O
Japan	O
.	O

An	O
analysis	O
is	O
presented	O
of	O
220	O
cases	O
of	O
possible	O
neurotoxic	B-Disease
reactions	O
to	O
halogenated	B-Chemical
hydroxyquinolines	I-Chemical
reported	O
from	O
outside	O
Japan	O
.	O

In	O
80	O
cases	O
insufficient	O
information	O
was	O
available	O
for	O
adequate	O
comment	O
and	O
in	O
29	O
a	O
relationship	O
to	O
the	O
administration	O
of	O
clioquinol	B-Chemical
could	O
be	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
a	O
relationship	O
to	O
clioquinol	B-Chemical
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases	O
.	O

In	O
six	O
of	O
the	O
probable	O
cases	O
the	O
neurological	B-Disease
disturbance	I-Disease
consisted	O
of	O
an	O
acute	O
reversible	O
encephalopathy	B-Disease
usually	O
related	O
to	O
the	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
clioquinol	B-Chemical
over	O
a	O
short	O
period	O
.	O

The	O
most	O
common	O
manifestation	O
,	O
observed	O
in	O
15	O
further	O
cases	O
,	O
was	O
isolated	O
optic	B-Disease
atrophy	I-Disease
.	O

This	O
was	O
most	O
frequently	O
found	O
in	O
children	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	B-Chemical
as	O
treatment	O
for	O
acrodermatitis	B-Disease
enteropathica	I-Disease
.	O

In	O
the	O
remaining	O
cases	O
,	O
a	O
combination	O
of	O
myelopathy	B-Disease
,	O
visual	B-Disease
disturbance	I-Disease
,	O
and	O
peripheral	B-Disease
neuropathy	I-Disease
was	O
the	O
most	O
common	O
manifestation	O
.	O

Isolated	O
myelopathy	B-Disease
or	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
or	O
these	O
manifestations	O
occurring	O
together	O
,	O
were	O
infrequent	O
.	O

The	O
onset	O
of	O
all	O
manifestations	O
(	O
except	O
toxic	O
encephalopathy	B-Disease
)	O
was	O
usually	O
subacute	O
,	O
with	O
subsequent	O
partial	O
recovery	O
.	O

Older	O
subjects	O
tended	O
to	O
display	O
more	O
side	O
effects	O
.	O

The	O
full	O
syndrome	O
of	O
subacute	O
myelo-optic	B-Disease
neuropathy	I-Disease
was	O
more	O
frequent	O
in	O
women	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quantities	O
of	O
the	O
drug	B-Drug
.	O

Epileptic	B-Disease
seizures	I-Disease
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	O
tranexamic	B-Chemical
acid	I-Chemical
in	O
rats	O
.	O

BACKGROUND	O
:	O
Fibrin	O
sealants	O
(	O
FS	O
)	O
derived	O
from	O
human	O
plasma	O
are	O
frequently	O
used	O
in	O
neurosurgery	O
.	O

In	O
order	O
to	O
increase	O
clot	O
stability	O
,	O
FS	O
typically	O
contain	O
aprotinin	O
,	O
a	O
natural	O
fibrinolysis	O
inhibitor	O
.	O

Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	O
such	O
as	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
tAMCA	B-Chemical
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin	O
.	O

However	O
,	O
tAMCA	B-Chemical
has	O
been	O
shown	O
to	O
cause	O
epileptic	B-Disease
seizures	I-Disease
.	O

We	O
wanted	O
to	O
study	O
whether	O
tAMCA	B-Chemical
retains	O
its	O
convulsive	B-Disease
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	O
of	O
tAMCA	B-Chemical
(	O
0.5-47.5	O
mg/ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O

The	O
response	O
of	O
the	O
animals	O
was	O
evaluated	O
using	O
electroencephalography	O
and	O
by	O
monitoring	O
the	O
clinical	O
behaviour	O
during	O
and	O
after	O
recovery	O
from	O
anaesthesia	O
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	B-Chemical
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	B-Disease
behaviours	O
.	O

The	O
degree	O
of	O
these	O
seizures	B-Disease
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	B-Chemical
.	O

Thus	O
,	O
FS	O
containing	O
47.5	O
mg/ml	O
tAMCA	B-Chemical
evoked	O
generalized	B-Disease
seizures	I-Disease
in	O
all	O
tested	O
rats	O
(	O
n=6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	B-Chemical
(	O
0.5	O
mg/ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk-correlated	O
convulsive	B-Disease
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

In	O
contrast	O
,	O
FS	O
containing	O
aprotinin	O
did	O
not	O
evoke	O
any	O
paroxysmal	O
activity	O
.	O

INTERPRETATION	O
:	O
Tranexamic	B-Chemical
acid	I-Chemical
retains	O
its	O
convulsive	B-Disease
action	O
within	O
FS	O
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	B-Chemical
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O

A	O
diet	O
promoting	O
sugar	B-Disease
dependency	I-Disease
causes	O
behavioral	B-Disease
cross-sensitization	I-Disease
to	O
a	O
low	O
dose	O
of	O
amphetamine	B-Chemical
.	O

Previous	O
research	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
a	O
diet	O
of	O
intermittent	O
excessive	O
sugar	O
consumption	O
produces	O
a	O
state	O
with	O
neurochemical	O
and	O
behavioral	O
similarities	O
to	O
drug	B-Disease
dependency	I-Disease
.	O

The	O
present	O
study	O
examined	O
whether	O
female	O
rats	O
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	O
show	O
behavioral	B-Disease
cross-sensitization	I-Disease
to	O
a	O
low	O
dose	O
of	O
amphetamine	B-Chemical
.	O

After	O
a	O
30-min	O
baseline	O
measure	O
of	O
locomotor	O
activity	O
(	O
day	O
0	O
)	O
,	O
animals	O
were	O
maintained	O
on	O
a	O
cyclic	O
diet	O
of	O
12-h	O
deprivation	O
followed	O
by	O
12-h	O
access	O
to	O
10	O
%	O
sucrose	B-Chemical
solution	O
and	O
chow	O
pellets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
dark	O
period	O
)	O
for	O
21	O
days	O
.	O

Locomotor	O
activity	O
was	O
measured	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
days	O
1	O
and	O
21	O
of	O
sugar	O
access	O
.	O

Beginning	O
on	O
day	O
22	O
,	O
all	O
rats	O
were	O
maintained	O
on	O
ad	O
libitum	O
chow	O
.	O

Nine	O
days	O
later	O
locomotor	O
activity	O
was	O
measured	O
in	O
response	O
to	O
a	O
single	O
low	O
dose	O
of	O
amphetamine	B-Chemical
(	O
0.5	O
mg/kg	O
)	O
.	O

The	O
animals	O
that	O
had	O
experienced	O
cyclic	O
sucrose	B-Chemical
and	O
chow	O
were	O
hyperactive	B-Disease
in	O
response	O
to	O
amphetamine	B-Chemical
compared	O
with	O
four	O
control	O
groups	O
(	O
ad	O
libitum	O
10	O
%	O
sucrose	B-Chemical
and	O
chow	O
followed	O
by	O
amphetamine	B-Chemical
injection	O
,	O
cyclic	O
chow	O
followed	O
by	O
amphetamine	B-Chemical
injection	O
,	O
ad	O
libitum	O
chow	O
with	O
amphetamine	B-Chemical
,	O
or	O
cyclic	O
10	O
%	O
sucrose	B-Chemical
and	O
chow	O
with	O
a	O
saline	O
injection	O
)	O
.	O

These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increased	O
sensitivity	O
to	O
amphetamine	B-Chemical
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	O
in	O
the	O
dopamine	B-Chemical
system	O
.	O

D-penicillamine-induced	B-Chemical
angiopathy	B-Disease
in	O
rats	O
.	O

The	O
effect	O
of	O
high	O
dose	O
D-penicillamine	B-Chemical
treatment	O
on	O
aortic	O
permeability	O
to	O
albumin	O
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel	O
.	O

Male	O
Sprague-Dawley	O
rats	O
were	O
treated	O
with	O
D-penicillamine	B-Chemical
(	O
D-pen	B-Chemical
)	O
500	O
mg/kg/day	O
for	O
10	O
or	O
42	O
days	O
.	O

Pair	O
fed	O
rats	O
served	O
as	O
controls	O
.	O

Changes	O
in	O
aortic	O
morphology	O
were	O
examined	O
by	O
light-	O
and	O
transmission-electron	O
microscopy	O
(	O
TEM	O
)	O
.	O

In	O
addition	O
,	O
the	O
endothelial	O
permeability	O
and	O
the	O
penetration	O
through	O
the	O
aortic	O
wall	O
of	O
albumin	O
were	O
studied	O
10	O
minutes	O
,	O
24	O
and	O
48	O
hours	O
after	O
i.	O
v.	O
injection	O
of	O
human	O
serum	O
131I-albumin	O
(	O
131I-HSA	O
)	O
.	O

TEM	O
revealed	O
extensive	O
elastolysis	O
in	O
the	O
arterial	O
wall	O
of	O
D-pen-treated	B-Chemical
rats	O
,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
crosslink	O
formation	O
.	O

In	O
experimental	O
animals	O
excess	O
deposition	O
of	O
collagen	O
and	O
glycoaminoglycans	O
was	O
observed	O
in	O
the	O
subendothelial	O
and	O
medial	O
layer	O
of	O
the	O
aortic	O
wall	O
,	O
together	O
with	O
prominent	O
basal	O
membrane	O
substance	O
around	O
aortic	O
smooth	O
muscle	O
cells	O
.	O

The	O
aorta/serum-ratio	O
and	O
the	O
radioactive	O
build-up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I-HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D-pen	B-Chemical
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	B-Chemical
.	O

The	O
endothelial	O
ultrastructure	O
was	O
unaffected	O
by	O
D-pen	B-Chemical
,	O
and	O
no	O
differences	O
in	O
aortic	O
131I-HSA	O
radioactivity	O
or	O
aorta/serum-ratio	O
were	O
recorded	O
between	O
experimental	O
and	O
control	O
groups	O
10	O
minutes	O
after	O
tracer	O
injection	O
,	O
indicating	O
that	O
the	O
permeability	O
of	O
the	O
endothelial	O
barrier	O
to	O
albumin	O
remained	O
unaffected	O
by	O
D-pen	B-Chemical
treatment	O
.	O

These	O
observations	O
support	O
the	O
hypothesis	O
that	O
treatment	O
with	O
high	O
doses	O
of	O
D-pen	B-Chemical
may	O
induce	O
a	O
fibroproliferative	O
response	O
in	O
rat	O
aorta	O
,	O
possibly	O
by	O
an	O
inhibitory	O
effect	O
on	O
the	O
cross-linking	O
of	O
collagen	O
and	O
elastin	O
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline-induced	B-Chemical
cardiotoxicity	B-Disease
.	O

Anthracyclines	B-Chemical
are	O
effective	O
antineoplastic	O
drugs	B-Drug
,	O
but	O
they	O
frequently	O
cause	O
dose-related	O
cardiotoxicity	B-Disease
.	O

The	O
cardiotoxicity	B-Disease
of	O
conventional	O
anthracycline	B-Chemical
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	B-Disease
dysfunction	I-Disease
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline-induced	B-Chemical
cardiotoxicity	B-Disease
in	O
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
treated	O
with	O
a	O
daunorubicin	B-Chemical
(	O
DNR	B-Chemical
)	O
-containing	O
regimen	O
.	O

Thirteen	O
patients	O
with	O
acute	B-Disease
leukemia	I-Disease
were	O
treated	O
with	O
a	O
DNR-containing	B-Chemical
regimen	O
.	O

Cardiac	O
functions	O
were	O
evaluated	O
with	O
radionuclide	O
angiography	O
before	O
chemotherapies	O
.	O

The	O
plasma	O
levels	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
and	O
BNP	O
were	O
measured	O
at	O
the	O
time	O
of	O
radionuclide	O
angiography	O
.	O

Three	O
patients	O
developed	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	B-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Disease
failure	I-Disease
increased	O
above	O
the	O
normal	O
limit	O
(	O
40	O
pg/ml	O
)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	B-Disease
failure	I-Disease
by	O
radionuclide	O
angiography	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	B-Disease
failure	I-Disease
given	O
DNR	B-Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg/m	O
(	O
2	O
)	O
.	O

The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-Disease
failure	I-Disease
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline-induced	B-Chemical
cardiotoxicity	B-Disease
.	O

Antibacterial	O
medication	O
use	O
during	O
pregnancy	O
and	O
risk	O
of	O
birth	B-Disease
defects	I-Disease
:	O
National	O
Birth	B-Disease
Defects	I-Disease
Prevention	O
Study	O
.	O

OBJECTIVE	O
:	O
To	O
estimate	O
the	O
association	O
between	O
antibacterial	O
medications	O
and	O
selected	O
birth	B-Disease
defects	I-Disease
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
Population-based	O
,	O
multisite	O
,	O
case-control	O
study	O
of	O
women	O
who	O
had	O
pregnancies	O
affected	O
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	O
birth	B-Disease
defects	I-Disease
identified	O
via	O
birth	B-Disease
defect	I-Disease
surveillance	O
programs	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
control	O
women	O
randomly	O
selected	O
from	O
the	O
same	O
geographical	O
regions	O
(	O
n	O
=	O
4941	O
)	O
.	O

MAIN	O
EXPOSURE	O
:	O
Reported	O
maternal	O
use	O
of	O
antibacterials	O
(	O
1	O
month	O
before	O
pregnancy	O
through	O
the	O
end	O
of	O
the	O
first	O
trimester	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
:	O
Odds	O
ratios	O
(	O
ORs	O
)	O
measuring	O
the	O
association	O
between	O
antibacterial	O
use	O
and	O
selected	O
birth	B-Disease
defects	I-Disease
adjusted	O
for	O
potential	O
confounders	O
.	O

RESULTS	O
:	O
The	O
reported	O
use	O
of	O
antibacterials	O
increased	O
during	O
pregnancy	O
,	O
peaking	O
during	O
the	O
third	O
month	O
.	O

Sulfonamides	B-Chemical
were	O
associated	O
with	O
anencephaly	B-Disease
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3.4	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.3-8.8	O
)	O
,	O
hypoplastic	B-Disease
left	I-Disease
heart	I-Disease
syndrome	I-Disease
(	O
AOR	O
=	O
3.2	O
;	O
95	O
%	O
CI	O
,	O
1.3-7.6	O
)	O
,	O
coarctation	B-Disease
of	I-Disease
the	I-Disease
aorta	I-Disease
(	O
AOR	O
=	O
2.7	O
;	O
95	O
%	O
CI	O
,	O
1.3-5.6	O
)	O
,	O
choanal	B-Disease
atresia	I-Disease
(	O
AOR	O
=	O
8.0	O
;	O
95	O
%	O
CI	O
,	O
2.7-23.5	O
)	O
,	O
transverse	B-Disease
limb	I-Disease
deficiency	I-Disease
(	O
AOR	O
=	O
2.5	O
;	O
95	O
%	O
CI	O
,	O
1.0-5.9	O
)	O
,	O
and	O
diaphragmatic	B-Disease
hernia	I-Disease
(	O
AOR	O
=	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.1-5.4	O
)	O
.	O

Nitrofurantoins	B-Chemical
were	O
associated	O
with	O
anophthalmia	B-Disease
or	O
microphthalmos	B-Disease
(	O
AOR	O
=	O
3.7	O
;	O
95	O
%	O
CI	O
,	O
1.1-12.2	O
)	O
,	O
hypoplastic	B-Disease
left	I-Disease
heart	I-Disease
syndrome	I-Disease
(	O
AOR	O
=	O
4.2	O
;	O
95	O
%	O
CI	O
,	O
1.9-9.1	O
)	O
,	O
atrial	B-Disease
septal	I-Disease
defects	I-Disease
(	O
AOR	O
=	O
1.9	O
;	O
95	O
%	O
CI	O
,	O
1.1-3.4	O
)	O
,	O
and	O
cleft	B-Disease
lip	I-Disease
with	O
cleft	B-Disease
palate	I-Disease
(	O
AOR	O
=	O
2.1	O
;	O
95	O
%	O
CI	O
,	O
1.2-3.9	O
)	O
.	O

Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	B-Chemical
(	O
2	O
defects	O
)	O
,	O
penicillins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
cephalosporins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	B-Chemical
(	O
1	O
defect	O
)	O
.	O

CONCLUSIONS	O
:	O
Reassuringly	O
,	O
penicillins	B-Chemical
,	O
erythromycins	B-Chemical
,	O
and	O
cephalosporins	B-Chemical
,	O
although	O
used	O
commonly	O
by	O
pregnant	O
women	O
,	O
were	O
not	O
associated	O
with	O
many	O
birth	B-Disease
defects	I-Disease
.	O

Sulfonamides	B-Chemical
and	O
nitrofurantoins	B-Chemical
were	O
associated	O
with	O
several	O
birth	B-Disease
defects	I-Disease
,	O
indicating	O
a	O
need	O
for	O
additional	O
scrutiny	O
.	O

Incidence	O
of	O
neoplasms	B-Disease
in	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
exposed	O
to	O
different	O
treatment	O
regimens	O
.	O

Immunosuppressive	O
drugs	B-Drug
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	O
in	O
treatment	O
of	O
patients	O
with	O
severe	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

The	O
drugs	B-Drug
commonly	O
used	O
are	O
cyclophosphamide	B-Chemical
and	O
chlorambucil	B-Chemical
(	O
alkylating	B-Chemical
agents	I-Chemical
)	O
,	O
azathioprine	B-Chemical
(	O
purine	B-Chemical
analogue	O
)	O
,	O
and	O
methotrexate	B-Chemical
(	O
folic	B-Chemical
acid	I-Chemical
analogue	O
)	O
.	O

There	O
is	O
evidence	O
that	O
all	O
four	O
immunosuppressive	O
drugs	B-Drug
can	O
reduce	O
synovitis	B-Disease
,	O
but	O
disease	O
activity	O
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped	O
.	O

Since	O
adverse	O
reactions	O
are	O
frequent	O
,	O
less	O
than	O
50	O
percent	O
of	O
patients	O
are	O
able	O
to	O
continue	O
a	O
particular	O
drug	B-Drug
for	O
more	O
than	O
one	O
year	O
.	O

Since	O
it	O
takes	O
three	O
to	O
12	O
months	O
to	O
achieve	O
maximal	O
effects	O
,	O
those	O
patients	O
who	O
are	O
unable	O
to	O
continue	O
the	O
drug	B-Drug
receive	O
little	O
benefit	O
from	O
it	O
.	O

Patients	O
treated	O
with	O
alkylating	B-Chemical
agents	I-Chemical
have	O
an	O
increased	O
risk	O
of	O
development	O
of	O
acute	B-Disease
nonlymphocytic	I-Disease
leukemia	I-Disease
,	O
and	O
both	O
alkylating	B-Chemical
agents	I-Chemical
and	O
azathioprine	B-Chemical
are	O
associated	O
with	O
the	O
development	O
of	O
non-Hodgkin	B-Disease
's	I-Disease
lymphoma	I-Disease
.	O

Cyclophosphamide	B-Chemical
therapy	O
increases	O
the	I-Disease
risk	O
of	I-Disease
carcinoma	B-Disease
of	I-Disease
the	I-Chemical
bladder	I-Chemical
.	O

There	O
have	O
been	O
several	O
long-term	O
studies	O
of	I-Chemical
patients	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
azathioprine	B-Drug
and	O
cyclophosphamide	B-Drug
and	O
the	I-Chemical
incidence	O
of	O
most	O
of	O
the	O
common	O
cancers	O
is	O
not	O
increased	O
.	O

Data	O
on	O
the	O
possible	O
increased	O
risk	O
of	O
malignancy	O
in	O
rheumatoid	O
arthritis	O
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
information	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppressive	O
drugs	B-Drug
,	O
particularly	O
alkylating	O
agents	O
,	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
should	O
be	O
reserved	O
for	O
patients	O
with	O
severe	O
progressive	O
disease	O
or	O
life-threatening	O
complications	O
.	O

Patterns	O
of	O
hepatic	B-Disease
injury	I-Disease
induced	O
by	O
methyldopa	B-Chemical
.	O

Twelve	O
patients	O
with	O
liver	B-Disease
disease	I-Disease
related	O
to	O
methyldopa	B-Chemical
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

Illness	O
occurred	O
within	O
1	O
--	O
9	O
weeks	O
of	O
commencement	O
of	O
therapy	O
in	O
9	O
patients	O
,	O
the	O
remaining	O
3	O
patients	O
having	O
received	O
the	O
drug	B-Drug
for	O
13	O
months	O
,	O
15	O
months	O
and	O
7	O
years	O
before	O
experiencing	O
symptoms	O
.	O

Jaundice	B-Disease
with	O
tender	O
hepatomegaly	B-Disease
,	O
usually	O
preceded	O
by	O
symptoms	O
of	O
malaise	O
,	O
anorexia	B-Disease
,	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
and	O
associated	O
with	O
upper	O
abdominal	B-Disease
pain	I-Disease
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients	O
.	O

Biochemical	O
liver	O
function	O
tests	O
indicated	O
hepatocellular	O
necrosis	B-Disease
and	O
correlated	O
with	O
histopathological	O
evidence	O
of	O
hepatic	B-Disease
injury	I-Disease
,	O
the	O
spectrum	O
of	O
which	O
ranged	O
from	O
fatty	B-Disease
change	I-Disease
and	O
focal	O
hepatocellular	O
necrosis	B-Disease
to	O
massive	B-Disease
hepatic	I-Disease
necrosis	I-Disease
.	O

Most	O
patients	O
showed	O
moderate	O
to	O
severe	O
acute	B-Disease
hepatitis	I-Disease
or	O
chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
with	O
associated	O
cholestasis	B-Disease
.	O

The	O
drug	B-Drug
was	O
withdrawn	O
on	O
presentation	O
to	O
hospital	O
in	O
11	O
patients	O
,	O
with	O
rapid	O
clinical	O
improvement	O
in	O
9	O
.	O

One	O
patient	O
died	O
,	O
having	O
presented	O
in	O
hepatic	B-Disease
failure	I-Disease
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopa	B-Chemical
for	O
7	O
years	O
,	O
showed	O
slower	O
clinical	O
and	O
biochemical	O
resolution	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

The	O
remaining	O
patient	O
in	O
the	O
series	O
developed	O
fulminant	B-Disease
hepatitis	I-Disease
when	O
the	O
drug	B-Drug
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	O
episode	O
of	O
methyldopa-induced	B-Chemical
hepatitis	B-Disease
.	O

In	O
this	O
latter	O
patient	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relationship	O
between	O
methyldopa	B-Chemical
and	O
hepatic	B-Disease
dysfunction	I-Disease
was	O
proved	O
with	O
the	O
recurrence	O
of	O
hepatitis	B-Disease
within	O
2	O
weeks	O
of	O
re-exposure	O
to	O
the	O
drug	B-Drug
.	O

A	O
phase	O
I/II	O
study	O
of	O
paclitaxel	B-Chemical
plus	O
cisplatin	B-Chemical
as	O
first-line	O
therapy	O
for	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
:	O
preliminary	O
results	O
.	O

Improved	O
outcomes	O
among	O
patients	O
with	O
head	B-Disease
and	I-Disease
neck	I-Disease
carcinomas	I-Disease
require	O
investigations	O
of	O
new	O
drugs	B-Drug
for	O
induction	O
therapy	O
.	O

Preliminary	O
results	O
of	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
of	O
single-agent	O
paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol-Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
response	O
rate	O
in	O
patients	O
with	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
,	O
and	O
the	O
paclitaxel/cisplatin	B-Chemical
combination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
improved	O
median	O
response	O
duration	O
in	O
ovarian	O
cancer	O
patients	O
.	O

We	O
initiated	O
a	O
phase	O
I/II	O
trial	O
to	O
determine	O
the	O
response	O
and	O
toxicity	O
of	O
escalating	O
paclitaxel	B-Drug
doses	O
combined	O
with	O
fixed-dose	O
cisplatin	B-Chemical
with	O
granulocyte	O
colony-stimulating	O
factor	O
support	O
in	O
patients	O
with	O
untreated	O
locally	O
advanced	O
inoperable	O
head	O
and	O
neck	O
carcinoma	O
.	O

To	O
date	O
,	O
23	O
men	O
with	O
a	O
median	O
age	O
of	O
50	O
years	O
and	O
good	O
performance	O
status	O
have	O
entered	O
the	O
trial	O
.	O

Primary	O
tumor	O
sites	O
were	O
oropharynx	O
,	O
10	O
patients	O
;	O
hypopharynx	O
,	O
four	O
;	O
larynx	O
,	O
two	O
;	O
oral	O
cavity	O
,	O
three	O
;	O
unknown	O
primary	O
,	O
two	O
;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland	O
,	O
one	O
each	O
.	O

Of	O
20	O
patients	O
evaluable	O
for	O
toxicity	O
,	O
four	O
had	O
stage	O
III	O
and	O
16	O
had	O
stage	O
IV	O
disease	O
.	O

Treatment	O
,	O
given	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
three	O
cycles	O
,	O
consisted	O
of	O
paclitaxel	B-Drug
by	O
3-hour	O
infusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	O
dose	O
of	O
cisplatin	B-Drug
(	O
75	O
mg/m2	O
)	O
.	O

The	O
dose	O
levels	O
incorporate	O
escalating	O
paclitaxel	B-Drug
doses	O
,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	O
level	O
are	O
permitted	O
if	O
toxicity	O
permits	O
.	O

At	O
the	O
time	O
of	O
this	O
writing	O
,	O
dose	O
level	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg/m2	O
)	O
is	O
being	O
evaluated	O
;	O
three	O
patients	O
from	O
this	O
level	O
are	O
evaluable	O
.	O

With	O
paclitaxel	B-Drug
doses	O
of	O
200	O
mg/m2	O
and	O
higher	O
,	O
granulocyte	O
colony-stimulating	O
factor	O
5	O
micrograms/kg/d	O
is	O
given	O
(	O
days	O
4	O
through	O
12	O
)	O
.	O

Of	O
18	O
patients	O
evaluable	O
for	O
response	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O

Three	O
patients	O
had	O
no	O
change	O
and	O
disease	O
progressed	O
in	O
two	O
.	O

The	O
overall	O
response	O
rate	O
is	O
72	O
%	O
.	O

Eleven	O
responding	O
patients	O
had	O
subsequent	O
surgery/radiotherapy	O
or	O
radical	O
radiotherapy	O
.	O

Two	O
pathologic	O
complete	O
responses	O
were	O
observed	O
in	O
patients	O
who	O
had	O
achieved	O
clinical	O
complete	O
responses	O
.	O

Alopecia	O
,	O
paresthesias	O
,	O
and	O
arthralgias/myalgias	O
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grade	O
3	O
myalgia	O
)	O
they	O
have	O
been	O
grade	O
1	O
or	O
2	O
.	O

No	O
dose-limiting	O
hematologic	O
toxicity	O
has	O
been	O
seen	O
.	O

Paclitaxel/cisplatin	O
is	O
an	O
effective	O
first-line	O
regimen	O
for	O
locoregionally	O
advanced	O
head	O
and	O
neck	O
cancer	I-Disease
and	O
continued	O
study	O
is	O
warranted	O
.	O

Results	O
thus	O
far	O
suggest	O
no	O
dose-response	O
effect	O
for	O
paclitaxel	B-Drug
doses	O
above	O
200	O
mg/m2	O
.	O

A	O
phase	O
I	O
study	O
of	O
4'-0-tetrahydropyranyladriamycin	B-Chemical
.	O

Clinical	O
pharmacology	O
and	O
pharmacokinetics	O
.	O

A	O
Phase	O
I	O
study	O
of	O
intravenous	O
(	O
IV	O
)	O
bolus	O
4'-0-tetrahydropyranyladriamycin	B-Chemical
(	O
Pirarubicin	B-Chemical
)	O
was	O
done	O
in	O
55	O
patients	O
in	O
good	O
performance	O
status	O
with	O
refractory	O
tumors	B-Disease
.	O

Twenty-six	O
had	O
minimal	O
prior	O
therapy	O
(	O
good	O
risk	O
)	O
,	O
23	O
had	O
extensive	O
prior	O
therapy	O
(	O
poor	O
risk	O
)	O
,	O
and	O
six	O
had	O
renal	B-Disease
and/or	I-Disease
hepatic	I-Disease
dysfunction	I-Disease
.	O

A	O
total	O
of	O
167	O
courses	O
at	O
doses	O
of	O
15	O
to	O
70	O
mg/m2	O
were	O
evaluable	O
.	O

Maximum	O
tolerated	O
dose	O
in	O
good-risk	O
patients	O
was	O
70	O
mg/m2	O
,	O
and	O
in	O
poor-risk	O
patients	O
,	O
60	O
mg/m2	O
.	O

The	O
dose-limiting	O
toxic	O
effect	O
was	O
transient	O
noncumulative	O
granulocytopenia	O
.	O

Granulocyte	O
nadir	O
was	O
on	O
day	O
14	O
(	O
range	O
,	O
4-22	O
)	O
.	O

Less	O
frequent	O
toxic	O
effects	O
included	O
thrombocytopenia	O
,	O
anemia	O
,	O
nausea	O
,	O
mild	O
alopecia	O
,	O
phlebitis	O
,	O
and	O
mucositis	O
.	O

Myelosuppression	O
was	O
more	O
in	O
patients	O
with	O
hepatic	O
dysfunction	I-Chemical
.	O

Pharmacokinetic	O
analyses	O
in	O
21	O
patients	O
revealed	O
Pirarubicin	O
plasma	O
T	O
1/2	O
alpha	O
(	O
+/-	O
SE	O
)	O
of	O
2.5	O
+/-	O
0.85	O
minutes	O
,	O
T	O
beta	O
1/2	O
of	O
25.6	O
+/-	O
6.5	O
minutes	O
,	O
and	O
T	O
1/2	O
gamma	O
of	O
23.6	O
+/-	O
7.6	O
hours	O
.	O

The	O
area	O
under	O
the	O
curve	O
was	O
537	O
+/-	O
149	O
ng/ml	O
x	O
hours	O
,	O
volume	O
of	O
distribution	O
(	O
Vd	O
)	O
3504	O
+/-	O
644	O
l/m2	O
,	O
and	O
total	O
clearance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39.3	O
l/hour/m2	O
.	O

Adriamycinol	O
,	O
doxorubicin	B-Drug
,	O
adriamycinone	O
,	O
and	O
tetrahydropyranyladriamycinol	O
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	B-Drug
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolites	O
.	O

Urinary	O
excretion	O
of	O
Pirarubicin	O
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
.	O

Activity	O
was	O
noted	O
in	O
mesothelioma	O
,	O
leiomyosarcoma	O
,	O
and	O
basal	O
cell	O
carcinoma	O
.	O

The	O
recommended	O
starting	O
dose	O
for	O
Phase	O
II	O
trials	O
is	O
60	O
mg/m2	O
IV	O
bolus	O
every	O
3	O
weeks	O
.	O

Differential	O
effects	O
of	O
gamma-hexachlorocyclohexane	B-Chemical
(	O
lindane	B-Chemical
)	O
on	O
pharmacologically-induced	O
seizures	B-Disease
.	O

Gamma-hexachlorocyclohexane	B-Chemical
(	O
gamma-HCH	B-Chemical
)	O
,	O
the	O
active	O
ingredient	O
of	O
the	O
insecticide	O
lindane	B-Chemical
,	O
has	O
been	O
shown	O
to	O
decrease	O
seizure	B-Disease
threshold	O
to	O
pentylenetrazol	O
(	O
PTZ	B-Chemical
)	O
3	O
h	O
after	O
exposure	O
to	O
gamma-HCH	B-Chemical
and	O
conversely	O
increase	O
threshold	O
to	O
PTZ-induced	B-Chemical
seizures	B-Disease
24	O
h	O
after	O
exposure	O
to	O
gamma-HCH	B-Chemical
(	O
Vohland	O
et	O
al	O
.	O

1981	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
severity	O
of	O
response	O
to	O
other	O
seizure-inducing	B-Disease
agents	O
was	O
tested	O
in	O
mice	O
1	O
and	O
24	O
h	O
after	O
intraperitoneal	O
administration	O
of	O
80	O
mg/kg	O
gamma-HCH	B-Chemical
.	O

One	O
hour	O
after	O
the	O
administration	O
of	O
gamma-HCH	B-Chemical
,	O
the	O
activity	O
of	O
seizure-inducing	B-Disease
agents	O
was	O
increased	O
,	O
regardless	O
of	O
their	O
mechanism	O
,	O
while	O
24	O
h	O
after	O
gamma-HCH	B-Chemical
a	O
differential	O
response	O
was	O
observed	O
.	O

Seizure	B-Disease
activity	O
due	O
to	O
PTZ	B-Chemical
and	O
picrotoxin	B-Chemical
(	O
PTX	B-Chemical
)	O
was	O
significantly	O
decreased	O
;	O
however	O
,	O
seizure	B-Disease
activity	O
due	O
to	O
3-mercaptopropionic	B-Chemical
acid	I-Chemical
(	O
MPA	B-Chemical
)	O
,	O
bicuculline	B-Chemical
(	O
BCC	B-Chemical
)	O
,	O
methyl	B-Chemical
6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate	I-Chemical
(	O
DMCM	B-Chemical
)	O
,	O
or	O
strychnine	B-Chemical
(	O
STR	B-Chemical
)	O
was	O
not	O
different	O
from	O
control	O
.	O

In	O
vitro	O
,	O
gamma-HCH	B-Chemical
,	O
pentylenetetrazol	B-Chemical
and	O
picrotoxin	B-Chemical
were	O
shown	O
to	O
inhibit	O
3H-TBOB	B-Chemical
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4.6	O
,	O
404	O
and	O
9.4	O
microM	O
,	O
respectively	O
.	O

MPA	B-Chemical
,	O
BCC	B-Chemical
,	O
DMCM	B-Chemical
,	O
and	O
STR	B-Chemical
showed	O
no	O
inhibition	O
of	O
3H-TBOB	B-Chemical
(	O
t-butyl	B-Chemical
bicyclo-orthobenzoate	I-Chemical
)	O
binding	O
at	O
concentrations	O
of	O
100	O
micron	O
.	O

The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	B-Disease
activity	O
induced	O
by	O
PTZ	B-Chemical
and	O
PTX	B-Chemical
24	O
h	O
after	O
gamma-HCH	B-Chemical
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure-inducing	B-Disease
agents	O
is	O
decreased	O
.	O

The	O
in	O
vitro	O
data	O
suggest	O
that	O
the	O
site	O
responsible	O
for	O
the	O
decrease	O
in	O
seizure	B-Disease
activity	O
24	O
h	O
after	O
gamma-HCH	B-Chemical
may	O
be	O
the	O
GABA-A	B-Chemical
receptor-linked	O
chloride	O
channel	O
.	O

Severe	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	B-Drug
for	O
recurrent	O
glioblastomas	O
.	O

BACKGROUND	O
:	O
Glioblastoma	B-Disease
is	O
a	O
malignant	B-Disease
tumor	I-Disease
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O

With	O
current	O
treatment	O
regimens	O
including	O
combined	O
surgery	O
,	O
radiation	O
and	O
chemotherapy	O
,	O
the	O
average	O
life	O
expectancy	O
of	O
the	O
patients	O
is	O
limited	O
to	O
approximately	O
1	O
year	O
.	O

Therefore	O
,	O
patients	O
with	O
glioblastoma	B-Disease
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Generally	O
,	O
carboplatin	B-Chemical
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	B-Chemical
,	O
whose	O
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
are	O
well	O
known	O
.	O

However	O
,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	B-Chemical
and	O
orbital	O
toxicity	I-Chemical
after	O
intracarotid	O
injection	O
of	O
carboplatin	B-Drug
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CASE	O
:	O
A	O
58-year-old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	B-Drug
for	O
recurrent	O
glioblastomas	O
in	O
his	O
left	O
temporal	O
lobe	O
.	O

He	O
complained	O
of	O
pain	O
and	O
visual	O
disturbance	O
in	O
the	O
ipsilateral	O
eye	O
30	O
h	O
after	O
the	O
injection	O
.	O

Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	B-Drug
toxicity	I-Chemical
were	O
seen	O
.	O

RESULTS	O
:	O
He	O
was	O
treated	O
with	O
intravenous	O
administration	O
of	O
corticosteroids	O
and	O
glycerin	O
for	O
6	O
days	O
after	O
the	O
injection	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle-closure	O
glaucoma	O
decreased	O
and	O
ocular	O
pain	O
diminished	O
,	O
inexorable	O
papilledema	O
and	O
exudative	O
retinal	O
detachment	O
continued	O
for	O
3	O
weeks	O
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	O
atrophy	O
with	O
optic	O
atrophy	O
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	B-Drug
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	O
toxicity	I-Chemical
.	O

It	O
is	O
recommended	O
that	O
further	O
studies	O
and	I-Disease
investigations	O
are	O
undertaken	O
in	O
the	O
effort	O
to	O
minimize	O
such	O
severe	O
side	O
effects	O
.	O

Phase	O
II	O
study	O
of	O
the	O
amsacrine	B-Chemical
analogue	O
CI-921	B-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
)	O
in	O
non-small	B-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
.	O

CI-921	B-Chemical
(	O
NSC	B-Chemical
343499	I-Chemical
;	O
9-	B-Chemical
[	I-Chemical
[	I-Chemical
2-methoxy-4-	I-Chemical
[	I-Chemical
(	I-Chemical
methylsulphonyl	I-Chemical
)	I-Chemical
amino	I-Chemical
]	I-Chemical
phenyl	I-Chemical
]	I-Chemical
amino	I-Chemical
]	I-Chemical
-N,5-dimethyl-	I-Chemical
4-acridinecarboxamide	I-Chemical
)	O
is	O
a	O
topoisomerase	O
II	O
poison	O
with	O
high	O
experimental	O
antitumour	O
activity	O
.	O

It	O
was	O
administered	O
by	O
15	O
min	O
infusion	O
to	O
16	O
evaluable	O
patients	O
with	O
non-small	B-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
(	O
NSCLC	B-Disease
)	O
(	O
7	O
with	O
no	O
prior	O
treatment	O
,	O
9	O
patients	O
in	O
relapse	O
following	O
surgery/radiotherapy	O
)	O
at	O
a	O
dose	O
(	O
648	O
mg/m2	O
divided	O
over	O
3	O
days	O
,	O
repeated	O
every	O
3	O
weeks	O
)	O
determined	O
by	O
phase	O
I	O
trial	O
.	O

Patients	O
had	O
a	O
median	O
performance	O
status	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
median	O
age	O
of	O
61	O
years	O
.	O

The	O
histology	O
comprised	O
squamous	B-Disease
carcinoma	I-Disease
(	O
11	O
)	O
,	O
adenocarcinoma	B-Disease
(	O
1	O
)	O
,	O
mixed	O
histology	O
(	O
2	O
)	O
,	O
bronchio-alveolar	B-Disease
carcinoma	I-Disease
(	O
1	O
)	O
and	O
large	O
cell	O
undifferentiated	B-Disease
carcinoma	I-Disease
(	O
1	O
)	O
.	O

Neutropenia	B-Disease
grade	O
greater	O
than	O
or	O
equal	O
to	O
3	O
was	O
seen	O
in	O
15	O
patients	O
,	O
infections	B-Disease
with	O
recovery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seizures	B-Disease
in	O
1	O
patient	O
.	O

Grade	O
less	O
than	O
or	O
equal	O
to	O
2	O
nausea	B-Disease
and	O
vomiting	B-Disease
occurred	O
in	O
66	O
%	O
courses	O
and	O
phlebitis	B-Disease
in	O
the	O
infusion	O
arm	O
in	O
37	O
%	O
.	O

1	O
patient	O
with	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
achieved	O
a	O
partial	O
response	O
lasting	O
5	O
months	O
.	O

Further	O
testing	O
in	O
this	O
and	O
other	O
tumour	B-Disease
types	O
using	O
multiple	O
daily	O
schedules	O
is	O
warranted	O
.	O

Alpha-lipoic	B-Chemical
acid	I-Chemical
prevents	O
mitochondrial	B-Disease
damage	I-Disease
and	O
neurotoxicity	B-Disease
in	O
experimental	O
chemotherapy	O
neuropathy	B-Disease
.	O

The	O
study	O
investigates	O
if	O
alpha-lipoic	B-Chemical
acid	I-Chemical
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
,	O
if	O
mitochondrial	B-Disease
damage	I-Disease
plays	O
a	O
critical	O
role	O
in	O
toxic	B-Disease
neurodegenerative	I-Disease
cascade	I-Disease
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha-lipoic	B-Chemical
acid	I-Chemical
depend	O
on	O
mitochondria	O
protection	O
.	O

We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	B-Drug
.	O

This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha-lipoic	B-Chemical
acid	I-Chemical
in	O
preventing	O
axonal	B-Disease
damage	I-Disease
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha-lipoic	B-Chemical
acid	I-Chemical
.	O

Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	B-Chemical
and	O
paclitaxel	B-Chemical
cause	O
early	O
mitochondrial	B-Disease
impairment	I-Disease
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O

Alpha-lipoic	B-Chemical
acid	I-Chemical
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	B-Disease
toxicity	I-Disease
and	O
induces	O
the	O
expression	O
of	O
frataxin	O
,	O
an	O
essential	O
mitochondrial	B-Disease
protein	O
with	O
anti-oxidant	O
and	O
chaperone	O
properties	O
.	O

In	O
conclusion	O
mitochondrial	B-Disease
toxicity	O
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
induced	O
neurotoxicity	B-Disease
.	O

Alpha-lipoic	B-Chemical
acid	I-Chemical
protects	O
sensory	O
neurons	O
through	O
its	O
anti-oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	O
.	O

These	O
findings	O
suggest	O
that	O
alpha-lipoic	B-Chemical
acid	I-Chemical
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	B-Disease
nerve	I-Disease
toxicity	I-Disease
in	O
patients	O
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O

Optimising	O
stroke	B-Disease
prevention	O
in	O
non-valvular	O
atrial	B-Disease
fibrillation	I-Disease
.	O

Atrial	B-Disease
fibrillation	I-Disease
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O

Pooled	O
data	O
from	O
trials	O
comparing	O
antithrombotic	O
treatment	O
with	O
placebo	O
have	O
shown	O
that	O
warfarin	B-Chemical
reduces	O
the	O
risk	O
of	O
stroke	B-Disease
by	O
62	O
%	O
,	O
and	O
that	O
aspirin	B-Chemical
alone	O
reduces	O
the	O
risk	O
by	O
22	O
%	O
.	O

Overall	O
,	O
in	O
high-risk	O
patients	O
,	O
warfarin	B-Chemical
is	O
superior	O
to	O
aspirin	B-Chemical
in	O
preventing	O
strokes	B-Disease
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36	O
%	O
.	O

Ximelagatran	B-Chemical
,	O
an	O
oral	O
direct	O
thrombin	O
inhibitor	O
,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	B-Chemical
K	I-Chemical
antagonist	O
drugs	B-Drug
in	O
the	O
prevention	O
of	O
embolic	B-Disease
events	I-Disease
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnormal	B-Disease
liver	I-Disease
function	I-Disease
tests	O
.	O

The	O
ACTIVE-W	O
(	O
Atrial	B-Disease
Fibrillation	I-Disease
Clopidogrel	B-Chemical
Trial	O
with	O
Irbesartan	B-Chemical
for	O
Prevention	O
of	O
Vascular	O
Events	O
)	O
study	O
has	O
demonstrated	O
that	O
warfarin	B-Chemical
is	O
superior	O
to	O
platelet	O
therapy	O
(	O
clopidogrel	B-Chemical
plus	O
aspirin	B-Chemical
)	O
in	O
the	O
prevention	O
af	O
embolic	B-Disease
events	I-Disease
.	O

Idraparinux	B-Chemical
,	O
a	O
Factor	O
Xa	O
inhibitor	O
,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	B-Disease
fibrillation	I-Disease
.	O

Angiotensin-converting	B-Chemical
enzyme	O
inhibitors	O
and	O
angiotensin	B-Chemical
II	I-Chemical
receptor-blocking	O
drugs	B-Drug
hold	O
promise	O
in	O
atrial	B-Disease
fibrillation	I-Disease
through	O
cardiac	B-Disease
remodelling	I-Disease
.	O

Preliminary	O
studies	O
suggest	O
that	O
statins	B-Chemical
could	O
interfere	O
with	O
the	O
risk	O
of	O
recurrence	O
after	O
electrical	O
cardioversion	O
.	O

Finally	O
,	O
percutaneous	O
methods	O
for	O
the	O
exclusion	O
of	O
left	O
atrial	O
appendage	O
are	O
under	O
investigation	O
in	O
high-risk	O
patients	O
.	O

Interaction	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
with	O
antineoplastic	O
agents	O
.	O

A	O
synergistic	O
effect	O
of	O
etoposide	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
was	O
observed	O
in	O
a	O
patient	O
with	O
acute	B-Disease
T-lymphocytic	I-Disease
leukemia	I-Disease
in	O
relapse	O
.	O

The	O
concomitant	O
administration	O
of	O
etoposide	B-Chemical
and	O
cyclosporin	B-Chemical
A	I-Chemical
resulted	O
in	O
eradication	O
of	O
hitherto	O
refractory	O
leukemic	B-Disease
infiltration	I-Disease
of	O
bone	O
marrow	O
.	O

Severe	O
side	O
effects	O
in	O
terms	O
of	O
mental	O
confusion	B-Disease
and	O
progressive	O
hyperbilirubinemia	B-Disease
,	O
however	O
,	O
point	O
to	O
an	O
enhancement	O
not	O
only	O
of	O
antineoplastic	O
effects	O
but	O
also	O
of	O
toxicity	B-Disease
in	O
normal	O
tissues	O
.	O

This	O
report	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	O
of	O
normal	O
T-cell	O
functions	O
.	O

The	O
hematologic	O
effects	O
of	O
cefonicid	B-Chemical
and	O
cefazedone	B-Chemical
in	O
the	O
dog	O
:	O
a	O
potential	O
model	O
of	O
cephalosporin	B-Chemical
hematotoxicity	B-Disease
in	O
man	O
.	O

Cephalosporin	B-Chemical
antibiotics	B-Drug
cause	O
a	O
variety	O
of	O
hematologic	B-Disease
disturbances	I-Disease
in	O
man	O
,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	O
characterized	O
.	O

There	O
is	O
a	O
need	O
for	O
a	O
well-defined	O
animal	O
model	O
in	O
which	O
these	O
blood	B-Disease
dyscrasias	I-Disease
can	O
be	O
studied	O
.	O

In	O
four	O
subacute	O
toxicity	B-Disease
studies	O
,	O
the	O
intravenous	O
administration	O
of	O
cefonicid	B-Chemical
or	O
cefazedone	B-Chemical
to	O
beagle	O
dogs	O
caused	O
a	O
dose-dependent	O
incidence	O
of	O
anemia	B-Disease
,	O
neutropenia	B-Disease
,	O
and	O
thrombocytopenia	B-Disease
after	O
1-3	O
months	O
of	O
treatment	O
.	O

A	O
nonregenerative	O
anemia	B-Disease
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	B-Disease
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dogs	O
receiving	O
400-500	O
mg/kg	O
cefonicid	B-Chemical
or	O
540-840	O
mg/kg	O
cefazedone	B-Chemical
.	O

All	O
three	O
cytopenias	B-Disease
were	O
completely	O
reversible	O
following	O
cessation	O
of	O
treatment	O
;	O
the	O
time	O
required	O
for	O
recovery	O
of	O
the	O
erythron	O
(	O
approximately	O
1	O
month	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(	O
hours	O
to	O
a	O
few	O
days	O
)	O
.	O

Upon	O
rechallenge	O
with	O
either	O
cephalosporin	B-Chemical
,	O
the	O
hematologic	B-Disease
syndrome	I-Disease
was	O
reproduced	O
in	O
most	O
dogs	O
tested	O
;	O
cefonicid	B-Chemical
(	O
but	O
not	O
cefazedone	B-Chemical
)	O
-treated	O
dogs	O
showed	O
a	O
substantially	O
reduced	O
induction	O
period	O
(	O
15	O
+/-	O
5	O
days	O
)	O
compared	O
to	O
that	O
of	O
the	O
first	O
exposure	O
to	O
the	O
drug	B-Drug
(	O
61	O
+/-	O
24	O
days	O
)	O
.	O

This	O
observation	O
,	O
along	O
with	O
the	O
rapid	O
rate	O
of	O
decline	O
in	O
red	O
cell	O
mass	O
parameters	O
of	O
affected	O
dogs	O
,	O
suggests	O
that	O
a	O
hemolytic	B-Disease
component	O
complicated	O
the	O
red	O
cell	O
production	O
problem	O
and	O
that	O
multiple	O
toxicologic	O
mechanisms	O
contributed	O
to	O
the	O
cytopenia	B-Disease
.	O

We	O
conclude	O
that	O
the	O
administration	O
of	O
high	O
doses	O
of	O
cefonicid	B-Chemical
or	O
cefazedone	B-Chemical
to	O
dogs	O
can	O
induce	O
hematotoxicity	B-Disease
similar	O
to	O
the	O
cephalosporin-induced	B-Chemical
blood	B-Disease
dyscrasias	I-Disease
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
model	O
for	O
studying	O
the	O
mechanisms	O
of	O
these	O
disorders	O
.	O

A	O
pyridoxine-dependent	B-Chemical
behavioral	B-Disease
disorder	I-Disease
unmasked	O
by	O
isoniazid	B-Chemical
.	O

A	O
3-year-old	O
girl	O
had	O
behavioral	B-Disease
deterioration	I-Disease
,	O
with	O
hyperkinesis	B-Disease
,	O
irritability	B-Disease
,	O
and	O
sleeping	B-Disease
difficulties	I-Disease
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	B-Chemical
.	O

The	O
administration	O
of	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-Chemical
hydrochloride	I-Chemical
led	O
to	O
a	O
disappearance	O
of	O
symptoms	O
.	O

After	O
discontinuing	O
isoniazid	B-Chemical
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	O
that	O
was	O
controlled	O
by	O
pyridoxine	B-Chemical
.	O

A	O
placebo	O
had	O
no	O
effect	O
,	O
but	O
niacinamide	B-Chemical
was	O
as	O
effective	O
as	O
pyridoxine	B-Chemical
.	O

Periodic	O
withdrawal	O
of	O
pyridoxine	B-Chemical
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkinesis	B-Disease
.	O

The	O
level	O
of	O
pyridoxal	B-Chemical
in	O
the	O
blood	O
was	O
normal	O
during	O
the	O
periods	O
of	O
relapse	O
.	O

Metabolic	O
studies	O
suggested	O
a	O
block	O
in	O
the	O
kynurenine	B-Chemical
pathway	O
of	O
tryptophan	B-Chemical
metabolism	O
.	O

The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-Chemical
to	O
control	O
her	O
behavior	O
.	O

A	O
selective	O
dopamine	B-Chemical
D4	O
receptor	O
antagonist	O
,	O
NRA0160	B-Chemical
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O

NRA0160	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
[	I-Chemical
2-	I-Chemical
(	I-Chemical
4-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorobenzylidene	I-Chemical
)	I-Chemical
piperidin-1-yl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4-fluorophenyl	I-Chemical
)	I-Chemical
thiazole-2-carboxamide	I-Chemical
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	B-Chemical
D4.2	O
,	O
D4.4	O
and	O
D4.7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0.5	O
,	O
0.9	O
and	O
2.7	O
nM	O
,	O
respectively	O
.	O

NRA0160	B-Chemical
is	O
over	O
20,000fold	O
more	O
potent	O
at	O
the	O
dopamine	B-Chemical
D4.2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D2L	O
receptor	O
.	O

NRA0160	B-Chemical
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D3	O
receptor	O
(	O
Ki=39	O
nM	O
)	O
,	O
rat	O
serotonin	B-Chemical
(	O
5-HT	B-Chemical
)	O
2A	O
receptors	O
(	O
Ki=180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki=237	O
nM	O
)	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
antagonized	O
locomotor	O
hyperactivity	B-Disease
induced	O
by	O
methamphetamine	B-Chemical
(	O
MAP	B-Chemical
)	O
in	O
mice	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
antagonized	O
MAP-induced	B-Chemical
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
induced	O
catalepsy	B-Disease
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	B-Chemical
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
shortened	O
the	O
phencyclidine	B-Chemical
(	O
PCP	B-Chemical
)	O
-induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

These	O
findings	O
suggest	O
that	O
NRA0160	B-Chemical
may	O
have	O
unique	O
antipsychotic	O
activities	O
without	O
the	O
liability	O
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	O
.	O

Prolonged	O
cholestasis	B-Disease
after	O
troleandomycin-induced	B-Chemical
acute	O
hepatitis	B-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
troleandomycin-induced	B-Chemical
hepatitis	B-Disease
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-Disease
.	O

Jaundice	B-Disease
occurred	O
after	O
administration	O
of	O
troleandomycin	B-Chemical
for	O
7	O
days	O
and	O
was	O
associated	O
with	O
hypereosinophilia	B-Disease
.	O

Jaundice	B-Disease
disappeared	O
within	O
3	O
months	O
but	O
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-Disease
marked	O
by	O
pruritus	B-Disease
and	O
high	O
levels	O
of	O
alkaline	O
phosphatase	O
and	O
gammaglutamyltransferase	O
activities	O
.	O

Finally	O
,	O
pruritus	B-Disease
disappeared	O
within	O
19	O
months	O
,	O
and	O
liver	O
tests	O
returned	O
to	O
normal	O
27	O
months	O
after	O
the	O
onset	O
of	O
hepatitis	B-Disease
.	O

This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	B-Disease
can	O
follow	O
troleandomycin-induced	B-Chemical
acute	O
hepatitis	B-Disease
.	O

HMG	O
CoA	O
reductase	O
inhibitors	O
.	O

Current	O
clinical	O
experience	O
.	O

Lovastatin	B-Chemical
and	O
simvastatin	B-Chemical
are	O
the	O
2	O
best-known	O
members	O
of	O
the	O
class	O
of	O
hypolipidaemic	O
agents	O
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors	O
.	O

Clinical	O
experience	O
with	O
lovastatin	B-Chemical
includes	O
over	O
5000	O
patients	O
,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	O
or	O
more	O
,	O
and	O
experience	O
with	O
simvastatin	B-Chemical
includes	O
over	O
3500	O
patients	O
,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	O
or	O
more	O
.	O

Lovastatin	B-Chemical
has	O
been	O
marketed	O
in	O
the	O
United	O
States	O
for	O
over	O
6	O
months	O
.	O

Both	O
agents	O
show	O
substantial	O
clinical	O
efficacy	O
,	O
with	O
reductions	O
in	O
total	O
cholesterol	B-Chemical
of	O
over	O
30	O
%	O
and	O
in	O
LDL-cholesterol	B-Chemical
of	O
40	O
%	O
in	O
clinical	O
studies	O
.	O

Modest	O
increases	O
in	O
HDL-cholesterol	B-Chemical
levels	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O

Clinical	O
tolerability	O
of	O
both	O
agents	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patients	O
withdrawn	O
from	O
treatment	O
because	O
of	O
clinical	O
adverse	O
experiences	O
.	O

Ophthalmological	O
examinations	O
in	O
over	O
1100	O
patients	O
treated	O
with	O
one	O
or	O
the	O
other	O
agent	O
have	O
revealed	O
no	O
evidence	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
years	O
)	O
cataractogenic	O
potential	O
.	O

One	O
to	O
2	O
%	O
of	O
patients	O
have	O
elevations	O
of	O
serum	O
transaminases	O
to	O
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

These	O
episodes	O
are	O
asymptomatic	O
and	O
reversible	O
when	O
therapy	O
is	O
discontinued	O
.	O

Minor	O
elevations	O
of	O
creatine	B-Chemical
kinase	O
levels	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patients	O
.	O

Myopathy	B-Disease
,	O
associated	O
in	O
some	O
cases	O
with	O
myoglobinuria	B-Disease
,	O
and	O
in	O
2	O
cases	O
with	O
transient	O
renal	B-Disease
failure	I-Disease
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatin	B-Chemical
,	O
especially	O
in	O
patients	O
concomitantly	O
treated	O
with	O
cyclosporin	B-Chemical
,	O
gemfibrozil	B-Chemical
or	O
niacin	B-Chemical
.	O

Lovastatin	B-Chemical
and	O
simvastatin	B-Chemical
are	O
both	O
effective	O
and	O
well-tolerated	O
agents	O
for	O
lowering	O
elevated	O
levels	O
of	O
serum	O
cholesterol	B-Chemical
.	O

As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile	O
,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	B-Disease
and	O
its	O
consequences	O
.	O

Sulfasalazine-induced	B-Chemical
lupus	B-Disease
erythematosus	I-Disease
.	O

Pneumonitis	B-Disease
,	O
bilateral	O
pleural	B-Disease
effusions	I-Disease
,	O
echocardiographic	O
evidence	O
of	O
cardiac	B-Disease
tamponade	I-Disease
,	O
and	O
positive	O
autoantibodies	O
developed	O
in	O
a	O
43-year-old	O
man	O
,	O
who	O
was	O
receiving	O
long-term	O
sulfasalazine	B-Chemical
therapy	O
for	O
chronic	O
ulcerative	B-Disease
colitis	I-Disease
.	O

After	O
cessation	O
of	O
the	O
sulfasalazine	B-Chemical
and	O
completion	O
of	O
a	O
six-week	O
course	O
of	O
corticosteroids	O
,	O
these	O
problems	O
resolved	O
over	O
a	O
period	O
of	O
four	O
to	O
six	O
months	O
.	O

It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine-induced	B-Chemical
lupus	B-Disease
,	O
which	O
manifested	O
with	O
serositis	B-Disease
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptoms	O
.	O

Physicians	O
who	O
use	O
sulfasalazine	B-Chemical
to	O
treat	O
patients	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine-induced	B-Chemical
lupus	B-Disease
syndrome	I-Disease
.	O

Optimization	O
of	O
levodopa	B-Chemical
therapy	O
.	O

While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	B-Chemical
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25/100	O
or	O
controlled-release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa-levodopa	B-Chemical
to	O
the	O
point	O
of	O
``	O
normality	O
,	O
''	O
which	O
can	O
lead	B-Drug
to	O
toxicity	O
.	O

The	O
physician	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjunctive	O
medications	O
;	O
such	O
combined	O
therapy	O
has	O
become	O
the	O
standard	O
approach	O
to	O
treatment	O
.	O

Following	O
the	O
initial	O
period	O
of	O
therapy	O
,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	O
approaches	O
,	O
such	O
as	O
dosage	O
adjustment	O
or	O
introduction	O
of	O
a	O
dopamine	B-Drug
agonist	O
.	O

Other	O
possible	O
adverse	O
effects	O
--	O
such	O
as	O
gastrointestinal	O
disorders	O
,	O
orthostatic	O
hypotension	O
,	O
levodopa-induced	B-Chemical
psychosis	O
,	O
sleep	O
disturbances	O
or	O
parasomnias	O
,	O
or	O
drug	B-Drug
interactions	O
--	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O

Nonpharmacologic	O
concerns	O
can	O
help	O
the	O
Parkinson	O
's	O
disease	O
patient	O
achieve	O
and	O
maintain	O
optimal	O
functioning	O
,	O
including	O
daily	O
exercise	O
,	O
physical	O
therapy	O
,	O
and	O
involvement	O
with	O
support	O
groups	O
.	O

Alpha	O
and	O
beta	O
coma	B-Disease
in	O
drug	B-Drug
intoxication	O
uncomplicated	O
by	O
cerebral	B-Disease
hypoxia	I-Disease
.	O

Four	O
patients	O
who	O
were	O
rendered	O
comatose	B-Disease
or	O
stuporous	B-Disease
by	O
drug	B-Drug
intoxication	O
,	O
but	O
who	O
were	O
not	O
hypoxic	O
,	O
are	O
described	O
.	O

Three	O
patients	O
received	O
high	O
doses	O
of	O
chlormethiazole	B-Chemical
for	O
alcohol	B-Chemical
withdrawal	B-Disease
symptoms	I-Disease
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	B-Disease
of	O
nitrazepam	B-Chemical
.	O

The	O
patient	O
with	O
nitrazepam	B-Chemical
overdose	B-Disease
and	O
two	O
of	O
those	O
with	O
chlormethiazole	B-Chemical
intoxication	O
conformed	O
to	O
the	O
criteria	O
of	O
'alpha	O
coma	B-Disease
'	O
,	O
showing	O
non-reactive	O
generalized	O
or	O
frontally	O
predominant	O
alpha	O
activity	O
in	O
the	O
EEG	O
.	O

The	O
fourth	O
patient	O
who	O
was	O
unconscious	O
after	O
chlormethiazole	B-Chemical
administration	O
exhibite	O
generalized	O
non-reactive	O
activity	O
in	O
the	O
slow	O
beta	O
range	O
.	O

All	O
four	O
recovered	O
completely	O
without	O
neurological	B-Disease
sequelae	I-Disease
following	O
the	O
withdrawal	O
of	O
the	O
offending	O
agents	O
.	O

The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	O
lesions	O
and	O
pharmacological	O
depression	B-Disease
of	O
the	O
brain	O
stem	O
reticular	O
formation	O
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
in	O
both	O
situations	O
disturbed	O
reticulo-thalamic	O
interactions	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
coma	B-Disease
.	O

It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	B-Drug
intoxication	O
,	O
in	O
the	O
absence	O
of	O
significant	O
hypoxaemia	B-Disease
,	O
a	O
favourable	O
outcome	O
may	O
be	O
anticipated	O
.	O

Omitting	O
fentanyl	B-Chemical
reduces	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
without	O
increasing	O
pain	B-Disease
,	O
after	O
sevoflurane	B-Chemical
for	O
day	O
surgery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	B-Chemical
,	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
occurs	O
frequently	O
.	O

Fentanyl	B-Chemical
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O

METHODS	O
:	O
This	O
double-blind	O
study	O
examined	O
the	O
incidence	O
and	I-Disease
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	O
and	O
pain	B-Disease
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-Chemical
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-Chemical
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-Chemical
in	O
addition	O
to	O
fentanyl	B-Chemical
.	O

RESULTS	O
:	O
Omission	O
of	O
fentanyl	B-Chemical
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B-Disease
and/or	O
moderate	O
to	O
severe	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	B-Chemical
and	O
fentanyl-dexamethasone	B-Chemical
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0.013	O
)	O
.	O

Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0.0012	O
)	O
.	O

Dexamethasone	B-Drug
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
.	O

Combining	O
the	O
two	O
fentanyl	B-Drug
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	O
nausea	O
and	O
vomiting	O
and	O
nausea	O
prior	O
to	O
discharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0.049	O
and	O
P	O
=	O
0.035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	O
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0.034	O
)	O
.	O

Pain	O
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	B-Drug
.	O

Fentanyl	B-Drug
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane-sparing	O
effect	O
and	O
increased	O
respiratory	O
depression	O
,	O
hypotension	O
and	O
bradycardia	O
.	O

CONCLUSION	O
:	O
As	O
fentanyl	B-Drug
exacerbated	O
postoperative	O
nausea	O
and	O
vomiting	O
without	O
an	O
improvement	O
in	O
postoperative	O
pain	O
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-Drug
in	O
day	O
surgery	O
.	O

Renal	B-Disease
Fanconi	I-Disease
syndrome	I-Disease
and	O
myopathy	B-Disease
after	O
liver	O
transplantation	O
:	O
drug-related	O
mitochondrial	B-Disease
cytopathy	I-Disease
?	O
Advances	O
in	O
the	O
field	O
of	O
transplantation	O
provide	O
a	O
better	O
quality	O
of	O
life	O
and	O
allow	O
more	O
favorable	O
conditions	O
for	O
growth	O
and	O
development	O
in	O
children	O
.	O

However	O
,	O
combinations	O
of	O
different	O
therapeutic	O
regimens	O
require	O
consideration	O
of	O
potential	O
adverse	O
reactions	O
.	O

We	O
describe	O
a	O
15-yr-old	O
girl	O
who	O
had	O
orthotopic	O
liver	O
transplantation	O
because	O
of	O
Wilson	B-Disease
's	I-Disease
disease	I-Disease
.	O

Tacrolimus	B-Chemical
,	O
MMF	B-Chemical
,	O
and	O
steroids	B-Chemical
were	O
given	O
as	O
immunosuppressant	O
.	O

Lamivudine	B-Chemical
was	O
added	O
because	O
of	O
de	O
nova	O
hepatitis	B-Disease
B	I-Disease
infection	I-Disease
during	O
her	O
follow-up	O
.	O

Three	O
yr	O
after	O
transplantation	O
she	O
developed	O
renal	B-Disease
Fanconi	I-Disease
syndrome	I-Disease
with	O
severe	O
metabolic	B-Disease
acidosis	I-Disease
,	O
hypophosphatemia	B-Disease
,	O
glycosuria	B-Disease
,	O
and	O
aminoaciduria	B-Disease
.	O

Although	O
tacrolimus	B-Chemical
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	O
post-transplant	O
renal	O
acidosis	B-Disease
and	O
was	O
replaced	O
by	O
sirolimus	B-Chemical
,	O
acidosis	B-Disease
,	O
and	O
electrolyte	O
imbalance	O
got	O
worse	O
.	O

Proximal	O
muscle	B-Disease
weakness	I-Disease
has	O
developed	O
during	O
her	O
follow-up	O
.	O

Fanconi	B-Disease
syndrome	I-Disease
,	O
as	O
well	O
as	O
myopathy	B-Disease
,	O
is	O
well	O
recognized	O
in	O
patients	O
with	O
mitochondrial	B-Disease
disorders	I-Disease
and	O
caused	O
by	O
depletion	O
of	O
mtDNA	O
.	O

We	O
suggest	O
that	O
our	O
patient	O
's	O
tubular	B-Disease
dysfunction	I-Disease
and	O
myopathy	B-Disease
may	O
have	O
resulted	O
from	O
mitochondrial	B-Disease
dysfunction	I-Disease
which	O
is	O
triggered	O
by	O
tacrolimus	B-Chemical
and	O
augmented	O
by	O
lamivudine	B-Chemical
.	O

Antipsychotic-like	O
profile	O
of	O
thioperamide	B-Chemical
,	O
a	O
selective	O
H3-receptor	O
antagonist	O
in	O
mice	O
.	O

Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-Disease
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	B-Chemical
H	O
(	O
3	O
)	O
-receptor	B-Drug
ligands	O
on	O
neuroleptic-induced	O
catalepsy	B-Disease
,	O
apomorphine-induced	B-Chemical
climbing	O
behavior	O
and	O
amphetamine-induced	B-Chemical
locomotor	O
activities	O
in	O
mice	O
.	O

Catalepsy	B-Disease
was	O
induced	O
by	O
haloperidol	B-Chemical
(	O
2	O
mg/kg	O
p.o	O
.	O

)	O
,	O
while	O
apomorphine	B-Chemical
(	O
1.5	O
mg/kg	O
s.c.	O
)	O
and	O
amphetamine	B-Chemical
(	B-Chemical
2	O
mg/kg	O
s.c.	O
)	I-Chemical
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
,	O
respectively	O
.	O

(	B-Chemical
R	I-Chemical
)	O
-alpha-methylhistamine	O
(	O
RAMH	B-Chemical
)	O
(	O
5	O
microg	O
i.c.v	O
.	O

)	O
and	O
thioperamide	B-Chemical
(	O
THP	B-Chemical
)	O
(	O
15	O
mg/kg	O
i.p	O
.	O

)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B-Disease
.	O

Administration	O
of	O
THP	B-Chemical
(	O
3.75	O
,	O
7.5	O
and	O
15	O
mg/kg	O
i.p	O
.	O

)	O
1	O
h	O
prior	O
to	O
haloperidol	B-Chemical
resulted	O
in	O
a	O
dose-dependent	O
increase	O
in	O
the	O
catalepsy	B-Disease
times	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
pretreatment	O
with	O
RAMH	B-Chemical
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	B-Chemical
(	O
15	O
mg/kg	O
i.p.	O
)	O
.	O

RAMH	B-Chemical
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	B-Chemical
(	O
15	O
mg/kg	O
i.p	O
.	O

)	O
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O

On	O
amphetamine-induced	B-Chemical
hyperactivity	B-Disease
,	O
THP	B-Chemical
(	O
3.75	O
and	O
7.5	O
mg/kg	O
i.p	O
.	O

)	O
reduced	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Pretreatment	O
with	O
RAMH	B-Chemical
(	O
5	O
microg	O
i.c.v	O
.	O

)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	B-Chemical
(	O
3.75	O
mg/kg	O
i.p.	O
)	O
.	O

Climbing	O
behavior	O
induced	O
by	O
apomorphine	B-Chemical
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	B-Chemical
.	O

Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	B-Chemical
.	O

THP	B-Chemical
exhibited	O
an	O
antipsychotic-like	O
profile	O
by	O
potentiating	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
,	O
reducing	O
amphetamine-induced	B-Chemical
hyperactivity	B-Disease
and	O
reducing	O
apomorphine-induced	B-Chemical
climbing	O
in	O
mice	O
.	O

Such	O
effects	O
of	O
THP	B-Chemical
were	O
reversed	O
by	O
RAMH	B-Chemical
indicating	O
the	O
involvement	O
of	O
histamine	B-Chemical
H	O
(	O
3	O
)	O
-receptors	O
.	O

Findings	O
suggest	O
a	O
potential	O
for	O
H	O
(	O
3	O
)	O
-receptor	B-Drug
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-Disease
.	O

Transient	O
platypnea-orthodeoxia-like	B-Disease
syndrome	I-Disease
induced	O
by	O
propafenone	B-Chemical
overdose	B-Disease
in	O
a	O
young	O
woman	O
with	O
Ebstein	B-Disease
's	I-Disease
anomaly	I-Disease
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37-year-old	O
white	O
woman	O
with	O
Ebstein	B-Disease
's	I-Disease
anomaly	I-Disease
,	O
who	O
developed	O
a	O
rare	O
syndrome	O
called	O
platypnea-orthodeoxia	B-Disease
,	O
characterized	O
by	O
massive	O
right-to-left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	B-Disease
and	O
cyanosis	B-Disease
.	O

This	O
shunt	O
of	O
blood	O
via	O
a	O
patent	B-Disease
foramen	I-Disease
ovale	I-Disease
occurred	O
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	B-Chemical
overdose	B-Disease
.	O

This	O
drug	B-Drug
caused	O
biventricular	B-Disease
dysfunction	I-Disease
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect	O
,	O
and	O
hypotension	B-Disease
,	O
due	O
to	O
its	O
peripheral	O
vasodilatory	O
effect	O
.	O

These	O
effects	O
gave	O
rise	O
to	O
an	O
increase	O
in	O
the	O
right	O
atrial	O
pressure	O
and	O
a	O
decrease	O
in	O
the	O
left	O
one	O
with	O
a	O
consequent	O
stretching	O
of	O
the	O
foramen	O
ovale	O
and	O
the	O
creation	O
of	O
massive	O
right-to-left	O
shunting	O
.	O

In	O
our	O
case	O
this	O
interatrial	O
shunt	O
was	O
very	O
accurately	O
detected	O
at	O
bubble	O
contrast	O
echocardiography	O
.	O

A	O
Phase	O
II	O
trial	O
of	O
cisplatin	B-Chemical
plus	O
WR-2721	B-Chemical
(	O
amifostine	B-Chemical
)	O
for	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatin	B-Chemical
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second-	O
or	O
third-line	O
treatment	O
of	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
.	O

Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8	O
%	O
when	O
60-120	O
mg/m2	O
of	O
cisplatin	B-Chemical
is	O
administered	O
every	O
3-4	O
weeks	O
.	O

Although	O
a	O
dose-response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	B-Chemical
,	O
the	O
dose-limiting	O
toxicities	B-Disease
associated	O
with	O
cisplatin	B-Chemical
(	O
e.g.	O
,	O
nephrotoxicity	B-Disease
,	O
ototoxicity	B-Disease
,	O
and	O
neurotoxicity	B-Disease
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B-Disease
carcinoma	I-Disease
.	O

WR-2721	B-Chemical
or	O
amifostine	B-Chemical
initially	O
was	O
developed	O
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

Amifostine	B-Chemical
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	B-Chemical
agents	I-Chemical
and	O
cisplatin	B-Chemical
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Early	O
trials	O
of	O
cisplatin	B-Chemical
and	O
amifostine	B-Chemical
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin-induced	B-Chemical
nephrotoxicity	B-Disease
,	O
ototoxicity	B-Disease
,	O
and	O
neuropathy	B-Disease
were	O
reduced	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	B-Chemical
plus	O
amifostine	B-Chemical
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	B-Disease
carcinoma	I-Disease
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

Patients	O
received	O
amifostine	B-Chemical
,	O
910	O
mg/m2	O
intravenously	O
over	O
15	O
minutes	O
.	O

After	O
completion	O
of	O
the	O
amifostine	B-Chemical
infusion	O
,	O
cisplatin	B-Chemical
120	O
mg/m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O

Intravenous	O
hydration	O
and	O
mannitol	B-Chemical
was	O
administered	O
before	O
and	O
after	O
cisplatin	B-Chemical
.	O

Treatment	O
was	O
administered	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
.	O

RESULTS	O
:	O
Forty-four	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineligible	O
.	O

A	O
median	O
of	O
2	O
cycles	O
of	O
therapy	O
was	O
administered	O
to	O
the	O
37	O
eligible	O
patients	O
.	O

Six	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

Most	O
patients	O
(	O
57	O
%	O
)	O
stopped	O
treatment	O
because	O
of	O
disease	O
progression	O
.	O

Neurologic	B-Disease
toxicity	I-Disease
was	O
reported	O
in	O
52	O
%	O
of	O
patients	O
.	O

Seven	O
different	O
life-threatening	O
toxicities	B-Disease
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
cisplatin	B-Chemical
and	O
amifostine	B-Chemical
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

Neither	O
a	O
tumor-protective	B-Disease
effect	O
nor	O
reduced	O
toxicity	B-Disease
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	B-Chemical
to	O
cisplatin	B-Chemical
in	O
this	O
trial	O
.	O

Warfarin-induced	B-Chemical
iliopsoas	O
hemorrhage	B-Disease
with	O
subsequent	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
.	O

We	O
present	O
the	O
case	O
of	O
a	O
28-year-old	O
man	O
on	O
chronic	O
warfarin	B-Chemical
therapy	O
who	O
sustained	O
a	O
minor	O
muscle	B-Disease
tear	I-Disease
and	O
developed	O
increasing	O
pain	B-Disease
and	O
a	O
flexure	O
contracture	B-Disease
of	O
the	O
right	O
hip	O
.	O

Surgical	O
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	B-Disease
and	O
femoral	O
nerve	B-Disease
entrapment	I-Disease
,	O
resulting	O
in	O
a	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
and	O
partial	B-Disease
loss	I-Disease
of	I-Disease
quadriceps	I-Disease
functions	I-Disease
.	O

Anticoagulant-induced	O
femoral	B-Disease
nerve	I-Disease
palsy	I-Disease
represents	O
the	O
most	O
common	O
form	O
of	O
warfarin-induced	B-Chemical
peripheral	B-Disease
neuropathy	I-Disease
;	O
it	O
is	O
characterized	O
by	O
severe	O
pain	B-Disease
in	O
the	O
inguinal	O
region	O
,	O
varying	O
degrees	O
of	O
motor	B-Disease
and	I-Disease
sensory	I-Disease
impairment	I-Disease
,	O
and	O
flexure	O
contracture	B-Disease
of	O
the	O
involved	O
extremity	O
.	O

Myasthenia	B-Disease
gravis	I-Disease
caused	O
by	O
penicillamine	B-Chemical
and	O
chloroquine	B-Chemical
therapy	O
for	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

We	O
have	O
described	O
a	O
unique	O
patient	O
who	O
had	O
reversible	O
and	O
dose-related	O
myasthenia	B-Disease
gravis	I-Disease
after	O
penicillamine	B-Chemical
and	O
chloroquine	B-Chemical
therapy	O
for	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Although	O
acetylcholine	B-Chemical
receptor	O
antibodies	O
were	O
not	O
detectable	O
,	O
the	O
time	O
course	O
was	O
consistent	O
with	O
an	O
autoimmune	O
process	O
.	O

Nephrotoxicity	B-Disease
of	O
combined	O
cephalothin-gentamicin	B-Chemical
regimen	O
.	O

Two	O
patients	O
developed	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	B-Disease
renal	I-Disease
failure	I-Disease
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	B-Drug
sodium	O
and	O
gentamicin	B-Drug
sulfate	O
therapy	O
.	O

Patients	O
who	O
are	O
given	O
this	O
drug	B-Drug
regimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
early	O
signs	O
of	O
nephrotoxicity	O
.	O

High	O
doses	O
of	O
this	O
antibiotic	O
combination	O
should	O
be	O
avoided	O
especially	O
in	O
elderly	O
patients	O
.	O

Patients	O
with	O
renal	O
insufficiency	O
should	O
not	O
be	O
given	O
this	O
regimen	O
.	O

Components	O
of	O
lemon	O
essential	O
oil	O
attenuate	O
dementia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
.	O

The	O
anti-dementia	B-Disease
effects	O
of	O
s-limonene	B-Chemical
and	O
s-perillyl	B-Chemical
alcohol	I-Chemical
were	O
observed	O
using	O
the	O
passive	O
avoidance	O
test	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituation	O
test	O
(	O
OFH	O
)	O
.	O

These	O
lemon	O
essential	O
oils	O
showed	O
strong	O
ability	O
to	O
improve	O
memory	B-Disease
impaired	I-Disease
by	O
scopolamine	B-Chemical
;	O
however	O
,	O
s-perillyl	B-Chemical
alcohol	I-Chemical
relieved	O
the	O
deficit	B-Disease
of	I-Disease
associative	I-Disease
memory	I-Disease
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
improve	O
non-associative	O
memory	O
significantly	O
in	O
OFH	O
.	O

Analysis	O
of	O
neurotransmitter	O
concentration	O
in	O
some	O
brain	O
regions	O
on	O
the	O
test	O
day	O
showed	O
that	O
dopamine	B-Chemical
concentration	O
of	O
the	O
vehicle/scopolamine	B-Chemical
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
vehicle/vehicle	O
group	O
,	O
but	O
this	O
phenomenon	O
was	O
reversed	O
when	O
s-limonene	B-Chemical
or	O
s-perillyl	B-Chemical
alcohol	I-Chemical
were	O
administered	O
before	O
the	O
injection	O
of	O
scopolamine	B-Chemical
.	O

Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
lemon	O
essential	O
oil	O
components	O
could	O
inhibit	O
acetylcholinesterase	O
activity	O
in	O
vitro	O
using	O
the	O
Ellman	O
method	O
.	O

The	O
selective	O
5-HT6	O
receptor	O
antagonist	O
Ro4368554	B-Chemical
restores	O
memory	B-Disease
performance	O
in	O
cholinergic	O
and	O
serotonergic	O
models	O
of	O
memory	B-Disease
deficiency	O
in	O
the	O
rat	O
.	O

Antagonists	O
at	O
serotonin	B-Chemical
type	O
6	O
(	O
5-HT	B-Chemical
(	O
6	O
)	O
)	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O

Although	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
levels	O
.	O

The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive-enhancing	O
effects	O
of	O
the	O
5-HT	B-Chemical
(	O
6	O
)	O
antagonist	O
Ro4368554	B-Chemical
(	I-Chemical
3-benzenesulfonyl-7-	B-Chemical
(	I-Chemical
4-methyl-piperazin-1-yl	I-Chemical
)	I-Chemical
1H-indole	O
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	O
(	O
scopolamine	B-Chemical
pretreatment	O
)	O
and	O
a	O
serotonergic-	O
(	O
tryptophan	B-Chemical
(	O
TRP	B-Chemical
)	O
depletion	O
)	O
deficient	O
model	O
,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
metrifonate	B-Chemical
.	O

Initial	O
testing	O
in	O
a	O
time-dependent	O
forgetting	O
task	O
employing	O
a	O
24-h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	B-Chemical
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg/kg	O
,	O
p.o	O
.	O

)	O
,	O
whereas	O
Ro4368554	B-Chemical
was	O
inactive	O
.	O

Both	O
,	O
Ro4368554	B-Chemical
(	O
3	O
and	O
10	O
mg/kg	O
,	O
intraperitoneally	O
(	O
i.p	O
.	O

)	O
)	O
and	O
metrifonate	B-Chemical
(	O
10	O
mg/kg	O
,	O
p.o.	O
,	O
respectively	O
)	O
reversed	O
memory	B-Disease
deficits	I-Disease
induced	O
by	O
scopolamine	B-Chemical
and	O
TRP	B-Chemical
depletion	O
(	O
10	O
mg/kg	O
,	O
i.p.	O
,	O
and	O
3	O
mg/kg	O
,	O
p.o.	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
although	O
Ro4368554	B-Chemical
did	O
not	O
improve	O
a	O
time-related	O
retention	O
deficit	I-Disease
,	O
it	O
reversed	O
a	O
cholinergic	O
and	O
a	O
serotonergic	O
memory	B-Disease
deficit	O
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	B-Chemical
and	O
,	O
possibly	O
,	O
other	O
5-HT	B-Chemical
(	O
6	O
)	O
receptor	O
antagonists	O
.	O

Lone	O
atrial	B-Disease
fibrillation	I-Disease
associated	O
with	O
creatine	B-Chemical
monohydrate	O
supplementation	O
.	O

Atrial	B-Disease
fibrillation	I-Disease
in	O
young	O
patients	O
without	O
structural	O
heart	B-Disease
disease	I-Disease
is	O
rare	O
.	O

Therefore	O
,	O
when	O
the	O
arrhythmia	B-Disease
is	O
present	O
in	O
this	O
population	O
,	O
reversible	O
causes	O
must	O
be	O
identified	O
and	O
resolved	O
.	O

Thyroid	B-Disease
disorders	I-Disease
,	O
illicit	O
drug	B-Drug
or	O
stimulant	O
use	O
,	O
and	O
acute	B-Disease
alcohol	I-Disease
intoxication	I-Disease
are	O
among	O
these	O
causes	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
30-year-old	O
Caucasian	O
man	O
who	O
came	O
to	O
the	O
emergency	O
department	O
in	O
atrial	B-Disease
fibrillation	I-Disease
with	O
rapid	O
ventricular	O
response	O
.	O

His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	B-Disease
of	O
the	O
fingers	O
and	O
foot	O
.	O

Thyroid-stimulating	O
hormone	O
,	O
magnesium	B-Chemical
,	O
and	O
potassium	B-Chemical
levels	O
were	O
within	O
normal	O
limits	O
,	O
urine	O
drug	B-Drug
screen	O
was	O
negative	O
,	O
and	O
alcohol	B-Chemical
use	O
was	O
denied	O
.	O

However	O
,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	B-Chemical
monohydrate	O
was	O
revealed	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	B-Chemical
,	O
and	O
given	O
intravenous	O
diltiazem	B-Chemical
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	B-Chemical
for	O
rate	O
and	O
rhythm	O
control	O
.	O

When	O
discharged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metoprolol	B-Chemical
and	O
aspirin	B-Chemical
,	O
with	O
follow-up	O
plans	O
for	O
echocardiography	O
and	O
nuclear	O
imaging	O
to	O
assess	O
perfusion	O
.	O

Exogenous	O
creatine	B-Chemical
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance	O
.	O

Vegetarians	O
may	O
also	O
take	O
creatine	B-Chemical
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat	O
,	O
fish	O
,	O
and	O
other	O
animal	O
products	O
.	O

Previous	O
anecdotal	O
reports	O
have	O
linked	O
creatine	B-Chemical
to	O
the	O
development	O
of	O
arrhythmia	B-Disease
.	O

Clinicians	O
must	O
be	O
diligent	O
when	O
interviewing	O
patients	O
about	O
their	O
drug	B-Drug
therapy	O
histories	O
and	O
include	O
questions	O
about	O
their	O
use	O
of	O
herbal	O
products	O
and	O
dietary	O
supplements	O
.	O

In	O
addition	O
,	O
it	O
is	O
important	O
to	O
report	O
adverse	O
effects	O
associated	O
with	O
frequently	O
consumed	O
supplements	O
and	O
herbal	O
products	O
to	O
the	O
Food	O
and	O
Drug	B-Drug
Administration	O
and	O
in	O
the	O
literature	O
.	O

Comparison	O
of	O
developmental	O
toxicity	B-Disease
of	O
selective	O
and	O
non-selective	O
cyclooxygenase-2	O
inhibitors	O
in	O
CRL	O
:	O
(	O
WI	O
)	O
WUBR	O
Wistar	O
rats	O
--	O
DFU	B-Chemical
and	O
piroxicam	B-Chemical
study	O
.	O

BACKGROUND	O
:	O
Cyclooxygenase	O
(	O
COX	O
)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
often	O
ingested	O
drugs	B-Drug
during	O
pregnancy	O
.	O

Unlike	O
general	O
toxicity	B-Disease
data	O
,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	B-Disease
of	O
the	O
non-selective	O
(	O
piroxicam	B-Chemical
)	O
and	O
selective	O
(	O
DFU	B-Chemical
;	O
5,5-dimethyl-3-	B-Chemical
(	I-Chemical
3-fluorophenyl	I-Chemical
)	I-Chemical
-4-	I-Chemical
(	I-Chemical
4-methylsulphonyl	I-Chemical
)	I-Chemical
phenyl-2	I-Chemical
(	I-Chemical
5H	I-Chemical
)	I-Chemical
-furanon	I-Chemical
)	O
COX-2	O
inhibitors	O
.	O

METHODS	O
:	O
Drugs	B-Drug
were	O
separately	O
,	O
orally	O
once	O
daily	O
dosed	O
to	O
pregnant	O
rats	O
from	O
day	O
8	O
to	O
21	O
(	O
GD1=plug	O
day	O
)	O
.	O

Doses	O
were	O
set	O
at	O
0.3	O
,	O
3.0	O
and	O
30.0mg/kg	O
for	O
piroxicam	B-Chemical
and	O
0.2	O
,	O
2.0	O
and	O
20.0mg/kg	O
for	O
DFU	B-Chemical
.	O

Fetuses	O
were	O
delivered	O
on	O
GD	O
21	O
and	I-Disease
routinely	O
examined	O
.	O

Comprehensive	O
clinical	O
and	I-Disease
developmental	O
measurements	O
were	O
done	O
.	O

The	O
pooled	O
statistical	O
analysis	O
for	O
ventricular	B-Disease
septal	I-Disease
(	I-Disease
VSD	I-Disease
)	I-Disease
and	I-Disease
midline	I-Disease
(	I-Disease
MD	I-Disease
)	I-Chemical
defects	I-Chemical
was	O
performed	O
for	O
rat	O
fetuses	O
exposed	O
to	O
piroxicam	B-Drug
,	O
selective	O
and	O
non-selective	O
COX-2	O
inhibitor	O
based	O
on	O
present	O
and	O
historic	O
data	O
.	O

RESULTS	O
:	O
Maternal	O
toxicity	O
,	O
intrauterine	O
growth	O
retardation	O
,	O
and	O
increase	O
of	O
external	O
and	O
skeletal	O
variations	O
were	O
found	O
in	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
piroxicam	B-Drug
.	O

Decrease	O
of	O
fetal	O
length	O
was	O
the	O
only	O
signs	O
of	O
the	O
DFU	O
developmental	O
toxicity	O
observed	O
in	O
pups	O
exposed	O
to	O
the	O
highest	O
compound	O
dose	O
.	O

Lack	O
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	B-Drug
and	O
DFU-exposed	O
groups	O
.	O

Prenatal	O
exposure	O
to	O
non-selective	O
COX	O
inhibitors	O
increases	O
the	O
risk	O
of	O
VSD	I-Chemical
and	O
MD	O
when	O
compared	O
to	O
historic	O
control	O
but	O
not	O
with	O
selective	O
COX-2	O
inhibitors	O
.	O

CONCLUSION	O
:	O
Both	O
selective	O
and	O
non-selective	O
COX-2	O
inhibitors	O
were	O
toxic	O
for	O
rats	O
fetuses	O
when	O
administered	O
in	O
the	O
highest	O
dose	O
.	O

Unlike	O
DFU	O
,	O
piroxicam	B-Drug
was	O
also	O
highly	O
toxic	O
to	O
the	O
dams	O
.	O

Prenatal	O
exposure	O
to	O
selective	O
COX-2	O
inhibitors	O
does	O
not	O
increase	O
the	O
risk	O
of	O
ventricular	B-Chemical
septal	I-Chemical
and	O
midline	O
defects	I-Chemical
in	O
rat	O
when	O
compared	O
to	O
non-selective	O
drugs	B-Drug
and	O
historic	O
control	O
.	O

Protective	O
efficacy	O
of	O
neuroactive	O
steroids	B-Chemical
against	O
cocaine	B-Chemical
kindled-seizures	B-Disease
in	O
mice	O
.	O

Neuroactive	O
steroids	B-Chemical
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	B-Disease
and	I-Disease
psychiatric	I-Disease
disorders	I-Disease
.	O

They	O
offer	O
protection	O
against	O
seizures	O
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	B-Drug
dependence	O
in	O
preclinical	O
assessments	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma-aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	B-Drug
engendered	O
by	O
repeated	O
cocaine	B-Drug
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

Allopregnanolone	O
(	O
3alpha-hydroxy-5alpha-pregnan-20-one	O
)	O
,	O
pregnanolone	O
(	O
3alpha-hydroxy-5beta-pregnan-20-one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine-kindled	O
seizures	O
in	O
male	O
,	O
Swiss-Webster	O
mice	O
.	O

Kindled	O
seizures	O
were	O
induced	O
by	O
daily	O
administration	O
of	O
60	O
mg/kg	O
cocaine	B-Drug
for	O
5	O
days	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	O
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

Allopregnanolone	O
and	O
pregnanolone	O
,	O
but	O
not	O
ganaxolone	O
,	O
also	O
reduced	O
cumulative	O
lethality	O
associated	O
with	O
kindling	O
.	O

These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	O
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	B-Drug
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	B-Drug
of	O
abuse	O
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short-term	O
combination	O
therapy	O
with	O
cyclosporine	B-Chemical
A	I-Chemical
,	O
tacrolimus	B-Chemical
and	O
sirolimus	B-Chemical
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
may	O
supplement	O
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

These	O
are	O
nephrotoxic	B-Disease
,	O
but	O
SRL	B-Chemical
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxic	B-Disease
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	B-Chemical
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	B-Disease
effect	O
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague-Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
,	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
or	O
SRL	B-Chemical
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	B-Chemical
15	O
mg/kg/day	O
(	O
given	O
orally	O
)	O
,	O
FK506	B-Chemical
3.0	O
mg/kg/day	O
(	O
given	O
orally	O
)	O
or	O
SRL	B-Chemical
0.4	O
mg/kg/day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague-Dawley	O
rats	O
.	O

In	O
the	O
'conscious	O
catheterized	O
rat	O
'	O
model	O
,	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
was	O
measured	O
as	O
the	O
clearance	O
of	O
Cr	O
(	O
EDTA	O
)	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi-quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	B-Disease
,	O
subcapsular	O
fibrosis	B-Disease
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-Disease
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

RESULTS	O
:	O
CsA	B-Chemical
,	O
FK506	B-Chemical
and	O
SRL	B-Chemical
all	O
significantly	O
decreased	O
the	O
GFR	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	B-Chemical
was	O
combined	O
with	O
either	O
FK506	B-Chemical
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

The	O
morphological	O
changes	O
presented	O
a	O
similar	O
pattern	O
.	O

The	O
semi-quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
(	O
P	O
<	O
0.001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-Disease
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0.02	O
)	O
.	O

The	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
combination	O
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	B-Disease
as	O
compared	O
with	O
controls	O
(	O
P=0.05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	B-Disease
effect	O
of	O
CsA	B-Chemical
plus	O
SRL	B-Chemical
,	O
whereas	O
FK506	B-Chemical
plus	O
SRL	B-Chemical
was	O
better	O
tolerated	O
.	O

Effect	O
of	O
fucoidan	B-Chemical
treatment	O
on	O
collagenase-induced	O
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
rats	O
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	B-Disease
damage	I-Disease
following	O
ischemic	B-Disease
stroke	I-Disease
.	O

Intracerebral	B-Disease
hemorrhage	I-Disease
is	O
associated	O
with	O
more	O
inflammation	B-Disease
than	O
ischemic	B-Disease
stroke	I-Disease
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	B-Chemical
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	B-Disease
damage	I-Disease
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	B-Disease
hemorrhage	I-Disease
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

Rats	O
were	O
treated	O
with	O
seven	O
day	O
intravenous	O
infusion	O
of	O
fucoidan	B-Chemical
(	O
30	O
micrograms	O
h-1	O
)	O
or	O
vehicle	O
.	O

The	O
hematoma	B-Disease
was	O
assessed	O
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging	O
.	O

Motor	O
behavior	O
,	O
passive	O
avoidance	O
,	O
and	O
skilled	O
forelimb	O
function	O
were	O
tested	O
repeatedly	O
for	O
six	O
weeks	O
.	O

Fucoidan-treated	B-Chemical
rats	O
exhibited	O
evidence	O
of	O
impaired	B-Disease
blood	I-Disease
clotting	I-Disease
and	O
hemodilution	B-Disease
,	O
had	O
larger	O
hematomas	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	B-Disease
in	O
the	O
vicinity	O
of	O
the	O
hematoma	B-Disease
after	O
three	O
days	O
.	O

They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	B-Disease
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O

Acute	O
white	B-Disease
matter	I-Disease
edema	I-Disease
and	O
eventual	O
neuronal	B-Disease
loss	I-Disease
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	B-Disease
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Investigation	O
of	O
more	O
specific	O
anti-inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	O
in	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O

Paracetamol-associated	B-Chemical
coma	B-Disease
,	O
metabolic	B-Disease
acidosis	I-Disease
,	O
renal	B-Disease
and	I-Disease
hepatic	I-Disease
failure	I-Disease
.	O

A	O
case	O
of	O
metabolic	B-Disease
acidosis	I-Disease
,	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
and	I-Disease
hepatic	I-Disease
failure	I-Disease
following	O
paracetamol	O
ingestion	O
is	O
presented	O
.	O

The	O
diagnostic	O
difficulty	O
at	O
presentation	O
is	O
highlighted	O
.	O

Continuous	O
arteriovenous	O
haemofiltration	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
fluid	O
and	O
electrolyte	O
balance	O
.	O

The	O
patient	O
recovered	O
.	O

Hepatic	O
reactions	O
associated	O
with	O
ketoconazole	B-Chemical
in	O
the	O
United	O
Kingdom	O
.	O

Ketoconazole	B-Chemical
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981	O
.	O

By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	B-Disease
associated	O
with	O
the	O
drug	B-Drug
,	O
including	O
five	O
deaths	B-Disease
.	O

An	O
analysis	O
of	O
the	O
75	O
cases	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
deaths	B-Disease
,	O
were	O
probably	O
related	O
to	O
treatment	O
with	O
the	O
drug	B-Drug
.	O

Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
treatment	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O

The	O
mean	O
age	O
of	O
patients	O
in	O
the	O
16	O
probable	O
cases	O
was	O
57.9	O
,	O
with	O
hepatotoxicity	B-Disease
being	O
more	O
common	O
in	O
women	O
.	O

The	O
average	O
duration	O
of	O
treatment	O
before	O
the	O
onset	O
of	O
jaundice	B-Disease
was	O
61	O
days	O
.	O

None	O
of	O
these	O
well	O
validated	O
cases	O
occurred	O
within	O
the	O
first	O
10	O
days	O
after	O
treatment	O
.	O

The	O
results	O
of	O
serum	O
liver	O
function	O
tests	O
suggested	O
hepatocellular	B-Disease
injury	I-Disease
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern	O
.	O

In	O
contrast	O
,	O
the	O
results	O
of	O
histological	O
examination	O
of	O
the	O
liver	O
often	O
showed	O
evidence	O
of	O
cholestasis	B-Disease
.	O

The	O
characteristics	O
of	O
the	O
48	O
patients	O
in	O
the	O
possible	O
cases	O
were	O
similar	O
.	O

Allergic	O
manifestations	O
such	O
as	O
rash	B-Disease
and	O
eosinophilia	B-Disease
were	O
rare	O
.	O

Hepatitis	B-Disease
was	O
usually	O
reversible	O
when	O
treatment	O
was	O
stopped	O
,	O
with	O
the	O
results	O
of	O
liver	O
function	O
tests	O
returning	O
to	O
normal	O
after	O
an	O
average	O
of	O
3.1	O
months	O
.	O

In	O
two	O
of	O
the	O
three	O
deaths	B-Disease
probably	O
associated	O
with	O
ketoconazole	B-Chemical
treatment	O
the	O
drug	B-Drug
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundice	B-Disease
and	O
other	O
symptoms	O
of	O
hepatitis	B-Disease
.	O

Clinical	O
and	O
biochemical	O
monitoring	O
at	O
regular	O
intervals	O
for	O
evidence	O
of	O
hepatitis	B-Disease
is	O
advised	O
during	O
long	O
term	O
treatment	O
with	O
ketoconazole	B-Chemical
to	O
prevent	O
possible	O
serious	O
hepatic	B-Disease
injury	I-Disease
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Chemical
E1-induced	O
hypotension	O
and	O
haemodilution	O
on	O
human	O
hepatic	O
function	O
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-Chemical
E1	I-Chemical
(	O
PGE1	B-Chemical
)	O
-induced	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
on	O
hepatic	O
function	O
were	O
studied	O
in	O
30	O
patients	O
undergoing	O
hip	O
surgery	O
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
;	O
those	O
in	O
group	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlled	O
hypotension	B-Disease
alone	O
,	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilution	B-Disease
alone	O
and	O
those	O
in	O
group	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	O
hypotension	B-Disease
and	O
haemodilution	B-Disease
.	O

Haemodilution	B-Disease
in	O
groups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blood	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	B-Chemical
solution	O
,	O
and	O
final	O
haematocrit	O
values	O
were	O
21	O
or	O
22	O
%	O
.	O

Controlled	O
hypotension	B-Disease
in	O
groups	O
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	B-Chemical
to	O
maintain	O
mean	O
arterial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O

Measurements	O
included	O
arterial	O
ketone	O
body	O
ratio	O
(	O
AKBR	O
,	O
aceto-acetate/3-hydroxybutyrate	B-Chemical
)	O
and	O
clinical	O
hepatic	O
function	O
parameters	O
.	O

AKBR	O
and	O
biological	O
hepatic	O
function	O
tests	O
showed	O
no	O
change	O
throughout	O
the	O
time	O
course	O
in	O
groups	O
A	O
and	O
B	O
.	O

In	O
group	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decrease	O
at	O
120	O
min	O
(	O
-40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-49	O
%	O
)	O
after	O
the	O
start	O
of	O
hypotension	O
and	O
at	O
60	O
min	O
(	O
-32	O
%	O
)	O
after	O
recovery	O
of	O
normotension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirubin	O
showed	O
significant	O
increases	O
after	O
operation	O
.	O

The	O
results	O
suggest	O
that	O
a	O
prolonged	O
combination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1-induced	O
hypotension	O
and	O
moderate	O
haemodilution	O
would	O
cause	O
impairment	O
of	O
hepatic	O
function	O
.	O

Levodopa-induced	B-Chemical
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
:	O
filling	O
the	O
bench-to-bedside	O
gap	O
.	O

Levodopa	B-Chemical
is	O
the	O
most	O
effective	O
drug	B-Drug
for	O
the	O
treatment	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

However	O
,	O
the	O
long-term	O
use	O
of	O
this	O
dopamine	B-Chemical
precursor	O
is	O
complicated	O
by	O
highly	O
disabling	O
fluctuations	O
and	O
dyskinesias	B-Disease
.	O

Although	O
preclinical	O
and	O
clinical	O
findings	O
suggest	O
pulsatile	O
stimulation	O
of	O
striatal	O
postsynaptic	O
receptors	O
as	O
a	O
key	O
mechanism	O
underlying	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
,	O
their	O
pathogenesis	O
is	O
still	O
unclear	O
.	O

In	O
recent	O
years	O
,	O
evidence	O
from	O
animal	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
has	O
provided	O
important	O
information	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
receptor	O
and	O
post-receptor	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dyskinetic	B-Disease
movements	I-Disease
.	O

Recent	O
preclinical	O
and	O
clinical	O
data	O
from	O
promising	O
lines	O
of	O
research	O
focus	O
on	O
the	O
differential	O
role	O
of	O
presynaptic	O
versus	O
postsynaptic	O
mechanisms	O
,	O
dopamine	B-Chemical
receptor	O
subtypes	O
,	O
ionotropic	O
and	O
metabotropic	O
glutamate	B-Chemical
receptors	O
,	O
and	O
non-dopaminergic	O
neurotransmitter	O
systems	O
in	O
the	O
pathophysiology	O
of	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
.	O

Prevention	O
of	O
seizures	B-Disease
and	O
reorganization	O
of	O
hippocampal	O
functions	O
by	O
transplantation	O
of	O
bone	O
marrow	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
experimental	O
epilepsy	B-Disease
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMCs	O
)	O
in	O
a	O
model	O
of	O
epilepsy	B-Disease
induced	O
by	O
pilocarpine	B-Chemical
in	O
rats	O
.	O

BMCs	O
obtained	O
from	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
transgenic	O
mice	O
or	O
rats	O
were	O
transplanted	O
intravenously	O
after	O
induction	O
of	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
.	O

Spontaneous	B-Disease
recurrent	I-Disease
seizures	I-Disease
(	O
SRS	B-Disease
)	O
were	O
monitored	O
using	O
Racine	O
's	O
seizure	B-Disease
severity	O
scale	O
.	O

All	O
of	O
the	O
rats	O
in	O
the	O
saline-treated	O
epileptic	B-Disease
control	O
group	O
developed	O
SRS	B-Disease
,	O
whereas	O
none	O
of	O
the	O
BMC-treated	O
epileptic	B-Disease
animals	O
had	O
seizures	B-Disease
in	O
the	O
short	O
term	O
(	O
15	O
days	O
after	O
transplantation	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O

Over	O
the	O
long-term	O
chronic	O
phase	O
(	O
120	O
days	O
after	O
transplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC-treated	O
epileptic	B-Disease
animals	O
had	O
seizures	B-Disease
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	B-Disease
control	O
group	O
.	O

The	O
density	O
of	O
hippocampal	O
neurons	O
in	O
the	O
brains	O
of	O
animals	O
treated	O
with	O
BMCs	O
was	O
markedly	O
preserved	O
.	O

At	O
hippocampal	O
Schaeffer	O
collateral-CA1	O
synapses	O
,	O
long-term	O
potentiation	O
was	O
preserved	O
in	O
BMC-transplanted	O
rats	O
compared	O
to	O
epileptic	B-Disease
controls	O
.	O

The	O
donor-derived	O
GFP	O
(	O
+	O
)	O
cells	O
were	O
rarely	O
found	O
in	O
the	O
brains	O
of	O
transplanted	O
epileptic	B-Disease
rats	O
.	O

In	O
conclusion	O
,	O
treatment	O
with	O
BMCs	O
can	O
prevent	O
the	O
development	O
of	O
chronic	O
seizures	B-Disease
,	O
reduce	O
neuronal	B-Disease
loss	I-Disease
,	O
and	O
influence	O
the	O
reorganization	O
of	O
the	O
hippocampal	O
neuronal	O
network	O
.	O

Cardioprotective	O
effect	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

Hemodynamic	O
parameters	O
and	O
lead	B-Drug
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O

Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured	O
.	O

Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed	O
.	O

Isoproterenol-treated	B-Chemical
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	B-Chemical
dehydrogenase	O
,	O
aspartate	B-Chemical
transaminase	O
,	O
creatine	B-Chemical
kinase	O
and	O
malondialdehyde	B-Chemical
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	B-Chemical
dismutase	O
,	O
catalase	O
and	O
glutathione	B-Chemical
peroxidase	O
in	O
serum	O
and	O
heart	O
.	O

These	O
rats	O
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure	O
,	O
and	O
elevation	O
of	O
left	O
ventricular	O
end-diastolic	O
pressure	O
and	O
ST-segment	O
.	O

In	O
addition	O
,	O
mitochondrial	O
respiratory	B-Disease
dysfunction	I-Disease
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP/O	B-Chemical
was	O
observed	O
in	O
isoproterenol-treated	B-Chemical
rats	O
.	O

Administration	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol-induced	B-Chemical
cardiac	B-Disease
dysfunction	I-Disease
and	O
myocardial	B-Disease
injury	I-Disease
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O

The	O
protective	O
role	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
against	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
.	O

Acute	O
effects	O
of	O
N-	B-Chemical
(	I-Chemical
2-propylpentanoyl	I-Chemical
)	I-Chemical
urea	I-Chemical
on	O
hippocampal	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
in	O
pilocarpine-induced	B-Chemical
seizure	B-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
(	O
glutamate	B-Chemical
,	O
aspartate	B-Chemical
,	O
glycine	B-Chemical
and	O
GABA	B-Chemical
)	I-Chemical
of	O
N-	B-Chemical
(	I-Chemical
2-propylpentanoyl	I-Chemical
)	I-Chemical
urea	O
(	O
VPU	B-Chemical
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
.	O

VPU	B-Chemical
was	O
more	O
potent	O
than	O
VPA	B-Chemical
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg/kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine-induced	B-Chemical
seizure	B-Disease
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	B-Chemical
was	O
322	O
mg/kg	O
.	O

In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	B-Chemical
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	B-Chemical
and	O
GABA	B-Chemical
.	O

Pretreatment	O
with	O
either	O
VPU	B-Chemical
(	O
50	O
and	O
100	O
mg/kg	O
)	O
or	O
VPA	B-Chemical
(	O
300	O
and	O
600	O
mg/kg	O
)	O
completely	O
abolished	O
pilocarpine-evoked	B-Chemical
increases	O
in	O
extracellular	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
.	O

In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	B-Chemical
and	O
glycine	B-Chemical
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
level	O
.	O

Based	O
on	O
the	O
finding	O
that	O
VPU	B-Chemical
and	O
VPA	B-Chemical
could	O
protect	O
the	O
animals	O
against	O
pilocarpine-induced	B-Chemical
seizure	B-Disease
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	B-Chemical
acid	I-Chemical
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
.	O

Therefore	O
,	O
like	O
VPA	B-Chemical
,	O
the	O
finding	O
that	O
VPU	B-Chemical
could	O
drastically	O
reduce	O
pilocarpine-induced	B-Chemical
increases	O
in	O
glutamate	B-Chemical
and	O
aspartate	B-Chemical
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine-induced	B-Chemical
seizure	B-Disease
in	O
experimental	O
animals	O
.	O

Some	O
other	O
mechanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investigated	O
.	O

Acute	O
hepatitis	B-Disease
attack	O
after	O
exposure	O
to	O
telithromycin	B-Chemical
.	O

INTRODUCTION	O
:	O
Antibiotic-associated	O
hepatotoxicity	B-Disease
is	O
rare	O
.	O

With	O
widespread	O
use	O
of	O
antimicrobial	O
agents	O
,	O
however	O
,	O
hepatic	B-Disease
injury	I-Disease
occurs	O
frequently	O
,	O
and	O
among	O
adverse	B-Disease
drug	I-Disease
reactions	I-Disease
,	O
idiosyncratic	O
reactions	O
are	O
the	O
most	O
serious	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
25-year-old	O
male	O
patient	O
,	O
with	O
a	O
height	O
of	O
175	O
cm	O
and	O
weight	O
of	O
72	O
kg	O
presented	O
to	O
Marmara	O
University	O
Hospital	O
Emergency	O
Department	O
,	O
Istanbul	O
,	O
Turkey	O
,	O
with	O
5	O
days	O
'	O
history	O
of	O
jaundice	B-Disease
,	O
malaise	O
,	O
nausea	B-Disease
,	O
and	O
vomiting	B-Disease
.	O

He	O
had	O
been	O
prescribed	O
telithromycin	B-Chemical
400	O
mg/d	O
PO	O
to	O
treat	O
an	O
upper	B-Disease
respiratory	I-Disease
tract	I-Disease
infection	I-Disease
7	O
days	O
prior	O
.	O

Admission	O
laboratory	O
tests	O
were	O
as	O
follows	O
:	O
alanine	B-Chemical
aminotransferase	O
,	O
67	O
U/L	O
(	O
reference	O
range	O
,	O
10-37	O
U/L	O
)	O
;	O
aspartate	B-Chemical
aminotransferase	O
,	O
98	O
U/L	O
(	O
10-40	O
U/L	O
)	O
;	O
alkaline	O
phosphatase	O
,	O
513	O
U/L	O
(	O
0-270	O
U/L	O
)	O
;	O
gamma-glutamyltransferase	O
,	O
32	O
U/L	O
(	O
7-49	O
U/L	O
)	O
;	O
amylase	B-Drug
,	O
46	O
U/L	O
(	O
0-220	O
U/L	O
)	O
;	O
total	O
bilirubin	B-Chemical
,	O
20.1	O
mg/dL	O
(	O
0.2-1.0	O
mg/dL	O
)	O
;	O
direct	O
bilirubin	B-Chemical
,	O
14.8	O
mg/dL	O
(	O
0-0.3	O
mg/dL	O
)	O
;	O
and	O
albumin	O
,	O
4.7	O
mg/dL	O
(	O
3.5-5.4	O
mg/dL	O
)	O
.	O

No	O
toxin	B-Drug
,	O
alcohol	B-Chemical
,	O
or	O
other	O
drugs	B-Drug
were	O
reported	O
.	O

The	O
patient	O
had	O
suffered	O
a	O
previous	O
episode	O
of	O
``	O
acute	O
hepatitis	B-Disease
of	O
unknown	O
origin	O
,	O
''	O
that	O
occurred	O
after	O
telithromycin	B-Chemical
usage	O
.	O

Both	O
incidents	O
occurred	O
within	O
a	O
year	O
.	O

DISCUSSION	O
:	O
Telithromycin	B-Chemical
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	B-Drug
Administration	O
approval	O
for	O
clinical	O
use	O
.	O

It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	O
severe	O
hepatic	B-Disease
dysfunction	I-Disease
.	O

Based	O
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
probability	O
scale	O
,	O
telithromycin	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
acute	O
hepatitis	B-Disease
in	O
this	O
patient	O
,	O
and	O
pathological	O
findings	O
suggested	O
drug-induced	O
toxic	B-Disease
hepatitis	I-Disease
.	O

Recurrence	O
of	O
hepatitis	B-Disease
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	B-Chemical
the	O
second	O
time	O
.	O

CONCLUSION	O
:	O
Here	O
we	O
report	O
a	O
case	O
of	O
acute	O
hepatitis	B-Disease
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	B-Chemical
.	O

Spironolactone-induced	B-Chemical
renal	B-Disease
insufficiency	I-Disease
and	O
hyperkalemia	B-Disease
in	O
patients	O
with	O
heart	B-Disease
failure	I-Disease
.	O

BACKGROUND	O
:	O
A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	B-Chemical
in	O
heart	B-Disease
failure	I-Disease
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	B-Disease
(	O
2	O
%	O
)	O
and	O
renal	B-Disease
insufficiency	I-Disease
(	O
0	O
%	O
)	O
.	O

Because	O
treatments	O
for	O
heart	B-Disease
failure	I-Disease
have	O
changed	O
since	O
the	O
benefits	O
of	O
spironolactone	B-Chemical
were	O
reported	O
,	O
the	O
prevalence	O
of	O
these	O
complications	O
may	O
differ	O
in	O
current	O
clinical	O
practice	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	B-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
in	O
heart	B-Disease
failure	I-Disease
patients	O
treated	O
with	O
spironolactone	B-Chemical
.	O

METHODS	O
:	O
We	O
performed	O
a	O
case	O
control	O
study	O
of	O
heart	B-Disease
failure	I-Disease
patients	O
treated	O
with	O
spironolactone	B-Chemical
in	O
our	O
clinical	O
practice	O
.	O

Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	B-Disease
(	O
K	B-Chemical
(	O
+	O
)	O
>	O
5.0	O
mEq/L	O
)	O
or	O
renal	B-Disease
insufficiency	I-Disease
(	O
Cr	B-Chemical
>	O
or=2.5	O
mg/dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O
.	O

Clinical	O
characteristics	O
,	O
medications	O
,	O
and	O
serum	O
chemistries	O
at	O
baseline	O
and	O
follow-up	O
time	O
periods	O
were	O
compared	O
.	O

RESULTS	O
:	O
Sixty-seven	O
of	O
926	O
patients	O
(	O
7.2	O
%	O
)	O
required	O
discontinuation	O
of	O
spironolactone	B-Chemical
due	O
to	O
hyperkalemia	B-Disease
(	O
n	O
=	O
33	O
)	O
or	O
renal	B-Disease
failure	I-Disease
(	O
n	O
=	O
34	O
)	O
.	O

Patients	O
who	O
developed	O
hyperkalemia	B-Disease
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	B-Disease
,	O
had	O
higher	O
baseline	O
serum	O
potassium	B-Chemical
levels	O
and	O
lower	O
baseline	O
potassium	B-Chemical
supplement	O
doses	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta-blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O

Patients	O
who	O
developed	O
renal	B-Disease
insufficiency	I-Disease
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	B-Chemical
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	B-Drug
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	B-Chemical
diuretics	B-Drug
than	O
controls	O
.	O

CONCLUSIONS	O
:	O
Spironolactone-induced	B-Chemical
hyperkalemia	B-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
are	O
more	O
common	O
in	O
our	O
clinical	O
experience	O
than	O
reported	O
previously	O
.	O

This	O
difference	O
is	O
explained	O
by	O
patient	O
comorbidities	O
and	O
more	O
frequent	O
use	O
of	O
beta-blockers	O
.	O

End-stage	B-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin-based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

BACKGROUND	O
:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-Disease
.	O

Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end-stage	B-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	B-Disease
)	O
in	O
OLTX	O
patients	O
.	O

METHODS	O
:	O
Patients	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n=834	O
)	O
.	O

Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-Disease
or	O
ESRD	B-Disease
,	O
n=748	O
;	O
CRF	B-Disease
,	O
sustained	O
serum	O
creatinine	B-Chemical
>	O
2.5	O
mg/dl	O
,	O
n=41	O
;	O
and	O
ESRD	B-Disease
,	O
n=45	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	B-Disease
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B-Disease
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-Disease
dysfunction	I-Disease
was	O
18.1	O
%	O
(	O
CRF	B-Disease
8.6	O
%	O
and	O
ESRD	B-Disease
9.5	O
%	O
)	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	B-Disease
and	O
ESRD	B-Disease
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	B-Chemical
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	B-Disease
syndrome	I-Disease
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1-year	O
serum	O
creatinine	B-Chemical
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2.6	O
,	O
2.2	O
,	O
and	O
1.6	O
,	O
respectively	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	B-Disease
was	O
only	O
28.2	O
%	O
compared	O
with	O
54.6	O
%	O
in	O
the	O
control	O
group	O
.	O

Patients	O
developing	O
ESRD	B-Disease
had	O
a	O
6-year	O
survival	O
after	O
onset	O
of	O
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71.4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	B-Disease
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post-OLTX	O
have	O
CRF	B-Disease
and	O
ESRD	B-Disease
at	O
a	O
high	O
rate	O
.	O

The	O
development	O
of	O
ESRD	B-Disease
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O

Patients	O
who	O
develop	O
ESRD	B-Disease
have	O
a	O
higher	O
preoperative	O
and	O
1-year	O
serum	O
creatinine	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-Disease
syndrome	I-Disease
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
.	O

New	O
strategies	O
for	O
long-term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O

Effect	O
of	O
intravenous	O
nimodipine	B-Chemical
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	B-Disease
stroke	I-Disease
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	B-Chemical
West	O
European	O
Stroke	B-Disease
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine-induced	B-Chemical
reduction	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	B-Disease
stroke	I-Disease
.	O

We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	O
levels	O
of	O
BP	B-Disease
reduction	I-Disease
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	B-Disease
stroke	I-Disease
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n=100	O
)	O
,	O
1	O
mg/h	O
(	O
low-dose	O
)	O
nimodipine	B-Chemical
(	O
n=101	O
)	O
,	O
or	O
2	O
mg/h	O
(	O
high-dose	O
)	O
nimodipine	B-Chemical
(	O
n=94	O
)	O
.	O

The	O
correlation	O
between	O
average	O
BP	O
change	O
during	O
the	O
first	O
2	O
days	O
and	O
the	O
outcome	O
at	O
day	O
21	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
sixty-five	O
patients	O
were	O
included	O
in	O
this	O
analysis	O
(	O
n=92	O
,	O
93	O
,	O
and	O
80	O
for	O
placebo	O
,	O
low	O
dose	O
,	O
and	O
high	O
dose	O
,	O
respectively	O
)	O
.	O

Nimodipine	B-Chemical
treatment	O
resulted	O
in	I-Disease
a	O
statistically	O
significant	O
reduction	B-Disease
in	I-Disease
systolic	I-Disease
BP	O
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	B-Disease
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	O
DBP	B-Disease
reduction	I-Disease
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high-dose	O
group	O
(	O
beta=0.49	O
,	O
P=0	O
.	O

048	O
)	O
.	O

Patients	O
with	O
a	O
DBP	B-Disease
reduction	O
of	O
>	O
or	O
=20	O
%	O
in	O
the	O
high-dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	B-Disease
or	O
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n/N=25/26	O
,	O
OR	O
10	O
.	O

16	O
,	O
95	O
%	O
CI	O
1.02	O
to	O
101.74	O
)	O
and	O
death	B-Disease
alone	O
(	O
n/N=9/26	O
,	O
OR	O
4.336	O
,	O
95	O
%	O
CI	O
1.131	O
16.619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n/N=62/92	O
and	O
14/92	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
correlation	O
between	O
SBP	O
change	O
and	O
outcome	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high-dose	O
nimodipine	B-Chemical
after	O
acute	B-Disease
stroke	I-Disease
.	O

For	O
low-dose	O
nimodipine	B-Chemical
,	O
the	O
results	O
were	O
not	O
conclusive	O
.	O

These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	B-Chemical
.	O

Transient	B-Disease
neurologic	I-Disease
symptoms	I-Disease
after	O
spinal	O
anesthesia	B-Drug
:	O
a	O
lower	O
incidence	O
with	O
prilocaine	B-Chemical
and	O
bupivacaine	B-Chemical
than	O
with	O
lidocaine	B-Chemical
.	O

BACKGROUND	O
:	O
Recent	O
evidence	O
suggests	O
that	O
transient	B-Disease
neurologic	I-Disease
symptoms	I-Disease
(	O
TNSs	B-Disease
)	O
frequently	O
follow	O
lidocaine	B-Chemical
spinal	O
anesthesia	B-Drug
but	O
are	O
infrequent	O
with	O
bupivacaine	B-Chemical
.	O

However	O
,	O
identification	O
of	O
a	O
short-acting	O
local	O
anesthetic	B-Drug
to	O
substitute	O
for	O
lidocaine	B-Chemical
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal	O
.	O

Prilocaine	B-Chemical
is	O
an	O
amide	O
local	O
anesthetic	B-Drug
with	O
a	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
lidocaine	B-Chemical
.	O

Accordingly	O
,	O
the	O
present	O
,	O
prospective	O
double-blind	O
study	O
compares	O
prilocaine	B-Chemical
with	O
lidocaine	B-Chemical
and	O
bupivacaine	B-Chemical
with	O
respect	O
to	O
duration	O
of	O
action	O
and	O
relative	O
risk	O
of	O
TNSs	B-Disease
.	O

METHODS	O
:	O
Ninety	O
patients	O
classified	O
as	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
I	O
or	O
II	O
who	O
were	O
scheduled	O
for	O
short	O
gynecologic	O
procedures	O
under	O
spinal	O
anesthesia	B-Drug
were	O
randomly	O
allocated	O
to	O
receive	O
2.5	O
ml	O
2	O
%	O
lidocaine	B-Chemical
in	O
7.5	O
%	O
glucose	B-Chemical
,	O
2	O
%	O
prilocaine	B-Chemical
in	O
7.5	O
%	O
glucose	B-Chemical
,	O
or	O
0.5	O
%	O
bupivacaine	B-Chemical
in	O
7.5	O
%	O
glucose	B-Chemical
.	O

All	O
solutions	O
were	O
provided	O
in	O
blinded	O
vials	O
by	O
the	O
hospital	O
pharmacy	O
.	O

Details	O
of	O
spinal	O
puncture	O
,	O
extension	O
and	O
regression	O
of	O
spinal	O
block	O
,	O
and	O
the	O
times	O
to	O
reach	O
discharge	O
criteria	O
were	O
noted	O
.	O

In	O
the	O
evening	O
of	O
postoperative	O
day	O
1	O
,	O
patients	O
were	O
evaluated	O
for	O
TNSs	B-Disease
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	B-Drug
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	B-Drug
procedure	O
.	O

RESULTS	O
:	O
Nine	O
of	O
30	O
patients	O
receiving	O
lidocaine	B-Chemical
experienced	O
TNSs	B-Disease
,	O
1	O
of	O
30	O
patients	O
receiving	O
prilocaine	B-Chemical
(	O
P	O
=	O
0.03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patients	O
receiving	O
bupivacaine	B-Chemical
had	O
TNSs	B-Disease
.	O

Times	O
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	O
after	O
lidocaine	B-Chemical
and	O
prilocaine	B-Chemical
(	O
150	O
vs.	O
165	O
min	O
and	O
238	O
vs.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prolonged	O
after	O
bupivacaine	B-Chemical
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
Prilocaine	B-Chemical
may	O
be	O
preferable	O
to	O
lidocaine	B-Chemical
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	B-Disease
.	O

The	O
role	O
of	O
nicotine	B-Chemical
in	O
smoking-related	O
cardiovascular	B-Disease
disease	I-Disease
.	O

Nicotine	B-Chemical
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascular	B-Disease
disease	I-Disease
.	O

Animal	O
studies	O
and	O
mechanistic	O
studies	O
indicate	O
that	O
nicotine	B-Chemical
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	B-Disease
,	O
but	O
evidence	O
among	O
humans	O
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect	O
.	O

Almost	O
certainly	O
,	O
nicotine	B-Chemical
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events	O
,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	B-Chemical
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	O
or	O
the	O
effects	O
of	O
carbon	B-Chemical
monoxide	I-Chemical
.	O

Nicotine	B-Chemical
does	O
not	O
appear	O
to	O
enhance	O
thrombosis	B-Disease
among	O
humans	O
.	O

Clinical	O
studies	O
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	B-Chemical
support	O
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	B-Chemical
are	O
the	O
most	O
important	O
causes	O
of	O
acute	O
cardiovascular	O
events	O
.	O

Finally	O
,	O
the	O
dose	O
response	O
for	O
cardiovascular	O
events	O
of	O
nicotine	B-Chemical
appears	O
to	O
be	O
flat	O
,	O
suggesting	O
that	O
if	O
nicotine	B-Chemical
is	O
involved	O
,	O
adverse	O
effects	O
might	O
be	O
seen	O
with	O
relatively	O
low-level	O
cigarette	O
exposures	O
.	O

Seizure	B-Disease
resulting	O
from	O
a	O
venlafaxine	B-Chemical
overdose	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
venlafaxine	B-Chemical
overdose	B-Disease
.	O

CASE	O
SUMMARY	O
:	O
A	O
40-year-old	O
woman	O
with	O
major	B-Disease
depression	I-Disease
took	O
an	O
overdose	B-Disease
of	O
venlafaxine	B-Chemical
in	O
an	O
apparent	O
suicide	O
attempt	O
.	O

After	O
the	O
ingestion	O
of	O
26	O
venlafaxine	B-Chemical
50-mg	O
tablets	O
,	O
the	O
patient	O
experienced	O
a	O
witnessed	O
generalized	O
seizure	B-Disease
.	O

She	O
was	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
,	O
venlafaxine	B-Chemical
was	O
discontinued	O
,	O
and	O
no	O
further	O
sequelae	O
were	O
seen	O
.	O

DISCUSSION	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
venlafaxine	B-Chemical
overdose	B-Disease
that	O
resulted	O
in	O
a	O
generalized	O
seizure	B-Disease
.	O

Based	O
on	O
nonoverdose	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
venlafaxine	B-Chemical
and	O
the	O
potential	O
risks	O
of	O
available	O
interventions	O
,	O
no	O
emergent	O
therapy	O
was	O
instituted	O
.	O

CONCLUSIONS	O
:	O
The	O
venlafaxine	B-Chemical
overdose	B-Disease
in	O
our	O
patient	O
resulted	O
in	O
a	O
single	O
episode	O
of	O
generalized	O
seizure	B-Disease
but	O
elicited	O
no	O
further	O
sequelae	O
.	O

Effect	O
of	O
nifedipine	B-Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
receiving	O
tacrolimus	B-Chemical
.	O

The	O
effect	O
of	O
nifedipine	B-Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
who	O
were	O
receiving	O
tacrolimus	B-Chemical
was	O
evaluated	O
between	O
January	O
1992	O
and	O
January	O
1996	O
.	O

Two	O
groups	O
of	O
patients	O
receiving	O
tacrolimus	B-Chemical
were	O
compared	O
over	O
a	O
period	O
of	O
1	O
year	O
,	O
one	O
group	O
comprising	O
hypertensive	B-Disease
patients	O
who	O
were	O
receiving	O
nifedipine	B-Chemical
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	O
not	O
receiving	O
nifedipine	B-Chemical
.	O

The	O
time	O
from	O
transplant	O
to	O
baseline	O
was	O
similar	O
in	O
all	O
patients	O
.	O

Nifedipine	B-Chemical
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	B-Chemical
levels	O
at	O
6	O
and	O
12	O
months	O
.	O

The	O
observed	O
positive	O
impact	O
of	O
nifedipine	B-Chemical
on	O
reducing	O
the	O
nephrotoxicity	B-Disease
associated	O
with	O
tacrolimus	B-Chemical
in	O
liver	O
transplant	O
recipients	O
should	O
be	O
an	O
important	O
factor	O
in	O
selecting	O
an	O
agent	O
to	O
treat	O
hypertension	B-Disease
in	O
this	O
population	O
.	O

Sinus	B-Disease
arrest	I-Disease
associated	O
with	O
continuous-infusion	O
cimetidine	B-Chemical
.	O

The	O
administration	O
of	O
intermittent	O
intravenous	O
infusions	O
of	O
cimetidine	B-Chemical
is	O
infrequently	O
associated	O
with	O
the	O
development	O
of	O
bradyarrhythmias	B-Disease
.	O

A	O
40-year-old	O
man	O
with	O
leukemia	B-Disease
and	O
no	O
history	O
of	O
cardiac	B-Disease
disease	I-Disease
developed	O
recurrent	O
,	O
brief	O
episodes	O
of	O
apparent	O
sinus	B-Disease
arrest	I-Disease
while	O
receiving	O
continuous-infusion	O
cimetidine	B-Chemical
50	O
mg/hour	O
.	O

The	O
arrhythmias	B-Disease
were	O
temporally	O
related	O
to	O
cimetidine	B-Chemical
administration	O
,	O
disappeared	O
after	O
dechallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	B-Chemical
treatment	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
sinus	B-Disease
arrest	I-Disease
associated	O
with	O
continuous-infusion	O
cimetidine	B-Chemical
.	O

Composition	O
of	O
gall	B-Disease
bladder	I-Disease
stones	I-Disease
associated	O
with	O
octreotide	B-Chemical
:	O
response	O
to	O
oral	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
.	O

Octreotide	B-Chemical
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	B-Disease
,	O
induces	O
gall	B-Disease
bladder	I-Disease
stones	I-Disease
in	O
13-60	O
%	O
of	O
patients	O
.	O

Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	O
for	O
studies	O
of	O
their	O
pathogenesis	O
,	O
treatment	O
,	O
and	O
prevention	O
,	O
this	O
was	O
investigated	O
by	O
direct	O
and	O
indirect	O
methods	O
in	O
14	O
octreotide	B-Chemical
treated	O
acromegalic	B-Disease
patients	O
with	O
gall	B-Disease
stones	I-Disease
.	O

Chemical	O
analysis	O
of	O
gall	B-Disease
stones	I-Disease
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholesterol	B-Chemical
by	O
weight	O
.	O

In	O
the	O
remaining	O
12	O
patients	O
,	O
localised	O
computed	O
tomography	O
of	O
the	O
gall	O
bladder	O
showed	O
that	O
eight	O
had	O
stones	O
with	O
maximum	O
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	O
(	O
values	O
of	O
<	O
100	O
HU	O
predict	O
cholesterol	B-Chemical
rich	O
,	O
dissolvable	O
stones	O
)	O
.	O

Gall	O
bladder	O
bile	O
was	O
obtained	O
by	O
ultrasound	O
guided	O
,	O
fine	O
needle	O
puncture	O
from	O
six	O
patients	O
.	O

All	O
six	O
patients	O
had	O
supersaturated	O
bile	O
(	O
mean	O
(	O
SEM	O
)	O
cholesterol	B-Chemical
saturation	O
index	O
of	O
1.19	O
(	O
0.08	O
)	O
(	O
range	O
1.01-1.53	O
)	O
)	O
and	O
all	O
had	O
abnormally	O
rapid	O
cholesterol	B-Chemical
microcrystal	O
nucleation	O
times	O
(	O
<	O
4	O
days	O
(	O
range	O
1-4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bile	O
contained	O
cholesterol	B-Chemical
microcrystals	O
immediately	O
after	O
sampling	O
.	O

Of	O
the	O
12	O
patients	O
considered	O
for	O
oral	O
ursodeoxycholic	B-Chemical
acid	I-Chemical
(	O
UDCA	B-Chemical
)	O
treatment	O
,	O
two	O
had	O
a	O
blocked	O
cystic	O
duct	O
and	O
were	O
not	O
started	O
on	O
UDCA	B-Chemical
while	O
one	O
was	O
lost	O
to	O
follow	O
up	O
.	O

After	O
one	O
year	O
of	O
treatment	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
patients	O
showed	O
either	O
partial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
gall	B-Disease
stone	I-Disease
dissolution	O
,	O
suggesting	O
that	O
their	O
stones	O
were	O
cholesterol	B-Chemical
rich	O
.	O

This	O
corresponds	O
,	O
by	O
actuarial	O
(	O
life	O
table	O
)	O
analysis	O
,	O
to	O
a	O
combined	O
gall	B-Disease
stone	I-Disease
dissolution	O
rate	O
of	O
58.3	O
(	O
15.9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
octreotide	B-Chemical
induced	O
gall	B-Disease
stones	I-Disease
are	O
generally	O
small	O
,	O
multiple	O
,	O
and	O
cholesterol	B-Chemical
rich	O
although	O
,	O
in	O
common	O
with	O
spontaneous	O
gall	B-Disease
stone	I-Disease
disease	I-Disease
,	O
at	O
presentation	O
some	O
patients	O
will	O
have	O
a	O
blocked	O
cystic	O
duct	O
and	O
some	O
gall	B-Disease
stones	I-Disease
containing	O
calcium	B-Chemical
.	O

Cardiovascular	B-Disease
complications	I-Disease
associated	O
with	O
terbutaline	B-Chemical
treatment	O
for	O
preterm	B-Disease
labor	I-Disease
.	O

Severe	O
cardiovascular	B-Disease
complications	I-Disease
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
.	O

Associated	O
corticosteroid	B-Drug
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O

Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O

Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2-chloroprocaine-CE	B-Chemical
,	O
bupivacaine	B-Chemical
,	O
and	O
low	O
pH	O
normal	O
saline	O
in	O
dogs	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
neurologic	O
consequences	O
of	O
deliberate	O
subarachnoid	O
injection	O
of	O
large	O
volumes	O
of	O
2-chloroprocaine-CE	B-Chemical
in	O
experimental	O
animals	O
.	O

The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volume	O
as	O
potential	O
factors	O
in	O
causing	O
neurotoxicity	B-Disease
was	O
evaluated	O
.	O

The	O
65	O
dogs	O
in	O
the	O
study	O
received	O
injections	O
in	O
the	O
subarachnoid	O
space	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivacaine	B-Chemical
(	O
N	O
=	O
15	O
)	O
,	O
2-chloroprocaine-CE	B-Chemical
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3.0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
normal	O
saline	O
(	O
N	O
=	O
10	O
)	O
.	O

Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2-chloroprocaine-CE	B-Chemical
seven	O
(	O
35	O
%	O
)	O
developed	O
hind-limb	O
paralysis	B-Disease
.	O

None	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	B-Chemical
,	O
normal	O
saline	O
,	O
or	O
normal	O
saline	O
titrated	O
to	O
a	O
pH	O
3.0	O
developed	O
hind-limb	O
paralysis	B-Disease
.	O

Of	O
the	O
15	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
2-chloroprocaine-CE	B-Chemical
,	O
13	O
showed	O
subpial	B-Disease
necrosis	I-Disease
;	O
the	O
nerve	O
roots	O
and	O
subarachnoid	O
vessels	O
were	O
normal	O
.	O

The	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	B-Chemical
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3.0	O
)	O
,	O
or	O
normal	O
saline	O
did	O
not	O
show	O
abnormal	O
findings	O
.	O

Early	O
adjuvant	O
adriamycin	B-Chemical
in	O
superficial	O
bladder	B-Disease
carcinoma	I-Disease
.	O

A	O
multicenter	O
study	O
was	O
performed	O
in	O
110	O
patients	O
with	O
superficial	O
transitional	O
cell	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
bladder	I-Disease
.	O

Adriamycin	O
(	O
50	O
mg/50	O
ml	O
)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	I-Chemical
TA-T1	O
(	O
O-A	O
)	O
bladder	I-Chemical
tumors	O
.	O

Instillation	O
was	O
repeated	O
twice	O
during	O
the	I-Chemical
first	O
week	O
,	O
then	O
weekly	O
during	O
the	I-Chemical
first	O
month	O
and	O
afterwards	O
monthly	O
for	O
1	O
year	O
.	O

The	O
tolerance	O
was	O
evaluated	O
in	O
these	O
110	O
patients	O
,	O
and	O
29	O
patients	O
presented	O
with	O
local	O
side-effects	O
.	O

In	O
24	O
of	O
these	O
patients	O
chemical	O
cystitis	O
was	O
severe	O
enough	O
for	O
them	O
to	O
drop	O
out	O
of	O
the	O
study	O
.	O

No	O
systemic	O
side-effects	O
were	O
observed	O
.	O

Recurrence	O
was	O
studied	O
in	O
82	O
evaluable	O
patients	O
after	O
1	O
year	O
of	O
follow-up	O
and	O
in	O
72	O
patients	O
followed	O
for	O
2-3	O
years	O
(	O
mean	O
32	O
months	O
)	O
.	O

Of	O
the	O
82	O
patients	O
studied	O
after	O
1	O
year	O
,	O
23	O
had	O
primary	O
and	O
59	O
recurrent	O
disease	O
.	O

Of	O
the	O
82	O
evaluable	O
patients	O
,	O
50	O
did	O
not	O
show	O
any	O
recurrence	O
after	O
1	O
year	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
recurrences	O
(	O
39	O
%	O
)	O
.	O

Of	O
these	O
recurrences	O
,	O
27	O
were	O
T1	O
tumors	O
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasive	O
lesions	O
.	O

In	O
patients	O
that	O
were	O
free	O
of	O
recurrence	O
during	O
the	O
first	O
year	O
,	O
80	O
%	O
remained	O
tumor-free	O
during	O
the	O
2-	O
to	O
3-year	O
follow-up	O
period	O
.	O

Of	O
the	O
patients	O
developing	O
one	O
or	O
more	O
recurrences	O
during	O
the	O
first	O
year	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
recurrence	O
once	O
the	O
instillations	O
were	O
stopped	O
.	O

The	O
beneficial	O
effect	O
of	O
Adriamycin	O
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drug	B-Drug
itself	O
,	O
the	O
early	O
and	O
repeated	O
instillations	O
after	O
TUR	O
,	O
or	O
both	O
.	O

Hyperkalemia	B-Disease
associated	O
with	O
sulindac	B-Chemical
therapy	O
.	O

Hyperkalemia	B-Disease
has	O
recently	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
nonsteroidal	O
antiinflammatory	O
agents	O
(	O
NSAID	O
)	O
such	O
as	O
indomethacin	B-Chemical
.	O

Several	O
recent	O
studies	O
have	O
stressed	O
the	O
renal	O
sparing	O
features	O
of	O
sulindac	B-Chemical
,	O
owing	O
to	O
its	O
lack	O
of	O
interference	O
with	O
renal	O
prostacyclin	B-Chemical
synthesis	O
.	O

We	O
describe	O
4	O
patients	O
in	O
whom	O
hyperkalemia	B-Disease
ranging	O
from	O
6.1	O
to	O
6.9	O
mEq/l	O
developed	O
within	O
3	O
to	O
8	O
days	O
of	O
sulindac	B-Chemical
administration	O
.	O

In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	B-Chemical
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	B-Chemical
.	O

As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	B-Chemical
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause-and-effect	O
relationship	O
between	O
sulindac	B-Chemical
and	O
hyperkalemia	B-Disease
.	O

These	O
observations	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindac	B-Chemical
may	O
not	O
be	O
associated	O
with	O
the	O
adverse	O
renal	O
effects	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O

Ventricular	B-Disease
tachyarrhythmias	I-Disease
during	O
cesarean	O
section	O
after	O
ritodrine	B-Chemical
therapy	O
:	O
interaction	O
with	O
anesthetics	B-Drug
.	O

This	O
case	O
illustrates	O
that	O
patients	O
receiving	O
ritodrine	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
may	O
risk	O
interactions	O
between	O
the	O
residual	O
betamimetic	O
effects	O
of	O
ritodrine	B-Chemical
and	O
the	O
effects	O
of	O
anesthetics	B-Drug
during	O
cesarean	O
section	O
.	O

Such	O
interactions	O
may	O
result	O
in	O
serious	O
cardiovascular	B-Disease
complications	I-Disease
even	O
after	O
cessation	O
of	O
an	O
infusion	O
of	O
ritodrine	B-Chemical
.	O

Preoperative	O
assessment	O
should	O
focus	O
on	O
cardiovascular	O
status	O
and	O
serum	O
potassium	B-Chemical
level	O
.	O

Delaying	O
induction	O
of	O
anesthesia	B-Drug
should	O
be	O
considered	O
whenever	O
possible	O
.	O

Careful	O
fluid	O
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	O
of	O
ephedrine	B-Chemical
are	O
advised	O
.	O

After	O
delivery	O
of	O
the	O
infant	O
,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha-adrenergic	O
vasopressor	O
such	O
as	O
phenylephrine	B-Chemical
to	O
treat	O
hypotensive	B-Disease
patients	O
with	O
tachycardia	B-Disease
.	O

Immunohistochemical	O
,	O
electron	O
microscopic	O
and	O
morphometric	O
studies	O
of	O
estrogen-induced	B-Chemical
rat	O
prolactinomas	B-Disease
after	O
bromocriptine	B-Chemical
treatment	O
.	O

To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	B-Chemical
on	O
prolactinoma	B-Disease
cells	O
in	O
vivo	O
,	O
immunohistochemical	O
,	O
ultrastructural	O
and	O
morphometrical	O
analyses	O
were	O
applied	O
to	O
estrogen-induced	B-Chemical
rat	O
prolactinoma	B-Disease
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injection	O
of	O
bromocriptine	B-Chemical
(	O
3	O
mg/kg	O
of	O
body	O
weight	O
)	O
.	O

One	O
h	O
after	O
treatment	O
,	O
serum	O
prolactin	O
levels	O
decreased	O
markedly	O
.	O

Electron	O
microscopy	O
disclosed	O
many	O
secretory	O
granules	O
,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum	O
,	O
and	O
partially	O
dilated	O
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	B-Disease
cells	O
.	O

Morphometric	O
analysis	O
revealed	O
that	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
increased	O
,	O
while	O
the	O
volume	O
density	O
of	O
cytoplasmic	O
microtubules	O
decreased	O
.	O

These	O
findings	O
suggest	O
that	O
lowered	O
serum	O
prolactin	O
levels	O
in	O
the	O
early	O
phase	O
of	O
bromocriptine	B-Chemical
treatment	O
may	O
result	O
from	O
an	O
impaired	O
secretion	O
of	O
prolactin	O
due	O
to	O
decreasing	O
numbers	O
of	O
cytoplasmic	O
microtubules	O
.	O

At	O
6	O
h	O
after	O
injection	O
,	O
serum	O
prolactin	O
levels	O
were	O
still	O
considerably	O
lower	O
than	O
in	O
controls	O
.	O

The	O
prolactinoma	B-Disease
cells	O
at	O
this	O
time	O
were	O
well	O
granulated	O
,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	O
Golgi	O
cisternae	O
.	O

Electron	O
microscopical	O
immunohistochemistry	O
revealed	O
positive	O
reaction	O
products	O
noted	O
on	O
the	O
secretory	O
granules	O
,	O
Golgi	O
cisternae	O
,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	O
rat	O
prolactinoma	B-Disease
cells	O
.	O

However	O
,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	O
reaction	O
products	O
for	O
prolactin	O
6	O
h	O
after	O
bromocriptine	B-Chemical
treatment	O
of	O
the	O
adenoma	B-Disease
cells	O
.	O

An	O
increase	O
in	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
and	O
a	O
decrease	O
in	O
the	O
volume	O
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	O
by	O
morphometric	O
analysis	O
,	O
suggesting	O
that	O
bromocriptine	B-Chemical
inhibits	O
protein	O
synthesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbance	O
of	O
the	O
prolactin	O
secretion	O
.	O

On	O
two	O
paradoxical	O
side-effects	O
of	O
prednisolone	B-Chemical
in	O
rats	O
,	O
ribosomal	O
RNA	O
biosyntheses	O
,	O
and	O
a	O
mechanism	O
of	O
action	O
.	O

Liver	B-Disease
enlargement	I-Disease
and	O
muscle	B-Disease
wastage	I-Disease
occurred	O
in	O
Wistar	O
rats	O
following	O
the	O
subcutaneous	O
administration	O
of	O
prednisolone	B-Chemical
.	O

In	O
the	O
liver	O
both	O
the	O
content	O
of	O
RNA	O
and	O
the	O
biosynthesis	O
of	O
ribosomal	O
RNA	O
increased	O
while	O
both	O
the	O
RNA	O
content	O
and	O
ribosomal	O
RNA	O
biosynthesis	O
were	O
reduced	O
in	O
the	O
gastrocnemius	O
muscle	O
.	O

It	O
is	O
suggested	O
that	O
the	O
drug	B-Drug
acted	O
in	O
a	O
selective	O
and	O
tissue-specific	O
manner	O
to	O
enhance	O
ribosomal	O
RNA	O
synthesis	O
in	O
the	O
liver	O
and	O
depress	O
such	O
synthesis	O
in	O
the	O
muscle	O
.	O

This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
liver	O
and	O
muscle	O
are	O
independent	O
sites	O
of	O
prednisolone	B-Chemical
action	O
.	O

Possible	O
intramuscular	O
midazolam-associated	B-Chemical
cardiorespiratory	B-Disease
arrest	I-Disease
and	O
death	B-Disease
.	O

Midazolam	B-Chemical
hydrochloride	I-Chemical
is	O
commonly	O
used	O
for	O
dental	O
or	O
endoscopic	O
procedures	O
.	O

Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscularly	O
,	O
intravenous	O
administration	O
is	O
known	O
to	O
cause	O
respiratory	B-Disease
and	I-Disease
cardiovascular	I-Disease
depression	I-Disease
.	O

This	O
report	O
describes	O
the	O
first	O
published	O
case	O
of	O
cardiorespiratory	B-Chemical
arrest	O
and	O
death	O
associated	O
with	O
intramuscular	O
administration	O
of	O
midazolam	B-Drug
.	O

Information	O
regarding	O
midazolam	B-Drug
use	O
is	O
reviewed	O
to	O
provide	O
recommendation	O
for	O
safe	O
administration	O
.	O

Serial	O
epilepsy	B-Disease
caused	O
by	O
levodopa/carbidopa	B-Chemical
administration	O
in	O
two	O
patients	O
on	O
hemodialysis	O
.	O

Two	O
patients	O
with	O
similar	O
clinical	O
features	O
are	O
presented	O
:	O
both	O
patients	O
had	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
on	O
hemodialysis	O
for	O
many	O
years	O
but	O
recently	O
begun	O
on	O
a	O
high-flux	O
dialyzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbidopa/levodopa	B-Chemical
preparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosis	B-Disease
and	O
recurrent	O
seizures	B-Disease
,	O
which	O
were	O
refractory	O
to	O
anticonvulsants	O
.	O

The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis	O
;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	B-Chemical
B6	I-Chemical
.	O

Neither	O
patient	O
was	O
considered	O
to	O
have	O
a	O
renal	O
state	O
sufficiently	O
severe	O
enough	O
to	O
explain	O
their	O
presentation	O
.	O

Effect	O
of	O
L-alpha-glyceryl-phosphorylcholine	B-Chemical
on	O
amnesia	B-Disease
caused	O
by	O
scopolamine	B-Chemical
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
effects	O
of	O
L-alpha-glycerylphosphorylcholine	B-Chemical
(	O
L-alpha-GFC	B-Chemical
)	O
on	O
memory	B-Disease
impairment	I-Disease
induced	O
by	O
scopolamine	B-Chemical
in	O
man	O
.	O

Thirty-two	O
healthy	O
young	O
volunteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
groups	O
.	O

They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	O
with	O
either	O
L-alpha-GFC	B-Chemical
or	O
placebo	O
,	O
p.o.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	B-Chemical
or	O
placebo	O
,	O
i.m	O
.	O

Before	O
and	I-Disease
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	I-Disease
6	O
h	O
after	O
injection	O
the	O
subjects	O
were	O
given	O
attention	I-Disease
and	I-Disease
mnemonic	O
tests	O
.	O

The	O
findings	O
of	I-Disease
this	O
study	O
indicate	O
that	O
the	O
drug	B-Drug
is	O
able	O
to	O
antagonize	O
impairment	O
of	O
attention	O
and	O
memory	O
induced	O
by	O
scopolamine	B-Chemical
.	O

Seizures	B-Disease
induced	O
by	O
the	O
cocaine	B-Chemical
metabolite	O
benzoylecgonine	B-Chemical
in	O
rats	O
.	O

The	O
half-life	O
(	O
t1/2	B-Drug
)	O
of	O
cocaine	B-Chemical
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seizures	B-Disease
and	O
strokes	B-Disease
,	O
can	O
occur	O
hours	O
after	O
exposure	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	O
of	O
cocaine	B-Chemical
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delayed	O
sequelae	O
.	O

We	O
evaluated	O
the	O
potential	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	B-Chemical
,	O
benzoylecgonine	B-Chemical
(	O
BE	B-Chemical
)	O
,	O
to	O
cause	O
seizures	B-Disease
.	O

Two	O
separate	O
equimolar	O
doses	O
(	O
0.2	O
and	O
0.4	O
mumol	O
)	O
of	O
either	O
cocaine	B-Chemical
or	O
BE	B-Chemical
were	O
injected	O
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats	O
.	O

Treated	O
rats	O
were	O
then	O
evaluated	O
for	O
incidence	O
,	O
latency	O
,	O
and	O
seizure	B-Disease
pattern	O
or	O
for	O
locomotor	O
activity	O
in	O
animals	O
without	O
seizures	B-Disease
.	O

BE-Induced	B-Chemical
seizures	B-Disease
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latencies	O
than	O
those	O
induced	O
by	O
equimolar	O
amounts	O
of	O
cocaine	B-Chemical
.	O

Whereas	O
cocaine-induced	B-Chemical
seizures	B-Disease
were	O
best	O
characterized	O
as	O
brief	O
,	O
generalized	O
,	O
and	O
tonic	O
and	O
resulted	O
in	O
death	B-Disease
,	O
those	O
induced	O
by	O
BE	B-Chemical
were	O
prolonged	O
,	O
often	O
multiple	O
and	O
mixed	O
in	O
type	O
,	O
and	O
rarely	O
resulted	O
in	O
death	B-Disease
.	O

Electrical	O
recordings	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhythmic	O
progression	O
in	O
EEG	O
frequency	O
and	O
voltage	O
with	O
clinical	O
seizure	B-Disease
expression	O
.	O

BE-Injected	B-Chemical
rats	O
that	O
did	O
not	O
have	O
seizures	B-Disease
had	O
significantly	O
more	O
locomotor	O
activity	O
than	O
cocaine-injected	B-Chemical
animals	O
without	O
seizures	B-Disease
.	O

The	O
finding	O
that	O
cocaine-	B-Chemical
and	O
BE-induced	B-Chemical
seizures	B-Disease
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	O
for	O
cocaine-induced	B-Chemical
seizures	B-Disease
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocaine	B-Chemical
metabolite	O
,	O
BE	B-Chemical
.	O

Protection	O
against	O
amphetamine-induced	B-Chemical
neurotoxicity	B-Disease
toward	O
striatal	O
dopamine	B-Chemical
neurons	O
in	O
rodents	O
by	O
LY274614	B-Chemical
,	O
an	O
excitatory	O
amino	B-Chemical
acid	I-Chemical
antagonist	O
.	O

LY274614	B-Chemical
,	O
3SR,4aRS,6SR,8aRS-6-	B-Chemical
[	I-Chemical
phosphonomethyl	I-Chemical
]	I-Chemical
decahydr	I-Chemical
oisoquinoline-3-	I-Chemical
carboxylic	I-Chemical
acid	I-Chemical
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N-methyl-D-aspartate	B-Chemical
(	O
NMDA	B-Chemical
)	O
subtype	O
of	O
glutamate	B-Chemical
receptor	O
.	O

Here	O
its	O
ability	O
to	O
antagonize	O
the	O
prolonged	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
by	O
amphetamine	B-Chemical
in	O
iprindole-treated	B-Chemical
rats	O
is	O
reported	O
.	O

A	O
single	O
18.4	O
mg/kg	O
(	O
i.p	O
.	O

)	O
dose	O
of	O
(	O
+/-	O
)	O
-amphetamine	B-Chemical
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	B-Chemical
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
1	O
week	O
later	O
.	O

This	O
prolonged	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	B-Chemical
(	O
MK-801	B-Chemical
,	O
a	O
non-competitive	O
antagonist	O
of	O
NMDA	B-Chemical
receptors	O
)	O
or	O
by	O
LY274614	B-Chemical
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	B-Chemical
receptors	O
)	O
.	O

The	O
protective	O
effect	O
of	O
LY274614	B-Chemical
was	O
dose-dependent	O
,	O
being	O
maximum	O
at	O
10-40	O
mgkg	O
(	O
i.p.	O
)	O
.	O

A	O
10	O
mg/kg	O
dose	O
of	O
LY274614	B-Chemical
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	B-Chemical
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	B-Chemical
.	O

Depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	B-Chemical
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	B-Chemical
;	O
LY274614	B-Chemical
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	B-Chemical
.	O

The	O
prolonged	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
in	O
mice	O
,	O
given	O
multiple	O
injections	O
of	O
methamphetamine	B-Chemical
,	O
was	O
also	O
antagonized	O
dose-dependently	O
and	O
completely	O
by	O
LY274614	B-Chemical
.	O

The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	B-Disease
effect	O
of	O
amphetamine	B-Chemical
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	B-Chemical
neurons	O
involves	O
NMDA	B-Chemical
receptors	O
and	O
that	O
LY274614	B-Chemical
is	O
an	O
NMDA	B-Chemical
receptor	O
antagonist	O
with	O
long-lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

Neonatal	O
pyridoxine	B-Chemical
responsive	O
convulsions	B-Disease
due	O
to	O
isoniazid	B-Chemical
therapy	O
.	O

A	O
17-day-old	O
infant	O
on	O
isoniazid	B-Chemical
therapy	O
13	O
mg/kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	B-Disease
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	B-Disease
fits	I-Disease
.	O

No	O
underlying	O
infective	O
or	O
biochemical	O
cause	O
could	O
be	O
found	O
.	O

The	O
fits	B-Disease
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	B-Chemical
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	B-Chemical
deficiency	O
secondary	O
to	O
isoniazid	B-Chemical
medication	O
.	O

Reversal	O
by	O
phenylephrine	B-Chemical
of	O
the	O
beneficial	O
effects	O
of	O
intravenous	O
nitroglycerin	B-Chemical
in	O
patients	O
with	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

Nitroglycerin	B-Chemical
has	O
been	O
shown	O
to	O
reduce	O
ST-segment	O
elevation	O
during	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
,	O
an	O
effect	O
potentiated	O
in	O
the	O
dog	O
by	O
agents	O
that	O
reverse	O
nitroglycerin-induced	B-Chemical
hypotension	B-Disease
.	O

Our	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
combined	O
nitroglycerin	B-Chemical
and	O
phenylephrine	B-Chemical
therapy	O
.	O

Ten	O
patients	O
with	O
acute	O
transmural	O
myocardial	B-Disease
infarctions	I-Disease
received	O
intravenous	O
nitroglycerin	B-Chemical
,	O
sufficient	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
from	O
107	O
+/-	O
6	O
to	O
85	O
+/-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
,	O
for	O
60	O
minutes	O
.	O

Left	O
ventricular	O
filling	O
pressure	O
decreased	O
from	O
19	O
+/-	O
2	O
to	O
11	O
+/-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

SigmaST	O
,	O
the	O
sum	O
of	O
ST-segment	O
elevations	O
in	O
16	O
precordial	O
leads	O
,	O
decreased	O
(	O
P	O
less	O
than	O
0.02	O
)	O
with	O
intravenous	O
nitroglycerin	B-Chemical
.	O

Subsequent	O
addition	O
of	O
phenylephrine	B-Chemical
infusion	O
,	O
sufficient	O
to	O
re-elevate	O
mean	O
arterial	O
pressure	O
to	O
106	O
+/-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
for	O
30	O
minutes	O
,	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
to	O
17	O
+/-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
also	O
significantly	O
increased	O
sigmaST	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
addition	O
of	O
phenylephrine	B-Chemical
to	O
nitroglycerin	B-Chemical
is	O
not	O
beneficial	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O

Elevation	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP-2	O
and	O
MMP-9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2-induced	B-Chemical
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
in	O
a	O
rat	O
model	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
(	O
TAA	B-Disease
)	O
by	O
calcium	B-Chemical
chloride	I-Chemical
(	I-Chemical
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	O
)	O
-induced	O
arterial	B-Disease
injury	I-Disease
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-Disease
formation	O
.	O

METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague-Dawley	O
rats	O
was	O
exposed	O
to	O
0.5M	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
or	O
normal	O
saline	O
(	O
NaCl	B-Chemical
)	I-Chemical
.	O

After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-treated	O
,	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	O
-untreated	O
(	O
n=12	O
)	O
and	O
NaCl-treated	B-Chemical
aortic	O
segments	O
(	I-Chemical
n=12	O
)	I-Chemical
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O

MMP-TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semi-quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-treated	O
,	O
non-CaCl	B-Chemical
(	I-Chemical
2	O
)	O
-treated	O
and	O
NaCl-treated	B-Chemical
segments	O
,	O
aneurymal	O
alteration	O
(	I-Chemical
n=6	O
,	O
50	O
%	O
)	I-Chemical
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	I-Chemical
n=12	O
,	O
100	O
%	O
)	I-Chemical
were	O
demonstrated	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-treated	O
segments	O
.	O

MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-treated	O
segments	O
(	O
all	O
p	O
<	O
0.01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	O
(	O
2	O
)	O
-untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl-treated	B-Chemical
segments	O
.	O

Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
(	I-Chemical
all	O
p	O
<	O
0.01	O
)	I-Chemical
in	O
intima	O
and	O
media	O
for	O
CaCl	B-Chemical
(	I-Chemical
2	O
)	O
-treated	O
segments	O
.	O

TIMP	O
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O

CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B-Disease
model	O
by	O
periarterial	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
exposure	O
in	O
rats	O
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O

When	O
drugs	B-Drug
disappear	O
from	O
the	O
patient	O
:	O
elimination	O
of	O
intravenous	O
medication	O
by	O
hemodiafiltration	O
.	O

Twenty-three	O
hours	O
after	O
heart	I-Disease
transplantation	O
,	O
life-threatening	O
acute	O
right	B-Disease
heart	I-Disease
failure	O
was	O
diagnosed	O
in	O
a	O
patient	O
requiring	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
.	O

Increasing	O
doses	O
of	O
catecholamines	B-Chemical
,	O
sedatives	O
,	O
and	O
muscle	O
relaxants	O
administered	O
through	O
a	O
central	O
venous	O
catheter	O
were	O
ineffective	O
.	O

However	O
,	O
a	O
bolus	O
of	O
epinephrine	B-Chemical
injected	O
through	O
an	O
alternative	O
catheter	O
provoked	O
a	O
hypertensive	B-Disease
crisis	O
.	O

Thus	O
,	O
interference	O
with	O
the	O
central	O
venous	O
infusion	O
by	O
the	O
dialysis	O
catheter	O
was	O
suspected	O
.	O

The	O
catheters	O
were	O
changed	O
,	O
and	O
hemodynamics	O
stabilized	O
at	O
lower	O
catecholamine	B-Chemical
doses	O
.	O

When	O
the	O
effects	O
of	O
IV	O
drugs	B-Drug
are	O
inadequate	O
in	O
patients	O
receiving	O
CVVHDF	O
,	O
interference	O
with	O
adjacent	O
catheters	O
resulting	O
in	O
elimination	O
of	O
the	O
drug	B-Drug
by	O
CVVHDF	O
should	O
be	O
suspected	O
.	O

Long-term	O
glutamate	B-Chemical
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	B-Disease
neurotoxicity	I-Disease
of	O
paclitaxel	B-Chemical
.	O

Toxic	O
peripheral	B-Disease
neuropathy	I-Disease
is	O
still	O
a	O
significant	O
limiting	O
factor	O
for	O
chemotherapy	O
with	O
paclitaxel	B-Chemical
(	O
PAC	B-Chemical
)	O
,	O
although	O
glutamate	B-Chemical
and	O
its	O
closely	O
related	O
amino	B-Chemical
acid	I-Chemical
glutamine	B-Chemical
were	O
claimed	O
to	O
ameliorate	O
PAC	B-Chemical
neurotoxicity	B-Disease
.	O

This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	B-Chemical
supplementation	O
for	O
preventing	O
PAC-induced	B-Chemical
peripheral	B-Disease
neuropathy	I-Disease
in	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blinded	O
clinical	O
and	O
electro-diagnostic	O
study	O
.	O

Forty-three	O
ovarian	B-Disease
cancer	I-Disease
patients	O
were	O
available	O
for	O
analysis	O
following	O
six	O
cycles	O
of	O
the	O
same	O
PAC-containing	B-Chemical
regimen	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	B-Chemical
all	O
along	O
the	O
treatment	O
period	O
,	O
at	O
a	O
daily	O
dose	O
of	O
three	O
times	O
500	O
mg	O
(	O
group	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placebo	O
(	O
group	O
P	O
)	O
.	O

Patients	O
were	O
evaluated	O
by	O
neurological	O
examinations	O
,	O
questionnaires	O
and	O
sensory-motor	O
nerve	O
conduction	O
studies	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
signs	O
or	O
symptoms	O
between	O
the	O
two	O
groups	O
although	O
neurotoxicity	B-Disease
symptoms	O
presented	O
mostly	O
with	O
lower	O
scores	O
of	O
severity	O
in	O
group	O
G.	O
However	O
,	O
this	O
difference	O
reached	O
statistical	O
significance	O
only	O
with	O
regard	O
to	O
reported	O
pain	B-Disease
sensation	O
(	O
P	O
=	O
0.011	O
)	O
.	O

Also	O
the	O
frequency	O
of	O
abnormal	O
electro-diagnostic	O
findings	O
showed	O
similarity	O
between	O
the	O
two	O
groups	O
(	O
G	O
:	O
7/23	O
=	O
30.4	O
%	O
;	O
P	O
:	O
6/20	O
=	O
30	O
%	O
)	O
.	O

This	O
pilot	O
study	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamate	B-Chemical
supplementation	O
at	O
the	O
chosen	O
regimen	O
fails	O
to	O
protect	O
against	O
peripheral	B-Disease
neurotoxicity	I-Disease
of	O
PAC	B-Chemical
.	O

Attentional	O
modulation	O
of	O
perceived	O
pain	B-Disease
intensity	O
in	O
capsaicin-induced	B-Chemical
secondary	O
hyperalgesia	B-Disease
.	O

Perceived	O
pain	B-Disease
intensity	O
is	O
modulated	O
by	O
attention	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	B-Disease
intensity	O
ratings	O
are	O
affected	O
by	O
attention	O
in	O
capsaicin-induced	B-Chemical
secondary	O
hyperalgesia	B-Disease
.	O

Here	O
we	O
show	O
that	O
perceived	O
pain	B-Disease
intensity	O
in	O
secondary	O
hyperalgesia	B-Disease
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitude	O
of	O
attentional	O
modulation	O
in	O
secondary	O
hyperalgesia	B-Disease
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicin-untreated	B-Chemical
,	O
control	O
condition	O
.	O

Our	O
findings	O
,	O
showing	O
no	O
interaction	O
between	O
capsaicin	B-Chemical
treatment	O
and	O
attentional	O
modulation	O
suggest	O
that	O
capsaicin-induced	B-Chemical
secondary	O
hyperalgesia	B-Disease
and	O
attention	O
might	O
affect	O
mechanical	O
pain	B-Disease
through	O
independent	O
mechanisms	O
.	O

Testosterone-dependent	B-Chemical
hypertension	B-Disease
and	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
in	O
Dahl	O
salt-sensitive	B-Chemical
rats	O
.	O

Blood	O
pressure	O
(	O
BP	O
)	O
is	O
more	O
salt	B-Chemical
sensitive	O
in	O
men	O
than	O
in	O
premenopausal	O
women	O
.	O

In	O
Dahl	O
salt-sensitive	B-Chemical
rats	O
(	O
DS	O
)	O
,	O
high-salt	B-Chemical
(	O
HS	O
)	O
diet	O
increases	O
BP	O
more	O
in	O
males	O
than	O
females	O
.	O

In	O
contrast	O
to	O
the	O
systemic	O
renin-angiotensin	B-Chemical
system	O
,	O
which	O
is	O
suppressed	O
in	O
response	O
to	O
HS	O
in	O
male	O
DS	O
,	O
intrarenal	O
angiotensinogen	O
expression	O
is	O
increased	O
,	O
and	O
intrarenal	O
levels	O
of	O
ANG	O
II	O
are	O
not	O
suppressed	O
.	O

In	O
this	O
study	O
,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS-induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	B-Chemical
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	B-Disease
injury	I-Disease
.	O

On	O
a	O
low-salt	B-Chemical
(	O
LS	O
)	O
diet	O
,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females	O
.	O

HS	O
diet	O
for	O
4	O
wk	O
increased	O
renal	O
cortical	O
angiotensinogen	O
mRNA	O
and	O
protein	O
only	O
in	O
male	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
castration	O
.	O

Ovariectomy	O
of	O
female	O
DS	O
had	O
no	O
effect	O
on	O
intrarenal	O
angiotensinogen	O
expression	O
on	O
either	O
diet	O
.	O

Radiotelemetric	O
BP	O
was	O
similar	O
between	O
males	O
and	O
castrated	O
rats	O
on	O
LS	O
diet	O
.	O

HS	O
diet	O
for	O
4	O
wk	O
caused	O
a	O
progressive	O
increase	O
in	O
BP	O
,	O
protein	O
and	O
albumin	O
excretion	O
,	O
and	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
male	O
DS	O
rats	O
,	O
which	O
were	O
attenuated	O
by	O
castration	O
.	O

Testosterone	B-Chemical
replacement	O
in	O
castrated	O
DS	O
rats	O
increased	O
BP	O
,	O
renal	B-Disease
injury	I-Disease
,	O
and	O
upregulation	O
of	O
renal	O
angiotensinogen	O
associated	O
with	O
HS	O
diet	O
.	O

Testosterone	B-Chemical
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin-angiotensin	B-Chemical
system	O
.	O

Prenatal	O
protein	O
deprivation	O
alters	O
dopamine-mediated	B-Chemical
behaviors	O
and	O
dopaminergic	B-Drug
and	O
glutamatergic	O
receptor	O
binding	O
.	O

Epidemiological	O
evidence	O
indicates	O
that	O
prenatal	O
nutritional	O
deprivation	O
may	O
increase	O
the	O
risk	O
of	O
schizophrenia	B-Disease
.	O

The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
use	O
an	O
animal	O
model	O
to	O
examine	O
the	O
effects	O
of	O
prenatal	O
protein	O
deprivation	O
on	O
behaviors	O
and	O
receptor	O
binding	O
with	O
relevance	O
to	O
schizophrenia	B-Disease
.	O

We	O
report	O
that	O
prenatally	O
protein	O
deprived	O
(	O
PD	O
)	O
female	O
rats	O
showed	O
an	O
increased	O
stereotypic	O
response	O
to	O
apomorphine	B-Chemical
and	O
an	O
increased	O
locomotor	O
response	O
to	O
amphetamine	B-Chemical
in	O
adulthood	O
.	O

These	O
differences	O
were	O
not	O
observed	O
during	O
puberty	O
.	O

No	O
changes	O
in	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
or	O
MK-801-induced	B-Chemical
locomotion	O
were	O
seen	O
following	O
PD	O
.	O

In	O
addition	O
,	O
PD	O
female	O
rats	O
showed	O
increased	O
(	O
3	O
)	O
H-MK-801	B-Chemical
binding	O
in	O
the	O
striatum	O
and	O
hippocampus	O
,	O
but	O
not	O
in	O
the	O
cortex	O
.	O

PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3	O
)	O
H-haloperidol	O
binding	O
and	O
decreased	O
dopamine	B-Drug
transporter	O
binding	O
in	O
striatum	O
.	O

No	O
statistically	O
significant	O
changes	O
in	O
behavior	O
or	O
receptor	O
binding	O
were	O
found	O
in	O
PD	O
males	O
with	O
the	O
exception	O
of	O
increased	O
(	O
3	O
)	O
H-MK-801	B-Chemical
binding	O
in	O
cortex	O
.	O

This	O
animal	O
model	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechanisms	O
by	O
which	O
prenatal	O
nutritional	O
deficiency	O
enhances	O
risk	O
for	O
schizophrenia	O
in	O
humans	O
and	O
may	O
also	O
have	O
implications	O
for	O
developmental	O
processes	O
leading	O
to	O
differential	O
sensitivity	O
to	O
drugs	B-Drug
of	O
abuse	O
.	O

mToR	O
inhibitors-induced	O
proteinuria	B-Disease
:	O
mechanisms	O
,	O
significance	O
,	O
and	O
management	O
.	O

Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	O
inhibitors	O
to	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
(	O
mToR	O
)	O
inhibitors	O
,	O
especially	O
sirolimus	B-Chemical
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
.	O

Because	O
proteinuria	B-Disease
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O

Whether	O
proteinuria	B-Disease
was	O
due	O
to	O
sirolimus	B-Chemical
or	O
only	O
a	O
consequence	O
of	O
calcineurin	O
inhibitors	O
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	B-Disease
has	O
been	O
observed	O
during	O
sirolimus	B-Chemical
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	B-Chemical
de	O
novo	O
.	O

Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	B-Disease
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O

We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade-induced	O
proteinuria	B-Disease
.	O

Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	B-Chemical
acid	I-Chemical
levels	O
,	O
prolactin	O
signaling	O
,	O
and	O
hyperprolactinemic	B-Disease
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	B-Chemical
.	O

Hyperprolactinemia	B-Disease
can	O
reduce	O
fertility	O
and	O
libido	O
.	O

Although	O
central	O
prolactin	O
actions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	B-Disease
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen-induced	B-Chemical
LH	O
surge	O
.	O

Chronic	O
hyperprolactinemia	B-Disease
induced	O
by	O
the	O
dopamine	B-Chemical
antagonist	O
sulpiride	B-Chemical
caused	O
a	O
40	O
%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	B-Chemical
.	O

Sulpiride	B-Chemical
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid-induced	B-Chemical
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O

Estradiol	B-Chemical
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(	O
PRL-R	O
)	O
and	O
components	O
of	O
prolactin	O
's	O
signaling	O
pathway	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
estrogen	B-Chemical
increases	O
PRL-R	O
expression	O
and	O
sensitivity	O
to	O
prolactin	O
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	B-Chemical
greatly	O
augments	O
prolactin-induced	O
STAT5	O
activation	O
.	O

Lastly	O
,	O
we	O
measured	O
PRL-R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS-1	O
and	O
-3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	B-Chemical
and	O
estradiol	B-Chemical
.	O

Sulpiride	B-Chemical
induced	O
only	O
SOCS-1	O
in	O
the	O
medial	O
preoptic	O
area	O
,	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
,	O
PRL-R	O
,	O
SOCS-3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced	O
.	O

Estradiol	B-Chemical
enhanced	O
these	O
effects	O
on	O
SOCS-3	O
and	O
CIS	O
.	O

Interestingly	O
,	O
estradiol	B-Chemical
also	O
induced	O
PRL-R	O
,	O
SOCS-3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
independently	O
.	O

These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	B-Disease
in	O
a	O
steroid-dependent	B-Chemical
manner	O
.	O

They	O
also	O
provide	O
evidence	O
for	O
estradiol-dependent	B-Chemical
and	O
brain	O
region-specific	O
regulation	O
of	O
PRL-R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O

Estrogen	O
prevents	O
cholesteryl	B-Chemical
ester	B-Chemical
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	B-Chemical
.	O

Individuals	O
with	O
HIV	O
can	O
now	O
live	O
long	O
lives	O
with	O
drug	B-Drug
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	B-Chemical
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long-term	O
side	O
effects	O
such	O
as	O
premature	B-Disease
atherosclerosis	I-Disease
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	B-Chemical
treatment	O
increases	O
atherosclerotic	B-Disease
lesion	I-Disease
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	O
.	O

Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir-treated	B-Chemical
females	O
had	O
less	O
cholesteryl	B-Chemical
ester	B-Chemical
accumulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	B-Chemical
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	B-Chemical
.	O

We	O
have	O
utilized	O
the	O
human	O
monocyte	O
cell	O
line	O
,	O
THP-1	O
as	O
a	O
model	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage-like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta-estradiol	B-Chemical
(	O
E2	B-Chemical
)	O
,	O
100	O
nM	O
progesterone	B-Chemical
or	O
vehicle	O
(	O
0.01	O
%	O
ethanol	B-Chemical
)	O
.	O

Cells	O
were	O
then	O
treated	O
with	O
30	O
ng/ml	O
ritonavir	B-Chemical
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h.	O
Cell	O
extracts	O
were	O
harvested	O
,	O
and	O
lipid	O
or	O
total	O
RNA	O
was	O
isolated	O
.	O

E2	B-Chemical
decreased	O
the	O
accumulation	O
of	O
cholesteryl	B-Chemical
esters	I-Chemical
in	O
macrophages	O
following	O
ritonavir	B-Chemical
treatment	O
.	O

Ritonavir	B-Chemical
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonavir	B-Chemical
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression	O
.	O

Treatment	O
with	O
E2	B-Chemical
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O

E2	B-Chemical
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

This	O
data	O
suggests	O
that	O
E2	B-Chemical
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte-derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	B-Chemical
ester	B-Chemical
accumulation	O
following	O
ritonavir	B-Chemical
treatment	O
.	O

Upregulation	O
of	O
brain	O
expression	O
of	O
P-glycoprotein	O
in	O
MRP2-deficient	O
TR	O
(	O
-	O
)	O
rats	O
resembles	O
seizure-induced	B-Disease
up-regulation	O
of	O
this	O
drug	B-Drug
efflux	O
transporter	O
in	O
normal	O
rats	O
.	O

PURPOSE	O
:	O
The	O
multidrug	O
resistance	O
protein	O
2	O
(	O
MRP2	O
)	O
is	O
a	O
drug	B-Drug
efflux	O
transporter	O
that	O
is	O
expressed	O
predominantly	O
at	O
the	O
apical	O
domain	O
of	O
hepatocytes	O
but	O
seems	O
also	O
to	O
be	O
expressed	O
at	O
the	O
apical	O
membrane	O
of	O
brain	O
capillary	O
endothelial	O
cells	O
that	O
form	O
the	O
blood-brain	O
barrier	O
(	O
BBB	O
)	O
.	O

MRP2	O
is	O
absent	O
in	O
the	O
transport-deficient	O
(	O
TR	O
(	O
-	O
)	O
)	O
Wistar	O
rat	O
mutant	O
,	O
so	O
that	O
this	O
rat	O
strain	O
was	O
very	O
helpful	O
in	O
defining	O
substrates	O
of	O
MRP2	O
by	O
comparing	O
tissue	O
concentrations	O
or	O
functional	O
activities	O
of	O
compounds	O
in	O
MRP2-deficient	O
rats	O
with	O
those	O
in	O
transport-competent	O
Wistar	O
rats	O
.	O

By	O
using	O
this	O
strategy	O
to	O
study	O
the	O
involvement	O
of	O
MRP2	O
in	O
brain	O
access	O
of	O
antiepileptic	O
drugs	B-Drug
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
phenytoin	B-Chemical
is	O
a	O
substrate	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O

However	O
,	O
one	O
drawback	O
of	O
such	O
studies	O
in	O
genetically	O
deficient	O
rats	O
is	O
the	O
fact	O
that	O
compensatory	O
changes	O
with	O
upregulation	O
of	O
other	O
transporters	O
can	O
occur	O
.	O

This	O
prompted	O
us	O
to	O
study	O
the	O
brain	O
expression	O
of	O
P-glycoprotein	O
(	O
Pgp	O
)	O
,	O
a	O
major	O
drug	B-Drug
efflux	O
transporter	O
in	O
many	O
tissues	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR	O
(	O
-	O
)	O
rats	O
compared	O
with	O
nonmutant	O
(	O
wild-type	O
)	O
Wistar	O
rats	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
MRP2	O
and	O
Pgp	O
in	O
brain	O
and	O
liver	O
sections	O
of	O
TR	O
(	O
-	O
)	O
rats	O
and	O
normal	O
Wistar	O
rats	O
was	O
determined	O
with	O
immunohistochemistry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
monoclonal	O
MRP2	O
antibody	O
and	O
the	O
monoclonal	O
Pgp	O
antibody	O
C219	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Immunofluorescence	O
staining	O
with	O
the	O
MRP2	O
antibody	O
was	O
found	O
to	O
label	O
a	O
high	O
number	O
of	O
microvessels	O
throughout	O
the	O
brain	O
in	O
normal	O
Wistar	O
rats	O
,	O
whereas	O
such	O
labeling	O
was	O
absent	O
in	O
TR	O
(	O
-	O
)	O
rats	O
.	O

TR	O
(	O
-	O
)	O
rats	O
exhibited	O
a	O
significant	O
up-regulation	O
of	O
Pgp	O
in	O
brain	O
capillary	O
endothelial	O
cells	O
compared	O
with	O
wild-type	O
controls	O
.	O

No	O
such	O
obvious	O
upregulation	O
of	O
Pgp	O
was	O
observed	O
in	O
liver	O
sections	O
.	O

A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
in	O
wild-type	O
Wistar	O
rats	O
.	O

Experiments	O
with	O
systemic	O
administration	O
of	O
the	O
Pgp	O
substrate	O
phenobarbital	B-Chemical
and	O
the	O
selective	O
Pgp	O
inhibitor	O
tariquidar	B-Chemical
in	O
TR	O
(	O
-	O
)	O
rats	O
substantiated	O
that	O
Pgp	O
is	O
functional	O
and	O
compensates	O
for	O
the	I-Disease
lack	O
of	O
MRP2	O
in	O
the	I-Disease
BBB	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
on	O
TR	O
(	O
-	O
)	O
rats	O
indicate	O
that	O
Pgp	O
plays	O
an	O
important	O
role	O
in	O
the	I-Disease
compensation	O
of	O
MRP2	O
deficiency	O
in	O
the	I-Disease
BBB	O
.	O

Because	O
such	O
a	O
compensatory	O
mechanism	O
most	O
likely	O
occurs	O
to	O
reduce	O
injury	O
to	O
the	O
brain	O
from	O
cytotoxic	O
compounds	O
,	O
the	O
present	O
data	O
substantiate	O
the	O
concept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O

Furthermore	O
,	O
our	O
data	O
suggest	O
that	O
TR	O
(	O
-	O
)	O
rats	O
are	O
an	O
interesting	O
tool	O
to	O
study	O
consequences	O
of	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drugs	B-Drug
in	O
the	O
brain	O
,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	B-Disease
or	O
other	O
Pgp-enhancing	O
events	O
for	O
this	O
purpose	O
.	O

Use	O
of	O
chromosome	O
substitution	O
strains	O
to	O
identify	O
seizure	B-Disease
susceptibility	O
loci	O
in	O
mice	O
.	O

Seizure	B-Disease
susceptibility	O
varies	O
among	O
inbred	O
mouse	O
strains	O
.	O

Chromosome	O
substitution	O
strains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chromosome	O
from	O
one	O
inbred	O
strain	O
(	O
donor	O
)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	O
(	O
host	O
)	O
by	O
repeated	O
backcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
that	O
contribute	O
to	O
seizure	B-Disease
susceptibility	O
.	O

QTLs	O
for	O
susceptibility	O
to	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
,	O
a	O
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localize	O
seizure	B-Disease
susceptibility	O
genes	O
.	O

We	O
report	O
QTLs	O
identified	O
using	O
a	O
B6	O
(	O
host	O
)	O
x	O
A/J	O
(	O
donor	O
)	O
CSS	O
panel	O
to	O
localize	O
genes	O
involved	O
in	O
susceptibility	O
to	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
.	O

Three	O
hundred	O
fifty-five	O
adult	O
male	O
CSS	O
mice	O
,	O
58	O
B6	O
,	O
and	O
39	O
A/J	O
were	O
tested	O
for	O
susceptibility	O
to	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
.	O

Highest	O
stage	O
reached	O
and	O
latency	O
to	O
each	O
stage	O
were	O
recorded	O
for	O
all	O
mice	O
.	O

B6	O
mice	O
were	O
resistant	O
to	O
seizures	B-Disease
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A/J	O
mice	O
.	O

The	O
CSS	O
for	O
Chromosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
severe	O
stages	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenotype	O
.	O

Latencies	O
to	O
stages	O
were	O
also	O
significantly	O
shorter	O
for	O
CSS10	O
and	O
CSS18	O
mice	O
.	O

CSS	O
mapping	O
suggests	O
seizure	B-Disease
susceptibility	O
loci	O
on	O
mouse	O
Chromosomes	O
10	O
and	O
18	O
.	O

This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	O
for	O
human	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

Investigation	O
of	O
mitochondrial	O
involvement	O
in	O
the	O
experimental	O
model	O
of	O
epilepsy	B-Disease
induced	O
by	O
pilocarpine	B-Chemical
.	O

Mitochondrial	B-Disease
abnormalities	I-Disease
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis	O
,	O
such	O
as	O
energy	O
generation	O
,	O
control	O
of	O
cell	O
death	B-Disease
,	O
neurotransmitter	O
synthesis	O
,	O
and	O
free	O
radical	O
(	O
FR	O
)	O
production	O
.	O

Increased	O
production	O
of	O
FRs	O
may	O
cause	O
mtDNA	O
damage	O
leading	O
to	O
decreased	O
activities	O
of	O
oxidative	O
phosphorylation	O
complexes	O
containing	O
mtDNA-encoded	O
subunits	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
increased	O
generation	O
of	O
FR	O
during	O
status	B-Disease
epilepticus	I-Disease
would	O
be	O
sufficient	O
to	O
provoke	O
abnormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expression	O
and	O
activity	O
of	O
cytochrome	O
c	O
oxidase	O
(	O
CCO	O
)	O
,	O
complex	O
IV	O
of	O
the	O
respiratory	O
chain	O
,	O
in	O
the	O
chronic	O
phase	O
of	O
the	O
pilocarpine	B-Chemical
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

DNA	O
analysis	O
revealed	O
low	O
amounts	O
of	O
a	O
4.8	O
kb	O
mtDNA	O
deletion	O
but	O
with	O
no	O
differences	O
in	O
frequency	O
or	O
quantity	O
in	O
the	O
control	O
and	O
experimental	O
groups	O
.	O

We	O
did	O
not	O
find	O
abnormalities	I-Disease
in	O
the	O
expression	O
and	O
distribution	O
of	O
an	O
mtDNA-encoded	O
subunit	O
of	O
CCO	O
(	O
CCO-I	O
)	O
or	O
a	O
relative	O
decrease	O
in	O
CCO-I	O
when	O
compared	O
with	O
nuclear-encoded	O
subunits	O
(	O
CCO-IV	O
and	O
SDH-fp	O
)	O
.	O

No	O
abnormality	O
in	O
CCO	O
activity	O
was	O
observed	O
through	O
histochemistry	O
.	O

Although	O
evidences	O
of	O
mitochondrial	B-Disease
abnormalities	O
were	O
found	O
in	O
previously	O
published	O
studies	O
,	O
our	O
results	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
acute	O
phase	O
,	O
determined	O
important	O
abnormalities	O
in	O
mtDNA	O
,	O
in	O
expression	O
of	O
CCO-I	O
,	O
and	O
in	O
CCO	O
activity	O
.	O

Causes	O
of	O
acute	O
thrombotic	B-Disease
microangiopathy	I-Disease
in	O
patients	O
receiving	O
kidney	O
transplantation	O
.	O

OBJECTIVES	O
:	O
Thrombotic	B-Disease
microangiopathy	I-Disease
is	O
a	O
well-known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation	O
.	O

In	O
postrenal	O
transplantation	O
,	O
thrombotic	B-Disease
microangiopathy	I-Disease
is	O
often	O
a	O
reflection	O
of	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O

We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investigated	O
the	O
causes	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
during	O
a	O
1-year	O
period	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
in	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	O
biopsies	O
(	O
n=25	O
)	O
performed	O
during	O
this	O
interval	O
.	O

Pre-	O
and	O
posttransplant	O
crossmatching	O
was	O
done	O
when	O
possible	O
.	O

RESULTS	O
:	O
Five	O
cases	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
were	O
found	O
.	O

Three	O
of	O
these	O
cases	O
were	O
from	O
the	O
25	O
transplantations	O
performed	O
at	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
,	O
while	O
the	O
other	O
2	O
transplantations	O
had	O
been	O
performed	O
abroad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow-up	O
.	O

Three	O
cases	O
were	O
related	O
to	O
cyclosporine	B-Chemical
,	O
and	O
1	O
case	O
was	O
secondary	O
to	O
both	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
.	O

The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
related	O
to	O
an	O
antiphospholipid	B-Disease
syndrome	I-Disease
in	O
a	O
patient	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O

CONCLUSIONS	O
:	O
In	O
the	O
literature	O
,	O
the	O
most-frequent	O
cause	O
of	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
in	O
patients	O
following	O
renal	O
transplantation	O
is	O
recurrence	O
of	O
the	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O

Other	O
causes	O
include	O
drug-related	O
(	O
cyclosporine	B-Chemical
,	O
tacrolimus	B-Chemical
)	O
toxicity	B-Disease
,	O
procoagulant	O
status	O
,	O
and	O
antibody-mediated	O
rejection	O
.	O

We	O
found	O
that	O
the	O
most-frequent	O
cause	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
was	O
drug	B-Drug
related	O
,	O
secondary	O
mainly	O
to	O
cyclosporine	B-Chemical
.	O

In	O
the	O
current	O
study	O
,	O
the	O
frequency	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
was	O
similar	O
to	O
the	O
percentage	O
reported	O
in	O
the	O
literature	O
(	O
20	O
%	O
)	O
.	O

Severe	O
reversible	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	B-Chemical
overdose	B-Disease
.	O

Catecholamine-induced	B-Chemical
cardiomyopathy	B-Disease
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	B-Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O

In	O
contrast	O
,	O
reports	O
of	O
myocardial	B-Disease
dysfunction	I-Disease
due	O
to	O
acute	O
iatrogenic	O
overdose	B-Disease
are	O
rare	O
.	O

A	O
35-year-old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	B-Chemical
developed	O
myocardial	B-Disease
stunning	I-Disease
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	B-Disease
necrosis	I-Disease
.	O

Our	O
case	O
illustrates	O
the	O
serious	O
consequences	O
of	O
medical	O
errors	O
that	O
can	O
be	O
avoided	O
through	O
improved	O
medication	O
labeling	O
and	O
staff	O
supervision	O
.	O

Urinary	B-Disease
bladder	I-Disease
cancer	I-Disease
in	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	B-Chemical
,	O
in	O
patients	O
with	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
,	O
1969-95	O
,	O
was	O
identified	O
.	O

Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	B-Disease
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B-Disease
cancer	I-Disease
were	O
identified	O
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case-control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	B-Chemical
and	O
bladder	B-Disease
cancer	I-Disease
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
after	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	B-Disease
cancer	I-Disease
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
,	O
were	O
also	O
estimated	O
.	O

RESULTS	O
:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	B-Chemical
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	B-Chemical
(	O
OR	O
=	O
2.0	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.8	O
to	O
4.9	O
)	O
.	O

Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(	O
OR	O
=	O
7.7	O
,	O
95	O
%	O
CI	O
0.9	O
to	O
69	O
)	O
.	O

The	O
absolute	O
risk	O
for	O
bladder	B-Disease
cancer	I-Disease
in	O
the	O
cohort	O
reached	O
10	O
%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
,	O
and	O
a	O
history	O
of	O
bladder	B-Disease
cancer	I-Disease
was	O
(	O
non-significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose-response	O
relationship	O
between	O
cyclophosphamide	B-Chemical
and	O
the	O
risk	O
of	O
bladder	B-Disease
cancer	I-Disease
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-Disease
's	I-Disease
granulomatosis	I-Disease
.	O

L-arginine	B-Chemical
transport	O
in	O
humans	O
with	O
cortisol-induced	B-Chemical
hypertension	B-Disease
.	O

A	O
deficient	O
L-arginine-nitric	B-Chemical
oxide	I-Chemical
system	O
is	O
implicated	O
in	O
cortisol-induced	O
hypertension	O
.	O

We	O
investigate	O
whether	O
abnormalities	O
in	O
L-arginine	B-Drug
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O

Eight	O
healthy	O
men	O
were	O
recruited	O
.	O

Hydrocortisone	B-Drug
acetate	O
(	O
50	O
mg	O
)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5-day	O
fixed-salt	O
diet	O
(	O
150	O
mmol/d	O
)	O
.	O

Crossover	O
studies	O
were	O
performed	O
2	O
weeks	O
apart	O
.	O

Thirty	O
milliliters	O
of	O
blood	O
was	O
obtained	O
for	O
isolation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
after	O
each	O
treatment	O
period	O
.	O

L-arginine	B-Drug
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L-arginine	B-Drug
(	O
1	O
to	O
300	O
micromol/L	O
)	O
,	O
incorporating	O
100	O
nmol/L	O
[	O
3H	O
]	O
-l-arginine	O
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C.	O
Forearm	O
[	O
3H	O
]	O
-L-arginine	O
extraction	O
was	O
calculated	O
after	O
infusion	O
of	O
[	O
3H	O
]	O
-L-arginine	O
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi/min	O
for	O
80	O
minutes	O
.	O

Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L-arginine	B-Drug
extraction	O
.	O

Plasma	O
cortisol	O
concentrations	O
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(	O
323+/-43	O
to	O
1082+/-245	O
mmol/L	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Systolic	O
blood	O
pressure	O
was	O
elevated	O
by	O
an	O
average	O
of	O
7	O
mm	O
Hg	O
.	O

Neither	O
L-arginine	B-Drug
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26.3+/-3.6	O
vs	O
29.0+/-2.1	O
pmol/10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l-arginine	B-Drug
concentration	O
of	O
300	O
micromol/L	O
)	O
nor	O
L-arginine	B-Drug
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904+/-434	O
962	O
vs	O
2	O
013	O
910+/-770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L-arginine	B-Drug
uptake	O
is	O
not	O
affected	O
by	O
short-term	O
cortisol	O
treatment	O
.	O

We	O
conclude	O
that	O
cortisol-induced	O
increases	O
in	O
blood	O
pressure	O
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l-arginine	B-Drug
transport	O
system	O
.	O

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus-induced	B-Chemical
neurotoxicity	B-Disease
in	O
organ	O
transplant	O
patients	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion-weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	O
tacrolimus	B-Chemical
therapy	O
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	B-Chemical
who	O
developed	O
neurologic	B-Disease
complications	I-Disease
.	O

In	O
each	O
patient	O
who	O
had	O
abnormalities	I-Disease
on	O
the	O
initial	O
MR	O
study	O
,	O
a	O
follow-up	O
MR	O
study	O
was	O
performed	O
1	O
month	O
later	O
.	O

Apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
values	O
on	O
the	O
initial	O
MR	O
study	O
were	O
correlated	O
with	O
reversibility	O
of	O
the	O
lesions	O
.	O

Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35.7	O
%	O
)	O
had	O
white	B-Disease
matter	I-Disease
abnormalities	O
,	O
1	O
(	O
7.1	O
%	O
)	O
had	O
putaminal	B-Disease
hemorrhage	I-Disease
,	O
and	O
8	O
(	O
57.1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

Among	O
the	O
5	O
patients	O
with	O
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
4	O
patients	O
(	O
80.0	O
%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow-up	O
images	O
.	O

The	O
remaining	O
1	O
patient	O
(	O
20.0	O
%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	B-Disease
laminar	I-Disease
necrosis	I-Disease
.	O

Diffusion-weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus-induced	B-Chemical
neurotoxicity	B-Disease
.	O

Octreotide-induced	B-Chemical
hypoxemia	B-Disease
and	O
pulmonary	B-Disease
hypertension	I-Disease
in	O
premature	O
neonates	O
.	O

The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	B-Disease
complicating	O
necrotizing	B-Disease
enterocolitis	I-Disease
.	O

Pulmonary	B-Disease
hypertension	I-Disease
developed	O
after	O
administration	O
of	O
a	O
somatostatin	B-Drug
analogue	O
,	O
octreotide	B-Chemical
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	B-Disease
.	O

The	O
authors	O
discuss	O
the	O
mechanism	O
of	O
the	O
occurrence	O
of	O
this	O
complication	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high-risk	O
premature	O
neonates	O
.	O

Sequential	O
observations	O
of	O
exencephaly	B-Disease
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O

Anencephaly	B-Disease
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	B-Disease
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

We	O
examined	O
this	O
theory	O
using	O
the	O
exo	O
utero	O
development	O
system	O
that	O
allows	O
direct	O
and	O
sequential	O
observations	O
of	O
mid-	O
to	O
late-gestation	O
mouse	O
embryos	O
.	O

We	O
observed	O
the	O
exencephaly	B-Disease
induced	O
by	O
5-azacytidine	B-Chemical
at	O
embryonic	O
day	O
13.5	O
(	O
E13.5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18.5	O
,	O
and	O
re-observed	O
the	O
same	O
embryos	O
at	O
E18.5	O
.	O

We	O
confirmed	O
several	O
cases	O
of	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O

However	O
,	O
in	O
many	O
cases	O
,	O
the	O
exencephalic	B-Disease
brain	O
tissue	O
was	O
preserved	O
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	O
.	O

To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	O
the	O
exencephaly	B-Disease
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	B-Disease
tissue	O
into	O
several	O
types	O
at	O
E13.5	O
and	O
E18.5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	B-Disease
tissue	O
was	O
not	O
simply	O
size-dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	B-Disease
at	O
E18.5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	B-Disease
tissue	O
at	O
E13.5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	B-Disease
at	O
E13.5	O
,	O
frequent	O
hemorrhaging	B-Disease
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	B-Disease
head	O
at	O
E15.5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	B-Disease
tissue	O
at	O
E18.5	O
.	O

From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	O
in	O
the	O
exencephalic	B-Disease
head	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	B-Disease
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	B-Disease
failure	I-Disease
and/or	O
hemorrhaging	B-Disease
in	O
various	O
parts	O
of	O
the	O
exencephalic	B-Disease
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O

Acute	O
cocaine-induced	B-Chemical
seizures	B-Disease
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	B-Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
cocaine	B-Chemical
.	O

Cocaine	B-Chemical
was	O
injected	O
ip	O
over	O
a	O
range	O
of	O
doses	O
(	O
50-100	O
mg/kg	O
)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes	O
.	O

Seizure	B-Disease
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	B-Disease
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	B-Disease
.	O

A	O
range	O
of	O
strain	O
specific	O
sensitivities	O
was	O
documented	O
with	O
A/J	O
and	O
SJL	O
mice	O
being	O
most	O
sensitive	O
and	O
C57BL/6J	O
most	O
resistant	O
.	O

DBA/2J	O
,	O
BALB/cByJ	O
and	O
NZW/LacJ	O
strains	O
exhibited	O
intermediate	O
sensitivity	O
.	O

EEG	O
recordings	O
were	O
made	O
in	O
SJL	O
,	O
A/J	O
and	O
C57BL/6J	O
mice	O
revealing	O
a	O
close	O
correspondence	O
between	O
electrical	O
activity	O
and	O
behavior	O
.	O

Additionally	O
,	O
levels	O
of	O
cocaine	B-Chemical
determined	O
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O

Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine-induced	B-Chemical
seizures	B-Disease
.	O

Microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
complicating	O
FK506	B-Chemical
(	O
tacrolimus	B-Chemical
)	O
therapy	O
.	O

We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
(	O
MAHA	B-Disease
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	B-Chemical
(	O
tacrolimus	B-Chemical
)	O
therapy	O
.	O

In	O
both	O
cases	O
,	O
discontinuation	O
of	O
FK506	B-Chemical
and	O
treatment	O
with	O
plasma	O
exchange	O
,	O
fresh	O
frozen	O
plasma	O
replacement	O
,	O
corticosteroids	B-Chemical
,	O
aspirin	B-Chemical
,	O
and	O
dipyridamole	B-Chemical
led	O
to	O
resolution	O
of	O
MAHA	B-Disease
.	O

In	O
one	O
patient	O
,	O
reintroduction	O
of	O
FK506	B-Chemical
led	O
to	O
rapid	O
recurrence	O
of	O
MAHA	B-Disease
.	O

FK506-associated	B-Chemical
MAHA	B-Disease
is	O
probably	O
rare	O
but	O
physicians	O
must	O
be	O
aware	O
of	O
this	O
severe	O
complication	O
.	O

In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature	O
,	O
FK506	B-Chemical
does	O
not	O
seem	O
to	O
cross-react	O
with	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CyA	B-Chemical
)	O
,	O
an	O
immuno-suppressive	O
drug	B-Drug
already	O
known	O
to	O
induce	O
MAHA	B-Disease
.	O

Variant	O
ventricular	B-Disease
tachycardia	I-Disease
in	O
desipramine	B-Chemical
toxicity	B-Disease
.	O

We	O
report	O
a	O
case	O
of	O
variant	O
ventricular	B-Disease
tachycardia	I-Disease
induced	O
by	O
desipramine	B-Chemical
toxicity	B-Disease
.	O

Unusual	O
features	O
of	O
the	O
arrhythmia	B-Disease
are	O
repetitive	O
group	O
beating	O
,	O
progressive	O
shortening	O
of	O
the	O
R-R	O
interval	O
,	O
progressive	O
widening	O
of	O
the	O
QRS	O
complex	O
with	O
eventual	O
failure	O
of	O
intraventricular	B-Disease
conduction	O
,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis	O
.	O

Recognition	O
of	O
variant	O
ventricular	B-Disease
tachycardia	I-Disease
is	O
important	O
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	O
ventricular	B-Disease
tachycardia	O
.	O

Desipramine-induced	B-Chemical
delirium	B-Disease
at	O
``	O
subtherapeutic	O
''	O
concentrations	O
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
patient	O
treated	O
with	O
low	O
dose	O
Desipramine	B-Chemical
developed	O
a	O
delirium	B-Disease
while	O
her	O
plasma	O
level	O
was	O
in	O
the	O
``	O
subtherapeutic	O
''	O
range	O
.	O

Delirium	B-Disease
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	O
drug	B-Drug
therapy	O
in	O
the	O
elderly	O
,	O
can	O
be	O
caused	O
by	O
tricyclics	O
with	O
low	O
anticholinergic	B-Drug
potency	O
.	O

Therapeutic	O
ranges	O
for	O
antidepressants	B-Chemical
that	O
have	O
been	O
derived	O
from	O
general	O
adult	O
population	O
studies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
elderly	O
.	O

Further	O
studies	O
of	O
specifically	O
elderly	O
patients	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
guidelines	O
for	O
drug	B-Drug
therapy	O
.	O

Mouse	O
strain-dependent	O
effect	O
of	O
amantadine	B-Chemical
on	O
motility	O
and	O
brain	O
biogenic	O
amines	B-Chemical
.	O

The	O
effect	O
of	O
amantadine	B-Chemical
hydrochloride	I-Chemical
,	O
injected	O
i.p	O
.	O

in	O
6	O
increments	O
of	O
100	O
mg/kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mouse	O
motility	O
and	O
whole	O
brain	O
content	O
of	O
selected	O
biogenic	O
amines	B-Chemical
and	O
major	O
metabolites	O
was	O
studied	O
in	O
4	O
strains	O
of	O
mice	O
.	O

These	O
were	O
the	O
albino	O
Sprague-Dawley	O
ICR	O
and	O
BALB/C	O
,	O
the	O
black	O
C57BL/6	O
and	O
the	O
brown	O
CDF-I	O
mouse	O
strains	O
.	O

Amantadine	B-Chemical
treatment	O
produced	O
a	O
biphasic	O
effect	O
on	O
mouse	O
motility	O
.	O

The	O
initial	O
dose	O
of	O
amantadine	B-Chemical
depressed	B-Disease
locomotor	O
activity	O
in	O
all	O
mouse	O
strains	O
studied	O
with	O
the	O
BALB/C	O
mice	O
being	O
the	O
most	O
sensitive	O
.	O

Subsequent	O
amantadine	B-Chemical
treatments	O
produced	O
enhancement	O
of	O
motility	O
from	O
corresponding	O
control	O
in	O
all	O
mouse	O
strains	O
with	O
the	O
BALB/C	O
mice	O
being	O
the	O
least	O
sensitive	O
.	O

The	O
locomotor	O
activity	O
was	O
decreased	O
from	O
corresponding	O
controls	O
in	O
all	O
strains	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mice	O
,	O
during	O
an	O
overnight	O
drug-free	O
period	O
following	O
the	O
fourth	O
amantadine	B-Chemical
treatment	O
.	O

Readministration	O
of	O
amantadine	B-Chemical
,	O
after	O
a	O
drug-free	O
overnight	O
period	O
,	O
increased	O
motility	I-Disease
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	I-Disease
the	O
BALB/C	O
mice	O
where	O
suppression	B-Disease
of	O
motility	O
occurred	O
.	O

Treatment	O
with	O
amantadine	B-Chemical
did	O
not	O
alter	O
whole	O
brain	O
dopamine	B-Chemical
levels	O
but	O
decreased	O
the	O
amounts	O
of	O
3,4-dihydroxyphenylacetic	B-Chemical
acid	I-Chemical
in	O
the	O
BALB/C	O
mice	O
compared	O
to	O
saline	O
control	O
.	O

Conversely	O
,	O
brain	O
normetanephrine	B-Chemical
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	B-Chemical
in	O
the	O
BALB/C	O
mice	O
.	O

The	O
results	O
suggest	O
a	O
strain-dependent	O
effect	O
of	O
amantadine	B-Chemical
on	O
motility	O
and	O
indicate	O
a	O
differential	O
response	O
to	O
the	O
acute	O
and	O
multiple	O
dose	O
regimens	O
used	O
.	O

The	O
BALB/C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	B-Chemical
.	O

The	O
biochemical	O
results	O
of	O
brain	O
biogenic	O
amines	B-Chemical
of	O
BALB/C	O
mouse	O
strain	O
suggest	O
a	O
probable	O
decrease	O
of	O
catecholamine	B-Chemical
turnover	O
rate	O
and/or	O
metabolism	O
by	O
monoamine	O
oxidase	O
and	O
a	O
resulting	O
increase	O
in	O
O-methylation	O
of	O
norepinephrine	B-Chemical
which	O
may	O
account	O
for	O
a	O
behavioral	B-Disease
depression	I-Disease
caused	O
by	O
amantadine	B-Chemical
in	O
the	O
BALB/C	O
mice	O
.	O

The	O
fluoroquinolones	B-Drug
for	O
urinary	O
tract	O
infections	O
:	O
a	O
review	O
.	O

The	O
fluoroquinolones	B-Drug
are	O
a	O
rapidly	O
growing	O
class	O
of	O
antibiotics	B-Drug
with	O
a	O
broad	O
spectrum	O
of	O
activity	O
against	O
gram-negative	O
and	O
some	O
gram-positive	O
aerobic	O
bacteria	O
.	O

These	O
agents	O
,	O
including	O
norfloxacin	B-Drug
,	O
ciprofloxacin	B-Drug
,	O
ofloxacin	B-Drug
,	O
enoxacin	B-Drug
,	O
and	O
lomefloxacin	B-Drug
,	O
have	O
been	O
extensively	O
studied	O
and	O
have	O
demonstrated	O
efficacy	O
and	O
safety	O
profiles	O
comparable	O
to	O
those	O
of	O
other	O
traditional	O
agents	O
for	O
the	O
treatment	O
of	O
complicated	O
or	O
uncomplicated	O
urinary	O
tract	O
infections	O
and	O
prostatitis	O
.	O

Advantages	O
offered	O
by	O
this	O
class	O
of	O
antibiotics	B-Drug
include	O
optimal	O
pharmacokinetics	O
,	O
effectiveness	O
against	O
multidrug-resistant	O
organisms	O
,	O
and	O
oral	O
administration	O
even	O
when	O
parenteral	O
antibiotics	B-Drug
are	O
generally	O
used	O
.	O

The	O
fluoroquinolones	B-Drug
are	O
also	O
extensively	O
used	O
in	O
urologic	O
surgery	O
.	O

Progestin-only	O
oral	O
contraception	O
:	O
a	O
comprehensive	O
review	O
.	O

In	O
order	O
to	O
provide	O
information	O
for	O
the	O
appropriate	O
package	O
insert	O
labeling	O
of	O
progestin-only	O
oral	O
contraceptives	O
(	O
POC	O
)	O
in	O
the	O
US	O
,	O
a	O
comprehensive	O
review	O
was	O
made	O
of	O
norgestrel	B-Drug
(	O
0.075	O
mg	O
)	O
and	O
norethindrone	B-Drug
(	O
0.35	O
mg	O
)	O
,	O
with	O
the	O
clinical	O
differences	O
indicated	O
where	O
applicable	O
.	O

The	O
goal	O
of	O
this	O
review	O
was	O
to	O
cite	O
primary	O
sources	O
for	O
virtually	O
all	O
research	O
specific	O
to	O
POPs	O
since	O
1975	O
.	O

Conclusions	O
and	O
the	O
types	O
of	O
studies	O
which	O
support	O
these	O
conclusions	O
are	O
given	O
for	O
each	O
major	O
section	O
.	O

The	O
introductory	O
chapter	O
discusses	O
the	O
advantages	O
and	O
disadvantages	O
of	O
POCs	O
and	O
the	O
magnitude	O
and	O
prevalence	O
of	O
their	O
use	O
.	O

Future	O
trends	O
are	O
also	O
predicted	O
.	O

Chapter	O
2	O
considers	O
the	O
mode	O
of	O
action	O
,	O
including	O
ovulation	O
prevention	O
;	O
suppression	O
of	O
midcycle	O
gonadotropin	O
peaks	O
;	O
changes	O
in	O
cervical	O
mucus	O
,	O
the	O
endometrium	O
,	O
and	O
the	O
fallopian	O
tubes	O
;	O
and	O
clinical	O
implications	O
.	O

Chapter	O
3	O
covers	O
pharmacology	O
(	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
potency	O
,	O
and	O
clinical	O
implications	O
)	O
.	O

The	O
next	O
chapter	O
presents	O
information	O
on	O
efficacy	O
and	O
pregnancy	O
outcomes	O
in	O
terms	O
of	O
pregnancy	O
rates	O
,	O
compliance	O
and	O
efficacy	O
,	O
ectopic	O
pregnancies	O
,	O
the	O
outcome	O
of	O
pregnancies	O
conceived	O
while	O
using	O
POCs	O
,	O
and	O
fertility	O
following	O
discontinuation	O
.	O

Chapter	O
5	O
focuses	O
on	O
metabolic	O
effects	O
,	O
specifically	O
lipid	O
metabolism	O
,	O
carbohydrate	O
metabolism	O
and	O
diabetes	O
,	O
coagulation	O
factors	O
,	O
and	O
blood	O
pressure	O
.	O

Cardiovascular	O
disease	O
is	O
considered	O
in	O
the	O
next	O
chapter	O
,	O
and	O
chapter	O
7	O
presents	O
findings	O
on	O
endometrial	O
,	O
ovarian	O
,	O
cervical	O
,	O
breast	O
,	O
and	O
other	O
cancers	O
.	O

A	O
host	O
of	O
other	O
medical	O
considerations	O
are	O
discussed	O
in	O
chapter	O
8	O
,	O
including	O
persistent	O
ovarian	O
follicles	O
;	O
reproductive	O
tract	O
infections	O
;	O
abnormal	O
vaginal	O
bleeding	O
;	O
uterine	O
fibroids	O
;	O
gestational	O
trophoblastic	O
disease	O
;	O
benign	O
breast	O
disease	O
;	O
diseases	O
of	O
the	O
liver	O
,	O
gallbladder	O
,	O
and	O
bowel	O
;	O
endocrine	O
dysfunction	O
;	O
epilepsy	O
;	O
bone	O
density	O
;	O
sickle	O
cell	O
disease	O
;	O
ocular	O
effects	O
;	O
surgery	O
;	O
and	O
overdose	O
.	O

The	O
last	O
4	O
chapters	O
cover	O
interactions	O
with	O
drugs	B-Drug
and	O
laboratory	O
tests	O
,	O
common	O
side	O
effects	O
,	O
breast	O
feeding	O
,	O
and	O
effective	O
use	O
of	O
POCs	O
.	O

Information	O
on	O
precautions	O
and	O
contraindications	O
,	O
indications	O
,	O
use	O
instructions	O
,	O
and	O
instructions	O
for	O
appropriate	O
actions	O
after	O
missing	O
a	O
pill	O
is	O
appended	O
.	O

Antimicrobial	O
activity	O
of	O
Ganoderma	B-Drug
lucidum	I-Drug
extract	I-Drug
alone	O
and	O
in	O
combination	O
with	O
some	O
antibiotics	B-Drug
.	O

Antimicrobial	O
activity	O
of	O
GL	B-Drug
(	O
the	O
aqueous	O
extract	O
from	O
the	O
carpophores	O
of	O
Ganoderma	O
lucidum	O
(	O
FR	O
)	O
KARST	O
)	O
was	O
tested	O
in	O
vitro	O
against	O
Gram	O
positive	O
and	O
Gram	O
negative	O
bacteria	O
by	O
serial	O
broth	O
dilution	O
method	O
,	O
and	O
the	O
antimicrobial	O
activity	O
was	O
expressed	O
by	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
.	O

Among	O
fifteen	O
species	O
of	O
bacteria	O
tested	O
,	O
the	O
antimicrobial	O
activity	O
of	O
GL	B-Drug
was	O
the	O
most	O
potent	O
against	O
Micrococcus	O
luteus	O
(	O
MIC	O
,	O
0.75	O
mg/ml	O
)	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
antimicrobial	O
combinations	O
of	O
GL	B-Drug
with	O
four	O
kinds	O
of	O
antibiotics	B-Drug
(	O
ampicillin	B-Drug
,	O
cefazolin	B-Drug
,	O
oxytetracycline	B-Drug
and	O
chloramphenicol	B-Drug
)	O
,	O
the	O
fractional	O
inhibitory	O
concentration	O
index	O
(	O
FICI	O
)	O
was	O
determined	O
by	O
checkerboard	O
assay	O
for	O
each	O
strain	O
.	O

The	O
antimicrobial	O
combinations	O
of	O
GL	B-Drug
with	O
four	O
antibiotics	B-Drug
resulted	O
in	O
additive	O
effect	O
in	O
most	O
instances	O
,	O
synergism	O
in	O
two	O
instances	O
,	O
and	O
antagonism	O
in	O
two	O
instances	O
.	O

Synergism	O
was	O
observed	O
when	O
GL	B-Drug
was	O
combined	O
with	O
cefazolin	B-Drug
against	O
Bacillus	O
subtilis	O
and	O
Klebsiella	O
oxytoca	O
.	O

Death	O
in	O
amphetamine	B-Drug
users	O
:	O
causes	O
and	O
rates	O
.	O

The	O
world	O
medical	O
literature	O
contains	O
43	O
reports	O
of	O
deaths	O
associated	O
with	O
amphetamines	B-Drug
in	O
a	O
35-year	O
period	O
.	O

These	O
included	O
seven	O
cerebrovascular	O
accidents	O
,	O
six	O
sudden	O
cardiac	O
deaths	O
,	O
three	O
cases	O
of	O
hyperpyrexia	O
,	O
eight	O
poisonings	O
of	O
uncertain	O
mechanism	O
and	O
seven	O
cases	O
of	O
medical	O
complications	O
of	O
intravenous	O
injection	O
;	O
the	O
remainder	O
were	O
of	O
uncertain	O
cause	O
.	O

In	O
contrast	O
,	O
in	O
Ontario	O
alone	O
,	O
in	O
1972	O
and	O
1973	O
there	O
were	O
26	O
deaths	O
in	O
amphetamine	B-Drug
users	O
,	O
of	O
which	O
16	O
were	O
due	O
to	O
accident	O
suicide	O
or	O
homicide	O
.	O

Of	O
the	O
remaining	O
cases	O
,	O
two	O
were	O
cardiac	O
,	O
two	O
hepatic	O
and	O
the	O
rest	O
were	O
mixed	O
drug	B-Drug
overdose	O
.	O

Pulmonary	O
granulomata	O
,	O
subacute	O
hepatitis	O
and	O
other	O
lesions	O
resulting	O
from	O
intravenous	O
drug	B-Drug
use	O
were	O
common	O
findings	O
at	O
autopsy	O
.	O

On	O
the	O
basis	O
of	O
the	O
estimated	O
number	O
of	O
regular	O
users	O
of	O
intravenous	O
amphetamine	B-Drug
in	O
Ontario	O
,	O
the	O
mortality	O
rate	O
in	O
such	O
users	O
is	O
at	O
least	O
four	O
times	O
as	O
high	O
as	O
in	O
the	O
general	O
population	O
of	O
the	O
same	O
age	O
,	O
and	O
is	O
comparable	O
to	O
that	O
in	O
alcoholics	O
and	O
heroin	B-Drug
addicts	O
.	O

However	O
,	O
the	O
absolute	O
number	O
of	O
alcohol-related	B-Drug
deaths	O
is	O
far	O
greater	O
than	O
the	O
number	O
of	O
deaths	O
in	O
amphetamine	B-Drug
or	O
heroin	B-Drug
users	O
.	O

Ascorbic	B-Drug
acid	I-Drug
and	O
the	O
common	O
cold	O
.	O

Evaluation	O
of	O
its	O
efficacy	O
and	O
toxicity	O
.	O

We	O
reviewed	O
the	O
clinical	O
data	O
relating	O
to	O
the	O
efficacy	O
and	O
safety	O
of	O
pharmacologic	O
doses	O
of	O
ascorbic	B-Drug
acid	I-Drug
in	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
common	O
cold	O
.	O

Although	O
one	O
study	O
tentatively	O
supports	O
the	O
hypothesis	O
that	O
such	O
doses	O
of	O
ascorbic	B-Drug
acid	I-Drug
may	O
be	O
efficacious	O
,	O
a	O
second	O
study	O
by	O
the	O
same	O
group	O
did	O
not	O
confirm	O
the	O
significant	O
findings	O
,	O
and	O
no	O
clear	O
,	O
reproducible	O
pattern	O
of	O
efficacy	O
has	O
emerged	O
from	O
the	O
review	O
of	O
all	O
the	O
evidence	O
.	O

Similarly	O
,	O
there	O
is	O
currently	O
little	O
adequate	O
evidence	O
on	O
either	O
the	O
presence	O
or	O
the	O
absence	O
of	O
serious	O
adverse	O
reactions	O
to	O
such	O
doses	O
of	O
ascorbic	B-Drug
acid	I-Drug
,	O
although	O
many	O
such	O
reactions	O
have	O
been	O
hypothesized	O
.	O

The	O
unrestricted	O
use	O
of	O
ascorbic	B-Drug
acid	I-Drug
for	O
these	O
purposes	O
can	O
not	O
be	O
advocated	O
on	O
the	O
basis	O
of	O
the	O
evidence	O
currently	O
available	O
.	O

Optimal	O
designs	O
for	O
the	O
individual	O
and	O
joint	O
exposure	O
general	O
logistic	O
regression	O
models	O
.	O

Interest	O
in	O
administering	O
compounds	O
in	O
combination	O
lies	O
both	O
in	O
enhancing	O
efficacious	O
effects	O
and	O
in	O
limiting	O
adverse	O
effects	O
.	O

Although	O
much	O
statistical	O
work	O
has	O
focused	O
on	O
developing	O
mathematical	O
functions	O
to	O
model	O
the	O
joint	O
dose-response	O
curves	O
,	O
relatively	O
little	O
work	O
exists	O
in	O
regard	O
to	O
designing	O
experiments	O
for	O
assessing	O
joint	O
action	O
.	O

A	O
variety	O
of	O
parametric	O
dose-response	O
models	O
based	O
on	O
either	O
the	O
normal	O
or	O
logistic	O
probability	O
distribution	O
have	O
been	O
proposed	O
in	O
the	O
literature	O
.	O

These	O
models	O
are	O
typically	O
nonlinear	O
in	O
the	O
parameters	O
,	O
and	O
as	O
such	O
,	O
a	O
nonlinear	O
weighted	O
least	O
squares	O
approach	O
can	O
be	O
employed	O
for	O
the	O
purpose	O
of	O
designing	O
experiments	O
.	O

The	O
approach	O
is	O
applicable	O
across	O
a	O
wide	O
variety	O
of	O
settings	O
commonly	O
associated	O
with	O
joint	O
action	O
data	O
,	O
including	O
continuous	O
and	O
discrete	O
responses	O
,	O
alternative	O
error	O
structures	O
,	O
and	O
nonzero	O
background	O
response	O
.	O

Further	O
,	O
designs	O
can	O
be	O
expressed	O
in	O
terms	O
of	O
proportionate	O
responses	O
associated	O
with	O
the	O
individual	O
compounds	O
rather	O
than	O
dose	O
levels	O
,	O
thereby	O
providing	O
for	O
results	O
that	O
are	O
applicable	O
across	O
compounds	O
.	O

As	O
a	O
precursor	O
to	O
this	O
effort	O
,	O
optimal	O
and	O
minimal	O
experimental	O
designs	O
for	O
the	O
case	O
in	O
which	O
a	O
single	O
compound	O
is	O
administered	O
have	O
also	O
been	O
developed	O
.	O

Although	O
the	O
proposed	O
methodology	O
for	O
deriving	O
experimental	O
designs	O
can	O
be	O
applied	O
to	O
any	O
nonlinear	O
regression	O
model	O
,	O
primary	O
focus	O
is	O
given	O
to	O
the	O
additive	O
and	O
nonadditive	O
independent	O
joint	O
action	O
(	O
IJA	O
)	O
models	O
for	O
individual	O
and	O
combined	O
exposures	O
proposed	O
by	O
Barton	O
,	O
Braunberg	O
,	O
and	O
Friedman	O
(	O
1	O
)	O
.	O

Differential	O
regulation	O
of	O
tyrosine	O
phosphorylation	O
in	O
tumor	O
cells	O
by	O
contortrostatin	B-Drug
,	O
a	O
homodimeric	O
disintegrin	O
,	O
and	O
monomeric	O
disintegrins	O
echistatin	B-Drug
and	O
flavoridin	B-Drug
.	O

The	O
homodimeric	O
disintegrin	O
contortrostatin	B-Drug
was	O
compared	O
directly	O
to	O
the	O
monomeric	O
disintegrins	O
echistatin	B-Drug
and	O
flavoridin	B-Drug
for	O
the	O
ability	O
to	O
affect	O
protein	O
tyrosine	O
phosphorylation	O
in	O
tumor	O
cells	O
.	O

It	O
was	O
observed	O
that	O
contortrostatin	B-Drug
had	O
a	O
dramatic	O
effect	O
on	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
several	O
proteins	O
in	O
T24	O
human	O
bladder	O
cancer	O
cells	O
,	O
including	O
robust	O
induction	O
of	O
phosphorylation	O
of	O
proteins	O
in	O
the	O
range	O
of	O
120-140	O
kDa	O
.	O

Echistatin	B-Drug
alone	O
had	O
no	O
effect	O
on	O
tyrosine	O
phosphorylation	O
in	O
T24	O
cells	O
,	O
but	O
dose-dependently	O
inhibits	O
the	O
effects	O
of	O
contortrostatin	B-Drug
when	O
both	O
are	O
added	O
simultaneously	O
.	O

Among	O
the	O
proteins	O
that	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
contortrostatin	B-Drug
treatment	O
is	O
CAS	O
,	O
a	O
130	O
kDa	O
adapter	O
protein	O
involved	O
in	O
integrin	O
signaling	O
.	O

Flavoridin	B-Drug
alone	O
was	O
found	O
to	O
have	O
no	O
effect	O
on	O
CAS	O
,	O
but	O
can	O
completely	O
block	O
contortrostatin-induced	B-Drug
phosphorylation	O
of	O
this	O
protein	O
in	O
MDA-MB-435	O
cells	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
homodimeric	O
structure	O
of	O
contortrostatin	B-Drug
functionally	O
distinguishes	O
it	O
from	O
other	O
monomeric	O
members	O
of	O
the	O
disintegrin	O
family	O
.	O

Modification	O
of	O
surface	O
histidine	O
residues	O
abolishes	O
the	O
cytotoxic	O
activity	O
of	O
Clostridium	B-Drug
difficile	I-Drug
toxin	I-Drug
A	I-Drug
.	O

Clostridium	B-Drug
difficile	I-Drug
toxin	I-Drug
A	I-Drug
displays	O
both	O
cytotoxic	O
and	O
enterotoxic	O
activities	O
.	O

It	O
has	O
recently	O
been	O
demonstrated	O
that	O
toxin	B-Drug
A	I-Drug
exerts	O
its	O
cytotoxic	O
effect	O
by	O
the	O
glucosylation	O
of	O
the	O
small	O
GTP-binding	O
proteins	O
of	O
the	O
Rho	O
family	O
.	O

Diethyl	B-Drug
pyrocarbonate	I-Drug
,	O
at	O
pH	O
7.0	O
,	O
was	O
used	O
to	O
chemically	O
modify	O
exposed	O
histidine	O
residues	O
on	O
toxin	B-Drug
A	I-Drug
.	O

Modification	O
of	O
toxin	B-Drug
A	I-Drug
with	O
diethyl	B-Drug
pyrocarbonate	I-Drug
abolished	O
both	O
its	O
cytotoxic	O
activity	O
and	O
the	O
ability	O
of	O
the	O
toxin	B-Drug
to	O
bind	O
Zn-Sepharose	O
gel	O
.	O

Treatment	O
of	O
toxin	B-Drug
A	I-Drug
with	O
[	O
(	O
14	O
)	O
C	O
]	O
-diethyl	B-Drug
pyrocarbonate	I-Drug
revealed	O
concentration	O
dependent	O
labelling	O
of	O
histidine	O
residues	O
on	O
the	O
toxin	B-Drug
molecules	O
.	O

The	O
effects	O
of	O
diethyl	B-Drug
pyrocarbonate	I-Drug
could	O
be	O
reversed	O
by	O
hydroxylamine	B-Drug
treatment	O
.	O

These	O
data	O
suggest	O
the	O
modified	O
histidine	O
residues	O
on	O
toxin	B-Drug
A	I-Drug
are	O
critical	O
to	O
its	O
cytotoxic	O
activity	O
.	O

Histidine	O
modification	O
had	O
no	O
effect	O
on	O
the	O
glucosyl	O
transferase	O
enzyme	O
activity	O
of	O
toxin	B-Drug
A	I-Drug
.	O

However	O
,	O
modification	O
abolished	O
the	O
'cold	O
'	O
binding	O
of	O
toxin	B-Drug
to	O
bovine	O
thyroglobulin	O
in	O
an	O
ELISA	O
and	O
reduced	O
ligand	O
binding	O
activity	O
in	O
a	O
rabbit	O
erythrocyte	O
haemagglutination	O
assay	O
.	O

The	O
data	O
suggest	O
that	O
the	O
histidine	O
residues	O
may	O
be	O
crucial	O
to	O
the	O
receptor-binding	O
activity	O
of	O
toxin	B-Drug
A	I-Drug
.	O

Exposed	O
histidines	O
on	O
toxin	B-Drug
A	I-Drug
are	O
available	O
for	O
zinc	B-Drug
chelation	O
,	O
and	O
these	O
have	O
been	O
exploited	O
in	O
the	O
development	O
of	O
a	O
novel	O
purification	O
protocol	O
for	O
toxin	B-Drug
A	I-Drug
using	O
zinc-chelating	B-Drug
chromatography	O
.	O

Note	O
:	O
dissolution	O
of	O
aerosol	O
particles	O
of	O
budesonide	B-Drug
in	O
Survanta	O
,	O
a	O
model	O
lung	O
surfactant	B-Drug
.	O

The	O
effect	O
of	O
a	O
pulmonary	O
surfactant	B-Drug
extract	O
from	O
bovine	O
lung	O
,	O
Survanta	O
,	O
on	O
the	O
dissolution	O
rate	O
of	O
aerosol	O
particles	O
of	O
budesonide	B-Drug
was	O
determined	O
.	O

Aerosol	O
particles	O
of	O
budesonide	B-Drug
were	O
generated	O
from	O
an	O
ethanol	B-Drug
solution	O
,	O
dried	O
,	O
and	O
collected	O
by	O
a	O
cascade	O
impactor	O
for	O
characterization	O
or	O
by	O
a	O
liquid	O
impinger	O
for	O
dissolution	O
experiments	O
.	O

Powder	O
x-ray	O
diffraction	O
,	O
differential	O
scanning	O
calorimetry	O
,	O
differential	O
thermal	O
analysis	O
,	O
and	O
scanning	O
electron	O
microscopy	O
were	O
used	O
to	O
characterize	O
the	O
aerosol	O
particles	O
and	O
starting	O
material	O
.	O

No	O
change	O
in	O
phase	O
was	O
detected	O
,	O
although	O
the	O
aerosol	O
particles	O
appeared	O
to	O
contain	O
residual	O
solvent	O
.	O

The	O
dissolution	O
rate	O
of	O
the	O
aerosol	O
particles	O
in	O
saline	O
was	O
low	O
and	O
variable	O
.	O

Survanta	O
increased	O
the	O
extent	O
of	O
dissolution	O
of	O
budesonide	B-Drug
in	O
proportion	O
to	O
the	O
added	O
concentration	O
,	O
which	O
was	O
also	O
verified	O
by	O
equilibrium	O
solubilization	O
studies	O
.	O

Survanta	O
also	O
increased	O
rate	O
of	O
dissolution	O
,	O
in	O
a	O
manner	O
similar	O
to	O
sodium	B-Drug
dodecyl	I-Drug
sulfate	I-Drug
.	O

Analysis	O
of	O
the	O
concentration	O
of	O
budesonide	B-Drug
following	O
ultracentrifugation	O
indicated	O
that	O
there	O
is	O
rapid	O
equilibration	O
of	O
budesonide	B-Drug
between	O
the	O
Survanta	O
and	O
aqueous	O
phase	O
.	O

These	O
results	O
show	O
that	O
lung	O
surfactant	B-Drug
has	O
the	O
potential	O
of	O
enhancing	O
the	O
rate	O
and	O
extent	O
of	O
dissolution	O
of	O
drugs	B-Drug
administered	O
to	O
the	O
lung	O
.	O

Activation	O
of	O
an	O
effector	O
immediate-early	O
gene	O
arc	O
by	O
methamphetamine	B-Drug
.	O

As	O
immediate-early	O
genes	O
(	O
IEGs	O
)	O
are	O
thought	O
to	O
play	O
a	O
critical	O
role	O
in	O
mediating	O
stimulus-induced	O
neural	O
plasticity	O
,	O
IEG	O
response	O
induced	O
by	O
methamphetamine	B-Drug
(	O
METH	B-Drug
)	O
has	O
been	O
characterized	O
to	O
define	O
the	O
changes	O
in	O
gene	O
expression	O
that	O
may	O
underlie	O
its	O
long-lasting	O
behavioral	O
effects	O
.	O

Although	O
activation	O
of	O
several	O
transcription	O
factor	O
IEGs	O
has	O
been	O
described	O
,	O
little	O
is	O
known	O
about	O
effector	O
IEGs	O
.	O

Here	O
,	O
we	O
have	O
examined	O
whether	O
METH	B-Drug
administration	O
affects	O
expression	O
of	O
an	O
effector	O
IEG	O
arc	O
(	O
activity-regulated	O
,	O
cytoskeleton-associated	O
)	O
that	O
encodes	O
a	O
protein	O
with	O
homology	O
to	O
spectrin	O
.	O

Using	O
in	O
situ	O
hybridization	O
,	O
we	O
observed	O
that	O
METH	B-Drug
caused	O
a	O
rapid	O
and	O
transient	O
dose-dependent	O
increase	O
in	O
arc	O
mRNA	O
level	O
in	O
the	O
striatum	O
and	O
cortex	O
that	O
was	O
abolished	O
by	O
pretreatment	O
with	O
the	O
specific	O
dopamine	B-Drug
D1	O
receptor	O
antagonist	O
SCH-23390	B-Drug
but	O
not	O
by	O
an	O
atypical	O
neuroleptic	B-Drug
clozapine	B-Drug
.	O

METH	B-Drug
induced	O
arc	O
mRNA	O
in	O
layers	O
IV	O
and	O
VI	O
of	O
the	O
cortex	O
which	O
dopamine	B-Drug
receptor	O
are	O
localized	O
to	O
.	O

These	O
results	O
suggest	O
that	O
D1	O
receptors	O
are	O
coupled	O
to	O
activation	O
of	O
arc	O
gene	O
,	O
which	O
may	O
be	O
involved	O
in	O
functional	O
or	O
structural	O
alterations	O
underlying	O
neural	O
plasticity	O
triggered	O
by	O
METH	B-Drug
.	O

The	O
effects	O
of	O
DCG-IV	B-Drug
and	O
L-CCG-1	B-Drug
upon	O
phencyclidine	B-Drug
(	O
PCP	B-Drug
)	O
-induced	O
locomotion	O
and	O
behavioral	O
changes	O
in	O
mice	O
.	O

The	O
behavioral	O
changes	O
of	O
mice	O
induced	O
by	O
acute	O
and	O
repeated	O
i.p	O
.	O

injection	O
of	O
phencyclidine	B-Drug
(	O
PCP	B-Drug
)	O
were	O
observed	O
by	O
measuring	O
locomotor	O
activity	O
and	O
stereotyped	O
behavior	O
.	O

Then	O
,	O
the	O
effects	O
of	O
metabotropic	O
glutamate	B-Drug
receptor	O
(	O
mGluR	O
)	O
agonists	O
,	O
DCG-IV	B-Drug
and	O
L-CCG-1	B-Drug
,	O
on	O
the	O
above	O
behavioral	O
changes	O
induced	O
by	O
PCP	B-Drug
were	O
found	O
.	O

The	O
effects	O
of	O
DCG-IV	B-Drug
were	O
very	O
strong	O
and	O
completely	O
depressed	O
the	O
PCP-induced	B-Drug
hyperlocomotion	O
.	O

The	O
effects	O
of	O
L-CCG-1	B-Drug
were	O
not	O
so	O
strong	O
.	O

Repeated	O
injection	O
of	O
PCP	B-Drug
for	O
20	O
days	O
into	O
mice	O
induced	O
lower	O
locomotor	O
activity	O
than	O
that	O
in	O
acutely	O
injected	O
mice	O
.	O

These	O
behavioral	O
changes	O
may	O
be	O
related	O
with	O
the	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

In	O
order	O
to	O
examine	O
some	O
molecular	O
mechanisms	O
of	O
PCP-induced	B-Drug
behavioral	O
changes	O
,	O
Northern	O
blot	O
analysis	O
of	O
total	O
RNA	O
from	O
prefrontal	O
cortical	O
tissues	O
of	O
mice	O
treated	O
with	O
PCP	B-Drug
,	O
DCG-IV	B-Drug
,	O
and	O
L-CCG-1	B-Drug
was	O
carried	O
out	O
.	O

Behavioral	O
responses	O
to	O
repeated	O
cocaine	B-Drug
exposure	O
in	O
mice	O
selectively	O
bred	O
for	O
differential	O
sensitivity	O
to	O
pentobarbital	B-Drug
.	O

Mice	O
from	O
the	O
20th	O
generation	O
of	O
three	O
lines	O
divergently	O
selected	O
for	O
response	O
to	O
pentobarbital-induced	B-Drug
sedation	O
times	O
[	O
long-sedation	O
time	O
(	O
LST	O
)	O
,	O
short	O
sedation	O
time	O
(	O
SST	O
)	O
,	O
and	O
randomly	O
bred	O
control	O
(	O
RBC	O
)	O
]	O
were	O
used	O
to	O
study	O
cocaine-induced	B-Drug
behavioral	O
sensitization	O
.	O

These	O
lines	O
showed	O
variable	O
degrees	O
of	O
locomotor	O
activities	O
in	O
response	O
to	O
cocaine	B-Drug
.	O

At	O
a	O
low	O
cocaine	B-Drug
dose	O
and	O
long	O
withdrawal	O
period	O
(	O
10	O
mg/kg	O
,	O
twice	O
a	O
day	O
for	O
5	O
days	O
followed	O
by	O
a	O
14-day	O
withdrawal	O
)	O
,	O
the	O
LST	O
mice	O
showed	O
tolerance	O
development	O
.	O

In	O
response	O
to	O
cocaine	B-Drug
,	O
the	O
locomotor	O
activities	O
of	O
the	O
SST	O
were	O
not	O
significantly	O
different	O
from	O
the	O
RBC	O
group	O
.	O

At	O
a	O
higher	O
dose	O
and	O
a	O
shorter	O
withdrawal	O
period	O
(	O
20	O
mg/kg	O
,	O
daily	O
for	O
7	O
days	O
followed	O
by	O
a	O
3-day	O
withdrawal	O
)	O
,	O
the	O
SST	O
mice	O
showed	O
behavioral	O
sensitization	O
similar	O
to	O
the	O
RBC	O
mice	O
,	O
but	O
the	O
LST	O
mice	O
did	O
not	O
develop	O
sensitization	O
.	O

The	O
different	O
responses	O
in	O
locomotor	O
activity	O
induced	O
by	O
cocaine	B-Drug
suggest	O
that	O
genetic	O
factors	O
may	O
play	O
a	O
role	O
in	O
determining	O
the	O
magnitude	O
of	O
response	O
to	O
this	O
drug	B-Drug
.	O

Dopamine	B-Drug
(	O
DA	O
)	O
levels	O
did	O
not	O
differ	O
significantly	O
in	O
either	O
striatum	O
(	O
STR	O
)	O
or	O
nucleus	O
accumbens	O
(	O
NAC	O
)	O
for	O
the	O
cocaine-treated	B-Drug
animals	O
to	O
their	O
corresponding	O
saline-treated	O
controls	O
.	O

The	O
affinity	O
(	O
Kd	O
)	O
of	O
D2	O
in	O
the	O
NAC	O
decreased	O
significantly	O
,	O
without	O
changes	O
in	O
density	O
(	O
Bmax	O
)	O
,	O
in	O
the	O
cocaine-treated	B-Drug
SST	O
and	O
RBC	O
mice	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
density	O
of	O
D2	O
binding	O
sites	O
in	O
the	O
SST	O
and	O
the	O
RBC	O
mice	O
in	O
the	O
STR	O
was	O
significantly	O
increased	O
in	O
cocaine-treated	B-Drug
groups	O
without	O
change	O
in	O
Kd	O
.	O

The	O
LST	O
mice	O
did	O
not	O
show	O
any	O
changes	O
in	O
the	O
Kd	O
and	O
Bmax	O
in	O
either	O
the	O
STR	O
or	O
the	O
NAC	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
changes	O
in	O
the	O
Kd	O
of	O
D2	O
in	O
the	O
NAC	O
and	O
the	O
Bmax	O
of	O
D2	O
in	O
the	O
STR	O
may	O
contribute	O
to	O
the	O
differences	O
in	O
locomotor	O
responses	O
to	O
cocaine	B-Drug
exposure	O
in	O
these	O
mouse	O
lines	O
.	O

18-Methoxycoronaridine	B-Drug
(	O
18-MC	B-Drug
)	O
and	O
ibogaine	B-Drug
:	O
comparison	O
of	O
antiaddictive	O
efficacy	O
,	O
toxicity	O
,	O
and	O
mechanisms	O
of	O
action	O
.	O

18-MC	B-Drug
,	O
a	O
novel	O
iboga	O
alkaloid	O
congener	O
,	O
is	O
being	O
developed	O
as	O
a	O
potential	O
treatment	O
for	O
multiple	O
forms	O
of	O
drug	B-Drug
abuse	O
.	O

Like	O
ibogaine	B-Drug
(	O
40	O
mg/kg	O
)	O
,	O
18-MC	B-Drug
(	O
40	O
mg/kg	O
)	O
decreases	O
the	O
intravenous	O
self-administration	O
of	O
morphine	B-Drug
and	O
cocaine	B-Drug
and	O
the	O
oral	O
self-administration	O
of	O
ethanol	B-Drug
and	O
nicotine	B-Drug
in	O
rats	O
;	O
unlike	O
ibogaine	B-Drug
,	O
18-MC	B-Drug
does	O
not	O
affect	O
responding	O
for	O
a	O
nondrug	O
reinforcer	O
(	O
water	O
)	O
.	O

Both	O
ibogaine	B-Drug
and	O
18-MC	B-Drug
ameliorate	O
opioid	O
withdrawal	O
signs	O
.	O

Both	O
ibogaine	B-Drug
and	O
18-MC	B-Drug
decrease	O
extracellular	O
levels	O
of	O
dopamine	B-Drug
in	O
the	O
nucleus	O
accumbens	O
,	O
but	O
only	O
ibogaine	B-Drug
increases	O
extracellular	O
levels	O
of	O
serotonin	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Both	O
ibogaine	B-Drug
and	O
18-MC	B-Drug
block	O
morphine-induced	B-Drug
and	O
nicotine-induced	B-Drug
dopamine	B-Drug
release	O
in	O
the	O
nucleus	O
accumbens	O
;	O
only	O
ibogaine	B-Drug
enhances	O
cocaine-induced	B-Drug
increases	O
in	O
accumbal	O
dopamine	B-Drug
.	O

Both	O
ibogaine	B-Drug
and	O
18-MC	B-Drug
enhance	O
the	O
locomotor	O
and/or	O
stereotypic	O
effects	O
of	O
stimulants	O
.	O

Ibogaine	B-Drug
attenuates	O
,	O
but	O
18-MC	B-Drug
potentiates	O
,	O
the	O
acute	O
locomotor	O
effects	O
of	O
morphine	B-Drug
;	O
both	O
compounds	O
attenuate	O
morphine-induced	B-Drug
locomotion	O
in	O
morphine-experienced	B-Drug
rats	O
.	O

Ibogaine	B-Drug
produces	O
whole	O
body	O
tremors	O
and	O
,	O
at	O
high	O
doses	O
(	O
>	O
or	O
=	O
100	O
mg/kg	O
)	O
,	O
cerebellar	O
damage	O
;	O
18-MC	B-Drug
does	O
not	O
produce	O
these	O
effects	O
.	O

Ibogaine	B-Drug
,	O
but	O
not	O
18-MC	B-Drug
,	O
decreases	O
heart	O
rate	O
at	O
high	O
doses	O
.	O

While	O
18-MC	B-Drug
and	O
ibogaine	B-Drug
have	O
similar	O
affinities	O
for	O
kappa	O
opioid	O
and	O
possibly	O
nicotinic	O
receptors	O
,	O
18-MC	B-Drug
has	O
much	O
lower	O
affinities	O
than	O
ibogaine	B-Drug
for	O
NMDA	O
and	O
sigma-2	O
receptors	O
,	O
sodium	O
channels	O
,	O
and	O
the	O
5-HT	O
transporter	O
.	O

Both	O
18-MC	B-Drug
and	O
ibogaine	B-Drug
are	O
sequestered	O
in	O
fat	O
and	O
,	O
like	O
ibogaine	B-Drug
,	O
18-MC	B-Drug
probably	O
has	O
an	O
active	O
metabolite	O
.	O

The	O
data	O
suggest	O
that	O
18-MC	B-Drug
has	O
a	O
narrower	O
spectrum	O
of	O
actions	O
and	O
will	O
have	O
a	O
substantially	O
greater	O
therapeutic	O
index	O
than	O
ibogaine	B-Drug
.	O

Clinical	O
implications	O
of	O
warfarin	B-Drug
interactions	O
with	O
five	O
sedatives	O
.	O

The	O
intensity	O
,	O
uniformity	O
and	O
time	O
course	O
of	O
anticoagulant	B-Drug
interference	O
by	O
phenobarbital	B-Drug
,	O
secobarbital	B-Drug
,	O
glutethimide	B-Drug
,	O
chloral	B-Drug
hydrate	I-Drug
and	O
methaqualone	B-Drug
were	O
systematically	O
investigated	O
in	O
16	O
patients	O
receiving	O
coumarin	O
therapy	O
.	O

Each	O
subject	O
received	O
an	O
individualized	O
fixed	O
daily	O
dose	O
of	O
warfarin	B-Drug
and	O
served	O
as	O
his	O
own	O
pre-	O
and	O
postsedative	O
treatment	O
control	O
.	O

Prothrombin	O
times	O
were	O
measured	O
four	O
times	O
weekly	O
during	O
five	O
long-term	O
experiments	O
.	O

Anticoagulant	B-Drug
inhibition	O
was	O
observed	O
during	O
the	O
administration	O
of	O
phenobarbital	B-Drug
,	O
secobarbital	B-Drug
and	O
glutethimide	B-Drug
;	O
there	O
was	O
no	O
significant	O
change	O
in	O
prothrombin	O
test	O
results	O
during	O
the	O
trials	O
of	O
chloral	B-Drug
hydrate	I-Drug
and	O
methaqualone	B-Drug
.	O

Barbiturates	B-Drug
and	O
glutethimide	B-Drug
should	O
not	O
be	O
administered	O
to	O
patients	O
receiving	O
coumarin	O
drugs	B-Drug
.	O

The	O
concurrent	O
use	O
of	O
drugs	B-Drug
from	O
these	O
groups	O
is	O
decreasing	O
according	O
to	O
a	O
survey	O
of	O
200	O
hospital	O
medical	O
records	O
.	O

Chloral	B-Drug
hydrate	I-Drug
and	O
methaqualone	B-Drug
interact	O
pharmacologically	O
with	O
orally	O
administered	O
anticoagulant	B-Drug
agents	O
,	O
but	O
the	O
effect	O
is	O
not	O
clinically	O
significant	O
.	O

It	O
is	O
concluded	O
that	O
chloral	B-Drug
hydrate	I-Drug
and	O
methaqualone	B-Drug
may	O
be	O
administered	O
safely	O
without	O
additional	O
caution	O
in	O
prothrombin	O
test	O
monitoring	O
during	O
oral	O
anticoagulant	B-Drug
therapy	O
.	O

Effects	O
of	O
low	O
temperatures	O
on	O
microtubules	O
in	O
the	O
non-myelinated	O
axons	O
of	O
post-ganglionic	O
sympathetic	O
nerves	O
.	O

The	O
effect	O
of	O
temperature	O
changes	O
on	O
the	O
number	O
of	O
microtubules	O
in	O
non-myelinated	O
axons	O
has	O
been	O
studied	O
in	O
cat	O
inferior	O
mesenteric	O
ganglion/hypogastric	O
nerve	O
preparations	O
incubated	O
at	O
various	O
temperatures	O
in	O
Eagles	O
minimal	O
essential	O
tissue	O
culture	O
medium	O
in	O
vitro	O
.	O

At	O
37	O
degrees	O
C	O
the	O
non-myelinated	O
axons	O
contained	O
28.4	O
plus	O
or	O
minus	O
0.8	O
S.E.M	O
.	O

(	O
54	O
)	O
microtubules	O
per	O
axon	O
.	O

After	O
incubation	O
at	O
0	O
degrees	O
C	O
for	O
4	O
h	O
this	O
number	O
fell	O
to	O
2.3	O
plus	O
or	O
minus	O
0.1	O
S.E.M	O
.	O

(	O
41	O
)	O
but	O
returned	O
to	O
normal	O
levels	O
when	O
the	O
nerves	O
were	O
rewarmed	O
.	O

This	O
loss	O
of	O
microtubules	O
on	O
cooling	O
the	O
nerves	O
and	O
their	O
reappearance	O
on	O
rewarming	O
was	O
a	O
rapid	O
process	O
;	O
it	O
was	O
independent	O
of	O
the	O
influence	O
of	O
the	O
nueronal	O
cell	O
body	O
and	O
of	O
protein	O
synthesis	O
within	O
the	O
axon	O
.	O

The	O
preservation	O
of	O
the	O
microtubules	O
was	O
improved	O
when	O
D2O	O
was	O
present	O
in	O
the	O
incubation	O
medium	O
.	O

Reformed	O
microtubules	O
appeared	O
to	O
function	O
normally	O
with	O
respect	O
to	O
their	O
possible	O
role	O
in	O
the	O
transport	O
of	O
noradrenaline	B-Drug
storage	O
vesicles	O
along	O
the	O
axons	O
.	O

Serum	O
digoxin	B-Drug
levels	O
using	O
an	O
125I-labelled	O
antigen	O
:	O
Validation	O
of	O
method	O
and	O
observations	O
on	O
cardiac	O
patients	O
.	O

1	O
.	O

Determinations	O
of	O
serum	O
digoxin	B-Drug
levels	O
utilizing	O
commercially	O
available	O
kits	O
with	O
an	O
125I-labelled	O
antigen	O
were	O
precise	O
and	O
not	O
materially	O
different	O
from	O
results	O
obtained	O
with	O
a	O
3H-labelled	O
antigen	O
.	O

2	O
.	O

In	O
order	O
to	O
approximate	O
the	O
steady	O
state	O
level	O
,	O
serum	O
digoxin	B-Drug
levels	O
should	O
be	O
drawn	O
either	O
before	O
or	O
at	O
least	O
six	O
hours	O
following	O
the	O
administration	O
of	O
an	O
oral	O
tablet	O
.	O

3	O
.	O

Concomitantly	O
given	O
thiazide	O
diuretics	B-Drug
did	O
not	O
interfere	O
with	O
the	O
absorption	O
of	O
a	O
tablet	O
of	O
digoxin	B-Drug
.	O

4	O
.	O

In	O
the	O
digitalized	O
patient	O
,	O
slow	O
alterations	O
in	O
serum	O
levels	O
after	O
oral	O
administration	O
appeared	O
well	O
correlated	O
with	O
,	O
at	O
least	O
,	O
the	O
negative	O
chronotropic	O
effects	O
of	O
the	O
drug	B-Drug
.	O

5	O
.	O

Maximal	O
exercise	O
testing	O
,	O
a	O
maneuver	O
often	O
applied	O
to	O
cardiac	O
patients	O
,	O
does	O
not	O
significantly	O
alter	O
the	O
serum	O
digoxin	B-Drug
level	O
.	O

Combinations	O
of	O
clozapine	B-Drug
and	O
phencyclidine	B-Drug
:	O
effects	O
on	O
drug	B-Drug
discrimination	O
and	O
behavioral	O
inhibition	O
in	O
rats	O
.	O

Phencyclidine	B-Drug
(	O
PCP	B-Drug
)	O
produces	O
psychotomimetic	O
effects	O
in	O
humans	O
that	O
resemble	O
schizophrenia	O
symptoms	O
.	O

In	O
an	O
effort	O
to	O
screen	O
compounds	O
for	O
antipsychotic	O
activity	O
,	O
preclinical	O
researchers	O
have	O
investigated	O
whether	O
these	O
compounds	O
block	O
PCP-induced	B-Drug
behaviors	O
in	O
animals	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
atypical	O
antipsychotic	O
clozapine	B-Drug
was	O
tested	O
in	O
combination	O
with	O
an	O
active	O
dose	O
of	O
PCP	B-Drug
in	O
two-lever	O
drug	B-Drug
discrimination	O
and	O
mixed	O
signalled-unsignalled	O
differential-reinforcement-of-low-rates	O
(	O
DRL	O
)	O
procedures	O
.	O

PCP	B-Drug
produced	O
distinctive	O
effects	O
in	O
each	O
task	O
:	O
it	O
substituted	O
for	O
the	O
training	O
dose	O
in	O
PCP	B-Drug
discrimination	O
and	O
it	O
increased	O
the	O
number	O
of	O
responses	O
with	O
short	O
(	O
<	O
3	O
s	O
)	O
interresponse	O
times	O
as	O
well	O
as	O
increasing	O
overall	O
response	O
rates	O
in	O
the	O
DRL	O
schedule	O
.	O

Acute	O
dosing	O
with	O
clozapine	B-Drug
failed	O
to	O
alter	O
the	O
behavioral	O
effects	O
of	O
PCP	B-Drug
in	O
either	O
procedure	O
even	O
when	O
tested	O
up	O
to	O
doses	O
that	O
produced	O
pharmacological	O
effects	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
acute	O
dosing	O
with	O
clozapine	B-Drug
would	O
not	O
affect	O
behaviors	O
most	O
closely	O
associated	O
with	O
PCP	B-Drug
intoxication	O
.	O

Further	O
,	O
they	O
bring	O
into	O
question	O
the	O
utility	O
of	O
using	O
PCP	B-Drug
combination	O
procedures	O
in	O
animals	O
to	O
screen	O
for	O
antipsychotic	O
potential	O
.	O

Since	O
chronic	O
dosing	O
is	O
required	O
for	O
therapeutic	O
efficacy	O
of	O
antipsychotics	O
,	O
future	O
studies	O
should	O
focus	O
on	O
investigation	O
of	O
chronic	O
dosing	O
effects	O
of	O
these	O
drugs	B-Drug
in	O
combination	O
with	O
PCP	B-Drug
.	O

The	O
mechanism	O
of	O
resveratrol-induced	B-Drug
vasorelaxation	O
differs	O
in	O
the	O
mesenteric	O
resistance	O
arteries	O
of	O
lean	O
and	O
obese	O
rats	O
.	O

Resveratrol	B-Drug
has	O
been	O
shown	O
to	O
induce	O
vasorelaxation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
resveratrol-induced	B-Drug
vasorelaxation	O
in	O
resistance	O
mesenteric	O
arteries	O
from	O
male	O
lean	O
and	O
dietary-induced	O
obese	O
rats	O
.	O

Compared	O
with	O
lean	O
rats	O
,	O
arteries	O
from	O
dietary-obese	O
rats	O
showed	O
significant	O
(	O
P	O
<	O
0.001	O
)	O
endothelial	O
dysfunction	O
,	O
as	O
indicated	O
by	O
a	O
decrease	O
(	O
>	O
20	O
%	O
)	O
in	O
maximal	O
acetylcholine-induced	O
vasorelaxation	O
.	O

Resveratrol	B-Drug
(	O
5-35	O
micromol/l	O
)	O
induced	O
concentration-dependent	O
relaxation	O
of	O
mesenteric	O
arteries	O
preconstricted	O
with	O
noradrenaline	B-Drug
(	O
8	O
micromol/l	O
)	O
or	O
KCl	B-Drug
(	O
125	O
mmol/l	O
)	O
from	O
both	O
lean	O
and	O
dietary-obese	O
rats	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
achieving	O
a	O
maximum	O
relaxation	O
of	O
>	O
95	O
%	O
at	O
a	O
concentration	O
of	O
35	O
micromol/l	O
.	O

However	O
,	O
L-NAME	B-Drug
(	O
100	O
and	O
300	O
micromol/l	O
)	O
did	O
not	O
alter	O
the	O
effects	O
of	O
reseveratrol	B-Drug
on	O
arteries	O
from	O
dietary-obese	O
rats	O
,	O
giving	O
superimposed	O
concentration-responses	O
curves	O
.	O

Indomethacin	B-Drug
was	O
also	O
ineffective	O
in	O
altering	O
resveratrol	B-Drug
activity	O
in	O
arteries	O
from	O
both	O
lean	O
and	O
dietary-obese	O
rats	O
.	O

In	O
noradrenaline-precontracted	B-Drug
arteries	O
from	O
dietary-obese	O
rats	O
,	O
responses	O
to	O
resveratrol	B-Drug
were	O
not	O
attenuated	O
by	O
endothelial	O
denudation	O
,	O
indicating	O
an	O
action	O
independent	O
of	O
the	O
endothelium	O
.	O

This	O
study	O
indicates	O
that	O
:	O
(	O
a	O
)	O
the	O
maximal	O
effects	O
of	O
resveratrol	B-Drug
on	O
resistance	O
arteries	O
from	O
lean	O
and	O
dietary-obese	O
rats	O
are	O
not	O
effected	O
by	O
endothelial	O
dysfunction	O
,	O
and	O
(	O
b	O
)	O
the	O
effects	O
of	O
resveratrol	B-Drug
in	O
lean	O
animals	O
(	O
where	O
endothelial	O
function	O
is	O
not	O
impaired	O
)	O
,	O
but	O
not	O
in	O
dietary-obese	O
rats	O
,	O
are	O
mediated	O
via	O
NO	O
.	O

If	O
taken	O
1	O
hour	O
before	O
indinavir	B-Drug
(	O
IDV	B-Drug
)	O
,	O
didanosine	B-Drug
does	O
not	O
affect	O
IDV	B-Drug
exposure	O
,	O
despite	O
persistent	O
buffering	O
effects	O
.	O

Concurrent	O
administration	O
of	O
indinavir	B-Drug
and	O
didanosine	B-Drug
significantly	O
reduces	O
the	O
level	O
of	O
exposure	O
to	O
indinavir	B-Drug
,	O
but	O
it	O
is	O
unclear	O
how	O
soon	O
after	O
didanosine	B-Drug
administration	O
indinavir	B-Drug
may	O
be	O
given	O
safely	O
.	O

We	O
compared	O
indinavir	B-Drug
pharmacokinetics	O
and	O
gastric	O
pH	O
in	O
12	O
human	O
immunodeficiency	O
virus-positive	O
patients	O
by	O
use	O
of	O
800	O
mg	O
of	O
indinavir	B-Drug
alone	O
versus	O
800	O
mg	O
of	O
indinavir	B-Drug
administered	O
1	O
h	O
after	O
didanosine	B-Drug
administration	O
.	O

Median	O
gastric	O
pH	O
was	O
significantly	O
higher	O
when	O
indinavir	B-Drug
was	O
taken	O
after	O
didanosine	B-Drug
administration	O
;	O
however	O
,	O
no	O
significant	O
difference	O
in	O
the	O
maximum	O
concentration	O
in	O
plasma	O
or	O
the	O
area	O
under	O
the	O
concentration-time	O
curve	O
from	O
time	O
zero	O
to	O
8	O
h	O
was	O
observed	O
.	O

Indinavir	B-Drug
may	O
be	O
taken	O
with	O
a	O
light	O
meal	O
1	O
h	O
following	O
the	O
administration	O
of	O
400	O
mg	O
of	O
didanosine	B-Drug
.	O

A	O
proposed	O
mechanism	O
for	O
the	O
potentiation	O
of	O
cAMP-mediated	O
acid	O
secretion	O
by	O
carbachol	B-Drug
.	O

Acid	O
secretion	O
in	O
isolated	O
rabbit	O
gastric	O
glands	O
was	O
monitored	O
by	O
the	O
accumulation	O
of	O
[	O
(	O
14	O
)	O
C	O
]	O
aminopyrine	B-Drug
.	O

Stimulation	O
of	O
the	O
glands	O
with	O
carbachol	B-Drug
synergistically	O
augmented	O
the	O
response	O
to	O
dibutyryl	O
cAMP	O
.	O

The	O
augmentation	O
persisted	O
even	O
after	O
carbachol	B-Drug
was	O
washed	O
out	O
and	O
was	O
resistant	O
to	O
chelated	O
extracellular	O
Ca	O
(	O
2+	O
)	O
and	O
to	O
inhibitors	O
of	O
either	O
protein	O
kinase	O
C	O
or	O
calmodulin	O
kinase	O
II	O
.	O

Cytochalasin	B-Drug
D	I-Drug
at	O
10	O
microM	O
preferentially	O
blocked	O
the	O
secretory	O
effect	O
of	O
carbachol	B-Drug
and	O
its	O
synergism	O
with	O
cAMP	O
,	O
whereas	O
it	O
had	O
no	O
effect	O
on	O
histamine-	O
or	O
cAMP-stimulated	O
acid	O
secretion	O
within	O
15	O
min	O
.	O

Cytochalasin	B-Drug
D	I-Drug
inhibited	O
the	O
carbachol-stimulated	B-Drug
intracellular	O
Ca	O
(	O
2+	O
)	O
concentration	O
(	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
(	O
i	O
)	O
)	O
increase	O
due	O
to	O
release	O
from	O
the	O
Ca	O
(	O
2+	O
)	O
store	O
.	O

Treatment	O
of	O
the	O
glands	O
with	O
cytochalasin	B-Drug
D	I-Drug
redistributed	O
type	O
3	O
inositol	O
1,4,5-trisphosphate	O
receptor	O
(	O
the	O
major	O
subtype	O
in	O
the	O
parietal	O
cell	O
)	O
from	O
the	O
fraction	O
containing	O
membranes	O
of	O
large	O
size	O
to	O
the	O
microsomal	O
fraction	O
,	O
suggesting	O
a	O
dissociation	O
of	O
the	O
store	O
from	O
the	O
plasma	O
membrane	O
.	O

These	O
findings	O
suggest	O
that	O
intracellular	O
Ca	O
(	O
2+	O
)	O
release	O
by	O
cholinergic	O
stimulation	O
is	O
critical	O
for	O
determining	O
synergism	O
with	O
cAMP	O
in	O
parietal	O
cell	O
activation	O
and	O
that	O
functional	O
coupling	O
between	O
the	O
Ca	O
(	O
2+	O
)	O
store	O
and	O
the	O
receptor	O
is	O
maintained	O
by	O
actin	O
microfilaments	O
.	O

Interference	O
of	O
biocytin	O
with	O
opioid-evoked	O
hyperpolarization	O
and	O
membrane	O
properties	O
of	O
rat	O
spinal	O
substantia	O
gelatinosa	O
neurons	O
.	O

In	O
our	O
laboratory	O
,	O
preliminary	O
whole-cell	O
,	O
tight	O
seal	O
recordings	O
of	O
rat	O
spinal	O
substantia	O
gelatinosa	O
neurons	O
including	O
biocytin	O
in	O
the	O
patch	O
pipette	O
yielded	O
a	O
significantly	O
smaller	O
proportion	O
of	O
neurons	O
hyperpolarized	O
by	O
selective	O
opioid	O
agonists	O
compared	O
with	O
recordings	O
without	O
biocytin	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
biocytin	O
inclusion	O
on	O
opioid	O
responses	O
and	O
other	O
membrane	O
properties	O
during	O
whole-cell	O
,	O
tight	O
seal	O
recordings	O
of	O
these	O
neurons	O
.	O

The	O
percentage	O
of	O
neurons	O
hyperpolarized	O
by	O
mu-	O
,	O
delta	O
(	O
1	O
)	O
-	O
,	O
and	O
kappa-selective	O
opioids	O
was	O
significantly	O
reduced	O
when	O
1	O
%	O
but	O
not	O
<	O
or	O
=0.2	O
%	O
biocytin	O
was	O
included	O
in	O
the	O
recording	O
pipette	O
,	O
compared	O
with	O
neurons	O
recorded	O
without	O
biocytin	O
.	O

However	O
,	O
a	O
significantly	O
higher	O
proportion	O
of	O
neurons	O
fired	O
spontaneous	O
action	O
potentials	O
with	O
either	O
0.05-0.2	O
or	O
1	O
%	O
biocytin	O
compared	O
to	O
no	O
biocytin	O
.	O

Resting	O
membrane	O
potential	O
,	O
input	O
impedance	O
and	O
the	O
proportion	O
of	O
neurons	O
displaying	O
transient	O
outward	O
rectification	O
were	O
each	O
significantly	O
altered	O
for	O
neurons	O
recorded	O
with	O
1	O
%	O
but	O
not	O
0.05-0.2	O
%	O
biocytin	O
.	O

These	O
effects	O
may	O
be	O
due	O
to	O
a	O
relatively	O
specific	O
blockade	O
of	O
diverse	O
potassium	B-Drug
channel	O
types	O
.	O

Because	O
efficient	O
labeling	O
can	O
be	O
achieved	O
with	O
0.1	O
%	O
biocytin	O
with	O
whole-cell	O
recording	O
,	O
higher	O
concentrations	O
are	O
contraindicated	O
.	O

Increased	O
stability	O
of	O
nucleophosmin/B23	O
in	O
anti-apoptotic	O
effect	O
of	O
ras	O
during	O
serum	O
deprivation	O
.	O

We	O
obtained	O
evidence	O
that	O
increased	O
stability	O
of	O
nucleophosmin/B23	O
is	O
involved	O
in	O
antiapoptotic	O
effect	O
of	O
ras	O
during	O
serum	O
deprivation	O
.	O

Nucleophosmin/B23	O
in	O
serum-deprived	O
(	O
0	O
%	O
serum	O
)	O
NIH-3T3	O
cells	O
was	O
found	O
to	O
be	O
highly	O
unstable	O
with	O
a	O
half-life	O
less	O
than	O
4	O
h	O
.	O

In	O
contrast	O
,	O
nucleophosmin/B23	O
in	O
serum-deprived	O
ras-transformed	O
(	O
RAS-3T3	O
)	O
cells	O
was	O
as	O
stable	O
as	O
that	O
in	O
serum-supplemented	O
NIH-3T3	O
or	O
RAS-3T3	O
cells	O
.	O

Treatment	O
of	O
RAS-3T3	O
cells	O
with	O
nucleophosmin/B23	O
antisense	O
oligomer	O
significantly	O
potentiated	O
the	O
apoptosis	O
induced	O
by	O
serum	O
deprivation	O
.	O

Much	O
less	O
caspase-3	O
activity	O
was	O
noted	O
in	O
the	O
lysate	O
derived	O
from	O
serum-deprived	O
RAS-3T3	O
cells	O
compared	O
with	O
that	O
in	O
the	O
lysate	O
of	O
serum-deprived	O
NIH-3T3	O
cells	O
.	O

Cell	O
permeable	O
caspase-3	O
inhibitor	O
added	O
in	O
the	O
medium	O
blocked	O
the	O
decrease	O
of	O
nucleophosmin/B23	O
and	O
apoptosis	O
induced	O
by	O
serum	O
deprivation	O
in	O
NIH-3T3	O
cells	O
.	O

The	O
inhibitor	O
,	O
on	O
the	O
other	O
hand	O
,	O
promoted	O
significant	O
decrease	O
of	O
nucleolin/C23	O
in	O
NIH-3T3	O
cells	O
during	O
serum	O
deprivation	O
.	O

Unlike	O
nucleolin/C23	O
,	O
down-regulation	O
of	O
nucleophosmin/B23	O
was	O
thus	O
not	O
proliferation-dependent	O
but	O
caspase-3-	O
and	O
apoptosis-dependent	O
.	O

Our	O
results	O
indicate	O
important	O
relationships	O
among	O
ras	O
,	O
nucleophosmin/B23	O
,	O
activation	O
of	O
caspase-3	O
,	O
and	O
induction	O
of	O
apoptosis	O
.	O

Suppression	O
by	O
verapamil	B-Drug
of	O
bombesin-enhanced	B-Drug
peritoneal	O
metastasis	O
of	O
intestinal	O
adenocarcinomas	O
induced	O
by	O
azoxymethane	B-Drug
in	O
wistar	O
rats	O
.	O

BACKGROUND	O
:	O
The	O
effects	O
of	O
combined	O
administration	O
of	O
bombesin	B-Drug
and	O
verapamil	B-Drug
hydrochloride	I-Drug
(	O
verapamil	B-Drug
)	O
,	O
a	O
calcium	B-Drug
channel	O
blocker	O
,	O
on	O
the	O
incidence	O
of	O
peritoneal	O
metastasis	O
of	O
intestinal	O
adenocarcinomas	O
induced	O
by	O
azoxymethane	B-Drug
(	O
AOM	B-Drug
)	O
and	O
the	O
labeling	O
index	O
of	O
intestinal	O
cancers	O
were	O
investigated	O
in	O
male	O
Wistar	O
rats	O
.	O

METHODS	O
:	O
From	O
the	O
beginning	O
of	O
the	O
experiment	O
,	O
rats	O
were	O
given	O
10	O
weekly	O
subcutaneous	O
injections	O
of	O
AOM	B-Drug
(	O
7.4	O
mg/kg	O
body	O
weight	O
)	O
and	O
subcutaneous	O
injections	O
of	O
bombesin	B-Drug
(	O
40	O
microg/kg	O
body	O
weight	O
)	O
every	O
other	O
day	O
,	O
and	O
from	O
week	O
16	O
,	O
intraperitoneal	O
injections	O
of	O
verapamil	B-Drug
(	O
10	O
or	O
20	O
mg/kg	O
body	O
weight	O
)	O
every	O
other	O
day	O
until	O
the	O
end	O
fo	O
the	O
experiment	O
in	O
week	O
45	O
.	O

RESULTS	O
:	O
Bombesin	B-Drug
significantly	O
increased	O
the	O
incidence	O
of	O
intestinal	O
tumors	O
and	O
cancer	O
metastasis	O
to	O
the	O
peritoneum	O
.	O

Although	O
verapamil	B-Drug
administered	O
at	O
either	O
dose	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
enhancement	O
of	O
intestinal	O
carcinogenesis	O
by	O
bombesin	B-Drug
or	O
on	O
the	O
location	O
,	O
histologic	O
type	O
,	O
depth	O
of	O
involvement	O
,	O
labeling	O
index	O
,	O
apoptotic	O
index	O
or	O
tumor	O
vascularity	O
of	O
intestinal	O
cancers	O
,	O
it	O
significantly	O
decreased	O
the	O
incidence	O
of	O
cancer	O
metastasis	O
.	O

Verapamil	B-Drug
also	O
significantly	O
decreased	O
the	O
incidence	O
of	O
lymphatic	O
invasion	O
of	O
adenocarcinomas	O
,	O
which	O
was	O
enhanced	O
by	O
bombesin	B-Drug
.	O

CONCLUSION	O
:	O
These	O
findings	O
indicate	O
that	O
verapamil	B-Drug
inhibits	O
cancer	O
metastasis	O
through	O
actions	O
that	O
do	O
not	O
affect	O
the	O
growth	O
of	O
intestinal	O
cancers	O
.	O

In	O
vitro	O
interaction	O
of	O
prostaglandin	B-Drug
F2alpha	I-Drug
and	O
oxytocin	B-Drug
in	O
placental	O
vessels	O
.	O

The	O
interaction	O
of	O
prostaglandin	B-Drug
F2alpha	I-Drug
and	O
synthetic	O
oxytocin	B-Drug
on	O
placental	O
vessels	O
was	O
studied	O
in	O
vitro	O
.	O

Resistance	O
was	O
measured	O
near	O
the	O
placental	O
margin	O
after	O
spontaneous	O
term	O
delivery	O
.	O

In	O
seven	O
experiments	O
reactions	O
to	O
norepinephrine	B-Drug
and	O
oxytocin	B-Drug
were	O
PGF2alpha	B-Drug
.	O

PGF2alpha	B-Drug
produced	O
significantly	O
increased	O
vasoconstriction	O
after	O
a	O
single	O
administration	O
of	O
oxytocin	B-Drug
.	O

In	O
eight	O
experiments	O
the	O
perfusion	O
medium	O
contained	O
oxytocin	B-Drug
.	O

There	O
was	O
no	O
change	O
after	O
a	O
single	O
dose	O
of	O
PGF2alpha	B-Drug
.	O

The	O
reaction	O
after	O
norepinephrine	B-Drug
remained	O
the	O
same	O
in	O
both	O
groups	O
of	O
experiments	O
.	O

There	O
is	O
thus	O
an	O
enhancement	O
effect	O
There	O
is	O
thus	O
an	O
enhancement	O
effect	O
of	O
PGF2alpha	B-Drug
upon	O
the	O
reaction	O
of	O
placental	O
vessels	O
to	O
oxytocin	B-Drug
in	O
vitro	O
.	O

Carbamazepine	B-Drug
overdose	O
recognized	O
by	O
a	O
tricyclic	O
antidepressant	O
assay	O
.	O

Altered	O
mental	O
status	O
in	O
an	O
adolescent	O
presents	O
a	O
diagnostic	O
challenge	O
,	O
and	O
the	O
clinician	O
depends	O
on	O
clinical	O
evaluation	O
and	O
laboratory	O
studies	O
to	O
determine	O
therapy	O
and	O
prognosis	O
.	O

We	O
report	O
the	O
case	O
of	O
an	O
adolescent	O
with	O
altered	O
consciousness	O
caused	O
by	O
carbamazepine	B-Drug
overdose	O
with	O
a	O
positive	O
tricyclic	O
antidepressant	O
level	O
to	O
alert	O
clinicians	O
to	O
the	O
cross-reactivity	O
of	O
carbamazepine	B-Drug
with	O
a	O
toxicology	O
screen	O
for	O
tricyclic	O
antidepressants	B-Drug
.	O

Cypermethrin-induced	B-Drug
oxidative	O
stress	O
in	O
rat	O
brain	O
and	O
liver	O
is	O
prevented	O
by	O
vitamin	B-Drug
E	I-Drug
or	O
allopurinol	B-Drug
.	O

Considering	O
that	O
the	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
has	O
been	O
implicated	O
in	O
the	O
toxicity	O
of	O
various	O
pesticides	O
,	O
this	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
possibility	O
of	O
oxidative	O
stress	O
induction	O
by	O
cypermethrin	B-Drug
,	O
a	O
Type	B-Drug
II	I-Drug
pyrethroid	I-Drug
.	O

Either	O
single	O
(	O
170	O
mg/kg	O
)	O
or	O
repeated	O
(	O
75	O
mg/kg	O
per	O
day	O
for	O
5	O
days	O
)	O
oral	O
administration	O
of	O
cypermethrin	B-Drug
was	O
found	O
to	O
produce	O
significant	O
oxidative	O
stress	O
in	O
cerebral	O
and	O
hepatic	O
tissues	O
of	O
rats	O
,	O
as	O
was	O
evident	O
by	O
the	O
elevation	O
of	O
the	O
level	O
of	O
thiobarbituric	O
acid	O
reactive	O
substances	O
(	O
TBARS	O
)	O
in	O
both	O
tissues	O
,	O
either	O
4	O
or	O
24	O
h	O
after	O
treatment	O
.	O

Much	O
higher	O
changes	O
were	O
observed	O
in	O
liver	O
,	O
increasing	O
from	O
a	O
level	O
of	O
60	O
%	O
at	O
4	O
h	O
up	O
to	O
nearly	O
4	O
times	O
the	O
control	O
at	O
24	O
h	O
for	O
single	O
dose	O
.	O

Reduced	O
levels	O
(	O
up	O
to	O
20	O
%	O
)	O
of	O
total	O
glutathione	O
(	O
total	O
GSH	O
)	O
,	O
and	O
elevation	O
of	O
conjugated	O
dienes	O
(	O
approximately	O
60	O
%	O
in	O
liver	O
by	O
single	O
dose	O
at	O
4	O
h	O
)	O
also	O
indicated	O
the	O
presence	O
of	O
an	O
oxidative	O
insult	O
.	O

Glutathione-S-transferase	O
(	O
GST	O
)	O
activity	O
,	O
however	O
,	O
did	O
not	O
differ	O
from	O
control	O
values	O
for	O
any	O
dose	O
or	O
at	O
any	O
time	O
point	O
in	O
cerebral	O
and	O
hepatic	O
tissues	O
.	O

Pretreatment	O
of	O
rats	O
with	O
allopurinol	B-Drug
(	O
100	O
mg/kg	O
,	O
ip	O
)	O
or	O
Vitamin	B-Drug
E	I-Drug
(	O
100	O
mg/kg	O
per	O
day	O
,	O
ig	O
,	O
for	O
3	O
days	O
and	O
a	O
dose	O
of	O
40	O
mg/kg	O
on	O
the	O
4th	O
day	O
)	O
provided	O
significant	O
protection	O
against	O
the	O
elevation	O
of	O
TBARS	O
levels	O
in	O
cerebral	O
and	O
hepatic	O
tissues	O
,	O
induced	O
by	O
single	O
high	O
dose	O
of	O
oral	O
cypermethrin	B-Drug
administration	O
within	O
4	O
h	O
.	O

Thus	O
,	O
the	O
results	O
suggest	O
that	O
cypermethrin	B-Drug
exposure	O
of	O
rats	O
results	O
in	O
free	O
radical-mediated	O
tissue	O
damage	O
,	O
as	O
indicated	O
by	O
elevated	O
cerebral	O
and	O
hepatic	O
lipid	O
peroxidation	O
,	O
which	O
was	O
prevented	O
by	O
allopurinol	B-Drug
and	O
Vitamin	B-Drug
E	I-Drug
.	O

Effect	O
of	O
ginsenosides	B-Drug
on	O
voltage-dependent	O
Ca	O
(	O
2+	O
)	O
channel	O
subtypes	O
in	O
bovine	O
chromaffin	O
cells	O
.	O

In	O
previous	O
reports	O
we	O
have	O
shown	O
that	O
ginsenosides	B-Drug
inhibit	O
high	O
threshold	O
voltage-dependent	O
Ca	O
(	O
2+	O
)	O
channels	O
in	O
neuronal	O
cells	O
.	O

However	O
,	O
these	O
studies	O
did	O
not	O
show	O
whether	O
ginsenosides-induced	B-Drug
inhibition	O
of	O
Ca	O
(	O
2+	O
)	O
currents	O
discriminates	O
among	O
the	O
various	O
Ca	O
(	O
2+	O
)	O
channel	O
subtypes	O
,	O
although	O
it	O
is	O
known	O
that	O
there	O
are	O
at	O
least	O
five	O
different	O
Ca	O
(	O
2+	O
)	O
channel	O
subtypes	O
in	O
neuronal	O
cells	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
ginsenosides	B-Drug
on	O
high	O
threshold	O
voltage-dependent	O
Ca	O
(	O
2+	O
)	O
channel	O
subtypes	O
using	O
their	O
selective	O
Ca	O
(	O
2+	O
)	O
channel	O
blockers	O
nimodipine	B-Drug
(	O
L-type	O
)	O
,	O
omega-conotoxin	B-Drug
GVIA	I-Drug
(	O
N-type	O
)	O
,	O
or	O
omega-agatoxin	B-Drug
IVA	I-Drug
(	O
P-type	O
)	O
in	O
bovine	O
chromaffin	O
cells	O
.	O

We	O
could	O
observe	O
that	O
ginsenosides	B-Drug
inhibited	O
high	O
threshold	O
voltage-dependent	O
Ca	O
(	O
2+	O
)	O
currents	O
in	O
a	O
dose-dependent	O
manner	O
.	O

The	O
IC	O
(	O
50	O
)	O
was	O
about	O
120	O
microgram/ml	O
.	O

Nimodipine	B-Drug
had	O
no	O
effect	O
on	O
ginsenosides	B-Drug
response	O
.	O

These	O
data	O
suggest	O
that	O
ginsenosides	B-Drug
are	O
negatively	O
coupled	O
to	O
three	O
types	O
of	O
calcium	B-Drug
channels	O
in	O
bovine	O
chromaffin	O
cell	O
,	O
including	O
an	O
omega-conotoxin	B-Drug
GVIA-sensitive	I-Drug
(	O
N-type	O
)	O
channel	O
,	O
an	O
omega-agatoxin	B-Drug
IVA-sensitive	I-Drug
(	O
P-type	O
)	O
channel	O
and	O
nimodipine/omega-conotoxin	B-Drug
GVIA/omega-agatoxin	O
VIA-resistant	O
(	O
presumptive	O
Q-type	O
)	O
channel	O
.	O

Thus	O
,	O
the	O
selective	O
regulation	O
of	O
voltage-dependent	O
Ca	O
(	O
2+	O
)	O
subtypes	O
by	O
ginsenosides	B-Drug
in	O
bovine	O
chromaffin	O
cell	O
could	O
be	O
the	O
cellular	O
basis	O
of	O
antistress	O
effects	O
induced	O
by	O
ginseng	B-Drug
.	O

In	O
vitro	O
activity	O
of	O
KRM-1648	B-Drug
,	O
either	O
singly	O
or	O
in	O
combination	O
with	O
ofloxacin	B-Drug
,	O
against	O
Mycobacterium	O
ulcerans	O
.	O

The	O
antimicrobial	O
effect	O
of	O
a	O
benzoxazinorifamycin	B-Drug
,	O
KRM-1648	B-Drug
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
ofloxacin	B-Drug
,	O
was	O
evaluated	O
in	O
vitro	O
against	O
two	O
type	O
strains	O
and	O
six	O
clinical	O
isolates	O
of	O
Mycobacterium	O
ulcerans	O
.	O

Growth	O
of	O
M	O
.	O

ulcerans	O
was	O
measured	O
by	O
plate	O
counts	O
and	O
the	O
BACTEC	O
radiometric	O
method	O
.	O

The	O
minimal	O
inhibitory	O
concentration	O
as	O
well	O
as	O
minimal	O
bactericidal	O
concentration	O
of	O
KRM-1648	B-Drug
against	O
M	O
.	O

ulcerans	O
was	O
between	O
0.012	O
and	O
0.025	O
mg/l	O
,	O
while	O
corresponding	O
values	O
for	O
rifampicin	B-Drug
and	O
rifabutin	B-Drug
were	O
in	O
the	O
range	O
of	O
0.1-0.8	O
mg/l	O
and	O
0.1-0.4	O
mg/l	O
respectively	O
.	O

When	O
combined	O
with	O
ofloxacin	B-Drug
,	O
KRM-1648	B-Drug
exhibited	O
strong	O
synergistic	O
activity	O
while	O
only	O
additive	O
effects	O
were	O
observed	O
with	O
the	O
combination	O
of	O
rifampicin	B-Drug
(	O
or	O
rifabutin	B-Drug
)	O
and	O
ofloxacin	B-Drug
.	O

These	O
results	O
suggest	O
that	O
KRM-1648	B-Drug
has	O
a	O
great	O
potential	O
in	O
the	O
treatment	O
of	O
M	O
.	O

ulcerans	O
infection	O
.	O

Inhibitory	O
effects	O
of	O
ruthenium	B-Drug
red	I-Drug
on	O
inositol	O
1,4	O
,	O
5-trisphosphate-induced	O
responses	O
in	O
rat	O
megakaryocytes	O
.	O

The	O
effects	O
of	O
ruthenium	B-Drug
red	I-Drug
(	O
RR	B-Drug
)	O
on	O
inositol	B-Drug
1,4,5-trisphosphate	I-Drug
(	I-Drug
InsP	B-Drug
(	I-Drug
3	I-Drug
)	O
)	O
-induced	O
responses	O
were	O
studied	O
in	O
rat	O
bone	O
marrow	O
megakaryocytes	O
with	O
the	O
patch-clamp	O
whole-cell	O
recording	O
technique	O
in	O
combination	O
with	O
fura-2	O
microfluorometry	O
.	O

Internal	O
application	O
of	O
InsP	B-Drug
(	I-Drug
3	I-Drug
)	I-Drug
(	O
100	O
microM	O
)	O
increased	O
intracellular	O
Ca	O
(	O
2+	O
)	O
concentration	O
(	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
(	O
i	O
)	O
)	O
and	O
activated	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
K	O
(	O
+	O
)	O
current	O
.	O

Administering	O
InsP	B-Drug
(	I-Drug
3	I-Drug
)	I-Drug
together	O
with	O
RR	B-Drug
(	O
100-500	O
microM	O
)	O
inhibited	O
InsP	O
(	O
3	O
)	O
-induced	O
responses	O
(	O
both	O
Ca	O
(	O
2+	O
)	O
and	O
current	O
responses	O
)	O
in	O
a	O
dose-dependent	O
fashion	O
.	O

Pretreatment	O
of	O
megakaryocytes	O
with	O
extracellular	O
RR	B-Drug
(	I-Drug
50	O
microM	O
)	I-Drug
also	O
inhibited	O
InsP	B-Drug
(	I-Drug
3	O
)	O
-induced	O
responses	O
.	O

Intracellular	O
and	O
extracellular	O
application	O
of	O
RR	B-Drug
reduced	O
ADP-induced	O
increases	O
in	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
(	O
i	O
)	O
.	O

In	O
contrast	O
,	O
in	O
isolated	O
single	O
pancreatic	O
acinar	O
cells	O
,	O
RR	B-Drug
had	O
no	O
effect	O
on	O
InsP	B-Drug
(	I-Drug
3	I-Drug
)	I-Drug
-induced	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
site	O
of	O
the	O
inhibitory	O
action	O
of	O
RR	B-Drug
is	O
at	O
the	O
InsP	O
(	O
3	O
)	O
receptor	O
,	O
or	O
its	O
closely	O
associated	O
proteins	O
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
RR	B-Drug
is	O
a	O
useful	O
pharmacological	O
tool	O
with	O
which	O
to	O
examine	O
the	O
InsP	B-Drug
(	I-Drug
3	I-Drug
)	I-Drug
-mediated	O
responses	O
of	O
megakaryocytes	O
.	O

Effect	O
of	O
rofecoxib	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
in	O
healthy	O
volunteers	O
.	O

The	O
authors	O
examined	O
the	O
effect	O
of	O
the	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
inhibitor	O
,	O
rofecoxib	B-Drug
,	O
at	O
steady	O
state	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
following	O
a	O
single	O
dose	O
in	O
healthy	O
subjects	O
.	O

Each	O
healthy	O
subject	O
(	O
N	O
=	O
10	O
)	O
received	O
rofecoxib	B-Drug
(	O
75	O
mg	O
once	O
daily	O
)	O
or	O
placebo	O
for	O
11	O
days	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
balanced	O
,	O
two-period	O
crossover	O
study	O
.	O

A	O
single	O
0.5	O
mg	O
oral	O
dose	O
of	O
digoxin	B-Drug
elixir	O
was	O
administered	O
on	O
the	O
7th	O
day	O
of	O
each	O
11-day	O
period	O
.	O

Each	O
treatment	O
period	O
was	O
separated	O
by	O
14	O
to	O
21	O
days	O
.	O

Samples	O
for	O
plasma	O
and	O
urine	O
immunoreactive	O
digoxin	B-Drug
concentrations	O
were	O
collected	O
through	O
120	O
hours	O
following	O
the	O
digoxin	B-Drug
dose	O
.	O

No	O
statistically	O
significant	O
differences	O
between	O
treatment	O
groups	O
were	O
observed	O
for	O
any	O
of	O
the	O
calculated	O
digoxin	B-Drug
pharmacokinetic	O
parameters	O
.	O

For	O
digoxin	B-Drug
AUC	O
(	O
0-infinity	O
)	O
,	O
AUC	O
(	O
0-24	O
)	O
,	O
and	O
Cmax	O
,	O
the	O
geometric	O
mean	O
ratios	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
for	O
(	O
rofecoxib	B-Drug
+	O
digoxin/placebo	B-Drug
+	O
digoxin	B-Drug
)	O
were	O
1.04	O
(	O
0.94	O
,	O
1.14	O
)	O
,	O
1.02	O
(	O
0.94	O
,	O
1.09	O
)	O
,	O
and	O
1.00	O
(	O
0.91	O
,	O
1.10	O
)	O
,	O
respectively	O
.	O

The	O
digoxin	B-Drug
median	O
tmax	O
was	O
0.5	O
hours	O
for	O
both	O
treatments	O
.	O

The	O
harmonic	O
mean	O
elimination	O
half-life	O
was	O
45.7	O
and	O
43.4	O
hours	O
for	O
rofecoxib	B-Drug
+	O
digoxin	B-Drug
and	O
placebo	O
+	O
digoxin	B-Drug
treatments	O
,	O
respectively	O
.	O

Digoxin	B-Drug
is	O
eliminated	O
renally	O
.	O

The	O
mean	O
(	O
SD	O
)	O
cumulative	O
urinary	O
excretion	O
of	O
immunoreactive	O
digoxin	B-Drug
after	O
concurrent	O
treatment	O
with	O
rofecoxib	B-Drug
or	O
placebo	O
was	O
228.2	O
(	O
+/-	O
30.8	O
)	O
and	O
235.1	O
(	O
+/-	O
39.1	O
)	O
micrograms/120	O
hours	O
,	O
respectively	O
.	O

Transient	O
and	O
minor	O
adverse	O
events	O
occurred	O
with	O
similar	O
frequency	O
on	O
placebo	O
and	O
rofecoxib	B-Drug
treatments	O
,	O
and	O
no	O
treatment-related	O
pattern	O
was	O
apparent	O
.	O

Rofecoxib	B-Drug
did	O
not	O
influence	O
the	O
plasma	O
pharmacokinetics	O
or	O
renal	O
elimination	O
of	O
a	O
single	O
oral	O
dose	O
of	O
digoxin	B-Drug
.	O

Concomitant	O
cyclophosphamide	B-Drug
,	O
doxorubicin	B-Drug
,	O
vincristine	B-Drug
,	O
and	O
prednisone	B-Drug
chemotherapy	O
plus	O
highly	O
active	O
antiretroviral	O
therapy	O
in	O
patients	O
with	O
human	O
immunodeficiency	O
virus-related	O
,	O
non-Hodgkin	O
lymphoma	O
.	O

BACKGROUND	O
:	O
The	O
feasibility	O
and	O
efficacy	O
of	O
concomitant	O
chemotherapy	O
and	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
still	O
unknown	O
in	O
patients	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-related	O
malignancies	O
.	O

To	O
evaluate	O
the	O
impact	O
of	O
chemotherapy	O
plus	O
HAART	O
on	O
the	O
clinical	O
course	O
of	O
patients	O
with	O
HIV-related	O
,	O
systemic	O
,	O
non-Hodgkin	O
lymphoma	O
(	O
HIV-NHL	O
)	O
,	O
the	O
authors	O
compared	O
retrospectively	O
a	O
group	O
of	O
24	O
patients	O
with	O
HIV-NHL	O
who	O
were	O
treated	O
with	O
the	O
cyclophosphamide	B-Drug
,	O
doxorubicin	B-Drug
,	O
vincristine	B-Drug
,	O
and	O
prednisone	B-Drug
(	O
CHOP	O
)	O
chemotherapy	O
regimen	O
plus	O
HAART	O
with	O
a	O
group	O
of	O
80	O
patients	O
who	O
were	O
treated	O
with	O
CHOP	O
chemotherapy	O
or	O
a	O
CHOP-like	O
regimen	O
(	O
i.e.	O
,	O
cyclophosphamide	B-Drug
,	O
doxorubicin	B-Drug
,	O
teniposide	B-Drug
,	O
and	O
prednisone	B-Drug
with	O
vincristine	B-Drug
plus	O
bleomycin	B-Drug
)	O
without	O
receiving	O
antiretroviral	O
therapy	O
.	O

METHODS	O
:	O
All	O
patients	O
were	O
enrolled	O
in	O
two	O
sequential	O
trials	O
performed	O
at	O
the	O
Aviano	O
Cancer	O
Center	O
,	O
Italy	O
,	O
from	O
April	O
1988	O
to	O
December	O
1998	O
.	O

HAART	O
was	O
included	O
with	O
combination	O
therapy	O
from	O
January	O
1997	O
.	O

Antiretroviral	O
regimens	O
consisted	O
of	O
two	O
reverse	O
transcriptase	O
inhibitors	O
and	O
one	O
protease	O
inhibitor	O
.	O

RESULTS	O
:	O
The	O
two	O
treatment	O
groups	O
were	O
well	O
matched	O
with	O
regard	O
to	O
patient	O
demographics	O
,	O
NHL	O
characteristics	O
,	O
HIV	O
status	O
,	O
and	O
treatment	O
,	O
i.e.	O
,	O
the	O
number	O
of	O
cycles	O
and	O
chemotherapy	O
dose	O
.	O

The	O
response	O
rates	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Severe	O
anemia	O
(	O
Grade	O
3-4	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
criteria	O
)	O
was	O
significantly	O
greater	O
in	O
the	O
patients	O
who	O
received	O
CHOP-HAART	O
compared	O
with	O
the	O
patients	O
who	O
received	O
CHOP	O
alone	O
(	O
33	O
%	O
vs.	O
7	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.001	O
)	O
.	O

Leukopenia	O
was	O
similar	O
between	O
the	O
two	O
groups	O
,	O
but	O
colony	O
stimulating	O
factor	O
support	O
was	O
significantly	O
greater	O
in	O
the	O
CHOP-HAART	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
92	O
%	O
vs.	O
66	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.03	O
)	O
.	O

Seventeen	O
percent	O
of	O
CHOP-HAART	O
patients	O
developed	O
severe	O
autonomic	O
neurotoxicity	O
,	O
whereas	O
none	O
of	O
the	O
CHOP	O
patients	O
developed	O
neurotoxicity	O
(	O
P	O
=	O
0.002	O
)	O
.	O

At	O
similar	O
median	O
follow-up	O
,	O
opportunistic	O
infection	O
(	O
OI	O
)	O
rates	O
and	O
mortality	O
were	O
significantly	O
lower	O
in	O
the	O
CHOP-HAART	O
patients	O
than	O
in	O
the	O
CHOP	O
patients	O
(	O
18	O
%	O
vs.	O
52	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.05	O
;	O
and	O
38	O
%	O
vs.	O
85	O
%	O
,	O
respectively	O
;	O
P	O
=	O
0.001	O
)	O
.	O

The	O
median	O
survival	O
for	O
CHOP-HAART	O
patients	O
was	O
not	O
reached	O
,	O
whereas	O
the	O
medial	O
survival	O
of	O
CHOP	O
patients	O
was	O
7	O
months	O
(	O
P	O
=	O
0.03	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
CHOP	O
plus	O
HAART	O
is	O
feasible	O
and	O
may	O
reduce	O
the	O
morbidity	O
from	O
OIs	O
in	O
HIV-NHL	O
patients	O
.	O

However	O
,	O
careful	O
attention	O
must	O
be	O
directed	O
to	O
cross	O
toxicity	O
and	O
possible	O
pharmacokinetic	O
interactions	O
between	O
antiretroviral	O
and	O
antineoplastic	O
drugs	B-Drug
.	O

The	O
impact	O
of	O
the	O
combined	O
chemotherapy	O
plus	O
HAART	O
treatment	O
on	O
patient	O
survival	O
needs	O
urgently	O
to	O
be	O
evaluated	O
in	O
prospective	O
studies	O
.	O

Acute	O
effect	O
of	O
different	O
antidepressants	B-Drug
on	O
glycemia	O
in	O
diabetic	O
and	O
non-diabetic	O
rats	O
.	O

Diabetic	O
patients	O
have	O
a	O
20	O
%	O
higher	O
risk	O
of	O
depression	O
than	O
the	O
general	O
population	O
.	O

Treatment	O
with	O
antidepressant	O
drugs	B-Drug
can	O
directly	O
interfere	O
with	O
blood	O
glucose	B-Drug
levels	O
or	O
may	O
interact	O
with	O
hypoglycemic	O
agents	O
.	O

The	O
treatment	O
of	O
depression	O
in	O
diabetic	O
patients	O
must	O
take	O
into	O
account	O
variations	O
of	O
glycemic	O
levels	O
at	O
different	O
times	O
and	O
a	O
comparison	O
of	O
the	O
available	O
antidepressant	O
agents	O
is	O
important	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
interference	O
of	O
antidepressants	B-Drug
with	O
blood	O
glucose	B-Drug
levels	O
of	O
diabetic	O
and	O
non-diabetic	O
rats	O
.	O

In	O
a	O
first	O
experiment	O
,	O
male	O
adult	O
Wistar	O
rats	O
were	O
fasted	O
for	O
12	O
h	O
.	O

Imipramine	B-Drug
(	O
5	O
mg/kg	O
)	O
,	O
moclobemide	B-Drug
(	O
30	O
mg/kg	O
)	O
,	O
clonazepam	B-Drug
(	O
0.25	O
mg/kg	O
)	O
,	O
fluoxetine	B-Drug
(	O
20	O
mg/kg	O
)	O
sertraline	B-Drug
(	O
30	O
mg/kg	O
)	O
or	O
vehicle	O
was	O
administered	O
.	O

After	O
30	O
min	O
,	O
fasting	O
glycemia	O
was	O
measured	O
.	O

An	O
oral	O
glucose	B-Drug
overload	O
of	O
1	O
ml	O
of	O
a	O
50	O
%	O
glucose	B-Drug
solution	O
was	O
given	O
to	O
rats	O
and	O
blood	O
glucose	B-Drug
was	O
determined	O
after	O
30	O
,	O
60	O
and	O
90	O
min	O
.	O

Imipramine	B-Drug
and	O
clonazepam	B-Drug
did	O
not	O
change	O
fasting	O
or	O
overload	O
glycemia	O
.	O

Fluoxetine	B-Drug
and	O
moclobemide	B-Drug
increased	O
blood	O
glucose	B-Drug
at	O
different	O
times	O
after	O
the	O
glucose	B-Drug
overload	O
.	O

Sertraline	B-Drug
neutralized	O
the	O
increase	O
of	O
glycemia	O
induced	O
by	O
oral	O
glucose	B-Drug
overload	O
.	O

In	O
the	O
second	O
experiment	O
,	O
non-diabetic	O
and	O
streptozotocin-induced	O
diabetic	O
rats	O
were	O
fasted	O
,	O
and	O
the	O
same	O
procedures	O
were	O
followed	O
for	O
estimation	O
of	O
glucose	B-Drug
tolerance	O
30	O
min	O
after	O
glucose	B-Drug
overload	O
.	O

Again	O
,	O
sertraline	B-Drug
neutralized	O
the	O
increase	O
in	O
glycemia	O
after	O
glucose	B-Drug
overload	O
both	O
in	O
diabetic	O
and	O
non-diabetic	O
rats	O
.	O

These	O
data	O
raise	O
the	O
question	O
of	O
whether	O
sertraline	B-Drug
is	O
the	O
best	O
choice	O
for	O
prolonged	O
use	O
for	O
diabetic	O
individuals	O
,	O
because	O
of	O
its	O
antihyperglycemic	O
effects	O
.	O

Clonazepam	B-Drug
would	O
be	O
useful	O
in	O
cases	O
with	O
potential	O
risk	O
of	O
hypoglycemia	O
.	O

Activity	O
of	O
buforin	B-Drug
II	I-Drug
alone	O
and	O
in	O
combination	O
with	O
azithromycin	B-Drug
and	O
minocycline	B-Drug
against	O
Cryptosporidium	O
parvum	O
in	O
cell	O
culture	O
.	O

The	O
in	O
vitro	O
anti-cryptosporidial	O
activity	O
of	O
buforin	B-Drug
II	I-Drug
alone	O
and	O
in	O
combination	O
with	O
azithromycin	B-Drug
and	O
minocycline	B-Drug
was	O
investigated	O
.	O

Buforin	B-Drug
II	I-Drug
showed	O
moderate	O
activity	O
,	O
which	O
increased	O
with	O
increasing	O
concentration	O
to	O
55.7	O
%	O
suppression	O
of	O
growth	O
at	O
20	O
microM	O
.	O

Moreover	O
,	O
its	O
activity	O
was	O
enhanced	O
when	O
it	O
was	O
combined	O
with	O
either	O
azithromycin	B-Drug
or	O
minocycline	B-Drug
with	O
90	O
%	O
parasite	O
reduction	O
at	O
the	O
highest	O
concentration	O
tested	O
.	O

Buforin	B-Drug
II	I-Drug
may	O
be	O
active	O
in	O
inhibiting	O
Cryptosporidium	O
parvum	O
growth	O
in	O
vitro	O
upon	O
combination	O
with	O
either	O
azithromycin	B-Drug
or	O
minocycline	B-Drug
.	O

Effect	O
of	O
dofetillide	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O

The	O
effect	O
of	O
dofetilide	B-Drug
on	O
the	O
steady-state	O
pharmacokinetics	O
of	O
digoxin	B-Drug
was	O
evaluated	O
in	O
a	O
randomized	O
,	O
double-blind	O
study	O
.	O

Five	O
days	O
of	O
dofetilide	B-Drug
treatment	O
did	O
not	O
significantly	O
affect	O
steady-state	O
pharmacokinetic	O
variables	O
of	O
digoxin	B-Drug
compared	O
with	O
placebo	O
;	O
therefore	O
,	O
the	O
use	O
of	O
dofetilide	B-Drug
does	O
not	O
necessitate	O
an	O
adjustment	O
in	O
digoxin	B-Drug
dose	O
to	O
maintain	O
therapeutic	O
digoxin	B-Drug
levels	O
.	O

Anaesthesia	O
and	O
the	O
epileptic	O
pateint	O
.	O

A	O
review	O
.	O

A	O
review	O
is	O
presented	O
of	O
some	O
of	O
the	O
problems	O
that	O
may	O
arise	O
in	O
association	O
with	O
anaesthesia	O
for	O
epileptic	O
patients	O
.	O

There	O
is	O
the	O
possibility	O
of	O
precipitating	O
anticonvulsant	O
drug	B-Drug
toxicity	O
.	O

Numerous	O
drug	B-Drug
interactions	O
are	O
possible	O
with	O
some	O
anticonvulsant	O
agents	O
,	O
such	O
as	O
phenobarbitone	B-Drug
and	O
phenytoin	B-Drug
,	O
which	O
affect	O
hepatic	O
microsomal	O
enzyme	O
systems	O
.	O

There	O
is	O
the	O
risk	O
of	O
convulsions	O
occurring	O
in	O
susceptible	O
patients	O
following	O
the	O
use	O
of	O
the	O
new	O
anaesthetic	O
agents	O
which	O
are	O
capable	O
of	O
inducing	O
CNS	O
excitability	O
.	O

Interaction	O
of	O
ketamine	B-Drug
and	O
halothane	B-Drug
in	O
rats	O
.	O

The	O
interaction	O
of	O
intramuscularly	O
injected	O
ketamine	B-Drug
and	O
its	O
N-demethylated	O
metabolite	O
(	O
metabolite	O
I	O
)	O
with	O
halothane	B-Drug
was	O
evaluated	O
in	O
rats	O
.	O

Five	O
,	O
10	O
,	O
20	O
,	O
or	O
50	O
mg/kg	O
of	O
ketamine	B-Drug
alone	O
or	O
20	O
,	O
50	O
,	O
or	O
100	O
mg/kg	O
of	O
metabolite	O
I	O
alone	O
produced	O
less	O
than	O
10	O
minutes	O
of	O
hypnosis	O
.	O

However	O
,	O
halothane	B-Drug
anesthetic	B-Drug
requirement	O
(	O
i.e.	O
,	O
MAC	O
)	O
was	O
depressed	O
in	O
a	O
dose-dependent	O
fashion	O
as	O
much	O
as	O
56	O
%	O
1-2	O
hours	O
and	O
as	O
much	O
as	O
14	O
%	O
5-6	O
hours	O
after	O
injection	O
of	O
ketamine	B-Drug
,	O
50	O
mg/kg	O
,	O
im	O
.	O

The	O
reduction	O
in	O
MAC	O
was	O
correlated	O
with	O
brain	O
levels	O
of	O
ketamine	B-Drug
or	O
metabolite	O
I	O
,	O
suggesting	O
a	O
ketamine	B-Drug
:	O
metabolite	O
I	O
potency	O
ration	O
of	O
3:1	O
.	O

The	O
half-life	O
of	O
ketamine	B-Drug
in	O
plasma	O
and	O
brain	O
was	O
longer	O
in	O
the	O
presence	O
of	O
halothane	B-Drug
than	O
when	O
ketamine	B-Drug
was	O
given	O
alone	O
.	O

It	O
is	O
concluded	O
that	O
ketamine	B-Drug
is	O
not	O
a	O
short-acting	O
drug	B-Drug
and	O
that	O
concomitant	O
use	O
with	O
halothane	B-Drug
would	O
be	O
expected	O
to	O
prolong	O
further	O
the	O
duration	O
of	O
its	O
action	O
on	O
the	O
central	O
nervous	O
system	O
.	O

Rifampin	B-Drug
and	O
warfarin	B-Drug
:	O
a	O
drug	B-Drug
interaction	O
.	O

The	O
drug	B-Drug
interaction	O
between	O
warfarin	B-Drug
and	O
rifampin	B-Drug
is	O
not	O
well	O
known	O
.	O

Rifampin	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
warfarin	B-Drug
requirements	O
in	O
human	O
subjects	O
ingesting	O
these	O
agents	O
simultaneously	O
.	O

The	O
concomitant	O
administration	O
of	O
rifampin	B-Drug
and	O
warfarin	B-Drug
resulted	O
in	O
the	O
need	O
for	O
an	O
unusually	O
high	O
maintenance	O
dose	O
of	O
warfarin	B-Drug
(	O
20	O
mg	O
per	O
day	O
)	O
in	O
order	O
to	O
produce	O
a	O
therapeutic	O
effect	O
.	O

Withdrawal	O
of	O
rifampin	B-Drug
decreased	O
the	O
warfarin	B-Drug
requirement	O
by	O
50	O
%	O
.	O

This	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
ability	O
of	O
rifampin	B-Drug
to	O
induce	O
microsomal	O
enzymes	O
and	O
,	O
thus	O
,	O
the	O
catabolism	O
of	O
warfarin	B-Drug
.	O

The	O
effect	O
of	O
rifampin	B-Drug
on	O
the	O
warfarin	B-Drug
requirement	O
of	O
our	O
patient	O
appeared	O
to	O
be	O
maximal	O
5	O
to	O
7	O
days	O
after	O
the	O
initiation	O
of	O
rifampin	B-Drug
and	O
extended	O
a	O
similar	O
length	O
of	O
time	O
after	O
rifampin	B-Drug
withdrawal	O
.	O

This	O
interaction	O
appears	O
to	O
be	O
clinically	O
significant	O
.	O

Thiolated	B-Drug
carboxymethylcellulose	I-Drug
:	O
in	O
vitro	O
evaluation	O
of	O
its	O
permeation	O
enhancing	O
effect	O
on	O
peptide	O
drugs	B-Drug
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
sodium	B-Drug
carboxymethylcellulose	I-Drug
(	O
NaCMC	B-Drug
)	O
and	O
carboxymethylcellulose-cysteine	B-Drug
(	O
CMC-Cys	B-Drug
)	O
conjugates	O
on	O
the	O
intestinal	O
permeation	O
of	O
sodium	B-Drug
fluorescein	I-Drug
(	O
NaFlu	B-Drug
)	O
and	O
model	O
peptide	O
drugs	B-Drug
,	O
bacitracin	B-Drug
and	O
insulin	B-Drug
.	O

Cysteine	B-Drug
was	O
covalently	O
linked	O
to	O
carbodiimide	O
activated	O
NaCMC	B-Drug
.	O

Iodometric	O
titration	O
of	O
the	O
polymer	O
conjugates	O
was	O
used	O
to	O
determine	O
the	O
extent	O
of	O
immobilised	O
cysteine	B-Drug
.	O

Permeation	O
studies	O
were	O
performed	O
on	O
guinea	O
pig	O
small	O
intestinal	O
mucosa	O
mounted	O
in	O
Ussing-type	O
chamber	O
.	O

Unmodified	O
NaCMC	B-Drug
(	O
1	O
%	O
m/v	O
)	O
significantly	O
improved	O
the	O
transport	O
ratio	O
(	O
R=	O
P	O
(	O
app	O
)	O
polymer/	O
P	O
(	O
app	O
)	O
control	O
)	O
of	O
NaFlu	B-Drug
to	O
1.3	O
and	O
1	O
%	O
(	O
m/v	O
)	O
NaCMC	B-Drug
conjugated	O
with	O
cysteine	B-Drug
further	O
enhanced	O
the	O
permeation	O
.	O

Cysteine	B-Drug
conjugation	O
at	O
3.6	O
,	O
5.3	O
and	O
7.3	O
%	O
(	O
m/m	O
)	O
resulted	O
in	O
R-values	O
of	O
1.4	O
,	O
1.7	O
and	O
1.8	O
,	O
respectively	O
.	O

Decreasing	O
the	O
concentration	O
of	O
CMC-Cys	B-Drug
,	O
exhibiting	O
7.3	O
%	O
(	O
m/m	O
)	O
of	O
immobilised	O
cysteine	B-Drug
(	O
CMC-Cys7.3	B-Drug
)	O
from	O
1	O
%	O
(	O
m/v	O
)	O
to	O
0.5	O
%	O
(	O
m/v	O
)	O
decreased	O
the	O
R-value	O
of	O
NaFlu	B-Drug
from	O
1.8	O
to	O
1.2	O
.	O

NaCMC	B-Drug
at	O
1	O
%	O
(	O
m/v	O
)	O
in	O
the	O
presence	O
of	O
free	O
cysteine	B-Drug
had	O
no	O
significant	O
effect	O
on	O
the	O
R-value	O
of	O
NaFlu	B-Drug
compared	O
to	O
NaCMC	B-Drug
alone	O
.	O

Formulation	O
of	O
fluorescence	O
labelled	O
bacitracin	B-Drug
and	O
insulin	B-Drug
in	O
unconjugated	O
NaCMC	B-Drug
(	O
1	O
%	O
m/v	O
)	O
did	O
not	O
significantly	O
improve	O
the	O
permeation	O
,	O
however	O
in	O
the	O
presence	O
of	O
1	O
%	O
(	O
m/v	O
)	O
CMC-Cys7.3	B-Drug
a	O
significantly	O
improved	O
permeation	O
was	O
observed	O
(	O
R=	O
1.3	O
)	O
.	O

Conjugation	O
at	O
NaCMC	B-Drug
with	O
cysteine	B-Drug
moieties	O
significantly	O
improves	O
the	O
intestinal	O
permeation	O
of	O
the	O
hydrophilic	O
molecule	O
NaFlu	B-Drug
and	O
the	O
model	O
peptide	O
drugs	B-Drug
bacitracin	B-Drug
and	O
insulin	B-Drug
in	O
vitro	O
,	O
therefore	O
this	O
conjugated	O
system	O
maybe	O
useful	O
for	O
peroral	O
administration	O
of	O
peptide	O
drugs	B-Drug
in	O
the	O
future	O
.	O

Systemic	O
antibiotic	O
agents	O
.	O

Understanding	O
the	O
breadth	O
of	O
systemic	O
antimicrobial	O
agents	O
available	O
for	O
use	O
by	O
the	O
dermatologist	O
and	O
their	O
associated	O
side-effect	O
profiles	O
and	O
drug	B-Drug
interactions	O
allows	O
the	O
clinician	O
to	O
offer	O
patients	O
optimal	O
care	O
in	O
the	O
management	O
of	O
cutaneous	O
infectious	O
disease	O
.	O

Drug	B-Drug
interactions	O
:	O
How	O
to	O
identify	O
them	O
.	O

Interactions	O
between	O
theraputic	O
agents	O
have	O
been	O
recognized	O
as	O
increasingly	O
important	O
causes	O
of	O
drug	B-Drug
at	O
their	O
usual	O
recommended	O
dose	O
may	O
,	O
under	O
certain	O
conditions	O
,	O
produce	O
toxicity	O
of	O
life-endangering	O
proportions	O
.	O

While	O
the	O
recognition	O
of	O
drug	B-Drug
toxicity	O
resulting	O
from	O
interactions	O
is	O
of	O
importance	O
to	O
all	O
physciains	O
,	O
it	O
is	O
especially	O
so	O
for	O
the	O
clinician	O
responsible	O
for	O
the	O
welfare	O
of	O
those	O
in	O
the	O
aerospace	O
environment	O
.	O

This	O
paper	O
attempts	O
to	O
provide	O
a	O
basis	O
for	O
the	O
understanding	O
and	O
identifications	O
of	O
important	O
drug	B-Drug
interactions	O
.	O

Guidelines	O
are	O
provided	O
to	O
assist	O
the	O
clinician	O
in	O
his	O
logical	O
approach	O
to	O
the	O
identification	O
of	O
drug	B-Drug
interactions	O
when	O
serious	O
drug	B-Drug
toxicity	O
is	O
encountered	O
in	O
a	O
pateint	O
.	O

Only	O
with	O
knowledge	O
of	O
the	O
interaction	O
can	O
the	O
therapeutic	O
regimen	O
be	O
altered	O
so	O
as	O
to	O
provide	O
therapeutic	O
levels	O
of	O
necessary	O
drugs	B-Drug
while	O
avoiding	O
toxicity	O
.	O

Pharmacokinetic	O
Interaction	O
between	O
amprenavir	B-Drug
and	O
rifabutin	B-Drug
or	O
rifampin	B-Drug
in	O
healthy	O
males	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
there	O
is	O
a	O
pharmacokinetic	O
interaction	O
when	O
amprenavir	B-Drug
is	O
given	O
with	O
rifabutin	B-Drug
or	O
rifampin	B-Drug
and	O
to	O
determine	O
the	O
effects	O
of	O
these	O
drugs	B-Drug
on	O
the	O
erythromycin	B-Drug
breath	O
test	O
(	O
ERMBT	O
)	O
.	O

Twenty-four	O
healthy	O
male	O
subjects	O
were	O
randomized	O
to	O
one	O
of	O
two	O
cohorts	O
.	O

All	O
subjects	O
received	O
amprenavir	B-Drug
(	O
1,200	O
mg	O
twice	O
a	O
day	O
)	O
for	O
4	O
days	O
,	O
followed	O
by	O
a	O
7-day	O
washout	O
period	O
,	O
followed	O
by	O
either	O
rifabutin	B-Drug
(	O
300	O
mg	O
once	O
a	O
day	O
[	O
QD	O
]	O
)	O
(	O
cohort	O
1	O
)	O
or	O
rifampin	B-Drug
(	O
600	O
mg	O
QD	O
)	O
(	O
cohort	O
2	O
)	O
for	O
14	O
days	O
.	O

Cohort	O
1	O
then	O
received	O
amprenavir	B-Drug
plus	O
rifabutin	B-Drug
for	O
10	O
days	O
,	O
and	O
cohort	O
2	O
received	O
amprenavir	B-Drug
plus	O
rifampin	B-Drug
for	O
4	O
days	O
.	O

Serial	O
plasma	O
and	O
urine	O
samples	O
for	O
measurement	O
of	O
amprenavir	B-Drug
,	O
rifabutin	B-Drug
,	O
and	O
rifampin	B-Drug
and	O
their	O
25-O-desacetyl	B-Drug
metabolites	I-Drug
,	O
were	O
measured	O
by	O
high-performance	O
liquid	O
chromatography	O
.	O

Rifabutin	B-Drug
did	O
not	O
significantly	O
affect	O
amprenavir	B-Drug
's	O
pharmacokinetics	O
.	O

Amprenavir	B-Drug
significantly	O
increased	O
the	O
area	O
under	O
the	O
curve	O
at	O
steady	O
state	O
(	O
AUC	O
(	O
ss	O
)	O
)	O
of	O
rifabutin	B-Drug
by	O
2.93-fold	O
and	O
the	O
AUC	O
(	O
ss	O
)	O
of	O
25-O-desacetylrifabutin	B-Drug
by	O
13.3-fold	O
.	O

Rifampin	B-Drug
significantly	O
decreased	O
the	O
AUC	O
(	O
ss	O
)	O
of	O
amprenavir	B-Drug
by	O
82	O
%	O
,	O
but	O
amprenavir	B-Drug
had	O
no	O
effect	O
on	O
rifampin	B-Drug
pharmacokinetics	O
.	O

Amprenavir	B-Drug
decreased	O
the	O
results	O
of	O
the	O
ERMBT	O
by	O
83	O
%	O
.	O

The	O
results	O
of	O
the	O
ERMBT	O
after	O
2	O
weeks	O
of	O
rifabutin	B-Drug
and	O
rifampin	B-Drug
therapy	O
were	O
increased	O
187	O
and	O
156	O
%	O
,	O
respectively	O
.	O

Amprenavir	B-Drug
plus	O
rifampin	B-Drug
was	O
well	O
tolerated	O
.	O

Amprenavir	B-Drug
plus	O
rifabutin	B-Drug
was	O
poorly	O
tolerated	O
,	O
and	O
5	O
of	O
11	O
subjects	O
discontinued	O
therapy	O
.	O

Rifampin	B-Drug
markedly	O
increases	O
the	O
metabolic	O
clearance	O
of	O
amprenavir	B-Drug
,	O
and	O
coadministration	O
is	O
contraindicated	O
.	O

Amprenavir	B-Drug
significantly	O
decreases	O
clearance	O
of	O
rifabutin	B-Drug
and	O
25-O-desacetylrifabutin	B-Drug
,	O
and	O
the	O
combination	O
is	O
poorly	O
tolerated	O
.	O

Amprenavir	B-Drug
inhibits	O
the	O
ERMBT	O
,	O
and	O
rifampin	B-Drug
and	O
rifabutin	B-Drug
are	O
equipotent	O
inducers	O
of	O
the	O
ERMBT	O
.	O

New	O
oral	O
therapies	O
for	O
type	O
2	O
diabetes	O
mellitus	O
:	O
The	O
glitazones	O
or	O
insulin	B-Drug
sensitizers	O
.	O

Type	O
2	O
diabetes	O
mellitus	O
is	O
a	O
growing	O
problem	O
not	O
only	O
in	O
the	O
United	O
States	O
but	O
also	O
across	O
the	O
world	O
.	O

There	O
is	O
now	O
strong	O
evidence	O
that	O
intensive	O
control	O
of	O
blood	O
glucose	B-Drug
can	O
significantly	O
reduce	O
and	O
retard	O
the	O
microvascular	O
complications	O
of	O
retinopathy	O
,	O
nephropathy	O
,	O
and	O
neuropathy	O
.	O

Ultimately	O
however	O
,	O
up	O
to	O
80	O
%	O
of	O
type	O
2	O
diabetics	O
die	O
from	O
macrovascular	O
cardiovascular	O
disease	O
.	O

This	O
increased	O
incidence	O
of	O
atherosclerotic	O
disease	O
is	O
intricately	O
associated	O
with	O
insulin	B-Drug
resistance	O
,	O
which	O
is	O
a	O
major	O
pathophysiologic	O
abnormality	O
in	O
type	O
2	O
diabetes	O
.	O

There	O
is	O
strong	O
evidence	O
that	O
insulin	B-Drug
resistance	O
is	O
involved	O
in	O
the	O
development	O
of	O
not	O
only	O
hyperglycemia	O
,	O
but	O
also	O
dyslipidemia	O
,	O
hypertension	O
,	O
hypercoagulation	O
,	O
vasculopathy	O
,	O
and	O
ultimately	O
atherosclerotic	O
cardiovascular	O
disease	O
.	O

This	O
cluster	O
of	O
metabolic	O
abnormalities	O
has	O
been	O
termed	O
the	O
insulin	B-Drug
resistance	O
or	O
cardiovascular	O
dysmetabolic	O
syndrome	O
.	O

The	O
thiazolidinediones	O
(	O
rosiglitazone	B-Drug
and	O
pioglitazone	B-Drug
)	O
,	O
a	O
new	O
class	O
of	O
oral	O
antidiabetic	B-Drug
agents	O
,	O
are	O
``	O
insulin	B-Drug
sensitizers	O
''	O
and	O
exert	O
direct	O
effects	O
on	O
the	O
mechanisms	O
of	O
insulin	B-Drug
resistance	O
.	O

These	O
effects	O
not	O
only	O
improve	O
insulin	B-Drug
sensitivity	O
and	O
glycemic	O
control	O
with	O
reduced	O
insulin	B-Drug
requirements	O
,	O
but	O
also	O
have	O
potentially	O
favorable	O
effects	O
on	O
other	O
components	O
of	O
the	O
cardiovascular	O
dysmetabolic	O
syndrome	O
.	O

Long-term	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
the	O
insulin-sensitizing	O
effects	O
of	O
the	O
glitazones	O
can	O
prevent	O
or	O
delay	O
premature	O
atherosclerotic	O
cardiovascular	O
disease	O
,	O
morbidity	O
,	O
and	O
death	O
.	O

Responses	O
to	O
arginine	B-Drug
of	O
the	O
perfused	O
pancreas	O
of	O
the	O
genetically	O
diabetic	O
Chinese	O
hamster	O
.	O

Nonketotic	O
,	O
genetically	O
diabetic	O
Cinese	O
hamsters	O
show	O
subnormal	O
pancreatic	O
insulin	B-Drug
release	O
and	O
impaired	O
suppression	O
of	O
glucagon	B-Drug
in	O
response	O
to	O
glucose	B-Drug
.	O

To	O
study	O
the	O
pancreatic	O
effects	O
of	O
other	O
agents	O
,	O
dynamic	O
insulin	B-Drug
and	O
glucagon	B-Drug
release	O
was	O
measured	O
from	O
the	O
in	O
vitro	O
perfused	O
pancreases	O
of	O
normal	O
and	O
diabetic	O
Chinese	O
hamsters	O
in	O
response	O
to	O
various	O
combinations	O
of	O
arginine	B-Drug
(	O
20mM	O
)	O
,	O
glucose	B-Drug
(	O
100	O
or	O
150	O
mg.	O
per	O
100	O
ml	O
.	O

)	O
,	O
and	O
theophylline	B-Drug
(	O
10	O
mM	O
)	O
.	O

Theophylline	B-Drug
alone	O
caused	O
identical	O
insulin	B-Drug
and	O
glucagon	B-Drug
release	O
in	O
diabetics	O
and	O
normals	O
.	O

Glucose	B-Drug
,	O
alone	O
and	O
in	O
the	O
presence	O
of	O
theophylline	B-Drug
,	O
caused	O
subnormal	O
insulin	B-Drug
release	O
and	O
less	O
suppression	O
of	O
glucagon	B-Drug
release	O
in	O
the	O
diabectics	O
than	O
in	O
the	O
normals	O
.	O

Arginine	B-Drug
,	O
in	O
the	O
presence	O
of	O
glucose	B-Drug
and	O
theophylline	B-Drug
,	O
caused	O
excessive	O
glucagon	B-Drug
release	O
but	O
nearly	O
normal	O
insulin	B-Drug
release	O
in	O
the	O
diabetics	O
.	O

Arginine	B-Drug
,	O
in	O
the	O
absence	O
of	O
glucose	B-Drug
or	O
theophylline	B-Drug
,	O
caused	O
excessive	O
glucagon	B-Drug
release	O
in	O
the	O
diabetics	O
and	O
undetectable	O
insulin	B-Drug
release	O
in	O
either	O
diabetics	O
or	O
normals	O
.	O

Pancreatic	O
content	O
after	O
perfusion	O
did	O
not	O
correlate	O
with	O
release	O
during	O
perfusion	O
.	O

Infusion	O
of	O
arginine	B-Drug
alone	O
markedly	O
decreased	O
the	O
amount	O
of	O
extractable	O
pancreatic	O
insulin	B-Drug
and	O
glucagon	B-Drug
.	O

These	O
results	O
indicate	O
that	O
the	O
pancreatic	O
alpha	O
cell	O
of	O
the	O
diabetic	O
Chinese	O
hamster	O
responds	O
excessively	O
to	O
arginine	B-Drug
,	O
as	O
is	O
seen	O
in	O
the	O
human	O
diabetic	O
.	O

This	O
defect	O
is	O
not	O
related	O
to	O
acute	O
insulin	B-Drug
release	O
or	O
the	O
presence	O
of	O
glucose	B-Drug
.	O

Further	O
,	O
these	O
results	O
confirm	O
that	O
the	O
diabetic	O
Chinese	O
hamster	O
's	O
alpha	O
and	O
beta	O
cells	O
respond	O
normally	O
to	O
theophylline	B-Drug
,	O
but	O
are	O
relatively	O
insensitive	O
to	O
glucose	B-Drug
.	O

Effects	O
of	O
etofibrate	B-Drug
upon	O
the	O
metabolism	O
of	O
chylomicron-like	O
emulsions	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

Slow	O
chylomicron	O
intravascular	O
catabolism	O
has	O
been	O
associated	O
with	O
coronary	O
artery	O
disease	O
and	O
screening	O
for	O
drugs	B-Drug
that	O
can	O
speed-up	O
this	O
process	O
can	O
be	O
important	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
etofibrate	B-Drug
upon	O
chylomicron	O
metabolism	O
was	O
tested	O
by	O
determination	O
of	O
the	O
plasma	O
kinetics	O
of	O
a	O
chylomicron-like	O
emulsion	O
model	O
in	O
12	O
patients	O
with	O
coronary	O
artery	O
disease	O
,	O
aged	O
59+/-11	O
years	O
,	O
(	O
total	O
cholesterol	O
:	O
240+/-41	O
mg/dl	O
;	O
triglycerides	O
:	O
188+/-42	O
mg/dl	O
)	O
submitted	O
to	O
a	O
randomized	O
,	O
crossover	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
with	O
administration	O
of	O
1	O
g	O
per	O
day	O
etofibrate	B-Drug
or	O
placebo	O
for	O
1-month	O
.	O

A	O
1-month	O
washout	O
period	O
was	O
inserted	O
between	O
the	O
treatment	O
periods	O
.	O

Patients	O
were	O
intravenously	O
injected	O
a	O
chylomicron-like	O
emulsion	O
doubly	O
labeled	O
with	O
14C-cholesteryl	O
oleate	O
and	O
3H-triolein	O
at	O
baseline	O
and	O
after	O
treatments	O
.	O

After	O
etofibrate	B-Drug
treatment	O
,	O
there	O
was	O
decrease	O
of	O
total	O
cholesterol	O
and	O
triglyceride	O
plasma	O
levels	O
and	O
a	O
trend	O
to	O
increase	O
high-density	O
lipoprotein	O
cholesterol	O
plasma	O
levels	O
.	O

Etofibrate	B-Drug
elicited	O
62	O
%	O
enhancement	O
of	O
post-heparin	B-Drug
lipolytic	O
activity	O
and	O
100	O
%	O
increase	O
of	O
3H-triglyceride	O
fractional	O
clearance	O
rate	O
compared	O
with	O
placebo	O
treatment	O
.	O

14C-cholesterol	O
ester	O
fractional	O
clearance	O
rate	O
was	O
260	O
%	O
greater	O
after	O
etofibrate	B-Drug
than	O
after	O
placebo	O
.	O

Therefore	O
,	O
a	O
potent	O
effect	O
of	O
etofibrate	B-Drug
on	O
both	O
chylomicron	O
lipolysis	O
and	O
remnant	O
removal	O
was	O
achieved	O
,	O
indicating	O
that	O
this	O
drug	B-Drug
can	O
be	O
used	O
to	O
improve	O
this	O
metabolism	O
in	O
future	O
prospective	O
studies	O
.	O

The	O
mode	O
of	O
toxic	O
action	O
of	O
the	O
pesticide	O
gliftor	B-Drug
:	O
the	O
metabolism	O
of	O
1,3-difluoroacetone	B-Drug
to	O
(	B-Drug
-	I-Drug
)	I-Drug
-erythro-fluorocitrate	I-Drug
.	O

The	O
biochemical	O
toxicology	O
of	O
1,3-difluoroacetone	B-Drug
,	O
a	O
known	O
metabolite	O
of	O
the	O
major	O
ingredient	O
of	O
the	O
pesticide	O
Gliftor	B-Drug
(	O
1,3-difluoro-2-propanol	B-Drug
)	O
,	O
was	O
investigated	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Rat	O
kidney	O
homogenates	O
supplemented	O
with	O
coenzyme	O
A	O
,	O
ATP	O
,	O
oxaloacetate	O
,	O
and	O
Mg2+	O
converted	O
1,3-difluoroacetone	B-Drug
to	O
(	B-Drug
-	I-Drug
)	I-Drug
-erythro-fluorocitrate	I-Drug
in	O
vitro	O
.	O

Administration	O
of	O
1,3-difluoroacetone	B-Drug
(	B-Drug
100	O
mg	O
kg	O
(	B-Drug
-1	O
)	I-Drug
body	O
weight	O
)	I-Drug
to	O
rats	O
in	O
vivo	O
resulted	O
in	O
(	O
-	O
)	O
-erythro-fluorocitrate	O
synthesis	O
in	O
the	O
kidney	O
,	O
which	O
was	O
preceded	O
by	O
an	O
elevation	O
in	O
fluoride	O
levels	O
and	O
followed	O
by	O
citrate	O
accumulation	O
.	O

Animals	O
dosed	O
with	O
1,3-difluoroacetone	B-Drug
did	O
not	O
display	O
the	O
2-3	O
hour	O
lag	O
phase	O
in	O
either	O
(	B-Drug
-	I-Drug
)	I-Drug
-erythro-fluorocitrate	I-Drug
synthesis	O
or	O
in	O
citrate	O
and	O
fluoride	O
accumulation	O
characteristic	O
of	O
animals	O
dosed	O
with	O
1,3-difluoro-2-propanol	B-Drug
.	O

We	O
demonstrate	O
that	O
the	O
conversion	O
of	O
1,3-difluoro-2-propanol	B-Drug
to	O
1,3-difluoroacetone	B-Drug
by	O
an	O
NAD+-dependent	O
oxidation	O
is	O
the	O
rate-limiting	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
toxic	O
product	O
,	O
(	B-Drug
-	I-Drug
)	I-Drug
-erythro-fluorocitrate	I-Drug
from	O
1,3-difluoro-2-propanol	B-Drug
.	O

Prior	O
administration	O
of	O
4-methylpyrazole	B-Drug
(	O
90	O
mg	O
kg	O
(	O
-1	O
)	O
body	O
weight	O
)	O
was	O
shown	O
to	O
prevent	O
the	O
conversion	O
of	O
1,3-difluoro-2-propanol	B-Drug
(	B-Drug
100	O
mg	O
kg	O
(	B-Drug
-1	O
)	I-Drug
body	O
weight	O
)	I-Drug
to	O
(	O
-	O
)	O
-erythro-fluorocitrate	O
in	O
vivo	O
and	O
to	O
eliminate	O
the	O
fluoride	O
and	O
citrate	O
elevations	O
seen	O
in	O
1,3-difluoro-2-propanol-intoxicated	B-Drug
animals	O
.	O

However	O
,	O
administration	O
of	O
4-methylpyrazole	B-Drug
(	O
90	O
mg	O
kg	O
(	O
-1	O
)	O
body	O
weight	O
)	O
to	O
rats	O
2	O
hours	O
prior	O
to	O
1,3-difluoroacetone	B-Drug
(	B-Drug
100	O
mg	O
kg	O
(	B-Drug
-1	O
)	I-Drug
body	O
weight	O
)	I-Drug
was	O
ineffective	O
in	O
preventing	O
(	O
-	O
)	O
-erythro-fluorocitrate	O
synthesis	O
and	O
did	O
not	O
diminish	O
fluoride	O
or	O
citrate	O
accumulation	O
in	O
vivo	O
.	O

We	O
conclude	O
that	O
the	O
prophylactic	O
and	O
antidotal	O
properties	O
of	O
4-methylpyrazole	B-Drug
seen	O
in	O
animals	O
treated	O
with	O
1,3-difluoro-2-propanol	B-Drug
derive	O
from	O
its	O
capacity	O
to	O
inhibit	O
the	O
NAD+-dependent	O
oxidation	O
responsible	O
for	O
converting	O
1,3-difluoro-2-propanol	B-Drug
to	O
1,3-difluoroacetone	B-Drug
in	O
the	O
committed	O
step	O
of	O
the	O
toxic	O
pathway	O
.	O

Pharmacology	O
and	O
pharmacotherapy	O
of	O
cardiovascular	O
drugs	B-Drug
in	O
patients	O
with	O
chronic	O
renal	O
disease	O
.	O

Cardiovascular	O
disease	O
is	O
a	O
common	O
comorbidity	O
and	O
a	O
major	O
cause	O
of	O
mortality	O
in	O
patients	O
with	O
chronic	O
renal	O
disease	O
.	O

Drug	B-Drug
regimens	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
are	O
frequently	O
complex	O
and	O
can	O
be	O
significantly	O
affected	O
by	O
alterations	O
in	O
renal	O
function	O
.	O

In	O
addition	O
,	O
several	O
cardiovascular	O
drugs	B-Drug
directly	O
affect	O
renal	O
function	O
and	O
the	O
management	O
of	O
patients	O
with	O
renal	O
disease	O
.	O

This	O
article	O
reviews	O
the	O
impact	O
of	O
renal	O
disease	O
on	O
the	O
pharmacokinetics	O
of	O
cardiovascular	O
drugs	B-Drug
and	O
identifies	O
clinically	O
important	O
interactions	O
between	O
these	O
and	O
other	O
drugs	B-Drug
commonly	O
used	O
in	O
the	O
management	O
of	O
chronic	O
renal	O
disease	O
.	O

Several	O
classes	O
of	O
cardiovascular	O
drugs	B-Drug
are	O
also	O
discussed	O
in	O
relationship	O
to	O
their	O
differential	O
effects	O
on	O
the	O
management	O
and	O
progression	O
of	O
renal	O
disease	O
.	O

Green	B-Drug
tea	I-Drug
polyphenols	I-Drug
as	O
potent	O
enhancers	B-Drug
of	O
glucocorticoid-induced	O
mouse	O
mammary	O
tumor	O
virus	O
gene	O
expression	O
.	O

The	O
effect	O
of	O
natural	O
and	O
synthetic	O
galloyl	O
esters	O
on	O
glucocorticoid-induced	O
gene	O
expression	O
was	O
evaluated	O
by	O
using	O
rat	O
fibroblast	O
3Y1	O
cells	O
stably	O
transfected	O
with	O
a	O
luciferase	O
reporter	O
gene	O
under	O
the	O
transcriptional	O
regulation	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
promoter	B-Drug
.	O

The	O
glucocorticoid-induced	O
gene	O
transcription	O
was	O
strongly	O
suppressed	O
by	O
synthetic	O
alkyl	O
esters	O
;	O
n-dodecyl	B-Drug
gallate	I-Drug
showed	O
the	O
most	O
potent	O
inhibition	O
(	O
66	O
%	O
inhibition	O
at	O
10	O
microM	O
)	O
,	O
which	O
was	O
far	O
more	O
potent	O
than	O
that	O
of	O
crude	O
tannic	B-Drug
acid	I-Drug
.	O

n-Octyl	O
and	O
n-cetyl	O
gallate	O
also	O
showed	O
good	O
inhibition	O
,	O
while	O
gallic	O
acid	O
itself	O
was	O
not	O
so	O
active	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
hydrophobic	O
side	O
chain	O
is	O
important	O
for	O
the	O
suppressive	O
effect	O
.	O

On	O
the	O
other	O
hand	O
,	O
surprisingly	O
,	O
green	B-Drug
tea	I-Drug
gallocatechins	I-Drug
,	O
(	O
-	O
)	O
-epigallocatechin-3-O-gallate	O
and	O
theasinensin	O
A	O
,	O
potently	O
enhanced	O
the	O
promoter	B-Drug
activity	O
(	O
182	O
and	O
247	O
%	O
activity	O
at	O
1	O
microM	O
,	O
respectively	O
)	O
.	O

The	O
regulation	O
of	O
the	O
level	O
of	O
the	O
glucocorticoid-induced	O
gene	O
expression	O
by	O
the	O
antioxidative	O
gallates	O
is	O
of	O
great	O
interest	O
from	O
a	O
therapeutic	O
point	O
of	O
view	O
.	O

Pharmacokinetic	O
interaction	O
between	O
single	O
oral	O
doses	O
of	O
diltiazem	B-Drug
and	O
sirolimus	B-Drug
in	O
healthy	O
volunteers	O
.	O

AIM	O
AND	O
BACKGROUND	O
:	O
The	O
pharmacokinetic	O
interaction	O
between	O
sirolimus	B-Drug
,	O
a	O
macrolide	O
immunosuppressant	O
metabolized	O
by	O
CYP3A4	B-Drug
,	O
and	O
the	O
calcium	B-Drug
channel	O
blocker	O
diltiazem	B-Drug
was	O
studied	O
in	O
18	O
healthy	O
subjects	O
.	O

Several	O
clinically	O
important	O
interactions	O
have	O
previously	O
been	O
reported	O
for	O
other	O
immunosuppressive	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
the	O
same	O
enzyme	O
and	O
for	O
calcium	B-Drug
antagonists	O
.	O

METHODS	O
:	O
Healthy	O
subjects	O
who	O
were	O
20	O
to	O
43	O
years	O
old	O
participated	O
in	O
an	O
open	O
,	O
three-period	O
,	O
randomized	O
,	O
crossover	O
study	O
of	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
10-mg	O
oral	O
dose	O
of	O
sirolimus	B-Drug
,	O
a	O
single	O
oral	O
120-mg	O
dose	O
of	O
diltiazem	B-Drug
,	O
and	O
the	O
two	O
drugs	B-Drug
given	O
together	O
.	O

The	O
three	O
study	O
periods	O
were	O
separated	O
by	O
a	O
21-day	O
washout	O
phase	O
.	O

RESULTS	O
:	O
The	O
geometric	O
mean	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
whole	O
blood	O
sirolimus	B-Drug
area	O
under	O
the	O
plasma	O
concentration	O
time-curve	O
increased	O
60	O
%	O
(	O
35	O
%	O
-90	O
%	O
)	O
,	O
from	O
736	O
to	O
1178	O
ng	O
x	O
h/mL	O
,	O
and	O
maximum	O
concentration	O
increased	O
43	O
%	O
(	O
14	O
%	O
-81	O
%	O
)	O
,	O
from	O
67	O
to	O
96	O
ng/mL	O
,	O
with	O
diltiazem	B-Drug
coadministration	O
,	O
whereas	O
the	O
mean	O
elimination	O
half-life	O
of	O
sirolimus	B-Drug
decreased	O
slightly	O
,	O
from	O
79	O
to	O
67	O
hours	O
.	O

Apparent	O
oral	O
clearance	O
and	O
volume	O
of	O
distribution	O
of	O
sirolimus	B-Drug
decreased	O
with	O
38	O
%	O
and	O
45	O
%	O
,	O
respectively	O
,	O
when	O
sirolimus	B-Drug
was	O
given	O
with	O
diltiazem	B-Drug
.	O

The	O
plasma	O
maximum	O
concentration	O
and	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
of	O
diltiazem	B-Drug
,	O
desacetyldiltiazem	B-Drug
,	O
and	O
desmethyldiltiazem	B-Drug
were	O
unchanged	O
after	O
coadministration	O
of	O
sirolimus	B-Drug
,	O
and	O
no	O
potentiation	O
of	O
the	O
effects	O
of	O
diltiazem	B-Drug
on	O
diastolic	O
or	O
systolic	O
blood	O
pressure	O
or	O
on	O
the	O
electrocardiographic	O
parameters	O
was	O
seen	O
.	O

CONCLUSIONS	O
:	O
Single-dose	O
diltiazem	B-Drug
coadministration	O
leads	O
to	O
higher	O
sirolimus	B-Drug
exposure	O
,	O
presumably	O
by	O
inhibition	O
of	O
the	O
first-pass	O
metabolism	O
of	O
sirolimus	B-Drug
.	O

Because	O
of	O
the	O
pronounced	O
intersubject	O
variability	O
in	O
the	O
extent	O
of	O
the	O
sirolimus-diltiazem	B-Drug
interaction	O
,	O
whole	O
blood	O
sirolimus	B-Drug
concentrations	O
should	O
be	O
monitored	O
closely	O
in	O
patients	O
treated	O
with	O
the	O
two	O
drugs	B-Drug
.	O

Fluvoxamine	B-Drug
inhibits	O
the	O
CYP2C9	B-Drug
catalyzed	O
biotransformation	O
of	O
tolbutamide	B-Drug
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
interaction	O
between	O
fluvoxamine	B-Drug
and	O
tolbutamide	B-Drug
to	O
confirm	O
that	O
fluvoxamine	B-Drug
inhibits	O
CYP2C9	B-Drug
.	O

METHODS	O
:	O
The	O
study	O
was	O
carried	O
out	O
as	O
an	O
open	O
,	O
randomized	O
,	O
crossover	O
design	O
with	O
14	O
healthy	O
participants	O
.	O

In	O
period	O
A	O
,	O
all	O
volunteers	O
took	O
500	O
mg	O
of	O
tolbutamide	B-Drug
orally	O
.	O

In	O
period	O
B	O
,	O
the	O
volunteers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
.	O

Each	O
group	O
took	O
either	O
150	O
mg	O
or	O
75	O
mg	O
of	O
fluvoxamine	B-Drug
a	O
day	O
for	O
5	O
days	O
(	O
day	O
-3	O
to	O
day	O
2	O
)	O
.	O

The	O
groups	O
then	O
took	O
500	O
mg	O
of	O
tolbutamide	B-Drug
as	O
a	O
single	O
dose	O
(	O
day	O
0	O
)	O
.	O

In	O
both	O
periods	O
,	O
blood	O
and	O
urine	O
were	O
sampled	O
at	O
regular	O
intervals	O
.	O

Plasma	O
was	O
analyzed	O
for	O
tolbutamide	B-Drug
,	O
and	O
urine	O
was	O
analyzed	O
for	O
tolbutamide	B-Drug
and	O
its	O
two	O
metabolites	O
,	O
4-hydroxytolbutamide	B-Drug
and	O
carboxytolbutamide	B-Drug
by	O
means	O
of	O
HPLC	O
.	O

RESULTS	O
:	O
During	O
treatment	O
with	O
fluvoxamine	B-Drug
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
median	O
of	O
the	O
total	O
clearance	O
of	O
tolbutamide	B-Drug
,	O
from	O
845	O
mL/h	O
to	O
688	O
mL/h	O
,	O
among	O
the	O
volunteers	O
who	O
received	O
75	O
mg/d	O
.	O

There	O
was	O
a	O
reduction	O
that	O
reached	O
borderline	O
statistical	O
significance	O
in	O
the	O
group	O
that	O
received	O
150	O
mg/d	O
of	O
tolbutamide	B-Drug
.	O

The	O
clearance	O
by	O
means	O
of	O
4-hydroxytolbutamide	B-Drug
and	O
carboxytolbutamide	B-Drug
was	O
significantly	O
reduced	O
in	O
both	O
groups	O
(	O
ie	O
,	O
from	O
901	O
mL/h	O
to	O
318	O
mL/h	O
in	O
the	O
group	O
that	O
received	O
150	O
mg	O
of	O
tolbutamide	B-Drug
per	O
day	O
and	O
from	O
723	O
mL/h	O
to	O
457	O
mL/h	O
in	O
the	O
group	O
that	O
received	O
75	O
mg	O
of	O
tolbutamide	B-Drug
per	O
day	O
)	O
.	O

Thus	O
there	O
was	O
a	O
tendency	O
toward	O
a	O
more	O
pronounced	O
inhibition	O
of	O
the	O
4-hydroxylation	O
during	O
treatment	O
with	O
150	O
mg/d	O
of	O
fluvoxamine	B-Drug
compared	O
with	O
75	O
mg/d	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

CONCLUSION	O
:	O
Fluvoxamine	B-Drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP2C9	B-Drug
in	O
vivo	O
.	O

Longitudinal	O
assessment	O
of	O
everolimus	B-Drug
in	O
de	O
novo	O
renal	O
transplant	O
recipients	O
over	O
the	O
first	O
post-transplant	O
year	O
:	O
pharmacokinetics	O
,	O
exposure-response	O
relationships	O
,	O
and	O
influence	O
on	O
cyclosporine	B-Drug
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
characterize	O
the	O
steady-state	O
pharmacokinetics	O
of	O
everolimus	B-Drug
and	O
cyclosporine	B-Drug
(	O
INN	O
,	O
ciclosporin	B-Drug
)	O
when	O
coadministered	O
in	O
de	O
novo	O
kidney	O
allograft	O
recipients	O
during	O
the	O
first	O
year	O
after	O
transplantation	O
.	O

METHOD	O
:	O
This	O
study	O
was	O
a	O
multicenter	O
randomized	O
double-blind	O
study	O
of	O
101	O
patients	O
who	O
were	O
randomly	O
assigned	O
1:1:1	O
to	O
receive	O
everolimus	B-Drug
tablets	O
at	O
doses	O
of	O
0.5	O
mg	O
,	O
1	O
mg	O
,	O
or	O
2	O
mg	O
twice	O
daily	O
with	O
cyclosporine	B-Drug
and	O
prednisone	B-Drug
.	O

Blood	O
sampling	O
for	O
the	O
pharmacokinetics	O
of	O
everolimus	B-Drug
and	O
cyclosporine	B-Drug
was	O
performed	O
on	O
day	O
1	O
,	O
on	O
weeks	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
and	O
on	O
months	O
2	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
.	O

Everolimus	B-Drug
dose-proportionality	O
and	O
stability	O
over	O
time	O
were	O
assessed	O
in	O
the	O
context	O
of	O
linear	O
regression	O
and	O
ANOVA	O
models	O
.	O

Everolimus	B-Drug
exposure-response	O
relationships	O
between	O
area	O
under	O
the	O
blood	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
and	O
changes	O
in	O
platelets	O
,	O
leukocytes	O
,	O
and	O
lipids	O
were	O
explored	O
with	O
the	O
median-effect	O
model	O
.	O

Potential	O
differences	O
in	O
cyclosporine	B-Drug
dosing	O
and	O
pharmacokinetics	O
at	O
different	O
levels	O
of	O
everolimus	B-Drug
exposure	O
were	O
assessed	O
in	O
the	O
context	O
of	O
ANOVA	O
.	O

RESULTS	O
:	O
Everolimus	B-Drug
steady	O
state	O
was	O
reached	O
on	O
or	O
before	O
day	O
7	O
,	O
with	O
a	O
median	O
3-fold	O
accumulation	O
of	O
drug	B-Drug
exposure	O
compared	O
with	O
that	O
after	O
the	O
first	O
postoperative	O
dose	O
.	O

Both	O
steady-state	O
maximum	O
concentration	O
and	O
AUC	O
were	O
dose	O
proportional	O
over	O
the	O
full	O
dose	O
range	O
when	O
assessed	O
on	O
day	O
1	O
,	O
as	O
well	O
as	O
for	O
the	O
full	O
duration	O
of	O
the	O
study	O
at	O
steady	O
state	O
.	O

There	O
was	O
evidence	O
for	O
longitudinal	O
stability	O
in	O
AUC	O
of	O
everolimus	B-Drug
during	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
interindividual	O
pharmacokinetic	O
variability	O
for	O
AUC	O
was	O
85.4	O
%	O
and	O
intraindividual	O
,	O
interoccasion	O
variability	O
was	O
40.8	O
%	O
.	O

Age	O
(	O
range	O
,	O
17-69	O
years	O
)	O
,	O
weight	O
(	O
range	O
,	O
49-106	O
kg	O
)	O
,	O
and	O
sex	O
(	O
65	O
men	O
and	O
36	O
women	O
)	O
were	O
not	O
significant	O
contributors	O
to	O
variability	O
.	O

There	O
was	O
an	O
increasing	O
incidence	O
of	O
transient	O
thrombocytopenia	O
(	O
or	O
=100	O
x	O
10	O
(	O
9	O
)	O
/L	O
)	O
with	O
increasing	O
everolimus	B-Drug
AUC	O
(	O
P	O
=	O
.03	O
)	O
.	O

Cyclosporine	B-Drug
doses	O
,	O
trough	O
concentrations	O
,	O
and	O
AUC	O
exhibited	O
similar	O
temporal	O
patterns	O
during	O
the	O
course	O
of	O
the	O
study	O
regardless	O
of	O
the	O
co-administered	O
everolimus	B-Drug
dose	O
level	O
(	O
P	O
=	O
.13	O
,	O
.82	O
,	O
and	O
.76	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
Everolimus	B-Drug
exhibited	O
dose-proportional	O
,	O
stable	O
exposure	O
during	O
the	O
first	O
post-transplant	O
year	O
.	O

For	O
a	O
4-fold	O
range	O
of	O
everolimus	B-Drug
doses	O
there	O
were	O
no	O
differential	O
effects	O
on	O
cyclosporine	B-Drug
dosing	O
or	O
pharmacokinetics	O
.	O

ADL	B-Drug
8-2698	I-Drug
,	O
a	O
trans-3,4-dimethyl-4-	O
(	O
3-hydroxyphenyl	O
)	O
piperidine	O
,	O
prevents	O
gastrointestinal	O
effects	O
of	O
intravenous	O
morphine	B-Drug
without	O
affecting	O
analgesia	O
.	O

ADL-8-2698	B-Drug
is	O
a	O
novel	O
peripherally	O
restricted	O
opioid	O
antagonist	O
that	O
may	O
selectively	O
prevent	O
opioid-induced	O
gastrointestinal	O
effects	O
without	O
reversing	O
analgesia	O
.	O

Gastrointestinal	O
transit	O
time	O
(	O
lactulose	B-Drug
hydrogen	O
breath	O
test	O
)	O
was	O
measured	O
in	O
14	O
volunteers	O
with	O
oral	O
and	O
intravenous	O
placebo	O
,	O
oral	O
placebo	O
and	O
intravenous	O
morphine	B-Drug
(	O
0.05	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
)	O
,	O
and	O
oral	O
ADL	B-Drug
8-2698	I-Drug
(	O
4	O
mg	O
)	O
and	O
intravenous	O
morphine	B-Drug
(	O
0.05	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
)	O
in	O
a	O
double	O
blind	O
,	O
cross-over	O
study	O
.	O

Morphine	B-Drug
prolonged	O
gastrointestinal	O
transit	O
time	O
from	O
69	O
to	O
103	O
minutes	O
(	O
P	O
=	O
.005	O
)	O
;	O
Morphine	B-Drug
prolonged	O
gastrointestinal	O
transit	O
time	O
from	O
69	O
to	O
103	O
minutes	O
(	O
P	O
=	O
.005	O
)	O
;	O
this	O
was	O
prevented	O
by	O
ADL	B-Drug
8-2698	I-Drug
(	O
P	O
=	O
.004	O
)	O
.	O

Postoperatively	O
,	O
45	O
patients	O
were	O
randomly	O
assigned	O
in	O
a	O
double-blind	O
fashion	O
to	O
receive	O
ADL	B-Drug
8-2698	I-Drug
(	O
4	O
mg	O
)	O
or	O
placebo	O
and	O
intravenous	O
morphine	B-Drug
(	O
0.15	O
mg/kg	O
)	O
or	O
to	O
receive	O
oral	O
and	O
intravenous	O
placebo	O
.	O

Analgesia	O
and	O
pupil	O
constriction	O
were	O
measured	O
.	O

Morphine	B-Drug
analgesia	O
and	O
pupil	O
constriction	O
were	O
unaffected	O
by	O
ADL	B-Drug
8-2698	I-Drug
and	O
differed	O
from	O
placebo	O
(	O
P	O
<	O
.002	O
)	O
.	O

We	O
conclude	O
that	O
ADL	B-Drug
8-2698	I-Drug
prevents	O
morphine-induced	B-Drug
increases	O
in	O
gastrointestinal	O
transit	O
time	O
by	O
means	O
of	O
selective	O
peripheral	O
opioid	O
anitagonism	O
without	O
affecting	O
central	O
opioid	O
analgesia	O
.	O

Restoration	O
of	O
vancomycin	B-Drug
susceptibility	O
in	O
Enterococcus	O
faecalis	O
by	O
antiresistance	O
determinant	O
gene	O
transfer	O
.	O

We	O
assessed	O
the	O
ability	O
of	O
gene	O
transfer	O
to	O
reverse	O
vancomycin	B-Drug
resistance	O
in	O
class	O
A	O
(	O
VanA	O
)	O
glycopeptide-resistant	O
Enterococcus	O
faecalis	O
.	O

Recombinant	O
shuttle	O
vectors	O
containing	O
a	O
vanH	O
promoter-vanA	O
antisense	O
gene	O
cassette	O
fully	O
restored	O
vancomycin	B-Drug
susceptibility	O
through	O
a	O
combined	O
transcriptional	O
activator	O
binding	O
domain	O
decoy	O
and	O
inducible	O
vanA	O
antisense	O
RNA	O
effect	O
.	O

Rhabdomyolysis	O
secondary	O
to	O
a	O
drug	B-Drug
interaction	O
between	O
simvastatin	B-Drug
and	O
clarithromycin	B-Drug
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
rhabdomyolysis	O
resulting	O
from	O
concomitant	O
use	O
of	O
clarithromycin	B-Drug
and	O
simvastatin	B-Drug
.	O

CASE	O
SUMMARY	O
:	O
A	O
64-year-old	O
African-American	O
man	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
worsening	O
renal	O
failure	O
,	O
elevated	O
creatine	O
phosphokinase	O
,	O
diffuse	O
muscle	O
pain	O
,	O
and	O
severe	O
muscle	O
weakness	O
.	O

About	O
three	O
weeks	O
prior	O
to	O
admission	O
,	O
the	O
patient	O
was	O
started	O
on	O
clarithromycin	B-Drug
for	O
sinusitis	O
.	O

The	O
patient	O
had	O
been	O
receiving	O
simvastatin	B-Drug
for	O
approximately	O
six	O
months	O
.	O

He	O
was	O
treated	O
aggressively	O
with	O
intravenous	O
hydration	O
,	O
sodium	B-Drug
bicarbonate	I-Drug
,	O
and	O
hemodialysis	O
.	O

A	O
muscle	O
biopsy	O
revealed	O
necrotizing	O
myopathy	O
secondary	O
to	O
a	O
toxin	B-Drug
.	O

The	O
patient	O
continued	O
to	O
receive	O
intermittent	O
hemodialysis	O
until	O
his	O
death	O
from	O
infectious	O
complications	O
that	O
occurred	O
three	O
months	O
after	O
admission	O
.	O

There	O
were	O
several	O
factors	O
that	O
could	O
have	O
increased	O
his	O
risk	O
for	O
developing	O
rhabdomyolysis	O
,	O
including	O
chronic	O
renal	O
failure	O
.	O

DISCUSSION	O
:	O
Clarithromycin	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	B-Drug
,	O
the	O
major	O
enzyme	O
responsible	O
for	O
simvastatin	B-Drug
metabolism	O
.	O

The	O
concomitant	O
administration	O
of	O
macrolide	O
antibiotics	B-Drug
and	O
other	O
hydroxymethylglutaryl	O
coenzyme	O
A	O
(	O
HMG-CoA	O
)	O
reductase	O
inhibitors	O
have	O
resulted	O
in	O
previous	O
reports	O
of	O
rhabdomyolysis	O
.	O

Other	O
factors	O
may	O
increase	O
the	O
risk	O
of	O
this	O
drug	B-Drug
interaction	O
,	O
including	O
the	O
administration	O
of	O
other	O
medications	O
that	O
are	O
associated	O
with	O
myopathy	O
,	O
underlying	O
renal	O
insufficiency	O
,	O
and	O
administration	O
of	O
high	O
doses	O
of	O
HMG-CoA	O
reductase	O
inhibitors	O
.	O

CONCLUSIONS	O
:	O
Macrolide	O
antibiotics	B-Drug
inhibit	O
the	O
metabolism	O
of	O
HMG-CoA	O
reductase	O
inhibitors	O
that	O
are	O
metabolized	O
by	O
CYP3A4	B-Drug
(	O
i.e.	O
,	O
atorvastatin	B-Drug
,	O
cerivastatin	B-Drug
,	O
lovastatin	B-Drug
,	O
simvastatin	B-Drug
)	O
.	O

This	O
interaction	O
may	O
result	O
in	O
myopathy	O
and	O
rhabdomyolysis	O
,	O
particularly	O
in	O
patients	O
with	O
renal	O
insufficiency	O
or	O
those	O
who	O
are	O
concurrently	O
taking	O
medications	O
associated	O
with	O
myopathy	O
.	O

Toxicity	O
of	O
cadmium	O
and	O
zinc	B-Drug
to	O
encystment	O
and	O
in	O
vitro	O
excystment	O
of	O
Parorchis	O
acanthus	O
(	O
Digenea	O
:	O
Philophthalmidae	O
)	O
.	O

The	O
toxicity	O
of	O
cadmium	O
,	O
zinc	B-Drug
and	O
cadmium/zinc	O
mixtures	O
at	O
concentrations	O
ranging	O
from	O
1000	O
to	O
50000	O
microg/l	O
were	O
investigated	O
against	O
cercariae	O
and	O
metacercariae	O
of	O
Parorchis	O
acanthus	O
obtained	O
from	O
the	O
dog	O
whelk	O
Nucella	O
lapillus	O
.	O

Cercarial	O
encystment	O
at	O
concentrations	O
of	O
25000	O
microg/l	O
or	O
higher	O
was	O
significantly	O
impaired	O
by	O
all	O
test	O
metals	O
;	O
however	O
,	O
at	O
lower	O
concentrations	O
only	O
zinc	B-Drug
demonstrated	O
toxicity	O
.	O

Mixtures	O
of	O
cadmium	O
and	O
zinc	B-Drug
had	O
a	O
synergistic	O
effect	O
compared	O
with	O
single	O
metal	O
toxicity	O
but	O
only	O
at	O
50000	O
microg/l	O
.	O

Excystment	O
in	O
vitro	O
was	O
only	O
significantly	O
affected	O
by	O
cercariae	O
exposed	O
to	O
cadmium/zinc	O
mixtures	O
whilst	O
encysting	O
.	O

Twenty-four	O
h	O
exposures	O
of	O
fully	O
formed	O
cysts	O
had	O
no	O
effect	O
on	O
excystment	O
in	O
vitro	O
.	O

Effects	O
on	O
in	O
vitro	O
excystment	O
rates	O
over	O
a	O
2	O
h	O
period	O
demonstrated	O
widespread	O
effects	O
for	O
cercariae-exposed	O
P	O
.	O

acanthus	O
.	O

No	O
effects	O
were	O
evident	O
on	O
excystment	O
rates	O
of	O
cyst-exposed	O
parasites	O
.	O

Toxicity	O
of	O
cadmium	O
and	O
zinc	B-Drug
to	O
miracidia	O
of	O
Schistosoma	O
mansoni	O
.	O

The	O
specific	O
objectives	O
of	O
this	O
study	O
were	O
to	O
elucidate	O
metal	O
toxicity	O
to	O
hatching	O
,	O
survival	O
and	O
avoidance	O
behaviour	O
of	O
Schistosoma	O
mansoni	O
miracidia	O
.	O

The	O
toxicity	O
of	O
cadmium	O
,	O
zinc	B-Drug
,	O
and	O
cadmium/zinc	O
mixtures	O
at	O
concentrations	O
ranging	O
from	O
10000	O
to	O
10	O
microg/l	O
was	O
investigated	O
.	O

Metal	O
mixture	O
toxicity	O
investigation	O
was	O
undertaken	O
with	O
equal	O
concentrations	O
of	O
the	O
metals	O
.	O

The	O
hatching	O
of	O
miracidia	O
from	O
eggs	O
was	O
inhibited	O
by	O
concentrations	O
of	O
1000-10000	O
microg/l	O
of	O
single	O
metals	O
.	O

Metal	O
mixtures	O
had	O
no	O
effect	O
on	O
egg	B-Drug
hatching	O
.	O

Survival	O
of	O
miracidia	O
was	O
reduced	O
by	O
increasing	O
metal	O
concentration	O
except	O
at	O
concentrations	O
of	O
10	O
microg/l	O
for	O
single	O
metal	O
toxicity	O
where	O
survival	O
was	O
increased	O
above	O
the	O
control	O
.	O

Miracidia	O
demonstrated	O
a	O
rapid	O
avoidance	O
behaviour	O
when	O
briefly	O
exposed	O
to	O
heavy	O
metals	O
.	O

The	O
mechanisms	O
of	O
metal	O
toxicity	O
to	O
miracidia	O
are	O
briefly	O
discussed	O
.	O

[	O
Importance	O
of	O
pharmacogenetics	O
]	O
Pharmacogenetics	O
deals	O
with	O
the	O
differences	O
in	O
effect	O
of	O
drugs	B-Drug
caused	O
by	O
genetic	O
variation	O
.	O

Differences	O
can	O
occur	O
in	O
therapeutic	O
effect	O
and	O
in	O
adverse	O
events	O
.	O

Genetic	O
variation	O
in	O
metabolism	O
may	O
result	O
in	O
high	O
concentrations	O
of	O
drugs	B-Drug
and	O
an	O
increased	O
risk	O
of	O
adverse	O
effects	O
in	O
slow	O
metabolizers	O
,	O
which	O
is	O
important	O
when	O
using	O
for	O
example	O
antidepressants	B-Drug
or	O
chemotherapy	O
.	O

Genetic	O
variation	O
also	O
occurs	O
in	O
proteins	O
interacting	O
with	O
drugs	B-Drug
,	O
which	O
may	O
change	O
the	O
effect	O
of	O
e.g	O
.	O

asthma	O
drugs	B-Drug
and	O
antipsychotics	O
.	O

The	O
selection	O
of	O
drugs	B-Drug
and	O
their	O
dosages	O
may	O
be	O
improved	O
,	O
and	O
the	O
number	O
of	O
adverse	O
effects	O
reduced	O
by	O
pharmacogenetic	O
investigations	O
.	O

However	O
,	O
it	O
may	O
be	O
important	O
also	O
in	O
case	O
of	O
medical	O
examinations	O
for	O
insurances	O
and	O
job	O
appointments	O
,	O
since	O
some	O
patients	O
may	O
turn	O
out	O
to	O
need	O
expensive	O
drugs	B-Drug
or	O
to	O
be	O
susceptible	O
to	O
a	O
certain	O
disease	O
.	O

Therefore	O
,	O
the	O
use	O
of	O
genetic	O
data	O
in	O
these	O
instances	O
has	O
to	O
be	O
regulated	O
.	O

The	O
effects	O
of	O
concomitant	O
phenytoin	B-Drug
administration	O
on	O
the	O
steady-state	O
pharmacokinetics	O
of	O
quetiapine	B-Drug
.	O

Quetiapine	B-Drug
fumarate	I-Drug
(	O
'Seroquel	O
'	O
)	O
is	O
a	O
newly	O
introduced	O
atypical	O
antipsychotic	O
with	O
demonstrated	O
efficacy	O
in	O
the	O
treatment	O
of	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

It	O
is	O
extensively	O
metabolized	O
,	O
predominantly	O
by	O
cytochrome	O
P450	O
3A4	O
.	O

Therefore	O
,	O
concurrent	O
administration	O
of	O
drugs	B-Drug
that	O
induce	O
or	O
inhibit	O
this	O
enzyme	O
may	O
affect	O
quetiapine	B-Drug
pharmacokinetics	O
.	O

This	O
study	O
demonstrated	O
that	O
the	O
potent	O
cytochrome	O
P450	O
enzyme-inducer	O
phenytoin	B-Drug
did	O
indeed	O
have	O
a	O
marked	O
effect	O
on	O
the	O
metabolism	O
of	O
quetiapine	B-Drug
,	O
resulting	O
in	O
a	O
5-fold	O
increase	O
in	O
clearance	O
when	O
administered	O
concomitantly	O
to	O
patients	O
with	O
DSM-IV-diagnosed	O
schizophrenia	O
,	O
schizoaffective	O
disorder	O
,	O
or	O
bipolar	O
disorder	O
.	O

These	O
results	O
indicate	O
that	O
dosage	O
adjustment	O
of	O
quetiapine	B-Drug
may	O
be	O
necessary	O
when	O
the	O
two	O
drugs	B-Drug
are	O
given	O
concurrently	O
and	O
that	O
caution	O
may	O
be	O
required	O
when	O
administering	O
other	O
drugs	B-Drug
that	O
inhibit	O
or	O
induce	O
cytochromes	O
,	O
particularly	O
P450	O
3A4	O
.	O

Effect	O
of	O
coadministered	O
drugs	B-Drug
and	O
ethanol	B-Drug
on	O
the	O
binding	O
of	O
therapeutic	O
drugs	B-Drug
to	O
human	O
serum	O
in	O
vitro	O
.	O

The	O
effects	O
of	O
coadministered	O
drugs	B-Drug
and	O
ethanol	B-Drug
on	O
the	O
binding	O
of	O
therapeutic	O
drugs	B-Drug
to	O
human	O
serum	O
in	O
vitro	O
was	O
investigated	O
.	O

Acetaminophen	B-Drug
,	O
lidocaine	B-Drug
,	O
phenobarbital	B-Drug
,	O
quinidine	B-Drug
,	O
theophylline	B-Drug
,	O
and	O
valproic	B-Drug
acid	I-Drug
were	O
added	O
to	O
pooled	O
human	O
serum	O
at	O
therapeutic	O
concentrations	O
.	O

To	O
each	O
preparation	O
was	O
added	O
one	O
additional	O
drug	B-Drug
at	O
three	O
concentrations	O
ranging	O
from	O
therapeutic	O
to	O
toxic	O
.	O

The	O
following	O
eight	O
target	O
drug/added	O
drug	B-Drug
combinations	O
were	O
studied	O
:	O
acetaminophen/phenobarbital	B-Drug
.	O

acetaminophen/theophylline	B-Drug
,	O
lidocaine/quinidine	O
,	O
phenobarbital/acetaminophen	O
,	O
phenobarbital/valproic	O
acid	O
,	O
quinidine/lidocaine	O
,	O
theophylline/acetaminophen	B-Drug
,	O
and	O
valproic	O
acid/phenobarbital	O
.	O

Each	O
serum	O
without	O
the	O
other	O
added	O
drug	B-Drug
as	O
well	O
as	O
the	O
serum	O
supplemented	O
with	O
the	O
other	O
drug	B-Drug
at	O
the	O
three	O
concentrations	O
was	O
dialyzed	O
against	O
phosphate	B-Drug
buffer	O
.	O

Similarly	O
dialyzed	O
were	O
phenobarbital	B-Drug
,	O
quinidine	B-Drug
,	O
and	O
theophylline	B-Drug
,	O
both	O
alone	O
at	O
therapeutic	O
concentrations	O
in	O
serum	O
and	O
with	O
ethanol	B-Drug
at	O
three	O
different	O
concentrations	O
in	O
serum	O
.	O

The	O
percentage	O
of	O
drug	B-Drug
binding	O
in	O
each	O
preparation	O
was	O
calculated	O
.	O

Acetaminophen	B-Drug
diminished	O
the	O
binding	O
of	O
theophylline	B-Drug
to	O
human	O
serum	O
by	O
a	O
net	O
change	O
of	O
5.7	O
%	O
(	O
percentage	O
increase	O
in	O
free	O
drug	B-Drug
fraction	O
[	O
FDF	O
]	O
,	O
11.0	O
%	O
)	O
at	O
662	O
micromol/L	O
and	O
by	O
a	O
net	O
change	O
of	O
7.1	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
13.7	O
%	O
)	O
at	O
1324	O
micromol/L	O
.	O

Theophylline	B-Drug
decreased	O
the	O
binding	O
of	O
acetaminophen	B-Drug
by	O
a	O
net	O
change	O
of	O
6.8	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
8.8	O
%	O
)	O
at	O
277.5	O
micromol/L	O
;	O
phenobarbital	B-Drug
reduced	O
it	O
by	O
a	O
net	O
change	O
of	O
6.6	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
8.5	O
%	O
)	O
at	O
431	O
micromol/L	O
.	O

Valproic	B-Drug
acid	I-Drug
diminished	O
binding	O
of	O
phenobarbital	B-Drug
by	O
a	O
net	O
change	O
of	O
9.9	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
21.2	O
%	O
)	O
at	O
1732	O
micromol/L	O
.	O

No	O
significant	O
effects	O
were	O
noted	O
with	O
other	O
drug	B-Drug
combinations	O
or	O
with	O
the	O
addition	O
of	O
ethanol	B-Drug
.	O

Coingestion	O
of	O
acetaminophen	B-Drug
with	O
theophylline	B-Drug
,	O
phenobarbital	B-Drug
with	O
acetaminophen	B-Drug
,	O
and	O
valproic	B-Drug
acid	I-Drug
with	O
phenobarbital	B-Drug
at	O
high	O
to	O
toxic	O
concentrations	O
decreases	O
the	O
binding	O
of	O
the	O
target	O
drug	B-Drug
.	O

The	O
resulting	O
increase	O
in	O
free	O
drug	B-Drug
concentration	O
may	O
lead	B-Drug
to	O
enhanced	O
drug	B-Drug
effect	O
in	O
vivo	O
.	O

Phenytoin	B-Drug
intoxication	O
induced	O
by	O
fluvoxamine	B-Drug
.	O

A	O
patient	O
had	O
phenytoin	B-Drug
intoxication	O
after	O
administration	O
of	O
fluvoxamine	B-Drug
,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
.	O

The	O
serum	O
concentration	O
of	O
phenytoin	B-Drug
increased	O
dramatically	O
from	O
16.6	O
to	O
49.1	O
microg/mL	O
when	O
fluvoxamine	B-Drug
was	O
coadministered	O
,	O
although	O
the	O
daily	O
dosage	O
of	O
phenytoin	B-Drug
and	O
other	O
drugs	B-Drug
had	O
not	O
changed	O
.	O

During	O
phenytoin	B-Drug
and	O
fluvoxamine	B-Drug
treatment	O
,	O
ataxia	O
,	O
a	O
typical	O
side	O
effect	O
of	O
phenytoin	B-Drug
,	O
was	O
observed	O
.	O

The	O
genotypes	O
of	O
CYP2C9	B-Drug
and	O
2C19	O
,	O
the	O
enzymes	O
responsible	O
for	O
phenytoin	B-Drug
metabolism	O
,	O
were	O
homozygous	O
for	O
the	O
wild-type	O
alleles	O
(	O
CYP2C9*1/*1	B-Drug
and	O
2C19*1/	O
*1	O
)	O
.	O

The	O
interaction	O
may	O
be	O
a	O
result	O
of	O
inhibition	O
of	O
both	O
CYP2C9	B-Drug
and	O
2C19	O
by	O
fluvoxamine	B-Drug
.	O

Vancomycin	B-Drug
resistance	O
reversal	O
in	O
enterococci	O
by	O
flavonoids	O
.	O

The	O
development	O
of	O
clinical	O
vancomycin-resistant	O
strains	O
of	O
enterococci	O
(	O
VRE	O
)	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Here	O
we	O
show	O
that	O
a	O
combination	O
of	O
galangin	B-Drug
or	O
3,7-dihydroxyflavone	O
with	O
vancomycin	B-Drug
may	O
be	O
used	O
to	O
sensitize	O
resistant	O
strains	O
of	O
Enterococcus	O
faecalis	O
and	O
Enterococcus	O
faecium	O
to	O
the	O
level	O
of	O
vancomycin-sensitive	O
strains	O
.	O

Minimum	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
and	O
viable	O
counts	O
were	O
determined	O
in	O
Iso-sensitest	O
broth	O
using	O
a	O
microtitre	O
method	O
.	O

MICs	O
of	O
vancomycin	B-Drug
against	O
67	O
%	O
of	O
resistant	O
clinical	O
isolates	O
and	O
a	O
type	O
strain	O
of	O
enterococci	O
were	O
lowered	O
from	O
>	O
250	O
microg	O
mL	O
(	O
-1	O
)	O
to	O
1	O
4	O
microg	O
mL	O
(	O
-1	O
)	O
in	O
the	O
presence	O
of	O
galangin	B-Drug
(	O
12.5	O
microg	O
mL	O
(	O
-1	O
)	O
)	O
or	O
3,7-dihydroxyflavone	O
(	O
6.25	O
microg	O
mL	O
(	O
-1	O
)	O
)	O
.	O

Viable	O
counts	O
for	O
type	O
culture	O
E	O
.	O

faecalis	O
ATCC	O
51299	O
showed	O
the	O
flavonoids	O
alone	O
significantly	O
lowered	O
numbers	O
of	O
colony	O
forming	O
units	O
(	O
CFUs	O
)	O
.	O

CFUs	O
were	O
maintained	O
at	O
low	O
levels	O
(	O
10	O
(	O
3	O
)	O
CFU	O
mL	O
(	O
-1	O
)	O
)	O
for	O
24	O
h	O
by	O
vancomycin/flavone	B-Drug
combinations	O
.	O

This	O
combinational	O
action	O
in	O
reversing	O
vancomycin	B-Drug
resistance	O
of	O
enterococci	O
highlights	O
novel	O
drug	B-Drug
targets	O
and	O
has	O
importance	O
in	O
the	O
design	O
of	O
new	O
therapeutic	O
regimes	O
against	O
resistant	O
pathogens	O
.	O

Glucose	B-Drug
and	O
insulin	B-Drug
exert	O
additive	O
ocular	O
and	O
renal	O
vasodilator	O
effects	O
on	O
healthy	O
humans	O
.	O

AIMS/HYPOTHESIS	O
:	O
There	O
is	O
evidence	O
that	O
insulin	B-Drug
and	O
glucose	B-Drug
cause	O
renal	O
and	O
ocular	O
vasodilation	O
.	O

There	O
is	O
,	O
however	O
,	O
currently	O
no	O
data	O
on	O
the	O
effect	O
of	O
combined	O
hyperglycaemia	O
and	O
hyperinsulinaemia	B-Drug
on	O
the	O
renal	O
and	O
ocular	O
blood	O
flow	O
seen	O
in	O
diabetic	O
patients	O
on	O
insulin	B-Drug
therapy	O
.	O

METHODS	O
:	O
We	O
carried	O
out	O
two	O
different	O
3-way	O
crossover	O
studies	O
in	O
healthy	O
subjects	O
(	O
each	O
,	O
n	O
=	O
9	O
)	O
.	O

In	O
study	O
one	O
,	O
hyperglycaemic	O
clamps	O
(	O
5.6	O
mmol/l	O
,	O
11.1	O
mmol/	O
1	O
,	O
16.7	O
mmol/l	O
)	O
were	O
carried	O
out	O
during	O
placebo	O
or	O
insulin	B-Drug
(	O
dose	O
1	O
:	O
1	O
mU/kg/min	O
;	O
dose	O
2	O
:	O
2	O
mU/kg/min	O
)	O
infusion	O
.	O

The	O
second	O
study	O
was	O
identical	O
but	O
endogenous	O
insulin	B-Drug
secretion	O
was	O
blocked	O
with	O
somatostatin	B-Drug
.	O

The	O
renal	O
plasma	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
and	O
pulsatile	O
choroidal	O
blood	O
flow	O
were	O
measured	O
using	O
the	O
paraaminohippurate	O
method	O
,	O
the	O
inulin	O
method	O
and	O
a	O
laser	O
interferometric	O
measurement	O
of	O
fundus	O
pulsation	O
amplitude	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Insulin	B-Drug
increased	O
renal	O
plasma	O
flow	O
and	O
fundus	O
pulsation	O
amplitude	O
but	O
not	O
the	O
glomerular	O
filtration	O
rate	O
.	O

Hyperglycaemia	O
increased	O
all	O
the	O
renal	O
and	O
ocular	O
parameters	O
studied	O
.	O

Haemodynamic	O
effects	O
of	O
glucose	B-Drug
and	O
insulin	B-Drug
were	O
additive	O
when	O
somatostatin	B-Drug
was	O
co-administered	O
but	O
not	O
under	O
basal	O
conditions	O
.	O

CONCLUSIONS/INTERPRETATION	O
:	O
Glucose	B-Drug
and	O
insulin	B-Drug
can	O
exert	O
additive	O
vasodilator	O
properties	O
on	O
renal	O
and	O
ocular	O
circulation	O
.	O

To	O
find	O
out	O
whether	O
this	O
observation	O
is	O
related	O
to	O
the	O
increased	O
regional	O
perfusion	O
in	O
diabetes	O
longitudinal	O
studies	O
on	O
patients	O
with	O
Type	O
I	O
(	O
insulin-dependent	O
)	O
diabetes	O
mellitus	O
are	O
needed	O
.	O

Lack	O
of	O
interaction	O
between	O
levofloxacin	B-Drug
and	O
oxycodone	B-Drug
:	O
pharmacokinetics	O
and	O
drug	B-Drug
disposition	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
a	O
significant	O
reduction	O
in	O
the	O
oral	O
bioavailability	O
of	O
trovafloxacin	B-Drug
and	O
ciprofloxacin	B-Drug
when	O
administered	O
concomitantly	O
with	O
an	O
intravenous	O
opiate	O
such	O
as	O
morphine	B-Drug
.	O

This	O
decrease	O
in	O
absorption	O
results	O
in	O
a	O
36	O
%	O
and	O
50	O
%	O
lower	O
AUC	O
for	O
trovafloxacin	B-Drug
and	O
ciprofloxacin	B-Drug
,	O
respectively	O
,	O
which	O
could	O
cause	O
clinical	O
failures	O
.	O

The	O
authors	O
investigated	O
the	O
possibility	O
of	O
a	O
similar	O
interaction	O
between	O
oxycodone	B-Drug
and	O
levofloxacin	B-Drug
.	O

Eight	O
healthy	O
volunteers	O
were	O
randomized	O
in	O
an	O
open-label	O
,	O
two-way	O
crossover	O
study	O
to	O
receive	O
oxycodone	B-Drug
,	O
5	O
mg	O
p.o	O
.	O

Q4H	O
,	O
and	O
levofloxacin	B-Drug
,	O
500	O
mg	O
p.o	O
.	O

1	O
hour	O
after	O
starting	O
the	O
oxycodone	B-Drug
or	O
levofloxacin	B-Drug
500	O
mg	O
p.o	O
.	O

alone	O
.	O

Blood	O
samples	O
were	O
drawn	O
at	O
0	O
,	O
0.5	O
,	O
1	O
,	O
1.5	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
8	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
hours	O
for	O
Cmax	O
,	O
tmax	O
,	O
and	O
AUC	O
determinations	O
.	O

There	O
was	O
not	O
a	O
significant	O
difference	O
(	O
p	O
>	O
0.05	O
)	O
in	O
AUC	O
(	O
48.59	O
+/-	O
8.52	O
vs.	O
49.9	O
+/-	O
9.93	O
)	O
,	O
Cmax	O
(	O
7.73	O
+/-	O
2.6	O
vs.	O
6.6	O
+/-	O
2.0	O
)	O
,	O
and	O
tmax	O
(	O
1.1	O
+/-	O
0.6	O
vs.	O
1.6	O
+/-	O
1.1	O
)	O
for	O
levofloxacin	B-Drug
versus	O
levofloxacin/oxycodone	B-Drug
regimens	O
.	O

It	O
was	O
concluded	O
that	O
oral	O
oxycodone	B-Drug
and	O
levofloxacin	B-Drug
can	O
be	O
administered	O
concomitantly	O
without	O
a	O
significant	O
decrease	O
in	O
AUC	O
,	O
Cmax	O
,	O
or	O
tmax	O
.	O

Lack	O
of	O
an	O
effect	O
of	O
azithromycin	B-Drug
on	O
the	O
disposition	O
of	O
zidovudine	B-Drug
and	O
dideoxyinosine	B-Drug
in	O
HIV-infected	O
patients	O
.	O

Two	O
studies	O
were	O
conducted	O
in	O
HIV-infected	O
subjects	O
to	O
assess	O
the	O
potential	O
for	O
azithromycin	B-Drug
to	O
interact	O
with	O
zidovudine	B-Drug
and	O
dideoxyinosine	B-Drug
.	O

Both	O
studies	O
used	O
12	O
subjects	O
.	O

The	O
zidovudine	B-Drug
study	O
dosed	O
subjects	O
with	O
1200	O
mg/day	O
of	O
azithromycin	B-Drug
(	O
n	O
=	O
7	O
)	O
(	O
later	O
changed	O
to	O
600	O
mg/day	O
[	O
n	O
=	O
5	O
]	O
)	O
for	O
Days	O
8	O
to	O
21	O
of	O
a	O
21-day	O
course	O
of	O
100	O
mg	O
,	O
five	O
times/day	O
of	O
zidovudine	B-Drug
.	O

Subjects	O
treated	O
with	O
200	O
mg	O
of	O
dideoxyinosine	B-Drug
twice	O
daily	O
for	O
21	O
days	O
received	O
1200	O
mg	O
of	O
azithromycin	B-Drug
or	O
an	O
equivalent	O
amount	O
of	O
placebo/day	O
for	O
Days	O
8	O
to	O
21	O
.	O

Antiretroviral	O
plasma	O
and	O
urine	O
sampling	O
were	O
conducted	O
on	O
Days	O
1	O
,	O
7	O
,	O
and	O
21	O
for	O
zidovudine	B-Drug
and	O
on	O
Days	O
7	O
and	O
21	O
for	O
dideoxyinosine	B-Drug
.	O

Peripheral	O
mononuclear	O
cells	O
were	O
also	O
collected	O
for	O
quantitation	O
of	O
phosphorylated	O
zidovudine	B-Drug
.	O

Azithromycin	B-Drug
had	O
no	O
significant	O
impact	O
on	O
the	O
Cmax	O
and	O
AUC	O
of	O
zidovudine	B-Drug
,	O
although	O
it	O
significantly	O
decreased	O
the	O
zidovudine	B-Drug
tmax	O
by	O
44	O
%	O
and	O
increased	O
the	O
intracellular	O
exposure	O
to	O
phosphorylated	O
zidovudine	B-Drug
by	O
110	O
%	O
.	O

Azithromycin	B-Drug
had	O
no	O
significant	O
effect	O
on	O
dideoxyinosine	B-Drug
pharmacokinetics	O
.	O

Based	O
on	O
the	O
results	O
of	O
these	O
studies	O
,	O
it	O
is	O
concluded	O
that	O
azithromycin	B-Drug
may	O
be	O
safely	O
coadministered	O
with	O
both	O
zidovudine	B-Drug
and	O
dideoxyinosine	B-Drug
.	O

Effect	O
of	O
diazepam	B-Drug
and	O
midazolam	B-Drug
on	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B-Drug
,	O
metamizol	B-Drug
and	O
indomethacin	B-Drug
in	O
mice	O
.	O

The	O
influence	O
of	O
midazolam	B-Drug
and	O
diazepam	B-Drug
on	O
antinociceptive	O
effect	O
of	O
morphine	B-Drug
(	O
10	O
mg/kg	O
)	O
,	O
metamizol	B-Drug
(	O
500	O
mg/kg	O
)	O
and	O
indomethacin	B-Drug
(	O
10	O
mg/kg	O
)	O
was	O
investigated	O
in	O
a	O
mouse	O
model	O
using	O
the	O
tail-flick	O
and	O
hot-plate	O
tests	O
.	O

All	O
drugs	B-Drug
were	O
injected	O
intraperitoneally	O
.	O

Benzodiazepines	B-Drug
were	O
administered	O
to	O
mice	O
30	O
min	O
before	O
applying	O
the	O
analgesic	O
drugs	B-Drug
.	O

Measurement	O
of	O
nociception	O
was	O
performed	O
within	O
2	O
h	O
after	O
benzodiazepine	O
administration	O
.	O

Diazepam	B-Drug
at	O
doses	O
of	O
0.25	O
mg/kg	O
and	O
2.5	O
mg/kg	O
injected	O
with	O
morphine	B-Drug
was	O
found	O
to	O
decrease	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B-Drug
.	O

Similarly	O
,	O
diazepam	B-Drug
decreased	O
the	O
antinociceptive	O
effect	O
of	O
metamizol	B-Drug
(	O
only	O
in	O
the	O
tail-flick	O
test	O
)	O
and	O
indomethacin	B-Drug
.	O

Midazolam	B-Drug
used	O
at	O
doses	O
of	O
1.25	O
mg/kg	O
and	O
2.5	O
mg/kg	O
decreased	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B-Drug
,	O
metamizol	B-Drug
(	O
only	O
in	O
the	O
tail-flick	O
test	O
)	O
and	O
indomethacin	B-Drug
.	O

Pharmacological	O
treatment	O
of	O
depression	O
:	O
the	O
role	O
of	O
paroxetine	B-Drug
.	O

Depression	O
is	O
reaching	O
epidemic	O
proportions	O
in	O
the	O
western	O
world	O
.	O

With	O
each	O
successive	O
generation	O
more	O
people	O
are	O
becoming	O
more	O
severely	O
depressed	O
at	O
a	O
younger	O
age	O
.	O

Influence	O
of	O
estradiol	B-Drug
and	O
progesterone	B-Drug
on	O
the	O
sensitivity	O
of	O
rat	O
thoracic	O
aorta	O
to	O
noradrenaline	B-Drug
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
low	O
and	O
high	O
doses	O
of	O
estradiol	B-Drug
,	O
and	O
of	O
progesterone	B-Drug
on	O
the	O
response	O
to	O
noradrenaline	B-Drug
in	O
rat	O
thoracic	O
aorta	O
.	O

Two	O
weeks	O
after	O
bilateral	O
ovariectomy	O
,	O
female	O
rats	O
received	O
a	O
s.c	O
.	O

injection	O
of	O
vehicle	O
(	O
corn	O
oil	O
,	O
0.1	O
mL/day	O
)	O
,	O
estradiol	B-Drug
(	O
10	O
microg/kg/day	O
or	O
4	O
mg/kg/day	O
)	O
and/or	O
progesterone	B-Drug
(	O
20	O
mg/kg/day	O
)	O
,	O
for	O
eight	O
days	O
.	O

On	O
the	O
ninth	O
day	O
,	O
the	O
rats	O
were	O
sacrificed	O
and	O
aortic	O
rings	O
,	O
with	O
or	O
without	O
endothelium	O
,	O
were	O
used	O
to	O
generate	O
concentration-response	O
curves	O
to	O
noradrenaline	B-Drug
.	O

Aortic	O
rings	O
with	O
intact	O
endothelium	O
from	O
the	O
high-dose	O
(	O
4	O
mg/kg/day	O
)	O
estradiol	B-Drug
group	O
were	O
supersensitive	O
to	O
noradrenaline	B-Drug
compared	O
to	O
the	O
vehicle	O
or	O
low-dose	O
(	O
10	O
microg/kg/day	O
)	O
estradiol	B-Drug
groups	O
(	O
pD2	O
values	O
=	O
7.86+/-0.09	O
,	O
7.30+/-0.11	O
and	O
7.35+/-0.04	O
,	O
respectively	O
)	O
.	O

Endothelium-intact	O
aortic	O
rings	O
from	O
high-estradiol	B-Drug
rats	O
were	O
supersensitive	O
to	O
noradrenaline	B-Drug
when	O
compared	O
to	O
vehicle-	O
,	O
progesterone-	B-Drug
and	O
progesterone	B-Drug
+	O
high-estradiol-treated	B-Drug
rats	O
(	O
pD2	O
values	O
=	O
7.77+/-0.12	O
,	O
7.21+/-0.13	O
,	O
6.93+/-0.04	O
and	O
7.22+/-0.18	O
,	O
respectively	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
pD2	O
values	O
for	O
noradrenaline	B-Drug
in	O
aortic	O
rings	O
without	O
endothelium	O
.	O

Both	O
of	O
these	O
effects	O
were	O
endothelium-dependent	O
.	O

[	O
Drug	B-Drug
treatment	O
of	O
erection	O
disorders	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
]	O
Erectile	O
dysfunction	O
is	O
a	O
frequent	O
condition	O
in	O
cardiovascular	O
patients	O
.	O

Since	O
the	O
arrival	O
of	O
oral	O
erection-supporting	O
medication	O
,	O
patients	O
want	O
to	O
know	O
how	O
safe	O
sexual	O
activity	O
is	O
in	O
cardiovascular	O
disease	O
in	O
general	O
and	O
during	O
use	O
of	O
erection-supporting	O
medication	O
in	O
particular	O
.	O

Sexual	O
intercourse	O
with	O
a	O
steady	O
partner	O
causes	O
no	O
more	O
cardiovascular	O
risk	O
than	O
normal	O
daily	O
activities	O
such	O
as	O
ironing	O
,	O
2	O
kilometers	O
of	O
walking	O
without	O
climbing	O
,	O
paperhanging	O
,	O
playing	O
golf	O
or	O
gardening	O
.	O

The	O
relative	O
risk	O
of	O
myocardial	O
infarction	O
during	O
sexual	O
activity	O
is	O
not	O
significantly	O
higher	O
than	O
for	O
healthy	O
persons	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
morbidity	O
and	O
mortality	O
is	O
not	O
higher	O
among	O
users	O
of	O
sildenafil	B-Drug
.	O

Sildenafil	B-Drug
is	O
contraindicated	O
in	O
patients	O
using	O
long-acting	O
nitrates	B-Drug
or	O
who	O
may	O
need	O
to	O
use	O
short-acting	O
nitrates	B-Drug
,	O
because	O
the	O
combination	O
may	O
cause	O
a	O
sharp	O
fall	O
of	O
the	O
blood	O
pressure	O
.	O

No	O
interactions	O
have	O
been	O
observed	O
with	O
beta-receptor	O
blockers	O
,	O
calcium	B-Drug
antagonists	O
,	O
thiazide	O
and	O
loop	O
diuretics	B-Drug
and	O
ACE	O
inhibitors	O
.	O

Before	O
prescribing	O
a	O
symptomatic	O
(	O
pharmaceutical	O
)	O
treatment	O
for	O
patients	O
with	O
an	O
erection	O
disorder	O
,	O
attention	O
should	O
be	O
given	O
tot	O
the	O
sexological	O
,	O
psychological	O
and	O
medical	O
backgrounds	O
of	O
the	O
disorder	O
.	O

Secondary	O
prevention	O
of	O
atherosclerotic	O
risk	O
factors	O
is	O
also	O
important	O
:	O
regulation	O
of	O
blood	O
pressure	O
and	O
blood	O
sugar	O
level	O
,	O
hyperlipidaemia	O
and	O
obesity	O
,	O
as	O
well	O
as	O
a	O
change	O
of	O
lifestyle	O
(	O
giving	O
up	O
smoking	O
,	O
adapting	O
of	O
diet	O
and	O
more	O
physical	O
exertion	O
)	O
.	O

Patients	O
with	O
a	O
very	O
low	O
cardiac	O
capacity	O
should	O
be	O
advised	O
to	O
refrain	O
from	O
treatment	O
of	O
the	O
erection	O
disorder	O
.	O

Influence	O
of	O
coadministration	O
of	O
fluoxetine	B-Drug
on	O
cisapride	B-Drug
pharmacokinetics	O
and	O
QTc	O
intervals	O
in	O
healthy	O
volunteers	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
fluoxetine	B-Drug
on	O
the	O
pharmacokinetics	O
and	O
cardiovascular	O
safety	O
of	O
cisapride	B-Drug
at	O
steady	O
state	O
in	O
healthy	O
men	O
.	O

DESIGN	O
:	O
Open-label	O
,	O
three-phase	O
,	O
sequential	O
study	O
.	O

SETTING	O
:	O
Clinical	O
research	O
center	O
.	O

SUBJECTS	O
:	O
Twelve	O
healthy	O
male	O
volunteers	O
.	O

INTERVENTIONS	O
:	O
Each	O
subject	O
was	O
treated	O
according	O
to	O
the	O
following	O
sequence	O
:	O
baseline	O
;	O
phase	O
1	O
(	O
days	O
1-6	O
)	O
:	O
cisapride	B-Drug
10	O
mg	O
4	O
times/day	O
;	O
washout	O
(	O
days	O
7-13	O
)	O
;	O
phase	O
2	O
(	O
days	O
14-44	O
)	O
:	O
fluoxetine	B-Drug
20	O
mg/day	O
;	O
and	O
phase	O
3	O
(	O
days	O
45-52	O
)	O
:	O
cisapride	B-Drug
10	O
mg	O
4	O
times/day	O
(	O
days	O
45-51	O
)	O
plus	O
fluoxetine	B-Drug
20	O
mg/day	O
(	O
days	O
45-52	O
)	O
.	O

MEASUREMENTS	O
and	O
MAIN	O
RESULTS	O
:	O
Blood	O
samples	O
were	O
drawn	O
and	O
12-lead	O
electrocardiograms	O
performed	O
at	O
specified	O
time	O
points	O
after	O
the	O
last	O
morning	O
dose	O
of	O
cisapride	B-Drug
in	O
phases	O
1	O
and	O
3	O
.	O

Blood	O
samples	O
also	O
were	O
taken	O
before	O
morning	O
doses	O
on	O
the	O
3rd	O
,	O
4th	O
,	O
and	O
5th	O
days	O
of	O
phases	O
1	O
and	O
3	O
.	O

Electrocardiograms	O
were	O
done	O
at	O
baseline	O
and	O
on	O
the	O
last	O
day	O
of	O
the	O
washout	O
period	O
and	O
phase	O
2	O
.	O

Coadministration	O
of	O
fluoxetine	B-Drug
significantly	O
decreased	O
cisapride	B-Drug
plasma	O
concentrations	O
.	O

There	O
were	O
no	O
clinically	O
significant	O
changes	O
in	O
corrected	O
QT	O
intervals	O
during	O
administration	O
of	O
cisapride	B-Drug
alone	O
or	O
with	O
fluoxetine	B-Drug
.	O

Cisapride	B-Drug
was	O
well	O
tolerated	O
when	O
administered	O
alone	O
or	O
with	O
fluoxetine	B-Drug
.	O

CONCLUSION	O
:	O
Cisapride	B-Drug
can	O
be	O
administered	O
safely	O
to	O
patients	O
receiving	O
low	O
therapeutic	O
dosages	O
of	O
fluoxetine	B-Drug
.	O

Olanzapine	B-Drug
:	O
an	O
updated	O
review	O
of	O
its	O
use	O
in	O
the	O
management	O
of	O
schizophrenia	O
.	O

Olanzapine	B-Drug
,	O
a	O
thienobenzodiazepine	O
derivative	O
,	O
is	O
a	O
second	O
generation	O
(	O
atypical	O
)	O
antipsychotic	O
agent	O
which	O
has	O
proven	O
efficacy	O
against	O
the	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

Compared	O
with	O
conventional	O
antipsychotics	O
,	O
it	O
has	O
greater	O
affinity	O
for	O
serotonin	O
5-HT2A	O
than	O
for	O
dopamine	B-Drug
D2	O
receptors	O
.	O

In	O
large	O
,	O
well	O
controlled	O
trials	O
in	O
patients	O
with	O
schizophrenia	O
or	O
related	O
psychoses	O
,	O
olanzapine	B-Drug
5	O
to	O
20	O
mg/day	O
was	O
significantly	O
superior	O
to	O
haloperidol	B-Drug
5	O
to	O
20	O
mg/day	O
in	O
overall	O
improvements	O
in	O
psychopathology	O
rating	O
scales	O
and	O
in	O
the	O
treatment	O
of	O
depressive	O
and	O
negative	O
symptoms	O
,	O
and	O
was	O
comparable	O
in	O
effects	O
on	O
positive	O
psychotic	O
symptoms	O
.	O

The	O
1-year	O
risk	O
of	O
relapse	O
(	O
rehospitalisation	O
)	O
was	O
significantly	O
lower	O
with	O
olanzapine	B-Drug
than	O
with	O
haloperidol	B-Drug
treatment	O
.	O

In	O
the	O
first	O
double-blind	O
comparative	O
study	O
(	O
28-week	O
)	O
of	O
olanzapine	B-Drug
and	O
risperidone	B-Drug
,	O
olanzapine	B-Drug
10	O
to	O
20	O
mg/day	O
proved	O
to	O
be	O
significantly	O
more	O
effective	O
than	O
risperidone	B-Drug
4	O
to	O
12	O
mg/day	O
in	O
the	O
treatment	O
of	O
negative	O
and	O
depressive	O
symptoms	O
but	O
not	O
on	O
overall	O
psychopathology	O
symptoms	O
.	O

In	O
contrast	O
,	O
preliminary	O
results	O
from	O
an	O
8-week	O
controlled	O
study	O
suggested	O
risperidone	B-Drug
2	O
to	O
6	O
mg/day	O
was	O
superior	O
to	O
olanzapine	B-Drug
5	O
to	O
20	O
mg/day	O
against	O
positive	O
and	O
anxiety/depressive	O
symptoms	O
(	O
p	O
<	O
0.05	O
)	O
,	O
although	O
consistent	O
with	O
the	O
first	O
study	O
,	O
both	O
agents	O
demonstrated	O
similar	O
efficacy	O
on	O
measures	O
of	O
overall	O
psychopathology	O
.	O

Improvements	O
in	O
general	O
cognitive	O
function	O
seen	O
with	O
olanzapine	B-Drug
treatment	O
in	O
a	O
1-year	O
controlled	O
study	O
of	O
patients	O
with	O
early-phase	O
schizophrenia	O
,	O
were	O
significantly	O
greater	O
than	O
changes	O
seen	O
with	O
either	O
risperidone	B-Drug
or	O
haloperidol	B-Drug
.	O

However	O
,	O
preliminary	O
results	O
from	O
an	O
8-week	O
trial	O
showed	O
comparable	O
cognitive	O
enhancing	O
effects	O
of	O
olanzapine	B-Drug
and	O
risperidone	B-Drug
treatment	O
in	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
.	O

Several	O
studies	O
indicate	O
that	O
olanzapine	B-Drug
has	O
benefits	O
against	O
symptoms	O
of	O
aggression	O
and	O
agitation	O
,	O
while	O
other	O
studies	O
strongly	O
support	O
the	O
effectiveness	O
of	O
olanzapine	B-Drug
in	O
the	O
treatment	O
of	O
depressive	O
symptomatology	O
.	O

Olanzapine	B-Drug
is	O
associated	O
with	O
significantly	O
fewer	O
extrapyramidal	O
symptoms	O
than	O
haloperidol	B-Drug
and	O
risperidone	B-Drug
.	O

In	O
addition	O
,	O
olanzapine	B-Drug
is	O
not	O
associated	O
with	O
a	O
risk	O
of	O
agranulocytosis	O
as	O
seen	O
with	O
clozapine	B-Drug
or	O
clinically	O
significant	O
hyperprolactinaemia	O
as	O
seen	O
with	O
risperidone	B-Drug
or	O
prolongation	O
of	O
the	O
QT	O
interval	O
.	O

The	O
most	O
common	O
adverse	O
effects	O
reported	O
with	O
olanzapine	B-Drug
are	O
bodyweight	O
gain	O
,	O
somnolence	O
,	O
dizziness	O
,	O
anticholinergic	B-Drug
effects	O
(	O
constipation	O
and	O
dry	O
mouth	O
)	O
and	O
transient	O
asymptomatic	O
liver	O
enzyme	O
elevations	O
.	O

In	O
comparison	O
with	O
haloperidol	B-Drug
,	O
the	O
adverse	O
events	O
reported	O
significantly	O
more	O
frequently	O
with	O
olanzapine	B-Drug
in	O
>	O
or	O
=	O
3.5	O
%	O
of	O
patients	O
were	O
dry	O
mouth	O
,	O
bodyweight	O
gain	O
and	O
increased	O
appetite	O
and	O
compared	O
with	O
risperidone	B-Drug
,	O
only	O
bodyweight	O
gain	O
occurred	O
significantly	O
more	O
frequently	O
with	O
olanzapine	B-Drug
.	O

The	O
high	O
acquisition	O
cost	O
of	O
olanzapine	B-Drug
is	O
offset	O
by	O
reductions	O
in	O
other	O
treatment	O
costs	O
(	O
inpatient	O
and/or	O
outpatient	O
services	O
)	O
of	O
schizophrenia	O
.	O

Pharmacoeconomic	O
analyses	O
indicate	O
that	O
olanzapine	B-Drug
does	O
not	O
significantly	O
increase	O
,	O
and	O
may	O
even	O
decrease	O
,	O
the	O
overall	O
direct	O
treatment	O
costs	O
of	O
schizophrenia	O
,	O
compared	O
with	O
haloperidol	B-Drug
.	O

Compared	O
with	O
risperidone	B-Drug
,	O
olanzapine	B-Drug
has	O
also	O
been	O
reported	O
to	O
decrease	O
overall	O
treatment	O
costs	O
,	O
despite	O
the	O
several-fold	O
higher	O
daily	O
acquisition	O
cost	O
of	O
the	O
drug	B-Drug
.	O

Olanzapine	B-Drug
treatment	O
improves	O
quality	O
of	O
life	O
in	O
patients	O
with	O
schizophrenia	O
and	O
related	O
psychoses	O
to	O
a	O
greater	O
extent	O
than	O
haloperidol	B-Drug
,	O
and	O
to	O
broadly	O
the	O
same	O
extent	O
as	O
risperidone	B-Drug
.	O

CONCLUSIONS	O
:	O
Olanzapine	B-Drug
demonstrated	O
superior	O
antipsychotic	O
efficacy	O
compared	O
with	O
haloperidol	B-Drug
in	O
the	O
treatment	O
of	O
acute	O
phase	O
schizophrenia	O
,	O
and	O
in	O
the	O
treatment	O
of	O
some	O
patients	O
with	O
first-episode	O
or	O
treatment-resistant	O
schizophrenia	O
.	O

The	O
reduced	O
risk	O
of	O
adverse	O
events	O
and	O
therapeutic	O
superiority	O
compared	O
with	O
haloperidol	B-Drug
and	O
risperidone	B-Drug
in	O
the	O
treatment	O
of	O
negative	O
and	O
depressive	O
symptoms	O
support	O
the	O
choice	O
of	O
olanzapine	B-Drug
as	O
a	O
first-line	O
option	O
in	O
the	O
management	O
of	O
schizophrenia	O
in	O
the	O
acute	O
phase	O
and	O
for	O
the	O
maintenance	O
of	O
treatment	O
response	O
.	O

The	O
emerging	O
roles	O
of	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
in	O
antiretroviral	O
therapy	O
.	O

The	O
availability	O
of	O
potent	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
(	O
NNRTI	O
)	O
-based	O
regimens	O
for	O
antiretroviral	O
therapy	O
and	O
concerns	O
regarding	O
protease	O
inhibitor	O
(	O
PI	O
)	O
-related	O
metabolic	O
disturbances	O
have	O
led	O
to	O
significant	O
shifts	O
in	O
treatment	O
practices	O
in	O
HIV	O
infection	O
.	O

NNRTI-based	O
regimens	O
may	O
have	O
several	O
advantages	O
over	O
PI-based	O
therapy	O
for	O
initial	O
or	O
prolonged	O
therapy	O
,	O
including	O
more	O
convenient	O
administration	O
regimens	O
,	O
lower	O
tablet	O
volume	O
,	O
fewer	O
drug	B-Drug
interactions	O
,	O
and	O
central	O
nervous	O
system	O
penetration	O
.	O

No	O
data	O
from	O
prospective	O
clinical	O
trials	O
currently	O
exist	O
comparing	O
the	O
3	O
approved	O
agents	O
(	O
efavirenz	B-Drug
,	O
nevirapine	B-Drug
or	O
delavirdine	B-Drug
)	O
.	O

Both	O
efavirenz	B-Drug
and	O
nevirapine	B-Drug
have	O
been	O
compared	O
to	O
triple	O
therapy	O
with	O
the	O
PI	O
indinavir	B-Drug
over	O
48	O
weeks	O
as	O
initial	O
therapy	O
,	O
with	O
similar	O
responses	O
being	O
observed	O
with	O
nevirapine	B-Drug
regimens	O
and	O
superiority	O
observed	O
with	O
efavirenz	B-Drug
.	O

A	O
smaller	O
24-week	O
study	O
has	O
suggested	O
nevirapine	B-Drug
may	O
be	O
superior	O
to	O
the	O
PI	O
nelfinavir	B-Drug
.	O

Limited	O
comparative	O
data	O
in	O
patients	O
with	O
high	O
viral	O
loads	O
treated	O
with	O
nevirapine-	B-Drug
or	O
delavirdine-based	B-Drug
regimens	O
currently	O
exist	O
.	O

However	O
,	O
cohort	O
data	O
and	O
selected	O
patient	O
data	O
from	O
clinical	O
trials	O
suggest	O
comparable	O
activity	O
to	O
PI-based	O
regimens	O
in	O
these	O
patients	O
.	O

The	O
superiority	O
of	O
efavirenz	B-Drug
over	O
indinavir-based	B-Drug
regimens	O
has	O
been	O
observed	O
in	O
comparative	O
data	O
in	O
a	O
subset	O
of	O
patients	O
with	O
high	O
viral	O
loads	O
.	O

In	O
treatment-experienced	O
patients	O
,	O
available	O
uncontrolled	O
data	O
suggest	O
these	O
agents	O
contribute	O
to	O
regimen	O
efficacy	O
in	O
NNRTI-na	O
ve	O
,	O
treatment-experienced	O
patients	O
.	O

Efavirenz	B-Drug
has	O
demonstrated	O
superiority	O
over	O
nelfinavir	B-Drug
in	O
nucleoside-experienced	O
patients	O
,	O
although	O
combining	O
these	O
2	O
agents	O
may	O
represent	O
the	O
best	O
approach	O
in	O
these	O
circumstances	O
.	O

The	O
tolerability	O
of	O
NNRTIs	O
appears	O
generally	O
good	O
with	O
few	O
individuals	O
discontinuing	O
in	O
clinical	O
studies	O
as	O
a	O
result	O
of	O
adverse	O
drug	B-Drug
events	O
.	O

The	O
majority	O
of	O
adverse	O
events	O
with	O
NNRTIs	O
occur	O
within	O
the	O
first	O
month	O
,	O
and	O
are	O
predictable	O
and	O
manageable	O
without	O
therapy	O
interruption	O
.	O

[	O
Pharmacologic	O
interactions	O
in	O
chronic	O
treatments	O
:	O
corrective	O
measures	O
for	O
its	O
prevention	O
in	O
a	O
basic	O
area	O
of	O
rural	O
health	O
]	O
OBJECTIVES	O
:	O
To	O
identify	O
the	O
pharmacological	O
interactions	O
of	O
clinical	O
relevance	O
(	O
PICR	O
)	O
in	O
the	O
medication	O
authorization	O
cards	O
(	O
MAC	O
)	O
of	O
the	O
chronically	O
ill	O
and	O
to	O
establish	O
strategies	O
to	O
minimise	O
their	O
appearance	O
.	O

DESIGN	O
:	O
Cross-sectional	O
descriptive	O
study	O
.	O

SETTING	O
:	O
Rural	O
primary	O
care	O
centre	O
.	O

PATIENTS	O
:	O
Random	O
sample	O
of	O
626	O
MAC	O
out	O
of	O
a	O
total	O
of	O
1306	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
In	O
December	O
1998	O
,	O
the	O
following	O
was	O
gathered	O
for	O
every	O
MAC	O
with	O
more	O
than	O
one	O
drug	B-Drug
treatment	O
:	O
age	O
,	O
sex	O
,	O
number	O
of	O
drugs	B-Drug
,	O
intrinsic	O
value	O
,	O
drugs	B-Drug
prescribed	O
,	O
daily	O
dose	O
and	O
pharmacological	O
interactions	O
(	O
PI	O
)	O
,	O
classified	O
(	O
using	O
the	O
scale	O
of	O
Hansten	O
1996	O
)	O
into	O
light	O
and	O
clinically	O
relevant	O
.	O

Statistical	O
analysis	O
:	O
Mantel-Haenszel	O
(	O
alpha	O
=	O
0.05	O
)	O
.	O

Patients	O
'	O
mean	O
age	O
was	O
69.1	O
(	O
95	O
%	O
CI	O
,	O
+/-	O
1.2	O
)	O
.	O

Mean	O
number	O
of	O
drugs	B-Drug
per	O
MAC	O
was	O
4	O
(	O
95	O
%	O
CI	O
,	O
+/-	O
0.2	O
)	O
.	O

341	O
PI	O
affecting	O
197	O
patients	O
(	O
31.5	O
%	O
,	O
95	O
%	O
CI	O
,	O
+/-	O
3.6	O
)	O
were	O
identified	O
.	O

24.9	O
%	O
(	O
95	O
%	O
CI	O
,	O
+/-	O
4.5	O
)	O
were	O
PICR	O
,	O
detected	O
in	O
11.7	O
%	O
(	O
95	O
%	O
CI	O
,	O
+/-	O
2.5	O
)	O
of	O
the	O
MAC	O
.	O

The	O
existence	O
of	O
PI	O
was	O
related	O
to	O
the	O
number	O
of	O
drugs	B-Drug
prescribed	O
to	O
each	O
patient	O
(	O
p	O
<	O
0.01	O
)	O
.	O

There	O
were	O
26	O
PI	O
with	O
drugs	B-Drug
of	O
low	O
intrinsic	O
value	O
(	O
7.6	O
%	O
;	O
95	O
%	O
CI	O
,	O
+/-	O
2.8	O
)	O
.	O

74.1	O
%	O
(	O
95	O
%	O
CI	O
,	O
+/-	O
9.3	O
)	O
of	O
the	O
total	O
PICR	O
could	O
be	O
avoided	O
by	O
simple	O
recommendations	O
;	O
and	O
the	O
remaining	O
25.9	O
%	O
(	O
95	O
%	O
CI	O
,	O
+/-	O
9.3	O
)	O
by	O
monitoring	O
and	O
follow-up	O
of	O
patients	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
important	O
to	O
identify	O
the	O
medications	O
most	O
commonly	O
involved	O
in	O
the	O
PICR	O
so	O
as	O
to	O
establish	O
corrective	O
measures	O
to	O
minimise	O
the	O
risks	O
arising	O
from	O
multiple	O
medication	O
.	O

Four	O
educational	O
messages	O
advise	O
on	O
over	O
60	O
%	O
of	O
the	O
PICR	O
detected	O
.	O

Prescribing	O
.	O

Keys	O
to	O
maximizing	O
benefit	O
while	O
avoiding	O
adverse	O
drug	B-Drug
effects	O
.	O

When	O
prescribing	O
for	O
older	O
patients	O
,	O
some	O
physicians	O
are	O
overly	O
cautious	O
,	O
and	O
this	O
strategy	O
can	O
result	O
in	O
a	O
less	O
than	O
optimal	O
treatment	O
outcome	O
.	O

The	O
reluctance	O
to	O
treat	O
aggressively	O
is	O
understandable	O
because	O
the	O
geriatric	O
population	O
is	O
susceptible	O
to	O
adverse	O
drug	B-Drug
reactions	O
.	O

The	O
key	O
to	O
maximizing	O
therapy	O
lies	O
in	O
individualizing	O
it	O
as	O
much	O
as	O
possible	O
.	O

There	O
are	O
a	O
number	O
of	O
steps	O
physicians	O
can	O
take	O
to	O
ensure	O
that	O
their	O
patients	O
are	O
not	O
being	O
undertreated	O
.	O

These	O
steps	O
include	O
regular	O
reevaluations	O
of	O
dosages	O
and	O
plasma	O
drug	B-Drug
concentrations	O
,	O
recognition	O
and	O
understanding	O
of	O
drug	B-Drug
side	O
effects	O
,	O
and	O
avoidance	O
of	O
certain	O
agents	O
.	O

Close	O
monitoring	O
allows	O
physicians	O
to	O
minimize	O
risks	O
,	O
maximize	O
benefits	O
,	O
and	O
get	O
the	O
most	O
out	O
of	O
what	O
modern	O
medications	O
can	O
do	O
to	O
help	O
older	O
patients	O
.	O

Sildenafil	B-Drug
citrate	I-Drug
:	O
a	O
therapeutic	O
update	O
.	O

BACKGROUND	O
:	O
Since	O
its	O
approval	O
by	O
the	O
US	O
Food	O
and	O
Drug	B-Drug
Administration	O
in	O
March	O
1998	O
,	O
sildenafil	B-Drug
citrate	I-Drug
has	O
been	O
used	O
by	O
millions	O
of	O
men	O
for	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
.	O

Recent	O
studies	O
and	O
consensus	O
reports	O
have	O
expanded	O
our	O
understanding	O
of	O
its	O
efficacy	O
,	O
safety	O
,	O
contraindications	O
,	O
and	O
drug	B-Drug
interactions	O
.	O

OBJECTIVE	O
:	O
This	O
paper	O
reviews	O
recent	O
studies	O
of	O
the	O
efficacy	O
of	O
sildenafil	B-Drug
,	O
its	O
adverse	O
effects	O
and	O
drug	B-Drug
interactions	O
,	O
and	O
socioeconomic	O
factors	O
involved	O
in	O
its	O
use	O
,	O
with	O
a	O
focus	O
on	O
specific	O
patient	O
populations	O
(	O
prostate	O
cancer	O
,	O
diabetes	O
mellitus	O
,	O
ischemic	O
heart	O
disease	O
,	O
spinal	O
cord	O
injuries	O
,	O
neurologic	O
disorders	O
)	O
.	O

METHODS	O
:	O
Clinical	O
studies	O
,	O
case	O
reports	O
,	O
and	O
commentaries	O
and	O
editorials	O
concerning	O
sildenafil	B-Drug
published	O
in	O
the	O
international	O
literature	O
between	O
January	O
1999	O
and	O
August	O
2000	O
were	O
identified	O
through	O
searches	O
of	O
MEDLINE	O
,	O
PREMEDLINE	O
,	O
and	O
International	O
Pharmaceutical	O
Abstracts	O
,	O
using	O
the	O
terms	O
sildenafil	B-Drug
,	O
Viagra	O
,	O
and	O
erectile	O
dysfunction	O
.	O

RESULTS	O
:	O
Sildenafil	B-Drug
has	O
demonstrated	O
effectiveness	O
in	O
men	O
with	O
erectile	O
dysfunction	O
associated	O
with	O
prostatectomy	O
,	O
radiation	O
therapy	O
,	O
diabetes	O
mellitus	O
,	O
certain	O
neurologic	O
disorders	O
,	O
and	O
drug	B-Drug
therapy	O
(	O
eg	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
.	O

It	O
has	O
not	O
been	O
as	O
effective	O
in	O
women	O
with	O
sexual	O
dysfunction	O
,	O
with	O
the	O
exception	O
of	O
SSRI-associated	O
sexual	O
dysfunction	O
.	O

Some	O
disorders	O
unrelated	O
to	O
sexual	O
dysfunction	O
(	O
eg	O
,	O
esophageal	O
motility	O
dysfunction	O
)	O
may	O
also	O
respond	O
to	O
sildenafil	B-Drug
.	O

In	O
the	O
general	O
population	O
,	O
sildenafil	B-Drug
is	O
considered	O
to	O
have	O
an	O
acceptable	O
tolerability	O
profile	O
;	O
however	O
,	O
patients	O
with	O
moderate	O
to	O
severe	O
cardiovascular	O
disease	O
or	O
those	O
taking	O
nitrate	O
therapy	O
are	O
at	O
increased	O
risk	O
for	O
potentially	O
serious	O
cardiovascular	O
adverse	O
effects	O
with	O
sildenafil	B-Drug
therapy	O
.	O

In	O
addition	O
,	O
patients	O
taking	O
drugs	B-Drug
that	O
inhibit	O
the	O
cytochrome	O
P450	O
3A4	O
isozyme	O
,	O
which	O
metabolizes	O
sildenafil	B-Drug
,	O
may	O
experience	O
increased	O
drug	B-Drug
concentrations	O
and	O
possible	O
toxicity	O
from	O
normal	O
doses	O
of	O
sildenafil	B-Drug
.	O

CONCLUSIONS	O
:	O
Sildenafil	B-Drug
is	O
an	O
effective	O
first-line	O
therapy	O
for	O
erectile	O
dysfunction	O
in	O
men	O
.	O

The	O
decision	O
to	O
prescribe	O
this	O
agent	O
should	O
include	O
such	O
considerations	O
as	O
the	O
cost-risk-benefit	O
balance	O
,	O
patient	O
access	O
,	O
drug	B-Drug
distribution	O
pathways	O
,	O
and	O
prescription	O
drug	B-Drug
coverage	O
.	O

Acute	O
hydrocortisone	B-Drug
administration	O
does	O
not	O
affect	O
subjective	O
responses	O
to	O
d-amphetamine	B-Drug
in	O
humans	O
.	O

RATIONALE	O
:	O
Stress	O
and	O
glucocorticoids	O
facilitate	O
and	O
reinstate	O
psychostimulant	O
self-administration	O
in	O
rodents	O
.	O

However	O
,	O
the	O
effects	O
of	O
stress	O
and	O
glucocorticoids	O
on	O
the	O
subjective	O
and	O
behavioral	O
effects	O
of	O
psychostimulants	O
have	O
not	O
been	O
well	O
studied	O
in	O
humans	O
.	O

OBJECTIVES	O
:	O
To	O
examine	O
the	O
effects	O
of	O
acute	O
hydrocortisone	B-Drug
pretreatment	O
on	O
the	O
subjective	O
and	O
behavioral	O
effects	O
of	O
d-amphetamine	B-Drug
.	O

METHODS	O
:	O
Hydrocortisone	B-Drug
(	O
100	O
mg	O
)	O
and	O
d-amphetamine	B-Drug
(	O
20	O
mg	O
)	O
were	O
administered	O
orally	O
to	O
16	O
healthy	O
male	O
and	O
female	O
volunteers	O
in	O
a	O
four-session	O
,	O
placebo-controlled	O
,	O
within-subject	O
,	O
crossover	O
design	O
.	O

To	O
prevent	O
stomach	O
irritation	O
,	O
subjects	O
received	O
rantidine	B-Drug
hydrochloride	I-Drug
before	O
each	O
experimental	O
session	O
.	O

Dependent	O
measures	O
included	O
self-reported	O
mood	O
and	O
subjective	O
effects	O
(	O
Addiction	O
Research	O
Center	O
inventory	O
,	O
the	O
profile	O
of	O
mood	O
states	O
,	O
and	O
a	O
series	O
of	O
visual	O
analogue	O
scales	O
)	O
,	O
vital	O
signs	O
,	O
salivary	O
cortisol	O
,	O
and	O
psychomotor	O
performance	O
.	O

RESULTS	O
:	O
Hydrocortisone	B-Drug
elevated	O
salivary	O
cortisol	O
levels	O
,	O
produced	O
modest	O
dysphoria	O
,	O
and	O
reduced	O
subjects	O
'	O
reports	O
of	O
wanting	O
more	O
drug	B-Drug
.	O

However	O
,	O
hydrocortisone	B-Drug
pretreatment	O
did	O
not	O
affect	O
any	O
of	O
the	O
physiological	O
,	O
behavioral	O
,	O
or	O
subjective	O
effects	O
of	O
d-amphetamine	B-Drug
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
the	O
effects	O
of	O
glucocorticoids	O
in	O
rodent	O
studies	O
,	O
these	O
results	O
indicate	O
that	O
an	O
acute	O
increase	O
in	O
cortisol	O
does	O
not	O
enhance	O
the	O
psychostimulant	O
effects	O
of	O
d-amphetamine	B-Drug
in	O
humans	O
.	O

The	O
effects	O
of	O
ketamine	B-Drug
and	O
of	O
Innovar	O
anesthesia	B-Drug
on	O
digitalis	B-Drug
tolerance	O
in	O
dogs	O
.	O

In	O
a	O
comparison	O
of	O
digitalis	B-Drug
tolerance	O
in	O
dogs	O
anesthetized	O
with	O
ketamine	B-Drug
,	O
Innovar	O
Vet	O
,	O
or	O
pentobarbital	B-Drug
,	O
the	O
dosage	O
of	O
ouabain	B-Drug
needed	O
to	O
cause	O
ventricular	O
tachycardia	O
was	O
significantly	O
higher	O
,	O
as	O
was	O
the	O
LD50	O
of	O
ouabain	B-Drug
,	O
with	O
ketamine	B-Drug
or	O
Innovar	O
than	O
with	O
pentobarbital	B-Drug
.	O

Ventricular	O
tachycardia	O
induced	O
by	O
ouabain	B-Drug
was	O
generally	O
converted	O
to	O
sinus	O
rhythm	O
following	O
administration	O
of	O
Innovar	O
,	O
ketamine	B-Drug
,	O
or	O
droperidol	B-Drug
but	O
not	O
after	O
administration	O
of	O
fentayl	B-Drug
alone	O
or	O
after	O
pentobarbital	B-Drug
.	O

Interaction	O
between	O
oxytocin	B-Drug
and	O
antidiuretic	O
hormone	O
and	O
its	O
effect	O
on	O
the	O
milk	O
secretion	O
by	O
alveoli	O
of	O
the	O
mammary	O
gland	O
of	O
lactating	O
rats	O
.	O

Interaction	O
between	O
exogenous	O
and	O
endogenous	O
oxytocin	B-Drug
and	O
vasopressin	O
was	O
found	O
to	O
affect	O
the	O
mechanism	O
of	O
milk	O
ejection	O
by	O
the	O
alveoli	O
of	O
the	O
mammary	O
gland	O
in	O
lactating	O
rats	O
.	O

Inhibition	O
and	O
stimulation	O
of	O
the	O
effect	O
of	O
oxytocin	B-Drug
on	O
milk	O
ejection	O
by	O
vasopressin	O
was	O
demonstrated	O
.	O

On	O
the	O
basis	O
of	O
the	O
principles	O
observed	O
the	O
concentrations	O
fo	O
these	O
hormones	O
were	O
investigated	O
in	O
the	O
plasma	O
of	O
dogs	O
deprived	O
of	O
water	O
for	O
3	O
days	O
and	O
then	O
allowed	O
to	O
drink	O
.	O

Interaction	O
of	O
clindamycin	B-Drug
and	O
gentamicin	B-Drug
in	O
vitro	O
.	O

The	O
minimal	O
inhibitory	O
concentrations	O
of	O
clindamycin	B-Drug
and	O
gentamicin	B-Drug
alone	O
and	O
in	O
combinations	O
were	O
determined	O
by	O
a	O
microdilution	O
method	O
for	O
163	O
aerobic	O
,	O
facultative	O
,	O
and	O
anaerobic	O
clinical	O
isolates	O
.	O

All	O
77	O
strains	O
of	O
Staphylococcus	O
aureus	O
,	O
Diplococcus	O
pneumoniae	O
,	O
Streptococcus	O
pyogenes	O
,	O
and	O
anaerobic	O
bacteria	O
(	O
except	O
for	O
three	O
strains	O
of	O
Clostridium	O
)	O
were	O
inhibited	O
by	O
1.6	O
mug	O
or	O
less	O
of	O
clindamycin	B-Drug
per	O
ml	O
.	O

Gentamicin	B-Drug
did	O
not	O
interfere	O
with	O
the	O
activity	O
of	O
clindamycin	B-Drug
within	O
the	O
range	O
of	O
concentrations	O
tested	O
(	O
0.1	O
to	O
100	O
mug/ml	O
)	O
;	O
for	O
some	O
strains	O
combinations	O
were	O
synergistic	O
.	O

Sixty-two	O
(	O
94	O
%	O
)	O
of	O
66	O
strains	O
of	O
Enterobacteriaceae	O
and	O
Pseudomonas	O
aeruginosa	O
were	O
inhibited	O
by	O
6.2	O
mug	O
or	O
less	O
of	O
gentamicin	B-Drug
per	O
ml	O
.	O

Combinations	O
of	O
clindamycin	B-Drug
and	O
gentamicin	B-Drug
were	O
indifferent	O
for	O
29	O
strains	O
and	O
synergistic	O
for	O
33	O
strains	O
.	O

All	O
20	O
strains	O
of	O
enterococcus	O
,	O
three	O
strains	O
of	O
Clostridium	O
,	O
three	O
strains	O
of	O
Escherichia	O
coli	O
,	O
and	O
one	O
strain	O
of	O
Proteus	O
rettgeri	O
were	O
resistant	O
to	O
both	O
clindamycin	B-Drug
(	O
minimal	O
inhibitory	O
concentration	O
greater	O
than	O
3.1	O
mug/ml	O
)	O
and	O
gentamicin	B-Drug
(	O
minimal	O
inhibitory	O
concentration	O
greater	O
than	O
6.2	O
mug/ml	O
)	O
.	O

Combinations	O
of	O
clindamycin	B-Drug
and	O
gentamicin	B-Drug
were	O
indifferent	O
for	O
16	O
and	O
synergistic	O
for	O
11	O
of	O
the	O
resistant	O
strains	O
.	O

Except	O
for	O
clindamycin-sensitive	B-Drug
isolates	O
,	O
synergy	O
was	O
usually	O
observed	O
only	O
at	O
concentrations	O
of	O
one	O
or	O
both	O
drugs	B-Drug
which	O
are	O
not	O
readily	O
obtainable	O
in	O
vivo	O
.	O

Antagonism	O
was	O
never	O
observed	O
.	O

Molecular	O
basis	O
for	O
the	O
selective	O
toxicity	O
of	O
amphotericin	B-Drug
B	I-Drug
for	O
yeast	O
and	O
filipin	B-Drug
for	O
animal	O
cells	O
.	O

Among	O
the	O
polyene	O
antibiotics	B-Drug
,	O
many	O
,	O
like	O
filipin	B-Drug
,	O
can	O
not	O
be	O
used	O
clinically	O
because	O
they	O
are	O
toxic	O
;	O
amphotericin	B-Drug
B	I-Drug
,	O
however	O
,	O
is	O
useful	O
in	O
therapy	O
of	O
human	O
fungal	O
infections	O
because	O
it	O
is	O
less	O
toxic	O
.	O

Both	O
the	O
toxicity	O
of	O
filipin	B-Drug
and	O
the	O
therapeutic	O
value	O
of	O
amphotericin	B-Drug
B	I-Drug
can	O
be	O
rationalized	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
by	O
the	O
following	O
observations	O
:	O
(	O
i	O
)	O
these	O
polyene	O
antibiotics	B-Drug
showed	O
differential	O
effects	O
on	O
cells	O
;	O
filipin	B-Drug
was	O
more	O
potent	O
in	O
lysing	O
human	O
red	O
blood	O
cells	O
,	O
whereas	O
amphotericin	B-Drug
B	I-Drug
was	O
more	O
potent	O
in	O
inhibiting	O
yeast	O
cell	O
growth	O
;	O
and	O
(	O
ii	O
)	O
the	O
effects	O
of	O
filipin	B-Drug
were	O
more	O
efficiently	O
inhibited	O
by	O
added	O
cholesterol	O
,	O
the	O
major	O
membrane	O
sterol	O
in	O
human	O
cells	O
,	O
whereas	O
the	O
effects	O
of	O
amphotericin	B-Drug
B	I-Drug
were	O
more	O
efficiently	O
inhibited	O
by	O
ergosterol	O
,	O
the	O
major	O
membrane	O
sterol	O
in	O
yeast	O
.	O

The	O
simplest	O
inference	O
is	O
that	O
the	O
toxicity	O
and	O
effectiveness	O
of	O
polyenes	O
are	O
determined	O
by	O
their	O
relative	O
avidities	O
for	O
the	O
predominant	O
sterol	O
in	O
cell	O
membranes	O
.	O

Studies	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
miconazole	B-Drug
:	O
effect	O
of	O
miconazole	B-Drug
on	O
respiration	O
and	O
cell	O
permeability	O
of	O
Candida	O
albicans	O
.	O

The	O
antifungal	O
drug	B-Drug
,	O
miconazole	B-Drug
nitrate	I-Drug
,	O
inhibits	O
the	O
growth	O
of	O
several	O
species	O
of	O
Candida	O
.	O

Candida	O
albicans	O
,	O
one	O
of	O
the	O
pathogenic	O
species	O
,	O
was	O
totally	O
inhibited	O
at	O
a	O
concentration	O
of	O
approximately	O
10	O
mug/ml	O
.	O

Endogenous	O
respiration	O
was	O
unaffected	O
by	O
the	O
drug	B-Drug
at	O
a	O
concentration	O
as	O
high	O
as	O
100	O
mug/ml	O
,	O
whereas	O
exogenous	O
respiration	O
was	O
markedly	O
sensitive	O
and	O
inhibited	O
to	O
an	O
extent	O
of	O
85	O
%	O
.	O

The	O
permeability	O
of	O
the	O
cell	O
membrane	O
was	O
changed	O
as	O
evidenced	O
by	O
the	O
leakage	O
of	O
260-nm	O
absorbing	O
materials	O
,	O
amino	O
acids	O
,	O
proteins	O
,	O
and	O
inorganic	O
cations	O
.	O

The	O
results	O
we	O
present	O
clearly	O
show	O
that	O
the	O
drug	B-Drug
alters	O
the	O
cellular	O
permeability	O
,	O
and	O
thus	O
the	O
exogenous	O
respiration	O
becomes	O
sensitive	O
to	O
the	O
drug	B-Drug
.	O

Effect	O
of	O
probenecid	B-Drug
on	O
the	O
apparent	O
volume	O
of	O
distribution	O
and	O
elimination	O
of	O
cloxacillin	B-Drug
.	O

According	O
to	O
Gibaldi	O
et	O
al	O
.	O

(	O
1968	O
,	O
1970	O
)	O
,	O
the	O
higher	O
serum	O
concentrations	O
of	O
penicillins	B-Drug
and	O
cephaloridine	B-Drug
reached	O
after	O
administration	O
of	O
probenecid	B-Drug
are	O
due	O
not	O
only	O
to	O
slower	O
renal	O
elimination	O
but	O
also	O
to	O
an	O
altered	O
distribution	O
in	O
the	O
body	O
.	O

To	O
determine	O
whether	O
probenecid	B-Drug
has	O
a	O
direct	O
effect	O
on	O
the	O
distribution	O
of	O
cloxacillin	B-Drug
,	O
the	O
elimination	O
and	O
distribution	O
of	O
cloxacillin	B-Drug
was	O
studied	O
in	O
six	O
patients	O
,	O
five	O
lacking	O
kidney	O
function	O
and	O
one	O
with	O
a	O
partially	O
impaired	O
renal	O
function	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
probenecid	B-Drug
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
mean	O
values	O
of	O
the	O
volume	O
of	O
distribution	O
of	O
cloxacillin	B-Drug
with	O
and	O
without	O
probenecid	B-Drug
(	O
13.0	O
and	O
12.6	O
liters	O
,	O
respectively	O
)	O
.	O

Thus	O
,	O
the	O
hypothesis	O
of	O
Gibaldi	O
et	O
al	O
.	O

could	O
not	O
be	O
confirmed	O
for	O
cloxacillin	B-Drug
in	O
patients	O
lacking	O
kidney	O
function	O
.	O

In	O
spite	O
of	O
the	O
absence	O
of	O
kidney	O
function	O
,	O
the	O
value	O
of	O
the	O
elimination	O
rate	O
constant	O
was	O
significantly	O
decreased	O
in	O
the	O
presence	O
of	O
probenecid	B-Drug
(	O
from	O
0.326	O
to	O
0.263/h	O
)	O
.	O

This	O
might	O
be	O
explained	O
by	O
a	O
blockade	O
by	O
probenecid	B-Drug
of	O
the	O
elimination	O
of	O
cloxacillin	B-Drug
by	O
the	O
liver	O
.	O

Behavioral	O
mechanisms	O
underlying	O
the	O
link	O
between	O
smoking	O
and	O
drinking	O
.	O

Many	O
people	O
use	O
both	O
alcohol	B-Drug
and	O
nicotine	B-Drug
(	O
i.e.	O
,	O
cigarettes	O
and	O
other	O
tobacco	O
products	O
)	O
.	O

The	O
behavioral	O
effects	O
of	O
these	O
two	O
drugs	B-Drug
differ	O
,	O
and	O
they	O
do	O
not	O
act	O
on	O
the	O
same	O
target	O
sites	O
in	O
the	O
brain	O
,	O
although	O
they	O
may	O
share	O
,	O
or	O
partly	O
share	O
,	O
certain	O
properties	O
.	O

The	O
initiation	O
of	O
alcohol	B-Drug
or	O
nicotine	B-Drug
use	O
may	O
be	O
precipitated	O
by	O
similar	O
personality	O
characteristics	O
in	O
the	O
user	O
,	O
such	O
as	O
impulsivity	O
and	O
sensation	O
seeking	O
.	O

Moreover	O
,	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dependence	O
may	O
be	O
similar	O
for	O
alcohol	B-Drug
and	O
nicotine	B-Drug
.	O

Thus	O
,	O
certain	O
factors	O
,	O
such	O
as	O
reinforcing	O
drug	B-Drug
effects	O
,	O
conditioning	O
processes	O
,	O
automatic	O
behavior	O
,	O
and	O
stress	O
,	O
may	O
influence	O
the	O
development	O
of	O
dependence	O
on	O
both	O
drugs	B-Drug
.	O

Other	O
factors	O
,	O
such	O
as	O
tolerance	O
and	O
sensitization	O
to	O
the	O
drugs	B-Drug
'	O
actions	O
and	O
the	O
development	O
of	O
withdrawal	O
symptoms	O
,	O
may	O
also	O
contribute	O
to	O
dependence	O
.	O

This	O
review	O
discusses	O
the	O
actions	O
of	O
the	O
two	O
drugs	B-Drug
on	O
certain	O
brain	O
chemical	O
(	O
i.e.	O
,	O
neurotransmitter	O
)	O
systems	O
and	O
the	O
extent	O
to	O
which	O
the	O
effects	O
of	O
the	O
two	O
drugs	B-Drug
may	O
interact	O
.	O

[	O
Dose-time	O
effects	O
of	O
competitive	O
displacement	O
of	O
radiopertechnetate	B-Drug
by	O
sodium	B-Drug
perchlorate	I-Drug
following	O
oral	O
and	O
intravenous	O
administration	O
]	O
The	O
effect	O
of	O
various	O
doses	O
of	O
sodium	B-Drug
perchlorate	I-Drug
in	O
several	O
dose	O
fractions	O
on	O
the	O
extent	O
and	O
the	O
time	O
scale	O
of	O
displacement	O
of	O
radiopertechnetate	B-Drug
,	O
in	O
dependence	O
on	O
application	O
mode	O
,	O
was	O
studied	O
.	O

An	O
intravenous	O
dose	O
of	O
50	O
mg	O
perchlorate	B-Drug
was	O
in	O
respect	O
of	O
competitive	O
suppression	O
of	O
organs	O
actively	O
concentrating	O
pertechnetate	B-Drug
as	O
effective	O
as	O
intravenous	O
1000	O
mg	O
ClO-4-	O
simultaneously	O
or	O
1000	O
mg	O
orally	O
30	O
min	O
before	O
the	O
injection	O
of	O
radiopertechnetate	B-Drug
.	O

An	O
intravenous	O
injection	O
of	O
perchlorate	B-Drug
given	O
later	O
also	O
produces	O
a	O
complete	O
and	O
immediately	O
beginning	O
depletion	O
of	O
pertechnetate	B-Drug
already	O
accumulated	O
in	O
the	O
thyroid	B-Drug
,	O
within	O
a	O
period	O
of	O
195	O
min	O
after	O
99m-TcO-4-injection	O
with	O
a	O
corresponding	O
increase	O
in	O
blood	O
levels	O
.	O

20	O
mg	O
result	O
in	O
incomplete	O
depletion	O
which	O
becomes	O
complete	O
after	O
a	O
second	O
additional	O
dose	O
.	O

The	O
intravenous	O
application	O
of	O
perchlorate	B-Drug
offers	O
advantages	O
in	O
clinical	O
use	O
.	O

Herbal	O
remedies	O
,	O
nephropathies	O
,	O
and	O
renal	O
disease	O
.	O

The	O
use	O
of	O
herbal	O
remedies	O
is	O
becoming	O
increasingly	O
popular	O
in	O
the	O
United	O
States	O
.	O

Research	O
has	O
shown	O
that	O
herbal	O
remedy	O
use	O
may	O
be	O
associated	O
with	O
acute	O
renal	O
failure	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
herbal	O
remedies	O
may	O
be	O
detrimental	O
for	O
the	O
patient	O
with	O
compromised	O
renal	O
function	O
.	O

Patients	O
with	O
renal	O
insufficiency	O
or	O
renal	O
failure	O
may	O
be	O
at	O
risk	O
for	O
further	O
kidney	O
damage	O
as	O
well	O
as	O
complications	O
related	O
to	O
interactions	O
of	O
herbal	O
remedies	O
with	O
complex	O
renal	O
therapy	O
regimens	O
.	O

This	O
article	O
will	O
describe	O
the	O
escalating	O
use	O
of	O
herbal	O
therapy	O
and	O
the	O
hazards	O
of	O
herbal	O
remedy	O
use	O
among	O
patients	O
.	O

Sirolimus	B-Drug
:	O
mammalian	O
target	O
of	O
rapamycin	B-Drug
inhibitor	O
to	O
prevent	O
kidney	O
rejection	O
.	O

Current	O
immunosuppressive	O
therapies	O
are	O
effective	O
but	O
can	O
be	O
associated	O
with	O
significant	O
adverse	O
reactions	O
.	O

Sirolimus	B-Drug
works	O
differently	O
from	O
the	O
immunosuppressants	O
currently	O
available	O
,	O
and	O
except	O
for	O
increased	O
lipid	O
levels	O
,	O
the	O
adverse	O
reaction	O
profile	O
of	O
sirolimus	B-Drug
does	O
not	O
appear	O
to	O
overlap	O
to	O
any	O
great	O
extent	O
with	O
that	O
associated	O
with	O
cyclosporine	B-Drug
or	O
tacrolimus	B-Drug
.	O

While	O
additional	O
research	O
is	O
needed	O
,	O
the	O
initial	O
clinical	O
data	O
in	O
kidney	O
recipients	O
suggest	O
that	O
sirolimus	B-Drug
,	O
in	O
combination	O
with	O
cyclosporine	B-Drug
or	O
tacrolimus	B-Drug
,	O
might	O
have	O
the	O
potential	O
to	O
reduce	O
the	O
frequency	O
of	O
rejection	O
episodes	O
,	O
permit	O
reductions	O
in	O
cyclosporine	B-Drug
or	O
tacrolimus	B-Drug
dosage	O
,	O
and	O
permit	O
steroid	O
withdrawal	O
(	O
Kelly	O
,	O
1999	O
)	O
.	O

The	O
effects	O
of	O
chlordiazepoxide	B-Drug
,	O
amphetamine	B-Drug
and	O
cocaine	B-Drug
on	O
bar-press	O
behavior	O
in	O
normal	O
and	O
genetically	O
nervous	O
dogs	O
.	O

Studies	O
on	O
two	O
strains	O
of	O
pointer	O
dogs	O
have	O
demonstrated	O
that	O
administration	O
of	O
a	O
benzodiazepine	O
(	O
chlordiazepoxide	B-Drug
)	O
facilitates	O
acquisition	O
of	O
goal-directed	O
behavior	O
in	O
``	O
genetically	O
nervous	O
''	O
subjects	O
.	O

Continued	O
admistration	O
of	O
the	O
drug	B-Drug
is	O
required	O
to	O
maintain	O
barpress	O
response	O
in	O
this	O
strain	O
of	O
dogs	O
.	O

The	O
concomitant	O
administration	O
of	O
either	O
cocaine	B-Drug
or	O
amphetamine	B-Drug
,	O
compounds	O
which	O
inhibit	O
neuronal	O
reuptake	O
of	O
norepinephrine	B-Drug
,	O
disrupts	O
the	O
behavioral	O
response	O
of	O
the	O
genetically	O
nervous	O
E-strain	O
subjects	O
to	O
a	O
far	O
greater	O
extent	O
than	O
the	O
stable	O
A-strain	O
subjects	O
.	O

It	O
is	O
also	O
shown	O
that	O
after	O
14	O
days	O
of	O
daily	O
administration	O
of	O
chlordiazepoxide	B-Drug
,	O
withdrawal	O
of	O
the	O
drug	B-Drug
not	O
only	O
re-results	O
in	O
almost	O
complete	O
loss	O
of	O
bar-press	O
response	O
in	O
the	O
E-strain	O
subjects	O
but	O
also	O
results	O
in	O
a	O
temporary	O
decrease	O
in	O
the	O
acquired	O
behavioral	O
response	O
of	O
the	O
stable	O
A-strain	O
subjects	O
.	O

Development	O
and	O
pharmacology	O
of	O
fluvastatin	B-Drug
.	O

Fluvastatin	B-Drug
is	O
the	O
first	O
synthetic	O
3-hydroxy-3-methylglutaryl	O
coenzyme	O
A	O
(	O
HMGCoA	O
)	O
reductase	O
inhibitor	O
to	O
be	O
approved	O
for	O
clinical	O
use	O
,	O
and	O
has	O
been	O
studied	O
extensively	O
in	O
humans	O
since	O
1986	O
.	O

It	O
is	O
structurally	O
distinct	O
from	O
the	O
other	O
currently	O
available	O
HMGCoA	O
reductase	O
inhibitors	O
(	O
lovastatin	B-Drug
,	O
simvastatin	B-Drug
,	O
and	O
pravastatin	B-Drug
)	O
,	O
leading	O
to	O
unique	O
biopharmaceutical	O
properties	O
relative	O
to	O
the	O
other	O
agents	O
of	O
this	O
class	O
.	O

Absorption	O
of	O
fluvastatin	B-Drug
is	O
virtually	O
complete	O
across	O
all	O
species	O
,	O
including	O
man	O
,	O
and	O
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
food	O
.	O

Systemic	O
exposure	O
is	O
limited	O
,	O
as	O
fluvastatin	B-Drug
is	O
subject	O
to	O
first-pass	O
metabolism	O
,	O
and	O
the	O
plasma	O
half-life	O
of	O
the	O
drug	B-Drug
is	O
approximately	O
30	O
minutes	O
.	O

Some	O
95	O
%	O
of	O
a	O
single	O
dosage	O
of	O
fluvastatin	B-Drug
is	O
excreted	O
via	O
the	O
biliary	O
route	O
,	O
with	O
less	O
than	O
2	O
%	O
of	O
this	O
being	O
the	O
parent	O
compound	O
.	O

Additionally	O
,	O
there	O
is	O
no	O
evidence	O
of	O
circulating	O
active	O
metabolites	O
or	O
accumulation	O
during	O
chronic	O
dosing	O
.	O

Studies	O
of	O
the	O
effect	O
of	O
food	O
on	O
the	O
pharmacokinetics	O
of	O
fluvastatin	B-Drug
have	O
demonstrated	O
marked	O
reductions	O
in	O
the	O
rate	O
of	O
bioavailability	O
--	O
from	O
40	O
%	O
to	O
60	O
%	O
;	O
however	O
,	O
a	O
comparison	O
of	O
fluvastatin	B-Drug
administration	O
with	O
the	O
evening	O
meal	O
or	O
at	O
bedtime	O
has	O
revealed	O
no	O
significant	O
differences	O
in	O
the	O
extent	O
of	O
bioavailability	O
(	O
area	O
under	O
the	O
curve	O
)	O
of	O
these	O
two	O
regimens	O
.	O

Furthermore	O
,	O
no	O
significant	O
difference	O
in	O
pharmacodynamic	O
effect	O
(	O
reduction	O
in	O
low-density	O
lipoprotein	O
cholesterol	O
levels	O
)	O
could	O
be	O
ascertained	O
between	O
mealtime	O
dosing	O
and	O
bedtime	O
dosing	O
.	O

The	O
pharmacokinetics	O
of	O
fluvastatin	B-Drug
have	O
also	O
been	O
assessed	O
in	O
various	O
demographic	O
groups	O
.	O

Relative	O
to	O
the	O
general	O
population	O
,	O
plasma	O
concentrations	O
of	O
fluvastatin	B-Drug
do	O
not	O
vary	O
as	O
a	O
function	O
of	O
either	O
age	O
or	O
gender	O
.	O

In	O
addition	O
,	O
administration	O
to	O
a	O
patient	O
population	O
with	O
hepatic	O
insufficiency	O
resulted	O
in	O
a	O
2.5-fold	O
increase	O
in	O
both	O
the	O
rate	O
and	O
extent	O
of	O
bioavailability	O
relative	O
to	O
controls	O
.	O

Also	O
,	O
although	O
minimal	O
alterations	O
of	O
fluvastatin	B-Drug
clearance	O
in	O
patients	O
with	O
renal	O
insufficiency	O
are	O
anticipated	O
due	O
to	O
limited	O
renal	O
excretion	O
(	O
5	O
%	O
)	O
,	O
a	O
study	O
in	O
this	O
patient	O
group	O
is	O
currently	O
underway	O
to	O
examine	O
this	O
further	O
.	O

Interaction	O
studies	O
have	O
been	O
performed	O
with	O
fluvastatin	B-Drug
and	O
several	O
drugs	B-Drug
with	O
which	O
it	O
might	O
be	O
coadministered	O
.	O

Cholestyramine	B-Drug
,	O
an	O
anionic-binding	O
resin	O
,	O
has	O
a	O
considerable	O
effect	O
in	O
lowering	O
the	O
rate	O
and	O
extent	O
of	O
fluvastatin	B-Drug
bioavailability	O
.	O

Although	O
this	O
effect	O
was	O
noted	O
even	O
when	O
cholestyramine	B-Drug
was	O
given	O
4	O
hours	O
prior	O
to	O
fluvastatin	B-Drug
,	O
this	O
regimen	O
did	O
not	O
result	O
in	O
diminished	O
efficacy	O
.	O

Further	O
,	O
no	O
effects	O
on	O
either	O
warfarin	B-Drug
levels	O
or	O
prothrombin	O
times	O
were	O
observed	O
in	O
a	O
study	O
involving	O
concomitant	O
administration	O
of	O
warfarin	B-Drug
and	O
fluvastatin	B-Drug
.	O

Moreover	O
,	O
additional	O
interaction	O
studies	O
with	O
niacin	B-Drug
and	O
propranolol	B-Drug
have	O
not	O
demonstrated	O
any	O
effect	O
on	O
fluvastatin	B-Drug
plasma	O
levels	O
,	O
and	O
administration	O
to	O
a	O
patient	O
population	O
chronically	O
receiving	O
digoxin	B-Drug
resulted	O
in	O
no	O
difference	O
in	O
the	O
extent	O
of	O
bioavailability	O
of	O
digoxin	B-Drug
relative	O
to	O
control	O
data	O
.	O

The	O
results	O
generated	O
to	O
date	O
in	O
clinical	O
pharmacokinetic	O
studies	O
with	O
fluvastatin	B-Drug
thus	O
support	O
its	O
use	O
in	O
a	O
broad	O
population	O
of	O
hypercholesterolaemic	O
patients	O
.	O

Tumor	O
phenotype	O
and	O
susceptibility	O
to	O
progression	O
as	O
an	O
expression	O
of	O
subpopulations	O
of	O
initiated	O
murine	O
cells	O
.	O

Currently	O
,	O
it	O
is	O
conceived	O
that	O
a	O
number	O
of	O
events	O
,	O
or	O
hits	O
,	O
are	O
required	O
for	O
the	O
induction	O
of	O
tumors	O
by	O
chemical	O
agents	O
.	O

The	O
first	O
phase	O
of	O
this	O
sequence	O
,	O
initiation	O
,	O
is	O
considered	O
to	O
result	O
from	O
at	O
least	O
one	O
event	O
in	O
the	O
genetic	O
apparatus	O
.	O

Analyses	O
of	O
this	O
sequence	O
,	O
however	O
,	O
usually	O
give	O
little	O
consideration	O
to	O
the	O
nature	O
of	O
the	O
target	O
cell	O
or	O
to	O
the	O
characteristics	O
of	O
the	O
resultant	O
tumors	O
.	O

Vesselinovitch	O
et	O
al	O
.	O

(	O
Cancer	O
Res.	O
,	O
38	O
:	O
2003-2010	O
,	O
1978	O
)	O
have	O
reported	O
that	O
a	O
single	O
,	O
small	O
pulse	O
of	O
carcinogen	O
can	O
induce	O
early	O
and	O
numerous	O
liver	O
tumors	O
when	O
administered	O
neonatally	O
to	O
mice	O
with	O
a	O
genetic	O
predisposition	O
to	O
hepatotumorigenesis	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
nonpredisposed	O
strain	O
C57BL/6N	O
was	O
also	O
shown	O
to	O
be	O
highly	O
susceptible	O
to	O
diethylnitrosamine	O
during	O
the	O
neonatal	O
period	O
.	O

C57BL/6N	O
demonstrated	O
large	O
numbers	O
of	O
two	O
of	O
the	O
three	O
types	O
of	O
liver	O
tumors	O
seen	O
in	O
livers	O
of	O
genetically	O
predisposed	O
mice	O
,	O
one	O
of	O
which	O
required	O
the	O
additional	O
stimulus	O
of	O
dietary	O
phenobarbital	B-Drug
for	O
growth	O
.	O

Tumors	O
of	O
more	O
malignant	O
phenotype	O
were	O
demonstrated	O
only	O
in	O
genetically	O
predisposed	O
mice	O
(	O
C57BL/6N	O
X	O
C3H/HeN	O
F1	O
)	O
that	O
received	O
one	O
dose	O
of	O
carcinogen	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
phenotype	O
of	O
a	O
tumor	O
that	O
results	O
from	O
a	O
pulse	O
of	O
a	O
chemical	O
carcinogen	O
may	O
depend	O
upon	O
the	O
target	O
cell	O
.	O

The	O
initiated	O
cells	O
that	O
result	O
from	O
this	O
hit	O
may	O
vary	O
from	O
those	O
that	O
demonstrate	O
very	O
little	O
progression	O
in	O
cell	O
type	O
and	O
may	O
or	O
may	O
not	O
require	O
exogenous	O
enhancement	O
of	O
growth	O
to	O
those	O
that	O
can	O
progress	O
very	O
rapidly	O
to	O
fully	O
malignant	O
behavior	O
.	O

The	O
latter	O
might	O
arise	O
from	O
a	O
hit	O
in	O
a	O
genetically	O
initiated	O
cell	O
,	O
the	O
result	O
of	O
which	O
is	O
a	O
more	O
rapid	O
progression	O
in	O
tumor	O
type	O
.	O

Analgesic	O
effects	O
of	O
antihistaminics	O
.	O

The	O
literature	O
provides	O
considerable	O
evidence	O
indicating	O
that	O
several	O
,	O
but	O
not	O
all	O
antihistaminics	O
,	O
are	O
indeed	O
analgesic	O
agents	O
and	O
some	O
are	O
analgesic	O
adjuvants	O
as	O
well	O
.	O

Those	O
for	O
which	O
effectiveness	O
is	O
reported	O
includes	O
diphenhydramine	B-Drug
,	O
hydroxyzine	B-Drug
,	O
orphenadrine	B-Drug
,	O
pyrilamine	B-Drug
,	O
phenyltoloxamine	B-Drug
,	O
promethazine	B-Drug
,	O
methdilazine	B-Drug
,	O
and	O
tripelennamine	B-Drug
.	O

The	O
proposed	O
mechanisms	O
of	O
analgesic	O
action	O
of	O
antihistaminics	O
are	O
reviewed	O
and	O
discussed	O
.	O

The	O
literature	O
suggests	O
that	O
more	O
than	O
one	O
mechanism	O
of	O
action	O
exists	O
for	O
them	O
.	O

There	O
is	O
considerable	O
evidence	O
suggesting	O
that	O
histaminergic	O
and	O
serotoninergic	O
central	O
pathways	O
are	O
involved	O
in	O
nociception	O
and	O
that	O
antihistaminic	O
drugs	B-Drug
can	O
modulate	O
their	O
responses	O
(	O
1	O
)	O
.	O

The	O
evidence	O
for	O
a	O
role	O
for	O
norepinephrine	B-Drug
and	O
dopamine	B-Drug
and	O
the	O
effects	O
of	O
antihistaminics	O
on	O
them	O
are	O
less	O
well	O
established	O
.	O

Still	O
other	O
pathways	O
have	O
been	O
proposed	O
.	O

A	O
greater	O
understanding	O
of	O
pain	O
mechanisms	O
will	O
aid	O
in	O
elucidating	O
the	O
role	O
of	O
antihistaminics	O
in	O
analgesia	O
.	O

[	O
The	O
GABA-ergic	O
system	O
and	O
brain	O
edema	O
]	O
It	O
has	O
been	O
shown	O
in	O
rats	O
with	O
experimental	O
toxic	O
and	O
traumatic	O
edemas	O
that	O
picrotoxin	B-Drug
(	O
1	O
mg/kg	O
)	O
removes	O
the	O
antiedematous	O
action	O
of	O
diazepam	B-Drug
,	O
phenazepam	B-Drug
,	O
phenibut	B-Drug
and	O
amizyl	B-Drug
and	O
reduces	O
the	O
action	O
of	O
phentolamine	B-Drug
.	O

When	O
the	O
dose	O
of	O
picrotoxin	B-Drug
is	O
minimized	O
to	O
0.5	O
mg/kg	O
such	O
an	O
effect	O
is	O
not	O
observed	O
.	O

Prolonged	O
daily	O
administration	O
of	O
picrotoxin	B-Drug
in	O
a	O
dose	O
of	O
1	O
mg/kg	O
results	O
in	O
the	O
development	O
of	O
brain	O
edema	O
.	O

It	O
is	O
recommended	O
that	O
GABA-positive	O
drugs	B-Drug
be	O
included	O
into	O
a	O
complex	O
of	O
treatment	O
measures	O
for	O
edema	O
.	O

[	O
Stimulation	O
by	O
cerulein	B-Drug
--	O
an	O
analog	O
of	O
the	O
octapeptide	O
cholecystokinin	O
--	O
of	O
3H-spiroperidol	B-Drug
binding	O
after	O
the	O
long-term	O
administration	O
of	O
neuroleptics	O
]	O
It	O
has	O
been	O
established	O
in	O
experiments	O
on	O
white	O
male	O
rats	O
that	O
prolonged	O
administration	O
(	O
twice	O
a	O
day	O
for	O
14	O
days	O
)	O
of	O
haloperidol	B-Drug
(	O
0.25	O
mg/kg	O
)	O
and	O
pyreneperone	B-Drug
(	O
0.25	O
mg/kg	O
)	O
resulted	O
in	O
the	O
reduced	O
interaction	O
between	O
3H-spiroperidol	B-Drug
and	O
low	O
affinity	O
binding	O
sites	O
for	O
apomorphine	B-Drug
in	O
subcortical	O
structures	O
,	O
whereas	O
3H-spiroperidol	B-Drug
binding	O
with	O
high	O
affinity	O
binding	O
sites	O
for	O
apomorphine	B-Drug
increased	O
both	O
in	O
the	O
frontal	O
cortex	O
and	O
subcortical	O
structures	O
of	O
the	O
forebrain	O
.	O

After	O
prolonged	O
administration	O
of	O
neuroleptics	O
the	O
displacing	O
effect	O
of	O
cerulein	B-Drug
,	O
an	O
analog	O
of	O
cholecystokinin	O
octapeptide	O
,	O
was	O
replaced	O
by	O
the	O
stimulant	O
action	O
on	O
3H-spiroperidol	B-Drug
binding	O
.	O

It	O
is	O
assumed	O
that	O
increased	O
interaction	O
between	O
3H-spiroperidol	B-Drug
and	O
high	O
affinity	O
binding	O
sites	O
for	O
apomorphine	B-Drug
on	O
dopamine2-	O
and	O
serotonin2-receptors	O
underlies	O
the	O
antipsychotic	O
action	O
of	O
neuroleptics	O
after	O
their	O
prolonged	O
administration	O
.	O

Cholecystokinin	O
octapeptide	O
is	O
a	O
necessary	O
factor	O
for	O
realization	O
of	O
this	O
action	O
of	O
neuroleptics	O
.	O

Dual	O
effect	O
of	O
ouabain	B-Drug
on	O
the	O
palytoxin-induced	B-Drug
contraction	O
and	O
norepinephrine	B-Drug
release	O
in	O
the	O
guinea-pig	O
vas	O
deferens	O
.	O

Palytoxin	B-Drug
(	O
PTX	B-Drug
)	O
,	O
C129H223N3O54	O
,	O
isolated	O
from	O
marine	O
coelenterates	O
of	O
Palythoa	O
tuberculosa	O
,	O
caused	O
a	O
first	O
rapid	O
contraction	O
followed	O
by	O
the	O
slow	O
phasic	O
contraction	O
of	O
guinea-pig	O
vas	O
deferens	O
.	O

In	O
the	O
presence	O
of	O
ouabain	B-Drug
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
,	O
PTX	B-Drug
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
failed	O
to	O
cause	O
the	O
first	O
contraction	O
;	O
however	O
,	O
the	O
second	O
contraction	O
was	O
potentiated	O
.	O

In	O
the	O
presence	O
of	O
phentolamine	B-Drug
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
,	O
the	O
second	O
contraction	O
was	O
inhibited	O
selectively	O
.	O

When	O
ouabain	B-Drug
was	O
applied	O
to	O
the	O
muscle	O
in	O
the	O
presence	O
of	O
phentolamine	B-Drug
,	O
both	O
first	O
and	O
second	O
contractile	O
responses	O
to	O
PTX	B-Drug
were	O
abolished	O
.	O

When	O
the	O
muscle	O
was	O
exposed	O
to	O
the	O
potassium-depleted	O
solution	O
,	O
the	O
first	O
contractile	O
response	O
to	O
PTX	B-Drug
was	O
rather	O
potentiated	O
.	O

PTX	B-Drug
caused	O
the	O
release	O
of	O
norepinephrine	B-Drug
from	O
the	O
muscle	O
.	O

Exposure	O
of	O
the	O
muscle	O
to	O
ouabain	B-Drug
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
markedly	O
increased	O
the	O
PTX-induced	B-Drug
release	O
.	O

It	O
is	O
indicated	O
that	O
the	O
first	O
and	O
second	O
contractile	O
responses	O
to	O
PTX	B-Drug
have	O
entirely	O
different	O
properties	O
.	O

The	O
second	O
response	O
is	O
due	O
to	O
a	O
release	O
of	O
norepinephrine	B-Drug
from	O
nerves	O
and	O
was	O
potentiated	O
by	O
ouabain	B-Drug
through	O
the	O
increase	O
in	O
the	O
norepinephrine	B-Drug
release	O
,	O
whereas	O
the	O
first	O
response	O
was	O
not	O
due	O
to	O
the	O
norepinephrine	B-Drug
release	O
but	O
presumably	O
to	O
a	O
direct	O
action	O
on	O
smooth	O
muscle	O
cell	O
and	O
was	O
inhibited	O
by	O
ouabain	B-Drug
.	O

The	O
mechanism	O
of	O
the	O
action	O
of	O
PTX	B-Drug
was	O
discussed	O
in	O
the	O
relation	O
with	O
Na	O
,	O
K-ATPase	O
.	O

[	O
Quantitative	O
approach	O
to	O
treatment	O
with	O
incisive	O
neuroleptics	O
by	O
therapeutic	O
monitoring	O
]	O
;	O
The	O
problems	O
encountered	O
during	O
the	O
longterm	O
treatment	O
of	O
psychotic	O
patients	O
with	O
neuroleptics	O
are	O
illustrated	O
by	O
six	O
typical	O
case	O
reports	O
.	O

A	O
group	O
of	O
patients	O
who	O
had	O
had	O
a	O
new	O
acute	O
episode	O
despite	O
seemingly	O
adequate	O
treatment	O
were	O
selected	O
.	O

In	O
these	O
six	O
cases	O
it	O
was	O
demonstrated	O
that	O
the	O
neuroleptics	O
dosage	O
was	O
inappropriate	O
,	O
being	O
either	O
too	O
high	O
or	O
too	O
low	O
as	O
judged	O
from	O
the	O
plasma	O
concentrations	O
.	O

Ways	O
of	O
improving	O
the	O
adequacy	O
of	O
the	O
treatment	O
of	O
psychotic	O
patients	O
with	O
neuroleptics	O
are	O
discussed	O
.	O

Intestinal	O
absorption	O
of	O
arsenate	B-Drug
in	O
the	O
chick	O
.	O

The	O
intestinal	O
absorption	O
of	O
arsenate	B-Drug
(	I-Drug
As	B-Drug
(	I-Drug
V	I-Drug
)	O
)	O
has	O
been	O
investigated	O
in	O
the	O
chick	O
by	O
means	O
of	O
the	O
in	O
situ	O
ligated	O
duodenal	O
loop	O
technique	O
.	O

By	O
this	O
procedure	O
,	O
it	O
was	O
observed	O
that	O
arsenate	B-Drug
is	O
rapidly	O
and	O
essentially	O
completely	O
absorbed	O
(	I-Drug
80-95	O
%	O
)	I-Drug
from	O
the	O
lumen	O
at	O
As	B-Drug
(	I-Drug
V	O
)	O
concentrations	O
up	O
to	O
5	O
mM	O
,	O
declining	O
to	O
about	O
50	O
%	O
absorption	O
at	O
50	O
mM	O
.	O

Transfer	O
from	O
the	O
intestinal	O
lumen	O
to	O
the	O
mucosal	O
cells	O
at	O
low	O
As	B-Drug
(	I-Drug
V	I-Drug
)	I-Drug
concentration	O
(	O
0.1	O
mM	O
)	O
is	O
rapid	O
,	O
while	O
transfer	O
from	O
the	O
mucosal	O
cells	O
to	O
the	O
body	O
occurs	O
more	O
slowly	O
.	O

At	O
stable	O
As	B-Drug
(	I-Drug
V	I-Drug
)	I-Drug
concentrations	O
greater	O
than	O
1	O
mM	O
,	O
fractional	O
mucosal	O
cell	O
accumulation	O
of	O
As	B-Drug
(	I-Drug
V	I-Drug
)	I-Drug
remains	O
constant	O
,	O
while	O
fractional	O
transfer	O
to	O
the	O
body	O
declines	O
.	O

However	O
,	O
total	O
mucosal	O
accumulation	O
of	O
As	B-Drug
(	I-Drug
V	I-Drug
)	I-Drug
and	O
that	O
transferred	O
to	O
the	O
body	O
increase	O
in	O
a	O
linear	O
logarithmic	O
fashion	O
from	O
0.05	O
to	O
5	O
mm	O
As	B-Drug
(	I-Drug
V	I-Drug
)	I-Drug
.	O

The	O
results	O
indicate	O
that	O
As	B-Drug
(	I-Drug
V	I-Drug
)	I-Drug
readily	O
penetrates	O
both	O
the	O
mucosal	O
and	O
serosal	O
surfaces	O
of	O
the	O
epithelial	O
membrane	O
.	O

Furthermore	O
,	O
arsenate	B-Drug
and	O
phosphate	B-Drug
do	O
not	O
appear	O
to	O
share	O
a	O
common	O
transport	O
pathway	O
in	O
the	O
duodenum	O
and	O
no	O
evidence	O
was	O
obtained	O
for	O
any	O
interaction	O
between	O
the	O
two	O
at	O
this	O
level	O
.	O

Vitamin	B-Drug
D3	I-Drug
administration	O
to	O
rachitic	O
chicks	O
was	O
effective	O
in	O
significantly	O
elevating	O
duodenal	O
arsenate	B-Drug
absorption	O
,	O
acting	O
primarily	O
to	O
enhance	O
serosal	O
transport	O
.	O

Spermine	B-Drug
promotes	O
the	O
translocation	O
of	O
phosphatidate	O
phosphohydrolase	O
from	O
the	O
cytosol	O
to	O
the	O
microsomal	O
fraction	O
of	O
rat	O
liver	O
and	O
it	O
enhances	O
the	O
effects	O
of	O
oleate	O
in	O
this	O
respect	O
.	O

Spermine	B-Drug
(	O
0.5-2	O
mM	O
)	O
promoted	O
the	O
translocation	O
of	O
phosphatidate	O
phosphohydrolase	O
from	O
the	O
soluble	O
to	O
the	O
microsomal	O
fraction	O
in	O
a	O
cell-free	O
system	O
derived	O
from	O
rat	O
liver	O
.	O

By	O
contrast	O
,	O
spermidine	B-Drug
(	O
1	O
mM	O
)	O
and	O
putrescine	B-Drug
(	O
1	O
mM	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
translocation	O
when	O
added	O
alone	O
.	O

Spermine	B-Drug
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
spermidine	B-Drug
,	O
enhanced	O
the	O
translocating	O
action	O
of	O
oleate	O
and	O
increased	O
its	O
effectiveness	O
in	O
transferring	O
the	O
phosphohydrolase	O
from	O
the	O
soluble	O
to	O
the	O
microsomal	O
fraction	O
.	O

It	O
is	O
proposed	O
that	O
the	O
phosphohydrolase	O
becomes	O
metabolically	O
active	O
when	O
it	O
combines	O
with	O
membranes	O
and	O
that	O
polyamines	O
might	O
help	O
to	O
regulate	O
this	O
interaction	O
.	O

This	O
could	O
facilitate	O
the	O
action	O
of	O
fatty	O
acids	O
and	O
enable	O
cells	O
to	O
increase	O
their	O
capacity	O
for	O
triacylglycerol	O
synthesis	O
to	O
match	O
an	O
increased	O
availability	O
of	O
fatty	O
acids	O
.	O

Influence	O
of	O
calcium-channel	O
blockers	O
on	O
platelet	O
function	O
and	O
arachidonic	O
acid	O
metabolism	O
.	O

Available	O
data	O
indicate	O
that	O
platelet	O
function	O
and	O
arachidonic	O
acid	O
metabolism	O
are	O
important	O
factors	O
in	O
hemostasis	O
and	O
regulation	O
of	O
vascular	O
tone	O
.	O

Plasma	O
membrane	O
and	O
intracellular	O
mobilization	O
of	O
calcium	B-Drug
ions	O
are	O
intimately	O
related	O
to	O
platelet	O
activation	O
and	O
release	O
of	O
platelet	O
contents	O
.	O

Release	O
of	O
arachidonic	O
acid	O
from	O
membrane	O
phospholipids	O
as	O
well	O
as	O
subsequent	O
synthesis	O
and	O
release	O
of	O
vasoconstrictor	O
thromboxane	O
A2	O
are	O
also	O
regulated	O
by	O
movement	O
of	O
calcium	B-Drug
ions	O
.	O

Adenosine	B-Drug
3':5'-cyclic	O
phosphate	B-Drug
in	O
turn	O
controls	O
levels	O
of	O
free	O
calcium	B-Drug
ions	O
in	O
platelets	O
and	O
regulates	O
calcium-dependent	O
reactions	O
.	O

Slow-channel	O
calcium	B-Drug
blockers	O
,	O
such	O
as	O
verapamil	B-Drug
,	O
diltiazem	B-Drug
and	O
nifedipine	B-Drug
,	O
inhibit	O
platelet	O
activation	O
in	O
vitro	O
,	O
and	O
decrease	O
platelet	O
adhesion	O
intravascularly	O
.	O

These	O
agents	O
have	O
also	O
been	O
shown	O
to	O
decrease	O
platelet	O
nucleotide	O
release	O
and	O
thromboxane	O
A2	O
generation	O
.	O

Some	O
preliminary	O
data	O
suggest	O
that	O
calcium	B-Drug
blockers	O
also	O
increase	O
generation	O
of	O
vasodilator	O
and	O
platelet	O
antiaggregant	O
prostacyclin	O
,	O
which	O
could	O
contribute	O
to	O
decrease	O
in	O
platelet	O
function	O
.	O

These	O
effects	O
of	O
calcium	B-Drug
blockers	O
on	O
platelet	O
function	O
and	O
arachidonic	O
acid	O
metabolism	O
could	O
contribute	O
in	O
part	O
to	O
their	O
efficacy	O
in	O
patients	O
with	O
ischemic	O
heart	O
disease	O
.	O

Differential	O
actions	O
of	O
intrathecal	O
naloxone	B-Drug
on	O
blocking	O
the	O
tail-flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta-endorphin	B-Drug
and	O
morphine	B-Drug
in	O
rats	O
.	O

In	O
the	O
present	O
study	O
,	O
it	O
is	O
proposed	O
that	O
the	O
opioids	O
applied	O
to	O
supraspinal	O
brain	O
sites	O
produced	O
their	O
analgesic	O
effects	O
by	O
the	O
activation	O
of	O
different	O
descending	O
pain	O
inhibitory	O
systems	O
.	O

The	O
blockade	O
of	O
the	O
spinal	O
endorphinergic	O
system	O
by	O
intrathecal	O
naloxone	B-Drug
on	O
the	O
production	O
of	O
tail-flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta-endorphin	B-Drug
and	O
morphine	B-Drug
was	O
then	O
studied	O
.	O

Intraventricular	O
injection	O
of	O
beta-endorphin	B-Drug
and	O
morphine	B-Drug
produced	O
an	O
inhibition	O
of	O
the	O
tail-flick	O
response	O
to	O
the	O
heat	O
stimulus	O
in	O
rats	O
.	O

Intrathecal	O
injection	O
of	O
naloxone	B-Drug
at	O
doses	O
of	O
0.4	O
to	O
40	O
micrograms	O
caused	O
a	O
dose-related	O
blockade	O
of	O
the	O
inhibition	O
of	O
the	O
tail-flick	O
response	O
induced	O
by	O
intraventricular	O
injection	O
of	O
beta-endorphin	B-Drug
,	O
and	O
a	O
high	O
dose	O
of	O
naloxone	B-Drug
(	O
40	O
micrograms	O
)	O
completely	O
blocked	O
the	O
tail-flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta-endorphin	B-Drug
(	O
16	O
micrograms	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
intrathecal	O
naloxone	B-Drug
(	O
12-120	O
micrograms	O
)	O
had	O
only	O
a	O
very	O
weak	O
effect	O
on	O
the	O
tail-flick	O
inhibition	O
induced	O
by	O
intraventricular	O
morphine	B-Drug
(	O
40	O
micrograms	O
)	O
.	O

Intraventricular	O
injection	O
of	O
naloxone	B-Drug
at	O
doses	O
of	O
1.2	O
to	O
12	O
micrograms	O
equally	O
antagonized	O
in	O
a	O
dose-dependent	O
manner	O
the	O
tail-flick	O
inhibition	O
induced	O
by	O
intraventricular	O
beta-endorphin	B-Drug
and	O
morphine	B-Drug
.	O

The	O
results	O
indicate	O
that	O
a	O
spinal	O
naloxone-sensitive	B-Drug
endorphinergic	O
system	O
is	O
involved	O
in	O
the	O
production	O
of	O
beta-endorphin	B-Drug
but	O
not	O
morphine-induced	B-Drug
tail-flick	O
inhibition	O
,	O
and	O
suggest	O
that	O
intraventricular	O
beta-endorphin	B-Drug
and	O
morphine	B-Drug
elicit	O
their	O
pharmacological	O
actions	O
via	O
the	O
activation	O
of	O
different	O
descending	O
pain	O
inhibitory	O
systems	O
;	O
descending	O
epsilon	O
and	O
mu	O
systems	O
for	O
beta-endorphin	B-Drug
and	O
morphine	B-Drug
,	O
respectively	O
,	O
are	O
proposed	O
.	O

Neurochemical	O
and	O
functional	O
consequences	O
following	O
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	B-Drug
(	O
MPTP	B-Drug
)	O
and	O
methamphetamine	B-Drug
.	O

The	O
neurochemical	O
and	O
functional	O
consequences	O
following	O
MPTP	B-Drug
administration	O
to	O
the	O
rat	O
were	O
evaluated	O
and	O
compared	O
to	O
similar	O
effects	O
following	O
methamphetamine	B-Drug
administration	O
.	O

It	O
was	O
observed	O
that	O
MPTP	B-Drug
induced	O
long	O
lasting	O
depletions	O
of	O
striatal	O
dopamine	B-Drug
concentrations	O
and	O
this	O
neurotoxic	O
effect	O
could	O
be	O
prevented	O
by	O
pargyline	B-Drug
pretreatment	O
.	O

The	O
MPTP-induced	B-Drug
neuronal	O
damage	O
produced	O
a	O
tolerance	O
to	O
the	O
disruptive	O
effects	O
of	O
amphetamine	B-Drug
and	O
a	O
supersensitivity	O
to	O
the	O
disruptive	O
effects	O
of	O
apomorphine	B-Drug
in	O
rats	O
responding	O
in	O
a	O
schedule	O
controlled	O
paradigm	O
.	O

Methamphetamine	B-Drug
,	O
like	O
MPTP	B-Drug
,	O
produced	O
depletions	O
of	O
striatal	O
dopamine	B-Drug
but	O
these	O
actions	O
were	O
potentiated	O
by	O
pargyline	B-Drug
pretreatment	O
.	O

These	O
observations	O
are	O
discussed	O
in	O
reference	O
to	O
possible	O
deleterious	O
effects	O
following	O
the	O
administration	O
of	O
pargyline	B-Drug
to	O
patients	O
with	O
Parkinson	O
's	O
Disease	O
.	O

Jacalin	B-Drug
:	O
an	O
IgA-binding	O
lectin	O
.	O

We	O
previously	O
reported	O
that	O
seeds	O
of	O
Artocarpus	O
integrifolia	O
(	O
jackfruit	O
)	O
contain	O
a	O
lectin	O
,	O
which	O
we	O
call	O
jacalin	B-Drug
,	O
that	O
is	O
both	O
a	O
potent	O
T	O
cell	O
mitogen	O
and	O
an	O
apparently	O
T	O
cell-independent	O
activator	O
of	O
human	O
B	O
cells	O
for	O
the	O
secretion	O
of	O
immunoglobulins	O
.	O

During	O
the	O
above	O
experiments	O
we	O
noted	O
a	O
massive	O
precipitation	O
in	O
cell	O
cultures	O
stimulated	O
with	O
greater	O
than	O
or	O
equal	O
to	O
100	O
micrograms	O
of	O
lectin	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
the	O
precipitate	O
is	O
formed	O
after	O
the	O
interaction	O
of	O
jacalin	B-Drug
and	O
the	O
serum	O
protein	O
added	O
to	O
the	O
culture	O
medium	O
.	O

More	O
importantly	O
,	O
we	O
demonstrate	O
that	O
IgA	O
is	O
probably	O
the	O
major	O
serum	O
constituent	O
precipitated	O
by	O
the	O
lectin	O
and	O
that	O
no	O
IgG	O
or	O
IgM	O
can	O
be	O
detected	O
in	O
the	O
precipitates	O
.	O

In	O
secretions	O
such	O
as	O
colostrum	O
,	O
IgA	O
is	O
the	O
only	O
protein	O
precipitated	O
by	O
jacalin	B-Drug
.	O

On	O
the	O
basis	O
of	O
this	O
specificity	O
we	O
describe	O
a	O
simple	O
and	O
reliable	O
affinity	O
chromatography	O
procedure	O
for	O
the	O
purification	O
of	O
both	O
human	O
serum	O
and	O
colostrum	O
IgA	O
.	O

Jacalin	B-Drug
is	O
a	O
D-Gal	O
binding	O
lectin	O
and	O
should	O
be	O
a	O
useful	O
tool	O
for	O
studying	O
of	O
serum	O
and	O
secretory	O
IgA	O
.	O

Cancer	O
in	O
the	O
elderly	O
:	O
basic	O
science	O
and	O
clinical	O
aspects	O
.	O

The	O
incidence	O
of	O
cancer	O
increases	O
progressively	O
with	O
age	O
.	O

Rearrangements	O
of	O
genomes	O
have	O
been	O
found	O
to	O
accompany	O
cellular	O
aging	O
.	O

These	O
factors	O
,	O
in	O
concert	O
with	O
age-dependent	O
alterations	O
in	O
immune	O
function	O
and	O
host	O
defense	O
,	O
may	O
help	O
to	O
explain	O
the	O
increased	O
risk	O
of	O
malignant	O
disease	O
in	O
aged	O
persons	O
.	O

The	O
clinical	O
presentation	O
and	O
natural	O
history	O
of	O
neoplasia	O
are	O
also	O
affected	O
by	O
aging	O
.	O

This	O
conference	O
reviews	O
recent	O
developments	O
in	O
these	O
areas	O
,	O
examines	O
the	O
effects	O
of	O
drug	B-Drug
use	O
in	O
the	O
elderly	O
and	O
implications	O
for	O
management	O
,	O
and	O
discusses	O
current	O
information	O
on	O
how	O
age	O
may	O
influence	O
the	O
response	O
of	O
cancer	O
to	O
therapy	O
.	O

Dexamethasone	B-Drug
and	O
retinyl	B-Drug
acetate	I-Drug
similarly	O
inhibit	O
and	O
stimulate	O
EGF-	B-Drug
or	O
insulin-induced	B-Drug
proliferation	O
of	O
prostatic	O
epithelium	O
.	O

Prostatic	O
epithelium	O
proliferates	O
in	O
a	O
defined	O
medium	O
consisting	O
of	O
basal	O
medium	O
RPMI1640	O
containing	O
transferrin	B-Drug
(	O
1	O
microgram/ml	O
)	O
,	O
EGF	B-Drug
(	O
10	O
ng/ml	O
)	O
,	O
and	O
insulin	B-Drug
(	O
3.7	O
micrograms/ml	O
or	O
0.1	O
IU/ml	O
)	O
.	O

Although	O
neither	O
dexamethasone	B-Drug
nor	O
retinyl	B-Drug
acetate	I-Drug
affected	O
the	O
proliferation	O
of	O
prostatic	O
epithelium	O
in	O
RPMI1640	O
containing	O
transferrin	B-Drug
alone	O
,	O
they	O
modify	O
the	O
mitogenic	O
effect	O
of	O
EGF	B-Drug
and	O
insulin	B-Drug
.	O

Dexamethasone	B-Drug
at	O
10	O
(	O
-10	O
)	O
M	O
or	O
retinyl	B-Drug
acetate	I-Drug
at	O
about	O
3	O
X	O
10	O
(	O
-9	O
)	O
M	O
inhibits	O
proliferation	O
stimulated	O
by	O
EGF	B-Drug
.	O

Higher	O
concentrations	O
of	O
dexamethasone	B-Drug
(	O
10	O
(	O
-8	O
)	O
-	O
10	O
(	O
-6	O
)	O
M	O
)	O
or	O
retinyl	B-Drug
acetate	I-Drug
(	O
3	O
X	O
10	O
(	O
-8	O
)	O
-	O
10	O
(	O
-7	O
)	O
M	O
)	O
enhance	O
the	O
mitogenic	O
activity	O
of	O
EGF	B-Drug
.	O

Dexamethasone	B-Drug
had	O
a	O
similar	O
effect	O
in	O
the	O
presence	O
of	O
insulin	B-Drug
.	O

However	O
,	O
retinyl	B-Drug
acetate	I-Drug
stimulated	O
,	O
but	O
did	O
not	O
significantly	O
inhibit	O
,	O
proliferation	O
in	O
the	O
presence	O
of	O
insulin	B-Drug
.	O

These	O
results	O
suggest	O
that	O
both	O
dexamethasone	B-Drug
and	O
retinyl	B-Drug
acetate	I-Drug
,	O
and	O
possibly	O
other	O
glucocorticoids	O
and	O
retinoids	O
,	O
may	O
regulate	O
the	O
proliferation	O
of	O
prostate	O
epithelium	O
by	O
a	O
dose-dependent	O
modification	O
of	O
the	O
activity	O
of	O
insulin	B-Drug
and	O
EGF	B-Drug
.	O

Pharmacokinetics	O
of	O
calcium-entry	O
blockers	O
.	O

Effective	O
use	O
of	O
drugs	B-Drug
in	O
therapy	O
depends	O
not	O
only	O
on	O
clinical	O
acumen	O
but	O
also	O
on	O
the	O
availability	O
of	O
relevant	O
pharmacokinetic	O
and	O
pharmacodynamic	O
data	O
.	O

Such	O
information	O
assists	O
in	O
development	O
of	O
safe	O
dosing	O
regimens	O
,	O
prediction	O
of	O
abnormal	O
handling	O
of	O
drugs	B-Drug
in	O
states	O
of	O
disease	O
and	O
disorder	O
and	O
anticipation	O
of	O
drug	B-Drug
interactions	O
.	O

For	O
the	O
calcium-entry	O
blocking	O
agents	O
now	O
available	O
in	O
the	O
United	O
States	O
(	O
verapamil	B-Drug
,	O
nifedipine	B-Drug
and	O
diltiazem	B-Drug
)	O
,	O
these	O
data	O
appeared	O
well	O
after	O
clinical	O
patterns	O
of	O
use	O
evolved	O
.	O

Nonetheless	O
,	O
their	O
relevance	O
continues	O
to	O
be	O
demonstrated	O
by	O
the	O
dependence	O
of	O
each	O
agent	O
on	O
intact	O
liver	O
blood	O
flow	O
and	O
function	O
for	O
normal	O
rates	O
of	O
elimination	O
;	O
by	O
the	O
nonlinear	O
kinetic	O
characteristics	O
for	O
verapamil	B-Drug
and	O
diltiazem	B-Drug
(	O
and	O
probably	O
for	O
nifedipine	B-Drug
,	O
as	O
well	O
)	O
and	O
the	O
derivative	O
implications	O
for	O
decreased	O
dosing	O
frequency	O
requirements	O
;	O
and	O
by	O
observations	O
now	O
appearing	O
on	O
the	O
relation	O
between	O
plasma	O
drug	B-Drug
levels	O
and	O
drug	B-Drug
effects	O
,	O
both	O
therapeutic	O
and	O
toxic	O
.	O

Such	O
data	O
are	O
discussed	O
herein	O
,	O
with	O
emphasis	O
on	O
those	O
aspects	O
that	O
impact	O
on	O
the	O
clinical	O
use	O
of	O
the	O
calcium-entry	O
antagonists	O
.	O

Selective	O
survival	O
in	O
pentazocine	B-Drug
and	O
tripelennamine	B-Drug
of	O
Pseudomonas	O
aeruginosa	O
serotype	O
O11	O
from	O
drug	B-Drug
addicts	O
.	O

The	O
growth	O
of	O
Pseudomonas	O
aeruginosa	O
,	O
particularly	O
serotype	O
O11	O
,	O
in	O
pentazocine	B-Drug
and	O
tripelennamine	B-Drug
was	O
evaluated	O
as	O
a	O
possible	O
explanation	O
for	O
the	O
association	O
of	O
deep-seated	O
infection	O
with	O
this	O
organism	O
and	O
abuse	O
of	O
these	O
drugs	B-Drug
.	O

The	O
mean	O
reduction	O
of	O
growth	O
caused	O
by	O
the	O
drugs	B-Drug
was	O
1,000-fold	O
greater	O
for	O
49	O
Pseudomonas	O
strains	O
from	O
normal	O
subjects	O
than	O
for	O
32	O
strains	O
from	O
drug	B-Drug
addicts	O
(	O
4.2	O
vs.	O
1.3	O
logs	O
of	O
reduction	O
at	O
2	O
hr	O
,	O
P	O
less	O
than	O
.0005	O
)	O
.	O

A	O
common	O
phenotypic	O
subset	O
of	O
the	O
serotype	O
O11	O
strains	O
from	O
drug	B-Drug
addicts	O
was	O
especially	O
resistant	O
to	O
the	O
inhibitory	O
effects	O
.	O

Twelve	O
strains	O
of	O
Staphylococcus	O
aureus	O
(	O
a	O
frequent	O
cause	O
of	O
infection	O
in	O
heroin	B-Drug
,	O
but	O
not	O
in	O
pentazocine	B-Drug
and	O
tripelennamine	B-Drug
,	O
addicts	O
)	O
were	O
completely	O
inhibited	O
by	O
the	O
drug	B-Drug
combination	O
.	O

Dose-response	O
curves	O
(	O
derived	O
from	O
the	O
results	O
of	O
using	O
the	O
tablets	O
as	O
well	O
as	O
pure	O
powders	O
)	O
showed	O
that	O
tripelennamine	B-Drug
was	O
responsible	O
for	O
the	O
inhibitory	O
activity	O
,	O
which	O
was	O
partially	O
antagonized	O
by	O
pentazocine	B-Drug
.	O

We	O
conclude	O
that	O
an	O
ability	O
of	O
some	O
P	O
.	O

aeruginosa	O
serotype	O
O11	O
strains	O
,	O
but	O
not	O
S	O
.	O

aureus	O
,	O
to	O
survive	O
in	O
pentazocine	B-Drug
and	O
tripelennamine	B-Drug
may	O
explain	O
in	O
part	O
a	O
shift	O
from	O
S	O
.	O

aureus	O
to	O
P	O
.	O

aeruginosa	O
as	O
common	O
pathogens	O
of	O
drug	B-Drug
addicts	O
in	O
areas	O
where	O
abuse	O
of	O
this	O
combination	O
of	O
drugs	B-Drug
has	O
increased	O
.	O

Pharmacokinetic	O
evaluation	O
of	O
the	O
digoxin-amiodarone	B-Drug
interaction	O
.	O

Amiodarone	B-Drug
is	O
known	O
to	O
raise	O
serum	O
digoxin	B-Drug
levels	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
pharmacokinetic	O
basis	O
of	O
this	O
interaction	O
in	O
10	O
normal	O
subjects	O
.	O

The	O
pharmacokinetic	O
variables	O
for	O
digoxin	B-Drug
were	O
determined	O
after	O
a	O
1.0	O
mg	O
intravenous	O
dose	O
of	O
digoxin	B-Drug
in	O
each	O
subject	O
,	O
before	O
and	O
after	O
oral	O
amiodarone	B-Drug
,	O
400	O
mg	O
daily	O
for	O
3	O
weeks	O
.	O

During	O
amiodarone	B-Drug
administration	O
,	O
systemic	O
clearance	O
of	O
digoxin	B-Drug
was	O
reduced	O
from	O
234	O
+/-	O
72	O
ml/min	O
(	O
mean	O
+/-	O
standard	O
deviation	O
)	O
to	O
172	O
+/-	O
33	O
ml/min	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

This	O
was	O
due	O
to	O
reductions	O
in	O
both	O
renal	O
clearance	O
(	O
from	O
105	O
+/-	O
39	O
to	O
84	O
+/-	O
15	O
ml/min	O
)	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
nonrenal	O
clearance	O
(	O
from	O
130	O
+/-	O
38	O
to	O
88	O
+/-	O
20	O
ml/min	O
)	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Digoxin	B-Drug
half-life	O
of	O
elimination	O
was	O
prolonged	O
from	O
34	O
+/-	O
13	O
to	O
40	O
+/-	O
16	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Digoxin	B-Drug
volume	O
of	O
distribution	O
was	O
not	O
significantly	O
changed	O
.	O

Amiodarone	B-Drug
caused	O
a	O
three-	O
to	O
fivefold	O
increase	O
in	O
serum	O
reverse	O
triiodothyronine	O
levels	O
,	O
but	O
changes	O
in	O
thyroid	B-Drug
function	O
were	O
not	O
quantitatively	O
related	O
to	O
the	O
changes	O
in	O
digoxin	B-Drug
pharmacokinetics	O
.	O

These	O
alterations	O
in	O
digoxin	B-Drug
pharmacokinetics	O
produced	O
by	O
amiodarone	B-Drug
explain	O
the	O
increase	O
in	O
serum	O
digoxin	B-Drug
level	O
that	O
has	O
been	O
observed	O
when	O
this	O
drug	B-Drug
combination	O
has	O
been	O
used	O
clinically	O
.	O

Misonidazole	B-Drug
protects	O
mouse	O
tumour	O
and	O
normal	O
tissues	O
from	O
the	O
toxicity	O
of	O
oral	O
CCNU	B-Drug
.	O

Because	O
the	O
nitrosourea	O
CCNU	B-Drug
is	O
given	O
exclusively	O
by	O
the	O
oral	O
route	O
in	O
man	O
,	O
we	O
have	O
carried	O
out	O
studies	O
in	O
mice	O
on	O
the	O
antitumour	O
activity	O
,	O
acute	O
toxicity	O
and	O
pharmacokinetics	O
of	O
oral	O
CCNU	B-Drug
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
the	O
chemosensitizer	O
misonidazole	B-Drug
.	O

In	O
both	O
plasma	O
and	O
KHT	O
tumour	O
the	O
peak	O
concentration	O
and	O
``	O
early	O
''	O
AUC	O
for	O
total	O
nitrosoureas	O
were	O
about	O
1.4-1.5	O
fold	O
greater	O
for	O
the	O
oral	O
compared	O
to	O
the	O
i.p	O
.	O

route	O
.	O

These	O
differences	O
were	O
reflected	O
in	O
the	O
roughly	O
twofold	O
greater	O
antitumour	O
activity	O
for	O
the	O
oral	O
route	O
.	O

In	O
contrast	O
,	O
acute	O
toxicity	O
tests	O
showed	O
that	O
oral	O
CCNU	B-Drug
was	O
1.45	O
times	O
less	O
toxic	O
to	O
normal	O
tissue	O
,	O
although	O
the	O
dose-limiting	O
organ	O
may	O
be	O
different	O
for	O
the	O
two	O
routes	O
.	O

Misonidazole	B-Drug
reduced	O
the	O
antitumour	O
activity	O
of	O
oral	O
CCNU	B-Drug
by	O
dose	O
modifying	O
factors	O
(	O
DMF	O
)	O
of	O
0.58-0.71	O
.	O

Similarly	O
,	O
the	O
acute	O
toxicity	O
was	O
also	O
diminished	O
by	O
a	O
DMF	O
of	O
0.74	O
.	O

Misonidazole	B-Drug
has	O
a	O
complex	O
effect	O
on	O
oral	O
CCNU	B-Drug
pharmacokinetics	O
.	O

The	O
plasma	O
and	O
tumour	O
total	O
nitrosourea	O
peak	O
concentrations	O
were	O
reduced	O
by	O
1.5	O
and	O
1.7	O
fold	O
respectively	O
.	O

Misonidazole	B-Drug
also	O
reduced	O
the	O
``	O
early	O
''	O
nitrosourea	O
AUC	O
,	O
with	O
the	O
extent	O
of	O
the	O
reduction	O
depending	O
on	O
the	O
minimum	O
effective	O
concentration	O
(	O
MEC	O
)	O
chosen	O
.	O

For	O
example	O
,	O
the	O
plasma	O
nitrosourea	O
AUC	O
was	O
reduced	O
by	O
factors	O
of	O
1.05	O
and	O
9.6	O
for	O
MEC	O
values	O
of	O
1	O
and	O
2	O
micrograms	O
ml-1	O
respectively	O
.	O

We	O
propose	O
these	O
pharmacokinetic	O
changes	O
to	O
be	O
the	O
underlying	O
mechanism	O
for	O
the	O
reduction	O
of	O
oral	O
CCNU	B-Drug
cytotoxicity	O
by	O
misonidazole	B-Drug
.	O

Clinical	O
trials	O
of	O
such	O
combinations	O
should	O
be	O
accompanied	O
by	O
detailed	O
pharmacokinetic	O
evaluation	O
.	O

Enhanced	O
theophylline	B-Drug
clearance	O
secondary	O
to	O
phenytoin	B-Drug
therapy	O
.	O

This	O
report	O
describes	O
two	O
cases	O
in	O
which	O
theophylline	B-Drug
clearance	O
accelerated	O
markedly	O
with	O
concomitant	O
phenytoin	B-Drug
administration	O
.	O

Maximum	O
calculated	O
theophylline	B-Drug
clearance	O
ranged	O
from	O
2	O
1/2	O
to	O
3	O
1/2	O
times	O
baseline	O
.	O

Onset	O
of	O
the	O
interaction	O
began	O
within	O
five	O
days	O
of	O
beginning	O
concurrent	O
therapy	O
.	O

With	O
combined	O
use	O
,	O
clinicians	O
should	O
be	O
aware	O
,	O
when	O
phenytoin	B-Drug
is	O
added	O
,	O
of	O
the	O
potential	O
for	O
reexacerbation	O
of	O
pulmonary	O
symptomatology	O
due	O
to	O
lowered	O
serum	O
theophylline	B-Drug
concentrations	O
.	O

Stereoselective	O
behavioral	O
effects	O
of	O
N-allylnormetazocine	B-Drug
in	O
pigeons	O
and	O
squirrel	O
monkeys	O
.	O

The	O
behavioral	O
effects	O
of	O
the	O
stereoisomers	O
of	O
N-allylnormetazocine	B-Drug
(	O
NANM	B-Drug
)	O
were	O
compared	O
with	O
those	O
of	O
phencyclidine	B-Drug
(	O
PCP	B-Drug
)	O
in	O
pigeons	O
and	O
squirrel	O
monkeys	O
responding	O
under	O
a	O
multiple	O
fixed-interval	O
fixed-ratio	O
(	O
FI	O
FR	O
)	O
schedule	O
of	O
food	O
presentation	O
.	O

Intermediate	O
doses	O
of	O
(	B-Drug
+	I-Drug
)	I-Drug
-NANM	I-Drug
or	O
PCP	B-Drug
produced	O
transient	O
increases	O
in	O
FI	O
responding	O
in	O
monkeys	O
and	O
sustained	O
increases	O
in	O
FI	O
responding	O
in	O
pigeons	O
;	O
higher	O
doses	O
decreased	O
FI	O
and	O
FR	O
responding	O
in	O
both	O
species	O
.	O

In	O
contrast	O
to	O
its	O
enantiomer	O
,	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
failed	O
to	O
increase	O
FI	O
responding	O
significantly	O
in	O
either	O
species	O
;	O
at	O
high	O
doses	O
,	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
decreased	O
FI	O
and	O
FR	O
responding	O
.	O

In	O
monkeys	O
,	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
was	O
about	O
10	O
times	O
more	O
potent	O
than	O
(	B-Drug
+	I-Drug
)	I-Drug
-NANM	I-Drug
in	O
decreasing	O
responding	O
,	O
whereas	O
in	O
pigeons	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
was	O
about	O
equipotent	O
with	O
(	B-Drug
+	I-Drug
)	I-Drug
-NANM	I-Drug
.	O

In	O
both	O
species	O
,	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
,	O
but	O
not	O
(	B-Drug
+	I-Drug
)	I-Drug
-NANM	I-Drug
,	O
antagonized	O
the	O
rate-decreasing	O
effects	O
of	O
morphine	B-Drug
on	O
FI	O
and	O
FR	O
responding	O
.	O

In	O
monkeys	O
,	O
the	O
effects	O
of	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
,	O
but	O
not	O
(	B-Drug
+	I-Drug
)	I-Drug
-NANM	I-Drug
or	O
PCP	B-Drug
,	O
were	O
antagonized	O
by	O
naloxone	B-Drug
;	O
the	O
doses	O
of	O
naloxone	B-Drug
required	O
to	O
antagonize	O
the	O
effects	O
of	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
were	O
more	O
than	O
100	O
times	O
higher	O
than	O
those	O
required	O
to	O
antagonize	O
the	O
effects	O
of	O
morphine	B-Drug
.	O

In	O
pigeons	O
,	O
naloxone	B-Drug
did	O
not	O
systematically	O
alter	O
the	O
effects	O
of	O
(	B-Drug
-	I-Drug
)	I-Drug
-NANM	I-Drug
,	O
(	B-Drug
+	I-Drug
)	I-Drug
-NANM	I-Drug
or	O
PCP	B-Drug
.	O

Haloperidol	B-Drug
reduced	O
or	O
eliminated	O
the	O
increases	O
in	O
FI	O
responding	O
produced	O
by	O
intermediate	O
doses	O
of	O
either	O
(	B-Drug
+	I-Drug
)	I-Drug
-NANM	I-Drug
or	O
PCP	B-Drug
in	O
pigeons	O
,	O
but	O
did	O
not	O
antagonize	O
the	O
decreases	O
in	O
FI	O
or	O
FR	O
responding	O
produced	O
by	O
high	O
doses	O
of	O
PCP	B-Drug
or	O
either	O
stereoisomer	O
of	O
NANM	B-Drug
.	O

The	O
results	O
demonstrate	O
a	O
high	O
degree	O
of	O
stereoselectivity	O
in	O
the	O
behavioral	O
effects	O
of	O
NANM	B-Drug
.	O

The	O
levorotatory	O
isomer	O
had	O
opioid-antagonist	O
and	O
non-opioid	O
agonist	O
effects	O
in	O
pigeons	O
and	O
mixed	O
opioid	O
agonist-antagonist	O
effects	O
in	O
monkeys	O
.	O

The	O
dextrorotatory	O
isomer	O
,	O
on	O
the	O
other	O
hand	O
,	O
had	O
effects	O
similar	O
to	O
those	O
of	O
PCP	B-Drug
in	O
both	O
species	O
.	O

Increased	O
hepatotoxicity	O
of	O
acetaminophen	B-Drug
by	O
concomitant	O
administration	O
of	O
caffeine	B-Drug
in	O
the	O
rat	O
.	O

Since	O
caffeine	B-Drug
is	O
frequently	O
co-administered	O
with	O
acetaminophen	B-Drug
,	O
it	O
is	O
of	O
clinical	O
interest	O
to	O
study	O
the	O
effect	O
of	O
caffeine	B-Drug
on	O
the	O
hepatotoxicity	O
of	O
acetaminophen	B-Drug
.	O

In	O
male	O
Sprague-Dawley	O
rats	O
fasted	O
for	O
18	O
h	O
,	O
concomitant	O
administration	O
of	O
caffeine	B-Drug
(	O
0.1	O
g/kg	O
,	O
i.p	O
.	O

)	O
as	O
judged	O
by	O
increased	O
serum	O
enzyme	O
activities	O
and	O
increased	O
incidence	O
of	O
hepatic	O
necrosis	O
.	O

Careful	O
observations	O
on	O
hepatotoxicity	O
are	O
suggested	O
when	O
acetaminophen	B-Drug
is	O
prescribed	O
with	O
caffeine	B-Drug
.	O

High-dose	O
cisplatin	B-Drug
with	O
sodium	B-Drug
thiosulfate	I-Drug
protection	O
.	O

Nephrotoxicity	O
frequently	O
limits	O
the	O
dose	O
of	O
cisplatin	B-Drug
to	O
less	O
than	O
120	O
mg/m2	O
per	O
injection	O
.	O

Sodium	B-Drug
thiosulfate	I-Drug
is	O
a	O
neutralizing	O
agent	O
for	O
cisplatin	B-Drug
that	O
protects	O
against	O
renal	O
damage	O
.	O

To	O
determine	O
whether	O
injection	O
of	O
thiosulfate	B-Drug
would	O
permit	O
larger	O
doses	O
of	O
cisplatin	B-Drug
to	O
be	O
administered	O
,	O
a	O
fixed	O
9.9-g/m2	O
dose	O
of	O
thiosulfate	B-Drug
was	O
given	O
intravenously	O
over	O
three	O
hours	O
concurrently	O
with	O
escalating	O
doses	O
of	O
cisplatin	B-Drug
.	O

Cisplatin	B-Drug
was	O
administered	O
over	O
the	O
last	O
two	O
hours	O
of	O
the	O
thiosulfate	B-Drug
infusion	O
.	O

Using	O
this	O
technique	O
,	O
it	O
was	O
possible	O
to	O
escalate	O
the	O
cisplatin	B-Drug
dose	O
to	O
225	O
mg/m2	O
before	O
dose-limiting	O
toxicities	O
were	O
encountered	O
.	O

Comparison	O
of	O
cisplatin	B-Drug
pharmacokinetics	O
in	O
patients	O
treated	O
with	O
202.5	O
mg/m2	O
plus	O
thiosulfate	B-Drug
to	O
those	O
in	O
patients	O
treated	O
with	O
100	O
mg/m2	O
without	O
thiosulfate	B-Drug
indicated	O
that	O
there	O
were	O
no	O
changes	O
in	O
the	O
elimination	O
rate	O
constant	O
,	O
volume	O
of	O
distribution	O
,	O
or	O
total	O
body	O
clearance	O
of	O
cisplatin	B-Drug
.	O

The	O
total	O
drug	B-Drug
exposure	O
for	O
the	O
plasma	O
was	O
approximately	O
twofold	O
at	O
the	O
higher	O
cisplatin	B-Drug
dose	O
.	O

This	O
study	O
demonstrates	O
that	O
concurrent	O
administration	O
of	O
thiosulfate	B-Drug
permits	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
dose	O
and	O
total	O
exposure	O
to	O
cisplatin	B-Drug
.	O

Interferon	O
induction	O
:	O
tool	O
for	O
establishing	O
interactions	O
among	O
homopolyribonucleotides	O
.	O

Hitherto	O
unrecognized	O
interactions	O
between	O
homopolyribonucleotides	O
and	O
complexes	O
thereof	O
are	O
suggested	O
by	O
interferon	O
induction	O
data	O
obtained	O
in	O
a	O
highly	O
sensitive	O
assay	O
system	O
of	O
primary	O
rabbit	O
kidney	O
cell	O
cultures	O
superinduced	O
by	O
metabolic	O
inhibitors	O
.	O

Repeated	O
oral	O
administration	O
of	O
coumaphos	B-Drug
in	O
sheep	O
:	O
interactions	O
of	O
coumaphos	B-Drug
with	O
bishydroxycoumarin	B-Drug
,	O
trichlorfon	B-Drug
,	O
and	O
phenobarbital	B-Drug
sodium	I-Drug
.	O

Interactions	O
between	O
treatments	O
with	O
coumaphos	B-Drug
,	O
bishydroxycoumarin	B-Drug
(	O
an	O
anticoagulant	B-Drug
)	O
,	O
trichlorfon	B-Drug
(	O
an	O
organophosphorous	O
compound	O
)	O
,	O
and	O
phenobarbital	B-Drug
sodium	I-Drug
(	O
an	O
inducer	O
of	O
microsomal	O
enzymes	O
)	O
were	O
investigated	O
in	O
sheep	O
.	O

A	O
daily	O
dose	O
of	O
2	O
mg	O
of	O
coumaphos/kg	B-Drug
of	O
body	O
weight	O
for	O
6	O
days	O
did	O
not	O
affect	O
the	O
plasma	O
enzymes	O
or	O
the	O
antiprothrombinemic	O
effect	O
of	O
bishydroxy-coumarin	B-Drug
in	O
wethers	O
.	O

The	O
treatment	O
of	O
ewes	O
with	O
an	O
intravenous	O
(	O
IV	O
)	O
injection	O
of	O
trichlorfon	B-Drug
,	O
insufficient	O
to	O
produce	O
significant	O
inhibition	O
of	O
erythrocyte	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
,	O
appeared	O
to	O
produce	O
additive	O
effects	O
with	O
those	O
produced	O
by	O
subsequent	O
treatment	O
with	O
4	O
mg	O
of	O
coumaphos/kg/day	B-Drug
.	O

In	O
ewes	O
given	O
40	O
mg	O
of	O
phenobarbital	B-Drug
sodium/kg	I-Drug
for	O
5	O
days	O
intraperitoneally	O
(	O
IP	O
)	O
,	O
the	O
anticholinesterase	O
effect	O
of	O
4	O
mg	O
of	O
coumaphos/kg	B-Drug
was	O
significantly	O
reduced	O
and	O
signs	O
of	O
toxicity	O
were	O
not	O
present	O
.	O

Treatment	O
with	O
daily	O
doses	O
of	O
2	O
mg	O
of	O
coumaphos/kg	B-Drug
for	O
6	O
days	O
did	O
not	O
modify	O
the	O
anticholinesterase	O
effect	O
of	O
a	O
2nd	O
series	O
of	O
treatments	O
given	O
6	O
weeks	O
later	O
.	O

Diagnostic	O
,	O
treatment	O
and	O
aftercare	O
approaches	O
to	O
cocaine	B-Drug
abuse	O
.	O

The	O
general	O
public	O
feels	O
that	O
cocaine	B-Drug
is	O
not	O
particularly	O
dangerous	O
because	O
it	O
does	O
not	O
produce	O
a	O
well	O
defined	O
physical	O
dependency	O
and	O
abstinence	O
syndrome	O
.	O

However	O
,	O
when	O
addiction	O
is	O
defined	O
as	O
compulsion	O
,	O
loss	O
of	O
control	O
and	O
continued	O
use	O
in	O
spite	O
of	O
adverse	O
consequences	O
,	O
cocaine	B-Drug
drug	B-Drug
hunger	O
can	O
be	O
seen	O
as	O
an	O
agent	O
of	O
addictive	O
disease	O
.	O

Withdrawal	O
from	O
cocaine	B-Drug
dependence	O
usually	O
involves	O
depression	O
,	O
anxiety	O
and	O
lethargy	O
.	O

These	O
usually	O
clear	O
within	O
a	O
week	O
,	O
leaving	O
only	O
the	O
``	O
drug	B-Drug
hunger	O
''	O
to	O
contend	O
with	O
.	O

Medication	O
is	O
rarely	O
needed	O
.	O

When	O
cocaine	B-Drug
is	O
the	O
primary	O
addiction	O
,	O
after	O
withdrawal	O
the	O
most	O
effective	O
treatment	O
is	O
group	O
therapy	O
with	O
other	O
recovering	O
cocaine	B-Drug
abusers	O
.	O

We	O
incorporate	O
the	O
principles	O
of	O
recovery	O
and	O
define	O
positive	O
and	O
constructive	O
alternatives	O
in	O
dealing	O
with	O
cocaine	B-Drug
hunger	O
.	O

Recovery	O
programs	O
should	O
be	O
flexible	O
and	O
involve	O
individual	O
and	O
family	O
education	O
on	O
recovery	O
and	O
the	O
nature	O
of	O
addictive	O
disease	O
.	O

Exercise	O
that	O
produces	O
cardiopulmonary	O
stimulation	O
is	O
a	O
helpful	O
means	O
of	O
reducing	O
drug	B-Drug
hunger	O
and	O
anxiety	O
during	O
recovery	O
therapy	O
.	O

Failure	O
of	O
neomycin	B-Drug
to	O
modify	O
ACTH	B-Drug
induced	O
hypertension	O
in	O
sheep	O
.	O

Studies	O
in	O
rats	O
have	O
shown	O
that	O
neomycin	B-Drug
administration	O
attenuates	O
certain	O
types	O
of	O
adrenocortical	O
steroid	O
dependent	O
hypertension	O
,	O
including	O
ACTH	B-Drug
hypertension	O
.	O

The	O
effects	O
of	O
oral	O
neomycin	B-Drug
on	O
ACTH	B-Drug
induced	O
hypertension	O
were	O
examined	O
in	O
conscious	O
sheep	O
.	O

Neomycin	B-Drug
has	O
no	O
effect	O
on	O
the	O
blood	O
pressure	O
or	O
metabolic	O
responses	O
to	O
ACTH	B-Drug
in	O
sheep	O
.	O

Changes	O
in	O
urinary	O
homocysteine	O
following	O
synthetic	O
steroidal	O
estrogen	O
and	O
progestogen	O
administration	O
to	O
rats	O
.	O

The	O
present	O
work	O
involved	O
the	O
administration	O
of	O
both	O
ethynyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
to	O
groups	O
of	O
rats	O
,	O
followed	O
by	O
determination	O
of	O
the	O
homocysteine	O
excretion	O
rate	O
in	O
urine	O
.	O

The	O
results	O
indicate	O
that	O
a	O
statistically	O
significant	O
difference	O
exists	O
between	O
the	O
excreted	O
levels	O
of	O
homocysteine	O
in	O
the	O
urine	O
of	O
both	O
control	O
and	O
levonorgestrel-treated	B-Drug
rats	O
and	O
the	O
levels	O
shown	O
by	O
rats	O
treated	O
with	O
ethynyl	B-Drug
estradiol	I-Drug
.	O

The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
,	O
especially	O
with	O
respect	O
to	O
observations	O
which	O
indicate	O
that	O
homocysteine	O
may	O
be	O
a	O
precipitating	O
factor	O
in	O
the	O
development	O
of	O
thrombosis	O
.	O

Also	O
included	O
in	O
this	O
paper	O
is	O
a	O
study	O
which	O
confirms	O
the	O
identity	O
of	O
the	O
HPLC	O
peak	O
as	O
being	O
homocysteine	O
by	O
forming	O
a	O
radioactive	O
derivative	O
of	O
this	O
particular	O
sulphydryl-containing	O
amino	O
acid	O
,	O
and	O
then	O
analysing	O
the	O
resulting	O
mixture	O
by	O
TLC	O
.	O

Altered	O
responsiveness	O
to	O
alcohol	B-Drug
after	O
exposure	O
to	O
organic	O
lead	B-Drug
.	O

Ethyl	B-Drug
alcohol	I-Drug
is	O
known	O
to	O
effect	O
the	O
functional	O
integrity	O
of	O
the	O
limbic	O
system	O
,	O
particularly	O
the	O
hippocampus	O
,	O
and	O
to	O
alter	O
behaviors	O
which	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
limbic	O
function	O
.	O

Organometals	O
also	O
compromise	O
the	O
limbic	O
system	O
and	O
result	O
in	O
deficits	O
in	O
learning	O
and	O
memory	O
.	O

Since	O
both	O
alcohol	B-Drug
and	O
organoleads	O
are	O
present	O
in	O
the	O
environment	O
and	O
seem	O
to	O
influence	O
limbic	O
integration	O
,	O
the	O
interaction	O
of	O
these	O
two	O
compounds	O
was	O
assessed	O
in	O
the	O
present	O
experiment	O
.	O

Thirty	O
male	O
rats	O
of	O
the	O
Fischer-344	O
strain	O
were	O
divided	O
into	O
three	O
equal	O
groups	O
and	O
were	O
given	O
injections	O
of	O
trimethyl	B-Drug
lead	I-Drug
(	O
TML	B-Drug
)	O
(	O
8.0	O
or	O
17.0	O
mg/kg/ml	O
SC	O
)	O
or	O
the	O
saline	O
vehicle	O
.	O

Fourteen	O
days	O
later	O
,	O
all	O
animals	O
were	O
challenged	O
with	O
a	O
single	O
hypnotic	O
dose	O
of	O
ethanol	B-Drug
(	O
3.5	O
g/kg	O
IP	O
)	O
.	O

The	O
20	O
%	O
v/v	O
solution	O
of	O
alcohol	B-Drug
was	O
prepared	O
in	O
water	O
from	O
a	O
stock	O
solution	O
of	O
95	O
%	O
ethanol	B-Drug
.	O

The	O
latency	O
to	O
loss	O
of	O
the	O
righting	O
reflex	O
and	O
duration	O
of	O
sleep	O
time	O
were	O
recorded	O
while	O
the	O
rats	O
were	O
kept	O
in	O
sound-attenuating	O
chambers	O
.	O

The	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
TML	B-Drug
manifested	O
significantly	O
longer	O
latencies	O
to	O
lose	O
the	O
righting	O
reflex	O
and	O
shorter	O
durations	O
of	O
sleep	O
than	O
did	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
exposure	O
to	O
environmental	O
lead	B-Drug
may	O
alter	O
the	O
biological	O
and	O
behavioral	O
responsiveness	O
of	O
an	O
animal	O
to	O
alcohol	B-Drug
.	O

Cholinergic	O
role	O
in	O
alcohol	B-Drug
's	O
effects	O
on	O
evoked	O
potentials	O
in	O
visual	O
cortex	O
of	O
the	O
albino	O
rat	O
.	O

Photic	O
evoked	O
potentials	O
were	O
recorded	O
from	O
the	O
visual	O
cortex	O
of	O
chronically	O
implanted	O
albino	O
rats	O
.	O

Since	O
photic	O
evoked	O
potential	O
components	O
are	O
representations	O
of	O
neural	O
pathways	O
which	O
are	O
activated	O
during	O
photic	O
stimulation	O
,	O
study	O
of	O
the	O
effects	O
of	O
alcohol	B-Drug
on	O
these	O
components	O
may	O
help	O
to	O
trace	O
pathways	O
which	O
are	O
affected	O
by	O
alcohol	B-Drug
.	O

In	O
the	O
present	O
study	O
,	O
evoked	O
potentials	O
were	O
recorded	O
at	O
5	O
,	O
20	O
,	O
and	O
40	O
min	O
following	O
IP	O
injections	O
of	O
saline	O
,	O
ethanol	B-Drug
(	O
2.0	O
g/kg	O
)	O
,	O
physostigmine	B-Drug
(	O
0.6	O
mg/kg	O
)	O
or	O
atropine	B-Drug
(	O
15.0	O
mg/kg	O
)	O
on	O
separate	O
days	O
.	O

Ethanol	B-Drug
depressed	O
the	O
amplitudes	O
of	O
most	O
evoked	O
potential	O
components	O
in	O
comparison	O
to	O
saline	O
administration	O
.	O

Component	O
P2	O
,	O
however	O
,	O
was	O
increased	O
in	O
amplitude	O
.	O

Physostigmine	B-Drug
briefly	O
reduced	O
the	O
amplitude	O
of	O
most	O
components	O
,	O
including	O
P2	O
.	O

In	O
contrast	O
,	O
atropine	B-Drug
increased	O
the	O
amplitudes	O
of	O
components	O
P1	O
and	O
P2	O
,	O
while	O
decreasing	O
components	O
N1	O
,	O
N2	O
and	O
N3	O
for	O
varying	O
durations	O
of	O
time	O
.	O

Physostigmine	B-Drug
pretreatment	O
augmented	O
the	O
depressant	O
effect	O
of	O
alcohol	B-Drug
on	O
the	O
early	O
components	O
P1	O
and	O
N1	O
,	O
while	O
attenuating	O
alcohol	B-Drug
's	O
influence	O
on	O
components	O
P2	O
and	O
P3	O
.	O

Pretreatment	O
with	O
atropine	B-Drug
likewise	O
further	O
reduced	O
the	O
amplitudes	O
of	O
components	O
P1	O
and	O
N1	O
,	O
and	O
produced	O
a	O
similar	O
effect	O
on	O
component	O
N3	O
.	O

Atropine	B-Drug
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
alcohol	B-Drug
,	O
produced	O
approximately	O
the	O
same	O
degree	O
of	O
enhancement	O
of	O
component	O
P2	O
.	O

In	O
comparison	O
to	O
saline	O
values	O
,	O
all	O
three	O
agents	O
produced	O
reliable	O
increases	O
in	O
peak	O
latency	O
for	O
most	O
of	O
the	O
components	O
,	O
with	O
only	O
N3	O
showing	O
no	O
effects	O
.	O

The	O
amplitude	O
data	O
from	O
this	O
study	O
suggest	O
that	O
ethanol	B-Drug
's	O
augmentation	O
of	O
component	O
P2	O
may	O
result	O
,	O
at	O
least	O
in	O
part	O
,	O
from	O
alterations	O
in	O
cholinergic	O
functions	O
.	O

Hypothermia	O
as	O
an	O
index	O
of	O
the	O
disulfiram-ethanol	B-Drug
reaction	O
in	O
the	O
rat	O
.	O

Decreased	O
core	O
temperature	O
in	O
female	O
rats	O
was	O
investigated	O
as	O
one	O
possible	O
index	O
of	O
the	O
disulfiram-ethanol	B-Drug
reaction	O
(	O
DER	O
)	O
.	O

Core	O
temperature	O
was	O
decreased	O
in	O
rats	O
in	O
a	O
dose-dependent	O
manner	O
when	O
ethanol	B-Drug
was	O
administered	O
to	O
rats	O
treated	O
with	O
disulfiram	B-Drug
8	O
hours	O
before	O
the	O
ethanol	B-Drug
challenge	O
.	O

The	O
decrease	O
in	O
temperature	O
began	O
within	O
20	O
minutes	O
after	O
ethanol	B-Drug
administration	O
,	O
reaching	O
a	O
maximal	O
decrease	O
between	O
60	O
and	O
120	O
minutes	O
post	O
ethanol	B-Drug
.	O

The	O
core	O
temperature	O
returned	O
to	O
normal	O
300	O
minutes	O
after	O
ethanol	B-Drug
.	O

The	O
blood	O
pressure	O
(	O
carotid	O
cannulation	O
)	O
decreased	O
along	O
with	O
the	O
core	O
temperature	O
.	O

Maximal	O
hypotension	O
was	O
found	O
120	O
minutes	O
post	O
ethanol	B-Drug
,	O
and	O
returned	O
to	O
normal	O
300	O
minutes	O
after	O
ethanol	B-Drug
.	O

Heart	O
rate	O
increased	O
initially	O
and	O
returned	O
to	O
normal	O
40	O
minutes	O
after	O
ethanol	B-Drug
challenge	O
.	O

Excretion	O
of	O
thioethers	O
in	O
urine	O
after	O
exposure	O
to	O
electrophilic	O
chemicals	O
.	O

Electrophilic	O
agents	O
--	O
a	O
class	O
of	O
chemicals	O
that	O
includes	O
most	O
genotoxic	O
compounds	O
--	O
can	O
be	O
inactivated	O
by	O
reaction	O
with	O
glutathione	O
or	O
other	O
SH-bearing	O
molecules	O
.	O

The	O
conjugates	O
so	O
formed	O
often	O
appear	O
in	O
the	O
urine	O
as	O
mercapturic	O
acids	O
or	O
other	O
thioether	O
products	O
.	O

This	O
paper	O
critically	O
reviews	O
the	O
suitability	O
of	O
the	O
urinary	O
thioether	O
assay	O
as	O
a	O
method	O
for	O
the	O
detection	O
of	O
exposure	O
to	O
electrophilic	O
agents	O
or	O
their	O
precursors	O
.	O

In	O
practice	O
,	O
the	O
greatest	O
value	O
of	O
the	O
thioether	O
assay	O
appears	O
to	O
lie	O
in	O
its	O
signal	O
function	O
.	O

This	O
is	O
demonstrated	O
for	O
cigarette	O
smokers	O
and	O
industrial	O
workers	O
involved	O
in	O
chemical	O
waste	O
incineration	O
.	O

Whenever	O
increased	O
thioether	O
excretion	O
is	O
observed	O
,	O
it	O
is	O
likely	O
to	O
be	O
due	O
to	O
exposure	O
to	O
one	O
or	O
more	O
suspect	O
compounds	O
.	O

However	O
,	O
when	O
the	O
thioether	O
concentration	O
ranges	O
within	O
the	O
limits	O
of	O
the	O
normal	O
value	O
,	O
one	O
must	O
not	O
conclude	O
that	O
there	O
is	O
no	O
,	O
or	O
negligible	O
,	O
exposure	O
.	O

More	O
specific	O
applications	O
of	O
the	O
assay	O
of	O
thio	O
compounds	O
in	O
urine	O
allow	O
development	O
of	O
selective	O
methods	O
that	O
may	O
be	O
useful	O
for	O
biological	O
monitoring	O
.	O

Interaction	O
on	O
the	O
antinociceptive	O
effect	O
between	O
neurotensin	B-Drug
and	O
enkephalins	B-Drug
or	O
tuftsin	B-Drug
.	O

The	O
aim	O
of	O
this	O
paper	O
was	O
to	O
study	O
the	O
interaction	O
between	O
neurotensin	B-Drug
and	O
both	O
enkephalins	B-Drug
or	O
its	O
synthetic	O
analogue	O
D-Ala2-metenkephalinamide	B-Drug
,	O
or	O
tuftsin	B-Drug
,	O
on	O
the	O
antinonciceptive	O
effect	O
of	O
these	O
peptides	O
in	O
mice	O
after	O
intracisternal	O
injection	O
.	O

Antinociception	O
was	O
measured	O
by	O
the	O
hot-plate	O
method	O
.	O

It	O
was	O
shown	O
that	O
neurotensin	B-Drug
antagonized	O
evidently	O
the	O
antinociceptive	O
effect	O
of	O
enkephalins	B-Drug
and	O
their	O
analogue	O
.	O

On	O
the	O
contrary	O
,	O
neurotensin	B-Drug
and	O
tuftsin	B-Drug
were	O
agonists	O
in	O
induction	O
of	O
analgesia	O
.	O

It	O
is	O
concluded	O
that	O
neurotensin	B-Drug
modulates	O
in	O
an	O
opposite	O
way	O
the	O
function	O
of	O
the	O
enkephalinergic	O
neurons	O
and	O
the	O
central	O
action	O
of	O
tuftsin	B-Drug
.	O

Drug-lab	O
interactions	O
:	O
implications	O
for	O
nutrition	O
support	O
.	O

Acetylcysteine	B-Drug
interference	O
with	O
urine	O
ketone	O
test	O
.	O

It	O
is	O
important	O
that	O
health	O
care	O
professionals	O
be	O
aware	O
of	O
the	O
potential	O
for	O
medications	O
to	O
interfere	O
with	O
clinical	O
laboratory	O
tests	O
.	O

Medications	O
can	O
cause	O
in	O
vivo	O
effects	O
when	O
the	O
concentration	O
or	O
activity	O
of	O
the	O
analyte	O
is	O
altered	O
before	O
the	O
analysis	O
and	O
therefore	O
the	O
assay	O
result	O
is	O
true	O
and	O
accurate	O
.	O

An	O
in	O
vitro	O
effect	O
occurs	O
when	O
the	O
medication	O
interferes	O
with	O
the	O
assay	O
,	O
and	O
the	O
result	O
is	O
erroneous	O
and	O
can	O
not	O
be	O
interpreted	O
.	O

This	O
report	O
describes	O
a	O
recently	O
identified	O
case	O
of	O
interference	O
of	O
acetylcysteine	B-Drug
with	O
the	O
urine	O
test	O
for	O
ketones	O
and	O
demonstrates	O
the	O
importance	O
of	O
a	O
thorough	O
medication	O
review	O
in	O
evaluating	O
abnormal	O
laboratory	O
tests	O
.	O

[	O
2	O
epidemics	O
of	O
arsenical	O
encephalopathy	O
in	O
the	O
treatment	O
of	O
trypanosomiasis	O
,	O
Uganda	O
,	O
1992-1993	O
]	O
Since	O
1988	O
,	O
the	O
french	O
non-governmental	O
organisation	O
M	O
decins	O
Sans	O
Fronti	O
res	O
is	O
running	O
a	O
control	O
program	O
of	O
human	O
african	O
trypanosomiasis	O
in	O
the	O
district	O
of	O
Moyo	O
,	O
North-Uganda	O
.	O

Between	O
1988	O
and	O
1993	O
,	O
more	O
than	O
7,000	O
patients	O
were	O
diagnosed	O
and	O
treated	O
.	O

Since	O
1988	O
,	O
it	O
has	O
been	O
noted	O
that	O
incidence	O
of	O
melarsoprol	B-Drug
reaction	O
had	O
increased	O
systematically	O
between	O
June	O
and	O
October	O
of	O
each	O
year	O
,	O
indicating	O
strong	O
seasonal	O
variation	O
.	O

In	O
1992	O
and	O
1993	O
,	O
two	O
outbreaks	O
of	O
arsenical	O
reactive	O
encephalopathy	O
(	O
ARE	O
)	O
occurred	O
in	O
the	O
sleeping	O
sickness	O
center	O
of	O
Adjumani	O
.	O

The	O
incidence	O
of	O
ARE	O
suddenly	O
exceeded	O
10	O
%	O
of	O
the	O
patients	O
treated	O
by	O
melarsoprol	B-Drug
during	O
August	O
1992	O
and	O
September	O
1993	O
.	O

The	O
onset	O
of	O
80	O
%	O
of	O
those	O
``	O
epidemic	O
''	O
cases	O
,	O
occurred	O
between	O
the	O
5th	O
and	O
the	O
11th	O
day	O
of	O
treatment	O
.	O

Two	O
retrospective	O
studies	O
were	O
conducted	O
in	O
1992	O
(	O
75	O
cases	O
)	O
and	O
in	O
1993	O
(	O
51	O
cases	O
)	O
.	O

Among	O
the	O
risk	O
factors	O
studied	O
,	O
two	O
appear	O
to	O
increase	O
the	O
risk	O
of	O
ARE	O
:	O
the	O
prescription	O
of	O
thiabendazole	B-Drug
to	O
treat	O
strongyloidiasis	O
during	O
the	O
melarsoprol	B-Drug
cure	O
and	O
the	O
bad	O
general	O
clinical	O
conditions	O
of	O
patients	O
.	O

These	O
observations	O
suggest	O
that	O
exogenous	O
co-factors	O
could	O
be	O
involved	O
in	O
the	O
occurrence	O
of	O
ARE	O
.	O

Recommendations	O
were	O
to	O
avoid	O
administration	O
of	O
diffusible	O
anti-helminthic	O
treatment	O
during	O
the	O
cure	O
,	O
and	O
to	O
improve	O
the	O
general	O
conditions	O
of	O
patients	O
before	O
the	O
cure	O
of	O
melarsoprol	B-Drug
.	O

Interactions	O
of	O
cobalt	B-Drug
and	O
iron	B-Drug
in	O
absorption	O
and	O
retention	O
.	O

The	O
effects	O
of	O
supplementary	O
oral	O
cobalt	B-Drug
and	O
iron	B-Drug
,	O
as	O
well	O
as	O
the	O
interaction	O
between	O
both	O
at	O
the	O
absorption	O
site	O
,	O
fecal	O
and	O
urinary	O
excretion	O
as	O
well	O
as	O
the	O
retention	O
of	O
these	O
trace	O
elements	O
were	O
determined	O
by	O
using	O
four	O
diets	O
containing	O
either	O
9	O
or	O
63	O
micrograms/kg	O
of	O
Co	B-Drug
and	O
48	O
or	O
446	O
mg/kg	O
of	O
Fe	B-Drug
over	O
a	O
period	O
of	O
19	O
days	O
in	O
a	O
total	O
of	O
24	O
rats	O
.	O

Retention	O
was	O
calculated	O
by	O
the	O
balance	O
technique	O
and	O
by	O
the	O
comparative	O
slaughter	O
technique	O
.	O

After	O
one	O
day	O
,	O
fecal	O
as	O
well	O
as	O
urinary	O
excretion	O
of	O
both	O
elements	O
had	O
already	O
responded	O
to	O
the	O
dietary	O
treatments	O
,	O
with	O
constant	O
values	O
being	O
reached	O
after	O
approximately	O
three	O
days	O
.	O

Cobalt	B-Drug
excretion	O
was	O
enhanced	O
by	O
supplementary	O
cobalt	B-Drug
;	O
fecal	O
excretion	O
,	O
too	O
,	O
was	O
increased	O
by	O
supplementary	O
iron	B-Drug
;	O
whereas	O
urinary	O
excretion	O
was	O
decreased	O
in	O
both	O
cases	O
.	O

Additional	O
iron	B-Drug
significantly	O
inhibited	O
the	O
absorption	O
of	O
cobalt	B-Drug
in	O
both	O
dietary	O
cobalt	B-Drug
treatments	O
.	O

The	O
lower	O
rate	O
of	O
absorption	O
in	O
the	O
groups	O
receiving	O
446	O
mg	O
Fe	B-Drug
instead	O
of	O
48	O
mg	O
of	O
Fe	B-Drug
per	O
kg	O
diet	O
resulted	O
in	O
a	O
decreased	O
renal	O
excretion	O
of	O
cobalt	B-Drug
.	O

Consequently	O
,	O
the	O
effect	O
of	O
iron	B-Drug
on	O
the	O
retention	O
of	O
cobalt	B-Drug
was	O
lower	O
than	O
on	O
absorption	O
.	O

This	O
suggests	O
that	O
interactions	O
between	O
the	O
two	O
elements	O
only	O
take	O
place	O
at	O
the	O
site	O
of	O
absorption	O
.	O

Because	O
of	O
the	O
low	O
dietary	O
cobalt	B-Drug
concentration	O
as	O
compared	O
to	O
the	O
iron	B-Drug
contents	O
of	O
the	O
diets	O
,	O
no	O
effect	O
of	O
cobalt	B-Drug
on	O
iron	B-Drug
absorption	O
and	O
excretion	O
occurred	O
.	O

Differences	O
in	O
iron	B-Drug
balance	O
were	O
only	O
observed	O
between	O
both	O
dietary	O
concentrations	O
,	O
showing	O
a	O
higher	O
absolute	O
but	O
a	O
lower	O
relative	O
absorption	O
as	O
well	O
as	O
retention	O
in	O
the	O
groups	O
fed	O
further	O
Fe	B-Drug
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Effect	O
of	O
estradiol	B-Drug
on	O
endotoxin-induced	B-Drug
changes	O
in	O
steroid	O
hormone	O
levels	O
and	O
lethality	O
in	O
male	O
rats	O
.	O

We	O
examined	O
the	O
effect	O
of	O
exogenous	O
estradiol	B-Drug
on	O
the	O
changes	O
in	O
serum	O
steroid	O
hormone	O
levels	O
induced	O
by	O
a	O
nonlethal	O
dose	O
of	O
Escherichia	O
coli	O
endotoxin	B-Drug
in	O
male	O
rats	O
and	O
the	O
deaths	O
due	O
to	O
nonlethal	O
and	O
lethal	O
doses	O
of	O
endotoxin	B-Drug
.	O

Injection	O
of	O
estradiol	B-Drug
5	O
min	O
before	O
a	O
nonlethal	O
dose	O
of	O
endotoxin	B-Drug
changed	O
the	O
serum	O
sex	O
steroid	O
hormone	O
response	O
of	O
male	O
rats	O
to	O
endotoxin	B-Drug
.	O

The	O
serum	O
estrogen	O
concentrations	O
of	O
estradiol	B-Drug
+	O
endotoxin-treated	B-Drug
rats	O
decreased	O
by	O
50	O
%	O
,	O
while	O
those	O
of	O
the	O
endotoxin-treated	B-Drug
rats	O
increased	O
(	O
2-	O
to	O
5-fold	O
)	O
.	O

The	O
serum	O
androgen	O
concentrations	O
of	O
estradiol	B-Drug
+	O
endotoxin-treated	B-Drug
rats	O
did	O
not	O
change	O
significantly	O
,	O
while	O
those	O
of	O
endotoxin-treated	B-Drug
rats	O
dropped	O
to	O
30-40	O
%	O
0.001	O
.	O

Exogenous	O
estradiol	B-Drug
also	O
appeared	O
to	O
influence	O
the	O
percentage	O
of	O
endotoxin-induced	B-Drug
deaths	O
in	O
a	O
dose-dependent	O
manner	O
.	O

It	O
reduced	O
the	O
number	O
of	O
deaths	O
induced	O
by	O
nonlethal	O
(	O
2	O
mg/kg	O
)	O
dose	O
of	O
endotoxin	B-Drug
but	O
increased	O
the	O
number	O
of	O
deaths	O
induced	O
by	O
a	O
highly	O
lethal	O
dose	O
(	O
8	O
mg/kg	O
)	O
.	O

These	O
results	O
,	O
together	O
with	O
the	O
known	O
relationships	O
between	O
estrogen	O
and	O
the	O
immune	O
response	O
,	O
suggest	O
that	O
estrogens	O
affect	O
the	O
course	O
of	O
septic	O
shock	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
have	O
either	O
protective	O
or	O
deleterious	O
effect	O
.	O

Analysis	O
of	O
16,16-dimethylprostaglandin	B-Drug
E2-induced	I-Drug
diarrhea	O
in	O
cecectomized	O
rats	O
.	O

The	O
16,16-dimethylprostaglandin	B-Drug
E2	I-Drug
(	O
dmPGE2	B-Drug
)	O
-induced	O
diarrhea	O
was	O
analyzed	O
in	O
cecectomized	O
rats	O
prepared	O
by	O
resecting	O
the	O
cecum	O
and	O
its	O
vasculature	O
without	O
disturbing	O
the	O
ileocecal	O
junction	O
.	O

dmPGE2	B-Drug
(	O
0.1-1.0	O
mg/kg	O
,	O
p.o	O
.	O

)	O
dose-dependently	O
increased	O
the	O
number	O
of	O
defecation	O
episodes	O
and	O
induced	O
a	O
soft	O
and	O
watery	O
stool	O
in	O
cecectomized	O
rats	O
.	O

At	O
0.3	O
mg/kg	O
,	O
the	O
diarrhea-inducing	O
effects	O
of	O
dmPGE2	B-Drug
were	O
more	O
pronounced	O
in	O
cecectomized	O
than	O
in	O
control	O
rats	O
.	O

When	O
given	O
i.p.	O
,	O
dmPGE2	B-Drug
(	O
0.3	O
mg/kg	O
)	O
induced	O
a	O
watery	O
stool	O
in	O
cecectomized	O
and	O
control	O
rats	O
with	O
the	O
same	O
efficacy	O
,	O
although	O
these	O
effects	O
were	O
short-lasting	O
as	O
compared	O
to	O
oral	O
administration	O
.	O

Castor	B-Drug
oil	I-Drug
(	O
4	O
ml/kg	O
,	O
p.o	O
.	O

)	O
also	O
induced	O
diarrhea	O
,	O
but	O
did	O
not	O
produce	O
a	O
watery	O
stool	O
in	O
cecectomized	O
rats	O
.	O

There	O
were	O
no	O
differences	O
between	O
cecectomized	O
and	O
control	O
rats	O
in	O
basal	O
small	O
intestinal	O
transits	O
or	O
in	O
dmPGE2	B-Drug
(	O
0.3	O
mg/kg	O
,	O
p.o	O
.	O

)	O
-induced	O
enhancements	O
.	O

Moreover	O
,	O
the	O
basal	O
and	O
dmPGE2-induced	B-Drug
jejunal	O
net	O
fluid	O
transfers	O
were	O
the	O
same	O
in	O
cecectomized	O
and	O
in	O
control	O
rats	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
enhanced	O
secretion	O
of	O
colonic	O
fluid	O
by	O
dmPGE2	B-Drug
,	O
given	O
intraluminally	O
,	O
was	O
only	O
half	O
of	O
that	O
in	O
control	O
rats	O
,	O
whereas	O
the	O
colonic	O
transit-enhancing	O
effect	O
of	O
dmPGE2	B-Drug
in	O
cecectomized	O
rats	O
was	O
more	O
pronounced	O
than	O
in	O
control	O
rats	O
at	O
15	O
but	O
not	O
at	O
30	O
min	O
after	O
its	O
administration	O
.	O

The	O
basal	O
colonic	O
fluid	O
contents	O
and	O
transits	O
were	O
the	O
same	O
in	O
cecectomized	O
and	O
in	O
control	O
rats	O
.	O

Loperamide	B-Drug
and	O
morphine	B-Drug
(	O
0.1	O
and	O
1.0	O
mg/kg	O
,	O
s.c	O
.	O

)	O
Loperamide	B-Drug
and	O
morphine	B-Drug
(	O
0.1	O
and	O
1.0	O
mg/kg	O
,	O
s.c.	O
)	O
inhibited	O
the	O
dmPGE2	B-Drug
(	O
0.3	O
mg/kg	O
,	O
p.o	O
.	O

)	O
-induced	O
diarrhea	O
in	O
cecectomized	O
rats	O
.	O

N-methyllevallorphan	B-Drug
(	O
5	O
mg/kg	O
,	O
s.c	O
.	O

)	O
N-methyllevallorphan	B-Drug
(	O
5	O
mg/kg	O
,	O
s.c.	O
)	O
completely	O
antagonized	O
the	O
inhibitory	O
effect	O
of	O
loperamide	B-Drug
and	O
partly	O
antagonized	O
the	O
effect	O
of	O
morphine	B-Drug
.	O

These	O
results	O
suggest	O
that	O
oral	O
administration	O
of	O
dmPGE2	B-Drug
induces	O
a	O
more	O
pronounced	O
secretory	O
diarrhea	O
in	O
cecectomized	O
than	O
in	O
control	O
rats	O
,	O
probably	O
due	O
to	O
the	O
lack	O
of	O
the	O
reservoir	O
function	O
of	O
the	O
cecum	O
in	O
the	O
operated	O
animals	O
.	O

This	O
secretory	O
diarrhea	O
model	O
is	O
suitable	O
for	O
evaluating	O
the	O
antidiarrheal	O
activity	O
of	O
drugs	B-Drug
.	O

Therapeutic	O
drug	B-Drug
monitoring	O
can	O
avoid	O
iatrogenic	O
alterations	O
caused	O
by	O
99mTc-methylene	B-Drug
diphosphonate	I-Drug
(	O
MDP	O
)	O
-gentamicin	B-Drug
interaction	O
.	O

Gentamicin	B-Drug
is	O
an	O
aminoglycoside	O
antibiotic	O
used	O
to	O
treat	O
a	O
wide	O
variety	O
of	O
infections	O
caused	O
by	O
gram-negative	O
organisms	O
,	O
but	O
it	O
is	O
potentially	O
toxic	O
to	O
the	O
kidneys	O
.	O

Due	O
to	O
its	O
nephrotoxicity	O
,	O
gentamicin	B-Drug
may	O
cause	O
abnormal	O
renal	O
uptake	O
to	O
be	O
seen	O
on	O
99mTc-MDP	B-Drug
bone	O
scintigraphy	O
.	O

The	O
presence	O
of	O
the	O
radiopharmaceutical	O
in	O
the	O
kidneys	O
,	O
along	O
with	O
an	O
increase	O
in	O
renal	O
retention	O
,	O
tend	O
to	O
produce	O
scintigraphic	O
results	O
that	O
falsely	O
identify	O
characteristics	O
related	O
to	O
diseases	O
such	O
as	O
renal	O
vascular	O
,	O
or	O
urinary	O
tract	O
obstruction	O
,	O
and	O
even	O
renal	O
cancer	O
.	O

An	O
altered	O
biodistribution	O
may	O
provide	O
misleading	O
information	O
that	O
can	O
either	O
mask	O
or	O
mimic	O
certain	O
disease	O
symptoms	O
.	O

A	O
method	O
to	O
maximize	O
the	O
therapeutic	O
benefit	O
of	O
gentamicin	B-Drug
while	O
minimizing	O
the	O
risk	O
of	O
nephrotoxicity	O
and	O
the	O
appearance	O
of	O
a	O
hot	O
kidney	O
on	O
scintigraphy	O
is	O
desirable	O
.	O

Serial	O
pharmacokinetic	O
dosing	O
has	O
been	O
proposed	O
as	O
a	O
method	O
to	O
accomplish	O
this	O
goal	O
.	O

Therapeutic	O
drug	B-Drug
monitoring	O
(	O
TDM	O
)	O
of	O
gentamicin	B-Drug
therapy	O
,	O
and	O
bone	O
scintigraphy	O
employing	O
99mTc-MDP	B-Drug
as	O
the	O
radiopharmaceutical	O
was	O
carried	O
out	O
in	O
22	O
patients	O
.	O

The	O
data	O
presented	O
here	O
demonstrate	O
that	O
with	O
serial	O
pharmacokinetic	O
dosing	O
of	O
gentamicin	B-Drug
,	O
the	O
iatrogenic	O
alteration	O
caused	O
by	O
gentamicin	B-Drug
therapy	O
can	O
be	O
avoided	O
.	O

Immunosuppressive	O
drugs	B-Drug
and	O
their	O
complications	O
.	O

Drugs	B-Drug
that	O
suppress	O
the	O
immune	O
system	O
are	O
widely	O
used	O
.	O

They	O
are	O
part	O
of	O
the	O
treatment	O
of	O
patients	O
with	O
organ	O
transplants	O
,	O
malignancy	O
,	O
and	O
increasingly	O
those	O
with	O
conditions	O
such	O
as	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
and	O
liver	O
and	O
bowel	O
disease	O
in	O
which	O
inflammation	O
is	O
an	O
aetiological	O
factor	O
.	O

Because	O
of	O
the	O
broadening	O
indications	O
for	O
immunosuppressive	O
drugs	B-Drug
,	O
and	O
the	O
prolonged	O
survival	O
in	O
conditions	O
for	O
which	O
they	O
are	O
being	O
used	O
,	O
many	O
patients	O
on	O
immunosuppression	O
are	O
now	O
cared	O
for	O
in	O
the	O
community	O
or	O
seen	O
in	O
non-specialist	O
hospitals	O
,	O
usually	O
in	O
close	O
collaboration	O
with	O
a	O
specialist	O
.	O

This	O
article	O
looks	O
at	O
five	O
commonly	O
used	O
immunosuppressive	O
drugs	B-Drug
in	O
turn	O
(	O
corticosteroids	O
,	O
cyclosporin	B-Drug
,	O
azathioprine	B-Drug
,	O
methotrexate	B-Drug
,	O
cyclophosphamide	B-Drug
)	O
,	O
discussing	O
the	O
main	O
,	O
non-infection	O
,	O
unwanted	O
effects	O
,	O
ways	O
to	O
avoid	O
them	O
and	O
what	O
to	O
do	O
if	O
problems	O
arise	O
.	O

The	O
management	O
of	O
infection	O
is	O
dealt	O
with	O
as	O
a	O
separate	O
section	O
.	O

Interaction	O
of	O
the	O
constituents	O
of	O
alcoholic	O
beverages	O
in	O
the	O
promotion	O
of	O
liver	O
damage	O
.	O

Little	O
has	O
been	O
studied	O
of	O
the	O
adverse	O
effects	O
of	O
the	O
exposure	O
of	O
the	O
liver	O
to	O
the	O
interaction	O
of	O
ethanol	B-Drug
with	O
its	O
congeners	O
and	O
acetaldehyde	B-Drug
,	O
coexisting	O
in	O
the	O
contents	O
of	O
alcoholic	O
beverages	O
.	O

Twenty	O
four	O
male	O
Wistar	O
rats	O
were	O
divided	O
into	O
four	O
groups	O
.	O

Two	O
groups	O
(	O
SH/DA	O
;	O
SH/FA	O
)	O
were	O
submitted	O
to	O
daily	O
treatment	O
with	O
synthetic	O
hydroalcoholic	O
solutions	O
containing	O
ethanol	B-Drug
,	O
methanol	B-Drug
,	O
higher	O
alcohols	B-Drug
and	O
acetaldehyde	B-Drug
in	O
the	O
same	O
proportions	O
as	O
those	O
found	O
in	O
most	O
common	O
distilled	O
and	O
fermented	O
alcoholic	O
beverages	O
;	O
the	O
third	O
group	O
(	O
SH/EA	O
)	O
was	O
treated	O
with	O
a	O
hydroalcoholic	O
solution	O
of	O
ethanol	B-Drug
;	O
the	O
fourth	O
group	O
served	O
as	O
control	O
and	O
received	O
an	O
equivalent	O
volume	O
of	O
an	O
isocaloric	O
solution	O
of	O
dextrose	B-Drug
.	O

All	O
the	O
animals	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
9th	O
week	O
of	O
the	O
experiment	O
.	O

The	O
ratio	O
between	O
the	O
liver	O
weight	O
and	O
body	O
weight	O
was	O
found	O
to	O
be	O
lower	O
in	O
the	O
treated	O
animals	O
than	O
in	O
the	O
control	O
group	O
.	O

The	O
histology	O
of	O
the	O
liver	O
was	O
altered	O
in	O
the	O
three	O
groups	O
which	O
were	O
submitted	O
to	O
treatment	O
with	O
the	O
hydroalcoholic	O
solutions	O
,	O
with	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
the	O
groups	O
.	O

These	O
results	O
suggest	O
that	O
the	O
hepatoxicity	O
of	O
ethanol	B-Drug
in	O
alcoholic	O
beverages	O
is	O
enhanced	O
by	O
interaction	O
with	O
its	O
congeners	O
and	O
acetaldehyde	B-Drug
;	O
they	O
also	O
suggest	O
that	O
alcoholic	O
beverages	O
are	O
not	O
equivalent	O
in	O
their	O
potential	O
to	O
cause	O
liver	O
damage	O
.	O

Induction	O
of	O
apoptosis	O
in	O
breast	O
cancer	O
cells	O
in	O
response	O
to	O
vitamin	O
D	O
and	O
antiestrogens	O
.	O

1,25-Dihydroxycholecalciferol	B-Drug
D3	I-Drug
(	I-Drug
1,25	B-Drug
(	I-Drug
OH	I-Drug
)	I-Drug
2D3	O
)	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
breast	O
cancer	O
cell	O
growth	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

We	O
have	O
shown	O
that	O
MCF-7	O
cells	O
treated	O
with	O
100	O
nM	O
1,25	B-Drug
(	I-Drug
OH	I-Drug
)	I-Drug
2D3	I-Drug
exhibit	O
characteristic	O
apoptotic	O
morphology	O
(	O
pyknotic	O
nuclei	O
,	O
chromatin	O
and	O
cytoplasmic	O
condensation	O
,	O
nuclear	O
matrix	O
protein	O
reorganization	O
)	O
within	O
48	O
h	O
.	O

In	O
the	O
experiments	O
reported	O
here	O
,	O
we	O
examined	O
the	O
interactions	O
between	O
1,25	B-Drug
(	I-Drug
OH	I-Drug
)	I-Drug
2D3	I-Drug
and	O
the	O
antiestrogen	O
4-hydroxytamoxifen	B-Drug
(	O
TAM	B-Drug
)	O
,	O
which	O
also	O
induces	O
apoptosis	O
in	O
MCF-7	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
TAM	B-Drug
significantly	O
potentiates	O
the	O
reduction	O
in	O
cell	O
number	O
induced	O
by	O
1,25	B-Drug
(	I-Drug
OH	I-Drug
)	I-Drug
2D3	I-Drug
alone	O
.	O

Combined	O
treatment	O
with	O
1,25	B-Drug
(	I-Drug
OH	I-Drug
)	I-Drug
2D3	I-Drug
and	O
TAM	B-Drug
enhances	O
the	O
degree	O
of	O
apoptosis	O
assessed	O
using	O
morphological	O
markers	O
that	O
identify	O
chromatin	O
and	O
nuclear	O
matrix	O
protein	O
condensation	O
.	O

We	O
have	O
selected	O
a	O
subclone	O
of	O
MCF-7	O
cells	O
resistant	O
to	O
1,25	B-Drug
(	I-Drug
OH	I-Drug
)	I-Drug
2D3	I-Drug
(	O
MCF-7D3Res	O
)	O
.	O

These	O
cells	O
express	O
the	O
vitamin	O
D	O
receptor	O
and	O
exhibit	O
doubling	O
times	O
comparable	O
to	O
the	O
parental	O
MCF-7	O
cells	O
,	O
even	O
when	O
grown	O
in	O
100	O
mM	O
1,25	B-Drug
(	I-Drug
OH	I-Drug
)	I-Drug
2D3	I-Drug
.	O

Treatment	O
of	O
both	O
parental	O
and	O
resistant	O
MCF-7	O
cells	O
with	O
TAM	B-Drug
induces	O
apoptosis	O
and	O
clusterin	O
.	O

These	O
data	O
emphasize	O
that	O
apoptosis	O
can	O
be	O
induced	O
in	O
MCF-7	O
cells	O
either	O
by	O
activation	O
of	O
vitamin-D-mediated	O
signalling	O
or	O
disruption	O
of	O
estrogen-dependent	O
signalling	O
.	O

Pharmacokinetic	O
profile	O
of	O
etodolac	B-Drug
in	O
special	O
populations	O
.	O

The	O
pharmacokinetics	O
of	O
etodolac	B-Drug
in	O
healthy	O
normal	O
volunteers	O
has	O
been	O
extensively	O
studied	O
and	O
is	O
well	O
described	O
.	O

Etodolac	B-Drug
is	O
characterised	O
by	O
a	O
high	O
oral	O
bioavailability	O
,	O
low	O
clearance	O
,	O
a	O
small	O
volume	O
of	O
distribution	O
,	O
and	O
a	O
7-hour	O
half-life	O
.	O

It	O
is	O
essentially	O
completely	O
metabolised	O
,	O
therefore	O
little	O
is	O
excreted	O
unchanged	O
.	O

Etodolac	B-Drug
is	O
highly	O
protein	O
bound	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
disease	O
states	O
or	O
concomitant	O
drug	B-Drug
administration	O
on	O
a	O
patient	O
's	O
response	O
to	O
etodolac	B-Drug
,	O
additional	O
pharmacokinetic	O
studies	O
were	O
carried	O
out	O
in	O
special	O
populations	O
.	O

Since	O
etodolac	B-Drug
has	O
a	O
well-defined	O
pharmacokinetic-pharmacodynamic	O
relationship	O
,	O
measurement	O
of	O
pharmacokinetic	O
parameters	O
is	O
clinically	O
relevant	O
.	O

Data	O
from	O
studies	O
to	O
date	O
show	O
that	O
disease	O
states	O
,	O
underlying	O
conditions	O
,	O
and	O
concomitantly	O
administered	O
highly	O
protein-bound	O
drugs	B-Drug
have	O
essentially	O
no	O
effect	O
on	O
etodolac	B-Drug
pharmacokinetics	O
.	O

Therefore	O
,	O
etodolac	B-Drug
can	O
generally	O
be	O
given	O
without	O
the	O
need	O
for	O
dosage	O
modifications	O
in	O
special	O
populations	O
such	O
as	O
uncompromised	O
elderly	O
patients	O
,	O
those	O
with	O
moderate	O
renal	O
impairment	O
,	O
and	O
patients	O
with	O
stable	O
hepatic	O
disease	O
.	O

Effects	O
of	O
xanthine	O
derivatives	O
in	O
a	O
light/dark	O
test	O
in	O
mice	O
and	O
the	O
contribution	O
of	O
adenosine	B-Drug
receptors	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
adenosine	B-Drug
receptor	O
antagonists	O
,	O
caffeine	B-Drug
,	O
theophylline	B-Drug
,	O
8-phenyltheophylline	B-Drug
,	O
and	O
8-cyclopentyl-1,3-dipropylxanthine	B-Drug
(	O
DPCPX	B-Drug
)	O
,	O
in	O
a	O
light/dark	O
test	O
in	O
mice	O
.	O

All	O
antagonists	O
decreased	O
the	O
time	O
spent	O
in	O
the	O
light	O
zone	O
in	O
this	O
test	O
,	O
which	O
suggested	O
that	O
these	O
compounds	O
have	O
anxiogenic	O
effects	O
.	O

The	O
anxiogenic	O
effects	O
of	O
theophylline	B-Drug
were	O
reduced	O
by	O
pretreatment	O
with	O
CGS	B-Drug
21680	I-Drug
,	O
an	O
A2-selective	O
agonist	O
,	O
but	O
not	O
by	O
N6-cyclopentyladenosine	B-Drug
(	O
CPA	B-Drug
)	O
,	O
an	O
A1-selective	O
agonist	O
.	O

However	O
,	O
the	O
antagonism	O
of	O
the	O
theophylline-induced	B-Drug
anxiogenic	O
effects	O
by	O
CGS21680	B-Drug
was	O
only	O
observed	O
in	O
the	O
time	O
spent	O
in	O
the	O
light	O
zone	O
,	O
and	O
DPCPX-induced	B-Drug
anxiogenic	O
effects	O
were	O
neither	O
reversed	O
by	O
CGS	B-Drug
21680	I-Drug
nor	O
by	O
CPA	B-Drug
.	O

Finally	O
,	O
it	O
is	O
notable	O
that	O
xanthine-derived	O
adenosine	B-Drug
antagonists	O
tested	O
here	O
commonly	O
showed	O
anxiogenic	O
effects	O
in	O
the	O
light/dark	O
test	O
in	O
mice	O
.	O

It	O
is	O
suggested	O
that	O
there	O
is	O
a	O
minor	O
contribution	O
of	O
adenosine	B-Drug
receptors	O
to	O
these	O
effects	O
,	O
although	O
theophylline-induced	B-Drug
anxiogenic	O
effects	O
were	O
antagonized	O
by	O
an	O
A2	O
receptor	O
agonist	O
.	O

[	O
The	O
effect	O
of	O
sandimmune	B-Drug
on	O
the	O
activity	O
of	O
mixed-function	O
mono-oxidases	O
in	O
the	O
liver	O
microsomes	O
]	O
The	O
effects	O
of	O
the	O
immunodepressant	O
--	O
the	O
drug	B-Drug
sandimmune	B-Drug
--	O
on	O
hepatic	O
microsomal	O
monooxygenase	O
activities	O
were	O
studied	O
.	O

The	O
agent	O
was	O
found	O
to	O
produce	O
some	O
inhibiting	O
activity	O
against	O
hepatic	O
microsomal	O
7-ethoxycoumarine	O
deethylase	O
in	O
male	O
Wistar	O
rats	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
.	O

When	O
given	O
in	O
a	O
dose	O
of	O
50	O
mg/kg	O
,	O
sandimmune	B-Drug
produced	O
no	O
statistically	O
significant	O
effect	O
on	O
the	O
duration	O
of	O
hexanal-induced	O
sleep	O
in	O
mice	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
agent	O
has	O
slight	O
effects	O
on	O
the	O
tested	O
activities	O
.	O

[	O
The	O
effect	O
of	O
cimetidine	B-Drug
on	O
the	O
renal	O
excretion	O
of	O
verografin	B-Drug
and	O
iodamide	B-Drug
in	O
dogs	O
]	O
The	O
intravenous	O
injection	O
of	O
cimetidine	B-Drug
in	O
a	O
dose	O
of	O
20	O
mg/kg	O
enhanced	O
verografine	B-Drug
and	O
iodamide	B-Drug
excretion	O
in	O
chronic	O
canine	O
experiments	O
.	O

The	O
higher	O
verografine	B-Drug
and	O
iodamide	B-Drug
excretion	O
was	O
due	O
to	O
their	O
increased	O
renal	O
tubular	O
secretion	O
.	O

In	O
dogs	O
,	O
cimetidine	B-Drug
unchanged	O
the	O
secretion	O
of	O
cardiotrast	B-Drug
,	O
a	O
test	O
agent	O
for	O
anionic	O
transport	O
.	O

Possible	O
extrarenal	O
mechanisms	O
of	O
action	O
of	O
cimetidine	B-Drug
on	O
verografine	B-Drug
and	O
iodamide	B-Drug
transport	O
were	O
also	O
examined	O
.	O

[	O
Hippocampus	O
as	O
interaction	O
sites	O
between	O
cerebral	O
memory	O
systems	O
]	O
Most	O
of	O
the	O
current	O
theories	O
assume	O
that	O
there	O
are	O
multiple	O
forms	O
of	O
memory	O
that	O
are	O
supported	O
by	O
separate	O
brain	O
systems	O
and	O
have	O
different	O
characteristics	O
.	O

Animals	O
studies	O
on	O
the	O
various	O
dual-memory	O
theories	O
have	O
been	O
carried	O
out	O
mainly	O
on	O
the	O
basis	O
of	O
hippocampal	O
system	O
function	O
.	O

Specifically	O
,	O
they	O
have	O
focused	O
on	O
aspects	O
of	O
learning	O
and	O
memory	O
that	O
are	O
impaired	O
(	O
vs.	O
spared	O
)	O
by	O
lesions	O
of	O
the	O
hippocampal	O
formation	O
.	O

However	O
,	O
there	O
are	O
several	O
instances	O
in	O
the	O
animal	O
literature	O
showing	O
that	O
hippocampal	O
lesions	O
actually	O
produced	O
enhanced	O
learning	O
and	O
memory	O
function	O
.	O

Moreover	O
,	O
the	O
acquisition	O
of	O
tasks	O
that	O
are	O
facilitated	O
by	O
hippocampal	O
lesions	O
(	O
or	O
dysfunction	O
)	O
is	O
nevertheless	O
associated	O
,	O
in	O
intact	O
subjects	O
,	O
with	O
specific	O
neurobiological	O
alterations	O
in	O
the	O
hippocampus	O
.	O

This	O
problem	O
has	O
been	O
analysed	O
using	O
two	O
different	O
tasks	O
in	O
mice	O
:	O
a	O
bar-press	O
conditioning	O
and	O
a	O
spatial	O
discrimination	O
task	O
.	O

Results	O
showed	O
that	O
,	O
depending	O
on	O
the	O
task	O
considered	O
,	O
the	O
same	O
pharmacological	O
treatment	O
produced	O
either	O
a	O
facilitation	O
or	O
an	O
impairment	O
of	O
acquisition	O
.	O

Moreover	O
,	O
each	O
task	O
induced	O
significant	O
alterations	O
in	O
hippocampal	O
adenylate	O
cyclase	O
activity	O
but	O
in	O
opposite	O
directions	O
.	O

Together	O
with	O
previous	O
findings	O
,	O
these	O
results	O
suggest	O
that	O
the	O
hippocampus	O
is	O
involved	O
in	O
both	O
the	O
so-called	O
``	O
hippocampal-dependent	O
''	O
``	O
hippocampal-independent	O
''	O
forms	O
of	O
memory	O
.	O

It	O
is	O
postulated	O
that	O
some	O
of	O
the	O
observed	O
training-induced	O
neurobiological	O
alterations	O
might	O
reflect	O
the	O
interaction	O
between	O
two	O
(	O
or	O
more	O
)	O
competing	O
memory	O
systems	O
at	O
the	O
hippocampal	O
level	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
its	O
proposed	O
specific	O
information	O
processing	O
functions	O
(	O
i.e.	O
,	O
relational	O
)	O
,	O
the	O
hippocampus	O
would	O
play	O
a	O
role	O
in	O
addressing	O
information	O
to	O
the	O
brain	O
memory	O
system	O
that	O
,	O
in	O
a	O
given	O
situation	O
,	O
has	O
the	O
best	O
adaptive	O
value	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Magnesium	B-Drug
and	O
therapeutics	O
.	O

Two	O
different	O
types	O
of	O
therapy	O
with	O
magnesium	B-Drug
are	O
used	O
:	O
physiological	O
oral	O
magnesium	B-Drug
supplementation	O
which	O
is	O
totally	O
atoxic	O
since	O
it	O
palliates	O
magnesium	B-Drug
deficiencies	O
by	O
simply	O
normalizing	O
the	O
magnesium	B-Drug
intake	O
and	O
pharmacological	O
magnesium	B-Drug
therapy	O
which	O
may	O
induce	O
toxicity	O
since	O
it	O
creates	O
iatrogenic	O
magnesium	B-Drug
overload	O
.	O

Primary	O
and	O
secondary	O
magnesium	B-Drug
deficiencies	O
constitute	O
the	O
sole	O
indication	O
of	O
physiological	O
oral	O
magnesium	B-Drug
therapy	O
.	O

It	O
is	O
therefore	O
necessary	O
to	O
be	O
well	O
acquainted	O
with	O
the	O
clinical	O
and	O
paraclinical	O
pattern	O
of	O
magnesium	B-Drug
deficit	O
and	O
to	O
discriminate	O
between	O
magnesium	B-Drug
deficiency	O
due	O
to	O
an	O
insufficient	O
magnesium	B-Drug
intake	O
which	O
only	O
requires	O
oral	O
physiological	O
supplementation	O
and	O
magnesium	B-Drug
depletion	O
related	O
to	O
a	O
dysregulation	O
of	O
the	O
control	O
mechanisms	O
of	O
magnesium	B-Drug
status	O
which	O
requires	O
more	O
or	O
less	O
specific	O
regulation	O
of	O
its	O
causal	O
dysregulation	O
.	O

Physiological	O
oral	O
magnesium	B-Drug
load	O
constitutes	O
the	O
best	O
tool	O
for	O
diagnosis	O
of	O
magnesium	B-Drug
deficiency	O
and	O
the	O
first	O
step	O
of	O
its	O
treatment	O
.	O

Physiological	O
oral	O
magnesium	B-Drug
supplementation	O
(	O
5	O
mg/kg/day	O
)	O
is	O
easy	O
and	O
can	O
be	O
carried	O
out	O
in	O
the	O
diet	O
or	O
with	O
magnesium	B-Drug
salts	I-Drug
,	O
with	O
practically	O
only	O
one	O
contra-indication	O
:	O
overt	O
renal	O
failure	O
.	O

Specific	O
and	O
aspecific	O
treatments	O
of	O
magnesium	B-Drug
depletion	O
are	O
tricky	O
using	O
for	O
example	O
magnesium	B-Drug
sparing	O
diuretics	B-Drug
,	O
pharmacological	O
doses	O
of	O
vitamin	B-Drug
B6	I-Drug
,	O
physiological	O
doses	O
of	O
vitamin	O
D	O
and	O
of	O
selenium	B-Drug
.	O

In	O
order	O
to	O
use	O
the	O
pharmacological	O
properties	O
of	O
induced	O
therapeutic	O
hypermagnesaemia	O
,	O
high	O
oral	O
doses	O
of	O
magnesium	B-Drug
(	O
>	O
10	O
mg/kg/day	O
)	O
are	O
advisable	O
for	O
chronic	O
indications	O
and	O
the	O
parenteral	O
route	O
is	O
suitable	O
for	O
acute	O
indications	O
.	O

There	O
are	O
3	O
types	O
of	O
indications	O
:	O
specific	O
(	O
for	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
magnesium	B-Drug
deficit	O
i.e	O
.	O

acute	O
)	O
,	O
pharmacological	O
(	O
i.e	O
.	O

without	O
alterations	O
of	O
magnesium	B-Drug
status	O
)	O
and	O
mixed	O
--	O
pharmacological	O
and	O
aetiopathogenic	O
--	O
(	O
for	O
example	O
complications	O
of	O
chronic	O
alcoholism	O
)	O
.	O

Today	O
pharmacological	O
magnesium	B-Drug
therapy	O
mainly	O
concerns	O
the	O
obstetrical	O
,	O
cardiological	O
and	O
anaesthesiological	O
fields	O
.	O

The	O
main	O
indications	O
are	O
eclampsia	O
,	O
some	O
dysrhythmias	O
(	O
torsades	O
de	O
pointe	O
particularly	O
)	O
and	O
myocardial	O
ischaemias	O
.	O

But	O
it	O
is	O
now	O
difficult	O
to	O
situate	O
the	O
exact	O
place	O
of	O
the	O
pharmacological	O
indications	O
of	O
magnesium	B-Drug
.	O

Magnesium	B-Drug
infusions	O
can	O
only	O
be	O
envisaged	O
in	O
intensive	O
care	O
units	O
with	O
careful	O
monitoring	O
of	O
pulse	O
,	O
arterial	O
pressure	O
,	O
deep	O
tendon	O
reflexes	O
,	O
hourly	O
diuresis	O
,	O
electrocardiogram	O
and	O
respiratory	O
recordings	O
.	O

High	O
oral	O
magnesium	B-Drug
doses	O
besides	O
their	O
laxative	O
action	O
may	O
bring	O
latent	O
complications	O
which	O
may	O
reduce	O
lifespan	O
.	O

There	O
may	O
remain	O
some	O
indications	O
of	O
the	O
laxative	O
and	O
antacid	O
properties	O
of	O
non	O
soluble	O
magnesium	B-Drug
,	O
particularly	O
during	O
intermittent	O
haemodialysis	O
.	O

Lastly	O
local	O
use	O
of	O
the	O
mucocutaneous	O
and	O
cytoprotective	O
properties	O
of	O
magnesium	B-Drug
is	O
still	O
valid	O
,	O
in	O
cardioplegic	B-Drug
solutions	I-Drug
and	O
for	O
preservation	O
of	O
transplants	O
particularly	O
.	O

Interaction	O
between	O
glycine	B-Drug
and	O
glutamate	B-Drug
in	O
the	O
development	O
of	O
spontaneous	O
motility	O
in	O
chick	O
embryos	O
.	O

In	O
this	O
study	O
we	O
investigated	O
whether	O
also	O
glycine	B-Drug
fulfils	O
the	O
function	O
as	O
co-activator	O
in	O
glutamatergic	O
activation	O
of	O
NMDA	O
receptors	O
in	O
the	O
neuronal	O
apparatus	O
of	O
spontaneous	O
motility	O
in	O
chick	O
embryos	O
.	O

The	O
successive	O
application	O
of	O
glycine	B-Drug
(	O
5	O
or	O
10	O
mg/kg	O
egg	B-Drug
weight	O
(	O
e.w	O
.	O

)	O
and	O
glutamate	B-Drug
(	O
15	O
mg/kg	O
e.w	O
.	O

)	O
The	O
successive	O
application	O
of	O
glycine	B-Drug
(	O
5	O
or	O
10	O
mg/kg	O
egg	B-Drug
weight	O
(	O
e.w	O
.	O

)	O
and	O
glutamate	B-Drug
(	O
15	O
mg/kg	O
e.w	O
.	O

)	O
in	O
a	O
10	O
min	O
interval	O
significantly	O
increased	O
the	O
activation	O
of	O
spontaneous	O
motility	O
of	O
17-day-old	O
chick	O
embryos	O
in	O
comparison	O
with	O
the	O
effect	O
of	O
glutamate	B-Drug
alone	O
.	O

This	O
effect	O
did	O
not	O
depend	O
on	O
the	O
order	O
of	O
application	O
of	O
the	O
drugs	B-Drug
.	O

In	O
13-day-old	O
embryos	O
,	O
glycine	B-Drug
was	O
ineffective	O
in	O
both	O
doses	O
.	O

It	O
is	O
concluded	O
from	O
these	O
results	O
that	O
the	O
modulatory	O
effect	O
of	O
glycine	B-Drug
is	O
evidently	O
a	O
later	O
developmental	O
acquisition	O
(	O
after	O
day	O
15	O
of	O
incubation	O
)	O
in	O
the	O
embryogenesis	O
of	O
NMDA-ergic	O
activation	O
of	O
spontaneous	O
motility	O
in	O
chick	O
embryos	O
similarly	O
as	O
glycinergic	O
inhibition	O
.	O

Evidence	O
for	O
reduction	O
of	O
norepinephrine	B-Drug
uptake	O
sites	O
in	O
the	O
failing	O
human	O
heart	O
.	O

OBJECTIVES	O
.	O

This	O
study	O
investigated	O
the	O
role	O
of	O
neuronal	O
uptake	O
of	O
norepinephrine	B-Drug
(	O
uptake-1	O
)	O
in	O
human	O
heart	O
failure	O
as	O
a	O
local	O
factor	O
for	O
altering	O
concentrations	O
of	O
norepinephrine	B-Drug
at	O
the	O
cardiac	O
myocyte	O
membranes	O
.	O

BACKGROUND	O
.	O

Several	O
beta-adrenergic	O
neuroeffector	O
defects	O
occur	O
in	O
heart	O
failure	O
.	O

Whether	O
an	O
alteration	O
in	O
norepinephrine	B-Drug
uptake-1	O
occurs	O
is	O
still	O
unresolved	O
.	O

METHODS	O
.	O

The	O
role	O
of	O
norepinephrine	B-Drug
uptake-1	O
was	O
studied	O
in	O
electrically	O
stimulated	O
(	O
1	O
Hz	O
,	O
37	O
degrees	O
C	O
)	O
human	O
ventricular	O
cardiac	O
preparations	O
and	O
isolated	O
myocardial	O
membranes	O
.	O

RESULTS	O
.	O

The	O
effectiveness	O
of	O
norepinephrine	B-Drug
in	O
increasing	O
the	O
force	O
of	O
contraction	O
was	O
decreased	O
in	O
relation	O
to	O
the	O
degree	O
of	O
heart	O
failure	O
.	O

In	O
contrast	O
,	O
the	O
potency	O
of	O
norepinephrine	B-Drug
was	O
increased	O
in	O
failing	O
hearts	O
(	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
IV	O
)	O
in	O
relation	O
to	O
the	O
concentrations	O
producing	O
50	O
%	O
of	O
the	O
maximal	O
effect	O
(	O
EC50	O
)	O
.	O

The	O
EC50	O
values	O
for	O
isoproterenol	B-Drug
,	O
which	O
is	O
not	O
a	O
substrate	O
for	O
norepinephrine	B-Drug
uptake-1	O
,	O
were	O
reduced	O
in	O
myocardium	O
in	O
functional	O
classes	O
II	O
to	O
III	O
and	O
IV	O
compared	O
with	O
those	O
in	O
nonfailing	O
myocardium	O
.	O

The	O
uptake	O
inhibitors	O
cocaine	B-Drug
and	O
desipramine	B-Drug
(	O
3	O
mumol/liter	O
)	O
potentiated	O
the	O
positive	O
inotropic	O
effects	O
of	O
norepinephrine	B-Drug
in	O
nonfailing	O
myocardium	O
(	O
p	O
<	O
0.05	O
)	O
but	O
not	O
in	O
functional	O
class	O
IV	O
myocardium	O
.	O

Radioligand	O
binding	O
experiments	O
using	O
the	O
uptake	O
inhibitor	O
hydrogen-3	O
mazindol	B-Drug
revealed	O
a	O
significant	O
decrease	O
by	O
approximately	O
30	O
%	O
in	O
norepinephrine	B-Drug
uptake-1	O
carrier	O
density	O
in	O
functional	O
classes	O
II	O
to	O
III	O
and	O
IV	O
myocardium	O
versus	O
nonfailing	O
myocardium	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
.	O

In	O
human	O
heart	O
failure	O
,	O
there	O
is	O
a	O
presynaptic	O
defect	O
in	O
the	O
sympathetic	O
nervous	O
system	O
,	O
leading	O
to	O
reduced	O
uptake-1	O
activity	O
.	O

This	O
defect	O
in	O
the	O
failing	O
heart	O
can	O
be	O
mimicked	O
by	O
the	O
effects	O
of	O
uptake	O
blocking	O
agents	O
,	O
such	O
as	O
cocaine	B-Drug
and	O
desipramine	B-Drug
,	O
in	O
the	O
nonfailing	O
heart	O
only	O
.	O

Compromised	O
norepinephrine	B-Drug
uptake-1	O
in	O
functional	O
class	O
IV	O
can	O
not	O
be	O
further	O
increased	O
by	O
cocaine	B-Drug
and	O
desipramine	B-Drug
.	O

The	O
pathophysiologic	O
consequences	O
could	O
be	O
an	O
increased	O
synaptic	O
concentration	O
of	O
norepinephrine	B-Drug
predisposing	O
to	O
adenylyl	O
cyclase	O
desensitization	O
.	O

[	O
A	O
pharmacological	O
analysis	O
of	O
the	O
effect	O
of	O
angiotensin	B-Drug
on	O
stimulated	O
gastric	O
secretion	O
]	O
Chronic	O
experiments	O
on	O
dogs	O
with	O
gastric	O
fistulas	O
were	O
carried	O
out	O
to	O
study	O
the	O
influence	O
of	O
angiotensin	B-Drug
1	I-Drug
and	O
angiotensin	B-Drug
2	I-Drug
on	O
pentagastrin-	B-Drug
and	O
histamine-induced	B-Drug
gastric	O
acid	O
secretion	O
.	O

It	O
was	O
established	O
that	O
both	O
angiotensins	B-Drug
inhibited	O
gastric	O
acid	O
secretion	O
stimulated	O
by	O
pentagastrin	B-Drug
but	O
not	O
by	O
histamine	B-Drug
.	O

Comparative	O
analysis	O
of	O
the	O
effects	O
of	O
stimulation	O
and	O
inhibition	O
of	O
cholino-	O
and	O
adrenoreceptors	O
on	O
this	O
inhibitory	O
action	O
of	O
angiotensins	B-Drug
suggested	O
the	O
mediation	O
of	O
angiotensin	B-Drug
influence	O
through	O
the	O
modulation	O
of	O
cholinergic	O
reactions	O
of	O
parietal	O
cells	O
in	O
the	O
stomach	O
.	O

Interaction	O
of	O
gentamycin	B-Drug
and	O
atracurium	B-Drug
in	O
anaesthetised	O
horses	O
.	O

Evoked	O
hind	O
limb	O
digital	O
extensor	O
tension	O
(	O
hoof	O
twitch	O
)	O
was	O
maintained	O
at	O
40	O
%	O
of	O
baseline	O
for	O
1	O
h	O
by	O
atracurium	B-Drug
infusion	O
in	O
7	O
horses	O
anaesthetised	O
with	O
halothane	B-Drug
.	O

After	O
1	O
h	O
,	O
atracurium	B-Drug
was	O
discontinued	O
and	O
hoof	O
twitch	O
allowed	O
to	O
recover	O
to	O
75	O
%	O
.	O

Atracurium	B-Drug
was	O
again	O
given	O
by	O
infusion	O
to	O
maintain	O
40	O
%	O
twitch	O
for	O
a	O
second	O
hour	O
,	O
then	O
2	O
mg	O
gentamycin/kg	B-Drug
bwt	O
were	O
given	O
i.v	O
.	O

Atracurium	B-Drug
infusion	O
was	O
continued	O
for	O
a	O
third	O
hour	O
,	O
and	O
then	O
hoof	O
twitch	O
was	O
again	O
allowed	O
to	O
recover	O
spontaneously	O
to	O
75	O
%	O
.	O

Gentamycin	B-Drug
reduced	O
twitch	O
strength	O
from	O
40	O
+/-	O
1	O
%	O
(	O
mean	O
+/-	O
sem	O
)	O
to	O
29	O
+/-	O
4	O
%	O
within	O
7.0	O
+/-	O
1.5	O
min	O
(	O
P	O
=	O
0.02	O
)	O
.	O

Twitch	O
gradually	O
returned	O
to	O
pre-gentamycin	B-Drug
strength	O
over	O
the	O
course	O
of	O
the	O
next	O
hour	O
.	O

Recovery	O
of	O
hoof	O
twitch	O
from	O
50	O
%	O
to	O
75	O
%	O
took	O
7.7	O
+/-	O
0.7	O
min	O
for	O
atracurium	B-Drug
alone	O
and	O
11.5	O
+/-	O
2.7	O
min	O
for	O
atracurium	B-Drug
plus	O
gentamycin	B-Drug
(	O
P	O
=	O
0.03	O
)	O
.	O

Recovery	O
from	O
50	O
%	O
twitch	O
to	O
75	O
%	O
fade	O
recovery	O
took	O
13.8	O
+/-	O
0.8	O
min	O
for	O
atracurium	B-Drug
alone	O
and	O
13.7	O
+/-	O
1.2	O
min	O
for	O
atracurium	B-Drug
plus	O
gentamycin	B-Drug
.	O

At	O
75	O
%	O
recovery	O
of	O
fade	O
,	O
hoof	O
twitch	O
was	O
87	O
+/-	O
3	O
%	O
for	O
atracurium	B-Drug
alone	O
and	O
82	O
+/-	O
4	O
%	O
for	O
atracurium	B-Drug
plus	O
gentamycin	B-Drug
.	O

Reversal	O
of	O
the	O
block	O
with	O
edrophonium	B-Drug
and	O
subsequent	O
recovery	O
of	O
the	O
horses	O
from	O
anaesthesia	O
were	O
uneventful	O
.	O

It	O
was	O
concluded	O
that	O
,	O
although	O
gentamycin	B-Drug
did	O
augment	O
the	O
neuromuscular	O
blockade	O
of	O
atracurium	B-Drug
,	O
the	O
effect	O
was	O
minimal	O
.	O

Anticoagulants	B-Drug
.	O

Treatment	O
plans	O
for	O
patients	O
taking	O
anticoagulants	B-Drug
can	O
become	O
complicated	O
.	O

Anticoagulants	B-Drug
predispose	O
a	O
patient	O
to	O
bleeding	O
problems	O
.	O

Many	O
drugs	B-Drug
used	O
in	O
dentistry	O
can	O
not	O
be	O
taken	O
concomitantly	O
with	O
these	O
medications	O
.	O

Administration	O
of	O
lithium	B-Drug
prophylaxis	O
.	O

Successful	O
prophylaxis	O
of	O
manic-depressive	O
disorder	O
requires	O
more	O
than	O
the	O
prescription	O
of	O
lithium	B-Drug
carbonate	I-Drug
.	O

The	O
administrative	O
arrangements	O
in	O
an	O
area	O
of	O
Scotland	O
were	O
accompanied	O
by	O
a	O
300	O
%	O
increase	O
in	O
the	O
frequency	O
of	O
admissions	O
for	O
mania	O
,	O
whereas	O
in	O
an	O
area	O
of	O
the	O
West	O
Midlands	O
,	O
a	O
large	O
decrease	O
was	O
achieved	O
.	O

[	O
Multiple	O
occupational	O
exposure	O
to	O
solvents	O
]	O
This	O
article	O
review	O
papers	O
published	O
over	O
the	O
last	O
20	O
years	O
on	O
multiple	O
occupational	O
exposure	O
to	O
solvents	O
.	O

At	O
low-levels	O
of	O
exposure	O
the	O
toxicokinetic	O
interferences	O
between	O
solvents	O
have	O
generally	O
not	O
been	O
observed	O
in	O
man	O
and	O
presumably	O
a	O
threshold	O
limit	O
exists	O
.	O

Conversely	O
,	O
at	O
exposure	O
levels	O
close	O
to	O
the	O
``	O
limit	O
values	O
''	O
metabolic	O
interference	O
has	O
sometimes	O
been	O
observed	O
and	O
the	O
behaviour	O
of	O
the	O
biological	O
indicators	O
differs	O
from	O
what	O
would	O
be	O
expected	O
.	O

Toxicodynamic	O
interference	O
between	O
solvents	O
can	O
give	O
rise	O
to	O
additive	O
,	O
potentiation	O
,	O
synergistic	O
,	O
antagonistic	O
effects	O
.	O

For	O
the	O
identification	O
of	O
``	O
limit	O
values	O
''	O
,	O
it	O
has	O
generally	O
been	O
suggested	O
in	O
the	O
literature	O
that	O
the	O
possible	O
effects	O
deriving	O
from	O
multiple	O
exposure	O
be	O
considered	O
as	O
additive	O
.	O

However	O
,	O
numerous	O
potentiation	O
effects	O
have	O
frequently	O
been	O
reported	O
for	O
combined	O
exposure	O
to	O
substances	O
of	O
widespread	O
use	O
.	O

In	O
this	O
paper	O
lists	O
of	O
multiple	O
exposure	O
in	O
which	O
the	O
doses	O
of	O
the	O
substances	O
,	O
the	O
types	O
of	O
interferences	O
and	O
the	O
behaviour	O
of	O
the	O
biological	O
levels	O
have	O
been	O
drawn	O
up	O
and	O
proposed	O
as	O
a	O
tool	O
for	O
easy	O
consultation	O
.	O

Determinants	O
of	O
cellular	O
sensitivity	O
to	O
topoisomerase-targeting	O
antitumor	O
drugs	B-Drug
.	O

It	O
is	O
now	O
clear	O
that	O
topoisomerase	O
activity	O
level	O
is	O
an	O
important	O
determinant	O
of	O
sensitivity	O
to	O
topo	O
drugs	B-Drug
.	O

The	O
regulation	O
of	O
topoisomerases	O
is	O
no	O
doubt	O
complex	O
and	O
multifaceted	O
and	O
is	O
probably	O
accomplished	O
through	O
redundancy	O
at	O
many	O
control	O
levels	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
altered	O
topo	O
I	O
expression	O
in	O
certain	O
tumor	O
types	O
is	O
unknown	O
,	O
but	O
may	O
be	O
related	O
to	O
the	O
central	O
importance	O
of	O
topoisomerases	O
in	O
proliferating	O
cell	O
functions	O
(	O
transcription	O
,	O
replication	O
,	O
etc	O
.	O

)	O
,	O
and	O
the	O
aberrant	O
and	O
chronic	O
activation	O
of	O
these	O
functions	O
as	O
a	O
result	O
of	O
specific	O
tumorigenic	O
alterations	O
.	O

Small	O
differences	O
in	O
sensitivity	O
to	O
chemotherapy	O
can	O
have	O
a	O
dramatic	O
effect	O
on	O
cure	O
rates	O
,	O
and	O
therefore	O
subtle	O
cell	O
type-specific	O
differences	O
may	O
be	O
important	O
determinants	O
of	O
drug	B-Drug
sensitivity	O
.	O

Whether	O
abnormal	O
topoisomerase	O
quantity	O
and	O
specific	O
activity	O
are	O
associated	O
with	O
resistance	O
or	O
sensitivity	O
to	O
topoisomerase-targeted	O
chemotherapy	O
in	O
the	O
clinic	O
is	O
now	O
being	O
studied	O
.	O

Determinants	O
downstream	O
of	O
cleavable	O
complex	O
formation	O
that	O
affect	O
the	O
sensitivity	O
of	O
tumor	O
versus	O
normal	O
cells	O
to	O
topo	O
drugs	B-Drug
in	O
particular	O
and	O
DNA-damaging	O
agents	O
in	O
general	O
are	O
little	O
known	O
.	O

The	O
goal	O
of	O
enhancing	O
selective	O
tumor	O
cell	O
killing	O
relative	O
to	O
the	O
normal	O
cells	O
that	O
are	O
dose	O
limiting	O
may	O
be	O
achieved	O
either	O
by	O
overcoming	O
tumor	O
cell	O
resistance	O
or	O
by	O
protecting	O
normal	O
cells	O
.	O

Both	O
of	O
these	O
strategies	O
will	O
become	O
more	O
feasible	O
as	O
specific	O
molecular	O
differences	O
between	O
tumor	O
and	O
normal	O
cells	O
are	O
being	O
rapidly	O
identified	O
and	O
new	O
combination	O
therapies	O
that	O
take	O
advantage	O
of	O
these	O
differences	O
are	O
being	O
designed	O
and	O
tested	O
.	O

Acid-catalyzed	O
ethanolysis	O
of	O
temazepam	B-Drug
in	O
anhydrous	O
and	O
aqueous	O
ethanol	B-Drug
solutions	O
.	O

The	O
benzodiazepines	B-Drug
are	O
a	O
family	O
of	O
anxiolytic	O
and	O
hypnotic	O
drugs	B-Drug
.	O

When	O
taken	O
concurrently	O
with	O
ethanol	B-Drug
,	O
a	O
pharmacological	O
interaction	O
may	O
occur	O
,	O
potentiating	O
the	O
central	O
nervous	O
system	O
depression	O
produced	O
by	O
either	O
drug	B-Drug
.	O

In	O
addition	O
to	O
this	O
pharmacological	O
interaction	O
,	O
this	O
report	O
describes	O
a	O
novel	O
chemical	O
reaction	O
between	O
temazepam	B-Drug
(	O
a	O
benzodiazepine	O
)	O
and	O
ethanol	B-Drug
under	O
acidic	O
conditions	O
similar	O
to	O
those	O
found	O
in	O
vivo	O
,	O
resulting	O
in	O
a	O
3-ethoxylated	O
product	O
.	O

Optimal	O
conditions	O
,	O
kinetics	O
,	O
equilibrium	O
,	O
and	O
the	O
mechanism	O
of	O
this	O
acid-catalyzed	O
ethanolysis	O
are	O
reported	O
.	O

The	O
results	O
raise	O
the	O
possibility	O
that	O
the	O
ethanolysis	O
reaction	O
may	O
occur	O
in	O
the	O
stomach	O
of	O
people	O
who	O
consume	O
alcohol	B-Drug
and	O
3-hydroxy-1,4-benzodiazepine	O
on	O
a	O
regular	O
basis	O
.	O

The	O
acid-catalyzed	O
ethanol-drug	B-Drug
reaction	O
is	O
a	O
relatively	O
unexplored	O
area	O
and	O
may	O
alter	O
the	O
pharmacological	O
action	O
of	O
some	O
drugs	B-Drug
.	O

No	O
drug	B-Drug
,	O
nutritional	O
supplement	O
,	O
food	O
or	O
herb	O
interactions	O
have	O
yet	O
been	O
reported	O
.	O

No	O
formal	O
drug/drug	O
interaction	O
studies	O
with	O
Plenaxis	B-Drug
were	O
performed	O
.	O

Cytochrome	O
P-450	O
is	O
not	O
known	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
Plenaxis	B-Drug
.	O

Plenaxis	B-Drug
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
96	O
to	O
99	O
%	O
)	O
.	O

Laboratory	O
Tests	O
Response	O
to	O
Plenaxis	B-Drug
should	O
be	O
monitored	O
by	O
measuring	O
serum	O
total	O
testosterone	B-Drug
concentrations	O
just	O
prior	O
to	O
administration	O
on	O
Day	O
29	O
and	O
every	O
8	O
weeks	O
thereafter	O
.	O

Serum	O
transaminase	O
levels	O
should	O
be	O
obtained	O
before	O
starting	O
treatment	O
with	O
Plenaxis	B-Drug
and	O
periodically	O
during	O
treatment	O
.	O

Periodic	O
measurement	O
of	O
serum	O
PSA	O
levels	O
may	O
also	O
be	O
considered	O
.	O

Formal	O
drug	B-Drug
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ORENCIA	B-Drug
.	O

Population	O
pharmacokinetic	O
analyses	O
revealed	O
that	O
MTX	B-Drug
,	O
NSAIDs	O
,	O
corticosteroids	O
,	O
and	O
TNF	O
blocking	O
agents	O
did	O
not	O
influence	O
abatacept	B-Drug
clearance	O
.	O

The	O
majority	O
of	O
patients	O
in	O
RA	O
clinical	O
studies	O
received	O
one	O
or	O
more	O
of	O
the	O
following	O
concomitant	O
medications	O
with	O
ORENCIA	B-Drug
:	O
MTX	B-Drug
,	O
NSAIDs	O
,	O
corticosteroids	O
,	O
TNF	O
blocking	O
agents	O
,	O
azathioprine	B-Drug
,	O
chloroquine	B-Drug
,	O
gold	B-Drug
,	O
hydroxychloroquine	B-Drug
,	O
leflunomide	B-Drug
,	O
sulfasalazine	B-Drug
,	O
and	O
anakinra	B-Drug
.	O

Concurrent	O
administration	O
of	O
a	O
TNF	O
antagonist	O
with	O
ORENCIA	B-Drug
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
and	O
no	O
significant	O
additional	O
efficacy	O
over	O
use	O
of	O
the	O
TNF	O
antagonists	O
alone	O
.	O

Concurrent	O
therapy	O
with	O
ORENCIA	B-Drug
and	O
TNF	O
antagonists	O
is	O
not	O
recommended	O
.	O

There	O
is	O
insufficient	O
experience	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ORENCIA	B-Drug
administered	O
concurrently	O
with	O
anakinra	B-Drug
,	O
and	O
therefore	O
such	O
use	O
is	O
not	O
recommended	O
.	O

Formal	O
drug	B-Drug
interaction	O
studies	O
with	O
Abciximab	B-Drug
have	O
not	O
been	O
conducted	O
.	O

Abciximab	B-Drug
has	O
been	O
administered	O
to	O
patients	O
with	O
ischemic	O
heart	O
disease	O
treated	O
concomitantly	O
with	O
a	O
broad	O
range	O
of	O
medications	O
used	O
in	O
the	O
treatment	O
of	O
angina	O
myocardial	O
infarction	O
and	O
hypertension	O
.	O

These	O
medications	O
have	O
included	O
heparin	B-Drug
,	O
warfarin	B-Drug
,	O
beta-adrenergic	O
receptor	O
blockers	O
,	O
calcium	B-Drug
channel	O
antagonists	O
,	O
angiotensin	B-Drug
converting	O
enzyme	O
inhibitors	O
,	O
intravenous	O
and	O
oral	O
nitrates	B-Drug
,	O
ticlopidine	B-Drug
,	O
and	O
aspirin	B-Drug
.	O

Heparin	B-Drug
,	O
other	O
anticoagulants	B-Drug
,	O
thrombolytics	O
,	O
and	O
anti	O
platelet	O
agents	O
are	O
associated	O
with	O
an	O
increase	O
in	O
bleeding	O
.	O

Patients	O
with	O
HACA	O
titers	O
may	O
have	O
allergic	O
or	O
hypersensitivity	O
reactions	O
when	O
treated	O
with	O
other	O
diagnostic	O
or	O
therapeutic	O
monoclonal	O
antibodies	O
.	O

The	O
concomitant	O
intake	O
of	O
alcohol	B-Drug
and	O
Acamprosate	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
alcohol	B-Drug
or	O
acamprosate	B-Drug
.	O

Pharmacokinetic	O
studies	O
indicate	O
that	O
administration	O
of	O
disulfiram	B-Drug
or	O
diazepam	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
acamprosate	B-Drug
.	O

Co-administration	O
of	O
naltrexone	B-Drug
with	O
Acamprosate	B-Drug
produced	O
a	O
25	O
%	O
increase	O
in	O
AUC	O
and	O
a	O
33	O
%	O
increase	O
in	O
the	O
Cmax	O
of	O
acamprosate	B-Drug
.	O

No	O
adjustment	O
of	O
dosage	O
is	O
recommended	O
in	O
such	O
patients	O
.	O

The	O
pharmacokinetics	O
of	O
naltrexone	B-Drug
and	O
its	O
major	O
metabolite	O
6-beta-naltrexol	B-Drug
were	O
unaffected	O
following	O
co-administration	O
with	O
Acamprosate	B-Drug
.	O

Other	O
concomitant	O
therapies	O
:	O
In	O
clinical	O
trials	O
,	O
the	O
safety	O
profile	O
in	O
subjects	O
treated	O
with	O
Acamprosate	B-Drug
concomitantly	O
with	O
anxiolytics	O
,	O
hypnotics	O
and	O
sedatives	O
(	O
including	O
benzodiazepines	B-Drug
)	O
,	O
or	O
non-opioid	O
analgesics	O
was	O
similar	O
to	O
that	O
of	O
subjects	O
taking	O
placebo	O
with	O
these	O
concomitant	O
medications	O
.	O

Patients	O
taking	O
Acamprosate	B-Drug
concomitantly	O
with	O
antidepressants	B-Drug
more	O
commonly	O
reported	O
both	O
weight	O
gain	O
and	O
weight	O
loss	O
,	O
compared	O
with	O
patients	O
taking	O
either	O
medication	O
alone	O
.	O

Certain	O
drugs	B-Drug
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	B-Drug
to	O
loss	O
of	O
blood	O
glucose	B-Drug
control	O
.	O

These	O
drugs	B-Drug
include	O
the	O
thiazides	O
and	O
other	O
diuretics	B-Drug
,	O
corticosteroids	O
,	O
phenothiazines	O
,	O
thyroid	B-Drug
products	O
,	O
estrogens	O
,	O
oral	O
contraceptives	O
,	O
phenytoin	B-Drug
,	O
nicotinic	B-Drug
acid	I-Drug
,	O
sympathomimetics	O
,	O
calcium	B-Drug
channel-blocking	O
drugs	B-Drug
,	O
and	O
isoniazid	B-Drug
.	O

When	O
such	O
drugs	B-Drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
Acarbose	B-Drug
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
blood	O
glucose	B-Drug
control	O
.	O

When	O
such	O
drugs	B-Drug
are	O
withdrawn	O
from	O
patients	O
receiving	O
Acarbose	B-Drug
in	O
combination	O
with	O
sulfonylureas	O
or	O
insulin	B-Drug
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
any	O
evidence	O
of	O
hypoglycemia	O
.	O

Intestinal	O
adsorbents	O
(	O
e.	O
g.	O
,	O
charcoal	B-Drug
)	O
and	O
digestive	O
enzyme	O
preparations	O
containing	O
carbohydrate-splitting	O
enzymes	O
(	O
e.	O
g.	O
,	O
amylase	B-Drug
,	O
pancreatin	B-Drug
)	O
may	O
reduce	O
the	O
effect	O
of	O
Acarbose	B-Drug
and	O
should	O
not	O
be	O
taken	O
concomitantly	O
.	O

Acarbose	B-Drug
has	O
been	O
shown	O
to	O
change	O
the	O
bioavailabillty	O
digoxin	B-Drug
when	O
they	O
are	O
co-administered	O
,	O
which	O
may	O
require	O
digoxin	B-Drug
dose	O
adjustment	O
.	O

Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
Acarbose	B-Drug
has	O
no	O
effect	O
on	O
either	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
digoxin	B-Drug
,	O
nifedipine	B-Drug
,	O
propranolol	B-Drug
,	O
or	O
ranitidine	B-Drug
.	O

Acarbose	B-Drug
did	O
not	O
interfere	O
with	O
the	O
absorption	O
or	O
disposition	O
of	O
the	O
sulfonylurea	B-Drug
glyburide	B-Drug
in	O
diabetic	O
patients	O
.	O

Acarbose	B-Drug
may	O
affect	O
digoxin	B-Drug
bioavailabillty	O
and	O
may	O
require	O
dose	O
adjustment	O
of	O
digoxin	B-Drug
by	O
16	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
8-23	O
%	O
)	O
,	O
decrease	O
mean	O
C	O
max	O
digoxin	B-Drug
by	O
26	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
16-34	O
%	O
)	O
and	O
decrease	O
mean	O
trough	O
concentrations	O
of	O
digoxin	B-Drug
by	O
9	O
%	O
(	O
90	O
%	O
confidence	O
limit	O
:	O
19	O
%	O
decrease	O
to	O
2	O
%	O
increase	O
)	O
.	O

The	O
amount	O
of	O
metformin	B-Drug
absorbed	O
while	O
taking	O
Acarbose	B-Drug
was	O
bioequivalent	O
to	O
the	O
amount	O
absorbed	O
when	O
taking	O
placebo	O
,	O
as	O
indicated	O
by	O
the	O
plasma	O
AUC	O
values	O
.	O

However	O
,	O
the	O
peak	O
plasma	O
level	O
of	O
metformin	B-Drug
was	O
reduced	O
by	O
approximately	O
20	O
%	O
when	O
taking	O
Acarbose	B-Drug
due	O
to	O
a	O
slight	O
delay	O
in	O
the	O
absorption	O
of	O
metformin	B-Drug
.	O

There	O
is	O
little	O
if	O
any	O
clinically	O
significant	O
interaction	O
between	O
Acarbose	B-Drug
and	O
metformin	B-Drug
.	O

Catecholamine-depleting	O
drugs	B-Drug
,	O
such	O
as	O
reserpine	B-Drug
,	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta-blocking	B-Drug
agents	O
.	O

Patients	O
treated	O
with	O
acebutolol	B-Drug
plus	O
catecholamine	O
depletors	O
should	O
,	O
therefore	O
,	O
be	O
observed	O
closely	O
for	O
evidence	O
of	O
marked	O
bradycardia	O
or	O
hypotension	O
which	O
may	O
present	O
as	O
vertigo	O
,	O
syncope/presyncope	O
,	O
or	O
orthostatic	O
changes	O
in	O
blood	O
pressure	O
without	O
compensatory	O
tachycardia	O
.	O

Exaggerated	O
hypertensive	O
responses	O
have	O
been	O
reported	O
from	O
the	O
combined	O
use	O
of	O
beta-adrenergic	O
antagonists	O
and	O
alpha-adrenergic	O
stimulants	O
,	O
including	O
those	O
contained	O
in	O
proprietary	O
cold	O
remedies	O
and	O
vasoconstrictive	O
nasal	O
drops	O
.	O

Patients	O
receiving	O
beta-blockers	O
should	O
be	O
warned	O
of	O
this	O
potential	O
hazard	O
.	O

Blunting	O
of	O
the	O
antihypertensive	B-Drug
effect	O
of	O
beta-adrenoceptor	O
blocking	O
agents	O
by	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
has	O
been	O
reported	O
.	O

No	O
significant	O
interactions	O
with	O
digoxin	B-Drug
,	O
hydrochlorothiazide	B-Drug
,	O
hydralazine	B-Drug
,	O
sulfinpyrazone	B-Drug
,	O
oral	O
contraceptives	O
,	O
tolbutamide	B-Drug
,	O
or	O
warfarin	B-Drug
have	O
been	O
observed	O
.	O

DIAMOX	B-Drug
modifies	O
phenytoin	B-Drug
metabolism	O
with	O
increased	O
serum	O
levels	O
of	O
phenytoin	B-Drug
.	O

This	O
may	O
increase	O
or	O
enhance	O
the	O
occurrence	O
of	O
osteomalacia	O
in	O
some	O
patients	O
receiving	O
chronic	O
phenytoin	B-Drug
therapy	O
.	O

Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
chronic	O
concomitant	O
therapy	O
.	O

By	O
decreasing	O
the	O
gastrointestinal	O
absorption	O
of	O
primidone	B-Drug
,	O
DIAMOX	B-Drug
may	O
decrease	O
serum	O
concentrations	O
of	O
primidone	B-Drug
and	O
its	O
metabolites	O
,	O
with	O
a	O
consequent	O
possible	O
decrease	O
in	O
anticonvulsant	O
effect	O
.	O

Caution	O
is	O
advised	O
when	O
beginning	O
,	O
discontinuing	O
,	O
or	O
changing	O
the	O
dose	O
of	O
DIAMOX	B-Drug
in	O
patients	O
receiving	O
primidone	B-Drug
.	O

Because	O
of	O
possible	O
additive	O
effects	O
with	O
other	O
carbonic	O
anhydrase	O
inhibitors	O
,	O
concomitant	O
use	O
is	O
not	O
advisable	O
.	O

Acetazolamide	B-Drug
may	O
increase	O
the	O
effects	O
of	O
other	O
folic	O
acid	O
antagonists	O
.	O

Acetazolamide	B-Drug
may	O
increase	O
or	O
decrease	O
blood	O
glucose	B-Drug
levels	O
.	O

Consideration	O
should	O
be	O
taken	O
in	O
patients	O
being	O
treated	O
with	O
antidiabetic	B-Drug
agents	O
.	O

Acetazolamide	B-Drug
decreases	O
urinary	O
excretion	O
of	O
amphetamine	B-Drug
and	O
may	O
enhance	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
effect	O
.	O

Acetazolamide	B-Drug
reduces	O
urinary	O
excretion	O
of	O
quinidine	B-Drug
and	O
may	O
enhance	O
its	O
effect	O
.	O

Acetazolamide	B-Drug
may	O
prevent	O
the	O
urinary	O
antiseptic	O
effect	O
of	O
methenamine	B-Drug
.	O

Acetazolamide	B-Drug
increases	O
lithium	B-Drug
excretion	O
and	O
the	O
lithium	B-Drug
may	O
be	O
decreased	O
.	O

Acetazolamide	B-Drug
and	O
sodium	B-Drug
bicarbonate	I-Drug
used	O
concurrently	O
increases	O
the	O
risk	O
of	O
renal	O
calculus	O
formation	O
.	O

Acetazolamide	B-Drug
may	O
elevate	O
cyclosporine	B-Drug
levels	O
.	O

Concomitant	O
use	O
with	O
iron	B-Drug
supplements	O
may	O
result	O
in	O
the	O
reduced	O
absorption	O
of	O
iron	B-Drug
.	O

Co-administration	O
of	O
probenecid	B-Drug
with	O
acyclovir	B-Drug
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
half-life	O
and	O
the	O
area	O
under	O
the	O
concentration-time	O
curve	O
.	O

Urinary	O
excretion	O
and	O
renal	O
clearance	O
were	O
correspondingly	O
reduced	O
.	O

The	O
clinical	O
effects	O
of	O
this	O
combination	O
have	O
not	O
been	O
studied	O
.	O

Ethanol	B-Drug
:	O
Clinical	O
evidence	O
has	O
shown	O
that	O
etretinate	B-Drug
can	O
be	O
formed	O
with	O
concurrent	O
ingestion	O
of	O
acitretin	B-Drug
and	O
ethanol	B-Drug
.	O

Glibenclamide	B-Drug
:	O
In	O
a	O
study	O
of	O
7	O
healthy	O
male	O
volunteers	O
,	O
acitretin	B-Drug
treatment	O
potentiated	O
the	O
blood	O
glucose	B-Drug
lowering	O
effect	O
of	O
glibenclamide	B-Drug
(	O
a	O
sulfonylurea	B-Drug
similar	O
to	O
chlorpropamide	B-Drug
)	O
in	O
3	O
of	O
the	O
7	O
subjects	O
.	O

Repeating	O
the	O
study	O
with	O
6	O
healthy	O
male	O
volunteers	O
in	O
the	O
absence	O
of	O
glibenclamide	B-Drug
did	O
not	O
detect	O
an	O
effect	O
of	O
acitretin	B-Drug
on	O
glucose	B-Drug
tolerance	O
.	O

Careful	O
supervision	O
of	O
diabetic	O
patients	O
under	O
treatment	O
with	O
Soriatane	B-Drug
is	O
recommended	O
.	O

Hormonal	O
Contraceptives	O
:	O
It	O
has	O
not	O
been	O
established	O
if	O
there	O
is	O
a	O
pharmacokinetic	O
interaction	O
between	O
acitretin	B-Drug
and	O
combined	O
oral	O
contraceptives	O
.	O

However	O
,	O
it	O
has	O
been	O
established	O
that	O
acitretin	B-Drug
interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin	B-Drug
minipill	O
preparations	O
.	O

Microdosed	O
minipill	O
progestin	B-Drug
preparations	O
are	O
not	O
recommended	O
for	O
use	O
with	O
Soriatane	B-Drug
.	O

It	O
is	O
not	O
known	O
whether	O
other	O
progestational	O
contraceptives	O
,	O
such	O
as	O
implants	O
and	O
injectables	O
,	O
are	O
adequate	O
methods	O
of	O
contraception	O
during	O
acitretin	B-Drug
therapy	O
.	O

Methotrexate	B-Drug
:	O
An	O
increased	O
risk	O
of	O
hepatitis	O
has	O
been	O
reported	O
to	O
result	O
from	O
combined	O
use	O
of	O
methotrexate	B-Drug
and	O
etretinate	B-Drug
.	O

Consequently	O
,	O
the	O
combination	O
of	O
methotrexate	B-Drug
with	O
acitretin	B-Drug
is	O
also	O
contraindicated	O
.	O

Phenytoin	B-Drug
:	O
If	O
acitretin	B-Drug
is	O
given	O
concurrently	O
with	O
phenytoin	B-Drug
,	O
the	O
protein	O
binding	O
of	O
phenytoin	B-Drug
may	O
be	O
reduced	O
.	O

Tetracyclines	O
:	O
Since	O
both	O
acitretin	B-Drug
and	O
tetracyclines	O
can	O
cause	O
increased	O
intracranial	O
pressure	O
,	O
their	O
combined	O
use	O
is	O
contraindicated	O
.	O

Vitamin	O
A	O
and	O
oral	O
retinoids	O
:	O
Concomitant	O
administration	O
of	O
vitamin	O
A	O
and/or	O
other	O
oral	O
retinoids	O
with	O
acitretin	B-Drug
must	O
be	O
avoided	O
because	O
of	O
the	O
risk	O
of	O
hypervitaminosis	O
A	O
.	O

Other	O
:	O
There	O
appears	O
to	O
be	O
no	O
pharmacokinetic	O
interaction	O
between	O
acitretin	B-Drug
and	O
cimetidine	B-Drug
,	O
digoxin	B-Drug
,	O
or	O
glyburide	B-Drug
.	O

Investigations	O
into	O
the	O
effect	O
of	O
acitretin	B-Drug
on	O
the	O
protein	O
binding	O
of	O
anticoagulants	B-Drug
of	O
the	O
coumarin	O
type	O
(	O
warfarin	B-Drug
)	O
revealed	O
no	O
interaction	O
.	O

Laboratory	O
Tests	O
If	O
significant	O
abnormal	O
laboratory	O
results	O
are	O
obtained	O
,	O
either	O
dosage	O
reduction	O
with	O
careful	O
monitoring	O
or	O
treatment	O
discontinuation	O
is	O
recommended	O
,	O
depending	O
on	O
clinical	O
judgement	O
.	O

Blood	O
Sugar	O
:	O
Some	O
patients	O
receiving	O
retinoids	O
have	O
experienced	O
problems	O
with	O
blood	O
sugar	O
control	O
.	O

In	O
addition	O
,	O
new	O
cases	O
of	O
diabetes	O
have	O
been	O
diagnosed	O
during	O
retinoid	O
therapy	O
,	O
including	O
diabetic	O
ketoacidosis	O
.	O

In	O
diabetics	O
,	O
blood-sugar	O
levels	O
should	O
be	O
monitored	O
very	O
carefully	O
.	O

Lipids	O
:	O
In	O
clinical	O
studies	O
,	O
the	O
incidence	O
of	O
hypertriglyceridemia	O
was	O
66	O
%	O
,	O
hypercholesterolemia	O
was	O
33	O
%	O
and	O
that	O
of	O
decreased	O
HDL	O
was	O
40	O
%	O
.	O

Pretreatment	O
and	O
follow-up	O
measurements	O
should	O
be	O
obtained	O
under	O
fasting	O
conditions	O
.	O

It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
weekly	O
or	O
every	O
other	O
week	O
until	O
the	O
lipid	O
response	O
to	O
Soriatane	B-Drug
has	O
stabilized	O
.	O

Liver	O
Function	O
Tests	O
:	O
Elevations	O
of	O
AST	O
(	O
SGOT	O
)	O
,	O
ALT	O
(	O
SGPT	O
)	O
or	O
LDH	O
were	O
experienced	O
by	O
approximately	O
1	O
in	O
3	O
patients	O
treated	O
with	O
Soriatane	B-Drug
.	O

It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
prior	O
to	O
initiation	O
of	O
Soriatane	B-Drug
therapy	O
,	O
at	O
1-	O
to	O
2-week	O
intervals	O
until	O
stable	O
and	O
thereafter	O
at	O
intervals	O
as	O
clinically	O
indicated	O
.	O

Methotrexate	B-Drug
:	O
HUMIRA	B-Drug
has	O
been	O
studied	O
in	O
rheumatoid	O
arthritis	O
patients	O
taking	O
concomitant	O
MTX	B-Drug
.	O

The	O
data	O
do	O
not	O
suggest	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
either	O
HUMIRA	B-Drug
or	O
MTX	B-Drug
.	O

Anakinra	B-Drug
:	O
Concurrent	O
administration	O
of	O
anakinra	B-Drug
(	O
an	O
interleukin-1	O
antagonist	O
)	O
and	O
another	O
TNF-blocking	O
agent	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
,	O
an	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
anakinra	B-Drug
used	O
in	O
combination	O
with	O
HUMIRA	B-Drug
has	O
not	O
been	O
studied	O
.	O

Therefore	O
the	O
,	O
combination	O
of	O
anakinra	B-Drug
with	O
other	O
TNF-blocking	O
agents	O
,	O
including	O
HUMIRA	B-Drug
,	O
may	O
also	O
result	O
i	O
n	O
similar	O
toxicities	O
.	O

As	O
DIFFERIN	B-Drug
Gel	O
has	O
the	O
potential	O
to	O
produce	O
local	O
irritation	O
in	O
some	O
patients	O
,	O
concomitant	O
use	O
of	O
other	O
potentially	O
irritating	O
topical	O
products	O
(	O
medicated	O
or	O
abrasive	O
soaps	O
and	O
cleansers	O
,	O
soaps	O
and	O
cosmetics	O
that	O
have	O
a	O
strong	O
drying	O
effect	O
,	O
and	O
products	O
with	O
high	O
concentrations	O
of	O
alcohol	B-Drug
,	O
astringents	O
,	O
spices	O
or	O
lime	O
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Particular	O
caution	O
should	O
be	O
exercised	O
in	O
using	O
preparations	O
containing	O
sulfur	B-Drug
,	O
resorcinol	B-Drug
,	O
or	O
salicylic	B-Drug
acid	I-Drug
in	O
combination	O
with	O
DIFFERIN	B-Drug
Gel	O
.	O

If	O
these	O
preparations	O
have	O
been	O
used	O
it	O
is	O
advisable	O
not	O
to	O
start	O
therapy	O
with	O
DIFFERIN	B-Drug
Gel	O
until	O
the	O
effects	O
of	O
such	O
preparations	O
in	O
the	O
skin	O
have	O
subsided	O
.	O

Before	O
using	O
this	O
medication	O
,	O
tell	O
your	O
doctor	O
or	O
pharmacist	O
of	O
all	O
prescription	O
and	O
nonprescription	O
products	O
you	O
may	O
use	O
,	O
especially	O
of	O
:	O
aminoglycosides	O
(	O
e.g.	O
,	O
gentamicin	B-Drug
,	O
amikacin	B-Drug
)	O
,	O
amphotericin	B-Drug
B	I-Drug
,	O
cyclosporine	B-Drug
,	O
non-steroidal	O
anti-inflammatory	O
drugs	B-Drug
(	O
e.g.	O
,	O
ibuprofen	B-Drug
)	O
,	O
tacrolimus	B-Drug
,	O
vancomycin	B-Drug
.	O

Do	O
not	O
start	O
or	O
stop	O
any	O
medicine	O
without	O
doctor	O
or	O
pharmacist	O
approval	O
.	O

Intravenous	O
Adenocard	B-Drug
(	O
adenosine	B-Drug
)	O
has	O
been	O
effectively	O
administered	O
in	O
the	O
presence	O
of	O
other	O
cardioactive	O
drugs	B-Drug
,	O
such	O
as	O
quinidine	B-Drug
,	O
beta-adrenergic	O
blocking	O
agents	O
,	O
calcium	B-Drug
channel	O
blocking	O
agents	O
,	O
and	O
angiotensin	B-Drug
converting	O
enzyme	O
inhibitors	O
,	O
without	O
any	O
change	O
in	O
the	O
adverse	O
reaction	O
profile	O
.	O

Digoxin	B-Drug
and	O
verapamil	B-Drug
use	O
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
when	O
combined	O
with	O
Adenocard	B-Drug
.	O

Because	O
of	O
the	O
potential	O
for	O
additive	O
or	O
synergistic	O
depressant	O
effects	O
on	O
the	O
SA	O
and	O
AV	O
nodes	O
,	O
however	O
,	O
Adenocard	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
presence	O
of	O
these	O
agents	O
.	O

The	O
use	O
of	O
Adenocard	B-Drug
in	O
patients	O
receiving	O
digitalis	B-Drug
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
.	O

The	O
effects	O
of	O
adenosine	B-Drug
are	O
antagonized	O
by	O
methylxanthines	O
such	O
as	O
caffeine	B-Drug
and	O
theophylline	B-Drug
.	O

In	O
the	O
presence	O
of	O
these	O
methylxanthines	O
,	O
larger	O
doses	O
of	O
adenosine	B-Drug
may	O
be	O
required	O
or	O
adenosine	B-Drug
may	O
not	O
be	O
effective	O
.	O

Adenosine	B-Drug
effects	O
are	O
potentiated	O
by	O
dipyridamole	B-Drug
.	O

Thus	O
,	O
smaller	O
doses	O
of	O
adenosine	B-Drug
may	O
be	O
effective	O
in	O
the	O
presence	O
of	O
dipyridamole	B-Drug
.	O

Carbamazepine	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
degree	O
of	O
heart	O
block	O
produced	O
by	O
other	O
agents	O
.	O

As	O
the	O
primary	O
effect	O
of	O
adenosine	B-Drug
is	O
to	O
decrease	O
conduction	O
through	O
the	O
A-V	O
node	O
,	O
higher	O
degrees	O
of	O
heart	O
block	O
may	O
be	O
produced	O
in	O
the	O
presence	O
of	O
carbamazepine	B-Drug
.	O

Co-administration	O
with	O
antifungal	O
agents	O
such	O
as	O
ketoconazole	B-Drug
or	O
itraconazole	B-Drug
is	O
not	O
recommended	O
.	O

Nafazodone	B-Drug
,	O
fluvoxamine	B-Drug
,	O
cimetidine	B-Drug
(	O
consider	O
Xanax	B-Drug
dose	O
reduction	O
)	O
.	O

Fluoxetine	B-Drug
,	O
OCs	O
,	O
sertraline	B-Drug
,	O
diltiazem	B-Drug
,	O
macrolide	O
antibiotics	B-Drug
(	O
exercise	O
caution	O
)	O
.	O

No	O
drug	B-Drug
interaction	O
studies	O
were	O
performed	O
.	O

No	O
in	O
vitro	O
metabolism	O
studies	O
were	O
performed	O
.	O

Dexamethasone	B-Drug
:	O
Steady-state	O
trough	O
concentrations	O
of	O
albendazole	B-Drug
sulfoxide	I-Drug
were	O
about	O
56	O
%	O
higher	O
when	O
8	O
mg	O
dexamethasone	B-Drug
was	O
coadministered	O
with	O
each	O
dose	O
of	O
albendazole	B-Drug
(	O
15	O
mg/kg/day	O
)	O
in	O
eight	O
neurocysticercosis	O
patients	O
.	O

Praziquantel	B-Drug
:	O
In	O
the	O
fed	O
state	O
,	O
praziquantel	B-Drug
(	O
40	O
mg/kg	O
)	O
increased	O
mean	O
maximum	O
plasma	O
concentration	O
and	O
area	O
under	O
the	O
curve	O
of	O
albendazole	B-Drug
sulfoxide	I-Drug
by	O
about	O
50	O
%	O
in	O
healthy	O
subjects	O
(	O
n=10	O
)	O
compared	O
with	O
a	O
separate	O
group	O
of	O
subjects	O
(	O
n=6	O
)	O
given	O
albendazole	B-Drug
alone	O
.	O

Mean	O
T	O
max	O
and	O
mean	O
plasma	O
elimination	O
half-life	O
of	O
albendazole	B-Drug
sulfoxide	I-Drug
were	O
unchanged	O
.	O

The	O
pharmacokinetics	O
of	O
praziquantel	B-Drug
were	O
unchanged	O
following	O
coadministration	O
with	O
albendazole	B-Drug
(	O
400	O
mg	O
)	O
.	O

Cimetidine	B-Drug
:	O
Albendazole	B-Drug
sulfoxide	I-Drug
concentrations	O
in	O
bile	O
and	O
cystic	O
fluid	O
were	O
increased	O
(	O
about	O
2-fold	O
)	O
in	O
hydatid	O
cyst	O
patients	O
treated	O
with	O
cimetidine	B-Drug
(	O
10	O
mg/kg/day	O
)	O
(	O
n=7	O
)	O
compared	O
with	O
albendazole	B-Drug
(	O
20	O
mg/kg/day	O
)	O
alone	O
(	O
n=12	O
)	O
.	O

Albendazole	B-Drug
sulfoxide	I-Drug
plasma	O
concentrations	O
were	O
unchanged	O
4	O
hours	O
after	O
dosing	O
.	O

Theophylline	B-Drug
:	O
The	O
pharmacokinetics	O
of	O
theophylline	B-Drug
(	O
aminophylline	B-Drug
5.8	O
mg/kg	O
infused	O
over	O
20	O
minutes	O
)	O
were	O
unchanged	O
following	O
a	O
single	O
oral	O
dose	O
of	O
albendazole	B-Drug
(	O
400	O
mg	O
)	O
in	O
6	O
healthy	O
subjects	O
.	O

No	O
information	O
provided	O
PROLEUKIN	B-Drug
may	O
affect	O
central	O
nervous	O
function	O
.	O

Therefore	O
,	O
interactions	O
could	O
occur	O
following	O
concomitant	O
administration	O
of	O
psychotropic	O
drugs	B-Drug
(	O
e.g.	O
,	O
narcotics	O
,	O
analgesics	O
,	O
antiemetics	O
,	O
sedatives	O
,	O
tranquilizers	O
)	O
.	O

Concurrent	O
administration	O
of	O
drugs	B-Drug
possessing	O
nephrotoxic	O
(	O
e.g.	O
,	O
aminoglycosides	O
,	O
indomethacin	B-Drug
)	O
,	O
myelotoxic	O
(	O
e.g.	O
,	O
cytotoxic	O
chemotherapy	O
)	O
,	O
cardiotoxic	O
(	O
e.g.	O
,	O
doxorubicin	B-Drug
)	O
or	O
hepatotoxic	O
(	O
e.g.	O
,	O
methotrexate	B-Drug
,	O
asparaginase	B-Drug
)	O
effects	O
with	O
PROLEUKIN	B-Drug
may	O
increase	O
toxicity	O
in	O
these	O
organ	O
systems	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
PROLEUKIN	B-Drug
in	O
combination	O
with	O
any	O
antineoplastic	O
agents	O
have	O
not	O
been	O
established	O
.	O

In	O
addition	O
,	O
reduced	O
kidney	O
and	O
liver	O
function	O
secondary	O
to	O
PROLEUKIN	B-Drug
treatment	O
may	O
delay	O
elimination	O
of	O
concomitant	O
medications	O
and	O
increase	O
the	O
risk	O
of	O
adverse	O
events	O
from	O
those	O
drugs	B-Drug
.	O

Hypersensitivity	O
reactions	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
combination	O
regimens	O
containing	O
sequential	O
high	O
dose	O
PROLEUKIN	B-Drug
and	O
antineoplastic	O
agents	O
,	O
specifically	O
,	O
dacarbazine	B-Drug
,	O
cis-platinum	B-Drug
,	O
tamoxifen	B-Drug
and	O
interferon-alfa	B-Drug
.	O

These	O
reactions	O
consisted	O
of	O
erythema	O
,	O
pruritus	O
,	O
and	O
hypotension	O
and	O
occurred	O
within	O
hours	O
of	O
administration	O
of	O
chemotherapy	O
.	O

These	O
events	O
required	O
medical	O
intervention	O
in	O
some	O
patients	O
.	O

Myocardial	O
injury	O
,	O
including	O
myocardial	O
infarction	O
,	O
myocarditis	O
,	O
ventricular	O
hypokinesia	O
,	O
and	O
severe	O
rhabdomyolysis	O
appear	O
to	O
be	O
increased	O
in	O
patients	O
receiving	O
PROLEUKIN	B-Drug
and	O
interferon-alfa	B-Drug
concurrently	O
.	O

Exacerbation	O
or	O
the	O
initial	O
presentation	O
of	O
a	O
number	O
of	O
autoimmune	O
and	O
inflammatory	O
disorders	O
has	O
been	O
observed	O
following	O
concurrent	O
use	O
of	O
interferon-alfa	B-Drug
and	O
PROLEUKIN	B-Drug
,	O
including	O
crescentic	O
IgA	O
glomerulonephritis	O
,	O
oculo-bulbar	O
myasthenia	O
gravis	O
,	O
inflammatory	O
arthritis	O
,	O
thyroiditis	O
,	O
bullous	O
pemphigoid	O
,	O
and	O
Stevens-Johnson	O
syndrome	O
.	O

Although	O
glucocorticoids	O
have	O
been	O
shown	O
to	O
reduce	O
PROLEUKIN-induced	B-Drug
side	O
effects	O
including	O
fever	O
,	O
renal	O
insufficiency	O
,	O
hyperbilirubinemia	O
,	O
confusion	O
,	O
and	O
dyspnea	O
,	O
concomitant	O
administration	O
of	O
these	O
agents	O
with	O
PROLEUKIN	B-Drug
may	O
reduce	O
the	O
antitumor	O
effectiveness	O
of	O
PROLEUKIN	B-Drug
and	O
thus	O
should	O
be	O
avoided	O
.	O

12	O
Beta-blockers	O
and	O
other	O
antihypertensives	B-Drug
may	O
potentiate	O
the	O
hypotension	O
seen	O
with	O
PROLEUKIN	B-Drug
.	O

Delayed	O
Adverse	O
Reactions	O
to	O
Iodinated	O
Contrast	O
Media	O
:	O
A	O
review	O
of	O
the	O
literature	O
revealed	O
that	O
12.6	O
%	O
(	O
range	O
11-28	O
%	O
)	O
of	O
501	O
patients	O
treated	O
with	O
various	O
interleukin-2	B-Drug
containing	O
regimens	O
who	O
were	O
subsequently	O
administered	O
radiographic	O
iodinated	O
contrast	O
media	O
experienced	O
acute	O
,	O
atypical	O
adverse	O
reactions	O
.	O

The	O
onset	O
of	O
symptoms	O
usually	O
occurred	O
within	O
hours	O
(	O
most	O
commonly	O
1	O
to	O
4	O
hours	O
)	O
following	O
the	O
administration	O
of	O
contrast	O
media	O
.	O

These	O
reactions	O
include	O
fever	O
,	O
chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
pruritus	O
,	O
rash	O
,	O
diarrhea	O
,	O
hypotension	O
,	O
edema	O
,	O
and	O
oliguria	O
.	O

Some	O
clinicians	O
have	O
noted	O
that	O
these	O
reactions	O
resemble	O
the	O
immediate	O
side	O
effects	O
caused	O
by	O
interleukin-2	B-Drug
administration	O
,	O
however	O
the	O
cause	O
of	O
contrast	O
reactions	O
after	O
interleukin-2	B-Drug
therapy	O
is	O
unknown	O
.	O

Most	O
events	O
were	O
reported	O
to	O
occur	O
when	O
contrast	O
media	O
was	O
given	O
within	O
4	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
interleukin-2	B-Drug
.	O

These	O
events	O
were	O
also	O
reported	O
to	O
occur	O
when	O
contrast	O
media	O
was	O
given	O
several	O
months	O
after	O
interleukin-2	B-Drug
treatment	O
.	O

No	O
formal	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

The	O
duration	O
of	O
the	O
period	O
following	O
treatment	O
with	O
AMEVIVE	B-Drug
before	O
one	O
should	O
consider	O
starting	O
other	O
immunosuppressive	O
therapy	O
has	O
not	O
been	O
evaluated	O
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
and	O
Fertility	O
In	O
a	O
chronic	O
toxicity	O
study	O
,	O
cynomolgus	O
monkeys	O
were	O
dosed	O
weekly	O
for	O
52	O
weeks	O
with	O
intravenous	O
alefacept	B-Drug
at	O
1	O
mg/kg/dose	O
or	O
20	O
mg/kg/dose	O
.	O

One	O
animal	O
in	O
the	O
high	O
dose	O
group	O
developed	O
a	O
B-cell	O
lymphoma	O
that	O
was	O
detected	O
after	O
28	O
weeks	O
of	O
dosing	O
.	O

Additional	O
animals	O
in	O
both	O
dose	O
groups	O
developed	O
B-cell	O
hyperplasia	O
of	O
the	O
spleen	O
and	O
lymph	O
nodes	O
.	O

All	O
animals	O
in	O
the	O
study	O
were	O
positive	O
for	O
an	O
endemic	O
primate	O
gammaherpes	O
virus	O
also	O
known	O
as	O
lymphocryptovirus	O
(	O
LCV	O
)	O
.	O

Latent	O
LCV	O
infection	O
is	O
generally	O
asymptomatic	O
,	O
but	O
can	O
lead	B-Drug
to	O
B-cell	O
lymphomas	O
when	O
animals	O
are	O
immune	O
suppressed	O
.	O

In	O
a	O
separate	O
study	O
,	O
baboons	O
given	O
3	O
doses	O
of	O
alefacept	B-Drug
at	O
1	O
mg/kg	O
every	O
8	O
weeks	O
were	O
found	O
to	O
have	O
centroblast	O
proliferation	O
in	O
B-cell	O
dependent	O
areas	O
in	O
the	O
germinal	O
centers	O
of	O
the	O
spleen	O
following	O
a	O
116-day	O
washout	O
period	O
.	O

The	O
role	O
of	O
AMEVIVE	B-Drug
in	O
the	O
development	O
of	O
the	O
lymphoid	O
malignancy	O
and	O
the	O
hyperplasia	O
observed	O
in	O
non-human	O
primates	O
and	O
the	O
relevance	O
to	O
humans	O
is	O
unknown	O
.	O

Immunodeficiency-associated	O
lymphocyte	O
disorders	O
(	O
plasmacytic	O
hyperplasia	O
,	O
polymorphic	O
proliferation	O
,	O
and	O
B-cell	O
lymphomas	O
)	O
occur	O
in	O
patients	O
who	O
have	O
congenital	O
or	O
acquired	O
immunodeficiencies	O
including	O
those	O
resulting	O
from	O
immunosuppressive	O
therapy	O
.	O

No	O
carcinogenicity	O
or	O
fertility	O
studies	O
were	O
conducted	O
.	O

Mutagenicity	O
studies	O
were	O
conducted	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O
no	O
evidence	O
of	O
mutagenicity	O
was	O
observed	O
.	O

Pregnancy	O
(	O
Category	O
B	O
)	O
Women	O
of	O
childbearing	O
potential	O
make	O
up	O
a	O
considerable	O
segment	O
of	O
the	O
patient	O
population	O
affected	O
by	O
psoriasis	O
.	O

Since	O
the	O
effect	O
of	O
AMEVIVE	B-Drug
on	O
pregnancy	O
and	O
fetal	O
development	O
,	O
including	O
immune	O
system	O
development	O
,	O
is	O
not	O
known	O
,	O
health	O
care	O
providers	O
are	O
encouraged	O
to	O
enroll	O
patients	O
currently	O
taking	O
AMEVIVE	B-Drug
who	O
become	O
pregnant	O
into	O
the	O
Biogen	O
Pregnancy	O
Registry	O
by	O
calling	O
1-866-AMEVIVE	B-Drug
(	O
1-866-263-8483	O
)	O
.	O

Reproductive	O
toxicology	O
studies	O
have	O
been	O
performed	O
in	O
cynomolgus	O
monkeys	O
at	O
doses	O
up	O
to	O
5	O
mg/kg/week	O
(	O
about	O
62	O
times	O
the	O
human	O
dose	O
based	O
on	O
body	O
weight	O
)	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
impaired	O
fertility	O
or	O
harm	O
to	O
the	O
fetus	O
due	O
to	O
AMEVIVE	B-Drug
.	O

No	O
abortifacient	O
or	O
teratogenic	O
effects	O
were	O
observed	O
in	O
cynomolgus	O
monkeys	O
following	O
intravenous	O
bolus	O
injections	O
of	O
AMEVIVE	B-Drug
administered	O
weekly	O
during	O
the	O
period	O
of	O
organogenesis	O
to	O
gestation	O
.	O

AMEVIVE	B-Drug
underwent	O
trans-placental	O
passage	O
and	O
produced	O
in	O
utero	O
exposure	O
in	O
the	O
developing	O
monkeys	O
.	O

In	O
utero	O
,	O
serum	O
levels	O
of	O
exposure	O
in	O
these	O
monkeys	O
were	O
23	O
%	O
of	O
maternal	O
serum	O
levels	O
.	O

No	O
evidence	O
of	O
fetal	O
toxicity	O
including	O
adverse	O
effects	O
on	O
immune	O
system	O
development	O
was	O
observed	O
in	O
any	O
of	O
these	O
animals	O
.	O

Animal	O
reproduction	O
studies	O
,	O
however	O
,	O
are	O
not	O
always	O
predictive	O
of	O
human	O
response	O
and	O
there	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
in	O
pregnant	O
women	O
.	O

Because	O
the	O
risk	O
to	O
the	O
development	O
of	O
the	O
fetal	O
immune	O
system	O
and	O
postnatal	O
immune	O
function	O
in	O
humans	O
is	O
unknown	O
,	O
AMEVIVE	B-Drug
should	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
clearly	O
needed	O
.	O

If	O
pregnancy	O
occurs	O
while	O
taking	O
AMEVIVE	B-Drug
,	O
continued	O
use	O
of	O
the	O
drug	B-Drug
should	O
be	O
assessed	O
.	O

Nursing	O
Mothers	O
It	O
is	O
not	O
known	O
whether	O
AMEVIVE	B-Drug
is	O
excreted	O
in	O
human	O
milk	O
.	O

Because	O
many	O
drugs	B-Drug
are	O
excreted	O
in	O
human	O
milk	O
,	O
and	O
because	O
there	O
exists	O
the	O
potential	O
for	O
serious	O
adverse	O
reactions	O
in	O
nursing	O
infants	O
from	O
AMEVIVE	B-Drug
,	O
a	O
decision	O
should	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
while	O
taking	O
the	O
drug	B-Drug
or	O
to	O
discontinue	O
the	O
use	O
of	O
the	O
drug	B-Drug
,	O
taking	O
into	O
account	O
the	O
importance	O
of	O
the	O
drug	B-Drug
to	O
the	O
mother	O
.	O

Geriatric	O
Use	O
Of	O
the	O
1357	O
patients	O
who	O
received	O
AMEVIVE	B-Drug
in	O
clinical	O
trials	O
,	O
a	O
total	O
of	O
100	O
patients	O
were	O
65	O
years	O
of	O
age	O
and	O
13	O
patients	O
were	O
75	O
years	O
of	O
age	O
.	O

No	O
differences	O
in	O
safety	O
or	O
efficacy	O
were	O
observed	O
between	O
older	O
and	O
younger	O
patients	O
,	O
but	O
there	O
were	O
not	O
sufficient	O
data	O
to	O
exclude	O
important	O
differences	O
.	O

Because	O
the	O
incidence	O
of	O
infections	O
and	O
certain	O
malignancies	O
is	O
higher	O
in	O
the	O
elderly	O
population	O
,	O
in	O
general	O
,	O
caution	O
should	O
be	O
used	O
in	O
treating	O
the	O
elderly	O
.	O

Pediatric	O
Use	O
The	O
safety	O
and	O
efficacy	O
of	O
AMEVIVE	B-Drug
in	O
pediatric	O
patients	O
have	O
not	O
been	O
studied	O
.	O

AMEVIVE	B-Drug
is	O
not	O
indicated	O
for	O
pediatric	O
patients	O
.	O

Drug/Laboratory	O
Interactions	O
No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Campath	B-Drug
.	O

An	O
immune	O
response	O
to	O
Campath	B-Drug
may	O
interfere	O
with	O
subsequent	O
diagnostic	O
serum	O
tests	O
that	O
utilize	O
antibodies	O
.	O

Intravenous	O
ranitidine	B-Drug
was	O
shown	O
to	O
double	O
the	O
bioavailability	O
of	O
oral	O
alendronate	B-Drug
.	O

The	O
clinical	O
significance	O
of	O
this	O
increased	O
bioavailability	O
and	O
whether	O
similar	O
increases	O
will	O
occur	O
in	O
patients	O
given	O
oral	O
H2-antagonists	O
is	O
unknown	O
;	O
no	O
other	O
specific	O
drug	B-Drug
interaction	O
studies	O
were	O
performed	O
.	O

Products	O
containing	O
calcium	B-Drug
and	O
other	O
multivalent	B-Drug
cations	I-Drug
likely	O
will	O
interfere	O
with	O
absorption	O
of	O
alendronate	B-Drug
.	O

Both	O
the	O
magnitude	O
and	O
duration	O
of	O
central	O
nervous	O
system	O
and	O
cardiovascular	O
effects	O
may	O
be	O
enhanced	O
when	O
ALFENTA	B-Drug
is	O
administered	O
in	O
combination	O
with	O
other	O
CNS	O
depressants	O
such	O
as	O
barbiturates	B-Drug
,	O
tranquilizers	O
,	O
opioids	O
,	O
or	O
inhalation	O
general	O
anesthetics	B-Drug
.	O

Postoperative	O
respiratory	O
depression	O
may	O
be	O
enhanced	O
or	O
prolonged	O
by	O
these	O
agents	O
.	O

In	O
such	O
cases	O
of	O
combined	O
treatment	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

Limited	O
clinical	O
experience	O
indicates	O
that	O
requirements	O
for	O
volatile	O
inhalation	O
anesthetics	B-Drug
are	O
reduced	O
by	O
30	O
to	O
50	O
%	O
for	O
the	O
first	O
sixty	O
(	O
60	O
)	O
minutes	O
following	O
ALFENTA	B-Drug
induction	O
The	O
concomitant	O
use	O
of	O
erythromycin	B-Drug
with	O
ALFENTA	B-Drug
can	O
significantly	O
inhibit	O
ALFENTA	B-Drug
clearance	O
and	O
may	O
increase	O
the	O
risk	O
of	O
prolonged	O
or	O
delayed	O
respiratory	O
depression	O
.	O

Cimetidine	B-Drug
reduces	O
the	O
clearance	O
of	O
ALFENTA	B-Drug
.	O

Therefore	O
smaller	O
ALFENTA	B-Drug
doses	O
will	O
be	O
required	O
with	O
prolonged	O
administration	O
and	O
the	O
duration	O
of	O
action	O
of	O
ALFENTA	B-Drug
my	O
be	O
extended	O
.	O

Perioperative	O
administration	O
of	O
drugs	B-Drug
affecting	O
hepatic	O
blood	O
flow	O
or	O
enzyme	O
function	O
may	O
reduce	O
plasma	O
clearance	O
and	O
prolong	O
recovery	O
.	O

Drug-Drug	O
Interactions	O
:	O
The	O
pharmacokinetic	O
and	O
pharmacodynamic	O
interactions	O
between	O
UROXATRAL	B-Drug
and	O
other	O
alpha-blockers	O
have	O
not	O
been	O
determined	O
.	O

However	O
,	O
interactions	O
may	O
be	O
expected	O
,	O
and	O
UROXATRAL	B-Drug
should	O
NOT	O
be	O
used	O
in	O
combination	O
with	O
other	O
alpha-blockers	O
.	O

No	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Effects	O
of	O
Other	O
Drugs	B-Drug
on	O
Aliskiren	B-Drug
Based	O
on	O
in-vitro	O
studies	O
,	O
aliskiren	B-Drug
is	O
metabolized	O
by	O
CYP	O
3A4	O
.	O

Co-administration	O
of	O
lovastatin	B-Drug
,	O
atenolol	B-Drug
,	O
warfarin	B-Drug
,	O
furosemide	B-Drug
,	O
digoxin	B-Drug
,	O
celecoxib	B-Drug
,	O
hydrochlorothiazide	B-Drug
,	O
ramipril	B-Drug
,	O
valsartan	B-Drug
,	O
metformin	B-Drug
and	O
amlodipine	B-Drug
did	O
not	O
result	O
in	O
clinically	O
significant	O
increases	O
in	O
aliskiren	B-Drug
exposure	O
.	O

Co-administration	O
of	O
irbesartan	B-Drug
reduced	O
aliskiren	B-Drug
Cmax	O
up	O
to	O
50	O
%	O
after	O
multiple	O
dosing	O
.	O

Co-administration	O
of	O
atorvastatin	B-Drug
resulted	O
in	O
about	O
a	O
50	O
%	O
increase	O
in	O
aliskiren	B-Drug
Cmax	O
and	O
AUC	O
after	O
multiple	O
dosing	O
.	O

Ketoconazole	B-Drug
:	O
Co-administration	O
of	O
200	O
mg	O
twice-daily	O
ketoconazole	B-Drug
with	O
aliskiren	B-Drug
resulted	O
in	O
an	O
approximate	O
80	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
aliskiren	B-Drug
.	O

A	O
400	O
mg	O
once-daily	O
dose	O
was	O
not	O
studied	O
but	O
would	O
be	O
expected	O
to	O
increase	O
aliskiren	B-Drug
blood	O
levels	O
further	O
.	O

Effects	O
of	O
Aliskiren	B-Drug
on	O
Other	O
Drugs	B-Drug
Aliskiren	B-Drug
does	O
not	O
inhibit	O
the	O
CYP450	O
isoenzymes	O
(	O
CYP1A2	B-Drug
,	O
2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
CYP	O
3A	O
)	O
or	O
induce	O
CYP	O
3A4	O
.	O

Co-administration	O
of	O
aliskiren	B-Drug
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
lovastatin	B-Drug
,	O
digoxin	B-Drug
,	O
valsartan	B-Drug
,	O
amlodipine	B-Drug
,	O
metformin	B-Drug
,	O
celecoxib	B-Drug
,	O
atenolol	B-Drug
,	O
atorvastatin	B-Drug
,	O
ramipril	B-Drug
or	O
hydrochlorothiazide	B-Drug
.	O

Warfarin	B-Drug
:	O
The	O
effects	O
of	O
aliskiren	B-Drug
on	O
warfarin	B-Drug
pharmacokinetics	O
have	O
not	O
been	O
evaluated	O
in	O
a	O
well-controlled	O
clinical	O
trial	O
.	O

Furosemide	B-Drug
:	O
When	O
aliskiren	B-Drug
was	O
co-administered	O
with	O
furosemide	B-Drug
,	O
the	O
AUC	O
and	O
Cmax	O
of	O
furosemide	B-Drug
were	O
reduced	O
by	O
about	O
30	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Patients	O
who	O
are	O
applying	O
Panretin	B-Drug
gel	O
should	O
not	O
concurrently	O
use	O
products	O
that	O
contain	O
DEET	B-Drug
(	O
N	O
,	O
N-diethyl-m-toluamide	B-Drug
)	O
,	O
a	O
common	O
component	O
of	O
insect	O
repellent	O
products	O
.	O

Animal	O
toxicology	O
studies	O
showed	O
increased	O
DEET	B-Drug
toxicity	O
when	O
DEET	B-Drug
was	O
included	O
as	O
proof	O
of	O
the	O
formulation	O
.	O

Although	O
there	O
was	O
no	O
clinical	O
evidence	O
in	O
the	O
vehicle-controlled	O
studies	O
of	O
drug	B-Drug
interactions	O
with	O
systemic	O
antiretroviral	O
agents	O
,	O
including	O
protease	O
inhibitors	O
,	O
macrolide	O
antibiotics	B-Drug
,	O
and	O
azole	O
antifungals	O
,	O
the	O
effect	O
of	O
Panretin	B-Drug
gel	O
on	O
the	O
steady-state	O
concentrations	O
of	O
these	O
drugs	B-Drug
is	O
not	O
known	O
.	O

No	O
drug	B-Drug
interaction	O
data	O
are	O
available	O
on	O
concomitant	O
administration	O
of	O
Panretin	B-Drug
gel	O
and	O
systemic	O
anti-KS	O
agents	O
.	O

The	O
following	O
drug	B-Drug
interactions	O
were	O
observed	O
in	O
some	O
patients	O
undergoing	O
treatment	O
with	O
oral	O
allopurinol	B-Drug
.	O

Although	O
the	O
pattern	O
of	O
use	O
for	O
oral	O
allopurinol	B-Drug
includes	O
longer	O
term	O
therapy	O
,	O
particularly	O
for	O
gout	O
and	O
renal	O
calculi	O
,	O
the	O
experience	O
gained	O
may	O
be	O
relevant	O
.	O

Mercaptopurine/Azathioprine	B-Drug
:	O
Allopurinol	B-Drug
inhibits	O
the	O
enzymatic	O
oxidation	O
of	O
mercaptopurine	B-Drug
and	O
azathioprine	B-Drug
to	O
6-thiouric	O
acid	O
.	O

This	O
oxidation	O
,	O
which	O
is	O
catalyzed	O
by	O
xanthine	O
oxidase	O
,	O
inactivates	O
mercaptopurine	B-Drug
.	O

In	O
patients	O
receiving	O
mercaptopurine	B-Drug
(	O
Purinethol	B-Drug
)	O
or	O
azathioprine	B-Drug
(	O
Imuran	B-Drug
)	O
,	O
the	O
concomitant	O
administration	O
of	O
300-600	O
mg	O
of	O
allopurinol	B-Drug
per	O
day	O
will	O
require	O
a	O
reduction	O
in	O
dose	O
to	O
approximately	O
one-third	O
to	O
one-fourth	O
of	O
the	O
usual	O
dose	O
of	O
mercaptopurine	B-Drug
or	O
azathioprine	B-Drug
.	O

Subsequent	O
adjustment	O
of	O
doses	O
of	O
mercaptopurine	B-Drug
or	O
azathioprine	B-Drug
should	O
be	O
made	O
on	O
the	O
basis	O
of	O
therapeutic	O
response	O
and	O
the	O
appearance	O
of	O
toxic	O
effects	O
.	O

Dicumarol	B-Drug
:	O
It	O
has	O
been	O
reported	O
that	O
allopurinol	B-Drug
prolongs	O
the	O
half-life	O
of	O
the	O
anticoagulant	B-Drug
,	O
dicumarol	B-Drug
.	O

The	O
clinical	O
basis	O
of	O
this	O
drug	B-Drug
interaction	O
has	O
not	O
been	O
established	O
but	O
should	O
be	O
noted	O
when	O
allopurinol	B-Drug
is	O
given	O
to	O
patients	O
already	O
on	O
dicumarol	B-Drug
therapy	O
.	O

Consequently	O
,	O
prothrombin	O
time	O
should	O
be	O
reassessed	O
periodically	O
in	O
patients	O
receiving	O
both	O
drugs	B-Drug
.	O

Uricosuric	O
Agents	O
:	O
Since	O
the	O
excretion	O
of	O
oxipurinol	B-Drug
is	O
similar	O
to	O
that	O
of	O
urate	O
,	O
uricosuric	O
agents	O
,	O
which	O
increase	O
the	O
excretion	O
of	O
urate	O
,	O
are	O
also	O
likely	O
to	O
increase	O
the	O
excretion	O
of	O
oxipurinol	B-Drug
and	O
thus	O
lower	O
the	O
degree	O
of	O
inhibition	O
of	O
xanthine	O
oxidase	O
.	O

The	O
concomitant	O
administration	O
of	O
uricosuric	O
agents	O
and	O
allopurinol	B-Drug
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
excretion	O
of	O
oxypurines	O
(	O
hypoxanthine	O
and	O
xanthine	O
)	O
and	O
an	O
increase	O
in	O
urinary	O
uric	O
acid	O
excretion	O
compared	O
with	O
that	O
observed	O
with	O
allopurinol	B-Drug
alone	O
.	O

Although	O
clinical	O
evidence	O
to	O
date	O
has	O
not	O
demonstrated	O
renal	O
precipitation	O
of	O
oxypurines	O
in	O
patients	O
either	O
on	O
allopurinol	B-Drug
alone	O
or	O
in	O
combination	O
with	O
uricosuric	O
agents	O
,	O
the	O
possibility	O
should	O
be	O
kept	O
in	O
mind	O
.	O

Thiazide	O
Diuretics	B-Drug
:	O
The	O
reports	O
that	O
the	O
concomitant	O
use	O
of	O
allopurinol	B-Drug
and	O
thiazide	O
diuretics	B-Drug
may	O
contribute	O
to	O
the	O
enhancement	O
of	O
allopurinol	B-Drug
toxicity	O
in	O
some	O
patients	O
have	O
been	O
reviewed	O
in	O
an	O
attempt	O
to	O
establish	O
a	O
cause-and-effect	O
relationship	O
and	O
a	O
mechanism	O
of	O
causation	O
.	O

Review	O
of	O
these	O
case	O
reports	O
indicates	O
that	O
the	O
patients	O
were	O
mainly	O
receiving	O
thiazide	O
diuretics	B-Drug
for	O
hypertension	O
and	O
that	O
tests	O
to	O
rule	O
out	O
decreased	O
renal	O
function	O
secondary	O
to	O
hypertensive	O
nephropathy	O
were	O
not	O
often	O
performed	O
.	O

In	O
those	O
patients	O
in	O
whom	O
renal	O
insufficiency	O
was	O
documented	O
,	O
however	O
,	O
the	O
recommendation	O
to	O
lower	O
the	O
dose	O
of	O
allopurinol	B-Drug
was	O
not	O
followed	O
.	O

Although	O
a	O
causal	O
mechanism	O
and	O
a	O
cause-and-effect	O
relationship	O
have	O
not	O
been	O
established	O
,	O
current	O
evidence	O
suggests	O
that	O
renal	O
function	O
should	O
be	O
monitored	O
in	O
patients	O
on	O
thiazide	O
diuretics	B-Drug
and	O
allopurinol	B-Drug
even	O
in	O
the	O
absence	O
of	O
renal	O
failure	O
,	O
and	O
dosage	O
levels	O
should	O
be	O
even	O
more	O
conservatively	O
adjusted	O
in	O
those	O
patients	O
on	O
such	O
combined	O
therapy	O
if	O
diminished	O
renal	O
function	O
is	O
detected..	O
Ampicillin/Amoxicillin	B-Drug
:	O
An	O
increase	O
in	O
the	O
frequency	O
of	O
skin	O
rash	O
has	O
been	O
reported	O
among	O
patients	O
receiving	O
ampicillin	B-Drug
or	O
amoxicillin	B-Drug
concurrently	O
with	O
allopurinol	B-Drug
compared	O
to	O
patients	O
who	O
are	O
not	O
receiving	O
both	O
drugs	B-Drug
.	O

The	O
cause	O
of	O
the	O
reported	O
association	O
has	O
not	O
been	O
established	O
.	O

Cytotoxic	O
Agents	O
:	O
Enhanced	O
bone	O
marrow	O
suppression	O
by	O
cyclophosphamide	B-Drug
and	O
other	O
cytotoxic	O
agents	O
has	O
been	O
reported	O
among	O
patients	O
with	O
neoplastic	O
disease	O
,	O
except	O
leukemia	O
,	O
in	O
the	O
presence	O
of	O
allopurinol	B-Drug
.	O

However	O
,	O
in	O
a	O
well-controlled	O
study	O
of	O
patients	O
with	O
lymphoma	O
on	O
combination	O
therapy	O
,	O
allopurinol	B-Drug
did	O
not	O
increase	O
the	O
marrow	O
toxicity	O
of	O
patients	O
treated	O
with	O
cyclophosphamide	B-Drug
,	O
doxorubicin	B-Drug
,	O
bleomycin	B-Drug
,	O
procarbazine	B-Drug
and/or	O
mechlorethamine	B-Drug
.	O

Chlorpropamide	B-Drug
:	O
Chlorpropamides	B-Drug
plasma	O
half-life	O
may	O
be	O
prolonged	O
by	O
allopurinol	B-Drug
,	O
since	O
allopurinol	B-Drug
and	O
chlorpropamide	B-Drug
may	O
compete	O
for	O
excretion	O
in	O
the	O
renal	O
tubule	O
.	O

The	O
risk	O
of	O
hypoglycemia	O
secondary	O
to	O
this	O
mechanism	O
may	O
be	O
increased	O
if	O
allopurinol	B-Drug
and	O
chlorpropamide	B-Drug
are	O
given	O
concomitantly	O
in	O
the	O
presence	O
of	O
renal	O
insufficiency	O
.	O

Cyclosporin	B-Drug
:	O
Reports	O
indicate	O
that	O
cyclosporine	B-Drug
levels	O
may	O
be	O
increased	O
during	O
concomitant	O
treatment	O
with	O
allopurinol	B-Drug
sodium	I-Drug
for	O
injection	O
.	O

Monitoring	O
of	O
cyclosporine	B-Drug
levels	O
and	O
possible	O
adjustment	O
of	O
cyclosporine	B-Drug
dosage	O
should	O
be	O
considered	O
when	O
these	O
drugs	B-Drug
are	O
co-administered	O
.	O

Tolbutamides	B-Drug
conversion	O
to	O
inactive	O
metabolites	O
has	O
been	O
shown	O
to	O
be	O
catalyzed	O
by	O
xanthine	O
oxidase	O
from	O
rat	O
liver	O
.	O

The	O
clinical	O
significance	O
,	O
if	O
any	O
,	O
of	O
these	O
observations	O
is	O
unknown	O
.	O

Ergot-Containing	O
Drugs	B-Drug
:	O
These	O
drugs	B-Drug
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine-containing	B-Drug
or	O
ergot-type	O
medications	O
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
AXERT	B-Drug
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
.	O

Monoamine	O
Oxidase	O
Inhibitors	O
:	O
Coadministration	O
of	O
moclobemide	B-Drug
resulted	O
in	O
a	O
27	O
%	O
decrease	O
in	O
almotriptan	B-Drug
clearance	O
and	O
an	O
increase	O
in	O
Cmax	O
of	O
approximately	O
6	O
%	O
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Other	O
5-HT1B/1D	O
Agonists	O
Concomitant	O
use	O
of	O
other	O
5-HT1B/1D	O
agonists	O
within	O
24	O
hours	O
of	O
treatment	O
with	O
AXERT	B-Drug
is	O
contraindicated	O
.	O

Propanolol	B-Drug
:	O
The	O
pharmacokinetics	O
of	O
almotriptan	B-Drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
propranolol	B-Drug
.	O

Selective	O
Serotonin	O
Reuptake	O
Inhibitors	O
(	O
SSRIs	O
)	O
:	O
SSRIs	O
(	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
paroxetine	B-Drug
,	O
sertraline	B-Drug
)	O
have	O
been	O
rarely	O
reported	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5-HT1	O
agonists	O
.	O

If	O
concomitant	O
treatment	O
with	O
AXERT	B-Drug
and	O
an	O
SSRI	O
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Verapamil	B-Drug
:	O
Coadministration	O
of	O
almotriptan	B-Drug
and	O
verapamil	B-Drug
resulted	O
in	O
a	O
24	O
%	O
increase	O
in	O
plasma	O
concentrations	O
of	O
almotriptan	B-Drug
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Coadministration	O
of	O
almotriptan	B-Drug
and	O
the	O
potent	O
CYP3A4	B-Drug
inhibitor	O
ketoconazole	B-Drug
(	O
400	O
mg	O
q.d	O
.	O

for	O
3	O
days	O
)	O
resulted	O
in	O
an	O
approximately	O
60	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
and	O
maximal	O
plasma	O
concentrations	O
of	O
almotriptan	B-Drug
.	O

Although	O
the	O
interaction	O
between	O
almotriptan	B-Drug
and	O
other	O
potent	O
CYP3A4	B-Drug
inhibitors	O
(	O
e.g.	O
,	O
itraconazole	B-Drug
,	O
ritonavir	B-Drug
,	O
and	O
erythromycin	B-Drug
)	O
has	O
not	O
been	O
studied	O
,	O
increased	O
exposures	O
to	O
almotriptan	B-Drug
may	O
be	O
expected	O
when	O
almotriptan	B-Drug
is	O
used	O
concomitantly	O
with	O
these	O
medications	O
.	O

AXERT	B-Drug
is	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O

Because	O
alosetron	B-Drug
is	O
metabolized	O
by	O
a	O
variety	O
of	O
hepatic	O
CYP	O
drug-metabolizing	O
enzymes	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
of	O
alosetron	B-Drug
.	O

Fluvoxamine	B-Drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP1A2	B-Drug
and	O
also	O
inhibits	O
CYP3A4	B-Drug
,	O
CYP2C9	B-Drug
,	O
and	O
CYP2C19	O
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
40	O
healthy	O
female	O
subjects	O
received	O
fluvoxamine	B-Drug
in	O
escalating	O
doses	O
from	O
50	O
to	O
200	O
mg	O
per	O
day	O
for	O
16	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B-Drug
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Fluvoxamine	B-Drug
increased	O
mean	O
alosetron	B-Drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
approximately	O
6-fold	O
and	O
prolonged	O
the	O
half-life	O
by	O
approximately	O
3-fold	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B-Drug
and	O
fluvoxamine	B-Drug
is	O
contraindicated	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B-Drug
and	O
moderate	O
CYP1A2	B-Drug
inhibitors	O
,	O
including	O
quinolone	O
antibiotics	B-Drug
and	O
cimetidine	B-Drug
,	O
has	O
not	O
been	O
evaluated	O
,	O
but	O
should	O
be	O
avoided	O
unless	O
clinically	O
necessary	O
because	O
of	O
similar	O
potential	O
drug	B-Drug
interactions	O
.	O

Ketoconazole	B-Drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP3A4	B-Drug
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
38	O
healthy	O
female	O
subjects	O
received	O
ketoconazole	B-Drug
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B-Drug
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Ketoconazole	B-Drug
increased	O
mean	O
alosetron	B-Drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
by	O
29	O
%	O
.	O

Caution	O
should	O
be	O
used	O
when	O
alosetron	B-Drug
and	O
ketoconazole	B-Drug
are	O
administered	O
concomitantly	O
.	O

Coadministration	O
of	O
alosetron	B-Drug
and	O
strong	O
CYP3A4	B-Drug
inhibitors	O
,	O
such	O
as	O
clarithromycin	B-Drug
,	O
telithromycin	B-Drug
,	O
protease	O
inhibitors	O
,	O
voriconazole	B-Drug
,	O
and	O
itraconazole	B-Drug
has	O
not	O
been	O
evaluated	O
but	O
should	O
be	O
undertaken	O
with	O
caution	O
because	O
of	O
similar	O
potential	O
drug	B-Drug
interactions	O
.	O

The	O
effect	O
of	O
induction	O
or	O
inhibition	O
of	O
other	O
pathways	O
on	O
exposure	O
to	O
alosetron	B-Drug
and	O
its	O
metabolites	O
is	O
not	O
known	O
.	O

In	O
vitro	O
human	O
liver	O
microsome	O
studies	O
and	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
demonstrated	O
that	O
alosetron	B-Drug
did	O
not	O
inhibit	O
CYP	O
enzymes	O
2D6	O
,	O
3A4	O
,	O
2C9	O
,	O
or	O
2C19	O
.	O

In	O
vitro	O
,	O
at	O
total	O
drug	B-Drug
concentrations	O
27-fold	O
higher	O
than	O
peak	O
plasma	O
concentrations	O
observed	O
with	O
the	O
1-mg	O
dosage	O
,	O
alosetron	B-Drug
inhibited	O
CYP	O
enzymes	O
1A2	O
(	O
60	O
%	O
)	O
and	O
2E1	O
(	O
50	O
%	O
)	O
.	O

In	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
,	O
alosetron	B-Drug
did	O
not	O
inhibit	O
CYP2E1	O
but	O
did	O
produce	O
30	O
%	O
inhibition	O
of	O
both	O
CYP1A2	B-Drug
and	O
N-acetyltransferase	O
.	O

Although	O
not	O
studied	O
with	O
alosetron	B-Drug
,	O
inhibition	O
of	O
N-acetyltransferase	O
may	O
have	O
clinically	O
relevant	O
consequences	O
for	O
drugs	B-Drug
such	O
as	O
isoniazid	B-Drug
,	O
procainamide	B-Drug
,	O
and	O
hydralazine	B-Drug
.	O

The	O
effect	O
on	O
CYP1A2	B-Drug
was	O
explored	O
further	O
in	O
a	O
clinical	O
interaction	O
study	O
with	O
theophylline	B-Drug
and	O
no	O
effect	O
on	O
metabolism	O
was	O
observed	O
.	O

Another	O
study	O
showed	O
that	O
alosetron	B-Drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
plasma	O
concentrations	O
of	O
the	O
oral	O
contraceptive	O
agents	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
levonorgestrel	B-Drug
(	O
CYP3A4	B-Drug
substrates	O
)	O
.	O

A	O
clinical	O
interaction	O
study	O
was	O
also	O
conducted	O
with	O
alosetron	B-Drug
and	O
the	O
CYP3A4	B-Drug
substrate	O
cisapride	B-Drug
.	O

No	O
significant	O
effects	O
on	O
cisapride	B-Drug
metabolism	O
or	O
QT	O
interval	O
were	O
noted	O
.	O

The	O
effect	O
of	O
alosetron	B-Drug
on	O
monoamine	O
oxidases	O
and	O
on	O
intestinal	O
first	O
pass	O
secondary	O
to	O
high	O
intraluminal	O
concentrations	O
have	O
not	O
been	O
examined	O
.	O

Based	O
on	O
the	O
above	O
data	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
,	O
it	O
is	O
unlikely	O
that	O
alosetron	B-Drug
will	O
inhibit	O
the	O
hepatic	O
metabolic	O
clearance	O
of	O
drugs	B-Drug
metabolized	O
by	O
the	O
major	O
CYP	O
enzyme	O
3A4	O
,	O
as	O
well	O
as	O
the	O
CYP	O
enzymes	O
2D6	O
,	O
2C9	O
,	O
2C19	O
,	O
2E1	O
,	O
or	O
1A2	O
.	O

Alosetron	B-Drug
does	O
not	O
appear	O
to	O
induce	O
the	O
major	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
drug	B-Drug
metabolizing	O
enzyme	O
3A	O
.	O

Alosetron	B-Drug
also	O
does	O
not	O
appear	O
to	O
induce	O
CYP	O
enzymes	O
2E1	O
or	O
2C19	O
.	O

It	O
is	O
not	O
known	O
whether	O
alosetron	B-Drug
might	O
induce	O
other	O
enzymes	O
.	O

The	O
benzodiazepines	B-Drug
,	O
including	O
alprazolam	B-Drug
,	O
produce	O
additive	O
CNS	O
depressant	O
effects	O
when	O
co-administered	O
with	O
other	O
psychotropic	O
medications	O
,	O
anticonvulsants	O
,	O
antihistaminics	O
,	O
ethanol	B-Drug
,	O
and	O
other	O
drugs	B-Drug
which	O
themselves	O
produce	O
CNS	O
depression	O
.	O

The	O
steady	O
state	O
plasma	O
concentrations	O
of	O
imipramine	B-Drug
and	O
desipramine	B-Drug
have	O
been	O
reported	O
to	O
be	O
increased	O
an	O
average	O
of	O
31	O
%	O
and	O
20	O
%	O
,	O
respectively	O
,	O
by	O
the	O
concomitant	O
administration	O
of	O
alprazolam	B-Drug
tablets	O
in	O
doses	O
up	O
to	O
4	O
mg/day	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
changes	O
is	O
unknown	O
.	O

Drugs	B-Drug
That	O
Inhibit	O
Alprazolam	B-Drug
Metabolism	O
Via	O
Cytochrome	O
P450	O
3A	O
:	O
The	O
initial	O
step	O
in	O
alprazolam	B-Drug
metabolism	O
is	O
hydroxylation	O
catalyzed	O
by	O
cytochrome	O
P450	O
3A	O
(	O
CYP	O
3A	O
)	O
.	O

Drugs	B-Drug
which	O
inhibit	O
this	O
metabolic	O
pathway	O
may	O
have	O
a	O
profound	O
effect	O
on	O
the	O
clearance	O
of	O
alprazolam	B-Drug
.	O

Drugs	B-Drug
Demonstrated	O
to	O
be	O
CYP	O
3A	O
Inhibitors	O
of	O
Possible	O
Clinical	O
Significance	O
on	O
the	O
Basis	O
of	O
Clinical	O
Studies	O
Involving	O
Alprazolam	B-Drug
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B-Drug
)	O
:	O
Coadministration	O
of	O
fluoxetine	B-Drug
with	O
alprazolam	B-Drug
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
46	O
%	O
,	O
decreased	O
clearance	O
by	O
21	O
%	O
,	O
increased	O
half-life	O
by	O
17	O
%	O
,	O
and	O
decreased	O
measured	O
psychomotor	O
performance	O
.	O

Coadministration	O
of	O
propoxyphene	B-Drug
decreased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
6	O
%	O
,	O
decreased	O
clearance	O
by	O
38	O
%	O
,	O
and	O
increased	O
half-life	O
by	O
58	O
%	O
.	O

Coadministration	O
of	O
oral	O
contraceptives	O
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B-Drug
by	O
18	O
%	O
,	O
decreased	O
clearance	O
by	O
22	O
%	O
,	O
and	O
increased	O
half-life	O
by	O
29	O
%	O
.	O

Drugs	B-Drug
and	O
other	O
substances	O
demonstrated	O
to	O
be	O
CYP	O
3A	O
inhibitors	O
on	O
the	O
basis	O
of	O
clinical	O
studies	O
involving	O
benzodiazepines	B-Drug
metabolized	O
similarly	O
to	O
alprazolam	B-Drug
or	O
on	O
the	O
basis	O
of	O
in	O
vitro	O
studies	O
with	O
alprazolam	B-Drug
or	O
other	O
benzodiazepines	B-Drug
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B-Drug
)	O
:	O
Available	O
data	O
from	O
clinical	O
studies	O
of	O
benzodiazepines	B-Drug
other	O
than	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	B-Drug
interaction	O
with	O
alprazolam	B-Drug
for	O
the	O
following	O
:	O
diltiazem	B-Drug
,	O
isoniazid	B-Drug
,	O
macrolide	O
antibiotics	B-Drug
such	O
as	O
erythromycin	B-Drug
and	O
clarithromycin	B-Drug
,	O
and	O
grapefruit	O
juice	O
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	B-Drug
interaction	O
with	O
alprazolam	B-Drug
for	O
the	O
following	O
:	O
sertraline	B-Drug
and	O
paroxetine	B-Drug
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
benzodiazepines	B-Drug
other	O
than	O
alprazolam	B-Drug
suggest	O
a	O
possible	O
drug	B-Drug
interaction	O
for	O
the	O
following	O
:	O
ergotamine	B-Drug
,	O
cyclosporine	B-Drug
,	O
amiodarone	B-Drug
,	O
nicardipine	B-Drug
,	O
and	O
nifedipine	B-Drug
.	O

Caution	O
is	O
recommended	O
during	O
the	O
coadministration	O
of	O
any	O
of	O
these	O
with	O
alprazolam	B-Drug
.	O

No	O
drug	B-Drug
interactions	O
have	O
been	O
reported	O
between	O
Prostin	B-Drug
VR	I-Drug
Pediatric	I-Drug
and	O
the	O
therapy	O
standard	O
in	O
neonates	O
with	O
restricted	O
pulmonary	O
or	O
systemic	O
blood	O
flow	O
.	O

Standard	O
therapy	O
includes	O
antibiotics	B-Drug
,	O
such	O
as	O
penicillin	B-Drug
and	O
gentamicin	B-Drug
;	O
vasopressors	O
,	O
such	O
as	O
dopamine	B-Drug
and	O
isoproterenol	B-Drug
;	O
cardiac	O
glycosides	O
;	O
and	O
diuretics	B-Drug
,	O
such	O
as	O
furosemide	B-Drug
.	O

Caverject	B-Drug
:	O
The	O
potential	O
for	O
pharmacokinetic	O
drug-drug	O
interactions	O
between	O
alprostadil	B-Drug
and	O
other	O
agents	O
has	O
not	O
been	O
formally	O
studied	O
.	O

The	O
interaction	O
of	O
Activase	B-Drug
with	O
other	O
cardioactive	O
or	O
cerebroactive	O
drugs	B-Drug
has	O
not	O
been	O
studied	O
.	O

In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	B-Drug
and	O
vitamin	O
K	O
antagonists	O
,	O
drugs	B-Drug
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
dipyridamole	B-Drug
and	O
Abciximab	B-Drug
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
,	O
during	O
,	O
or	O
after	O
Activase	B-Drug
therapy	O
.	O

Use	O
of	O
Antithrombotics	O
Aspirin	B-Drug
and	O
heparin	B-Drug
have	O
been	O
administered	O
concomitantly	O
with	O
and	O
following	O
infusions	O
of	O
Activase	B-Drug
in	O
the	O
management	O
of	O
acute	O
myocardial	O
infarction	O
or	O
pulmonary	O
embolism	O
.	O

Because	O
heparin	B-Drug
,	O
aspirin	B-Drug
,	O
or	O
Activase	B-Drug
may	O
cause	O
bleeding	O
complications	O
,	O
careful	O
monitoring	O
for	O
bleeding	O
is	O
advised	O
,	O
especially	O
at	O
arterial	O
puncture	O
sites	O
.	O

The	O
concomitant	O
use	O
of	O
heparin	B-Drug
or	O
aspirin	B-Drug
during	O
the	O
first	O
24	O
hours	O
following	O
symptom	O
onset	O
were	O
prohibited	O
in	O
The	O
NINDS	O
t-PA	O
Stroke	O
Trial	O
.	O

The	O
safety	O
of	O
such	O
concomitant	O
use	O
with	O
Activase	B-Drug
for	O
the	O
management	O
of	O
acute	O
ischemic	O
stroke	O
is	O
unknown	O
.	O

Concurrent	O
administration	O
of	O
HEXALEN	B-Drug
and	O
antidepressants	B-Drug
of	O
the	O
MAO	O
inhibitor	O
class	O
may	O
cause	O
severe	O
orthostatic	O
hypotension.Cimetidine	B-Drug
,	O
an	O
inhibitor	O
of	O
microsomal	O
drug	B-Drug
metabolism	O
,	O
increased	O
altretamines	B-Drug
half-life	O
and	O
toxicity	O
in	O
a	O
rat	O
model	O
.	O

Data	O
from	O
a	O
randomized	O
trial	O
of	O
HEXALEN	B-Drug
and	O
cisplatin	B-Drug
plus	O
or	O
minus	O
pyridoxine	B-Drug
in	O
ovarian	O
cancer	O
indicated	O
that	O
pyridoxine	B-Drug
significantly	O
reduced	O
neurotoxicity	O
;	O
however	O
,	O
it	O
adversely	O
affected	O
response	O
duration	O
suggesting	O
that	O
pyridoxine	B-Drug
should	O
not	O
be	O
administered	O
with	O
HEXALEN	B-Drug
and/or	O
cisplatin.1	B-Drug
Careful	O
observation	O
is	O
required	O
when	O
amantadine	B-Drug
is	O
administered	O
concurrently	O
with	O
central	O
nervous	O
system	O
stimulants	O
.	O

Coadministration	O
of	O
thioridazine	B-Drug
has	O
been	O
reported	O
to	O
worsen	O
the	O
tremor	O
in	O
elderly	O
patients	O
with	O
Parkinsons	O
disease	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
if	O
other	O
phenothiazines	O
produce	O
a	O
similar	O
response	O
.	O

Special	O
consideration	O
should	O
be	O
given	O
to	O
the	O
administration	O
of	O
ETHYOL	B-Drug
in	O
patients	O
receiving	O
antihypertensive	B-Drug
medications	O
or	O
other	O
drugs	B-Drug
that	O
could	O
cause	O
or	O
potentiate	O
hypotension	O
.	O

When	O
amiloride	B-Drug
HCl	O
is	O
administered	O
concomitantly	O
with	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
,	O
the	O
risk	O
of	O
hyperkalemia	O
may	O
be	O
increased	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	B-Drug
.	O

Lithium	B-Drug
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Drug
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O

Read	O
circulars	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non-steroidal	O
anti-inflammatory	O
agent	O
can	O
reduce	O
the	O
diuretic	B-Drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-Drug
effects	O
of	O
loop	O
,	O
potassium-sparing	O
and	O
thiazide	O
diuretics	B-Drug
.	O

Therefore	O
,	O
when	O
MIDAMOR	B-Drug
and	O
non-steroidal	O
anti-inflammatory	O
agents	O
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Drug
is	O
obtained	O
.	O

Since	O
indomethacin	B-Drug
and	O
potassium-sparing	O
diuretics	B-Drug
,	O
including	O
MIDAMOR	B-Drug
,	O
may	O
each	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	B-Drug
levels	O
,	O
the	O
potential	O
effects	O
on	O
potassium	B-Drug
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Drug	B-Drug
Laboratory	O
Test	O
Interactions	O
:	O
Prolongation	O
of	O
the	O
template	O
bleeding	O
time	O
has	O
been	O
reported	O
during	O
continuous	O
intravenous	O
infusion	O
of	O
AMICAR	B-Drug
at	O
dosages	O
exceeding	O
24	O
g/day	O
.	O

Platelet	O
function	O
studies	O
in	O
these	O
patients	O
have	O
not	O
demonstrated	O
any	O
significant	O
platelet	O
dysfunction	O
.	O

However	O
,	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
at	O
high	O
concentrations	O
(	O
7.4	O
mMol/L	O
or	O
0.97	O
mg/mL	O
and	O
greater	O
)	O
EACA	B-Drug
inhibits	O
ADP	O
and	O
collagen-induced	O
platelet	O
aggregation	O
,	O
the	O
release	O
of	O
ATP	O
and	O
serotonin	O
,	O
and	O
the	O
binding	O
of	O
fibrinogen	B-Drug
to	O
the	O
platelets	O
in	O
a	O
concentration-response	O
manner	O
.	O

Following	O
a	O
10	O
g	O
bolus	O
of	O
AMICAR	B-Drug
,	O
transient	O
peak	O
plasma	O
concentrations	O
of	O
4.6	O
mMol/L	O
or	O
0.60	O
mg/mL	O
have	O
been	O
obtained	O
.	O

The	O
concentration	O
of	O
AMICAR	B-Drug
necessary	O
to	O
maintain	O
inhibition	O
of	O
fibrinolysis	O
is	O
0.99	O
mMol/L	O
or	O
0.13	O
mg/mL	O
.	O

Administration	O
of	O
a	O
5	O
g	O
bolus	O
followed	O
by	O
1	O
to	O
1.25	O
g/hr	O
should	O
achieve	O
and	O
sustain	O
plasma	O
levels	O
of	O
0.13	O
mg/mL	O
.	O

Thus	O
,	O
concentrations	O
which	O
have	O
been	O
obtained	O
in	O
vivo	O
clinically	O
in	O
patients	O
with	O
normal	O
renal	O
function	O
are	O
considerably	O
lower	O
than	O
the	O
in	O
vitro	O
concentrations	O
found	O
to	O
induce	O
abnormalities	O
in	O
platelet	O
function	O
tests	O
.	O

However	O
,	O
higher	O
plasma	O
concentrations	O
of	O
AMICAR	B-Drug
may	O
occur	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
.	O

Cytadren	B-Drug
accelerates	O
the	O
metabolism	O
of	O
dexamethasone	B-Drug
;	O
therefore	O
,	O
if	O
glucocorticoid	O
replacement	O
is	O
needed	O
,	O
hydrocortisone	B-Drug
should	O
be	O
prescribed	O
.	O

Aminoglutethimide	B-Drug
diminishes	O
the	O
effect	O
of	O
coumarin	O
and	O
warfarin	B-Drug
.	O

Renal	O
clearance	O
measurements	O
of	O
PAH	B-Drug
can	O
not	O
be	O
made	O
with	O
any	O
significant	O
accuracy	O
in	O
patients	O
receiving	O
sulfonamides	O
,	O
procaine	B-Drug
,	O
or	O
thiazolesulfone	B-Drug
.	O

These	O
compounds	O
interfere	O
with	O
chemical	O
color	O
development	O
essential	O
to	O
the	O
analytical	O
procedures	O
.	O

Probenecid	B-Drug
depresses	O
tubular	O
secretion	O
of	O
certain	O
weak	O
acids	O
such	O
as	O
PAH	B-Drug
.	O

Therefore	O
,	O
patients	O
receiving	O
probenecid	B-Drug
will	O
have	O
erroneously	O
low	O
ERPF	O
and	O
Tm	O
PAH	B-Drug
values	O
.	O

There	O
have	O
been	O
no	O
formal	O
studies	O
of	O
the	O
interaction	O
of	O
LEVULAN	B-Drug
KERASTICK	I-Drug
for	O
Topical	O
Solution	O
with	O
any	O
other	O
drugs	B-Drug
,	O
and	O
no	O
drug-specific	O
interactions	O
were	O
noted	O
during	O
any	O
of	O
the	O
controlled	O
clinical	O
trials	O
.	O

It	O
is	O
,	O
however	O
,	O
possible	O
that	O
concomitant	O
use	O
of	O
other	O
known	O
photosensitizing	O
agents	O
such	O
as	O
griseofulvin	B-Drug
,	O
thiazide	O
diuretics	B-Drug
,	O
sulfonylureas	O
,	O
phenothiazines	O
,	O
sulfonamides	O
and	O
tetracyclines	O
might	O
increase	O
the	O
photosensitivity	O
reaction	O
of	O
actinic	O
keratoses	O
treated	O
with	O
the	O
LEVULAN	B-Drug
KERASTICK	I-Drug
for	O
Topical	O
Solution	O
.	O

Aminosalicylic	B-Drug
acid	I-Drug
may	O
decrease	O
the	O
amount	O
of	O
digoxin	B-Drug
(	O
Lanoxin	B-Drug
,	O
Lanoxicaps	B-Drug
)	O
that	O
gets	O
absorbed	O
into	O
your	O
body	O
.	O

In	O
the	O
case	O
that	O
you	O
are	O
taking	O
digoxin	B-Drug
while	O
taking	O
aminosalicylic	B-Drug
acid	I-Drug
,	O
higher	O
doses	O
of	O
digoxin	B-Drug
may	O
be	O
needed	O
.	O

Aminosalicylic	B-Drug
acid	I-Drug
may	O
also	O
decrease	O
the	O
absorption	O
of	O
vitamin	B-Drug
B12	I-Drug
,	O
which	O
can	O
lead	B-Drug
to	O
a	O
deficiency	O
.	O

Therefore	O
you	O
may	O
need	O
to	O
take	O
a	O
vitamin	B-Drug
B12	I-Drug
supplement	O
while	O
taking	O
aminosalicylic	B-Drug
acid	I-Drug
.	O

Amiodarone	B-Drug
is	O
metabolized	O
to	O
desethylamiodarone	B-Drug
by	O
the	O
cytochrome	O
P450	O
(	O
CYP450	O
)	O
enzyme	O
group	O
,	O
specifically	O
cytochromes	O
P450	O
3A4	O
(	O
CYP3A4	B-Drug
)	O
and	O
CYP2C8	O
.	O

The	O
CYP3A4	B-Drug
isoenzyme	O
is	O
present	O
in	O
both	O
the	O
liver	O
and	O
intestines	O
.	O

Amiodarone	B-Drug
is	O
also	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
CYP3A4	B-Drug
.	O

Therefore	O
,	O
amiodarone	B-Drug
has	O
the	O
potential	O
for	O
interactions	O
with	O
drugs	B-Drug
or	O
substances	O
that	O
may	O
be	O
substrates	O
,	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	B-Drug
.	O

While	O
only	O
a	O
limited	O
number	O
of	O
in	O
vivo	O
drug-drug	O
interactions	O
with	O
amiodarone	B-Drug
have	O
been	O
reported	O
,	O
chiefly	O
with	O
the	O
oral	O
formulation	O
,	O
the	O
potential	O
for	O
other	O
interactions	O
should	O
be	O
anticipated	O
.	O

This	O
is	O
especially	O
important	O
for	O
drugs	B-Drug
associated	O
with	O
serious	O
toxicity	O
,	O
such	O
as	O
other	O
antiarrhythmics	B-Drug
.	O

If	O
such	O
drugs	B-Drug
are	O
needed	O
,	O
their	O
dose	O
should	O
be	O
reassessed	O
and	O
,	O
where	O
appropriate	O
,	O
plasma	O
concentration	O
measured	O
.	O

In	O
view	O
of	O
the	O
long	O
and	O
variable	O
half-life	O
of	O
amiodarone	B-Drug
,	O
potential	O
for	O
drug	B-Drug
interactions	O
exists	O
not	O
only	O
with	O
concomitant	O
medication	O
but	O
also	O
with	O
drugs	B-Drug
administered	O
after	O
discontinuation	O
of	O
amiodarone	B-Drug
.	O

Since	O
amiodarone	B-Drug
is	O
a	O
substrate	O
for	O
CYP3A4	B-Drug
and	O
CYP2C8	O
,	O
drugs/substances	B-Drug
that	O
inhibit	O
these	O
isoenzymes	O
may	O
decrease	O
the	O
metabolism	O
and	O
increase	O
serum	O
concentration	O
of	O
amiodarone	B-Drug
.	O

Reported	O
examples	O
include	O
the	O
following	O
:	O
Protease	O
Inhibitors	O
:	O
Protease	O
inhibitors	O
are	O
known	O
to	O
inhibit	O
CYP3A4	B-Drug
to	O
varying	O
degrees	O
.	O

A	O
case	O
report	O
of	O
one	O
patient	O
taking	O
amiodarone	B-Drug
200	O
mg	O
and	O
indinavir	B-Drug
800	O
mg	O
three	O
times	O
a	O
day	O
resulted	O
in	O
increases	O
in	O
amiodarone	B-Drug
concentrations	O
from	O
0.9	O
mg/L	O
to	O
1.3	O
mg/L	O
.	O

DEA	O
concentrations	O
were	O
not	O
affected	O
.	O

There	O
was	O
no	O
evidence	O
of	O
toxicity	O
.	O

Monitoring	O
for	O
amiodarone	B-Drug
toxicity	O
and	O
serial	O
measurement	O
of	O
amiodarone	B-Drug
serum	O
concentration	O
during	O
concomitant	O
protease	O
inhibitor	O
therapy	O
should	O
be	O
considered	O
.	O

Histamine	B-Drug
H2	O
antagonists	O
:	O
Cimetidine	B-Drug
inhibits	O
CYP3A4	B-Drug
and	O
can	O
increase	O
serum	O
amiodarone	B-Drug
levels	O
.	O

Other	O
substances	O
:	O
Grapefruit	O
juice	O
given	O
to	O
healthy	O
volunteers	O
increased	O
amiodarone	B-Drug
AUC	O
by	O
50	O
%	O
and	O
Cmax	O
by	O
84	O
%	O
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
amiodarone	B-Drug
.	O

Grapefruit	O
juice	O
should	O
not	O
be	O
taken	O
during	O
treatment	O
with	O
oral	O
amiodarone	B-Drug
.	O

This	O
information	O
should	O
be	O
considered	O
when	O
changing	O
from	O
intravenous	O
amiodarone	B-Drug
to	O
oral	O
amiodarone	B-Drug
.	O

Amiodarone	B-Drug
may	O
suppress	O
certain	O
CYP450	O
enzymes	O
,	O
including	O
CYP1A2	B-Drug
,	O
CYP2C9	B-Drug
,	O
CYP2D6	B-Drug
,	O
and	O
CYP3A4	B-Drug
.	O

This	O
inhibition	O
can	O
result	O
in	O
unexpectedly	O
high	O
plasma	O
levels	O
of	O
other	O
drugs	B-Drug
which	O
are	O
metabolized	O
by	O
those	O
CYP450	O
enzymes	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Immunosuppressives	B-Drug
:	O
Cyclosporine	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
administered	O
in	O
combination	O
with	O
oral	O
amiodarone	B-Drug
has	O
been	O
reported	O
to	O
produce	O
persistently	O
elevated	O
plasma	O
concentrations	O
of	O
cyclosporine	B-Drug
resulting	O
in	O
elevated	O
creatinine	O
,	O
despite	O
reduction	O
in	O
dose	O
of	O
cyclosporine	B-Drug
.	O

HMG-CoA	B-Drug
Reductase	I-Drug
Inhibitors	I-Drug
:	O
Simvastatin	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-Drug
has	O
been	O
associated	O
with	O
reports	O
of	O
myopathy/rhabdomyolysis	O
.	O

Cardiovasculars	O
:	O
Cardiac	B-Drug
glycosides	I-Drug
:	O
In	O
patients	O
receiving	O
digoxin	B-Drug
therapy	O
,	O
administration	O
of	O
oral	O
amiodarone	B-Drug
regularly	O
results	O
in	O
an	O
increase	O
in	O
serum	O
digoxin	B-Drug
concentration	O
that	O
may	O
reach	O
toxic	O
levels	O
with	O
resultant	O
clinical	O
toxicity	O
.	O

Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
digoxin	B-Drug
increases	O
the	O
serum	O
digoxin	B-Drug
concentration	O
by	O
70	O
%	O
after	O
one	O
day	O
.	O

On	O
administration	O
of	O
oral	O
amiodarone	B-Drug
,	O
the	O
need	O
for	O
digitalis	B-Drug
therapy	O
should	O
be	O
reviewed	O
and	O
the	O
dose	O
reduced	O
by	O
approximately	O
50	O
%	O
or	O
discontinued	O
.	O

If	O
digitalis	B-Drug
treatment	O
is	O
continued	O
,	O
serum	O
levels	O
should	O
be	O
closely	O
monitored	O
and	O
patients	O
observed	O
for	O
clinical	O
evidence	O
of	O
toxicity	O
.	O

These	O
precautions	O
probably	O
should	O
apply	O
to	O
digitoxin	B-Drug
administration	O
as	O
well	O
.	O

Antiarrhythmics	B-Drug
:	O
Other	O
antiarrhythmic	B-Drug
drugs	B-Drug
,	O
such	O
as	O
quinidine	B-Drug
,	O
procainamide	B-Drug
,	O
disopyramide	B-Drug
,	O
and	O
phenytoin	B-Drug
,	O
have	O
been	O
used	O
concurrently	O
with	O
amiodarone	B-Drug
.	O

There	O
have	O
been	O
case	O
reports	O
of	O
increased	O
steady-state	O
levels	O
of	O
quinidine	B-Drug
,	O
procainamide	B-Drug
,	O
and	O
phenytoin	B-Drug
during	O
concomitant	O
therapy	O
with	O
amiodarone	B-Drug
.	O

Phenytoin	B-Drug
decreases	O
serum	O
amiodarone	B-Drug
levels	O
.	O

Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
quinidine	B-Drug
increases	O
quinidine	B-Drug
serum	O
concentration	O
by	O
33	O
%	O
after	O
two	O
days	O
.	O

Amiodarone	B-Drug
taken	O
concomitantly	O
with	O
procainamide	B-Drug
for	O
less	O
than	O
seven	O
days	O
increases	O
plasma	O
concentrations	O
of	O
procainamide	B-Drug
and	O
n-acetyl	O
procainamide	B-Drug
by	O
55	O
%	O
and	O
33	O
%	O
,	O
respectively	O
.	O

Quinidine	B-Drug
and	O
procainamide	B-Drug
doses	O
should	O
be	O
reduced	O
by	O
one-third	O
when	O
either	O
is	O
administered	O
with	O
amiodarone	B-Drug
.	O

Plasma	O
levels	O
of	O
flecainide	B-Drug
have	O
been	O
reported	O
to	O
increase	O
in	O
the	O
presence	O
of	O
oral	O
amiodarone	B-Drug
;	O
because	O
of	O
this	O
,	O
the	O
dosage	O
of	O
flecainide	B-Drug
should	O
be	O
adjusted	O
when	O
these	O
drugs	B-Drug
are	O
administered	O
concomitantly	O
.	O

In	O
general	O
,	O
any	O
added	O
antiarrhythmic	B-Drug
drug	I-Drug
should	O
be	O
initiated	O
at	O
a	O
lower	O
than	O
usual	O
dose	O
with	O
careful	O
monitoring	O
.	O

Combination	O
of	O
amiodarone	B-Drug
with	O
other	O
antiarrhythmic	B-Drug
therapy	O
should	O
be	O
reserved	O
for	O
patients	O
with	O
life-threatening	O
ventricular	O
arrhythmias	O
who	O
are	O
incompletely	O
responsive	O
to	O
a	O
single	O
agent	O
or	O
incompletely	O
responsive	O
to	O
amiodarone	B-Drug
.	O

During	O
transfer	O
to	O
oral	O
amiodarone	B-Drug
,	O
the	O
dose	O
levels	O
of	O
previously	O
administered	O
agents	O
should	O
be	O
reduced	O
by	O
30	O
to	O
50	O
%	O
several	O
days	O
after	O
the	O
addition	O
of	O
oral	O
amiodarone	B-Drug
.	O

The	O
continued	O
need	O
for	O
the	O
other	O
antiarrhythmic	B-Drug
agent	O
should	O
be	O
reviewed	O
after	O
the	O
effects	O
of	O
amiodarone	B-Drug
have	O
been	O
established	O
,	O
and	O
discontinuation	O
ordinarily	O
should	O
be	O
attempted	O
.	O

If	O
the	O
treatment	O
is	O
continued	O
,	O
these	O
patients	O
should	O
be	O
particularly	O
carefully	O
monitored	O
for	O
adverse	O
effects	O
,	O
especially	O
conduction	O
disturbances	O
and	O
exacerbation	O
of	O
tachyarrhythmias	O
,	O
as	O
amiodarone	B-Drug
is	O
continued	O
.	O

In	O
amiodarone-treated	B-Drug
patients	O
who	O
require	O
additional	O
antiarrhythmic	B-Drug
therapy	O
,	O
the	O
initial	O
dose	O
of	O
such	O
agents	O
should	O
be	O
approximately	O
half	O
of	O
the	O
usual	O
recommended	O
dose	O
.	O

Antihypertensives	B-Drug
:	O
Amiodarone	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
-receptor	B-Drug
blocking	O
agents	O
(	O
e.g.	O
,	O
propranolol	B-Drug
,	O
a	O
CYP3A4	B-Drug
inhibitor	O
)	O
or	O
calcium	B-Drug
channel	I-Drug
antagonists	O
(	O
e.g.	O
,	O
verapamil	B-Drug
,	O
a	O
CYP3A4	B-Drug
substrate	O
,	O
and	O
diltiazem	B-Drug
,	O
a	O
CYP3A4	B-Drug
inhibitor	O
)	O
because	O
of	O
the	O
possible	O
potentiation	O
of	O
bradycardia	O
,	O
sinus	O
arrest	O
,	O
and	O
AV	O
block	O
;	O
if	O
necessary	O
,	O
amiodarone	B-Drug
can	O
continue	O
to	O
be	O
used	O
after	O
insertion	O
of	O
a	O
pacemaker	O
in	O
patients	O
with	O
severe	O
bradycardia	O
or	O
sinus	O
arrest	O
.	O

Anticoagulants	B-Drug
:	O
Potentiation	O
of	O
warfarin-type	B-Drug
(	O
CYP2C9	B-Drug
and	O
CYP3A4	B-Drug
substrate	O
)	O
anticoagulant	B-Drug
response	O
is	O
almost	O
always	O
seen	O
in	O
patients	O
receiving	O
amiodarone	B-Drug
and	O
can	O
result	O
in	O
serious	O
or	O
fatal	O
bleeding	O
.	O

Since	O
the	O
concomitant	O
administration	O
of	O
warfarin	B-Drug
with	O
amiodarone	B-Drug
increases	O
the	O
prothrombin	O
time	O
by	O
100	O
%	O
after	O
3	O
to	O
4	O
days	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	B-Drug
should	O
be	O
reduced	O
by	O
one-third	O
to	O
one-half	O
,	O
and	O
prothrombin	O
times	O
should	O
be	O
monitored	O
closely	O
.	O

Some	O
drugs/substances	B-Drug
are	O
known	O
to	O
accelerate	O
the	O
metabolism	O
of	O
amiodarone	B-Drug
by	O
stimulating	O
the	O
synthesis	O
of	O
CYP3A4	B-Drug
(	O
enzyme	O
induction	O
)	O
.	O

This	O
may	O
lead	B-Drug
to	O
low	O
amiodarone	B-Drug
serum	O
levels	O
and	O
potential	O
decrease	O
in	O
efficacy	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Antibiotics	B-Drug
:	O
Rifampin	B-Drug
is	O
a	O
potent	O
inducer	O
of	O
CYP3A4	B-Drug
.	O

Administration	O
of	O
rifampin	B-Drug
concomitantly	O
with	O
oral	O
amiodarone	B-Drug
has	O
been	O
shown	O
to	O
result	O
in	O
decreases	O
in	O
serum	O
concentrations	O
of	O
amiodarone	B-Drug
and	O
desethylamiodarone	B-Drug
.	O

Other	O
substances	O
,	O
including	O
herbal	O
preparations	O
:	O
St.	O
John	O
s	O
Wort	O
(	O
Hypericum	O
perforatum	O
)	O
induces	O
CYP3A4	B-Drug
.	O

Since	O
amiodarone	B-Drug
is	O
a	O
substrate	O
for	O
CYP3A4	B-Drug
,	O
there	O
is	O
the	O
potential	O
that	O
the	O
use	O
of	O
St.	O
John	O
s	O
Wort	O
in	O
patients	O
receiving	O
amiodarone	B-Drug
could	O
result	O
in	O
reduced	O
amiodarone	B-Drug
levels	O
.	O

Other	O
reported	O
interactions	O
with	O
amiodarone	B-Drug
:	O
Fentanyl	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-Drug
may	O
cause	O
hypotension	O
,	O
bradycardia	O
,	O
and	O
decreased	O
cardiac	O
output	O
.	O

Sinus	O
bradycardia	O
has	O
been	O
reported	O
with	O
oral	O
amiodarone	B-Drug
in	O
combination	O
with	O
lidocaine	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
given	O
for	O
local	O
anesthesia	B-Drug
.	O

Seizure	O
,	O
associated	O
with	O
increased	O
lidocaine	B-Drug
concentrations	O
,	O
has	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
intravenous	O
amiodarone	B-Drug
.	O

Dextromethorphan	B-Drug
is	O
a	O
substrate	O
for	O
both	O
CYP2D6	B-Drug
and	O
CYP3A4	B-Drug
.	O

Amiodarone	B-Drug
inhibits	O
CYP2D6	B-Drug
.	O

Cholestyramine	B-Drug
increases	O
enterohepatic	O
elimination	O
of	O
amiodarone	B-Drug
and	O
may	O
reduce	O
its	O
serum	O
levels	O
and	O
t1/2	B-Drug
.	O

Disopyramide	B-Drug
increases	O
QT	O
prolongation	O
which	O
could	O
cause	O
arrhythmia	O
.	O

Fluoroquinolones	B-Drug
,	O
macrolide	B-Drug
antibiotics	I-Drug
,	O
and	O
azoles	O
are	O
known	O
to	O
cause	O
QTc	O
prolongation	O
.	O

There	O
have	O
been	O
reports	O
of	O
QTc	O
prolongation	O
,	O
with	O
or	O
without	O
TdP	O
,	O
in	O
patients	O
taking	O
amiodarone	B-Drug
when	O
fluoroquinolones	B-Drug
,	O
macrolide	B-Drug
antibiotics	I-Drug
,	O
or	O
azoles	O
were	O
administered	O
concomitantly	O
.	O

Hemodynamic	O
and	O
electrophysiologic	O
interactions	O
have	O
also	O
been	O
observed	O
after	O
concomitant	O
administration	O
with	O
propranolol	B-Drug
,	O
diltiazem	B-Drug
,	O
and	O
verapamil	B-Drug
.	O

Volatile	O
Anesthetic	B-Drug
Agents	O
:	O
.	O

In	O
addition	O
to	O
the	O
interactions	O
noted	O
above	O
,	O
chronic	O
(	O
2	O
weeks	O
)	O
oral	O
Cordarone	B-Drug
administration	O
impairs	O
metabolism	O
of	O
phenytoin	B-Drug
,	O
dextromethorphan	B-Drug
,	O
and	O
methotrexate	B-Drug
.	O

Electrolyte	O
Disturbances	O
Patients	O
with	O
hypokalemia	O
or	O
hypomagnesemia	O
should	O
have	O
the	O
condition	O
corrected	O
whenever	O
possible	O
before	O
being	O
treated	O
with	O
Cordarone	B-Drug
I.V.	I-Drug
,	O
as	O
these	O
disorders	O
can	O
exaggerate	O
the	O
degree	O
of	O
QTc	O
prolongation	O
and	O
increase	O
the	O
potential	O
for	O
TdP	O
.	I-Drug
Special	O
attention	O
should	O
be	O
given	O
to	O
electrolyte	O
and	O
acid-base	O
balance	O
in	O
patients	O
experiencing	O
severe	O
or	O
prolonged	O
diarrhea	O
or	O
in	O
patients	O
receiving	O
concomitant	O
diuretics	B-Drug
.	O

Drugs	B-Drug
Metabolized	O
by	O
P450	O
2D6	O
-	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	B-Drug
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	B-Drug
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7-10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	B-Drug
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8-fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-Drug
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	O
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	B-Drug
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	B-Drug
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B-Drug
,	O
phenothiazines	O
,	O
and	O
the	O
Type	O
1C	O
antiarrhythmics	B-Drug
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
sertraline	B-Drug
,	O
and	O
paroxetine	B-Drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI-TCA	O
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	O
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
TCAs	O
with	O
any	O
of	O
the	O
SSRIs	O
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
,	O
given	O
the	O
long	O
half-life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	O
antidepressants	B-Drug
with	O
drugs	B-Drug
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	O
antidepressant	O
or	O
the	O
other	O
drug	B-Drug
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	B-Drug
is	O
withdrawn	O
from	O
co-therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-Drug
antidepressant	I-Drug
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	O
plasma	O
levels	O
whenever	O
a	O
TCA	O
is	O
going	O
to	O
be	O
coadministered	O
with	O
another	O
drug	B-Drug
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Monoamine	B-Drug
Oxidase	I-Drug
Inhibitors	I-Drug
:	O
Guanethidine	B-Drug
or	O
similarly	O
acting	O
compounds	O
;	O
thyroid	B-Drug
medication	O
;	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
and	O
other	O
CNS	B-Drug
depressants	I-Drug
;	O
and	O
disulfiram	B-Drug
When	O
amitriptyline	B-Drug
HCl	I-Drug
is	O
given	O
with	O
anticholinergic	B-Drug
agents	O
or	O
sympathomimetic	B-Drug
drugs	B-Drug
,	O
including	O
epinephrine	B-Drug
combined	O
with	O
local	O
anesthetics	B-Drug
,	O
close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosages	O
are	O
required	O
.	O

Hyperpyrexia	O
has	O
been	O
reported	O
when	O
amitriptyline	B-Drug
HCl	I-Drug
is	O
administered	O
with	O
anticholinergic	B-Drug
agents	O
or	O
with	O
neuroleptic	B-Drug
drugs	B-Drug
,	O
particularly	O
during	O
hot	O
weather	O
.	O

Paralytic	O
ileus	O
may	O
occur	O
in	O
patients	O
taking	O
tricyclic	B-Drug
antidepressants	I-Drug
in	O
combination	O
with	O
anticholinergic-type	B-Drug
drugs	B-Drug
.	O

Cimetidine	B-Drug
is	O
reported	O
to	O
reduce	O
hepatic	O
metabolism	O
of	O
certain	O
tricyclic	B-Drug
antidepressants	I-Drug
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
steady-state	O
concentrations	O
of	O
these	O
drugs	B-Drug
.	O

Clinically	O
significant	O
effects	O
have	O
been	O
reported	O
with	O
the	O
tricyclic	B-Drug
antidepressants	I-Drug
when	O
used	O
concomitantly	O
with	O
cimetidine	B-Drug
.	O

Increases	O
in	O
plasma	O
levels	O
of	O
tricyclic	B-Drug
antidepressants	I-Drug
,	O
and	O
in	O
the	O
frequency	O
and	O
severity	O
of	O
side	O
effects	O
,	O
particularly	O
anticholinergic	B-Drug
,	O
have	O
been	O
reported	O
when	O
cimetidine	B-Drug
was	O
added	O
to	O
the	O
drug	B-Drug
regimen	O
.	O

Discontinuation	O
of	O
cimetidine	B-Drug
in	O
well-controlled	O
patients	O
receiving	O
tricyclic	B-Drug
antidepressants	I-Drug
and	O
cimetidine	B-Drug
may	O
decrease	O
the	O
plasma	O
levels	O
and	O
efficacy	O
of	O
the	O
antidepressants	B-Drug
.	O

Caution	O
is	O
advised	O
if	O
patients	O
receive	O
large	O
doses	O
of	O
ethchlorvynol	B-Drug
concurrently	O
.	O

Transient	O
delirium	O
has	O
been	O
reported	O
in	O
patients	O
who	O
were	O
treated	O
with	O
one	O
gram	O
of	O
ethchlorvynol	B-Drug
and	O
75	O
-	O
150	O
mg	O
of	O
amitriptyline	B-Drug
HCl	I-Drug
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	B-Drug
may	O
interact	O
with	O
amphotericin	B-Drug
B	I-Drug
:	O
Antineoplastic	O
agents	O
:	O
may	O
enhance	O
the	O
potential	O
for	O
renal	O
toxicity	O
,	O
bronchospasm	O
and	O
hypotension	O
.	O

Antineoplastic	O
agents	O
(	O
e.	O
g.	O
,	O
nitrogen	B-Drug
mustard	I-Drug
,	O
etc	O
.	O

)	O
should	O
be	O
given	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O

Corticosteroids	O
and	O
Corticotropin	B-Drug
(	O
ACTH	B-Drug
)	O
:	O
may	O
potentiate	O
amphotericin	B-Drug
B-	I-Drug
induced	O
hypokalemia	O
which	O
may	O
predispose	O
the	O
patient	O
to	O
cardiac	O
dysfunction	O
.	O

Avoid	O
concomitant	O
use	O
unless	O
necessary	O
to	O
control	O
side	O
effects	O
of	O
amphotericin	B-Drug
B	I-Drug
.	O

If	O
used	O
concomitantly	O
,	O
closely	O
monitor	O
serum	O
electrolytes	O
and	O
cardiac	O
function	O
.	O

Digitalis	B-Drug
glycosides	O
:	O
amphotericin	B-Drug
B-induced	I-Drug
hypokalemia	O
may	O
potentiate	O
digitalis	B-Drug
toxicity	O
.	O

Serum	O
potassium	B-Drug
levels	O
and	O
cardiac	O
function	O
should	O
be	O
closely	O
monitored	O
and	O
any	O
deficit	O
promptly	O
corrected	O
.	O

Flucytosine	B-Drug
:	O
while	O
a	O
synergistic	O
relationship	O
with	O
amphotericin	B-Drug
B	I-Drug
has	O
been	O
reported	O
,	O
concomitant	O
use	O
may	O
increase	O
the	O
toxicity	O
of	O
flucytosine	B-Drug
by	O
possibly	O
increasing	O
its	O
cellular	O
uptake	O
and/or	O
impairing	O
its	O
renal	O
excretion	O
.	O

Imidazoles	O
(	O
e.	O
g.	O
,	O
ketoconazole	B-Drug
,	O
miconazole	B-Drug
,	O
clotrimazole	B-Drug
,	O
fluconazole	B-Drug
,	O
etc	O
.	O

)	O
:	O
in	O
vitro	O
and	O
animal	O
studies	O
with	O
the	O
combination	O
of	O
amphotericin	B-Drug
B	I-Drug
and	O
imidazoles	O
suggest	O
that	O
imidazoles	O
may	O
induce	O
fungal	O
resistance	O
to	O
amphotericin	B-Drug
B	I-Drug
.	O

Combination	O
therapy	O
should	O
be	O
administered	O
with	O
caution	O
,	O
especially	O
in	O
immunocompromised	O
patients	O
.	O

Other	O
nephrotoxic	O
medications	O
:	O
agents	O
such	O
as	O
aminoglycosides	O
,	O
cyclosporine	B-Drug
,	O
and	O
pentamidine	B-Drug
may	O
enhance	O
the	O
potential	O
for	O
drug-induced	O
renal	O
toxicity	O
,	O
and	O
should	O
be	O
used	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O

Intensive	O
monitoring	O
of	O
renal	O
function	O
is	O
recommended	O
in	O
patients	O
requiring	O
any	O
combination	O
of	O
nephrotoxic	O
medications	O
.	O

Skeletal	O
muscle	O
relaxants	O
:	O
amphotericin	B-Drug
B-induced	I-Drug
hypokalemia	O
may	O
enhance	O
the	O
curariform	O
effect	O
of	O
skeletal	O
muscle	O
relaxants	O
(	O
e.g.	O
,	O
tubocurarine	B-Drug
)	O
.	O

Serum	O
potassium	B-Drug
levels	O
should	O
be	O
monitored	O
and	O
deficiencies	O
corrected	O
.	O

Leukocyte	B-Drug
transfusions	I-Drug
:	O
acute	O
pulmonary	O
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
intravenous	O
amphotericin	B-Drug
B	I-Drug
and	O
leukocyte	B-Drug
transfusions	I-Drug
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	B-Drug
may	O
interact	O
with	O
ampicillin	B-Drug
.	O

Allopurinol	B-Drug
:	O
Increased	O
possibility	O
of	O
skin	O
rash	O
,	O
particularly	O
in	O
hyperuricemic	O
patients	O
may	O
occur	O
.	O

Bacteriostatic	O
Antibiotics	B-Drug
:	O
Chloramphenicol	B-Drug
,	O
erythromycins	B-Drug
,	O
sulfonamides	O
,	O
or	O
tetracyclines	O
may	O
interfere	O
with	O
the	O
bactericidal	O
effect	O
of	O
penicillins	B-Drug
.	O

This	O
has	O
been	O
demonstrated	O
in	O
view	O
,	O
however	O
,	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
well	O
documented	O
.	O

Oral	O
Contraceptives	O
:	O
May	O
be	O
less	O
effective	O
and	O
increased	O
breakthrough	O
bleeding	O
may	O
occur	O
.	O

Probenecid	B-Drug
:	O
May	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
ampicillin	B-Drug
resulting	O
in	O
increased	O
blood	O
levels	O
and/or	O
ampicillin	B-Drug
toxicity	O
.	O

Drug/Laboratory	O
Test	O
Interaction	O
After	O
treatment	O
with	O
ampicillin	B-Drug
,	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	B-Drug
sulfate	I-Drug
tests	O
(	O
Benedicts	O
solution	O
,	O
Fehlings	O
solution	O
,	O
or	O
Clinitest	O
tablets	O
)	O
but	O
not	O
with	O
enzyme	O
based	O
tests	O
such	O
as	O
Clinistix	O
and	O
Glucose	B-Drug
Enzymatic	O
Test	O
Strip	O
USP	O
.	O

Amprenavir	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
by	O
the	O
cytochrome	O
P450	O
enzyme	O
system	O
.	O

Amprenavir	B-Drug
inhibits	O
CYP3A4	B-Drug
.	O

Caution	O
should	O
be	O
used	O
when	O
coadministering	O
medications	O
that	O
are	O
substrates	O
,	O
inhibitors	O
,	O
or	O
inducers	O
of	O
CYP3A4	B-Drug
,	O
or	O
potentially	O
toxic	O
medications	O
that	O
are	O
metabolized	O
by	O
CYP3A4	B-Drug
.	O

Amprenavir	B-Drug
does	O
not	O
inhibit	O
CYP2D6	B-Drug
,	O
CYP1A2	B-Drug
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
CYP2E1	O
,	O
or	O
uridine	O
glucuronosyltransferase	O
(	O
UDPGT	O
)	O
.	O

HIV	O
Protease	O
Inhibitors	O
:	O
The	O
effect	O
of	O
amprenavir	B-Drug
on	O
total	O
drug	B-Drug
concentrations	O
of	O
other	O
HIV	O
protease	O
inhibitors	O
in	O
subjects	O
receiving	O
both	O
agents	O
was	O
evaluated	O
using	O
comparisons	O
to	O
historical	O
data	O
.	O

Indinavir	B-Drug
steady-state	O
Cmax	O
,	O
A.C.	O
and	O
Cmin	O
were	O
decreased	O
by	O
22	O
%	O
,	O
38	O
%	O
,	O
and	O
27	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	B-Drug
.	O

Similar	O
decreases	O
in	O
Cmax	O
and	O
AUC	O
were	O
seen	O
after	O
the	O
first	O
dose	O
.	O

Saquinavir	B-Drug
steady-state	O
Cmax	O
,	O
A.C.	O
and	O
Cmin	O
were	O
increased	O
21	O
%	O
,	O
decreased	O
19	O
%	O
,	O
and	O
decreased	O
48	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	B-Drug
.	O

Nelfinavir	B-Drug
steady-state	O
Cmax	O
,	O
A.C.	O
and	O
Cmin	O
were	O
increased	O
by	O
12	O
%	O
,	O
15	O
%	O
,	O
and	O
14	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	B-Drug
.	O

Methadone	B-Drug
:	O
Coadministration	O
of	O
amprenavir	B-Drug
and	O
methadone	B-Drug
can	O
decrease	O
plasma	O
levels	O
of	O
methadone	B-Drug
.	O

Coadministration	O
of	O
amprenavir	B-Drug
and	O
methadone	B-Drug
as	O
compared	O
to	O
a	O
non-matched	O
historicalcontrol	O
group	O
resulted	O
in	O
a	O
30	O
%	O
,	O
27	O
%	O
,	O
and	O
25	O
%	O
decrease	O
in	O
serum	O
amprenavir	B-Drug
AUC	O
,	O
Cmax	O
,	O
andCmin	O
,	O
respectively	O
.	O

Amprenavir	B-Drug
is	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
C.P.A	O
.	O

metabolism	O
and	O
therefore	O
should	O
not	O
be	O
administered	O
concurrently	O
with	O
medications	O
with	O
narrow	O
therapeutic	O
windows	O
that	O
are	O
substrates	O
of	O
CYP3A4	B-Drug
.	O

There	O
are	O
other	O
agents	O
that	O
may	O
result	O
in	O
serious	O
and/or	O
life-threatening	O
drug	B-Drug
interactions	O
.	O

Laboratory	O
Tests	O
:	O
The	O
combination	O
of	O
Amprenavir	B-Drug
and	O
low-dose	O
ritonavir	B-Drug
has	O
been	O
associated	O
with	O
elevations	O
of	O
cholesterol	O
and	O
triglycerides	O
,	O
SGOT	O
(	O
AST	O
)	O
,	O
and	O
SGPT	O
(	O
ALT	O
)	O
in	O
some	O
patients	O
.	O

Appropriate	O
laboratory	O
testing	O
should	O
be	O
considered	O
prior	O
to	O
initiating	O
combination	O
therapy	O
with	O
Amprenavir	B-Drug
and	O
ritonavir	B-Drug
and	O
at	O
periodic	O
intervals	O
or	O
if	O
any	O
clinical	O
signs	O
or	O
symptoms	O
of	O
hyperlipidemia	O
or	O
elevated	O
liver	O
function	O
tests	O
occur	O
during	O
therapy	O
.	O

For	O
comprehensive	O
information	O
concerning	O
laboratory	O
test	O
alterations	O
associated	O
with	O
ritonavir	B-Drug
,	O
physicians	O
should	O
refer	O
to	O
the	O
complete	O
prescribing	O
information	O
for	O
NORVIR	B-Drug
(	O
ritonavir	B-Drug
)	O
.	O

Taking	O
amyl	B-Drug
nitrite	I-Drug
after	O
drinking	O
alcohol	B-Drug
may	O
worsen	O
side	O
effects	O
and	O
may	O
cause	O
severe	O
hypotension	O
and	O
cardiovascular	O
collapse	O
.	O

Limited	O
PK	O
and/or	O
PD	O
studies	O
investigating	O
possible	O
interactions	O
between	O
anagrelide	B-Drug
and	O
other	O
medicinal	O
products	O
have	O
been	O
conducted	O
.	O

In	O
vivo	O
interaction	O
studies	O
in	O
humans	O
have	O
demonstrated	O
that	O
digoxin	B-Drug
and	O
warfarin	B-Drug
do	O
not	O
affect	O
the	O
PK	O
properties	O
of	O
anagrelide	B-Drug
,	O
nor	O
does	O
anagrelide	B-Drug
affect	O
the	O
PK	O
properties	O
of	O
digoxin	B-Drug
or	O
warfarin	B-Drug
.	O

Although	O
additional	O
drug	B-Drug
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
,	O
the	O
most	O
common	O
medications	O
used	O
concomitantly	O
with	O
anagrelide	B-Drug
in	O
clinical	O
trials	O
were	O
aspirin	B-Drug
,	O
acetaminophen	B-Drug
,	O
furosemide	B-Drug
,	O
iron	B-Drug
,	O
ranitidine	B-Drug
,	O
hydroxyurea	B-Drug
,	O
and	O
allopurinol	B-Drug
.	O

There	O
is	O
no	O
clinical	O
evidence	O
to	O
suggest	O
that	O
anagrelide	B-Drug
interacts	O
with	O
any	O
of	O
these	O
compounds	O
.	O

An	O
in	O
vivo	O
interaction	O
study	O
in	O
humans	O
demonstrated	O
that	O
a	O
single	O
1mg	O
dose	O
of	O
anagrelide	B-Drug
administered	O
concomitantly	O
with	O
a	O
single	O
900	O
mg	O
dose	O
of	O
aspirin	B-Drug
was	O
generally	O
well	O
tolerated	O
.	O

There	O
was	O
no	O
effect	O
on	O
bleeding	O
time	O
,	O
PT	O
or	O
aPTT	O
.	O

No	O
clinically	O
relevant	O
pharmacokinetic	O
interactions	O
between	O
anagrelide	B-Drug
and	O
acetylsalicylic	B-Drug
acid	I-Drug
were	O
observed	O
.	O

In	O
that	O
same	O
study	O
,	O
aspirin	B-Drug
alone	O
produced	O
a	O
marked	O
inhibition	O
in	O
platelet	O
aggregation	O
ex	O
vivo	O
.	O

Anagrelide	B-Drug
alone	O
had	O
no	O
effect	O
on	O
platelet	O
aggregation	O
,	O
but	O
did	O
slightly	O
enhance	O
the	O
inhibition	O
of	O
platelet	O
aggregation	O
by	O
aspirin	B-Drug
.	O

Anagrelide	B-Drug
is	O
metabolized	O
at	O
least	O
in	O
part	O
by	O
CYP1A2	B-Drug
.	O

It	O
is	O
known	O
that	O
CYP1A2	B-Drug
is	O
inhibited	O
by	O
several	O
medicinal	O
products	O
,	O
including	O
fluvoxamine	B-Drug
,	O
and	O
such	O
medicinal	O
products	O
could	O
theoretically	O
adversely	O
influence	O
the	O
clearance	O
of	O
anagrelide	B-Drug
.	O

Anagrelide	B-Drug
demonstrates	O
some	O
limited	O
inhibitory	O
activity	O
towards	O
CYP1A2	B-Drug
which	O
may	O
present	O
a	O
theoretical	O
potential	O
for	O
interaction	O
with	O
other	O
coadministered	O
medicinal	O
products	O
sharing	O
that	O
clearance	O
mechanism	O
e.g	O
.	O

Anagrelide	B-Drug
demonstrates	O
some	O
limited	O
inhibitory	O
activity	O
towards	O
CYP1A2	B-Drug
which	O
may	O
present	O
a	O
theoretical	O
potential	O
for	O
interaction	O
with	O
other	O
coadministered	O
medicinal	O
products	O
sharing	O
that	O
clearance	O
mechanism	O
e.g	O
.	O

theophylline	B-Drug
.	O

Anagrelide	B-Drug
is	O
an	O
inhibitor	O
of	O
cyclic	O
AMP	O
PDE	O
III	O
.	O

The	O
effects	O
of	O
medicinal	O
products	O
with	O
similar	O
properties	O
such	O
as	O
inotropes	O
milrinone	B-Drug
,	O
enoximone	B-Drug
,	O
amrinone	B-Drug
,	O
olprinone	B-Drug
and	O
cilostazol	B-Drug
may	O
be	O
exacerbated	O
by	O
anagrelide	B-Drug
.	O

There	O
is	O
a	O
single	O
case	O
report	O
,	O
which	O
suggests	O
that	O
sucralfate	B-Drug
may	O
interfere	O
with	O
anagrelide	B-Drug
absorption	O
.	O

Food	O
has	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
anagrelide	B-Drug
.	O

No	O
drug-drug	O
interaction	O
studies	O
in	O
human	O
subjects	O
have	O
been	O
conducted	O
.	O

Toxicologic	O
and	O
toxicokinetic	O
studies	O
in	O
rats	O
did	O
not	O
demonstrate	O
any	O
alterations	O
in	O
the	O
clearance	O
or	O
toxicologic	O
profile	O
of	O
either	O
methotrexate	B-Drug
or	O
Kineret	B-Drug
when	O
the	O
two	O
agents	O
were	O
administered	O
together	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
Kineret	B-Drug
and	O
etanercept	B-Drug
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
etanercept	B-Drug
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
Kineret	B-Drug
and	O
etanercept	B-Drug
developed	O
neutropenia	O
(	O
ANC	O
1	O
x	O
109/L	O
)	O
.	O

Anastrozole	B-Drug
inhibited	O
in	O
vitro	O
metabolic	O
reactions	O
catalyzed	O
by	O
cytochromes	O
P450	O
1A2	O
,	O
2C8/9	O
,	O
and	O
3A4	O
but	O
only	O
at	O
relatively	O
high	O
concentrations	O
.	O

Anastrozole	B-Drug
did	O
not	O
inhibit	O
P450	O
2A6	O
or	O
the	O
polymorphic	O
P450	O
2D6	O
in	O
human	O
liver	O
microsomes	O
.	O

Anastrozole	B-Drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
antipyrine	B-Drug
.	O

Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
other	O
than	O
with	O
antipyrine	B-Drug
,	O
based	O
on	O
these	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
,	O
it	O
is	O
unlikely	O
that	O
co-administration	O
of	O
a	O
1	O
mg	O
dose	O
of	O
ARIMIDEX	B-Drug
with	O
other	O
drugs	B-Drug
will	O
result	O
in	O
clinically	O
significant	O
drug	B-Drug
inhibition	O
of	O
cytochrome	O
P450-mediated	O
metabolism	O
of	O
the	O
other	O
drugs	B-Drug
.	O

An	O
interaction	O
study	O
with	O
warfarin	B-Drug
showed	O
no	O
clinically	O
significant	O
effect	O
of	O
anastrozole	B-Drug
on	O
warfarin	B-Drug
pharmacokinetics	O
or	O
anticoagulant	B-Drug
activity	O
.	O

At	O
a	O
median	O
follow-up	O
of	O
33	O
months	O
,	O
the	O
combination	O
of	O
ARIMIDEX	B-Drug
and	O
tamoxifen	B-Drug
did	O
not	O
demonstrate	O
any	O
efficacy	O
benefit	O
when	O
compared	O
with	O
tamoxifen	B-Drug
in	O
all	O
patients	O
as	O
well	O
as	O
in	O
the	O
hormone	O
receptor-positive	O
subpopulation	O
.	O

This	O
treatment	O
arm	O
was	O
discontinued	O
from	O
the	O
trial	O
.	O

Based	O
on	O
clinical	O
and	O
pharmacokinetic	O
results	O
from	O
the	O
ATAC	O
trial	O
,	O
tamoxifen	B-Drug
should	O
not	O
be	O
administered	O
with	O
anastrozole	B-Drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
Drug	B-Drug
Interactions	O
and	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Clinical	O
Studies	O
-	O
Adjuvant	O
Treatment	O
of	O
Breast	O
Cancer	O
in	O
Postmenopausal	O
Women	O
subsections	O
)	O
.	O

Co-administration	O
of	O
anastrozole	B-Drug
and	O
tamoxifen	B-Drug
resulted	O
in	O
a	O
reduction	O
of	O
anastrozole	B-Drug
plasma	O
levels	O
by	O
27	O
%	O
compared	O
with	O
those	O
achieved	O
with	O
anastrozole	B-Drug
alone	O
.	O

Estrogen-containing	O
therapies	O
should	O
not	O
be	O
used	O
with	O
ARIMIDEX	B-Drug
as	O
they	O
may	O
diminish	O
its	O
pharmacologic	O
action	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
No	O
clinically	O
significant	O
changes	O
in	O
the	O
results	O
of	O
clinical	O
laboratory	O
tests	O
have	O
been	O
observed	O
.	O

No	O
clinically	O
relevant	O
drug-drug	O
interactions	O
have	O
been	O
observed	O
with	O
drugs	B-Drug
likely	O
to	O
be	O
co-administered	O
with	O
anidulafungin	B-Drug
.	O

Caution	O
should	O
be	O
observed	O
when	O
anileridine	B-Drug
is	O
coadministered	O
with	O
other	O
opioids	O
,	O
sedatives	O
,	O
phenothiazines	O
,	O
or	O
anesthetics	B-Drug
,	O
as	O
these	O
agents	O
may	O
increase	O
respiratory	O
and	O
circulatory	O
depression	O
.	O

Addition	O
or	O
deletion	O
of	O
any	O
drug	B-Drug
from	O
the	O
therapeutic	O
regimen	O
of	O
patients	O
receiving	O
oral	O
anticoagulants	B-Drug
may	O
affect	O
patient	O
response	O
to	O
the	O
anticoagulant	B-Drug
.	O

Frequent	O
determination	O
of	O
prothrombin	O
time	O
and	O
close	O
monitoring	O
of	O
the	O
patient	O
is	O
essential	O
to	O
ascertain	O
when	O
adjustment	O
of	O
dosage	O
of	O
anticoagulant	B-Drug
may	O
be	O
needed	O
.	O

Because	O
of	O
the	O
variability	O
of	O
individual	O
patient	O
response	O
,	O
multiple	O
interacting	O
mechanisms	O
with	O
some	O
drugs	B-Drug
,	O
the	O
dependency	O
of	O
the	O
extent	O
of	O
the	O
interaction	O
on	O
the	O
dosage	O
and	O
duration	O
of	O
therapy	O
,	O
and	O
the	O
possible	O
administration	O
of	O
several	O
interacting	O
drugs	B-Drug
simultaneously	O
,	O
it	O
is	O
difficult	O
to	O
predict	O
the	O
direction	O
and	O
degree	O
of	O
the	O
ultimate	O
effect	O
of	O
concomitant	O
medications	O
on	O
anticoagulant	B-Drug
response	O
.	O

For	O
example	O
,	O
since	O
cholestyramine	B-Drug
may	O
reduce	O
the	O
gastrointestinal	O
absorption	O
of	O
both	O
the	O
oral	O
anticoagulants	B-Drug
and	O
vitamin	O
K	O
,	O
the	O
net	O
effects	O
are	O
unpredictable	O
.	O

Chloral	B-Drug
hydrate	I-Drug
may	O
cause	O
an	O
increased	O
prothrombin	O
response	O
by	O
displacing	O
the	O
anticoagulant	B-Drug
from	O
protein	O
binding	O
sites	O
or	O
a	O
diminished	O
prothrombin	O
response	O
through	O
increased	O
metabolism	O
of	O
the	O
unbound	O
drug	B-Drug
by	O
hepatic	O
enzyme	O
induction	O
,	O
thus	O
leading	O
to	O
inter-patient	O
variation	O
in	O
ultimate	O
prothrombin	O
effect	O
.	O

An	O
interacting	O
drug	B-Drug
which	O
leads	O
to	O
a	O
decrease	O
in	O
prothrombin	O
time	O
necessitating	O
an	O
increased	O
dose	O
of	O
oral	O
anticoagulant	B-Drug
to	O
maintain	O
an	O
adequate	O
degree	O
of	O
anticoagulation	O
may	O
,	O
if	O
abruptly	O
discontinued	O
,	O
increase	O
the	O
risk	O
of	O
subsequent	O
bleeding	O
.	O

Drugs	B-Drug
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	B-Drug
response	O
,	O
ie	O
,	O
decreased	O
prothrom-bin	O
time	O
response	O
,	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	O
steroids	O
;	O
alcohol*	B-Drug
;	O
antacids	O
;	O
antihistamines	B-Drug
;	O
barbiturates	B-Drug
;	O
carbamazepine	B-Drug
;	O
chloral	B-Drug
hydrate*	I-Drug
;	O
chlordiazepoxide	B-Drug
;	O
cholestyramine	B-Drug
;	O
diet	O
high	O
in	O
vitamin	O
K	O
;	O
diuretics*	O
;	O
ethchlorvynol	B-Drug
;	O
glutethimide	B-Drug
;	O
griseofulvin	B-Drug
;	O
haloperidol	B-Drug
;	O
meprobamate	B-Drug
;	O
oral	O
contraceptives	O
;	O
paraldehyde	B-Drug
;	O
primidone	B-Drug
;	O
ranitidine*	B-Drug
;	O
rifampin	B-Drug
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
vitamin	B-Drug
C	I-Drug
;	O
Drugs	B-Drug
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	B-Drug
response	O
,	O
ie	O
,	O
decreased	O
prothrom-bin	O
time	O
response	O
,	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	O
steroids	O
;	O
alcohol*	B-Drug
;	O
antacids	O
;	O
antihistamines	B-Drug
;	O
barbiturates	B-Drug
;	O
carbamazepine	B-Drug
;	O
chloral	B-Drug
hydrate*	I-Drug
;	O
chlordiazepoxide	B-Drug
;	O
cholestyramine	B-Drug
;	O
diet	O
high	O
in	O
vitamin	O
K	O
;	O
diuretics*	O
;	O
ethchlorvynol	B-Drug
;	O
glutethimide	B-Drug
;	O
griseofulvin	B-Drug
;	O
haloperidol	B-Drug
;	O
meprobamate	B-Drug
;	O
oral	O
contraceptives	O
;	O
paraldehyde	B-Drug
;	O
primidone	B-Drug
;	O
ranitidine*	B-Drug
;	O
rifampin	B-Drug
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
vitamin	B-Drug
C	I-Drug
;	O
warfarin	B-Drug
sodium	I-Drug
under-dosage	O
.	O

Drugs	B-Drug
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	B-Drug
response	O
,	O
ie	O
,	O
increased	O
prothrombin	O
response	O
,	O
in	O
man	O
include	O
:	O
alcohol*	B-Drug
;	O
allopurinol	B-Drug
;	O
aminosalicylic	B-Drug
acid	I-Drug
;	O
amiodarone	B-Drug
;	O
anabolic	O
steroids	O
;	O
antibiotics	B-Drug
;	O
bromelains	B-Drug
;	O
chloral	B-Drug
hydrate*	I-Drug
;	O
chlorpropamide	B-Drug
;	O
chymotrypsin	B-Drug
;	O
cimetidine	B-Drug
;	O
cinchophen	B-Drug
;	O
clofibrate	B-Drug
;	O
dextran	B-Drug
;	O
dextrothyroxine	B-Drug
;	O
diazoxide	B-Drug
;	O
dietary	O
deficiencies	O
;	O
diflunisal	B-Drug
;	O
diuretics*	O
;	O
disulfiram	B-Drug
;	O
drugs	B-Drug
affecting	O
blood	O
elements	O
;	O
ethacrynic	B-Drug
acid	I-Drug
;	O
fenoprofen	B-Drug
;	O
glucagon	B-Drug
;	O
hepatotoxic	O
drugs	B-Drug
;	O
ibuprofen	B-Drug
;	O
indomethacin	B-Drug
;	O
influenza	O
virus	O
vaccine	O
;	O
inhalation	O
anesthetics	B-Drug
;	O
mefenamic	B-Drug
acid	I-Drug
;	O
methyldopa	B-Drug
;	O
methylphenidate	B-Drug
;	O
metronidazole	B-Drug
;	O
miconazole	B-Drug
;	O
monoamine	O
oxidase	O
inhibitors	O
;	O
nalidixic	B-Drug
acid	I-Drug
;	O
naproxen	B-Drug
;	O
oxolinic	B-Drug
acid	I-Drug
;	O
oxyphenbutazone	B-Drug
;	O
pentoxifylline	B-Drug
;	O
phenylbutazone	B-Drug
;	O
phenyramidol	B-Drug
;	O
phenytoin	B-Drug
;	O
prolonged	O
hot	O
weather	O
;	O
prolonged	O
narcotics	O
;	O
pyrazolones	O
;	O
quinidine	B-Drug
;	O
quinine	B-Drug
;	O
ranitidine*	B-Drug
;	O
salicylates	O
;	O
sulfinpyrazone	B-Drug
;	O
sulfonamides	O
,	O
long	O
acting	O
;	O
sulindac	B-Drug
;	O
thyroid	B-Drug
drugs	B-Drug
;	O
tolbutamide	B-Drug
;	O
triclofos	B-Drug
sodium	I-Drug
;	O
trimethoprim/sulfamethoxazole	B-Drug
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
Drugs	B-Drug
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	B-Drug
response	O
,	O
ie	O
,	O
increased	O
prothrombin	O
response	O
,	O
in	O
man	O
include	O
:	O
alcohol*	B-Drug
;	O
allopurinol	B-Drug
;	O
aminosalicylic	B-Drug
acid	I-Drug
;	O
amiodarone	B-Drug
;	O
anabolic	O
steroids	O
;	O
antibiotics	B-Drug
;	O
bromelains	B-Drug
;	O
chloral	B-Drug
hydrate*	I-Drug
;	O
chlorpropamide	B-Drug
;	O
chymotrypsin	B-Drug
;	O
cimetidine	B-Drug
;	O
cinchophen	B-Drug
;	O
clofibrate	B-Drug
;	O
dextran	B-Drug
;	O
dextrothyroxine	B-Drug
;	O
diazoxide	B-Drug
;	O
dietary	O
deficiencies	O
;	O
diflunisal	B-Drug
;	O
disulfiram	B-Drug
;	O
drugs	B-Drug
affecting	O
blood	O
elements	O
;	O
ethacrynic	B-Drug
acid	I-Drug
;	O
fenoprofen	B-Drug
;	O
glucagon	B-Drug
;	O
hepatotoxic	O
drugs	B-Drug
;	O
ibuprofen	B-Drug
;	O
indomethacin	B-Drug
;	O
influenza	O
virus	O
vaccine	O
;	O
inhalation	O
anesthetics	B-Drug
;	O
mefenamic	B-Drug
acid	I-Drug
;	O
methyldopa	B-Drug
;	O
methylphenidate	B-Drug
;	O
metronidazole	B-Drug
;	O
miconazole	B-Drug
;	O
monoamine	O
oxidase	O
inhibitors	O
;	O
nalidixic	B-Drug
acid	I-Drug
;	O
naproxen	B-Drug
;	O
oxolinic	B-Drug
acid	I-Drug
;	O
oxyphenbutazone	B-Drug
;	O
pentoxifylline	B-Drug
;	O
phenylbutazone	B-Drug
;	O
phenyramidol	B-Drug
;	O
phenytoin	B-Drug
;	O
prolonged	O
hot	O
weather	O
;	O
prolonged	O
narcotics	O
;	O
pyrazolones	O
;	O
quinidine	B-Drug
;	O
quinine	B-Drug
;	O
ranitidine*	B-Drug
;	O
salicylates	O
;	O
sulfinpyrazone	B-Drug
;	O
sulfonamides	O
,	O
long	O
acting	O
;	O
sulindac	B-Drug
;	O
thyroid	B-Drug
drugs	B-Drug
;	O
tolbutamide	B-Drug
;	O
triclofos	B-Drug
sodium	I-Drug
;	O
trimethoprim/sulfamethoxazole	B-Drug
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
warfarin	B-Drug
sodium	O
overdosage	O
.	O

Oral	O
anticoagulants	B-Drug
may	O
potentiate	O
the	O
hypoglycemic	O
action	O
of	O
hypoglycemic	O
agents	O
,	O
eg	O
,	O
tolbutamide	B-Drug
and	O
chlorpropamide	B-Drug
,	O
by	O
inhibiting	O
their	O
metabolism	O
in	O
the	O
liver	O
.	O

Because	O
oral	O
anticoagulants	B-Drug
may	O
interfere	O
with	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	B-Drug
,	O
toxic	O
levels	O
of	O
the	O
anticonvulsant	O
may	O
occur	O
when	O
an	O
oral	O
anticoagulant	B-Drug
and	O
phenytoin	B-Drug
are	O
administered	O
concurrently	O
.	O

Drugs	B-Drug
that	O
reduce	O
the	O
number	O
of	O
blood	O
platelets	O
by	O
causing	O
bone	O
marrow	O
depression	O
(	O
such	O
as	O
antineoplastic	O
agents	O
)	O
or	O
drugs	B-Drug
which	O
inhibit	O
platelet	O
function	O
(	O
eg	O
,	O
aspirin	B-Drug
and	O
other	O
non-steroidal	O
anti-inflammatory	O
drugs	B-Drug
,	O
dipyridamole	B-Drug
,	O
hydrochloroquine	B-Drug
,	O
clofibrate	B-Drug
,	O
dextran	B-Drug
)	O
may	O
increase	O
the	O
bleeding	O
tendency	O
produced	O
by	O
anticoagulants	B-Drug
without	O
altering	O
prothrombin	O
time	O
determinations	O
.	O

The	O
beneficial	O
effects	O
on	O
arterial	O
thrombus	O
formation	O
from	O
combined	O
therapy	O
with	O
antiplatelet	O
and	O
anticoagulant	B-Drug
medication	O
must	O
be	O
weighed	O
against	O
an	O
increased	O
risk	O
of	O
inducing	O
hemorrhage	O
.	O

*Increased	O
and	O
decreased	O
prothrombin	O
time	O
responses	O
have	O
been	O
reported	O
.	O

Drug/Laboratory	O
Test	O
Interferences	O
:	O
Dicumarol	B-Drug
and	O
indanedione	O
anticoagulants	B-Drug
,	O
including	O
anisindione	B-Drug
,	O
or	O
their	O
metabolites	O
may	O
color	O
alkaline	O
urine	O
red-orange	O
,	O
which	O
may	O
interfere	O
with	O
spectrophotometrically	O
determined	O
urinary	O
laboratory	O
tests	O
.	O

The	O
color	O
reverses	O
when	O
the	O
test	O
sample	O
is	O
acidified	O
in	O
vitro	O
to	O
a	O
pH	O
below	O
4	O
.	O

5HT3	O
Antagonists	O
:	O
Based	O
on	O
reports	O
of	O
profound	O
hypotension	O
and	O
loss	O
of	O
consciousness	O
when	O
apomorphine	B-Drug
was	O
administered	O
with	O
ondansetron	B-Drug
,	O
the	O
concomitant	O
use	O
of	O
apomorphine	B-Drug
with	O
drugs	B-Drug
of	O
the	O
5HT3	O
antagonist	O
class	O
(	O
including	O
,	O
for	O
example	O
,	O
ondansetron	B-Drug
,	O
granisetron	B-Drug
,	O
dolasetron	B-Drug
,	O
palonosetron	B-Drug
,	O
and	O
alosetron	B-Drug
)	O
is	O
contraindicated	O
.	O

Antihypertensive	B-Drug
Medications	O
and	O
Vasodilators	O
:	O
The	O
following	O
adverse	O
events	O
were	O
experienced	O
more	O
commonly	O
in	O
patients	O
receiving	O
concomitant	O
antihypertensive	B-Drug
medications	O
or	O
vasodilators	O
(	O
n	O
=	O
94	O
)	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
drugs	B-Drug
(	O
n	O
=	O
456	O
)	O
:	O
hypotension	O
10	O
%	O
vs	O
4	O
%	O
,	O
myocardial	O
infarction	O
3	O
%	O
vs	O
1	O
%	O
,	O
serious	O
pneumonia	O
5	O
%	O
vs	O
3	O
%	O
,	O
serious	O
falls	O
9	O
%	O
vs	O
3	O
%	O
,	O
and	O
bone	O
and	O
joint	O
injuries	O
6	O
%	O
vs	O
2	O
%	O
.	O

The	O
mechanism	O
underlying	O
many	O
of	O
these	O
events	O
is	O
unknown	O
,	O
but	O
may	O
represent	O
increased	O
hypotension	O
.	O

Dopamine	B-Drug
Antagonists	O
:	O
Since	O
apomorphine	B-Drug
is	O
a	O
dopamine	B-Drug
agonist	O
,	O
it	O
is	O
possible	O
that	O
dopamine	B-Drug
antagonists	O
,	O
such	O
as	O
the	O
neuroleptics	O
(	O
phenothiazines	O
,	O
butyrophenones	O
,	O
thioxanthenes	O
)	O
or	O
metoclopramide	B-Drug
,	O
may	O
diminish	O
the	O
effectiveness	O
of	O
APOKYN	B-Drug
.	O

Patients	O
with	O
major	O
psychotic	O
disorders	O
,	O
treated	O
with	O
neuroleptics	O
,	O
should	O
be	O
treated	O
with	O
dopamine	B-Drug
agonists	O
only	O
if	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
.	O

Drugs	B-Drug
Prolonging	O
the	O
QT/QTc	O
Interval	O
Caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
apomorphine	B-Drug
concomitantly	O
with	O
drugs	B-Drug
that	O
prolong	O
the	O
QT/QTc	O
interval	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
APOKYN	B-Drug
and	O
laboratory	O
tests	O
.	O

Apraclonidine	B-Drug
should	O
not	O
be	O
used	O
in	O
patients	O
receiving	O
MAO	O
inhibitors..	O
Although	O
no	O
specific	O
drug	B-Drug
interactions	O
with	O
topical	O
glaucoma	O
drugs	B-Drug
or	O
systemic	O
medications	O
were	O
identified	O
in	O
clinical	O
studies	O
of	O
IOPIDINE	B-Drug
0.5	O
%	O
Ophthalmic	O
Solution	O
,	O
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	O
depressants	O
(	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
opiates	O
,	O
sedatives	O
,	O
anesthetics	B-Drug
)	O
should	O
be	O
considered	O
.	O

Tricyclic	O
antidepressants	B-Drug
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine	B-Drug
.	O

It	O
is	O
not	O
known	O
whether	O
the	O
concurrent	O
use	O
of	O
these	O
agents	O
with	O
apraclonidine	B-Drug
can	O
lead	B-Drug
to	O
a	O
reduction	O
in	O
IOP	O
lowering	O
effect	O
.	O

No	O
data	O
on	O
the	O
level	O
of	O
circulating	O
catecholamines	O
after	O
apraclonidine	B-Drug
withdrawal	O
are	O
available	O
.	O

Caution	O
,	O
however	O
,	O
is	O
advised	O
in	O
patients	O
taking	O
tricyclic	O
antidepressants	B-Drug
which	O
can	O
affect	O
the	O
metabolism	O
and	O
uptake	O
of	O
circulating	O
amines	O
.	O

An	O
additive	O
hypotensive	O
effect	O
has	O
been	O
reported	O
with	O
the	O
combination	O
of	O
systemic	O
clonidine	B-Drug
and	O
neuroleptic	B-Drug
therapy	O
.	O

Systemic	O
clonidine	B-Drug
may	O
inhibit	O
the	O
production	O
of	O
catecholamines	O
in	O
response	O
to	O
insulin-induced	B-Drug
hypoglycemia	O
and	O
mask	O
the	O
signs	O
and	O
symptoms	O
of	O
hypoglycemia	O
.	O

Since	O
apraclonidine	B-Drug
may	O
reduce	O
pulse	O
and	O
blood	O
pressure	O
,	O
caution	O
in	O
using	O
drugs	B-Drug
such	O
as	O
beta-blockers	O
(	O
ophthalmic	O
and	O
systemic	O
)	O
,	O
antihypertensives	B-Drug
,	O
and	O
cardiac	O
glycosides	O
is	O
advised	O
.	O

Patients	O
using	O
cardiovascular	O
drugs	B-Drug
concurrently	O
with	O
IOPIDINE	B-Drug
0.5	O
%	O
Ophthalmic	O
Solution	O
should	O
have	O
pulse	O
and	O
blood	O
pressures	O
frequently	O
monitored	O
.	O

Caution	O
should	O
be	O
exercised	O
with	O
simultaneous	O
use	O
of	O
clonidine	B-Drug
and	O
other	O
similar	O
pharmacologic	O
agents	O
.	O

Aprepitant	B-Drug
is	O
a	O
substrate	O
,	O
a	O
moderate	O
inhibitor	O
,	O
and	O
an	O
inducer	O
of	O
CYP3A4	B-Drug
.	O

Aprepitant	B-Drug
is	O
also	O
an	O
inducer	O
of	O
CYP2C9	B-Drug
.	O

Effect	O
of	O
aprepitant	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
other	O
agents	O
As	O
a	O
moderate	O
inhibitor	O
of	O
CYP3A4	B-Drug
,	O
aprepitant	B-Drug
can	O
increase	O
plasma	O
concentrations	O
of	O
coadministered	O
medicinal	O
products	O
that	O
are	O
metabolized	O
through	O
CYP3A4	B-Drug
.	O

Aprepitant	B-Drug
has	O
been	O
shown	O
to	O
induce	O
the	O
metabolism	O
of	O
S	B-Drug
(	I-Drug
-	I-Drug
)	I-Drug
warfarin	I-Drug
and	O
tolbutamide	B-Drug
,	O
which	O
are	O
metabolized	O
through	O
CYP2C9	B-Drug
.	O

Coadministration	O
of	O
Aprepitant	B-Drug
with	O
these	O
drugs	B-Drug
or	O
other	O
drugs	B-Drug
that	O
are	O
known	O
to	O
be	O
metabolized	O
by	O
CYP2C9	B-Drug
,	O
such	O
as	O
phenytoin	B-Drug
,	O
may	O
result	O
in	O
lower	O
plasma	O
concentrations	O
of	O
these	O
drugs	B-Drug
.	O

Aprepitant	B-Drug
is	O
unlikely	O
to	O
interact	O
with	O
drugs	B-Drug
that	O
are	O
substrates	O
for	O
the	O
P-glycoprotein	O
transporter	O
,	O
as	O
demonstrated	O
by	O
the	O
lack	O
of	O
interaction	O
of	O
Aprepitant	B-Drug
with	O
digoxin	B-Drug
in	O
a	O
clinical	O
drug	B-Drug
interaction	O
study	O
.	O

5-HT3	O
antagonists	O
:	O
In	O
clinical	O
drug	B-Drug
interaction	O
studies	O
,	O
aprepitant	B-Drug
did	O
not	O
have	O
clinically	O
important	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
ondansetron	B-Drug
or	O
granisetron	B-Drug
.	O

No	O
clinical	O
or	O
drug	B-Drug
interaction	O
study	O
was	O
conducted	O
with	O
dolasetron	B-Drug
.	O

Corticosteroids	O
:	O
Dexamethasone	B-Drug
:	O
Aprepitant	B-Drug
,	O
when	O
given	O
as	O
a	O
regimen	O
of	O
125mg	O
with	O
dexamethasone	B-Drug
coadministered	O
orally	O
as	O
20	O
mg	O
on	O
Day	O
1	O
,	O
and	O
Aprepitant	B-Drug
when	O
given	O
as	O
80	O
mg/day	O
with	O
dexamethasone	B-Drug
coadministered	O
orally	O
as	O
8	O
mg	O
on	O
Days	O
2	O
through	O
5	O
,	O
increased	O
the	O
AUC	O
of	O
dexamethasone	B-Drug
,	O
a	O
CYP3A4	B-Drug
substrate	O
by	O
2.2-fold	O
,	O
on	O
Days	O
1	O
and	O
5	O
.	O

The	O
oral	O
dexamethasone	B-Drug
doses	O
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
when	O
coadministered	O
with	O
Aprepitant	B-Drug
,	O
to	O
achieve	O
exposures	O
of	O
dexamethasone	B-Drug
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	B-Drug
.	O

The	O
daily	O
dose	O
of	O
dexamethasone	B-Drug
administered	O
in	O
clinical	O
studies	O
with	O
Aprepitant	B-Drug
reflects	O
an	O
approximate	O
50	O
%	O
reduction	O
of	O
the	O
dose	O
of	O
dexamethasone	B-Drug
.	O

Methylprednisolone	B-Drug
Aprepitant	B-Drug
,	O
when	O
given	O
as	O
a	O
regimen	O
of	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg/day	O
on	O
Days	O
2	O
and	O
3	O
,	O
increased	O
the	O
AUC	O
of	O
methylprednisolone	B-Drug
,	O
a	O
CYP3A4	B-Drug
substrate	O
,	O
by	O
1.34-fold	O
on	O
Day	O
1	O
and	O
by	O
2.5-fold	O
on	O
Day	O
3	O
,	O
when	O
methylprednisolone	B-Drug
was	O
coadministered	O
intravenously	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
orally	O
as	O
40	O
mg	O
on	O
Days	O
2	O
and	O
3	O
.	O

The	O
IV	O
methylprednisolone	B-Drug
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
25	O
%	O
,	O
and	O
the	O
oral	O
methylprednisolone	B-Drug
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
when	O
coadministered	O
with	O
Aprepitant	B-Drug
to	O
achieve	O
exposures	O
of	O
methylprednisolone	B-Drug
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	B-Drug
.	O

Warfarin	B-Drug
:	O
A	O
single	O
125-mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day	O
1	O
and	O
80	O
mg/day	O
on	O
Days	O
2	O
and	O
3	O
to	O
healthy	O
subjects	O
who	O
were	O
stabilized	O
on	O
chronic	O
warfarin	B-Drug
therapy	O
.	O

Although	O
there	O
was	O
no	O
effect	O
of	O
Aprepitant	B-Drug
on	O
the	O
plasma	O
AUC	O
of	O
R	B-Drug
(	I-Drug
+	I-Drug
)	I-Drug
or	O
S	O
(	I-Drug
-	I-Drug
)	I-Drug
warfarin	I-Drug
determined	O
on	O
Day	O
3	O
,	O
there	O
was	O
a	O
34	O
%	O
decrease	O
in	O
S	B-Drug
(	I-Drug
-	I-Drug
)	I-Drug
warfarin	I-Drug
(	I-Drug
a	O
CYP2C9	B-Drug
substrate	O
)	I-Drug
trough	O
concentration	O
accompanied	O
by	O
a	O
14	O
%	O
decrease	O
in	O
the	O
prothrombin	O
time	O
(	O
reported	O
as	O
International	O
Normalized	O
Ratio	O
or	O
INR	O
)	O
5	O
days	O
after	O
completion	O
of	O
dosing	O
with	O
Aprepitant	B-Drug
.	O

In	O
patients	O
on	O
chronic	O
warfarin	B-Drug
therapy	O
,	O
the	O
prothrombin	O
time	O
(	O
INR	O
)	O
should	O
be	O
closely	O
monitored	O
in	O
the	O
2-week	O
period	O
,	O
particularly	O
at	O
7	O
to	O
10	O
days	O
,	O
following	O
initiation	O
of	O
the	O
3-day	O
regimen	O
of	O
Aprepitant	B-Drug
with	O
each	O
chemotherapy	O
cycle	O
.	O

Tolbutamide	B-Drug
:	O
Aprepitant	B-Drug
,	O
when	O
given	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg/day	O
on	O
Days	O
2	O
and	O
3	O
,	O
decreased	O
the	O
AUC	O
of	O
tolbutamide	B-Drug
(	O
a	O
CYP2C9	B-Drug
substrate	O
)	O
by	O
23	O
%	O
on	O
Day	O
4	O
,	O
28	O
%	O
on	O
Day	O
8	O
,	O
and	O
15	O
%	O
on	O
Day	O
15	O
,	O
when	O
a	O
single	O
dose	O
of	O
tolbutamide	B-Drug
500	O
mg	O
was	O
admini	O
,	O
stered	O
orally	O
prior	O
to	O
the	O
administration	O
of	O
the	O
3-day	O
regimen	O
of	O
Aprepitant	B-Drug
and	O
on	O
Days	O
4,8	O
,	O
and	O
15	O
.	O

Oral	O
contraceptives	O
:	O
Aprepitant	B-Drug
,	O
when	O
given	O
once	O
daily	O
for	O
14	O
days	O
as	O
a	O
100-mg	O
capsule	O
with	O
an	O
oral	O
contraceptive	O
containing	O
35	O
mcg	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
1	O
mg	O
of	O
norethindrone	B-Drug
,	O
decreased	O
the	O
AUC	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
by	O
43	O
%	O
,	O
and	O
decreased	O
the	O
AUC	O
of	O
norethindrone	B-Drug
by	O
8	O
%	O
;	O
therefore	O
,	O
the	O
efficacy	O
of	O
oral	O
contraceptives	O
during	O
administration	O
of	O
Aprepitant	B-Drug
may	O
be	O
reduced	O
.	O

Although	O
a	O
3-day	O
regimen	O
of	O
Aprepitant	B-Drug
given	O
concomitantly	O
with	O
oral	O
contraceptives	O
has	O
not	O
been	O
studied	O
,	O
alternative	O
or	O
back-up	O
methods	O
of	O
contraception	O
should	O
be	O
used	O
.	O

Midazolam	B-Drug
:	O
Aprepitant	B-Drug
increased	O
the	O
AUC	O
of	O
midazolam	B-Drug
,	O
a	O
sensitive	O
CYP3A4	B-Drug
substrate	O
,	O
by	O
2.3-fold	O
on	O
Day	O
1	O
and	O
3.3-fold	O
on	O
Day	O
5	O
,	O
when	O
a	O
single	O
oral	O
dose	O
of	O
midazolam	B-Drug
2	O
mg	O
was	O
coadministered	O
on	O
Day	O
1	O
and	O
Day	O
5	O
of	O
a	O
regimen	O
of	O
Aprepitant	B-Drug
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg/day	O
on	O
Days	O
2	O
through	O
5	O
.	O

The	O
potential	O
effects	O
of	O
increased	O
plasma	O
concentrations	O
of	O
midazolam	B-Drug
or	O
other	O
benzodiazepines	B-Drug
metabolized	O
via	O
CYP3A4	B-Drug
(	O
alprazolam	B-Drug
,	O
triazolam	B-Drug
)	O
should	O
be	O
considered	O
when	O
coadministering	O
these	O
agents	O
with	O
Aprepitant	B-Drug
.	O

In	O
another	O
study	O
with	O
intravenous	O
administration	O
of	O
midazolam	B-Drug
,	O
Aprepitant	B-Drug
was	O
given	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg/day	O
on	O
Days	O
2	O
and	O
3	O
,	O
and	O
midazolam	B-Drug
2	O
mg	O
IV	O
was	O
given	O
prior	O
to	O
the	O
administration	O
of	O
the	O
3-day	O
regimen	O
of	O
Aprepitant	B-Drug
and	O
on	O
Days	O
4	O
,	O
8	O
,	O
and	O
15	O
.	O

Aprepitant	B-Drug
increased	O
the	O
AUC	O
of	O
midazolam	B-Drug
by	O
25	O
%	O
on	O
Day	O
4	O
and	O
decreased	O
the	O
AUC	O
of	O
midazolam	B-Drug
by	O
19	O
%	O
on	O
Day	O
8	O
relative	O
to	O
the	O
dosing	O
of	O
Aprepitant	B-Drug
on	O
Days	O
1	O
through	O
3	O
.	O

These	O
effects	O
were	O
not	O
considered	O
clinically	O
important	O
.	O

The	O
AUC	O
of	O
midazolam	B-Drug
on	O
Day	O
15	O
was	O
similar	O
to	O
that	O
observed	O
at	O
baseline	O
.	O

Effect	O
of	O
other	O
agents	O
on	O
the	O
pharmacokinefics	O
of	O
aprepitant	B-Drug
Aprepitant	B-Drug
is	O
a	O
substrate	O
for	O
CYP3A4	B-Drug
;	O
therefore	O
,	O
coadministration	O
of	O
Aprepitant	B-Drug
with	O
drugs	B-Drug
that	O
inhibit	O
CYP3A4	B-Drug
activity	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
aprepitant	B-Drug
.	O

Consequently	O
,	O
concomitant	O
administration	O
of	O
Aprepitant	B-Drug
with	O
strong	O
CYP3A4	B-Drug
inhibitors	O
(	O
e.g.	O
,	O
ketoconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
nefazodone	B-Drug
,	O
troleandomycin	B-Drug
,	O
clarithromycin	B-Drug
,	O
ritonavir	B-Drug
,	O
nelfinavir	B-Drug
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Because	O
moderate	O
CYP3A4	B-Drug
inhibitors	O
(	O
e.g.	O
,	O
diltiazem	B-Drug
)	O
result	O
in	O
2-fold	O
increase	O
in	O
plasma	O
concentrations	O
of	O
aprepitant	B-Drug
,	O
concomitant	O
administration	O
should	O
also	O
be	O
approached	O
with	O
caution	O
.	O

Aprepitant	B-Drug
is	O
a	O
substrate	O
for	O
CYP3A4	B-Drug
;	O
therefore	O
,	O
coadministration	O
of	O
Aprepitant	B-Drug
with	O
drugs	B-Drug
that	O
strongly	O
induce	O
CYP3A4	B-Drug
activity	O
(	O
e.g.	O
,	O
rifampin	B-Drug
,	O
carbamazepine	B-Drug
,	O
phenytoin	B-Drug
)	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
of	O
aprepitant	B-Drug
that	O
may	O
result	O
in	O
decreased	O
efficacy	O
of	O
Aprepitant	B-Drug
.	O

Ketoconazole	B-Drug
:	O
When	O
a	O
single	O
125-mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day5	O
of	O
a	O
Ketoconazole	B-Drug
:	O
When	O
a	O
single	O
125-mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day5	O
of	O
a	O
10-day	O
regimen	O
of	O
400	O
mg/day	O
of	O
ketoconazole	B-Drug
,	O
a	O
strong	O
CYP3A4	B-Drug
inhibitor	O
,	O
the	O
AUC	O
of	O
aprepitant	B-Drug
increased	O
approximately	O
5-fold	O
and	O
the	O
mean	O
terminal	O
half-life	O
of	O
aprepitant	B-Drug
increased	O
approximately	O
3-fold	O
.	O

Concomitant	O
administration	O
of	O
Aprepitant	B-Drug
with	O
strong	O
CYP3A4	B-Drug
inhibitors	O
should	O
be	O
approached	O
cautiously	O
.	O

Rifampin	B-Drug
:	O
When	O
a	O
single	O
375-mg	O
dose	O
of	O
Aprepitant	B-Drug
was	O
administered	O
on	O
Day9	O
of	O
a	O
14-day	O
regimen	O
of	O
600	O
mg/day	O
of	O
rifampin	B-Drug
,	O
a	O
strong	O
CYP3A4	B-Drug
inducer	O
,	O
the	O
AUC	O
of	O
aprepitant	B-Drug
decreased	O
approximately	O
11-fold	O
and	O
the	O
mean	O
terminal	O
half-life	O
decreased	O
approximately	O
3-fold	O
.	O

Coadministration	O
of	O
Aprepitant	B-Drug
with	O
drugs	B-Drug
that	O
induce	O
CYP3A4	B-Drug
activity	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
and	O
decreased	O
efficacy	O
of	O
Aprepitant	B-Drug
.	O

Additional	O
interactions	O
Diltiazem	B-Drug
:	O
In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
,	O
administration	O
of	O
aprepitant	B-Drug
once	O
daily	O
,	O
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
230	O
mg	O
of	O
the	O
capsule	O
formulation	O
,	O
with	O
diltiazem	B-Drug
120	O
mg	O
3	O
times	O
daily	O
for	O
5	O
days	O
,	O
resulted	O
in	O
a	O
2-fold	O
increase	O
of	O
aprepitant	B-Drug
AUC	O
and	O
a	O
simultaneous	O
1.7-fold	O
increase	O
of	O
diltiazem	B-Drug
AUC	O
.	O

These	O
pharmacokinetic	O
effects	O
did	O
not	O
result	O
in	O
clinically	O
meaningful	O
changes	O
in	O
ECG	O
,	O
heart	O
rate	O
or	O
blood	O
pressure	O
beyond	O
those	O
changes	O
induced	O
by	O
diltiazem	B-Drug
alone	O
.	O

Paroxetine	B-Drug
:	O
Coadministration	O
of	O
once	O
daily	O
doses	O
of	O
aprepitant	B-Drug
,	O
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
85	O
mg	O
or	O
170	O
mg	O
of	O
the	O
capsule	O
formulation	O
,	O
with	O
paroxetine	B-Drug
20	O
mg	O
once	O
daily	O
,	O
resulted	O
in	O
a	O
decrease	O
in	O
AUC	O
by	O
approximately	O
25	O
%	O
and	O
Cmax	O
,	O
by	O
approximately	O
20	O
%	O
of	O
both	O
aprepitant	B-Drug
and	O
paroxetine	B-Drug
.	O

Beta-adrenergic	O
blocking	O
agents	O
:	O
concurrent	O
use	O
may	O
blunt	O
the	O
response	O
to	O
arbutamine	B-Drug
.	O

Beta-adrenergic	O
blocking	O
agents	O
should	O
be	O
withdrawn	O
at	O
least	O
48	O
hours	O
before	O
conducting	O
an	O
arbutamine-mediated	B-Drug
stress	O
test	O
.	O

Antiarrhythmic	B-Drug
agents	I-Drug
,	I-Drug
class	I-Drug
I	I-Drug
(	O
such	O
as	O
flecainide	B-Drug
,	O
lidocaine	B-Drug
,	O
or	O
quinidine	B-Drug
)	O
:	O
concurrent	O
use	O
with	O
arbutamine	B-Drug
may	O
have	O
a	O
proarrhythmic	O
effect	O
.	O

Antidepressants	B-Drug
(	O
tricyclic	O
)	O
,	O
atropine	B-Drug
or	O
other	O
anticholinergic	B-Drug
agents	O
,	O
or	O
digitalis	B-Drug
glycosides	O
:	O
concurrent	O
use	O
with	O
arbutamine	B-Drug
may	O
produce	O
additive	O
inotropic	O
and/or	O
chronotropic	O
effects	O
.	O

Anticoagulants	B-Drug
including	O
coumarin	O
derivatives	O
,	O
indandione	O
derivatives	O
,	O
and	O
platelet	O
aggregation	O
inhibitors	O
such	O
as	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
(	O
NSAIDs	O
)	O
,	O
and	O
aspirin	B-Drug
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
when	O
administered	O
concomitantly	O
with	O
ardeparin	B-Drug
.	O

If	O
additional	O
adrenergic	O
drugs	B-Drug
are	O
to	O
be	O
administered	O
by	O
any	O
route	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
pharmacologically	O
predictable	O
sympathetic	O
effects	O
of	O
BROVANA	B-Drug
may	O
be	O
potentiated	O
.	O

When	O
paroxetine	B-Drug
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	B-Drug
,	O
was	O
co-administered	O
with	O
BROVANA	B-Drug
at	O
steady-state	O
,	O
exposure	O
to	O
either	O
drug	B-Drug
was	O
not	O
altered	O
.	O

Dosage	O
adjustments	O
of	O
BROVANA	B-Drug
are	O
not	O
necessary	O
when	O
the	O
drug	B-Drug
is	O
given	O
concomitantly	O
with	O
potent	O
CYP2D6	B-Drug
inhibitors	O
.	O

Concomitant	O
treatment	O
with	O
methylxanthines	O
(	O
aminophylline	B-Drug
,	O
theophylline	B-Drug
)	O
,	O
steroids	O
,	O
or	O
diuretics	B-Drug
may	O
potentiate	O
any	O
hypokalemic	O
effect	O
of	O
adrenergic	O
agonists	O
.	O

The	O
ECG	O
changes	O
and/or	O
hypokalemia	O
that	O
may	O
result	O
from	O
the	O
administration	O
of	O
non-potassium	O
sparing	O
diuretics	B-Drug
(	O
such	O
as	O
loop	O
or	O
thiazide	O
diuretics	B-Drug
)	O
can	O
be	O
acutely	O
worsened	O
by	O
beta-agonists	O
,	O
especially	O
when	O
the	O
recommended	O
dose	O
of	O
the	O
beta-agonist	O
is	O
exceeded	O
.	O

Although	O
the	O
clinical	O
significance	O
of	O
these	O
effects	O
is	O
not	O
known	O
,	O
caution	O
is	O
advised	O
in	O
the	O
co-administration	O
of	O
beta-agonists	O
with	O
non-potassium	O
sparing	O
diuretics	B-Drug
.	O

BROVANA	B-Drug
,	O
as	O
with	O
other	O
beta2-agonists	O
,	O
should	O
be	O
administered	O
with	O
extreme	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
monoamine	O
oxidase	O
inhibitors	O
,	O
tricyclic	O
antidepressants	B-Drug
,	O
or	O
drugs	B-Drug
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
because	O
the	O
action	O
of	O
adrenergic	O
agonists	O
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O

Drugs	B-Drug
that	O
are	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
have	O
an	O
increased	O
risk	O
of	O
ventricular	O
arrhythmias	O
.	O

The	O
concurrent	O
use	O
of	O
intravenously	O
or	O
orally	O
administered	O
methylxanthines	O
(	O
e.g.	O
,	O
aminophylline	B-Drug
,	O
theophylline	B-Drug
)	O
by	O
patients	O
receiving	O
BROVANA	B-Drug
has	O
not	O
been	O
completely	O
evaluated	O
.	O

In	O
two	O
combined	O
12-week	O
placebo	O
controlled	O
trials	O
that	O
included	O
BROVANA	B-Drug
doses	O
of	O
15	O
mcg	O
twice	O
daily	O
,	O
25	O
mcg	O
twice	O
daily	O
,	O
and	O
50	O
mcg	O
once	O
daily	O
,	O
54	O
of	O
873	O
BROVANA	B-Drug
-treated	O
subjects	O
received	O
concomitant	O
theophylline	B-Drug
at	O
study	O
entry	O
.	O

In	O
a	O
12-month	O
controlled	O
trial	O
that	O
included	O
a	O
50	O
mcg	O
once	O
daily	O
BROVANA	B-Drug
dose	O
,	O
30	O
of	O
the	O
528	O
BROVANA	B-Drug
-treated	O
subjects	O
received	O
concomitant	O
theophylline	B-Drug
at	O
study	O
entry	O
.	O

In	O
these	O
trials	O
,	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
were	O
approximately	O
2-3	O
bpm	O
and	O
6-8	O
mm	O
Hg	O
higher	O
,	O
respectively	O
,	O
in	O
subjects	O
on	O
concomitant	O
theophylline	B-Drug
compared	O
with	O
the	O
overall	O
population	O
.	O

Beta-adrenergic	O
receptor	O
antagonists	O
(	O
beta-blockers	O
)	O
and	O
BROVANA	B-Drug
may	O
interfere	O
with	O
the	O
effect	O
of	O
each	O
other	O
when	O
administered	O
concurrently	O
.	O

Beta-blockers	O
not	O
only	O
block	O
the	O
therapeutic	O
effects	O
of	O
beta-agonists	O
,	O
but	O
may	O
produce	O
severe	O
bronchospasm	O
in	O
COPD	O
patients	O
.	O

Therefore	O
,	O
patients	O
with	O
COPD	O
should	O
not	O
normally	O
be	O
treated	O
with	O
beta-blockers	O
.	O

However	O
,	O
under	O
certain	O
circumstances	O
,	O
e.g.	O
,	O
as	O
prophylaxis	O
after	O
myocardial	O
infarction	O
,	O
there	O
may	O
be	O
no	O
acceptable	O
alternatives	O
to	O
the	O
use	O
of	O
beta-blockers	O
in	O
patients	O
with	O
COPD	O
.	O

In	O
this	O
setting	O
,	O
cardioselective	O
beta-blockers	O
could	O
be	O
considered	O
,	O
although	O
they	O
should	O
be	O
administered	O
with	O
caution	O
.	O

Heparin	B-Drug
:	O
Since	O
heparin	B-Drug
is	O
contraindicated	O
in	O
patients	O
with	O
heparin-induced	B-Drug
thrombocytopenia	O
,	O
the	O
co-administration	O
of	O
Argatroban	B-Drug
and	O
heparin	B-Drug
is	O
unlikely	O
for	O
this	O
indication	O
.	O

However	O
,	O
if	O
Argatroban	B-Drug
is	O
to	O
be	O
initiated	O
after	O
cessation	O
of	O
heparin	B-Drug
therapy	O
,	O
allow	O
sufficient	O
time	O
for	O
heparins	O
effect	O
on	O
the	O
aPTT	O
to	O
decrease	O
prior	O
to	O
initiation	O
of	O
Argatroban	B-Drug
therapy	O
.	O

Aspirin/Acetaminophen	B-Drug
:	O
Pharmacokinetic	O
or	O
pharmacodynamic	O
drug-drug	O
interactions	O
have	O
not	O
been	O
demonstrated	O
between	O
Argatroban	B-Drug
and	O
concomitantly	O
administered	O
aspirin	B-Drug
(	O
162.5	O
mg	O
orally	O
given	O
26	O
and	O
2	O
hours	O
prior	O
to	O
initiation	O
of	O
Argatroban	B-Drug
1	O
g/kg/min	O
.	O

over	O
4	O
hours	O
)	O
or	O
acetaminophen	B-Drug
(	O
1000	O
mg	O
orally	O
given	O
12	O
,	O
6	O
and	O
0	O
hours	O
prior	O
to	O
,	O
and	O
6	O
and	O
12	O
hours	O
subsequent	O
to	O
,	O
initiation	O
of	O
Argatroban	B-Drug
1.5	O
g/kg/min	O
.	O

over	O
18	O
hours	O
)	O
.	O

Oral	O
anticoagulant	B-Drug
agents	O
:	O
Pharmacokinetic	O
drug-drug	O
interactions	O
between	O
Argatroban	B-Drug
and	O
warfarin	B-Drug
(	O
7.5	O
mg	O
single	O
oral	O
dose	O
)	O
have	O
not	O
been	O
demonstrated	O
.	O

However	O
,	O
the	O
concomitant	O
use	O
of	O
Argatroban	B-Drug
and	O
warfarin	B-Drug
(	O
5-7.5	O
mg	O
initial	O
oral	O
dose	O
followed	O
by	O
2.5-6	O
mg/day	O
orally	O
for	O
6-10	O
days	O
)	O
results	O
in	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
.	O

Thrombolytic	O
agents	O
:	O
The	O
safety	O
and	O
effectiveness	O
of	O
Argatroban	B-Drug
with	O
thrombolytic	O
agents	O
have	O
not	O
been	O
established	O
.	O

Co-administration	O
:	O
Concomitant	O
use	O
of	O
Argatroban	B-Drug
with	O
antiplatelet	O
agents	O
,	O
thrombolytics	O
,	O
and	O
other	O
anticoagulants	B-Drug
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

Drug-drug	O
interactions	O
have	O
not	O
been	O
observed	O
between	O
Argatroban	B-Drug
and	O
digoxin	B-Drug
or	O
erythromycin	B-Drug
.	O

Drug-Drug	O
Interactions	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
aripiprazole	B-Drug
,	O
caution	O
should	O
be	O
used	O
when	O
ABILIFY	B-Drug
is	O
taken	O
in	O
combination	O
with	O
other	O
centrally	O
acting	O
drugs	B-Drug
and	O
alcohol	B-Drug
.	O

Due	O
to	O
its	O
1-	O
adrenergic	O
receptor	O
antagonism	O
,	O
aripiprazole	B-Drug
has	O
the	O
potential	O
to	O
enhance	O
the	O
effect	O
of	O
certain	O
antihypertensive	B-Drug
agents	O
.	O

Potential	O
for	O
Other	O
Drugs	B-Drug
to	O
Affect	O
ABILIFY	B-Drug
Aripiprazole	B-Drug
is	O
not	O
a	O
substrate	O
of	O
CYP1A1	O
,	O
CYP1A2	B-Drug
,	O
CYP2A6	O
,	O
CYP2B6	O
,	O
CYP2C8	O
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
or	O
CYP2E1	O
enzymes	O
.	O

Aripiprazole	B-Drug
also	O
does	O
not	O
undergo	O
direct	O
glucuronidation	O
.	O

This	O
suggests	O
that	O
an	O
interaction	O
of	O
aripiprazole	B-Drug
with	O
inhibitors	O
or	O
inducers	O
of	O
these	O
enzymes	O
,	O
or	O
other	O
factors	O
,	O
like	O
smoking	O
,	O
is	O
unlikely	O
.	O

Both	O
CYP3A4	B-Drug
and	O
CYP2D6	B-Drug
are	O
responsible	O
for	O
aripiprazole	B-Drug
metabolism	O
.	O

Agents	O
that	O
induce	O
CYP3A4	B-Drug
(	O
eg	O
,	O
carbamazepine	B-Drug
)	O
could	O
cause	O
an	O
increase	O
in	O
aripiprazole	B-Drug
clearance	O
and	O
lower	O
blood	O
levels	O
.	O

Inhibitors	O
of	O
CYP3A4	B-Drug
(	O
eg	O
,	O
ketoconazole	B-Drug
)	O
or	O
CYP2D6	B-Drug
(	O
eg	O
,	O
quinidine	B-Drug
,	O
fluoxetine	B-Drug
,	O
or	O
paroxetine	B-Drug
)	O
can	O
inhibit	O
aripiprazole	B-Drug
elimination	O
and	O
cause	O
increased	O
blood	O
levels	O
.	O

Ketoconazole	B-Drug
:	O
Coadministration	O
of	O
ketoconazole	B-Drug
(	O
200	O
mg/day	O
for	O
14	O
days	O
)	O
with	O
a	O
15-mg	O
single	O
dose	O
of	O
aripiprazole	B-Drug
increased	O
the	O
AUC	O
of	O
aripiprazole	B-Drug
and	O
its	O
active	O
metabolite	O
by	O
63	O
%	O
and	O
77	O
%	O
,	O
respectively	O
.	O

The	O
effect	O
of	O
a	O
higher	O
ketoconazole	B-Drug
dose	O
(	O
400	O
mg/day	O
)	O
has	O
not	O
been	O
studied	O
.	O

When	O
concomitant	O
administration	O
of	O
ketoconazole	B-Drug
with	O
aripiprazole	B-Drug
occurs	O
,	O
aripiprazole	B-Drug
dose	O
should	O
be	O
reduced	O
to	O
one-half	O
of	O
its	O
normal	O
dose	O
.	O

Other	O
strong	O
inhibitors	O
of	O
CYP3A4	B-Drug
(	O
itraconazole	B-Drug
)	O
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
need	O
similar	O
dose	O
reductions	O
;	O
weaker	O
inhibitors	O
(	O
erythromycin	B-Drug
,	O
grapefruit	O
juice	O
)	O
have	O
not	O
been	O
studied	O
.	O

When	O
the	O
CYP3A4	B-Drug
inhibitor	O
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
,	O
aripiprazole	B-Drug
dose	O
should	O
then	O
be	O
increased	O
.	O

Quinidine	B-Drug
:	O
Coadministration	O
of	O
a	O
10-mg	O
single	O
dose	O
of	O
aripiprazole	B-Drug
with	O
quinidine	B-Drug
(	O
166	O
mg/day	O
for	O
13	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	B-Drug
,	O
increased	O
the	O
AUC	O
of	O
aripiprazole	B-Drug
by	O
112	O
%	O
but	O
decreased	O
the	O
AUC	O
of	O
its	O
active	O
metabolite	O
,	O
dehydroaripiprazole	B-Drug
,	O
by	O
35	O
%	O
.	O

Aripiprazole	B-Drug
dose	O
should	O
be	O
reduced	O
to	O
one-half	O
of	O
its	O
normal	O
dose	O
when	O
concomitant	O
administration	O
of	O
quinidine	B-Drug
with	O
aripiprazole	B-Drug
occurs	O
.	O

Other	O
significant	O
inhibitors	O
of	O
CYP2D6	B-Drug
,	O
such	O
as	O
fluoxetine	B-Drug
or	O
paroxetine	B-Drug
,	O
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
,	O
therefore	O
,	O
should	O
be	O
accompanied	O
by	O
similar	O
dose	O
reductions	O
.	O

When	O
the	O
CYP2D6	B-Drug
inhibitor	O
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
,	O
aripiprazole	B-Drug
dose	O
should	O
then	O
be	O
increased	O
.	O

Carbamazepine	B-Drug
:	O
Coadministration	O
of	O
carbamazepine	B-Drug
(	O
200	O
mg	O
BID	O
)	O
,	O
a	O
potent	O
CYP3A4	B-Drug
inducer	O
,	O
with	O
aripiprazole	B-Drug
(	O
30	O
mg	O
QD	O
)	O
resulted	O
in	O
an	O
approximate	O
70	O
%	O
decrease	O
in	O
Cmax	O
and	O
AUC	O
values	O
of	O
both	O
aripiprazole	B-Drug
and	O
its	O
active	O
metabolite	O
,	O
dehydro-aripiprazole	B-Drug
.	O

When	O
carbamazepine	B-Drug
is	O
added	O
to	O
aripiprazole	B-Drug
therapy	O
,	O
aripiprazole	B-Drug
dose	O
should	O
be	O
doubled	O
.	O

Additional	O
dose	O
increases	O
should	O
be	O
based	O
on	O
clinical	O
evaluation	O
.	O

When	O
carbamazepine	B-Drug
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
,	O
aripiprazole	B-Drug
dose	O
should	O
then	O
be	O
reduced	O
.	O

No	O
clinically	O
significant	O
effect	O
of	O
famotidine	B-Drug
,	O
valproate	B-Drug
,	O
or	O
lithium	B-Drug
was	O
seen	O
on	O
the	O
pharmacokinetics	O
of	O
aripiprazole	B-Drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug-	O
Drug	B-Drug
Interactions	O
)	O
.	O

Potential	O
for	O
ABILIFY	B-Drug
to	O
Affect	O
Other	O
Drugs	B-Drug
Aripiprazole	B-Drug
is	O
unlikely	O
to	O
cause	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
drugs	B-Drug
metabolized	O
by	O
cytochrome	O
P450	O
enzymes	O
.	O

In	O
in	O
vivo	O
studies	O
,	O
10-	O
to	O
30-mg/day	O
doses	O
of	O
aripiprazole	B-Drug
had	O
no	O
significant	O
effect	O
on	O
metabolism	O
by	O
CYP2D6	B-Drug
(	O
dextromethorphan	B-Drug
)	O
,	O
CYP2C9	B-Drug
(	O
warfarin	B-Drug
)	O
,	O
CYP2C19	O
(	O
omeprazole	B-Drug
,	O
warfarin	B-Drug
)	O
,	O
and	O
CYP3A4	B-Drug
(	O
dextromethorphan	B-Drug
)	O
substrates	O
.	O

Additionally	O
,	O
aripiprazole	B-Drug
and	O
dehydroaripiprazole	B-Drug
did	O
not	O
show	O
potential	O
for	O
altering	O
CYP1A2-mediated	O
metabolism	O
in	O
vitro	O
.	O

Alcohol	B-Drug
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
aripiprazole	B-Drug
coadministered	O
with	O
ethanol	B-Drug
and	O
placebo	O
coadministered	O
with	O
ethanol	B-Drug
on	O
performance	O
of	O
gross	O
motor	O
skills	O
or	O
stimulus	O
response	O
in	O
healthy	O
subjects	O
.	O

As	O
with	O
most	O
psychoactive	O
medications	O
,	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
alcohol	B-Drug
while	O
taking	O
ABILIFY	B-Drug
.	O

No	O
formal	O
assessments	O
of	O
pharmacokinetic	O
drug-drug	O
interactions	O
between	O
TRISENOX	B-Drug
and	O
other	O
agents	O
have	O
been	O
conducted	O
.	O

Caution	O
is	O
advised	O
when	O
TRISENOX	B-Drug
is	O
coadministered	O
with	O
other	O
medications	O
that	O
can	O
prolong	O
the	O
QT	O
interval	O
(	O
e.g	O
.	O

certain	O
antiarrhythmics	B-Drug
or	O
thioridazine	B-Drug
)	O
or	O
lead	B-Drug
to	O
electrolyte	O
abnormalities	O
(	O
such	O
as	O
diuretics	B-Drug
or	O
amphotericin	B-Drug
B	I-Drug
)	O
.	O

Tissue	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
ELSPAR	B-Drug
can	O
diminish	O
or	O
abolish	O
the	O
effect	O
of	O
methotrexate	B-Drug
on	O
malignant	O
cells.14	O
This	O
effect	O
on	O
methotrexate	B-Drug
activity	O
persists	O
as	O
long	O
as	O
plasma	O
asparagine	O
levels	O
are	O
suppressed	O
.	O

These	O
results	O
would	O
seem	O
to	O
dictate	O
against	O
the	O
clinical	O
use	O
of	O
methotrexate	B-Drug
with	O
ELSPAR	B-Drug
,	O
or	O
during	O
the	O
period	O
following	O
ELSPAR	B-Drug
therapy	O
when	O
plasma	O
asparagine	O
levels	O
are	O
below	O
normal	O
.	O

Uricosuric	O
Agents	O
:	O
Aspirin	B-Drug
may	O
decrease	O
the	O
effects	O
of	O
probenecid	B-Drug
,	O
sulfinpyrazone	B-Drug
,	O
and	O
phenylbutazone	B-Drug
.	O

Alcohol	B-Drug
:	O
Has	O
a	O
synergistic	O
effect	O
with	O
aspirin	B-Drug
in	O
causing	O
gastrointestinal	O
bleeding	O
.	O

Corticosteroids	O
:	O
Concomitant	O
administration	O
with	O
aspirin	B-Drug
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
and	O
may	O
reduce	O
serum	O
salicylate	B-Drug
levels	O
.	O

Pyrazolone	O
Derivatives	O
(	O
phenylbutazone	B-Drug
,	O
oxyphenbutazone	B-Drug
,	O
and	O
possibly	O
dipyrone	B-Drug
)	O
:	O
Concomitant	O
administration	O
with	O
aspirin	B-Drug
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
.	O

Nonsteroidal	B-Drug
Antiinflammatory	I-Drug
Agents	O
:	O
Aspirin	B-Drug
is	O
contraindicated	O
in	O
patients	O
who	O
are	O
hypersensitive	O
to	O
nonsteroidal	B-Drug
anti-inflammatory	I-Drug
agents	O
.	O

Urinary	O
Alkalinizers	O
:	O
Decrease	O
aspirin	B-Drug
effectiveness	O
by	O
increasing	O
the	O
rate	O
of	O
salicylate	B-Drug
renal	O
excretion	O
.	O

Phenobarbital	B-Drug
:	O
Decreases	O
aspirin	B-Drug
effectiveness	O
by	O
enzyme	O
induction	O
.	O

Phenytoin	B-Drug
:	O
Serum	O
phenytoin	B-Drug
levels	O
may	O
be	O
increased	O
by	O
aspirin	B-Drug
.	O

Propranolol	B-Drug
:	O
May	O
decrease	O
aspirins	B-Drug
anti-inflammatory	O
action	O
by	O
competing	O
for	O
the	O
same	O
receptors	O
.	O

Antacids	O
:	O
Enteric	O
Coated	O
Aspirin	B-Drug
should	O
not	O
be	O
given	O
concurrently	O
with	O
antacids	O
,	O
since	O
an	O
increase	O
in	O
the	O
pH	O
of	O
the	O
stomach	O
may	O
effect	O
the	O
enteric	O
coating	O
of	O
the	O
tablets	O
.	O

Ketoconazole/Itraconazole	B-Drug
,	O
Macrolides	O
,	O
Including	O
Erythromycin	B-Drug
Catecholamine-depleting	O
drugs	B-Drug
(	O
eg	O
,	O
reserpine	B-Drug
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta-blocking	B-Drug
agents	O
.	O

Patients	O
treated	O
with	O
TENORMIN	B-Drug
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
and/or	O
marked	O
bradycardia	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Calcium	B-Drug
channel	O
blockers	O
may	O
also	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
TENORMIN	B-Drug
.	O

Beta	O
blockers	O
may	O
exacerbate	O
the	O
rebound	O
hypertension	O
which	O
can	O
follow	O
the	O
withdrawal	O
of	O
clonidine	B-Drug
.	O

If	O
the	O
two	O
drugs	B-Drug
are	O
coadministered	O
,	O
the	O
beta	O
blocker	O
should	O
be	O
withdrawn	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	B-Drug
.	O

If	O
replacing	O
clonidine	B-Drug
by	O
beta-blocker	O
therapy	O
,	O
the	O
introduction	O
of	O
beta	O
blockers	O
should	O
be	O
delayed	O
for	O
several	O
days	O
after	O
clonidine	B-Drug
administration	O
has	O
stopped	O
.	O

Concomitant	O
use	O
of	O
prostaglandin	O
synthase	O
inhibiting	O
drugs	B-Drug
,	O
eg	O
,	O
indomethacin	B-Drug
,	O
may	O
decrease	O
the	O
hypotensive	O
effects	O
of	O
beta	O
blockers	O
.	O

Information	O
on	O
concurrent	O
usage	O
of	O
atenolol	B-Drug
and	O
aspirin	B-Drug
is	O
limited	O
.	O

Data	O
from	O
several	O
studies	O
,	O
ie	O
,	O
TIMI-II	O
,	O
ISIS-2	O
,	O
currently	O
do	O
not	O
suggest	O
any	O
clinical	O
interaction	O
between	O
aspirin	B-Drug
and	O
beta	O
blockers	O
in	O
the	O
acute	O
myocardial	O
infarction	O
setting	O
.	O

While	O
taking	O
beta	O
blockers	O
,	O
patients	O
with	O
a	O
history	O
of	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
have	O
a	O
more	O
severe	O
reaction	O
on	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
the	O
allergic	O
reaction	O
.	O

Drug-Drug	O
Interactions	O
Albuterol	B-Drug
-	O
STRATTERA	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
systemically-administered	O
(	O
oral	O
or	O
intravenous	O
)	O
albuterol	B-Drug
(	O
or	O
other	O
beta2	O
agonists	O
)	O
because	O
the	O
action	O
of	O
albuterol	B-Drug
on	O
the	O
cardiovascular	O
system	O
can	O
be	O
potentiated	O
resulting	O
in	O
increases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O

CYP2D6	B-Drug
inhibitors	O
-	O
Atomoxetine	B-Drug
is	O
primarily	O
metabolized	O
by	O
the	O
CYP2D6	B-Drug
pathway	O
to	O
4-hydroxyatomoxetine	B-Drug
.	O

In	O
EMs	O
,	O
selective	O
inhibitors	O
of	O
CYP2D6	B-Drug
increase	O
atomoxetine	B-Drug
steady-state	O
plasma	O
concentrations	O
to	O
exposures	O
similar	O
to	O
those	O
observed	O
in	O
PMs	O
.	O

Dosage	O
adjustment	O
of	O
STRATTERA	B-Drug
may	O
be	O
necessary	O
when	O
coadministered	O
with	O
CYP2D6	B-Drug
inhibitors	O
,	O
e.g.	O
,	O
paroxetine	B-Drug
,	O
fluoxetine	B-Drug
,	O
and	O
quinidine	B-Drug
.	O

In	O
EM	O
individuals	O
treated	O
with	O
paroxetine	B-Drug
or	O
fluoxetine	B-Drug
,	O
the	O
AUC	O
of	O
atomoxetine	B-Drug
is	O
approximately	O
6-	O
to	O
8-fold	O
and	O
Css	O
,	O
max	O
is	O
about	O
3-	O
to	O
4-fold	O
greater	O
than	O
atomoxetine	B-Drug
alone	O
.	O

In	O
vitro	O
studies	O
suggest	O
that	O
coadministration	O
of	O
cytochrome	O
P450	O
inhibitors	O
to	O
PMs	O
will	O
not	O
increase	O
the	O
plasma	O
concentrations	O
of	O
atomoxetine	B-Drug
.	O

Pressor	O
agents	O
-	O
Because	O
of	O
possible	O
effects	O
on	O
blood	O
pressure	O
,	O
STRATTERA	B-Drug
should	O
be	O
used	O
cautiously	O
with	O
pressor	O
agents	O
.	O

The	O
risk	O
of	O
myopathy	O
during	O
treatment	O
with	O
drugs	B-Drug
of	O
this	O
class	O
is	O
increased	O
with	O
concurrent	O
administration	O
of	O
cyclosporine	B-Drug
,	O
fibric	O
acid	O
derivatives	O
,	O
niacin	B-Drug
(	O
nicotinic	B-Drug
acid	I-Drug
)	O
,	O
erythromycin	B-Drug
,	O
azole	O
antifungals	O
.	O

Antacid	O
:	O
When	O
atorvastatin	B-Drug
and	O
Maalox	B-Drug
TC	I-Drug
suspension	O
were	O
coadministered	O
,	O
plasma	O
concentrations	O
of	O
atorvastatin	B-Drug
decreased	O
approximately	O
35	O
%	O
.	O

However	O
,	O
LDL-C	O
reduction	O
was	O
not	O
altered	O
.	O

Antipyrine	B-Drug
:	O
Because	O
atorvastatin	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
antipyrine	B-Drug
,	O
interactions	O
with	O
other	O
drugs	B-Drug
metabolized	O
via	O
the	O
same	O
cytochrome	O
isozymes	O
are	O
not	O
expected	O
.	O

Colestipol	B-Drug
:	O
Plasma	O
concentrations	O
of	O
atorvastatin	B-Drug
decreased	O
approximately	O
25	O
%	O
when	O
colestipol	B-Drug
and	O
atorvastatin	B-Drug
were	O
coadministered	O
.	O

However	O
,	O
LDL-C	O
reduction	O
was	O
greater	O
when	O
atorvastatin	B-Drug
and	O
colestipol	B-Drug
were	O
coadministered	O
than	O
when	O
either	O
drug	B-Drug
was	O
given	O
alone	O
.	O

Cimetidine	B-Drug
:	O
Atorvastatin	B-Drug
plasma	O
concentrations	O
and	O
LDL-C	O
reduction	O
were	O
not	O
altered	O
by	O
coadministration	O
of	O
cimetidine	B-Drug
.	O

Digoxin	B-Drug
:	O
When	O
multiple	O
doses	O
of	O
atorvastatin	B-Drug
and	O
digoxin	B-Drug
were	O
coadministered	O
,	O
steady-state	O
plasma	O
digoxin	B-Drug
concentrations	O
increased	O
by	O
approximately	O
20	O
%	O
.	O

Patients	O
taking	O
digoxin	B-Drug
should	O
be	O
monitored	O
appropriately	O
.	O

Erythromycin	B-Drug
:	O
In	O
healthy	O
individuals	O
,	O
plasma	O
concentrations	O
of	O
atorvastatin	B-Drug
increased	O
approximately	O
40	O
%	O
with	O
coadministration	O
of	O
atorvastatin	B-Drug
and	O
erythromycin	B-Drug
,	O
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
.	O

Oral	O
Contraceptives	O
:	O
Coadministration	O
of	O
atorvastatin	B-Drug
and	O
an	O
oral	O
contraceptive	O
increased	O
AUC	O
values	O
for	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
by	O
approximately	O
30	O
%	O
and	O
20	O
%	O
.	O

These	O
increases	O
should	O
be	O
considered	O
when	O
selecting	O
an	O
oral	O
contraceptive	O
for	O
a	O
woman	O
taking	O
atorvastatin	B-Drug
.	O

Warfarin	B-Drug
:	O
Atorvastatin	B-Drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
prothrombin	O
time	O
when	O
administered	O
to	O
patients	O
receiving	O
chronic	O
warfarin	B-Drug
treatment	O
.	O

Endocrine	O
Function	O
HMG-CoA	O
reductase	O
inhibitors	O
interfere	O
with	O
cholesterol	O
synthesis	O
and	O
theoretically	O
might	O
blunt	O
adrenal	O
and/or	O
gonadal	O
steroid	O
production	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
atorvastatin	B-Drug
does	O
not	O
reduce	O
basal	O
plasma	O
cortisol	O
concentration	O
or	O
impair	O
adrenal	O
reserve	O
.	O

The	O
effects	O
of	O
HMG-CoA	O
reductase	O
inhibitors	O
on	O
male	O
fertility	O
have	O
not	O
been	O
studied	O
in	O
adequate	O
numbers	O
of	O
patients	O
.	O

The	O
effects	O
,	O
if	O
any	O
,	O
on	O
the	O
pituitary-gonadal	O
axis	O
in	O
premenopausal	O
women	O
are	O
unknown	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
an	O
HMG-CoA	O
reductase	O
inhibitor	O
is	O
administered	O
concomitantly	O
with	O
drugs	B-Drug
that	O
may	O
decrease	O
the	O
levels	O
or	O
activity	O
of	O
endogenous	O
steroid	O
hormones	O
,	O
such	O
as	O
ketoconazole	B-Drug
,	O
spironolactone	B-Drug
,	O
and	O
cimetidine	B-Drug
.	O

CNS	O
Toxicity	O
Brain	O
hemorrhage	O
was	O
seen	O
in	O
a	O
female	O
dog	O
treated	O
for	O
3	O
months	O
at	O
120	O
mg/kg/day	O
.	O

Brain	O
hemorrhage	O
and	O
optic	O
nerve	O
vacuolation	O
were	O
seen	O
in	O
another	O
female	O
dog	O
that	O
was	O
sacrificed	O
in	O
moribund	O
condition	O
after	O
11	O
weeks	O
of	O
escalating	O
doses	O
up	O
to	O
280	O
mg/kg/day	O
.	O

The	O
120	O
mg/kg	O
dose	O
resulted	O
in	O
a	O
systemic	O
exposure	O
approximately	O
16	O
times	O
the	O
human	O
plasma	O
area-under-the-curve	O
(	O
AUC	O
,	O
0-24	O
hours	O
)	O
based	O
on	O
the	O
maximum	O
human	O
dose	O
of	O
80	O
mg/day	O
.	O

A	O
single	O
tonic	O
convulsion	O
was	O
seen	O
in	O
each	O
of	O
2	O
male	O
dogs	O
(	O
one	O
treated	O
at	O
10	O
mg/kg/day	O
and	O
one	O
at	O
120	O
mg/kg/day	O
)	O
in	O
a	O
2-year	O
study	O
.	O

No	O
CNS	O
lesions	O
have	O
been	O
observed	O
in	O
mice	O
after	O
chronic	O
treatment	O
for	O
up	O
to	O
2	O
years	O
at	O
doses	O
up	O
to	O
400	O
mg/kg/day	O
or	O
in	O
rats	O
at	O
doses	O
up	O
to	O
100	O
mg/kg/day	O
.	O

These	O
doses	O
were	O
6	O
to	O
11	O
times	O
(	O
mouse	O
)	O
and	O
8	O
to	O
16	O
times	O
(	O
rat	O
)	O
the	O
human	O
AUC	O
(	O
0-24	O
)	O
based	O
on	O
the	O
maximum	O
recommended	O
human	O
dose	O
of	O
80	O
mg/day	O
.	O

CNS	O
vascular	O
lesions	O
,	O
characterized	O
by	O
perivascular	O
hemorrhages	O
,	O
edema	O
,	O
and	O
mononuclear	O
cell	O
infiltration	O
of	O
perivascular	O
spaces	O
,	O
have	O
been	O
observed	O
in	O
dogs	O
treated	O
with	O
other	O
members	O
of	O
this	O
class	O
.	O

A	O
chemically	O
similar	O
drug	B-Drug
in	O
this	O
class	O
produced	O
optic	O
nerve	O
degeneration	O
(	O
Wallerian	O
degeneration	O
of	O
retinogeniculate	O
fibers	O
)	O
in	O
clinically	O
normal	O
dogs	O
in	O
a	O
dose-dependent	O
fashion	O
at	O
a	O
dose	O
that	O
produced	O
plasma	O
drug	B-Drug
levels	O
about	O
30	O
times	O
higher	O
than	O
the	O
mean	O
drug	B-Drug
level	O
in	O
humans	O
taking	O
the	O
highest	O
recommended	O
dose	O
.	O

Atovaquone	B-Drug
is	O
highly	O
bound	O
to	O
plasma	O
protein	O
(	O
99.9	O
%	O
)	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
MEPRON	B-Drug
concurrently	O
with	O
other	O
highly	O
plasma	O
protein-	O
bound	O
drugs	B-Drug
with	O
narrow	O
therapeutic	O
indices	O
,	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
.	O

The	O
extent	O
of	O
plasma	O
protein	O
binding	O
of	O
atovaquone	B-Drug
in	O
human	O
plasma	O
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
therapeutic	O
concentrations	O
of	O
phenytoin	B-Drug
(	O
15	O
mcg/	O
mL	O
)	O
,	O
nor	O
is	O
the	O
binding	O
of	O
phenytoin	B-Drug
affected	O
by	O
the	O
presence	O
of	O
atovaquone	B-Drug
.	O

Rifampin	B-Drug
:	O
Coadministration	O
of	O
rifampin	B-Drug
and	O
MEPRON	B-Drug
Suspension	O
results	O
in	O
a	O
significant	O
decrease	O
in	O
average	O
steady-	O
state	O
plasma	O
atovaquone	B-Drug
concentrations	O
.	O

Alternatives	O
to	O
rifampin	B-Drug
should	O
be	O
considered	O
during	O
the	O
course	O
of	O
PCP	B-Drug
treatment	O
with	O
MEPRON	B-Drug
.	O

Rifabutin	B-Drug
,	O
another	O
rifamycin	B-Drug
,	O
is	O
structurally	O
similar	O
to	O
rifampin	B-Drug
and	O
may	O
possibly	O
have	O
some	O
of	O
the	O
same	O
drug	B-Drug
interactions	O
as	O
rifampin	B-Drug
.	O

No	O
interaction	O
trials	O
have	O
been	O
conducted	O
with	O
MEPRON	B-Drug
and	O
rifabutin	B-Drug
.	O

Drug/	O
Laboratory	O
Test	O
Interactions	O
:	O
It	O
is	O
not	O
known	O
if	O
MEPRON	B-Drug
interferes	O
with	O
clinical	O
laboratory	O
test	O
or	O
assay	O
results	O
.	O

Drugs	B-Drug
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	B-Drug
include	O
:	O
enflurane	B-Drug
;	O
isoflurane	B-Drug
;	O
halothane	B-Drug
;	O
certain	O
antibiotics	B-Drug
,	O
especially	O
the	O
aminoglycosides	O
and	O
polymyxins	O
;	O
lithium	B-Drug
;	O
magnesium	B-Drug
salts	O
;	O
procainamide	B-Drug
;	O
Drugs	B-Drug
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	B-Drug
include	O
:	O
enflurane	B-Drug
;	O
isoflurane	B-Drug
;	O
halothane	B-Drug
;	O
certain	O
antibiotics	B-Drug
,	O
especially	O
the	O
aminoglycosides	O
and	O
polymyxins	O
;	O
lithium	B-Drug
;	O
magnesium	B-Drug
salts	O
;	O
procainamide	B-Drug
;	O
and	O
quinidine	B-Drug
.	O

If	O
other	O
muscle	O
relaxants	O
are	O
used	O
during	O
the	O
same	O
procedure	O
,	O
the	O
possibility	O
of	O
a	O
synergistic	O
or	O
antagonist	O
effect	O
should	O
be	O
considered	O
.	O

The	O
prior	O
administration	O
of	O
succinylcholine	B-Drug
does	O
not	O
enhance	O
the	O
duration	O
,	O
but	O
quickens	O
the	O
onset	O
and	O
may	O
increase	O
the	O
depth	O
,	O
of	O
neuromuscular	O
block	O
induced	O
by	O
TRACRIUM	B-Drug
.	O

TRACRIUM	B-Drug
should	O
not	O
be	O
administered	O
until	O
a	O
patient	O
has	O
recovered	O
from	O
succinylcholine-induced	B-Drug
neuromuscular	O
block	O
.	O

When	O
atropine	B-Drug
and	O
pralidoxime	B-Drug
are	O
used	O
together	O
,	O
the	O
signs	O
of	O
atropinization	O
(	O
flushing	O
,	O
mydriasis	O
,	O
tachycardia	O
,	O
dryness	O
of	O
the	O
mouth	O
and	O
nose	O
)	O
may	O
occur	O
earlier	O
than	O
might	O
be	O
expected	O
than	O
when	O
atropine	B-Drug
is	O
used	O
alone	O
because	O
pralidoxime	B-Drug
may	O
potentiate	O
the	O
effect	O
of	O
atropine	B-Drug
.	O

The	O
following	O
precautions	O
should	O
be	O
kept	O
in	O
mind	O
in	O
the	O
treatment	O
of	O
anticholinesterase	O
poisoning	O
although	O
they	O
do	O
not	O
bear	O
directly	O
on	O
the	O
use	O
of	O
atropine	B-Drug
and	O
pralidoxime	B-Drug
.	O

Since	O
barbiturates	B-Drug
are	O
potentiated	O
by	O
the	O
anticholinesterases	O
,	O
they	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
convulsions	O
.	O

Auranofin	B-Drug
should	O
be	O
avoided	O
by	O
patients	O
with	O
a	O
history	O
of	O
serious	O
reaction	O
to	O
any	O
gold	B-Drug
medication	O
,	O
including	O
Solganal	B-Drug
and	O
Myochrysine	B-Drug
.	O

Auranofin	B-Drug
should	O
not	O
be	O
used	O
together	O
with	O
penicillamine	B-Drug
(	O
Depen	B-Drug
,	O
Cuprimine	B-Drug
)	O
,	O
another	O
arthritis	O
medication	O
.	O

It	O
should	O
also	O
be	O
avoided	O
in	O
patients	O
with	O
blood	O
,	O
liver	O
or	O
kidney	O
diseases	O
,	O
recent	O
radiation	O
treatment	O
,	O
or	O
uncontrolled	O
diabetes	O
.	O

Patients	O
should	O
report	O
to	O
their	O
practitioners	O
any	O
new	O
rashes	O
,	O
itching	O
,	O
mouth	O
sores	O
,	O
or	O
unusual	O
taste	O
while	O
taking	O
auranofin	B-Drug
.	O

Gold	B-Drug
is	O
excreted	O
slowly	O
from	O
the	O
body	O
.	O

Safety	O
and	O
effectiveness	O
in	O
children	O
has	O
not	O
been	O
established	O
.	O

No	O
formal	O
assessments	O
of	O
drug-drug	O
interactions	O
between	O
Vidaza	B-Drug
and	O
other	O
agents	O
have	O
been	O
conducted	O
.	O

MAO	O
inhibitors	O
prolong	O
and	O
intensify	O
the	O
effects	O
of	O
antihistamines	B-Drug
.	O

Concomitant	O
use	O
of	O
antihistamines	B-Drug
with	O
alcohol	B-Drug
,	O
tricyclic	O
antidepressants	B-Drug
,	O
barbiturates	B-Drug
,	O
or	O
other	O
central	O
nervous	O
system	O
depressants	O
may	O
have	O
an	O
additive	O
effect	O
.	O

When	O
sympathomimetic	B-Drug
drugs	B-Drug
are	O
given	O
to	O
patients	O
receiving	O
monoamine	O
oxidase	O
inhibitors	O
,	O
hypertensive	O
reactions	O
,	O
including	O
hypertensive	O
crises	O
,	O
may	O
occur	O
.	O

The	O
antihypertensive	B-Drug
effects	O
of	O
methyldopa	B-Drug
,	O
mecamylamine	B-Drug
,	O
reserpine	B-Drug
,	O
and	O
veratrum	B-Drug
alkaloids	I-Drug
may	O
be	O
reduced	O
by	O
sympathomimetics	O
.	O

Beta-adrenergic	O
blocking	O
agents	O
may	O
also	O
interact	O
with	O
sympathomimetics	O
.	O

Increased	O
ectopic	O
pacemaker	O
activity	O
can	O
occur	O
when	O
pseudoephedrine	B-Drug
is	O
used	O
concomitantly	O
with	O
digitalis	B-Drug
.	O

Antacids	O
increase	O
the	O
rate	O
of	O
absorption	O
of	O
pseudoephedrine	B-Drug
,	O
while	O
kaolin	B-Drug
decreases	O
it	O
.	O

Use	O
with	O
Allopurinol	B-Drug
:	O
The	O
principal	O
pathway	O
for	O
detoxification	O
of	O
azathioprine	B-Drug
is	O
inhibited	O
by	O
allopurinol	B-Drug
.	O

Patients	O
receiving	O
azathioprine	B-Drug
and	O
allopurinol	B-Drug
concomitantly	O
should	O
have	O
a	O
dose	O
reduction	O
of	O
azathioprine	B-Drug
,	O
to	O
approximately	O
1/3	O
to	O
1/4	O
the	O
usual	O
dose	O
.	O

Use	O
with	O
Other	O
Agents	O
Affecting	O
Myelopoesis	O
:	O
Drugs	B-Drug
which	O
may	O
affect	O
leukocyte	O
production	O
,	O
including	O
co-trimoxazole	B-Drug
,	O
may	O
lead	B-Drug
to	O
exaggerated	O
leukopenia	O
,	O
especially	O
in	O
renal	O
transplant	O
recipients	O
.	O

Use	O
with	O
Angiotensln	O
Converting	O
Enzyme	O
Inhibitors	O
:	O
The	O
use	O
of	O
angiotensin	B-Drug
converting	O
enzyme	O
inhibitors	O
to	O
control	O
hypertension	O
in	O
patients	O
on	O
azathioprine	B-Drug
has	O
been	O
reported	O
to	O
induce	O
severe	O
leukopenia	O
.	O

No	O
information	O
provided	O
Co-administration	O
of	O
nelfinavir	B-Drug
at	O
steady-state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	B-Drug
.	O

Co-administration	O
of	O
nelfinavir	B-Drug
at	O
steady-state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	B-Drug
(	O
2	O
x	O
600	O
mg	O
tablets	O
)	O
results	O
in	O
increased	O
azithromycin	B-Drug
serum	O
concentrations	O
.	O

Although	O
a	O
dose	O
adjustment	O
of	O
azithromycin	B-Drug
is	O
not	O
recommended	O
when	O
administered	O
in	O
combination	O
with	O
nelfinavir	B-Drug
,	O
close	O
monitoring	O
for	O
known	O
side	O
effects	O
of	O
azithromycin	B-Drug
,	O
such	O
as	O
liver	O
enzyme	O
abnormalities	O
and	O
hearing	O
impairment	O
,	O
is	O
warranted	O
.	O

Azithromycin	B-Drug
did	O
not	O
affect	O
the	O
prothrombin	O
time	O
response	O
to	O
a	O
single	O
dose	O
of	O
warfarin	B-Drug
.	O

However	O
,	O
prudent	O
medical	O
practice	O
dictates	O
careful	O
monitoring	O
of	O
prothrombin	O
time	O
in	O
all	O
patients	O
treated	O
with	O
azithromycin	B-Drug
and	O
warfarin	B-Drug
concomitantly	O
.	O

Concurrent	O
use	O
of	O
macrolides	O
and	O
warfarin	B-Drug
in	O
clinical	O
practice	O
has	O
been	O
associated	O
with	O
increased	O
anticoagulant	B-Drug
effects	O
.	O

Drug	B-Drug
interaction	O
studies	O
were	O
performed	O
with	O
azithromycin	B-Drug
and	O
other	O
drugs	B-Drug
likely	O
to	O
be	O
co-administered	O
.	O

When	O
used	O
in	O
therapeutic	O
doses	O
,	O
azithromycin	B-Drug
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
atorvastatin	B-Drug
,	O
carbamazepine	B-Drug
,	O
cetirizine	B-Drug
,	O
didanosine	B-Drug
,	O
efavirenz	B-Drug
,	O
fluconazole	B-Drug
,	O
indinavir	B-Drug
,	O
midazolam	B-Drug
,	O
rifabutin	B-Drug
,	O
sildenafil	B-Drug
,	O
theophylline	B-Drug
(	O
intravenous	O
and	O
oral	O
)	O
,	O
triazolam	B-Drug
,	O
trimethoprim/sulfamethoxazole	B-Drug
or	O
zidovudine	B-Drug
.	O

Co-administration	O
with	O
efavirenz	B-Drug
or	O
fluconazole	B-Drug
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
azithromycin	B-Drug
.	O

No	O
dosage	O
adjustment	O
of	O
either	O
drug	B-Drug
is	O
recommended	O
when	O
azithromycin	B-Drug
is	O
co	B-Drug
administered	O
with	O
any	O
of	O
the	O
above	O
agents	O
.	O

Interactions	O
with	O
the	O
drugs	B-Drug
listed	O
below	O
have	O
not	O
been	O
reported	O
in	O
clinical	O
trials	O
with	O
azithromycin	B-Drug
;	O
however	O
,	O
no	O
specific	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
to	O
evaluate	O
potential	O
drug-drug	O
interaction	O
.	O

Nonetheless	O
,	O
they	O
have	O
been	O
observed	O
with	O
macrolide	O
products	O
.	O

Until	O
further	O
data	O
are	O
developed	O
regarding	O
drug	B-Drug
interactions	O
when	O
azithromycin	B-Drug
and	O
these	O
drugs	B-Drug
are	O
used	O
concomitantly	O
,	O
careful	O
monitoring	O
of	O
patients	O
is	O
advised	O
:	O
Digoxin	B-Drug
elevated	O
digoxin	B-Drug
concentrations	O
.	O

Ergotamine	B-Drug
or	O
dihydroergotamine	B-Drug
acute	O
ergot	B-Drug
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Cyclosporine	B-Drug
,	O
hexobarbital	B-Drug
and	O
phenytoin	B-Drug
concentrations	O
.	O

Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
laboratory	O
test	O
interactions	O
.	O

Repeat	O
Treatment	O
Studies	O
evaluating	O
the	O
use	O
of	O
repeated	O
courses	O
of	O
Zmax	B-Drug
have	O
not	O
been	O
conducted	O
.	O

Azlocillin	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
amikacin	B-Drug
,	O
ciprofloxacin	B-Drug
,	O
gentamicin	B-Drug
,	O
netilmicin	B-Drug
,	O
or	O
tobramycin	B-Drug
.	O

Injection	O
There	O
is	O
inadequate	O
systematic	O
experience	O
with	O
the	O
use	O
of	O
baclofen	B-Drug
injection	O
in	O
combination	O
with	O
other	O
medications	O
to	O
predict	O
specific	O
drug-drug	O
interactions	O
.	O

Interactions	O
attributed	O
to	O
the	O
combined	O
use	O
of	O
baclofen	B-Drug
injection	O
and	O
epidural	O
morphine	B-Drug
include	O
hypotension	O
and	O
dyspnea	O
.	O

SIDE	O
EFFECTS	O
(	O
KEMSTRO	B-Drug
)	O
The	O
most	O
common	O
adverse	O
reaction	O
during	O
treatment	O
with	O
baclofen	B-Drug
is	O
transient	O
drowsiness	O
(	O
10-63	O
%	O
)	O
.	O

In	O
one	O
controlled	O
study	O
of	O
175	O
patients	O
,	O
transient	O
drowsiness	O
was	O
observed	O
in	O
63	O
%	O
of	O
those	O
receiving	O
baclofen	B-Drug
tablets	O
compared	O
to	O
36	O
%	O
of	O
those	O
in	O
the	O
placebo	O
group	O
.	O

Other	O
common	O
adverse	O
reactions	O
are	O
dizziness	O
(	O
5-15	O
%	O
)	O
,	O
weakness	O
(	O
5-15	O
%	O
)	O
and	O
fatigue	O
(	O
2-4	O
%	O
)	O
.	O

Others	O
reported	O
:	O
Neuropsychiatric	O
:	O
Confusion	O
(	O
1-11	O
%	O
)	O
,	O
headache	O
(	O
4-8	O
%	O
)	O
,	O
insomnia	O
(	O
2-7	O
%	O
)	O
;	O
and	O
,	O
rarely	O
,	O
euphoria	O
,	O
excitement	O
,	O
depression	O
,	O
hallucinations	O
,	O
paresthesia	O
,	O
muscle	O
pain	O
,	O
tinnitus	O
,	O
slurred	O
speech	O
,	O
coordination	O
disorder	O
,	O
tremor	O
,	O
rigidity	O
,	O
dystonia	O
,	O
ataxia	O
,	O
blurred	O
vision	O
,	O
nystagmus	O
,	O
strabismus	O
,	O
miosis	O
,	O
mydriasis	O
,	O
diplopia	O
,	O
dysarthria	O
,	O
epileptic	O
seizure	O
.	O

Cardiovascular	O
:	O
Hypotension	O
(	O
0-9	O
%	O
)	O
.	O

Rare	O
instances	O
of	O
dyspnea	O
,	O
palpitation	O
,	O
chest	O
pain	O
,	O
syncope	O
.	O

Gastrointestinal	O
:	O
Nausea	O
(	O
4-12	O
%	O
)	O
,	O
constipation	O
(	O
2-6	O
%	O
)	O
;	O
and	O
,	O
rarely	O
,	O
dry	O
mouth	O
,	O
anorexia	O
,	O
taste	O
disorder	O
,	O
abdominal	O
pain	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
and	O
positive	O
test	O
for	O
occult	O
blood	O
in	O
stool	O
.	O

Genitourinary	O
:	O
Urinary	O
frequency	O
(	O
2-6	O
%	O
)	O
;	O
and	O
,	O
rarely	O
,	O
enuresis	O
,	O
urinary	O
retention	O
,	O
dysuria	O
,	O
impotence	O
,	O
inability	O
to	O
ejaculate	O
,	O
nocturia	O
,	O
hematuria	O
.	O

Other	O
:	O
Instances	O
of	O
rash	O
,	O
pruritus	O
,	O
ankle	O
edema	O
,	O
excessive	O
perspiration	O
,	O
weight	O
gain	O
,	O
nasal	O
congestion	O
.	O

Some	O
of	O
the	O
CNS	O
and	O
genitourinary	O
symptoms	O
may	O
be	O
related	O
to	O
the	O
underlying	O
disease	O
rather	O
than	O
to	O
drug	B-Drug
therapy	O
.	O

The	O
following	O
laboratory	O
tests	O
have	O
been	O
found	O
to	O
be	O
abnormal	O
in	O
a	O
few	O
patients	O
receiving	O
baclofen	B-Drug
:	O
increased	O
SGOT	O
,	O
elevated	O
alkaline	O
phosphatase	O
,	O
and	O
elevation	O
of	O
blood	O
sugar	O
.	O

The	O
adverse	O
experience	O
profile	O
seen	O
with	O
KEMSTROTM	B-Drug
was	O
similar	O
to	O
that	O
seen	O
with	O
baclofen	B-Drug
tablets	O
.	O

No	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
for	O
COLAZAL	B-Drug
,	O
however	O
the	O
use	O
of	O
orally	O
administered	O
antibiotics	B-Drug
could	O
,	O
theoretically	O
,	O
interfere	O
with	O
the	O
release	O
of	O
mesalamine	B-Drug
in	O
the	O
colon	O
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
when	O
Simulect	B-Drug
is	O
added	O
to	O
triple-immunosuppression	O
regimens	O
including	O
cyclosporine	B-Drug
,	O
corticosteroids	O
,	O
and	O
either	O
azathioprine	B-Drug
or	O
mycophenolate	B-Drug
mofetil	I-Drug
.	O

Three	O
clinical	O
trials	O
have	O
investigated	O
Simulect	B-Drug
use	O
in	O
combination	O
with	O
triple-therapy	O
regimens	O
.	O

Pharmacokinetics	O
were	O
assessed	O
in	O
two	O
of	O
these	O
trials	O
.	O

Total	O
body	O
clearance	O
of	O
Simulect	B-Drug
was	O
reduced	O
by	O
an	O
average	O
22	O
%	O
and	O
51	O
%	O
when	O
azathioprine	B-Drug
and	O
mycophenolate	B-Drug
mofetil	I-Drug
,	O
respectively	O
,	O
were	O
added	O
to	O
a	O
regimen	O
consisting	O
of	O
cyclosporine	B-Drug
,	O
USP	O
(	O
MODIFIED	O
)	O
and	O
corticosteroids	O
.	O

Nonetheless	O
,	O
the	O
range	O
of	O
individual	O
Simulect	B-Drug
clearance	O
values	O
in	O
the	O
presence	O
of	O
azathioprine	B-Drug
(	O
12-57	O
mL/h	O
)	O
or	O
mycophenolate	B-Drug
mofetil	I-Drug
(	O
7-54	O
mL/h	O
)	O
did	O
not	O
extend	O
outside	O
the	O
range	O
observed	O
with	O
dual	O
therapy	O
(	O
10-78	O
mL/h	O
)	O
.	O

The	O
following	O
medications	O
have	O
been	O
administered	O
in	O
clinical	O
trials	O
with	O
Simulect	B-Drug
with	O
no	O
increase	O
in	O
adverse	O
reactions	O
:	O
ATG/ALG	O
,	O
azathioprine	B-Drug
,	O
corticosteroids	O
,	O
cyclosporine	B-Drug
,	O
mycophenolate	B-Drug
mofetil	I-Drug
,	O
and	O
muromonab-CD3	B-Drug
.	O

It	O
is	O
not	O
known	O
if	O
REGRANEX	B-Drug
Gel	O
interacts	O
with	O
other	O
topical	O
medications	O
applied	O
to	O
the	O
ulcer	O
site	O
.	O

The	O
use	O
of	O
REGRANEX	B-Drug
Gel	O
with	O
other	O
topical	O
drugs	B-Drug
has	O
not	O
been	O
studied	O
.	O

Albuterol	B-Drug
,	O
Antihistamines	B-Drug
,	O
antidiabetic	B-Drug
drugs	B-Drug
,	O
diuretics	B-Drug
,	O
digitalis	B-Drug
.	O

Diuretics	B-Drug
:	O
Patients	O
on	O
diuretics	B-Drug
,	O
especially	O
those	O
in	O
whom	O
diuretic	B-Drug
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
Lotensin	B-Drug
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
Lotensin	B-Drug
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Drug
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
Lotensin	B-Drug
.	O

If	O
this	O
is	O
not	O
possible	O
,	O
the	O
starting	O
dose	O
should	O
be	O
reduced	O
.	O

Potassium	B-Drug
Supplements	O
and	O
Potassium-Sparing	O
Diuretics	B-Drug
Lotensin	B-Drug
can	O
attenuate	O
potassium	B-Drug
loss	O
caused	O
by	O
thiazide	O
diuretics	B-Drug
.	O

Potassium-sparing	O
diuretics	B-Drug
(	O
spironolactone	B-Drug
,	O
amiloride	B-Drug
,	O
triamterene	B-Drug
,	O
and	O
others	O
)	O
or	O
potassium	B-Drug
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
,	O
they	O
should	O
be	O
given	O
with	O
caution	O
,	O
and	O
the	O
patient	O
's	O
serum	O
potassium	B-Drug
should	O
be	O
monitored	O
frequently	O
.	O

Oral	O
Anticoagulants	B-Drug
Interaction	O
studies	O
with	O
warfarin	B-Drug
and	O
acenocoumarol	B-Drug
failed	O
to	O
identify	O
any	O
clinically	O
important	O
effects	O
on	O
the	O
serum	O
concentrations	O
or	O
clinical	O
effects	O
of	O
these	O
anticoagulants	B-Drug
.	O

Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
levels	O
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	O
inhibitors	O
during	O
therapy	O
with	O
lithium	B-Drug
.	O

These	O
drugs	B-Drug
should	O
be	O
coadministered	O
with	O
caution	O
,	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	B-Drug
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
may	O
be	O
increased	O
.	O

Other	O
No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
Lotensin	B-Drug
was	O
administered	O
concomitantly	O
with	O
hydrochlorothiazide	B-Drug
,	O
chlorthalidone	B-Drug
,	O
furosemide	B-Drug
,	O
digoxin	B-Drug
,	O
propranolol	B-Drug
,	O
atenolol	B-Drug
,	O
naproxen	B-Drug
,	O
or	O
cimetidine	B-Drug
.	O

Lotensin	B-Drug
has	O
been	O
used	O
concomitantly	O
with	O
beta-adrenergic-blocking	O
agents	O
,	O
calcium-channel-blocking	O
agents	O
,	O
diuretics	B-Drug
,	O
digoxin	B-Drug
,	O
and	O
hydralazine	B-Drug
,	O
without	O
evidence	O
of	O
clinically	O
important	O
adverse	O
interactions	O
.	O

Benazepril	B-Drug
,	O
like	O
other	O
ACE	O
inhibitors	O
,	O
has	O
had	O
less	O
than	O
additive	O
effects	O
with	O
beta-adrenergic	O
blockers	O
,	O
presumably	O
because	O
both	O
drugs	B-Drug
lower	O
blood	O
pressure	O
by	O
inhibiting	O
parts	O
of	O
the	O
renin-angiotensin	O
system	O
.	O

May	O
interact	O
with	O
the	O
following	O
:	O
cholestyramine	B-Drug
,	O
colestipol	B-Drug
(	O
use	O
with	O
thiazide	O
diuretics	B-Drug
may	O
prevent	O
the	O
diuretic	B-Drug
from	O
working	O
properly	O
;	O
Bentiromide	B-Drug
may	O
interact	O
with	O
acetaminophen	B-Drug
(	O
e.g.	O
,	O
Tylenol	B-Drug
)	O
,	O
chloramphenicol	B-Drug
(	O
e.g.	O
,	O
Chloromycetin	B-Drug
)	O
,	O
local	O
anesthetics	B-Drug
(	O
e.g.	O
,	O
benzocaine	B-Drug
and	O
lidocaine	B-Drug
)	O
,	O
para-aminobenzoic	B-Drug
acid	I-Drug
(	O
PABA	B-Drug
)	O
-containing	O
preparations	O
(	O
e.g.	O
,	O
sunscreens	O
and	O
some	O
multivitamins	O
)	O
,	O
procainamide	B-Drug
(	O
e.g.	O
,	O
Pronestyl	B-Drug
)	O
,	O
sulfonamides	O
(	O
sulfa	O
medicines	O
)	O
,	O
thiazide	O
diuretics	B-Drug
(	O
use	O
of	O
these	O
medicines	O
during	O
the	O
test	O
period	O
will	O
affect	O
the	O
test	O
results	O
)	O
,	O
and	O
pancreatic	O
supplements	O
(	O
use	O
of	O
pancreatic	O
supplements	O
may	O
give	O
false	O
test	O
results	O
)	O
.	O

May	O
interact	O
with	O
other	O
creams	O
,	O
lotions	O
,	O
or	O
skin	O
medicines	O
when	O
placed	O
on	O
the	O
same	O
areas	O
of	O
your	O
skin	O
that	O
you	O
are	O
using	O
bentoquatam	B-Drug
.	O

No	O
information	O
is	O
available	O
.	O

Hypertensive	O
crises	O
have	O
resulted	O
when	O
sympathomimetic	B-Drug
amines	O
have	O
been	O
used	O
concomitantly	O
within14	O
days	O
following	O
use	O
of	O
monoamine	O
oxidase	O
inhibitors	O
.	O

DIDREX	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
CNS	O
stimulants	O
.	O

Amphetamines	B-Drug
may	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
antihypertensives	B-Drug
.	O

Amphetamines	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	O
antidepressants	B-Drug
.	O

Urinary	O
alkalinizing	O
agents	O
increase	O
blood	O
levels	O
and	O
decrease	O
excretion	O
of	O
amphetamines	B-Drug
.	O

Urinary	B-Drug
acidifying	I-Drug
agents	O
decrease	O
blood	O
levels	O
and	O
increase	O
excretion	O
of	O
amphetamines	B-Drug
.	O

Benzthiazide	B-Drug
may	O
interact	O
with	O
alcohol	B-Drug
,	O
blood	O
thinners	O
,	O
decongestant	O
drugs	B-Drug
(	O
allergy	O
,	O
cold	O
,	O
and	O
sinus	O
medicines	O
)	O
,	O
diabetic	O
drugs	B-Drug
,	O
lithium	B-Drug
,	O
norepinephrine	B-Drug
,	O
NSAIDs	O
like	O
Aleve	B-Drug
or	O
Ibuprofen	B-Drug
,	O
and	O
high	O
blood	O
pressure	O
medications	O
.	O

Antipsychotic	O
drugs	B-Drug
such	O
as	O
phenothiazines	O
or	O
haloperidol	B-Drug
;	O
tricyclic	O
antidepressants	B-Drug
.	O

Nitrates	B-Drug
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	B-Drug
with	O
long-	O
and	O
short-acting	O
nitrates	B-Drug
has	O
been	O
safely	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
pectoris	O
.	O

Sublingual	O
nitroglycerin	B-Drug
may	O
be	O
taken	O
if	O
necessary	O
for	O
the	O
control	O
of	O
acute	O
angina	O
attacks	O
during	O
Bepridil	B-Drug
therapy	O
.	O

Beta-blocking	B-Drug
Agents	O
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	B-Drug
and	O
beta-blocking	B-Drug
agents	O
has	O
been	O
well	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
.	O

Available	O
data	O
are	O
not	O
sufficient	O
,	O
however	O
,	O
to	O
predict	O
the	O
effects	O
of	O
concomitant	O
medication	O
on	O
patients	O
with	O
impaired	O
ventricular	O
function	O
or	O
cardiac	O
conduction	O
abnormalities	O
.	O

Digoxin	B-Drug
:	O
In	O
controlled	O
studies	O
in	O
healthy	O
volunteers	O
,	O
bepridil	B-Drug
hydrochloride	I-Drug
either	O
had	O
no	O
effect	O
(	O
one	O
study	O
)	O
or	O
was	O
associated	O
with	O
modest	O
increases	O
,	O
about	O
30	O
%	O
(	O
two	O
studies	O
)	O
in	O
steady-state	O
serum	O
digoxin	B-Drug
concentrations	O
.	O

Limited	O
clinical	O
data	O
in	O
angina	O
patients	O
receiving	O
concomitant	O
bepridil	B-Drug
hydrochloride	I-Drug
and	O
digoxin	B-Drug
therapy	O
indicate	O
no	O
discernible	O
changes	O
in	O
serum	O
digoxin	B-Drug
levels	O
.	O

Available	O
data	O
are	O
neither	O
sufficient	O
to	O
rule	O
out	O
possible	O
increases	O
in	O
serum	O
digoxin	B-Drug
with	O
concomitant	O
treatment	O
in	O
some	O
patients	O
,	O
nor	O
other	O
possible	O
interactions	O
,	O
particularly	O
in	O
patients	O
with	O
cardiac	O
conduction	O
abnormalities	O
(	O
Also	O
see	O
WARNINGS	O
Congestive	O
Heart	O
Failure	O
)	O
.	O

Oral	O
Hypoglycemics	O
:	O
Bepridil	B-Drug
has	O
been	O
safely	O
used	O
in	O
diabetic	O
patients	O
without	O
significantly	O
lowering	O
their	O
blood	O
glucose	B-Drug
levels	O
or	O
altering	O
their	O
need	O
for	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	O
agents	O
.	O

General	O
Interactions	O
:	O
Certain	O
drugs	B-Drug
could	O
increase	O
the	O
likelihood	O
of	O
potentially	O
serious	O
adverse	O
effects	O
with	O
bepridil	B-Drug
hydrochloride	I-Drug
.	O

In	O
general	O
,	O
these	O
are	O
drugs	B-Drug
that	O
have	O
one	O
or	O
more	O
pharmacologic	O
activities	O
similar	O
to	O
bepridil	B-Drug
hydrochloride	I-Drug
,	O
including	O
anti-arrhythmic	B-Drug
agents	O
such	O
as	O
quinidine	B-Drug
and	O
procainamide	B-Drug
,	O
cardiac	O
glycosides	O
and	O
tricyclic	O
anti-depressants	O
.	O

Anti-arrhythmics	O
and	O
tricyclic	O
anti-depressants	O
could	O
exaggerate	O
the	O
prolongation	O
of	O
the	O
QT	O
interval	O
observed	O
with	O
bepridil	B-Drug
hydrochloride	I-Drug
.	O

Cardiac	O
glycosides	O
could	O
exaggerate	O
the	O
depression	O
of	O
AV	O
nodal	O
conduction	O
observed	O
with	O
bepridil	B-Drug
hydrochloride	I-Drug
.	O

APRD00513_IN	O
,	O
txt	O
The	O
following	O
drugs	B-Drug
have	O
been	O
coadministered	O
with	O
Kerlone	B-Drug
and	O
have	O
not	O
altered	O
its	O
pharmacokinetics	O
:	O
cimetidine	B-Drug
,	O
nifedipine	B-Drug
,	O
chlorthalidone	B-Drug
,	O
and	O
hydrochlorothiazide	B-Drug
.	O

Concomitant	O
administration	O
of	O
Kerlone	B-Drug
with	O
the	O
oral	O
anticoagulant	B-Drug
warfarin	B-Drug
has	O
been	O
shown	O
not	O
to	O
potentiate	O
the	O
anticoagulant	B-Drug
effect	O
of	O
warfarin	B-Drug
.	O

Catecholamine-depleting	O
drugs	B-Drug
(	O
e.g.	O
,	O
reserpine	B-Drug
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta-blocking	B-Drug
agents	O
.	O

Patients	O
treated	O
with	O
a	O
beta-adrenergic	O
receptor	O
blocking	O
agent	O
plus	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Should	O
it	O
be	O
decided	O
to	O
discontinue	O
therapy	O
in	O
patients	O
receiving	O
beta-blockers	O
and	O
clonidine	B-Drug
concurrently	O
,	O
the	O
beta-blocker	O
should	O
be	O
discontinued	O
slowly	O
over	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	B-Drug
.	O

Literature	O
reports	O
suggest	O
that	O
oral	O
calcium	B-Drug
antagonists	O
may	O
be	O
used	O
in	O
combination	O
with	O
beta-adrenergic	O
blocking	O
agents	O
when	O
heart	O
function	O
is	O
normal	O
,	O
but	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
impaired	O
cardiac	O
function	O
.	O

Hypotension	O
,	O
AV	O
conduction	O
disturbances	O
,	O
and	O
left	O
ventricular	O
failure	O
have	O
been	O
reported	O
in	O
some	O
patients	O
receiving	O
beta-adrenergic	O
blocking	O
agents	O
when	O
an	O
oral	O
calcium	B-Drug
antagonist	O
was	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Hypotension	O
was	O
more	O
likely	O
to	O
occur	O
if	O
the	O
calcium	B-Drug
antagonist	O
were	O
a	O
dihydropyridine	O
derivative	O
,	O
e.g.	O
,	O
nifedipine	B-Drug
,	O
while	O
left	O
ventricular	O
failure	O
and	O
AV	O
conduction	O
disturbances	O
,	O
including	O
complete	O
heart	O
block	O
,	O
were	O
more	O
likely	O
to	O
occur	O
with	O
either	O
verapamil	B-Drug
or	O
diltiazem	B-Drug
.	O

Risk	O
of	O
Anaphylactic	O
Reaction	O
:	O
Although	O
it	O
is	O
known	O
that	O
patients	O
on	O
beta-blockers	O
may	O
be	O
refractory	O
to	O
epinephrine	B-Drug
in	O
the	O
treatment	O
of	O
anaphylactic	O
shock	O
,	O
beta-blockers	O
can	O
,	O
in	O
addition	O
,	O
interfere	O
with	O
the	O
modulation	O
of	O
allergic	O
reaction	O
and	O
lead	B-Drug
to	O
an	O
increased	O
severity	O
and/or	O
frequency	O
of	O
attacks	O
.	O

Severe	O
allergic	O
reactions	O
including	O
anaphylaxis	O
have	O
been	O
reported	O
in	O
patients	O
exposed	O
to	O
a	O
variety	O
of	O
allergens	O
either	O
by	O
repeated	O
challenge	O
,	O
or	O
accidental	O
contact	O
,	O
and	O
with	O
diagnostic	O
or	O
therapeutic	O
agents	O
while	O
receiving	O
beta-blockers	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

Special	O
care	O
is	O
required	O
if	O
this	O
drug	B-Drug
is	O
given	O
to	O
patients	O
receiving	O
ganglion	O
blocking	O
compounds	O
because	O
a	O
critical	O
fall	O
in	O
blood	O
pressure	O
may	O
occur	O
.	O

Usually	O
,	O
severe	O
abdominal	O
symptoms	O
appear	O
before	O
there	O
is	O
such	O
a	O
fall	O
in	O
the	O
blood	O
pressure	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
with	O
anti-neoplastic	O
agents	O
have	O
been	O
conducted	O
.	O

In	O
Study	O
1	O
,	O
patients	O
with	O
colorectal	O
cancer	O
were	O
given	O
irinotecan/5-FU/leucovorin	B-Drug
(	O
bolus-IFL	O
)	O
with	O
or	O
without	O
AVASTIN	B-Drug
.	O

Irinotecan	B-Drug
concentrations	O
were	O
similar	O
in	O
patients	O
receiving	O
bolus-IFL	O
alone	O
and	O
in	O
combination	O
with	O
AVASTIN	B-Drug
.	O

The	O
concentrations	O
of	O
SN38	B-Drug
,	O
the	O
active	O
metabolite	O
of	O
irinotecan	B-Drug
,	O
were	O
on	O
average	O
33	O
%	O
higher	O
in	O
patients	O
receiving	O
bolus-IFL	O
in	O
combination	O
with	O
AVASTIN	B-Drug
when	O
compared	O
with	O
bolus-IFL	O
alone	O
.	O

In	O
Study	O
1	O
,	O
patients	O
receiving	O
bolus-IFL	O
plus	O
AVASTIN	B-Drug
had	O
a	O
higher	O
incidence	O
of	O
Grade	O
3-4	O
diarrhea	O
and	O
neutropenia	O
.	O

Due	O
to	O
high	O
inter-patient	O
variability	O
and	O
limited	O
sampling	O
,	O
the	O
extent	O
of	O
the	O
increase	O
in	O
SN38	B-Drug
levels	O
in	O
patients	O
receiving	O
concurrent	O
irinotecan	B-Drug
and	O
AVASTIN	B-Drug
is	O
uncertain	O
.	O

No	O
formal	O
studies	O
to	O
evaluate	O
drug	B-Drug
interactions	O
with	O
bexarotene	B-Drug
have	O
been	O
conducted	O
.	O

Bexarotene	B-Drug
oxidative	O
metabolites	O
appear	O
to	O
be	O
formed	O
by	O
cytochrome	O
P450	O
3A4	O
.	O

On	O
the	O
basis	O
of	O
the	O
metabolism	O
of	O
bexarotene	B-Drug
by	O
cytochrome	O
P450	O
3A4	O
,	O
ketoconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
erythromycin	B-Drug
,	O
gemfibrozil	B-Drug
,	O
grapefruit	O
juice	O
,	O
and	O
other	O
inhibitors	O
of	O
cytochrome	O
P450	O
3A4	O
would	O
be	O
expected	O
to	O
lead	B-Drug
to	O
an	O
increase	O
in	O
plasma	O
bexarotene	B-Drug
concentrations	O
.	O

Furthermore	O
,	O
rifampin	B-Drug
,	O
phenytoin	B-Drug
,	O
phenobarbital	B-Drug
,	O
and	O
other	O
inducers	O
of	O
cytochrome	O
P450	O
3A4	O
may	O
cause	O
a	O
reduction	O
in	O
plasma	O
bexarotene	B-Drug
concentrations	O
.	O

Concomitant	O
administration	O
of	O
Targretin	B-Drug
capsules	O
and	O
gemfibrozil	B-Drug
resulted	O
in	O
substantial	O
increases	O
in	O
plasma	O
concentrations	O
of	O
bexarotene	B-Drug
,	O
probably	O
at	O
least	O
partially	O
related	O
to	O
cytochrome	O
P450	O
3A4	O
inhibition	O
by	O
gemfibrozil	B-Drug
.	O

Under	O
similar	O
conditions	O
,	O
bexarotene	B-Drug
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
atorvastatin	B-Drug
administration	O
.	O

Concomitant	O
administration	O
of	O
gemfibrozil	B-Drug
with	O
Targretin	B-Drug
capsules	O
is	O
not	O
recommended	O
.	O

When	O
Bezalip	B-Drug
or	O
Bezalip	B-Drug
retard	I-Drug
is	O
used	O
at	O
the	O
same	O
time	O
as	O
other	O
medicines	O
or	O
substances	O
the	O
following	O
interactions	O
must	O
be	O
taken	O
into	O
account	O
:	O
-	O
Bezalip	B-Drug
and	O
Bezalip	B-Drug
retard	I-Drug
may	O
enhance	O
the	O
action	O
of	O
anticoagulants	B-Drug
of	O
the	O
coumarin	O
type	O
.	O

For	O
this	O
reason	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	B-Drug
should	O
be	O
reduced	O
by	O
30	O
-	O
50	O
%	O
at	O
the	O
start	O
of	O
treatment	O
with	O
Bezalip	B-Drug
or	O
Bezalip	B-Drug
retard	O
and	O
then	O
titrated	O
according	O
to	O
the	O
blood	O
clotting	O
parameters	O
.	O

-	O
The	O
action	O
of	O
sulphonylureas	O
and	O
insulin	B-Drug
may	O
be	O
enhanced	O
by	O
Bezalip	B-Drug
or	O
Bezalip	B-Drug
retard	I-Drug
.	O

This	O
may	O
be	O
due	O
to	O
an	O
improved	O
glucose	B-Drug
utilization	O
with	O
simultaneous	O
reduction	O
in	O
insulin	B-Drug
requirement	O
.	O

-	O
In	O
isolated	O
cases	O
,	O
a	O
pronounced	O
though	O
reversible	O
,	O
impairment	O
of	O
renal	O
function	O
(	O
accompanied	O
by	O
a	O
corresponding	O
increase	O
in	O
the	O
serum	O
creatinine	O
level	O
)	O
has	O
been	O
reported	O
in	O
organ	O
transplant	O
patients	O
receiving	O
immuno-suppressant	O
therapy	O
and	O
concomitant	O
bezafibrate	B-Drug
.	O

Accordingly	O
,	O
renal	O
function	O
should	O
be	O
closely	O
monitored	O
in	O
these	O
patients	O
and	O
,	O
in	O
the	O
event	O
of	O
relevant	O
significant	O
changes	O
in	O
laboratory	O
parameters	O
,	O
bezafibrate	B-Drug
should	O
,	O
if	O
necessary	O
,	O
be	O
discontinued	O
.	O

-	O
When	O
Bezalip	B-Drug
or	O
Bezalip	B-Drug
retard	I-Drug
is	O
used	O
concurrently	O
with	O
anion-exchange	O
resins	O
(	O
e.g	O
.	O

cholestryramine	B-Drug
)	O
,	O
an	O
interval	O
of	O
at	O
least	O
2	O
hours	O
should	O
be	O
maintained	O
between	O
the	O
two	O
medicines	O
,	O
since	O
the	O
absorption	O
of	O
Bezalip	B-Drug
or	O
Bezalip	B-Drug
retard	I-Drug
is	O
impaired	O
.	O

-	O
Perhexiline	B-Drug
hydrogen	I-Drug
maleate	I-Drug
or	O
MAO-inhibitors	O
(	O
with	O
hepatotoxic	O
potential	O
)	O
must	O
not	O
be	O
administered	O
together	O
with	O
Bezalip	B-Drug
or	O
Bezalip	B-Drug
retard	I-Drug
.	O

In	O
vitro	O
studies	O
have	O
shown	O
CASODEX	B-Drug
can	O
displace	O
coumarin	O
anticoagulants	B-Drug
,	O
such	O
as	O
warfarin	B-Drug
,	O
from	O
their	O
protein-binding	O
sites	O
.	O



Bosentan	B-Drug
had	O
no	O
relevant	O
inhibitory	O
effect	O
on	O
any	O
CYP	O
isoenzymes	O
tested	O
(	O
CYP1A2	B-Drug
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
CYP2D6	B-Drug
,	O
CYP3A4	B-Drug
)	O
.	O

Consequently	O
,	O
TRACLEER	B-Drug
is	O
not	O
expected	O
to	O
increase	O
the	O
plasma	O
concentrations	O
of	O
drugs	B-Drug
metabolized	O
by	O
these	O
enzymes	O
.	O

Hormonal	O
Contraceptives	O
,	O
Including	O
Oral	O
,	O
Injectable	O
,	O
Transdermal	O
,	O
and	O
Implantable	O
Contraceptives	O
:	O
An	O
interaction	O
study	O
demonstrated	O
that	O
co-administration	O
of	O
bosentan	B-Drug
and	O
the	O
oral	O
hormonal	O
contraceptive	O
Ortho-Novum	B-Drug
produced	O
average	O
decreases	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
levels	O
of	O
14	O
%	O
and	O
31	O
%	O
,	O
respectively	O
.	O

However	O
,	O
decreases	O
in	O
exposure	O
were	O
as	O
much	O
as	O
56	O
%	O
and	O
66	O
%	O
,	O
respectively	O
,	O
in	O
individual	O
subjects	O
.	O

Therefore	O
,	O
hormonal	O
contraceptives	O
,	O
including	O
oral	O
,	O
injectable	O
,	O
transdermal	O
,	O
and	O
implantable	O
forms	O
,	O
may	O
not	O
be	O
reliable	O
when	O
TRACLEER	B-Drug
is	O
co-administered	O
.	O

Women	O
should	O
practice	O
additional	O
methods	O
of	O
contraception	O
and	O
not	O
rely	O
on	O
hormonal	O
contraception	O
alone	O
when	O
taking	O
TRACLEER	B-Drug
.	O

Specific	O
interaction	O
studies	O
have	O
demonstrated	O
the	O
following	O
:	O
Cyclosporine	B-Drug
A	I-Drug
:	O
During	O
the	O
first	O
day	O
of	O
concomitant	O
administration	O
,	O
trough	O
concentrations	O
of	O
bosentan	B-Drug
were	O
increased	O
by	O
about	O
30-fold	O
.	O

Steady-state	O
bosentan	B-Drug
plasma	O
concentrations	O
were	O
3-	O
to	O
4-fold	O
higher	O
than	O
in	O
the	O
absence	O
of	O
cyclosporine	B-Drug
A	I-Drug
.	O

The	O
concomitant	O
administration	O
of	O
bosentan	B-Drug
and	O
cyclosporine	B-Drug
A	I-Drug
is	O
contraindicated	O
.	O

Co-administration	O
of	O
bosentan	B-Drug
decreased	O
the	O
plasma	O
concentrations	O
of	O
cyclosporine	B-Drug
A	I-Drug
(	O
a	O
CYP3A4	B-Drug
substrate	O
)	O
by	O
approximately	O
50	O
%	O
.	O

Tacrolimus	B-Drug
:	O
Co-administration	O
of	O
tacrolimus	B-Drug
and	O
bosentan	B-Drug
has	O
not	O
been	O
studied	O
in	O
man	O
.	O

Co-administration	O
of	O
tacrolimus	B-Drug
and	O
bosentan	B-Drug
resulted	O
in	O
markedly	O
increased	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
in	O
animals	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
tacrolimus	B-Drug
and	O
bosentan	B-Drug
are	O
used	O
together	O
.	O

Glyburide	B-Drug
:	O
An	O
increased	O
risk	O
of	O
elevated	O
liver	O
aminotransferases	O
was	O
observed	O
in	O
patients	O
receiving	O
concomitant	O
therapy	O
with	O
glyburide	B-Drug
.	O

Therefore	O
,	O
the	O
concomitant	O
administration	O
of	O
TRACLEER	B-Drug
and	O
glyburide	B-Drug
is	O
contraindicated	O
,	O
and	O
alternative	O
hypoglycemic	O
agents	O
should	O
be	O
considered	O
.	O

Co-administration	O
of	O
bosentan	B-Drug
decreased	O
the	O
plasma	O
concentrations	O
of	O
glyburide	B-Drug
by	O
approximately	O
40	O
%	O
.	O

The	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
were	O
also	O
decreased	O
by	O
approximately	O
30	O
%	O
.	O

Bosentan	B-Drug
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
oral	O
hypoglycemic	O
agents	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2C9	B-Drug
or	O
CYP3A4	B-Drug
.	O

The	O
possibility	O
of	O
worsened	O
glucose	B-Drug
control	O
in	O
patients	O
using	O
these	O
agents	O
should	O
be	O
considered	O
.	O

Ketoconazole	B-Drug
:	O
Co-administration	O
of	O
bosentan	B-Drug
125	O
mg	O
b.i.d	O
.	O

and	O
ketoconazole	B-Drug
,	O
a	O
potent	O
CYP3A4	B-Drug
inhibitor	O
,	O
increased	O
the	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
by	O
approximately	O
2-fold	O
.	O

No	O
dose	O
adjustment	O
of	O
bosentan	B-Drug
is	O
necessary	O
,	O
but	O
increased	O
effects	O
of	O
bosentan	B-Drug
should	O
be	O
considered	O
.	O

Simvastatin	B-Drug
and	O
Other	O
Statins	O
:	O
Co-administration	O
of	O
bosentan	B-Drug
decreased	O
the	O
plasma	O
concentrations	O
of	O
simvastatin	B-Drug
(	O
a	O
CYP3A4	B-Drug
substrate	O
)	O
,	O
and	O
its	O
active	O
-hydroxy	O
acid	O
metabolite	O
,	O
by	O
approximately	O
50	O
%	O
.	O

The	O
plasma	O
concentrations	O
of	O
bosentan	B-Drug
were	O
not	O
affected	O
.	O

Bosentan	B-Drug
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
statins	O
that	O
have	O
significant	O
metabolism	O
by	O
CYP3A4	B-Drug
,	O
such	O
as	O
lovastatin	B-Drug
and	O
atorvastatin	B-Drug
.	O

The	O
possibility	O
of	O
reduced	O
statin	O
efficacy	O
should	O
be	O
considered	O
.	O

Patients	O
using	O
CYP3A4	B-Drug
metabolized	O
statins	O
should	O
have	O
cholesterol	O
levels	O
monitored	O
after	O
TRACLEER	B-Drug
is	O
initiated	O
to	O
see	O
whether	O
the	O
statin	O
dose	O
needs	O
adjustment	O
.	O

Warfarin	B-Drug
:	O
Co-administration	O
of	O
bosentan	B-Drug
500	O
mg	O
b.i.d	O
.	O

for	O
6	O
days	O
decreased	O
the	O
plasma	O
concentrations	O
of	O
both	O
S-warfarin	B-Drug
(	O
a	O
CYP2C9	B-Drug
substrate	O
)	O
and	O
R-warfarin	B-Drug
(	O
a	O
CYP3A4	B-Drug
substrate	O
)	O
by	O
29	O
and	O
38	O
%	O
,	O
respectively	O
.	O

Clinical	O
experience	O
with	O
concomitant	O
administration	O
of	O
bosentan	B-Drug
and	O
warfarin	B-Drug
in	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
did	O
not	O
show	O
clinically	O
relevant	O
changes	O
in	O
INR	O
or	O
warfarin	B-Drug
dose	O
(	O
baseline	O
vs.	O
end	O
of	O
the	O
clinical	O
studies	O
)	O
,	O
and	O
the	O
need	O
to	O
change	O
the	O
warfarin	B-Drug
dose	O
during	O
the	O
trials	O
due	O
to	O
changes	O
in	O
INR	O
or	O
due	O
to	O
adverse	O
events	O
was	O
similar	O
among	O
bosentan-	B-Drug
and	O
placebo-treated	O
patients	O
.	O

Digoxin	B-Drug
,	O
Nimodipine	B-Drug
and	O
Losartan	B-Drug
:	O
Bosentan	B-Drug
has	O
no	O
significant	O
pharmacokinetic	O
interactions	O
with	O
digoxin	B-Drug
and	O
nimodipine	B-Drug
,	O
and	O
losartan	B-Drug
has	O
no	O
significant	O
effect	O
on	O
plasma	O
levels	O
of	O
bosentan	B-Drug
.	O

Co-administration	O
of	O
BOTOX	B-Drug
and	O
aminoglycosides	O
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e.g.	O
,	O
curare-like	O
compounds	O
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	B-Drug
may	O
be	O
potentiated	O
.	O

The	O
effect	O
of	O
administering	O
different	O
botulinum	O
neurotoxin	O
serotypes	O
at	O
the	O
same	O
time	O
or	O
within	O
several	O
months	O
of	O
each	O
other	O
is	O
unknown	O
.	O

Excessive	O
neuromuscular	O
weakness	O
may	O
be	O
exacerbated	O
by	O
administration	O
of	O
another	O
botulinum	O
toxin	B-Drug
prior	O
to	O
the	O
resolution	O
of	O
the	O
effects	O
of	O
a	O
previously	O
administered	O
botulinum	O
toxin	B-Drug
.	O

Co-administration	O
of	O
MYOBLOC	B-Drug
and	O
aminoglycosides	O
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e.g.	O
,	O
curare-like	O
compounds	O
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	B-Drug
may	O
be	O
potentiated	O
.	O

The	O
effect	O
of	O
administering	O
different	O
botulinum	O
neurotoxin	O
serotypes	O
at	O
the	O
same	O
time	O
or	O
within	O
less	O
than	O
4	O
months	O
of	O
each	O
other	O
is	O
unknown	O
.	O

However	O
,	O
neuromuscular	O
paralysis	O
may	O
be	O
potentiated	O
by	O
co-administration	O
or	O
overlapping	O
administration	O
of	O
different	O
botulinum	O
toxin	B-Drug
serotypes	O
.	O

Digitalis	B-Drug
toxicity	O
may	O
be	O
aggravated	O
by	O
the	O
initial	O
release	O
of	O
norepinephrine	B-Drug
caused	O
by	O
Bretylium	B-Drug
Tosylate	I-Drug
Injection	O
.	O

The	O
pressor	O
effects	O
of	O
catecholamines	O
such	O
as	O
dopamine	B-Drug
or	O
norepinephrine	B-Drug
are	O
enhanced	O
by	O
Bretylium	B-Drug
Tosylate	I-Drug
.	O

When	O
catecholamines	O
are	O
administered	O
,	O
dilute	O
solutions	O
should	O
be	O
used	O
and	O
blood	O
pressure	O
should	O
be	O
monitored	O
closely	O
.	O

Although	O
there	O
is	O
little	O
published	O
information	O
on	O
concomitant	O
administration	O
of	O
lidocaine	B-Drug
and	O
Bretylium	B-Drug
Tosylate	I-Drug
,	O
these	O
drugs	B-Drug
are	O
often	O
administered	O
concurrently	O
without	O
any	O
evidence	O
of	O
interactions	O
resulting	O
in	O
adverse	O
effects	O
or	O
diminished	O
efficacy	O
.	O

Although	O
specific	O
drug	B-Drug
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ALPHAGAN	B-Drug
P	B-Drug
,	O
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	O
depressants	O
(	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
opiates	O
,	O
sedatives	O
,	O
or	O
anesthetics	B-Drug
)	O
should	O
be	O
considered	O
.	O

Alpha-agonists	O
,	O
as	O
a	O
class	O
,	O
may	O
reduce	O
pulse	O
and	O
blood	O
pressure	O
.	O

Caution	O
in	O
using	O
concomitant	O
drugs	B-Drug
such	O
as	O
beta-blockers	O
(	O
ophthalmic	O
and	O
systemic	O
)	O
,	O
anti-hypertensives	O
and/or	O
cardiac	O
glycosides	O
is	O
advised	O
.	O

Tricyclic	O
antidepressants	B-Drug
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine.It	B-Drug
is	O
not	O
known	O
whether	O
the	O
concurrent	O
use	O
of	O
these	O
agents	O
with	O
ALPHAGAN	B-Drug
P	B-Drug
in	O
humans	O
can	O
lead	B-Drug
to	O
resulting	O
interference	O
with	O
the	O
IOP	O
lowering	O
effect	O
.	O

No	O
data	O
on	O
the	O
level	O
of	O
circulating	O
catecholamines	O
after	O
ALPHAGAN	B-Drug
P	B-Drug
administration	O
are	O
available	O
.	O

Caution	O
,	O
however	O
,	O
is	O
advised	O
in	O
patients	O
taking	O
tricyclic	O
antidepressants	B-Drug
which	O
can	O
affect	O
the	O
metabolism	O
and	O
uptake	O
of	O
circulating	O
amines	O
.	O

AZOPT	B-Drug
(	O
brinzolamide	B-Drug
ophthalmic	O
suspension	O
)	O
1	O
%	O
contains	O
a	O
carbonic	O
anhydrase	O
inhibitor	O
.	O

Acid-base	O
and	O
electrolyte	O
alterations	O
were	O
not	O
reported	O
in	O
the	O
clinical	O
trials	O
with	O
brinzolamide	B-Drug
.	O

However	O
,	O
in	O
patients	O
treated	O
with	O
oral	O
carbonic	O
anhydrase	O
inhibitors	O
,	O
rare	O
instances	O
of	O
drug	B-Drug
interactions	O
have	O
occurred	O
with	O
high-dose	O
salicylate	B-Drug
therapy	O
.	O

Therefore	O
,	O
the	O
potential	O
for	O
such	O
drug	B-Drug
interaction	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
AZOPT	B-Drug
(	O
brinzolamide	B-Drug
ophthalmic	O
suspension	O
)	O
1	O
%	O
.	O

The	O
risk	O
of	O
using	O
bromocriptine	B-Drug
mesylate	I-Drug
in	O
combination	O
with	O
other	O
drugs	B-Drug
has	O
not	O
been	O
systematically	O
evaluated	O
,	O
but	O
alcohol	B-Drug
may	O
potentiate	O
the	O
side	O
effects	O
of	O
bromocriptine	B-Drug
mesylate	I-Drug
.	O

Bromocriptine	B-Drug
mesylate	I-Drug
may	O
interact	O
with	O
dopamine	B-Drug
antagonists	O
,	O
butyrophenones	O
,	O
and	O
certain	O
other	O
agents	O
.	O

Compounds	O
in	O
these	O
categories	O
result	O
in	O
a	O
decreased	O
efficacy	O
of	O
bromocriptine	B-Drug
mesylate	I-Drug
:	O
phenothiazines	O
,	O
haloperidol	B-Drug
,	O
metoclopramide	B-Drug
,	O
pimozide	B-Drug
.	O

Concomitant	O
use	O
of	O
bromocriptine	B-Drug
mesylate	I-Drug
with	O
other	O
ergot	B-Drug
alkaloids	O
is	O
not	O
recommended	O
.	O

Dexbrompheniramine	B-Drug
can	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	O
depressants	O
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Drug
)	O
,	O
anticholinergics	O
or	O
other	O
medications	O
with	O
anticholinergic	B-Drug
activity	O
(	O
anticholinergic	B-Drug
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Drug
)	O
,	O
and	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
(	O
concurrent	O
use	O
with	O
antihistamines	B-Drug
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Drug
)	O
.	O

This	O
drug	B-Drug
may	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	O
depressants	O
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Drug
)	O
,	O
anticholinergics	O
or	O
other	O
medications	O
with	O
anticholinergic	B-Drug
activity	O
(	O
anticholinergic	B-Drug
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Drug
)	O
,	O
and	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
(	O
concurrent	O
use	O
with	O
antihistamines	B-Drug
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Drug
)	O
.	O

Concomitant	O
oral	O
administration	O
of	O
ketoconazole	B-Drug
(	O
a	O
known	O
inhibitor	O
of	O
CYP3A4	B-Drug
activity	O
in	O
the	O
liver	O
and	O
in	O
the	O
intestinal	O
mucosa	O
)	O
caused	O
an	O
eight-fold	O
increase	O
of	O
the	O
systemic	O
exposure	O
to	O
oral	O
budesonide	B-Drug
.	O

If	O
treatment	O
with	O
inhibitors	O
of	O
CYP3A4	B-Drug
activity	O
(	O
such	O
as	O
ketoconazole	B-Drug
,	O
intraconazole	B-Drug
,	O
ritonavir	B-Drug
,	O
indinavir	B-Drug
,	O
saquinavir	B-Drug
,	O
erythromycin	B-Drug
,	O
etc	O
.	O

)	O
is	O
indicated	O
,	O
reduction	O
of	O
the	O
budesonide	B-Drug
dose	O
should	O
be	O
considered	O
.	O

After	O
extensive	O
intake	O
of	O
grapefruit	O
juice	O
(	O
which	O
inhibits	O
CYP3A4	B-Drug
activity	O
predominantly	O
in	O
the	O
intestinal	O
mucosa	O
)	O
,	O
the	O
systemic	O
exposure	O
for	O
oral	O
budesonide	B-Drug
increased	O
about	O
two	O
times	O
.	O

As	O
with	O
other	O
drugs	B-Drug
primarily	O
being	O
metabolized	O
through	O
CYP3A4	B-Drug
,	O
ingestion	O
of	O
grapefruit	O
or	O
grapefruit	O
juice	O
should	O
be	O
avoided	O
in	O
connection	O
with	O
budesonide	B-Drug
administration	O
.	O

-	O
Drugs	B-Drug
with	O
ototoxic	O
potential	O
:	O
Especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
,	O
the	O
use	O
of	O
parenterally	O
administered	O
bumetanide	B-Drug
in	O
patients	O
to	O
whom	O
aminoglycoside	O
antibiotics	B-Drug
are	O
also	O
being	O
given	O
should	O
be	O
avoided	O
,	O
except	O
in	O
life-threatening	O
conditions	O
.	O

-	O
Drugs	B-Drug
with	O
nephrotoxic	O
potential	O
:	O
There	O
has	O
been	O
no	O
experience	O
on	O
the	O
concurrent	O
use	O
of	O
bumetanide	B-Drug
with	O
drugs	B-Drug
known	O
to	O
have	O
a	O
nephrotoxic	O
potential	O
.	O

Therefore	O
,	O
the	O
simultaneous	O
administration	O
of	O
these	O
drugs	B-Drug
should	O
be	O
avoided	O
.	O

-	O
Lithium	B-Drug
:	O
Lithium	B-Drug
should	O
generally	O
not	O
be	O
given	O
with	O
diuretics	B-Drug
(	O
such	O
as	O
bumetanide	B-Drug
)	O
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O

-	O
Probenecid	B-Drug
:	O
Pretreatment	O
with	O
probenecid	B-Drug
reduces	O
both	O
the	O
natriuresis	O
and	O
hyperreninemia	O
produced	O
by	O
bumetanide	B-Drug
.	O

This	O
antagonistic	O
effect	O
of	O
probenecid	B-Drug
on	O
bumetanide	B-Drug
natriuresis	O
is	O
not	O
due	O
to	O
a	O
direct	O
action	O
on	O
sodium	O
excretion	O
but	O
is	O
probably	O
secondary	O
to	O
its	O
inhibitory	O
effect	O
on	O
renal	O
tubular	O
secretion	O
of	O
bumetanide	B-Drug
.	O

Thus	O
,	O
probenecid	B-Drug
should	O
not	O
be	O
administered	O
concurrently	O
with	O
bumetanide	B-Drug
.	O

-	O
Indomethacin	B-Drug
:	O
Indomethacin	B-Drug
blunts	O
the	O
increases	O
in	O
urine	O
volume	O
and	O
sodium	O
excretion	O
seen	O
during	O
bumetanide	B-Drug
treatment	O
and	O
inhibits	O
the	O
bumetanide-induced	B-Drug
increase	O
in	O
plasma	O
renin	O
activity	O
.	O

Concurrent	O
therapy	O
with	O
bumetanide	B-Drug
is	O
thus	O
not	O
recommended	O
.	O

-	O
Antihypertensives	B-Drug
:	O
Bumetanide	B-Drug
may	O
potentiate	O
the	O
effect	O
of	O
various	O
antihypertensive	B-Drug
drugs	B-Drug
,	O
necessitating	O
a	O
reduction	O
in	O
the	O
dosage	O
of	O
these	O
drugs	B-Drug
.	O

-	O
Digoxin	B-Drug
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
no	O
effect	O
on	O
digoxin	B-Drug
blood	O
levels	O
.	O

-	O
Anticoagulants	B-Drug
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
bumetanide	B-Drug
to	O
have	O
no	O
effect	O
on	O
warfarin	B-Drug
metabolism	O
or	O
on	O
plasma	O
prothrombin	O
activity	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B-Drug
solutions	O
containing	O
epinephrine	B-Drug
or	O
norepinephrine	B-Drug
to	O
patients	O
receiving	O
monoamine	O
oxidase	O
inhibitors	O
or	O
tricyclic	O
antidepressants	B-Drug
may	O
produce	O
severe	O
,	O
prolonged	O
hypertension	O
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
in	O
which	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	O
drugs	B-Drug
and	O
of	O
ergot-type	O
oxytocic	O
drugs	B-Drug
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Phenothiazines	O
and	O
butyrophenones	O
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	B-Drug
.	O

Buprenorphine	B-Drug
is	O
metabolized	O
to	O
norbuprenorphine	B-Drug
by	O
cytochrome	O
CYP	O
3A4	O
.	O

Because	O
CYP	O
3A4	O
inhibitors	O
may	O
increase	O
plasma	O
concentrations	O
of	O
buprenorphine	B-Drug
,	O
patients	O
already	O
on	O
CYP	O
3A4	O
inhibitors	O
such	O
as	O
azole	O
antifungals	O
(	O
e.g	O
.	O

ketoconazole	B-Drug
)	O
,	O
macrolide	O
antibiotics	B-Drug
(	O
e.g	O
.	O

erythromycin	B-Drug
)	O
,	O
and	O
HIV	O
protease	O
inhibitors	O
(	O
e.g	O
.	O

ritonavir	B-Drug
,	O
indinavir	B-Drug
and	O
saquinavir	B-Drug
)	O
should	O
have	O
their	O
dose	O
of	O
SUBUTEX	B-Drug
or	O
SUBOXONE	B-Drug
adjusted	O
.	O

Based	O
on	O
anecdotal	O
reports	O
,	O
there	O
may	O
be	O
an	O
interaction	O
between	O
buprenorphine	B-Drug
and	O
benzodiazepines	B-Drug
.	O

There	O
have	O
been	O
a	O
number	O
of	O
reports	O
in	O
the	O
post-marketing	O
experience	O
of	O
coma	O
and	O
death	O
associated	O
with	O
the	O
concomitant	O
intravenous	O
misuse	O
of	O
buprenorphine	B-Drug
and	O
benzodiazepines	B-Drug
by	O
addicts	O
.	O

In	O
many	O
of	O
these	O
cases	O
,	O
buprenorphine	B-Drug
was	O
misused	O
by	O
self-injection	O
of	O
crushed	O
SUBUTEX	B-Drug
tablets	O
.	O

SUBUTEX	B-Drug
and	O
SUBOXONE	B-Drug
should	O
be	O
prescribed	O
with	O
caution	O
to	O
patients	O
on	O
benzodiazepines	B-Drug
or	O
other	O
drugs	B-Drug
that	O
act	O
on	O
the	O
central	O
nervous	O
system	O
,	O
regardless	O
of	O
whether	O
these	O
drugs	B-Drug
are	O
taken	O
on	O
the	O
advice	O
of	O
a	O
physician	O
or	O
are	O
taken	O
as	O
drugs	B-Drug
of	O
abuse	O
.	O

Patients	O
should	O
be	O
warned	O
of	O
the	O
potential	O
danger	O
of	O
the	O
intravenous	O
self-administration	O
of	O
benzodiazepines	B-Drug
while	O
under	O
treatment	O
with	O
SUBOXONE	B-Drug
or	O
SUBUTEX	B-Drug
.	O

Few	O
systemic	O
data	O
have	O
been	O
collected	O
on	O
the	O
metabolism	O
of	O
WELLBUTRIN	B-Drug
following	O
concomitant	O
administration	O
with	O
other	O
drugs	B-Drug
or	O
,	O
alternatively	O
,	O
the	O
effect	O
of	O
concomitant	O
administration	O
of	O
WELLBUTRIN	B-Drug
on	O
the	O
metabolism	O
of	O
other	O
drugs	B-Drug
.	O

Because	O
bupropion	B-Drug
is	O
extensively	O
metabolized	O
,	O
the	O
coadministration	O
of	O
other	O
drugs	B-Drug
may	O
affect	O
its	O
clinical	O
activity	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
bupropion	B-Drug
is	O
primarily	O
metabolized	O
to	O
hydroxybupropion	B-Drug
by	O
the	O
CYP2B6	O
isoenzyme	O
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
a	O
drug	B-Drug
interaction	O
between	O
WELLBUTRIN	B-Drug
and	O
drugs	B-Drug
that	O
affect	O
the	O
CYP2B6	O
isoenzyme	O
(	O
e.g.	O
,	O
orphenadrine	B-Drug
and	O
cyclophosphamide	B-Drug
)	O
.	O

The	O
threohydrobupropion	B-Drug
metabolite	O
of	O
bupropion	B-Drug
does	O
not	O
appear	O
to	O
be	O
produced	O
by	O
the	O
cytochrome	O
P450	O
isoenzymes	O
.	O

The	O
effects	O
of	O
concomitant	O
administration	O
of	O
cimetidine	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
bupropion	B-Drug
and	O
its	O
active	O
metabolites	O
were	O
studied	O
in	O
24	O
healthy	O
young	O
male	O
volunteers	O
.	O

Following	O
oral	O
administration	O
of	O
two	O
150-mg	O
sustained-release	O
tablets	O
with	O
and	O
without	O
800	O
mg	O
of	O
cimetidine	B-Drug
,	O
the	O
pharmacokinetics	O
of	O
bupropion	B-Drug
and	O
hydroxybupropion	B-Drug
were	O
unaffected	O
.	O

However	O
,	O
there	O
were	O
16	O
%	O
and	O
32	O
%	O
increases	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
respectively	O
,	O
of	O
the	O
combined	O
moieties	O
of	O
threohydrobupropion	B-Drug
and	O
erythrohydrobupropion	B-Drug
.	O

While	O
not	O
systematically	O
studied	O
,	O
certain	O
drugs	B-Drug
may	O
induce	O
the	O
metabolism	O
of	O
bupropion	B-Drug
(	O
e.g.	O
,	O
carbamazepine	B-Drug
,	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
)	O
.	O

Animal	O
data	O
indicated	O
that	O
bupropion	B-Drug
may	O
be	O
an	O
inducer	O
of	O
drug-metabolizing	O
enzymes	O
in	O
humans	O
.	O

In	O
one	O
study	O
,	O
following	O
chronic	O
administration	O
of	O
bupropion	B-Drug
,	O
100	O
mg	O
3	O
times	O
daily	O
to	O
8	O
healthy	O
male	O
volunteers	O
for	O
14	O
days	O
,	O
there	O
was	O
no	O
evidence	O
of	O
induction	O
of	O
its	O
own	O
metabolism	O
.	O

Nevertheless	O
,	O
there	O
may	O
be	O
the	O
potential	O
for	O
clinically	O
important	O
alterations	O
of	O
blood	O
levels	O
of	O
coadministered	O
drugs	B-Drug
.	O

Drugs	B-Drug
Metabolized	O
by	O
Cytochrome	O
P450IID6	O
(	O
CYP2D6	B-Drug
)	O
:	O
Many	O
drugs	B-Drug
,	O
including	O
most	O
antidepressants	B-Drug
(	O
SSRIs	O
,	O
many	O
tricyclics	O
)	O
,	O
beta-blockers	O
,	O
antiarrhythmics	B-Drug
,	O
and	O
antipsychotics	O
are	O
metabolized	O
by	O
the	O
CYP2D6	B-Drug
isoenzyme	O
.	O

Although	O
bupropion	B-Drug
is	O
not	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
bupropion	B-Drug
and	O
hydroxybupropion	B-Drug
are	O
inhibitors	O
of	O
the	O
CYP2D6	B-Drug
isoenzyme	O
in	O
vitro	O
.	O

In	O
a	O
study	O
of	O
15	O
male	O
subjects	O
(	O
ages	O
19	O
to	O
35	O
years	O
)	O
who	O
were	O
extensive	O
metabolizers	O
of	O
the	O
CYP2D6	B-Drug
isoenzyme	O
,	O
daily	O
doses	O
of	O
bupropion	B-Drug
given	O
as	O
150	O
mg	O
twice	O
daily	O
followed	O
by	O
a	O
single	O
dose	O
of	O
50	O
mg	O
desipramine	B-Drug
increased	O
the	O
Cmax	O
,	O
AUC	O
,	O
and	O
t1/2	B-Drug
of	O
desipramine	B-Drug
by	O
an	O
average	O
of	O
approximately	O
2-	O
,	O
5-	O
and	O
2-fold	O
,	O
respectively	O
.	O

The	O
effect	O
was	O
present	O
for	O
at	O
least	O
7	O
days	O
after	O
the	O
last	O
dose	O
of	O
bupropion	B-Drug
.	O

Concomitant	O
use	O
of	O
bupropion	B-Drug
with	O
other	O
drugs	B-Drug
metabolized	O
by	O
CYP2D6	B-Drug
has	O
not	O
been	O
formally	O
studied	O
.	O

Therefore	O
,	O
co-administration	O
of	O
bupropion	B-Drug
with	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
CYP2D6	B-Drug
isoenzyme	O
including	O
certain	O
antidepressants	B-Drug
(	O
e.g.	O
,	O
nortriptyline	B-Drug
,	O
imipramine	B-Drug
,	O
desipramine	B-Drug
,	O
paroxetine	B-Drug
,	O
fluoxetine	B-Drug
,	O
sertraline	B-Drug
)	O
,	O
antipsychotics	O
(	O
e.g.	O
,	O
haloperidol	B-Drug
,	O
risperidone	B-Drug
,	O
thioridazine	B-Drug
)	O
,	O
beta-blockers	O
(	O
e.g.	O
,	O
metoprolol	B-Drug
)	O
,	O
and	O
Type	O
1C	O
antiarrhythmics	B-Drug
(	O
e.g.	O
,	O
propafenone	B-Drug
,	O
flecainide	B-Drug
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
and	O
should	O
be	O
initiated	O
at	O
the	O
lower	O
end	O
of	O
the	O
dose	O
range	O
of	O
the	O
concomitant	O
medication	O
.	O

If	O
bupropion	B-Drug
is	O
added	O
to	O
the	O
treatment	O
regimen	O
of	O
a	O
patient	O
already	O
receiving	O
a	O
drug	B-Drug
metabolized	O
by	O
CYP2D6	B-Drug
,	O
the	O
need	O
to	O
decrease	O
the	O
dose	O
of	O
the	O
original	O
medication	O
should	O
be	O
considered	O
,	O
particularly	O
for	O
those	O
concomitant	O
medications	O
with	O
a	O
narrow	O
therapeutic	O
index	O
.	O

MAO	O
Inhibitors	O
:	O
Studies	O
in	O
animals	O
demonstrate	O
that	O
the	O
acute	O
toxicity	O
of	O
bupropion	B-Drug
is	O
enhanced	O
by	O
the	O
MAO	O
inhibitor	O
phenelzine	B-Drug
.	O

Levodopa	B-Drug
and	O
Amantadine	B-Drug
:	O
Limited	O
clinical	O
data	O
suggest	O
a	O
higher	O
incidence	O
of	O
adverse	O
experiences	O
in	O
patients	O
receiving	O
bupropion	B-Drug
concurrently	O
with	O
either	O
levodopa	B-Drug
or	O
amantadine	B-Drug
.	O

Administration	O
of	O
WELLBUTRIN	B-Drug
Tablets	O
to	O
patients	O
receiving	O
either	O
levodopa	B-Drug
or	O
amantadine	B-Drug
concurrently	O
should	O
be	O
undertaken	O
with	O
caution	O
,	O
using	O
small	O
initial	O
doses	O
and	O
small	O
gradual	O
dose	O
increases	O
.	O

Drugs	B-Drug
that	O
Lower	O
Seizure	O
Threshold	O
:	O
Concurrent	O
administration	O
of	O
WELLBUTRIN	B-Drug
and	O
agents	O
(	O
e.g.	O
,	O
antipsychotics	O
,	O
other	O
antidepressants	B-Drug
,	O
theophylline	B-Drug
,	O
systemic	O
steroids	O
,	O
etc	O
.	O

)	O
that	O
lower	O
seizure	O
threshold	O
should	O
be	O
undertaken	O
only	O
with	O
extreme	O
caution	O
.	O

Low	O
initial	O
dosing	O
and	O
small	O
gradual	O
dose	O
increases	O
should	O
be	O
employed	O
.	O

Nicotine	B-Drug
Transdermal	O
System	O
:	O
.	O

Alcohol	B-Drug
:	O
In	O
post-marketing	O
experience	O
,	O
there	O
have	O
been	O
rare	O
reports	O
of	O
adverse	O
neuropsychiatric	O
events	O
or	O
reduced	O
alcohol	B-Drug
tolerance	O
in	O
patients	O
who	O
were	O
drinking	O
alcohol	B-Drug
during	O
treatment	O
with	O
WELLBUTRIN	B-Drug
.	O

The	O
consumption	O
of	O
alcohol	B-Drug
during	O
treatment	O
with	O
WELLBUTRIN	B-Drug
should	O
be	O
minimized	O
or	O
avoided	O
(	O
also	O
see	O
a	O
href=	O
bupropz_od.htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O
.	O

It	O
is	O
recommended	O
that	O
buspirone	B-Drug
hydrochloride	I-Drug
not	O
be	O
used	O
concomitantly	O
with	O
MAO	O
inhibitors	O
Because	O
the	O
effects	O
of	O
concomitant	O
administration	O
of	O
buspirone	B-Drug
HCl	I-Drug
with	O
most	O
other	O
psychotropic	O
drugs	B-Drug
have	O
not	O
been	O
studied	O
,	O
the	O
concomitant	O
use	O
of	O
buspirone	B-Drug
HCl	I-Drug
with	O
other	O
CNS-active	O
drugs	B-Drug
should	O
be	O
approached	O
with	O
caution	O
.	O

There	O
is	O
one	O
report	O
suggesting	O
that	O
the	O
concomitant	O
use	O
of	O
trazodone	B-Drug
hydrochloride	I-Drug
(	O
Desyrel	B-Drug
)	O
and	O
buspirone	B-Drug
HCl	I-Drug
may	O
have	O
caused	O
3-	O
to	O
6-fold	O
elevations	O
on	O
SGPT	O
(	O
ALT	O
)	O
in	O
a	O
few	O
patients	O
.	O

In	O
a	O
similar	O
study	O
,	O
attempting	O
to	O
replicate	O
this	O
finding	O
,	O
no	O
interactive	O
effect	O
on	O
hepatic	O
transaminases	O
was	O
identified	O
.	O

In	O
a	O
study	O
in	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
buspirone	B-Drug
HCl	I-Drug
and	O
haloperidol	B-Drug
resulted	O
in	O
increased	O
serum	O
haloperidol	B-Drug
concentrations	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
not	O
clear	O
.	O

In	O
vitro	O
,	O
buspirone	B-Drug
does	O
not	O
displace	O
tightly	O
bound	O
drugs	B-Drug
like	O
phenytoin	B-Drug
,	O
propranolol	B-Drug
,	O
and	O
warfarin	B-Drug
from	O
serum	O
proteins	O
.	O

However	O
,	O
there	O
has	O
been	O
one	O
report	O
of	O
prolonged	O
prothrombin	O
time	O
when	O
buspirone	B-Drug
was	O
added	O
to	O
the	O
regimen	O
of	O
a	O
patient	O
treated	O
with	O
warfarin	B-Drug
.	O

The	O
patient	O
was	O
also	O
chronically	O
receiving	O
phenytoin	B-Drug
,	O
phenobarbital	B-Drug
,	O
digoxin	B-Drug
,	O
and	O
levothyroxine	B-Drug
sodium	I-Drug
.	O

In	O
vitro	O
,	O
buspirone	B-Drug
may	O
displace	O
less	O
firmly	O
bound	O
drugs	B-Drug
like	O
digoxin	B-Drug
.	O

The	O
clinical	O
significance	O
of	O
this	O
property	O
is	O
unknown	O
.	O

Itraconazole	B-Drug
decreases	O
busulfan	B-Drug
clearance	O
by	O
up	O
to	O
25	O
%	O
,	O
and	O
may	O
produce	O
AUCs	O
1500	O
M	O
min	O
in	O
some	O
patients	O
.	O

Fluconazole	B-Drug
,	O
and	O
the	O
5-HT3	O
antiemetics	O
ondansetron	B-Drug
(	O
Zofran	B-Drug
)	O
and	O
granisetron	B-Drug
(	O
Kytril	B-Drug
)	O
have	O
all	O
been	O
used	O
with	O
BUSULFEX	B-Drug
.	O

Phenytoin	B-Drug
increases	O
the	O
clearance	O
of	O
busulfan	B-Drug
by	O
15	O
%	O
or	O
more	O
,	O
possibly	O
due	O
to	O
the	O
induction	O
of	O
glutathione-S-transferase	O
.	O

Since	O
the	O
pharmacokinetics	O
of	O
BUSULFEX	B-Drug
were	O
studied	O
in	O
patients	O
treated	O
with	O
phenytoin	B-Drug
,	O
the	O
clearance	O
of	O
BUSULFEX	B-Drug
at	O
the	O
recommended	O
dose	O
may	O
be	O
lower	O
and	O
exposure	O
(	O
AUC	O
)	O
higher	O
in	O
patients	O
not	O
treated	O
with	O
phenytoin	B-Drug
.	O

Because	O
busulfan	B-Drug
is	O
eliminated	O
from	O
the	O
body	O
via	O
conjugation	O
with	O
glutathione	O
,	O
use	O
of	O
acetaminophen	B-Drug
prior	O
to	O
(	O
72	O
hours	O
)	O
or	O
concurrent	O
with	O
BUSULFEX	B-Drug
may	O
result	O
in	O
reduced	O
busulfan	B-Drug
clearance	O
based	O
upon	O
the	O
known	O
property	O
of	O
acetaminophen	B-Drug
to	O
decrease	O
glutathione	O
levels	O
in	O
the	O
blood	O
and	O
tissues	O
.	O

Interactions	O
may	O
occur	O
with	O
the	O
following	O
:	O
adrenocorticoids	O
(	O
cortisone-like	O
medicine	O
)	O
,	O
anticoagulants	B-Drug
(	O
blood	O
thinners	O
)	O
,	O
carbamazepine	B-Drug
,	O
corticotropin	B-Drug
(	O
barbiturates	B-Drug
may	O
decrease	O
the	O
effects	O
of	O
these	O
medicines	O
)	O
,	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
depressants	O
(	O
using	O
these	O
medicines	O
with	O
barbiturates	B-Drug
may	O
result	O
in	O
increased	O
CNS	O
depressant	O
effects	O
)	O
,	O
divalproex	B-Drug
sodium	I-Drug
,	O
valproic	B-Drug
acid	I-Drug
(	O
using	O
these	O
medicines	O
with	O
barbiturates	B-Drug
may	O
change	O
the	O
amount	O
of	O
either	O
medicine	O
that	O
you	O
need	O
to	O
take	O
)	O
,	O
and	O
oral	O
contraceptives	O
containing	O
estrogens	O
(	O
barbiturates	B-Drug
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
oral	O
contraceptives	O
,	O
and	O
you	O
may	O
need	O
to	O
change	O
to	O
a	O
different	O
type	O
of	O
birth	O
control	O
)	O
.	O

The	O
CNS	O
effects	O
of	O
butalbital	B-Drug
may	O
be	O
enhanced	O
by	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
.	O

Butalbital	B-Drug
,	O
acetaminophen	B-Drug
and	O
caffeine	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
:	O
other	O
narcotic	O
analgesics	O
,	O
alcohol	B-Drug
,	O
general	O
anesthetics	B-Drug
,	O
tranquilizers	O
such	O
as	O
chlordiazepoxide	B-Drug
,	O
sedative-hypnotics	O
,	O
or	O
other	O
CNS	O
depressants	O
,	O
causing	O
increased	O
CNS	O
depression	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Acetaminophen	B-Drug
may	O
produce	O
false-positive	O
test	O
results	O
for	O
urinary	O
5-hydroxyindoleacetic	O
acid	O
.	O

Potential	O
drug	B-Drug
interactions	O
between	O
Mentax	B-Drug
(	O
butenafine	B-Drug
HCl	I-Drug
cream	O
)	O
Cream	O
,	O
1	O
%	O
,	O
and	O
other	O
drugs	B-Drug
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

Concurrent	O
use	O
of	O
butorphanol	B-Drug
with	O
central	O
nervous	O
system	O
depressants	O
(	O
e.g.	O
,	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
tranquilizers	O
,	O
and	O
antihistamines	B-Drug
)	O
may	O
result	O
in	O
increased	O
central	O
nervous	O
system	O
depressant	O
effects	O
.	O

When	O
used	O
concurrently	O
with	O
such	O
drugs	B-Drug
,	O
the	O
dose	O
of	O
butorphanol	B-Drug
should	O
be	O
the	O
smallest	O
effective	O
dose	O
and	O
the	O
frequency	O
of	O
dosing	O
reduced	O
as	O
much	O
as	O
possible	O
when	O
administered	O
concomitantly	O
with	O
drugs	B-Drug
that	O
potentiate	O
the	O
action	O
of	O
opioids	O
.	O

In	O
healthy	O
volunteers	O
,	O
the	O
pharmacokinetics	O
of	O
a	O
1-mg	O
dose	O
of	O
butorphanol	B-Drug
administered	O
as	O
STADOL	B-Drug
NS	I-Drug
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
a	O
single	O
6-mg	O
subcutaneous	O
dose	O
of	O
sumatriptan	B-Drug
.	O

However	O
,	O
in	O
another	O
study	O
in	O
healthy	O
volunteers	O
,	O
the	O
pharmacokinetics	O
of	O
butorphanol	B-Drug
were	O
significantly	O
altered	O
(	O
29	O
%	O
decrease	O
in	O
AUC	O
and	O
38	O
%	O
decrease	O
in	O
Cmax	O
)	O
when	O
a	O
1-mg	O
dose	O
of	O
STADOL	B-Drug
NS	I-Drug
was	O
administered	O
1	O
minute	O
after	O
a	O
20-mg	O
dose	O
of	O
sumatriptan	B-Drug
nasal	O
spray	O
.	O

(	O
The	O
two	O
drugs	B-Drug
were	O
administered	O
in	O
opposite	O
nostrils	O
.	O

)	O
When	O
the	O
STADOL	B-Drug
NS	I-Drug
was	O
administered	O
30	O
minutes	O
after	O
the	O
sumatriptan	B-Drug
nasal	O
spray	O
,	O
the	O
AUC	O
of	O
butorphanol	B-Drug
increased	O
11	O
%	O
and	O
Cmax	O
decreased	O
18	O
%	O
.	O

In	O
neither	O
case	O
were	O
the	O
pharmacokinetics	O
of	O
sumatriptan	B-Drug
affected	O
by	O
coadministration	O
with	O
STADOL	B-Drug
NS	I-Drug
.	O

These	O
results	O
suggest	O
that	O
the	O
analgesic	O
effect	O
of	O
STADOL	B-Drug
NS	I-Drug
may	O
be	O
diminished	O
when	O
it	O
is	O
administered	O
shortly	O
after	O
sumatriptan	B-Drug
nasal	O
spray	O
,	O
but	O
by	O
30	O
minutes	O
any	O
such	O
reduction	O
in	O
effect	O
should	O
be	O
minimal	O
.	O

The	O
safety	O
of	O
using	O
STADOL	B-Drug
NS	I-Drug
and	O
IMITREX	B-Drug
(	O
sumatriptan	B-Drug
)	O
Nasal	O
Spray	O
during	O
the	O
same	O
episode	O
of	O
migraine	O
has	O
not	O
been	O
established	O
.	O

However	O
,	O
it	O
should	O
be	O
noted	O
that	O
both	O
products	O
are	O
capable	O
of	O
producing	O
transient	O
increases	O
in	O
blood	O
pressure	O
.	O

The	O
pharmacokinetics	O
of	O
a	O
1-mg	O
dose	O
of	O
butorphanol	B-Drug
administered	O
as	O
STADOL	B-Drug
NS	I-Drug
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
cimetidine	B-Drug
(	O
300	O
mg	O
QID	O
)	O
.	O

Conversely	O
,	O
the	O
administration	O
of	O
STADOL	B-Drug
NS	I-Drug
(	O
1	O
mg	O
butorphanol	B-Drug
QID	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
300-mg	O
dose	O
of	O
cimetidine	B-Drug
.	O

It	O
is	O
not	O
known	O
if	O
the	O
effects	O
of	O
butorphanol	B-Drug
are	O
altered	O
by	O
concomitant	O
medications	O
that	O
affect	O
hepatic	O
metabolism	O
of	O
drugs	B-Drug
(	O
erythromycin	B-Drug
,	O
etc	O
.	O

)	O
,	O
but	O
physicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
that	O
a	O
smaller	O
initial	O
dose	O
and	O
longer	O
intervals	O
between	O
doses	O
may	O
be	O
needed	O
.	O

The	O
fraction	O
of	O
STADOL	B-Drug
NS	I-Drug
absorbed	O
is	O
unaffected	O
by	O
the	O
concomitant	O
administration	O
of	O
a	O
nasal	O
vasoconstrictor	O
(	O
oxymetazoline	B-Drug
)	O
,	O
but	O
the	O
rate	O
of	O
absorption	O
is	O
decreased	O
.	O

Therefore	O
,	O
a	O
slower	O
onset	O
can	O
be	O
anticipated	O
if	O
STADOL	B-Drug
NS	I-Drug
is	O
administered	O
concomitantly	O
with	O
,	O
or	O
immediately	O
following	O
,	O
a	O
nasal	O
vasoconstrictor	O
.	O

No	O
information	O
is	O
available	O
about	O
the	O
use	O
of	O
butorphanol	B-Drug
concurrently	O
with	O
MAO	O
inhibitors	O
.	O

DOSTINEX	B-Drug
should	O
not	O
be	O
administered	O
concurrently	O
with	O
D2-antagonists	O
,	O
such	O
as	O
phenothiazines	O
,	O
butyrophenones	O
,	O
thioxanthines	O
,	O
or	O
metoclopramide	B-Drug
.	O

Cytochrome	O
P450	O
1A2	O
(	O
CYP1A2	B-Drug
)	O
is	O
known	O
to	O
be	O
the	O
major	O
enzyme	O
involved	O
in	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O

Therefore	O
,	O
caffeine	B-Drug
has	O
the	O
potential	O
to	O
interact	O
with	O
drugs	B-Drug
that	O
are	O
substrates	O
for	O
CYP1A2	B-Drug
,	O
inhibit	O
CYP1A2	B-Drug
,	O
or	O
induce	O
CYP1A2	B-Drug
.	O

Few	O
data	O
exist	O
on	O
drug	B-Drug
interactions	O
with	O
caffeine	B-Drug
in	O
preterm	O
neonates	O
.	O

Based	O
on	O
adult	O
data	O
,	O
lower	O
doses	O
of	O
caffeine	B-Drug
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	B-Drug
which	O
are	O
reported	O
to	O
decrease	O
caffeine	B-Drug
elimination	O
(	O
e.g.	O
,	O
cimetidine	B-Drug
and	O
ketoconazole	B-Drug
)	O
and	O
higher	O
caffeine	B-Drug
doses	O
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	B-Drug
that	O
increase	O
caffeine	B-Drug
elimination	O
(	O
e.g.	O
,	O
phenobarbital	B-Drug
and	O
phenytoin	B-Drug
)	O
.	O

Caffeine	B-Drug
administered	O
concurrently	O
with	O
ketoprofen	B-Drug
reduced	O
the	O
urine	O
volume	O
in	O
4	O
healthy	O
volunteers	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
interaction	O
in	O
preterm	O
neonates	O
is	O
not	O
known	O
.	O

Interconversion	O
between	O
caffeine	B-Drug
and	O
theophylline	B-Drug
has	O
been	O
reported	O
in	O
preterm	O
neonates	O
.	O

The	O
concurrent	O
use	O
of	O
these	O
drugs	B-Drug
is	O
not	O
recommended	O
.	O

Interactions	O
for	O
vitamin	O
D	O
analogues	O
(	O
Vitamin	B-Drug
D2	I-Drug
,	O
Vitamin	B-Drug
D3	I-Drug
,	O
Calcitriol	B-Drug
,	O
and	O
Calcidiol	B-Drug
)	O
:	O
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	O
soluble	O
vitamins	O
;	O
as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	O
D	O
.	O

Phenytoin/Phenobarbital	B-Drug
:	O
The	O
coadministration	O
of	O
phenytoin	B-Drug
or	O
phenobarbital	B-Drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	O
D	O
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol/ergocalcitriol	B-Drug
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol/ergocalcitriol	B-Drug
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	B-Drug
may	O
be	O
necessary	O
if	O
these	O
drugs	B-Drug
are	O
administered	O
simultaneously	O
.	O

Thiazides	O
:	O
Thiazides	O
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	B-Drug
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	O
with	O
vitamin	O
D	O
causes	O
hypercalcemia	O
.	O

Therefore	O
,	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O

Digitalis	B-Drug
:	O
Vitamin	O
D	O
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B-Drug
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	O
D	O
.	O

Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
300	O
mg/day	O
to	O
1200	O
mg/day	O
ketoconazole	B-Drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O

However	O
,	O
in	O
vivo	O
drug	B-Drug
interaction	O
studies	O
of	O
ketoconazole	B-Drug
with	O
vitamin	O
D	O
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	O
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	O
D	O
analogues	O
,	O
which	O
promote	O
calcium	B-Drug
absorption	O
,	O
and	O
corticosteroids	O
,	O
which	O
inhibit	O
calcium	B-Drug
absorption	O
.	O

Phosphate-Binding	O
Agents	O
:	O
Since	O
vitamin	O
D	O
also	O
has	O
an	O
effect	O
on	O
phosphate	B-Drug
transport	O
in	O
the	O
intestine	O
,	O
kidneys	O
and	O
bones	O
,	O
the	O
dosage	O
of	O
phosphate-binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	B-Drug
concentration	O
.	O

Vitamin	O
D	O
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	O
D	O
analogues	O
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	B-Drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium-containing	B-Drug
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	B-Drug
:	O
Magnesium-containing	B-Drug
preparations	O
(	O
eg	O
,	O
antacids	O
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	O
D	O
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Interactions	O
for	O
vitamin	O
D	O
analogues	O
(	O
Vitamin	B-Drug
D2	I-Drug
,	O
Vitamin	B-Drug
D3	I-Drug
,	O
Calcitriol	B-Drug
,	O
and	O
Calcidiol	B-Drug
)	O
:	O
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	O
soluble	O
vitamins	O
;	O
as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	O
D	O
.	O

Phenytoin/Phenobarbital	B-Drug
:	O
The	O
coadministration	O
of	O
phenytoin	B-Drug
or	O
phenobarbital	B-Drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	O
D	O
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol/ergocalcitriol	B-Drug
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol/ergocalcitriol	B-Drug
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	B-Drug
may	O
be	O
necessary	O
if	O
these	O
drugs	B-Drug
are	O
administered	O
simultaneously	O
.	O

Thiazides	O
:	O
Thiazides	O
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	B-Drug
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	O
with	O
vitamin	O
D	O
causes	O
hypercalcemia	O
.	O

Therefore	O
,	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O

Digitalis	B-Drug
:	O
Vitamin	O
D	O
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B-Drug
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	O
D	O
.	O

Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
300	O
mg/day	O
to	O
1200	O
mg/day	O
ketoconazole	B-Drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O

However	O
,	O
in	O
vivo	O
drug	B-Drug
interaction	O
studies	O
of	O
ketoconazole	B-Drug
with	O
vitamin	O
D	O
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	O
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	O
D	O
analogues	O
,	O
which	O
promote	O
calcium	B-Drug
absorption	O
,	O
and	O
corticosteroids	O
,	O
which	O
inhibit	O
calcium	B-Drug
absorption	O
.	O

Phosphate-Binding	O
Agents	O
:	O
Since	O
vitamin	O
D	O
also	O
has	O
an	O
effect	O
on	O
phosphate	B-Drug
transport	O
in	O
the	O
intestine	O
,	O
kidneys	O
and	O
bones	O
,	O
the	O
dosage	O
of	O
phosphate-binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	B-Drug
concentration	O
.	O

Vitamin	O
D	O
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	O
D	O
analogues	O
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	B-Drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium-containing	B-Drug
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	B-Drug
:	O
Magnesium-containing	B-Drug
preparations	O
(	O
eg	O
,	O
antacids	O
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	O
D	O
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Concomitant	O
use	O
with	O
other	O
calcium-containing	B-Drug
medicines	O
(	O
including	O
antacids	O
)	O
may	O
cause	O
too	O
much	O
calcium	B-Drug
in	O
the	O
blood	O
or	O
urine	O
,	O
which	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O

Using	O
calcium	B-Drug
acetate	I-Drug
with	O
digitalis	B-Drug
glycosides	O
(	O
heart	O
medicine	O
)	O
may	O
cause	O
hypercalcemia	O
(	O
too	O
much	O
calcium	B-Drug
in	O
the	O
blood	O
)	O
,	O
which	O
could	O
increase	O
the	O
chance	O
of	O
developing	O
an	O
irregular	O
heartbeat	O
.	O

May	O
interact	O
with	O
cefamandole	B-Drug
naftate	I-Drug
,	O
cephalothin	B-Drug
sodium	I-Drug
,	O
magnesium	B-Drug
sulfate	I-Drug
,	O
prednisolone	B-Drug
sodium	I-Drug
succinate	I-Drug
,	O
and	O
prochlorperazine	B-Drug
edisylate	I-Drug
.	O

No	O
significant	O
drug	B-Drug
interactions	O
have	O
been	O
reported	O
in	O
studies	O
of	O
candesartan	B-Drug
cilexetil	I-Drug
given	O
with	O
other	O
drugs	B-Drug
such	O
as	O
glyburide	B-Drug
,	O
nifedipine	B-Drug
,	O
digoxin	B-Drug
,	O
warfarin	B-Drug
,	O
hydrochlorothiazide	B-Drug
,	O
and	O
oral	O
contraceptives	O
in	O
healthy	O
volunteers	O
,	O
or	O
given	O
with	O
enalapril	B-Drug
to	O
patients	O
with	O
heart	O
failure	O
(	O
NYHA	O
class	O
II	O
and	O
III	O
)	O
.	O

Because	O
candesartan	B-Drug
is	O
not	O
significantly	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
and	O
at	O
therapeutic	O
concentrations	O
has	O
no	O
effects	O
on	O
P450	O
enzymes	O
,	O
interactions	O
with	O
drugs	B-Drug
that	O
inhibit	O
or	O
are	O
metabolized	O
by	O
those	O
enzymes	O
would	O
not	O
be	O
expected	O
.	O

Lithium	B-Drug
Reversible	O
increases	O
in	O
serum	O
lithium	B-Drug
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-Drug
with	O
ACE	O
inhibitors	O
,	O
and	O
with	O
some	O
angiotensin	B-Drug
II	O
receptor	O
antagonists	O
.	O

An	O
increase	O
in	O
serum	O
lithium	B-Drug
concentration	O
has	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-Drug
with	O
ATACAND	B-Drug
,	O
so	O
careful	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
during	O
concomitant	O
use	O
.	O

Antacid	O
:	O
The	O
effect	O
of	O
an	O
aluminum	B-Drug
hydroxide-	I-Drug
and	O
magnesium	B-Drug
hydroxide-containing	I-Drug
antacid	O
(	O
Maalox	B-Drug
)	O
*	O
on	O
the	O
pharmacokinetics	O
of	O
capecitabine	B-Drug
was	O
investigated	O
in	O
12	O
cancer	O
patients	O
.	O

There	O
was	O
a	O
small	O
increase	O
in	O
plasma	O
concentrations	O
of	O
capecitabine	B-Drug
and	O
one	O
metabolite	O
(	O
5-DFCR	B-Drug
)	O
;	O
there	O
was	O
no	O
effect	O
on	O
the	O
3	O
major	O
metabolites	O
(	O
5-DFUR	B-Drug
,	O
5-FU	B-Drug
and	O
FBAL	B-Drug
)	O
.	O

Coumarin	O
Anticoagulants	B-Drug
Altered	O
coagulation	O
parameters	O
and/or	O
bleeding	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
capecitabine	B-Drug
concomitantly	O
with	O
coumarin-derivative	O
anticoagulants	B-Drug
such	O
as	O
warfarin	B-Drug
and	O
phenprocoumon	B-Drug
.	O

Patients	O
taking	O
coumarin-derivative	O
anticoagulants	B-Drug
concomitantly	O
with	O
capecitabine	B-Drug
should	O
be	O
monitored	O
regularly	O
for	O
alterations	O
in	O
their	O
coagulation	O
parameters	O
(	O
PT	O
or	O
INR	O
)	O
.	O

Leucovorin	B-Drug
:	O
The	O
concentration	O
of	O
5-fluorouracil	B-Drug
is	O
increased	O
and	O
its	O
toxicity	O
may	O
be	O
enhanced	O
by	O
leucovorin	B-Drug
.	O

Deaths	O
from	O
severe	O
enterocolitis	O
,	O
diarrhea	O
,	O
and	O
dehydration	O
have	O
been	O
reported	O
in	O
elderly	O
patients	O
receiving	O
weekly	O
leucovorin	B-Drug
and	O
fluorouracil	B-Drug
.	O

Hypotension	O
Patients	O
on	O
Diuretic	B-Drug
Therapy	O
:	O
Patients	O
on	O
diuretics	B-Drug
and	O
especially	O
those	O
in	O
whom	O
diuretic	B-Drug
therapy	O
was	O
recently	O
instituted	O
,	O
as	O
well	O
as	O
those	O
on	O
severe	O
dietary	O
salt	O
restriction	O
or	O
dialysis	O
,	O
may	O
occasionally	O
experience	O
a	O
precipitous	O
reduction	O
of	O
blood	O
pressure	O
usually	O
within	O
the	O
first	O
hour	O
after	O
receiving	O
the	O
initial	O
dose	O
of	O
captopril	B-Drug
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
captopril	B-Drug
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Drug
or	O
increasing	O
the	O
salt	O
intake	O
approximately	O
one	O
week	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
captopril	B-Drug
(	O
captopril	B-Drug
tablets	O
,	O
USP	O
)	O
or	O
initiating	O
therapy	O
with	O
small	O
doses	O
(	O
6.25	O
or	O
12.5	O
mg	O
)	O
.	O

Alternatively	O
,	O
provide	O
medical	O
supervision	O
for	O
at	O
least	O
one	O
hour	O
after	O
the	O
initial	O
dose	O
.	O

If	O
hypotension	O
occurs	O
,	O
the	O
patient	O
should	O
be	O
placed	O
in	O
a	O
supine	O
position	O
and	O
,	O
if	O
necessary	O
,	O
receive	O
an	O
intravenous	O
infusion	O
of	O
normal	O
saline	O
.	O

This	O
transient	O
hypotensive	O
response	O
is	O
not	O
a	O
contraindication	O
to	O
further	O
doses	O
which	O
can	O
be	O
given	O
without	O
difficulty	O
once	O
the	O
blood	O
pressure	O
has	O
increased	O
after	O
volume	O
expansion	O
.	O

Agents	O
Having	O
Vasodilator	O
Activity	O
:	O
Data	O
on	O
the	O
effect	O
of	O
concomitant	O
use	O
of	O
other	O
vasodilators	O
in	O
patients	O
receiving	O
captopril	B-Drug
for	O
heart	O
failure	O
are	O
not	O
available	O
;	O
therefore	O
,	O
nitroglycerin	B-Drug
or	O
other	O
nitrates	B-Drug
(	O
as	O
used	O
for	O
management	O
of	O
angina	O
)	O
or	O
other	O
drugs	B-Drug
having	O
vasodilator	O
activity	O
should	O
,	O
if	O
possible	O
,	O
be	O
discontinued	O
before	O
starting	O
captopril	B-Drug
.	O

If	O
resumed	O
during	O
captopril	B-Drug
therapy	O
,	O
such	O
agents	O
should	O
be	O
administered	O
cautiously	O
,	O
and	O
perhaps	O
at	O
lower	O
dosage	O
.	O

Agents	O
Causing	O
Renin	O
Release	O
Captopril	B-Drug
's	O
effect	O
will	O
be	O
augmented	O
by	O
antihypertensive	B-Drug
agents	O
that	O
cause	O
renin	O
release	O
.	O

For	O
example	O
,	O
diuretics	B-Drug
(	O
e.g.	O
,	O
thiazides	O
)	O
may	O
activate	O
the	O
renin-angiotensin-aldosterone	O
system	O
.	O

Agents	O
Affecting	O
Sympathetic	O
Activity	O
The	O
sympathetic	O
nervous	O
system	O
may	O
be	O
especially	O
important	O
in	O
supporting	O
blood	O
pressure	O
in	O
patients	O
receiving	O
captopril	B-Drug
alone	O
or	O
with	O
diuretics	B-Drug
.	O

Therefore	O
,	O
agents	O
affecting	O
sympathetic	O
activity	O
(	O
e.g.	O
,	O
ganglionic	O
blocking	O
agents	O
or	O
adrenergic	O
neuron	O
blocking	O
agents	O
)	O
should	O
be	O
used	O
with	O
caution	O
.	O

Beta-adrenergic	O
blocking	O
drugs	B-Drug
add	O
some	O
further	O
antihypertensive	B-Drug
effect	O
to	O
captopril	B-Drug
,	O
but	O
the	O
overall	O
response	O
is	O
less	O
than	O
additive	O
.	O

Agents	O
Increasing	O
Serum	O
Potassium	B-Drug
Since	O
captopril	B-Drug
decreases	O
aldosterone	O
production	O
,	O
elevation	O
of	O
serum	O
potassium	B-Drug
may	O
occur	O
.	O

Potassium-sparing	O
diuretics	B-Drug
such	O
as	O
spironolactone	B-Drug
,	O
triamterene	B-Drug
,	O
or	O
amiloride	B-Drug
,	O
or	O
potassium	B-Drug
supplements	O
should	O
be	O
given	O
only	O
for	O
documented	O
hypokalemia	O
,	O
and	O
then	O
with	O
caution	O
,	O
since	O
they	O
may	O
lead	B-Drug
to	O
a	O
significant	O
increase	O
of	O
serum	O
potassium	B-Drug
.	O

Salt	O
substitutes	O
containing	O
potassium	B-Drug
should	O
also	O
be	O
used	O
with	O
caution	O
.	O

Inhibitors	O
Of	O
Endogenous	O
Prostaglandin	O
Synthesis	O
It	O
has	O
been	O
reported	O
that	O
indomethacin	B-Drug
may	O
reduce	O
the	O
antihypertensive	B-Drug
effect	O
of	O
captopril	B-Drug
,	O
especially	O
in	O
cases	O
of	O
low	O
renin	O
hypertension	O
.	O

Other	O
nonsteroidal	O
anti-inflammatory	O
agents	O
(	O
e.g.	O
,	O
aspirin	B-Drug
)	O
may	O
also	O
have	O
this	O
effect	O
.	O

Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
levels	O
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	B-Drug
and	O
ACE	O
inhibitor	O
therapy	O
.	O

These	O
drugs	B-Drug
should	O
be	O
coad-ministered	O
with	O
caution	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	B-Drug
is	O
also	O
used	O
,	O
it	O
may	O
increase	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O

Cardiac	O
Glycosides	O
:	O
In	O
a	O
study	O
of	O
young	O
healthy	O
male	O
subjects	O
no	O
evidence	O
of	O
a	O
direct	O
pharmacokinetic	O
captopril-digoxin	B-Drug
interaction	O
could	O
be	O
found	O
.	O

Loop	O
Diuretics	B-Drug
:	O
Furosemide	B-Drug
administered	O
concurrently	O
with	O
captopril	B-Drug
does	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
captopril	B-Drug
in	O
renally	O
impaired	O
hypertensive	O
patients	O
.	O

Allopurinol	B-Drug
:	O
In	O
a	O
study	O
of	O
healthy	O
male	O
volunteers	O
no	O
significant	O
pharmacokinetic	O
interaction	O
occurred	O
when	O
captopril	B-Drug
and	O
allopurinol	B-Drug
were	O
administered	O
concomitantly	O
for	O
6	O
days	O
.	O

Drug/Laboratory	O
Test	O
Interaction	O
Captopril	B-Drug
may	O
cause	O
a	O
false-positive	O
urine	O
test	O
for	O
acetone	O
.	O

Clinically	O
meaningful	O
drug	B-Drug
interactions	O
have	O
occurred	O
with	O
concomitant	O
medications	O
and	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
the	O
following	O
:	O
Agents	O
Highly	O
Bound	O
to	O
Plasma	O
Protein	O
Carbamazepine	B-Drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
;	O
therefore	O
,	O
administration	O
of	O
EQUETROTM	B-Drug
to	O
a	O
patient	O
taking	O
another	O
drug	B-Drug
that	O
is	O
highly	O
protein	O
bound	O
should	O
not	O
cause	O
increased	O
free	O
concentrations	O
of	O
the	O
other	O
drug	B-Drug
.	O

Agents	O
that	O
Inhibit	O
Cytochrome	O
P450	O
Isoenzymes	O
and/or	O
Epoxide	O
Hydrolase	O
Carbamazepine	B-Drug
is	O
metabolized	O
mainly	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A4	O
to	O
the	O
active	O
carbamazepine	B-Drug
10,11-epoxide	I-Drug
,	O
which	O
is	O
further	O
metabolized	O
to	O
the	O
trans-diol	O
by	O
epoxide	O
hydrolase	O
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	B-Drug
and	O
any	O
agent	O
that	O
inhibits	O
CYP3A4	B-Drug
and/or	O
epoxide	O
hydrolase	O
.	O

Agents	O
that	O
are	O
CYP3A4	B-Drug
inhibitors	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
,	O
to	O
increase	O
plasma	O
levels	O
of	O
EQUETROTM	B-Drug
are	O
the	O
following	O
:	O
Acetazolamide	B-Drug
,	O
azole	O
antifungals	O
,	O
cimetidine	B-Drug
,	O
clarithromycin	B-Drug
(	O
1	O
)	O
,	O
dalfopristin	B-Drug
,	O
danazol	B-Drug
,	O
delavirdine	B-Drug
,	O
diltiazem	B-Drug
,	O
erythromycin	B-Drug
(	O
1	O
)	O
,	O
fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
grapefruit	O
juice	O
,	O
isoniazid	B-Drug
,	O
itraconazole	B-Drug
,	O
ketoconazole	B-Drug
,	O
loratadine	B-Drug
,	O
nefazodone	B-Drug
,	O
niacinamide	B-Drug
,	O
nicotinamide	B-Drug
,	O
protease	O
inhibitors	O
,	O
propoxyphene	B-Drug
,	O
quinine	B-Drug
,	O
quinupristin	B-Drug
,	O
troleandomycin	B-Drug
,	O
valproate	B-Drug
(	O
1	O
)	O
,	O
verapamil	B-Drug
,	O
zileuton	B-Drug
.	O

Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
of	O
EQUETROTM	B-Drug
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP3A4	B-Drug
or	O
epoxide	O
hydrolase	O
inhibitors	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
reduction	O
for	O
EQUETROTM	B-Drug
may	O
be	O
necessary	O
.	O

Agents	O
that	O
Induce	O
Cytochrome	O
P450	O
Isoenzymes	O
Carbamazepine	B-Drug
is	O
metabolized	O
by	O
CYP3A4	B-Drug
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	B-Drug
and	O
any	O
agent	O
that	O
induces	O
CYP3A4	B-Drug
.	O

Agents	O
that	O
are	O
CYP	O
inducers	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
,	O
to	O
decrease	O
plasma	O
levels	O
of	O
EQUETROTM	B-Drug
are	O
the	O
following	O
:	O
Cisplatin	B-Drug
,	O
doxorubicin	B-Drug
HCL	I-Drug
,	O
felbamate	B-Drug
,	O
rifampin	B-Drug
,	O
phenobarbital	B-Drug
,	O
Phenytoin	B-Drug
(	O
2	O
)	O
,	O
primidone	B-Drug
,	O
methsuximide	B-Drug
,	O
and	O
theophylline	B-Drug
Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
EQUETROTM	B-Drug
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP3A4	B-Drug
inducers	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
increase	O
for	O
EQUETROTM	B-Drug
may	O
be	O
necessary	O
.	O

Agents	O
with	O
Decreased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	B-Drug
due	O
to	O
Induction	O
of	O
Cytochrome	O
P450	O
Enzymes	O
Carbamazepine	B-Drug
is	O
known	O
to	O
induce	O
CYP1A2	B-Drug
and	O
CYP3A4	B-Drug
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
interaction	O
between	O
carbamazepine	B-Drug
and	O
any	O
agent	O
metabolized	O
by	O
one	O
(	O
or	O
more	O
)	O
of	O
these	O
enzymes	O
.	O

Agents	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
to	O
have	O
decreased	O
plasma	O
levels	O
in	O
the	O
presence	O
of	O
EQUETROTM	B-Drug
due	O
to	O
induction	O
of	O
CYP	O
enzymes	O
are	O
the	O
following	O
:	O
Acetaminophen	B-Drug
,	O
alprazolam	B-Drug
,	O
amitriptyline	B-Drug
,	O
bupropion	B-Drug
,	O
buspirone	B-Drug
,	O
citalopram	B-Drug
,	O
clobazam	B-Drug
,	O
clonazepam	B-Drug
,	O
clozapine	B-Drug
,	O
cyclosporin	B-Drug
,	O
delavirdine	B-Drug
,	O
desipramine	B-Drug
,	O
diazepam	B-Drug
,	O
dicumarol	B-Drug
,	O
doxycycline	B-Drug
,	O
ethosuximide	B-Drug
,	O
felbamate	B-Drug
,	O
felodipine	B-Drug
,	O
glucocorticoids	O
,	O
haloperidol	B-Drug
,	O
itraconazole	B-Drug
,	O
lamotrigine	B-Drug
,	O
levothyroxine	B-Drug
,	O
lorazepam	B-Drug
,	O
methadone	B-Drug
,	O
midazolam	B-Drug
,	O
mirtazapine	B-Drug
,	O
nortriptyline	B-Drug
,	O
olanzapine	B-Drug
,	O
oral	O
contraceptives	O
(	O
3	O
)	O
,	O
oxcarbazepine	B-Drug
,	O
Phenytoin	B-Drug
(	O
4	O
)	O
,	O
praziquantel	B-Drug
,	O
protease	O
inhibitors	O
,	O
quetiapine	B-Drug
,	O
risperidone	B-Drug
,	O
theophylline	B-Drug
,	O
topiramate	B-Drug
,	O
tiagabine	B-Drug
,	O
tramadol	B-Drug
,	O
triazolam	B-Drug
,	O
valproate	B-Drug
,	O
warfarin	B-Drug
(	O
5	O
)	O
,	O
ziprasidone	B-Drug
,	O
and	O
zonisamide	B-Drug
.	O

Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
EQUETROTM	B-Drug
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
increase	O
for	O
the	O
concomitant	O
agent	O
may	O
be	O
necessary	O
.	O

Agents	O
with	O
Increased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	B-Drug
:	O
EQUETROTM	B-Drug
increases	O
the	O
plasma	O
levels	O
of	O
the	O
following	O
agents	O
:	O
Clomipramine	B-Drug
HCl	I-Drug
,	O
Phenytoin	B-Drug
(	O
6	O
)	O
,	O
and	O
primidone	B-Drug
Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
the	O
treatment	O
with	O
EQUETROTM	B-Drug
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
decrease	O
for	O
the	O
concomitant	O
agent	O
may	O
be	O
necessary	O
.	O

Pharmacological/Pharmacodynamic	O
Interactions	O
with	O
Carbamazepine	B-Drug
Concomitant	O
administration	O
of	O
carbamazepine	B-Drug
and	O
lithium	B-Drug
may	O
increase	O
the	O
risk	O
of	O
neurotoxic	O
side	O
effects	O
.	O

Given	O
the	O
anticonvulsant	O
properties	O
of	O
carbamazepine	B-Drug
,	O
EQUETROTM	B-Drug
may	O
reduce	O
the	O
thyroid	B-Drug
function	O
as	O
has	O
been	O
reported	O
with	O
other	O
anticonvulsants	O
.	O

Additionally	O
,	O
anti-malarial	O
drugs	B-Drug
,	O
such	O
as	O
chloroquine	B-Drug
and	O
mefloquine	B-Drug
,	O
may	O
antagonize	O
the	O
activity	O
of	O
carbamazepine	B-Drug
.	O

Thus	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
EQUETROTM	B-Drug
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
adjustment	O
may	O
be	O
necessary	O
.	O

Because	O
of	O
its	O
primary	O
CNS	O
effect	O
,	O
caution	O
should	O
be	O
used	O
when	O
EQUETROTM	B-Drug
is	O
taken	O
with	O
other	O
centrally	O
acting	O
drugs	B-Drug
and	O
alcohol	B-Drug
.	O

Geocillin	B-Drug
(	O
carbenicillin	B-Drug
indanyl	I-Drug
sodium	I-Drug
)	O
blood	O
levels	O
may	O
be	O
increased	O
and	O
prolonged	O
by	O
concurrent	O
administration	O
of	O
probenecid	B-Drug
.	O

Caution	O
should	O
be	O
exercised	O
when	O
the	O
following	O
drugs	B-Drug
are	O
administered	O
concomitantly	O
with	O
LODOSYN	B-Drug
(	O
Carbidopa	B-Drug
)	O
given	O
with	O
levodopa	B-Drug
or	O
carbidopa-levodopa	B-Drug
combination	O
products	O
.	O

For	O
patients	O
receiving	O
monoamine	O
oxidase	O
inhibitors	O
,	O
see	O
CONTRAINDICATIONS	O
.	O

Dopamine	B-Drug
D2	O
receptor	O
antagonists	O
(	O
e.g.	O
,	O
phenothiazines	O
,	O
butyrophenones	O
,	O
risperidone	B-Drug
)	O
and	O
isoniazid	B-Drug
may	O
reduce	O
the	O
therapeutic	O
effects	O
of	O
levodopa	B-Drug
.	O

In	O
addition	O
,	O
the	O
beneficial	O
effects	O
of	O
levodopa	B-Drug
in	O
Parkinsons	O
disease	O
have	O
been	O
reported	O
to	O
be	O
reversed	O
by	O
phenytoin	B-Drug
and	O
papaverine	B-Drug
.	O

Patients	O
taking	O
these	O
drugs	B-Drug
with	O
LODOSYN	B-Drug
and	O
levodopa	B-Drug
or	O
carbidopa-levodopa	B-Drug
combination	O
products	O
should	O
be	O
carefully	O
observed	O
for	O
loss	O
of	O
therapeutic	O
response	O
.	O

Iron	B-Drug
salts	O
may	O
reduce	O
the	O
bioavailability	O
of	O
carbidopa	B-Drug
and	O
levodopa	B-Drug
.	O

The	O
clinical	O
relevance	O
is	O
unclear	O
.	O

Although	O
metoclopramide	B-Drug
may	O
increase	O
the	O
bioavailability	O
of	O
levodopa	B-Drug
by	O
increasing	O
gastric	O
emptying	O
,	O
metoclopramide	B-Drug
may	O
also	O
adversely	O
affect	O
disease	O
control	O
by	O
its	O
dopamine	B-Drug
receptor	O
antagonistic	O
properties	O
.	O

Iodine	B-Drug
or	O
iodine	B-Drug
excess	O
may	O
decrease	O
the	O
effect	O
of	O
Carbimazole	B-Drug
,	O
and	O
an	O
iodine	B-Drug
deficiency	O
can	O
increase	O
the	O
effect	O
of	O
Carbimazole	B-Drug
.	O

Serum	O
concentration	O
of	O
digoxin	B-Drug
and	O
digitoxin	B-Drug
may	O
increase	O
when	O
patients	O
take	O
antithyroid	O
agents	O
.	O

A	O
decrease	O
of	O
the	O
dosage	O
may	O
be	O
necessary	O
when	O
patient	O
becomes	O
euthyroid	O
.	O

Antithyroid	O
agents	O
may	O
decrease	O
thyroidal	O
uptake	O
of	O
sodium	B-Drug
iodide	I-Drug
I131	I-Drug
,	O
a	O
rebound	O
in	O
uptake	O
may	O
occur	O
up	O
to	O
5	O
days	O
after	O
sudden	O
withdrawal	O
of	O
Carbimazole	B-Drug
.	O

Patients	O
response	O
to	O
oral	O
anticoagulants	B-Drug
may	O
be	O
affected	O
by	O
his/her	O
thyroid	B-Drug
and	O
metabolic	O
status	O
.	O

An	O
evaluation	O
of	O
prothrombin	O
time	O
and	O
an	O
adjustment	O
of	O
anticoagulant	B-Drug
dosage	O
are	O
recommended	O
Antihistamines	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	O
antidepressants	B-Drug
,	O
barbiturates	B-Drug
,	O
alcohol	B-Drug
,	O
and	O
other	O
CNS	O
depressants	O
.	O

MAO	O
inhibitors	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
effects	O
of	O
antihistamines	B-Drug
.	O

Sympathomimetic	B-Drug
amines	O
may	O
reduce	O
the	O
antihypertensive	B-Drug
effects	O
of	O
reserpine	B-Drug
,	O
veratrum	O
alkaloids	O
,	O
methyldopa	B-Drug
and	O
mecamylamine	B-Drug
.	O

Effects	O
of	O
sympathomimetics	O
are	O
increased	O
with	O
MAO	O
inhibitors	O
and	O
beta	O
adrenergic	O
blockers	O
.	O

The	O
renal	O
effects	O
of	O
nephrotoxic	O
compounds	O
may	O
be	O
potentiated	O
by	O
Carboplatin	B-Drug
.	O

HEMABATE	B-Drug
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	O
agents	O
.	O

Concomitant	O
use	O
with	O
other	O
oxytocic	O
agents	O
is	O
not	O
recommended	O
.	O

Ocupress	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
beta-adrenergic	O
blocking	O
agent	O
orally	O
because	O
of	O
the	O
potential	O
for	O
additive	O
effects	O
on	O
systemic	O
beta-blockade	O
.	O

Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta-blocker	O
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine-depleting	O
drugs	B-Drug
such	O
as	O
reserpine	B-Drug
,	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and/or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

Inhibitors	O
of	O
CYP2D6	B-Drug
;	O
poor	O
metabolizers	O
of	O
debrisoquin	B-Drug
:	O
Interactions	O
of	O
carvedilol	B-Drug
with	O
strong	O
inhibitors	O
of	O
CYP2D6	B-Drug
(	O
such	O
as	O
quinidine	B-Drug
,	O
fluoxetine	B-Drug
,	O
paroxetine	B-Drug
,	O
and	O
propafenone	B-Drug
)	O
have	O
not	O
been	O
studied	O
,	O
but	O
these	O
drugs	B-Drug
would	O
be	O
expected	O
to	O
increase	O
blood	O
levels	O
of	O
the	O
R	O
(	O
+	O
)	O
enantiomer	O
of	O
carvedilol	B-Drug
.	O

Retrospective	O
analysis	O
of	O
side	O
effects	O
in	O
clinical	O
trials	O
showed	O
that	O
poor	O
2D6	O
metabolizers	O
had	O
a	O
higher	O
rate	O
of	O
dizziness	O
during	O
up-titration	O
,	O
presumably	O
resulting	O
from	O
vasodilating	O
effects	O
of	O
the	O
higher	O
concentrations	O
of	O
the	O
a-blocking	O
R	O
(	O
+	O
)	O
enantiomer	O
.	O

Catecholamine-depleting	O
Agents	O
:	O
Patients	O
taking	O
both	O
agents	O
with	O
b-blocking	O
properties	O
and	O
a	O
drug	B-Drug
that	O
can	O
deplete	O
catecholamines	O
(	O
e.g.	O
,	O
reserpine	B-Drug
and	O
monoamine	O
oxidase	O
inhibitors	O
)	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
hypotension	O
and/or	O
severe	O
bradycardia	O
.	O

Clonidine	B-Drug
:	O
Concomitant	O
administration	O
of	O
clonidine	B-Drug
with	O
agents	O
with	O
b-blocking	O
properties	O
may	O
potentiate	O
blood-pressure-	O
and	O
heart-rate-lowering	O
effects	O
.	O

When	O
concomitant	O
treatment	O
with	O
agents	O
with	O
b-blocking	O
properties	O
and	O
clonidine	B-Drug
is	O
to	O
be	O
terminated	O
,	O
the	O
b-blocking	O
agent	O
should	O
be	O
discontinued	O
first	O
.	O

Clonidine	B-Drug
therapy	O
can	O
then	O
be	O
discontinued	O
several	O
days	O
later	O
by	O
gradually	O
decreasing	O
the	O
dosage	O
.	O

Cyclosporine	B-Drug
:	O
Modest	O
increases	O
in	O
mean	O
trough	O
cyclosporine	B-Drug
concentrations	O
were	O
observed	O
following	O
initiation	O
of	O
carvedilol	B-Drug
treatment	O
in	O
21	O
renal	O
transplant	O
patients	O
suffering	O
from	O
chronic	O
vascular	O
rejection	O
.	O

In	O
about	O
30	O
%	O
of	O
patients	O
,	O
the	O
dose	O
of	O
cyclosporine	B-Drug
had	O
to	O
be	O
reduced	O
in	O
order	O
to	O
maintain	O
cyclosporine	B-Drug
concentrations	O
within	O
the	O
therapeutic	O
range	O
,	O
while	O
in	O
the	O
remainder	O
no	O
adjustment	O
was	O
needed	O
.	O

On	O
the	O
average	O
for	O
the	O
group	O
,	O
the	O
dose	O
of	O
cyclosporine	B-Drug
was	O
reduced	O
about	O
20	O
%	O
in	O
these	O
patients	O
.	O

Due	O
to	O
wide	O
interindividual	O
variability	O
in	O
the	O
dose	O
adjustment	O
required	O
,	O
it	O
is	O
recommended	O
that	O
cyclosporine	B-Drug
concentrations	O
be	O
monitored	O
closely	O
after	O
initiation	O
of	O
carvedilol	B-Drug
therapy	O
and	O
that	O
the	O
dose	O
of	O
cyclosporine	B-Drug
be	O
adjusted	O
as	O
appropriate	O
.	O

Digoxin	B-Drug
:	O
Digoxin	B-Drug
concentrations	O
are	O
increased	O
by	O
about	O
15	O
%	O
when	O
digoxin	B-Drug
and	O
carvedilol	B-Drug
are	O
administered	O
concomitantly	O
.	O

Both	O
digoxin	B-Drug
and	O
COREG	B-Drug
slow	O
AV	O
conduction	O
.	O

Therefore	O
,	O
increased	O
monitoring	O
of	O
digoxin	B-Drug
is	O
recommended	O
when	O
initiating	O
,	O
adjusting	O
,	O
or	O
discontinuing	O
COREG	B-Drug
.	O

Inducers	O
and	O
Inhibitors	O
of	O
Hepatic	O
Metabolism	O
:	O
Rifampin	B-Drug
reduced	O
plasma	O
concentrations	O
of	O
carvedilol	B-Drug
by	O
about	O
70	O
%	O
.	O

Cimetidine	B-Drug
increased	O
AUC	O
by	O
about	O
30	O
%	O
but	O
caused	O
no	O
change	O
in	O
Cmax	O
.	O

Calcium	B-Drug
Channel	O
Blockers	O
:	O
Isolated	O
cases	O
of	O
conduction	O
disturbance	O
(	O
rarely	O
with	O
hemodynamic	O
compromise	O
)	O
have	O
been	O
observed	O
when	O
COREG	B-Drug
is	O
co-administered	O
with	O
diltiazem	B-Drug
.	O

As	O
with	O
other	O
agents	O
with	O
b-blocking	O
properties	O
,	O
if	O
COREG	B-Drug
is	O
to	O
be	O
administered	O
orally	O
with	O
calcium	B-Drug
channel	O
blockers	O
of	O
the	O
verapamil	B-Drug
or	O
diltiazem	B-Drug
type	O
,	O
it	O
is	O
recommended	O
that	O
ECG	O
and	O
blood	O
pressure	O
be	O
monitored	O
.	O

Insulin	B-Drug
or	O
Oral	O
Hypoglycemics	O
:	O
Agents	O
with	O
b-blocking	O
properties	O
may	O
enhance	O
the	O
blood-sugar-reducing	O
effect	O
of	O
insulin	B-Drug
and	O
oral	O
hypoglycemics	O
.	O

Therefore	O
,	O
in	O
patients	O
taking	O
insulin	B-Drug
or	O
oral	O
hypoglycemics	O
,	O
regular	O
monitoring	O
of	O
blood	O
glucose	B-Drug
is	O
recommended	O
.	O

Studies	O
in	O
vitro	O
show	O
that	O
caspofungin	B-Drug
acetate	I-Drug
is	O
not	O
an	O
inhibitor	O
of	O
any	O
enzyme	O
in	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
system	O
.	O

In	O
clinical	O
studies	O
,	O
caspofungin	B-Drug
did	O
not	O
induce	O
the	O
CYP3A4	B-Drug
metabolism	O
of	O
other	O
drugs	B-Drug
.	O

Caspofungin	B-Drug
is	O
not	O
a	O
substrate	O
for	O
P-glycoprotein	O
and	O
is	O
a	O
poor	O
substrate	O
for	O
cytochrome	O
P450	O
enzymes	O
.	O

Clinical	O
studies	O
in	O
healthy	O
volunteers	O
show	O
that	O
the	O
pharmacokinetics	O
of	O
CANCIDAS	B-Drug
are	O
not	O
altered	O
by	O
itraconazole	B-Drug
,	O
amphotericin	B-Drug
B	I-Drug
,	O
mycophenolate	B-Drug
,	O
nelfinavir	B-Drug
,	O
or	O
tacrolimus	B-Drug
.	O

CANCIDAS	B-Drug
has	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
itraconazole	B-Drug
,	O
amphotericin	B-Drug
B	I-Drug
,	O
or	O
the	O
active	O
metabolite	O
of	O
mycophenolate	B-Drug
.	O

CANCIDAS	B-Drug
reduced	O
the	O
blood	O
AUC0-12	O
of	O
tacrolimus	B-Drug
by	O
approximately	O
20	O
%	O
,	O
peak	O
blood	O
concentration	O
(	O
Cmax	O
)	O
by	O
16	O
%	O
,	O
and	O
12-hour	O
blood	O
concentration	O
(	O
C12hr	O
)	O
by	O
26	O
%	O
in	O
healthy	O
subjects	O
when	O
tacrolimus	B-Drug
(	O
2	O
doses	O
of	O
0.1	O
mg/kg	O
12	O
hours	O
apart	O
)	O
was	O
administered	O
on	O
the	O
10th	O
day	O
of	O
CANCIDAS	B-Drug
70	O
mg	O
daily	O
,	O
as	O
compared	O
to	O
results	O
from	O
a	O
control	O
period	O
in	O
which	O
tacrolimus	B-Drug
was	O
administered	O
alone	O
.	O

For	O
patients	O
receiving	O
both	O
therapies	O
,	O
standard	O
monitoring	O
of	O
tacrolimus	B-Drug
blood	O
concentrations	O
and	O
appropriate	O
tacrolimus	B-Drug
dosage	O
adjustments	O
are	O
recommended	O
.	O

In	O
two	O
clinical	O
studies	O
,	O
cyclosporine	B-Drug
(	O
one	O
4	O
mg/kg	O
dose	O
or	O
two	O
3	O
mg/kg	O
doses	O
)	O
increased	O
the	O
AUC	O
of	O
caspofungin	B-Drug
by	O
approximately	O
35	O
%	O
.	O

CANCIDAS	B-Drug
did	O
not	O
increase	O
the	O
plasma	O
levels	O
of	O
cyclosporine	B-Drug
.	O

There	O
were	O
transient	O
increases	O
in	O
liver	O
ALT	O
and	O
AST	O
when	O
CANCIDAS	B-Drug
and	O
cyclosporine	B-Drug
were	O
co-administered	O
.	O

A	O
drug-drug	O
interaction	O
study	O
with	O
rifampin	B-Drug
in	O
healthy	O
volunteers	O
has	O
shown	O
a	O
30	O
%	O
decrease	O
in	O
caspofungin	B-Drug
trough	O
concentrations	O
.	O

Patients	O
on	O
rifampin	B-Drug
should	O
receive	O
70	O
mg	O
of	O
CANCIDAS	B-Drug
daily	O
.	O

In	O
addition	O
,	O
results	O
from	O
regression	O
analyses	O
of	O
patient	O
pharmacokinetic	O
data	O
suggest	O
that	O
co-administration	O
of	O
other	O
inducers	O
of	O
drug	B-Drug
clearance	O
(	O
efavirenz	B-Drug
,	O
nevirapine	B-Drug
,	O
phenytoin	B-Drug
,	O
dexamethasone	B-Drug
,	O
or	O
carbamazepine	B-Drug
)	O
with	O
CANCIDAS	B-Drug
may	O
result	O
in	O
clinically	O
meaningful	O
reductions	O
in	O
caspofungin	B-Drug
concentrations	O
.	O

It	O
is	O
not	O
known	O
which	O
drug	B-Drug
clearance	O
mechanism	O
involved	O
in	O
caspofungin	B-Drug
disposition	O
may	O
be	O
inducible	O
.	O

When	O
CANCIDAS	B-Drug
is	O
co-administered	O
with	O
inducers	O
of	O
drug	B-Drug
clearance	O
,	O
such	O
as	O
efavirenz	B-Drug
,	O
nevirapine	B-Drug
,	O
phenytoin	B-Drug
,	O
dexamethasone	B-Drug
,	O
or	O
carbamazepine	B-Drug
,	O
use	O
of	O
a	O
daily	O
dose	O
of	O
70	O
mg	O
of	O
CANCIDAS	B-Drug
should	O
be	O
considered	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Positive	O
direct	O
Coombs	O
tests	O
have	O
been	O
reported	O
during	O
treatment	O
with	O
the	O
cephalosporin	O
antibiotics	B-Drug
.	O

In	O
hematologic	O
studies	O
or	O
in	O
transfusion	O
cross-matching	O
procedures	O
when	O
anti-globulin	O
tests	O
are	O
performed	O
on	O
the	O
minor	O
side	O
or	O
in	O
Coombs	O
testing	O
of	O
newborns	O
whose	O
mothers	O
have	O
received	O
cephalosporin	O
antibiotics	B-Drug
before	O
parturition	O
,	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
may	O
be	O
due	O
to	O
the	O
drug	B-Drug
.	O

Probenecid	B-Drug
may	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
cephalosporins	O
when	O
used	O
concurrently	O
,	O
resulting	O
in	O
increased	O
and	O
more	O
prolonged	O
cephalosporin	O
blood	O
levels	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
A	O
false	O
positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
may	O
occur	O
with	O
Benedicts	O
solution	O
,	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
tablets	O
,	O
but	O
not	O
with	O
enzyme-based	O
tests	O
such	O
as	O
CLINISTIX	O
.	O

Positive	O
direct	O
and	O
indirect	O
antiglobulin	O
(	O
Coombs	O
)	O
tests	O
have	O
occurred	O
;	O
these	O
may	O
also	O
occur	O
in	O
neonates	O
whose	O
mothers	O
received	O
cephalosporins	O
before	O
delivery	O
.	O

Antacids	O
(	O
aluminum-	B-Drug
or	O
magnesium-containing	B-Drug
)	O
:	O
Concomitant	O
administration	O
of	O
300-mg	O
cefdinir	B-Drug
capsules	O
with	O
30	O
mL	O
Maalox	B-Drug
TC	I-Drug
suspension	O
reduces	O
the	O
rate	O
(	O
Cmax	O
)	O
and	O
extent	O
(	O
AUC	O
)	O
of	O
absorption	O
by	O
approximately	O
40	O
%	O
.	O

Time	O
to	O
reach	O
Cmax	O
is	O
also	O
prolonged	O
by	O
1	O
hour	O
.	O

There	O
are	O
no	O
significant	O
effects	O
on	O
cefdinir	B-Drug
pharmacokinetics	O
if	O
the	O
antacid	O
is	O
administered	O
2	O
hours	O
before	O
or	O
2	O
hours	O
after	O
cefdinir	B-Drug
.	O

If	O
antacids	O
are	O
required	O
during	O
OMNICEF	B-Drug
therapy	O
,	O
OMNICEF	B-Drug
should	O
be	O
taken	O
at	O
least	O
2	O
hours	O
before	O
or	O
after	O
the	O
antacid	O
.	O

Probenecid	B-Drug
:	O
As	O
with	O
other	O
b-lactam	O
antibiotics	B-Drug
,	O
probenecid	B-Drug
inhibits	O
the	O
renal	O
excretion	O
of	O
cefdinir	B-Drug
,	O
resulting	O
in	O
an	O
approximate	O
doubling	O
in	O
A.C.	O
a	O
54	O
%	O
increase	O
in	O
peak	O
cefdinir	B-Drug
plasma	O
levels	O
,	O
and	O
a	O
50	O
%	O
prolongation	O
in	O
the	O
apparent	O
elimination	O
half-life	O
.	O

Iron	B-Drug
Supplements	O
and	O
Foods	O
Fortified	O
With	O
Iron	B-Drug
Concomitant	O
administration	O
of	O
cefdinir	B-Drug
with	O
a	O
therapeutic	O
iron	B-Drug
supplement	O
containing	O
60	O
mg	O
of	O
elemental	O
iron	B-Drug
(	O
as	O
FeSO4	O
)	O
or	O
vitamins	O
supplemented	O
with	O
10	O
mg	O
of	O
elemental	O
iron	B-Drug
reduced	O
extent	O
of	O
absorption	O
by	O
80	O
%	O
and	O
31	O
%	O
,	O
respectively	O
.	O

If	O
iron	B-Drug
supplements	O
are	O
required	O
during	O
OMNICEF	B-Drug
therapy	O
,	O
OMNICEF	B-Drug
should	O
be	O
taken	O
at	O
least	O
2	O
hours	O
before	O
or	O
after	O
the	O
supplement	O
.	O

The	O
effect	O
of	O
foods	O
highly	O
fortified	O
with	O
elemental	O
iron	B-Drug
(	O
primarily	O
iron-fortified	B-Drug
breakfast	O
cereals	O
)	O
on	O
cefdinir	B-Drug
absorption	O
has	O
not	O
been	O
studied	O
.	O

Concomitantly	O
administered	O
iron-fortified	B-Drug
infant	O
formula	O
(	O
2.2	O
mg	O
elemental	O
iron/6	B-Drug
oz	O
)	O
has	O
no	O
significant	O
effect	O
on	O
cefdinir	B-Drug
pharmacokinetics	O
.	O

Therefore	O
,	O
OMNICEF	B-Drug
for	O
Oral	O
Suspension	O
can	O
be	O
administered	O
with	O
iron-fortified	B-Drug
infant	O
formula	O
.	O

There	O
have	O
been	O
rare	O
reports	O
of	O
reddish	O
stools	O
in	O
patients	O
who	O
have	O
received	O
cefdinir	B-Drug
in	O
Japan	O
.	O

The	O
reddish	O
color	O
is	O
due	O
to	O
the	O
formation	O
of	O
a	O
nonabsorbable	O
complex	O
between	O
cefdinir	B-Drug
or	O
its	O
breakdown	O
products	O
and	O
iron	B-Drug
in	O
the	O
gastrointestinal	O
tract	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
A	O
false-positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	B-Drug
,	O
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	B-Drug
.	O

The	O
administration	O
of	O
cefdinir	B-Drug
may	O
result	O
in	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
urine	O
using	O
Clinitest	O
,	O
Benedict	O
s	O
solution	O
,	O
or	O
Fehlings	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	B-Drug
tests	O
based	O
on	O
enzymatic	O
glucose	B-Drug
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
or	O
Tes-Tape	O
)	O
be	O
used	O
.	O

Cephalosporins	O
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

Oral	O
Contraceptives	O
Multiple	O
doses	O
of	O
cefditoren	B-Drug
pivoxil	I-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
,	O
the	O
estrogenic	O
component	O
in	O
most	O
oral	O
contraceptives	O
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-Drug
pivoxil	I-Drug
be	O
taken	O
concomitantly	O
with	O
antacids	O
.	O

H2-Receptor	O
Antagonists	O
:	O
Co-administration	O
of	O
a	O
single	O
dose	O
of	O
intravenously	O
administered	O
famotidine	B-Drug
(	O
20	O
mg	O
)	O
reduced	O
the	O
oral	O
absorption	O
of	O
a	O
single	O
400	O
mg	O
dose	O
of	O
cefditoren	B-Drug
pivoxil	I-Drug
administered	O
following	O
a	O
meal	O
,	O
as	O
evidenced	O
by	O
a	O
27	O
%	O
decrease	O
in	O
mean	O
Cmax	O
and	O
a	O
22	O
%	O
decrease	O
in	O
mean	O
AUC	O
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-Drug
pivoxil	I-Drug
be	O
taken	O
concomitantly	O
with	O
H2	O
receptor	O
antagonists	O
.	O

Probenecid	B-Drug
:	O
As	O
with	O
other	O
b-lactam	O
antibiotics	B-Drug
,	O
co-administration	O
of	O
probenecid	B-Drug
with	O
cefditoren	B-Drug
pivoxil	I-Drug
resulted	O
in	O
an	O
increase	O
in	O
the	O
plasma	O
exposure	O
of	O
cefditoren	B-Drug
,	O
with	O
a	O
49	O
%	O
increase	O
in	O
mean	O
Cmax	O
,	O
a	O
122	O
%	O
increase	O
in	O
mean	O
AUC	O
,	O
and	O
a	O
53	O
%	O
increase	O
in	O
half-life	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Cephalosporins	O
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

A	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	O
reduction	O
tests	O
(	O
Benedicts	O
or	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
tablets	O
)	O
,	O
but	O
not	O
with	O
enzyme-based	O
tests	O
for	O
glycosuria	O
(	O
e.g.	O
,	O
CLINISTIX	O
,	O
TES-TAPE	O
)	O
.	O

As	O
a	O
false-negative	O
result	O
may	O
occur	O
in	O
the	O
ferricyanide	O
test	O
,	O
it	O
is	O
recommended	O
that	O
either	O
the	O
glucose	B-Drug
oxidase	O
or	O
hexokinase	O
method	O
be	O
used	O
to	O
determine	O
blood/plasma	O
glucose	B-Drug
levels	O
in	O
patients	O
receiving	O
cefditoren	B-Drug
pivoxil	I-Drug
.	O

Renal	O
function	O
should	O
be	O
monitored	O
carefully	O
if	O
high	O
doses	O
of	O
aminoglycosides	O
are	O
to	O
be	O
administered	O
with	O
MAXIPIME	B-Drug
because	O
of	O
the	O
increased	O
potential	O
of	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycoside	O
antibiotics	B-Drug
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	O
with	O
potent	O
diuretics	B-Drug
such	O
as	O
furosemide	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
The	O
administration	O
of	O
cefepime	B-Drug
may	O
result	O
in	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
when	O
using	O
Clinitest	O
tablets	O
.	O

It	O
is	O
recommended	O
that	O
glucose	B-Drug
tests	O
based	O
on	O
enzymatic	O
glucose	B-Drug
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
or	O
Tes-Tape	O
)	O
be	O
used	O
.	O

Carbamazepine	B-Drug
:	O
Elevated	O
carbamazepine	B-Drug
levels	O
have	O
been	O
reported	O
in	O
postmarketing	O
experience	O
when	O
SUPRAX	B-Drug
is	O
administered	O
concomitantly	O
.	O

Drug	B-Drug
monitoring	O
may	O
be	O
of	O
assistance	O
in	O
detecting	O
alterations	O
in	O
carbamazepine	B-Drug
plasma	O
concentrations	O
.	O

Warfarin	B-Drug
and	O
Anticoagulants	B-Drug
:	O
Increased	O
prothrombin	O
time	O
,	O
with	O
or	O
without	O
clinical	O
bleeding	O
,	O
has	O
been	O
reported	O
when	O
cefixime	B-Drug
is	O
administered	O
concomitantly	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
A	O
false-positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	B-Drug
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	B-Drug
.	O

The	O
administration	O
of	O
SUPRAX	B-Drug
may	O
result	O
in	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
using	O
Clinitest	O
**	O
,	O
Benedict	O
s	O
solution	O
,	O
or	O
Fehling	O
s	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	B-Drug
tests	O
based	O
on	O
enzymatic	O
glucose	B-Drug
oxidase	O
reactions	O
(	O
such	O
as	O
Clinistix	O
**	O
or	O
Tes-Tape	O
**	O
)	O
be	O
used	O
.	O

A	O
false-positive	O
direct	O
Coombs	O
test	O
has	O
been	O
reported	O
during	O
treatment	O
with	O
other	O
cephalosporin	O
antibiotics	B-Drug
;	O
therefore	O
,	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
may	O
be	O
due	O
to	O
the	O
drug	B-Drug
.	O

Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	O
and	O
aminoglycoside	O
antibiotics	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Cephalosporins	O
,	O
including	O
cefotaxime	B-Drug
sodium	I-Drug
,	O
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

Increases	O
in	O
serum	O
creatinine	O
have	O
occurred	O
when	O
CEFOTAN	B-Drug
was	O
given	O
alone	O
.	O

If	O
CEFOTAN	B-Drug
and	O
an	O
aminoglycoside	O
are	O
used	O
concomitantly	O
,	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
,	O
because	O
nephrotoxicity	O
may	O
be	O
potentiated	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
:	O
The	O
administration	O
of	O
CEFOTAN	B-Drug
may	O
result	O
in	O
a	O
false	O
positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
using	O
Clinitest	O
,	O
Benedicts	O
solution	O
,	O
or	O
Fehlings	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	B-Drug
tests	O
based	O
on	O
enzymatic	O
glucose	B-Drug
oxidase	O
be	O
used	O
.	O

As	O
with	O
other	O
cephalosporins	O
,	O
high	O
concentrations	O
of	O
cefotetan	B-Drug
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
Jaffe	O
reaction	O
and	O
produce	O
false	O
increases	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O

Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	O
and	O
aminoglycoside	O
antibiotics	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
As	O
with	O
cephalothin	B-Drug
,	O
high	O
concentrations	O
of	O
cefoxitin	B-Drug
(	O
100	O
micrograms/mL	O
)	O
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
the	O
Jaff	O
reaction	O
,	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O

Serum	O
samples	O
from	O
patients	O
treated	O
with	O
cefoxitin	B-Drug
should	O
not	O
be	O
analyzed	O
for	O
creatinine	O
if	O
withdrawn	O
within	O
2	O
hours	O
of	O
drug	B-Drug
administration	O
.	O

High	O
concentrations	O
of	O
cefoxitin	B-Drug
in	O
the	O
urine	O
may	O
interfere	O
with	O
measurement	O
of	O
urinary	O
17-hydroxy-corticosteroids	O
by	O
the	O
Porter-Silber	O
reaction	O
,	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
reported	O
.	O

A	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
may	O
occur	O
.	O

This	O
has	O
been	O
observed	O
with	O
CLINITEST	O
reagent	O
tablets	O
.	O

Registered	O
trademark	O
of	O
Ames	O
Company	O
,	O
Division	O
of	O
Miles	O
Laboratories	O
,	O
Inc	O
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
aminoglycoside	O
antibiotics	B-Drug
and	O
cephalosporin	O
antibiotics	B-Drug
.	O

Concomitant	O
administration	O
of	O
probenecid	B-Drug
doubled	O
the	O
AUC	O
for	O
cefprozil	B-Drug
.	O

The	O
bioavailability	O
of	O
the	O
capsule	O
formulation	O
of	O
cefprozil	B-Drug
was	O
not	O
affected	O
when	O
administered	O
5	O
minutes	O
following	O
an	O
antacid	O
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	O
with	O
aminoglycoside	O
antibiotics	B-Drug
or	O
potent	O
diuretics	B-Drug
such	O
as	O
furosemide	B-Drug
.	O

Renal	O
function	O
should	O
be	O
carefully	O
monitored	O
,	O
especially	O
if	O
higher	O
dosages	O
of	O
the	O
aminoglycosides	O
are	O
to	O
be	O
administered	O
or	O
if	O
therapy	O
is	O
prolonged	O
,	O
because	O
of	O
the	O
potential	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycosidic	O
antibiotics	B-Drug
.	O

Nephrotoxicity	O
and	O
ototoxicity	O
were	O
not	O
noted	O
when	O
ceftazidime	B-Drug
was	O
given	O
alone	O
in	O
clinical	O
trials	O
.	O

Chloramphenicol	B-Drug
has	O
been	O
shown	O
to	O
be	O
antagonistic	O
to	O
beta-lactam	O
antibiotics	B-Drug
,	O
including	O
ceftazidime	B-Drug
,	O
based	O
on	O
in	O
vitro	O
studies	O
and	O
time	O
kill	O
curves	O
with	O
enteric	O
gram-negative	O
bacilli	O
.	O

Due	O
to	O
the	O
possibility	O
of	O
antagonism	O
in	O
vivo	O
,	O
particularly	O
when	O
bactericidal	O
activity	O
is	O
desired	O
,	O
this	O
drug	B-Drug
combination	O
should	O
be	O
avoided	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
The	O
administration	O
of	O
ceftazidime	B-Drug
may	O
result	O
in	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
when	O
using	O
CLINITEST	O
tablets	O
,	O
Benedicts	O
solution	O
,	O
or	O
Fehlings	O
solution	O
.	O

It	O
is	O
recommended	O
that	O
glucose	B-Drug
tests	O
based	O
on	O
enzymatic	O
glucose	B-Drug
oxidase	O
reactions	O
(	O
such	O
as	O
CLINISTIX	O
or	O
TES-TAPE	O
)	O
be	O
used	O
.	O

Theophylline	B-Drug
:	O
Twelve	O
healthy	O
male	O
volunteers	O
were	O
administered	O
one	O
200-mg	O
ceftibuten	B-Drug
capsule	O
twice	O
daily	O
for	O
6	O
days	O
.	O

With	O
the	O
morning	O
dose	O
of	O
ceftibuten	B-Drug
on	O
day	O
6	O
,	O
each	O
volunteer	O
received	O
a	O
single	O
intravenous	O
infusion	O
of	O
theophylline	B-Drug
(	O
4	O
mg/kg	O
)	O
.	O

The	O
pharmacokinetics	O
of	O
theophylline	B-Drug
were	O
not	O
altered	O
.	O

The	O
effect	O
of	O
ceftibuten	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
theophylline	B-Drug
administered	O
orally	O
has	O
not	O
been	O
investigated	O
.	O

Antacids	O
or	O
H	O
2	O
-receptor	B-Drug
antagonists	O
:	O
The	O
effect	O
of	O
increased	O
gastric	O
pH	O
on	O
the	O
bioavailability	O
of	O
ceftibuten	B-Drug
was	O
evaluated	O
in	O
18	O
healthy	O
adult	O
volunteers	O
.	O

Each	O
volunteer	O
was	O
administered	O
one	O
400-mg	O
ceftibuten	B-Drug
capsule	O
.	O

A	O
single	O
dose	O
of	O
liquid	O
antacid	O
did	O
not	O
affect	O
the	O
C	O
max	O
or	O
AUC	O
of	O
ceftibuten	B-Drug
;	O
however	O
,	O
150	O
mg	O
of	O
ranitidine	B-Drug
q12h	O
for	O
3	O
days	O
increased	O
the	O
ceftibuten	B-Drug
C	O
max	O
by	O
23	O
%	O
and	O
ceftibuten	B-Drug
AUC	O
by	O
16	O
%	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
increases	O
is	O
not	O
known	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
:	O
There	O
have	O
been	O
no	O
chemical	O
or	O
laboratory	O
test	O
interactions	O
with	O
ceftibuten	B-Drug
noted	O
to	O
date	O
.	O

False-positive	O
direct	O
Coombs	O
tests	O
have	O
been	O
reported	O
during	O
treatment	O
with	O
other	O
cephalosporins	O
.	O

Therefore	O
,	O
it	O
should	O
be	O
recognized	O
that	O
a	O
positive	O
Coombs	O
test	O
could	O
be	O
due	O
to	O
the	O
drug	B-Drug
.	O

The	O
results	O
of	O
assays	O
using	O
red	O
cells	O
from	O
healthy	O
subjects	O
to	O
determine	O
whether	O
ceftibuten	B-Drug
would	O
cause	O
direct	O
Coombs	O
reactions	O
in	O
vitro	O
showed	O
no	O
positive	O
reaction	O
at	O
ceftibuten	B-Drug
concentrations	O
as	O
high	O
as	O
40	O
g/mL	O
.	O

Although	O
the	O
occurrence	O
has	O
not	O
been	O
reported	O
with	O
Cefizox	B-Drug
,	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	O
and	O
aminoglycosides	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
:	O
A	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	O
reduction	O
tests	O
(	O
Benedict	O
s	O
or	O
Fehling	O
s	O
solution	O
or	O
with	O
Clinitest	O
tablets	O
)	O
but	O
not	O
with	O
enzyme-based	O
tests	O
for	O
glycosuria	O
.	O

As	O
a	O
false-negative	O
result	O
may	O
occur	O
in	O
the	O
ferricyanide	O
test	O
,	O
it	O
is	O
recommended	O
that	O
either	O
the	O
glucose	B-Drug
oxidase	O
or	O
hexokinase	O
method	O
be	O
used	O
to	O
determine	O
blood	O
plasma	O
glucose	B-Drug
levels	O
in	O
patients	O
receiving	O
cefuroxime	B-Drug
.	O

Cefuroxime	B-Drug
does	O
not	O
interfere	O
with	O
the	O
assay	O
of	O
serum	O
and	O
urine	O
creatinine	O
by	O
the	O
alkaline	O
picrate	O
method	O
.	O

General	O
:	O
Significant	O
interactions	O
may	O
occur	O
when	O
celecoxib	B-Drug
is	O
administered	O
together	O
with	O
drugs	B-Drug
that	O
inhibit	O
P450	O
2C9	O
.	O

Celecoxib	B-Drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
cytochrome	O
P450	O
2C9	O
in	O
the	O
liver	O
.	O

Co-administration	O
of	O
celecoxib	B-Drug
with	O
drugs	B-Drug
that	O
are	O
known	O
to	O
inhibit	O
2C9	O
should	O
be	O
done	O
with	O
caution	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
celecoxib	B-Drug
is	O
not	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
2C9	O
,	O
2C19	O
or	O
3A4	O
.	O

In	O
vitro	O
studies	O
also	O
indicate	O
that	O
celecoxib	B-Drug
,	O
although	O
not	O
a	O
substrate	O
,	O
is	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
2D6	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
in	O
vivo	O
drug	B-Drug
interaction	O
with	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
P450	O
2D6	O
.	O

Clinical	O
studies	O
with	O
celecoxib	B-Drug
have	O
identified	O
potentially	O
significant	O
interactions	O
with	O
fluconazole	B-Drug
and	O
lithium	B-Drug
.	O

Experience	O
with	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
(	O
NSAIDs	O
)	O
suggests	O
the	O
potential	O
for	O
interactions	O
with	O
furosemide	B-Drug
and	O
ACE	O
inhibitors	O
.	O

The	O
effects	O
celecoxib	B-Drug
on	O
the	O
pharmacokinetics	O
and/or	O
pharmacodynamics	O
of	O
glyburide	B-Drug
,	O
ketoconazole	B-Drug
,	O
methotrexate	B-Drug
,	O
phenytoin	B-Drug
,	O
tolbutamide	B-Drug
,	O
and	O
warfarin	B-Drug
have	O
been	O
studied	O
in	O
vivo	O
and	O
clinically	O
important	O
interactions	O
have	O
not	O
been	O
found	O
.	O

ACE	O
inhibitors	O
:	O
Reports	O
suggest	O
that	O
NSAIDs	O
may	O
diminish	O
the	O
antihypertensive	B-Drug
effect	O
of	O
Angiotensin	B-Drug
Converting	O
Enzyme	O
(	O
ACE	O
)	O
inhibitors	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
CELEBREX	B-Drug
concomitantly	O
with	O
ACE-inhibitors	O
.	O

Furosemide	B-Drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	O
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	O
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

Aspirin	B-Drug
:	O
CELEBREX	B-Drug
can	O
be	O
used	O
with	O
low	O
dose	O
aspirin	B-Drug
.	O

However	O
,	O
concomitant	O
administration	O
of	O
aspirin	B-Drug
with	O
CELEBREX	B-Drug
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
,	O
compared	O
to	O
use	O
of	O
CELEBREX	B-Drug
alone	O
.	O

Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
,	O
CELEBREX	B-Drug
is	O
not	O
a	O
substitute	O
for	O
aspirin	B-Drug
for	O
cardiovascular	O
prophylaxis	O
.	O

Fluconazole	B-Drug
:	O
Concomitant	O
administration	O
of	O
fluconazole	B-Drug
at	O
200	O
mg	O
QD	O
resulted	O
in	O
a	O
two-fold	O
increase	O
in	O
celecoxib	B-Drug
plasma	O
concentration	O
.	O

This	O
increase	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
celecoxib	B-Drug
metabolism	O
via	O
P450	O
2C9	O
by	O
fluconazole	B-Drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
:	O
Metabolism	O
)	O
.	O

CELEBREX	B-Drug
should	O
be	O
introduced	O
at	O
the	O
lowest	O
recommended	O
dose	O
in	O
patients	O
receiving	O
fluconazole	B-Drug
.	O

Lithium	B-Drug
:	O
In	O
a	O
study	O
conducted	O
in	O
healthy	O
subjects	O
,	O
mean	O
steady-state	O
lithium	B-Drug
plasma	O
levels	O
increased	O
approximately	O
17	O
%	O
in	O
subjects	O
receiving	O
lithium	B-Drug
450	O
mg	O
BID	O
with	O
CELEBREX	B-Drug
200	O
mg	O
BID	O
as	O
compared	O
to	O
subjects	O
receiving	O
lithium	B-Drug
alone	O
.	O

Patients	O
on	O
lithium	B-Drug
treatment	O
should	O
be	O
closely	O
monitored	O
when	O
CELEBREX	B-Drug
is	O
introduced	O
or	O
withdrawn	O
.	O

Methotrexate	B-Drug
:	O
In	O
an	O
interaction	O
study	O
of	O
rheumatoid	O
arthritis	O
patients	O
taking	O
methotrexate	B-Drug
,	O
CELEBREX	B-Drug
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
methotrexate	B-Drug
.	O

Warfarin	B-Drug
:	O
The	O
effect	O
of	O
celecoxib	B-Drug
on	O
the	O
anti-coagulant	O
effect	O
of	O
warfarin	B-Drug
was	O
studied	O
in	O
a	O
group	O
of	O
healthy	O
subjects	O
receiving	O
daily	O
doses	O
of	O
2-5	O
mg	O
of	O
warfarin	B-Drug
.	O

In	O
these	O
subjects	O
,	O
celecoxib	B-Drug
did	O
not	O
alter	O
the	O
anticoagulant	B-Drug
effect	O
of	O
warfarin	B-Drug
as	O
determined	O
by	O
prothrombin	O
time	O
.	O

However	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CELEBREX	B-Drug
with	O
warfarin	B-Drug
since	O
these	O
patients	O
are	O
at	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O

Metformin	B-Drug
:	O
In	O
healthy	O
subjects	O
given	O
single	O
500	O
mg	O
doses	O
of	O
cephalexin	B-Drug
and	O
metformin	B-Drug
,	O
plasma	O
metformin	B-Drug
mean	O
cmax	O
and	O
AUC	O
increased	O
by	O
an	O
average	O
of	O
34	O
%	O
and	O
24	O
%	O
,	O
respectively	O
,	O
and	O
metformin	B-Drug
mean	O
renal	O
clearance	O
decreased	O
by	O
14	O
%	O
.	O

No	O
information	O
is	O
available	O
about	O
the	O
interaction	O
of	O
cephalexin	B-Drug
and	O
metformin	B-Drug
following	O
multiple	O
doses	O
of	O
either	O
drug	B-Drug
.	O

Although	O
not	O
observed	O
in	O
this	O
study	O
,	O
adverse	O
effects	O
could	O
potentially	O
arise	O
from	O
co-administration	O
of	O
cephalexin	B-Drug
and	O
metformin	B-Drug
by	O
inhibition	O
of	O
tubular	O
secretion	O
via	O
organic	O
cationic	O
transporter	O
systems	O
.	O

Accordingly	O
,	O
careful	O
patient	O
monitoring	O
and	O
dose	O
adjustment	O
of	O
metformin	B-Drug
is	O
recommended	O
in	O
patients	O
concomitantly	O
taking	O
cephalexin	B-Drug
and	O
metformin	B-Drug
.	O

Probenecid	B-Drug
:	O
As	O
with	O
other	O
b-lactams	O
,	O
the	O
renal	O
excretion	O
of	O
cephalexin	B-Drug
is	O
inhibited	O
by	O
probenecid	B-Drug
.	O

Drug	B-Drug
/	O
Laboratory	O
Test	O
Interactions	O
As	O
a	O
result	O
of	O
administration	O
of	O
Keflex	B-Drug
,	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
may	O
occur	O
.	O

This	O
has	O
been	O
observed	O
with	O
Benedict	O
s	O
and	O
Fehling	O
s	O
solutions	O
and	O
also	O
with	O
Clinitest	O
tablets	O
.	O

Immunosuppressive	O
Drugs	B-Drug
,	O
Fibric	O
Acid	O
Derivatives	O
,	O
Niacin	B-Drug
(	O
Nicotinic	B-Drug
Acid	I-Drug
,	O
Erythromycin	B-Drug
,	O
Azole	O
Antifungals	O
:	O
Skeletal	O
Muscle	O
.	O

ANTACID	O
(	O
Magnesium-Aluminum	B-Drug
Hydroxide	I-Drug
)	O
:	O
Cerivastatin	B-Drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co-administration	O
of	O
antacid	O
.	O

CIMETlDINE	B-Drug
:	O
Cerivastatin	B-Drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co-administration	O
of	O
cimetidine	B-Drug
.	O

CHOLESTYRAMINE	B-Drug
:	O
The	O
influence	O
of	O
the	O
bile-acidsequestering	O
agent	O
cholestyramine	B-Drug
on	O
the	O
pharmacokinetits	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
was	O
evaluated	O
in	O
12	O
healthy	O
males	O
in	O
2	O
separate	O
randomized	O
crossover	O
studies	O
.	O

In	O
the	O
first	O
study	O
,	O
concomitant	O
administration	O
of	O
0.2	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
and	O
12	O
g	O
cholestyramine	B-Drug
resulted	O
in	O
decreases	O
of	O
more	O
than	O
22	O
%	O
for	O
AUC	O
and	O
40	O
%	O
for	O
Cmax	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-Drug
sodium	I-Drug
alone	O
.	O

However	O
,	O
in	O
the	O
second	O
study	O
,	O
administration	O
of	O
12	O
g	O
cholestyramine	B-Drug
1	O
hour	O
before	O
the	O
evening	O
meal	O
and	O
0.3	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
approximately	O
4	O
hours	O
after	O
the	O
same	O
evening	O
meal	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
cerivastatin	B-Drug
AUC	O
of	O
less	O
than	O
8	O
%	O
,	O
and	O
a	O
decrease	O
in	O
Cmax	O
of	O
about	O
30	O
%	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-Drug
sodium	I-Drug
alone	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
expected	O
that	O
a	O
dosing	O
schedule	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
given	O
at	O
bedtime	O
and	O
cholestyramine	B-Drug
given	O
before	O
the	O
evening	O
meal	O
would	O
not	O
result	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
clinical	O
effect	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
.	O

DIGOXIN	B-Drug
:	O
Plasma	O
digoxin	B-Drug
levels	O
and	O
digoxin	B-Drug
clearance	O
at	O
steady-state	O
were	O
not	O
affected	O
by	O
co-administration	O
of	O
0.2	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
.	O

Cerivastatin	B-Drug
plasma	O
concentrations	O
were	O
also	O
not	O
affected	O
by	O
co-administration	O
of	O
digoxin	B-Drug
.	O

WARFARIN	B-Drug
:	O
Co-	O
administration	O
of	O
warfarin	B-Drug
and	O
cerivastatin	B-Drug
to	O
healthy	O
volunteers	O
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
prothrombin	O
time	O
or	O
clotting	O
factor	O
VII	O
when	O
compared	O
to	O
co-administration	O
of	O
warfarin	B-Drug
and	O
placebo	O
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
both	O
the	O
(	O
R	O
)	O
and	O
(	O
S	O
)	O
isomers	O
of	O
warfarin	B-Drug
were	O
unaffected	O
by	O
concurrent	O
dosing	O
of	O
0.3	O
mg	O
cerivastatin	B-Drug
sodium	I-Drug
.	O

Co-administration	O
of	O
warfarin	B-Drug
and	O
cerivastatin	B-Drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
cerivastatin	B-Drug
sodium	I-Drug
.	O

ERYTHROMYCIN	B-Drug
:	O
In	O
hypercholesterolemic	O
patients	O
,	O
steady-state	O
cerivastatin	B-Drug
AUC	O
and	O
Cmax	O
increased	O
approximately	O
50	O
%	O
and	O
24	O
%	O
respectively	O
after	O
10	O
days	O
with	O
co-administration	O
of	O
erythromycin	B-Drug
,	O
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
.	O

OTHER	O
CONCOMITANT	O
THERAPY	O
:	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
in	O
clinical	O
studies	O
,	O
cerivastatin	B-Drug
sodium	I-Drug
was	O
used	O
concomitantly	O
with	O
angiotensin-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
,	O
betablockers	B-Drug
,	O
calcium-channel	O
blockers	O
,	O
diuretics	B-Drug
,	O
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
(	O
NSAIDs	O
)	O
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Pharmacokinetic	O
interaction	O
studies	O
with	O
cetirizine	B-Drug
in	O
adults	O
were	O
conducted	O
with	O
pseudoephedrine	B-Drug
,	O
antipyrine	B-Drug
,	O
ketoconazole	B-Drug
,	O
erythromycin	B-Drug
and	O
azithromycin	B-Drug
.	O

No	O
interactions	O
were	O
observed	O
.	O

In	O
a	O
multiple	O
dose	O
study	O
of	O
theophylline	B-Drug
(	O
400	O
mg	O
once	O
daily	O
for	O
3	O
days	O
)	O
and	O
cetirizine	B-Drug
(	O
20	O
mg	O
once	O
daily	O
for	O
3	O
days	O
)	O
,	O
a	O
16	O
%	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	B-Drug
was	O
observed	O
.	O

The	O
disposition	O
of	O
theophylline	B-Drug
was	O
not	O
altered	O
by	O
concomitant	O
cetirizine	B-Drug
administration	O
.	O

Drug-Drug	O
Interactions	O
:	O
No	O
clinically	O
significant	O
drug	B-Drug
interactions	O
have	O
been	O
found	O
with	O
theophylline	B-Drug
at	O
a	O
low	O
dose	O
,	O
azithromycin	B-Drug
,	O
pseudoephedrine	B-Drug
,	O
ketoconazole	B-Drug
,	O
or	O
erythromycin	B-Drug
.	O

There	O
was	O
a	O
small	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	B-Drug
caused	O
by	O
a	O
400-mg	O
dose	O
of	O
theophylline	B-Drug
;	O
it	O
is	O
possible	O
that	O
larger	O
theophylline	B-Drug
doses	O
could	O
have	O
a	O
greater	O
effect	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Cetrotide	B-Drug
.	O

A	O
drug	B-Drug
interaction	O
study	O
was	O
performed	O
in	O
which	O
ERBITUX	B-Drug
was	O
administered	O
in	O
combination	O
with	O
irinotecan	B-Drug
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
pharmacokinetic	O
interactions	O
between	O
ERBITUX	B-Drug
and	O
irinotecan	B-Drug
.	O

Cevimeline	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
taking	O
beta	O
adrenergic	O
antagonists	O
,	O
because	O
of	O
the	O
possibility	O
of	O
conduction	O
disturbances	O
.	O

Drugs	B-Drug
with	O
parasympathomimetic	O
effects	O
administered	O
concurrently	O
with	O
cevimeline	B-Drug
can	O
be	O
expected	O
to	O
have	O
additive	O
effects	O
.	O

Cevimeline	B-Drug
might	O
interfere	O
with	O
desirable	O
antimuscarinic	O
effects	O
of	O
drugs	B-Drug
used	O
concomitantly	O
.	O

Drugs	B-Drug
which	O
inhibit	O
CYP2D6	B-Drug
and	O
CYP3A3/4	O
also	O
inhibit	O
the	O
metabolism	O
of	O
cevimeline	B-Drug
.	O

Cevimeline	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
individuals	O
known	O
or	O
suspected	O
to	O
be	O
deficient	O
in	O
CYP2D6	B-Drug
activity	O
,	O
based	O
on	O
previous	O
experience	O
,	O
as	O
they	O
may	O
be	O
at	O
a	O
higher	O
risk	O
of	O
adverse	O
events	O
.	O

In	O
an	O
in	O
vitro	O
study	O
,	O
cytochrome	O
P450	O
isozymes	O
1A2	O
,	O
2A6	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
were	O
not	O
inhibited	O
by	O
exposure	O
to	O
cevimeline	B-Drug
.	O

There	O
are	O
no	O
known	O
drug/drug	O
interactions	O
with	O
chlorambucil	B-Drug
.	O

Although	O
clinical	O
studies	O
have	O
not	O
established	O
a	O
cause	O
and	O
effect	O
relationship	O
,	O
physicians	O
should	O
be	O
aware	O
that	O
variable	O
effects	O
an	O
blood	O
coagulation	O
have	O
been	O
reported	O
very	O
rarely	O
in	O
patients	O
receiving	O
oral	O
anticoagulants	B-Drug
and	O
chlordiazepoxide	B-Drug
.	O

The	O
concomitant	O
use	O
of	O
alcohol	B-Drug
or	O
other	O
central	O
nervous	O
system	O
depressants	O
may	O
have	O
an	O
additive	O
effect	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B-Drug
solutions	O
containing	O
epinephrine	B-Drug
or	O
norepinephrine	B-Drug
to	O
patients	O
receiving	O
monoamine	O
oxidase	O
inhibitors	O
,	O
tricyclic	O
antidepressants	B-Drug
or	O
phenothiazines	O
may	O
produce	O
severe	O
,	O
prolonged	O
hypotension	O
or	O
hypertension	O
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
when	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	O
drugs	B-Drug
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot-type	O
oxytocic	O
drugs	B-Drug
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

The	O
para-aminobenzoic	O
acid	O
metabolite	O
of	O
chloroprocaine	B-Drug
inhibits	O
the	O
action	O
of	O
sulfonamides	O
.	O

Therefore	O
,	O
chloroprocaine	B-Drug
should	O
not	O
be	O
used	O
in	O
any	O
condition	O
in	O
which	O
a	O
sulfonamide	O
drug	B-Drug
is	O
being	O
employed	O
.	O

Antacids	O
and	O
kaolin	B-Drug
:	O
Antacids	O
and	O
kaolin	B-Drug
can	O
reduce	O
absorption	O
of	O
chloroquine	B-Drug
;	O
an	O
interval	O
of	O
at	O
least	O
4	O
hours	O
between	O
intake	O
of	O
these	O
agents	O
and	O
chloroquine	B-Drug
should	O
be	O
observed	O
.	O

Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
can	O
inhibit	O
the	O
metabolism	O
of	O
chloroquine	B-Drug
,	O
increasing	O
its	O
plasma	O
level	O
.	O

Concomitant	O
use	O
of	O
cimetidine	B-Drug
should	O
be	O
avoided	O
.	O

Ampicillin	B-Drug
:	O
In	O
a	O
study	O
of	O
healthy	O
volunteers	O
,	O
chloroquine	B-Drug
significantly	O
reduced	O
the	O
bioavailability	O
of	O
ampicillin	B-Drug
.	O

An	O
interval	O
of	O
at	O
least	O
two	O
hours	O
between	O
intake	O
of	O
this	O
agent	O
and	O
chloroquine	B-Drug
should	O
be	O
observed	O
.	O

Cyclosporin	B-Drug
:	O
After	O
introduction	O
of	O
chloroquine	B-Drug
(	O
oral	O
form	O
)	O
,	O
a	O
sudden	O
increase	O
in	O
serum	O
cyclosporin	B-Drug
level	O
has	O
been	O
reported	O
.	O

Therefore	O
,	O
close	O
monitoring	O
of	O
serum	O
cyclosporin	B-Drug
level	O
is	O
recommended	O
and	O
,	O
if	O
necessary	O
,	O
chloroquine	B-Drug
should	O
be	O
discontinued	O
.	O

When	O
given	O
concurrently	O
the	O
following	O
drugs	B-Drug
may	O
interact	O
with	O
thiazide	O
diuretics	B-Drug
.	O

-	O
Alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
or	O
narcotics	O
:	O
Potentiation	O
of	O
otthostatic	O
hypotension	O
may	O
occur	O
.	O

-	O
Antidiabetic	B-Drug
drugs	B-Drug
:	O
(	O
Oral	O
agents	O
and	O
insulin	B-Drug
)	O
Dosage	O
adjustment	O
of	O
the	O
antidiabetic	B-Drug
drug	B-Drug
may	O
be	O
required	O
.	O

-	O
Other	O
antihypertensive	B-Drug
drugs	B-Drug
:	O
Additive	O
effect	O
or	O
potentiation	O
.	O

-	O
Cholestyramine	B-Drug
and	O
colestipol	B-Drug
resins	O
:	O
Cholestytamine	B-Drug
and	O
colestipol	B-Drug
resins	O
have	O
the	O
potential	O
of	O
binding	O
thiazide	O
diuretics	B-Drug
and	O
reducing	O
diuretic	B-Drug
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
.	O

-	O
Corticosteroids	O
,	O
ACTH	B-Drug
:	O
Intensified	O
electrolyte	O
depletion	O
,	O
particularly	O
hypokalemia	O
.	O

-	O
Pressor	O
amines	O
(	O
e.g.	O
,	O
norepinephrine	B-Drug
)	O
:	O
Possible	O
decreased	O
response	O
to	O
pressor	O
amines	O
but	O
not	O
sufficient	O
to	O
preclude	O
their	O
use	O
.	O

-	O
Skeletal	O
muscle	O
relaxants	O
,	O
nondepolarizing	O
(	O
e.g.	O
,	O
tubocurarine	B-Drug
)	O
:	O
Possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	O
relaxant	O
.	O

-	O
Lithium	B-Drug
:	O
Generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Drug
.	O

Diuretic	B-Drug
agents	O
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-Drug
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O

Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
chlorothiazide	B-Drug
.	O

-	O
Non-steroidal	O
Anti-inflammatory	O
Drugs	B-Drug
:	O
In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non-steroidal	O
anti-inflammatory	O
agent	O
can	O
reduce	O
the	O
diuretic	B-Drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-Drug
effects	O
of	O
loop	O
,	O
potassium-sparing	O
and	O
thiazide	B-Drug
diuretics	I-Drug
.	O

Therefore	O
,	O
when	O
chlorothiazide	B-Drug
and	O
non-steroidal	O
anti-inflammatory	O
agents	O
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Drug
is	O
obtained	O
.	O

-	O
Drug/Laboratory	O
Test	O
Interactions	O
:	O
Thiazides	O
should	O
be	O
discontinued	O
before	O
carrying	O
out	O
tests	O
for	O
parathyroid	O
function	O
.	O

Chlorotrianisene	B-Drug
may	O
interact	O
with	O
antidepressants	B-Drug
,	O
aspirin	B-Drug
,	O
barbiturates	B-Drug
,	O
bromocriptine	B-Drug
,	O
calcium	B-Drug
supplements	O
,	O
corticosteroids	O
,	O
corticotropin	B-Drug
,	O
cyclosporine	B-Drug
,	O
dantrolene	B-Drug
,	O
nicotine	B-Drug
,	O
somatropin	B-Drug
,	O
tamoxifen	B-Drug
,	O
and	O
warfarin	B-Drug
.	O

May	O
interact	O
with	O
skin	O
products	O
or	O
shampoos	O
for	O
dandruff	O
or	O
psoriasis	O
.	O

Substrate	O
of	O
CYP2D6	B-Drug
(	O
minor	O
)	O
,	O
3A4	O
(	O
major	O
)	O
;	O
Inhibits	O
CYP2D6	B-Drug
(	O
weak	O
)	O
.	O

Increased	O
toxicity	O
(	O
CNS	O
depression	O
)	O
:	O
CNS	O
depressants	O
,	O
MAO	O
inhibitors	O
,	O
tricyclic	O
antidepressants	B-Drug
,	O
phenothiazines	O
.	O

CYP3A4	B-Drug
inhibitors	O
:	O
May	O
increase	O
the	O
levels/effects	O
of	O
chlorpheniramine	B-Drug
.	O

Example	O
inhibitors	O
include	O
azole	O
antifungals	O
,	O
ciprofloxacin	B-Drug
,	O
clarithromycin	B-Drug
,	O
diclofenac	B-Drug
,	O
doxycycline	B-Drug
,	O
erythromycin	B-Drug
,	O
imatinib	B-Drug
,	O
isoniazid	B-Drug
,	O
nefazodone	B-Drug
,	O
nicardipine	B-Drug
,	O
propofol	B-Drug
,	O
protease	O
inhibitors	O
,	O
quinidine	B-Drug
,	O
and	O
verapamil	B-Drug
.	O

The	O
concurrent	O
use	O
of	O
two	O
or	O
more	O
drugs	B-Drug
with	O
anticholinergic	B-Drug
activity	O
--	O
such	O
as	O
an	O
antipsychotic	O
drug	B-Drug
(	O
eg	O
,	O
chlorpromazine	B-Drug
)	O
,	O
an	O
antiparkinsonian	O
drug	B-Drug
(	O
eg	O
,	O
trihexyphenidyl	B-Drug
)	O
,	O
and/or	O
a	O
tricyclic	O
antidepressant	O
(	O
eg	O
,	O
amitriptyline	B-Drug
)	O
--	O
commonly	O
results	O
in	O
excessive	O
anticholinergic	B-Drug
effects	O
,	O
including	O
dry	O
mouth	O
and	O
associated	O
dental	O
complications	O
,	O
blurred	O
vision	O
,	O
and	O
,	O
in	O
patients	O
exposed	O
to	O
high	O
temperature	O
and	O
humidity	O
,	O
hyperpyrexia	O
.	O

Interactions	O
may	O
also	O
occur	O
with	O
the	O
following	O
:	O
anti-depressants/anti-anxiety	O
drugs	B-Drug
,	O
drugs	B-Drug
used	O
to	O
treat	O
an	O
overactive	O
thyroid	B-Drug
,	O
beta-blockers	O
(	O
e.g.	O
,	O
propranolol	B-Drug
)	O
,	O
sparfloxacin	B-Drug
,	O
grepafloxacin	B-Drug
,	O
guanethidine	B-Drug
,	O
guanadrel	B-Drug
,	O
metrizamide	B-Drug
,	O
cabergoline	B-Drug
,	O
lithium	B-Drug
,	O
narcotic	O
pain	O
medication	O
(	O
e.g.	O
,	O
codeine	B-Drug
)	O
,	O
drugs	B-Drug
used	O
to	O
aid	O
sleep	O
,	O
drowsiness-causing	O
antihistamines	B-Drug
(	O
e.g.	O
,	O
diphenhydramine	B-Drug
)	O
,	O
any	O
other	O
drugs	B-Drug
that	O
may	O
make	O
you	O
drowsy	O
.	O

The	O
hypoglycemic	O
action	O
of	O
sulfonylurea	B-Drug
may	O
be	O
potentiated	O
by	O
certain	O
drugs	B-Drug
including	O
nonsteroidal	O
anti-inflammatory	O
agents	O
and	O
other	O
drugs	B-Drug
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	O
,	O
sulfonamides	O
,	O
chloramphenicol	B-Drug
,	O
probenecid	B-Drug
,	O
coumarins	O
,	O
monoamine	O
oxidase	O
inhibitors	O
,	O
and	O
beta	O
adrenergic	O
blocking	O
agents	O
.	O

When	O
such	O
drugs	B-Drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
DIABINESE	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

When	O
such	O
drugs	B-Drug
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
DIABINESE	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O

Certain	O
drugs	B-Drug
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	B-Drug
to	O
loss	O
of	O
control	O
.	O

These	O
drugs	B-Drug
include	O
the	O
thiazides	O
and	O
other	O
diuretics	B-Drug
,	O
corticosteroids	O
,	O
phenothiazines	O
,	O
thyroid	B-Drug
products	O
,	O
estrogens	O
,	O
oral	O
contraceptives	O
,	O
phenytoin	B-Drug
,	O
nicotinic	B-Drug
acid	I-Drug
,	O
sympathomimetics	O
,	O
calcium	B-Drug
channel	O
blocking	O
drugs	B-Drug
,	O
and	O
isoniazid	B-Drug
.	O

When	O
such	O
drugs	B-Drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
DIABINESE	B-Drug
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O

When	O
such	O
drugs	B-Drug
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
DIABINESE	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

Since	O
animal	O
studies	O
suggest	O
that	O
the	O
action	O
of	O
barbiturates	B-Drug
may	O
be	O
prolonged	O
by	O
therapy	O
with	O
chlorpropamide	B-Drug
,	O
barbiturates	B-Drug
should	O
be	O
employed	O
with	O
caution	O
.	O

In	O
some	O
patients	O
,	O
a	O
disulfiram-like	B-Drug
reaction	O
may	O
be	O
produced	O
by	O
the	O
ingestion	O
of	O
alcohol	B-Drug
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B-Drug
and	O
oral	O
hypoglycemic	O
agents	O
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
,	O
topical	O
,	O
or	O
vaginal	O
preparations	O
of	O
miconazole	B-Drug
is	O
not	O
known	O
.	O

Chlorprothixene	B-Drug
may	O
increase	O
the	O
plasma-level	O
of	O
concomitantly	O
given	O
lithium	B-Drug
.	O

In	O
order	O
to	O
avoid	O
lithium	B-Drug
intoxication	O
,	O
lithium	B-Drug
plasma	O
levels	O
should	O
be	O
monitored	O
closely	O
.	O

If	O
chlorprothixene	B-Drug
is	O
given	O
concomitantly	O
with	O
opioids	O
,	O
the	O
opioid	O
dose	O
should	O
be	O
reduced	O
(	O
by	O
approx	O
.	O

50	O
%	O
)	O
,	O
because	O
chlorprothixene	B-Drug
amplifies	O
the	O
therapeutic	O
actions	O
and	O
side-effects	O
of	O
opioids	O
massively	O
.	O

Avoid	O
the	O
concomitant	O
use	O
of	O
chlorprothixene	B-Drug
and	O
tramadol	B-Drug
(	O
Ultram	B-Drug
)	O
.	O

Massive	O
seizures	O
may	O
be	O
encountered	O
with	O
this	O
combination	O
.	O

Consider	O
additive	O
sedative	O
effects	O
and	O
confusional	O
states	O
to	O
emerge	O
,	O
if	O
chlorprothixene	B-Drug
is	O
given	O
with	O
benzodiazepines	B-Drug
or	O
barbituates	O
.	O

Choose	O
particular	O
low	O
doses	O
of	O
these	O
drugs	B-Drug
.	O

Exert	O
particular	O
caution	O
in	O
combining	O
chlorprothixene	B-Drug
with	O
other	O
anticholinergic	B-Drug
drugs	B-Drug
(	O
tricyclic	O
antidepressants	B-Drug
and	O
antiparkinsonian	O
agents	O
)	O
:	O
Particularly	O
the	O
elderly	O
may	O
develop	O
delirium	O
,	O
high	O
fever	O
,	O
severe	O
obstipation	O
,	O
even	O
ileus	O
and	O
glaucoma	O
.	O

Chlorthalidone	B-Drug
may	O
add	O
to	O
or	O
potentiate	O
the	O
action	O
of	O
other	O
antihypertensive	B-Drug
drugs	B-Drug
.	O

Potentiation	O
occurs	O
with	O
ganglionic	O
peripheral	O
adrenergic	O
blocking	O
drugs	B-Drug
.	O

Medication	O
such	O
as	O
digitalis	B-Drug
may	O
also	O
influence	O
serum	O
electrolytes	O
.	O

Warning	O
signs	O
,	O
irrespective	O
of	O
cause	O
,	O
are	O
:	O
dryness	O
of	O
mouth	O
,	O
thirst	O
,	O
weakness	O
,	O
lethargy	O
,	O
drowsiness	O
,	O
restlessness	O
,	O
muscle	O
pains	O
or	O
cramps	O
,	O
muscular	O
fatigue	O
,	O
hypotension	O
,	O
oliguria	O
,	O
tachycardia	O
,	O
and	O
gastrointestinal	O
disturbances	O
such	O
as	O
nausea	O
and	O
vomiting	O
.	O

Insulin	B-Drug
requirements	O
in	O
diabetic	O
patients	O
may	O
be	O
increased	O
,	O
decreased	O
,	O
or	O
unchanged	O
.	O

Higher	O
dosage	O
of	O
oral	O
hypoglycemic	O
agents	O
may	O
be	O
required	O
.	O

Latent	O
diabetes	O
mellitus	O
may	O
become	O
manifest	O
during	O
chlorthalidone	B-Drug
administration	O
.	O

Chlorthalidone	B-Drug
and	O
related	O
drugs	B-Drug
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	B-Drug
.	O

Chlorthalidone	B-Drug
and	O
related	O
drugs	B-Drug
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
.	O

This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O

The	O
concomitant	O
use	O
of	O
alcohol	B-Drug
or	O
other	O
central	O
nervous	O
system	O
depressants	O
may	O
have	O
an	O
additive	O
effect	O
.	O

Interactions	O
for	O
vitamin	O
D	O
analogues	O
(	O
Vitamin	B-Drug
D2	I-Drug
,	O
Vitamin	B-Drug
D3	I-Drug
,	O
Calcitriol	B-Drug
,	O
and	O
Calcidiol	B-Drug
)	O
:	O
Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	O
soluble	O
vitamins	O
;	O
as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	O
D	O
.	O

Phenytoin/Phenobarbital	B-Drug
:	O
The	O
coadministration	O
of	O
phenytoin	B-Drug
or	O
phenobarbital	B-Drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	O
D	O
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol/ergocalcitriol	B-Drug
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol/ergocalcitriol	B-Drug
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	B-Drug
may	O
be	O
necessary	O
if	O
these	O
drugs	B-Drug
are	O
administered	O
simultaneously	O
.	O

Thiazides	O
:	O
Thiazides	O
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	B-Drug
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	O
with	O
vitamin	O
D	O
causes	O
hypercalcemia	O
.	O

Therefore	O
,	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O

Digitalis	B-Drug
:	O
Vitamin	O
D	O
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B-Drug
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	O
D	O
.	O

Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
300	O
mg/day	O
to	O
1200	O
mg/day	O
ketoconazole	B-Drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O

However	O
,	O
in	O
vivo	O
drug	B-Drug
interaction	O
studies	O
of	O
ketoconazole	B-Drug
with	O
vitamin	O
D	O
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	O
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	O
D	O
analogues	O
,	O
which	O
promote	O
calcium	B-Drug
absorption	O
,	O
and	O
corticosteroids	O
,	O
which	O
inhibit	O
calcium	B-Drug
absorption	O
.	O

Phosphate-Binding	O
Agents	O
:	O
Since	O
vitamin	O
D	O
also	O
has	O
an	O
effect	O
on	O
phosphate	B-Drug
transport	O
in	O
the	O
intestine	O
,	O
kidneys	O
and	O
bones	O
,	O
the	O
dosage	O
of	O
phosphate-binding	O
agents	O
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	B-Drug
concentration	O
.	O

Vitamin	O
D	O
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	O
D	O
analogues	O
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	B-Drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium-containing	B-Drug
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	B-Drug
:	O
Magnesium-containing	B-Drug
preparations	O
(	O
eg	O
,	O
antacids	O
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	O
D	O
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Cholestyramine	B-Drug
resin	O
may	O
delay	O
or	O
reduce	O
the	O
absorption	O
of	O
concomitant	O
oral	O
medication	O
such	O
as	O
phenylbutazone	B-Drug
,	O
warfarin	B-Drug
,	O
thiazide	O
diuretics	B-Drug
(	O
acidic	O
)	O
or	O
propranolol	B-Drug
(	O
basic	O
)	O
,	O
as	O
well	O
as	O
tetracycline	B-Drug
penicillin	B-Drug
G	I-Drug
,	O
phenobarbital	B-Drug
,	O
thyroid	B-Drug
and	O
thyroxine	B-Drug
preparations	O
,	O
estrogens	O
and	O
progestins	O
,	O
and	O
digitalis	B-Drug
.	O

Interference	O
with	O
the	O
absorption	O
of	O
oral	O
phosphate	B-Drug
supplements	O
has	O
been	O
observed	O
with	O
another	O
positively-charged	O
bile	O
acid	O
sequestrant	O
.	O

Cholestyramine	B-Drug
resin	O
may	O
interfere	O
with	O
the	O
pharmacokinetics	O
of	O
drugs	B-Drug
that	O
undergo	O
enterohepatic	O
circulation	O
,	O
The	O
discontinuance	O
of	O
cholestyramine	B-Drug
resin	O
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	B-Drug
such	O
as	O
digitalis	B-Drug
has	O
been	O
filtrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
cholestyramine	B-Drug
resin	O
.	O

Because	O
cholestyramine	B-Drug
binds	O
bile	O
acids	O
,	O
cholestyramine	B-Drug
resin	O
may	O
interfere	O
with	O
normal	O
fat	O
digestion	O
and	O
absorption	O
and	O
thus	O
may	O
prevent	O
absorption	O
of	O
fat	O
soluble	O
vitamins	O
such	O
as	O
A	O
,	O
D	O
,	O
E	O
,	O
and	O
K	O
.	O

When	O
cholestyramine	B-Drug
resin	O
is	O
given	O
for	O
long	O
periods	O
of	O
time	O
,	O
concomitant	O
supplementation	O
with	O
water-miscible	O
(	O
or	O
parenteral	O
)	O
forms	O
of	O
fat-soluble	O
vitamins	O
should	O
be	O
considered	O
.	O

SINCE	O
CHOLESTYRAMINE	B-Drug
RESIN	O
MAY	O
BIND	O
OTHER	O
DRUGS	B-Drug
GIVEN	O
CONCURRENTLY	O
,	O
IT	O
IS	O
RECOMMENDED	O
THAT	O
PATIENTS	O
TAKE	O
OTHER	O
DRUGS	B-Drug
AT	O
LEAST	O
1	O
HOUR	O
BEFORE	O
OR	O
4	O
TO	O
6	O
HOURS	O
AFTER	O
CHOLESTYRAMINE	B-Drug
RESIN	O
(	O
OR	O
AT	O
AS	O
GREAT	O
AN	O
INTERVAL	O
AS	O
POSSIBLE	O
)	O
TO	O
AVOID	O
IMPEDING	O
THEIR	O
ABSORPTION	O
.	O

Based	O
on	O
in	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
,	O
des-ciclesonide	B-Drug
appears	O
to	O
have	O
no	O
inhibitory	O
or	O
induction	O
potential	O
on	O
the	O
metabolism	O
of	O
other	O
drugs	B-Drug
metabolized	O
by	O
CYP	O
450	O
enzymes	O
.	O

The	O
inhibitory	O
potential	O
of	O
ciclesonide	B-Drug
on	O
CYP450	O
isoenzymes	O
has	O
not	O
been	O
studied	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
the	O
plasma	O
protein	O
binding	O
of	O
des-ciclesonide	B-Drug
was	O
not	O
affected	O
by	O
warfarin	B-Drug
or	O
salicylic	B-Drug
acid	I-Drug
,	O
indicating	O
no	O
potential	O
for	O
protein	O
binding-based	O
drug	B-Drug
interactions	O
.	O

In	O
a	O
drug	B-Drug
interaction	O
study	O
,	O
co-administration	O
of	O
orally	O
inhaled	O
ciclesonide	B-Drug
and	O
oral	O
erythromycin	B-Drug
,	O
an	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
,	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
des-ciclesonide	B-Drug
or	O
erythromycin	B-Drug
.	O

In	O
another	O
drug	B-Drug
interaction	O
study	O
,	O
co-administration	O
of	O
orally	O
inhaled	O
ciclesonide	B-Drug
and	O
oral	O
ketoconazole	B-Drug
,	O
a	O
potent	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
,	O
increased	O
the	O
exposure	O
(	O
AUC	O
)	O
of	O
des-ciclesonide	B-Drug
by	O
approximately	O
3.6-fold	O
at	O
steady	O
state	O
,	O
while	O
levels	O
of	O
ciclesonide	B-Drug
remained	O
unchanged	O
.	O

Therefore	O
,	O
ketoconazole	B-Drug
should	O
be	O
administered	O
with	O
caution	O
with	O
intranasal	O
ciclesonide	B-Drug
.	O

Probenecid	B-Drug
:	O
Probenecid	B-Drug
is	O
known	O
to	O
interact	O
with	O
the	O
metabolism	O
or	O
renal	O
tubular	O
excretion	O
of	O
many	O
drugs	B-Drug
(	O
e.g.	O
,	O
acetaminophen	B-Drug
,	O
acyclovir	B-Drug
,	O
angiotensin-converting	O
enzyme	O
inhibitors	O
,	O
aminosalicylic	B-Drug
acid	I-Drug
,	O
barbiturates	B-Drug
,	O
benzodiazepines	B-Drug
,	O
bumetanide	B-Drug
,	O
clofibrate	B-Drug
,	O
methotrexate	B-Drug
,	O
famotidine	B-Drug
,	O
furosemide	B-Drug
,	O
nonsteroidal	O
anti-inflammatory	O
agents	O
,	O
theophylline	B-Drug
,	O
and	O
zidovudine	B-Drug
)	O
.	O

Concomitant	O
medications	O
should	O
be	O
carefully	O
assessed	O
.	O

Zidovudine	B-Drug
should	O
either	O
be	O
temporarily	O
discontinued	O
or	O
decreased	O
by	O
50	O
%	O
when	O
coadministered	O
with	O
probenecid	B-Drug
on	O
the	O
day	O
of	O
VISTIDE	B-Drug
infusion	O
.	O

Nephrotoxic	O
agents	O
:	O
Concomitant	O
administration	O
of	O
VISTIDE	B-Drug
and	O
agents	O
with	O
nephrotoxic	O
potential	O
[	O
e.g.	O
,	O
intravenous	O
aminoglycosides	O
(	O
e.g.	O
,	O
tobramycin	B-Drug
,	O
gentamicin	B-Drug
,	O
and	O
amikacin	B-Drug
)	O
,	O
amphotericin	B-Drug
B	I-Drug
,	O
foscarnet	B-Drug
,	O
intravenous	O
pentamidine	B-Drug
,	O
vancomycin	B-Drug
,	O
and	O
non-steroidal	O
anti-inflammatory	O
agents	O
]	O
is	O
contraindicated	O
.	O

Such	O
agents	O
must	O
be	O
discontinued	O
at	O
least	O
seven	O
days	O
prior	O
to	O
starting	O
therapy	O
with	O
VISTIDE	B-Drug
.	O

Since	O
PLETAL	B-Drug
is	O
extensively	O
metabolized	O
by	O
cytochrome	O
P-450	O
isoenzymes	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
PLETAL	B-Drug
is	O
coadministered	O
with	O
inhibitors	O
of	O
C.P.A	O
.	O

such	O
as	O
ketoconazole	B-Drug
and	O
erythromycin	B-Drug
or	O
inhibitors	O
of	O
CYP2C19	O
such	O
as	O
omeprazole	B-Drug
.	O

Pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
omeprazole	B-Drug
and	O
erythromycin	B-Drug
significantly	O
increased	O
the	O
systemic	O
exposure	O
of	O
cilostazol	B-Drug
and/or	O
its	O
major	O
metabolites	O
.	O

Population	O
pharmacokinetic	O
studies	O
showed	O
higher	O
concentrations	O
of	O
cilostazol	B-Drug
among	O
patients	O
concurrently	O
treated	O
with	O
diltiazem	B-Drug
,	O
an	O
inhibitor	O
of	O
C.P.A..	O
Pletal	B-Drug
does	O
not	O
,	O
however	O
,	O
appear	O
to	O
cause	O
increased	O
blood	O
levels	O
of	O
drugs	B-Drug
metabolized	O
by	O
CYP3A4	B-Drug
,	O
as	O
it	O
had	O
no	O
effect	O
on	O
lovastatin	B-Drug
,	O
a	O
drug	B-Drug
with	O
metabolism	O
very	O
sensitive	O
to	O
C.P.A	O
.	O

inhibition	O
.	O

Tagamet	B-Drug
,	O
apparently	O
through	O
an	O
effect	O
on	O
certain	O
microsomal	O
enzyme	O
systems	O
,	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
hepatic	O
metabolism	O
of	O
warfarin-type	B-Drug
anticoagulants	B-Drug
,	O
phenytoin	B-Drug
,	O
propranolol	B-Drug
,	O
nifedipine	B-Drug
,	O
chlordiazepoxide	B-Drug
,	O
diazepam	B-Drug
,	O
certain	O
tricyclic	O
antidepressants	B-Drug
,	O
lidocaine	B-Drug
,	O
theophylline	B-Drug
and	O
metronidazole	B-Drug
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
blood	O
levels	O
of	O
these	O
drugs	B-Drug
.	O

Clinically	O
significant	O
effects	O
have	O
been	O
reported	O
with	O
the	O
warfarin	B-Drug
anticoagulants	B-Drug
;	O
therefore	O
,	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
,	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B-Drug
dose	O
may	O
be	O
necessary	O
when	O
Tagamet	B-Drug
is	O
administered	O
concomitantly	O
.	O

Interaction	O
with	O
phenytoin	B-Drug
,	O
lidocaine	B-Drug
and	O
theophylline	B-Drug
has	O
also	O
been	O
reported	O
to	O
produce	O
adverse	O
clinical	O
effects	O
.	O

However	O
,	O
a	O
crossover	O
study	O
in	O
healthy	O
subjects	O
receiving	O
either	O
Tagamet	B-Drug
300	O
mg	O
q.i.d	O
.	O

or	O
800	O
mg	O
h.s	O
.	O

concomitantly	O
with	O
a	O
300	O
mg	O
b.i.d	O
.	O

dosage	O
of	O
theophylline	B-Drug
(	O
Theo-Dur	B-Drug
,	O
Key	O
Pharmaceuticals	O
,	O
Inc.	O
)	O
demonstrated	O
less	O
alteration	O
in	O
steady-state	O
theophylline	B-Drug
peak	O
serum	O
levels	O
with	O
the	O
800	O
mg	O
h.s	O
.	O

regimen	O
,	O
particularly	O
in	O
subjects	O
aged	O
54	O
years	O
and	O
older	O
.	O

Data	O
beyond	O
10	O
days	O
are	O
not	O
available	O
.	O

(	O
Note	O
:	O
All	O
patients	O
receiving	O
theophylline	B-Drug
should	O
be	O
monitored	O
appropriately	O
,	O
regardless	O
of	O
concomitant	O
drug	B-Drug
therapy	O
.	O

)	O
Dosage	O
of	O
the	O
drugs	B-Drug
mentioned	O
above	O
and	O
other	O
similarly	O
metabolized	O
drugs	B-Drug
,	O
particularly	O
those	O
of	O
low	O
therapeutic	O
ratio	O
or	O
in	O
patients	O
with	O
renal	O
and/or	O
hepatic	O
impairment	O
,	O
may	O
require	O
adjustment	O
when	O
starting	O
or	O
stopping	O
concomitantly	O
administered	O
Tagamet	B-Drug
to	O
maintain	O
optimum	O
therapeutic	O
blood	O
levels	O
.	O

Alteration	O
of	O
pH	O
may	O
affect	O
absorption	O
of	O
certain	O
drugs	B-Drug
(	O
e.g.	O
,	O
ketoconazole	B-Drug
)	O
.	O

If	O
these	O
products	O
are	O
needed	O
,	O
they	O
should	O
be	O
given	O
at	O
least	O
2	O
hours	O
before	O
cimetidine	B-Drug
administration	O
.	O

Additional	O
clinical	O
experience	O
may	O
reveal	O
other	O
drugs	B-Drug
affected	O
by	O
the	O
concomitant	O
administration	O
of	O
Tagamet	B-Drug
.	O

and/or	O
Drug/Laboratory	O
Test	O
Interactions	O
See	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Pharmacokinetics	O
and	O
Drug	B-Drug
Interactions	O
.	O

Effect	O
of	O
Sensipar	B-Drug
on	O
other	O
drugs	B-Drug
:	O
Drugs	B-Drug
metabolized	O
by	O
cytochrome	O
P450	O
2D6	O
(	O
CYP2D6	B-Drug
)	O
:	O
Sensipar	B-Drug
is	O
a	O
strong	O
in	O
vitro	O
inhibitor	O
of	O
CYP2D6	B-Drug
.	O

Therefore	O
,	O
dose	O
adjustments	O
of	O
concomitant	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2D6	B-Drug
and	O
have	O
a	O
narrow	O
therapeutic	O
index	O
(	O
e.g.	O
,	O
flecainide	B-Drug
,	O
vinblastine	B-Drug
,	O
thioridazine	B-Drug
and	O
most	O
tricyclic	O
antidepressants	B-Drug
)	O
may	O
be	O
required	O
.	O

Amitriptyline	B-Drug
:	O
Concurrent	O
administration	O
of	O
25	O
mg	O
or	O
100	O
mg	O
cinacalcet	B-Drug
with	O
50	O
mg	O
amitriptyline	B-Drug
increased	O
amitriptyline	B-Drug
exposure	O
and	O
nortriptyline	B-Drug
(	O
active	O
metabolite	O
)	O
exposure	O
by	O
approximately	O
20	O
%	O
in	O
CYP2D6	B-Drug
extensive	O
metabolizers	O
.	O

Effect	O
of	O
other	O
drugs	B-Drug
on	O
Sensipar	B-Drug
:	O
Sensipar	B-Drug
is	O
metabolized	O
by	O
multiple	O
cytochrome	O
P450	O
enzymes	O
,	O
primarily	O
CYP3A4	B-Drug
,	O
CYP2D6	B-Drug
,	O
and	O
CYP1A2	B-Drug
.	O

Ketoconazole	B-Drug
:	O
Sensipar	B-Drug
is	O
metabolized	O
in	O
part	O
by	O
CYP3A4	B-Drug
.	O

Co-administration	O
of	O
ketoconazole	B-Drug
,	O
a	O
strong	O
inhibitor	O
of	O
CYP3A4	B-Drug
,	O
increased	O
cinacalcet	B-Drug
exposure	O
following	O
a	O
single	O
90	O
mg	O
dose	O
of	O
Sensipar	B-Drug
by	O
2.3	O
fold	O
.	O

Dose	O
adjustment	O
of	O
Sensipar	B-Drug
may	O
be	O
required	O
and	O
PTH	O
and	O
serum	O
calcium	B-Drug
concentrations	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
patient	O
initiates	O
or	O
discontinues	O
therapy	O
with	O
a	O
strong	O
CYP3A4	B-Drug
inhibitor	O
(	O
e.g.	O
,	O
ketoconazole	B-Drug
,	O
erythromycin	B-Drug
,	O
itraconazole	B-Drug
;	O
see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
)	O
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
some	O
quinolones	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline-related	B-Drug
side-effects	O
in	O
patients	O
on	O
concomitant	O
theophylline-quinolone	B-Drug
therapy	O
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B-Drug
adjusted	O
as	O
required	O
.	O

Quinolones	O
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O

This	O
may	O
lead	B-Drug
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
a	O
prolongation	O
of	O
its	O
plasma	O
half-life	O
.	O

Although	O
this	O
interaction	O
has	O
not	O
been	O
reported	O
with	O
cinoxacin	B-Drug
,	O
caution	O
should	O
be	O
exercised	O
when	O
cinoxacin	B-Drug
is	O
given	O
concomitantly	O
with	O
caffeine-containing	B-Drug
products	O
.	O

Antacids	O
or	O
sucralfate	B-Drug
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
some	O
quinolones	O
,	O
resulting	O
in	O
low	O
urine	O
levels	O
.	O

Also	O
,	O
concomitant	O
administration	O
of	O
quinolones	O
with	O
products	O
containing	O
iron	B-Drug
,	O
multivitamins	O
containing	O
zinc	B-Drug
,	O
or	O
Videx	B-Drug
(	O
didanosine	B-Drug
)	O
chewable/buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
result	O
in	O
low	O
urine	O
levels	O
.	O

Quinolones	O
,	O
including	O
cinoxacin	B-Drug
,	O
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	B-Drug
,	O
such	O
as	O
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
closely	O
monitored	O
.	O

Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
another	O
quinolone	O
class	O
antimicrobial	O
and	O
the	O
nonsteroidal	O
anti-inflammatory	O
drug	B-Drug
fenbufen	B-Drug
concurrently	O
.	O

Animal	O
studies	O
also	O
suggest	O
an	O
increased	O
potential	O
for	O
seizures	O
when	O
these	O
2	O
drugs	B-Drug
are	O
given	O
concomitantly	O
.	O

Fenbufen	B-Drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
at	O
this	O
time	O
.	O

Physicians	O
are	O
provided	O
this	O
information	O
to	O
increase	O
awareness	O
of	O
the	O
potential	O
for	O
serious	O
interactions	O
when	O
cinoxacin	B-Drug
and	O
certain	O
nonsteroidal	O
anti-inflammatory	O
agents	O
are	O
administered	O
concomitantly	O
.	O

Elevated	O
cyclosporine	B-Drug
serum	O
levels	O
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
quinolones	O
and	O
cyclosporine	B-Drug
.	O

Some	O
quinolones	O
,	O
including	O
ciprofloxacin	B-Drug
,	O
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O

This	O
may	O
lead	B-Drug
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
a	O
prolongation	O
of	O
its	O
serum	O
half-life	O
.	O

Some	O
quinolones	O
,	O
including	O
ciprofloxacin	B-Drug
,	O
have	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
cyclosporine	B-Drug
concomitantly	O
.	O

Glyburide	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
ciprofloxacin	B-Drug
with	O
the	O
sulfonylurea	B-Drug
glyburide	B-Drug
has	O
,	O
on	O
rare	O
occasions	O
,	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O

Histamine	B-Drug
H2-receptor	O
antagonists	O
:	O
Histamine	B-Drug
H2-receptor	O
antagonists	O
appear	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
ciprofloxacin	B-Drug
.	O

Methotrexate	B-Drug
Renal	O
tubular	O
transport	O
of	O
methotrexate	B-Drug
may	O
be	O
inhibited	O
by	O
concomitant	O
administration	O
of	O
ciprofloxacin	B-Drug
,	O
potentially	O
leading	O
to	O
increased	O
plasma	O
levels	O
of	O
methotrexate	B-Drug
.	O

This	O
might	O
increase	O
the	O
risk	O
of	O
methotrexate	B-Drug
toxic	O
reactions	O
.	O

Therefore	O
,	O
patients	O
under	O
methotrexate	B-Drug
therapy	O
should	O
be	O
carefully	O
monitored	O
when	O
concomitant	O
ciprofloxacin	B-Drug
therapy	O
is	O
indicated	O
.	O

Multivalent	O
Cation-Containing	O
Products	O
:	O
Concurrent	O
administration	O
of	O
a	O
quinolone	O
,	O
including	O
ciprofloxacin	B-Drug
,	O
with	O
multivalent	O
cation-containing	O
products	O
such	O
as	O
magnesium	B-Drug
or	O
aluminum	B-Drug
antacids	O
,	O
sucralfate	B-Drug
,	O
VIDEX	B-Drug
chewable/buffered	O
tablets	O
or	O
pediatric	O
powder	O
,	O
or	O
products	O
containing	O
calcium	B-Drug
,	O
iron	B-Drug
,	O
or	O
zinc	B-Drug
may	O
substantially	O
decrease	O
the	O
absorption	O
of	O
ciprofloxacin	B-Drug
,	O
resulting	O
in	O
serum	O
and	O
urine	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O

Proquin	B-Drug
XR	I-Drug
should	O
be	O
administered	O
at	O
least	O
4	O
hours	O
before	O
or	O
2	O
hours	O
after	O
these	O
products	O
.	O

This	O
time	O
window	O
is	O
different	O
than	O
for	O
other	O
oral	O
formulations	O
of	O
ciprofloxacin	B-Drug
,	O
which	O
are	O
usually	O
administered	O
2	O
hours	O
before	O
or	O
6	O
hours	O
after	O
antacids	O
.	O

Non-steroidal	O
anti-inflammatory	O
drugs	B-Drug
(	O
but	O
not	O
aspirin	B-Drug
)	O
:	O
These	O
drugs	B-Drug
in	O
combination	O
with	O
very	O
high	O
doses	O
of	O
quinolones	O
have	O
been	O
shown	O
to	O
provoke	O
convulsions	O
in	O
pre-clinical	O
studies	O
.	O

Omeprazole	B-Drug
:	O
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
ciprofloxacin	B-Drug
was	O
bioequivalent	O
when	O
Proquin	B-Drug
XR	I-Drug
was	O
given	O
alone	O
or	O
when	O
Proquin	B-Drug
XR	I-Drug
was	O
given	O
2	O
hours	O
after	O
omeprazole	B-Drug
at	O
the	O
dose	O
that	O
maximally	O
suppresses	O
gastric	O
acid	O
secretion	O
.	O

Omeprazole	B-Drug
should	O
be	O
taken	O
as	O
directed	O
and	O
Proquin	B-Drug
XR	I-Drug
should	O
be	O
taken	O
with	O
a	O
main	O
meal	O
of	O
the	O
day	O
,	O
preferably	O
the	O
evening	O
meal..	O
Phenytoin	B-Drug
:	O
Altered	O
serum	O
levels	O
of	O
phenytoin	B-Drug
(	O
increased	O
and	O
decreased	O
)	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
ciprofloxacin	B-Drug
.	O

Probenecid	B-Drug
:	O
Probenecid	B-Drug
interferes	O
with	O
renal	O
tubular	O
secretion	O
of	O
ciprofloxacin	B-Drug
and	O
produces	O
an	O
increase	O
in	O
the	O
level	O
of	O
ciprofloxacin	B-Drug
in	O
serum	O
.	O

Theophylline	B-Drug
:	O
As	O
with	O
some	O
other	O
quinolones	O
,	O
concurrent	O
administration	O
of	O
ciprofloxacin	B-Drug
with	O
theophylline	B-Drug
may	O
lead	B-Drug
to	O
elevated	O
serum	O
concentrations	O
of	O
theophylline	B-Drug
and	O
prolongation	O
of	O
its	O
elimination	O
half-life	O
.	O

This	O
may	O
result	O
in	O
increased	O
risk	O
of	O
theophylline-related	B-Drug
adverse	O
reactions	O
.	O

If	O
concomitant	O
use	O
can	O
not	O
be	O
avoided	O
,	O
serum	O
levels	O
of	O
theophylline	B-Drug
should	O
be	O
monitored	O
and	O
dosage	O
adjustments	O
made	O
as	O
appropriate	O
.	O

Warfarin	B-Drug
:	O
Quinolones	O
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Drug
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
monitored	O
.	O

Cisapride	B-Drug
is	O
metabolized	O
mainly	O
via	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
.	O

In	O
some	O
cases	O
where	O
serious	O
ventricular	O
arrhythmias	O
,	O
QT	O
prolongation	O
,	O
and	O
torsades	O
de	O
pointes	O
have	O
occurred	O
when	O
cisapride	B-Drug
was	O
taken	O
in	O
conjunction	O
with	O
one	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
inhibitors	O
,	O
elevated	O
blood	O
cisapride	B-Drug
levels	O
were	O
noted	O
at	O
the	O
time	O
of	O
the	O
QT	O
prolongation	O
.	O

Antibiotics	B-Drug
:	O
In	O
vitro	O
and/or	O
in	O
vivo	O
data	O
show	O
that	O
clarithromycin	B-Drug
,	O
erythromycin	B-Drug
,	O
and	O
troleandomycin	B-Drug
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B-Drug
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Anticholinergics	O
:	O
Concurrent	O
administration	O
of	O
certain	O
anticholinergic	B-Drug
compounds	O
,	O
such	O
as	O
belladonna	O
alkaloids	O
and	O
dicyclomine	B-Drug
,	O
would	O
be	O
expected	O
to	O
compromise	O
the	O
beneficial	O
effects	O
of	O
cisapride	B-Drug
.	O

Anticoagulants	B-Drug
(	O
Oral	O
)	O
:	O
In	O
patients	O
receiving	O
oral	O
anticoagulants	B-Drug
,	O
the	O
coagulation	O
times	O
were	O
increased	O
in	O
some	O
cases	O
.	O

It	O
is	O
advisable	O
to	O
check	O
coagulation	O
time	O
within	O
the	O
first	O
few	O
days	O
after	O
the	O
start	O
and	O
discontinuation	O
of	O
cisapride	B-Drug
therapy	O
,	O
with	O
an	O
appropriate	O
adjustment	O
of	O
the	O
anticoagulant	B-Drug
dose	O
,	O
if	O
necessary	O
.	O

Antidepressants	B-Drug
:	O
In	O
vitro	O
data	O
indicate	O
that	O
nefazodone	B-Drug
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Antifungals	O
:	O
In	O
vitro	O
and/or	O
in	O
vivo	O
data	O
indicate	O
that	O
fluconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
and	O
oral	O
ketoconazole	B-Drug
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B-Drug
,	O
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Human	O
pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
markedly	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
,	O
resulting	O
in	O
a	O
mean	O
eight-fold	O
increase	O
in	O
AUC	O
of	O
cisapride	B-Drug
.	O

A	O
study	O
in	O
14	O
normal	O
male	O
and	O
female	O
volunteers	O
suggests	O
that	O
coadministration	O
of	O
cisapride	B-Drug
and	O
ketoconazole	B-Drug
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

H2	O
Receptor	O
Antagonists	O
:	O
Cimetidine	B-Drug
coadministration	O
leads	O
to	O
an	O
increased	O
peak	O
plasma	O
concentration	O
and	O
AUC	O
of	O
cisapride	B-Drug
,	O
there	O
is	O
no	O
effect	O
on	O
cisapride	B-Drug
absorption	O
when	O
it	O
is	O
coadministered	O
with	O
ranitidine	B-Drug
.	O

The	O
gastrointestinal	O
absorption	O
of	O
cimetidine	B-Drug
and	O
ranitidine	B-Drug
is	O
accelerated	O
when	O
they	O
are	O
coadministered	O
with	O
cisapride	B-Drug
.	O

Protease	O
Inhibitors	O
:	O
In	O
vitro	O
data	O
indicate	O
that	O
indinavir	B-Drug
and	O
ritonavir	B-Drug
markedly	O
inhibit	O
the	O
metabolism	O
of	O
cisapride	B-Drug
which	O
can	O
result	O
in	O
an	O
increase	O
in	O
plasma	O
cisapride	B-Drug
levels	O
and	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Other	O
:	O
Coadministration	O
of	O
grapefruit	O
juice	O
with	O
cisapride	B-Drug
increases	O
the	O
bioavailability	O
of	O
cisapride	B-Drug
and	O
concomitant	O
use	O
should	O
be	O
avoided	O
.	O

Cisapride	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
drugs	B-Drug
known	O
to	O
prolong	O
the	O
QT	O
interval	O
:	O
certain	O
antiarrhythmics	B-Drug
,	O
including	O
those	O
of	O
Class	O
IA	O
(	O
such	O
as	O
quinidine	B-Drug
and	O
procainamide	B-Drug
)	O
and	O
Class	O
III	O
(	O
such	O
as	O
sotalol	B-Drug
)	O
;	O
tricyclic	O
antidepressants	B-Drug
(	O
such	O
as	O
amitriptyline	B-Drug
)	O
;	O
certain	O
tetracyclic	O
antidepressants	B-Drug
(	O
such	O
as	O
maprotiline	B-Drug
)	O
;	O
certain	O
antipsychotic	O
medications	O
(	O
such	O
as	O
sertindole	B-Drug
)	O
;	O
astemizole	B-Drug
,	O
bepridil	B-Drug
,	O
sparfloxacin	B-Drug
,	O
and	O
terodiline	B-Drug
.	O

The	O
preceding	O
lists	O
of	O
drugs	B-Drug
are	O
not	O
comprehensive	O
.	O

The	O
acceleration	O
of	O
gastric	O
emptying	O
by	O
cisapride	B-Drug
could	O
affect	O
the	O
rate	O
of	O
absorption	O
of	O
other	O
drugs	B-Drug
.	O

Patients	O
receiving	O
narrow	O
therapeutic	O
ratio	O
drugs	B-Drug
or	O
other	O
drugs	B-Drug
that	O
require	O
careful	O
titration	O
should	O
be	O
followed	O
closely	O
;	O
if	O
plasma	O
levels	O
are	O
being	O
monitored	O
,	O
they	O
should	O
be	O
reassessed	O
.	O

Administration	O
of	O
0.1-mg/kg	O
(	O
2	O
x	O
ED95	O
)	O
NIMBEX	B-Drug
at	O
10	O
%	O
or	O
95	O
%	O
recovery	O
following	O
an	O
intubating	O
dose	O
of	O
succinylcholine	B-Drug
(	O
1	O
mg/kg	O
)	O
produced	O
95	O
%	O
neuromuscular	O
block	O
.	O

The	O
time	O
to	O
onset	O
of	O
maximum	O
block	O
following	O
NIMBEX	B-Drug
is	O
approximately	O
2	O
minutes	O
faster	O
with	O
prior	O
administration	O
of	O
succinylcholine	B-Drug
.	O

Prior	O
administration	O
of	O
succinylcholine	B-Drug
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
neuromuscular	O
block	O
following	O
initial	O
or	O
maintenance	O
bolus	O
doses	O
of	O
NIMBEX	B-Drug
.	O

Infusion	O
requirements	O
of	O
NIMBEX	B-Drug
in	O
patients	O
administered	O
succinylcholine	B-Drug
prior	O
to	O
infusions	O
of	O
NIMBEX	B-Drug
were	O
comparable	O
to	O
or	O
slightly	O
greater	O
than	O
when	O
succinylcholine	B-Drug
was	O
not	O
administered	O
.	O

The	O
use	O
of	O
NIMBEX	B-Drug
before	O
succinylcholine	B-Drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B-Drug
has	O
not	O
been	O
studied	O
.	O

Although	O
not	O
studied	O
systematically	O
in	O
clinical	O
trials	O
,	O
no	O
drug	B-Drug
interactions	O
were	O
observed	O
when	O
vecuronium	B-Drug
,	O
pancuronium	B-Drug
,	O
or	O
atracurium	B-Drug
were	O
administered	O
following	O
varying	O
degrees	O
of	O
recovery	O
from	O
single	O
doses	O
or	O
infusions	O
of	O
NIMBEX	B-Drug
.	O

Isoflurane	B-Drug
or	O
enflurane	B-Drug
administered	O
with	O
nitrous	B-Drug
oxide/oxygen	I-Drug
to	O
achieve	O
1.25	O
MAC	O
[	O
Minimum	O
Alveolar	O
Concentration	O
]	O
may	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
of	O
initial	O
and	O
maintenance	O
doses	O
of	O
NIMBEX	B-Drug
and	O
decrease	O
the	O
required	O
infusion	O
rate	O
of	O
NIMBEX	B-Drug
.	O

The	O
magnitude	O
of	O
these	O
effects	O
may	O
depend	O
on	O
the	O
duration	O
of	O
administration	O
of	O
the	O
volatile	O
agents	O
.	O

Fifteen	O
to	O
30	O
minutes	O
of	O
exposure	O
to	O
1.25	O
MAC	O
isoflurane	B-Drug
or	O
enflurane	B-Drug
had	O
minimal	O
effects	O
on	O
the	O
duration	O
of	O
action	O
of	O
initial	O
doses	O
of	O
NIMBEX	B-Drug
and	O
therefore	O
,	O
no	O
adjustment	O
to	O
the	O
initial	O
dose	O
should	O
be	O
necessary	O
when	O
NIMBEX	B-Drug
is	O
administered	O
shortly	O
after	O
initiation	O
of	O
volatile	O
agents	O
.	O

In	O
long	O
surgical	O
procedures	O
during	O
enflurane	B-Drug
or	O
isoflurane	B-Drug
anesthesia	B-Drug
,	O
less	O
frequent	O
maintenance	O
dosing	O
,	O
lower	O
maintenance	O
doses	O
,	O
or	O
reduced	O
infusion	O
rates	O
of	O
NIMBEX	B-Drug
may	O
be	O
necessary	O
.	O

The	O
average	O
infusion	O
rate	O
requirement	O
may	O
be	O
decreased	O
by	O
as	O
much	O
as	O
30	O
%	O
to	O
40	O
%	O
.	O

In	O
clinical	O
studies	O
propofol	B-Drug
had	O
no	O
effect	O
on	O
the	O
duration	O
of	O
action	O
or	O
dosing	O
requirements	O
for	O
NIMBEX	B-Drug
.	O

Other	O
drugs	B-Drug
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
agents	O
such	O
as	O
NIMBEX	B-Drug
include	O
certain	O
antibiotics	B-Drug
(	O
e.	O
g.	O
,	O
aminoglycosides	O
,	O
tetracyclines	O
,	O
bacitracin	B-Drug
,	O
polymyxins	O
,	O
lincomycin	B-Drug
,	O
clindamycin	B-Drug
,	O
colistin	B-Drug
,	O
and	O
sodium	B-Drug
colistemethate	I-Drug
)	O
,	O
magnesium	B-Drug
salts	O
,	O
lithium	B-Drug
,	O
local	O
anesthetics	B-Drug
,	O
procainamide	B-Drug
,	O
and	O
quinidine	B-Drug
.	O

Resistance	O
to	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
neuromuscular	O
blocking	O
agents	O
has	O
been	O
demonstrated	O
in	O
patients	O
chronically	O
administered	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
.	O

While	O
the	O
effects	O
of	O
chronic	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
therapy	O
on	O
the	O
action	O
of	O
NIMBEX	B-Drug
are	O
unknown	O
,	O
slightly	O
shorter	O
durations	O
of	O
neuromuscular	O
block	O
may	O
be	O
anticipated	O
and	O
infusion	O
rate	O
requirements	O
may	O
be	O
higher	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

Plasma	O
levels	O
of	O
anticonvulsant	O
agents	O
may	O
become	O
subtherapeutic	O
during	O
cisplatin	B-Drug
therapy	O
.	O

Central	O
nervous	O
system	O
depressant	O
(	O
CNS	O
)	O
drugs	B-Drug
including	O
alcohol	B-Drug
,	O
antidepressants	B-Drug
,	O
antihistamines	B-Drug
,	O
antipsychotics	O
,	O
blood	O
pressure	O
medications	O
(	O
reserpine	B-Drug
,	O
methyldopa	B-Drug
,	O
beta-blockers	O
)	O
,	O
motion	O
sickness	O
medications	O
,	O
muscle	O
relaxants	O
,	O
narcotics	O
,	O
sedatives	O
,	O
sleeping	O
pills	O
and	O
tranquilizers	O
There	O
are	O
no	O
known	O
drug	B-Drug
interactions	O
with	O
LEUSTATIN	B-Drug
Injection	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
LEUSTATIN	B-Drug
Injection	O
is	O
administered	O
before	O
,	O
after	O
,	O
or	O
in	O
conjunction	O
with	O
other	O
drugs	B-Drug
known	O
to	O
cause	O
immunosuppression	O
or	O
myelosuppression	O
.	O

The	O
concurrent	O
administration	O
of	O
allopurinol	B-Drug
and	O
ampicillin	B-Drug
increases	O
substantially	O
the	O
incidence	O
of	O
rashes	O
in	O
patients	O
receiving	O
both	O
drugs	B-Drug
as	O
compared	O
to	O
patients	O
receiving	O
ampicillin	B-Drug
alone	O
.	O

It	O
is	O
not	O
known	O
whether	O
this	O
potentiation	O
of	O
ampicillin	B-Drug
rashes	O
is	O
due	O
to	O
allopurinol	B-Drug
or	O
the	O
hyperuricemia	O
present	O
in	O
these	O
patients	O
.	O

In	O
controlled	O
clinical	O
trials	O
of	O
AUGMENTIN	B-Drug
XR	I-Drug
,	O
22	O
patients	O
received	O
concomitant	O
allopurinol	B-Drug
and	O
AUGMENTIN	B-Drug
XR	I-Drug
.	O

No	O
rashes	O
were	O
reported	O
in	O
these	O
patients	O
.	O

However	O
,	O
this	O
sample	O
size	O
is	O
too	O
small	O
to	O
allow	O
for	O
any	O
conclusions	O
to	O
be	O
drawn	O
regarding	O
the	O
risk	O
of	O
rashes	O
with	O
concomitant	O
AUGMENTIN	B-Drug
XR	I-Drug
and	O
allopurinol	B-Drug
use	O
.	O

In	O
common	O
with	O
other	O
broad-spectrum	O
antibiotics	B-Drug
,	O
AUGMENTIN	B-Drug
XR	I-Drug
may	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	O
Additive	O
CNS	O
depression	O
may	O
occur	O
when	O
antihistamines	B-Drug
are	O
administered	O
concomitantly	O
with	O
other	O
CNS	O
depressants	O
including	O
barbiturates	B-Drug
,	O
tranquilizers	O
,	O
and	O
alcohol	B-Drug
.	O

Patients	O
receiving	O
antihistamines	B-Drug
should	O
be	O
advised	O
against	O
the	O
concurrent	O
use	O
of	O
other	O
CNS	O
depressant	O
drugs	B-Drug
.	O

Monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
effects	O
of	O
antihistamines	B-Drug
.	O

Amantadine	B-Drug
,	O
tricyclic	O
antidepressants	B-Drug
,	O
and	O
MAOIs	O
may	O
increase	O
anticholinergic	B-Drug
effect	O
of	O
clidinium	B-Drug
.	O

Clidinium	B-Drug
may	O
decrease	O
the	O
effect	O
of	O
phenothiazines	O
,	O
levodopa	B-Drug
,	O
and	O
ketoconazole	B-Drug
.	O

Clindamycin	B-Drug
has	O
been	O
shown	O
to	O
have	O
neuromuscular	O
blocking	O
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	O
blocking	O
agents	O
.	O

Therefore	O
,	O
it	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
such	O
agents	O
.	O

Antagonism	O
has	O
been	O
demonstrated	O
between	O
clindamycin	B-Drug
and	O
erythromycin	B-Drug
in	O
vitro	O
.	O

Because	O
of	O
possible	O
clinical	O
significance	O
,	O
these	O
two	O
drugs	B-Drug
should	O
not	O
be	O
administered	O
concurrently	O
.	O

Alcohol	B-Drug
(	O
increases	O
bioavailability	O
by	O
50	O
%	O
)	O
,	O
cimetidine	B-Drug
,	O
and	O
valproates	O
.	O

No	O
separate	O
information	O
available	O
Although	O
no	O
clinical	O
drug-drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
to	O
date	O
,	O
on	O
the	O
basis	O
of	O
the	O
in	O
vitro	O
studies	O
,	O
cytochrome	O
p450	O
inhibitors	O
and	O
inducers	O
are	O
unlikely	O
to	O
affect	O
the	O
metabolism	O
of	O
clofarabine	B-Drug
.	O

The	O
effect	O
of	O
clofarabine	B-Drug
on	O
the	O
metabolism	O
of	O
cytochrome	O
p450	O
substrates	O
has	O
not	O
been	O
studied	O
.	O

Drug/Laboratory	O
Tests	O
Interactions	O
There	O
are	O
no	O
known	O
clinically	O
significant	O
interactions	O
of	O
CLOLAR	B-Drug
with	O
other	O
medications	O
or	O
laboratory	O
tests	O
.	O

No	O
formal	O
drug/laboratory	O
test	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
CLOLAR	B-Drug
.	O

Preliminary	O
data	O
which	O
suggest	O
that	O
dapsone	B-Drug
may	O
inhibit	O
the	O
anti-inflammatory	O
activity	O
of	O
Lamprene	B-Drug
have	O
not	O
been	O
confirmed	O
.	O

If	O
leprosy-associated	O
inflammatory	O
reactions	O
develop	O
in	O
patients	O
being	O
treated	O
with	O
dapsone	B-Drug
and	O
clofazimine	B-Drug
,	O
it	O
is	O
still	O
advisable	O
to	O
continue	O
treatment	O
with	O
both	O
drugs	B-Drug
.	O

Caution	O
should	O
be	O
exercised	O
when	O
anticoagulants	B-Drug
are	O
given	O
in	O
conjunction	O
with	O
Atromid-S	B-Drug
.	O

Usually	O
,	O
the	O
dosage	O
of	O
the	O
anticoagulant	B-Drug
should	O
be	O
reduced	O
by	O
one-half	O
(	O
depending	O
on	O
the	O
individual	O
case	O
)	O
to	O
maintain	O
the	O
prothrombin	O
time	O
at	O
the	O
desired	O
level	O
to	O
prevent	O
bleeding	O
complications	O
.	O

Frequent	O
prothrombin	O
determinations	O
are	O
advisable	O
until	O
it	O
has	O
been	O
determined	O
definitely	O
that	O
the	O
prothrombin	O
level	O
has	O
been	O
stabilized	O
.	O

Atromid-S	B-Drug
may	O
displace	O
acidic	O
drugs	B-Drug
such	O
as	O
phenytoin	B-Drug
or	O
tolbutamide	B-Drug
from	O
their	O
binding	O
sites	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
treating	O
patients	O
with	O
either	O
of	O
these	O
drugs	B-Drug
or	O
other	O
highly	O
protein-bound	O
drugs	B-Drug
and	O
Atromid-S	B-Drug
.	O

The	O
hypoglycemic	O
effect	O
of	O
tolbutamide	B-Drug
has	O
been	O
reported	O
to	O
increase	O
when	O
Atromid-S	B-Drug
is	O
given	O
concurrently	O
.	O

Fulminant	O
rhabdomyolysis	O
has	O
been	O
seen	O
as	O
early	O
as	O
three	O
weeks	O
after	O
initiation	O
of	O
combined	O
therapy	O
with	O
another	O
fibrate	O
and	O
lovastatin	B-Drug
but	O
may	O
be	O
seen	O
after	O
several	O
months	O
.	O

For	O
these	O
reasons	O
,	O
it	O
is	O
felt	O
that	O
,	O
in	O
most	O
subjects	O
who	O
have	O
had	O
an	O
unsatisfactory	O
lipid	O
response	O
to	O
either	O
drug	B-Drug
alone	O
,	O
the	O
possible	O
benefits	O
of	O
combined	O
therapy	O
with	O
lovastatin	B-Drug
and	O
a	O
fibrate	O
do	O
not	O
outweigh	O
the	O
risks	O
of	O
severe	O
myopathy	O
,	O
rhabdomyolysis	O
,	O
and	O
acute	O
renal	O
failure	O
.	O

While	O
it	O
is	O
not	O
known	O
whether	O
this	O
interaction	O
occurs	O
with	O
fibrates	O
other	O
than	O
gemfibrozil	B-Drug
,	O
myopathy	O
and	O
rhabdomyolysis	O
have	O
occasionally	O
been	O
associated	O
with	O
the	O
use	O
of	O
fibrates	O
alone	O
,	O
including	O
clofibrate	B-Drug
.	O

Therefore	O
,	O
the	O
combined	O
use	O
of	O
lovastatin	B-Drug
with	O
fibrates	O
should	O
generally	O
be	O
avoided	O
.	O

Drug	B-Drug
interactions	O
with	O
clomiphene	B-Drug
citrate	I-Drug
tablets	O
USP	O
have	O
not	O
been	O
documented	O
.	O

The	O
risks	O
of	O
using	O
Anafranil	B-Drug
in	O
combination	O
with	O
other	O
drugs	B-Drug
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Anafranil	B-Drug
,	O
caution	O
is	O
advised	O
in	O
using	O
it	O
concomitantly	O
with	O
other	O
CNS-active	O
drugs	B-Drug
.	O

Anafranil	B-Drug
should	O
not	O
be	O
used	O
with	O
MAO	O
inhibitors	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
Anafranil	B-Drug
is	O
administered	O
with	O
anticholinergic	B-Drug
or	O
sympathomimetic	B-Drug
drugs	B-Drug
.	O

Several	O
tricyclic	O
antidepressants	B-Drug
have	O
been	O
reported	O
to	O
block	O
the	O
pharmacologic	O
effects	O
of	O
guanethidine	B-Drug
,	O
clonidine	B-Drug
,	O
or	O
similar	O
agents	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B-Drug
because	O
of	O
its	O
structural	O
similarity	O
to	O
other	O
tricyclic	O
antidepressants	B-Drug
.	O

The	O
plasma	O
concentration	O
of	O
CMI	B-Drug
has	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
haloperidol	B-Drug
;	O
plasma	O
levels	O
of	O
several	O
closely	O
related	O
tricyclic	O
antidepressants	B-Drug
have	O
been	O
reported	O
to	O
be	O
increased	O
by	O
the	O
concomitant	O
administration	O
of	O
methylphenidate	B-Drug
or	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e.g.	O
,	O
cimetidine	B-Drug
,	O
fluoxetine	B-Drug
)	O
and	O
decreased	O
by	O
the	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
barbiturates	B-Drug
,	O
phenytoin	B-Drug
)	O
,	O
and	O
such	O
an	O
effect	O
may	O
be	O
anticipated	O
with	O
CMI	B-Drug
as	O
well	O
.	O

Administration	O
of	O
CMI	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
of	O
phenobarbital	B-Drug
,	O
if	O
given	O
concomitantly	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
P450	O
2D6	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	B-Drug
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	B-Drug
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
aucasian	O
population	O
(	O
about	O
7	O
%	O
-10	O
%	O
of	O
Caucasians	O
are	O
so-called	O
poor	O
metabolizers	O
)	O
;	O
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
lasma	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	B-Drug
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-Drug
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCAmay	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	B-Drug
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	B-Drug
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B-Drug
,	O
phenothiazines	O
,	O
and	O
the	O
Type	O
1C	O
antiarrhythmics	B-Drug
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
sertraline	B-Drug
,	O
paroxetine	B-Drug
,	O
and	O
fluvoxamine	B-Drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

Fluvoxamine	B-Drug
has	O
also	O
been	O
shown	O
to	O
inhibit	O
P450	O
1A2	O
,	O
an	O
isoform	O
also	O
involved	O
in	O
TCAmetabolism	O
.	O

The	O
extent	O
to	O
which	O
SSRI-TCAinteractions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	O
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co-administration	O
of	O
TCAs	O
with	O
any	O
of	O
the	O
SSRIs	O
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCAtreatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
,	O
given	O
the	O
long	O
half-life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
agents	O
in	O
the	O
tricyclic	O
antidepressant	O
class	O
(	O
which	O
includes	O
Anafranil	B-Drug
)	O
with	O
drugs	B-Drug
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	O
antidepressant	O
agent	O
or	O
the	O
other	O
drug	B-Drug
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
drugs	B-Drug
is	O
withdrawn	O
from	O
co-therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	O
antidepressant	O
agent	O
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCAplasma	O
levels	O
whenever	O
an	O
agent	O
of	O
the	O
tricyclic	O
antidepressant	O
class	O
including	O
Anafranil	B-Drug
is	O
going	O
to	O
be	O
co-administered	O
with	O
another	O
drug	B-Drug
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
(	O
and/or	O
P450	O
1A2	O
)	O
.	O

Because	O
Anafranil	B-Drug
is	O
highly	O
bound	O
to	O
serum	O
protein	O
,	O
the	O
administration	O
of	O
Anafranil	B-Drug
to	O
patients	O
taking	O
other	O
drugs	B-Drug
that	O
are	O
highly	O
bound	O
to	O
protein	O
(	O
e.g.	O
,	O
warfarin	B-Drug
,	O
digoxin	B-Drug
)	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
these	O
drugs	B-Drug
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Conversely	O
,	O
adverse	O
effects	O
may	O
result	O
from	O
displacement	O
of	O
protein-bound	O
Anafranil	B-Drug
by	O
other	O
highly	O
bound	O
drugs	B-Drug
.	O

Effect	O
of	O
Clonazepam	B-Drug
on	O
the	O
Pharmacokinetics	O
of	O
Other	O
Drugs	B-Drug
:	O
Clonazepam	B-Drug
does	O
not	O
appear	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
or	O
phenobarbital	B-Drug
.	O

The	O
effect	O
of	O
clonazepam	B-Drug
on	O
the	O
metabolism	O
of	O
other	O
drugs	B-Drug
has	O
not	O
been	O
investigated	O
.	O

Effect	O
of	O
Other	O
Drugs	B-Drug
on	O
the	O
Pharmacokinetics	O
of	O
Clonazepam	B-Drug
:	O
Literature	O
reports	O
suggest	O
that	O
ranitidine	B-Drug
,	O
an	O
agent	O
that	O
decreases	O
stomach	O
acidity	O
,	O
does	O
not	O
greatly	O
alter	O
clonazepam	B-Drug
pharmacokinetics	O
.	O

In	O
a	O
study	O
in	O
which	O
the	O
2	O
mg	O
clonazepam	B-Drug
orally	O
disintegrating	O
tablet	O
was	O
administered	O
with	O
and	O
without	O
propantheline	B-Drug
(	O
an	O
anticholinergic	B-Drug
agent	O
with	O
multiple	O
effects	O
on	O
the	O
GI	O
tract	O
)	O
to	O
healthy	O
volunteers	O
,	O
the	O
AUC	O
of	O
clonazepam	B-Drug
was	O
10	O
%	O
lower	O
and	O
the	O
Cmax	O
of	O
clonazepam	B-Drug
was	O
20	O
%	O
lower	O
when	O
the	O
orally	O
disintegrating	O
tablet	O
was	O
given	O
with	O
propantheline	B-Drug
compared	O
to	O
when	O
it	O
was	O
given	O
alone	O
.	O

Fluoxetine	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
clonazepam	B-Drug
.	O

Cytochrome	O
P-450	O
inducers	O
,	O
such	O
as	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
and	O
phenobarbital	B-Drug
,	O
induce	O
clonazepam	B-Drug
metabolism	O
,	O
causing	O
an	O
approximately	O
30	O
%	O
decrease	O
in	O
plasma	O
clonazepam	B-Drug
levels	O
.	O

Although	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
,	O
based	O
on	O
the	O
involvement	O
of	O
the	O
cytochrome	O
P-450	O
3A	O
family	O
in	O
clonazepam	B-Drug
metabolism	O
,	O
inhibitors	O
of	O
this	O
enzyme	O
system	O
,	O
notably	O
oral	O
antifungal	O
agents	O
,	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
receiving	O
clonazepam	B-Drug
.	O

Pharmacodynamic	O
Interactions	O
:	O
The	O
CNS-depressant	O
action	O
of	O
the	O
benzodiazepine	O
class	O
of	O
drugs	B-Drug
may	O
be	O
potentiated	O
by	O
alcohol	B-Drug
,	O
narcotics	O
,	O
barbiturates	B-Drug
,	O
nonbarbiturate	O
hypnotics	O
,	O
antianxiety	O
agents	O
,	O
the	O
phenothiazines	O
,	O
thioxanthene	O
and	O
butyrophenone	O
classes	O
of	O
antipsychotic	O
agents	O
,	O
monoamine	O
oxidase	O
inhibitors	O
and	O
the	O
tricyclic	O
antidepressants	B-Drug
,	O
and	O
by	O
other	O
anticonvulsant	O
drugs	B-Drug
.	O

Tablet	O
If	O
a	O
patient	O
receiving	O
clonidine	B-Drug
hydrochloride	I-Drug
is	O
also	O
taking	O
tricyclic	O
antidepressants	B-Drug
,	O
the	O
effect	O
of	O
clonidine	B-Drug
may	O
be	O
reduced	O
,	O
thus	O
necessitating	O
an	O
increase	O
in	O
dosage	O
.	O

Clonidine	B-Drug
hydrochloride	I-Drug
may	O
enhance	O
the	O
CNS-depressive	O
effects	O
of	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
or	O
other	O
sedatives	O
.	O

Amitriptyline	B-Drug
in	O
combination	O
with	O
clonidine	B-Drug
enhances	O
the	O
manifestation	O
of	O
corneal	O
lesions	O
in	O
rats	O
Epidural	O
Injection	O
Clonidine	B-Drug
may	O
potentiate	O
the	O
CNS-depressive	O
effect	O
of	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
or	O
other	O
sedating	O
drugs	B-Drug
.	O

Narcotic	O
analgesics	O
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B-Drug
.	O

Tricyclic	O
antidepressants	B-Drug
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B-Drug
.	O

The	O
effects	O
of	O
tricyclic	O
antidepressants	B-Drug
on	O
clonidines	B-Drug
analgesic	O
actions	O
are	O
not	O
known	O
.	O

Beta	O
blockers	O
may	O
exacerbate	O
the	O
hypertensive	O
response	O
seen	O
with	O
clonidine	B-Drug
withdrawl	O
.	O

Also	O
,	O
due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
such	O
as	O
bradycardia	O
and	O
AV	O
block	O
,	O
caution	O
is	O
warranted	O
in	O
patients	O
receiving	O
clonidine	B-Drug
with	O
agents	O
known	O
to	O
affect	O
sinus	O
node	O
function	O
or	O
AV	O
nodal	O
conduction	O
(	O
e.g.	O
,	O
digitalis	B-Drug
,	O
calcium	B-Drug
channel	O
blockers	O
,	O
and	O
beta-blockers	O
.	O

)	O
There	O
is	O
one	O
reported	O
case	O
of	O
a	O
patient	O
with	O
acute	O
delirium	O
associated	O
with	O
the	O
simultaneous	O
use	O
of	O
fluphenazine	B-Drug
and	O
oral	O
clonidine	B-Drug
.	O

Symptoms	O
resolved	O
when	O
clonidine	B-Drug
was	O
withdrawn	O
and	O
recurred	O
when	O
the	O
patient	O
was	O
rechallenged	O
with	O
clonidine	B-Drug
.	O

Epidural	O
clonidine	B-Drug
may	O
prolong	O
the	O
duration	O
of	O
pharmacologic	O
effects	O
of	O
epidural	O
local	O
anesthetics	B-Drug
,	O
including	O
both	O
sensory	O
and	O
motor	O
blockade	O
.	O

Aspirin	B-Drug
,	O
warfarin	B-Drug
,	O
heparin	B-Drug
,	O
NSAIDs	O
If	O
TRANXENE	B-Drug
is	O
to	O
be	O
combined	O
with	O
other	O
drugs	B-Drug
acting	O
on	O
the	O
central	O
nervous	O
system	O
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	O
to	O
be	O
employed	O
.	O

Animal	O
experience	O
indicates	O
that	O
clorazepate	B-Drug
dipotassium	I-Drug
prolongs	O
the	O
sleeping	O
time	O
after	O
hexobarbital	B-Drug
or	O
after	O
ethyl	B-Drug
alcohol	I-Drug
,	O
increases	O
the	O
inhibitory	O
effects	O
of	O
chlorpromazine	B-Drug
,	O
but	O
does	O
not	O
exhibit	O
monoamine	O
oxidase	O
inhibition	O
.	O

Clinical	O
studies	O
have	O
shown	O
increased	O
sedation	O
with	O
concurrent	O
hypnotic	O
medications	O
.	O

The	O
actions	O
of	O
the	O
benzodiazepines	B-Drug
may	O
be	O
potentiated	O
by	O
barbiturates	B-Drug
,	O
narcotics	O
,	O
phenothiazines	O
,	O
monoamine	O
oxidase	O
inhibitors	O
or	O
other	O
antidepressants	B-Drug
.	O

If	O
TRANXENE	B-Drug
tablets	O
are	O
used	O
to	O
treat	O
anxiety	O
associated	O
with	O
somatic	O
disease	O
states	O
,	O
careful	O
attention	O
must	O
be	O
paid	O
to	O
possible	O
drug	B-Drug
interaction	O
with	O
concomitant	O
medication	O
.	O

In	O
bioavailability	O
studies	O
with	O
normal	O
subjects	O
,	O
the	O
concurrent	O
administration	O
of	O
antacids	O
at	O
therapeutic	O
levels	O
did	O
not	O
significantly	O
influence	O
the	O
bioavailability	O
of	O
TRANXENE	B-Drug
tablets	O
.	O

The	O
risks	O
of	O
using	O
Clozapine	B-Drug
in	O
combination	O
with	O
other	O
drugs	B-Drug
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

Pharmacodynamic-related	O
Interactions	O
:	O
The	O
mechanism	O
of	O
Clozapine	B-Drug
induced	O
agranulocytosis	O
is	O
unknown	O
;	O
nonetheless	O
,	O
the	O
possibility	O
that	O
causative	O
factors	O
may	O
interact	O
synergistically	O
to	O
increase	O
the	O
risk	O
and/or	O
severity	O
of	O
bone	O
marrow	O
suppression	O
warrants	O
consideration	O
.	O

Therefore	O
,	O
Clozapine	B-Drug
should	O
not	O
be	O
used	O
with	O
other	O
agents	O
having	O
a	O
well-known	O
potential	O
to	O
suppress	O
bone	O
marrow	O
function	O
.	O

Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Clozapine	B-Drug
,	O
caution	O
is	O
advised	O
in	O
using	O
it	O
concomitantly	O
with	O
other	O
CNS-active	O
drugs	B-Drug
or	O
alcohol	B-Drug
.	O

Orthostatic	O
hypotension	O
in	O
patients	O
taking	O
clozapine	B-Drug
can	O
,	O
in	O
rare	O
cases	O
(	O
approximately	O
1	O
case	O
per	O
3,000	O
patients	O
)	O
,	O
be	O
accompanied	O
by	O
profound	O
collapse	O
and	O
respiratory	O
and/or	O
cardiac	O
arrest	O
.	O

Some	O
of	O
the	O
cases	O
of	O
collapse/respiratory	O
arrest/cardiac	O
arrest	O
during	O
initial	O
treatment	O
occurred	O
in	O
patients	O
who	O
were	O
being	O
administered	O
benzodiazepines	B-Drug
;	O
similar	O
events	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
other	O
psychotropic	O
drugs	B-Drug
or	O
even	O
Clozapine	B-Drug
by	O
itself	O
.	O

Although	O
it	O
has	O
not	O
been	O
established	O
that	O
there	O
is	O
an	O
interaction	O
between	O
Clozapine	B-Drug
and	O
benzodiazepines	B-Drug
or	O
other	O
psychotropics	O
,	O
caution	O
is	O
advised	O
when	O
clozapine	B-Drug
is	O
initiated	O
in	O
patients	O
taking	O
a	O
benzodiazepine	O
or	O
any	O
other	O
psychotropic	O
drug	B-Drug
.	O

Clozapine	B-Drug
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
antihypertensive	B-Drug
drugs	B-Drug
and	O
the	O
anticholinergic	B-Drug
effects	O
of	O
atropine-type	B-Drug
drugs	B-Drug
.	O

The	O
administration	O
of	O
epinephrine	B-Drug
should	O
be	O
avoided	O
in	O
the	O
treatment	O
of	O
drug	B-Drug
induced	O
hypotension	O
because	O
of	O
a	O
possible	O
reverse	O
epinephrine	B-Drug
effect	O
.	O

Pharmacokinetic-related	O
Interactions	O
:	O
Clozapine	B-Drug
is	O
a	O
substrate	O
for	O
many	O
CYP	O
450	O
isozymes	O
,	O
in	O
particular	O
1A2	O
,	O
2D6	O
,	O
and	O
3A4	O
.	O

The	O
risk	O
of	O
metabolic	O
interactions	O
caused	O
by	O
an	O
effect	O
on	O
an	O
individual	O
isoform	O
is	O
therefore	O
minimized	O
.	O

Nevertheless	O
,	O
caution	O
should	O
be	O
used	O
in	O
patients	O
receiving	O
concomitant	O
treatment	O
with	O
other	O
drugs	B-Drug
that	O
are	O
either	O
inhibitors	O
or	O
inducers	O
of	O
these	O
enzymes	O
.	O

Concomitant	O
administration	O
of	O
drugs	B-Drug
known	O
to	O
induce	O
cytochrome	O
P450	O
enzymes	O
may	O
decrease	O
the	O
plasma	O
levels	O
of	O
clozapine	B-Drug
.	O

Phenytoin	B-Drug
,	O
nicotine	B-Drug
,	O
and	O
rifampin	B-Drug
may	O
decrease	O
Clozapine	B-Drug
plasma	O
levels	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
effectiveness	O
of	O
a	O
previously	O
effective	O
Clozapine	B-Drug
dose	O
.	O

Concomitant	O
administration	O
of	O
drugs	B-Drug
known	O
to	O
inhibit	O
the	O
activity	O
of	O
cytochrome	O
P450	O
isozymes	O
may	O
increase	O
the	O
plasma	O
levels	O
of	O
clozapine	B-Drug
.	O

Cimetidine	B-Drug
,	O
caffeine	B-Drug
,	O
and	O
erythromycin	B-Drug
may	O
increase	O
plasma	O
levels	O
of	O
Clozapine	B-Drug
,	O
potentially	O
resulting	O
in	O
adverse	O
effects	O
.	O

Although	O
concomitant	O
use	O
of	O
Clozapine	B-Drug
and	O
carbamazepine	B-Drug
is	O
not	O
recommended	O
,	O
it	O
should	O
be	O
noted	O
that	O
discontinuation	O
of	O
concomitant	O
carbamazepine	B-Drug
administration	O
may	O
result	O
in	O
an	O
increase	O
in	O
Clozapine	B-Drug
plasma	O
levels	O
.	O

In	O
a	O
study	O
of	O
schizophrenic	O
patients	O
who	O
received	O
clozapine	B-Drug
under	O
steady	O
state	O
conditions	O
,	O
fluvoxamine	B-Drug
or	O
paroxetine	B-Drug
was	O
added	O
in	O
16	O
and	O
14	O
patients	O
,	O
respectively	O
.	O

After	O
14	O
days	O
of	O
co-administration	O
,	O
mean	O
trough	O
concentrations	O
of	O
clozapine	B-Drug
and	O
its	O
metabolites	O
,	O
N-desmethylclozapine	B-Drug
and	O
clozapine	B-Drug
N-oxide	I-Drug
,	O
were	O
elevated	O
with	O
fluvoxamine	B-Drug
by	O
about	O
three-fold	O
compared	O
to	O
baseline	O
concentrations	O
.	O

Paroxetine	B-Drug
produced	O
only	O
minor	O
changes	O
in	O
the	O
levels	O
of	O
clozapine	B-Drug
and	O
its	O
metabolites	O
.	O

However	O
,	O
other	O
published	O
reports	O
describe	O
modest	O
elevations	O
(	O
less	O
than	O
two-fold	O
)	O
of	O
clozapine	B-Drug
and	O
metabolite	O
concentrations	O
when	O
clozapine	B-Drug
was	O
taken	O
with	O
paroxetine	B-Drug
,	O
fluoxetine	B-Drug
,	O
and	O
sertraline	B-Drug
.	O

Therefore	O
,	O
such	O
combined	O
treatment	O
should	O
be	O
approached	O
with	O
caution	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
when	O
Clozapine	B-Drug
is	O
combined	O
with	O
these	O
drugs	B-Drug
,	O
particularly	O
with	O
fluvoxamine	B-Drug
.	O

A	O
reduced	O
Clozapine	B-Drug
dose	O
should	O
be	O
considered	O
.	O

A	O
subset	O
(	O
3	O
%	O
-10	O
%	O
)	O
of	O
the	O
population	O
has	O
reduced	O
activity	O
of	O
certain	O
drug	B-Drug
metabolizing	O
enzymes	O
such	O
as	O
the	O
cytochrome	O
P450	O
isozyme	O
P450	O
2D6	O
.	O

Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	B-Drug
such	O
as	O
debrisoquin	B-Drug
,	O
dextromethorphan	B-Drug
,	O
the	O
tricyclic	O
antidepressants	B-Drug
,	O
and	O
clozapine	B-Drug
.	O

These	O
individuals	O
may	O
develop	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
clozapine	B-Drug
when	O
given	O
usual	O
doses	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
,	O
including	O
many	O
antidepressants	B-Drug
(	O
clozapine	B-Drug
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
,	O
and	O
others	O
)	O
,	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
,	O
and	O
thus	O
may	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	B-Drug
metabolized	O
by	O
this	O
enzyme	O
system	O
,	O
leading	O
to	O
drug	B-Drug
interaction	O
.	O

Concomitant	O
use	O
of	O
clozapine	B-Drug
with	O
other	O
drugs	B-Drug
metabolized	O
by	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
clozapine	B-Drug
or	O
the	O
other	O
drug	B-Drug
.	O

Therefore	O
,	O
co-administration	O
of	O
clozapine	B-Drug
with	O
other	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
this	O
isozyme	O
,	O
including	O
antidepressants	B-Drug
,	O
phenothiazines	O
,	O
carbamazepine	B-Drug
,	O
and	O
Type	O
1C	O
antiarrhythmics	B-Drug
(	O
e.g.	O
,	O
propafenone	B-Drug
,	O
flecainide	B-Drug
and	O
encainide	B-Drug
)	O
,	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
e.g.	O
,	O
quinidine	B-Drug
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

The	O
risk	O
of	O
a	O
potential	O
interaction	O
between	O
NovoSeven	B-Drug
and	O
coagulation	O
factor	O
concentrates	O
has	O
not	O
been	O
adequately	O
evaluated	O
in	O
preclinical	O
or	O
clinical	O
studies	O
.	O

Simultaneous	O
use	O
of	O
activated	O
prothrombin	O
complex	O
concentrates	O
or	O
prothrombin	O
complex	O
concentrates	O
should	O
be	O
avoided	O
.	O

Although	O
the	O
specific	O
drug	B-Drug
interaction	O
was	O
not	O
studied	O
in	O
a	O
clinical	O
trial	O
,	O
there	O
have	O
been	O
more	O
than	O
50	O
episodes	O
of	O
concomitant	O
use	O
of	O
antifibrinolytic	O
therapies	O
(	O
i.e.	O
,	O
tranexamic	B-Drug
acid	I-Drug
,	O
aminocaproic	B-Drug
acid	I-Drug
)	O
and	O
NovoSeven	B-Drug
.	O

NovoSeven	B-Drug
should	O
not	O
be	O
mixed	O
with	O
infusion	O
solutions	O
until	O
clinical	O
data	O
are	O
available	O
to	O
direct	O
this	O
use	O
.	O

Codeine	B-Drug
in	O
combination	O
with	O
other	O
narcotic	O
analgesics	O
,	O
general	O
anesthetics	B-Drug
,	O
phenothiazines	O
,	O
tranquilizers	O
,	O
sedative-hypnotics	O
,	O
or	O
other	O
CNS	O
depressants	O
(	O
including	O
alcohol	B-Drug
)	O
has	O
additive	O
depressant	O
effects	O
.	O

When	O
s.c	O
.	O

combination	O
therapy	O
is	O
contemplated	O
,	O
the	O
dosage	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

Colchicine	B-Drug
is	O
inhibited	O
by	O
acidifying	O
agents	O
.	O

The	O
action	O
of	O
colchicine	B-Drug
is	O
potentiated	O
by	O
alkalinizing	O
agents	O
.	O

Colchicine	B-Drug
may	O
increase	O
sensitivity	O
to	O
the	O
CNS	O
depressants	O
.	O

Response	O
to	O
sympathomimetic	B-Drug
agents	O
may	O
be	O
enhanced	O
by	O
colchicine	B-Drug
.	O

WelChol	B-Drug
has	O
been	O
studied	O
in	O
several	O
human	O
drug	B-Drug
interaction	O
studies	O
in	O
which	O
it	O
was	O
administered	O
with	O
a	O
meal	O
and	O
the	O
test	O
drug	B-Drug
.	O

WelChol	B-Drug
was	O
found	O
to	O
have	O
no	O
significant	O
effect	O
on	O
the	O
bioavailability	O
of	O
digoxin	B-Drug
,	O
lovastatin	B-Drug
,	O
metoprolol	B-Drug
,	O
quinidine	B-Drug
,	O
valproic	B-Drug
acid	I-Drug
,	O
and	O
warfarin	B-Drug
.	O

WelChol	B-Drug
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
sustained-release	O
verapamil	B-Drug
(	O
Calan	B-Drug
SR	I-Drug
)	O
by	O
approximately	O
31	O
%	O
and	O
11	O
%	O
,	O
respectively	O
.	O

Since	O
there	O
is	O
a	O
high	O
degree	O
of	O
variability	O
in	O
the	O
bioavailability	O
of	O
verapamil	B-Drug
,	O
the	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unclear	O
.	O

In	O
clinical	O
studies	O
,	O
coadministration	O
of	O
WelChol	B-Drug
with	O
atorvastatin	B-Drug
,	O
lovastatin	B-Drug
,	O
or	O
simvastatin	B-Drug
did	O
not	O
interfere	O
with	O
the	O
lipid-lowering	O
activity	O
of	O
the	O
HMG-CoA	O
reductase	O
inhibitor	O
.	O

Other	O
drugs	B-Drug
have	O
not	O
been	O
studied	O
.	O

When	O
administering	O
other	O
drugs	B-Drug
for	O
which	O
alterations	O
in	O
blood	O
levels	O
could	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
safety	O
or	O
efficacy	O
,	O
physicians	O
should	O
consider	O
monitoring	O
drug	B-Drug
levels	O
or	O
effects	O
.	O

Since	O
colestipol	B-Drug
hydrochloride	I-Drug
is	O
an	O
anion	O
exchange	O
resin	O
,	O
it	O
may	O
have	O
a	O
strong	O
affinity	O
for	O
anions	O
other	O
than	O
the	O
bile	O
acids	O
.	O

In	O
vitro	O
studies	O
have	O
indicated	O
that	O
colestipol	B-Drug
hydrochloride	I-Drug
binds	O
a	O
number	O
of	O
drugs	B-Drug
.	O

Therefore	O
,	O
COLESTlD	B-Drug
Tablets	O
may	O
delay	O
or	O
reduce	O
the	O
absorption	O
of	O
concomitant	O
oral	O
medication	O
.	O

The	O
interval	O
between	O
the	O
administration	O
of	O
COLESTID	B-Drug
Tablets	O
and	O
any	O
other	O
medication	O
should	O
be	O
as	O
long	O
as	O
possible	O
.	O

Patients	O
should	O
take	O
other	O
drugs	B-Drug
at	O
least	O
one	O
hour	O
before	O
or	O
four	O
hours	O
after	O
COLESTID	B-Drug
Tablets	O
to	O
avoid	O
impeding	O
their	O
absorption	O
.	O

Repeated	O
doses	O
of	O
colestipol	B-Drug
hydrochloride	I-Drug
given	O
prior	O
to	O
a	O
single	O
dose	O
of	O
propranolol	B-Drug
in	O
human	O
trials	O
have	O
been	O
reported	O
to	O
decrease	O
propranolol	B-Drug
absorption	O
.	O

However	O
,	O
in	O
a	O
follow-up	O
study	O
in	O
normal	O
subjects	O
,	O
single-dose	O
administration	O
of	O
colestipol	B-Drug
hydrochloride	I-Drug
and	O
propranolol	B-Drug
and	O
twice-a-day	O
administration	O
for	O
5	O
days	O
of	O
both	O
agents	O
did	O
not	O
affect	O
the	O
extent	O
of	O
propranolol	B-Drug
absorption	O
,	O
but	O
had	O
a	O
small	O
yet	O
statistically	O
significant	O
effect	O
on	O
its	O
rate	O
of	O
absorption	O
;	O
the	O
time	O
to	O
reach	O
maximum	O
concentration	O
was	O
delayed	O
approximately	O
30	O
minutes	O
.	O

Effects	O
on	O
the	O
absorption	O
of	O
other	O
beta-blockers	O
have	O
not	O
been	O
determined	O
.	O

Therefore	O
,	O
patients	O
on	O
propranolol	B-Drug
should	O
be	O
observed	O
when	O
COLESTID	B-Drug
Tablets	O
are	O
either	O
added	O
or	O
deleted	O
from	O
a	O
therapeutic	O
regimen	O
.	O

Studies	O
in	O
humans	O
show	O
that	O
the	O
absorption	O
of	O
chlorothiazide	B-Drug
as	O
reflected	O
in	O
urinary	O
excretion	O
is	O
markedly	O
decreased	O
even	O
when	O
administered	O
one	O
hour	O
before	O
colestipol	B-Drug
hydrochloride	I-Drug
.	O

The	O
absorption	O
of	O
tetracycline	B-Drug
,	O
furosemide	B-Drug
,	O
penicillin	B-Drug
G	I-Drug
,	O
hydrochlorothiazide	B-Drug
,	O
and	O
gemfibrozil	B-Drug
was	O
significantly	O
decreased	O
when	O
given	O
simultaneously	O
with	O
colestipol	B-Drug
hydrochloride	I-Drug
;	O
these	O
drugs	B-Drug
were	O
not	O
tested	O
to	O
determine	O
the	O
effect	O
of	O
administration	O
one	O
hour	O
before	O
colestipol	B-Drug
hydrochloride	I-Drug
.	O

No	O
depressant	O
effect	O
on	O
blood	O
levels	O
in	O
humans	O
was	O
noted	O
when	O
colestipol	B-Drug
hydrochloride	I-Drug
was	O
administered	O
with	O
any	O
of	O
the	O
following	O
drugs	B-Drug
:	O
aspirin	B-Drug
,	O
clindamycin	B-Drug
,	O
clofibrate	B-Drug
,	O
methyldopa	B-Drug
,	O
nicotinic	B-Drug
acid	I-Drug
(	O
niacin	B-Drug
)	O
,	O
tolbutamide	B-Drug
,	O
phenytoin	B-Drug
or	O
warfarin	B-Drug
.	O

Particular	O
caution	O
should	O
be	O
observed	O
with	O
digitalis	B-Drug
preparations	O
since	O
there	O
are	O
conflicting	O
results	O
for	O
the	O
effect	O
of	O
colestipol	B-Drug
hydrochloride	I-Drug
on	O
the	O
availability	O
of	O
digoxin	B-Drug
and	O
digitoxin	B-Drug
.	O

The	O
potential	O
for	O
binding	O
of	O
these	O
drugs	B-Drug
if	O
given	O
concomitantly	O
is	O
present	O
.	O

Discontinuing	O
colestipol	B-Drug
hydrochloride	I-Drug
could	O
pose	O
a	O
hazard	O
to	O
health	O
if	O
a	O
potentially	O
toxic	O
drug	B-Drug
that	O
is	O
significantly	O
bound	O
to	O
the	O
resin	O
has	O
been	O
titrated	O
to	O
a	O
maintenance	O
level	O
while	O
the	O
patient	O
was	O
taking	O
colestipol	B-Drug
hydrochloride	I-Drug
.	O

Bile	O
acid	O
binding	O
resins	O
may	O
also	O
interfere	O
with	O
the	O
absorption	O
of	O
oral	O
phosphate	B-Drug
supplements	O
and	O
hydrocortisone	B-Drug
.	O

Certain	O
other	O
antibiotics	B-Drug
(	O
aminoglycosides	O
and	O
polymyxin	O
)	O
have	O
also	O
been	O
reported	O
to	O
interfere	O
with	O
the	O
nerve	O
transmission	O
at	O
the	O
neuromuscular	O
junction	O
.	O

Based	O
on	O
this	O
reported	O
activity	O
,	O
they	O
should	O
not	O
be	O
given	O
concomitantly	O
with	O
Coly-Mycin	B-Drug
M	B-Drug
Parenteral	O
except	O
with	O
the	O
greatest	O
caution	O
.	O

Curariform	B-Drug
muscle	I-Drug
relaxants	I-Drug
(	O
eg	O
,	O
tubocurarine	B-Drug
)	O
and	O
other	O
drugs	B-Drug
,	O
including	O
ether	O
,	O
succinylcholine	B-Drug
,	O
gallamine	B-Drug
,	O
decamethonium	B-Drug
and	O
sodium	B-Drug
citrate	I-Drug
,	O
potentiate	O
the	O
neuromuscular	O
blocking	O
effect	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
Coly-Mycin	B-Drug
M	B-Drug
Parenteral	O
.	O

Sodium	B-Drug
cephalothin	I-Drug
may	O
enhance	O
the	O
nephrotoxicity	O
of	O
Coly-Mycin	B-Drug
M	B-Drug
Parenteral	O
.	O

The	O
concomitant	O
use	O
of	O
sodium	B-Drug
cephalothin	I-Drug
and	O
Coly-Mycin	B-Drug
M	B-Drug
Parenteral	O
should	O
be	O
avoided	O
.	O

Digoxin	B-Drug
:	O
Coadministration	O
of	O
digoxin	B-Drug
,	O
a	O
P-glycoprotein	O
substrate	O
,	O
with	O
oral	O
conivaptan	B-Drug
resulted	O
in	O
a	O
reduction	O
in	O
clearance	O
and	O
an	O
increase	O
in	O
digoxin	B-Drug
Cmax	O
and	O
AUC	O
values	O
.	O

Therefore	O
,	O
if	O
digoxin	B-Drug
is	O
administered	O
with	O
VAPRISOL	B-Drug
,	O
the	O
clinician	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
increases	O
in	O
digoxin	B-Drug
levels	O
.	O

DRUG/LABORATORY	O
TEST	O
INTERACTIONS	O
1	O
.	O

Accelerated	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
and	O
platelet	O
aggregation	O
time	O
;	O
increased	O
platelet	O
count	O
;	O
increased	O
factors	O
II	O
,	O
VII	O
antigen	O
,	O
VIII	O
antigen	O
,	O
VIII	O
coagulant	O
activity	O
,	O
IX	O
,	O
X	O
,	O
XII	O
,	O
VII-X	O
complex	O
,	O
II-VII-X	O
complex	O
,	O
and	O
beta-thromboglobulin	O
;	O
decreased	O
levels	O
of	O
anti-factor	O
Xa	O
and	O
antithrombin	B-Drug
III	I-Drug
,	O
decreased	O
antithrombin	B-Drug
III	I-Drug
activity	O
;	O
increased	O
levels	O
of	O
fibrinogen	B-Drug
and	O
fibrinogen	B-Drug
activity	O
;	O
increased	O
plasminogen	O
antigen	O
and	O
activity	O
.	O

2	O
.	O

Increased	O
thyroid-binding	O
globulin	O
(	O
TBG	O
)	O
levels	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	B-Drug
hormone	O
levels	O
as	O
measured	O
by	O
protein-bound	O
iodine	B-Drug
(	O
PBI	O
)	O
,	O
T4	B-Drug
levels	O
(	O
by	O
column	O
or	O
by	O
radioimmunoassay	O
)	O
or	O
T3	B-Drug
levels	O
by	O
radioimmunoassay	O
.	O

T3	B-Drug
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
.	O

Free	O
T4	B-Drug
and	O
free	O
T3	B-Drug
concentrations	O
are	O
unaltered	O
.	O

Patients	O
on	O
thyroid	B-Drug
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	B-Drug
hormone	O
.	O

3	O
.	O

Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
,	O
(	O
i.e.	O
,	O
corticosteroid	B-Drug
binding	O
globulin	O
(	O
CBG	O
)	O
,	O
sex	O
hormone	O
binding	O
globulin	O
(	O
SHBG	O
)	O
)	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	O
and	O
sex	O
steroids	O
,	O
respectively	O
.	O

Free	O
hormone	O
concentrations	O
may	O
be	O
decreased	O
.	O

Other	O
plasma	O
proteins	O
may	O
be	O
increased	O
(	O
angiotensinogen/renin	O
substrate	O
,	O
alpha-1-antitrypsin	O
,	O
ceruloplasmin	O
)	O
.	O

4	O
.	O

Increased	O
plasma	O
HDL	O
and	O
HDL2	O
cholesterol	O
subfraction	O
concentrations	O
,	O
reduced	O
LDL	O
cholesterol	O
concentration	O
,	O
increased	O
triglyceride	O
levels	O
.	O

5	O
.	O

Impaired	O
glucose	B-Drug
tolerance	O
.	O

6	O
.	O

Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O

Corticotropin	B-Drug
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	B-Drug
therapy	O
.	O

The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O

Drugs	B-Drug
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
and	O
rifampin	B-Drug
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	O
and	O
may	O
require	O
increases	O
in	O
corticosteroid	B-Drug
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Drugs	B-Drug
such	O
as	O
troleandomycin	B-Drug
and	O
ketoconazole	B-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
corticosteroids	O
and	O
thus	O
decrease	O
their	O
clearance	O
.	O

Therefore	O
,	O
the	O
dose	O
of	O
corticosteroid	B-Drug
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O

Corticosteroids	O
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	B-Drug
.	O

This	O
could	O
lead	B-Drug
to	O
decreased	O
salicylate	B-Drug
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	B-Drug
toxicity	O
when	O
corticosteroid	B-Drug
is	O
withdrawn	O
.	O

Aspirin	B-Drug
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
cortico-steroids	O
in	O
patients	O
suffering	O
from	O
hypopro-thrombinemia	O
.	O

The	O
effect	O
of	O
corticosteroids	O
on	O
oral	O
anticoagulants	B-Drug
is	O
variable	O
.	O

There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulants	B-Drug
when	O
given	O
concurrently	O
with	O
corticosteroids	O
.	O

Therefore	O
,	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	B-Drug
effect	O
.	O

Corticotropin	B-Drug
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	B-Drug
therapy	O
.	O

Drug	B-Drug
Interaction	O
During	O
Pregnancy	O
:	O
Cromolyn	B-Drug
sodium	I-Drug
and	O
isoproterenol	B-Drug
were	O
studied	O
following	O
subcutaneous	O
injections	O
in	O
pregnant	O
mice	O
.	O

Cromolyn	B-Drug
sodium	I-Drug
alone	O
in	O
doses	O
up	O
to	O
540	O
mg/kg/day	O
(	O
approximately	O
340	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg/m2	O
basis	O
)	O
did	O
not	O
cause	O
significant	O
increases	O
in	O
resorptions	O
or	O
major	O
malformations	O
.	O

Isoproterenol	B-Drug
alone	O
at	O
a	O
dose	O
of	O
2.7	O
mg/kg/day	O
(	O
approximately	O
7	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg/m2	O
basis	O
)	O
increased	O
both	O
resorptions	O
and	O
malformations	O
.	O

The	O
addition	O
of	O
540	O
mg/kg/day	O
of	O
cromolyn	B-Drug
sodium	I-Drug
(	O
approximately	O
340	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg/m2	O
basis	O
)	O
to	O
2.7	O
mg/kg/day	O
of	O
isoproterenol	B-Drug
(	O
approximately	O
7	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg/m2	O
basis	O
)	O
appears	O
to	O
have	O
increased	O
the	O
incidence	O
of	O
both	O
resorptions	O
and	O
malformations	O
.	O

None	O
known	O
.	O

Persons	O
taking	O
most	O
antibiotics	B-Drug
,	O
methotrexate	B-Drug
and	O
pyrimethamine	B-Drug
invalidate	O
folic	B-Drug
acid	I-Drug
and	O
vitamin	B-Drug
B12	I-Drug
diagnostic	O
blood	O
assays	O
.	O

Colchicine	B-Drug
para-aminosalicylic	B-Drug
acid	I-Drug
and	O
heavy	O
alcohol	B-Drug
intake	O
for	O
longer	O
than	O
2	O
weeks	O
may	O
produce	O
malabsorption	O
of	O
vitamin	B-Drug
B12	I-Drug
.	O

FLEXERIL	B-Drug
may	O
have	O
life-threatening	O
interactions	O
with	O
MAO	O
inhibitors	O
.	O

FLEXERIL	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
and	O
other	O
CNS	O
depressants	O
.	O

Tricyclic	O
antidepressants	B-Drug
may	O
block	O
the	O
antihypertensive	B-Drug
action	O
of	O
guanethidine	B-Drug
and	O
similarly	O
acting	O
compounds	O
.	O

Tricyclic	O
antidepressants	B-Drug
may	O
enhance	O
the	O
seizure	O
risk	O
in	O
patients	O
taking	O
tramadol	B-Drug
.	O

Cyclopentolate	B-Drug
may	O
interfere	O
with	O
the	O
anti-glaucoma	O
action	O
of	O
carbachol	B-Drug
or	O
pilocarpine	B-Drug
;	O
also	O
,	O
concurrent	O
use	O
of	O
this	O
medication	O
may	O
antagonise	O
the	O
anti-glaucoma	O
and	O
miotic	O
actions	O
of	O
ophthalmic	O
cholinesterase	O
inhibitors	O
.	O

The	O
rate	O
of	O
metabolism	O
and	O
the	O
leukopenic	O
activity	O
of	O
cyclophosphamide	B-Drug
reportedly	O
are	O
increased	O
by	O
chronic	O
administration	O
of	O
high	O
doses	O
of	O
phenobarbital	B-Drug
.	O

The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	B-Drug
actions	O
,	O
desirable	O
or	O
undesirable	O
,	O
involving	O
cyclophosphamide	B-Drug
even	O
though	O
cyclophosphamide	B-Drug
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	B-Drug
,	O
including	O
other	O
cytotoxic	O
drugs	B-Drug
.	O

Cyclophosphamide	B-Drug
treatment	O
,	O
which	O
causes	O
a	O
marked	O
and	O
persistent	O
inhibition	O
of	O
cholinesterase	O
activity	O
,	O
potentiates	O
the	O
effect	O
of	O
succinylcholine	B-Drug
chloride	I-Drug
.	O

If	O
a	O
patient	O
has	O
been	O
treated	O
with	O
cyclophosphamide	B-Drug
within	O
10	O
days	O
of	O
general	O
anesthesia	B-Drug
,	O
the	O
anesthesiologist	O
should	O
be	O
alerted	O
.	O

May	O
interact	O
with	O
wthionamide	O
(	O
Trecator-SC	B-Drug
)	O
and	O
isoniazid	B-Drug
(	O
Nydrazid	B-Drug
)	O
.	O

MAO	O
inhibitors	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
effects	O
of	O
antihistamines	B-Drug
.	O

Antihistamines	B-Drug
may	O
have	O
additive	O
effects	O
with	O
alcohol	B-Drug
and	O
other	O
CNS	O
depressants	O
,	O
e.g.	O
,	O
hypnotics	O
,	O
sedatives	O
,	O
tranquilizers	O
,	O
antianxiety	O
agents	O
.	O

No	O
drug	B-Drug
interactions	O
have	O
been	O
reported	O
.	O

Steady	O
state	O
plasma	O
digitoxin	B-Drug
concentrations	O
did	O
not	O
appear	O
to	O
change	O
.	O

Therefore	O
,	O
monitoring	O
of	O
plasma	O
digoxin	B-Drug
levels	O
may	O
be	O
indicated	O
in	O
patients	O
receiving	O
similar	O
combination	O
chemotherapy	O
regimens	O
.	O

The	O
utilization	O
of	O
digitoxin	B-Drug
for	O
such	O
patients	O
may	O
be	O
considered	O
as	O
an	O
alternative	O
.	O

Also	O
flucytosine	B-Drug
.	O

Drug/LaboratoryTest	O
Interactions	O
Dactinomycin	B-Drug
may	O
interfere	O
with	O
bioassay	O
procedures	O
for	O
the	O
determination	O
of	O
antibacterial	O
drug	B-Drug
levels	O
.	O

Dantrium	B-Drug
is	O
metabolized	O
by	O
the	O
liver	O
,	O
and	O
it	O
is	O
theoretically	O
possible	O
that	O
its	O
metabolism	O
may	O
be	O
enhanced	O
by	O
drugs	B-Drug
known	O
to	O
induce	O
hepatic	O
microsomal	O
enzymes	O
.	O

However	O
,	O
neither	O
phenobarbital	B-Drug
nor	O
diazepam	B-Drug
appears	O
to	O
affect	O
Dantrium	B-Drug
metabolism	O
.	O

Binding	O
to	O
plasma	O
protein	O
is	O
not	O
significantly	O
altered	O
by	O
diazepam	B-Drug
,	O
diphenylhydantoin	B-Drug
,	O
or	O
phenylbutazone	B-Drug
.	O

Binding	O
to	O
plasma	O
proteins	O
is	O
reduced	O
by	O
warfarin	B-Drug
and	O
clotibrate	O
and	O
increased	O
by	O
tolbutamide	B-Drug
.	O

Cardiovascular	O
collapse	O
in	O
patients	O
treated	O
simultaneously	O
with	O
varapamil	O
and	O
dantrolene	B-Drug
sodium	I-Drug
is	O
rare	O
.	O

The	O
combination	O
of	O
therapeutic	O
doses	O
of	O
intravenous	O
dantrolene	B-Drug
sodium	I-Drug
and	O
verapamil	B-Drug
in	O
halothane	B-Drug
a-chloralose	O
anesthetized	O
swine	O
has	O
resulted	O
in	O
ventricular	O
fibrillation	O
and	O
cardiovascular	O
collapse	O
in	O
association	O
with	O
marked	O
hyperkalemia	O
.	O

It	O
is	O
recommended	O
that	O
the	O
combination	O
of	O
intravenous	O
dantrolene	B-Drug
sodium	I-Drug
and	O
calcium	B-Drug
channel	O
blockers	O
,	O
such	O
as	O
verapamil	B-Drug
,	O
not	O
be	O
used	O
together	O
during	O
the	O
management	O
of	O
malignant	O
hyperthermia	O
crisis	O
until	O
the	O
relevance	O
of	O
these	O
findings	O
to	O
humans	O
is	O
established	O
.	O

Administration	O
of	O
dantrolene	B-Drug
may	O
potentiate	O
vecuronium-induced	B-Drug
neuromuscular	O
block	O
.	O

A	O
drug-drug	O
interaction	O
study	O
evaluated	O
the	O
effect	O
of	O
the	O
use	O
of	O
ACZONE	B-Drug
Gel	O
,	O
5	O
%	O
,	O
in	O
combination	O
with	O
double	O
strength	O
(	O
160	O
mg/800	O
mg	O
)	O
trimethoprim/sulfamethoxazole	B-Drug
(	O
TMP/SMX	B-Drug
)	O
.	O

During	O
co-administration	O
,	O
systemic	O
levels	O
of	O
TMP	B-Drug
and	O
SMX	B-Drug
were	O
essentially	O
unchanged	O
.	O

Notably	O
,	O
systemic	O
exposure	O
(	O
AUC0-12	O
)	O
of	O
dapsone	B-Drug
hydroxylamine	I-Drug
(	O
DHA	B-Drug
)	O
was	O
more	O
than	O
doubled	O
in	O
the	O
presence	O
of	O
TMP/SMX	B-Drug
.	O

Exposure	O
from	O
the	O
proposed	O
topical	O
dose	O
is	O
about	O
1	O
%	O
of	O
that	O
from	O
the	O
100	O
mg	O
oral	O
dose	O
,	O
even	O
when	O
co-administered	O
with	O
TMP/SMX	B-Drug
.	O

Certain	O
concomitant	O
medications	O
(	O
such	O
as	O
rifampin	B-Drug
,	O
anticonvulsants	O
,	O
St	O
.	O

John	O
s	O
wort	O
)	O
may	O
increase	O
the	O
formation	O
of	O
dapsone	B-Drug
hydroxylamine	I-Drug
,	O
a	O
metabolite	O
of	O
dapsone	B-Drug
associated	O
with	O
hemolysis	O
.	O

With	O
oral	O
dapsone	B-Drug
treatment	O
,	O
folic	O
acid	O
antagonists	O
such	O
as	O
pyrimethamine	B-Drug
have	O
been	O
noted	O
to	O
possibly	O
increase	O
the	O
likelihood	O
of	O
hematologic	O
reactions	O
.	O

Warfarin	B-Drug
:	O
Concomitant	O
administration	O
of	O
daptomycin	B-Drug
(	O
6	O
mg/kg	O
once	O
every	O
24	O
hours	O
for	O
5	O
days	O
)	O
and	O
warfarin	B-Drug
(	O
25	O
mg	O
single	O
oral	O
dose	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
drug	B-Drug
,	O
and	O
the	O
INR	O
was	O
not	O
significantly	O
altered	O
.	O

HMG-CoA	O
Reductase	O
Inhibitors	O
:	O
Inhibitors	O
of	O
HMG-CoA	O
reductase	O
may	O
cause	O
myopathy	O
,	O
which	O
is	O
manifested	O
as	O
muscle	O
pain	O
or	O
weakness	O
associated	O
with	O
elevated	O
levels	O
of	O
CPK	O
.	O

There	O
were	O
no	O
reports	O
of	O
skeletal	O
myopathy	O
in	O
a	O
placebo-controlled	O
Phase	O
I	O
trial	O
in	O
which	O
10	O
healthy	O
subjects	O
on	O
stable	O
simvastatin	B-Drug
therapy	O
were	O
treated	O
concurrently	O
with	O
daptomycin	B-Drug
(	O
4	O
mg/kg	O
once	O
every	O
24	O
hours	O
)	O
for	O
14	O
days	O
.	O

Experience	O
with	O
co-administration	O
of	O
HMG-CoA	O
reductase	O
inhibitors	O
and	O
Fentanyl	B-Drug
in	O
patients	O
is	O
limited	O
,	O
therefore	O
,	O
consideration	O
should	O
be	O
given	O
to	O
temporarily	O
suspending	O
use	O
of	O
HMG-CoA	O
reductase	O
inhibitors	O
in	O
patients	O
receiving	O
Fentanyl	B-Drug
.	O

Drug-Laboratory	O
Test	O
Interactions	O
:	O
There	O
are	O
no	O
reported	O
drug-laboratory	O
test	O
interactions	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
of	O
Aranesp	B-Drug
have	O
been	O
performed	O
.	O

The	O
daily	O
dose	O
of	O
ENABLEX	B-Drug
should	O
not	O
exceed	O
7.5	O
mg	O
when	O
coadministered	O
with	O
potent	O
CYP3A4	B-Drug
inhibitors	O
(	O
e.g.	O
,	O
ketoconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
ritonavir	B-Drug
,	O
nelfinavir	B-Drug
,	O
clarithromycin	B-Drug
and	O
nefazadone	B-Drug
)	O
.	O

Caution	O
should	O
be	O
taken	O
when	O
ENABLEX	B-Drug
is	O
used	O
concomitantly	O
with	O
medications	O
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2D6	B-Drug
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
window	O
,	O
such	O
as	O
flecainide	B-Drug
,	O
thioridazine	B-Drug
and	O
tricyclic	O
antidepressants	B-Drug
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
)	O
.	O

The	O
concomitant	O
use	O
of	O
ENABLEX	B-Drug
with	O
other	O
anticholinergic	B-Drug
agents	O
may	O
increase	O
the	O
frequency	O
and/or	O
severity	O
of	O
dry	O
mouth	O
,	O
constipation	O
,	O
blurred	O
vision	O
and	O
other	O
anticholinergic	B-Drug
pharmacological	O
effects	O
.	O

Anticholinergic	B-Drug
agents	O
may	O
potentially	O
alter	O
the	O
absorption	O
of	O
some	O
concomitantly	O
administered	O
drugs	B-Drug
due	O
to	O
effects	O
on	O
gastrointestinal	O
motility	O
.	O

Drug	B-Drug
Laboratory	O
Test	O
Interactions	O
Interactions	O
between	O
darifenacin	B-Drug
and	O
laboratory	O
tests	O
have	O
not	O
been	O
studied	O
.	O

Drugs	B-Drug
that	O
may	O
increase	O
dasatinib	B-Drug
plasma	O
concentrations	O
CYP3A4	B-Drug
Inhibitors	O
:	O
Dasatinib	B-Drug
is	O
a	O
CYP3A4	B-Drug
substrate	O
.	O

Concomitant	O
use	O
of	O
SPRYCEL	B-Drug
and	O
drugs	B-Drug
that	O
inhibit	O
CYP3A4	B-Drug
(	O
eg	O
,	O
ketoconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
erythromycin	B-Drug
,	O
clarithromycin	B-Drug
,	O
ritonavir	B-Drug
,	O
atazanavir	B-Drug
,	O
indinavir	B-Drug
,	O
nefazodone	B-Drug
,	O
nelfinavir	B-Drug
,	O
saquinavir	B-Drug
,	O
telithromycin	B-Drug
)	O
may	O
increase	O
exposure	O
to	O
dasatinib	B-Drug
and	O
should	O
be	O
avoided	O
.	O

In	O
patients	O
receiving	O
treatment	O
with	O
SPRYCEL	B-Drug
,	O
close	O
monitoring	O
for	O
toxicity	O
and	O
a	O
SPRYCEL	B-Drug
dose	O
reduction	O
should	O
be	O
considered	O
if	O
systemic	O
administration	O
of	O
a	O
potent	O
CYP3A4	B-Drug
inhibitor	O
can	O
not	O
be	O
avoided	O
.	O

Drugs	B-Drug
that	O
may	O
decrease	O
dasatinib	B-Drug
plasma	O
concentrations	O
CYP3A4	B-Drug
Inducers	O
:	O
Drugs	B-Drug
that	O
induce	O
CYP3A4	B-Drug
activity	O
may	O
decrease	O
dasatinib	B-Drug
plasma	O
concentrations	O
.	O

In	O
patients	O
in	O
whom	O
CYP3A4	B-Drug
inducers	O
(	O
eg	O
,	O
dexamethasone	B-Drug
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
rifampicin	B-Drug
,	O
phenobarbital	B-Drug
)	O
are	O
indicated	O
,	O
alternative	O
agents	O
with	O
less	O
enzyme	O
induction	O
potential	O
should	O
be	O
used	O
.	O

If	O
SPRYCEL	B-Drug
must	O
be	O
administered	O
with	O
a	O
CYP3A4	B-Drug
inducer	O
,	O
a	O
dose	O
increase	O
in	O
SPRYCEL	B-Drug
should	O
be	O
considered	O
.	O

St.	O
Johns	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
may	O
decrease	O
SPRYCEL	B-Drug
plasma	O
concentrations	O
unpredictably	O
.	O

Patients	O
receiving	O
SPRYCEL	B-Drug
should	O
not	O
take	O
St.	O
Johns	O
wort	O
.	O

Antacids	O
:	O
Nonclinical	O
data	O
demonstrate	O
that	O
the	O
solubility	O
of	O
dasatinib	B-Drug
is	O
pH	O
dependent	O
.	O

Simultaneous	O
administration	O
of	O
SPRYCEL	B-Drug
with	O
antacids	O
should	O
be	O
avoided	O
.	O

If	O
antacid	O
therapy	O
is	O
needed	O
,	O
the	O
antacid	O
dose	O
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
prior	O
to	O
or	O
2	O
hours	O
after	O
the	O
dose	O
of	O
SPRYCEL	B-Drug
.	O

H2	O
Blockers/Proton	O
Pump	O
Inhibitors	O
:	O
Long-term	O
suppression	O
of	O
gastric	O
acid	O
secretion	O
by	O
H2	O
blockers	O
or	O
proton	O
pump	O
inhibitors	O
(	O
eg	O
,	O
famotidine	B-Drug
and	O
omeprazole	B-Drug
)	O
is	O
likely	O
to	O
reduce	O
dasatinib	B-Drug
exposure	O
.	O

The	O
concomitant	O
use	O
of	O
H2	O
blockers	O
or	O
proton	O
pump	O
inhibitors	O
with	O
SPRYCEL	B-Drug
is	O
not	O
recommended	O
.	O

The	O
use	O
of	O
antacids	O
should	O
be	O
considered	O
in	O
place	O
of	O
H2	O
blockers	O
or	O
proton	O
pump	O
inhibitors	O
in	O
patients	O
receiving	O
SPRYCEL	B-Drug
therapy	O
.	O

Drugs	B-Drug
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
dasatinib	B-Drug
CYP3A4	B-Drug
Substrates	O
:	O
Dasatinib	B-Drug
is	O
a	O
time-dependent	O
inhibitor	O
of	O
CYP3A4	B-Drug
.	O

Therefore	O
,	O
CYP3A4	B-Drug
substrates	O
known	O
to	O
have	O
a	O
narrow	O
therapeutic	O
index	O
such	O
as	O
alfentanil	B-Drug
,	O
astemizole	B-Drug
,	O
terfenadine	B-Drug
,	O
cisapride	B-Drug
,	O
cyclosporine	B-Drug
,	O
fentanyl	B-Drug
,	O
pimozide	B-Drug
,	O
quinidine	B-Drug
,	O
sirolimus	B-Drug
,	O
tacrolimus	B-Drug
,	O
or	O
ergot	B-Drug
alkaloids	O
(	O
ergotamine	B-Drug
,	O
dihydroergotamine	B-Drug
)	O
should	O
be	O
administered	O
with	O
caution	O
in	O
patients	O
receiving	O
SPRYCEL	B-Drug
.	O

Hepatic	O
Impairment	O
There	O
are	O
currently	O
no	O
clinical	O
studies	O
with	O
SPRYCEL	B-Drug
in	O
patients	O
with	O
impaired	O
liver	O
function	O
(	O
clinical	O
studies	O
have	O
excluded	O
patients	O
with	O
ALT	O
and/or	O
AST	O
2.5	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
and/or	O
total	O
bilirubin	O
2	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
)	O
.	O

Metabolism	O
of	O
dasatinib	B-Drug
is	O
mainly	O
hepatic	O
.	O

Caution	O
is	O
recommended	O
in	O
patients	O
with	O
hepatic	O
impairment	O
.	O

Renal	O
Impairment	O
There	O
are	O
currently	O
no	O
clinical	O
studies	O
with	O
SPRYCEL	B-Drug
in	O
patients	O
with	O
impaired	O
renal	O
function	O
(	O
clinical	O
studies	O
have	O
excluded	O
patients	O
with	O
serum	O
creatinine	O
concentration	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
)	O
.	O

Dasatinib	B-Drug
and	O
its	O
metabolites	O
are	O
minimally	O
excreted	O
via	O
the	O
kidney	O
.	O

Since	O
the	O
renal	O
excretion	O
of	O
unchanged	O
dasatinib	B-Drug
and	O
its	O
metabolites	O
is	O
4	O
%	O
,	O
a	O
decrease	O
in	O
total	O
body	O
clearance	O
is	O
not	O
expected	O
in	O
patients	O
with	O
renal	O
insufficiency	O
.	O

Use	O
of	O
Cerubidine	B-Drug
in	O
a	O
patient	O
who	O
has	O
previously	O
received	O
doxorubicin	B-Drug
increases	O
the	O
risk	O
of	O
cardiotoxicity	O
.	O

Cerubidine	B-Drug
should	O
not	O
be	O
used	O
in	O
patients	O
who	O
have	O
previously	O
received	O
the	O
recommended	O
maximum	O
cumulative	O
doses	O
of	O
doxorubicin	B-Drug
or	O
Cerubidine	B-Drug
.	O

Cyclophosphamide	B-Drug
used	O
concurrently	O
with	O
Cerubidine	B-Drug
may	O
also	O
result	O
in	O
increased	O
cardiotoxicity	O
.	O

Dosage	O
reduction	O
of	O
Cerubidine	B-Drug
may	O
be	O
required	O
when	O
used	O
concurrently	O
with	O
other	O
myelosuppressive	O
agents	O
.	O

Hepatotoxic	O
medications	O
,	O
such	O
as	O
high-dose	O
methotrexate	B-Drug
,	O
may	O
impair	O
liver	O
function	O
and	O
increase	O
the	O
risk	O
of	O
toxicity	O
.	O

Potentially	O
fatal	O
drug	B-Drug
interactions	O
may	O
occur	O
when	O
coadministered	O
with	O
digoxin	B-Drug
,	O
as	O
this	O
may	O
enhance	O
cardiovascular	O
depression	O
and	O
bradyarrhythmias	O
may	O
occur	O
.	O

Anticholinesterases	O
(	O
neostgmine	O
,	O
physostigmine	B-Drug
)	O
,	O
lignocaine	B-Drug
,	O
quinine	B-Drug
,	O
procainamide	B-Drug
can	O
enhance	O
toxicity	O
and	O
cause	O
cardio	O
respiratory	O
depression	O
.	O

In	O
addition	O
,	O
neuromuscular	O
blocking	O
action	O
is	O
enhanced	O
by	O
general	O
anesthetics	B-Drug
,	O
local	O
anesthetics	B-Drug
like	O
lidocaine	B-Drug
,	O
procaine	B-Drug
,	O
beta-blockers	O
,	O
metaclopramide	B-Drug
,	O
lithium	B-Drug
carbonate	I-Drug
,	O
and	O
terbutaline	B-Drug
.	O

Drug	B-Drug
interaction	O
studies	O
with	O
decitabine	B-Drug
have	O
not	O
been	O
conducted	O
.	O

In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
suggest	O
that	O
decitabine	B-Drug
is	O
unlikely	O
to	O
inhibit	O
or	O
induce	O
cytochrome	O
P450	O
enzymes	O
.	O

In	O
vitro	O
metabolism	O
studies	O
have	O
suggested	O
that	O
decitabine	B-Drug
is	O
not	O
a	O
substrate	O
for	O
the	O
human	O
liver	O
cytochrome	O
P450	O
enzymes	O
.	O

As	O
plasma	O
protein	O
binding	O
of	O
decitabine	B-Drug
is	O
negligible	O
(	O
1	O
%	O
)	O
,	O
interactions	O
due	O
to	O
displacement	O
of	O
more	O
highly	O
protein	O
bound	O
drugs	B-Drug
from	O
plasma	O
proteins	O
are	O
not	O
expected	O
.	O

The	O
concomitant	O
administration	O
of	O
Exjade	B-Drug
and	O
aluminum-containing	B-Drug
antacid	O
preparations	O
has	O
not	O
been	O
formally	O
studied	O
.	O

Although	O
deferasirox	B-Drug
has	O
a	O
lower	O
affinity	O
for	O
aluminum	B-Drug
than	O
for	O
iron	B-Drug
,	O
Exjade	B-Drug
should	O
not	O
be	O
taken	O
with	O
aluminum-containing	B-Drug
antacid	O
preparations	O
.	O

In	O
healthy	O
volunteers	O
,	O
Exjade	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O

The	O
effect	O
of	O
digoxin	B-Drug
on	O
Exjade	B-Drug
pharmacokinetics	O
has	O
not	O
been	O
studied	O
.	O

The	O
concomitant	O
administration	O
of	O
Exjade	B-Drug
and	O
vitamin	B-Drug
C	I-Drug
has	O
not	O
been	O
formally	O
studied	O
.	O

Doses	O
of	O
vitamin	B-Drug
C	I-Drug
up	O
to	O
200	O
mg	O
were	O
allowed	O
in	O
clinical	O
studies	O
without	O
negative	O
consequences	O
.	O

The	O
interaction	O
of	O
Exjade	B-Drug
with	O
hydroxyurea	B-Drug
has	O
not	O
been	O
formally	O
studied	O
.	O

No	O
inhibition	O
of	O
deferasirox	B-Drug
metabolism	O
by	O
hydroxyurea	B-Drug
is	O
expected	O
based	O
on	O
the	O
results	O
of	O
an	O
in	O
vitro	O
study	O
.	O

Exjade	B-Drug
should	O
not	O
be	O
combined	O
with	O
other	O
iron	B-Drug
chelator	O
therapies	O
,	O
as	O
safety	O
of	O
such	O
combinations	O
has	O
not	O
been	O
established	O
.	O

Drug/Food	O
Interactions	O
The	O
bioavailability	O
(	O
AUC	O
)	O
of	O
deferasirox	B-Drug
was	O
variably	O
increased	O
when	O
taken	O
with	O
a	O
meal	O
.	O

Deferasirox	B-Drug
should	O
be	O
taken	O
on	O
an	O
empty	O
stomach	O
30	O
minutes	O
before	O
eating	O
.	O

Exjade	B-Drug
tablets	O
for	O
oral	O
suspension	O
can	O
be	O
dispersed	O
in	O
water	O
,	O
orange	O
juice	O
,	O
or	O
apple	O
juice	O
.	O

Antiacid	O
,	O
clarithromycin	B-Drug
,	O
Didanosine	B-Drug
,	O
Fluconazole	B-Drug
,	O
Fluoxetine	B-Drug
,	O
Indanavir	O
,	O
Ketoconazole	B-Drug
,	O
Phenytoin	B-Drug
,	O
Phenobarbitol	O
,	O
carbamazepine	B-Drug
,	O
Rifabutin	B-Drug
,	O
Rifampin	B-Drug
,	O
Ritanovir	O
,	O
Saquinavir	B-Drug
.	O

Possible	O
drug	B-Drug
interactions	O
of	O
HUMORSOL	B-Drug
with	O
succinylcholine	B-Drug
or	O
with	O
other	O
anticholinesterase	O
agents	O
.	O

Because	O
the	O
tetracyclines	O
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	B-Drug
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B-Drug
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	B-Drug
,	O
such	O
as	O
the	O
tetracycline	B-Drug
class	O
of	O
antibiotics	B-Drug
,	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillins	B-Drug
,	O
it	O
is	O
not	O
advisable	O
to	O
administer	O
these	O
drugs	B-Drug
concomitantly	O
.	O

Concurrent	O
use	O
of	O
tetracyclines	O
with	O
oral	O
contraceptives	O
may	O
render	O
oral	O
contraceptives	O
less	O
effective	O
.	O

Breakthrough	O
bleeding	O
has	O
been	O
reported	O
No	O
clinical	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

However	O
,	O
in	O
a	O
single	O
in	O
vivo	O
rodent	O
study	O
denileukin	B-Drug
diftitox	I-Drug
had	O
no	O
effect	O
on	O
P450	O
levels	O
.	O

Taking	O
a	O
rauwolfia	O
alkaloid	O
while	O
you	O
are	O
taking	O
or	O
within	O
2	O
weeks	O
of	O
taking	O
MAO	O
inhibitors	O
may	O
increase	O
the	O
risk	O
of	O
central	O
nervous	O
system	O
depression	O
or	O
may	O
cause	O
a	O
severe	O
high	O
blood	O
pressure	O
reaction	O
.	O

No	O
clinically	O
significant	O
adverse	O
interactions	O
with	O
commonly	O
used	O
preanesthetic	O
drugs	B-Drug
,	O
or	O
drugs	B-Drug
used	O
during	O
anesthesia	B-Drug
(	O
muscle	O
relaxants	O
,	O
intravenous	O
agents	O
,	O
and	O
local	O
anesthetic	B-Drug
agents	O
)	O
were	O
reported	O
in	O
clinical	O
trials	O
.	O

The	O
effect	O
of	O
desflurane	B-Drug
on	O
the	O
disposition	O
of	O
other	O
drugs	B-Drug
has	O
not	O
been	O
determined	O
.	O

Like	O
isoflurane	B-Drug
,	O
desflurane	B-Drug
does	O
not	O
predispose	O
to	O
premature	O
ventricular	O
arrhythmias	O
in	O
the	O
presence	O
of	O
exogenously	O
infused	O
epinephrine	B-Drug
in	O
swine	O
.	O

1	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
P450	O
2D6	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	B-Drug
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	B-Drug
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7	O
to	O
10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
traction	O
of	O
drug	B-Drug
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-Drug
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O

metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	O
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	B-Drug
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	B-Drug
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B-Drug
,	O
phenothiazines	O
,	O
and	O
the	O
Type	O
1C	O
antiarrhythrnics	O
propatenone	O
and	O
flecainide	B-Drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
seriraline	O
,	O
and	O
paroxetine	B-Drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI-TCA	O
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	O
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co-administration	O
of	O
T.A	O
.	O

with	O
any	O
of	O
the	O
SSRIs	O
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
,	O
given	O
the	O
long	O
half-life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	O
antidepressants	B-Drug
with	O
drugs	B-Drug
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	O
antidepressant	O
or	O
the	O
other	O
drug	B-Drug
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	B-Drug
is	O
withdrawn	O
from	O
co-therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	O
antidepressant	O
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	O
plasma	O
levels	O
whenever	O
a	O
TCA	O
is	O
going	O
to	O
be	O
co-administered	O
with	O
another	O
drug	B-Drug
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

2	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
this	O
drug	B-Drug
is	O
given	O
concomitantly	O
with	O
anticholinergic	B-Drug
or	O
sympathomimetic	B-Drug
drugs	B-Drug
.	O

3	O
.	O

Clinical	O
experience	O
in	O
the	O
concurrent	O
administration	O
of	O
ECT	O
and	O
antidepressant	O
drugs	B-Drug
is	O
limited	O
.	O

Thus	O
,	O
if	O
such	O
treatment	O
is	O
essential	O
,	O
the	O
possibility	O
of	O
increased	O
risk	O
relative	O
to	O
benefits	O
should	O
be	O
considered	O
.	O

4	O
.	O

If	O
desipramine	B-Drug
hydrochloride	I-Drug
is	O
to	O
be	O
combined	O
with	O
other	O
psychotropic	O
agents	O
such	O
as	O
tranquilizers	O
or	O
sedative/hypnotics	O
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	O
employed	O
since	O
the	O
sedative	O
effects	O
of	O
desipramine	B-Drug
and	O
benzodiazepines	B-Drug
(	O
e.g.	O
,	O
chlordiazepoxide	B-Drug
or	O
diazepam	B-Drug
)	O
are	O
additive	O
.	O

Both	O
the	O
sedative	O
and	O
anticholinergic	B-Drug
effects	O
of	O
the	O
major	O
tranquilizers	O
are	O
also	O
additive	O
to	O
those	O
of	O
desipramine	B-Drug
.	O

5	O
.	O

Concurrent	O
administration	O
of	O
cimetidine	B-Drug
and	O
tricyclic	O
antidepressants	B-Drug
can	O
produce	O
clinically	O
significant	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
the	O
tricyclic	O
antidepressants	B-Drug
.	O

Conversely	O
,	O
decreases	O
in	O
plasma	O
levels	O
of	O
the	O
tricyclic	O
antidepressants	B-Drug
have	O
been	O
reported	O
upon	O
discontinuation	O
of	O
cimetidine	B-Drug
which	O
may	O
result	O
in	O
the	O
loss	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
tricyclic	O
antidepressant	O
6	O
.	O

There	O
have	O
been	O
greater	O
than	O
two-fold	O
increases	O
of	O
previously	O
stable	O
plasma	O
levels	O
of	O
tricyclic	O
antidepressants	B-Drug
when	O
fluoxetine	B-Drug
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O

In	O
two	O
controlled	O
crossover	O
clinical	O
pharmacology	O
studies	O
in	O
healthy	O
male	O
(	O
n=12	O
in	O
each	O
study	O
)	O
a	O
nd	O
female	O
(	O
n=12	O
in	O
each	O
study	O
)	O
volunteers	O
,	O
desloratadine	B-Drug
7.5	O
mg	O
(	O
1.5	O
times	O
the	O
daily	O
dose	O
)	O
once	O
daily	O
was	O
coadministered	O
with	O
erythromycin	B-Drug
500	O
mg	O
every	O
8	O
hours	O
or	O
ketoconazole	B-Drug
200	O
mg	O
every	O
12	O
hours	O
for	O
10	O
days	O
.	O

In	O
three	O
separate	O
controlled	O
,	O
parallel	O
group	O
clinical	O
pharmacology	O
studies	O
,	O
desloratadine	B-Drug
at	O
the	O
clinical	O
dose	O
of	O
5	O
mg	O
has	O
been	O
coadministered	O
with	O
azithromycin	B-Drug
500	O
mg	O
followed	O
by	O
250	O
mg	O
once	O
daily	O
for	O
4	O
days	O
(	O
n=18	O
)	O
or	O
with	O
fluoxetine	B-Drug
20	O
mg	O
once	O
daily	O
for	O
7	O
days	O
after	O
a	O
23	O
day	O
pretreatment	O
period	O
with	O
fluoxetine	B-Drug
(	O
n=18	O
)	O
or	O
with	O
cimetidine	B-Drug
600	O
mg	O
every	O
12	O
hours	O
for	O
14	O
days	O
(	O
n=18	O
)	O
under	O
steady	O
state	O
conditions	O
to	O
normal	O
healthy	O
male	O
and	O
female	O
volunteers	O
.	O

Although	O
increased	O
plasma	O
concentrations	O
(	O
C	O
max	O
and	O
AUC	O
0-24	O
hrs	O
)	O
of	O
desloratadine	B-Drug
and	O
3-hydroxydesloratadine	B-Drug
were	O
observed	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
desloratadine	B-Drug
,	O
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
(	O
including	O
the	O
corrected	O
QT	O
interval	O
)	O
,	O
clinical	O
laboratory	O
tests	O
,	O
vital	O
signs	O
,	O
and	O
adverse	O
events	O
.	O

Table	O
1	O
Changes	O
in	O
Desloratadine	B-Drug
and	O
3-Hydroxydesloratadine	B-Drug
Pharmacokinetics	O
in	O
Healthy	O
Male	O
and	O
Female	O
Volunteers	O
Desloratadine	B-Drug
3-Hydroxydesloratadine	B-Drug
C	O
max	O
AUC	O
0-24	O
hrs	O
C	O
max	O
AUC	O
0-24	O
hrs	O
Erythromycin	B-Drug
(	O
500	O
mg	O
Q8h	O
)	O
+24	O
%	O
+14	O
%	O
+43	O
%	O
+40	O
%	O
Ketoconazole	B-Drug
(	O
200	O
mg	O
Q12h	O
)	O
+45	O
%	O
+39	O
%	O
+43	O
%	O
+72	O
%	O
Azithromycin	B-Drug
(	O
500	O
mg	O
day	O
1	O
,	O
250	O
mg	O
QD	O
4	O
days	O
)	O
+15	O
%	O
+5	O
%	O
+15	O
%	O
+4	O
%	O
Fluoxetine	B-Drug
(	O
20	O
mg	O
QD	O
)	O
+15	O
%	O
+0	O
%	O
+17	O
%	O
+13	O
%	O
Cimetidine	B-Drug
(	O
600	O
mg	O
Q12h	O
)	O
+12	O
%	O
+19	O
%	O
-11	O
%	O
-3	O
%	O
Although	O
the	O
pressor	O
activity	O
of	O
Desmopressin	B-Drug
is	O
very	O
low	O
compared	O
to	O
its	O
antidiuretic	O
activity	O
,	O
large	O
doses	O
of	O
Desmopressin	B-Drug
Tablets	O
should	O
be	O
used	O
with	O
other	O
pressor	O
agents	O
only	O
with	O
careful	O
patient	O
monitoring	O
.	O

Reduced	O
efficacy	O
and	O
increased	O
incidence	O
of	O
breakthrough	O
bleeding	O
and	O
menstrual	O
irregularities	O
have	O
been	O
associated	O
with	O
concomitant	O
use	O
of	O
rifampin	B-Drug
.	O

A	O
similar	O
association	O
,	O
though	O
less	O
marked	O
,	O
has	O
been	O
suggested	O
with	O
barbiturates	B-Drug
,	O
phenyl-butazone	O
,	O
phenytoin	B-Drug
sodium	I-Drug
,	O
carbamazepine	B-Drug
and	O
possibly	O
with	O
griseofulvin	B-Drug
,	O
ampicillin	B-Drug
,	O
and	O
tetracyclines	O
(	O
72	O
)	O
.	O

No	O
specific	O
information	O
available	O
.	O

Aminoglutethimide	B-Drug
:	O
Aminoglutethimide	B-Drug
may	O
diminish	O
adrenal	O
suppression	O
by	O
corticosteroids	O
.	O

Amphotericin	B-Drug
B	I-Drug
injection	O
and	O
potassium-depleting	O
agents	O
:	O
When	O
corticosteroids	O
are	O
administered	O
concomitantly	O
with	O
potassium-depleting	O
agents	O
(	O
e.g.	O
,	O
amphotericin	B-Drug
B	I-Drug
,	O
diuretics	B-Drug
)	O
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
development	O
of	O
hypokalemia	O
.	O

In	O
addition	O
,	O
there	O
have	O
been	O
cases	O
reported	O
in	O
which	O
concomitant	O
use	O
of	O
amphotericin	B-Drug
B	I-Drug
and	O
hydrocortisone	B-Drug
was	O
followed	O
by	O
cardiac	O
enlargement	O
and	O
congestive	O
heart	O
failure	O
.	O

Antibiotics	B-Drug
:	O
Macrolide	O
antibiotics	B-Drug
have	O
been	O
reported	O
to	O
cause	O
a	O
significant	O
decrease	O
in	O
corticosteroid	B-Drug
clearance	O
.	O

Anticholinesterases	O
:	O
Concomitant	O
use	O
of	O
anticholinesterase	O
agents	O
and	O
corticosteroids	O
may	O
produce	O
severe	O
weakness	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
.	O

If	O
possible	O
,	O
anticholinesterase	O
agents	O
should	O
be	O
withdrawn	O
at	O
least	O
24	O
hours	O
before	O
initiating	O
corticosteroid	B-Drug
therapy	O
.	O

Anticoagulants	B-Drug
,	O
oral	O
:	O
Co-administration	O
of	O
corticosteroids	O
and	O
warfarin	B-Drug
usually	O
results	O
in	O
inhibition	O
of	O
response	O
to	O
warfarin	B-Drug
,	O
although	O
there	O
have	O
been	O
some	O
conflicting	O
reports	O
.	O

Therefore	O
,	O
coagulation	O
indices	O
should	O
be	O
monitored	O
frequently	O
to	O
maintain	O
the	O
desired	O
anticoagulant	B-Drug
effect	O
.	O

Antidiabetics	O
:	O
Because	O
corticosteroids	O
may	O
increase	O
blood	O
glucose	B-Drug
concentrations	O
,	O
dosage	O
adjustments	O
of	O
antidiabetic	B-Drug
agents	O
may	O
be	O
required	O
.	O

Antitubercular	O
drugs	B-Drug
:	O
Serum	O
concentrations	O
of	O
isoniazid	B-Drug
may	O
be	O
decreased	O
.	O

Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	O
.	O

Cyclosporine	B-Drug
:	O
Increased	O
activity	O
of	O
both	O
cyclosporine	B-Drug
and	O
corticosteroids	O
may	O
occur	O
when	O
the	O
two	O
are	O
used	O
concurrently	O
.	O

Convulsions	O
have	O
been	O
reported	O
with	O
this	O
concurrent	O
use	O
.	O

Dexamethasone	B-Drug
suppression	O
test	O
(	O
DST	O
)	O
:	O
False-negative	O
results	O
in	O
the	O
dexamethasone	B-Drug
suppression	O
test	O
(	O
DST	O
)	O
in	O
patients	O
being	O
treated	O
with	O
indomethacin	B-Drug
have	O
been	O
reported	O
.	O

Thus	O
,	O
results	O
of	O
the	O
DST	O
should	O
be	O
interpreted	O
with	O
caution	O
in	O
these	O
patients	O
.	O

Digitalis	B-Drug
glycosides	O
:	O
Patients	O
on	O
digitalis	B-Drug
glycosides	O
may	O
be	O
at	O
increased	O
risk	O
of	O
arrhythmias	O
due	O
to	O
hypokalemia	O
.	O

Ephedrine	B-Drug
:	O
Ephedrine	B-Drug
may	O
enhance	O
the	O
metabolic	O
clearance	O
of	O
corticosteroids	O
,	O
resulting	O
in	O
decreased	O
blood	O
levels	O
and	O
lessened	O
physiologic	O
activity	O
,	O
thus	O
requiring	O
an	O
increase	O
in	O
corticosteroid	B-Drug
dosage	O
.	O

Estrogens	O
,	O
including	O
oral	O
contraceptives	O
:	O
Estrogens	O
may	O
decrease	O
the	O
hepatic	O
metabolism	O
of	O
certain	O
corticosteroids	O
,	O
thereby	O
increasing	O
their	O
effect	O
.	O

Hepatic	O
Enzyme	O
Inducers	O
,	O
Inhibitors	O
and	O
Substrates	O
:	O
Drugs	B-Drug
which	O
induce	O
cytochrome	O
P450	O
3A4	O
(	O
CYP	O
3A4	O
)	O
enzyme	O
activity	O
(	O
e.g.	O
,	O
barbiturates	B-Drug
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
rifampin	B-Drug
)	O
may	O
enhance	O
the	O
metabolism	O
of	O
corticosteroids	O
and	O
require	O
that	O
the	O
dosage	O
of	O
the	O
corticosteroid	B-Drug
be	O
increased	O
.	O

Drugs	B-Drug
which	O
inhibit	O
CYP	O
3A4	O
(	O
e.g.	O
,	O
ketoconazole	B-Drug
,	O
macrolide	O
antibiotics	B-Drug
such	O
as	O
erythromycin	B-Drug
)	O
have	O
the	O
potential	O
to	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
corticosteroids	O
.	O

Dexamethasone	B-Drug
is	O
a	O
moderate	O
inducer	O
of	O
CYP	O
3A4	O
.	O

Co-administration	O
with	O
other	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
CYP	O
3A4	O
(	O
e.g.	O
,	O
indinavir	B-Drug
,	O
erythromycin	B-Drug
)	O
may	O
increase	O
their	O
clearance	O
,	O
resulting	O
in	O
decreased	O
plasma	O
concentration	O
.	O

Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
metabolism	O
of	O
certain	O
corticosteroids	O
by	O
up	O
to	O
60	O
%	O
,	O
leading	O
to	O
increased	O
risk	O
of	O
corticosteroid	B-Drug
side	O
effects	O
.	O

In	O
addition	O
,	O
ketoconazole	B-Drug
alone	O
can	O
inhibit	O
adrenal	O
corticosteroid	B-Drug
synthesis	O
and	O
may	O
cause	O
adrenal	O
insufficiency	O
during	O
corticosteroid	B-Drug
withdrawal	O
.	O

Nonsteroidal	O
anti-inflammatory	O
agents	O
(	O
NSAIDS	O
)	O
:	O
Concomitant	O
use	O
of	O
aspirin	B-Drug
(	O
or	O
other	O
nonsteroidal	O
antiinflammatory	O
agents	O
)	O
and	O
corticosteroids	O
increases	O
the	O
risk	O
of	O
gastrointestinal	O
side	O
effects	O
.	O

Aspirin	B-Drug
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
corticosteroids	O
in	O
hypoprothrombinemia	O
.	O

The	O
clearance	O
of	O
salicylates	O
may	O
be	O
increased	O
with	O
concurrent	O
use	O
of	O
corticosteroids	O
.	O

Phenytoin	B-Drug
:	O
In	O
post-marketing	O
experience	O
,	O
there	O
have	O
been	O
reports	O
of	O
both	O
increases	O
and	O
decreases	O
in	O
phenytoin	B-Drug
levels	O
with	O
dexamethasone	B-Drug
co-administration	O
,	O
leading	O
to	O
alterations	O
in	O
seizure	O
control	O
.	O

Skin	O
tests	O
:	O
Corticosteroids	O
may	O
suppress	O
reactions	O
to	O
skin	O
tests	O
.	O

Thalidomide	B-Drug
:	O
Co-administration	O
with	O
thalidomide	B-Drug
should	O
be	O
employed	O
cautiously	O
,	O
as	O
toxic	O
epidermal	O
necrolysis	O
has	O
been	O
reported	O
with	O
concomitant	O
use	O
.	O

Vaccines	O
:	O
Patients	O
on	O
corticosteroid	B-Drug
therapy	O
may	O
exhibit	O
a	O
diminished	O
response	O
to	O
toxoids	O
and	O
live	O
or	O
inactivated	O
vaccines	O
due	O
to	O
inhibition	O
of	O
antibody	O
response	O
.	O

Corticosteroids	O
may	O
also	O
potentiate	O
the	O
replication	O
of	O
some	O
organisms	O
contained	O
in	O
live	O
attenuated	O
vaccines	O
.	O

Routine	O
administration	O
of	O
vaccines	O
or	O
toxoids	O
should	O
be	O
deferred	O
until	O
corticosteroid	B-Drug
therapy	O
is	O
discontinued	O
if	O
possible	O
.	O

Dexbrompheniramine	B-Drug
can	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	O
depressants	O
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Drug
)	O
,	O
anticholinergics	O
or	O
other	O
medications	O
with	O
anticholinergic	B-Drug
activity	O
(	O
anticholinergic	B-Drug
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Drug
)	O
,	O
and	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
(	O
concurrent	O
use	O
with	O
antihistamines	B-Drug
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Drug
)	O
.	O

In	O
patients	O
receiving	O
nonselective	O
monoamine	O
oxidase	O
inhibitors	O
(	O
MAOIs	O
)	O
(	O
e.g.	O
,	O
selegiline	B-Drug
hydrochloride	I-Drug
)	O
in	O
combination	O
with	O
serotoninergic	O
agents	O
(	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
paroxetine	B-Drug
,	O
sertraline	B-Drug
,	O
venlafaxine	B-Drug
)	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
,	O
sometimes	O
fatal	O
,	O
reactions	O
.	O

Because	O
dexfenfluramine	B-Drug
is	O
a	O
serotonin	O
releaser	O
and	O
reuptake	O
inhibitor	O
,	O
dexfenfluramine	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
a	O
MAO	O
inhibitor	O
.	O

At	O
least	O
14	O
days	O
should	O
elapse	O
between	O
discontinuation	O
of	O
a	O
MAO	O
inhibitor	O
and	O
initiation	O
of	O
treatment	O
with	O
dexfenfluramine	B-Drug
.	O

At	O
least	O
3	O
weeks	O
should	O
elapse	O
between	O
discontinuation	O
of	O
dexfenfluramine	B-Drug
and	O
initiation	O
of	O
treatment	O
with	O
a	O
MAO	O
inhibitor	O
.	O

A	O
rare	O
,	O
but	O
serious	O
,	O
constellation	O
of	O
symptoms	O
,	O
termed	O
serotonin	O
syndrome	O
,	O
has	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
and	O
agents	O
for	O
migraine	O
therapy	O
,	O
such	O
as	O
Imitrex	B-Drug
(	O
sumatriptan	B-Drug
succinate	I-Drug
)	O
and	O
dihydroergotamine	B-Drug
.	O

The	O
syndrome	O
requires	O
immediate	O
medical	O
attention	O
and	O
may	O
include	O
one	O
or	O
more	O
of	O
the	O
following	O
symptoms	O
:	O
excitement	O
,	O
hypomania	O
,	O
restlessness	O
,	O
loss	O
of	O
consciousness	O
,	O
confusion	O
,	O
disorientation	O
,	O
anxiety	O
,	O
agitation	O
,	O
motor	O
weakness	O
,	O
myoclonus	O
,	O
tremor	O
,	O
hemiballismus	O
,	O
hyperreflexia	O
,	O
ataxia	O
,	O
dysarthria	O
,	O
incoordination	O
,	O
hyperthermia	O
,	O
shivering	O
,	O
pupillary	O
dilation	O
,	O
diaphoresis	O
,	O
emesis	O
,	O
and	O
tachycardia	O
.	O

Dexfenfluramine	B-Drug
should	O
not	O
be	O
administered	O
with	O
other	O
serotoninergic	O
agents	O
.	O

The	O
appropriate	O
interval	O
between	O
administration	O
of	O
these	O
agents	O
and	O
dexfenfluramine	B-Drug
has	O
not	O
been	O
established	O
.	O

The	O
use	O
of	O
dexfenfluramine	B-Drug
with	O
other	O
CNS-active	O
drugs	B-Drug
has	O
not	O
been	O
systematically	O
evaluated	O
;	O
consequently	O
,	O
caution	O
is	O
advised	O
if	O
dexfenfluramine	B-Drug
and	O
such	O
drugs	B-Drug
are	O
prescribed	O
concurrently	O
.	O

General	O
In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
demonstrated	O
no	O
evidence	O
of	O
cytochrome	O
P450-mediated	O
drug	B-Drug
interactions	O
that	O
are	O
likely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O

Anesthetics/Sedatives/Hypnotics/Opioids	O
:	O
Co-administration	O
of	O
PRECEDEX	B-Drug
with	O
anesthetics	B-Drug
,	O
sedatives	O
,	O
hypnotics	O
,	O
and	O
opioids	O
is	O
likely	O
to	O
lead	B-Drug
to	O
an	O
enhancement	O
of	O
effects	O
.	O

Specific	O
studies	O
have	O
confirmed	O
these	O
effects	O
with	O
sevoflurane	B-Drug
,	O
isoflurane	B-Drug
,	O
propofol	B-Drug
,	O
alfentanil	B-Drug
,	O
and	O
midazolam	B-Drug
.	O

No	O
pharmacokinetic	O
interactions	O
between	O
dexmedetomidine	B-Drug
and	O
isoflurane	B-Drug
,	O
propofol	B-Drug
,	O
alfentanil	B-Drug
,	O
and	O
midazolam	B-Drug
have	O
been	O
demonstrated	O
.	O

However	O
,	O
due	O
to	O
possible	O
pharmacodynamic	O
interactions	O
,	O
when	O
co-administered	O
with	O
PRECEDEX	B-Drug
,	O
a	O
reduction	O
in	O
dosage	O
of	O
PRECEDEX	B-Drug
on	O
the	O
concomitant	O
anesthetic	B-Drug
,	O
sedative	O
,	O
hypnotic	O
or	O
opioid	O
may	O
be	O
required	O
.	O

Neuromuscular	O
Blockers	O
:	O
In	O
one	O
study	O
of	O
10	O
healthy	O
volunteers	O
,	O
administration	O
of	O
PRECEDEX	B-Drug
for	O
45	O
minutes	O
at	O
a	O
plasma	O
concentration	O
of	O
1	O
(	O
one	O
)	O
ng/mL	O
resulted	O
in	O
no	O
clinically	O
meaningful	O
increases	O
in	O
the	O
magnitude	O
or	O
neuromuscular	O
blockade	O
associated	O
with	O
rocuronium	B-Drug
administration	O
.	O

ZINECARD	B-Drug
does	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
doxorubicin	B-Drug
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
Impairment	O
of	O
Fertility	O
No	O
long-term	O
carcinogenicity	O
studies	O
have	O
been	O
carried	O
out	O
with	O
dexrazoxane	B-Drug
in	O
animals	O
.	O

Dexrazoxane	B-Drug
was	O
not	O
mutagenic	O
in	O
the	O
Ames	O
test	O
but	O
was	O
found	O
to	O
be	O
clastogenic	O
to	O
human	O
lymphocytes	O
in	O
vitro	O
and	O
to	O
mouse	O
bone	O
marrow	O
erythrocytes	O
in	O
vivo	O
(	O
micronucleus	O
test	O
)	O
.	O

The	O
possible	O
adverse	O
effects	O
of	O
ZINECARD	B-Drug
on	O
the	O
fertility	O
of	O
humans	O
and	O
experimental	O
animals	O
,	O
male	O
or	O
female	O
,	O
have	O
not	O
been	O
adequately	O
studied	O
.	O

Testicular	O
atrophy	O
was	O
seen	O
with	O
dexrazoxane	B-Drug
administration	O
at	O
doses	O
as	O
low	O
as	O
30	O
mg/kg	O
weekly	O
for	O
6	O
weeks	O
in	O
rats	O
(	O
1/3	O
the	O
human	O
dose	O
on	O
a	O
mg/m	O
2	O
basis	O
)	O
and	O
as	O
low	O
as	O
20	O
mg/kg	O
weekly	O
for	O
13	O
weeks	O
in	O
dogs	O
(	O
approximately	O
equal	O
to	O
the	O
human	O
dose	O
on	O
a	O
mg/m	O
2	O
basis	O
)	O
.	O

Acidifying	O
agents	O
:	O
Gastrointestinal	O
acidifying	O
agents	O
(	O
guanethidine	B-Drug
,	O
reserpine	B-Drug
,	O
glutamic	B-Drug
acid	I-Drug
HCl	I-Drug
,	O
ascorbic	B-Drug
acid	I-Drug
,	O
fruit	O
juices	O
,	O
etc	O
.	O

)	O
lower	O
absorption	O
of	O
amphetamines	B-Drug
.	O

Urinary	O
acidifying	O
agents	O
(	O
ammonium	B-Drug
chloride	I-Drug
,	O
sodium	B-Drug
acid	I-Drug
phosphate	I-Drug
,	O
etc	O
.	O

)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	B-Drug
molecule	O
,	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O

Both	O
groups	O
of	O
agents	O
lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	B-Drug
.	O

Adrenergic	O
blockers	O
:	O
Adrenergic	O
blockers	O
are	O
inhibited	O
by	O
amphetamines	B-Drug
.	O

Alkalinizing	O
agents	O
:	O
Gastrointestinal	O
alkalinizing	O
agents	O
(	O
sodium	B-Drug
bicarbonate	I-Drug
,	O
etc	O
.	O

)	O
increase	O
absorption	O
of	O
amphetamines	B-Drug
.	O

Urinary	O
alkalinizing	O
agents	O
(	O
acetazolamide	B-Drug
,	O
some	O
thiazides	O
)	O
increase	O
the	O
concentration	O
of	O
the	O
non-ionized	O
species	O
of	O
the	O
amphetamine	B-Drug
molecule	O
,	O
thereby	O
decreasing	O
urinary	O
excretion	O
.	O

Both	O
groups	O
of	O
agents	O
increase	O
blood	O
levels	O
and	O
therefore	O
potentiate	O
the	O
actions	O
of	O
amphetamines	B-Drug
.	O

Antidepressants	B-Drug
,	O
tricyclic	O
:	O
Amphetamines	B-Drug
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	O
or	O
sympathomimetic	B-Drug
agents	O
;	O
d-amphetamine	B-Drug
with	O
desipramine	B-Drug
or	O
protriptyline	B-Drug
and	O
possibly	O
other	O
tricyclics	O
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d-amphetamine	B-Drug
in	O
the	O
brain	O
;	O
cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O

MAO	O
inhibitors	O
:	O
MAOI	O
antidepressants	B-Drug
,	O
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	B-Drug
,	O
slow	O
amphetamine	B-Drug
metabolism	O
.	O

This	O
slowing	O
potentiates	O
amphetamines	B-Drug
,	O
increasing	O
their	O
effect	O
on	O
the	O
release	O
of	O
norepinephrine	B-Drug
and	O
other	O
monoamines	O
from	O
adrenergic	O
nerve	O
endings	O
;	O
this	O
can	O
cause	O
headaches	O
and	O
other	O
signs	O
of	O
hypertensive	O
crisis	O
.	O

A	O
variety	O
of	O
neurological	O
toxic	O
effects	O
and	O
malignant	O
hyperpyrexia	O
can	O
occur	O
,	O
sometimes	O
with	O
fatal	O
results	O
.	O

Antihistamines	B-Drug
:	O
Amphetamines	B-Drug
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	B-Drug
.	O

Antihypertensives	B-Drug
:	O
Amphetamines	B-Drug
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	B-Drug
.	O

Chlorpromazine	B-Drug
:	O
Chlorpromazine	B-Drug
blocks	O
dopamine	B-Drug
and	O
norepinephrine	B-Drug
reuptake	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Drug
,	O
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	B-Drug
poisoning	O
.	O

Ethosuximide	B-Drug
:	O
Amphetamines	B-Drug
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	B-Drug
.	O

Haloperidol	B-Drug
:	O
Haloperidol	B-Drug
blocks	O
dopamine	B-Drug
and	O
norepinephrine	B-Drug
reuptake	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Drug
.	O

Lithium	B-Drug
carbonate	I-Drug
:	O
The	O
stimulatory	O
effects	O
of	O
amphetamines	B-Drug
may	O
be	O
inhibited	O
by	O
lithium	B-Drug
carbonate	I-Drug
.	O

Meperidine	B-Drug
:	O
Amphetamines	B-Drug
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	B-Drug
.	O

Methenamine	B-Drug
therapy	O
:	O
Urinary	O
excretion	O
of	O
amphetamines	B-Drug
is	O
increased	O
,	O
and	O
efficacy	O
is	O
reduced	O
,	O
by	O
acidifying	O
agents	O
used	O
in	O
methenamine	B-Drug
therapy	O
.	O

Norepinephrine	B-Drug
:	O
Amphetamines	B-Drug
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	B-Drug
.	O

Phenobarbital	B-Drug
:	O
Amphetamines	B-Drug
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	B-Drug
;	O
co-administration	O
of	O
phenobarbital	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Phenytoin	B-Drug
:	O
Amphetamines	B-Drug
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	B-Drug
;	O
co-administration	O
of	O
phenytoin	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Propoxyphene	B-Drug
:	O
In	O
cases	O
of	O
propoxyphene	B-Drug
overdosage	O
,	O
amphetamine	B-Drug
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O

Veratrum	O
alkaloids	O
:	O
Amphetamines	B-Drug
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	O
alkaloids	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
:	O
Amphetamines	B-Drug
can	O
cause	O
a	O
significant	O
elevation	O
in	O
plasma	O
corticosteroid	B-Drug
levels	O
.	O

This	O
increase	O
is	O
greatest	O
in	O
the	O
evening	O
.	O

Amphetamines	B-Drug
may	O
interfere	O
with	O
urinary	O
steroid	O
determinations	O
.	O

Additive	O
depressant	O
effect	O
when	O
used	O
with	O
general	O
anesthetics	B-Drug
,	O
sedatives	O
,	O
antianxiety	O
drugs	B-Drug
,	O
hypnotics	O
,	O
alcohol	B-Drug
,	O
and	O
other	O
opiate	O
analgesics	O
.	O

May	O
interact	O
with	O
thyroid	B-Drug
medication	O
(	O
e.g.	O
,	O
levothyroxine	B-Drug
)	O
,	O
iodine-containing	B-Drug
products	O
,	O
antacids	O
,	O
H2-antagonists	O
(	O
e.g.	O
,	O
famotidine	B-Drug
,	O
ranitidine	B-Drug
)	O
,	O
and	O
proton	O
pump	O
inhibitors	O
(	O
e.g.	O
,	O
lansoprazole	B-Drug
,	O
omeprazole	B-Drug
)	O
.	O

This	O
product	O
can	O
affect	O
the	O
results	O
of	O
certain	O
lab	O
tests	O
.	O

Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
concomitant	O
high-dose	O
aspirin	B-Drug
and	O
carbonic	O
anhydrase	O
inhibitors	O
,	O
as	O
anorexia	O
,	O
tachypnea	O
,	O
lethargy	O
and	O
coma	O
have	O
been	O
rarely	O
reported	O
due	O
to	O
a	O
possible	O
drug	B-Drug
interaction	O
.	O

Aspirin	B-Drug
:	O
Concomitant	O
administration	O
of	O
diclofenac	B-Drug
and	O
aspirin	B-Drug
is	O
not	O
recommended	O
because	O
diclofenac	B-Drug
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	B-Drug
,	O
resulting	O
in	O
lower	O
plasma	O
concentrations	O
,	O
peak	O
plasma	O
levels	O
,	O
and	O
AUC	O
values	O
.	O

Anticoagulants	B-Drug
:	O
While	O
studies	O
have	O
not	O
shown	O
diclofenac	B-Drug
to	O
interact	O
with	O
anticoagulants	B-Drug
of	O
the	O
warfarin	B-Drug
type	O
,	O
caution	O
should	O
be	O
exercised	O
,	O
nonetheless	O
,	O
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	O
.	O

Because	O
prostaglandins	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
,	O
and	O
NSAIDs	O
affect	O
platelet	O
function	O
as	O
well	O
,	O
concurrent	O
therapy	O
with	O
all	O
NSAIDs	O
,	O
including	O
diclofenac	B-Drug
,	O
and	O
warfarin	B-Drug
requires	O
close	O
monitoring	O
of	O
patients	O
to	O
be	O
certain	O
that	O
no	O
change	O
in	O
their	O
anticoagulant	B-Drug
dosage	O
is	O
required	O
.	O

Digoxin	B-Drug
,	O
Methotrexate	B-Drug
,	O
Cyclosporine	B-Drug
:	O
Diclofenac	B-Drug
,	O
like	O
other	O
NSAIDs	O
,	O
may	O
affect	O
renal	O
prostaglandins	O
and	O
increase	O
the	O
toxicity	O
of	O
certain	O
drugs	B-Drug
.	O

Ingestion	O
of	O
diclofenac	B-Drug
may	O
increase	O
serum	O
concentrations	O
of	O
digoxin	B-Drug
and	O
methotrexate	B-Drug
and	O
increase	O
cyclosporine	B-Drug
s	O
nephrotoxicity	O
.	O

Patients	O
who	O
begin	O
taking	O
diclofenac	B-Drug
or	O
who	O
increase	O
their	O
diclofenac	B-Drug
dose	O
or	O
any	O
other	O
NSAID	O
while	O
taking	O
digoxin	B-Drug
,	O
methotrexate	B-Drug
,	O
or	O
cyclosporine	B-Drug
may	O
develop	O
toxicity	O
characteristics	O
for	O
these	O
drugs	B-Drug
.	O

They	O
should	O
be	O
observed	O
closely	O
,	O
particularly	O
if	O
renal	O
function	O
is	O
impaired	O
.	O

In	O
the	O
case	O
of	O
digoxin	B-Drug
,	O
serum	O
levels	O
should	O
be	O
monitored	O
.	O

Lithium	B-Drug
:	O
Diclofenac	B-Drug
decreases	O
lithium	B-Drug
renal	O
clearance	O
and	O
increases	O
lithium	B-Drug
plasma	O
levels	O
.	O

In	O
patients	O
taking	O
diclofenac	B-Drug
and	O
lithium	B-Drug
concomitantly	O
,	O
lithium	B-Drug
toxicity	O
may	O
develop	O
.	O

Oral	O
Hypoglycemics	O
:	O
Diclofenac	B-Drug
does	O
not	O
alter	O
glucose	B-Drug
metabolism	O
in	O
normal	O
subjects	O
nor	O
does	O
it	O
alter	O
the	O
effects	O
of	O
oral	O
hypoglycemic	O
agents	O
.	O

There	O
are	O
rare	O
reports	O
,	O
however	O
,	O
from	O
marketing	O
experiences	O
,	O
of	O
changes	O
in	O
effects	O
of	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	O
agents	O
in	O
the	O
presence	O
of	O
diclofenac	B-Drug
that	O
necessitated	O
changes	O
in	O
the	O
doses	O
of	O
such	O
agents	O
.	O

Both	O
hypo-	O
and	O
hyperglycemic	O
effects	O
have	O
been	O
reported	O
.	O

A	O
direct	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
,	O
but	O
physicians	O
should	O
consider	O
the	O
possibility	O
that	O
diclofenac	B-Drug
may	O
alter	O
a	O
diabetic	O
patient	O
s	O
response	O
to	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	O
agents	O
.	O

Diuretics	B-Drug
:	O
Diclofenac	B-Drug
and	O
other	O
NSAIDs	O
can	O
inhibit	O
the	O
activity	O
of	O
diuretics	B-Drug
.	O

Concomitant	O
treatment	O
with	O
potassium-sparing	O
diuretics	B-Drug
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	B-Drug
levels	O
.	O

Other	O
Drugs	B-Drug
:	O
In	O
small	O
groups	O
of	O
patients	O
(	O
7-10/interaction	O
study	O
)	O
,	O
the	O
concomitant	O
administration	O
of	O
azathioprine	B-Drug
,	O
gold	B-Drug
,	O
chloroquine	B-Drug
,	O
D-penicillamine	B-Drug
,	O
prednisolone	B-Drug
,	O
doxycycline	B-Drug
,	O
or	O
digitoxin	B-Drug
did	O
not	O
significantly	O
affect	O
the	O
peak	O
levels	O
and	O
AUC	O
values	O
of	O
diclofenac	B-Drug
.	O

Phenobarbital	B-Drug
toxicity	O
has	O
been	O
reported	O
to	O
have	O
occurred	O
in	O
a	O
patient	O
on	O
chronic	O
phenobarbital	B-Drug
treatment	O
following	O
the	O
initiation	O
of	O
diclofenac	B-Drug
therapy	O
.	O

Protein	O
Binding	O
In	O
vitro	O
,	O
diclofenac	B-Drug
interferes	O
minimally	O
or	O
not	O
at	O
all	O
with	O
the	O
protein	O
binding	O
of	O
salicylic	B-Drug
acid	I-Drug
(	O
20	O
%	O
decrease	O
in	O
binding	O
)	O
,	O
tolbutamide	B-Drug
,	O
prednisolone	B-Drug
(	O
10	O
%	O
decrease	O
in	O
binding	O
)	O
,	O
or	O
warfarin	B-Drug
.	O

Benzylpenicillin	B-Drug
,	O
ampicillin	B-Drug
,	O
oxacillin	B-Drug
,	O
chlortetracycline	B-Drug
,	O
doxycycline	B-Drug
,	O
cephalothin	B-Drug
,	O
erythromycin	B-Drug
,	O
and	O
sulfamethoxazole	B-Drug
have	O
no	O
influence	O
in	O
vitro	O
on	O
the	O
protein	O
binding	O
of	O
diclofenac	B-Drug
in	O
human	O
serum	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Effect	O
on	O
Blood	O
Coagulation	O
:	O
Diclofenac	B-Drug
increases	O
platelet	O
aggregation	O
time	O
but	O
does	O
not	O
affect	O
bleeding	O
time	O
,	O
plasma	O
thrombin	O
clotting	O
time	O
,	O
plasma	O
fibrinogen	B-Drug
,	O
or	O
factors	O
V	O
and	O
VII	O
to	O
XII	O
.	O

Statistically	O
significant	O
changes	O
in	O
prothrombin	O
and	O
partial	O
thromboplastin	O
times	O
have	O
been	O
reported	O
in	O
normal	O
volunteers	O
.	O

The	O
mean	O
changes	O
were	O
observed	O
to	O
be	O
less	O
than	O
1	O
second	O
in	O
both	O
instances	O
,	O
however	O
,	O
and	O
are	O
unlikely	O
to	O
be	O
clinically	O
important	O
.	O

Diclofenac	B-Drug
is	O
a	O
prostaglandin	O
synthetase	O
inhibitor	O
,	O
however	O
,	O
and	O
all	O
drugs	B-Drug
that	O
inhibit	O
prostaglandin	O
synthesis	O
interfere	O
with	O
platelet	O
function	O
to	O
some	O
degree	O
;	O
therefore	O
,	O
patients	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
such	O
an	O
action	O
should	O
be	O
carefully	O
observed	O
.	O

Tetracycline	B-Drug
,	O
a	O
bacteriostatic	O
antibiotic	O
,	O
may	O
antagonize	O
the	O
bactercidal	O
effect	O
of	O
penicillin	B-Drug
and	O
concurrent	O
use	O
of	O
these	O
drugs	B-Drug
should	O
be	O
avoided	O
.	O

The	O
following	O
agents	O
may	O
increase	O
certain	O
actions	O
or	O
side	O
effects	O
of	O
anticholinergic	B-Drug
drugs	B-Drug
.	O

amantadine	B-Drug
antiarrhythmic	B-Drug
agents	O
of	O
class	O
(	O
e.g	O
.	O

quinidine	B-Drug
)	O
,	O
antihistamines	B-Drug
antipsychotic	O
agents	O
(	O
e.g	O
.	O

phenothiazines	O
)	O
,	O
benzodiazepines	B-Drug
.	O

MAO	O
inhibitors	O
,	O
narcotic	O
analgesics	O
(	O
e.g.	O
,	O
meperidine	B-Drug
)	O
,	O
nitrates	B-Drug
and	O
nitrites	O
,	O
sympathomimetic	B-Drug
agents	O
,	O
tricyclic	O
antidepressants	B-Drug
,	O
and	O
other	O
drugs	B-Drug
having	O
anticholinergic	B-Drug
activity	O
.	O

Anticholinergics	O
antagonize	O
the	O
effects	O
of	O
antiglaucoma	O
agents	O
.	O

Anticholinergic	B-Drug
drugs	B-Drug
in	O
the	O
presence	O
of	O
increased	O
intraocular	O
pressure	O
may	O
be	O
hazardous	O
when	O
taken	O
concurrently	O
with	O
agents	O
such	O
as	O
corti	O
costeroids..	O
Anticholinergic	B-Drug
agents	O
may	O
affect	O
gastrointestinal	O
absorption	O
of	O
various	O
drugs	B-Drug
,	O
such	O
as	O
slowly	O
dissolving	O
dosage	O
forms	O
of	O
digoxin	B-Drug
;	O
increased	O
serum	O
digoxin	B-Drug
concentrations	O
may	O
result	O
.	O

Anticholinergic	B-Drug
drugs	B-Drug
may	O
antagonize	O
the	O
effects	O
of	O
the	O
drugs	B-Drug
that	O
alter	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
metoclopramide	B-Drug
.	O

Because	O
antacids	O
may	O
interfere	O
with	O
the	O
absorption	O
of	O
anticholinergic	B-Drug
agents	O
,	O
simultaneous	O
use	O
of	O
these	O
drugs	B-Drug
should	O
be	O
avoided	O
.	O

The	O
inhibiting	O
effects	O
of	O
anticholinergic	B-Drug
drugs	B-Drug
on	O
gastric	O
hydrochloric	O
acid	O
secretion	O
are	O
antagonized	O
by	O
agents	O
used	O
to	O
treat	O
achlorhydria	O
and	O
those	O
used	O
to	O
test	O
gastric	O
secretion	O
.	O

Coadministration	O
of	O
VIDEX	B-Drug
with	O
drugs	B-Drug
that	O
are	O
known	O
to	O
cause	O
pancreatitis	O
may	O
increase	O
the	O
risk	O
of	O
this	O
toxicity	O
(	O
see	O
WARNINGS	O
)	O
and	O
should	O
be	O
done	O
with	O
extreme	O
caution	O
,	O
only	O
if	O
other	O
alternatives	O
are	O
not	O
available	O
,	O
and	O
only	O
if	O
clearly	O
indicated	O
.	O

Neuropathy	O
has	O
occurred	O
more	O
frequently	O
in	O
patients	O
with	O
a	O
history	O
of	O
neuropathy	O
or	O
neurotoxic	O
drug	B-Drug
therapy	O
,	O
including	O
stavudine	B-Drug
,	O
and	O
these	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
neuropathy	O
during	O
VIDEX	B-Drug
therapy	O
(	O
see	O
ADVERSE	O
REACTIONS	O
)	O
.	O

Allopurinol	B-Drug
:	O
The	O
AUC	O
of	O
didanosine	B-Drug
was	O
increased	O
about	O
4-fold	O
when	O
allopurinol	B-Drug
at	O
300	O
mg/day	O
was	O
coadministered	O
with	O
a	O
single	O
200-mg	O
dose	O
of	O
VIDEX	B-Drug
to	O
two	O
patients	O
with	O
renal	O
impairment	O
(	O
CLcr=15	O
and	O
18	O
mL/min	O
)	O
.	O

The	O
effects	O
of	O
allopurinol	B-Drug
on	O
didanosine	B-Drug
pharmacokinetics	O
in	O
subjects	O
with	O
normal	O
renal	O
function	O
are	O
not	O
known	O
.	O

Antacids	O
:	O
Concomitant	O
administration	O
of	O
antacids	O
containing	O
magnesium	B-Drug
or	O
aluminum	B-Drug
with	O
VIDEX	B-Drug
Chewable/Dispersible	O
Buffered	O
Tablets	O
or	O
Pediatric	O
Powder	O
for	O
Oral	O
Solution	O
may	O
potentiate	O
adverse	O
events	O
associated	O
with	O
the	O
antacid	O
components	O
.	O

Drugs	B-Drug
Whose	O
Absorption	O
Can	O
Be	O
Affected	O
by	O
the	O
Level	O
of	O
Acidity	O
in	O
the	O
Stomach	O
:	O
Drugs	B-Drug
such	O
as	O
ketoconazole	B-Drug
and	O
itraconazole	B-Drug
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
prior	O
to	O
dosing	O
with	O
VIDEX	B-Drug
.	O

Ganciclovir	B-Drug
:	O
Administration	O
of	O
VIDEX	B-Drug
2	O
hours	O
prior	O
to	O
or	O
concurrent	O
with	O
oral	O
ganciclovir	B-Drug
was	O
associated	O
with	O
a	O
111	O
(	O
114	O
)	O
%	O
increase	O
in	O
the	O
steady-state	O
AUC	O
of	O
didanosine	B-Drug
(	O
n	O
=	O
12	O
)	O
.	O

A	O
21	O
(	O
17	O
)	O
%	O
decrease	O
in	O
the	O
steady-state	O
AUC	O
of	O
ganciclovir	B-Drug
was	O
observed	O
when	O
VIDEX	B-Drug
was	O
administered	O
2	O
hours	O
prior	O
to	O
ganciclovir	B-Drug
,	O
but	O
not	O
when	O
the	O
two	O
drugs	B-Drug
were	O
administered	O
simultaneously	O
(	O
n	O
=	O
12	O
)	O
.	O

Quinolone	O
Antibiotics	B-Drug
:	O
VIDEX	B-Drug
should	O
be	O
administered	O
at	O
least	O
2	O
hours	O
after	O
or	O
6	O
hours	O
before	O
dosing	O
with	O
ciprofloxacin	B-Drug
because	O
plasma	O
concentrations	O
of	O
ciprofloxacin	B-Drug
are	O
decreased	O
when	O
administered	O
with	O
antacids	O
containing	O
magnesium	B-Drug
,	O
calcium	B-Drug
,	O
or	O
aluminum	B-Drug
.	O

In	O
eight	O
HIV-infected	O
patients	O
,	O
the	O
steady-state	O
AUC	O
of	O
ciprofloxacin	B-Drug
was	O
decreased	O
an	O
average	O
of	O
26	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
%	O
,	O
37	O
%	O
)	O
when	O
ciprofloxacin	B-Drug
was	O
administered	O
2	O
hours	O
prior	O
to	O
a	O
marketed	O
chewable/dispersible	O
tablet	O
formulation	O
of	O
VIDEX	B-Drug
.	O

The	O
AUC	O
of	O
ciprofloxacin	B-Drug
was	O
decreased	O
an	O
average	O
of	O
15-fold	O
in	O
12	O
healthy	O
subjects	O
given	O
ciprofloxacin	B-Drug
and	O
didanosine-placebo	B-Drug
tablets	O
concurrently	O
.	O

In	O
a	O
single	O
subject	O
given	O
one	O
dose	O
of	O
ciprofloxacin	B-Drug
2	O
hours	O
after	O
a	O
dose	O
of	O
didanosine-placebo	B-Drug
tablets	O
,	O
a	O
greater	O
than	O
50	O
%	O
reduction	O
in	O
the	O
AUC	O
of	O
ciprofloxacin	B-Drug
was	O
observed	O
.	O

Plasma	O
concentrations	O
of	O
quinolone	O
antibiotics	B-Drug
are	O
decreased	O
when	O
administered	O
with	O
antacids	O
containing	O
magnesium	B-Drug
,	O
calcium	B-Drug
,	O
or	O
aluminum	B-Drug
.	O

The	O
optimal	O
dosing	O
interval	O
for	O
coadministration	O
with	O
VIDEX	B-Drug
should	O
be	O
determined	O
by	O
consulting	O
the	O
appropriate	O
quinolone	O
package	O
insert	O
.	O

Interactions	O
with	O
Other	O
Antiretroviral	O
Drugs	B-Drug
:	O
Significant	O
decreases	O
in	O
the	O
AUC	O
of	O
delavirdine	B-Drug
(	O
20	O
%	O
)	O
and	O
indinavir	B-Drug
(	O
84	O
%	O
)	O
occurred	O
following	O
simultaneous	O
administration	O
of	O
these	O
agents	O
with	O
VIDEX	B-Drug
.	O

To	O
avoid	O
this	O
interaction	O
,	O
delavirdine	B-Drug
or	O
indinavir	B-Drug
should	O
be	O
given	O
1	O
hour	O
prior	O
to	O
dosing	O
with	O
VIDEX	B-Drug
.	O

The	O
pharmacokinetics	O
of	O
nelfinavir	B-Drug
are	O
not	O
altered	O
to	O
a	O
clinically	O
significant	O
degree	O
when	O
it	O
is	O
administered	O
with	O
a	O
light	O
meal	O
1	O
hour	O
after	O
VIDEX	B-Drug
.	O

Drug/	O
Laboratory	O
Test	O
Interactions	O
Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen-containing	O
oral	O
contraceptives	O
.	O

The	O
following	O
similar	O
changes	O
may	O
be	O
expected	O
with	O
larger	O
doses	O
of	O
estrogen	O
:	O
-	O
Increased	O
sulfobromophthalein	O
retention	O
.	O

-	O
Increased	O
prothrombin	O
and	O
factors	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
;	O
decreased	O
antithrombin	B-Drug
3	I-Drug
;	O
increased	O
norepinephrine-induced	O
platelet	O
aggregability	O
.	O

-	O
Increased	O
thyroid-binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
in-creased	O
circulating	O
total	O
thyroid	B-Drug
hormone	O
;	O
as	O
measured	O
by	O
PBI	O
,	O
T4	B-Drug
by	O
column	O
,	O
or	O
T4	B-Drug
by	O
radioimmunoassay	O
.	O

Free	O
T3	B-Drug
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
;	O
free	O
T4	B-Drug
concentration	O
is	O
unaltered	O
.	O

-	O
Impaired	O
glucose	B-Drug
tolerance	O
.	O

-	O
Decreased	O
pregnanediol	O
excretion	O
.	O

-	O
Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O

-	O
Reduced	O
serum	O
folate	O
concentration	O
.	O

-	O
Increased	O
serum	O
triglyceride	O
and	O
phospholipid	O
concentration	O
.	O

Antidiabetic	B-Drug
drug	B-Drug
requirements	O
(	O
i.e.	O
,	O
insulin	B-Drug
)	O
may	O
be	O
altered	O
.	O

Concurrent	O
use	O
with	O
general	O
anesthetics	B-Drug
may	O
result	O
in	O
arrhythmias	O
.	O

The	O
pressor	O
effects	O
of	O
diethylpropion	B-Drug
and	O
those	O
of	O
other	O
drugs	B-Drug
may	O
be	O
additive	O
when	O
the	O
drugs	B-Drug
are	O
used	O
concomitantly	O
;	O
conversely	O
,	O
diethylpropion	B-Drug
may	O
interfere	O
with	O
antihypertensive	B-Drug
drugs	B-Drug
(	O
i.e.	O
,	O
guanethidine	B-Drug
,	O
a-methyldopa	B-Drug
)	O
.	O

Concurrent	O
use	O
of	O
phenothiazines	O
may	O
antagonize	O
the	O
anorectic	O
effect	O
of	O
diethylpropion	B-Drug
.	O

May	O
interact	O
anticoagulants	B-Drug
(	O
altered	O
hypo-prothrombinemic	O
effect	O
)	O
,	O
barbiturates	B-Drug
,	O
rifampin	B-Drug
and	O
other	O
inducers	O
of	O
hepatic	O
microsomal	O
enzyme	O
oxidation	O
system	O
(	O
decreased	O
effect	O
of	O
diethylstilbestrol	B-Drug
)	O
,	O
corticosteroids	O
(	O
increased	O
effect	O
of	O
corticosteroids	O
)	O
.	O

Oral	O
Anticoagulants	B-Drug
:	O
In	O
some	O
normal	O
volunteers	O
,	O
the	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
warfarin	B-Drug
,	O
acenocoumarol	B-Drug
,	O
or	O
phenprocoumon	B-Drug
resulted	O
in	O
prolongation	O
of	O
prothrombin	O
time	O
.	O

This	O
may	O
occur	O
because	O
diflunisal	B-Drug
competitively	O
displaces	O
coumarins	O
from	O
protein	O
binding	O
sites	O
.	O

Accordingly	O
,	O
when	O
diflunisal	B-Drug
is	O
administered	O
with	O
oral	O
anticoagulants	B-Drug
,	O
the	O
prothrombin	O
time	O
should	O
be	O
closely	O
monitored	O
during	O
and	O
for	O
several	O
days	O
after	O
concomitant	O
drug	B-Drug
administration	O
.	O

Adjustment	O
of	O
dosage	O
of	O
oral	O
anticoagulants	B-Drug
may	O
be	O
required	O
.	O

Tolbutamide	B-Drug
:	O
In	O
diabetic	O
patients	O
receiving	O
diflunisal	B-Drug
and	O
tolbutamide	B-Drug
,	O
no	O
significant	O
effects	O
were	O
seen	O
on	O
tolbutamide	B-Drug
plasma	O
levels	O
or	O
fasting	O
blood	O
glucose	B-Drug
.	O

Hydrochlorothiazide	B-Drug
:	O
In	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
hydrochlorothiazide	B-Drug
resulted	O
in	O
significantly	O
increased	O
plasma	O
levels	O
of	O
hydrochlorothiazide	B-Drug
.	O

Diflunisal	B-Drug
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
hydrochlorothiazide	B-Drug
.	O

Furosemide	B-Drug
:	O
In	O
normal	O
volunteers	O
,	O
the	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
furosemide	B-Drug
had	O
no	O
effect	O
on	O
the	O
diuretic	B-Drug
activity	O
of	O
furosemide	B-Drug
.	O

Diflunisal	B-Drug
decreased	O
the	O
hyperuricemic	O
effect	O
of	O
furosemide	B-Drug
.	O

Antacids	O
:	O
Concomitant	O
administration	O
of	O
antacids	O
may	O
reduce	O
plasma	O
levels	O
of	O
diflunisal	B-Drug
.	O

This	O
effect	O
is	O
small	O
with	O
occasional	O
doses	O
of	O
antacids	O
,	O
but	O
may	O
be	O
clinically	O
significant	O
when	O
antacids	O
are	O
used	O
on	O
a	O
continuous	O
schedule	O
.	O

Acetaminophen	B-Drug
:	O
In	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
acetaminophen	B-Drug
resulted	O
in	O
an	O
approximate	O
50	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
acetaminophen	B-Drug
.	O

Acetaminophen	B-Drug
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	B-Drug
.	O

Since	O
acetaminophen	B-Drug
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
hepatotoxicity	O
,	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
acetaminophen	B-Drug
should	O
be	O
used	O
cautiously	O
,	O
with	O
careful	O
monitoring	O
of	O
patients	O
.	O

Concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
acetaminophen	B-Drug
in	O
dogs	O
,	O
but	O
not	O
in	O
rats	O
,	O
at	O
approximately	O
2	O
times	O
the	O
recommended	O
maximum	O
human	O
therapeutic	O
dose	O
of	O
each	O
(	O
40	O
to	O
52	O
mg/kg/day	O
of	O
diflunisal/acetaminophen	B-Drug
)	O
resulted	O
in	O
greater	O
gastrointestinal	O
toxicity	O
than	O
when	O
either	O
drug	B-Drug
was	O
administered	O
alone	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
has	O
not	O
been	O
established	O
.	O

Methotrexate	B-Drug
:	O
Caution	O
should	O
be	O
used	O
if	O
diflunisal	B-Drug
is	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O

Nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
have	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O

Cyclosporine	B-Drug
:	O
Administration	O
of	O
nonsteroial	O
anti-inflammatory	O
drugs	B-Drug
concomitantly	O
with	O
cyclosporine	B-Drug
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine-induced	B-Drug
toxicity	O
,	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O

NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	B-Drug
,	O
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O

Nonsteroidal	O
Anti-Inflammatory	O
Drugs	B-Drug
:	O
The	O
administration	O
of	O
diflunisal	B-Drug
to	O
normal	O
volunteers	O
receiving	O
indomethacin	B-Drug
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	B-Drug
.	O

In	O
some	O
patients	O
the	O
combined	O
use	O
of	O
indomethacin	B-Drug
and	O
diflunisal	B-Drug
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O

Therefore	O
,	O
indomethacin	B-Drug
and	O
diflunisal	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
.	O

The	O
concomitant	O
use	O
of	O
diflunisal	B-Drug
tablets	O
and	O
other	O
NSAIDs	O
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
,	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O

The	O
following	O
information	O
was	O
obtained	O
from	O
studies	O
in	O
normal	O
volunteers	O
.	O

Aspirin	B-Drug
:	O
In	O
normal	O
volunteers	O
,	O
a	O
small	O
decrease	O
in	O
diflunisal	B-Drug
levels	O
was	O
observed	O
when	O
multiple	O
doses	O
of	O
diflunisal	B-Drug
and	O
aspirin	B-Drug
were	O
administered	O
concomitantly	O
.	O

Sulindac	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
sulindac	B-Drug
in	O
normal	O
volunteers	O
resulted	O
in	O
lowering	O
of	O
the	O
plasma	O
levels	O
of	O
the	O
active	O
sulindac	B-Drug
sulfide	O
metabolite	O
by	O
approximately	O
one-third	O
.	O

Naproxen	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
diflunisal	B-Drug
and	O
naproxen	B-Drug
in	O
normal	O
volunteers	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
levels	O
of	O
naproxen	B-Drug
,	O
but	O
significantly	O
decreased	O
the	O
urinary	O
excretion	O
of	O
naproxen	B-Drug
and	O
its	O
glucuronide	O
metabolite	O
.	O

Naproxen	B-Drug
had	O
no	O
effect	O
on	O
plasma	O
levels	O
of	O
diflunisal	B-Drug
.	O

Drug	B-Drug
laboratory	O
Test	O
Interactions	O
Serum	O
Salicylate	B-Drug
Assays	O
:	O
Caution	O
should	O
be	O
used	O
in	O
interpreting	O
the	O
results	O
of	O
serum	O
salicylate	B-Drug
assays	O
when	O
diflunisal	B-Drug
is	O
present	O
.	O

Salicylate	B-Drug
levels	O
have	O
been	O
found	O
to	O
be	O
falsely	O
elevated	O
with	O
some	O
assay	O
methods	O
.	O

Potassium-depleting	O
diuretics	B-Drug
are	O
a	O
major	O
contributing	O
factor	O
to	O
digitalis	B-Drug
toxicity	O
.	O

Calcium	B-Drug
,	O
particularly	O
if	O
administered	O
rapidly	O
by	O
the	O
intravenous	O
route	O
,	O
may	O
produce	O
serious	O
arrhythmias	O
in	O
digitalized	O
patients	O
.	O

Quinidine	B-Drug
,	O
verapamil	B-Drug
,	O
amiodarone	B-Drug
,	O
propafenone	B-Drug
,	O
indomethacin	B-Drug
,	O
itraconazole	B-Drug
,	O
alprazolam	B-Drug
,	O
and	O
spironolactone	B-Drug
raise	O
the	O
serum	O
digoxin	B-Drug
concentration	O
due	O
to	O
a	O
reduction	O
in	O
clearance	O
and/or	O
in	O
volume	O
of	O
distribution	O
of	O
the	O
drug	B-Drug
,	O
with	O
the	O
implication	O
that	O
digitalis	B-Drug
intoxication	O
may	O
result	O
.	O

Erythromycin	B-Drug
and	O
clarithromycin	B-Drug
(	O
and	O
possibly	O
other	O
macrolide	O
antibiotics	B-Drug
)	O
and	O
tetracycline	B-Drug
may	O
increase	O
digoxin	B-Drug
absorption	O
in	O
patients	O
who	O
inactivate	O
digoxin	B-Drug
by	O
bacterial	O
metabolism	O
in	O
the	O
lower	O
intestine	O
,	O
so	O
that	O
digitalis	B-Drug
intoxication	O
may	O
result	O
.	O

The	O
risk	O
of	O
this	O
interaction	O
may	O
be	O
reduced	O
if	O
digoxin	B-Drug
is	O
given	O
as	O
capsules	O
.	O

Propantheline	B-Drug
and	O
diphenoxylate	B-Drug
,	O
by	O
decreasing	O
gut	O
motility	O
,	O
may	O
increase	O
digoxin	B-Drug
absorption	O
.	O

Antacids	O
,	O
kaolin-pectin	B-Drug
,	O
sulfasalazine	B-Drug
,	O
neomycin	B-Drug
,	O
cholestyramine	B-Drug
,	O
certain	O
anticancer	O
drugs	B-Drug
,	O
and	O
metoclopramide	B-Drug
may	O
interfere	O
with	O
intestinal	O
digoxin	B-Drug
absorption	O
,	O
resulting	O
in	O
unexpectedly	O
low	O
serum	O
concentrations	O
.	O

Rifampin	B-Drug
may	O
decrease	O
serum	O
digoxin	B-Drug
concentration	O
,	O
especially	O
in	O
patients	O
with	O
renal	O
dysfunction	O
,	O
by	O
increasing	O
the	O
non-renal	O
clearance	O
of	O
digoxin	B-Drug
.	O

There	O
have	O
been	O
inconsistent	O
reports	O
regarding	O
the	O
effects	O
of	O
other	O
drugs	B-Drug
(	O
e.g.	O
,	O
quinine	B-Drug
,	O
penicillamine	B-Drug
)	O
on	O
serum	O
digoxin	B-Drug
concentration	O
.	O

Thyroid	B-Drug
administration	O
to	O
a	O
digitalized	O
,	O
hypothyroid	O
patient	O
may	O
increase	O
the	O
dose	O
requirement	O
of	O
digoxin	B-Drug
.	O

Concomitant	O
use	O
of	O
digoxin	B-Drug
and	O
sympathomimetics	O
increases	O
the	O
risk	O
of	O
cardiac	O
arrhythmias	O
.	O

Succinylcholine	B-Drug
may	O
cause	O
a	O
sudden	O
extrusion	O
of	O
potassium	B-Drug
from	O
muscle	O
cells	O
,	O
and	O
may	O
thereby	O
cause	O
arrhythmias	O
in	O
digitalized	O
patients	O
.	O

Although	O
beta-adrenergic	O
blockers	O
or	O
calcium	B-Drug
channel	O
blockers	O
and	O
digoxin	B-Drug
may	O
be	O
useful	O
in	O
combination	O
to	O
control	O
atrial	O
fibrillation	O
,	O
their	O
additive	O
effects	O
on	O
AV	O
node	O
conduction	O
can	O
result	O
in	O
advanced	O
or	O
complete	O
heart	O
block	O
.	O

Due	O
to	O
the	O
considerable	O
variability	O
of	O
these	O
interactions	O
,	O
the	O
dosage	O
of	O
digoxin	B-Drug
should	O
be	O
individualized	O
when	O
patients	O
receive	O
these	O
medications	O
concurrently	O
.	O

Furthermore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
combining	O
digoxin	B-Drug
with	O
any	O
drug	B-Drug
that	O
may	O
cause	O
a	O
significant	O
deterioration	O
in	O
renal	O
function	O
,	O
since	O
a	O
decline	O
in	O
glomerular	O
filtration	O
or	O
tubular	O
secretion	O
may	O
impair	O
the	O
excretion	O
of	O
digoxin	B-Drug
.	O

Vasoconstrictors	O
:	O
D.H.E	B-Drug
.	B-Drug
45	I-Drug
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
,	O
USP	O
should	O
not	O
be	O
used	O
with	O
peripheral	O
vasoconstrictors	O
because	O
the	O
combination	O
may	O
cause	O
synergistic	O
elevation	O
of	O
blood	O
pressure	O
.	O

Sumatriptan	B-Drug
:	O
Sumatriptan	B-Drug
has	O
been	O
reported	O
to	O
cause	O
coronary	O
artery	O
vasospasm	O
,	O
and	O
its	O
effect	O
could	O
be	O
additive	O
with	O
D.H.E	B-Drug
.	B-Drug
45	I-Drug
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
,	O
USP	O
.	O

Sumatriptan	B-Drug
and	O
D.H.E	B-Drug
.	B-Drug
45	I-Drug
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
,	O
USP	O
should	O
not	O
be	O
taken	O
within	O
24	O
hours	O
of	O
each	O
other..	O
Beta	O
Blockers	O
:	O
Although	O
the	O
results	O
of	O
a	O
clinical	O
study	O
did	O
not	O
indicate	O
a	O
safe	O
problem	O
associated	O
with	O
the	O
administration	O
of	O
D.H.E	B-Drug
.	B-Drug
45	I-Drug
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
,	O
USP	O
to	O
subjects	O
already	O
receiving	O
propranolol	B-Drug
,	O
there	O
have	O
been	O
reports	O
that	O
propranolol	B-Drug
may	O
potentiate	O
the	O
vasoconstrictive	O
action	O
of	O
ergotamine	B-Drug
by	O
blocking	O
the	O
vasodilating	O
property	O
of	O
epinephrine	B-Drug
.	O

Nicotine	B-Drug
:	O
Nicotine	B-Drug
may	O
provoke	O
vasoconstriction	O
in	O
some	O
patients	O
,	O
predisposing	O
to	O
a	O
greater	O
ischemic	O
response	O
to	O
ergot	B-Drug
therapy	O
.	O

Macrolide	O
Antibiotics	B-Drug
(	O
e.	O
g.	O
erythromycin	B-Drug
and	O
troleandomycin	B-Drug
)	O
:	O
Agents	O
of	O
the	O
ergot	B-Drug
alkaloid	O
class	O
,	O
of	O
which	O
D.H.E	B-Drug
.	B-Drug
45	I-Drug
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
,	O
USP	O
is	O
a	O
member	O
,	O
have	O
been	O
shown	O
to	O
interact	O
with	O
antibiotics	B-Drug
of	O
the	O
macrolide	O
class	O
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
unchanged	O
alkaloids	O
and	O
peripheral	O
vasoconstriction	O
.	O

Vasospastic	O
reactions	O
have	O
been	O
reported	O
with	O
therapeutic	O
doses	O
of	O
ergotamine-containing	B-Drug
drugs	B-Drug
when	O
co-administered	O
with	O
these	O
antibiotics	B-Drug
.	O

SSRIs	O
:	O
Weakness	O
hyperreflexia	O
,	O
and	O
incoordination	O
have	O
been	O
reported	O
rarely	O
when	O
5-HT1	O
agonists	O
have	O
been	O
co-administered	O
with	O
SSRIs	O
(	O
e.	O
g	O
.	O

fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
paroxetine	B-Drug
,	O
sertraline	B-Drug
)	O
.	O

There	O
have	O
been	O
no	O
reported	O
cases	O
from	O
spontaneous	O
reports	O
of	O
drug	B-Drug
interaction	O
between	O
SSRIs	O
and	O
D.H.E	B-Drug
.	B-Drug
45	I-Drug
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
,	O
USP	O
.	O

Oral	O
Contraceptives	O
:	O
The	O
effect	O
of	O
oral	O
contraceptives	O
on	O
the	O
pharmacokinetics	O
of	O
D.H.E	B-Drug
.	B-Drug
45	I-Drug
(	O
dihydroergotamine	B-Drug
mesylate	I-Drug
)	O
Injection	O
,	O
USP	O
has	O
not	O
been	O
studied	O
.	O

Administration	O
of	O
thiazide	O
diuretics	B-Drug
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
dihydrotachysterol	B-Drug
may	O
cause	O
hypercalcemia	O
.	O

Due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
,	O
caution	O
and	O
careful	O
titration	O
are	O
warranted	O
in	O
patients	O
receiving	O
diltiazem	B-Drug
hydrochloride	I-Drug
concomitantly	O
with	O
other	O
agents	O
known	O
to	O
affect	O
cardiac	O
contractility	O
and/or	O
conduction	O
.	O

Pharmacologic	O
studies	O
indicate	O
that	O
there	O
may	O
be	O
additive	O
effects	O
in	O
prolonging	O
AV	O
conduction	O
when	O
using	O
beta-blockers	O
or	O
digitalis	B-Drug
concomitantly	O
with	O
Tiazac	B-Drug
.	O

As	O
with	O
all	O
drugs	B-Drug
,	O
care	O
should	O
be	O
exercised	O
when	O
treating	O
patients	O
with	O
multiple	O
medications	O
.	O

Diltiazem	B-Drug
is	O
both	O
a	O
substrate	O
and	O
an	O
inhibitor	O
of	O
the	O
cytochrome	O
P-450	O
3A4	O
enzyme	O
system	O
.	O

Other	O
drugs	B-Drug
that	O
are	O
specific	O
substrates	O
,	O
inhibitors	O
,	O
or	O
inducers	O
of	O
the	O
enzyme	O
system	O
may	O
have	O
a	O
significant	O
impact	O
on	O
the	O
efficacy	O
and	O
side	O
effect	O
profile	O
of	O
diltiazem	B-Drug
.	O

Patients	O
taking	O
other	O
drugs	B-Drug
that	O
are	O
substrates	O
of	O
CYP450	O
3A4	O
,	O
especially	O
patients	O
with	O
renal	O
and/or	O
hepatic	O
impairment	O
,	O
may	O
require	O
dosage	O
adjustment	O
when	O
starting	O
or	O
stopping	O
concomitantly	O
administered	O
diltiazem	B-Drug
in	O
order	O
to	O
maintain	O
optimum	O
therapeutic	O
blood	O
levels	O
.	O

Beta	O
Blockers	O
Controlled	O
and	O
uncontrolled	O
domestic	O
studies	O
suggest	O
that	O
concomitant	O
use	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
and	O
beta-blockers	O
is	O
usually	O
well	O
tolerated	O
,	O
but	O
available	O
data	O
are	O
not	O
sufficient	O
to	O
predict	O
the	O
effects	O
of	O
concomitant	O
treatment	O
in	O
patients	O
with	O
left	O
ventricular	O
dysfunction	O
or	O
cardiac	O
conduction	O
abnormalities	O
.	O

Administration	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
concomitantly	O
with	O
propranolol	B-Drug
in	O
five	O
normal	O
volunteers	O
resulted	O
in	O
increased	O
propranolol	B-Drug
levels	O
in	O
all	O
subjects	O
and	O
bioavailability	O
of	O
propranolol	B-Drug
was	O
increased	O
approximately	O
50	O
%	O
.	O

In	O
vitro	O
,	O
propranolol	B-Drug
appears	O
to	O
be	O
displaced	O
from	O
its	O
binding	O
sites	O
by	O
diltiazem	B-Drug
.	O

If	O
combination	O
therapy	O
is	O
initiated	O
or	O
withdrawn	O
in	O
conjunction	O
with	O
propranolol	B-Drug
,	O
an	O
adjustment	O
in	O
the	O
propranolol	B-Drug
dose	O
may	O
be	O
warranted	O
.	O

Cimetidine	B-Drug
A	O
study	O
in	O
six	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
diltiazem	B-Drug
plasma	O
levels	O
(	O
58	O
%	O
)	O
and	O
AUC	O
(	O
53	O
%	O
)	O
after	O
a	O
1-week	O
course	O
of	O
cimetidine	B-Drug
1200	O
mg/day	O
and	O
a	O
single	O
dose	O
of	O
diltiazem	B-Drug
60mg	O
.	O

Ranitidine	B-Drug
produced	O
smaller	O
,	O
nonsignificant	O
increases	O
.	O

The	O
effect	O
may	O
be	O
mediated	O
by	O
cimetidines	B-Drug
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P-450	O
,	O
the	O
enzyme	O
system	O
responsible	O
for	O
the	O
first-pass	O
metabolism	O
of	O
diltiazem	B-Drug
.	O

Patients	O
currently	O
receiving	O
diltiazem	B-Drug
therapy	O
should	O
be	O
carefully	O
monitored	O
for	O
a	O
change	O
in	O
pharmacological	O
effect	O
when	O
initiating	O
and	O
discontinuing	O
therapy	O
with	O
cimetidine	B-Drug
.	O

An	O
adjustment	O
in	O
the	O
diltiazem	B-Drug
dose	O
may	O
be	O
warranted	O
.	O

Digitalis	B-Drug
Administration	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
with	O
digoxin	B-Drug
in	O
24	O
healthy	O
male	O
subjects	O
increased	O
plasma	O
digoxin	B-Drug
concentrations	O
approximately	O
20	O
%	O
.	O

Another	O
investigator	O
found	O
no	O
increase	O
in	O
digoxin	B-Drug
levels	O
in	O
12	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

Since	O
there	O
have	O
been	O
conflicting	O
results	O
regarding	O
the	O
effect	O
of	O
digoxin	B-Drug
levels	O
,	O
it	O
is	O
recommended	O
that	O
digoxin	B-Drug
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
diltiazem	B-Drug
hydrochloride	I-Drug
therapy	O
to	O
avoid	O
possible	O
over-	O
or	O
under-digitalization	O
.	O

Anesthetics	B-Drug
The	O
depression	O
of	O
cardiac	O
contractility	O
,	O
conductivity	O
,	O
and	O
automaticity	O
as	O
well	O
as	O
the	O
vascular	O
dilation	O
associated	O
with	O
anesthetics	B-Drug
may	O
be	O
potentiated	O
by	O
calcium	B-Drug
channel	O
blockers	O
.	O

When	O
used	O
concomitantly	O
,	O
anesthetics	B-Drug
and	O
calcium	B-Drug
channel	O
blockers	O
should	O
be	O
titrated	O
carefully	O
.	O

Cyclosporine	B-Drug
A	O
pharmacokinetic	O
interaction	O
between	O
diltiazem	B-Drug
and	O
cyclosporine	B-Drug
has	O
been	O
observed	O
during	O
studies	O
involving	O
renal	O
and	O
cardiac	O
transplant	O
patients	O
.	O

In	O
renal	O
and	O
cardiac	O
transplant	O
recipients	O
,	O
a	O
reduction	O
of	O
cyclosporine	B-Drug
dose	O
ranging	O
from	O
15	O
%	O
to	O
48	O
%	O
was	O
necessary	O
to	O
maintain	O
cyclosporine	B-Drug
trough	O
concentrations	O
similar	O
to	O
those	O
seen	O
prior	O
to	O
the	O
addition	O
of	O
diltiazem	B-Drug
.	O

If	O
these	O
agents	O
are	O
to	O
be	O
administered	O
concurrently	O
,	O
cyclosporine	B-Drug
concentrations	O
should	O
be	O
monitored	O
,	O
especially	O
when	O
diltiazem	B-Drug
therapy	O
is	O
initiated	O
,	O
adjusted	O
,	O
or	O
discontinued	O
.	O

The	O
effect	O
of	O
cyclosporine	B-Drug
on	O
diltiazem	B-Drug
plasma	O
concentrations	O
has	O
not	O
been	O
evaluated	O
.	O

Carbamazepine	B-Drug
Concomitant	O
administration	O
of	O
diltiazem	B-Drug
with	O
carbamazepine	B-Drug
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
carbamazepine	B-Drug
(	O
40	O
%	O
to	O
72	O
%	O
increase	O
)	O
,	O
resulting	O
in	O
toxicity	O
in	O
some	O
cases	O
.	O

Patients	O
receiving	O
these	O
drugs	B-Drug
concurrently	O
should	O
be	O
monitored	O
for	O
a	O
potential	O
drug	B-Drug
interaction	O
.	O

Benzodiazepines	B-Drug
Studies	O
showed	O
that	O
diltiazem	B-Drug
increased	O
the	O
AUC	O
of	O
midazolam	B-Drug
and	O
triazolam	B-Drug
by	O
3-4	O
fold	O
and	O
the	O
Cmax	O
by	O
2-fold	O
,	O
compared	O
to	O
placebo	O
.	O

The	O
elimination	O
half	O
life	O
of	O
midazolam	B-Drug
and	O
triazolam	B-Drug
also	O
increased	O
(	O
1.5-2.5	O
fold	O
)	O
during	O
coadministration	O
with	O
diltiazem	B-Drug
.	O

These	O
pharmacokinetic	O
effects	O
seen	O
during	O
diltiazem	B-Drug
coadministration	O
can	O
result	O
in	O
increased	O
clinical	O
effects	O
(	O
e.g.	O
,	O
prolonged	O
sodation	O
)	O
of	O
both	O
midazolam	B-Drug
and	O
triazolam	B-Drug
.	O

Lovastatin	B-Drug
In	O
a	O
ten-subject	O
study	O
,	O
coadministration	O
of	O
diltiazem	B-Drug
(	O
120	O
mg	O
bid	O
)	O
with	O
lovastatin	B-Drug
resulted	O
in	O
a	O
3-4	O
times	O
increase	O
in	O
mean	O
lovastatin	B-Drug
AUC	O
and	O
Cmax	O
vs.	O
lovastatin	B-Drug
alone	O
;	O
no	O
change	O
in	O
pravastatin	B-Drug
AUC	O
and	O
Cmax	O
was	O
observed	O
during	O
diltiazem	B-Drug
coadministration	O
.	O

Diltiazem	B-Drug
plasma	O
levels	O
were	O
not	O
significantly	O
affected	O
by	O
lovastatin	B-Drug
or	O
pravastatin	B-Drug
.	O

Rifampin	B-Drug
Coadministration	O
of	O
rifampin	B-Drug
with	O
diltiazem	B-Drug
lowered	O
the	O
diltiazem	B-Drug
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Coadministration	O
of	O
diltiazem	B-Drug
with	O
rifampin	B-Drug
or	O
any	O
known	O
CYP3A4	B-Drug
inducer	O
should	O
be	O
avoided	O
when	O
possible	O
,	O
and	O
alternative	O
therapy	O
considered	O
.	O

Dimenhydrinate	B-Drug
may	O
decrease	O
emetic	O
response	O
to	O
apomorphine	B-Drug
.	O

Oxytocin	B-Drug
or	O
other	O
oxytocics	O
(	O
concurrent	O
use	O
with	O
dinoprost	B-Drug
may	O
result	O
in	O
uterine	O
hypertonus	O
,	O
possibly	O
causing	O
uterine	O
rupture	O
or	O
cervical	O
laceration	O
,	O
especially	O
in	O
the	O
absence	O
of	O
adequate	O
cervical	O
dilatation	O
;	O
although	O
combinations	O
are	O
sometimes	O
used	O
for	O
therapeutic	O
advantage	O
,	O
when	O
used	O
concurrently	O
,	O
patient	O
should	O
be	O
closely	O
monitored	O
.	O

PROSTIN	B-Drug
E2	I-Drug
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	O
drugs	B-Drug
.	O

Concomitant	O
use	O
with	O
other	O
oxytocic	O
agents	O
is	O
not	O
recommended	O
.	O

Diphenhydramine	B-Drug
hydrochloride	I-Drug
has	O
additive	O
effects	O
with	O
alcohol	B-Drug
and	O
other	O
CNS	O
depressants	O
(	O
hypnotics	O
,	O
sedatives	O
,	O
tranquilizers	O
,	O
etc	O
)	O
.	O

MAO	O
inhibitors	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
(	O
drying	O
)	O
effects	O
of	O
antihistamines	B-Drug
.	O

CNS	O
depression	O
producing	O
medications	O
-	O
concurrent	O
use	O
may	O
potentiate	O
the	O
effects	O
of	O
either	O
these	O
medications	O
or	O
diphenidol	B-Drug
;	O
anticholinergics	O
or	O
other	O
medications	O
with	O
anticholinergic	B-Drug
activity	O
-	O
anticholinergic	B-Drug
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
diphenidol	B-Drug
;	O
apomorphine	B-Drug
-	O
prior	O
ingestion	O
of	O
diphenidol	B-Drug
may	O
decrease	O
the	O
emetic	O
response	O
to	O
apomorphine	B-Drug
in	O
the	O
treatment	O
of	O
poisoning	O
.	O

Known	O
drug	B-Drug
interactions	O
include	O
barbiturates	B-Drug
,	O
tranquilizers	O
,	O
and	O
alcohol	B-Drug
.	O

Diphenoxylate	B-Drug
HCl	I-Drug
and	O
atropine	B-Drug
sulfate	I-Drug
may	O
interact	O
with	O
MAO	O
inhibitors	O
In	O
studies	O
with	O
male	O
rats	O
,	O
diphenoxylate	B-Drug
hydrochloride	I-Drug
was	O
found	O
to	O
inhibit	O
the	O
hepatic	O
microsomal	O
enzyme	O
system	O
at	O
a	O
dose	O
of	O
2	O
mg/kg/day	O
.	O

Therefore	O
,	O
diphenoxylate	B-Drug
has	O
the	O
potential	O
to	O
prolong	O
the	O
biological	O
half-lives	O
of	O
drugs	B-Drug
for	O
which	O
the	O
rate	O
of	O
elimination	O
is	O
dependent	O
on	O
the	O
microsomal	O
drug	B-Drug
metabolizing	O
enzyme	O
system	O
.	O

This	O
drug	B-Drug
may	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	O
depressants	O
(	O
may	O
potentiate	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B-Drug
)	O
,	O
anticholinergics	O
or	O
other	O
medications	O
with	O
anticholinergic	B-Drug
activity	O
(	O
anticholinergic	B-Drug
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B-Drug
)	O
,	O
and	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
(	O
concurrent	O
use	O
with	O
antihistamines	B-Drug
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-Drug
and	O
CNS	O
depressant	O
effects	O
of	O
antihistamines	B-Drug
)	O
.	O

No	O
pharmacokinetic	O
drug-drug	O
interaction	O
studies	O
were	O
conducted	O
with	O
PERSANTINE	B-Drug
(	O
dipyridamole	B-Drug
USP	O
)	O
Tablets	O
.	O

The	O
following	O
information	O
was	O
obtained	O
from	O
the	O
literature	O
.	O

Adenosine	B-Drug
:	O
Dipyridamole	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
plasma	O
levels	O
and	O
cardiovascular	O
effects	O
of	O
adenosine	B-Drug
.	O

Adjustment	O
of	O
adenosine	B-Drug
dosage	O
may	O
be	O
necessary	O
.	O

Cholinesterase	O
Inhibitors	O
:	O
Dipyridamole	B-Drug
may	O
counteract	O
the	O
anticholinesterase	O
effect	O
of	O
cholinesterase	O
inhibitors	O
,	O
thereby	O
potentially	O
aggravating	O
myasthenia	O
gravis	O
.	O

Terfenadine	B-Drug
:	O
In	O
a	O
prospective	O
study	O
involving	O
six-healthy-male	O
volunteers	O
,	O
dirithromycin	B-Drug
did	O
not	O
affect	O
the	O
metabolism	O
of	O
terfenadine	B-Drug
.	O

These	O
six	O
volunteers	O
received	O
terfenadine	B-Drug
alone	O
(	O
60	O
mg	O
twice	O
daily	O
)	O
for	O
8	O
days	O
,	O
followed	O
by	O
terfenadine	B-Drug
in	O
combination	O
with	O
dirithromycin	B-Drug
(	O
500	O
mg	O
once	O
daily	O
)	O
for	O
10	O
days	O
.	O

(	O
Both	O
drugs	B-Drug
were	O
thus	O
dosed	O
to	O
steady	O
state	O
.	O

)	O
The	O
pharmacokinetics	O
of	O
terfenadine	B-Drug
and	O
its	O
acid	O
metabolite	O
and	O
the	O
electrocardiographic	O
QT	O
c	O
interval	O
were	O
measured	O
during	O
both	O
periods	O
:	O
with	O
terfenadine	B-Drug
alone	O
,	O
and	O
with	O
terfenadine	B-Drug
plus	O
dirithromycin	B-Drug
.	O

In	O
five	O
men	O
,	O
terfenadine	B-Drug
levels	O
were	O
undetectable	O
(	O
5	O
ng/mL	O
)	O
throughout	O
the	O
study	O
;	O
in	O
one	O
man	O
,	O
the	O
C	O
max	O
of	O
terfenadine	B-Drug
was	O
8.1	O
ng/mL	O
with	O
terfenadine	B-Drug
alone	O
and	O
7.2	O
ng/mL	O
with	O
terfenadine	B-Drug
plus	O
dirithromycin	B-Drug
.	O

The	O
mean	O
C	O
max	O
,	O
T	O
max	O
,	O
and	O
AUC	O
of	O
the	O
acid	O
metabolite	O
of	O
terfenadine	B-Drug
were	O
not	O
significantly	O
changed	O
.	O

The	O
mean	O
QT	O
c	O
interval	O
(	O
msec	O
)	O
was	O
369	O
with	O
terfenadine	B-Drug
alone	O
and	O
367	O
with	O
terfenadine	B-Drug
plus	O
dirithromycin	B-Drug
.	O

Also	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
lack	O
of	O
interaction	O
between	O
dirithromycin	B-Drug
and	O
terfenadine	B-Drug
.	O

Thus	O
,	O
the	O
interaction	O
observed	O
between	O
erythromycin	B-Drug
and	O
terfenadine	B-Drug
is	O
not	O
expected	O
for	O
dirithromycin	B-Drug
.	O

Serious	O
cardiac	O
dysrhythmias	O
,	O
some	O
resulting	O
in	O
death	O
,	O
have	O
occurred	O
in	O
patients	O
receiving	O
terfenadine	B-Drug
concomitantly	O
with	O
other	O
macrolide	O
antibiotics	B-Drug
.	O

In	O
addition	O
,	O
most	O
macrolides	O
are	O
contraindicated	O
in	O
patients	O
receiving	O
terfenadine	B-Drug
therapy	O
who	O
have	O
pre-existing	O
cardiac	O
abnormalities	O
(	O
arrhythmia	O
,	O
bradycardia	O
,	O
QT	O
c	O
interval	O
prolongation	O
,	O
ischemic	O
heart	O
disease	O
,	O
congestive	O
heart	O
failure	O
,	O
etc	O
.	O

)	O
or	O
electrolyte	O
disturbances	O
.	O

Theophylline	B-Drug
:	O
Following	O
co-administration	O
of	O
two	O
250-mg	O
dirithromycin	B-Drug
tablets	O
administered	O
once	O
daily	O
with	O
200-mg	O
theophylline	B-Drug
tablets	O
administered	O
twice	O
daily	O
for	O
10	O
days	O
to	O
14	O
healthy	O
subjects	O
,	O
the	O
steady-state	O
plasma	O
concentration	O
of	O
theophylline	B-Drug
was	O
not	O
significantly	O
altered	O
.	O

In	O
general	O
,	O
most	O
patients	O
treated	O
with	O
dirithromycin	B-Drug
who	O
are	O
receiving	O
concomitant	O
theophylline	B-Drug
therapy	O
may	O
not	O
require	O
empiric	O
adjustment	O
of	O
theophylline	B-Drug
dosage	O
or	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
concentrations	O
.	O

However	O
,	O
theophylline	B-Drug
plasma	O
concentrations	O
should	O
be	O
monitored	O
,	O
with	O
dosage	O
adjustment	O
as	O
appropriate	O
,	O
in	O
patients	O
whose	O
pulmonary	O
disease	O
requires	O
maintaining	O
a	O
given	O
theophylline	B-Drug
plasma	O
concentration	O
for	O
optimal	O
pulmonary	O
function	O
or	O
in	O
patients	O
with	O
theophylline	B-Drug
concentrations	O
at	O
the	O
higher	O
end	O
of	O
the	O
therapeutic	O
range	O
.	O

Antacids	O
or	O
H	O
2	O
receptor	O
antagonists	O
:	O
When	O
dirithromycin	B-Drug
is	O
administered	O
immediately	O
following	O
antacids	O
or	O
H	O
2	O
-receptor	B-Drug
antagonists	O
,	O
the	O
absorption	O
of	O
dirithromycin	B-Drug
is	O
slightly	O
enhanced	O
.	O

The	O
following	O
drug	B-Drug
interactions	O
have	O
been	O
reported	O
with	O
erythromycin	B-Drug
products	O
.	O

It	O
is	O
presently	O
not	O
known	O
whether	O
these	O
same	O
drug	B-Drug
interactions	O
occur	O
with	O
dirithromycin	B-Drug
.	O

Until	O
further	O
data	O
are	O
available	O
regarding	O
the	O
potential	O
interaction	O
of	O
dirithromycin	B-Drug
with	O
these	O
compounds	O
,	O
caution	O
should	O
be	O
used	O
during	O
coadministration	O
.	O

Triazolam	B-Drug
:	O
Erythromycin	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	B-Drug
and	O
,	O
thus	O
,	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
triazolam	B-Drug
.	O

Digoxin	B-Drug
:	O
Concomitant	O
administration	O
of	O
erythromycin	B-Drug
and	O
digoxin	B-Drug
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	B-Drug
serum	O
levels	O
.	O

Anticoagulants	B-Drug
:	O
There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	B-Drug
effects	O
when	O
erythromycin	B-Drug
and	O
oral	O
anticoagulants	B-Drug
were	O
used	O
concomitantly	O
.	O

Increased	O
anticoagulation	O
effects	O
due	O
to	O
a	O
drug	B-Drug
interaction	O
with	O
erythromycin	B-Drug
may	O
be	O
more	O
pronounced	O
in	O
the	O
elderly	O
.	O

Ergotamine	B-Drug
:	O
Concurrent	O
use	O
of	O
erythromycin	B-Drug
and	O
ergotamine	B-Drug
or	O
dihydroergotamine	B-Drug
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	B-Drug
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Other	O
drugs	B-Drug
Drug	B-Drug
interactions	O
have	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
erythromycin	B-Drug
and	O
other	O
medications	O
,	O
including	O
cyclosporine	B-Drug
,	O
hexobarbital	B-Drug
,	O
carbamazepine	B-Drug
,	O
alfentanil	B-Drug
,	O
disopyramide	B-Drug
,	O
phenytoin	B-Drug
,	O
bromocriptine	B-Drug
,	O
valproate	B-Drug
,	O
astemizole	B-Drug
,	O
and	O
lovastatin	B-Drug
.	O

If	O
phenytoin	B-Drug
or	O
other	O
hepatic	O
enzyme	O
inducers	O
are	O
taken	O
concurrently	O
with	O
Norpace	B-Drug
or	O
Norpace	B-Drug
CR	I-Drug
,	O
lower	O
plasma	O
levels	O
of	O
disopyramide	B-Drug
may	O
occur	O
.	O

Monitoring	O
of	O
disopyramide	B-Drug
plasma	O
levels	O
is	O
recommended	O
in	O
such	O
concurrent	O
use	O
to	O
avoid	O
ineffective	O
therapy	O
.	O

Other	O
antiarrhythmic	B-Drug
drugs	B-Drug
(	O
eg	O
,	O
quinidine	B-Drug
,	O
procainamide	B-Drug
,	O
lidocaine	B-Drug
,	O
propranolol	B-Drug
)	O
have	O
occasionally	O
been	O
used	O
concurrently	O
with	O
Norpace	B-Drug
.	O

Excessive	O
widening	O
of	O
the	O
QRS	O
complex	O
and/or	O
prolongation	O
of	O
the	O
Q-T	O
interval	O
may	O
occur	O
in	O
these	O
situations	O
.	O

In	O
healthy	O
subjects	O
,	O
no	O
significant	O
drug-drug	O
interaction	O
was	O
observed	O
when	O
Norpace	B-Drug
was	O
coadministered	O
with	O
either	O
propranolol	B-Drug
or	O
diazepam	B-Drug
.	O

Concomitant	O
administration	O
of	O
Norpace	B-Drug
and	O
quinidine	B-Drug
resulted	O
in	O
slight	O
increases	O
in	O
plasma	O
disopyramide	B-Drug
levels	O
and	O
slight	O
decreases	O
in	O
plasma	O
quinidine	B-Drug
levels	O
.	O

Norpace	B-Drug
does	O
not	O
increase	O
serum	O
digoxin	B-Drug
levels	O
.	O

Patients	O
taking	O
disopyramide	B-Drug
phosphate	I-Drug
and	O
erythromycin	B-Drug
concomitantly	O
may	O
develop	O
increased	O
serum	O
concentrations	O
of	O
disopyramide	B-Drug
resulting	O
in	O
excessive	O
widening	O
of	O
the	O
QRS	O
complex	O
and/or	O
prolongation	O
of	O
the	O
Q-T	O
interval	O
.	O

Patients	O
taking	O
disopyramide	B-Drug
phosphate	I-Drug
and	O
hepatic	O
enzyme	O
inhibitors	O
concomitantly	O
should	O
be	O
closely	O
monitored	O
.	O

Until	O
data	O
on	O
possible	O
interactions	O
between	O
verapamil	B-Drug
and	O
disopyramide	B-Drug
phosphate	I-Drug
are	O
obtained	O
,	O
disopyramide	B-Drug
should	O
not	O
be	O
administered	O
within	O
48	O
hours	O
before	O
or	O
24	O
hours	O
after	O
verapamil	B-Drug
administration	O
.	O

Disulfiram	B-Drug
appears	O
to	O
decrease	O
the	O
rate	O
at	O
which	O
certain	O
drugs	B-Drug
are	O
metabolized	O
and	O
therefore	O
may	O
increase	O
the	O
blood	O
levels	O
and	O
the	O
possibility	O
of	O
clinical	O
toxicity	O
of	O
drugs	B-Drug
given	O
concomitantly	O
.	O

DISULFIRAM	B-Drug
SHOULD	O
BE	O
USED	O
WITH	O
CAUTION	O
IN	O
THOSE	O
PATIENTS	O
REVEIVING	O
PHENYTOIN	B-Drug
AND	O
ITS	O
CONGENERS	O
.	O

SINCE	O
THE	O
CONCOMITANT	O
ADMINISTRATION	O
OF	O
THESE	O
TWO	O
DRUGS	B-Drug
CAN	O
LEAD	B-Drug
TO	O
PHENYTOIN	B-Drug
INTOXICATION	O
,	O
PRIOR	O
TO	O
ADMINISTERING	O
DISULFIRAM	B-Drug
TO	O
A	O
PATIENT	O
ON	O
PHENYTOIN	B-Drug
THERAPY	O
,	O
A	O
BASELINE	O
PHENYTOIN	B-Drug
SERUM	O
LEVEL	O
SHOULD	O
BE	O
OBTAINED	O
.	O

SUBSEQUENT	O
TO	O
INITIATION	O
OF	O
DISULFIRAM	B-Drug
THERAPY	O
.	O

SERUM	O
LEVELS	O
OF	O
PHENYTOIN	B-Drug
SHOULD	O
BE	O
DETERMINED	O
ON	O
DIFFERENT	O
DAYS	O
FOR	O
EVIDENCE	O
OF	O
AN	O
INCREASE	O
OR	O
FOR	O
A	O
CONTINUING	O
RISE	O
IN	O
LEVELS	O
.	O

INCREASED	O
PHENYTOIN	B-Drug
LEVELS	O
SHOULD	O
BE	O
TREATED	O
WITH	O
APPROPRIATE	O
DOSAGE	O
ADJUSTMENT	O
.	O

It	O
may	O
be	O
necessary	O
to	O
adjust	O
the	O
dosage	O
of	O
oral	O
anticoagulants	B-Drug
upon	O
beginning	O
or	O
stopping	O
disulfiram	B-Drug
.	O

since	O
disulfiram	B-Drug
may	O
prolong	O
prothrombin	O
time	O
.	O

Patients	O
taking	O
isoniazid	B-Drug
when	O
disulfiram	B-Drug
is	O
given	O
should	O
be	O
observed	O
for	O
the	O
appearance	O
of	O
unsteady	O
gait	O
or	O
marked	O
changes	O
in	O
mental	O
status	O
;	O
the	O
disulfiram	B-Drug
should	O
be	O
discontinued	O
if	O
such	O
signs	O
appear	O
.	O

In	O
rats	O
,	O
simultaneous	O
ingestion	O
of	O
disulfiram	B-Drug
and	O
nitrite	B-Drug
in	O
the	O
diet	O
for	O
78	O
weeks	O
has	O
been	O
reported	O
to	O
cause	O
tumors	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
disulfiram	B-Drug
may	O
react	O
with	O
nitrites	O
in	O
the	O
rat	O
stomach	O
to	O
form	O
a	O
nitrosamine	O
,	O
which	O
is	O
tumorigenic	O
.	O

Disulfiram	B-Drug
alone	O
in	O
the	O
rat	O
s	O
diet	O
did	O
not	O
lead	B-Drug
to	O
such	O
tumors	O
.	O

The	O
relevance	O
of	O
this	O
finding	O
to	O
humans	O
is	O
not	O
known	O
at	O
this	O
time	O
.	O

Animal	O
studies	O
indicate	O
that	O
dobutamine	B-Drug
may	O
be	O
ineffective	O
if	O
the	O
patient	O
has	O
recently	O
received	O
a	O
b-blocking	O
drug	B-Drug
.	O

In	O
such	O
a	O
case	O
,	O
the	O
peripheral	O
vascular	O
resistance	O
may	O
increase	O
.	O

Preliminary	O
studies	O
indicate	O
that	O
the	O
concomitant	O
use	O
of	O
dobutamine	B-Drug
and	O
nitroprusside	B-Drug
results	O
in	O
a	O
higher	O
cardiac	O
output	O
and	O
,	O
usually	O
,	O
a	O
lower	O
pulmonary	O
wedge	O
pressure	O
than	O
when	O
either	O
drug	B-Drug
is	O
used	O
alone	O
.	O

There	O
was	O
no	O
evidence	O
of	O
drug	B-Drug
interactions	O
in	O
clinical	O
studies	O
in	O
which	O
dobutamine	B-Drug
was	O
administered	O
concurrently	O
with	O
other	O
drugs	B-Drug
,	O
including	O
digitalis	B-Drug
preparations	O
,	O
furosemide	B-Drug
,	O
spironolactone	B-Drug
,	O
lidocaine	B-Drug
,	O
glyceryl	B-Drug
trinitrate	I-Drug
,	O
isosorbide	B-Drug
dinitrate	I-Drug
,	O
morphine	B-Drug
,	O
atropine	B-Drug
,	O
heparin	B-Drug
,	O
protamine	B-Drug
,	O
potassium	B-Drug
chloride	I-Drug
,	O
folic	B-Drug
acid	I-Drug
,	O
and	O
acetaminophen	B-Drug
.	O

There	O
have	O
been	O
no	O
formal	O
clinical	O
studies	O
to	O
evaluate	O
the	O
drug	B-Drug
interactions	O
of	O
TAXOTERE	B-Drug
with	O
other	O
medications	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
metabolism	O
of	O
docetaxel	B-Drug
may	O
be	O
modified	O
by	O
the	O
concomitant	O
administration	O
of	O
compounds	O
that	O
induce	O
,	O
inhibit	O
,	O
or	O
are	O
metabolized	O
by	O
cytochrome	O
P450	O
3A4	O
,	O
such	O
as	O
cyclosporine	B-Drug
,	O
terfenadine	B-Drug
,	O
ketoconazole	B-Drug
,	O
erythromycin	B-Drug
,	O
and	O
troleandomycin	B-Drug
.	O

Caution	O
should	O
be	O
exercised	O
with	O
these	O
drugs	B-Drug
when	O
treating	O
patients	O
receiving	O
TAXOTERE	B-Drug
as	O
there	O
is	O
a	O
potential	O
for	O
a	O
significant	O
interaction	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

Drug-Drug	O
Interactions	O
Cimetidine	B-Drug
:	O
Concomitant	O
use	O
of	O
cimetidine	B-Drug
is	O
contraindicated	O
.	O

Cimetidine	B-Drug
at	O
400	O
mg	O
BID	O
(	O
the	O
usual	O
prescription	O
dose	O
)	O
co-administered	O
with	O
TIKOSYN	B-Drug
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B-Drug
plasma	O
levels	O
by	O
58	O
%	O
.	O

Cimetidine	B-Drug
at	O
doses	O
of	O
100	O
mg	O
BID	O
(	O
OTC	O
dose	O
)	O
resulted	O
in	O
a	O
13	O
%	O
increase	O
in	O
dofetilide	B-Drug
plasma	O
levels	O
(	O
500	O
mcg	O
single	O
dose	O
)	O
.	O

No	O
studies	O
have	O
been	O
conducted	O
at	O
intermediate	O
doses	O
of	O
cimetidine	B-Drug
.	O

If	O
a	O
patient	O
requires	O
TIKOSYN	B-Drug
and	O
anti-ulcer	O
therapy	O
,	O
it	O
is	O
suggested	O
that	O
omeprazole	B-Drug
,	O
ranitidine	B-Drug
,	O
or	O
antacids	O
(	O
aluminum	B-Drug
and	O
magnesium	B-Drug
hydroxides	I-Drug
)	O
be	O
used	O
as	O
alternatives	O
to	O
cimetidine	B-Drug
,	O
as	O
these	O
agents	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
profile	O
of	O
TIKOSYN	B-Drug
.	O

Verapamil	B-Drug
:	O
Concomitant	O
use	O
of	O
verapamil	B-Drug
is	O
contraindicated	O
.	O

Co-administration	O
of	O
TIKOSYN	B-Drug
with	O
verapamil	B-Drug
resulted	O
in	O
increases	O
in	O
dofetilide	B-Drug
peak	O
plasma	O
levels	O
of	O
42	O
%	O
,	O
although	O
overall	O
exposure	O
to	O
dofetilide	B-Drug
was	O
not	O
significantly	O
increased	O
.	O

In	O
an	O
analysis	O
of	O
the	O
supraventricular	O
arrhythmia	O
and	O
DIAMOND	O
patient	O
populations	O
,	O
the	O
concomitant	O
administration	O
of	O
verapamil	B-Drug
with	O
dofetilide	B-Drug
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O

Ketoconazole	B-Drug
:	O
Concomitant	O
use	O
of	O
ketoconazole	B-Drug
is	O
contraindicated	O
.	O

Ketoconazole	B-Drug
at	O
400	O
mg	O
daily	O
(	O
the	O
maximum	O
approved	O
prescription	O
dose	O
)	O
co-administered	O
with	O
TIKOSYN	B-Drug
(	O
500	O
mcg	O
BID	O
)	O
for	O
7	O
days	O
has	O
been	O
shown	O
to	O
increase	O
dofetilide	B-Drug
Cmax	O
by	O
53	O
%	O
in	O
males	O
and	O
97	O
%	O
in	O
females	O
,	O
and	O
AUC	O
by	O
41	O
%	O
in	O
males	O
and	O
69	O
%	O
in	O
females	O
.	O

Trimethoprim	B-Drug
Alone	O
or	O
in	O
Combination	O
with	O
Sulfamethoxazole	B-Drug
:	O
Concomitant	O
use	O
of	O
trimethoprim	B-Drug
alone	O
or	O
in	O
combination	O
with	O
sulfamethoxazole	B-Drug
is	O
contraindicated	O
.	O

Hydrochlorothiazide	B-Drug
(	O
HCTZ	B-Drug
)	O
Alone	O
or	O
in	O
Combination	O
with	O
Triamterene	B-Drug
:	O
Concomitant	O
use	O
of	O
HCTZ	B-Drug
alone	O
or	O
in	O
combination	O
with	O
triamterene	B-Drug
is	O
contraindicated	O
.	O

HCTZ	B-Drug
50	O
mg	O
QD	O
or	O
HCTZ/triamterene	B-Drug
50/100	O
mg	O
QD	O
was	O
co-administered	O
with	O
TIKOSYN	B-Drug
(	O
500	O
mcg	O
BID	O
)	O
for	O
5	O
days	O
(	O
following	O
2	O
days	O
of	O
diuretic	B-Drug
use	O
at	O
half	O
dose	O
)	O
.	O

In	O
patients	O
receiving	O
HCTZ	B-Drug
alone	O
,	O
dofetilide	B-Drug
AUC	O
increased	O
by	O
27	O
%	O
and	O
Cmax	O
by	O
21	O
%	O
.	O

However	O
,	O
the	O
pharmacodynamic	O
effect	O
increased	O
by	O
197	O
%	O
(	O
QTc	O
increase	O
over	O
time	O
)	O
and	O
by	O
95	O
%	O
(	O
maximum	O
QTc	O
increase	O
)	O
.	O

However	O
,	O
the	O
pharmacodynamic	O
effect	O
increased	O
by	O
190	O
%	O
(	O
QTc	O
increase	O
over	O
time	O
)	O
and	O
by	O
84	O
%	O
(	O
Maximum	O
QTc	O
increase	O
)	O
.	O

The	O
pharmacodynamic	O
effects	O
can	O
be	O
explained	O
by	O
a	O
combination	O
of	O
the	O
increase	O
in	O
dofetilide	B-Drug
exposure	O
and	O
the	O
reductions	O
in	O
serum	O
potassium	B-Drug
.	O

In	O
the	O
DIAMOND	O
trials	O
,	O
1252	O
patients	O
were	O
treated	O
with	O
TIKOSYN	B-Drug
and	O
diuretics	B-Drug
concomitantly	O
of	O
whom	O
493	O
died	O
compared	O
to	O
508	O
deaths	O
among	O
the	O
1248	O
patients	O
receiving	O
placebo	O
and	O
diuretics	B-Drug
.	O

Of	O
the	O
229	O
patients	O
who	O
had	O
potassium	B-Drug
depleting	O
diuretics	B-Drug
added	O
to	O
their	O
concomitant	O
medications	O
in	O
the	O
DIAMOND	O
trials	O
,	O
the	O
patients	O
on	O
TIKOSYN	B-Drug
had	O
a	O
non-significantly	O
reduced	O
relative	O
risk	O
for	O
death	O
of	O
0.68	O
(	O
95	O
%	O
CI	O
0.376	O
,	O
1.230	O
)	O
.	O

Potential	O
Drug	B-Drug
Interactions	O
Dofetilide	B-Drug
is	O
eliminated	O
in	O
the	O
kidney	O
by	O
cationic	O
secretion	O
.	O

Inhibitors	O
of	O
renal	O
cationic	O
secretion	O
are	O
contraindicated	O
with	O
TIKOSYN	B-Drug
.	O

In	O
addition	O
,	O
drugs	B-Drug
that	O
are	O
actively	O
secreted	O
via	O
this	O
route	O
(	O
e.g.	O
,	O
triamterene	B-Drug
,	O
metformin	B-Drug
and	O
amiloride	B-Drug
)	O
should	O
be	O
co-administered	O
with	O
care	O
as	O
they	O
might	O
increase	O
dofetilide	B-Drug
levels	O
.	O

Dofetilide	B-Drug
is	O
metabolized	O
to	O
a	O
small	O
extent	O
by	O
the	O
CYP3A4	B-Drug
isoenzyme	O
of	O
the	O
cytochrome	O
P450	O
system	O
.	O

Inhibitors	O
of	O
the	O
CYP3A4	B-Drug
isoenzyme	O
could	O
increase	O
systemic	O
dofetilide	B-Drug
exposure	O
.	O

Inhibitors	O
of	O
this	O
isoenzyme	O
(	O
e.g.	O
,	O
macrolide	O
antibiotics	B-Drug
,	O
azole	O
antifungal	O
agents	O
,	O
protease	O
inhibitors	O
,	O
serotonin	O
reuptake	O
inhibitors	O
,	O
amiodarone	B-Drug
,	O
cannabinoids	O
,	O
diltiazem	B-Drug
,	O
grapefruit	O
juice	O
,	O
nefazadone	B-Drug
,	O
norfloxacin	B-Drug
,	O
quinine	B-Drug
,	O
zafirlukast	B-Drug
)	O
should	O
be	O
cautiously	O
coadministered	O
with	O
TIKOSYN	B-Drug
as	O
they	O
can	O
potentially	O
increase	O
dofetilide	B-Drug
levels	O
.	O

Dofetilide	B-Drug
is	O
not	O
an	O
inhibitor	O
of	O
CYP3A4	B-Drug
nor	O
of	O
other	O
cytochrome	O
P450	O
isoenzymes	O
(	O
e.g.	O
,	O
CYP2C9	B-Drug
,	O
CYP2D6	B-Drug
)	O
and	O
is	O
not	O
expected	O
to	O
increase	O
levels	O
of	O
drugs	B-Drug
metabolized	O
by	O
CYP3A4	B-Drug
.	O

Other	O
Drug	B-Drug
Interaction	O
Information	O
Digoxin	B-Drug
:	O
Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O

In	O
patients	O
,	O
the	O
concomitant	O
administration	O
of	O
digoxin	B-Drug
with	O
dofetilide	B-Drug
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
.	O

It	O
is	O
not	O
clear	O
whether	O
this	O
represents	O
an	O
interaction	O
with	O
TIKOSYN	B-Drug
or	O
the	O
presence	O
of	O
more	O
severe	O
structural	O
heart	O
disease	O
in	O
patients	O
on	O
digoxin	B-Drug
;	O
structural	O
heart	O
disease	O
is	O
a	O
known	O
risk	O
factor	O
for	O
arrhythmia	O
.	O

No	O
increase	O
in	O
mortality	O
was	O
observed	O
in	O
patients	O
taking	O
digoxin	B-Drug
as	O
concomitant	O
medication	O
.	O

Other	O
Drugs	B-Drug
:	O
In	O
healthy	O
volunteers	O
,	O
amlodipine	B-Drug
,	O
phenytoin	B-Drug
,	O
glyburide	B-Drug
,	O
ranitidine	B-Drug
,	O
omeprazole	B-Drug
,	O
hormone	O
replacement	O
therapy	O
(	O
a	O
combination	O
of	O
conjugated	O
estrogens	O
and	O
medroxyprogesterone	B-Drug
)	O
,	O
antacid	O
(	O
aluminum	B-Drug
and	O
magnesium	B-Drug
hydroxides	I-Drug
)	O
and	O
theophylline	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
TIKOSYN	B-Drug
.	O

In	O
addition	O
,	O
studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
TIKOSYN	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	B-Drug
,	O
or	O
the	O
pharmacokinetics	O
of	O
propranolol	B-Drug
(	O
40	O
mg	O
twice	O
daily	O
)	O
,	O
phenytoin	B-Drug
,	O
theophylline	B-Drug
,	O
or	O
oral	O
contraceptives	O
.	O

Population	O
pharmacokinetic	O
analyses	O
were	O
conducted	O
on	O
plasma	O
concentration	O
data	O
from	O
1445	O
patients	O
in	O
clinical	O
trials	O
to	O
examine	O
the	O
effects	O
of	O
concomitant	O
medications	O
on	O
clearance	O
or	O
volume	O
of	O
distribution	O
of	O
dofetilide	B-Drug
.	O

Concomitant	O
medications	O
were	O
grouped	O
as	O
ACE	O
inhibitors	O
,	O
oral	O
anticoagulants	B-Drug
,	O
calcium	B-Drug
channel	O
blockers	O
,	O
beta	O
blockers	O
,	O
cardiac	O
glycosides	O
,	O
inducers	O
of	O
CYP3A4	B-Drug
,	O
substrates	O
and	O
inhibitors	O
of	O
CYP3A4	B-Drug
,	O
substrates	O
and	O
inhibitors	O
of	O
P-glycoprotein	O
,	O
nitrates	B-Drug
,	O
sulphonylureas	O
,	O
loop	O
diuretics	B-Drug
,	O
potassium	B-Drug
sparing	O
diuretics	B-Drug
,	O
thiazide	O
diuretics	B-Drug
,	O
substrates	O
and	O
inhibitors	O
of	O
tubular	O
organic	O
cation	O
transport	O
,	O
and	O
QTc-prolonging	O
drugs	B-Drug
.	O

Differences	O
in	O
clearance	O
between	O
patients	O
on	O
these	O
medications	O
(	O
at	O
any	O
occasion	O
in	O
the	O
study	O
)	O
and	O
those	O
off	O
medications	O
varied	O
between	O
-16	O
%	O
and	O
+3	O
%	O
.	O

The	O
mean	O
clearances	O
of	O
dofetilide	B-Drug
were	O
16	O
%	O
and	O
15	O
%	O
lower	O
in	O
patients	O
on	O
thiazide	O
diuretics	B-Drug
and	O
inhibitors	O
of	O
tubular	O
organic	O
cation	O
transport	O
,	O
respectively	O
.	O

The	O
potential	O
for	O
clinically	O
significant	O
drug-drug	O
interactions	O
posed	O
by	O
dolasetron	B-Drug
and	O
hydrodolasetron	B-Drug
appears	O
to	O
be	O
low	O
for	O
drugs	B-Drug
commonly	O
used	O
in	O
chemotherapy	O
or	O
surgery	O
,	O
because	O
hydrodolasetron	B-Drug
is	O
eliminated	O
by	O
multiple	O
routes	O
.	O

Blood	O
levels	O
of	O
hydrodolasetron	B-Drug
increased	O
24	O
%	O
when	O
dolasetron	B-Drug
was	O
coadministered	O
with	O
cimetidine	B-Drug
(	O
nonselective	O
inhibitor	O
of	O
cytochrome	O
P-450	O
)	O
for	O
7	O
days	O
,	O
and	O
decreased	O
28	O
%	O
with	O
coadministration	O
of	O
rifampin	B-Drug
(	O
potent	O
inducer	O
of	O
cytochrome	O
P-450	O
)	O
for	O
7	O
days	O
.	O

Dolasetron	B-Drug
has	O
been	O
safely	O
coadministered	O
with	O
drugs	B-Drug
used	O
in	O
chemotherapy	O
and	O
surgery	O
.	O

As	O
with	O
other	O
agents	O
which	O
prolong	O
ECG	O
intervals	O
,	O
caution	O
should	O
be	O
exercised	O
in	O
patients	O
taking	O
drugs	B-Drug
which	O
prolong	O
ECG	O
intervals	O
,	O
particularly	O
QTc	O
.	O

In	O
patients	O
taking	O
furosemide	B-Drug
,	O
nifedipine	B-Drug
,	O
diltiazem	B-Drug
,	O
ACE	O
inhibitors	O
,	O
verapamil	B-Drug
,	O
glyburide	B-Drug
,	O
propranolol	B-Drug
,	O
and	O
various	O
chemotherapy	O
agents	O
,	O
no	O
effect	O
was	O
shown	O
on	O
the	O
clearance	O
of	O
hydrodolasetron	B-Drug
.	O

Clearance	O
of	O
hydrodolasetron	B-Drug
decreased	O
by	O
about	O
27	O
%	O
when	O
dolasetron	B-Drug
mesylate	I-Drug
was	O
administered	O
intravenously	O
concomitantly	O
with	O
atenolol	B-Drug
.	O

Dolasetron	B-Drug
does	O
not	O
influence	O
anesthesia	B-Drug
recovery	O
time	O
in	O
patients	O
.	O

Dolasetron	B-Drug
mesylate	I-Drug
did	O
not	O
inhibit	O
the	O
antitumor	O
activity	O
of	O
four	O
chemotherapeutic	O
agents	O
(	O
cisplatin	B-Drug
,	O
5-fluorouracil	B-Drug
,	O
doxorubicin	B-Drug
,	O
cyclophosphamide	B-Drug
)	O
in	O
four	O
murine	O
models	O
.	O

Drugs	B-Drug
that	O
inhibit	O
or	O
Induce	O
CYP	O
2D6	O
and	O
CYP	O
3A4	O
may	O
affect	O
the	O
concentration	O
on	O
Aricept	B-Drug
.	O

Because	O
dopamine	B-Drug
is	O
metabolized	O
by	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
,	O
inhibition	O
of	O
this	O
enzyme	O
prolongs	O
and	O
potentiates	O
the	O
effect	O
of	O
dopamine	B-Drug
.	O

Patients	O
who	O
have	O
been	O
treated	O
with	O
MAO	O
inhibitors	O
within	O
two	O
to	O
three	O
weeks	O
prior	O
to	O
the	O
administration	O
of	O
dopamine	B-Drug
HCl	I-Drug
should	O
receive	O
initial	O
doses	O
of	O
dopamine	B-Drug
HCl	I-Drug
no	O
greater	O
than	O
one-tenth	O
(	O
1/10	O
)	O
of	O
the	O
usual	O
dose	O
.	O

Concurrent	O
administration	O
of	O
low-dose	O
dopamine	B-Drug
HCl	I-Drug
and	O
diuretic	B-Drug
agents	O
may	O
produce	O
an	O
additive	O
or	O
potentiating	O
effect	O
on	O
urine	O
flow	O
.	O

Tricyclic	O
antidepressants	B-Drug
may	O
potentiate	O
the	O
cardiovascular	O
effects	O
of	O
adreneric	O
agents	O
.	O

Cardiac	O
effects	O
of	O
dopamine	B-Drug
are	O
antagonized	O
by	O
beta-adrenergic	O
blocking	O
agents	O
,	O
such	O
as	O
propranolol	B-Drug
and	O
metoprolol	B-Drug
.	O

The	O
peripheral	O
vasoconstriction	O
caused	O
by	O
high	O
doses	O
of	O
dopamine	B-Drug
HCl	I-Drug
is	O
antagonized	O
by	O
alpha-adrenergic	O
blocking	O
agents	O
.	O

Dopamine-induced	B-Drug
renal	O
and	O
mesenteric	O
vasodilation	O
is	O
not	O
antagonized	O
by	O
either	O
alpha-	O
or	O
beta-adrenergic	B-Drug
blocking	I-Drug
agents	I-Drug
.	O

Butyrophenones	O
(	O
such	O
as	O
haloperidol	B-Drug
)	O
and	O
phenothiazines	O
can	O
suppress	O
the	O
dopaminergic	B-Drug
renal	O
and	O
mesenteric	O
vasodilation	O
induced	O
with	O
low	O
dose	O
dopamine	B-Drug
infusion	O
.	O

Cyclopropane	B-Drug
or	O
halogenated	O
hydrocarbon	O
anesthetics	B-Drug
increase	O
cardiac	O
autonomic	O
irritability	O
and	O
may	O
sensitize	O
the	O
myocardium	O
to	O
the	O
action	O
of	O
certain	O
intravenously	O
administered	O
catecholamines	O
,	O
such	O
as	O
dopamine	B-Drug
.	O

This	O
interaction	O
appears	O
to	O
be	O
related	O
both	O
to	O
pressor	O
activity	O
and	O
to	O
beta-adrenergic	O
stimulating	O
properties	O
of	O
these	O
catecholamines	O
and	O
may	O
produce	O
ventricular	O
arrhythmias	O
and	O
hypertension	O
.	O

Therefore	O
,	O
EXTREME	O
CAUTION	O
should	O
be	O
exercised	O
when	O
administering	O
dopamine	B-Drug
HCl	I-Drug
to	O
patients	O
receiving	O
cyclopropane	B-Drug
or	O
halogenated	O
hydrocarbon	O
anesthetics	B-Drug
.	O

It	O
has	O
been	O
reported	O
that	O
results	O
of	O
studies	O
in	O
animals	O
indicate	O
that	O
dopamine-induced	B-Drug
ventricular	O
arrhythmias	O
during	O
anesthesia	B-Drug
can	O
be	O
reversed	O
by	O
propranolol	B-Drug
.	O

The	O
concomitant	O
use	O
of	O
vasopressors	O
,	O
vasoconstricting	O
agents	O
(	O
such	O
as	O
ergonovine	B-Drug
)	O
and	O
some	O
oxytocic	O
drugs	B-Drug
may	O
result	O
in	O
severe	O
hypertension	O
.	O

Administration	O
of	O
phenytoin	B-Drug
to	O
patients	O
receiving	O
dopamine	B-Drug
HCl	I-Drug
has	O
been	O
reported	O
to	O
lead	B-Drug
to	O
hypotension	O
and	O
bradycardia	O
.	O

It	O
is	O
suggested	O
that	O
in	O
patients	O
receiving	O
dopamine	B-Drug
HCl	I-Drug
,	O
alternatives	O
to	O
phenytoin	B-Drug
should	O
be	O
used	O
if	O
anticonvulsant	O
therapy	O
is	O
needed	O
.	O

Clinical	O
trials	O
have	O
indicated	O
that	O
Pulmozyme	B-Drug
can	O
be	O
effectively	O
and	O
safely	O
used	O
in	O
conjunction	O
with	O
standard	O
cystic	O
fibrosis	O
therapies	O
including	O
oral	O
,	O
inhaled	O
and/or	O
parenteral	O
antibiotics	B-Drug
,	O
bronchodilators	O
,	O
enzyme	O
supplements	O
,	O
vitamins	O
,	O
oral	O
or	O
inhaled	O
corticosteroids	O
,	O
and	O
analgesics	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Although	O
acid-base	O
and	O
electrolyte	O
disturbances	O
were	O
not	O
reported	O
in	O
the	O
clinical	O
trials	O
with	O
dorzolamide	B-Drug
,	O
these	O
disturbances	O
have	O
been	O
reported	O
with	O
oral	O
carbonic	O
anhydrase	O
inhibitors	O
and	O
have	O
,	O
in	O
some	O
instances	O
,	O
resulted	O
in	O
drug	B-Drug
interactions	O
(	O
e.g.	O
,	O
toxicity	O
associated	O
with	O
high-dose	O
salicylate	B-Drug
therapy	O
)	O
.	O

Therefore	O
,	O
the	O
potential	O
for	O
such	O
drug	B-Drug
interactions	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
dorzolamide	B-Drug
.	O

Prior	O
administration	O
of	O
succinylcholine	B-Drug
has	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
NUROMAX	B-Drug
.	O

The	O
use	O
of	O
NUROMAX	B-Drug
before	O
succinylcholine	B-Drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B-Drug
has	O
not	O
been	O
studied	O
.	O

There	O
are	O
no	O
clinical	O
data	O
on	O
concomitant	O
use	O
of	O
NUROMAX	B-Drug
and	O
other	O
nondepolarizing	O
neuromuscular	O
blocking	O
agents	O
.	O

Isoflurane	B-Drug
,	O
enflurane	B-Drug
,	O
and	O
halothane	B-Drug
decrease	O
the	O
ED50	O
of	O
NUROMAX	B-Drug
by	O
30	O
%	O
to	O
45	O
%	O
.	O

These	O
agents	O
may	O
also	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
by	O
up	O
to	O
25	O
%	O
.	O

Other	O
drugs	B-Drug
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	O
agents	O
such	O
as	O
NUROMAX	B-Drug
include	O
certain	O
antibiotics	B-Drug
(	O
e.	O
g.	O
,	O
aminoglycosides	O
,	O
tetracyclines	O
,	O
bacitracin	B-Drug
,	O
polymyxins	O
,	O
lincomycin	B-Drug
,	O
clindamycin	B-Drug
,	O
colistin	B-Drug
,	O
and	O
sodium	B-Drug
colistimethate	I-Drug
)	O
,	O
magnesium	B-Drug
salts	O
,	O
lithium	B-Drug
,	O
local	O
anesthetics	B-Drug
,	O
procainamide	B-Drug
,	O
and	O
quinidine	B-Drug
.	O

As	O
with	O
some	O
other	O
nondepolarizing	O
neuromuscular	O
blocking	O
agents	O
,	O
the	O
time	O
of	O
onset	O
of	O
neuromuscular	O
block	O
induced	O
by	O
NUROMAX	B-Drug
is	O
lengthened	O
and	O
the	O
duration	O
of	O
block	O
is	O
shortened	O
in	O
patients	O
receiving	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
.	O

Administration	O
of	O
doxapram	B-Drug
to	O
patients	O
who	O
are	O
receiving	O
sympathomimetic	B-Drug
or	O
monoamine	O
oxidase	O
inhibiting	O
drugs	B-Drug
may	O
result	O
in	O
an	O
additive	O
pressor	O
effect	O
.	O

In	O
patients	O
who	O
have	O
received	O
muscle	O
relaxants	O
,	O
doxapram	B-Drug
may	O
temporarily	O
mask	O
the	O
residual	O
effects	O
of	O
muscle	O
relaxant	O
drugs	B-Drug
.	O

In	O
patients	O
who	O
have	O
received	O
general	O
anesthesia	B-Drug
utilizing	O
a	O
volatile	O
agent	O
known	O
to	O
sensitize	O
the	O
myocardium	O
to	O
catecholamines	O
,	O
administration	O
of	O
doxapram	B-Drug
should	O
be	O
delayed	O
until	O
the	O
volatile	O
agent	O
has	O
been	O
excreted	O
in	O
order	O
to	O
lessen	O
the	O
potential	O
for	O
arrhythmias	O
,	O
including	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
.	O

Most	O
(	O
98	O
%	O
)	O
of	O
plasma	O
doxazosin	B-Drug
is	O
protein	O
bound	O
.	O

In	O
vitro	O
data	O
in	O
human	O
plasma	O
indicate	O
that	O
doxazosin	B-Drug
mesylate	I-Drug
has	O
no	O
effect	O
on	O
protein	O
binding	O
of	O
digoxin	B-Drug
,	O
warfarin	B-Drug
,	O
phenytoin	B-Drug
or	O
indomethacin	B-Drug
.	O

There	O
is	O
no	O
information	O
on	O
the	O
effect	O
of	O
other	O
highly	O
plasma	O
protein	O
bound	O
drugs	B-Drug
on	O
doxazosin	B-Drug
binding	O
.	O

Doxazosin	B-Drug
mesylate	I-Drug
has	O
been	O
administered	O
without	O
any	O
evidence	O
of	O
an	O
adverse	O
drug	B-Drug
interaction	O
to	O
patients	O
receiving	O
thiazide	O
diuretics	B-Drug
,	O
beta-blocking	B-Drug
agents	O
,	O
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
.	O

In	O
a	O
placebo-controlled	O
trial	O
in	O
normal	O
volunteers	O
,	O
the	O
administration	O
of	O
a	O
single	O
1	O
mg	O
dose	O
of	O
doxazosin	B-Drug
on	O
day	O
1	O
of	O
a	O
four-day	O
regimen	O
of	O
oral	O
cimetidine	B-Drug
(	O
400	O
mg	O
twice	O
daily	O
)	O
resulted	O
in	O
a	O
10	O
%	O
increase	O
in	O
mean	O
AUC	O
of	O
doxazosin	B-Drug
(	O
p=0.006	O
)	O
,	O
and	O
a	O
slight	O
but	O
not	O
statistically	O
significant	O
increase	O
in	O
mean	O
Cmax	O
and	O
mean	O
half-life	O
of	O
doxazosin	B-Drug
.	O

The	O
clinical	O
significance	O
of	O
this	O
increase	O
in	O
doxazosin	B-Drug
AUC	O
is	O
unknown	O
.	O

In	O
clinical	O
trials	O
,	O
doxazosin	B-Drug
mesylate	I-Drug
tablets	O
have	O
been	O
administered	O
to	O
patients	O
on	O
a	O
variety	O
of	O
concomitant	O
medications	O
;	O
while	O
no	O
formal	O
interaction	O
studies	O
have	O
been	O
conducted	O
,	O
no	O
interactions	O
were	O
observed	O
.	O

Doxazosin	B-Drug
mesylate	I-Drug
tablets	O
have	O
been	O
used	O
with	O
the	O
following	O
drugs	B-Drug
or	O
drug	B-Drug
classes	O
:	O
1	O
.	O

Analgesic/anti-inflammatory	O
(	O
e.g.	O
,	O
acetaminophen	B-Drug
,	O
aspirin	B-Drug
,	O
codeine	B-Drug
and	O
codeine	B-Drug
combinations	O
,	O
ibuprofen	B-Drug
,	O
indomethacin	B-Drug
)	O
.	O

2	O
.	O

Antibiotics	B-Drug
(	O
e.g.	O
,	O
erythromycin	B-Drug
,	O
trimethoprim	B-Drug
and	O
sulfamethoxazole	B-Drug
,	O
amoxicillin	B-Drug
)	O
.	O

3	O
.	O

Antihistamines	B-Drug
(	O
e.g.	O
,	O
chlorpheniramine	B-Drug
)	O
.	O

4	O
.	O

Cardiovascular	O
agents	O
(	O
e.g.	O
,	O
atenolol	B-Drug
,	O
hydrochlorothiazide	B-Drug
,	O
propranolol	B-Drug
)	O
.	O

5	O
.	O

Corticosteroids	O
.	O

6	O
.	O

Gastrointestinal	O
agents	O
(	O
e.g.	O
,	O
antacids	O
)	O
.	O

7	O
.	O

Hypoglycemics	O
and	O
endocrine	O
drugs	B-Drug
.	O

8	O
.	O

Sedatives	O
and	O
tranquilizers	O
(	O
e.g.	O
,	O
diazepam	B-Drug
)	O
.	O

9	O
.	O

Cold	O
and	O
flu	O
remedies	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
P450	O
2D6	O
:	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	B-Drug
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	B-Drug
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
Caucasian	O
population	O
(	O
about	O
7-10	O
%	O
of	O
Caucasians	O
are	O
so-called	O
poor	O
metabolizers	O
)	O
;	O
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	B-Drug
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8-fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-Drug
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
poor	O
metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	O
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	B-Drug
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	B-Drug
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B-Drug
,	O
phenothiazines	O
,	O
and	O
the	O
Type	O
1C	O
antiarrhythmics	B-Drug
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
e.g.	O
,	O
citalopram	B-Drug
,	O
escitalopram	B-Drug
,	O
fluoxetine	B-Drug
,	O
sertraline	B-Drug
,	O
and	O
paroxetine	B-Drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI-TCA	O
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	O
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co-administration	O
of	O
TCAs	O
with	O
any	O
of	O
the	O
SSRIs	O
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
,	O
given	O
the	O
long	O
half-life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	O
antidepressants	B-Drug
with	O
drugs	B-Drug
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	O
antidepressant	O
or	O
the	O
other	O
drug	B-Drug
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	B-Drug
is	O
withdrawn	O
from	O
co-therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	O
antidepressant	O
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	O
plasma	O
levels	O
whenever	O
a	O
TCA	O
is	O
going	O
to	O
be	O
co-administered	O
with	O
another	O
drug	B-Drug
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Doxepin	B-Drug
is	O
primarily	O
metabolized	O
by	O
CYP2D6	B-Drug
(	O
with	O
CYP1A2	B-Drug
and	O
CYP3A4	B-Drug
as	O
minor	O
pathways	O
)	O
.	O

Inhibitors	O
or	O
substrates	O
of	O
CYP2D6	B-Drug
(	O
i.e.	O
,	O
quinidine	B-Drug
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
may	O
increase	O
the	O
plasma	O
concentration	O
of	O
doxepin	B-Drug
when	O
administered	O
concomitantly	O
.	O

The	O
extent	O
of	O
interaction	O
depends	O
on	O
the	O
variability	O
of	O
effect	O
on	O
CYP2D6	B-Drug
.	O

The	O
clinical	O
significance	O
of	O
this	O
interaction	O
with	O
doxepin	B-Drug
has	O
not	O
been	O
systematically	O
evaluated	O
.	O

MAO	O
Inhibitors	O
:	O
Serious	O
side	O
effects	O
and	O
even	O
death	O
have	O
been	O
reported	O
following	O
the	O
concomitant	O
use	O
of	O
certain	O
drugs	B-Drug
with	O
MAO	O
inhibitors	O
.	O

Therefore	O
,	O
MAO	O
inhibitors	O
should	O
be	O
discontinued	O
at	O
least	O
two	O
weeks	O
prior	O
to	O
the	O
cautious	O
initiation	O
of	O
therapy	O
with	O
SINEQUAN	B-Drug
.	O

The	O
exact	O
length	O
of	O
time	O
may	O
vary	O
and	O
is	O
dependent	O
upon	O
the	O
particular	O
MAO	O
inhibitor	O
being	O
used	O
,	O
the	O
length	O
of	O
time	O
it	O
has	O
been	O
administered	O
,	O
and	O
the	O
dosage	O
involved	O
.	O

Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
has	O
been	O
reported	O
to	O
produce	O
clinically	O
significant	O
fluctuations	O
in	O
steady-state	O
serum	O
concentrations	O
of	O
various	O
tricyclic	O
antidepressants	B-Drug
.	O

Serious	O
anticholinergic	B-Drug
symptoms	O
(	O
i.e.	O
,	O
severe	O
dry	O
mouth	O
,	O
urinary	O
retention	O
and	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	O
antidepressant	O
when	O
cimetidine	B-Drug
therapy	O
is	O
initiated	O
.	O

Additionally	O
,	O
higher	O
than	O
expected	O
tricyclic	O
antidepressant	O
levels	O
have	O
been	O
observed	O
when	O
they	O
are	O
begun	O
in	O
patients	O
already	O
taking	O
cimetidine	B-Drug
.	O

In	O
patients	O
who	O
have	O
been	O
reported	O
to	O
be	O
well	O
controlled	O
on	O
tricyclic	O
antidepressants	B-Drug
receiving	O
concurrent	O
cimetidine	B-Drug
therapy	O
,	O
discontinuation	O
of	O
cimetidine	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
established	O
steady-state	O
serum	O
tricyclic	O
antidepressant	O
levels	O
and	O
compromise	O
their	O
therapeutic	O
effects	O
.	O

Alcohol	B-Drug
:	O
It	O
should	O
be	O
borne	O
in	O
mind	O
that	O
alcohol	B-Drug
ingestion	O
may	O
increase	O
the	O
danger	O
inherent	O
in	O
any	O
intentional	O
or	O
unintentional	O
SINEQUAN	B-Drug
overdosage	O
.	O

This	O
is	O
especially	O
important	O
in	O
patients	O
who	O
may	O
use	O
alcohol	B-Drug
excessively	O
.	O

Tolazamide	B-Drug
:	O
A	O
case	O
of	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
a	O
type	O
II	O
diabetic	O
patient	O
maintained	O
on	O
tolazamide	B-Drug
(	O
1	O
gm/day	O
)	O
11	O
days	O
after	O
the	O
addition	O
of	O
doxepin	B-Drug
(	O
75	O
mg/day	O
)	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
DOXIL	B-Drug
.	O

Until	O
specific	O
compatibility	O
data	O
are	O
available	O
,	O
it	O
is	O
not	O
recommended	O
that	O
DOXIL	B-Drug
be	O
mixed	O
with	O
other	O
drugs	B-Drug
.	O

DOXIL	B-Drug
may	O
interact	O
with	O
drugs	B-Drug
known	O
to	O
interact	O
with	O
the	O
conventional	O
formulation	O
of	O
doxorubicin	B-Drug
HCl	I-Drug
.	O

Because	O
tetracyclines	O
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	B-Drug
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B-Drug
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	B-Drug
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillin	B-Drug
,	O
it	O
is	O
advisable	O
to	O
avoid	O
giving	O
tetracyclines	O
in	O
conjunction	O
with	O
penicillin	B-Drug
.	O

Absorption	O
of	O
tetracyclines	O
is	O
impaired	O
by	O
antacids	O
containing	O
aluminum	B-Drug
,	O
calcium	B-Drug
,	O
or	O
magnesium	B-Drug
,	O
and	O
iron-containing	B-Drug
preparations	O
.	O

Absorption	O
of	O
tetracycline	B-Drug
is	O
impaired	O
by	O
bismuth	B-Drug
subsalicylate	I-Drug
.	O

Barbiturates	B-Drug
,	O
carbamazepine	B-Drug
,	O
and	O
phenytoin	B-Drug
decrease	O
the	O
half-life	O
of	O
doxycycline	B-Drug
.	O

The	O
concurrent	O
use	O
of	O
tetracycline	B-Drug
and	O
Penthrane	B-Drug
(	O
methoxyflurane	B-Drug
)	O
has	O
been	O
reported	O
to	O
result	O
in	O
fatal	O
renal	O
toxicity	O
.	O

Concurrent	O
use	O
of	O
tetracycline	B-Drug
may	O
render	O
oral	O
contraceptives	O
less	O
effective	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
False	O
elevations	O
of	O
urinary	O
catecholamine	O
levels	O
may	O
occur	O
due	O
to	O
interference	O
with	O
the	O
fluorescence	O
test	O
.	O

Potential	O
drug	B-Drug
interactions	O
for	O
doxylamine	B-Drug
include	O
,	O
increased	O
sedation	O
if	O
doxylamine	B-Drug
is	O
combined	O
with	O
other	O
CNS	O
depressant	O
drugs	B-Drug
.	O

Antihistamines	B-Drug
may	O
partially	O
counteract	O
the	O
anticoagulation	O
effects	O
of	O
heparin	B-Drug
or	O
warfarin	B-Drug
.	O

Doxylamine	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
epinephrine	B-Drug
.	O

Androgens	O
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulahts	O
.	O

Dosage	O
of	O
the	O
anticoagulant	B-Drug
may	O
require	O
reduction	O
in	O
order	O
to	O
maintain	O
satisfactory	O
therapeutic	O
hypoprothrombinemia	O
.	O

Concurrent	O
administration	O
of	O
oxyphenbutazone	B-Drug
and	O
androgens	O
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	B-Drug
.	O

In	O
diabetic	O
patients	O
,	O
the	O
metabolic	O
effects	O
of	O
androgens	O
may	O
decrease	O
blood	O
glucose	B-Drug
and	O
therefore	O
,	O
insulin	B-Drug
requirements	O
.	O

Other	O
CNS	O
depressant	O
drugs	B-Drug
(	O
e.g	O
.	O

barbiturates	B-Drug
,	O
tranquilizers	O
,	O
opioids	O
and	O
general	O
anesthetics	B-Drug
)	O
have	O
additive	O
or	O
potentiating	O
effects	O
with	O
INAPSINE	B-Drug
.	O

When	O
patients	O
have	O
received	O
such	O
drugs	B-Drug
,	O
the	O
dose	O
of	O
INAPSINE	B-Drug
required	O
will	O
be	O
less	O
than	O
usual	O
.	O

Following	O
the	O
administration	O
of	O
INAPSINE	B-Drug
,	O
the	O
dose	O
of	O
other	O
CNS	O
depressant	O
drugs	B-Drug
should	O
be	O
reduced	O
.	O

Drug	B-Drug
interaction	O
studies	O
with	O
Xigris	B-Drug
have	O
not	O
been	O
performed	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

However	O
,	O
since	O
there	O
is	O
an	O
increased	O
risk	O
of	O
bleeding	O
with	O
Xigris	B-Drug
,	O
caution	O
should	O
be	O
employed	O
when	O
Xigris	B-Drug
is	O
used	O
with	O
other	O
drugs	B-Drug
that	O
affect	O
hemostasis	O
.	O

Approximately	O
2/3	O
of	O
the	O
patients	O
in	O
the	O
Phase	O
3	O
study	O
received	O
either	O
prophylactic	O
low	O
dose	O
heparin	B-Drug
(	O
unfractionated	B-Drug
heparin	I-Drug
up	O
to	O
15,000	O
units/day	O
)	O
or	O
prophylactic	O
doses	O
of	O
low	O
molecular	O
weight	O
heparins	O
as	O
indicated	O
in	O
the	O
prescribing	O
information	O
for	O
the	O
specific	O
products	O
.	O

Concomitant	O
use	O
of	O
prophylactic	O
low	O
dose	O
heparin	B-Drug
did	O
not	O
appear	O
to	O
affect	O
safety	O
,	O
however	O
,	O
its	O
effects	O
on	O
the	O
efficacy	O
of	O
Xigris	B-Drug
have	O
not	O
been	O
evaluated	O
in	O
an	O
adequate	O
and	O
well-controlled	O
clinical	O
trial	O
.	O

Drug/Laboratory	O
Test	O
Interaction	O
Because	O
Xigris	B-Drug
may	O
affect	O
the	O
APTT	O
assay	O
,	O
Xigris	B-Drug
present	O
in	O
plasma	O
samples	O
may	O
interfere	O
with	O
one-stage	O
coagulation	O
assays	O
based	O
on	O
the	O
APTT	O
(	O
such	O
as	O
factor	O
VIII	O
,	O
IX	O
,	O
and	O
XI	O
assays	O
)	O
.	O

This	O
interference	O
may	O
result	O
in	O
an	O
apparent	O
factor	O
concentration	O
that	O
is	O
lower	O
than	O
the	O
true	O
concentration	O
.	O

Xigris	B-Drug
present	O
in	O
plasma	O
samples	O
does	O
not	O
interfere	O
with	O
one-stage	O
factor	O
assays	O
based	O
on	O
the	O
PT	O
(	O
such	O
as	O
factor	O
II	O
,	O
V	O
,	O
VII	O
,	O
and	O
X	O
assays	O
)	O
.	O

Potential	O
for	O
Other	O
Drugs	B-Drug
to	O
Affect	O
Duloxetine	B-Drug
:	O
Both	O
CYP1A2	B-Drug
and	O
CYP2D6	B-Drug
are	O
responsible	O
for	O
duloxetine	B-Drug
metabolism	O
.	O

Inhibitors	O
of	O
CYP1A2	B-Drug
:	O
Concomitant	O
use	O
of	O
duloxetine	B-Drug
with	O
fluvoxamine	B-Drug
,	O
an	O
inhibitor	O
of	O
CYP1A2	B-Drug
,	O
results	O
in	O
approximately	O
a	O
6-fold	O
increase	O
in	O
AUC	O
and	O
about	O
a	O
2.5-fold	O
increase	O
in	O
Cmax	O
of	O
duloxetine	B-Drug
.	O

Some	O
quinolone	O
antibiotics	B-Drug
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
these	O
combinations	O
should	O
be	O
avoided	O
.	O

Inhibitors	O
of	O
CYP2D6	B-Drug
:	O
Because	O
CYP2D6	B-Drug
is	O
involved	O
in	O
duloxetine	B-Drug
metabolism	O
,	O
concomitant	O
use	O
of	O
duloxetine	B-Drug
with	O
potent	O
inhibitors	O
of	O
CYP2D6	B-Drug
may	O
result	O
in	O
higher	O
concentrations	O
of	O
duloxetine	B-Drug
.	O

Paroxetine	B-Drug
(	O
20	O
mg	O
QD	O
)	O
increased	O
the	O
concentration	O
of	O
duloxetine	B-Drug
(	O
40	O
mg	O
QD	O
)	O
by	O
about	O
60	O
%	O
,	O
and	O
greater	O
degrees	O
of	O
inhibition	O
are	O
expected	O
with	O
higher	O
doses	O
of	O
paroxetine	B-Drug
.	O

Similar	O
effects	O
would	O
be	O
expected	O
with	O
other	O
potent	O
CYP2D6	B-Drug
inhibitors	O
(	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
quinidine	B-Drug
)	O
.	O

Potential	O
for	O
Duloxetine	B-Drug
to	O
Affect	O
Other	O
Drugs	B-Drug
:	O
Drugs	B-Drug
Metabolized	O
by	O
CYP1A2	B-Drug
:	O
In	O
vitro	O
drug	B-Drug
interaction	O
studies	O
demonstrate	O
that	O
duloxetine	B-Drug
does	O
not	O
induce	O
CYP1A2	B-Drug
activity	O
,	O
and	O
it	O
is	O
unlikely	O
to	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
the	O
metabolism	O
of	O
CYP1A2	B-Drug
substrates	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
CYP2D6	B-Drug
:	O
Duloxetine	B-Drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP2D6	B-Drug
.	O

When	O
duloxetine	B-Drug
was	O
administered	O
(	O
at	O
a	O
dose	O
of	O
60	O
mg	O
BID	O
)	O
in	O
conjunction	O
with	O
a	O
single	O
50-mg	O
dose	O
of	O
desipramine	B-Drug
,	O
a	O
CYP2D6	B-Drug
substrate	O
,	O
the	O
AUC	O
of	O
desipramine	B-Drug
increased	O
3-fold	O
.	O

Therefore	O
,	O
co-administration	O
of	O
Duloxetine	B-Drug
with	O
other	O
drugs	B-Drug
that	O
are	O
extensively	O
metabolized	O
by	O
this	O
isozyme	O
and	O
which	O
have	O
a	O
narrow	O
therapeutic	O
index	O
,	O
including	O
certain	O
antidepressants	B-Drug
(	O
tricyclic	O
antidepressants	B-Drug
[	O
TCAs	O
]	O
,	O
such	O
as	O
nortriptyline	B-Drug
,	O
amitriptyline	B-Drug
,	O
and	O
imipramine	B-Drug
)	O
,	O
phenothiazines	O
and	O
Type	O
1C	O
antiarrhythmics	B-Drug
(	O
e.g.	O
,	O
propafenone	B-Drug
,	O
flecainide	B-Drug
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Plasma	O
TCA	O
concentrations	O
may	O
need	O
to	O
be	O
monitored	O
and	O
the	O
dose	O
of	O
the	O
TCA	O
may	O
need	O
to	O
be	O
reduced	O
if	O
a	O
TCA	O
is	O
co-administered	O
with	O
Duloxetine	B-Drug
.	O

Because	O
of	O
the	O
risk	O
of	O
serious	O
ventricular	O
arrhythmias	O
and	O
sudden	O
death	O
potentially	O
associated	O
with	O
elevated	O
plasma	O
levels	O
of	O
thioridazine	B-Drug
,	O
Duloxetine	B-Drug
and	O
thioridazine	B-Drug
should	O
not	O
be	O
co-administered	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
CYP3A	O
:	O
Results	O
of	O
in	O
vitro	O
studies	O
demonstrate	O
that	O
duloxetine	B-Drug
does	O
not	O
inhibit	O
or	O
induce	O
CYP3A	O
activity	O
.	O

Duloxetine	B-Drug
May	O
Have	O
a	O
Clinically	O
Important	O
Interaction	O
with	O
the	O
Following	O
Other	O
Drugs	B-Drug
:	O
Alcohol	B-Drug
:	O
When	O
Duloxetine	B-Drug
and	O
ethanol	B-Drug
were	O
administered	O
several	O
hours	O
apart	O
so	O
that	O
peak	O
concentrations	O
of	O
each	O
would	O
coincide	O
,	O
Duloxetine	B-Drug
did	O
not	O
increase	O
the	O
impairment	O
of	O
mental	O
and	O
motor	O
skills	O
caused	O
by	O
alcohol	B-Drug
.	O

In	O
the	O
Duloxetine	B-Drug
clinical	O
trials	O
database	O
,	O
three	O
Duloxetine-treated	B-Drug
patients	O
had	O
liver	O
injury	O
as	O
manifested	O
by	O
ALT	O
and	O
total	O
bilirubin	O
elevations	O
,	O
with	O
evidence	O
of	O
obstruction	O
.	O

Substantial	O
intercurrent	O
ethanol	B-Drug
use	O
was	O
present	O
in	O
each	O
of	O
these	O
cases	O
,	O
and	O
this	O
may	O
have	O
contributed	O
to	O
the	O
abnormalities	O
seen	O
.	O

CNS	O
Acting	O
Drugs	B-Drug
:	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
Duloxetine	B-Drug
,	O
it	O
should	O
be	O
used	O
with	O
caution	O
when	O
it	O
is	O
taken	O
in	O
combination	O
with	O
or	O
substituted	O
for	O
other	O
centrally	O
acting	O
drugs	B-Drug
,	O
including	O
those	O
with	O
a	O
similar	O
mechanism	O
of	O
action	O
.	O

Potential	O
for	O
Interaction	O
with	O
Drugs	B-Drug
that	O
Affect	O
Gastric	O
Acidity	O
:	O
Duloxetine	B-Drug
has	O
an	O
enteric	O
coating	O
that	O
resists	O
dissolution	O
until	O
reaching	O
a	O
segment	O
of	O
the	O
gastrointestinal	O
tract	O
where	O
the	O
pH	O
exceeds	O
5.5	O
.	O

In	O
extremely	O
acidic	O
conditions	O
,	O
Duloxetine	B-Drug
,	O
unprotected	O
by	O
the	O
enteric	O
coating	O
,	O
may	O
undergo	O
hydrolysis	O
to	O
form	O
naphthol	O
.	O

Caution	O
is	O
advised	O
in	O
using	O
Duloxetine	B-Drug
in	O
patients	O
with	O
conditions	O
that	O
may	O
slow	O
gastric	O
emptying	O
(	O
e.g.	O
,	O
some	O
diabetics	O
)	O
.	O

Drugs	B-Drug
that	O
raise	O
the	O
gastrointestinal	O
pH	O
may	O
lead	B-Drug
to	O
an	O
earlier	O
release	O
of	O
duloxetine	B-Drug
.	O

However	O
,	O
co-administration	O
of	O
Duloxetine	B-Drug
with	O
aluminum-	B-Drug
and	O
magnesium-containing	B-Drug
antacids	O
(	O
51	O
mEq	O
)	O
or	O
Duloxetine	B-Drug
with	O
famotidine	B-Drug
,	O
had	O
no	O
significant	O
effect	O
on	O
the	O
rate	O
or	O
extent	O
of	O
duloxetine	B-Drug
absorption	O
after	O
administration	O
of	O
a	O
40-mg	O
oral	O
dose	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
concomitant	O
administration	O
of	O
proton	O
pump	O
inhibitors	O
affects	O
duloxetine	B-Drug
absorption	O
.	O

Synergism	O
between	O
xanthine	O
bronchodilators	O
(	O
e.g.	O
,	O
theophylline	B-Drug
)	O
,	O
ephedrine	B-Drug
,	O
and	O
other	O
sympathomimetic	B-Drug
bronchodilators	O
has	O
been	O
reported	O
.	O

This	O
should	O
be	O
considered	O
whenever	O
these	O
agents	O
are	O
prescribed	O
concomitantly	O
.	O

Concurrent	O
administration	O
of	O
dyphylline	B-Drug
and	O
probenecid	B-Drug
,	O
which	O
competes	O
for	O
tubular	O
secretion	O
,	O
has	O
been	O
shown	O
to	O
increase	O
the	O
plasma	O
half-life	O
of	O
dyphylline	B-Drug
.	O

Phospholine	B-Drug
Iodide	I-Drug
potentiates	O
other	O
cholinesterase	O
inhibitors	O
such	O
as	O
succinylcholine	B-Drug
or	O
organophosphate	B-Drug
and	O
carbamate	O
insecticides	I-Drug
.	O

Patients	O
undergoing	O
systemic	O
anticholinesterase	O
treatment	O
should	O
be	O
warned	O
of	O
the	O
possible	O
additive	O
effects	O
of	O
Phospholine	B-Drug
Iodide	I-Drug
.	O

Drug	B-Drug
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
Soliris	B-Drug
.	O

There	O
is	O
no	O
known	O
drug	B-Drug
interference	O
with	O
standard	O
clinical	O
laboratory	O
tests	O
.	O

Steroids	O
enhance	O
the	O
renal	O
toxicity	O
of	O
edetate	B-Drug
calcium	I-Drug
disodium	I-Drug
in	O
animals	O
.	O

7	O
Edetate	B-Drug
calcium	I-Drug
disodium	I-Drug
interferes	O
with	O
the	O
action	O
of	O
zinc	B-Drug
insulin	I-Drug
preparations	O
by	O
chelating	O
the	O
zinc	B-Drug
.	O

7	O
Care	O
should	O
be	O
given	O
when	O
administering	O
this	O
drug	B-Drug
to	O
patients	O
with	O
symptoms	O
of	O
myasthenic	O
weakness	O
who	O
are	O
also	O
on	O
anticholinesterase	O
drugs	B-Drug
.	O

Since	O
symptoms	O
of	O
anticholinesterase	O
overdose	O
(	O
cholinergic	O
crisis	O
)	O
may	O
mimic	O
underdosage	O
(	O
myasthenic	O
weakness	O
)	O
,	O
their	O
condition	O
may	O
be	O
worsened	O
by	O
the	O
use	O
of	O
this	O
drug	B-Drug
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
with	O
RAPTIVA	B-Drug
.	O

RAPTIVA	B-Drug
should	O
not	O
be	O
used	O
with	O
other	O
immunosuppressive	O
drugs	B-Drug
.	O

Acellular	O
,	O
live	O
and	O
live-attenuated	O
vaccines	O
should	O
not	O
be	O
administered	O
during	O
RAPTIVA	B-Drug
treatment	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Increases	O
in	O
lymphocyte	O
counts	O
related	O
to	O
the	O
pharmacologic	O
mechanism	O
of	O
action	O
are	O
frequently	O
observed	O
during	O
RAPTIVA	B-Drug
treatment	O
.	O

Efavirenz	B-Drug
has	O
been	O
shown	O
in	O
vivo	O
to	O
induce	O
CYP3A4	B-Drug
.	O

Other	O
compounds	O
that	O
are	O
substrates	O
of	O
CYP3A4	B-Drug
may	O
have	O
decreased	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
SUSTIVA	B-Drug
(	O
efavirenz	B-Drug
)	O
.	O

In	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
efavirenz	B-Drug
inhibits	O
2C9	O
,	O
2C19	O
,	O
and	O
3A4	O
isozymes	O
in	O
the	O
range	O
of	O
observed	O
efavirenz	B-Drug
plasma	O
concentrations	O
.	O

Coadministration	O
of	O
efavirenz	B-Drug
with	O
drugs	B-Drug
primarily	O
metabolized	O
by	O
these	O
isozymes	O
may	O
result	O
in	O
altered	O
plasma	O
concentrations	O
of	O
the	O
coadministered	O
drug	B-Drug
.	O

Therefore	O
,	O
appropriate	O
dose	O
adjustments	O
may	O
be	O
necessary	O
for	O
these	O
drugs	B-Drug
.	O

Drugs	B-Drug
which	O
induce	O
CYP3A4	B-Drug
activity	O
(	O
eg	O
,	O
phenobarbital	B-Drug
,	O
rifampin	B-Drug
,	O
rifabutin	B-Drug
)	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
efavirenz	B-Drug
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
.	O

Drug	B-Drug
interactions	O
with	O
SUSTIVA	B-Drug
are	O
summarized	O
in	O
Table	O
5	O
.	O

Table	O
5a	O
:	O
Drugs	B-Drug
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
SUSTIVA	B-Drug
Drug	B-Drug
Class	O
Drugs	B-Drug
Within	O
Class	O
Not	O
To	O
Be	O
Coadministered	O
With	O
SUSTIVA	B-Drug
Antihistamines	B-Drug
:	O
Benzodiazepines	B-Drug
GI	O
Motility	O
Agents	O
Anti-Migraine	O
Antifungal	O
astemizole	B-Drug
midazolam	B-Drug
,	O
triazolam	B-Drug
cisapride	B-Drug
ergot	B-Drug
derivatives	O
voriconazole	B-Drug
Established	O
Drug	B-Drug
Interactions	O
Drug	B-Drug
Name	O
Effect	O
Clinical	O
Comment	O
Atazanavir	B-Drug
atazanavir	B-Drug
When	O
coadministered	O
with	O
SUSTIVA	B-Drug
in	O
treatment-naive	O
patients	O
,	O
the	O
recommended	O
dose	O
of	O
atazanavir	B-Drug
is	O
300	O
mg	O
with	O
ritonavir	B-Drug
100	O
mg	O
and	O
SUSTIVA	B-Drug
600	O
mg	O
(	O
all	O
once	O
daily	O
)	O
.	O

Dosing	O
recommendations	O
for	O
SUSTIVA	B-Drug
and	O
atazanavir	B-Drug
in	O
treatment-experienced	O
patients	O
have	O
not	O
been	O
established	O
.	O

Established	O
Drug	B-Drug
Interactions	O
(	O
continued	O
)	O
Drug	B-Drug
Name	O
Effect	O
Clinical	O
Comment	O
Clarithromycin	B-Drug
clarithromycin	B-Drug
concentration	O
Plasma	O
concentrations	O
decreased	O
by	O
SUSTIVA	B-Drug
;	O
clinical	O
significance	O
unknown	O
.	O

In	O
uninfected	O
volunteers	O
,	O
46	O
%	O
developed	O
rash	O
while	O
receiving	O
SUSTIVA	B-Drug
and	O
clarithromycin	B-Drug
.	O

No	O
dose	O
adjustment	O
of	O
SUSTIVA	B-Drug
is	O
recommended	O
when	O
given	O
with	O
clarithromycin	B-Drug
.	O

Alternatives	O
to	O
clarithromycin	B-Drug
,	O
such	O
as	O
azithromycin	B-Drug
,	O
should	O
be	O
considered	O
.	O

Other	O
macrolide	O
antibiotics	B-Drug
,	O
such	O
as	O
erythromycin	B-Drug
,	O
have	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B-Drug
.	O

14-OH	O
metabolite	O
concentration	O
Indinavir	B-Drug
indinavir	B-Drug
concentration	O
The	O
optimal	O
dose	O
of	O
indinavir	B-Drug
,	O
when	O
given	O
in	O
combination	O
with	O
SUSTIVA	B-Drug
,	O
is	O
not	O
known	O
.	O

Increasing	O
the	O
indinavir	B-Drug
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B-Drug
metabolism	O
due	O
to	O
SUSTIVA	B-Drug
.	O

When	O
indinavir	B-Drug
at	O
an	O
increased	O
dose	O
(	O
1000	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
with	O
SUSTIVA	B-Drug
(	O
600	O
mg	O
once	O
daily	O
)	O
,	O
the	O
indinavir	B-Drug
AUC	O
and	O
Cmin	O
were	O
decreased	O
on	O
average	O
by	O
33-46	O
%	O
and	O
39-57	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
when	O
indinavir	B-Drug
(	O
800	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
alone	O
.	O

Lopinavir/ritonavir	B-Drug
lopinavir	B-Drug
concentration	O
A	O
dose	O
increase	O
of	O
lopinavir/ritonavir	B-Drug
to	O
533/133	O
mg	O
(	O
4	O
capsules	O
or	O
6.5	O
mL	O
)	O
twice	O
daily	O
taken	O
with	O
food	O
is	O
recommended	O
when	O
used	O
in	O
combination	O
with	O
SUSTIVA	B-Drug
.	O

Methadone	B-Drug
methadone	B-Drug
concentration	O
Coadministration	O
in	O
HIV-infected	O
individuals	O
with	O
a	O
history	O
of	O
injection	O
drug	B-Drug
use	O
resulted	O
in	O
decreased	O
plasma	O
levels	O
of	O
methadone	B-Drug
and	O
signs	O
of	O
opiate	O
withdrawal	O
.	O

Methadone	B-Drug
dose	O
was	O
increased	O
by	O
a	O
mean	O
of	O
22	O
%	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O

Patients	O
should	O
be	O
monitored	O
for	O
signs	O
of	O
withdrawal	O
and	O
their	O
methadone	B-Drug
dose	O
increased	O
as	O
required	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O

Ethinyl	B-Drug
estradiol	I-Drug
ethinyl	B-Drug
estradiol	I-Drug
concentration	O
Plasma	O
concentrations	O
increased	O
by	O
SUSTIVA	B-Drug
(	O
efavirenz	B-Drug
)	O
;	O
clinical	O
significance	O
unknown	O
.	O

Because	O
the	O
potential	O
interaction	O
of	O
efavirenz	B-Drug
with	O
oral	O
contraceptives	O
has	O
not	O
been	O
fully	O
characterized	O
,	O
a	O
reliable	O
method	O
of	O
barrier	O
contraception	O
should	O
be	O
used	O
in	O
addition	O
to	O
oral	O
contraceptives	O
.	O

Rifabutin	B-Drug
rifabutin	B-Drug
concentration	O
Increase	O
daily	O
dose	O
of	O
rifabutin	B-Drug
by	O
50	O
%	O
.	O

Consider	O
doubling	O
the	O
rifabutin	B-Drug
dose	O
in	O
regimens	O
where	O
rifabutin	B-Drug
is	O
given	O
2	O
or	O
3	O
times	O
a	O
week	O
.	O

Rifampin	B-Drug
efavirenz	B-Drug
concentration	O
Clinical	O
significance	O
of	O
reduced	O
efavirenz	B-Drug
concentrations	O
unknown	O
.	O

Ritonavir	B-Drug
ritonavir	B-Drug
concentration	O
Combination	O
was	O
associated	O
with	O
a	O
higher	O
frequency	O
of	O
adverse	O
clinical	O
experiences	O
(	O
eg	O
,	O
dizziness	O
,	O
nausea	O
,	O
paresthesia	O
)	O
and	O
laboratory	O
abnormalities	O
(	O
elevated	O
liver	O
enzymes	O
)	O
.	O

Monitoring	O
of	O
liver	O
enzymes	O
is	O
recommended	O
when	O
SUSTIVA	B-Drug
is	O
used	O
in	O
combination	O
with	O
ritonavir	B-Drug
.	O

efavirenz	B-Drug
concentration	O
Saquinavir	B-Drug
saquinavir	B-Drug
concentration	O
Should	O
not	O
be	O
used	O
as	O
sole	O
protease	O
inhibitor	O
in	O
combination	O
with	O
SUSTIVA	B-Drug
.	O

Sertraline	B-Drug
sertraline	B-Drug
concentration	O
Increases	O
in	O
sertraline	B-Drug
dose	O
should	O
be	O
guided	O
by	O
clinical	O
response	O
.	O

Other	O
Potentially	O
Clinically	O
Significant	O
Drug	B-Drug
or	O
Herbal	O
Product	O
Interactions	O
With	O
SUSTIVAb	O
Anticoagulants	B-Drug
:	O
Warfarin	B-Drug
Plasma	O
concentrations	O
and	O
effects	O
potentially	O
increased	O
or	O
decreased	O
by	O
SUSTIVA	B-Drug
.	O

Anticonvulsants	O
:	O
Phenytoin	B-Drug
Phenobarbital	B-Drug
Carbamazepine	B-Drug
Potential	O
for	O
reduction	O
in	O
anticonvulsant	O
and/or	O
efavirenz	B-Drug
plasma	O
levels	O
;	O
periodic	O
monitoring	O
of	O
anticonvulsant	O
plasma	O
levels	O
should	O
be	O
conducted	O
.	O

Antifungals	O
:	O
Itraconazole	B-Drug
Ketoconazole	B-Drug
Drug	B-Drug
interaction	O
studies	O
with	O
SUSTIVA	B-Drug
and	O
these	O
imidazole	O
and	O
triazole	O
antifungals	O
have	O
not	O
been	O
conducted	O
.	O

SUSTIVA	B-Drug
has	O
the	O
potential	O
to	O
decrease	O
plasma	O
concentrations	O
of	O
itraconazole	B-Drug
and	O
ketoconazole	B-Drug
.	O

Anti-HIV	O
protease	O
inhibitors	O
:	O
Saquinavir/ritonavir	B-Drug
combination	O
No	O
pharmacokinetic	O
data	O
are	O
available	O
.	O

Amprenavir	B-Drug
SUSTIVAhas	O
the	O
potential	O
to	O
decrease	O
serum	O
concentrations	O
of	O
amprenavir	B-Drug
.	O

Non-nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
No	O
studies	O
have	O
been	O
performed	O
with	O
other	O
NNRTIs	O
.	O

St.	O
John	O
s	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
Expected	O
to	O
substantially	O
decrease	O
plasma	O
levels	O
of	O
efavirenz	B-Drug
;	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B-Drug
.	O

a	O
See	O
Tables	O
1	O
and	O
2	O
.	O

b	O
This	O
table	O
is	O
not	O
all-inclusive	O
.	O

Other	O
Drugs	B-Drug
:	O
Based	O
on	O
the	O
results	O
of	O
drug	B-Drug
interaction	O
studies	O
,	O
no	O
dosage	O
adjustment	O
is	O
recommended	O
when	O
SUSTIVA	B-Drug
(	O
efavirenz	B-Drug
)	O
is	O
given	O
with	O
the	O
following	O
:	O
aluminum/magnesium	O
hydroxide	O
antacids	O
,	O
azithromycin	B-Drug
,	O
cetirizine	B-Drug
,	O
famotidine	B-Drug
,	O
fluconazole	B-Drug
,	O
lamivudine	B-Drug
,	O
lorazepam	B-Drug
,	O
nelfinavir	B-Drug
,	O
paroxetine	B-Drug
,	O
and	O
zidovudine	B-Drug
.	O

Specific	O
drug	B-Drug
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
SUSTIVA	B-Drug
and	O
NRTIs	O
other	O
than	O
lamivudine	B-Drug
and	O
zidovudine	B-Drug
.	O

Clinically	O
significant	O
interactions	O
would	O
not	O
be	O
expected	O
since	O
the	O
NRTIs	O
are	O
metabolized	O
via	O
a	O
different	O
route	O
than	O
efavirenz	B-Drug
and	O
would	O
be	O
unlikely	O
to	O
compete	O
for	O
the	O
same	O
metabolic	O
enzymes	O
and	O
elimination	O
pathways	O
.	O

The	O
potential	O
for	O
drug	B-Drug
interactions	O
with	O
EMTRIVA	B-Drug
has	O
been	O
studied	O
in	O
combination	O
with	O
indinavir	B-Drug
,	O
stavudine	B-Drug
,	O
famciclovir	B-Drug
,	O
and	O
tenofovir	B-Drug
disoproxil	I-Drug
fumarate	I-Drug
.	O

There	O
were	O
no	O
clinically	O
significant	O
drug	B-Drug
interactions	O
for	O
any	O
of	O
these	O
drugs	B-Drug
.	O

Hypotension	O
:	O
Patients	O
on	O
Diuretic	B-Drug
Therapy	O
:	O
Patients	O
on	O
diuretics	B-Drug
and	O
especially	O
those	O
in	O
whom	O
diuretic	B-Drug
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
enalapril	B-Drug
or	O
enalaprilat	B-Drug
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
enalapril	B-Drug
or	O
enalaprilat	B-Drug
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Drug
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
enalapril	B-Drug
or	O
enalaprilat	B-Drug
.	O

If	O
it	O
is	O
necessary	O
to	O
continue	O
the	O
diuretic	B-Drug
,	O
provide	O
close	O
medical	O
supervision	O
after	O
the	O
initial	O
dose	O
for	O
at	O
least	O
two	O
hours	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
for	O
at	O
least	O
an	O
additional	O
hour..	O
Agents	O
Causing	O
Renin	O
Release	O
:	O
The	O
antihypertensive	B-Drug
effect	O
of	O
enalapril	B-Drug
and	O
enalapril	B-Drug
IV	O
is	O
augmented	O
by	O
antihypertensive	B-Drug
agents	O
that	O
cause	O
renin	O
release	O
(	O
e.g.	O
,	O
diuretics	B-Drug
)	O
.	O

Non-steroidal	O
Anti-inflammatory	O
Agents	O
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
,	O
the	O
co-administration	O
of	O
enalapril	B-Drug
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O

These	O
effects	O
are	O
usually	O
reversible	O
.	O

In	O
a	O
clinical	O
pharmacology	O
study	O
,	O
indomethacin	B-Drug
or	O
sulindac	B-Drug
was	O
administered	O
to	O
hypertensive	O
patients	O
receiving	O
VASOTEC	B-Drug
.	O

In	O
this	O
study	O
there	O
was	O
no	O
evidence	O
of	O
a	O
blunting	O
of	O
the	O
antihypertensive	B-Drug
action	O
of	O
VASOTEC	B-Drug
.	O

However	O
,	O
reports	O
suggest	O
that	O
NSAIDs	O
may	O
diminish	O
the	O
antihypertensive	B-Drug
effect	O
of	O
ACE	O
inhibitors	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	O
concomitantly	O
with	O
ACE	O
inhibitors	O
.	O

Other	O
Cardiovascular	O
Agents	O
:	O
Enalapril	B-Drug
and	O
enalapril	B-Drug
IV	O
have	O
been	O
used	O
concomitantly	O
with	O
beta	O
adrenergic-blocking	O
agents	O
,	O
methyldopa	B-Drug
,	O
nitrates	B-Drug
,	O
calcium-blocking	O
agents	O
,	O
hydralazine	B-Drug
,	O
prazosin	B-Drug
and	O
digoxin	B-Drug
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Enalapril	B-Drug
IV	O
has	O
been	O
used	O
concomitantly	O
with	O
digitalis	B-Drug
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
reactions	O
.	O

Agents	O
Increasing	O
Serum	O
Potassium	B-Drug
:	O
Enalapril	B-Drug
and	O
enalapril	B-Drug
IV	O
attenuate	O
potassium	B-Drug
loss	O
caused	O
by	O
thiazide-type	O
diuretics	B-Drug
.	O

Potassium-sparing	O
diuretics	B-Drug
(	O
e.g.	O
,	O
spironolactone	B-Drug
,	O
triamterene	B-Drug
,	O
or	O
amiloride	B-Drug
)	O
,	O
potassium	B-Drug
supplements	O
,	O
or	O
potassium-containing	B-Drug
salt	O
substitutes	O
may	O
lead	B-Drug
to	O
significant	O
increases	O
in	O
serum	O
potassium	B-Drug
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	B-Drug
.	O

Potassium	B-Drug
sparing	O
agents	O
should	O
generally	O
not	O
be	O
used	O
in	O
patients	O
with	O
heart	O
failure	O
receiving	O
enalapril	B-Drug
.	O

Lithium	B-Drug
:	O
Lithium	B-Drug
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B-Drug
concomitantly	O
with	O
drugs	B-Drug
which	O
cause	O
elimination	O
of	O
sodium	O
,	O
including	O
ACE	O
inhibitors	O
.	O

It	O
is	O
recommended	O
that	O
serum	O
lithium	B-Drug
levels	O
be	O
monitored	O
frequently	O
if	O
enalapril	B-Drug
is	O
administered	O
concomitantly	O
with	O
lithium	B-Drug
.	O

The	O
action	O
of	O
nondepolarizing	O
relaxants	O
is	O
augmented	O
by	O
Enflurane	B-Drug
.	O

Less	O
than	O
the	O
usual	O
amounts	O
of	O
these	O
medicines	O
should	O
be	O
used	O
.	O

If	O
the	O
usual	O
amounts	O
of	O
nondepolarizing	O
relaxants	O
are	O
given	O
,	O
the	O
time	O
for	O
recovery	O
from	O
neuromuscular	O
blockade	O
will	O
be	O
longer	O
in	O
the	O
presence	O
of	O
Enflurane	B-Drug
than	O
when	O
halothane	B-Drug
or	O
nitrous	B-Drug
oxide	I-Drug
with	O
a	O
balanced	O
technique	O
are	O
used	O
.	O

CYP450	O
Metabolized	O
Drugs	B-Drug
Results	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
suggest	O
that	O
enfuvirtide	B-Drug
is	O
unlikely	O
to	O
have	O
significant	O
drug	B-Drug
interactions	O
with	O
concomitantly	O
administered	O
drugs	B-Drug
metabolized	O
by	O
CYP450	O
enzymes	O
.	O

Antiretroviral	O
Agents	O
:	O
No	O
drug	B-Drug
interactions	O
with	O
other	O
antiretroviral	O
medications	O
have	O
been	O
identified	O
that	O
would	O
warrant	O
alteration	O
of	O
either	O
the	O
enfuvirtide	B-Drug
dose	O
or	O
the	O
dose	O
of	O
the	O
other	O
antiretroviral	O
medication	O
.	O

Bismuth	B-Drug
:	O
Bismuth	B-Drug
subsalicylate	I-Drug
,	O
given	O
concomitantly	O
with	O
enoxacin	B-Drug
or	O
60	O
minutes	O
following	O
enoxacin	B-Drug
administration	O
,	O
decreased	O
enoxacin	B-Drug
bioavailability	O
by	O
approximately	O
25	O
%	O
.	O

Thus	O
,	O
concomitant	O
administration	O
of	O
enoxacin	B-Drug
and	O
bismuth	B-Drug
subsalicylate	I-Drug
should	O
be	O
avoided	O
.	O

Caffeine	B-Drug
:	O
Enoxacin	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P-450	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	O
.	O

In	O
a	O
multiple-dose	O
study	O
,	O
enoxacin	B-Drug
caused	O
a	O
dose-related	O
increase	O
in	O
the	O
mean	O
elimination	O
half-life	O
of	O
caffeine	B-Drug
,	O
thereby	O
decreasing	O
the	O
clearance	O
of	O
caffeine	B-Drug
by	O
up	O
to	O
80	O
%	O
and	O
leading	O
to	O
a	O
five-fold	O
increase	O
in	O
the	O
AUC	O
and	O
the	O
half-life	O
of	O
caffeine	B-Drug
.	O

Trough	O
plasma	O
enoxacin	B-Drug
levels	O
were	O
also	O
20	O
%	O
higher	O
when	O
caffeine	B-Drug
and	O
enoxacin	B-Drug
were	O
administered	O
concomitantly	O
.	O

Caffeine-related	B-Drug
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
consuming	O
caffeine	B-Drug
while	O
on	O
therapy	O
with	O
enoxacin	B-Drug
.	O

Cyclosporine	B-Drug
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B-Drug
with	O
other	O
members	O
of	O
the	O
quinolone	O
class	O
.	O

Digoxin	B-Drug
:	O
Enoxacin	B-Drug
may	O
raise	O
serum	O
digoxin	B-Drug
levels	O
in	O
some	O
individuals	O
.	O

If	O
signs	O
and	O
symptoms	O
suggestive	O
of	O
digoxin	B-Drug
toxicity	O
occur	O
when	O
enoxacin	B-Drug
and	O
digoxin	B-Drug
are	O
given	O
concomitantly	O
,	O
physicians	O
are	O
advised	O
to	O
obtain	O
serum	O
digoxin	B-Drug
levels	O
and	O
adjust	O
digoxin	B-Drug
doses	O
appropriately	O
.	O

Non-steroidal	O
anti-inflammatory	O
agents	O
:	O
Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
enoxacin	B-Drug
concomitantly	O
with	O
the	O
nonsteroidal	O
anti-inflammatory	O
drug	B-Drug
fenbufen	B-Drug
.	O

Animal	O
studies	O
also	O
suggest	O
an	O
increased	O
potential	O
for	O
seizures	O
when	O
these	O
two	O
drugs	B-Drug
are	O
given	O
concomitantly	O
.	O

Fenbufen	B-Drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
at	O
this	O
time	O
.	O

Sucralfate	B-Drug
and	O
antacids	O
:	O
Quinolones	O
form	O
chelates	O
with	O
metal	O
cations	O
.	O

Therefore	O
,	O
administration	O
of	O
quinolones	O
with	O
antacids	O
containing	O
calcium	B-Drug
,	O
magnesium	B-Drug
,	O
or	O
aluminum	B-Drug
;	O
with	O
sucralfate	B-Drug
;	O
with	O
divalent	O
or	O
trivalent	O
cations	O
such	O
as	O
iron	B-Drug
;	O
or	O
with	O
multivitamins	O
containing	O
zinc	B-Drug
may	O
substantially	O
interfere	O
with	O
drug	B-Drug
absorption	O
and	O
result	O
in	O
insufficient	O
plasma	O
and	O
tissue	O
quinolone	O
concentrations	O
.	O

Antacids	O
containing	O
aluminum	B-Drug
hydroxide	I-Drug
and	O
magnesium	B-Drug
hydroxide	I-Drug
reduce	O
the	O
oral	O
absorption	O
of	O
enoxacin	B-Drug
by	O
75	O
%	O
.	O

The	O
oral	O
bioavailability	O
of	O
enoxacin	B-Drug
is	O
reduced	O
by	O
60	O
%	O
with	O
coadministration	O
of	O
ranitidine	B-Drug
.	O

These	O
agents	O
should	O
not	O
be	O
taken	O
for	O
8	O
hours	O
before	O
or	O
for	O
2	O
hours	O
after	O
enoxacin	B-Drug
administration	O
.	O

Theophylline	B-Drug
:	O
Enoxacin	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P-450	O
isozymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
methylxanthines	O
.	O

Enoxacin	B-Drug
interferes	O
with	O
the	O
metabolism	O
of	O
theophylline	B-Drug
resulting	O
in	O
a	O
42	O
%	O
to	O
74	O
%	O
dose-related	O
decrease	O
in	O
theophylline	B-Drug
clearance	O
and	O
a	O
subsequent	O
260	O
%	O
to	O
350	O
%	O
increase	O
in	O
serum	O
theophylline	B-Drug
levels	O
.	O

Theophylline-related	B-Drug
adverse	O
effects	O
have	O
occurred	O
in	O
patients	O
when	O
theophylline	B-Drug
and	O
enoxacin	B-Drug
were	O
coadministered	O
.	O

Warfarin	B-Drug
:	O
Quinolones	O
,	O
including	O
enoxacin	B-Drug
,	O
decrease	O
the	O
clearance	O
of	O
R-warfarin	B-Drug
,	O
the	O
less	O
active	O
isomer	O
of	O
racemic	O
warfarin	B-Drug
.	O

Enoxacin	B-Drug
does	O
not	O
affect	O
the	O
clearance	O
of	O
the	O
active	O
S-isomer	O
,	O
and	O
changes	O
in	O
clotting	O
time	O
have	O
not	O
been	O
observed	O
when	O
enoxacin	B-Drug
and	O
warfarin	B-Drug
were	O
coadministered	O
.	O

Nevertheless	O
,	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
monitored	O
when	O
warfarin	B-Drug
or	O
its	O
derivatives	O
and	O
enoxacin	B-Drug
are	O
given	O
concomitantly	O
.	O

Unless	O
really	O
needed	O
,	O
agents	O
which	O
may	O
enhance	O
the	O
risk	O
of	O
hemorrhage	O
should	O
be	O
discontinued	O
prior	O
to	O
initiation	O
of	O
Lovenox	B-Drug
Injection	O
therapy	O
.	O

These	O
agents	O
include	O
medications	O
such	O
as	O
:	O
anticoagulants	B-Drug
,	O
platelet	O
inhibitors	O
including	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
sali-cylates	O
,	O
NSAIDs	O
(	O
including	O
ketorolac	B-Drug
tromethamine	I-Drug
)	O
,	O
dipyridamole	B-Drug
,	O
or	O
sulfinpyrazone	B-Drug
.	O

If	O
co-administration	O
is	O
essential	O
,	O
conduct	O
close	O
clinical	O
and	O
laboratory	O
monitoring	O
.	O

In	O
vitro	O
studies	O
of	O
human	O
CYP	O
enzymes	O
showed	O
that	O
entacapone	B-Drug
inhibited	O
the	O
CYP	O
enzymes	O
1A2	O
,	O
2A6	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
and	O
3A	O
only	O
at	O
very	O
high	O
concentrations	O
(	O
IC50	O
from	O
200	O
to	O
over	O
1000	O
uM	O
;	O
an	O
oral	O
200	O
mg	O
dose	O
achieves	O
a	O
highest	O
level	O
of	O
approximately	O
5	O
uM	O
in	O
people	O
)	O
;	O
these	O
enzymes	O
would	O
therefore	O
not	O
be	O
expected	O
to	O
be	O
inhibited	O
in	O
clinical	O
use	O
.	O

Protein	O
Binding	O
:	O
Entacapone	B-Drug
is	O
highly	O
protein	O
bound	O
(	O
98	O
%	O
)	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
no	O
binding	O
displacement	O
between	O
entacapone	B-Drug
and	O
other	O
highly	O
bound	O
drugs	B-Drug
,	O
such	O
as	O
warfarin	B-Drug
,	O
salicylic	B-Drug
acid	I-Drug
,	O
phenylbutazone	B-Drug
,	O
and	O
diazepam	B-Drug
.	O

Drugs	B-Drug
Metabolized	O
by	O
Catechol-O-methyltransferase	O
(	O
COMT	O
)	O
:	O
Hormone	O
levels	O
:	O
Levodopa	B-Drug
is	O
known	O
to	O
depress	O
prolactin	O
secretion	O
and	O
increase	O
growth	O
hormone	O
levels	O
.	O

Treatment	O
with	O
entacapone	B-Drug
coadministered	O
with	O
levodopa/dopa	B-Drug
decarboxylase	O
inhibitor	O
does	O
not	O
change	O
these	O
effects	O
.	O

No	O
interaction	O
was	O
noted	O
with	O
the	O
MAO-B	O
inhibitor	O
selegiline	B-Drug
in	O
two	O
multiple-dose	O
interaction	O
studies	O
when	O
entacapone	B-Drug
was	O
coadministered	O
with	O
a	O
levodopa/dopa	B-Drug
decarboxylase	O
inhibitor	O
(	O
n=29	O
)	O
.	O

More	O
than	O
600	O
Parkinsons	O
disease	O
patients	O
in	O
clinical	O
trials	O
have	O
used	O
selegiline	B-Drug
in	O
combination	O
with	O
entacapone	B-Drug
and	O
levodopa/dopa	B-Drug
decarboxylase	O
inhibitor	O
.	O

As	O
most	O
entacapone	B-Drug
excretion	O
is	O
via	O
the	O
bile	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
drugs	B-Drug
known	O
to	O
interfere	O
with	O
biliary	O
excretion	O
,	O
glucuronidation	O
,	O
and	O
intestinal	O
beta-glucuronidase	O
are	O
given	O
concurrently	O
with	O
entacapone	B-Drug
.	O

These	O
include	O
probenecid	B-Drug
,	O
cholestyramine	B-Drug
,	O
and	O
some	O
antibiotics	B-Drug
(	O
e.g	O
.	O

erythromycin	B-Drug
,	O
rifamipicin	O
,	O
ampicillin	B-Drug
and	O
chloramphenicol	B-Drug
)	O
.	O

No	O
interaction	O
with	O
the	O
tricyclic	O
antidepressant	O
imipramine	B-Drug
was	O
shown	O
in	O
a	O
single-dose	O
study	O
with	O
entacapone	B-Drug
without	O
coadministered	O
levodopa/dopa-decarboxylase	B-Drug
inhibitor	O
.	O

Since	O
entecavir	B-Drug
is	O
primarily	O
eliminated	O
by	O
the	O
kidneys	O
,	O
coadministration	O
of	O
BARACLUDE	B-Drug
with	O
drugs	B-Drug
that	O
reduce	O
renal	O
function	O
or	O
compete	O
for	O
active	O
tubular	O
secretion	O
may	O
increase	O
serum	O
concentrations	O
of	O
either	O
entecavir	B-Drug
or	O
the	O
coadministered	O
drug	B-Drug
.	O

Coadministration	O
of	O
entecavir	B-Drug
with	O
lamivudine	B-Drug
,	O
adefovir	B-Drug
dipivoxil	I-Drug
,	O
or	O
tenofovir	B-Drug
disoproxil	I-Drug
fumarate	I-Drug
did	O
not	O
result	O
in	O
significant	O
drug	B-Drug
interactions	O
.	O

The	O
effects	O
of	O
coadministration	O
of	O
BARACLUDE	B-Drug
with	O
other	O
drugs	B-Drug
that	O
are	O
renally	O
eliminated	O
or	O
are	O
known	O
to	O
affect	O
renal	O
function	O
have	O
not	O
been	O
evaluated	O
,	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
adverse	O
events	O
when	O
BARACLUDE	B-Drug
is	O
coadministered	O
with	O
such	O
drugs	B-Drug
.	O

None	O
Reported	O
Epinephrine	B-Drug
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
hyperthyroidism	O
,	O
hypertension	O
and	O
cardiac	O
arrhythmias	O
.	O

All	O
vasopressors	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
taking	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
.	O

Epinephrine	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
other	O
sympathomimetic	B-Drug
drugs	B-Drug
(	O
such	O
as	O
isoproterenol	B-Drug
)	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
increased	O
toxicity	O
.	O

Combined	O
effects	O
may	O
induce	O
serious	O
cardiac	O
arrhythmias	O
.	O

They	O
may	O
be	O
administered	O
alternately	O
when	O
the	O
preceding	O
effect	O
of	O
other	O
such	O
drug	B-Drug
has	O
subsided	O
.	O

Administration	O
of	O
epinephrine	B-Drug
to	O
patients	O
receiving	O
cyclopropane	B-Drug
or	O
halogenated	O
hydrocarbon	O
general	O
anesthetics	B-Drug
such	O
as	O
halothane	B-Drug
which	O
sensitize	O
the	O
myocardium	O
,	O
may	O
induce	O
cardiac	O
arrhythmia..	O
When	O
encountered	O
,	O
such	O
arrhythmias	O
may	O
respond	O
to	O
administration	O
of	O
a	O
beta-adrenergic	O
blocking	O
drug	B-Drug
.	O

Epinephrine	B-Drug
also	O
should	O
be	O
used	O
cautiously	O
with	O
other	O
drugs	B-Drug
(	O
e.g.	O
,	O
digitalis	B-Drug
,	O
glycosides	O
)	O
that	O
sensitize	O
the	O
myocardium	O
to	O
the	O
actions	O
of	O
sympathomimetic	B-Drug
drugs	B-Drug
.	O

Diuretic	B-Drug
agents	O
may	O
decrease	O
vascular	O
response	O
to	O
pressor	O
drugs	B-Drug
such	O
as	O
epinephrine	B-Drug
.	O

Epinephrine	B-Drug
may	O
antagonize	O
the	O
neuron	O
blockade	O
produced	O
by	O
guanethidine	B-Drug
resulting	O
in	O
decreased	O
antihypertensive	B-Drug
effect	O
and	O
requiring	O
increased	O
dosage	O
of	O
the	O
latter	O
.	O

ELLENCE	B-Drug
when	O
used	O
in	O
combination	O
with	O
other	O
cytotoxic	O
drugs	B-Drug
may	O
show	O
on-treatment	O
additive	O
toxicity	O
,	O
especially	O
hematologic	O
and	O
gastrointestinal	O
effects	O
.	O

Concomitant	O
use	O
of	O
ELLENCE	B-Drug
with	O
other	O
cardioactive	O
compounds	O
that	O
could	O
cause	O
heart	O
failure	O
(	O
e.g.	O
,	O
calcium	B-Drug
channel	O
blockers	O
)	O
,	O
requires	O
close	O
monitoring	O
of	O
cardiac	O
function	O
throughout	O
treatment	O
.	O

There	O
are	O
few	O
data	O
regarding	O
the	O
coadministration	O
of	O
radiation	O
therapy	O
and	O
epirubicin	B-Drug
.	O

In	O
adjuvant	O
trials	O
of	O
epirubicin-containing	B-Drug
CEF-120	O
or	O
FEC-100	O
chemotherapies	O
,	O
breast	O
irradiation	O
was	O
delayed	O
until	O
after	O
chemotherapy	O
was	O
completed	O
.	O

This	O
practice	O
resulted	O
in	O
no	O
apparent	O
increase	O
in	O
local	O
breast	O
cancer	O
recurrence	O
relative	O
to	O
published	O
accounts	O
in	O
the	O
literature	O
.	O

A	O
small	O
number	O
of	O
patients	O
received	O
epirubicin-based	B-Drug
chemotherapy	O
concomitantly	O
with	O
radiation	O
therapy	O
but	O
had	O
chemotherapy	O
interrupted	O
in	O
order	O
to	O
avoid	O
potential	O
overlapping	O
toxicities	O
.	O

It	O
is	O
likely	O
that	O
use	O
of	O
epirubicin	B-Drug
with	O
radiotherapy	O
may	O
sensitize	O
tissues	O
to	O
the	O
cytotoxic	O
actions	O
of	O
irradiation	O
.	O

Administration	O
of	O
ELLENCE	B-Drug
after	O
previous	O
radiation	O
therapy	O
may	O
induce	O
an	O
inflammatory	O
recall	O
reaction	O
at	O
the	O
site	O
of	O
the	O
irradiation	O
.	O

Epirubicin	B-Drug
is	O
extensively	O
metabolized	O
by	O
the	O
liver	O
.	O

Changes	O
in	O
hepatic	O
function	O
induced	O
by	O
concomitant	O
therapies	O
may	O
affect	O
epirubicin	B-Drug
metabolism	O
,	O
pharmacokinetics	O
,	O
therapeutic	O
efficacy	O
,	O
and/or	O
toxicity	O
.	O

Cimetidine	B-Drug
increased	O
the	O
AUC	O
of	O
epirubicin	B-Drug
by	O
50	O
%	O
.	O

Cimetidine	B-Drug
treatment	O
should	O
be	O
stopped	O
during	O
treatment	O
with	O
ELLENCE	B-Drug
.	O

Drug-Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
ELLENCE	B-Drug
and	O
laboratory	O
tests	O
.	O

Inhibitors	O
of	O
CYP3A4-Eplerenone	B-Drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
CYP3A4	B-Drug
.	O

A	O
pharmacokinetic	O
study	O
evaluating	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
INSPRA	B-Drug
100	O
mg	O
with	O
ketoconazole	B-Drug
200	O
mg	O
BID	O
,	O
a	O
potent	O
inhibitor	O
of	O
the	O
CYP3A4	B-Drug
pathway	O
,	O
showed	O
a	O
1.7-fold	O
increase	O
in	O
Cmax	O
of	O
eplerenone	B-Drug
and	O
a	O
5.4-fold	O
increase	O
in	O
AUC	O
of	O
eplerenone	B-Drug
.	O

INSPRA	B-Drug
should	O
not	O
be	O
used	O
with	O
drugs	B-Drug
described	O
as	O
strong	O
inhibitors	O
of	O
CYP3A4	B-Drug
in	O
their	O
labeling	O
.	O

Administration	O
of	O
eplerenone	B-Drug
with	O
other	O
CYP3A4	B-Drug
inhibitors	O
(	O
e.g.	O
,	O
erythromycin	B-Drug
500	O
mg	O
BID	O
,	O
verapamil	B-Drug
240	O
mg	O
QD	O
,	O
saquinavir	B-Drug
1200	O
mg	O
TID	O
,	O
fluconazole	B-Drug
200	O
mg	O
QD	O
)	O
resulted	O
in	O
increases	O
in	O
Cmax	O
of	O
eplerenone	B-Drug
ranging	O
from	O
1.4-	O
to	O
1.6-	O
fold	O
and	O
AUC	O
from	O
2.0-	O
to	O
2.9-	O
fold	O
.	O

ACE	O
Inhibitors	O
and	O
Angiotensin	B-Drug
II	O
Receptor	O
Antagonists	O
(	O
Congestive	O
Heart	O
Failure	O
Post-Myocardial	O
Infarction	O
)	O
-	O
In	O
EPHESUS	O
,	O
3020	O
(	O
91	O
%	O
)	O
patients	O
receiving	O
INSPRA	B-Drug
25	O
to	O
50	O
mg	O
also	O
received	O
ACE	O
inhibitors	O
or	O
angiotensin	B-Drug
II	O
receptor	O
antagonists	O
(	O
ACEI/ARB	O
)	O
.	O

Rates	O
of	O
patients	O
with	O
maximum	O
potassium	B-Drug
levels	O
5.5	O
mEq/L	O
were	O
similar	O
regardless	O
of	O
the	O
use	O
of	O
ACEI/ARB	O
.	O

ACE	O
Inhibitors	O
and	O
Angiotensin	B-Drug
II	O
Receptor	O
Antagonists	O
(	O
Hypertension	O
)	O
-	O
In	O
clinical	O
studies	O
of	O
patients	O
with	O
hypertension	O
,	O
the	O
addition	O
of	O
INSPRA	B-Drug
50	O
to	O
100	O
mg	O
to	O
ACE	O
inhibitors	O
and	O
angiotensin	B-Drug
II	O
receptor	O
antagonists	O
increased	O
mean	O
serum	O
potassium	B-Drug
slightly	O
(	O
about	O
0.09-0.13	O
mEq/L	O
)	O
.	O

In	O
a	O
study	O
in	O
diabetics	O
with	O
microalbuminuria	O
INSPRA	B-Drug
200	O
mg	O
combined	O
with	O
the	O
ACE	O
inhibitor	O
enalapril	B-Drug
10	O
mg	O
increased	O
the	O
frequency	O
of	O
hyperkalemia	O
(	O
serum	O
potassium	B-Drug
5.5	O
mEq/L	O
)	O
from	O
17	O
%	O
on	O
enalapril	B-Drug
alone	O
to	O
38	O
%	O
.	O

Lithium-A	B-Drug
drug	B-Drug
interaction	O
study	O
of	O
eplerenone	B-Drug
with	O
lithium	B-Drug
has	O
not	O
been	O
conducted	O
.	O

Serum	O
lithium	B-Drug
levels	O
should	O
be	O
monitored	O
frequently	O
if	O
INSPRA	B-Drug
is	O
administered	O
concomitantly	O
with	O
lithium	B-Drug
.	O

Nonsteroidal	O
Anti-Inflammatory	O
Drugs	B-Drug
(	O
NSAIDs	O
)	O
-A	O
drug	B-Drug
interaction	O
study	O
of	O
eplerenone	B-Drug
with	O
an	O
NSAID	O
has	O
not	O
been	O
conducted	O
.	O

The	O
administration	O
of	O
other	O
potassium-sparing	O
antihypertensives	B-Drug
with	O
NSAIDs	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
antihypertensive	B-Drug
effect	O
in	O
some	O
patients	O
and	O
result	O
in	O
severe	O
hyperkalemia	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O

Therefore	O
,	O
when	O
INSPRA	B-Drug
and	O
NSAIDs	O
are	O
used	O
concomitantly	O
,	O
patients	O
should	O
be	O
observed	O
to	O
determine	O
whether	O
the	O
desired	O
effect	O
on	O
blood	O
pressure	O
is	O
obtained	O
.	O

No	O
evidence	O
of	O
interaction	O
of	O
PROCRIT	B-Drug
with	O
other	O
drugs	B-Drug
was	O
observed	O
in	O
the	O
course	O
of	O
clinical	O
trials	O
.	O

Additional	O
reductions	O
in	O
blood	O
pressure	O
may	O
occur	O
when	O
FLOLAN	B-Drug
is	O
administered	O
with	O
diuretics	B-Drug
,	O
antihypertensive	B-Drug
agents	O
,	O
or	O
other	O
vasodilators	O
.	O

When	O
other	O
antiplatelet	O
agents	O
or	O
anticoagulants	B-Drug
are	O
used	O
concomitantly	O
,	O
there	O
is	O
the	O
potential	O
for	O
FLOLAN	B-Drug
to	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

However	O
,	O
patients	O
receiving	O
infusions	O
of	O
FLOLAN	B-Drug
in	O
clinical	O
trials	O
were	O
maintained	O
on	O
anticoagulants	B-Drug
without	O
evidence	O
of	O
increased	O
bleeding	O
.	O

In	O
clinical	O
trials	O
,	O
FLOLAN	B-Drug
was	O
used	O
with	O
digoxin	B-Drug
,	O
diuretics	B-Drug
,	O
anticoagulants	B-Drug
,	O
oral	O
vasodilators	O
,	O
and	O
supplemental	O
oxygen.In	B-Drug
a	O
pharmacokinetic	O
substudy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
receiving	O
furosemide	B-Drug
or	O
digoxin	B-Drug
in	O
whom	O
therapy	O
with	O
FLOLAN	B-Drug
was	O
initiated	O
,	O
apparent	O
oral	O
clearance	O
values	O
for	O
furosemide	B-Drug
(	O
n	O
=	O
23	O
)	O
and	O
digoxin	B-Drug
(	O
n	O
=	O
30	O
)	O
were	O
decreased	O
by	O
13	O
%	O
and	O
15	O
%	O
,	O
respectively	O
,	O
on	O
the	O
second	O
day	O
of	O
therapy	O
and	O
had	O
returned	O
to	O
baseline	O
values	O
by	O
day	O
87	O
.	O

The	O
change	O
in	O
furosemide	B-Drug
clearance	O
value	O
is	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O

However	O
,	O
patients	O
on	O
digoxin	B-Drug
may	O
show	O
elevations	O
of	O
digoxin	B-Drug
concentrations	O
after	O
initiation	O
of	O
therapy	O
with	O
FLOLAN	B-Drug
,	O
which	O
may	O
be	O
clinically	O
significant	O
in	O
patients	O
prone	O
to	O
digoxin	B-Drug
toxicity	O
.	O

Eprosartan	B-Drug
has	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
and	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
and	O
glyburide	B-Drug
.	O

Thus	O
no	O
dosing	O
adjustments	O
are	O
necessary	O
during	O
concomitant	O
use	O
with	O
these	O
agents	O
.	O

Because	O
eprosartan	B-Drug
is	O
not	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
,	O
inhibitors	O
of	O
CYP450	O
enzyme	O
would	O
not	O
be	O
expected	O
to	O
affect	O
its	O
metabolism	O
,	O
and	O
ketoconazole	B-Drug
and	O
fluconazole	B-Drug
,	O
potent	O
inhibitors	O
of	O
CYP3A	O
and	O
2C9	O
,	O
respectively	O
,	O
have	O
been	O
shown	O
to	O
have	O
no	O
effect	O
on	O
eprosartan	B-Drug
pharmacokinetics	O
.	O

Ranitidine	B-Drug
also	O
has	O
no	O
effect	O
on	O
eprosartan	B-Drug
pharmacokinetics	O
.	O

Eprosartan	B-Drug
(	O
up	O
to	O
400	O
mg	O
b.i.d	O
.	O

or	O
800	O
mg	O
q.d	O
.	O

)	O
doses	O
have	O
been	O
safely	O
used	O
concomitantly	O
with	O
a	O
thiazide	O
diuretic	B-Drug
(	O
hydrochlorothiazide	B-Drug
)	O
.	O

Eprosartan	B-Drug
doses	O
of	O
up	O
to	O
300	O
mg	O
b.i.d	O
.	O

have	O
been	O
safely	O
used	O
concomitantly	O
with	O
sustained-release	O
calcium	B-Drug
channel	O
blockers	O
(	O
sustained-release	O
nifedipine	B-Drug
)	O
with	O
no	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Enoxaparin	B-Drug
dosed	O
as	O
a	O
1.0	O
mg/kg	O
subcutaneous	O
injection	O
q12h	O
for	O
four	O
doses	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
eptifibatide	B-Drug
or	O
the	O
level	O
of	O
platelet	O
aggregation	O
in	O
healthy	O
adults	O
.	O

Mineral	B-Drug
oil	I-Drug
interferes	O
with	O
the	O
absorption	O
of	O
fat-soluble	O
vitamins	O
,	O
including	O
vitamin	O
D	O
preparations	O
.	O

Administration	O
of	O
thiazide	O
diuretics	B-Drug
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
ergocalciferol	B-Drug
may	O
cause	O
hypercalcemia	O
.	O

No	O
reported	O
interactions	O
.	O

The	O
effects	O
of	O
ERGOMAR	B-Drug
may	O
be	O
potentiated	O
by	O
triacetyloleandomycin	B-Drug
which	O
inhibits	O
the	O
metabolism	O
of	O
ergotamine	B-Drug
.	O

The	O
pressor	O
effects	O
of	O
ERGOMAR	B-Drug
and	O
other	O
vasoconstrictor	O
drugs	B-Drug
can	O
combine	O
to	O
cause	O
dangerous	O
hypertension	O
.	O

Co-treatment	O
with	O
the	O
potent	O
CYP3A4	B-Drug
inhibitor	O
ketoconazole	B-Drug
increases	O
erlotinib	B-Drug
AUC	O
by	O
2/3	O
.	O

Caution	O
should	O
be	O
used	O
when	O
administering	O
or	O
taking	O
TARCEVA	B-Drug
with	O
ketoconazole	B-Drug
and	O
other	O
strong	O
CYP3A4	B-Drug
inhibitors	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
atazanavir	B-Drug
,	O
clarithromycin	B-Drug
,	O
indinavir	B-Drug
,	O
itraconazole	B-Drug
,	O
nefazodone	B-Drug
,	O
nelfinavir	B-Drug
,	O
ritonavir	B-Drug
,	O
saquinavir	B-Drug
,	O
telithromycin	B-Drug
,	O
troleandomycin	B-Drug
(	O
TAO	B-Drug
)	O
,	O
and	O
voriconazole	B-Drug
.	O

Pre-treatment	O
with	O
the	O
CYP3A4	B-Drug
inducer	O
rifampicin	B-Drug
decreased	O
erlotinib	B-Drug
AUC	O
by	O
about	O
2/3	O
.	O

Alternate	O
treatments	O
lacking	O
CYP3A4	B-Drug
inducing	O
activity	O
should	O
be	O
considered	O
.	O

If	O
an	O
alternative	O
treatment	O
is	O
unavailable	O
,	O
a	O
TARCEVA	B-Drug
dose	O
greater	O
than	O
150	O
mg	O
should	O
be	O
considered	O
for	O
NSCLC	O
patients	O
,	O
and	O
greater	O
than	O
100	O
mg	O
considered	O
for	O
pancreatic	O
cancer	O
patients	O
.	O

If	O
the	O
TARCEVA	B-Drug
dose	O
is	O
adjusted	O
upward	O
,	O
the	O
dose	O
will	O
need	O
to	O
be	O
reduced	O
upon	O
discontinuation	O
of	O
rifampicin	B-Drug
or	O
other	O
inducers	O
.	O

Other	O
CYP3A4	B-Drug
inducers	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
rifabutin	B-Drug
,	O
rifapentine	B-Drug
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
phenobarbital	B-Drug
and	O
St.	O
Johns	O
Wort	O
.	O

Hepatotoxicity	O
Asymptomatic	O
increases	O
in	O
liver	O
transaminases	O
have	O
been	O
observed	O
in	O
TARCEVA	B-Drug
treated	O
patients	O
;	O
therefore	O
,	O
periodic	O
liver	O
function	O
testing	O
(	O
transaminases	O
,	O
bilirubin	O
,	O
and	O
alkaline	O
phosphatase	O
)	O
should	O
be	O
considered	O
.	O

Dose	O
reduction	O
or	O
interruption	O
of	O
TARCEVA	B-Drug
should	O
be	O
considered	O
if	O
changes	O
in	O
liver	O
function	O
are	O
severe	O
.	O

Patients	O
with	O
Hepatic	O
Impairment	O
In	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
erlotinib	B-Drug
is	O
cleared	O
primarily	O
by	O
the	O
liver	O
.	O

Therefore	O
,	O
erlotinib	B-Drug
exposure	O
may	O
be	O
increased	O
in	O
patients	O
with	O
hepatic	O
dysfunction	O
.	O

Elevated	O
International	O
Normalized	O
Ratio	O
and	O
Potential	O
Bleeding	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and	O
infrequent	O
reports	O
of	O
bleeding	O
events	O
including	O
gastrointestinal	O
and	O
non-gastrointestinal	O
bleedings	O
have	O
been	O
reported	O
in	O
clinical	O
studies	O
,	O
some	O
associated	O
with	O
concomitant	O
warfarin	B-Drug
administration	O
.	O

Patients	O
taking	O
warfarin	B-Drug
or	O
other	O
coumarin-derivative	O
anticoagulants	B-Drug
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O
.	O

When	O
ertapenem	B-Drug
is	O
co-administered	O
with	O
probenecid	B-Drug
(	O
500	O
mg	O
p.o	O
.	O

every	O
6	O
hours	O
)	O
,	O
probenecid	B-Drug
competes	O
for	O
active	O
tubular	O
secretion	O
and	O
reduces	O
the	O
renal	O
clearance	O
of	O
ertapenem	B-Drug
.	O

Based	O
on	O
total	O
ertapenem	B-Drug
concentrations	O
,	O
probenecid	B-Drug
increased	O
the	O
AUC	O
by	O
25	O
%	O
and	O
reduced	O
the	O
plasma	O
and	O
renal	O
clearances	O
by	O
20	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

The	O
half-life	O
increased	O
from	O
4.0	O
to	O
4.8	O
hours	O
.	O

Because	O
of	O
the	O
small	O
effect	O
on	O
half-life	O
,	O
the	O
coadministration	O
with	O
probenecid	B-Drug
to	O
extend	O
the	O
half-life	O
of	O
ertapenem	B-Drug
is	O
not	O
recommended	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
ertapenem	B-Drug
does	O
not	O
inhibit	O
P-glycoprotein-mediated	O
transport	O
of	O
digoxin	B-Drug
or	O
vinblastine	B-Drug
and	O
that	O
ertapenem	B-Drug
is	O
not	O
a	O
substrate	O
for	O
P-glycoprotein-mediated	O
transport	O
.	O

In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
indicate	O
that	O
ertapenem	B-Drug
does	O
not	O
inhibit	O
metabolism	O
mediated	O
by	O
any	O
of	O
the	O
following	O
six	O
cytochrome	O
p450	O
(	O
CYP	O
)	O
isoforms	O
:	O
1A2	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
and	O
3A4	O
.	O

Drug	B-Drug
interactions	O
caused	O
by	O
inhibition	O
of	O
P-glycoprotein-mediated	O
drug	B-Drug
clearance	O
or	O
CYP-mediated	O
drug	B-Drug
clearance	O
with	O
the	O
listed	O
isoforms	O
are	O
unlikely	O
.	O

Other	O
than	O
with	O
probenecid	B-Drug
,	O
no	O
specific	O
clinical	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

Erythromycin	B-Drug
use	O
in	O
patients	O
who	O
are	O
receiving	O
high	O
doses	O
of	O
theophylline	B-Drug
may	O
be	O
associated	O
with	O
an	O
increase	O
in	O
serum	O
theophylline	B-Drug
levels	O
and	O
potential	O
theophylline	B-Drug
toxicity	O
.	O

In	O
case	O
of	O
theophylline	B-Drug
toxicity	O
and/or	O
elevated	O
serum	O
theophylline	B-Drug
levels	O
,	O
the	O
dose	O
of	O
theophylline	B-Drug
should	O
be	O
reduced	O
while	O
the	O
patient	O
is	O
receiving	O
concomitant	O
erythromycin	B-Drug
therapy	O
.	O

Concomitant	O
administration	O
of	O
erythromycin	B-Drug
and	O
digoxin	B-Drug
has	O
been	O
reported	O
to	O
result	O
in	O
elevated	O
digoxin	B-Drug
serum	O
levels	O
.	O

There	O
have	O
been	O
reports	O
of	O
increased	O
anticoagulant	B-Drug
effects	O
when	O
erythromycin	B-Drug
and	O
oral	O
anticoagulants	B-Drug
were	O
used	O
concomitantly	O
.	O

Increased	O
anticoagulation	O
effects	O
due	O
to	O
interactions	O
of	O
erythromycin	B-Drug
with	O
various	O
oral	O
anticoagulents	O
may	O
be	O
more	O
pronounced	O
in	O
the	O
elderly	O
.	O

Concurrent	O
use	O
of	O
erythromycin	B-Drug
and	O
ergotamine	B-Drug
or	O
dihydroergotamine	B-Drug
has	O
been	O
associated	O
in	O
some	O
patients	O
with	O
acute	O
ergot	B-Drug
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Erythromycin	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
clearance	O
of	O
triazolam	B-Drug
and	O
midazolam	B-Drug
and	O
thus	O
may	O
increase	O
the	O
pharmacologic	O
effect	O
of	O
these	O
benzodiazepines	B-Drug
.	O

The	O
use	O
of	O
erythromycin	B-Drug
in	O
patients	O
concurrently	O
taking	O
drugs	B-Drug
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
may	O
be	O
associated	O
with	O
elevations	O
in	O
serum	O
levels	O
of	O
these	O
other	O
drugs	B-Drug
.	O

There	O
have	O
been	O
reports	O
of	O
interactions	O
of	O
erythromycin	B-Drug
with	O
carbamazepine	B-Drug
,	O
cyclosporine	B-Drug
,	O
tacrolimus	B-Drug
,	O
hexobarbital	B-Drug
,	O
phenytoin	B-Drug
,	O
alfentanil	B-Drug
,	O
cisapride	B-Drug
,	O
disopyramide	B-Drug
,	O
lovastatin	B-Drug
,	O
bromocriptine	B-Drug
,	O
valproate	B-Drug
,	O
terfenadine	B-Drug
,	O
and	O
astemizole	B-Drug
.	O

Serum	O
concentrations	O
of	O
drugs	B-Drug
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
should	O
be	O
monitored	O
closely	O
in	O
patients	O
concurrently	O
receiving	O
erythromycin	B-Drug
.	O

Erythromycin	B-Drug
has	O
been	O
reported	O
to	O
significantly	O
alter	O
the	O
metabolism	O
of	O
nonsedating	O
antihistamines	B-Drug
terfenadine	B-Drug
and	O
astemizole	B-Drug
when	O
taken	O
concomitantly	O
.	O

Rare	O
cases	O
of	O
serious	O
cardiovascular	O
adverse	O
events	O
,	O
including	O
electrocardiographic	O
QT/QTc	O
interval	O
prolongation	O
,	O
cardiac	O
arrest	O
,	O
torsades	O
de	O
pointes	O
,	O
and	O
other	O
ventricular	O
arrhythmias	O
have	O
been	O
observed	O
.	O

In	O
addition	O
,	O
deaths	O
have	O
been	O
reported	O
rarely	O
with	O
concomitant	O
administration	O
of	O
terfenadine	B-Drug
and	O
erythromycin	B-Drug
.	O

There	O
have	O
been	O
postmarketing	O
reports	O
of	O
drug	B-Drug
interactions	O
when	O
erythromycin	B-Drug
is	O
coadministered	O
with	O
cisapride	B-Drug
,	O
resulting	O
in	O
QT	O
prolongation	O
,	O
cardiac	O
arrythmias	O
,	O
ventricular	O
tachycardia	O
,	O
ventricular	O
fibrulation	O
,	O
and	O
torsades	O
de	O
pointes	O
,	O
most	O
like	O
due	O
to	O
inhibition	O
of	O
hepatic	O
metabolism	O
of	O
cisapride	B-Drug
by	O
erythromycin	B-Drug
.	O

Fatalities	O
have	O
been	O
reported	O
.	O

Patients	O
receiving	O
concomitant	O
lovastatin	B-Drug
and	O
erythromycin	B-Drug
should	O
be	O
carefully	O
monitored	O
;	O
cases	O
of	O
rhabdomyolysis	O
have	O
been	O
reported	O
in	O
seriously	O
ill	O
patients	O
.	O

CNS	O
Drugs	B-Drug
-	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
escitalopram	B-Drug
,	O
caution	O
should	O
be	O
used	O
when	O
it	O
is	O
taken	O
in	O
combination	O
with	O
other	O
centrally	O
acting	O
drugs	B-Drug
.	O

Alcohol	B-Drug
-	O
Although	O
LEXAPRO	B-Drug
did	O
not	O
potentiate	O
the	O
cognitive	O
and	O
motor	O
effects	O
of	O
alcohol	B-Drug
in	O
a	O
clinical	O
trial	O
,	O
as	O
with	O
other	O
psychotropic	O
medications	O
,	O
the	O
use	O
of	O
alcohol	B-Drug
by	O
patients	O
taking	O
LEXAPRO	B-Drug
is	O
not	O
recommended	O
.	O

Monoamine	O
Oxidase	O
Inhibitors	O
(	O
MAOIs	O
)	O
Drugs	B-Drug
That	O
Interfere	O
With	O
Hemostasis	O
(	O
NSAIDs	O
,	O
Aspirin	B-Drug
,	O
Warfarin	B-Drug
,	O
etc	O
.	O

)	O
Serotonin	O
release	O
by	O
platelets	O
plays	O
an	O
important	O
role	O
in	O
hemostasis	O
.	O

Epidemiological	O
studies	O
of	O
the	O
case-control	O
and	O
cohort	O
design	O
that	O
have	O
demonstrated	O
an	O
association	O
between	O
use	O
of	O
psychotropic	O
drugs	B-Drug
that	O
interfere	O
with	O
serotonin	O
reuptake	O
and	O
the	O
occurrence	O
of	O
upper	O
gastrointestinal	O
bleeding	O
have	O
also	O
shown	O
that	O
concurrent	O
use	O
of	O
an	O
NSAID	O
or	O
aspirin	B-Drug
potentiated	O
the	O
risk	O
of	O
bleeding	O
.	O

Thus	O
,	O
patients	O
should	O
be	O
cautioned	O
about	O
the	O
use	O
of	O
such	O
drugs	B-Drug
concurrently	O
with	O
LEXAPRO	B-Drug
.	O

Cimetidine	B-Drug
-	O
In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg/day	O
racemic	O
citalopram	B-Drug
,	O
combined	O
administration	O
of	O
400	O
mg/day	O
cimetidine	B-Drug
for	O
8	O
days	O
resulted	O
in	O
an	O
increase	O
in	O
citalopram	B-Drug
AUC	O
and	O
Cmax	O
of	O
43	O
%	O
and	O
39	O
%	O
,	O
respectively	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O

Digoxin	B-Drug
-	O
In	O
subjects	O
who	O
had	O
received	O
21	O
days	O
of	O
40	O
mg/day	O
racemic	O
citalopram	B-Drug
,	O
combined	O
administration	O
of	O
citalopram	B-Drug
and	O
digoxin	B-Drug
(	O
single	O
dose	O
of	O
1	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	B-Drug
or	O
digoxin	B-Drug
.	O

Lithium	B-Drug
-	O
Coadministration	O
of	O
racemic	O
citalopram	B-Drug
(	O
40	O
mg/day	O
for	O
10	O
days	O
)	O
and	O
lithium	B-Drug
(	O
30	O
mmol/day	O
for	O
5	O
days	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
citalopram	B-Drug
or	O
lithium	B-Drug
.	O

Nevertheless	O
,	O
plasma	O
lithium	B-Drug
levels	O
should	O
be	O
monitored	O
with	O
appropriate	O
adjustment	O
to	O
the	O
lithium	B-Drug
dose	O
in	O
accordance	O
with	O
standard	O
clinical	O
practice	O
.	O

Because	O
lithium	B-Drug
may	O
enhance	O
the	O
serotonergic	O
effects	O
of	O
escitalopram	B-Drug
,	O
caution	O
should	O
be	O
exercised	O
when	O
LEXAPRO	B-Drug
and	O
lithium	B-Drug
are	O
coadministered	O
.	O

Pimozide	B-Drug
and	O
Celexa	B-Drug
-	O
In	O
a	O
controlled	O
study	O
,	O
a	O
single	O
dose	O
of	O
pimozide	B-Drug
2	O
mg	O
co-administered	O
with	O
racemic	O
citalopram	B-Drug
40	O
mg	O
given	O
once	O
daily	O
for	O
11	O
days	O
was	O
associated	O
with	O
a	O
mean	O
increase	O
in	O
QTc	O
values	O
of	O
approximately	O
10	O
msec	O
compared	O
to	O
pimozide	B-Drug
given	O
alone	O
.	O

Racemic	O
citalopram	B-Drug
did	O
not	O
alter	O
the	O
mean	O
AUC	O
or	O
Cmax	O
of	O
pimozide	B-Drug
.	O

The	O
mechanism	O
of	O
this	O
pharmacodynamic	O
interaction	O
is	O
not	O
known	O
.	O

Sumatriptan	B-Drug
-	O
There	O
have	O
been	O
rare	O
postmarketing	O
reports	O
describing	O
patients	O
with	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
following	O
the	O
use	O
of	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
and	O
sumatriptan	B-Drug
.	O

If	O
concomitant	O
treatment	O
with	O
sumatriptan	B-Drug
and	O
an	O
SSRI	O
(	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
paroxetine	B-Drug
,	O
sertraline	B-Drug
,	O
citalopram	B-Drug
,	O
escitalopram	B-Drug
)	O
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Theophylline	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
40	O
mg/day	O
for	O
21	O
days	O
)	O
and	O
the	O
CYP1A2	B-Drug
substrate	O
theophylline	B-Drug
(	O
single	O
dose	O
of	O
300	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	B-Drug
.	O

The	O
effect	O
of	O
theophylline	B-Drug
on	O
the	O
pharmacokinetics	O
of	O
citalopram	B-Drug
was	O
not	O
evaluated	O
.	O

Warfarin	B-Drug
-	O
Administration	O
of	O
40	O
mg/day	O
racemic	O
citalopram	B-Drug
for	O
21	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	B-Drug
,	O
a	O
CYP3A4	B-Drug
substrate	O
.	O

Prothrombin	O
time	O
was	O
increased	O
by	O
5	O
%	O
,	O
the	O
clinical	O
significance	O
of	O
which	O
is	O
unknown	O
.	O

Carbamazepine	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
40	O
mg/day	O
for	O
14	O
days	O
)	O
and	O
carbamazepine	B-Drug
(	O
titrated	O
to	O
400	O
mg/day	O
for	O
35	O
days	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
carbamazepine	B-Drug
,	O
a	O
CYP3A4	B-Drug
substrate	O
.	O

Although	O
trough	O
citalopram	B-Drug
plasma	O
levels	O
were	O
unaffected	O
,	O
given	O
the	O
enzyme-inducing	O
properties	O
of	O
carbamazepine	B-Drug
,	O
the	O
possibility	O
that	O
carbamazepine	B-Drug
might	O
increase	O
the	O
clearance	O
of	O
escitalopram	B-Drug
should	O
be	O
considered	O
if	O
the	O
two	O
drugs	B-Drug
are	O
coadministered	O
.	O

Triazolam	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
titrated	O
to	O
40	O
mg/day	O
for	O
28	O
days	O
)	O
and	O
the	O
CYP3A4	B-Drug
substrate	O
triazolam	B-Drug
(	O
single	O
dose	O
of	O
0.25	O
mg	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
citalopram	B-Drug
or	O
triazolam	B-Drug
.	O

Ketoconazole	B-Drug
-	O
Combined	O
administration	O
of	O
racemic	O
citalopram	B-Drug
(	O
40	O
mg	O
)	O
and	O
ketoconazole	B-Drug
(	O
200	O
mg	O
)	O
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
ketoconazole	B-Drug
by	O
21	O
%	O
and	O
10	O
%	O
,	O
respectively	O
,	O
and	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
citalopram	B-Drug
.	O

Ritonavir	B-Drug
-	O
Combined	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ritonavir	B-Drug
(	O
600	O
mg	O
)	O
,	O
both	O
a	O
CYP3A4	B-Drug
substrate	O
and	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	B-Drug
,	O
and	O
escitalopram	B-Drug
(	O
20	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
ritonavir	B-Drug
or	O
escitalopram	B-Drug
.	O

CYP3A4	B-Drug
and	O
-2C19	O
Inhibitors	O
-	O
In	O
vitro	O
studies	O
indicated	O
that	O
CYP3A4	B-Drug
and	O
-2C19	O
are	O
the	O
primary	O
enzymes	O
involved	O
in	O
the	O
metabolism	O
of	O
escitalopram	B-Drug
.	O

However	O
,	O
coadministration	O
of	O
escitalopram	B-Drug
(	O
20	O
mg	O
)	O
and	O
ritonavir	B-Drug
(	O
600	O
mg	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	B-Drug
,	O
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
escitalopram	B-Drug
.	O

Because	O
escitalopram	B-Drug
is	O
metabolized	O
by	O
multiple	O
enzyme	O
systems	O
,	O
inhibition	O
of	O
a	O
single	O
enzyme	O
may	O
not	O
appreciably	O
decrease	O
escitalopram	B-Drug
clearance	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
Cytochrome	O
P4502D6	O
-	O
In	O
vitro	O
studies	O
did	O
not	O
reveal	O
an	O
inhibitory	O
effect	O
of	O
escitalopram	B-Drug
on	O
CYP2D6	B-Drug
.	O

In	O
addition	O
,	O
steady	O
state	O
levels	O
of	O
racemic	O
citalopram	B-Drug
were	O
not	O
significantly	O
different	O
in	O
poor	O
metabolizers	O
and	O
extensive	O
CYP2D6	B-Drug
metabolizers	O
after	O
multiple-dose	O
administration	O
of	O
citalopram	B-Drug
,	O
suggesting	O
that	O
coadministration	O
,	O
with	O
escitalopram	B-Drug
,	O
of	O
a	O
drug	B-Drug
that	O
inhibits	O
CYP2D6	B-Drug
,	O
is	O
unlikely	O
to	O
have	O
clinically	O
significant	O
effects	O
on	O
escitalopram	B-Drug
metabolism	O
.	O

However	O
,	O
there	O
are	O
limited	O
in	O
vivo	O
data	O
suggesting	O
a	O
modest	O
CYP2D6	B-Drug
inhibitory	O
effect	O
for	O
escitalopram	B-Drug
,	O
i.e.	O
,	O
coadministration	O
of	O
escitalopram	B-Drug
(	O
20	O
mg/day	O
for	O
21	O
days	O
)	O
with	O
the	O
tricyclic	O
antidepressant	O
desipramine	B-Drug
(	O
single	O
dose	O
of	O
50	O
mg	O
)	O
,	O
a	O
substrate	O
for	O
CYP2D6	B-Drug
,	O
resulted	O
in	O
a	O
40	O
%	O
increase	O
in	O
Cmax	O
and	O
a	O
100	O
%	O
increase	O
in	O
AUC	O
of	O
desipramine	B-Drug
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
escitalopram	B-Drug
and	O
drugs	B-Drug
metabolized	O
by	O
CYP2D6	B-Drug
.	O

Metoprolol	B-Drug
-	O
Administration	O
of	O
20	O
mg/day	O
LEXAPRO	B-Drug
for	O
21	O
days	O
in	O
healthy	O
volunteers	O
resulted	O
in	O
a	O
50	O
%	O
increase	O
in	O
Cmax	O
and	O
82	O
%	O
increase	O
in	O
AUC	O
of	O
the	O
beta-adrenergic	O
blocker	O
metoprolol	B-Drug
(	O
given	O
in	O
a	O
single	O
dose	O
of	O
100	O
mg	O
)	O
.	O

Increased	O
metoprolol	B-Drug
plasma	O
levels	O
have	O
been	O
associated	O
with	O
decreased	O
cardioselectivity	O
.	O

Coadministration	O
of	O
LEXAPRO	B-Drug
and	O
metoprolol	B-Drug
had	O
no	O
clinically	O
significant	O
effects	O
on	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

Electroconvulsive	O
Therapy	O
(	O
ECT	O
)	O
-	O
There	O
are	O
no	O
clinical	O
studies	O
of	O
the	O
combined	O
use	O
of	O
ECT	O
and	O
escitalopram	B-Drug
.	O

Concomitant	O
Administration	O
with	O
Racemic	O
Citalopram	B-Drug
Citalopram	B-Drug
-	O
Since	O
escitalopram	B-Drug
is	O
the	O
active	O
isomer	O
of	O
racemic	O
citalopram	B-Drug
(	O
Celexa	B-Drug
)	O
,	O
the	O
two	O
agents	O
should	O
not	O
be	O
coadministered	O
.	O

Catecholamine-depleting	O
drugs	B-Drug
,	O
e.g.	O
,	O
reserpine	B-Drug
,	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	O
blocking	O
agents	O
.	O

Patients	O
treated	O
concurrently	O
with	O
BREVIBLOC	B-Drug
(	O
esmolol	B-Drug
HCl	I-Drug
)	O
and	O
a	O
catecholamine	O
depletor	O
should	O
therefore	O
be	O
closely	O
observed	O
for	O
evidence	O
of	O
hypotension	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
result	O
in	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

A	O
study	O
of	O
interaction	O
between	O
BREVIBLOC	B-Drug
and	O
warfarin	B-Drug
showed	O
that	O
concomitant	O
administration	O
of	O
BREVIBLOC	B-Drug
and	O
warfarin	B-Drug
does	O
not	O
alter	O
warfarin	B-Drug
plasma	O
levels	O
.	O

BREVIBLOC	B-Drug
concentrations	O
were	O
equivocally	O
higher	O
when	O
given	O
with	O
warfarin	B-Drug
,	O
but	O
this	O
is	O
not	O
likely	O
to	O
be	O
clinically	O
important	O
.	O

When	O
digoxin	B-Drug
and	O
BREVIBLOC	B-Drug
were	O
concomitantly	O
administered	O
intravenously	O
to	O
normal	O
volunteers	O
,	O
there	O
was	O
a	O
10-20	O
%	O
increase	O
in	O
digoxin	B-Drug
blood	O
levels	O
at	O
some	O
time	O
points	O
.	O

Digoxin	B-Drug
did	O
not	O
affect	O
BREVIBLOC	B-Drug
pharmacokinetics	O
.	O

When	O
intravenous	O
morphine	B-Drug
and	O
BREVIBLOC	B-Drug
were	O
concomitantly	O
administered	O
in	O
normal	O
subjects	O
,	O
no	O
effect	O
on	O
morphine	B-Drug
blood	O
levels	O
was	O
seen	O
,	O
but	O
BREVIBLOC	B-Drug
steady-state	O
blood	O
levels	O
were	O
increased	O
by	O
46	O
%	O
in	O
the	O
presence	O
of	O
morphine	B-Drug
.	O

No	O
other	O
pharmacokinetic	O
parameters	O
were	O
changed	O
.	O

The	O
effect	O
of	O
BREVIBLOC	B-Drug
on	O
the	O
duration	O
of	O
succinylcholine-induced	B-Drug
neuromuscular	O
blockade	O
was	O
studied	O
in	O
patients	O
undergoing	O
surgery	O
.	O

The	O
onset	O
of	O
neuromuscular	O
blockade	O
by	O
succinylcholine	B-Drug
was	O
unaffected	O
by	O
BREVIBLOC	B-Drug
,	O
but	O
the	O
duration	O
of	O
neuromuscular	O
blockade	O
was	O
prolonged	O
from	O
5	O
minutes	O
to	O
8	O
minutes	O
.	O

Although	O
the	O
interactions	O
observed	O
in	O
these	O
studies	O
do	O
not	O
appear	O
to	O
be	O
of	O
major	O
clinical	O
importance	O
,	O
BREVIBLOC	B-Drug
should	O
be	O
titrated	O
with	O
caution	O
in	O
patients	O
being	O
treated	O
concurrently	O
with	O
digoxin	B-Drug
,	O
morphine	B-Drug
,	O
succinylcholine	B-Drug
or	O
warfarin	B-Drug
.	O

While	O
taking	O
beta	O
blockers	O
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
use	O
of	O
BREVIBLOC	B-Drug
and	O
verapamil	B-Drug
in	O
patients	O
with	O
depressed	O
myocardial	O
function	O
.	O

Fatal	O
cardiac	O
arrests	O
have	O
occurred	O
in	O
patients	O
receiving	O
both	O
drugs	B-Drug
.	O

Additionally	O
,	O
BREVIBLOC	B-Drug
should	O
not	O
be	O
used	O
to	O
control	O
supraventricular	O
tachycardia	O
in	O
the	O
presence	O
of	O
agents	O
which	O
are	O
vasoconstrictive	O
and	O
inotropic	O
such	O
as	O
dopamine	B-Drug
,	O
epinephrine	B-Drug
,	O
and	O
norepinephrine	B-Drug
because	O
of	O
the	O
danger	O
of	O
blocking	O
cardiac	O
contractility	O
when	O
systemic	O
vascular	O
resistance	O
is	O
high	O
.	O

Esomeprazole	B-Drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver	O
by	O
CYP2C19	O
and	O
CYP3A4	B-Drug
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
esomeprazole	B-Drug
is	O
not	O
likely	O
to	O
inhibit	O
CYPs	O
1A2	O
,	O
2A6	O
,	O
2C9	O
,	O
2D6	O
,	O
2E1	O
and	O
3A4	O
.	O

No	O
clinically	O
relevant	O
interactions	O
with	O
drugs	B-Drug
metabolized	O
by	O
these	O
CYP	O
enzymes	O
would	O
be	O
expected	O
.	O

Drug	B-Drug
interaction	O
studies	O
have	O
shown	O
that	O
esomeprazole	B-Drug
does	O
not	O
have	O
any	O
clinically	O
significant	O
interactions	O
with	O
phenytoin	B-Drug
,	O
warfarin	B-Drug
,	O
quinidine	B-Drug
,	O
clarithromycin	B-Drug
or	O
amoxicillin	B-Drug
.	O

Post-marketing	O
reports	O
of	O
changes	O
in	O
prothrombin	O
measures	O
have	O
been	O
received	O
among	O
patients	O
on	O
concomitant	O
warfarin	B-Drug
and	O
esomeprazole	B-Drug
therapy	O
.	O

Increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
may	O
lead	B-Drug
to	O
abnormal	O
bleeding	O
and	O
even	O
death	O
.	O

Patients	O
treated	O
with	O
proton	O
pump	O
inhibitors	O
and	O
warfarin	B-Drug
concomitantly	O
may	O
need	O
to	O
be	O
monitored	O
for	O
increases	O
in	O
INR	O
and	O
prothrombin	O
time	O
.	O

Esomeprazole	B-Drug
may	O
potentially	O
interfere	O
with	O
CYP2C19	O
,	O
the	O
major	O
esomeprazole	B-Drug
metabolizing	O
enzyme	O
.	O

Coadministration	O
of	O
esomeprazole	B-Drug
30	O
mg	O
and	O
diazepam	B-Drug
,	O
a	O
CYP2C19	O
substrate	O
,	O
resulted	O
in	O
a	O
45	O
%	O
decrease	O
in	O
clearance	O
of	O
diazepam	B-Drug
.	O

Increased	O
plasma	O
levels	O
of	O
diazepam	B-Drug
were	O
observed	O
12	O
hours	O
after	O
dosing	O
and	O
onwards	O
.	O

However	O
,	O
at	O
that	O
time	O
,	O
the	O
plasma	O
levels	O
of	O
diazepam	B-Drug
were	O
below	O
the	O
therapeutic	O
interval	O
,	O
and	O
thus	O
this	O
interaction	O
is	O
unlikely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O

Esomeprazole	B-Drug
inhibits	O
gastric	O
acid	O
secretion	O
.	O

Therefore	O
,	O
esomeprazole	B-Drug
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	B-Drug
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
eg	O
,	O
ketoconazole	B-Drug
,	O
iron	B-Drug
salts	O
and	O
digoxin	B-Drug
)	O
.	O

Coadministration	O
of	O
oral	O
contraceptives	O
,	O
diazepam	B-Drug
,	O
phenytoin	B-Drug
,	O
or	O
quinidine	B-Drug
did	O
not	O
seem	O
to	O
change	O
the	O
pharmacokinetic	O
profile	O
of	O
esomeprazole	B-Drug
.	O

Concomitant	O
administration	O
of	O
clarithromycin	B-Drug
with	O
pimozide	B-Drug
is	O
contraindicated	O
.	O

If	O
ProSom	B-Drug
is	O
given	O
concomitantly	O
with	O
other	O
drugs	B-Drug
acting	O
on	O
the	O
central	O
nervous	O
system	O
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
all	O
agents	O
.	O

The	O
action	O
of	O
the	O
benzodiazepines	B-Drug
may	O
be	O
potentiated	O
by	O
anticonvulsants	O
,	O
antihistamines	B-Drug
,	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
monoamine	O
oxidase	O
inhibitors	O
,	O
narcotics	O
,	O
phenothiazines	O
,	O
psychotropic	O
medications	O
,	O
or	O
other	O
drugs	B-Drug
that	O
produce	O
CNS	O
depression	O
.	O

Smokers	O
have	O
an	O
increased	O
clearance	O
of	O
benzodiazepines	B-Drug
as	O
compared	O
to	O
nonsmokers	O
;	O
this	O
was	O
seen	O
in	O
studies	O
with	O
estazolam	B-Drug
.	O

While	O
no	O
in	O
vivo	O
drug-drug	O
interaction	O
studies	O
were	O
conducted	O
between	O
estazolam	B-Drug
and	O
inducers	O
of	O
CYP3A	O
,	O
compounds	O
that	O
are	O
potent	O
CYP3A	O
inducers	O
(	O
such	O
as	O
carbamazepine	B-Drug
,	O
phenytoin	B-Drug
,	O
rifampin	B-Drug
,	O
and	O
barbiturates	B-Drug
)	O
would	O
be	O
expected	O
to	O
decrease	O
estazolam	B-Drug
concentrations	O
.	O

Estazolam	B-Drug
:	O
Interaction	O
with	O
Drugs	B-Drug
that	O
Inhibit	O
Metabolism	O
via	O
Cytochrome	O
P450	O
3A	O
(	O
CYP3A	O
)	O
:	O
The	O
metabolism	O
of	O
estazolam	B-Drug
to	O
the	O
major	O
circulating	O
metabolite	O
4-hydroxy-estazolam	B-Drug
and	O
the	O
metabolism	O
of	O
other	O
triazolobenzodiazepines	O
is	O
catalyzed	O
by	O
CYP3A	O
.	O

Consequently	O
,	O
estazolam	B-Drug
should	O
be	O
avoided	O
in	O
patients	O
receiving	O
ketoconazole	B-Drug
and	O
itraconazole	B-Drug
,	O
which	O
are	O
very	O
potent	O
inhibitors	O
of	O
CYP3A	O
.	O

With	O
drugs	B-Drug
inhibiting	O
CYP3A	O
to	O
a	O
lesser	O
,	O
but	O
still	O
significant	O
degree	O
,	O
estazolam	B-Drug
should	O
be	O
used	O
only	O
with	O
caution	O
and	O
consideration	O
of	O
appropriate	O
dosage	O
reduction	O
.	O

The	O
following	O
are	O
examples	O
of	O
drugs	B-Drug
known	O
to	O
inhibit	O
the	O
metabolism	O
of	O
other	O
related	O
benzodiazepines	B-Drug
,	O
presumably	O
through	O
inhibition	O
of	O
CYP3A	O
:	O
nefazodone	B-Drug
,	O
fluvoxamine	B-Drug
,	O
cimetidine	B-Drug
,	O
diltiazem	B-Drug
,	O
isoniazide	B-Drug
,	O
and	O
some	O
macrolide	O
antibiotics	B-Drug
.	O

Drug	B-Drug
Interaction	O
with	O
Fluoxetine	B-Drug
:	O
A	O
multiple-dose	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
effect	O
of	O
fluoxetine	B-Drug
20	O
mg	O
BID	O
on	O
the	O
pharmacokinetics	O
of	O
estazolam	B-Drug
2	O
mg	O
QHS	O
after	O
seven	O
days	O
.	O

The	O
pharmacokinetics	O
of	O
estazolam	B-Drug
(	O
Cmax	O
and	O
AUC	O
)	O
were	O
not	O
affected	O
during	O
multiple-dose	O
fluoxetine	B-Drug
,	O
suggesting	O
no	O
clinically	O
significant	O
pharmacokinetic	O
interaction	O
.	O

Estazolam	B-Drug
:	O
Interaction	O
with	O
Other	O
Drugs	B-Drug
that	O
are	O
Metabolized	O
by	O
Cytochrome	O
P450	O
(	O
CYP	O
)	O
:	O
At	O
clinically	O
relevant	O
concentrations	O
,	O
in	O
vitro	O
studies	O
indicate	O
that	O
estazolam	B-Drug
(	O
0.6	O
M	O
)	O
was	O
not	O
inhibitory	O
towards	O
the	O
major	O
cytochrome	O
P450	O
isoforms	O
CYP1A2	B-Drug
,	O
CYP2A6	O
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
CYP2D6	B-Drug
,	O
CYP2E1	O
,	O
and	O
CYP3A	O
.	O

Therefore	O
,	O
based	O
on	O
these	O
in	O
vitro	O
data	O
,	O
estazolam	B-Drug
is	O
very	O
unlikely	O
to	O
inhibit	O
the	O
biotransformation	O
of	O
other	O
drugs	B-Drug
metabolized	O
by	O
these	O
CYP	O
isoforms	O
.	O

D	O
.	O

Drug	B-Drug
and	O
Laboratory	O
Test	O
Interactions	O
1	O
.	O

Accelerated	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
and	O
platelet	O
aggregation	O
time	O
;	O
increased	O
platelet	O
count	O
;	O
increased	O
factors	O
II	O
,	O
VII	O
antigen	O
,	O
VIII	O
antigen	O
,	O
VIII	O
coagulant	O
activity	O
,	O
IX	O
,	O
X	O
,	O
XII	O
,	O
VII-X	O
complex	O
,	O
II-VII-X	O
complex	O
,	O
and	O
beta-thromboglobulin	O
;	O
decreased	O
levels	O
of	O
anti-factor	O
Xa	O
and	O
antithrombin	O
III	O
,	O
decreased	O
antithrombin	O
III	O
activity	O
;	O
increased	O
levels	O
of	O
fibrinogen	B-Drug
and	O
fibrinogen	B-Drug
activity	O
;	O
increased	O
plasminogen	O
antigen	O
and	O
activity	O
.	O

2	O
.	O

Increased	O
thyroid-binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	B-Drug
hormone	O
levels	O
,	O
as	O
measured	O
by	O
protein-bound	O
iodine	B-Drug
(	O
PBI	O
)	O
,	O
T4	B-Drug
levels	O
(	O
by	O
column	O
or	O
by	O
radioimmunoassay	O
)	O
or	O
T3	B-Drug
levels	O
by	O
radioimmunoassay	O
.	O

T3	B-Drug
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
.	O

Free	O
T4	B-Drug
and	O
T3	B-Drug
concentrations	O
are	O
unaltered	O
.	O

Patients	O
on	O
thyroid	B-Drug
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	B-Drug
hormone	O
.	O

3	O
.	O

Other	O
binding	O
proteins	O
may	O
be	O
elevated	O
in	O
serum	O
,	O
i.e.	O
,	O
corticosteroid	B-Drug
binding	O
globulin	O
(	O
CBG	O
)	O
,	O
sex	O
hormone-binding	O
globulin	O
(	O
SHBG	O
)	O
,	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	O
and	O
sex	O
steroids	O
,	O
respectively	O
.	O

Free	O
hormone	O
concentrations	O
may	O
be	O
decreased	O
.	O

Other	O
plasma	O
proteins	O
may	O
be	O
increased	O
(	O
angiotensinogen/renin	O
substrate	O
,	O
alpha-1-antitrypsin	O
,	O
ceruloplasmin	O
)	O
.	O

4	O
.	O

Increased	O
plasma	O
HDL	O
and	O
HDL2	O
cholesterol	O
subfraction	O
concentrations	O
,	O
reduced	O
LDL	O
cholesterol	O
concentration	O
,	O
increased	O
triglyceride	O
levels	O
.	O

5	O
.	O

Impaired	O
glucose	B-Drug
tolerance	O
.	O

6	O
.	O

Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O

Milk	O
,	O
milk	O
products	O
,	O
and	O
calcium-rich	B-Drug
foods	O
or	O
drugs	B-Drug
may	O
impair	O
the	O
absorption	O
of	O
EMCYT	B-Drug
.	O

CNS-Active	O
Drugs	B-Drug
Ethanol	B-Drug
An	O
additive	O
effect	O
on	O
psychomotor	O
performance	O
was	O
seen	O
with	O
coadministration	O
of	O
eszopiclone	B-Drug
and	O
ethanol	B-Drug
0.70	O
g/kg	O
for	O
up	O
to	O
4	O
hours	O
after	O
ethanol	B-Drug
administration	O
.	O

Paroxetine	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	B-Drug
3	O
mg	O
and	O
paroxetine	B-Drug
20	O
mg	O
daily	O
for	O
7	O
days	O
produced	O
no	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
.	O

Lorazepam	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
eszopiclone	B-Drug
3	O
mg	O
and	O
lorazepam	B-Drug
2	O
mg	O
did	O
not	O
have	O
clinically	O
relevant	O
effects	O
on	O
the	O
pharmacodynamics	O
or	O
pharmacokinetics	O
of	O
either	O
drug	B-Drug
.	O

Olanzapine	B-Drug
:	O
Coadministration	O
of	O
eszopiclone	B-Drug
3	O
mg	O
and	O
olanzapine	B-Drug
10	O
mg	O
produced	O
a	O
decrease	O
in	O
DSST	O
scores	O
.	O

The	O
interaction	O
was	O
pharmacodynamic	O
;	O
there	O
was	O
no	O
alteration	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
drug	B-Drug
.	O

Drugs	B-Drug
That	O
Inhibit	O
CYP3A4	B-Drug
(	O
Ketoconazole	B-Drug
)	O
CYP3A4	B-Drug
is	O
a	O
major	O
metabolic	O
pathway	O
for	O
elimination	O
of	O
eszopiclone	B-Drug
.	O

The	O
AUC	O
of	O
eszopiclone	B-Drug
was	O
increased	O
2.2-fold	O
by	O
coadministration	O
of	O
ketoconazole	B-Drug
,	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	B-Drug
,	O
400	O
mg	O
daily	O
for	O
5	O
days	O
.	O

Cmax	O
and	O
t1/2	B-Drug
were	O
increased	O
1.4-fold	O
and	O
1.3-fold	O
,	O
respectively	O
.	O

Other	O
strong	O
inhibitors	O
of	O
CYP3A4	B-Drug
(	O
e.g.	O
,	O
itraconazole	B-Drug
,	O
clarithromycin	B-Drug
,	O
nefazodone	B-Drug
,	O
troleandomycin	B-Drug
,	O
ritonavir	B-Drug
,	O
nelfinavir	B-Drug
)	O
would	O
be	O
expected	O
to	O
behave	O
similarly	O
.	O

Drugs	B-Drug
That	O
Induce	O
CYP3A4	B-Drug
(	O
Rifampicin	B-Drug
)	O
Racemic	O
zopiclone	B-Drug
exposure	O
was	O
decreased	O
80	O
%	O
by	O
concomitant	O
useof	O
rifampicin	B-Drug
,	O
a	O
potent	O
inducer	O
of	O
CYP3A4	B-Drug
.	O

A	O
similar	O
effect	O
would	O
be	O
expected	O
with	O
eszopiclone	B-Drug
.	O

Drugs	B-Drug
Highly	O
Bound	O
To	O
Plasma	O
Protein	O
Eszopiclone	B-Drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
52-59	O
%	O
bound	O
)	O
;	O
therefore	O
,	O
the	O
disposition	O
of	O
eszopiclone	B-Drug
is	O
not	O
expected	O
to	O
be	O
sensitive	O
to	O
alterations	O
in	O
protein	O
binding	O
.	O

Administration	O
of	O
eszopiclone	B-Drug
3	O
mg	O
to	O
a	O
patient	O
taking	O
another	O
drug	B-Drug
that	O
is	O
highly	O
protein-bound	O
would	O
not	O
be	O
expected	O
to	O
cause	O
an	O
alteration	O
in	O
the	O
free	O
concentration	O
of	O
either	O
drug	B-Drug
.	O

Drugs	B-Drug
With	O
A	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	B-Drug
A	O
single	O
dose	O
of	O
eszopiclone	B-Drug
3	O
mg	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
measured	O
at	O
steady	O
state	O
following	O
dosing	O
of	O
0.5	O
mg	O
twice	O
daily	O
for	O
one	O
day	O
and	O
0.25	O
mg	O
daily	O
for	O
the	O
next	O
6	O
days	O
.	O

Warfarin	B-Drug
:	O
Eszopiclone	B-Drug
3	O
mg	O
administered	O
daily	O
for	O
5	O
days	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
(	B-Drug
R	I-Drug
)	I-Drug
-	O
or	O
(	B-Drug
S	I-Drug
)	I-Drug
-warfarin	I-Drug
,	O
nor	O
were	O
there	O
any	O
changes	O
in	O
the	O
pharmacodynamic	O
profile	O
(	B-Drug
prothrombin	O
time	O
)	O
following	O
a	O
single	O
25	O
mg	O
oral	O
dose	O
of	O
warfarin	B-Drug
.	O

Specific	O
drug	B-Drug
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ENBREL	B-Drug
.	O

However	O
,	O
it	O
was	O
observed	O
that	O
the	O
pharmacokinetics	O
of	O
ENBREL	B-Drug
was	O
unaltered	O
by	O
concomitant	O
methotrexate	B-Drug
in	O
rheumatoid	O
arthritis	O
patients	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
ENBREL	B-Drug
and	O
anakinra	B-Drug
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
ENBREL	B-Drug
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
ENBREL	B-Drug
and	O
anakinra	B-Drug
developed	O
neutropenia	O
(	O
ANC	O
1	O
x	O
109/L	O
)	O
.	O

Patients	O
in	O
a	O
clinical	O
study	O
who	O
were	O
on	O
established	O
therapy	O
with	O
sulfasalazine	B-Drug
,	O
to	O
which	O
ENBREL	B-Drug
was	O
added	O
,	O
were	O
noted	O
to	O
develop	O
a	O
mild	O
decrease	O
in	O
mean	O
neutrophil	O
counts	O
in	O
comparison	O
to	O
groups	O
treated	O
with	O
either	O
ENBREL	B-Drug
CI	O
or	O
sulfasalazine	B-Drug
alone	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
observation	O
is	O
unknown	O
.	O

Lithium	B-Drug
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Drug
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O

Read	O
circulars	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O

EDECRIN	B-Drug
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
other	O
drugs	B-Drug
such	O
as	O
aminoglycoside	O
and	O
some	O
cephalosporin	O
antibiotics	B-Drug
.	O

Their	O
concurrent	O
use	O
should	O
be	O
avoided	O
.	O

A	O
number	O
of	O
drugs	B-Drug
,	O
including	O
ethacrynic	B-Drug
acid	I-Drug
,	O
have	O
been	O
shown	O
to	O
displace	O
warfarin	B-Drug
from	O
plasma	O
protein	O
;	O
a	O
reduction	O
in	O
the	O
usual	O
anticoagulant	B-Drug
dosage	O
may	O
be	O
required	O
in	O
patients	O
receiving	O
both	O
drugs	B-Drug
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non-	O
steroidal	O
antiinflammatory	O
agent	O
can	O
reduce	O
the	O
diuretic	B-Drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-Drug
effects	O
of	O
loop	O
,	O
potassium-	O
sparing	O
and	O
thiazide	O
diuretics	B-Drug
.	O

Therefore	O
,	O
when	O
EDECRIN	B-Drug
and	O
non-	O
steroidal	O
anti-	O
inflammatory	O
agents	O
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Drug
is	O
obtained	O
.	O

The	O
results	O
of	O
a	O
study	O
of	O
coadministration	O
of	O
ethambutol	B-Drug
(	O
50	O
mg/kg	O
)	O
with	O
an	O
aluminum	B-Drug
hydroxide	I-Drug
containing	O
antacid	O
to	O
13	O
patients	O
with	O
tuberculosis	O
showed	O
a	O
reduction	O
of	O
mean	O
serum	O
concentrations	O
and	O
urinary	O
excretion	O
of	O
ethambutol	B-Drug
of	O
approximately	O
20	O
%	O
and	O
13	O
%	O
,	O
respectively	O
,	O
suggesting	O
that	O
the	O
oral	O
absorption	O
of	O
ethambutol	B-Drug
may	O
be	O
reduced	O
by	O
these	O
antacid	O
products	O
.	O

It	O
is	O
recommended	O
to	O
avoid	O
concurrent	O
administration	O
of	O
ethambutol	B-Drug
with	O
aluminum	B-Drug
hydroxide	I-Drug
containing	O
antacids	O
for	O
at	O
least	O
4	O
hours	O
following	O
ethambutol	B-Drug
administration	O
.	O

Dicumarol	B-Drug
and	O
warfarin	B-Drug
may	O
decrease	O
hypoprothrombinemic	O
effect	O
.	O

Other	O
depressasnts	O
such	O
as	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
and	O
MAOIs	O
may	O
enhance	O
CNS	O
depression	O
when	O
administered	O
with	O
ethchlorvynol	B-Drug
.	O

May	O
interact	O
with	O
addictive	O
medications	O
,	O
especially	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
depressants	O
with	O
habituating	O
potential	O
(	O
prolonged	O
concurrent	O
use	O
may	O
increase	O
the	O
risk	O
of	O
habituation	O
)	O
,	O
alcohol	B-Drug
or	O
CNS	O
depression	O
producing	O
medications	O
(	O
concurrent	O
use	O
may	O
increase	O
the	O
CNS	O
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
ethinamate	B-Drug
)	O
.	O

Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen-containing	O
oral	O
contraceptives	O
.	O

The	O
following	O
similar	O
changes	O
may	O
be	O
expected	O
with	O
larger	O
doses	O
of	O
estrogen	O
:	O
Increased	O
sulfobromophthalein	O
retention	O
;	O
increased	O
prothrombin	O
and	O
factors	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
;	O
decreased	O
antithrombin	O
3	O
;	O
increased	O
norepinephrine-induced	O
platel	O
et	O
aggregation	O
;	O
increased	O
thyroid	B-Drug
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	B-Drug
hormone	O
,	O
as	O
measured	O
by	O
PBI	O
,	O
T4	B-Drug
by	O
column	O
,	O
or	O
T4	B-Drug
by	O
radioimmunoassay	O
.	O

Free	O
T3	B-Drug
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
;	O
free	O
T4	B-Drug
concentration	O
is	O
unaltered	O
:	O
impaired	O
glucose	B-Drug
tolerance	O
;	O
decreased	O
pregnanediol	O
excretion	O
;	O
reduced	O
response	O
to	O
metyrapone	O
test	O
;	O
reduced	O
serum	O
folate	O
concentration	O
;	O
increased	O
serum	O
triglyceride	O
and	O
phospholipid	O
concentration	O
.	O

Trecator	B-Drug
has	O
been	O
found	O
to	O
temporarily	O
raise	O
serum	O
concentrations	O
of	O
isoniazid	B-Drug
.	O

Trecator	B-Drug
may	O
potentiate	O
the	O
adverse	O
effects	O
of	O
other	O
antituberculous	O
drugs	B-Drug
administered	O
concomitantly	O
.	O

In	O
particular	O
,	O
convulsions	O
have	O
been	O
reported	O
when	O
ethionamide	B-Drug
is	O
administered	O
with	O
cycloserine	B-Drug
and	O
special	O
care	O
should	O
be	O
taken	O
when	O
the	O
treatment	O
regimen	O
includes	O
both	O
of	O
these	O
drugs	B-Drug
.	O

Excessive	O
ethanol	B-Drug
ingestion	O
should	O
be	O
avoided	O
because	O
a	O
psychotic	O
reaction	O
has	O
been	O
reported	O
.	O

Ethopropazine	B-Drug
may	O
interact	O
with	O
alcohol	B-Drug
or	O
other	O
CNS	O
depressants	O
,	O
causing	O
increased	O
sedative	O
effects	O
.	O

It	O
may	O
also	O
interact	O
with	O
amantadine	B-Drug
or	O
other	O
anticholinergic	B-Drug
drugs	B-Drug
or	O
MAOIs	O
,	O
which	O
may	O
intensify	O
the	O
anticholinergic	B-Drug
action	O
.	O

Ethopropazine	B-Drug
can	O
interact	O
with	O
chlorpromazine	B-Drug
,	O
increasing	O
the	O
metabolism	O
of	O
chlorpromazine	B-Drug
.	O

Since	O
Zarontin	B-Drug
(	O
ethosuximide	B-Drug
)	O
may	O
interact	O
with	O
concurrently	O
administered	O
antiepileptic	O
drugs	B-Drug
,	O
periodic	O
serum	O
level	O
determinations	O
of	O
these	O
drugs	B-Drug
may	O
be	O
necessary	O
(	O
eg	O
,	O
ethosuximide	B-Drug
may	O
elevate	O
phenytoin	B-Drug
serum	O
levels	O
and	O
valproic	B-Drug
acid	I-Drug
has	O
been	O
reported	O
to	O
both	O
increase	O
and	O
decrease	O
ethosuximide	B-Drug
levels	O
)	O
.	O

PEGANONE	B-Drug
used	O
in	O
combination	O
with	O
other	O
drugs	B-Drug
known	O
to	O
adversely	O
affect	O
the	O
hematopoietic	O
system	O
should	O
be	O
avoided	O
if	O
possible	O
.	O

Considerable	O
caution	O
should	O
be	O
exercised	O
if	O
PEGANONE	B-Drug
is	O
administered	O
concurrently	O
with	O
Phenurone	B-Drug
(	O
phenacemide	B-Drug
)	O
since	O
paranoid	O
symptoms	O
have	O
been	O
reported	O
during	O
therapy	O
with	O
this	O
combination	O
.	O

A	O
two-way	O
interaction	O
between	O
the	O
hydantoin	O
antiepileptic	O
,	O
phenytoin	B-Drug
,	O
and	O
the	O
coumarin	O
anticoagulants	B-Drug
has	O
been	O
suggested	O
.	O

Presumably	O
,	O
phenytoin	B-Drug
acts	O
as	O
a	O
stimulator	O
of	O
coumarin	O
metabolism	O
and	O
has	O
been	O
reported	O
to	O
cause	O
decreased	O
serum	O
levels	O
of	O
the	O
coumarin	O
anticoagulants	B-Drug
and	O
increased	O
prothrombin-proconvertin	O
concentrations	O
.	O

Conversely	O
,	O
the	O
coumarin	O
anticoagulants	B-Drug
have	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
levels	O
and	O
prolong	O
the	O
serum	O
half-life	O
of	O
phenytoin	B-Drug
by	O
inhibiting	O
its	O
metabolism	O
.	O

Although	O
there	O
is	O
no	O
documentation	O
of	O
such	O
,	O
a	O
similar	O
interaction	O
between	O
ethotoin	B-Drug
and	O
the	O
coumarin	O
anticoagulants	B-Drug
may	O
occur	O
.	O

Caution	O
is	O
therefore	O
advised	O
when	O
administering	O
PEGANONE	B-Drug
to	O
patients	O
receiving	O
coumarin	O
anticoagulants	B-Drug
.	O

Ethoxzolamide	B-Drug
may	O
increase	O
the	O
action	O
of	O
tricyclics	O
,	O
amphetamines	B-Drug
,	O
procainamide	B-Drug
,	O
and	O
quinidine	B-Drug
.	O

It	O
may	O
increase	O
excretion	O
of	O
barbiturates	B-Drug
,	O
lithium	B-Drug
,	O
and	O
ASA	B-Drug
and	O
may	O
also	O
increase	O
the	O
toxicity	O
of	O
salicylates	O
.	O

Coadministration	O
of	O
ethoxzolamide	B-Drug
with	O
other	O
diuretics	B-Drug
,	O
amphotericin	B-Drug
B	I-Drug
,	O
and	O
corticosteroids	O
may	O
cause	O
hypokalemia	O
.	O

Ethinyl	B-Drug
estradiol	I-Drug
:	O
Substrate	O
of	O
CYP3A4	B-Drug
(	O
major	O
)	O
,	O
3A5-7	O
(	O
minor	O
)	O
;	O
Inhibits	O
CYP1A2	B-Drug
(	O
weak	O
)	O
,	O
2B6	O
(	O
weak	O
)	O
,	O
2C19	O
(	O
weak	O
)	O
,	O
3A4	O
(	O
weak	O
)	O
.	O

Acetaminophen	B-Drug
:	O
May	O
increase	O
plasma	O
concentration	O
of	O
synthetic	O
estrogens	O
,	O
possibly	O
by	O
inhibiting	O
conjugation	O
.	O

Combination	O
hormonal	O
contraceptives	O
may	O
also	O
decrease	O
the	O
plasma	O
concentration	O
of	O
acetaminophen	B-Drug
.	O

Acitretin	B-Drug
:	O
Interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin-containing	O
minipill	O
preparations	O
.	O

The	O
effect	O
on	O
other	O
progestational	O
contraceptives	O
(	O
eg	O
,	O
implants	O
,	O
injectables	O
)	O
is	O
unknown	O
.	O

Aminoglutethimide	B-Drug
:	O
May	O
increase	O
CYP	O
metabolism	O
of	O
progestins	O
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	O
product	O
is	O
recommended	O
.	O

Antibiotics	B-Drug
(	O
ampicillin	B-Drug
,	O
tetracycline	B-Drug
)	O
:	O
Pregnancy	O
has	O
been	O
reported	O
following	O
concomitant	O
use	O
,	O
however	O
,	O
pharmacokinetic	O
studies	O
have	O
not	O
shown	O
consistent	O
effects	O
with	O
these	O
antibiotics	B-Drug
on	O
plasma	O
concentrations	O
of	O
synthetic	O
steroids	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	O
product	O
is	O
recommended	O
.	O

Anticoagulants	B-Drug
:	O
Combination	O
hormonal	O
contraceptives	O
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
coumarin	O
derivatives	O
.	O

Combination	O
hormonal	O
contraceptives	O
may	O
also	O
increase	O
risk	O
of	O
thromboembolic	O
disorders	O
.	O

Anticonvulsants	O
(	O
carbamazepine	B-Drug
,	O
felbamate	B-Drug
,	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
,	O
topiramate	B-Drug
)	O
:	O
Increase	O
the	O
metabolism	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and/or	O
some	O
progestins	O
,	O
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	O
product	O
is	O
recommended	O
.	O

Ascorbic	B-Drug
acid	I-Drug
:	O
Doses	O
of	O
ascorbic	B-Drug
acid	I-Drug
(	O
vitamin	B-Drug
C	I-Drug
)	O
1	O
g/day	O
have	O
been	O
reported	O
to	O
increase	O
plasma	O
concentration	O
of	O
synthetic	O
estrogens	O
by	O
~47	O
%	O
,	O
possibly	O
by	O
inhibiting	O
conjugation	O
;	O
clinical	O
implications	O
are	O
unclear	O
.	O

Atorvastatin	B-Drug
:	O
Atorvastatin	B-Drug
increases	O
the	O
AUC	O
for	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
.	O

Benzodiazepines	B-Drug
:	O
Combination	O
hormonal	O
contraceptives	O
may	O
decrease	O
the	O
clearance	O
of	O
some	O
benzodiazepines	B-Drug
(	O
alprazolam	B-Drug
,	O
chlordiazepoxide	B-Drug
,	O
diazepam	B-Drug
)	O
and	O
increase	O
the	O
clearance	O
of	O
others	O
(	O
lorazepam	B-Drug
,	O
oxazepam	B-Drug
,	O
temazepam	B-Drug
)	O
.	O

Clofibric	B-Drug
acid	I-Drug
:	O
Combination	O
hormonal	O
contraceptives	O
may	O
increase	O
the	O
clearance	O
of	O
clofibric	B-Drug
acid	I-Drug
.	O

Cyclosporine	B-Drug
:	O
Combination	O
hormonal	O
contraceptives	O
may	O
inhibit	O
the	O
metabolism	O
of	O
cyclosporine	B-Drug
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
;	O
monitor	O
cyclosporine	B-Drug
levels	O
.	O

CYP3A4	B-Drug
inducers	O
:	O
CYP3A4	B-Drug
inducers	O
may	O
decrease	O
the	O
levels/effects	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
.	O

Example	O
inducers	O
include	O
aminoglutethimide	B-Drug
,	O
carbamazepine	B-Drug
,	O
nafcillin	B-Drug
,	O
nevirapine	B-Drug
,	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
,	O
and	O
rifamycins	O
.	O

Griseofulvin	B-Drug
:	O
Griseofulvin	B-Drug
may	O
induce	O
the	O
metabolism	O
of	O
combination	O
hormonal	O
contraceptives	O
causing	O
menstrual	O
changes	O
;	O
pregnancies	O
have	O
been	O
reported	O
.	O

Use	O
of	O
barrier	O
form	O
of	O
contraception	O
is	O
suggested	O
while	O
on	O
griseofulvin	B-Drug
therapy	O
.	O

Morphine	B-Drug
:	O
Combination	O
hormonal	O
contraceptives	O
may	O
increase	O
the	O
clearance	O
of	O
morphine	B-Drug
.	O

Non-nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
(	O
NNRTIs	O
)	O
:	O
Nevirapine	B-Drug
may	O
decrease	O
plasma	O
levels	O
of	O
combination	O
hormonal	O
contraceptives	O
;	O
use	O
of	O
a	O
nonhormonal	O
contraceptive	O
product	O
is	O
recommended	O
.	O

No	O
data	O
for	O
delavirdine	B-Drug
;	O
incomplete	O
data	O
for	O
efavirenz	B-Drug
.	O

Prednisolone	B-Drug
:	O
Ethinyl	B-Drug
estradiol	I-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
prednisolone	B-Drug
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Protease	O
inhibitors	O
:	O
Amprenavir	B-Drug
,	O
lopinavir	B-Drug
,	O
nelfinavir	B-Drug
,	O
and	O
ritonavir	B-Drug
have	O
been	O
shown	O
to	O
decrease	O
plasma	O
levels	O
of	O
combination	O
hormonal	O
contraceptives	O
;	O
use	O
of	O
a	O
nonhormonal	O
contraceptive	O
product	O
is	O
recommended	O
.	O

Indinavir	B-Drug
has	O
been	O
shown	O
to	O
increase	O
plasma	O
levels	O
of	O
combination	O
hormonal	O
contraceptives	O
.	O

No	O
data	O
for	O
saquinavir	B-Drug
.	O

Rifampin	B-Drug
:	O
Rifampin	B-Drug
increases	O
the	O
metabolism	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
some	O
progestins	O
(	O
norethindrone	B-Drug
)	O
resulting	O
in	O
decreased	O
contraceptive	O
effectiveness	O
and	O
increased	O
menstrual	O
irregularities	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	O
product	O
is	O
recommended	O
.	O

Salicylic	B-Drug
acid	I-Drug
:	O
Combination	O
hormonal	O
contraceptives	O
may	O
increase	O
the	O
clearance	O
of	O
salicylic	B-Drug
acid	I-Drug
.	O

Selegiline	B-Drug
:	O
Combination	O
hormonal	O
contraceptives	O
may	O
increase	O
the	O
serum	O
concentration	O
of	O
selegiline	B-Drug
.	O

Theophylline	B-Drug
:	O
Ethinyl	B-Drug
estradiol	I-Drug
may	O
inhibit	O
the	O
metabolism	O
of	O
theophylline	B-Drug
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Tricyclic	O
antidepressants	B-Drug
(	O
amitriptyline	B-Drug
,	O
imipramine	B-Drug
,	O
nortriptyline	B-Drug
)	O
:	O
Metabolism	O
may	O
be	O
inhibited	O
by	O
combination	O
hormonal	O
contraceptives	O
,	O
increasing	O
plasma	O
levels	O
of	O
antidepressant	O
;	O
use	O
caution	O
.	O

ETHANOL	B-Drug
/	O
NUTRITION	O
/	O
HERB	O
INTERACTIONS	O
:	O
Food	O
:	O
CNS	O
effects	O
of	O
caffeine	B-Drug
may	O
be	O
enhanced	O
if	O
combination	O
hormonal	O
contraceptives	O
are	O
used	O
concurrently	O
with	O
caffeine	B-Drug
.	O

Grapefruit	O
juice	O
increases	O
ethinyl	B-Drug
estradiol	I-Drug
concentrations	O
and	O
would	O
be	O
expected	O
to	O
increase	O
progesterone	B-Drug
serum	O
levels	O
as	O
well	O
;	O
clinical	O
implications	O
are	O
unclear	O
.	O

Herb/Nutraceutical	O
:	O
St	O
Johns	O
wort	O
may	O
decrease	O
the	O
effectiveness	O
of	O
combination	O
hormonal	O
contraceptives	O
by	O
inducing	O
hepatic	O
enzymes	O
.	O

Avoid	O
dong	O
quai	O
and	O
black	O
cohosh	O
(	O
have	O
estrogen	O
activity	O
)	O
.	O

Avoid	O
saw	O
palmetto	O
,	O
red	O
clover	O
,	O
ginseng	B-Drug
.	O

There	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
experiencing	O
increases	O
in	O
their	O
prothrombin	O
times	O
when	O
etidronate	B-Drug
was	O
added	O
to	O
warfarin	B-Drug
therapy	O
.	O

The	O
majority	O
of	O
these	O
reports	O
concerned	O
variable	O
elevations	O
in	O
prothrombin	O
times	O
without	O
clinically	O
significant	O
sequelae	O
.	O

Although	O
the	O
relevance	O
of	O
these	O
reports	O
and	O
any	O
mechanism	O
of	O
coagulation	O
alterations	O
is	O
unclear	O
,	O
patients	O
on	O
warfarin	B-Drug
should	O
have	O
their	O
prothrombin	O
time	O
monitored	O
.	O

ACE-inhibitors	O
Reports	O
suggest	O
that	O
NSAIDs	O
may	O
diminish	O
the	O
antihypertensive	B-Drug
effect	O
of	O
ACE-inhibitors	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	O
concomitantly	O
with	O
ACE-inhibitors	O
.	O

Antacids	O
:	O
The	O
concomitant	O
administration	O
of	O
antacids	O
has	O
no	O
apparent	O
effect	O
on	O
the	O
extent	O
of	O
absorption	O
of	O
Lodine	B-Drug
.	O

However	O
,	O
antacids	O
can	O
decrease	O
the	O
peak	O
concentration	O
reached	O
by	O
15	O
%	O
to	O
20	O
%	O
but	O
have	O
no	O
detectable	O
effect	O
on	O
the	O
time-to-peak	O
.	O

Aspirin	B-Drug
:	O
When	O
Lodine	B-Drug
is	O
administered	O
with	O
aspirin	B-Drug
,	O
its	O
protein	O
binding	O
is	O
reduced	O
,	O
although	O
the	O
clearance	O
of	O
free	O
etodolac	B-Drug
is	O
not	O
altered	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
known	O
;	O
however	O
,	O
as	O
with	O
other	O
NSAIDs	O
,	O
concomitant	O
administration	O
of	O
Lodine	B-Drug
and	O
aspirin	B-Drug
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O

Cyclosporine	B-Drug
,	O
Digoxin	B-Drug
,	O
Methotrexate	B-Drug
Lodine	B-Drug
,	O
like	O
other	O
NSAIDs	O
,	O
through	O
effects	O
on	O
renal	O
prostaglandins	O
,	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
these	O
drugs	B-Drug
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
,	O
digoxin	B-Drug
,	O
methotrexate	B-Drug
,	O
and	O
increased	O
toxicity	O
.	O

Nephrotoxicity	O
associated	O
with	O
cyclosporine	B-Drug
may	O
also	O
be	O
enhanced	O
.	O

Patients	O
receiving	O
these	O
drugs	B-Drug
who	O
are	O
given	O
Lodine	B-Drug
,	O
or	O
any	O
other	O
NSAID	O
,	O
and	O
particularly	O
those	O
patients	O
with	O
altered	O
renal	O
function	O
,	O
should	O
be	O
observed	O
for	O
the	O
development	O
of	O
the	O
specific	O
toxicities	O
of	O
these	O
drugs	B-Drug
.	O

Diuretics	B-Drug
:	O
Etodolac	B-Drug
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
furosemide	B-Drug
or	O
hydrochlorothiazide	B-Drug
.	O

Nevertheless	O
,	O
clinical	O
studies	O
,	O
as	O
well	O
as	O
postmarketing	O
observations	O
have	O
shown	O
that	O
Lodine	B-Drug
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	O
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

During	O
concomitant	O
therapy	O
with	O
NSAIDs	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	B-Drug
efficacy	O
.	O

Glyburide	B-Drug
:	O
Etodolac	B-Drug
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
glyburide	B-Drug
.	O

Lithium	B-Drug
:	O
NSAIDs	O
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
.	O

The	O
mean	O
minimum	O
lithium	B-Drug
concentration	O
increased	O
15	O
%	O
and	O
the	O
renal	O
clearance	O
was	O
decreased	O
by	O
approximately	O
20	O
%	O
.	O

These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
the	O
NSAID	O
.	O

Thus	O
,	O
when	O
NSAIDs	O
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O

Phenylbutazone	B-Drug
:	O
Phenylbutazone	B-Drug
causes	O
increase	O
(	O
by	O
about	O
80	O
%	O
)	O
in	O
the	O
free	O
fraction	O
of	O
etodolac	B-Drug
.	O

Although	O
in	O
vivo	O
studies	O
have	O
not	O
been	O
done	O
to	O
see	O
if	O
etodolac	B-Drug
clearance	O
is	O
changed	O
by	O
coadministration	O
of	O
phenylbutazone	B-Drug
,	O
it	O
is	O
not	O
recommended	O
that	O
they	O
be	O
coadministered	O
.	O

Phenytoin	B-Drug
:	O
Etodolac	B-Drug
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
phenytoin	B-Drug
.	O

Warfarin	B-Drug
:	O
The	O
effects	O
of	O
warfarin	B-Drug
and	O
NSAIDs	O
on	O
GI	O
bleeding	O
are	O
synergistic	O
,	O
such	O
that	O
users	O
of	O
both	O
drugs	B-Drug
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
that	O
of	O
users	O
of	O
either	O
drug	B-Drug
alone	O
.	O

Short-term	O
pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
administration	O
of	O
warfarin	B-Drug
and	O
Lodine	B-Drug
(	O
etodolac	B-Drug
capsules	O
and	O
tablets	O
)	O
results	O
in	O
reduced	O
protein	O
binding	O
of	O
warfarin	B-Drug
,	O
but	O
there	O
was	O
no	O
change	O
in	O
the	O
clearance	O
of	O
free	O
warfarin	B-Drug
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
pharmacodynamic	O
effect	O
of	O
warfarin	B-Drug
administered	O
alone	O
and	O
warfarin	B-Drug
administered	O
with	O
Lodine	B-Drug
as	O
measured	O
by	O
prothrombin	O
time	O
.	O

Thus	O
,	O
concomitant	O
therapy	O
with	O
warfarin	B-Drug
and	O
Lodine	B-Drug
should	O
not	O
require	O
dosage	O
adjustment	O
of	O
either	O
drug	B-Drug
.	O

However	O
,	O
caution	O
should	O
be	O
exercised	O
because	O
there	O
have	O
been	O
a	O
few	O
spontaneous	O
reports	O
of	O
prolonged	O
prothrombin	O
times	O
,	O
with	O
or	O
without	O
bleeding	O
,	O
in	O
etodolac-treated	B-Drug
patients	O
receiving	O
concomitant	O
warfarin	B-Drug
therapy	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
The	O
urine	O
of	O
patients	O
who	O
take	O
Lodine	B-Drug
can	O
give	O
a	O
false-positive	O
reaction	O
for	O
urinary	O
bilirubin	O
(	O
urobilin	O
)	O
due	O
to	O
the	O
presence	O
of	O
phenolic	O
metabolites	O
of	O
etodolac	B-Drug
.	O

Diagnostic	O
dip-stick	O
methodology	O
,	O
used	O
to	O
detect	O
ketone	O
bodies	O
in	O
urine	O
,	O
has	O
resulted	O
in	O
false-positive	O
findings	O
in	O
some	O
patients	O
treated	O
with	O
Lodine	B-Drug
.	O

Generally	O
,	O
this	O
phenomenon	O
has	O
not	O
been	O
associated	O
with	O
other	O
clinically	O
significant	O
events	O
.	O

No	O
dose	O
relationship	O
has	O
been	O
observed	O
.	O

Lodine	B-Drug
treatment	O
is	O
associated	O
with	O
a	O
small	O
decrease	O
in	O
serum	O
uric	O
acid	O
levels	O
.	O

In	O
clinical	O
trials	O
,	O
mean	O
decreases	O
of	O
1	O
to	O
2	O
mg/dL	O
were	O
observed	O
in	O
arthritic	O
patients	O
receiving	O
etodolac	B-Drug
(	O
600	O
mg	O
to	O
1000	O
mg/day	O
)	O
after	O
4	O
weeks	O
of	O
therapy	O
.	O

These	O
levels	O
then	O
remained	O
stable	O
for	O
up	O
to	O
1	O
year	O
of	O
therapy	O
.	O

The	O
following	O
drug	B-Drug
interactions	O
have	O
been	O
reported	O
with	O
etomidate	B-Drug
.	O

Drug	B-Drug
Effect	O
Probenecid	B-Drug
Prolonged	O
action	O
of	O
etomidate	B-Drug
Diazoxide	B-Drug
Hypotension	O
Zimelidine	B-Drug
etomidate	B-Drug
antagonism	O
Opioid	O
analgesics	O
Decreased	O
antinociceptive	O
action	O
Aminophylline	B-Drug
Etomidate	B-Drug
antagonism	O
Midazolam	B-Drug
Synergism	O
Etonogestrel	B-Drug
may	O
interact	O
with	O
the	O
following	O
medications	O
:	O
acetaminophen	B-Drug
(	O
Tylenol	B-Drug
)	O
,	O
antibiotics	B-Drug
such	O
as	O
ampicillin	B-Drug
and	O
tetracycline	B-Drug
,	O
anticonvulsants	O
(	O
Dilantin	B-Drug
,	O
Phenobarbital	B-Drug
,	O
Tegretol	B-Drug
,	O
Trileptal	B-Drug
,	O
Topamax	B-Drug
,	O
Felbatol	B-Drug
)	O
,	O
antifungals	O
(	O
Gris-PEG	B-Drug
,	O
Nizoral	B-Drug
,	O
Sporanox	B-Drug
)	O
,	O
atorvastatin	B-Drug
(	O
Lipitor	B-Drug
)	O
,	O
clofibrate	B-Drug
(	O
Atromid-S	B-Drug
)	O
,	O
cyclosporine	B-Drug
(	O
Neoral	B-Drug
,	O
Sandimmune	B-Drug
)	O
,	O
HIV	O
drugs	B-Drug
classified	O
as	O
protease	O
inhibitors	O
(	O
Agenerase	B-Drug
,	O
Crixivan	B-Drug
,	O
Fortovase	B-Drug
,	O
Invirase	B-Drug
,	O
Kaletra	B-Drug
,	O
Norvir	B-Drug
,	O
Viracept	B-Drug
)	O
,	O
morphine	B-Drug
(	O
Astramorph	B-Drug
,	O
Kadian	B-Drug
,	O
MS	B-Drug
Contin	I-Drug
)	O
,	O
phenylbutazone	B-Drug
,	O
prednisolone	B-Drug
(	O
Prelone	B-Drug
)	O
,	O
rifadin	B-Drug
(	O
rifampin	B-Drug
)	O
,	O
St.	O
Johns	O
wort	O
,	O
temazepam	B-Drug
,	O
theophylline	B-Drug
(	O
Theo-Dur	B-Drug
)	O
,	O
and	O
vitamin	B-Drug
C	I-Drug
.	O

Caution	O
should	O
be	O
exercised	O
when	O
administering	O
ETOPOPHOS	B-Drug
with	O
drugs	B-Drug
that	O
are	O
known	O
to	O
inhibit	O
phosphatase	O
activities	O
(	O
e.g.	O
,	O
levamisole	B-Drug
hydrochloride	I-Drug
)	O
.	O

High-dose	O
cyclosporin	B-Drug
A	I-Drug
resulting	O
in	O
concentrations	O
above	O
2000	O
ng/mL	O
administered	O
with	O
oral	O
etoposide	B-Drug
has	O
led	O
to	O
an	O
80	O
%	O
increase	O
in	O
etoposide	B-Drug
exposure	O
with	O
a	O
38	O
%	O
decrease	O
in	O
total	O
body	O
clearance	O
of	O
etoposide	B-Drug
compared	O
to	O
etoposide	B-Drug
alone	O
.	O

Exemestane	B-Drug
is	O
extensively	O
metabolized	O
by	O
CYP	O
3A4	O
,	O
but	O
coadministration	O
of	O
ketoconazole	B-Drug
,	O
a	O
potent	O
inhibitor	O
of	O
CYP	O
3A4	O
,	O
has	O
no	O
significant	O
effect	O
on	O
exemestane	B-Drug
pharmacokinetics	O
.	O

Significant	O
pharmacokinetic	O
interactions	O
mediated	O
by	O
inhibition	O
of	O
CYP	O
isoenzymes	O
therefore	O
appear	O
unlikely	O
.	O

Co-medications	O
that	O
induce	O
CYP	O
3A4	O
(	O
e.g.	O
,	O
rifampicin	B-Drug
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
phenobarbital	B-Drug
,	O
or	O
St.	O
John	O
s	O
wort	O
)	O
may	O
significantly	O
decrease	O
exposure	O
to	O
exemestane	B-Drug
.	O

Dose	O
modification	O
is	O
recommended	O
for	O
patients	O
who	O
are	O
also	O
receiving	O
a	O
potent	O
CYP	O
3A4	O
inducer	O
.	O

Drug/Laboratory	O
Tests	O
Interactions	O
No	O
clinically	O
relevant	O
changes	O
in	O
the	O
results	O
of	O
clinical	O
laboratory	O
tests	O
have	O
been	O
observed	O
.	O

Concurrent	O
use	O
with	O
probenecid	B-Drug
or	O
other	O
drugs	B-Drug
significantly	O
eliminated	O
by	O
active	O
renal	O
tubular	O
secretion	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
penciclovir	B-Drug
.	O

The	O
conversion	O
of	O
6-deoxy	B-Drug
penciclovir	I-Drug
to	O
penciclovir	B-Drug
is	O
catalyzed	O
by	O
aldehyde	O
oxidase	O
.	O

Interactions	O
with	O
other	O
drugs	B-Drug
metabolized	O
by	O
this	O
enzyme	O
could	O
potentially	O
occur	O
.	O

No	O
drug	B-Drug
interactions	O
have	O
been	O
identified	O
.	O

Studies	O
with	O
famotidine	B-Drug
in	O
man	O
,	O
in	O
animal	O
models	O
,	O
and	O
in	O
vitro	O
have	O
shown	O
no	O
significant	O
interference	O
with	O
the	O
disposition	O
of	O
compounds	O
metabolized	O
by	O
the	O
hepatic	O
microsomal	O
enzymes	O
,	O
e.g.	O
,	O
cytochrome	O
P450	O
system	O
.	O

Compounds	O
tested	O
in	O
man	O
include	O
warfarin	B-Drug
,	O
theophylline	B-Drug
,	O
phenytoin	B-Drug
,	O
diazepam	B-Drug
,	O
aminopyrine	B-Drug
and	O
antipyrine	B-Drug
.	O

Indocyanine	B-Drug
green	I-Drug
as	O
an	O
index	O
of	O
hepatic	O
drug	B-Drug
extraction	O
has	O
been	O
tested	O
and	O
no	O
significant	O
effects	O
have	O
been	O
found	O
.	O

The	O
drug	B-Drug
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
controlled	O
clinical	O
trials	O
and	O
studies	O
involving	O
otherwise	O
healthy	O
adults	O
with	O
epilepsy	O
.	O

Use	O
in	O
Conjunction	O
with	O
Other	O
Antiepileptic	O
Drugs	B-Drug
:	O
The	O
addition	O
of	O
Felbatol	B-Drug
to	O
antiepileptic	O
drugs	B-Drug
(	O
AEDs	O
)	O
affects	O
the	O
steady-state	O
plasma	O
concentrations	O
of	O
AEDs	O
.	O

The	O
net	O
effect	O
of	O
these	O
interactions	O
is	O
summarized	O
in	O
the	O
following	O
table	O
:	O
AED	O
AED	O
Felbatol	B-Drug
Coadministered	O
Concentration	O
Concentration	O
Phenytoin	B-Drug
Valproate	B-Drug
**	O
Carbamazepine	B-Drug
(	O
CBZ	B-Drug
)	O
*CBZ	O
epoxide	O
Phenobarbital	B-Drug
*Not	O
administered	O
,	O
but	O
an	O
active	O
metabolite	O
of	O
carbamazepine	B-Drug
.	O

**No	O
significant	O
effect	O
.	O

Specific	O
Effects	O
of	O
Felbatol	B-Drug
on	O
Other	O
Antiepileptic	O
Drugs	B-Drug
Phenytoin	B-Drug
:	O
Felbatol	B-Drug
causes	O
an	O
increase	O
in	O
steady-state	O
phenytoin	B-Drug
plasma	O
concentrations	O
.	O

In	O
10	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
phenytoin	B-Drug
,	O
the	O
steadystate	O
trough	O
(	O
Cmin	O
)	O
phenytoin	B-Drug
plasma	O
concentration	O
was	O
17	O
5	O
micrograms/mL	O
.	O

The	O
steady-state	O
Cmin	O
increased	O
to	O
21	O
5	O
micrograms/mL	O
when	O
1200	O
mg/day	O
of	O
felbamate	B-Drug
was	O
coadministered	O
.	O

Increasing	O
the	O
felbamate	B-Drug
dose	O
to	O
1800	O
mg/day	O
in	O
six	O
of	O
these	O
subjects	O
increased	O
the	O
steady-state	O
phenytoin	B-Drug
Cmin	O
to	O
25	O
7	O
micrograms/mL	O
.	O

In	O
order	O
to	O
maintain	O
phenytoin	B-Drug
levels	O
,	O
limit	O
adverse	O
experiences	O
,	O
and	O
achieve	O
the	O
felbamate	B-Drug
dose	O
of	O
3600	O
mg/day	O
,	O
a	O
phenytoin	B-Drug
dose	O
reduction	O
of	O
approximately	O
40	O
%	O
was	O
necessary	O
for	O
eight	O
of	O
these	O
10	O
subjects	O
.	O

In	O
a	O
controlled	O
clinical	O
trial	O
,	O
a	O
20	O
%	O
reduction	O
of	O
the	O
phenytoin	B-Drug
dose	O
at	O
the	O
initiation	O
of	O
Felbatol	B-Drug
therapy	O
resulted	O
in	O
phenytoin	B-Drug
levels	O
comparable	O
to	O
those	O
prior	O
to	O
Felbatol	B-Drug
administration	O
.	O

Carbamazepine	B-Drug
:	O
Felbatol	B-Drug
causes	O
a	O
decrease	O
in	O
the	O
steady-state	O
carbamazepine	B-Drug
plasma	O
concentrations	O
and	O
an	O
increase	O
in	O
the	O
steady-state	O
carbamazepine	B-Drug
epoxide	I-Drug
plasma	O
concentration	O
.	O

In	O
nine	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
carbamazepine	B-Drug
,	O
the	O
steady-state	O
trough	O
(	O
Cmin	O
)	O
carbamazepine	B-Drug
concentration	O
was	O
8	O
2	O
micrograms/mL	O
.	O

The	O
carbamazepine	B-Drug
steady-state	O
Cmin	O
decreased	O
31	O
%	O
to	O
5	O
1	O
micrograms/mL	O
when	O
felbamate	B-Drug
(	O
3000	O
mg/day	O
,	O
divided	O
into	O
three	O
doses	O
)	O
was	O
coadministered	O
.	O

Carbamazepine	B-Drug
epoxide	I-Drug
steady-state	O
Cmin	O
concentrations	O
increased	O
57	O
%	O
from	O
1.0	O
0.3	O
to	O
1.6	O
0.4	O
micrograms/mL	O
with	O
the	O
addition	O
of	O
felbamate	B-Drug
.	O

In	O
clinical	O
trials	O
,	O
similar	O
changes	O
in	O
carbamazepine	B-Drug
and	O
carbamazepine	B-Drug
epoxide	I-Drug
were	O
seen	O
.	O

Valproate	B-Drug
:	O
Felbatol	B-Drug
causes	O
an	O
increase	O
in	O
steady-state	O
valproate	B-Drug
concentrations	O
.	O

In	O
four	O
subjects	O
with	O
epilepsy	O
ingesting	O
valproate	B-Drug
,	O
the	O
steady-state	O
trough	O
(	O
Cmin	O
)	O
valproate	B-Drug
plasma	O
concentration	O
was	O
63	O
16	O
micrograms/mL	O
.	O

The	O
steady-state	O
Cmin	O
increased	O
to	O
78	O
14	O
micrograms/mL	O
when	O
1200	O
mg/day	O
of	O
felbamate	B-Drug
was	O
coadministered	O
.	O

Increasing	O
the	O
felbamate	B-Drug
dose	O
to	O
2400	O
mg/day	O
increased	O
the	O
steadystate	O
valproate	B-Drug
Cmin	O
to	O
96	O
25	O
micrograms/mL	O
.	O

Corresponding	O
values	O
for	O
free	O
valproate	B-Drug
Cmin	O
concentrations	O
were	O
7	O
3	O
,	O
9	O
4	O
,	O
and	O
11	O
6	O
micrograms/mL	O
for	O
0	O
,	O
1200	O
,	O
and	O
2400	O
mg/day	O
Felbatol	B-Drug
,	O
respectively	O
.	O

The	O
ratios	O
of	O
the	O
AUCs	O
of	O
unbound	O
valproate	B-Drug
to	O
the	O
AUCs	O
of	O
the	O
total	O
valproate	B-Drug
were	O
11.1	O
%	O
,	O
13.0	O
%	O
,	O
and	O
11.5	O
%	O
,	O
with	O
coadministration	O
of	O
0	O
,	O
1200	O
,	O
and	O
2400	O
mg/day	O
of	O
Felbatol	B-Drug
,	O
respectively	O
.	O

Phenobarbital	B-Drug
:	O
Coadministration	O
of	O
felbamate	B-Drug
with	O
phenobarbital	B-Drug
causes	O
an	O
increase	O
in	O
phenobarbital	B-Drug
plasma	O
concentrations	O
,	O
In	O
12	O
otherwise	O
healthy	O
male	O
volunteers	O
ingesting	O
phenobarbital	B-Drug
,	O
the	O
steady-state	O
trough	O
(	O
Cmin	O
)	O
phenobarbital	B-Drug
concentration	O
was	O
14.2	O
micrograms/mL	O
.	O

The	O
steady-state	O
Cmin	O
concentration	O
increased	O
to	O
17.8	O
micrograms/mL	O
when	O
2400	O
mg/day	O
of	O
felbamate	B-Drug
was	O
coadministered	O
for	O
one	O
week	O
.	O

Effects	O
of	O
Other	O
Antiepileptic	O
Drugs	B-Drug
on	O
Felbatol	B-Drug
Phenytoin	B-Drug
:	O
Phenytoin	B-Drug
causes	O
an	O
approximate	O
doubling	O
of	O
the	O
clearance	O
of	O
Felbatol	B-Drug
(	O
felbamate	B-Drug
)	O
at	O
steady	O
state	O
and	O
,	O
therefore	O
,	O
the	O
addition	O
of	O
phenytoin	B-Drug
causes	O
an	O
approximate	O
45	O
%	O
decrease	O
in	O
the	O
steady-state	O
trough	O
concentrations	O
of	O
Felbatol	B-Drug
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	B-Drug
given	O
as	O
monotherapy	O
.	O

Carbamazepine	B-Drug
:	O
Carbamazepine	B-Drug
causes	O
an	O
approximate	O
50	O
%	O
increase	O
in	O
the	O
clearance	O
of	O
Felbatol	B-Drug
at	O
steady	O
state	O
and	O
,	O
therefore	O
,	O
the	O
addition	O
of	O
carbamazepine	B-Drug
results	O
in	O
an	O
approximate	O
40	O
%	O
decrease	O
in	O
the	O
steady-state	O
trough	O
concentrations	O
of	O
Felbatol	B-Drug
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	B-Drug
given	O
as	O
monotherapy	O
.	O

Valproate	B-Drug
:	O
Available	O
data	O
suggest	O
that	O
there	O
is	O
no	O
significant	O
effect	O
of	O
valproate	B-Drug
on	O
the	O
clearance	O
of	O
Felbatol	B-Drug
at	O
steady	O
state	O
,	O
Therefore	O
,	O
the	O
addition	O
of	O
valproate	B-Drug
is	O
not	O
expected	O
to	O
cause	O
a	O
clinically	O
important	O
effect	O
on	O
Felbatol	B-Drug
(	O
felbamate	B-Drug
)	O
plasma	O
concentrations	O
.	O

Phenobarbital	B-Drug
:	O
It	O
appears	O
that	O
phenobarbital	B-Drug
may	O
reduce	O
plasma	O
felbamate	B-Drug
concentrations	O
.	O

Steady-state	O
plasma	O
felbamate	B-Drug
concentrations	O
were	O
found	O
to	O
be	O
29	O
%	O
lower	O
than	O
the	O
mean	O
concentrations	O
of	O
a	O
group	O
of	O
newly	O
diagnosed	O
subjects	O
with	O
epilepsy	O
also	O
receiving	O
2400	O
mg	O
of	O
felbamate	B-Drug
a	O
day	O
.	O

Effects	O
of	O
Antacids	O
on	O
Felbatol	B-Drug
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
a	O
2400	O
mg	O
dose	O
of	O
Felbatol	B-Drug
as	O
monotherapy	O
given	O
as	O
tablets	O
was	O
not	O
affected	O
when	O
coadministered	O
with	O
antacids	O
.	O

Effects	O
of	O
Erythromycin	B-Drug
on	O
Felbatol	B-Drug
The	O
coadministration	O
of	O
erythromycin	B-Drug
(	O
1000	O
mg/day	O
)	O
for	O
10	O
days	O
did	O
not	O
alter	O
the	O
pharmacokinetic	O
parameters	O
of	O
Cmax	O
,	O
Cmin	O
,	O
AUC	O
,	O
CI/kg	O
or	O
tmax	O
at	O
felbamate	B-Drug
daily	O
doses	O
of	O
3000	O
or	O
3600	O
mg/day	O
in	O
10	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
.	O

Effects	O
of	O
Felbatol	B-Drug
on	O
Low-Dose	O
Combination	O
Oral	O
Contraceptives	O
A	O
group	O
of	O
24	O
nonsmoking	O
,	O
healthy	O
white	O
female	O
volunteers	O
established	O
on	O
an	O
oral	O
contraceptive	O
regimen	O
containing	O
30	O
mg	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
75	O
mg	O
gestodene	B-Drug
for	O
at	O
least	O
3	O
months	O
received	O
2400	O
mg/day	O
of	O
felbamate	B-Drug
from	O
midcycle	O
(	O
day	O
15	O
)	O
to	O
midcycle	O
(	O
day	O
14	O
)	O
of	O
two	O
consecutive	O
oral	O
contraceptive	O
cycles	O
.	O

Felbamate	B-Drug
treatment	O
resulted	O
in	O
a	O
42	O
%	O
decrease	O
in	O
the	O
gestodene	B-Drug
AUC	O
0-24	O
,	O
but	O
no	O
clinically	O
relevant	O
effect	O
was	O
observed	O
on	O
the	O
pharmacokinetic	O
parameters	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
.	O

No	O
volunteer	O
showed	O
hormonal	O
evidence	O
of	O
ovulation	O
,	O
but	O
one	O
volunteer	O
reported	O
intermenstrual	O
bleeding	O
during	O
felbamate	B-Drug
treatment	O
.	O

CYP3A4	B-Drug
Inhibitors	O
Felodipine	B-Drug
is	O
metabolized	O
by	O
CYP3A4	B-Drug
.	O

Co-administration	O
of	O
CYP3A4	B-Drug
inhibitors	O
(	O
eg	O
,	O
ketoconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
erythromycin	B-Drug
,	O
grapefruit	O
juice	O
,	O
cimetidine	B-Drug
)	O
with	O
felodipine	B-Drug
may	O
lead	B-Drug
to	O
several-	O
fold	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
felodipine	B-Drug
,	O
either	O
due	O
to	O
an	O
increase	O
in	O
bioavailability	O
or	O
due	O
to	O
a	O
decrease	O
in	O
metabolism	O
.	O

These	O
increases	O
in	O
concentration	O
may	O
lead	B-Drug
to	O
increased	O
effects	O
,	O
(	O
lower	O
blood	O
pressure	O
and	O
increased	O
heart	O
rate	O
)	O
.	O

These	O
effects	O
have	O
been	O
observed	O
with	O
co-administration	O
of	O
itraconazole	B-Drug
(	O
a	O
potent	O
CYP3A4	B-Drug
inhibitor	O
)	O
.	O

Caution	O
should	O
be	O
used	O
when	O
CYP3A4	B-Drug
inhibitors	O
are	O
co-administered	O
with	O
felodipine	B-Drug
.	O

A	O
conservative	O
approach	O
to	O
dosing	O
felodipine	B-Drug
should	O
be	O
taken	O
.	O

The	O
following	O
specific	O
interactions	O
have	O
been	O
reported	O
:	O
Itraconazole	B-Drug
Co-administration	O
of	O
another	O
extended	O
release	O
formulation	O
of	O
felodipine	B-Drug
with	O
itraconazole	B-Drug
resulted	O
in	O
approximately	O
8-fold	O
increase	O
in	O
the	O
AUC	O
,	O
more	O
than	O
6-	O
fold	O
increase	O
in	O
the	O
Cmax	O
,	O
and	O
2-fold	O
prolongation	O
in	O
the	O
half-	O
life	O
of	O
felodipine	B-Drug
.	O

Erythromycin	B-Drug
Co-administration	O
of	O
felodipine	B-Drug
(	O
PLENDIL	B-Drug
)	O
with	O
erythromycin	B-Drug
resulted	O
in	O
approximately	O
2.5-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
and	O
about	O
2-	O
fold	O
prolongation	O
in	O
the	O
half-	O
life	O
of	O
felodipine	B-Drug
.	O

Grapefruit	O
juice	O
Co-administration	O
of	O
felodipine	B-Drug
with	O
grapefruit	O
juice	O
resulted	O
in	O
more	O
than	O
2-fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
but	O
no	O
prolongation	O
in	O
the	O
half-	O
life	O
of	O
felodipine	B-Drug
.	O

Cimetidine	B-Drug
Co-administration	O
of	O
felodipine	B-Drug
with	O
cimetidine	B-Drug
(	O
a	O
non-specific	O
CYP-450	O
inhibitor	O
)	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
50	O
%	O
in	O
the	O
AUC	O
and	O
the	O
Cmax	O
,	O
of	O
felodipine	B-Drug
.	O

Beta-Blocking	B-Drug
Agents	O
A	O
pharmacokinetic	O
study	O
of	O
felodipine	B-Drug
in	O
conjunction	O
with	O
metoprolol	B-Drug
demonstrated	O
no	O
significant	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
felodipine	B-Drug
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
metoprolol	B-Drug
,	O
however	O
,	O
were	O
increased	O
approximately	O
31	O
and	O
38	O
%	O
,	O
respectively	O
.	O

In	O
controlled	O
clinical	O
trials	O
,	O
however	O
,	O
beta	B-Drug
blockers	I-Drug
including	O
metoprolol	B-Drug
were	O
concurrently	O
administered	O
with	O
felodipine	B-Drug
and	O
were	O
well	O
tolerated	O
.	O

Digoxin	B-Drug
When	O
given	O
concomitantly	O
with	O
PLENDIL	B-Drug
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
in	O
patients	O
with	O
heart	O
failure	O
were	O
not	O
significantly	O
altered	O
.	O

Anticonvulsants	O
:	O
In	O
a	O
pharmacokinetic	O
study	O
,	O
maximum	O
plasma	O
concentrations	O
of	O
felodipine	B-Drug
were	O
considerably	O
lower	O
in	O
epileptic	O
patients	O
on	O
long-term	O
anticonvulsant	O
therapy	O
(	O
eg	O
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
or	O
phenobarbital	B-Drug
)	O
than	O
in	O
healthy	O
volunteers	O
.	O

In	O
such	O
patients	O
,	O
the	O
mean	O
area	O
under	O
the	O
felodipine	B-Drug
plasma	O
concentration-time	O
curve	O
was	O
also	O
reduced	O
to	O
approximately	O
6	O
%	O
of	O
that	O
observed	O
in	O
healthy	O
volunteers	O
.	O

Since	O
a	O
clinically	O
significant	O
interaction	O
may	O
be	O
anticipated	O
,	O
alternative	O
antihypertensive	B-Drug
therapy	O
should	O
be	O
considered	O
in	O
these	O
patients	O
.	O

Tacrolimus	B-Drug
Felodipine	B-Drug
may	O
increase	O
the	O
blood	O
concentration	O
of	O
tacrolimus	B-Drug
.	O

When	O
given	O
concomitantly	O
with	O
felodipine	B-Drug
,	O
the	O
tacrolimus	B-Drug
blood	O
concentration	O
should	O
be	O
followed	O
and	O
the	O
tacrolimus	B-Drug
dose	O
may	O
need	O
to	O
be	O
adjusted	O
.	O

Other	O
Concomitant	O
Therapy	O
In	O
healthy	O
subjects	O
there	O
were	O
no	O
clinically	O
significant	O
interactions	O
when	O
felodipine	B-Drug
was	O
given	O
concomitantly	O
with	O
indomethacin	B-Drug
or	O
spironolactone	B-Drug
.	O

Interaction	O
with	O
Food	O
See	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Pharmacokinetics	O
and	O
Metabolism	O
.	O

Fenfluramine	B-Drug
may	O
increase	O
slightly	O
the	O
effect	O
of	O
antihypertensive	B-Drug
drugs	B-Drug
,	O
e.g.	O
,	O
guanethidine	B-Drug
,	O
methyldopa	B-Drug
,	O
reserpine	B-Drug
.	O

Other	O
CNS	O
depressant	O
drugs	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
fenfluramine	B-Drug
,	O
since	O
the	O
effects	O
may	O
be	O
additive	O
.	O

Oral	O
Anticoagulants	B-Drug
CAUTION	O
SHOULD	O
BE	O
EXERCISED	O
WHEN	O
COUMARIN	O
ANTICOAGULANTS	B-Drug
ARE	O
GIVEN	O
IN	O
CONJUNCTION	O
WITH	O
TRICOR	B-Drug
.	O

THE	O
DOSAGE	O
OF	O
THE	O
ANTICOAGULANTS	B-Drug
SHOULD	O
BE	O
REDUCED	O
TO	O
MAINTAIN	O
THE	O
PROTHROMBIN	O
TIME/INR	O
AT	O
THE	O
DESIRED	O
LEVEL	O
TO	O
PREVENT	O
BLEEDING	O
COMPLICATIONS	O
.	O

FREQUENT	O
PROTHROMBIN	O
TIME/INR	O
DETERMINATIONS	O
ARE	O
ADVISABLE	O
UNTIL	O
IT	O
HAS	O
BEEN	O
DEFINITELY	O
DETERMINED	O
THAT	O
THE	O
PROTHROMBIN	O
TIME/INR	O
HAS	O
STABILIZED	O
.	O

HMG-CoA	O
reductase	O
inhibitors	O
:	O
The	O
combined	O
use	O
of	O
TRICOR	B-Drug
and	O
HMG-CoA	O
reductase	O
inhibitors	O
should	O
be	O
avoided	O
unless	O
the	O
benefit	O
of	O
further	O
alterations	O
in	O
lipid	O
levels	O
is	O
likely	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
this	O
drug	B-Drug
combination	O
.	O

Resins	O
:	O
Since	O
bile	O
acid	O
sequestrants	O
may	O
bind	O
other	O
drugs	B-Drug
given	O
concurrently	O
,	O
patients	O
should	O
take	O
TRICOR	B-Drug
at	O
least	O
1	O
hour	O
before	O
or	O
4-6	O
hours	O
after	O
a	O
bile	O
acid	O
binding	O
resin	O
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Cyclosporine	B-Drug
:	O
Because	O
cyclosporine	B-Drug
can	O
produce	O
nephrotoxicity	O
with	O
decreases	O
in	O
creatinine	O
clearance	O
and	O
rises	O
in	O
serum	O
creatinine	O
,	O
and	O
because	O
renal	O
excretion	O
is	O
the	O
primary	O
elimination	O
route	O
of	O
fibrate	O
drugs	B-Drug
including	O
TRICOR	B-Drug
,	O
there	O
is	O
a	O
risk	O
that	O
an	O
interaction	O
will	O
lead	B-Drug
to	O
deterioration	O
.	O

The	O
benefits	O
and	O
risks	O
of	O
using	O
TRICOR	B-Drug
with	O
immunosuppressants	O
and	O
other	O
potentially	O
nephrotoxic	O
agents	O
should	O
be	O
carefully	O
considered	O
,	O
and	O
the	O
lowest	O
effective	O
dose	O
employed	O
.	O

Drug-drug	O
interactions	O
In	O
vitro	O
studies	O
using	O
human	O
liver	O
microsomes	O
indicate	O
that	O
fenofibrate	B-Drug
and	O
fenofibric	B-Drug
acid	I-Drug
are	O
not	O
inhibitors	O
of	O
cytochrome	O
(	O
CYP	O
)	O
P450	O
isoforms	O
CYP3A4	B-Drug
,	O
CYP2D6	B-Drug
,	O
CYP2E1	O
,	O
or	O
CYP1A2	B-Drug
.	O

They	O
are	O
weak	O
inhibitors	O
of	O
CYP2C19	O
and	O
CYP2A6	O
,	O
and	O
mild-to-moderate	O
inhibitors	O
of	O
CYP2C9	B-Drug
at	O
therapeutic	O
concentrations	O
.	O

Potentiation	O
of	O
coumarin-type	O
anticoagulants	B-Drug
has	O
been	O
observed	O
with	O
prolongation	O
of	O
the	O
prothrombin	O
time/INR	O
.	O

Bile	O
acid	O
sequestrants	O
have	O
been	O
shown	O
to	O
bind	O
other	O
drugs	B-Drug
given	O
concurrently	O
.	O

Therefore	O
,	O
fenofibrate	B-Drug
should	O
be	O
taken	O
at	O
least	O
1	O
hour	O
before	O
or	O
4-6	O
hours	O
after	O
a	O
bile	O
acid	O
binding	O
resin	O
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Concomitant	O
administration	O
of	O
fenofibrate	B-Drug
(	O
equivalent	O
to	O
145mg	O
TRICOR	B-Drug
)	O
with	O
pravastatin	B-Drug
(	O
40	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
Cmax	O
and	O
AUC	O
values	O
for	O
pravastatin	B-Drug
by	O
36	O
%	O
(	O
range	O
from	O
69	O
%	O
decrease	O
to	O
321	O
%	O
increase	O
)	O
and	O
28	O
%	O
(	O
range	O
from	O
54	O
%	O
decrease	O
to	O
128	O
%	O
increase	O
)	O
,	O
respectively	O
,	O
and	O
for	O
3	O
-hydroxy-iso-pravastatin	O
by	O
55	O
%	O
(	O
range	O
from	O
32	O
%	O
decrease	O
to	O
314	O
%	O
increase	O
)	O
and	O
39	O
%	O
(	O
range	O
from	O
24	O
%	O
decrease	O
to	O
261	O
%	O
increase	O
)	O
,	O
respectively	O
in	O
23	O
healthy	O
adults	O
.	O

A	O
single	O
dose	O
of	O
pravastatin	B-Drug
had	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
fenofibric	B-Drug
acid	I-Drug
.	O

Concomitant	O
administration	O
of	O
fenofibrate	B-Drug
(	O
equivalent	O
to	O
145	O
mg	O
TRICOR	B-Drug
)	O
with	O
atorvastatin	B-Drug
(	O
20	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
resulted	O
in	O
approximately	O
17	O
%	O
decrease	O
(	O
range	O
from	O
67	O
%	O
decrease	O
to	O
44	O
%	O
increase	O
)	O
in	O
atorvastatin	B-Drug
AUC	O
values	O
in	O
22	O
healthy	O
males	O
.	O

The	O
atorvastatin	B-Drug
Cmax	O
values	O
were	O
not	O
significantly	O
affected	O
by	O
fenofibrate	B-Drug
.	O

The	O
pharmacokinetics	O
of	O
fenofibric	B-Drug
acid	I-Drug
were	O
not	O
significantly	O
affected	O
by	O
atorvastatin	B-Drug
.	O

Drug	B-Drug
Interactions	O
with	O
Beta-Blockers	O
:	O
Concomitant	O
use	O
of	O
fenoldopam	B-Drug
with	O
beta-blockers	O
should	O
be	O
avoided	O
.	O

If	O
the	O
drugs	B-Drug
are	O
used	O
together	O
,	O
caution	O
should	O
be	O
exercised	O
because	O
unexpected	O
hypotension	O
could	O
result	O
from	O
beta-blocker	O
inhibition	O
of	O
the	O
sympathetic	O
reflex	O
response	O
to	O
fenoldopam	B-Drug
.	O

Drug	B-Drug
Interactions	O
,	O
General	O
:	O
Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
,	O
intravenous	O
fenoldopam	B-Drug
has	O
been	O
administered	O
safely	O
with	O
drugs	B-Drug
such	O
as	O
digitalis	B-Drug
and	O
sublingual	O
nitroglycerin	B-Drug
.	O

There	O
is	O
limited	O
experience	O
with	O
concomitant	O
antihypertensive	B-Drug
agents	O
such	O
as	O
alpha-blockers	O
,	O
calcium	B-Drug
channel-blockers	O
,	O
ACE	O
inhibitors	O
,	O
and	O
diuretics	B-Drug
(	O
both	O
thiazide-like	O
and	O
loop	O
)	O
.	O

The	O
coadministration	O
of	O
aspirin	B-Drug
decreases	O
the	O
biologic	O
half-life	O
of	O
fenoprofen	B-Drug
because	O
of	O
an	O
increase	O
in	O
metabolic	O
clearance	O
that	O
results	O
in	O
a	O
greater	O
amount	O
of	O
hydroxylated	B-Drug
fenoprofen	I-Drug
in	O
the	O
urine	O
.	O

Although	O
the	O
mechanism	O
of	O
interaction	O
between	O
fenoprofen	B-Drug
and	O
aspirin	B-Drug
is	O
not	O
totally	O
known	O
,	O
enzyme	O
induction	O
and	O
displacement	O
of	O
fenoprofen	B-Drug
from	O
plasma	O
albumin	O
binding	O
sites	O
are	O
possibilities	O
.	O

Because	O
Nalfon	B-Drug
has	O
not	O
been	O
shown	O
to	O
produce	O
any	O
additional	O
effect	O
beyond	O
that	O
obtained	O
with	O
aspirin	B-Drug
alone	O
and	O
because	O
aspirin	B-Drug
increases	O
the	O
rate	O
of	O
excretion	O
of	O
Nalfon	B-Drug
,	O
the	O
concomitant	O
use	O
of	O
Nalfon	B-Drug
and	O
salicylates	O
is	O
not	O
recommended	O
.	O

Chronic	O
administration	O
of	O
phenobarbital	B-Drug
,	O
a	O
known	O
enzyme	O
inducer	O
,	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
plasma	O
half-life	O
of	O
fenoprofen	B-Drug
.	O

When	O
phenobarbital	B-Drug
is	O
added	O
to	O
or	O
withdrawn	O
from	O
treatment	O
,	O
dosage	O
adjustment	O
of	O
Nalfon	B-Drug
may	O
be	O
required	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
fenoprofen	B-Drug
,	O
because	O
of	O
its	O
affinity	O
for	O
albumin	O
,	O
may	O
displace	O
from	O
their	O
binding	O
sites	O
other	O
drugs	B-Drug
that	O
are	O
also	O
albumin	O
bound	O
,	O
and	O
this	O
may	O
lead	B-Drug
to	O
drug	B-Drug
interaction	O
.	O

Theoretically	O
,	O
fenoprofen	B-Drug
could	O
likewise	O
be	O
displaced	O
.	O

Patients	O
receiving	O
hydantoins	O
,	O
sulfonamides	O
,	O
or	O
sulfonylureas	O
should	O
be	O
observed	O
for	O
increased	O
activity	O
of	O
these	O
drugs	B-Drug
and	O
,	O
therefore	O
,	O
signs	O
of	O
toxicity	O
from	O
these	O
drugs	B-Drug
.	O

In	O
patients	O
receiving	O
coumarin-type	O
anticoagulants	B-Drug
,	O
the	O
addition	O
of	O
Nalfon	B-Drug
to	O
therapy	O
could	O
prolong	O
the	O
prothrombin	O
time	O
.	O

Patients	O
receiving	O
both	O
drugs	B-Drug
should	O
be	O
under	O
careful	O
observation	O
.	O

Patients	O
treated	O
with	O
Nalfon	B-Drug
may	O
be	O
resistant	O
to	O
the	O
effects	O
of	O
loop	O
diuretics	B-Drug
.	O

In	O
patients	O
receiving	O
Nalfon	B-Drug
and	O
a	O
steroid	O
concomitantly	O
,	O
any	O
reduction	O
in	O
steroid	O
dosage	O
should	O
be	O
gradual	O
in	O
order	O
to	O
avoid	O
the	O
possible	O
complications	O
of	O
sudden	O
steroid	O
withdrawal	O
.	O

Agents	O
Affecting	O
Cytochrome	O
P450	O
3A4	O
Isoenzyme	O
System	O
Fentanyl	B-Drug
is	O
metabolized	O
mainly	O
via	O
the	O
human	O
cytochrome	O
P450	O
3A4	O
isoenzyme	O
system	O
(	O
CYP3A4	B-Drug
)	O
,	O
therefore	O
potential	O
interactions	O
may	O
occur	O
when	O
DURAGESIC	B-Drug
is	O
given	O
concurrently	O
with	O
agents	O
that	O
affect	O
CYP3A4	B-Drug
activity	O
.	O

Coadminstration	O
with	O
agents	O
that	O
induce	O
3A4	O
activity	O
may	O
reduce	O
the	O
efficacy	O
of	O
DURAGESIC	B-Drug
.	O

The	O
concomitant	O
use	O
of	O
transdermal	O
fentanyl	B-Drug
with	O
ritonavir	B-Drug
or	O
other	O
potent	O
3A4	O
inhibitors	O
such	O
as	O
ketoconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
troleandomycin	B-Drug
,	O
clarithromycin	B-Drug
,	O
nelfinavir	B-Drug
,	O
and	O
nefazadone	B-Drug
may	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	B-Drug
plasma	O
concentrations	O
.	O

The	O
concomitant	O
use	O
of	O
other	O
CYP3A4	B-Drug
inhibitors	O
such	O
as	O
diltiazem	B-Drug
and	O
erythromycin	B-Drug
with	O
transdermal	O
fentanyl	B-Drug
may	O
also	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	B-Drug
plasma	O
concentrations	O
,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
drug	B-Drug
effects	O
and	O
may	O
cause	O
serious	O
respiratory	O
depression	O
.	O

In	O
this	O
situation	O
,	O
special	O
patient	O
care	O
and	O
observation	O
are	O
appropriate	O
.	O

Central	O
Nervous	O
System	O
Depressants	O
:	O
The	O
concomitant	O
use	O
of	O
DURAGESIC	B-Drug
(	O
fentanyl	B-Drug
transdermal	O
system	O
)	O
with	O
other	O
central	O
nervous	O
system	O
depressants	O
,	O
including	O
but	O
not	O
limited	O
to	O
other	O
opioids	O
,	O
sedatives	O
,	O
hypnotics	O
,	O
tranquilizers	O
(	O
e.g.	O
,	O
benzodiazepines	B-Drug
)	O
,	O
general	O
anesthetics	B-Drug
,	O
phenothiazines	O
,	O
skeletal	O
muscle	O
relaxants	O
,	O
and	O
alcohol	B-Drug
,	O
may	O
cause	O
respiratory	O
depression	O
,	O
hypotension	O
,	O
and	O
profound	O
sedation	O
,	O
or	O
potentially	O
result	O
in	O
coma	O
or	O
death	O
.	O

When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
significantly	O
reduced	O
.	O

MAO	O
Inhibitors	O
:	O
DURAGESIC	B-Drug
is	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
who	O
have	O
received	O
MAOI	O
within	O
14	O
days	O
because	O
severe	O
and	O
unpredictable	O
potentiation	O
by	O
MAO	O
inhibitors	O
has	O
been	O
reported	O
with	O
opioid	O
analgesics	O
.	O

Drug	B-Drug
Interaction	O
with	O
Erythromycin	B-Drug
and	O
Ketoconazole	B-Drug
Fexofenadine	B-Drug
has	O
been	O
shown	O
to	O
exhibit	O
minimal	O
(	O
ca	O
.	O

5	O
%	O
)	O
metabolism	O
.	O

However	O
,	O
co	B-Drug
administration	O
of	O
fexofenadine	B-Drug
hydrochloride	I-Drug
with	O
either	O
ketoconazole	B-Drug
or	O
erythromycin	B-Drug
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
fexofenadine	B-Drug
.	O

Fexofenadine	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
erythromycin	B-Drug
or	O
ketoconazole	B-Drug
.	O

In	O
2	O
separate	O
studies	O
,	O
fexofenadine	B-Drug
hydrochloride	I-Drug
120	O
mg	O
twice	O
daily	O
(	O
240	O
mg	O
total	O
daily	O
dose	O
)	O
was	O
co-administered	O
with	O
either	O
erythromycin	B-Drug
500	O
mg	O
every	O
8	O
hours	O
or	O
ketoconazole	B-Drug
400	O
mg	O
once	O
daily	O
under	O
steady-state	O
conditions	O
to	O
healthy	O
volunteers	O
(	O
n=24	O
,	O
each	O
study	O
)	O
.	O

No	O
differences	O
in	O
adverse	O
events	O
or	O
QTc	O
interval	O
were	O
observed	O
when	O
subjects	O
were	O
administered	O
fexofenadine	B-Drug
hydrochloride	I-Drug
alone	O
or	O
in	O
combination	O
with	O
either	O
erythromycin	B-Drug
or	O
ketoconazole	B-Drug
.	O

The	O
findings	O
of	O
these	O
studies	O
are	O
summarized	O
in	O
the	O
following	O
table	O
:	O
Effects	O
on	O
steady-state	O
fexofenadine	B-Drug
pharmacokinetics	O
after	O
7	O
days	O
of	O
co-administration	O
with	O
fexofenadine	B-Drug
hydrochloride	I-Drug
120	O
mg	O
every	O
12	O
hours	O
(	O
two	O
times	O
the	O
recommended	O
twice	O
daily	O
dose	O
)	O
in	O
healthy	O
volunteers	O
(	O
n=24	O
)	O
Concomitant	O
Drug	B-Drug
cmaxSS	O
(	O
Peak	O
plasma	O
concentration	O
)	O
AUCss	O
(	O
0-12h	O
)	O
(	O
Extent	O
of	O
systemic	O
exposure	O
)	O
Erythromycin	B-Drug
(	O
500	O
mg	O
every	O
8	O
hrs	O
)	O
+82	O
%	O
+109	O
%	O
Ketoconazole	B-Drug
(	O
400	O
mg	O
once	O
daily	O
)	O
+135	O
%	O
+164	O
%	O
The	O
changes	O
in	O
plasma	O
levels	O
were	O
within	O
the	O
range	O
of	O
plasma	O
levels	O
achieved	O
in	O
adequate	O
and	O
well-controlled	O
clinical	O
trials	O
.	O

The	O
mechanism	O
of	O
these	O
interactions	O
has	O
been	O
evaluated	O
in	O
in	O
vitro	O
,	O
in	O
situ	O
,	O
and	O
in	O
vivo	O
animal	O
models	O
.	O

These	O
studies	O
indicate	O
that	O
ketoconazole	B-Drug
or	O
erythromycin	B-Drug
co-administration	O
enhances	O
fexofenadine	B-Drug
gastrointestinal	O
absorption	O
.	O

This	O
observed	O
increase	O
in	O
the	O
bioavailability	O
of	O
fexofenadine	B-Drug
may	O
be	O
due	O
to	O
transport-related	O
effects	O
,	O
such	O
as	O
p-glycoprotein	O
.	O

in	O
vivo	O
animal	O
studies	O
also	O
suggest	O
that	O
in	O
addition	O
to	O
enhancing	O
absorption	O
,	O
ketoconazole	B-Drug
decreases	O
fexofenadine	B-Drug
gastrointestinal	O
secretion	O
,	O
while	O
erythromycin	B-Drug
may	O
also	O
decrease	O
biliary	O
excretion	O
.	O

Drug	B-Drug
Interactions	O
with	O
Antacids	O
Administration	O
of	O
120	O
mg	O
of	O
fexofenadine	B-Drug
hydrochloride	I-Drug
(	O
2	O
x	O
60	O
mg	O
capsule	O
)	O
within	O
15	O
minutes	O
of	O
an	O
aluminum	B-Drug
and	O
magnesium	B-Drug
containing	O
antacid	O
(	O
Maalox	B-Drug
)	O
decreased	O
fexofenadine	B-Drug
AUC	O
by	O
41	O
%	O
and	O
cmax	O
by	O
43	O
%	O
.	O

ALLEGRA	B-Drug
should	O
not	O
be	O
taken	O
closely	O
in	O
time	O
with	O
aluminum	B-Drug
and	O
magnesium	B-Drug
containing	O
antacids	O
.	O

Interactions	O
with	O
Fruit	O
Juices	O
Fruit	O
juices	O
such	O
as	O
grapefruit	O
,	O
orange	O
and	O
apple	O
may	O
reduce	O
the	O
bioavailability	O
and	O
exposure	O
of	O
fexofenadine	B-Drug
.	O

This	O
is	O
based	O
on	O
the	O
results	O
from	O
3	O
clinical	O
studies	O
using	O
histamine	B-Drug
induced	O
skin	O
wheals	O
and	O
flares	O
coupled	O
with	O
population	O
pharmacokinetic	O
analysis	O
.	O

The	O
size	O
of	O
wheal	O
and	O
flare	O
were	O
significantly	O
larger	O
when	O
fexofenadine	B-Drug
hydrochloride	I-Drug
was	O
administered	O
with	O
either	O
grapefruit	O
or	O
orange	O
juices	O
compared	O
to	O
water	O
.	O

Based	O
on	O
the	O
literature	O
reports	O
,	O
the	O
same	O
effects	O
may	O
be	O
extrapolated	O
to	O
other	O
fruit	O
juices	O
such	O
as	O
apple	O
juice	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
observations	O
is	O
unknown	O
.	O

In	O
addition	O
,	O
based	O
on	O
the	O
population	O
pharmacokinetics	O
analysis	O
of	O
the	O
combined	O
data	O
from	O
grapefruit	O
and	O
orange	O
juices	O
studies	O
with	O
the	O
data	O
from	O
a	O
bioequivalence	O
study	O
,	O
the	O
bioavailability	O
of	O
fexofenadine	B-Drug
was	O
reduced	O
by	O
36	O
%	O
.	O

Therefore	O
,	O
to	O
maximize	O
the	O
effects	O
of	O
fexofenadine	B-Drug
,	O
it	O
is	O
recommended	O
that	O
ALLEGRA	B-Drug
should	O
be	O
taken	O
with	O
water	O
.	O

Drug	B-Drug
interactions	O
between	O
NEUPOGEN	B-Drug
and	O
other	O
drugs	B-Drug
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Drugs	B-Drug
which	O
may	O
potentiate	O
the	O
release	O
of	O
neutrophils	O
,	O
such	O
as	O
lithium	B-Drug
,	O
should	O
be	O
used	O
with	O
caution	O
.	O

No	O
drug	B-Drug
interactions	O
of	O
clinical	O
importance	O
have	O
been	O
identified	O
.	O

Finasteride	B-Drug
does	O
not	O
appear	O
to	O
affect	O
the	O
cytochrome	O
P450-linked	O
drug-metabolizing	O
enzyme	O
system	O
.	O

Compounds	O
that	O
have	O
been	O
tested	O
in	O
man	O
include	O
antipyrine	B-Drug
,	O
digoxin	B-Drug
,	O
propranolol	B-Drug
,	O
theophylline	B-Drug
,	O
and	O
warfarin	B-Drug
and	O
no	O
clinically	O
meaningful	O
interactions	O
were	O
found	O
.	O

Other	O
concomitant	O
therapy	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
finasteride	B-Drug
doses	O
of	O
1	O
mg	O
or	O
more	O
were	O
concomitantly	O
used	O
in	O
clinical	O
studies	O
with	O
acetaminophen	B-Drug
,	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
a-blockers	O
,	O
analgesics	O
,	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
,	O
anticonvulsants	O
,	O
benzodiazepines	B-Drug
,	O
beta	O
blockers	O
,	O
calcium-channel	O
blockers	O
,	O
cardiac	O
nitrates	B-Drug
,	O
diuretics	B-Drug
,	O
H2	O
antagonists	O
,	O
HMG-CoA	O
reductase	O
inhibitors	O
,	O
prostaglandin	O
synthetase	O
inhibitors	O
(	O
also	O
referred	O
to	O
as	O
NSAIDs	O
)	O
,	O
and	O
quinolone	O
anti-infectives	O
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Finasteride	B-Drug
had	O
no	O
effect	O
on	O
circulating	O
levels	O
of	O
cortisol	O
,	O
thyroid-stimulating	O
hormone	O
,	O
or	O
thyroxine	B-Drug
,	O
nor	O
did	O
it	O
affect	O
the	O
plasma	O
lipid	O
profile	O
(	O
e.g.	O
,	O
total	O
cholesterol	O
,	O
low-density	O
lipoproteins	O
,	O
high-density	O
lipoproteins	O
and	O
triglycerides	O
)	O
or	O
bone	O
mineral	O
density	O
.	O

In	O
studies	O
with	O
finasteride	B-Drug
,	O
no	O
clinically	O
meaningful	O
changes	O
in	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
,	O
follicle-stimulating	O
hormone	O
(	O
FSH	O
)	O
or	O
prolactin	O
were	O
detected	O
.	O

In	O
healthy	O
volunteers	O
,	O
treatment	O
with	O
finasteride	B-Drug
did	O
not	O
alter	O
the	O
response	O
of	O
LH	O
and	O
FSH	O
to	O
gonadotropin-releasing	O
hormone	O
indicating	O
that	O
the	O
hypothalamic-pituitary-testicular	O
axis	O
was	O
not	O
affected	O
.	O

In	O
clinical	O
studies	O
with	O
PROPECIA	B-Drug
(	O
finasteride	B-Drug
,	O
1	O
mg	O
)	O
in	O
men	O
18-41	O
years	O
of	O
age	O
,	O
the	O
mean	O
value	O
of	O
serum	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
decreased	O
from	O
0.7	O
ng/mL	O
at	O
baseline	O
to	O
0.5	O
ng/mL	O
at	O
Month	O
12	O
.	O

Further	O
,	O
in	O
clinical	O
studies	O
with	O
PROSCAR	B-Drug
(	O
finasteride	B-Drug
,	O
5	O
mg	O
)	O
when	O
used	O
in	O
older	O
men	O
who	O
have	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
PSA	O
levels	O
are	O
decreased	O
by	O
approximately	O
50	O
%	O
.	O

These	O
findings	O
should	O
be	O
taken	O
into	O
account	O
for	O
proper	O
interpretation	O
of	O
serum	O
PSA	O
when	O
evaluating	O
men	O
treated	O
with	O
finasteride	B-Drug
.	O

Drug	B-Drug
Interactions	O
.	O

TAMBOCOR	B-Drug
has	O
been	O
administered	O
to	O
patients	O
receiving	O
digitalis	B-Drug
preparations	O
or	O
beta-adrenergic	O
blocking	O
agents	O
without	O
adverse	O
effects	O
.	O

During	O
administration	O
of	O
multiple	O
oral	O
doses	O
of	O
TAMBOCOR	B-Drug
to	O
healthy	O
subjects	O
stabilized	O
on	O
a	O
maintenance	O
dose	O
of	O
digoxin	B-Drug
,	O
a	O
13	O
%	O
-19	O
%	O
increase	O
in	O
plasma	O
digoxin	B-Drug
levels	O
occurred	O
at	O
six	O
hours	O
postdose	O
.	O

In	O
a	O
study	O
involving	O
healthy	O
subjects	O
receiving	O
TAMBOCOR	B-Drug
and	O
propranolol	B-Drug
concurrently	O
,	O
plasma	O
flecainide	B-Drug
levels	O
were	O
increased	O
about	O
20	O
%	O
and	O
propranolol	B-Drug
levels	O
were	O
increased	O
about	O
30	O
%	O
compared	O
to	O
control	O
values	O
.	O

In	O
this	O
formal	O
interaction	O
study	O
,	O
TAMBOCOR	B-Drug
and	O
propranolol	B-Drug
were	O
each	O
found	O
to	O
have	O
negative	O
inotropic	O
effects	O
;	O
when	O
the	O
drugs	B-Drug
were	O
administered	O
together	O
,	O
the	O
effects	O
were	O
additive	O
.	O

The	O
effects	O
of	O
concomitant	O
administration	O
of	O
TAMBOCOR	B-Drug
and	O
propranolol	B-Drug
on	O
the	O
PR	O
interval	O
were	O
less	O
than	O
additive	O
.	O

In	O
TAMBOCOR	B-Drug
clinical	O
trials	O
,	O
patients	O
who	O
were	O
receiving	O
beta	O
blockers	O
concurrently	O
did	O
not	O
experience	O
an	O
increased	O
incidence	O
of	O
side	O
effects	O
.	O

Nevertheless	O
,	O
the	O
possibility	O
of	O
additive	O
negative	O
inotropic	O
effects	O
of	O
beta	O
blockers	O
and	O
flecainide	B-Drug
should	O
be	O
recognized	O
.	O

Flecainide	B-Drug
is	O
not	O
extensively	O
bound	O
to	O
plasma	O
proteins	O
.	O

In	O
vitro	O
studies	O
with	O
several	O
drugs	B-Drug
which	O
may	O
be	O
administered	O
concomitantly	O
showed	O
that	O
the	O
extent	O
of	O
flecainide	B-Drug
binding	O
to	O
human	O
plasma	O
proteins	O
is	O
either	O
unchanged	O
or	O
only	O
slightly	O
less	O
.	O

Consequently	O
,	O
interactions	O
with	O
other	O
drugs	B-Drug
which	O
are	O
highly	O
protein	O
bound	O
(	O
e.g.	O
,	O
anticoagulants	B-Drug
)	O
would	O
not	O
be	O
expected	O
.	O

TAMBOCOR	B-Drug
has	O
been	O
used	O
in	O
a	O
large	O
number	O
of	O
patients	O
receiving	O
diuretics	B-Drug
without	O
apparent	O
interaction	O
.	O

Limited	O
data	O
in	O
patients	O
receiving	O
known	O
enzyme	O
inducers	O
(	O
phenytoin	B-Drug
,	O
phenobarbital	B-Drug
,	O
carbamazepine	B-Drug
)	O
indicate	O
only	O
a	O
30	O
%	O
increase	O
in	O
the	O
rate	O
of	O
flecainide	B-Drug
elimination	O
.	O

In	O
healthy	O
subjects	O
receiving	O
cimetidine	B-Drug
(	O
1	O
gm	O
daily	O
)	O
for	O
one	O
week	O
,	O
plasma	O
flecainide	B-Drug
levels	O
increased	O
by	O
about	O
30	O
%	O
and	O
half-life	O
increased	O
by	O
about	O
10	O
%	O
.	O

When	O
amiodarone	B-Drug
is	O
added	O
to	O
flecainide	B-Drug
therapy	O
,	O
plasma	O
flecainide	B-Drug
levels	O
may	O
increase	O
two-fold	O
or	O
more	O
in	O
some	O
patients	O
,	O
if	O
flecainide	B-Drug
dosage	O
is	O
not	O
reduced	O
.	O

Drugs	B-Drug
that	O
inhibit	O
cytochrome	O
P450IID6	O
,	O
such	O
as	O
quinidine	B-Drug
,	O
might	O
increase	O
the	O
plasma	O
concentrations	O
of	O
flecainide	B-Drug
in	O
patients	O
that	O
are	O
on	O
chronic	O
flecainide	B-Drug
therapy	O
;	O
especially	O
if	O
these	O
patients	O
are	O
extensive	O
metabolizers	O
.	O

There	O
has	O
been	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	B-Drug
and	O
either	O
disopyramide	B-Drug
or	O
verapamil	B-Drug
.	O

Because	O
both	O
of	O
these	O
drugs	B-Drug
have	O
negative	O
inotropic	O
properties	O
and	O
the	O
effects	O
of	O
coadministration	O
with	O
TAMBOCOR	B-Drug
are	O
unknown	O
,	O
neither	O
disopyramide	B-Drug
nor	O
verapamil	B-Drug
should	O
be	O
administered	O
concurrently	O
with	O
TAMBOCOR	B-Drug
unless	O
,	O
in	O
the	O
judgment	O
of	O
the	O
physician	O
,	O
the	O
benefits	O
of	O
this	O
combination	O
outweigh	O
the	O
risks	O
.	O

There	O
has	O
been	O
too	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	B-Drug
with	O
nifedipine	B-Drug
or	O
diltiazem	B-Drug
to	O
recommend	O
concomitant	O
use	O
.	O

Combination	O
Therapy	O
:	O
Any	O
form	O
of	O
therapy	O
which	O
adds	O
to	O
the	O
stress	O
of	O
the	O
patient	O
,	O
interferes	O
with	O
nutrition	O
or	O
depresses	O
bone	O
marrow	O
function	O
will	O
increase	O
the	O
toxicity	O
of	O
Floxuridine	B-Drug
.	O

Cytosine	B-Drug
arabinoside	I-Drug
,	O
a	O
cytostatic	O
agent	O
,	O
has	O
been	O
reported	O
to	O
inactivate	O
the	O
antifungal	O
activity	O
of	O
flucytosine	B-Drug
by	O
competitive	O
inhibition	O
.	O

Drugs	B-Drug
which	O
impair	O
glomerular	O
filtration	O
may	O
prolong	O
the	O
biological	O
half-life	O
of	O
flucytosine	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
:	O
Measurement	O
of	O
serum	O
creatinine	O
levels	O
should	O
be	O
determined	O
by	O
the	O
Jaffe	O
reaction	O
,	O
since	O
Ancobon	B-Drug
does	O
not	O
interfere	O
with	O
the	O
determination	O
of	O
creatinine	O
values	O
by	O
this	O
method	O
.	O

Most	O
automated	O
equipment	O
for	O
measurement	O
of	O
creatinine	O
makes	O
use	O
of	O
the	O
Jaffe	O
reaction	O
.	O

The	O
use	O
of	O
FLUDARA	B-Drug
FOR	O
INJECTION	O
in	O
combination	O
with	O
pentostatin	B-Drug
is	O
not	O
recommended	O
due	O
to	O
the	O
risk	O
of	O
severe	O
pulmonary	O
toxicity	O
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	B-Drug
may	O
interact	O
with	O
adrenal	O
corticosteroids	O
.	O

Amphotericin	B-Drug
B	I-Drug
or	O
potassium-depleting	O
diuretics	B-Drug
(	O
benzothiadiazines	O
and	O
related	O
drugs	B-Drug
,	O
ethacrynic	B-Drug
acid	I-Drug
and	O
furosemide	B-Drug
)	O
enhanced	O
hypokalemia	O
.	O

Check	O
serum	O
potassium	B-Drug
levels	O
at	O
frequent	O
intervals	O
;	O
use	O
potassium	B-Drug
supplements	O
if	O
necessary	O
.	O

Digitalis	B-Drug
glycosides	O
enhanced	O
possibility	O
of	O
arrhythmias	O
or	O
digitalis	B-Drug
toxicity	O
associated	O
with	O
hypokalemia	O
.	O

Monitor	O
serum	O
potassium	B-Drug
levels	O
;	O
use	O
potassium	B-Drug
supplements	O
if	O
necessary	O
.	O

Oral	O
anticoagulants	B-Drug
decreased	O
prothrombin	O
time	O
response	O
.	O

Monitor	O
prothrombin	O
levels	O
and	O
adjust	O
anticoagulant	B-Drug
dosage	O
accordingly	O
.	O

Antidiabetic	B-Drug
drugs	B-Drug
(	O
oral	O
agents	O
and	O
insulin	B-Drug
)	O
diminished	O
antidiabetic	B-Drug
effect	O
.	O

Monitor	O
for	O
symptoms	O
of	O
hyperglycemia	O
;	O
adjust	O
dosage	O
of	O
antidiabetic	B-Drug
drug	B-Drug
upward	O
if	O
necessary	O
.	O

Aspirin	B-Drug
increased	O
ulcerogenic	O
effect	O
;	O
decreased	O
pharmacologic	O
effect	O
of	O
aspirin	B-Drug
.	O

Rarely	O
salicylate	B-Drug
toxicity	O
may	O
occur	O
in	O
patients	O
who	O
discontinue	O
steroids	O
after	O
concurrent	O
high-dose	O
aspirin	B-Drug
therapy	O
.	O

Monitor	O
salicylate	B-Drug
levels	O
or	O
the	O
therapeutic	O
effect	O
for	O
which	O
aspirin	B-Drug
is	O
given	O
;	O
adjust	O
salicylate	B-Drug
dosage	O
accordingly	O
if	O
effect	O
is	O
altered	O
.	O

Barbiturates	B-Drug
,	O
phenytoin	B-Drug
,	O
or	O
rifampin	B-Drug
increased	O
metabolic	O
clearance	O
of	O
fludrocortisone	B-Drug
acetate	I-Drug
because	O
of	O
the	O
induction	O
of	O
hepatic	O
enzymes	O
.	O

Observe	O
the	O
patient	O
for	O
possible	O
diminished	O
effect	O
of	O
steroid	O
and	O
increase	O
the	O
steroid	O
dosage	O
accordingly	O
.	O

Anabolic	O
steroids	O
(	O
particularly	O
C-17	O
alkylated	O
androgens	O
such	O
as	O
oxymetholone	B-Drug
,	O
methandrostenolone	B-Drug
,	O
norethandrolone	B-Drug
,	O
and	O
similar	O
compounds	O
)	O
enhanced	O
tendency	O
toward	O
edema	O
.	O

Use	O
caution	O
when	O
giving	O
these	O
drugs	B-Drug
together	O
,	O
especially	O
in	O
patients	O
with	O
hepatic	O
or	O
cardiac	O
disease	O
.	O

Vaccines	O
neurological	O
complications	O
and	O
lack	O
of	O
antibody	O
response	O
.	O

Estrogen	O
increased	O
levels	O
of	O
corticosteroid-binding	O
globulin	O
,	O
thereby	O
increasing	O
the	O
bound	O
(	O
inactive	O
)	O
fraction	O
;	O
this	O
effect	O
is	O
at	O
least	O
balanced	O
by	O
decreased	O
metabolism	O
of	O
corticosteroids	O
.	O

When	O
estrogen	O
therapy	O
is	O
initiated	O
,	O
a	O
reduction	O
in	O
corticosteroid	B-Drug
dosage	O
may	O
be	O
required	O
,	O
and	O
increased	O
amounts	O
may	O
be	O
required	O
when	O
estrogen	O
is	O
terminated	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Corticosteroids	O
may	O
affect	O
the	O
nitrobluetetrazolium	O
test	O
for	O
bacterial	O
infection	O
and	O
produce	O
false-negative	O
results	O
.	O

Interaction	O
with	O
central	O
nervous	O
system	O
depressants	O
other	O
than	O
benzodiazepines	B-Drug
has	O
not	O
been	O
specifically	O
studied	O
;	O
however	O
,	O
no	O
deleterious	O
interactions	O
were	O
seen	O
when	O
ROMAZICON	B-Drug
was	O
administered	O
after	O
narcotics	O
,	O
inhalational	O
anesthetics	B-Drug
,	O
muscle	O
relaxants	O
and	O
muscle	O
relaxant	O
antagonists	O
administered	O
in	O
conjunction	O
with	O
sedation	O
or	O
anesthesia	B-Drug
.	O

Particular	O
caution	O
is	O
necessary	O
when	O
using	O
ROMAZICON	B-Drug
in	O
cases	O
of	O
mixed	O
drug	B-Drug
overdosage	O
since	O
the	O
toxic	O
effects	O
(	O
such	O
as	O
convulsions	O
and	O
cardiac	O
dysrhythmias	O
)	O
of	O
other	O
drugs	B-Drug
taken	O
in	O
overdose	O
(	O
especially	O
cyclic	O
antidepressants	B-Drug
)	O
may	O
emerge	O
with	O
the	O
reversal	O
of	O
the	O
benzodiazepine	O
effect	O
by	O
flumazenil	B-Drug
.	O

The	O
use	O
of	O
ROMAZICON	B-Drug
is	O
not	O
recommended	O
in	O
epileptic	O
patients	O
who	O
have	O
been	O
receiving	O
benzodiazepine	O
treatment	O
for	O
a	O
prolonged	O
period	O
.	O

Although	O
ROMAZICON	B-Drug
exerts	O
a	O
slight	O
intrinsic	O
anticonvulsant	O
effect	O
,	O
its	O
abrupt	O
suppression	O
of	O
the	O
protective	O
effect	O
of	O
a	O
benzodiazepine	O
agonist	O
can	O
give	O
rise	O
to	O
convulsions	O
in	O
epileptic	O
patients	O
.	O

ROMAZICON	B-Drug
blocks	O
the	O
central	O
effects	O
of	O
benzodiazepines	B-Drug
by	O
competitive	O
interaction	O
at	O
the	O
receptor	O
level	O
.	O

The	O
effects	O
of	O
nonbenzodiazepine	O
agonists	O
at	O
benzodiazepine	O
receptors	O
,	O
such	O
as	O
zopiclone	B-Drug
,	O
triazolopyridazines	O
and	O
others	O
,	O
are	O
also	O
blocked	O
by	O
ROMAZICON	B-Drug
.	O

The	O
pharmacokinetics	O
of	O
benzodiazepines	B-Drug
are	O
unaltered	O
in	O
the	O
presence	O
of	O
flumazenil	B-Drug
and	O
vice	O
versa	O
.	O

There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
ethanol	B-Drug
and	O
flumazenil	B-Drug
.	O

Use	O
in	O
Ambulatory	O
Patients	O
The	O
effects	O
of	O
ROMAZICON	B-Drug
may	O
wear	O
off	O
before	O
a	O
long-acting	O
benzodiazepine	O
is	O
completely	O
cleared	O
from	O
the	O
body	O
.	O

In	O
general	O
,	O
if	O
a	O
patient	O
shows	O
no	O
signs	O
of	O
sedation	O
within	O
2	O
hours	O
after	O
a	O
1-mg	O
dose	O
of	O
flumazenil	B-Drug
,	O
serious	O
resedation	O
at	O
a	O
later	O
time	O
is	O
unlikely	O
.	O

An	O
adequate	O
period	O
of	O
observation	O
must	O
be	O
provided	O
for	O
any	O
patient	O
in	O
whom	O
either	O
long-acting	O
benzodiazepines	B-Drug
(	O
such	O
as	O
diazepam	B-Drug
)	O
or	O
large	O
doses	O
of	O
short-acting	O
benzodiazepines	B-Drug
(	O
such	O
as	O
10	O
mg	O
of	O
midazolam	B-Drug
)	O
have	O
been	O
used	O
.	O

Because	O
of	O
the	O
increased	O
risk	O
of	O
adverse	O
reactions	O
in	O
patients	O
who	O
have	O
been	O
taking	O
benzodiazepines	B-Drug
on	O
a	O
regular	O
basis	O
,	O
it	O
is	O
particularly	O
important	O
that	O
physicians	O
query	O
patients	O
or	O
their	O
guardians	O
carefully	O
about	O
benzodiazepine	O
,	O
alcohol	B-Drug
and	O
sedative	O
use	O
as	O
part	O
of	O
the	O
history	O
prior	O
to	O
any	O
procedure	O
in	O
which	O
the	O
use	O
of	O
ROMAZICON	B-Drug
is	O
planned	O
.	O

No	O
information	O
available	O
.	O

Do	O
not	O
take	O
this	O
medicine	O
with	O
thioridizine	O
,	O
or	O
within	O
5	O
weeks	O
of	O
taking	O
fluoxetine	B-Drug
.	O

Talk	O
to	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
certain	O
antibiotics	B-Drug
such	O
as	O
erythromycin	B-Drug
,	O
clarithromycin	B-Drug
or	O
azithromycin	B-Drug
.	O

This	O
medicine	O
should	O
not	O
be	O
taken	O
with	O
MAO	O
inhibitors	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
taking	O
this	O
medicine	O
certain	O
antibiotics	B-Drug
,	O
such	O
as	O
erythromycin	B-Drug
,	O
clarithromycin	B-Drug
,	O
or	O
azithromycin	B-Drug
.	O

This	O
medicine	O
should	O
not	O
be	O
taken	O
with	O
MAO	O
inhibitors	O
.	O

If	O
you	O
think	O
you	O
are	O
taking	O
an	O
MAO	O
inhibitor	O
talk	O
to	O
your	O
doctor	O
or	O
pharmacist	O
.	O

Do	O
not	O
take	O
this	O
medicine	O
with	O
St.	O
Johns	O
Wort	O
because	O
of	O
the	O
additive	O
effects	O
of	O
sertonin	O
.	O

This	O
medication	O
should	O
not	O
be	O
taken	O
with	O
MAO	O
inhibitors	O
.	O

Your	O
doctor	O
or	O
pharmacist	O
can	O
give	O
you	O
more	O
information	O
on	O
MAO	O
inhibitors	O
.	O

Wait	O
5	O
weeks	O
after	O
stopping	O
escitalopram	B-Drug
before	O
starting	O
a	O
non-selective	O
MAO	O
inhibitor	O
.	O

Wait	O
2	O
weeks	O
after	O
stopping	O
an	O
MAO	O
inhibitor	O
before	O
starting	O
escitalopram	B-Drug
.	O

If	O
you	O
are	O
taking	O
medications	O
for	O
migraines	O
such	O
as	O
Imitrex	B-Drug
,	O
talk	O
to	O
your	O
doctor	O
before	O
starting	O
this	O
medicine	O
.	O

If	O
you	O
are	O
taking	O
a	O
tricyclic	O
antidepressant	O
,	O
talk	O
to	O
your	O
doctor	O
before	O
taking	O
this	O
medicine	O
.	O

St.	O
John	O
s	O
Wort	O
should	O
be	O
avoided	O
while	O
taking	O
this	O
medicine	O
due	O
to	O
the	O
additive	O
effects	O
of	O
serotonin	O
.	O

Tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
drugs	B-Drug
:	O
blood	O
thinners	O
(	O
Coumadin	B-Drug
)	O
other	O
antidepressants	B-Drug
metoprolol	B-Drug
antihistamines	B-Drug
carbamazepine	B-Drug
(	O
Tegretol	B-Drug
)	O
cimetidine	B-Drug
(	O
Tagamet	B-Drug
)	O
estrogens	O
fluoxetine	B-Drug
(	O
Prozac	B-Drug
)	O
intraconazole	B-Drug
(	O
Sporanox	B-Drug
)	O
ketoconazole	B-Drug
(	O
Nizoral	B-Drug
)	O
levodopa	B-Drug
lithium	B-Drug
muscle	O
relaxants	O
birth	O
control	O
pills	O
sleeping	O
pills	O
thyroid	B-Drug
medications	O
Androgens	O
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulahts	O
.	O

Dosage	O
of	O
the	O
anticoagulant	B-Drug
may	O
require	O
reduction	O
in	O
order	O
to	O
maintain	O
satisfactory	O
therapeutic	O
hypoprothrombinemia	O
.	O

Concurrent	O
administration	O
of	O
oxyphenbutazone	B-Drug
and	O
androgens	O
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	B-Drug
.	O

In	O
diabetic	O
patients	O
,	O
the	O
metabolic	O
effects	O
of	O
androgens	O
may	O
decrease	O
blood	O
glucose	B-Drug
and	O
therefore	O
,	O
insulin	B-Drug
requirements	O
.	O

Drug	B-Drug
Interactions	O
:	O
Flupenthixol	B-Drug
may	O
interact	O
with	O
some	O
drugs	B-Drug
,	O
like	O
Monoamine	O
oxidase	O
inhibitors	O
(	O
MAOI	O
)	O
:	O
MAOI	O
could	O
theoretically	O
affect	O
flupenthixol	B-Drug
pharmacodynamics	O
-	O
Arecoline	B-Drug
-	O
Eproxindine	O
-	O
Ethanol	B-Drug
:	O
Flupenthixol	B-Drug
and	O
Ethanol	B-Drug
cause	O
additive	O
CNS	O
depression	O
-	O
Tricyclic	O
antidepressants	B-Drug
:	O
Flupenthixol	B-Drug
increases	O
the	O
effect	O
of	O
Tricyclic	O
antidepressants	B-Drug
Antacids	O
:	O
Administration	O
of	O
flurbiprofen	B-Drug
to	O
volunteers	O
under	O
fasting	O
conditions	O
,	O
or	O
with	O
antacid	O
suspension	O
yielded	O
similar	O
serum	O
flurbiprofen	B-Drug
time	O
profiles	O
in	O
young	O
subjects	O
(	O
n=12	O
)	O
.	O

In	O
geriatric	O
subjects	O
(	O
n=7	O
)	O
there	O
was	O
a	O
reduction	O
in	O
the	O
rate	O
but	O
not	O
the	O
extent	O
of	O
flurbiprofen	B-Drug
absorption	O
.	O

Anticoagulants	B-Drug
:	O
Flurbiprofen	B-Drug
like	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
,	O
has	O
been	O
shown	O
to	O
affect	O
bleeding	O
parameters	O
in	O
patients	O
receiving	O
anti-coagulants	O
,	O
and	O
serious	O
clinical	O
bleeding	O
has	O
been	O
reported	O
.	O

The	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
flurbiprofen	B-Drug
to	O
patients	O
taking	O
anticoagulants	B-Drug
.	O

Aspirin	B-Drug
:	O
Concurrent	O
administration	O
of	O
aspirin	B-Drug
and	O
flurbiprofen	B-Drug
resulted	O
in	O
50	O
%	O
lower	O
serum	O
flurbiprofen	B-Drug
concentrations	O
.	O

This	O
effect	O
of	O
aspirin	B-Drug
(	O
which	O
also	O
lowers	O
serum	O
concentrations	O
of	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
given	O
with	O
it	O
)	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
n=	O
15	O
)	O
as	O
well	O
as	O
normal	O
volunteers	O
(	O
n=	O
16	O
)	O
.	O

Concurrent	O
use	O
of	O
flurbiprofen	B-Drug
and	O
aspirin	B-Drug
is	O
therefore	O
not	O
recommended	O
.	O

Beta-adrenergic	O
Blocking	O
Agents	O
:	O
The	O
effect	O
of	O
flurbiprofen	B-Drug
on	O
blood	O
pressure	O
response	O
to	O
propranolol	B-Drug
and	O
atenolol	B-Drug
was	O
evaluated	O
in	O
men	O
with	O
mild	O
uncomplicated	O
hypertension	O
(	O
n	O
=	O
10	O
)	O
.	O

Flurbiprofen	B-Drug
pretreatment	O
attenuated	O
the	O
hypotensive	O
effect	O
of	O
a	O
single	O
dose	O
of	O
propranolol	B-Drug
but	O
not	O
atenolol	B-Drug
.	O

Flurbiprofen	B-Drug
did	O
not	O
appear	O
to	O
affect	O
the	O
beta-blocker-mediated	O
reduction	O
in	O
heart	O
rate	O
.	O

Flurbiprofen	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	B-Drug
,	O
and	O
the	O
mechanism	O
under	O
lying	O
the	O
interference	O
with	O
propranolols	B-Drug
hypotensive	O
effect	O
is	O
unknown	O
.	O

Patients	O
taking	O
both	O
flurbiprofen	B-Drug
and	O
a	O
beta-blocker	O
should	O
be	O
monitored	O
to	O
ensure	O
that	O
a	O
satisfactory	O
hypotensive	O
effect	O
is	O
achieved	O
.	O

Cimetidine	B-Drug
,	O
Ranitidine	B-Drug
:	O
In	O
normal	O
volunteers	O
(	O
n=9	O
)	O
,	O
pretreatment	O
with	O
cimetidine	B-Drug
or	O
ranitidine	B-Drug
did	O
not	O
affect	O
flurbiprofen	B-Drug
pharmacokinetics	O
except	O
that	O
a	O
small	O
(	O
13	O
%	O
)	O
but	O
statistically	O
significant	O
increase	O
in	O
the	O
area	O
under	O
the	O
serum	O
concentration	O
curve	O
of	O
flurbiprofen	B-Drug
resulted	O
with	O
cimetidine	B-Drug
.	O

Digoxin	B-Drug
:	O
Studies	O
of	O
concomitant	O
administration	O
of	O
flurbiprofen	B-Drug
and	O
digoxin	B-Drug
to	O
healthy	O
men	O
(	O
n=	O
14	O
)	O
did	O
not	O
show	O
a	O
change	O
in	O
the	O
steady	O
state	O
serum	O
levels	O
of	O
either	O
drug	B-Drug
.	O

Diuretics	B-Drug
:	O
Studies	O
in	O
normal	O
volunteers	O
have	O
shown	O
that	O
flurbiprofen	B-Drug
like	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
,	O
can	O
interfere	O
with	O
the	O
effects	O
of	O
furosemide	B-Drug
.	O

Although	O
results	O
have	O
varied	O
from	O
study	O
to	O
study	O
,	O
effects	O
have	O
been	O
shown	O
on	O
furosemide-stimulated	B-Drug
diuresis	O
,	O
natriuresis	O
,	O
and	O
kaliuresis	O
.	O

Other	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
that	O
inhibit	O
prostaglandin	O
synthesis	O
have	O
been	O
shown	O
to	O
interfere	O
with	O
thiazide	O
diuretics	B-Drug
in	O
some	O
studies	O
and	O
with	O
potassium-sparing	O
diuretics	B-Drug
.	O

Patients	O
receiving	O
flurbiprofen	B-Drug
and	O
furosemide	B-Drug
or	O
other	O
diuretics	B-Drug
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
is	O
obtained	O
.	O

Oral	O
Hypoglycemic	O
Agents	O
:	O
In	O
one	O
study	O
,	O
flurbiprofen	B-Drug
was	O
given	O
to	O
adult	O
diabetics	O
who	O
were	O
already	O
receiving	O
glyburide	B-Drug
(	O
n=4	O
)	O
,	O
metformin	B-Drug
(	O
n=2	O
)	O
chlorpropamide	B-Drug
with	O
phenformin	B-Drug
(	O
n=	O
3	O
)	O
or	O
glyburide	B-Drug
with	O
phenformin	B-Drug
(	O
n=6	O
)	O
.	O

Although	O
there	O
was	O
a	O
slight	O
reduction	O
in	O
blood	O
sugar	O
concentrations	O
during	O
concomitant	O
administration	O
of	O
flurbiprofen	B-Drug
and	O
hypoglycemic	O
agents	O
,	O
there	O
were	O
no	O
signs	O
or	O
symptoms	O
of	O
hypoglycemia	O
.	O

Increases	O
in	O
prothrombin	O
time	O
have	O
been	O
noted	O
in	O
patients	O
receiving	O
long-	O
term	O
warfarin	B-Drug
therapy	O
after	O
flutamide	B-Drug
was	O
initiated	O
.	O

Therefore	O
,	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B-Drug
dose	O
may	O
be	O
necessary	O
when	O
EULEXIN	B-Drug
Capsules	O
are	O
administered	O
concomitantly	O
with	O
warfarin	B-Drug
.	O

Potential	O
for	O
Interaction	O
with	O
Monoamine	O
Oxidase	O
Inhibitors	O
In	O
patients	O
receiving	O
another	O
serotonin	O
reuptake	O
inhibitor	O
drug	B-Drug
in	O
combination	O
with	O
monoamine	O
oxidase	O
inhibitors	O
(	O
MAOI	O
)	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
,	O
sometimes	O
fatal	O
,	O
reactions	O
including	O
hyperthermia	O
,	O
rigidity	O
,	O
myoclonus	O
,	O
autonomic	O
instability	O
with	O
possible	O
rapid	O
fluctuations	O
of	O
vital	O
signs	O
,	O
and	O
mental	O
status	O
changes	O
that	O
include	O
extreme	O
agitation	O
progressing	O
to	O
delirium	O
and	O
coma	O
.	O

These	O
reactions	O
have	O
also	O
been	O
reported	O
in	O
patients	O
who	O
have	O
discontinued	O
that	O
drug	B-Drug
and	O
have	O
been	O
started	O
on	O
a	O
MAOI	O
.	O

Some	O
cases	O
presented	O
with	O
features	O
resembling	O
neuroleptic	B-Drug
malignant	O
syndrome	O
.	O

Therefore	O
,	O
it	O
is	O
recommended	O
that	O
Fluvoxamine	B-Drug
Tablets	O
not	O
be	O
used	O
in	O
combination	O
with	O
MAOIs	O
,	O
or	O
within	O
14	O
days	O
of	O
discontinuing	O
treatment	O
with	O
a	O
MAOI	O
.	O

After	O
stopping	O
Fluvoxamine	B-Drug
Tablets	O
,	O
at	O
least	O
2	O
weeks	O
should	O
be	O
allowed	O
before	O
starting	O
a	O
MAOI	O
.	O

Potential	O
Terfenadine	B-Drug
,	O
Astemizole	B-Drug
,	O
and	O
Cisapride	B-Drug
Interactions	O
Terfenadine	B-Drug
,	O
astemizole	B-Drug
and	O
cisapride	B-Drug
are	O
all	O
metabolized	O
by	O
the	O
cytochrome	O
P450IIIA4	O
isozyme	O
,	O
and	O
it	O
has	O
been	O
demonstrated	O
that	O
ketoconazole	B-Drug
,	O
a	O
potent	O
inhibitor	O
of	O
IIIA4	O
,	O
blocks	O
the	O
metabolism	O
of	O
these	O
drugs	B-Drug
,	O
resulting	O
in	O
increased	O
plasma	O
concentrations	O
of	O
parent	O
drug	B-Drug
.	O

Increased	O
plasma	O
concentrations	O
of	O
terfenadine	B-Drug
,	O
astemizole	B-Drug
,	O
and	O
cisapride	B-Drug
cause	O
QT	O
prolongation	O
and	O
have	O
been	O
associated	O
with	O
torsades	O
de	O
pointes-type	O
ventricular	O
tachycardia	O
,	O
sometimes	O
fatal	O
.	O

As	O
noted	O
below	O
,	O
a	O
sub-	O
for	O
fluvoxamine	B-Drug
in	O
combination	O
with	O
alprazolam	B-Drug
,	O
a	O
drug	B-Drug
that	O
is	O
known	O
to	O
be	O
metabolized	O
by	O
the	O
IIIA4	O
isozyme	O
.	O

Although	O
it	O
has	O
not	O
been	O
definitively	O
demonstrated	O
that	O
fluvoxamine	B-Drug
is	O
a	O
potent	O
IIIA4	O
inhibitor	O
,	O
it	O
is	O
likely	O
to	O
be	O
,	O
given	O
the	O
substantial	O
interaction	O
of	O
fluvoxamine	B-Drug
with	O
alprazolam	B-Drug
.	O

Consequently	O
,	O
it	O
is	O
recommended	O
that	O
fluvoxamine	B-Drug
not	O
be	O
used	O
in	O
combination	O
with	O
either	O
terbinafine	B-Drug
,	O
astemizole	B-Drug
,	O
or	O
cisapride	B-Drug
.	O

Other	O
Potentially	O
Important	O
Drug	B-Drug
Interactions	O
:	O
Benzodiazepines	B-Drug
:	O
Benzodiazepines	B-Drug
metabolized	O
by	O
hepatic	O
oxidation	O
(	O
e.g.	O
,	O
alprazolam	B-Drug
,	O
midazolam	B-Drug
,	O
triazolam	B-Drug
elc	O
.	O

)	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
clearance	O
of	O
these	O
drugs	B-Drug
is	O
likely	O
to	O
be	O
reduced	O
by	O
fluvoxamine	B-Drug
.	O

The	O
clearance	O
of	O
benzodiazepines	B-Drug
metabolized	O
by	O
glucuronidation	O
(	O
e.	O
g.	O
,	O
lorazepam	B-Drug
,	O
oxazepam	B-Drug
,	O
temazepam	B-Drug
)	O
is	O
unlikely	O
to	O
be	O
affected	O
by	O
fluvoxamine	B-Drug
.	O

Alprazolam	B-Drug
:	O
When	O
fluvoxamine	B-Drug
maleate	I-Drug
(	O
100	O
mg	O
qd	O
)	O
and	O
alprazolam	B-Drug
(	O
1	O
mg	O
q.d	O
.	O

were	O
co-administered	O
to	O
steady	O
state	O
,	O
plasma	O
concentration	O
and	O
other	O
pharmacokinetics	O
parameters	O
(	O
AUC	O
,	O
Cmax	O
,	O
T1/2	B-Drug
,	O
)	O
of	O
alprazolam	B-Drug
were	O
approximately	O
twice	O
those	O
observed	O
when	O
alprazolam	B-Drug
was	O
administered	O
alone	O
;	O
oral	O
clearance	O
was	O
reduced	O
by	O
about	O
50	O
%	O
.	O

The	O
elevated	O
plasma	O
alprazolam	B-Drug
concentrations	O
resulted	O
in	O
decreased	O
psychomotor	O
performance	O
and	O
memory	O
.	O

This	O
interaction	O
,	O
which	O
has	O
not	O
been	O
investigated	O
using	O
higher	O
doses	O
of	O
fluvoxamine	B-Drug
,	O
may	O
be	O
more	O
pronounced	O
if	O
a	O
300	O
mg	O
daily	O
dose	O
is	O
co-administered	O
,	O
particularly	O
since	O
fluvoxamine	B-Drug
exhibits	O
non-linear	O
pharmacokinetics	O
over	O
the	O
dosage	O
range	O
100-300	O
mg	O
.	O

If	O
alprazolam	B-Drug
is	O
co-administered	O
with	O
Fluvoxamine	B-Drug
Tablets	O
,	O
the	O
initial	O
alprazolam	B-Drug
dosage	O
should	O
be	O
at	O
least	O
halved	O
and	O
titration	O
to	O
the	O
lowest	O
effective	O
dose	O
is	O
recommended	O
.	O

No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	B-Drug
Tablets	O
.	O

Diazepam	B-Drug
:	O
The	O
co-administration	O
of	O
Fluvoxamine	B-Drug
Tablets	O
and	O
diazepam	B-Drug
is	O
generally	O
not	O
advisable	O
.	O

Because	O
fluvoxamine	B-Drug
reduces	O
the	O
clearance	O
of	O
both	O
diazepam	B-Drug
and	O
its	O
active	O
metabolite	O
,	O
N-desmethyldiazepam	B-Drug
,	O
there	O
is	O
a	O
strong	O
likelihood	O
of	O
substantial	O
accumulation	O
of	O
both	O
species	O
during	O
chronic	O
co-administration	O
.	O

Evidence	O
supporting	O
the	O
conclusion	O
that	O
it	O
is	O
inadvisable	O
to	O
co-administer	O
fluvoxamine	B-Drug
and	O
diazepam	B-Drug
is	O
derived	O
from	O
a	O
study	O
in	O
which	O
healthy	O
volunteers	O
taking	O
150	O
mg/day	O
of	O
fluvoxamine	B-Drug
were	O
administered	O
a	O
single	O
oral	O
dose	O
of	O
10	O
mg	O
of	O
diazepam	B-Drug
.	O

In	O
these	O
subjects	O
(	O
R=	O
B	O
)	O
,	O
the	O
clearance	O
of	O
diazepam	B-Drug
was	O
reduced	O
by	O
65	O
%	O
and	O
that	O
of	O
N-desmethyldiazepam	B-Drug
to	O
a	O
level	O
that	O
was	O
too	O
low	O
to	O
measure	O
over	O
the	O
course	O
of	O
the	O
2	O
week	O
long	O
study	O
.	O

It	O
is	O
likely	O
that	O
experience	O
significantly	O
underestimates	O
the	O
degree	O
of	O
accumulation	O
that	O
might	O
occur	O
with	O
repealed	O
diazepam	B-Drug
administration	O
.	O

Moreover	O
,	O
as	O
noted	O
with	O
alprazolam	B-Drug
,	O
the	O
effect	O
of	O
fluvoxamine	B-Drug
may	O
even	O
be	O
more	O
pronounced	O
when	O
it	O
is	O
administered	O
at	O
higher	O
doses	O
.	O

Accordingly	O
,	O
diazepam	B-Drug
and	O
fluvoxamine	B-Drug
should	O
not	O
ordinarily	O
be	O
co-administered	O
.	O

Theophylline	B-Drug
:	O
The	O
effect	O
of	O
steady-state	O
fluvoxamine	B-Drug
l50	O
mg	O
bid	O
on	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
dose	O
of	O
Theophylline	B-Drug
(	O
375	O
mg	O
)	O
as	O
442	O
mg	O
aminophylline	B-Drug
was	O
evaluated	O
in	O
12	O
healthy	O
non-smoking	O
,	O
male	O
volunteers	O
.	O

The	O
clearance	O
of	O
theophylline	B-Drug
was	O
decreased	O
approximately	O
3-fold	O
.	O

Therefore	O
,	O
if	O
theophylline	B-Drug
is	O
co-administered	O
with	O
fluvoxamine	B-Drug
maleate	I-Drug
,	O
its	O
dose	O
should	O
be	O
reduced	O
to	O
one	O
third	O
of	O
the	O
usual	O
daily	O
maintenance	O
dose	O
and	O
plasma	O
concentrations	O
of	O
theophylline	B-Drug
should	O
to	O
monitored	O
.	O

No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	B-Drug
Tablets	O
.	O

Warfarin	B-Drug
:	O
When	O
fluvoxamine	B-Drug
maleate	I-Drug
(	O
50	O
mg	O
tid	O
)	O
was	O
administered	O
concomitantly	O
with	O
warfarin	B-Drug
for	O
two	O
weeks	O
,	O
warfarin	B-Drug
plasma	O
concentrations	O
increased	O
by	O
98	O
%	O
and	O
prothrombin	O
times	O
were	O
prolonged	O
.	O

Thus	O
patients	O
receiving	O
oral	O
anticoagulants	B-Drug
and	O
Fluvoxamine	B-Drug
Tablets	O
should	O
have	O
their	O
prothrombin	O
time	O
monitored	O
and	O
their	O
anticoagulant	B-Drug
dose	O
adjusted	O
accordingly	O
.	O

No	O
dosage	O
adjustment	O
is	O
required	O
for	O
Fluvoxamine	B-Drug
Tablets	O
.	O

Medications	O
that	O
interfere	O
with	O
your	O
bodys	O
ability	O
to	O
use	O
folate	O
may	O
also	O
increase	O
the	O
need	O
for	O
this	O
vitamin	O
.	O

Medications	O
can	O
interfere	O
with	O
folate	O
utilization	O
,	O
including	O
:	O
anticonvulsant	O
medications	O
(	O
such	O
as	O
phenytoin	B-Drug
,	O
and	O
primidone	B-Drug
)	O
metformin	B-Drug
(	O
sometimes	O
prescribed	O
to	O
control	O
blood	O
sugar	O
in	O
type	O
2	O
diabetes	O
)	O
sulfasalazine	B-Drug
(	O
used	O
to	O
control	O
inflammation	O
associated	O
with	O
Crohns	O
disease	O
and	O
ulcerative	O
colitis	O
)	O
triamterene	B-Drug
(	O
a	O
diuretic	B-Drug
)	O
Methotrexate	B-Drug
There	O
has	O
been	O
concern	O
about	O
the	O
interaction	O
between	O
vitamin	B-Drug
B12	I-Drug
and	O
folic	B-Drug
acid	I-Drug
.	O

Folic	B-Drug
acid	I-Drug
supplements	O
can	O
correct	O
the	O
anemia	O
associated	O
with	O
vitamin	O
B12	O
deficiency	O
.	O

Unfortunately	O
,	O
folic	B-Drug
acid	I-Drug
will	O
not	O
correct	O
changes	O
in	O
the	O
nervous	O
system	O
that	O
result	O
from	O
vitamin	O
B12	O
deficiency	O
.	O

Permanent	O
nerve	O
damage	O
could	O
theoretically	O
occur	O
if	O
vitamin	O
B12	O
deficiency	O
is	O
not	O
treated	O
.	O

Therefore	O
,	O
intake	O
of	O
supplemental	O
folic	B-Drug
acid	I-Drug
should	O
not	O
exceed	O
1000	O
micrograms	O
(	O
g	O
,	O
sometimes	O
mcg	O
)	O
per	O
day	O
to	O
prevent	O
folic	B-Drug
acid	I-Drug
from	O
masking	O
symptoms	O
of	O
vitamin	O
B12	O
deficiency	O
.	O

It	O
is	O
important	O
for	O
older	O
adults	O
to	O
be	O
aware	O
of	O
the	O
relationship	O
between	O
folic	B-Drug
acid	I-Drug
and	O
vitamin	B-Drug
B12	I-Drug
because	O
they	O
are	O
at	O
greater	O
risk	O
of	O
having	O
a	O
vitamin	O
B12	O
deficiency	O
.	O

If	O
you	O
are	O
50	O
years	O
of	O
age	O
or	O
older	O
,	O
ask	O
your	O
physician	O
to	O
check	O
your	O
B12	O
status	O
before	O
you	O
take	O
a	O
supplement	O
that	O
contains	O
folic	B-Drug
acid	I-Drug
.	O

No	O
drug/drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Oral	O
doses	O
of	O
Antizol	B-Drug
(	O
10-20	O
mg/kg	O
)	O
,	O
via	O
alcohol	B-Drug
dehydrogenase	O
inhibition	O
,	O
significantly	O
reduced	O
the	O
rate	O
of	O
elimination	O
of	O
ethanol	B-Drug
(	O
by	O
approximately	O
40	O
%	O
)	O
given	O
to	O
healthy	O
volunteers	O
in	O
moderate	O
doses	O
.	O

Similarly	O
,	O
ethanol	B-Drug
decreased	O
the	O
rate	O
of	O
elimination	O
of	O
Antizol	B-Drug
(	O
by	O
approximately	O
50	O
%	O
)	O
by	O
the	O
same	O
mechanism	O
.	O

Reciprocal	O
interactions	O
may	O
occur	O
with	O
concomitant	O
use	O
of	O
Antizol	B-Drug
and	O
drugs	B-Drug
that	O
increase	O
or	O
inhibit	O
the	O
cytochrome	O
P450	O
system	O
(	O
e.g.	O
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
cimetidine	B-Drug
,	O
ketoconazole	B-Drug
)	O
,	O
though	O
this	O
has	O
not	O
been	O
studied	O
.	O

In	O
clinical	O
studies	O
performed	O
with	O
Fondaparinux	B-Drug
,	O
the	O
concomitant	O
use	O
of	O
oral	O
anticoagulants	B-Drug
(	O
warfarin	B-Drug
)	O
,	O
platelet	O
inhibitors	O
(	O
acetylsalicylic	B-Drug
acid	I-Drug
)	O
,	O
NSAIDs	O
(	O
piroxicam	B-Drug
)	O
,	O
and	O
digoxin	B-Drug
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics/pharmacodynamics	O
of	O
fondaparinux	B-Drug
sodium	I-Drug
.	O

In	O
addition	O
,	O
Fondaparinux	B-Drug
neither	O
influenced	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
,	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
piroxicam	B-Drug
,	O
and	O
digoxin	B-Drug
,	O
nor	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
at	O
steady	O
state	O
.	O

Agents	O
that	O
may	O
enhance	O
the	O
risk	O
of	O
hemorrhage	O
should	O
be	O
discontinued	O
prior	O
to	O
initiation	O
of	O
Fondaparinux	B-Drug
therapy	O
.	O

If	O
co-administration	O
is	O
essential	O
,	O
close	O
monitoring	O
may	O
be	O
appropriate	O
.	O

In	O
an	O
in	O
vitro	O
study	O
in	O
human	O
liver	O
microsomes	O
,	O
inhibition	O
of	O
CYP2A6	O
hydroxylation	O
of	O
coumarin	O
by	O
fondaparinux	B-Drug
(	O
200	O
m	O
m	O
M	O
i.e.	O
,	O
350	O
mg/L	O
)	O
was	O
17-28	O
%	O
.	O

Inhibition	O
of	O
the	O
other	O
isozymes	O
evaluated	O
(	O
CYPs	O
2A1	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
3A4	O
,	O
and	O
3E1	O
)	O
was	O
0-16	O
%	O
.	O

Since	O
fondaparinux	B-Drug
does	O
not	O
markedly	O
inhibit	O
CYP450s	O
(	O
CYP1A2	B-Drug
,	O
CYP2A6	O
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
CYP2D6	B-Drug
,	O
CYP2E1	O
,	O
or	O
CYP3A4	B-Drug
)	O
in	O
vitro	O
,	O
fondaparinux	B-Drug
sodium	I-Drug
is	O
not	O
expected	O
to	O
significantly	O
interact	O
with	O
other	O
drugs	B-Drug
in	O
vivo	O
by	O
inhibition	O
of	O
metabolism	O
mediated	O
by	O
these	O
isozymes	O
.	O

Since	O
fondaparinux	B-Drug
sodium	I-Drug
does	O
not	O
bind	O
significantly	O
to	O
plasma	O
proteins	O
other	O
than	O
ATIII	O
,	O
no	O
drug	B-Drug
interactions	O
by	O
protein-binding	O
displacement	O
are	O
expected	O
.	O

Short-Acting	O
beta2-agonists	O
:	O
Aerosol	O
bronchodilators	O
of	O
the	O
short-acting	O
adrenergic	O
stimulant	O
type	O
may	O
be	O
used	O
for	O
relief	O
of	O
breakthrough	O
symptoms	O
while	O
using	O
formoterol	B-Drug
.	O

However	O
,	O
increasing	O
use	O
of	O
such	O
preparations	O
to	O
control	O
symptoms	O
indicates	O
deterioration	O
of	O
asthma	O
control	O
and	O
the	O
need	O
to	O
reassess	O
the	O
patient	O
s	O
therapy	O
.	O

Concomitant	O
administration	O
of	O
other	O
sympathomimetic	B-Drug
agents	O
may	O
potentiate	O
the	O
undesirable	O
effects	O
of	O
FORADIL	B-Drug
.	O

Monoamine	O
Oxidase	O
Inhibitors	O
and	O
Tricyclic	O
Antidepressants	B-Drug
:	O
FORADIL	B-Drug
should	O
be	O
administered	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
monoamine	O
oxidase	O
inhibitors	O
or	O
tricyclic	O
antidepressants	B-Drug
because	O
the	O
action	O
of	O
formoterol	B-Drug
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O

Corticosteroids	O
,	O
Methylxanthines	O
and	O
Diuretics	B-Drug
:	O
Concomitant	O
treatment	O
with	O
xanthine	O
derivatives	O
,	O
steroids	O
,	O
or	O
diuretics	B-Drug
may	O
potentiate	O
a	O
possible	O
hypokalemic	O
effect	O
of	O
beta2-agonists	O
.	O

Hypokalemia	O
may	O
increase	O
susceptibility	O
to	O
cardiac	O
arrhythmias	O
in	O
patients	O
treated	O
with	O
digitalis	B-Drug
.	O

-adrenergic	O
Blockers	O
:	O
-adrenergic	O
blockers	O
may	O
weaken	O
or	O
antagonise	O
the	O
effect	O
of	O
FORADIL	B-Drug
.	O

Therefore	O
FORADIL	B-Drug
should	O
not	O
be	O
given	O
together	O
with	O
-adrenergic	O
blockers	O
(	O
including	O
eye	O
drops	O
)	O
unless	O
there	O
are	O
compelling	O
reasons	O
for	O
their	O
use	O
.	O

Other	O
Drugs	B-Drug
:	O
Drugs	B-Drug
such	O
as	O
quinidine	B-Drug
,	O
disopyramide	B-Drug
,	O
procainamide	B-Drug
,	O
phenothiazines	O
,	O
antihistamines	B-Drug
,	O
and	O
tricyclic	O
antidepressants	B-Drug
may	O
be	O
associated	O
with	O
QT-interval	O
prolongation	O
and	O
an	O
increased	O
risk	O
of	O
ventricular	O
arrhythmia	O
.	O

INFORMATION	O
TO	O
BE	O
PROVIDED	O
TO	O
THE	O
PATIENT	O
OR	O
GUARDIAN	O
See	O
illustrated	O
Information	O
For	O
The	O
Patient	O
or	O
Guardian	O
section	O
.	O

It	O
is	O
important	O
that	O
patients	O
understand	O
how	O
to	O
use	O
FORADIL	B-Drug
(	O
formoterol	B-Drug
fumarate	I-Drug
)	O
capsules	O
with	O
the	O
supplied	O
AerolizerTM	O
inhalation	O
device	O
and	O
how	O
it	O
should	O
be	O
used	O
in	O
relation	O
to	O
other	O
asthma	O
or	O
COPD	O
medications	O
they	O
are	O
taking	O
.	O

Patients/Guardians	O
should	O
be	O
given	O
the	O
following	O
information	O
:	O
i	O
.	O

The	O
recommended	O
dosage	O
(	O
one	O
or	O
two	O
capsules	O
twice	O
daily	O
,	O
morning	O
and	O
evening	O
)	O
should	O
not	O
be	O
exceeded	O
.	O

ii	O
.	O

FORADIL	B-Drug
is	O
not	O
meant	O
to	O
relieve	O
acute	O
asthma	O
or	O
COPD	O
symptoms	O
and	O
extra	O
doses	O
should	O
not	O
be	O
used	O
for	O
that	O
purpose	O
.	O

Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
a	O
short-acting	O
,	O
inhaled	O
beta2-agonist	O
such	O
as	O
salbutamol	B-Drug
(	O
the	O
physician	O
should	O
provide	O
the	O
patient	O
with	O
such	O
medication	O
and	O
instruct	O
the	O
patient	O
in	O
how	O
it	O
should	O
be	O
used	O
)	O
.	O

iii	O
.	O

The	O
physician	O
should	O
be	O
notified	O
immediately	O
if	O
any	O
of	O
the	O
following	O
situations	O
occur	O
,	O
which	O
may	O
be	O
a	O
sign	O
of	O
seriously	O
worsening	O
asthma	O
:	O
Decreased	O
effectiveness	O
of	O
short-acting	O
,	O
inhaled	O
beta2-agonists	O
;	O
Need	O
for	O
more	O
inhalations	O
than	O
usual	O
of	O
short-acting	O
,	O
inhaled	O
beta2-agonists	O
.	O

iv	O
.	O

FORADIL	B-Drug
should	O
not	O
be	O
used	O
as	O
a	O
substitute	O
for	O
oral	O
or	O
inhaled	O
corticosteroids	O
.	O

The	O
dosage	O
of	O
these	O
medications	O
should	O
not	O
be	O
changed	O
and	O
they	O
should	O
not	O
be	O
stopped	O
without	O
consulting	O
the	O
physician	O
,	O
even	O
if	O
the	O
patient	O
feels	O
better	O
after	O
initiating	O
treatment	O
with	O
FORADIL	B-Drug
.	O

v.	O
Patients	O
should	O
be	O
cautioned	O
regarding	O
potential	O
adverse	O
cardiovascular	O
effects	O
,	O
such	O
as	O
palpitations	O
or	O
chest	O
pain	O
.	O

vi	O
.	O

In	O
patients	O
receiving	O
FORADIL	B-Drug
,	O
other	O
inhaled	O
medications	O
should	O
be	O
used	O
only	O
as	O
directed	O
by	O
the	O
physician	O
.	O

vii	O
.	O

Guardians	O
of	O
children	O
who	O
have	O
been	O
prescribed	O
FORADIL	B-Drug
should	O
be	O
alerted	O
to	O
the	O
general	O
concern	O
regarding	O
asthma	O
therapy	O
compliance	O
,	O
especially	O
neglect	O
of	O
anti-inflammatory	O
therapy	O
and	O
overuse	O
of	O
short-acting	O
beta2-agonists	O
.	O

A	O
possible	O
drug	B-Drug
interaction	O
of	O
FOSCAVIR	B-Drug
and	O
intravenous	O
pentamidine	B-Drug
has	O
been	O
described	O
.	O

Concomitant	O
treatment	O
of	O
four	O
patients	O
in	O
the	O
United	O
Kingdom	O
with	O
FOSCAVIR	B-Drug
and	O
intravenous	O
pentamidine	B-Drug
may	O
have	O
caused	O
hypocalcemia	O
;	O
one	O
patient	O
died	O
with	O
severe	O
hypocalcemia	O
.	O

Toxicity	O
associated	O
with	O
concomitant	O
use	O
of	O
aerosolized	O
pentamidine	B-Drug
has	O
not	O
been	O
reported	O
.	O

Because	O
of	O
foscarnets	B-Drug
tendency	O
to	O
cause	O
renal	O
impairment	O
,	O
the	O
use	O
of	O
FOSCAVIR	B-Drug
should	O
be	O
avoided	O
in	O
combination	O
with	O
potentially	O
nephrotoxic	O
drugs	B-Drug
such	O
as	O
aminoglycosides	O
,	O
amphotericin	B-Drug
B	I-Drug
and	O
intravenous	O
pentamidine	B-Drug
unless	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
to	O
the	O
patient	O
.	O

Since	O
FOSCAVIR	B-Drug
decreases	O
serum	O
concentrations	O
of	O
ionized	O
calcium	B-Drug
,	O
concurrent	O
treatment	O
with	O
other	O
drugs	B-Drug
known	O
to	O
influence	O
serum	O
calcium	B-Drug
concentrations	O
should	O
be	O
used	O
with	O
particular	O
caution	O
.	O

Ganciclovir	B-Drug
:	O
The	O
pharmacokinetics	O
of	O
foscarnet	B-Drug
and	O
ganciclovir	B-Drug
were	O
not	O
altered	O
in	O
13	O
patients	O
receiving	O
either	O
concomitant	O
therapy	O
or	O
daily	O
alternating	O
therapy	O
for	O
maintenance	O
of	O
CMV	O
disease	O
.	O

Metoclopramide	B-Drug
:	O
When	O
coadministered	O
with	O
MONUROL	B-Drug
,	O
metoclopramide	B-Drug
,	O
a	O
drug	B-Drug
which	O
increases	O
gastrointestinal	O
motility	O
,	O
lowers	O
the	O
serum	O
concentration	O
and	O
urinary	O
excretion	O
of	O
fosfomycin	B-Drug
.	O

Other	O
drugs	B-Drug
that	O
increase	O
gastrointestinal	O
motility	O
may	O
produce	O
similar	O
effects	O
.	O

Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
fosfomycin	B-Drug
when	O
coadministered	O
with	O
MONUROL	B-Drug
.	O

Diuretics	B-Drug
:	O
Patients	O
on	O
diuretics	B-Drug
,	O
especially	O
those	O
with	O
intravascular	O
volume	O
depletion	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
fosinopril	B-Drug
sodium	I-Drug
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Drug
or	O
increasing	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
fosinopril	B-Drug
sodium	I-Drug
.	O

If	O
this	O
is	O
not	O
possible	O
,	O
the	O
starting	O
dose	O
should	O
be	O
reduced	O
and	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
several	O
hours	O
following	O
an	O
initial	O
dose	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
(	O
see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
.	O

)	O
Potassium	B-Drug
Supplements	O
and	O
Potassium-Sparing	O
Diuretics	B-Drug
:	O
Fosinopril	B-Drug
sodium	I-Drug
can	O
attenuate	O
potassium	B-Drug
loss	O
caused	O
by	O
thiazide	O
diuretics	B-Drug
.	O

Potassium-sparing	O
diuretics	B-Drug
(	O
spironolactone	B-Drug
,	O
amiloride	B-Drug
,	O
triamterene	B-Drug
,	O
and	O
others	O
)	O
or	O
potassium	B-Drug
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
,	O
they	O
should	O
be	O
given	O
with	O
caution	O
,	O
and	O
the	O
patients	O
serum	O
potassium	B-Drug
should	O
be	O
monitored	O
frequently	O
.	O

Lithium	B-Drug
:	O
Increased	O
serum	O
lithium	B-Drug
levels	O
and	O
symptoms	O
of	O
lithium	B-Drug
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	O
inhibitors	O
during	O
therapy	O
with	O
lithium	B-Drug
.	O

These	O
drugs	B-Drug
should	O
be	O
coadministered	O
with	O
caution	O
,	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	B-Drug
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	B-Drug
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	B-Drug
toxicity	O
may	O
be	O
increased	O
.	O

Antacids	O
:	O
In	O
a	O
clinical	O
pharmacology	O
study	O
,	O
coadministration	O
of	O
an	O
antacid	O
(	O
aluminum	B-Drug
hydroxide	I-Drug
,	O
magnesium	B-Drug
hydroxide	I-Drug
,	O
and	O
simethicone	B-Drug
)	O
with	O
fosinopril	B-Drug
reduced	O
serum	O
levels	O
and	O
urinary	O
excretion	O
of	O
fosinoprilat	B-Drug
as	O
compared	O
with	O
fosinopril	B-Drug
administered	O
alone	O
,	O
suggesting	O
that	O
antacids	O
may	O
impair	O
absorption	O
of	O
fosinopril	B-Drug
.	O

Therefore	O
,	O
if	O
concomitant	O
administration	O
of	O
these	O
agents	O
is	O
indicated	O
,	O
dosing	O
should	O
be	O
separated	O
by	O
2	O
hours	O
.	O

Other	O
:	O
Neither	O
fosinopril	B-Drug
sodium	I-Drug
nor	O
its	O
metabolites	O
have	O
been	O
found	O
to	O
interact	O
with	O
food	O
.	O

In	O
separate	O
single	O
or	O
multiple	O
dose	O
pharmacokinetic	O
interaction	O
studies	O
with	O
chlorthalidone	B-Drug
,	O
nifedipine	B-Drug
,	O
propanolol	B-Drug
,	O
hydrochlorothiazide	B-Drug
,	O
cimetidine	B-Drug
,	O
metoclopramide	B-Drug
,	O
propantheline	B-Drug
,	O
digoxin	B-Drug
,	O
and	O
warfarin	B-Drug
,	O
the	O
bioavailability	O
of	O
fosinoprilat	B-Drug
was	O
not	O
altered	O
by	O
coadministration	O
of	O
fosinopril	B-Drug
with	O
any	O
one	O
of	O
these	O
drugs	B-Drug
.	O

In	O
a	O
study	O
with	O
concomitant	O
administration	O
of	O
aspirin	B-Drug
and	O
fosinopril	B-Drug
sodium	I-Drug
,	O
the	O
bioavailability	O
of	O
unbound	O
fosinoprilat	B-Drug
was	O
not	O
altered	O
.	O

In	O
a	O
pharmacokinetic	O
interaction	O
study	O
with	O
warfarin	B-Drug
,	O
bioavailability	O
parameters	O
,	O
the	O
degree	O
of	O
protein	O
binding	O
,	O
and	O
the	O
anticoagulant	B-Drug
effect	O
(	O
measured	O
by	O
prothrombin	O
time	O
)	O
of	O
warfarin	B-Drug
were	O
not	O
significantly	O
changed	O
.	O

Drug/Laboratory	O
Test	O
Interaction	O
Fosinopril	B-Drug
may	O
cause	O
a	O
false	O
low	O
measurement	O
of	O
serum	O
digoxin	B-Drug
levels	O
with	O
the	O
Digi-	O
Tab	O
RIA	O
Kit	O
for	O
Digoxin	B-Drug
.	O

Other	O
kits	O
,	O
such	O
as	O
the	O
Coat-A-Count	O
RIA	O
Kit	O
,	O
may	O
be	O
used	O
.	O

No	O
drugs	B-Drug
are	O
known	O
to	O
interfere	O
with	O
the	O
conversion	O
of	O
fosphenytoin	B-Drug
to	O
phenytoin	B-Drug
.	O

Conversion	O
could	O
be	O
affected	O
by	O
alterations	O
in	O
the	O
level	O
of	O
phosphatase	O
activity	O
,	O
but	O
given	O
the	O
abundance	O
and	O
wide	O
distribution	O
of	O
phosphatases	O
in	O
the	O
body	O
it	O
is	O
unlikely	O
that	O
drugs	B-Drug
would	O
affect	O
this	O
activity	O
enough	O
to	O
affect	O
conversion	O
of	O
fosphenytoin	B-Drug
to	O
phenytoin	B-Drug
.	O

Drugs	B-Drug
highly	O
bound	O
to	O
albumin	O
could	O
increase	O
the	O
unbound	O
fraction	O
of	O
fosphenytoin	B-Drug
.	O

Although	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
could	O
result	O
in	O
clinically	O
significant	O
effects	O
,	O
caution	O
is	O
advised	O
when	O
administering	O
Cerebyx	B-Drug
with	O
other	O
drugs	B-Drug
that	O
significantly	O
bind	O
to	O
serum	O
albumin	O
.	O

The	O
pharmacokinetics	O
and	O
protein	O
binding	O
of	O
fosphenytoin	B-Drug
,	O
phenytoin	B-Drug
,	O
and	O
diazepam	B-Drug
were	O
not	O
altered	O
when	O
diazepam	B-Drug
and	O
Cerebyx	B-Drug
were	O
concurrently	O
administered	O
in	O
single	O
submaximal	O
doses	O
.	O

The	O
most	O
significant	O
drug	B-Drug
interactions	O
following	O
administration	O
of	O
Cerebyx	B-Drug
are	O
expected	O
to	O
occur	O
with	O
drugs	B-Drug
that	O
interact	O
with	O
phenytoin	B-Drug
.	O

Phenytoin	B-Drug
is	O
extensively	O
bound	O
to	O
serum	O
plasma	O
proteins	O
and	O
is	O
prone	O
to	O
competitive	O
displacement	O
.	O

Phenytoin	B-Drug
is	O
metabolized	O
by	O
hepatic	O
cytochrome	O
P450	O
enzymes	O
and	O
is	O
particularly	O
susceptible	O
to	O
inhibitory	O
drug	B-Drug
interactions	O
because	O
it	O
is	O
subject	O
to	O
saturable	O
metabolism	O
.	O

Inhibition	O
of	O
metabolism	O
may	O
produce	O
significant	O
increases	O
in	O
circulating	O
phenytoin	B-Drug
concentrations	O
and	O
enhance	O
the	O
risk	O
of	O
drug	B-Drug
toxicity	O
.	O

Phenytoin	B-Drug
is	O
a	O
potent	O
inducer	O
of	O
hepatic	O
drug-metabolizing	O
enzymes	O
.	O

The	O
most	O
commonly	O
occurring	O
drug	B-Drug
interactions	O
are	O
listed	O
below	O
:	O
-	O
Drugs	B-Drug
that	O
may	O
increase	O
plasma	O
phenytoin	B-Drug
concentrations	O
include	O
:	O
acute	O
alcohol	B-Drug
intake	O
,	O
amiodarone	B-Drug
,	O
chboramphenicol	O
,	O
chlordiazepoxide	B-Drug
,	O
cimetidine	B-Drug
,	O
diazepam	B-Drug
,	O
dicumarol	B-Drug
,	O
disulfiram	B-Drug
,	O
estrogens	O
,	O
ethosuximide	B-Drug
,	O
fluoxetine	B-Drug
,	O
H2-antagonists	O
,	O
halothane	B-Drug
,	O
isoniazid	B-Drug
,	O
methylphenidate	B-Drug
,	O
phenothiazines	O
,	O
phenylbutazone	B-Drug
,	O
salicylates	O
,	O
succinimides	O
,	O
sulfonamides	O
,	O
tolbutamide	B-Drug
,	O
trazodone	B-Drug
.	O

-	O
Drugs	B-Drug
that	O
may	O
decrease	O
plasma	O
phenytoin	B-Drug
concentrations	O
include	O
:	O
carbamazepine	B-Drug
,	O
chronic	O
alcohol	B-Drug
abuse	O
,	O
reserpine	B-Drug
.	O

-	O
Drugs	B-Drug
that	O
may	O
either	O
increase	O
or	O
decrease	O
plasma	O
phenytoin	B-Drug
concentrations	O
include	O
:	O
phenobarbital	B-Drug
,	O
vaiproic	O
acid	O
,	O
and	O
sodium	B-Drug
valproate	I-Drug
.	O

Similarly	O
,	O
the	O
effects	O
of	O
phenytoin	B-Drug
on	O
phenobarbital	B-Drug
,	O
valproic	B-Drug
acid	I-Drug
and	O
sodium	O
plasma	O
valproate	B-Drug
concentrations	O
are	O
unpredictable	O
.	O

-	O
Although	O
not	O
a	O
true	O
drug	B-Drug
interaction	O
,	O
tricyclic	O
antidepressants	B-Drug
may	O
precipitate	O
seizures	O
in	O
susceptible	O
patients	O
and	O
Cerebyx	B-Drug
dosage	O
may	O
need	O
to	O
be	O
adjusted	O
.	O

-	O
Drugs	B-Drug
whose	O
efficacy	O
is	O
impaired	O
by	O
phenytoin	B-Drug
include	O
:	O
anticoagulants	B-Drug
,	O
corticosteroids	O
,	O
coumarin	O
,	O
digitoxin	B-Drug
,	O
doxycycline	B-Drug
,	O
estrogens	O
,	O
furosemide	B-Drug
,	O
oral	O
contraceptives	O
,	O
rifampin	B-Drug
,	O
quinidine	B-Drug
,	O
theophylline	B-Drug
,	O
vitamin	O
D	O
.	O

Monitoring	O
of	O
plasma	O
phenytoin	B-Drug
concentrations	O
may	O
be	O
helpful	O
when	O
possible	O
drug	B-Drug
interactions	O
are	O
suspected	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Phenytoin	B-Drug
may	O
decrease	O
serum	O
concentrations	O
of	O
14	O
.	O

It	O
may	O
also	O
produce	O
artifactually	O
low	O
results	O
in	O
dexamethasone	B-Drug
or	O
metyrapone	O
tests	O
.	O

Phenytoin	B-Drug
may	O
also	O
cause	O
increased	O
serum	O
concentrations	O
of	O
glucose	B-Drug
,	O
alkaline	O
phosphatase	O
,	O
and	O
gamma	O
glutamyl	O
transpeptidase	O
(	O
GGT	O
)	O
.	O

Care	O
should	O
be	O
taken	O
when	O
using	O
immunoanalytical	O
methods	O
to	O
measure	O
plasma	O
phenytoin	B-Drug
concentrations	O
following	O
Cerebyx	B-Drug
administration	O
.	O

Ergot-containing	O
drugs	B-Drug
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Due	O
to	O
a	O
theoretical	O
risk	O
of	O
a	O
pharmacodynamic	O
interaction	O
,	O
use	O
of	O
ergotamine-containing	B-Drug
or	O
ergot-type	O
medications	O
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
FROVA	B-Drug
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
(	O
see	O
a	O
href=	O
frova_od.htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O
.	O

Concomitant	O
use	O
of	O
other	O
5-HT1B/1D	O
agonists	O
within	O
24	O
hours	O
of	O
FROVA	B-Drug
treatment	O
is	O
not	O
recommended	O
.	O

Selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
(	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
paroxetine	B-Drug
,	O
sertraline	B-Drug
)	O
have	O
been	O
reported	O
,	O
rarely	O
,	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5-HT1	O
agonists	O
.	O

If	O
concomitant	O
treatment	O
with	O
frovatriptan	B-Drug
and	O
an	O
SSRI	O
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
FROVA	B-Drug
is	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O

Fulvestrant	B-Drug
is	O
metabolized	O
by	O
CYP	O
3A4	O
in	O
vitro	O
.	O

Clinical	O
studies	O
of	O
the	O
effect	O
of	O
strong	O
CYP	O
3A4	O
inhibitors	O
on	O
the	O
pharmacokinetics	O
of	O
fulvestrant	B-Drug
have	O
not	O
been	O
performed	O
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
and	O
Impairment	O
of	O
Fertility	O
A	O
two-year	O
carcinogenesis	O
study	O
was	O
conducted	O
in	O
female	O
and	O
male	O
rats	O
,	O
at	O
intramuscular	O
doses	O
of	O
15	O
mg/kg/30	O
days	O
,	O
10	O
mg/rat/30	O
days	O
and	O
10	O
mg/rat/15	O
days	O
.	O

These	O
doses	O
correspond	O
to	O
approximately	O
1-	O
,	O
3-	O
,	O
and	O
5-fold	O
(	O
in	O
females	O
)	O
and	O
1.3-	O
,	O
1.3-	O
,	O
and	O
1.6-fold	O
(	O
in	O
males	O
)	O
the	O
systemic	O
exposure	O
[	O
AUC0-30	O
days	O
]	O
]	O
achieved	O
in	O
women	O
receiving	O
the	O
recommended	O
dose	O
of	O
250	O
mg/month	O
.	O

An	O
increased	O
incidence	O
of	O
benign	O
ovarian	O
granulosa	O
cell	O
tumors	O
and	O
testicular	O
Leydig	O
cell	O
tumors	O
was	O
evident	O
,	O
in	O
females	O
dosed	O
at	O
10	O
mg/rat/15	O
days	O
and	O
males	O
dosed	O
at	O
15	O
mg/rat/30	O
days	O
,	O
respectively	O
.	O

Induction	O
of	O
such	O
tumors	O
is	O
consistent	O
with	O
the	O
pharmacology-related	O
endocrine	O
feedback	O
alterations	O
in	O
gonadotropin	O
levels	O
caused	O
by	O
an	O
antiestrogen	O
.	O

Fulvestrant	B-Drug
was	O
not	O
mutagenic	O
or	O
clastogenic	O
in	O
multiple	O
in	O
vitro	O
tests	O
with	O
and	O
without	O
the	O
addition	O
of	O
a	O
mammalian	O
liver	O
metabolic	O
activation	O
factor	O
(	O
bacterial	O
mutation	O
assay	O
in	O
strains	O
of	O
Salmonella	O
typhimurium	O
and	O
Escherichia	O
coli	O
,	O
in	O
vitro	O
cytogenetics	O
study	O
in	O
human	O
lymphocytes	O
,	O
mammalian	O
cell	O
mutation	O
assay	O
in	O
mouse	O
lymphoma	O
cells	O
and	O
in	O
vivo	O
micronucleus	O
test	O
in	O
rat	O
.	O

In	O
female	O
rats	O
,	O
fulvestrant	B-Drug
administered	O
at	O
doses	O
0.01	O
mg/kg/day	O
(	O
approximately	O
one-hundredth	O
of	O
the	O
human	O
recommended	O
dose	O
based	O
on	O
body	O
surface	O
area	O
[	O
BSA	O
]	O
,	O
for	O
2	O
weeks	O
prior	O
to	O
and	O
for	O
1	O
week	O
following	O
mating	O
,	O
caused	O
a	O
reduction	O
in	O
fertility	O
and	O
embryonic	O
survival	O
.	O

No	O
adverse	O
effects	O
on	O
female	O
fertility	O
and	O
embryonic	O
survival	O
were	O
evident	O
in	O
female	O
animals	O
dosed	O
at	O
0.001	O
mg/kg/day	O
(	O
approximately	O
one-thousandth	O
of	O
the	O
human	O
dose	O
based	O
on	O
BSA	O
)	O
.	O

Restoration	O
of	O
female	O
fertility	O
to	O
values	O
similar	O
to	O
controls	O
was	O
evident	O
following	O
a	O
29-day	O
withdrawal	O
period	O
after	O
dosing	O
at	O
2	O
mg/kg/day	O
(	O
twice	O
the	O
human	O
dose	O
based	O
on	O
BSA	O
)	O
.	O

The	O
effects	O
of	O
fulvestrant	B-Drug
on	O
the	O
fertility	O
of	O
female	O
rats	O
appear	O
to	O
be	O
consistent	O
with	O
its	O
anti-estrogenic	O
activity	O
.	O

The	O
potential	O
effects	O
of	O
fulvestrant	B-Drug
on	O
the	O
fertility	O
of	O
male	O
animals	O
were	O
not	O
studied	O
but	O
in	O
a	O
6-month	O
toxicology	O
study	O
,	O
male	O
rats	O
treated	O
with	O
intramuscular	O
doses	O
of	O
15	O
mg/kg/30	O
days	O
,	O
10	O
mg/rat/30	O
days	O
,	O
or	O
10	O
mg/rat/15	O
days	O
fulvestrant	B-Drug
showed	O
a	O
loss	O
of	O
spermatozoa	O
from	O
the	O
seminiferous	O
tubules	O
,	O
seminiferous	O
tubular	O
atrophy	O
,	O
and	O
degenerative	O
changes	O
in	O
the	O
epididymides	O
.	O

Changes	O
in	O
the	O
testes	O
and	O
epididymides	O
had	O
not	O
recovered	O
20	O
weeks	O
after	O
cessation	O
of	O
dosing	O
.	O

These	O
fulvestrant	B-Drug
doses	O
correspond	O
to	O
approximately	O
2-	O
,	O
3-	O
,	O
and	O
3-fold	O
the	O
systemic	O
exposure	O
[	O
AUC0-30	O
days	O
]	O
achieved	O
in	O
women	O
.	O

Pregnancy	O
Pregnancy	O
Category	O
D	O
:	O
.	O

In	O
studies	O
in	O
female	O
rats	O
at	O
doses	O
0.01	O
mg/kg/day	O
(	O
IM	O
;	O
approximately	O
one-hundredth	O
of	O
the	O
human	O
recommended	O
dose	O
based	O
on	O
body	O
surface	O
area	O
[	O
BSA	O
]	O
)	O
,	O
fulvestrant	B-Drug
caused	O
a	O
reversible	O
reduction	O
in	O
female	O
fertility	O
,	O
as	O
well	O
as	O
effects	O
on	O
embryo/fetal	O
development	O
consistent	O
with	O
its	O
anti-estrogenic	O
activity	O
.	O

Fulvestrant	B-Drug
caused	O
an	O
increased	O
incidence	O
of	O
fetal	O
abnormalities	O
in	O
rats	O
(	O
tarsal	O
flexure	O
of	O
the	O
hind	O
paw	O
at	O
2	O
mg/kg/day	O
IM	O
;	O
twice	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
and	O
non-ossification	O
of	O
the	O
odontoid	O
and	O
ventral	O
tubercle	O
of	O
the	O
first	O
cervical	O
vertebra	O
at	O
doses	O
0.1	O
mg/kg/day	O
IM	O
(	O
approximately	O
one-tenth	O
of	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
when	O
administered	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O

Rabbits	O
failed	O
to	O
maintain	O
pregnancy	O
when	O
dosed	O
with	O
1	O
mg/kg/day	O
fulvestrant	B-Drug
IM	O
(	O
twice	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O

Further	O
,	O
in	O
rabbits	O
dosed	O
at	O
0.25	O
mg/kg/day	O
(	O
about	O
one-half	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
,	O
increases	O
in	O
placental	O
weight	O
and	O
post-implantation	O
loss	O
were	O
observed	O
but	O
,	O
there	O
were	O
no	O
observed	O
effects	O
on	O
fetal	O
development	O
.	O

Fulvestrant	B-Drug
was	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
fetal	O
variations	O
in	O
rabbits	O
(	O
backwards	O
displacement	O
of	O
the	O
pelvic	O
girdle	O
,	O
and	O
27	O
pre-sacral	O
vertebrae	O
at	O
0.25	O
mg/kg/day	O
IM	O
;	O
one-half	O
the	O
human	O
dose	O
on	O
BSA	O
)	O
when	O
administered	O
during	O
the	O
period	O
of	O
organogenesis	O
.	O

Because	O
pregnancy	O
could	O
not	O
be	O
maintained	O
in	O
the	O
rabbit	O
following	O
doses	O
of	O
fulvestrant	B-Drug
of	O
1	O
mg/kg/day	O
and	O
above	O
,	O
this	O
study	O
was	O
inadequate	O
to	O
fully	O
define	O
the	O
possible	O
adverse	O
effects	O
on	O
fetal	O
development	O
at	O
clinically	O
relevant	O
exposures	O
.	O

Nursing	O
Mothers	O
Fulvestrant	B-Drug
is	O
found	O
in	O
rat	O
milk	O
at	O
levels	O
significantly	O
higher	O
(	O
approximately	O
12-fold	O
)	O
than	O
plasma	O
after	O
administration	O
of	O
2	O
mg/kg	O
.	O

Drug	B-Drug
exposure	O
in	O
rodent	O
pups	O
from	O
fulvestrant-treated	B-Drug
lactating	O
dams	O
was	O
estimated	O
as	O
10	O
%	O
of	O
the	O
administered	O
dose	O
.	O

It	O
is	O
not	O
known	O
if	O
fulvestrant	B-Drug
is	O
excreted	O
in	O
human	O
milk	O
.	O

Because	O
many	O
drugs	B-Drug
are	O
excreted	O
in	O
human	O
milk	O
,	O
and	O
because	O
of	O
the	O
potential	O
for	O
serious	O
adverse	O
reactions	O
from	O
FASLODEX	B-Drug
in	O
nursing	O
infants	O
,	O
a	O
decision	O
should	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
or	O
to	O
discontinue	O
the	O
drug	B-Drug
taking	O
into	O
account	O
the	O
importance	O
of	O
the	O
drug	B-Drug
to	O
the	O
mother	O
.	O

Pediatric	O
Use	O
The	O
safety	O
and	O
efficacy	O
of	O
FASLODEX	B-Drug
in	O
pediatric	O
patients	O
have	O
not	O
been	O
established	O
.	O

Geriatric	O
Use	O
When	O
tumor	O
response	O
was	O
considered	O
by	O
age	O
,	O
objective	O
responses	O
were	O
seen	O
in	O
24	O
%	O
and	O
22	O
%	O
of	O
patients	O
under	O
65	O
years	O
of	O
age	O
and	O
in	O
16	O
%	O
and	O
11	O
%	O
of	O
patients	O
65	O
years	O
of	O
age	O
and	O
older	O
,	O
who	O
were	O
treated	O
with	O
FASLODEX	B-Drug
in	O
the	O
European	O
and	O
North	O
American	O
trials	O
,	O
respectively	O
.	O

Furosemide	B-Drug
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
aminoglycoside	O
antibiotics	B-Drug
,	O
especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
.	O

Except	O
in	O
life-threatening	O
situations	O
,	O
avoid	O
this	O
combination	O
.	O

Furosemide	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
ethacrynic	B-Drug
acid	I-Drug
because	O
of	O
the	O
possibility	O
of	O
ototoxicity	O
.	O

Patients	O
receiving	O
high	O
doses	O
of	O
salicylates	O
concomitantly	O
with	O
furosemide	B-Drug
,	O
as	O
in	O
rheumatic	O
disease	O
,	O
may	O
experience	O
salicylate	B-Drug
toxicity	O
at	O
lower	O
doses	O
because	O
of	O
competitive	O
renal	O
excretory	O
sites	O
.	O

Furosemide	B-Drug
has	O
a	O
tendency	O
to	O
antagonize	O
the	O
skeletal	O
muscle	O
relaxing	O
effect	O
of	O
tubocurarine	B-Drug
and	O
may	O
potentiate	O
the	O
action	O
of	O
succinylcholine	B-Drug
.	O

Lithium	B-Drug
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Drug
because	O
they	O
reduce	O
lithiums	B-Drug
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O

Furosemide	B-Drug
may	O
add	O
to	O
or	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
other	O
antihypertensive	B-Drug
drugs	B-Drug
.	O

Potentiation	O
occurs	O
with	O
ganglionic	O
or	O
peripheral	O
adrenergic	O
blocking	O
drugs	B-Drug
.	O

Furosemide	B-Drug
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
.	O

However	O
,	O
norepinephrine	B-Drug
may	O
still	O
be	O
used	O
effectively	O
.	O

Tablets	O
Simultaneous	O
administration	O
of	O
sucralfate	B-Drug
and	O
furosemide	B-Drug
tablets	O
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	B-Drug
effects	O
of	O
furosemide	B-Drug
.	O

Patients	O
receiving	O
both	O
drugs	B-Drug
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
diuretic	B-Drug
and/or	O
antihypertensive	B-Drug
effect	O
of	O
furosemide	B-Drug
is	O
achieved	O
.	O

The	O
intake	O
of	O
furosemide	B-Drug
and	O
sucralfate	B-Drug
should	O
be	O
separated	O
by	O
at	O
least	O
two	O
hours	O
.	O

Tablets	O
,	O
Injection	O
,	O
and	O
Oral	O
Solution	O
One	O
study	O
in	O
six	O
subjects	O
demonstrated	O
that	O
the	O
combination	O
of	O
furosemide	B-Drug
and	O
acetylsalicylic	B-Drug
acid	I-Drug
temporarily	O
reduced	O
creatinine	O
clearance	O
in	O
patients	O
with	O
chronic	O
renal	O
insufficiency	O
.	O

There	O
are	O
case	O
reports	O
of	O
patients	O
who	O
developed	O
increased	O
BUN	O
,	O
serum	O
creatinine	O
and	O
serum	O
potassium	B-Drug
levels	O
,	O
and	O
weight	O
gain	O
when	O
furosemide	B-Drug
was	O
used	O
in	O
conjunction	O
with	O
NSAIDs	O
.	O

Literature	O
reports	O
indicate	O
that	O
coadministration	O
of	O
indomethacin	B-Drug
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	B-Drug
effects	O
of	O
furosemide	B-Drug
in	O
some	O
patients	O
by	O
inhibiting	O
prostaglandin	O
synthesis	O
.	O

Indomethacin	B-Drug
may	O
also	O
affect	O
plasma	O
renin	O
levels	O
,	O
aldosterone	O
excretion	O
,	O
and	O
renin	O
profile	O
evaluation	O
.	O

Patients	O
receiving	O
both	O
indomethacin	B-Drug
and	O
furosemide	B-Drug
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
diuretic	B-Drug
and/or	O
antihypertensive	B-Drug
effect	O
of	O
furosemide	B-Drug
is	O
achieved	O
.	O

In	O
vitro	O
studies	O
were	O
conducted	O
to	O
investigate	O
the	O
potential	O
of	O
gabapentin	B-Drug
to	O
inhibit	O
the	O
major	O
cytochrome	O
P450	O
enzymes	O
(	O
CYP1A2	B-Drug
,	O
CYP2A6	O
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
CYP2D6	B-Drug
,	O
CYP2E1	O
,	O
and	O
CYP3A4	B-Drug
)	O
that	O
mediate	O
drug	B-Drug
and	O
xenobiotic	O
metabolism	O
using	O
isoform	O
selective	O
marker	O
substrates	O
and	O
human	O
liver	O
microsomal	O
preparations	O
.	O

Only	O
at	O
the	O
highest	O
concentration	O
tested	O
(	O
171	O
g/mL	O
;	O
1	O
mM	O
)	O
was	O
a	O
slight	O
degree	O
of	O
inhibition	O
(	O
14	O
%	O
-30	O
%	O
)	O
of	O
isoform	O
CYP2A6	O
observed	O
.	O

No	O
inhibition	O
of	O
any	O
of	O
the	O
other	O
isoforms	O
tested	O
was	O
observed	O
at	O
gabapentin	B-Drug
concentrations	O
up	O
to	O
171	O
mg/mL	O
(	O
approximately	O
15	O
times	O
the	O
Cmax	O
at	O
3600	O
mg/day	O
)	O
.	O

Gabapentin	B-Drug
is	O
not	O
appreciably	O
metabolized	O
nor	O
does	O
it	O
interfere	O
with	O
the	O
metabolism	O
of	O
commonly	O
coadministered	O
antiepileptic	O
drugs	B-Drug
.	O

The	O
drug	B-Drug
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
studies	O
involving	O
healthy	O
adults	O
and	O
adult	O
patients	O
with	O
epilepsy	O
.	O

Phenytoin	B-Drug
:	O
In	O
a	O
single	O
(	O
400	O
mg	O
)	O
and	O
multiple	O
dose	O
(	O
400	O
mg	O
TID	O
)	O
study	O
of	O
Neurontin	B-Drug
in	O
epileptic	O
patients	O
(	O
N=8	O
)	O
maintained	O
on	O
phenytoin	B-Drug
monotherapy	O
for	O
at	O
least	O
2	O
months	O
,	O
gabapentin	B-Drug
had	O
no	O
effect	O
on	O
the	O
steady-state	O
trough	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
and	O
phenytoin	B-Drug
had	O
no	O
effect	O
on	O
gabapentin	B-Drug
pharmacokinetics	O
.	O

Carbamazepine	B-Drug
:	O
Steady-state	O
trough	O
plasma	O
carbamazepine	B-Drug
and	O
carbamazepine	B-Drug
10	I-Drug
,	I-Drug
11	I-Drug
epoxide	I-Drug
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
gabapentin	B-Drug
(	O
400	O
mg	O
TID	O
;	O
N=12	O
)	O
administration	O
.	O

Likewise	O
,	O
gabapentin	B-Drug
pharmacokinetics	O
were	O
unaltered	O
by	O
carbamazepine	B-Drug
administration	O
.	O

Valproic	B-Drug
Acid	I-Drug
:	O
The	O
mean	O
steady-state	O
trough	O
serum	O
valproic	B-Drug
acid	I-Drug
concentrations	O
prior	O
to	O
and	O
during	O
concomitant	O
gabapentin	B-Drug
administration	O
(	O
400	O
mg	O
TID	O
;	O
N=17	O
)	O
were	O
not	O
different	O
and	O
neither	O
were	O
gabapentin	B-Drug
pharmacokinetic	O
parameters	O
affected	O
by	O
valproic	B-Drug
acid	I-Drug
.	O

Phenobarbital	B-Drug
:	O
Estimates	O
of	O
steady-state	O
pharmacokinetic	O
parameters	O
for	O
phenobarbital	B-Drug
or	O
gabapentin	B-Drug
(	O
300	O
mg	O
TID	O
;	O
N=12	O
)	O
are	O
identical	O
whether	O
the	O
drugs	B-Drug
are	O
administered	O
alone	O
or	O
together	O
.	O

Naproxen	B-Drug
:	O
Coadministration	O
(	O
N=18	O
)	O
of	O
naproxen	B-Drug
sodium	I-Drug
capsules	O
(	O
250	O
mg	O
)	O
with	O
Neurontin	B-Drug
(	O
125	O
mg	O
)	O
appears	O
to	O
increase	O
the	O
amount	O
of	O
gabapentin	B-Drug
absorbed	O
by	O
12	O
%	O
to	O
15	O
%	O
.	O

Gabapentin	B-Drug
had	O
no	O
effect	O
on	O
naproxen	B-Drug
pharmacokinetic	O
parameters	O
.	O

These	O
doses	O
are	O
lower	O
than	O
the	O
therapeutic	O
doses	O
for	O
both	O
drugs	B-Drug
.	O

The	O
magnitude	O
of	O
interaction	O
within	O
the	O
recommended	O
dose	O
ranges	O
of	O
either	O
drug	B-Drug
is	O
not	O
known	O
.	O

Hydrocodone	B-Drug
:	O
Coadministration	O
of	O
Neurontin	B-Drug
(	O
125	O
to	O
500	O
mg	O
;	O
N=48	O
)	O
decreases	O
hydrocodone	B-Drug
(	O
10	O
mg	O
;	O
N=50	O
)	O
Cmax	O
and	O
AUC	O
values	O
in	O
a	O
dose-dependent	O
manner	O
relative	O
to	O
administration	O
of	O
hydrocodone	B-Drug
alone	O
;	O
Cmax	O
and	O
AUC	O
values	O
are	O
3	O
%	O
to	O
4	O
%	O
lower	O
,	O
respectively	O
,	O
after	O
administration	O
of	O
125	O
mg	O
Neurontin	B-Drug
and	O
21	O
%	O
to	O
22	O
%	O
lower	O
,	O
respectively	O
,	O
after	O
administration	O
of	O
500	O
mg	O
Neurontin	B-Drug
.	O

The	O
mechanism	O
for	O
this	O
interaction	O
is	O
unknown	O
.	O

Hydrocodone	B-Drug
increases	O
gabapentin	B-Drug
AUC	O
values	O
by	O
14	O
%	O
.	O

The	O
magnitude	O
of	O
interaction	O
at	O
other	O
doses	O
is	O
not	O
known	O
.	O

Morphine	B-Drug
:	O
A	O
literature	O
article	O
reported	O
that	O
when	O
a	O
60-mg	O
controlled-release	O
morphine	B-Drug
capsule	O
was	O
administered	O
2	O
hours	O
prior	O
to	O
a	O
600-mg	O
Neurontin	B-Drug
capsule	O
(	O
N=12	O
)	O
,	O
mean	O
gabapentin	B-Drug
AUC	O
increased	O
by	O
44	O
%	O
compared	O
to	O
gabapentin	B-Drug
administered	O
without	O
morphine	B-Drug
.	O

Morphine	B-Drug
pharmacokinetic	O
parameter	O
values	O
were	O
not	O
affected	O
by	O
administration	O
of	O
Neurontin	B-Drug
2	O
hours	O
after	O
morphine	B-Drug
.	O

The	O
magnitude	O
of	O
interaction	O
at	O
other	O
doses	O
is	O
not	O
known	O
.	O

Cimetidine	B-Drug
:	O
In	O
the	O
presence	O
of	O
cimetidine	B-Drug
at	O
300	O
mg	O
QID	O
(	O
N=12	O
)	O
the	O
mean	O
apparent	O
oral	O
clearance	O
of	O
gabapentin	B-Drug
fell	O
by	O
14	O
%	O
and	O
creatinine	O
clearance	O
fell	O
by	O
10	O
%	O
.	O

Thus	O
cimetidine	B-Drug
appeared	O
to	O
alter	O
the	O
renal	O
excretion	O
of	O
both	O
gabapentin	B-Drug
and	O
creatinine	O
,	O
an	O
endogenous	O
marker	O
of	O
renal	O
function	O
.	O

This	O
small	O
decrease	O
in	O
excretion	O
of	O
gabapentin	B-Drug
by	O
cimetidine	B-Drug
is	O
not	O
expected	O
to	O
be	O
of	O
clinical	O
importance	O
.	O

The	O
effect	O
of	O
gabapentin	B-Drug
on	O
cimetidine	B-Drug
was	O
not	O
evaluated	O
.	O

Oral	O
Contraceptive	O
:	O
Based	O
on	O
AUC	O
and	O
half-life	O
,	O
multiple-dose	O
pharmacokinetic	O
profiles	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
following	O
administration	O
of	O
tablets	O
containing	O
2.5	O
mg	O
of	O
norethindrone	B-Drug
acetate	I-Drug
and	O
50	O
mcg	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
were	O
similar	O
with	O
and	O
without	O
coadministration	O
of	O
gabapentin	B-Drug
(	O
400	O
mg	O
TID	O
;	O
N=13	O
)	O
.	O

The	O
Cmax	O
of	O
norethindrone	B-Drug
was	O
13	O
%	O
higher	O
when	O
it	O
was	O
coadministered	O
with	O
gabapentin	B-Drug
;	O
this	O
interaction	O
is	O
not	O
expected	O
to	O
be	O
of	O
clinical	O
importance	O
.	O

Antacid	O
(	O
Maalox	B-Drug
)	O
:	O
Maalox	B-Drug
reduced	O
the	O
bioavailability	O
of	O
gabapentin	B-Drug
(	O
N=16	O
)	O
by	O
about	O
20	O
%	O
.	O

This	O
decrease	O
in	O
bioavailability	O
was	O
about	O
5	O
%	O
when	O
gabapentin	B-Drug
was	O
administered	O
2	O
hours	O
after	O
Maalox	B-Drug
.	O

It	O
is	O
recommended	O
that	O
gabapentin	B-Drug
be	O
taken	O
at	O
least	O
2	O
hours	O
following	O
Maalox	B-Drug
administration	O
.	O

Effect	O
of	O
Probenecid	B-Drug
:	O
Probenecid	B-Drug
is	O
a	O
blocker	O
of	O
renal	O
tubular	O
secretion	O
.	O

Gabapentin	B-Drug
pharmacokinetic	O
parameters	O
without	O
and	O
with	O
probenecid	B-Drug
were	O
comparable	O
.	O

This	O
indicates	O
that	O
gabapentin	B-Drug
does	O
not	O
undergo	O
renal	O
tubular	O
secretion	O
by	O
the	O
pathway	O
that	O
is	O
blocked	O
by	O
probenecid	B-Drug
.	O

Drug/Laboratory	O
Tests	O
Interactions	O
Because	O
false	O
positive	O
readings	O
were	O
reported	O
with	O
the	O
Ames	O
N-Multistix	O
SG	O
dipstick	O
test	O
for	O
urinary	O
protein	O
when	O
gabapentin	B-Drug
was	O
added	O
to	O
other	O
antiepileptic	O
drugs	B-Drug
,	O
the	O
more	O
specific	O
sulfosalicylic	O
acid	O
precipitation	O
procedure	O
is	O
recommended	O
to	O
determine	O
the	O
presence	O
of	O
urine	O
protein	O
.	O

LABORATORY	O
TEST	O
FINDINGS	O
Asymptomatic	O
,	O
transitory	O
changes	O
in	O
serum	O
iron	B-Drug
have	O
been	O
observed	O
.	O

The	O
clinical	O
significance	O
is	O
unknown	O
.	O

Omniscan	B-Drug
interferes	O
with	O
serum	O
calcium	B-Drug
measurements	O
with	O
some	O
colorimetric	O
(	O
complexometric	O
)	O
methods	O
commonly	O
used	O
in	O
hospitals	O
,	O
resulting	O
in	O
serum	O
calcium	B-Drug
concentrations	O
lower	O
than	O
the	O
true	O
values	O
.	O

Thus	O
,	O
it	O
is	O
recommended	O
not	O
to	O
use	O
such	O
methods	O
for	O
12-24	O
hours	O
after	O
administration	O
of	O
Omniscan	B-Drug
.	O

If	O
such	O
measurements	O
are	O
necessary	O
,	O
the	O
use	O
of	O
other	O
methods	O
is	O
recommended	O
.	O

All	O
patients	O
in	O
whom	O
this	O
effect	O
was	O
observed	O
remained	O
asymptomatic	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

No	O
drug	B-Drug
interactions	O
have	O
been	O
observed	O
with	O
the	O
Vitrasert	B-Drug
Implant	O
.	O

There	O
is	O
limited	O
experience	O
with	O
use	O
of	O
retinal	O
tamponades	O
in	O
conjunction	O
with	O
the	O
Vitrasert	B-Drug
Implant	O
.	O

Substances	O
that	O
are	O
inducers	O
of	O
CYP3A4	B-Drug
activity	O
increase	O
the	O
metabolism	O
of	O
gefitinib	B-Drug
and	O
decrease	O
its	O
plasma	O
concentrations	O
.	O

In	O
patients	O
receiving	O
a	O
potent	O
CYP3A4	B-Drug
inducer	O
such	O
as	O
rifampicin	B-Drug
or	O
phenytoin	B-Drug
,	O
a	O
dose	O
increase	O
to	O
500	O
mg	O
daily	O
should	O
be	O
considered	O
in	O
the	O
absence	O
of	O
severe	O
adverse	O
drug	B-Drug
reaction	O
,	O
and	O
clinical	O
response	O
and	O
adverse	O
events	O
should	O
be	O
carefully	O
monitored	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY-Pharmacokinetics-Drug-Drug	O
Interactions	O
and	O
DOSAGE	O
AND	O
ADMINISTRATION-Dosage	O
Adjustment	O
sections	O
)	O
.	O

International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and/or	O
bleeding	O
events	O
have	O
been	O
reported	O
in	O
some	O
patients	O
taking	O
warfarin	B-Drug
while	O
on	O
IRESSA	B-Drug
therapy	O
.	O

Patients	O
taking	O
warfarin	B-Drug
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O
.	O

Substances	O
that	O
are	O
potent	O
inhibitors	O
of	O
CYP3A4	B-Drug
activity	O
(	O
eg	O
,	O
ketoconazole	B-Drug
and	O
itraconazole	B-Drug
)	O
decrease	O
gefitinib	B-Drug
metabolism	O
and	O
increase	O
gefitinib	B-Drug
plasma	O
concentrations	O
.	O

This	O
increase	O
may	O
be	O
clinically	O
relevant	O
as	O
adverse	O
experiences	O
are	O
related	O
to	O
dose	O
and	O
exposure	O
;	O
therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CYP3A4	B-Drug
inhibitors	O
with	O
IRESSA	B-Drug
.	O

Drugs	B-Drug
that	O
cause	O
significant	O
sustained	O
elevation	O
in	O
gastric	O
pH	O
(	O
histamine	B-Drug
H2-receptor	O
antagonists	O
such	O
as	O
ranitidine	B-Drug
or	O
cimetidine	B-Drug
)	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
IRESSA	B-Drug
and	O
therefore	O
potentially	O
may	O
reduce	O
efficacy	O
.	O

Phase	O
II	O
clinical	O
trial	O
data	O
,	O
where	O
IRESSA	B-Drug
and	O
vinorelbine	B-Drug
have	O
been	O
used	O
concomitantly	O
,	O
indicate	O
that	O
IRESSA	B-Drug
may	O
exacerbate	O
the	O
neutropenic	O
effect	O
of	O
vinorelbine	B-Drug
.	O

No	O
specific	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

For	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
Gemzar	B-Drug
and	O
cisplatin	B-Drug
in	O
combination	O
,	O
see	O
Drug	B-Drug
Interactions	O
under	O
CLINICAL	O
PHARMACOLOGY	O
section	O
.	O

)	O
Clinical	O
Laboratory	O
increased	O
creatine	O
positive	O
antinuclear	O
phosphokinase	O
antibody	O
increased	O
bilirubin	O
increased	O
liver	O
transaminases	O
(	O
AST	O
(	O
SGOT	O
)	O
,	O
ALT	O
(	O
SGPT	O
)	O
increased	O
alkaline	O
phophatase	O
Hematopoietic	O
anemia	O
thrombocytopenia	O
leukopenia	O
bone	O
marrow	O
hypoplasia	O
eosinophilia	O
Immunologic	O
angioedema	O
anaphylaxis	O
laryngeal	O
edema	O
Lupus-like	O
syndrome	O
urticaria	O
vasculitis	O
Integumentary	O
exfoliative	O
dermatitis	O
alopecia	O
rash	O
dermatitis	O
pruritus	O
Administration	O
of	O
repeat	O
doses	O
of	O
FACTIVE	B-Drug
had	O
no	O
effect	O
on	O
the	O
repeat	O
dose	O
pharmacokinetics	O
of	O
theophylline	B-Drug
,	O
digoxin	B-Drug
or	O
an	O
ethinylestradiol/levonorgestrol	B-Drug
oral	O
contraceptive	O
product	O
in	O
healthy	O
subjects	O
.	O

Concomitant	O
administration	O
of	O
FACTIVE	B-Drug
and	O
calcium	B-Drug
carbonate	I-Drug
,	O
cimetidine	B-Drug
,	O
omeprazole	B-Drug
,	O
or	O
an	O
estrogen/progesterone	B-Drug
oral	O
contraceptive	O
produced	O
minor	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
gemifloxacin	B-Drug
,	O
which	O
were	O
considered	O
to	O
be	O
without	O
clinical	O
significance	O
.	O

Concomitant	O
administration	O
of	O
FACTIVE	B-Drug
with	O
probenecid	B-Drug
resulted	O
in	O
a	O
45	O
%	O
increase	O
in	O
systemic	O
exposure	O
to	O
gemifloxacin	B-Drug
.	O

FACTIVE	B-Drug
had	O
no	O
significant	O
effect	O
on	O
the	O
anticoagulant	B-Drug
effect	O
of	O
warfarin	B-Drug
in	O
healthy	O
subjects	O
on	O
stable	O
warfarin	B-Drug
therapy	O
.	O

However	O
,	O
because	O
some	O
quinolones	O
have	O
been	O
reported	O
to	O
enhance	O
the	O
anticoagulant	B-Drug
effects	O
of	O
warfarin	B-Drug
or	O
its	O
derivatives	O
in	O
patients	O
,	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
quinolone	O
antimicrobial	O
is	O
administered	O
concomitantly	O
with	O
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O

Quinolones	O
form	O
chelates	O
with	O
alkaline	O
earth	O
and	O
transition	O
metals	O
.	O

The	O
absorption	O
of	O
oral	O
gemifloxacin	B-Drug
is	O
significantly	O
reduced	O
by	O
the	O
concomitant	O
administration	O
of	O
an	O
antacid	O
containing	O
aluminum	B-Drug
and	O
magnesium	B-Drug
.	O

Magnesium-	B-Drug
and/or	O
aluminum-containing	B-Drug
antacids	O
,	O
products	O
containing	O
ferrous	B-Drug
sulfate	I-Drug
(	O
iron	B-Drug
)	O
,	O
multivitamin	O
preparations	O
containing	O
zinc	B-Drug
or	O
other	O
metal	O
cations	O
,	O
or	O
Videx	B-Drug
(	O
didanosine	B-Drug
)	O
chewable/buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
taken	O
within	O
3	O
hours	O
before	O
or	O
2	O
hours	O
after	O
FACTIVE	B-Drug
.	O

Sucralfate	B-Drug
should	O
not	O
be	O
taken	O
within	O
2	O
hours	O
of	O
FACTIVE	B-Drug
.	O

There	O
have	O
been	O
no	O
formal	O
drug-interaction	O
studies	O
performed	O
with	O
Mylotarg	B-Drug
.	O

The	O
potential	O
for	O
drug-drug	O
interaction	O
with	O
drugs	B-Drug
affected	O
by	O
cytochrome	O
P450	O
enzymes	O
may	O
not	O
be	O
ruled	O
out	O
.	O

Laboratory	O
Test	O
Interactions	O
Mylotarg	B-Drug
is	O
not	O
known	O
to	O
interfere	O
with	O
any	O
routine	O
diagnostic	O
tests	O
.	O

Interactions	O
between	O
COPAXONE	B-Drug
and	O
other	O
drugs	B-Drug
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Results	O
from	O
existing	O
clinical	O
trials	O
suggest	O
no	O
significant	O
interactions	O
between	O
COPAXONE	B-Drug
and	O
other	O
therapies	O
commonly	O
used	O
in	O
MS	O
patients	O
,	O
including	O
the	O
concurrent	O
use	O
of	O
corticosteroids	O
for	O
up	O
to	O
28	O
days	O
.	O

COPAXONE	B-Drug
has	O
not	O
been	O
formally	O
evaluated	O
in	O
combination	O
with	O
Interferon	B-Drug
beta	I-Drug
.	O

However	O
,	O
10	O
patients	O
who	O
switched	O
from	O
therapy	O
with	O
Interferon	B-Drug
beta	I-Drug
to	O
COPAXONE	B-Drug
did	O
not	O
report	O
any	O
serious	O
and	O
unexpected	O
adverse	O
reactions	O
thought	O
to	O
be	O
related	O
to	O
treatment	O
.	O

The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	O
may	O
be	O
potentiated	O
by	O
certain	O
drugs	B-Drug
including	O
nonsteroidal	O
anti-inflammatory	O
agents	O
and	O
other	O
drugs	B-Drug
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	O
,	O
sulfonamides	O
,	O
chloramphenicol	B-Drug
,	O
probenecid	B-Drug
,	O
coumarins	O
,	O
monoamine	O
oxidase	O
inhibitors	O
,	O
and	O
beta	O
adrenergic	O
blocking	O
agents	O
.	O

When	O
such	O
drugs	B-Drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
MICRONASE	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

When	O
such	O
drugs	B-Drug
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
MICRONASE	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O

Certain	O
drugs	B-Drug
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	B-Drug
to	O
loss	O
of	O
control	O
.	O

These	O
drugs	B-Drug
include	O
the	O
thiazides	O
and	O
other	O
diuretics	B-Drug
,	O
corticosteroids	O
,	O
phe-nothiazines	O
,	O
thyroid	B-Drug
products	O
,	O
estrogens	O
,	O
oral	O
contraceptives	O
,	O
phenytoin	B-Drug
,	O
nicotinic	B-Drug
acid	I-Drug
,	O
sympathomimet-ics	O
,	O
calcium	B-Drug
channel	O
blocking	O
drugs	B-Drug
,	O
and	O
isoniazid	B-Drug
.	O

When	O
such	O
drugs	B-Drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
MICRONASE	B-Drug
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O

When	O
such	O
drugs	B-Drug
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
MICRONASE	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

A	O
possible	O
interaction	O
between	O
glyburide	B-Drug
and	O
ciprofloxacin	B-Drug
,	O
a	O
fluoroquinolone	O
antibiotic	O
,	O
has	O
been	O
reported	O
,	O
resulting	O
in	O
a	O
potentiation	O
of	O
the	O
hypoglycemic	O
action	O
of	O
glyburide	B-Drug
.	O

The	O
mechanism	O
for	O
this	O
interaction	O
is	O
not	O
known	O
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B-Drug
and	O
oral	O
hypoglycemic	O
agents	O
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
,	O
topical	O
or	O
vaginal	O
preparations	O
of	O
miconazole	B-Drug
is	O
not	O
known	O
.	O

Metformin	B-Drug
:	O
In	O
a	O
single-dose	O
interaction	O
study	O
in	O
NIDDM	O
subjects	O
,	O
decreases	O
in	O
glyburide	B-Drug
AUC	O
and	O
Cmax	O
were	O
observed	O
,	O
but	O
were	O
highly	O
variable	O
.	O

The	O
single-dose	O
nature	O
of	O
this	O
study	O
and	O
the	O
lack	O
of	O
correlation	O
between	O
glyburide	B-Drug
blood	O
levels	O
and	O
pharmaco-dynamic	O
effects	O
,	O
makes	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
uncertain	O
.	O

Coadministration	O
of	O
gly-buride	O
and	O
metformin	B-Drug
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
either	O
metformin	B-Drug
pharmacokinetics	O
or	O
pharmaco-dynamics	O
.	O

Many	O
other	O
medicines	O
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
glimepiride	B-Drug
or	O
affect	O
your	O
condition	O
.	O

Before	O
taking	O
glimepiride	B-Drug
,	O
tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
medicines	O
:	O
-	O
aspirin	B-Drug
or	O
another	O
salicylate	I-Drug
such	O
as	O
magnesium/choline	B-Drug
salicylate	B-Drug
(	O
Trilisate	B-Drug
)	O
,	O
salsalate	B-Drug
(	O
Disalcid	B-Drug
,	O
others	O
)	O
,	O
choline	B-Drug
salicylate	I-Drug
(	O
Arthropan	B-Drug
)	O
,	O
magnesium	B-Drug
salicylate	I-Drug
(	O
Magan	B-Drug
)	O
,	O
or	O
bismuth	B-Drug
subsalicylate	I-Drug
(	O
Pepto-Bismol	B-Drug
)	O
;	O
-	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	B-Drug
(	O
NSAID	O
)	O
such	O
as	O
ibuprofen	B-Drug
(	O
Motrin	B-Drug
,	O
Advil	B-Drug
,	O
Nuprin	B-Drug
,	O
others	O
)	O
,	O
ketoprofen	B-Drug
(	O
Orudis	B-Drug
,	O
Orudis	B-Drug
KT	I-Drug
,	O
Oruvail	B-Drug
)	O
,	O
diclofenac	B-Drug
(	O
Voltaren	B-Drug
,	O
Cataflam	B-Drug
)	O
,	O
etodolac	B-Drug
(	O
Lodine	B-Drug
)	O
,	O
indomethacin	B-Drug
(	O
Indocin	B-Drug
)	O
,	O
nabumetone	B-Drug
(	O
Relafen	B-Drug
)	O
,	O
oxaprozin	B-Drug
(	O
Daypro	B-Drug
)	O
,	O
and	O
naproxen	B-Drug
(	O
Anaprox	B-Drug
,	O
Naprosyn	B-Drug
,	O
Aleve	B-Drug
)	O
;	O
-	O
a	O
sulfa-based	O
drug	B-Drug
such	O
as	O
sulfamethoxazole-trimethoprim	B-Drug
(	O
Bactrim	O
,	O
Septra	O
)	O
,	O
sulfisoxazole	O
(	O
Gantrisin	O
)	O
,	O
or	O
sulfasalazine	B-Drug
(	O
Azulfidine	O
)	O
;	O
-	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(	O
MAOI	O
)	O
such	O
as	O
isocarboxazid	B-Drug
(	O
Marplan	B-Drug
)	O
,	O
tranylcypromine	B-Drug
(	O
Parnate	B-Drug
)	O
,	O
or	O
phenelzine	B-Drug
(	O
Nardil	B-Drug
)	O
;	O
-	O
a	O
beta-blocker	O
such	O
as	O
propranolol	B-Drug
(	O
Inderal	B-Drug
)	O
,	O
atenolol	B-Drug
(	O
Tenormin	B-Drug
)	O
,	O
acebutolol	B-Drug
(	O
Sectral	B-Drug
)	O
,	O
metoprolol	B-Drug
(	O
Lopressor	B-Drug
)	O
,	O
and	O
others	O
;	O
-	O
a	O
diuretic	B-Drug
(	O
water	O
pill	O
)	O
such	O
as	O
hydrochlorothiazide	B-Drug
(	O
HCTZ	B-Drug
,	O
Hydrodiuril	B-Drug
)	O
,	O
chlorothiazide	B-Drug
(	O
Diuril	B-Drug
)	O
,	O
and	O
others	O
;	O
-	O
a	O
steroid	O
medicine	O
such	O
as	O
prednisone	B-Drug
(	O
Deltasone	B-Drug
,	O
Orasone	B-Drug
,	O
others	O
)	O
,	O
methylprednisolone	B-Drug
(	O
Medrol	B-Drug
,	O
others	O
)	O
,	O
prednisolone	B-Drug
(	O
Prelone	B-Drug
,	O
Pediapred	B-Drug
,	O
others	O
)	O
,	O
and	O
others	O
;	O
-	O
a	O
phenothiazine	O
such	O
as	O
chlorpromazine	B-Drug
(	O
Thorazine	B-Drug
)	O
,	O
fluphenazine	B-Drug
(	O
Prolixin	B-Drug
,	O
Permitil	B-Drug
)	O
,	O
prochlorperazine	B-Drug
(	O
Compazine	B-Drug
)	O
,	O
promethazine	B-Drug
(	O
Phenergan	B-Drug
)	O
,	O
and	O
others	O
;	O
-	O
phenytoin	B-Drug
(	O
Dilantin	B-Drug
)	O
;	O
-	O
isoniazid	B-Drug
(	O
Nydrazid	B-Drug
)	O
;	O
-	O
rifampin	B-Drug
(	O
Rifadin	B-Drug
,	O
Rifamate	B-Drug
)	O
;	O
or	O
-	O
over-the-counter	O
cough	O
,	O
cold	O
,	O
allergy	O
,	O
or	O
weight	O
loss	O
medications	O
.	O

You	O
may	O
require	O
a	O
dosage	O
adjustment	O
or	O
special	O
monitoring	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
medicines	O
listed	O
above	O
.	O

Drugs	B-Drug
other	O
than	O
those	O
listed	O
here	O
may	O
also	O
interact	O
with	O
glimepiride	B-Drug
or	O
affect	O
your	O
condition	O
.	O

Talk	O
to	O
your	O
doctor	O
and	O
pharmacist	O
before	O
taking	O
any	O
prescription	O
or	O
over-the-counter	O
medicines	O
,	O
including	O
herbal	O
products	O
.	O

Immediate	O
and	O
Extended	O
Release	O
Tablets	O
The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	O
may	O
be	O
potentiated	O
by	O
certain	O
drugs	B-Drug
including	O
nonsteroidal	O
anti-inflammatory	O
agents	O
,	O
some	O
azoles	O
and	O
other	O
drugs	B-Drug
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	O
,	O
sulfonamides	O
,	O
chloramphenicol	B-Drug
,	O
probenecid	B-Drug
,	O
coumarins	O
,	O
monoamine	O
oxidase	O
inhibitors	O
,	O
and	O
beta	O
adrenergic	O
blocking	O
agents	O
.	O

When	O
such	O
drugs	B-Drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
glipizide	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

When	O
such	O
drugs	B-Drug
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
glipizide	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
loss	O
of	O
control	O
.	O

In	O
vitro	O
binding	O
studies	O
with	O
human	O
serum	O
proteins	O
indicate	O
that	O
glipizide	B-Drug
binds	O
differently	O
than	O
tolbutamide	B-Drug
and	O
does	O
not	O
interact	O
with	O
salicylate	B-Drug
or	O
dicumarol	B-Drug
.	O

However	O
,	O
caution	O
must	O
be	O
exercised	O
in	O
extrapolating	O
these	O
findings	O
to	O
the	O
clinical	O
situation	O
and	O
in	O
the	O
use	O
of	O
glipizide	B-Drug
with	O
these	O
drugs	B-Drug
.	O

Certain	O
drugs	B-Drug
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	B-Drug
to	O
loss	O
of	O
control	O
.	O

These	O
drugs	B-Drug
include	O
the	O
thiazides	O
and	O
other	O
diuretics	B-Drug
,	O
corticosteroids	O
,	O
phenothiazines	O
,	O
thyroid	B-Drug
products	O
,	O
estrogens	O
,	O
oral	O
contraceptives	O
,	O
phenytoin	B-Drug
,	O
nicotinic	B-Drug
acid	I-Drug
,	O
sympathomimetics	O
,	O
calcium	B-Drug
channel	O
blocking	O
drugs	B-Drug
,	O
and	O
isoniazid	B-Drug
.	O

When	O
such	O
drugs	B-Drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
glipizide	B-Drug
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
control	O
.	O

When	O
such	O
drugs	B-Drug
are	O
withdrawn	O
from	O
a	O
patient	O
receiving	O
glipizide	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
hypoglycemia	O
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B-Drug
and	O
oral	O
hypoglycemic	O
agents	O
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Whether	O
this	O
interaction	O
also	O
occurs	O
with	O
the	O
intravenous	O
,	O
topical	O
,	O
or	O
vaginal	O
preparations	O
of	O
miconazole	B-Drug
is	O
not	O
known	O
.	O

The	O
effect	O
of	O
concomitant	O
administration	O
of	O
fluconazole	B-Drug
and	O
glipizide	B-Drug
has	O
been	O
demonstrated	O
in	O
a	O
placebo-controlled	O
crossover	O
study	O
in	O
normal	O
volunteers	O
.	O

All	O
subjects	O
received	O
glipizide	B-Drug
alone	O
and	O
following	O
treatment	O
with	O
100	O
mg	O
of	O
fluconazole	B-Drug
as	O
a	O
single	O
daily	O
oral	O
dose	O
for	O
seven	O
days	O
.	O

The	O
mean	O
percentage	O
increase	O
in	O
the	O
glipizide	B-Drug
AUC	O
after	O
fluconazole	B-Drug
administration	O
was	O
56.9	O
%	O
(	O
range	O
:	O
35	O
to	O
81	O
)	O
.	O

The	O
concurrent	O
use	O
of	O
Robinul	B-Drug
Injection	O
with	O
other	O
anticholinergics	O
or	O
medications	O
with	O
anticholinergic	B-Drug
activity	O
,	O
such	O
as	O
phenothiazines	O
,	O
antiparkinson	O
drugs	B-Drug
,	O
or	O
tricyclic	O
antidepressants	B-Drug
,	O
may	O
intensify	O
the	O
antimuscarinic	O
effects	O
and	O
may	O
result	O
in	O
an	O
increase	O
in	O
anticholinergic	B-Drug
side	O
effects	O
.	O

Concomitant	O
administration	O
of	O
Robinul	B-Drug
Injection	O
and	O
potassium	B-Drug
chloride	I-Drug
in	O
a	O
wax	O
matrix	O
may	O
increase	O
the	O
severity	O
of	O
potassium	B-Drug
chloride-induced	O
gastrointestinal	O
lesions	O
as	O
a	O
result	O
of	O
a	O
slower	O
gastrointestinal	O
transit	O
time	O
.	O

The	O
Factrel	B-Drug
test	O
should	O
be	O
conducted	O
in	O
the	O
absence	O
of	O
other	O
drugs	B-Drug
which	O
directly	O
affect	O
the	O
pituitary	O
secretion	O
of	O
the	O
gonadotropins	O
.	O

These	O
would	O
include	O
a	O
variety	O
of	O
preparations	O
which	O
contain	O
androgens	O
,	O
estrogens	O
,	O
progestins	O
,	O
or	O
glucocorticoids	O
.	O

The	O
gonadotropin	O
levels	O
may	O
be	O
transiently	O
elevated	O
by	O
spironolactone	B-Drug
,	O
minimally	O
elevated	O
by	O
levodopa	B-Drug
,	O
and	O
suppressed	O
by	O
oral	O
contraceptives	O
and	O
digoxin	B-Drug
.	O

The	O
response	O
to	O
Factrel	B-Drug
may	O
be	O
blunted	O
by	O
phenothiazines	O
and	O
dopamine	B-Drug
antagonists	O
which	O
cause	O
a	O
rise	O
in	O
prolactin	O
.	O

No	O
formal	O
drug-drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

No	O
confirmed	O
interactions	O
have	O
been	O
reported	O
between	O
ZOLADEX	B-Drug
and	O
other	O
drugs	B-Drug
Antacids	O
,	O
Sucralfate	B-Drug
,	O
Metal	O
Cations	O
,	O
Multivitamins	O
Quinolones	O
form	O
chelates	O
with	O
alkaline	O
earth	O
and	O
transition	O
metal	O
cations	O
.	O

Administration	O
of	O
quinolones	O
with	O
antacids	O
containing	O
aluminum	B-Drug
,	O
magnesium	B-Drug
,	O
or	O
calcium	B-Drug
,	O
with	O
sucralfate	B-Drug
,	O
with	O
metal	O
cations	O
such	O
as	O
iron	B-Drug
,	O
or	O
with	O
multivitamins	O
containing	O
iron	B-Drug
or	O
zinc	B-Drug
,	O
or	O
with	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
VIDEX	B-Drug
(	O
didanosine	B-Drug
)	O
chewable/buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
,	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	O
,	O
resulting	O
in	O
systemic	O
concentrations	O
considerably	O
lower	O
than	O
desired	O
.	O

These	O
agents	O
should	O
not	O
be	O
taken	O
within	O
4	O
hours	O
before	O
or	O
4	O
hours	O
after	O
grepafloxacin	B-Drug
administration	O
.	O

Caffeine	B-Drug
Theobromine	B-Drug
Grepafloxacin	B-Drug
,	O
like	O
other	O
quinolones	O
,	O
may	O
inhibit	O
the	O
metabolism	O
of	O
caffeine	B-Drug
and	O
theobromine	B-Drug
.	O

These	O
stimulants	O
are	O
commonly	O
found	O
in	O
coffee	O
and	O
tea	O
,	O
respectively	O
.	O

In	O
some	O
patients	O
,	O
this	O
may	O
lead	B-Drug
to	O
reduced	O
clearance	O
,	O
prolongation	O
of	O
plasma	O
half-life	O
,	O
and	O
enhanced	O
effects	O
of	O
caffeine	B-Drug
and	O
theobromine	B-Drug
.	O

Theophylline	B-Drug
:	O
Grepafloxacin	B-Drug
is	O
a	O
competitive	O
inhibitor	O
of	O
the	O
metabolism	O
of	O
theophylline	B-Drug
.	O

Serum	O
theophylline	B-Drug
concentrations	O
increase	O
when	O
grepafloxacin	B-Drug
is	O
initiated	O
in	O
a	O
patient	O
maintained	O
on	O
theophylline	B-Drug
.	O

When	O
initiating	O
a	O
multi-day	O
course	O
of	O
grepafloxacin	B-Drug
in	O
a	O
patient	O
maintained	O
on	O
theophylline	B-Drug
,	O
the	O
theophylline	B-Drug
maintenance	O
dose	O
should	O
be	O
halved	O
for	O
the	O
period	O
of	O
concurrent	O
use	O
of	O
grepafloxacin	B-Drug
and	O
monitoring	O
of	O
serum	O
theophylline	B-Drug
concentrations	O
should	O
be	O
initiated	O
as	O
a	O
guide	O
to	O
further	O
dosage	O
adjustments	O
.	O

Warfarin	B-Drug
:	O
In	O
subjects	O
receiving	O
warfarin	B-Drug
,	O
no	O
significant	O
change	O
in	O
clotting	O
time	O
was	O
observed	O
when	O
grepafloxacin	B-Drug
was	O
coadministered	O
.	O

However	O
,	O
because	O
some	O
quinolones	O
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
warfarin	B-Drug
or	O
its	O
derivatives	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
anticoagulation	O
test	O
should	O
be	O
monitored	O
closely	O
if	O
a	O
quinolone	O
antimicrobial	O
is	O
administered	O
with	O
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
Cytochrome	O
P450	O
Enzymes	O
The	O
drug	B-Drug
interaction	O
study	O
evaluating	O
the	O
effect	O
of	O
grepafloxacin	B-Drug
on	O
theophylline	B-Drug
indicates	O
that	O
grepafloxacin	B-Drug
inhibits	O
theophylline	B-Drug
metabolism	O
,	O
which	O
is	O
mediated	O
by	O
CYP1A2	B-Drug
.	O

While	O
no	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
grepafloxacin	B-Drug
on	O
the	O
metabolism	O
of	O
C.P.A	O
.	O

substrates	O
,	O
in	O
vitro	O
data	O
suggest	O
similar	O
effects	O
of	O
grepafloxacin	B-Drug
in	O
CYP3A4	B-Drug
mediated	O
metabolism	O
and	O
theophylline	B-Drug
metabolism	O
.	O

In	O
addition	O
,	O
other	O
quinolones	O
have	O
been	O
reported	O
to	O
decrease	O
the	O
CYP3A4-mediated	O
metabolism	O
of	O
cyclosporine	B-Drug
.	O

Other	O
drugs	B-Drug
metabolized	O
by	O
C.P.A	O
.	O

include	O
terfenadine	B-Drug
,	O
astemizole	B-Drug
,	O
cisapride	B-Drug
,	O
midazolam	B-Drug
,	O
and	O
triazolam	B-Drug
.	O

The	O
clinical	O
relevance	O
of	O
the	O
potential	O
effect	O
of	O
grepafloxacin	B-Drug
on	O
the	O
metabolism	O
of	O
C.P.A	O
.	O

substrates	O
is	O
not	O
known	O
.	O

Patients	O
receiving	O
concurrent	O
administration	O
of	O
substrates	O
of	O
C.P.A	O
.	O

were	O
not	O
excluded	O
from	O
clinical	O
trials	O
of	O
grepafloxacin	B-Drug
.	O

Nonsteroidal	O
Anti-inflammatory	O
Drugs	B-Drug
(	O
NSAIDs	O
)	O
:	O
The	O
concomitant	O
administration	O
of	O
a	O
nonsteroidal	O
anti	O
inflammatory	O
drug	B-Drug
with	O
a	O
quinolone	O
may	O
increase	O
the	O
risks	O
of	O
CNS	O
stimulation	O
and	O
convulsions	O
.	O

Antidiabetic	B-Drug
Agents	O
:	O
Disturbances	O
of	O
blood	O
glucose	B-Drug
,	O
including	O
hyperglycemia	O
and	O
hypoglycemia	O
,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
concomitantly	O
with	O
quinolones	O
and	O
an	O
antidiabetic	B-Drug
agent	O
.	O

Therefore	O
,	O
careful	O
monitoring	O
of	O
blood	O
glucose	B-Drug
is	O
recommended	O
when	O
these	O
agents	O
are	O
coadministered	O
.	O

Patients	O
on	O
warfarin-type	B-Drug
anticoagulant	B-Drug
therapy	O
may	O
require	O
dosage	O
adjustment	O
of	O
the	O
anticoagulant	B-Drug
during	O
and	O
after	O
griseofulvin	B-Drug
therapy	O
.	O

Concomitant	O
use	O
of	O
barbiturates	B-Drug
usually	O
depresses	O
griseofulvin	B-Drug
activity	O
and	O
may	O
necessitate	O
raising	O
the	O
dosage	O
.	O

The	O
concomitant	O
administration	O
of	O
griseofulvin	B-Drug
has	O
been	O
reported	O
to	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	O
and	O
to	O
increase	O
the	O
incidence	O
of	O
breakthrough	O
bleeding	O
.	O

The	O
use	O
of	O
codeine	B-Drug
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	B-Drug
,	O
antihistamines	B-Drug
,	O
psychotropics	O
or	O
other	O
drugs	B-Drug
that	O
produce	O
CNS	O
depression	O
.	O

Serious	O
toxicity	O
may	O
result	O
if	O
dextromethorphan	B-Drug
is	O
coadministered	O
with	O
monoamine	O
oxidase	O
inhibitors	O
(	O
MAOIs	O
)	O
.	O

The	O
use	O
of	O
dextromethorphan	B-Drug
hydrobromide	I-Drug
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	B-Drug
,	O
antihistamines	B-Drug
,	O
psychotropics	O
or	O
other	O
drugs	B-Drug
that	O
produce	O
CNS	O
depression	O
.	O

http	O
:	O
//www.rxlist.com/cgi/generic3/guanethidine_od.htm	O
The	O
potential	O
for	O
increased	O
sedation	O
when	O
guanfacine	B-Drug
is	O
given	O
with	O
other	O
CNS-depressant	O
drug	B-Drug
should	O
be	O
appreciated	O
.	O

The	O
administration	O
of	O
guanfacine	B-Drug
concomitantly	O
with	O
known	O
microsomal	O
enzyme	O
inducer	O
(	O
phenobarbital	B-Drug
or	O
phenytoin	B-Drug
)	O
to	O
two	O
patients	O
with	O
renal	O
impairment	O
reportedly	O
resulted	O
in	O
significant	O
reductions	O
in	O
elimination	O
half-life	O
and	O
plasma	O
concentration	O
.	O

In	O
such	O
cases	O
,	O
therefore	O
,	O
more	O
frequent	O
dosing	O
may	O
be	O
required	O
to	O
achieve	O
or	O
maintain	O
the	O
desired	O
hypotensive	O
response	O
.	O

Further	O
,	O
if	O
guanfacine	B-Drug
is	O
to	O
be	O
discontinued	O
in	O
such	O
patients	O
,	O
careful	O
tapering	O
of	O
the	O
dosage	O
may	O
be	O
necessary	O
in	O
order	O
to	O
avoid	O
rebound	O
phenomena	O
.	O

TCAs	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
guanfacine	B-Drug
.	O

Noncardioselective	O
beta-blockers	O
(	O
nadolol	B-Drug
,	O
porpranolol	O
,	O
timolol	B-Drug
)	O
may	O
exacerbate	O
rebound	O
hypertension	O
when	O
guanfacine	B-Drug
is	O
withdrawn	O
.	O

The	O
beta-blocker	O
should	O
be	O
withdrawn	O
first	O
.	O

The	O
gradual	O
withdrawal	O
of	O
guafacine	B-Drug
or	O
a	O
cardioselective	O
beta-blocker	O
could	O
be	O
substituted	O
.	O

Anticoagulants	B-Drug
:	O
Ten	O
patients	O
who	O
were	O
stabilized	O
on	O
oral	O
anticoagulants	B-Drug
were	O
given	O
guanfacine	B-Drug
,	O
1-2	O
mg/day	O
,	O
for	O
4	O
weeks	O
.	O

No	O
changes	O
were	O
observed	O
in	O
the	O
degree	O
of	O
anticoagulation	O
.	O

In	O
several	O
well-controlled	O
studies	O
,	O
guanfacine	B-Drug
was	O
administered	O
together	O
with	O
diuretics	B-Drug
with	O
no	O
drug	B-Drug
interactions	O
reported	O
.	O

In	O
the	O
long-term	O
safety	O
studies	O
,	O
guanfacine	B-Drug
was	O
given	O
concomitantly	O
with	O
many	O
drugs	B-Drug
without	O
evidence	O
of	O
any	O
interactions	O
.	O

The	O
principal	O
drugs	B-Drug
given	O
(	O
number	O
of	O
patients	O
in	O
parentheses	O
)	O
were	O
:	O
cardiac	O
glycosides	O
(	O
115	O
)	O
,	O
sedatives	O
and	O
hypnotics	O
(	O
103	O
)	O
,	O
coronary	O
vasodilators	O
(	O
52	O
)	O
,	O
oral	O
hypoglycemics	O
(	O
45	O
)	O
,	O
cough	O
and	O
cold	O
preparations	O
(	O
45	O
)	O
,	O
NSAIDs	O
(	O
38	O
)	O
,	O
antihyperlipidemics	O
(	O
29	O
)	O
,	O
antigout	O
drugs	B-Drug
(	O
24	O
)	O
,	O
oral	O
contraceptives	O
(	O
18	O
)	O
,	O
bronchodilators	O
(	O
13	O
)	O
,	O
insulin	B-Drug
(	O
10	O
)	O
,	O
and	O
beta	O
blockers	O
(	O
10	O
)	O
.	O

Laboratory	O
Test	O
In	O
clinical	O
trials	O
,	O
no	O
clinically	O
relevant	O
laboratory	O
test	O
abnormalities	O
were	O
identified	O
as	O
causally	O
related	O
to	O
drug	B-Drug
during	O
short-term	O
treatment	O
with	O
guanfacine	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
No	O
laboratory	O
test	O
abnormalities	O
related	O
to	O
the	O
use	O
of	O
guanfacine	B-Drug
have	O
been	O
identified	O
.	O

An	O
encephalopathic	O
syndrome	O
(	O
characterized	O
by	O
weakness	O
,	O
lethargy	O
,	O
fever	O
,	O
tremulousness	O
and	O
confusion	O
,	O
extrapyramidal	O
symptoms	O
,	O
leukocytosis	O
,	O
elevated	O
serum	O
enzymes	O
,	O
BUN	O
,	O
and	O
FBS	O
)	O
followed	O
by	O
irreversible	O
brain	O
damage	O
has	O
occurred	O
in	O
a	O
few	O
patients	O
treated	O
with	O
lithium	B-Drug
plus	O
HALDOL	B-Drug
.	O

A	O
causal	O
relationship	O
between	O
these	O
events	O
and	O
the	O
concomitant	O
administration	O
of	O
lithium	B-Drug
and	O
HALDOL	B-Drug
has	O
not	O
been	O
established	O
;	O
however	O
,	O
patients	O
receiving	O
such	O
combined	O
therapy	O
should	O
be	O
monitored	O
closely	O
for	O
early	O
evidence	O
of	O
neurological	O
toxicity	O
and	O
treatment	O
discontinued	O
promptly	O
if	O
such	O
signs	O
appear	O
.	O

As	O
with	O
other	O
antipsychotic	O
agents	O
,	O
it	O
should	O
be	O
noted	O
that	O
HALDOL	B-Drug
may	O
be	O
capable	O
of	O
potentiating	O
CNS	O
depressants	O
such	O
as	O
anesthetics	B-Drug
,	O
opiates	O
,	O
and	O
alcohol	B-Drug
.	O

In	O
a	O
study	O
of	O
12	O
schizophrenic	O
patients	O
coadministered	O
oral	O
haloperidol	B-Drug
and	O
rifampin	B-Drug
,	O
plasma	O
haloperidol	B-Drug
levels	O
were	O
decreased	O
by	O
a	O
mean	O
of	O
70	O
%	O
and	O
mean	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
were	O
increased	O
from	O
baseline	O
.	O

In	O
5	O
other	O
schizophrenic	O
patients	O
treated	O
with	O
oral	O
haloperidol	B-Drug
and	O
rifampin	B-Drug
,	O
discontinuation	O
of	O
rifampin	B-Drug
produced	O
a	O
mean	O
3.3-fold	O
increase	O
in	O
haloperidol	B-Drug
concentrations	O
.	O

Thus	O
,	O
careful	O
monitoring	O
of	O
clinical	O
status	O
is	O
warranted	O
when	O
rifampin	B-Drug
is	O
administered	O
or	O
discontinued	O
in	O
haloperidol-treated	B-Drug
patients	O
.	O

FLUOTHANE	B-Drug
augments	O
the	O
action	O
of	O
non-depolarising	O
muscle	O
relaxants	O
and	O
the	O
muscle	O
relaxant	O
effects	O
of	O
aminoglycosides	O
.	O

FLUOTHANE	B-Drug
may	O
augment	O
the	O
hypotension	O
caused	O
by	O
the	O
ganglionic-blocking	O
effect	O
of	O
tubocurarine	B-Drug
.	O

Caution	O
should	O
be	O
exercised	O
during	O
the	O
administration	O
of	O
adrenaline	B-Drug
to	O
patients	O
anaesthetised	O
with	O
FLUOTHANE	B-Drug
as	O
arrhythmias	O
may	O
be	O
precipitated	O
.	O

For	O
this	O
reason	O
the	O
dose	O
of	O
adrenaline	B-Drug
should	O
be	O
restricted	O
and	O
an	O
antiarrhythmic	B-Drug
agent	O
administered	O
as	O
appropriate	O
.	O

Caution	O
should	O
also	O
be	O
applied	O
for	O
other	O
sympathomimetics	O
,	O
and	O
for	O
aminophylline	B-Drug
and	O
theophylline	B-Drug
and	O
tricyclic	O
antidepressants	B-Drug
,	O
which	O
may	O
also	O
precipitate	O
arrhythmias	O
.	O

Drug	B-Drug
Interactions	O
:	O
a	O
.	O

Drugs	B-Drug
Enhancing	O
Heparin	B-Drug
Effect	O
:	O
Oral	O
anticoagulants	B-Drug
:	O
Heparin	B-Drug
sodium	I-Drug
may	O
prolong	O
the	O
one-stage	O
prothrombin	O
time	O
.	O

Therefore	O
,	O
when	O
heparin	B-Drug
sodium	I-Drug
is	O
given	O
with	O
dicumarol	B-Drug
or	O
warfarin	B-Drug
sodium	I-Drug
,	O
a	O
period	O
of	O
at	O
least	O
5	O
hours	O
after	O
the	O
last	O
intravenous	O
dose	O
or	O
24	O
hours	O
after	O
the	O
last	O
subcutaneous	O
dose	O
should	O
elapse	O
before	O
blood	O
is	O
drawn	O
if	O
a	O
valid	O
prothrombin	O
time	O
is	O
to	O
be	O
obtained	O
.	O

Platelet	O
inhibitors	O
:	O
Drugs	B-Drug
such	O
as	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
dextran	B-Drug
,	O
phenylbutazone	B-Drug
,	O
ibuprofen	B-Drug
,	O
indomethacin	B-Drug
,	O
dipyridamole	B-Drug
,	O
hydroxychloroquine	B-Drug
and	O
others	O
that	O
interfere	O
with	O
platelet-aggregation	O
reactions	O
(	O
the	O
main	O
hemostatic	O
defense	O
of	O
heparinized	B-Drug
patients	O
)	O
may	O
induce	O
bleeding	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
heparin	B-Drug
sodium	O
.	O

The	O
anticoagulant	B-Drug
effect	O
of	O
heparin	B-Drug
is	O
enhanced	O
by	O
concurrent	O
treatment	O
with	O
antithrombin	B-Drug
III	I-Drug
(	O
human	O
)	O
in	O
patients	O
with	O
hereditary	O
antithrombin	O
III	O
deficiency	O
.	O

Thus	O
in	O
order	O
to	O
avoid	O
bleeding	O
,	O
reduced	O
dosage	O
of	O
heparin	B-Drug
is	O
recommended	O
during	O
treatment	O
with	O
antithrombin	B-Drug
III	I-Drug
(	O
human	O
)	O
.	O

b	O
.	O

Drugs	B-Drug
Decreasing	O
Heparin	B-Drug
Effect	O
:	O
Digitalis	B-Drug
,	O
tetracyclines	O
,	O
nicotine	B-Drug
,	O
or	O
antihistamines	B-Drug
may	O
partially	O
counteract	O
the	O
anticoagulant	B-Drug
action	O
of	O
heparin	B-Drug
sodium	I-Drug
.	O

Heparin	B-Drug
Sodium	I-Drug
Injection	O
should	O
not	O
be	O
mixed	O
with	O
doxorubicin	B-Drug
,	O
droperidol	B-Drug
,	O
ciprofloxacin	B-Drug
,	O
or	O
mitoxantrone	B-Drug
,	O
since	O
it	O
has	O
been	O
reported	O
that	O
these	O
drugs	B-Drug
are	O
incompatible	O
with	O
heparin	B-Drug
and	O
a	O
precipitate	O
may	O
form	O
.	O

Drug/	O
Laboratory	O
Tests	O
Interactions	O
Hyperaminotransferasemia	O
:	O
Significant	O
elevations	O
of	O
aminotransferase	O
(	O
SGOT	O
[	O
S-AST	O
]	O
and	O
SGPT	O
[	O
S-ALT	O
]	O
)	O
levels	O
have	O
occurred	O
in	O
a	O
high	O
percentage	O
of	O
patients	O
(	O
and	O
healthy	O
subjects	O
)	O
who	O
have	O
received	O
heparin	B-Drug
sodium	I-Drug
.	O

Since	O
aminotransferase	O
determinations	O
are	O
important	O
in	O
the	O
differential	O
diagnosis	O
of	O
myocardial	O
infarction	O
,	O
liver	O
disease	O
and	O
pulmonary	O
emboli	O
,	O
rises	O
that	O
might	O
be	O
caused	O
by	O
drugs	B-Drug
(	O
heparin	B-Drug
sodium	I-Drug
)	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

Opioids	O
are	O
strong	O
central	O
nervous	O
system	O
depressants	O
,	O
but	O
regular	O
users	O
develop	O
physiological	O
tolerance	O
allowing	O
gradually	O
increased	O
dosages	O
.	O

In	O
combination	O
with	O
other	O
central	O
nervous	O
system	O
depressants	O
,	O
heroin	B-Drug
may	O
still	O
kill	O
even	O
experienced	O
users	O
,	O
particularly	O
if	O
their	O
tolerance	O
to	O
the	O
drug	B-Drug
has	O
reduced	O
or	O
the	O
strength	O
of	O
their	O
usual	O
dose	O
has	O
increased	O
.	O

Toxicology	O
studies	O
of	O
heroin-related	B-Drug
deaths	O
reveal	O
frequent	O
involvement	O
of	O
other	O
central	O
nervous	O
system	O
depressants	O
,	O
including	O
alcohol	B-Drug
,	O
benzodiazepines	B-Drug
such	O
as	O
diazepam	B-Drug
(	O
Valium	B-Drug
)	O
,	O
and	O
,	O
to	O
a	O
rising	O
degree	O
,	O
methadone	B-Drug
.	O

Ironically	O
,	O
benzodiazepines	B-Drug
are	O
often	O
used	O
in	O
the	O
treatment	O
of	O
heroin	B-Drug
addiction	O
while	O
they	O
cause	O
much	O
more	O
severe	O
withdrawal	O
symptoms	O
.	O

Cocaine	B-Drug
sometimes	O
proves	O
to	O
be	O
fatal	O
when	O
used	O
in	O
combination	O
with	O
heroin	B-Drug
.	O

No	O
information	O
available	O
.	O

Barbiturates	B-Drug
may	O
decrease	O
the	O
effectiveness	O
of	O
oral	O
contraceptives	O
,	O
certain	O
antibiotics	B-Drug
,	O
quinidine	B-Drug
,	O
theophylline	B-Drug
,	O
corticosteroids	O
,	O
anticoagulants	B-Drug
,	O
and	O
beta	O
blockers	O
.	O

MAO	O
inhibitors	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
hydralazine	B-Drug
.	O

When	O
other	O
potent	O
parental	O
antihypertensive	B-Drug
drugs	B-Drug
,	O
such	O
as	O
diazoxide	B-Drug
,	O
are	O
used	O
in	O
combination	O
with	O
hydralazine	B-Drug
,	O
patients	O
should	O
be	O
continuously	O
observed	O
for	O
several	O
hours	O
for	O
any	O
excessive	O
fall	O
in	O
blood	O
pressure	O
.	O

Profound	O
hypotensive	O
episodes	O
may	O
occur	O
when	O
diazoxide	B-Drug
infection	O
and	O
hydralazine	B-Drug
are	O
used	O
concomitantly	O
.	O

Beta-blockers	O
(	O
metoprolol	B-Drug
,	O
propranolol	B-Drug
)	O
serum	O
concentrations	O
and	O
pharmacologic	O
effects	O
may	O
be	O
increased	O
.	O

Monitor	O
cardiovascular	O
status	O
.	O

Propranolol	B-Drug
increases	O
hydralazines	B-Drug
serum	O
concentrations	O
.	O

Acebutolol	B-Drug
,	O
atenolol	B-Drug
,	O
and	O
nadolol	B-Drug
(	O
low	O
hepatic	O
clearance	O
or	O
no	O
first-pass	O
metabolism	O
)	O
are	O
unlikely	O
to	O
be	O
affected	O
.	O

NSAIDs	O
may	O
decrease	O
the	O
hemodynamic	O
effects	O
of	O
hydralazine	B-Drug
;	O
avoid	O
use	O
if	O
possible	O
or	O
closely	O
monitor	O
cardiovascular	O
status	O
at	O
the	O
end	O
of	O
drug	B-Drug
interactions	O
When	O
given	O
concurrently	O
the	O
following	O
drugs	B-Drug
may	O
interact	O
with	O
thiazide	O
diuretics	B-Drug
.	O

Alcohol	B-Drug
,	O
barbiturates	B-Drug
,	O
or	O
narcotics	O
:	O
potentiation	O
of	O
orthostatic	O
hypotension	O
may	O
occur	O
.	O

Antidiabetic	B-Drug
drugs	B-Drug
:	O
(	O
oral	O
agents	O
and	O
insulin	B-Drug
)	O
-	O
dosage	O
adjustment	O
of	O
the	O
antidiabetic	B-Drug
drug	B-Drug
may	O
be	O
required	O
.	O

Other	O
antihypertensive	B-Drug
drugs	B-Drug
:	O
additive	O
effect	O
or	O
potentiation	O
.	O

Cholestyramine	B-Drug
and	O
colestipol	B-Drug
resins	O
:	O
Absorption	O
of	O
hydrochlorothiazide	B-Drug
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	O
exchange	O
resins	O
.	O

Single	O
doses	O
of	O
either	O
cholestyramine	B-Drug
or	O
colestipol	B-Drug
resins	O
bind	O
the	O
hydrochlorothiazide	B-Drug
and	O
reduce	O
its	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
85	O
and	O
43	O
percent	O
,	O
respectively	O
.	O

Corticosteroids	O
,	O
ACTH	B-Drug
:	O
intensified	O
electrolyte	O
depletion	O
,	O
particularly	O
hypokalemia	O
.	O

Pressor	O
amines	O
(	O
e.g.	O
,	O
norepinephrine	B-Drug
)	O
:	O
possible	O
decreased	O
response	O
to	O
pressor	O
amines	O
but	O
not	O
sufficient	O
to	O
preclude	O
their	O
use	O
.	O

Skeletal	O
muscle	O
relaxants	O
,	O
nondepolarizing	O
(	O
e.g.	O
,	O
tubocurarine	B-Drug
)	O
:	O
possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	O
relaxant	O
.	O

Lithium	B-Drug
:	O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-Drug
.	O

Diuretic	B-Drug
agents	O
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-Drug
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-Drug
toxicity	O
.	O

Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
Hydrochlorothiazide	B-Drug
.	O

Non-steroidal	O
Anti-inflammatory	O
Drugs	B-Drug
:	O
In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non-steroidal	O
anti-inflammatory	O
agent	O
can	O
reduce	O
the	O
diuretic	B-Drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-Drug
effects	O
of	O
loop	O
,	O
potassium-sparing	O
and	O
thiazide	O
diuretics	B-Drug
.	O

Therefore	O
,	O
when	O
Hydrochlorothiazide	B-Drug
and	O
non-steroidal	O
anti-inflammatory	O
agents	O
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Drug
is	O
obtained	O
.	O

Patients	O
receiving	O
other	O
narcotic	O
analgesics	O
,	O
antipsychotics	O
,	O
antianxiety	O
agents	O
,	O
or	O
other	O
CNS	O
depressants	O
(	O
including	O
alcohol	B-Drug
)	O
concomitantly	O
with	O
hydrocodone	B-Drug
and	O
acetaminophen	B-Drug
tablets	O
may	O
exhibit	O
an	O
additive	O
CNS	O
depression	O
.	O

When	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

The	O
use	O
of	O
MAO	O
inhibitors	O
or	O
tricyclic	O
antidepressants	B-Drug
with	O
hydrocodone	B-Drug
preparations	O
may	O
increase	O
the	O
effect	O
of	O
either	O
the	O
antidepressant	O
or	O
hydrocodone	B-Drug
.	O

The	O
concurrent	O
use	O
of	O
anticholinergics	O
with	O
hydrocodone	B-Drug
may	O
produce	O
paralytic	O
ileus	O
.	O

No	O
information	O
available	O
.	O

Anticoagulants	B-Drug
,	O
oral	O
(	O
Effects	O
may	O
be	O
decreased	O
when	O
used	O
concurrently	O
with	O
thiazide	O
diuretics	B-Drug
;	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

)	O
Antigout	O
medications	O
(	O
Thiazide	O
diuretics	B-Drug
may	O
raise	O
the	O
level	O
of	O
blood	O
uric	O
acid	O
;	O
dosage	O
adjustment	O
of	O
antigout	O
medications	O
may	O
be	O
necessary	O
to	O
control	O
hyperuricemia	O
and	O
gout	O
.	O

)	O
Antihypertensive	B-Drug
medications	O
,	O
other	O
,	O
especially	O
diazoxide	B-Drug
,	O
or	O
preanesthetic	O
and	O
anesthetic	B-Drug
agents	O
used	O
in	O
surgery	O
or	O
skeletal-muscle	O
relaxants	O
,	O
nondepolarizing	O
,	O
used	O
in	O
surgery	O
(	O
Effects	O
may	O
be	O
potentiated	O
when	O
used	O
concurrently	O
with	O
thiazide	O
diuretics	B-Drug
;	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

)	O
Amphotericin	B-Drug
B	I-Drug
or	O
Corticosteroids	O
or	O
Corticotropin	B-Drug
(	O
ACTH	B-Drug
)	O
(	O
Concurrent	O
use	O
with	O
thiazide	O
diuretics	B-Drug
may	O
intensify	O
electrolyte	O
imbalance	O
,	O
particularly	O
hypokalemia	O
.	O

)	O
Cardiac	O
glycosides	O
(	O
Concurrent	O
use	O
with	O
thiazide	O
diuretics	B-Drug
may	O
enhance	O
the	O
possibility	O
of	O
digitalis	B-Drug
toxicity	O
associated	O
with	O
hypokalemia	O
.	O

)	O
Colestipol	B-Drug
(	O
May	O
inhibit	O
gastrointestinal	O
absorption	O
of	O
the	O
thiazide	O
diuretics	B-Drug
;	O
administration	O
1	O
hour	O
before	O
or	O
4	O
hours	O
after	O
colestipol	B-Drug
is	O
recommended	O
.	O

)	O
Hypoglycemics	O
(	O
Thiazide	O
diuretics	B-Drug
may	O
raise	O
blood	O
glucose	B-Drug
levels	O
;	O
for	O
adult-onset	O
diabetics	O
,	O
dosage	O
adjustment	O
of	O
hypoglycemic	O
medications	O
may	O
be	O
necessary	O
during	O
and	O
after	O
thiazide	O
diuretic	B-Drug
therapy	O
;	O
insulin	B-Drug
requirements	O
may	O
be	O
increased	O
,	O
decreased	O
,	O
or	O
unchanged	O
.	O

)	O
Lithium	B-Drug
salts	O
(	O
Concurrent	O
use	O
with	O
thiazide	O
diuretics	B-Drug
is	O
not	O
recommended	O
,	O
as	O
they	O
may	O
provoke	O
lithium	B-Drug
toxicity	O
because	O
of	O
reduced	O
renal	O
clearance	O
.	O

)	O
Methenamine	B-Drug
(	O
Effectiveness	O
may	O
be	O
decreased	O
when	O
used	O
concurrently	O
with	O
thiazide	O
diuretics	B-Drug
because	O
of	O
alkalinization	O
of	O
the	O
urine	O
.	O

)	O
Nonsteroidal	O
anti-inflammatory	O
agents	O
(	O
In	O
some	O
patients	O
,	O
the	O
steroidal	O
anti-inflammatory	O
agent	O
can	O
reduce	O
the	O
diuretic	B-Drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-Drug
effects	O
of	O
loop	O
,	O
potassium	B-Drug
sparing	O
,	O
and	O
thiazide	O
diuretics	B-Drug
.	O

Therefore	O
,	O
when	O
hydroflumethiazide	B-Drug
and	O
nonsteroidal	O
anti-inflammatory	O
agents	O
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Drug
is	O
obtained	O
.	O

)	O
Norepinephrine	B-Drug
(	O
Thiazides	O
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B-Drug
.	O

This	O
diminution	O
is	O
not	O
sufficient	O
to	O
preclude	O
effectiveness	O
of	O
the	O
pressor	O
agent	O
for	O
therapeutic	O
use	O
.	O

)	O
Tubocurarine	B-Drug
(	O
Thiazide	O
drugs	B-Drug
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	B-Drug
.	O

)	O
DIAGNOSTIC	O
INTERFERENCE	O
With	O
expected	O
physiologic	O
effects	O
:	O
Blood	O
and	O
urine	O
glucose	B-Drug
levels	O
(	O
usually	O
only	O
in	O
patients	O
with	O
a	O
predisposition	O
for	O
glucose	B-Drug
intolerance	O
)	O
and	O
Serum	O
bilirubin	O
levels	O
(	O
by	O
displacement	O
from	O
albumin	O
binding	O
)	O
and	O
Serum	O
calcium	B-Drug
levels	O
(	O
thiazide	O
diuretics	B-Drug
should	O
be	O
discontinued	O
before	O
parathyroid-function	O
tests	O
are	O
carried	O
out	O
)	O
and	O
Serum	O
uric	O
acid	O
levels	O
(	O
may	O
be	O
increased	O
)	O
Serum	O
magnesium	B-Drug
,	O
potassium	B-Drug
,	O
and	O
sodium	O
levels	O
(	O
may	O
be	O
decreased	O
;	O
serum	O
magnesium	B-Drug
levels	O
may	O
increase	O
in	O
uremic	O
patients	O
)	O
Serum	O
protein-bound	O
iodine	B-Drug
(	O
PBI	O
)	O
levels	O
(	O
may	O
be	O
decreased	O
)	O
Thiazides	O
should	O
be	O
discontinued	O
before	O
carrying	O
out	O
tests	O
for	O
parathyroid	O
function	O
.	O

Patients	O
receiving	O
other	O
narcotic	O
analgesics	O
,	O
general	O
anesthetics	B-Drug
,	O
phenothiazines	O
,	O
tranquilizers	O
,	O
sedative-hypnotics	O
,	O
tricyclic	O
antidepressants	B-Drug
or	O
other	O
CNS	O
depressants	O
(	O
including	O
alcohol	B-Drug
)	O
concomitantly	O
with	O
DILAUDID	B-Drug
may	O
exhibit	O
an	O
additive	O
CNS	O
depression	O
.	O

When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Cyanokit	B-Drug
.	O

Prospective	O
studies	O
on	O
the	O
potential	O
for	O
hydroxyurea	B-Drug
to	O
interact	O
with	O
other	O
drugs	B-Drug
have	O
not	O
been	O
performed	O
.	O

Concurrent	O
use	O
of	O
hydroxyurea	B-Drug
and	O
other	O
myelosuppressive	O
agents	O
or	O
radiation	O
therapy	O
may	O
increase	O
the	O
likelihood	O
of	O
bone	O
marrow	O
depression	O
or	O
other	O
adverse	O
events	O
.	O

Since	O
hydroxyurea	B-Drug
may	O
raise	O
the	O
serum	O
uric	O
acid	O
level	O
,	O
dosage	O
adjustment	O
of	O
uricosuric	O
medication	O
may	O
be	O
necessary	O
.	O

THE	O
POTENTIATING	O
ACTION	O
OF	O
HYDROXYZINE	B-Drug
MUST	O
BE	O
CONSIDERED	O
WHEN	O
THE	O
DRUG	B-Drug
IS	O
USED	O
IN	O
CONJUNCTION	O
WITH	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
DEPRESSANTS	O
SUCH	O
AS	O
NARCOTICS	O
,	O
NON-NARCOTIC	O
ANALGESICS	O
AND	O
BARBITURATES	B-Drug
.	O

Therefore	O
when	O
central	O
nervous	O
system	O
depressants	O
are	O
administered	O
concomitantly	O
with	O
hydroxyzine	B-Drug
their	O
dosage	O
should	O
be	O
reduced	O
.	O

Since	O
drowsiness	O
may	O
occur	O
with	O
use	O
of	O
this	O
drug	B-Drug
,	O
patients	O
should	O
be	O
warned	O
of	O
this	O
possibility	O
and	O
cautioned	O
against	O
driving	O
a	O
car	O
or	O
operating	O
dangerous	O
machinery	O
while	O
taking	O
Atarax	B-Drug
.	O

Patients	O
should	O
be	O
advised	O
against	O
the	O
simultaneous	O
use	O
of	O
other	O
CNS	O
depressant	O
drugs	B-Drug
,	O
and	O
cautioned	O
that	O
the	O
effect	O
of	O
alcohol	B-Drug
may	O
be	O
increased	O
.	O

Additive	O
adverse	O
effects	O
resulting	O
from	O
cholinergic	O
blockade	O
may	O
occur	O
when	O
LEVSIN	B-Drug
is	O
administered	O
concomitantly	O
with	O
other	O
antimuscarinics	O
,	O
amantadine	B-Drug
,	O
haloperidol	B-Drug
,	O
phenothiazines	O
,	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
,	O
tricyclic	O
antidepressants	B-Drug
or	O
some	O
antihistamines	B-Drug
.	O

Antacids	O
may	O
interfere	O
with	O
the	O
absorption	O
of	O
LEVSIN	B-Drug
.	O

Administer	O
LEVSIN	B-Drug
before	O
meals	O
;	O
antacids	O
after	O
meals	O
.	O

Calcium	B-Drug
Supplements/Antacids	O
Products	O
containing	O
calcium	B-Drug
and	O
other	O
multivalent	O
cations	O
(	O
such	O
as	O
aluminum	B-Drug
,	O
magnesium	B-Drug
,	O
iron	B-Drug
)	O
are	O
likely	O
to	O
interfere	O
with	O
absorption	O
of	O
Ibandronate	B-Drug
.	O

Ibandronate	B-Drug
should	O
be	O
taken	O
at	O
least	O
60	O
minutes	O
before	O
any	O
oral	O
medications	O
containing	O
multivalent	O
cations	O
(	O
including	O
antacids	O
,	O
supplements	O
or	O
vitamins	O
)	O
.	O

H2	O
Blockers	O
and	O
Proton	O
Pump	O
Inhibitors	O
(	O
PPIs	O
)	O
Of	O
over	O
3500	O
patients	O
enrolled	O
in	O
the	O
Ibandronate	B-Drug
osteoporosis	O
Treatment	O
and	O
Prevention	O
Studies	O
,	O
15	O
%	O
used	O
anti-peptic	O
agents	O
(	O
primarily	O
H2	O
blockers	O
and	O
PPIs	O
)	O
.	O

Among	O
these	O
patients	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	B-Drug
was	O
similar	O
to	O
that	O
in	O
placebo-treated	O
patients	O
.	O

Similarly	O
,	O
of	O
over	O
1600	O
patients	O
enrolled	O
in	O
a	O
study	O
comparing	O
once-monthly	O
with	O
daily	O
dosing	O
regimens	O
of	O
ibandronate	B-Drug
,	O
14	O
%	O
of	O
patients	O
used	O
anti-peptic	O
agents	O
.	O

Among	O
these	O
patients	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	B-Drug
150	O
mg	O
once	O
monthly	O
was	O
similar	O
to	O
that	O
in	O
patients	O
treated	O
with	O
Ibandronate	B-Drug
2.5	O
mg	O
once	O
daily	O
.	O

Aspirin/Nonsteroidal	B-Drug
Antiinflammatory	O
Drugs	B-Drug
(	O
NSAIDs	O
)	O
In	O
the	O
large	O
,	O
placebo-controlled	O
osteoporosis	O
Treatment	O
Study	O
,	O
aspirin	B-Drug
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
were	O
taken	O
by	O
62	O
%	O
of	O
the	O
2946	O
patients	O
.	O

Among	O
aspirin	B-Drug
or	O
NSAID	O
users	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
ibandronate	B-Drug
2.5	O
mg	O
daily	O
(	O
28.9	O
%	O
)	O
was	O
similar	O
to	O
that	O
in	O
placebo-treated	O
patients	O
(	O
30.7	O
%	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
1-year	O
monthly	O
comparison	O
study	O
,	O
aspirin	B-Drug
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
were	O
taken	O
by	O
39	O
%	O
of	O
the	O
1602	O
patients	O
.	O

The	O
incidence	O
of	O
upper	O
gastrointestinal	O
events	O
in	O
patients	O
concomitantly	O
taking	O
aspirin	B-Drug
or	O
NSAIDs	O
was	O
similar	O
in	O
patients	O
taking	O
ibandronate	B-Drug
2.5	O
mg	O
daily	O
(	O
21.7	O
%	O
)	O
and	O
150	O
mg	O
once	O
monthly	O
(	O
22.0	O
%	O
)	O
.	O

However	O
,	O
since	O
aspirin	B-Drug
,	O
NSAIDs	O
,	O
and	O
bisphosphonates	O
are	O
all	O
associated	O
with	O
gastrointestinal	O
irritation	O
,	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
concomitant	O
use	O
of	O
aspirin	B-Drug
or	O
NSAIDs	O
with	O
Ibandronate	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Bisphosphonates	O
are	O
known	O
to	O
interfere	O
with	O
the	O
use	O
of	O
bone-imaging	O
agents	O
.	O

Specific	O
studies	O
with	O
ibandronate	B-Drug
have	O
not	O
been	O
performed	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
performed	O
with	O
ZEVALIN	B-Drug
.	O

Due	O
to	O
the	O
frequent	O
occurrence	O
of	O
severe	O
and	O
prolonged	O
thrombocytopenia	O
,	O
the	O
potential	O
benefits	O
of	O
medications	O
which	O
interfere	O
with	O
platelet	O
function	O
and/or	O
anticoagulation	O
should	O
be	O
weighed	O
against	O
the	O
potential	O
increased	O
risks	O
of	O
bleeding	O
and	O
hemorrhage	O
.	O

Patients	O
receiving	O
medications	O
that	O
interfere	O
with	O
platelet	O
function	O
or	O
coagulation	O
should	O
have	O
more	O
frequent	O
laboratory	O
monitoring	O
for	O
thrombocytopenia	O
.	O

In	O
addition	O
,	O
the	O
transfusion	O
practices	O
for	O
such	O
patients	O
may	O
need	O
to	O
be	O
modified	O
given	O
the	O
increased	O
risk	O
of	O
bleeding	O
.	O

Patients	O
in	O
clinical	O
studies	O
were	O
prohibited	O
from	O
receiving	O
growth	O
factor	O
treatment	O
for	O
2	O
weeks	O
prior	O
to	O
the	O
ZEVALIN	B-Drug
therapeutic	O
regimen	O
as	O
well	O
as	O
for	O
2	O
weeks	O
following	O
completion	O
of	O
the	O
regimen	O
.	O

Coumarin-Type	O
Anticoagulants	B-Drug
:	O
Several	O
short-term	O
controlled	O
studies	O
failed	O
to	O
wshow	O
that	O
ibuprofen	B-Drug
significantly	O
affected	O
prothrombin	O
times	O
or	O
a	O
variety	O
of	O
other	O
clotting	O
factors	O
when	O
administered	O
to	O
individuals	O
on	O
coumarin-type	O
anticoagulants	B-Drug
.	O

However	O
,	O
because	O
bleeding	O
has	O
been	O
reported	O
when	O
ibuprofen	B-Drug
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
agents	O
have	O
been	O
administered	O
to	O
patients	O
on	O
coumarin-type	O
anticoagulants	B-Drug
,	O
the	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
ibuprofen	B-Drug
to	O
patients	O
on	O
anticoagulants	B-Drug
.	O

Aspirin	B-Drug
:	O
Animal	O
studies	O
wshow	O
that	O
aspirin	B-Drug
given	O
with	O
nonsteroidal	O
anti-inflammatory	O
agents	O
,	O
including	O
ibuprofen	B-Drug
,	O
yields	O
a	O
net	O
decrease	O
in	O
anti-inflammatory	O
activity	O
with	O
lowered	O
blood	O
levels	O
of	O
the	O
non-aspirin	O
drug	B-Drug
.	O

Single	O
dose	O
bioavailability	O
studies	O
in	O
normal	O
volunteers	O
have	O
failed	O
to	O
wshow	O
an	O
effect	O
of	O
aspirin	B-Drug
on	O
ibuprofen	B-Drug
blood	O
levels	O
.	O

Correlative	O
clinical	O
studies	O
have	O
not	O
been	O
performed	O
.	O

Methotrexate	B-Drug
:	O
Ibuprofen	B-Drug
,	O
as	O
well	O
as	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
,	O
probably	O
reduces	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
based	O
on	O
in	O
vitro	O
studies	O
in	O
rabbit	O
kidney	O
slices	O
.	O

This	O
may	O
indicate	O
that	O
ibuprofen	B-Drug
could	O
enhance	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O

Caution	O
should	O
be	O
used	O
if	O
ibuprofen	B-Drug
is	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O

H-2	O
Antagonists	O
:	O
In	O
studies	O
with	O
human	O
volunteers	O
,	O
co-administration	O
of	O
cimetidine	B-Drug
or	O
ranitidine	B-Drug
with	O
ibuprofen	B-Drug
had	O
no	O
substantive	O
effect	O
on	O
ibuprofen	B-Drug
serum	O
concentrations	O
.	O

Furosemide	B-Drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
random	O
observations	O
,	O
have	O
shown	O
that	O
ibuprofen	B-Drug
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	O
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

During	O
concomitant	O
therapy	O
with	O
ibuprofen	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	B-Drug
efficacy	O
.	O

Lithium	B-Drug
:	O
Ibuprofen	B-Drug
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
in	O
a	O
study	O
of	O
eleven	O
normal	O
volunteers	O
.	O

The	O
mean	O
minimum	O
lithium	B-Drug
concentration	O
increased	O
15	O
%	O
and	O
the	O
renal	O
clearance	O
of	O
lithium	B-Drug
was	O
decreased	O
by	O
19	O
%	O
during	O
this	O
period	O
of	O
concomitant	O
drug	B-Drug
administration	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
ibuprofen	B-Drug
.	O

Thus	O
,	O
when	O
ibuprofen	B-Drug
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O

(	O
Read	O
circulars	O
for	O
lithium	B-Drug
preparation	O
before	O
use	O
of	O
such	O
concurrent	O
therapy	O
)	O
.	O

No	O
specific	O
pharmacokinetic	O
or	O
other	O
formal	O
drug	B-Drug
interaction	O
studies	O
were	O
conducted	O
.	O

Digoxin	B-Drug
:	O
Supraventricular	O
arrhythmias	O
may	O
mask	O
the	O
cardiotoxicity	O
associated	O
with	O
excessive	O
digoxin	B-Drug
levels	O
.	O

Therefore	O
,	O
it	O
is	O
advisable	O
to	O
be	O
particularly	O
cautious	O
in	O
patients	O
whose	O
plasma	O
digoxin	B-Drug
levels	O
are	O
above	O
or	O
suspected	O
to	O
be	O
above	O
the	O
usual	O
therapeutic	O
range	O
.	O

Coadministration	O
of	O
digoxin	B-Drug
did	O
not	O
have	O
effects	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B-Drug
in	O
the	O
clinical	O
trials	O
.	O

Calcium	B-Drug
channel	O
blocking	O
agents	O
:	O
Coadministration	O
of	O
calcium	B-Drug
channel	O
blockers	O
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B-Drug
in	O
the	O
clinical	O
trials	O
.	O

Beta-adrenergic	O
blocking	O
agents	O
:	O
Coadministration	O
of	O
beta-adrenergic	O
blocking	O
agents	O
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B-Drug
in	O
the	O
clinical	O
trials	O
.	O

General	O
No	O
clinical	O
drug	B-Drug
interaction	O
studies	O
were	O
performed	O
.	O

No	O
evaluation	O
of	O
EXTRANEALs	B-Drug
effects	O
on	O
the	O
cytochrome	O
P450	O
system	O
was	O
conducted	O
.	O

As	O
with	O
other	O
dialysis	O
solutions	O
,	O
blood	O
concentrations	O
of	O
dialyzable	O
drugs	B-Drug
may	O
be	O
reduced	O
by	O
dialysis	O
.	O

Dosage	O
adjustment	O
of	O
concomitant	O
medications	O
may	O
be	O
necessary	O
.	O

In	O
patients	O
using	O
cardiac	O
glycosides	O
(	O
digoxin	B-Drug
and	O
others	O
)	O
,	O
plasma	O
levels	O
of	O
calcium	B-Drug
,	O
potassium	B-Drug
and	O
magnesium	B-Drug
must	O
be	O
carefully	O
monitored	O
.	O

Insulin	B-Drug
:	O
A	O
clinical	O
study	O
in	O
6	O
insulin-dependent	O
diabetic	O
patients	O
demonstrated	O
no	O
effect	O
of	O
EXTRANEAL	B-Drug
on	O
insulin	B-Drug
absorption	O
from	O
the	O
peritoneal	O
cavity	O
or	O
on	O
insulins	B-Drug
ability	O
to	O
control	O
blood	O
glucose	B-Drug
when	O
insulin	B-Drug
was	O
administered	O
intraperitoneally	O
with	O
EXTRANEAL	B-Drug
.	O

However	O
,	O
appropriate	O
monitoring	O
of	O
blood	O
glucose	B-Drug
should	O
be	O
performed	O
when	O
initiating	O
EXTRANEAL	B-Drug
in	O
diabetic	O
patients	O
and	O
insulin	B-Drug
dosage	O
should	O
be	O
adjusted	O
if	O
needed	O
.	O

Heparin	B-Drug
:	O
No	O
human	O
drug	B-Drug
interaction	O
studies	O
with	O
heparin	B-Drug
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
heparin	B-Drug
with	O
EXTRANEAL	B-Drug
.	O

Antibiotics	B-Drug
:	O
No	O
human	O
drug	B-Drug
interaction	O
studies	O
with	O
antibiotics	B-Drug
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
evaluating	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
vancomycin	B-Drug
,	O
cefazolin	B-Drug
,	O
ampicillin	B-Drug
,	O
ampicillin/flucoxacillin	B-Drug
,	O
ceftazidime	B-Drug
,	O
gentamicin	B-Drug
,	O
and	O
amphotericin	B-Drug
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
these	O
antibiotics	B-Drug
with	O
EXTRANEAL	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Blood	O
Glucose	B-Drug
Blood	O
glucose	B-Drug
measurement	O
must	O
be	O
done	O
with	O
a	O
glucose-specific	O
method	O
to	O
prevent	O
maltose	O
interference	O
with	O
test	O
results	O
.	O

Since	O
falsely	O
elevated	O
glucose	B-Drug
levels	O
have	O
been	O
observed	O
with	O
blood	O
glucose	B-Drug
monitoring	O
devices	O
and	O
test	O
strips	O
that	O
use	O
glucose	B-Drug
dehydrogenase	O
pyrroloquinolinequinone	O
(	O
GDH	O
PQQ	O
)	O
-based	O
methods	O
,	O
GDH	O
PQQ-based	O
methods	O
should	O
not	O
be	O
used	O
to	O
measure	O
glucose	B-Drug
levels	O
in	O
patients	O
administered	O
EXTRANEAL..	B-Drug
Serum	O
Amylase	B-Drug
An	O
apparent	O
decrease	O
in	O
serum	O
amylase	B-Drug
activity	O
has	O
been	O
observed	O
in	O
patients	O
administered	O
EXTRANEAL	B-Drug
.	O

Preliminary	O
investigations	O
indicate	O
that	O
icodextrin	B-Drug
and	O
its	O
metabolites	O
interfere	O
with	O
enzymatic-based	O
amylase	B-Drug
assays	O
,	O
resulting	O
in	O
inaccurately	O
low	O
values	O
.	O

This	O
should	O
be	O
taken	O
into	O
account	O
when	O
evaluating	O
serum	O
amylase	B-Drug
levels	O
for	O
diagnosis	O
or	O
monitoring	O
of	O
pancreatitis	O
in	O
patients	O
using	O
EXTRANEAL	B-Drug
.	O

Interactions	O
may	O
occur	O
between	O
EPA	B-Drug
supplements	O
and	O
aspirin	B-Drug
and	O
other	O
non-steroidal	O
anti-inflammatory	O
drugs	B-Drug
and	O
herbs	O
such	O
as	O
garlic	O
(	O
Allium	O
sativum	O
)	O
and	O
ginkgo	B-Drug
(	O
Ginkgo	B-Drug
biloba	I-Drug
)	O
.	O

Such	O
interactions	O
might	O
be	O
manifested	O
by	O
increased	O
susceptibility	O
to	O
bruising	O
,	O
nosebleeds	O
,	O
hemoptysis	O
,	O
hematemesis	O
,	O
hematuria	O
and	O
blood	O
in	O
the	O
stool	O
.	O

Most	O
who	O
take	O
EPA	B-Drug
supplements	O
and	O
the	O
above	O
drugs	B-Drug
or	O
herbs	O
do	O
not	O
suffer	O
from	O
these	O
problems	O
and	O
if	O
they	O
occur	O
,	O
they	O
are	O
rare	O
.	O

If	O
they	O
do	O
occur	O
,	O
the	O
EPA	B-Drug
dose	O
should	O
be	O
lowered	O
or	O
discontinued	O
.	O

Conflicting	O
results	O
have	O
been	O
reported	O
regarding	O
the	O
effects	O
of	O
EPA	B-Drug
supplements	O
on	O
glycemic	O
control	O
in	O
non-diabetics	O
with	O
glucose	B-Drug
intolerance	O
,	O
and	O
those	O
with	O
type	O
2	O
diabetes	O
.	O

Some	O
early	O
studies	O
indicated	O
that	O
EPA	B-Drug
supplements	O
might	O
have	O
detrimental	O
effects	O
in	O
those	O
groups	O
.	O

Recent	O
,	O
better	O
designed	O
studies	O
have	O
not	O
reported	O
these	O
adverse	O
effects	O
.	O

There	O
is	O
no	O
evidence	O
that	O
EPA	B-Drug
supplements	O
have	O
detrimental	O
effects	O
on	O
glucose	B-Drug
tolerance	O
,	O
insulin	B-Drug
secretion	O
or	O
insulin	B-Drug
resistance	O
in	O
non-diabetic	O
subjects	O
.	O

Diabetics	O
should	O
discuss	O
the	O
use	O
of	O
these	O
supplements	O
with	O
their	O
physicians	O
and	O
note	O
if	O
the	O
supplements	O
affect	O
their	O
glycemic	O
control	O
.	O

Diabetics	O
who	O
take	O
EPA	B-Drug
supplements	O
should	O
be	O
monitored	O
by	O
their	O
physicians	O
.	O

Other	O
medicines	O
-	O
Although	O
certain	O
medicines	O
should	O
not	O
be	O
used	O
together	O
at	O
all	O
,	O
in	O
other	O
cases	O
two	O
different	O
medicines	O
may	O
be	O
used	O
together	O
even	O
if	O
an	O
interaction	O
might	O
occur	O
.	O

In	O
these	O
cases	O
,	O
your	O
doctor	O
may	O
want	O
to	O
change	O
the	O
dose	O
,	O
or	O
other	O
precautions	O
may	O
be	O
necessary	O
.	O

When	O
you	O
are	O
using	O
idoxuridine	B-Drug
,	O
it	O
is	O
especially	O
important	O
that	O
your	O
health	O
care	O
professional	O
know	O
if	O
you	O
are	O
using	O
the	O
following	O
:	O
Eye	O
product	O
containing	O
boric	B-Drug
acid	I-Drug
.	O

Boric	B-Drug
acid	I-Drug
may	O
interact	O
with	O
the	O
idoxuridine	B-Drug
preparation	O
causing	O
a	O
gritty	O
substance	O
to	O
form	O
or	O
may	O
interact	O
with	O
the	O
preservative	O
in	O
the	O
idoxuridine	B-Drug
preparation	O
causing	O
a	O
toxic	O
effect	O
in	O
the	O
eye	O
.	O

The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	B-Drug
actions	O
,	O
desirable	O
or	O
undesirable	O
,	O
involving	O
ifosfamide	B-Drug
even	O
though	O
ifosfamide	B-Drug
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	B-Drug
,	O
including	O
other	O
cytotoxic	O
drugs	B-Drug
.	O

In	O
studies	O
in	O
normal	O
volunteers	O
,	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
between	O
intravenous	O
iloprost	B-Drug
and	O
either	O
nifedipine	B-Drug
,	O
diltiazem	B-Drug
,	O
or	O
captopril	B-Drug
.	O

However	O
,	O
iloprost	B-Drug
has	O
the	O
potential	O
to	O
increase	O
the	O
hypotensive	O
effect	O
of	O
vasodilators	O
and	O
antihypertensive	B-Drug
agents	O
.	O

Since	O
iloprost	B-Drug
inhibits	O
platelet	O
function	O
,	O
there	O
is	O
a	O
potential	O
for	O
increased	O
risk	O
of	O
bleeding	O
,	O
particularly	O
in	O
patients	O
maintained	O
on	O
anticoagulants	B-Drug
.	O

During	O
clinical	O
trials	O
,	O
iloprost	B-Drug
was	O
used	O
concurrently	O
with	O
anticoagulants	B-Drug
,	O
diuretics	B-Drug
,	O
cardiac	O
glycosides	O
,	O
calcium	B-Drug
channel	O
blockers	O
,	O
analgesics	O
,	O
antipyretics	O
,	O
nonsteroidal	O
antiinflammatories	O
,	O
corticosteroids	O
,	O
and	O
other	O
medications	O
.	O

Intravenous	O
infusion	O
of	O
iloprost	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O

Acetylsalicylic	B-Drug
acid	I-Drug
did	O
not	O
alter	O
the	O
clearance	O
(	O
pharmacokinetics	O
)	O
of	O
iloprost	B-Drug
.	O

Although	O
clinical	O
studies	O
have	O
not	O
been	O
conducted	O
,	O
in	O
vitro	O
studies	O
of	O
iloprost	B-Drug
indicate	O
that	O
no	O
relevant	O
inhibition	O
of	O
cytochrome	O
P450	O
drug	B-Drug
metabolism	O
would	O
be	O
expected	O
.	O

Drugs	B-Drug
that	O
may	O
alter	O
imatinib	B-Drug
plasma	O
concentrations	O
Drugs	B-Drug
that	O
may	O
increase	O
imatinib	B-Drug
plasma	O
concentrations	O
:	O
Caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	B-Drug
with	O
inhibitors	O
of	O
the	O
CYP3A4	B-Drug
family	O
(	O
e.g.	O
,	O
ketoconazole	B-Drug
,	O
itraconazole	B-Drug
,	O
erythromycin	B-Drug
,	O
clarithromycin	B-Drug
)	O
.	O

Substances	O
that	O
inhibit	O
the	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP3A4	B-Drug
)	O
activity	O
may	O
decrease	O
metabolism	O
and	O
increase	O
imatinib	B-Drug
concentrations	O
.	O

There	O
is	O
a	O
significant	O
increase	O
in	O
exposure	O
to	O
imatinib	B-Drug
when	O
Gleevec	B-Drug
is	O
coadministered	O
with	O
ketoconazole	B-Drug
(	O
CYP3A4	B-Drug
inhibitor	O
)	O
.	O

Drugs	B-Drug
that	O
may	O
decrease	O
imatinib	B-Drug
plasma	O
concentrations	O
:	O
Substances	O
that	O
are	O
inducers	O
of	O
CYP3A4	B-Drug
activity	O
may	O
increase	O
metabolism	O
and	O
decrease	O
imatinib	B-Drug
plasma	O
concentrations	O
.	O

Co-medications	O
that	O
induce	O
CYP3A4	B-Drug
(	O
e.g.	O
,	O
dexamethasone	B-Drug
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
rifampin	B-Drug
,	O
phenobarbital	B-Drug
or	O
St	O
.	O

Johns	O
Wort	O
)	O
may	O
significantly	O
reduce	O
exposure	O
to	O
Gleevec	B-Drug
.	O

Pretreatment	O
of	O
healthy	O
volunteers	O
with	O
multiple	O
doses	O
of	O
rifampin	B-Drug
followed	O
by	O
a	O
single	O
dose	O
of	O
Gleevec	B-Drug
,	O
increased	O
Gleevec	B-Drug
oral-dose	O
clearance	O
by	O
3.8-fold	O
,	O
which	O
significantly	O
(	O
p	O
0.05	O
)	O
decreased	O
mean	O
cmax	O
and	O
AUC	O
(	O
0-8	O
)	O
.	O

In	O
patients	O
where	O
rifampin	B-Drug
or	O
other	O
CYP3A4	B-Drug
inducers	O
are	O
indicated	O
,	O
alternative	O
therapeutic	O
agents	O
with	O
less	O
enzyme	O
induction	O
potential	O
should	O
be	O
considered	O
.	O

Drugs	B-Drug
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
Gleevec	B-Drug
Gleevec	B-Drug
increases	O
the	O
mean	O
cmax	O
and	O
AUC	O
of	O
simvastatin	B-Drug
(	O
CYP3A4	B-Drug
substrate	O
)	O
2-	O
and	O
3.5-fold	O
,	O
respectively	O
,	O
suggesting	O
an	O
inhibition	O
of	O
the	O
CYP3A4	B-Drug
by	O
Gleevec	B-Drug
.	O

Particular	O
caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	B-Drug
with	O
CYP3A4	B-Drug
substrates	O
that	O
have	O
a	O
narrow	O
therapeutic	O
window	O
(	O
e.g.	O
,	O
cyclosporine	B-Drug
or	O
pimozide	B-Drug
)	O
.	O

Gleevec	B-Drug
will	O
increase	O
plasmaconcentration	O
of	O
other	O
CYP3A4	B-Drug
metabolized	O
drugs	B-Drug
(	O
e.g.	O
,	O
triazolo-benzodiazepines	O
,	O
dihydropyridine	O
calcium	B-Drug
channel	O
blockers	O
,	O
certain	O
HMG-CoA	O
reductase	O
inhibitors	O
,	O
etc	O
.	O

)	O
.	O

Because	O
warfarin	B-Drug
is	O
metabolized	O
by	O
CYP2C9	B-Drug
and	O
CYP3A4	B-Drug
,	O
patients	O
who	O
require	O
anticoagulation	O
should	O
receive	O
low-molecular	O
weight	O
or	O
standard	O
heparin	B-Drug
.	O

in	O
vitro	O
,	O
Gleevec	B-Drug
inhibits	O
the	O
cytochrome	O
P450	O
isoenzyme	O
CYP2D6	B-Drug
activity	O
at	O
similar	O
concentrations	O
that	O
affect	O
CYP3A4	B-Drug
activity	O
.	O

Systemic	O
exposure	O
to	O
substrates	O
of	O
CYP2D6	B-Drug
is	O
expected	O
to	O
be	O
increased	O
when	O
coadministered	O
with	O
Gleevec	B-Drug
.	O

No	O
specific	O
studies	O
have	O
been	O
performed	O
and	O
caution	O
is	O
recommended	O
.	O

in	O
vitro	O
,	O
Gleevec	B-Drug
inhibits	O
acetaminophen	B-Drug
O-glucuronidation	O
(	O
Ki	O
value	O
of	O
58.5	O
M	O
)	O
at	O
therapeutic	O
levels	O
.	O

Systemic	O
exposure	O
to	O
acetaminophen	B-Drug
is	O
expected	O
to	O
be	O
increased	O
when	O
coadministered	O
with	O
Gleevec	B-Drug
.	O

No	O
specific	O
studies	O
in	O
humans	O
have	O
been	O
performed	O
and	O
caution	O
is	O
recommended	O
.	O

In	O
occasional	O
susceptible	O
patients	O
or	O
in	O
those	O
receiving	O
anticholinergic	B-Drug
drugs	B-Drug
(	O
including	O
antiparkinsonism	O
agents	O
)	O
in	O
addition	O
,	O
the	O
atropine-like	O
effects	O
may	O
become	O
more	O
pronounced	O
(	O
e.g.	O
,	O
paralytic	O
ileus	O
)	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
is	O
required	O
when	O
this	O
drug	B-Drug
is	O
administered	O
concomitantly	O
with	O
anticholinergic	B-Drug
drugs	B-Drug
.	O

Avoid	O
the	O
use	O
of	O
preparations	O
such	O
as	O
decongestants	O
and	O
local	O
anesthetics	B-Drug
which	O
contain	O
any	O
sympathomimetic	B-Drug
amine	O
(	O
e.g.	O
,	O
epinephrine	B-Drug
,	O
norepinephrine	B-Drug
)	O
,	O
since	O
it	O
has	O
been	O
reported	O
that	O
tricyclic	O
antidepressants	B-Drug
can	O
potentiate	O
the	O
effects	O
of	O
catecholamines	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
imipramine	B-Drug
hydrochloride	I-Drug
is	O
used	O
with	O
agents	O
that	O
lower	O
blood	O
pressure	O
.	O

Imipramine	B-Drug
hydrochloride	I-Drug
may	O
potentiate	O
the	O
effects	O
of	O
CNS	O
depressant	O
drugs	B-Drug
.	O

The	O
plasma	O
concentration	O
of	O
imipramine	B-Drug
may	O
increase	O
when	O
the	O
drug	B-Drug
is	O
given	O
concomitantly	O
with	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e.g.	O
,	O
cimetidine	B-Drug
,	O
fluoxetine	B-Drug
)	O
and	O
decrease	O
by	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
barbiturates	B-Drug
,	O
phenytoin	B-Drug
)	O
,	O
and	O
adjustment	O
of	O
the	O
dosage	O
of	O
imipramine	B-Drug
may	O
therefore	O
be	O
necessary	O
.	O

Drugs	B-Drug
Metabolized	O
by	O
P450	O
2D6	O
The	O
biochemical	O
activity	O
of	O
the	O
drug	B-Drug
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	B-Drug
hydroxylase	O
)	O
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7	O
to	O
10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O
reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	O
2D6	O
isozyme	O
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	B-Drug
metabolized	O
by	O
P450	O
2D6	O
,	O
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8-fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-Drug
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	O
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O

metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	O
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	B-Drug
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	B-Drug
that	O
inhibit	O
cytochrome	O
P450	O
2D6	O
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-Drug
;	O
cimetidine	B-Drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B-Drug
,	O
phenothiazines	O
,	O
and	O
the	O
Type	O
1C	O
antiarrhythmics	B-Drug
propafenone	B-Drug
and	O
flecainide	B-Drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
e.	O
g.	O
,	O
fluoxetine	B-Drug
,	O
sertraline	B-Drug
,	O
and	O
paroxetine	B-Drug
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI-TCA	O
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
,	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	O
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co-administration	O
of	O
TCA5	O
with	O
any	O
of	O
the	O
SSRIs	O
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-Drug
,	O
given	O
the	O
long	O
half-life	O
of	O
the	O
parent	O
and	O
active	O
metabolite	O
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	O
antidepressants	B-Drug
with	O
drugs	B-Drug
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	O
antidepressant	O
or	O
the	O
other	O
drug	B-Drug
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	B-Drug
is	O
withdrawn	O
from	O
cotherapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	O
antidepressant	O
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	O
plasma	O
levels	O
whenever	O
a	O
TCA	O
is	O
going	O
to	O
be	O
co-administered	O
with	O
another	O
drug	B-Drug
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

No	O
information	O
available	O
.	O

Indinavir	B-Drug
is	O
an	O
inhibitor	O
of	O
the	O
cytochrome	O
P450	O
isoform	O
CYP3A4	B-Drug
.	O

Coadministration	O
of	O
CRIXIVAN	B-Drug
and	O
drugs	B-Drug
primarily	O
metabolized	O
by	O
CYP3A4	B-Drug
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
other	O
drug	B-Drug
,	O
which	O
could	O
increase	O
or	O
prolong	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Indinavir	B-Drug
is	O
metabolized	O
by	O
CYP3A4	B-Drug
.	O

Drugs	B-Drug
that	O
induce	O
CYP3A4	B-Drug
activity	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
indinavir	B-Drug
,	O
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
of	O
indinavir	B-Drug
.	O

Coadministration	O
of	O
CRIXIVAN	B-Drug
and	O
other	O
drugs	B-Drug
that	O
inhibit	O
CYP3A4	B-Drug
may	O
decrease	O
the	O
clearance	O
of	O
indinavir	B-Drug
and	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
indinavir	B-Drug
.	O

Table	O
8	O
Drugs	B-Drug
That	O
Should	O
Not	O
Be	O
Coadministered	O
with	O
CRIXIVAN	B-Drug
Drug	B-Drug
Class	O
:	O
Drug	B-Drug
Name	O
Clinical	O
Comment	O
Antiarrhythmics	B-Drug
:	O
amiodarone	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Ergot	B-Drug
derivatives	O
:	O
dihydroergotamine	B-Drug
,	O
ergonovine	B-Drug
,	O
ergotamine	B-Drug
,	O
methylergonovine	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
such	O
as	O
acute	O
ergot	B-Drug
toxicity	O
characterized	O
by	O
peripheral	O
vasospasm	O
and	O
ischemia	O
of	O
the	O
extremities	O
and	O
other	O
tissues	O
.	O

Sedative/hypnotics	O
:	O
midazolam	B-Drug
,	O
triazolam	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
such	O
as	O
prolonged	O
or	O
increased	O
sedation	O
or	O
respiratory	O
depression	O
.	O

GI	O
motility	O
agents	O
:	O
cisapride	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Neuroleptic	B-Drug
:	O
pimozide	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Herbal	O
products	O
:	O
St.	O
John	O
s	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
May	O
lead	B-Drug
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	B-Drug
or	O
to	O
the	O
class	O
of	O
protease	O
inhibitors	O
.	O

Antimycobacterial	O
:	O
rifampin	B-Drug
May	O
lead	B-Drug
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	B-Drug
or	O
to	O
the	O
class	O
of	O
protease	O
inhibitors	O
or	O
other	O
coadministered	O
antiretroviral	O
agents	O
.	O

HMG-CoA	O
Reductase	O
inhibitors	O
:	O
lovastatin	B-Drug
,	O
simvastatin	B-Drug
Potential	O
for	O
serious	O
reactions	O
such	O
as	O
risk	O
of	O
myopathy	O
including	O
rhabdomyolysis	O
.	O

Protease	O
inhibitor	O
:	O
atazanavir	B-Drug
Both	O
CRIXIVAN	B-Drug
and	O
atazanavir	B-Drug
are	O
associated	O
with	O
indirect	O
(	O
unconjugated	O
)	O
hyperbilirubinemia	O
.	O

Combinations	O
of	O
these	O
drugs	B-Drug
have	O
not	O
been	O
studied	O
and	O
coadministration	O
of	O
CRIXIVAN	B-Drug
and	O
atazanavir	B-Drug
is	O
not	O
recommended	O
.	O

Table	O
9	O
Established	O
and	O
Other	O
Potentially	O
Significant	O
Drug	B-Drug
Interactions	O
:	O
Alteration	O
in	O
Dose	O
or	O
Regimen	O
May	O
Be	O
Recommended	O
Based	O
on	O
Drug	B-Drug
Interaction	O
Studies	O
or	O
Predicted	O
Interaction	O
Drug	B-Drug
Name	O
Effect	O
Clinical	O
Comment	O
HIV	O
Antiviral	O
Agents	O
Delavirdine	B-Drug
indinavir	B-Drug
concentration	O
Dose	O
reduction	O
of	O
CRIXIVAN	B-Drug
to	O
600	O
mg	O
every	O
8	O
hours	O
should	O
be	O
considered	O
when	O
taking	O
delavirdine	B-Drug
400	O
mg	O
three	O
times	O
a	O
day	O
.	O

Didanosine	B-Drug
Indinavir	B-Drug
and	O
didanosine	B-Drug
formulations	O
containing	O
buffer	O
should	O
be	O
administered	O
at	O
least	O
one	O
hour	O
apart	O
on	O
an	O
empty	O
stomach	O
.	O

Efavirenz	B-Drug
indinavir	B-Drug
concentration	O
The	O
optimal	O
dose	O
of	O
indinavir	B-Drug
,	O
when	O
given	O
in	O
combination	O
with	O
efavirenz	B-Drug
,	O
is	O
not	O
known	O
.	O

Increasing	O
the	O
indinavir	B-Drug
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B-Drug
metabolism	O
due	O
to	O
efavirenz	B-Drug
.	O

Nelfinavir	B-Drug
indinavir	B-Drug
concentration	O
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

Nevirapine	B-Drug
indinavir	B-Drug
concentration	O
Indinavir	B-Drug
concentrations	O
may	O
be	O
decreased	O
in	O
the	O
presence	O
of	O
nevirapine	B-Drug
.	O

The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

Ritonavir	B-Drug
indinavir	B-Drug
concentration	O
ritonavir	B-Drug
concentration	O
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

Preliminary	O
clinical	O
data	O
suggest	O
that	O
the	O
incidence	O
of	O
nephrolithiasis	O
is	O
higher	O
in	O
patients	O
receiving	O
indinavir	B-Drug
in	O
combination	O
with	O
ritonavir	B-Drug
than	O
those	O
receiving	O
CRIXIVAN	B-Drug
800	O
mg	O
q8h	O
.	O

Saquinavir	B-Drug
saquinavir	B-Drug
concentration	O
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

Other	O
Agents	O
Antiarrhythmics	B-Drug
:	O
bepridil	B-Drug
,	O
lidocaine	B-Drug
(	O
systemic	O
)	O
and	O
quinidine	B-Drug
antiarrhythmic	B-Drug
agents	O
concentration	O
Caution	O
is	O
warranted	O
and	O
therapeutic	O
concentration	O
monitoring	O
is	O
recommended	O
for	O
antiarrhythmics	B-Drug
when	O
coadministered	O
with	O
CRIXIVAN	B-Drug
.	O

Anticonvulsants	O
:	O
carbamazepine	B-Drug
,	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
indinavir	B-Drug
concentration	O
Use	O
with	O
caution	O
.	O

CRIXIVAN	B-Drug
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
indinavir	B-Drug
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O
.	O

Calcium	B-Drug
Channel	O
Blockers	O
,	O
Dihydropyridine	O
:	O
e.g.	O
,	O
felodipine	B-Drug
,	O
nifedipine	B-Drug
,	O
nicardipine	B-Drug
dihydropyridine	O
calcium	B-Drug
channel	O
blockers	O
concentration	O
Caution	O
is	O
warranted	O
and	O
clinical	O
monitoring	O
of	O
patients	O
is	O
recommended	O
.	O

Clarithromycin	B-Drug
clarithromycin	B-Drug
concentration	O
indinavir	B-Drug
concentration	O
The	O
appropriate	O
doses	O
for	O
this	O
combination	O
,	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
,	O
have	O
not	O
been	O
established	O
.	O

HMG-CoA	O
Reductase	O
Inhibitor	O
:	O
atorvastatin	B-Drug
atorvastatin	B-Drug
concentration	O
Use	O
lowest	O
possible	O
dose	O
of	O
atorvastatin	B-Drug
with	O
careful	O
monitoring	O
,	O
or	O
consider	O
HMG-CoA	O
reductase	O
inhibitors	O
that	O
are	O
not	O
primarily	O
metabolized	O
by	O
CYP3A4	B-Drug
,	O
such	O
as	O
pravastatin	B-Drug
,	O
fluvastatin	B-Drug
,	O
or	O
rosuvastatin	B-Drug
in	O
combination	O
with	O
CRIXIVAN	B-Drug
.	O

Immunosuppressants	O
:	O
cyclosporine	B-Drug
,	O
tacrolimus	B-Drug
,	O
sirolimus	B-Drug
immunosuppressant	O
agents	O
concentration	O
Plasma	O
concentrations	O
may	O
be	O
increased	O
by	O
CRIXIVAN	B-Drug
.	O

Itraconazole	B-Drug
indinavir	B-Drug
concentration	O
Dose	O
reduction	O
of	O
CRIXIVAN	B-Drug
to	O
600	O
mg	O
every	O
8	O
hours	O
is	O
recommended	O
when	O
administering	O
itraconazole	B-Drug
concurrently	O
.	O

Ketoconazole	B-Drug
indinavir	B-Drug
concentration	O
Dose	O
reduction	O
of	O
CRIXIVAN	B-Drug
to	O
600	O
mg	O
every	O
8	O
hours	O
should	O
be	O
considered	O
.	O

Rifabutin	B-Drug
indinavir	B-Drug
concentration	O
rifabutin	B-Drug
concentration	O
Dose	O
reduction	O
of	O
rifabutin	B-Drug
to	O
half	O
the	O
standard	O
dose	O
and	O
a	O
dose	O
increase	O
of	O
CRIXIVAN	B-Drug
to	O
1000	O
mg	O
(	O
three	O
333-mg	O
capsules	O
)	O
every	O
8	O
hours	O
are	O
recommended	O
when	O
rifabutin	B-Drug
and	O
CRIXIVAN	B-Drug
are	O
coadministered	O
.	O

Sildenafil	B-Drug
sildenafil	B-Drug
concentration	O
Sildenafil	B-Drug
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
25	O
mg	O
in	O
a	O
48-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B-Drug
therapy	O
.	O

Tadalafil	B-Drug
tadalafil	B-Drug
concentration	O
Tadalafil	B-Drug
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
10	O
mg	O
in	O
a	O
72-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B-Drug
therapy	O
.	O

Vardenafil	B-Drug
vardenafil	B-Drug
concentration	O
Vardenafil	B-Drug
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
2.5	O
mg	O
in	O
a	O
24-hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B-Drug
therapy	O
.	O

Note	O
:	O
=	O
increase	O
;	O
=	O
decrease	O
In	O
normal	O
volunteers	O
receiving	O
indomethacin	B-Drug
,	O
the	O
administration	O
of	O
diflunisal	B-Drug
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	B-Drug
.	O

In	O
some	O
patients	O
,	O
combined	O
use	O
of	O
INDOCIN	B-Drug
and	O
diflunisal	B-Drug
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O

Therefore	O
,	O
diflunisal	B-Drug
and	O
INDOCIN	B-Drug
should	O
not	O
be	O
used	O
concomitantly	O
.	O

In	O
a	O
study	O
in	O
normal	O
volunteers	O
,	O
it	O
was	O
found	O
that	O
chronic	O
concurrent	O
administration	O
of	O
3.6	O
g	O
of	O
aspirin	B-Drug
per	O
day	O
decreases	O
indomethacin	B-Drug
blood	O
levels	O
approximately	O
20	O
%	O
.	O

The	O
concomitant	O
use	O
of	O
INDOCIN	B-Drug
with	O
other	O
NSAIDs	O
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
,	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
INDOCIN	B-Drug
does	O
not	O
influence	O
the	O
hypoprothrombinemia	O
produced	O
by	O
anticoagulants	B-Drug
.	O

However	O
,	O
when	O
any	O
additional	O
drug	B-Drug
,	O
including	O
INDOCIN	B-Drug
,	O
is	O
added	O
to	O
the	O
treatment	O
of	O
patients	O
on	O
anticoagulant	B-Drug
therapy	O
,	O
the	O
patients	O
should	O
be	O
observed	O
for	O
alterations	O
of	O
the	O
prothrombin	O
time	O
.	O

In	O
post-marketing	O
experience	O
,	O
bleeding	O
has	O
been	O
reported	O
in	O
patients	O
on	O
concomitant	O
treatment	O
with	O
anticoagulants	B-Drug
and	O
INDOCIN	B-Drug
.	O

Caution	O
should	O
be	O
exercised	O
when	O
INDOCIN	B-Drug
and	O
anticoagulants	B-Drug
are	O
administered	O
concomitantly	O
.	O

When	O
INDOCIN	B-Drug
is	O
given	O
to	O
patients	O
receiving	O
probenecid	B-Drug
,	O
the	O
plasma	O
levels	O
of	O
indomethacin	B-Drug
are	O
likely	O
to	O
be	O
increased	O
.	O

Therefore	O
,	O
a	O
lower	O
total	O
daily	O
dosage	O
of	O
INDOCIN	B-Drug
may	O
produce	O
a	O
satisfactory	O
therapeutic	O
effect	O
.	O

When	O
increases	O
in	O
the	O
dose	O
of	O
INDOCIN	B-Drug
are	O
made	O
,	O
they	O
should	O
be	O
made	O
carefully	O
and	O
in	O
small	O
increments	O
.	O

Caution	O
should	O
be	O
used	O
if	O
INDOCIN	B-Drug
is	O
administered	O
simultaneously	O
with	O
methotrexate	B-Drug
.	O

INDOCIN	B-Drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O

Administration	O
of	O
non-steroidal	O
anti-inflammatory	O
drugs	B-Drug
concomitantly	O
with	O
cyclosporine	B-Drug
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine-induced	B-Drug
toxicity	O
,	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O

NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	B-Drug
,	O
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O

Capsules	O
INDOCIN	B-Drug
50	O
mg	O
t.i.d	O
.	O

produced	O
a	O
clinically	O
relevant	O
elevation	O
of	O
plasma	O
lithium	B-Drug
and	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
in	O
psychiatric	O
patients	O
and	O
normal	O
subjects	O
with	O
steady	O
state	O
plasma	O
lithium	B-Drug
concentrations	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
.	O

As	O
a	O
consequence	O
,	O
when	O
INDOCIN	B-Drug
and	O
lithium	B-Drug
are	O
given	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
carefully	O
observed	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O

(	O
Read	O
circulars	O
for	O
lithium	B-Drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O

)	O
In	O
addition	O
,	O
the	O
frequency	O
of	O
monitoring	O
serum	O
lithium	B-Drug
concentration	O
should	O
be	O
increased	O
at	O
the	O
outset	O
of	O
such	O
combination	O
drug	B-Drug
treatment	O
.	O

INDOCIN	B-Drug
given	O
concomitantly	O
with	O
digoxin	B-Drug
has	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
concentration	O
and	O
prolong	O
the	O
half-life	O
of	O
digoxin	B-Drug
.	O

Therefore	O
,	O
when	O
INDOCIN	B-Drug
and	O
digoxin	B-Drug
are	O
used	O
concomitantly	O
,	O
serum	O
digoxin	B-Drug
levels	O
should	O
be	O
closely	O
monitored	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
INDOCIN	B-Drug
can	O
reduce	O
the	O
diuretic	B-Drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-Drug
effects	O
of	O
loop	O
,	O
potassium-sparing	O
,	O
and	O
thiazide	O
diuretics	B-Drug
.	O

Therefore	O
,	O
when	O
INDOCIN	B-Drug
and	O
INDOCIN	B-Drug
.	O

(	O
Indomethacin	B-Drug
)	O
diuretics	B-Drug
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-Drug
is	O
obtained	O
.	O

INDOCIN	B-Drug
reduces	O
basal	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
,	O
as	O
well	O
as	O
those	O
elevations	O
of	O
PRA	O
induced	O
by	O
furosemide	B-Drug
administration	O
,	O
or	O
salt	O
or	O
volume	O
depletion	O
.	O

These	O
facts	O
should	O
be	O
considered	O
when	O
evaluating	O
plasma	O
renin	O
activity	O
in	O
hypertensive	O
patients	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
triamterene	B-Drug
to	O
a	O
maintenance	O
schedule	O
of	O
INDOCIN	B-Drug
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	O
volunteers	O
.	O

INDOCIN	B-Drug
and	O
triamterene	B-Drug
should	O
not	O
be	O
administered	O
together	O
.	O

INDOCIN	B-Drug
and	O
potassium-sparing	O
diuretics	B-Drug
each	O
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	B-Drug
levels	O
.	O

The	O
potential	O
effects	O
of	O
INDOCIN	B-Drug
and	O
potassium-sparing	O
diuretics	B-Drug
on	O
potassium	B-Drug
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Most	O
of	O
the	O
above	O
effects	O
concerning	O
diuretics	B-Drug
have	O
been	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
mechanisms	O
involving	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
by	O
INDOCIN	B-Drug
.	O

Blunting	O
of	O
the	O
antihypertensive	B-Drug
effect	O
of	O
beta-adrenoceptor	O
blocking	O
agents	O
by	O
non-steroidal	O
antiinflammatory	O
drugs	B-Drug
including	O
INDOCIN	B-Drug
has	O
been	O
reported	O
.	O

Therefore	O
,	O
when	O
using	O
these	O
blocking	O
agents	O
to	O
treat	O
hypertension	O
,	O
patients	O
should	O
be	O
observed	O
carefully	O
in	O
order	O
to	O
confirm	O
that	O
the	O
desired	O
therapeutic	O
effect	O
has	O
been	O
obtained	O
.	O

INDOCIN	B-Drug
can	O
reduce	O
the	O
antihypertensive	B-Drug
effects	O
of	O
captopril	B-Drug
and	O
losartan	B-Drug
.	O

False-negative	O
results	O
in	O
the	O
dexamethasone	B-Drug
suppression	O
test	O
(	O
DST	O
)	O
in	O
patients	O
being	O
treated	O
with	O
INDOCIN	B-Drug
have	O
been	O
reported	O
.	O

Thus	O
,	O
results	O
of	O
the	O
DST	O
should	O
be	O
interpreted	O
with	O
caution	O
in	O
these	O
patients	O
.	O

Concurrent	O
administration	O
of	O
etanercept	B-Drug
(	O
another	O
TNF	O
-blocking	O
agent	O
)	O
and	O
anakinra	B-Drug
(	O
an	O
interleukin-1	O
antagonist	O
)	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
,	O
and	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O

Other	O
TNFa-blocking	O
agents	O
(	O
including	O
REMICADE	B-Drug
)	O
used	O
in	O
combination	O
with	O
anakinra	B-Drug
may	O
also	O
result	O
in	O
similar	O
toxicities	O
.	O

Specific	O
drug	B-Drug
interaction	O
studies	O
,	O
including	O
interactions	O
with	O
MTX	B-Drug
,	O
have	O
not	O
been	O
conducted	O
.	O

The	O
majority	O
of	O
patients	O
in	O
rheumatoid	O
arthritis	O
or	O
Crohn	O
s	O
disease	O
clinical	O
studies	O
received	O
one	O
or	O
more	O
concomitant	O
medications	O
.	O

In	O
rheumatoid	O
arthritis	O
,	O
concomitant	O
medications	O
besides	O
MTX	B-Drug
were	O
nonsteroidal	O
anti-inflammatory	O
agents	O
,	O
folic	B-Drug
acid	I-Drug
,	O
corticosteroids	O
and/or	O
narcotics	O
.	O

Concomitant	O
Crohn	O
s	O
disease	O
medications	O
were	O
antibiotics	B-Drug
,	O
antivirals	O
,	O
corticosteroids	O
,	O
6-MP/AZA	B-Drug
and	O
aminosalicylates	O
.	O

In	O
psoriatic	O
arthritis	O
clinical	O
trials	O
,	O
concomitant	O
medications	O
included	O
MTX	B-Drug
in	O
approximately	O
half	O
of	O
the	O
patients	O
as	O
well	O
as	O
nonsteroidal	O
anti-inflammatory	O
agents	O
,	O
folic	B-Drug
acid	I-Drug
and	O
corticosteroids	O
.	O

Patients	O
with	O
Crohn	O
s	O
disease	O
who	O
received	O
immunosuppressants	O
tended	O
to	O
experience	O
fewer	O
infusion	O
reactions	O
compared	O
to	O
patients	O
on	O
no	O
immunosuppressants	O
.	O

Serum	O
infliximab	B-Drug
concentrations	O
appeared	O
to	O
be	O
unaffected	O
by	O
baseline	O
use	O
of	O
medications	O
for	O
the	O
treatment	O
of	O
Crohn	O
s	O
disease	O
including	O
corticosteroids	O
,	O
antibiotics	B-Drug
(	O
metronidazole	B-Drug
or	O
ciprofloxacin	B-Drug
)	O
and	O
aminosalicylates	O
.	O

A	O
number	O
of	O
substances	O
affect	O
glucose	B-Drug
metabolism	O
and	O
may	O
require	O
insulin	B-Drug
dose	O
adjustment	O
and	O
particularly	O
close	O
monitoring	O
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood-glucose-lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetes	O
products	O
,	O
ACE	O
inhibitors	O
,	O
disopyramide	B-Drug
,	O
fibrates	O
,	O
fluoxetine	B-Drug
,	O
MAO	O
inhibitors	O
,	O
propoxyphene	B-Drug
,	O
salicylates	O
,	O
somatostatin	B-Drug
analog	O
(	O
e.g.	O
,	O
octreotide	B-Drug
)	O
,	O
sulfonamide	O
antibiotics	B-Drug
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood-glucose-lowering	O
effect	O
of	O
insulin	B-Drug
:	O
corticosteroids	O
,	O
danazol	B-Drug
,	O
diuretics	B-Drug
,	O
sympathomimetic	B-Drug
agents	O
(	O
e.g.	O
,	O
epinephrine	B-Drug
,	O
albuterol	B-Drug
,	O
terbutaline	B-Drug
)	O
,	O
isoniazid	B-Drug
,	O
phenothiazine	O
derivatives	O
,	O
somatropin	B-Drug
,	O
thyroid	B-Drug
hormones	O
,	O
estrogens	O
,	O
progestogens	O
(	O
e.g.	O
,	O
in	O
oral	O
contraceptives	O
)	O
.	O

Beta-blockers	O
,	O
clonidine	B-Drug
,	O
lithium	B-Drug
salts	O
,	O
and	O
alcohol	B-Drug
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood-glucose-lowering	O
effect	O
of	O
insulin	B-Drug
.	O

Pentamidine	B-Drug
may	O
cause	O
hypoglycemia	O
,	O
which	O
may	O
sometimes	O
be	O
followed	O
by	O
hyperglycemia	O
.	O

In	O
addition	O
,	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta-blockers	O
,	O
clonidine	B-Drug
,	O
guanethidine	B-Drug
,	O
and	O
reserpine	B-Drug
,	O
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O

A	O
number	O
of	O
substances	O
affect	O
glucose	B-Drug
metabolism	O
and	O
may	O
require	O
insulin	B-Drug
dose	O
adjustment	O
and	O
particularly	O
close	O
monitoring	O
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood-glucose-lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetic	B-Drug
products	O
,	O
ACE	O
inhibitors	O
,	O
disopyramide	B-Drug
,	O
fibrates	O
,	O
fluoxetine	B-Drug
,	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
,	O
propoxyphene	B-Drug
,	O
salicylates	O
,	O
somatostatin	B-Drug
analog	O
(	O
e.g.	O
,	O
octreotide	B-Drug
)	O
,	O
sulfonamide	O
antibiotics	B-Drug
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood-glucose-lowering	O
effect	O
:	O
corticosteroids	O
,	O
niacin	B-Drug
,	O
danazol	B-Drug
,	O
diuretics	B-Drug
,	O
sympathomimetic	B-Drug
agents	O
(	O
e.g.	O
,	O
epinephrine	B-Drug
,	O
salbutamol	B-Drug
,	O
terbutaline	B-Drug
)	O
,	O
isoniazid	B-Drug
,	O
phenothiazine	O
derivatives	O
,	O
somatropin	B-Drug
,	O
thyroid	B-Drug
hormones	O
,	O
estrogens	O
,	O
progestogens	O
(	O
e.g.	O
,	O
in	O
oral	O
contraceptives	O
)	O
.	O

Beta-blockers	O
,	O
clonidine	B-Drug
,	O
lithium	B-Drug
salts	O
,	O
and	O
alcohol	B-Drug
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood-glucose-lowering	O
effect	O
of	O
insulin	B-Drug
.	O

Pentamidine	B-Drug
may	O
cause	O
hypoglycemia	O
,	O
which	O
may	O
sometimes	O
be	O
followed	O
by	O
hyperglycemia	O
.	O

In	O
addition	O
,	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta-blockers	O
,	O
clonidine	B-Drug
,	O
guanethidine	B-Drug
,	O
and	O
reserpine	B-Drug
,	O
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O

Mixing	O
of	O
Insulins	B-Drug
A	O
clinical	O
study	O
in	O
healthy	O
male	O
volunteers	O
(	O
n=24	O
)	O
demonstrated	O
that	O
mixing	O
NovoLog	B-Drug
with	O
NPH	B-Drug
human	I-Drug
insulin	I-Drug
immediately	O
before	O
injection	O
produced	O
some	O
attenuation	O
in	O
the	O
peak	O
concentration	O
of	O
NovoLog	B-Drug
,	O
but	O
that	O
the	O
time	O
to	O
peak	O
and	O
the	O
total	O
bioavailability	O
of	O
NovoLog	B-Drug
were	O
not	O
significantly	O
affected	O
.	O

If	O
NovoLog	B-Drug
is	O
mixed	O
with	O
NPH	B-Drug
human	I-Drug
insulin	I-Drug
,	O
NovoLog	B-Drug
should	O
be	O
drawn	O
into	O
the	O
syringe	O
first	O
.	O

The	O
injection	O
should	O
be	O
made	O
immediately	O
after	O
mixing	O
.	O

Because	O
there	O
are	O
no	O
data	O
on	O
the	O
compatibility	O
of	O
NovoLog	B-Drug
and	O
crystalline	O
zinc	B-Drug
insulin	I-Drug
preparations	O
,	O
NovoLog	B-Drug
should	O
not	O
be	O
mixed	O
with	O
these	O
preparations	O
.	O

The	O
effects	O
of	O
mixing	O
NovoLog	B-Drug
with	O
insulins	B-Drug
of	O
animal	O
source	O
or	O
insulin	B-Drug
preparations	O
produced	O
by	O
other	O
manufacturers	O
have	O
not	O
been	O
studied	O
.	O

Mixtures	O
should	O
not	O
be	O
administered	O
intravenously	O
.	O

When	O
used	O
in	O
external	O
subcutaneous	O
infusion	O
pumps	O
for	O
insulin	B-Drug
,	O
NovoLog	B-Drug
should	O
not	O
be	O
mixed	O
with	O
any	O
other	O
insulins	B-Drug
or	O
diluent	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Rebif	B-Drug
.	O

Due	O
to	O
its	O
potential	O
to	O
cause	O
neutropenia	O
and	O
lymphopenia	O
,	O
proper	O
monitoring	O
of	O
patients	O
is	O
required	O
if	O
Rebif	B-Drug
is	O
given	O
in	O
combination	O
with	O
myelosuppressive	O
agents	O
.	O

Also	O
,	O
the	O
potential	O
for	O
hepatic	O
injury	O
should	O
be	O
considered	O
when	O
Rebif	B-Drug
is	O
used	O
in	O
combination	O
with	O
other	O
products	O
associated	O
with	O
hepatic	O
injury	O
,	O
or	O
when	O
new	O
agents	O
are	O
added	O
to	O
the	O
regimen	O
of	O
patients	O
already	O
on	O
Rebif	B-Drug
.	O

Interactions	O
between	O
Betaseron	B-Drug
and	O
other	O
drugs	B-Drug
have	O
not	O
been	O
fully	O
evaluated	O
.	O

Although	O
studies	O
designed	O
to	O
examine	O
drug	B-Drug
interactions	O
have	O
not	O
been	O
done	O
,	O
it	O
was	O
noted	O
that	O
corticosteroid	B-Drug
or	O
ACTH	B-Drug
treatment	O
of	O
relapses	O
for	O
periods	O
of	O
up	O
to	O
28	O
days	O
has	O
been	O
administered	O
to	O
patients	O
(	O
N=180	O
)	O
receiving	O
Betaseron	B-Drug
.	O

Betaseron	B-Drug
administration	O
to	O
three	O
cancer	O
patients	O
over	O
a	O
dose	O
range	O
of	O
0.025	O
mg	O
to	O
2.2	O
mg	O
led	O
to	O
a	O
dose-dependent	O
inhibition	O
of	O
antipyrine	B-Drug
elimination.14	O
The	O
effect	O
of	O
alternate-day	O
administration	O
of	O
0.25	O
mg	O
of	O
Betaseron	B-Drug
on	O
drug	B-Drug
metabolism	O
in	O
MS	O
patients	O
is	O
unknown	O
.	O

ATROVENT	B-Drug
Inhalation	O
Aerosol	O
has	O
been	O
used	O
concomitantly	O
with	O
other	O
drugs	B-Drug
,	O
including	O
sympathomimetic	B-Drug
bronchodilators	O
,	O
methylxanthines	O
,	O
and	O
steroids	O
,	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

With	O
the	O
exception	O
of	O
albuterol	B-Drug
,	O
there	O
are	O
no	O
formal	O
studies	O
fully	O
evaluating	O
the	O
interaction	O
effects	O
of	O
ATROVENT	B-Drug
Inhalation	O
Aerosol	O
and	O
these	O
drugs	B-Drug
with	O
respect	O
to	O
effectiveness	O
.	O

Anticholinergic	B-Drug
agents	O
:	O
Although	O
ipratropium	B-Drug
bromide	I-Drug
is	O
minimally	O
absorbed	O
into	O
the	O
systemic	O
circulation	O
,	O
there	O
is	O
some	O
potential	O
for	O
an	O
additive	O
interaction	O
with	O
concomitantly	O
used	O
anticholinergic	B-Drug
medications	O
.	O

Caution	O
is	O
therefore	O
advised	O
in	O
the	O
coadministration	O
of	O
ATROVENT	B-Drug
Inhalation	O
Aerosol	O
with	O
other	O
anticholinergic-containing	O
drugs	B-Drug
.	O

No	O
significant	O
drug-drug	O
pharmacokinetic	O
(	O
or	O
pharmacodynamic	O
)	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B-Drug
,	O
digoxin	B-Drug
,	O
warfarin	B-Drug
,	O
and	O
nifedipine	B-Drug
.	O

In	O
vitro	O
studies	O
show	O
significant	O
inhibition	O
of	O
the	O
formation	O
of	O
oxidized	O
irbesartan	B-Drug
metabolites	O
with	O
the	O
known	O
cytochrome	O
CYP	O
2C9	O
substrates/inhibitors	O
sulphenazole	B-Drug
,	O
tolbutamide	B-Drug
and	O
nifedipine	B-Drug
.	O

However	O
,	O
in	O
clinical	O
studies	O
the	O
consequences	O
of	O
concomitant	O
irbesartan	B-Drug
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
were	O
negligible	O
.	O

Based	O
on	O
in	O
vitro	O
data	O
,	O
no	O
interaction	O
would	O
be	O
expected	O
with	O
drugs	B-Drug
whose	O
metabolism	O
is	O
dependent	O
upon	O
cytochrome	O
P450	O
isozymes	O
1A1	O
,	O
1A2,2A6,2B6,2D6,2E1	O
,	O
or	O
3A4	O
.	O

In	O
separate	O
studies	O
of	O
patients	O
receiving	O
maintenance	O
doses	O
of	O
warfarin	B-Drug
,	O
hydrochlorothiazide	B-Drug
,	O
or	O
digoxin	B-Drug
,	O
irbesartan	B-Drug
administration	O
for	O
7	O
days	O
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B-Drug
(	O
prothrombin	O
time	O
)	O
or	O
pharmacokinetics	O
of	O
digoxin	B-Drug
.	O

The	O
pharmacokinetics	O
of	O
irbesartan	B-Drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
nifedipine	B-Drug
or	O
hydrochlorothiazide	B-Drug
.	O

The	O
adverse	O
effects	O
of	O
CAMPTOSAR	B-Drug
,	O
such	O
as	O
myelosuppression	O
and	O
diarrhea	O
,	O
would	O
be	O
expected	O
to	O
be	O
exacerbated	O
by	O
other	O
antineoplastic	O
agents	O
having	O
similar	O
adverse	O
effects	O
.	O

Patients	O
who	O
have	O
previously	O
received	O
pelvic/	O
abdominal	O
irradiation	O
are	O
at	O
increased	O
risk	O
of	O
severe	O
myelosuppression	O
following	O
the	O
administration	O
of	O
CAMPTOSAR	B-Drug
.	O

The	O
concurrent	O
administration	O
of	O
CAMPTOSAR	B-Drug
with	O
irradiation	O
has	O
not	O
been	O
adequately	O
studied	O
and	O
is	O
not	O
recommended	O
.	O

Lymphocytopenia	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	B-Drug
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
administration	O
of	O
dexamethasone	B-Drug
as	O
antiemetic	O
prophylaxis	O
may	O
have	O
enhanced	O
the	O
likelihood	O
of	O
this	O
effect	O
.	O

However	O
,	O
serious	O
opportunistic	O
infections	O
have	O
not	O
been	O
observed	O
,	O
and	O
no	O
complications	O
have	O
specifically	O
been	O
attributed	O
to	O
lymphocytopenia	O
.	O

Hyperglycemia	O
has	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	B-Drug
.	O

Usually	O
,	O
this	O
has	O
been	O
observed	O
in	O
patients	O
with	O
a	O
history	O
of	O
diabetes	O
mellitus	O
or	O
evidence	O
of	O
glucose	B-Drug
intolerance	O
prior	O
to	O
administration	O
of	O
CAMPTOSAR	B-Drug
.	O

It	O
is	O
probable	O
that	O
dexamethasone	B-Drug
,	O
given	O
as	O
antiemetic	O
prophylaxis	O
,	O
contributed	O
to	O
hyperglycemia	O
in	O
some	O
patients	O
.	O

The	O
incidence	O
of	O
akathisia	O
in	O
clinical	O
trials	O
of	O
the	O
weekly	O
dosage	O
schedule	O
was	O
greater	O
(	O
8.5	O
%	O
,	O
4/47	O
patients	O
)	O
when	O
prochlorperazine	B-Drug
was	O
administered	O
on	O
the	O
same	O
day	O
as	O
CAMPTOSAR	B-Drug
than	O
when	O
these	O
drugs	B-Drug
were	O
given	O
on	O
separate	O
days	O
(	O
1.3	O
%	O
,	O
1/80	O
patients	O
)	O
.	O

The	O
8.5	O
%	O
incidence	O
of	O
akathisia	O
,	O
however	O
,	O
is	O
within	O
the	O
range	O
reported	O
for	O
use	O
of	O
prochlorperazine	B-Drug
when	O
given	O
as	O
a	O
premedication	O
for	O
other	O
chemotherapies	O
.	O

It	O
would	O
be	O
expected	O
that	O
laxative	O
use	O
during	O
therapy	O
with	O
CAMPTOSAR	B-Drug
would	O
worsen	O
the	O
incidence	O
or	O
severity	O
of	O
diarrhea	O
,	O
but	O
this	O
has	O
not	O
been	O
studied	O
.	O

In	O
view	O
of	O
the	O
potential	O
risk	O
of	O
dehydration	O
secondary	O
to	O
vomiting	O
and/or	O
diarrhea	O
induced	O
by	O
CAMPTOSAR	B-Drug
,	O
the	O
physician	O
may	O
wish	O
to	O
withhold	O
diuretics	B-Drug
during	O
dosing	O
with	O
CAMPTOSAR	B-Drug
and	O
,	O
certainly	O
,	O
during	O
periods	O
of	O
active	O
vomiting	O
or	O
diarrhea	O
.	O

Drug-Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
CAMPTOSAR	B-Drug
and	O
laboratory	O
tests	O
.	O

Isocarboxazid	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
receiving	O
Antabuse	B-Drug
(	O
disulfiram	B-Drug
,	O
Wyeth-Ayerst	O
Laboratories	O
)	O
.	O

In	O
a	O
single	O
study	O
,	O
rats	O
given	O
high	O
intraperitoneal	O
doses	O
of	O
an	O
MAO	O
inhibitor	O
plus	O
disulfiram	B-Drug
experienced	O
severe	O
toxicity	O
,	O
including	O
convulsions	O
and	O
death	O
.	O

Concomitant	O
use	O
of	O
Isocarboxazid	B-Drug
and	O
other	O
psychotropic	O
agents	O
is	O
generally	O
not	O
recommended	O
because	O
of	O
possible	O
potentiating	O
effects	O
.	O

This	O
is	O
especially	O
true	O
in	O
patients	O
who	O
may	O
subject	O
themselves	O
to	O
an	O
overdosage	O
of	O
drugs	B-Drug
.	O

If	O
combination	O
therapy	O
is	O
needed	O
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
all	O
agents	O
to	O
be	O
used	O
.	O

The	O
monoamine	O
oxidase	O
inhibitory	O
effects	O
of	O
Isocarboxazid	B-Drug
may	O
persist	O
for	O
a	O
substantial	O
period	O
after	O
discontinuation	O
of	O
the	O
drug	B-Drug
,	O
and	O
this	O
should	O
be	O
borne	O
in	O
mind	O
when	O
another	O
drug	B-Drug
is	O
prescribed	O
following	O
Isocarboxazid	B-Drug
.	O

To	O
avoid	O
potentiation	O
,	O
the	O
physician	O
wishing	O
to	O
terminate	O
treatment	O
with	O
Isocarboxazid	B-Drug
and	O
begin	O
therapy	O
with	O
another	O
agent	O
should	O
allow	O
for	O
an	O
interval	O
of	O
10	O
days	O
.	O

May	O
interact	O
with	O
the	O
following	O
:	O
beta-adrenergic	O
blocking	O
agents	O
(	O
these	O
medicines	O
may	O
make	O
your	O
condition	O
worse	O
and	O
prevent	O
the	O
adrenergic	O
bronchodilators	O
from	O
working	O
properly	O
)	O
and	O
disopyramide	B-Drug
,	O
quinidine	B-Drug
,	O
phenothiazines	O
,	O
and	O
procainamide	B-Drug
(	O
these	O
medicines	O
may	O
increase	O
the	O
risk	O
of	O
heart	O
problems	O
)	O
.	O

Isoflurane	B-Drug
potentiates	O
the	O
muscle	O
relaxant	O
effect	O
of	O
all	O
muscle	O
relaxants	O
,	O
most	O
notably	O
nondepolarizing	O
muscle	O
relaxants	O
,	O
and	O
MAC	O
(	O
minimum	O
alveolar	O
concentration	O
)	O
is	O
reduced	O
by	O
concomitant	O
administration	O
of	O
N	O
2O	O
.	O

See	O
CLINICAL	O
PHARMACOLOGY	O
.	O

Food	O
:	O
Isoniazid	B-Drug
should	O
not	O
be	O
administered	O
with	O
food	O
.	O

Studies	O
have	O
shown	O
that	O
the	O
bioavailability	O
of	O
isoniazid	B-Drug
is	O
reduced	O
significantly	O
when	O
administered	O
with	O
food	O
.	O

Acetaminophen	B-Drug
:	O
A	O
report	O
of	O
severe	O
acetaminophen	B-Drug
toxicity	O
was	O
reported	O
in	O
a	O
patient	O
receiving	O
Isoniazid	B-Drug
.	O

It	O
is	O
believed	O
that	O
the	O
toxicity	O
may	O
have	O
resulted	O
from	O
a	O
previously	O
unrecognized	O
interaction	O
between	O
isoniazid	B-Drug
and	O
acetaminophen	B-Drug
and	O
a	O
molecular	O
basis	O
for	O
this	O
interaction	O
has	O
been	O
proposed	O
.	O

However	O
,	O
current	O
evidence	O
suggests	O
that	O
isoniazid	B-Drug
does	O
induce	O
P-450IIE1	O
,	O
a	O
mixed-function	O
oxidase	O
enzyme	O
that	O
appears	O
to	O
generate	O
the	O
toxic	O
metabolites	O
,	O
in	O
the	O
liver	O
.	O

Furthermore	O
it	O
has	O
been	O
proposed	O
that	O
isoniazid	B-Drug
resulted	O
In	O
induction	O
of	O
P-450IIE1	O
in	O
the	O
patients	O
liver	O
which	O
,	O
in	O
turn	O
,	O
resulted	O
in	O
a	O
greater	O
proportion	O
of	O
the	O
ingested	O
acetaminophen	B-Drug
being	O
converted	O
to	O
the	O
toxic	O
metabolites	O
.	O

Studies	O
have	O
demonstrated	O
that	O
pretreatment	O
with	O
isoniazid	B-Drug
potentiates	O
a	O
cetaminophen	O
hepatoxicity	O
in	O
rats	O
.	O

Carbamazepine	B-Drug
:	O
Isoniazid	B-Drug
is	O
known	O
to	O
slow	O
the	O
metabolism	O
of	O
carbamazepine	B-Drug
and	O
increase	O
its	O
serum	O
levels	O
Carbamazepine	B-Drug
levels	O
should	O
be	O
determined	O
prior	O
to	O
concurrent	O
administration	O
with	O
isoniazid	B-Drug
,	O
signs	O
and	O
symptoms	O
of	O
carbamazepine	B-Drug
toxicity	O
should	O
be	O
monitored	O
closely	O
,	O
and	O
appropriate	O
dosage	O
adjustment	O
of	O
the	O
anticonvulsant	O
should	O
be	O
made	O
.	O

Ketoconazole	B-Drug
:	O
Potential	O
interaction	O
of	O
Ketoconazole	B-Drug
and	O
Isoniazid	B-Drug
may	O
exist	O
.	O

Phenytoin	B-Drug
:	O
Isoniazid	B-Drug
may	O
increase	O
serum	O
levels	O
of	O
phenytoin	B-Drug
.	O

To	O
avoid	O
phenytoin	B-Drug
intoxication	O
,	O
appropriate	O
adjustment	O
of	O
the	O
anticonvulsant	O
should	O
be	O
made	O
.	O

Therophylline	O
:	O
A	O
recent	O
study	O
has	O
shown	O
that	O
concomitan	O
administration	O
of	O
isoniazid	B-Drug
and	O
theophylline	B-Drug
may	O
cause	O
elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
,	O
and	O
in	O
some	O
instances	O
a	O
slight	O
decrease	O
in	O
the	O
elimination	O
of	O
isoniazid	B-Drug
.	O

Since	O
the	O
therapeutic	O
range	O
of	O
theophylline	B-Drug
is	O
narrow	O
theophylline	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
closely	O
,	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
theophylline	B-Drug
should	O
be	O
made	O
.	O

Valproate	B-Drug
:	O
A	O
recent	O
case	O
study	O
has	O
shown	O
a	O
possible	O
increase	O
in	O
the	O
plasma	O
level	O
of	O
valproate	B-Drug
when	O
co	B-Drug
administered	O
with	O
isoniazid	B-Drug
.	O

Plasma	O
valproate	B-Drug
concentration	O
should	O
be	O
monitored	O
when	O
isoniazid	B-Drug
and	O
valproate	B-Drug
are	O
co	B-Drug
administered	O
,	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
valproate	B-Drug
should	O
be	O
made	O
.	O

Isoproterenol	B-Drug
hydrochloride	I-Drug
injection	O
and	O
epinephrine	B-Drug
should	O
not	O
be	O
administered	O
simultaneously	O
because	O
both	O
drugs	B-Drug
are	O
direct	O
cardiac	O
stimulants	O
and	O
their	O
combined	O
effects	O
may	O
induce	O
serious	O
arrhythmias	O
.	O

The	O
drugs	B-Drug
may	O
,	O
however	O
,	O
be	O
administered	O
alternately	O
provided	O
a	O
proper	O
interval	O
has	O
elapsed	O
between	O
doses	O
.	O

ISUPREL	B-Drug
should	O
be	O
used	O
with	O
caution	O
,	O
if	O
at	O
all	O
,	O
when	O
potent	O
inhalational	O
anesthetics	B-Drug
such	O
as	O
halothane	B-Drug
are	O
employed	O
because	O
of	O
potential	O
to	O
sensitize	O
the	O
myocardium	O
to	O
effects	O
of	O
sympathomimetic	B-Drug
amines	O
.	O

The	O
vasodilating	O
effects	O
of	O
isosorbide	B-Drug
dinitrate	I-Drug
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	O
.	O

Alcohol	B-Drug
,	O
in	O
particular	O
,	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O

The	O
vasodilating	O
effects	O
of	O
isosorbide	B-Drug
mononitrate	I-Drug
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	O
.	O

Alcohol	B-Drug
,	O
in	O
particular	O
,	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O

Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B-Drug
channel	O
blockers	O
and	O
organic	O
nitrates	B-Drug
were	O
used	O
in	O
combination	O
.	O

Dose	O
adjustments	O
of	O
either	O
class	O
of	O
agents	O
may	O
be	O
necessary	O
.	O

Vitamin	O
A	O
:	O
Because	O
of	O
the	O
relationship	O
of	O
Accutane	B-Drug
to	O
vitamin	O
A	O
,	O
patients	O
should	O
be	O
advised	O
against	O
taking	O
vitamin	O
supplements	O
containing	O
vitamin	O
A	O
to	O
avoid	O
additive	O
toxic	O
effects	O
.	O

Tetracyclines	O
:	O
Concomitant	O
treatment	O
with	O
Accutane	B-Drug
and	O
tetracyclines	O
should	O
be	O
avoided	O
because	O
Accutane	B-Drug
use	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
cases	O
of	O
pseudotumor	O
cerebri	O
(	O
benign	O
intracranial	O
hypertension	O
)	O
,	O
some	O
of	O
which	O
involved	O
concomitant	O
use	O
of	O
tetracyclines	O
.	O

Micro-dosed	O
Progesterone	B-Drug
Preparations	O
:	O
Micro-dosed	O
progesterone	B-Drug
preparations	O
(	O
minipills	O
that	O
do	O
not	O
contain	O
an	O
estrogen	O
)	O
may	O
be	O
an	O
inadequate	O
method	O
of	O
contraception	O
during	O
Accutane	B-Drug
therapy	O
.	O

Although	O
other	O
hormonal	O
contraceptives	O
are	O
highly	O
effective	O
,	O
there	O
have	O
been	O
reports	O
of	O
pregnancy	O
from	O
women	O
who	O
have	O
used	O
combined	O
oral	O
contraceptives	O
,	O
as	O
well	O
as	O
topical/injectable/implantable/insertable	O
hormonal	O
birth	O
control	O
products	O
.	O

These	O
reports	O
are	O
more	O
frequent	O
for	O
women	O
who	O
use	O
only	O
a	O
single	O
method	O
of	O
contraception	O
.	O

It	O
is	O
not	O
known	O
if	O
hormonal	O
contraceptives	O
differ	O
in	O
their	O
effectiveness	O
when	O
used	O
with	O
Accutane	B-Drug
.	O

Therefore	O
,	O
it	O
is	O
critically	O
important	O
for	O
women	O
of	O
childbearing	O
potential	O
to	O
select	O
and	O
commit	O
to	O
use	O
2	O
forms	O
of	O
effective	O
contraception	O
simultaneously	O
,	O
at	O
least	O
1	O
of	O
which	O
must	O
be	O
a	O
primary	O
form	O
,	O
unless	O
absolute	O
abstinence	O
is	O
the	O
chosen	O
method	O
,	O
or	O
the	O
patient	O
has	O
undergone	O
a	O
hysterectomy	O
.	O

Phenytoin	B-Drug
:	O
Accutane	B-Drug
has	O
not	O
been	O
shown	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	B-Drug
in	O
a	O
study	O
in	O
seven	O
healthy	O
volunteers	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
in	O
vitro	O
finding	O
that	O
neither	O
isotretinoin	B-Drug
nor	O
its	O
metabolites	O
induce	O
or	O
inhibit	O
the	O
activity	O
of	O
the	O
CYP	O
2C9	O
human	O
hepatic	O
P450	O
enzyme	O
.	O

Phenytoin	B-Drug
is	O
known	O
to	O
cause	O
osteomalacia	O
.	O

No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
phenytoin	B-Drug
and	O
Accutane	B-Drug
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
using	O
these	O
drugs	B-Drug
together	O
.	O

Systemic	O
Corticosteroids	O
:	O
Systemic	O
corticosteroids	O
are	O
known	O
to	O
cause	O
osteoporosis	O
.	O

No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
systemic	O
corticosteroids	O
and	O
Accutane	B-Drug
.	O

Therefore	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
using	O
these	O
drugs	B-Drug
together	O
.	O

Prescribers	O
are	O
advised	O
to	O
consult	O
the	O
package	O
insert	O
of	O
medication	O
administered	O
concomitantly	O
with	O
hormonal	O
contraceptives	O
,	O
since	O
some	O
medications	O
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
birth	O
control	O
products	O
.	O

Accutane	B-Drug
use	O
is	O
associated	O
with	O
depression	O
in	O
some	O
patients	O
.	O

Pregnancies	O
have	O
been	O
reported	O
by	O
users	O
of	O
combined	O
hormonal	O
contraceptives	O
who	O
also	O
used	O
some	O
form	O
of	O
St.	O
Johns	O
Wort	O
.	O

Laboratory	O
Tests	O
Pregnancy	O
Test	O
Female	O
patients	O
of	O
childbearing	O
potential	O
must	O
have	O
negative	O
results	O
from	O
2	O
urine	O
or	O
serum	O
pregnancy	O
tests	O
with	O
a	O
sensitivity	O
of	O
at	O
least	O
25	O
mIU/mL	O
before	O
receiving	O
the	O
initial	O
Accutane	B-Drug
prescription	O
.	O

The	O
first	O
test	O
is	O
obtained	O
by	O
the	O
prescriber	O
when	O
the	O
decision	O
is	O
made	O
to	O
pursue	O
qualification	O
of	O
the	O
patient	O
for	O
Accutane	B-Drug
(	O
a	O
screening	O
test	O
)	O
.	O

The	O
second	O
pregnancy	O
test	O
(	O
a	O
confirmation	O
test	O
)	O
should	O
be	O
done	O
during	O
the	O
first	O
5	O
days	O
of	O
the	O
menstrual	O
period	O
immediately	O
preceding	O
the	O
beginning	O
of	O
Accutane	B-Drug
therapy	O
.	O

For	O
patients	O
with	O
amenorrhea	O
,	O
the	O
second	O
test	O
should	O
be	O
done	O
at	O
least	O
11	O
days	O
after	O
the	O
last	O
act	O
of	O
unprotected	O
sexual	O
intercourse	O
(	O
without	O
using	O
2	O
effective	O
forms	O
of	O
contraception	O
)	O
.	O

Each	O
month	O
of	O
therapy	O
,	O
the	O
patient	O
must	O
have	O
a	O
negative	O
result	O
from	O
a	O
urine	O
or	O
serum	O
pregnancy	O
test	O
.	O

A	O
pregnancy	O
test	O
must	O
be	O
repeated	O
each	O
month	O
prior	O
to	O
the	O
female	O
patient	O
receiving	O
each	O
prescription	O
.	O

Lipids	O
:	O
Pretreatment	O
and	O
follow-up	O
blood	O
lipids	O
should	O
be	O
obtained	O
under	O
fasting	O
conditions	O
.	O

After	O
consumption	O
of	O
alcohol	B-Drug
,	O
at	O
least	O
36	O
hours	O
should	O
elapse	O
before	O
these	O
determinations	O
are	O
made	O
.	O

It	O
is	O
recommended	O
that	O
these	O
tests	O
be	O
performed	O
at	O
weekly	O
or	O
biweekly	O
intervals	O
until	O
the	O
lipid	O
response	O
to	O
Accutane	B-Drug
is	O
established	O
.	O

The	O
incidence	O
of	O
hypertriglyceridemia	O
is	O
1	O
patient	O
in	O
4	O
on	O
Accutane	B-Drug
therapy	O
.	O

Liver	O
Function	O
Tests	O
:	O
Since	O
elevations	O
of	O
liver	O
enzymes	O
have	O
been	O
observed	O
during	O
clinical	O
trials	O
,	O
and	O
hepatitis	O
has	O
been	O
reported	O
,	O
pretreatment	O
and	O
follow-up	O
liver	O
function	O
tests	O
should	O
be	O
performed	O
at	O
weekly	O
or	O
biweekly	O
intervals	O
until	O
the	O
response	O
to	O
Accutane	B-Drug
has	O
been	O
established	O
.	O

Glucose	B-Drug
:	O
Some	O
patients	O
receiving	O
Accutane	B-Drug
have	O
experienced	O
problems	O
in	O
the	O
control	O
of	O
their	O
blood	O
sugar	O
.	O

In	O
addition	O
,	O
new	O
cases	O
of	O
diabetes	O
have	O
been	O
diagnosed	O
during	O
Accutane	B-Drug
therapy	O
,	O
although	O
no	O
causal	O
relationship	O
has	O
been	O
established	O
.	O

CPK	O
:	O
Some	O
patients	O
undergoing	O
vigorous	O
physical	O
activity	O
while	O
on	O
Accutane	B-Drug
therapy	O
have	O
experienced	O
elevated	O
CPK	O
levels	O
;	O
however	O
,	O
the	O
clinical	O
significance	O
is	O
unknown	O
.	O

There	O
have	O
been	O
rare	O
postmarketing	O
reports	O
of	O
rhabdomyolysis	O
,	O
some	O
associated	O
with	O
strenuous	O
physical	O
activity	O
.	O

In	O
a	O
clinical	O
trial	O
of	O
217	O
pediatric	O
patients	O
(	O
12	O
to	O
17	O
years	O
)	O
with	O
severe	O
recalcitrant	O
nodular	O
acne	O
,	O
transient	O
elevations	O
in	O
CPK	O
were	O
observed	O
in	O
12	O
%	O
of	O
patients	O
,	O
including	O
those	O
undergoing	O
strenuous	O
physical	O
activity	O
in	O
association	O
with	O
reported	O
musculoskeletal	O
adverse	O
events	O
such	O
as	O
back	O
pain	O
,	O
arthralgia	O
,	O
limb	O
injury	O
,	O
or	O
muscle	O
sprain	O
.	O

In	O
these	O
patients	O
,	O
approximately	O
half	O
of	O
the	O
CPK	O
elevations	O
returned	O
to	O
normal	O
within	O
2	O
weeks	O
and	O
half	O
returned	O
to	O
normal	O
within	O
4	O
weeks	O
.	O

No	O
cases	O
of	O
rhabdomyolysis	O
were	O
reported	O
in	O
this	O
trial	O
.	O

Nitroglycerin	B-Drug
:	O
DynaCirc	B-Drug
(	O
isradipine	B-Drug
)	O
has	O
been	O
safely	O
coadministered	O
with	O
nitroglycerin	B-Drug
.	O

Hydrochlorothiazide	B-Drug
:	O
A	O
study	O
in	O
normal	O
healthy	O
volunteers	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
DynaCirc	B-Drug
(	O
isradipine	B-Drug
)	O
and	O
hydrochlorothiazide	B-Drug
does	O
not	O
result	O
in	O
altered	O
pharmacoktnetics	O
of	O
either	O
drug	B-Drug
.	O

In	O
a	O
study	O
in	O
hypertensive	O
patients	O
,	O
addition	O
of	O
isradipine	B-Drug
to	O
existing	O
hydrochlorothiazide	B-Drug
therapy	O
did	O
not	O
result	O
in	O
any	O
unexpected	O
adverse	O
effects	O
,	O
and	O
isradipine	B-Drug
had	O
an	O
additional	O
antihypertensive	B-Drug
effect	O
.	O

Propranolol	B-Drug
:	O
In	O
a	O
single	O
dose	O
study	O
in	O
normal	O
volunteers	O
,	O
coadministration	O
of	O
propranolol	B-Drug
had	O
a	O
small	O
effect	O
on	O
the	O
rate	O
but	O
no	O
effect	O
on	O
the	O
extent	O
of	O
isradipine	B-Drug
bioavailability	O
.	O

Significant	O
increases	O
In	O
AUC	O
(	O
27	O
%	O
)	O
and	O
Cmax	O
(	O
58	O
%	O
)	O
and	O
decreases	O
in	O
tmax	O
(	O
23	O
%	O
)	O
of	O
propranolol	B-Drug
were	O
noted	O
in	O
this	O
study	O
.	O

However	O
,	O
concomitant	O
administration	O
of	O
5	O
mg	O
b.i.d	O
.	O

isradipine	B-Drug
and	O
40	O
mg	O
b.i.d	O
.	O

propranolol	B-Drug
to	O
healthy	O
volunteers	O
under	O
steady-state	O
conditions	O
had	O
no	O
relevant	O
effect	O
on	O
either	O
drug	B-Drug
s	O
bioavailability	O
,	O
AUC	O
and	O
Cmax	O
,	O
differences	O
were	O
20	O
%	O
between	O
isradipine	B-Drug
given	O
singly	O
and	O
in	O
combination	O
with	O
propranolol	B-Drug
,	O
and	O
between	O
propranolol	B-Drug
given	O
singly	O
and	O
in	O
combination	O
with	O
isradipine	B-Drug
.	O

Cimetidine	B-Drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
a	O
one-week	O
course	O
of	O
cimetidine	B-Drug
at	O
400	O
mg	O
b.i.d	O
.	O

with	O
a	O
single	O
5	O
mg	O
dose	O
of	O
isradipine	B-Drug
on	O
the	O
sixth	O
day	O
showed	O
an	O
increase	O
in	O
isradipine	B-Drug
mean	O
peak	O
plasma	O
concentrations	O
(	O
36	O
%	O
)	O
and	O
significant	O
increase	O
in	O
area	O
under	O
the	O
curve	O
(	O
50	O
%	O
)	O
.	O

If	O
isradipine	B-Drug
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	B-Drug
careful	O
monitoring	O
for	O
adverse	O
reactions	O
is	O
advised	O
and	O
downward	O
dose	O
adjustment	O
may	O
be	O
required	O
.	O

Rifampicin	B-Drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
a	O
six-day	O
course	O
of	O
rifampicin	B-Drug
at	O
600	O
mg/day	O
followed	O
by	O
a	O
single	O
5	O
mg	O
dose	O
of	O
isradipine	B-Drug
resulted	O
in	O
a	O
reduction	O
in	O
isradipine	B-Drug
levels	O
to	O
below	O
detectable	O
limits	O
.	O

If	O
rifampicin	B-Drug
therapy	O
is	O
required	O
,	O
isradipine	B-Drug
concentrations	O
and	O
therapeutic	O
effects	O
are	O
likely	O
to	O
be	O
markedly	O
reduced	O
or	O
abolished	O
as	O
a	O
consequence	O
of	O
increased	O
metabolism	O
and	O
higher	O
clearance	O
of	O
isradipine	B-Drug
.	O

Warfarin	B-Drug
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
no	O
clinically	O
relevant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
between	O
isradipine	B-Drug
and	O
racemic	O
warfarin	B-Drug
was	O
seen	O
when	O
two	O
single	O
oral	O
doses	O
of	O
warfarin	B-Drug
(	O
0.7	O
mg/kg	O
body	O
weight	O
)	O
were	O
administered	O
during	O
11	O
days	O
of	O
multipledose	O
treatment	O
with	O
5	O
mg	O
b.i.d	O
.	O

isradipine	B-Drug
.	O

Neither	O
racemic	O
warfarin	B-Drug
nor	O
isradipine	B-Drug
binding	O
to	O
plasma	O
proteins	O
in	O
vitro	O
was	O
altered	O
by	O
the	O
addition	O
of	O
the	O
other	O
drug	B-Drug
.	O

Digoxin	B-Drug
:	O
The	O
concomitant	O
administration	O
of	O
DynaCirc	B-Drug
(	O
isradipine	B-Drug
)	O
and	O
digoxin	B-Drug
in	O
a	O
single-dose	O
pharmacokinetic	O
study	O
did	O
not	O
affect	O
renal	O
,	O
nonrenal	O
and	O
total	O
body	O
clearance	O
of	O
digoxin	B-Drug
.	O

Fentanyl	B-Drug
Anesthesia	B-Drug
:	O
Severe	O
hypotension	O
has	O
been	O
reported	O
during	O
fentanyl	B-Drug
anesthesia	B-Drug
with	O
concomitant	O
use	O
of	O
a	O
beta	O
blocker	O
and	O
a	O
calcium	B-Drug
channel	O
blocker	O
.	O

Even	O
though	O
such	O
interactions	O
have	O
not	O
been	O
seen	O
in	O
clinical	O
studies	O
with	O
DynaCirc	B-Drug
(	O
isradipine	B-Drug
)	O
,	O
an	O
increased	O
volume	O
of	O
circulating	O
fluids	O
might	O
be	O
required	O
if	O
such	O
an	O
interaction	O
were	O
to	O
occur	O
.	O

Both	O
itraconazole	B-Drug
and	O
its	O
major	O
metabolite	O
,	O
hydroxyitraconazole	B-Drug
,	O
are	O
inhibitors	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
.	O

Coadministration	O
of	O
Itraconazole	B-Drug
and	O
drugs	B-Drug
primarily	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
drugs	B-Drug
that	O
could	O
increase	O
or	O
prolong	O
both	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Therefore	O
,	O
unless	O
otherwise	O
specified	O
,	O
appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

Coadministration	O
of	O
terfenadine	B-Drug
with	O
Itraconazole	B-Drug
has	O
led	O
to	O
elevated	O
plasma	O
concentrations	O
of	O
terfenadine	B-Drug
,	O
resulting	O
in	O
rare	O
instances	O
of	O
life-	O
threatening	O
cardiac	O
dysrhythmias	O
and	O
one	O
death	O
.	O

Another	O
oral	O
azole	O
antifungal	O
,	O
ketoconazole	B-Drug
,	O
inhibits	O
the	O
metabolism	O
of	O
astemizole	B-Drug
,	O
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
astemizole	B-Drug
and	O
its	O
active	O
metabolite	O
desmethylastermizole	B-Drug
which	O
may	O
prolong	O
QT	O
intervals	O
.	O

In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	B-Drug
,	O
when	O
compared	O
to	O
ketoconazole	B-Drug
,	O
has	O
a	O
less	O
pronounced	O
effect	O
on	O
the	O
biotransformation	O
system	O
responsible	O
for	O
the	O
metabolism	O
of	O
astemizole	B-Drug
.	O

Based	O
on	O
the	O
chemical	O
resemblance	O
of	O
itraconazole	B-Drug
and	O
ketoconazole	B-Drug
,	O
coadministration	O
of	O
astemizole	B-Drug
with	O
itraconazole	B-Drug
is	O
contraindicated	O
.	O

Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
resulting	O
in	O
an	O
eight-fold	O
increase	O
in	O
the	O
mean	O
AUC	O
of	O
cisapride	B-Drug
.	O

Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	B-Drug
and	O
cisapride	B-Drug
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	B-Drug
also	O
markedly	O
inhibits	O
the	O
biotransformation	O
system	O
mainly	O
responsible	O
for	O
the	O
metabolism	O
of	O
cisapride	B-Drug
;	O
therefore	O
concomitant	O
administration	O
of	O
Itraconazole	B-Drug
with	O
cisapride	B-Drug
is	O
contraindicated	O
.	O

Coadministration	O
of	O
Itraconazole	B-Drug
with	O
oral	O
midazolam	B-Drug
or	O
triazolam	B-Drug
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	B-Drug
.	O

This	O
may	O
potentiate	O
and	O
prolong	O
hypnotic	O
and	O
sedative	O
effects	O
.	O

These	O
agents	O
should	O
not	O
be	O
used	O
in	O
patients	O
treated	O
with	O
Itraconazole	B-Drug
.	O

If	O
midazolam	B-Drug
is	O
administered	O
parenterally	O
,	O
special	O
precaution	O
is	O
required	O
since	O
the	O
sedative	O
effect	O
may	O
be	O
prolonged	O
.	O

Coadministration	O
of	O
Itraconazole	B-Drug
and	O
cyclosporine	B-Drug
,	O
tacrolimus	B-Drug
or	O
digoxin	B-Drug
has	O
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
the	O
latter	O
three	O
drugs	B-Drug
.	O

Cyclosporine	B-Drug
,	O
tacrolimus	B-Drug
and	O
digoxin	B-Drug
concentrations	O
should	O
be	O
monitored	O
at	O
the	O
initiation	O
of	O
Itraconazole	B-Drug
therapy	O
and	O
frequently	O
thereafter	O
,	O
and	O
the	O
dose	O
of	O
these	O
three	O
drug	B-Drug
products	O
adjusted	O
appropriately	O
.	O

Rhabdomyolysis	O
has	O
been	O
observed	O
in	O
patients	O
receiving	O
HMG-CoA	O
reductase	O
inhibitors	O
administered	O
alone	O
(	O
at	O
recommended	O
dosages	O
)	O
or	O
concomitantly	O
with	O
immunosuppressive	O
drugs	B-Drug
including	O
cyclosporine	B-Drug
.	O

When	O
Itraconazole	B-Drug
was	O
coadministered	O
with	O
phenytoin	B-Drug
,	O
rifampin	B-Drug
,	O
or	O
H2antagonists	O
,	O
reduced	O
plasma	O
concentrations	O
of	O
itraconazole	B-Drug
were	O
reported	O
.	O

The	O
physician	O
is	O
advised	O
to	O
monitor	O
the	O
plasma	O
concentrations	O
of	O
itraconazole	B-Drug
when	O
any	O
of	O
these	O
drugs	B-Drug
is	O
taken	O
concurrently	O
,	O
and	O
to	O
increase	O
the	O
dose	O
of	O
Itraconazole	B-Drug
if	O
necessary	O
.	O

Although	O
no	O
studies	O
have	O
been	O
conducted	O
,	O
concomitant	O
administration	O
of	O
Itraconazole	B-Drug
and	O
phenytoin	B-Drug
may	O
alter	O
the	O
metabolism	O
of	O
phenytoin	B-Drug
;	O
therefore	O
,	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
should	O
also	O
be	O
monitored	O
when	O
it	O
is	O
given	O
concurrently	O
with	O
Itraconazole	B-Drug
.	O

It	O
has	O
been	O
reported	O
that	O
Itraconazole	B-Drug
enhances	O
the	O
anticoagulant	B-Drug
effect	O
of	O
coumarin-like	O
drugs	B-Drug
.	O

Therefore	O
,	O
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
in	O
patients	O
receiving	O
Itraconazole	B-Drug
and	O
coumarin-like	O
drugs	B-Drug
simultaneously	O
.	O

Plasma	O
concentrations	O
of	O
azole	O
antifungal	O
agents	O
are	O
reduced	O
when	O
given	O
concurrently	O
with	O
isoniazid	B-Drug
.	O

Itraconazole	B-Drug
plasma	O
concentrations	O
should	O
be	O
monitored	O
when	O
Itraconazole	B-Drug
and	O
isoniazid	B-Drug
are	O
coadministered	O
.	O

Severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
azole	O
antifungal	O
agents	O
and	O
oral	O
hypoglycemic	O
agents	O
.	O

Blood	O
glucose	B-Drug
concentrations	O
should	O
be	O
carefully	O
monitored	O
when	O
Itraconazole	B-Drug
and	O
oral	O
hypoglycemic	O
agents	O
are	O
coadministered	O
.	O

Tinnitus	O
and	O
decreased	O
hearing	O
have	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	B-Drug
and	O
quinidine	B-Drug
.	O

Edema	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	B-Drug
and	O
dihydropyridine	O
calcium	B-Drug
channel	O
blockers	O
.	O

Appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

The	O
results	O
from	O
a	O
study	O
in	O
which	O
eight	O
HIV-infected	O
individuals	O
were	O
treated	O
with	O
zidovudine	B-Drug
,	O
8	O
+/-	O
0.4	O
mg/kg/day	O
,	O
showed	O
that	O
the	O
pharmacokinetics	O
of	O
zidovudine	B-Drug
were	O
not	O
affected	O
during	O
concomitant	O
administration	O
of	O
Itraconazole	B-Drug
,	O
100	O
mg	O
b.i.d	O
.	O

In	O
vitro	O
mixing	O
of	O
an	O
aminoglycoside	O
with	O
beta-lactamtype	O
antibiotics	B-Drug
(	O
penicillins	B-Drug
or	O
cephalosporins	O
)	O
may	O
result	O
in	O
a	O
significant	O
mutual	O
inactivation	O
.	O

Even	O
when	O
an	O
aminoglycoside	O
and	O
a	O
penicillin-type	O
drug	B-Drug
are	O
administered	O
separately	O
by	O
different	O
routes	O
,	O
a	O
reduction	O
in	O
aminoglycoside	O
serum	O
half-life	O
or	O
serum	O
levels	O
has	O
been	O
reported	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
and	O
in	O
some	O
patients	O
with	O
normal	O
renal	O
function	O
.	O

Usually	O
,	O
such	O
inactivation	O
of	O
the	O
aminoglycoside	O
is	O
clinically	O
significant	O
only	O
in	O
patients	O
with	O
severely	O
impaired	O
renal	O
function..	O
See	O
Prolonged	O
recovery	O
time	O
may	O
occur	O
if	O
barbiturates	B-Drug
and/or	O
narcotics	O
are	O
used	O
concurrently	O
with	O
ketamine	B-Drug
.	O

Ketamine	B-Drug
is	O
clinically	O
compatible	O
with	O
the	O
commonly	O
used	O
general	O
and	O
local	O
anesthetic	B-Drug
agents	O
when	O
an	O
adequate	O
respiratory	O
exchange	O
is	O
maintained	O
.	O

Ketoconazole	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
.	O

Coadministration	O
of	O
NIZORAL	B-Drug
Tablets	O
and	O
drugs	B-Drug
primarily	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
drugs	B-Drug
that	O
could	O
increase	O
or	O
prolong	O
both	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Therefore	O
,	O
unless	O
otherwise	O
specified	O
,	O
appropriate	O
dosage	O
adjustments	O
may	O
be	O
necessary	O
.	O

The	O
following	O
drug	B-Drug
interactions	O
have	O
been	O
identified	O
involving	O
NIZORAL	B-Drug
Tablets	O
and	O
other	O
drugs	B-Drug
metabolized	O
by	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
:	O
Ketoconazole	B-Drug
tablets	O
inhibit	O
the	O
metabolism	O
of	O
terfenadine	B-Drug
,	O
resulting	O
in	O
an	O
increased	O
plasma	O
concentration	O
of	O
terfenadine	B-Drug
and	O
a	O
delay	O
in	O
the	O
elimination	O
of	O
its	O
acid	O
metabolite	O
.	O

The	O
increased	O
plasma	O
concentration	O
of	O
terfenadine	B-Drug
or	O
its	O
metabolite	O
may	O
result	O
in	O
prolonged	O
QT	O
intervals	O
.	O

Pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
inhibits	O
the	O
metabolism	O
of	O
astemizole	B-Drug
,	O
resulting	O
in	O
elevated	O
plasma	O
levels	O
of	O
astemizole	B-Drug
and	O
its	O
active	O
metabolite	O
desmethylastemizole	B-Drug
which	O
may	O
prolong	O
QT	O
intervals	O
.	O

Coadministration	O
of	O
astemizole	B-Drug
with	O
ketoconazole	B-Drug
tablets	O
is	O
therefore	O
contraindicated	O
.	O

Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B-Drug
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B-Drug
resulting	O
in	O
a	O
mean	O
eight-fold	O
increase	O
in	O
AUC	O
of	O
cisapride	B-Drug
.	O

Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	B-Drug
and	O
cisapride	B-Drug
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Therefore	O
concomitant	O
administration	O
of	O
ketoconazole	B-Drug
tablets	O
with	O
cisapride	B-Drug
is	O
contraindicated	O
.	O

Ketoconazole	B-Drug
tablets	O
may	O
alter	O
the	O
metabolism	O
of	O
cyclosporine	B-Drug
,	O
tacrolimus	B-Drug
,	O
and	O
methylprednisolone	B-Drug
,	O
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
drugs	B-Drug
.	O

Dosage	O
adjustment	O
may	O
be	O
required	O
if	O
cyclosporine	B-Drug
,	O
tacrolimus	B-Drug
,	O
or	O
methylprednisolone	B-Drug
are	O
given	O
concomitantly	O
with	O
NIZORAL	B-Drug
Tablets	O
.	O

Coadministration	O
of	O
NIZORAL	B-Drug
Tablets	O
with	O
midazolam	B-Drug
or	O
triazolam	B-Drug
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	B-Drug
.	O

This	O
may	O
potentiate	O
and	O
prolong	O
hypnotic	O
and	O
sedative	O
effects	O
,	O
especially	O
with	O
repeated	O
dosing	O
or	O
chronic	O
administration	O
of	O
these	O
agents	O
.	O

These	O
agents	O
should	O
not	O
be	O
used	O
in	O
patients	O
treated	O
with	O
NIZORAL	B-Drug
Tablets	O
.	O

If	O
midazolam	B-Drug
is	O
administered	O
parenterally	O
,	O
special	O
precaution	O
is	O
required	O
since	O
the	O
sedative	O
effect	O
may	O
be	O
prolonged	O
.	O

Rare	O
cases	O
of	O
elevated	O
plasma	O
concentrations	O
of	O
digoxin	B-Drug
have	O
been	O
reported	O
.	O

It	O
is	O
not	O
clear	O
whether	O
this	O
was	O
due	O
to	O
the	O
combination	O
of	O
therapy	O
.	O

It	O
is	O
,	O
therefore	O
,	O
advisable	O
to	O
monitor	O
digoxin	B-Drug
concentrations	O
in	O
patients	O
receiving	O
ketoconazole	B-Drug
.	O

When	O
taken	O
orally	O
,	O
imidazole	O
compounds	O
like	O
ketoconazole	B-Drug
may	O
enhance	O
the	O
anticoagulant	B-Drug
effect	O
of	O
coumarin-like	O
drugs	B-Drug
.	O

In	O
simultaneous	O
treatment	O
with	O
imidazole	O
drugs	B-Drug
and	O
coumarin	O
drugs	B-Drug
,	O
the	O
anticoagulant	B-Drug
effect	O
should	O
be	O
carefully	O
titrated	O
and	O
monitored	O
.	O

Because	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
oral	O
miconazole	B-Drug
(	O
an	O
imidazole	O
)	O
and	O
oral	O
hypoglycemic	O
agents	O
,	O
such	O
a	O
potential	O
interaction	O
involving	O
the	O
latter	O
agents	O
when	O
used	O
concomitantly	O
with	O
ketoconazole	B-Drug
tablets	O
(	O
an	O
imidazole	O
)	O
can	O
not	O
be	O
ruled	O
out	O
.	O

Concomitant	O
administration	O
of	O
ketoconazole	B-Drug
tablets	O
with	O
phenytoin	B-Drug
may	O
alter	O
the	O
metabolism	O
of	O
one	O
or	O
both	O
of	O
the	O
drugs	B-Drug
.	O

It	O
is	O
suggested	O
to	O
monitor	O
both	O
ketoconazole	B-Drug
and	O
phenytoin	B-Drug
.	O

Concomitant	O
administration	O
of	O
rifampin	B-Drug
with	O
ketoconazole	B-Drug
tablets	O
reduces	O
the	O
blood	O
levels	O
of	O
the	O
latter	O
.	O

INH	B-Drug
(	O
Isoniazid	B-Drug
)	O
is	O
also	O
reported	O
to	O
affect	O
ketoconazole	B-Drug
concentrations	O
adversely	O
.	O

These	O
drugs	B-Drug
should	O
not	O
be	O
given	O
concomitantly	O
.	O

After	O
the	O
coadministration	O
of	O
200	O
mg	O
oral	O
ketoconazole	B-Drug
twice	O
daily	O
and	O
one	O
20	O
mg	O
dose	O
of	O
loratadine	B-Drug
to	O
11	O
subjects	O
,	O
the	O
AUC	O
and	O
Cmax	O
of	O
loratadine	B-Drug
averaged	O
302	O
%	O
(	O
142	O
S.D	O
.	O

)	O
and	O
251	O
%	O
(	O
68	O
S.D	O
.	O

)	O
,	O
respectively	O
,	O
of	O
those	O
obtained	O
after	O
co-treatment	O
with	O
placebo	O
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
descarboethoxyloratadine	B-Drug
,	O
an	O
active	O
metabolite	O
,	O
averaged	O
155	O
%	O
(	O
27	O
S.D	O
.	O

)	O
and	O
141	O
%	O
(	O
35	O
S.D	O
.	O

)	O
,	O
respectively	O
.	O

However	O
,	O
no	O
related	O
changes	O
were	O
noted	O
in	O
the	O
QT0	O
on	O
ECG	O
taken	O
at	O
2	O
,	O
6	O
,	O
and	O
24	O
hours	O
after	O
the	O
coadministration	O
.	O

Also	O
,	O
there	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
adverse	O
events	O
when	O
loratadine	B-Drug
was	O
administered	O
with	O
or	O
without	O
ketoconazole	B-Drug
.	O

Rare	O
cases	O
of	O
a	O
disulfiram-like	B-Drug
reaction	O
to	O
alcohol	B-Drug
have	O
been	O
reported	O
.	O

These	O
experiences	O
have	O
been	O
characterized	O
by	O
flushing	O
,	O
rash	O
,	O
peripheral	O
edema	O
,	O
nausea	O
,	O
and	O
headache	O
.	O

Symptoms	O
resolved	O
within	O
a	O
few	O
hours	O
.	O

The	O
following	O
drug	B-Drug
interactions	O
were	O
studied	O
with	O
ketoprofen	B-Drug
doses	O
of	O
200	O
mg/day	O
.	O

The	O
possibility	O
of	O
increased	O
interaction	O
should	O
be	O
kept	O
in	O
mind	O
when	O
Orudis	B-Drug
doses	O
greater	O
than	O
50	O
mg	O
as	O
a	O
single	O
dose	O
or	O
200	O
mg	O
of	O
ketoprofen	B-Drug
per	O
day	O
are	O
used	O
concomitantly	O
with	O
highly	O
bound	O
drugs	B-Drug
.	O

1	O
.	O

Antacids	O
:	O
Concomitant	O
administration	O
of	O
magnesium	B-Drug
hydroxide	I-Drug
and	O
aluminum	B-Drug
hydroxide	I-Drug
does	O
not	O
interfere	O
with	O
the	O
rate	O
or	O
extent	O
of	O
the	O
absorption	O
of	O
ketoprofen	B-Drug
administered	O
as	O
Orudis	B-Drug
.	O

2	O
.	O

Aspirin	B-Drug
:	O
Ketoprofen	B-Drug
does	O
not	O
alter	O
aspirin	B-Drug
absorption	O
;	O
however	O
,	O
in	O
a	O
study	O
of	O
12	O
normal	O
subjects	O
,	O
concurrent	O
administration	O
of	O
aspirin	B-Drug
decreased	O
ketoprofen	B-Drug
protein	O
binding	O
and	O
increased	O
ketoprofen	B-Drug
plasma	O
clearance	O
from	O
0.07	O
L/kg/h	O
without	O
aspirin	B-Drug
to	O
0.11	O
L/kg/h	O
with	O
aspirin	B-Drug
.	O

The	O
clinical	O
significance	O
of	O
these	O
changes	O
has	O
not	O
been	O
adequately	O
studied	O
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
aspirin	B-Drug
and	O
ketoprofen	B-Drug
is	O
not	O
recommended	O
.	O

3	O
.	O

Diuretic	B-Drug
:	O
Hydrochlorothiazide	B-Drug
,	O
given	O
concomitantly	O
with	O
ketoprofen	B-Drug
,	O
produces	O
a	O
reduction	O
in	O
urinary	O
potassium	B-Drug
and	O
chloride	O
excretion	O
compared	O
to	O
hydrochlorothiazide	B-Drug
alone	O
.	O

Patients	O
taking	O
diuretics	B-Drug
are	O
at	O
a	O
greater	O
risk	O
of	O
developing	O
renal	O
failure	O
secondary	O
to	O
a	O
decrease	O
in	O
renal	O
blood	O
flow	O
caused	O
by	O
prostaglandin	O
inhibition	O
.	O

4	O
.	O

Digoxin	B-Drug
:	O
In	O
a	O
study	O
in	O
12	O
patients	O
with	O
congestive	O
heart	O
failure	O
where	O
ketoprofen	B-Drug
and	O
digoxin	B-Drug
were	O
concomitantly	O
administered	O
,	O
ketoprofen	B-Drug
did	O
not	O
alter	O
the	O
serum	O
levels	O
of	O
digoxin	B-Drug
.	O

5	O
.	O

Warfarin	B-Drug
:	O
In	O
a	O
short-term	O
controlled	O
study	O
in	O
14	O
normal	O
volunteers	O
,	O
ketoprofen	B-Drug
did	O
not	O
significantly	O
interfere	O
with	O
the	O
effect	O
of	O
warfarin	B-Drug
on	O
prothrombin	O
time	O
.	O

Bleeding	O
from	O
a	O
number	O
of	O
sites	O
may	O
be	O
a	O
complication	O
of	O
warfarin	B-Drug
treatment	O
and	O
GI	O
bleeding	O
a	O
complication	O
of	O
ketoprofen	B-Drug
treatment	O
.	O

Because	O
prostaglandina	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
and	O
ketoprofen	B-Drug
has	O
an	O
effect	O
on	O
platelet	O
function	O
as	O
well	O
,	O
concurent	O
therapy	O
with	O
ketoprofen	B-Drug
and	O
warfarin	B-Drug
requires	O
close	O
monitoring	O
of	O
patients	O
on	O
both	O
drugs	B-Drug
.	O

6	O
.	O

Probenecid	B-Drug
:	O
Probenecid	B-Drug
increases	O
both	O
free	O
and	O
bound	O
ketoprofen	B-Drug
by	O
reducing	O
the	O
plasma	O
clearance	O
of	O
ketoprofen	B-Drug
to	O
about	O
one-third	O
,	O
as	O
well	O
as	O
decreasing	O
its	O
protein	O
binding	O
.	O

Therefore	O
,	O
the	O
combination	O
of	O
ketoprofen	B-Drug
and	O
probenecid	B-Drug
is	O
not	O
recommended	O
.	O

7	O
.	O

Methotrexate	B-Drug
:	O
Ketoprofen	B-Drug
,	O
like	O
other	O
NSAIDs	O
,	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
methotrexate	B-Drug
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
the	O
drug	B-Drug
and	O
increased	O
toxicity	O
.	O

8	O
.	O

Lithium	B-Drug
:	O
Nonsteroidal	O
anti-inflammatory	O
agents	O
have	O
been	O
reported	O
to	O
increase	O
steadystate	O
plasma	O
lithium	B-Drug
levels	O
.	O

It	O
is	O
recommended	O
that	O
plasma	O
lithium	B-Drug
levels	O
be	O
monitored	O
when	O
ketoprofen	B-Drug
is	O
coadministered	O
with	O
lithium	B-Drug
.	O

DRUG/LABORATORY	O
TEST	O
INTERACTIONS	O
:	O
EFFECT	O
ON	O
BLOOD	O
COAGULATION	O
Ketoprofen	B-Drug
decreases	O
platelet	O
adhesion	O
and	O
aggregation	O
.	O

Therefore	O
,	O
it	O
can	O
prolong	O
bleeding	O
time	O
by	O
approximately	O
3	O
to	O
4	O
minutes	O
from	O
baseline	O
values	O
.	O

There	O
is	O
no	O
significant	O
change	O
in	O
platelet	O
count	O
,	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
or	O
thrombin	O
time	O
.	O

Ketorolac	B-Drug
is	O
highly	O
bound	O
to	O
human	O
plasma	O
protein	O
(	O
mean	O
99.2	O
%	O
)	O
.	O

Warfarin	B-Drug
,	O
Digoxin	B-Drug
,	O
Salicylate	B-Drug
,	O
and	O
Heparin	B-Drug
The	O
in	O
vitro	O
binding	O
of	O
warfarin	B-Drug
to	O
plasma	O
proteins	O
is	O
only	O
slightly	O
reduced	O
by	O
ketorolac	B-Drug
tromethamine	I-Drug
(	O
99.5	O
%	O
control	O
vs	O
99.3	O
%	O
)	O
when	O
ketorolac	B-Drug
plasma	O
concentrations	O
reach	O
5	O
to10	O
m	O
g/mL	O
.	O

Ketorolac	B-Drug
does	O
not	O
alter	O
digoxin	B-Drug
protein	O
binding	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
,	O
at	O
therapeutic	O
concentrations	O
of	O
salicylate	B-Drug
(	O
300	O
m	O
g/mL	O
)	O
,	O
the	O
binding	O
of	O
ketorolac	B-Drug
was	O
reduced	O
from	O
approximately	O
99.2	O
%	O
to	O
97.5	O
%	O
,	O
representing	O
a	O
potential	O
twofold	O
increase	O
in	O
unbound	O
ketorolac	B-Drug
plasma	O
levels	O
.	O

Therapeutic	O
concentrations	O
of	O
digoxin	B-Drug
,	O
warfarin	B-Drug
,	O
ibuprofen	B-Drug
,	O
naproxen	B-Drug
,	O
piroxicam	B-Drug
,	O
acetaminophen	B-Drug
,	O
phenytoin	B-Drug
andtolbutamide	O
did	O
not	O
alter	O
ketorolac	B-Drug
tromethamine	I-Drug
protein	O
binding	O
.	O

In	O
a	O
study	O
involving	O
12	O
adult	O
volunteers	O
,	O
TORADOLORAL	O
was	O
coadministered	O
with	O
a	O
single	O
dose	O
of	O
25	O
mg	O
warfarin	B-Drug
,	O
causing	O
no	O
significant	O
changes	O
in	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	B-Drug
.	O

In	O
another	O
study	O
,	O
TORADOLIV/IM	O
was	O
given	O
with	O
two	O
doses	O
of	O
5000	O
U	O
of	O
heparin	B-Drug
to	O
11	O
healthy	O
volunteers	O
,	O
resulting	O
in	O
a	O
mean	O
template	O
bleeding	O
time	O
of	O
6.4	O
minutes	O
(	O
3.2	O
to	O
11.4	O
min	O
)	O
compared	O
to	O
a	O
mean	O
of	O
6.0	O
minutes	O
(	O
3.4	O
to	O
7.5	O
min	O
)	O
for	O
heparin	B-Drug
alone	O
and	O
5.1	O
minutes	O
(	O
3.5	O
to	O
8.5	O
min	O
)	O
for	O
placebo	O
.	O

Although	O
these	O
results	O
do	O
not	O
indicate	O
a	O
significant	O
interaction	O
between	O
TORADOL	B-Drug
and	O
warfarin	B-Drug
or	O
heparin	B-Drug
,	O
the	O
administration	O
of	O
TORADOL	B-Drug
to	O
patients	O
taking	O
anticoagulants	B-Drug
should	O
be	O
done	O
extremely	O
cautiously	O
,	O
and	O
patients	O
should	O
be	O
closely	O
monitored	O
.	O

Furosemide	B-Drug
:	O
TORADOL	B-Drug
IV/IM	O
reduced	O
the	O
diuretic	B-Drug
response	O
to	O
furosemide	B-Drug
in	O
normovolemic	O
healthy	O
subjects	O
by	O
approximately	O
20	O
%	O
(	O
mean	O
sodium	O
and	O
urinary	O
output	O
decreased	O
17	O
%	O
)	O
.	O

Probenecid	B-Drug
:	O
Concomitant	O
administration	O
of	O
TORADOL	B-Drug
ORAL	O
and	O
probenecid	B-Drug
resulted	O
in	O
decreased	O
clearance	O
of	O
ketorolac	B-Drug
and	O
significant	O
increases	O
in	O
ketorolac	B-Drug
plasma	O
levels	O
(	O
total	O
AUC	O
increased	O
approximately	O
threefold	O
from	O
5.4	O
to	O
17.8	O
m	O
g/h/mL	O
)	O
and	O
terminal	O
half-life	O
increased	O
approximately	O
twofold	O
from	O
6.6	O
to	O
15.1	O
hours	O
.	O

Therefore	O
,	O
concomitant	O
use	O
of	O
TORADOL	B-Drug
and	O
probenecid	B-Drug
is	O
contraindicated	O
.	O

Lithium	B-Drug
:	O
Inhibition	O
of	O
renal	O
lithium	B-Drug
clearance	O
,	O
leading	O
to	O
an	O
increase	O
in	O
plasma	O
lithium	B-Drug
concentration	O
,	O
has	O
been	O
reported	O
with	O
some	O
prostaglandin	O
synthesis-inhibiting	O
drugs	B-Drug
.	O

The	O
effect	O
of	O
TORADOL	B-Drug
on	O
plasma	O
lithium	B-Drug
has	O
not	O
been	O
studied	O
,	O
but	O
cases	O
of	O
increased	O
lithium	B-Drug
plasma	O
levels	O
during	O
TORADOL	B-Drug
therapy	O
have	O
been	O
reported	O
.	O

Methotrexate	B-Drug
:	O
Concomitant	O
administration	O
of	O
methotrexate	B-Drug
and	O
some	O
NSAIDs	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
clearance	O
of	O
methotrexate	B-Drug
,	O
enhancing	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O

The	O
effect	O
of	O
TORADOL	B-Drug
on	O
methotrexate	B-Drug
clearance	O
has	O
not	O
been	O
studied	O
.	O

Nondepolarizing	O
Muscle	O
Relaxants	O
:	O
In	O
postmarketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
a	O
possible	O
interaction	O
between	O
TORADOLIV/IM	O
and	O
nondepolarizing	O
muscle	O
relaxants	O
that	O
resulted	O
in	O
apnea	O
.	O

The	O
concurrent	O
use	O
of	O
TORADOL	B-Drug
with	O
muscle	O
relaxants	O
has	O
not	O
been	O
formally	O
studied	O
.	O

ACE	O
Inhibitors	O
:	O
Concomitant	O
use	O
of	O
ACE	O
inhibitors	O
may	O
increase	O
the	O
risk	O
of	O
renal	O
impairment	O
,	O
particularly	O
in	O
volume-depleted	O
patients	O
.	O

Antiepileptic	O
Drugs	B-Drug
:	O
Sporadic	O
cases	O
of	O
seizures	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
TORADOL	B-Drug
and	O
antiepileptic	O
drugs	B-Drug
(	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
)	O
.	O

Psychoactive	O
Drugs	B-Drug
:	O
Hallucinations	O
have	O
been	O
reported	O
when	O
TORADOL	B-Drug
was	O
used	O
in	O
patients	O
taking	O
psychoactive	O
drugs	B-Drug
(	O
fluoxetine	B-Drug
,	O
thiothixene	B-Drug
,	O
alprazolam	B-Drug
)	O
.	O

Morphine	B-Drug
:	O
TORADOLIV/IM	O
has	O
been	O
administered	O
concurrently	O
with	O
morphine	B-Drug
in	O
several	O
clinical	O
trials	O
of	O
postoperative	O
pain	O
without	O
evidence	O
of	O
adverse	O
interactions	O
.	O

Do	O
not	O
mix	O
TORADOL	B-Drug
and	O
morphine	B-Drug
in	O
the	O
same	O
syringe	O
.	O

There	O
is	O
no	O
evidence	O
in	O
animal	O
or	O
human	O
studies	O
that	O
TORADOL	B-Drug
induces	O
or	O
inhibits	O
hepatic	O
enzymes	O
capable	O
of	O
metabolizing	O
itself	O
or	O
other	O
drugs	B-Drug
.	O

Cyclosporine	B-Drug
-	O
L-arginine	B-Drug
may	O
counteract	O
the	O
antinaturetic	O
effect	O
of	O
cyclosporin	B-Drug
.	O

Ibuprofen	B-Drug
-	O
L-arginine	B-Drug
may	O
increase	O
the	O
absorption	O
of	O
ibuprofen	B-Drug
if	O
taken	O
concomitantly	O
.	O

Organic	O
nitrates	B-Drug
-	O
L-arginine	B-Drug
supplements	O
theoretically	O
may	O
potentiate	O
the	O
effects	O
of	O
organic	O
nitrates	B-Drug
if	O
taken	O
concomitantly	O
.	O

Sildenafil	B-Drug
citrate	I-Drug
-	O
Theoretically	O
,	O
L-arginine	B-Drug
supplements	O
taken	O
concomitantly	O
with	O
sildenafil	B-Drug
citrate	I-Drug
,	O
may	O
potentiate	O
the	O
effects	O
of	O
the	O
drug	B-Drug
.	O

No	O
drug	B-Drug
,	O
nutritional	O
supplement	O
,	O
food	O
or	O
herb	O
interactions	O
are	O
known	O
.	O

Interacts	O
with	O
valproic	B-Drug
acid	I-Drug
No	O
well-known	O
drug	B-Drug
interactions	O
with	O
glutamic	B-Drug
acid	I-Drug
Human	B-Drug
growth	I-Drug
hormone	I-Drug
-	O
Concomitant	O
use	O
of	O
L-glutamine	B-Drug
and	O
human	B-Drug
growth	I-Drug
hormone	I-Drug
may	O
enhance	O
nutrient	O
absorption	O
in	O
those	O
with	O
severe	O
short	O
bowel	O
syndrome	O
.	O

L-glutamine	B-Drug
has	O
orphan	O
drug	B-Drug
status	O
for	O
this	O
indication	O
.	O

Indomethacin	B-Drug
-	O
Concomitant	O
use	O
of	O
L-glutamine	B-Drug
and	O
indomethacin	B-Drug
may	O
ameliorate	O
increased	O
intestinal	O
permeability	O
caused	O
by	O
indomethacin	B-Drug
.	O

The	O
reported	O
dose	O
used	O
for	O
L-glutamine	B-Drug
was	O
21	O
grams	O
daily	O
taken	O
in	O
divided	O
doses	O
three	O
times	O
a	O
day	O
.	O

Further	O
,	O
misoprostol	B-Drug
is	O
reported	O
to	O
have	O
a	O
synergistic	O
effect	O
with	O
this	O
combination	O
in	O
ameliorating	O
intestinal	O
permeability	O
.	O

Methotrexate	B-Drug
-	O
There	O
is	O
one	O
report	O
that	O
methotrexate	B-Drug
may	O
decrease	O
the	O
possible	O
effectiveness	O
of	O
supplemental	O
L-glutamine	B-Drug
for	O
chemotherapy-induced	O
mucositis	O
.	O

In	O
another	O
report	O
,	O
nine	O
patients	O
with	O
breast	O
cancer	O
were	O
reported	O
to	O
have	O
decreased	O
symptoms	O
of	O
methotrexate-related	B-Drug
toxicity	O
when	O
given	O
supplemental	O
L-glutamine	B-Drug
at	O
a	O
dose	O
of	O
0.5	O
gram/kilogram/day	O
.	O

Paclitaxel	B-Drug
-	O
In	O
one	O
report	O
,	O
L-glutamine	B-Drug
at	O
a	O
dose	O
of	O
10	O
grams	O
three	O
times	O
daily	O
,	O
given	O
24	O
hours	O
after	O
receiving	O
paclitaxel	B-Drug
,	O
appeared	O
to	O
prevent	O
the	O
development	O
of	O
myalgia	O
and	O
arthralgia	O
,	O
adverse	O
reactions	O
of	O
paclitaxel	B-Drug
.	O

Medroxyprogesterone	B-Drug
Acetate	I-Drug
-	O
L-histidine	B-Drug
was	O
observed	O
to	O
enhance	O
(	O
in	O
tissue	O
culture	O
)	O
the	O
effect	O
of	O
medroxyprogesterone	B-Drug
acetate	I-Drug
in	O
reducing	O
the	O
number	O
of	O
human	O
breast	O
cancer	O
cells	O
that	O
were	O
in	O
the	O
S	O
phase	O
.	O

H1	O
and	O
H2	O
Blockers	O
-	O
Although	O
not	O
reported	O
,	O
L-histidine	B-Drug
,	O
via	O
its	O
metabolism	O
to	O
histamine	B-Drug
,	O
might	O
decrease	O
the	O
efficacy	O
of	O
H1	O
and	O
H2	O
blockers	O
.	O

Concomitant	O
use	O
of	O
calcium	B-Drug
supplements	O
and	O
L-lysine	B-Drug
may	O
increase	O
calcium	B-Drug
absorption	O
Acetaminophen	B-Drug
and	O
methotrexate	B-Drug
-	O
L-methionine	B-Drug
may	O
decrease	O
hepatic	O
toxicity	O
in	O
those	O
with	O
acetaminophen	B-Drug
overdosage	O
or	O
in	O
those	O
taking	O
methotrexate	B-Drug
.	O

Theoretically	O
,	O
it	O
may	O
decrease	O
hepatic	O
toxicity	O
in	O
the	O
case	O
of	O
other	O
potential	O
hepatotoxic	O
drugs	B-Drug
,	O
as	O
well	O
.	O

Gentamicin	B-Drug
-	O
Methionine	B-Drug
may	O
protect	O
against	O
the	O
ototoxic	O
effects	O
of	O
gentamicin	B-Drug
.	O

Non-selective	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
-	O
including	O
phenelzine	B-Drug
sulfate	I-Drug
,	O
tranylcypromine	B-Drug
sulfate	I-Drug
and	O
pargyline	B-Drug
HC1	O
.	O

Concomitant	O
use	O
of	O
L-phenylalanine	B-Drug
and	O
non-selective	O
MAO	O
inhibitors	O
may	O
cause	O
hypertension	O
.	O

Selegiline	B-Drug
-	O
L-phenylalanine	B-Drug
and	O
the	O
selective	O
MAO	O
inhibitor	O
selegiline	B-Drug
may	O
have	O
synergistic	O
antidepressant	O
activity	O
if	O
used	O
concomitantly	O
.	O

Neuroleptic	B-Drug
Drugs	B-Drug
-	O
L-phenylalanine	B-Drug
may	O
potentiate	O
the	O
tardive	O
dyskinesia	O
side	O
reactions	O
of	O
neuroleptic	B-Drug
drugs	B-Drug
if	O
used	O
concomitantly	O
with	O
them	O
.	O

Monoamine	O
oxidase	O
(	O
MAO	O
)	O
inhibitors	O
such	O
as	O
isocarboxazid	B-Drug
(	O
e.g.	O
,	O
Marplan	B-Drug
)	O
,	O
phenelzine	B-Drug
(	O
e.g.	O
,	O
Nardil	B-Drug
)	O
,	O
procarbazine	B-Drug
(	O
e.g.	O
,	O
Matulane	B-Drug
)	O
,	O
selegiline	B-Drug
(	O
e.g.	O
,	O
Eldepryl	B-Drug
)	O
,	O
and	O
tranylcypromine	B-Drug
(	O
e.g.	O
,	O
Parnate	B-Drug
)	O
:	O
Using	O
these	O
medicines	O
with	O
L-tryptophan	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O

Non-selective	O
MAO	O
inhibitors	O
including	O
tranylcypromine	B-Drug
sulfate	I-Drug
,	O
phenelzine	B-Drug
sulfate	I-Drug
,	O
and	O
pargyline	B-Drug
HC1	O
:	O
Concomitant	O
use	O
of	O
L-tyrosine	B-Drug
and	O
non-selective	O
MAO	O
inhibitors	O
may	O
cause	O
hypertension	O
.	O

In	O
one	O
survey	O
,	O
2.3	O
%	O
of	O
patients	O
taking	O
labetalol	B-Drug
HCl	I-Drug
in	O
combination	O
with	O
tricyclic	O
antidepressants	B-Drug
experienced	O
tremor	O
,	O
as	O
compared	O
to	O
0.7	O
%	O
reported	O
to	O
occur	O
with	O
labetalol	B-Drug
HCl	I-Drug
alone	O
.	O

The	O
contribution	O
of	O
each	O
of	O
the	O
treatments	O
to	O
this	O
adverse	O
reaction	O
is	O
unknown	O
but	O
the	O
possibility	O
of	O
a	O
drug	B-Drug
interaction	O
can	O
not	O
be	O
excluded	O
.	O

Drugs	B-Drug
possessing	O
beta-blocking	B-Drug
properties	O
can	O
blunt	O
the	O
bronchodilator	O
effect	O
of	O
beta-receptor	O
agonist	O
drugs	B-Drug
in	O
patients	O
with	O
bronchospasm	O
;	O
therefore	O
,	O
doses	O
greater	O
than	O
the	O
normal	O
antiasthmatic	O
dose	O
of	O
beta-agonist	O
bronchodilator	O
drugs	B-Drug
may	O
be	O
required	O
.	O

Cimetidine	B-Drug
has	O
been	O
shown	O
to	O
increase	O
the	O
bioavailability	O
of	O
labetalol	B-Drug
HCl	I-Drug
.	O

Since	O
this	O
could	O
be	O
explained	O
either	O
by	O
enhanced	O
absorption	O
or	O
by	O
an	O
alteration	O
of	O
hepatic	O
metabolism	O
of	O
labetalol	B-Drug
HCl	I-Drug
,	O
special	O
care	O
should	O
be	O
used	O
in	O
establishing	O
the	O
dose	O
required	O
for	O
blood	O
pressure	O
control	O
in	O
such	O
patients	O
.	O

Synergism	O
has	O
been	O
shown	O
between	O
halothane	B-Drug
anesthesia	B-Drug
and	O
intravenously	O
administered	O
labetalol	B-Drug
HCl	I-Drug
.	O

During	O
controlled	O
hypotensive	O
anesthesia	B-Drug
using	O
labetalol	B-Drug
HCl	I-Drug
in	O
association	O
with	O
halothane	B-Drug
,	O
high	O
concentrations	O
(	O
3	O
%	O
or	O
above	O
)	O
of	O
halothane	B-Drug
should	O
not	O
be	O
used	O
because	O
the	O
degree	O
of	O
hypotension	O
will	O
be	O
increased	O
and	O
because	O
of	O
the	O
possibility	O
of	O
a	O
large	O
reduction	O
in	O
cardiac	O
output	O
and	O
an	O
increase	O
in	O
central	O
venous	O
pressure	O
.	O

The	O
anesthesiologist	O
should	O
be	O
informed	O
when	O
a	O
patient	O
is	O
receiving	O
labetalol	B-Drug
HCl	I-Drug
.	O

Labetalol	B-Drug
HCl	I-Drug
blunts	O
the	O
reflex	O
tachycardia	O
produced	O
by	O
nitroglycerin	B-Drug
without	O
preventing	O
its	O
hypotensive	O
effect	O
.	O

If	O
labetalol	B-Drug
HCl	I-Drug
is	O
used	O
with	O
nitroglycerin	B-Drug
in	O
patients	O
with	O
angina	O
pectoris	O
,	O
additional	O
antihypertensive	B-Drug
effects	O
may	O
occur	O
.	O

Care	O
should	O
be	O
taken	O
if	O
labetalol	B-Drug
is	O
used	O
concomitantly	O
with	O
calcium	B-Drug
antagonists	O
of	O
the	O
verapamil	B-Drug
type	O
.	O

Risk	O
of	O
Anaphylactic	O
Reaction	O
While	O
taking	O
beta-blockers	O
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
The	O
presence	O
of	O
labetalol	B-Drug
metabolites	O
in	O
the	O
urine	O
may	O
result	O
in	O
falsely	O
elevated	O
levels	O
of	O
urinary	O
catecholamines	O
,	O
metanephrine	O
,	O
normetanephrine	O
and	O
vanillylmandelic	O
acid	O
when	O
measured	O
by	O
fluorimetric	O
or	O
photometric	O
methods	O
.	O

In	O
screening	O
patients	O
suspected	O
of	O
having	O
a	O
pheochromocytoma	O
and	O
being	O
treated	O
with	O
labetalol	B-Drug
HCl	I-Drug
,	O
a	O
specific	O
method	O
,	O
such	O
as	O
a	O
high	O
performance	O
liquid	O
chromatographic	O
assay	O
with	O
solid	O
phase	O
extraction	O
(	O
e.g.	O
,	O
J	O
Chromatogr	O
385:241,1987	O
)	O
should	O
be	O
employed	O
in	O
determining	O
levels	O
of	O
catecholamines	O
.	O

Labetalol	B-Drug
HCl	I-Drug
has	O
also	O
been	O
reported	O
to	O
produce	O
a	O
false	O
positive	O
test	O
for	O
amphetamine	B-Drug
when	O
screening	O
urine	O
for	O
the	O
presence	O
of	O
drugs	B-Drug
using	O
the	O
commercially	O
available	O
assay	O
methods	O
Toxi-Lab	O
A	O
(	O
thin-layer	O
chromatographic	O
assay	O
)	O
and	O
Emit-d.a.u	O
.	O

(	O
radioenzymatic	O
assay	O
)	O
.	O

When	O
patients	O
being	O
treated	O
with	O
labetalol	B-Drug
have	O
a	O
positive	O
urine	O
test	O
for	O
amphetamine	B-Drug
using	O
these	O
techniques	O
confirmation	O
should	O
be	O
made	O
by	O
using	O
more	O
specific	O
methods	O
such	O
as	O
a	O
gas	O
chromatographic-mass	O
spectrometer	O
technique	O
.	O

Results	O
of	O
preliminary	O
studies	O
in	O
humans	O
and	O
rats	O
suggest	O
that	O
nonabsorbable	O
antacids	O
given	O
concurrently	O
with	O
lactulose	B-Drug
may	O
inhibit	O
the	O
desired	O
lactulose-induced	B-Drug
drop	O
in	O
colonic	O
pH	O
.	O

Therefore	O
,	O
a	O
possible	O
lack	O
of	O
desired	O
effect	O
of	O
treatment	O
should	O
be	O
taken	O
into	O
consideration	O
before	O
such	O
drugs	B-Drug
are	O
given	O
concomitantly	O
with	O
lactulose	B-Drug
.	O

Lamivudine	B-Drug
is	O
predominantly	O
eliminated	O
in	O
the	O
urine	O
by	O
active	O
organic	O
cationic	O
secretion	O
.	O

The	O
possibility	O
of	O
interactions	O
with	O
other	O
drugs	B-Drug
administered	O
concurrently	O
should	O
be	O
considered	O
,	O
particularly	O
when	O
their	O
main	O
route	O
of	O
elimination	O
is	O
active	O
renal	O
secretion	O
via	O
the	O
organic	O
cationic	O
transport	O
system	O
(	O
e.g.	O
,	O
trimethoprim	B-Drug
)	O
.	O

No	O
change	O
in	O
dose	O
of	O
either	O
drug	B-Drug
is	O
recommended	O
.	O

There	O
is	O
no	O
information	O
regarding	O
the	O
effect	O
on	O
lamivudine	B-Drug
pharmacokinetics	O
of	O
higher	O
doses	O
of	O
TMP/SMX	B-Drug
such	O
as	O
those	O
used	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
.	O

No	O
data	O
are	O
available	O
regarding	O
interactions	O
with	O
other	O
drugs	B-Drug
that	O
have	O
renal	O
clearance	O
mechanisms	O
similar	O
to	O
that	O
of	O
lamivudine	B-Drug
.	O

Lamivudine	B-Drug
and	O
zalcitabine	B-Drug
may	O
inhibit	O
the	O
intracellular	O
phosphorylation	O
of	O
one	O
another	O
.	O

Therefore	O
,	O
use	O
of	O
lamivudine	B-Drug
in	O
combination	O
with	O
zalcitabine	B-Drug
is	O
not	O
recommended	O
.	O

Lansoprazole	B-Drug
is	O
metabolized	O
through	O
the	O
cytochrome	O
P450	O
system	O
,	O
specifically	O
through	O
the	O
CYP3A	O
and	O
CYP2C19	O
isozymes	O
.	O

Studies	O
have	O
shown	O
that	O
lansoprazole	B-Drug
does	O
not	O
have	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	B-Drug
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
,	O
such	O
as	O
warfarin	B-Drug
,	O
antipyrine	B-Drug
,	O
indomethacin	B-Drug
,	O
ibuprofen	B-Drug
,	O
phenytoin	B-Drug
,	O
propranolol	B-Drug
,	O
prednisone	B-Drug
,	O
diazepam	B-Drug
,	O
clarithromycin	B-Drug
,	O
or	O
terfenadine	B-Drug
in	O
healthy	O
subjects	O
.	O

These	O
compounds	O
are	O
metabolized	O
through	O
various	O
cytochrome	O
P450	O
isozymes	O
including	O
CYP1A2	B-Drug
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
CYP2D6	B-Drug
,	O
and	O
CYP3A	O
.	O

When	O
lansoprazole	B-Drug
was	O
administered	O
concomitantly	O
with	O
theophylline	B-Drug
(	O
CYP1A2	B-Drug
,	O
CYP3A	O
)	O
,	O
a	O
minor	O
increase	O
(	O
10	O
%	O
)	O
in	O
the	O
clearance	O
of	O
theophylline	B-Drug
was	O
seen	O
.	O

Because	O
the	O
small	O
magnitude	O
and	O
the	O
direction	O
of	O
the	O
effect	O
on	O
theophylline	B-Drug
clearance	O
,	O
this	O
interaction	O
is	O
unlikely	O
to	O
be	O
clinical	O
concern	O
.	O

Nonetheless	O
,	O
individual	O
patients	O
may	O
require	O
additional	O
titration	O
of	O
their	O
theophylline	B-Drug
dosage	O
when	O
lansoprazole	B-Drug
is	O
started	O
or	O
stopped	O
to	O
ensure	O
clinically	O
effective	O
blood	O
levels	O
.	O

Lansoprazole	B-Drug
has	O
also	O
been	O
shown	O
to	O
have	O
no	O
clinically	O
significant	O
interaction	O
with	O
amoxicillin	B-Drug
.	O

In	O
a	O
single-dose	O
crossover	O
study	O
examining	O
lansoprazole	B-Drug
30	O
mg	O
and	O
omeprazole	B-Drug
20	O
mg	O
each	O
administered	O
alone	O
and	O
concomitantly	O
with	O
sucralfate	B-Drug
1	O
gram	O
,	O
absorption	O
of	O
the	O
proton	O
pump	O
inhibitors	O
was	O
delayed	O
and	O
their	O
bioavailability	O
was	O
reduced	O
by	O
17	O
%	O
and	O
16	O
%	O
,	O
respectively	O
,	O
when	O
administered	O
concomitantly	O
with	O
sucralfate	B-Drug
.	O

Therefore	O
,	O
proton	O
pump	O
inhibitors	O
should	O
be	O
taken	O
at	O
least	O
30	O
minutes	O
prior	O
to	O
sucralfate	B-Drug
.	O

In	O
clinical	O
trials	O
,	O
antacids	O
were	O
administered	O
concomitantly	O
with	O
lansoprazole	B-Drug
delayed-release	O
capsules	O
;	O
this	O
did	O
not	O
interfere	O
with	O
its	O
effect	O
.	O

Lansoprazole	B-Drug
causes	O
a	O
profound	O
and	O
long	O
lasting	O
inhibition	O
of	O
gastric	O
acid	O
secretion	O
;	O
therefore	O
,	O
it	O
is	O
theoretically	O
possible	O
that	O
lansoprazole	B-Drug
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	B-Drug
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
e.g	O
.	O

ketoconazole	B-Drug
,	O
ampicillin	B-Drug
esters	O
,	O
iron	B-Drug
salts	O
,	O
digoxin	B-Drug
)	O
.	O

Effects	O
of	O
Lapatinib	B-Drug
on	O
Drug	B-Drug
Metabolizing	O
Enzymes	O
and	O
Drug	B-Drug
Transport	O
Systems	O
Lapatinib	B-Drug
inhibits	O
CYP3A4	B-Drug
and	O
CYP2C8	O
in	O
vitro	O
at	O
clinically	O
relevant	O
concentrations	O
.	O

Caution	O
should	O
be	O
exercised	O
and	O
dose	O
reduction	O
of	O
the	O
concomitant	O
substrate	O
drug	B-Drug
should	O
be	O
considered	O
when	O
dosing	O
lapatinib	B-Drug
concurrently	O
with	O
medications	O
with	O
narrow	O
therapeutic	O
windows	O
that	O
are	O
substrates	O
of	O
CYP3A4	B-Drug
or	O
CYP2C8	O
.	O

Lapatinib	B-Drug
did	O
not	O
significantly	O
inhibit	O
the	O
following	O
enzymes	O
in	O
human	O
liver	O
microsomes	O
:	O
CYP1A2	B-Drug
,	O
CYP2C9	B-Drug
,	O
CYP2C19	O
,	O
and	O
CYP2D6	B-Drug
or	O
UGT	O
enzymes	O
in	O
vitro	O
,	O
however	O
,	O
the	O
clinical	O
significance	O
is	O
unknown	O
.	O

Lapatinib	B-Drug
inhibits	O
human	O
P-glycoprotein	O
.	O

If	O
TYKERB	B-Drug
is	O
administered	O
with	O
drugs	B-Drug
that	O
are	O
substrates	O
of	O
Pgp	O
,	O
increased	O
concentrations	O
of	O
the	O
substrate	O
drug	B-Drug
are	O
likely	O
,	O
and	O
caution	O
should	O
be	O
exercised	O
.	O

Drugs	B-Drug
that	O
Inhibit	O
or	O
Induce	O
Cytochrome	O
P450	O
3A4	O
Enzymes	O
Lapatinib	B-Drug
undergoes	O
extensive	O
metabolism	O
by	O
CYP3A4	B-Drug
,	O
and	O
concomitant	O
administration	O
of	O
strong	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	B-Drug
alter	O
lapatinib	B-Drug
concentrations	O
significantly	O
.	O

Dose	O
adjustment	O
of	O
lapatinib	B-Drug
should	O
be	O
considered	O
for	O
patients	O
who	O
must	O
receive	O
concomitant	O
strong	O
inhibitors	O
or	O
concomitant	O
strong	O
inducers	O
of	O
CYP3A4	B-Drug
enzymes	O
.	O

Ketoconazole	B-Drug
:	O
In	O
healthy	O
subjects	O
receiving	O
ketoconazole	B-Drug
,	O
a	O
CYP3A4	B-Drug
inhibitor	O
,	O
at	O
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B-Drug
was	O
increased	O
to	O
approximately	O
3.6-fold	O
of	O
control	O
and	O
half-life	O
increased	O
to	O
1.7-fold	O
of	O
control	O
.	O

Carbamazepine	B-Drug
:	O
In	O
healthy	O
subjects	O
receiving	O
the	O
CYP3A4	B-Drug
inducer	O
,	O
carbamazepine	B-Drug
,	O
at	O
100	O
mg	O
twice	O
daily	O
for	O
3	O
days	O
and	O
200	O
mg	O
twice	O
daily	O
for	O
17	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B-Drug
was	O
decreased	O
approximately	O
72	O
%	O
.	O

Drugs	B-Drug
that	O
Inhibit	O
Drug	B-Drug
Transport	O
Systems	O
Lapatinib	B-Drug
is	O
a	O
substrate	O
of	O
the	O
efflux	O
transporter	O
P-glycoprotein	O
(	O
Pgp	O
,	O
ABCB1	O
)	O
.	O

If	O
TYKERB	B-Drug
is	O
administered	O
with	O
drugs	B-Drug
that	O
inhibit	O
Pgp	O
,	O
increased	O
concentrations	O
of	O
lapatinib	B-Drug
are	O
likely	O
,	O
and	O
caution	O
should	O
be	O
exercised	O
.	O

Other	O
Chemotherapy	O
Agents	O
In	O
a	O
separate	O
study	O
,	O
concomitant	O
administration	O
of	O
lapatinib	B-Drug
with	O
capecitabine	B-Drug
did	O
not	O
meaningfully	O
alter	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
(	O
or	O
the	O
metabolites	O
of	O
capecitabine	B-Drug
)	O
.	O

No	O
formal	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
precipitation	O
occurs	O
when	O
eye	O
drops	O
containing	O
thimerosal	B-Drug
are	O
mixed	O
with	O
latanoprost	B-Drug
.	O

If	O
such	O
drugs	B-Drug
are	O
used	O
they	O
should	O
be	O
administered	O
with	O
an	O
interval	O
of	O
at	O
least	O
5	O
minutes	O
between	O
applications	O
.	O

Cholestyramine	B-Drug
and	O
Charcoal	B-Drug
Administration	O
of	O
cholestyramine	B-Drug
or	O
activated	B-Drug
charcoal	I-Drug
in	O
patients	O
(	O
n=13	O
)	O
and	O
volunteers	O
(	O
n=96	O
)	O
resulted	O
in	O
a	O
rapid	O
and	O
significant	O
decrease	O
in	O
plasma	O
M1	O
(	O
the	O
active	O
metabolite	O
of	O
leflunomide	B-Drug
)	O
concentration	O
.	O

Hepatotoxic	O
Drugs	B-Drug
Increased	O
side	O
effects	O
may	O
occur	O
when	O
leflunomide	B-Drug
is	O
given	O
concomitantly	O
with	O
hepatotoxic	O
substances	O
.	O

This	O
is	O
also	O
to	O
be	O
considered	O
when	O
leflunomide	B-Drug
treatment	O
is	O
followed	O
by	O
such	O
drugs	B-Drug
without	O
a	O
drug	B-Drug
elimination	O
procedure	O
.	O

In	O
a	O
small	O
(	O
n=30	O
)	O
combination	O
study	O
of	O
ARAVA	B-Drug
with	O
methotrexate	B-Drug
,	O
a	O
2-	O
to	O
3-fold	O
elevation	O
in	O
liver	O
enzymes	O
was	O
seen	O
in	O
5	O
of	O
30	O
patients	O
.	O

All	O
elevations	O
resolved	O
,	O
2	O
with	O
continuation	O
of	O
both	O
drugs	B-Drug
and	O
3	O
after	O
discontinuation	O
of	O
leflunomide	B-Drug
.	O

A	O
3-fold	O
increase	O
was	O
seen	O
in	O
another	O
5	O
patients	O
.	O

All	O
of	O
these	O
also	O
resolved	O
,	O
2	O
with	O
continuation	O
of	O
both	O
drugs	B-Drug
and	O
3	O
after	O
discontinuation	O
of	O
leflunomide	B-Drug
.	O

Three	O
patients	O
met	O
ACR	O
criteria	O
for	O
liver	O
biopsy	O
(	O
1	O
:	O
Roegnik	O
Grade	O
I	O
,	O
2	O
:	O
Roegnik	O
Grade	O
IIIa	O
)	O
.	O

No	O
pharmacokinetic	O
interaction	O
was	O
identified	O
.	O

NSAIDs	O
:	O
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
diclofenac	B-Drug
and	O
ibuprofen	B-Drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
;	O
however	O
,	O
there	O
was	O
extensive	O
concomitant	O
use	O
of	O
NSAIDs	O
in	O
clinical	O
studies	O
and	O
no	O
differential	O
effect	O
was	O
observed	O
.	O

Tolbutamide	B-Drug
:	O
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
tolbutamide	B-Drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O

Rifampin	B-Drug
:	O
Following	O
concomitant	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ARAVA	B-Drug
to	O
subjects	O
receiving	O
multiple	O
doses	O
of	O
rifampin	B-Drug
,	O
M1	O
peak	O
levels	O
were	O
increased	O
(	O
~40	O
%	O
)	O
over	O
those	O
seen	O
when	O
ARAVA	B-Drug
was	O
given	O
alone	O
.	O

Because	O
of	O
the	O
potential	O
for	O
ARAVA	B-Drug
levels	O
to	O
continue	O
to	O
increase	O
with	O
multiple	O
dosing	O
,	O
caution	O
should	O
be	O
used	O
if	O
patients	O
are	O
to	O
be	O
receiving	O
both	O
ARAVA	B-Drug
and	O
rifampin	B-Drug
.	O

Warfarin	B-Drug
:	O
Increased	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
when	O
ARAVA	B-Drug
and	O
warfarin	B-Drug
were	O
co-administered	O
has	O
been	O
rarely	O
reported	O
.	O

Results	O
from	O
human	O
in	O
vitro	O
metabolism	O
studies	O
and	O
nonclinical	O
studies	O
show	O
that	O
REVLIMID	B-Drug
(	O
lenalidomide	B-Drug
)	O
is	O
neither	O
metabolized	O
by	O
nor	O
inhibits	O
or	O
induces	O
the	O
cytochrome	O
P450	O
pathway	O
suggesting	O
that	O
lenalidomide	B-Drug
is	O
not	O
likely	O
to	O
cause	O
or	O
be	O
subject	O
to	O
P450-based	O
metabolic	O
drug	B-Drug
interactions	O
in	O
man	O
.	O

Co-administration	O
of	O
multiple	O
doses	O
of	O
10	O
mg	O
of	O
lenalidomide	B-Drug
had	O
no	O
effect	O
on	O
the	O
single	O
dose	O
pharmacokinetics	O
of	O
R-	B-Drug
and	O
S-	O
warfarin	I-Drug
.	O

Co-administration	O
of	O
single	O
25-mg	O
dose	O
warfarin	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
total	O
lenalidomide	B-Drug
.	O

Expected	O
changes	O
in	O
laboratory	O
assessments	O
of	O
PT	O
and	O
INR	O
were	O
observed	O
after	O
warfarin	B-Drug
administration	O
,	O
but	O
these	O
changes	O
were	O
not	O
affected	O
by	O
concomitant	O
lenalidomide	B-Drug
administration	O
.	O

Concomitant	O
treatment	O
with	O
thrombolytics	O
(	O
eg	O
,	O
rt-PA	O
or	O
streptokinase	B-Drug
)	O
may	O
:	O
-	O
increase	O
the	O
risk	O
of	O
bleeding	O
complications	O
-	O
considerably	O
enhance	O
the	O
effect	O
of	O
REFLUDAN	B-Drug
on	O
aPTT	O
prolongation	O
Concomitant	O
treatment	O
with	O
coumarin	O
derivatives	O
(	O
vitamin	O
K	O
antagonists	O
)	O
and	O
drugs	B-Drug
that	O
affect	O
platelet	O
function	O
may	O
also	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

Clinical	O
interaction	O
studies	O
with	O
cimetidine	B-Drug
and	O
warfarin	B-Drug
indicated	O
that	O
the	O
coadministration	O
of	O
Femara	B-Drug
with	O
these	O
drugs	B-Drug
does	O
not	O
result	O
in	O
clinically-	O
significant	O
drug	B-Drug
interactions	O
.	O

(	O
See	O
CLINICAL	O
PHARMACOLOGY	O
)	O
Coadministration	O
of	O
Femara	B-Drug
and	O
tamoxifen	B-Drug
20	O
mg	O
daily	O
resulted	O
in	O
a	O
reduction	O
of	O
letrozole	B-Drug
plasma	O
levels	O
by	O
38	O
%	O
on	O
average	O
.	O

There	O
is	O
no	O
clinical	O
experience	O
to	O
date	O
on	O
the	O
use	O
of	O
Femara	B-Drug
in	O
combination	O
with	O
other	O
anticancer	O
agents	O
.	O

Drug/Laboratory	O
Test-Interactions	O
None	O
observed	O
.	O

Folic	B-Drug
acid	I-Drug
in	O
large	O
amounts	O
may	O
counteract	O
the	O
antiepileptic	O
effect	O
of	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
and	O
primidone	B-Drug
,	O
and	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
susceptible	O
pediatric	O
patients	O
.	O

Preliminary	O
animal	O
and	O
human	O
studies	O
have	O
shown	O
that	O
small	O
quantities	O
of	O
systemically	O
administered	O
leucovorin	B-Drug
enter	O
the	O
CSF	O
primarily	O
as	O
5-methyltetrahydro-folate	O
and	O
,	O
in	O
humans	O
,	O
remain	O
1	O
to	O
3	O
orders	O
of	O
magnitude	O
lower	O
than	O
the	O
usual	O
methotrexate	B-Drug
concentrations	O
following	O
intrathecal	O
administration	O
.	O

However	O
,	O
high	O
doses	O
of	O
leucovorin	B-Drug
may	O
reduce	O
the	O
efficacy	O
of	O
intrathecally	O
administered	O
methotrexate	B-Drug
.	O

Leucovorin	B-Drug
may	O
enhance	O
the	O
toxicity	O
of	O
5-fluorouracil	B-Drug
.	O

ERGAMISOL	B-Drug
(	O
levamisole	B-Drug
hydrochloride	I-Drug
)	O
has	O
been	O
reported	O
to	O
produce	O
ANTABUSE-like	O
side	O
effects	O
when	O
given	O
concomitantly	O
with	O
alcohol	B-Drug
.	O

The	O
physician	O
is	O
advised	O
to	O
monitor	O
plasma	O
levels	O
of	O
phenytoin	B-Drug
and	O
to	O
decrease	O
the	O
dose	O
if	O
necessary	O
.	O

Because	O
of	O
reports	O
of	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
beyond	O
the	O
therapeutic	O
range	O
in	O
patients	O
taking	O
concurrent	O
levamisole	B-Drug
and	O
warfarin	B-Drug
sodium	I-Drug
,	O
it	O
is	O
suggested	O
that	O
the	O
prothrombin	O
time	O
be	O
monitored	O
carefully	O
,	O
and	O
the	O
dose	O
of	O
warfarin	B-Drug
sodium	I-Drug
or	O
other	O
coumarin-like	O
drugs	B-Drug
should	O
be	O
adjusted	O
accordingly	O
,	O
in	O
patients	O
taking	O
both	O
drugs	B-Drug
.	O

in	O
vitro	O
data	O
on	O
metabolic	O
interactions	O
indicate	O
that	O
Keppra	B-Drug
is	O
unlikely	O
to	O
produce	O
,	O
or	O
be	O
subject	O
to	O
,	O
pharmacokinetic	O
interactions	O
.	O

Levetiracetam	B-Drug
and	O
its	O
major	O
metabolite	O
,	O
at	O
concentrations	O
well	O
above	O
cmax	O
levels	O
achieved	O
within	O
the	O
therapeutic	O
dose	O
range	O
,	O
are	O
neither	O
inhibitors	O
of	O
nor	O
high	O
affinity	O
substrates	O
for	O
human	O
liver	O
cytochrome	O
P450	O
isoforms	O
,	O
epoxide	O
hydrolase	O
or	O
UDP-glucuronidation	O
enzymes	O
.	O

In	O
addition	O
,	O
levetiracetam	B-Drug
does	O
not	O
affect	O
the	O
in	O
vitro	O
glucuronidation	O
of	O
valproic	B-Drug
acid	I-Drug
.	O

Levetiracetam	B-Drug
circulates	O
largely	O
unbound	O
(	O
10	O
%	O
bound	O
)	O
to	O
plasma	O
proteins	O
;	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	B-Drug
through	O
competition	O
for	O
protein	O
binding	O
sites	O
are	O
therefore	O
unlikely	O
.	O

Potential	O
pharmacokinetic	O
interactions	O
were	O
assessed	O
in	O
clinical	O
pharmacokinetic	O
studies	O
(	O
phenytoin	B-Drug
,	O
valproate	B-Drug
,	O
oral	O
contraceptive	O
,	O
digoxin	B-Drug
,	O
warfarin	B-Drug
,	O
probenecid	B-Drug
)	O
and	O
through	O
pharmacokinetic	O
screening	O
in	O
the	O
placebo-controlled	O
clinical	O
studies	O
in	O
epilepsy	O
patients	O
.	O

Drug-Drug	O
Interactions	O
Between	O
Keppra	B-Drug
And	O
Other	O
Antiepileptic	O
Drugs	B-Drug
(	O
AEDs	O
)	O
Phenytoin	B-Drug
Keppra	B-Drug
(	O
3000	O
mg	O
daily	O
)	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
disposition	O
of	O
phenytoin	B-Drug
in	O
patients	O
with	O
refractory	O
epilepsy	O
.	O

Pharmacokinetics	O
of	O
levetiracetam	B-Drug
were	O
also	O
not	O
affected	O
by	O
phenytoin	B-Drug
.	O

Valproate	B-Drug
Keppra	B-Drug
(	O
1500	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
valproate	B-Drug
in	O
healthy	O
volunteers	O
.	O

Valproate	B-Drug
500	O
mg	O
twice	O
daily	O
did	O
not	O
modify	O
the	O
rate	O
or	O
extent	O
of	O
levetiracetam	B-Drug
absorption	O
or	O
its	O
plasma	O
clearance	O
or	O
urinary	O
excretion	O
.	O

There	O
also	O
was	O
no	O
effect	O
on	O
exposure	O
to	O
and	O
the	O
excretion	O
of	O
the	O
primary	O
metabolite	O
,	O
ucb	O
L057	O
.	O

Potential	O
drug	B-Drug
interactions	O
between	O
Keppra	B-Drug
and	O
other	O
AEDs	O
(	O
carbamazepine	B-Drug
,	O
gabapentin	B-Drug
,	O
lamotrigine	B-Drug
,	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
,	O
primidone	B-Drug
and	O
valproate	B-Drug
)	O
were	O
also	O
assessed	O
by	O
evaluating	O
the	O
serum	O
concentrations	O
of	O
levetiracetam	B-Drug
and	O
these	O
AEDs	O
during	O
placebo-controlled	O
clinical	O
studies	O
.	O

These	O
data	O
indicate	O
that	O
levetiracetam	B-Drug
does	O
not	O
influence	O
the	O
plasma	O
concentration	O
of	O
other	O
AEDs	O
and	O
that	O
these	O
AEDs	O
do	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O

Effect	O
of	O
AEDs	O
in	O
Pediatric	O
Patients	O
There	O
was	O
about	O
a	O
22	O
%	O
increase	O
of	O
apparent	O
total	O
body	O
clearance	O
of	O
levetiracetam	B-Drug
when	O
it	O
was	O
co-administered	O
with	O
enzyme-inducing	O
AEDs	O
.	O

Dose	O
adjustment	O
is	O
not	O
recommended.Levetiracetam	B-Drug
had	O
no	O
effect	O
on	O
plasma	O
concentrations	O
of	O
carbamazepine	B-Drug
,	O
valproate	B-Drug
,	O
topiramate	B-Drug
,	O
or	O
lamotrigine	B-Drug
.	O

Other	O
Drug	B-Drug
Interactions	O
Oral	O
Contraceptives	O
Keppra	B-Drug
(	O
500	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
an	O
oral	O
contraceptive	O
containing	O
0.03	O
mg	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
0.15	O
mg	O
levonorgestrel	B-Drug
,	O
or	O
of	O
the	O
luteinizing	O
hormone	O
and	O
progesterone	B-Drug
levels	O
,	O
indicating	O
that	O
impairment	O
of	O
contraceptive	O
efficacy	O
is	O
unlikely	O
.	O

Coadministration	O
of	O
this	O
oral	O
contraceptive	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O

Digoxin	B-Drug
Keppra	B-Drug
(	O
1000	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
(	O
ECG	O
)	O
of	O
digoxin	B-Drug
given	O
as	O
a	O
0.25	O
mg	O
dose	O
every	O
day	O
.	O

Coadministration	O
of	O
digoxin	B-Drug
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O

Warfarin	B-Drug
Keppra	B-Drug
(	O
1000	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
R	B-Drug
and	O
S	O
warfarin	I-Drug
.	O

Prothrombin	O
time	O
was	O
not	O
affected	O
by	O
levetiracetam	B-Drug
.	O

Coadministration	O
of	O
warfarin	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
.	O

Probenecid	B-Drug
:	O
Probenecid	B-Drug
,	O
a	O
renal	O
tubular	O
secretion	O
blocking	O
agent	O
,	O
administered	O
at	O
a	O
dose	O
of	O
500	O
mg	O
four	O
times	O
a	O
day	O
,	O
did	O
not	O
change	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B-Drug
1000	O
mg	O
twice	O
daily	O
.	O

Cssmax	O
of	O
the	O
metabolite	O
,	O
ucb	O
L057	O
,	O
was	O
approximately	O
doubled	O
in	O
the	O
presence	O
of	O
probenecid	B-Drug
while	O
the	O
fraction	O
of	O
drug	B-Drug
excreted	O
unchanged	O
in	O
the	O
urine	O
remained	O
the	O
same	O
.	O

Renal	O
clearance	O
of	O
ucb	O
L057	O
in	O
the	O
presence	O
of	O
probenecid	B-Drug
decreased	O
60	O
%	O
,	O
probably	O
related	O
to	O
competitive	O
inhibition	O
of	O
tubular	O
secretion	O
of	O
ucb	O
L057	O
.	O

The	O
effect	O
of	O
Keppra	B-Drug
on	O
probenecid	B-Drug
was	O
not	O
studied	O
.	O

Although	O
BETAGAN	B-Drug
used	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
pupil	O
size	O
,	O
mydriasis	O
resulting	O
from	O
concomitant	O
therapy	O
with	O
BETAGAN	B-Drug
and	O
epinephrine	B-Drug
may	O
occur	O
.	O

Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta-blocker	O
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine-depleting	O
drugs	B-Drug
such	O
as	O
reserpine	B-Drug
,	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and/or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
or	O
postural	O
hypotension	O
.	O

Patients	O
receiving	O
beta-adrenergic	O
blocking	O
agents	O
along	O
with	O
either	O
oral	O
or	O
intravenous	O
calcium	B-Drug
antagonists	O
should	O
be	O
monitored	O
for	O
possible	O
atrioventricular	O
conduction	O
disturbances	O
,	O
left	O
ventricular	O
failure	O
and	O
hypotension	O
.	O

In	O
patients	O
with	O
impaired	O
cardiac	O
function	O
,	O
simultaneous	O
use	O
should	O
be	O
avoided	O
altogether	O
.	O

The	O
concomitant	O
use	O
of	O
beta-adrenergic	O
blocking	O
agents	O
with	O
digitalis	B-Drug
and	O
calcium	B-Drug
antagonists	O
may	O
have	O
additive	O
effects	O
on	O
prolonging	O
atrioventricular	O
conduction	O
time	O
.	O

Phenothiazine-related	O
compounds	O
and	O
beta-adrenergic	O
blocking	O
agents	O
may	O
have	O
additive	O
hypotensite	O
effects	O
due	O
to	O
the	O
inhibition	O
of	O
each	O
other	O
s	O
metabolism	O
.	O

Chirocaine	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
other	O
local	O
anesthetics	B-Drug
or	O
agents	O
structurally	O
related	O
to	O
amide-type	O
local	O
anesthetics	B-Drug
since	O
the	O
toxic	O
effects	O
of	O
these	O
drugs	B-Drug
could	O
be	O
additive	O
.	O

In	O
vitro	O
studies	O
indicate	O
CYP3A4	B-Drug
isoform	O
and	O
CYP1A2	B-Drug
isoform	O
mediate	O
the	O
metabolism	O
of	O
levobupivacaine	B-Drug
to	O
desbutyl	B-Drug
levobupivacaine	I-Drug
and	O
3-hydroxy	B-Drug
levobupivacaine	I-Drug
,	O
respectively	O
.	O

Thus	O
agents	O
likely	O
to	O
be	O
concomitantly	O
administered	O
with	O
Chirocaine	B-Drug
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
family	O
may	O
potentially	O
interact	O
with	O
Chirocaine	B-Drug
.	O

Although	O
no	O
clinical	O
studies	O
have	O
been	O
conducted	O
,	O
it	O
is	O
likely	O
that	O
the	O
metabolism	O
of	O
levobupivacaine	B-Drug
may	O
be	O
affected	O
by	O
the	O
known	O
CYP3A4	B-Drug
inducers	O
(	O
such	O
as	O
phenytoin	B-Drug
,	O
phenobarbital	B-Drug
,	O
rifampin	B-Drug
)	O
,	O
CYP3A4	B-Drug
inhibitors	O
(	O
azole	O
antimycotics	O
e.g.	O
,	O
ketoconazole	B-Drug
;	O
certain	O
protease	O
inhibitors	O
e.g.	O
,	O
ritanovir	O
;	O
macrolide	O
antibiotics	B-Drug
e.g.	O
,	O
erythromycin	B-Drug
;	O
and	O
calcium	B-Drug
channel	O
antagonists	O
e.g.	O
,	O
verapamil	B-Drug
)	O
,	O
CYP1A2	B-Drug
inducers	O
(	O
omeprazole	B-Drug
)	O
and	O
CYP1A2	B-Drug
inhibitors	O
(	O
furafylline	B-Drug
and	O
clarithromycin	B-Drug
)	O
.	O

Dosage	O
adjustment	O
may	O
be	O
warranted	O
when	O
levobupivacaine	B-Drug
is	O
concurrently	O
administered	O
with	O
CYP3A4	B-Drug
inhibitors	O
and	O
CYP1A2	B-Drug
inhibitors	O
as	O
systemic	O
levobupivacaine	B-Drug
levels	O
may	O
rise	O
resulting	O
in	O
toxicity	O
.	O

Specific	O
drug	B-Drug
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
Levofloxacin	B-Drug
.	O

However	O
,	O
the	O
systemic	O
administration	O
of	O
some	O
quinolones	O
has	O
been	O
shown	O
to	O
elevate	O
plasma	O
concentrations	O
of	O
theophylline	B-Drug
,	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
,	O
and	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Drug
warfarin	B-Drug
and	O
its	O
derivatives	O
,	O
and	O
has	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
systemic	O
cyclosporine	B-Drug
concomitantly	O
.	O

Interactions	O
with	O
Other	O
CNS	O
Agents	O
:	O
Concurrent	O
use	O
of	O
Levo-Dromoran	B-Drug
with	O
all	O
central	O
nervous	O
system	O
depressants	O
(	O
eg	O
,	O
alcohol	B-Drug
,	O
sedatives	O
,	O
hypnotics	O
,	O
other	O
opioids	O
,	O
general	O
anesthetics	B-Drug
,	O
barbiturates	B-Drug
,	O
tricyclic	O
antidepressants	B-Drug
,	O
phenothiazines	O
,	O
tranquilizers	O
,	O
skeletal	O
muscle	O
relaxants	O
and	O
antihistamines	B-Drug
)	O
may	O
result	O
in	O
additive	O
central	O
nervous	O
system	O
depressant	O
effects	O
.	O

Respiratory	O
depression	O
,	O
hypotension	O
,	O
and	O
profound	O
sedation	O
or	O
coma	O
may	O
occur	O
.	O

When	O
such	O
combined	O
therapy	O
is	O
contemplated	O
,	O
the	O
dose	O
of	O
one	O
or	O
both	O
agents	O
should	O
be	O
reduced	O
.	O

Although	O
no	O
interaction	O
between	O
MAO	O
inhibitors	O
and	O
Levo-Dromoran	B-Drug
has	O
been	O
observed	O
,	O
it	O
is	O
not	O
recommended	O
for	O
use	O
with	O
MAO	O
inhibitors	O
.	O

Most	O
cases	O
of	O
serious	O
or	O
fatal	O
adverse	O
events	O
involving	O
Levo-Dromoran	B-Drug
reported	O
to	O
the	O
manufacturer	O
or	O
the	O
FDA	O
have	O
involved	O
either	O
the	O
administration	O
of	O
large	O
initial	O
doses	O
or	O
too	O
frequent	O
doses	O
of	O
the	O
drug	B-Drug
to	O
nonopioid	O
tolerant	O
patients	O
,	O
or	O
the	O
simultaneous	O
administration	O
of	O
levorphanol	B-Drug
with	O
other	O
drugs	B-Drug
affecting	O
respiration	O
.	O

The	O
initial	O
dose	O
of	O
levorphanol	B-Drug
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
or	O
more	O
when	O
it	O
is	O
given	O
to	O
patients	O
along	O
with	O
another	O
drug	B-Drug
affecting	O
respiration	O
.	O

Interactions	O
with	O
Mixed	O
Agonist/Antagonist	O
Opioid	O
Analgesics	O
:	O
Agonist/antagonist	O
analgesics	O
(	O
eg	O
,	O
pentazocine	B-Drug
,	O
nalbuphine	B-Drug
,	O
butorphanol	B-Drug
,	O
dezocine	B-Drug
and	O
buprenorphine	B-Drug
)	O
should	O
NOT	O
be	O
administered	O
to	O
a	O
patient	O
who	O
has	O
received	O
or	O
is	O
receiving	O
a	O
course	O
of	O
therapy	O
with	O
a	O
pure	O
agonist	O
opioid	O
analgesic	O
such	O
as	O
Levo-Dromoran	B-Drug
.	O

In	O
opioid-dependent	O
patients	O
,	O
mixed	O
agonist/antagonist	O
analgesics	O
may	O
precipitate	O
withdrawal	O
symptoms	O
.	O

No	O
Important	O
Interactions	O
To	O
Date	O
Levosimendan	B-Drug
does	O
not	O
have	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
captopril	B-Drug
,	O
beta-blockers	O
,	O
felodipine	B-Drug
,	O
digoxin	B-Drug
,	O
warfarin	B-Drug
,	O
isosorbide	B-Drug
mononitrate	I-Drug
,	O
carvedilol	B-Drug
,	O
ethanol	B-Drug
or	O
itraconazole	B-Drug
.	O

The	O
magnitude	O
and	O
relative	O
importance	O
of	O
the	O
effects	O
noted	O
below	O
are	O
likely	O
to	O
be	O
patient	O
specific	O
and	O
may	O
vary	O
by	O
such	O
factors	O
as	O
age	O
,	O
gender	O
,	O
race	O
,	O
intercurrent	O
illnesses	O
,	O
dose	O
of	O
either	O
agent	O
,	O
additional	O
concomitant	O
medications	O
,	O
and	O
timing	O
of	O
drug	B-Drug
administration	O
.	O

Any	O
agent	O
that	O
alters	O
thyroid	B-Drug
hormone	O
synthesis	O
,	O
secretion	O
,	O
distribution	O
,	O
effect	O
on	O
target	O
tissues	O
,	O
metabolism	O
,	O
or	O
elimination	O
may	O
alter	O
the	O
optimal	O
therapeutic	O
dose	O
of	O
levothyroxine	B-Drug
sodium	O
.	O

Levothyroxine	B-Drug
Sodium	I-Drug
Absorption	O
:	O
The	O
following	O
agents	O
may	O
bind	O
and	O
decrease	O
absorption	O
of	O
levothyroxine	B-Drug
sodium	I-Drug
from	O
the	O
gastrointestinal	O
tract	O
:	O
aluminum	B-Drug
hydoxide	I-Drug
,	O
cholestyramine	B-Drug
resin	O
,	O
colestipol	B-Drug
hydrochloride	I-Drug
,	O
ferrous	B-Drug
sulfate	I-Drug
,	O
sodium	B-Drug
polystyrene	I-Drug
sulfonate	I-Drug
,	O
soybean	O
flour	O
(	O
e.g.	O
,	O
infant	O
formula	O
)	O
,	O
sucralfate	B-Drug
.	O

Binding	O
to	O
Serum	O
Proteins	O
:	O
The	O
following	O
agents	O
may	O
either	O
inhibit	O
levothyroxine	B-Drug
sodium	I-Drug
binding	O
to	O
serum	O
proteins	O
or	O
alter	O
the	O
concentrations	O
of	O
serum	O
binding	O
proteins	O
:	O
androgens	O
and	O
related	O
anabolic	O
hormones	O
,	O
asparaginase	B-Drug
,	O
clofibrate	B-Drug
,	O
estrogens	O
and	O
estrogen-containing	O
compounds	O
,	O
5-fluorouracil	B-Drug
,	O
furosemide	B-Drug
,	O
glucocorticoids	O
,	O
meclofenamic	B-Drug
acid	I-Drug
,	O
mefenamic	B-Drug
acid	I-Drug
,	O
methadone	B-Drug
,	O
perphenazine	B-Drug
,	O
phenylbutazone	B-Drug
,	O
phenytoin	B-Drug
,	O
salicylates	O
,	O
tamoxifen	B-Drug
.	O

Thyroid	B-Drug
Physiology	O
:	O
The	O
following	O
agents	O
may	O
alter	O
thyroid	B-Drug
hormone	O
or	O
TSH	O
levels	O
,	O
generally	O
by	O
effects	O
on	O
thyroid	B-Drug
hormone	O
synthesis	O
,	O
secretion	O
,	O
distribution	O
,	O
metabolism	O
,	O
hormone	O
action	O
,	O
or	O
elimination	O
,	O
or	O
altered	O
TSH	O
secretion	O
:	O
aminoglutethimide	B-Drug
,	O
p-aminosalicylic	B-Drug
acid	I-Drug
,	O
amiodarone	B-Drug
,	O
androgens	O
and	O
related	O
anabolic	O
hormones	O
,	O
complex	O
anions	O
(	O
thiocyanate	B-Drug
,	O
perchlorate	B-Drug
,	O
pertechnetate	B-Drug
)	O
,	O
antithyroid	O
drugs	B-Drug
,	O
b-adrenergic	O
blocking	O
agents	O
,	O
carbamazepine	B-Drug
,	O
chloral	B-Drug
hydrate	I-Drug
,	O
diazepam	B-Drug
,	O
dopamine	B-Drug
and	O
dopamine	B-Drug
agonists	O
,	O
ethionamide	B-Drug
,	O
glucocorticoids	O
,	O
heparin	B-Drug
,	O
hepatic	O
enzyme	O
inducers	O
,	O
insulin	B-Drug
,	O
iodinated	O
cholestographic	O
agents	O
,	O
iodine-containing	B-Drug
compounds	O
,	O
levodopa	B-Drug
,	O
lovastatin	B-Drug
,	O
lithium	B-Drug
,	O
6-mercaptopurine	B-Drug
,	O
metoclopramide	B-Drug
,	O
mitotane	B-Drug
,	O
nitroprusside	B-Drug
,	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
,	O
resorcinol	B-Drug
,	O
rifampin	B-Drug
,	O
somatostatin	B-Drug
analogs	O
,	O
sulfonamides	O
,	O
sulfonylureas	O
,	O
thiazide	O
diuretics	B-Drug
.	O

Adrenocorticoids	O
:	O
Metabolic	O
clearance	O
of	O
adrenocorticoids	O
is	O
decreased	O
in	O
hypothyroid	O
patients	O
and	O
increased	O
in	O
hyperthyroid	O
patients	O
,	O
and	O
may	O
therefore	O
change	O
with	O
changing	O
thyroid	B-Drug
status	O
.	O

Amiodarone	B-Drug
:	O
Amiodarone	B-Drug
therapy	O
alone	O
can	O
cause	O
hypothyroidism	O
or	O
hyperthyroidism	O
.	O

Anticoagulants	B-Drug
(	O
Oral	O
)	O
:	O
The	O
hypoprothrombinemic	O
effect	O
of	O
anticoagulants	B-Drug
may	O
be	O
potentiated	O
,	O
apparently	O
by	O
increased	O
catabloism	O
of	O
vitamin	O
K-dependent	O
clotting	O
factors	O
.	O

Antidiabetic	B-Drug
Agents	O
(	O
Insulin	B-Drug
,	O
Sulfonylureas	O
)	O
:	O
Requirements	O
for	O
insulin	B-Drug
or	O
oral	O
antidiabetic	B-Drug
agents	O
may	O
be	O
reduced	O
in	O
hypothyroid	O
patients	O
with	O
diabetes	O
mellitus	O
and	O
may	O
subsequently	O
increase	O
with	O
the	O
initiation	O
of	O
thyroid	B-Drug
hormone	O
replacement	O
therapy	O
.	O

b-Adrenergic	O
Blocking	O
Agents	O
:	O
Actions	O
of	O
some	O
of	O
beta-blocking	B-Drug
agents	O
may	O
be	O
impaired	O
when	O
hypothyroid	O
patients	O
become	O
euthyroid	O
.	O

Cytokines	O
(	O
interferon	O
,	O
interleukin	O
)	O
:	O
Cytokines	O
have	O
been	O
reported	O
to	O
induce	O
both	O
hyperthyroidism	O
and	O
hypothyroidism	O
.	O

Digitalis	B-Drug
Glycosides	O
:	O
Therapeutic	O
effects	O
of	O
digitalis	B-Drug
glycosides	O
may	O
be	O
reduced	O
.	O

Serum	O
digitalis	B-Drug
levels	O
may	O
be	O
decreased	O
in	O
hyperthyroidism	O
or	O
when	O
a	O
hypothyroid	O
patient	O
becomes	O
euthyroid	O
.	O

Ketamine	B-Drug
:	O
Marked	O
hypertension	O
and	O
tachycardia	O
have	O
been	O
reported	O
in	O
association	O
with	O
concomitant	O
administration	O
of	O
levothyroxine	B-Drug
sodium	I-Drug
and	O
ketamine	B-Drug
.	O

Maprotiline	B-Drug
:	O
Risk	O
of	O
cardiac	O
arrhythmias	O
may	O
increase	O
.	O

Sodium	B-Drug
Iodide	I-Drug
(	O
123I	O
and	O
131I	O
)	O
,	O
Sodium	B-Drug
Pertechnetate	I-Drug
Tc99m	I-Drug
:	O
Uptake	O
of	O
radiolabeled	O
ions	O
may	O
be	O
decreased	O
.	O

Somatrem/Somatropin	B-Drug
:	O
Excessive	O
concurrent	O
use	O
of	O
thyroid	B-Drug
hormone	O
may	O
accelerate	O
epiphyseal	O
closure	O
.	O

Untreated	O
hypothyroidism	O
may	O
interfere	O
with	O
the	O
growth	O
response	O
to	O
somatrem	B-Drug
or	O
somatropin	B-Drug
.	O

Theophylline	B-Drug
:	O
Theophylline	B-Drug
clearance	O
may	O
decrease	O
in	O
hypothyroid	O
patients	O
and	O
return	O
toward	O
normal	O
when	O
a	O
euthyroid	O
state	O
is	O
achieved	O
.	O

Tricyclic	O
Antidepressants	B-Drug
:	O
Concurrent	O
use	O
may	O
increase	O
the	O
therapeutic	O
and	O
toxic	O
effects	O
of	O
both	O
drugs	B-Drug
,	O
possibly	O
due	O
to	O
increased	O
catecholamine	O
sensitivity	O
.	O

Onset	O
of	O
action	O
of	O
tricyclics	O
may	O
be	O
accelerated	O
.	O

Sympathomimetic	B-Drug
Agents	O
:	O
Possible	O
increased	O
risk	O
of	O
coronary	O
insufficiency	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B-Drug
solutions	O
containing	O
epinephrine	B-Drug
or	O
norepinephrine	B-Drug
to	O
patients	O
receiving	O
monoamine	O
oxidase	O
inhibitors	O
or	O
tricyclic	O
antidepressants	B-Drug
may	O
produce	O
severe	O
,	O
prolonged	O
hypertension	O
.	O

Phenothiazines	O
and	O
butyrophenones	O
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	B-Drug
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
when	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	O
drugs	B-Drug
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot-type	O
oxytocic	O
drugs	B-Drug
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Lincomycin	B-Drug
has	O
been	O
shown	O
to	O
have	O
neuromuscular	O
blocking	O
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	O
blocking	O
agents	O
.	O

Therefore	O
,	O
it	O
should	O
be	O
used	O
in	O
caution	O
in	O
patients	O
receiving	O
such	O
agents	O
.	O

Antagonism	O
between	O
lincomycin	B-Drug
and	O
erythromycin	B-Drug
in	O
vitro	O
has	O
been	O
demonstrated	O
.	O

Because	O
of	O
possible	O
clinical	O
significance	O
,	O
the	O
two	O
drugs	B-Drug
should	O
not	O
be	O
administered	O
concurrently	O
.	O

Oils	O
may	O
enhance	O
absorption	O
.	O

Therefore	O
,	O
simultaneous	O
use	O
of	O
creams	O
,	O
ointments	O
or	O
oils	O
should	O
be	O
avoided	O
.	O

Monoamine	O
Oxidase	O
Inhibition	O
:	O
Linezolid	B-Drug
is	O
a	O
reversible	O
,	O
nonselective	O
inhibitor	O
of	O
monoamine	O
oxidase	O
.	O

Therefore	O
,	O
linezolid	B-Drug
has	O
the	O
potential	O
for	O
interaction	O
with	O
adrenergic	O
and	O
serotonergic	O
agents	O
.	O

Adrenergic	O
Agents	O
:	O
Some	O
individuals	O
receiving	O
ZYVOX	B-Drug
may	O
experience	O
a	O
reversible	O
enhancement	O
of	O
the	O
pressor	O
response	O
to	O
indirect-acting	O
sympathomimetic	B-Drug
agents	O
,	O
vasopressor	O
or	O
dopaminergic	B-Drug
agents	O
.	O

Commonly	O
used	O
drugs	B-Drug
such	O
as	O
phenylpropanolamine	B-Drug
and	O
pseudoephedrine	B-Drug
have	O
been	O
specifically	O
studied	O
.	O

Initial	O
doses	O
of	O
adrenergic	O
agents	O
,	O
such	O
as	O
dopamine	B-Drug
or	O
epinephrine	B-Drug
,	O
should	O
be	O
reduced	O
and	O
titrated	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Serotonergic	O
Agents	O
:	O
Co-administration	O
of	O
linezolid	B-Drug
and	O
serotonergic	O
agents	O
was	O
not	O
associated	O
with	O
serotonin	O
syndrome	O
in	O
Phase	O
1	O
,	O
2	O
or	O
3	O
studies	O
.	O

Spontaneous	O
reports	O
of	O
serotonin	O
syndrome	O
associated	O
with	O
co-administration	O
of	O
ZYVOX	B-Drug
and	O
serotonergic	O
agents	O
,	O
including	O
antidepressants	B-Drug
such	O
as	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
have	O
been	O
reported	O
.	O

Patients	O
who	O
are	O
treated	O
with	O
ZYVOX	B-Drug
and	O
concomitant	O
serotonergic	O
agents	O
should	O
be	O
closely	O
observed	O
for	O
signs	O
and	O
symptoms	O
of	O
serotonin	O
syndrome	O
(	O
e.g.	O
,	O
cognitive	O
dysfunction	O
,	O
hyperpyrexia	O
,	O
hyperreflexia	O
,	O
incoordination	O
)	O
.	O

If	O
any	O
signs	O
or	O
symptoms	O
occur	O
physicians	O
should	O
consider	O
discontinuation	O
of	O
either	O
one	O
or	O
both	O
agents	O
(	O
ZYVOX	B-Drug
or	O
concomitant	O
serotonergic	O
agents	O
)	O
.	O

Drug-Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
drug-laboratory	O
test	O
interactions	O
.	O

Oral	O
Anticoagulants	B-Drug
:	O
Thyroid	B-Drug
hormones	O
appear	O
to	O
increase	O
catabolism	O
of	O
vitamin	O
K-dependent	O
clotting	O
factors	O
.	O

If	O
oral	O
anticoagulants	B-Drug
are	O
also	O
being	O
given	O
,	O
compensatory	O
increases	O
in	O
clotting	O
factor	O
synthesis	O
are	O
impaired	O
.	O

Patients	O
stabilized	O
on	O
oral	O
anticoagulants	B-Drug
who	O
are	O
found	O
to	O
require	O
thyroid	B-Drug
replacement	O
therapy	O
should	O
be	O
watched	O
very	O
closely	O
when	O
thyroid	B-Drug
is	O
started	O
.	O

If	O
a	O
patient	O
is	O
truly	O
hypothyroid	O
,	O
it	O
is	O
likely	O
that	O
a	O
reduction	O
in	O
anticoagulant	B-Drug
dosage	O
will	O
be	O
required	O
.	O

No	O
special	O
precautions	O
appear	O
to	O
be	O
necessary	O
when	O
oral	O
anticoagulant	B-Drug
therapy	O
is	O
begun	O
in	O
a	O
patient	O
already	O
stabilized	O
on	O
maintenance	O
thyroid	B-Drug
replacement	O
therapy	O
.	O

Insulin	B-Drug
or	O
Oral	O
Hypoglycemics	O
:	O
Initiating	O
thyroid	B-Drug
replacement	O
therapy	O
may	O
cause	O
increases	O
in	O
insulin	B-Drug
or	O
oral	O
hypoglycemic	O
requirements	O
.	O

The	O
effects	O
seen	O
are	O
poorly	O
understood	O
and	O
depend	O
upon	O
a	O
variety	O
of	O
factors	O
such	O
as	O
dose	O
and	O
type	O
of	O
thyroid	B-Drug
preparations	O
and	O
endocrine	O
status	O
of	O
the	O
patient	O
.	O

Patients	O
receiving	O
insulin	B-Drug
or	O
oral	O
hypoglycemics	O
should	O
be	O
closely	O
watched	O
during	O
initiation	O
of	O
thyroid	B-Drug
replacement	O
therapy	O
.	O

Cholestyramine	B-Drug
:	O
Cholestyramine	B-Drug
binds	O
both	O
T4	B-Drug
and	O
T3	B-Drug
in	O
the	O
intestine	O
,	O
thus	O
impairing	O
absorption	O
of	O
these	O
thyroid	B-Drug
hormones	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
the	O
binding	O
is	O
not	O
easily	O
removed	O
.	O

Therefore	O
,	O
4	O
to	O
5	O
hours	O
should	O
elapse	O
between	O
administration	O
of	O
cholestyramine	B-Drug
and	O
thyroid	B-Drug
hormones	O
.	O

Estrogen	O
,	O
Oral	O
Contraceptives	O
:	O
Estrogens	O
tend	O
to	O
increase	O
serum	O
thyroxine-binding	O
globulin	O
(	O
TBg	O
)	O
.	O

In	O
a	O
patient	O
with	O
a	O
nonfunctioning	O
thyroid	B-Drug
gland	O
who	O
is	O
receiving	O
thyroid	B-Drug
replacement	O
therapy	O
,	O
free	O
levothyroxine	B-Drug
may	O
be	O
decreased	O
when	O
estrogens	O
are	O
started	O
thus	O
increasing	O
thyroid	B-Drug
requirements	O
.	O

However	O
,	O
if	O
the	O
patients	O
thyroid	B-Drug
gland	O
has	O
sufficient	O
function	O
,	O
the	O
decreased	O
free	O
thyroxine	B-Drug
will	O
result	O
in	O
a	O
compensatory	O
increase	O
in	O
thyroxine	B-Drug
output	O
by	O
the	O
thyroid	B-Drug
.	O

Therefore	O
,	O
patients	O
without	O
a	O
functioning	O
thyroid	B-Drug
gland	O
who	O
are	O
on	O
thyroid	B-Drug
replacement	O
therapy	O
may	O
need	O
to	O
increase	O
their	O
thyroid	B-Drug
dose	O
if	O
estrogens	O
or	O
estrogen-containing	O
oral	O
contraceptives	O
are	O
given	O
.	O

Tricyclic	O
Antidepressants	B-Drug
:	O
Use	O
of	O
thyroid	B-Drug
products	O
with	O
imipramine	B-Drug
and	O
other	O
tricyclic	O
antidepressants	B-Drug
may	O
increase	O
receptor	O
sensitivity	O
and	O
enhance	O
antidepressant	O
activity	O
transient	O
cardiac	O
arrhythmias	O
have	O
been	O
observed	O
.	O

Thyroid	B-Drug
hormone	O
activity	O
may	O
also	O
be	O
enhanced	O
.	O

Digitalis	B-Drug
:	O
Thyroid	B-Drug
preparations	O
may	O
potentiate	O
the	O
toxic	O
effects	O
of	O
digitalis	B-Drug
.	O

Thyroid	B-Drug
hormonal	O
replacement	O
increases	O
metabolic	O
rate	O
,	O
which	O
requires	O
an	O
increase	O
in	O
digitalis	B-Drug
dosage	O
.	O

Ketamine	B-Drug
:	O
When	O
administered	O
to	O
patients	O
on	O
a	O
thyroid	B-Drug
preparation	O
,	O
this	O
parenteral	O
anesthetic	B-Drug
may	O
cause	O
hypertension	O
and	O
tachycardia	O
.	O

Use	O
with	O
caution	O
and	O
be	O
prepared	O
to	O
treat	O
hypertension	O
,	O
if	O
necessary	O
.	O

Vasopressors	O
:	O
Thyroxine	B-Drug
increases	O
the	O
adrenergic	O
effect	O
of	O
catecholamines	O
such	O
as	O
epinephrine	B-Drug
and	O
norepinephrine	B-Drug
.	O

Therefore	O
,	O
injection	O
of	O
these	O
agents	O
into	O
patients	O
receiving	O
thyroid	B-Drug
preparations	O
increases	O
the	O
risk	O
of	O
precipitating	O
coronary	O
insufficiency	O
especially	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

Careful	O
observation	O
is	O
required	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
The	O
following	O
drugs	B-Drug
or	O
moieties	O
are	O
known	O
to	O
interfere	O
with	O
laboratory	O
tests	O
performed	O
in	O
patients	O
on	O
thyroid	B-Drug
hormone	O
therapy	O
:	O
androgens	O
,	O
corticosteroids	O
,	O
estrogens	O
,	O
oral	O
contraceptives	O
containing	O
estrogens	O
,	O
iodine-containing	B-Drug
preparations	O
and	O
the	O
numerous	O
preparations	O
containing	O
salicylates	O
.	O

-	O
Changes	O
in	O
TBg	O
concentration	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
the	O
interpretation	O
of	O
T4	B-Drug
and	O
T3	B-Drug
values	O
.	O

In	O
such	O
cases	O
,	O
the	O
unbound	O
(	O
free	O
)	O
hormone	O
should	O
be	O
measured	O
.	O

Pregnancy	O
estrogens	O
and	O
estrogen-containing	O
oral	O
contraceptives	O
increase	O
TBg	O
concentrations	O
.	O

TBg	O
may	O
also	O
be	O
increased	O
during	O
infectious	O
hepatitis	O
.	O

Decreases	O
in	O
TBg	O
concentrations	O
are	O
observed	O
in	O
nephrosis	O
,	O
acromegaly	O
and	O
after	O
androgen	O
or	O
corticosteroid	B-Drug
therapy	O
.	O

Familial	O
hyper-	O
or	O
hypo-thyroxine-binding-globulinemias	O
have	O
been	O
described	O
.	O

The	O
incidence	O
of	O
TBg	O
deficiency	O
approximates	O
1	O
in	O
9000	O
.	O

The	O
binding	O
of	O
thyroxine	B-Drug
by	O
thyroxine-binding	O
prealbumin	O
(	O
TBPA	O
)	O
is	O
inhibited	O
by	O
salicylates	O
.	O

-	O
Medicinal	O
or	O
dietary	O
iodine	B-Drug
interferes	O
with	O
all	O
in	O
vivo	O
tests	O
of	O
radio-iodine	O
uptake	O
producing	O
low	O
uptakes	O
which	O
may	O
not	O
be	O
reflective	O
of	O
a	O
true	O
decrease	O
in	O
hormone	O
synthesis	O
.	O

-	O
The	O
persistence	O
of	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
hypothyroidism	O
in	O
spite	O
of	O
adequate	O
dosage	O
replacement	O
indicates	O
either	O
poor	O
patient	O
compliance	O
,	O
poor	O
absorption	O
,	O
excessive	O
fecal	O
loss	O
,	O
or	O
inactivity	O
of	O
the	O
preparation	O
.	O

Intracellular	O
resistance	O
to	O
thyroid	B-Drug
hormone	O
is	O
quite	O
rare	O
.	O

Urinary	O
acidifying	O
agents	O
These	O
agents	O
(	O
ammonium	B-Drug
chloride	I-Drug
,	O
sodium	B-Drug
acid	I-Drug
phosphate	I-Drug
,	O
etc	O
.	O

)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	B-Drug
molecule	O
,	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O

Both	O
groups	O
of	O
agents	O
lower	O
blood	O
levels	O
and	O
efficacy	O
of	O
amphetamines	B-Drug
.	O

Adrenergic	O
blockers	O
Adrenergic	O
blockers	O
are	O
inhibited	O
by	O
amphetamines	B-Drug
.	O

Antidepressants	B-Drug
,	O
tricyclic	B-Drug
Amphetamines	B-Drug
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	B-Drug
antidepressants	B-Drug
or	O
sympathomimetic	B-Drug
agents	O
;	O
d-amphetamine	B-Drug
with	O
desipramine	B-Drug
or	O
protriptyline	B-Drug
and	O
possibly	O
other	O
tricyclics	O
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d-amphetamine	B-Drug
in	O
the	O
brain	O
;	O
cardiovascular	O
effects	O
can	O
be	O
potentiated	O
.	O

MAO	O
inhibitors	O
MAOI	O
antidepressants	B-Drug
,	O
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	B-Drug
,	O
slow	O
amphetamine	B-Drug
metabolism	O
.	O

This	O
slowing	O
potentiates	O
amphetamines	B-Drug
,	O
increasing	O
their	O
effect	O
on	O
the	O
release	O
of	O
norepinephrine	B-Drug
and	O
other	O
monoamines	O
from	O
adrenergic	O
nerve	O
endings	O
;	O
this	O
can	O
cause	O
headaches	O
and	O
other	O
signs	O
of	O
hypertensive	O
crisis	O
.	O

A	O
variety	O
of	O
toxic	O
neurological	O
effects	O
and	O
malignant	O
hyperpyrexia	O
can	O
occur	O
,	O
sometimes	O
with	O
fatal	O
results	O
.	O

Antihistamines	B-Drug
:	O
Amphetamines	B-Drug
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	B-Drug
.	O

Antihypertensives	B-Drug
:	O
Amphetamines	B-Drug
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	B-Drug
.	O

Chlorpromazine	B-Drug
:	O
Chlorpromazine	B-Drug
blocks	O
dopamine	B-Drug
and	O
norepinephrine	B-Drug
receptors	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Drug
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	B-Drug
poisoning	O
.	O

Ethosuximide	B-Drug
:	O
Amphetamines	B-Drug
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	B-Drug
.	O

Haloperidol	B-Drug
:	O
Haloperidol	B-Drug
blocks	O
dopamine	B-Drug
receptors	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B-Drug
.	O

Lithium	B-Drug
carbonate	I-Drug
:	O
The	O
anorectic	O
and	O
stimulatory	O
effects	O
of	O
amphetamines	B-Drug
may	O
be	O
inhibited	O
by	O
lithium	B-Drug
carbonate	I-Drug
.	O

Meperidine	B-Drug
:	O
Amphetamines	B-Drug
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	B-Drug
.	O

Methenamine	B-Drug
therapy	O
Urinary	O
excretion	O
of	O
amphetamines	B-Drug
is	O
increased	O
,	O
and	O
efficacy	O
is	O
reduced	O
by	O
acidifying	O
agents	O
used	O
in	O
methenamine	B-Drug
therapy	O
.	O

Norepinephrine	B-Drug
:	O
Amphetamines	B-Drug
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	B-Drug
.	O

Phenobarbital	B-Drug
:	O
Amphetamines	B-Drug
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	B-Drug
;	O
co-administration	O
of	O
phenobarbital	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Phenytoin	B-Drug
:	O
Amphetamines	B-Drug
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	B-Drug
;	O
co-administration	O
of	O
phenytoin	B-Drug
may	O
produce	O
a	O
synergistic	O
anticonvulsant	O
action	O
.	O

Propoxyphene	B-Drug
:	O
In	O
cases	O
of	O
propoxyphene	B-Drug
overdosage	O
,	O
amphetamine	B-Drug
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O

Veratrum	O
alkaloids	O
:	O
Amphetamines	B-Drug
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	O
alkaloids	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
:	O
Amphetamines	B-Drug
can	O
cause	O
a	O
significant	O
elevation	O
in	O
plasma	O
corticosteroid	B-Drug
levels	O
.	O

This	O
increase	O
is	O
greatest	O
in	O
the	O
evening	O
.	O

Amphetamines	B-Drug
may	O
interfere	O
with	O
urinary	O
steroid	O
determinations	O
.	O

Hypotension	O
-	O
Patients	O
on	O
Diuretic	B-Drug
Therapy	O
:	O
Patients	O
on	O
diuretics	B-Drug
,	O
and	O
especially	O
those	O
in	O
whom	O
diuretic	B-Drug
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
PRINIVIL	B-Drug
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
PRINIVIL	B-Drug
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-Drug
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
PRINIVIL	B-Drug
.	O

If	O
it	O
is	O
necessary	O
to	O
continue	O
the	O
diuretic	B-Drug
,	O
initiate	O
therapy	O
with	O
PRINIVIL	B-Drug
at	O
a	O
dose	O
of	O
5	O
mg	O
daily	O
,	O
and	O
provide	O
close	O
medical	O
supervision	O
after	O
the	O
initial	O
dose	O
until	O
blood	O
pressure	O
has	O
stabilized	O
.	O

When	O
a	O
diuretic	B-Drug
is	O
added	O
to	O
the	O
therapy	O
of	O
a	O
patient	O
receiving	O
PRINIVIL	B-Drug
,	O
an	O
additional	O
antihypertensive	B-Drug
effect	O
is	O
usually	O
observed	O
.	O

Studies	O
with	O
ACE	O
inhibitors	O
in	O
combination	O
with	O
diuretics	B-Drug
indicate	O
that	O
the	O
dose	O
of	O
the	O
ACE	O
inhibitor	O
can	O
be	O
reduced	O
when	O
it	O
is	O
given	O
with	O
a	O
diuretic	B-Drug
.	O

Non-steroidal	O
Anti-inflammatory	O
Agents	O
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
drugs	B-Drug
,	O
the	O
co-administration	O
of	O
lisinopril	B-Drug
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O

These	O
effects	O
are	O
usually	O
reversible	O
.	O

Reports	O
suggest	O
that	O
NSAIDs	O
may	O
diminish	O
the	O
antihypertensive	B-Drug
effect	O
of	O
ACE	O
inhibitors	O
,	O
including	O
lisinopril	B-Drug
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	O
concomitantly	O
with	O
ACE	O
inhibitors	O
.	O

In	O
a	O
study	O
in	O
36	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
where	O
the	O
antihypertensive	B-Drug
effects	O
of	O
PRINIVIL	B-Drug
alone	O
were	O
compared	O
to	O
PRINIVIL	B-Drug
given	O
concomitantly	O
with	O
indomethacin	B-Drug
,	O
the	O
use	O
of	O
indomethacin	B-Drug
was	O
associated	O
with	O
a	O
reduced	O
antihypertensive	B-Drug
effect	O
,	O
although	O
the	O
difference	O
between	O
the	O
two	O
regimens	O
was	O
not	O
significant	O
.	O

Other	O
Agents	O
:	O
PRINIVIL	B-Drug
has	O
been	O
used	O
concomitantly	O
with	O
nitrates	B-Drug
and/or	O
digoxin	B-Drug
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

This	O
included	O
post	O
myocardial	O
infarction	O
patients	O
who	O
were	O
receiving	O
intravenous	O
or	O
transdermal	O
nitroglycerin	B-Drug
.	O

No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
PRINIVIL	B-Drug
was	O
used	O
concomitantly	O
with	O
propranolol	B-Drug
or	O
hydrochlorothiazide	B-Drug
.	O

The	O
presence	O
of	O
food	O
in	O
the	O
stomach	O
does	O
not	O
alter	O
the	O
bioavailability	O
of	O
PRINIVIL	B-Drug
.	O

Agents	O
Increasing	O
Serum	O
Potassium	B-Drug
:	O
PRINIVIL	B-Drug
attenuates	O
potassium	B-Drug
loss	O
caused	O
by	O
thiazide-type	O
diuretics	B-Drug
.	O

Use	O
of	O
PRINIVIL	B-Drug
with	O
potassium-sparing	O
diuretics	B-Drug
(	O
e.g.	O
,	O
spironolactone	B-Drug
,	O
triamterene	B-Drug
,	O
or	O
amiloride	B-Drug
)	O
,	O
potassium	B-Drug
supplements	O
,	O
or	O
potassium-containing	B-Drug
salt	O
substitutes	O
may	O
lead	B-Drug
to	O
significant	O
increases	O
in	O
serum	O
potassium	B-Drug
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
these	O
agents	O
is	O
indicated	O
because	O
of	O
demonstrated	O
hypokalemia	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
and	O
with	O
frequent	O
monitoring	O
of	O
serum	O
potassium	B-Drug
.	O

Potassium	B-Drug
sparing	O
agents	O
should	O
generally	O
not	O
be	O
used	O
in	O
patients	O
with	O
heart	O
failure	O
who	O
are	O
receiving	O
PRINIVIL	B-Drug
.	O

Lithium	B-Drug
:	O
Lithium	B-Drug
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B-Drug
concomitantly	O
with	O
drugs	B-Drug
which	O
cause	O
elimination	O
of	O
sodium	O
,	O
including	O
ACE	O
inhibitors	O
.	O

Lithium	B-Drug
toxicity	O
was	O
usually	O
reversible	O
upon	O
discontinuation	O
of	O
lithium	B-Drug
and	O
the	O
ACE	O
inhibitor	O
.	O

It	O
is	O
recommended	O
that	O
serum	O
lithium	B-Drug
levels	O
be	O
monitored	O
frequently	O
if	O
PRINIVIL	B-Drug
is	O
administered	O
concomitantly	O
with	O
lithium	B-Drug
.	O

-	O
Lofexidine	B-Drug
may	O
enhance	O
the	O
CNS	O
depressive	O
effects	O
of	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
and	O
other	O
sedatives	O
.	O

-	O
Lofexidine	B-Drug
may	O
enhance	O
the	O
effects	O
of	O
anti-hypertensive	O
drug	B-Drug
therapy	O
.	O

-	O
Concomitant	O
use	O
of	O
tricyclic	O
antidepressants	B-Drug
may	O
reduce	O
the	O
efficacy	O
of	O
lofexidine	B-Drug
.	O

Theophylline	B-Drug
:	O
In	O
three	O
pharmacokinetic	O
studies	O
including	O
46	O
normal	O
,	O
healthy	O
subjects	O
,	O
theophylline	B-Drug
clearance	O
and	O
concentration	O
were	O
not	O
significantly	O
altered	O
by	O
the	O
addition	O
of	O
lomefloxacin	B-Drug
.	O

In	O
clinical	O
studies	O
where	O
patients	O
were	O
on	O
chronic	O
theophylline	B-Drug
therapy	O
,	O
lomefloxacin	B-Drug
had	O
no	O
measurable	O
effect	O
on	O
the	O
mean	O
distribution	O
of	O
theophylline	B-Drug
concentrations	O
or	O
the	O
mean	O
estimates	O
of	O
theophylline	B-Drug
clearance	O
.	O

Though	O
individual	O
theophylline	B-Drug
levels	O
fluctuated	O
,	O
there	O
were	O
no	O
clinically	O
significant	O
symptoms	O
of	O
drug	B-Drug
inter-action	O
.	O

Antacids	O
and	O
sucralfate	B-Drug
:	O
Sucralfate	B-Drug
and	O
antacids	O
containing	O
magnesium	B-Drug
or	O
aluminum	B-Drug
,	O
as	O
well	O
as	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
Videx	B-Drug
(	O
didanosine	B-Drug
)	O
,	O
chewable/buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
can	O
form	O
chelation	O
complexes	O
with	O
lomefloxacin	B-Drug
and	O
interfere	O
with	O
its	O
bioavailability	O
.	O

Sucralfate	B-Drug
administered	O
2	O
hours	O
before	O
lomefloxacin	B-Drug
resulted	O
in	O
a	O
slower	O
absorption	O
(	O
mean	O
C	O
max	O
decreased	O
by	O
30	O
%	O
and	O
mean	O
T	O
max	O
increased	O
by	O
1	O
hour	O
)	O
and	O
a	O
lesser	O
extent	O
of	O
absorption	O
(	O
mean	O
AUC	O
decreased	O
by	O
approximately	O
25	O
%	O
)	O
.	O

Magnesium-	B-Drug
and	O
aluminum-containing	B-Drug
antacids	O
,	O
administered	O
concomitantly	O
with	O
lomefloxacin	B-Drug
,	O
significantly	O
decreased	O
the	O
bioavailability	O
(	O
48	O
%	O
)	O
of	O
lomefloxacin	B-Drug
.	O

Separating	O
the	O
doses	O
of	O
antacid	O
and	O
lomefloxacin	B-Drug
minimizes	O
this	O
decrease	O
in	O
bioavailability	O
;	O
therefore	O
,	O
administration	O
of	O
these	O
agents	O
should	O
precede	O
lomefloxacin	B-Drug
dosing	O
by	O
4	O
hours	O
or	O
follow	O
lomefloxacin	B-Drug
dosing	O
by	O
at	O
least	O
2	O
hours	O
.	O

Caffeine	B-Drug
:	O
Two	O
hundred	O
mg	O
of	O
caffeine	B-Drug
(	O
equivalent	O
to	O
1	O
to	O
3	O
cups	O
of	O
American	O
coffee	O
)	O
was	O
administered	O
to	O
16	O
normal	O
,	O
healthy	O
volunteers	O
who	O
had	O
achieved	O
steady-state	O
blood	O
concentrations	O
of	O
lomefloxacin	B-Drug
after	O
being	O
dosed	O
at	O
400	O
mg	O
qd	O
.	O

This	O
did	O
not	O
result	O
in	O
any	O
statistically	O
or	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetic	O
parameters	O
of	O
either	O
caffeine	B-Drug
or	O
its	O
major	O
metabolite	O
,	O
paraxanthine	B-Drug
.	O

No	O
data	O
are	O
available	O
on	O
potential	O
interactions	O
in	O
individuals	O
who	O
consume	O
greater	O
than	O
200	O
mg	O
of	O
caffeine	B-Drug
per	O
day	O
or	O
in	O
those	O
,	O
such	O
as	O
the	O
geriatric	O
population	O
,	O
who	O
are	O
generally	O
believed	O
to	O
be	O
more	O
susceptible	O
to	O
the	O
development	O
of	O
drug-induced	O
CNS-related	O
adverse	O
effects	O
.	O

Other	O
quinolones	O
have	O
demonstrated	O
moderate	O
to	O
marked	O
interference	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
,	O
resulting	O
in	O
a	O
reduced	O
clearance	O
,	O
a	O
prolongation	O
of	O
plasma	O
half-life	O
,	O
and	O
an	O
increase	O
in	O
symptoms	O
that	O
accompany	O
high	O
levels	O
of	O
caffeine	B-Drug
.	O

Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
has	O
been	O
demonstrated	O
to	O
interfere	O
with	O
the	O
elimination	O
of	O
other	O
quinolones	O
.	O

This	O
interference	O
has	O
resulted	O
in	O
significant	O
increases	O
in	O
half-life	O
and	O
AUC	O
.	O

The	O
interaction	O
between	O
lomefloxacin	B-Drug
and	O
cimetidine	B-Drug
has	O
not	O
been	O
studied	O
.	O

Cyclosporine	B-Drug
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B-Drug
with	O
other	O
members	O
of	O
the	O
quinolone	O
class	O
.	O

Interaction	O
between	O
lomefloxacin	B-Drug
and	O
cyclosporine	B-Drug
has	O
not	O
been	O
studied	O
.	O

Omeprazole	B-Drug
:	O
No	O
clinically	O
significant	O
changes	O
in	O
lomefloxacin	B-Drug
pharmacokinetics	O
(	O
AUC	O
,	O
C	O
max	O
,	O
or	O
T	O
max	O
)	O
were	O
observed	O
when	O
a	O
single	O
dose	O
of	O
lomefloxacin	B-Drug
400	O
mg	O
was	O
given	O
after	O
multiple	O
doses	O
of	O
omeprazole	B-Drug
(	O
20	O
mg	O
qd	O
)	O
in	O
13	O
healthy	O
volunteers	O
.	O

Changes	O
in	O
omeprazole	B-Drug
pharmacokinetics	O
were	O
not	O
studied	O
.	O

Phenytoin	B-Drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
mean	O
phenytoin	B-Drug
AUC	O
,	O
C	O
max	O
,	O
C	O
min	O
or	O
T	O
max	O
(	O
although	O
C	O
max	O
increased	O
by	O
11	O
%	O
)	O
when	O
extended	O
phenytoin	B-Drug
sodium	I-Drug
capsules	O
(	O
100	O
mg	O
tid	O
)	O
were	O
coadministered	O
with	O
lomefloxacin	B-Drug
(	O
400	O
mg	O
qd	O
)	O
for	O
five	O
days	O
in	O
15	O
healthy	O
males	O
.	O

Lomefloxacin	B-Drug
is	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
phenytoin	B-Drug
metabolism	O
.	O

Probenecid	B-Drug
:	O
Probenecid	B-Drug
slows	O
the	O
renal	O
elimination	O
of	O
lome-floxacin	O
.	O

An	O
increase	O
of	O
63	O
%	O
in	O
the	O
mean	O
AUC	O
and	O
increases	O
of	O
50	O
%	O
and	O
4	O
%	O
,	O
respectively	O
,	O
in	O
the	O
mean	O
T	O
max	O
and	O
mean	O
C	O
max	O
were	O
noted	O
in	O
1	O
study	O
of	O
6	O
individuals	O
.	O

Terfenadine	B-Drug
:	O
No	O
clinically	O
significant	O
changes	O
occurred	O
in	O
heart	O
rate	O
or	O
corrected	O
QT	O
intervals	O
,	O
or	O
in	O
terfenadine	B-Drug
metabolite	O
or	O
lomefloxacin	B-Drug
pharmacokinetics	O
,	O
during	O
concurrent	O
administration	O
of	O
lomefloxacin	B-Drug
and	O
terfenadine	B-Drug
at	O
steady-state	O
in	O
28	O
healthy	O
males	O
.	O

Warfarin	B-Drug
:	O
Quinolones	O
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Drug
,	O
warfarin	B-Drug
,	O
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
monitored	O
closely	O
.	O

However	O
,	O
no	O
clinically	O
or	O
statistically	O
significant	O
differences	O
in	O
prothrombin	O
time	O
ratio	O
or	O
warfarin	B-Drug
enantiomer	O
pharmacokinetics	O
were	O
observed	O
in	O
a	O
small	O
study	O
of	O
7	O
healthy	O
males	O
who	O
received	O
both	O
warfarin	B-Drug
and	O
lomefloxacin	B-Drug
under	O
steady-state	O
conditions	O
.	O

There	O
was	O
no	O
evidence	O
in	O
clinical	O
trials	O
of	O
drug	B-Drug
interactions	O
with	O
concurrent	O
medications	O
.	O

Probenecid	B-Drug
:	O
As	O
with	O
other	O
b-lactam	O
antibiotics	B-Drug
,	O
renal	O
excretion	O
of	O
loracarbef	B-Drug
is	O
inhibited	O
by	O
probenecid	B-Drug
and	O
resulted	O
in	O
an	O
approximate	O
80	O
%	O
increase	O
in	O
the	O
AUC	O
for	O
loracarbef	B-Drug
.	O

Loratadine	B-Drug
(	O
10	O
mg	O
once	O
daily	O
)	O
has	O
been	O
coadministered	O
with	O
therapeutic	O
doses	O
of	O
erythromycin	B-Drug
,	O
cimetidine	B-Drug
,	O
and	O
ketoconazole	B-Drug
in	O
controlled	O
clinical	O
pharmacology	O
studies	O
in	O
adult	O
volunteers	O
.	O

Although	O
increased	O
plasma	O
concentrations	O
(	O
AUC	O
0-24	O
hrs	O
)	O
of	O
loratadine	B-Drug
and/or	O
descarboethoxyloratadine	B-Drug
were	O
observed	O
following	O
coadministration	O
of	O
loratadine	B-Drug
with	O
each	O
of	O
these	O
drugs	B-Drug
in	O
normal	O
volunteers	O
(	O
n	O
=	O
24	O
in	O
each	O
study	O
)	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
loratadine	B-Drug
,	O
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
,	O
clinical	O
laboratory	O
tests	O
,	O
vital	O
signs	O
,	O
and	O
adverse	O
events	O
.	O

There	O
were	O
no	O
significant	O
effects	O
on	O
QTc	O
intervals	O
,	O
and	O
no	O
reports	O
of	O
sedation	O
or	O
syncope	O
.	O

No	O
effects	O
on	O
plasma	O
concentrations	O
of	O
cimetidine	B-Drug
or	O
ketoconazole	B-Drug
were	O
observed	O
.	O

Plasma	O
concentrations	O
(	O
AUC	O
0-24	O
hrs	O
)	O
of	O
erythromycin	B-Drug
decreased	O
15	O
%	O
with	O
coadministration	O
of	O
loratadine	B-Drug
relative	O
to	O
that	O
observed	O
with	O
erythromycin	B-Drug
alone	O
.	O

The	O
clinical	O
relevance	O
of	O
this	O
difference	O
is	O
unknown	O
.	O

These	O
above	O
findings	O
are	O
summarized	O
in	O
TABLE	O
1	O
.	O

TABLE	O
1	O
Effects	O
on	O
Plasma	O
Concentrations	O
(	O
AUC	O
0-24	O
hrs	O
)	O
of	O
Loratadine	B-Drug
and	O
Descarboethoxyloratadine	B-Drug
After	O
10	O
Days	O
of	O
Coadministration	O
(	O
Loratadine	B-Drug
10	O
mg	O
)	O
in	O
Normal	O
Volunteers	O
Loratadine	B-Drug
Descarboethoxyloratadine	B-Drug
Erythromycin	B-Drug
(	O
500	O
mg	O
q8h	O
)	O
+	O
40	O
%	O
+46	O
%	O
Cimetidine	B-Drug
(	O
300	O
mg	O
qid	O
)	O
+103	O
%	O
+	O
6	O
%	O
Ketoconazole	B-Drug
(	O
200	O
mg	O
q12h	O
)	O
+307	O
%	O
+73	O
%	O
There	O
does	O
not	O
appear	O
to	O
be	O
an	O
increase	O
in	O
adverse	O
events	O
in	O
subjects	O
who	O
received	O
oral	O
contraceptives	O
and	O
loratadine	B-Drug
.	O

Tablets	O
:	O
The	O
benzodiazepines	B-Drug
,	O
including	O
lorazepam	B-Drug
,	O
produce	O
CNS-depressant	O
effects	O
when	O
administered	O
with	O
such	O
medications	O
as	O
barbiturates	B-Drug
or	O
alcohol	B-Drug
.	O

Injection	O
:	O
Lorazepam	B-Drug
injection	O
,	O
like	O
other	O
injectable	O
benzodiazepines	B-Drug
,	O
produces	O
depression	O
of	O
the	O
central	O
nervous	O
system	O
when	O
administered	O
with	O
ethyl	B-Drug
alcohol	I-Drug
,	O
phenothiazines	O
,	O
barbiturates	B-Drug
,	O
MAO	O
inhibitors	O
,	O
and	O
other	O
antidepressants.When	O
scopolamine	B-Drug
is	O
used	O
concomitantly	O
with	O
injectable	O
lorazepam	B-Drug
,	O
an	O
increased	O
incidence	O
of	O
sedation	O
,	O
hallucinations	O
,	O
and	O
irrational	O
behavior	O
has	O
been	O
observed	O
.	O

No	O
significant	O
drug-drug	O
pharmacokinetic	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B-Drug
,	O
digoxin	B-Drug
,	O
warfarin	B-Drug
,	O
cimetidine	B-Drug
and	O
phenobarbital	B-Drug
.	O

Rifampin	B-Drug
,	O
an	O
inducer	O
of	O
drug	B-Drug
metabolism	O
,	O
decreased	O
the	O
concentrations	O
of	O
losartan	B-Drug
and	O
its	O
active	O
metabolite	O
.	O

In	O
humans	O
,	O
two	O
inhibitors	O
of	O
P450	O
3A4	O
have	O
been	O
studied	O
.	O

Ketoconazole	B-Drug
did	O
not	O
affect	O
the	O
conversion	O
of	O
losartan	B-Drug
to	O
the	O
active	O
metabolite	O
after	O
intravenous	O
administration	O
of	O
losartan	B-Drug
,	O
and	O
erythromycin	B-Drug
had	O
no	O
clinically	O
significant	O
effect	O
after	O
oral	O
administration	O
.	O

Fluconazole	B-Drug
,	O
an	O
inhibitor	O
of	O
P450	O
2C9	O
,	O
decreased	O
active	O
metabolite	O
concentration	O
and	O
increased	O
losartan	B-Drug
concentration	O
.	O

The	O
pharmacodynamic	O
consequences	O
of	O
concomitant	O
use	O
of	O
losartan	B-Drug
and	O
inhibitors	O
of	O
P450	O
2C9	O
have	O
not	O
been	O
examined	O
.	O

Subjects	O
who	O
do	O
not	O
metabolize	O
losartan	B-Drug
to	O
active	O
metabolite	O
have	O
been	O
shown	O
to	O
have	O
a	O
specific	O
,	O
rare	O
defect	O
in	O
cytochrome	O
P450	O
2C9	O
.	O

These	O
data	O
suggest	O
that	O
the	O
conversion	O
of	O
losartan	B-Drug
to	O
its	O
active	O
metabolite	O
is	O
mediated	O
primarily	O
by	O
P450	O
2C9	O
and	O
not	O
P450	O
3A4	O
.	O

As	O
with	O
other	O
drugs	B-Drug
that	O
block	O
angiotensin	B-Drug
II	O
or	O
its	O
effects	O
,	O
concomitant	O
use	O
of	O
potassium-sparing	O
diuretics	B-Drug
(	O
e.g.	O
,	O
spironolactone	B-Drug
,	O
triamterene	B-Drug
,	O
amiloride	B-Drug
)	O
,	O
potassium	B-Drug
supplements	O
,	O
or	O
salt	O
substitutes	O
containing	O
potassium	B-Drug
may	O
lead	B-Drug
to	O
increases	O
in	O
serum	O
potassium	B-Drug
.	O

As	O
with	O
other	O
antihypertensive	B-Drug
agents	O
,	O
the	O
antihypertensive	B-Drug
effect	O
of	O
losartan	B-Drug
may	O
be	O
blunted	O
by	O
the	O
non-steroidal	O
anti-inflammatory	O
drug	B-Drug
indomethacin	B-Drug
.	O

CYP3A4	B-Drug
Interactions	O
Lovastatin	B-Drug
is	O
metabolized	O
by	O
CYP3A4	B-Drug
but	O
has	O
no	O
CYP3A4	B-Drug
inhibitory	O
activity	O
;	O
therefore	O
it	O
is	O
not	O
expected	O
to	O
affect	O
the	O
plasma	O
concentrations	O
of	O
other	O
drugs	B-Drug
metabolized	O
by	O
CYP3A4	B-Drug
.	O

Potent	O
inhibitors	O
of	O
CYP3A4	B-Drug
(	O
below	O
)	O
increase	O
the	O
risk	O
of	O
myopathy	O
by	O
reducing	O
the	O
elimination	O
of	O
lovastatin	B-Drug
.	O

Pharmacokinetics	O
.	O

Itraconazole	B-Drug
Ketoconazole	B-Drug
Erythromycin	B-Drug
Clarithromycin	B-Drug
Telithromycin	B-Drug
HIV	O
protease	O
inhibitors	O
Nefazodone	B-Drug
Cyclosporine	B-Drug
Large	O
quantities	O
of	O
grapefruit	O
juice	O
(	O
1	O
quart	O
daily	O
)	O
Interactions	O
with	O
lipid-lowering	O
drugs	B-Drug
that	O
can	O
cause	O
myopathy	O
when	O
given	O
alone	O
.	O

The	O
risk	O
of	O
myopathy	O
is	O
also	O
increased	O
by	O
the	O
following	O
lipid-lowering	O
drugs	B-Drug
that	O
are	O
not	O
potent	O
CYP3A4	B-Drug
inhibitors	O
,	O
but	O
which	O
can	O
cause	O
myopathy	O
when	O
given	O
alone	O
.	O

See	O
WARNINGS	O
,	O
Myopathy/Rhabdomyolysis	O
.	O

Gemfibrozil	B-Drug
Other	O
fibrates	O
Niacin	B-Drug
(	O
nicotinic	B-Drug
acid	I-Drug
)	O
(	O
=1	O
g/day	O
)	O
Other	O
drug	B-Drug
interactions	O
Danazol	B-Drug
:	O
The	O
risk	O
of	O
myopathy/rhabdomyolysis	O
is	O
increased	O
by	O
concomitant	O
administration	O
of	O
danazol	B-Drug
particularly	O
with	O
higher	O
doses	O
of	O
lovastatin	B-Drug
(	O
see	O
WARNINGS	O
,	O
Myopathy/Rhabdomyolysis	O
)	O
.	O

Amiodarone	B-Drug
or	O
Verapamil	B-Drug
:	O
The	O
risk	O
of	O
myopathy/rhabdomyolysis	O
is	O
increased	O
when	O
either	O
amiodarone	B-Drug
or	O
verapamil	B-Drug
is	O
used	O
concomitantly	O
with	O
a	O
closely	O
related	O
member	O
of	O
the	O
HMG-CoA	O
reductase	O
inhibitor	O
class	O
(	O
see	O
WARNINGS	O
,	O
Myopathy/Rhabdomyolysis	O
)	O
.	O

Coumarin	O
Anticoagulants	B-Drug
:	O
In	O
a	O
small	O
clinical	O
trial	O
in	O
which	O
lovastatin	B-Drug
was	O
administered	O
to	O
warfarin	B-Drug
treated	O
patients	O
,	O
no	O
effect	O
on	O
prothrombin	O
time	O
was	O
detected	O
.	O

However	O
,	O
another	O
HMG-CoA	O
reductase	O
inhibitor	O
has	O
been	O
found	O
to	O
produce	O
a	O
less	O
than	O
two-second	O
increase	O
in	O
prothrombin	O
time	O
in	O
healthy	O
volunteers	O
receiving	O
low	O
doses	O
of	O
warfarin	B-Drug
.	O

Also	O
,	O
bleeding	O
and/or	O
increased	O
prothrombin	O
time	O
have	O
been	O
reported	O
in	O
a	O
few	O
patients	O
taking	O
coumarin	O
anticoagulants	B-Drug
concomitantly	O
with	O
lovastatin	B-Drug
.	O

It	O
is	O
recommended	O
that	O
in	O
patients	O
taking	O
anticoagulants	B-Drug
,	O
prothrombin	O
time	O
be	O
determined	O
before	O
starting	O
lovastatin	B-Drug
and	O
frequently	O
enough	O
during	O
early	O
therapy	O
to	O
insure	O
that	O
no	O
significant	O
alteration	O
of	O
prothrombin	O
time	O
occurs	O
.	O

Once	O
a	O
stable	O
prothrombin	O
time	O
has	O
been	O
documented	O
,	O
prothrombin	O
times	O
can	O
be	O
monitored	O
at	O
the	O
intervals	O
usually	O
recommended	O
for	O
patients	O
on	O
coumarin	O
anticoagulants	B-Drug
.	O

If	O
the	O
dose	O
of	O
lovastatin	B-Drug
is	O
changed	O
,	O
the	O
same	O
procedure	O
should	O
be	O
repeated	O
.	O

Lovastatin	B-Drug
therapy	O
has	O
not	O
been	O
associated	O
with	O
bleeding	O
or	O
with	O
changes	O
in	O
prothrombin	O
time	O
in	O
patients	O
not	O
taking	O
anticoagulants	B-Drug
.	O

Propranolol	B-Drug
:	O
In	O
normal	O
volunteers	O
,	O
there	O
was	O
no	O
clinically	O
significant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
with	O
concomitant	O
administration	O
of	O
single	O
doses	O
of	O
lovastatin	B-Drug
and	O
propranolol	B-Drug
.	O

Digoxin	B-Drug
:	O
In	O
patients	O
with	O
hypercholesterolemia	O
,	O
concomitant	O
administration	O
of	O
lovastatin	B-Drug
and	O
digoxin	B-Drug
resulted	O
in	O
no	O
effect	O
on	O
digoxin	B-Drug
plasma	O
concentrations	O
.	O

Oral	O
Hypoglycemic	O
Agents	O
:	O
In	O
pharmacokinetic	O
studies	O
of	O
MEVACOR	B-Drug
in	O
hypercholesterolemic	O
noninsulin	O
dependent	O
diabetic	O
patients	O
,	O
there	O
was	O
no	O
drug	B-Drug
interaction	O
with	O
glipizide	B-Drug
or	O
with	O
chlorpropamide	B-Drug
There	O
have	O
been	O
rare	O
reports	O
of	O
significant	O
respiratory	O
depression	O
,	O
stupor	O
and/or	O
hypotension	O
with	O
the	O
concomitant	O
use	O
of	O
loxapine	B-Drug
and	O
lorazepam	B-Drug
.	O

The	O
risk	O
of	O
using	O
loxapine	B-Drug
in	O
combination	O
with	O
CNS-active	O
drugs	B-Drug
has	O
not	O
been	O
systematically	O
evaluated	O
.	O

Therefore	O
,	O
caution	O
is	O
advised	O
if	O
the	O
concomitant	O
administration	O
of	O
loxapine	B-Drug
and	O
CNS-active	O
drugs	B-Drug
is	O
required	O
.	O

The	O
absorption	O
of	O
lymecycline	B-Drug
may	O
be	O
affected	O
by	O
the	O
simultaneous	O
administration	O
of	O
indigestion	O
remedies	O
,	O
iron	B-Drug
or	O
zinc	B-Drug
supplements	O
.	O

Oral	O
contraceptives	O
may	O
be	O
less	O
effective	O
while	O
you	O
are	O
taking	O
lymecycline	B-Drug
.	O

Warfarin	B-Drug
:	O
Meclofenamate	B-Drug
sodium	I-Drug
enhances	O
the	O
effect	O
of	O
warfarin	B-Drug
.	O

Therefore	O
,	O
when	O
meclofenamate	B-Drug
sodium	I-Drug
is	O
given	O
to	O
a	O
patient	O
receiving	O
warfarin	B-Drug
,	O
the	O
dosage	O
of	O
warfarin	B-Drug
should	O
be	O
reduced	O
to	O
prevent	O
excessive	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
.	O

Aspirin	B-Drug
:	O
Concurrent	O
administration	O
of	O
aspirin	B-Drug
may	O
lower	O
meclofenamate	B-Drug
sodium	I-Drug
plasma	O
levels	O
,	O
possibly	O
by	O
competing	O
for	O
protein-binding	O
sites	O
.	O

The	O
urinary	O
excretion	O
of	O
meclofenamate	B-Drug
sodium	I-Drug
is	O
unaffected	O
by	O
aspirin	B-Drug
,	O
indicating	O
no	O
change	O
in	O
meclofenamate	B-Drug
sodium	I-Drug
absorption	O
.	O

Meclofenamate	B-Drug
sodium	I-Drug
does	O
not	O
affect	O
serum	O
salicylate	B-Drug
levels	O
.	O

Greater	O
fecal	O
blood	O
loss	O
results	O
from	O
concomitant	O
administration	O
of	O
both	O
drugs	B-Drug
than	O
from	O
either	O
drug	B-Drug
alone	O
.	O

Propoxyphene	B-Drug
:	O
The	O
concurrent	O
administration	O
of	O
propoxyphene	B-Drug
hydrochloride	I-Drug
does	O
not	O
affect	O
the	O
bioavailability	O
of	O
meclofenamate	B-Drug
sodium	I-Drug
.	O

Antacids	O
:	O
Concomitant	O
administration	O
of	O
aluminum	B-Drug
and	O
magnesium	B-Drug
hydroxides	I-Drug
does	O
not	O
interfere	O
with	O
absorption	O
of	O
meclofenamate	O
sodium	O
.	O

Aspirin	B-Drug
:	O
As	O
with	O
other	O
NSAIDs	O
,	O
concomitant	O
administration	O
of	O
Ponstel	B-Drug
and	O
aspirin	B-Drug
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O

Methotrexate	B-Drug
:	O
NSAIDs	O
have	O
been	O
reported	O
to	O
competitively	O
inhibit	O
methotrexate	B-Drug
accumulation	O
in	O
rabbit	O
kidney	O
slices	O
.	O

This	O
may	O
indicate	O
that	O
they	O
could	O
enhance	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O

Caution	O
should	O
be	O
used	O
when	O
NSAIDs	O
are	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O

ACE	O
inhibitors	O
:	O
Reports	O
suggest	O
that	O
NSAIDs	O
may	O
diminish	O
the	O
antihypertensive	B-Drug
effect	O
of	O
ACE	O
inhibitors	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	O
concomitantly	O
with	O
ACE	O
inhibitors	O
.	O

Furosemide	B-Drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post-marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	O
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	O
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

During	O
concomitant	O
therapy	O
of	O
Ponstel	B-Drug
with	O
furosemide	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	B-Drug
efficacy	O
.	O

Lithium	B-Drug
:	O
NSAIDs	O
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
.	O

The	O
mean	O
minimum	O
lithium	B-Drug
concentration	O
increased	O
15	O
%	O
and	O
the	O
renal	O
clearance	O
was	O
decreased	O
by	O
approximately	O
20	O
%	O
.	O

These	O
effects	O
have	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
by	O
the	O
NSAID	O
.	O

Thus	O
,	O
when	O
NSAIDs	O
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O

Warfarin	B-Drug
:	O
The	O
effects	O
of	O
warfarin	B-Drug
and	O
NSAIDs	O
on	O
GI	O
bleeding	O
are	O
synergistic	O
,	O
such	O
that	O
users	O
of	O
both	O
drugs	B-Drug
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
users	O
of	O
either	O
drug	B-Drug
alone	O
.	O

Antacids	O
:	O
In	O
a	O
single	O
dose	O
study	O
(	O
n=6	O
)	O
,	O
ingestion	O
of	O
an	O
antacid	O
containing	O
1.7-gram	O
of	O
magnesium	B-Drug
hydroxide	I-Drug
with	O
500-mg	O
of	O
mefenamic	B-Drug
acid	I-Drug
increased	O
the	O
Cmax	O
and	O
AUC	O
of	O
mefenamic	B-Drug
acid	I-Drug
by	O
125	O
%	O
and	O
36	O
%	O
,	O
respectively	O
.	O

A	O
number	O
of	O
compounds	O
are	O
inhibitors	O
of	O
CYP2C9	B-Drug
including	O
fluconazole	B-Drug
,	O
lovastatin	B-Drug
and	O
trimethoprim	B-Drug
.	O

Drug	B-Drug
interaction	O
studies	O
of	O
mefenamic	B-Drug
acid	I-Drug
and	O
these	O
compounds	O
have	O
not	O
been	O
conducted	O
.	O

The	O
possibility	O
of	O
altered	O
safety	O
and	O
efficacy	O
should	O
be	O
considered	O
when	O
Ponstel	B-Drug
is	O
used	O
concomitantly	O
with	O
these	O
drugs	B-Drug
.	O

Drug-drug	O
interactions	O
with	O
Mefloquine	B-Drug
have	O
not	O
been	O
explored	O
in	O
detail	O
.	O

There	O
is	O
one	O
report	O
of	O
cardiopulmonary	O
arrest	O
,	O
with	O
full	O
recovery	O
,	O
in	O
a	O
patient	O
who	O
was	O
taking	O
a	O
beta	O
blocker	O
(	O
propranolol	B-Drug
)	O
.	O

The	O
effects	O
of	O
Mefloquineuine	O
on	O
the	O
compromised	O
cardiovascular	O
system	O
have	O
not	O
been	O
evaluated	O
.	O

The	O
benefits	O
of	O
Mefloquine	B-Drug
therapy	O
should	O
be	O
weighed	O
against	O
the	O
possibility	O
of	O
adverse	O
effects	O
in	O
patients	O
with	O
cardiac	O
disease	O
.	O

Because	O
of	O
the	O
danger	O
of	O
a	O
potentially	O
fatal	O
prolongation	O
of	O
the	O
QTc	O
interval	O
,	O
halofantrine	B-Drug
must	O
not	O
be	O
given	O
simultaneously	O
with	O
or	O
subsequent	O
to	O
Mefloquine	B-Drug
.	O

Concomitant	O
administration	O
of	O
Mefloquine	B-Drug
and	O
other	O
related	O
compounds	O
(	O
eg	O
,	O
quinine	B-Drug
,	O
quinidine	B-Drug
and	O
chloroquine	B-Drug
)	O
may	O
produce	O
electrocardiographic	O
abnormalities	O
and	O
increase	O
the	O
risk	O
of	O
convulsions	O
.	O

If	O
these	O
drugs	B-Drug
are	O
to	O
be	O
used	O
in	O
the	O
initial	O
treatment	O
of	O
severe	O
malaria	O
,	O
Mefloquine	B-Drug
administration	O
should	O
be	O
delayed	O
at	O
least	O
12	O
hours	O
after	O
the	O
last	O
dose	O
.	O

There	O
is	O
evidence	O
that	O
the	O
use	O
of	O
halofantrine	B-Drug
after	O
Mefloquineuine	O
causes	O
a	O
significant	O
lengthening	O
of	O
the	O
QTc	O
interval	O
.	O

Clinically	O
significant	O
QTc	O
prolongation	O
has	O
not	O
been	O
found	O
with	O
Mefloquineuine	O
alone	O
.	O

This	O
appears	O
to	O
be	O
the	O
only	O
clinically	O
relevant	O
interaction	O
of	O
this	O
kind	O
with	O
Mefloquine	B-Drug
,	O
although	O
theoretically	O
,	O
coadministration	O
of	O
other	O
drugs	B-Drug
known	O
to	O
alter	O
cardiac	O
conduction	O
(	O
eg	O
,	O
anti-arrhythmic	B-Drug
or	O
beta-adrenergic	O
blocking	O
agents	O
,	O
calcium	B-Drug
channel	O
blockers	O
,	O
antihistamines	B-Drug
or	O
H1-blocking	O
agents	O
,	O
tricyclic	O
antidepressants	B-Drug
and	O
phenothiazines	O
)	O
might	O
also	O
contribute	O
to	O
a	O
prolongation	O
of	O
the	O
QTc	O
interval	O
.	O

There	O
are	O
no	O
data	O
that	O
conclusively	O
establish	O
whether	O
the	O
concomitant	O
administration	O
of	O
Mefloquineuine	O
and	O
the	O
above	O
listed	O
agents	O
has	O
an	O
effect	O
on	O
cardiac	O
function	O
.	O

In	O
patients	O
taking	O
an	O
anticonvulsant	O
(	O
eg	O
,	O
valproic	B-Drug
acid	I-Drug
,	O
carbamazepine	B-Drug
,	O
phenobarbital	B-Drug
or	O
phenytoin	B-Drug
)	O
,	O
the	O
concomitant	O
use	O
of	O
Mefloquine	B-Drug
may	O
reduce	O
seizure	O
control	O
by	O
lowering	O
the	O
plasma	O
levels	O
of	O
the	O
anticonvulsant	O
.	O

Therefore	O
,	O
patients	O
concurrently	O
taking	O
antiseizure	O
medication	O
and	O
Mefloquine	B-Drug
should	O
have	O
the	O
blood	O
level	O
of	O
their	O
antiseizure	O
medication	O
monitored	O
and	O
the	O
dosage	O
adjusted	O
appropriately	O
.	O

When	O
Mefloquine	B-Drug
is	O
taken	O
concurrently	O
with	O
oral	O
live	O
typhoid	O
vaccines	O
,	O
attenuation	O
of	O
immunization	O
can	O
not	O
be	O
excluded	O
.	O

Vaccinations	O
with	O
attenuated	O
live	O
bacteria	O
should	O
therefore	O
be	O
completed	O
at	O
least	O
3	O
days	O
before	O
the	O
first	O
dose	O
of	O
Mefloquine	B-Drug
.	O

No	O
other	O
drug	B-Drug
interactions	O
are	O
known	O
.	O

Nevertheless	O
,	O
the	O
effects	O
of	O
Mefloquine	B-Drug
on	O
travelers	O
receiving	O
comedication	O
,	O
particularly	O
diabetics	O
or	O
patients	O
using	O
anticoagulants	B-Drug
,	O
should	O
be	O
checked	O
before	O
departure	O
.	O

In	O
clinical	O
trials	O
,	O
the	O
concomitant	O
administration	O
of	O
sulfadoxine	B-Drug
and	O
pyrimethamine	B-Drug
did	O
not	O
alter	O
the	O
adverse	O
reaction	O
profile	O
.	O

Broad-Spectrum	O
Antibiotics-Broad-spectrum	O
antibiotics	B-Drug
may	O
sterilize	O
the	O
bowel	O
and	O
decrease	O
the	O
vitamin	O
K	O
contribution	O
to	O
the	O
body	O
by	O
the	O
intestinal	O
microflora	O
.	O

Cephalosporins-Cephalosporins	O
containing	O
side	O
chains	O
of	O
N-methylthiotetrazole	O
(	O
cefmenoxime	B-Drug
,	O
cefoperazone	B-Drug
,	O
cefotetan	B-Drug
,	O
cefamandole	B-Drug
,	O
latamoxef	B-Drug
)	O
or	O
methylthiadiazole	O
(	O
cefazolin	B-Drug
)	O
can	O
cause	O
vitamin	O
K	O
deficiency	O
and	O
hypoprothrombinemia	O
.	O

These	O
cephalosporins	O
are	O
inhibitors	O
of	O
hepatic	O
vitamin	O
K	O
epoxide	O
reductase	O
.	O

Cholestyramine-Concomitant	B-Drug
intake	O
of	O
cholestyramine	B-Drug
and	O
vitamin	O
K	O
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	O
K	O
.	O

Colestipol-Concomitant	B-Drug
intake	O
of	O
colestipol	B-Drug
and	O
vitamin	O
K	O
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	O
K	O
.	O

Mineral	B-Drug
Oil-Concomitant	I-Drug
intake	O
of	O
mineral	B-Drug
oil	I-Drug
and	O
vitamin	O
K	O
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	O
K	O
.	O

Orlistat-Orlistat	B-Drug
may	O
decrease	O
the	O
absorption	O
of	O
vitamin	O
K	O
.	O

Salicylates-Salicylates	O
in	O
large	O
doses	O
may	O
inhibit	O
vitamin	O
K	O
epoxide	O
reductase	O
resulting	O
in	O
vitamin	O
K	O
deficiency	O
.	O

Warfarin-Vitamin	B-Drug
K	O
can	O
antagonize	O
the	O
effect	O
of	O
warfarin	B-Drug
Nabilone	B-Drug
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
who	O
are	O
taking	O
other	O
psychoactive	O
drugs	B-Drug
or	O
CNS	O
depressants	O
,	O
including	O
alcohol	B-Drug
,	O
barbiturates	B-Drug
and	O
narcotic	O
analgesics	O
,	O
or	O
to	O
those	O
with	O
a	O
history	O
of	O
psychiatric	O
disorder	O
(	O
including	O
manic-depressive	O
illness	O
and	O
schizophrenia	O
)	O
.	O

Nabilone	B-Drug
has	O
been	O
shown	O
to	O
have	O
an	O
additive	O
CNS	O
depressant	O
effect	O
when	O
given	O
with	O
either	O
diazepam	B-Drug
,	O
secobarbitone	B-Drug
sodium	I-Drug
,	O
alcohol	B-Drug
or	O
codeine	B-Drug
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
,	O
because	O
of	O
its	O
affinity	O
for	O
protein	O
,	O
6MNA	B-Drug
may	O
displace	O
other	O
protein-bound	O
drugs	B-Drug
from	O
their	O
binding	O
site	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
administering	O
nabumetone	B-Drug
with	O
warfarin	B-Drug
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	O
.	O

Concomitant	O
administration	O
of	O
an	O
aluminum-containing	B-Drug
antacid	O
had	O
no	O
significant	O
effect	O
in	O
the	O
bioavailability	O
of	O
6MNA	B-Drug
.	O

When	O
administered	O
with	O
food	O
or	O
milk	O
,	O
there	O
is	O
more	O
rapid	O
absorption	O
;	O
however	O
,	O
the	O
total	O
amount	O
of	O
6MNA	B-Drug
in	O
the	O
plasma	O
is	O
unchanged	O
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	B-Drug
may	O
interact	O
with	O
beta-adrenergic	O
receptor	O
blocking	O
agents	O
:	O
Anesthetics	B-Drug
,	O
general	O
:	O
exaggeration	O
of	O
the	O
hypotension	O
induced	O
by	O
general	O
anesthetics	B-Drug
.	O

Antidiabetic	B-Drug
drugs	B-Drug
(	O
oral	O
agents	O
and	O
insulin	B-Drug
)	O
:	O
hypoglycemia	O
or	O
hyperglycemia	O
;	O
adjust	O
dosage	O
of	O
antidiabetic	B-Drug
drug	B-Drug
accordingly	O
.	O

Catecholamine-depleting	O
drugs	B-Drug
(	O
e.g.	O
,	O
reserpine	B-Drug
)	O
:	O
additive	O
effect	O
;	O
monitor	O
closely	O
for	O
evidence	O
of	O
hypotension	O
and/or	O
excessive	O
bradycardia	O
(	O
e.g.	O
,	O
vertigo	O
,	O
syncope	O
,	O
postural	O
hypotension	O
)	O
.	O

Response	O
to	O
Treatment	O
for	O
Anaphylactic	O
Reaction	O
:	O
While	O
taking	O
beta-blockers	O
,	O
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-Drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

No	O
pharmacokinetic-based	O
drug-drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
SYNAREL	B-Drug
.	O

However	O
,	O
because	O
nafarelin	B-Drug
acetate	I-Drug
is	O
a	O
peptide	O
that	O
is	O
primarily	O
degraded	O
by	O
peptidase	O
and	O
not	O
by	O
cytochrome	O
P-450	O
enzymes	O
,	O
and	O
the	O
drug	B-Drug
is	O
only	O
about	O
80	O
%	O
bound	O
to	O
plasma	O
proteins	O
at	O
4	O
C	O
,	O
drug	B-Drug
interactions	O
would	O
not	O
be	O
expected	O
to	O
occur	O
.	O

Tetracycline	B-Drug
,	O
a	O
bacteriostatic	O
antibiotic	O
,	O
may	O
antagonize	O
the	O
bactericidal	O
effect	O
of	O
penicillin	B-Drug
and	O
concurrent	O
use	O
of	O
these	O
drugs	B-Drug
should	O
be	O
avoided	O
.	O

No	O
specific	O
information	O
available	O
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	O
use	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline-related	B-Drug
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
quinolones	O
and	O
theophylline	B-Drug
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B-Drug
adjusted	O
,	O
as	O
required	O
.	O

Quinolones	O
have	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O

This	O
may	O
lead	B-Drug
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
the	O
prolongation	O
of	O
its	O
plasma	O
half-life	O
.	O

Quinolones	O
,	O
including	O
nalidixic	B-Drug
acid	I-Drug
,	O
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B-Drug
warfarin	B-Drug
or	O
its	O
derivatives	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
.	O

Nitrofurantoin	B-Drug
interferes	O
with	O
the	O
therapeutic	O
action	O
of	O
nalidixic	B-Drug
acid	I-Drug
.	O

Antacids	O
containing	O
magnesium	B-Drug
,	O
aluminum	B-Drug
,	O
or	O
calcium	B-Drug
;	O
sucralfate	B-Drug
or	O
divalent	O
or	O
trivalent	O
cations	O
such	O
as	O
iron	B-Drug
;	O
multivitamins	O
containing	O
zinc	B-Drug
;	O
and	O
Videx	B-Drug
,	O
(	O
Didanosine	B-Drug
)	O
,	O
chewable/buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	O
,	O
resulting	O
in	O
systemic	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O

These	O
agents	O
should	O
not	O
be	O
taken	O
within	O
the	O
two	O
hour	O
period	O
before	O
or	O
within	O
the	O
two-hour	O
period	O
after	O
nalidixic	B-Drug
acid	I-Drug
administration	O
.	O

Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
some	O
quinolones	O
and	O
cyclosporine	B-Drug
.	O

Therefore	O
,	O
cyclosporine	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	B-Drug
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	B-Drug
are	O
used	O
concomitantly	O
.	O

Studies	O
to	O
evaluate	O
possible	O
interactions	O
between	O
REVIA	B-Drug
and	O
drugs	B-Drug
other	O
than	O
opiates	O
have	O
not	O
been	O
performed	O
.	O

Consequently	O
,	O
caution	O
is	O
advised	O
if	O
the	O
concomitant	O
administration	O
of	O
REVIA	B-Drug
and	O
other	O
drugs	B-Drug
is	O
required	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
concomitant	O
use	O
of	O
REVIA	B-Drug
and	O
disulfiram	B-Drug
is	O
unknown	O
,	O
and	O
the	O
concomitant	O
use	O
of	O
two	O
potentially	O
hepatotoxic	O
medications	O
is	O
not	O
ordinarily	O
recommended	O
unless	O
the	O
probable	O
benefits	O
outweigh	O
the	O
known	O
risks	O
.	O

Lethargy	O
and	O
somnolence	O
have	O
been	O
reported	O
following	O
doses	O
of	O
REVIA	B-Drug
and	O
thioridazine	B-Drug
.	O

Patients	O
taking	O
REVIA	B-Drug
may	O
not	O
benefit	O
from	O
opioid	O
containing	O
medicines	O
,	O
such	O
as	O
cough	O
and	O
cold	O
preparations	O
,	O
antidiarrheal	O
preparations	O
,	O
and	O
opioid	O
analgesics	O
.	O

In	O
an	O
emergency	O
situation	O
when	O
opioid	O
analgesia	O
must	O
be	O
administered	O
to	O
a	O
patient	O
receiving	O
REVIA	B-Drug
,	O
the	O
amount	O
of	O
opioid	O
required	O
may	O
be	O
greater	O
than	O
usual	O
,	O
and	O
the	O
resulting	O
respiratory	O
depression	O
may	O
be	O
deeper	O
and	O
more	O
prolonged	O
.	O

The	O
use	O
of	O
NSAIDs	O
in	O
patients	O
who	O
are	O
receiving	O
ACE	O
inhibitors	O
may	O
potentiate	O
renal	O
disease	O
states	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
naproxen	B-Drug
anion	O
,	O
because	O
of	O
its	O
affinity	O
for	O
protein	O
,	O
may	O
displace	O
from	O
their	O
binding	O
sites	O
other	O
drugs	B-Drug
which	O
are	O
also	O
albumin-bound	O
.	O

Theoretically	O
,	O
the	O
naproxen	B-Drug
anion	O
itself	O
could	O
likewise	O
be	O
displaced	O
.	O

Short-term	O
controlled	O
studies	O
failed	O
to	O
show	O
that	O
taking	O
the	O
drug	B-Drug
significantly	O
affects	O
prothrombin	O
times	O
when	O
administered	O
to	O
individuals	O
on	O
coumarin-type	O
anticoagulants	B-Drug
.	O

Caution	O
is	O
advised	O
nonetheless	O
,	O
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
nonsteroidal	O
agents	O
of	O
this	O
class	O
.	O

Similarly	O
,	O
patients	O
receiving	O
the	O
drug	B-Drug
and	O
a	O
hydantoin	O
,	O
sulfonamide	O
or	O
sulfonylurea	B-Drug
should	O
be	O
observed	O
for	O
signs	O
of	O
toxicity	O
to	O
these	O
drugs	B-Drug
.	O

Concomitant	O
administration	O
of	O
naproxen	B-Drug
and	O
aspirin	B-Drug
is	O
not	O
recommended	O
because	O
naproxen	B-Drug
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	B-Drug
,	O
resulting	O
in	O
lower	O
plasma	O
concentrations	O
and	O
peak	O
plasma	O
levels	O
.	O

The	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
has	O
been	O
reported	O
to	O
be	O
inhibited	O
by	O
some	O
drugs	B-Drug
of	O
this	O
class	O
.	O

Inhibition	O
of	O
renal	O
lithium	B-Drug
clearance	O
leading	O
to	O
increases	O
in	O
plasma	O
lithium	B-Drug
concentrations	O
has	O
also	O
been	O
reported	O
.	O

Naproxen	B-Drug
and	O
other	O
NSAIDs	O
can	O
reduce	O
the	O
antihypertensive	B-Drug
effect	O
of	O
propranolol	B-Drug
and	O
other	O
beta-blockers	O
.	O

Probenecid	B-Drug
given	O
concurrently	O
increases	O
naproxen	B-Drug
anion	O
plasma	O
levels	O
and	O
extends	O
its	O
plasma	O
half-life	O
significantly	O
.	O

Caution	O
should	O
be	O
used	O
if	O
naproxen	B-Drug
is	O
administered	O
concomitantly	O
with	O
methotrexate	B-Drug
.	O

Naproxen	B-Drug
,	O
naproxen	B-Drug
sodium	I-Drug
and	O
other	O
NSAIDs	O
have	O
been	O
reported	O
to	O
reduce	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-Drug
in	O
an	O
animal	O
model	O
,	O
possibly	O
increasing	O
the	O
toxicity	O
of	O
methotrexate	B-Drug
.	O

Drug/Laboratory	O
Test	O
Interactions	O
Naproxen	B-Drug
may	O
decrease	O
platelet	O
aggregation	O
and	O
prolong	O
bleeding	O
time	O
.	O

This	O
effect	O
should	O
be	O
kept	O
in	O
mind	O
when	O
bleeding	O
times	O
are	O
determined	O
.	O

The	O
administration	O
of	O
naproxen	B-Drug
may	O
result	O
in	O
increased	O
urinary	O
values	O
for	O
17-ketogenic	O
steroids	O
because	O
of	O
an	O
interaction	O
between	O
the	O
drug	B-Drug
and/or	O
its	O
metabolites	O
with	O
m-dinitrobenzene	O
used	O
in	O
this	O
assay	O
.	O

Although	O
17-hydroxy-corticosteroid	O
measurements	O
(	O
Porter-Silber	O
test	O
)	O
do	O
not	O
appear	O
to	O
be	O
artifactually	O
altered	O
,	O
it	O
is	O
suggested	O
that	O
therapy	O
with	O
naproxen	B-Drug
be	O
temporarily	O
discontinued	O
72	O
hours	O
before	O
adrenal	O
function	O
tests	O
are	O
performed	O
if	O
the	O
Porter-Silber	O
test	O
is	O
to	O
be	O
used	O
.	O

Naproxen	B-Drug
may	O
interfere	O
with	O
some	O
urinary	O
assays	O
of	O
5-hydroxy	O
indoleacetic	O
acid	O
(	O
5HIAA	O
)	O
.	O

Ergot-containing	O
drugs	B-Drug
have	O
been	O
reported	O
to	O
cause	O
prolonged	O
vasospastic	O
reactions	O
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine-containing	B-Drug
or	O
ergot-type	O
medications	O
(	O
like	O
dihydroergotamine	B-Drug
or	O
methysergide	B-Drug
)	O
and	O
naratriptan	B-Drug
within	O
24	O
hours	O
is	O
contraindicated	O
.	O

The	O
administration	O
of	O
naratriptan	B-Drug
with	O
other	O
5-HT1	O
agonists	O
has	O
not	O
been	O
evaluated	O
in	O
migraine	O
patients	O
.	O

Because	O
their	O
vasospastic	O
effects	O
may	O
be	O
additive	O
,	O
coadministration	O
of	O
naratriptan	B-Drug
and	O
other	O
5-HT1	O
agonists	O
within	O
24	O
hours	O
of	O
each	O
other	O
is	O
not	O
recommended	O
.	O

Selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
(	O
e.g.	O
,	O
fluoxetine	B-Drug
,	O
fluvoxamine	B-Drug
,	O
paroxetine	B-Drug
,	O
sertraline	B-Drug
)	O
have	O
been	O
reported	O
,	O
rarely	O
,	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5-HTv	O
agonists	O
.	O

If	O
concomitant	O
treatment	O
with	O
naratriptan	B-Drug
and	O
an	O
SSRI	O
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Drug/	O
Laboratory	O
Test	O
Interactions	O
AMERGE	B-Drug
Tablets	O
are	O
not	O
known	O
to	O
interfere	O
with	O
commonly	O
employed	O
clinical	O
laboratory	O
tests	O
.	O

After	O
multiple	O
dosing	O
,	O
interferon	B-Drug
beta-1a	I-Drug
(	O
AVONEX	B-Drug
30	O
mcg	O
IM	O
once	O
weekly	O
)	O
reduced	O
TYSABRI	B-Drug
clearance	O
by	O
approximately	O
30	O
%	O
.	O

The	O
similarity	O
of	O
the	O
TYSABRI	B-Drug
-associated	O
adverse	O
event	O
profile	O
between	O
Study	O
1	O
(	O
without	O
co-administered	O
AVONEX	B-Drug
)	O
and	O
Study	O
2	O
(	O
with	O
co-administered	O
AVONEX	B-Drug
)	O
indicates	O
that	O
this	O
alteration	O
in	O
clearance	O
does	O
not	O
necessitate	O
reduction	O
of	O
the	O
TYSABRI	B-Drug
dose	O
to	O
maintain	O
safety	O
,	O
General	O
)	O
.	O

Results	O
of	O
studies	O
in	O
multiple	O
sclerosis	O
patients	O
taking	O
TYSABRI	B-Drug
and	O
concomitant	O
interferon	B-Drug
beta-1a	I-Drug
(	O
AVONEX	B-Drug
30	O
mcg	O
IM	O
once	O
weekly	O
)	O
or	O
glatiramer	B-Drug
acetate	I-Drug
were	O
inconclusive	O
with	O
regard	O
to	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
the	O
beta-interferon	B-Drug
or	O
glatiramer	B-Drug
acetate	I-Drug
.	O

In	O
vitro	O
drug	B-Drug
metabolism	O
studies	O
indicate	O
that	O
Starlix	B-Drug
is	O
predominantly	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
isozyme	O
CYP2C9	B-Drug
(	O
70	O
%	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
CYP3A4	B-Drug
(	O
30	O
%	O
)	O
.	O

Starlix	B-Drug
is	O
a	O
potential	O
inhibitor	O
of	O
the	O
CYP2C9	B-Drug
isoenzyme	O
in	O
vivo	O
as	O
indicated	O
by	O
its	O
ability	O
to	O
inhibit	O
the	O
in	O
vitro	O
metabolism	O
of	O
tolbutamide	B-Drug
.	O

Inhibition	O
of	O
CYP3A4	B-Drug
metabolic	O
reactions	O
was	O
not	O
detected	O
in	O
in	O
vitro	O
experiments	O
.	O

Glyburide	B-Drug
:	O
In	O
a	O
randomized	O
,	O
multiple-dose	O
crossover	O
study	O
,	O
patients	O
with	O
Type	O
2	O
diabetes	O
were	O
administered	O
120	O
mg	O
Starlix	B-Drug
three	O
times	O
a	O
day	O
before	O
meals	O
for	O
1	O
day	O
in	O
combination	O
with	O
glyburide	B-Drug
10	O
mg	O
daily	O
.	O

There	O
were	O
no	O
clinically	O
relevant	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Metformin	B-Drug
:	O
When	O
Starlix	B-Drug
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
metformin	B-Drug
500	O
mg	O
three	O
times	O
daily	O
to	O
patients	O
with	O
Type	O
2	O
diabetes	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Digoxin	B-Drug
:	O
When	O
Starlix	B-Drug
120	O
mg	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
a	O
single	O
1-mg	O
dose	O
of	O
digoxin	B-Drug
to	O
healthy	O
volunteers	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Warfarin	B-Drug
:	O
When	O
healthy	O
subjects	O
were	O
administered	O
Starlix	B-Drug
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
for	O
four	O
days	O
in	O
combination	O
with	O
a	O
single	O
dose	O
of	O
warfarin	B-Drug
30	O
mg	O
on	O
day	O
2	O
,	O
there	O
were	O
no	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Prothrombin	O
time	O
was	O
not	O
affected	O
.	O

Diclofenac	B-Drug
:	O
Administration	O
of	O
morning	O
and	O
lunch	O
doses	O
of	O
Starlix	B-Drug
120	O
mg	O
in	O
combination	O
with	O
a	O
single	O
75-mg	O
dose	O
of	O
diclofenac	B-Drug
in	O
healthy	O
volunteers	O
resulted	O
in	O
no	O
significant	O
changes	O
to	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Nateglinide	B-Drug
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
98	O
%	O
)	O
,	O
mainly	O
albumin	O
.	O

In	O
vitro	O
displacement	O
studies	O
with	O
highly	O
protein-bound	O
drugs	B-Drug
such	O
as	O
furosemide	B-Drug
,	O
propranolol	B-Drug
,	O
captopril	B-Drug
,	O
nicardipine	B-Drug
,	O
pravastatin	B-Drug
,	O
glyburide	B-Drug
,	O
warfarin	B-Drug
,	O
phenytoin	B-Drug
,	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
tolbutamide	B-Drug
,	O
and	O
metformin	B-Drug
showed	O
no	O
influence	O
on	O
the	O
extent	O
of	O
nateglinide	B-Drug
protein	O
binding	O
.	O

Similarly	O
,	O
nateglinide	B-Drug
had	O
no	O
influence	O
on	O
the	O
serum	O
protein	O
binding	O
of	O
propranolol	B-Drug
,	O
glyburide	B-Drug
,	O
nicardipine	B-Drug
,	O
warfarin	B-Drug
,	O
phenytoin	B-Drug
,	O
acetylsalicylic	B-Drug
acid	I-Drug
,	O
and	O
tolbutamide	B-Drug
in	O
vitro	O
.	O

However	O
,	O
prudent	O
evaluation	O
of	O
individual	O
cases	O
is	O
warranted	O
in	O
the	O
clinical	O
setting	O
.	O

Certain	O
drugs	B-Drug
,	O
including	O
nonsteroidal	O
anti-inflammatory	O
agents	O
(	O
NSAIDs	O
)	O
,	O
salicylates	O
,	O
monoamine	O
oxidase	O
inhibitors	O
,	O
and	O
non-selective	O
beta-adrenergic-blocking	O
agents	O
may	O
potentiate	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	B-Drug
and	O
other	O
oral	O
antidiabetic	B-Drug
drugs	B-Drug
.	O

Certain	O
drugs	B-Drug
including	O
thiazides	O
,	O
corticosteroids	O
,	O
thyroid	B-Drug
products	O
,	O
and	O
sympathomimetics	O
may	O
reduce	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	B-Drug
and	O
other	O
oral	O
antidiabetic	B-Drug
drugs	B-Drug
.	O

When	O
these	O
drugs	B-Drug
are	O
administered	O
to	O
or	O
withdrawn	O
from	O
patients	O
receiving	O
Starlix	B-Drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
changes	O
in	O
glycemic	O
control	O
.	O

In	O
clinical	O
studies	O
,	O
Tilade	B-Drug
has	O
been	O
co-administered	O
with	O
other	O
anti-asthma	O
medications	O
,	O
including	O
inhaled	O
and	O
oral	O
bronchodilators	O
,	O
and	O
inhaled	O
corticosteroids	O
,	O
with	O
no	O
evidence	O
of	O
increased	O
frequency	O
of	O
adverse	O
events	O
or	O
laboratory	O
abnormalities	O
.	O

No	O
formal	O
drug-drug	O
interaction	O
studies	O
,	O
however	O
,	O
have	O
been	O
conducted	O
.	O

Nelfinavir	B-Drug
is	O
an	O
inhibitor	O
of	O
CYP3A	O
(	O
cytochrome	O
P450	O
3A	O
)	O
.	O

Coadministration	O
of	O
VIRACEPT	B-Drug
and	O
drugs	B-Drug
primarily	O
metabolized	O
by	O
CYP3A	O
(	O
e.g.	O
,	O
dihydropyridine	O
calcium	B-Drug
channel	O
blockers	O
)	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
other	O
drug	B-Drug
that	O
could	O
increase	O
or	O
prolong	O
both	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Nelfinavir	B-Drug
is	O
metabolized	O
in	O
proof	O
by	O
C.P.A	O
.	O

Coadministration	O
of	O
VIRACEPT	B-Drug
and	O
drugs	B-Drug
that	O
induce	O
CYP3A	O
may	O
decrease	O
nelfinavir	B-Drug
plasma	O
concentrations	O
and	O
reduce	O
its	O
therapeutic	O
effect	O
.	O

Coadministration	O
of	O
VIRACEPT	B-Drug
and	O
drugs	B-Drug
that	O
inhibit	O
CYP3A	O
may	O
increase	O
nelfinavir	B-Drug
plasma	O
concentrations	O
.	O

Based	O
on	O
known	O
metabolic	O
profiles	O
,	O
clinically	O
significant	O
drug	B-Drug
interactions	O
are	O
not	O
expected	O
between	O
VIRACEPT	B-Drug
and	O
dapsone	B-Drug
,	O
trimethoprim/sulfamethoxazole	B-Drug
,	O
clarithromycin	B-Drug
,	O
erythromycin	B-Drug
,	O
itraconazole	B-Drug
or	O
fluconazole	B-Drug
.	O

Drugs	B-Drug
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
VIRACEPT	B-Drug
Antiarrhythmics	B-Drug
:	O
amiodarone	B-Drug
,	O
quinidine	B-Drug
Antihistamines	B-Drug
:	O
astemizole	B-Drug
,	O
terfenadine	B-Drug
Antimigraine	O
:	O
ergot	B-Drug
derivatives	O
Antimycobacterial	O
agents	O
:	O
rifampin	B-Drug
Benzodiazepines	B-Drug
midazolam	B-Drug
,	O
triazolam	B-Drug
GI	O
motility	O
agents	O
:	O
cisapride	B-Drug
Drugs	B-Drug
Which	O
Require	O
a	O
Dose	O
Reduction	O
When	O
Coadminstered	O
With	O
VIRACEPT	B-Drug
Antimycobacterial	O
agents	O
:	O
rifabutin	B-Drug
*	O
This	O
table	O
is	O
not	O
all	O
inclusive	O
**	O
VIRACEPT	B-Drug
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
nelfinavir	B-Drug
plasma	O
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O
Antihistamines	B-Drug
Terfenadine	B-Drug
:	O
Administration	O
of	O
terfenadine	B-Drug
with	O
VIRACEPT	B-Drug
resulted	O
in	O
the	O
appearance	O
of	O
unchanged	O
terfenadine	B-Drug
in	O
plasma	O
;	O
therefore	O
,	O
VIRACEPT	B-Drug
should	O
not	O
be	O
administered	O
concurrently	O
with	O
terfenadine	B-Drug
because	O
of	O
the	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
cardiac	O
arrhythmias	O
.	O

Because	O
a	O
similar	O
interaction	O
is	O
likely	O
,	O
VIRACEPT	B-Drug
should	O
also	O
not	O
be	O
administered	O
concurrently	O
with	O
astemizole	B-Drug
.	O

Anti-HIV	O
Protease	O
Inhibitors	O
Indinavir	B-Drug
:	O
Coadministration	O
of	O
indinavir	B-Drug
with	O
VIRACEPT	B-Drug
resulted	O
in	O
an	O
83	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
a	O
51	O
%	O
increase	O
in	O
indinavir	B-Drug
plasma	O
A.C	O
.	O

Currently	O
,	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O

Ritonavir	B-Drug
:	O
Coadministration	O
of	O
ritonavir	B-Drug
with	O
VIRACEPT	B-Drug
resulted	O
in	O
a	O
152	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
very	O
little	O
change	O
in	O
ritonavir	B-Drug
plasma	O
A.C	O
.	O

Currently	O
,	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O

Saquinavir	B-Drug
:	O
Coadministration	O
of	O
saquinavir	B-Drug
(	O
using	O
an	O
experimental	O
soft-gelatin	O
capsule	O
formulation	O
of	O
saquinavir	B-Drug
1200mg	O
)	O
with	O
VIRACEPT	B-Drug
resulted	O
in	O
an	O
18	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
a	O
4-fold	O
increase	O
in	O
saquinavir	B-Drug
plasma	O
A.C	O
.	O

If	O
used	O
in	O
combination	O
with	O
saquinavir	B-Drug
hard	O
gelatin	O
capsules	O
at	O
the	O
recommended	O
dose	O
of	O
600	O
mg	O
tid	O
,	O
no	O
dose	O
adjustments	O
are	O
needed	O
.	O

Currently	O
,	O
there	O
are	O
no	O
safety	O
and	O
efficacy	O
data	O
available	O
from	O
the	O
use	O
of	O
this	O
combination	O
.	O

Antifungal	O
Agents	O
Ketoconazole	B-Drug
:	O
Coadministration	O
of	O
ketoconazole	B-Drug
with	O
VIRACEPT	B-Drug
resulted	O
in	O
a	O
35	O
%	O
increase	O
in	O
nelfinavir	B-Drug
plasma	O
A.C	O
.	O

This	O
change	O
was	O
not	O
considered	O
clinically	O
significant	O
and	O
no	O
dose	O
adjustment	O
is	O
needed	O
when	O
ketoconazole	B-Drug
and	O
VIRACEPT	B-Drug
are	O
coadministered	O
.	O

Anti-HIV	O
Reverse	O
Transcriptase	O
Inhibitors	O
Didanosine	B-Drug
:	O
It	O
is	O
recommended	O
that	O
didanosine	B-Drug
be	O
administered	O
on	O
an	O
empty	O
stomach	O
;	O
therefore	O
,	O
nelfinavir	B-Drug
should	O
be	O
administered	O
(	O
with	O
food	O
)	O
one	O
hour	O
after	O
or	O
more	O
than	O
two	O
hours	O
before	O
didanosine	B-Drug
.	O

A	O
dose	O
adjustment	O
is	O
not	O
needed	O
when	O
zidovudine	B-Drug
is	O
administered	O
with	O
VIRACEPT	B-Drug
.	O

Little	O
or	O
no	O
change	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
drug	B-Drug
was	O
observed	O
when	O
VIRACEPT	B-Drug
was	O
coadministered	O
with	O
lamivudine	B-Drug
or	O
stavudine	B-Drug
.	O

Antimycobacterial	O
Agents	O
Rifabutin	B-Drug
:	O
Coadministration	O
of	O
rifabutin	B-Drug
and	O
VIRACEPT	B-Drug
resulted	O
in	O
a	O
32	O
%	O
decrease	O
in	O
nelfinavir	B-Drug
plasma	O
AUC	O
and	O
a	O
207	O
%	O
increase	O
in	O
rifabutin	B-Drug
plasma	O
A.C	O
.	O

It	O
is	O
recommended	O
that	O
the	O
dose	O
of	O
rifabutin	B-Drug
be	O
reduced	O
to	O
one-half	O
the	O
usual	O
dose	O
when	O
administered	O
with	O
VIRACEPT	B-Drug
.	O

Rifampin	B-Drug
:	O
Coadministration	O
of	O
rifampin	B-Drug
and	O
VIRACEPT	B-Drug
resulted	O
in	O
an	O
82	O
%	O
decrease	O
in	O
nelfinavir	B-Drug
plasma	O
A.C	O
.	O

VIRACEPT	B-Drug
and	O
rifampin	B-Drug
should	O
not	O
be	O
coadministered	O
.	O

Oral	O
Contraceptives	O
Ethinyl	B-Drug
Estradiol	I-Drug
and	O
Norethindrone	B-Drug
:	O
Coadministration	O
of	O
VIRACEPT	B-Drug
with	O
OVCON-35	B-Drug
resulted	O
in	O
a	O
47	O
%	O
decrease	O
in	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
an	O
18	O
%	O
decrease	O
in	O
norethindrone	B-Drug
plasma	O
concentrations	O
.	O

Alternate	O
or	O
additional	O
contraceptive	O
measures	O
should	O
be	O
used	O
during	O
therapy	O
with	O
VIRACEPT	B-Drug
Caution	O
should	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
neurotoxic	O
and/	O
or	O
nephrotoxic	O
drugs	B-Drug
because	O
of	O
possible	O
enhancement	O
of	O
the	O
nephrotoxicity	O
and/or	O
ototoxicity	O
of	O
neomycin	B-Drug
.	O

Caution	O
should	O
also	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
aminoglycosides	O
and	O
polymyxins	O
because	O
they	O
may	O
enhance	O
neomycin	B-Drug
s	O
nephrotoxicity	O
and/or	O
ototoxicity	O
and	O
potentiate	O
neomycin	B-Drug
sulfate	O
neuromuscular	O
blocking	O
effects	O
.	O

Oral	O
neomycin	B-Drug
inhibits	O
the	O
gastrointestinal	O
absorption	O
of	O
penicillin	B-Drug
V	I-Drug
,	O
oral	O
vitamin	B-Drug
B-12	I-Drug
,	O
methotrexate	B-Drug
and	O
5-fluorouracil	B-Drug
.	O

The	O
gastrointestinal	O
absorption	O
of	O
digoxin	B-Drug
also	O
appears	O
to	O
be	O
inhibited	O
.	O

Therefore	O
,	O
digoxin	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
.	O

Oral	O
neomycin	B-Drug
sulfate	I-Drug
may	O
enhance	O
the	O
effect	O
of	O
coumarin	O
in	O
anticoagulants	B-Drug
by	O
decreasing	O
vitamin	O
K	O
availability	O
.	O

Certain	O
antibiotics	B-Drug
,	O
especially	O
neomycin	B-Drug
,	O
streptomycin	B-Drug
and	O
kanamycin	B-Drug
,	O
have	O
a	O
mild	O
but	O
definite	O
nondepolarizing	O
blocking	O
action	O
which	O
may	O
accentuate	O
neuromuscular	O
block	O
.	O

These	O
antibiotics	B-Drug
should	O
be	O
used	O
in	O
the	O
myasthenic	O
patient	O
only	O
where	O
definitely	O
indicated	O
,	O
and	O
then	O
careful	O
adjustment	O
should	O
be	O
made	O
of	O
adjunctive	O
anticholinesterase	O
dosage	O
.	O

Local	O
and	O
some	O
general	O
anesthetics	B-Drug
,	O
antiarrhythmic	B-Drug
agents	O
and	O
other	O
drugs	B-Drug
that	O
interfere	O
with	O
neuromuscular	O
transmission	O
should	O
be	O
used	O
cautiously	O
,	O
if	O
at	O
all	O
,	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
;	O
the	O
dose	O
of	O
Prostigmin	B-Drug
may	O
have	O
to	O
be	O
increased	O
accordingly	O
.	O

No	O
trials	O
specifically	O
examining	O
potential	O
drug	B-Drug
interactions	O
with	O
Natrecor	B-Drug
were	O
conducted	O
,	O
although	O
many	O
concomitant	O
drugs	B-Drug
were	O
used	O
in	O
clinical	O
trials	O
.	O

No	O
drug	B-Drug
interactions	O
were	O
detected	O
except	O
for	O
an	O
increase	O
in	O
symptomatic	O
hypotension	O
in	O
patients	O
receiving	O
oral	O
ACE	O
inhibitors	O
.	O

The	O
co-administration	O
of	O
Natrecor	B-Drug
with	O
IV	O
vasodilators	O
such	O
as	O
nitroglycerin	B-Drug
,	O
nitroprusside	B-Drug
,	O
milrinone	B-Drug
,	O
or	O
IV	O
ACE	O
inhibitors	O
has	O
not	O
been	O
evaluated	O
(	O
these	O
drugs	B-Drug
were	O
not	O
co-administered	O
with	O
Natrecor	B-Drug
in	O
clinical	O
trials	O
)	O
.	O

Netilmicin	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
potent	O
loop	O
diuretics	B-Drug
such	O
as	O
furosemide	B-Drug
and	O
ethacrynic	B-Drug
acid	I-Drug
as	O
the	O
potential	O
for	O
ototoxicity	O
is	O
enhanced	O
by	O
the	O
combination	O
.	O

Nevirapine	B-Drug
is	O
principally	O
metabolized	O
by	O
the	O
liver	O
via	O
the	O
cytochrome	O
P450	O
isoenzymes	O
,	O
3A4	O
and	O
2B6	O
.	O

Nevirapine	B-Drug
is	O
known	O
to	O
be	O
an	O
inducer	O
of	O
these	O
enzymes	O
.	O

As	O
a	O
result	O
,	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
these	O
enzyme	O
systems	O
may	O
have	O
lower	O
than	O
expected	O
plasma	O
levels	O
when	O
coadministered	O
with	O
nevirapine	B-Drug
.	O

The	O
specific	O
pharmacokinetic	O
changes	O
that	O
occur	O
with	O
co-administration	O
of	O
nevirapine	B-Drug
and	O
other	O
drugs	B-Drug
are	O
listed	O
in	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Table	O
1	O
.	O

Clinical	O
comments	O
about	O
possible	O
dosage	O
modifications	O
based	O
on	O
these	O
pharmacokinetic	O
changes	O
are	O
listed	O
in	O
Table	O
3	O
.	O

The	O
data	O
inTables	O
1	O
and	O
3	O
are	O
based	O
on	O
the	O
results	O
of	O
drug	B-Drug
interaction	O
studies	O
conducted	O
in	O
HIV-1	O
seropositive	O
subjects	O
unless	O
otherwise	O
indicated	O
.	O

In	O
addition	O
to	O
established	O
drug	B-Drug
interactions	O
,	O
there	O
may	O
be	O
potential	O
pharmacokinetic	O
interactions	O
between	O
nevirapine	B-Drug
and	O
other	O
drug	B-Drug
classes	O
that	O
are	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
.	O

These	O
potential	O
drug	B-Drug
interactions	O
are	O
listed	O
in	O
Table	O
4	O
.	O

Although	O
specific	O
drug	B-Drug
interaction	O
studies	O
in	O
HIV-1	O
seropositive	O
subjects	O
have	O
not	O
been	O
conducted	O
for	O
the	O
classes	O
of	O
drugs	B-Drug
listed	O
in	O
Table	O
4	O
,	O
additional	O
clinical	O
monitoring	O
may	O
be	O
warranted	O
when	O
co-administering	O
these	O
drugs	B-Drug
.	O

The	O
in	O
vitro	O
interaction	O
between	O
nevirapine	B-Drug
and	O
the	O
antithrombotic	O
agent	O
warfarin	B-Drug
is	O
complex	O
.	O

As	O
a	O
result	O
,	O
when	O
giving	O
these	O
drugs	B-Drug
concomitantly	O
,	O
plasma	O
warfarin	B-Drug
levels	O
may	O
change	O
with	O
the	O
potential	O
for	O
increases	O
in	O
coagulation	O
time	O
.	O

When	O
warfarin	B-Drug
is	O
co-administered	O
with	O
nevirapine	B-Drug
,	O
anticoagulation	O
levels	O
should	O
be	O
monitored	O
frequently	O
.	O

Table	O
3	O
Established	O
Drug	B-Drug
Interactions	O
:	O
Alteration	O
in	O
Dose	O
or	O
Regimen	O
May	O
Be	O
Recommended	O
Based	O
on	O
Drug	B-Drug
Interaction	O
Studies	O
Drug	B-Drug
Name	O
Effect	O
on	O
Concentration	O
of	O
Nevirapine	B-Drug
or	O
Concomitant	O
Drug	B-Drug
Clinical	O
Comment	O
Clarithromycin	B-Drug
Clarithromycin	B-Drug
14OH-	O
clarithromycin	B-Drug
Clarithromycin	B-Drug
exposure	O
was	O
significantly	O
decreased	O
by	O
nevirapine	B-Drug
;	O
however	O
,	O
14-OH	O
metabolite	O
concentrations	O
were	O
increased.Because	O
clarithromycin	B-Drug
active	O
metabolite	O
has	O
reduced	O
activity	O
against	O
Mycobacteriumavium-intracellulare	O
complex	O
,	O
overallactivity	O
against	O
this	O
pathogen	O
may	O
bealtered	O
.	O

Alternatives	O
to	O
clarithromycin	B-Drug
,	O
such	O
as	O
azithromycin	B-Drug
,	O
should	O
be	O
considered	O
.	O

Efavirenz	B-Drug
Efavirenz	B-Drug
Appropriate	O
doses	O
for	O
this	O
combination	O
are	O
not	O
established	O
.	O

Ethinyl	B-Drug
estradiol	I-Drug
and	O
Norethindrone	B-Drug
Ethinyl	B-Drug
estradiol	I-Drug
Norethindrone	B-Drug
Oral	O
contraceptives	O
and	O
other	O
hormonalmethods	O
of	O
birth	O
control	O
should	O
not	O
be	O
usedas	O
the	O
sole	O
method	O
of	O
contraception	O
inwomen	O
taking	O
nevirapine	B-Drug
,	O
since	O
nevirapinemay	O
lower	O
the	O
plasma	O
levels	O
of	O
thesemedications	O
.	O

An	O
alternative	O
or	O
additional	O
method	O
of	O
contraception	O
is	O
recommended	O
.	O

Fluconazole	B-Drug
Nevirapine	B-Drug
Because	O
of	O
the	O
risk	O
of	O
increased	O
exposure	O
tonevirapine	B-Drug
,	O
caution	O
should	O
be	O
used	O
inconcomitant	O
administration	O
,	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
for	O
nevirapine-associated	O
adverse	O
events	O
.	O

Indinavir	B-Drug
Indinavir	B-Drug
Appropriate	O
doses	O
for	O
this	O
combination	O
arenot	O
established	O
,	O
but	O
an	O
increase	O
in	O
thedosage	O
of	O
indinavir	B-Drug
may	O
be	O
required	O
.	O

Ketoconazole	B-Drug
Ketoconazole	B-Drug
Nevirapine	B-Drug
and	O
ketoconazole	B-Drug
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
ketoconazole	B-Drug
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
of	O
the	O
drug	B-Drug
.	O

Lopinavir/Ritonavir	B-Drug
Lopinavir	B-Drug
A	O
dose	O
increase	O
of	O
lopinavir/ritonavir	B-Drug
to	O
533/133	O
mg	O
twice	O
daily	O
with	O
food	O
isrecommended	O
in	O
combination	O
with	O
nevirapine	B-Drug
.	O

Methadone	B-Drug
Methadonea	O
Methadone	B-Drug
levels	O
may	O
be	O
decreased	O
;	O
increased	O
dosages	O
may	O
be	O
required	O
to	O
prevent	O
symptoms	O
of	O
opiate	O
withdrawal	O
.	O

Methadone	B-Drug
maintained	O
patients	O
beginning	O
nevirapine	B-Drug
therapy	O
should	O
be	O
monitored	O
forevidence	O
of	O
withdrawal	O
and	O
methadone	B-Drug
dose	O
should	O
be	O
adjusted	O
accordingly	O
.	O

Nelfinavir	B-Drug
Nelfinavir	B-Drug
M8	O
The	O
appropriate	O
dose	O
for	O
nelfinavir	B-Drug
incombination	O
with	O
nevirapine	B-Drug
,	O
with	O
respectto	O
safety	O
and	O
efficacy	O
,	O
has	O
not	O
been	O
established	O
.	O

Rifabutin	B-Drug
Rifabutin	B-Drug
Rifabutin	B-Drug
and	O
its	O
metabolite	O
concentrationswere	O
moderately	O
increased	O
.	O

Due	O
to	O
highintersubject	O
variability	O
,	O
however	O
,	O
somepatients	O
may	O
experience	O
large	O
increases	O
inrifabutin	B-Drug
exposure	O
and	O
may	O
be	O
at	O
higher	O
riskfor	O
rifabutin	B-Drug
toxicity	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
in	O
concomitant	O
administration	O
.	O

Rifampin	B-Drug
Nevirapine	B-Drug
Nevirapine	B-Drug
and	O
rifampin	B-Drug
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
nevirapine	B-Drug
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
ofthe	O
drug	B-Drug
.	O

Physicians	O
needing	O
to	O
treatpatients	O
co-infected	O
with	O
tuberculosis	O
andusing	O
a	O
nevirapine	B-Drug
containing	O
regimen	O
mayuse	O
rifabutin	B-Drug
instead	O
.	O

Saquinavir	B-Drug
Saquinavir	B-Drug
Appropriate	O
doses	O
for	O
this	O
combination	O
arenot	O
established	O
,	O
but	O
an	O
increase	O
in	O
thedosage	O
of	O
saquinavir	B-Drug
may	O
be	O
required	O
.	O

aBased	O
on	O
reports	O
of	O
narcotic	O
withdrawal	O
syndrome	O
in	O
patients	O
treated	O
with	O
nevirapine	B-Drug
and	O
methadone	B-Drug
concurrently	O
,	O
and	O
evidence	O
of	O
decreased	O
plasma	O
concentrations	O
of	O
methadone	B-Drug
.	O

Table	O
4	O
Potential	O
Drug	B-Drug
Interactions	O
:	O
Use	O
With	O
Caution	O
,	O
Dose	O
Adjustment	O
of	O
Co-administered	O
Drug	B-Drug
May	O
Be	O
Needed	O
due	O
to	O
Possible	O
Decrease	O
in	O
Clinical	O
Effect	O
Examples	O
of	O
Drugs	B-Drug
in	O
Which	O
Plasma	O
Concentrations	O
May	O
Be	O
Decreased	O
By	O
Co-administration	O
With	O
Nevirapine	B-Drug
Drug	B-Drug
Class	O
Examples	O
of	O
Drugs	B-Drug
Antiarrhythmics	B-Drug
Amiodarone	B-Drug
,	O
disopyramide	B-Drug
,	O
lidocaine	B-Drug
Anticonvulsants	O
Carbamazepine	B-Drug
,	O
clonazepam	B-Drug
,	O
ethosuximide	B-Drug
Antifungals	O
Itraconazole	B-Drug
Calcium	B-Drug
channel	O
blockers	O
Diltiazem	B-Drug
,	O
nifedipine	B-Drug
,	O
verapamil	B-Drug
Cancer	O
chemotherapy	O
Cyclophosphamide	B-Drug
Ergot	B-Drug
alkaloids	O
Ergotamine	B-Drug
Immunosuppressants	O
Cyclosporin	B-Drug
,	O
tacrolimus	B-Drug
,	O
sirolimus	B-Drug
Motility	O
agents	O
Cisapride	B-Drug
Opiate	O
agonists	O
Fentanyl	B-Drug
Examples	O
of	O
Drugs	B-Drug
in	O
Which	O
Plasma	O
Concentrations	O
May	O
Be	O
Increased	O
By	O
Co-administration	O
With	O
Nevirapine	B-Drug
Antithrombotics	O
Warfarin	B-Drug
Potential	O
effect	O
on	O
anticoagulation	O
.	O

Monitoring	O
of	O
anticoagulation	O
levels	O
is	O
recommended	O
.	O

Fat	O
redistribution	O
:	O
Redistribution/accumulation	O
of	O
body	O
fat	O
including	O
central	O
obesity	O
,	O
dorsocervical	O
fat	O
enlargement	O
(	O
buffalo	O
hump	O
)	O
,	O
peripheral	O
wasting	O
,	O
facial	O
wasting	O
,	O
breast	O
enlargement	O
,	O
and	O
cushingoid	O
appearance	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O

The	O
mechanism	O
and	O
long-term	O
consequences	O
of	O
these	O
events	O
are	O
currently	O
unknown	O
.	O

A	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
.	O

Interactions	O
for	O
Vitamin	B-Drug
B3	I-Drug
(	O
Niacin	B-Drug
)	O
:	O
Antihypertensive	B-Drug
Therapy	O
:	O
Nicotinic	B-Drug
acid	I-Drug
may	O
potentiate	O
the	O
effects	O
of	O
ganglionic	O
blocking	O
agents	O
and	O
vasoactive	O
drugs	B-Drug
resulting	O
in	O
postural	O
hypotension	O
.	O

Aspirin	B-Drug
:	O
Concomitant	O
aspirin	B-Drug
may	O
decrease	O
the	O
metabolic	O
clearance	O
of	O
nicotinic	B-Drug
acid	I-Drug
.	O

The	O
clinical	O
relevance	O
of	O
this	O
finding	O
is	O
unclear	O
.	O

Other	O
:	O
Concomitant	O
alcohol	B-Drug
or	O
hot	O
drinks	O
may	O
increase	O
the	O
side	O
effects	O
of	O
flushing	O
and	O
pruritus	O
and	O
should	O
be	O
avoided	O
at	O
the	O
time	O
of	O
drug	B-Drug
ingestion	O
.	O

Beta-Blockers	O
:	O
In	O
controlled	O
clinical	O
studies	O
,	O
adrenergic	O
beta-receptor	O
blockers	O
have	O
been	O
frequently	O
administered	O
concomitantly	O
with	O
nicardipine	B-Drug
HCl	I-Drug
.	O

The	O
combination	O
is	O
well	O
tolerated	O
.	O

Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
increases	O
nicardipine	B-Drug
HCl	I-Drug
plasma	O
levels	O
.	O

Patients	O
receiving	O
the	O
two	O
drugs	B-Drug
concomitantly	O
should	O
be	O
carefully	O
monitored	O
.	O

Digoxin	B-Drug
:	O
Some	O
calcium	B-Drug
blockers	O
may	O
increase	O
the	O
concentration	O
of	O
digitalis	B-Drug
preparations	O
in	O
the	O
blood	O
.	O

Nicardipine	B-Drug
HCl	I-Drug
usually	O
does	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
digoxin	B-Drug
,	O
however	O
,	O
serum	O
digoxin	B-Drug
levels	O
should	O
be	O
evaluated	O
after	O
concomitant	O
therapy	O
with	O
nicardipine	B-Drug
HCl	I-Drug
is	O
initiated	O
.	O

Maalox	B-Drug
*	O
Coadministration	O
of	O
Maalox	B-Drug
TC	I-Drug
had	O
no	O
effect	O
on	O
nicardipine	B-Drug
HCl	I-Drug
absorption	O
.	O

Even	O
though	O
such	O
interactions	O
were	O
not	O
seen	O
during	O
clinical	O
studies	O
with	O
nicardipine	B-Drug
HCl	I-Drug
,	O
an	O
increased	O
volume	O
of	O
circulating	O
fluids	O
might	O
be	O
required	O
if	O
such	O
an	O
interaction	O
were	O
to	O
occur	O
.	O

Cyclosporine	B-Drug
:	O
Concomitant	O
administration	O
of	O
nicardipine	B-Drug
and	O
cyclosporine	B-Drug
levels	O
.	O

Plasma	O
concentrations	O
of	O
cyclosporine	B-Drug
should	O
therefore	O
be	O
closely	O
monitored	O
,	O
and	O
its	O
dosage	O
reduced	O
accordingly	O
,	O
in	O
patients	O
treated	O
with	O
nicardipine	B-Drug
.	O

When	O
therapeutic	O
concentrations	O
of	O
furosemide	B-Drug
,	O
propranolol	B-Drug
,	O
dipyridamole	B-Drug
,	O
warfarin	B-Drug
,	O
quinidine	B-Drug
,	O
or	O
naproxen	B-Drug
were	O
added	O
to	O
human	O
plasma	O
(	O
in	O
vitro	O
)	O
,	O
the	O
plasma	O
protein	O
binding	O
of	O
nicardipine	B-Drug
HCl	I-Drug
was	O
not	O
altered	O
.	O

Physiological	O
changes	O
resulting	O
from	O
smoking	O
cessation	O
,	O
with	O
or	O
without	O
nicotine	B-Drug
replacement	O
,	O
may	O
alter	O
the	O
pharmacokinetics	O
of	O
certain	O
concomitant	O
medications	O
,	O
such	O
as	O
tricyclic	O
antidepressants	B-Drug
and	O
theophylline	B-Drug
.	O

Doses	O
of	O
these	O
and	O
perhaps	O
other	O
medications	O
may	O
need	O
to	O
be	O
adjusted	O
in	O
patients	O
who	O
successfully	O
quit	O
smoking	O
.	O

Beta-adrenergic	O
Blocking	O
Agents	O
:	O
Experience	O
in	O
over	O
1400	O
patients	O
in	O
a	O
non-comparative	O
clinical	O
trial	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
nifedipine	B-Drug
and	O
beta-blocking	B-Drug
agents	O
is	O
usually	O
well	O
tolerated	O
,	O
but	O
there	O
have	O
been	O
occasional	O
literature	O
reports	O
suggesting	O
that	O
the	O
combination	O
may	O
increase	O
the	O
likelihood	O
of	O
congestive	O
heart	O
failure	O
,	O
severe	O
hypotension	O
or	O
exacerbation	O
of	O
angina	O
.	O

Long	O
Acting	O
Nitrates	B-Drug
:	O
Nifedipine	B-Drug
may	O
be	O
safely	O
co-administered	O
with	O
nitrates	B-Drug
,	O
but	O
there	O
have	O
been	O
no	O
controlled	O
studies	O
to	O
evaluate	O
the	O
antianginal	O
effectiveness	O
of	O
this	O
combination	O
.	O

Digitalis	B-Drug
:	O
Immediate	O
Release	O
Capsules	O
:	O
Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	B-Drug
levels	O
,	O
and	O
there	O
is	O
a	O
possible	O
interaction	O
between	O
digoxin	B-Drug
and	O
nifedipine	B-Drug
,	O
it	O
is	O
recommended	O
that	O
digoxin	B-Drug
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	B-Drug
to	O
avoid	O
possible	O
over-	O
or	O
under-digitalization	O
.	O

Extended	O
Release	O
Tablets	O
:	O
Administration	O
of	O
nifedipine	B-Drug
with	O
digoxin	B-Drug
increased	O
digoxin	B-Drug
levels	O
in	O
9	O
of	O
12	O
normal	O
volunteers	O
.	O

The	O
average	O
increase	O
was	O
45	O
%	O
.	O

Another	O
investigator	O
found	O
no	O
increase	O
in	O
digoxin	B-Drug
levels	O
in	O
13	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

In	O
an	O
uncontrolled	O
study	O
of	O
over	O
200	O
patients	O
with	O
congestive	O
heart	O
failure	O
during	O
which	O
digoxin	B-Drug
blood	O
levels	O
were	O
not	O
measured	O
,	O
digitalis	B-Drug
toxicity	O
was	O
not	O
observed	O
.	O

Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	B-Drug
levels	O
,	O
it	O
is	O
recommended	O
that	O
digoxin	B-Drug
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	B-Drug
to	O
avoid	O
possible	O
over-	O
or	O
under-digitalization	O
.	O

Quinidine	B-Drug
:	O
Immediate	O
Release	O
Capsules	O
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
an	O
interaction	O
between	O
quinidine	B-Drug
and	O
nifedipine	B-Drug
(	O
with	O
a	O
decreased	O
plasma	O
level	O
of	O
quinidine	B-Drug
)	O
.	O

Coumarin	O
Anticoagulants	B-Drug
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
increased	O
prothrombin	O
time	O
in	O
patients	O
taking	O
coumarin	O
anticoagulants	B-Drug
to	O
whom	O
nifedipine	B-Drug
was	O
administered	O
.	O

However	O
,	O
the	O
relationship	O
to	O
nifedipine	B-Drug
therapy	O
is	O
uncertain	O
.	O

Cimetidine	B-Drug
:	O
A	O
study	O
in	O
6	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
nifedipine	B-Drug
plasma	O
levels	O
(	O
80	O
%	O
)	O
and	O
area-under-the-curve	O
(	O
74	O
%	O
)	O
after	O
a	O
1	O
week	O
course	O
of	O
cimetidine	B-Drug
at	O
1000	O
mg	O
per	O
day	O
and	O
nifedipine	B-Drug
at	O
40	O
mg	O
per	O
day	O
.	O

Ranitidine	B-Drug
produced	O
smaller	O
,	O
non-significant	O
increases	O
.	O

The	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
cimetidine	B-Drug
on	O
hepatic	O
cytochrome	O
P-450	O
,	O
the	O
enzyme	O
system	O
probably	O
responsible	O
for	O
the	O
first-pass	O
metabolism	O
of	O
nifedipine	B-Drug
.	O

If	O
nifedipine	B-Drug
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	B-Drug
,	O
cautious	O
titration	O
is	O
advised	O
.	O

In	O
vitro	O
,	O
nilutamide	B-Drug
has	O
been	O
shown	O
to	O
inhibit	O
the	O
activity	O
of	O
liver	O
cytochrome	O
P-450	O
isoenzymes	O
and	O
therefore	O
,	O
may	O
reduce	O
the	O
metabolism	O
of	O
compounds	O
requiring	O
these	O
systems	O
.	O

Consequently	O
,	O
drugs	B-Drug
with	O
a	O
low	O
therapeutic	O
margin	O
,	O
such	O
as	O
vitamin	O
K	O
antagonists	O
,	O
phenytoin	B-Drug
,	O
and	O
theophylline	B-Drug
,	O
could	O
have	O
a	O
delayed	O
elimination	O
and	O
increases	O
in	O
their	O
serum	O
half-life	O
leading	O
to	O
a	O
toxic	O
level	O
.	O

The	O
dosage	O
of	O
these	O
drugs	B-Drug
or	O
others	O
with	O
a	O
similar	O
metabolism	O
may	O
need	O
to	O
be	O
modified	O
if	O
they	O
are	O
administered	O
concomitantly	O
with	O
nilutamide	B-Drug
.	O

For	O
example	O
,	O
when	O
vitamin	O
K	O
antagonists	O
are	O
administered	O
concomitantly	O
with	O
nilutamide	B-Drug
,	O
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
and	O
if	O
necessary	O
,	O
the	O
dosage	O
of	O
vitamin	O
K	O
antagonists	O
should	O
be	O
reduced	O
.	O

It	O
is	O
possible	O
that	O
the	O
cardiovascular	O
action	O
of	O
other	O
calcium	B-Drug
channel	O
blockers	O
could	O
be	O
enhanced	O
by	O
the	O
addition	O
of	O
Nimotop	B-Drug
.	O

In	O
Europe	O
,	O
Nimotop	B-Drug
was	O
observed	O
to	O
occasionally	O
intensify	O
the	O
effect	O
of	O
antihypertensive	B-Drug
compounds	O
taken	O
concomitantly	O
by	O
patients	O
suffering	O
from	O
hypertension	O
;	O
this	O
phenomenon	O
was	O
not	O
observed	O
in	O
North	O
American	O
clinical	O
trials	O
.	O

A	O
study	O
in	O
eight	O
healthy	O
volunteers	O
has	O
shown	O
a	O
50	O
%	O
increase	O
in	O
mean	O
peak	O
nimodipine	B-Drug
plasma	O
concentrations	O
and	O
a	O
90	O
%	O
increase	O
in	O
mean	O
area	O
under	O
the	O
curve	O
,	O
after	O
a	O
one	O
week	O
course	O
of	O
cimetidine	B-Drug
at	O
1,000	O
mg/day	O
and	O
nimodipine	B-Drug
at	O
90	O
mg/day	O
.	O

This	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P-	O
450	O
by	O
cimetidine	B-Drug
,	O
which	O
could	O
decrease	O
first	O
pass	O
metabolism	O
of	O
nimodipine	B-Drug
.	O

A	O
30	O
to	O
45	O
%	O
increase	O
in	O
AUC	O
and	O
Cmax	O
of	O
nisoldipine	B-Drug
was	O
observed	O
with	O
concomitant	O
administration	O
of	O
cimetidine	B-Drug
400	I-Drug
mg	I-Drug
twice	O
daily	O
.	O

Ranitidine	B-Drug
150	O
mg	O
twice	O
daily	O
did	O
not	O
interact	O
significantly	O
with	O
nisoldipine	B-Drug
(	O
AUC	O
was	O
decreased	O
by	O
15-20	O
%	O
)	O
.	O

No	O
pharmacodynamic	O
effects	O
of	O
either	O
histamine	B-Drug
H2	O
receptor	O
antagonist	O
were	O
observed	O
.	O

Coadministration	O
of	O
phenytoin	B-Drug
with	O
40	O
mg	O
SULAR	B-Drug
tablets	O
in	O
epileptic	O
patients	O
lowered	O
the	O
nisoldipine	B-Drug
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Coadministration	O
of	O
SULAR	B-Drug
with	O
phenytoin	B-Drug
or	O
any	O
known	O
CYP3A4	B-Drug
inducer	O
should	O
be	O
avoided	O
and	O
alternative	O
antihypertensive	B-Drug
therapy	O
should	O
be	O
considered	O
.	O

Pharmacokinetic	O
interactions	O
between	O
nisoldipine	B-Drug
and	O
beta-blockers	O
(	O
atenolol	B-Drug
,	O
propranolol	B-Drug
)	O
were	O
variable	O
and	O
not	O
significant	O
.	O

Propranolol	B-Drug
attenuated	O
the	O
heart	O
rate	O
increase	O
following	O
administration	O
of	O
immediate	O
release	O
nisoldipine	B-Drug
.	O

The	O
blood	O
pressure	O
effect	O
of	O
SULAR	B-Drug
tended	O
to	O
be	O
greater	O
in	O
patients	O
on	O
atenolol	B-Drug
than	O
in	O
patients	O
on	O
no	O
other	O
antihypertensive	B-Drug
therapy	O
.	O

Quinidine	B-Drug
at	O
648	O
mg	O
bid	O
decreased	O
the	O
bioavailability	O
(	O
AUC	O
)	O
of	O
nisoldipine	B-Drug
by	O
26	O
%	O
,	O
but	O
not	O
the	O
peak	O
concentration	O
.	O

The	O
immediate	O
release	O
,	O
but	O
not	O
the	O
coat-core	O
formulation	O
of	O
nisoldipine	B-Drug
increased	O
plasma	O
quinidine	B-Drug
concentrations	O
by	O
about	O
20	O
%	O
.	O

This	O
interaction	O
was	O
not	O
accompanied	O
by	O
ECG	O
changes	O
and	O
its	O
clinical	O
significance	O
is	O
not	O
known	O
.	O

No	O
significant	O
interactions	O
were	O
found	O
between	O
nisoldipine	B-Drug
and	O
warfarin	B-Drug
or	O
digoxin	B-Drug
.	O

Tizoxanide	B-Drug
is	O
highly	O
bound	O
to	O
plasma	O
protein	O
(	O
99.9	O
%	O
)	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
nitazoxanide	B-Drug
concurrently	O
with	O
other	O
highly	O
plasma	O
protein-bound	O
drugs	B-Drug
with	O
narrow	O
therapeutic	O
indices	O
,	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
(	O
e.g.	O
,	O
warfarin	B-Drug
)	O
.	O

In	O
vitro	O
metabolism	O
studies	O
have	O
demonstrated	O
that	O
tizoxanide	B-Drug
has	O
no	O
significant	O
inhibitory	O
effect	O
on	O
cytochrome	O
P450	O
enzymes	O
.	O

Although	O
no	O
drug-drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
in	O
vivo	O
,	O
it	O
is	O
expected	O
that	O
no	O
significant	O
interaction	O
would	O
occur	O
when	O
nitazoxanide	B-Drug
is	O
co-administered	O
with	O
drugs	B-Drug
that	O
either	O
are	O
metabolized	O
by	O
or	O
inhibit	O
cytochrome	O
P450	O
enzymes	O
.	O

No	O
formal	O
drug-interaction	O
studies	O
have	O
been	O
performed	O
,	O
and	O
a	O
clinically	O
significant	O
interaction	O
with	O
other	O
medications	O
used	O
in	O
the	O
treatment	O
of	O
hypoxic	O
respiratory	O
failure	O
can	O
not	O
be	O
excluded	O
based	O
on	O
the	O
available	O
data	O
.	O

INOmax	B-Drug
has	O
been	O
administered	O
with	O
tolazoline	B-Drug
,	O
dopamine	B-Drug
,	O
dobutamine	B-Drug
,	O
steroids	O
,	O
surfactant	B-Drug
,	O
and	O
high-frequency	O
ventilation	O
.	O

Although	O
there	O
are	O
no	O
study	O
data	O
to	O
evaluate	O
the	O
possibility	O
,	O
nitric	O
oxide	O
donor	O
compounds	O
,	O
including	O
sodium	B-Drug
nitroprusside	I-Drug
and	O
nitroglycerin	B-Drug
,	O
may	O
have	O
an	O
additive	O
effect	O
with	O
INOmax	B-Drug
on	O
the	O
risk	O
of	O
developing	O
methemoglobinemia	O
.	O

An	O
association	O
between	O
prilocaine	B-Drug
and	O
an	O
increased	O
risk	O
of	O
methaemoglobinaemia	O
,	O
particularly	O
in	O
infants	O
,	O
has	O
specifically	O
been	O
described	O
in	O
a	O
literature	O
case	O
report	O
.	O

This	O
risk	O
is	O
present	O
whether	O
the	O
drugs	B-Drug
are	O
administered	O
as	O
oral	O
,	O
parenteral	O
,	O
or	O
topical	O
formulations	O
.	O

Antacids	O
containing	O
magnesium	B-Drug
trisilicate	I-Drug
,	O
when	O
administered	O
concomitantly	O
with	O
nitrofurantoin	B-Drug
,	O
reduce	O
both	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
.	O

The	O
mechanism	O
for	O
this	O
interaction	O
probably	O
is	O
adsorption	O
of	O
nitrofurantoin	B-Drug
onto	O
the	O
surface	O
of	O
magnesium	B-Drug
trisilicate	I-Drug
.	O

Uricosuric	O
drugs	B-Drug
,	O
such	O
as	O
probenecid	B-Drug
and	O
sulfinpyrazone	B-Drug
,	O
can	O
inhibit	O
renal	O
tubular	O
secretion	O
of	O
nitrofurantoin	B-Drug
.	O

The	O
resulting	O
increase	O
in	O
nitrofurantoin	B-Drug
serum	O
levels	O
may	O
increase	O
toxicity	O
,	O
and	O
the	O
decreased	O
urinary	O
levels	O
could	O
lessen	O
its	O
efficacy	O
as	O
a	O
urinary	O
tract	O
antibacterial	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
As	O
a	O
result	O
of	O
the	O
presence	O
of	O
nitrofurantoin	B-Drug
,	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
may	O
occur	O
.	O

This	O
has	O
been	O
observed	O
with	O
Benedict	O
s	O
and	O
Fehling	O
s	O
solutions	O
but	O
not	O
with	O
the	O
glucose	B-Drug
enzymatic	O
test	O
.	O

The	O
vasodilating	O
effects	O
of	O
nitroglycerin	B-Drug
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	O
.	O

Alcohol	B-Drug
,	O
in	O
particular	O
,	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O

Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B-Drug
channel	O
blockers	O
and	O
organic	O
nitrates	B-Drug
were	O
used	O
in	O
combination	O
.	O

Dose	O
adjustments	O
of	O
either	O
class	O
of	O
agents	O
may	O
be	O
necessary	O
.	O

The	O
hypotensive	O
effect	O
of	O
sodium	B-Drug
nitroprusside	I-Drug
is	O
augmented	O
by	O
that	O
of	O
most	O
other	O
hypotensive	O
drugs	B-Drug
,	O
including	O
ganglionic	O
blocking	O
agents	O
,	O
negative	O
inotropic	O
agents	O
,	O
and	O
inhaled	O
anesthetics	B-Drug
.	O

No	O
interactions	O
have	O
been	O
observed	O
between	O
nizatidine	B-Drug
and	O
theophylline	B-Drug
,	O
chlordiazepoxide	B-Drug
,	O
lorazepam	B-Drug
,	O
lidocaine	B-Drug
,	O
phenytoin	B-Drug
,	O
and	O
warfarin	B-Drug
.	O

Nizatidine	B-Drug
does	O
not	O
inhibit	O
the	O
cytochrome	O
P-450-linked	O
drug-metabolizing	O
enzyme	O
system	O
;	O
therefore	O
,	O
drug	B-Drug
interactions	O
mediated	O
by	O
inhibition	O
of	O
hepatic	O
metabolism	O
are	O
not	O
expected	O
to	O
occur	O
.	O

In	O
patients	O
given	O
very	O
high	O
doses	O
(	O
3900	O
mg	O
)	O
of	O
aspirin	B-Drug
daily	O
,	O
increases	O
in	O
serum	O
salicylate	B-Drug
levels	O
were	O
seen	O
when	O
nizatidine	B-Drug
,	O
150	O
mg	O
b.i.d.	O
,	O
was	O
administered	O
concurrently	O
.	O

The	O
effectiveness	O
of	O
progestin-only	O
pills	O
is	O
reduced	O
by	O
hepatic	O
enzyme-inducing	O
drugs	B-Drug
such	O
as	O
the	O
anticonvulsants	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
and	O
barbiturates	B-Drug
,	O
and	O
the	O
antituberculosis	O
drug	B-Drug
rifampin	B-Drug
.	O

No	O
significant	O
interaction	O
has	O
been	O
found	O
with	O
broad-spectrum	O
antibiotics	B-Drug
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	O
use	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline-related	B-Drug
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
norfloxacin	B-Drug
and	O
theophylline	B-Drug
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B-Drug
adjusted	O
as	O
required	O
.	O

Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-Drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B-Drug
with	O
norfloxacin	B-Drug
.	O

Therefore	O
,	O
cyclosporine	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	B-Drug
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	B-Drug
are	O
used	O
concomitantly	O
.	O

Quinolones	O
,	O
including	O
norfloxacin	B-Drug
,	O
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	B-Drug
,	O
including	O
warfarin	B-Drug
or	O
its	O
derivatives	O
or	O
similar	O
agents	O
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
closely	O
monitored	O
.	O

The	O
concomitant	O
administration	O
of	O
quinolones	O
including	O
norfloxacin	B-Drug
with	O
glyburide	B-Drug
(	O
a	O
sulfonylurea	B-Drug
agent	O
)	O
has	O
,	O
on	O
rare	O
occasions	O
,	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O

Therefore	O
,	O
monitoring	O
of	O
blood	O
glucose	B-Drug
is	O
recommended	O
when	O
these	O
agents	O
are	O
co-administered	O
.	O

Diminished	O
urinary	O
excretion	O
of	O
norfloxacin	B-Drug
has	O
been	O
reported	O
during	O
the	O
concomitant	O
administration	O
of	O
probenecid	B-Drug
and	O
norfloxacin	B-Drug
.	O

The	O
concomitant	O
use	O
of	O
nitrofurantoin	B-Drug
is	O
not	O
recommended	O
since	O
nitrofurantoin	B-Drug
may	O
antagonize	O
the	O
antibacterial	O
effect	O
of	O
Norfloxacin	B-Drug
in	O
the	O
urinary	O
tract	O
.	O

Multivitamins	O
,	O
or	O
other	O
products	O
containing	O
iron	B-Drug
or	O
zinc	B-Drug
,	O
antacids	O
or	O
sucralfate	B-Drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
,	O
or	O
within	O
2	O
hours	O
of	O
,	O
the	O
administration	O
of	O
norfloxacin	B-Drug
,	O
because	O
they	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	B-Drug
.	O

Videx	B-Drug
(	O
Didanosine	B-Drug
)	O
chewable/buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
,	O
or	O
within	O
2	O
hours	O
of	O
,	O
the	O
administration	O
of	O
norfloxacin	B-Drug
,	O
because	O
these	O
products	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	B-Drug
.	O

Some	O
quinolones	O
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-Drug
.	O

This	O
may	O
lead	B-Drug
to	O
reduced	O
clearance	O
of	O
caffeine	B-Drug
and	O
a	O
prolongation	O
of	O
its	O
plasma	O
half-life	O
.	O

Reduced	O
efficacy	O
and	O
increased	O
incidence	O
of	O
breakthrough	O
bleeding	O
and	O
menstrual	O
irregularities	O
have	O
been	O
associated	O
with	O
concomitant	O
use	O
of	O
rifampin	B-Drug
.	O

A	O
similar	O
association	O
,	O
though	O
less	O
marked	O
,	O
has	O
been	O
suggested	O
with	O
barbiturates	B-Drug
,	O
phenylbutazone	B-Drug
,	O
phenytoin	B-Drug
sodium	I-Drug
,	O
carbamazepine	B-Drug
,	O
griseofulvin	B-Drug
,	O
topiramate	B-Drug
,	O
and	O
possibly	O
with	O
ampicillin	B-Drug
and	O
tetracyclines	O
72	O
.	O

A	O
possible	O
interaction	O
has	O
been	O
suggested	O
with	O
hormonal	O
contraceptives	O
and	O
the	O
herbal	O
supplement	O
St.	O
Johns	O
Wort	O
based	O
on	O
some	O
reports	O
of	O
oral	O
contraceptive	O
users	O
experiencing	O
breakthrough	O
bleeding	O
shortly	O
after	O
starting	O
St.	O
Johns	O
Wort	O
.	O

Pregnancies	O
have	O
been	O
reported	O
by	O
users	O
of	O
combined	O
hormonal	O
contraceptives	O
who	O
also	O
used	O
some	O
form	O
of	O
St.	O
Johns	O
Wort	O
.	O

Healthcare	O
prescribers	O
are	O
advised	O
to	O
consult	O
the	O
package	O
inserts	O
of	O
medication	O
administered	O
concomitantly	O
with	O
oral	O
contraceptives	O
.	O

Steady-state	O
serum	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
are	O
reported	O
to	O
fluctuate	O
significantly	O
when	O
cimetidine	B-Drug
is	O
either	O
added	O
or	O
deleted	O
from	O
the	O
drug	B-Drug
regimen	O
.	O

Serious	O
anticholinergic	B-Drug
symptoms	O
(	O
severe	O
dry	O
mouth	O
,	O
urinary	O
retention	O
,	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	O
antidepressants	B-Drug
when	O
cimetidine	B-Drug
is	O
added	O
to	O
the	O
drug	B-Drug
regimen	O
.	O

In	O
addition	O
,	O
higher-than	O
expected	O
steady-state	O
serum	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
have	O
been	O
observed	O
when	O
therapy	O
is	O
initiated	O
in	O
patients	O
already	O
taking	O
cimetidine	B-Drug
.	O

In	O
well-controlled	O
patients	O
undergoing	O
concurrent	O
therapy	O
with	O
cimetidine	B-Drug
,	O
a	O
decrease	O
in	O
the	O
steady-state	O
serum	O
concentrations	O
of	O
tricyclic	O
antidepressants	B-Drug
may	O
occur	O
when	O
cime-tidine	O
therapy	O
is	O
discontinued	O
.	O

The	O
therapeutic	O
efficacy	O
of	O
tricyclic	O
antidepressants	B-Drug
may	O
be	O
compromised	O
in	O
these	O
patients	O
when	O
cimetidine	B-Drug
is	O
discontinued	O
.	O

Several	O
of	O
the	O
tricyclic	O
antidepressants	B-Drug
have	O
been	O
cited	O
in	O
these	O
reports	O
.	O

There	O
have	O
been	O
greater	O
than	O
2-fold	O
increases	O
in	O
previously	O
stable	O
plasma	O
levels	O
of	O
other	O
antidepressants	B-Drug
,	O
including	O
nortriptyline	B-Drug
,	O
when	O
fluoxetine	B-Drug
hydrochloride	I-Drug
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O

Oxcarbazepine	B-Drug
can	O
inhibit	O
CYP2C19	O
and	O
induce	O
CYP3A4/5	O
with	O
potentially	O
important	O
effects	O
on	O
plasma	O
concentrations	O
of	O
other	O
drugs	B-Drug
.	O

In	O
addition	O
,	O
several	O
AED	O
s	O
that	O
are	O
cytochrome	O
P450	O
inducers	O
can	O
decrease	O
plasma	O
concentrations	O
of	O
oxcarbazepine	B-Drug
and	O
MHD	B-Drug
.	O

Oxcarbazepine	B-Drug
was	O
evaluated	O
in	O
human	O
liver	O
microsomes	O
to	O
determine	O
its	O
capacity	O
to	O
inhibit	O
the	O
major	O
cytochrome	O
P450	O
enzymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
other	O
drugs	B-Drug
.	O

Results	O
demonstrate	O
that	O
oxcarbazepine	B-Drug
and	O
its	O
pharmacologically	O
active	O
10-monohydroxy	O
metabolite	O
(	O
MHD	B-Drug
)	O
have	O
little	O
or	O
no	O
capacity	O
to	O
function	O
as	O
inhibitors	O
for	O
most	O
of	O
the	O
human	O
cytochrome	O
P450	O
enzymes	O
evaluated	O
(	O
CYP1A2	B-Drug
,	O
CYP2A6	O
,	O
CYP2C9	B-Drug
,	O
CYP2D6	B-Drug
,	O
CYP2E1	O
,	O
CYP4A9	O
and	O
CYP4A11	O
)	O
with	O
the	O
exception	O
of	O
CYP2C19	O
and	O
CYP3A4/5	O
.	O

Although	O
inhibition	O
of	O
CYP	O
3A4/5	O
by	O
OXC	B-Drug
and	O
MHD	B-Drug
did	O
occur	O
at	O
high	O
concentrations	O
,	O
it	O
is	O
not	O
likely	O
to	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
inhibition	O
of	O
CYP-2C19	O
by	O
OXC	B-Drug
and	O
MHD	B-Drug
,	O
however	O
,	O
is	O
clinically	O
relevant	O
.	O

In	O
vitro	O
,	O
the	O
UDP-glucuronyl	O
transferase	O
level	O
was	O
increased	O
,	O
indicating	O
induction	O
of	O
this	O
enzyme	O
.	O

Increases	O
of	O
22	O
%	O
with	O
MHD	B-Drug
and	O
47	O
%	O
with	O
oxcarbazepine	B-Drug
were	O
observed	O
.	O

As	O
MHD	B-Drug
,	O
the	O
predominant	O
plasma	O
substrate	O
,	O
is	O
only	O
a	O
weak	O
inducer	O
of	O
UDP-glucuronyl	O
transferase	O
,	O
it	O
is	O
unlikely	O
to	O
have	O
an	O
effect	O
on	O
drugs	B-Drug
that	O
are	O
mainly	O
eliminated	O
by	O
conjugation	O
through	O
UDP-glucuronyl	O
transferase	O
(	O
e.g.	O
,	O
valproic	B-Drug
acid	I-Drug
,	O
lamotrigine	B-Drug
)	O
.	O

In	O
addition	O
,	O
oxcarbazepine	B-Drug
and	O
MHD	B-Drug
induce	O
a	O
subgroup	O
of	O
the	O
cytochrome	O
P450	O
3A	O
family	O
(	O
CYP3A4	B-Drug
and	O
CYP3A5	O
)	O
responsible	O
for	O
the	O
metabolism	O
of	O
dihydropyridine	O
calcium	B-Drug
antagonists	O
and	O
oral	O
contraceptives	O
,	O
resulting	O
in	O
a	O
lower	O
plasma	O
concentration	O
of	O
these	O
drugs	B-Drug
.	O

As	O
binding	O
of	O
MHD	B-Drug
to	O
plasma	O
proteins	O
is	O
low	O
(	O
40	O
%	O
)	O
,	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	B-Drug
through	O
competition	O
for	O
protein	O
binding	O
sites	O
are	O
unlikely	O
.	O

Antiepileptic	O
drugs	B-Drug
:	O
Potential	O
interactions	O
between	O
Trileptal	B-Drug
and	O
other	O
AEDs	O
were	O
assessed	O
in	O
clinical	O
studies	O
.	O

The	O
effect	O
of	O
these	O
interactions	O
on	O
mean	O
AUCs	O
and	O
Cmin	O
are	O
summarized	O
in	O
Table	O
2	O
:	O
Table	O
2	O
:	O
Summary	O
of	O
AED	O
interactions	O
with	O
Trileptal	B-Drug
AED	O
Co-administered	O
Dose	O
of	O
AED	O
(	O
mg/day	O
)	O
Trileptal	B-Drug
dose	O
(	O
mg/day	O
)	O
Influence	O
of	O
Trileptal	B-Drug
on	O
AED	O
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O
Influence	O
of	O
AED	O
On	O
MHD	B-Drug
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O
Carbamazepine	B-Drug
400-2000	O
900	O
nc1	O
40	O
%	O
decrease	O
[	O
CI	O
:	O
17	O
%	O
decrease	O
,	O
57	O
%	O
decrease	O
]	O
Phenobarbital	B-Drug
100-150	O
600-1800	O
14	O
%	O
increase	O
[	O
CI	O
:	O
2	O
%	O
increase	O
,	O
24	O
%	O
increase	O
]	O
25	O
%	O
decrease	O
[	O
CI	O
:	O
12	O
%	O
decrease	O
,	O
51	O
%	O
decrease	O
]	O
Phenytoin	B-Drug
250-500	O
600-1800	O
nc1,2	O
30	O
%	O
decrease	O
[	O
CI	O
:	O
3	O
%	O
decrease	O
,	O
48	O
%	O
decrease	O
]	O
1200-2400	O
up	O
to	O
40	O
%	O
increase3	O
[	O
CI	O
:	O
12	O
%	O
increase	O
,	O
60	O
%	O
increase	O
]	O
Valproic	B-Drug
acid	I-Drug
400-2800	O
600-1800	O
nc1	O
18	O
%	O
decrease	O
[	O
CI	O
:	O
13	O
%	O
decrease	O
,	O
40	O
%	O
decrease	O
]	O
1-	O
nc	O
denotes	O
a	O
mean	O
change	O
of	O
less	O
than	O
10	O
%	O
2-	O
Pediatrics	O
3-	O
Mean	O
increase	O
in	O
adults	O
at	O
high	O
Trileptal	B-Drug
doses	O
In	O
vivo	O
,	O
the	O
plasma	O
levels	O
of	O
phenytoin	B-Drug
increased	O
by	O
up	O
to	O
40	O
%	O
,	O
when	O
Trileptal	B-Drug
was	O
given	O
at	O
doses	O
above	O
1200	O
mg/day	O
.	O

Therefore	O
,	O
when	O
using	O
doses	O
of	O
Trileptal	B-Drug
greater	O
than	O
1200	O
mg/day	O
during	O
adjunctive	O
therapy	O
,	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
phenytoin	B-Drug
may	O
be	O
required	O
.	O

The	O
increase	O
of	O
phenobarbital	B-Drug
level	O
,	O
however	O
,	O
is	O
small	O
(	O
15	O
%	O
)	O
when	O
given	O
with	O
Trileptal	B-Drug
.	O

Strong	O
inducers	O
of	O
cytochrome	O
P450	O
enzymes	O
(	O
i.e	O
.	O

carbamazepine	B-Drug
,	O
phenytoin	B-Drug
and	O
phenobarbital	B-Drug
)	O
have	O
been	O
shown	O
to	O
decrease	O
the	O
plasma	O
levels	O
of	O
MHD	B-Drug
(	O
29-40	O
%	O
)	O
.	O

No	O
autoinduction	O
has	O
been	O
observed	O
with	O
Trileptal	B-Drug
.	O

Hormonal	O
contraceptives	O
Co-administration	O
of	O
Trileptal	B-Drug
with	O
an	O
oral	O
contraceptive	O
has	O
been	O
shown	O
to	O
influence	O
the	O
plasma	O
concentrations	O
of	O
the	O
two	O
hormonal	O
components	O
,	O
ethinylestradiol	B-Drug
(	O
EE	O
)	O
and	O
levonorgestrel	B-Drug
(	O
LNG	O
)	O
.	O

The	O
mean	O
AUC	O
values	O
of	O
EE	O
were	O
decreased	O
by	O
48	O
%	O
[	O
90	O
%	O
CI	O
:	O
22-65	O
]	O
in	O
one	O
study	O
and	O
52	O
%	O
[	O
90	O
%	O
CI	O
:	O
38-52	O
]	O
in	O
another	O
study	O
[	O
1,2	O
]	O
.	O

The	O
mean	O
AUC	O
values	O
of	O
LNG	O
were	O
decreased	O
by	O
32	O
%	O
[	O
90	O
%	O
CI	O
:	O
20-45	O
]	O
in	O
one	O
study	O
and	O
52	O
%	O
[	O
90	O
%	O
CI	O
:	O
42-52	O
]	O
in	O
another	O
study	O
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
Trileptal	B-Drug
with	O
hormonal	O
contraceptives	O
may	O
render	O
these	O
contraceptives	O
less	O
effective	O
.	O

Studies	O
with	O
other	O
oral	O
or	O
implant	O
contraceptives	O
have	O
not	O
been	O
conducted	O
.	O

Calcium	B-Drug
Antagonists	O
:	O
After	O
repeated	O
co-administration	O
of	O
Trileptal	B-Drug
,	O
the	O
AUC	O
of	O
felodipine	B-Drug
was	O
lowered	O
by	O
28	O
%	O
[	O
90	O
%	O
CI	O
:	O
20-33	O
]	O
.	O

Verapamil	B-Drug
produced	O
a	O
decrease	O
of	O
20	O
%	O
[	O
90	O
%	O
CI	O
:	O
18-27	O
]	O
of	O
the	O
plasma	O
levels	O
of	O
MHD	B-Drug
.	O

Other	O
drug	B-Drug
interactions	O
Cimetidine	B-Drug
,	O
erythromycin	B-Drug
and	O
dextropropoxyphene	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
MHD	B-Drug
.	O

Results	O
with	O
warfarin	B-Drug
wshow	O
no	O
evidence	O
of	O
interaction	O
with	O
either	O
single	O
or	O
repeated	O
doses	O
of	O
Trileptal	B-Drug
.	O

In	O
a	O
Phase	O
I	O
trial	O
using	O
escalating	O
doses	O
of	O
TAXOL	B-Drug
(	O
110-200	O
mg/m2	O
)	O
and	O
cisplatin	B-Drug
(	O
50	O
or	O
75	O
mg/m2	O
)	O
given	O
as	O
sequential	O
infusions	O
,	O
myelosuppression	O
was	O
more	O
profound	O
when	O
TAXOL	B-Drug
was	O
given	O
after	O
cisplatin	B-Drug
than	O
with	O
the	O
alternate	O
sequence	O
(	O
ie	O
,	O
TAXOL	B-Drug
before	O
cisplatin	B-Drug
)	O
.	O

Pharmacokinetic	O
data	O
from	O
these	O
patients	O
demonstrated	O
a	O
decrease	O
in	O
paclitaxel	B-Drug
clearance	O
of	O
approximately	O
33	O
%	O
when	O
TAXOL	B-Drug
was	O
administered	O
following	O
cisplatin	B-Drug
.	O

The	O
metabolism	O
of	O
TAXOL	B-Drug
is	O
catalyzed	O
by	O
cytochrome	O
P450	O
isoen-zymes	O
CYP2C8	O
and	O
CYP3A4	B-Drug
.	O

In	O
the	O
absence	O
of	O
formal	O
clinical	O
drug	B-Drug
interaction	O
studies	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	B-Drug
concomitantly	O
with	O
known	O
substrates	O
or	O
inhibitors	O
of	O
the	O
cytochrome	O
P450	O
isoenzymes	O
CYP2C8	O
and	O
CYP3A4	B-Drug
.	O

Potential	O
interactions	O
between	O
TAXOL	B-Drug
,	O
a	O
substrate	O
of	O
CYP3A4	B-Drug
,	O
and	O
protease	O
inhibitors	O
(	O
ritonavir	B-Drug
,	O
saquinavir	B-Drug
,	O
indinavir	B-Drug
,	O
and	O
nelfinavir	B-Drug
)	O
,	O
which	O
are	O
substrates	O
and/or	O
inhibitors	O
of	O
CYP3A4	B-Drug
,	O
have	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	O
.	O

Reports	O
in	O
the	O
literature	O
suggest	O
that	O
plasma	O
levels	O
of	O
doxorubicin	B-Drug
(	O
and	O
its	O
active	O
metabolite	O
doxorubicinol	B-Drug
)	O
may	O
be	O
increased	O
when	O
paclitaxel	B-Drug
and	O
doxorubicin	B-Drug
are	O
used	O
in	O
combination	O
.	O

Hematology	O
:	O
TAXOL	B-Drug
therapy	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
baseline	O
neutrophil	O
counts	O
of	O
less	O
than	O
1,500	O
cells/mm3	O
.	O

In	O
order	O
to	O
monitor	O
the	O
occurrence	O
of	O
myelotoxicity	O
,	O
it	O
is	O
recommended	O
that	O
frequent	O
peripheral	O
blood	O
cell	O
counts	O
be	O
performed	O
on	O
all	O
patients	O
receiving	O
TAXOL	B-Drug
.	O

Patients	O
should	O
not	O
be	O
re-treated	O
with	O
subsequent	O
cycles	O
of	O
TAXOL	B-Drug
until	O
neutrophils	O
recover	O
to	O
a	O
level	O
1500	O
cells/mm3	O
and	O
platelets	O
recover	O
to	O
a	O
level	O
100,000	O
cells/mm3	O
.	O

In	O
the	O
case	O
of	O
severe	O
neutropenia	O
(	O
500	O
cells/mm3	O
for	O
seven	O
days	O
or	O
more	O
)	O
during	O
a	O
course	O
of	O
TAXOL	B-Drug
therapy	O
,	O
a	O
20	O
%	O
reduction	O
in	O
dose	O
for	O
subsequent	O
courses	O
of	O
therapy	O
is	O
recommended	O
.	O

For	O
patients	O
with	O
advanced	O
HIV	O
disease	O
and	O
poor-risk	O
AIDS-related	O
Kaposi	O
s	O
sarcoma	O
,	O
TAXOL	B-Drug
,	O
at	O
the	O
recommended	O
dose	O
for	O
this	O
disease	O
,	O
can	O
be	O
initiated	O
and	O
repeated	O
if	O
the	O
neutrophil	O
count	O
is	O
at	O
least	O
1000	O
cells/mm3	O
.	O

Hypersensitivity	O
Reactions	O
:	O
Patients	O
with	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
products	O
containing	O
Cremophor	O
EL	O
(	O
eg	O
,	O
cyclosporin	B-Drug
for	O
injection	O
concentrate	O
and	O
teniposide	B-Drug
for	O
injection	O
concentrate	O
)	O
should	O
not	O
be	O
treated	O
with	O
TAXOL	B-Drug
.	O

In	O
order	O
to	O
avoid	O
the	O
occurrence	O
of	O
severe	O
hypersensitivity	O
reactions	O
,	O
all	O
patients	O
treated	O
with	O
TAXOL	B-Drug
should	O
be	O
premedicated	O
with	O
corticosteroids	O
(	O
such	O
as	O
dexamethasone	B-Drug
)	O
,	O
diphen-hydramine	O
and	O
H2	O
antagonists	O
(	O
such	O
as	O
cimetidine	B-Drug
or	O
ranitidine	B-Drug
)	O
.	O

Minor	O
symptoms	O
such	O
as	O
flushing	O
,	O
skin	O
reactions	O
,	O
dyspnea	O
,	O
hypotension	O
,	O
or	O
tachycardia	O
do	O
not	O
require	O
interruption	O
of	O
therapy	O
.	O

However	O
,	O
severe	O
reactions	O
,	O
such	O
as	O
hypotension	O
requiring	O
treatment	O
,	O
dyspnea	O
requiring	O
bronchodilators	O
,	O
angioedema	O
,	O
or	O
generalized	O
urticaria	O
require	O
immediate	O
discontinuation	O
of	O
TAXOL	B-Drug
and	O
aggressive	O
symptomatic	O
therapy	O
.	O

Patients	O
who	O
have	O
developed	O
severe	O
hypersensitivity	O
reactions	O
should	O
not	O
be	O
rechallenged	O
with	O
TAXOL	B-Drug
.	O

Cardiovascular	O
:	O
Hypotension	O
,	O
bradycardia	O
,	O
and	O
hypertension	O
have	O
been	O
observed	O
during	O
administration	O
of	O
TAXOL	B-Drug
,	O
but	O
generally	O
do	O
not	O
require	O
treatment	O
.	O

Occasionally	O
TAXOL	B-Drug
infusions	O
must	O
be	O
interrupted	O
or	O
discontinued	O
because	O
of	O
initial	O
or	O
recurrent	O
hypertension	O
.	O

Frequent	O
vital	O
sign	O
monitoring	O
,	O
particularly	O
during	O
the	O
first	O
hour	O
of	O
TAXOL	B-Drug
infusion	O
,	O
is	O
recommended	O
.	O

Continuous	O
cardiac	O
monitoring	O
is	O
not	O
required	O
except	O
for	O
patients	O
with	O
serious	O
conduction	O
abnormalities	O
.	O

Nervous	O
System	O
:	O
Although	O
the	O
occurrence	O
of	O
peripheral	O
neuropathy	O
is	O
frequent	O
,	O
the	O
development	O
of	O
severe	O
symptomatology	O
is	O
unusual	O
and	O
requires	O
a	O
dose	O
reduction	O
of	O
20	O
%	O
for	O
all	O
subsequentcourses	O
of	O
TAXOL	B-Drug
.	O

TAXOL	B-Drug
contains	O
dehydrated	O
alcohol	B-Drug
USP	O
,	O
396	O
mg/mL	O
;	O
consideration	O
should	O
be	O
given	O
to	O
possible	O
CNS	O
and	O
other	O
effects	O
of	O
alcohol	B-Drug
.	O

Hepatic	O
:	O
There	O
is	O
limited	O
evidence	O
that	O
the	O
myelotoxicity	O
of	O
TAXOL	B-Drug
may	O
be	O
exacerbated	O
in	O
patients	O
with	O
serum	O
total	O
bilirubin	O
2	O
times	O
ULN	O
.	O

Extreme	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	B-Drug
to	O
such	O
patients	O
,	O
with	O
dose	O
reduction	O
as	O
recommended	O
in	O
DOSAGE	O
AND	O
ADMINISTRATION	O
,	O
Table	O
17	O
.	O

InjectionSite	O
Reaction	O
:	O
Injection	O
site	O
reactions	O
,	O
including	O
reactions	O
secondary	O
to	O
extravasation	O
,	O
were	O
usually	O
mild	O
and	O
consisted	O
of	O
erythema	O
,	O
tenderness	O
,	O
skin	O
discoloration	O
,	O
or	O
swelling	O
at	O
the	O
injection	O
site	O
.	O

These	O
reactions	O
have	O
been	O
observed	O
more	O
frequently	O
with	O
the	O
24-hour	O
infusion	O
than	O
with	O
the	O
3-hour	O
infusion	O
.	O

Recurrence	O
of	O
skin	O
reactions	O
at	O
a	O
site	O
of	O
previous	O
extravasation	O
following	O
administration	O
of	O
TAXOL	B-Drug
at	O
a	O
different	O
site	O
,	O
ie	O
,	O
recall	O
,	O
has	O
been	O
reported	O
rarely	O
.	O

Rare	O
reports	O
of	O
more	O
severe	O
events	O
such	O
as	O
phlebitis	O
,	O
cellulitis	O
,	O
induration	O
,	O
skin	O
exfoliation	O
,	O
necrosis	O
,	O
and	O
fibrosis	O
have	O
been	O
received	O
as	O
part	O
of	O
the	O
continuing	O
surveillance	O
of	O
TAXOL	B-Drug
safety	O
.	O

In	O
some	O
cases	O
the	O
onset	O
of	O
the	O
injection	O
site	O
reaction	O
either	O
occurred	O
during	O
a	O
prolonged	O
infusion	O
or	O
was	O
delayed	O
by	O
a	O
week	O
to	O
ten	O
days	O
.	O

A	O
specific	O
treatment	O
for	O
extravasation	O
reactions	O
is	O
unknown	O
at	O
this	O
time	O
.	O

Given	O
the	O
possibility	O
of	O
extravasation	O
,	O
it	O
is	O
advisable	O
to	O
closely	O
monitor	O
the	O
infusion	O
site	O
for	O
possible	O
infiltration	O
during	O
drug	B-Drug
administration	O
.	O

Treatment	O
with	O
PEGASYS	B-Drug
once	O
weekly	O
for	O
4	O
weeks	O
in	O
healthy	O
subjects	O
was	O
associated	O
with	O
an	O
inhibition	O
of	O
P450	O
1A2	O
and	O
a	O
25	O
%	O
increase	O
in	O
theophylline	B-Drug
AUC	O
.	O

Theophylline	B-Drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
dose	O
adjustments	O
considered	O
for	O
patients	O
given	O
both	O
theophylline	B-Drug
and	O
PEGASYS	B-Drug
.	O

There	O
was	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
representative	O
drugs	B-Drug
metabolized	O
by	O
CYP	O
2C9	O
,	O
CYP	O
2C19	O
,	O
CYP	O
2D6	O
or	O
CYP	O
3A4	O
.	O

In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
treated	O
with	O
PEGASYS	B-Drug
in	O
combination	O
with	O
COPEGUS	B-Drug
,	O
PEGASYS	B-Drug
treatment	O
did	O
not	O
affect	O
ribavirin	B-Drug
distribution	O
or	O
clearance	O
.	O

Nucleoside	O
Analogues	O
Didanosine	B-Drug
Co-administration	O
of	O
COPEGUS	B-Drug
and	O
didanosine	B-Drug
is	O
not	O
recommended	O
.	O

Reports	O
of	O
fatal	O
hepatic	O
failure	O
,	O
as	O
well	O
as	O
peripheral	O
neuropathy	O
,	O
pancreatitis	O
,	O
and	O
symptomatic	O
hyperlactatemia/lactic	O
acidosis	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O

Stavudine	B-Drug
and	O
Zidovudine	B-Drug
Ribavirin	B-Drug
can	O
antagonize	O
the	O
in	O
vitro	O
antiviral	O
activity	O
of	O
stavudine	B-Drug
and	O
zidovudine	B-Drug
against	O
HIV	O
.	O

Therefore	O
,	O
concomitant	O
use	O
of	O
ribavirin	B-Drug
with	O
either	O
of	O
these	O
drugs	B-Drug
should	O
be	O
avoided	O
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
Impairment	O
of	O
Fertility	O
Carcinogenesis	O
PEGASYS	B-Drug
has	O
not	O
been	O
tested	O
for	O
its	O
carcinogenic	O
potential	O
.	O

Mutagenesis	O
PEGASYS	B-Drug
did	O
not	O
cause	O
DNA	O
damage	O
when	O
tested	O
in	O
the	O
Ames	O
bacterial	O
mutagenicity	O
assay	O
and	O
in	O
the	O
in	O
vitro	O
chromosomal	O
aberration	O
assay	O
in	O
human	O
lymphocytes	O
,	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
metabolic	O
activation	O
.	O

Use	O
With	O
Ribavirin	B-Drug
Ribavirin	B-Drug
is	O
genotoxic	O
and	O
mutagenic	O
.	O

The	O
carcinogenic	O
potential	O
of	O
ribavirin	B-Drug
has	O
not	O
been	O
fully	O
determined	O
.	O

In	O
a	O
p53	O
(	O
+/-	O
)	O
mouse	O
carcinogenicity	O
study	O
at	O
doses	O
up	O
to	O
the	O
maximum	O
tolerated	O
dose	O
of	O
100	O
mg/kg/day	O
ribavirin	B-Drug
was	O
not	O
oncogenic	O
.	O

However	O
,	O
on	O
a	O
body	O
surface	O
area	O
basis	O
,	O
this	O
dose	O
was	O
0.5	O
times	O
maximum	O
recommended	O
human	O
24-hour	O
dose	O
of	O
ribavirin	B-Drug
.	O

A	O
study	O
in	O
rats	O
to	O
assess	O
the	O
carcinogenic	O
potential	O
of	O
ribavirin	B-Drug
is	O
ongoing	O
.	O

Mutagenesis	O
Impairment	O
of	O
Fertility	O
PEGASYS	B-Drug
may	O
impair	O
fertility	O
in	O
women	O
.	O

Prolonged	O
menstrual	O
cycles	O
and/or	O
amenorrhea	O
were	O
observed	O
in	O
female	O
cynomolgus	O
monkeys	O
given	O
sc	O
injections	O
of	O
600	O
m	O
g/kg/dose	O
(	O
7200	O
m	O
g/m2/dose	O
)	O
of	O
PEGASYS	B-Drug
every	O
other	O
day	O
for	O
one	O
month	O
,	O
at	O
approximately	O
180	O
times	O
the	O
recommended	O
weekly	O
human	O
dose	O
for	O
a	O
60	O
kg	O
person	O
(	O
based	O
on	O
body	O
surface	O
area	O
)	O
.	O

Menstrual	O
cycle	O
irregularities	O
were	O
accompanied	O
by	O
both	O
a	O
decrease	O
and	O
delay	O
in	O
the	O
peak	O
17b	O
-estradiol	O
and	O
progesterone	B-Drug
levels	O
following	O
administration	O
of	O
PEGASYS	B-Drug
to	O
female	O
monkeys	O
.	O

A	O
return	O
to	O
normal	O
menstrual	O
rhythm	O
followed	O
cessation	O
of	O
treatment	O
.	O

Every	O
other	O
day	O
dosing	O
with	O
100m	O
g/kg	O
(	O
1200m	O
g/m2	O
)	O
PEGASYS	B-Drug
(	O
equivalent	O
to	O
approximately	O
30	O
times	O
the	O
recommended	O
human	O
dose	O
)	O
had	O
no	O
effects	O
on	O
cycle	O
duration	O
or	O
reproductive	O
hormone	O
status	O
.	O

The	O
effects	O
of	O
PEGASYS	B-Drug
on	O
male	O
fertility	O
have	O
not	O
been	O
studied	O
.	O

However	O
,	O
no	O
adverse	O
effects	O
on	O
fertility	O
were	O
observed	O
in	O
male	O
Rhesus	O
monkeys	O
treated	O
with	O
non-pegylated	B-Drug
interferon	I-Drug
alfa-2a	I-Drug
for	O
5	O
months	O
at	O
doses	O
up	O
to	O
25	O
x	O
106	O
IU/kg/day	O
.	O

Pregnancy	O
Pregnancy	O
:	O
Category	O
C	O
PEGASYS	B-Drug
has	O
not	O
been	O
studied	O
for	O
its	O
teratogenic	O
effect	O
.	O

Non-pegylated	B-Drug
interferon	I-Drug
alfa-2a	I-Drug
treatment	O
of	O
pregnant	O
Rhesus	O
monkeys	O
at	O
approximately	O
20	O
to	O
500	O
times	O
the	O
human	O
weekly	O
dose	O
resulted	O
in	O
a	O
statistically	O
significant	O
increase	O
in	O
abortions	O
.	O

No	O
teratogenic	O
effects	O
were	O
seen	O
in	O
the	O
offspring	O
delivered	O
at	O
term	O
.	O

PEGASYS	B-Drug
should	O
be	O
assumed	O
to	O
have	O
abortifacient	O
potential	O
.	O

There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
PEGASYS	B-Drug
in	O
pregnant	O
women	O
.	O

PEGASYS	B-Drug
is	O
to	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
the	O
potential	O
benefit	O
justifies	O
the	O
potential	O
risk	O
to	O
the	O
fetus	O
.	O

PEGASYS	B-Drug
is	O
recommended	O
for	O
use	O
in	O
women	O
of	O
childbearing	O
potential	O
only	O
when	O
they	O
are	O
using	O
effective	O
contraception	O
during	O
therapy	O
.	O

Pregnancy	O
:	O
Category	O
X	O
:	O
Use	O
With	O
Ribavirin	B-Drug
(	O
see	O
CONTRAINDICATIONS	O
)	O
Significant	O
teratogenic	O
and/or	O
embryocidal	O
effects	O
have	O
been	O
demonstrated	O
in	O
all	O
animal	O
species	O
exposed	O
to	O
ribavirin	B-Drug
.	O

COPEGUS	B-Drug
therapy	O
is	O
contraindicated	O
in	O
women	O
who	O
are	O
pregnant	O
and	O
in	O
the	O
male	O
partners	O
of	O
women	O
who	O
are	O
pregnant	O
.	O

If	O
pregnancy	O
occurs	O
in	O
a	O
patient	O
or	O
partner	O
of	O
a	O
patient	O
during	O
treatment	O
or	O
during	O
the	O
6	O
months	O
after	O
treatment	O
cessation	O
,	O
such	O
cases	O
should	O
be	O
reported	O
to	O
the	O
COPEGUS	B-Drug
Pregnancy	O
Registry	O
at	O
1-800-526-6367	O
.	O

Nursing	O
Mothers	O
It	O
is	O
not	O
known	O
whether	O
peginterferon	B-Drug
or	O
ribavirin	B-Drug
or	O
its	O
components	O
are	O
excreted	O
in	O
human	O
milk	O
.	O

The	O
effect	O
of	O
orally	O
ingested	O
peginterferon	B-Drug
or	O
ribavirin	B-Drug
from	O
breast	O
milk	O
on	O
the	O
nursing	O
infant	O
has	O
not	O
been	O
evaluated	O
.	O

Because	O
of	O
the	O
potential	O
for	O
adverse	O
reactions	O
from	O
the	O
drugs	B-Drug
in	O
nursing	O
infants	O
,	O
a	O
decision	O
must	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
or	O
discontinue	O
PEGASYS	B-Drug
and	O
COPEGUS	B-Drug
treatment	O
.	O

Pediatric	O
Use	O
The	O
safety	O
and	O
effectiveness	O
of	O
PEGASYS	B-Drug
,	O
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	B-Drug
in	O
patients	O
below	O
the	O
age	O
of	O
18	O
years	O
have	O
not	O
been	O
established	O
.	O

PEGASYS	B-Drug
contains	O
benzyl	B-Drug
alcohol	I-Drug
.	O

Benzyl	B-Drug
alcohol	I-Drug
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
neurological	O
and	O
other	O
complications	O
in	O
neonates	O
and	O
infants	O
,	O
which	O
are	O
sometimes	O
fatal	O
.	O

Geriatric	O
Use	O
Younger	O
patients	O
have	O
higher	O
virologic	O
response	O
rates	O
than	O
older	O
patients	O
.	O

Clinical	O
studies	O
of	O
PEGASYS	B-Drug
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	B-Drug
did	O
not	O
include	O
sufficient	O
numbers	O
of	O
subjects	O
aged	O
65	O
or	O
over	O
to	O
determine	O
whether	O
they	O
respond	O
differently	O
from	O
younger	O
subjects	O
.	O

Adverse	O
reactions	O
related	O
to	O
alpha	B-Drug
interferons	I-Drug
,	O
such	O
as	O
CNS	O
,	O
cardiac	O
,	O
and	O
systemic	O
(	O
eg	O
,	O
flu-like	O
)	O
effects	O
may	O
be	O
more	O
severe	O
in	O
the	O
elderly	O
and	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
use	O
of	O
PEGASYS	B-Drug
in	O
this	O
population	O
.	O

PEGASYS	B-Drug
and	O
COPEGUS	B-Drug
are	O
excreted	O
by	O
the	O
kidney	O
,	O
and	O
the	O
risk	O
of	O
toxic	O
reactions	O
to	O
this	O
therapy	O
may	O
be	O
greater	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O

Because	O
elderly	O
patients	O
are	O
more	O
likely	O
to	O
have	O
decreased	O
renal	O
function	O
,	O
care	O
should	O
be	O
taken	O
in	O
dose	O
selection	O
and	O
it	O
may	O
be	O
useful	O
to	O
monitor	O
renal	O
function	O
.	O

PEGASYS	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
creatinine	O
clearance	O
50	O
mL/min	O
and	O
COPEGUS	B-Drug
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
creatinine	O
clearance	O
50	O
mL/min	O
.	O

Aminoglycosides	O
:	O
The	O
mixing	O
of	O
piperacillin	B-Drug
with	O
an	O
aminoglycoside	O
in	O
vitro	O
can	O
result	O
in	O
substantial	O
inactivation	O
of	O
the	O
aminoglycoside	O
.	O

Vecuronium	B-Drug
:	O
When	O
used	O
in	O
the	O
perioperative	O
period	O
,	O
piperacillin	B-Drug
has	O
been	O
implicated	O
in	O
the	O
prolongation	O
of	O
the	O
neuromuscular	O
blockade	O
of	O
vecuronium	B-Drug
.	O

Caution	O
is	O
indicated	O
when	O
piperacillin	B-Drug
is	O
used	O
perioperatively	O
.	O

In	O
one	O
controlled	O
clinical	O
study	O
,	O
the	O
ureidopenicillins	O
,	O
including	O
piperacillin	B-Drug
,	O
were	O
reported	O
to	O
prolong	O
the	O
action	O
of	O
vecuronium	B-Drug
.	O

Due	O
to	O
their	O
similar	O
mechanism	O
of	O
action	O
,	O
it	O
is	O
expected	O
that	O
the	O
neuromuscular	O
blockade	O
produced	O
by	O
any	O
of	O
the	O
non-depolarizing	O
muscle	O
relaxants	O
could	O
be	O
prolonged	O
in	O
the	O
presence	O
of	O
piperacillin	B-Drug
.	O

Probenecid	B-Drug
:	O
The	O
oral	O
combination	O
of	O
probenecid	B-Drug
before	O
intramuscular	O
injection	O
of	O
PIPRACIL	B-Drug
produces	O
an	O
increase	O
in	O
piperacillin	B-Drug
peak	O
serum	O
level	O
of	O
about	O
30	O
%	O
.	O

Anticoagulants	B-Drug
:	O
Coagulation	O
parameters	O
should	O
be	O
tested	O
more	O
frequently	O
and	O
monitored	O
regularly	O
during	O
simultaneous	O
administration	O
of	O
high	O
doses	O
of	O
heparin	B-Drug
,	O
oral	O
anticoagulants	B-Drug
,	O
or	O
other	O
drugs	B-Drug
that	O
may	O
affect	O
the	O
blood	O
coagulation	O
system	O
or	O
the	O
thrombocyte	O
function	O
.	O

Methotrexate	B-Drug
:	O
Piperacillin	B-Drug
sodium	I-Drug
may	O
reduce	O
the	O
excretion	O
of	O
methotrexate	B-Drug
.	O

Therefore	O
,	O
serum	O
levels	O
of	O
methotrexate	B-Drug
should	O
be	O
monitored	O
in	O
patients	O
to	O
avoid	O
drug	B-Drug
toxicity	O
.	O

Drug/Laboratory	O
Test	O
Interactions	O
As	O
with	O
other	O
penicillins	B-Drug
,	O
the	O
administration	O
of	O
PIPRACIL	B-Drug
may	O
result	O
in	O
a	O
false-positive	O
reaction	O
for	O
glucose	B-Drug
in	O
the	O
urine	O
using	O
a	O
copper-reduction	O
method	O
.	O

It	O
is	O
recommended	O
that	O
glucose	B-Drug
tests	O
based	O
on	O
enzymatic	O
glucose	B-Drug
oxidase	O
reactions	O
be	O
used	O
.	O

There	O
have	O
been	O
reports	O
of	O
positive	O
test	O
results	O
using	O
the	O
Bio-Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
in	O
patients	O
receiving	O
piperacillin/tazobactam	B-Drug
injection	O
who	O
were	O
subsequently	O
found	O
to	O
be	O
free	O
of	O
Aspergillus	O
infection	O
.	O

Cross-reactions	O
with	O
non-Aspergillus	O
polysaccharides	O
and	O
polyfuranoses	O
with	O
the	O
Bio-Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
have	O
been	O
reported	O
.	O

Therefore	O
,	O
positive	O
test	O
results	O
in	O
patients	O
receiving	O
piperacillin	B-Drug
should	O
be	O
interpreted	O
cautiously	O
and	O
confirmed	O
by	O
other	O
diagnostic	O
methods	O
.	O

Phenothiazines	O
-	O
Taking	O
piperazine	B-Drug
and	O
a	O
phenothiazine	O
together	O
may	O
increase	O
the	O
risk	O
of	O
convulsions	O
(	O
seizures	O
)	O
.	O

Pyrantel	B-Drug
(	O
e.g.	O
,	O
Antiminth	B-Drug
)	O
-	O
Taking	O
piperazine	B-Drug
and	O
pyrantel	B-Drug
together	O
may	O
decrease	O
the	O
effects	O
of	O
piperazine	B-Drug
.	O

ACE	O
inhibitors	O
:	O
Reports	O
suggest	O
that	O
NSAIDs	O
may	O
diminish	O
the	O
antihypertensive	B-Drug
effect	O
of	O
Angiotensin	B-Drug
Converting	O
Enzyme	O
(	O
ACE	O
)	O
inhibitors	O
.	O

In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
,	O
administration	O
of	O
25	O
mg	O
daily	O
of	O
VIOXX	B-Drug
with	O
the	O
ACE	O
inhibitor	O
benazepril	B-Drug
,	O
10	O
to	O
40	O
mg	O
for	O
4	O
weeks	O
,	O
was	O
associated	O
with	O
an	O
average	O
increase	O
in	O
mean	O
arterial	O
pressure	O
of	O
about	O
3	O
mm	O
Hg	O
compared	O
to	O
ACE	O
inhibitor	O
alone	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
VIOXX	B-Drug
concomitantly	O
with	O
ACE	O
inhibitors	O
.	O

Aspirin	B-Drug
:	O
Concomitant	O
administration	O
of	O
low-dose	O
aspirin	B-Drug
with	O
VIOXX	B-Drug
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
,	O
compared	O
to	O
use	O
of	O
VIOXX	B-Drug
alone	O
.	O

In	O
a	O
12-week	O
endoscopy	O
study	O
conducted	O
in	O
OA	O
patients	O
there	O
was	O
no	O
difference	O
in	O
the	O
cumulative	O
incidence	O
of	O
endoscopic	O
gastroduodenal	O
ulcers	O
in	O
patients	O
taking	O
low-dose	O
(	O
81	O
mg	O
)	O
enteric	O
coated	O
aspirin	B-Drug
plus	O
VIOXX	B-Drug
25	O
mg	O
daily	O
,	O
as	O
compared	O
to	O
those	O
taking	O
ibuprofen	B-Drug
2400	O
mg	O
daily	O
alone	O
.	O

Patients	O
taking	O
low-dose	O
aspirin	B-Drug
plus	O
ibuprofen	B-Drug
were	O
not	O
studied	O
.	O

At	O
steady	O
state	O
,	O
VIOXX	B-Drug
50	O
mg	O
once	O
daily	O
had	O
no	O
effect	O
on	O
the	O
anti-platelet	O
activity	O
of	O
low-dose	O
(	O
81	O
mg	O
once	O
daily	O
)	O
aspirin	B-Drug
,	O
as	O
assessed	O
by	O
ex	O
vivo	O
platelet	O
aggregation	O
and	O
serum	O
TXB2	O
generation	O
in	O
clotting	O
blood	O
.	O

Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
,	O
VIOXX	B-Drug
is	O
not	O
a	O
substitute	O
for	O
aspirin	B-Drug
for	O
cardiovascular	O
prophylaxis	O
.	O

Therefore	O
,	O
in	O
patients	O
taking	O
VIOXX	B-Drug
,	O
antiplatelet	O
therapies	O
should	O
not	O
be	O
discontinued	O
and	O
should	O
be	O
considered	O
in	O
patients	O
with	O
an	O
indication	O
for	O
cardiovascular	O
prophylaxis	O
.	O

Prospective	O
,	O
long-term	O
studies	O
on	O
concomitant	O
administration	O
of	O
VIOXX	B-Drug
and	O
aspirin	B-Drug
have	O
not	O
been	O
conducted	O
.	O

Cimetidine	B-Drug
:	O
Co-administration	O
with	O
high	O
doses	O
of	O
cimetidine	B-Drug
[	O
800	O
mg	O
twice	O
daily	O
]	O
increased	O
the	O
Cmax	O
of	O
rofecoxib	B-Drug
by	O
21	O
%	O
,	O
the	O
AUC0-120hr	O
by	O
23	O
%	O
and	O
the	O
t1/2	B-Drug
by	O
15	O
%	O
.	O

These	O
small	O
changes	O
are	O
not	O
clinically	O
significant	O
and	O
no	O
dose	O
adjustment	O
is	O
necessary	O
.	O

Digoxin	B-Drug
:	O
Rofecoxib	B-Drug
75	O
mg	O
once	O
daily	O
for	O
11	O
days	O
does	O
not	O
alter	O
the	O
plasma	O
concentration	O
profile	O
or	O
renal	O
elimination	O
of	O
digoxin	B-Drug
after	O
a	O
single	O
0.5	O
mg	O
oral	O
dose	O
.	O

Furosemide	B-Drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post-marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	O
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	O
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
400	O
mg	O
daily	O
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
rofecoxib	B-Drug
.	O

Lithium	B-Drug
:	O
NSAIDs	O
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B-Drug
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B-Drug
clearance	O
.	O

In	O
post-marketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
increases	O
in	O
plasma	O
lithium	B-Drug
levels	O
.	O

Thus	O
,	O
when	O
VIOXX	B-Drug
and	O
lithium	B-Drug
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B-Drug
toxicity	O
.	O

Methotrexate	B-Drug
VIOXX	B-Drug
12.5	O
,	O
25	O
,	O
and	O
50	O
mg	O
,	O
each	O
dose	O
administered	O
once	O
daily	O
for	O
7	O
days	O
,	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
concentration	O
of	O
methotrexate	B-Drug
as	O
measured	O
by	O
AUC0-24hr	O
in	O
patients	O
receiving	O
single	O
weekly	O
methotrexate	B-Drug
doses	O
of	O
7.5	O
to	O
20	O
mg	O
for	O
rheumatoid	O
arthritis	O
.	O

At	O
higher	O
than	O
recommended	O
doses	O
,	O
VIOXX	B-Drug
75	O
mg	O
administered	O
once	O
daily	O
for	O
10	O
days	O
increased	O
plasma	O
concentrations	O
by	O
23	O
%	O
as	O
measured	O
by	O
AUC0-24hr	O
in	O
patients	O
receiving	O
methotrexate	B-Drug
7.5	O
to	O
15	O
mg/week	O
for	O
rheumatoid	O
arthritis	O
.	O

At	O
24	O
hours	O
postdose	O
,	O
a	O
similar	O
proportion	O
of	O
patients	O
treated	O
with	O
methotrexate	B-Drug
alone	O
(	O
94	O
%	O
)	O
and	O
subsequently	O
treated	O
with	O
methotrexate	B-Drug
co-administered	O
with	O
75	O
mg	O
of	O
rofecoxib	B-Drug
(	O
88	O
%	O
)	O
had	O
methotrexate	B-Drug
plasma	O
concentrations	O
below	O
the	O
measurable	O
limit	O
(	O
5	O
ng/mL	O
)	O
.	O

Standard	O
monitoring	O
of	O
methotrexate-related	B-Drug
toxicity	O
should	O
be	O
continued	O
if	O
VIOXX	B-Drug
and	O
methotrexate	B-Drug
are	O
administered	O
concomitantly	O
.	O

Oral	O
Contraceptives	O
Rofecoxib	B-Drug
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B-Drug
estradiol	I-Drug
and	O
norethindrone	B-Drug
.	O

Prednisone/prednisolone	B-Drug
:	O
Rofecoxib	B-Drug
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
prednisolone	B-Drug
or	O
prednisone	B-Drug
.	O

Rifampin	B-Drug
:	O
Co-administration	O
of	O
VIOXX	B-Drug
with	O
rifampin	B-Drug
600	O
mg	O
daily	O
,	O
a	O
potent	O
inducer	O
of	O
hepatic	O
metabolism	O
,	O
produced	O
an	O
approximate	O
50	O
%	O
decrease	O
in	O
rofecoxib	B-Drug
plasma	O
concentrations	O
.	O

Therefore	O
,	O
a	O
starting	O
daily	O
dose	O
of	O
25	O
mg	O
of	O
VIOXX	B-Drug
should	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
when	O
VIOXX	B-Drug
is	O
co-administered	O
with	O
potent	O
inducers	O
of	O
hepatic	O
metabolism	O
.	O

Theophylline	B-Drug
VIOXX	B-Drug
12.5	O
,	O
25	O
,	O
and	O
50	O
mg	O
administered	O
once	O
daily	O
for	O
7	O
days	O
increased	O
plasma	O
theophylline	B-Drug
concentrations	O
(	O
AUC	O
(	O
0-	O
)	O
)	O
by	O
38	O
to	O
60	O
%	O
in	O
healthy	O
subjects	O
administered	O
a	O
single	O
300-mg	O
dose	O
of	O
theophylline	B-Drug
.	O

Adequate	O
monitoring	O
of	O
theophylline	B-Drug
plasma	O
concentrations	O
should	O
be	O
considered	O
when	O
therapy	O
with	O
VIOXX	B-Drug
is	O
initiated	O
or	O
changed	O
in	O
patients	O
receiving	O
theophylline	B-Drug
.	O

These	O
data	O
suggest	O
that	O
rofecoxib	B-Drug
may	O
produce	O
a	O
modest	O
inhibition	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
1A2	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
interaction	O
with	O
other	O
drugs	B-Drug
that	O
are	O
metabolized	O
by	O
CYP	O
1A2	O
(	O
e.g.	O
,	O
amitriptyline	B-Drug
,	O
tacrine	B-Drug
,	O
and	O
zileuton	B-Drug
)	O
.	O

Warfarin	B-Drug
:	O
Anticoagulant	B-Drug
activity	O
should	O
be	O
monitored	O
,	O
particularly	O
in	O
the	O
first	O
few	O
days	O
after	O
initiating	O
or	O
changing	O
VIOXX	B-Drug
therapy	O
in	O
patients	O
receiving	O
warfarin	B-Drug
or	O
similar	O
agents	O
,	O
since	O
these	O
patients	O
are	O
at	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O

In	O
single	O
and	O
multiple	O
dose	O
studies	O
in	O
healthy	O
subjects	O
receiving	O
both	O
warfarin	B-Drug
and	O
rofecoxib	B-Drug
,	O
prothrombin	O
time	O
(	O
measured	O
as	O
INR	O
)	O
was	O
increased	O
by	O
approximately	O
8	O
%	O
to	O
11	O
%	O
.	O

In	O
post-marketing	O
experience	O
,	O
bleeding	O
events	O
have	O
been	O
reported	O
,	O
predominantly	O
in	O
the	O
elderly	O
,	O
in	O
association	O
with	O
increases	O
in	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
VIOXX	B-Drug
concurrently	O
with	O
warfarin	B-Drug
.	O

DRUG	B-Drug
INTERACTIONS	O
Several	O
drug	B-Drug
interaction	O
studies	O
have	O
been	O
completed	O
with	O
both	O
INVIRASE	B-Drug
and	O
FORTOVASE	B-Drug
.	O

Observations	O
from	O
drug	B-Drug
interaction	O
studies	O
with	O
FORTOVASE	B-Drug
may	O
not	O
be	O
predictive	O
for	O
INVIRASE	B-Drug
.	O

Because	O
ritonavir	B-Drug
is	O
coadministered	O
,	O
prescribers	O
should	O
also	O
refer	O
to	O
the	O
prescribing	O
information	O
for	O
ritonavir	B-Drug
regarding	O
drug	B-Drug
interactions	O
associated	O
with	O
this	O
agent	O
.	O

The	O
metabolism	O
of	O
saquinavir	B-Drug
is	O
mediated	O
by	O
cytochrome	O
P450	O
,	O
with	O
the	O
specific	O
isoenzyme	O
CYP3A4	B-Drug
responsible	O
for	O
90	O
%	O
of	O
the	O
hepatic	O
metabolism	O
.	O

Additionally	O
,	O
saquinavir	B-Drug
is	O
a	O
substrate	O
for	O
P-Glycoprotein	O
(	O
Pgp	O
)	O
.	O

Therefore	O
,	O
drugs	B-Drug
that	O
affect	O
CYP3A4	B-Drug
and/or	O
Pgp	O
,	O
may	O
modify	O
the	O
pharmacokinetics	O
of	O
saquinavir	B-Drug
.	O

Similarly	O
,	O
saquinavir	B-Drug
might	O
also	O
modify	O
the	O
pharmacokinetics	O
of	O
other	O
drugs	B-Drug
that	O
are	O
substrates	O
for	O
CYP3A4	B-Drug
or	O
Pgp	O
.	O

Drugs	B-Drug
that	O
are	O
contraindicated	O
specifically	O
due	O
to	O
the	O
expected	O
magnitude	O
of	O
interaction	O
and	O
potential	O
for	O
serious	O
adverse	O
events	O
are	O
listed	O
CONTRAINDICATIONS	O
.	O

Additional	O
drugs	B-Drug
that	O
are	O
not	O
recommended	O
for	O
coadministration	O
with	O
INVIRASE	B-Drug
and	O
ritonavir	B-Drug
are	O
included	O
below	O
.	O

These	O
recommendations	O
are	O
based	O
on	O
either	O
drug	B-Drug
interaction	O
studies	O
or	O
predicted	O
interactions	O
due	O
to	O
the	O
expected	O
magnitude	O
of	O
interaction	O
and	O
potential	O
for	O
serious	O
events	O
or	O
loss	O
of	O
efficacy	O
.	O

With	O
some	O
agents	O
,	O
the	O
metabolism	O
may	O
be	O
induced	O
,	O
resulting	O
in	O
decreased	O
concentrations	O
.	O

Drugs	B-Drug
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
INVIRASE/Ritonavir	B-Drug
Drug	B-Drug
Class	O
:	O
Drug	B-Drug
Name	O
Clinical	O
Comment	O
Antiarrhythmics	B-Drug
:	O
Amiodarone	B-Drug
,	O
bepridil	B-Drug
,	O
flecainide	B-Drug
,	O
propafenone	B-Drug
,	O
quinidine	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
.	O

Antihistamines	B-Drug
:	O
astemizole*	B-Drug
,	O
terfenadine*	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
cardiac	O
arrhythmias	O
.	O

Ergot	B-Drug
Derivatives	O
:	O
Dihydroergotamine	B-Drug
,	O
ergonovine	B-Drug
,	O
ergotamine	B-Drug
,	O
methylergonovine	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
life-threatening	O
reactions	O
such	O
as	O
acute	O
ergot	B-Drug
toxicity	O
characterized	O
by	O
peripheral	O
vasospasm	O
and	O
ischemia	O
of	O
the	O
extremities	O
and	O
other	O
tissues	O
.	O

Antimycobacterial	O
Agents	O
:	O
rifampin	B-Drug
CONTRAINDICATED	O
since	O
the	O
coadministration	O
of	O
this	O
product	O
with	O
saquinavir	B-Drug
in	O
an	O
antiretroviral	O
regimen	O
reduces	O
the	O
plasma	O
concentrations	O
of	O
saquinavir	B-Drug
.	O

Garlic	O
Capsules	O
Garlic	O
capsules	O
should	O
not	O
be	O
used	O
while	O
taking	O
saquinavir	B-Drug
(	O
FORTOVASE	B-Drug
)	O
as	O
the	O
sole	O
protease	O
inhibitor	O
due	O
to	O
the	O
risk	O
of	O
decreased	O
saquinavir	B-Drug
plasma	O
concentrations	O
.	O

No	O
data	O
are	O
available	O
for	O
the	O
coadministration	O
of	O
INVIRASE/ritonavir	B-Drug
or	O
FORTOVASE/ritonavir	B-Drug
and	O
garlic	O
capsules	O
.	O

GI	O
Motility	O
Agent	O
:	O
cisapride*	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
such	O
as	O
cardiac	O
arrhythmias	O
.	O

Herbal	O
Products	O
:	O
St.	O
John	O
s	O
wort	O
(	O
hypericum	O
perforatum	O
)	O
WARNING	O
coadministration	O
may	O
lead	B-Drug
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
INVIRASE	B-Drug
or	O
to	O
the	O
class	O
of	O
protease	O
inhibitors	O
.	O

HMG-CoA	O
Reductase	O
Inhibitors	O
:	O
lovastatin	B-Drug
,	O
simvastatin	B-Drug
WARNING	O
potential	O
for	O
serious	O
reactions	O
such	O
as	O
risk	O
of	O
myopathy	O
including	O
rhabdomyolysis	O
.	O

Sedatives/Hypnotics	O
:	O
triazolam	B-Drug
,	O
midazolam	B-Drug
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and/or	O
life-threatening	O
reactions	O
such	O
as	O
prolonged	O
or	O
increased	O
sedation	O
or	O
respiratory	O
depression	O
.	O

*	O
No	O
longer	O
marketed	O
in	O
the	O
US	O
.	O

Drugs	B-Drug
That	O
Are	O
Mainly	O
Metabolized	O
by	O
CYP3A4	B-Drug
Although	O
specific	O
studies	O
have	O
not	O
been	O
performed	O
,	O
coadministration	O
with	O
drugs	B-Drug
that	O
are	O
mainly	O
metabolized	O
by	O
CYP3A4	B-Drug
(	O
eg	O
,	O
calcium	B-Drug
channel	O
blockers	O
,	O
dapsone	B-Drug
,	O
disopyramide	B-Drug
,	O
quinine	B-Drug
,	O
amiodarone	B-Drug
,	O
quinidine	B-Drug
,	O
warfarin	B-Drug
,	O
tacrolimus	B-Drug
,	O
cyclosporine	B-Drug
,	O
ergot	B-Drug
derivatives	O
,	O
pimozide	B-Drug
,	O
carbamazepine	B-Drug
,	O
fentanyl	B-Drug
,	O
alfentanyl	B-Drug
,	O
alprazolam	B-Drug
,	O
and	O
triazolam	B-Drug
)	O
may	O
have	O
elevated	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
saquinavir	B-Drug
;	O
therefore	O
,	O
these	O
combinations	O
should	O
be	O
used	O
with	O
caution	O
.	O

Since	O
INVIRASE	B-Drug
is	O
coadministered	O
with	O
ritonavir	B-Drug
,	O
the	O
ritonavir	B-Drug
label	O
should	O
be	O
reviewed	O
for	O
additional	O
drugs	B-Drug
that	O
should	O
not	O
be	O
coadministered	O
.	O

Inducers	O
of	O
CYP3A4	B-Drug
Coadministration	O
with	O
compounds	O
that	O
are	O
potent	O
inducers	O
of	O
CYP3A4	B-Drug
(	O
eg	O
,	O
phenobarbital	B-Drug
,	O
phenytoin	B-Drug
,	O
dexamethasone	B-Drug
,	O
carbamazepine	B-Drug
)	O
may	O
result	O
in	O
decreased	O
plasma	O
levels	O
of	O
saquinavir	B-Drug
.	O

Sulfacetamide	B-Drug
preparations	O
are	O
incompatible	O
with	O
silver	B-Drug
preparations	O
.	O

Interations	O
Sulfapyridine	B-Drug
may	O
interact	O
with	O
any	O
of	O
the	O
following	O
:	O
-	O
Acetaminophen	B-Drug
(	O
e.g.	O
,	O
Tylenol	B-Drug
)	O
(	O
with	O
long-term	O
,	O
high-dose	O
use	O
)	O
or	O
-	O
Amiodarone	B-Drug
(	O
e.g.	O
,	O
Cordarone	B-Drug
)	O
or	O
-	O
Anabolic	O
steroids	O
(	O
nandrolone	B-Drug
[	O
e.g.	O
,	O
Anabolin	B-Drug
]	O
,	O
oxandrolone	B-Drug
[	O
e.g.	O
,	O
Anavar	B-Drug
]	O
,	O
oxymetholone	B-Drug
[	O
e.g.	O
,	O
Anadrol	B-Drug
]	O
,	O
stanozolol	B-Drug
[	O
e.g.	O
,	O
Winstrol	B-Drug
]	O
)	O
or	O
-	O
Androgens	O
(	O
male	O
hormones	O
)	O
or	O
-	O
Antithyroid	O
agents	O
(	O
medicine	O
for	O
overactive	O
thyroid	B-Drug
)	O
or	O
-	O
Carbamazepine	B-Drug
(	O
e.g.	O
,	O
Tegretol	B-Drug
)	O
or	O
-	O
Carmustine	B-Drug
(	O
e.g.	O
,	O
BiCNU	B-Drug
)	O
or	O
-	O
Chloroquine	B-Drug
(	O
e.g.	O
,	O
Aralen	B-Drug
)	O
or	O
-	O
Dantrolene	B-Drug
(	O
e.g.	O
,	O
Dantrium	B-Drug
)	O
or	O
-	O
Daunorubicin	B-Drug
(	O
e.g.	O
,	O
Cerubidine	B-Drug
)	O
or	O
-	O
Disulfiram	B-Drug
(	O
e.g.	O
,	O
Antabuse	B-Drug
)	O
or	O
-	O
Divalproex	B-Drug
(	O
e.g.	O
,	O
Depakote	B-Drug
)	O
or	O
-	O
Estrogens	O
(	O
female	O
hormones	O
)	O
or	O
-	O
Etretinate	B-Drug
(	O
e.g.	O
,	O
Tegison	B-Drug
)	O
or	O
-	O
Gold	B-Drug
salts	O
(	O
medicine	O
for	O
arthritis	O
)	O
or	O
-	O
Hydroxychloroquine	B-Drug
(	O
e.g.	O
,	O
Plaquenil	B-Drug
)	O
or	O
-	O
Mercaptopurine	B-Drug
(	O
e.g.	O
,	O
Purinethol	B-Drug
)	O
or	O
-	O
Naltrexone	B-Drug
(	O
e.g.	O
,	O
Trexan	B-Drug
)	O
(	O
with	O
long-term	O
,	O
high-dose	O
use	O
)	O
or	O
-	O
Oral	O
contraceptives	O
(	O
birth	O
control	O
pills	O
)	O
containing	O
estrogen	O
or	O
-	O
Other	O
anti-infectives	O
by	O
mouth	O
or	O
by	O
injection	O
(	O
medicine	O
for	O
infection	O
)	O
or	O
-	O
Phenothiazines	O
(	O
acetophenazine	B-Drug
[	O
e.g.	O
,	O
Tindal	B-Drug
]	O
,	O
chlorpromazine	B-Drug
[	O
e.g.	O
,	O
Thorazine	B-Drug
]	O
,	O
fluphenazine	B-Drug
[	O
e.g.	O
,	O
Prolixin	B-Drug
]	O
,	O
mesoridazine	B-Drug
[	O
e.g.	O
,	O
Serentil	B-Drug
]	O
,	O
perphenazine	B-Drug
[	O
e.g.	O
,	O
Trilafon	B-Drug
]	O
,	O
prochlorperazine	B-Drug
[	O
e.g.	O
,	O
Compazine	B-Drug
]	O
,	O
promazine	B-Drug
[	O
e.g.	O
,	O
Sparine	B-Drug
]	O
,	O
promethazine	B-Drug
[	O
e.g.	O
,	O
Phenergan	B-Drug
]	O
,	O
thioridazine	B-Drug
[	O
e.g.	O
,	O
Mellaril	B-Drug
]	O
,	O
trifluoperazine	B-Drug
[	O
e.g.	O
,	O
Stelazine	B-Drug
]	O
,	O
triflupromazine	B-Drug
[	O
e.g.	O
,	O
Vesprin	B-Drug
]	O
,	O
trimeprazine	B-Drug
[	O
e.g.	O
,	O
Temaril	B-Drug
]	O
)	O
or	O
-	O
Plicamycin	B-Drug
(	O
e.g.	O
,	O
Mithracin	B-Drug
)	O
or	O
-	O
Valproic	B-Drug
acid	I-Drug
(	O
e.g.	O
,	O
Depakene	B-Drug
)	O
Use	O
of	O
sulfapyridine	B-Drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
-	O
Acetohydroxamic	B-Drug
acid	I-Drug
(	O
e.g.	O
,	O
Lithostat	B-Drug
)	O
or	O
-	O
Dapsone	B-Drug
or	O
-	O
Furazolidone	B-Drug
(	O
e.g.	O
,	O
Furoxone	B-Drug
)	O
or	O
-	O
Nitrofurantoin	B-Drug
(	O
e.g.	O
,	O
Furadantin	B-Drug
)	O
or	O
-	O
Primaquine	B-Drug
or	O
-	O
Procainamide	B-Drug
(	O
e.g.	O
,	O
Pronestyl	B-Drug
)	O
or	O
-	O
Quinidine	B-Drug
(	O
e.g.	O
,	O
Quinidex	B-Drug
)	O
or	O
-	O
Quinine	B-Drug
(	O
e.g.	O
,	O
Quinamm	B-Drug
)	O
or	O
-	O
Sulfoxone	B-Drug
(	O
e.g.	O
,	O
Diasone	B-Drug
)	O
or	O
-	O
Vitamin	O
K	O
(	O
e.g.	O
,	O
AquaMEPHYTON	B-Drug
,	O
Synkayvite	B-Drug
)	O
Use	O
of	O
sulfapyridine	B-Drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O
-	O
Anticoagulants	B-Drug
(	O
blood	O
thinners	O
)	O
or	O
-	O
Ethotoin	B-Drug
(	O
e.g.	O
,	O
Peganone	B-Drug
)	O
or	O
-	O
Mephenytoin	B-Drug
(	O
e.g.	O
,	O
Mesantoin	B-Drug
)	O
Use	O
of	O
sulfapyridine	B-Drug
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
of	O
these	O
medicines	O
-	O
Antidiabetics	O
,	O
oral	O
(	O
diabetes	O
medicine	O
you	O
take	O
by	O
mouth	O
)	O
Use	O
of	O
oral	O
antidiabetics	O
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O
and/or	O
the	O
side	O
effects	O
or	O
oral	O
antidiabetics	O
-	O
Methotrexate	B-Drug
(	O
e.g.	O
,	O
Mexate	B-Drug
)	O
Use	O
of	O
methotrexate	B-Drug
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and/or	O
the	O
side	O
effects	O
of	O
methotrexate	B-Drug
-	O
Methyldopa	B-Drug
(	O
e.g.	O
,	O
Aldomet	B-Drug
)	O
Use	O
of	O
methyldopa	B-Drug
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and/or	O
the	O
blood	O
-	O
Phenytoin	B-Drug
(	O
e.g.	O
,	O
Dilantin	B-Drug
)	O
Use	O
of	O
phenytoin	B-Drug
with	O
sulfapyridine	B-Drug
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and/or	O
the	O
side	O
effects	O
of	O
phenytoin	B-Drug
In	O
evaluating	O
the	O
potential	O
for	O
interactions	O
among	O
co-administered	O
antiepilepsy	O
drugs	B-Drug
(	O
AEDs	O
)	O
,	O
whether	O
or	O
not	O
an	O
AED	O
induces	O
or	O
does	O
not	O
induce	O
metabolic	O
enzymes	O
is	O
an	O
important	O
consideration	O
.	O

Phenytoin	B-Drug
,	O
phenobarbital	B-Drug
and	O
carbamazepine	B-Drug
are	O
ge	O
nerally	O
classified	O
as	O
enzyme	O
inducers	O
;	O
valproate	B-Drug
and	O
gabapentin	B-Drug
are	O
not	O
.	O

GABITRIL	B-Drug
is	O
considered	O
to	O
be	O
a	O
non-enzyme	O
inducing	O
AED	O
.	O

The	O
drug	B-Drug
interaction	O
data	O
described	O
in	O
this	O
section	O
were	O
obtained	O
from	O
studies	O
involving	O
either	O
healthy	O
subjects	O
or	O
patients	O
with	O
epilepsy	O
.	O

Effects	O
of	O
GABITRIL	B-Drug
on	O
other	O
Antiepilepsy	O
Drugs	B-Drug
(	O
AEDs	O
)	O
:	O
Phenytoin	B-Drug
:	O
Tiagabine	B-Drug
had	O
no	O
effect	O
on	O
the	O
steady-state	O
plasma	O
concentrations	O
of	O
phenytoin	B-Drug
in	O
patients	O
with	O
epilepsy	O
.	O

Carbamazepine	B-Drug
:	O
Tiagabine	B-Drug
had	O
no	O
effect	O
on	O
the	O
steady-state	O
plasma	O
concentrations	O
of	O
carbamazepine	B-Drug
or	O
its	O
epoxide	O
metabolite	O
in	O
patients	O
with	O
epilepsy	O
.	O

Valproate	B-Drug
:	O
Tiagabine	B-Drug
causes	O
a	O
slight	O
decrease	O
(	O
about	O
10	O
%	O
)	O
in	O
steady-state	O
valproate	B-Drug
concentrations	O
.	O

Phenobarbital	B-Drug
or	O
Primidone	B-Drug
:	O
No	O
formal	O
pharmacokinetic	O
studies	O
have	O
been	O
performed	O
examining	O
the	O
addition	O
of	O
tiagabine	B-Drug
to	O
regimens	O
containing	O
phenobarbital	B-Drug
or	O
primidone	B-Drug
.	O

The	O
addition	O
of	O
tiagabine	B-Drug
in	O
a	O
limited	O
number	O
of	O
patients	O
in	O
three	O
well-controlled	O
studies	O
caused	O
no	O
systematic	O
changes	O
in	O
phenobarbital	B-Drug
or	O
primidone	B-Drug
concentrations	O
when	O
compared	O
to	O
placebo	O
.	O

Effects	O
of	O
other	O
Antiepilepsy	O
Drugs	B-Drug
(	O
AEDs	O
)	O
on	O
GABITRIL	B-Drug
:	O
Carbamazepine	B-Drug
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B-Drug
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
carbamazepine	B-Drug
with	O
or	O
without	O
other	O
enzyme-	O
inducing	O
AEDs	O
.	O

Phenytoin	B-Drug
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B-Drug
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
phenytoin	B-Drug
with	O
or	O
without	O
other	O
enzyme-	O
inducing	O
AEDs	O
.	O

Phenobarbital	B-Drug
(	O
Primidone	B-Drug
)	O
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B-Drug
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
phenobarbital	B-Drug
(	O
primidone	B-Drug
)	O
with	O
or	O
without	O
other	O
enzyme-inducing	O
AEDs	O
.	O

Valproate	B-Drug
:	O
The	O
addition	O
of	O
tiagabine	B-Drug
to	O
patients	O
taking	O
valproate	B-Drug
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	B-Drug
pharmacokinetics	O
,	O
but	O
valproate	B-Drug
significantly	O
decreased	O
tiagabine	B-Drug
binding	O
in	O
vitro	O
from	O
96.3	O
to	O
94.8	O
%	O
,	O
which	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
40	O
%	O
in	O
the	O
free	O
tiagabine	B-Drug
concentration	O
.	O

The	O
clinical	O
relevance	O
of	O
this	O
in	O
vitro	O
finding	O
is	O
unknown	O
.	O

Interaction	O
of	O
GABITRIL	B-Drug
with	O
Other	O
Drugs	B-Drug
:	O
Cimetidine	B-Drug
:	O
Co-administration	O
of	O
cimetidine	B-Drug
(	O
800	O
mg/day	O
)	O
to	O
patients	O
taking	O
tiagabine	B-Drug
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	B-Drug
pharmacokinetics	O
.	O

Theophylline	B-Drug
:	O
A	O
single	O
10	O
mg	O
dose	O
of	O
tiagabine	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	B-Drug
at	O
steady	O
state	O
.	O

Warfarin	B-Drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
steady-state	O
pharmacokinetics	O
of	O
R-warfarin	B-Drug
or	O
S-warfarin	B-Drug
with	O
the	O
addition	O
of	O
tiagabine	B-Drug
given	O
as	O
a	O
single	O
dose	O
.	O

Prothrombin	O
times	O
were	O
not	O
affected	O
by	O
tiagabine	B-Drug
.	O

Digoxin	B-Drug
:	O
Concomitant	O
administration	O
of	O
tiagabine	B-Drug
did	O
not	O
affect	O
the	O
steady-state	O
pharmacokinetics	O
of	O
digoxin	B-Drug
or	O
the	O
mean	O
daily	O
trough	O
serum	O
level	O
of	O
digoxin	B-Drug
.	O

Ethanol	B-Drug
or	O
Triazolam	B-Drug
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
pharmacokinetics	O
of	O
triazolam	B-Drug
(	O
0.125	O
mg	O
)	O
and	O
tiagabine	B-Drug
(	O
10	O
mg	O
)	O
when	O
given	O
together	O
as	O
a	O
single	O
dose	O
.	O

The	O
pharmacokinetics	O
of	O
ethanol	B-Drug
were	O
not	O
affected	O
by	O
multiple-dose	O
administration	O
of	O
tiagabine	B-Drug
.	O

Tiagabine	B-Drug
has	O
shown	O
no	O
clinically	O
important	O
potentiation	O
of	O
the	O
pharmacodynamic	O
effects	O
of	O
triazo	O
lam	O
or	O
alcohol	B-Drug
.	O

Because	O
of	O
the	O
possible	O
additive	O
effects	O
of	O
drugs	B-Drug
that	O
may	O
depress	O
the	O
nervous	O
system	O
,	O
ethanol	B-Drug
or	O
triazolam	B-Drug
should	O
be	O
used	O
cautiously	O
in	O
combination	O
with	O
tiagabine	B-Drug
.	O

Oral	O
Contraceptives	O
:	O
Multiple	O
dose	O
administration	O
of	O
tiagabine	B-Drug
(	O
8	O
mg/day	O
monotherapy	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
oral	O
contraceptives	O
in	O
healthy	O
women	O
of	O
childbearing	O
age	O
.	O

Antipyrine	B-Drug
:	O
Antipyrine	B-Drug
pharmacokinetics	O
were	O
not	O
significantly	O
different	O
before	O
and	O
after	O
tiagabine	B-Drug
multiple-dose	O
regimens	O
.	O

This	O
indicates	O
that	O
tiagabine	B-Drug
does	O
not	O
cause	O
induction	O
or	O
inhibition	O
of	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
responsible	O
for	O
the	O
metabolism	O
of	O
antipyrine	B-Drug
.	O

Interaction	O
of	O
GABITRIL	B-Drug
with	O
Highly	O
Protein	O
Bound	O
Drugs	B-Drug
:	O
In	O
vitro	O
data	O
showed	O
that	O
tiagabine	B-Drug
is	O
96	O
%	O
bound	O
to	O
human	O
plasma	O
protein	O
and	O
therefore	O
has	O
the	O
potential	O
to	O
interact	O
with	O
other	O
highly	O
protein	O
bound	O
compounds	O
.	O

Such	O
an	O
interaction	O
can	O
potentially	O
lead	B-Drug
to	O
higher	O
free	O
fractions	O
of	O
either	O
tiagabine	B-Drug
or	O
the	O
competing	O
drug	B-Drug
.	O

The	O
drug	B-Drug
interaction	O
studies	O
with	O
valdecoxib	B-Drug
were	O
performed	O
both	O
with	O
valdecoxib	B-Drug
and	O
a	O
rapidly	O
hydrolyzed	O
intravenous	O
prodrug	O
form	O
.	O

The	O
results	O
from	O
trials	O
using	O
the	O
intravenous	O
prodrug	O
are	O
reported	O
in	O
this	O
section	O
as	O
they	O
relate	O
to	O
the	O
role	O
of	O
valdecoxib	B-Drug
in	O
drug	B-Drug
interactions	O
.	O

General	O
:	O
In	O
humans	O
,	O
valdecoxib	B-Drug
metabolism	O
is	O
predominantly	O
mediated	O
via	O
CYP	O
3A4	O
and	O
2C9	O
with	O
glucuronidation	O
being	O
a	O
further	O
(	O
20	O
%	O
)	O
route	O
of	O
metabolism	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
valdecoxib	B-Drug
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP	O
2C19	O
(	O
IC50	O
=	O
6	O
g/mL	O
or	O
19	O
M	O
)	O
and	O
2C9	O
(	O
IC50	O
=	O
13	O
g/mL	O
or	O
41	O
M	O
)	O
,	O
and	O
a	O
weak	O
inhibitor	O
of	O
CYP	O
2D6	O
(	O
IC50	O
=	O
31	O
g/mL	O
or	O
100	O
M	O
)	O
and	O
3A4	O
(	O
IC50	O
=	O
44	O
g/mL	O
or	O
141	O
M	O
)	O
..	O
Aspirin	B-Drug
:	O
Concomitant	O
administration	O
of	O
aspirin	B-Drug
with	O
valdecoxib	B-Drug
may	O
result	O
in	O
an	O
increased	O
risk	O
of	O
GI	O
ulceration	O
and	O
complications	O
compared	O
to	O
valdecoxib	B-Drug
alone	O
.	O

Because	O
of	O
its	O
lack	O
of	O
anti-platelet	O
effect	O
valdecoxib	B-Drug
is	O
not	O
a	O
substitute	O
for	O
aspirin	B-Drug
for	O
cardiovascular	O
prophylaxis	O
.	O

In	O
a	O
parallel	O
group	O
drug	B-Drug
interaction	O
study	O
comparing	O
the	O
intravenous	O
prodrug	O
form	O
of	O
valdecoxib	B-Drug
at	O
40	O
mg	O
BID	O
(	O
n=10	O
)	O
vs	O
placebo	O
(	O
n=9	O
)	O
,	O
valdecoxib	B-Drug
had	O
no	O
effect	O
on	O
in	O
vitro	O
aspirin-mediated	B-Drug
inhibition	O
of	O
arachidonate-	O
or	O
collagen-stimulated	O
platelet	O
aggregation	O
.	O

Methotrexate	B-Drug
:	O
Valdecoxib	B-Drug
10	I-Drug
mg	I-Drug
BID	O
did	O
not	O
show	O
a	O
significant	O
effect	O
on	O
the	O
plasma	O
exposure	O
or	O
renal	O
clearance	O
of	O
methotrexate	B-Drug
.	O

ACE-inhibitors	O
:	O
Reports	O
suggest	O
that	O
NSAIDs	O
may	O
diminish	O
the	O
antihypertensive	B-Drug
effect	O
of	O
ACE-inhibitors	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
BEXTRA	B-Drug
concomitantly	O
with	O
ACE-inhibitors	O
.	O

Furosemide	B-Drug
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post-marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	O
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B-Drug
and	O
thiazides	O
in	O
some	O
patients	O
.	O

This	O
response	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
renal	O
prostaglandin	O
synthesis	O
.	O

Anticonvulsants	O
(	O
Phenytoin	B-Drug
)	O
:	O
Steady	O
state	O
plasma	O
exposure	O
(	O
AUC	O
)	O
of	O
valdecoxib	B-Drug
(	O
40	O
mg	O
BID	O
for	O
12	O
days	O
)	O
was	O
decreased	O
by	O
27	O
%	O
when	O
co-administered	O
with	O
multiple	O
doses	O
(	O
300	O
mg	O
QD	O
for	O
12	O
days	O
)	O
of	O
phenytoin	B-Drug
(	O
a	O
CYP	O
3A4	O
inducer	O
)	O
.	O

Patients	O
already	O
stabilized	O
on	O
valdecoxib	B-Drug
should	O
be	O
closely	O
monitored	O
for	O
loss	O
of	O
symptom	O
control	O
with	O
phenytoin	B-Drug
coadministration	O
.	O

Valdecoxib	B-Drug
did	O
not	O
have	O
a	O
statistically	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
phenytoin	B-Drug
(	O
a	O
CYP	O
2C9	O
and	O
CYP	O
2C19	O
substrate	O
)	O
.	O

Drug	B-Drug
interaction	O
studies	O
with	O
other	O
anticonvulsants	O
have	O
not	O
been	O
conducted	O
.	O

Routine	O
monitoring	O
should	O
be	O
performed	O
when	O
therapy	O
with	O
BEXTRA	B-Drug
is	O
either	O
initiated	O
or	O
discontinued	O
in	O
patients	O
on	O
anticonvulsant	O
therapy	O
.	O

Dextromethorphan	B-Drug
:	O
Dextromethorphan	B-Drug
is	O
primarily	O
metabolized	O
by	O
CYP	O
2D6	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
3A4	O
.	O

Coadministration	O
with	O
valdecoxib	B-Drug
(	O
40	O
mg	O
BID	O
for	O
7	O
days	O
)	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
dextromethorphan	B-Drug
plasma	O
levels	O
suggesting	O
that	O
,	O
at	O
these	O
doses	O
,	O
valdecoxib	B-Drug
is	O
a	O
weak	O
inhibitor	O
of	O
2D6	O
.	O

Even	O
so	O
dextromethorphan	B-Drug
plasma	O
concentrations	O
in	O
the	O
presence	O
of	O
high	O
doses	O
of	O
valdecoxib	B-Drug
were	O
almost	O
5-fold	O
lower	O
than	O
those	O
seen	O
in	O
CYP	O
2D6	O
poor	O
metabolizers	O
suggesting	O
that	O
dose	O
adjustment	O
is	O
not	O
necessary	O
.	O

Lithium	B-Drug
:	O
Valdecoxib	B-Drug
40	O
mg	O
BID	O
for	O
7	O
days	O
produced	O
significant	O
decreases	O
in	O
lithium	B-Drug
serum	O
clearance	O
(	O
25	O
%	O
)	O
and	O
renal	O
clearance	O
(	O
30	O
%	O
)	O
with	O
a	O
34	O
%	O
higher	O
serum	O
exposure	O
compared	O
to	O
lithium	B-Drug
alone	O
.	O

Lithium	B-Drug
serum	O
concentrations	O
should	O
be	O
monitored	O
closely	O
when	O
initiating	O
or	O
changing	O
therapy	O
with	O
BEXTRA	B-Drug
in	O
patients	O
receiving	O
lithium	B-Drug
.	O

Lithium	B-Drug
carbonate	I-Drug
(	O
450	O
mg	O
BID	O
for	O
7	O
days	O
)	O
had	O
no	O
effect	O
on	O
valdecoxib	B-Drug
pharmacokinetics	O
.	O

Warfarin	B-Drug
:	O
The	O
effect	O
of	O
valdecoxib	B-Drug
on	O
the	O
anticoagulant	B-Drug
effect	O
of	O
warfarin	B-Drug
(	O
1	O
-	O
8	O
mg/day	O
)	O
was	O
studied	O
in	O
healthy	O
subjects	O
by	O
coadministration	O
of	O
BEXTRA	B-Drug
40	O
mg	O
BID	O
for	O
7	O
days	O
.	O

Valdecoxib	B-Drug
caused	O
a	O
statistically	O
significant	O
increase	O
in	O
plasma	O
exposures	O
of	O
R-warfarin	B-Drug
and	O
S-warfarin	B-Drug
(	O
12	O
%	O
and	O
15	O
%	O
,	O
respectively	O
)	O
,	O
and	O
in	O
the	O
pharmacodynamic	O
effects	O
(	O
prothrombin	O
time	O
,	O
measured	O
as	O
INR	O
)	O
of	O
warfarin	B-Drug
.	O

While	O
mean	O
INR	O
values	O
were	O
only	O
slightly	O
increased	O
with	O
coadministration	O
of	O
valdecoxib	B-Drug
,	O
the	O
day-to-day	O
variability	O
in	O
individual	O
INR	O
values	O
was	O
increased	O
.	O

Anticoagulant	B-Drug
therapy	O
should	O
be	O
monitored	O
,	O
particularly	O
during	O
the	O
first	O
few	O
weeks	O
,	O
after	O
initiating	O
therapy	O
with	O
BEXTRA	B-Drug
in	O
patients	O
receiving	O
warfarin	B-Drug
or	O
similar	O
agents	O
.	O

Fluconazole	B-Drug
and	O
Ketoconazole	B-Drug
:	O
Ketoconazole	B-Drug
and	O
fluconazole	B-Drug
are	O
predominantly	O
CYP	O
3A4	O
and	O
2C9	O
inhibitors	O
,	O
respectively	O
.	O

Concomitant	O
single	O
dose	O
administration	O
of	O
valdecoxib	B-Drug
20	O
mg	O
with	O
multiple	O
doses	O
of	O
ketoconazole	B-Drug
and	O
fluconazole	B-Drug
produced	O
a	O
significant	O
increase	O
in	O
exposure	O
of	O
valdecoxib	B-Drug
.	O

Plasma	O
exposure	O
(	O
AUC	O
)	O
to	O
valdecoxib	B-Drug
was	O
increased	O
62	O
%	O
when	O
coadministered	O
with	O
fluconazole	B-Drug
and	O
38	O
%	O
when	O
coadministered	O
with	O
ketoconazole	B-Drug
.	O

Glyburide	B-Drug
:	O
Glyburide	B-Drug
is	O
a	O
CYP	O
2C9	O
substrate	O
.	O

Coadministration	O
of	O
valdecoxib	B-Drug
(	O
10	O
mg	O
BID	O
for	O
7	O
days	O
)	O
with	O
glyburide	B-Drug
(	O
5	O
mg	O
QD	O
or	O
10	O
mg	O
BID	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
of	O
glyburide	B-Drug
.	O

Coadministration	O
of	O
valdecoxib	B-Drug
(	O
40	O
mg	O
BID	O
(	O
day	O
1	O
)	O
and	O
40	O
mg	O
QD	O
(	O
days	O
2-7	O
)	O
)	O
with	O
glyburide	B-Drug
(	O
5	O
mg	O
QD	O
)	O
did	O
not	O
affect	O
either	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
or	O
the	O
pharmacodynamics	O
(	O
blood	O
glucose	B-Drug
and	O
insulin	B-Drug
levels	O
)	O
of	O
glyburide	B-Drug
.	O

Coadministration	O
of	O
valdecoxib	B-Drug
(	O
40	O
mg	O
BID	O
(	O
day	O
1	O
)	O
and	O
40	O
mg	O
QD	O
(	O
days	O
2-7	O
)	O
)	O
with	O
glyburide	B-Drug
(	O
10	O
mg	O
glyburide	B-Drug
BID	O
)	O
resulted	O
in	O
21	O
%	O
increase	O
in	O
glyburide	B-Drug
AUC0-12	O
and	O
a	O
16	O
%	O
increase	O
in	O
glyburide	B-Drug
Cmax	O
leading	O
to	O
a	O
16	O
%	O
decrease	O
in	O
glucose	B-Drug
AUC0-24	O
.	O

Insulin	B-Drug
parameters	O
were	O
not	O
affected	O
.	O

Because	O
changes	O
in	O
glucose	B-Drug
concentrations	O
with	O
valdecoxib	B-Drug
coadministration	O
were	O
within	O
the	O
normal	O
variability	O
and	O
individual	O
glucose	B-Drug
concentrations	O
were	O
above	O
or	O
near	O
70	O
mg/dL	O
,	O
dose	O
adjustment	O
for	O
glyburide	B-Drug
(	O
5	O
mg	O
QD	O
and	O
10	O
mg	O
BID	O
)	O
with	O
valdecoxib	B-Drug
coadministration	O
(	O
up	O
to	O
40	O
mg	O
QD	O
)	O
is	O
not	O
indicated	O
.	O

Coadministration	O
of	O
glyburide	B-Drug
with	O
doses	O
higher	O
than	O
40	O
mg	O
valdecoxib	B-Drug
(	O
e.g.	O
,	O
40	O
mg	O
BID	O
)	O
have	O
not	O
been	O
studied	O
.	O

Omeprazole	B-Drug
:	O
Omeprazole	B-Drug
is	O
a	O
CYP	O
3A4	O
substrate	O
and	O
CYP	O
2C19	O
substrate	O
and	O
inhibitor	O
.	O

Valdecoxib	B-Drug
steady	O
state	O
plasma	O
concentrations	O
(	O
40	O
mg	O
BID	O
)	O
were	O
not	O
affected	O
significantly	O
with	O
multiple	O
doses	O
of	O
omeprazole	B-Drug
(	O
40	O
mg	O
QD	O
)	O
.	O

Coadministration	O
with	O
valdecoxib	B-Drug
increased	O
exposure	O
of	O
omeprazole	B-Drug
(	O
AUC	O
)	O
by	O
46	O
%	O
.	O

Drugs	B-Drug
whose	O
absorption	O
is	O
sensitive	O
to	O
pH	O
may	O
be	O
negatively	O
impacted	O
by	O
concomitant	O
administration	O
of	O
omeprazole	B-Drug
and	O
valdecoxib	B-Drug
.	O

However	O
,	O
because	O
higher	O
doses	O
(	O
up	O
to	O
360	O
mg	O
QD	O
)	O
of	O
omeprazole	B-Drug
are	O
tolerated	O
in	O
Zollinger-Ellison	O
(	O
ZE	O
)	O
patients	O
,	O
no	O
dose	O
adjustment	O
for	O
omeprazole	B-Drug
is	O
recommended	O
at	O
current	O
doses	O
.	O

Coadministration	O
of	O
valdecoxib	B-Drug
with	O
doses	O
higher	O
than	O
40	O
mg	O
QD	O
omeprazole	B-Drug
has	O
not	O
been	O
studied	O
.	O

Oral	O
Contraceptives	O
:	O
Valdecoxib	B-Drug
(	O
40	O
mg	O
BID	O
)	O
did	O
not	O
induce	O
the	O
metabolism	O
of	O
the	O
combination	O
oral	O
contraceptive	O
norethindrone/ethinyl	B-Drug
estradiol	I-Drug
(	O
1	O
mg	O
/35	O
mcg	O
combination	O
,	O
Ortho-Novum	B-Drug
1/35	O
)	O
.	O

Coadministration	O
of	O
valdecoxib	B-Drug
and	O
Ortho-Novum	B-Drug
1/35	O
increased	O
the	O
exposure	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
by	O
20	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

Although	O
there	O
is	O
little	O
risk	O
for	O
loss	O
of	O
contraceptive	O
efficacy	O
,	O
the	O
clinical	O
significance	O
of	O
these	O
increased	O
exposures	O
in	O
terms	O
of	O
safety	O
is	O
not	O
known	O
.	O

These	O
increased	O
exposures	O
of	O
norethindrone	B-Drug
and	O
ethinyl	B-Drug
estradiol	I-Drug
should	O
be	O
taken	O
into	O
consideration	O
when	O
selecting	O
an	O
oral	O
contraceptive	O
for	O
women	O
taking	O
valdecoxib	B-Drug
.	O

Diazepam	B-Drug
:	O
Diazepam	B-Drug
(	O
Valium	B-Drug
)	O
is	O
a	O
CYP	O
3A4	O
and	O
CYP	O
2C19	O
substrate	O
.	O

Plasma	O
exposure	O
of	O
diazepam	B-Drug
(	O
10	O
mg	O
BID	O
)	O
was	O
increased	O
by	O
28	O
%	O
following	O
administration	O
of	O
valdecoxib	B-Drug
(	O
40	O
mg	O
BID	O
)	O
for	O
12	O
days	O
,	O
while	O
plasma	O
exposure	O
of	O
valdecoxib	B-Drug
(	O
40	O
mg	O
BID	O
)	O
was	O
not	O
substantially	O
increased	O
following	O
administration	O
of	O
diazepam	B-Drug
(	O
10	O
mg	O
BID	O
)	O
for	O
12	O
days	O
.	O

Although	O
the	O
magnitude	O
of	O
changes	O
in	O
diazepam	B-Drug
plasma	O
exposure	O
when	O
coadministered	O
with	O
valdecoxib	B-Drug
were	O
not	O
sufficient	O
to	O
warrant	O
dosage	O
adjustments	O
,	O
patients	O
may	O
experience	O
enhanced	O
sedative	O
side	O
effects	O
caused	O
by	O
increased	O
exposure	O
of	O
diazepam	B-Drug
under	O
this	O
circumstance	O
.	O

Patients	O
should	O
be	O
cautioned	O
against	O
engaging	O
in	O
hazardous	O
activities	O
requiring	O
complete	O
mental	O
alertness	O
such	O
as	O
operating	O
machinery	O
or	O
driving	O
a	O
motor	O
vehicle	O
.	O

Effect	O
of	O
other	O
drugs	B-Drug
on	O
Vardenafil	B-Drug
In	O
vitro	O
studies	O
:	O
Studies	O
in	O
human	O
liver	O
microsomes	O
showed	O
that	O
vardenafil	B-Drug
is	O
metabolized	O
primarily	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
isoforms	O
3A4/5	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
by	O
CYP2C9	B-Drug
.	O

Therefore	O
,	O
inhibitors	O
of	O
these	O
enzymes	O
are	O
expected	O
to	O
reduce	O
vardenafil	B-Drug
clearance	O
.	O

In	O
vivo	O
studies	O
:	O
Cytochrome	O
P450	O
Inhibitors	O
Cimetidine	B-Drug
(	O
400	O
mg	O
b.i.d	O
.	O

)	O
had	O
no	O
effect	O
on	O
vardenafil	B-Drug
bioavailability	O
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
vardenafil	B-Drug
when	O
co-administered	O
with	O
20	O
mg	O
Vardenafil	B-Drug
in	O
healthy	O
volunteers	O
.	O

Erythromycin	B-Drug
(	O
500	O
mg	O
t.i.d	O
)	O
produced	O
a	O
4-fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
and	O
a	O
3-fold	O
increase	O
in	O
Cmax	O
when	O
co-administered	O
with	O
Vardenafil	B-Drug
5	O
mg	O
in	O
healthy	O
volunteers	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
5	O
mg	O
dose	O
of	O
Vardenafil	B-Drug
in	O
a	O
24-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
erythromycin	B-Drug
.	O

Ketoconazole	B-Drug
(	O
200	O
mg	O
once	O
daily	O
)	O
produced	O
a	O
10-fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
and	O
a	O
4-fold	O
increase	O
in	O
Cmax	O
when	O
co-administered	O
with	O
Vardenafil	B-Drug
(	O
5	O
mg	O
)	O
in	O
healthy	O
volunteers	O
.	O

A	O
5-mg	O
Vardenafil	B-Drug
dose	O
should	O
not	O
be	O
exceeded	O
when	O
used	O
in	O
combination	O
with	O
200	O
mg	O
once	O
daily	O
ketoconazole	B-Drug
.	O

Since	O
higher	O
doses	O
of	O
ketoconazole	B-Drug
(	O
400	O
mg	O
daily	O
)	O
may	O
result	O
in	O
higher	O
increases	O
in	O
Cmax	O
and	O
AUC	O
,	O
a	O
single	O
2.5	O
mg	O
dose	O
of	O
Vardenafil	B-Drug
should	O
not	O
be	O
exceeded	O
in	O
a	O
24-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ketoconazole	B-Drug
400	O
mg	O
daily	O
.	O

HIV	O
Protease	O
Inhibitors	O
:	O
Indinavir	B-Drug
(	O
800	O
mg	O
t.i.d	O
.	O

)	O
co-administered	O
with	O
Vardenafil	B-Drug
10	O
mg	O
resulted	O
in	O
a	O
16-fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
,	O
a	O
7-fold	O
increase	O
in	O
vardenafil	B-Drug
Cmax	O
and	O
a	O
2-fold	O
increase	O
in	O
vardenafil	B-Drug
half-life	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2.5	O
mg	O
Vardenafil	B-Drug
dose	O
in	O
a	O
24-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
indinavir	B-Drug
.	O

Ritonavir	B-Drug
(	O
600	O
mg	O
b.i.d	O
.	O

)	O
co-administered	O
with	O
Vardenafil	B-Drug
5	O
mg	O
resulted	O
in	O
a	O
49-fold	O
increase	O
in	O
vardenafil	B-Drug
AUC	O
and	O
a	O
13-fold	O
increase	O
in	O
vardenafil	B-Drug
Cmax	O
.	O

The	O
interaction	O
is	O
a	O
consequence	O
of	O
blocking	O
hepatic	O
metabolism	O
of	O
vardenafil	B-Drug
by	O
ritonavir	B-Drug
,	O
a	O
highly	O
potent	O
CYP3A4	B-Drug
inhibitor	O
,	O
which	O
also	O
inhibits	O
CYP2C9	B-Drug
.	O

Ritonavir	B-Drug
significantly	O
prolonged	O
the	O
half-life	O
of	O
vardenafil	B-Drug
to	O
26	O
hours	O
.	O

Consequently	O
,	O
it	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2.5	O
mg	O
Vardenafil	B-Drug
dose	O
in	O
a	O
72-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ritonavir	B-Drug
.	O

Other	O
Drug	B-Drug
Interactions	O
:	O
No	O
pharmacokinetic	O
interactions	O
were	O
observed	O
between	O
vardenafil	B-Drug
and	O
the	O
following	O
drugs	B-Drug
:	O
glyburide	B-Drug
,	O
warfarin	B-Drug
,	O
digoxin	B-Drug
,	O
Maalox	B-Drug
,	O
and	O
ranitidine	B-Drug
.	O

In	O
the	O
warfarin	B-Drug
study	O
,	O
vardenafil	B-Drug
had	O
no	O
effect	O
on	O
the	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
.	O

Effects	O
of	O
Vardenafil	B-Drug
on	O
other	O
drugs	B-Drug
In	O
vitro	O
studies	O
:	O
Vardenafil	B-Drug
and	O
its	O
metabolites	O
had	O
no	O
effect	O
on	O
CYP1A2	B-Drug
,	O
2A6	O
,	O
and	O
2E1	O
(	O
Ki	O
100uM	O
)	O
.	O

Weak	O
inhibitory	O
effects	O
toward	O
other	O
isoforms	O
(	O
CYP2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
3A4	O
)	O
were	O
found	O
,	O
but	O
Ki	O
values	O
were	O
in	O
excess	O
of	O
plasma	O
concentrations	O
achieved	O
following	O
dosing	O
.	O

The	O
most	O
potent	O
inhibitory	O
activity	O
was	O
observed	O
for	O
vardenafil	B-Drug
metabolite	O
M1	O
,	O
which	O
had	O
a	O
Ki	O
of	O
1.4	O
uM	O
toward	O
CYP3A4	B-Drug
,	O
which	O
is	O
about	O
20	O
times	O
higher	O
than	O
the	O
M1	O
Cmax	O
values	O
after	O
an	O
80	O
mg	O
Vardenafil	B-Drug
dose	O
.	O

In	O
vivo	O
studies	O
:	O
Nitrates	B-Drug
:	O
The	O
blood	O
pressure	O
lowering	O
effects	O
of	O
sublingual	O
nitrates	B-Drug
(	O
0.4	O
mg	O
)	O
taken	O
1	O
and	O
4	O
hours	O
after	O
vardenafil	B-Drug
and	O
increases	O
in	O
heart	O
rate	O
when	O
taken	O
at	O
1	O
,	O
4	O
and	O
8	O
hours	O
were	O
potentiated	O
by	O
a	O
20	O
mg	O
dose	O
of	O
Vardenafil	B-Drug
in	O
healthy	O
middle-aged	O
subjects	O
.	O

These	O
effects	O
were	O
not	O
observed	O
when	O
Vardenafil	B-Drug
20	O
mg	O
was	O
taken	O
24	O
hours	O
before	O
the	O
NTG	B-Drug
.	O

Potentiation	O
of	O
the	O
hypotensive	O
effects	O
of	O
nitrates	B-Drug
for	O
patients	O
with	O
ischemic	O
heart	O
disease	O
has	O
not	O
been	O
evaluated	O
,	O
and	O
concomitant	O
use	O
of	O
Vardenafil	B-Drug
and	O
nitrates	B-Drug
is	O
contraindicated	O
.	O

Nifedipine	B-Drug
:	O
Vardenafil	B-Drug
20	O
mg	O
,	O
when	O
co-administered	O
with	O
slow-release	O
nifedipine	B-Drug
30	O
mg	O
or	O
60	O
mg	O
once	O
daily	O
,	O
did	O
not	O
affect	O
the	O
relative	O
bioavailability	O
(	O
AUC	O
)	O
or	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
nifedipine	B-Drug
,	O
a	O
drug	B-Drug
that	O
is	O
metabolized	O
via	O
CYP3A4	B-Drug
.	O

Nifedipine	B-Drug
did	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
Vardenafil	B-Drug
when	O
taken	O
in	O
combination	O
.	O

In	O
these	O
patients	O
whose	O
hypertension	O
was	O
controlled	O
with	O
nifedipine	B-Drug
,	O
Vardenafil	B-Drug
20	O
mg	O
produced	O
mean	O
additional	O
supine	O
systolic/diastolic	O
blood	O
pressure	O
reductions	O
of	O
6/5	O
mm	O
Hg	O
compared	O
to	O
placebo	O
.	O

Alpha-blockers	O
:	O
When	O
Vardenafil	B-Drug
10	O
or	O
20	O
mg	O
was	O
given	O
to	O
healthy	O
volunteers	O
either	O
simultaneously	O
or	O
6	O
hours	O
after	O
a	O
10	O
mg	O
dose	O
of	O
terazosin	B-Drug
,	O
significant	O
hypotension	O
developed	O
in	O
a	O
substantial	O
number	O
of	O
subjects	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B-Drug
10	O
mg	O
and	O
terazosin	B-Drug
10	O
mg	O
,	O
6	O
of	O
8	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B-Drug
20	O
mg	O
and	O
terazosin	B-Drug
10	O
mg	O
,	O
2	O
of	O
9	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

When	O
Vardenafil	B-Drug
dosing	O
was	O
separated	O
from	O
terazosin	B-Drug
10	O
mg	O
by	O
6	O
hours	O
,	O
7	O
of	O
28	O
subjects	O
who	O
received	O
20	O
mg	O
of	O
Vardenafil	B-Drug
experienced	O
a	O
decrease	O
in	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

In	O
a	O
similar	O
study	O
with	O
tamsulosin	B-Drug
in	O
healthy	O
volunteers	O
,	O
1	O
of	O
24	O
subjects	O
dosed	O
with	O
Vardenafil	B-Drug
20	O
mg	O
and	O
tamsulosin	B-Drug
0.4	O
mg	O
separated	O
by	O
6	O
hours	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

Two	O
of	O
16	O
subjects	O
dosed	O
simultaneously	O
with	O
Vardenafil	B-Drug
10	O
mg	O
and	O
tamsulosin	B-Drug
0.4	O
mg	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

The	O
administration	O
of	O
lower	O
doses	O
of	O
Vardenafil	B-Drug
with	O
alpha-blockers	O
has	O
not	O
been	O
completely	O
evaluated	O
to	O
determine	O
if	O
they	O
can	O
be	O
safely	O
administered	O
together	O
.	O

Based	O
on	O
these	O
data	O
,	O
Vardenafil	B-Drug
should	O
not	O
be	O
used	O
in	O
patients	O
on	O
alpha-blocker	O
therapy	O
.	O

Ritonavir	B-Drug
and	O
indinavir	B-Drug
:	O
Upon	O
concomitant	O
administration	O
of	O
5	O
mg	O
of	O
Vardenafil	B-Drug
with	O
600	O
mg	O
BID	O
ritonavir	B-Drug
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
ritonavir	B-Drug
were	O
reduced	O
by	O
approximately	O
20	O
%	O
.	O

Upon	O
administration	O
of	O
10	O
mg	O
of	O
Vardenafil	B-Drug
with	O
800	O
mg	O
TID	O
indinavir	B-Drug
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
indinavir	B-Drug
were	O
reduced	O
by	O
40	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O

Alcohol	B-Drug
:	O
Alcohol	B-Drug
(	O
0.5	O
g/kg	O
body	O
weight	O
:	O
approximately	O
40	O
mL	O
of	O
absolute	O
alcohol	B-Drug
in	O
a	O
70	O
kg	O
person	O
)	O
and	O
vardenafil	B-Drug
plasma	O
levels	O
were	O
not	O
altered	O
when	O
dosed	O
simultaneously	O
.	O

Vardenafil	B-Drug
(	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
alcohol	B-Drug
during	O
the	O
4-hour	O
observation	O
period	O
in	O
healthy	O
volunteers	O
when	O
administered	O
with	O
alcohol	B-Drug
(	O
0.5	O
g/kg	O
body	O
weight	O
)	O
.	O

Aspirin	B-Drug
:	O
Vardenafil	B-Drug
(	O
10	O
mg	O
and	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
increase	O
in	O
bleeding	O
time	O
caused	O
by	O
aspirin	B-Drug
(	O
two	O
81	O
mg	O
tablets	O
)	O
.	O

Other	O
interactions	O
:	O
Vardenafil	B-Drug
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
glyburide	B-Drug
(	O
glucose	B-Drug
and	O
insulin	B-Drug
concentrations	O
)	O
and	O
warfarin	B-Drug
(	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
)	O
.	O

Zidovudine	B-Drug
:	O
There	O
is	O
no	O
significant	O
pharmacokinetic	O
interaction	O
between	O
ZDV	B-Drug
and	O
zalcitabine	B-Drug
which	O
has	O
been	O
confirmed	O
clinically	O
.	O

Zalcitabine	B-Drug
also	O
has	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
ZDV	B-Drug
,	O
as	O
shown	O
in	O
vitro	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
in	O
two	O
other	O
cell	O
lines	O
(	O
U937	O
and	O
Molt-4	O
)	O
.	O

In	O
the	O
same	O
study	O
it	O
was	O
shown	O
that	O
didanosine	B-Drug
and	O
stavudine	B-Drug
had	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	B-Drug
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Lamivudine	B-Drug
:	O
In	O
vitro	O
studies	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
U937	O
and	O
Molt-4	O
cells	O
revealed	O
that	O
lamivudine	B-Drug
significantly	O
inhibited	O
zalcitabine	B-Drug
phosphorylation	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

Effects	O
were	O
already	O
seen	O
with	O
doses	O
corresponding	O
to	O
relevant	O
plasma	O
levels	O
in	O
humans	O
,	O
and	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	B-Drug
to	O
its	O
three	O
metabolites	O
(	O
including	O
the	O
active	O
zalcitabine	B-Drug
triphosphate	O
metabolite	O
)	O
was	O
significantly	O
inhibited	O
.	O

Zalcitabine	B-Drug
inhibited	O
lamivudine	B-Drug
phosphorylation	O
at	O
high	O
concentration	O
ratios	O
(	O
10	O
and	O
100	O
)	O
;	O
however	O
,	O
it	O
is	O
considered	O
to	O
be	O
unlikely	O
that	O
this	O
decrease	O
of	O
phosphorylated	O
lamivudine	B-Drug
concentration	O
is	O
of	O
clinical	O
significance	O
,	O
as	O
lamivudine	B-Drug
is	O
a	O
more	O
efficient	O
substrate	O
for	O
deoxycytidine	O
kinase	O
than	O
zalcitabine	B-Drug
.	O

These	O
in	O
vitro	O
studies	O
suggest	O
that	O
concomitant	O
administration	O
of	O
zalcitabine	B-Drug
and	O
lamivudine	B-Drug
in	O
humans	O
may	O
result	O
in	O
sub-therapeutic	O
concentrations	O
of	O
active	O
phosphorylated	O
zalcitabine	B-Drug
,	O
which	O
may	O
lead	B-Drug
to	O
a	O
decreased	O
antiretroviral	O
effect	O
of	O
zalcitabine	B-Drug
.	O

It	O
is	O
unknown	O
how	O
the	O
effect	O
seen	O
in	O
these	O
in	O
vitro	O
studies	O
translates	O
into	O
clinical	O
consequences	O
.	O

Concomitant	O
use	O
of	O
zalcitabine	B-Drug
and	O
lamivudine	B-Drug
is	O
not	O
recommended	O
.	O

Saquinavir	B-Drug
:	O
The	O
combination	O
of	O
HIVID	B-Drug
,	O
saquinavir	B-Drug
,	O
and	O
ZDV	B-Drug
has	O
been	O
studied	O
(	O
as	O
triple	O
combination	O
)	O
in	O
adults	O
.	O

Pharmacokinetic	O
data	O
suggest	O
that	O
absorption	O
,	O
metabolism	O
,	O
and	O
elimination	O
of	O
each	O
of	O
these	O
drugs	B-Drug
are	O
unchanged	O
when	O
they	O
are	O
used	O
together	O
.	O

Drugs	B-Drug
Associated	O
With	O
Peripheral	O
Neuropathy	O
:	O
The	O
concomitant	O
use	O
of	O
HIVID	B-Drug
with	O
drugs	B-Drug
that	O
have	O
the	O
potential	O
to	O
cause	O
peripheral	O
neuropathy	O
should	O
be	O
avoided	O
where	O
possible	O
.	O

Drugs	B-Drug
that	O
have	O
been	O
associated	O
with	O
peripheral	O
neuropathy	O
include	O
antiretroviral	B-Drug
nucleoside	I-Drug
analogues	I-Drug
,	O
chloramphenicol	B-Drug
,	O
cisplatin	B-Drug
,	O
dapsone	B-Drug
,	O
disulfiram	B-Drug
,	O
ethionamide	B-Drug
,	O
glutethimide	B-Drug
,	O
gold	B-Drug
,	O
hydralazine	B-Drug
,	O
iodoquinol	B-Drug
,	O
isoniazid	B-Drug
,	O
metronidazole	B-Drug
,	O
nitrofurantoin	B-Drug
,	O
phenytoin	B-Drug
,	O
ribavirin	B-Drug
,	O
and	O
vincristine	B-Drug
.	O

Concomitant	O
use	O
of	O
HIVID	B-Drug
with	O
didanosine	B-Drug
is	O
not	O
recommended	O
.	O

Intravenous	O
Pentamidine	B-Drug
:	O
Treatment	O
with	O
HIVID	B-Drug
should	O
be	O
interrupted	O
when	O
the	O
use	O
of	O
a	O
drug	B-Drug
that	O
has	O
the	O
potential	O
to	O
cause	O
pancreatitis	O
is	O
required	O
.	O

Death	O
due	O
to	O
fulminant	O
pancreatitis	O
possibly	O
related	O
to	O
intravenous	O
pentamidine	B-Drug
and	O
HIVID	B-Drug
has	O
been	O
reported	O
.	O

If	O
intravenous	O
pentamidine	B-Drug
is	O
required	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
,	O
treatment	O
with	O
HIVID	B-Drug
should	O
be	O
interrupted	O
.	O

Amphotericin	B-Drug
,	O
Foscarnet	B-Drug
,	O
and	O
Aminoglycosides	O
:	O
Drugs	B-Drug
such	O
as	O
amphotericin	B-Drug
,	O
foscarnet	B-Drug
,	O
and	O
aminoglycosides	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
peripheral	O
neuropathy	O
or	O
other	O
HIVID-associated	B-Drug
adverse	O
events	O
by	O
interfering	O
with	O
the	O
renal	O
clearance	O
of	O
zalcitabine	B-Drug
(	O
thereby	O
raising	O
systemic	O
exposure	O
)	O
.	O

Patients	O
who	O
require	O
the	O
use	O
of	O
one	O
of	O
these	O
drugs	B-Drug
with	O
HIVID	B-Drug
should	O
have	O
frequent	O
clinical	O
and	O
laboratory	O
monitoring	O
with	O
dosage	O
adjustment	O
for	O
any	O
significant	O
change	O
in	O
renal	O
function	O
.	O

Probenecid	B-Drug
or	O
Cimetidine	B-Drug
:	O
Concomitant	O
administration	O
of	O
probenecid	B-Drug
or	O
cimetidine	B-Drug
decreases	O
the	O
elimination	O
of	O
zalcitabine	B-Drug
,	O
most	O
likely	O
by	O
inhibition	O
of	O
renal	O
tubular	O
secretion	O
of	O
zalcitabine	B-Drug
.	O

Patients	O
receiving	O
these	O
drugs	B-Drug
in	O
combination	O
with	O
zalcitabine	B-Drug
should	O
be	O
monitored	O
for	O
signs	O
of	O
toxicity	O
and	O
the	O
dose	O
of	O
zalcitabine	B-Drug
reduced	O
if	O
warranted	O
.	O

Magnesium/Aluminum-containing	B-Drug
Antacid	O
Products	O
:	O
Absorption	O
of	O
zalcitabine	B-Drug
is	O
moderately	O
reduced	O
(	O
approximately	O
25	O
%	O
)	O
when	O
coadministered	O
with	O
magnesium/aluminum-containing	B-Drug
antacid	O
products	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
reduction	O
is	O
not	O
known	O
,	O
hence	O
zalcitabine	B-Drug
is	O
not	O
recommended	O
to	O
be	O
ingested	O
simultaneously	O
with	O
magnesium/aluminum-containing	B-Drug
antacids	O
.	O

Metoclopramide	B-Drug
:	O
Bioavailability	O
is	O
mildly	O
reduced	O
(	O
approximately	O
10	O
%	O
)	O
when	O
zalcitabine	B-Drug
and	O
metoclopramide	B-Drug
are	O
coadministered	O
.	O

Doxorubicin	B-Drug
:	O
Doxorubicin	B-Drug
caused	O
a	O
decrease	O
in	O
zalcitabine	B-Drug
phosphorylation	O
(	O
50	O
%	O
inhibition	O
of	O
total	O
phosphate	B-Drug
formation	O
)	O
in	O
U937/Molt	O
4	O
cells	O
.	O

Although	O
there	O
may	O
be	O
decreased	O
zalcitabine	B-Drug
activity	O
because	O
of	O
lessened	O
active	O
metabolite	O
formation	O
,	O
the	O
clinical	O
relevance	O
of	O
these	O
in	O
vitro	O
results	O
are	O
not	O
known	O
.	O

As	O
with	O
all	O
drugs	B-Drug
,	O
the	O
potential	O
exists	O
for	O
interaction	O
with	O
other	O
drugs	B-Drug
by	O
a	O
variety	O
of	O
mechanisms	O
.	O

CNS-Active	O
Drugs	B-Drug
Ethanol	B-Drug
:	O
Sonata	B-Drug
10	O
mg	O
potentiated	O
the	O
CNS-impairing	O
effects	O
of	O
ethanol	B-Drug
0.75	O
g/kg	O
on	O
balance	O
testing	O
and	O
reaction	O
time	O
for	O
1	O
hour	O
after	O
ethanol	B-Drug
administration	O
and	O
on	O
the	O
digit	O
symbol	O
substitution	O
test	O
(	O
DSST	O
)	O
,	O
symbol	O
copying	O
test	O
,	O
and	O
the	O
variability	O
component	O
of	O
the	O
divided	O
attention	O
test	O
for	O
2.5	O
hours	O
after	O
ethanol	B-Drug
administration	O
.	O

The	O
potentiation	O
resulted	O
from	O
a	O
CNS	O
pharmacodynamic	O
interaction	O
;	O
zaleplon	B-Drug
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
ethanol	B-Drug
.	O

Imipramine	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	B-Drug
20	O
mg	O
and	O
imipramine	B-Drug
75	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
2	O
to	O
4	O
hours	O
after	O
administration	O
.	O

The	O
interaction	O
was	O
pharmacodynamic	O
with	O
no	O
alteration	O
of	O
the	O
pharmacokinetics	O
of	O
either	O
drug	B-Drug
.	O

Paroxetine	B-Drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
Sonata	B-Drug
20	O
mg	O
and	O
paroxetine	B-Drug
20	O
mg	O
daily	O
for	O
7	O
days	O
did	O
not	O
produce	O
any	O
interaction	O
on	O
psychomotor	O
performance	O
.	O

Additionally	O
,	O
paroxetine	B-Drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
Sonata	B-Drug
,	O
reflecting	O
the	O
absence	O
of	O
a	O
role	O
of	O
CYP2D6	B-Drug
in	O
zaleplon	B-Drug
s	O
metabolism	O
.	O

Thioridazine	B-Drug
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	B-Drug
20	O
mg	O
and	O
thioridazine	B-Drug
50	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
2	O
to	O
4	O
hours	O
after	O
administration	O
.	O

The	O
interaction	O
was	O
pharmacodynamic	O
with	O
no	O
alteration	O
of	O
the	O
pharmacokinetics	O
of	O
either	O
drug	B-Drug
.	O

Venlafaxine	B-Drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	B-Drug
10	O
mg	O
and	O
multiple	O
doses	O
of	O
venlafaxine	B-Drug
ER	O
(	O
extended	O
release	O
)	O
150	O
mg	O
did	O
not	O
result	O
in	O
any	O
significant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
zaleplon	B-Drug
or	O
venlafaxine	B-Drug
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
as	O
a	O
result	O
of	O
coadministration	O
of	O
zaleplon	B-Drug
and	O
venlafaxine	B-Drug
ER	O
.	O

Promethazine	B-Drug
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	B-Drug
and	O
promethazine	B-Drug
(	O
10	O
and	O
25	O
mg	O
,	O
respectively	O
)	O
resulted	O
in	O
a	O
15	O
%	O
decrease	O
in	O
maximal	O
plasma	O
concentrations	O
of	O
zaleplon	B-Drug
,	O
but	O
no	O
change	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
.	O

However	O
,	O
the	O
pharmacodynamics	O
of	O
coadministration	O
of	O
zaleplon	B-Drug
and	O
promethazine	B-Drug
have	O
not	O
been	O
evaluated	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
these	O
2	O
agents	O
are	O
coadministered	O
.	O

Drugs	B-Drug
That	O
Induce	O
CYP3A4	B-Drug
Rifampin	B-Drug
:	O
CYP3A4	B-Drug
is	O
ordinarily	O
a	O
minor	O
metabolizing	O
enzyme	O
of	O
zaleplon	B-Drug
.	O

Multiple-dose	O
administration	O
of	O
the	O
potent	O
CYP3A4	B-Drug
inducer	O
rifampin	B-Drug
(	O
600	O
mg	O
every	O
24	O
hours	O
,	O
q24h	O
,	O
for	O
14	O
days	O
)	O
,	O
however	O
,	O
reduced	O
zaleplon	B-Drug
Cmax	O
and	O
AUC	O
by	O
approximately	O
80	O
%	O
.	O

The	O
coadministration	O
of	O
a	O
potent	O
CYP3A4	B-Drug
enzyme	O
inducer	O
,	O
although	O
not	O
posing	O
a	O
safety	O
concern	O
,	O
thus	O
could	O
lead	B-Drug
to	O
ineffectiveness	O
of	O
zaleplon	B-Drug
.	O

An	O
alternative	O
non-CYP3A4	O
substrate	O
hypnotic	O
agent	O
may	O
be	O
considered	O
in	O
patients	O
taking	O
CYP3A4	B-Drug
inducers	O
such	O
as	O
rifampin	B-Drug
,	O
phenytoin	B-Drug
,	O
carbamazepine	B-Drug
,	O
and	O
phenobarbital	B-Drug
.	O

Drugs	B-Drug
That	O
Inhibit	O
CYP3A4	B-Drug
CYP3A4	B-Drug
is	O
a	O
minor	O
metabolic	O
pathway	O
for	O
the	O
elimination	O
of	O
zaleplon	B-Drug
because	O
the	O
sum	O
of	O
desethylzaleplon	O
(	O
formed	O
via	O
CYP3A4	B-Drug
in	O
vitro	O
)	O
and	O
its	O
metabolites	O
,	O
5-oxo-desethylzaleplon	B-Drug
and	O
5-oxo-desethylzaleplon	B-Drug
glucuronide	I-Drug
,	O
account	O
for	O
only	O
9	O
%	O
of	O
the	O
urinary	O
recovery	O
of	O
a	O
zaleplon	B-Drug
dose	O
.	O

Coadministration	O
of	O
single	O
,	O
oral	O
doses	O
of	O
zaleplon	B-Drug
with	O
erythromycin	B-Drug
(	O
10	O
mg	O
and	O
800	O
mg	O
,	O
respectively	O
)	O
,	O
a	O
strong	O
,	O
selective	O
CYP3A4	B-Drug
inhibitor	O
produced	O
a	O
34	O
%	O
increase	O
in	O
zaleplons	B-Drug
maximal	O
plasma	O
concentrations	O
and	O
a	O
20	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
.	O

The	O
magnitude	O
of	O
interaction	O
with	O
multiple	O
doses	O
of	O
erythromycin	B-Drug
is	O
unknown	O
.	O

Other	O
strong	O
selective	O
CYP3A4	B-Drug
inhibitors	O
such	O
as	O
ketoconazole	B-Drug
can	O
also	O
be	O
expected	O
to	O
increase	O
the	O
exposure	O
of	O
zaleplon	B-Drug
.	O

A	O
routine	O
dosage	O
adjustment	O
of	O
zaleplon	B-Drug
is	O
not	O
considered	O
necessary	O
.	O

Drugs	B-Drug
That	O
Inhibit	O
Aldehyde	O
Oxidase	O
The	O
aldehyde	O
oxidase	O
enzyme	O
system	O
is	O
less	O
well	O
studied	O
than	O
the	O
cytochrome	O
P450	O
enzyme	O
system	O
.	O

Diphenhydramine	B-Drug
:	O
Diphenhydramine	B-Drug
is	O
reported	O
to	O
be	O
a	O
weak	O
inhibitor	O
of	O
aldehyde	O
oxidase	O
in	O
rat	O
liver	O
,	O
but	O
its	O
inhibitory	O
effects	O
in	O
human	O
liver	O
are	O
not	O
known	O
.	O

There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	B-Drug
and	O
diphenhydramine	B-Drug
following	O
the	O
administration	O
of	O
a	O
single	O
dose	O
(	O
10	O
mg	O
and	O
50	O
mg	O
,	O
respectively	O
)	O
of	O
each	O
drug	B-Drug
.	O

However	O
,	O
because	O
both	O
of	O
these	O
compounds	O
have	O
CNS	O
effects	O
,	O
an	O
additive	O
pharmacodynamic	O
effect	O
is	O
possible	O
.	O

Drugs	B-Drug
That	O
Inhibit	O
Both	O
Aldehyde	O
Oxidase	O
and	O
CYP3A4	B-Drug
Cimetidine	B-Drug
:	O
Cimetidine	B-Drug
inhibits	O
both	O
aldehyde	O
oxidase	O
(	O
in	O
vitro	O
)	O
and	O
CYP3A4	B-Drug
(	O
in	O
vitro	O
and	O
in	O
vivo	O
)	O
,	O
the	O
primary	O
and	O
secondary	O
enzymes	O
,	O
respectively	O
,	O
responsible	O
for	O
zaleplon	B-Drug
metabolism	O
.	O

Concomitant	O
administration	O
of	O
Sonata	B-Drug
(	O
10	O
mg	O
)	O
and	O
cimetidine	B-Drug
(	O
800	O
mg	O
)	O
produced	O
an	O
85	O
%	O
increase	O
in	O
the	O
mean	O
Cmax	O
and	O
AUC	O
of	O
zaleplon	B-Drug
.	O

An	O
initial	O
dose	O
of	O
5	O
mg	O
should	O
be	O
given	O
to	O
patients	O
who	O
are	O
concomitantly	O
being	O
treated	O
with	O
cimetidine	B-Drug
.	O

Drugs	B-Drug
Highly	O
Bound	O
to	O
Plasma	O
Protein	O
Zaleplon	B-Drug
is	O
not	O
highly	O
bound	O
to	O
plasma	O
proteins	O
(	O
fraction	O
bound	O
60	O
%	O
15	O
%	O
)	O
;	O
therefore	O
,	O
the	O
disposition	O
of	O
zaleplon	B-Drug
is	O
not	O
expected	O
to	O
be	O
sensitive	O
to	O
alterations	O
in	O
protein	O
binding	O
.	O

In	O
addition	O
,	O
administration	O
of	O
Sonata	B-Drug
to	O
a	O
patient	O
taking	O
another	O
drug	B-Drug
that	O
is	O
highly	O
protein	O
bound	O
should	O
not	O
cause	O
transient	O
increase	O
in	O
free	O
concentrations	O
of	O
the	O
other	O
drug	B-Drug
.	O

Drugs	B-Drug
with	O
a	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	B-Drug
:	O
Sonata	B-Drug
(	O
10	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetic	O
or	O
pharmacodynamic	O
profile	O
of	O
digoxin	B-Drug
(	O
0.375	O
mg	O
q24h	O
for	O
8	O
days	O
)	O
.	O

Warfarin	B-Drug
:	O
Multiple	O
oral	O
doses	O
of	O
Sonata	B-Drug
(	O
20	O
mg	O
q24h	O
for	O
13	O
days	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	B-Drug
(	O
R+	O
)	O
-	O
or	O
(	O
S-	O
)	O
-enantiomers	O
or	O
the	O
pharmacodynamics	O
(	O
prothrombin	O
time	O
)	O
following	O
a	O
single	O
25-mg	O
oral	O
dose	O
of	O
warfarin	B-Drug
.	O

Drugs	B-Drug
That	O
Alter	O
Renal	O
Excretion	O
Ibuprofen	B-Drug
:	O
Ibuprofen	B-Drug
is	O
known	O
to	O
affect	O
renal	O
function	O
and	O
,	O
consequently	O
,	O
alter	O
the	O
renal	O
excretion	O
of	O
other	O
drugs	B-Drug
.	O

There	O
was	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	B-Drug
and	O
ibuprofen	B-Drug
following	O
single	O
dose	O
administration	O
(	O
10	O
mg	O
and	O
600	O
mg	O
,	O
respectively	O
)	O
of	O
each	O
drug	B-Drug
.	O

This	O
was	O
expected	O
because	O
zaleplon	B-Drug
is	O
primarily	O
metabolized	O
and	O
renal	O
excretion	O
of	O
unchanged	O
zaleplon	B-Drug
accounts	O
for	O
less	O
than	O
1	O
%	O
of	O
the	O
administered	O
dose	O
.	O

No	O
enhancement	O
by	O
phenobarbital	B-Chemical
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline-devoid	B-Chemical
diet	O
in	O
the	O
rat	O
.	O

An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	B-Chemical
in	O
a	O
choline-devoid	B-Chemical
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O

Groups	O
of	O
5-week	O
old	O
male	O
Fischer-344	O
rats	O
were	O
fed	O
for	O
7-25	O
months	O
semipurified	O
choline-devoid	B-Chemical
or	O
choline-supplemented	B-Chemical
diets	O
,	O
containing	O
or	O
not	O
0.06	O
%	O
phenobarbital	B-Chemical
.	O

No	O
hepatic	O
preneoplastic	O
nodules	O
or	O
hepatocellular	B-Disease
carcinomas	I-Disease
developed	O
in	O
rats	O
fed	O
the	O
plain	O
choline-supplemented	B-Chemical
diet	O
,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	B-Disease
carcinoma	I-Disease
developed	O
in	O
two	O
rats	O
fed	O
the	O
same	O
diet	O
containing	O
phenobarbital	B-Chemical
.	O

The	O
incidence	O
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	B-Disease
carcinomas	I-Disease
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
fed	O
the	O
plain	O
choline-devoid	B-Chemical
diet	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rats	O
fed	O
the	O
phenobarbital-containing	B-Chemical
choline-devoid	B-Chemical
diet	O
.	O

The	O
results	O
evinced	O
no	O
enhancement	O
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline-devoid	B-Chemical
diet	O
by	O
phenobarbital	B-Chemical
.	O

Sporadic	O
neoplastic	O
lesions	O
were	O
observed	O
in	O
organs	O
other	O
than	O
the	O
liver	O
of	O
some	O
of	O
the	O
animals	O
,	O
irrespective	O
of	O
the	O
diet	O
fed	O
.	O

Effect	O
of	O
direct	O
intracoronary	O
administration	O
of	O
methylergonovine	B-Chemical
in	O
patients	O
with	O
and	O
without	O
variant	B-Disease
angina	I-Disease
.	O

The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	B-Chemical
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	B-Disease
angina	I-Disease
and	O
22	O
patients	O
with	O
atypical	O
chest	B-Disease
pain	I-Disease
and	O
in	O
others	O
without	O
angina	B-Disease
pectoris	I-Disease
(	O
control	O
group	O
)	O
.	O

Methylergonovine	B-Chemical
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms/min	O
up	O
to	O
50	O
micrograms	O
.	O

In	O
all	O
patients	O
with	O
variant	B-Disease
angina	I-Disease
,	O
coronary	B-Disease
spasm	I-Disease
was	O
provoked	O
at	O
a	O
mean	O
dose	O
of	O
28	O
+/-	O
13	O
micrograms	O
(	O
mean	O
+/-	O
SD	O
)	O
.	O

In	O
the	O
control	O
group	O
neither	O
ischemic	O
ST	O
change	O
nor	O
localized	O
spasm	B-Disease
occurred	O
.	O

The	O
basal	O
tone	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O

The	O
percentage	O
of	O
vasoconstriction	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O

These	O
results	O
suggest	O
that	O
spasm	B-Disease
provocation	O
tests	O
,	O
which	O
use	O
an	O
intracoronary	O
injection	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
methylergonovine	B-Chemical
,	O
have	O
a	O
high	O
sensitivity	O
in	O
variant	B-Disease
angina	I-Disease
and	O
the	O
vasoreactivity	O
of	O
the	O
right	O
coronary	O
artery	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
coronary	O
arteries	O
.	O

Dobutamine	B-Chemical
stress	O
echocardiography	O
:	O
a	O
sensitive	O
indicator	O
of	O
diminished	O
myocardial	O
function	O
in	O
asymptomatic	O
doxorubicin-treated	B-Chemical
long-term	O
survivors	O
of	O
childhood	O
cancer	B-Disease
.	O

Doxorubicin	B-Chemical
is	O
an	O
effective	O
anticancer	O
chemotherapeutic	O
agent	O
known	O
to	O
cause	O
acute	O
and	O
chronic	O
cardiomyopathy	B-Disease
.	O

To	O
develop	O
a	O
more	O
sensitive	O
echocardiographic	O
screening	O
test	O
for	O
cardiac	B-Disease
damage	I-Disease
due	O
to	O
doxorubicin	B-Chemical
,	O
a	O
cohort	O
study	O
was	O
performed	O
using	O
dobutamine	B-Chemical
infusion	O
to	O
differentiate	O
asymptomatic	O
long-term	O
survivors	O
of	O
childhood	O
cancer	B-Disease
treated	O
with	O
doxorubicin	B-Chemical
from	O
healthy	O
control	O
subjects	O
.	O

Echocardiographic	O
data	O
from	O
the	O
experimental	O
group	O
of	O
21	O
patients	O
(	O
mean	O
age	O
16	O
+/-	O
5	O
years	O
)	O
treated	O
from	O
1.6	O
to	O
14.3	O
years	O
(	O
median	O
5.3	O
)	O
before	O
this	O
study	O
with	O
27	O
to	O
532	O
mg/m2	O
of	O
doxorubicin	B-Chemical
(	O
mean	O
196	O
)	O
were	O
compared	O
with	O
echocardiographic	O
data	O
from	O
12	O
normal	O
age-matched	O
control	O
subjects	O
.	O

Graded	O
dobutamine	B-Chemical
infusions	O
of	O
0.5	O
,	O
2.5	O
,	O
5	O
and	O
10	O
micrograms/kg	O
per	O
min	O
were	O
administered	O
.	O

Echocardiographic	O
Doppler	O
studies	O
were	O
performed	O
before	O
infusion	O
and	O
after	O
15	O
min	O
of	O
infusion	O
at	O
each	O
rate	O
.	O

Dobutamine	B-Chemical
infusion	O
at	O
10	O
micrograms/kg	O
per	O
min	O
was	O
discontinued	O
after	O
six	O
studies	O
secondary	O
to	O
a	O
50	O
%	O
incidence	O
rate	O
of	O
adverse	O
symptoms	O
.	O

The	O
most	O
important	O
findings	O
were	O
that	O
compared	O
with	O
values	O
in	O
control	O
subjects	O
,	O
end-systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
and	O
percent	O
of	O
left	O
ventricular	O
posterior	O
wall	O
thickening	O
in	O
doxorubicin-treated	B-Chemical
patients	O
were	O
decreased	O
at	O
baseline	O
study	O
and	O
these	O
findings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	B-Chemical
stimulation	O
.	O

End-systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
baseline	O
for	O
the	O
doxorubicin-treated	B-Chemical
group	O
was	O
11	O
+/-	O
1.9	O
mm	O
versus	O
13.1	O
+/-	O
1.5	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

End-systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
the	O
5-micrograms/kg	O
per	O
min	O
dobutamine	B-Chemical
infusion	O
for	O
the	O
doxorubicin-treated	B-Chemical
group	O
was	O
14.1	O
+/-	O
2.4	O
mm	O
versus	O
19.3	O
+/-	O
2.6	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Effects	O
of	O
aminophylline	B-Chemical
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	B-Disease
fibrillation	I-Disease
during	O
respiratory	B-Disease
failure	I-Disease
.	O

Cardiac	B-Disease
arrhythmias	I-Disease
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respiratory	B-Disease
failure	I-Disease
.	O

The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	O
in	O
precipitating	O
cardiac	B-Disease
disturbances	I-Disease
in	O
patients	O
with	O
respiratory	B-Disease
failure	I-Disease
has	O
only	O
recently	O
been	O
emphasized	O
.	O

The	O
effects	O
of	O
aminophylline	B-Chemical
on	O
the	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
during	O
normal	O
acid-base	O
conditions	O
and	O
during	O
respiratory	B-Disease
failure	I-Disease
were	O
studied	O
in	O
anesthetized	O
open	O
chest	O
dogs	O
.	O

The	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
was	O
measured	O
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	O
pulses	O
through	O
the	O
ventricular	O
myocardium	O
during	O
the	O
vulnerable	O
period	O
of	O
the	O
cardiac	O
cycle	O
.	O

During	O
the	O
infusion	O
of	O
aminophylline	B-Chemical
,	O
the	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
was	O
reduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
control	O
when	O
pH	O
and	O
partial	O
pressures	O
of	O
oxygen	B-Chemical
(	O
PO2	B-Chemical
)	O
and	O
carbon	B-Chemical
dioxide	I-Chemical
(	O
CO2	B-Chemical
)	O
were	O
kept	O
within	O
normal	O
limits	O
.	O

When	O
respiratory	B-Disease
failure	I-Disease
was	O
produced	O
by	O
hypoventilation	B-Disease
(	O
pH	O
7.05	O
to	O
7.25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infusion	O
of	O
aminophylline	B-Chemical
resulted	O
in	O
an	O
even	O
greater	O
decrease	O
in	O
ventricular	B-Disease
fibrillation	I-Disease
threshold	O
to	O
60	O
percent	O
of	O
the	O
control	O
level	O
.	O

These	O
experiments	O
suggest	O
that	O
although	O
many	O
factors	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
ventricular	B-Disease
arrhythmias	I-Disease
in	O
respiratory	B-Disease
failure	I-Disease
,	O
pharmacologic	O
agents	O
,	O
particularly	O
aminophylline	B-Chemical
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Case	O
report	O
:	O
acute	O
unintentional	O
carbachol	B-Chemical
intoxication	O
.	O

INTRODUCTION	O
:	O
Intoxications	O
with	O
carbachol	B-Chemical
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
agonist	O
are	O
rare	O
.	O

We	O
report	O
an	O
interesting	O
case	O
investigating	O
a	O
(	O
near	O
)	O
fatal	O
poisoning	B-Disease
.	O

METHODS	O
:	O
The	O
son	O
of	O
an	O
84-year-old	O
male	O
discovered	O
a	O
newspaper	O
report	O
stating	O
clinical	O
success	O
with	O
plant	O
extracts	O
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

The	O
mode	O
of	O
action	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	O
'carbamylcholin	B-Chemical
'	O
;	O
that	O
is	O
,	O
carbachol	B-Chemical
.	O

He	O
bought	O
25	O
g	O
of	O
carbachol	B-Chemical
as	O
pure	O
substance	O
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg.	O
Carbachol	B-Chemical
concentrations	O
in	O
serum	O
and	O
urine	O
on	O
day	O
1	O
and	O
2	O
of	O
hospital	O
admission	O
were	O
analysed	O
by	O
HPLC-mass	O
spectrometry	O
.	O

RESULTS	O
:	O
Minutes	O
after	O
oral	O
administration	O
,	O
the	O
patient	O
developed	O
nausea	B-Disease
,	O
sweating	O
and	O
hypotension	B-Disease
,	O
and	O
finally	O
collapsed	O
.	O

Bradycardia	B-Disease
,	O
cholinergic	O
symptoms	O
and	O
asystole	B-Disease
occurred	O
.	O

Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	B-Chemical
(	O
epinephrine	B-Chemical
)	O
,	O
atropine	B-Chemical
and	O
furosemide	B-Chemical
was	O
successful	O
.	O

On	O
hospital	O
admission	O
,	O
blood	O
pressure	O
of	O
the	O
intubated	O
,	O
bradyarrhythmic	O
patient	O
was	O
100/65	O
mmHg	O
.	O

Further	O
signs	O
were	O
hyperhidrosis	B-Disease
,	O
hypersalivation	B-Disease
,	O
bronchorrhoea	B-Disease
,	O
and	O
severe	O
miosis	B-Disease
;	O
the	O
electrocardiographic	O
finding	O
was	O
atrio-ventricular	B-Disease
dissociation	I-Disease
.	O

High	O
doses	O
of	O
atropine	B-Chemical
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenaline	B-Chemical
and	O
dopamine	B-Chemical
were	O
necessary	O
.	O

The	O
patient	O
was	O
extubated	O
1	O
week	O
later	O
.	O

However	O
,	O
increased	O
dyspnoea	B-Disease
and	O
bronchospasm	B-Disease
necessitated	O
reintubation	O
.	O

Respiratory	B-Disease
insufficiency	I-Disease
was	O
further	O
worsened	O
by	O
Proteus	B-Disease
mirabilis	I-Disease
infection	I-Disease
and	O
severe	O
bronchoconstriction	O
.	O

One	O
week	O
later	O
,	O
the	O
patient	O
was	O
again	O
extubated	O
and	O
3	O
days	O
later	O
was	O
transferred	O
to	O
a	O
peripheral	O
ward	O
.	O

On	O
the	O
next	O
day	O
he	O
died	O
,	O
probably	O
as	O
a	O
result	O
of	O
heart	B-Disease
failure	I-Disease
.	O

Serum	O
samples	O
from	O
the	O
first	O
and	O
second	O
days	O
contained	O
3.6	O
and	O
1.9	O
mg/l	O
carbachol	B-Chemical
,	O
respectively	O
.	O

The	O
corresponding	O
urine	O
concentrations	O
amounted	O
to	O
374	O
and	O
554	O
mg/l	O
.	O

CONCLUSION	O
:	O
This	O
case	O
started	O
with	O
a	O
media	O
report	O
in	O
a	O
popular	O
newspaper	O
,	O
initiated	O
by	O
published	O
,	O
peer-reviewed	O
research	O
on	O
herbals	O
,	O
and	O
involved	O
human	O
failure	O
in	O
a	O
case	O
history	O
,	O
medical	O
examination	O
and	O
clinical	O
treatment	O
.	O

For	O
the	O
first	O
time	O
,	O
an	O
analytical	O
method	O
for	O
the	O
determination	O
of	O
carbachol	B-Chemical
in	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
.	O

The	O
analysed	O
carbachol	B-Chemical
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260	O
.	O

Especially	O
in	O
old	O
patients	O
,	O
intensivists	O
should	O
consider	O
intoxications	O
(	O
with	O
cholinergics	O
)	O
as	O
a	O
cause	O
of	O
acute	B-Disease
cardiovascular	I-Disease
failure	I-Disease
.	O

Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	B-Chemical
10	O
mg	O
versus	O
ergotamine/caffeine	B-Chemical
in	O
migraine	O
.	O

Rizatriptan	B-Chemical
is	O
a	O
selective	O
5-HT	B-Chemical
(	O
1B/1D	O
)	O
receptor	O
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	B-Disease
.	O

This	O
randomized	O
double-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	B-Chemical
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	B-Chemical
1	O
mg/caffeine	B-Chemical
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	B-Disease
attack	O
with	O
each	O
therapy	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89.1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	B-Chemical
to	O
ergotamine/caffeine	B-Chemical
(	O
69.9	O
vs.	O
30.1	O
%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

Faster	O
relief	O
of	O
headache	O
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67.3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	O
and	O
54.2	O
%	O
of	O
patients	O
who	O
preferred	O
ergotamine/caffeine	B-Chemical
.	O

The	O
co-primary	O
endpoint	O
of	O
being	O
pain	O
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	O
.	O

Forty-nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
2	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
24.3	O
%	O
treated	O
with	O
ergotamine/caffeine	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Headache	O
relief	O
at	O
2	O
h	O
was	O
75.9	O
%	O
for	O
rizatriptan	O
and	O
47.3	O
%	O
for	O
ergotamine/caffeine	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine/caffeine	O
within	O
30	O
min	O
of	O
dosing	O
.	O

Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	O
were	O
pain	O
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	O
on	O
ergotamine/caffeine	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine/caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	B-Drug
intake	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	O
(	O
69.8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine/caffeine	O
(	O
38.6	O
%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

Recurrence	O
rates	O
were	O
31.4	O
%	O
with	O
rizatriptan	O
and	O
15.3	O
%	O
with	O
ergotamine/caffeine	O
.	O

Both	O
active	O
treatments	O
were	O
well	O
tolerated	O
.	O

The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine/caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
6.7	O
and	O
5.3	O
%	O
)	O
,	O
nausea	O
(	O
4.2	O
and	O
8.5	O
%	O
)	O
and	O
somnolence	O
(	O
5.5	O
and	O
2.3	O
%	O
)	O
.	O

Thrombotic	B-Disease
microangiopathy	I-Disease
and	O
renal	B-Disease
failure	I-Disease
associated	O
with	O
antineoplastic	O
chemotherapy	O
.	O

Five	O
patients	O
with	O
carcinoma	B-Disease
developed	O
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
characterized	O
by	O
renal	B-Disease
insufficiency	I-Disease
,	O
microangiopathic	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
usually	O
thrombocytopenia	B-Disease
)	O
after	O
treatment	O
with	O
cisplatin	B-Chemical
,	O
bleomycin	B-Chemical
,	O
and	O
a	O
vinca	B-Chemical
alkaloid	I-Chemical
.	O

One	O
patient	O
had	O
thrombotic	B-Disease
thrombocytopenic	I-Disease
purpura	I-Disease
,	O
three	O
the	O
hemolytic-uremic	B-Disease
syndrome	I-Disease
,	O
and	O
one	O
an	O
apparent	O
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders	O
.	O

Histologic	O
examination	O
of	O
the	O
renal	O
tissue	O
showed	O
evidence	O
of	O
intravascular	B-Disease
coagulation	I-Disease
,	O
primarily	O
affecting	O
the	O
small	O
arteries	O
,	O
arterioles	O
,	O
and	O
glomeruli	O
.	O

Because	O
each	O
patient	O
was	O
tumor-free	B-Disease
or	O
had	O
only	O
a	O
small	O
tumor	B-Disease
at	O
the	O
onset	O
of	O
this	O
syndrome	O
,	O
the	O
thrombotic	B-Disease
microangiopathy	I-Disease
may	O
have	O
been	O
induced	O
by	O
chemotherapy	O
.	O

Diagnosis	O
of	O
this	O
potentially	O
fatal	O
complication	O
may	O
be	O
delayed	O
or	O
missed	O
if	O
renal	B-Disease
tissue	O
or	O
the	O
peripheral	O
blood	O
smear	O
is	O
not	O
examined	O
,	O
because	O
renal	B-Disease
failure	O
may	O
be	O
ascribed	O
to	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
and	O
the	O
anemia	B-Disease
and	O
thrombocytopenia	B-Disease
to	O
drug-induced	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O

Salvage	O
therapy	O
with	O
nelarabine	B-Chemical
,	O
etoposide	B-Chemical
,	O
and	O
cyclophosphamide	B-Chemical
in	O
relapsed/refractory	O
paediatric	O
T-cell	B-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
and	I-Disease
lymphoma	I-Disease
.	O

A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	B-Chemical
(	O
AraG	B-Chemical
)	O
with	O
5	O
d	O
of	O
etoposide	B-Chemical
(	O
VP	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CPM	B-Chemical
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	I-Disease
relapsed	O
T-cell	B-Disease
leukaemia	I-Disease
or	I-Disease
lymphoma	O
.	O

The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	O
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	O
and	O
musculoskeletal	O
pain	O
.	O

Haematological	O
toxicity	O
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	O
alone	O
,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O

All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG/VP/CPM	O
.	O

Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	O
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	B-Drug
and	O
cyclophosphamide	B-Drug
,	O
although	O
neurological	O
toxicity	O
must	O
be	O
closely	O
monitored	O
.	O

The	O
3-week	O
sulphasalazine	B-Chemical
syndrome	O
strikes	O
again	O
.	O

A	O
34-year-old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	B-Disease
,	O
fever	B-Disease
,	O
lymphadenopathy	B-Disease
and	O
hepatitis	B-Disease
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-Chemical
for	O
sero-negative	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	B-Disease
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B-Disease
drug	I-Disease
reaction.A	O
week	O
later	O
,	O
fulminant	O
drug-induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti-nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi-organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	I-Disease
therapy.Post-mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo-interstitial	O
nephritis	O
and	O
extensive	O
bone	O
marrow	O
necrosis	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

It	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so-called	O
``	O
3-week	O
sulphasalazine	O
syndrome	O
''	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
.	O

Bupropion	B-Chemical
(	O
Zyban	B-Chemical
)	O
toxicity	B-Disease
.	O

Bupropion	B-Chemical
is	O
a	O
monocyclic	O
antidepressant	B-Chemical
structurally	O
related	O
to	O
amphetamine	B-Chemical
.	O

Zyban	B-Chemical
,	O
a	O
sustained-release	O
formulation	O
of	O
bupropion	B-Chemical
hydrochloride	I-Chemical
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
months	O
since	O
it	O
's	O
introduction	O
,	O
12	O
overdose	B-Disease
cases	O
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O

8	O
patients	O
developed	O
symptoms	O
of	O
toxicity	B-Disease
.	O

Common	O
features	O
included	O
tachycardia	B-Disease
,	O
drowsiness	O
,	O
hallucinations	B-Disease
and	O
convulsions	B-Disease
.	O

Two	O
patients	O
developed	O
severe	O
cardiac	B-Disease
arrhythmias	I-Disease
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	B-Disease
arrest	I-Disease
.	O

All	O
patients	O
recovered	O
without	O
sequelae	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	O
of	O
13.5g	O
bupropion	B-Chemical
.	O

Recurrent	O
seizures	B-Disease
were	O
treated	O
with	O
diazepam	B-Chemical
and	O
broad	O
complex	O
tachycardia	B-Disease
was	O
successfully	O
treated	O
with	O
adenosine	B-Chemical
.	O

Zyban	B-Chemical
caused	O
significant	O
neurological	B-Disease
and	I-Disease
cardiovascular	I-Disease
toxicity	I-Disease
in	O
overdose	O
.	O

The	O
potential	O
toxic	O
effects	O
should	O
be	O
considered	O
when	O
prescribing	O
it	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

Survey	O
of	O
complications	O
of	O
indocyanine	B-Chemical
green	I-Chemical
angiography	O
in	O
Japan	O
.	O

PURPOSE	O
:	O
We	O
evaluated	O
the	O
safety	O
of	O
indocyanine	B-Chemical
green	I-Chemical
for	O
use	O
in	O
fundus	O
angiography	O
.	O

METHODS	O
:	O
We	O
sent	O
a	O
questionnaire	O
concerning	O
complications	O
of	O
indocyanine	B-Chemical
green	I-Chemical
to	O
32	O
institutions	O
in	O
Japan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company	O
,	O
which	O
manufactures	O
the	O
indocyanine	B-Chemical
green	I-Chemical
fundus	O
camera	O
.	O

RESULTS	O
:	O
Ophthalmologists	O
at	O
15	O
institutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3,774	O
indocyanine	B-Chemical
green	I-Chemical
angiograms	O
performed	O
on	O
2,820	O
patients	O
between	O
June	O
1984	O
and	O
September	O
1992	O
.	O

Before	O
angiography	O
,	O
intradermal	O
or	O
intravenous	O
indocyanine	B-Chemical
green	I-Chemical
testing	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
institutions	O
.	O

For	O
three	O
patients	O
,	O
the	O
decision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiography	O
after	O
positive	O
preangiographic	O
testing	O
.	O

The	O
dosage	O
of	O
indocyanine	B-Chemical
green	I-Chemical
used	O
for	O
angiography	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
institution	O
.	O

There	O
were	O
13	O
cases	O
of	O
adverse	O
reactions	O
(	O
0.34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mild	O
reactions	O
such	O
as	O
nausea	B-Disease
,	O
exanthema	B-Disease
,	O
urtication	B-Disease
,	O
itchiness	B-Disease
,	O
and	O
urgency	O
to	O
defecate	O
,	O
and	O
did	O
not	O
require	O
treatment	O
.	O

Also	O
recorded	O
were	O
one	O
case	O
of	O
pain	B-Disease
of	O
the	O
vein	O
,	O
which	O
required	O
treatment	O
,	O
and	O
two	O
cases	O
of	O
hypotension	B-Disease
.	O

The	O
two	O
hypotensive	B-Disease
patients	O
required	O
treatment	O
for	O
shock	B-Disease
.	O

CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	B-Chemical
green	I-Chemical
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	B-Chemical
sodium	I-Chemical
indicated	O
that	O
indocyanine	B-Chemical
green	I-Chemical
is	O
a	O
safe	O
as	O
fluorescein	B-Chemical
for	O
use	O
in	O
angiography	O
.	O

Bradykinin	B-Chemical
receptors	O
antagonists	O
and	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
inhibitors	O
in	O
vincristine	B-Chemical
and	O
streptozotocin	B-Chemical
induced	O
hyperalgesia	B-Disease
in	O
chemotherapy	O
and	O
diabetic	B-Disease
neuropathy	I-Disease
rat	O
model	O
.	O

PURPOSE	O
:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	O
NO	B-Chemical
synthase	O
(	O
L-NOArg	B-Chemical
;	O
1.0	O
mg/kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	B-Chemical
synthase	O
(	O
L-NIL	O
;	O
1.0	O
mg/kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	O
synthase	O
(	O
7-NI	O
;	O
0.1	O
mg/kg	O
ip	O
)	O
,	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors	O
:	O
D-Arg-	O
[	O
Hyp3	O
,	O
Thi5	O
,	O
D-Tic7	O
,	O
Oic8	O
]	O
bradykinin	B-Chemical
(	O
HOE	B-Chemical
140	I-Chemical
;	O
70	O
nmol/kg	O
ip	O
)	O
or	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
(	I-Disease
70	O
nmol/kg	O
ip	O
)	I-Disease
respectively	O
,	O
in	O
model	O
of	O
diabetic	B-Disease
(	I-Disease
streptozotocin-induced	I-Disease
)	I-Disease
and	I-Disease
toxic	I-Disease
(	I-Disease
vincristine-induced	I-Disease
)	I-Chemical
neuropathy	I-Chemical
was	O
investigated	O
.	O

METHODS	O
:	O
The	O
changes	O
in	O
pain	O
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
--	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall-Selitto	O
.	O

RESULTS	O
:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	O
receptors	O
and	O
inducible	O
NO	O
synthase	O
but	O
not	O
neuronal	O
NO	O
synthase	O
activity	O
reduces	O
diabetic	B-Chemical
hyperalgesia	O
.	O

Pretreatment	O
with	O
L-NOArg	O
and	O
L-NIL	O
but	O
not	O
7-NI	O
,	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	O
140	O
and	O
des	O
Arg10	O
HOE	O
140	O
.	O

It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	O
synthase	O
and	O
neuronal	O
NO	O
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	O
are	O
involved	O
in	O
hyperalgesia	O
produced	O
by	O
vincristine	B-Drug
.	O

Moreover	O
,	O
L-NOArg	O
and	O
7-NI	O
but	O
not	O
L-NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	O
140	O
or	O
des-Arg10HOE	O
140	O
in	O
toxic	O
neuropathy	I-Chemical
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-Chemical
and	O
toxic	B-Chemical
neuropathy	I-Chemical
.	O

In	O
streptozotocin-induced	O
hyperalgesia	O
,	O
inducible	O
NO	O
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	O
,	O
whereas	O
in	O
vincristine-induced	I-Chemical
hyperalgesia	O
bradykinin	O
seemed	O
to	O
activate	O
neuronal	O
NO	O
synthase	O
pathway	O
.	O

Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	O
receptor	O
antagonists	O
and	O
NO	O
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	O
pain	O
,	O
even	O
in	O
hospital	O
care	O
.	O

Cardiac	B-Disease
toxicity	I-Disease
observed	O
in	O
association	O
with	O
high-dose	O
cyclophosphamide-based	B-Chemical
chemotherapy	O
for	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O

INTRODUCTION	O
:	O
Cyclophosphamide	B-Chemical
is	O
an	O
alkylating	O
agent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
conditioning	O
regimens	O
.	O

In	O
high	O
doses	O
,	O
its	O
nonhematological	O
dose-limiting	O
toxicity	B-Disease
is	O
cardiomyopathy	B-Disease
.	O

STUDY	O
DESIGN	O
:	O
We	O
combined	O
paclitaxel	B-Chemical
,	O
melphalan	B-Chemical
and	O
high-dose	O
cyclophosphamide	B-Chemical
,	O
thiotepa	B-Chemical
,	O
and	O
carboplatin	B-Chemical
in	O
a	O
triple	O
sequential	O
high-dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O

Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy-responsive	O
metastatic	O
breast	B-Disease
cancer	I-Disease
receiving	O
96-h	O
infusional	O
cyclophosphamide	B-Chemical
as	O
part	O
of	O
a	O
triple	O
sequential	O
high-dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
(	O
CHF	B-Disease
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	B-Disease
,	O
prior	O
cardiac	O
history	O
,	O
smoking	O
,	O
diabetes	B-Disease
mellitus	I-Disease
,	O
prior	O
use	O
of	O
anthracyclines	B-Chemical
,	O
and	O
left-sided	O
chest	O
irradiation	O
.	O

RESULTS	O
:	O
Six	O
of	O
61	O
women	O
(	O
10	O
%	O
)	O
developed	O
clinically	O
reversible	O
grade	O
3	O
CHF	B-Disease
following	O
infusional	O
cyclophosphamide	B-Chemical
with	O
a	O
median	O
percent	O
decline	O
in	O
ejection	O
fraction	O
of	O
31	O
%	O
.	O

Incidence	O
of	O
transient	O
cyclophosphamide-related	B-Chemical
cardiac	B-Disease
toxicity	I-Disease
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literature	O
.	O

Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	B-Disease
development	O
;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	B-Disease
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

No	O
association	O
was	O
found	O
with	O
other	O
pretreatment	O
characteristics	O
.	O

CONCLUSIONS	O
:	O
As	O
a	O
result	O
of	O
these	O
findings	O
,	O
oncologists	O
should	O
carefully	O
monitor	O
fluid	O
balance	O
in	O
older	O
patients	O
.	O

Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	B-Chemical
did	O
not	O
predict	O
CHF	B-Disease
development	O
.	O

Inappropriate	O
use	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O

Carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
are	O
contraindicated	O
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O

Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-Chemical
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add-on	O
.	O

Vigabatrin	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O

Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	B-Chemical
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-Disease
jerks	I-Disease
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	B-Chemical
.	O

Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	B-Chemical
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O

Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-Chemical
valproate	I-Chemical
,	O
lamotrigine	B-Chemical
,	O
or	O
ethosuximide	B-Chemical
alone	O
or	O
in	O
combination	O
.	O

Hemolytic	B-Disease
anemia	I-Disease
associated	O
with	O
the	O
use	O
of	O
omeprazole	B-Chemical
.	O

Omeprazole	B-Chemical
is	O
the	O
first	O
drug	B-Drug
designed	O
to	O
block	O
the	O
final	O
step	O
in	O
the	O
acid	O
secretory	O
process	O
within	O
the	O
parietal	O
cell	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effective	O
in	O
the	O
treatment	O
of	O
peptic	B-Disease
ulcer	I-Disease
disease	I-Disease
,	O
reflux	B-Disease
esophagitis	I-Disease
,	O
and	O
the	O
Zollinger-Ellison	B-Disease
syndrome	I-Disease
.	O

Although	O
clinical	O
experience	O
with	O
omeprazole	B-Chemical
is	O
still	O
limited	O
,	O
many	O
controlled	O
studies	O
have	O
established	O
the	O
short-term	O
safety	O
of	O
this	O
drug	B-Drug
.	O

We	O
report	O
the	O
first	O
case	O
of	O
a	O
serious	O
short-term	O
adverse	O
reaction	O
with	O
the	O
use	O
of	O
omeprazole	B-Chemical
:	O
hemolytic	B-Disease
anemia	I-Disease
.	O

The	O
patient	O
developed	O
weakness	O
,	O
lethargy	B-Disease
,	O
and	O
shortness	B-Disease
of	I-Disease
breath	I-Disease
2	O
days	O
after	O
starting	O
therapy	O
with	O
omeprazole	B-Chemical
.	O

Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44.1	O
%	O
to	O
20.4	O
%	O
,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	B-Chemical
.	O

After	O
she	O
discontinued	O
the	O
omeprazole	B-Chemical
,	O
her	O
hemoglobin	O
and	O
hematocrit	O
gradually	O
returned	O
to	O
normal	O
.	O

The	O
mechanism	O
by	O
which	O
omeprazole	B-Chemical
caused	O
the	O
patient	O
's	O
hemolytic	B-Disease
anemia	I-Disease
is	O
uncertain	O
,	O
but	O
physicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	O
effect	O
.	O

The	O
use	O
and	O
toxicity	B-Disease
of	O
didanosine	B-Chemical
(	O
ddI	B-Chemical
)	O
in	O
HIV	B-Disease
antibody-positive	I-Disease
individuals	O
intolerant	O
to	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
One	O
hundred	O
and	O
fifty-one	O
patients	O
intolerant	O
to	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
received	O
didanosine	B-Chemical
(	O
ddI	B-Chemical
)	O
to	O
a	O
maximum	O
dose	O
of	O
12.5	O
mg/kg/day	O
.	O

Patient	O
response	O
was	O
assessed	O
using	O
changes	O
in	O
CD4+	O
lymphocyte	O
subset	O
count	O
,	O
HIV	O
p24	O
antigen	O
,	O
weight	O
,	O
and	O
quality	O
of	O
life	O
.	O

Seventy	O
patients	O
developed	O
major	O
opportunistic	B-Disease
infections	I-Disease
whilst	O
on	O
therapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	B-Disease
diagnosis	O
in	O
17	O
.	O

Only	O
minor	O
changes	O
in	O
CD4+	O
lymphocyte	O
subset	O
count	O
were	O
observed	O
in	O
AIDS	B-Disease
patients	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
stages	O
of	O
disease	O
.	O

Of	O
those	O
positive	O
for	O
p24	O
antigen	O
at	O
the	O
commencement	O
of	O
the	O
study	O
67	O
%	O
showed	O
a	O
positive	O
response	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4+	O
lymphocyte	O
subset	O
counts	O
above	O
100	O
mm3	O
.	O

A	O
positive	O
weight	O
response	O
was	O
seen	O
in	O
16	O
%	O
of	O
patients	O
.	O

Most	O
patients	O
showed	O
improvement	O
in	O
individual	O
parameters	O
and	O
global	O
score	O
of	O
quality	O
of	O
life	O
.	O

Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	B-Chemical
were	O
common	O
.	O

The	O
most	O
common	O
side-effect	O
was	O
diarrhoea	B-Disease
,	O
which	O
resulted	O
in	O
cessation	O
of	O
therapy	O
in	O
19	O
individuals	O
.	O

Peripheral	B-Disease
neuropathy	I-Disease
occurred	O
in	O
12	O
patients	O
and	O
pancreatitis	B-Disease
in	O
six	O
.	O

Thirteen	O
patients	O
developed	O
a	O
raised	O
serum	O
amylase	B-Drug
without	O
abdominal	B-Disease
pain	I-Disease
.	O

Seven	O
patients	O
developed	O
glucose	B-Disease
tolerance	I-Disease
curves	I-Disease
characteristic	O
of	O
diabetes	B-Disease
but	O
these	O
were	O
mild	O
,	O
did	O
not	O
require	O
treatment	O
and	O
returned	O
to	O
normal	O
on	O
ceasing	O
didanosine	B-Chemical
.	O

Can	O
angiogenesis	O
be	O
a	O
target	O
of	O
treatment	O
for	O
ribavirin	B-Chemical
associated	O
hemolytic	B-Disease
anemia	I-Disease
?	O
BACKGROUND/AIMS	O
:	O
Recently	O
ribavirin	B-Chemical
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	O
and	O
a	O
number	O
of	O
angiogenesis	O
inhibitors	O
such	O
as	O
sunitinib	B-Chemical
and	O
sorafenib	B-Chemical
have	O
been	O
found	O
to	O
cause	O
acute	O
hemolysis	B-Disease
.	O

We	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
soluble	O
markers	O
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemia	B-Disease
.	O

METHODS	O
:	O
Fourteen	O
patients	O
chronically	B-Disease
infected	I-Disease
with	I-Disease
hepatitis	I-Disease
C	I-Disease
virus	I-Disease
were	O
treated	O
by	O
pegylated	B-Chemical
interferon	I-Chemical
alpha	I-Chemical
2a	I-Chemical
and	O
ribavirin	B-Chemical
.	O

Serum	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
markers	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
angiopoetin-2	O
were	O
investigated	O
before	O
and	O
after	O
therapy	O
.	O

RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
decrease	O
in	O
haptoglobin	O
levels	O
at	O
the	O
end	O
of	O
the	O
treatment	O
period	O
.	O

Hemoglobin	O
levels	O
also	O
decreased	O
but	O
insignificantly	O
by	O
treatment	O
.	O

In	O
contrast	O
with	O
the	O
literature	O
,	O
serum	O
levels	O
of	O
angiogenesis	O
factors	O
did	O
not	O
change	O
significantly	O
by	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
ribavirin	B-Chemical
therapy	O
.	O

We	O
found	O
no	O
correlation	O
of	O
angiogenesis	O
soluble	O
markers	O
with	O
either	O
hemoglobin	O
or	O
haptoglobin	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
in	O
the	O
literature	O
investigating	O
a	O
link	O
between	O
angiogenesis	O
soluble	O
markers	O
and	O
ribavirin	B-Chemical
induced	O
anemia	B-Disease
in	O
patients	O
with	O
hepatitis	B-Disease
C	I-Disease
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O

Future	O
research	O
with	O
larger	O
number	O
of	O
patients	O
is	O
needed	O
to	O
find	O
out	O
modifiable	O
factors	O
that	O
will	O
improve	O
the	O
safety	O
of	O
ribavirin	B-Chemical
therapy	O
.	O

Cocaine	B-Chemical
causes	O
memory	B-Disease
and	I-Disease
learning	I-Disease
impairments	I-Disease
in	O
rats	O
:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	B-Drug
.	O

Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	B-Chemical
toxicity	B-Disease
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	B-Chemical
induced-behaviour	O
is	O
poorly	O
understood	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	B-Drug
toxicity	B-Disease
and	O
addiction	O
mechanisms	O
.	O

Therefore	O
NFkappaB	O
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
(	O
nNOS	O
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	B-Chemical
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-Disease
addiction	I-Disease
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-Chemical
administration	O
in	O
rats	O
.	O

NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	B-Chemical
treated	O
rats	O
,	O
as	O
well	O
as	O
GSH	B-Chemical
concentration	O
and	O
glutathione	B-Chemical
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	B-Chemical
peroxidase	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	B-Chemical
.	O

Topiramate	B-Chemical
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O

Antinociceptive	O
and	O
antiamnesic	O
properties	O
of	O
the	O
presynaptic	O
cholinergic	O
amplifier	O
PG-9	B-Chemical
.	O

The	O
antinociceptive	O
effect	O
of	O
3	B-Chemical
alpha-tropyl	I-Chemical
2-	I-Chemical
(	I-Chemical
p-bromophenyl	I-Chemical
)	I-Chemical
propionate	I-Chemical
[	O
(	O
+/-	O
)	O
-PG-9	B-Chemical
]	O
(	O
10-40	O
mg	O
kg-1	O
s.c.	O
;	O
30-60	O
mg	O
kg-1	O
p.o	O
.	O

;	O
10-30	O
mg	O
kg-1	O
i.v	O
.	O

;	O
10-30	O
micrograms/mouse	O
i.c.v	O
.	O

)	O
was	O
examined	O
in	O
mice	O
,	O
rats	O
and	O
guinea	O
pigs	O
by	O
use	O
of	O
the	O
hot-plate	O
,	O
abdominal-constriction	O
,	O
tail-flick	O
and	O
paw-pressure	O
tests	O
.	O

(	O
+/-	O
)	O
-PG-9	B-Chemical
antinociception	O
peaked	O
15	O
min	O
after	O
injection	O
and	O
then	O
slowly	O
diminished	O
.	O

The	O
antinociception	O
produced	O
by	O
(	O
+/-	O
)	O
-PG-9	B-Chemical
was	O
prevented	O
by	O
the	O
unselective	O
muscarinic	O
antagonist	O
atropine	B-Chemical
,	O
the	O
M1-selective	O
antagonists	O
pirenzepine	B-Chemical
and	O
dicyclomine	B-Chemical
and	O
the	O
acetylcholine	B-Chemical
depletor	O
hemicholinium-3	B-Chemical
,	O
but	O
not	O
by	O
the	O
opioid	O
antagonist	O
naloxone	B-Chemical
,	O
the	O
gamma-aminobutyric	B-Chemical
acidB	I-Chemical
antagonist	O
3-aminopropyl-diethoxy-methyl-phosphinic	B-Chemical
acid	I-Chemical
,	O
the	O
H3	O
agonist	O
R-	B-Chemical
(	I-Chemical
alpha	I-Chemical
)	I-Chemical
-methylhistamine	I-Chemical
,	O
the	O
D2	O
antagonist	O
quinpirole	B-Chemical
,	O
the	O
5-hydroxytryptamine4	B-Chemical
antagonist	O
2-methoxy-4-amino-5-chlorobenzoic	B-Chemical
acid	I-Chemical
2-	B-Chemical
(	I-Chemical
diethylamino	I-Chemical
)	I-Chemical
ethyl	I-Chemical
ester	I-Chemical
hydrochloride	O
,	O
the	O
5-hydroxytryptamin1A	B-Chemical
antagonist	O
1-	B-Chemical
(	I-Chemical
2-methoxyphenyl	I-Chemical
)	I-Chemical
-4-	I-Chemical
[	I-Chemical
4-	I-Chemical
(	I-Chemical
2-phthalimido	I-Chemical
)	I-Chemical
butyl	I-Chemical
]	I-Chemical
piperazine	I-Chemical
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	B-Chemical
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+/-	O
)	O
-PG-9	B-Chemical
exerted	O
an	O
antinociceptive	O
effect	O
mediated	O
by	O
a	O
central	O
potentiation	O
of	O
cholinergic	O
transmission	O
.	O

(	O
+/-	O
)	O
-PG-9	B-Chemical
(	O
10-40	O
mg	O
kg-1	O
i.p	O
.	O

)	O
was	O
able	O
to	O
prevent	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
1	O
mg	O
kg-1	O
i.p	O
.	O

)	O
and	O
dicyclomine	B-Chemical
(	O
2	O
mg	O
kg-1	O
i.p	O
.	O

)	O
in	O
the	O
mouse	O
passive-avoidance	O
test	O
.	O

Affinity	O
profiles	O
of	O
(	O
+/-	O
)	O
-PG-9	B-Chemical
for	O
muscarinic	O
receptor	O
subtypes	O
,	O
determined	O
by	O
functional	O
studies	O
(	O
rabbit	O
vas	O
deferens	O
for	O
M1	O
,	O
guinea	O
pig	O
atrium	O
for	O
M2	O
,	O
guinea	O
pig	O
ileum	O
for	O
M3	O
and	O
immature	O
guinea	O
pig	O
uterus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4/M1	O
selectivity	O
ratio	O
of	O
10.2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinociception	O
and	O
the	O
anti-amnesic	B-Disease
effect	O
induced	O
by	O
(	O
+/-	O
)	O
-PG-9	B-Chemical
through	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
extracellular	O
levels	O
.	O

In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range	O
,	O
(	O
+/-	O
)	O
-PG-9	B-Chemical
did	O
not	O
impair	O
mouse	O
performance	O
evaluated	O
by	O
the	O
rota-rod	O
test	O
and	O
Animex	O
apparatus	O
.	O

Hyperbaric	O
oxygen	B-Chemical
therapy	O
for	O
control	O
of	O
intractable	O
cyclophosphamide-induced	B-Chemical
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
intractable	O
hemorrhagic	B-Disease
cystitis	I-Disease
due	O
to	O
cyclophosphamide	B-Drug
therapy	O
for	O
Wegener	O
's	O
granulomatosis	O
.	O

Conservative	O
treatment	O
,	O
including	O
bladder	O
irrigation	O
with	O
physiological	O
saline	O
and	O
instillation	O
of	O
prostaglandin	O
F2	O
alpha	O
,	O
failed	O
to	O
totally	O
control	O
hemorrhage	O
.	O

We	O
then	O
used	O
hyperbaric	O
oxygen	O
at	O
an	O
absolute	O
pressure	O
of	O
2	O
atm	O
,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks	O
.	O

The	O
bleeding	O
ceased	O
completely	O
by	O
the	O
end	O
of	O
treatment	O
and	O
the	O
patient	O
remained	O
free	O
of	O
hematuria	O
thereafter	O
.	O

No	O
side	O
effect	O
was	O
noted	O
during	O
the	O
course	O
of	O
therapy	O
.	O

In	O
future	O
,	O
this	O
form	O
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	O
in	O
the	O
treatment	O
of	O
cyclophosphamide-induced	O
hemorrhagic	B-Chemical
cystitis	B-Chemical
.	O

Further	O
studies	O
on	O
effects	O
of	O
irrigation	O
solutions	O
on	O
rat	O
bladders	O
.	O

Further	O
studies	O
on	O
the	O
effects	O
of	O
certain	O
irrigating	O
fluids	O
on	O
the	O
rat	O
bladder	O
for	O
18	O
hours	O
are	O
reported	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p-choloroaniline	B-Chemical
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine-digluconate	B-Chemical
associated	O
erosive	O
cystitis	B-Disease
.	O

A	O
high	O
percentage	O
of	O
kanamycin-colistin	B-Chemical
and	O
povidone-iodine	O
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

Picloxydine	O
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	O
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Clinical	O
experiences	O
in	O
an	O
open	O
and	O
a	O
double-blind	O
trial	O
.	O

A	O
total	O
of	O
sixty	O
patients	O
were	O
trated	O
with	O
bromperidol	B-Chemical
first	O
in	O
open	O
conditions	O
(	O
20	O
patients	O
)	O
,	O
then	O
on	O
a	O
double	O
blind	O
basis	O
(	O
40	O
patients	O
)	O
with	O
haloperidol	B-Chemical
as	O
the	O
reference	O
substance	O
.	O

The	O
open	O
study	O
lasted	O
for	O
four	O
weeks	O
;	O
the	O
drug	B-Drug
was	O
administrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
tablets	O
.	O

The	O
daily	O
dose	O
(	O
initial	O
dose	O
:	O
1	O
mg	O
;	O
mean	O
dose	O
at	O
the	O
end	O
of	O
the	O
trial	O
:	O
4.47	O
mg	O
)	O
was	O
always	O
administered	O
in	O
one	O
single	O
dose	O
.	O

Nineteen	O
patients	O
finished	O
the	O
trial	O
,	O
and	O
in	O
18	O
cases	O
the	O
therapeutic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
statistical	O
analysis	O
.	O

Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	B-Disease
concomitant	I-Disease
symptoms	I-Disease
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O

The	O
results	O
of	O
detailed	O
laboratory	O
tests	O
and	O
evaluations	O
of	O
various	O
quantitative	O
and	O
qualitative	O
tolerability	O
parameters	O
were	O
not	O
indicative	O
of	O
toxic	O
effects	O
.	O

In	O
the	O
double	O
blind	O
study	O
with	O
haloperidol	B-Chemical
,	O
both	O
substances	O
were	O
found	O
to	I-Disease
be	O
highly	O
effective	O
in	O
the	I-Disease
treatment	O
of	O
psychotic	B-Disease
syndromes	I-Disease
belonging	I-Disease
predominantly	I-Disease
to	I-Disease
the	I-Disease
schizophrenia	O
group	O
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
action	O
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	B-Chemical
.	O

No	O
differences	O
were	O
observed	O
with	O
respect	O
to	O
side	O
effects	O
and	O
general	O
tolerability	O
.	O

Curcumin	B-Chemical
ameliorates	O
cognitive	B-Disease
dysfunction	I-Disease
and	O
oxidative	O
damage	O
in	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
administered	O
rats	O
.	O

The	O
antiepileptic	O
drugs	B-Drug
,	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
are	O
well	O
known	O
to	O
cause	O
cognitive	B-Disease
impairment	I-Disease
on	O
chronic	O
use	O
.	O

The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	B-Disease
impairment	I-Disease
by	O
antiepileptic	O
drugs	B-Drug
.	O

Curcumin	B-Chemical
has	O
shown	O
antioxidant	O
,	O
anti-inflammatory	O
and	O
neuro-protective	O
properties	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	B-Chemical
administration	O
on	O
phenobarbitone-	B-Chemical
and	O
carbamazepine-induced	B-Chemical
cognitive	B-Disease
impairment	I-Disease
and	O
oxidative	O
stress	O
in	O
rats	O
.	O

Pharmacokinetic	O
interactions	O
of	O
curcumin	B-Chemical
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
were	O
also	O
studied	O
.	O

Vehicle/drugs	O
were	O
administered	O
daily	O
for	O
21days	O
to	O
male	O
Wistar	O
rats	O
.	O

Passive	O
avoidance	O
paradigm	O
and	O
elevated	O
plus	O
maze	O
test	O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
.	O

At	O
the	O
end	O
of	O
study	O
period	O
,	O
serum	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
,	O
whole	O
brain	O
malondialdehyde	B-Chemical
and	O
reduced	O
glutathione	B-Chemical
levels	O
were	O
estimated	O
.	O

The	O
administration	O
of	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	O
.	O

Concomitant	O
curcumin	B-Chemical
administration	O
prevented	O
the	O
cognitive	B-Disease
impairment	I-Disease
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	O
drugs	B-Drug
.	O

Curcumin	B-Chemical
co-administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	B-Chemical
as	O
well	O
as	O
carbamazepine	B-Chemical
.	O

These	O
results	O
show	O
that	O
curcumin	B-Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B-Disease
of	I-Disease
cognitive	I-Disease
functions	I-Disease
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O

The	O
findings	O
suggest	O
that	O
curcumin	B-Chemical
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
therapy	O
in	O
preventing	O
cognitive	B-Disease
impairment	I-Disease
associated	O
with	O
these	O
drugs	B-Drug
.	O

Pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
protects	O
the	O
piriform	O
cortex	O
in	O
the	O
pilocarpine	B-Chemical
status	B-Disease
epilepticus	I-Disease
model	O
.	O

Pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
has	O
a	O
dual	O
mechanism	O
of	O
action	O
as	O
an	O
antioxidant	O
and	O
an	O
inhibitor	O
of	O
the	O
transcription	O
factor	O
kappa-beta	O
.	O

Both	O
,	O
production	O
of	O
reactive	O
oxygen	B-Chemical
species	O
as	O
well	O
as	O
activation	O
of	O
NF-kappaB	O
have	O
been	O
implicated	O
in	O
severe	O
neuronal	B-Disease
damage	I-Disease
in	O
different	O
sub-regions	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices	O
.	O

The	O
effect	O
of	O
PDTC	B-Chemical
on	O
status	B-Disease
epilepticus-associated	O
cell	O
loss	O
in	O
the	O
hippocampus	O
and	O
piriform	O
cortex	O
was	O
evaluated	O
in	O
the	O
rat	O
fractionated	O
pilocarpine	B-Drug
model	O
.	O

Treatment	O
with	O
150	O
mg/kg	O
PDTC	O
before	O
and	O
following	O
status	B-Disease
epilepticus	O
significantly	O
increased	O
the	O
mortality	O
rate	O
to	O
100	O
%	O
.	O

Administration	O
of	O
50	O
mg/kg	O
PDTC	O
(	O
low-dose	O
)	O
did	O
not	O
exert	O
major	O
effects	O
on	O
the	O
development	O
of	O
a	O
status	O
epilepticus	O
or	O
the	O
mortality	O
rate	O
.	O

In	O
vehicle-treated	O
rats	O
,	O
status	O
epilepticus	O
caused	O
pronounced	O
neuronal	O
damage	O
in	O
the	O
piriform	O
cortex	O
comprising	O
both	O
pyramidal	O
cells	O
and	O
interneurons	O
.	O

Low-dose	O
PDTC	O
treatment	O
almost	O
completely	O
protected	O
from	O
lesions	O
in	O
the	O
piriform	O
cortex	O
.	O

A	O
significant	O
decrease	O
in	O
neuronal	O
density	O
of	O
the	O
hippocampal	O
hilar	O
formation	O
was	O
identified	O
in	O
vehicle-	O
and	O
PDTC-treated	O
rats	O
following	O
status	O
epilepticus	O
.	O

In	O
conclusion	O
,	O
the	O
NF-kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	O
protected	O
the	O
piriform	O
cortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	O
loss	O
.	O

These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
and	O
activation	O
of	O
NF-kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure-associated	O
neuronal	O
damage	O
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O

However	O
,	O
future	O
investigations	O
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
PDTC	O
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
piriform	O
cortex	O
.	O

Safety	O
profile	O
of	O
a	O
nicotine	B-Chemical
lozenge	O
compared	O
with	O
that	O
of	O
nicotine	B-Chemical
gum	O
in	O
adult	O
smokers	O
with	O
underlying	O
medical	O
conditions	O
:	O
a	O
12-week	O
,	O
randomized	O
,	O
open-label	O
study	O
.	O

BACKGROUND	O
:	O
Nicotine	B-Chemical
polacrilex	O
lozenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nicotine	B-Chemical
compared	O
with	O
equivalent	O
doses	O
of	O
nicotine	B-Chemical
polacrilex	O
gum	O
.	O

The	O
increased	O
nicotine	B-Chemical
exposure	O
from	O
the	O
lozenge	O
has	O
raised	O
questions	O
about	O
the	O
relative	O
safety	O
of	O
the	O
lozenge	O
and	O
gum	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
profiles	O
of	O
the	O
4-mg	O
nicotine	B-Chemical
lozenge	O
and	O
4-mg	O
nicotine	B-Chemical
gum	O
in	O
smokers	O
with	O
selected	O
label-restricted	O
diseases	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
open-label	O
study	O
in	O
adult	O
smokers	O
with	O
heart	B-Disease
disease	I-Disease
,	O
hypertension	B-Disease
not	O
controlled	O
by	O
medication	O
,	O
and/or	O
diabetes	B-Disease
mellitus	I-Disease
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
the	O
4-mg	O
nicotine	B-Chemical
lozenge	O
or	O
4-mg	O
nicotine	B-Chemical
gum	O
.	O

Safety	O
assessments	O
were	O
made	O
at	O
baseline	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
weeks	O
after	O
the	O
start	O
of	O
product	O
use	O
.	O

RESULTS	O
:	O
Nine	O
hundred	O
one	O
patients	O
were	O
randomized	O
to	O
treatment	O
,	O
447	O
who	O
received	O
the	O
lozenge	O
and	O
454	O
who	O
received	O
the	O
gum	O
(	O
safety	O
population	O
)	O
.	O

The	O
majority	O
were	O
women	O
(	O
52.7	O
%	O
)	O
.	O

Patients	O
'	O
mean	O
age	O
was	O
53.9	O
years	O
,	O
their	O
mean	O
weight	O
was	O
193.9	O
pounds	O
,	O
and	O
they	O
smoked	O
a	O
mean	O
of	O
25.2	O
cigarettes	O
per	O
day	O
at	O
baseline	O
.	O

Five	O
hundred	O
fifty-three	O
patients	O
,	O
264	O
taking	O
the	O
lozenge	O
and	O
289	O
taking	O
the	O
gum	O
,	O
used	O
the	O
study	O
product	O
for	O
>	O
or	O
=4	O
days	O
per	O
week	O
during	O
the	O
first	O
2	O
weeks	O
(	O
evaluable	O
population	O
)	O
.	O

The	O
nicotine	B-Chemical
lozenge	O
and	O
nicotine	B-Chemical
gum	O
were	O
equally	O
well	O
tolerated	O
,	O
despite	O
increased	O
nicotine	B-Chemical
exposure	O
from	O
the	O
lozenge	O
.	O

The	O
incidence	O
of	O
adverse	O
events	O
in	O
the	O
2	O
groups	O
was	O
similar	O
during	O
the	O
first	O
2	O
weeks	O
of	O
product	O
use	O
(	O
evaluation	O
population	O
:	O
55.3	O
%	O
lozenge	O
,	O
54.7	O
%	O
gum	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
study	O
(	O
safety	O
population	O
:	O
63.8	O
%	O
and	O
58.6	O
%	O
,	O
respectively	O
)	O
.	O

Stratification	O
of	O
patients	O
by	O
sex	O
,	O
age	O
,	O
extent	O
of	O
concurrent	O
smoking	O
,	O
extent	O
of	O
product	O
use	O
,	O
and	O
severity	O
of	O
adverse	O
events	O
revealed	O
no	O
clinically	O
significant	O
differences	O
between	O
the	O
lozenge	O
and	O
gum	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	B-Disease
(	O
17.2	O
%	O
and	O
16.1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-3.7	O
to	O
6.0	O
)	O
,	O
hiccups	B-Disease
(	O
10.7	O
%	O
and	O
6.6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0.5	O
to	O
7.8	O
)	O
,	O
and	O
headache	B-Disease
(	O
8.7	O
%	O
and	O
9.9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-5.0	O
to	O
2.6	O
)	O
.	O

Serious	O
adverse	O
events	O
were	O
reported	O
in	O
11	O
and	O
13	O
patients	O
in	O
the	O
respective	O
groups	O
.	O

Fewer	O
than	O
6	O
%	O
of	O
patients	O
in	O
either	O
group	O
were	O
considered	O
by	O
the	O
investigator	O
to	O
have	O
a	O
worsening	O
of	O
their	O
overall	O
disease	O
condition	O
during	O
the	O
study	O
.	O

The	O
majority	O
of	O
patients	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
disease	O
status	O
from	O
baseline	O
.	O

CONCLUSION	O
:	O
The	O
4-mg	O
nicotine	B-Chemical
lozenge	O
and	O
4-mg	O
nicotine	B-Chemical
gum	O
had	O
comparable	O
safety	O
profiles	O
in	O
these	O
patients	O
with	O
label-restricted	O
medical	O
conditions	O
.	O

Development	O
of	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
in	O
parkinsonian	B-Disease
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and/or	O
duration	O
of	O
symptoms	O
.	O

Levodopa-induced	B-Chemical
dyskinesias	B-Disease
(	O
LIDs	B-Disease
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long-term	O
management	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
patients	O
.	O

Due	O
to	O
the	O
interdependence	O
of	O
risk	O
factors	O
in	O
clinical	O
populations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factors	O
that	O
may	O
influence	O
the	O
development	O
of	O
LIDs	B-Disease
.	O

Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP-induced	B-Chemical
parkinsonism	B-Disease
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	B-Disease
.	O

Monkeys	O
with	O
acute	O
(	O
short-term	O
)	O
MPTP	B-Chemical
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	B-Chemical
therapy	O
developed	O
dyskinesia	B-Disease
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	B-Chemical
administration	O
.	O

In	O
contrast	O
,	O
monkeys	O
with	O
long-term	O
MPTP	B-Chemical
exposure	O
,	O
slow	O
symptom	O
progression	O
and/or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	B-Chemical
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	B-Disease
(	O
e.g.	O
,	O
dyskinesia	B-Disease
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	B-Chemical
administration	O
)	O
.	O

All	O
animals	O
were	O
similarly	O
symptomatic	O
at	O
the	O
start	O
of	O
levodopa	B-Chemical
treatment	O
and	O
had	O
similar	O
therapeutic	O
responses	O
to	O
the	O
drug	B-Drug
.	O

These	O
data	O
suggest	O
distinct	O
differences	O
in	O
the	O
propensity	O
to	O
develop	O
LIDs	B-Disease
in	O
monkeys	O
with	O
different	O
rates	O
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	B-Chemical
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	B-Disease
.	O

Propylthiouracil-induced	B-Chemical
perinuclear-staining	O
antineutrophil	O
cytoplasmic	O
autoantibody-positive	O
vasculitis	B-Disease
in	O
conjunction	O
with	O
pericarditis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil-induced	B-Chemical
vasculitis	B-Disease
manifesting	O
with	O
pericarditis	B-Disease
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B-Disease
treated	O
with	O
propylthiouracil	B-Chemical
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	B-Disease
,	O
fever	B-Disease
,	O
and	O
glomerulonephritis	B-Disease
developed	O
.	O

Serologic	O
testing	O
and	O
immunologic	O
studies	O
were	O
done	O
,	O
and	O
a	O
pericardial	O
biopsy	O
was	O
performed	O
.	O

RESULTS	O
:	O
A	O
25-year-old	O
woman	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
had	O
a	O
febrile	B-Disease
illness	I-Disease
and	O
evidence	O
of	O
pericarditis	B-Disease
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O

Serologic	O
evaluation	O
revealed	O
the	O
presence	O
of	O
perinuclear-staining	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
pANCA	O
)	O
against	O
myeloperoxidase	O
(	O
MPO	O
)	O
.	O

Propylthiouracil	B-Chemical
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1-month	O
course	O
of	O
prednisone	B-Chemical
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	B-Disease
in	O
anti-MPO	O
pANCA-positive	O
vasculitis	B-Disease
associated	O
with	O
propylthio-	B-Chemical
uracil	I-Chemical
therapy	O
.	O

CONCLUSION	O
:	O
Pericarditis	B-Disease
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug-induced	O
vasculitis	B-Disease
attributable	O
to	O
propylthio-	B-Chemical
uracil	I-Chemical
therapy	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta-carboline-induced	B-Chemical
seizures	B-Disease
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	B-Disease
induced	O
by	O
a	O
single	O
i.p	O
.	O

injection	O
of	O
methyl	B-Chemical
beta-carboline-3-carboxylate	I-Chemical
(	O
beta-CCM	B-Chemical
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
benzodiazepine	B-Chemical
site	O
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
.	O

We	O
measured	O
diazepam-induced	B-Chemical
anxiolysis	O
with	O
the	O
elevated	O
plus-maze	O
test	O
,	O
diazepam-induced	B-Chemical
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin-	B-Chemical
and	O
pentylenetetrazol-induced	B-Chemical
seizures	B-Disease
after	O
i.p	O
.	O

injections	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta-CCM	B-Chemical
can	O
be	O
extended	O
to	O
diazepam	B-Chemical
,	O
picrotoxin	B-Chemical
,	O
and	O
pentylenetetrazol	B-Chemical
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
.	O

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	B-Chemical
in	O
cancer	B-Disease
patients	O
on	O
morphine	B-Chemical
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double-blind	O
,	O
crossover	O
,	O
double-dose	O
study	O
.	O

Pain	B-Disease
not	O
responsive	O
to	O
morphine	B-Chemical
is	O
often	O
problematic	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N-methyl-D-aspartate	B-Chemical
(	O
NMDA	B-Chemical
)	O
antagonists	O
,	O
such	O
as	O
ketamine	B-Chemical
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	B-Chemical
(	O
0.25	O
mg/kg	O
or	O
0.50	O
mg/kg	O
)	O
was	O
given	O
to	O
10	O
cancer	B-Disease
patients	O
whose	O
pain	B-Disease
was	O
unrelieved	O
by	O
morphine	B-Chemical
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
,	O
double-dose	O
study	O
.	O

Pain	B-Disease
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
drowsiness	O
,	O
confusion	B-Disease
,	O
and	O
dry	B-Disease
mouth	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini-Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0-30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	B-Drug
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Ketamine	B-Chemical
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	O
the	O
pain	B-Disease
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O

This	O
effect	O
was	O
more	O
relevant	O
in	O
patients	O
treated	O
with	O
higher	O
doses	O
.	O

Hallucinations	B-Disease
occurred	O
in	O
4	O
patients	O
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
``	O
empty	O
head	O
''	O
)	O
was	O
also	O
reported	O
by	O
2	O
patients	O
.	O

These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	B-Chemical
1	O
mg	O
intravenously	O
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	B-Chemical
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	B-Chemical
0.50	O
mg/kg	O
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0.50	O
mg/kg	O
of	O
ketamine	B-Chemical
.	O

Ketamine	B-Chemical
can	O
improve	O
morphine	B-Chemical
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

However	O
,	O
the	O
occurrence	O
of	O
central	O
adverse	O
effects	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
higher	O
doses	O
.	O

This	O
observation	O
should	O
be	O
tested	O
in	O
studies	O
of	O
prolonged	O
ketamine	B-Chemical
administration	O
.	O

Endocrine	O
screening	O
in	O
1,022	O
men	O
with	O
erectile	B-Disease
dysfunction	I-Disease
:	O
clinical	O
significance	O
and	O
cost-effective	O
strategy	O
.	O

PURPOSE	O
:	O
We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	B-Chemical
and	O
prolactin	O
determination	O
in	O
1,022	O
patients	O
referred	O
because	O
of	O
erectile	B-Disease
dysfunction	I-Disease
and	O
compared	O
the	O
data	O
with	O
history	O
,	O
results	O
of	O
physical	O
examination	O
,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost-effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Testosterone	B-Chemical
and	O
prolactin	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O

Every	O
patient	O
was	O
screened	O
for	O
testosterone	B-Chemical
and	O
451	O
were	O
screened	O
for	O
prolactin	O
on	O
the	O
basis	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
gynecomastia	B-Disease
or	O
testosterone	B-Chemical
less	O
than	O
4	O
ng./ml	O
.	O

Determination	O
was	O
repeated	O
in	O
case	O
of	O
abnormal	O
first	O
results	O
.	O

Prolactin	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
previous	O
personal	O
cohort	O
of	O
1,340	O
patients	O
with	O
erectile	B-Disease
dysfunction	I-Disease
and	O
systematic	O
prolactin	O
determination	O
.	O

Main	O
clinical	O
criteria	O
tested	O
regarding	O
efficiency	O
in	O
hormone	O
determination	O
were	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
small	O
testes	O
and	O
gynecomastia	B-Disease
.	O

Endocrine	O
therapy	O
consisted	O
of	O
testosterone	B-Chemical
heptylate	I-Chemical
or	O
human	O
chorionic	O
gonadotropin	O
for	O
hypogonadism	B-Disease
and	O
bromocriptine	B-Chemical
for	O
hyperprolactinemia	B-Disease
.	O

RESULTS	O
:	O
Testosterone	B-Chemical
was	O
less	O
than	O
3	O
ng./ml	O
.	O

in	O
107	O
patients	O
but	O
normal	O
in	O
40	O
%	O
at	O
repeat	O
determination	O
.	O

The	O
prevalence	O
of	O
repeatedly	O
low	O
testosterone	B-Chemical
increased	O
with	O
age	O
(	O
4	O
%	O
before	O
age	O
50	O
years	O
and	O
9	O
%	O
50	O
years	O
or	O
older	O
)	O
.	O

Two	O
pituitary	B-Disease
tumors	I-Disease
were	O
discovered	O
after	O
testosterone	B-Chemical
determination	O
.	O

Most	O
of	O
the	O
other	O
low	O
testosterone	B-Chemical
levels	O
seemed	O
to	O
result	O
from	O
nonorganic	O
hypothalamic	B-Disease
dysfunction	I-Disease
because	O
of	O
normal	O
serum	O
luteinizing	O
hormone	O
and	O
prolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
erectile	B-Disease
dysfunction	I-Disease
(	O
definite	O
improvement	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
androgen	O
therapy	O
,	O
normal	O
morning	O
or	O
nocturnal	O
erections	O
in	O
30	O
%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42	O
%	O
)	O
.	O

Determining	O
testosterone	B-Chemical
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
or	O
abnormal	O
physical	O
examination	O
would	O
have	O
missed	O
40	O
%	O
of	O
the	O
cases	O
with	O
low	O
testosterone	B-Chemical
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
improved	O
by	O
androgen	O
therapy	O
.	O

Prolactin	O
exceeded	O
20	O
ng./ml	O
.	O

in	O
5	O
men	O
and	O
was	O
normal	O
in	O
2	O
at	O
repeat	O
determination	O
.	O

Only	O
1	O
prolactinoma	B-Disease
was	O
discovered	O
.	O

These	O
data	O
are	O
lower	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolactin	O
greater	O
than	O
20	O
ng./ml	O
.	O

in	O
1.86	O
%	O
of	O
1,821	O
patients	O
,	O
prolactinomas	B-Disease
in	O
7	O
,	O
0.38	O
%	O
)	O
.	O

Bromocriptine	B-Chemical
was	O
definitely	O
effective	O
in	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml	O
.	O

(	O
8	O
of	O
12	O
compared	O
to	O
only	O
9	O
of	O
22	O
cases	O
with	O
prolactin	O
between	O
20	O
and	O
35	O
ng./ml.	O
)	O
.	O

Testosterone	B-Chemical
was	O
low	O
in	O
less	O
than	O
50	O
%	O
of	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml	O
.	O

CONCLUSIONS	O
:	O
Low	O
prevalences	O
and	O
effects	O
of	O
low	O
testosterone	B-Chemical
and	O
high	O
prolactin	O
in	O
erectile	B-Disease
dysfunction	I-Disease
can	O
not	O
justify	O
their	O
routine	O
determination	O
.	O

However	O
,	O
cost-effective	O
screening	O
strategies	O
recommended	O
so	O
far	O
missed	O
40	O
to	O
50	O
%	O
of	O
cases	O
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	B-Disease
tumors	I-Disease
.	O

We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
years	O
testosterone	B-Chemical
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
and	O
abnormal	O
physical	O
examination	O
but	O
that	O
it	O
be	O
measured	O
in	O
all	O
men	O
older	O
than	O
50	O
years	O
.	O

Prolactin	O
should	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-Disease
sexual	I-Disease
desire	I-Disease
,	O
gynecomastia	B-Disease
and/or	O
testosterone	B-Chemical
less	O
than	O
4	O
ng./ml	O
.	O

Thiopentone	B-Chemical
pretreatment	O
for	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
ambulatory	O
patients	O
.	O

This	O
study	O
investigated	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
patients	O
undergoing	O
ambulatory	O
anaesthesia	O
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
trial	O
,	O
90	O
women	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatments	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
with	O
propofol	B-Chemical
.	O

Patients	O
in	O
Group	O
C	O
received	O
2	O
ml	O
normal	O
saline	O
,	O
Group	O
L	O
,	O
2	O
ml	O
,	O
lidocaine	B-Chemical
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Group	O
T	O
,	O
2	O
ml	O
thiopentone	B-Chemical
2.5	O
%	O
(	O
50	O
mg	O
)	O
.	O

Venous	O
discomfort	O
was	O
assessed	O
with	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
5-15	O
sec	O
after	O
commencing	O
propofol	B-Chemical
administration	O
using	O
an	O
infusion	O
pump	O
(	O
rate	O
1000	O
micrograms.kg-1.min-1	O
)	O
.	O

Loss	B-Disease
of	I-Disease
consciousness	I-Disease
occurred	O
in	O
60-90	O
sec	O
.	O

Visual	O
analogue	O
scores	O
(	O
mean	O
+/-	O
SD	O
)	O
during	O
induction	O
were	O
lower	O
in	O
Groups	O
L	O
(	O
3.3	O
+/-	O
2.5	O
)	O
and	O
T	O
(	O
4.1	O
+/-	O
2.7	O
)	O
than	O
in	O
Group	O
C	O
(	O
5.6	O
+/-	O
2.3	O
)	O
;	O
P	O
=	O
0.0031	O
.	O

The	O
incidence	O
of	O
venous	O
discomfort	O
was	O
lower	O
in	O
Group	O
L	O
(	O
76.6	O
%	O
;	O
P	O
<	O
0.05	O
)	O
than	O
in	O
Group	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Group	O
T	O
(	O
90	O
%	O
)	O
.	O

The	O
VAS	O
scores	O
for	O
recall	O
of	O
pain	B-Disease
in	O
the	O
recovery	O
room	O
were	O
correlated	O
with	O
the	O
VAS	O
scores	O
during	O
induction	O
(	O
r	O
=	O
0.7045	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Recovery	O
room	O
discharge	O
times	O
were	O
similar	O
:	O
C	O
(	O
75.9	O
+/-	O
19.4	O
min	O
)	O
;	O
L	O
73.6	O
+/-	O
21.6	O
min	O
)	O
;	O
T	O
(	O
77.1	O
+/-	O
18.9	O
min	O
)	O
.	O

Assessing	O
their	O
overall	O
satisfaction	O
,	O
89.7	O
%	O
would	O
choose	O
propofol	B-Chemical
anaesthesia	O
again	O
.	O

We	O
conclude	O
that	O
lidocaine	B-Chemical
reduces	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	B-Chemical
injection	O
pain	B-Disease
in	O
ambulatory	O
patients	O
whereas	O
thiopentone	B-Chemical
only	O
reduces	O
its	O
severity	O
.	O

Comparison	O
of	O
i.v	O
.	O

glycopyrrolate	B-Chemical
and	O
atropine	B-Chemical
in	O
the	O
prevention	O
of	O
bradycardia	B-Disease
and	O
arrhythmias	B-Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	B-Chemical
in	O
children	O
.	O

The	O
effectiveness	O
of	O
administration	O
of	O
glycopyrrolate	B-Chemical
5	O
and	O
10	O
micrograms	O
kg-1	O
and	O
atropine	B-Chemical
10	O
and	O
20	O
micrograms	O
kg-1	O
i.v	O
.	O

immediately	O
before	O
the	O
induction	O
of	O
anaesthesia	O
,	O
to	O
prevent	O
arrhythmia	B-Disease
and	O
bradycardia	B-Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	B-Chemical
in	O
children	O
,	O
was	O
studied	O
.	O

A	O
control	O
group	O
was	O
included	O
for	O
comparison	O
with	O
the	O
lower	O
dose	O
range	O
of	O
glycopyrrolate	B-Chemical
and	O
atropine	B-Chemical
.	O

A	O
frequency	O
of	O
bradycardia	B-Disease
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	B-Drug
.	O

Bradycardia	B-Disease
(	O
defined	O
as	O
a	O
decrease	O
in	O
heart	O
rate	O
to	O
less	O
than	O
50	O
beat	O
min-1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dose	O
of	O
either	O
active	O
drug	B-Drug
was	O
used	O
.	O

It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	B-Chemical
10	O
micrograms	O
kg-1	O
or	O
atropine	B-Chemical
20	O
micrograms	O
kg-1	O
i.v	O
.	O

should	O
immediately	O
precede	O
induction	O
of	O
anaesthesia	O
,	O
in	O
children	O
,	O
if	O
the	O
repeated	O
administration	O
of	O
suxamethonium	B-Chemical
is	O
anticipated	O
.	O

Reduction	O
in	O
caffeine	B-Chemical
toxicity	B-Disease
by	O
acetaminophen	B-Chemical
.	O

A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over-the-counter	O
analgesic	O
containing	O
sodium	B-Chemical
acetylsalicylate	I-Chemical
,	O
caffeine	B-Chemical
,	O
and	O
acetaminophen	B-Chemical
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	B-Chemical
per	O
mL	O
of	O
serum	O
.	O

Because	O
salicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	B-Chemical
on	O
the	O
CNS	O
,	O
attention	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	B-Chemical
(	O
52	O
micrograms/mL	O
)	O
reduced	O
the	O
CNS	O
toxicity	B-Disease
of	O
caffeine	B-Chemical
.	O

Studies	O
in	O
DBA/2J	O
mice	O
showed	O
that	O
:	O
1	O
)	O
pretreatment	O
with	O
acetaminophen	B-Chemical
(	O
100	O
mg/kg	O
)	O
increased	O
the	O
interval	O
between	O
the	O
administration	O
of	O
caffeine	B-Chemical
(	O
300	O
to	O
450	O
mg/kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
fatal	O
convulsions	B-Disease
by	O
a	O
factor	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatment	O
with	O
acetaminophen	B-Chemical
(	O
75	O
mg/kg	O
)	O
reduced	O
the	O
incidence	O
of	O
audiogenic	O
seizures	B-Disease
produced	O
in	O
the	O
presence	O
of	O
caffeine	B-Chemical
(	O
12.5	O
to	O
75	O
mg/kg	O
IP	O
)	O
.	O

The	O
frequency	O
of	O
sound-induced	O
seizures	B-Disease
after	O
12.5	O
or	O
25	O
mg/kg	O
caffeine	B-Chemical
was	O
reduced	O
from	O
50	O
to	O
5	O
%	O
by	O
acetaminophen	B-Chemical
.	O

In	O
the	O
absence	O
of	O
caffeine	B-Chemical
,	O
acetaminophen	B-Chemical
(	O
up	O
to	O
300	O
mg/kg	O
)	O
did	O
not	O
modify	O
the	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	O
dose	O
of	O
pentylenetetrezol	B-Chemical
in	O
mice	O
(	O
tests	O
performed	O
by	O
the	O
Anticonvulsant	O
Screening	O
Project	O
of	O
NINCDS	O
)	O
.	O

Acetaminophen	B-Chemical
(	O
up	O
to	O
150	O
micrograms/mL	O
)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	B-Chemical
into	O
ATP	B-Chemical
in	O
slices	O
of	O
rat	O
cerebral	O
cortex	O
.	O

Thus	O
the	O
mechanism	O
by	O
which	O
acetaminophen	B-Chemical
antagonizes	O
the	O
actions	O
of	O
caffeine	B-Chemical
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

Flestolol	B-Chemical
:	O
an	O
ultra-short-acting	O
beta-adrenergic	O
blocking	O
agent	O
.	O

Flestolol	B-Chemical
(	O
ACC-9089	B-Chemical
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ultra-short-acting	O
beta-adrenergic	O
blocking	O
agent	O
,	O
without	O
any	O
intrinsic	O
sympathomimetic	B-Drug
activity	O
.	O

Flestolol	B-Chemical
is	O
metabolized	O
by	O
plasma	O
esterases	O
and	O
has	O
an	O
elimination	O
half-life	O
of	O
approximately	O
6.5	O
minutes	O
.	O

This	O
agent	O
was	O
well	O
tolerated	O
in	O
healthy	O
volunteers	O
at	O
doses	O
up	O
to	O
100	O
micrograms/kg/min	O
.	O

In	O
long-term	O
infusion	O
studies	O
,	O
flestolol	B-Chemical
was	O
well	O
tolerated	O
at	O
the	O
effective	O
beta-blocking	B-Drug
dose	O
(	O
5	O
micrograms/kg/min	O
)	O
for	O
up	O
to	O
seven	O
days	O
.	O

Flestolol	B-Chemical
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	B-Chemical
and	O
beta-adrenergic	O
blockade	O
.	O

Flestolol	B-Chemical
produced	O
a	O
dose-dependent	O
attenuation	O
of	O
isoproterenol-induced	B-Chemical
tachycardia	B-Disease
.	O

Electrophysiologic	O
and	O
hemodynamic	O
effects	O
of	O
flestolol	B-Chemical
are	O
similar	O
to	O
those	O
of	O
other	O
beta	O
blockers	O
.	O

In	O
contrast	O
with	O
other	O
beta	O
blockers	O
,	O
flestolol-induced	B-Chemical
effects	O
reverse	O
rapidly	O
(	O
within	O
30	O
minutes	O
)	O
following	O
discontinuation	O
because	O
of	O
its	O
short	O
half-life	O
.	O

Flestolol	B-Chemical
effectively	O
reduced	O
heart	O
rate	O
in	O
patients	O
with	O
supraventricular	B-Disease
tachyarrhythmia	I-Disease
.	O

In	O
patients	O
with	O
unstable	B-Disease
angina	I-Disease
,	O
flestolol	B-Chemical
infusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chest	B-Disease
pain	I-Disease
.	O

It	O
is	O
concluded	O
that	O
flestolol	B-Chemical
is	O
a	O
potent	O
,	O
well-tolerated	O
,	O
ultra-short-acting	O
beta-adrenergic	O
blocking	O
agent	O
.	O

Use	O
of	O
flestolol	B-Chemical
in	O
the	O
critical	O
care	O
setting	O
is	O
currently	O
undergoing	O
investigation	O
.	O

Adverse	O
effect	O
of	O
the	O
calcium	B-Chemical
channel	O
blocker	O
nitrendipine	B-Chemical
on	O
nephrosclerosis	B-Disease
in	O
rats	O
with	O
renovascular	B-Disease
hypertension	I-Disease
.	O

The	O
effect	O
of	O
a	O
6-week	O
treatment	O
with	O
the	O
calcium	B-Chemical
channel	O
blocker	O
nitrendipine	B-Chemical
or	O
the	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
enalapril	B-Chemical
on	O
blood	O
pressure	O
,	O
albuminuria	B-Disease
,	O
renal	O
hemodynamics	O
,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	O
was	O
studied	O
in	O
rats	O
with	O
two-kidney	O
,	O
one	O
clip	O
renovascular	B-Disease
hypertension	I-Disease
.	O

Six	O
weeks	O
after	O
clipping	O
of	O
one	O
renal	O
artery	O
,	O
hypertensive	B-Disease
rats	O
(	O
178	O
+/-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
untreated	O
hypertensive	B-Disease
controls	O
(	O
n	O
=	O
8	O
)	O
,	O
enalapril-treated	B-Chemical
(	O
n	O
=	O
8	O
)	O
,	O
or	O
nitrendipine-treated	B-Chemical
(	O
n	O
=	O
10	O
)	O
.	O

Sham-operated	O
rats	O
served	O
as	O
normotensive	O
controls	O
(	O
128	O
+/-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8	O
)	O
.	O

After	O
6	O
weeks	O
of	O
treatment	O
,	O
renal	O
hemodynamics	O
(	O
glomerular	O
filtration	O
rate	O
and	O
renal	O
plasma	O
flow	O
)	O
were	O
measured	O
in	O
the	O
anesthetized	O
rats	O
.	O

Renal	O
tissue	O
was	O
obtained	O
for	O
determination	O
of	O
glomerular	O
size	O
and	O
sclerosis	O
.	O

Enalapril	B-Chemical
but	O
not	O
nitrendipine	B-Chemical
reduced	O
blood	O
pressure	O
significantly	O
.	O

After	O
6	O
weeks	O
of	O
therapy	O
,	O
glomerular	O
filtration	O
rate	O
was	O
not	O
different	O
among	O
the	O
studied	O
groups	O
.	O

Renal	O
plasma	O
flow	O
increased	O
,	O
but	O
albumin	O
excretion	O
and	O
glomerulosclerosis	B-Disease
did	O
not	O
change	O
after	O
enalapril	B-Chemical
treatment	O
.	O

In	O
contrast	O
,	O
in	O
the	O
nitrendipine-treated	B-Chemical
group	O
albuminuria	B-Disease
increased	O
from	O
12.8	O
+/-	O
2	O
progressively	O
to	O
163	O
+/-	O
55	O
compared	O
with	O
19.2	O
+/-	O
9	O
mg/24	O
hr	O
in	O
the	O
hypertensive	B-Disease
controls	O
.	O

Furthermore	O
,	O
glomerulosclerosis	B-Disease
index	O
was	O
significantly	O
increased	O
in	O
the	O
nitrendipine-treated	B-Chemical
group	O
compared	O
with	O
the	O
hypertensive	B-Disease
controls	O
(	O
0.38	O
+/-	O
0.1	O
versus	O
0.13	O
+/-	O
0.04	O
)	O
.	O

In	O
addition	O
,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine-treated	B-Chemical
group	O
(	O
14.9	O
+/-	O
0.17	O
10	O
(	O
-3	O
)	O
mm2	O
)	O
but	O
lower	O
in	O
the	O
enalapril-treated	B-Chemical
group	O
(	O
11.5	O
+/-	O
0.15	O
10	O
(	O
-3	O
)	O
mm2	O
)	O
compared	O
with	O
the	O
hypertensive	B-Disease
controls	O
(	O
12.1	O
+/-	O
0.17	O
10	O
(	O
-3	O
)	O
mm2	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Treatment	O
of	O
tinnitus	B-Disease
by	O
intratympanic	O
instillation	O
of	O
lignocaine	B-Chemical
(	O
lidocaine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
ventilation	O
tubes	O
.	O

Idiopathic	B-Disease
subjective	I-Disease
tinnitus	I-Disease
(	O
IST	B-Disease
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies	O
.	O

This	O
paper	O
presents	O
the	O
results	O
of	O
treating	O
IST	B-Disease
by	O
intratympanic	O
instillation	O
of	O
lignocaine	B-Chemical
(	O
lidocaine	B-Chemical
)	O
2	O
per	O
cent	O
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	O
courses	O
.	O

Fifty-two	O
patients	O
suffering	O
from	O
intractable	O
tinnitus	B-Disease
entered	O
this	O
therapeutic	O
trial	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses	O
.	O

In	O
one	O
patient	O
,	O
the	O
tinnitus	B-Disease
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patients	O
the	O
decompensated	O
tinnitus	B-Disease
changed	O
to	O
a	O
compensated	O
one	O
.	O

We	O
suggest	O
this	O
mode	O
of	O
treatment	O
for	O
patients	O
that	O
were	O
previously	O
treated	O
by	O
drugs	B-Drug
,	O
acupuncture	O
and	O
biofeedback	O
,	O
with	O
disappointing	O
results	O
.	O

Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	B-Disease
and	O
vomiting	B-Disease
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	O
,	O
and	O
that	O
the	O
tinnitus	B-Disease
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	O
and	O
lead	B-Drug
a	O
more	O
normal	O
life	O
.	O

Perhexiline	B-Chemical
maleate	I-Chemical
and	O
peripheral	B-Disease
neuropathy	I-Disease
.	O

Peripheral	B-Disease
neuropathy	I-Disease
has	O
been	O
noted	O
as	O
a	O
complication	O
of	O
therapy	O
with	O
perhexiline	B-Chemical
maleate	I-Chemical
,	O
a	O
drug	B-Drug
widely	O
used	O
in	O
France	O
(	O
and	O
in	O
clinical	O
trials	O
in	O
the	O
United	O
States	O
)	O
for	O
the	O
prophylactic	O
treatment	O
of	O
angina	B-Disease
pectoris	I-Disease
.	O

In	O
24	O
patients	O
with	O
this	O
complication	O
,	O
the	O
marked	O
slowing	O
of	O
motor	O
nerve	O
conduction	O
velocity	O
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	B-Disease
disorder	I-Disease
.	O

Improvement	O
was	O
noted	O
with	O
cessation	O
of	O
therapy	O
.	O

In	O
a	O
few	O
cases	O
the	O
presence	O
of	O
active	O
denervation	O
signified	O
a	O
poor	O
prognosis	O
,	O
with	O
only	O
slight	O
improvement	O
.	O

The	O
underlying	O
mechanism	O
causing	O
the	O
neuropathy	B-Disease
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidence	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lipid	O
storage	O
process	O
.	O

Effect	O
of	O
humoral	O
modulators	O
of	O
morphine-induced	B-Chemical
increase	B-Disease
in	B-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
.	O

The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine-induced	B-Chemical
increase	B-Disease
in	B-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
was	O
studied	O
.	O

The	O
subcutaneous	O
administration	O
of	O
10	O
mg/kg	O
of	O
morphine-HC1	B-Chemical
produced	O
a	O
marked	O
increase	B-Disease
in	B-Disease
locomotor	I-Disease
activity	I-Disease
in	O
mice	O
.	O

The	O
morphine-induced	B-Chemical
hyperactivity	B-Disease
was	O
potentiated	O
by	O
scopolamine	B-Chemical
and	O
attenuated	O
by	O
physostigmine	B-Chemical
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	B-Chemical
and	O
neostigmine	B-Chemical
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood-brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	B-Disease
produced	O
by	O
morphine	B-Chemical
.	O

Pretreatment	O
of	O
mice	O
with	O
alpha-methyltyrosine	B-Chemical
(	O
20	O
mg/kg	O
i.p.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	B-Chemical
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity-increasing	O
effects	O
of	O
morphine	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p-chlorophenylalamine	B-Chemical
(	O
3	O
X	O
320	O
mg/kg	O
i.p.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	B-Chemical
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	B-Disease
.	O

The	O
study	O
suggests	O
that	O
the	O
activity-increasing	O
effects	O
of	O
morphine	B-Chemical
are	O
mediated	O
by	O
the	O
release	O
of	O
catecholamines	B-Chemical
from	O
adrenergic	O
neurons	O
in	O
the	O
brain	O
.	O

And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	B-Chemical
acts	O
by	O
retarding	O
the	O
release	O
of	O
acetylcholine	B-Chemical
at	O
some	O
central	O
cholinergic	O
synapses	O
.	O

It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	O
activity-increasing	O
effects	O
of	O
morphine	B-Chemical
in	O
mice	O
are	O
mediated	O
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activity-increasing	O
effects	O
of	O
morphine	B-Chemical
in	O
rats	O
.	O

Mechanisms	O
of	O
FK	B-Chemical
506-induced	O
hypertension	O
in	O
the	O
rat	O
.	O

-Tacrolimus	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppressant	O
.	O

The	O
clinical	O
utility	O
of	O
FK	B-Chemical
506	I-Chemical
is	O
complicated	O
by	O
substantial	O
hypertension	B-Disease
and	O
nephrotoxicity	B-Disease
.	O

To	O
clarify	O
the	O
mechanisms	O
of	O
FK	B-Chemical
506-induced	O
hypertension	O
,	O
we	O
studied	O
the	O
chronic	O
effects	O
of	O
FK	B-Chemical
506	O
on	O
the	O
synthesis	O
of	O
endothelin-1	O
(	O
ET-1	O
)	O
,	O
the	O
expression	O
of	O
mRNA	O
of	O
ET-1	O
and	O
endothelin-converting	O
enzyme-1	O
(	O
ECE-1	O
)	O
,	O
the	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
activity	O
,	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C-type	O
natriuretic	O
peptide	O
(	O
CNP	O
)	O
in	O
rat	O
blood	O
vessels	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	O
139317	O
on	O
FK	O
506-induced	O
hypertension	B-Disease
in	O
rats	O
was	O
studied	O
.	O

FK	B-Chemical
506	I-Chemical
,	O
5	O
mg.	O
kg-1	O
.	O

d-1	O
given	O
for	O
4	O
weeks	O
,	O
elevated	O
blood	O
pressure	O
from	O
102+/-13	O
to	O
152+/-15	O
mm	O
Hg	O
and	O
increased	O
the	O
synthesis	O
of	O
ET-1	O
and	O
the	O
levels	O
of	O
ET-1	O
mRNA	O
in	O
the	O
mesenteric	O
artery	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O

Little	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
ECE-1	O
mRNA	O
and	O
CNP	O
mRNA	O
.	O

FK	O
506	O
decreased	O
eNOS	O
activity	O
and	O
the	O
levels	O
of	O
eNOS	O
mRNA	O
in	O
the	O
aorta	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O

The	O
administration	O
of	O
FR	O
139317	O
(	O
10	O
mg.	O
kg-1	O
.	O

d-1	O
)	O
prevented	O
FK	O
506-induced	O
hypertension	O
in	O
rats	O
.	O

These	O
results	O
indicate	O
that	O
FK	O
506	O
may	O
increase	O
blood	O
pressure	O
not	O
only	O
by	O
increasing	O
ET-1	O
production	O
but	O
also	O
by	O
decreasing	O
NO	O
synthesis	O
in	O
the	O
vasculature	O
.	O

Suxamethonium	B-Chemical
induced	O
prolonged	O
apnea	B-Disease
in	O
a	O
patient	O
receiving	O
electroconvulsive	O
therapy	O
.	O

Suxamethonium	B-Chemical
causes	O
prolonged	O
apnea	B-Disease
in	O
patients	O
in	O
whom	O
pseudocholinesterase	O
enzyme	O
gets	O
deactivated	O
by	O
organophosphorus	B-Chemical
(	I-Chemical
OP	I-Chemical
)	I-Chemical
poisons	I-Chemical
.	O

Here	O
,	O
we	O
present	O
a	O
similar	O
incident	O
in	O
a	O
severely	O
depressed	B-Disease
patient	O
who	O
received	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Prolonged	O
apnea	B-Disease
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	B-Chemical
compound	I-Chemical
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O

The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	B-Chemical
on	O
male	O
sexual	B-Disease
dysfunction	I-Disease
induced	O
by	O
a	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitor	I-Chemical
:	O
a	O
double-blind	O
placebo-controlled	O
and	O
randomized	O
study	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
adjunctive	O
bupropion	B-Chemical
sustained-release	O
(	O
SR	O
)	O
on	O
male	O
sexual	B-Disease
dysfunction	I-Disease
(	O
SD	B-Disease
)	O
induced	O
by	O
a	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitor	I-Chemical
(	O
SSRI	B-Chemical
)	O
,	O
as	O
SD	B-Disease
is	O
a	O
common	O
side-effect	O
of	O
SSRIs	B-Chemical
and	O
the	O
most	O
effective	O
treatments	O
have	O
yet	O
to	O
be	O
determined	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
randomized	O
sample	O
consisted	O
of	O
234	O
euthymic	O
men	O
who	O
were	O
receiving	O
some	O
type	O
of	O
SSRI	B-Chemical
.	O

The	O
men	O
were	O
randomly	O
assigned	O
to	O
bupropion	B-Chemical
SR	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
117	O
)	O
or	O
placebo	O
(	O
twice	O
daily	O
,	O
117	O
)	O
for	O
12	O
weeks	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Clinical	O
Global	O
Impression-Sexual	O
Function	O
(	O
CGI-SF	O
;	O
the	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
International	O
Index	O
of	O
Erectile	B-Disease
Function	O
(	O
IIEF	O
)	O
,	O
Arizona	O
Sexual	O
Experience	O
Scale	O
(	O
ASEX	O
)	O
,	O
and	O
Erectile	B-Disease
Dysfunction	O
Inventory	O
of	O
Treatment	O
Satisfaction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcome	O
measures	O
)	O
.	O

Participants	O
were	O
followed	O
biweekly	O
during	O
study	O
period	O
.	O

RESULTS	O
:	O
After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scores	O
for	O
CGI-SF	O
were	O
significantly	O
lower	O
,	O
i.e	O
.	O

better	O
,	O
in	O
patients	O
on	O
bupropion	B-Chemical
SR	O
,	O
at	O
2.4	O
(	O
1.2	O
)	O
,	O
than	O
in	O
the	O
placebo	O
group	O
,	O
at	O
3.9	O
(	O
1.1	O
)	O
(	O
P=	O
0.01	O
)	O
.	O

Men	O
who	O
received	O
bupropion	B-Chemical
had	O
a	O
significant	O
increase	O
in	O
the	O
total	O
IIEF	O
score	O
(	O
54.4	O
%	O
vs	O
1.2	O
%	O
;	O
P=	O
0.003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF	O
.	O

Total	O
ASEX	O
scores	O
were	O
significantly	O
lower	O
,	O
i.e	O
.	O

better	O
,	O
among	O
men	O
who	O
received	O
bupropion	B-Chemical
than	O
placebo	O
,	O
at	O
15.5	O
(	O
4.3	O
)	O
vs	O
21.5	O
(	O
4.7	O
)	O
(	O
P=	O
0.002	O
)	O
.	O

The	O
EDITS	O
scores	O
were	O
67.4	O
(	O
10.2	O
)	O
for	O
the	O
bupropion	B-Chemical
and	O
36.3	O
(	O
11.7	O
)	O
for	O
the	O
placebo	O
group	O
(	O
P=	O
0.001	O
)	O
.	O

The	O
ASEX	O
score	O
and	O
CGI-SF	O
score	O
were	O
correlated	O
(	O
P=	O
0.003	O
)	O
.	O

In	O
linear	O
regression	O
analyses	O
the	O
CGI-SF	O
score	O
was	O
not	O
affected	O
significantly	O
by	O
the	O
duration	O
of	O
SD	B-Disease
,	O
type	O
of	O
SSRI	B-Chemical
used	O
and	O
age	O
.	O

CONCLUSIONS	O
:	O
Bupropion	B-Chemical
is	O
an	O
effective	O
treatment	O
for	O
male	O
SD	B-Disease
induced	O
by	O
SSRIs	B-Chemical
.	O

These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	B-Chemical
.	O

Lamivudine	B-Chemical
for	O
the	O
prevention	O
of	O
hepatitis	B-Disease
B	I-Disease
virus	O
reactivation	O
in	O
hepatitis-B	B-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBSAG	B-Chemical
)	O
seropositive	O
cancer	B-Disease
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O

Hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronic	O
liver	B-Disease
disease	I-Disease
worldwide	O
.	O

Cancer	B-Disease
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
HBV	O
have	O
a	O
higher	O
hepatic	B-Disease
complication	I-Disease
rate	O
while	O
receiving	O
cytotoxic	O
chemotherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivation	O
.	O

In	O
this	O
study	O
,	O
cancer	B-Disease
patients	O
who	O
have	O
solid	O
and	O
hematological	B-Disease
malignancies	I-Disease
with	O
chronic	O
HBV	B-Disease
infection	I-Disease
received	O
the	O
antiviral	O
agent	O
lamivudine	B-Chemical
prior	O
and	O
during	O
CT	O
compared	O
with	O
historical	O
control	O
group	O
who	O
did	O
not	O
receive	O
lamivudine	B-Chemical
.	O

The	O
objectives	O
were	O
to	O
assess	O
the	O
efficacy	O
of	O
lamivudine	B-Chemical
in	O
reducing	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
,	O
and	O
diminishing	O
morbidity	O
and	O
mortality	O
during	O
CT.	O
Two	O
groups	O
were	O
compared	O
in	O
this	O
study	O
.	O

The	O
prophylactic	O
lamivudin	B-Chemical
group	O
consisted	O
of	O
37	O
patients	O
who	O
received	O
prophylactic	O
lamivudine	B-Chemical
treatment	O
.	O

The	O
historical	O
controls	O
consisted	O
of	O
50	O
consecutive	O
patients	O
who	O
underwent	O
CT	O
without	O
prophylactic	O
lamivudine	B-Chemical
.	O

They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	O
after	O
CT	O
.	O

The	O
outcomes	O
were	O
compared	O
for	O
both	O
groups	O
.	O

Of	O
our	O
control	O
group	O
(	O
n=	O
50	O
)	O
,	O
21	O
patients	O
(	O
42	O
%	O
)	O
were	O
established	O
hepatitis	B-Disease
.	O

Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evaluated	O
as	O
severe	O
hepatitis	B-Disease
.	O

In	O
the	O
prophylactic	O
lamivudine	B-Chemical
group	O
severe	O
hepatitis	B-Disease
were	O
observed	O
only	O
in	O
1	O
patient	O
(	O
2.7	O
%	O
)	O
of	O
37	O
patients	O
(	O
p	O
<	O
0.006	O
)	O
.	O

Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	B-Chemical
aminotransferase	O
(	O
ALT	O
)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	B-Chemical
group	O
;	O
154:64	O
(	O
p	O
<	O
0.32	O
)	O
.	O

Our	O
study	O
suggests	O
that	O
prophylactic	O
lamivudine	B-Chemical
significantly	O
decreases	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
and	O
overall	O
morbidity	O
in	O
cancer	B-Disease
patients	O
during	O
and	O
after	O
immunosuppressive	O
therapy	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleoside	B-Chemical
or	O
nucleotide	B-Chemical
analogue	O
for	O
antiviral	O
prophylaxis	O
during	O
CT	O
and	O
the	O
optimal	O
duration	O
of	O
administration	O
after	O
completion	O
of	O
CT	O
.	O

Ginsenoside	B-Chemical
Rg1	I-Chemical
restores	O
the	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
induced	O
by	O
chronic	O
morphine	B-Chemical
administration	O
in	O
rats	O
.	O

Rg1	B-Chemical
,	O
as	O
a	O
ginsenoside	B-Chemical
extracted	O
from	O
Panax	O
ginseng	B-Drug
,	O
could	O
ameliorate	O
spatial	O
learning	B-Disease
impairment	I-Disease
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	B-Chemical
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	B-Chemical
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	B-Chemical
on	O
learning	B-Disease
impairment	I-Disease
by	O
chronic	O
morphine	B-Chemical
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O

Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	B-Chemical
(	O
10	O
mg/kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	B-Chemical
(	O
30	O
mg/kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	B-Chemical
once	O
a	O
day	O
for	O
10	O
days	O
.	O

Spatial	O
learning	O
capacity	O
was	O
assessed	O
in	O
the	O
Morris	O
water	O
maze	O
.	O

The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine/Rg1	B-Chemical
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O

By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
,	O
the	O
results	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
long-term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	B-Drug
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	O
.	O

The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	B-Chemical
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline-	O
or	O
morphine/Rg1-treated	B-Chemical
rats	O
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N-methyl-D-aspartate	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
MK801	O
.	O

We	O
conclude	O
that	O
Rg1	O
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	B-Chemical
administration	O
and	O
restore	O
the	O
morphine-inhibited	B-Chemical
LTP	O
.	O

This	O
effect	O
is	O
NMDA	O
receptor	O
dependent	O
.	O

A	O
study	O
on	O
the	O
effect	O
of	O
the	O
duration	O
of	O
subcutaneous	O
heparin	B-Chemical
injection	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
.	O

AIM	O
:	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
different	O
methods	O
to	O
prevent	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-Chemical
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	B-Disease
and	O
pain	B-Disease
is	O
little	O
documented	O
.	O

DESIGN	O
:	O
This	O
study	O
was	O
designed	O
as	O
within-subject	O
,	O
quasi-experimental	O
research	O
.	O

METHOD	O
:	O
The	O
sample	O
for	O
the	O
study	O
consisted	O
of	O
50	O
patients	O
to	O
whom	O
subcutaneous	O
heparin	B-Chemical
was	O
administered	O
.	O

Heparin	B-Chemical
was	O
injected	O
over	O
10	O
seconds	O
on	O
the	O
right	O
abdominal	O
site	O
and	O
30	O
seconds	O
on	O
the	O
left	O
abdominal	O
site	O
.	O

Injections	O
areas	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
bruising	B-Disease
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injection	O
.	O

Dimensions	O
of	O
the	O
bruising	B-Disease
on	O
the	O
heparin	B-Chemical
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper	O
.	O

The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measure	O
pain	B-Disease
intensity	O
and	O
a	O
stop-watch	O
was	O
used	O
to	O
time	O
the	O
pain	B-Disease
period	O
.	O

Data	O
were	O
analysed	O
using	O
chi-square	O
test	O
,	O
Mann-Whitney	O
U	O
,	O
Wilcoxon	O
signed	O
ranks	O
tests	O
and	O
correlation	O
.	O

RESULTS	O
:	O
The	O
percentage	O
of	O
bruising	B-Disease
occurrence	O
was	O
64	O
%	O
with	O
the	O
injection	O
of	O
10	O
seconds	O
duration	O
and	O
42	O
%	O
in	O
the	O
30-second	O
injection	O
.	O

It	O
was	O
determined	O
that	O
the	O
size	O
of	O
the	O
bruising	B-Disease
was	O
smaller	O
in	O
the	O
30-second	O
injection	O
.	O

Pain	B-Disease
intensity	O
and	O
pain	B-Disease
period	O
were	O
statistically	O
significantly	O
lower	O
for	O
the	O
30-second	O
injection	O
than	O
for	O
the	O
10-second	O
injection	O
.	O

CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injection	O
duration	O
had	O
an	O
effect	O
on	O
bruising	B-Disease
and	O
pain	B-Disease
following	O
the	O
subcutaneous	O
administration	O
of	O
heparin	B-Chemical
.	O

This	O
study	O
should	O
be	O
repeated	O
on	O
a	O
larger	O
sample	O
.	O

RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
administering	O
subcutaneous	O
heparin	B-Chemical
injections	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duration	O
of	O
the	O
injection	O
.	O

Acute	O
reserpine	B-Chemical
and	O
subchronic	O
haloperidol	B-Chemical
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	B-Chemical
uptake	O
and	O
elicit	O
orofacial	B-Disease
dyskinesia	I-Disease
in	O
rats	O
.	O

Reserpine-	B-Chemical
and	O
haloperidol-induced	B-Chemical
orofacial	B-Disease
dyskinesia	I-Disease
are	O
putative	O
animal	O
models	O
of	O
tardive	B-Disease
dyskinesia	I-Disease
(	O
TD	B-Disease
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
induced	O
orofacial	B-Disease
dyskinesia	I-Disease
by	O
acute	O
reserpine	B-Chemical
and	O
subchronic	O
haloperidol	B-Chemical
administration	O
to	O
rats	O
.	O

Reserpine	B-Chemical
injection	O
(	O
one	O
dose	O
of	O
1	O
mg/kg	O
s.c.	O
)	O
every	O
other	O
day	O
for	O
3	O
days	O
caused	O
a	O
significant	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
,	O
compared	O
to	O
the	O
control	O
.	O

Haloperidol	B-Chemical
administration	O
(	O
one	O
dose	O
of	O
12	O
mg/kg	O
once	O
a	O
week	O
s.c.	O
)	O
for	O
4	O
weeks	O
caused	O
an	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
observed	O
in	O
four	O
weekly	O
evaluations	O
.	O

After	O
the	O
treatments	O
and	O
behavioral	O
observation	O
,	O
glutamate	B-Chemical
uptake	O
by	O
segments	O
of	O
the	O
brain	O
was	O
analyzed	O
.	O

A	O
decreased	O
glutamate	B-Chemical
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	O
with	O
reserpine	B-Chemical
and	O
haloperidol	B-Chemical
,	O
compared	O
to	O
the	O
control	O
.	O

Importantly	O
,	O
a	O
decrease	O
in	O
glutamate	B-Chemical
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
orofacial	B-Disease
diskinesia	I-Disease
.	O

These	O
results	O
indicate	O
that	O
early	O
changes	O
in	O
glutamate	B-Chemical
transport	O
may	O
be	O
related	O
to	O
the	O
development	O
of	O
vacuous	O
chewing	O
movements	O
in	O
rats	O
.	O

Acute	B-Disease
psychosis	I-Disease
due	O
to	O
treatment	O
with	O
phenytoin	B-Chemical
in	O
a	O
nonepileptic	O
patient	O
.	O

The	O
development	O
of	O
psychosis	B-Disease
related	O
to	O
antiepileptic	B-Disease
drug	B-Drug
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	O
between	O
the	O
epileptic	O
brain	O
substratum	O
and	O
the	O
antiepileptic	O
drugs	B-Drug
.	O

The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	O
psychosis	B-Disease
following	O
phenytoin	B-Chemical
treatment	O
for	O
trigeminal	B-Disease
neuralgia	I-Disease
is	O
described	O
.	O

This	O
case	O
suggests	O
that	O
the	O
psychotic	B-Disease
symptoms	I-Disease
that	O
occur	O
following	O
phenytoin	B-Chemical
treatment	O
in	O
some	O
epileptic	B-Disease
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication	O
,	O
unrelated	O
to	O
seizures	B-Disease
.	O

The	O
effect	O
of	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	O
gentamicin	B-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	B-Chemical
Arabic	I-Chemical
on	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
induced	O
by	O
gentamicin	B-Chemical
(	O
GM	B-Chemical
)	O
nephrotoxicity	B-Disease
.	O

Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL/kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w/v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	B-Chemical
Arabic	I-Chemical
(	O
2	O
mL/kg	O
of	O
a	O
10	O
%	O
w/v	O
aqueous	O
suspension	O
of	O
gum	B-Chemical
Arabic	I-Chemical
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	B-Chemical
Arabic	I-Chemical
concomitantly	O
with	O
GM	B-Chemical
(	O
80mg/kg/day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Nephrotoxicity	B-Disease
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	B-Chemical
and	O
urea	B-Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	B-Chemical
Arabic	I-Chemical
and	O
GM	B-Chemical
significantly	O
increased	O
creatinine	B-Chemical
and	O
urea	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	B-Chemical
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	B-Chemical
group	O
)	O
The	O
GM-induced	B-Chemical
proximal	O
tubular	B-Disease
necrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	B-Chemical
together	O
with	O
gum	B-Chemical
Arabic	I-Chemical
than	O
in	O
those	O
given	O
GM	B-Chemical
and	O
cellulose	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	B-Chemical
Arabic	I-Chemical
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	B-Chemical
nephrotoxicity	B-Disease
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	I-Disease
functional	O
aspects	O
in	O
models	O
of	O
chronic	B-Disease
renal	I-Disease
failure	O
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O

Visual	B-Disease
hallucinations	I-Disease
associated	O
with	O
zonisamide	B-Chemical
.	O

Zonisamide	B-Chemical
is	O
a	O
broad-spectrum	O
antiepileptic	O
drug	B-Drug
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	B-Disease
.	O

Although	O
visual	B-Disease
hallucinations	I-Disease
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	B-Disease
hallucinations	I-Disease
and	O
altered	O
mental	O
status	O
after	O
zonisamide	B-Chemical
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	B-Disease
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	O
.	O

During	O
monitoring	O
,	O
visual	B-Disease
hallucinations	I-Disease
did	O
not	O
correlate	O
with	O
EEG	O
readings	O
,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O

None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	B-Disease
hallucinations	I-Disease
before	O
this	O
event	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	O
or	O
increased	O
dosage	O
of	O
zonisamide	B-Chemical
.	O

With	O
either	O
discontinuation	O
or	O
decreased	O
dosage	O
of	O
the	O
drug	B-Drug
the	O
symptoms	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O

Further	O
observations	O
and	O
reports	O
will	O
help	O
clarify	O
this	O
adverse	O
effect	O
.	O

Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	O
associated	O
with	O
zonisamide	B-Chemical
.	O

GLEPP1	O
receptor	O
tyrosine	B-Chemical
phosphatase	O
(	O
Ptpro	O
)	O
in	O
rat	O
PAN	B-Chemical
nephrosis	B-Disease
.	O

A	O
marker	O
of	O
acute	O
podocyte	O
injury	O
.	O

Glomerular	O
epithelial	O
protein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyte	O
receptor	O
membrane	O
protein	O
tyrosine	B-Chemical
phosphatase	O
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	B-Disease
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O

This	O
receptor	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
structure	O
and	O
function	O
of	O
podocyte	O
foot	O
process	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	B-Disease
injury	O
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

Puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
,	O
20	O
mg/100g	O
BW	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	B-Chemical
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5-11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	B-Disease
associated	O
with	O
glomerulosclerosis	B-Disease
(	O
days	O
45-126	O
)	O
.	O

At	O
day	O
5	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
reduced	O
from	O
the	O
normal	O
range	O
(	O
265.2	O
+/-	O
79.6	O
x	O
10	O
(	O
6	O
)	O
moles/glomerulus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
normal	O
(	O
41.8	O
+/-	O
4.8	O
x	O
10	O
(	O
6	O
)	O
moles/glomerulus	O
,	O
p	O
<	O
0.005	O
)	O
.	O

This	O
occurred	O
in	O
association	O
with	O
an	O
increase	O
in	O
urinary	O
protein	O
content	O
from	O
1.8	O
+/-	O
1	O
to	O
99.0	O
+/-	O
61	O
mg/day	O
(	O
p	O
<	O
0.001	O
)	O
.	O

In	O
contrast	O
,	O
podocalyxin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
time	O
.	O

By	O
day	O
11	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
had	O
begun	O
to	O
return	O
towards	O
baseline	O
.	O

By	O
day	O
45-126	O
,	O
at	O
a	O
time	O
when	O
glomerular	O
scarring	O
was	O
present	O
,	O
GLEPP1	O
was	O
absent	O
from	O
glomerulosclerotic	O
areas	O
although	O
the	O
total	O
glomerular	O
content	O
of	O
GLEPP1	O
was	O
not	O
different	O
from	O
normal	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	O
podocyte	O
injury	O
induced	O
by	O
PAN	B-Chemical
.	O

GLEPP1	O
expression	O
may	O
be	O
a	O
useful	O
marker	O
of	O
podocyte	O
injury	O
.	O

Ticlopidine-induced	B-Chemical
aplastic	B-Disease
anemia	I-Disease
:	O
report	O
of	O
three	O
Chinese	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O

In	O
this	O
study	O
,	O
three	O
Chinese	O
patients	O
with	O
ticlopidine-induced	B-Chemical
aplastic	B-Disease
anemia	I-Disease
were	O
reported	O
and	O
another	O
13	O
patients	O
in	O
the	O
English	O
literature	O
were	O
reviewed	O
.	O

We	O
attempted	O
to	O
find	O
underlying	O
similarities	O
,	O
evaluate	O
the	O
risk	O
factors	O
,	O
and	O
identify	O
appropriate	O
treatment	O
for	O
this	O
complication	O
.	O

All	O
but	O
one	O
of	O
the	O
patients	O
were	O
over	O
60	O
years	O
old	O
,	O
and	O
the	O
6	O
who	O
died	O
were	O
all	O
older	O
than	O
65	O
.	O

Therefore	O
,	O
old	O
age	O
may	O
be	O
a	O
risk	O
factor	O
for	O
developing	O
this	O
complication	O
.	O

Agranulocytosis	B-Disease
occurred	O
3-20	O
weeks	O
after	O
initiation	O
of	O
ticlopidine	B-Chemical
,	O
so	O
frequent	O
examination	O
of	O
white	O
cell	O
count	O
during	O
treatment	O
is	O
recommended	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O

Treatment	O
for	O
ticlopidine-induced	B-Chemical
aplastic	B-Disease
anemia	I-Disease
with	O
colony-stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect	O
.	O

The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patients	O
who	O
received	O
concurrent	O
calcium	B-Chemical
channel	O
blockers	O
died	O
,	O
should	O
alert	O
clinicians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drugs	B-Drug
simultaneously	O
.	O

Facilitation	O
of	O
memory	O
retrieval	O
by	O
pre-test	O
morphine	B-Chemical
and	O
its	O
state	O
dependency	O
in	O
the	O
step-through	O
type	O
passive	O
avoidance	O
learning	O
test	O
in	O
mice	O
.	O

Amnesia	B-Disease
produced	O
by	O
scopolamine	B-Chemical
and	O
cycloheximide	B-Chemical
were	O
reversed	O
by	O
morphine	B-Chemical
given	O
30	O
min	O
before	O
the	O
test	O
trial	O
(	O
pre-test	O
)	O
,	O
and	O
pre-test	O
morphine	B-Chemical
also	O
facilitated	O
the	O
memory	O
retrieval	O
in	O
the	O
animals	O
administered	O
naloxone	B-Chemical
during	O
the	O
training	O
trial	O
.	O

Similarly	O
,	O
pre-test	O
scopolamine	B-Chemical
partially	O
reversed	O
the	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
,	O
but	O
not	O
significantly	O
;	O
and	O
pre-test	O
cycloheximide	B-Chemical
failed	O
to	O
reverse	O
the	O
cycloheximide-induced	B-Chemical
amnesia	B-Disease
.	O

These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre-test	O
morphine	B-Chemical
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	B-Chemical
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O

Test	O
conditions	O
influence	O
the	O
response	O
to	O
a	O
drug	B-Drug
challenge	O
in	O
rodents	O
.	O

These	O
studies	O
were	O
conducted	O
to	O
examine	O
the	O
differential	O
response	O
to	O
a	O
drug	B-Drug
challenge	O
under	O
varied	O
experimental	O
test	O
conditions	O
routinely	O
employed	O
to	O
study	O
drug-induced	O
behavioral	O
and	O
neurophysiological	O
responses	O
in	O
rodents	O
.	O

Apomorphine	B-Chemical
,	O
a	O
nonselective	O
dopamine	B-Chemical
agonist	I-Chemical
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	B-Disease
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	B-Chemical
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine-induced	B-Chemical
activity	O
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed	O
.	O

In	O
rats	O
,	O
detection	O
of	O
apomorphine-induced	B-Chemical
hyperactivity	B-Disease
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	B-Chemical
such	O
as	O
drug-induced	O
hypothermia	B-Disease
.	O

In	O
mice	O
,	O
apomorphine	B-Chemical
produced	O
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O

Drug-induced	O
gross	O
activity	O
counts	O
were	O
increased	O
in	O
the	O
novel	O
exploratory	O
box	O
only	O
,	O
while	O
measures	O
of	O
stereotypic	O
behavior	O
were	O
similar	O
in	O
both	O
.	O

By	O
contrast	O
,	O
apomorphine-induced	B-Chemical
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O

Dopamine	B-Chemical
turnover	O
ratios	O
(	O
DOPAC	B-Chemical
:	O
DA	B-Chemical
and	O
HVA	B-Chemical
:	O
DA	B-Chemical
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

However	O
,	O
apomorphine-induced	B-Chemical
reductions	O
in	O
striatal	O
dopamine	B-Chemical
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O

The	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psychopharmacological	O
challenge	O
tests	O
in	O
rodents	O
.	O

Tricuspid	B-Disease
valve	I-Disease
regurgitation	I-Disease
and	O
lithium	B-Chemical
carbonate	I-Chemical
toxicity	B-Disease
in	O
a	O
newborn	O
infant	O
.	O

A	O
newborn	O
with	O
massive	O
tricuspid	B-Disease
regurgitation	I-Disease
,	O
atrial	B-Disease
flutter	I-Disease
,	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
and	O
a	O
high	O
serum	O
lithium	B-Chemical
level	O
is	O
described	O
.	O

This	O
is	O
the	O
first	O
patient	O
to	O
initially	O
manifest	O
tricuspid	B-Disease
regurgitation	I-Disease
and	O
atrial	B-Disease
flutter	I-Disease
,	O
and	O
the	O
11th	O
described	O
patient	O
with	O
cardiac	B-Disease
disease	I-Disease
among	O
infants	O
exposed	O
to	O
lithium	B-Chemical
compounds	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
.	O

Sixty-three	O
percent	O
of	O
these	O
infants	O
had	O
tricuspid	O
valve	O
involvement	O
.	O

Lithium	B-Chemical
carbonate	I-Chemical
may	O
be	O
a	O
factor	O
in	O
the	O
increasing	O
incidence	O
of	O
congenital	B-Disease
heart	I-Disease
disease	I-Disease
when	O
taken	O
during	O
early	O
pregnancy	O
.	O

It	O
also	O
causes	O
neurologic	B-Disease
depression	I-Disease
,	O
cyanosis	B-Disease
,	O
and	O
cardiac	B-Disease
arrhythmia	I-Disease
when	O
consumed	O
prior	O
to	O
delivery	O
.	O

Phenobarbital-induced	B-Chemical
dyskinesia	B-Disease
in	O
a	O
neurologically-impaired	B-Disease
child	O
.	O

A	O
2-year-old	O
child	O
with	O
known	O
neurologic	B-Disease
impairment	I-Disease
developed	O
a	O
dyskinesia	B-Disease
soon	O
after	O
starting	O
phenobarbital	B-Chemical
therapy	O
for	O
seizures	B-Disease
.	O

Known	O
causes	O
of	O
movement	B-Disease
disorders	I-Disease
were	O
eliminated	O
after	O
evaluation	O
.	O

On	O
repeat	O
challenge	O
with	O
phenobarbital	B-Chemical
,	O
the	O
dyskinesia	B-Disease
recurred	O
.	O

Phenobarbital	B-Chemical
should	O
be	O
added	O
to	O
the	O
list	O
of	O
anticonvulsant	O
drugs	B-Drug
that	O
can	O
cause	O
movement	B-Disease
disorders	I-Disease
.	O

Acute	O
changes	O
of	O
blood	O
ammonia	B-Chemical
may	O
predict	O
short-term	O
adverse	O
effects	O
of	O
valproic	B-Chemical
acid	I-Chemical
.	O

Valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
was	O
given	O
to	O
24	O
epileptic	B-Disease
patients	O
who	O
were	O
already	O
being	O
treated	O
with	O
other	O
antiepileptic	O
drugs	B-Drug
.	O

A	O
standardized	O
loading	O
dose	O
of	O
VPA	B-Chemical
was	O
administered	O
,	O
and	O
venous	O
blood	O
was	O
sampled	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
hours	O
.	O

Ammonia	B-Chemical
(	O
NH3	B-Chemical
)	O
was	O
higher	O
in	O
patients	O
who	O
,	O
during	O
continuous	O
therapy	O
,	O
complained	O
of	O
drowsiness	B-Disease
(	O
7	O
patients	O
)	O
than	O
in	O
those	O
who	O
were	O
symptom-free	O
(	O
17	O
patients	O
)	O
,	O
although	O
VPA	B-Chemical
plasma	O
levels	O
were	O
similar	O
in	O
both	O
groups	O
.	O

By	O
measuring	O
VPA-induced	B-Chemical
changes	O
of	O
blood	O
NH3	B-Chemical
content	O
,	O
it	O
may	O
be	O
possible	O
to	O
identify	O
patients	O
at	O
higher	O
risk	O
of	O
obtundation	O
when	O
VPA	B-Chemical
is	O
given	O
chronically	O
.	O

Effects	O
of	O
calcitonin	O
on	O
rat	O
extrapyramidal	O
motor	O
system	O
:	O
behavioral	O
and	O
biochemical	O
data	O
.	O

The	O
effects	O
of	O
i.v.c	O
.	O

injection	O
of	O
human	O
and	O
salmon	O
calcitonin	O
on	O
biochemical	O
and	O
behavioral	O
parameters	O
related	O
to	O
the	O
extrapyramidal	O
motor	O
system	O
,	O
were	O
investigated	O
in	O
male	O
rats	O
.	O

Calcitonin	O
injection	O
resulted	O
in	O
a	O
potentiation	O
of	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
and	O
a	O
partial	O
prevention	O
of	O
apomorphine-induced	B-Chemical
hyperactivity	B-Disease
.	O

Moreover	O
calcitonin	O
induced	O
a	O
significant	O
decrease	O
in	O
nigral	O
GAD	O
activity	O
but	O
no	O
change	O
in	O
striatal	O
DA	B-Chemical
and	O
DOPAC	B-Chemical
concentration	O
or	O
GAD	O
activity	O
.	O

The	O
results	O
are	O
discussed	O
in	O
view	O
of	O
a	O
primary	O
action	O
of	O
calcitonin	O
on	O
the	O
striatonigral	O
GABAergic	O
pathway	O
mediating	O
the	O
DA-related	B-Chemical
behavioral	O
messages	O
of	O
striatal	O
origin	O
.	O

Development	O
of	O
isoproterenol-induced	B-Chemical
cardiac	B-Disease
hypertrophy	I-Disease
.	O

The	O
development	O
of	O
cardiac	B-Disease
hypertrophy	I-Disease
was	O
studied	O
in	O
adult	O
female	O
Wistar	O
rats	O
following	O
daily	O
subcutaneous	O
injections	O
of	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
(	O
0.3	O
mg/kg	O
body	O
weight	O
)	O
.	O

A	O
time	O
course	O
was	O
established	O
for	O
the	O
change	O
in	O
tissue	O
mass	O
,	O
RNA	O
and	O
DNA	O
content	O
,	O
as	O
well	O
as	O
hydroxyproline	B-Chemical
content	O
.	O

Heart	O
weight	O
increased	O
44	O
%	O
after	O
8	O
days	O
of	O
treatment	O
with	O
a	O
half	O
time	O
of	O
3.4	O
days	O
.	O

Ventricular	O
RNA	O
content	O
was	O
elevated	O
26	O
%	O
after	O
24	O
h	O
of	O
a	O
single	O
injection	O
and	O
reached	O
a	O
maximal	O
level	O
following	O
8	O
days	O
of	O
therapy	O
.	O

The	O
half	O
time	O
for	O
RNA	O
accumulation	O
was	O
2.0	O
days	O
.	O

The	O
total	O
content	O
of	O
hydroxyproline	B-Chemical
remained	O
stable	O
during	O
the	O
first	O
2	O
days	O
of	O
treatment	O
but	O
increased	O
46	O
%	O
after	O
4	O
days	O
of	O
therapy	O
.	O

Ventricular	O
DNA	O
content	O
was	O
unchanged	O
during	O
the	O
early	O
stage	O
(	O
1-4	O
days	O
)	O
of	O
hypertrophic	B-Disease
growth	O
but	O
increased	O
to	O
a	O
new	O
steady-state	O
level	O
19	O
%	O
above	O
the	O
controls	O
after	O
8	O
days	O
of	O
treatment	O
.	O

Intraventricular	O
pressures	O
and	O
coronary	O
flow	O
measures	O
were	O
similar	O
for	O
control	O
and	O
experimental	O
animals	O
following	O
4	O
days	O
of	O
developed	O
hypertrophy	B-Disease
.	O

However	O
,	O
dP/dt	O
in	O
the	O
ISO-treated	B-Chemical
hearts	O
was	O
slightly	O
but	O
significantly	O
(	O
P	O
less	O
than	O
0.05	O
)	O
elevated	O
.	O

These	O
data	O
indicate	O
that	O
the	O
adaptive	O
response	O
to	O
ISO	B-Chemical
shows	O
an	O
early	O
hypertrophic	B-Disease
phase	O
(	O
1-4	O
days	O
)	O
characterized	O
by	O
a	O
substantial	O
increase	O
in	O
RNA	O
content	O
and	O
cardiac	O
mass	O
in	O
the	O
absence	O
of	O
changes	O
in	O
DNA	O
.	O

However	O
,	O
prolonged	O
stimulation	O
(	O
8-12	O
days	O
)	O
appears	O
to	O
represent	O
a	O
complex	O
integration	O
of	O
both	O
cellular	O
hypertrophy	B-Disease
and	O
hyperplasia	B-Disease
within	O
the	O
heart	O
.	O

Co-carcinogenic	B-Disease
effect	O
of	O
retinyl	B-Chemical
acetate	I-Chemical
on	O
forestomach	B-Disease
carcinogenesis	I-Disease
of	O
male	O
F344	O
rats	O
induced	O
with	O
butylated	B-Chemical
hydroxyanisole	I-Chemical
.	O

The	O
potential	O
modifying	O
effect	O
of	O
retinyl	B-Chemical
acetate	I-Chemical
(	O
RA	B-Chemical
)	O
on	O
butylated	B-Chemical
hydroxyanisole	I-Chemical
(	O
BHA	B-Chemical
)	O
-induced	O
rat	O
forestomach	B-Disease
tumorigenesis	I-Disease
was	O
examined	O
.	O

Male	O
F344	O
rats	O
,	O
5	O
weeks	O
of	O
age	O
,	O
were	O
maintained	O
on	O
diet	O
containing	O
1	O
%	O
or	O
2	O
%	O
BHA	B-Chemical
by	O
weight	O
and	O
simultaneously	O
on	O
drinking	O
water	O
supplemented	O
with	O
RA	B-Chemical
at	O
various	O
concentrations	O
(	O
w/v	O
)	O
for	O
52	O
weeks	O
.	O

In	O
groups	O
given	O
2	O
%	O
BHA	B-Chemical
,	O
although	O
marked	O
hyperplastic	O
changes	O
of	O
the	O
forestomach	O
epithelium	O
were	O
observed	O
in	O
all	O
animals	O
,	O
co-administration	O
of	O
0.25	O
%	O
RA	B-Chemical
significantly	O
(	O
P	O
less	O
than	O
0.05	O
)	O
increased	O
the	O
incidence	O
of	O
forestomach	B-Disease
tumors	I-Disease
(	O
squamous	B-Disease
cell	I-Disease
papilloma	I-Disease
and	O
carcinoma	B-Disease
)	O
to	O
60	O
%	O
(	O
9/15	O
,	O
2	O
rats	O
with	O
carcinoma	B-Disease
)	O
from	O
15	O
%	O
(	O
3/20	O
,	O
one	O
rat	O
with	O
carcinoma	B-Disease
)	O
in	O
the	O
group	O
given	O
RA-free	B-Chemical
water	O
.	O

In	O
rats	O
given	O
1	O
%	O
BHA	B-Chemical
,	O
RA	B-Chemical
co-administered	O
at	O
a	O
dose	O
of	O
0.05	O
,	O
0.1	O
,	O
0.2	O
or	O
0.25	O
%	O
showed	O
a	O
dose-dependent	O
enhancing	O
effect	O
on	O
the	O
development	O
of	O
the	O
BHA-induced	B-Chemical
epithelial	B-Disease
hyperplasia	I-Disease
.	O

Tumors	B-Disease
,	O
all	O
papillomas	B-Disease
,	O
were	O
induced	O
in	O
3	O
rats	O
(	O
17	O
%	O
)	O
with	O
0.25	O
%	O
RA	B-Chemical
and	O
in	O
one	O
rat	O
(	O
10	O
%	O
)	O
with	O
0.05	O
%	O
RA	B-Chemical
co-administration	O
.	O

RA	B-Chemical
alone	O
did	O
not	O
induce	O
hyperplastic	O
changes	O
in	O
the	O
forestomach	O
.	O

These	O
findings	O
indicate	O
that	O
RA	B-Chemical
acted	O
as	O
a	O
co-carcinogen	O
in	O
the	O
BHA	B-Chemical
forestomach	B-Disease
carcinogenesis	I-Disease
of	O
the	O
rat	O
.	O

Ketanserin	B-Chemical
pretreatment	O
reverses	O
alfentanil-induced	B-Chemical
muscle	B-Disease
rigidity	I-Disease
.	O

Systemic	O
pretreatment	O
with	O
ketanserin	B-Chemical
,	O
a	O
relatively	O
specific	O
type-2	O
serotonin	B-Chemical
receptor	O
antagonist	O
,	O
significantly	O
attenuated	O
the	O
muscle	B-Disease
rigidity	I-Disease
produced	O
in	O
rats	O
by	O
the	O
potent	O
short-acting	O
opiate	O
agonist	O
alfentanil	B-Chemical
.	O

Following	O
placement	O
of	O
subcutaneous	O
electrodes	O
in	O
each	O
animal	O
's	O
left	O
gastrocnemius	O
muscle	O
,	O
rigidity	B-Disease
was	O
assessed	O
by	O
analyzing	O
root-mean-square	O
electromyographic	O
activity	O
.	O

Intraperitoneal	O
ketanserin	B-Chemical
administration	O
at	O
doses	O
of	O
0.63	O
and	O
2.5	O
mg/kg	O
prevented	O
the	O
alfentanil-induced	B-Chemical
increase	O
in	O
electromyographic	O
activity	O
compared	O
with	O
animals	O
pretreated	O
with	O
saline	O
.	O

Chlordiazepoxide	B-Chemical
at	O
doses	O
up	O
to	O
10	O
mg/kg	O
failed	O
to	O
significantly	O
influence	O
the	O
rigidity	B-Disease
produced	O
by	O
alfentanil	B-Chemical
.	O

Despite	O
the	O
absence	O
of	O
rigidity	B-Disease
,	O
animals	O
that	O
received	O
ketanserin	B-Chemical
(	O
greater	O
than	O
0.31	O
mg/kg	O
i.p	O
.	O

)	O
followed	O
by	O
alfentanil	B-Chemical
were	O
motionless	O
,	O
flaccid	O
,	O
and	O
less	O
responsive	O
to	O
external	O
stimuli	O
than	O
were	O
animals	O
receiving	O
alfentanil	B-Chemical
alone	O
.	O

Rats	O
that	O
received	O
ketanserin	B-Chemical
and	O
alfentanil	B-Chemical
exhibited	O
less	O
rearing	O
and	O
exploratory	O
behavior	O
at	O
the	O
end	O
of	O
the	O
60-min	O
recording	O
period	O
than	O
did	O
animals	O
that	O
received	O
ketanserin	B-Chemical
alone	O
.	O

These	O
results	O
,	O
in	O
combination	O
with	O
previous	O
work	O
,	O
suggest	O
that	O
muscle	B-Disease
rigidity	I-Disease
,	O
a	O
clinically	O
relevant	O
side-effect	O
of	O
parenteral	O
narcotic	O
administration	O
,	O
may	O
be	O
partly	O
mediated	O
via	O
serotonergic	O
pathways	O
.	O

Pretreatment	O
with	O
type-2	O
serotonin	B-Chemical
antagonists	O
may	O
be	O
clinically	O
useful	O
in	O
attenuating	O
opiate-induced	O
rigidity	B-Disease
,	I-Disease
although	O
further	O
studies	O
will	O
be	O
necessary	O
to	O
assess	O
the	O
interaction	O
of	O
possibly	O
enhanced	O
CNS	O
,	I-Disease
cardiovascular	B-Disease
,	I-Disease
and	I-Disease
respiratory	O
depression	I-Chemical
.	O

Glycopyrronium	B-Chemical
requirements	O
for	O
antagonism	O
of	O
the	O
muscarinic	O
side	O
effects	O
of	O
edrophonium	B-Chemical
.	O

We	O
have	O
compared	O
,	O
in	O
60	O
adult	O
patients	O
,	O
the	O
cardiovascular	O
effects	O
of	O
glycopyrronium	B-Chemical
5	O
micrograms	O
kg-1	O
and	O
10	O
micrograms	O
kg-1	O
given	O
either	O
simultaneously	O
or	O
1	O
min	O
before	O
edrophonium	B-Chemical
1	O
mg	O
kg-1	O
.	O

Significant	O
differences	O
between	O
the	O
four	O
groups	O
were	O
detected	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

Both	O
groups	O
receiving	O
10	O
micrograms	O
kg-1	O
showed	O
increases	O
in	O
heart	O
rate	O
of	O
up	O
to	O
30	O
beat	O
min-1	O
(	O
95	O
%	O
confidence	O
limits	O
28-32	O
beat	O
min-1	O
)	O
.	O

Use	O
of	O
glycopyrronium	B-Chemical
5	O
micrograms	O
kg-1	O
provided	O
greater	O
cardiovascular	O
stability	O
and	O
,	O
given	O
1	O
min	O
before	O
the	O
edrophonium	B-Chemical
,	O
was	O
sufficient	O
to	O
minimize	O
early	O
,	O
edrophonium-induced	B-Chemical
bradycardias	B-Disease
.	O

This	O
low	O
dose	O
of	O
glycopyrronium	B-Chemical
provided	O
good	O
control	O
of	O
oropharyngeal	O
secretions	O
.	O

Involvement	O
of	O
locus	O
coeruleus	O
and	O
noradrenergic	O
neurotransmission	O
in	O
fentanyl-induced	B-Chemical
muscular	B-Disease
rigidity	I-Disease
in	O
the	O
rat	O
.	O

Whereas	O
muscular	B-Disease
rigidity	I-Disease
is	O
a	O
well-known	O
side	O
effect	O
that	O
is	O
associated	O
with	O
high-dose	O
fentanyl	B-Chemical
anesthesia	B-Drug
,	O
a	O
paucity	O
of	O
information	O
exists	O
with	O
regard	O
to	O
its	O
underlying	O
mechanism	O
(	O
s	O
)	O
.	O

We	O
investigated	O
in	O
this	O
study	O
the	O
possible	O
engagement	O
of	O
locus	O
coeruleus	O
of	O
the	O
pons	O
in	O
this	O
phenomenon	O
,	O
using	O
male	O
Sprague-Dawley	O
rats	O
anesthetized	O
with	O
ketamine	B-Chemical
.	O

Under	O
proper	O
control	O
of	O
respiration	O
,	O
body	O
temperature	O
and	O
end-tidal	O
CO2	B-Chemical
,	O
intravenous	O
administration	O
of	O
fentanyl	B-Chemical
(	O
50	O
or	O
100	O
micrograms/kg	O
)	O
consistently	O
promoted	O
an	O
increase	O
in	O
electromyographic	O
activity	O
recorded	O
from	O
the	O
gastrocnemius	O
and	O
abdominal	O
rectus	O
muscles	O
.	O

Such	O
an	O
induced	O
muscular	B-Disease
rigidity	I-Disease
by	O
the	O
narcotic	O
agent	O
was	O
significantly	O
antagonized	O
or	O
even	O
reduced	O
by	O
prior	O
electrolytic	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
or	O
pretreatment	O
with	O
the	O
alpha-adrenoceptor	O
blocker	O
,	O
prazosin	B-Chemical
.	O

Microinjection	O
of	O
fentanyl	B-Chemical
(	O
2.5	O
micrograms/50	O
nl	O
)	O
directly	O
into	O
this	O
pontine	O
nucleus	O
,	O
on	O
the	O
other	O
hand	O
,	O
elicited	O
discernible	O
electromyographic	O
excitation	O
.	O

It	O
is	O
speculated	O
that	O
the	O
induction	O
of	O
muscular	B-Disease
rigidity	I-Disease
by	O
fentanyl	B-Chemical
may	O
involve	O
the	O
coerulospinal	O
noradrenergic	O
fibers	O
to	O
the	O
spinal	O
motoneurons	O
.	O

Cerebral	B-Disease
sinus	I-Disease
thrombosis	I-Disease
as	O
a	O
potential	O
hazard	O
of	O
antifibrinolytic	O
treatment	O
in	O
menorrhagia	B-Disease
.	O

We	O
describe	O
a	O
42-year-old	O
woman	O
who	O
developed	O
superior	O
sagittal	B-Disease
and	I-Disease
left	I-Disease
transverse	I-Disease
sinus	I-Disease
thrombosis	I-Disease
associated	O
with	O
prolonged	O
epsilon-aminocaproic	O
acid	O
therapy	O
for	O
menorrhagia	O
.	O

This	O
antifibrinolytic	O
agent	O
has	O
been	O
used	O
in	O
women	O
with	O
menorrhagia	O
to	O
promote	O
clotting	O
and	O
reduce	O
blood	O
loss	O
.	O

Although	O
increased	O
risk	O
of	O
thromboembolic	O
disease	O
has	O
been	O
reported	O
during	O
treatment	O
with	O
epsilon-aminocaproic	O
acid	O
,	O
cerebral	O
sinus	I-Chemical
thrombosis	I-Chemical
has	O
not	O
been	O
previously	O
described	O
.	O

Careful	O
use	O
of	O
epsilon-aminocaproic	O
acid	O
therapy	O
is	O
recommended	O
.	O

Hemorrhagic	B-Disease
cystitis	I-Disease
complicating	O
bone	O
marrow	O
transplantation	O
.	O

Hemorrhagic	B-Disease
cystitis	I-Disease
is	O
a	O
potentially	O
serious	O
complication	O
of	O
high-dose	O
cyclophosphamide	B-Drug
therapy	O
administered	O
before	O
bone	O
marrow	O
transplantation	O
.	O

As	O
standard	O
practice	O
at	O
our	O
institution	O
,	O
patients	O
who	O
are	O
scheduled	O
to	O
receive	O
a	O
bone	O
marrow	O
transplant	O
are	O
treated	O
prophylactically	O
with	O
forced	O
hydration	O
and	O
bladder	O
irrigation	O
.	O

In	O
an	O
attempt	O
to	O
obviate	O
the	O
inconvenience	O
of	O
bladder	O
irrigation	O
,	O
we	O
conducted	O
a	O
feasibility	O
trial	O
of	O
uroprophylaxis	O
with	O
mesna	O
,	O
which	O
neutralizes	O
the	O
hepatic	O
metabolite	O
of	O
cyclophosphamide	B-Drug
that	O
causes	O
hemorrhagic	O
cystitis	O
.	O

Of	O
97	O
patients	O
who	O
received	O
standard	O
prophylaxis	O
,	O
4	O
had	O
symptomatic	O
hemorrhagic	O
cystitis	O
.	O

In	O
contrast	O
,	O
two	O
of	O
four	O
consecutive	O
patients	O
who	O
received	O
mesna	O
uroprophylaxis	O
before	O
allogeneic	O
bone	O
marrow	O
transplantation	O
had	O
severe	O
hemorrhagic	O
cystitis	O
for	O
at	O
least	O
2	O
weeks	O
.	O

Because	O
of	O
this	O
suboptimal	O
result	O
,	O
we	O
resumed	O
the	O
use	O
of	O
bladder	O
irrigation	O
and	O
forced	O
hydration	O
to	O
minimize	O
the	O
risk	O
of	O
hemorrhagic	O
cystitis	O
.	O

Reversal	O
of	O
central	O
benzodiazepine	B-Chemical
effects	O
by	O
flumazenil	B-Chemical
after	O
intravenous	O
conscious	O
sedation	O
with	O
diazepam	B-Chemical
and	O
opioids	O
:	O
report	O
of	O
a	O
double-blind	O
multicenter	O
study	O
.	O

The	O
Flumazenil	B-Chemical
in	O
Intravenous	O
Conscious	O
Sedation	O
with	O
Diazepam	B-Chemical
Multicenter	O
Study	O
Group	O
II	O
.	O

The	O
efficacy	O
and	O
safety	O
of	O
a	O
new	O
benzodiazepine	B-Chemical
antagonist	O
,	O
flumazenil	B-Chemical
,	O
were	O
assessed	O
in	O
a	O
double-blind	O
multicenter	O
study	O
.	O

Flumazenil	B-Chemical
(	O
mean	O
dose	O
,	O
0.76	O
mg	O
)	O
or	O
placebo	O
(	O
mean	O
dose	O
,	O
8.9	O
ml	O
)	O
was	O
administered	O
intravenously	O
to	O
130	O
and	O
67	O
patients	O
,	O
respectively	O
,	O
who	O
had	O
been	O
given	O
diazepam	B-Chemical
in	O
conjunction	O
with	O
an	O
opioid	O
(	O
fentanyl	B-Chemical
,	O
meperidine	B-Chemical
,	O
or	O
morphine	B-Chemical
)	O
for	O
the	O
induction	O
and	O
maintenance	O
of	O
intravenous	O
conscious	O
sedation	O
for	O
diagnostic	O
or	O
therapeutic	O
surgical	O
procedures	O
.	O

The	O
group	O
assessable	O
for	O
efficacy	O
comprised	O
122	O
patients	O
treated	O
with	O
flumazenil	B-Chemical
and	O
64	O
patients	O
given	O
placebo	O
.	O

After	O
5	O
minutes	O
,	O
80/115	O
(	O
70	O
%	O
)	O
flumazenil-treated	B-Chemical
patients	O
,	O
compared	O
with	O
21/63	O
(	O
33	O
%	O
)	O
placebo-treated	O
patients	O
,	O
were	O
completely	O
awake	O
and	O
alert	O
,	O
as	O
indicated	O
by	O
a	O
score	O
of	O
5	O
on	O
the	O
Observer	O
's	O
Assessment	O
of	O
Alertness/Sedation	O
Scale	O
.	O

Ninety-five	O
percent	O
of	O
patients	O
in	O
each	O
group	O
who	O
attained	O
a	O
score	O
of	O
5	O
at	O
the	O
5-minute	O
assessment	O
showed	O
no	O
loss	O
of	O
alertness	O
throughout	O
the	O
180-minute	O
assessment	O
period	O
.	O

Flumazenil-treated	B-Chemical
patients	O
also	O
performed	O
significantly	O
better	O
on	O
the	O
Finger-to-Nose	O
Test	O
and	O
the	O
recall	O
of	O
pictures	O
shown	O
at	O
the	O
5-minute	O
assessment	O
.	O

Flumazenil	B-Chemical
was	O
well	O
tolerated	O
,	O
with	O
no	O
serious	O
adverse	O
effects	O
reported	O
.	O

Thirty-nine	O
(	O
30	O
%	O
)	O
of	O
flumazenil-treated	B-Chemical
patients	O
,	O
compared	O
with	O
17	O
(	O
25	O
%	O
)	O
of	O
placebo-treated	O
patients	O
had	O
one	O
or	O
more	O
drug-related	O
adverse	O
experiences	O
.	O

The	O
most	O
common	O
adverse	O
effects	O
were	O
nausea	B-Disease
and	O
vomiting	B-Disease
in	O
the	O
flumazenil	B-Chemical
group	O
and	O
nausea	B-Disease
and	O
injection-site	O
pain	B-Disease
in	O
the	O
placebo	O
group	O
.	O

Flumazenil	B-Chemical
was	O
found	O
to	O
promptly	O
reverse	O
sedation	O
induced	O
by	O
diazepam	B-Chemical
in	O
the	O
presence	O
of	O
opioids	O
.	O

Hepatic	O
adenomas	B-Disease
and	O
focal	B-Disease
nodular	I-Disease
hyperplasia	I-Disease
of	O
the	O
liver	O
in	O
young	O
women	O
on	O
oral	B-Chemical
contraceptives	I-Chemical
:	O
case	O
reports	O
.	O

Two	O
cases	O
of	O
hepatic	O
adenoma	B-Disease
and	O
one	O
of	O
focal	B-Disease
nodular	I-Disease
hyperplasia	I-Disease
presumably	O
associated	O
with	O
the	O
use	O
of	O
oral	B-Chemical
contraceptives	I-Chemical
,	O
are	O
reported	O
.	O

Special	O
reference	O
is	O
made	O
to	O
their	O
clinical	O
presentation	O
,	O
which	O
may	O
be	O
totally	O
asymptomatic	O
.	O

Liver-function	O
tests	O
are	O
of	O
little	O
diagnostic	O
value	O
,	O
but	O
valuable	O
information	O
may	O
be	O
obtained	O
from	O
both	O
liver	O
scanning	O
and	O
hepatic	O
angiography	O
.	O

Histologic	O
differences	O
and	O
clinical	O
similarities	O
between	O
hepatic	O
adenoma	B-Disease
and	O
focal	B-Disease
nodular	I-Disease
hyperplasia	I-Disease
of	O
the	O
liver	O
are	O
discussed	O
.	O

Arterial	O
thromboembolism	B-Disease
in	O
patients	O
receiving	O
systemic	O
heparin	B-Chemical
therapy	O
:	O
a	O
complication	O
associated	O
with	O
heparin-induced	B-Chemical
thrombocytopenia	B-Disease
.	O

Arterial	O
thromboembolism	B-Disease
is	O
a	O
recognized	O
complication	O
of	O
systemic	O
heparin	B-Chemical
therapy	O
.	O

Characteristic	O
of	O
the	O
entity	O
is	O
arterial	B-Disease
occlusion	I-Disease
by	O
platelet-fibrin	O
thrombi	B-Disease
with	O
distal	O
ischemia	B-Disease
occurring	O
four	O
to	O
twenty	O
days	O
after	O
the	O
initiation	O
of	O
heparin	B-Chemical
therapy	O
,	O
preceded	O
by	O
profound	O
thrombocytopenia	B-Disease
with	O
platelet	O
counts	O
in	O
the	O
range	O
of	O
30,000	O
to	O
40,000	O
per	O
cubic	O
millimeter	O
.	O

The	O
clinically	O
apparent	O
occlusion	O
may	O
be	O
preceded	O
by	O
gastrointestinal	B-Disease
and	I-Disease
musculoskeletal	I-Disease
symptoms	I-Disease
that	O
appear	O
to	O
be	O
ischemic	O
in	O
origin	O
,	O
and	O
might	O
serve	O
to	O
warn	O
the	O
clinician	O
of	O
these	O
complications	O
.	O

Previous	O
reports	O
of	O
these	O
phenomena	O
as	O
well	O
as	O
recent	O
studies	O
of	O
the	O
effect	O
of	O
heparin	B-Drug
are	O
reviewed	O
.	O

The	O
common	O
factor	O
relating	O
thromboembolism	O
and	O
thrombocytopenia	O
is	O
heparin-induced	B-Drug
platelet	O
aggregation	O
.	O

Appropriate	O
treatment	O
consists	O
of	O
discontinuation	O
of	O
heparin	B-Drug
,	O
and	O
anticoagulation	O
with	O
sodium	O
warfarin	B-Drug
if	O
necessary	O
.	O

Vascular	O
procedures	O
are	O
performed	O
as	O
indicated	O
.	O

Long-term	O
prognosis	O
for	O
transplant-free	O
survivors	O
of	O
paracetamol-induced	B-Chemical
acute	B-Disease
liver	I-Disease
failure	I-Disease
.	O

BACKGROUND	O
:	O
The	O
prognosis	O
for	O
transplant-free	O
survivors	O
of	O
paracetamol-induced	B-Chemical
acute	B-Disease
liver	I-Disease
failure	I-Disease
remains	O
unknown	O
.	O

AIM	O
:	O
To	O
examine	O
whether	O
paracetamol-induced	B-Chemical
acute	B-Disease
liver	I-Disease
failure	I-Disease
increases	O
long-term	O
mortality	O
.	O

METHODS	O
:	O
We	O
followed	O
up	O
all	O
transplant-free	O
survivors	O
of	O
paracetamol-induced	B-Chemical
acute	B-Disease
liver	I-Disease
injury	I-Disease
,	O
hospitalized	O
in	O
a	O
Danish	O
national	O
referral	O
centre	O
during	O
1984-2004	O
.	O

We	O
compared	O
age-specific	O
mortality	O
rates	O
from	O
1	O
year	O
post-discharge	O
through	O
2008	O
between	O
those	O
in	O
whom	O
the	O
liver	B-Disease
injury	I-Disease
led	O
to	O
an	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
and	O
those	O
in	O
whom	O
it	O
did	O
not	O
.	O

RESULTS	O
:	O
We	O
included	O
641	O
patients	O
.	O

On	O
average	O
,	O
age-specific	O
mortality	O
rates	O
were	O
slightly	O
higher	O
for	O
the	O
101	O
patients	O
whose	O
paracetamol-induced	B-Chemical
liver	B-Disease
injury	I-Disease
had	O
caused	O
an	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
adjusted	O
mortality	O
rate	O
ratio	O
=	O
1.70	O
,	O
95	O
%	O
CI	O
1.02-2.85	O
)	O
,	O
but	O
the	O
association	O
was	O
age-dependent	O
,	O
and	O
no	O
survivors	O
of	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
died	O
of	O
liver	B-Disease
disease	I-Disease
,	O
whereas	O
suicides	O
were	O
frequent	O
in	O
both	O
groups	O
.	O

These	O
observations	O
speak	O
against	O
long-term	O
effects	O
of	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
.	O

More	O
likely	O
,	O
the	O
elevated	O
mortality	O
rate	O
ratio	O
resulted	O
from	O
incomplete	O
adjustment	O
for	O
the	O
greater	O
prevalence	O
of	O
substance	B-Disease
abuse	I-Disease
among	O
survivors	O
of	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
.	O

CONCLUSIONS	O
:	O
Paracetamol-induced	B-Chemical
acute	B-Disease
liver	I-Disease
failure	I-Disease
did	O
not	O
affect	O
long-term	O
mortality	O
.	O

Clinical	O
follow-up	O
may	O
be	O
justified	O
by	O
the	O
cause	O
of	O
the	O
liver	B-Disease
failure	I-Disease
,	O
but	O
not	O
by	O
the	O
liver	B-Disease
failure	I-Disease
itself	O
.	O

Serotonin	B-Chemical
6	O
receptor	O
gene	O
is	O
associated	O
with	O
methamphetamine-induced	B-Chemical
psychosis	B-Disease
in	O
a	O
Japanese	O
population	O
.	O

BACKGROUND	O
:	O
Altered	O
serotonergic	O
neural	O
transmission	O
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	O
factor	O
for	O
psychotic	B-Disease
disorders	I-Disease
such	O
as	O
schizophrenia	B-Disease
.	O

The	O
serotonin	B-Chemical
6	O
(	O
5-HT6	B-Chemical
)	O
receptor	O
is	O
therapeutically	O
targeted	O
by	O
several	O
second	O
generation	O
antipsychotics	O
,	O
such	O
as	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
,	O
and	O
d-amphetamine-induced	B-Chemical
hyperactivity	B-Disease
in	O
rats	O
is	O
corrected	O
with	O
the	O
use	O
of	O
a	O
selective	O
5-HT6	B-Chemical
receptor	O
antagonist	O
.	O

In	O
addition	O
,	O
the	O
disrupted	O
prepulse	O
inhibition	O
induced	O
by	O
d-amphetamine	B-Chemical
or	O
phencyclidine	B-Chemical
was	O
restored	O
by	O
5-HT6	B-Chemical
receptor	O
antagonist	O
in	O
an	O
animal	O
study	O
using	O
rats	O
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	B-Disease
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5-HT6	B-Chemical
receptors	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	B-Disease
disorders	I-Disease
.	O

The	O
symptoms	O
of	O
methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
-induced	O
psychosis	B-Disease
are	O
similar	O
to	O
those	O
of	O
paranoid	B-Disease
type	I-Disease
schizophrenia	I-Disease
.	O

Therefore	O
,	O
we	O
conducted	O
an	O
analysis	O
of	O
the	O
association	O
of	O
the	O
5-HT6	B-Chemical
gene	O
(	O
HTR6	O
)	O
with	O
METH-induced	B-Chemical
psychosis	B-Disease
.	O

METHOD	B-Chemical
:	O
Using	O
five	O
tagging	O
SNPs	O
(	O
rs6693503	O
,	O
rs1805054	O
,	O
rs4912138	O
,	O
rs3790757	O
and	O
rs9659997	O
)	O
,	O
we	O
conducted	O
a	O
genetic	O
association	O
analysis	O
of	O
case-control	O
samples	O
(	O
197	O
METH-induced	O
psychosis	B-Disease
patients	O
and	O
337	O
controls	O
)	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
age	O
and	O
sex	O
of	O
the	O
control	O
subjects	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
methamphetamine	B-Chemical
dependence	O
patients	O
.	O

RESULTS	O
:	O
rs6693503	O
was	O
associated	O
with	O
METH-induced	B-Chemical
psychosis	B-Disease
patients	O
in	O
the	O
allele/genotype-wise	O
analysis	O
.	O

Moreover	O
,	O
this	O
association	O
remained	O
significant	O
after	O
Bonferroni	O
correction	O
.	O

In	O
the	O
haplotype-wise	O
analysis	O
,	O
we	O
detected	O
an	O
association	O
between	O
two	O
markers	O
(	O
rs6693503	O
and	O
rs1805054	O
)	O
and	O
three	O
markers	O
(	O
rs6693503	O
,	O
rs1805054	O
and	O
rs4912138	O
)	O
in	O
HTR6	O
and	O
METH-induced	B-Chemical
psychosis	B-Disease
patients	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
HTR6	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
METH-induced	B-Chemical
psychosis	B-Disease
in	O
the	O
Japanese	O
population	O
.	O

Effect	O
of	O
increasing	O
intraperitoneal	O
infusion	O
rates	O
on	O
bupropion	B-Chemical
hydrochloride-induced	O
seizures	O
in	O
mice	O
.	O

BACKGROUND	O
:	O
It	O
is	O
not	O
known	O
if	O
there	O
is	O
a	O
relationship	O
between	O
input	O
rate	O
and	O
incidence	O
of	O
bupropion-induced	B-Chemical
seizures	B-Disease
.	O

This	O
is	O
important	O
,	O
since	O
different	O
controlled	O
release	O
formulations	O
of	O
bupropion	B-Chemical
release	O
the	O
active	O
drug	B-Drug
at	O
different	O
rates	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
varying	O
the	O
intraperitoneal	O
infusion	O
rates	O
of	O
bupropion	B-Chemical
HCl	I-Chemical
120	O
mg/kg	O
,	O
a	O
known	O
convulsive	B-Disease
dose	O
50	O
(	O
CD50	O
)	O
,	O
on	O
the	O
incidence	O
and	O
severity	O
of	O
bupropion-induced	B-Chemical
convulsions	B-Disease
in	O
the	O
Swiss	O
albino	O
mice	O
.	O

A	O
total	O
of	O
69	O
mice	O
,	O
approximately	O
7	O
weeks	O
of	O
age	O
,	O
and	O
weighing	O
21.0	O
to	O
29.1	O
g	O
were	O
randomly	O
assigned	O
to	O
bupropion	B-Chemical
HCl	I-Chemical
120	O
mg/kg	O
treatment	O
by	O
intraperitoneal	O
(	O
IP	O
)	O
administration	O
in	O
7	O
groups	O
(	O
9	O
to	O
10	O
animals	O
per	O
group	O
)	O
.	O

Bupropion	B-Chemical
HCl	I-Chemical
was	O
infused	O
through	O
a	O
surgically	O
implanted	O
IP	O
dosing	O
catheter	O
with	O
infusions	O
in	O
each	O
group	O
of	O
0	O
min	O
,	O
15	O
min	O
,	O
30	O
min	O
,	O
60	O
min	O
,	O
90	O
min	O
,	O
120	O
min	O
,	O
and	O
240	O
min	O
.	O

The	O
number	O
,	O
time	O
of	O
onset	O
,	O
duration	O
and	O
the	O
intensity	O
of	O
the	O
convulsions	B-Disease
or	O
absence	O
of	O
convulsions	B-Disease
were	O
recorded	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
IP	O
administration	O
of	O
bupropion	B-Chemical
HCl	I-Chemical
120	O
mg/kg	O
by	O
bolus	O
injection	O
induced	O
convulsions	B-Disease
in	O
6	O
out	O
of	O
10	O
mice	O
(	O
60	O
%	O
of	O
convulsing	O
mice	O
)	O
in	O
group	O
1	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
that	O
infusion	O
time	O
was	O
significant	O
(	O
p	O
=	O
0.0004	O
;	O
odds	O
ratio	O
=	O
0.974	O
)	O
and	O
increasing	O
the	O
IP	O
infusion	O
time	O
of	O
bupropion	B-Chemical
HCl	I-Chemical
120	O
mg/kg	O
was	O
associated	O
with	O
a	O
91	O
%	O
reduced	O
odds	O
of	O
convulsions	B-Disease
at	O
infusion	O
times	O
of	O
15	O
to	O
90	O
min	O
compared	O
to	O
bolus	O
injection	O
.	O

Further	O
increase	O
in	O
infusion	O
time	O
resulted	O
in	O
further	O
reduction	O
in	O
the	O
odds	O
of	O
convulsions	B-Disease
to	O
99.8	O
%	O
reduction	O
at	O
240	O
min	O
.	O

CONCLUSION	O
:	O
In	O
conclusion	O
,	O
the	O
demonstration	O
of	O
an	O
inverse	O
relationship	O
between	O
infusion	O
time	O
of	O
a	O
fixed	O
and	O
convulsive	B-Disease
dose	O
of	O
bupropion	B-Chemical
and	O
the	O
risk	O
of	O
convulsions	B-Disease
in	O
a	O
prospective	O
study	O
is	O
novel	O
.	O

Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin-induced	B-Chemical
epileptiform	B-Disease
activity	I-Disease
in	O
anesthetized	O
rats	O
.	O

Penicillin	B-Chemical
model	O
is	O
a	O
widely	O
used	O
experimental	O
model	O
for	O
epilepsy	B-Disease
research	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin-induced	B-Chemical
epileptiform	B-Disease
activity	I-Disease
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	O
.	O

Male	O
Wistar	O
rats	O
were	O
anesthetized	O
with	O
i.p	O
.	O

urethane	B-Chemical
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O

After	O
a	O
short	O
period	O
of	O
basal	O
activity	O
recording	O
,	O
epileptic	B-Disease
focus	O
was	O
induced	O
by	O
injecting	O
400IU/2	O
microl	O
penicillin-G	B-Chemical
potassium	I-Chemical
into	O
the	O
left	O
lateral	O
ventricle	O
while	O
the	O
cortical	O
activity	O
was	O
continuously	O
recorded	O
.	O

Basal	O
activity	O
,	O
latent	O
period	O
and	O
the	O
penicillin-induced	B-Chemical
epileptiform	B-Disease
activity	I-Disease
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O

Spectral	O
analyses	O
were	O
conducted	O
by	O
dividing	O
the	O
whole	O
spectrum	O
into	O
different	O
frequency	O
bands	O
including	O
delta	O
,	O
theta	O
(	O
slow	O
and	O
fast	O
)	O
,	O
alpha-sigma	O
,	O
beta	O
(	O
1	O
and	O
2	O
)	O
and	O
gamma	O
(	O
1	O
and	O
2	O
)	O
bands	O
.	O

Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta-2	O
and	O
gamma-2	O
bands	O
during	O
the	O
epileptiform	B-Disease
activity	I-Disease
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	I-Disease
,	O
latent	O
period	O
and	O
epileptiform	B-Disease
activity	O
)	O
.	O

Our	O
results	O
may	O
help	O
to	O
analyze	O
novel	O
data	O
obtained	O
using	O
similar	O
experimental	O
models	O
and	O
the	O
simple	O
analysis	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
similar	O
studies	O
to	O
investigate	O
the	O
basic	O
neuronal	O
mechanism	O
of	O
this	O
or	O
other	O
types	O
of	O
experimental	O
epilepsies	B-Disease
.	O

High	O
dose	O
dexmedetomidine	B-Chemical
as	O
the	O
sole	O
sedative	O
for	O
pediatric	O
MRI	O
.	O

OBJECTIVE	O
:	O
This	O
large-scale	O
retrospective	O
review	O
evaluates	O
the	O
sedation	O
profile	O
of	O
dexmedetomidine	B-Chemical
.	O

AIM	O
:	O
To	O
determine	O
the	O
hemodynamic	O
responses	O
,	O
efficacy	O
and	O
adverse	O
events	O
associated	O
with	O
the	O
use	O
of	O
high	O
dose	O
dexmedetomidine	B-Chemical
as	O
the	O
sole	O
sedative	O
for	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
studies	O
.	O

BACKGROUND	O
:	O
Dexmedetomidine	B-Chemical
has	O
been	O
used	O
at	O
our	O
institution	O
since	O
2005	O
to	O
provide	O
sedation	O
for	O
pediatric	O
radiological	O
imaging	O
studies	O
.	O

Over	O
time	O
,	O
an	O
effective	O
protocol	O
utilizing	O
high	O
dose	O
dexmedetomidine	B-Chemical
as	O
the	O
sole	O
sedative	O
agent	O
has	O
evolved	O
.	O

METHODS/MATERIALS	O
:	O
As	O
part	O
of	O
the	O
ongoing	O
Quality	O
Assurance	O
process	O
,	O
data	O
on	O
all	O
sedations	O
are	O
reviewed	O
monthly	O
and	O
protocols	O
modified	O
as	O
needed	O
.	O

Data	O
were	O
analyzed	O
from	O
all	O
747	O
consecutive	O
patients	O
who	O
received	O
dexmedetomidine	B-Chemical
for	O
MRI	O
sedation	O
from	O
April	O
2005	O
to	O
April	O
2007	O
.	O

RESULTS	O
:	O
Since	O
2005	O
,	O
the	O
10-min	O
loading	O
dose	O
of	O
our	O
dexmedetomidine	B-Chemical
protocol	O
increased	O
from	O
2	O
to	O
3	O
microg.kg	O
(	O
-1	O
)	O
,	O
and	O
the	O
infusion	O
rate	O
increased	O
from	O
1	O
to	O
1.5	O
to	O
2	O
microg.kg	O
(	O
-1	O
)	O
.h	O
(	O
-1	O
)	O
.	O

The	O
current	O
sedation	O
protocol	O
progressively	O
increased	O
the	O
rate	O
of	O
successful	O
sedation	O
(	O
able	O
to	O
complete	O
the	O
imaging	O
study	O
)	O
when	O
using	O
dexmedetomidine	B-Chemical
alone	O
from	O
91.8	O
%	O
to	O
97.6	O
%	O
(	O
P	O
=	O
0.009	O
)	O
,	O
reducing	O
the	O
requirement	O
for	O
adjuvant	O
pentobarbital	B-Chemical
in	O
the	O
event	O
of	O
sedation	O
failure	O
with	O
dexmedetomidine	B-Chemical
alone	O
and	O
decreased	O
the	O
mean	O
recovery	O
time	O
by	O
10	O
min	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Although	O
dexmedetomidine	B-Chemical
sedation	O
was	O
associated	O
with	O
a	O
16	O
%	O
incidence	O
of	O
bradycardia	B-Disease
,	O
all	O
concomitant	O
mean	O
arterial	O
blood	O
pressures	O
were	O
within	O
20	O
%	O
of	O
age-adjusted	O
normal	O
range	O
and	O
oxygen	B-Chemical
saturations	O
were	O
95	O
%	O
or	O
higher	O
.	O

CONCLUSION	O
:	O
Dexmedetomidine	B-Chemical
in	O
high	O
doses	O
provides	O
adequate	O
sedation	O
for	O
pediatric	O
MRI	O
studies	O
.	O

While	O
use	O
of	O
high	O
dose	O
dexmedetomidine	B-Chemical
is	O
associated	O
with	O
decreases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
outside	O
the	O
established	O
'awake	O
'	O
norms	O
,	O
this	O
deviation	O
is	O
generally	O
within	O
20	O
%	O
of	O
norms	O
,	O
and	O
is	O
not	O
associated	O
with	O
adverse	O
sequelae	O
.	O

Dexmedetomidine	B-Chemical
is	O
useful	O
as	O
the	O
sole	O
sedative	O
for	O
pediatric	O
MRI	O
.	O

Methamphetamine	B-Chemical
causes	O
alterations	O
in	O
the	O
MAP	O
kinase-related	O
pathways	O
in	O
the	O
brains	O
of	O
mice	O
that	O
display	O
increased	O
aggressiveness	B-Disease
.	O

Aggressive	B-Disease
behaviors	I-Disease
have	O
been	O
reported	O
in	O
patients	O
who	O
suffer	O
from	O
some	O
psychiatric	B-Disease
disorders	I-Disease
,	O
and	O
are	O
common	O
in	O
methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
abusers	O
.	O

Herein	O
,	O
we	O
report	O
that	O
multiple	O
(	O
but	O
not	O
single	O
)	O
injections	O
of	O
METH	B-Chemical
significantly	O
increased	O
aggressiveness	B-Disease
in	O
male	O
CD-1	O
mice	O
.	O

This	O
increase	O
in	O
aggressiveness	B-Disease
was	O
not	O
secondary	O
to	O
METH-induced	B-Chemical
hyperactivity	B-Disease
.	O

Analysis	O
of	O
protein	O
expression	O
using	O
antibody	O
microarrays	O
and	O
Western	O
blotting	O
revealed	O
differential	O
changes	O
in	O
MAP	O
kinase-related	O
pathways	O
after	O
multiple	O
and	O
single	O
METH	B-Chemical
injections	O
.	O

There	O
were	O
statistically	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
decreases	O
in	O
MEK1	O
,	O
Erk2p	O
,	O
GSK3alpha	O
,	O
14-3-3e	O
,	O
and	O
MEK7	O
in	O
the	O
striata	O
of	O
mice	O
after	O
multiple	O
injections	O
of	O
METH	B-Chemical
.	O

MEK1	O
was	O
significantly	O
decreased	O
also	O
after	O
a	O
single	O
injection	O
of	O
METH	B-Chemical
,	O
but	O
to	O
a	O
much	O
lesser	O
degree	O
than	O
after	O
multiple	O
injections	O
of	O
METH	B-Chemical
.	O

In	O
the	O
frontal	O
cortex	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
GSK3alpha	O
after	O
multiple	O
(	O
but	O
not	O
single	O
)	O
injections	O
of	O
METH	B-Chemical
.	O

These	O
findings	O
suggest	O
that	O
alterations	O
in	O
MAP	O
kinase-related	O
pathways	O
in	O
the	O
prefronto-striatal	O
circuitries	O
might	O
be	O
involved	O
in	O
the	O
manifestation	O
of	O
aggressive	B-Disease
behaviors	I-Disease
in	O
mice	O
.	O

Lamotrigine	B-Chemical
associated	O
with	O
exacerbation	O
or	O
de	O
novo	O
myoclonus	B-Disease
in	O
idiopathic	B-Disease
generalized	I-Disease
epilepsies	I-Disease
.	O

Five	O
patients	O
with	O
idiopathic	B-Disease
generalized	I-Disease
epilepsies	I-Disease
(	O
IGE	B-Disease
)	O
treated	O
with	O
lamotrigine	B-Chemical
(	O
LTG	B-Chemical
)	O
experienced	O
exacerbation	O
or	O
de	O
novo	O
appearance	O
of	O
myoclonic	B-Disease
jerks	I-Disease
(	O
MJ	B-Disease
)	O
.	O

In	O
three	O
patients	O
,	O
LTG	B-Chemical
exacerbated	O
MJ	B-Disease
in	O
a	O
dose-dependent	O
manner	O
with	O
early	O
aggravation	O
during	O
titration	O
.	O

MJ	B-Disease
disappeared	O
when	O
LTG	B-Chemical
dose	O
was	O
decreased	O
by	O
25	O
to	O
50	O
%	O
.	O

In	O
two	O
patients	O
,	O
LTG	B-Chemical
exacerbated	O
MJ	B-Disease
in	O
a	O
delayed	O
but	O
more	O
severe	O
manner	O
,	O
with	O
myoclonic	B-Disease
status	I-Disease
that	O
only	O
ceased	O
after	O
LTG	B-Chemical
withdrawal	O
.	O

rTMS	O
of	O
supplementary	O
motor	O
area	O
modulates	O
therapy-induced	O
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
disease	I-Disease
.	O

The	O
neural	O
mechanisms	O
and	O
circuitry	O
involved	O
in	O
levodopa-induced	B-Chemical
dyskinesia	B-Disease
are	O
unclear	O
.	O

Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
over	O
the	O
supplementary	O
motor	O
area	O
(	O
SMA	O
)	O
in	O
a	O
group	O
of	O
patients	O
with	O
advanced	O
Parkinson	B-Disease
disease	I-Disease
,	O
the	O
authors	O
investigated	O
whether	O
modulation	O
of	O
SMA	O
excitability	O
may	O
result	O
in	O
a	O
modification	O
of	O
a	O
dyskinetic	B-Disease
state	O
induced	O
by	O
continuous	O
apomorphine	B-Chemical
infusion	O
.	O

rTMS	O
at	O
1	O
Hz	O
was	O
observed	O
to	O
markedly	O
reduce	O
drug-induced	B-Disease
dyskinesias	I-Disease
,	O
whereas	O
5-Hz	O
rTMS	O
induced	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
.	O

Assessment	O
of	O
the	O
onset	O
and	O
persistence	O
of	O
amnesia	B-Disease
during	O
procedural	O
sedation	O
with	O
propofol	B-Chemical
.	O

OBJECTIVES	O
:	O
To	O
assess	O
patients	O
'	O
ability	O
to	O
repeat	O
and	O
recall	O
words	O
presented	O
to	O
them	O
while	O
undergoing	O
procedural	O
sedation	O
with	O
propofol	B-Chemical
,	O
and	O
correlate	O
their	O
recall	O
with	O
their	O
level	O
of	O
awareness	O
as	O
measured	O
by	O
bispectral	O
index	O
(	O
BIS	O
)	O
monitoring	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
prospective	O
,	O
single-intervention	O
study	O
of	O
consenting	O
adult	O
patients	O
undergoing	O
procedural	O
sedation	O
with	O
propofol	B-Chemical
between	O
December	O
28	O
,	O
2002	O
,	O
and	O
October	O
31	O
,	O
2003	O
.	O

BIS	O
monitoring	O
was	O
initiated	O
starting	O
3	O
minutes	O
before	O
the	O
procedure	O
and	O
continuing	O
until	O
the	O
patient	O
had	O
regained	O
baseline	O
mental	O
status	O
.	O

At	O
1-minute	O
intervals	O
during	O
the	O
procedural	O
sedation	O
,	O
until	O
the	O
patient	O
regained	O
baseline	O
mental	O
status	O
at	O
the	O
end	O
of	O
the	O
procedure	O
,	O
a	O
word	O
from	O
a	O
standardized	O
list	O
was	O
read	O
aloud	O
,	O
and	O
the	O
patient	O
was	O
asked	O
to	I-Disease
immediately	O
repeat	I-Disease
the	O
word	O
to	I-Disease
the	O
investigator	O
.	O

The	O
BIS	O
score	O
at	O
the	O
time	O
the	O
word	O
was	O
read	O
and	O
the	O
patient	O
's	O
ability	O
to	I-Disease
repeat	O
the	O
word	O
were	O
recorded	O
.	O

After	O
the	O
procedure	O
,	O
the	O
patient	O
was	O
asked	O
to	O
state	O
all	O
of	O
the	O
words	O
from	O
the	O
list	O
that	O
he	O
or	O
she	O
could	O
recall	O
,	O
and	O
to	O
identify	O
the	O
last	O
word	O
recalled	O
from	O
prior	O
to	O
the	O
start	O
of	O
the	O
procedure	O
and	O
the	O
first	O
word	O
recalled	O
from	O
after	O
the	O
procedure	O
was	O
completed	O
.	O

RESULTS	O
:	O
Seventy-five	O
consenting	O
patients	O
were	O
enrolled	O
;	O
one	O
patient	O
was	O
excluded	O
from	O
data	O
analysis	O
for	O
a	O
protocol	O
violation	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
noted	O
during	O
the	O
procedural	O
sedations	O
.	O

The	O
mean	O
(	O
+/-standard	O
deviation	O
)	O
time	O
of	O
data	O
collection	O
was	O
16.4	O
minutes	O
(	O
+/-7.1	O
;	O
range	O
5	O
to	O
34	O
minutes	O
)	O
.	O

The	O
mean	O
initial	O
(	O
preprocedure	O
)	O
BIS	O
score	O
was	O
97.1	O
(	O
+/-2.3	O
;	O
range	O
92	O
to	O
99	O
)	O
.	O

The	O
mean	O
lowest	O
BIS	O
score	O
occurring	O
during	O
these	O
procedural	O
sedations	O
was	O
66.9	O
(	O
+/-14.4	O
;	O
range	O
33	O
to	O
91	O
)	O
.	O

The	O
mean	O
lowest	O
BIS	O
score	O
corresponding	O
to	O
the	O
ability	O
of	O
the	O
patient	O
to	O
immediately	O
repeat	O
words	O
read	O
from	O
the	O
list	O
was	O
77.1	O
(	O
95	O
%	O
CI	O
=	O
74.3	O
to	O
80.0	O
)	O
.	O

The	O
mean	O
highest	O
BIS	O
score	O
corresponding	O
to	O
the	O
inability	O
to	O
repeat	O
words	O
was	O
81.5	O
(	O
95	O
%	O
CI	O
=	O
78.1	O
to	O
84.8	O
)	O
.	O

The	O
mean	O
BIS	O
score	O
corresponding	O
to	O
the	O
last	O
word	O
recalled	O
from	O
prior	O
to	O
the	O
initiation	O
of	O
the	O
sedation	O
was	O
96.7	O
(	O
+/-2.4	O
;	O
range	O
84	O
to	O
98	O
)	O
.	O

The	O
mean	O
BIS	O
score	O
corresponding	O
to	O
the	O
first	O
word	O
recalled	O
after	O
the	O
procedure	O
was	O
completed	O
was	O
91.2	O
(	O
95	O
%	O
CI	O
=	O
88.1	O
to	O
94.3	O
)	O
.	O

All	O
patients	O
recalled	O
at	O
least	O
one	O
word	O
that	O
had	O
been	O
read	O
to	O
them	O
during	O
the	O
protocol	O
.	O

The	O
mean	O
lowest	O
BIS	O
score	O
for	O
any	O
recalled	O
word	O
was	O
91.5	O
(	O
+/-11.1	O
;	O
range	O
79	O
to	O
98	O
)	O
,	O
and	O
no	O
words	O
were	O
recalled	O
when	O
the	O
corresponding	O
BIS	O
score	O
was	O
less	O
than	O
90	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
range	O
of	O
BIS	O
scores	O
during	O
which	O
sedated	O
patients	O
are	O
able	O
to	O
repeat	O
words	O
read	O
to	O
them	O
but	O
are	O
not	O
able	O
to	O
subsequently	O
recall	O
these	O
words	O
.	O

Furthermore	O
,	O
patients	O
had	O
no	O
recall	O
of	O
words	O
repeated	O
prior	O
to	O
procedural	O
sedation	O
in	O
BIS	O
ranges	O
associated	O
with	O
recall	O
after	O
procedural	O
sedation	O
,	O
suggestive	O
of	O
retrograde	B-Disease
amnesia	I-Disease
.	O

Assessment	O
of	O
perinatal	O
hepatitis	B-Disease
B	I-Disease
and	O
rubella	B-Disease
prevention	O
in	O
New	O
Hampshire	O
delivery	O
hospitals	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
current	O
performance	O
on	O
recommended	O
perinatal	O
hepatitis	B-Disease
B	I-Disease
and	O
rubella	B-Disease
prevention	O
practices	O
in	O
New	O
Hampshire	O
.	O

METHODS	O
:	O
Data	O
were	O
extracted	O
from	O
2021	O
paired	O
mother-infant	O
records	O
for	O
the	O
year	O
2000	O
birth	O
cohort	O
in	O
New	O
Hampshire	O
's	O
25	O
delivery	O
hospitals	O
.	O

Assessment	O
was	O
done	O
on	O
the	O
following	O
:	O
prenatal	O
screening	O
for	O
hepatitis	B-Disease
B	I-Disease
and	O
rubella	B-Disease
,	O
administration	O
of	O
the	O
hepatitis	B-Disease
B	I-Disease
vaccine	O
birth	O
dose	O
to	O
all	O
infants	O
,	O
administration	O
of	O
hepatitis	B-Disease
B	I-Disease
immune	O
globulin	O
to	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	B-Chemical
B	I-Chemical
surface	I-Chemical
antigen-positive	O
mothers	O
,	O
rubella	O
immunity	O
,	O
and	O
administration	O
of	O
in-hospital	O
postpartum	O
rubella	O
vaccine	O
to	O
rubella	O
nonimmune	O
women	O
.	O

RESULTS	O
:	O
Prenatal	O
screening	O
rates	O
for	O
hepatitis	B-Chemical
B	O
(	O
98.8	O
%	O
)	O
and	O
rubella	B-Disease
(	O
99.4	O
%	O
)	O
were	O
high	O
.	O

Hepatitis	O
B	O
vaccine	O
birth	O
dose	O
was	O
administered	O
to	O
76.2	O
%	O
of	O
all	O
infants	O
.	O

All	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	O
B	O
surface	O
antigen-positive	O
mothers	O
also	O
received	O
hepatitis	O
B	O
immune	O
globulin	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
the	O
month	O
of	O
delivery	O
and	O
infant	O
birth	O
weight	O
were	O
independent	O
predictors	O
of	O
hepatitis	O
B	O
vaccination	O
.	O

The	O
proportion	O
of	O
infants	O
who	O
were	O
vaccinated	O
in	O
January	O
and	O
February	O
2000	O
(	O
48.5	O
%	O
and	O
67.5	O
%	O
,	O
respectively	O
)	O
was	O
less	O
than	O
any	O
other	O
months	O
,	O
whereas	O
the	O
proportion	O
who	O
were	O
vaccinated	O
in	O
December	O
2000	O
(	O
88.2	O
%	O
)	O
was	O
the	O
highest	O
.	O

Women	O
who	O
were	O
born	O
between	O
1971	O
and	O
1975	O
had	O
the	O
highest	O
rate	O
of	O
rubella	B-Disease
nonimmunity	O
(	O
9.5	O
%	O
)	O
.	O

In-hospital	O
postpartum	O
rubella	B-Disease
vaccine	O
administration	O
was	O
documented	O
for	O
75.6	O
%	O
of	O
nonimmune	O
women	O
.	O

CONCLUSION	O
:	O
This	O
study	O
documents	O
good	O
compliance	O
in	O
New	O
Hampshire	O
's	O
birthing	O
hospitals	O
with	O
national	O
guidelines	O
for	O
perinatal	O
hepatitis	B-Disease
B	I-Disease
and	O
rubella	B-Disease
prevention	O
and	O
highlights	O
potential	O
areas	O
for	O
improvement	O
.	O

Expression	O
of	O
p300	O
protects	O
cardiac	O
myocytes	O
from	O
apoptosis	O
in	O
vivo	O
.	O

Doxorubicin	B-Chemical
is	O
an	O
anti-tumor	B-Disease
agent	O
that	O
represses	O
cardiac-specific	O
gene	O
expression	O
and	O
induces	O
myocardial	O
cell	O
apoptosis	O
.	O

Doxorubicin	B-Chemical
depletes	O
cardiac	O
p300	O
,	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
required	O
for	O
the	O
maintenance	O
of	O
the	O
differentiated	O
phenotype	O
of	O
cardiac	O
myocytes	O
.	O

However	O
,	O
the	O
role	O
of	O
p300	O
in	O
protection	O
against	O
doxorubicin-induced	B-Chemical
apoptosis	O
is	O
unknown	O
.	O

Transgenic	O
mice	O
overexpressing	O
p300	O
in	O
the	O
heart	O
and	O
wild-type	O
mice	O
were	O
subjected	O
to	O
doxorubicin	B-Chemical
treatment	O
.	O

Compared	O
with	O
wild-type	O
mice	O
,	O
transgenic	O
mice	O
exhibited	O
higher	O
survival	O
rate	O
as	O
well	O
as	O
more	O
preserved	O
left	O
ventricular	O
function	O
and	O
cardiac	O
expression	O
of	O
alpha-sarcomeric	O
actin	O
.	O

Doxorubicin	B-Chemical
induced	O
myocardial	O
cell	O
apoptosis	O
in	O
wild-type	O
mice	O
but	O
not	O
in	O
transgenic	O
mice	O
.	O

Expression	O
of	O
p300	O
increased	O
the	O
cardiac	O
level	O
of	O
bcl-2	O
and	O
mdm-2	O
,	O
but	O
not	O
that	O
of	O
p53	O
or	O
other	O
members	O
of	O
the	O
bcl-2	O
family	O
.	O

These	O
findings	O
demonstrate	O
that	O
overexpression	O
of	O
p300	O
protects	O
cardiac	O
myocytes	O
from	O
doxorubicin-induced	B-Chemical
apoptosis	O
and	O
reduces	O
the	O
extent	O
of	O
acute	O
heart	B-Disease
failure	I-Disease
in	O
adult	O
mice	O
in	O
vivo	O
.	O

Mitochondrial	O
DNA	O
and	O
its	O
respiratory	O
chain	O
products	O
are	O
defective	O
in	O
doxorubicin	B-Chemical
nephrosis	B-Disease
.	O

BACKGROUND	O
:	O
Doxorubicin	B-Chemical
induces	O
a	O
self-perpetuating	O
nephropathy	B-Disease
characterized	O
by	O
early	O
glomerular	B-Disease
and	I-Disease
late-onset	I-Disease
tubular	I-Disease
lesions	I-Disease
in	O
rats	O
.	O

We	O
investigated	O
the	O
potential	O
role	O
of	O
mitochondrial	B-Disease
injury	I-Disease
in	O
the	O
onset	O
of	O
these	O
lesions	O
.	O

METHODS	O
:	O
Rats	O
were	O
treated	O
with	O
intravenous	O
doxorubicin	B-Chemical
(	O
1	O
mg	O
kg	O
(	O
-1	O
)	O
week	O
(	O
-1	O
)	O
)	O
for	O
7	O
weeks	O
and	I-Disease
were	O
sacrificed	O
either	O
1	O
week	O
(	O
'short-term	O
'	O
)	O
or	O
30	O
weeks	O
(	O
'long-term	O
'	O
)	O
following	O
the	O
last	O
dose	O
.	O

Additional	O
rats	O
received	O
a	O
single	O
dose	O
either	O
6	O
days	O
or	O
2	O
h	O
prior	O
to	O
euthanasia	O
.	O

All	O
rats	O
were	O
killed	O
at	O
48	O
weeks	O
of	O
age	O
.	O

Glomerular	B-Disease
and	I-Disease
tubular	I-Disease
injury	O
was	O
monitored	O
and	O
correlated	O
to	O
the	O
activity	O
or	O
expression	O
of	O
respiratory	O
chain	O
components	O
.	O

Finally	O
,	O
we	O
quantified	O
both	O
nuclear	O
and	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
as	O
well	O
as	O
superoxide	B-Chemical
production	O
and	I-Disease
the	O
4834	O
base	O
pair	O
'common	O
'	O
mtDNA	O
deletion	O
.	O

RESULTS	O
:	O
The	O
'long-term	O
'	O
group	O
had	O
significant	O
glomerular	B-Disease
and	I-Disease
tubular	I-Disease
lesions	O
,	O
depressed	O
activities	O
of	O
mtDNA-encoded	O
NADH	O
dehydrogenase	O
and	O
cytochrome-c	O
oxidase	O
(	O
COX	O
)	O
and	O
increased	O
citrate	B-Chemical
synthase	O
activity	O
.	O

In	O
addition	O
,	O
expression	O
of	O
the	O
mtDNA-encoded	O
COX	O
subunit	O
I	O
was	O
reduced	O
and	O
mtDNA	O
levels	O
were	O
decreased	O
.	O

In	O
'short-term	O
'	O
rats	O
,	O
there	O
were	O
fewer	O
tubular	B-Disease
lesions	I-Disease
,	O
but	O
similar	O
numbers	O
of	O
glomerular	B-Disease
lesions	I-Disease
activity	O
.	O

Among	O
all	O
animals	O
,	O
glomerular	B-Disease
and	I-Disease
tubular	I-Disease
injury	I-Disease
were	O
inversely	O
correlated	O
with	O
mtDNA	O
levels	O
,	O
mtDNA-encoded	O
respiratory	O
chain	O
activities	O
and	O
with	O
the	O
expression	O
of	O
the	O
mtDNA-encoded	O
respiratory	O
chain	O
subunit	O
COX-I	O
.	O

Injury	O
was	O
positively	O
correlated	O
with	O
superoxide	B-Chemical
production	O
and	O
the	O
activities	O
of	O
nucleus-encoded	O
mitochondrial	O
or	O
cytoplasmic	O
enzymes	O
.	O

Kidneys	O
from	O
the	O
'long-term	O
'	O
group	O
showed	O
more	O
mtDNA	O
deletions	O
than	O
in	O
'short-term	O
'	O
animals	O
and	O
these	O
were	O
not	O
observed	O
in	O
the	O
other	O
groups	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
an	O
important	O
role	O
for	O
quantitative	O
and	O
qualitative	O
mtDNA	O
alterations	O
through	O
the	O
reduction	O
of	O
mtDNA-encoded	O
respiratory	O
chain	O
function	O
and	O
induction	O
of	O
superoxide	B-Chemical
in	O
doxorubicin-induced	B-Chemical
renal	B-Disease
lesions	I-Disease
.	O

Amphotericin	B-Chemical
B-induced	O
seizures	O
in	O
a	O
patient	O
with	O
AIDS	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
multiple	O
episodes	O
of	O
seizure	B-Disease
activity	O
in	O
an	O
AIDS	B-Disease
patent	O
following	O
amphotericin	B-Chemical
B	I-Chemical
infusion	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
46-year-old	O
African-American	O
man	O
experienced	O
recurrent	O
grand	B-Disease
mal	I-Disease
seizures	I-Disease
during	O
intravenous	O
infusion	O
of	O
amphotericin	B-Chemical
B	I-Chemical
,	O
then	O
petit	O
mal	O
seizures	B-Disease
as	O
the	O
infusion	O
was	O
stopped	O
and	O
the	O
drug	B-Drug
concentrations	O
decreased	O
with	O
time	O
.	O

The	O
patients	O
concurrent	O
medications	O
included	O
didanosine	B-Chemical
,	O
hydroxyzine	B-Chemical
,	O
promethazine	B-Chemical
,	O
hydrocortisone	B-Chemical
,	O
and	O
prochlorperazine	B-Chemical
.	O

Despite	O
administration	O
of	O
phenytoin	B-Chemical
and	O
lorazepam	B-Chemical
,	O
the	O
seizures	B-Disease
persisted	O
and	O
occurred	O
only	O
during	O
amphotercin	B-Chemical
B	I-Chemical
administration	O
.	O

DISCUSSION	O
:	O
AIDS	B-Disease
and	O
cryptococcal	B-Disease
meningitis	I-Disease
,	O
both	O
of	O
which	O
the	O
patient	O
had	O
,	O
can	O
potentially	O
cause	O
seizures	B-Disease
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
alcohol	B-Disease
abuse	I-Disease
;	O
alcohol	B-Chemical
intake	O
as	O
well	O
as	O
withdrawal	O
can	O
also	O
cause	O
seizures	B-Disease
.	O

Didanosine	B-Chemical
also	O
has	O
a	O
potential	O
for	O
inducing	O
seizures	B-Disease
.	O

However	O
,	O
these	O
other	O
potential	O
causes	O
of	O
seizure	B-Disease
were	O
ruled	O
out	O
.	O

The	O
time	O
course	O
of	O
events	O
suggested	O
that	O
amphotericin	B-Chemical
B	I-Chemical
was	O
the	O
cause	O
of	O
the	O
seizures	B-Disease
in	O
this	O
AIDS	B-Disease
patient	O
.	O

CONCLUSIONS	O
:	O
Amphotericin	B-Chemical
B	I-Chemical
seems	O
to	O
be	O
the	O
probable	O
cause	O
of	O
the	O
seizures	B-Disease
.	O

To	O
date	O
,	O
only	O
three	O
cases	O
of	O
seizures	B-Disease
associated	O
with	O
amphotericin	B-Chemical
B	I-Chemical
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
but	O
healthcare	O
providers	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
this	O
rare	O
adverse	O
effect	O
.	O

Therapeutic	O
drug	B-Drug
monitoring	O
of	O
tobramycin	B-Chemical
:	O
once-daily	O
versus	O
twice-daily	O
dosage	O
schedules	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
dosage	O
regimen	O
(	O
once-daily	O
vs.	O
twice-daily	O
)	O
of	O
tobramicyn	B-Chemical
on	O
steady-state	O
serum	O
concentrations	O
and	O
toxicity	B-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Patients	O
undergoing	O
treatment	O
with	O
i.v	O
.	O

tobramycin	B-Chemical
(	O
4	O
mg/kg/day	O
)	O
were	O
randomised	O
to	O
two	O
groups	O
.	O

Group	O
OD	O
(	O
n	O
=	O
22	O
)	O
received	O
a	O
once-daily	O
dose	O
of	O
tobramycin	B-Chemical
and	O
group	O
TD	O
(	O
n	O
=	O
21	O
)	O
received	O
the	O
same	O
dose	O
divided	O
into	O
two	O
doses	O
daily	O
.	O

Tobramycin	B-Chemical
serum	O
concentrations	O
(	O
peak	O
and	O
trough	O
)	O
were	O
measured	O
by	O
enzyme	O
multiplied	O
immunoassay	O
.	O

The	O
renal	O
and	O
auditory	O
functions	O
of	O
the	O
patients	O
were	O
monitored	O
before	O
,	O
during	O
and	O
immediately	O
after	O
treatment	O
.	O

RESULTS	O
:	O
The	O
two	O
groups	O
were	O
comparable	O
with	O
respect	O
to	O
sex	O
,	O
age	O
,	O
body	O
weight	O
and	O
renal	O
function	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
mean	O
daily	O
dose	O
,	O
duration	O
of	O
treatment	O
,	O
or	O
cumulative	O
dose	O
.	O

Trough	O
concentrations	O
were	O
<	O
2	O
g/ml	O
in	O
the	O
two	O
groups	O
(	O
100	O
%	O
)	O
.	O

Peak	O
concentrations	O
were	O
>	O
6	O
microg/ml	O
in	O
100	O
%	O
of	O
the	O
OD	O
group	O
and	O
in	O
67	O
%	O
of	O
the	O
TD	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Mean	O
peak	O
concentrations	O
were	O
markedly	O
different	O
:	O
11.00+/-2.89	O
microg/ml	O
in	O
OD	O
vs.	O
6.53+/-1.45	O
microg/ml	O
in	O
TD	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
pharmacokinetics	O
parameters	O
were	O
:	O
Ke	O
,	O
(	O
0.15+/-0.03/h	O
in	O
OD	O
vs.	O
0.24+/-0.06/h	O
in	O
TD	O
)	O
,	O
t1/2	B-Drug
,	O
(	O
4.95+/-1.41	O
h	O
in	O
OD	O
vs.	O
3.07+/-0.71	O
h	O
in	O
TD	O
)	O
,	O
Vd	O
(	O
0.35+/-0.11	O
l/kg	O
in	O
OD	O
vs.	O
0.33+/-0.09	O
l/kg	O
in	O
TD	O
)	O
,	O
Cl	O
(	O
0.86+/-0.29	O
ml/min/kg	O
in	O
OD	O
vs.	O
1.28+/-0.33	O
ml/min/kg	O
in	O
TD	O
)	O
.	O

Increased	O
serum	O
creatinine	B-Chemical
was	O
observed	O
in	O
73	O
%	O
of	O
patients	O
in	O
OD	O
versus	O
57	O
%	O
of	O
patients	O
in	O
TD	O
,	O
without	O
evidence	O
of	O
nephrotoxicity	B-Disease
.	O

In	O
TD	O
group	O
,	O
three	O
patients	O
developed	O
decreased	B-Disease
auditory	I-Disease
function	I-Disease
,	O
of	O
which	O
one	O
presented	O
with	O
an	O
auditory	B-Disease
loss	I-Disease
of	O
-30	O
dB	O
,	O
whereas	O
in	O
the	O
OD	O
group	O
only	O
one	O
patient	O
presented	O
decreased	B-Disease
auditory	I-Disease
function	I-Disease
.	O

CONCLUSION	O
:	O
This	O
small	O
study	O
suggests	O
that	O
a	O
once-daily	O
dosing	O
regimen	O
of	O
tobramycin	B-Chemical
is	O
at	O
least	O
as	O
effective	O
as	O
and	O
is	O
no	O
more	O
and	O
possibly	O
less	O
toxic	O
than	O
the	O
twice-daily	O
regimen	O
.	O

Using	O
a	O
single-dose	O
therapy	O
,	O
peak	O
concentration	O
determination	O
is	O
not	O
necessary	O
,	O
only	O
trough	O
samples	O
should	O
be	O
monitored	O
to	O
ensure	O
levels	O
below	O
2	O
microg/ml	O
.	O

Chronic	O
effects	O
of	O
a	O
novel	O
synthetic	O
anthracycline	B-Chemical
derivative	O
(	O
SM-5887	B-Chemical
)	O
on	O
normal	O
heart	O
and	O
doxorubicin-induced	B-Chemical
cardiomyopathy	B-Disease
in	O
beagle	O
dogs	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
chronic	O
cardiotoxic	B-Disease
potential	O
of	O
SM-5887	B-Chemical
and	O
a	O
possible	O
deteriorating	O
effect	O
of	O
SM-5887	B-Chemical
on	O
low-grade	O
cardiotoxicity	B-Disease
pre-induced	O
by	O
doxorubicin	B-Chemical
in	O
beagle	O
dogs	O
.	O

In	O
the	O
chronic	O
treatment	O
,	O
beagle	O
dogs	O
of	O
each	O
sex	O
were	O
given	O
intravenously	O
once	O
every	O
3	O
weeks	O
,	O
either	O
a	O
sublethal	O
dose	O
of	O
doxorubicin	B-Chemical
(	O
1.5	O
mg/kg	O
)	O
or	O
SM-5887	B-Chemical
(	O
2.5	O
mg/kg	O
)	O
.	O

The	O
experiment	O
was	O
terminated	O
3	O
weeks	O
after	O
the	O
ninth	O
dosing	O
.	O

Animals	O
which	O
received	O
over	O
six	O
courses	O
of	O
doxorubicin	B-Chemical
demonstrated	O
the	O
electrocardiogram	O
(	O
ECG	O
)	O
changes	O
,	O
decrease	O
of	O
blood	O
pressure	O
and	O
high-grade	O
histopathological	O
cardiomyopathy	B-Disease
,	O
while	O
animals	O
which	O
were	O
terminally	O
sacrificed	O
after	O
the	O
SM-5887	B-Chemical
administration	O
did	O
not	O
show	O
any	O
changes	O
in	O
ECG	O
,	O
blood	O
pressure	O
and	O
histopathological	O
examinations	O
.	O

To	O
examine	O
a	O
possibly	O
deteriorating	O
cardiotoxic	B-Disease
effect	O
of	O
SM-5887	B-Chemical
,	O
low-grade	O
cardiomyopathy	B-Disease
was	O
induced	O
in	O
dogs	O
by	O
four	O
courses	O
of	O
doxorubicin	B-Chemical
(	O
1.5	O
mg/kg	O
)	O
.	O

Nine	O
weeks	O
after	O
pre-treatment	O
,	O
dogs	O
were	O
given	O
four	O
courses	O
of	O
either	O
doxorubicin	B-Chemical
(	O
1.5	O
mg/kg	O
)	O
or	O
SM-5887	B-Chemical
(	O
2.5	O
mg/kg	O
)	O
once	O
every	O
3	O
weeks	O
.	O

The	O
low-grade	O
cardiotoxic	B-Disease
changes	O
were	O
enhanced	O
by	O
the	O
additional	O
doxorubicin	B-Chemical
treatment	O
.	O

On	O
the	O
contrary	O
,	O
the	O
SM-5887	B-Chemical
treatment	O
did	O
not	O
progress	O
the	O
grade	O
of	O
cardiomyopathy	B-Disease
.	O

In	O
conclusion	O
,	O
SM-5887	B-Chemical
does	O
not	O
have	O
any	O
potential	O
of	O
chronic	O
cardiotoxicity	B-Disease
and	O
deteriorating	O
effect	O
on	O
doxorubicin-induced	B-Chemical
cardiotoxicity	B-Disease
in	O
dogs	O
.	O

Posteroventral	O
medial	O
pallidotomy	O
in	O
advanced	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

BACKGROUND	O
:	O
Posteroventral	O
medial	O
pallidotomy	O
sometimes	O
produces	O
striking	O
improvement	O
in	O
patients	O
with	O
advanced	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
,	O
but	O
the	O
studies	O
to	O
date	O
have	O
involved	O
small	O
numbers	O
of	O
patients	O
and	O
short-term	O
follow-up	O
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
underwent	O
serial	O
,	O
detailed	O
assessments	O
both	O
after	O
drug	B-Drug
withdrawal	O
(	O
``	O
off	O
''	O
period	O
)	O
and	O
while	O
taking	O
their	O
optimal	O
medical	O
regimens	O
(	O
``	O
on	O
''	O
period	O
)	O
.	O

All	O
patients	O
were	O
examined	O
preoperatively	O
and	O
39	O
were	O
examined	O
at	O
six	O
months	O
;	O
27	O
of	O
the	O
patients	O
were	O
also	O
examined	O
at	O
one	O
year	O
,	O
and	O
11	O
at	O
two	O
years	O
.	O

RESULTS	O
:	O
The	O
percent	O
improvements	O
at	O
six	O
months	O
were	O
as	O
follows	O
:	O
off-period	O
score	O
for	O
overall	O
motor	O
function	O
,	O
28	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
38	O
percent	O
)	O
,	O
with	O
most	O
of	O
the	O
improvement	O
in	O
the	O
contralateral	O
limbs	O
;	O
off-period	O
score	O
for	O
activities	O
of	O
daily	O
living	O
,	O
29	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
39	O
percent	O
)	O
;	O
on-period	O
score	O
for	O
contralateral	O
dyskinesias	B-Disease
,	O
82	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
72	O
to	O
91	O
percent	O
)	O
;	O
and	O
on-period	O
score	O
for	O
ipsilateral	O
dyskinesias	B-Disease
,	O
44	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
29	O
to	O
59	O
percent	O
)	O
.	O

The	O
improvements	O
in	O
dyskinesias	B-Disease
and	O
the	O
total	O
scores	O
for	O
off-period	O
parkinsonism	B-Disease
,	O
contralateral	O
bradykinesia	B-Disease
,	O
and	O
rigidity	B-Disease
were	O
sustained	O
in	O
the	O
11	O
patients	O
examined	O
at	O
two	O
years	O
.	O

The	O
improvement	O
in	O
ipsilateral	O
dyskinesias	B-Disease
was	O
lost	O
after	O
one	O
year	O
,	O
and	O
the	O
improvements	O
in	O
postural	O
stability	O
and	O
gait	O
lasted	O
only	O
three	O
to	O
six	O
months	O
.	O

Approximately	O
half	O
the	O
patients	O
who	O
had	O
been	O
dependent	O
on	O
assistance	O
in	O
activities	O
of	O
daily	O
living	O
in	O
the	O
off	O
period	O
before	O
surgery	O
became	O
independent	O
after	O
surgery	O
.	O

The	O
complications	O
of	O
surgery	O
were	O
generally	O
well	O
tolerated	O
,	O
and	O
there	O
were	O
no	O
significant	O
changes	O
in	O
the	O
use	O
of	O
medication	O
.	O

CONCLUSIONS	O
:	O
In	O
late-stage	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
,	O
pallidotomy	O
significantly	O
reduces	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
and	O
off-period	O
disability	O
.	O

Much	O
of	O
the	O
benefit	O
is	O
sustained	O
at	O
two	O
years	O
,	O
although	O
some	O
improvements	O
,	O
such	O
as	O
those	O
on	O
the	O
ipsilateral	O
side	O
and	O
in	O
axial	O
symptoms	O
,	O
wane	O
within	O
the	O
first	O
year	O
.	O

The	O
on-period	O
symptoms	O
that	O
are	O
resistant	O
to	O
dopaminergic	B-Drug
therapy	O
do	O
not	O
respond	O
to	O
pallidotomy	O
.	O

Neuropeptide-Y	O
immunoreactivity	O
in	O
the	O
pilocarpine	B-Chemical
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

Neuropeptide-Y	O
(	O
NPY	O
)	O
is	O
expressed	O
by	O
granule	O
cells	O
and	O
mossy	O
fibres	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
during	O
experimental	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
(	O
TLE	B-Disease
)	O
.	O

This	O
expression	O
may	O
represent	O
an	O
endogenous	O
damping	O
mechanism	O
since	O
NPY	O
has	O
been	O
shown	O
to	O
block	O
seizure-like	B-Disease
events	O
following	O
high-frequency	O
stimulation	O
in	O
hippocampal	O
slices	O
.	O

The	O
pilocarpine	B-Chemical
(	O
PILO	B-Chemical
)	O
model	O
of	O
epilepsy	B-Disease
is	O
characterized	O
by	O
an	O
acute	O
period	O
of	O
status	B-Disease
epilepticus	I-Disease
followed	O
by	O
spontaneous	O
recurrent	O
seizures	B-Disease
and	O
related	O
brain	B-Disease
damage	I-Disease
.	O

We	O
report	O
peroxidase-antiperoxidase	O
immunostaining	O
for	O
NPY	O
in	O
several	O
brain	O
regions	O
in	O
this	O
model	O
.	O

PILO-injected	B-Chemical
animals	O
exhibited	O
NPY	O
immunoreactivity	O
in	O
the	O
region	O
of	O
the	O
mossy	O
fibre	O
terminals	O
,	O
in	O
the	O
dentate	O
gyrus	O
inner	O
molecular	O
layer	O
and	O
,	O
in	O
a	O
few	O
cases	O
,	O
within	O
presumed	O
granule	O
cells	O
.	O

NPY	O
immunoreactivity	O
was	O
also	O
dramatically	O
changed	O
in	O
the	O
entorhinal	O
cortex	O
,	O
amygdala	O
and	O
sensorimotor	O
areas	O
.	O

In	O
addition	O
,	O
PILO	B-Chemical
injected	O
animals	O
exhibited	O
a	O
reduction	O
in	O
the	O
number	O
of	O
NPY-immunoreactive	O
interneurons	O
compared	O
with	O
controls	O
.	O

The	O
results	O
demonstrate	O
that	O
changes	O
in	O
NPY	O
expression	O
,	O
including	O
expression	O
in	O
the	O
granule	O
cells	O
and	O
mossy	O
fibres	O
and	O
the	O
loss	O
of	O
vulnerable	O
NPY	O
neurons	O
,	O
are	O
present	O
in	O
the	O
PILO	B-Chemical
model	O
of	O
TLE	B-Disease
.	O

However	O
,	O
the	O
significance	O
of	O
this	O
changed	O
synthesis	O
of	O
NPY	O
remains	O
to	O
be	O
determined	O
.	O

Effect	O
of	O
myopic	O
excimer	O
laser	O
photorefractive	O
keratectomy	O
on	O
the	O
electrophysiologic	O
function	O
of	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

PURPOSE	O
:	O
To	O
assess	O
by	O
electrophysiologic	O
testing	O
the	O
effect	O
of	O
photorefractive	O
keratectomy	O
(	O
PRK	O
)	O
on	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

SETTING	O
:	O
Eye	O
Clinic	O
,	O
S.	O
Salvatore	O
Hospital	O
,	O
L'Aquila	O
University	O
,	O
Italy	O
.	O

METHODS	O
:	O
Standard	O
pattern	O
electroretinograms	O
(	O
P-ERGs	O
)	O
and	O
standard	O
pattern	O
visual	O
evoked	O
potentials	O
(	O
P-VEPs	O
)	O
were	O
done	O
in	O
25	O
eyes	O
of	O
25	O
patients	O
who	O
had	O
myopic	O
PRK	O
for	O
an	O
attempted	O
correction	O
between	O
5.00	O
and	O
15.00	O
diopters	O
(	O
D	O
)	O
(	O
mean	O
8.00	O
D	O
)	O
.	O

Testing	O
was	O
done	O
preoperatively	O
and	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	O
postoperatively	O
.	O

The	O
contralateral	O
eyes	O
served	O
as	O
controls	O
.	O

During	O
the	O
follow-up	O
,	O
3	O
patients	O
(	O
12	O
%	O
)	O
developed	O
steroid-induced	B-Chemical
elevated	B-Disease
intraocular	I-Disease
pressure	I-Disease
(	O
IOP	O
)	O
that	O
resolved	O
after	O
corticosteroid	B-Chemical
therapy	O
was	O
discontinued	O
.	O

RESULTS	O
:	O
No	O
statistically	O
significant	O
differences	O
were	O
seen	O
between	O
treated	O
and	O
control	O
eyes	O
nor	O
between	O
treated	O
eyes	O
preoperatively	O
and	O
postoperatively	O
.	O

CONCLUSION	O
:	O
Myopic	O
excimer	O
laser	O
PRK	O
did	O
not	O
seem	O
to	O
affect	O
the	O
posterior	O
segment	O
.	O

The	O
transient	O
steroid-induced	B-Chemical
IOP	B-Disease
rise	I-Disease
did	O
not	O
seem	O
to	O
cause	O
functional	O
impairment	O
.	O

Liposomal	O
daunorubicin	B-Chemical
in	O
advanced	O
Kaposi	B-Disease
's	I-Disease
sarcoma	I-Disease
:	O
a	O
phase	O
II	O
study	O
.	O

We	O
report	O
a	O
non-randomized	O
Phase	O
II	O
clinical	O
trial	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
liposomal	O
daunorubicin	B-Chemical
(	O
DaunoXome	O
)	O
in	O
the	O
treatment	O
of	O
AIDS	B-Disease
related	O
Kaposi	B-Disease
's	I-Disease
sarcoma	I-Disease
.	O

Eleven	O
homosexual	O
men	O
with	O
advanced	O
Kaposi	B-Disease
's	I-Disease
sarcoma	I-Disease
were	O
entered	O
in	O
the	O
trial	O
.	O

Changes	O
in	O
size	O
,	O
colour	O
and	O
associated	O
oedema	B-Disease
of	O
selected	O
'target	O
'	O
lesions	O
were	O
measured	O
.	O

Clinical	O
,	O
biochemical	O
and	O
haematological	O
toxicities	B-Disease
were	O
assessed	O
.	O

Ten	O
subjects	O
were	O
evaluated	O
.	O

A	O
partial	O
response	O
was	O
achieved	O
in	O
four	O
,	O
of	O
whom	O
two	O
subsequently	O
relapsed	O
.	O

Stabilization	O
of	O
Kaposi	B-Disease
's	I-Disease
sarcoma	I-Disease
occurred	O
in	O
the	O
remaining	O
six	O
,	O
maintained	O
until	O
the	O
end	O
of	O
the	O
trial	O
period	O
in	O
four	O
.	O

The	O
drug	B-Drug
was	O
generally	O
well	O
tolerated	O
,	O
with	O
few	O
mild	O
symptoms	O
of	O
toxicity	B-Disease
.	O

The	O
main	O
problem	O
encountered	O
was	O
haematological	O
toxicity	B-Disease
,	O
with	O
three	O
subjects	O
experiencing	O
severe	O
neutropenia	B-Disease
(	O
neutrophil	O
count	O
<	O
0.5	O
x	O
10	O
(	O
9	O
)	O
/l	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
cardiotoxicity	B-Disease
.	O

In	O
this	O
small	O
patient	O
sample	O
,	O
liposomal	O
daunorubicin	B-Chemical
was	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	O
in	O
the	O
treatment	O
of	O
Kaposi	B-Disease
's	I-Disease
sarcoma	I-Disease
.	O

Failure	O
of	O
ancrod	O
in	O
the	O
treatment	O
of	O
heparin-induced	B-Chemical
arterial	O
thrombosis	B-Disease
.	O

The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
heparin-induced	B-Chemical
thrombosis	B-Disease
remain	O
high	O
despite	O
numerous	O
empirical	O
therapies	O
.	O

Ancrod	O
has	O
been	O
used	O
successfully	O
for	O
prophylaxis	O
against	O
development	O
of	O
thrombosis	B-Disease
in	O
patients	O
with	O
heparin	B-Chemical
induced	O
platelet	B-Disease
aggregation	I-Disease
who	O
require	O
brief	O
reexposure	O
to	O
heparin	B-Chemical
,	O
but	O
its	O
success	O
in	O
patients	O
who	O
have	O
developed	O
the	O
thrombosis	B-Disease
syndrome	O
is	O
not	O
well	O
defined	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
failure	O
of	O
ancrod	O
treatment	O
in	O
a	O
patient	O
with	O
heparin-induced	B-Chemical
thrombosis	B-Disease
.	O

Seizure	B-Disease
after	O
flumazenil	B-Chemical
administration	O
in	O
a	O
pediatric	O
patient	O
.	O

Flumazenil	B-Chemical
is	O
a	O
benzodiazepine	B-Chemical
receptor	O
antagonist	O
used	O
to	O
reverse	O
sedation	O
and	O
respiratory	B-Disease
depression	I-Disease
induced	O
by	O
benzodiazepines	B-Chemical
.	O

Seizures	B-Disease
and	O
cardiac	B-Disease
arrhythmias	I-Disease
have	O
complicated	O
its	O
use	O
in	O
adult	O
patients	O
.	O

Overdose	B-Disease
patients	O
who	O
have	O
coingested	O
tricyclic	O
antidepressants	B-Drug
have	O
a	O
higher	O
risk	O
of	O
these	O
complications	O
.	O

Little	O
information	O
exists	O
concerning	O
adverse	O
effects	O
of	O
flumazenil	B-Chemical
in	O
children	O
.	O

We	O
report	O
the	O
occurrence	O
of	O
a	O
generalized	O
tonic-clonic	B-Disease
seizure	I-Disease
in	O
a	O
pediatric	O
patient	O
following	O
the	O
administration	O
of	O
flumazenil	B-Chemical
.	O

Remodelling	O
of	O
nerve	O
structure	O
in	O
experimental	O
isoniazid	B-Chemical
neuropathy	B-Disease
in	O
the	O
rat	O
.	O

The	O
neuropathy	B-Disease
caused	O
by	O
a	O
single	O
dose	O
of	O
isoniazid	B-Chemical
in	O
rats	O
was	O
studied	O
with	O
a	O
computer-assisted	O
morphometric	O
method	O
.	O

Scatter	O
diagrams	O
of	O
the	O
g	O
ratio	O
(	O
quotient	O
fibre	O
diameter/axon	O
diameter	O
)	O
define	O
regenerating	O
fibres	O
as	O
a	O
distinct	O
population	O
,	O
distinguishable	O
from	O
the	O
surviving	O
fibres	O
by	O
reduced	O
sheath	O
thickness	O
and	O
reduced	O
axon	O
calibre	O
.	O

There	O
was	O
also	O
evidence	O
of	O
a	O
subtle	O
direct	O
toxic	O
effect	O
on	O
the	O
entire	O
fibre	O
population	O
,	O
causing	O
axon	O
shrinkage	O
masked	O
by	O
readjustment	O
of	O
the	O
myelin	O
sheath	O
.	O

Selective	O
injection	O
of	O
iopentol	B-Chemical
,	O
iohexol	B-Chemical
and	O
metrizoate	B-Chemical
into	O
the	O
left	O
coronary	O
artery	O
of	O
the	O
dog	O
.	O

Induction	O
of	O
ventricular	B-Disease
fibrillation	I-Disease
and	O
decrease	O
of	O
aortic	O
pressure	O
.	O

In	O
twenty	O
beagle	O
dogs	O
selective	O
injections	O
were	O
made	O
into	O
the	O
left	O
coronary	O
artery	O
with	O
iopentol	B-Chemical
,	O
iohexol	B-Chemical
and	O
metrizoate	B-Chemical
in	O
doses	O
of	O
4	O
ml	O
,	O
8	O
ml	O
and	O
16	O
ml	O
.	O

Thirty-six	O
iopentol	B-Chemical
injections	O
,	O
35	O
iohexol	B-Chemical
injections	O
and	O
37	O
metrizoate	B-Chemical
injections	O
were	O
made	O
.	O

Frequencies	O
of	O
ventricular	B-Disease
fibrillation	I-Disease
were	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0.05	O
)	O
after	O
iopentol	B-Chemical
(	O
0	O
%	O
)	O
and	O
iohexol	B-Chemical
(	O
3	O
%	O
)	O
than	O
after	O
metrizoate	B-Chemical
(	O
22	O
%	O
)	O
.	O

Iopentol	B-Chemical
and	O
iohexol	B-Chemical
also	O
produced	O
significantly	O
less	O
decrease	O
in	O
aortic	O
blood	O
pressure	O
than	O
metrizoate	B-Chemical
at	O
the	O
different	O
doses	O
.	O

Magnetic	O
resonance	O
imaging	O
of	O
cerebral	O
venous	B-Disease
thrombosis	I-Disease
secondary	O
to	O
``	O
low-dose	O
''	O
birth	O
control	O
pills	O
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
cerebral	O
deep	B-Disease
venous	I-Disease
thrombosis	I-Disease
in	O
a	O
21-year-old	O
white	O
woman	O
are	O
presented	O
.	O

This	O
nulliparous	O
patient	O
presented	O
with	O
relatively	O
mild	O
clinical	O
symptoms	O
and	O
progressing	O
mental	O
status	O
changes	O
.	O

The	O
only	O
known	O
risk	O
factor	O
was	O
``	O
low-dose	O
''	O
oral	B-Chemical
contraceptive	I-Chemical
pills	O
.	O

The	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
increased	O
signal	O
intensity	O
from	O
the	O
internal	O
cerebral	O
veins	O
,	O
vein	O
of	O
Galen	O
,	O
and	O
straight	O
sinus	O
.	O

The	O
diagnosis	O
was	O
confirmed	O
by	O
arterial	O
angiography	O
.	O

Relation	O
of	O
perfusion	O
defects	O
observed	O
with	O
myocardial	O
contrast	O
echocardiography	O
to	O
the	O
severity	O
of	O
coronary	B-Disease
stenosis	I-Disease
:	O
correlation	O
with	O
thallium-201	B-Chemical
single-photon	O
emission	O
tomography	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
myocardial	O
contrast	O
echocardiography	O
is	O
a	O
valuable	O
technique	O
for	O
delineating	O
regions	O
of	O
myocardial	O
underperfusion	O
secondary	O
to	O
coronary	B-Disease
occlusion	I-Disease
and	O
to	O
critical	O
coronary	B-Disease
stenoses	I-Disease
in	O
the	O
presence	O
of	O
hyperemic	B-Disease
stimulation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
myocardial	O
contrast	O
echocardiography	O
performed	O
with	O
a	O
stable	O
solution	O
of	O
sonicated	O
albumin	O
could	O
detect	O
regions	O
of	O
myocardial	O
underperfusion	O
resulting	O
from	O
various	O
degrees	O
of	O
coronary	B-Disease
stenosis	I-Disease
.	O

The	O
perfusion	O
defect	O
produced	O
in	O
16	O
open	O
chest	O
dogs	O
was	O
compared	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
measured	O
by	O
the	O
postmortem	O
dual-perfusion	O
technique	O
and	O
with	O
thallium-201	B-Chemical
single-photon	O
emission	O
tomography	O
(	O
SPECT	O
)	O
.	O

During	O
a	O
transient	O
(	O
20-s	O
)	O
coronary	B-Disease
occlusion	I-Disease
,	O
a	O
perfusion	O
defect	O
was	O
observed	O
with	O
contrast	O
echocardiography	O
in	O
14	O
of	O
the	O
15	O
dogs	O
in	O
which	O
the	O
occlusion	O
was	O
produced	O
.	O

The	O
perfusion	O
defect	O
correlated	O
significantly	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
(	O
r	O
=	O
0.74	O
;	O
p	O
less	O
than	O
0.002	O
)	O
.	O

During	O
dipyridamole-induced	B-Chemical
hyperemia	B-Disease
,	O
12	O
of	O
the	O
16	O
dogs	O
with	O
a	O
partial	O
coronary	B-Disease
stenosis	I-Disease
had	O
a	O
visible	O
area	O
of	O
hypoperfusion	O
by	O
contrast	O
echocardiography	O
.	O

The	O
four	O
dogs	O
without	O
a	O
perfusion	O
defect	O
had	O
a	O
stenosis	O
that	O
resulted	O
in	O
a	O
mild	O
(	O
0	O
%	O
to	O
50	O
%	O
)	O
reduction	O
in	O
dipyridamole-induced	B-Chemical
hyperemia	B-Disease
.	O

The	O
size	O
of	O
the	O
perfusion	O
defect	O
during	O
stenosis	O
correlated	O
significantly	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
(	O
r	O
=	O
0.61	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Thallium-201	B-Chemical
SPECT	O
demonstrated	O
a	O
perfusion	O
defect	O
in	O
all	O
14	O
dogs	O
analyzed	O
during	O
dipyridamole-induced	B-Chemical
hyperemia	B-Disease
;	O
the	O
size	O
of	O
the	O
perfusion	O
defect	O
correlated	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
(	O
r	O
=	O
0.58	O
;	O
p	O
less	O
than	O
0.03	O
)	O
and	O
with	O
the	O
perfusion	O
defect	O
by	O
contrast	O
echocardiography	O
(	O
r	O
=	O
0.58	O
;	O
p	O
less	O
than	O
0.03	O
)	O
.	O

Thus	O
,	O
myocardial	O
contrast	O
echocardiography	O
can	O
be	O
used	O
to	O
visualize	O
and	O
quantitate	O
the	O
amount	O
of	O
jeopardized	O
myocardium	O
during	O
moderate	O
to	O
severe	O
degrees	O
of	O
coronary	B-Disease
stenosis	I-Disease
.	O

The	O
results	O
obtained	O
show	O
a	O
correlation	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
similar	O
to	O
that	O
obtained	O
with	O
thallium-201	B-Chemical
SPECT	O
.	O

Potential	O
deleterious	O
effect	O
of	O
furosemide	B-Chemical
in	O
radiocontrast	O
nephropathy	B-Disease
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
furosemide	B-Chemical
in	O
addition	O
to	O
intravenous	O
fluids	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	B-Disease
.	O

18	O
patients	O
,	O
referred	O
to	O
a	O
radiocontrast	O
study	O
,	O
considered	O
at	O
risk	O
because	O
of	O
preexisting	O
renal	B-Disease
insufficiency	I-Disease
,	O
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
,	O
performed	O
at	O
the	O
secondary	O
care	O
center	O
of	O
a	O
1,100-bed	O
private	O
university	O
hospital	O
.	O

In	O
addition	O
to	O
fluids	O
,	O
the	O
treatment	O
group	O
received	O
furosemide	B-Chemical
(	O
mean	O
dose	O
110	O
mg	O
)	O
intravenously	O
30	O
min	O
prior	O
to	O
the	O
injection	O
of	O
contrast	O
material	O
.	O

The	O
control	O
group	O
received	O
fluids	O
(	O
mean	O
3	O
liters	O
)	O
.	O

Radiological	O
studies	O
were	O
mostly	O
angiographies	O
performed	O
with	O
both	O
ionic	O
and	O
non-ionic	O
contrast	O
material	O
,	O
at	O
an	O
average	O
dose	O
of	O
245	O
ml	O
.	O

Renal	B-Disease
function	I-Disease
significantly	I-Disease
deteriorated	I-Disease
in	O
the	O
group	O
pretreated	O
with	O
furosemide	B-Chemical
(	O
p	O
<	O
0.005	O
by	O
ANOVA	O
)	O
,	O
with	O
a	O
rise	O
in	O
serum	O
creatinine	B-Chemical
from	O
145	O
+/-	O
13	O
to	O
182	O
+/-	O
16	O
mumol/l	O
at	O
24	O
h	O
,	O
while	O
no	O
change	O
occurred	O
in	O
the	O
control	O
group	O
(	O
from	O
141	O
+/-	O
6	O
to	O
142	O
+/-	O
7	O
mumol/l	O
)	O
.	O

Renal	B-Disease
failure	I-Disease
was	O
associated	O
with	O
weight	B-Disease
loss	I-Disease
in	O
the	O
furosemide-treated	B-Chemical
group	O
.	O

Furosemide	B-Chemical
may	O
be	O
deleterious	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	B-Disease
.	O

The	O
renal	O
pathology	O
in	O
a	O
case	O
of	O
lithium-induced	B-Chemical
diabetes	B-Disease
insipidus	I-Disease
.	O

A	O
case	O
of	O
lithium-induced	B-Chemical
diabetes	B-Disease
insipidus	I-Disease
is	O
reported	O
.	O

At	O
necropsy	O
microscopy	O
shoed	O
unique	O
and	O
extensive	O
damage	O
to	O
cells	O
lining	O
the	O
distal	O
nephron	O
.	O

It	O
is	O
suggested	O
that	O
these	O
changes	O
represent	O
a	O
specific	O
toxic	O
effect	O
of	O
lithium	B-Chemical
,	O
reported	O
here	O
for	O
the	O
first	O
time	O
in	O
man	O
.	O

Etiologic	O
factors	O
in	O
the	O
pathogenesis	O
of	O
liver	B-Disease
tumors	I-Disease
associated	O
with	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

Within	O
the	O
last	O
several	O
years	O
,	O
previously	O
rare	O
liver	B-Disease
tumors	I-Disease
have	O
been	O
seen	O
in	O
young	O
women	O
using	O
oral	B-Chemical
contraceptive	I-Chemical
steroids	B-Chemical
.	O

The	O
Registry	O
for	O
Liver	B-Disease
Tumors	I-Disease
Associated	O
with	O
Oral	B-Chemical
Contraceptives	I-Chemical
at	O
the	O
University	O
of	O
California	O
,	O
Irvine	O
,	O
has	O
clearly	O
identified	O
27	O
cases	O
.	O

The	O
recent	O
literature	O
contains	O
44	O
case	O
reports	O
.	O

Common	O
to	O
these	O
71	O
cases	O
has	O
been	O
a	O
histopathologic	O
diagnosis	O
of	O
focal	B-Disease
nodular	I-Disease
hyperplasia	I-Disease
,	O
adenoma	B-Disease
,	O
hamartoma	B-Disease
,	O
and	O
hepatoma	B-Disease
.	O

Significant	O
statistical	O
etiologic	O
factors	O
include	O
prolonged	O
uninterrupted	O
usage	O
of	O
oral	B-Chemical
contraceptive	I-Chemical
steroids	B-Chemical
.	O

Eight	O
deaths	O
and	O
liver	O
rupture	B-Disease
in	O
18	O
patients	O
attest	O
to	O
the	O
seriousness	O
of	O
this	O
new	O
potentially	O
lethal	O
adverse	O
phenomenon	O
.	O

Graft-versus-host	B-Disease
disease	I-Disease
prophylaxis	O
with	O
everolimus	B-Chemical
and	O
tacrolimus	B-Chemical
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
sinusoidal	B-Disease
obstruction	I-Disease
syndrome	I-Disease
and	O
microangiopathy	B-Disease
:	O
results	O
of	O
the	O
EVTAC	O
trial	O
.	O

A	O
calcineurin	O
inhibitor	O
combined	O
with	O
methotrexate	B-Chemical
is	O
the	O
standard	O
prophylaxis	O
for	O
graft-versus-host	B-Disease
disease	I-Disease
(	O
GVHD	B-Disease
)	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
.	O

Everolimus	B-Chemical
,	O
a	O
derivative	O
of	O
sirolimus	B-Chemical
,	O
seems	O
to	O
mediate	O
antileukemia	O
effects	O
.	O

We	O
report	O
on	O
a	O
combination	O
of	O
everolimus	B-Chemical
and	O
tacrolimus	B-Chemical
in	O
24	O
patients	O
(	O
median	O
age	O
,	O
62	O
years	O
)	O
with	O
either	O
myelodysplastic	B-Disease
syndrome	I-Disease
(	O
MDS	B-Disease
;	O
n	O
=	O
17	O
)	O
or	O
acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
(	O
AML	B-Disease
;	O
n	O
=	O
7	O
)	O
undergoing	O
intensive	O
conditioning	O
followed	O
by	O
HSCT	O
from	O
related	O
(	O
n	O
=	O
4	O
)	O
or	O
unrelated	O
(	O
n	O
=	O
20	O
)	O
donors	O
.	O

All	O
patients	O
engrafted	O
,	O
and	O
only	O
1	O
patient	O
experienced	O
grade	O
IV	O
mucositis	B-Disease
.	O

Nine	O
patients	O
(	O
37	O
%	O
)	O
developed	O
acute	O
grade	O
II-IV	O
GVHD	B-Disease
,	O
and	O
11	O
of	O
17	O
evaluable	O
patients	O
(	O
64	O
%	O
)	O
developed	O
chronic	O
extensive	O
GVHD	B-Disease
.	O

Transplantation-associated	B-Disease
microangiopathy	I-Disease
(	O
TMA	B-Disease
)	O
occurred	O
in	O
7	O
patients	O
(	O
29	O
%	O
)	O
,	O
with	O
2	O
cases	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

The	O
study	O
was	O
terminated	O
prematurely	O
because	O
an	O
additional	O
6	O
patients	O
(	O
25	O
%	O
)	O
developed	O
sinusoidal	B-Disease
obstruction	I-Disease
syndrome	I-Disease
(	O
SOS	B-Disease
)	O
,	O
which	O
was	O
fatal	O
in	O
2	O
cases	O
.	O

With	O
a	O
median	O
follow-up	O
of	O
26	O
months	O
,	O
the	O
2-year	O
overall	O
survival	O
rate	O
was	O
47	O
%	O
.	O

Although	O
this	O
new	O
combination	O
appears	O
to	O
be	O
effective	O
as	O
a	O
prophylactic	O
regimen	O
for	O
acute	O
GVHD	B-Disease
,	O
the	O
incidence	O
of	O
TMA	B-Disease
and	O
SOS	B-Disease
is	O
considerably	O
higher	O
than	O
seen	O
with	O
other	O
regimens	O
.	O

Effect	O
of	O
some	O
convulsants	O
on	O
the	O
protective	O
activity	O
of	O
loreclezole	B-Chemical
and	O
its	O
combinations	O
with	O
valproate	B-Chemical
or	O
clonazepam	B-Chemical
in	O
amygdala-kindled	O
rats	O
.	O

Loreclezole	B-Chemical
(	O
5	O
mg/kg	O
)	O
exerted	O
a	O
significant	O
protective	O
action	O
in	O
amygdala-kindled	O
rats	O
,	O
reducing	O
both	O
seizure	B-Disease
and	O
afterdischarge	O
durations	O
.	O

The	O
combinations	O
of	O
loreclezole	B-Chemical
(	O
2.5	O
mg/kg	O
)	O
with	O
valproate	B-Chemical
,	O
clonazepam	B-Chemical
,	O
or	O
carbamazepine	B-Chemical
(	O
applied	O
at	O
their	O
subprotective	O
doses	O
)	O
also	O
exhibited	O
antiseizure	O
effect	O
in	O
this	O
test	O
.	O

However	O
,	O
only	O
two	O
first	O
combinations	O
occurred	O
to	O
be	O
of	O
pharmacodynamic	O
nature	O
.	O

Among	O
several	O
chemoconvulsants	O
,	O
bicuculline	B-Chemical
,	O
N-methyl-D-aspartic	B-Chemical
acid	I-Chemical
and	O
BAY	B-Chemical
k-8644	I-Chemical
(	O
the	O
opener	O
of	O
L-type	O
calcium	B-Chemical
channels	O
)	O
reversed	O
the	O
protective	O
activity	O
of	O
loreclezole	B-Chemical
alone	O
and	O
its	O
combination	O
with	O
valproate	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
bicuculline	B-Chemical
,	O
aminophylline	B-Chemical
and	O
BAY	B-Chemical
k-8644	I-Chemical
inhibited	O
the	O
anticonvulsive	O
action	O
of	O
loreclezole	B-Chemical
combined	O
with	O
clonazepam	B-Chemical
.	O

The	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
protective	O
activity	O
of	O
loreclezole	B-Chemical
and	O
its	O
combinations	O
with	O
other	O
antiepileptics	O
may	O
involve	O
potentiation	O
of	O
GABAergic	O
neurotransmission	O
and	O
blockade	O
of	O
L-type	O
of	O
calcium	B-Chemical
channels	O
.	O

Acute	B-Disease
liver	I-Disease
failure	I-Disease
with	O
concurrent	O
bupropion	B-Chemical
and	O
carbimazole	B-Chemical
therapy	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
fatal	O
liver	B-Disease
failure	I-Disease
possibly	O
associated	O
with	O
concurrent	O
use	O
of	O
bupropion	B-Chemical
and	O
carbimazole	B-Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
41-year-old	O
Chinese	O
man	O
with	O
a	O
history	O
of	O
hyperthyroidism	B-Disease
had	O
been	O
treated	O
with	O
carbimazole	B-Chemical
and	O
propranolol	B-Chemical
for	O
the	O
past	O
5	O
years	O
.	O

He	O
received	O
a	O
10-day	O
course	O
of	O
bupropion	B-Chemical
as	O
an	O
aid	O
for	O
smoking	O
cessation	O
10	O
weeks	O
prior	O
to	O
presentation	O
.	O

He	O
developed	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
with	O
rapid	O
deterioration	O
of	O
renal	O
function	O
.	O

Liver	O
biopsy	O
showed	O
evidence	O
of	O
nonspecific	O
drug-induced	B-Disease
acute	I-Disease
liver	I-Disease
injury	I-Disease
.	O

His	O
condition	O
was	O
further	O
complicated	O
by	O
sepsis	B-Disease
and	O
coagulopathy	B-Disease
.	O

Death	O
resulted	O
19	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

The	O
likelihood	O
that	O
bupropion	B-Chemical
induced	O
hepatotoxicity	B-Disease
in	O
our	O
patient	O
was	O
possible	O
,	O
based	O
on	O
the	O
Naranjo	O
probability	O
scale	O
.	O

DISCUSSION	O
:	O
Although	O
there	O
is	O
increasing	O
evidence	O
of	O
hepatotoxicity	B-Disease
induced	O
by	O
bupropion	B-Chemical
,	O
this	O
is	O
the	O
first	O
case	O
of	O
fatality	O
that	O
could	O
have	O
resulted	O
from	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
in	O
a	O
patient	O
receiving	O
bupropion	B-Chemical
while	O
on	O
concomitant	O
treatment	O
with	O
carbimazole	B-Chemical
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
acute	B-Disease
liver	I-Disease
insult	I-Disease
induced	O
by	O
bupropion	B-Chemical
given	O
concurrently	O
with	O
other	O
hepatotoxic	B-Disease
drugs	B-Drug
.	O

Long	O
term	O
hormone	O
therapy	O
for	O
perimenopausal	O
and	O
postmenopausal	O
women	O
.	O

BACKGROUND	O
:	O
Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	O
symptoms	O
and	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B-Disease
disease	I-Disease
,	O
osteoporosis	B-Disease
and	O
dementia	B-Disease
in	O
older	O
women	O
.	O

This	O
is	O
an	O
updated	O
version	O
of	O
the	O
original	O
Cochrane	O
review	O
first	O
published	O
in	O
2005	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long-term	O
HT	O
on	O
mortality	O
,	O
cardiovascular	O
outcomes	O
,	O
cancer	B-Disease
,	O
gallbladder	B-Disease
disease	I-Disease
,	O
cognition	O
,	O
fractures	B-Disease
and	O
quality	O
of	O
life	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
to	O
November	O
2007	O
:	O
Trials	O
Register	O
of	O
the	O
Cochrane	O
Menstrual	B-Disease
Disorders	I-Disease
and	O
Subfertility	O
Group	O
,	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biological	O
Abstracts	O
.	O

Also	O
relevant	O
non-indexed	O
journals	O
and	O
conference	O
abstracts	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
double-blind	O
trials	O
of	O
HT	O
versus	O
placebo	O
,	O
taken	O
for	O
at	O
least	O
one	O
year	O
by	O
perimenopausal	O
or	O
postmenopausal	O
women	O
.	O

HT	O
included	O
oestrogens	B-Chemical
,	O
with	O
or	O
without	O
progestogens	B-Chemical
,	O
via	O
oral	O
,	O
transdermal	O
,	O
subcutaneous	O
or	O
transnasal	O
routes	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
authors	O
independently	O
assessed	O
trial	O
quality	O
and	O
extracted	O
data	O
.	O

MAIN	O
RESULTS	O
:	O
Nineteen	O
trials	O
involving	O
41,904	O
women	O
were	O
included	O
.	O

In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Disease
thrombo-embolism	I-Disease
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
's	O
use	O
)	O
,	O
stroke	B-Disease
(	O
after	O
three	O
years	O
)	O
,	O
breast	B-Disease
cancer	I-Disease
and	O
gallbladder	B-Disease
disease	I-Disease
.	O

Long-term	O
oestrogen-only	B-Chemical
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Disease
thrombo-embolism	I-Disease
,	O
stroke	B-Disease
and	O
gallbladder	B-Disease
disease	I-Disease
(	O
after	O
one	O
to	O
two	O
years	O
,	O
three	O
years	O
and	O
seven	O
years	O
'	O
use	O
respectively	O
)	O
,	O
but	O
did	O
not	O
significantly	O
increase	O
the	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
.	O

The	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	B-Disease
and	O
(	O
for	O
combined	O
HT	O
)	O
colon	B-Disease
cancer	I-Disease
,	O
with	O
long-term	O
use	O
.	O

Among	O
women	O
aged	O
over	O
65	O
who	O
were	O
relatively	O
healthy	O
(	O
i.e	O
.	O

generally	O
fit	O
,	O
without	O
overt	O
disease	O
)	O
and	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	B-Disease
.	O

Among	O
women	O
with	O
cardiovascular	B-Disease
disease	I-Disease
,	O
long-term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Disease
thrombo-embolism.One	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year	O
old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen-only	O
HT	O
,	O
versus	O
similar-sized	O
placebo	O
groups	O
.	O

The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B-Disease
thrombo-embolism	O
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
:	O
their	O
absolute	O
risk	O
remained	O
low	O
,	O
at	O
less	O
than	O
1/500	O
.	O

However	O
,	O
this	O
study	O
was	O
not	O
powered	O
to	O
detect	O
differences	O
between	O
groups	O
of	O
younger	O
women	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	O
disease	O
.	O

We	O
need	O
more	O
evidence	O
on	O
the	O
safety	O
of	O
HT	O
for	O
menopausal	O
symptom	O
control	O
,	O
though	O
short-term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
healthy	O
younger	O
women	O
.	O

Passage	O
of	O
mannitol	B-Chemical
into	O
the	O
brain	O
around	O
gliomas	B-Disease
:	O
a	O
potential	O
cause	O
of	O
rebound	O
phenomenon	O
.	O

A	O
study	O
on	O
21	O
patients	O
.	O

AIM	O
:	O
Widespread	O
use	O
of	O
mannitol	B-Chemical
to	O
reduce	O
brain	B-Disease
edema	I-Disease
and	O
lower	O
elevated	B-Disease
ICP	I-Disease
in	O
brain	B-Disease
tumor	I-Disease
patients	O
continues	O
to	O
be	O
afflicted	O
by	O
the	O
so-called	O
rebound	O
phenomenon	O
.	O

Leakage	O
of	O
mannitol	B-Chemical
into	O
the	O
brain	O
parenchyma	O
through	O
an	O
altered	O
BBB	O
and	O
secondary	O
reversal	O
of	O
osmotic	O
gradient	O
is	O
considered	O
the	O
major	O
cause	O
of	O
rebound	O
.	O

This	O
has	O
only	O
been	O
demonstrated	O
experimentally	O
in	O
animals	O
.	O

As	O
a	O
contribution	O
to	O
this	O
issue	O
we	O
decided	O
to	O
research	O
the	O
possible	O
passage	O
of	O
mannitol	B-Chemical
into	O
the	O
brain	B-Disease
after	O
administration	O
to	O
21	O
brain	B-Disease
tumor	O
patients	O
.	O

METHODS	O
:	O
Mannitol	B-Chemical
(	O
18	O
%	O
solution	O
;	O
1	O
g/kg	O
)	O
was	O
administered	O
as	O
a	O
bolus	O
to	O
patients	O
(	O
ten	O
had	O
malignant	B-Disease
glioma	I-Disease
,	O
seven	O
brain	O
metastases	B-Disease
and	O
four	O
meningioma	B-Disease
)	O
about	O
30	O
minutes	O
before	O
craniotomy	O
.	O

During	O
resection	O
,	O
a	O
sample	O
of	O
the	O
surrounding	O
edematous	B-Disease
white	O
matter	O
was	O
taken	O
at	O
the	O
same	O
time	O
as	O
a	O
10	O
ml	O
venous	O
blood	O
sample	O
.	O

Mannitol	B-Chemical
concentrations	O
were	O
measured	O
in	O
plasma	O
and	O
white	O
matter	O
by	O
a	O
modified	O
version	O
of	O
the	O
enzyme	O
assay	O
of	O
Blonquist	O
et	O
al	O
.	O

RESULTS	O
:	O
In	O
most	O
glioma	B-Disease
patients	O
,	O
mannitol	B-Chemical
concentrations	O
in	O
white	O
matter	O
were	O
2	O
to	O
6	O
times	O
higher	O
than	O
in	O
plasma	O
(	O
mean	O
3.5	O
times	O
)	O
.	O

In	O
meningioma	B-Disease
and	O
metastases	B-Disease
patients	O
plasma	O
concentrations	O
of	O
mannitol	B-Chemical
were	O
higher	O
than	O
white	O
matter	O
concentrations	O
except	O
in	O
three	O
cases	O
with	O
infiltration	O
by	O
neoplastic	O
cells	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
of	O
our	O
study	O
show	O
that	O
even	O
after	O
a	O
single	O
bolus	O
,	O
mannitol	B-Chemical
may	O
leak	O
through	O
the	O
altered	O
BBB	O
near	O
gliomas	B-Disease
,	O
reversing	O
the	O
initial	O
plasma-to-blood	O
osmotic	O
gradient	O
,	O
aggravating	O
peritumoral	O
edema	B-Disease
and	O
promoting	O
rebound	O
of	O
ICP	O
.	O

Can	O
lidocaine	B-Chemical
reduce	O
succinylcholine	B-Chemical
induced	O
postoperative	B-Disease
myalgia	I-Disease
?	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
lidocaine	B-Chemical
pretreatment	O
on	O
reduction	O
of	O
succinylcholine-induced	B-Chemical
myalgia	B-Disease
in	O
patients	O
undergoing	O
general	O
anesthesia	B-Drug
for	O
gynecological	O
surgery	O
.	O

One	O
hundred	O
and	O
thirty-five	O
patients	O
were	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
in	O
a	O
prospective	O
,	O
double	O
blind	O
,	O
randomized	O
manner	O
.	O

Group	O
PS	O
,	O
the	O
control	O
group	O
,	O
received	O
normal	O
saline	O
and	O
succinylcholine	B-Chemical
1.5	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
;	O
Group	O
LS	O
,	O
lidocaine	B-Chemical
1.5	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
and	O
succinylcholine	B-Chemical
1.5	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
;	O
Group	O
PR	O
,	O
normal	O
saline	O
and	O
rocuronium	B-Chemical
0.6	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
.	O

Morphine	B-Chemical
0.1	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
iv	O
was	O
given	O
for	O
premedication	O
and	O
all	O
patients	O
were	O
monitored	O
with	O
a	O
noninvasive	O
blood	O
pressure	O
monitor	O
,	O
ECG	O
and	O
pulse	O
oximetry	O
.	O

Anesthesia	B-Drug
was	O
induced	O
with	O
5	O
mg.kg	O
(	O
-1	O
)	O
thiopental	B-Chemical
iv	O
.	O

followed	O
by	O
succinylcholine	B-Chemical
(	O
Group	O
PS	O
,	O
LS	O
)	O
or	O
rocuronium	B-Chemical
(	O
Group	O
PR	O
)	O
for	O
tracheal	O
intubation	O
.	O

Following	O
administration	O
of	O
these	O
agents	O
,	O
the	O
presence	O
,	O
and	O
degree	O
of	O
fasciculation	B-Disease
were	O
assessed	O
visually	O
on	O
a	O
four	O
point	O
scale	O
by	O
one	O
investigator	O
who	O
was	O
blinded	O
to	O
the	O
drug	B-Drug
administered	O
.	O

The	O
blood	O
pressure	O
and	O
heart	O
rate	O
of	O
each	O
patient	O
were	O
monitored	O
on	O
nine	O
occasions	O
.	O

Twenty-four	O
hours	O
later	O
,	O
any	O
myalgia	B-Disease
experienced	O
was	O
assessed	O
according	O
to	O
a	O
structured	O
questionaire	O
and	O
graded	O
by	O
a	O
four	O
point	O
scale	O
by	O
one	O
investigator	O
blinded	O
to	O
the	O
intraoperative	O
management	O
.	O

The	O
results	O
indicate	O
that	O
muscle	B-Disease
fasciculation	I-Disease
was	O
not	O
found	O
in	O
Group	O
PR	O
while	O
the	O
patients	O
in	O
Group	O
LS	O
had	O
a	O
lower	O
incidence	O
of	O
muscle	B-Disease
fasciculation	I-Disease
than	O
those	O
in	O
Group	O
PS	O
(	O
p	O
<	O
0.001	O
)	O
.	O

At	O
24	O
h	O
,	O
the	O
incidence	O
of	O
myalgia	B-Disease
was	O
higher	O
in	O
Group	O
PS	O
than	O
in	O
Group	O
LS	O
and	O
PR	O
(	O
p	O
<	O
0.05	O
)	O
.	O

A	O
correlation	O
was	O
not	O
found	O
between	O
the	O
incidence	O
of	O
myalgia	B-Disease
and	O
the	O
occurrence	O
of	O
muscle	B-Disease
fasciculation	I-Disease
.	O

The	O
changes	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
not	O
significant	O
among	O
the	O
three	O
groups	O
.	O

In	O
conclusion	O
,	O
where	O
succinylcholine	B-Chemical
is	O
used	O
,	O
lidocaine	B-Chemical
is	O
proven	O
to	O
be	O
the	O
useful	O
pretreatment	O
agent	O
for	O
the	O
reduction	O
of	O
postoperative	B-Disease
myalgia	I-Disease
.	O

Open-label	O
assessment	O
of	O
levofloxacin	B-Chemical
for	O
the	O
treatment	O
of	O
acute	O
bacterial	O
sinusitis	B-Disease
in	O
adults	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
levofloxacin	B-Chemical
(	O
500	O
mg	O
orally	O
once	O
daily	O
for	O
10	O
to	O
14	O
days	O
)	O
in	O
treating	O
adult	O
outpatients	O
with	O
acute	O
bacterial	O
sinusitis	B-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
329	O
patients	O
enrolled	O
in	O
the	O
study	O
at	O
24	O
centers	O
.	O

All	O
patients	O
had	O
a	O
pre-therapy	O
Gram	O
's	O
stain	O
and	O
culture	O
of	O
sinus	O
exudate	O
obtained	O
by	O
antral	O
puncture	O
or	O
nasal	O
endoscopy	O
.	O

Clinical	O
response	O
was	O
assessed	O
on	O
the	O
basis	O
of	O
signs	O
and	O
symptoms	O
and	O
sinus	O
radiograph	O
or	O
computed	O
tomography	O
results	O
.	O

Microbiologic	O
cure	O
rates	O
were	O
determined	O
on	O
the	O
basis	O
of	O
presumed	O
plus	O
documented	O
eradication	O
of	O
the	O
pre-therapy	O
pathogen	O
(	O
s	O
)	O
.	O

RESULTS	O
:	O
The	O
most	O
common	O
pathogens	O
were	O
Haemophilus	O
influenzae	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Staphylococcus	O
aureus	O
,	O
and	O
Moraxella	O
catarrhalis	O
.	O

Of	O
300	O
clinically	O
evaluable	O
patients	O
,	O
175	O
(	O
58	O
%	O
)	O
were	O
cured	O
and	O
90	O
(	O
30	O
%	O
)	O
were	O
improved	O
at	O
the	O
post-therapy	O
evaluation	O
,	O
resulting	O
in	O
a	O
clinical	O
success	O
rate	O
of	O
88	O
%	O
.	O

Thirty-five	O
patients	O
(	O
12	O
%	O
)	O
clinically	O
failed	O
treatment	O
.	O

The	O
microbiologic	O
eradication	O
rate	O
(	O
presumed	O
plus	O
documented	O
)	O
among	O
138	O
microbiologically	O
evaluable	O
patients	O
was	O
92	O
%	O
.	O

Microbiologic	O
eradication	O
rates	O
(	O
presumed	O
plus	O
documented	O
)	O
of	O
the	O
most	O
common	O
pathogens	O
ranged	O
from	O
93	O
%	O
(	O
M.	O
catarrhalis	O
)	O
to	O
100	O
%	O
(	O
S.	O
pneumoniae	O
)	O
at	O
the	O
post-therapy	O
visit	O
.	O

All	O
but	O
one	O
of	O
the	O
265	O
patients	O
who	O
were	O
cured	O
or	O
improved	O
at	O
post-therapy	O
returned	O
for	O
a	O
long-term	O
follow-up	O
visit	O
;	O
243	O
(	O
92	O
%	O
)	O
remained	O
well	O
4	O
to	O
6	O
weeks	O
after	O
therapy	O
;	O
and	O
21	O
(	O
8	O
%	O
)	O
had	O
a	O
relapse	O
of	O
symptoms	O
.	O

Adverse	O
events	O
considered	O
to	O
be	O
related	O
to	O
levofloxacin	B-Chemical
administration	O
were	O
reported	O
by	O
29	O
patients	O
(	O
9	O
%	O
)	O
.	O

The	O
most	O
common	O
drug-related	O
adverse	O
events	O
were	O
diarrhea	B-Disease
,	O
flatulence	B-Disease
,	O
and	O
nausea	B-Disease
;	O
most	O
adverse	O
events	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
levofloxacin	B-Chemical
500	O
mg	O
once	O
daily	O
is	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
acute	O
bacterial	O
sinusitis	B-Disease
.	O

Clinical	O
evaluation	O
on	O
combined	O
administration	O
of	O
oral	O
prostacyclin	B-Chemical
analogue	O
beraprost	B-Chemical
and	O
phosphodiesterase	O
inhibitor	O
cilostazol	B-Chemical
.	O

Among	O
various	O
oral	O
antiplatelets	O
,	O
a	O
combination	O
of	O
a	O
novel	O
prostacyclin	B-Chemical
analogue	O
beraprost	B-Chemical
(	O
BPT	B-Chemical
)	O
and	O
a	O
potent	O
phosphodiesterase	O
inhibitor	O
cilostazol	B-Chemical
(	O
CLZ	B-Chemical
)	O
may	O
result	O
in	O
untoward	O
clinical	O
effects	O
due	O
to	O
possible	O
synergistic	O
elevation	O
of	O
intracellular	O
cAMP	B-Chemical
(	O
cyclic	B-Chemical
adenosine	I-Chemical
3',5'-monophosphate	I-Chemical
)	O
.	O

Thereby	O
,	O
a	O
clinical	O
study	O
of	O
the	O
combined	O
administration	O
of	O
the	O
two	O
agents	O
was	O
attempted	O
.	O

Twelve	O
healthy	O
volunteers	O
were	O
assigned	O
to	O
take	O
BPT/CLZ	B-Chemical
in	O
the	O
following	O
schedule	O
;	O
BPT	O
:	O
40	O
micrograms	O
at	O
day	O
1	O
and	O
120	O
micrograms	O
t.i.d	O
.	O

from	O
day	O
7	O
to	O
14	O
,	O
CLZ	B-Chemical
:	O
200	O
mg	O
t.i.d	O
.	O

from	O
day	O
3	O
to	O
14	O
.	O

At	O
various	O
time	O
intervals	O
,	O
physical	O
examination	O
and	O
blood	O
collection	O
for	O
ex	O
vivo	O
platelet	O
aggregation	O
and	O
determination	O
of	O
intraplatelet	O
cAMP	O
were	O
performed	O
.	O

Throughout	O
the	O
observation	O
period	O
,	O
no	O
significant	O
alteration	O
in	O
vital	O
signs	O
was	O
observed	O
.	O

Seven	O
out	O
of	O
12	O
subjects	O
experienced	O
headache	O
of	O
a	O
short	O
duration	O
accompanying	O
facial	O
flush	O
in	O
one	O
and	O
nausea	O
in	O
one	O
,	O
especially	O
after	O
ingestion	O
of	O
CLZ	O
.	O

All	O
of	O
these	O
symptoms	O
,	O
probably	O
caused	O
by	O
the	O
vasodilating	O
effect	O
of	O
the	O
two	O
agents	O
,	O
were	O
of	O
mild	O
degree	O
and	O
no	O
special	O
treatment	O
was	O
required	O
.	O

Intraplatelet	O
cAMP	O
content	O
was	O
gradually	O
but	O
significantly	O
increased	O
to	O
9.84	O
+/-	O
4.59	O
pmol	O
per	O
10	O
(	O
9	O
)	O
platelets	O
at	O
day	O
14	O
in	O
comparison	O
with	O
the	O
initial	O
value	O
(	O
6.87	O
+/-	O
2.25	O
pmol	O
)	O
.	O

The	O
platelet	O
aggregability	O
was	O
significantly	O
suppressed	O
at	O
various	O
time	O
intervals	O
but	O
no	O
additive	O
or	O
synergistic	O
inhibitory	O
effect	O
by	O
the	O
combined	O
administration	O
was	O
noted	O
.	O

In	O
conclusion	O
,	O
the	O
combined	O
administration	O
of	O
BPT/CLZ	B-Chemical
is	O
safe	O
at	O
doses	O
used	O
in	O
the	O
study	O
,	O
though	O
the	O
beneficial	O
clinical	O
effect	O
of	O
the	O
combined	O
administration	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Gastrointestinal	O
tolerability	O
of	O
etoricoxib	B-Chemical
in	O
rheumatoid	B-Disease
arthritis	I-Disease
patients	O
:	O
results	O
of	O
the	O
etoricoxib	B-Chemical
vs	O
diclofenac	B-Chemical
sodium	I-Chemical
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE-II	O
)	O
.	O

OBJECTIVE	O
:	O
A	O
randomised	O
,	O
double-blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
,	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
in	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
4086	O
patients	O
(	O
mean	O
age	O
60.8	O
years	O
)	O
diagnosed	O
with	O
RA	B-Disease
were	O
enrolled	O
and	O
received	O
etoricoxib	B-Chemical
90	O
mg	O
daily	O
(	O
n	O
=	O
2032	O
)	O
or	O
diclofenac	B-Chemical
75	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
2054	O
)	O
.	O

Use	O
of	O
gastroprotective	O
agents	O
and	O
low-dose	O
aspirin	B-Chemical
was	O
allowed	O
.	O

The	O
prespecified	O
primary	O
end	O
point	O
consisted	O
of	O
the	O
cumulative	O
rate	O
of	O
patient	O
discontinuations	O
due	O
to	O
clinical	O
and	O
laboratory	O
GI	O
adverse	O
experiences	O
(	O
AEs	O
)	O
.	O

General	O
safety	O
was	O
also	O
assessed	O
,	O
including	O
adjudicated	O
thrombotic	B-Disease
cardiovascular	I-Disease
event	O
data	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Patient	O
Global	O
Assessment	O
of	O
Disease	O
Status	O
(	O
PGADS	O
;	O
0-4	O
point	O
scale	O
)	O
.	O

RESULTS	O
:	O
Mean	O
(	O
SD	O
;	O
maximum	O
)	O
duration	O
of	O
treatment	O
was	O
19.3	O
(	O
10.3	O
;	O
32.9	O
)	O
and	O
19.1	O
(	O
10.4	O
;	O
33.1	O
)	O
months	O
in	O
the	O
etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
groups	O
,	O
respectively	O
.	O

The	O
cumulative	O
discontinuation	O
rate	O
due	O
to	O
GI	B-Disease
AEs	I-Disease
was	O
significantly	O
lower	O
with	O
etoricoxib	B-Chemical
than	O
diclofenac	B-Chemical
(	O
5.2	O
vs	O
8.5	O
events	O
per	O
100	O
patient-years	O
,	O
respectively	O
;	O
hazard	O
ratio	O
0.62	O
(	O
95	O
%	O
CI	O
:	O
0.47	O
,	O
0.81	O
;	O
p	O
<	O
or=0.001	O
)	O
)	O
.	O

The	O
incidence	O
of	O
discontinuations	O
for	O
hypertension-related	B-Disease
and	O
oedema-related	B-Disease
AEs	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-Chemical
(	O
2.5	O
%	O
and	O
1.1	O
%	O
respectively	O
)	O
compared	O
with	O
diclofenac	B-Chemical
(	O
1.5	O
%	O
and	O
0.4	O
%	O
respectively	O
;	O
p	O
<	O
0.001	O
for	O
hypertension	B-Disease
and	O
p	O
<	O
0.01	O
for	O
oedema	B-Disease
)	O
.	O

Etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
treatment	O
resulted	O
in	O
similar	O
efficacy	O
(	O
PGADS	O
mean	O
changes	O
from	O
baseline	O
-0.62	O
vs	O
-0.58	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
Etoricoxib	B-Chemical
90	O
mg	O
demonstrated	O
a	O
significantly	O
lower	O
risk	O
for	O
discontinuing	O
treatment	O
due	O
to	O
GI	B-Disease
AEs	I-Disease
compared	O
with	O
diclofenac	B-Chemical
150	O
mg.	O
Discontinuations	O
from	O
renovascular	O
AEs	I-Disease
,	O
although	O
less	O
common	O
than	O
discontinuations	O
from	O
GI	B-Disease
AEs	O
,	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-Chemical
.	O

Placebo-level	O
incidence	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
with	O
quetiapine	B-Chemical
in	O
controlled	O
studies	O
of	O
patients	O
with	O
bipolar	B-Disease
mania	I-Disease
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
,	O
including	O
akathisia	B-Disease
,	O
with	O
quetiapine	B-Chemical
in	O
patients	O
with	O
bipolar	B-Disease
mania	I-Disease
.	O

METHODS	O
:	O
Data	O
were	O
analyzed	O
from	O
four	O
similarly	O
designed	O
,	O
randomized	O
,	O
double-blind	O
,	O
3-	O
to	O
12-week	O
studies	O
.	O

Two	O
studies	O
evaluated	O
quetiapine	B-Chemical
monotherapy	O
(	O
up	O
to	O
800	O
mg/day	O
)	O
(	O
n	O
=	O
209	O
)	O
versus	O
placebo	O
(	O
n	O
=	O
198	O
)	O
,	O
with	O
lithium	B-Chemical
or	O
haloperidol	B-Chemical
monotherapy	O
as	O
respective	O
active	O
controls	O
.	O

Two	O
studies	O
evaluated	O
quetiapine	B-Chemical
(	O
up	O
to	O
800	O
mg/day	O
)	O
in	O
combination	O
with	O
a	O
mood	O
stabilizer	O
(	O
lithium	B-Chemical
or	O
divalproex	B-Chemical
,	O
QTP	B-Chemical
+	O
Li/DVP	B-Chemical
)	O
(	O
n	O
=	O
196	O
)	O
compared	O
to	O
placebo	O
and	O
mood	O
stabilizer	O
(	O
PBO	O
+	O
Li/DVP	B-Chemical
)	O
(	O
n	O
=	O
203	O
)	O
.	O

Extrapyramidal	O
symptoms	O
were	O
evaluated	O
using	O
the	O
Simpson-Angus	O
Scale	O
(	O
SAS	O
)	O
,	O
the	O
Barnes	O
Akathisia	O
Rating	O
Scale	O
(	O
BARS	O
)	O
,	O
adverse	O
event	O
reports	O
and	O
anticholinergic	B-Drug
drug	B-Drug
usage	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
EPS-related	O
adverse	O
events	O
,	O
including	O
akathisia	O
,	O
was	O
no	O
different	O
with	O
quetiapine	B-Drug
monotherapy	O
(	O
12.9	O
%	O
)	O
than	O
with	O
placebo	O
(	O
13.1	O
%	O
)	O
.	O

Similarly	O
,	O
EPS-related	O
adverse	O
events	O
with	O
QTP	O
+	O
Li/DVP	B-Chemical
(	O
21.4	O
%	O
)	O
were	O
no	O
different	O
than	O
with	O
PBO	O
+	O
Li/DVP	B-Chemical
(	O
19.2	O
%	O
)	O
.	O

Adverse	O
events	O
related	O
to	O
EPS	O
occurred	O
in	O
59.6	O
%	O
of	O
patients	O
treated	O
with	O
haloperidol	B-Drug
(	O
n	O
=	O
99	O
)	O
monotherapy	O
,	O
whereas	O
26.5	O
%	O
of	O
patients	O
treated	O
with	O
lithium	B-Drug
(	O
n	O
=	O
98	O
)	O
monotherapy	O
experienced	O
adverse	O
events	O
related	O
to	O
EPS	O
.	O

The	O
incidence	O
of	O
akathisia	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	B-Drug
monotherapy	O
(	O
3.3	O
%	O
)	O
and	O
placebo	O
(	O
6.1	O
%	O
)	O
,	O
and	O
with	O
QTP	O
+	O
Li/DVP	O
(	O
3.6	O
%	O
)	O
and	O
PBO	O
+	O
Li/DVP	O
(	O
4.9	O
%	O
)	O
.	O

Lithium	B-Drug
was	O
associated	O
with	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0.05	O
)	O
of	O
tremor	O
(	O
18.4	O
%	O
)	O
than	O
quetiapine	B-Drug
(	O
5.6	O
%	O
)	O
;	O
cerebellar	O
tremor	O
,	O
which	O
is	O
a	O
known	O
adverse	O
effect	O
of	O
lithium	B-Drug
,	O
may	O
have	O
contributed	O
to	O
the	O
elevated	O
rate	O
of	O
tremor	O
in	O
patients	O
receiving	O
lithium	B-Drug
therapy	O
.	O

Haloperidol	B-Drug
induced	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0.001	O
)	O
of	O
akathisia	O
(	O
33.3	O
%	O
versus	O
5.9	O
%	O
)	O
,	O
tremor	O
(	O
30.3	O
%	O
versus	O
7.8	O
%	O
)	O
,	O
and	O
extrapyramidal	O
syndrome	O
(	O
35.4	O
%	O
versus	O
5.9	O
%	O
)	O
than	O
quetiapine	B-Drug
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
quetiapine	B-Drug
and	O
placebo	O
on	O
SAS	O
and	O
BARS	O
scores	O
.	O

Anticholinergic	B-Drug
use	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	B-Drug
or	O
placebo	O
.	O

CONCLUSIONS	O
:	O
In	O
bipolar	O
mania	O
,	O
the	O
incidence	O
of	O
EPS	O
,	O
including	O
akathisia	O
,	O
with	O
quetiapine	B-Drug
therapy	O
is	O
similar	O
to	O
that	O
with	O
placebo	O
.	O

Contribution	O
of	O
the	O
sympathetic	O
nervous	O
system	O
to	O
salt-sensitivity	O
in	O
lifetime	O
captopril-treated	B-Chemical
spontaneously	O
hypertensive	B-Disease
rats	O
.	O

OBJECTIVE	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
,	O
in	O
lifetime	O
captopril-treated	B-Chemical
spontaneously	O
hypertensive	B-Disease
rats	O
(	O
SHR	O
)	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
importantly	O
to	O
the	O
hypertensive	B-Disease
effect	O
of	O
dietary	B-Chemical
sodium	I-Chemical
chloride	I-Chemical
supplementation	O
.	O

METHODS	O
:	O
Male	O
SHR	O
(	O
aged	O
6	O
weeks	O
)	O
that	O
had	O
been	O
treated	O
from	O
conception	O
onward	O
with	O
either	O
captopril	B-Chemical
or	O
vehicle	O
remained	O
on	O
a	O
basal	O
sodium	B-Chemical
chloride	I-Chemical
diet	O
or	O
were	O
fed	O
a	O
high	O
sodium	B-Chemical
chloride	I-Chemical
diet	O
.	O

After	O
2	O
weeks	O
,	O
the	O
rats	O
were	O
subjected	O
to	O
ganglionic	O
blockade	O
and	O
2	O
days	O
later	O
,	O
an	O
infusion	O
of	O
clonidine	B-Chemical
.	O

RESULTS	O
:	O
Lifetime	O
captopril	B-Chemical
treatment	O
significantly	O
lowered	O
mean	O
arterial	O
pressure	O
in	O
both	O
groups	O
.	O

Intravenous	O
infusion	O
of	O
the	O
ganglionic	O
blocker	O
hexamethonium	B-Chemical
resulted	O
in	O
a	O
rapid	O
decline	O
in	O
MAP	O
that	O
eliminated	O
the	O
dietary	B-Chemical
sodium	I-Chemical
chloride-induced	O
increase	O
in	O
MAP	O
in	O
both	O
groups	O
.	O

Infusion	O
of	O
the	O
central	O
nervous	O
system	O
alpha2-adrenergic	O
receptor	O
agonist	O
clonidine	B-Drug
also	O
resulted	O
in	O
a	O
greater	O
reduction	O
in	O
MAP	O
in	O
both	O
groups	O
of	O
SHR	O
that	O
were	O
fed	O
the	O
high	O
(	O
compared	O
with	O
the	O
basal	O
)	O
sodium	I-Chemical
chloride	O
diet	O
.	O

CONCLUSIONS	O
:	O
In	O
both	O
lifetime	O
captopril-treated	O
and	O
control	O
SHR	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
to	O
the	O
pressor	O
effects	O
of	O
a	O
high	O
sodium	O
chloride	O
diet	O
.	O

Dose-related	O
beneficial	O
and	O
adverse	O
effects	O
of	O
dietary	O
corticosterone	B-Chemical
on	O
organophosphorus-induced	B-Chemical
delayed	O
neuropathy	B-Disease
in	O
chickens	O
.	O

Tri-ortho-tolyl	B-Chemical
phosphate	I-Chemical
(	O
TOTP	B-Chemical
)	O
,	O
360	O
mg/kg	O
,	O
po	O
,	O
and	O
0,0'-diisopropyl	B-Chemical
phosphorofluoridate	I-Chemical
(	O
DFP	B-Chemical
)	O
,	O
1	O
mg/kg	O
sc	O
,	O
were	O
administered	O
to	O
adult	O
White	O
Leghorn	O
chickens	O
24	O
hr	O
after	O
they	O
were	O
placed	O
on	O
diets	O
containing	O
0	O
to	O
300	O
ppm	O
corticosterone	B-Chemical
.	O

Supplemented	O
diets	O
were	O
continued	O
until	O
clinical	O
signs	O
and	O
lesions	O
of	O
delayed	O
neuropathy	B-Disease
appeared	O
.	O

Although	O
low	O
concentrations	O
(	O
less	O
than	O
or	O
equal	O
to	O
50	O
ppm	O
)	O
of	O
corticosterone	B-Chemical
had	O
beneficial	O
effects	O
on	O
TOTP-induced	B-Chemical
neuropathy	B-Disease
,	O
greater	O
than	O
or	O
equal	O
to	O
200	O
ppm	O
exacerbated	O
clinical	O
signs	O
in	O
chickens	O
given	O
either	O
TOTP	B-Chemical
or	O
DFP	B-Chemical
.	O

Neurotoxic	B-Disease
esterase	O
activities	O
24	O
hr	O
after	O
TOTP	B-Chemical
or	O
DFP	B-Chemical
were	O
less	O
than	O
20	O
%	O
of	O
values	O
measured	O
in	O
chickens	O
not	O
given	O
organophosphorous	B-Chemical
compounds	O
.	O

Chickens	O
given	O
200	O
ppm	O
corticosterone	B-Chemical
without	O
TOTP	B-Chemical
or	O
DFP	B-Chemical
had	O
significantly	O
elevated	O
activity	O
of	O
plasma	O
cholinesterase	O
and	O
significantly	O
inhibited	O
activity	O
of	O
liver	O
carboxylesterase	O
.	O

Degenerating	B-Disease
myelinated	I-Disease
fibers	I-Disease
were	O
also	O
evident	O
in	O
distal	O
levels	O
of	O
the	O
peripheral	O
nerves	O
of	O
chickens	O
given	O
TOTP	B-Chemical
or	O
DFP	B-Chemical
.	O

In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Chemical
A2A/A1	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
animal	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Chemical
A	I-Chemical
(	I-Chemical
2A	I-Chemical
)	I-Chemical
/A	I-Chemical
(	I-Chemical
1	I-Chemical
)	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
several	O
animal	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
is	O
described	O
.	O

Discovery	O
and	O
scale-up	O
syntheses	O
of	O
compound	O
1	O
are	O
described	O
in	O
detail	O
,	O
highlighting	O
optimization	O
steps	O
that	O
increased	O
the	O
overall	O
yield	O
of	O
1	O
from	O
10.0	O
%	O
to	O
30.5	O
%	O
.	O

Compound	O
1	O
is	O
a	O
potent	O
A	O
(	O
2A	O
)	O
/A	O
(	O
1	O
)	O
receptor	O
antagonist	O
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4.1	O
nM	O
;	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17.0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
including	O
mouse	O
and	O
rat	O
models	O
of	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
,	O
mouse	O
model	O
of	O
reserpine-induced	B-Chemical
akinesia	B-Disease
,	O
rat	O
6-hydroxydopamine	B-Chemical
(	O
6-OHDA	B-Chemical
)	O
lesion	O
model	O
of	O
drug-induced	O
rotation	O
,	O
and	O
MPTP-treated	B-Chemical
non-human	O
primate	O
model	O
.	O

An	O
extremely	O
rare	O
case	O
of	O
delusional	B-Disease
parasitosis	I-Disease
in	O
a	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
patient	O
during	O
pegylated	B-Chemical
interferon	I-Chemical
alpha-2b	I-Chemical
and	O
ribavirin	B-Chemical
treatment	O
.	O

During	O
treatment	O
of	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
patients	O
with	O
interferon	O
and	O
ribavirin	B-Chemical
,	O
a	O
lot	O
of	O
side	O
effects	O
are	O
described	O
.	O

Twenty-three	O
percent	O
to	O
44	O
%	O
of	O
patients	O
develop	O
depression	B-Disease
.	O

A	O
minority	O
of	O
patients	O
evolve	O
to	O
psychosis	B-Disease
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
cases	O
of	O
psychogenic	B-Disease
parasitosis	I-Disease
occurring	O
during	O
interferon	O
therapy	O
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

We	O
present	O
a	O
49-year-old	O
woman	O
who	O
developed	O
a	O
delusional	B-Disease
parasitosis	I-Disease
during	O
treatment	O
with	O
pegylated	B-Chemical
interferon	I-Chemical
alpha-2b	I-Chemical
weekly	O
and	O
ribavirin	B-Chemical
.	O

She	O
complained	O
of	O
seeing	O
parasites	O
and	O
the	O
larvae	O
of	O
fleas	O
in	O
her	O
stools	O
.	O

This	O
could	O
not	O
be	O
confirmed	O
by	O
any	O
technical	O
examination	O
.	O

All	O
the	O
complaints	O
disappeared	O
after	O
stopping	O
pegylated	B-Chemical
interferon	I-Chemical
alpha-2b	I-Chemical
and	O
reappeared	O
after	O
restarting	O
it	O
.	O

She	O
had	O
a	O
complete	O
sustained	O
viral	O
response	O
.	O

Possible	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
.	O

A	O
74-year-old	O
man	O
with	O
depressive	B-Disease
symptoms	I-Disease
was	O
admitted	O
to	O
a	O
psychiatric	B-Disease
hospital	O
due	O
to	O
insomnia	B-Disease
,	O
loss	B-Disease
of	I-Disease
appetite	I-Disease
,	O
exhaustion	O
,	O
and	O
agitation	B-Disease
.	O

Medical	O
treatment	O
was	O
initiated	O
at	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
paroxetine	B-Chemical
and	O
1.2	O
mg	O
alprazolam	B-Chemical
.	O

On	O
the	O
10th	O
day	O
of	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
treatment	O
,	O
the	O
patient	O
exhibited	O
marked	O
psychomotor	B-Disease
retardation	I-Disease
,	O
disorientation	O
,	O
and	O
severe	O
muscle	B-Disease
rigidity	I-Disease
with	O
tremors	B-Disease
.	O

The	O
patient	O
had	O
a	O
fever	B-Disease
(	O
38.2	O
degrees	O
C	O
)	O
,	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165/90	O
and	O
130/70	O
mg	O
mm	O
Hg	O
)	O
,	O
and	O
severe	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O

Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
creatine	B-Chemical
phosphokinase	O
(	O
2218	O
IU/L	O
)	O
,	O
aspartate	B-Chemical
aminotransferase	O
(	O
134	O
IU/L	O
)	O
,	O
alanine	B-Chemical
aminotransferase	O
(	O
78	O
IU/L	O
)	O
,	O
and	O
BUN	O
(	O
27.9	O
mg/ml	O
)	O
levels	O
.	O

The	O
patient	O
received	O
bromocriptine	B-Chemical
and	O
diazepam	B-Chemical
to	O
treat	O
his	O
symptoms	O
.	O

7	O
days	O
later	O
,	O
the	O
fever	B-Disease
disappeared	O
and	O
the	O
patient	O
's	O
serum	O
CPK	O
levels	O
were	O
normalized	O
(	O
175	O
IU/L	O
)	O
.	O

This	O
patient	O
presented	O
with	O
symptoms	O
of	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
(	O
NMS	B-Disease
)	O
,	O
thus	O
demonstrating	O
that	O
NMS-like	B-Disease
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
treatment	O
.	O

The	O
adverse	O
drug	B-Drug
reaction	O
score	O
obtained	O
by	O
the	O
Naranjo	O
algorithm	O
was	O
6	O
in	O
our	O
case	O
,	O
indicating	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
's	O
NMS-like	B-Disease
adverse	O
symptoms	O
and	O
the	O
combined	O
treatment	O
used	O
in	O
this	O
case	O
.	O

The	O
involvement	O
of	O
physiologic	O
and	O
environmental	O
aspects	O
specific	O
to	O
this	O
patient	O
was	O
suspected	O
.	O

Several	O
risk	O
factors	O
for	O
NMS	B-Disease
should	O
be	O
noted	O
in	O
elderly	O
depressive	B-Disease
patients	O
whose	O
symptoms	O
often	O
include	O
dehydration	B-Disease
,	O
agitation	B-Disease
,	O
malnutrition	B-Disease
,	O
and	O
exhaustion	O
.	O

Careful	O
therapeutic	O
intervention	O
is	O
necessary	O
in	O
cases	O
involving	O
elderly	O
patients	O
who	O
suffer	O
from	O
depression	B-Disease
.	O

Pilocarpine	B-Chemical
seizures	B-Disease
cause	O
age-dependent	O
impairment	B-Disease
in	I-Disease
auditory	I-Disease
location	I-Disease
discrimination	I-Disease
.	O

Children	O
who	O
have	O
status	B-Disease
epilepticus	I-Disease
have	O
continuous	O
or	O
rapidly	O
repeating	O
seizures	B-Disease
that	O
may	O
be	O
life-threatening	O
and	O
may	O
cause	O
life-long	O
changes	O
in	O
brain	O
and	O
behavior	O
.	O

The	O
extent	O
to	O
which	O
status	B-Disease
epilepticus	I-Disease
causes	O
deficits	B-Disease
in	I-Disease
auditory	I-Disease
discrimination	I-Disease
is	O
unknown	O
.	O

A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	B-Disease
epilepticus	I-Disease
.	O

Male	O
Sprague-Dawley	O
rats	O
were	O
injected	O
with	O
saline	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
20	O
,	O
or	O
a	O
convulsant	O
dose	O
of	O
pilocarpine	B-Chemical
on	O
P20	O
or	O
P45	O
.	O

Pilocarpine	B-Chemical
on	O
either	O
day	O
induced	O
status	B-Disease
epilepticus	I-Disease
;	O
status	B-Disease
epilepticus	I-Disease
at	O
P45	O
resulted	O
in	O
CA3	O
cell	O
loss	O
and	O
spontaneous	O
seizures	B-Disease
,	O
whereas	O
P20	O
rats	O
had	O
no	O
cell	O
loss	O
or	O
spontaneous	O
seizures	B-Disease
.	O

Mature	O
rats	O
were	O
trained	O
with	O
sound-source	O
location	O
and	O
sound-silence	O
discriminations	O
.	O

Control	O
(	O
saline	O
P20	O
)	O
rats	O
acquired	O
both	O
discriminations	O
immediately	O
.	O

In	O
status	B-Disease
epilepticus	I-Disease
(	O
P20	O
)	O
rats	O
,	O
acquisition	O
of	O
the	O
sound-source	O
location	O
discrimination	O
was	O
moderately	O
impaired	O
.	O

Status	B-Disease
epilepticus	I-Disease
(	O
P45	O
)	O
rats	O
failed	O
to	O
acquire	O
either	O
sound-source	O
location	O
or	O
sound-silence	O
discriminations	O
.	O

Status	B-Disease
epilepticus	I-Disease
in	I-Disease
rat	O
causes	O
an	O
age-dependent	O
,	O
long-term	O
impairment	B-Disease
in	I-Disease
auditory	I-Disease
discrimination	I-Disease
.	O

This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	B-Disease
auditory	I-Disease
location	I-Disease
discrimination	O
in	O
humans	O
.	O

Cardiovascular	O
risk	O
with	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
:	O
general	O
problem	O
with	O
substance	O
specific	O
differences	O
?	O
Randomised	O
clinical	O
trials	O
and	O
observational	O
studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
,	O
stroke	B-Disease
,	O
hypertension	B-Disease
and	O
heart	B-Disease
failure	I-Disease
during	O
treatment	O
with	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
.	O

Adverse	O
cardiovascular	O
effects	O
occurred	O
mainly	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
patients	O
with	O
concomitant	O
risk	O
factors	O
.	O

Cyclooxygenase	B-Chemical
inhibitors	I-Chemical
cause	O
complex	O
changes	O
in	O
renal	O
,	O
vascular	O
and	O
cardiac	O
prostanoid	O
profiles	O
thereby	O
increasing	O
vascular	O
resistance	O
and	O
fluid	O
retention	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
adverse	O
events	O
tends	O
to	O
increase	O
with	O
the	O
daily	O
dose	O
and	O
total	O
exposure	O
time	O
.	O

A	O
comparison	O
of	O
individual	O
selective	O
and	O
unselective	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
suggests	O
substance-specific	O
differences	O
,	O
which	O
may	O
depend	O
on	O
differences	O
in	O
pharmacokinetic	O
parameters	O
or	O
inhibitory	O
potency	O
and	O
may	O
be	O
contributed	O
by	O
prostaglandin-independent	B-Chemical
effects	O
.	O

Diagnostic	O
markers	O
such	O
as	O
N-terminal	B-Chemical
pro	I-Chemical
brain	I-Chemical
natriuretic	I-Chemical
peptide	I-Chemical
(	O
NT-proBNP	B-Chemical
)	O
or	O
high-sensitive	O
C-reactive	O
protein	O
might	O
help	O
in	O
the	O
early	O
identification	O
of	O
patients	O
at	O
risk	O
,	O
thus	O
avoiding	O
the	O
occurrence	O
of	O
serious	O
cardiovascular	B-Disease
toxicity	I-Disease
.	O

Predictors	O
of	O
decreased	B-Disease
renal	I-Disease
function	I-Disease
in	O
patients	O
with	O
heart	B-Disease
failure	I-Disease
during	O
angiotensin-converting	B-Chemical
enzyme	O
inhibitor	O
therapy	O
:	O
results	O
from	O
the	O
studies	O
of	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
(	O
SOLVD	O
)	O
BACKGROUND	O
:	O
Although	O
angiotensin-converting	B-Chemical
enzyme	O
inhibitor	O
therapy	O
reduces	O
mortality	O
rates	O
in	O
patients	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
(	O
CHF	B-Disease
)	O
,	O
it	O
may	O
also	O
cause	O
decreased	B-Disease
renal	I-Disease
function	I-Disease
.	O

Little	O
information	O
is	O
available	O
to	O
predict	O
which	O
patients	O
are	O
at	O
highest	O
risk	O
for	O
this	O
complication	O
.	O

OBJECTIVE	O
:	O
To	O
quantify	O
specific	O
clinical	O
predictors	O
of	O
reduction	B-Disease
in	I-Disease
renal	I-Disease
function	I-Disease
in	O
patients	O
with	O
CHF	B-Disease
who	O
are	O
prescribed	O
angiotensin-converting	B-Chemical
enzyme	O
inhibitor	O
therapy	O
.	O

METHOD	O
:	O
We	O
analyzed	O
data	O
from	O
the	O
Studies	O
of	O
Left	B-Disease
Ventricular	I-Disease
Dysfunction	I-Disease
(	O
SOLVD	O
)	O
,	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
enalapril	B-Chemical
for	O
the	O
treatment	O
of	O
CHF	B-Disease
.	O

There	O
were	O
3379	O
patients	O
randomly	O
assigned	O
to	O
enalapril	B-Chemical
with	O
a	O
median	O
follow-up	O
of	O
974	O
days	O
and	O
3379	O
patients	O
randomly	O
assigned	O
to	O
placebo	O
with	O
a	O
mean	O
follow-up	O
of	O
967	O
days	O
.	O

Decreased	B-Disease
renal	I-Disease
function	I-Disease
was	O
defined	O
as	O
a	O
rise	O
in	O
serum	O
creatinine	B-Chemical
>	O
/=0.5	O
mg/dL	O
(	O
44	O
micromol/L	O
)	O
from	O
baseline	O
.	O

We	O
used	O
time-to-event	O
analysis	O
to	O
identify	O
potential	O
predictors	O
of	O
decrease	O
in	O
renal	O
function	O
including	O
age	O
,	O
baseline	O
ejection	O
fraction	O
,	O
baseline	O
creatinine	B-Chemical
,	O
low	O
systolic	O
blood	O
pressure	O
(	O
<	O
100	O
mm	O
Hg	O
)	O
,	O
history	O
of	O
hypertension	B-Disease
,	O
diabetes	B-Disease
,	O
and	O
use	O
of	O
antiplatelet	O
,	O
diuretic	B-Chemical
,	O
and	O
beta-blocker	O
therapy	O
.	O

RESULTS	O
:	O
Patients	O
randomly	O
assigned	O
to	O
enalapril	B-Chemical
had	O
a	O
33	O
%	O
greater	O
likelihood	O
of	O
decreased	B-Disease
renal	I-Disease
function	I-Disease
than	O
controls	O
(	O
P	O
=.003	O
)	O
.	O

By	O
multivariate	O
analysis	O
,	O
in	O
both	O
the	O
placebo	O
and	O
enalapril	B-Chemical
groups	O
older	O
age	O
,	O
diuretic	B-Chemical
therapy	O
,	O
and	O
diabetes	B-Disease
were	O
associated	O
with	O
decreased	B-Disease
renal	I-Disease
function	I-Disease
,	O
whereas	O
beta-blocker	O
therapy	O
and	O
higher	O
ejection	O
fraction	O
were	O
renoprotective	O
.	O

Older	O
age	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
developing	O
decreased	B-Disease
renal	I-Disease
function	I-Disease
in	O
both	O
groups	O
,	O
but	O
significantly	O
more	O
so	O
in	O
the	O
enalapril	B-Chemical
group	O
(	O
enalapril	B-Chemical
:	O
risk	O
ratio	O
[	O
RR	B-Drug
]	O
1.42	O
per	O
10	O
years	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.32-1.52	O
with	O
enalapril	B-Chemical
;	O
placebo	O
:	O
RR	B-Drug
1.18	O
,	O
95	O
%	O
CI	O
1.12-1.25	O
)	O
.	O

Diuretic	B-Chemical
therapy	O
was	O
likewise	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
decreased	B-Disease
renal	I-Disease
function	I-Disease
in	O
the	O
enalapril	B-Chemical
group	O
(	O
RR	B-Drug
1.89	O
,	O
95	O
%	O
CI	O
1.70-2.08	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
RR	B-Drug
1.35	O
,	O
95	O
%	O
CI	O
1.09-1.66	O
)	O
.	O

Conversely	O
,	O
enalapril	B-Chemical
had	O
a	O
relative	O
renoprotective	O
effect	O
(	O
RR	B-Drug
1.33	O
,	O
95	O
%	O
CI	O
1.13-1.53	O
)	O
compared	O
with	O
placebo	O
(	O
RR	B-Drug
1.96	O
,	O
95	O
%	O
CI	O
1.57-2.44	O
)	O
in	O
patients	O
with	O
diabetes	B-Disease
.	O

A	O
lower	O
risk	O
of	O
renal	B-Disease
impairment	I-Disease
was	O
seen	O
in	O
both	O
groups	O
with	O
beta-blocker	O
therapy	O
(	O
RR	B-Drug
0.70	O
,	O
95	O
%	O
CI	O
0.57-0.85	O
)	O
and	O
higher	O
baseline	O
ejection	O
fraction	O
(	O
RR	B-Drug
0.93	O
per	O
5	O
%	O
increment	O
,	O
95	O
%	O
CI	O
0.91-0	O
.	O

96	O
)	O
.	O

CONCLUSIONS	O
:	O
Enalapril	B-Chemical
use	O
caused	O
a	O
33	O
%	O
increase	O
in	O
the	O
risk	O
of	O
decreased	B-Disease
renal	I-Disease
function	I-Disease
in	O
patients	O
with	O
CHF	B-Disease
.	O

Diuretic	B-Chemical
use	O
and	O
advanced	O
age	O
increased	O
this	O
risk	O
.	O

Diabetes	B-Disease
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
renal	B-Disease
impairment	I-Disease
in	O
all	O
patients	O
with	O
CHF	B-Disease
,	O
but	O
this	O
risk	O
was	O
reduced	O
in	O
the	O
enalapril	B-Chemical
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

beta-Blocker	O
therapy	O
and	O
higher	O
ejection	O
fraction	O
were	O
renoprotective	O
in	O
all	O
patients	O
regardless	O
of	O
therapy	O
.	O

Pemoline	B-Chemical
induced	O
acute	O
choreoathetosis	B-Disease
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

BACKGROUND	O
:	O
Pemoline	B-Chemical
is	O
an	O
oxazolidine	B-Chemical
derivative	O
that	O
is	O
structurally	O
different	O
from	O
amphetamines	B-Chemical
and	O
used	O
in	O
the	O
treatment	O
of	O
attention	B-Disease
deficit	I-Disease
disorder	I-Disease
.	O

Pemoline	B-Chemical
has	O
not	O
been	O
commonly	O
associated	O
in	O
the	O
literature	O
as	O
a	O
cause	O
of	O
acute	O
movement	B-Disease
disorders	I-Disease
.	O

The	O
following	O
case	O
describes	O
two	O
children	O
acutely	O
poisoned	O
with	O
pemoline	B-Chemical
who	O
experienced	O
profound	O
choreoathetosis	B-Disease
.	O

CASE	O
REPORT	O
:	O
Two	O
,	O
3-year-old	O
male	O
,	O
identical	O
twin	O
siblings	O
presented	O
to	O
the	O
emergency	O
department	O
after	O
found	O
playing	O
with	O
a	O
an	O
empty	O
bottle	O
of	O
pemoline	B-Chemical
originally	O
containing	O
59	O
tablets	O
.	O

The	O
children	O
had	O
a	O
medical	O
history	O
significant	O
for	O
attention	B-Disease
deficit	I-Disease
disorder	I-Disease
previously	O
treated	O
with	O
methylphenidate	B-Chemical
without	O
success	O
.	O

This	O
was	O
their	O
first	O
day	O
of	O
pemoline	B-Chemical
therapy	O
.	O

The	O
choreoathetoid	B-Disease
movements	B-Disease
began	O
45	O
min	O
to	O
1	O
h	O
after	O
ingestion	O
.	O

The	O
children	O
gave	O
no	O
history	O
of	O
prior	O
movement	B-Disease
disorders	I-Disease
and	O
there	O
was	O
no	O
family	O
history	O
of	O
movement	B-Disease
disorders	O
.	O

The	O
children	O
received	O
gastrointestinal	O
decontamination	O
and	O
high	O
doses	O
of	O
intravenous	O
benzodiazepines	B-Chemical
in	O
an	O
attempt	O
to	O
control	O
the	O
choreoathetoid	B-Disease
movements	O
.	O

Despite	O
treatment	O
,	O
the	O
children	O
continued	O
to	O
have	O
choreoathetosis	B-Disease
for	O
approximately	O
24	O
hours	O
.	O

Forty-eight	O
hours	O
after	O
admission	O
,	O
the	O
children	O
appeared	O
to	O
be	O
at	O
their	O
baseline	O
and	O
were	O
discharged	O
home	O
.	O

CONCLUSION	O
:	O
Pemoline	B-Chemical
associated	O
movement	B-Disease
disorder	I-Disease
has	O
been	O
rarely	O
reported	O
in	O
the	O
acute	O
toxicology	O
literature	O
.	O

The	O
possibility	O
of	O
choreoathetoid	B-Disease
movements	O
should	O
be	O
considered	O
in	O
patients	O
presenting	O
after	O
pemoline	B-Chemical
overdose	B-Disease
.	O

Continuous	O
subcutaneous	O
administration	O
of	O
mesna	B-Chemical
to	O
prevent	O
ifosfamide-induced	B-Chemical
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

Hemorrhagic	B-Disease
cystitis	I-Disease
is	O
a	O
major	O
potential	O
toxicity	O
of	O
ifosfamide	B-Drug
that	O
can	O
be	O
prevented	O
by	O
administering	O
mesna	O
along	O
with	O
the	O
cytotoxic	O
agent	O
.	O

Mesna	O
is	O
generally	O
administered	O
by	O
the	O
intravenous	O
route	O
,	O
although	O
experience	O
with	O
oral	O
delivery	O
of	O
the	O
drug	B-Drug
has	O
increased	O
.	O

The	O
continuous	O
subcutaneous	O
administration	O
of	O
mesna	O
has	O
the	O
advantage	O
of	O
not	O
requiring	O
intravenous	O
access	O
.	O

In	O
addition	O
,	O
subcutaneous	O
delivery	O
of	O
the	O
neutralizing	O
agent	O
will	O
not	O
be	O
associated	O
with	O
the	O
risk	O
of	O
inadequate	O
urinary	O
mesna	O
concentrations	O
,	O
such	O
as	O
in	O
a	O
patient	O
taking	O
oral	O
mesna	O
who	O
experiences	O
severe	O
ifosfamide-induced	O
emesis	O
and	O
is	O
unable	O
to	O
absorb	O
the	O
drug	B-Drug
.	O

Limited	O
clinical	O
experience	O
with	O
continuous	O
subcutaneous	O
mesna	O
administration	O
suggests	O
it	O
is	O
a	O
safe	O
,	O
practical	O
,	O
and	O
economic	O
method	O
of	O
drug	B-Drug
delivery	O
that	O
permits	O
ifosfamide	B-Drug
to	O
be	O
administered	O
successfully	O
in	O
the	O
outpatient	O
setting	O
.	O

Modification	O
of	O
drug	B-Drug
action	O
by	O
hyperammonemia	B-Disease
.	O

Pretreatment	O
with	O
ammonium	B-Chemical
acetate	I-Chemical
(	O
NH4Ac	B-Chemical
)	O
(	O
6	O
mmol/kg	O
s.c.	O
)	O
approximately	O
doubled	O
the	O
time	O
morphine-treated	B-Chemical
mice	O
remained	O
on	O
a	O
hot	O
surface	O
and	O
similarly	O
increased	O
muscular	O
incoordination	B-Disease
by	O
diazepam	B-Chemical
,	O
but	O
NH4Ac	B-Chemical
treatment	O
alone	O
had	O
no	O
effect	O
.	O

Thus	O
,	O
hyperammonemia	B-Disease
is	O
capable	O
of	O
altering	O
drug	B-Drug
action	O
and	O
must	O
be	O
considered	O
along	O
with	O
impaired	O
drug	B-Drug
metabolism	O
in	O
enhanced	O
drug	B-Drug
responses	O
associated	O
with	O
liver	B-Disease
disease	I-Disease
.	O

Experiments	O
in	O
vitro	O
showed	O
that	O
acetylcholine-induced	B-Chemical
catecholamine	B-Chemical
release	O
from	O
bovine	O
adrenal	O
medulla	O
is	O
depressed	O
as	O
much	O
as	O
50	O
%	O
by	O
0.3	O
mM	O
NH4Ac	B-Chemical
and	O
KCl-induced	B-Chemical
contractions	O
of	O
guinea-pig	O
ileum	O
were	O
inhibited	O
20	O
%	O
by	O
5	O
mM	O
NH4Ac	B-Chemical
.	O

Addition	O
of	O
excess	O
calcium	B-Chemical
reversed	O
the	O
depression	B-Disease
in	O
both	O
tissues	O
,	O
but	O
calcium-independent	B-Chemical
catecholamine	B-Chemical
release	O
by	O
acetaldehyde	B-Chemical
was	O
not	O
blocked	O
by	O
NH4Ac	B-Chemical
.	O

These	O
results	O
suggested	O
that	O
ammonia	B-Chemical
blocks	O
calcium	B-Chemical
channels	O
.	O

Parallels	O
in	O
the	O
actions	O
of	O
NH4Ac	B-Chemical
and	O
the	O
calcium	B-Chemical
channel	O
blocker	O
verapamil	B-Chemical
support	O
this	O
concept	O
.	O

Both	O
verapamil	B-Chemical
(	O
10	O
mg/kg	O
i.p	O
.	O

)	O
and	O
NH4Ac	B-Chemical
pretreatment	O
enhanced	O
morphine	B-Chemical
analgesia-	B-Disease
and	O
diazepam-induced	B-Chemical
muscular	O
incoordination	B-Disease
and	O
antagonized	O
amphetamine-induced	B-Chemical
motor	O
activity	O
,	O
and	O
neither	O
verapamil	B-Chemical
nor	O
NH4Ac	B-Chemical
affected	O
the	O
convulsant	O
action	O
of	O
metrazol	B-Chemical
.	O

The	O
data	O
suggest	O
that	O
hyperammonemia	B-Disease
exerts	O
a	O
calcium	B-Chemical
channel	O
blocking	O
action	O
which	O
enhances	O
the	O
effects	O
of	O
central	O
nervous	O
system	O
depressants	O
and	O
certain	O
opioid	O
analgesics	O
.	O

Risk	O
of	O
nephropathy	B-Disease
after	O
consumption	O
of	O
nonionic	O
contrast	B-Chemical
media	I-Chemical
by	O
children	O
undergoing	O
cardiac	O
angiography	O
:	O
a	O
prospective	O
study	O
.	O

Despite	O
increasing	O
reports	O
on	O
nonionic	O
contrast	B-Chemical
media-induced	O
nephropathy	O
(	O
CIN	O
)	O
in	O
hospitalized	O
adult	O
patients	O
during	O
cardiac	O
procedures	O
,	O
the	O
studies	O
in	O
pediatrics	O
are	O
limited	O
,	O
with	O
even	O
less	O
focus	O
on	O
possible	O
predisposing	O
factors	O
and	O
preventive	O
measures	O
for	O
patients	O
undergoing	O
cardiac	O
angiography	O
.	O

This	O
prospective	O
study	O
determined	O
the	O
incidence	O
of	O
CIN	O
for	O
two	O
nonionic	O
contrast	B-Chemical
media	O
(	O
CM	O
)	O
,	O
iopromide	O
and	O
iohexol	O
,	O
among	O
80	O
patients	O
younger	O
than	O
18	O
years	O
and	O
compared	O
the	O
rates	O
for	O
this	O
complication	O
in	O
relation	O
to	O
the	O
type	O
and	O
dosage	O
of	O
CM	O
and	O
the	O
presence	O
of	O
cyanosis	O
.	O

The	O
80	O
patients	O
in	O
the	O
study	O
consecutively	O
received	O
either	O
iopromide	O
(	O
group	O
A	O
,	O
n	O
=	O
40	O
)	O
or	O
iohexol	O
(	O
group	O
B	O
,	O
n	O
=	O
40	O
)	O
.	O

Serum	O
sodium	O
(	O
Na	O
)	O
,	O
potassium	B-Drug
(	O
K	O
)	O
,	O
and	O
creatinine	O
(	O
Cr	O
)	O
were	O
measured	O
24	O
h	O
before	O
angiography	O
as	O
baseline	O
values	O
,	O
then	O
measured	O
again	O
at	O
12-	O
,	O
24-	O
,	O
and	O
48-h	O
intervals	O
after	O
CM	O
use	O
.	O

Urine	O
samples	O
for	O
Na	O
and	O
Cr	O
also	O
were	O
checked	O
at	O
the	O
same	O
intervals	O
.	O

Risk	O
of	O
renal	O
failure	O
,	O
Injury	O
to	O
the	O
kidney	O
,	O
Failure	O
of	O
kidney	O
function	O
,	O
Loss	O
of	O
kidney	O
function	O
,	O
and	O
End-stage	O
renal	O
damage	O
(	O
RIFLE	O
criteria	O
)	O
were	O
used	O
to	O
define	O
CIN	O
and	O
its	O
incidence	O
in	O
the	O
study	O
population	O
.	O

Accordingly	O
,	O
among	O
the	O
15	O
CIN	O
patients	O
(	O
18.75	O
%	O
)	O
,	O
7.5	O
%	O
of	O
the	O
patients	O
in	O
group	O
A	O
had	O
increased	O
risk	O
and	O
3.75	O
%	O
had	O
renal	O
injury	O
,	O
whereas	O
5	O
%	O
of	O
group	O
B	O
had	O
increased	O
risk	O
and	O
2.5	O
%	O
had	O
renal	O
injury	O
.	O

Whereas	O
33.3	O
%	O
of	O
the	O
patients	O
with	O
CIN	O
were	O
among	O
those	O
who	O
received	O
the	O
proper	O
dosage	O
of	O
CM	O
,	O
the	O
percentage	O
increased	O
to	O
66.6	O
%	O
among	O
those	O
who	O
received	O
larger	O
doses	O
,	O
with	O
a	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
CIN	O
related	O
to	O
the	O
different	O
dosages	O
of	O
CM	O
(	O
p	O
=	O
0.014	O
)	O
.	O

Among	O
the	O
15	O
patients	O
with	O
CIN	O
,	O
6	O
had	O
cyanotic	O
congenital	O
heart	O
diseases	O
,	O
but	O
the	O
incidence	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
for	O
the	O
noncyanotic	O
patients	O
(	O
p	O
=	O
0.243	O
)	O
.	O

Although	O
clinically	O
silent	O
,	O
CIN	O
is	O
not	O
rare	O
in	O
pediatrics	O
.	O

The	O
incidence	O
depends	O
on	O
dosage	O
but	O
not	O
on	O
the	O
type	O
of	O
consumed	O
nonionic	O
CM	O
,	O
nor	O
on	O
the	O
presence	O
of	O
cyanosis	O
,	O
and	O
although	O
CIN	O
usually	O
is	O
reversible	O
,	O
more	O
concern	O
is	O
needed	O
for	O
the	O
prevention	O
of	O
such	O
a	O
complication	O
in	O
children	O
.	O

A	O
case	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
related	O
to	O
caffeine	B-Chemical
pretreatment	O
.	O

Suboptimal	O
seizure	B-Disease
duration	O
is	O
commonly	O
encountered	O
in	O
electroconvulsive	O
therapy	O
practice	O
,	O
especially	O
in	O
older	O
patients	O
with	O
higher	O
seizure	B-Disease
thresholds	O
.	O

Intravenous	O
caffeine	B-Chemical
is	O
commonly	O
used	O
to	O
improve	O
seizure	B-Disease
duration	O
and	O
quality	O
in	O
such	O
patients	O
and	O
is	O
generally	O
well	O
tolerated	O
aside	O
from	O
occasional	O
reports	O
of	O
relatively	O
benign	O
ventricular	B-Disease
ectopy	I-Disease
.	O

We	O
describe	O
a	O
patient	O
with	O
no	O
previous	O
history	O
of	O
cardiac	B-Disease
disease	I-Disease
or	O
arrhythmia	B-Disease
who	O
developed	O
sustained	O
bigeminy	O
and	O
2	O
brief	O
runs	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
after	O
caffeine	B-Chemical
administration	O
.	O

Although	O
intravenous	O
caffeine	B-Chemical
is	O
generally	O
well	O
tolerated	O
,	O
the	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
unpredictable	O
and	O
serious	O
ventricular	B-Disease
arrhythmias	I-Disease
.	O

Optical	O
coherence	O
tomography	O
can	O
measure	O
axonal	O
loss	O
in	O
patients	O
with	O
ethambutol-induced	B-Chemical
optic	B-Disease
neuropathy	I-Disease
.	O

PURPOSE	O
:	O
To	O
map	O
and	O
identify	O
the	O
pattern	O
,	O
in	O
vivo	O
,	O
of	O
axonal	B-Disease
degeneration	I-Disease
in	O
ethambutol-induced	B-Chemical
optic	B-Disease
neuropathy	I-Disease
using	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
.	O

Ethambutol	B-Chemical
is	O
an	O
antimycobacterial	O
agent	O
often	O
used	O
to	O
treat	O
tuberculosis	B-Disease
.	O

A	O
serious	O
complication	O
of	O
ethambutol	B-Chemical
is	O
an	O
optic	B-Disease
neuropathy	I-Disease
that	O
impairs	O
visual	O
acuity	O
,	O
contrast	O
sensitivity	O
,	O
and	O
color	O
vision	O
.	O

However	O
,	O
early	O
on	O
,	O
when	O
the	O
toxic	O
optic	B-Disease
neuropathy	I-Disease
is	O
mild	O
and	O
partly	O
reversible	O
,	O
the	O
funduscopic	O
findings	O
are	O
often	O
subtle	O
and	O
easy	O
to	O
miss	O
.	O

METHODS	O
:	O
Three	O
subjects	O
with	O
a	O
history	O
of	O
ethambutol	B-Chemical
(	O
EMB	B-Chemical
)	O
-induced	O
optic	B-Disease
neuropathy	I-Disease
of	O
short-	O
,	O
intermediate-	O
,	O
and	O
long-term	O
visual	B-Disease
deficits	I-Disease
were	O
administered	O
a	O
full	O
neuro-ophthalmologic	O
examination	O
including	O
visual	O
acuity	O
,	O
color	O
vision	O
,	O
contrast	O
sensitivity	O
,	O
and	O
fundus	O
examination	O
.	O

In	O
addition	O
,	O
OCT	O
(	O
OCT	O
3000	O
,	O
Humphrey-Zeiss	O
,	O
Dublin	O
,	O
CA	O
)	O
was	O
performed	O
on	O
both	O
eyes	O
of	O
each	O
subject	O
using	O
the	O
retinal	O
nerve	O
fiber	O
layer	O
(	O
RNFL	O
)	O
analysis	O
protocol	O
.	O

OCT	O
interpolates	O
data	O
from	O
100	O
points	O
around	O
the	O
optic	O
nerve	O
to	O
effectively	O
map	O
out	O
the	O
RNFL	O
.	O

RESULTS	O
:	O
The	O
results	O
were	O
compared	O
to	O
the	O
calculated	O
average	O
RNFL	O
of	O
normal	O
eyes	O
accumulated	O
from	O
four	O
prior	O
studies	O
using	O
OCT	O
,	O
n=661	O
.	O

In	O
all	O
subjects	O
with	O
history	O
of	O
EMB-induced	B-Chemical
optic	B-Disease
neuropathy	I-Disease
,	O
there	O
was	O
a	O
mean	O
loss	O
of	O
72	O
%	O
nerve	O
fiber	O
layer	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
(	O
patient	O
A	O
,	O
with	O
eventual	O
recovery	O
of	O
visual	B-Disease
acuity	O
and	O
fields	O
,	O
58	O
%	O
loss	O
;	O
patient	O
B	O
,	O
with	O
intermediate	O
visual	B-Disease
deficits	I-Disease
,	O
68	O
%	O
loss	O
;	O
patient	O
C	O
,	O
with	O
chronic	O
visual	B-Disease
deficits	I-Disease
,	O
90	O
%	O
loss	O
)	O
,	O
with	O
an	O
average	O
mean	O
optic	O
nerve	O
thickness	O
of	O
26+/-16	O
microm	O
.	O

There	O
was	O
a	O
combined	O
mean	O
loss	O
of	O
46	O
%	O
of	O
fibers	O
from	O
the	O
superior	O
,	O
inferior	O
,	O
and	O
nasal	O
quadrants	O
in	O
the	O
(	O
six	O
)	O
eyes	O
of	O
all	O
three	O
subjects	O
(	O
mean	O
average	O
thickness	O
of	O
55+/-29	O
microm	O
)	O
.	O

In	O
both	O
sets	O
(	O
four	O
)	O
of	O
eyes	O
of	O
the	O
subjects	O
with	O
persistent	O
visual	B-Disease
deficits	O
(	O
patients	O
B	O
and	O
C	O
)	O
,	O
there	O
was	O
an	O
average	O
loss	O
of	O
79	O
%	O
of	O
nerve	O
fiber	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
.	O

CONCLUSIONS	O
:	O
The	O
OCT	O
results	O
in	O
these	O
patients	O
with	O
EMB-induced	B-Chemical
optic	B-Disease
neuropathy	I-Disease
show	O
considerable	O
loss	O
especially	O
of	O
the	O
temporal	O
fibers	O
.	O

This	O
is	O
consistent	O
with	O
prior	O
histopathological	O
studies	O
that	O
show	O
predominant	O
loss	O
of	O
parvo-cellular	O
axons	O
(	O
or	O
small-caliber	O
axons	O
)	O
within	O
the	O
papillo-macular	O
bundle	O
in	O
toxic	O
or	O
hereditary	O
optic	B-Disease
neuropathies	I-Disease
.	O

OCT	O
can	O
be	O
a	O
valuable	O
tool	O
in	O
the	O
quantitative	O
analysis	O
of	O
optic	B-Disease
neuropathies	I-Disease
.	O

Additionally	O
,	O
in	O
terms	O
of	O
management	O
of	O
EMB-induced	B-Chemical
optic	B-Disease
neuropathy	I-Disease
,	O
it	O
is	O
important	O
to	O
properly	O
manage	O
ethambutol	B-Chemical
dosing	O
in	O
patients	O
with	O
renal	B-Disease
impairment	I-Disease
and	O
to	O
achieve	O
proper	O
transition	O
to	O
a	O
maintenance	O
dose	O
once	O
an	O
appropriate	O
loading	O
dose	O
has	O
been	O
reached	O
.	O

Effects	O
of	O
the	O
cyclooxygenase-2	O
specific	O
inhibitor	O
valdecoxib	B-Chemical
versus	O
nonsteroidal	O
antiinflammatory	O
agents	O
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	B-Disease
events	O
in	O
patients	O
with	O
arthritis	B-Disease
.	O

There	O
have	O
been	O
concerns	O
that	O
the	O
risk	O
of	O
cardiovascular	O
thrombotic	B-Disease
events	O
may	O
be	O
higher	O
with	O
cyclooxygenase	O
(	O
COX	O
)	O
-2-specific	O
inhibitors	O
than	O
nonselective	O
nonsteroidal	O
antiinflammatory	O
drugs	B-Drug
(	O
NSAIDs	O
)	O
.	O

We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	B-Chemical
,	O
a	O
new	O
COX-2-specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	O
with	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
thrombotic	B-Disease
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	B-Disease
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	B-Chemical
(	O
10-80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	O
(	O
diclofenac	B-Chemical
75	O
mg	O
bid	O
,	O
ibuprofen	B-Chemical
800	O
mg	O
tid	O
,	O
or	O
naproxen	B-Chemical
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
trials	O
that	O
were	O
6-52	O
weeks	O
in	O
duration	O
.	O

The	O
incidence	O
rates	O
of	O
events	O
were	O
determined	O
in	O
all	O
patients	O
(	O
n	O
=	O
7934	O
)	O
and	O
in	O
users	O
of	O
low-dose	O
(	O
<	O
or	O
=325	O
mg	O
daily	O
)	O
aspirin	B-Chemical
(	O
n	O
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	B-Chemical
(	O
n	O
=	O
6883	O
)	O
.	O

Crude	O
and	O
exposure-adjusted	O
incidences	O
of	O
thrombotic	B-Disease
events	O
were	O
similar	O
for	O
valdecoxib	B-Chemical
,	O
NSAIDs	O
,	O
and	O
placebo	O
.	O

The	O
risk	O
of	O
serious	O
thrombotic	B-Disease
events	O
was	O
also	O
similar	O
for	O
each	O
valdecoxib	B-Chemical
dose	O
.	O

Thrombotic	B-Disease
risk	O
was	O
consistently	O
higher	O
for	O
users	O
of	O
aspirin	B-Chemical
users	O
than	O
nonusers	O
of	O
aspirin	B-Chemical
(	O
placebo	O
,	O
1.4	O
%	O
vs.	O
0	O
%	O
;	O
valdecoxib	B-Chemical
,	O
1.7	O
%	O
vs.	O
0.2	O
%	O
;	O
NSAIDs	O
,	O
1.9	O
%	O
vs.	O
0.5	O
%	O
)	O
.	O

The	O
rates	O
of	O
events	O
in	O
users	O
of	O
aspirin	B-Chemical
were	O
similar	O
for	O
all	O
3	O
treatment	O
groups	O
and	O
across	O
valdecoxib	B-Chemical
doses	O
.	O

Short-	O
and	O
intermediate-term	O
treatment	O
with	O
therapeutic	O
(	O
10	O
or	O
20	O
mg	O
daily	O
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	O
daily	O
)	O
valdecoxib	B-Chemical
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	B-Disease
events	O
relative	O
to	O
nonselective	O
NSAIDs	O
or	O
placebo	O
in	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
patients	O
in	O
controlled	O
clinical	O
trials	O
.	O

A	O
randomized	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
of	O
ephedrine	B-Chemical
for	O
SSRI-induced	O
female	O
sexual	B-Disease
dysfunction	I-Disease
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
ephedrine	B-Chemical
,	O
an	O
alpha-	O
and	O
beta-adrenergic	O
agonist	O
previously	O
shown	O
to	O
enhance	O
genital	O
blood	O
flow	O
in	O
women	O
,	O
has	O
beneficial	O
effects	O
in	O
reversing	O
antidepressant-induced	O
sexual	B-Disease
dysfunction	I-Disease
.	O

Nineteen	O
sexually	B-Disease
dysfunctional	I-Disease
women	O
receiving	O
either	O
fluoxetine	B-Chemical
,	O
sertraline	B-Chemical
,	O
or	O
paroxetine	B-Chemical
participated	O
in	O
an	O
eight-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
cross-over	O
study	O
of	O
the	O
effects	O
of	O
ephedrine	B-Chemical
(	O
50	O
mg	O
)	O
on	O
self-report	O
measures	O
of	O
sexual	O
desire	O
,	O
arousal	O
,	O
orgasm	O
,	O
and	O
sexual	O
satisfaction	O
.	O

Although	O
there	O
were	O
significant	O
improvements	O
relative	O
to	O
baseline	O
in	O
sexual	O
desire	O
and	O
orgasm	O
intensity/pleasure	O
on	O
50	O
mg	O
ephedrine	B-Chemical
1-hr	O
prior	O
to	O
sexual	O
activity	O
,	O
significant	O
improvements	O
in	O
these	O
measures	O
,	O
as	O
well	O
as	O
in	O
sexual	O
arousal	O
and	O
orgasmic	O
ability	O
also	O
were	O
noted	O
with	O
placebo	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
conducting	O
placebo-controlled	O
trials	O
for	O
this	O
condition	O
.	O

Erectile	B-Disease
dysfunction	I-Disease
occurs	O
following	O
substantia	O
nigra	O
lesions	O
in	O
the	O
rat	O
.	O

Erectile	O
function	O
was	O
assessed	O
6	O
weeks	O
following	O
uni-	O
and	O
bilateral	O
injections	O
of	O
6-hydroxydopamine	B-Chemical
in	O
the	O
substantia	O
nigra	O
nucleus	O
of	O
the	O
brain	O
.	O

Behavioral	O
apomorphine-induced	B-Chemical
penile	O
erections	O
were	O
reduced	O
(	O
5/8	O
)	O
and	O
increased	O
(	O
3/8	O
)	O
in	O
uni-	O
and	O
bilateral	O
lesioned	O
animals	O
.	O

Intracavernous	O
pressures	O
,	O
following	O
electrical	O
stimulation	O
of	O
the	O
cavernous	O
nerve	O
,	O
decreased	O
in	O
lesioned	O
animals	O
.	O

Lesions	O
of	O
the	O
substantia	O
nigra	O
were	O
confirmed	O
by	O
histology	O
.	O

Concentration	O
of	O
dopamine	B-Chemical
and	O
its	O
metabolites	O
were	O
decreased	O
in	O
the	O
striatum	O
of	O
substantia	O
nigra	O
lesioned	O
rats	O
.	O

Lesions	O
of	O
the	O
substantia	O
nigra	O
are	O
therefore	O
associated	O
with	O
erectile	B-Disease
dysfunction	I-Disease
in	O
rats	O
and	O
may	O
serve	O
as	O
a	O
model	O
to	O
study	O
erectile	B-Disease
dysfunction	I-Disease
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

Potential	O
therapeutic	O
use	O
of	O
the	O
selective	O
dopamine	B-Chemical
D1	O
receptor	O
agonist	O
,	O
A-86929	B-Chemical
:	O
an	O
acute	O
study	O
in	O
parkinsonian	B-Disease
levodopa-primed	B-Chemical
monkeys	O
.	O

The	O
clinical	O
utility	O
of	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
D1	O
receptor	O
agonists	O
in	O
the	O
treatment	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
is	O
still	O
unclear	O
.	O

The	O
therapeutic	O
use	O
of	O
selective	O
DA	B-Chemical
D1	O
receptor	O
agonists	O
such	O
as	O
SKF-82958	B-Chemical
(	O
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze	B-Chemical
pine	I-Chemical
hydrobromide	I-Chemical
)	O
and	O
A-77636	B-Chemical
(	O
[	B-Chemical
1R	I-Chemical
,	I-Chemical
3S	I-Chemical
]	I-Chemical
3-	I-Chemical
[	B-Chemical
1'-admantyl	I-Chemical
]	I-Chemical
-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo	I-Chemical
pyran	I-Chemical
hydrochloride	I-Chemical
)	O
seems	O
limited	O
because	O
of	O
their	O
duration	O
of	O
action	O
,	O
which	O
is	O
too	O
short	O
for	O
SKF-82958	B-Chemical
(	O
<	O
1	O
hr	O
)	O
and	O
too	O
long	O
for	O
A-77636	B-Chemical
(	O
>	O
20	O
hr	O
,	O
leading	O
to	O
behavioral	O
tolerance	O
)	O
.	O

We	O
therefore	O
conducted	O
the	O
present	O
acute	O
dose-response	O
study	O
in	O
four	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	B-Chemical
(	O
MPTP	B-Chemical
)	O
-exposed	O
cynomolgus	O
monkeys	O
primed	O
to	O
exhibit	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
to	O
evaluate	O
the	O
locomotor	O
and	O
dyskinetic	B-Disease
effects	O
on	O
challenge	O
with	O
four	O
doses	O
(	O
from	O
0.03	O
to	O
1.0	O
mg/kg	O
)	O
of	O
A-86929	B-Chemical
(	O
[	B-Chemical
-	I-Chemical
]	I-Chemical
-	I-Chemical
[	B-Chemical
5aR,11bS	I-Chemical
]	I-Chemical
-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+	I-Chemical
++azacyclopent-1-	I-Chemical
ena	I-Chemical
[	B-Chemical
c	I-Chemical
]	I-Chemical
phenathrene-9-10-diol	I-Chemical
)	O
,	O
a	O
selective	O
and	O
full	O
DA	B-Chemical
D1-like	O
receptor	O
agonist	O
with	O
an	O
intermediate	O
duration	O
of	O
action	O
.	O

Levodopa	B-Chemical
and	O
the	O
DA	B-Chemical
D2-like	O
receptor	O
agonist	O
,	O
LY-171555	B-Chemical
(	O
[	B-Chemical
4aR-trans	I-Chemical
]	I-Chemical
-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo	I-Chemical
lo-3-4-quinoline	I-Chemical
hydrochloride	I-Chemical
)	O
were	O
also	O
used	O
for	O
comparison	O
.	O

Acute	O
administration	O
of	O
A-86929	B-Chemical
was	O
as	O
efficacious	O
in	O
alleviating	O
MPTP-induced	B-Chemical
parkinsonism	B-Disease
as	O
levodopa	B-Chemical
and	O
LY-171555	B-Chemical
,	O
but	O
was	O
less	O
likely	O
to	O
reproduce	O
the	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
in	O
these	O
animals	O
than	O
with	O
either	O
LY-171555	B-Chemical
or	O
subsequent	O
challenge	O
of	O
levodopa	B-Chemical
.	O

Selective	O
stimulation	O
of	O
the	O
DA	B-Chemical
D1	O
receptor	O
may	O
provide	O
better	O
integration	O
of	O
neural	O
inputs	O
transmitted	O
to	O
the	O
internal	O
segment	O
of	O
the	O
globus	O
pallidus	O
(	O
referred	O
to	O
as	O
the	O
basal	O
ganglia	O
output	O
)	O
compared	O
with	O
levodopa	B-Chemical
and	O
selective	O
DA	B-Chemical
D2	O
receptor	O
agonist	O
.	O

Potent	O
DA	B-Chemical
D1	O
receptor	O
agents	O
with	O
an	O
intermediate	O
duration	O
of	O
efficacy	O
such	O
as	O
A-86929	B-Chemical
(	O
approximately	O
4	O
hr	O
at	O
higher	O
doses	O
tested	O
)	O
are	O
potential	O
therapeutic	O
tools	O
in	O
PD	B-Disease
and	O
merit	O
further	O
attention	O
.	O

Deaths	O
from	O
local	O
anesthetic-induced	O
convulsions	B-Disease
in	O
mice	O
.	O

Median	O
convulsant	O
(	O
CD50	O
)	O
and	O
median	O
lethal	O
(	O
LD50	O
)	O
doses	O
of	O
three	O
representative	O
local	O
anesthetics	B-Drug
were	O
determined	O
in	O
adult	O
mice	O
to	O
evaluate	O
the	O
threat	O
to	O
life	O
of	O
local	O
anesthetic-induced	O
convulsions	B-Disease
.	O

The	O
CD50	O
and	O
LD50	O
,	O
respectively	O
,	O
were	O
57.7	O
and	O
58.7	O
mg/kg	O
for	O
bupivacaine	B-Chemical
,	O
111.0	O
and	O
133.1	O
mg/kg	O
for	O
lidocaine	B-Chemical
,	O
and	O
243.4	O
and	O
266.5	O
mg/kg	O
for	O
chloroprocaine	B-Chemical
.	O

When	O
given	O
intraperitoneally	O
,	O
bupivacaine	B-Chemical
thus	O
was	O
only	O
about	O
twice	O
as	O
toxic	O
as	O
lidocaine	B-Chemical
and	O
four	O
times	O
as	O
toxic	O
as	O
chloroprocaine	B-Chemical
.	O

Convulsions	B-Disease
always	O
preceded	O
death	O
,	O
except	O
after	O
precipitous	O
cardiopulmonary	B-Disease
arrest	I-Disease
from	O
extreme	O
doses	O
.	O

A	O
CD50	O
dose	O
of	O
local	O
anesthetic	B-Drug
(	O
causing	O
convulsions	B-Disease
in	O
50	O
%	O
of	O
mice	O
)	O
was	O
fatal	O
in	O
90	O
%	O
of	O
bupivacaine-induced	B-Chemical
seizures	B-Disease
,	O
in	O
57	O
%	O
of	O
the	O
chloroprocaine	B-Chemical
group	O
,	O
and	O
in	O
6	O
%	O
of	O
the	O
lidocaine	B-Chemical
group	O
.	O

The	O
narrow	O
gap	O
between	O
convulsant	O
and	O
lethal	O
doses	O
of	O
local	O
anesthetics	B-Drug
indicates	O
that	O
untreated	O
convulsions	B-Disease
present	O
much	O
more	O
of	O
a	O
threat	O
to	O
life	O
than	O
heretofore	O
appreciated	O
.	O

Myoclonic	B-Disease
,	I-Disease
atonic	I-Disease
,	I-Disease
and	I-Disease
absence	I-Disease
seizures	I-Disease
following	O
institution	O
of	O
carbamazepine	B-Drug
therapy	O
in	O
children	O
.	O

Five	O
children	O
,	O
aged	O
3	O
to	O
11	O
years	O
,	O
treated	O
with	O
carbamazepine	B-Chemical
for	O
epilepsy	B-Disease
,	I-Disease
had	O
an	O
acute	O
aberrant	O
reaction	O
characterized	O
by	O
the	O
onset	O
of	O
myoclonic	B-Disease
,	I-Disease
atypical	I-Disease
absence	I-Disease
and/or	I-Disease
atonic	I-Disease
(	I-Disease
minor	I-Disease
motor	I-Disease
)	I-Disease
seizures	I-Chemical
within	O
a	O
few	O
days	O
.	O

When	O
the	O
carbamazepine	B-Drug
was	O
discontinued	O
,	O
two	O
of	O
the	O
children	O
returned	O
to	O
their	O
former	O
state	O
very	O
quickly	O
,	O
two	O
had	O
the	O
minor	O
motor	O
seizures	I-Chemical
resolve	O
in	O
3	O
and	O
6	O
months	O
,	O
and	O
one	O
had	O
the	O
seizures	I-Chemical
persist	O
.	O

The	O
child	O
in	O
whom	O
the	O
seizures	I-Chemical
persisted	O
was	O
later	O
found	O
to	O
have	O
ceroid	O
lipofuscinosis	O
.	O

The	O
other	O
children	O
are	O
doing	O
well	O
on	O
other	O
anticonvulsants	O
.	O

Naloxone	B-Chemical
reversal	O
of	O
hypotension	B-Disease
due	O
to	O
captopril	B-Chemical
overdose	B-Disease
.	O

The	O
hemodynamic	O
effects	O
of	O
captopril	B-Chemical
and	O
other	O
angiotensin-converting	B-Chemical
enzyme	I-Chemical
inhibitors	I-Chemical
may	O
be	O
mediated	O
by	O
the	O
endogenous	O
opioid	O
system	O
.	O

The	O
opioid	O
antagonist	O
naloxone	B-Chemical
has	O
been	O
shown	O
to	O
block	O
or	O
reverse	O
the	O
hypotensive	B-Disease
actions	O
of	O
captopril	B-Chemical
.	O

We	O
report	O
a	O
case	O
of	O
an	O
intentional	O
captopril	B-Chemical
overdose	B-Disease
,	O
manifested	O
by	O
marked	O
hypotension	B-Disease
,	O
that	O
resolved	O
promptly	O
with	O
the	O
administration	O
of	O
naloxone	B-Chemical
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
captopril-induced	B-Chemical
hypotension	B-Disease
treated	O
with	O
naloxone	B-Chemical
.	O

Our	O
experience	O
demonstrates	O
a	O
possible	O
role	O
of	O
naloxone	B-Chemical
in	O
the	O
reversal	O
of	O
hypotension	B-Disease
resulting	O
from	O
captopril	B-Chemical
.	O

Carbamazepine-induced	B-Chemical
cardiac	B-Disease
dysfunction	I-Disease
.	O

Characterization	O
of	O
two	O
distinct	O
clinical	O
syndromes	O
.	O

A	O
patient	O
with	O
sinus	O
bradycardia	B-Disease
and	O
atrioventricular	B-Disease
block	I-Disease
,	O
induced	O
by	O
carbamazepine	B-Chemical
,	O
prompted	O
an	O
extensive	O
literature	O
review	O
of	O
all	O
previously	O
reported	O
cases	O
.	O

From	O
the	O
analysis	O
of	O
these	O
cases	O
,	O
two	O
distinct	O
forms	O
of	O
carbamazepine-associated	B-Chemical
cardiac	B-Disease
dysfunction	I-Disease
emerged	O
.	O

One	O
patient	O
group	O
developed	O
sinus	B-Disease
tachycardias	I-Disease
in	O
the	O
setting	O
of	O
a	O
massive	O
carbamazepine	B-Chemical
overdose	B-Disease
.	O

The	O
second	O
group	O
consisted	O
almost	O
exclusively	O
of	O
elderly	O
women	O
who	O
developed	O
potentially	O
life-threatening	O
bradyarrhythmias	B-Disease
or	O
atrioventricular	B-Disease
conduction	I-Disease
delay	I-Disease
,	O
associated	O
with	O
either	O
therapeutic	O
or	O
modestly	O
elevated	O
carbamazepine	B-Chemical
serum	O
levels	O
.	O

Because	O
carbamazepine	B-Chemical
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
many	O
neurologic	O
and	O
psychiatric	B-Disease
conditions	O
,	O
the	O
recognition	O
of	O
the	O
latter	O
syndrome	O
has	O
important	O
implications	O
for	O
the	O
use	O
of	O
this	O
drug	B-Drug
in	O
elderly	O
patients	O
.	O

Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	B-Chemical
receptors	O
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
.	O

The	O
inferior	O
colliculus	O
(	O
IC	O
)	O
is	O
primarily	O
involved	O
in	O
the	O
processing	O
of	O
auditory	O
information	O
,	O
but	O
it	O
is	O
distinguished	O
from	O
other	O
auditory	O
nuclei	O
in	O
the	O
brainstem	O
by	O
its	O
connections	O
with	O
structures	O
of	O
the	O
motor	O
system	O
.	O

Functional	O
evidence	O
relating	O
the	O
IC	O
to	O
motor	O
behavior	O
derives	O
from	O
experiments	O
showing	O
that	O
activation	O
of	O
the	O
IC	O
by	O
electrical	O
stimulation	O
or	O
excitatory	O
amino	B-Chemical
acid	I-Chemical
microinjection	O
causes	O
freezing	O
,	O
escape-like	O
behavior	O
,	O
and	O
immobility	O
.	O

However	O
,	O
the	O
nature	O
of	O
this	O
immobility	O
is	O
still	O
unclear	O
.	O

The	O
present	O
study	O
examined	O
the	O
influence	O
of	O
excitatory	O
amino	B-Chemical
acid-mediated	O
mechanisms	O
in	O
the	O
IC	O
on	O
the	O
catalepsy	O
induced	O
by	O
the	O
dopamine	B-Drug
receptor	O
blocker	O
haloperidol	B-Drug
administered	O
systemically	O
(	O
1	O
or	O
0.5	O
mg/kg	O
)	O
in	O
rats	O
.	O

Haloperidol-induced	O
catalepsy	O
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	B-Drug
NMDA	O
receptor	O
antagonists	O
,	O
MK-801	O
(	O
15	O
or	O
30	O
mmol/0.5	O
microl	O
)	O
and	O
AP7	O
(	O
10	O
or	O
20	O
nmol/0.5	O
microl	O
)	O
,	O
or	O
of	O
the	O
NMDA	O
receptor	O
agonist	O
N-methyl-d-aspartate	O
(	O
NMDA	O
,	O
20	O
or	O
30	O
nmol/0.5	O
microl	O
)	O
.	O

The	O
results	O
showed	O
that	O
intracollicular	O
microinjection	O
of	O
MK-801	O
and	O
AP7	O
previous	O
to	O
systemic	O
injections	O
of	O
haloperidol	B-Drug
significantly	O
attenuated	O
the	O
catalepsy	O
,	O
as	O
indicated	O
by	O
a	O
reduced	O
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O

Accordingly	O
,	O
intracollicular	O
microinjection	O
of	O
NMDA	O
increased	O
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O

These	O
findings	O
suggest	O
that	O
glutamate-mediated	O
mechanisms	O
in	O
the	O
neural	O
circuits	O
at	O
the	O
IC	O
level	O
influence	O
haloperidol-induced	O
catalepsy	O
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	O
activity	O
.	O

Metabotropic	O
glutamate	B-Chemical
7	O
receptor	O
subtype	O
modulates	O
motor	O
symptoms	O
in	O
rodent	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

Metabotropic	O
glutamate	B-Chemical
(	O
mGlu	O
)	O
receptors	O
modulate	O
synaptic	O
transmission	O
in	O
the	O
central	O
nervous	O
system	O
and	O
represent	O
promising	O
therapeutic	O
targets	O
for	O
symptomatic	O
treatment	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
.	O

Among	O
the	O
eight	O
mGlu	O
receptor	O
subtypes	O
,	O
mGlu7	O
receptor	O
is	O
prominently	O
expressed	O
in	O
the	O
basal	O
ganglia	O
,	O
but	O
its	O
role	O
in	O
restoring	O
motor	O
function	O
in	O
animal	O
models	O
of	O
PD	B-Disease
is	O
not	O
known	O
.	O

The	O
effects	O
of	O
N	B-Chemical
,	I-Chemical
N'-dibenzhydrylethane-1,2-diamine	B-Chemical
dihydrochloride	I-Chemical
(	O
AMN082	B-Chemical
)	O
,	O
the	O
first	O
selective	O
allosteric	O
activator	O
of	O
mGlu7	O
receptors	O
,	O
were	O
thus	O
tested	O
in	O
different	O
rodent	O
models	O
of	O
PD	B-Disease
.	O

Here	O
,	O
we	O
show	O
that	O
oral	O
(	O
5	O
mg/kg	O
)	O
or	O
intrastriatal	O
administration	O
(	O
0.1	O
and	O
0.5	O
nmol	O
)	O
of	O
AMN082	B-Chemical
reverses	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
in	O
rats	O
.	O

AMN082	B-Chemical
(	O
2.5	O
and	O
5	O
mg/kg	O
)	O
reduces	O
apomorphine-induced	B-Chemical
rotations	O
in	O
unilateral	O
6-hydroxydopamine	B-Chemical
(	O
6-OHDA	B-Chemical
)	O
-lesioned	O
rats	O
.	O

In	O
a	O
more	O
complex	O
task	O
commonly	O
used	O
to	O
evaluate	O
major	O
akinetic	B-Disease
symptoms	O
of	O
PD	B-Disease
patients	O
,	O
5	O
mg/kg	O
AMN082	B-Chemical
reverses	O
the	O
increased	O
reaction	O
time	O
to	O
respond	O
to	O
a	O
cue	O
of	O
bilateral	O
6-OHDA-lesioned	B-Chemical
rats	O
.	O

In	O
addition	O
,	O
AMN082	B-Chemical
reduces	O
the	O
duration	O
of	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
in	O
a	O
mGlu7	O
receptor-dependent	O
manner	O
in	O
wild-type	O
but	O
not	O
mGlu7	O
receptor	O
knockout	O
mice	O
.	O

Higher	O
doses	O
of	O
AMN082	B-Chemical
(	O
10	O
and	O
20	O
mg/kg	O
p.o	O
.	O

)	O
have	O
no	O
effect	O
on	O
the	O
same	O
models	O
of	O
PD	B-Disease
.	O

Overall	O
these	O
findings	O
suggest	O
that	O
mGlu7	O
receptor	O
activation	O
can	O
reverse	O
motor	O
dysfunction	O
associated	O
with	O
reduced	O
dopamine	B-Chemical
activity	O
.	O

Selective	O
ligands	O
of	O
mGlu7	O
receptor	O
subtypes	O
may	O
thus	O
be	O
considered	O
as	O
promising	O
compounds	O
for	O
the	O
development	O
of	O
antiparkinsonian	O
therapeutic	O
strategies	O
.	O

Nimodipine	B-Chemical
prevents	O
memory	B-Disease
impairment	I-Disease
caused	O
by	O
nitroglycerin-induced	B-Chemical
hypotension	B-Disease
in	O
adult	O
mice	O
.	O

BACKGROUND	O
:	O
Hypotension	B-Disease
and	O
a	O
resultant	O
decrease	O
in	O
cerebral	O
blood	O
flow	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
cognitive	B-Disease
dysfunction	I-Disease
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
nimodipine	B-Chemical
(	O
NIMO	B-Chemical
)	O
administered	O
at	O
the	O
onset	O
of	O
nitroglycerin	B-Chemical
(	O
NTG	B-Chemical
)	O
-induced	O
hypotension	B-Disease
would	O
preserve	O
long-term	O
associative	O
memory	O
.	O

METHODS	O
:	O
The	O
passive	O
avoidance	O
(	O
PA	O
)	O
paradigm	O
was	O
used	O
to	O
assess	O
memory	O
retention	O
.	O

For	O
PA	O
training	O
,	O
latencies	O
(	O
seconds	O
)	O
were	O
recorded	O
for	O
entry	O
from	O
a	O
suspended	O
platform	O
into	O
a	O
Plexiglas	O
tube	O
where	O
a	O
shock	O
was	O
automatically	O
delivered	O
.	O

Latencies	O
were	O
recorded	O
48	O
h	O
later	O
for	O
a	O
testing	O
trial	O
.	O

Ninety-six	O
Swiss-Webster	O
mice	O
(	O
30-35	O
g	O
,	O
6-8	O
wk	O
)	O
,	O
were	O
randomized	O
into	O
6	O
groups	O
1	O
)	O
saline	O
(	O
control	O
)	O
,	O
2	O
)	O
NTG	B-Chemical
immediately	O
after	O
learning	O
,	O
3	O
)	O
NTG	B-Chemical
3	O
h	O
after	O
learning	O
,	O
4	O
)	O
NTG	B-Chemical
and	O
NIMO	B-Chemical
,	O
5	O
)	O
vehicle	O
,	O
and	O
6	O
)	O
NIMO	B-Chemical
alone	O
.	O

The	O
extent	O
of	O
hypotension	B-Disease
and	O
changes	O
in	O
brain	O
tissue	O
oxygenation	O
(	O
PbtO	O
(	O
2	O
)	O
)	O
and	O
in	O
cerebral	O
blood	O
flow	O
were	O
studied	O
in	O
a	O
separate	O
group	O
of	O
animals	O
.	O

RESULTS	O
:	O
All	O
groups	O
exhibited	O
similar	O
training	O
latencies	O
(	O
17.0	O
+/-	O
4.6	O
s	O
)	O
.	O

Mice	O
subjected	O
to	O
hypotensive	B-Disease
episodes	O
showed	O
a	O
significant	O
decrease	O
in	O
latency	O
time	O
(	O
178	O
+/-	O
156	O
s	O
)	O
compared	O
with	O
those	O
injected	O
with	O
saline	O
,	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
,	O
or	O
delayed	O
NTG	B-Chemical
(	O
580	O
+/-	O
81	O
s	O
,	O
557	O
+/-	O
67	O
s	O
,	O
and	O
493	O
+/-	O
146	O
s	O
,	O
respectively	O
)	O
.	O

A	O
Kruskal-Wallis	O
1-way	O
analysis	O
of	O
variance	O
indicated	O
a	O
significant	O
difference	O
among	O
the	O
4	O
treatment	O
groups	O
(	O
H	O
=	O
15.34	O
;	O
P	O
<	O
0.001	O
)	O
.	O

In	O
a	O
separate	O
group	O
of	O
mice	O
not	O
subjected	O
to	O
behavioral	O
studies	O
,	O
the	O
same	O
dose	O
of	O
NTG	B-Chemical
(	O
n	O
=	O
3	O
)	O
and	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
(	O
n	O
=	O
3	O
)	O
caused	O
mean	O
arterial	O
blood	O
pressure	O
to	O
decrease	O
from	O
85.9	O
+/-	O
3.8	O
mm	O
Hg	O
sem	O
to	O
31.6	O
+/-	O
0.8	O
mm	O
Hg	O
sem	O
and	O
from	O
86.2	O
+/-	O
3.7	O
mm	O
Hg	O
sem	O
to	O
32.6	O
+/-	O
0.2	O
mm	O
Hg	O
sem	O
,	O
respectively	O
.	O

Mean	O
arterial	O
blood	O
pressure	O
in	O
mice	O
treated	O
with	O
NIMO	B-Chemical
alone	O
decreased	O
from	O
88.1	O
+/-	O
3.8	O
mm	O
Hg	O
to	O
80.0	O
+/-	O
2.9	O
mm	O
Hg	O
.	O

The	O
intergroup	O
difference	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
.	O

PbtO	O
(	O
2	O
)	O
decreased	O
from	O
51.7	O
+/-	O
4.5	O
mm	O
Hg	O
sem	O
to	O
33.8	O
+/-	O
5.2	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-Chemical
group	O
and	O
from	O
38.6	O
+/-	O
6.1	O
mm	O
Hg	O
sem	O
to	O
25.4	O
+/-	O
2.0	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
groups	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
among	O
groups	O
.	O

CONCLUSION	O
:	O
In	O
a	O
PA	O
retention	O
paradigm	O
,	O
the	O
injection	O
of	O
NTG	B-Chemical
immediately	O
after	O
learning	O
produced	O
a	O
significant	O
impairment	O
of	O
long-term	O
associative	O
memory	O
in	O
mice	O
,	O
whereas	O
delayed	O
induced	O
hypotension	B-Disease
had	O
no	O
effect	O
.	O

NIMO	B-Chemical
attenuated	O
the	O
disruption	O
in	O
consolidation	O
of	O
long-term	O
memory	O
caused	O
by	O
NTG	B-Chemical
but	O
did	O
not	O
improve	O
latency	O
in	O
the	O
absence	O
of	O
hypotension	B-Disease
.	O

The	O
observed	O
effect	O
of	O
NIMO	B-Chemical
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	B-Chemical
homeostasis	O
during	O
hypotension	B-Disease
,	O
because	O
there	O
were	O
no	O
differences	O
in	O
the	O
PbtO	O
(	O
2	O
)	O
indices	O
among	O
groups	O
.	O

Fatal	O
haemopericardium	B-Disease
and	O
gastrointestinal	B-Disease
haemorrhage	I-Disease
due	O
to	O
possible	O
interaction	O
of	O
cranberry	O
juice	O
with	O
warfarin	B-Chemical
.	O

We	O
report	O
a	O
case	O
of	O
fatal	O
internal	O
haemorrhage	B-Disease
in	O
an	O
elderly	O
man	O
who	O
consumed	O
only	O
cranberry	O
juice	O
for	O
two	O
weeks	O
while	O
maintaining	O
his	O
usual	O
dosage	O
of	O
warfarin	B-Chemical
.	O

We	O
propose	O
that	O
naturally	O
occurring	O
compounds	O
such	O
as	O
flavonoids	B-Chemical
,	O
which	O
are	O
present	O
in	O
fruit	O
juices	O
,	O
may	O
increase	O
the	O
potency	O
of	O
warfarin	B-Chemical
by	O
competing	O
for	O
the	O
enzymes	O
that	O
normally	O
inactivate	O
warfarin	B-Chemical
.	O

While	O
traditionally	O
regarded	O
as	O
foodstuffs	O
,	O
consumption	O
of	O
fruit	O
juices	O
should	O
be	O
considered	O
when	O
patients	O
develop	O
adverse	O
drug	B-Drug
reactions	O
.	O

Isoproterenol	B-Chemical
induces	O
primary	O
loss	O
of	O
dystrophin	O
in	O
rat	O
hearts	O
:	O
correlation	O
with	O
myocardial	B-Disease
injury	I-Disease
.	O

The	O
mechanism	O
of	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
damage	I-Disease
is	O
unknown	O
,	O
but	O
a	O
mismatch	O
of	O
oxygen	B-Chemical
supply	O
vs.	O
demand	O
following	O
coronary	O
hypotension	B-Disease
and	O
myocardial	B-Disease
hyperactivity	I-Disease
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O

Severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	O
to	O
be	O
caused	O
by	O
isoproterenol	B-Chemical
.	O

Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	O
integrity	O
is	O
stabilized	O
by	O
the	O
dystrophin-glycoprotein	O
complex	O
(	O
DGC	O
)	O
that	O
connects	O
actin	O
and	O
laminin	O
in	O
contractile	O
machinery	O
and	O
extracellular	O
matrix	O
and	O
by	O
integrins	O
,	O
this	O
study	O
tests	O
the	O
hypothesis	O
that	O
isoproterenol	B-Chemical
affects	O
sarcolemmal	O
stability	O
through	O
changes	O
in	O
the	O
DGC	O
and	O
integrins	O
.	O

We	O
found	O
different	O
sensitivity	O
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	B-Chemical
subcutaneous	O
administration	O
.	O

Immunofluorescent	O
staining	O
revealed	O
that	O
dystrophin	O
is	O
the	O
most	O
sensitive	O
among	O
the	O
structures	O
connecting	O
the	O
actin	O
in	O
the	O
cardiomyocyte	O
cytoskeleton	O
and	O
the	O
extracellular	O
matrix	O
.	O

The	O
sarcomeric	O
actin	O
dissolution	O
occurred	O
after	O
the	O
reduction	O
or	O
loss	O
of	O
dystrophin	O
.	O

Subsequently	O
,	O
after	O
lysis	O
of	O
myofilaments	O
,	O
gamma-sarcoglycan	O
,	O
beta-dystroglycan	O
,	O
beta1-integrin	O
,	O
and	O
laminin	O
alpha-2	O
expressions	O
were	O
reduced	O
followed	O
by	O
their	O
breakdown	O
,	O
as	O
epiphenomena	O
of	O
the	O
myocytolytic	O
process	O
.	O

In	O
conclusion	O
,	O
administration	O
of	O
isoproterenol	B-Chemical
to	O
rats	O
results	O
in	O
primary	O
loss	O
of	O
dystrophin	O
,	O
the	O
most	O
sensitive	O
among	O
the	O
structural	O
proteins	O
that	O
form	O
the	O
DGC	O
that	O
connects	O
the	O
extracellular	O
matrix	O
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O

These	O
changes	O
,	O
related	O
to	O
ischaemic	B-Disease
injury	I-Disease
,	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	B-Chemical
.	O

High	O
fat	B-Chemical
diet-fed	O
obese	B-Disease
rats	O
are	O
highly	O
sensitive	O
to	O
doxorubicin-induced	B-Chemical
cardiotoxicity	B-Disease
.	O

Often	O
,	O
chemotherapy	O
by	O
doxorubicin	B-Chemical
(	O
Adriamycin	B-Chemical
)	O
is	O
limited	O
due	O
to	O
life	O
threatening	O
cardiotoxicity	B-Disease
in	O
patients	O
during	O
and	O
posttherapy	O
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin-induced	B-Chemical
cardiotoxicity	B-Disease
.	O

This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	O
cardiac	O
oxidative	O
stress	O
and	O
triglycerides	B-Chemical
and	O
increased	O
cardiac	O
fatty-acid	O
oxidation	O
,	O
ATP	B-Chemical
synthesis	O
,	O
and	O
upregulated	O
JAK/STAT3	O
pathway	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40	O
%	O
high	O
fat	B-Chemical
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	B-Disease
in	O
male	O
Sprague-Dawley	O
rats	O
(	O
250-275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin-induced	B-Chemical
cardiotoxicity	B-Disease
.	O

A	O
LD	O
(	O
10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin/kg	B-Chemical
,	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	B-Disease
,	O
cardiac	B-Disease
dysfunction	I-Disease
,	O
lipid	O
peroxidation	O
,	O
and	O
80	O
%	O
mortality	O
in	O
the	O
obese	B-Disease
(	O
OB	B-Disease
)	O
rats	O
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	B-Disease
or	I-Disease
hepatic	I-Disease
toxicity	I-Disease
.	O

Doxorubicin	B-Drug
toxicokinetics	O
studies	O
revealed	O
no	O
change	O
in	O
accumulation	O
of	O
doxorubicin	B-Drug
and	O
doxorubicinol	B-Drug
(	O
toxic	O
metabolite	O
)	O
in	O
the	O
normal	O
diet-fed	O
(	O
ND	O
)	O
and	O
OB	O
hearts	O
.	O

Mechanistic	O
studies	O
revealed	O
that	O
OB	O
rats	O
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	O
oxyradical	O
stress	O
leading	O
to	O
upregulation	O
of	O
uncoupling	O
proteins	O
2	O
and	O
3	O
,	O
(	O
2	O
)	O
downregulation	O
of	O
cardiac	O
peroxisome	O
proliferators	O
activated	O
receptor-alpha	O
,	O
(	O
3	O
)	O
decreased	O
plasma	O
adiponectin	O
levels	O
,	O
(	O
4	O
)	O
decreased	O
cardiac	O
fatty-acid	O
oxidation	O
(	O
666.9+/-14.0	O
nmol/min/g	O
heart	O
in	O
ND	O
versus	O
400.2+/-11.8	O
nmol/min/g	O
heart	O
in	O
OB	O
)	O
,	O
(	O
5	O
)	O
decreased	O
mitochondrial	O
AMP-alpha2	O
protein	O
kinase	O
,	O
and	O
(	O
6	O
)	O
86	O
%	O
drop	O
in	O
cardiac	O
ATP	O
levels	O
accompanied	O
by	O
decreased	O
ATP/ADP	O
ratio	O
after	O
doxorubicin	B-Drug
administration	O
.	O

Decreased	O
cardiac	O
erythropoietin	O
and	O
increased	O
SOCS3	O
further	O
downregulated	O
the	O
cardioprotective	O
JAK/STAT3	O
pathway	O
.	O

In	O
conclusion	O
,	O
HFD-induced	O
obese	O
rats	O
are	O
highly	O
sensitized	O
to	O
doxorubicin-induced	O
cardiotoxicity	O
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	O
generation	O
,	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK/STAT3	O
pathway	O
.	O

Complete	O
atrioventricular	B-Disease
block	I-Disease
secondary	O
to	O
lithium	B-Chemical
therapy	O
.	O

Sinus	B-Disease
node	I-Disease
dysfunction	I-Disease
has	O
been	O
reported	O
most	O
frequently	O
among	O
the	O
adverse	O
cardiovascular	O
effects	O
of	O
lithium	B-Chemical
.	O

In	O
the	O
present	O
case	O
,	O
complete	O
atrioventricular	B-Disease
(	I-Disease
AV	I-Disease
)	I-Disease
block	I-Disease
with	O
syncopal	B-Disease
attacks	I-Disease
developed	O
secondary	O
to	O
lithium	B-Chemical
therapy	O
,	O
necessitating	O
permanent	O
pacemaker	O
implantation	O
.	O

Serum	O
lithium	B-Chemical
levels	O
remained	O
under	O
or	O
within	O
the	O
therapeutic	O
range	O
during	O
the	O
syncopal	B-Disease
attacks	I-Disease
.	O

Lithium	B-Chemical
should	O
be	O
used	O
with	O
extreme	O
caution	O
,	O
especially	O
in	O
patients	O
with	O
mild	O
disturbance	O
of	O
AV	O
conduction	O
.	O

Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
induced	O
by	O
ziprasidone	B-Chemical
on	O
the	O
second	O
day	O
of	O
treatment	O
.	O

Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
(	O
NMS	B-Disease
)	O
is	O
the	O
rarest	O
and	O
most	O
serious	O
of	O
the	O
neuroleptic-induced	O
movement	B-Disease
disorders	I-Disease
.	O

We	O
describe	O
a	O
case	O
of	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
(	O
NMS	B-Disease
)	O
associated	O
with	O
the	O
use	O
of	O
ziprasidone	B-Chemical
.	O

Although	O
conventional	O
neuroleptics	O
are	O
more	O
frequently	O
associated	O
with	O
NMS	B-Disease
,	O
atypical	O
antipsychotic	O
drugs	B-Drug
like	O
ziprasidone	B-Chemical
may	O
also	O
be	O
a	O
cause	O
.	O

The	O
patient	O
is	O
a	O
24-year-old	O
male	O
with	O
a	O
history	O
of	O
schizophrenia	B-Disease
who	O
developed	O
signs	O
and	O
symptoms	O
of	O
NMS	B-Disease
after	O
2	O
days	O
of	O
treatment	O
with	O
an	O
80-mg/day	O
dose	O
of	O
orally	O
administrated	O
ziprasidone	B-Chemical
.	O

This	O
case	O
is	O
the	O
earliest	O
(	O
second	O
day	O
of	O
treatment	O
)	O
NMS	B-Disease
due	O
to	O
ziprasidone	B-Chemical
reported	O
in	O
the	O
literature	O
.	O

Role	O
of	O
mangiferin	B-Chemical
on	O
biochemical	O
alterations	O
and	O
antioxidant	O
status	O
in	O
isoproterenol-induced	B-Chemical
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O

The	O
current	O
study	O
dealt	O
with	O
the	O
protective	O
role	O
of	O
mangiferin	B-Chemical
,	O
a	O
polyphenol	B-Chemical
from	O
Mangifera	O
indica	O
Linn	O
.	O

(	O
Anacardiaceae	O
)	O
,	O
on	O
isoproterenol	B-Chemical
(	O
ISPH	B-Chemical
)	O
-induced	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
in	O
rats	O
through	O
its	O
antioxidative	O
mechanism	O
.	O

Subcutaneous	O
injection	O
of	O
ISPH	B-Chemical
(	O
200	O
mg/kg	O
body	O
weight	O
in	O
1	O
ml	O
saline	O
)	O
to	O
rats	O
for	O
2	O
consecutive	O
days	O
caused	O
myocardial	B-Disease
damage	I-Disease
in	O
rat	O
heart	O
,	O
which	O
was	O
determined	O
by	O
the	O
increased	O
activity	O
of	O
serum	O
lactate	B-Chemical
dehydrogenase	O
(	O
LDH	O
)	O
and	O
creatine	B-Chemical
phosphokinase	O
isoenzymes	O
(	O
CK-MB	O
)	O
,	O
increased	O
uric	B-Chemical
acid	I-Chemical
level	O
and	O
reduced	O
plasma	O
iron	B-Chemical
binding	O
capacity	O
.	O

The	O
protective	O
role	O
of	O
mangiferin	B-Chemical
was	O
analyzed	O
by	O
triphenyl	B-Chemical
tetrazolium	I-Chemical
chloride	I-Chemical
(	O
TTC	B-Chemical
)	O
test	O
used	O
for	O
macroscopic	O
enzyme	O
mapping	O
assay	O
of	O
the	O
ischemic	B-Disease
myocardium	I-Disease
.	O

The	O
heart	O
tissue	O
antioxidant	O
enzymes	O
such	O
as	O
superoxide	B-Chemical
dismutase	O
,	O
catalase	O
,	O
glutathione	B-Chemical
peroxidase	O
,	O
glutathione	B-Chemical
transferase	O
and	O
glutathione	B-Chemical
reductase	O
activities	O
,	O
non-enzymic	O
antioxidants	O
such	O
as	O
cerruloplasmin	O
,	O
Vitamin	B-Chemical
C	I-Chemical
,	O
Vitamin	B-Chemical
E	I-Chemical
and	O
glutathione	B-Chemical
levels	O
were	O
altered	O
in	O
MI	B-Disease
rats	O
.	O

Upon	O
pretreatment	O
with	O
mangiferin	B-Chemical
(	O
100	O
mg/kg	O
body	O
weight	O
suspended	O
in	O
2	O
ml	O
of	O
dimethyl	B-Chemical
sulphoxide	I-Chemical
)	O
given	O
intraperitoneally	O
for	O
28	O
days	O
to	O
MI	B-Disease
rats	O
protected	O
the	O
above-mentioned	O
parameters	O
to	O
fall	O
from	O
the	O
normal	O
levels	O
.	O

Activities	O
of	O
heart	O
tissue	O
enzymic	O
antioxidants	O
and	O
serum	O
non-enzymic	O
antioxidants	O
levels	O
rose	O
significantly	O
upon	O
mangiferin	B-Chemical
administration	O
as	O
compared	O
to	O
ISPH-induced	B-Chemical
MI	B-Disease
rats	O
.	O

From	O
the	O
present	O
study	O
it	O
is	O
concluded	O
that	O
mangiferin	B-Chemical
exerts	O
a	O
beneficial	O
effect	O
against	O
ISPH-induced	B-Chemical
MI	B-Disease
due	O
to	O
its	O
antioxidant	O
potential	O
,	O
which	O
regulated	O
the	O
tissues	O
defense	O
system	O
against	O
cardiac	B-Disease
damage	I-Disease
.	O

Remifentanil	B-Chemical
pretreatment	O
reduces	O
myoclonus	B-Disease
after	O
etomidate	B-Chemical
.	O

STUDY	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
pretreatment	O
with	O
remifentanil	B-Chemical
1	O
microg/kg	O
and	O
the	O
effect	O
of	O
gender	O
on	O
the	O
incidence	O
of	O
myoclonus	B-Disease
after	O
anesthesia	B-Drug
induction	O
with	O
etomidate	B-Chemical
.	O

DESIGN	O
:	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	O
study	O
.	O

SETTING	O
:	O
The	O
study	O
was	O
conducted	O
at	O
a	O
university	O
hospital	O
.	O

PATIENTS	O
:	O
Sixty	O
patients	O
were	O
pretreated	O
in	O
a	O
randomized	O
double-blinded	O
fashion	O
with	O
remifentanil	B-Chemical
1	O
microg/kg	O
or	O
placebo	O
.	O

Two	O
minutes	O
after	O
remifentanil	B-Chemical
or	O
placebo	O
injection	O
,	O
etomidate	B-Chemical
0.3	O
mg/kg	O
was	O
given	O
.	O

MEASUREMENTS	O
:	O
Myoclonus	B-Disease
was	O
recorded	O
with	O
a	O
scale	O
of	O
0	O
to	O
3	O
.	O

The	O
grade	O
of	O
sedation	O
(	O
none	O
,	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
,	O
nausea	B-Disease
,	O
pruritus	B-Disease
,	O
and	O
apnea	B-Disease
were	O
recorded	O
after	O
injection	O
of	O
both	O
drugs	B-Drug
.	O

MAIN	O
RESULTS	O
:	O
The	O
incidence	O
of	O
myoclonus	B-Disease
was	O
significantly	O
lower	O
in	O
the	O
remifentanil	B-Chemical
group	O
(	O
6.7	O
%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
70	O
%	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

None	O
of	O
the	O
patients	O
experienced	O
sedation	O
,	O
apnea	B-Disease
,	O
nausea	B-Disease
,	O
or	O
pruritus	B-Disease
after	O
injection	O
of	O
both	O
drugs	B-Drug
.	O

In	O
the	O
placebo	O
group	O
,	O
male	O
patients	O
were	O
associated	O
with	O
significantly	O
increased	O
incidence	O
of	O
myoclonus	B-Disease
after	O
etomidate	B-Chemical
administration	O
.	O

CONCLUSION	O
:	O
Pretreatment	O
with	O
remifentanil	B-Chemical
1	O
microg/kg	O
reduced	O
myoclonus	B-Disease
after	O
etomidate	B-Chemical
induction	O
without	O
side	O
effects	O
such	O
as	O
sedation	O
,	O
apnea	B-Disease
,	O
nausea	B-Disease
,	O
or	O
pruritus	B-Disease
.	O

Men	O
experience	O
increased	O
incidence	O
of	O
myoclonus	B-Disease
than	O
women	O
after	O
etomidate	B-Chemical
administration	O
.	O

Daidzein	B-Chemical
activates	O
choline	B-Chemical
acetyltransferase	O
from	O
MC-IXC	O
cells	O
and	O
improves	O
drug-induced	O
amnesia	B-Disease
.	O

The	O
choline	B-Chemical
acetyltransferase	O
(	O
ChAT	O
)	O
activator	O
,	O
which	O
enhances	O
cholinergic	O
transmission	O
via	O
an	O
augmentation	O
of	O
the	O
enzymatic	O
production	O
of	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
,	O
is	O
an	O
important	O
factor	O
in	O
the	O
treatment	O
of	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
.	O

Methanolic	O
extracts	O
from	O
Pueraria	O
thunbergiana	O
exhibited	O
an	O
activation	O
effect	O
(	O
46	O
%	O
)	O
on	O
ChAT	O
in	O
vitro	O
.	O

Via	O
the	O
sequential	O
isolation	O
of	O
Pueraria	O
thunbergiana	O
,	O
the	O
active	O
component	O
was	O
ultimately	O
identified	O
as	O
daidzein	B-Chemical
(	O
4',7-dihydroxy-isoflavone	B-Chemical
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
daidzein	B-Chemical
from	O
Pueraria	O
thunbergiana	O
on	O
scopolamine-induced	B-Chemical
impairments	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
,	O
we	O
conducted	O
a	O
series	O
of	I-Chemical
in	O
vivo	O
tests	O
.	O

Administration	O
of	I-Chemical
daidzein	O
(	O
4.5	O
mg/kg	O
body	O
weight	O
)	O
to	O
mice	O
was	O
shown	O
significantly	O
to	O
reverse	O
scopolamine-induced	O
amnesia	O
,	O
according	O
to	O
the	O
results	O
of	I-Chemical
a	O
Y-maze	O
test	O
.	O

Injections	O
of	I-Chemical
scopolamine	B-Drug
into	O
mice	O
resulted	O
in	O
impaired	O
performance	O
on	O
Y-maze	O
tests	O
(	O
a	O
37	O
%	O
decreases	O
in	O
alternation	O
behavior	O
)	O
.	O

By	O
way	O
of	I-Chemical
contrast	O
,	O
mice	O
treated	O
with	O
daidzein	O
prior	O
to	O
the	O
scopolamine	B-Drug
injections	O
were	O
noticeably	O
protected	O
from	O
this	O
performance	O
impairment	O
(	O
an	O
approximately	O
12	O
%	O
-21	O
%	O
decrease	O
in	O
alternation	O
behavior	O
)	O
.	O

These	O
results	O
indicate	O
that	O
daidzein	O
might	O
play	O
a	O
role	O
in	O
acetylcholine	O
biosynthesis	O
as	O
a	O
ChAT	O
activator	O
,	O
and	O
that	O
it	O
also	O
ameliorates	O
scopolamine-induced	O
amnesia	O
.	O

Possible	O
azithromycin-associated	B-Chemical
hiccups	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
persistent	O
hiccups	B-Disease
associated	O
by	O
azithromycin	B-Chemical
therapy	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
76-year-old	O
man	O
presented	O
with	O
persistent	O
hiccups	B-Disease
after	O
beginning	O
azithromycin	B-Chemical
for	O
the	O
treatment	O
of	O
pharyngitis	B-Disease
.	O

Hiccups	B-Disease
were	O
persistent	O
and	O
exhausting	O
.	O

Discontinuation	O
of	O
azithromycin	B-Chemical
and	O
therapy	O
with	O
baclofen	B-Chemical
finally	O
resolved	O
hiccups	B-Disease
.	O

No	O
organic	O
cause	O
of	O
hiccups	B-Disease
was	O
identified	O
despite	O
extensive	O
investigation	O
.	O

DISCUSSION	O
:	O
Pharmacotherapeutic	O
agents	O
have	O
been	O
uncommonly	O
associated	O
with	O
hiccups	B-Disease
.	O

Corticosteroids	O
(	O
dexamethasone	B-Chemical
and	O
methylprednisolone	B-Chemical
)	O
,	O
benzodiazepines	B-Chemical
(	O
midazolam	B-Chemical
)	O
and	O
general	O
anaesthesia	O
have	O
been	O
the	O
specific	O
agents	O
mentioned	O
most	O
frequently	O
in	O
the	O
literature	O
as	O
being	O
associated	O
with	O
the	O
development	O
of	O
hiccups	B-Disease
.	O

Few	O
cases	O
of	O
drug-induced	O
hiccups	B-Disease
have	O
been	O
reported	O
related	O
to	O
macrolide	B-Chemical
antimicrobials	O
.	O

Using	O
the	O
Naranjo	O
adverse	O
effect	O
reaction	O
probability	O
scale	O
this	O
event	O
could	O
be	O
classified	O
as	O
possible	O
(	O
score	O
5	O
points	O
)	O
,	O
mostly	O
because	O
of	O
the	O
close	O
temporal	O
sequence	O
,	O
previous	O
reports	O
on	O
this	O
reaction	O
with	O
other	O
macrolides	B-Chemical
and	O
the	O
absence	O
of	O
any	O
alternative	O
explanation	O
for	O
hiccups	B-Disease
.	O

Our	O
hypothesis	O
is	O
that	O
a	O
vagal	O
mechanism	O
mediated	O
by	O
azithromycin	B-Chemical
could	O
be	O
the	O
pathogenesis	O
of	O
hiccups	B-Disease
in	O
our	O
patient	O
.	O

CONCLUSIONS	O
:	O
Diagnosis	O
of	O
drug-induced	O
hiccups	B-Disease
is	O
difficult	O
and	O
often	O
achieved	O
only	O
by	O
a	O
process	O
of	O
elimination	O
.	O

However	O
,	O
macrolide	B-Chemical
antimicrobials	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
hiccups	B-Disease
and	O
vagal	O
mechanism	O
could	O
explain	O
the	O
development	O
of	O
this	O
side-effect	O
.	O

Time	O
trends	O
in	O
warfarin-associated	B-Chemical
hemorrhage	B-Disease
.	O

The	O
annual	O
incidence	O
of	O
warfarin-related	B-Chemical
bleeding	B-Disease
at	O
Brigham	O
and	O
Women	O
's	O
Hospital	O
increased	O
from	O
0.97/1,000	O
patient	O
admissions	O
in	O
the	O
first	O
time	O
period	O
(	O
January	O
1995	O
to	O
October	O
1998	O
)	O
to	O
1.19/1,000	O
patient	O
admissions	O
in	O
the	O
second	O
time	O
period	O
(	O
November	O
1998	O
to	O
August	O
2002	O
)	O
of	O
this	O
study	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
major	O
and	O
intracranial	B-Disease
bleeding	I-Disease
increased	O
from	O
20.2	O
%	O
and	O
1.9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
first	O
time	O
period	O
,	O
to	O
33.3	O
%	O
and	O
7.8	O
%	O
,	O
respectively	O
,	O
in	O
the	O
second	O
.	O

Fatal	O
haemorrhagic	B-Disease
myocarditis	I-Disease
secondary	O
to	O
cyclophosphamide	B-Drug
therapy	O
.	O

Haemorrhagic	B-Disease
myocarditis	I-Disease
is	O
a	O
rare	O
but	O
important	O
complication	O
of	O
cyclophosphamide	B-Drug
therapy	O
.	O

Echocardiographic	O
identification	O
of	O
the	O
disorder	O
can	O
be	O
made	O
.	O

We	O
believe	O
that	O
the	O
ultrasound	O
features	O
of	O
this	O
disorder	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Glyceryl	B-Chemical
trinitrate	I-Chemical
induces	O
attacks	O
of	O
migraine	B-Disease
without	I-Disease
aura	I-Disease
in	O
sufferers	O
of	O
migraine	B-Disease
with	I-Disease
aura	I-Disease
.	O

Migraine	B-Disease
with	I-Disease
aura	I-Disease
and	O
migraine	B-Disease
without	I-Disease
aura	I-Disease
have	O
the	O
same	O
pain	B-Disease
phase	O
,	O
thus	O
indicating	O
that	O
migraine	B-Disease
with	I-Disease
aura	I-Disease
and	O
migraine	B-Disease
without	I-Disease
aura	I-Disease
share	O
a	O
common	O
pathway	O
of	O
nociception	O
.	O

In	O
recent	O
years	O
,	O
increasing	O
evidence	O
has	O
suggested	O
that	O
the	O
messenger	O
molecule	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
is	O
involved	O
in	O
pain	B-Disease
mechanisms	O
of	O
migraine	B-Disease
without	I-Disease
aura	I-Disease
.	O

In	O
order	O
to	O
clarify	O
whether	O
the	O
same	O
is	O
true	O
for	O
migraine	B-Disease
with	I-Disease
aura	I-Disease
,	O
in	O
the	O
present	O
study	O
we	O
examined	O
the	O
headache	B-Disease
response	O
to	O
intravenous	O
infusion	O
of	O
glyceryl	B-Chemical
trinitrate	I-Chemical
(	O
GTN	B-Chemical
)	O
(	O
0.5	O
microg/kg/min	O
for	O
20	O
min	O
)	O
in	O
12	O
sufferers	O
of	O
migraine	B-Disease
with	I-Disease
aura	I-Disease
.	O

The	O
specific	O
aim	O
was	O
to	O
elucidate	O
whether	O
an	O
aura	I-Disease
and/or	O
an	O
attack	O
of	O
migraine	B-Disease
without	I-Disease
aura	O
could	O
be	O
induced	O
.	O

Fourteen	O
healthy	O
subjects	O
served	O
as	O
controls	O
.	O

Aura	O
symptoms	O
were	O
not	O
elicited	O
in	O
any	O
subject	O
.	O

Headache	B-Disease
was	O
more	O
severe	O
in	O
migraineurs	B-Disease
than	O
in	O
the	O
controls	O
during	O
and	O
immediately	O
after	O
GTN	B-Chemical
infusion	O
(	O
p=0.037	O
)	O
as	O
well	O
as	O
during	O
the	O
following	O
11	O
h	O
(	O
p	O
=	O
0.008	O
)	O
.	O

In	O
the	O
controls	O
,	O
the	O
GTN-induced	B-Chemical
headache	B-Disease
gradually	O
disappeared	O
,	O
whereas	O
in	O
migraineurs	B-Disease
peak	O
headache	B-Disease
intensity	O
occurred	O
at	O
a	O
mean	O
time	O
of	O
240	O
min	O
post-infusion	O
.	O

At	O
this	O
time	O
the	O
induced	O
headache	B-Disease
in	O
6	O
of	O
12	O
migraineurs	B-Disease
fulfilled	O
the	O
diagnostic	O
criteria	O
for	O
migraine	B-Disease
without	I-Disease
aura	I-Disease
of	O
the	O
International	O
Headache	B-Disease
Society	O
.	O

The	O
results	O
therefore	O
suggest	O
that	O
NO	B-Chemical
is	O
involved	O
in	O
the	O
pain	B-Disease
mechanisms	O
of	O
migraine	B-Disease
with	I-Disease
aura	I-Disease
.	O

Since	O
cortical	O
spreading	O
depression	B-Disease
has	O
been	O
shown	O
to	O
liberate	O
NO	B-Chemical
in	O
animals	O
,	O
this	O
finding	O
may	O
help	O
our	O
understanding	O
of	O
the	O
coupling	O
between	O
cortical	O
spreading	O
depression	B-Disease
and	O
headache	B-Disease
in	O
migraine	B-Disease
with	I-Disease
aura	I-Disease
.	O

Stroke	B-Disease
and	O
cocaine	B-Chemical
or	O
amphetamine	B-Chemical
use	O
.	O

The	O
association	O
of	O
cocaine	B-Chemical
and	O
amphetamine	B-Chemical
use	O
with	O
hemorrhagic	O
and	O
ischemic	B-Disease
stroke	B-Disease
is	O
based	O
almost	O
solely	O
on	O
data	O
from	O
case	O
series	O
.	O

The	O
limited	O
number	O
of	O
epidemiologic	O
studies	O
of	O
stroke	B-Disease
and	O
use	O
of	O
cocaine	B-Chemical
and/or	O
amphetamine	B-Chemical
have	O
been	O
done	O
in	O
settings	O
that	O
serve	O
mostly	O
the	O
poor	O
and/or	O
minorities	O
.	O

This	O
case-control	O
study	O
was	O
conducted	O
in	O
the	O
defined	O
population	O
comprising	O
members	O
of	O
Kaiser	O
Permanente	O
of	O
Northern	O
and	O
Southern	O
California	O
.	O

We	O
attempted	O
to	O
identify	O
all	O
incident	O
strokes	B-Disease
in	O
women	O
ages	O
15-44	O
years	O
during	O
a	O
3-year	O
period	O
using	O
hospital	O
admission	O
and	O
discharge	O
records	O
,	O
emergency	O
department	O
logs	O
,	O
and	O
payment	O
requests	O
for	O
out-of-plan	O
hospitalizations	O
.	O

We	O
selected	O
controls	O
,	O
matched	O
on	O
age	O
and	O
facility	O
of	O
usual	O
care	O
,	O
at	O
random	O
from	O
healthy	O
members	O
of	O
the	O
health	O
plan	O
.	O

We	O
obtained	O
information	O
in	O
face-to-face	O
interviews	O
.	O

There	O
were	O
347	O
confirmed	O
stroke	B-Disease
cases	O
and	O
1,021	O
controls	O
.	O

The	O
univariate	O
matched	O
odds	O
ratio	O
for	O
stroke	B-Disease
in	O
women	O
who	O
admitted	O
to	O
using	O
cocaine	B-Chemical
and/or	O
amphetamine	B-Chemical
was	O
8.5	O
(	O
95	O
%	O
confidence	O
interval	O
=	O
3.6-20.0	O
)	O
.	O

After	O
further	O
adjustment	O
for	O
potential	O
confounders	O
,	O
the	O
odds	O
ratio	O
in	O
women	O
who	O
reported	O
using	O
cocaine	B-Chemical
and/or	O
amphetamine	B-Chemical
was	O
7.0	O
(	O
95	O
%	O
confidence	O
interval	O
=	O
2.8-17.9	O
)	O
.	O

The	O
use	O
of	O
cocaine	B-Chemical
and/or	O
amphetamine	B-Chemical
is	O
a	O
strong	O
risk	O
factor	O
for	O
stroke	B-Disease
in	O
this	O
socioeconomically	O
heterogeneous	O
,	O
insured	O
urban	O
population	O
.	O

Prevention	O
of	O
breast	B-Disease
cancer	I-Disease
with	O
tamoxifen	B-Chemical
:	O
preliminary	O
findings	O
from	O
the	O
Italian	O
randomised	O
trial	O
among	O
hysterectomised	O
women	O
.	O

Italian	O
Tamoxifen	B-Chemical
Prevention	O
Study	O
.	O

BACKGROUND	O
:	O
Tamoxifen	B-Chemical
is	O
a	O
candidate	O
chemopreventive	O
agent	O
in	O
breast	B-Disease
cancer	I-Disease
,	O
although	O
the	O
drug	B-Drug
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
endometrial	B-Disease
cancer	I-Disease
.	O

Therefore	O
we	O
did	O
a	O
trial	O
in	O
hysterectomised	O
women	O
of	O
tamoxifen	B-Chemical
as	O
a	O
chemopreventive	O
.	O

METHODS	O
:	O
In	O
October	O
,	O
1992	O
,	O
we	O
started	O
a	O
double-blind	O
placebo-controlled	O
,	O
randomised	O
trial	O
of	O
tamoxifen	B-Chemical
in	O
women	O
(	O
mainly	O
in	O
Italy	O
)	O
who	O
did	O
not	O
have	O
breast	B-Disease
cancer	I-Disease
and	O
who	O
had	O
had	O
a	O
hysterectomy	O
.	O

Women	O
were	O
randomised	O
to	O
receive	O
tamoxifen	B-Chemical
20	O
mg	O
per	O
day	O
or	O
placebo	O
,	O
both	O
orally	O
for	O
5	O
years	O
.	O

The	O
original	O
plan	O
was	O
to	O
follow	O
the	O
intervention	O
phase	O
by	O
5	O
years	O
'	O
follow-up	O
.	O

In	O
June	O
,	O
1997	O
,	O
the	O
trialists	O
and	O
the	O
data-monitoring	O
committee	O
decided	O
to	O
end	O
recruitment	O
primarily	O
because	O
of	O
the	O
number	O
of	O
women	O
dropping	O
out	O
of	O
the	O
study	O
.	O

Recruitment	O
ended	O
on	O
July	O
11	O
,	O
1997	O
,	O
and	O
the	O
study	O
will	O
continue	O
as	O
planned	O
.	O

The	O
primary	O
endpoints	O
are	O
the	O
occurrence	O
of	O
and	O
deaths	O
from	O
breast	B-Disease
cancer	I-Disease
.	O

This	O
preliminary	O
interim	O
analysis	O
is	O
based	O
on	O
intention-to-treat	O
.	O

FINDINGS	O
:	O
5408	O
women	O
were	O
randomised	O
;	O
participating	O
women	O
have	O
a	O
median	O
follow-up	O
of	O
46	O
months	O
for	O
major	O
endpoints	O
.	O

41	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
occurred	O
so	O
far	O
;	O
there	O
have	O
been	O
no	O
deaths	O
from	O
breast	B-Disease
cancer	I-Disease
.	O

There	O
is	O
no	O
difference	O
in	O
breast-cancer	B-Disease
frequency	O
between	O
the	O
placebo	O
(	O
22	O
cases	O
)	O
and	O
tamoxifen	B-Chemical
(	O
19	O
)	O
arms	O
.	O

There	O
is	O
a	O
statistically	O
significant	O
reduction	O
of	O
breast	B-Disease
cancer	I-Disease
among	O
women	O
receiving	O
tamoxifen	B-Chemical
who	O
also	O
used	O
hormone-replacement	O
therapy	O
during	O
the	O
trial	O
:	O
among	O
390	O
women	O
on	O
such	O
therapy	O
and	O
allocated	O
to	O
placebo	O
,	O
we	O
found	O
eight	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
compared	O
with	O
one	O
case	O
among	O
362	O
women	O
allocated	O
to	O
tamoxifen	B-Chemical
.	O

Compared	O
with	O
the	O
placebo	O
group	O
,	O
there	O
was	O
a	O
significantly	O
increased	O
risk	O
of	O
vascular	B-Disease
events	I-Disease
and	O
hypertriglyceridaemia	B-Disease
among	O
women	O
on	O
tamoxifen	B-Chemical
.	O

INTERPRETATION	O
:	O
Although	O
this	O
preliminary	O
analysis	O
has	O
low	O
power	O
,	O
in	O
this	O
cohort	O
of	O
women	O
at	O
low-to-normal	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
the	O
postulated	O
protective	O
effects	O
of	O
tamoxifen	B-Chemical
are	O
not	O
yet	O
apparent	O
.	O

Women	O
using	O
hormone-replacement	O
therapy	O
appear	O
to	O
have	O
benefited	O
from	O
use	O
of	O
tamoxifen	B-Chemical
.	O

There	O
were	O
no	O
deaths	O
from	O
breast	B-Disease
cancer	I-Disease
recorded	O
in	O
women	O
in	O
the	O
study	O
.	O

It	O
is	O
essential	O
to	O
continue	O
follow-up	O
to	O
quantify	O
the	O
long-term	O
risks	O
and	O
benefits	O
of	O
tamoxifen	B-Chemical
therapy	O
.	O

A	O
measure	O
of	O
pupillary	B-Disease
oscillation	I-Disease
as	O
a	O
marker	O
of	O
cocaine-induced	B-Chemical
paranoia	B-Disease
.	O

Cocaine-induced	B-Chemical
paranoia	B-Disease
(	O
CIP	B-Disease
)	O
remains	O
an	O
important	O
drug-induced	O
model	O
of	O
idiopathic	O
paranoia	B-Disease
for	O
which	O
no	O
psychophysiologic	O
marker	O
has	O
yet	O
emerged	O
.	O

Measures	O
of	O
pupillary	B-Disease
oscillation	I-Disease
were	O
able	O
to	O
significantly	O
distinguish	O
a	O
group	O
of	O
abstinent	O
crack	B-Chemical
cocaine	I-Chemical
abusers	O
endorsing	O
past	O
CIP	B-Disease
(	O
n	O
=	O
32	O
)	O
from	O
another	O
group	O
of	O
crack	B-Chemical
addicts	O
who	O
denied	O
past	O
CIP	B-Disease
(	O
n	O
=	O
29	O
)	O
.	O

Seizures	B-Disease
induced	O
by	O
combined	O
levomepromazine-fluvoxamine	B-Chemical
treatment	O
.	O

We	O
report	O
a	O
case	O
of	O
combined	O
levomepromazine-fluvoxamine	B-Chemical
treatment-induced	O
seizures	O
.	O

It	O
seems	O
that	O
combined	O
treatment	O
of	O
fluvoxamine	B-Chemical
with	O
phenothiazines	O
may	O
possess	O
proconvulsive	O
activity	O
.	O

Why	O
may	O
epsilon-aminocaproic	B-Chemical
acid	I-Chemical
(	O
EACA	B-Chemical
)	O
induce	O
myopathy	B-Disease
in	O
man	O
?	O
Report	O
of	O
a	O
case	O
and	O
literature	O
review	O
.	O

A	O
case	O
of	O
necrotizing	B-Disease
myopathy	I-Disease
due	O
to	O
a	O
short	O
epsilon-aminocaproic	O
acid	O
(	O
EACA	B-Drug
)	O
treatment	O
in	O
a	O
72	O
year-old	O
patient	O
with	O
subarachnoid	O
haemorrhage	O
(	O
SAH	O
)	O
is	O
described	O
.	O

Pathogenetic	O
hypotheses	O
are	O
discussed	O
.	O

Comparison	O
of	O
the	O
effectiveness	O
of	O
ranitidine	B-Chemical
and	O
cimetidine	B-Chemical
in	O
inhibiting	O
acid	O
secretion	O
in	O
patients	O
with	O
gastric	O
hypersecretory	O
states	O
.	O

The	O
H2-histamine	B-Chemical
receptor	O
antagonists	O
ranitidine	B-Chemical
and	O
cimetidine	B-Chemical
were	O
compared	O
for	O
their	O
abilities	O
to	O
control	O
gastric	O
acid	O
hypersecretion	O
on	O
a	O
short-	O
and	O
long-term	O
basis	O
in	O
22	O
patients	O
with	O
gastric	O
acid	O
hypersecretory	O
states	O
.	O

Nineteen	O
patients	O
had	O
Zollinger-Ellison	B-Disease
syndrome	I-Disease
,	O
one	O
patient	O
had	O
systemic	B-Disease
mastocytosis	I-Disease
,	O
and	O
two	O
patients	O
had	O
idiopathic	O
hypersecretion	O
.	O

The	O
rates	O
of	O
onset	O
of	O
the	O
action	O
of	O
cimetidine	B-Chemical
and	O
ranitidine	B-Chemical
were	O
the	O
same	O
.	O

The	O
actions	O
of	O
both	O
drugs	B-Drug
were	O
increased	O
by	O
anticholinergic	B-Drug
agents	O
,	O
and	O
there	O
was	O
a	O
close	O
correlation	O
between	O
the	O
daily	O
maintenance	O
dose	O
of	O
each	O
drug	B-Drug
needed	O
to	O
control	O
acid	O
secretion	O
.	O

However	O
,	O
ranitidine	B-Chemical
was	O
threefold	O
more	O
potent	O
than	O
cimetidine	B-Chemical
both	O
in	O
acute	O
inhibition	O
studies	O
and	O
in	O
the	O
median	O
maintenance	O
dose	O
needed	O
(	O
1.2	O
g	O
per	O
day	O
for	O
ranitidine	B-Chemical
and	O
3.6	O
g	O
per	O
day	O
for	O
cimetidine	B-Chemical
)	O
.	O

Sixty	O
percent	O
of	O
the	O
males	O
developed	O
breast	O
changes	O
or	O
impotence	B-Disease
while	O
taking	O
cimetidine	B-Chemical
and	O
in	O
all	O
cases	O
these	O
changes	O
disappeared	O
when	O
cimetidine	B-Chemical
was	O
replaced	O
by	O
ranitidine	B-Chemical
.	O

Treatment	O
with	O
high	O
doses	O
of	O
cimetidine	B-Chemical
(	O
one	O
to	O
60	O
months	O
;	O
median	O
,	O
11	O
months	O
)	O
or	O
ranitidine	B-Chemical
(	O
two	O
to	O
31	O
months	O
;	O
median	O
,	O
14	O
months	O
)	O
was	O
not	O
associated	O
with	O
hepatic	B-Disease
or	I-Disease
hematologic	I-Disease
toxicity	I-Disease
or	O
alterations	O
of	O
serum	O
gastrin	O
concentrations	O
,	O
but	O
ranitidine	B-Drug
therapy	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
serum	O
creatinine	O
level	O
than	O
seen	O
with	O
cimetidine	B-Drug
therapy	O
.	O

The	O
results	O
show	O
that	O
both	O
drugs	B-Drug
can	O
adequately	O
inhibit	O
acid	O
secretion	O
in	O
patients	O
with	O
gastric	O
hypersecretory	O
states	O
.	O

Both	O
are	O
safe	O
at	O
high	O
doses	O
,	O
but	O
ranitidine	B-Drug
is	O
threefold	O
more	O
potent	O
and	O
does	O
not	O
cause	O
the	O
antiandrogen	O
side	O
effects	O
frequently	O
seen	O
with	O
high	O
doses	O
of	O
cimetidine	B-Drug
.	O

A	O
catch	O
in	O
the	O
Reye	B-Disease
.	O

Twenty-six	O
cases	O
of	O
Reye	B-Disease
syndrome	I-Disease
from	O
The	O
Children	O
's	O
Hospital	O
,	O
Camperdown	O
,	O
Australia	O
,	O
occurring	O
between	O
1973	O
and	O
1982	O
were	O
reviewed	O
.	O

Of	O
these	O
,	O
20	O
cases	O
met	O
the	O
US	O
Public	O
Health	O
Service	O
Centers	O
for	O
Disease	O
Control	O
criteria	O
for	O
the	O
diagnosis	O
of	O
Reye	B-Disease
syndrome	I-Disease
.	O

Aspirin	B-Chemical
or	O
salicylate	B-Chemical
ingestion	O
had	O
occurred	O
in	O
only	O
one	O
of	O
the	O
20	O
cases	O
(	O
5	O
%	O
)	O
,	O
and	O
paracetamol	B-Chemical
(	O
acetaminophen	B-Chemical
)	O
had	O
been	O
administered	O
in	O
only	O
six	O
of	O
the	O
cases	O
(	O
30	O
%	O
)	O
.	O

Pathologic	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
Reye	B-Disease
syndrome	I-Disease
was	O
accomplished	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

The	O
incidence	O
of	O
Reye	B-Disease
syndrome	I-Disease
in	O
New	O
South	O
Wales	O
,	O
Australia	O
,	O
is	O
estimated	O
from	O
this	O
study	O
to	O
be	O
approximately	O
nine	O
cases	O
per	O
1	O
million	O
children	O
compared	O
with	O
recent	O
US	O
data	O
of	O
ten	O
to	O
20	O
cases	O
per	O
1	O
million	O
children	O
and	O
three	O
to	O
seven	O
cases	O
per	O
1	O
million	O
children	O
in	O
Great	O
Britain	O
.	O

The	O
mortality	O
for	O
these	O
Reye	B-Disease
syndrome	I-Disease
cases	O
in	O
Australia	O
was	O
45	O
%	O
as	O
compared	O
with	O
a	O
32	O
%	O
case-fatality	O
rate	O
in	O
the	O
United	O
States	O
.	O

In	O
Australia	O
,	O
the	O
pediatric	O
usage	O
of	O
aspirin	B-Chemical
has	O
been	O
extremely	O
low	O
for	O
the	O
past	O
25	O
years	O
(	O
less	O
than	O
1	O
%	O
of	O
total	O
dosage	O
units	O
sold	O
)	O
,	O
with	O
paracetamol	B-Chemical
(	O
acetaminophen	B-Chemical
)	O
dominating	O
the	O
pediatric	O
analgesic	O
and	O
antipyretic	O
market	O
.	O

Reye	B-Disease
syndrome	I-Disease
may	O
be	O
disappearing	O
from	O
Australia	O
despite	O
a	O
total	O
lack	O
of	O
association	O
with	O
salicylates	B-Chemical
or	O
aspirin	B-Chemical
ingestion	O
,	O
since	O
there	O
were	O
no	O
cases	O
found	O
at	O
The	O
Children	O
's	O
Hospital	O
in	O
1983	O
,	O
1984	O
,	O
or	O
1985	O
.	O

St.	B-Disease
Anthony	I-Disease
's	I-Disease
fire	I-Disease
,	O
then	O
and	O
now	O
:	O
a	O
case	O
report	O
and	O
historical	O
review	O
.	O

A	O
rare	O
case	O
of	O
morbid	O
vasospasm	B-Disease
,	O
together	O
with	O
striking	O
angiographic	O
findings	O
,	O
is	O
described	O
secondary	O
to	O
the	O
ingestion	O
of	O
methysergide	B-Chemical
by	O
a	O
48-year-old	O
woman	O
.	O

A	O
brief	O
review	O
of	O
the	O
literature	O
on	O
similar	O
cases	O
is	O
presented	O
.	O

A	O
discussion	O
of	O
the	O
history	O
of	O
ergot	B-Chemical
includes	O
its	O
original	O
discovery	O
,	O
the	O
epidemics	O
of	O
gangrene	B-Disease
that	O
it	O
has	O
caused	O
through	O
the	O
ages	O
and	O
its	O
past	O
and	O
present	O
role	O
in	O
the	O
management	O
of	O
migraine	B-Disease
headache	I-Disease
.	O

Despite	O
the	O
advent	O
of	O
calcium	B-Chemical
channel	O
blockers	O
and	O
beta-adrenergic	O
antagonists	O
,	O
ergot	B-Chemical
preparations	O
continue	O
to	O
play	O
a	O
major	O
role	O
in	O
migraine	B-Disease
therapy	O
,	O
so	O
that	O
the	O
danger	O
of	O
St.	B-Disease
Anthony	I-Disease
's	I-Disease
fire	I-Disease
persists	O
.	O

Beta-2-adrenoceptor-mediated	O
hypokalemia	B-Disease
and	O
its	O
abolishment	O
by	O
oxprenolol	B-Chemical
.	O

The	O
time	O
course	O
and	O
concentration-effect	O
relationship	O
of	O
terbutaline-induced	B-Chemical
hypokalemia	B-Disease
was	O
studied	O
,	O
using	O
computer-aided	O
pharmacokinetic-dynamic	O
modeling	O
.	O

Subsequently	O
we	O
investigated	O
the	O
efficacy	O
of	O
oxprenolol	B-Chemical
in	O
antagonizing	O
such	O
hypokalemia	B-Disease
,	O
together	O
with	O
the	O
pharmacokinetic	O
interaction	O
between	O
both	O
drugs	B-Drug
.	O

Six	O
healthy	O
subjects	O
were	O
given	O
a	O
0.5	O
mg	O
subcutaneous	O
dose	O
of	O
terbutaline	B-Chemical
on	O
two	O
occasions	O
:	O
1	O
hour	O
after	O
oral	O
administration	O
of	O
a	O
placebo	O
and	O
1	O
hour	O
after	O
80	O
mg	O
oxprenolol	B-Chemical
orally	O
.	O

In	O
the	O
7-hour	O
period	O
after	O
terbutaline	B-Chemical
administration	O
,	O
plasma	O
samples	O
were	O
taken	O
for	O
determination	O
of	O
plasma	O
potassium	B-Chemical
levels	O
and	O
drug	B-Drug
concentrations	O
.	O

The	O
sigmoid	O
Emax	O
model	O
offered	O
a	O
good	O
description	O
of	O
the	O
relation	O
between	O
terbutaline	B-Chemical
concentrations	O
and	O
potassium	B-Chemical
effects	O
.	O

Oxprenolol	B-Chemical
caused	O
decreases	O
of	O
65	O
%	O
and	O
56	O
%	O
of	O
terbutaline	B-Chemical
volume	O
of	O
distribution	O
and	O
clearance	O
,	O
respectively	O
,	O
and	O
an	O
increase	O
of	O
130	O
%	O
of	O
its	O
AUC	O
.	O

In	O
spite	O
of	O
higher	O
terbutaline	B-Chemical
concentrations	O
after	O
oxprenolol	B-Chemical
pretreatment	O
,	O
the	O
hypokalemia	B-Disease
was	O
almost	O
completely	O
antagonized	O
by	O
the	O
beta	O
2-blocking	O
action	O
.	O

Midline	O
B3	O
serotonin	B-Chemical
nerves	O
in	O
rat	O
medulla	O
are	O
involved	O
in	O
hypotensive	B-Disease
effect	O
of	O
methyldopa	B-Chemical
.	O

Previous	O
experiments	O
in	O
this	O
laboratory	O
have	O
shown	O
that	O
microinjection	O
of	O
methyldopa	B-Chemical
onto	O
the	O
ventrolateral	O
cells	O
of	O
the	O
B3	O
serotonin	B-Chemical
neurons	O
in	O
the	O
medulla	O
elicits	O
a	O
hypotensive	B-Disease
response	O
mediated	O
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	O
cord	O
.	O

The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	B-Chemical
neurons	O
in	O
the	O
medulla	O
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O

In	O
spontaneously	O
hypertensive	B-Disease
,	O
stroke-prone	B-Disease
rats	O
,	O
microinjection	O
of	O
methyldopa	B-Chemical
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	B-Chemical
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	B-Disease
of	O
30-40	O
mm	O
Hg	O
,	O
which	O
was	O
maximal	O
2-3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	B-Chemical
neurotoxin	O
5,7-dihydroxytryptamine	B-Chemical
(	O
5,7-DHT	B-Chemical
)	O
injected	O
intracerebroventricularly	O
.	O

However	O
,	O
intraspinal	O
injection	O
of	O
5,7-DHT	B-Chemical
to	O
produce	O
a	O
more	O
selective	O
lesion	O
of	O
only	O
descending	O
serotonin	B-Chemical
projections	O
in	O
the	O
spinal	O
cord	O
did	O
not	O
affect	O
this	O
hypotension	B-Disease
.	O

Further	O
,	O
5,7-DHT	B-Chemical
lesion	O
of	O
serotonin	B-Chemical
nerves	O
travelling	O
in	O
the	O
median	O
forebrain	O
bundle	O
,	O
one	O
of	O
the	O
main	O
ascending	O
pathways	O
from	O
the	O
B3	O
serotonin	B-Chemical
cells	O
,	O
did	O
not	O
affect	O
the	O
fall	O
in	O
blood	O
pressure	O
associated	O
with	O
a	O
midline	O
B3	O
serotonin	B-Chemical
methyldopa	B-Chemical
injection	O
.	O

It	O
is	O
concluded	O
therefore	O
that	O
,	O
unlike	O
the	O
ventrolateral	O
B3	O
cells	O
which	O
mediate	O
a	O
methyldopa-induced	B-Chemical
hypotension	B-Disease
via	O
descending	O
projections	O
,	O
the	O
midline	O
serotonin	B-Chemical
B3	O
cells	O
in	O
the	O
medulla	O
contribute	O
to	O
the	O
hypotensive	B-Disease
action	O
of	O
methyldopa	B-Chemical
,	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	O
forebrain	O
bundle	O
,	O
or	O
through	O
a	O
projection	O
restricted	O
to	O
the	O
caudal	O
brainstem	O
.	O

Yohimbine	B-Chemical
treatment	O
of	O
sexual	B-Disease
side	I-Disease
effects	I-Disease
induced	O
by	O
serotonin	B-Chemical
reuptake	O
blockers	O
.	O

BACKGROUND	O
:	O
Preclinical	O
and	O
clinical	O
studies	O
suggest	O
that	O
yohimbine	B-Chemical
facilitates	O
sexual	O
behavior	O
and	O
may	O
be	O
helpful	O
in	O
the	O
treatment	O
of	O
male	B-Disease
impotence	I-Disease
.	O

A	O
single	O
case	O
report	O
suggests	O
that	O
yohimbine	B-Chemical
may	O
be	O
used	O
to	O
treat	O
the	O
sexual	B-Disease
side	I-Disease
effects	I-Disease
of	O
clomipramine	B-Chemical
.	O

This	O
study	O
evaluated	O
yohimbine	B-Chemical
as	O
a	O
treatment	O
for	O
the	O
sexual	B-Disease
side	I-Disease
effects	I-Disease
caused	O
by	O
serotonin	B-Chemical
reuptake	O
blockers	O
.	O

METHOD	O
:	O
Six	O
patients	O
with	O
either	O
obsessive	B-Disease
compulsive	I-Disease
disorder	I-Disease
,	O
trichotillomania	B-Disease
,	O
anxiety	B-Disease
,	O
or	O
affective	B-Disease
disorders	I-Disease
who	O
suffered	O
sexual	B-Disease
side	I-Disease
effects	I-Disease
after	O
treatment	O
with	O
serotonin	B-Chemical
reuptake	O
blockers	O
were	O
given	O
yohimbine	B-Chemical
on	O
a	O
p.r.n	O
.	O

basis	O
in	O
an	O
open	O
clinical	O
trial	O
.	O

Various	O
doses	O
of	O
yohimbine	B-Chemical
were	O
used	O
to	O
determine	O
the	O
ideal	O
dose	O
for	O
each	O
patient	O
.	O

RESULTS	O
:	O
Five	O
of	O
the	O
six	O
patients	O
experienced	O
improved	O
sexual	O
functioning	O
after	O
taking	O
yohimbine	B-Chemical
.	O

One	O
patient	O
who	O
failed	O
to	O
comply	O
with	O
yohimbine	B-Chemical
treatment	O
had	O
no	O
therapeutic	O
effects	O
.	O

Side	O
effects	O
of	O
yohimbine	B-Chemical
included	O
excessive	O
sweating	O
,	O
increased	O
anxiety	B-Disease
,	O
and	O
a	O
wound-up	O
feeling	O
in	O
some	O
patients	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
yohimbine	B-Chemical
may	O
be	O
an	O
effective	O
treatment	O
for	O
the	O
sexual	B-Disease
side	I-Disease
effects	I-Disease
caused	O
by	O
serotonin	B-Chemical
reuptake	O
blockers	O
.	O

Future	O
controlled	O
studies	O
are	O
needed	O
to	O
further	O
investigate	O
the	O
effectiveness	O
and	O
safety	O
of	O
yohimbine	B-Chemical
for	O
this	O
indication	O
.	O

Hypersensitivity	B-Disease
immune	O
reaction	O
as	O
a	O
mechanism	O
for	O
dilevalol-associated	B-Chemical
hepatitis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
assess	O
lymphocyte	O
reactivity	O
to	O
dilevalol	B-Chemical
and	O
to	O
serum	O
containing	O
putative	O
ex	O
vivo	O
dilevalol	B-Chemical
antigens	O
or	O
metabolites	O
in	O
a	O
case	O
of	O
dilevalol-induced	B-Chemical
liver	B-Disease
injury	I-Disease
.	O

PATIENT	O
:	O
A	O
58-year-old	O
woman	O
with	O
a	O
clinical	O
diagnosis	O
of	O
dilevalol-induced	B-Chemical
liver	B-Disease
injury	I-Disease
.	O

METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
collected	O
from	O
the	O
patient	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
a	O
solution	O
of	O
dilevalol	B-Chemical
and	O
also	O
with	O
sera	O
collected	O
from	O
a	O
volunteer	O
before	O
and	O
after	O
dilevalol	B-Chemical
intake	O
.	O

A	O
similar	O
protocol	O
was	O
performed	O
with	O
lymphocytes	O
from	O
a	O
healthy	O
subject	O
.	O

RESULTS	O
:	O
No	O
lymphocyte	O
proliferation	O
was	O
observed	O
either	O
in	O
the	O
patient	O
or	O
in	O
the	O
healthy	O
volunteer	O
in	O
the	O
presence	O
of	O
dilevalol	B-Chemical
solutions	O
.	O

A	O
significant	O
proliferative	O
response	O
to	O
serum	O
collected	O
after	O
dilevalol	B-Chemical
intake	O
was	O
observed	O
in	O
the	O
case	O
of	O
the	O
patient	O
compared	O
with	O
the	O
proliferative	O
response	O
to	O
the	O
serum	O
collected	O
before	O
the	O
drug	B-Drug
intake	O
.	O

No	O
reactivity	O
was	O
found	O
when	O
lymphocytes	O
from	O
the	O
healthy	O
subject	O
were	O
tested	O
under	O
similar	O
conditions	O
.	O

CONCLUSIONS	O
:	O
The	O
methodology	O
used	O
allowed	O
the	O
detection	O
of	O
lymphocyte	O
sensitization	O
to	O
sera	O
containing	O
ex	O
vivo-prepared	O
dilevalol	B-Chemical
antigens	O
,	O
suggesting	O
the	O
involvement	O
of	O
an	O
immunologic	O
mechanism	O
in	O
dilevalol-induced	B-Chemical
liver	B-Disease
injury	I-Disease
.	O

Reversible	O
myocardial	B-Disease
hypertrophy	I-Disease
induced	O
by	O
tacrolimus	B-Chemical
in	O
a	O
pediatric	O
heart	O
transplant	O
recipient	O
:	O
case	O
report	O
.	O

Tacrolimus	B-Chemical
is	O
a	O
potent	O
immunosuppressant	O
that	O
is	O
frequently	O
used	O
in	O
organ	O
transplantation	O
.	O

However	O
,	O
adverse	O
effects	O
include	O
cardiac	B-Disease
toxicity	I-Disease
.	O

Herein	O
we	O
describe	O
transient	O
myocardial	B-Disease
hypertrophy	I-Disease
induced	O
by	O
tacrolimus	B-Chemical
after	O
heart	O
transplantation	O
.	O

The	O
hypertrophy	B-Disease
caused	O
no	O
clinical	O
symptoms	O
but	O
was	O
noted	O
because	O
of	O
elevation	O
of	O
plasma	O
brain	O
natriuretic	O
peptide	O
concentration	O
and	O
confirmed	O
at	O
echocardiography	O
.	O

Initially	O
,	O
allograft	O
rejection	O
was	O
feared	O
;	O
however	O
,	O
myocardial	O
biopsy	O
samples	O
revealed	O
only	O
interstitial	O
edema	B-Disease
and	O
mild	O
myocardial	B-Disease
hypertrophy	I-Disease
;	O
neither	O
cellular	O
nor	O
humoral	O
rejection	O
was	O
detected	O
.	O

The	O
blood	O
tacrolimus	B-Chemical
concentration	O
was	O
higher	O
than	O
usual	O
at	O
that	O
time	O
;	O
thus	O
,	O
tacrolimus	B-Chemical
dosage	O
was	O
reduced	O
.	O

Myocardial	B-Disease
hypertrophy	I-Disease
completely	O
resolved	O
upon	O
reducing	O
the	O
target	O
concentration	O
of	O
tacrolimus	B-Chemical
and	O
did	O
not	O
recur	O
,	O
as	O
confirmed	O
at	O
echocardiography	O
and	O
myocardial	O
biopsy	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
tacrolimus	B-Chemical
induces	O
reversible	O
myocardial	B-Disease
hypertrophy	I-Disease
.	O

In	O
patients	O
receiving	O
tacrolimus	B-Chemical
therapy	O
,	O
blood	O
concentration	O
should	O
be	O
carefully	O
controlled	O
and	O
extreme	O
attention	O
paid	O
to	O
cardiac	O
involvement	O
.	O

Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	B-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	B-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O

Ten	O
consecutive	O
patients	O
(	O
mean	O
age	O
,	O
58.4	O
+/-	O
6.8	O
years	O
;	O
7	O
men	O
,	O
3	O
women	O
)	O
with	O
similar	O
characteristics	O
at	O
the	O
duration	O
of	O
disease	O
(	O
mean	O
disease	O
time	O
,	O
8.4	O
+/-	O
3.5	O
years	O
)	O
,	O
disabling	O
motor	O
fluctuations	O
(	O
Hoehn	O
_	O
Yahr	O
stage	O
3-5	O
in	O
off-drug	O
phases	O
)	O
and	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
were	O
selected	O
.	O

All	O
patients	O
had	O
bilateral	O
symptoms	O
and	O
their	O
levodopa	B-Chemical
equivalent	O
dosing	O
were	O
analysed	O
.	O

Six	O
patients	O
were	O
operated	O
on	O
in	O
the	O
globus	O
pallidus	O
interna	O
(	O
GPi	O
)	O
and	O
four	O
in	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
.	O

Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	B-Disease
's	I-Disease
Disease	I-Disease
Rating	O
Scale	O
(	O
UPDRS	O
)	O
,	O
Hoehn_Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'on'-	O
and	O
'off'-drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O

There	O
was	O
statistically	O
significant	O
improvement	O
in	O
all	O
contralateral	O
major	O
parkinsonian	B-Disease
motor	O
signs	O
in	O
all	O
patients	O
followed	O
for	O
6	O
months	O
.	O

Levodopa	B-Chemical
equivalent	O
daily	O
intake	O
was	O
significantly	O
reduced	O
in	O
the	O
STN	O
group	O
.	O

Changes	O
in	O
UPDRS	O
,	O
Hoehn	O
_	O
Yahr	O
and	O
Schwab	O
England	O
ADL	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Cognitive	O
functions	O
were	O
unchanged	O
in	O
both	O
groups	O
.	O

Complications	O
were	O
observed	O
in	O
two	O
patients	O
:	O
one	O
had	O
a	O
left	O
homonymous	B-Disease
hemianopsia	I-Disease
after	O
pallidotomy	O
and	O
another	O
one	O
developed	O
left	O
hemiballistic	O
movements	O
3	O
days	O
after	O
subthalamotomy	O
which	O
partly	O
improved	O
within	O
1	O
month	O
with	O
Valproate	B-Chemical
1000	O
mg/day	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
lesions	O
of	O
the	O
unilateral	O
STN	O
and	O
GPi	O
are	O
equally	O
effective	O
treatment	O
for	O
patients	O
with	O
advanced	O
PD	B-Disease
refractory	O
to	O
medical	O
treatment	O
.	O

Protective	O
effects	O
of	O
antithrombin	O
on	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
in	O
rats	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
antithrombin	O
,	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
,	O
in	O
rats	O
with	O
puromycin	B-Chemical
aminonucleoside-induced	O
nephrosis	O
,	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	O
nephrotic	O
syndrome	O
.	O

Antithrombin	O
(	O
50	O
or	O
500	O
IU/kg/i.v	O
.	O

)	O
was	O
administered	O
to	O
rats	O
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	O
(	O
50	O
mg/kg/i.v.	O
)	O
.	O

Treatment	O
with	O
antithrombin	O
attenuated	O
the	O
puromycin	O
aminonucleoside-induced	O
hematological	O
abnormalities	O
.	O

Puromycin	O
aminonucleoside-induced	O
renal	O
dysfunction	O
and	O
hyperlipidemia	O
were	O
also	O
suppressed	O
.	O

Histopathological	O
examination	O
revealed	O
severe	O
renal	O
damage	O
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	O
,	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin-treated	O
rats	O
.	O

In	O
addition	O
,	O
antithrombin	O
treatment	O
markedly	O
suppressed	O
puromycin	O
aminonucleoside-induced	O
apoptosis	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
.	O

Furthermore	O
,	O
puromycin	O
aminonucleoside-induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O

These	O
findings	O
suggest	O
that	O
thrombin	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	O
aminonucleoside-induced	O
nephrotic	O
syndrome	O
.	O

Treatment	O
with	O
antithrombin	O
may	O
be	O
clinically	O
effective	O
in	O
patients	O
with	O
nephrotic	O
syndrome	O
.	O

Reverse	O
or	O
inverted	O
left	B-Disease
ventricular	I-Disease
apical	I-Disease
ballooning	I-Disease
syndrome	I-Disease
(	O
reverse	O
Takotsubo	B-Disease
cardiomyopathy	I-Disease
)	O
in	O
a	O
young	O
woman	O
in	O
the	O
setting	O
of	O
amphetamine	B-Chemical
use	O
.	O

Transient	O
left	B-Disease
ventricular	I-Disease
apical	I-Disease
ballooning	I-Disease
syndrome	I-Disease
was	O
first	O
described	O
in	O
Japan	O
as	O
``	O
Takotsubo	B-Disease
cardiomyopathy	I-Disease
.	O

''	O
This	O
syndrome	O
has	O
been	O
identified	O
in	O
many	O
other	O
countries	O
.	O

Many	O
variations	O
of	O
this	O
syndrome	O
have	O
been	O
recently	O
described	O
in	O
the	O
literature	O
.	O

One	O
of	O
the	O
rarest	O
is	O
the	O
reverse	O
type	O
of	O
this	O
syndrome	O
,	O
with	O
hyperdynamic	O
apex	O
and	O
complete	O
akinesia	B-Disease
of	O
the	O
base	O
(	O
as	O
opposed	O
to	O
the	O
classic	O
apical	B-Disease
ballooning	I-Disease
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
an	O
interesting	O
case	O
of	O
a	O
young	O
woman	O
who	O
presented	O
with	O
this	O
rare	O
type	O
of	O
reverse	O
apical	B-Disease
ballooning	I-Disease
syndrome	I-Disease
occurring	O
after	O
amphetamine	B-Chemical
use	O
.	O

This	O
report	O
is	O
followed	O
by	O
review	O
of	O
the	O
literature	O
.	O

Attenuated	O
disruption	O
of	O
prepulse	O
inhibition	O
by	O
dopaminergic	B-Drug
stimulation	O
after	O
maternal	O
deprivation	O
and	O
adolescent	O
corticosterone	B-Chemical
treatment	O
in	O
rats	O
.	O

The	O
development	O
of	O
schizophrenia	B-Disease
may	O
include	O
an	O
early	O
neurodevelopmental	O
stress	O
component	O
which	O
increases	O
vulnerability	O
to	O
later	O
stressful	O
life	O
events	O
,	O
in	O
combination	O
leading	O
to	O
overt	O
disease	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
an	O
early	O
stress	O
,	O
in	O
the	O
form	O
of	O
maternal	O
deprivation	O
,	O
combined	O
with	O
a	O
later	O
stress	O
,	O
simulated	O
by	O
chronic	O
periadolescent	O
corticosterone	B-Chemical
treatment	O
,	O
on	O
behaviour	O
in	O
rats	O
.	O

Acute	O
treatment	O
with	O
apomorphine	B-Chemical
caused	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
controls	O
and	O
in	O
rats	O
that	O
had	O
undergone	O
either	O
maternal	O
deprivation	O
or	O
corticosterone	B-Chemical
treatment	O
,	O
but	O
was	O
surprisingly	O
absent	O
in	O
rats	O
that	O
had	O
undergone	O
the	O
combined	O
early	O
and	O
late	O
stress	O
.	O

Amphetamine	B-Chemical
treatment	O
significantly	O
disrupted	O
PPI	O
in	O
both	O
non-deprived	O
groups	O
,	O
but	O
was	O
absent	O
in	O
both	O
maternally	O
deprived	O
groups	O
.	O

The	O
serotonin-1A	B-Chemical
receptor	O
agonist	O
,	O
8-OH-DPAT	B-Chemical
,	O
induced	O
a	O
significant	O
disruption	O
of	O
PPI	O
in	O
all	O
groups	O
.	O

Amphetamine-induced	B-Chemical
locomotor	B-Disease
hyperactivity	I-Disease
was	O
similar	O
in	O
all	O
groups	O
.	O

These	O
results	O
show	O
an	O
inhibitory	O
interaction	O
of	O
early	O
stress	O
,	O
caused	O
by	O
maternal	O
deprivation	O
,	O
combined	O
with	O
'adolescent	O
'	O
stress	O
,	O
simulated	O
by	O
corticosterone	B-Chemical
treatment	O
,	O
on	O
dopaminergic	B-Drug
regulation	O
of	O
PPI	O
.	O

The	O
altered	O
effects	O
of	O
apomorphine	B-Chemical
and	O
amphetamine	B-Chemical
could	O
indicate	O
differential	O
changes	O
in	O
dopamine	B-Chemical
receptor	O
signalling	O
leading	O
to	O
functional	O
desensitisation	O
,	O
or	O
altered	O
modulation	O
of	O
sensory	O
gating	O
in	O
the	O
nucleus	O
accumbens	O
by	O
limbic	O
structures	O
such	O
as	O
the	O
hippocampus	O
.	O

Peripheral	O
iron	B-Chemical
dextran	I-Chemical
induced	O
degeneration	B-Disease
of	I-Disease
dopaminergic	I-Disease
neurons	I-Disease
in	O
rat	O
substantia	O
nigra	O
.	O

Iron	B-Chemical
accumulation	O
is	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

To	O
demonstrate	O
the	O
relationship	O
between	O
peripheral	O
iron	B-Chemical
overload	O
and	O
dopaminergic	B-Drug
neuron	O
loss	O
in	O
rat	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
in	O
the	O
present	O
study	O
we	O
used	O
fast	O
cyclic	O
voltammetry	O
,	O
tyrosine	B-Chemical
hydroxylase	O
(	O
TH	O
)	O
immunohistochemistry	O
,	O
Perls	O
'	O
iron	B-Chemical
staining	O
,	O
and	O
high	O
performance	O
liquid	O
chromatography-electrochemical	O
detection	O
to	O
study	O
the	O
degeneration	B-Disease
of	I-Disease
dopaminergic	I-Disease
neurons	I-Disease
and	O
increased	O
iron	B-Chemical
content	O
in	O
the	O
SN	O
of	O
iron	B-Chemical
dextran	I-Chemical
overloaded	O
animals	O
.	O

The	O
findings	O
showed	O
that	O
peripheral	O
iron	B-Chemical
dextran	I-Chemical
overload	O
increased	O
the	O
iron	B-Chemical
staining	O
positive	O
cells	O
and	O
reduced	O
the	O
number	O
of	O
TH-immunoreactive	O
neurons	O
in	O
the	O
SN	O
.	O

As	O
a	O
result	O
,	O
dopamine	B-Chemical
release	O
and	O
content	O
,	O
as	O
well	O
as	O
its	O
metabolites	O
contents	O
were	O
decreased	O
in	O
caudate	O
putamen	O
.	O

Even	O
more	O
dramatic	O
changes	O
were	O
found	O
in	O
chronic	O
overload	O
group	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
iron	B-Chemical
dextran	I-Chemical
can	O
increase	O
the	O
iron	B-Chemical
level	O
in	O
the	O
SN	O
,	O
where	O
excessive	O
iron	B-Chemical
causes	O
the	O
degeneration	B-Disease
of	I-Disease
dopaminergic	I-Disease
neurons	I-Disease
.	O

The	O
chronic	O
iron	B-Chemical
overload	O
may	O
be	O
more	O
destructive	O
to	O
dopaminergic	B-Drug
neurons	O
than	O
the	O
acute	O
iron	B-Chemical
overload	O
.	O

Warfarin-induced	B-Chemical
leukocytoclastic	B-Disease
vasculitis	I-Disease
.	O

Skin	O
reactions	O
associated	O
with	O
oral	O
coumarin-derived	B-Chemical
anticoagulants	B-Drug
are	O
an	O
uncommon	O
occurrence	O
.	O

Leukocytoclastic	B-Disease
vasculitis	I-Disease
(	O
LV	B-Disease
)	O
is	O
primarily	O
a	O
cutaneous	B-Disease
small	I-Disease
vessel	I-Disease
vasculitis	I-Disease
,	O
though	O
systemic	O
involvement	O
may	O
be	O
encountered	O
.	O

We	O
report	O
4	O
patients	O
with	O
late-onset	O
LV	B-Disease
probably	O
due	O
to	O
warfarin	B-Chemical
.	O

All	O
4	O
patients	O
presented	O
with	O
skin	B-Disease
eruptions	I-Disease
that	O
developed	O
after	O
receiving	O
warfarin	B-Chemical
for	O
several	O
years	O
.	O

The	O
results	O
of	O
skin	B-Disease
lesion	I-Disease
biopsies	O
were	O
available	O
in	O
3	O
patients	O
,	O
confirming	O
LV	B-Disease
Cutaneous	I-Disease
lesions	I-Disease
resolved	O
in	O
all	O
patients	O
after	O
warfarin	B-Chemical
was	O
discontinued	O
.	O

In	O
2	O
of	O
the	O
4	O
patients	O
,	O
rechallenge	O
with	O
warfarin	B-Chemical
led	O
to	O
recurrence	O
of	O
the	O
lesions	O
.	O

LV	B-Disease
may	O
be	O
a	O
late-onset	O
adverse	O
reaction	O
associated	O
with	O
warfarin	B-Chemical
therapy	O
.	O

The	O
activation	O
of	O
spinal	O
N-methyl-D-aspartate	B-Chemical
receptors	O
may	O
contribute	O
to	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
induced	O
by	O
neuraxial	O
morphine	B-Chemical
after	O
a	O
noninjurious	O
interval	O
of	O
spinal	B-Disease
cord	I-Disease
ischemia	I-Disease
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
and	O
activation	O
of	O
N-methyl-d-aspartate	B-Chemical
(	O
NMDA	B-Chemical
)	O
receptors	O
after	O
neuraxial	O
morphine	B-Chemical
following	O
a	O
noninjurious	O
interval	O
of	O
aortic	B-Disease
occlusion	I-Disease
in	O
rats	O
.	O

Spinal	B-Disease
cord	I-Disease
ischemia	I-Disease
was	O
induced	O
by	O
aortic	B-Disease
occlusion	I-Disease
for	O
6	O
min	O
with	O
a	O
balloon	O
catheter	O
.	O

In	O
a	O
microdialysis	O
study	O
,	O
10	O
muL	O
of	O
saline	O
(	O
group	O
C	O
;	O
n	O
=	O
8	O
)	O
or	O
30	O
mug	O
of	O
morphine	B-Chemical
(	O
group	O
M	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
intrathecally	O
(	O
IT	O
)	O
0.5	O
h	O
after	O
reflow	O
,	O
and	O
30	O
mug	O
of	O
morphine	B-Chemical
(	O
group	O
SM	O
;	O
n	O
=	O
8	O
)	O
or	O
10	O
muL	O
of	O
saline	O
(	O
group	O
SC	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
IT	O
0.5	O
h	O
after	O
sham	O
operation	O
.	O

Microdialysis	O
samples	O
were	O
collected	O
preischemia	O
,	O
before	O
IT	O
injection	O
,	O
and	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
24	O
,	O
and	O
48	O
h	O
of	O
reperfusion	O
(	O
after	O
IT	O
injection	O
)	O
.	O

Second	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
IT	O
MK-801	B-Chemical
(	O
30	O
mug	O
)	O
on	O
the	O
histopathologic	O
changes	O
in	O
the	O
spinal	O
cord	O
after	O
morphine-induced	B-Chemical
spastic	B-Disease
paraparesis	I-Disease
.	O

After	O
IT	O
morphine	B-Chemical
,	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
glutamate	B-Chemical
concentration	O
was	O
increased	O
in	O
group	O
M	O
relative	O
to	O
both	O
baseline	O
and	O
group	O
C	O
(	O
P	O
<	O
0.05	O
)	O
.	O

This	O
increase	O
persisted	O
for	O
8	O
hrs	O
.	O

IT	O
MK-801	B-Chemical
significantly	O
reduced	O
the	O
number	O
of	O
dark-stained	O
alpha-motoneurons	O
after	O
morphine-induced	B-Chemical
spastic	B-Disease
paraparesis	I-Disease
compared	O
with	O
the	O
saline	O
group	O
.	O

These	O
data	O
indicate	O
that	O
IT	O
morphine	B-Chemical
induces	O
spastic	B-Disease
paraparesis	I-Disease
with	O
a	O
concomitant	O
increase	O
in	O
CSF	O
glutamate	B-Chemical
,	O
which	O
is	O
involved	O
in	O
NMDA	B-Chemical
receptor	O
activation	O
.	O

We	O
suggest	O
that	O
opioids	O
may	O
be	O
neurotoxic	B-Disease
in	O
the	O
setting	O
of	O
spinal	B-Disease
cord	I-Disease
ischemia	I-Disease
via	O
NMDA	B-Chemical
receptor	O
activation	O
.	O

Reduced	O
sodium	B-Chemical
channel	O
density	O
,	O
altered	O
voltage	O
dependence	O
of	O
inactivation	O
,	O
and	O
increased	O
susceptibility	O
to	O
seizures	B-Disease
in	O
mice	O
lacking	O
sodium	B-Chemical
channel	O
beta	O
2-subunits	O
.	O

Sodium	B-Chemical
channel	O
beta-subunits	O
modulate	O
channel	O
gating	O
,	O
assembly	O
,	O
and	O
cell	O
surface	O
expression	O
in	O
heterologous	O
cell	O
systems	O
.	O

We	O
generated	O
beta2	O
(	O
-/-	O
)	O
mice	O
to	O
investigate	O
the	O
role	O
of	O
beta2	O
in	O
control	O
of	O
sodium	B-Chemical
channel	O
density	O
,	O
localization	O
,	O
and	O
function	O
in	O
neurons	O
in	O
vivo	O
.	O

Measurements	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
saxitoxin	B-Chemical
(	O
STX	B-Chemical
)	O
binding	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
level	O
of	O
plasma	O
membrane	O
sodium	B-Chemical
channels	O
in	O
beta2	O
(	O
-/-	O
)	O
neurons	O
.	O

The	O
loss	O
of	O
beta2	O
resulted	O
in	O
negative	O
shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
inactivation	O
as	O
well	O
as	O
significant	O
decreases	O
in	O
sodium	B-Chemical
current	O
density	O
in	O
acutely	O
dissociated	O
hippocampal	O
neurons	O
.	O

The	O
integral	O
of	O
the	O
compound	O
action	O
potential	O
in	O
optic	O
nerve	O
was	O
significantly	O
reduced	O
,	O
and	O
the	O
threshold	O
for	O
action	O
potential	O
generation	O
was	O
increased	O
,	O
indicating	O
a	O
reduction	O
in	O
the	O
level	O
of	O
functional	O
plasma	O
membrane	O
sodium	B-Chemical
channels	O
.	O

In	O
contrast	O
,	O
the	O
conduction	O
velocity	O
,	O
the	O
number	O
and	O
size	O
of	O
axons	O
in	O
the	O
optic	O
nerve	O
,	O
and	O
the	O
specific	O
localization	O
of	O
Na	B-Chemical
(	O
v	O
)	O
1.6	O
channels	O
in	O
the	O
nodes	O
of	O
Ranvier	O
were	O
unchanged	O
.	O

beta2	O
(	O
-/-	O
)	O
mice	O
displayed	O
increased	O
susceptibility	O
to	O
seizures	B-Disease
,	O
as	O
indicated	O
by	O
reduced	O
latency	O
and	O
threshold	O
for	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
,	O
but	O
seemed	O
normal	O
in	O
other	O
neurological	O
tests	O
.	O

Our	O
observations	O
show	O
that	O
beta2-subunits	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
sodium	B-Chemical
channel	O
density	O
and	O
function	O
in	O
neurons	O
in	O
vivo	O
and	O
are	O
required	O
for	O
normal	O
action	O
potential	O
generation	O
and	O
control	O
of	O
excitability	O
.	O

Screening	O
for	O
stimulant	O
use	O
in	O
adult	O
emergency	O
department	O
seizure	B-Disease
patients	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
positive	O
plasma	O
drug	B-Drug
screening	O
for	O
cocaine	B-Chemical
or	O
amphetamine	B-Chemical
in	O
adult	O
emergency	O
department	O
seizure	B-Disease
patients	O
.	O

METHODS	O
:	O
This	O
prospective	O
study	O
evaluated	O
consecutive	O
eligible	O
seizure	B-Disease
patients	O
who	O
had	O
a	O
plasma	O
sample	O
collected	O
as	O
part	O
of	O
their	O
clinical	O
evaluation	O
.	O

Plasma	O
was	O
tested	O
for	O
amphetamine	B-Chemical
and	O
the	O
cocaine	B-Chemical
metabolite	O
benzoylecgonine	B-Chemical
using	O
enzyme-mediated	O
immunoassay	O
methodology	O
.	O

Plasma	O
samples	O
with	O
benzoylecgonine	B-Chemical
greater	O
than	O
150	O
ng/mL	O
or	O
an	O
amphetamine	B-Chemical
greater	O
than	O
500	O
ng/mL	O
were	O
defined	O
as	O
positive	O
.	O

Patient	O
demographics	O
,	O
history	O
of	O
underlying	O
drug	B-Drug
or	O
alcohol-related	B-Chemical
seizure	B-Disease
disorder	O
,	O
estimated	O
time	O
from	O
seizure	B-Disease
to	O
sample	O
collection	O
,	O
history	O
or	I-Disease
suspicion	O
of	O
cocaine	B-Disease
or	I-Disease
amphetamine	I-Disease
abuse	I-Chemical
,	O
results	O
of	O
clinical	O
urine	O
testing	O
for	O
drugs	B-Drug
of	O
abuse	I-Chemical
,	O
and	O
assay	O
results	O
were	O
recorded	O
without	O
patient	O
identifiers	O
.	O

RESULTS	O
:	O
Fourteen	O
of	O
248	O
(	O
5.6	O
%	O
,	O
95	O
%	O
CI	O
2.7	O
%	O
-8.5	O
%	O
)	O
plasma	O
samples	O
were	O
positive	O
by	O
immunoassay	O
testing	O
for	O
benzoylecgonine	O
and	O
no	O
samples	O
(	O
0	O
%	O
,	O
95	O
%	O
CI	O
0-1.2	O
%	O
)	O
were	O
positive	O
for	O
amphetamine	B-Chemical
.	O

Positive	O
test	O
results	O
were	O
more	O
common	O
in	O
patient	O
visits	O
where	O
there	O
was	O
a	O
history	O
or	O
suspicion	O
of	O
cocaine	B-Drug
or	O
amphetamine	B-Chemical
abuse	O
(	O
p	O
<	O
0.0005	O
)	O
.	O

CONCLUSIONS	O
:	O
During	O
this	O
study	O
period	O
,	O
routine	O
plasma	O
screening	O
for	O
cocaine	B-Drug
and	O
amphetamines	B-Drug
in	O
adult	O
seizure	O
patients	O
had	O
a	O
low	O
yield	O
.	O

As	O
a	O
result	O
,	O
routine	O
plasma	O
screening	O
would	O
yield	O
few	O
cases	O
of	O
stimulant	O
drug	B-Drug
in	O
which	O
there	O
was	O
neither	O
a	O
history	O
nor	O
suspicion	O
of	O
drug	B-Drug
abuse	O
in	O
this	O
population	O
.	O

Evidence	O
of	O
functional	O
somatotopy	O
in	O
GPi	O
from	O
results	O
of	O
pallidotomy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
functional	O
anatomy	O
of	O
the	O
globus	O
pallidus	O
internus	O
(	O
GPi	O
)	O
by	O
studying	O
the	O
effects	O
of	O
unilateral	O
pallidotomy	O
on	O
parkinsonian	B-Disease
'off	O
'	O
signs	O
and	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
(	O
LID	B-Disease
)	O
.	O

We	O
found	O
significant	O
positive	O
correlations	O
between	O
the	O
preoperative	O
levodopa	B-Chemical
responsiveness	O
of	O
motor	O
signs	O
and	O
the	O
levodopa	B-Chemical
responsiveness	O
of	O
scores	O
in	O
timed	O
tests	O
(	O
Core	O
Assessment	O
Program	O
for	O
Intracerebral	O
Transplantations	O
)	O
in	O
the	O
contralateral	O
limbs	O
and	O
the	O
improvement	O
in	O
these	O
scores	O
after	O
surgery	O
,	O
whereas	O
there	O
was	O
no	O
correlation	O
with	O
the	O
improvement	O
in	O
LID	B-Disease
.	O

We	O
also	O
found	O
a	O
highly	O
significant	O
correlation	O
(	O
P	O
:	O
<	O
0.0001	O
,	O
r	O
=	O
0.8	O
)	O
between	O
the	O
volume	O
of	O
the	O
ventral	O
lesion	O
in	O
the	O
GPi	O
and	O
the	O
improvement	O
in	O
LID	B-Disease
in	O
the	O
contralateral	O
limbs	O
,	O
whereas	O
there	O
was	O
no	O
correlation	O
between	O
the	O
ventral	O
volume	O
and	O
the	O
improvement	O
in	O
parkinsonian	B-Disease
'off	O
'	O
signs	O
.	O

The	O
volumes	O
of	O
the	O
total	O
lesion	O
cylinder	O
and	O
the	O
dorsal	O
lesion	O
did	O
not	O
correlate	O
with	O
the	O
outcome	O
of	O
either	O
dyskinesias	B-Disease
or	O
parkinsonian	B-Disease
'off	O
'	O
signs	O
.	O

The	O
differential	O
predictive	O
value	O
of	O
levodopa	B-Chemical
responsiveness	O
for	O
the	O
outcome	O
of	O
parkinsonian	B-Disease
'off	O
'	O
signs	O
and	O
LID	B-Disease
and	O
the	O
different	O
correlations	O
of	O
ventral	O
lesion	O
volume	O
with	O
dyskinesias	B-Disease
and	O
parkinsonian	B-Disease
'off	O
'	O
signs	O
indicate	O
that	O
different	O
anatomical	O
or	O
pathophysiological	O
substrates	O
may	O
be	O
responsible	O
for	O
the	O
generation	O
of	O
parkinsonian	B-Disease
'off	O
'	O
signs	O
and	O
dyskinesias	B-Disease
.	O

Whereas	O
cells	O
in	O
a	O
wider	O
area	O
of	O
the	O
GPi	O
may	O
be	O
implicated	O
in	O
parkinsonism	B-Disease
,	O
the	O
ventral	O
GPi	O
seems	O
to	O
be	O
crucial	O
for	O
the	O
manifestation	O
of	O
LID	B-Disease
.	O

We	O
suggest	O
that	O
our	O
observations	O
are	O
additional	O
proof	O
of	O
the	O
functional	O
somatotopy	O
of	O
the	O
systems	O
within	O
the	O
GPi	O
that	O
mediate	O
parkinsonism	B-Disease
and	O
dyskinesias	B-Disease
,	O
especially	O
along	O
the	O
dorsoventral	O
trajectory	O
used	O
in	O
pallidotomy	O
.	O

The	O
outcome	O
of	O
pallidotomy	O
in	O
which	O
the	O
lesion	O
involves	O
the	O
ventral	O
and	O
dorsal	O
GPi	O
could	O
be	O
the	O
net	O
effect	O
of	O
alteration	O
in	O
the	O
activity	O
of	O
pathways	O
which	O
mediate	O
different	O
symptoms	O
,	O
and	O
hence	O
could	O
be	O
variable	O
.	O

Pain	B-Disease
responses	O
in	O
methadone-maintained	B-Chemical
opioid	O
abusers	O
.	O

Providing	O
pain	B-Disease
management	O
for	O
known	O
opioid	O
abusers	O
is	O
a	O
challenging	O
clinical	O
task	O
,	O
in	O
part	O
because	O
little	O
is	O
known	O
about	O
their	O
pain	B-Disease
experience	O
and	O
analgesic	O
requirements	O
.	O

This	O
study	O
was	O
designed	O
to	O
describe	O
pain	B-Disease
tolerance	O
and	O
analgesic	O
response	O
in	O
a	O
sample	O
of	O
opioid	B-Disease
addicts	I-Disease
stabilized	O
in	O
methadone-maintenance	B-Chemical
(	O
MM	O
)	O
treatment	O
(	O
n	O
=	O
60	O
)	O
in	O
comparison	O
to	O
matched	O
nondependent	O
control	O
subjects	O
(	O
n	O
=	O
60	O
)	O
.	O

By	O
using	O
a	O
placebo-controlled	O
,	O
two-way	O
factorial	O
design	O
,	O
tolerance	O
to	O
cold-pressor	O
(	O
CP	O
)	O
pain	B-Disease
was	O
examined	O
,	O
both	O
before	O
and	O
after	O
oral	O
administration	O
of	O
therapeutic	O
doses	O
of	O
common	O
opioid	O
(	O
hydromorphone	B-Chemical
2	O
mg	O
)	O
and	O
nonsteroidal	O
anti-inflammatory	O
(	O
ketorolac	B-Chemical
10	O
mg	O
)	O
analgesic	O
agents	O
.	O

Results	O
showed	O
that	O
MM	O
individuals	O
were	O
significantly	O
less	O
tolerant	O
of	O
CP	O
pain	B-Disease
than	O
control	O
subjects	O
,	O
replicating	O
previous	O
work	O
.	O

Analgesic	O
effects	O
were	O
significant	O
neither	O
for	O
medication	O
nor	O
group	O
.	O

These	O
data	O
indicate	O
that	O
MM	O
opioid	O
abusers	O
represent	O
a	O
pain-intolerant	B-Disease
subset	O
of	O
clinical	O
patients	O
.	O

Their	O
complaints	O
of	O
pain	B-Disease
should	O
be	O
evaluated	O
seriously	O
and	O
managed	O
aggressively	O
.	O

Urine	O
N-acetyl-beta-D-glucosaminidase	O
--	O
a	O
marker	O
of	O
tubular	O
damage	O
?	O
BACKGROUND	O
:	O
Although	O
an	O
indicator	O
of	O
renal	B-Disease
tubular	I-Disease
dysfunction	I-Disease
,	O
an	O
increased	O
urinary	O
N-acetyl-beta-D-glucosaminidase	O
(	O
NAG	O
)	O
activity	O
might	O
reflect	O
increased	O
lysosomal	O
activity	O
in	O
renal	O
tubular	O
cells	O
.	O

METHODS	O
:	O
Puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
was	O
administered	O
to	O
Sprague	O
Dawley	O
rats	O
to	O
induce	O
proteinuria	B-Disease
.	O

Total	O
protein	O
,	O
albumin	O
,	O
NAG	O
activity	O
and	O
protein	O
electrophoretic	O
pattern	O
were	O
assessed	O
in	O
daily	O
urine	O
samples	O
for	O
33	O
days	O
.	O

The	O
morphological	O
appearance	O
of	O
the	O
kidneys	O
was	O
examined	O
on	O
days	O
three	O
,	O
four	O
,	O
six	O
,	O
eight	O
and	O
thirty	O
three	O
and	O
the	O
NAG	O
isoenzyme	O
patterns	O
on	O
days	O
zero	O
,	O
four	O
,	O
eight	O
and	O
thirty	O
three	O
.	O

RESULTS	O
:	O
Following	O
intravenous	O
PAN	B-Chemical
urine	O
volume	O
and	O
urine	O
NAG	O
activity	O
increased	O
significantly	O
by	O
day	O
two	O
,	O
but	O
returned	O
to	O
normal	O
by	O
day	O
four	O
.	O

After	O
day	O
four	O
all	O
treated	O
animals	O
exhibited	O
a	O
marked	O
rise	O
in	O
urine	O
albumin	O
,	O
total	O
protein	O
excretion	O
and	O
NAG	O
activity	O
.	O

Electrophoresis	O
showed	O
a	O
generalised	O
increase	O
in	O
middle	O
and	O
high	O
molecular	O
weight	O
urine	O
proteins	O
from	O
day	O
four	O
onwards	O
.	O

Protein	O
droplets	O
first	O
appeared	O
prominent	O
in	O
tubular	O
cells	O
on	O
day	O
four	O
.	O

Peak	O
urine	O
NAG	O
activity	O
and	O
a	O
change	O
in	O
NAG	O
isoenzyme	O
pattern	O
coincided	O
with	O
both	O
the	O
peak	O
proteinuria	B-Disease
and	O
the	O
reduction	O
in	O
intracellular	O
protein	O
and	O
NAG	O
droplets	O
(	O
day	O
six	O
onwards	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
animal	O
model	O
demonstrates	O
that	O
an	O
increase	O
in	O
lysosomal	O
turnover	O
and	O
hence	O
urine	O
NAG	O
activity	O
,	O
occurs	O
when	O
increased	O
protein	O
is	O
presented	O
to	O
the	O
tubular	O
cells	O
.	O

Urine	O
NAG	O
activity	O
is	O
thus	O
a	O
measure	O
of	O
altered	O
function	O
in	O
the	O
renal	O
tubules	O
and	O
not	O
simply	O
an	O
indicator	O
of	O
damage	O
.	O

Over	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
its	O
receptor	O
during	O
the	O
development	O
of	O
estrogen-induced	B-Chemical
rat	O
pituitary	B-Disease
tumors	I-Disease
may	O
mediate	O
estrogen-initiated	B-Chemical
tumor	B-Disease
angiogenesis	O
.	O

Estrogens	B-Chemical
,	O
which	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
human	O
and	O
animal	O
cancers	B-Disease
,	O
can	O
induce	O
tumor	B-Disease
angiogenesis	O
in	O
the	O
pituitary	O
of	O
Fischer	O
344	O
rats	O
.	O

The	O
mechanistic	O
details	O
of	O
tumor	B-Disease
angiogenesis	O
induction	O
,	O
during	O
estrogen	B-Chemical
carcinogenesis	B-Disease
,	O
are	O
still	O
unknown	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
estrogen	B-Chemical
in	O
the	O
regulation	O
of	O
tumor	B-Disease
angiogenesis	O
in	O
the	O
pituitary	O
of	O
female	O
rats	O
,	O
the	O
density	O
of	O
blood	O
vessels	O
was	O
analysed	O
using	O
factor	O
VIII	O
related	O
antigen	O
(	O
FVIIIRAg	O
)	O
immunohistochemistry	O
and	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor/vascular	O
permeability	O
factor	O
(	O
VEGF/VPF	O
)	O
was	O
examined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analysis	O
.	O

The	O
expression	O
of	O
VEGF	O
receptor	O
(	O
VEGFR-2/Flk-1/KDR	O
)	O
was	O
also	O
examined	O
by	O
immunohistochemistry	O
.	O

The	O
results	O
demonstrated	O
that	O
17beta-estradiol	B-Chemical
(	O
E2	B-Chemical
)	O
induces	O
neovascularization	O
,	O
as	O
well	O
as	O
the	O
growth	O
and	O
enlargement	O
of	O
blood	O
vessels	O
after	O
7	O
days	O
of	O
exposure	O
.	O

The	O
high	O
tumor	B-Disease
angiogenic	O
potential	O
was	O
associated	O
with	O
an	O
elevated	O
VEGF/VPF	O
protein	O
expression	O
in	O
the	O
E2	B-Chemical
exposed	O
pituitary	O
of	O
ovariectomized	O
(	O
OVEX	O
)	O
rats	O
.	O

VEGF/VPF	O
and	O
FVIIIRAg	O
immunohistochemistry	O
and	O
endothelial	O
specific	O
lectin	O
(	O
UEA1	O
)	O
binding	O
studies	O
,	O
indicate	O
that	O
the	O
elevation	O
of	O
VEGF	O
protein	O
expression	O
initially	O
occurred	O
in	O
both	O
blood	O
vessels	O
and	O
non-endothelial	O
cells	O
.	O

After	O
15	O
days	O
of	O
E2	B-Chemical
exposure	O
,	O
VEGF/VPF	O
protein	O
expression	O
,	O
in	O
the	O
non-endothelial	O
cell	O
population	O
,	O
sharply	O
declined	O
and	O
was	O
restricted	O
to	O
the	O
blood	O
vessels	O
.	O

The	O
function	O
of	O
non-endothelial-derived	O
VEGF	O
is	O
not	O
clear	O
.	O

Furthermore	O
,	O
immunohistochemical	O
studies	O
demonstrated	O
that	O
VEGFR-2	O
(	O
flk-1/KDR	O
)	O
,	O
expression	O
was	O
elevated	O
significantly	O
in	O
the	O
endothelial	O
cells	O
of	O
microblood	O
vessels	O
after	O
7	O
days	O
of	O
E2	B-Chemical
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
over	O
expression	O
of	O
VEGF	O
and	O
its	O
receptor	O
(	O
VEGFR-2	O
)	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
initial	O
step	O
of	O
the	O
regulation	O
of	O
estrogen	B-Chemical
induced	O
tumor	B-Disease
angiogenesis	O
in	O
the	O
rat	O
pituitary	O
.	O

Pravastatin-associated	B-Chemical
myopathy	B-Disease
.	O

Report	O
of	O
a	O
case	O
.	O

A	O
case	O
of	O
acute	O
inflammatory	B-Disease
myopathy	I-Disease
associated	O
with	O
the	O
use	O
of	O
pravastatin	B-Chemical
,	O
a	O
new	O
hydrophilic	O
3-hydroxy-3	O
methylglutaril	O
coenzyme	O
A	O
reductase	O
inhibitor	O
,	O
is	O
reported	O
.	O

The	O
patient	O
,	O
a	O
69-year-old	O
man	O
was	O
affected	O
by	O
non-insulin-dependent	B-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
hypertension	B-Disease
.	O

He	O
assumed	O
pravastatin	B-Chemical
(	O
20	O
mg/day	O
)	O
because	O
of	O
hypercholesterolemia	B-Disease
.	O

He	O
was	O
admitted	O
with	O
acute	O
myopathy	B-Disease
of	O
the	O
lower	O
limbs	O
which	O
resolved	O
in	O
a	O
few	O
days	O
after	O
pravastatin	B-Chemical
discontinuation	O
.	O

A	O
previously	O
unknown	O
hypothyroidism	B-Disease
,	O
probably	O
due	O
to	O
chronic	O
autoimmune	B-Disease
thyroiditis	I-Disease
,	O
was	O
evidenced	O
.	O

Muscle	O
biopsy	O
(	O
left	O
gastrocnemius	O
)	O
revealed	O
a	O
perimysial	O
and	O
endomysial	O
inflammatory	O
infiltrate	O
with	O
a	O
prevalence	O
of	O
CD4+	O
lymphocytes	O
.	O

While	O
lovastatin	B-Chemical
and	O
simvastatin	B-Chemical
have	O
been	O
associated	O
with	O
toxic	O
myopathy	B-Disease
,	O
pravastatin-associated	B-Chemical
myopathy	B-Disease
could	O
represent	O
a	O
distinct	O
,	O
inflammatory	O
entity	O
.	O

Dose-effect	O
and	O
structure-function	O
relationships	O
in	O
doxorubicin	B-Chemical
cardiomyopathy	B-Disease
.	O

The	O
cardiomyopathy	B-Disease
(	O
CM	B-Disease
)	O
produced	O
by	O
the	O
anticancer	O
drug	B-Drug
doxorubicin	B-Chemical
(	O
DXR	B-Chemical
)	O
(	O
Adriamycin	B-Chemical
)	O
provides	O
a	O
unique	O
opportunity	O
to	O
analyze	O
dose-effect	O
and	O
structure-function	O
relationships	O
during	O
development	O
of	O
myocardial	B-Disease
disease	I-Disease
.	O

We	O
measured	O
the	O
degree	O
of	O
morphologic	O
damage	O
by	O
ultrastructural	O
examination	O
of	O
endomyocardial	O
biopsy	O
and	O
the	O
degree	O
of	O
performance	O
abnormally	O
by	O
right	O
heart	O
catheterization	O
in	O
patients	O
receiving	O
DXR	B-Chemical
.	O

Morphologic	O
damage	O
was	O
variable	O
but	O
was	O
proportional	O
to	O
the	O
total	O
cumulative	O
DXR	B-Chemical
dose	O
between	O
100	O
and	O
600	O
mg/m2	O
.	O

Performance	O
abnormalities	O
correlated	O
weakly	O
with	O
dose	O
,	O
exhibited	O
a	O
curvilinear	O
relationship	O
,	O
and	O
had	O
a	O
``	O
threshold	O
''	O
for	O
expression	O
.	O

Catheterization	O
abnormalities	O
correlated	O
well	O
with	O
morphologic	O
damage	O
(	O
r	O
=	O
0.57	O
to	O
0.78	O
)	O
in	O
a	O
subgroup	O
of	O
patients	O
in	O
whom	O
exercise	O
hemodynamics	O
were	O
measured	O
,	O
and	O
this	O
relationship	O
also	O
exhibited	O
a	O
curvilinear	O
,	O
threshold	O
configuration	O
.	O

In	O
DXR-CM	B-Chemical
myocardial	O
damage	O
is	O
proportional	O
to	O
the	O
degree	O
of	O
cytotoxic	O
insult	O
(	O
DXR	O
dose	O
)	O
while	O
myocardial	O
function	O
is	O
preserved	O
until	O
a	O
critical	O
dose	O
or	O
degree	O
of	O
damage	O
is	O
reached	O
,	O
after	O
which	O
myocardial	O
performance	O
deteriorates	O
rapidly	O
.	O

Fatal	O
aplastic	B-Disease
anemia	I-Disease
following	O
topical	O
administration	O
of	O
ophthalmic	O
chloramphenicol	B-Chemical
.	O

A	O
73-year-old	O
woman	O
died	O
of	O
aplastic	B-Disease
anemia	I-Disease
less	O
than	O
two	O
months	O
after	O
undergoing	O
cataract	B-Disease
extraction	O
and	O
beginning	O
topical	O
therapy	O
with	O
chloramphenicol	B-Chemical
.	O

The	O
first	O
signs	O
of	O
pancytopenia	B-Disease
began	O
within	O
one	O
month	O
of	O
the	O
surgery	O
.	O

The	O
pattern	O
of	O
the	O
aplastic	B-Disease
anemia	I-Disease
was	O
associated	O
with	O
an	O
idiosyncratic	O
response	O
to	O
chloramphenicol	B-Chemical
.	O

This	O
was	O
the	O
second	O
report	O
of	O
fatal	O
aplastic	B-Disease
anemia	I-Disease
after	O
topical	O
treatment	O
with	O
chloramphenicol	B-Chemical
for	O
ocular	O
conditions	O
,	O
although	O
two	O
cases	O
of	O
reversible	O
bone	B-Disease
marrow	I-Disease
hypoplasia	I-Disease
have	O
also	O
been	O
reported	O
.	O

Any	O
other	O
suspected	O
cases	O
of	O
ocular	B-Disease
toxicity	I-Disease
associated	O
with	O
topically	O
applied	O
chloramphenicol	B-Chemical
should	O
be	O
reported	O
to	O
the	O
National	O
Registry	O
of	O
Drug-Induced	O
Ocular	O
Side	O
Effects	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
OR	O
97201	O
.	O

Bradycardia	B-Disease
due	O
to	O
trihexyphenidyl	B-Chemical
hydrochloride	I-Chemical
.	O

A	O
chronic	O
schizophrenic	B-Disease
patient	O
was	O
treated	O
with	O
an	O
anticholinergic	B-Drug
drug	B-Drug
,	O
trihexyphenidyl	B-Chemical
hydrochloride	I-Chemical
.	O

The	O
patient	O
developed	O
,	O
paradoxically	O
,	O
sinus	O
bradycardia	B-Disease
.	O

The	O
reaction	O
was	O
specific	O
to	O
trihexyphenidyl	B-Chemical
and	O
not	O
to	O
other	O
anticholinergic	B-Drug
drugs	B-Drug
.	O

This	O
antidyskinetic	O
drug	B-Drug
is	O
widely	O
used	O
in	O
clinical	O
psychiatric	B-Disease
practice	O
and	O
physicians	O
should	O
be	O
aware	O
of	O
this	O
side	O
effect	O
.	O

Experimental	O
cyclosporine	B-Chemical
nephrotoxicity	B-Disease
:	O
risk	O
of	O
concomitant	O
chemotherapy	O
.	O

The	O
role	O
of	O
cyclosporine	B-Chemical
(	O
CSA	B-Chemical
)	O
alone	O
or	O
in	O
combination	O
with	O
various	O
chemotherapeutics	O
in	O
the	O
development	O
of	O
renal	B-Disease
toxicity	I-Disease
was	O
evaluated	O
in	O
rats	O
.	O

Administration	O
of	O
20	O
mg/kg/day	O
CSA	B-Chemical
for	O
4	O
weeks	O
caused	O
renal	O
functional	O
and	O
structural	O
changes	O
similar	O
to	O
those	O
reported	O
in	O
man	O
.	O

The	O
combined	O
administration	O
of	O
CSA	B-Chemical
and	O
various	O
chemotherapeutic	O
drugs	B-Drug
with	O
a	O
nephrotoxic	B-Disease
potential	O
,	O
such	O
as	O
gentamicin	B-Chemical
(	O
at	O
therapeutic	O
doses	O
)	O
,	O
amphothericin	B-Chemical
B	I-Chemical
and	O
ketoconazole	B-Chemical
,	O
which	O
are	O
frequently	O
used	O
in	O
immunosuppressed	O
patients	O
,	O
did	O
not	O
aggravate	O
the	O
CSA	B-Chemical
induced	O
toxicity	B-Disease
in	O
the	O
rat	O
model	O
.	O

Gentamicin	B-Chemical
at	O
toxic	O
doses	O
,	O
however	O
,	O
increased	O
CSA	B-Chemical
nephrotoxicity	B-Disease
.	O

Thus	O
,	O
the	O
nephrotoxicity	B-Disease
induced	O
by	O
CSA	B-Chemical
has	O
a	O
different	O
pathogenetic	O
mechanism	O
.	O

Receptor	O
mechanisms	O
of	O
nicotine-induced	B-Chemical
locomotor	B-Disease
hyperactivity	I-Disease
in	O
chronic	O
nicotine-treated	B-Chemical
rats	O
.	O

Rats	O
were	O
pretreated	O
with	O
saline	O
or	O
nicotine	B-Chemical
(	O
1.5	O
mg/kg	O
per	O
day	O
)	O
by	O
subcutaneously	O
implanting	O
each	O
animal	O
with	O
an	O
Alzet	O
osmotic	O
mini-pump	O
which	O
continuously	O
released	O
saline	O
or	O
nicotine	B-Chemical
for	O
1	O
,	O
5	O
and	O
14	O
days	O
.	O

At	O
the	O
end	O
of	O
each	O
pretreatment	O
period	O
,	O
animals	O
were	O
used	O
for	O
(	O
i	O
)	O
determining	O
their	O
locomotor	O
response	O
to	O
acutely	O
injected	O
nicotine	B-Chemical
(	O
0.2	O
mg/kg	O
,	O
s.c.	O
)	O
and	O
(	O
ii	O
)	O
measuring	O
the	O
density	O
of	O
L-	O
[	O
3H	O
]	O
nicotine	B-Chemical
and	O
[	O
3H	O
]	O
spiperone	B-Chemical
binding	O
sites	O
in	O
the	O
striatum	O
.	O

We	O
observed	O
no	O
changes	O
in	O
nicotine-induced	B-Chemical
locomotor	O
response	O
,	O
striatal	O
L-	O
[	O
3H	O
]	O
nicotine	B-Chemical
and	O
[	O
3H	O
]	O
spiperone	B-Chemical
binding	O
in	O
the	O
animals	O
pretreated	O
with	O
nicotine	B-Chemical
for	O
1	O
day	O
.	O

In	O
rats	O
which	O
were	O
pretreated	O
with	O
nicotine	B-Chemical
for	O
5	O
days	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
nicotine-stimulated	B-Chemical
locomotor	O
response	O
which	O
was	O
associated	O
with	O
an	O
increase	O
in	O
the	O
number	O
of	O
L-	O
[	O
3H	O
]	O
nicotine	B-Chemical
binding	O
sites	O
and	O
also	O
with	O
an	O
elevated	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
level	O
in	O
the	O
striatum	O
.	O

The	O
number	O
of	O
striatal	O
[	O
3H	O
]	O
spiperone	B-Chemical
binding	O
sites	O
was	O
not	O
affected	O
.	O

In	O
animals	O
pretreated	O
with	O
nicotine	B-Chemical
for	O
14	O
days	O
,	O
the	O
nicotine-induced	B-Chemical
locomotor	O
response	O
remained	O
to	O
be	O
potentiated	O
.	O

However	O
,	O
this	O
response	O
was	O
correlated	O
with	O
an	O
elevated	O
number	O
of	O
striatal	O
[	O
3H	O
]	O
spiperone	B-Chemical
binding	O
sites	O
,	O
whereas	O
the	O
number	O
of	O
striatal	O
L-	O
[	O
3H	O
]	O
nicotine	B-Chemical
binding	O
sites	O
and	O
the	O
striatal	O
DA	B-Chemical
level	O
were	O
normal	O
.	O

These	O
results	O
suggest	O
that	O
chronic	O
nicotine-treated	B-Chemical
rats	O
develop	O
locomotor	B-Disease
hyperactivity	I-Disease
in	O
response	O
to	O
nicotine	B-Chemical
initially	O
due	O
to	O
increases	O
of	O
both	O
the	O
density	O
of	O
nicotinic	O
receptors	O
and	O
DA	B-Chemical
concentration	O
,	O
followed	O
by	O
inducing	O
DA	B-Chemical
receptor	O
supersensitivity	O
in	O
the	O
striatum	O
.	O

Hydrocortisone-induced	B-Chemical
hypertension	B-Disease
in	O
humans	O
:	O
pressor	O
responsiveness	O
and	O
sympathetic	O
function	O
.	O

Oral	O
hydrocortisone	B-Chemical
increases	O
blood	O
pressure	O
and	O
enhances	O
pressor	O
responsiveness	O
in	O
normal	O
human	O
subjects	O
.	O

We	O
studied	O
the	O
effects	O
of	O
1	O
week	O
of	O
oral	O
hydrocortisone	B-Chemical
(	O
200	O
mg/day	O
)	O
on	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
total	O
peripheral	O
resistance	O
,	O
forearm	O
vascular	O
resistance	O
,	O
and	O
norepinephrine	B-Chemical
spillover	O
to	O
plasma	O
in	O
eight	O
healthy	O
male	O
volunteers	O
.	O

Although	O
diastolic	O
blood	O
pressure	O
remained	O
unchanged	O
,	O
systolic	O
blood	O
pressure	O
increased	B-Disease
from	O
119	O
to	O
135	O
mm	O
Hg	O
(	O
SED	O
+/-	O
3.4	O
,	O
p	O
less	O
than	O
0.01	O
)	O
,	O
associated	O
with	O
an	O
increased	B-Disease
cardiac	I-Disease
output	O
(	O
5.85-7.73	O
l/min	O
,	O
SED	O
+/-	O
0.46	O
,	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Total	O
peripheral	O
vascular	O
resistance	O
fell	O
from	O
15.1	O
to	O
12.2	O
mm	O
Hg/l/min	O
(	O
SED	O
+/-	O
1.03	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Resting	O
forearm	O
vascular	O
resistance	O
remained	O
unchanged	O
,	O
but	O
the	O
reflex	O
response	O
to	O
the	O
cold	O
pressor	O
test	O
was	O
accentuated	O
,	O
the	O
rise	O
in	O
resistance	O
increasing	O
from	O
10.5	O
mm	O
Hg/ml/100	O
ml/min	O
(	O
R	O
units	O
)	O
before	O
treatment	O
to	O
32.6	O
R	O
units	O
after	O
treatment	O
(	O
SED	O
+/-	O
6.4	O
,	O
p	O
less	O
than	O
0.025	O
)	O
.	O

The	O
rise	O
in	O
forearm	O
vascular	O
resistance	O
accompanying	O
intra-arterial	O
norepinephrine	B-Chemical
(	O
25	O
,	O
50	O
,	O
and	O
100	O
ng/min	O
)	O
was	O
also	O
significantly	O
greater	O
after	O
hydrocortisone	B-Chemical
,	O
increasing	O
from	O
an	O
average	O
of	O
14.9	O
+/-	O
2.4	O
R	O
units	O
before	O
treatment	O
to	O
35.1	O
+/-	O
5.5	O
R	O
units	O
after	O
hydrocortisone	B-Chemical
(	O
SED	O
+/-	O
6.0	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

A	O
shift	O
to	O
the	O
left	O
in	O
the	O
dose-response	O
relation	O
and	O
fall	O
in	O
threshold	O
suggested	O
increased	O
sensitivity	O
to	O
norepinephrine	B-Chemical
after	O
treatment	O
.	O

Measurement	O
of	O
resting	O
norepinephrine	B-Chemical
spillover	O
rate	O
to	O
plasma	O
and	O
norepinephrine	B-Chemical
uptake	O
indicated	O
that	O
overall	O
resting	I-Disease
sympathetic	O
nervous	O
system	O
activity	O
was	O
not	O
increased	O
.	O

The	O
rise	B-Disease
in	I-Disease
resting	I-Disease
blood	I-Disease
pressure	O
with	O
hydrocortisone	B-Chemical
is	O
associated	O
with	O
an	O
increased	B-Disease
cardiac	I-Disease
output	I-Disease
(	O
presumably	O
due	O
to	O
increased	O
blood	O
volume	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Effects	O
of	O
suprofen	B-Chemical
on	O
the	O
isolated	O
perfused	O
rat	O
kidney	O
.	O

Although	O
suprofen	B-Chemical
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
in	O
greater	O
than	O
100	O
subjects	O
,	O
the	O
mechanism	O
of	O
damage	O
remains	O
unclear	O
.	O

The	O
direct	O
nephrotoxic	B-Disease
effects	O
of	O
a	O
single	O
dose	O
of	O
15	O
mg	O
of	O
suprofen	B-Chemical
were	O
compared	O
in	O
the	O
recirculating	O
isolated	O
rat	O
kidney	O
perfused	O
with	O
cell-free	O
buffer	O
with	O
or	O
without	O
the	O
addition	O
of	O
5	O
mg/dL	O
of	O
uric	B-Chemical
acid	I-Chemical
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
renal	O
sodium	B-Chemical
excretion	O
,	O
oxygen	B-Chemical
consumption	O
,	O
or	O
urinary	O
flow	O
rates	O
in	O
kidneys	O
perfused	O
with	O
suprofen	B-Chemical
compared	O
with	O
the	O
drug-free	O
control	O
groups	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
decline	O
in	O
glomerular	O
filtration	O
rate	O
was	O
found	O
after	O
the	O
introduction	O
of	O
suprofen	B-Chemical
to	O
the	O
kidney	O
perfused	O
with	O
uric	B-Chemical
acid	I-Chemical
;	O
no	O
changes	O
were	O
found	O
with	O
suprofen	B-Chemical
in	O
the	O
absence	O
of	O
uric	B-Chemical
acid	I-Chemical
.	O

A	O
significant	O
decrease	O
in	O
the	O
baseline	O
excretion	O
rate	O
of	O
uric	B-Chemical
acid	I-Chemical
was	O
found	O
in	O
rats	O
given	O
suprofen	B-Chemical
,	O
compared	O
with	O
drug-free	O
controls	O
.	O

However	O
,	O
the	O
fractional	O
excretion	O
of	O
uric	B-Chemical
acid	I-Chemical
was	O
unchanged	O
between	O
the	O
groups	O
over	O
the	O
experimental	O
period	O
.	O

In	O
summary	O
,	O
suprofen	B-Chemical
causes	O
acute	B-Disease
declines	I-Disease
in	I-Disease
renal	I-Disease
function	I-Disease
,	O
most	O
likely	O
by	O
directly	O
altering	O
the	O
intrarenal	O
distribution	O
of	O
uric	B-Chemical
acid	I-Chemical
.	O

Cocaine-induced	B-Chemical
brainstem	O
seizures	B-Disease
and	O
behavior	O
.	O

A	O
variety	O
of	O
abnormal	O
sensory/motor	O
behaviors	O
associated	O
with	O
electrical	O
discharges	O
recorded	O
from	O
the	O
bilateral	O
brainstem	O
were	O
induced	O
in	O
adult	O
WKY	O
rats	O
by	O
mechanical	O
(	O
electrode	O
implants	O
)	O
and	O
DC	O
electrical	O
current	O
stimulations	O
and	O
by	O
acute	O
and	O
chronic	O
administration	O
of	O
cocaine	B-Chemical
.	O

The	O
electrode	O
implant	O
implicated	O
one	O
side	O
or	O
the	O
other	O
of	O
the	O
reticular	O
system	O
of	O
the	O
brainstem	O
but	O
subjects	O
were	O
not	O
incapacitated	O
by	O
the	O
stimulations	O
.	O

Cocaine	B-Chemical
(	O
40	O
mg/kg	O
)	O
was	O
injected	O
subcutaneously	O
for	O
an	O
acute	O
experiment	O
and	O
subsequent	O
20	O
mg/kg	O
doses	O
twice	O
daily	O
for	O
3	O
days	O
in	O
a	O
chronic	O
study	O
.	O

Cocaine	B-Chemical
generated	O
more	O
abnormal	O
behaviors	O
in	O
the	O
brainstem	O
perturbation	O
group	O
,	O
especially	O
the	O
electrically	O
perturbated	O
subjects	O
.	O

The	O
abnormal	O
behaviors	O
were	O
yawning	O
,	O
retrocollis	O
,	O
hyperactivity	B-Disease
,	O
hypersensitivity	B-Disease
,	O
``	O
beating	O
drum	O
''	O
behavior	O
,	O
squealing	O
,	O
head	O
bobbing	O
,	O
circling	O
,	O
sniffing	O
,	O
abnormal	O
posturing	O
,	O
and	O
facial	O
twitching	O
.	O

Shifts	O
in	O
the	O
power	O
frequency	O
spectra	O
of	O
the	O
discharge	O
patterns	O
were	O
noted	O
between	O
quiet	O
and	O
pacing	O
behavioral	O
states	O
.	O

Hypersensitivity	B-Disease
to	O
various	O
auditory	O
,	O
tactile	O
,	O
and	O
visual	O
stimulation	O
was	O
present	O
and	O
shifts	O
in	O
the	O
brainstem	O
ambient	O
power	O
spectral	O
frequency	O
occurred	O
in	O
response	O
to	O
tactile	O
stimulation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
brainstem	O
generates	O
and	O
propagates	O
pathological	O
discharges	O
that	O
can	O
be	O
elicited	O
by	O
mechanical	O
and	O
DC	O
electrical	O
perturbation	O
.	O

Cocaine	B-Chemical
was	O
found	O
to	O
activate	O
the	O
discharge	O
system	O
and	O
thus	O
induce	O
abnormal	O
behaviors	O
that	O
are	O
generated	O
at	O
the	O
discharge	O
site	O
and	O
at	O
distant	O
sites	O
to	O
which	O
the	O
discharge	O
propagates	O
.	O

Cognitive	O
functions	O
may	O
also	O
be	O
involved	O
since	O
dopaminergic	B-Drug
and	O
serotonergic	O
cellular	O
elements	O
at	O
the	O
brainstem	O
level	O
are	O
also	O
implicated	O
.	O

Increased	O
sulfation	O
and	O
decreased	O
7alpha-hydroxylation	O
of	O
deoxycholic	B-Chemical
acid	I-Chemical
in	O
ethinyl	B-Chemical
estradiol-induced	O
cholestasis	O
in	O
rats	O
.	O

Deoxycholic	B-Chemical
acid	I-Chemical
conjugation	O
,	O
transport	O
capacity	O
,	O
and	O
metabolism	O
were	O
compared	O
in	O
control	O
and	O
ethinyl	B-Chemical
estradiol-treated	O
rats	O
.	O

Control	O
rats	O
were	O
found	O
to	O
have	O
a	O
lower	O
capacity	O
to	O
transport	O
deoxycholic	O
acid	O
than	O
taurodeoxycholic	O
acid	O
,	O
and	O
both	O
were	O
decreased	O
by	O
ethinyl	B-Chemical
estradiol	B-Drug
treatment	O
.	O

During	O
[	O
24-14C	O
]	O
sodium	O
deoxycholate	O
infusion	O
,	O
[	O
14C	O
]	O
biliary	O
bile	O
acid	I-Chemical
secretion	O
increased	O
,	O
but	O
bile	O
flow	O
did	O
not	O
change	O
significantly	O
in	O
either	O
control	O
or	O
ethinyl	O
estradiol-treated	O
rats	O
.	O

Ethinyl	O
estradiol-treated	O
animals	O
excreted	O
significantly	O
less	O
14C	O
as	O
taurocholic	O
acid	I-Chemical
than	O
did	O
control	O
animals	O
,	O
consistent	O
with	O
an	O
impairment	O
of	O
7alpha-hydroxylation	O
of	O
taurodeoxycholic	B-Chemical
acid	I-Chemical
.	O

Ethinyl	O
estradiol	I-Chemical
treatment	O
did	O
not	O
impair	O
conjugation	O
of	O
deoxycholic	O
acid	O
,	O
but	O
did	O
result	O
in	O
an	O
increase	O
in	O
sulfation	O
of	O
taurodeoxycholic	O
acid	O
from	O
1.5	O
%	O
in	O
controls	O
to	O
nearly	O
4.0	O
%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
rat	O
has	O
a	O
poorer	O
tolerance	O
for	O
deoxycholic	O
acid	O
than	O
do	O
certain	O
other	O
species	O
.	O

Furthermore	O
,	O
the	O
rat	O
converts	O
deoxycholic	O
acid	O
,	O
a	O
poor	O
choleretic	O
,	O
to	O
taurocholic	O
acid	O
,	O
a	O
good	O
choleretic	O
.	O

When	O
this	O
conversion	O
is	O
impaired	O
with	O
ethinyl	B-Chemical
estradiol	B-Drug
treatment	O
,	O
sulfation	O
may	O
be	O
an	O
important	O
alternate	O
pathway	O
for	O
excretion	O
of	O
this	O
potentially	O
harmful	O
bile	O
acid	O
.	O

Effects	O
of	O
ouabain	B-Chemical
on	O
myocardial	O
oxygen	B-Chemical
supply	O
and	O
demand	O
in	O
patients	O
with	O
chronic	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O

A	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
study	O
in	O
patients	O
without	O
heart	B-Disease
failure	I-Disease
.	O

The	O
effects	O
of	O
digitalis	B-Chemical
glycosides	I-Chemical
on	O
myocardial	O
oxygen	B-Chemical
supply	O
and	O
demand	O
are	O
of	O
particular	O
interest	O
in	O
the	O
presence	O
of	O
obstructive	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
but	O
have	O
not	O
been	O
measured	O
previously	O
in	O
man	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
ouabain	B-Chemical
(	O
0.015	O
mg/kg	O
body	O
weight	O
)	O
on	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
parameters	O
in	O
11	O
patients	O
with	O
severe	O
chronic	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
without	O
clinical	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O

Because	O
the	O
protocol	O
was	O
long	O
and	O
involved	O
interventions	O
which	O
might	O
affect	O
the	O
determinations	O
,	O
we	O
also	O
studied	O
in	O
nine	O
patients	O
using	O
an	O
identical	O
protocol	O
except	O
that	O
ouabain	B-Chemical
administration	O
was	O
omitted	O
.	O

Left	O
ventricular	O
end-diastolic	O
pressure	O
and	O
left	O
ventricular	O
end-diastolic	O
volume	O
fell	O
in	O
each	O
patient	O
given	O
ouabain	B-Chemical
,	O
even	O
though	O
they	O
were	O
initially	O
elevated	O
in	O
only	O
two	O
patients	O
.	O

Left	O
ventricular	O
end-diastolic	O
pressure	O
fell	O
from	O
11.5+/-1.4	O
(	O
mean+/-SE	O
)	O
to	O
5.6+/-0.9	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
left	O
ventricular	O
end-diastolic	O
volume	O
fell	O
from	O
100+/-17	O
to	O
82+/-12	O
ml/m2	O
(	O
P	O
less	O
than	O
0.01	O
)	O
1	O
h	O
after	O
ouabain	B-Chemical
infusion	O
was	O
completed	O
.	O

The	O
maximum	O
velocity	O
of	O
contractile	O
element	O
shortening	O
increased	O
from	O
1.68+/-0.11	O
ml/s	O
to	O
2.18+/-0.21	O
muscle-lengths/s	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
is	O
consistent	O
with	O
an	O
increase	O
in	O
contractility	O
.	O

No	O
significant	O
change	O
in	O
these	O
parameters	O
occurred	O
in	O
the	O
control	O
patients	O
.	O

No	O
significant	O
change	O
in	O
myocardial	O
oxygen	B-Chemical
consumption	O
occurred	O
after	O
ouabain	B-Chemical
administration	O
but	O
this	O
may	O
be	O
related	O
to	O
a	O
greater	O
decrease	O
in	O
mean	O
arterial	O
pressure	O
in	O
the	O
ouabain	B-Chemical
patients	O
than	O
in	O
the	O
control	O
patients	O
.	O

We	O
conclude	O
that	O
in	O
patients	O
with	O
chronic	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
who	O
are	O
not	O
in	O
clinical	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
left	B-Disease
ventricular	I-Disease
end-diastolic	I-Disease
volume	I-Disease
falls	I-Disease
after	O
ouabain	B-Chemical
administration	O
even	O
when	O
it	O
is	O
initially	O
normal	O
.	O

Though	O
this	O
fall	O
would	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
wall	O
tension	O
,	O
and	O
,	O
therefore	O
,	O
of	O
myocardial	O
oxygen	B-Chemical
consumption	O
,	O
it	O
may	O
not	O
be	O
of	O
sufficient	O
magnitude	O
to	O
prevent	O
a	O
net	O
increase	O
in	O
myocardial	O
oxygen	B-Chemical
consumption	O
.	O

Nevertheless	O
,	O
compensatory	O
mechanisms	O
prevent	O
a	O
deterioration	O
of	O
resting	O
myocardial	O
metabolism	O
.	O

Prolongation	B-Disease
of	I-Disease
the	I-Disease
QT	I-Disease
interval	I-Disease
related	O
to	O
cisapride-diltiazem	B-Chemical
interaction	O
.	O

Cisapride	B-Chemical
,	O
a	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	B-Drug
)	O
substrate	O
,	O
is	O
widely	O
prescribed	O
for	O
the	O
treatment	O
of	O
gastrointestinal	B-Disease
motility	I-Disease
disorders	I-Disease
.	O

Prolongation	B-Disease
of	I-Disease
QT	I-Disease
interval	I-Disease
,	O
torsades	B-Disease
de	B-Disease
pointes	I-Disease
,	O
and	O
sudden	B-Disease
cardiac	I-Disease
death	I-Disease
have	O
been	O
reported	O
after	O
concomitant	O
administration	O
with	O
erythromycin	B-Chemical
or	O
azole	B-Chemical
antifungal	O
agents	O
,	O
but	O
not	O
with	O
other	O
CYP3A4	B-Drug
inhibitors	O
.	O

A	O
possible	O
drug	B-Drug
interaction	O
occurred	O
in	O
a	O
45-year-old	O
woman	O
who	O
was	O
taking	O
cisapride	B-Chemical
for	O
gastroesophageal	B-Disease
reflux	I-Disease
disorder	I-Disease
and	O
diltiazem	B-Chemical
,	O
an	O
agent	O
that	O
has	O
inhibitory	O
effect	O
on	O
CYP3A4	B-Drug
,	O
for	O
hypertension	B-Disease
.	O

The	O
patient	O
was	O
in	O
near	O
syncope	B-Disease
and	O
had	O
QT-interval	B-Disease
prolongation	I-Disease
.	O

After	O
discontinuing	O
cisapride	B-Chemical
,	O
the	O
QT	O
interval	O
returned	O
to	O
normal	O
and	O
symptoms	O
did	O
not	O
recur	O
.	O

We	O
suggest	O
that	O
caution	O
be	O
taken	O
when	O
cisapride	B-Chemical
is	O
prescribed	O
with	O
any	O
potent	O
inhibitor	O
of	O
CYP3A4	B-Drug
,	O
including	O
diltiazem	B-Chemical
.	O

Paclitaxel	B-Chemical
combined	O
with	O
carboplatin	B-Chemical
in	O
the	O
first-line	O
treatment	O
of	O
advanced	O
ovarian	B-Disease
cancer	I-Disease
.	O

In	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol-Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
given	O
as	O
a	O
3-hour	O
infusion	O
in	O
combination	O
with	O
carboplatin	B-Chemical
administered	O
every	O
21	O
days	O
to	O
women	O
with	O
advanced	O
ovarian	B-Disease
cancer	I-Disease
,	O
paclitaxel	B-Chemical
doses	O
were	O
escalated	O
as	O
follows	O
:	O
level	O
1	O
,	O
135	O
mg/m2	O
;	O
level	O
2	O
,	O
160	O
mg/m2	O
;	O
level	O
3	O
,	O
185	O
mg/m2	O
;	O
and	O
level	O
4,210	O
mg/m2	O
.	O

The	O
fixed	O
dose	O
of	O
carboplatin	B-Chemical
at	O
levels	O
1	O
through	O
4	O
was	O
given	O
to	O
achieve	O
an	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
of	O
5	O
using	O
the	O
Calvert	O
formula	O
.	O

In	O
levels	O
5	O
and	O
6	O
the	O
carboplatin	B-Chemical
dose	O
was	O
targeted	O
at	O
AUCs	O
of	O
6	O
and	O
7.5	O
,	O
respectively	O
,	O
combined	O
with	O
a	O
fixed	O
paclitaxel	B-Chemical
dose	O
of	O
185	O
mg/m2	O
.	O

To	O
date	O
,	O
30	O
previously	O
untreated	O
patients	O
,	O
all	O
with	O
a	O
good	O
performance	O
status	O
(	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
0	O
to	O
2	O
)	O
have	O
been	O
entered	O
into	O
this	O
ongoing	O
study	O
.	O

The	O
dose-limiting	O
toxicity	B-Disease
of	O
the	O
combination	O
was	O
myelosuppression	B-Disease
(	O
leukopenia	B-Disease
,	O
granulocytopenia	B-Disease
,	O
and	O
thrombocytopenia	B-Disease
)	O
.	O

Neurotoxicity	B-Disease
was	O
largely	O
moderate	O
.	O

So	O
far	O
,	O
14	O
patients	O
are	O
evaluable	O
for	O
response	O
;	O
of	O
these	O
,	O
eight	O
(	O
57	O
%	O
)	O
showed	O
objective	O
(	O
complete	O
or	O
partial	O
)	O
response	O
and	O
disease	O
stabilized	O
in	O
six	O
patients	O
.	O

No	O
patient	O
had	O
disease	O
progression	O
.	O

We	O
conclude	O
that	O
the	O
combination	O
of	O
paclitaxel	B-Chemical
185	O
mg/m2	O
administered	O
as	O
a	O
3-hour	O
infusion	O
followed	O
immediately	O
by	O
a	O
1-hour	O
infusion	O
of	O
carboplatin	B-Chemical
at	O
an	O
AUC	O
of	O
6	O
can	O
be	O
administered	O
safely	O
in	O
a	O
21-day	O
schedule	O
in	O
the	O
outpatient	O
setting	O
.	O

The	O
recommended	O
dose	O
for	O
phase	O
III	O
studies	O
is	O
paclitaxel	B-Chemical
185	O
mg/m2	O
and	O
carboplatin	B-Chemical
AUC	O
6	O
.	O

Treatment	O
of	O
tacrolimus-related	B-Chemical
adverse	O
effects	O
by	O
conversion	O
to	O
cyclosporine	B-Chemical
in	O
liver	O
transplant	O
recipients	O
.	O

When	O
tacrolimus	B-Chemical
side	O
effects	O
persist	O
despite	O
dose	O
reduction	O
,	O
conversion	O
to	O
cyclosporine-based	B-Chemical
immunosuppression	O
(	O
CyA	O
)	O
is	O
necessary	O
.	O

We	O
characterized	O
tacrolimus	B-Chemical
side	O
effects	O
that	O
warranted	O
discontinuation	O
of	O
the	O
drug	B-Drug
,	O
and	O
outcomes	O
after	O
conversion	O
.	O

Of	O
388	O
liver	O
recipients	O
who	O
received	O
tacrolimus	B-Chemical
as	O
primary	O
immunosuppression	O
,	O
70	O
required	O
conversion	O
to	O
CyA	O
.	O

We	O
recorded	O
indication	O
for	O
conversion	O
,	O
whether	O
conversion	O
was	O
early	O
or	O
late	O
after	O
transplantation	O
,	O
tacrolimus	B-Chemical
dose	O
and	O
trough	O
blood	O
level	O
at	O
conversion	O
,	O
and	O
incidence	O
of	O
rejection	O
after	O
conversion	O
.	O

Conversion	O
was	O
early	O
in	O
29	O
patients	O
(	O
41.4	O
%	O
)	O
and	O
late	O
in	O
41	O
(	O
58.6	O
%	O
)	O
.	O

Indications	O
for	O
early	O
conversion	O
were	O
neurotoxicity	B-Disease
(	B-Disease
20	O
)	I-Disease
,	O
(	B-Disease
insulin-dependent	I-Disease
)	I-Disease
diabetes	O
mellitus	O
(	O
IDDM	B-Disease
)	O
(	O
5	O
)	O
,	O
nephrotoxicity	B-Disease
(	I-Disease
3	O
)	I-Disease
,	O
gastrointestinal	B-Disease
(	I-Disease
GI	I-Disease
)	O
toxicity	O
(	O
6	O
)	O
,	O
and	O
cardiomyopathy	B-Disease
(	O
1	O
)	O
,	O
and	O
for	O
late	O
conversion	O
were	O
neurotoxicity	B-Disease
(	O
15	O
)	O
,	O
IDDM	B-Disease
(	O
12	O
)	O
,	O
nephrotoxicity	B-Disease
(	O
3	O
)	O
,	O
GI	B-Disease
toxicity	I-Disease
(	O
5	O
)	O
,	O
hepatotoxicity	B-Disease
(	O
6	O
)	O
,	O
post-transplant	B-Disease
lmphoproliferate	I-Disease
disease	I-Disease
(	O
PTLD	B-Disease
)	O
(	O
2	O
)	O
,	O
cardiomyopathy	B-Disease
(	O
1	O
)	O
,	O
hemolytic	B-Disease
anemia	I-Disease
(	O
1	O
)	O
,	O
and	O
pruritus	B-Disease
(	O
1	O
)	O
.	O

All	O
early-conversion	O
patients	O
showed	O
improvement/resolution	O
of	O
symptoms	O
.	O

Among	O
late-conversion	O
patients	O
,	O
37	O
(	O
90.2	O
%	O
)	O
had	O
improvement/resolution	O
;	O
in	O
4	O
(	O
9.8	O
%	O
)	O
,	O
adverse	O
effects	O
persisted	O
.	O

The	O
overall	O
rejection	O
rate	O
was	O
30	O
%	O
.	O

Sixty-two	O
patients	O
(	O
88.6	O
%	O
)	O
are	O
alive	O
with	O
functioning	O
grafts	O
686	O
+/-	O
362	O
days	O
(	O
range	O
,	O
154-1433	O
days	O
)	O
after	O
conversion	O
.	O

When	O
tacrolimus	B-Chemical
side	O
effects	O
are	O
unresponsive	O
to	O
dose	O
reduction	O
,	O
conversion	O
to	O
CyA	O
can	O
be	O
accomplished	O
safely	O
,	O
with	O
no	O
increased	O
risk	O
of	O
rejection	O
and	O
excellent	O
long-term	O
outcome	O
.	O

Relative	O
efficacy	O
and	O
toxicity	B-Disease
of	O
netilmicin	B-Chemical
and	O
tobramycin	B-Chemical
in	O
oncology	O
patients	O
.	O

We	O
prospectively	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
netilmicin	B-Chemical
sulfate	I-Chemical
or	O
tobramycin	B-Chemical
sulfate	I-Chemical
in	O
conjunction	O
with	O
piperacillin	B-Chemical
sodium	I-Chemical
in	O
118	O
immunocompromised	O
patients	O
with	O
presumed	O
severe	O
infections	B-Disease
.	O

The	O
two	O
treatment	O
regimens	O
were	O
equally	O
efficacious	O
.	O

Nephrotoxicity	B-Disease
occurred	O
in	O
a	O
similar	O
proportion	O
in	O
patients	O
treated	O
with	O
netilmicin	B-Chemical
and	O
tobramycin	B-Chemical
(	O
17	O
%	O
vs	O
11	O
%	O
)	O
.	O

Ototoxicity	B-Disease
occurred	O
in	O
four	O
(	O
9.5	O
%	O
)	O
of	O
42	O
netilmicin	B-Chemical
and	O
piperacillin	B-Chemical
and	O
in	O
12	O
(	O
22	O
%	O
)	O
of	O
54	O
tobramycin	B-Chemical
and	O
piperacillin-treated	B-Chemical
patients	O
.	O

Of	O
those	O
evaluated	O
with	O
posttherapy	O
audiograms	O
,	O
three	O
of	O
four	O
netilmicin	B-Chemical
and	O
piperacillin-treated	B-Chemical
patients	O
had	O
auditory	O
thresholds	O
return	O
to	O
baseline	O
compared	O
with	O
one	O
of	O
nine	O
tobramycin	B-Chemical
and	O
piperacillin-treated	B-Chemical
patients	O
.	O

The	O
number	O
of	O
greater	O
than	O
or	O
equal	O
to	O
15-dB	O
increases	O
in	O
auditory	O
threshold	O
as	O
a	O
proportion	O
of	O
total	O
greater	O
than	O
or	O
equal	O
to	O
15-dB	O
changes	O
(	O
increases	O
and	O
decreases	O
)	O
was	O
significantly	O
lower	O
in	O
netilmicin	B-Chemical
and	O
piperacillin-	B-Chemical
vs	O
tobramycin	B-Chemical
and	O
piperacillin-treated	B-Chemical
patients	O
(	O
18	O
of	O
78	O
vs	O
67	O
of	O
115	O
)	O
.	O

We	O
conclude	O
that	O
aminoglycoside-associated	B-Chemical
ototoxicity	B-Disease
was	O
less	O
severe	O
and	O
more	O
often	O
reversible	O
with	O
netilmicin	B-Chemical
than	O
with	O
tobramycin	B-Chemical
.	O

Effect	O
of	O
prostaglandin	B-Chemical
synthetase	O
inhibitors	O
on	O
experimentally	O
induced	O
convulsions	B-Disease
in	O
rats	O
.	O

To	O
investigate	O
the	O
relationship	O
of	O
prostaglandins	B-Chemical
(	O
PGs	B-Chemical
)	O
to	O
seizure	B-Disease
induction	O
,	O
the	O
effects	O
of	O
six	O
PG	O
synthetase	O
inhibitors	O
on	O
convulsions	B-Disease
induced	O
by	O
flurothyl	B-Chemical
,	O
picrotoxin	B-Chemical
,	O
pentetrazol	B-Chemical
(	O
PTZ	B-Chemical
)	O
,	O
electroshock	O
or	O
bicuculline	B-Chemical
were	O
evaluated	O
.	O

Ibuprofen	B-Chemical
,	O
sulindac	B-Chemical
,	O
mefenamic	B-Chemical
acid	I-Chemical
,	O
and	O
low	O
dose	O
meclofenamic	B-Chemical
acid	I-Chemical
increased	O
the	O
latency-to-onset	O
in	O
the	O
flurothyl	B-Chemical
and/or	O
PTZ	B-Chemical
models	O
;	O
the	O
electroshock	O
,	O
picrotoxin	B-Chemical
and	O
bicuculline	B-Chemical
models	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
pretreatment	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
PGs	B-Chemical
are	O
involved	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
underlying	O
fluorthyl-	B-Chemical
and	O
PTZ-induced	B-Chemical
convulsions	B-Disease
,	O
but	O
not	O
picrotoxin-	B-Chemical
,	O
electroshock-	O
,	O
or	O
bicuculline-induced	B-Chemical
convulsions	B-Disease
.	O

Angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor-associated	O
angioedema	B-Disease
of	O
the	O
stomach	O
and	O
small	O
intestine	O
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
on	O
a	O
45-year	O
old	O
African-American	O
female	O
with	O
newly	O
diagnosed	O
hypertension	B-Disease
,	O
who	O
was	O
started	O
on	O
a	O
combination	O
pill	O
of	O
amlodipine/benazapril	B-Chemical
10/5	O
mg	O
.	O

The	O
very	O
next	O
day	O
,	O
she	O
presented	O
at	O
the	O
emergency	O
room	O
(	O
ER	O
)	O
with	O
abdominal	O
pain	O
,	O
nausea	O
and	O
vomiting	O
.	O

Physical	O
exam	O
,	O
complete	O
metabolic	O
panel	O
,	O
and	O
hemogram	O
were	O
in	O
the	O
normal	O
range	O
.	O

She	O
was	O
discharged	O
from	O
the	O
ER	O
after	O
a	O
few	O
hours	O
of	O
treatment	O
with	O
fluid	O
and	O
analgesics	O
.	O

However	O
,	O
she	O
returned	O
to	O
the	O
ER	O
the	O
next	O
day	O
with	O
the	O
same	O
complaints	O
.	O

This	O
time	O
the	O
physical	O
exam	O
was	O
significant	O
for	O
a	O
distended	O
abdomen	O
with	O
dullness	O
to	O
percussion	O
.	O

CT	O
scan	O
of	O
the	O
abdomen	O
revealed	O
markedly	O
thickened	O
antrum	O
of	O
the	O
stomach	O
,	O
duodenum	O
and	O
jejunum	O
,	O
along	O
with	O
fluid	O
in	O
the	O
abdominal	O
and	O
pelvic	O
cavity	O
.	O

Angiotensin-converting	O
enzyme	O
inhibitor	O
(	O
ACEI	O
)	O
-induced	O
angioedema	O
was	O
suspected	O
,	O
and	O
anti-hypertensive	O
medications	O
were	O
discontinued	O
.	O

Her	O
symptoms	O
improved	O
within	O
the	O
next	O
24	O
hours	O
,	O
and	O
repeat	O
CT	O
after	O
72	O
hours	O
revealed	O
marked	O
improvement	O
in	O
stomach	O
and	O
small	O
bowel	O
thickening	O
and	O
resolution	O
of	O
ascites	O
.	O

The	O
recognition	O
of	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
and	O
angiotensin	B-Drug
receptor	O
blocker	O
(	O
ARB	O
)	O
intestinal	O
angioedema	O
constitutes	O
a	O
challenge	O
to	O
primary	O
care	O
physicians	O
,	O
internists	O
,	O
emergency	O
room	O
personal	O
and	O
surgeons	O
.	O

Valproic	B-Chemical
acid	I-Chemical
I	O
:	O
time	O
course	O
of	O
lipid	O
peroxidation	O
biomarkers	O
,	O
liver	B-Disease
toxicity	I-Disease
,	O
and	O
valproic	B-Chemical
acid	I-Chemical
metabolite	O
levels	O
in	O
rats	O
.	O

A	O
single	O
dose	O
of	O
valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	I-Chemical
,	O
which	O
is	O
a	O
widely	O
used	O
antiepileptic	O
drug	B-Drug
,	O
is	O
associated	O
with	O
oxidative	O
stress	O
in	O
rats	O
,	O
as	O
recently	O
demonstrated	O
by	O
elevated	O
levels	O
of	O
15-F	B-Chemical
(	I-Chemical
2t	I-Chemical
)	I-Chemical
-isoprostane	O
(	I-Chemical
15-F	B-Chemical
(	I-Chemical
2t	I-Chemical
)	I-Chemical
-IsoP	O
)	O
.	O

To	O
determine	O
whether	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
VPA-associated	B-Chemical
oxidative	O
stress	O
and	O
hepatotoxicity	B-Disease
,	O
adult	O
male	O
Sprague-Dawley	O
rats	O
were	O
treated	O
ip	O
with	O
VPA	B-Chemical
(	I-Chemical
500	O
mg/kg	O
)	I-Chemical
or	O
0.9	O
%	O
saline	O
(	I-Chemical
vehicle	O
)	I-Chemical
once	O
daily	O
for	O
2	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
or	O
14	O
days	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
determining	O
plasma	O
and	O
liver	O
levels	O
of	O
15-F	B-Chemical
(	O
2t	O
)	O
-IsoP	O
,	O
lipid	B-Chemical
hydroperoxides	I-Chemical
(	O
LPO	B-Chemical
)	O
,	O
and	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	I-Chemical
substances	I-Chemical
(	O
TBARs	B-Chemical
)	I-Chemical
.	O

Plasma	O
and	O
liver	O
15-F	B-Chemical
(	I-Chemical
2t	I-Chemical
)	I-Chemical
-IsoP	O
were	O
elevated	O
and	O
reached	O
a	O
plateau	O
after	O
day	O
2	O
of	O
VPA	B-Chemical
treatment	O
compared	O
to	O
control	O
.	O

Liver	O
LPO	B-Chemical
levels	O
were	O
not	O
elevated	O
until	O
day	O
7	O
of	O
treatment	O
(	O
1.8-fold	O
versus	O
control	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Liver	O
and	O
plasma	O
TBARs	B-Chemical
were	O
not	O
increased	O
until	O
14	O
days	O
(	O
2-fold	O
vs.	O
control	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Liver	B-Disease
toxicity	I-Disease
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha-glutathione	B-Chemical
S-transferase	O
(	O
alpha-GST	O
)	O
and	O
by	O
histology	O
.	O

Serum	O
alpha-GST	O
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	B-Disease
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	B-Disease
of	O
the	O
liver	O
capsule	O
,	O
necrosis	B-Disease
,	O
and	O
steatosis	B-Disease
throughout	O
the	O
study	O
.	O

The	O
liver	O
levels	O
of	O
beta-oxidation	O
metabolites	O
of	O
VPA	B-Chemical
were	O
decreased	O
by	O
day	O
14	O
,	O
while	O
the	O
levels	O
of	O
4-ene-VPA	B-Chemical
and	O
(	O
E	O
)	O
-2,4-diene-VPA	B-Chemical
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O

Overall	O
,	O
these	O
findings	O
indicate	O
that	O
VPA	B-Chemical
treatment	O
results	O
in	O
oxidative	O
stress	O
,	O
as	O
measured	O
by	O
levels	O
of	O
15-F	B-Chemical
(	I-Chemical
2t	I-Chemical
)	I-Chemical
-IsoP	I-Chemical
,	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	B-Disease
,	O
steatosis	B-Disease
,	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha-GST	O
.	O

Pheochromocytoma	B-Disease
unmasked	O
by	O
amisulpride	B-Chemical
and	O
tiapride	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
unmasking	O
of	O
pheochromocytoma	B-Disease
in	O
a	O
patient	O
treated	O
with	O
amisulpride	B-Chemical
and	O
tiapride	B-Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
42-year-old	O
white	O
man	O
developed	O
acute	O
hypertension	B-Disease
with	O
severe	O
headache	B-Disease
and	O
vomiting	B-Disease
2	O
hours	O
after	O
the	O
first	O
doses	O
of	O
amisulpride	B-Chemical
100	O
mg	O
and	O
tiapride	B-Chemical
100	O
mg	O
.	O

Both	O
drugs	B-Drug
were	O
immediately	O
discontinued	O
,	O
and	O
the	O
patient	O
recovered	O
after	O
subsequent	O
nicardipine	B-Chemical
and	O
verapamil	B-Chemical
treatment	O
.	O

Abdominal	O
ultrasound	O
showed	O
an	O
adrenal	O
mass	O
,	O
and	O
postoperative	O
histologic	O
examination	O
confirmed	O
the	O
diagnosis	O
of	O
pheochromocytoma	B-Disease
.	O

DISCUSSION	O
:	O
Drug-induced	O
symptoms	O
of	O
pheochromocytoma	B-Disease
are	O
often	O
associated	O
with	O
the	O
use	O
of	O
substituted	O
benzamide	B-Chemical
drugs	B-Drug
,	O
but	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

In	O
our	O
case	O
,	O
use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
possible	O
relationship	O
between	O
the	O
hypertensive	B-Disease
crisis	O
and	O
amisulpride	B-Chemical
and	O
tiapride	B-Chemical
therapy	O
.	O

CONCLUSIONS	O
:	O
As	O
of	O
March	O
24	O
,	O
2005	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
amisulpride-	B-Chemical
and	O
tiapride-induced	B-Chemical
hypertensive	B-Disease
crisis	O
in	O
a	O
patient	O
with	O
pheochromocytoma	B-Disease
.	O

Physicians	O
and	O
other	O
healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
this	O
potential	O
adverse	O
effect	O
of	O
tiapride	B-Chemical
and	O
amisulpride	B-Chemical
.	O

Quantitative	O
drug	B-Drug
levels	O
in	O
stimulant	O
psychosis	B-Disease
:	O
relationship	O
to	O
symptom	O
severity	O
,	O
catecholamines	B-Chemical
and	O
hyperkinesia	B-Disease
.	O

To	O
examine	O
the	O
relationship	O
between	O
quantitative	O
stimulant	O
drug	B-Drug
levels	O
,	O
catecholamines	B-Chemical
,	O
and	O
psychotic	B-Disease
symptoms	I-Disease
,	O
nineteen	O
patients	O
in	O
a	O
psychiatric	B-Disease
emergency	O
service	O
with	O
a	O
diagnosis	O
of	O
amphetamine-	B-Chemical
or	O
cocaine-induced	B-Chemical
psychosis	B-Disease
were	O
interviewed	O
,	O
and	O
plasma	O
and	O
urine	O
were	O
collected	O
for	O
quantitative	O
assays	O
of	O
stimulant	O
drug	B-Drug
and	O
catecholamine	B-Chemical
metabolite	O
levels	O
.	O

Methamphetamine	B-Chemical
or	O
amphetamine	B-Chemical
levels	O
were	O
related	O
to	O
several	O
psychopathology	O
scores	O
and	O
the	O
global	O
hyperkinesia	B-Disease
rating	O
.	O

HVA	O
levels	O
were	O
related	O
to	O
global	O
hyperkinesia	B-Disease
but	O
not	O
to	O
psychopathology	O
ratings	O
.	O

Although	O
many	O
other	O
factors	O
such	O
as	O
sensitization	O
may	O
play	O
a	O
role	O
,	O
intensity	O
of	O
stimulant-induced	O
psychotic	B-Disease
symptoms	I-Disease
and	O
stereotypies	B-Disease
appears	O
to	O
be	O
at	O
least	O
in	O
part	O
dose-related	O
.	O

Delayed	O
asystolic	B-Disease
cardiac	B-Disease
arrest	I-Disease
after	O
diltiazem	B-Chemical
overdose	B-Disease
;	O
resuscitation	O
with	O
high	O
dose	O
intravenous	O
calcium	B-Chemical
.	O

A	O
51	O
year	O
old	O
man	O
took	O
a	O
mixed	O
overdose	B-Disease
including	O
1.8-3.6	O
g	O
of	O
diltiazem	B-Chemical
,	O
paracetamol	B-Chemical
,	O
aspirin	B-Chemical
,	O
isosorbide	B-Chemical
nitrate	B-Chemical
,	O
and	O
alcohol	B-Chemical
.	O

He	O
initially	O
presented	O
to	O
hospital	O
after	O
six	O
hours	O
with	O
mild	O
hypotension	B-Disease
and	O
was	O
treated	O
with	O
activated	O
charcoal	B-Drug
and	O
intravenous	O
fluids	O
.	O

Eighteen	O
hours	O
after	O
the	O
overdose	B-Disease
he	O
had	O
two	O
generalised	O
tonic-clonic	B-Disease
seizures	I-Disease
.	O

The	O
patient	O
remained	O
unresponsive	O
with	O
junctional	O
bradycardia	B-Disease
,	O
unrecordable	O
blood	O
pressure	O
,	O
and	O
then	O
became	O
asystolic	B-Disease
.	O

He	O
was	O
resuscitated	O
with	O
high	O
dose	O
(	O
13.5	O
g	O
)	O
intravenous	O
calcium	B-Chemical
and	O
adrenaline	B-Chemical
(	O
epinephrine	B-Chemical
)	O
.	O

He	O
required	O
inotropic	O
support	O
and	O
temporary	O
pacing	O
over	O
the	O
next	O
48	O
hours	O
.	O

This	O
case	O
suggests	O
there	O
is	O
a	O
role	O
for	O
aggressive	O
high	O
dose	O
intravenous	O
calcium	B-Chemical
therapy	O
in	O
severe	O
diltiazem	B-Chemical
overdose	B-Disease
,	O
particularly	O
with	O
the	O
onset	O
of	O
asystole	B-Disease
.	O

It	O
should	O
be	O
considered	O
early	O
in	O
cases	O
of	O
cardiac	B-Disease
arrest	I-Disease
after	O
diltiazem	B-Chemical
overdose	B-Disease
.	O

The	O
case	O
also	O
highlights	O
the	O
problems	O
with	O
delayed	O
toxicity	B-Disease
when	O
whole	O
bowel	O
irrigation	O
is	O
not	O
administered	O
.	O

Renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
due	O
to	O
naproxen	B-Chemical
.	O

A	O
31-year-old	O
man	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
,	O
who	O
had	O
previously	O
been	O
treated	O
with	O
sulindac	B-Chemical
,	O
fenoprofen	B-Chemical
calcium	I-Chemical
,	O
high	O
dose	O
salicylates	B-Chemical
and	O
gold	B-Chemical
salts	O
,	O
developed	O
renal	B-Disease
papillary	I-Disease
necrosis	I-Disease
(	O
RPN	B-Disease
)	O
4	O
months	O
after	O
institution	O
of	O
naproxen	B-Chemical
therapy	O
.	O

No	O
other	O
factor	O
predisposing	O
to	O
RPN	B-Disease
could	O
be	O
discovered	O
.	O

Sulindac	B-Chemical
was	O
substituted	O
for	O
naproxen	B-Chemical
and	O
no	O
further	O
adverse	O
renal	O
effects	O
occurred	O
over	O
the	O
next	O
12	O
months	O
.	O

We	O
review	O
previous	O
reports	O
linking	O
RPN	B-Disease
to	O
antiinflammatory	O
drug	B-Drug
use	O
and	O
discuss	O
possible	O
advantages	O
of	O
sulindac	B-Chemical
in	O
patients	O
who	O
have	O
experienced	O
renal	B-Disease
toxicity	I-Disease
from	O
other	O
antiinflammatory	O
agents	O
.	O

Adverse	O
interaction	O
between	O
beta-adrenergic	B-Chemical
blocking	I-Chemical
drugs	I-Chemical
and	O
verapamil	B-Chemical
--	O
report	O
of	O
three	O
cases	O
.	O

Three	O
patients	O
with	O
ischaemic	B-Disease
heart	I-Disease
disease	I-Disease
developed	O
profound	O
cardiac	B-Disease
failure	I-Disease
,	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
during	O
combined	O
therapy	O
with	O
verapamil	B-Chemical
and	O
beta-adrenergic	B-Chemical
blocking	I-Chemical
drugs	I-Chemical
.	O

This	O
clinical	O
picture	O
resolved	O
completely	O
with	O
cessation	O
of	O
the	O
combined	O
therapy	O
.	O

Baseline	O
left	O
ventricular	O
function	O
,	O
assessed	O
by	O
cardiac	O
catheterisation	O
or	O
nuclear	O
angiography	O
,	O
was	O
normal	O
in	O
two	O
patients	O
and	O
only	O
mildly	O
reduced	O
in	O
the	O
other	O
.	O

Simultaneously	O
administration	O
of	O
beta-adrenergic	B-Chemical
blocking	I-Chemical
drugs	I-Chemical
and	O
verapamil	B-Chemical
may	O
result	O
in	O
profound	O
adverse	O
interactions	O
and	O
should	O
only	O
be	O
administered	O
with	O
great	O
caution	O
.	O

Adverse	O
reactions	O
to	O
bendrofluazide	B-Chemical
and	O
propranolol	B-Chemical
for	O
the	O
treatment	O
of	O
mild	O
hypertension	B-Disease
.	O

Report	O
of	O
Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Mild	O
to	O
Moderate	O
Hypertension	B-Disease
.	O

Participants	O
in	O
the	O
Medical	O
Research	O
Council	O
treatment	O
trial	O
for	O
mild	O
hypertension	B-Disease
are	O
randomly	O
allocated	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
:	O
bendrofluazide	B-Chemical
,	O
propranolol	B-Chemical
,	O
or	O
a	O
placebo	O
for	O
either	O
of	O
these	O
drugs	B-Drug
.	O

The	O
trial	O
is	O
single-blind	O
.	O

23	O
582	O
patient-years	O
of	O
observation	O
have	O
been	O
completed	O
so	O
far	O
,	O
10	O
684	O
on	O
active	O
drugs	B-Drug
and	O
12	O
898	O
on	O
placebos	O
.	O

The	O
results	O
show	O
an	O
association	O
between	O
bendrofluazide	B-Chemical
treatment	O
and	O
impotence	B-Disease
,	O
and	O
impotence	B-Disease
also	O
occurred	O
more	O
frequently	O
in	O
patients	O
taking	O
propranolol	B-Chemical
than	O
in	O
those	O
taking	O
placebos	O
.	O

Other	O
adverse	O
reactions	O
significantly	O
linked	O
with	O
active	O
drugs	B-Drug
include	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
in	O
men	O
and	O
women	O
and	O
gout	B-Disease
in	O
men	O
,	O
associated	O
with	O
bendrofluazide	B-Chemical
treatment	O
,	O
and	O
Raynaud	B-Disease
's	I-Disease
phenomenon	I-Disease
and	O
dyspnoea	B-Disease
in	O
men	O
and	O
women	O
taking	O
propranolol	B-Chemical
.	O

No	O
corneal	B-Disease
disease	I-Disease
is	O
known	O
to	O
have	O
occurred	O
in	O
the	O
propranolol	B-Chemical
group	O
.	O

Mean	O
serum	O
potassium	B-Chemical
level	O
fell	O
,	O
and	O
urea	B-Chemical
and	O
uric	B-Chemical
acid	I-Chemical
levels	O
rose	O
,	O
in	O
men	O
and	O
women	O
taking	O
bendrofluazide	B-Chemical
.	O

In	O
the	O
propranolol	B-Chemical
group	O
,	O
serum	O
potassium	B-Chemical
and	O
uric	B-Chemical
acid	I-Chemical
levels	O
rose	O
in	O
both	O
sexes	O
,	O
but	O
the	O
urea	B-Chemical
level	O
rose	O
significantly	O
in	O
women	O
only	O
.	O

Dexmedetomidine	B-Chemical
and	O
cardiac	O
protection	O
for	O
non-cardiac	O
surgery	O
:	O
a	O
meta-analysis	O
of	O
randomised	O
controlled	O
trials	O
.	O

We	O
conducted	O
a	O
systematic	O
review	O
of	O
the	O
effects	O
of	O
dexmedetomidine	B-Chemical
on	O
cardiac	O
outcomes	O
following	O
non-cardiac	O
surgery	O
.	O

We	O
included	O
prospective	O
,	O
randomised	O
peri-operative	O
studies	O
of	O
dexmedetomidine	B-Chemical
that	O
reported	O
mortality	O
,	O
cardiac	O
morbidity	O
or	O
adverse	O
drug	B-Drug
events	O
.	O

A	O
PubMed	O
Central	O
and	O
EMBASE	O
search	O
was	O
conducted	O
up	O
to	O
July	O
2007	O
.	O

The	O
reference	O
lists	O
of	O
identified	O
papers	O
were	O
examined	O
for	O
further	O
trials	O
.	O

Of	O
425	O
studies	O
identified	O
,	O
20	O
were	O
included	O
in	O
the	O
meta-analysis	O
(	O
840	O
patients	O
)	O
.	O

Dexmedetomidine	B-Chemical
was	O
associated	O
with	O
a	O
trend	O
towards	O
improved	O
cardiac	O
outcomes	O
;	O
all-cause	O
mortality	O
(	O
OR	O
0.27	O
,	O
95	O
%	O
CI	O
0.01-7.13	O
,	O
p	O
=	O
0.44	O
)	O
,	O
non-fatal	O
myocardial	B-Disease
infarction	I-Disease
(	O
OR	O
0.26	O
,	O
95	O
%	O
CI	O
0.04-1.60	O
,	O
p	O
=	O
0.14	O
)	O
,	O
and	O
myocardial	B-Disease
ischaemia	I-Disease
(	O
OR	O
0.65	O
,	O
95	O
%	O
CI	O
0.26-1.63	O
,	O
p	O
=	O
0.36	O
)	O
.	O

Peri-operative	O
hypotension	B-Disease
(	O
26	O
%	O
,	O
OR	O
3.80	O
,	O
95	O
%	O
CI	O
1.91-7.54	O
,	O
p	O
=	O
0.0001	O
)	O
and	O
bradycardia	B-Disease
(	O
17	O
%	O
,	O
OR	O
5.45	O
,	O
95	O
%	O
CI	O
2.98-9.95	O
,	O
p	O
<	O
0.00001	O
)	O
were	O
significantly	O
increased	O
.	O

An	O
anticholinergic	B-Drug
did	O
not	O
reduce	O
the	O
incidence	O
of	O
bradycardia	B-Disease
(	O
p	O
=	O
0.43	O
)	O
.	O

A	O
randomised	O
placebo-controlled	O
trial	O
of	O
dexmedetomidine	B-Chemical
is	O
warranted	O
.	O

Differential	O
diagnosis	O
of	O
high	O
serum	O
creatine	B-Chemical
kinase	O
levels	O
in	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
.	O

We	O
report	O
the	O
clinical	O
and	O
bioptic	O
findings	O
for	O
a	O
57-year-old	O
woman	O
with	O
severe	O
chloroquine-induced	B-Chemical
myopathy	B-Disease
.	O

Since	O
1989	O
,	O
she	O
had	O
been	O
suffering	O
from	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
with	O
renal	B-Disease
involvement	I-Disease
and	O
undergone	O
periods	O
of	O
treatment	O
with	O
azathioprine	B-Chemical
and	O
cyclophosphamide	B-Chemical
.	O

Additional	O
therapy	O
with	O
chloroquine	B-Chemical
(	O
CQ	B-Chemical
)	O
was	O
started	O
because	O
of	O
arthralgia	B-Disease
.	O

At	O
the	O
same	O
time	O
,	O
slightly	O
increased	O
creatine	B-Chemical
kinase	O
(	O
CK	O
)	O
levels	O
were	O
noted	O
.	O

Myositis	B-Disease
was	O
suspected	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
steroids	B-Chemical
.	O

The	O
CK	O
increase	O
persisted	O
,	O
however	O
,	O
and	O
she	O
developed	O
progressive	O
muscular	B-Disease
weakness	I-Disease
and	O
muscular	B-Disease
atrophy	I-Disease
.	O

Routine	O
controls	O
revealed	O
markedly	O
elevated	O
CK	O
levels	O
of	O
1,700	O
U/l	O
.	O

The	O
neurological	O
and	O
electrophysiological	O
findings	O
were	O
not	O
typical	O
of	O
myositis	B-Disease
.	O

Thus	O
,	O
muscle	O
biopsy	O
of	O
the	O
deltoid	O
muscle	O
was	O
performed	O
in	O
order	O
to	O
exclude	O
polymyositis	B-Disease
or	O
toxic	O
myopathy	B-Disease
.	O

As	O
it	O
revealed	O
chloroquine-induced	B-Chemical
myopathy	B-Disease
,	O
medication	O
was	O
stopped	O
.	O

Discriminating	O
between	O
primary	O
SLE-induced	B-Disease
affection	B-Disease
of	I-Disease
the	I-Disease
musculoskeletal	I-Disease
system	I-Disease
and	O
drug-induced	O
side	O
effects	O
is	O
important	O
for	O
appropriate	O
treatment	O
of	O
SLE	B-Disease
patients	O
.	O

Intravenous	O
ribavirin	B-Chemical
treatment	O
for	O
severe	O
adenovirus	B-Disease
disease	I-Disease
in	O
immunocompromised	O
children	O
.	O

BACKGROUND	O
:	O
Adenovirus	O
is	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
immunocompromised	O
host	O
.	O

The	O
incidence	O
of	O
severe	O
adenovirus	B-Disease
disease	I-Disease
in	O
pediatrics	O
is	O
increasing	O
in	O
association	O
with	O
growing	O
numbers	O
of	O
immunocompromised	O
children	O
,	O
where	O
case	O
fatality	O
rates	O
as	O
high	O
as	O
50	O
%	O
to	O
80	O
%	O
have	O
been	O
reported	O
.	O

There	O
are	O
no	O
approved	O
antiviral	O
agents	O
with	O
proven	O
efficacy	O
for	O
the	O
treatment	O
of	O
severe	O
adenovirus	B-Disease
disease	I-Disease
,	O
nor	O
are	O
there	O
any	O
prospective	O
randomized	O
,	O
controlled	O
trials	O
of	O
potentially	O
useful	O
anti-adenovirus	B-Disease
therapies	O
.	O

Apparent	O
clinical	O
success	O
in	O
the	O
treatment	O
of	O
severe	O
adenovirus	B-Disease
disease	O
is	O
limited	O
to	O
a	O
few	O
case	O
reports	O
and	O
small	O
series	O
.	O

Experience	O
is	O
greatest	O
with	O
intravenous	O
ribavirin	B-Chemical
and	O
cidofovir	B-Chemical
.	O

Ribavirin	B-Chemical
,	O
a	O
guanosine	B-Chemical
analogue	O
,	O
has	O
broad	O
antiviral	O
activity	O
against	O
both	O
RNA	O
and	O
DNA	O
viruses	O
,	O
including	O
documented	O
activity	O
against	O
adenovirus	O
in	O
vitro	O
.	O

Ribavirin	B-Chemical
is	O
licensed	O
in	O
aerosol	O
form	O
for	O
the	O
treatment	O
of	O
respiratory	B-Disease
syncytial	I-Disease
virus	I-Disease
infection	I-Disease
,	O
and	O
orally	O
in	O
combination	O
with	O
interferon	O
to	O
treat	O
hepatitis	B-Disease
C.	O
Intravenous	O
ribavirin	B-Drug
is	O
the	O
treatment	O
of	O
choice	O
for	O
infection	O
with	O
hemorrhagic	O
fever	O
viruses	O
.	O

The	O
most	O
common	O
adverse	O
effect	O
of	O
intravenous	O
ribavirin	B-Drug
is	O
reversible	O
mild	O
anemia	O
.	O

The	O
use	O
of	O
cidofovir	O
in	O
severe	O
adenovirus	O
infection	O
has	O
been	O
limited	O
by	O
adverse	O
effects	O
,	O
the	O
most	O
significant	O
of	O
which	O
is	O
nephrotoxicity	O
.	O

OBJECTIVE	O
:	O
We	O
report	O
our	O
experience	O
with	O
intravenous	O
ribavirin	B-Drug
therapy	O
for	O
severe	O
adenovirus	O
disease	O
in	O
a	O
series	O
of	O
immunocompromised	O
children	O
and	O
review	O
the	O
literature	O
.	O

DESIGN/METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
of	O
5	O
children	O
treated	O
with	O
intravenous	O
ribavirin	B-Drug
for	O
documented	O
severe	O
adenovirus	O
disease	O
.	O

Two	O
patients	O
developed	O
adenovirus	O
hemorrhagic	O
cystitis	O
after	O
cardiac	O
and	O
bone	O
marrow	O
transplants	O
,	O
respectively	O
.	O

The	O
bone	O
marrow	O
transplant	O
patient	O
also	O
received	O
intravenous	O
cidofovir	O
for	O
progressive	O
disseminated	O
disease	O
.	O

An	O
additional	O
3	O
children	O
developed	O
adenovirus	O
pneumonia	O
;	O
2	O
were	O
neonates	O
,	O
1	O
of	O
whom	O
had	O
partial	O
DiGeorge	O
syndrome	O
.	O

The	O
remaining	O
infant	O
had	O
recently	O
undergone	O
a	O
cardiac	O
transplant	O
.	O

Intravenous	O
ribavirin	B-Drug
was	O
administered	O
on	O
a	O
compassionate-use	O
protocol	O
.	O

RESULTS	O
:	O
Complete	O
clinical	O
recovery	O
followed	O
later	O
by	O
viral	O
clearance	O
was	O
observed	O
in	O
2	O
children	O
:	O
the	O
cardiac	O
transplant	O
recipient	O
with	O
adenovirus	O
hemorrhagic	O
cystitis	O
and	O
the	O
immunocompetent	O
neonate	O
with	O
adenovirus	O
pneumonia	O
.	O

The	O
remaining	O
3	O
children	O
died	O
of	O
adenovirus	O
disease	O
.	O

Intravenous	O
ribavirin	B-Drug
therapy	O
was	O
well	O
tolerated	O
.	O

Use	O
of	O
cidofovir	O
in	O
1	O
child	O
was	O
associated	O
with	O
progressive	O
renal	O
failure	O
and	O
neutropenia	O
.	O

DISCUSSION	O
:	O
Our	O
series	O
of	O
patients	O
is	O
representative	O
of	O
the	O
spectrum	O
of	O
immunocompromised	O
children	O
at	O
greatest	O
risk	O
for	O
severe	O
adenovirus	O
disease	O
,	O
namely	O
solid-organ	O
and	O
bone	O
marrow	O
transplant	O
recipients	O
,	O
neonates	O
,	O
and	O
children	O
with	O
immunodeficiency	O
.	O

Although	O
intravenous	O
ribavirin	B-Drug
was	O
not	O
effective	O
for	O
all	O
children	O
with	O
severe	O
adenovirus	O
disease	O
in	O
this	O
series	O
or	O
in	O
the	O
literature	O
,	O
therapy	O
is	O
unlikely	O
to	O
be	O
of	O
benefit	O
if	O
begun	O
late	O
in	O
the	O
course	O
of	O
the	O
infection	O
.	O

Early	O
identification	O
,	O
eg	O
by	O
polymerase	O
chain	O
reaction	O
of	O
those	O
patients	O
at	O
risk	O
of	O
disseminated	O
adenovirus	O
disease	O
may	O
permit	O
earlier	O
antiviral	O
treatment	O
and	O
better	O
evaluation	O
of	O
therapeutic	O
response	O
.	O

CONCLUSIONS	O
:	O
Two	O
of	O
5	O
children	O
with	O
severe	O
adenovirus	O
disease	O
treated	O
with	O
intravenous	O
ribavirin	B-Drug
recovered	O
.	O

The	O
availability	O
of	O
newer	O
rapid	O
diagnostic	O
techniques	O
,	O
such	O
as	O
polymerase	O
chain	O
reaction	O
,	O
may	O
make	O
earlier	O
,	O
more	O
effective	O
treatment	O
of	O
adenovirus	O
infection	O
possible	O
.	O

Given	O
the	O
seriousness	O
and	O
increasing	O
prevalence	O
of	O
adenovirus	O
disease	O
in	O
certain	O
hosts	O
,	O
especially	O
children	O
,	O
a	O
large	O
,	O
multicenter	O
clinical	O
trial	O
of	O
potentially	O
useful	O
anti-adenoviral	O
therapies	O
,	O
such	O
as	O
intravenous	O
ribavirin	B-Drug
,	O
is	O
clearly	O
required	O
to	O
demonstrate	O
the	O
most	O
effective	O
and	O
least	O
toxic	O
therapy	O
.	O

Hepatotoxicity	B-Disease
of	O
amiodarone	B-Chemical
.	O

Amiodarone	B-Chemical
has	O
proved	O
very	O
effective	O
in	O
the	O
treatment	O
of	O
otherwise	O
resistant	O
cardiac	O
tachyarrhythmias	B-Disease
.	O

The	O
use	O
of	O
amiodarone	B-Chemical
has	O
,	O
however	O
,	O
been	O
limited	O
due	O
to	O
its	O
serious	O
side-effects	O
.	O

A	O
patient	O
with	O
cholestatic	B-Disease
hepatitis	I-Disease
due	O
to	O
amiodarone	B-Drug
treatment	O
is	O
presented	O
below	O
and	O
a	O
review	O
of	O
the	O
hepatotoxicity	O
of	O
amiodarone	B-Drug
is	O
given	O
.	O

It	O
is	O
concluded	O
that	O
solid	O
evidence	O
exists	O
of	O
hepatic	O
injury	O
due	O
to	O
amiodarone	B-Drug
treatment	O
,	O
including	O
steatosis	O
,	O
alterations	O
resembling	O
alcoholic	O
hepatitis	O
,	O
cholestatic	B-Chemical
hepatitis	B-Chemical
and	O
micronodular	O
cirrhosis	O
of	O
the	O
liver	O
.	O

Patients	O
receiving	O
amiodarone	B-Disease
should	O
be	O
regularly	O
screened	O
with	O
respect	O
to	O
hepatic	O
enzyme	O
levels	O
.	O

Therapy	O
should	O
be	O
discontinued	O
on	O
the	O
suspicion	O
of	O
cholestatic	O
injury	O
or	O
hepatomegaly	O
.	O

Catalepsy	B-Disease
induced	O
by	O
combinations	O
of	O
ketamine	B-Chemical
and	O
morphine	B-Chemical
:	O
potentiation	O
,	O
antagonism	O
,	O
tolerance	O
and	O
cross-tolerance	O
in	O
the	O
rat	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
both	O
ketamine	B-Chemical
and	O
morphine	B-Chemical
induced	O
analgesia	B-Disease
and	O
catalepsy	B-Disease
in	O
the	O
rat	O
.	O

Pre-treatment	O
with	O
ketamine	B-Chemical
produced	O
cross-tolerance	O
to	O
morphine	B-Chemical
,	O
whereas	O
pretreatment	O
with	O
morphine	B-Chemical
did	O
not	O
induce	O
cross-tolerance	O
to	O
ketamine	B-Chemical
but	O
rather	O
augmented	O
the	O
cataleptic	B-Disease
response	O
;	O
this	O
augmentation	O
was	O
attributed	O
to	O
residual	O
morphine	B-Chemical
in	O
the	O
brain	O
.	O

The	O
present	O
studies	O
explored	O
the	O
duration	O
of	O
the	O
loss	O
of	O
righting	O
reflex	O
induced	O
by	O
sub-effective	O
doses	O
of	O
ketamine	B-Chemical
and	O
morphine	B-Chemical
,	O
administered	O
simultaneously	O
.	O

There	O
was	O
mutual	O
potentiation	O
between	O
sub-effective	O
doses	O
of	O
ketamine	B-Chemical
and	O
morphine	B-Chemical
,	O
but	O
sub-effective	O
doses	O
of	O
ketamine	B-Chemical
partly	O
antagonized	O
fully-effective	O
doses	O
of	O
morphine	B-Chemical
.	O

Latency	O
to	O
the	O
loss	O
of	O
righting	O
reflex	O
,	O
rigidity	B-Disease
and	O
behavior	O
on	O
recovery	O
,	O
reflected	O
the	O
relative	O
predominance	O
of	O
ketamine	B-Chemical
or	O
morphine	B-Chemical
in	O
each	O
combination	O
.	O

Naloxone	B-Chemical
inhibited	O
the	O
induced	O
cataleptic	B-Disease
effects	O
.	O

The	O
degree	O
and	O
time	O
course	O
of	O
development	O
of	O
tolerance	O
to	O
daily	O
administration	O
of	O
sub-effective	O
dose	O
combinations	O
of	O
ketamine	B-Chemical
and	O
morphine	B-Chemical
were	O
similar	O
.	O

Rats	O
,	O
tolerant	O
to	O
ketamine-dominant	B-Chemical
combinations	O
,	O
were	O
cross-tolerant	O
to	O
both	O
drugs	B-Drug
,	O
while	O
those	O
tolerant	O
to	O
morphine-dominant	B-Chemical
combinations	O
were	O
cross-tolerant	O
to	O
morphine	B-Chemical
but	O
showed	O
either	O
no	O
cross-tolerance	O
or	O
an	O
augmented	O
response	O
to	O
ketamine	B-Chemical
.	O

While	O
the	O
mutual	O
potentiation	O
,	O
antagonism	O
and	O
tolerance	O
suggest	O
common	O
mechanisms	O
for	O
the	O
induced	O
catalepsy	B-Disease
,	O
differences	O
in	O
latency	O
,	O
rigidity	B-Disease
and	O
behavior	O
,	O
asymmetry	O
of	O
cross-tolerance	O
and	O
a	O
widely-different	O
ID50	O
for	O
naloxone	B-Chemical
would	O
argue	O
against	O
an	O
action	O
at	O
a	O
single	O
opioid	O
site	O
.	O

Acute	B-Disease
renal	I-Disease
failure	I-Disease
in	O
patients	O
with	O
AIDS	B-Disease
on	O
tenofovir	B-Chemical
while	O
receiving	O
prolonged	O
vancomycin	B-Chemical
course	O
for	O
osteomyelitis	B-Disease
.	O

Renal	B-Disease
failure	I-Disease
developed	O
after	O
a	O
prolonged	O
course	O
of	O
vancomycin	B-Chemical
therapy	O
in	O
2	O
patients	O
who	O
were	O
receiving	O
tenofovir	B-Chemical
disoproxil	I-Chemical
fumarate	I-Chemical
as	O
part	O
of	O
an	O
antiretroviral	O
regimen	O
.	O

Tenofovir	B-Chemical
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
Fanconi	B-Disease
syndrome	I-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
because	O
of	O
its	O
effects	O
on	O
the	O
proximal	O
renal	O
tubule	O
.	O

Vancomycin	B-Chemical
nephrotoxicity	B-Disease
is	O
infrequent	O
but	O
may	O
result	O
from	O
coadministration	O
with	O
a	O
nephrotoxic	B-Disease
agent	O
.	O

Clinicians	O
should	O
be	O
aware	O
that	O
tenofovir	B-Chemical
may	O
raise	O
the	O
risk	O
of	O
renal	B-Disease
failure	I-Disease
during	O
prolonged	O
administration	O
of	O
vancomycin	B-Chemical
.	O

Delayed	O
leukoencephalopathy	B-Disease
with	O
stroke-like	B-Disease
presentation	O
in	O
chemotherapy	O
recipients	O
.	O

BACKGROUND	O
:	O
A	O
transient	O
leukoencephalopathy	B-Disease
mimicking	O
cerebrovascular	B-Disease
accident	I-Disease
has	O
been	O
described	O
as	O
a	O
complication	O
of	O
chemotherapy	O
,	O
most	O
commonly	O
in	O
recipients	O
of	O
intrathecal	O
methotrexate	B-Chemical
for	O
childhood	O
leukaemia	B-Disease
.	O

Recently	O
published	O
neuroimaging	O
data	O
suggest	O
a	O
common	O
pathophysiology	O
associated	O
with	O
a	O
variety	O
of	O
chemotherapy	O
agents	O
and	O
modes	O
of	O
administration	O
.	O

METHODS	O
:	O
We	O
reviewed	O
the	O
medical	O
literature	O
for	O
single	O
reports	O
and	O
case	O
series	O
of	O
patients	O
presenting	O
with	O
stroke-like	B-Disease
episodes	O
while	O
receiving	O
systemic	O
or	O
intrathecal	O
chemotherapy	O
.	O

We	O
only	O
included	O
studies	O
providing	O
detailed	O
neuroimaging	O
data	O
.	O

Patients	O
with	O
cerebrovascular	B-Disease
accidents	I-Disease
were	O
excluded	O
.	O

RESULTS	O
:	O
We	O
identified	O
27	O
reports	O
of	O
toxic	O
leukoencephalopathy	B-Disease
in	O
patients	O
treated	O
with	O
methotrexate	B-Chemical
(	O
intrathecal	O
,	O
systemic	O
)	O
,	O
5-fluorouracil	B-Chemical
and	O
its	O
derivative	O
carmofur	B-Chemical
,	O
and	O
capecitabine	B-Chemical
.	O

Diffusion	O
weighted	O
imaging	O
(	O
DWI	O
)	O
of	O
all	O
patients	O
revealed	O
well	O
demarcated	O
hyperintense	O
lesions	B-Disease
within	I-Disease
the	I-Disease
subcortical	I-Disease
white	I-Disease
matter	I-Disease
of	O
the	O
cerebral	O
hemispheres	O
and	O
the	O
corpus	O
callosum	O
,	O
corresponding	O
to	O
areas	O
of	O
decreased	O
proton	O
diffusion	O
on	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
maps	O
(	O
available	O
in	O
21/27	O
patients	O
)	O
.	O

Lesions	O
exceeded	O
the	O
confines	O
of	O
adjacent	O
vascular	O
territories	O
.	O

Complete	O
resolution	O
of	O
symptoms	O
within	O
1-4	O
days	O
was	O
accompanied	O
by	O
normalisation	O
of	O
ADC	O
abnormalities	I-Disease
.	O

However	O
,	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
sequences	O
frequently	O
revealed	O
persistent	O
white	B-Disease
matter	I-Disease
abnormalities	O
.	O

CONCLUSIONS	O
:	O
Several	O
pathophysiological	O
models	O
of	O
delayed	O
leukoencephalopathy	B-Disease
after	O
exposure	O
to	O
intrathecal	O
or	O
systemic	O
chemotherapy	O
have	O
been	O
proposed	O
.	O

DWI	O
findings	O
in	O
this	O
cohort	O
are	O
indicative	O
of	O
cytotoxic	B-Disease
oedema	I-Disease
within	I-Disease
cerebral	I-Disease
white	I-Disease
matter	I-Disease
and	O
lend	O
support	O
to	O
an	O
at	O
least	O
partially	O
reversible	O
metabolic	O
derangement	O
as	O
the	O
basis	O
for	O
this	O
syndrome	O
.	O

Down-regulation	O
of	O
norepinephrine	B-Chemical
transporter	O
function	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-Chemical
linking	O
to	O
the	O
alteration	O
of	O
sensitivity	O
of	O
local-anesthetics-induced	O
convulsions	B-Disease
and	O
the	O
counteraction	O
by	O
co-administration	O
with	O
local	O
anesthetics	B-Drug
.	O

Alterations	O
of	O
norepinephrine	B-Chemical
transporter	O
(	O
NET	O
)	O
function	O
by	O
chronic	O
inhibition	O
of	O
NET	O
in	O
relation	O
to	O
sensitization	O
to	O
seizures	B-Disease
induce	O
by	O
cocaine	B-Chemical
and	O
local	O
anesthetics	B-Drug
were	O
studied	O
in	O
mice	O
.	O

Daily	O
administration	O
of	O
desipramine	B-Chemical
,	O
an	O
inhibitor	O
of	O
the	O
NET	O
,	O
for	O
5	O
days	O
decreased	O
[	O
(	O
3	O
)	O
H	O
]	O
norepinephrine	B-Chemical
uptake	O
in	O
the	O
P2	O
fractions	O
of	O
hippocampus	O
but	O
not	O
cortex	O
,	O
striatum	O
or	O
amygdalae	O
.	O

Co-administration	O
of	O
lidocaine	B-Chemical
,	O
bupivacaine	B-Chemical
or	O
tricaine	B-Chemical
with	O
desipramine	B-Chemical
reversed	O
this	O
effect	O
.	O

Daily	O
treatment	O
of	O
cocaine	B-Chemical
increased	O
[	O
(	O
3	O
)	O
H	O
]	O
norepinephrine	B-Chemical
uptake	O
into	O
the	O
hippocampus	O
.	O

Daily	O
administration	O
of	O
desipramine	B-Chemical
increased	O
the	O
incidence	O
of	O
appearance	O
of	O
lidocaine-induced	B-Chemical
convulsions	B-Disease
and	O
decreased	O
that	O
of	O
cocaine-induced	B-Chemical
convulsions	B-Disease
.	O

Co-administration	O
of	O
lidocaine	B-Chemical
with	O
desipramine	B-Chemical
reversed	O
the	O
changes	O
of	O
convulsive	B-Disease
activity	O
of	O
lidocaine	B-Chemical
and	O
cocaine	B-Chemical
induced	O
by	O
repeated	O
administration	O
of	O
desipramine	B-Chemical
.	O

These	O
results	O
suggest	O
that	O
down-regulation	O
of	O
hippocampal	O
NET	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-Chemical
may	O
be	O
relevant	O
to	O
desipramine-induced	B-Chemical
sensitization	O
of	O
lidocaine	B-Chemical
convulsions	B-Disease
.	O

Inhibition	O
of	O
Na	B-Chemical
(	O
+	O
)	O
channels	O
by	O
local	O
anesthetics	B-Drug
may	O
regulate	O
desipramine-induced	B-Chemical
down-regulation	O
of	O
NET	O
function	O
.	O

Repeated	O
administration	O
of	O
cocaine	B-Chemical
induces	O
up-regulation	O
of	O
hippocampal	O
NET	O
function	O
.	O

Desipramine-induced	B-Chemical
sensitization	O
of	O
lidocaine	B-Chemical
seizures	B-Disease
may	O
have	O
a	O
mechanism	O
distinct	O
from	O
kindling	O
resulting	O
from	O
repeated	O
administration	O
of	O
cocaine	B-Chemical
.	O

Definition	O
and	O
management	O
of	O
anemia	B-Disease
in	O
patients	O
infected	B-Disease
with	I-Disease
hepatitis	I-Disease
C	I-Disease
virus	I-Disease
.	O

Chronic	B-Disease
infection	I-Disease
with	I-Disease
hepatitis	I-Disease
C	B-Disease
virus	I-Disease
(	O
HCV	O
)	O
can	O
progress	O
to	O
cirrhosis	B-Disease
,	O
hepatocellular	B-Disease
carcinoma	I-Disease
,	O
and	O
end-stage	B-Disease
liver	I-Disease
disease	I-Disease
.	O

The	O
current	O
best	O
treatment	O
for	O
HCV	B-Disease
infection	I-Disease
is	O
combination	O
therapy	O
with	O
pegylated	O
interferon	B-Chemical
and	O
ribavirin	B-Chemical
.	O

Although	O
this	O
regimen	O
produces	O
sustained	O
virologic	O
responses	O
(	O
SVRs	O
)	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
,	O
it	O
can	O
be	O
associated	O
with	O
a	O
potentially	O
dose-limiting	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Hemoglobin	O
concentrations	O
decrease	O
mainly	O
as	O
a	O
result	O
of	O
ribavirin-induced	B-Chemical
hemolysis	B-Disease
,	O
and	O
this	O
anemia	B-Disease
can	O
be	O
problematic	O
in	O
patients	O
with	O
HCV	B-Disease
infection	I-Disease
,	O
especially	O
those	O
who	O
have	O
comorbid	O
renal	B-Disease
or	I-Disease
cardiovascular	I-Disease
disorders	I-Disease
.	O

In	O
general	O
,	O
anemia	O
can	O
increase	O
the	O
risk	O
of	O
morbidity	O
and	O
mortality	O
,	O
and	O
may	O
have	O
negative	O
effects	O
on	O
cerebral	O
function	O
and	O
quality	O
of	O
life	O
.	O

Although	O
ribavirin-associated	O
anemia	O
can	O
be	O
reversed	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
,	O
this	O
approach	O
compromises	O
outcomes	O
by	O
significantly	O
decreasing	O
SVR	O
rates	O
.	O

Recombinant	O
human	O
erythropoietin	O
has	O
been	O
used	O
to	O
manage	O
ribavirin-associated	O
anemia	O
but	O
has	O
other	O
potential	O
disadvantages	O
.	O

Viramidine	O
,	O
a	O
liver-targeting	O
prodrug	O
of	O
ribavirin	B-Drug
,	O
has	O
the	O
potential	O
to	O
maintain	O
the	O
virologic	O
efficacy	O
of	O
ribavirin	B-Drug
while	O
decreasing	O
the	O
risk	O
of	O
hemolytic	O
anemia	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

Calcium	B-Chemical
carbonate	I-Chemical
toxicity	B-Disease
:	O
the	O
updated	O
milk-alkali	B-Disease
syndrome	I-Disease
;	O
report	O
of	O
3	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
3	O
patients	O
with	O
calcium	B-Chemical
carbonate-induced	O
hypercalcemia	O
and	O
gain	O
insights	O
into	O
the	O
cause	O
and	O
management	O
of	O
the	O
milk-alkali	O
syndrome	O
.	O

METHODS	O
:	O
We	O
report	O
the	O
clinical	O
and	O
laboratory	O
data	O
in	O
3	O
patients	O
who	O
presented	O
with	O
severe	O
hypercalcemia	O
(	O
corrected	O
serum	O
calcium	B-Chemical
>	O
or	O
=	O
14	O
mg/dL	O
)	O
and	O
review	O
the	O
pertinent	O
literature	O
on	O
milk-alkali	O
syndrome	O
.	O

RESULTS	O
:	O
The	O
3	O
patients	O
had	O
acute	O
renal	O
insufficiency	O
,	O
relative	O
metabolic	O
alkalosis	O
,	O
and	O
low	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
,	O
PTH-related	O
peptide	O
,	O
and	O
1,25-dihydroxyvitamin	O
D	O
concentrations	O
.	O

No	O
malignant	O
lesion	O
was	O
found	O
.	O

Treatment	O
included	O
aggressive	O
hydration	O
and	O
varied	O
amounts	O
of	O
furosemide	B-Drug
.	O

The	O
2	O
patients	O
with	O
the	O
higher	O
serum	O
calcium	B-Drug
concentrations	O
received	O
pamidronate	O
intravenously	O
(	O
60	O
and	O
30	O
mg	O
,	O
respectively	O
)	O
,	O
which	O
caused	O
severe	O
hypocalcemia	O
.	O

Of	O
the	O
3	O
patients	O
,	O
2	O
were	O
ingesting	O
acceptable	O
doses	O
of	O
elemental	O
calcium	B-Drug
(	O
1	O
g	O
and	O
2	O
g	O
daily	O
,	O
respectively	O
)	O
in	O
the	O
form	O
of	O
calcium	B-Drug
carbonate	O
.	O

In	O
addition	O
to	O
our	O
highlighted	O
cases	O
,	O
we	O
review	O
the	O
history	O
,	O
classification	O
,	O
pathophysiologic	O
features	O
,	O
and	O
treatment	O
of	O
milk-alkali	O
syndrome	O
and	O
summarize	O
the	O
cases	O
reported	O
from	O
early	O
1995	O
to	O
November	O
2003	O
.	O

CONCLUSION	O
:	O
Milk-alkali	O
syndrome	O
may	O
be	O
a	O
common	O
cause	O
of	O
unexplained	O
hypercalcemia	B-Disease
and	O
can	O
be	O
precipitated	O
by	O
small	O
amounts	O
of	O
orally	O
ingested	O
calcium	B-Drug
carbonate	O
in	O
susceptible	O
persons	O
.	O

Treatment	O
with	O
hydration	O
,	O
furosemide	B-Drug
,	O
and	O
discontinuation	O
of	O
the	O
calcium	B-Drug
and	O
vitamin	O
D	O
source	O
is	O
adequate	O
.	O

Pamidronate	O
treatment	O
is	O
associated	O
with	O
considerable	O
risk	O
for	O
hypocalcemia	O
,	O
even	O
in	O
cases	O
of	O
initially	O
severe	O
hypercalcemia	O
.	O

Management	O
strategies	O
for	O
ribavirin-induced	B-Chemical
hemolytic	B-Disease
anemia	I-Disease
in	O
the	O
treatment	O
of	O
hepatitis	B-Disease
C	I-Disease
:	O
clinical	O
and	O
economic	O
implications	O
.	O

OBJECTIVES	O
:	O
Recently	O
published	O
studies	O
have	O
demonstrated	O
increased	O
efficacy	O
and	O
cost-effectiveness	O
of	O
combination	O
therapy	O
with	O
interferon	O
and	O
alpha-2b/ribavirin	B-Chemical
compared	O
with	O
interferon-alpha	B-Chemical
monotherapy	O
in	O
the	O
treatment	O
of	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
(	O
CHC	B-Disease
)	O
.	O

Combination	O
therapy	O
is	O
associated	O
with	O
a	O
clinically	O
important	O
adverse	O
effect	O
:	O
ribavirin-induced	B-Chemical
hemolytic	B-Disease
anemia	I-Disease
(	O
RIHA	B-Disease
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
direct	O
health-care	O
costs	O
and	O
management	O
of	O
RIHA	B-Disease
during	O
treatment	O
of	O
CHC	B-Disease
in	O
a	O
clinical	O
trial	O
setting	O
.	O

METHODS	O
:	O
A	O
systematic	O
literature	O
review	O
was	O
conducted	O
to	O
synthesize	O
information	O
on	O
the	O
incidence	O
and	O
management	O
of	O
RIHA	B-Disease
.	O

Decision-analytic	O
techniques	O
were	O
used	O
to	O
estimate	O
the	O
cost	O
of	O
treating	O
RIHA	B-Disease
.	O

Uncertainty	O
was	O
evaluated	O
using	O
sensitivity	O
analyses	O
.	O

RESULTS	O
:	O
RIHA	B-Disease
,	O
defined	O
as	O
a	O
reduction	O
in	O
hemoglobin	O
to	O
less	O
than	O
100	O
g/L	O
,	O
occurs	O
in	O
approximately	O
7	O
%	O
to	O
9	O
%	O
of	O
patients	O
treated	O
with	O
combination	O
therapy	O
.	O

The	O
standard	O
of	O
care	O
for	O
management	O
of	O
RIHA	B-Disease
is	O
reduction	O
or	O
discontinuation	O
of	O
the	O
ribavirin	B-Chemical
dosage	O
.	O

We	O
estimated	O
the	O
direct	O
cost	O
of	O
treating	O
clinically	O
significant	O
RIHA	B-Disease
to	O
be	O
170	O
per	O
patient	O
receiving	O
combination	O
therapy	O
per	O
48-week	O
treatment	O
course	O
(	O
range	O
68-	O
692	O
)	O
.	O

The	O
results	O
of	O
the	O
one-way	O
sensitivity	O
analyses	O
ranged	O
from	O
57	O
to	O
317	O
.	O

In	O
comparison	O
,	O
the	O
cost	O
of	O
48	O
weeks	O
of	O
combination	O
therapy	O
is	O
16,459	O
.	O

CONCLUSIONS	O
:	O
The	O
direct	O
cost	O
of	O
treating	O
clinically	O
significant	O
RIHA	B-Disease
is	O
1	O
%	O
(	O
170/	O
16,459	O
)	O
of	O
drug	B-Drug
treatment	O
costs	O
.	O

Questions	O
remain	O
about	O
the	O
optimal	O
dose	O
of	O
ribavirin	B-Chemical
and	O
the	O
incidence	O
of	O
RIHA	B-Disease
in	O
a	O
real-world	O
population	O
.	O

Despite	O
these	O
uncertainties	O
,	O
this	O
initial	O
evaluation	O
of	O
the	O
direct	O
cost	O
of	O
treating	O
RIHA	B-Disease
provides	O
an	O
estimate	O
of	O
the	O
cost	O
and	O
management	O
implications	O
of	O
this	O
clinically	O
important	O
adverse	O
effect	O
.	O

Effects	O
of	O
amine	B-Chemical
pretreatment	O
on	O
ketamine	B-Chemical
catatonia	B-Disease
in	O
pinealectomized	O
or	O
hypophysectomized	O
animals	O
.	O

The	O
present	O
studies	O
were	O
designed	O
to	O
clarify	O
the	O
role	O
of	O
catecholamines	B-Chemical
and	O
pineal	O
idolamines	O
on	O
ketamine-induced	B-Chemical
catatonia	B-Disease
in	O
the	O
intact	O
,	O
pinealectomized	O
or	O
hypophysectomized	O
chick	O
and	O
rat	O
.	O

In	O
the	O
pinealectomized	O
chick	O
,	O
pretreatment	O
with	O
dopamine	B-Chemical
increased	O
the	O
duration	O
of	O
catatonia	B-Disease
(	O
DOC	O
)	O
after	O
ketamine	B-Chemical
,	O
but	O
pretreatment	O
with	O
norepinephrine	B-Chemical
did	O
not	O
.	O

The	O
pineal	O
indolamines	O
exhibited	O
mixed	O
actions	O
.	O

Serotonin	B-Chemical
and	O
N-acetyl	B-Chemical
serotonin	I-Chemical
which	O
augmented	O
ketamine	B-Chemical
DOC	O
,	O
did	O
not	O
do	O
so	O
in	O
the	O
absence	O
of	O
the	O
pineal	O
gland	O
,	O
whereas	O
melatonin	B-Chemical
potentiated	O
the	O
ketamine	B-Chemical
DOC	O
in	O
both	O
the	O
intact	O
and	O
pinealectomized	O
chick	O
.	O

Ketamine	B-Chemical
was	O
more	O
potent	O
in	O
the	O
hypophysectomized	O
chick	O
and	O
the	O
circadian	O
rhythm	O
noted	O
in	O
the	O
intact	O
chick	O
was	O
absent	O
;	O
furthermore	O
,	O
melatonin	B-Chemical
did	O
not	O
augment	O
the	O
ketamine	B-Chemical
DOC	O
whereas	O
dopamine	B-Chemical
continued	O
to	O
do	O
so	O
.	O

This	O
study	O
did	O
not	O
demonstrate	O
a	O
species	O
difference	O
regarding	O
the	O
role	O
of	O
the	O
amines	B-Chemical
on	O
the	O
pineal	O
in	O
spite	O
of	O
the	O
immature	O
blood-brain	O
barrier	O
in	O
the	O
young	O
chick	O
and	O
the	O
intact	O
barrier	O
in	O
the	O
rat	O
.	O

In	O
addition	O
,	O
these	O
data	O
indicate	O
a	O
direct	O
role	O
of	O
the	O
pituitary	O
in	O
the	O
augmentation	O
of	O
ketamine	B-Chemical
DOC	O
induced	O
by	O
melatonin	B-Chemical
.	O

Furthermore	O
,	O
dopamine	B-Chemical
appeared	O
to	O
act	O
on	O
systems	O
more	O
closely	O
involved	O
with	O
the	O
induction	O
of	O
ketamine	B-Chemical
catatonia	B-Disease
rather	O
than	O
directly	O
on	O
the	O
pituitary	O
.	O

Multicenter	O
,	O
double-blind	O
,	O
multiple-dose	O
,	O
parallel-groups	O
efficacy	O
and	O
safety	O
trial	O
of	O
azelastine	B-Chemical
,	O
chlorpheniramine	B-Chemical
,	O
and	O
placebo	O
in	O
the	O
treatment	O
of	O
spring	B-Disease
allergic	I-Disease
rhinitis	I-Disease
.	O

Azelastine	B-Chemical
,	O
a	O
novel	O
antiallergic	O
medication	O
,	O
was	O
compared	O
with	O
chlorpheniramine	B-Chemical
maleate	I-Chemical
and	O
placebo	O
for	O
efficacy	O
and	O
safety	O
in	O
the	O
treatment	O
of	O
spring	B-Disease
allergic	I-Disease
rhinitis	I-Disease
in	O
a	O
multicenter	O
,	O
double-blind	O
,	O
multiple-dose	O
,	O
parallel-groups	O
study	O
.	O

One	O
hundred	O
fifty-five	O
subjects	O
participated	O
.	O

Subjects	O
ranged	O
in	O
age	O
from	O
18	O
to	O
60	O
years	O
of	O
age	O
and	O
had	O
at	O
least	O
a	O
2-year	O
history	O
of	O
spring	B-Disease
allergic	I-Disease
rhinitis	I-Disease
,	O
confirmed	O
by	O
positive	O
skin	O
test	O
to	O
spring	O
aeroallergens	O
.	O

Medications	O
were	O
given	O
four	O
times	O
daily	O
;	O
the	O
azelastine	B-Chemical
groups	O
received	O
0.5	O
,	O
1.0	O
,	O
or	O
2.0	O
mg	O
in	O
the	O
morning	O
and	O
evening	O
with	O
placebo	O
in	O
the	O
early	O
and	O
late	O
afternoon	O
;	O
the	O
chlorpheniramine	B-Chemical
group	O
received	O
4.0	O
mg	O
four	O
times	O
daily	O
.	O

Daily	O
subject	O
symptom	O
cards	O
were	O
completed	O
during	O
a	O
screening	O
period	O
to	O
assess	O
pretreatment	O
symptoms	O
and	O
during	O
a	O
4-week	O
treatment	O
period	O
while	O
subjects	O
received	O
study	O
medications	O
.	O

Individual	O
symptoms	O
,	O
total	O
symptoms	O
,	O
and	O
major	O
symptoms	O
were	O
compared	O
to	O
determine	O
efficacy	O
of	O
medication	O
.	O

Elicited	O
,	O
volunteered	O
,	O
and	O
observed	O
adverse	O
experiences	O
were	O
recorded	O
for	O
each	O
subject	O
and	O
compared	O
among	O
groups	O
.	O

Vital	O
signs	O
,	O
body	O
weights	O
,	O
serum	O
chemistry	O
values	O
,	O
complete	O
blood	O
cell	O
counts	O
,	O
urine	O
studies	O
,	O
and	O
electrocardiograms	O
were	O
obtained	O
for	O
each	O
subject	O
and	O
compared	O
among	O
groups	O
.	O

Symptoms	O
relief	O
in	O
the	O
group	O
receiving	O
the	O
highest	O
concentration	O
of	O
azelastine	B-Chemical
(	O
2.0	O
mg	O
twice	O
daily	O
)	O
was	O
statistically	O
greater	O
than	O
in	O
the	O
placebo	O
group	O
during	O
all	O
weeks	O
of	O
the	O
study	O
.	O

Lower	O
doses	O
of	O
azelastine	B-Chemical
were	O
statistically	O
more	O
effective	O
than	O
placebo	O
only	O
during	O
portions	O
of	O
the	O
first	O
3	O
weeks	O
of	O
the	O
study	O
.	O

In	O
contrast	O
,	O
although	O
the	O
chlorpheniramine	B-Chemical
group	O
did	O
have	O
fewer	O
symptoms	O
than	O
the	O
placebo	O
group	O
during	O
the	O
study	O
,	O
the	O
difference	O
never	O
reached	O
statistical	O
significance	O
during	O
any	O
week	O
of	O
the	O
study	O
.	O

There	O
were	O
no	O
serious	O
side	O
effects	O
in	O
any	O
of	O
the	O
treatment	O
groups	O
.	O

Drowsiness	B-Disease
and	O
altered	B-Disease
taste	I-Disease
perception	I-Disease
were	O
increased	O
significantly	O
over	O
placebo	O
only	O
in	O
the	O
high-dose	O
azelastine	B-Chemical
group	O
.	O

Azelastine	B-Chemical
appears	O
to	O
be	O
a	O
safe	O
,	O
efficacious	O
medication	O
for	O
seasonal	B-Disease
allergic	I-Disease
rhinitis	I-Disease
.	O

Obsolete	O
but	O
dangerous	O
antacid	O
preparations	O
.	O

One	O
case	O
of	O
acute	O
hypercalcaemia	B-Disease
and	O
two	O
of	O
recurrent	O
nephrolithiasis	B-Disease
are	O
reported	O
in	O
patients	O
who	O
had	O
regularly	O
consumed	O
large	O
amounts	O
of	O
calcium	B-Chemical
carbon-ate-sodium	O
bicarbonate	O
powders	O
for	O
more	O
than	O
20	O
years	O
.	O

The	O
powders	O
had	O
been	O
obtained	O
from	O
pharmacists	O
unknown	O
to	O
the	O
patients	O
'	O
medical	O
practitioners	O
.	O

It	O
is	O
suggested	O
that	O
these	O
preparations	O
were	O
responsible	O
for	O
the	O
patient	O
's	O
problems	O
,	O
and	O
that	O
such	O
powders	O
should	O
no	O
longer	O
be	O
freely	O
obtainable	O
.	O

Prolonged	O
paralysis	B-Disease
due	O
to	O
nondepolarizing	B-Chemical
neuromuscular	I-Chemical
blocking	I-Chemical
agents	I-Chemical
and	O
corticosteroids	B-Chemical
.	O

The	O
long-term	O
use	O
of	O
nondepolarizing	B-Chemical
neuromuscular	I-Chemical
blocking	I-Chemical
agents	I-Chemical
(	O
ND-NMBA	B-Chemical
)	O
has	O
recently	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
prolonged	O
muscle	B-Disease
weakness	I-Disease
,	O
although	O
the	O
site	O
of	O
the	O
lesion	O
and	O
the	O
predisposing	O
factors	O
have	O
been	O
unclear	O
.	O

We	O
report	O
3	O
patients	O
(	O
age	O
37-52	O
years	O
)	O
with	O
acute	O
respiratory	B-Disease
insufficiency	I-Disease
who	O
developed	O
prolonged	O
weakness	B-Disease
following	O
the	O
discontinuation	O
of	O
ND-NMBAs	B-Chemical
.	O

Two	O
patients	O
also	O
received	O
intravenous	O
corticosteroids	B-Chemical
.	O

Renal	O
function	O
was	O
normal	O
but	O
hepatic	O
function	O
was	O
impaired	O
in	O
all	O
patients	O
,	O
and	O
all	O
had	O
acidosis	B-Disease
.	O

Electrophysiologic	O
studies	O
revealed	O
low	O
amplitude	O
compound	O
motor	O
action	O
potentials	O
,	O
normal	O
sensory	O
studies	O
,	O
and	O
fibrillations	O
.	O

Repetitive	O
stimulation	O
at	O
2	O
Hz	O
showed	O
a	O
decremental	O
response	O
in	O
2	O
patients	O
.	O

The	O
serum	O
vecuronium	B-Chemical
level	O
measured	O
in	O
1	O
patient	O
14	O
days	O
after	O
the	O
drug	B-Drug
had	O
been	O
discontinued	O
was	O
172	O
ng/mL	O
.	O

A	O
muscle	O
biopsy	O
in	O
this	O
patient	O
showed	O
loss	B-Disease
of	I-Disease
thick	I-Disease
,	I-Disease
myosin	I-Disease
filaments	I-Disease
.	O

The	O
weakness	B-Disease
in	O
these	O
patients	O
is	O
due	O
to	O
pathology	B-Disease
at	B-Disease
both	I-Disease
the	I-Disease
neuromuscular	I-Disease
junction	I-Disease
(	O
most	O
likely	O
due	O
to	O
ND-NMBA	B-Chemical
)	O
and	O
muscle	O
(	O
most	O
likely	O
due	O
to	O
corticosteroids	B-Chemical
)	O
.	O

Hepatic	B-Disease
dysfunction	I-Disease
and	O
acidosis	B-Disease
are	O
contributing	O
risk	O
factors	O
.	O

Prostaglandin	B-Chemical
E2-induced	O
bladder	O
hyperactivity	O
in	O
normal	O
,	O
conscious	O
rats	O
:	O
involvement	O
of	O
tachykinins	O
?	O
In	O
normal	O
conscious	O
rats	O
investigated	O
by	O
continuous	O
cystometry	O
,	O
intravesically	O
instilled	O
prostaglandin	B-Chemical
(	I-Chemical
PG	I-Chemical
)	I-Chemical
E2	I-Chemical
facilitated	O
micturition	O
and	O
increased	O
basal	O
intravesical	O
pressure	O
.	O

The	O
effect	O
was	O
attenuated	O
by	O
both	O
the	O
NK1	O
receptor	O
selective	O
antagonist	O
RP	B-Chemical
67,580	I-Chemical
and	O
the	O
NK2	O
receptor	O
selective	O
antagonist	O
SR	B-Chemical
48,968	I-Chemical
,	O
given	O
intra-arterially	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
stimulation	O
of	O
both	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Intra-arterially	O
given	O
PGE2	B-Chemical
produced	O
a	O
distinct	O
increase	O
in	O
bladder	O
pressure	O
before	O
initiating	O
a	O
micturition	O
reflex	O
,	O
indicating	O
that	O
the	O
PG	B-Chemical
had	O
a	O
direct	O
contractant	O
effect	O
on	O
the	O
detrusor	O
smooth	O
muscle	O
.	O

The	O
effect	O
of	O
intra-arterial	O
PGE2	B-Chemical
could	O
not	O
be	O
blocked	O
by	O
intra-arterial	O
RP	B-Chemical
67,580	I-Chemical
or	O
SR	B-Chemical
48,968	I-Chemical
,	O
which	O
opens	O
the	O
possibility	O
that	O
the	O
micturition	O
reflex	O
elicited	O
by	O
intra-arterial	O
PGE2	B-Chemical
was	O
mediated	O
by	O
pathways	O
other	O
than	O
the	O
reflex	O
initiated	O
when	O
the	O
PG	B-Chemical
was	O
given	O
intravesically	O
.	O

The	O
present	O
results	O
thus	O
suggest	O
that	O
intra-arterial	O
PGE2	B-Chemical
,	O
given	O
near	O
the	O
bladder	O
,	O
may	O
initiate	O
micturition	O
in	O
the	O
normal	O
rat	O
chiefly	O
by	O
directly	O
contracting	O
the	O
smooth	O
muscle	O
of	O
the	O
detrusor	O
.	O

However	O
,	O
when	O
given	O
intravesically	O
,	O
PGE2	B-Chemical
may	O
stimulate	O
micturition	O
by	O
releasing	O
tachykinins	B-Chemical
from	O
nerves	O
in	O
and/or	O
immediately	O
below	O
the	O
urothelium	O
.	O

These	O
tachykinins	B-Chemical
,	O
in	O
turn	O
,	O
initiate	O
a	O
micturition	O
reflex	O
by	O
stimulating	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Prostanoids	B-Chemical
may	O
,	O
via	O
release	O
of	O
tachykinins	B-Chemical
,	O
contribute	O
to	O
both	O
urge	O
and	O
bladder	B-Disease
hyperactivity	I-Disease
seen	O
in	O
inflammatory	O
conditions	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O

Thiazide	B-Chemical
diuretics	B-Drug
,	O
hypokalemia	B-Disease
and	O
cardiac	B-Disease
arrhythmias	I-Disease
.	O

Thiazide	B-Chemical
diuretics	B-Drug
are	O
widely	O
accepted	O
as	O
the	O
cornerstone	O
of	O
antihypertensive	B-Drug
treatment	O
programs	O
.	O

Hypokalemia	B-Disease
is	O
a	O
commonly	O
encountered	O
metabolic	O
consequence	O
of	O
chronic	O
thiazide	B-Chemical
therapy	O
.	O

We	O
treated	O
38	O
patients	O
(	O
22	O
low	O
renin	O
,	O
16	O
normal	O
renin	O
)	O
with	O
moderate	O
diastolic	B-Disease
hypertension	I-Disease
with	O
hydrochlorothiazide	B-Chemical
(	O
HCTC	B-Chemical
)	O
administered	O
on	O
a	O
twice	O
daily	O
schedule	O
.	O

Initial	O
dose	O
was	O
50	O
mg	O
and	O
the	O
dose	O
was	O
increased	O
at	O
monthly	O
intervals	O
to	O
100	O
mg	O
,	O
150	O
mg	O
and	O
200	O
mg	O
daily	O
until	O
blood	O
pressure	O
normalized	O
.	O

The	O
serum	O
K	B-Chemical
during	O
the	O
control	O
period	O
was	O
4.5	O
+/-	O
0.2	O
mEq/l	O
an	O
on	O
50	O
,	O
100	O
,	O
150	O
and	O
200	O
mg	O
HCTZ	B-Chemical
daily	O
3.9	O
+/-	O
0.3	O
,	O
3.4	O
+/-	O
0.2	O
,	O
2.9	O
+/-	O
0.2	O
,	O
and	O
2.4	O
+/-	O
0.3	O
mEq/l	O
,	O
respectively	O
.	O

Corresponding	O
figures	O
for	O
whole	O
body	O
K	B-Chemical
were	O
4107	O
+/-	O
208	O
,	O
3722	O
+/-	O
319	O
,	O
3628	O
+/-	O
257	O
,	O
3551	O
+/-	O
336	O
,	O
and	O
3269	O
+/-	O
380	O
mEq	O
,	O
respectively	O
.	O

In	O
13	O
patients	O
we	O
observed	O
the	O
effects	O
of	O
HCTZ	B-Chemical
therapy	O
(	O
100	O
mg	O
daily	O
)	O
on	O
the	O
occurrence	O
of	O
PVC	O
's	O
during	O
rest	O
as	O
well	O
as	O
during	O
static	O
and	O
dynamic	O
exercise	O
.	O

During	O
rest	O
we	O
observed	O
0.6	O
+/-	O
0.08	O
PVC	O
beats/min	O
+/-	O
SEM	O
and	O
during	O
static	O
and	O
dynamic	O
exercise	O
0.6	O
+/-	O
0.06	O
and	O
0.8	O
+/-	O
0.15	O
,	O
respectively	O
.	O

Corresponding	O
figures	O
during	O
HCTZ	B-Chemical
therapy	O
100	O
mg	O
daily	O
were	O
1.4	O
+/-	O
0.1	O
,	O
3.6	O
+/-	O
0.7	O
and	O
5.7	O
4/-	O
0.8	O
,	O
respectively	O
.	O

The	O
occurrence	O
of	O
PVC	O
's	O
correlated	O
significantly	O
with	O
the	O
fall	O
in	O
serum	O
K+	B-Chemical
observed	O
r	O
=	O
0.72	O
,	O
p	O
less	O
than	O
0.001	O
.	O

In	O
conclusion	O
we	O
found	O
that	O
thiazide	B-Chemical
diuretics	B-Drug
cause	O
hypokalemia	B-Disease
and	O
depletion	O
of	O
body	O
potassium	B-Chemical
.	O

The	O
more	O
profound	O
hypokalemia	B-Disease
,	O
the	O
greater	O
the	O
propensity	O
for	O
the	O
occurrence	O
of	O
PVC	O
's	O
.	O

Diuretics	B-Drug
,	O
potassium	B-Chemical
and	O
arrhythmias	B-Disease
in	O
hypertensive	B-Disease
coronary	B-Disease
disease	I-Disease
.	O

It	O
has	O
been	O
proposed	O
that	O
modest	O
changes	O
in	O
plasma	O
potassium	B-Chemical
can	O
alter	O
the	O
tendency	O
towards	O
cardiac	B-Disease
arrhythmias	I-Disease
.	O

If	O
this	O
were	O
so	O
,	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
might	O
be	O
especially	O
susceptible	O
.	O

Thus	O
,	O
myocardial	O
electrical	O
excitability	O
was	O
measured	O
in	O
patients	O
with	O
mild	O
essential	O
hypertension	B-Disease
and	O
known	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
after	O
8	O
weeks	O
of	O
treatment	O
with	O
a	O
potassium-conserving	B-Chemical
diuretic	B-Drug
(	O
amiloride	B-Chemical
)	O
and	O
a	O
similar	O
period	O
on	O
a	O
potassium-losing	B-Chemical
diuretic	B-Drug
(	O
chlorthalidone	B-Chemical
)	O
in	O
a	O
randomised	O
study	O
.	O

Plasma	O
potassium	B-Chemical
concentrations	O
were	O
on	O
average	O
1	O
mmol/L	O
lower	O
during	O
the	O
chlorthalidone	B-Chemical
phase	O
compared	O
to	O
amiloride	B-Chemical
therapy	O
.	O

Blood	O
pressure	O
and	O
volume	O
states	O
as	O
assessed	O
by	O
bodyweight	O
,	O
plasma	O
renin	O
and	O
noradrenaline	B-Chemical
(	O
norepinephrine	B-Chemical
)	O
concentrations	O
were	O
similar	O
on	O
the	O
2	O
regimens	O
.	O

Compared	O
to	O
amiloride	B-Chemical
treatment	O
,	O
the	O
chlorthalidone	B-Chemical
phase	O
was	O
associated	O
with	O
an	O
increased	O
frequency	O
of	O
ventricular	B-Disease
ectopic	I-Disease
beats	I-Disease
(	O
24-hour	O
Holter	O
monitoring	O
)	O
and	O
a	O
higher	O
Lown	O
grading	O
,	O
increased	O
upslope	O
and	O
duration	O
of	O
the	O
monophasic	O
action	O
potential	O
,	O
prolonged	O
ventricular	O
effective	O
refractory	O
period	O
,	O
and	O
increased	O
electrical	O
instability	O
during	O
programmed	O
ventricular	O
stimulation	O
.	O

The	O
above	O
results	O
indicate	O
that	O
because	O
potassium-losing	B-Chemical
diuretic	B-Drug
therapy	O
can	O
increase	O
myocardial	O
electrical	O
excitability	O
in	O
patients	O
with	O
ischaemic	B-Disease
heart	I-Disease
disease	I-Disease
,	O
even	O
minor	O
falls	O
in	O
plasma	O
potassium	B-Chemical
concentrations	O
are	O
probably	O
best	O
avoided	O
in	O
such	O
patients	O
.	O

GABA	B-Chemical
involvement	O
in	O
naloxone	B-Chemical
induced	O
reversal	O
of	O
respiratory	B-Disease
paralysis	I-Disease
produced	O
by	O
thiopental	B-Chemical
.	O

No	O
agent	O
is	O
yet	O
available	O
to	O
reverse	O
respiratory	B-Disease
paralysis	I-Disease
produced	O
by	O
CNS	O
depressants	O
,	O
such	O
as	O
general	O
anesthetics	B-Drug
.	O

In	O
this	O
study	O
naloxone	B-Chemical
reversed	O
respiratory	B-Disease
paralysis	I-Disease
induced	O
by	O
thiopental	B-Chemical
in	O
rats	O
.	O

25	O
mg/kg	O
,	O
i.v	O
.	O

thiopental	B-Chemical
produced	O
anesthesia	B-Drug
without	O
altering	O
respiratory	O
rate	O
,	O
increased	O
GABA	B-Chemical
,	O
decreased	O
glutamate	B-Chemical
,	O
and	O
had	O
no	O
effect	O
on	O
aspartate	B-Chemical
or	O
glycine	B-Chemical
levels	O
compared	O
to	O
controls	O
in	O
rat	O
cortex	O
and	O
brain	O
stem	O
.	O

Pretreatment	O
of	O
rats	O
with	O
thiosemicarbazide	B-Chemical
for	O
30	O
minutes	O
abolished	O
the	O
anesthetic	B-Drug
action	O
as	O
well	O
as	O
the	O
respiratory	O
depressant	O
action	O
of	O
thiopental	B-Chemical
.	O

50	O
mg/kg	O
,	O
i.v	O
.	O

thiopental	B-Chemical
produced	O
respiratory	B-Disease
arrest	I-Disease
with	O
further	O
increase	O
in	O
GABA	B-Chemical
and	O
decrease	O
in	O
glutamate	B-Chemical
again	O
in	O
cortex	O
and	O
brain	O
stem	O
without	O
affecting	O
any	O
of	O
the	O
amino	B-Chemical
acids	I-Chemical
studied	O
in	O
four	O
regions	O
of	O
rat	O
brain	O
.	O

Naloxone	B-Chemical
(	O
2.5	O
mg/kg	O
,	O
i.v	O
.	O

)	O
reversed	O
respiratory	B-Disease
paralysis	I-Disease
,	O
glutamate	B-Chemical
and	O
GABA	B-Chemical
levels	O
to	O
control	O
values	O
in	O
brain	O
stem	O
and	O
cortex	O
with	O
no	O
changes	O
in	O
caudate	O
or	O
cerebellum	O
.	O

These	O
data	O
suggest	O
naloxone	B-Chemical
reverses	O
respiratory	B-Disease
paralysis	I-Disease
produced	O
by	O
thiopental	B-Chemical
and	O
involves	O
GABA	B-Chemical
in	O
its	O
action	O
.	O

National	O
project	O
on	O
the	O
prevention	O
of	O
mother-to-infant	O
infection	B-Disease
by	I-Disease
hepatitis	I-Disease
B	I-Disease
virus	I-Disease
in	O
Japan	O
.	O

In	O
Japan	O
,	O
a	O
nationwide	O
prevention	O
program	O
against	O
mother-to-infant	O
infection	B-Disease
by	I-Disease
hepatitis	I-Disease
B	I-Disease
virus	I-Disease
(	O
HBV	O
)	O
started	O
in	O
1985	O
.	O

This	O
program	O
consists	O
of	O
double	O
screenings	O
of	O
pregnant	O
women	O
and	O
prophylactic	O
treatment	O
to	O
the	O
infants	O
born	O
to	O
both	O
hepatitis	B-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBsAg	B-Chemical
)	O
and	O
hepatitis	B-Chemical
B	I-Chemical
e	B-Chemical
antigen	I-Chemical
(	O
HBeAg	B-Chemical
)	O
positive	O
mothers	O
.	O

These	O
infants	O
are	O
treated	O
with	O
two	O
injections	O
of	O
hepatitis	B-Disease
B	I-Disease
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
at	O
least	O
three	O
injections	O
of	O
plasma	O
derived	O
hepatitis	B-Chemical
B	I-Chemical
vaccine	I-Chemical
.	O

We	O
sent	O
questionnaires	O
about	O
the	O
numbers	O
of	O
each	O
procedure	O
or	O
examination	O
during	O
nine	O
months	O
of	O
investigation	O
period	O
to	O
each	O
local	O
government	O
in	O
1986	O
and	O
1987	O
.	O

93.4	O
%	O
pregnant	O
women	O
had	O
the	O
chance	O
to	O
be	O
examined	O
for	O
HBsAg	B-Chemical
,	O
and	O
the	O
positive	O
rate	O
was	O
1.4	O
to	O
1.5	O
%	O
.	O

The	O
HBeAg	B-Chemical
positive	O
rate	O
in	O
HBsAg	B-Chemical
positive	O
was	O
23	O
to	O
26	O
%	O
.	O

The	O
HBsAg	B-Chemical
positive	O
rate	O
in	O
neonates	O
and	O
in	O
infants	O
before	O
two	O
months	O
were	O
3	O
%	O
and	O
2	O
%	O
respectively	O
.	O

Some	O
problems	O
may	O
arise	O
,	O
because	O
27	O
to	O
30	O
%	O
of	O
infants	O
need	O
the	O
fourth	O
vaccination	O
in	O
some	O
restricted	O
areas	O
.	O

Nociceptive	O
effects	O
induced	O
by	O
intrathecal	O
administration	O
of	O
prostaglandin	B-Chemical
D2	I-Chemical
,	I-Chemical
E2	I-Chemical
,	I-Chemical
or	I-Chemical
F2	I-Chemical
alpha	I-Chemical
to	O
conscious	O
mice	O
.	O

The	O
effects	O
of	O
intrathecal	O
administration	O
of	O
prostaglandins	B-Chemical
on	O
pain	B-Disease
responses	O
in	O
conscious	O
mice	O
were	O
evaluated	O
by	O
using	O
hot	O
plate	O
and	O
acetic	B-Chemical
acid	I-Chemical
writhing	O
tests	O
.	O

Prostaglandin	B-Chemical
D2	I-Chemical
(	O
0.5-3	O
ng/mouse	O
)	O
had	O
a	O
hyperalgesic	B-Disease
action	O
on	O
the	O
response	O
to	O
a	O
hot	O
plate	O
during	O
a	O
3-60	O
min	O
period	O
after	O
injection	O
.	O

Prostaglandin	B-Chemical
E2	I-Chemical
showed	O
a	O
hyperalgesic	B-Disease
effect	O
at	O
doses	O
of	O
1	O
pg	B-Chemical
to	O
10	O
ng/mouse	O
,	O
but	O
the	O
effect	O
lasted	O
shorter	O
(	O
3-30	O
min	O
)	O
than	O
that	O
of	O
prostaglandin	B-Chemical
D2	I-Chemical
.	O

Similar	O
results	O
were	O
obtained	O
by	O
acetic	B-Chemical
acid	I-Chemical
writhing	O
tests	O
.	O

The	O
hyperalgesic	B-Disease
effect	O
of	O
prostaglandin	B-Chemical
D2	I-Chemical
was	O
blocked	O
by	O
simultaneous	O
injection	O
of	O
a	O
substance	O
P	O
antagonist	O
(	O
greater	O
than	O
or	O
equal	O
to	O
100	O
ng	O
)	O
but	O
not	O
by	O
AH6809	B-Chemical
,	O
a	O
prostanoid	O
EP1-receptor	O
antagonist	O
.	O

Conversely	O
,	O
prostaglandin	B-Chemical
E2-induced	O
hyperalgesia	O
was	O
blocked	O
by	O
AH6809	O
(	O
greater	O
than	O
or	O
equal	O
to	O
500	O
ng	O
)	O
but	O
not	O
by	O
the	O
substance	O
P	O
antagonist	O
.	O

Prostaglandin	O
F2	O
alpha	O
had	O
little	O
effect	O
on	O
pain	O
responses	O
.	O

These	O
results	O
demonstrate	O
that	O
both	O
prostaglandin	B-Chemical
D2	O
and	O
prostaglandin	O
E2	O
exert	O
hyperalgesia	B-Disease
in	O
the	O
spinal	O
cord	O
,	O
but	O
in	O
different	O
ways	O
.	O

Swallowing-induced	O
atrial	B-Disease
tachyarrhythmia	I-Disease
triggered	O
by	O
salbutamol	B-Chemical
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

CASE	O
:	O
A	O
49-year-old	O
patient	O
experienced	O
chest	O
discomfort	O
while	O
swallowing	O
.	O

On	O
electrocardiogram	O
,	O
episodes	O
of	O
atrial	B-Disease
tachyarrhythmia	I-Disease
were	O
recorded	O
immediately	O
after	O
swallowing	O
;	O
24-hour	O
Holter	O
monitoring	O
recorded	O
several	O
events	O
.	O

The	O
arrhythmia	B-Disease
resolved	O
after	O
therapy	O
with	O
atenolol	B-Chemical
,	O
but	O
recurred	O
a	O
year	O
later	O
.	O

The	O
patient	O
noticed	O
that	O
before	O
these	O
episodes	O
he	O
had	O
been	O
using	O
an	O
inhalator	O
of	O
salbutamol	B-Chemical
.	O

After	O
stopping	O
the	O
beta-agonist	O
,	O
and	O
after	O
a	O
week	O
with	O
the	O
atenolol	B-Chemical
,	O
the	O
arrhythmia	B-Disease
disappeared	O
.	O

DISCUSSION	O
:	O
Swallowing-induced	O
atrial	B-Disease
tachyarrhythmia	I-Disease
(	O
SIAT	B-Disease
)	O
is	O
a	O
rare	O
phenomenon	O
.	O

Fewer	O
than	O
50	O
cases	O
of	O
SIAT	B-Disease
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

This	O
article	O
summarizes	O
all	O
the	O
cases	O
published	O
,	O
creating	O
a	O
comprehensive	O
review	O
of	O
the	O
current	O
knowledge	O
and	O
approach	O
to	O
SIAT	B-Disease
.	O

It	O
discusses	O
demographics	O
,	O
clinical	O
characteristics	O
and	O
types	O
of	O
arrhythmia	B-Disease
,	O
postulated	O
mechanisms	O
of	O
SIAT	B-Disease
,	O
and	O
different	O
treatment	O
possibilities	O
such	O
as	O
medications	O
,	O
surgery	O
,	O
and	O
radiofrequency	O
catheter	O
ablation	O
(	O
RFCA	O
)	O
.	O

CONCLUSION	O
:	O
Salbutamol	B-Chemical
is	O
presented	O
here	O
as	O
a	O
possible	O
trigger	O
for	O
SIAT	B-Disease
.	O

Although	O
it	O
is	O
difficult	O
to	O
define	O
causality	O
in	O
a	O
case	O
report	O
,	O
it	O
is	O
logical	O
to	O
think	O
that	O
a	O
beta-agonist	O
like	O
salbutamol	B-Chemical
(	O
known	O
to	O
induce	O
tachycardia	B-Disease
)	O
may	O
be	O
the	O
trigger	O
of	O
adrenergic	O
reflexes	O
originating	O
in	O
the	O
esophagus	O
while	O
swallowing	O
and	O
that	O
a	O
beta-blocker	O
such	O
as	O
atenolol	B-Chemical
(	O
that	O
blocks	O
the	O
adrenergic	O
activity	O
)	O
may	O
relieve	O
it	O
.	O

Coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
ameliorates	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
in	O
mice	O
.	O

The	O
nephroprotective	O
effect	O
of	O
coenzyme	B-Chemical
Q10	I-Chemical
was	O
investigated	O
in	O
mice	O
with	O
acute	B-Disease
renal	I-Disease
injury	I-Disease
induced	O
by	O
a	O
single	O
i.p	O
.	O

injection	O
of	O
cisplatin	B-Chemical
(	O
5	O
mg/kg	O
)	O
.	O

Coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
(	O
10	O
mg/kg/day	O
,	O
i.p	O
.	O

)	O
was	O
applied	O
for	O
6	O
consecutive	O
days	O
,	O
starting	O
1	O
day	O
before	O
cisplatin	B-Chemical
administration	O
.	O

Coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
reduced	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
and	O
serum	O
creatinine	B-Chemical
levels	O
which	O
were	O
increased	O
by	O
cisplatin	B-Chemical
.	O

Coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	B-Chemical
glutathione	I-Chemical
level	O
and	O
superoxide	B-Chemical
dismutase	O
activity	O
)	O
,	O
suppressed	O
lipid	O
peroxidation	O
,	O
decreased	O
the	O
elevations	O
of	O
tumor	B-Disease
necrosis	B-Disease
factor-alpha	O
,	O
nitric	B-Chemical
oxide	I-Chemical
and	O
platinum	B-Chemical
ion	O
concentration	O
,	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	B-Chemical
and	O
zinc	B-Chemical
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	B-Chemical
administration	O
.	O

Also	O
,	O
histopathological	O
renal	B-Disease
tissue	I-Disease
damage	I-Disease
mediated	O
by	O
cisplatin	B-Chemical
was	O
ameliorated	O
by	O
coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
.	O

Immunohistochemical	O
analysis	O
revealed	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
decreased	O
the	O
cisplatin-induced	B-Chemical
overexpression	O
of	O
inducible	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
,	O
nuclear	O
factor-kappaB	O
,	O
caspase-3	O
and	O
p53	O
in	O
renal	O
tissue	O
.	O

It	O
was	O
concluded	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O

Metformin	B-Chemical
prevents	O
experimental	O
gentamicin-induced	B-Chemical
nephropathy	B-Disease
by	O
a	O
mitochondria-dependent	O
pathway	O
.	O

The	O
antidiabetic	B-Drug
drug	B-Drug
metformin	B-Chemical
can	O
diminish	O
apoptosis	O
induced	O
by	O
oxidative	O
stress	O
in	O
endothelial	O
cells	O
and	O
prevent	O
vascular	B-Disease
dysfunction	I-Disease
even	O
in	O
nondiabetic	O
patients	O
.	O

Here	O
we	O
tested	O
whether	O
it	O
has	O
a	O
beneficial	O
effect	O
in	O
a	O
rat	O
model	O
of	O
gentamicin	B-Chemical
toxicity	B-Disease
.	O

Mitochondrial	O
analysis	O
,	O
respiration	O
intensity	O
,	O
levels	O
of	O
reactive	O
oxygen	B-Chemical
species	O
,	O
permeability	O
transition	O
,	O
and	O
cytochrome	O
c	O
release	O
were	O
assessed	O
3	O
and	O
6	O
days	O
after	O
gentamicin	B-Chemical
administration	O
.	O

Metformin	B-Chemical
treatment	O
fully	O
blocked	O
gentamicin-mediated	B-Chemical
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

This	O
was	O
accompanied	O
by	O
a	O
lower	O
activity	O
of	O
N-acetyl-beta-D-glucosaminidase	O
,	O
together	O
with	O
a	O
decrease	O
of	O
lipid	O
peroxidation	O
and	O
increase	O
of	O
antioxidant	O
systems	O
.	O

Metformin	B-Chemical
also	O
protected	O
the	O
kidney	O
from	O
histological	O
damage	O
6	O
days	O
after	O
gentamicin	B-Chemical
administration	O
.	O

These	O
in	O
vivo	O
markers	O
of	O
kidney	B-Disease
dysfunction	I-Disease
and	O
their	O
correction	O
by	O
metformin	B-Chemical
were	O
complemented	O
by	O
in	O
vitro	O
studies	O
of	O
mitochondrial	O
function	O
.	O

We	O
found	O
that	O
gentamicin	B-Chemical
treatment	O
depleted	O
respiratory	O
components	O
(	O
cytochrome	O
c	O
,	O
NADH	O
)	O
,	O
probably	O
due	O
to	O
the	O
opening	O
of	O
mitochondrial	O
transition	O
pores	O
.	O

These	O
injuries	O
,	O
partly	O
mediated	O
by	O
a	O
rise	O
in	O
reactive	O
oxygen	B-Chemical
species	O
from	O
the	O
electron	O
transfer	O
chain	O
,	O
were	O
significantly	O
decreased	O
by	O
metformin	B-Chemical
.	O

Thus	O
,	O
our	O
study	O
suggests	O
that	O
pleiotropic	O
effects	O
of	O
metformin	B-Chemical
can	O
lessen	O
gentamicin	B-Chemical
nephrotoxicity	B-Disease
and	O
improve	O
mitochondrial	O
homeostasis	O
.	O

Sedation	O
depth	O
during	O
spinal	O
anesthesia	B-Drug
and	O
the	O
development	O
of	O
postoperative	B-Disease
delirium	I-Disease
in	O
elderly	O
patients	O
undergoing	O
hip	O
fracture	O
repair	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
limiting	O
intraoperative	O
sedation	O
depth	O
during	O
spinal	O
anesthesia	B-Drug
for	O
hip	B-Disease
fracture	I-Disease
repair	O
in	O
elderly	O
patients	O
can	O
decrease	O
the	O
prevalence	O
of	O
postoperative	B-Disease
delirium	I-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
performed	O
a	O
double-blind	O
,	O
randomized	O
controlled	O
trial	O
at	O
an	O
academic	O
medical	O
center	O
of	O
elderly	O
patients	O
(	O
>	O
or=65	O
years	O
)	O
without	O
preoperative	O
delirium	I-Chemical
or	O
severe	O
dementia	O
who	O
underwent	O
hip	O
fracture	O
repair	O
under	O
spinal	O
anesthesia	B-Drug
with	O
propofol	B-Drug
sedation	O
.	O

Sedation	O
depth	O
was	O
titrated	O
using	O
processed	O
electroencephalography	O
with	O
the	O
bispectral	O
index	O
(	O
BIS	O
)	O
,	O
and	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
deep	O
(	O
BIS	O
,	O
approximately	O
50	O
)	O
or	O
light	O
(	O
BIS	O
,	O
>	O
or=80	O
)	O
sedation	O
.	O

Postoperative	O
delirium	I-Chemical
was	O
assessed	O
as	O
defined	O
by	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
(	O
Third	O
Edition	O
Revised	O
)	O
criteria	O
using	O
the	O
Confusion	O
Assessment	O
Method	O
beginning	O
at	O
any	O
time	O
from	O
the	O
second	O
day	O
after	O
surgery	O
.	O

RESULTS	O
:	O
From	O
April	O
2	O
,	O
2005	O
,	O
through	O
October	O
30	O
,	O
2008	O
,	O
a	O
total	O
of	O
114	O
patients	O
were	O
randomized	O
.	O

The	O
prevalence	O
of	O
postoperative	O
delirium	B-Chemical
was	O
significantly	O
lower	O
in	O
the	O
light	O
sedation	O
group	O
(	O
11/57	O
[	O
19	O
%	O
]	O
vs	O
23/57	O
[	O
40	O
%	O
]	O
in	O
the	O
deep	O
sedation	O
group	O
;	O
P=.02	O
)	O
,	O
indicating	O
that	O
1	O
incident	O
of	O
delirium	B-Disease
will	O
be	O
prevented	O
for	O
every	O
4.7	O
patients	O
treated	O
with	O
light	O
sedation	O
.	O

The	O
mean	O
+/-	O
SD	O
number	O
of	O
days	O
of	O
delirium	O
during	O
hospitalization	O
was	O
lower	O
in	O
the	O
light	O
sedation	O
group	O
than	O
in	O
the	O
deep	O
sedation	O
group	O
(	O
0.5+/-1.5	O
days	O
vs	O
1.4+/-4.0	O
days	O
;	O
P=.01	O
)	O
.	O

CONCLUSION	O
:	O
The	O
use	O
of	O
light	O
propofol	B-Drug
sedation	O
decreased	O
the	O
prevalence	O
of	O
postoperative	O
delirium	O
by	O
50	O
%	O
compared	O
with	O
deep	O
sedation	O
.	O

Limiting	O
depth	O
of	O
sedation	O
during	O
spinal	O
anesthesia	B-Drug
is	O
a	O
simple	O
,	O
safe	O
,	O
and	O
cost-effective	O
intervention	O
for	O
preventing	O
postoperative	O
delirium	O
in	O
elderly	O
patients	O
that	O
could	O
be	O
widely	O
and	O
readily	O
adopted	O
.	O

Sorafenib-induced	B-Chemical
acute	O
myocardial	B-Disease
infarction	I-Disease
due	O
to	O
coronary	B-Disease
artery	I-Disease
spasm	I-Disease
.	O

A	O
65-year-old	O
man	O
with	O
advanced	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
was	O
admitted	O
due	O
to	O
continuing	O
chest	B-Disease
pain	I-Disease
at	O
rest	O
.	O

Two	O
weeks	O
before	O
his	O
admission	O
,	O
sorafenib	B-Chemical
had	O
been	O
started	O
.	O

He	O
was	O
diagnosed	O
with	O
non-ST-elevation	O
myocardial	B-Disease
infarction	I-Disease
by	O
laboratory	O
data	O
and	O
electrocardiogram	O
.	O

Enhanced	O
heart	O
magnetic	O
resonance	O
imaging	O
also	O
showed	O
subendocardial	B-Disease
infarction	I-Disease
.	O

However	O
,	O
there	O
was	O
no	O
stenosis	O
in	O
coronary	O
arteries	O
on	O
angiography	O
.	O

Coronary	B-Disease
artery	I-Disease
spasm	I-Disease
was	O
induced	O
by	O
a	O
provocative	O
test	O
.	O

Cessation	O
of	O
sorafenib	B-Chemical
and	O
administration	O
of	O
Ca-channel	B-Chemical
blocker	O
and	O
nitrates	B-Chemical
ameliorated	O
his	O
symptoms	O
,	O
but	O
relapse	O
occurred	O
after	O
resumption	O
of	O
sorafenib	B-Chemical
.	O

Addition	O
of	O
oral	O
nicorandil	B-Chemical
reduced	O
his	O
symptoms	O
and	O
maintained	O
stable	B-Disease
angina	I-Disease
status	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
sorafenib-induced	B-Chemical
coronary	B-Disease
artery	I-Disease
spasm	I-Disease
.	O

Sorafenib	B-Chemical
is	O
a	O
multikinase	O
inhibitor	O
that	O
targets	O
signaling	O
pathways	O
necessary	O
for	O
cellular	O
proliferation	O
and	O
survival	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
Rho/ROCK	O
pathway	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
coronary	B-Disease
artery	I-Disease
spasm	I-Disease
.	O

Our	O
report	O
may	O
show	O
an	O
adverse	O
effect	O
on	O
the	O
Rho/ROCK	O
pathway	O
by	O
sorafenib	B-Chemical
use	O
.	O

Anxiogenic	O
potential	O
of	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
in	O
rats	O
.	O

INTRODUCTION	O
:	O
The	O
possible	O
anxiogenic	O
effects	O
of	O
fluoroquinolones	B-Chemical
,	O
namely	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
,	O
were	O
investigated	O
in	O
adult	O
Charles	O
Foster	O
albino	O
rats	O
of	O
either	O
sex	O
,	O
weighing	O
150-200	O
g.	O
METHODS	O
:	O
The	O
drugs	B-Drug
were	O
given	O
orally	O
,	O
in	O
doses	O
of	O
50	O
mg/kg	O
for	O
five	O
consecutive	O
days	O
and	O
the	O
experiments	O
were	O
performed	O
on	O
the	O
fifth	O
day	O
.	O

The	O
tests	O
included	O
open-field	O
exploratory	O
behaviour	O
,	O
elevated	O
plus	O
maze	O
and	O
elevated	O
zero	O
maze	O
,	O
social	O
interaction	O
and	O
novelty-suppressed	O
feeding	O
latency	O
behaviour	O
.	O

RESULTS	O
:	O
The	O
results	O
indicate	O
that	O
ciprofloxacin-	B-Chemical
and	O
norfloxacin-treated	B-Chemical
rats	O
showed	O
anxious	B-Disease
behaviour	I-Disease
in	O
comparison	O
to	O
control	O
rats	O
in	O
all	O
the	O
parameters	O
studied	O
.	O

However	O
,	O
ciprofloxacin-	B-Chemical
and	O
norfloxacin-treated	B-Chemical
rats	O
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
in	O
various	O
behavioural	O
parameters	O
.	O

CONCLUSION	O
:	O
The	O
present	O
experimental	O
findings	O
substantiate	O
the	O
clinically	O
observed	O
anxiogenic	O
potential	O
of	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
.	O

Myocardial	O
Fas	O
ligand	O
expression	O
increases	O
susceptibility	O
to	O
AZT-induced	B-Chemical
cardiomyopathy	B-Disease
.	O

BACKGROUND	O
:	O
Dilated	B-Disease
cardiomyopathy	I-Disease
(	O
DCM	B-Disease
)	O
and	O
myocarditis	B-Disease
occur	O
in	O
many	O
HIV-infected	B-Disease
individuals	O
,	O
resulting	O
in	O
symptomatic	O
heart	B-Disease
failure	I-Disease
in	O
up	O
to	O
5	O
%	O
of	O
patients	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
significantly	O
reduced	O
morbidity	O
and	O
mortality	O
of	O
acquired	B-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
(	O
AIDS	B-Disease
)	O
,	O
but	O
has	O
resulted	O
in	O
an	O
increase	O
in	O
cardiac	B-Disease
and	I-Disease
skeletal	I-Disease
myopathies	I-Disease
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
order	O
to	O
investigate	O
whether	O
the	O
HAART	O
component	O
zidovudine	B-Chemical
(	O
3'-azido-2',3'-deoxythymidine	B-Chemical
;	O
AZT	B-Chemical
)	O
triggers	O
the	O
Fas-dependent	O
cell-death	O
pathway	O
and	O
cause	O
cytoskeletal	O
disruption	O
in	O
a	O
murine	O
model	O
of	O
DCM	B-Disease
,	O
8-week-old	O
transgenic	O
(	O
expressing	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
:	O
FasL	O
Tg	O
)	O
and	O
non-transgenic	O
(	O
NTg	B-Drug
)	O
mice	O
received	O
water	O
ad	O
libitum	O
containing	O
different	O
concentrations	O
of	O
AZT	B-Chemical
(	O
0	O
,	O
0.07	O
,	O
0.2	O
,	O
and	O
0.7	O
mg/ml	O
)	O
.	O

After	O
6	O
weeks	O
,	O
cardiac	O
function	O
was	O
assessed	O
by	O
echocardiography	O
and	O
morphology	O
was	O
assessed	O
by	O
histopathologic	O
and	O
immunohistochemical	O
methods	O
.	O

NTg	B-Drug
and	O
untreated	O
FasL	O
Tg	O
mice	O
showed	O
little	O
or	O
no	O
change	O
in	O
cardiac	O
structure	O
or	O
function	O
.	O

In	O
contrast	O
,	O
AZT-treated	B-Chemical
FasL	O
Tg	O
mice	O
developed	O
cardiac	B-Disease
dilation	I-Disease
and	O
depressed	O
cardiac	O
function	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
concomitant	O
inflammatory	O
infiltration	O
of	O
both	O
ventricles	O
.	O

These	O
changes	O
were	O
associated	O
with	O
an	O
increased	O
sarcolemmal	O
expression	O
of	O
Fas	O
and	O
FasL	O
,	O
as	O
well	O
as	O
increased	O
activation	O
of	O
caspase	O
3	O
,	O
translocation	O
of	O
calpain	O
1	O
to	O
the	O
sarcolemma	O
and	O
sarcomere	O
,	O
and	O
increased	O
numbers	O
of	O
cells	O
undergoing	O
apoptosis	O
.	O

These	O
were	O
associated	O
with	O
changes	O
in	O
dystrophin	O
and	O
cardiac	O
troponin	O
I	O
localization	O
,	O
as	O
well	O
as	O
loss	O
of	O
sarcolemmal	O
integrity	O
.	O

CONCLUSIONS	O
:	O
The	O
expression	O
of	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
,	O
as	O
identified	O
in	O
HIV-positive	O
patients	O
,	O
might	O
increase	O
the	O
susceptibility	O
to	O
HAART-induced	O
cardiomyopathy	B-Disease
due	O
to	O
activation	O
of	O
apoptotic	O
pathways	O
,	O
resulting	O
in	O
cardiac	B-Disease
dilation	I-Disease
and	I-Disease
dysfunction	I-Disease
.	O

Valproate-induced	B-Chemical
chorea	B-Disease
and	O
encephalopathy	B-Disease
in	O
atypical	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
.	O

Nonketotic	B-Disease
hyperglycinemia	I-Disease
is	O
a	O
disorder	B-Disease
of	I-Disease
amino	I-Disease
acid	I-Disease
metabolism	I-Disease
in	O
which	O
a	O
defect	O
in	O
the	O
glycine	B-Chemical
cleavage	O
system	O
leads	O
to	O
an	O
accumulation	O
of	O
glycine	B-Chemical
in	O
the	O
brain	O
and	O
other	O
body	O
compartments	O
.	O

In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	B-Disease
,	O
intractable	O
seizures	B-Disease
,	O
and	O
hypotonia	B-Disease
,	O
followed	O
by	O
significant	O
psychomotor	B-Disease
retardation	I-Disease
.	O

An	O
important	O
subset	O
of	O
children	O
with	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
are	O
atypical	O
variants	O
who	O
present	O
in	O
a	O
heterogeneous	O
manner	O
.	O

This	O
report	O
describes	O
a	O
patient	O
with	O
mild	O
language	B-Disease
delay	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
,	O
who	O
was	O
found	O
to	O
have	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
following	O
her	O
presentation	O
with	O
acute	O
encephalopathy	B-Disease
and	O
chorea	B-Disease
shortly	O
after	O
initiation	O
of	O
valproate	B-Chemical
therapy	O
.	O

Microinjection	O
of	O
ritanserin	B-Chemical
into	O
the	O
CA1	O
region	O
of	O
hippocampus	O
improves	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
in	O
adult	O
male	O
rats	O
.	O

The	O
effect	O
of	O
ritanserin	B-Chemical
(	O
5-HT2	O
antagonist	O
)	O
on	O
scopolamine	B-Chemical
(	O
muscarinic	O
cholinergic	O
antagonist	O
)	O
-induced	O
amnesia	B-Disease
in	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
was	O
investigated	O
.	O

Rats	O
were	O
divided	O
into	O
eight	O
groups	O
and	O
bilaterally	O
cannulated	O
into	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

One	O
week	O
later	O
,	O
they	O
received	O
repeatedly	O
vehicles	O
(	O
saline	O
,	O
DMSO	B-Chemical
,	O
saline+DMSO	B-Chemical
)	O
,	O
scopolamine	B-Chemical
(	O
2	O
microg/0.5	O
microl	O
saline/side	O
;	O
30	O
min	O
before	O
training	O
)	O
,	O
ritanserin	B-Chemical
(	O
2	O
,	O
4	O
and	O
8	O
microg/0.5	O
microl	O
DMSO/side	B-Chemical
;	O
20	O
min	O
before	O
training	O
)	O
and	O
scopolamine	B-Chemical
(	O
2	O
microg/0.5	O
microl	O
;	O
30	O
min	O
before	O
ritanserin	B-Chemical
injection	O
)	O
+ritanserin	B-Chemical
(	O
4	O
microg/0.5	O
microl	O
DMSO	B-Chemical
)	O
through	O
cannulae	O
each	O
day	O
.	O

Animals	O
were	O
tested	O
for	O
four	O
consecutive	O
days	O
(	O
4	O
trial/day	O
)	O
in	O
MWM	O
during	O
which	O
the	O
position	O
of	O
hidden	O
platform	O
was	O
unchanged	O
.	O

In	O
the	O
fifth	O
day	O
,	O
the	O
platform	O
was	O
elevated	O
above	O
the	O
water	O
surface	O
in	O
another	O
position	O
to	O
evaluate	O
the	O
function	O
of	O
motor	O
,	O
motivational	O
and	O
visual	O
systems	O
.	O

The	O
results	O
showed	O
a	O
significant	O
increase	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	O
in	O
scopolamine-treated	B-Chemical
group	O
as	O
compared	O
to	O
saline	O
group	O
.	O

Ritanserin-treated	B-Chemical
rats	O
(	O
4	O
microg/0.5	O
microl/side	O
)	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
mentioned	O
parameters	O
as	O
compared	O
to	O
DMSO-treated	B-Chemical
group	O
.	O

However	O
,	O
scopolamine	B-Chemical
and	O
ritanserin	B-Chemical
co-administration	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
as	O
compared	O
to	O
the	O
scopolamine-treated	B-Chemical
rats	O
.	O

Our	O
findings	O
show	O
that	O
microinjection	O
of	O
ritanserin	B-Chemical
into	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
improves	O
the	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
.	O

Hypoxia	B-Disease
in	O
renal	B-Disease
disease	I-Disease
with	O
proteinuria	B-Disease
and/or	O
glomerular	O
hypertension	B-Disease
.	O

Despite	O
the	O
increasing	O
need	O
to	O
identify	O
and	O
quantify	O
tissue	O
oxygenation	O
at	O
the	O
cellular	O
level	O
,	O
relatively	O
few	O
methods	O
have	O
been	O
available	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
new	O
hypoxia-responsive	B-Disease
reporter	O
vector	O
using	O
a	O
hypoxia-responsive	B-Disease
element	O
of	O
the	O
5	O
'	O
vascular	O
endothelial	O
growth	O
factor	O
untranslated	O
region	O
and	O
generated	O
a	O
novel	O
hypoxia-sensing	B-Disease
transgenic	O
rat	O
.	O

We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	B-Disease
in	O
the	O
diseased	B-Disease
kidney	I-Disease
.	O

With	O
this	O
model	O
,	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	B-Disease
in	O
the	O
puromycin	B-Chemical
aminonucleoside-induced	O
nephrotic	O
syndrome	O
and	O
focal	O
and	O
segmental	O
hypoxia	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O

Expression	O
of	O
the	O
hypoxia-responsive	O
transgene	O
increased	O
throughout	O
the	O
observation	O
period	O
,	O
reaching	O
2.2-fold	O
at	O
2	O
weeks	O
in	O
the	O
puromycin	B-Chemical
aminonucleoside	O
model	O
and	O
2.6-fold	O
at	O
4	O
weeks	O
in	O
the	O
remnant	O
kidney	O
model	O
,	O
whereas	O
that	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
showed	O
a	O
mild	O
decrease	O
,	O
reflecting	O
distinct	O
behaviors	O
of	O
the	O
two	O
genes	O
.	O

The	O
degree	O
of	O
hypoxia	O
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	O
injury	O
in	O
both	O
models	O
.	O

Finally	O
,	O
we	O
identified	O
the	O
localization	O
of	O
proliferating	O
cell	O
nuclear	O
antigen-positive	O
,	O
ED-1-positive	O
,	O
and	O
terminal	O
dUTP	O
nick-end	O
labeled-positive	O
cells	O
in	O
the	O
hypoxic	O
cortical	O
area	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O

We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	O
and	O
progressive	O
glomerular	O
diseases	O
.	O

Consensus	O
statement	O
concerning	O
cardiotoxicity	B-Disease
occurring	O
during	O
haematopoietic	O
stem	O
cell	O
transplantation	O
in	O
the	O
treatment	O
of	O
autoimmune	B-Disease
diseases	I-Disease
,	O
with	O
special	O
reference	O
to	O
systemic	B-Disease
sclerosis	I-Disease
and	O
multiple	B-Disease
sclerosis	I-Disease
.	O

Autologous	O
haematopoietic	O
stem	O
cell	O
transplantation	O
is	O
now	O
a	O
feasible	O
and	O
effective	O
treatment	O
for	O
selected	O
patients	O
with	O
severe	O
autoimmune	B-Disease
diseases	I-Disease
.	O

Worldwide	O
,	O
over	O
650	O
patients	O
have	O
been	O
transplanted	O
in	O
the	O
context	O
of	O
phase	O
I	O
and	O
II	O
clinical	O
trials	O
.	O

The	O
results	O
are	O
encouraging	O
enough	O
to	O
begin	O
randomised	O
phase	O
III	O
trials	O
.	O

However	O
,	O
as	O
predicted	O
,	O
significant	O
transplant-related	O
morbidity	O
and	O
mortality	O
have	O
been	O
observed	O
.	O

This	O
is	O
primarily	O
due	O
to	O
complications	O
related	O
to	O
either	O
the	O
stage	O
of	O
the	O
disease	O
at	O
transplant	O
or	O
due	O
to	O
infections	B-Disease
.	O

The	O
number	O
of	O
deaths	O
related	O
to	O
cardiac	B-Disease
toxicity	I-Disease
is	O
low	O
.	O

However	O
,	O
caution	O
is	O
required	O
when	O
cyclophosphamide	B-Chemical
or	O
anthracyclines	B-Chemical
such	O
as	O
mitoxantrone	B-Chemical
are	O
used	O
in	O
patients	O
with	O
a	O
possible	O
underlying	O
heart	B-Disease
damage	I-Disease
,	O
for	O
example	O
,	O
systemic	B-Disease
sclerosis	I-Disease
patients	O
.	O

In	O
November	O
2002	O
,	O
a	O
meeting	O
was	O
held	O
in	O
Florence	O
,	O
bringing	O
together	O
a	O
number	O
of	O
experts	O
in	O
various	O
fields	O
,	O
including	O
rheumatology	O
,	O
cardiology	O
,	O
neurology	O
,	O
pharmacology	O
and	O
transplantation	O
medicine	O
.	O

The	O
object	O
of	O
the	O
meeting	O
was	O
to	O
analyse	O
existing	O
data	O
,	O
both	O
published	O
or	O
available	O
,	O
in	O
the	O
European	O
Group	O
for	O
Blood	O
and	O
Marrow	O
Transplantation	O
autoimmune	B-Disease
disease	I-Disease
database	O
,	O
and	O
to	O
propose	O
a	O
safe	O
approach	O
to	O
such	O
patients	O
.	O

A	O
full	O
cardiological	O
assessment	O
before	O
and	O
during	O
the	O
transplant	O
emerged	O
as	O
the	O
major	O
recommendation	O
.	O

Immunohistochemical	O
study	O
on	O
inducible	O
type	O
of	O
nitric	B-Chemical
oxide	I-Chemical
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	B-Disease
growth	O
factor-beta1	O
(	O
TGF-beta1	O
)	O
in	O
arteritis	B-Disease
induced	O
in	O
rats	O
by	O
fenoldopam	B-Chemical
and	O
theophylline	B-Chemical
,	O
vasodilators	O
.	O

Arteritis	B-Disease
induced	O
in	O
rats	O
by	O
vasodilators	O
,	O
fenoldopam	B-Chemical
and	O
theophylline	B-Chemical
,	O
was	O
examined	O
immunohistochemically	O
for	O
expressions	O
of	O
inducible	O
type	O
of	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	B-Disease
growth	O
factor-beta1	O
(	O
TGF-beta1	O
)	O
.	O

Rats	O
were	O
administered	O
fenoldopam	B-Chemical
for	O
24	O
hours	O
by	O
intravenous	O
infusion	O
with	O
or	O
without	O
following	O
repeated	O
daily	O
oral	O
administrations	O
of	O
theophylline	B-Chemical
.	O

Irrespective	O
of	O
theophylline	B-Chemical
administration	O
,	O
iNOS	O
antigens	O
were	O
remarkably	O
abundant	O
in	O
ED-1-positive	O
cells	O
on	O
day	O
5	O
and	O
8	O
post-fenoldopam-infusion	B-Chemical
(	O
DPI	O
)	O
;	O
bFGF	O
antigens	O
were	O
remarkably	O
abundant	O
in	O
ED-1-positive	O
cells	O
on	O
1	O
and	O
3	O
DPI	O
;	O
TGF-beta1	O
antigens	O
were	O
observed	O
in	O
ED-1-positive	O
cells	O
on	O
and	O
after	O
5	O
DPI	O
.	O

These	O
results	O
suggest	O
that	O
the	O
peak	O
expression	O
of	O
iNOS	O
antigen	O
was	O
followed	O
by	O
that	O
of	O
bFGF	O
antigen	O
,	O
and	O
bFGF	O
may	O
have	O
a	O
suppressive	O
effect	O
on	O
iNOS	O
expression	O
in	O
these	O
rat	O
arteritis	B-Disease
models	O
.	O

On	O
the	O
other	O
hand	O
,	O
TGF-beta1	O
was	O
not	O
considered	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
iNOS	O
expression	O
in	O
these	O
models	O
.	O

Low-molecular-weight	B-Chemical
heparin	I-Chemical
for	O
the	O
treatment	O
of	O
patients	O
with	O
mechanical	O
heart	O
valves	O
.	O

BACKGROUND	O
:	O
The	O
interruption	O
of	O
oral	O
anticoagulant	B-Drug
(	O
OAC	O
)	O
administration	O
is	O
sometimes	O
indicated	O
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
,	O
mainly	O
before	O
noncardiac	O
surgery	O
,	O
non-surgical	O
interventions	O
,	O
and	O
pregnancy	O
.	O

Unfractionated	B-Chemical
heparin	I-Chemical
(	O
UH	B-Chemical
)	O
is	O
currently	O
the	O
substitute	O
for	O
selected	O
patients	O
.	O

Low-molecular-weight	B-Chemical
heparin	I-Chemical
(	O
LMWH	B-Chemical
)	O
offers	O
theoretical	O
advantages	O
over	O
UH	B-Chemical
,	O
but	O
is	O
not	O
currently	O
considered	O
in	O
clinical	O
guidelines	O
as	O
an	O
alternative	O
to	O
UH	B-Chemical
in	O
patients	O
with	O
prosthetic	O
valves	O
.	O

HYPOTHESIS	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
review	O
the	O
data	O
accumulated	O
so	O
far	O
on	O
the	O
use	O
of	O
LMWH	B-Chemical
in	O
this	O
patient	O
population	O
and	O
to	O
discuss	O
its	O
applicability	O
in	O
common	O
practice	O
.	O

METHODS	O
:	O
For	O
this	O
paper	O
,	O
the	O
current	O
medical	O
literature	O
on	O
LMWH	B-Chemical
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
was	O
extensively	O
reviewed	O
.	O

RESULTS	O
:	O
There	O
were	O
eight	O
series	O
and	O
six	O
case	O
reports	O
.	O

None	O
of	O
the	O
studies	O
was	O
randomized	O
,	O
and	O
only	O
one	O
was	O
prospective	O
.	O

Data	O
to	O
establish	O
the	O
thromboembolic	B-Disease
risk	O
were	O
incomplete	O
.	O

After	O
excluding	O
case	O
reports	O
,	O
the	O
following	O
groups	O
were	O
constructed	O
:	O
(	O
a	O
)	O
short-term	O
administration	O
,	O
after	O
valve	O
insertion	O
(	O
n	O
=	O
212	O
)	O
;	O
(	O
b	O
)	O
short-term	O
,	O
perioperative	O
(	O
noncardiac	O
)	O
/periprocedural	O
(	O
n	O
=	O
114	O
)	O
;	O
(	O
c	O
)	O
long-term	O
,	O
due	O
to	O
intolerance	O
to	O
OAC	O
(	O
n	O
=	O
16	O
)	O
;	O
(	O
d	O
)	O
long-term	O
,	O
in	O
pregnancy	O
(	O
n	O
=	O
10	O
)	O
.	O

The	O
incidence	O
rate	O
of	O
thromboembolism	B-Disease
was	O
0.9	O
%	O
for	O
all	O
the	O
studies	O
and	O
0.5	O
,	O
0	O
,	O
20	O
,	O
and	O
0	O
%	O
in	O
groups	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
,	O
respectively	O
;	O
for	O
hemorrhage	B-Disease
,	O
the	O
overall	O
rate	O
was	O
3.4	O
%	O
(	O
3.8	O
,	O
2.6	O
,	O
10	O
,	O
and	O
0	O
%	O
for	O
the	O
respective	O
groups	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
mechanical	O
heart	O
valves	O
,	O
short-term	O
LMWH	B-Chemical
therapy	O
compares	O
favorably	O
with	O
UH	B-Chemical
.	O

Data	O
on	O
mid-	O
and	O
long-term	O
LMWH	B-Chemical
administration	O
in	O
these	O
patients	O
are	O
sparse	O
.	O

Further	O
randomized	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
safety	O
and	O
precise	O
indications	O
for	O
the	O
use	O
of	O
LMWH	B-Chemical
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
.	O

Topiramate-induced	B-Chemical
nephrolithiasis	B-Disease
.	O

Topiramate	B-Chemical
is	O
a	O
recently	O
developed	O
antiepileptic	O
medication	O
that	O
is	O
becoming	O
more	O
widely	O
prescribed	O
because	O
of	O
its	O
efficacy	O
in	O
treating	O
refractory	B-Disease
seizures	I-Disease
.	O

Urologists	O
should	O
be	O
aware	O
that	O
this	O
medication	O
can	O
cause	O
metabolic	B-Disease
acidosis	I-Disease
in	O
patients	O
secondary	O
to	O
inhibition	O
of	O
carbonic	O
anhydrase	O
.	O

In	O
addition	O
,	O
a	O
distal	O
tubular	O
acidification	O
defect	O
may	O
result	O
,	O
thus	O
impairing	O
the	O
normal	O
compensatory	O
drop	O
in	O
urine	O
pH	O
.	O

These	O
factors	O
can	O
lead	B-Drug
to	O
the	O
development	O
of	O
calcium	B-Chemical
phosphate	I-Chemical
nephrolithiasis	B-Disease
.	O

We	O
report	O
the	O
first	O
two	O
cases	O
of	O
topiramate-induced	B-Chemical
nephrolithiasis	B-Disease
in	O
the	O
urologic	O
literature	O
.	O

Spironolactone	B-Chemical
:	O
is	O
it	O
a	O
novel	O
drug	B-Drug
for	O
the	O
prevention	O
of	O
amphotericin	B-Chemical
B-related	O
hypokalemia	O
in	O
cancer	O
patients	O
?	O
OBJECTIVE	O
:	O
Nephrotoxicity	B-Disease
is	O
the	O
major	O
adverse	O
effect	O
of	O
amphotericin	B-Chemical
B	I-Chemical
(	O
AmB	B-Chemical
)	O
,	O
often	O
limiting	O
administration	O
of	O
full	O
dosage	O
.	O

Selective	O
distal	O
tubular	O
epithelial	O
toxicity	B-Disease
seems	O
to	O
be	O
responsible	O
for	O
the	O
profound	O
potassium	B-Chemical
wasting	O
that	O
is	O
a	O
major	O
clinical	O
side	O
effect	O
of	O
treatment	O
with	O
AmB	B-Chemical
.	O

Potassium	B-Chemical
depletion	O
also	O
potentiates	O
the	O
tubular	O
toxicity	B-Disease
of	O
AmB	B-Chemical
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
ability	O
of	O
spironolactone	B-Chemical
to	O
reduce	O
potassium	B-Chemical
requirements	O
and	O
to	O
prevent	O
hypokalemia	B-Disease
in	O
neutropenic	B-Disease
patients	O
on	O
AmB	B-Chemical
treatment	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
26	O
patients	O
with	O
various	O
hematological	B-Disease
disorders	I-Disease
were	O
randomized	O
to	O
receive	O
either	O
intravenous	O
AmB	B-Chemical
alone	O
or	O
AmB	B-Chemical
and	O
oral	O
spironolactone	B-Chemical
100	O
mg	O
twice	O
daily	O
when	O
developing	O
a	O
proven	O
or	O
suspected	O
fungal	B-Disease
infection	I-Disease
.	O

RESULTS	O
:	O
Patients	O
receiving	O
concomitant	O
AmB	B-Chemical
and	O
spironolactone	B-Chemical
had	O
significantly	O
higher	O
plasma	O
potassium	B-Chemical
levels	O
than	O
those	O
receiving	O
AmB	B-Chemical
alone	O
(	O
P	O
=	O
0.0027	O
)	O
.	O

Those	O
patients	O
receiving	O
AmB	B-Chemical
and	O
spironolactone	B-Chemical
required	O
significantly	O
less	O
potassium	B-Chemical
supplementation	O
to	O
maintain	O
their	O
plasma	O
potassium	B-Chemical
within	O
the	O
normal	O
range	O
(	O
P	O
=	O
0.022	O
)	O
.	O

Moreover	O
,	O
urinary	O
potassium	B-Chemical
losses	O
were	O
significantly	O
less	O
in	O
patients	O
receiving	O
AmB	B-Chemical
and	O
spironolactone	B-Chemical
than	O
those	O
receiving	O
AmB	B-Chemical
alone	O
(	O
P	O
=	O
0.040	O
)	O
.	O

CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
spironolactone	B-Chemical
can	O
reduce	O
potassium	B-Chemical
requirements	O
and	O
prevent	O
hypokalemia	B-Disease
by	O
reducing	O
urinary	O
potassium	B-Chemical
loss	O
in	O
neutropenic	B-Disease
patients	O
on	O
AmB	B-Chemical
treatment	O
.	O

Dopamine	B-Chemical
D2	O
receptor	O
signaling	O
controls	O
neuronal	O
cell	O
death	O
induced	O
by	O
muscarinic	O
and	O
glutamatergic	O
drugs	B-Drug
.	O

Dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
,	O
through	O
D1/D2	O
receptor-mediated	O
signaling	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
control	O
of	O
epileptic	B-Disease
seizures	I-Disease
arising	O
in	O
the	O
limbic	O
system	O
.	O

Excitotoxicity	B-Disease
leading	O
to	O
neuronal	O
cell	O
death	O
in	O
the	O
affected	O
areas	O
is	O
a	O
major	O
consequence	O
of	O
seizures	B-Disease
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
respect	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
DA	B-Chemical
receptors	O
in	O
the	O
occurrence	O
of	O
epilepsy-induced	B-Disease
neuronal	O
cell	O
death	O
.	O

Here	O
we	O
analyze	O
the	O
occurrence	O
of	O
seizures	B-Disease
and	O
neurotoxicity	B-Disease
in	O
D2R	O
-/-	O
mice	O
treated	O
with	O
the	O
cholinergic	O
agonist	O
pilocarpine	B-Chemical
.	O

We	O
compared	O
these	O
results	O
with	O
those	O
previously	O
obtained	O
with	O
kainic	B-Chemical
acid	I-Chemical
(	O
KA	B-Chemical
)	O
,	O
a	O
potent	O
glutamate	B-Chemical
agonist	O
.	O

Importantly	O
,	O
D2R	O
-/-	O
mice	O
develop	O
seizures	B-Disease
at	O
doses	O
of	O
both	O
drugs	B-Drug
that	O
are	O
not	O
epileptogenic	O
for	O
WT	O
littermates	O
and	O
show	O
greater	O
neurotoxicity	B-Disease
.	O

However	O
,	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
result	O
in	O
a	O
more	O
widespread	O
neuronal	O
death	O
in	O
both	O
WT	O
and	O
D2R	O
-/-	O
brains	O
in	O
comparison	O
to	O
KA	B-Chemical
.	O

Thus	O
,	O
the	O
absence	O
of	O
D2R	O
lowers	O
the	O
threshold	O
for	O
seizures	B-Disease
induced	O
by	O
both	O
glutamate	B-Chemical
and	O
acetylcholine	B-Chemical
.	O

Moreover	O
,	O
the	O
dopaminergic	B-Drug
control	O
of	O
epilepsy-induced	B-Disease
neurodegeneration	B-Disease
seems	O
to	O
be	O
mediated	O
by	O
distinct	O
interactions	O
of	O
D2R	O
signaling	O
with	O
these	O
two	O
neurotransmitters	O
.	O

Treatment	O
of	O
risperidone-induced	B-Chemical
hyperprolactinemia	B-Disease
with	O
a	O
dopamine	B-Chemical
agonist	O
in	O
children	O
.	O

BACKGROUND	O
:	O
Risperidone	B-Chemical
,	O
a	O
potent	O
antagonist	O
of	O
both	O
serotonergic	O
(	O
5HT2A	O
)	O
and	O
dopaminergic	B-Drug
D2	O
receptors	O
is	O
associated	O
with	O
hyperprolactinemia	B-Disease
in	O
adults	O
and	O
children	O
.	O

Chronically	O
elevated	O
prolactin	O
levels	O
in	O
children	O
with	O
prolactinomas	B-Disease
may	O
be	O
associated	O
with	O
arrested	O
growth	O
and	O
development	O
resulting	O
in	O
either	O
delayed	B-Disease
puberty	I-Disease
or	O
short	O
stature	O
.	O

These	O
possibilities	O
stress	O
the	O
importance	O
of	O
developing	O
a	O
safe	O
and	O
effective	O
approach	O
to	O
drug-induced	O
hyperprolactinemia	B-Disease
in	O
youth	O
.	O

We	O
report	O
the	O
successful	O
treatment	O
of	O
risperidone-induced	B-Chemical
hyperprolactinemia	B-Disease
with	O
cabergoline	B-Chemical
in	O
youth	O
.	O

METHODS	O
:	O
We	O
undertook	O
a	O
retrospective	O
case	O
review	O
of	O
four	O
children	O
with	O
risperidone-induced	B-Chemical
hyperprolactinemia	B-Disease
treated	O
with	O
cabergoline	B-Chemical
.	O

RESULTS	O
:	O
Four	O
males	O
(	O
age	O
6-11	O
years	O
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-Disease
Disorders	I-Disease
(	O
fourth	O
edition	O
)	O
bipolar	B-Disease
disorder	I-Disease
or	O
psychoses	B-Disease
,	O
with	O
risperidone-induced	B-Chemical
elevations	O
in	O
serum	O
prolactin	O
levels	O
(	O
57.5-129	O
ng/mL	O
,	O
normal	O
5-15	O
ng/mL	O
)	O
,	O
were	O
treated	O
with	O
cabergoline	B-Chemical
(	O
mean	O
dose	O
2.13	O
+/-	O
0.09	O
mg/week	O
)	O
.	O

When	O
serum	O
prolactin	O
levels	O
normalized	O
in	O
all	O
four	O
subjects	O
(	O
mean	O
11.2	O
+/-	O
10.9	O
ng/mL	O
)	O
,	O
the	O
cabergoline	B-Chemical
dose	O
was	O
reduced	O
to	O
1	O
mg/week	O
in	O
three	O
of	O
four	O
subjects	O
.	O

The	O
mean	O
duration	O
of	O
therapy	O
with	O
cabergoline	B-Chemical
was	O
523.5	O
+/-	O
129.7	O
days	O
,	O
and	O
the	O
mean	O
duration	O
of	O
therapy	O
with	O
risperidone	B-Chemical
was	O
788.5	O
+/-	O
162.5	O
days	O
.	O

Cabergoline	B-Chemical
was	O
well	O
tolerated	O
without	O
adverse	O
effects	O
.	O

CONCLUSIONS	O
:	O
Cabergoline	B-Chemical
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
risperidone-induced	B-Chemical
hyperprolactinemia	B-Disease
in	O
youth	O
;	O
however	O
,	O
further	O
research	O
is	O
needed	O
.	O

Cholestatic	B-Disease
jaundice	I-Disease
associated	O
with	O
the	O
use	O
of	O
metformin	B-Chemical
.	O

We	O
report	O
a	O
patient	O
who	O
developed	O
cholestatic	B-Disease
jaundice	I-Disease
shortly	O
after	O
initiation	O
of	O
treatment	O
with	O
metformin	B-Chemical
hydrochloride	I-Chemical
.	O

Ultrasound	O
of	O
the	O
liver	O
and	O
abdominal	O
CT	O
were	O
normal	O
.	O

An	O
ERCP	O
showed	O
normal	O
biliary	O
anatomy	O
.	O

A	O
percutaneous	O
liver	O
biopsy	O
was	O
obtained	O
showing	O
marked	O
cholestasis	B-Disease
,	O
with	O
portal	O
edema	B-Disease
,	O
ductular	O
proliferation	O
,	O
and	O
acute	O
inflammation	B-Disease
.	O

Metformin	B-Chemical
hydrochloride	I-Chemical
was	O
discontinued	O
,	O
and	O
the	O
patient	O
's	O
jaundice	B-Disease
resolved	O
slowly	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

Given	O
the	O
onset	O
of	O
his	O
jaundice	B-Disease
2	O
wk	O
after	O
the	O
initiation	O
of	O
metformin	B-Chemical
,	O
we	O
believe	O
that	O
this	O
case	O
represents	O
an	O
example	O
of	O
metformin-associated	B-Chemical
hepatotoxicity	B-Disease
,	O
the	O
first	O
such	O
case	O
reported	O
.	O

Electro-oculography	O
,	O
electroretinography	O
,	O
visual	O
evoked	O
potentials	O
,	O
and	O
multifocal	O
electroretinography	O
in	O
patients	O
with	O
vigabatrin-attributed	B-Chemical
visual	B-Disease
field	I-Disease
constriction	I-Disease
.	O

PURPOSE	O
:	O
Symptomatic	O
visual	B-Disease
field	I-Disease
constriction	I-Disease
thought	O
to	O
be	O
associated	O
with	O
vigabatrin	B-Chemical
has	O
been	O
reported	O
.	O

The	O
current	O
study	O
investigated	O
the	O
visual	O
fields	O
and	O
visual	O
electrophysiology	O
of	O
eight	O
patients	O
with	O
known	O
vigabatrin-attributed	B-Chemical
visual	B-Disease
field	I-Disease
loss	I-Disease
,	O
three	O
of	O
whom	O
were	O
reported	O
previously	O
.	O

Six	O
of	O
the	O
patients	O
were	O
no	O
longer	O
receiving	O
vigabatrin	B-Chemical
.	O

METHODS	O
:	O
The	O
central	O
and	O
peripheral	O
fields	O
were	O
examined	O
with	O
the	O
Humphrey	O
Visual	O
Field	O
Analyzer	O
.	O

Full	O
visual	B-Disease
electrophysiology	O
,	O
including	O
flash	O
electroretinography	O
(	O
ERG	O
)	O
,	O
pattern	O
electroretinography	O
,	O
multifocal	O
ERG	O
using	O
the	O
VERIS	O
system	O
,	O
electro-oculography	O
,	O
and	O
flash	O
and	O
pattern	O
visual	B-Disease
evoked	O
potentials	O
,	O
was	O
undertaken	O
.	O

RESULTS	O
:	O
Seven	O
patients	O
showed	O
marked	O
visual	B-Disease
field	I-Disease
constriction	I-Disease
with	O
some	O
sparing	O
of	O
the	O
temporal	O
visual	B-Disease
field	O
.	O

The	O
eighth	O
exhibited	O
concentric	O
constriction	O
.	O

Most	O
electrophysiological	O
responses	O
were	O
usually	O
just	O
within	O
normal	O
limits	O
;	O
two	O
patients	O
had	O
subnormal	O
Arden	O
electro-oculography	O
indices	O
;	O
and	O
one	O
patient	O
showed	O
an	O
abnormally	O
delayed	O
photopic	O
b	O
wave	O
.	O

However	O
,	O
five	O
patients	O
showed	O
delayed	O
30-Hz	O
flicker	O
b	O
waves	O
,	O
and	O
seven	O
patients	O
showed	O
delayed	O
oscillatory	O
potentials	O
.	O

Multifocal	O
ERG	O
showed	O
abnormalities	O
that	O
sometimes	O
correlated	O
with	O
the	O
visual	O
field	O
appearance	O
and	O
confirmed	O
that	O
the	O
deficit	O
occurs	O
at	O
the	O
retinal	O
level	O
.	O

CONCLUSION	O
:	O
Marked	O
visual	O
field	O
constriction	O
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	B-Chemical
therapy	O
.	O

The	O
field	O
defects	O
and	O
some	O
electrophysiological	O
abnormalities	O
persist	O
when	O
vigabatrin	B-Chemical
therapy	O
is	O
withdrawn	O
.	O

Conversion	O
to	O
rapamycin	B-Chemical
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
:	O
report	O
of	O
an	O
initial	O
experience	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effects	O
of	O
RAPA	B-Chemical
conversion	O
in	O
patients	O
undergoing	O
cyclosporine	B-Chemical
(	O
CsA	B-Chemical
)	O
or	O
tacrolimus	B-Chemical
(	O
Tac	B-Chemical
)	O
toxicity	B-Disease
.	O

METHODS	O
:	O
Twenty	O
renal	O
transplant	O
recipients	O
were	O
switched	O
to	O
fixed	O
dose	O
rapamycin	B-Chemical
(	O
RAPA	B-Chemical
)	O
(	O
5	O
mg/day	O
)	O
0	O
to	O
204	O
months	O
posttransplant	O
.	O

Drug	B-Drug
monitoring	O
was	O
not	O
initially	O
used	O
to	O
adjust	O
doses	O
.	O

The	O
indications	O
for	O
switch	O
were	O
chronic	O
CsA	B-Chemical
or	O
Tac	B-Chemical
nephrotoxicity	B-Disease
(	O
12	O
)	O
,	O
acute	O
CsA	B-Chemical
or	O
Tac	B-Chemical
toxicity	B-Disease
(	O
3	O
)	O
,	O
severe	O
facial	B-Disease
dysmorphism	I-Disease
(	O
2	O
)	O
,	O
posttransplant	B-Disease
lymphoproliferative	I-Disease
disorder	I-Disease
(	O
PTLD	B-Disease
)	O
in	O
remission	O
(	O
2	O
)	O
,	O
and	O
hepatotoxicity	B-Disease
in	O
1	O
.	O

Follow-up	O
is	O
7	O
to	O
24	O
months	O
.	O

RESULTS	O
:	O
In	O
the	O
12	O
patients	O
switched	O
because	O
of	O
chronic	O
nephrotoxicity	B-Disease
there	O
was	O
a	O
significant	O
decrease	O
in	O
serum	O
creatinine	B-Chemical
[	O
233+/-34	O
to	O
210+/-56	O
micromol/liter	O
(	O
P	O
<	O
0.05	O
)	O
at	O
6	O
months	O
]	O
.	O

Facial	B-Disease
dysmorphism	I-Disease
improved	O
in	O
two	O
patients	O
.	O

No	O
relapse	O
of	O
PTLD	B-Disease
was	O
observed	O
.	O

Five	O
patients	O
developed	O
pneumonia	B-Disease
(	O
two	O
Pneumocystis	B-Disease
carinii	I-Disease
pneumonia	I-Disease
,	O
one	O
infectious	B-Disease
mononucleosis	I-Disease
with	O
polyclonal	O
PTLD	B-Disease
lung	O
infiltrate	O
)	O
and	O
two	O
had	O
bronchiolitis	B-Disease
obliterans	I-Disease
.	O

There	O
were	O
no	O
deaths	O
.	O

RAPA	B-Chemical
was	O
discontinued	O
in	O
four	O
patients	O
,	O
because	O
of	O
pneumonia	B-Disease
in	O
two	O
,	O
PTLD	B-Disease
in	O
one	O
,	O
and	O
oral	O
aphtous	B-Disease
ulcers	I-Disease
in	O
one	O
.	O

RAPA	B-Chemical
levels	O
were	O
high	O
(	O
>	O
15	O
ng/ml	O
)	O
in	O
7	O
of	O
13	O
(	O
54	O
%	O
)	O
patients	O
.	O

CONCLUSIONS	O
:	O
RAPA	B-Chemical
conversion	O
provides	O
adequate	O
immunosuppression	O
to	O
enable	O
CsA	B-Chemical
withdrawal	O
.	O

However	O
,	O
when	O
converting	O
patients	O
to	O
RAPA	B-Chemical
drug	B-Drug
levels	O
should	O
be	O
monitored	O
to	O
avoid	O
over-immunosuppression	O
and	O
adequate	O
antiviral	O
and	O
Pneumocystis	B-Disease
carinii	I-Disease
pneumonia	I-Disease
prophylaxis	O
should	O
be	O
given	O
.	O

Worsening	O
of	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
by	O
motor	O
and	O
mental	O
tasks	O
.	O

Ten	O
patients	O
who	O
had	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
with	O
disabling	O
dyskinesia	B-Disease
were	O
included	O
in	O
this	O
study	O
to	O
evaluate	O
the	O
role	O
of	O
mental	O
(	O
mental	O
calculation	O
)	O
and	O
motor	O
(	O
flexion/extension	O
of	O
right	O
fingers	O
,	O
flexion/extension	O
of	O
left	O
fingers	O
,	O
flexion/extension	O
of	O
the	O
neck	O
,	O
speaking	O
aloud	O
)	O
tasks	O
on	O
the	O
worsening	O
of	O
peak-dose	O
dyskinesia	B-Disease
following	O
administration	O
of	O
an	O
effective	O
single	O
dose	O
of	O
apomorphine	B-Chemical
.	O

Compared	O
with	O
the	O
score	O
at	O
rest	O
(	O
1.3+/-0.3	O
)	O
,	O
a	O
significant	O
aggravation	O
of	O
the	O
dyskinesia	B-Disease
score	O
was	O
observed	O
during	O
speaking	O
aloud	O
(	O
5.2+/-1.1	O
,	O
p	O
<	O
0.05	O
)	O
,	O
movements	O
of	O
right	O
(	O
4.5+/-1.0	O
,	O
p	O
<	O
0.05	O
)	O
and	O
left	O
(	O
3.7+/-0.8	O
,	O
p	O
<	O
0.05	O
)	O
fingers	O
,	O
movements	O
of	O
the	O
neck	O
(	O
5.1+/-1.0	O
,	O
p	O
<	O
0.05	O
)	O
,	O
and	O
mental	O
calculation	O
(	O
3.1+/-1.0	O
,	O
p	O
<	O
0.05	O
)	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
tasks	O
such	O
as	O
``	O
speaking	O
aloud	O
''	O
could	O
be	O
used	O
for	O
objective	O
assessment	O
of	O
dyskinesia	B-Disease
severity	O
.	O

Structural	B-Disease
and	I-Disease
functional	I-Disease
impairment	I-Disease
of	I-Disease
mitochondria	I-Disease
in	O
adriamycin-induced	B-Chemical
cardiomyopathy	B-Disease
in	O
mice	O
:	O
suppression	O
of	O
cytochrome	O
c	O
oxidase	O
II	O
gene	O
expression	O
.	O

The	O
use	O
of	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
in	O
cancer	B-Disease
chemotherapy	O
has	O
been	O
limited	O
due	O
to	O
its	O
cumulative	O
cardiovascular	B-Disease
toxicity	I-Disease
.	O

Earlier	O
observations	O
that	O
ADR	B-Chemical
interacts	O
with	O
mitochondrial	O
cytochrome	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
suppresses	O
its	O
enzyme	O
activity	O
led	O
us	O
to	O
investigate	O
ADR	B-Chemical
's	O
action	O
on	O
the	O
cardiovascular	O
functions	O
and	O
heart	O
mitochondrial	O
morphology	O
in	O
Balb-c	O
mice	O
i.p	O
.	O

treated	O
with	O
ADR	B-Chemical
for	O
several	O
weeks	O
.	O

At	O
various	O
times	O
during	O
treatment	O
,	O
the	O
animals	O
were	O
assessed	O
for	O
cardiovascular	O
functions	O
by	O
electrocardiography	O
and	O
for	O
heart	O
tissue	O
damage	O
by	O
electron	O
microscopy	O
.	O

In	O
parallel	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
samples	O
of	O
dissected	O
heart	O
and	O
analyzed	O
by	O
Northern	O
blot	O
hybridization	O
to	O
determine	O
the	O
steady-state	O
level	O
of	O
three	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
COXII	O
,	O
COXIII	O
,	O
and	O
COXIV	O
genes	O
.	O

Similarly	O
,	O
samples	O
obtained	O
from	O
the	O
liver	O
of	O
the	O
same	O
animals	O
were	O
analyzed	O
for	O
comparative	O
studies	O
.	O

Our	O
results	O
indicated	O
that	O
1	O
)	O
treatment	O
of	O
mice	O
with	O
ADR	B-Chemical
caused	O
cardiovascular	B-Disease
arrhythmias	I-Disease
characterized	O
by	O
bradycardia	B-Disease
,	O
extension	O
of	O
ventricular	O
depolarization	O
time	O
(	O
tQRS	O
)	O
,	O
and	O
failure	O
of	O
QRS	O
at	O
high	O
concentrations	O
(	O
10-14	O
mg/kg	O
body	O
weight	O
cumulative	O
dose	O
)	O
;	O
2	O
)	O
the	O
heart	O
mitochondria	O
underwent	O
swelling	B-Disease
,	O
fusion	O
,	O
dissolution	O
,	O
and/or	O
disruption	O
of	O
mitochondrial	O
cristae	O
after	O
several	O
weeks	O
of	O
treatment	O
.	O

Such	O
abnormalities	O
were	O
not	O
observed	O
in	O
the	O
mitochondria	O
of	O
liver	O
tissue	O
;	O
and	O
3	O
)	O
among	O
the	O
three	O
genes	O
of	O
COX	O
enzyme	O
examined	O
,	O
only	O
COXII	O
gene	O
expression	O
was	O
suppressed	O
by	O
ADR	B-Chemical
treatment	O
,	O
mainly	O
after	O
8	O
weeks	O
in	O
both	O
heart	O
and	O
liver	O
.	O

Knowing	O
that	O
heart	O
mitochondria	O
represent	O
almost	O
40	O
%	O
of	O
heart	O
muscle	O
by	O
weight	O
,	O
we	O
conclude	O
that	O
the	O
deteriorating	O
effects	O
of	O
ADR	B-Chemical
on	O
cardiovascular	O
function	O
involve	O
mitochondrial	B-Disease
structural	I-Disease
and	I-Disease
functional	I-Disease
impairment	I-Disease
.	O

Enhanced	O
bradycardia	B-Disease
induced	O
by	O
beta-adrenoceptor	O
antagonists	O
in	O
rats	O
pretreated	O
with	O
isoniazid	B-Chemical
.	O

High	O
doses	O
of	O
isoniazid	B-Chemical
increase	O
hypotension	B-Disease
induced	O
by	O
vasodilators	O
and	O
change	O
the	O
accompanying	O
reflex	O
tachycardia	B-Disease
to	O
bradycardia	B-Disease
,	O
an	O
interaction	O
attributed	O
to	O
decreased	O
synthesis	O
of	O
brain	O
gamma-aminobutyric	B-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
possible	O
enhancement	O
by	O
isoniazid	B-Chemical
of	O
bradycardia	B-Disease
induced	O
by	O
beta-adrenoceptor	O
antagonists	O
was	O
determined	O
in	O
rats	O
anaesthetised	O
with	O
chloralose-urethane	B-Chemical
.	O

Isoniazid	B-Drug
significantly	O
increased	O
bradycardia	O
after	O
propranolol	B-Drug
,	O
pindolol	O
,	O
labetalol	B-Drug
and	O
atenolol	B-Drug
,	O
as	O
well	O
as	O
after	O
clonidine	B-Drug
,	O
but	O
not	O
after	O
hexamethonium	O
or	O
carbachol	B-Drug
.	O

Enhancement	O
was	O
not	O
observed	O
in	O
rats	O
pretreated	O
with	O
methylatropine	O
or	O
previously	O
vagotomised	O
.	O

These	O
results	O
are	O
compatible	O
with	O
interference	O
by	O
isoniazid	B-Drug
with	O
GABAergic	O
inhibition	O
of	O
cardiac	O
parasympathetic	O
tone	O
.	O

Such	O
interference	O
could	O
be	O
exerted	O
centrally	O
,	O
possibly	O
at	O
the	O
nucleus	O
ambiguus	O
,	O
or	O
peripherally	O
at	O
the	O
sinus	O
node	O
.	O

Epileptogenic	O
activity	O
of	O
folic	B-Chemical
acid	I-Chemical
after	O
drug	B-Drug
induces	O
SLE	B-Disease
(	O
folic	B-Chemical
acid	I-Chemical
and	O
epilepsy	B-Disease
)	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
effect	O
of	O
folic	B-Chemical
acid-containing	O
multivitamin	O
supplementation	O
in	O
epileptic	O
women	O
before	O
and	O
during	O
pregnancy	O
in	O
order	O
to	O
determine	O
the	O
rate	O
of	O
structural	O
birth	O
defects	O
and	O
epilepsy-related	O
side	O
effects	O
.	O

STUDY	O
DESIGN	O
:	O
First	O
a	O
randomised	O
trial	O
,	O
later	O
periconception	O
care	O
including	O
in	O
total	O
12225	O
females	O
.	O

RESULTS	O
:	O
Of	O
60	O
epileptic	O
women	O
with	O
periconceptional	O
folic	B-Chemical
acid	O
(	O
0.8	O
mg	O
)	O
-containing	O
multivitamin	O
supplementation	O
,	O
no	O
one	O
developed	O
epilepsy-related	O
side	O
effects	O
during	O
the	O
periconception	O
period	O
.	O

One	O
epileptic	B-Disease
woman	O
delivered	O
a	O
newborn	O
with	O
cleft	O
lip	O
and	O
palate	O
.	O

Another	O
patient	O
exhibited	O
with	O
a	O
cluster	O
of	O
seizures	O
after	O
the	O
periconception	O
period	O
using	O
another	O
multivitamin	O
.	O

This	O
22-year-old	O
epileptic	O
woman	O
was	O
treated	O
continuously	O
by	O
carbamazepine	B-Drug
and	O
a	O
folic	O
acid	O
(	O
1	O
mg	O
)	O
-containing	O
multivitamin	O
from	O
the	O
20th	O
week	O
of	O
gestation	O
.	O

She	O
developed	O
status	O
epilepticus	O
and	O
later	O
symptoms	O
of	O
systemic	O
lupus	O
erythematodes	O
.	O

Her	O
pregnancy	O
ended	O
with	O
stillbirth	B-Disease
.	O

CONCLUSIONS	O
:	O
The	O
epileptic	O
pregnant	O
patient	O
's	O
autoimmune	O
disease	O
(	O
probably	O
drug-induced	O
lupus	O
)	O
could	O
damage	O
the	O
blood-brain	O
barrier	O
,	O
therefore	O
the	O
therapeutic	O
dose	O
(	O
>	O
or	O
=1	O
mg	O
)	O
of	O
folic	O
acid	O
triggered	O
a	O
cluster	O
of	O
seizures	O
.	O

Physiological	O
dose	O
(	O
<	O
1	O
mg	O
)	O
of	O
folic	O
acid	O
both	O
in	O
healthy	O
and	O
60	O
epileptic	O
women	O
,	O
all	O
without	O
any	O
autoimmune	O
disease	O
,	O
did	O
not	O
increase	O
the	O
risk	O
for	O
epileptic	O
seizures	O
.	O

Effects	O
of	O
cisapride	B-Chemical
on	O
symptoms	O
and	O
postcibal	O
small-bowel	O
motor	O
function	O
in	O
patients	O
with	O
irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
is	O
a	O
common	O
cause	O
of	O
abdominal	B-Disease
pain	I-Disease
and	O
discomfort	O
and	O
may	O
be	O
related	O
to	O
disordered	B-Disease
gastrointestinal	I-Disease
motility	I-Disease
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
effects	O
of	O
long-term	O
treatment	O
with	O
a	O
prokinetic	O
agent	O
,	O
cisapride	B-Chemical
,	O
on	O
postprandial	O
jejunal	O
motility	O
and	O
symptoms	O
in	O
the	O
irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
(	O
IBS	B-Disease
)	O
.	O

METHODS	O
:	O
Thirty-eight	O
patients	O
with	O
IBS	B-Disease
(	O
constipation-predominant	B-Disease
,	O
n	O
=	O
17	O
;	O
diarrhoea-predominant	B-Disease
,	O
n	O
=	O
21	O
)	O
underwent	O
24-h	O
ambulatory	O
jejunal	O
manometry	O
before	O
and	O
after	O
12	O
week	O
's	O
treatment	O
[	O
cisapride	B-Chemical
,	O
5	O
mg	O
three	O
times	O
daily	O
(	O
n	O
=	O
19	O
)	O
or	O
placebo	O
(	O
n	O
=	O
19	O
)	O
]	O
.	O

RESULTS	O
:	O
In	O
diarrhoea-predominant	B-Disease
patients	O
significant	O
differences	O
in	O
contraction	O
characteristics	O
were	O
observed	O
between	O
the	O
cisapride	B-Chemical
and	O
placebo	O
groups	O
.	O

In	O
cisapride-treated	B-Chemical
diarrhoea-predominant	B-Disease
patients	O
the	O
mean	O
contraction	O
amplitude	O
was	O
higher	O
(	O
29.3	O
+/-	O
3.2	O
versus	O
24.9	O
+/-	O
2.6	O
mm	O
Hg	O
,	O
cisapride	B-Chemical
versus	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
;	O
pretreatment	O
,	O
25.7	O
+/-	O
6.0	O
mm	O
Hg	O
)	O
,	O
the	O
mean	O
contraction	O
duration	O
longer	O
(	O
3.4	O
+/-	O
0.2	O
versus	O
3.0	O
+/-	O
0.2	O
sec	O
,	O
cisapride	B-Chemical
versus	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
;	O
pretreatment	O
,	O
3.1	O
+/-	O
0.5	O
sec	O
)	O
,	O
and	O
the	O
mean	O
contraction	O
frequency	O
lower	O
(	O
2.0	O
+/-	O
0.2	O
versus	O
2.5	O
+/-	O
0.4	O
cont./min	O
,	O
cisapride	B-Chemical
versus	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
;	O
pretreatment	O
,	O
2.5	O
+/-	O
1.1	O
cont./min	O
]	O
than	O
patients	O
treated	O
with	O
placebo	O
.	O

No	O
significant	O
differences	O
in	O
jejunal	O
motility	O
were	O
found	O
in	O
the	O
constipation-predominant	B-Disease
IBS	B-Disease
group	O
.	O

Symptoms	O
were	O
assessed	O
by	O
using	O
a	O
visual	O
analogue	O
scale	O
before	O
and	O
after	O
treatment	O
.	O

Symptom	O
scores	O
relating	O
to	O
the	O
severity	O
of	O
constipation	B-Disease
were	O
lower	O
in	O
cisapride-treated	B-Chemical
constipation-predominant	B-Disease
IBS	B-Disease
patients	O
[	O
score	O
,	O
54	O
+/-	O
5	O
versus	O
67	O
+/-	O
14	O
mm	O
,	O
cisapride	B-Chemical
versus	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
;	O
pretreatment	O
,	O
62	O
+/-	O
19	O
mm	O
]	O
.	O

Diarrhoea-predominant	B-Disease
IBS	B-Disease
patients	O
had	O
a	O
higher	O
pain	B-Disease
score	O
after	O
cisapride	B-Chemical
therapy	O
[	O
score	O
,	O
55	O
+/-	O
15	O
versus	O
34	O
+/-	O
12	O
mm	O
,	O
cisapride	B-Chemical
versus	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
;	O
pretreatment	O
,	O
67	O
+/-	O
19	O
mm	O
]	O
.	O

CONCLUSION	O
:	O
Cisapride	B-Chemical
affects	O
jejunal	O
contraction	O
characteristics	O
and	O
some	O
symptoms	O
in	O
IBS	B-Disease
.	O

Clarithromycin-induced	B-Chemical
ventricular	B-Disease
tachycardia	I-Disease
.	O

Clarithromycin	B-Chemical
is	O
a	O
relatively	O
new	O
macrolide	B-Chemical
antibiotic	O
that	O
offers	O
twice-daily	O
dosing	O
.	O

It	O
differs	O
from	O
erythromycin	B-Chemical
only	O
in	O
the	O
methylation	O
of	O
the	O
hydroxyl	O
group	O
at	O
position	O
6	O
.	O

Although	O
the	O
side-effect	O
profile	O
of	O
erythromycin	B-Chemical
is	O
established	O
,	O
including	O
gastroenteritis	B-Disease
and	O
interactions	O
with	O
other	O
drugs	B-Drug
subject	O
to	O
hepatic	O
mixed-function	O
oxidase	O
metabolism	O
,	O
experience	O
with	O
the	O
newer	O
macrolides	B-Chemical
is	O
still	O
being	O
recorded	O
.	O

Cardiotoxicity	B-Disease
has	O
been	O
demonstrated	O
after	O
both	O
intravenous	O
and	O
oral	O
administration	O
of	O
erythromycin	B-Chemical
but	O
has	O
never	O
been	O
reported	O
with	O
the	O
newer	O
macrolides	B-Chemical
.	O

We	O
report	O
a	O
case	O
of	O
ventricular	B-Disease
dysrhythmias	I-Disease
that	O
occurred	O
after	O
six	O
therapeutic	O
doses	O
of	O
clarithromycin	B-Chemical
.	O

The	O
dysrhythmias	B-Disease
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	B-Drug
.	O

Persistent	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
following	O
lithium	B-Chemical
therapy	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
severe	O
hypernatraemic	O
dehydration	B-Disease
following	O
a	O
head	B-Disease
injury	I-Disease
.	O

Ten	O
years	O
previously	O
he	O
had	O
been	O
diagnosed	O
to	O
have	O
lithium-induced	B-Chemical
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
and	O
lithium	B-Chemical
therapy	O
had	O
been	O
discontinued	O
.	O

He	O
remained	O
thirsty	O
and	O
polyuric	B-Disease
despite	O
cessation	O
of	O
lithium	B-Chemical
and	O
investigations	O
on	O
admission	O
showed	O
him	O
to	O
have	O
normal	O
osmoregulated	O
thirst	O
and	O
vasopressin	B-Chemical
secretion	O
,	O
with	O
clear	O
evidence	O
of	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O

Lithium	B-Chemical
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
is	O
considered	O
to	O
be	O
reversible	O
on	O
cessation	O
of	O
therapy	O
but	O
polyuria	B-Disease
persisted	O
in	O
this	O
patient	O
for	O
ten	O
years	O
after	O
lithium	B-Chemical
was	O
stopped	O
.	O

We	O
discuss	O
the	O
possible	O
renal	O
mechanisms	O
and	O
the	O
implications	O
for	O
management	O
of	O
patients	O
with	O
lithium-induced	B-Chemical
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O

Late	O
cardiotoxicity	B-Disease
after	O
treatment	O
for	O
a	O
malignant	O
bone	B-Disease
tumor	I-Disease
.	O

Cardiac	O
function	O
was	O
assessed	O
in	O
long-term	O
survivors	O
of	O
malignant	O
bone	B-Disease
tumors	I-Disease
who	O
were	O
treated	O
according	O
to	O
Rosen	B-Chemical
's	I-Chemical
T5	I-Chemical
or	I-Chemical
T10	I-Chemical
protocol	I-Chemical
,	O
both	O
including	O
doxorubicin	B-Chemical
.	O

Thirty-one	O
patients	O
,	O
age	O
10-45	O
years	O
(	O
median	O
age	O
17.8	O
years	O
)	O
were	O
evaluated	O
2.3-14.1	O
years	O
(	O
median	O
8.9	O
years	O
)	O
following	O
completion	O
of	O
treatment	O
.	O

Cumulative	O
doses	O
of	O
doxorubicin	B-Chemical
were	O
225-550	O
mg/m2	O
(	O
median	O
dose	O
360	O
)	O
.	O

The	O
evaluation	O
consisted	O
of	O
a	O
history	O
,	O
physical	O
examination	O
,	O
electrocardiogram	O
(	O
ECG	O
)	O
,	O
signal	O
averaged	O
ECG	O
,	O
24-hour	O
ambulatory	O
ECG	O
,	O
echocardiography	O
and	O
radionuclide	O
angiography	O
.	O

Eighteen	O
of	O
31	O
(	O
58	O
%	O
)	O
patients	O
showed	O
cardiac	B-Disease
toxicity	I-Disease
,	O
defined	O
as	O
having	O
one	O
or	O
more	O
of	O
the	O
following	O
abnormalities	O
:	O
late	O
potentials	O
,	O
complex	O
ventricular	B-Disease
arrhythmias	I-Disease
,	O
left	O
ventricular	B-Disease
dilation	I-Disease
,	O
decreased	O
shortening	O
fraction	O
,	O
or	O
decreased	O
ejection	O
fraction	O
.	O

The	O
incidence	O
of	O
cardiac	B-Disease
abnormalities	I-Disease
increased	O
with	O
length	O
of	O
follow-up	O
(	O
P	O
<	O
or	O
=	O
.05	O
)	O
.	O

No	O
correlation	O
could	O
be	O
demonstrated	O
between	O
cumulative	O
dose	O
of	O
doxorubicin	B-Chemical
and	O
cardiac	O
status	O
,	O
except	O
for	O
heart	O
rate	O
variability	O
.	O

When	O
adjusted	O
to	O
body	O
surface	O
area	O
,	O
the	O
left	O
ventricular	O
posterior	O
wall	O
thickness	O
(	O
LVPW	O
index	O
)	O
was	O
decreased	O
in	O
all	O
patients	O
.	O

The	O
incidence	O
of	O
doxorubicin-induced	B-Chemical
cardiotoxicity	B-Disease
is	O
high	O
and	O
increases	O
with	O
follow-up	O
,	O
irrespective	O
of	O
cumulative	O
dose	O
.	O

Life-long	O
cardiac	O
follow-up	O
in	O
these	O
patients	O
is	O
warranted	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
heart	O
rate	O
variability	O
and	O
LVPW	O
index	O
could	O
be	O
sensitive	O
indicators	O
for	O
cardiotoxicity	B-Disease
.	O

Venous	B-Disease
complications	I-Disease
of	O
midazolam	B-Chemical
versus	O
diazepam	B-Chemical
.	O

Although	O
some	O
studies	O
have	O
suggested	O
fewer	O
venous	B-Disease
complications	I-Disease
are	O
associated	O
with	O
midazolam	B-Chemical
than	O
with	O
diazepam	B-Chemical
for	O
endoscopic	O
procedures	O
,	O
this	O
variable	O
has	O
not	O
been	O
well	O
documented	O
.	O

We	O
prospectively	O
evaluated	O
the	O
incidence	O
of	O
venous	B-Disease
complications	I-Disease
after	O
intravenous	O
injection	O
of	O
diazepam	B-Chemical
or	O
midazolam	B-Chemical
in	O
122	O
consecutive	O
patients	O
undergoing	O
colonoscopy	O
and	O
esophagogastroduodenoscopy	O
.	O

Overall	O
,	O
venous	B-Disease
complications	I-Disease
were	O
more	O
frequent	O
with	O
diazepam	B-Chemical
(	O
22	O
of	O
62	O
patients	O
)	O
than	O
with	O
midazolam	B-Chemical
(	O
4	O
of	O
60	O
patients	O
)	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
palpable	O
venous	O
cord	O
was	O
present	O
in	O
23	O
%	O
(	O
14	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	B-Chemical
group	O
,	O
compared	O
with	O
2	O
%	O
(	O
1	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	B-Chemical
group	O
(	O
p	O
<	O
0.002	O
)	O
.	O

Pain	B-Disease
at	O
the	O
injection	O
site	O
occurred	O
in	O
35	O
%	O
(	O
22	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	B-Chemical
group	O
compared	O
with	O
7	O
%	O
(	O
4	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	B-Chemical
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Swelling	B-Disease
and	O
warmth	O
at	O
the	O
injection	O
site	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Smoking	O
,	O
nonsteroidal	O
anti-inflammatory	O
drug	B-Drug
use	O
,	O
intravenous	O
catheter	O
site	O
,	O
dwell	O
time	O
of	O
the	O
needle	O
,	O
alcohol	B-Chemical
use	O
,	O
and	O
pain	B-Disease
during	O
the	O
injection	O
had	O
no	O
effect	O
on	O
the	O
incidence	O
of	O
venous	B-Disease
complications	I-Disease
.	O

Tetany	B-Disease
and	O
rhabdomyolysis	B-Disease
due	O
to	O
surreptitious	O
furosemide	B-Chemical
--	O
importance	O
of	O
magnesium	B-Chemical
supplementation	O
.	O

Diuretics	B-Drug
may	O
induce	O
hypokalemia	B-Disease
,	O
hypocalcemia	B-Disease
and	O
hypomagnesemia	B-Disease
.	O

While	O
severe	O
hypokalemia	B-Disease
may	O
cause	O
muscle	B-Disease
weakness	I-Disease
,	O
severe	O
hypomagnesemia	B-Disease
is	O
associated	O
with	O
muscle	B-Disease
spasms	I-Disease
and	O
tetany	B-Disease
which	O
can	O
not	O
be	O
corrected	O
by	O
potassium	B-Chemical
and	O
calcium	B-Chemical
supplementation	O
alone	O
(	O
1,2	O
)	O
.	O

Surreptitious	O
diuretic	B-Drug
ingestion	O
has	O
been	O
described	O
,	O
mainly	O
in	O
women	O
who	O
are	O
concerned	O
that	O
they	O
are	O
obese	B-Disease
or	O
edematous	B-Disease
.	O

Symptomatic	O
hypokalemia	B-Disease
has	O
been	O
reported	O
in	O
such	O
patients	O
(	O
3-7	O
)	O
and	O
in	O
one	O
case	O
hypocalcemia	B-Disease
was	O
observed	O
(	O
8	O
)	O
,	O
but	O
the	O
effects	O
of	O
magnesium	B-Chemical
depletion	O
were	O
not	O
noted	O
in	O
these	O
patients	O
.	O

Loss	O
of	O
glutamate	B-Chemical
decarboxylase	O
mRNA-containing	O
neurons	O
in	O
the	O
rat	O
dentate	O
gyrus	O
following	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
.	O

In	O
situ	O
hybridization	O
methods	O
were	O
used	O
to	O
determine	O
if	O
glutamic	B-Chemical
acid	I-Chemical
decarboxylase	O
(	O
GAD	O
)	O
mRNA-containing	O
neurons	O
within	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
are	O
vulnerable	O
to	O
seizure-induced	B-Disease
damage	O
in	O
a	O
model	O
of	O
chronic	O
seizures	B-Disease
.	O

Sprague-Dawley	O
rats	O
were	O
injected	O
intraperitoneally	O
with	O
pilocarpine	B-Chemical
,	O
and	O
the	O
hippocampal	O
formation	O
was	O
studied	O
histologically	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
8	O
week	O
intervals	O
after	O
pilocarpine-induced	B-Chemical
seizures	B-Disease
.	O

In	O
situ	O
hybridization	O
histochemistry	O
,	O
using	O
a	O
digoxigenin-labeled	B-Chemical
GAD	O
cRNA	O
probe	O
,	O
demonstrated	O
a	O
substantial	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA-containing	O
neurons	O
in	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
in	O
the	O
pilocarpine-treated	B-Chemical
rats	O
as	O
compared	O
to	O
controls	O
at	O
all	O
time	O
intervals	O
.	O

Additional	O
neuronanatomical	O
studies	O
,	O
including	O
cresyl	B-Chemical
violet	I-Chemical
staining	O
,	O
neuronal	B-Disease
degeneration	I-Disease
methods	O
,	O
and	O
histochemical	O
localization	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
suggested	O
that	O
the	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA-containing	O
neurons	O
was	O
related	O
to	O
neuronal	B-Disease
loss	I-Disease
rather	O
than	O
to	O
a	O
decrease	O
in	O
GAD	O
mRNA	O
levels	O
.	O

The	O
loss	O
of	O
GAD	O
mRNA-containing	O
neurons	O
in	O
the	O
hilus	O
contrasted	O
with	O
the	O
relative	O
preservation	O
of	O
labeled	O
putative	O
basket	O
cells	O
along	O
the	O
inner	O
margin	O
of	O
the	O
granule	O
cell	O
layer	O
.	O

Quantitative	O
analyses	O
of	O
labeled	O
neurons	O
in	O
three	O
regions	O
of	O
the	O
dentate	O
gyrus	O
in	O
the	O
1	O
and	O
2	O
week	O
groups	O
showed	O
statistically	O
significant	O
decreases	O
in	O
the	O
mean	O
number	O
of	O
GAD	O
mRNA-containing	O
neurons	O
in	O
the	O
hilus	O
of	O
both	O
groups	O
of	O
experimental	O
animals	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
molecular	O
layer	O
or	O
the	O
granule	O
cell	O
layer	O
,	O
which	O
included	O
labeled	O
neurons	O
along	O
the	O
lower	O
margin	O
of	O
the	O
granule	O
cell	O
layer	O
.	O

The	O
results	O
indicate	O
that	O
,	O
in	O
this	O
model	O
,	O
a	O
subpopulation	O
of	O
GAD	O
mRNA-containing	O
neurons	O
within	O
the	O
dentate	O
gyrus	O
is	O
selectively	O
vulnerable	O
to	O
seizure-induced	B-Disease
damage	O
.	O

Such	O
differential	O
vulnerability	O
appears	O
to	O
be	O
another	O
indication	O
of	O
the	O
heterogeneity	O
of	O
GABA	B-Chemical
neurons	O
.	O

Protective	O
effect	O
of	O
misoprostol	B-Chemical
on	O
indomethacin	B-Chemical
induced	O
renal	B-Disease
dysfunction	I-Disease
in	O
elderly	O
patients	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
possible	O
protective	O
effects	O
of	O
misoprostol	B-Chemical
on	O
renal	O
function	O
in	O
hospitalized	O
elderly	O
patients	O
treated	O
with	O
indomethacin	B-Chemical
.	O

METHODS	O
:	O
Forty-five	O
hospitalized	O
elderly	O
patients	O
(	O
>	O
65	O
years	O
old	O
)	O
who	O
required	O
therapy	O
with	O
nonsteroidal	O
antiinflammatory	O
drugs	B-Drug
(	O
NSAID	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
indomethacin	B-Chemical
,	O
150	O
mg/day	O
(	O
Group	O
A	O
)	O
,	O
or	O
indomethacin	B-Chemical
150	O
mg/day	O
plus	O
misoprostol	B-Chemical
at	O
0.6	O
mg/day	O
(	O
Group	O
B	O
)	O
.	O

Laboratory	O
variables	O
of	O
renal	O
function	O
[	O
serum	O
creatinine	B-Chemical
,	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
and	O
electrolytes	O
]	O
were	O
evaluated	O
before	O
initiation	O
of	O
therapy	O
and	O
every	O
2	O
days	O
,	O
until	O
termination	O
of	O
the	O
study	O
(	O
a	O
period	O
of	O
at	O
least	O
6	O
days	O
)	O
.	O

Response	O
to	O
treatment	O
was	O
estimated	O
by	O
the	O
visual	O
analog	O
scale	O
for	O
severity	O
of	O
pain	B-Disease
.	O

RESULTS	O
:	O
Forty-two	O
patients	O
completed	O
the	O
study	O
,	O
22	O
in	O
Group	O
A	O
and	O
20	O
in	O
Group	O
B.	O
BUN	B-Chemical
and	O
creatinine	B-Chemical
increased	O
by	O
>	O
50	O
%	O
of	O
baseline	O
levels	O
in	O
54	O
and	O
45	O
%	O
of	O
Group	O
A	O
patients	O
,	O
respectively	O
,	O
compared	O
to	O
only	O
20	O
and	O
10	O
%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Potassium	B-Chemical
(	O
K	B-Chemical
)	O
increment	O
of	O
0.6	O
mEq/l	O
or	O
more	O
was	O
observed	O
in	O
50	O
%	O
of	O
Group	O
A	O
,	O
but	O
in	O
only	O
15	O
%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
mean	O
increments	O
in	O
BUN	B-Chemical
,	O
creatinine	B-Chemical
,	O
and	O
K	B-Chemical
were	O
reduced	O
by	O
63	O
,	O
80	O
,	O
and	O
42	O
%	O
,	O
respectively	O
,	O
in	O
Group	O
B	O
patients	O
compared	O
to	O
Group	O
A	O
.	O

Response	O
to	O
treatment	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSION	O
:	O
Hospitalized	O
elderly	O
patients	O
are	O
at	O
risk	O
for	O
developing	O
indomethacin	B-Chemical
related	O
renal	B-Disease
dysfunction	I-Disease
.	O

Addition	O
of	O
misoprostol	B-Chemical
can	O
minimize	O
this	O
renal	B-Disease
impairment	I-Disease
without	O
affecting	O
pain	B-Disease
control	O
.	O

Nephrotoxic	B-Disease
effects	O
of	O
aminoglycoside	B-Chemical
treatment	O
on	O
renal	O
protein	O
reabsorption	O
and	O
accumulation	O
.	O

To	O
quantify	O
the	O
effects	O
of	O
gentamicin	B-Chemical
,	O
kanamycin	B-Chemical
and	O
netilmicin	B-Chemical
on	O
renal	O
protein	O
reabsorption	O
and	O
accumulation	O
,	O
these	O
drugs	B-Drug
were	O
administered	O
to	O
rats	O
intraperitoneally	O
(	O
30	O
mg/kg/day	O
)	O
for	O
7	O
,	O
14	O
or	O
21	O
days	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
the	O
glomerular	O
endothelia	O
,	O
urinary	O
measurements	O
of	O
sodium	B-Chemical
,	O
potassium	B-Chemical
,	O
endogenous	O
lysozyme	O
,	O
N-acetyl-beta-D-glucosaminidase	O
(	O
NAG	O
)	O
as	O
well	O
as	O
clearance	O
and	O
accumulation	O
experiments	O
after	O
i.v	O
.	O

administration	O
of	O
egg-white	O
lysozyme	O
and	O
measurements	O
of	O
inulin	O
clearance	O
(	O
GFR	O
)	O
were	O
done	O
in	O
each	O
treatment	O
group	O
.	O

Gentamicin	B-Chemical
administration	O
decreased	O
diameter	O
,	O
density	O
and	O
shape	O
of	O
endothelial	O
fenestrae	O
.	O

Kanamycin	B-Chemical
and	O
netilmicin	B-Chemical
appeared	O
to	O
have	O
no	O
effect	O
at	O
the	O
dose	O
used	O
.	O

All	O
three	O
aminoglycosides	B-Chemical
decreased	O
GFR	O
and	O
increased	O
urinary	O
excretion	O
of	O
sodium	B-Chemical
and	O
potassium	B-Chemical
.	O

While	O
gentamicin	B-Chemical
and	O
kanamycin	B-Chemical
decreased	O
the	O
percentage	O
reabsorption	O
and	O
accumulation	O
of	O
lysozyme	O
after	O
i.v	O
.	O

administration	O
of	O
egg-white	O
lysozyme	O
netilmicin	B-Chemical
had	O
no	O
effect	O
.	O

Daily	O
excretion	O
of	O
total	O
protein	O
,	O
endogenous	O
lysozyme	O
and	O
NAG	O
increased	O
only	O
after	O
treatment	O
with	O
kanamycin	B-Chemical
and	O
gentamicin	B-Chemical
.	O

Thus	O
,	O
aminoglycosides	B-Chemical
may	O
act	O
as	O
nephrotoxicants	O
at	O
glomerular	O
and/or	O
tubular	O
level	O
inducing	O
impairment	B-Disease
of	I-Disease
renal	I-Disease
reabsorption	I-Disease
and	O
accumulation	O
of	O
proteins	O
.	O

Pharmacology	O
of	O
GYKI-41	B-Chemical
099	I-Chemical
(	O
chlorpropanol	B-Chemical
,	O
Tobanum	B-Chemical
)	O
a	O
new	O
potent	O
beta-adrenergic	O
antagonist	O
.	O

The	O
compound	O
GYKI-41	B-Chemical
099	I-Chemical
,	O
as	O
a	O
beta-adrenergic	O
antagonist	O
,	O
is	O
3-8	O
times	O
more	O
potent	O
than	O
propranolol	B-Chemical
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Its	O
antiarrhythmic	B-Drug
effectiveness	O
surpasses	O
that	O
of	O
propranolol	B-Chemical
and	O
pindolol	B-Chemical
inhibiting	O
the	O
ouabain	B-Chemical
arrhythmia	B-Disease
in	O
dogs	O
and	O
cats	O
.	O

GYKI-41	B-Chemical
900	I-Chemical
has	O
a	O
negligible	O
cardiodepressant	O
activity	O
;	O
it	O
is	O
not	O
cardioselective	O
.	O

The	O
compound	O
shows	O
a	O
rapid	O
and	O
long	O
lasting	O
effect	O
.	O

There	O
was	O
a	O
prolonged	O
elimination	O
of	O
the	O
radioactivity	O
after	O
the	O
injection	O
of	O
14C-41	B-Chemical
099	I-Chemical
to	O
rats	O
and	O
dogs	O
.	O

The	O
half	O
life	O
of	O
the	O
unlabeled	O
substance	O
in	O
humans	O
was	O
more	O
than	O
10	O
hours	O
.	O

Chorea	B-Disease
associated	O
with	O
oral	B-Chemical
contraception	I-Chemical
.	O

Three	O
patients	O
developed	O
chorea	B-Disease
while	O
receiving	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

Two	O
were	O
young	O
patients	O
whose	O
chorea	B-Disease
developed	O
long	O
after	O
treatment	O
had	O
been	O
started	O
and	O
disappeared	O
soon	O
after	O
it	O
had	O
been	O
discontinued	O
.	O

The	O
third	O
patient	O
had	O
acute	O
amphetamine-induced	B-Chemical
chorea	B-Disease
after	O
prolonged	O
oral	B-Chemical
contraception	I-Chemical
.	O

Prolonged	O
administration	O
of	O
female	O
sex	O
hormones	O
is	O
a	O
possible	O
cause	O
of	O
chorea	B-Disease
in	O
women	O
who	O
have	O
not	O
previously	O
had	O
chorea	B-Disease
or	O
rheumatic	B-Disease
fever	I-Disease
.	O

Reversal	O
of	O
ammonia	B-Chemical
coma	B-Disease
in	O
rats	O
by	O
L-dopa	B-Chemical
:	O
a	O
peripheral	O
effect	O
.	O

Ammonia	B-Chemical
coma	B-Disease
was	O
produced	O
in	O
rats	O
within	O
10	O
to	O
15	O
minutes	O
of	O
an	O
intraperitonealinjection	O
of	O
1.7	O
mmol	O
NH4CL	B-Chemical
.	O

This	O
coma	B-Disease
was	O
prevented	O
with	O
1.68	O
mmol	O
L-dopa	B-Chemical
given	O
by	O
gastric	O
intubation	O
15	O
minutes	O
before	O
the	O
ammonium	B-Chemical
salt	I-Chemical
injection	O
.	O

The	O
effect	O
of	O
L-dopa	B-Chemical
was	O
correlated	O
with	O
a	O
decrease	O
in	O
blood	O
and	O
brain	O
ammonia	B-Chemical
,	O
an	O
increase	O
in	O
brain	O
dopamine	B-Chemical
,	O
and	O
an	O
increase	O
in	O
renal	O
excretion	O
of	O
ammonia	B-Chemical
and	O
urea	B-Chemical
.	O

Intraventricular	O
infusion	O
of	O
dopamine	B-Chemical
sufficient	O
to	O
raise	O
the	O
brain	O
dopamine	B-Chemical
to	O
the	O
same	O
extent	O
did	O
not	O
prevent	O
the	O
ammonia	B-Chemical
coma	B-Disease
nor	O
affect	O
the	O
blood	O
and	O
brain	O
ammonia	B-Chemical
concentrations	O
.	O

Bilateral	O
nephrectomy	O
eliminated	O
the	O
beneficial	O
effect	O
of	O
L-dopa	B-Chemical
on	O
blood	O
and	O
brain	O
ammonia	B-Chemical
and	O
the	O
ammonia	B-Chemical
coma	B-Disease
was	O
not	O
prevented	O
.	O

Thus	O
,	O
the	O
reduction	O
in	O
blood	O
and	O
brain	O
ammonia	B-Chemical
and	O
the	O
prevention	O
of	O
ammonia	B-Chemical
coma	B-Disease
after	O
L-dopa	B-Chemical
,	O
can	O
be	O
accounted	O
for	O
by	O
the	O
peripheral	O
effect	O
of	O
dopamine	B-Chemical
on	O
renal	O
function	O
rather	O
than	O
its	O
central	O
action	O
.	O

These	O
results	O
provide	O
a	O
reasonable	O
explanation	O
for	O
the	O
beneficial	O
effects	O
observed	O
in	O
some	O
encephalopathic	B-Disease
patients	O
receiving	O
L-dopa	B-Chemical
.	O

Heparin-induced	B-Chemical
thrombocytopenia	B-Disease
after	O
liver	O
transplantation	O
.	O

BACKGROUND	O
:	O
Unfractionated	B-Chemical
heparin	I-Chemical
sodium	I-Chemical
(	O
UFH	B-Chemical
)	O
or	O
low-molecular	B-Chemical
weight	I-Chemical
heparin	I-Chemical
(	O
LMWH	O
)	O
is	O
used	O
in	O
anticoagulant	B-Drug
protocols	O
at	O
several	O
institutions	O
to	O
prevent	O
thrombosis	B-Disease
after	O
liver	O
transplantation	O
.	O

Heparin-induced	B-Chemical
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
is	O
an	O
adverse	O
immune-mediated	O
reaction	O
to	O
heparin	B-Chemical
,	O
resulting	O
in	O
platelet	O
count	O
decreases	O
of	O
more	O
than	O
50	O
%	O
.	O

The	O
frequencies	O
of	O
HIT	B-Disease
after	O
liver	O
transplantation	O
and	O
platelet	O
factor	O
4/heparin-reactive	B-Chemical
antibody	O
(	O
HIT	B-Disease
antibody	O
)	O
positivity	O
in	O
liver	O
transplantation	O
patients	O
,	O
however	O
,	O
are	O
unknown	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
32	O
men	O
and	O
20	O
women	O
underwent	O
living	O
donor	O
liver	O
transplantation	O
.	O

We	O
started	O
LMWH	O
(	O
25	O
IU/kg/h	O
)	O
on	O
postoperative	O
day	O
(	O
POD	O
)	O
1	O
,	O
switching	O
to	O
UFH	B-Chemical
(	O
5000	O
U/d	O
)	O
on	O
POD	O
2	O
or	O
3	O
.	O

The	O
dose	O
of	O
UFH	B-Chemical
was	O
changed	O
according	O
to	O
the	O
activated	O
clotting	O
time	O
level	O
.	O

HIT	B-Disease
antibody	O
levels	O
were	O
measured	O
the	O
day	O
before	O
surgery	O
and	O
on	O
POD	O
7	O
and	O
14	O
.	O

Platelet	O
count	O
was	O
measured	O
daily	O
for	O
3	O
weeks	O
.	O

RESULTS	O
:	O
The	O
average	O
platelet	O
counts	O
preoperatively	O
,	O
and	O
on	O
POD	O
7	O
,	O
14	O
,	O
and	O
21	O
were	O
65	O
,	O
88	O
,	O
149	O
,	O
and	O
169	O
x	O
10	O
(	O
9	O
)	O
/L	O
,	O
respectively	O
.	O

Two	O
patients	O
developed	O
hepatic	O
artery	O
thrombosis	B-Disease
on	O
POD	O
11	O
and	O
19	O
,	O
respectively	O
,	O
although	O
they	O
were	O
HIT	B-Disease
antibody-negative	O
and	O
their	O
platelet	O
counts	O
were	O
stable	O
.	O

In	O
2	O
other	O
patients	O
,	O
the	O
platelet	O
count	O
decreased	O
suddenly	O
from	O
107	O
x	O
10	O
(	O
9	O
)	O
/L	O
on	O
POD	O
4	O
to	O
65	O
x	O
10	O
(	O
9	O
)	O
/L	O
on	O
POD	O
6	O
and	O
from	O
76	O
x	O
10	O
(	O
9	O
)	O
/L	O
on	O
POD	O
7	O
to	O
33	O
x	O
10	O
(	O
9	O
)	O
/L	O
on	O
POD	O
9	O
,	O
respectively	O
.	O

The	O
heparin-induced	B-Chemical
platelet	B-Disease
aggregation	I-Disease
test	O
was	O
negative	O
in	O
these	O
patients	O
.	O

The	O
percentage	O
of	O
HIT	B-Disease
antibody-positive	O
patients	O
was	O
0.5	O
%	O
preoperatively	O
,	O
5.6	O
%	O
on	O
POD	O
7	O
,	O
and	O
5.6	O
%	O
on	O
POD	O
14	O
.	O

None	O
of	O
the	O
subjects/patients	O
developed	O
UFH-related	B-Chemical
HIT	B-Disease
.	O

CONCLUSIONS	O
:	O
In	O
our	O
series	O
,	O
the	O
occurrence	O
of	O
HIT	B-Disease
after	O
liver	O
transplantation	O
was	O
uncommon	O
.	O

PTU-associated	B-Chemical
vasculitis	B-Disease
in	O
a	O
girl	O
with	O
Turner	B-Disease
Syndrome	I-Disease
and	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
.	O

Palpable	O
purpura	B-Disease
is	O
a	O
concerning	O
clinical	O
finding	O
in	O
pediatric	O
patients	O
and	O
can	O
have	O
many	O
causes	O
,	O
including	O
infectious	O
and	O
autoimmune	O
processes	O
.	O

A	O
rare	O
cause	O
,	O
drug-induced	O
vasculitis	B-Disease
,	O
may	O
result	O
from	O
the	O
production	O
of	O
antineutrophil	O
cytoplasmic	O
antibodies	O
(	O
ANCAs	O
)	O
in	O
response	O
to	O
a	O
medication	O
.	O

We	O
report	O
a	O
girl	O
with	O
Turner	B-Disease
syndrome	I-Disease
and	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
who	O
presented	O
with	O
palpable	O
purpuric	B-Disease
lesions	I-Disease
.	O

The	O
diagnosis	O
of	O
propylthiouracil	B-Chemical
(	O
PTU	B-Chemical
)	O
-associated	O
vasculitis	B-Disease
was	O
made	O
by	O
observation	O
of	O
consistent	O
clinical	O
features	O
,	O
the	O
detection	O
of	O
elevated	O
ANA	O
and	O
ANCA	O
in	O
the	O
blood	O
,	O
and	O
the	O
observed	O
clinical	O
resolution	O
of	O
symptoms	O
following	O
withdrawal	O
of	O
PTU	B-Chemical
.	O

Subsequent	O
treatment	O
of	O
persistent	O
hyperthyroidism	B-Disease
with	O
radioablation	O
did	O
not	O
result	O
in	O
an	O
exacerbation	O
of	O
the	O
vasculitis	B-Disease
,	O
a	O
complication	O
described	O
in	O
prior	O
case	O
reports	O
.	O

Succinylcholine-induced	B-Chemical
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
during	O
general	O
anesthesia	B-Drug
is	O
considered	O
an	O
early	O
warning	O
sign	O
of	O
a	O
possible	O
episode	O
of	O
malignant	B-Disease
hyperthermia	I-Disease
.	O

The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	O
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	O
and	O
severity	O
of	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
.	O

Here	O
,	O
we	O
describe	O
a	O
case	O
of	O
severe	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
(	O
jaw	B-Disease
of	I-Disease
steel	I-Disease
)	O
after	O
succinylcholine	B-Chemical
(	O
Sch	B-Chemical
)	O
administration	O
during	O
general	O
anesthetic	B-Drug
management	O
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Anesthesia	B-Drug
was	O
continued	O
uneventfully	O
with	O
propofol	B-Chemical
infusion	O
while	O
all	O
facilities	O
were	O
available	O
to	O
detect	O
and	O
treat	O
malignant	B-Disease
hyperthermia	I-Disease
.	O

Minor	O
neurological	B-Disease
dysfunction	I-Disease
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
at	O
the	O
age	O
of	O
3	O
to	O
7	O
years	O
after	O
dexamethasone	B-Chemical
treatment	O
in	O
very-low	O
birth-weight	O
infants	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
minor	O
neurological	B-Disease
dysfunction	I-Disease
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
after	O
dexamethasone	B-Chemical
therapy	O
in	O
very-low-birthweight	O
infants	O
.	O

Thirty-three	O
children	O
after	O
dexamethasone	B-Chemical
treatment	O
were	O
matched	O
to	O
33	O
children	O
without	O
dexamethasone	B-Chemical
treatment	O
.	O

Data	O
were	O
assessed	O
at	O
the	O
age	O
of	O
3-7	O
years	O
.	O

Dexamethasone	B-Chemical
was	O
started	O
between	O
the	O
7th	O
and	O
the	O
28th	O
day	O
of	O
life	O
over	O
7	O
days	O
with	O
a	O
total	O
dose	O
of	O
2.35	O
mg/kg/day	O
.	O

Exclusion	O
criteria	O
were	O
asphyxia	B-Disease
,	O
malformations	B-Disease
,	O
major	O
surgical	O
interventions	O
,	O
small	O
for	O
gestational	O
age	O
,	O
intraventricular	O
haemorrhage	B-Disease
grades	O
III	O
and	O
IV	O
,	O
periventricular	B-Disease
leukomalacia	I-Disease
,	O
and	O
severe	O
psychomotor	B-Disease
retardation	I-Disease
.	O

Each	O
child	O
was	O
examined	O
by	O
a	O
neuropediatrician	O
for	O
minor	O
neurological	B-Disease
dysfunctions	I-Disease
and	O
tested	O
by	O
a	O
psychologist	O
for	O
cognitive	O
development	O
with	O
a	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
and	O
a	O
Draw-a-Man	O
Test	O
.	O

There	O
were	O
no	O
differences	O
in	O
demographic	O
data	O
,	O
growth	O
,	O
and	O
socio-economic	O
status	O
between	O
the	O
two	O
groups	O
.	O

Fine	O
motor	O
skills	O
and	O
gross	O
motor	O
function	O
were	O
significantly	O
better	O
in	O
the	O
control	O
group	O
(	O
p	O
<	O
0.01	O
)	O
.	O

In	O
the	O
Draw-a-Man	O
Test	O
,	O
the	O
control	O
group	O
showed	O
better	O
results	O
(	O
p	O
<	O
0.001	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
development	O
of	O
speech	O
,	O
social	O
development	O
,	O
and	O
the	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
.	O

After	O
dexamethasone	B-Chemical
treatment	O
,	O
children	O
showed	O
a	O
higher	O
rate	O
of	O
minor	O
neurological	B-Disease
dysfunctions	I-Disease
.	O

Neurological	O
development	O
was	O
affected	O
even	O
without	O
neurological	O
diagnosis	O
.	O

Further	O
long-term	O
follow-up	O
studies	O
will	O
be	O
necessary	O
to	O
fully	O
evaluate	O
the	O
impact	O
of	O
dexamethasone	B-Chemical
on	O
neurological	O
and	O
cognitive	O
development	O
.	O

Force	O
overflow	O
and	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

We	O
assessed	O
force	O
coordination	O
of	O
the	O
hand	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
and	O
its	O
relationship	O
to	O
motor	O
complications	O
of	O
levodopa	B-Chemical
therapy	O
,	O
particularly	O
to	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
(	O
LID	B-Disease
)	O
.	O

We	O
studied	O
two	O
groups	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
patients	O
with	O
(	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
+	O
LID	B-Disease
,	O
n	O
=	O
23	O
)	O
and	O
without	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
(	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
-	O
LID	B-Disease
,	O
n	O
=	O
10	O
)	O
,	O
and	O
age-matched	O
healthy	O
controls	O
.	O

The	O
motor	O
score	O
of	O
the	O
Unified	O
Parkinson	B-Disease
's	I-Disease
Disease	I-Disease
Rating	O
Scale	O
,	O
a	O
dyskinesia	B-Disease
score	O
and	O
force	O
in	O
a	O
grip-lift	O
paradigm	O
were	O
assessed	O
ON	O
and	O
OFF	O
levodopa	B-Chemical
.	O

A	O
pathological	O
increase	O
of	O
forces	O
was	O
seen	O
in	O
ON-state	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
+	O
LID	B-Disease
only	O
.	O

In	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
+	O
LID	B-Disease
,	O
the	O
force	O
involved	O
in	O
pressing	O
down	O
the	O
object	O
before	O
lifting	O
was	O
significantly	O
increased	O
by	O
levodopa	B-Chemical
(	O
by	O
61	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

An	O
overshooting	O
of	O
peak	O
grip	O
force	O
by	O
51	O
%	O
(	O
P	O
<	O
0.05	O
)	O
and	O
of	O
static	O
grip	O
force	O
by	O
45	O
%	O
(	O
P	O
<	O
0.01	O
)	O
was	O
observed	O
in	O
the	O
ON-	O
compared	O
with	O
the	O
OFF-drug	O
condition	O
.	O

In	O
contrast	O
,	O
no	O
excessive	O
force	O
was	O
found	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
-	O
LID	B-Disease
.	O

Peak	O
grip	O
force	O
in	O
ON-state	O
was	O
140	O
%	O
(	O
P	O
<	O
0.05	O
)	O
higher	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
+	O
LID	B-Disease
than	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
-	O
LID	B-Disease
,	O
while	O
static	O
grip	O
force	O
was	O
increased	O
by	O
138	O
%	O
(	O
P	O
<	O
0.01	O
)	O
between	O
groups	O
.	O

Severity	O
of	O
peak-dose	O
dyskinesias	B-Disease
was	O
strongly	O
correlated	O
with	O
grip	O
force	O
in	O
ON-state	O
(	O
r	O
=	O
0.79	O
with	O
peak	O
force	O
,	O
P	O
<	O
0.01	O
)	O
.	O

No	O
correlation	O
was	O
observed	O
between	O
forces	O
and	O
the	O
motor	O
score	O
as	O
well	O
as	O
with	O
the	O
daily	O
dose	O
of	O
dopaminergic	B-Drug
medication	O
.	O

Force	O
excess	O
was	O
only	O
observed	O
in	O
patients	O
with	O
LID	B-Disease
and	O
motor	O
fluctuations	O
.	O

A	O
close	O
relationship	O
was	O
seen	O
between	O
the	O
overshooting	O
of	O
forces	O
and	O
dyskinesias	B-Disease
in	O
the	O
ON-drug	O
condition	O
.	O

We	O
postulate	O
that	O
both	O
LID	B-Disease
and	O
grip	O
force	O
excess	O
share	O
common	O
pathophysiological	O
mechanisms	O
related	O
to	O
motor	O
fluctuations	O
.	O

Postinfarction	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
associated	O
with	O
long-term	O
steroid	B-Chemical
therapy	O
.	O

Two	O
cases	O
of	O
postinfarction	O
ventricular	B-Disease
septal	I-Disease
rupture	I-Disease
in	O
patients	O
on	O
long-term	O
steroid	B-Chemical
therapy	O
are	O
presented	O
and	O
the	O
favourable	O
outcome	O
in	O
both	O
cases	O
described	O
.	O

A	O
possible	O
association	O
between	O
steroid	B-Chemical
therapy	O
and	O
subsequent	O
postinfarction	O
septal	B-Disease
rupture	I-Disease
is	O
discussed	O
.	O

Angioedema	B-Disease
associated	O
with	O
droperidol	B-Chemical
administration	O
.	O

Angioedema	B-Disease
,	O
also	O
known	O
as	O
angioneurotic	B-Disease
edema	I-Disease
or	O
Quincke	B-Disease
's	I-Disease
disease	I-Disease
,	O
is	O
a	O
well-demarcated	O
,	O
localized	O
edema	B-Disease
involving	O
the	O
subcutaneous	O
tissues	O
that	O
may	O
cause	O
upper-airway	B-Disease
obstruction	I-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
previously	O
healthy	O
19-year-old	O
man	O
with	O
no	O
known	O
drug	B-Disease
allergies	I-Disease
in	O
whom	O
angioedema	B-Disease
with	O
significant	O
tongue	B-Disease
swelling	I-Disease
and	O
protrusion	O
developed	O
within	O
10	O
minutes	O
of	O
the	O
administration	O
of	O
a	O
single	O
IV	O
dose	O
of	O
droperidol	B-Drug
.	O

Clarithromycin-associated	B-Chemical
visual	B-Disease
hallucinations	I-Disease
in	O
a	O
patient	O
with	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
.	O

Visual	B-Disease
hallucinations	I-Disease
are	O
a	O
rare	O
event	O
in	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
not	O
related	O
to	O
uremia	B-Disease
per	O
se	O
.	O

Unreported	O
in	O
the	O
literature	O
is	O
visual	B-Disease
hallucinations	I-Disease
occurring	O
in	O
association	O
with	O
the	O
new	O
macrolide	B-Chemical
antibiotic	O
,	O
clarithromycin	B-Chemical
.	O

We	O
describe	O
such	O
a	O
case	O
in	O
a	O
patient	O
with	O
end-stage	B-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
maintained	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

The	O
combination	O
of	O
a	O
relatively	O
high	O
dose	O
of	O
clarithromycin	B-Chemical
in	O
face	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	O
a	O
functionally	O
anephric	O
patient	O
,	O
with	O
underlying	O
aluminum	B-Chemical
intoxication	O
,	O
may	O
have	O
facilitated	O
the	O
appearance	O
of	O
this	O
neurotoxic	B-Disease
side	O
effect	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
pharmacokinetics	O
of	O
medications	O
in	O
face	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
the	O
possibility	O
of	O
drug	B-Drug
interactions	O
,	O
and	O
how	O
these	O
factors	O
should	O
help	O
guide	O
medication	O
therapy	O
in	O
the	O
ESRD	B-Disease
patient	O
.	O

Acute	O
renal	B-Disease
toxicity	I-Disease
of	O
doxorubicin	B-Chemical
(	O
adriamycin	B-Chemical
)	O
-loaded	O
cyanoacrylate	B-Chemical
nanoparticles	O
.	O

Acute	O
doxorubicin-loaded	B-Chemical
nanoparticle	O
(	O
DXNP	O
)	O
renal	B-Disease
toxicity	I-Disease
was	O
explored	O
in	O
both	O
normal	O
rats	O
and	O
rats	O
with	O
experimental	O
glomerulonephritis	B-Disease
.	O

In	O
normal	O
rats	O
,	O
2/6	O
rats	O
given	O
free	O
doxorubicin	B-Chemical
(	O
DX	B-Chemical
)	O
(	O
5	O
mg/kg	O
)	O
died	O
within	O
one	O
week	O
,	O
whereas	O
all	O
control	O
animals	O
and	O
all	O
rats	O
having	O
received	O
free	O
NP	O
or	O
DXNP	O
survived	O
.	O

A	O
3	O
times	O
higher	O
proteinuria	B-Disease
appeared	O
in	O
animals	O
treated	O
with	O
DXNP	B-Chemical
than	O
in	O
those	O
treated	O
with	O
DX	O
.	O

Free	O
NP	O
did	O
not	O
provoke	O
any	O
proteinuria	B-Disease
.	O

Two	O
hr	O
post-injection	O
,	O
DXNP	B-Chemical
was	O
2.7	O
times	O
more	O
concentrated	O
in	O
kidneys	O
than	O
free	O
DX	O
(	O
p	O
<	O
0.025	O
)	O
.	O

In	O
rats	O
with	O
immune	O
experimental	O
glomerulonephritis	B-Disease
,	O
5/6	O
rats	O
given	O
DX	B-Chemical
died	O
within	O
7	O
days	O
,	O
in	O
contrast	O
to	O
animals	O
treated	O
by	O
DXNP	O
,	O
NP	O
,	O
or	O
untreated	O
,	O
which	O
all	O
survived	O
.	O

Proteinuria	B-Disease
appeared	O
in	O
all	O
series	O
,	O
but	O
was	O
2-5	O
times	O
more	O
intense	O
(	O
p	O
>	O
0.001	O
)	O
and	O
prolonged	O
after	O
doxorubicin	B-Chemical
treatment	O
(	O
400-700	O
mg/day	O
)	O
,	O
without	O
significant	O
difference	O
between	O
DXNP	B-Chemical
and	O
DX	B-Chemical
.	O

Rats	O
treated	O
by	O
unloaded	O
NP	O
behaved	O
as	O
controls	O
.	O

These	O
results	O
demonstrate	O
that	O
,	O
in	O
these	O
experimental	O
conditions	O
,	O
DXNP	O
killed	O
less	O
animals	O
than	O
free	O
DX	O
,	O
despite	O
of	O
an	O
enhanced	O
renal	B-Disease
toxicity	I-Disease
of	O
the	O
former	O
.	O

Both	O
effects	O
(	O
better	O
survival	O
and	O
nephrosis	B-Disease
)	O
are	O
most	O
probably	O
related	O
to	O
an	O
enhanced	O
capture	O
of	O
DXNP	O
by	O
cells	O
of	O
the	O
mononuclear	O
phagocyte	O
system	O
,	O
including	O
mesangial	O
cells	O
.	O

Etoposide-related	B-Chemical
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
occurrence	O
of	O
a	O
myocardial	B-Disease
infarction	I-Disease
is	O
reported	O
after	O
chemotherapy	O
containing	O
etoposide	B-Chemical
,	O
in	O
a	O
man	O
with	O
no	O
risk	O
factors	O
for	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O

Possible	O
causal	O
mechanisms	O
are	O
discussed	O
.	O

Subjective	O
assessment	O
of	O
sexual	B-Disease
dysfunction	I-Disease
of	O
patients	O
on	O
long-term	O
administration	O
of	O
digoxin	B-Chemical
.	O

Various	O
data	O
suggest	O
that	O
male	O
patients	O
who	O
have	O
received	O
digoxin	B-Chemical
on	O
a	O
longterm	O
basis	O
have	O
increased	O
levels	O
of	O
serum	O
estrogen	B-Chemical
and	O
decreased	O
levels	O
of	O
plasma	O
testosterone	B-Chemical
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
links	O
between	O
the	O
long-term	O
administration	O
of	O
digoxin	B-Chemical
therapy	O
and	O
sexual	O
behavior	O
,	O
and	O
the	O
effect	O
of	O
digoxin	B-Chemical
on	O
plasma	O
levels	O
of	O
estradiol	B-Chemical
,	O
testosterone	B-Chemical
,	O
and	O
LH	O
.	O

The	O
patients	O
of	O
the	O
study	O
and	O
control	O
group	O
(	O
without	O
digoxin	B-Chemical
)	O
were	O
of	O
similar	O
cardiac	O
functional	O
capacity	O
and	O
age	O
(	O
25-40	O
years	O
)	O
and	O
were	O
randomly	O
selected	O
from	O
the	O
rheumatic	B-Disease
heart	I-Disease
disease	I-Disease
patients	O
.	O

A	O
subjective	O
assessment	O
of	O
sexual	O
behavior	O
in	O
the	O
study	O
and	O
control	O
groups	O
was	O
carried	O
out	O
,	O
using	O
parameters	O
such	O
as	O
sexual	O
desire	O
,	O
sexual	O
excitement	O
,	O
and	O
frequency	O
of	O
sexual	O
relations	O
.	O

Personal	O
interviews	O
and	O
a	O
questionnaire	O
were	O
also	O
used	O
for	O
the	O
evaluation	O
of	O
sexual	O
behavior	O
.	O

The	O
findings	O
support	O
the	O
reports	O
concerning	O
digoxin	B-Chemical
effect	O
on	O
plasma	O
estradiol	B-Chemical
,	O
testosterone	B-Chemical
,	O
and	O
LH	O
.	O

The	O
differences	O
in	I-Disease
the	O
means	O
were	O
significant	O
.	O

Tests	O
used	O
to	O
evaluate	O
the	O
changes	O
in	I-Disease
sexual	I-Disease
behavior	O
showed	O
a	O
significant	O
decrease	B-Disease
in	O
sexual	O
desire	O
,	O
sexual	O
excitement	O
phase	O
(	O
erection	O
)	O
,	O
and	O
frequency	O
of	O
sexual	O
relations	O
in	O
the	O
study	O
group	O
.	O

Fatal	O
aplastic	B-Disease
anemia	I-Disease
due	O
to	O
indomethacin	B-Chemical
--	O
lymphocyte	O
transformation	O
tests	O
in	O
vitro	O
.	O

Although	O
indomethacin	B-Chemical
has	O
been	O
implicated	O
as	O
a	O
possible	O
cause	O
of	O
aplastic	B-Disease
anemia	I-Disease
on	O
the	O
basis	O
of	O
a	O
few	O
clinical	O
observations	O
,	O
its	O
role	O
has	O
not	O
been	O
definitely	O
established	O
.	O

A	O
case	O
of	O
fatal	O
aplastic	B-Disease
anemia	I-Disease
is	O
described	O
in	O
which	O
no	O
drugs	B-Drug
other	O
than	O
allopurinol	B-Chemical
and	O
indomethacin	B-Chemical
were	O
given	O
.	O

Indomethacin	B-Chemical
was	O
first	O
given	O
four	O
weeks	O
prior	O
to	O
the	O
onset	O
of	O
symptoms	O
.	O

A	O
positive	O
lymphocyte	O
transformation	O
test	O
with	O
indomethacin	B-Chemical
in	O
vitro	O
further	O
substantiates	O
the	O
potential	O
role	O
of	O
this	O
drug	B-Drug
in	O
causing	O
aplastic	B-Disease
anemia	I-Disease
in	O
a	O
susceptible	O
patient	O
.	O

Fortunately	O
,	O
this	O
seems	O
to	O
be	O
a	O
very	O
rare	O
complication	O
.	O

Plasma	O
and	O
urinary	O
lipids	O
and	O
lipoproteins	O
during	O
the	O
development	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
induced	O
in	O
the	O
rat	O
by	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
.	O

This	O
study	O
was	O
undertaken	O
to	O
ascertain	O
whether	O
the	O
alterations	O
of	O
plasma	O
lipoproteins	O
found	O
in	O
nephrotic	B-Disease
syndrome	I-Disease
induced	O
by	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
were	O
due	O
to	O
nephrotic	B-Disease
syndrome	I-Disease
per	O
se	O
,	O
or	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
aminonucleoside	B-Chemical
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
changes	O
in	O
plasma	O
and	O
urinary	O
lipoproteins	O
during	O
the	O
administration	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
20	O
mg/kg	O
for	O
7	O
days	O
)	O
and	O
the	O
subsequent	O
development	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

Since	O
massive	O
albuminuria	B-Disease
occurred	O
after	O
6	O
days	O
of	O
treatment	O
,	O
the	O
time-course	O
study	O
was	O
divided	O
into	O
two	O
stages	O
:	O
pre-nephrotic	B-Disease
stage	O
(	O
day	O
1-5	O
)	O
and	O
nephrotic	B-Disease
stage	O
(	O
day	O
6-11	O
)	O
.	O

In	O
pre-nephrotic	B-Disease
stage	O
the	O
plasma	O
level	O
of	O
fatty	B-Chemical
acids	I-Chemical
,	O
triacylglycerol	B-Chemical
and	O
VLDL	O
decreased	O
while	O
that	O
of	O
phospholipid	O
,	O
cholesteryl	B-Chemical
esters	I-Chemical
and	O
HDL	O
remained	O
constant	O
.	O

Plasma	O
apolipoprotein	O
A-I	O
tended	O
to	O
increase	O
(	O
40	O
%	O
increase	O
at	O
day	O
5	O
)	O
.	O

At	O
the	O
beginning	O
of	O
nephrotic	B-Disease
stage	O
(	O
day	O
6	O
)	O
the	O
concentration	O
of	O
plasma	O
albumin	O
dropped	O
to	O
a	O
very	O
low	O
level	O
,	O
while	O
that	O
of	O
apolipoprotein	O
A-I	O
increased	O
abruptly	O
(	O
4-fold	O
increase	O
)	O
and	O
continued	O
to	O
rise	O
,	O
although	O
less	O
steeply	O
,	O
in	O
the	O
following	O
days	O
.	O

The	O
plasma	O
concentration	O
of	O
HDL	O
followed	O
the	O
same	O
pattern	O
.	O

Plasma	O
VLDL	O
and	O
LDL	O
increased	O
at	O
a	O
later	O
stage	O
(	O
day	O
9	O
)	O
.	O

Plasma	O
apolipoprotein	O
A-I	O
was	O
found	O
not	O
only	O
in	O
HDL	O
(	O
1.063-1.210	O
g/ml	O
)	O
but	O
also	O
in	O
the	O
LDL	O
density	O
class	O
(	O
1.025-1.050	O
g/ml	O
)	O
.	O

In	O
the	O
pre-nephrotic	B-Disease
stage	O
lipoproteinuria	O
was	O
negligible	O
,	O
while	O
in	O
the	O
early	O
nephrotic	B-Disease
stage	O
the	O
urinary	O
loss	O
of	O
plasma	O
lipoproteins	O
consisted	O
mainly	O
of	O
HDL	O
.	O

These	O
observations	O
indicate	O
that	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
alters	O
plasma	O
lipoproteins	O
by	O
lowering	O
VLDL	O
and	O
increasing	O
HDL	O
.	O

It	O
is	O
likely	O
that	O
the	O
early	O
and	O
striking	O
increase	O
of	O
plasma	O
HDL	O
found	O
in	O
nephrotic	B-Disease
rats	O
is	O
related	O
to	O
a	O
direct	O
effect	O
of	O
the	O
drug	B-Drug
on	O
HDL	O
metabolism	O
.	O

Circulating	O
lysosomal	O
enzymes	O
and	O
acute	B-Disease
hepatic	I-Disease
necrosis	I-Disease
.	O

The	O
activities	O
of	O
the	O
lysosomal	O
enzymes	O
acid	O
and	O
neutral	O
protease	O
,	O
N-acetylglucosaminidase	O
,	O
and	O
acid	O
phosphatase	O
were	O
measured	O
in	O
the	O
serum	O
of	O
patients	O
with	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
.	O

Acid	O
protease	O
(	O
cathepsin	O
D	O
)	O
activity	O
was	O
increased	O
about	O
tenfold	O
in	O
patients	O
who	O
died	O
and	O
nearly	O
fourfold	O
in	O
those	O
who	O
survived	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
after	O
paracetamol	B-Chemical
overdose	B-Disease
,	O
whereas	O
activities	O
were	O
increased	O
equally	O
in	O
patients	O
with	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
due	O
to	O
viral	B-Disease
hepatitis	I-Disease
whether	O
or	O
not	O
they	O
survived	O
.	O

A	O
correlation	O
was	O
found	O
between	O
serum	O
acid	O
protease	O
activity	O
and	O
prothrombin	O
time	O
,	O
and	O
the	O
increase	O
in	O
cathepsin	O
D	O
activity	O
was	O
sustained	O
over	O
several	O
days	O
compared	O
with	O
aspartate	B-Chemical
aminotransferase	O
,	O
which	O
showed	O
a	O
sharp	O
early	O
peak	O
and	O
then	O
a	O
fall	O
.	O

Circulating	O
lysosomal	O
proteases	O
can	O
damage	O
other	O
organs	O
,	O
and	O
measurement	O
of	O
their	O
activity	O
may	O
therefore	O
be	O
of	O
added	O
value	O
in	O
assessing	O
prognosis	O
in	O
this	O
condition	O
.	O

Transketolase	O
abnormality	O
in	O
tolazamide-induced	B-Chemical
Wernicke	B-Disease
's	I-Disease
encephalopathy	I-Disease
.	O

We	O
studied	O
a	O
thiamine-dependent	B-Chemical
enzyme	O
,	O
transketolase	O
,	O
from	O
fibroblasts	O
of	O
a	O
diabetic	B-Disease
patient	O
who	O
developed	O
Wernicke	B-Disease
's	I-Disease
encephalopathy	I-Disease
when	O
treated	O
with	O
tolazamide	B-Chemical
,	O
in	O
order	O
to	O
delineate	O
if	O
this	O
patient	O
also	O
had	O
transketolase	O
abnormality	O
[	O
high	O
Km	O
for	O
thiamine	B-Chemical
pyrophosphate	I-Chemical
(	O
TPP	B-Chemical
)	O
]	O
,	O
as	O
previously	O
reported	O
in	O
postalcoholic	O
Wernicke-Korsakoff	B-Disease
syndrome	I-Disease
.	O

In	O
addition	O
to	O
this	O
patient	O
,	O
we	O
also	O
studied	O
this	O
enzyme	O
from	O
three	O
diabetic	B-Disease
kindreds	O
without	O
any	O
history	O
of	O
Wernicke	B-Disease
's	I-Disease
encephalopathy	I-Disease
and	O
from	O
four	O
normal	O
controls	O
.	O

We	O
found	O
that	O
the	O
above-mentioned	O
patient	O
and	O
one	O
of	O
the	O
diabetic	B-Disease
kindreds	O
with	O
no	O
history	O
of	O
Wernicke	B-Disease
's	I-Disease
encephalopathy	I-Disease
had	O
abnormal	O
transketolase	O
as	O
determined	O
by	O
its	O
Km	O
for	O
TPP	B-Chemical
.	O

These	O
data	O
suggest	O
a	O
similarity	O
between	O
postalcoholic	O
Wernicke-Korsakoff	B-Disease
syndrome	I-Disease
and	O
the	O
patient	O
with	O
tolazamide-induced	B-Chemical
Wernicke	B-Disease
's	I-Disease
encephalopathy	I-Disease
from	O
the	O
standpoint	O
of	O
transketolase	O
abnormality	O
.	O

Mechanisms	O
of	O
myocardial	B-Disease
ischemia	I-Disease
induced	O
by	O
epinephrine	B-Chemical
:	O
comparison	O
with	O
exercise-induced	O
ischemia	B-Disease
.	O

The	O
role	O
of	O
epinephrine	B-Chemical
in	O
eliciting	O
myocardial	B-Disease
ischemia	I-Disease
was	O
examined	O
in	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O

Objective	O
signs	O
of	O
ischemia	B-Disease
and	O
factors	O
increasing	O
myocardial	O
oxygen	B-Chemical
consumption	O
were	O
compared	O
during	O
epinephrine	B-Chemical
infusion	O
and	O
supine	O
bicycle	O
exercise	O
.	O

Both	O
epinephrine	B-Chemical
and	O
exercise	O
produced	O
myocardial	B-Disease
ischemia	I-Disease
as	O
evidenced	O
by	O
ST	O
segment	O
depression	B-Disease
and	O
angina	B-Disease
.	O

However	O
,	O
the	O
mechanisms	O
of	O
myocardial	B-Disease
ischemia	I-Disease
induced	O
by	O
epinephrine	B-Chemical
were	O
significantly	O
different	O
from	O
those	O
of	O
exercise	O
.	O

Exercise-induced	O
myocardial	B-Disease
ischemia	I-Disease
was	O
marked	O
predominantly	O
by	O
increased	O
heart	O
rate	O
and	O
rate-pressure	O
product	O
with	O
a	O
minor	O
contribution	O
of	O
end-diastolic	O
volume	O
,	O
while	O
epinephrine-induced	B-Chemical
ischemia	B-Disease
was	O
characterized	O
by	O
a	O
marked	O
increase	O
in	O
contractility	O
and	O
a	O
less	O
pronounced	O
increase	O
in	O
heart	O
rate	O
and	O
rate-pressure	O
product	O
.	O

These	O
findings	O
indicate	O
that	O
ischemia	B-Disease
produced	O
by	O
epinephrine	B-Chemical
,	O
as	O
may	O
occur	O
during	O
states	O
of	O
emotional	O
distress	O
,	O
has	O
a	O
mechanism	O
distinct	O
from	O
that	O
due	O
to	O
physical	O
exertion	O
.	O

Transient	O
contralateral	B-Disease
rotation	I-Disease
following	O
unilateral	O
substantia	B-Disease
nigra	I-Disease
lesion	I-Disease
reflects	O
susceptibility	O
of	O
the	O
nigrostriatal	O
system	O
to	O
exhaustion	O
by	O
amphetamine	B-Chemical
.	O

Following	O
unilateral	O
6-OHDA	B-Chemical
induced	O
SN	B-Disease
lesion	I-Disease
,	O
a	O
transient	O
period	O
of	O
contralateral	B-Disease
rotation	I-Disease
has	O
been	O
reported	O
to	O
precede	O
the	O
predominant	O
ipsilateral	B-Disease
circling	I-Disease
.	O

In	O
order	O
to	O
clarify	O
the	O
nature	O
of	O
this	O
initial	O
contralateral	B-Disease
rotation	I-Disease
we	O
examined	O
the	O
effect	O
of	O
the	O
duration	O
of	O
recovery	O
period	O
after	O
the	O
lesion	O
,	O
on	O
amphetamine-induced	B-Chemical
rotational	B-Disease
behavior	I-Disease
.	O

Three	O
days	O
post	O
lesion	O
,	O
most	O
rats	O
circled	O
predominantly	O
contralaterally	B-Disease
to	O
the	O
lesion	O
.	O

Such	O
contralateral	B-Disease
rotation	O
may	O
result	O
from	O
either	O
degeneration-induced	O
breakdown	O
of	O
the	O
DA	O
pool	O
,	O
or	O
lesion-induced	O
increase	O
of	O
DA	O
turnover	O
in	O
the	O
spared	O
neurons	O
.	O

A	O
substantial	O
degree	O
of	O
contralateral	O
preference	O
was	O
still	O
evident	O
when	O
amphetamine	B-Chemical
was	O
administered	O
for	O
the	O
first	O
time	O
24	O
days	O
after	O
lesioning	O
,	O
indicating	O
involvement	O
of	O
spared	O
cells	O
in	O
the	O
contralateral	B-Disease
rotation	I-Disease
.	O

However	O
,	O
regardless	O
of	O
the	O
duration	O
of	O
recovery	O
(	O
and	O
irrespective	O
of	O
either	O
lesion	O
volume	O
,	O
amphetamine	B-Chemical
dose	O
,	O
or	O
post-lesion	O
motor	O
exercise	O
)	O
,	O
amphetamine-induced	B-Chemical
rotation	B-Disease
tended	O
to	O
become	O
gradually	O
more	O
ipsilateral	O
as	O
the	O
observation	O
session	O
progressed	O
,	O
and	O
all	O
rats	O
circled	O
ipsilaterally	O
to	O
the	O
lesion	O
in	O
response	O
to	O
further	O
amphetamine	B-Chemical
injections	O
.	O

These	O
findings	O
suggest	O
that	O
amphetamine	B-Chemical
has	O
an	O
irreversible	O
effect	O
on	O
the	O
post-lesion	O
DA	O
pool	O
contributing	O
to	O
contralateral	B-Disease
rotation	I-Disease
.	O

Thyroid	B-Drug
function	O
and	O
urine-concentrating	O
ability	O
during	O
lithium	B-Chemical
treatment	O
.	O

It	O
has	O
been	O
suggested	O
that	O
adenylate	O
cyclase	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
development	O
of	O
both	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
and	O
hypothyroidism	B-Disease
during	O
lithium	B-Chemical
treatment	O
.	O

We	O
measured	O
serum	O
thyroxine	B-Chemical
and	O
urine-concentrating	O
ability	O
(	O
Umax	O
)	O
in	O
response	O
to	O
desmopressin	B-Drug
(	O
DDAVP	O
)	O
in	O
85	O
patients	O
receiving	O
lithium	B-Chemical
.	O

Hypothyroidism	B-Disease
developed	O
in	O
eight	O
patients	O
while	O
they	O
were	O
taking	O
lithium	B-Chemical
.	O

Impaired	O
Umax	O
was	O
found	O
in	O
both	O
euthyroid	O
and	O
hypothyroid	B-Disease
patients	O
while	O
some	O
hypothyroid	B-Disease
patients	O
concentrated	O
their	O
urine	O
well	O
.	O

It	O
is	O
concluded	O
that	O
the	O
dominant	O
mechanisms	O
by	O
which	O
lithium	B-Chemical
exerts	O
these	O
two	O
effects	O
are	O
different	O
.	O

Sensitivity	O
of	O
erythroid	O
progenitor	O
colonies	O
to	O
erythropoietin	O
in	O
azidothymidine	B-Chemical
treated	O
immunodeficient	B-Disease
mice	O
.	O

The	O
anaemia	B-Disease
induced	O
by	O
3'-azido-3'dideoxythymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
is	O
poorly	O
understood	O
.	O

We	O
have	O
used	O
a	O
murine	O
model	O
of	O
AIDS	B-Disease
,	O
infection	B-Disease
of	O
female	O
C57BL/6	O
mice	O
with	O
LP-BM5	O
murine	O
leukaemia	B-Disease
(	O
MuLV	O
)	O
virus	O
,	O
to	O
determine	O
if	O
AZT-induced	B-Chemical
anaemia	B-Disease
is	O
due	O
,	O
in	O
part	O
,	O
to	O
decreased	O
responsiveness	O
of	O
erythropoietic	O
precursors	O
(	O
BFU-e	O
)	O
to	O
erythropoietin	O
(	O
EPO	O
)	O
.	O

Mice	O
in	O
the	O
early	O
stage	O
of	O
LP-BM5	O
MuLV	O
disease	O
were	O
given	O
AZT	B-Chemical
in	O
their	O
drinking	O
water	O
at	O
1.0	O
and	O
2.5	O
mg/ml	O
.	O

AZT	B-Chemical
produced	O
anaemia	B-Disease
in	O
both	O
groups	O
,	O
in	O
a	O
dose-dependent	O
fashion	O
.	O

Despite	O
the	O
anaemia	B-Disease
,	O
the	O
number	O
of	O
splenic	O
and	O
bone	O
marrow	O
BFU-e	O
in	O
AZT	B-Chemical
treated	O
mice	O
increased	O
up	O
to	O
five-fold	O
over	O
levels	O
observed	O
in	O
infected	O
untreated	O
animals	O
after	O
15	O
d	O
of	O
treatment	O
.	O

Colony	O
formation	O
by	O
splenic	O
and	O
bone	O
marrow	O
BFUe	O
was	O
stimulated	O
at	O
lower	O
concentrations	O
of	O
EPO	O
in	O
mice	O
receiving	O
AZT	B-Chemical
for	O
15	O
d	O
than	O
for	O
infected	O
,	O
untreated	O
mice	O
.	O

By	O
day	O
30	O
,	O
sensitivity	O
of	O
both	O
splenic	O
and	O
bone	O
marrow	O
BFU-e	O
of	O
treated	O
animals	O
returned	O
to	O
that	O
observed	O
from	O
cells	O
of	O
infected	O
untreated	O
animals	O
.	O

The	O
mean	O
plasma	O
levels	O
of	O
EPO	O
observed	O
in	O
AZT	B-Chemical
treated	O
mice	O
were	O
appropriate	O
for	O
the	O
degree	O
of	O
anaemia	B-Disease
observed	O
when	O
compared	O
with	O
phenylhydrazine	B-Chemical
(	O
PHZ	B-Chemical
)	O
treated	O
mice	O
.	O

The	O
numbers	O
of	O
BFU-e	O
and	O
the	O
percentage	O
of	O
bone	O
marrow	O
erythroblasts	O
observed	O
were	O
comparable	O
in	O
AZT	B-Chemical
and	O
PHZ	B-Chemical
treated	O
mice	O
with	O
similar	O
degrees	O
of	O
anaemia	B-Disease
.	O

However	O
,	O
reticulocytosis	B-Disease
was	O
inappropriate	O
for	O
the	O
degree	O
of	O
anaemia	B-Disease
observed	O
in	O
AZT	B-Chemical
treated	O
infected	O
mice	O
.	O

AZT-induced	B-Chemical
peripheral	O
anaemia	B-Disease
in	O
the	O
face	O
of	O
increased	O
numbers	O
of	O
BFU-e	O
and	O
increased	O
levels	O
of	O
plasma	O
EPO	O
suggest	O
a	O
lesion	O
in	O
terminal	O
differentiation	O
.	O

Detection	O
of	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
adriamycin-induced	B-Chemical
cardiomyopathy	B-Disease
with	O
iodine-125-metaiodobenzylguanidine	B-Chemical
.	O

Radiolabeled	B-Chemical
metaiodobenzylguanidine	I-Chemical
(	O
MIBG	B-Chemical
)	O
,	O
an	O
analog	O
of	O
norepinephrine	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
serves	O
as	O
an	O
index	O
of	O
adrenergic	O
neuron	O
integrity	O
and	O
function	O
.	O

Using	O
a	O
rat	O
model	O
of	O
adriamycin-induced	B-Chemical
cardiomyopathy	B-Disease
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
may	O
appear	O
and	O
be	O
exacerbated	O
dose-dependently	O
in	O
adriamycin	B-Chemical
cardiomyopathy	B-Disease
.	O

The	O
degree	O
of	I-Disease
vacuolar	B-Disease
degeneration	I-Disease
of	I-Disease
myocardial	I-Disease
cells	O
was	O
analyzed	O
in	O
relation	O
to	O
the	O
duration	O
of	O
adriamycin	B-Chemical
treatment	O
(	O
2	O
mg/kg	O
,	O
once	O
a	O
week	O
)	O
.	O

There	O
were	O
no	O
abnormalities	O
or	O
only	O
isolated	O
degeneration	O
in	O
the	O
1-	O
or	O
2-wk	O
treatment	O
groups	O
,	O
isolated	O
or	O
scattered	O
degeneration	O
in	O
half	O
of	O
the	O
3-wk	O
group	O
,	O
frequent	O
scattered	O
degeneration	O
in	O
the	O
4-wk	O
group	O
,	O
scattered	O
or	O
focal	O
degeneration	O
in	O
the	O
5-wk	O
group	O
,	O
and	O
extensive	O
degeneration	O
in	O
the	O
8-wk	O
group	O
.	O

Myocardial	O
accumulation	O
of	O
[	O
125I	O
]	O
MIBG	B-Chemical
4	O
hr	O
after	O
intravenous	O
injection	O
did	O
not	O
differ	O
between	O
the	O
controls	O
and	O
the	O
groups	O
treated	O
3	O
wk	O
or	O
less	O
.	O

However	O
,	O
the	O
4-wk	O
group	O
had	O
a	O
slightly	O
lower	O
accumulation	O
in	O
the	O
right	O
ventricular	O
wall	O
(	O
82	O
%	O
of	O
the	O
control	O
)	O
and	O
significantly	O
lower	O
accumulation	O
in	O
the	O
left	O
ventricular	O
wall	O
(	O
about	O
66	O
%	O
of	O
the	O
control	O
:	O
p	O
less	O
than	O
0.05	O
)	O
.	O

In	O
the	O
5-wk	O
group	O
,	O
MIBG	B-Chemical
accumulation	O
in	O
the	O
right	O
and	O
left	O
ventricular	O
wall	O
was	O
35	O
%	O
and	O
27	O
%	O
of	O
that	O
in	O
controls	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

In	O
the	O
8-wk	O
group	O
,	O
MIBG	B-Chemical
accumulation	O
in	O
the	O
right	O
and	O
left	O
ventricular	O
wall	O
was	O
18	O
%	O
and	O
14	O
%	O
of	O
that	O
in	O
controls	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Thus	O
,	O
MIBG	B-Chemical
accumulation	O
in	O
the	O
myocardium	O
decreased	O
in	O
an	O
adriamycin	B-Chemical
dose-dependent	O
manner	O
.	O

The	O
appearance	O
of	O
impaired	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
the	O
presence	O
of	O
slight	O
myocardial	B-Disease
impairment	I-Disease
(	O
scattered	O
or	O
focal	O
vacuolar	B-Disease
degeneration	I-Disease
)	O
indicates	O
that	O
MIBG	B-Chemical
scintigraphy	O
may	O
be	O
a	O
useful	O
method	O
for	O
detection	O
of	O
adriamycin-induced	B-Chemical
cardiomyopathy	B-Disease
.	O

Amnestic	B-Disease
syndrome	I-Disease
associated	O
with	O
propranolol	B-Chemical
toxicity	B-Disease
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
woman	O
developed	O
an	O
Alzheimer-like	B-Disease
subacute	O
dementia	B-Disease
as	O
a	O
result	O
of	O
propranolol	B-Chemical
toxicity	B-Disease
.	O

Analysis	O
of	O
the	O
manifestations	O
showed	O
that	O
severe	O
impairment	O
of	O
memory	O
accounted	O
for	O
virtually	O
all	O
of	O
the	O
abnormalities	O
.	O

There	O
is	O
evidence	O
that	O
cerebral	O
reactions	O
to	O
drug	B-Drug
toxicity	B-Disease
can	O
exhibit	O
patterns	O
that	O
suggest	O
highly	O
selective	O
involvement	O
of	O
functional	O
subdivisions	O
of	O
the	O
brain	O
.	O

Biphasic	O
response	O
of	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
in	O
vivo	O
to	O
selective	O
administration	O
of	O
ketamine	B-Chemical
.	O

Effect	O
of	O
ketamine	B-Chemical
on	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
was	O
studied	O
in	O
vivo	O
using	O
a	O
selective	O
perfusion	O
technique	O
of	O
the	O
SA	O
node	O
artery	O
.	O

Injections	O
of	O
ketamine	B-Chemical
in	O
doses	O
from	O
100	O
microgram	O
to	O
3	O
mg	O
into	O
the	O
artery	O
produced	O
a	O
depression	B-Disease
of	O
the	O
SA	O
nodal	O
activity	O
by	O
a	O
direct	O
action	O
.	O

This	O
depression	B-Disease
was	O
followed	O
by	O
the	O
sudden	O
appearance	O
of	O
a	O
stimulatory	O
phase	O
.	O

Bilateral	O
vagotomy	O
and	O
sympathectomy	O
or	O
prior	O
administration	O
of	O
a	O
ganglion	O
blocker	O
failed	O
to	O
inhibit	O
the	O
occurrence	O
of	O
the	O
ketamine-induced	B-Chemical
tachycardia	B-Disease
,	O
while	O
it	O
was	O
completely	O
abolished	O
in	O
the	O
reserpinized	O
dogs	O
or	O
by	O
a	O
prior	O
injection	O
of	O
a	O
beta-blocking	B-Drug
agent	O
into	O
the	O
SA	O
node	O
artery	O
.	O

This	O
may	O
indicate	O
that	O
an	O
activation	O
of	O
the	O
peripheral	O
adrenergic	O
mechanism	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
the	O
excitatory	O
effect	O
of	O
ketamine	B-Chemical
injected	O
in	O
the	O
SA	O
node	O
artery	O
.	O

The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	B-Chemical
apnoea	B-Disease
.	O

Fifteen	O
patients	O
demonstrating	O
unexpected	O
prolonged	O
apnoea	B-Disease
lasting	O
several	O
hours	O
after	O
succinylcholine	B-Chemical
have	O
been	O
treated	O
by	O
a	O
new	O
preparation	O
of	O
human	O
serum	O
cholinesterase	O
.	O

Adequate	O
spontaneous	O
respiration	O
was	O
re-established	O
in	O
an	O
average	O
period	O
of	O
ten	O
minutes	O
after	O
the	O
injection	O
.	O

In	O
12	O
patients	O
biochemical	O
genetic	O
examinations	O
confirmed	O
the	O
presence	O
of	O
an	O
atypical	O
serum	O
cholinesterase	O
.	O

In	O
three	O
patients	O
none	O
of	O
the	O
usual	O
variants	O
were	O
found	O
.	O

It	O
is	O
therefore	O
supposed	O
that	O
other	O
unknown	O
variants	O
of	O
serum	O
cholinesterase	O
exist	O
which	O
can	O
not	O
hydrolyze	O
succinylcholine	B-Chemical
.	O

The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	B-Chemical
apnoea	B-Disease
provided	O
considerable	O
relief	O
to	O
both	O
patient	O
and	O
anaesthetist	O
.	O

Orthostatic	B-Disease
hypotension	I-Disease
occurs	O
following	O
alpha	O
2-adrenoceptor	O
blockade	O
in	O
chronic	O
prazosin-pretreated	B-Chemical
conscious	O
spontaneously	O
hypertensive	B-Disease
rats	O
.	O

1	O
.	O

Studies	O
were	O
performed	O
to	O
evaluate	O
whether	O
chronic	O
prazosin	B-Chemical
treatment	O
alters	O
the	O
alpha	O
2-adrenoceptor	O
function	O
for	O
orthostatic	O
control	O
of	O
arterial	O
blood	O
pressure	O
in	O
conscious	O
spontaneously	O
hypertensive	B-Disease
rats	O
(	O
SHR	O
)	O
.	O

2	O
.	O

Conscious	O
SHR	O
(	O
male	O
300-350	O
g	O
)	O
were	O
subjected	O
to	O
90	O
degrees	O
head-up	O
tilts	O
for	O
60	O
s	O
following	O
acute	O
administration	O
of	O
prazosin	B-Chemical
(	O
0.1	O
mg	O
kg-1	O
i.p	O
.	O

)	O
or	O
rauwolscine	B-Chemical
(	O
3	O
mg	O
kg-1	O
i.v.	O
)	O
.	O

Orthostatic	B-Disease
hypotension	I-Disease
was	O
determined	O
by	O
the	O
average	O
decrease	O
(	O
%	O
)	O
in	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
femoral	O
)	O
over	O
the	O
60-s	O
tilt	O
period	O
.	O

The	O
basal	O
MAP	O
of	O
conscious	O
SHR	O
was	O
reduced	O
to	O
a	O
similar	O
extent	O
by	O
prazosin	B-Chemical
(	O
-23	O
%	O
(	O
-	O
)	O
-26	O
%	O
MAP	O
)	O
and	O
rauwolscine	B-Chemical
(	O
-16	O
%	O
(	O
-	O
)	O
-33	O
%	O
MAP	O
)	O
.	O

However	O
,	O
the	O
head-up	O
tilt	O
induced	O
orthostatic	B-Disease
hypotension	I-Disease
in	O
the	O
SHR	O
treated	O
with	O
prazosin	B-Chemical
(	O
-16	O
%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
,	O
but	O
not	O
in	O
the	O
SHR	O
treated	O
with	O
rauwolscine	B-Chemical
(	O
less	O
than	O
+2	O
%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
.	O

3	O
.	O

Conscious	O
SHR	O
were	O
treated	O
for	O
4	O
days	O
with	O
prazosin	B-Chemical
at	O
2	O
mg	O
kg-1	O
day-1	O
i.p	O
.	O

for	O
chronic	O
alpha	O
1-adrenoceptor	O
blockade	O
.	O

MAP	O
in	O
conscious	O
SHR	O
after	O
chronic	O
prazosin	B-Chemical
treatment	O
was	O
14	O
%	O
lower	O
than	O
in	O
the	O
untreated	O
SHR	O
(	O
n	O
=	O
8	O
)	O
.	O

Head-up	O
tilts	O
in	O
these	O
rats	O
did	O
not	O
produce	O
orthostatic	B-Disease
hypotension	I-Disease
when	O
performed	O
either	O
prior	O
to	O
or	O
after	O
acute	O
dosing	O
of	O
prazosin	B-Chemical
(	O
0.1	O
mg	O
kg-1	O
i.p.	O
)	O
.	O

Conversely	O
,	O
administration	O
of	O
rauwolscine	B-Chemical
(	O
3	O
mg	O
kg-1	O
i.v	O
.	O

)	O
in	O
chronic	O
prazosin	B-Chemical
treated	O
SHR	O
decreased	O
the	O
basal	O
MAP	O
by	O
12-31	O
%	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
subsequent	O
tilts	O
induced	O
further	O
drops	O
of	O
MAP	O
by	O
19-23	O
%	O
in	O
these	O
rats	O
.	O

4	O
.	O

The	O
pressor	O
responses	O
and	O
bradycardia	B-Disease
to	O
the	O
alpha	O
1-agonist	O
cirazoline	B-Chemical
(	O
0.6	O
and	O
2	O
micrograms	O
kg-1	O
i.v	O
.	O

)	O
,	O
the	O
alpha	O
2-agonist	O
Abbott-53693	B-Chemical
(	O
1	O
and	O
3	O
micrograms	O
kg-1	O
i.v	O
.	O

)	O
,	O
and	O
noradrenaline	B-Chemical
(	O
0.1	O
and	O
1.0	O
micrograms	O
kg-1	O
i.v	O
.	O

)	O
were	O
determined	O
in	O
conscious	O
SHR	O
with	O
and	O
without	O
chronic	O
prazosin	B-Chemical
pretreatment	O
.	O

Both	O
the	O
pressor	O
and	O
bradycardia	B-Disease
effects	O
of	O
cirazoline	B-Chemical
were	O
abolished	O
in	O
chronic	O
prazosin	B-Chemical
treated	O
SHR	O
(	O
n	O
=	O
4	O
)	O
as	O
compared	O
to	O
the	O
untreated	O
SHR	O
(	O
n	O
=	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
pressor	O
effects	O
of	O
Abbott-53693	B-Chemical
were	O
similar	O
in	O
both	O
groups	O
of	O
SHR	O
,	O
but	O
the	O
accompanying	O
bradycardia	B-Disease
was	O
greater	O
in	O
SHR	O
with	O
chronic	O
prazosin	B-Chemical
treatment	O
than	O
without	O
such	O
treatment	O
.	O

Furthermore	O
,	O
the	O
bradycardia	B-Disease
that	O
accompanied	O
the	O
noradrenaline-induced	B-Chemical
pressor	O
effect	O
in	O
SHR	O
was	O
similar	O
with	O
and	O
without	O
chronic	O
prazosin	B-Chemical
treatment	O
despite	O
a	O
47-71	O
%	O
reduction	O
of	O
the	O
pressor	O
effect	O
in	O
chronic	O
alpha	O
1-receptor	O
blocked	O
SHR	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Coexistence	O
of	O
cerebral	B-Disease
venous	I-Disease
sinus	I-Disease
and	I-Disease
internal	I-Disease
carotid	I-Disease
artery	I-Disease
thrombosis	I-Disease
associated	O
with	O
exogenous	O
sex	O
hormones	O
.	O

A	O
case	O
report	O
.	O

A	O
forty-six	O
year-old	O
premenopausal	O
woman	O
developed	O
headache	B-Disease
,	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
left	O
hemiparesis	B-Disease
and	O
seizure	B-Disease
two	O
days	O
after	O
parenteral	O
use	O
of	O
progesterone	B-Chemical
and	O
estradiol	B-Chemical
.	O

Diabetes	B-Disease
mellitus	I-Disease
(	O
DM	B-Disease
)	O
was	O
found	O
during	O
admission	O
.	O

Computed	O
tomography	O
showed	O
a	O
hemorrhagic	B-Disease
infarct	I-Disease
in	O
the	O
right	O
frontal	O
lobe	O
and	O
increased	O
density	O
in	O
the	O
superior	O
sagittal	O
sinus	O
(	O
SSS	O
)	O
.	O

Left	O
carotid	O
angiography	O
found	O
occlusion	O
of	O
the	O
left	O
internal	O
carotid	O
artery	O
(	O
ICA	O
)	O
.	O

Right	O
carotid	O
angiograms	O
failed	O
to	O
show	O
the	O
SSS	O
and	O
inferior	O
sagittal	O
sinus	O
,	O
suggestive	O
of	O
venous	O
sinus	O
thrombosis	O
.	O

Coexistence	O
of	O
the	O
cerebral	O
artery	O
and	O
the	O
venous	O
sinus	O
occlusion	O
has	O
been	O
described	O
infrequently	O
.	O

In	O
this	O
case	O
,	O
the	O
authors	O
postulate	O
that	O
the	O
use	O
of	O
estradiol	B-Drug
and	O
progesterone	B-Drug
and	O
the	O
underlying	O
DM	O
increased	O
vascular	O
thrombogenicity	O
,	O
which	O
provided	O
a	O
common	O
denominator	O
for	O
thrombosis	O
of	O
both	O
the	O
ICA	O
and	O
the	O
venous	O
sinus	O
.	O

Chloroquine	B-Chemical
related	O
complete	O
heart	B-Disease
block	I-Disease
with	O
blindness	B-Disease
:	O
case	O
report	O
.	O

A	O
27-year	O
old	O
African	O
woman	O
with	O
history	O
of	O
regular	O
chloroquine	B-Chemical
ingestion	O
presented	O
with	O
progressive	O
deterioration	B-Disease
of	I-Disease
vision	I-Disease
,	O
easy	O
fatiguability	B-Disease
,	O
dyspnoea	B-Disease
,	O
dizziness	B-Disease
progressing	O
to	O
syncopal	B-Disease
attacks	I-Disease
.	O

Ophthalmological	O
assessment	O
revealed	O
features	O
of	O
chloroquine	B-Chemical
retinopathy	B-Disease
,	O
cardiac	O
assessment	O
revealed	O
features	O
of	O
heart	B-Disease
failure	I-Disease
and	O
a	O
complete	O
heart	B-Disease
block	I-Disease
with	O
right	B-Disease
bundle	I-Disease
branch	I-Disease
block	I-Disease
pattern	O
.	O

The	O
heart	B-Disease
block	I-Disease
was	O
treated	O
by	O
pacemaker	O
insertion	O
and	O
the	O
heart	B-Disease
failure	I-Disease
resolved	O
spontaneously	O
following	O
chloroquine	B-Chemical
discontinuation	O
.	O

She	O
however	O
remains	O
blind	B-Disease
.	O

Systemic	O
toxicity	B-Disease
and	O
resuscitation	O
in	O
bupivacaine-	B-Chemical
,	O
levobupivacaine-	B-Chemical
,	O
or	O
ropivacaine-infused	B-Chemical
rats	O
.	O

We	O
compared	O
the	O
systemic	O
toxicity	B-Disease
of	O
bupivacaine	B-Chemical
,	O
levobupivacaine	B-Chemical
,	O
and	O
ropivacaine	B-Chemical
in	O
anesthetized	O
rats	O
.	O

We	O
also	O
compared	O
the	O
ability	O
to	O
resuscitate	O
rats	O
after	O
lethal	O
doses	O
of	O
these	O
local	O
anesthetics	B-Drug
.	O

Bupivacaine	B-Chemical
,	O
levobupivacaine	B-Chemical
,	O
or	O
ropivacaine	B-Chemical
was	O
infused	O
at	O
a	O
rate	O
of	O
2	O
mg.	O
kg	O
(	O
-1	O
)	O
.	O

min	O
(	O
-1	O
)	O
while	O
electrocardiogram	O
,	O
electroencephalogram	O
,	O
and	O
arterial	O
pressure	O
were	O
continuously	O
monitored	O
.	O

When	O
asystole	B-Disease
was	O
recorded	O
,	O
drug	B-Drug
infusion	O
was	O
stopped	O
and	O
a	O
resuscitation	O
sequence	O
was	O
begun	O
.	O

Epinephrine	B-Chemical
0.01	O
mg/kg	O
was	O
administered	O
at	O
1-min	O
intervals	O
while	O
external	O
cardiac	O
compressions	O
were	O
applied	O
.	O

Resuscitation	O
was	O
considered	O
successful	O
when	O
a	O
systolic	O
arterial	O
pressure	O
>	O
or	O
=100	O
mm	O
Hg	O
was	O
achieved	O
within	O
5	O
min	O
.	O

The	O
cumulative	O
doses	O
of	O
levobupivacaine	B-Chemical
and	O
ropivacaine	B-Chemical
that	O
produced	O
seizures	B-Disease
were	O
similar	O
and	O
were	O
larger	O
than	O
those	O
of	O
bupivacaine	B-Chemical
.	O

The	O
cumulative	O
doses	O
of	O
levobupivacaine	B-Chemical
that	O
produced	O
dysrhythmias	B-Disease
and	O
asystole	B-Disease
were	O
smaller	O
than	O
the	O
corresponding	O
doses	O
of	O
ropivacaine	B-Chemical
,	O
but	O
they	O
were	O
larger	O
than	O
those	O
of	O
bupivacaine	B-Chemical
.	O

The	O
number	O
of	O
successful	O
resuscitations	O
did	O
not	O
differ	O
among	O
groups	O
.	O

However	O
,	O
a	O
smaller	O
dose	O
of	O
epinephrine	B-Chemical
was	O
required	O
in	O
the	O
Ropivacaine	B-Chemical
group	O
than	O
in	O
the	O
other	O
groups	O
.	O

We	O
conclude	O
that	O
the	O
systemic	O
toxicity	B-Disease
of	O
levobupivacaine	B-Chemical
is	O
intermediate	O
between	O
that	O
of	O
ropivacaine	B-Chemical
and	O
bupivacaine	B-Chemical
when	O
administered	O
at	O
the	O
same	O
rate	O
and	O
that	O
ropivacaine-induced	B-Chemical
cardiac	B-Disease
arrest	I-Disease
appears	O
to	O
be	O
more	O
susceptible	O
to	O
treatment	O
than	O
that	O
induced	O
by	O
bupivacaine	B-Chemical
or	O
levobupivacaine	B-Chemical
.	O

22-oxacalcitriol	B-Chemical
suppresses	O
secondary	B-Disease
hyperparathyroidism	I-Disease
without	O
inducing	O
low	B-Disease
bone	I-Disease
turnover	I-Disease
in	O
dogs	O
with	O
renal	B-Disease
failure	I-Disease
.	O

BACKGROUND	O
:	O
Calcitriol	B-Chemical
therapy	O
suppresses	O
serum	O
levels	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
in	O
patients	O
with	O
renal	B-Disease
failure	I-Disease
but	O
has	O
several	O
drawbacks	O
,	O
including	O
hypercalcemia	B-Disease
and/or	O
marked	O
suppression	B-Disease
of	I-Disease
bone	I-Disease
turnover	I-Disease
,	O
which	O
may	O
lead	B-Drug
to	O
adynamic	B-Disease
bone	I-Disease
disease	I-Disease
.	O

A	O
new	O
vitamin	B-Chemical
D	I-Chemical
analogue	O
,	O
22-oxacalcitriol	B-Chemical
(	O
OCT	B-Chemical
)	O
,	O
has	O
been	O
shown	O
to	O
have	O
promising	O
characteristics	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effects	O
of	O
OCT	B-Chemical
on	O
serum	O
PTH	O
levels	O
and	O
bone	O
turnover	O
in	O
states	O
of	O
normal	O
or	O
impaired	B-Disease
renal	I-Disease
function	I-Disease
.	O

METHODS	O
:	O
Sixty	O
dogs	O
were	O
either	O
nephrectomized	O
(	O
Nx	O
,	O
N	O
=	O
38	O
)	O
or	O
sham-operated	O
(	O
Sham	O
,	O
N	O
=	O
22	O
)	O
.	O

The	O
animals	O
received	O
supplemental	O
phosphate	B-Chemical
to	O
enhance	O
PTH	O
secretion	O
.	O

Fourteen	O
weeks	O
after	O
the	O
start	O
of	O
phosphate	B-Chemical
supplementation	O
,	O
half	O
of	O
the	O
Nx	O
and	O
Sham	O
dogs	O
received	O
doses	O
of	O
OCT	B-Chemical
(	O
three	O
times	O
per	O
week	O
)	O
;	O
the	O
other	O
half	O
were	O
given	O
vehicle	O
for	O
60	O
weeks	O
.	O

Thereafter	O
,	O
the	O
treatment	O
modalities	O
for	O
a	O
subset	O
of	O
animals	O
were	O
crossed	O
over	O
for	O
an	O
additional	O
eight	O
months	O
.	O

Biochemical	O
and	O
hormonal	O
indices	O
of	O
calcium	B-Chemical
and	O
bone	O
metabolism	O
were	O
measured	O
throughout	O
the	O
study	O
,	O
and	O
bone	O
biopsies	O
were	O
done	O
at	O
baseline	O
,	O
60	O
weeks	O
after	O
OCT	B-Chemical
or	O
vehicle	O
treatment	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
crossover	O
period	O
.	O

RESULTS	O
:	O
In	O
Nx	O
dogs	O
,	O
OCT	B-Chemical
significantly	O
decreased	O
serum	O
PTH	O
levels	O
soon	O
after	O
the	O
induction	O
of	O
renal	B-Disease
insufficiency	I-Disease
.	O

In	O
long-standing	O
secondary	B-Disease
hyperparathyroidism	I-Disease
,	O
OCT	B-Chemical
(	O
0.03	O
microg/kg	O
)	O
stabilized	O
serum	O
PTH	O
levels	O
during	O
the	O
first	O
months	O
.	O

Serum	O
PTH	O
levels	O
rose	O
thereafter	O
,	O
but	O
the	O
rise	O
was	O
less	O
pronounced	O
compared	O
with	O
baseline	O
than	O
the	O
rise	O
seen	O
in	O
Nx	O
control	O
.	O

These	O
effects	O
were	O
accompanied	O
by	O
episodes	O
of	O
hypercalcemia	B-Disease
and	O
hyperphosphatemia	B-Disease
.	O

In	O
animals	O
with	O
normal	O
renal	O
function	O
,	O
OCT	B-Chemical
induced	O
a	O
transient	O
decrease	O
in	O
serum	O
PTH	O
levels	O
at	O
a	O
dose	O
of	O
0.1	O
microg/kg	O
,	O
which	O
was	O
not	O
sustained	O
with	O
lowering	O
of	O
the	O
doses	O
.	O

In	O
Nx	O
dogs	O
,	O
OCT	B-Chemical
reversed	O
abnormal	O
bone	O
formation	O
,	O
such	O
as	O
woven	B-Disease
osteoid	I-Disease
and	O
fibrosis	B-Disease
,	O
but	O
did	O
not	O
significantly	O
alter	O
the	O
level	O
of	O
bone	O
turnover	O
.	O

In	O
addition	O
,	O
OCT	B-Chemical
improved	O
mineralization	O
lag	O
time	O
,	O
(	O
that	O
is	O
,	O
the	O
rate	O
at	O
which	O
osteoid	O
mineralizes	O
)	O
in	O
both	O
Nx	O
and	O
Sham	O
dogs	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
even	O
though	O
OCT	B-Chemical
does	O
not	O
completely	O
prevent	O
the	O
occurrence	O
of	O
hypercalcemia	B-Disease
in	O
experimental	O
dogs	O
with	O
renal	B-Disease
insufficiency	I-Disease
,	O
it	O
may	O
be	O
of	O
use	O
in	O
the	O
management	O
of	O
secondary	B-Disease
hyperparathyroidism	I-Disease
because	O
it	O
does	O
not	O
induce	O
low	B-Disease
bone	I-Disease
turnover	I-Disease
and	O
,	O
therefore	O
,	O
does	O
not	O
increase	O
the	O
risk	O
of	O
adynamic	B-Disease
bone	I-Disease
disease	I-Disease
.	O

Chemotherapy	O
of	O
advanced	O
inoperable	O
non-small	B-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
with	O
paclitaxel	B-Chemical
:	O
a	O
phase	O
II	O
trial	O
.	O

Paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol-Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
has	O
demonstrated	O
significant	O
antineoplastic	O
activity	O
against	O
different	O
tumor	B-Disease
types	O
,	O
notably	O
ovarian	B-Disease
and	I-Disease
breast	I-Disease
carcinoma	I-Disease
.	O

Two	O
phase	O
II	O
trials	O
of	O
24-hour	O
paclitaxel	B-Drug
infusions	O
in	O
chemotherapy-naive	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
reported	O
response	O
rates	O
of	O
21	O
%	O
and	O
24	O
%	O
.	O

Leukopenia	O
was	O
dose	O
limiting	O
:	O
as	O
many	O
as	O
62.5	O
%	O
of	O
patients	O
experienced	O
grade	O
4	O
leukopenia	O
.	O

We	O
investigated	O
the	O
efficacy	O
and	O
toxicity	O
of	O
a	O
3-hour	O
paclitaxel	B-Drug
infusion	O
in	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
inoperable	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	O
.	O

The	O
58	O
patients	O
treated	O
(	O
41	O
men	O
and	O
17	O
women	O
)	O
had	O
a	O
median	O
age	O
of	O
59	O
years	O
(	O
age	O
range	O
,	O
25	O
to	O
75	O
)	O
and	O
a	O
performance	O
status	O
of	O
0	O
through	O
2	O
.	O

Most	O
patients	O
(	O
72.4	O
%	O
)	O
had	O
stage	O
IV	O
NSCLC	O
.	O

Paclitaxel	B-Drug
225	O
mg/m2	O
was	O
infused	O
over	O
3	O
hours	O
every	O
3	O
weeks	O
with	O
standard	O
prophylactic	O
premedication	O
.	O

Of	O
50	O
patients	O
evaluable	O
for	O
response	O
,	O
12	O
(	O
24	O
%	O
)	O
had	O
partial	O
remission	O
,	O
26	O
(	O
52	O
%	O
)	O
had	O
no	O
change	O
,	O
and	O
12	O
had	O
disease	O
progression	O
(	O
24	O
%	O
)	O
.	O

Hematologic	O
toxicities	O
were	O
mild	O
:	O
only	O
one	O
patient	O
(	O
2	O
%	O
)	O
developed	O
grade	O
3	O
or	O
4	O
neutropenia	O
,	O
while	O
29	O
%	O
had	O
grade	O
1	O
or	O
2	O
.	O

Grade	O
1	O
or	O
2	O
polyneuropathy	O
affected	O
56	O
%	O
of	O
patients	O
while	O
only	O
one	O
(	O
2	O
%	O
)	O
experienced	O
severe	O
polyneuropathy	O
.	O

Similarly	O
,	O
grade	O
1	O
or	O
2	O
myalgia/arthralgia	O
was	O
observed	O
in	O
63.2	O
%	O
of	O
patients	O
,	O
but	O
only	O
14.3	O
%	O
experienced	O
grade	O
3	O
or	O
4	O
.	O

Nausea	O
and	O
vomiting	O
were	O
infrequent	O
,	O
with	O
14	O
%	O
of	O
patients	O
experiencing	O
grade	O
1	O
or	O
2	O
and	O
only	O
2	O
%	O
experiencing	O
grade	O
3	O
or	O
4	O
.	O

Paclitaxel	B-Drug
is	O
thus	O
an	O
active	O
single	O
agent	O
in	O
this	O
patient	O
population	O
,	O
with	O
a	O
3-hour	O
infusion	O
proving	O
comparably	O
effective	O
to	O
a	O
24-hour	O
infusion	O
and	O
superior	O
in	O
terms	O
of	O
the	O
incidence	O
of	O
hematologic	O
and	O
nonhematologic	O
toxicity	O
.	O

Further	O
phase	O
II	O
studies	O
with	O
paclitaxel	B-Drug
combined	O
with	O
other	O
drugs	B-Drug
active	O
against	O
NSCLC	O
are	O
indicated	O
,	O
and	O
phase	O
III	O
studies	O
comparing	O
paclitaxel	B-Drug
with	O
standard	O
chemotherapy	O
remain	O
to	O
be	O
completed	O
.	O

Cerebral	B-Disease
hemorrhage	I-Disease
associated	O
with	O
phenylpropanolamine	B-Chemical
in	O
combination	O
with	O
caffeine	B-Chemical
.	O

Phenylpropanolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
is	O
a	O
drug	B-Drug
that	O
has	O
been	O
associated	O
with	O
serious	O
side	O
effects	O
including	O
stroke	B-Disease
.	O

It	O
is	O
often	O
combined	O
with	O
caffeine	B-Chemical
in	O
diet	O
preparations	O
and	O
``	O
look-alike	O
''	O
pills	O
.	O

In	O
order	O
to	O
determine	O
if	O
PPA/caffeine	B-Chemical
can	O
lead	B-Drug
to	O
stroke	O
in	O
normotensive	O
and/or	O
hypertensive	O
rats	O
,	O
we	O
administered	O
the	O
combination	O
in	O
six	O
times	O
the	O
allowed	O
human	O
dose	O
calculated	O
on	O
a	O
per	O
weight	O
basis	O
for	O
the	O
rats	O
two	O
times	O
per	O
day	O
for	O
five	O
days	O
.	O

Subarachnoid	O
and	O
cerebral	O
hemorrhage	O
was	O
noted	O
in	O
18	O
%	O
of	O
the	O
hypertensive	O
rats	O
.	O

A	O
single	O
PPA/caffeine	B-Chemical
administration	O
(	O
same	O
dose	O
)	O
lead	B-Drug
to	O
acute	O
hypertension	O
in	O
both	O
the	O
normotensive	O
and	O
hypertensive	O
animals	O
.	O

These	O
results	O
suggest	O
that	O
PPA/caffeine	O
can	O
lead	B-Drug
to	O
cerebral	O
hemorrhage	O
in	O
previously	O
hypertensive	O
animals	O
when	O
administered	O
in	O
greater	O
than	O
the	O
allowed	O
dosage	O
.	O

An	O
acute	O
elevation	O
in	O
blood	O
pressure	O
may	O
be	O
a	O
contributing	O
factor	O
.	O

Long-term	O
efficacy	O
and	O
toxicity	B-Disease
of	O
high-dose	O
amiodarone	B-Chemical
therapy	O
for	O
ventricular	B-Disease
tachycardia	I-Disease
or	O
ventricular	B-Disease
fibrillation	I-Disease
.	O

Amiodarone	B-Chemical
was	O
administered	O
to	O
154	O
patients	O
who	O
had	O
sustained	O
,	O
symptomatic	O
ventricular	B-Disease
tachycardia	I-Disease
(	O
VT	B-Disease
)	O
(	O
n	O
=	O
118	O
)	O
or	O
a	O
cardiac	B-Disease
arrest	I-Disease
(	O
n	O
=	O
36	O
)	O
and	O
who	O
were	O
refractory	O
to	O
conventional	O
antiarrhythmic	B-Drug
drugs	B-Drug
.	O

The	O
loading	O
dose	O
was	O
800	O
mg/day	O
for	O
6	O
weeks	O
and	O
the	O
maintenance	O
dose	O
was	O
600	O
mg/day	O
.	O

Sixty-nine	O
percent	O
of	O
patients	O
continued	O
treatment	O
with	O
amiodarone	B-Chemical
and	O
had	O
no	O
recurrence	O
of	O
symptomatic	O
VT	B-Disease
or	O
ventricular	B-Disease
fibrillation	I-Disease
(	O
VF	B-Disease
)	O
over	O
a	O
follow-up	O
of	O
6	O
to	O
52	O
months	O
(	O
mean	O
+/-	O
standard	O
deviation	O
14.2	O
+/-	O
8.2	O
)	O
.	O

Six	O
percent	O
of	O
the	O
patients	O
had	O
a	O
nonfatal	O
recurrence	O
of	O
VT	B-Disease
and	O
were	O
successfully	O
managed	O
by	O
continuing	O
amiodarone	B-Chemical
at	O
a	O
higher	O
dose	O
or	O
by	O
the	O
addition	O
of	O
a	O
conventional	O
antiarrhythmic	B-Drug
drug	B-Drug
.	O

One	O
or	O
more	O
adverse	O
drug	B-Drug
reactions	O
occurred	O
in	O
51	O
%	O
of	O
patients	O
.	O

Adverse	O
effects	O
forced	O
a	O
reduction	O
in	O
the	O
dose	O
of	O
amiodarone	B-Chemical
in	O
41	O
%	O
and	O
discontinuation	O
of	O
amiodarone	B-Chemical
in	O
10	O
%	O
of	O
patients	O
.	O

The	O
most	O
common	O
symptomatic	O
adverse	O
reactions	O
were	O
tremor	B-Disease
or	O
ataxia	B-Disease
(	O
35	O
%	O
)	O
,	O
nausea	B-Disease
and	O
anorexia	B-Disease
(	O
8	O
%	O
)	O
,	O
visual	B-Disease
halos	I-Disease
or	I-Disease
blurring	I-Disease
(	O
6	O
%	O
)	O
,	O
thyroid	B-Disease
function	I-Disease
abnormalities	I-Disease
(	O
6	O
%	O
)	O
and	O
pulmonary	B-Disease
interstitial	I-Disease
infiltrates	I-Disease
(	O
5	O
%	O
)	O
.	O

Although	O
large-dose	O
amiodarone	B-Chemical
is	O
highly	O
effective	O
in	O
the	O
long-term	O
treatment	O
of	O
VT	B-Disease
or	O
VF	B-Disease
refractory	O
to	O
conventional	O
antiarrhythmic	B-Drug
drugs	B-Drug
,	O
it	O
causes	O
significant	O
toxicity	B-Disease
in	O
approximately	O
50	O
%	O
of	O
patients	O
.	O

However	O
,	O
when	O
the	O
dose	O
is	O
adjusted	O
based	O
on	O
clinical	O
response	O
or	O
the	O
development	O
of	O
adverse	O
effects	O
,	O
75	O
%	O
of	O
patients	O
with	O
VT	B-Disease
or	O
VF	B-Disease
can	O
be	O
successfully	O
managed	O
with	O
amiodarone	B-Chemical
.	O

Effect	O
of	O
calcium	B-Chemical
chloride	I-Chemical
and	O
4-aminopyridine	B-Chemical
therapy	O
on	O
desipramine	B-Chemical
toxicity	B-Disease
in	O
rats	O
.	O

BACKGROUND	O
:	O
Hypotension	B-Disease
is	O
a	O
major	O
contributor	O
to	O
mortality	O
in	O
tricyclic	O
antidepressant	O
overdose	B-Disease
.	O

Recent	O
data	O
suggest	O
that	O
tricyclic	O
antidepressants	B-Drug
inhibit	O
calcium	B-Chemical
influx	O
in	O
some	O
tissues	O
.	O

This	O
study	O
addressed	O
the	O
potential	O
role	O
of	O
calcium	B-Chemical
channel	O
blockade	O
in	O
tricyclic	O
antidepressant-induced	O
hypotension	B-Disease
.	O

METHODS	O
:	O
Two	O
interventions	O
were	O
studied	O
that	O
have	O
been	O
shown	O
previously	O
to	O
improve	O
blood	O
pressure	O
with	O
calcium	B-Chemical
channel	O
blocker	O
overdose	B-Disease
.	O

CaCl2	B-Chemical
and	O
4-aminopyridine	B-Chemical
.	O

Anesthetized	O
rats	O
received	O
the	O
tricyclic	O
antidepressant	O
desipramine	B-Chemical
IP	O
to	O
produce	O
hypotension	B-Disease
,	O
QRS	O
prolongation	O
,	O
and	O
bradycardia	B-Disease
.	O

Fifteen	O
min	O
later	O
,	O
animals	O
received	O
CaCl2	B-Chemical
,	O
NaHCO3	B-Chemical
,	O
or	O
saline	O
.	O

In	O
a	O
second	O
experiment	O
,	O
rats	O
received	O
tricyclic	O
antidepressant	O
desipramine	B-Chemical
IP	O
followed	O
in	O
15	O
min	O
by	O
4-aminopyridine	B-Chemical
or	O
saline	O
.	O

RESULTS	O
:	O
NaHCO3	B-Chemical
briefly	O
(	O
5	O
min	O
)	O
reversed	O
hypotension	B-Disease
and	O
QRS	O
prolongation	O
.	O

CaCl2	B-Chemical
and	O
4-aminopyridine	B-Chemical
failed	O
to	O
improve	O
blood	O
pressure	O
.	O

The	O
incidence	O
of	O
ventricular	B-Disease
arrhythmias	I-Disease
(	O
p	O
=	O
0.004	O
)	O
and	O
seizures	B-Disease
(	O
p	O
=	O
0.03	O
)	O
in	O
the	O
CaCl2	B-Chemical
group	O
was	O
higher	O
than	O
the	O
other	O
groups	O
.	O

CONCLUSION	O
:	O
The	O
administration	O
of	O
CaCl2	B-Chemical
or	O
4-aminopyridine	B-Chemical
did	O
not	O
reverse	O
tricyclic	O
antidepressant-induced	O
hypotension	B-Disease
in	O
rats	O
.	O

CaCl2	B-Chemical
therapy	O
may	O
possibly	O
worsen	O
both	O
cardiovascular	B-Disease
and	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
toxicity	I-Disease
.	O

These	O
findings	O
do	O
not	O
support	O
a	O
role	O
for	O
calcium	B-Drug
channel	O
inhibition	O
in	O
the	O
pathogenesis	O
of	O
tricyclic	O
antidepressant-induced	O
hypotension	O
.	O

Phase	O
I	O
trial	O
of	O
13-cis-retinoic	B-Chemical
acid	I-Chemical
in	O
children	O
with	O
neuroblastoma	B-Disease
following	O
bone	O
marrow	O
transplantation	O
.	O

PURPOSE	O
:	O
Treatment	O
of	O
neuroblastoma	B-Disease
cell	O
lines	O
with	O
13-cis-retinoic	B-Chemical
acid	I-Chemical
(	O
cis-RA	B-Chemical
)	O
can	O
cause	O
sustained	O
inhibition	O
of	O
proliferation	O
.	O

Since	O
cis-RA	B-Chemical
has	O
demonstrated	O
clinical	O
responses	O
in	O
neuroblastoma	B-Disease
patients	O
,	O
it	O
may	O
be	O
effective	O
in	O
preventing	O
relapse	O
after	O
cytotoxic	O
therapy	O
.	O

This	O
phase	O
I	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
maximal-tolerated	O
dosage	O
(	O
MTD	O
)	O
,	O
toxicities	B-Disease
,	O
and	O
pharmacokinetics	O
of	O
cis-RA	B-Chemical
administered	O
on	O
an	O
intermittent	O
schedule	O
in	O
children	O
with	O
neuroblastoma	B-Disease
following	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Fifty-one	O
assessable	O
patients	O
,	O
2	O
to	O
12	O
years	O
of	O
age	O
,	O
were	O
treated	O
with	O
oral	O
cis-RA	B-Chemical
administered	O
in	O
two	O
equally	O
divided	O
doses	O
daily	O
for	O
2	O
weeks	O
,	O
followed	O
by	O
a	O
2-week	O
rest	O
period	O
,	O
for	O
up	O
to	O
12	O
courses	O
.	O

The	O
dose	O
was	O
escalated	O
from	O
100	O
to	O
200	O
mg/m2/d	O
until	O
dose-limiting	O
toxicity	B-Disease
(	O
DLT	O
)	O
was	O
observed	O
.	O

A	O
single	O
intrapatient	O
dose	O
escalation	O
was	O
permitted	O
.	O

RESULTS	O
:	O
The	O
MTD	O
of	O
cis-RA	B-Chemical
was	O
160	O
mg/m2/d	O
.	O

Dose-limiting	O
toxicities	B-Disease
in	O
six	O
of	O
nine	O
patients	O
at	O
200	O
mg/m2/d	O
included	O
hypercalcemia	B-Disease
(	O
n	O
=	O
3	O
)	O
,	O
rash	B-Disease
(	O
n	O
=	O
2	O
)	O
,	O
and	O
anemia/thrombocytopenia/emesis/rash	B-Disease
(	O
n	O
=	O
1	O
)	O
.	O

All	O
toxicities	O
resolved	O
after	O
cis-RA	O
was	O
discontinued	O
.	O

Three	O
complete	O
responses	O
were	O
observed	O
in	O
marrow	O
metastases	O
.	O

Serum	O
levels	O
of	O
7.4	O
+/-	O
3.0	O
mumol/L	O
(	O
peak	O
)	O
and	O
4.0	O
+/-	O
2.8	O
mumol/L	O
(	O
trough	O
)	O
at	O
the	O
MTD	O
were	O
maintained	O
during	O
14	O
days	O
of	O
therapy	O
.	O

The	O
DLT	O
correlated	O
with	O
serum	O
levels	O
>	O
or	O
=	O
10	O
mumol/L	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
of	O
cis-RA	O
given	O
on	O
this	O
intermittent	O
schedule	O
was	O
160	O
mg/m2/d	O
.	O

Serum	O
levels	O
known	O
to	O
be	O
effective	O
against	O
neuroblastoma	O
in	O
vitro	O
were	O
achieved	O
at	O
this	O
dose	O
.	O

The	O
DLT	O
included	O
hypercalcemia	O
,	O
and	O
may	O
be	O
predicted	O
by	O
serum	O
cis-RA	O
levels	O
.	O

Monitoring	O
of	O
serum	O
calcium	B-Drug
and	O
cis-RA	O
levels	O
is	O
indicated	O
in	O
future	O
trials	O
.	O

Effect	O
of	O
calcium	B-Chemical
chloride	I-Chemical
on	O
gross	O
behavioural	O
changes	O
produced	O
by	O
carbachol	B-Chemical
and	O
eserine	B-Chemical
in	O
cats	O
.	O

The	O
effect	O
of	O
calcium	B-Chemical
chloride	I-Chemical
injected	O
into	O
the	O
cerebral	O
ventricles	O
of	O
group-housed	O
unanaesthetized	O
cats	O
upon	O
vocalization	O
(	O
rage	O
,	O
hissing	O
and	O
snarling	O
)	O
,	O
fighting	O
(	O
attack	O
with	O
paws	O
and	O
claws	O
,	O
defense	O
with	O
paws	O
and	O
claws	O
and	O
biting	O
)	O
,	O
mydriasis	B-Disease
,	O
tremor	B-Disease
and	O
clonic-tonic	B-Disease
convulsions	I-Disease
produced	O
by	O
carbachol	B-Chemical
and	O
eserine	B-Chemical
injected	O
similarly	O
was	O
investigated	O
.	O

Calcium	B-Chemical
chloride	I-Chemical
depressed	O
or	O
almost	O
completely	O
abolished	O
the	O
vocalization	O
and	O
fighting	O
due	O
to	O
carbachol	B-Chemical
and	O
eserine	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
mydriasis	B-Disease
,	O
tremor	B-Disease
and	O
clonic-tonic	B-Disease
convulsions	I-Disease
evoked	O
by	O
carbachol	B-Chemical
and	O
eserine	B-Chemical
were	O
not	O
significantly	O
changed	O
by	O
calcium	B-Chemical
chloride	I-Chemical
.	O

It	O
is	O
apparent	O
that	O
calcium	B-Chemical
chloride	I-Chemical
can	O
``	O
dissociate	O
''	O
vocalization	O
and	O
fighting	O
from	O
autonomic	O
and	O
motor	O
phenomena	O
such	O
as	O
mydriasis	B-Disease
,	O
tremor	B-Disease
and	O
clonic-tonic	B-Disease
convulsions	I-Disease
caused	O
by	O
carbachol	B-Chemical
and	O
eserine	B-Chemical
.	O

Calcium	B-Chemical
chloride	I-Chemical
inhibited	O
the	O
vocalization	O
and	O
fighting	O
produced	O
by	O
carbachol	B-Chemical
and	O
eserine	B-Chemical
most	O
probably	O
by	O
a	O
nonspecific	O
stabilizing	O
action	O
on	O
central	O
muscarinic	O
cholinoceptive	O
sites	O
.	O

These	O
results	O
further	O
support	O
the	O
view	O
that	O
calcium	B-Chemical
ions	O
in	O
excess	O
have	O
an	O
atropine-like	B-Chemical
action	O
also	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Multiple	O
side	O
effects	O
of	O
penicillamine	B-Chemical
therapy	O
in	O
one	O
patient	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Skin	B-Disease
rashes	I-Disease
,	O
proteinuria	B-Disease
,	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
,	O
polymyositis	B-Disease
and	O
myasthenia	B-Disease
gravis	I-Disease
have	O
all	O
been	O
recorded	O
as	O
complications	O
of	O
penicillamine	B-Chemical
therapy	O
in	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

A	O
patient	O
who	O
had	O
developed	O
all	O
5	O
is	O
now	O
described	O
.	O

The	O
skin	B-Disease
lesion	I-Disease
resembled	O
elastosis	B-Disease
perforans	I-Disease
serpiginosa	I-Disease
,	O
which	O
has	O
been	O
reported	O
as	O
a	O
rare	O
side	O
effect	O
in	O
patients	O
with	O
Wilson	B-Disease
's	I-Disease
disease	I-Disease
but	O
not	O
in	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
treated	O
with	O
penicillamine	B-Chemical
.	O

Electrocardiographic	O
changes	O
and	O
cardiac	B-Disease
arrhythmias	I-Disease
in	O
patients	O
receiving	O
psychotropic	O
drugs	B-Drug
.	O

Eight	O
patients	O
had	O
cardiac	O
manifestations	O
that	O
were	O
life-threatening	O
in	O
five	O
while	O
taking	O
psychotropic	O
drugs	B-Drug
,	O
either	O
phenothiazines	B-Chemical
or	O
tricyclic	O
antidepressants	B-Drug
.	O

Although	O
most	O
patients	O
were	O
receiving	O
several	O
drugs	B-Drug
,	O
Mellaril	B-Chemical
(	O
thioridazine	B-Chemical
)	O
appeared	O
to	O
be	O
responsible	O
for	O
five	O
cases	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
,	O
one	O
of	O
which	O
was	O
fatal	O
in	O
a	O
35	O
year	O
old	O
woman	O
.	O

Supraventricular	B-Disease
tachycardia	I-Disease
developed	O
in	O
one	O
patient	O
receiving	O
Thorazine	B-Chemical
(	O
chlorpromazine	B-Chemical
)	O
.	O

Aventyl	B-Chemical
(	O
nortriptyline	B-Chemical
)	O
and	O
Elavil	B-Chemical
(	O
amitriptyline	B-Chemical
)	O
each	O
produced	O
left	B-Disease
bundle	I-Disease
branch	I-Disease
block	I-Disease
in	O
a	O
73	O
year	O
old	O
woman	O
.	O

Electrocardiographic	O
T	O
and	O
U	O
wave	O
abnormalities	O
were	O
present	O
in	O
most	O
patients	O
.	O

The	O
ventricular	B-Disease
arrhythmias	I-Disease
responded	O
to	O
intravenous	O
administration	O
of	O
lidocaine	B-Chemical
and	O
to	O
direct	O
current	O
electric	O
shock	O
;	O
ventricular	O
pacing	O
was	O
required	O
in	O
some	O
instances	O
and	O
intravenous	O
administration	O
of	O
propranolol	B-Chemical
combined	O
with	O
ventricular	O
pacing	O
in	O
one	O
.	O

The	O
tachyarrhythmias	B-Disease
generally	O
subsided	O
within	O
48	O
hours	O
after	O
administration	O
of	O
the	O
drugs	B-Drug
was	O
stopped	O
.	O

Five	O
of	O
the	O
eight	O
patients	O
were	O
50	O
years	O
of	O
age	O
or	O
younger	O
;	O
only	O
one	O
clearly	O
had	O
antecedent	O
heart	B-Disease
disease	I-Disease
.	O

Major	O
cardiac	B-Disease
arrhythmias	I-Disease
are	O
a	O
potential	O
hazard	O
in	O
patients	O
without	O
heart	B-Disease
disease	I-Disease
who	O
are	O
receiving	O
customary	O
therapeutic	O
doses	O
of	O
psychotropic	O
drugs	B-Drug
.	O

A	O
prospective	O
clinical	O
trial	O
is	O
suggested	O
to	O
quantify	O
the	O
risk	O
of	O
cardiac	B-Disease
complications	I-Disease
to	O
patients	O
receiving	O
phenothiazines	B-Chemical
or	O
tricyclic	O
antidepressant	O
drugs	B-Drug
.	O

Serotonergic	O
drugs	B-Drug
,	O
benzodiazepines	B-Chemical
and	O
baclofen	B-Chemical
block	O
muscimol-induced	B-Chemical
myoclonic	B-Disease
jerks	I-Disease
in	O
a	O
strain	O
of	O
mice	O
.	O

In	O
male	O
Swiss	O
mice	O
,	O
muscimol	B-Chemical
produced	O
myoclonic	B-Disease
jerks	I-Disease
.	O

A	O
3	O
mg/kg	O
(	O
i.p	O
.	O

)	O
dose	O
induced	O
this	O
response	O
in	O
all	O
of	O
the	O
mice	O
tested	O
and	O
the	O
peak	O
response	O
of	O
73	O
jerks	O
per	O
min	O
was	O
observed	O
between	O
27	O
and	O
45	O
min	O
.	O

Increasing	O
the	O
brain	O
serotonin	B-Chemical
levels	O
by	O
the	O
administration	O
of	O
5-hydroxytryptophan	B-Chemical
(	O
80-160	O
mg/kg	O
)	O
in	O
combination	O
with	O
a	O
peripheral	O
decarboxylase	O
inhibitor	O
resulted	O
in	O
an	O
inhibition	O
of	O
the	O
muscimol	B-Chemical
effect	O
.	O

However	O
,	O
in	O
a	O
similar	O
experiment	O
l-dopa	B-Chemical
(	O
80-160	O
mg/kg	O
)	O
was	O
without	O
effect	O
.	O

In	O
doses	O
of	O
3-10	O
mg/kg	O
,	O
the	O
serotonin	B-Chemical
receptor	O
agonist	O
MK-212	B-Chemical
caused	O
a	O
dose-dependent	O
blockade	O
of	O
the	O
response	O
of	O
muscimol	B-Chemical
.	O

Of	O
the	O
benzodiazepines	B-Chemical
,	O
clonazepam	B-Chemical
(	O
0.1-0.3	O
mg/kg	O
)	O
was	O
found	O
to	O
be	O
several	O
fold	O
more	O
potent	O
than	O
diazepam	B-Chemical
(	O
0.3-3	O
mg/kg	O
)	O
in	O
blocking	O
the	O
myoclonic	B-Disease
jerks	I-Disease
.	O

While	O
(	O
-	O
)	O
-baclofen	B-Chemical
(	O
1-3	O
mg/kg	O
)	O
proved	O
to	O
be	O
an	O
effective	O
antagonist	O
of	O
muscimol	B-Chemical
,	O
its	O
(	O
+	O
)	O
-isomer	O
(	O
5-20	O
mg/kg	O
)	O
lacked	O
this	O
property	O
.	O

Considering	O
the	O
fact	O
that	O
5-HTP	B-Chemical
and	O
the	O
benzodiazepines	B-Chemical
have	O
been	O
found	O
to	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
clinical	O
myoclonus	B-Disease
,	O
the	O
muscimol-induced	B-Chemical
myoclonus	B-Disease
seems	O
to	O
be	O
a	O
satisfactory	O
animal	O
model	O
that	O
may	O
prove	O
useful	O
for	O
the	O
development	O
of	O
new	O
drug	B-Drug
treatments	O
for	O
this	O
condition	O
.	O

Our	O
present	O
study	O
indicated	O
the	O
possible	O
value	O
of	O
MK-212	B-Chemical
and	O
(	O
-	O
)	O
-baclofen	B-Chemical
in	O
the	O
management	O
of	O
clinical	O
myoclonus	B-Disease
.	O

Hyperglycemic	B-Disease
acidotic	I-Disease
coma	I-Disease
and	O
death	O
in	O
Kearns-Sayre	O
syndrome	O
.	O

This	O
paper	O
presents	O
the	O
clinical	O
and	O
metabolic	O
findings	O
in	O
two	O
young	O
boys	O
with	O
long-standing	O
Kearns-Sayre	B-Disease
syndrome	I-Disease
.	O

Following	O
short	O
exposure	O
to	O
oral	O
prednisone	B-Chemical
,	O
both	O
boys	O
developed	O
lethargy	B-Disease
,	O
increasing	O
somnolence	B-Disease
,	O
polydipsia	B-Disease
,	O
polyphagia	B-Disease
,	O
and	O
polyuria	B-Disease
.	O

Both	O
presented	O
in	O
the	O
emergency	O
room	O
with	O
profound	O
coma	B-Disease
,	O
hypotension	B-Disease
,	O
severe	O
hyperglycemia	B-Disease
,	O
and	O
acidosis	B-Disease
.	O

Nonketotic	O
lactic	B-Disease
acidosis	I-Disease
was	O
present	O
in	O
one	O
and	O
ketosis	B-Disease
without	O
a	O
known	O
serum	O
lactate	B-Chemical
level	O
was	O
present	O
in	O
the	O
other	O
.	O

Respiratory	B-Disease
failure	I-Disease
rapidly	O
ensued	O
and	O
both	O
patients	O
expired	O
in	O
spite	O
of	O
efforts	O
at	O
resuscitation	O
.	O

We	O
believe	O
these	O
two	O
cases	O
represent	O
a	O
newly	O
described	O
and	O
catastrophic	O
metabolic-endocrine	B-Disease
failure	I-Disease
in	O
the	O
Kearns-Sayre	B-Disease
syndrome	I-Disease
.	O

Effects	O
of	O
active	O
constituents	O
of	O
Crocus	O
sativus	O
L.	O
,	O
crocin	B-Chemical
on	O
streptozocin-induced	B-Chemical
model	O
of	O
sporadic	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
in	O
male	O
rats	O
.	O

BACKGROUND	O
:	O
The	O
involvement	O
of	O
water-soluble	O
carotenoids	B-Chemical
,	O
crocins	B-Chemical
,	O
as	O
the	O
main	O
and	O
active	O
components	O
of	O
Crocus	O
sativus	O
L.	O
extract	O
in	O
learning	O
and	O
memory	O
processes	O
has	O
been	O
proposed	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
crocins	B-Chemical
on	O
sporadic	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
induced	O
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	B-Chemical
(	O
STZ	B-Chemical
)	O
in	O
male	O
rats	O
was	O
investigated	O
.	O

METHODS	O
:	O
Male	O
adult	O
Wistar	O
rats	O
(	O
n	O
=	O
90	O
and	O
260-290	O
g	O
)	O
were	O
divided	O
into	O
1	O
,	O
control	O
;	O
2	O
and	O
3	O
,	O
crocins	B-Chemical
(	O
15	O
and	O
30	O
mg/kg	O
)	O
;	O
4	O
,	O
STZ	B-Chemical
;	O
5	O
and	O
6	O
,	O
STZ	B-Chemical
+	O
crocins	B-Chemical
(	O
15	O
and	O
30	O
mg/kg	O
)	O
groups	O
.	O

In	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
groups	O
,	O
rats	O
were	O
injected	O
with	O
STZ-icv	B-Chemical
bilaterally	O
(	O
3	O
mg/kg	O
)	O
in	O
first	O
day	O
and	O
3	O
days	O
later	O
,	O
a	O
similar	O
STZ-icv	B-Chemical
application	O
was	O
repeated	O
.	O

In	O
STZ	B-Chemical
+	O
crocin	B-Chemical
animal	O
groups	O
,	O
crocin	B-Chemical
was	O
applied	O
in	O
doses	O
of	O
15	O
and	O
30	O
mg/kg	O
,	O
i.p.	O
,	O
one	O
day	O
pre-surgery	O
and	O
continued	O
for	O
three	O
weeks	O
.	O

Prescription	O
of	O
crocin	B-Chemical
in	O
each	O
dose	O
was	O
repeated	O
once	O
for	O
two	O
days	O
.	O

However	O
,	O
the	O
learning	O
and	O
memory	O
performance	O
was	O
assessed	O
using	O
passive	O
avoidance	O
paradigm	O
,	O
and	O
for	O
spatial	O
cognition	O
evaluation	O
,	O
Y-maze	O
task	O
was	O
used	O
.	O

RESULTS	O
:	O
It	O
was	O
found	O
out	O
that	O
crocin	B-Chemical
(	O
30	O
mg/kg	O
)	O
-treated	O
STZ-injected	B-Chemical
rats	O
show	O
higher	O
correct	O
choices	O
and	O
lower	O
errors	O
in	O
Y-maze	O
than	O
vehicle-treated	O
STZ-injected	B-Chemical
rats	O
.	O

In	O
addition	O
,	O
crocin	B-Chemical
in	O
the	O
mentioned	O
dose	O
could	O
significantly	O
attenuated	O
learning	B-Disease
and	I-Disease
memory	I-Disease
impairment	I-Disease
in	O
treated	O
STZ-injected	O
group	O
in	O
passive	O
avoidance	O
test	O
.	O

CONCLUSION	O
:	O
Therefore	O
,	O
these	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
crocin	O
(	O
30	O
mg/kg	O
)	O
in	O
antagonizing	O
the	O
cognitive	O
deficits	O
caused	O
by	O
STZ-icv	O
in	O
rats	O
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases	O
such	O
as	O
Alzheimer	O
's	O
disease	O
.	O

Rosaceiform	O
dermatitis	B-Disease
associated	O
with	O
topical	O
tacrolimus	B-Chemical
treatment	O
.	O

We	O
describe	O
herein	O
3	O
patients	O
who	O
developed	O
rosacea-like	B-Disease
dermatitis	B-Disease
eruptions	B-Disease
while	O
using	O
0.03	O
%	O
or	O
0.1	O
%	O
tacrolimus	B-Chemical
ointment	O
for	O
facial	B-Disease
dermatitis	I-Disease
.	O

Skin	O
biopsy	O
specimens	O
showed	O
telangiectasia	B-Disease
and	O
noncaseating	O
epithelioid	O
granulomatous	O
tissue	O
formation	O
in	O
the	O
papillary	O
to	O
mid	O
dermis	O
.	O

Continuous	O
topical	O
use	O
of	O
immunomodulators	O
such	O
as	O
tacrolimus	B-Chemical
or	O
pimecrolimus	B-Chemical
should	O
be	O
regarded	O
as	O
a	O
potential	O
cause	O
of	O
rosaceiform	O
dermatitis	B-Disease
,	O
although	O
many	O
cases	O
have	O
not	O
been	O
reported	O
.	O

A	O
novel	O
animal	O
model	O
to	O
evaluate	O
the	O
ability	O
of	O
a	O
drug	B-Drug
delivery	O
system	O
to	O
promote	O
the	O
passage	O
through	O
the	O
BBB	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
explore	O
the	O
potentiality	O
of	O
a	O
novel	O
animal	O
model	O
to	O
be	O
used	O
for	O
the	O
in	O
vivo	O
evaluation	O
of	O
the	O
ability	O
of	O
a	O
drug	B-Drug
delivery	O
system	O
to	O
promote	O
the	O
passage	O
through	O
the	O
blood-brain	O
barrier	O
(	O
BBB	O
)	O
and/or	O
to	O
improve	O
the	O
brain	O
localization	O
of	O
a	O
bioactive	O
compound	O
.	O

A	O
Tween	O
80-coated	O
poly-L-lactid	B-Chemical
acid	I-Chemical
nanoparticles	O
was	O
used	O
as	O
a	O
model	O
of	O
colloidal	O
drug	B-Drug
delivery	O
system	O
,	O
able	O
to	O
trespass	O
the	O
BBB	O
.	O

Tacrine	B-Chemical
,	O
administered	O
in	O
LiCl	B-Chemical
pre-treated	O
rats	O
,	O
induces	O
electrocorticographic	O
seizures	B-Disease
and	O
delayed	O
hippocampal	B-Disease
damage	I-Disease
.	O

The	O
toxic	O
effects	O
of	O
tacrine-loaded	B-Chemical
poly-L-lactid	B-Chemical
acid	I-Chemical
nanoparticles	O
(	O
5mg/kg	O
)	O
,	O
a	O
saline	O
solution	O
of	O
tacrine	B-Chemical
(	O
5mg/kg	O
)	O
and	O
an	O
empty	O
colloidal	O
nanoparticle	O
suspension	O
were	O
compared	O
following	O
i.p	O
.	O

administration	O
in	O
LiCl-pre-treated	B-Chemical
Wistar	O
rats	O
.	O

All	O
the	O
animals	O
treated	O
with	O
tacrine-loaded	B-Chemical
nanoparticles	O
showed	O
an	O
earlier	O
outcome	O
of	O
CNS	O
adverse	O
symptoms	O
,	O
i.e	O
.	O

epileptic	B-Disease
onset	O
,	O
with	O
respect	O
to	O
those	O
animals	O
treated	O
with	O
the	O
free	O
compound	O
(	O
10	O
min	O
vs.	O
22	O
min	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
tacrine-loaded	B-Chemical
nanoparticles	O
administration	O
induced	O
damage	B-Disease
of	I-Disease
neuronal	I-Disease
cells	I-Disease
in	O
CA1	O
field	O
of	O
the	O
hippocampus	O
in	O
all	O
treated	O
animals	O
,	O
while	O
the	O
saline	O
solution	O
of	O
tacrine	B-Chemical
only	O
in	O
60	O
%	O
of	O
animals	O
.	O

Empty	O
nanoparticles	O
provided	O
similar	O
results	O
to	O
control	O
(	O
saline-treated	O
)	O
group	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
the	O
evaluation	O
of	O
time-to-onset	O
of	O
symptoms	O
and	O
the	O
severity	O
of	O
neurodegenerative	O
processes	O
induced	O
by	O
the	O
tacrine-lithium	B-Chemical
model	O
of	O
epilepsy	O
in	O
the	O
rat	O
,	O
could	O
be	O
used	O
to	O
evaluate	O
preliminarily	O
the	O
capability	O
of	O
a	O
drug	B-Drug
delivery	O
system	O
to	O
trespass	O
(	O
or	O
not	O
)	O
the	O
BBB	O
in	O
vivo	O
.	O

The	O
antiarrhythmic	B-Drug
effect	O
and	O
possible	O
ionic	O
mechanisms	O
of	O
pilocarpine	B-Chemical
on	O
animal	O
models	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
pilocarpine	B-Chemical
and	O
explore	O
the	O
underlying	O
ionic	O
mechanism	O
,	O
using	O
both	O
aconitine-induced	B-Chemical
rat	O
and	O
ouabain-induced	B-Chemical
guinea	O
pig	O
arrhythmia	B-Disease
models	O
.	O

Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free-calcium	B-Chemical
concentrations	O
(	O
[	O
Ca	B-Chemical
(	O
2+	O
)	O
]	O
(	O
i	O
)	O
)	O
in	O
isolated	O
myocytes	O
.	O

The	O
current	O
data	O
showed	O
that	O
pilocarpine	B-Chemical
significantly	O
delayed	O
onset	O
of	O
arrhythmias	B-Disease
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
and	I-Disease
fibrillation	I-Disease
,	O
reduced	O
arrhythmia	O
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	O
rats	O
and	O
guinea	O
pigs	O
.	O

[	O
Ca	O
(	O
2+	O
)	O
]	O
(	O
i	O
)	O
overload	O
induced	O
by	O
aconitine	O
or	O
ouabain	B-Drug
was	O
reduced	O
in	O
isolated	O
myocytes	O
pretreated	O
with	O
pilocarpine	B-Drug
.	O

Moreover	O
,	O
M	O
(	O
3	O
)	O
-muscarinic	O
acetylcholine	O
receptor	O
(	O
mAChR	O
)	O
antagonist	O
4-DAMP	O
(	O
4-diphenylacetoxy-N-methylpiperidine-methiodide	O
)	O
partially	O
abolished	O
the	O
beneficial	O
effects	O
of	O
pilocarpine	B-Drug
.	O

These	O
data	O
suggest	O
that	O
pilocarpine	B-Drug
produced	O
antiarrhythmic	B-Drug
actions	O
on	O
arrhythmic	O
rat	O
and	O
guinea	O
pig	O
models	O
induced	O
by	O
aconitine	O
or	O
ouabain	B-Drug
via	O
stimulating	O
the	O
cardiac	O
M	O
(	O
3	O
)	O
-mAChR	O
.	O

The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
improvement	O
of	O
Ca	O
(	O
2+	O
)	O
handling	O
.	O

Disulfiram-induced	B-Chemical
transient	O
optic	B-Disease
and	I-Disease
peripheral	I-Disease
neuropathy	I-Disease
:	O
a	O
case	O
report	O
.	O

AIM	O
:	O
To	O
report	O
a	O
case	O
of	O
optic	B-Disease
and	I-Disease
peripheral	I-Disease
neuropathy	I-Disease
after	O
chronic	O
use	O
of	O
disulfiram	B-Drug
for	O
alcohol	B-Drug
dependence	O
management	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
case	O
report	O
.	O

RESULTS	O
:	O
A	O
57-year-old	O
male	O
presented	O
with	O
gradual	O
loss	O
of	O
vision	O
in	O
both	O
eyes	O
with	O
intermittent	O
headaches	O
for	O
2	O
months	O
.	O

He	O
also	O
complained	O
of	O
paraesthesia	O
with	O
numbness	O
in	O
both	O
feet	O
.	O

His	O
vision	O
was	O
6/15	O
and	O
2/60	O
in	O
the	O
right	O
and	O
left	O
eyes	O
,	O
respectively	O
.	O

Fundoscopy	O
revealed	O
bilaterally	O
swollen	O
optic	B-Chemical
nerve	O
heads	O
.	O

Visual	O
field	O
testing	O
confirmed	O
bilateral	O
central-caecal	O
scotomata	O
.	O

He	O
had	O
been	O
taking	O
disulfiram	B-Drug
for	O
alcohol	B-Drug
dependence	O
for	O
the	O
preceding	O
3	O
years	O
.	O

Disulfiram	B-Drug
discontinuation	O
lead	B-Drug
to	O
an	O
immediate	O
symptomatic	O
improvement	O
.	O

CONCLUSION	O
:	O
Physicians	O
initiating	O
long-term	O
disulfiram	B-Drug
therapy	O
should	O
be	O
aware	O
of	O
these	O
adverse	O
effects	O
.	O

They	O
should	O
recommend	O
annual	O
ophthalmic	O
reviews	O
with	O
visual	O
field	O
testing	O
.	O

Patients	O
should	O
be	O
reassured	O
with	O
respect	O
to	O
the	O
reversibility	O
of	O
these	O
adverse	O
effects	O
.	O

Sustained	O
clinical	O
improvement	O
of	O
a	O
patient	O
with	O
decompensated	O
hepatitis	B-Disease
B	I-Disease
virus-related	O
cirrhosis	B-Disease
after	O
treatment	O
with	O
lamivudine	B-Chemical
monotherapy	O
.	O

Hepatitis	B-Disease
B	I-Disease
virus	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infection	I-Disease
,	O
which	O
causes	O
liver	B-Disease
cirrhosis	I-Disease
and	O
hepatocellular	B-Disease
carcinoma	I-Disease
,	O
remains	O
a	O
major	O
health	O
problem	O
in	O
Asian	O
countries	O
.	O

Recent	O
development	O
of	O
vaccine	O
for	O
prevention	O
is	O
reported	O
to	O
be	O
successful	O
in	O
reducing	O
the	O
size	O
of	O
chronically	O
infected	O
carriers	O
,	O
although	O
the	O
standard	O
medical	O
therapies	O
have	O
not	O
been	O
established	O
up	O
to	O
now	O
.	O

In	O
this	O
report	O
,	O
we	O
encountered	O
a	O
patient	O
with	O
decompensated	O
HBV-related	O
cirrhosis	B-Disease
who	O
exhibited	O
the	O
dramatic	O
improvements	O
after	O
antiviral	O
therapy	O
.	O

The	O
patient	O
was	O
a	O
50-year-old	O
woman	O
.	O

Previous	O
conventional	O
medical	O
treatments	O
were	O
not	O
effective	O
for	O
this	O
patient	O
,	O
thus	O
this	O
patient	O
had	O
been	O
referred	O
to	O
our	O
hospital	O
.	O

However	O
,	O
the	O
administration	O
of	O
lamivudine	B-Chemical
,	O
a	O
reverse	O
transcriptase	O
inhibitor	O
,	O
for	O
23	O
months	O
dramatically	O
improved	O
her	O
liver	O
severity	O
.	O

During	O
this	O
period	O
,	O
no	O
drug	B-Drug
resistant	O
mutant	O
HBV	O
emerged	O
,	O
and	I-Chemical
the	O
serum	O
HBV-DNA	O
level	O
was	O
continuously	O
suppressed	O
.	O

These	O
virological	O
responses	O
were	O
also	O
maintained	O
even	O
after	O
the	O
antiviral	O
therapy	O
was	O
discontinued	O
.	O

Moreover	O
,	O
both	O
hepatitis	B-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
and	I-Chemical
e	B-Chemical
antigen	I-Chemical
were	O
observed	O
to	O
have	O
disappeared	O
in	O
this	O
patient	O
.	O

The	O
administration	O
of	O
lamivudine	B-Drug
to	O
patients	O
with	O
HBV-related	O
cirrhosis	O
,	O
like	O
our	O
present	O
case	O
,	O
should	O
be	O
considered	O
as	O
an	O
initial	O
medical	O
therapeutic	O
option	O
,	O
especially	O
in	O
countries	O
where	O
liver	O
transplantation	O
is	O
not	O
reliably	O
available	O
.	O

Dual	O
effects	O
of	O
melatonin	B-Chemical
on	O
barbiturate-induced	B-Chemical
narcosis	B-Disease
in	O
rats	O
.	O

Melatonin	B-Chemical
affects	O
the	O
circadian	O
sleep/wake	O
cycle	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
it	O
may	O
influence	O
drug-induced	O
narcosis	B-Disease
.	O

Sodium	B-Chemical
thiopenthal	I-Chemical
was	O
administered	O
intraperitoneally	O
into	O
male	O
rats	O
pre-treated	O
with	O
melatonin	B-Chemical
(	O
0.05	O
,	O
0.5	O
,	O
5	O
and	O
50	O
mg/kg	O
)	O
.	O

Melatonin	B-Chemical
pre-treatment	O
affected	O
in	O
a	O
dual	O
manner	O
barbiturate	B-Chemical
narcosis	B-Disease
,	O
however	O
,	O
no	O
dose-effect	O
correlation	O
was	O
found	O
.	O

In	O
particular	O
,	O
low	O
doses	O
reduced	O
the	O
latency	O
to	O
and	O
prolonged	O
the	O
duration	O
of	O
barbiturate	B-Chemical
narcosis	B-Disease
.	O

In	O
contrast	O
,	O
the	O
highest	O
dose	O
of	O
melatonin	B-Chemical
(	O
50	O
mg/kg	O
)	O
caused	O
a	O
paradoxical	O
increase	O
in	O
the	O
latency	O
and	O
produced	O
a	O
sustained	O
reduction	O
of	O
the	O
duration	O
of	O
narcosis	B-Disease
,	O
and	O
a	O
reduction	O
in	O
mortality	O
rate	O
.	O

Melatonin	B-Chemical
0.5	O
and	O
5	O
mg/kg	O
influenced	O
the	O
duration	O
but	O
not	O
the	O
latency	O
of	O
ketamine-	B-Chemical
or	O
diazepam-induced	B-Chemical
narcosis	B-Disease
.	O

Thus	O
,	O
the	O
dual	O
action	O
of	O
melatonin	B-Chemical
on	O
pharmacological	O
narcosis	B-Disease
seems	O
to	O
be	O
specific	O
for	O
the	O
barbiturate	B-Chemical
mechanism	O
of	O
action	O
.	O

Effects	O
of	O
NIK-247	B-Chemical
on	O
cholinesterase	O
and	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
.	O

The	O
effects	O
of	O
NIK-247	B-Chemical
on	O
cholinesterase	O
,	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
and	O
spontaneous	O
movement	O
were	O
examined	O
and	O
compared	O
with	O
those	O
of	O
the	O
well-known	O
cholinesterase	O
inhibitors	O
tacrine	B-Chemical
and	O
E-2020	B-Chemical
.	O

NIK-247	B-Chemical
,	O
tacrine	B-Chemical
and	O
E-2020	B-Chemical
all	O
strongly	O
inhibited	O
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
human	O
red	O
blood	O
cells	O
(	O
IC50s	O
=	O
1.0	O
x	O
10	O
(	O
-6	O
)	O
,	O
2.9	O
x	O
10	O
(	O
-7	O
)	O
and	O
3.7	O
x	O
10	O
(	O
-8	O
)	O
M	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
NIK-247	B-Chemical
and	O
tacrine	B-Chemical
,	O
but	O
not	O
E-2020	B-Chemical
,	O
strongly	O
inhibited	O
butyrylcholinestrase	O
(	O
BuChE	O
)	O
in	O
human	O
serum	O
.	O

All	O
three	O
drugs	B-Drug
produced	O
mixed	O
inhibition	O
of	O
AChE	O
activity	O
.	O

Moreover	O
,	O
the	O
inhibitory	O
effect	O
of	O
NIK-247	B-Chemical
on	O
AChE	O
was	O
reversible	O
.	O

All	O
compounds	O
at	O
0.1-1	O
mg/kg	O
p.o	O
.	O

significantly	O
improved	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
0.5	O
mg/kg	O
s.c.	O
)	O
in	O
rats	O
performing	O
a	O
passive	O
avoidance	O
task	O
.	O

The	O
three	O
compounds	O
at	O
1	O
and	O
3	O
mg/kg	O
p.o	O
.	O

did	O
not	O
significantly	O
decrease	O
spontaneous	O
movement	O
by	O
rats	O
.	O

These	O
findings	O
suggest	O
that	O
NIK-247	B-Chemical
at	O
a	O
low	O
dose	O
(	O
0.1-1	O
mg/kg	O
p.o	O
.	O

)	O
improves	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
but	O
does	O
not	O
affect	O
spontaneous	O
movement	O
.	O

The	O
findings	O
suggest	O
that	O
NIK-247	B-Chemical
may	O
be	O
a	O
useful	O
drug	B-Drug
for	O
the	O
treatment	O
of	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

Nightmares	O
and	O
hallucinations	B-Disease
after	O
long-term	O
intake	O
of	O
tramadol	B-Chemical
combined	O
with	O
antidepressants	B-Drug
.	O

Tramadol	B-Chemical
is	O
a	O
weak	O
opioid	O
with	O
effects	O
on	O
adrenergic	O
and	O
serotonergic	O
neurotransmission	O
that	O
is	O
used	O
to	O
treat	O
cancer	B-Disease
pain	B-Disease
and	O
chronic	O
non	O
malignant	O
pain	B-Disease
.	O

This	O
drug	B-Drug
was	O
initiated	O
in	O
association	O
with	O
paroxetine	B-Chemical
and	O
dosulepine	B-Chemical
hydrochloride	I-Chemical
in	O
a	O
tetraparetic	B-Disease
patient	O
with	O
chronic	B-Disease
pain	I-Disease
.	O

Fifty-six	O
days	O
after	O
initiation	O
of	O
the	O
treatment	O
the	O
patient	O
presented	O
hallucinations	B-Disease
that	O
only	O
stopped	O
after	O
the	O
withdrawal	O
of	O
psycho-active	O
drugs	B-Drug
and	O
tramadol	B-Chemical
.	O

The	O
case	O
report	O
questions	O
the	O
long	O
term	O
use	O
of	O
pain	B-Disease
killers	O
combined	O
with	O
psycho-active	O
drugs	B-Drug
in	O
chronic	O
non	O
malignant	O
pain	B-Disease
,	O
especially	O
if	O
pain	B-Disease
is	O
under	O
control	O
.	O

Apparent	O
cure	O
of	O
rheumatoid	B-Disease
arthritis	I-Disease
by	O
bone	O
marrow	O
transplantation	O
.	O

We	O
describe	O
the	O
induction	O
of	O
sustained	O
remissions	O
and	O
possible	O
cure	O
of	O
severe	O
erosive	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
by	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
2	O
patients	O
.	O

BMT	O
was	O
used	O
to	O
treat	O
severe	O
aplastic	B-Disease
anemia	I-Disease
which	O
was	O
caused	O
by	O
gold	B-Chemical
in	O
one	O
case	O
and	O
D-penicillamine	B-Chemical
in	O
the	O
other	O
.	O

In	O
the	O
8	O
and	O
6	O
years	O
since	O
the	O
transplants	O
(	O
representing	O
8	O
and	O
4	O
years	O
since	O
cessation	O
of	O
all	O
immunosuppressive	O
therapy	O
,	O
respectively	O
)	O
,	O
the	O
RA	B-Disease
in	O
each	O
case	O
has	O
been	O
completely	O
quiescent	O
.	O

Although	O
short	O
term	O
remission	O
of	O
severe	O
RA	B-Disease
following	O
BMT	O
has	O
been	O
reported	O
,	O
these	O
are	O
the	O
first	O
cases	O
for	O
which	O
prolonged	O
followup	O
has	O
been	O
available	O
.	O

This	O
experience	O
raises	O
the	O
question	O
of	O
the	O
role	O
of	O
BMT	O
itself	O
as	O
a	O
therapeutic	O
option	O
for	O
patients	O
with	O
uncontrolled	O
destructive	O
synovitis	B-Disease
.	O

Urinary	O
enzymes	O
and	O
protein	O
patterns	O
as	O
indicators	O
of	I-Disease
injury	B-Disease
to	I-Disease
different	I-Disease
regions	I-Disease
of	I-Disease
the	I-Disease
kidney	O
.	O

Acute	B-Disease
experimental	I-Disease
models	I-Disease
of	I-Disease
renal	I-Disease
damage	I-Disease
to	O
the	O
proximal	O
tubular	O
,	O
glomerular	O
,	O
and	O
papillary	O
regions	O
of	O
the	O
rat	O
were	O
produced	O
by	O
administration	O
of	O
hexachloro-1:3-butadiene	B-Chemical
(	O
HCBD	B-Chemical
)	O
,	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
,	O
and	O
2-bromoethylamine	B-Chemical
(	O
BEA	B-Chemical
)	O
,	O
respectively	O
.	O

Several	O
routine	O
indicators	O
of	O
nephrotoxicity	B-Disease
,	O
the	O
enzymes	O
alkaline	O
phosphatase	O
and	O
N-acetyl-beta-glucosaminidase	O
,	O
and	O
the	O
molecular	O
weight	O
of	O
protein	B-Disease
excretion	I-Disease
were	O
determined	O
on	O
urine	O
samples	O
.	O

Tubular	O
damage	O
produced	O
by	O
HCBD	B-Chemical
or	O
BEA	B-Chemical
was	O
discriminated	O
both	O
quantitatively	O
and	O
qualitatively	O
from	O
glomerular	B-Disease
damage	I-Disease
produced	O
by	O
PAN	B-Chemical
.	O

The	O
latter	O
was	O
characterized	O
by	O
a	O
pronounced	O
increase	O
in	O
protein	B-Disease
excretion	I-Disease
,	O
especially	O
proteins	B-Disease
with	O
molecular	O
weight	O
greater	O
than	O
40,000	O
Da	O
.	O

In	O
contrast	O
,	O
protein	B-Disease
excretion	B-Disease
in	O
tubular	O
damage	O
was	O
raised	O
only	O
slightly	O
and	O
characterized	O
by	O
excretion	B-Disease
of	I-Disease
proteins	O
of	O
a	O
wide	O
range	O
of	O
molecular	O
weights	O
.	O

Proximal	O
tubular	O
damage	O
caused	O
by	O
HCBD	B-Chemical
and	O
papillary	O
damage	O
caused	O
by	O
BEA	B-Chemical
were	O
distinguished	O
both	O
by	O
conventional	O
urinalysis	O
(	O
volume	O
and	O
specific	O
gravity	O
)	O
and	O
by	O
measurement	O
of	O
the	O
two	O
urinary	O
enzymes	O
.	O

Alkaline	O
phosphatase	O
and	O
glucose	B-Chemical
were	O
markedly	O
and	O
transiently	O
elevated	O
in	O
proximal	O
tubular	O
damage	I-Disease
and	O
N-acetyl-beta-glucosaminidase	O
showed	O
a	O
sustained	O
elevation	O
in	O
papillary	O
damage	I-Disease
.	O

It	O
is	O
concluded	O
that	O
both	O
selective	O
urinary	O
enzymes	O
and	O
the	O
molecular	O
weight	O
pattern	O
of	O
urinary	O
proteins	O
can	O
be	O
used	O
to	O
provide	O
diagnostic	O
information	O
about	O
the	O
possible	O
site	O
of	O
renal	O
damage	O
.	O

Neuromuscular	B-Disease
blockade	I-Disease
with	O
magnesium	B-Chemical
sulfate	I-Chemical
and	O
nifedipine	B-Chemical
.	O

A	O
patient	O
who	O
received	O
tocolysis	O
with	O
nifedipine	B-Chemical
developed	O
neuromuscular	B-Disease
blockade	I-Disease
after	O
500	O
mg	O
of	O
magnesium	B-Chemical
sulfate	I-Chemical
was	O
administered	O
.	O

This	O
reaction	O
demonstrates	O
that	O
nifedipine	B-Chemical
can	O
seriously	O
potentiate	O
the	O
toxicity	B-Disease
of	O
magnesium	B-Chemical
.	O

Caution	O
should	O
be	O
exercised	O
when	O
these	O
two	O
tocolytics	O
are	O
combined	O
.	O

Ifosfamide	B-Chemical
continuous	O
infusion	O
without	O
mesna	B-Chemical
.	O

A	O
phase	O
I	O
trial	O
of	O
a	O
14-day	O
cycle	O
.	O

Twenty	O
patients	O
received	O
27	O
courses	O
of	O
ifosfamide	B-Chemical
administered	O
as	O
a	O
24-hour	O
continuous	O
infusion	O
for	O
14	O
days	O
without	O
Mesna	B-Chemical
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
deliver	O
a	O
dose	O
rate	O
and	O
total	O
cumulative	O
dose	O
of	O
ifosfamide	B-Chemical
that	O
would	O
be	O
comparable	O
to	O
standard	O
bolus	O
or	O
short-term	O
infusions	O
administered	O
with	O
Mesna	B-Chemical
.	O

Dose	O
escalations	O
proceeded	O
from	O
200	O
to	O
300	O
,	O
400	O
,	O
450	O
,	O
500	O
,	O
and	O
550	O
mg/m2/d	O
.	O

Four	O
patients	O
developed	O
transient	O
microscopic	O
hematuria	B-Disease
at	O
400	O
,	O
450	O
,	O
and	O
500	O
mg/m2/d	O
.	O

There	O
were	O
no	O
instances	O
of	O
macroscopic	O
hematuria	B-Disease
.	O

At	O
550	O
mg/m2/d	O
,	O
three	O
patients	O
experienced	O
nonurologic	O
toxicity	B-Disease
;	O
confusion	B-Disease
(	O
1	O
)	O
,	O
nausea	B-Disease
(	O
1	O
)	O
,	O
and	O
Grade	O
2	O
leukopenia	B-Disease
(	O
1	O
)	O
.	O

The	O
recommended	O
dose	O
of	O
500	O
mg/m2/d	O
delivers	O
a	O
total	O
dose	O
of	O
7	O
g/m2	O
per	O
cycle	O
,	O
which	O
is	O
comparable	O
to	O
that	O
delivered	O
in	O
clinical	O
practice	O
for	O
bolus	O
or	O
short-term	O
infusion	O
.	O

Because	O
few	O
patients	O
received	O
multiple	O
courses	O
over	O
time	O
,	O
the	O
cumulative	O
effects	O
are	O
indeterminate	O
in	O
the	O
present	O
trial	O
.	O

The	O
frequency	O
and	O
predictability	O
of	O
hematuria	B-Disease
are	O
not	O
precise	O
,	O
and	O
at	O
least	O
daily	O
monitoring	O
by	O
urine	O
Hematest	O
is	O
essential	O
,	O
adding	O
Mesna	B-Chemical
to	O
the	O
infusate	O
in	O
patients	O
with	O
persistent	O
hematuria	B-Disease
.	O

The	O
protracted	O
infusion	O
schedule	O
for	O
ifosfamide	B-Chemical
permits	O
convenient	O
outpatient	O
administration	O
without	O
Mesna	B-Chemical
and	O
reduces	O
the	O
drug	B-Drug
cost	O
of	O
clinical	O
usage	O
of	O
this	O
agent	O
by	O
up	O
to	O
890	O
per	O
cycle	O
.	O

Clinical	O
activity	O
was	O
demonstrated	O
in	O
a	O
single	O
patient	O
,	O
but	O
a	O
comparative	O
trial	O
of	O
standard	O
bolus	O
schedules	O
with	O
the	O
protracted	O
infusion	O
schedule	O
will	O
be	O
necessary	O
to	O
determine	O
if	O
the	O
clinical	O
effectiveness	O
of	O
the	O
drug	B-Drug
is	O
maintained	O
.	O

Myocardial	B-Disease
infarction	I-Disease
in	O
pregnancy	O
associated	O
with	O
clomiphene	B-Chemical
citrate	I-Chemical
for	O
ovulation	O
induction	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Clomiphene	B-Chemical
citrate	I-Chemical
(	O
CC	B-Chemical
)	O
is	O
commonly	O
prescribed	O
for	O
ovulation	O
induction	O
.	O

It	O
is	O
considered	O
safe	O
,	O
with	O
minimal	O
side	O
effects	O
.	O

Thromboembolism	B-Disease
is	O
a	O
rare	O
but	O
life-threatening	O
complication	O
that	O
has	O
been	O
reported	O
after	O
ovulation	O
induction	O
with	O
CC	B-Chemical
.	O

Spontaneous	O
coronary	B-Disease
thrombosis	I-Disease
or	O
thromboembolism	B-Disease
with	O
subsequent	O
clot	O
lysis	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
during	O
pregnancy	O
,	O
with	O
a	O
subsequently	O
normal	O
coronary	O
angiogram	O
.	O

CASE	O
:	O
A	O
33-year-old	O
woman	O
with	O
a	O
5-week	O
gestation	O
had	O
recently	O
received	O
CC	B-Chemical
for	O
ovulation	O
induction	O
and	O
presented	O
with	O
chest	B-Disease
pain	I-Disease
.	O

An	O
electrocardiogram	O
showed	O
a	O
lateral	O
and	O
anterior	O
wall	O
myocardial	B-Disease
infarction	I-Disease
.	O

Cardiac	O
enzymes	O
showed	O
a	O
peak	O
rise	O
in	O
troponin	O
I	O
to	O
9.10	O
ng/mL	O
.	O

An	O
initial	O
exercise	O
stress	O
test	O
was	O
normal	O
.	O

At	O
the	O
time	O
of	O
admission	O
,	O
the	O
patient	O
was	O
at	O
high	O
risk	O
of	O
radiation	B-Disease
injury	I-Disease
to	O
the	O
fetus	O
,	O
so	O
a	O
coronary	O
angiogram	O
was	O
postponed	O
until	O
the	O
second	O
trimester	O
.	O

It	O
showed	O
normal	O
coronary	O
vessels	O
.	O

CONCLUSION	O
:	O
This	O
appears	O
to	O
be	O
the	O
first	O
reported	O
case	O
documenting	O
a	O
possible	O
association	O
between	O
CC	B-Chemical
and	O
myocardial	B-Disease
infarction	I-Disease
.	O

Thrombosis	B-Disease
might	O
be	O
a	O
rare	O
but	O
hazardous	O
complication	O
of	O
CC	B-Chemical
.	O

Given	O
this	O
life-threatening	O
complication	O
,	O
appropriate	O
prophylactic	O
measures	O
should	O
be	O
used	O
in	O
high-risk	O
woman	O
undergoing	O
ovarian	O
stimulation	O
.	O

Hepatonecrosis	B-Disease
and	O
cholangitis	B-Disease
related	O
to	O
long-term	O
phenobarbital	B-Chemical
therapy	O
:	O
an	O
autopsy	O
report	O
of	O
two	O
patients	O
.	O

Phenobarbital	B-Chemical
(	O
PB	B-Chemical
)	O
has	O
a	O
reputation	O
for	O
safety	O
,	O
and	O
it	O
is	O
commonly	O
believed	O
that	O
PB-related	B-Chemical
increases	O
in	O
serum	O
aminotransferase	O
levels	O
do	O
not	O
indicate	O
or	O
predict	O
the	O
development	O
of	O
significant	O
chronic	O
liver	B-Disease
disease	I-Disease
.	O

Here	O
we	O
report	O
of	O
two	O
adult	O
patients	O
with	O
a	O
long	O
history	O
of	O
epilepsy	B-Disease
treated	O
with	O
PB	B-Chemical
who	O
died	O
suddenly	O
:	O
one	O
as	O
consequence	O
of	O
cardiac	B-Disease
arrest	I-Disease
,	O
the	O
other	O
of	O
acute	O
bronchopneumonia	B-Disease
.	O

At	O
autopsy	O
,	O
analysis	O
of	O
liver	O
parenchyma	O
revealed	O
rich	O
portal	O
inflammatory	O
infiltrate	O
,	O
which	O
consisted	O
of	O
mixed	O
eosinophil	O
and	O
monocyte	O
cells	O
,	O
associated	O
with	O
several	O
foci	O
of	O
necrosis	B-Disease
surrounded	O
by	O
a	O
hard	O
ring	O
of	O
non-specific	O
granulomatous	O
tissue	O
.	O

Inflammatory	O
reactions	O
of	O
internal	O
and	O
external	O
hepatic	O
biliary	O
ducts	O
were	O
also	O
seen	O
.	O

Our	O
findings	O
illustrate	O
that	O
PB	B-Chemical
may	O
be	O
associated	O
with	O
chronic	O
liver	B-Disease
damage	I-Disease
,	O
which	O
may	O
lead	B-Drug
to	O
more	O
serious	O
and	O
deleterious	O
consequences	O
.	O

For	O
this	O
reason	O
,	O
each	O
clinician	O
should	O
recognize	O
this	O
entity	O
in	O
the	O
differential	O
diagnosis	O
of	O
PB-related	B-Chemical
asymptomatic	O
chronic	B-Disease
hepatic	I-Disease
enzyme	I-Disease
dysfunction	I-Disease
.	O

Ethambutol-associated	B-Chemical
optic	B-Disease
neuropathy	I-Disease
.	O

INTRODUCTION	O
:	O
Ethambutol	B-Chemical
is	O
used	O
in	O
the	O
treatment	O
of	O
tuberculosis	B-Disease
,	O
which	O
is	O
still	O
prevalent	O
in	O
Southeast	O
Asia	O
,	O
and	O
can	O
be	O
associated	O
with	O
permanent	O
visual	B-Disease
loss	I-Disease
.	O

We	O
report	O
3	O
cases	O
which	O
presented	O
with	O
bitemporal	B-Disease
hemianopia	I-Disease
.	O

CLINICAL	O
PICTURE	O
:	O
Three	O
patients	O
with	O
ethambutol-associated	B-Chemical
toxic	O
optic	B-Disease
neuropathy	I-Disease
are	O
described	O
.	O

All	O
3	O
patients	O
had	O
loss	B-Disease
of	I-Disease
central	I-Disease
visual	I-Disease
acuity	I-Disease
,	I-Disease
colour	I-Disease
vision	I-Disease
(	I-Disease
Ishihara	I-Disease
)	I-Disease
and	I-Disease
visual	I-Disease
field	I-Disease
.	O

The	O
visual	B-Disease
field	I-Disease
loss	I-Disease
had	O
a	O
bitemporal	O
flavour	O
,	O
suggesting	O
involvement	O
of	O
the	O
optic	O
chiasm	O
.	O

TREATMENT	O
:	O
Despite	O
stopping	O
ethambutol	B-Chemical
on	O
diagnosis	O
,	O
visual	I-Disease
function	I-Disease
continued	O
to	O
deteriorate	O
for	O
a	O
few	O
months	O
.	O

Subsequent	O
improvement	O
was	O
mild	O
in	O
2	O
cases	O
.	O

In	O
the	O
third	O
case	O
,	O
visual	I-Disease
acuity	O
and	O
colour	O
vision	O
normalised	O
but	O
the	O
optic	O
discs	O
were	O
pale	O
.	O

OUTCOME	O
:	O
All	O
3	O
patients	O
had	O
some	O
permanent	O
loss	B-Disease
of	O
visual	O
function	O
.	O

CONCLUSIONS	O
:	O
Ethambutol	B-Chemical
usage	O
is	O
associated	O
with	O
permanent	O
visual	B-Disease
loss	I-Disease
and	O
should	O
be	O
avoided	O
if	O
possible	O
or	O
used	O
with	O
caution	O
and	O
proper	O
ophthalmological	O
follow-up	O
.	O

The	O
author	O
postulates	O
that	O
in	O
cases	O
of	O
ethambutol	B-Chemical
associated	O
chiasmopathy	O
,	O
ethambutol	B-Chemical
may	O
initially	O
affect	O
the	O
optic	O
nerves	O
and	O
subsequently	O
progress	O
to	O
involve	O
the	O
optic	O
chiasm	O
.	O

Tolerability	O
of	O
nimesulide	B-Chemical
and	O
paracetamol	B-Chemical
in	O
patients	O
with	O
NSAID-induced	B-Chemical
urticaria/angioedema	B-Disease
.	O

Previous	O
studies	O
evaluated	O
the	O
tolerance	O
of	O
nimesulide	B-Chemical
and	O
paracetamol	B-Chemical
in	O
subjects	O
with	O
cutaneous	O
,	O
respiratory	O
and	O
anaphylactoid	O
reactions	O
induced	O
by	O
nonsteroidal	B-Chemical
anti-inflammatory	I-Chemical
drugs	I-Chemical
(	O
NSAIDs	B-Chemical
)	O
.	O

In	O
this	O
study	O
we	O
investigated	O
tolerability	O
and	O
reliability	O
of	O
nimesulide	B-Chemical
and	O
paracetamol	B-Chemical
in	O
a	O
very	O
large	O
number	O
of	O
patients	O
with	O
an	O
exclusive	O
well-documented	O
history	O
of	O
NSAID-induced	B-Chemical
urticaria/angioedema	B-Disease
.	O

Furthermore	O
,	O
we	O
evaluated	O
whether	O
some	O
factors	O
have	O
the	O
potential	O
to	O
increase	O
the	O
risk	O
of	O
reaction	O
to	O
paracetamol	O
and	O
nimesulide	O
.	O

A	O
single-placebo-controlled	O
oral	O
challenge	O
procedure	O
with	O
nimesulide	O
or	O
paracetamol	O
was	O
applied	O
to	O
829	O
patients	O
with	O
a	O
history	O
of	O
NSAID-induced	O
urticaria/angioedema	B-Disease
.	O

A	O
total	O
of	O
75/829	O
(	O
9.4	O
%	O
)	O
patients	O
experienced	O
reactions	O
to	O
nimesulide	O
or	O
paracetamol	B-Chemical
.	O

Of	O
the	O
715	O
patients	O
tested	O
with	O
nimesulide	B-Chemical
62	O
(	O
8.6	O
%	O
)	O
showed	O
a	O
positive	O
test	O
,	O
while	O
of	O
114	O
subjects	O
submitted	O
to	O
the	O
challenge	O
with	O
paracetamol	O
,	O
13	O
(	O
9.6	O
%	O
)	O
did	O
not	O
tolerate	O
this	O
drug	B-Drug
.	O

Furthermore	O
,	O
18.28	O
%	O
of	O
patients	O
with	O
a	O
history	O
of	O
chronic	O
urticaria	O
and	O
11.8	O
%	O
of	O
subjects	O
with	O
an	O
history	O
of	O
NSAID-induced	O
urticaria/angioedema	O
or	O
angioedema	O
alone	O
(	O
with	O
or	O
without	O
chronic	O
urticaria	O
)	O
resulted	O
to	O
be	O
intolerant	O
to	O
alternative	O
drugs	B-Drug
.	O

Taken	O
together	O
,	O
our	O
results	O
confirm	O
the	O
good	O
tolerability	O
of	O
nimesulide	B-Chemical
and	O
paracetamol	B-Chemical
in	O
patients	O
who	O
experienced	O
urticaria/angioedema	O
caused	O
by	O
NSAIDs	B-Chemical
.	O

However	O
,	O
the	O
risk	O
of	O
reaction	O
to	O
these	O
alternative	O
study	O
drugs	B-Drug
is	O
statistically	O
increased	O
by	O
a	O
history	O
of	O
chronic	O
urticaria	B-Disease
and	O
,	O
above	O
all	O
,	O
by	O
a	O
history	O
of	O
NSAID-induced	O
angioedema	B-Disease
.	O

Effects	O
of	O
verapamil	B-Chemical
on	O
atrial	B-Disease
fibrillation	I-Disease
and	O
its	O
electrophysiological	O
determinants	O
in	O
dogs	O
.	O

BACKGROUND	O
:	O
Atrial	B-Disease
tachycardia-induced	O
remodeling	O
promotes	O
the	O
occurrence	O
and	O
maintenance	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
and	O
decreases	O
L-type	O
Ca	O
(	O
2+	O
)	O
current	O
.	O

There	O
is	O
also	O
a	O
clinical	O
suggestion	O
that	O
acute	O
L-type	O
Ca	O
(	O
2	O
)	O
channel	O
blockade	O
can	O
promote	O
AF	O
,	O
consistent	O
with	O
an	O
AF	O
promoting	O
effect	O
of	O
Ca	O
(	O
2+	O
)	O
channel	O
inhibition	O
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
potential	O
mechanisms	O
of	O
AF	O
promotion	O
by	O
Ca	O
(	O
2+	O
)	O
channel	O
blockers	O
,	O
we	O
administered	O
verapamil	B-Drug
to	O
morphine-chloralose	O
anesthetized	O
dogs	O
.	O

Diltiazem	B-Drug
was	O
used	O
as	O
a	O
comparison	O
drug	B-Drug
and	O
autonomic	O
blockade	O
with	O
atropine	B-Drug
and	O
nadolol	B-Drug
was	O
applied	O
in	O
some	O
experiments	O
.	O

Epicardial	O
mapping	O
with	O
240	O
epicardial	O
electrodes	O
was	O
used	O
to	O
evaluate	O
activation	O
during	O
AF	O
.	O

RESULTS	O
:	O
Verapamil	B-Drug
caused	O
AF	O
promotion	O
in	O
six	O
dogs	O
,	O
increasing	O
mean	O
duration	O
of	O
AF	O
induced	O
by	O
burst	O
pacing	O
,	O
from	O
8+/-4	O
s	O
(	O
mean+/-S.E	O
.	O

)	O
to	O
95+/-39	O
s	O
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
at	O
a	O
loading	O
dose	O
of	O
0.1	O
mg/kg	O
and	O
228+/-101	O
s	O
(	O
P	O
<	O
0.0005	O
vs.	O
control	O
)	O
at	O
a	O
dose	O
of	O
0.2	O
mg/kg	O
.	O

Underlying	O
electrophysiological	O
mechanisms	O
were	O
studied	O
in	O
detail	O
in	O
five	O
additional	O
dogs	O
under	O
control	O
conditions	O
and	O
in	O
the	O
presence	O
of	O
the	O
higher	O
dose	O
of	O
verapamil	B-Drug
.	O

In	O
these	O
experiments	O
,	O
verapamil	B-Drug
shortened	O
mean	O
effective	O
refractory	O
period	O
(	O
ERP	O
)	O
from	O
122+/-5	O
to	O
114+/-4	O
ms	O
(	O
P	O
<	O
0.02	O
)	O
at	O
a	O
cycle	O
length	O
of	O
300	O
ms	O
,	O
decreased	O
ERP	O
heterogeneity	O
(	O
from	O
15+/-1	O
to	O
10+/-1	O
%	O
,	O
P	O
<	O
0.05	O
)	O
,	O
heterogeneously	O
accelerated	O
atrial	O
conduction	O
and	O
decreased	O
the	O
cycle	O
length	O
of	O
AF	O
(	O
94+/-4	O
to	O
84+/-3	O
ms	O
,	O
P	O
<	O
0.005	O
)	O
.	O

Diltiazem	B-Drug
did	O
not	O
affect	O
ERP	O
,	O
AF	O
cycle	O
length	O
or	O
AF	O
duration	O
,	O
but	O
produced	O
conduction	O
acceleration	O
similar	O
to	O
that	O
caused	O
by	O
verapamil	B-Drug
(	O
n=5	O
)	O
.	O

In	O
the	O
presence	O
of	O
autonomic	O
blockade	O
,	O
verapamil	B-Drug
failed	O
to	O
promote	O
AF	O
and	O
increased	O
,	O
rather	O
than	O
decreasing	O
,	O
refractoriness	O
.	O

Neither	O
verapamil	B-Drug
nor	O
diltiazem	B-Drug
affected	O
atrial	O
conduction	O
in	O
the	O
presence	O
of	O
autonomic	O
blockade	O
.	O

Epicardial	O
mapping	O
suggested	O
that	O
verapamil	B-Drug
promoted	O
AF	O
by	O
increasing	O
the	O
number	O
of	O
simultaneous	O
wavefronts	O
reflected	O
by	O
separate	O
zones	O
of	O
reactivation	O
in	O
each	O
cycle	O
.	O

CONCLUSIONS	O
:	O
Verapamil	B-Drug
promotes	O
AF	O
in	O
normal	O
dogs	O
by	O
promoting	O
multiple	O
circuit	O
reentry	O
,	O
an	O
effect	O
dependent	O
on	O
intact	O
autonomic	O
tone	O
and	O
not	O
shared	O
by	O
diltiazem	B-Drug
.	O

Hypotension	B-Disease
,	O
bradycardia	B-Disease
,	O
and	O
asystole	B-Disease
after	O
high-dose	O
intravenous	O
methylprednisolone	B-Chemical
in	O
a	O
monitored	O
patient	O
.	O

We	O
report	O
a	O
case	O
of	O
hypotension	B-Disease
,	O
bradycardia	B-Disease
,	O
and	O
asystole	B-Disease
after	O
intravenous	O
administration	O
of	O
high-dose	O
methylprednisolone	B-Chemical
in	O
a	O
73-year-old	O
patient	O
who	O
underwent	O
electrocardiographic	O
(	O
ECG	O
)	O
monitoring	O
throughout	O
the	O
episode	O
.	O

There	O
was	O
a	O
history	O
of	O
ischemic	B-Disease
cardiac	B-Disease
disease	I-Disease
9	O
years	O
earlier	O
.	O

The	O
patient	O
was	O
admitted	O
with	O
a	O
pulmonary-renal	B-Disease
syndrome	I-Disease
with	O
hemoptysis	B-Disease
,	O
rapidly	O
progressive	O
renal	B-Disease
failure	I-Disease
,	O
and	O
hypoxemia	B-Disease
that	O
required	O
mechanical	O
ventilation	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

After	O
receiving	O
advanced	O
cardiopulmonary	O
resuscitation	O
,	O
the	O
patient	O
recovered	O
cardiac	O
rhythm	O
.	O

The	O
ECG	O
showed	O
a	O
junctional	O
rhythm	O
without	O
ventricular	B-Disease
arrhythmia	I-Disease
.	O

This	O
study	O
reviews	O
the	O
current	O
proposed	O
mechanisms	O
of	O
sudden	B-Disease
death	I-Disease
after	O
a	O
high	O
dose	O
of	O
intravenous	O
methylprednisolone	B-Chemical
(	O
IVMP	B-Chemical
)	O
.	O

These	O
mechanisms	O
are	O
not	O
well	O
understood	O
because	O
,	O
in	O
most	O
cases	O
,	O
the	O
patients	O
were	O
not	O
monitored	O
at	O
the	O
moment	O
of	O
the	O
event	O
.	O

Rapid	O
infusion	O
and	O
underlying	O
cardiac	B-Disease
disease	I-Disease
were	O
important	O
risk	O
factors	O
in	O
the	O
case	O
reported	O
here	O
,	O
and	O
the	O
authors	O
discount	O
ventricular	B-Disease
arrhythmia	I-Disease
as	O
the	O
main	O
mechanism	O
.	O

Lifetime	O
treatment	O
of	O
mice	O
with	O
azidothymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
produces	O
myelodysplasia	B-Disease
.	O

AZT	B-Chemical
has	O
induced	O
a	O
macrocytic	B-Disease
anemia	I-Disease
in	O
AIDS	B-Disease
patients	O
on	O
long	O
term	O
AZT	B-Chemical
therapy	O
.	O

It	O
is	O
generally	O
assumed	O
that	O
DNA	O
elongation	O
is	O
stopped	O
by	O
the	O
insertion	O
of	O
AZT	B-Chemical
into	O
the	O
chain	O
in	O
place	O
of	O
thymidine	B-Chemical
thus	O
preventing	O
the	O
phosphate	B-Chemical
hydroxyl	O
linkages	O
and	O
therefore	O
suppresses	O
hemopoietic	O
progenitor	O
cell	O
proliferation	O
in	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O

CBA/Ca	O
male	O
mice	O
started	O
on	O
AZT	B-Chemical
0.75	O
mg/ml	O
H2O	O
at	O
84	O
days	O
of	O
age	O
and	O
kept	O
on	O
it	O
for	O
687	O
days	O
when	O
dosage	O
reduced	O
to	O
0.5	O
mg/ml	O
H2O	O
for	O
a	O
group	O
,	O
another	O
group	O
removed	O
from	O
AZT	B-Chemical
to	O
see	O
recovery	O
,	O
and	O
third	O
group	O
remained	O
on	O
0.75	O
mg.	O
At	O
687	O
days	O
mice	O
that	O
had	O
been	O
on	O
0.75	O
mg	O
had	O
average	O
platelet	O
counts	O
of	O
2.5	O
x	O
10	O
(	O
6	O
)	O
.	O

Histological	O
examination	O
on	O
9	O
of	O
10	O
mice	O
with	O
such	O
thrombocytopenia	B-Disease
showed	O
changes	O
compatible	O
with	O
myelodysplastic	B-Disease
syndrome	I-Disease
(	O
MDS	B-Disease
)	O
.	O

A	O
variety	O
of	O
histological	O
patterns	O
was	O
observed	O
.	O

There	O
were	O
two	O
cases	O
of	O
hypocellular	O
myelodysplasia	B-Disease
,	O
two	O
cases	O
of	O
hypersegmented	O
myelodysplastic	B-Disease
granulocytosis	O
,	O
two	O
cases	O
of	O
hypercellular	O
marrow	I-Disease
with	O
abnormal	O
megakaryocytes	O
with	O
bizarre	O
nuclei	O
,	O
one	O
case	O
of	O
megakaryocytic	O
myelosis	O
associated	O
with	O
a	O
hyperplastic	B-Disease
marrow	O
,	O
dysmyelopoiesis	B-Disease
and	O
a	O
hypocellular	B-Disease
marrow	I-Disease
and	O
two	O
cases	O
of	O
myelodysplasia	B-Disease
with	O
dyserythropoiesis	B-Disease
,	O
hemosiderosis	B-Disease
and	O
a	O
hypocellular	B-Disease
marrow	I-Disease
.	O

Above	O
mentioned	O
AZT	B-Chemical
incorporation	O
may	O
have	O
induced	O
an	O
ineffective	O
hemopoiesis	O
in	O
the	O
primitive	O
hemopoietic	O
progenitor	O
cells	O
,	O
which	O
is	O
known	O
to	O
be	O
seen	O
commonly	O
in	O
the	O
myelodysplastic	B-Disease
syndrome	I-Disease
.	O

Influence	O
of	O
diet	O
free	O
of	O
NAD-precursors	B-Chemical
on	O
acetaminophen	B-Chemical
hepatotoxicity	B-Disease
in	O
mice	O
.	O

Recently	O
,	O
we	O
demonstrated	O
the	O
hepatoprotective	O
effects	O
of	O
nicotinic	B-Chemical
acid	I-Chemical
amide	I-Chemical
,	O
a	O
selective	O
inhibitor	O
of	O
poly	B-Chemical
(	I-Chemical
ADP-ribose	I-Chemical
)	I-Chemical
polymerase	O
(	O
PARP	O
;	O
EC	O
2.4.2.30	O
)	O
on	O
mice	O
suffering	O
from	O
acetaminophen	B-Chemical
(	O
AAP	B-Chemical
)	O
-hepatitis	B-Disease
,	O
suggesting	O
that	O
the	O
AAP-induced	B-Chemical
liver	B-Disease
injury	I-Disease
involves	O
a	O
step	O
which	O
depends	O
on	O
adenoribosylation	O
.	O

The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	B-Chemical
,	O
the	O
substrate	O
on	O
which	O
PARP	O
acts	O
,	O
in	O
female	O
NMRI	O
mice	O
with	O
AAP	B-Chemical
hepatitis	B-Disease
and	O
evaluates	O
the	O
influence	O
of	O
simultaneous	O
ethanol	B-Chemical
consumption	O
in	O
these	O
animals	O
.	O

Liver	B-Disease
injuries	I-Disease
were	O
quantified	O
as	O
serum	O
activities	O
of	O
glutamate-oxaloacetate	B-Chemical
transaminase	O
(	O
GOT	O
)	O
and	O
glutamate-pyruvate	O
transaminase	O
(	O
GPT	O
)	O
.	O

While	O
AAP	O
caused	O
a	O
117-fold	O
elevation	O
of	O
serum	O
transaminase	O
activities	O
in	O
mice	O
kept	O
on	O
a	O
standard	O
laboratory	O
diet	O
,	O
which	O
was	O
significantly	O
exacerbated	O
by	O
ethanol	B-Drug
and	O
inhibited	O
by	O
nicotinic	O
acid	O
amide	O
(	O
NAA	O
)	O
,	O
adverse	O
effects	O
were	O
noted	O
in	O
animals	O
fed	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	O
.	O

In	O
these	O
animals	O
,	O
only	O
minor	O
increases	O
of	O
serum	O
transaminase	O
activities	O
were	O
measured	O
in	O
the	O
presence	O
of	O
AAP	O
,	O
and	O
unlike	O
the	O
exacerbation	O
caused	O
by	O
ethanol	B-Drug
in	O
mice	O
on	O
a	O
standard	O
diet	O
,	O
the	O
liver	O
damage	O
was	O
inhibited	O
by	O
50	O
%	O
by	O
ethanol	B-Drug
.	O

A	O
further	O
64	O
%	O
reduction	O
of	O
hepatitis	O
was	O
observed	O
,	O
when	O
NAA	O
was	O
given	O
to	O
ethanol/AAP-mice	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
AAP-induced	O
hepatitis	O
and	O
its	O
exacerbation	O
by	O
ethanol	B-Drug
can	O
either	O
be	O
reduced	O
by	O
end-product	O
inhibition	O
of	O
PARP	O
by	O
NAA	O
or	O
by	O
dietary	O
depletion	O
of	O
the	O
enzyme	O
's	O
substrate	O
NAD	O
.	O

We	O
see	O
the	O
main	O
application	O
of	O
NAA	O
as	O
for	O
the	O
combinational	O
use	O
in	O
pharmaceutical	O
preparations	O
of	O
acetaminophen	B-Drug
in	O
order	O
to	O
avoid	O
hepatic	O
damage	O
in	O
patients	O
treated	O
with	O
this	O
widely	O
used	O
analgesic	O
.	O

Antiarrhythmic	B-Drug
plasma	O
concentrations	O
of	O
cibenzoline	B-Chemical
on	O
canine	O
ventricular	B-Disease
arrhythmias	I-Disease
.	O

Using	O
two-stage	O
coronary	O
ligation-	O
,	O
digitalis-	B-Chemical
,	O
and	O
adrenaline-induced	B-Chemical
canine	O
ventricular	B-Disease
arrhythmias	I-Disease
,	O
antiarrhythmic	B-Drug
effects	O
of	O
cibenzoline	B-Chemical
were	O
examined	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentration	O
for	O
each	O
arrhythmia	B-Disease
model	O
was	O
determined	O
.	O

Cibenzoline	B-Chemical
suppressed	O
all	O
the	O
arrhythmias	B-Disease
,	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentrations	O
for	O
arrhythmias	B-Disease
induced	O
by	O
24-h	O
coronary	O
ligation	O
,	O
48-h	O
coronary	O
ligation	O
,	O
digitalis	B-Chemical
,	O
and	O
adrenaline	B-Chemical
were	O
1.9	O
+/-	O
0.9	O
(	O
by	O
8	O
mg/kg	O
i.v	O
.	O

)	O
,	O
1.6	O
+/-	O
0.5	O
(	O
by	O
8	O
mg/kg	O
i.v	O
.	O

)	O
,	O
0.6	O
+/-	O
0.2	O
(	O
by	O
2	O
mg/kg	O
i.v	O
.	O

)	O
,	O
and	O
3.5	O
+/-	O
1.3	O
(	O
by	O
5	O
mg/kg	O
i.v	O
.	O

)	O
micrograms/ml	O
,	O
respectively	O
(	O
mean	O
+/-	O
SDM	O
,	O
n	O
=	O
6-7	O
)	O
.	O

The	O
concentration	O
for	O
adrenaline-induced	B-Chemical
arrhythmia	B-Disease
was	O
significantly	O
higher	O
than	O
those	O
for	O
the	O
other	O
types	O
of	O
arrhythmias	B-Disease
.	O

This	O
pharmacological	O
profile	O
is	O
similar	O
to	O
those	O
of	O
mexiletine	B-Chemical
and	O
tocainide	B-Chemical
,	O
and	O
all	O
three	O
drugs	B-Drug
have	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
stimulant	O
action	O
.	O

Because	O
cibenzoline	B-Chemical
had	O
only	O
weak	O
hypotensive	B-Disease
and	O
sinus	O
node	O
depressive	B-Disease
effects	O
and	O
was	O
found	O
to	O
be	O
orally	O
active	O
when	O
given	O
to	O
coronary	O
ligation	O
arrhythmia	B-Disease
dogs	O
,	O
its	O
clinical	O
usefulness	O
is	O
expected	O
.	O

Immunopathology	O
of	O
penicillamine-induced	B-Chemical
glomerular	B-Disease
disease	I-Disease
.	O

Four	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
developed	O
heavy	O
proteinuria	B-Disease
after	O
five	O
to	O
12	O
months	O
of	O
treatment	O
with	O
D-penicillamine	B-Chemical
.	O

Light	O
microscopy	O
of	O
renal	O
biopsy	O
samples	O
showed	O
minimal	O
glomerular	O
capillary	O
wall	O
thickening	O
and	O
mesangial	O
matrix	O
increase	O
,	O
or	O
no	O
departure	O
from	O
normal	O
.	O

Electron	O
microscopy	O
,	O
however	O
,	O
revealed	O
subepithelial	O
electron-dense	O
deposits	O
,	O
fusion	O
of	O
epithelial	O
cell	O
foot	O
processes	O
,	O
and	O
evidence	O
of	O
mesangial	O
cell	O
hyperactivity	O
.	O

Immunofluorescence	O
microscopy	O
demonstrated	O
granular	O
capillary	O
wall	O
deposits	O
of	O
IgG	O
and	O
C3	O
.	O

The	O
findings	O
were	O
similar	O
to	O
those	O
in	O
early	O
membranous	B-Disease
glomerulonephritis	I-Disease
,	O
differences	O
being	O
observed	O
however	O
in	O
the	O
results	O
of	O
staining	O
for	O
the	O
early-acting	O
complement	O
components	O
C1q	O
and	O
C4	O
.	O

It	O
is	O
tentatively	O
concluded	O
that	O
complement	O
was	O
activated	O
by	O
the	O
classical	O
pathway	O
.	O

Ventricular	B-Disease
fibrillation	I-Disease
from	O
diatrizoate	B-Chemical
with	O
and	O
without	O
chelating	O
agents	O
.	O

The	O
toxicity	B-Disease
of	O
Renografin	B-Chemical
76	I-Chemical
%	I-Chemical
was	O
compared	O
with	O
that	O
of	O
Hypaque	B-Chemical
76	I-Chemical
%	I-Chemical
by	O
selective	O
injection	O
of	O
each	O
into	O
the	O
right	O
coronary	O
artery	O
of	O
dogs	O
.	O

Renografin	B-Chemical
contains	O
the	O
chelating	O
agents	O
sodium	B-Chemical
citrate	I-Chemical
and	O
disodium	B-Chemical
edetate	I-Chemical
,	O
while	O
Hypaque	B-Chemical
contains	O
calcium	B-Chemical
disodium	I-Chemical
edetate	I-Chemical
and	O
no	O
sodium	B-Chemical
citrate	I-Chemical
.	O

Ventricular	B-Disease
fibrillation	I-Disease
occurred	O
significantly	O
more	O
often	O
with	O
Renografin	B-Chemical
,	O
suggesting	O
that	O
chelating	O
agents	O
contribute	O
to	O
toxicity	B-Disease
in	O
coronary	O
angiography	O
.	O

Rapid	O
reversal	O
of	O
anticoagulation	O
reduces	O
hemorrhage	B-Disease
volume	O
in	O
a	O
mouse	O
model	O
of	O
warfarin-associated	B-Chemical
intracerebral	B-Disease
hemorrhage	I-Disease
.	O

Warfarin-associated	B-Chemical
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
W-ICH	B-Disease
)	O
is	O
a	O
severe	O
type	O
of	O
stroke	B-Disease
.	O

There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	O
treatment	O
for	O
W-ICH	B-Disease
.	O

Using	O
a	O
mouse	O
model	O
,	O
we	O
tested	O
whether	O
the	O
rapid	O
reversal	O
of	O
anticoagulation	O
using	O
human	O
prothrombin	B-Chemical
complex	I-Chemical
concentrate	I-Chemical
(	O
PCC	B-Chemical
)	O
can	O
reduce	O
hemorrhagic	O
blood	O
volume	O
.	O

Male	O
CD-1	O
mice	O
were	O
treated	O
with	O
warfarin	B-Chemical
(	O
2	O
mg/kg	O
over	O
24	O
h	O
)	O
,	O
resulting	O
in	O
a	O
mean	O
(	O
+/-s.d	O
.	O

)	O
International	O
Normalized	O
Ratio	O
of	O
3.5+/-0.9	O
.	O

First	O
,	O
we	O
showed	O
that	O
an	O
intravenous	O
administration	O
of	O
human	O
PCC	B-Chemical
rapidly	O
reversed	O
anticoagulation	O
in	O
mice	O
.	O

Second	O
,	O
a	O
stereotactic	O
injection	O
of	O
collagenase	O
was	O
administered	O
to	O
induce	O
hemorrhage	B-Disease
in	O
the	O
right	O
striatum	O
.	O

Forty-five	O
minutes	O
later	O
,	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	B-Chemical
(	O
100	O
U/kg	O
)	O
or	O
saline	O
i.v	O
.	O

(	O
n=12	O
per	O
group	O
)	O
.	O

Twenty-four	O
hours	O
after	O
hemorrhage	B-Disease
induction	O
,	O
hemorrhagic	O
blood	O
volume	O
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	O
assay	O
.	O

The	O
mean	O
hemorrhagic	O
blood	O
volume	O
was	O
reduced	O
in	O
PCC-treated	B-Chemical
animals	O
(	O
6.5+/-3.1	O
microL	O
)	O
compared	O
with	O
saline	O
controls	O
(	O
15.3+/-11.2	O
microL	O
,	O
P=0.015	O
)	O
.	O

In	O
the	O
saline	O
group	O
,	O
45	O
%	O
of	O
the	O
mice	O
developed	O
large	O
hematomas	B-Disease
(	O
i.e.	O
,	O
>	O
15	O
microL	O
)	O
.	O

In	O
contrast	O
,	O
such	O
extensive	O
lesions	O
were	O
never	O
found	O
in	O
the	O
PCC	B-Chemical
group	O
.	O

We	O
provide	O
experimental	O
data	O
suggesting	O
PCC	B-Chemical
to	O
be	O
an	O
effective	O
acute	O
treatment	O
for	O
W-ICH	B-Disease
in	O
terms	O
of	O
reducing	O
hemorrhagic	O
blood	O
volume	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
therapeutic	O
potential	O
emerging	O
from	O
our	O
finding	O
for	O
human	O
W-ICH	B-Disease
.	O

Impact	O
of	O
alcohol	B-Chemical
exposure	O
after	O
pregnancy	O
recognition	O
on	O
ultrasonographic	O
fetal	O
growth	O
measures	O
.	O

BACKGROUND	O
:	O
More	O
than	O
3	O
decades	O
after	O
Jones	O
and	O
Smith	O
(	O
1973	O
)	O
reported	O
on	O
the	O
devastation	O
caused	O
by	O
alcohol	B-Chemical
exposure	O
on	O
fetal	O
development	O
,	O
the	O
rates	O
of	O
heavy	O
drinking	O
during	O
pregnancy	O
remain	O
relatively	O
unchanged	O
.	O

Early	O
identification	O
of	O
fetal	O
alcohol	B-Chemical
exposure	O
and	O
maternal	O
abstinence	O
led	O
to	O
better	O
infant	O
outcomes	O
.	O

This	O
study	O
examined	O
the	O
utility	O
of	O
biometry	O
for	O
detecting	O
alcohol-related	B-Chemical
fetal	O
growth	B-Disease
impairment	I-Disease
.	O

METHODS	O
:	O
We	O
obtained	O
fetal	O
ultrasound	O
measures	O
from	O
routine	O
ultrasound	O
examinations	O
for	O
167	O
pregnant	O
hazardous	O
drinkers	O
who	O
were	O
enrolled	O
in	O
a	O
brief	O
alcohol	B-Chemical
intervention	O
study	O
.	O

The	O
fetal	O
measures	O
for	O
women	O
who	O
quit	O
after	O
learning	O
of	O
their	O
pregnancies	O
were	O
compared	O
with	O
measures	O
for	O
women	O
who	O
continued	O
some	O
drinking	O
throughout	O
the	O
course	O
of	O
their	O
pregnancies	O
.	O

Because	O
intensity	O
of	O
alcohol	B-Chemical
consumption	O
is	O
associated	O
with	O
poorer	O
fetal	O
outcomes	O
,	O
separate	O
analyses	O
were	O
conducted	O
for	O
the	O
heavy	O
(	O
average	O
of	O
>	O
or=5	O
drinks	O
per	O
drinking	O
day	O
)	O
alcohol	B-Chemical
consumers	O
.	O

Fetal	O
measures	O
from	O
the	O
heavy-exposed	O
fetuses	O
were	O
also	O
compared	O
with	O
measures	O
from	O
a	O
nondrinking	O
group	O
that	O
was	O
representative	O
of	O
normal	O
,	O
uncomplicated	O
pregnancies	O
from	O
our	O
clinics	O
.	O

Analyses	O
of	O
covariance	O
were	O
used	O
to	O
determine	O
whether	O
there	O
were	O
differences	O
between	O
groups	O
after	O
controlling	O
for	O
influences	O
of	O
gestational	O
age	O
and	O
drug	B-Disease
abuse	I-Disease
.	O

RESULTS	O
:	O
Nearly	O
half	O
of	O
the	O
pregnant	O
drinkers	O
abstained	O
after	O
learning	O
of	O
their	O
pregnancies	O
.	O

When	O
women	O
reportedly	O
quit	O
drinking	O
early	O
in	O
their	O
pregnancies	O
,	O
fetal	O
growth	O
measures	O
were	O
not	O
significantly	O
different	O
from	O
a	O
non-alcohol-exposed	B-Chemical
group	O
,	O
regardless	O
of	O
prior	O
drinking	O
patterns	O
.	O

Any	O
alcohol	B-Chemical
consumption	O
postpregnancy	O
recognition	O
among	O
the	O
heavy	O
drinkers	O
resulted	O
in	O
reduced	B-Disease
cerebellar	I-Disease
growth	I-Disease
as	O
well	O
as	O
decreased	B-Disease
cranial	I-Disease
to	I-Disease
body	I-Disease
growth	I-Disease
in	O
comparison	O
with	O
women	O
who	O
either	O
quit	O
drinking	O
or	O
who	O
were	O
nondrinkers	O
.	O

Amphetamine	B-Chemical
abuse	O
was	O
predictive	O
of	O
larger	O
cranial	O
to	O
body	O
growth	O
ratios	O
.	O

CONCLUSIONS	O
:	O
Alterations	O
in	O
fetal	O
biometric	O
measurements	O
were	O
observed	O
among	O
the	O
heavy	O
drinkers	O
only	O
when	O
they	O
continued	O
drinking	O
after	O
becoming	O
aware	O
of	O
their	O
pregnancies	O
.	O

Although	O
the	O
reliance	O
on	O
self-reported	O
drinking	O
is	O
a	O
limitation	O
in	O
this	O
study	O
,	O
these	O
findings	O
support	O
the	O
benefits	O
of	O
early	O
abstinence	O
and	O
the	O
potential	O
for	O
ultrasound	O
examinations	O
in	O
the	O
detection	O
of	O
fetal	O
alcohol	B-Chemical
effects	O
.	O

Urinary	O
symptoms	O
and	O
quality	O
of	O
life	O
changes	O
in	O
Thai	O
women	O
with	O
overactive	B-Disease
bladder	I-Disease
after	O
tolterodine	B-Chemical
treatment	O
.	O

OBJECTIVES	O
:	O
To	O
study	O
the	O
urinary	O
symptoms	O
and	O
quality	O
of	O
life	O
changes	O
in	O
Thai	O
women	O
with	O
overactive	B-Disease
bladder	I-Disease
(	O
OAB	B-Disease
)	O
after	O
tolterodine	B-Chemical
treatment	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
Thirty	O
women	O
(	O
aged	O
30-77	O
years	O
)	O
diagnosed	O
as	O
having	O
OAB	B-Disease
at	O
the	O
Gynecology	O
Clinic	O
,	O
King	O
Chulalongkorn	O
Memorial	O
Hospital	O
from	O
January	O
to	O
April	O
2004	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

Tolterodine	B-Chemical
2	O
mg	O
,	O
twice	O
daily	O
was	O
given	O
.	O

After	O
8	O
weeks	O
treatment	O
,	O
changes	O
in	O
micturition	O
diary	O
variables	O
and	O
tolerability	O
were	O
determined	O
.	O

Short	O
form	O
36	O
(	O
SF36	O
)	O
questionaires	O
(	O
Thai	O
version	O
)	O
were	O
given	O
before	O
and	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O

RESULTS	O
:	O
At	O
8	O
weeks	O
,	O
all	O
micturition	O
per	O
day	O
decreased	O
from	O
16	O
.	O

7	O
+/-	O
5	O
.	O

3	O
to	O
6	O
.	O

7	O
+/-	O
2.4	O
times	O
per	O
day	O
.	O

The	O
number	O
of	O
nocturia	B-Disease
episodes	O
decreased	O
from	O
5.4	O
+/-	O
4.2	O
to	O
1.1	O
+/-	O
1.0	O
times	O
per	O
night	O
.	O

The	O
most	O
common	O
side	O
effect	O
was	O
dry	B-Disease
month	I-Disease
in	O
5	O
cases	O
(	O
16.7	O
%	O
)	O
with	O
2	O
cases	O
reporting	O
a	O
moderate	O
degree	O
and	O
1	O
case	O
with	O
severe	O
degree	O
.	O

Only	O
one	O
case	O
(	O
3.3	O
%	O
)	O
withdrew	O
from	O
the	O
present	O
study	O
due	O
to	O
a	O
severe	O
dry	B-Disease
mouth	I-Disease
.	O

The	O
SF-36	O
scores	O
changed	O
significantly	O
in	O
the	O
domains	O
of	O
physical	O
functioning	O
,	O
role	O
function	O
emotional	O
,	O
social	O
function	O
and	O
mental	O
heath	O
.	O

CONCLUSION	O
:	O
Tolterodine	B-Chemical
was	O
well	O
tolerated	O
and	O
its	O
effects	O
improved	O
the	O
quality	O
of	O
life	O
in	O
Thai	O
women	O
with	O
OAB	B-Disease
.	O

Absence	O
of	O
acute	O
cerebral	O
vasoconstriction	O
after	O
cocaine-associated	B-Chemical
subarachnoid	B-Disease
hemorrhage	I-Disease
.	O

INTRODUCTION	O
:	O
Cocaine	B-Chemical
use	O
has	O
been	O
associated	O
with	O
neurovascular	B-Disease
complications	I-Disease
,	O
including	O
arterial	O
vasoconstriction	O
and	O
vasculitis	B-Disease
.	O

However	O
,	O
there	O
are	O
few	O
studies	O
of	O
angiographic	O
effects	O
of	O
cocaine	B-Chemical
on	O
human	O
cerebral	O
arteries	O
.	O

Information	O
on	O
these	O
effects	O
could	O
be	O
obtained	O
from	O
angiograms	O
of	O
patients	O
with	O
cocaine-associated	B-Chemical
subarachnoid	B-Disease
hemorrhage	I-Disease
(	O
SAH	B-Disease
)	O
who	O
underwent	O
angiography	O
shortly	O
after	O
cocaine	B-Chemical
use	O
.	O

METHODS	O
:	O
We	O
screened	O
patients	O
with	O
SAH	B-Disease
retrospectively	O
and	O
identified	O
those	O
with	O
positive	O
urine	O
toxicology	O
for	O
cocaine	B-Chemical
or	O
its	O
metabolites	O
.	O

Quantitative	O
arterial	O
diameter	O
measurements	O
from	O
angiograms	O
of	O
these	O
patients	O
were	O
compared	O
to	O
measurements	O
from	O
control	O
patients	O
with	O
SAH	B-Disease
who	O
were	O
matched	O
for	O
factors	O
known	O
to	O
influence	O
arterial	O
diameter	O
.	O

Qualitative	O
comparisons	O
of	O
small	O
artery	O
changes	O
also	O
were	O
made	O
.	O

RESULTS	O
:	O
Thirteen	O
patients	O
with	O
positive	O
cocaine	B-Chemical
toxicology	O
were	O
compared	O
to	O
26	O
controls	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
the	O
mean	O
diameters	O
of	O
the	O
intradural	O
internal	O
carotid	O
,	O
sphenoidal	O
segment	O
of	O
the	O
middle	O
cerebral	O
,	O
precommunicating	O
segment	O
of	O
the	O
anterior	O
cerebral	O
,	O
or	O
basilar	O
arteries	O
(	O
p	O
greater	O
than	O
0.05	O
for	O
all	O
comparisons	O
,	O
unpaired	O
t-tests	O
)	O
.	O

There	O
also	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
when	O
expressing	O
diameters	O
as	O
the	O
sum	O
of	O
the	O
precommunicating	O
segment	O
of	O
the	O
anterior	O
cerebral	O
+	O
sphenoidal	O
segment	O
of	O
the	O
middle	O
cerebral	O
+	O
supraclinoid	O
internal	O
carotid	O
artery	O
+	O
basilar	O
artery	O
divided	O
by	O
the	O
diameter	O
of	O
the	O
petrous	O
internal	O
carotid	O
artery	O
(	O
p	O
greater	O
than	O
0.05	O
,	O
unpaired	O
t-tests	O
)	O
.	O

Qualitative	O
assessments	O
showed	O
two	O
arterial	O
irregularities	O
in	O
the	O
distal	O
vasculature	O
in	O
each	O
group	O
.	O

CONCLUSION	O
:	O
No	O
quantitative	O
evidence	O
for	O
narrowing	O
of	O
large	O
cerebral	O
arteries	O
or	O
qualitative	O
angiographic	O
evidence	O
for	O
distal	O
narrowing	O
or	O
vasculitis	B-Disease
could	O
be	O
found	O
in	O
patients	O
who	O
underwent	O
angiography	O
after	O
aneurysmal	B-Disease
SAH	B-Disease
associated	O
with	O
cocaine	B-Chemical
use	O
.	O

Atrial	B-Disease
fibrillation	I-Disease
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B-cell	O
gastric	B-Disease
lymphoma	I-Disease
in	O
a	O
patient	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
Steinert	B-Disease
's	I-Disease
disease	I-Disease
)	O
.	O

The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B-cell	O
gastric	B-Disease
lymphoma	I-Disease
and	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Disease
dystrophy	I-Disease
,	O
and	O
sudden	O
atrial	B-Disease
fibrillation	I-Disease
following	O
one	O
cycle	O
of	O
doxorubicin-based	B-Chemical
chemotherapy	O
in	O
the	O
same	O
patient	O
.	O

Atrial	B-Disease
fibrillation	I-Disease
or	O
other	O
cardiac	B-Disease
arrhythmias	I-Disease
are	O
unusual	O
complications	O
in	O
patients	O
treated	O
with	O
chemotherapy	O
.	O

The	O
cardiac	B-Disease
toxicity	I-Disease
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	B-Disease
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	O
.	O

A	O
phase	O
II	O
study	O
of	O
thalidomide	B-Chemical
in	O
advanced	O
metastatic	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
toxicity	B-Disease
and	O
activity	O
of	O
thalidomide	B-Chemical
in	O
patients	O
with	O
advanced	O
metastatic	O
renal	B-Disease
cell	I-Disease
cancer	I-Disease
and	O
to	O
measure	O
changes	O
of	O
one	O
angiogenic	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
165	O
,	O
with	O
therapy	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
29	O
patients	O
were	O
enrolled	O
on	O
a	O
study	O
of	O
thalidomide	B-Chemical
using	O
an	O
intra-patient	O
dose	O
escalation	O
schedule	O
.	O

Patients	O
began	O
thalidomide	B-Chemical
at	O
400	O
mg/d	O
and	O
escalated	O
as	O
tolerated	O
to	O
1200	O
mg/d	O
by	O
day	O
54	O
.	O

Fifty-nine	O
per	O
cent	O
of	O
patients	O
had	O
had	O
previous	O
therapy	O
with	O
IL-2	O
and	O
52	O
%	O
were	O
performance	O
status	O
2	O
or	O
3	O
.	O

Systemic	O
plasma	O
VEGF165	O
levels	O
were	O
measured	O
by	O
dual	O
monoclonal	O
ELISA	O
in	O
8	O
patients	O
.	O

RESULTS	O
:	O
24	O
patients	O
were	O
evaluable	O
for	O
response	O
with	O
one	O
partial	O
response	O
of	O
11	O
months	O
duration	O
of	O
a	O
patient	O
with	O
hepatic	O
and	O
pulmonary	O
metastases	B-Disease
(	O
4	O
%	O
)	O
,	O
one	O
minor	O
response	O
,	O
and	O
2	O
patients	O
stable	O
for	O
over	O
6	O
months	O
.	O

Somnolence	B-Disease
and	O
constipation	B-Disease
were	O
prominent	O
toxicities	B-Disease
and	O
most	O
patients	O
could	O
not	O
tolerate	O
the	O
1200	O
mg/day	O
dose	O
level	O
.	O

Systemic	O
plasma	O
VEGF165	O
levels	O
did	O
not	O
change	O
with	O
therapy	O
.	O

CONCLUSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
a	O
low	O
level	O
of	O
activity	O
of	O
thalidomide	B-Chemical
in	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
.	O

Administration	O
of	O
doses	O
over	O
800	O
mg/day	O
was	O
difficult	O
to	O
achieve	O
in	O
this	O
patient	O
population	O
,	O
however	O
lower	O
doses	O
were	O
practical	O
.	O

The	O
dose-response	O
relationship	O
,	O
if	O
any	O
,	O
of	O
thalidomide	B-Chemical
for	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
is	O
unclear	O
.	O

The	O
striatum	O
as	O
a	O
target	O
for	O
anti-rigor	O
effects	O
of	O
an	O
antagonist	O
of	O
mGluR1	O
,	O
but	O
not	O
an	O
agonist	O
of	O
group	O
II	O
metabotropic	O
glutamate	B-Chemical
receptors	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
the	O
metabotropic	O
receptor	O
1	O
(	O
mGluR1	O
)	O
and	O
group	O
II	O
mGluRs	O
,	O
localized	O
in	O
the	O
striatum	O
,	O
are	O
involved	O
in	O
antiparkinsonian-like	O
effects	O
in	O
rats	O
.	O

Haloperidol	B-Chemical
(	O
1	O
mg/kg	O
ip	O
)	O
induced	O
parkinsonian-like	B-Disease
muscle	B-Disease
rigidity	I-Disease
,	O
measured	O
as	O
an	O
increased	O
resistance	O
of	O
a	O
rat	O
's	O
hind	O
foot	O
to	O
passive	O
flexion	O
and	O
extension	O
at	O
the	O
ankle	O
joint	O
.	O

(	B-Chemical
RS	I-Chemical
)	I-Chemical
-1-aminoindan-1,5-dicarboxylic	I-Chemical
acid	I-Chemical
(	O
AIDA	B-Chemical
;	O
0.5-15	O
microg/0.5	O
microl	O
)	I-Chemical
,	O
a	O
potent	O
and	O
selective	O
mGluR1	O
antagonist	O
,	O
or	O
(	B-Chemical
2R,4R	I-Chemical
)	I-Chemical
-4-aminopyrrolidine-2,4-dicarboxylate	O
(	O
2R,4R-APDC	B-Chemical
;	O
7.5-15	O
microg/0.5	O
microl	O
)	O
,	O
a	O
selective	O
group	O
II	O
agonist	O
,	O
was	O
injected	O
bilaterally	O
into	O
the	O
striatum	O
of	O
haloperidol-treated	B-Chemical
animals	O
.	O

AIDA	B-Chemical
in	O
doses	O
of	O
7.5-15	O
microg/0.5	O
microl	O
diminished	O
the	O
haloperidol-induced	B-Chemical
muscle	B-Disease
rigidity	I-Disease
.	O

In	O
contrast	O
,	O
2R,4R-APDC	B-Chemical
injections	O
were	O
ineffective	O
.	O

The	O
present	O
results	O
may	O
suggest	O
that	O
the	O
blockade	O
of	O
striatal	O
mGluR1	O
,	O
but	O
not	O
the	O
stimulation	O
of	O
group	O
II	O
mGluRs	O
,	O
may	O
ameliorate	O
parkinsonian	B-Disease
muscle	B-Disease
rigidity	I-Disease
.	O

Acute	O
cholestatic	B-Disease
hepatitis	I-Disease
after	O
exposure	O
to	O
isoflurane	B-Drug
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
acute	O
cholestatic	B-Disease
hepatitis	I-Disease
following	O
exposure	O
to	O
the	O
inhalational	O
anesthetic	B-Drug
isoflurane	B-Drug
.	O

CASE	O
SUMMARY	O
:	O
A	O
70-year-old	O
healthy	O
woman	O
from	O
Iraq	O
developed	O
acute	O
cholestatic	B-Chemical
hepatitis	B-Chemical
3	O
weeks	O
following	O
repair	O
of	O
the	O
right	O
rotator	O
cuff	O
under	O
general	O
anesthesia	B-Drug
.	O

There	O
was	O
no	O
evidence	O
for	O
viral	O
,	O
autoimmune	O
,	O
or	O
metabolic	O
causes	O
of	O
hepatitis	O
.	O

No	O
other	O
medications	O
were	O
involved	O
except	O
for	O
dipyrone	B-Drug
for	O
analgesia	O
.	O

The	O
alanine	O
aminotransferase	O
was	O
elevated	O
to	O
a	O
peak	O
concentration	O
of	O
1533	O
U/L	O
and	O
the	O
serum	O
bilirubin	O
reached	O
a	O
peak	O
of	O
17.0	O
mg/dL	O
.	O

There	O
was	O
slow	O
improvement	O
over	O
4	O
months	O
.	O

Accidental	O
reexposure	O
by	O
the	O
patient	O
to	O
dipyrone	B-Drug
was	O
uneventful	O
.	O

DISCUSSION	O
:	O
The	O
clinical	O
and	O
histologic	O
picture	O
of	O
this	O
case	O
resembles	O
halothane	B-Drug
hepatitis	O
,	O
which	O
has	O
a	O
significant	O
mortality	O
rate	O
.	O

CONCLUSIONS	O
:	O
Isoflurane	B-Drug
,	O
a	O
common	O
anesthetic	B-Drug
agent	O
,	O
can	O
cause	O
severe	O
cholestatic	O
hepatitis	O
.	O

Calcitonin	O
gene-related	O
peptide	O
levels	O
during	O
nitric	B-Chemical
oxide-induced	O
headache	O
in	O
patients	O
with	O
chronic	O
tension-type	O
headache	O
.	O

It	O
has	O
been	O
proposed	O
that	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
induced	O
headache	B-Disease
in	O
primary	B-Disease
headaches	I-Disease
may	O
be	O
associated	O
with	O
release	O
of	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
investigate	O
plasma	O
levels	O
of	O
CGRP	O
during	O
headache	B-Disease
induced	O
by	O
the	O
NO	B-Chemical
donor	O
glyceryl	B-Chemical
trinitrate	I-Chemical
(	O
GTN	B-Chemical
)	O
in	O
16	O
patients	O
with	O
chronic	O
tension-type	B-Disease
headache	I-Disease
and	O
16	O
healthy	O
controls	O
.	O

The	O
subjects	O
were	O
randomly	O
allocated	O
to	O
receive	O
0.5	O
microg/kg/min	O
GTN	B-Chemical
or	O
placebo	O
over	O
20	O
min	O
on	O
two	O
headache-free	B-Disease
days	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
baseline	O
,	O
10	O
,	O
20	O
and	O
60	O
min	O
after	O
start	O
of	O
infusion	O
.	O

Both	O
patients	O
and	O
controls	O
developed	O
significantly	O
stronger	O
immediate	O
headache	B-Disease
on	O
the	O
GTN	B-Chemical
day	O
than	O
on	O
the	O
placebo	O
day	O
and	O
the	O
headache	B-Disease
was	O
significantly	O
more	O
pronounced	O
in	O
patients	O
than	O
in	O
controls	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
area	O
under	O
the	O
CGRP	O
curve	O
(	O
AUCCGRP	O
)	O
on	O
GTN	B-Chemical
vs.	O
placebo	O
day	O
in	O
either	O
patients	O
(	O
P=0.65	O
)	O
or	O
controls	O
(	O
P=0.48	O
)	O
.	O

The	O
AUCCGRP	O
recorded	O
on	O
the	O
GTN	B-Chemical
day	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
(	O
P=0.36	O
)	O
.	O

Both	O
in	O
patients	O
and	O
controls	O
,	O
CGRP	O
levels	O
changed	O
significantly	O
over	O
time	O
,	O
on	O
both	O
the	O
GTN	B-Chemical
and	O
placebo	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
present	O
study	O
indicates	O
that	O
NO-induced	B-Chemical
immediate	O
headache	B-Disease
is	O
not	O
associated	O
with	O
release	O
of	O
CGRP	O
.	O

Myocardial	B-Disease
ischemia	I-Disease
due	O
to	O
coronary	B-Disease
artery	I-Disease
spasm	I-Disease
during	O
dobutamine	B-Chemical
stress	O
echocardiography	O
.	O

Dobutamine	B-Chemical
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
useful	O
and	O
safe	O
provocation	O
test	O
for	O
myocardial	B-Disease
ischemia	I-Disease
.	O

Until	O
now	O
,	O
the	O
test	O
has	O
been	O
focused	O
only	O
on	O
the	O
organic	O
lesion	O
in	O
the	O
coronary	B-Disease
artery	I-Disease
,	O
and	O
positive	O
DSE	O
has	O
indicated	O
the	O
presence	O
of	O
significant	O
fixed	O
coronary	B-Disease
artery	O
stenosis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
myocardial	B-Disease
ischemia	I-Disease
due	O
to	O
coronary	B-Disease
spasm	I-Disease
is	O
induced	O
by	O
dobutamine	B-Chemical
.	O

We	O
performed	O
DSE	O
on	O
51	O
patients	O
with	O
coronary	B-Disease
spastic	I-Disease
angina	I-Disease
but	O
without	O
significant	O
fixed	O
coronary	B-Disease
artery	I-Disease
stenosis	I-Disease
.	O

All	O
patients	O
had	O
anginal	B-Disease
attacks	O
at	O
rest	O
with	O
ST	O
elevation	O
on	O
the	O
electrocardiogram	O
(	O
variant	B-Disease
angina	I-Disease
)	O
.	O

Coronary	O
spasm	O
was	O
induced	O
by	O
intracoronary	O
injection	O
of	O
acetylcholine	B-Chemical
,	O
and	O
no	O
fixed	O
coronary	B-Disease
artery	I-Disease
stenosis	I-Disease
was	O
documented	O
on	O
angiograms	O
in	O
all	O
patients	O
.	O

DSE	O
was	O
performed	O
with	O
intravenous	O
dobutamine	B-Chemical
infusion	O
with	O
an	O
incremental	O
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
30	O
,	O
and	O
40	O
microg/kg/min	O
every	O
5	O
minutes	O
.	O

Of	O
the	O
51	O
patients	O
,	O
7	O
patients	O
showed	O
asynergy	O
with	O
ST	O
elevation	O
.	O

All	O
7	O
patients	O
(	O
13.7	O
%	O
)	O
had	O
chest	B-Disease
pain	I-Disease
during	O
asynergy	O
,	O
and	O
both	O
chest	B-Disease
pain	I-Disease
and	O
electrocardiographic	O
changes	O
were	O
preceded	O
by	O
asynergy	O
.	O

These	O
findings	O
indicate	O
that	O
dobutamine	B-Chemical
can	O
provoke	O
coronary	B-Disease
spasm	I-Disease
in	O
some	O
patients	O
with	O
coronary	B-Disease
spastic	I-Disease
angina	I-Disease
.	O

When	O
DSE	O
is	O
performed	O
to	O
evaluate	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
not	O
only	O
fixed	O
coronary	B-Disease
stenosis	I-Disease
,	O
but	O
also	O
coronary	B-Disease
spasm	I-Disease
should	O
be	O
considered	O
as	O
a	O
genesis	O
of	O
asynergy	O
.	O

Nitric	B-Chemical
oxide	I-Chemical
synthase	O
expression	O
in	O
the	O
course	O
of	O
lead-induced	B-Chemical
hypertension	B-Disease
.	O

We	O
recently	O
showed	O
elevated	O
reactive	O
oxygen	B-Chemical
species	O
(	O
ROS	O
)	O
,	O
reduced	O
urinary	O
excretion	O
of	O
NO	B-Chemical
metabolites	O
(	O
NOx	B-Chemical
)	O
,	O
and	O
increased	O
NO	O
sequestration	O
as	O
nitrotyrosine	B-Chemical
in	O
various	O
tissues	O
in	O
rats	O
with	O
lead-induced	B-Chemical
hypertension	B-Disease
.	O

This	O
study	O
was	O
designed	O
to	O
discern	O
whether	O
the	O
reduction	O
in	O
urinary	O
NOx	O
in	O
lead-induced	B-Chemical
hypertension	B-Disease
is	O
,	O
in	O
part	O
,	O
due	O
to	O
depressed	O
NO	B-Chemical
synthase	O
(	O
NOS	O
)	O
expression	O
.	O

Male	O
Sprague-Dawley	O
rats	O
were	O
randomly	O
assigned	O
to	O
a	O
lead-treated	B-Chemical
group	O
(	O
given	O
lead	B-Chemical
acetate	I-Chemical
,	O
100	O
ppm	O
,	O
in	O
drinking	O
water	O
and	O
regular	O
rat	O
chow	O
)	O
,	O
a	O
group	O
given	O
lead	B-Chemical
and	O
vitamin	B-Chemical
E-fortified	O
chow	O
,	O
or	O
a	O
normal	O
control	O
group	O
given	O
either	O
regular	O
food	O
and	O
water	O
or	O
vitamin	B-Chemical
E-fortified	O
food	O
for	O
12	O
weeks	O
.	O

Tail	O
blood	O
pressure	O
,	O
urinary	O
NOx	O
excretion	O
,	O
plasma	O
malondialdehyde	O
(	O
MDA	O
)	O
,	O
and	O
endothelial	O
and	O
inducible	O
NOS	O
(	O
eNOS	O
and	O
iNOS	O
)	O
isotypes	O
in	O
the	O
aorta	O
and	O
kidney	O
were	O
measured	O
.	O

The	O
lead-treated	O
group	O
exhibited	O
a	O
rise	O
in	O
blood	O
pressure	O
and	O
plasma	O
MDA	O
concentration	O
,	O
a	O
fall	O
in	O
urinary	O
NOx	O
excretion	O
,	O
and	O
a	O
paradoxical	O
rise	O
in	O
vascular	O
and	O
renal	O
tissue	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

Vitamin	O
E	I-Chemical
supplementation	O
ameliorated	O
hypertension	O
,	O
lowered	O
plasma	O
MDA	O
concentration	O
,	O
and	O
raised	O
urinary	O
NOx	O
excretion	O
while	O
significantly	O
lowering	O
vascular	O
,	O
but	O
not	O
renal	O
,	O
tissue	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

Vitamin	O
E	I-Chemical
supplementation	O
had	O
no	O
effect	O
on	O
either	O
blood	O
pressure	O
,	O
plasma	O
MDA	O
,	O
or	O
NOS	O
expression	O
in	O
the	O
control	O
group	O
.	O

The	O
study	O
also	O
revealed	O
significant	O
inhibition	O
of	O
NOS	O
enzymatic	O
activity	O
by	O
lead	B-Drug
in	O
cell-free	O
preparations	O
.	O

In	O
conclusion	O
,	O
lead-induced	O
hypertension	O
in	O
this	O
model	O
was	O
associated	O
with	O
a	O
compensatory	O
upregulation	O
of	O
renal	O
and	O
vascular	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

This	O
is	O
,	O
in	O
part	O
,	O
due	O
to	O
ROS-mediated	O
NO	O
inactivation	O
,	O
lead-associated	O
inhibition	O
of	O
NOS	O
activity	O
,	O
and	O
perhaps	O
stimulatory	O
actions	O
of	O
increased	O
shear	O
stress	O
associated	O
with	O
hypertension	O
.	O

Risk	O
for	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
among	O
users	O
of	O
fenfluramine	B-Chemical
and	O
dexfenfluramine	B-Chemical
who	O
underwent	O
echocardiography	O
before	O
use	O
of	O
medication	O
.	O

BACKGROUND	O
:	O
Because	O
uncontrolled	O
echocardiographic	O
surveys	O
suggested	O
that	O
up	O
to	O
30	O
%	O
to	O
38	O
%	O
of	O
users	O
of	O
fenfluramine	B-Chemical
and	O
dexfenfluramine	B-Chemical
had	O
valvular	B-Disease
disease	I-Disease
,	O
these	O
drugs	B-Drug
were	O
withdrawn	O
from	O
the	O
market	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
risk	O
for	O
new	O
or	O
worsening	O
valvular	B-Disease
abnormalities	I-Disease
among	O
users	O
of	O
fenfluramine	B-Chemical
or	O
dexfenfluramine	B-Chemical
who	O
underwent	O
echocardiography	O
before	O
they	O
began	O
to	O
take	O
these	O
medications	O
.	O

DESIGN	O
:	O
Cohort	O
study	O
.	O

SETTING	O
:	O
Academic	O
primary	O
care	O
practices	O
.	O

PATIENTS	O
:	O
46	O
patients	O
who	O
used	O
fenfluramine	B-Chemical
or	O
dexfenfluramine	B-Chemical
for	O
14	O
days	O
or	O
more	O
and	O
had	O
echocardiograms	O
obtained	O
before	O
therapy	O
.	O

MEASUREMENTS	O
:	O
Follow-up	O
echocardiography	O
.	O

The	O
primary	O
outcome	O
was	O
new	O
or	O
worsening	O
valvulopathy	B-Disease
,	O
defined	O
as	O
progression	O
of	O
either	O
aortic	B-Disease
or	B-Disease
mitral	I-Disease
regurgitation	I-Disease
by	O
at	O
least	O
one	O
degree	O
of	O
severity	O
and	O
disease	O
that	O
met	O
U.S.	O
Food	O
and	O
Drug	B-Drug
Administration	O
criteria	O
(	O
at	O
least	O
mild	O
aortic	B-Chemical
regurgitation	I-Chemical
or	O
moderate	O
mitral	B-Chemical
regurgitation	I-Chemical
)	O
.	O

RESULTS	O
:	O
Two	O
patients	O
(	O
4.3	O
%	O
[	O
95	O
%	O
CI	O
,	O
0.6	O
%	O
to	O
14.8	O
%	O
]	O
)	O
receiving	O
fenfluramine-phentermine	O
developed	O
valvular	O
heart	O
disease	O
.	O

One	O
had	O
baseline	O
bicuspid	O
aortic	B-Disease
valve	O
and	O
mild	O
aortic	B-Disease
regurgitation	I-Chemical
that	O
progressed	O
to	O
moderate	O
regurgitation	I-Chemical
.	O

The	O
second	O
patient	O
developed	O
new	O
moderate	O
aortic	O
insufficiency	O
.	O

CONCLUSION	O
:	O
Users	O
of	O
diet	O
medications	O
are	O
at	O
risk	O
for	O
valvular	O
heart	O
disease	O
.	O

However	O
,	O
the	O
incidence	O
may	O
be	O
lower	O
than	O
that	O
reported	O
previously	O
.	O

Carboplatin	B-Chemical
toxic	O
effects	O
on	O
the	O
peripheral	O
nervous	O
system	O
of	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
The	O
most	O
striking	O
of	O
carboplatin	B-Chemical
's	O
advantages	O
(	O
CBDCA	B-Chemical
)	O
over	O
cisplatin	B-Chemical
(	O
CDDP	B-Chemical
)	O
is	O
its	O
markedly	O
reduced	O
rate	O
of	O
neurotoxic	B-Disease
effects	O
.	O

However	O
,	O
the	O
use	O
of	O
CBDCA	B-Chemical
higher-intensity	O
schedules	O
and	O
the	O
association	O
with	O
other	O
neurotoxic	B-Disease
drugs	B-Drug
in	O
polychemotherapy	O
may	O
cause	O
some	O
concern	O
about	O
its	O
safety	O
with	O
respect	O
to	O
peripheral	B-Disease
nervous	I-Disease
system	I-Disease
damage	I-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Two	O
different	O
schedules	O
of	O
CBDCA	B-Chemical
administration	O
(	O
10	O
mg/kg	O
and	O
15	O
mg/kg	O
i.p	O
.	O

twice	O
a	O
week	O
for	O
nine	O
times	O
)	O
were	O
evaluated	O
in	O
Wistar	O
rats	O
.	O

Neurotoxicity	B-Disease
was	O
assessed	O
for	O
behavioral	O
(	O
tail-flick	O
test	O
)	O
,	O
neurophysiological	O
(	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
nerve	O
)	O
,	O
morphological	O
,	O
morphometrical	O
and	O
analytical	O
effects	O
.	O

RESULTS	O
:	O
CBDCA	B-Chemical
administration	O
induced	O
dose-dependent	O
peripheral	B-Disease
neurotoxicity	I-Disease
.	O

Pain	B-Disease
perception	O
and	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
were	O
significantly	O
impaired	O
,	O
particularly	O
after	O
the	O
high-dose	O
treatment	O
.	O

The	O
dorsal	O
root	O
ganglia	O
sensory	O
neurons	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
satellite	O
cells	O
showed	O
the	O
same	O
changes	O
as	O
those	O
induced	O
by	O
CDDP	B-Chemical
,	O
mainly	O
affecting	O
the	O
nucleus	O
and	O
nucleolus	O
of	O
ganglionic	O
sensory	O
neurons	O
.	O

Moreover	O
,	O
significant	O
amounts	O
of	O
platinum	B-Chemical
were	O
detected	O
in	O
the	O
dorsal	O
root	O
ganglia	O
and	O
kidney	O
after	O
CBDCA	B-Chemical
treatment	O
.	O

CONCLUSIONS	O
:	O
CBDCA	B-Chemical
is	O
neurotoxic	B-Disease
in	O
our	O
model	O
,	O
and	O
the	O
type	O
of	O
pathological	O
changes	O
it	O
induces	O
are	O
so	O
closely	O
similar	O
to	O
those	O
caused	O
by	O
CDDP	B-Chemical
that	O
it	O
is	O
probable	O
that	O
neurotoxicity	B-Disease
is	O
induced	O
in	O
the	O
two	O
drugs	B-Drug
by	O
the	O
same	O
mechanism	O
.	O

This	O
model	O
can	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
other	O
drugs	B-Drug
to	O
explore	O
the	O
effect	O
of	O
CBDCA	B-Chemical
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Iatrogenic	O
risks	O
of	O
endometrial	B-Disease
carcinoma	I-Disease
after	O
treatment	O
for	O
breast	B-Disease
cancer	I-Disease
in	O
a	O
large	O
French	O
case-control	O
study	O
.	O

F	O
d	O
ration	O
Nationale	O
des	O
Centres	O
de	O
Lutte	O
Contre	O
le	O
Cancer	O
(	O
FNCLCC	O
)	O
.	O

Since	O
tamoxifen	B-Chemical
is	O
widely	O
used	O
in	O
breast	B-Disease
cancer	I-Disease
treatment	O
and	O
has	O
been	O
proposed	O
for	O
the	O
prevention	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
its	O
endometrial	B-Disease
iatrogenic	O
effects	O
must	O
be	O
carefully	O
examined	O
.	O

We	O
have	O
investigated	O
the	O
association	O
between	O
endometrial	B-Disease
cancer	O
and	O
tamoxifen	B-Chemical
use	O
or	O
other	O
treatments	O
in	O
women	O
treated	O
for	O
breast	B-Disease
cancer	I-Disease
in	O
a	O
case-control	O
study	O
.	O

Cases	O
of	O
endometrial	B-Disease
cancer	I-Disease
diagnosed	O
after	O
breast	B-Disease
cancer	I-Disease
(	O
n	O
=	O
135	O
)	O
and	O
467	O
controls	O
matched	O
for	O
age	O
,	O
year	O
of	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
and	O
hospital	O
and	O
survival	O
time	O
with	O
an	O
intact	O
uterus	O
were	O
included	O
.	O

Women	O
who	O
had	O
received	O
tamoxifen	B-Chemical
were	O
significantly	O
more	O
likely	O
to	O
have	O
endometrial	B-Disease
cancer	I-Disease
diagnosed	O
than	O
those	O
who	O
had	O
not	O
(	O
crude	O
relative	O
risk	O
=	O
4.9	O
,	O
p	O
=	O
0.0001	O
)	O
.	O

Univariate	O
and	O
adjusted	O
analyses	O
showed	O
that	O
the	O
risk	O
increased	O
with	O
the	O
length	O
of	O
treatment	O
(	O
p	O
=	O
0.0001	O
)	O
or	O
the	O
cumulative	O
dose	O
of	O
tamoxifen	B-Chemical
received	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
irrespective	O
of	O
the	O
daily	O
dose	O
.	O

Women	O
who	O
had	O
undergone	O
pelvic	O
radiotherapy	O
also	O
had	O
a	O
higher	O
risk	O
(	O
crude	O
relative	O
risk	O
=	O
7.8	O
,	O
p	O
=	O
0.0001	O
)	O
.	O

After	O
adjusting	O
for	O
confounding	O
factors	O
,	O
the	O
risk	O
was	O
higher	O
for	O
tamoxifen	B-Chemical
users	O
(	O
p	O
=	O
0.0012	O
)	O
,	O
treatment	O
for	O
more	O
than	O
3	O
years	O
(	O
all	O
p	O
<	O
0.03	O
)	O
and	O
pelvic	O
radiotherapy	O
(	O
p	O
=	O
0.012	O
)	O
.	O

Women	O
who	O
had	O
endometrial	B-Disease
cancer	I-Disease
and	O
had	O
received	O
tamoxifen	B-Chemical
had	O
more	O
advanced	B-Disease
disease	I-Disease
and	O
poorer	O
prognosis	O
than	O
those	O
with	O
endometrial	B-Disease
cancer	I-Disease
who	O
had	O
not	O
received	O
this	O
treatment	O
.	O

Our	O
results	O
suggest	O
a	O
causal	O
role	O
of	O
tamoxifen	B-Chemical
in	O
endometrial	B-Disease
cancer	I-Disease
,	O
particularly	O
when	O
used	O
as	O
currently	O
proposed	O
for	O
breast	B-Disease
cancer	I-Disease
prevention	O
.	O

Pelvic	O
radiotherapy	O
may	O
be	O
an	O
additional	O
iatrogenic	O
factor	O
for	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

Endometrial	B-Disease
cancers	I-Disease
diagnosed	O
in	O
women	O
treated	O
with	O
tamoxifen	B-Chemical
have	O
poorer	O
prognosis	O
.	O

Women	O
who	O
receive	O
tamoxifen	B-Chemical
for	O
breast	B-Disease
cancer	I-Disease
should	O
be	O
offered	O
gynaecological	O
surveillance	O
during	O
and	O
after	O
treatment	O
.	O

A	O
long-term	O
evaluation	O
of	O
the	O
risk-benefit	O
ratio	O
of	O
tamoxifen	B-Chemical
as	O
a	O
preventive	O
treatment	O
for	O
breast	B-Disease
cancer	I-Disease
is	O
clearly	O
warranted	O
.	O

Granulosa	B-Disease
cell	I-Disease
tumor	I-Disease
of	I-Disease
the	I-Disease
ovary	I-Disease
associated	O
with	O
antecedent	O
tamoxifen	B-Chemical
use	O
.	O

BACKGROUND	O
:	O
Increased	O
attention	O
has	O
been	O
focused	O
recently	O
on	O
the	O
estrogenic	O
effects	O
of	O
tamoxifen	B-Chemical
.	O

Review	O
of	O
the	O
literature	O
reveals	O
an	O
association	O
between	O
tamoxifen	B-Chemical
use	O
and	O
gynecologic	O
tumors	B-Disease
.	O

CASE	O
:	O
A	O
52-year-old	O
postmenopausal	O
woman	O
was	O
treated	O
with	O
tamoxifen	B-Chemical
for	O
stage	O
II	O
estrogen	B-Chemical
receptor-positive	O
breast	B-Disease
carcinoma	I-Disease
.	O

Her	O
aspartate	B-Chemical
transaminase	O
and	O
alanine	B-Chemical
transaminase	O
levels	O
increase	O
markedly	O
after	O
6	O
months	O
of	O
tamoxifen	B-Chemical
use	O
.	O

After	O
an	O
additional	O
17	O
months	O
of	I-Disease
elevated	O
serum	O
transaminases	O
,	O
the	I-Disease
patient	O
was	O
found	O
to	O
have	O
a	O
stage	O
Ic	O
granulosa	B-Disease
cell	I-Disease
tumor	I-Disease
of	I-Disease
the	O
ovary	O
.	O

CONCLUSION	O
:	O
Patients	O
with	O
tamoxifen-induced	B-Chemical
liver	B-Disease
dysfunction	I-Disease
may	O
be	O
at	O
increased	O
risk	O
for	O
granulosa	B-Disease
cell	I-Disease
tumors	I-Disease
because	O
of	O
alterations	O
in	O
tamoxifen	B-Chemical
metabolism	O
.	O

A	O
murine	O
model	O
of	O
adenomyosis	B-Disease
:	O
the	O
effects	O
of	O
hyperprolactinemia	B-Disease
induced	O
by	O
fluoxetine	B-Chemical
hydrochloride	I-Chemical
,	O
a	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitor	O
,	O
on	O
adenomyosis	B-Disease
induction	O
in	O
Wistar	O
albino	O
rats	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
fluoxetine	B-Chemical
given	O
to	O
castrated	O
and	O
noncastrated	O
rats	O
caused	O
hyperprolactinemia	B-Disease
and	O
its	O
effects	O
with	O
respect	O
to	O
adenomyosis	B-Disease
.	O

DESIGN	O
:	O
Fluoxetine	B-Chemical
,	O
a	O
serotonin	B-Chemical
reuptake	O
inhibitor	O
,	O
was	O
given	O
to	O
Wistar	O
Albino	O
rats	O
for	O
98	O
days	O
to	O
produce	O
hyperprolactinemia	B-Disease
.	O

The	O
drug	B-Drug
was	O
given	O
to	O
two	O
groups	O
consisting	O
of	O
castrated	O
and	O
noncastrated	O
rats	O
and	O
compared	O
to	O
two	O
groups	O
of	O
castrated	O
and	O
noncastrated	O
controls	O
.	O

Prolactin	O
levels	O
were	O
measured	O
and	O
the	O
uteri	O
of	O
the	O
rats	O
were	O
removed	O
for	O
histopathological	O
analysis	O
at	O
the	O
end	O
of	O
98	O
days	O
.	O

SETTING	O
:	O
Marmara	O
University	O
School	O
of	O
Medicine	O
,	O
Department	O
of	O
Histology	O
and	O
Embryology	O
,	O
Zeynep	O
Kamil	O
Women	O
and	O
Children	O
's	O
Hospital	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Serum	O
prolactin	O
levels	O
,	O
uterine	O
histopathology	O
.	O

RESULTS	O
:	O
The	O
prolactin	O
levels	O
of	O
castrated	O
and	O
noncastrated	O
groups	O
treated	O
with	O
fluoxetine	B-Chemical
were	O
statistically	O
significantly	O
higher	O
when	O
compared	O
to	O
their	O
respective	O
control	O
groups	O
.	O

Histological	O
studies	O
revealed	O
11	O
cases	O
of	O
adenomyosis	B-Disease
,	O
all	O
within	O
the	O
noncastrated	O
group	O
receiving	O
fluoxetine	B-Chemical
.	O

CONCLUSION	O
:	O
It	O
was	O
suggested	O
that	O
high	O
serum	O
prolactin	O
levels	O
cause	O
degeneration	O
of	O
myometrial	O
cells	O
in	O
the	O
presence	O
of	O
ovarian	O
steroids	B-Chemical
that	O
results	O
in	O
a	O
myometrial	O
invasion	O
by	O
endometrial	O
stroma	O
.	O

This	O
invasion	O
eventually	O
progresses	O
to	O
adenomyosis	B-Disease
.	O

Effects	O
of	O
deliberate	O
hypotension	B-Disease
induced	O
by	O
labetalol	B-Chemical
with	O
isoflurane	B-Chemical
on	O
neuropsychological	O
function	O
.	O

The	O
effect	O
of	O
deliberate	O
hypotension	B-Disease
on	O
brain	O
function	O
measured	O
by	O
neuropsychological	O
tests	O
was	O
studied	O
in	O
41	O
adult	O
patients	O
.	O

Twenty-four	O
patients	O
were	O
anaesthetized	O
for	O
middle-ear	O
surgery	O
with	O
deliberate	O
hypotension	B-Disease
induced	O
by	O
labetalol	B-Chemical
with	O
isoflurane	B-Chemical
(	O
hypotensive	B-Disease
group	O
)	O
.	O

Seventeen	O
patients	O
without	O
hypotension	B-Disease
served	O
as	O
a	O
control	O
group	O
.	O

The	O
mean	O
arterial	O
pressure	O
was	O
77	O
+/-	O
2	O
mmHg	O
(	O
10.3	O
+/-	O
0.3	O
kPa	O
)	O
before	O
hypotension	B-Disease
and	O
50	O
+/-	O
0	O
mmHg	O
(	O
6.7	O
+/-	O
0.0	O
kPa	O
)	O
during	O
hypotension	B-Disease
in	O
the	O
hypotensive	B-Disease
group	O
,	O
and	O
86	O
+/-	O
2	O
mmHg	O
(	O
11.5	O
+/-	O
0.3	O
kPa	O
)	O
during	O
anaesthesia	O
in	O
the	O
control	O
group	O
.	O

The	O
following	O
psychological	O
tests	O
were	O
performed	O
:	O
four	O
subtests	O
of	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
(	O
similarities	O
,	O
digit	O
span	O
,	O
vocabulary	O
and	O
digit	O
symbol	O
)	O
,	O
Trail-Making	O
tests	O
A	O
and	O
B	O
,	O
Zung	O
tests	O
(	O
self-rating	O
anxiety	B-Disease
scale	O
and	O
self-rating	O
depression	B-Disease
scale	O
)	O
and	O
two-part	O
memory	O
test	O
battery	O
with	O
immediate	O
and	O
delayed	O
recall	O
.	O

The	O
tests	O
were	O
performed	O
preoperatively	O
and	O
2	O
days	O
postoperatively	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
any	O
of	O
the	O
tests	O
in	O
the	O
changes	O
from	O
preoperative	O
value	O
to	O
postoperative	O
value	O
.	O

The	O
results	O
indicate	O
that	O
hypotension	B-Disease
induced	O
by	O
labetalol	B-Chemical
with	O
isoflurane	B-Chemical
has	O
no	O
significant	O
harmful	O
effects	O
on	O
mental	O
functions	O
compared	O
to	O
normotensive	O
anaesthesia	O
.	O

Auditory	O
disturbance	O
associated	O
with	O
interscalene	O
brachial	O
plexus	O
block	O
.	O

We	O
performed	O
an	O
audiometric	O
study	O
in	O
20	O
patients	O
who	O
underwent	O
surgery	O
of	O
the	O
shoulder	O
region	O
under	O
an	O
interscalene	O
brachial	O
plexus	O
block	O
(	O
IBPB	O
)	O
.	O

Bupivacaine	B-Chemical
0.75	O
%	O
with	O
adrenaline	B-Chemical
was	O
given	O
followed	O
by	O
a	O
24-hr	O
continuous	O
infusion	O
of	O
0.25	O
%	O
bupivacaine	B-Chemical
.	O

Three	O
audiometric	O
threshold	O
measurements	O
(	O
0.25-18	O
kHz	O
)	O
were	O
made	O
:	O
the	O
first	O
before	O
IBPB	O
,	O
the	O
second	O
2-6	O
h	O
after	O
surgery	O
and	O
the	O
third	O
on	O
the	O
first	O
day	O
after	O
operation	O
.	O

In	O
four	O
patients	O
hearing	B-Disease
impairment	I-Disease
on	O
the	O
side	O
of	O
the	O
block	O
was	O
demonstrated	O
after	O
operation	O
,	O
in	O
three	O
measurements	O
on	O
the	O
day	O
of	O
surgery	O
and	O
in	O
one	O
on	O
the	O
following	O
day	O
.	O

The	O
frequencies	O
at	O
which	O
the	O
impairment	O
occurred	O
varied	O
between	O
patients	O
;	O
in	O
one	O
only	O
low	O
frequencies	O
(	O
0.25-0.5	O
kHz	O
)	O
were	O
involved	O
.	O

The	O
maximum	O
change	O
in	O
threshold	O
was	O
35	O
dB	O
at	O
6	O
kHz	O
measured	O
at	O
the	O
end	O
of	O
the	O
continuous	O
infusion	O
of	O
bupivacaine	B-Chemical
.	O

This	O
patient	O
had	O
hearing	O
threshold	O
changes	O
(	O
15-20	O
dB	O
)	O
at	O
6-10	O
kHz	O
on	O
the	O
opposite	O
side	O
also	O
.	O

IBPB	O
may	O
cause	O
transient	O
auditory	B-Disease
dysfunction	I-Disease
in	O
the	O
ipsilateral	O
ear	O
,	O
possibly	O
via	O
an	O
effect	O
on	O
sympathetic	O
innervation	O
.	O

Midazolam	B-Chemical
compared	O
with	O
thiopentone	B-Chemical
as	O
an	O
induction	O
agent	O
.	O

In	O
patients	O
premedicated	O
with	O
scopolamine	B-Chemical
+	O
morphine	B-Chemical
(	O
+5	O
mg	O
nitrazepam	B-Chemical
the	O
evening	O
before	O
surgery	O
)	O
,	O
the	O
sleep-inducing	O
effect	O
of	O
midazolam	B-Chemical
0.15	O
mg/kg	O
i.v	O
.	O

was	O
clearly	O
slower	O
in	O
onset	O
than	O
that	O
of	O
thiopentone	B-Chemical
4.67	O
mg/kg	O
i.v	O
.	O

Somewhat	O
fewer	O
cardiovascular	O
and	O
local	O
sequelae	O
were	O
found	O
in	O
the	O
midazolam	B-Chemical
group	O
,	O
but	O
,	O
although	O
apnoea	B-Disease
occurred	O
less	O
often	O
in	O
the	O
midazolam	B-Chemical
group	O
it	O
lasted	O
longer	O
.	O

On	O
the	O
whole	O
,	O
the	O
differences	O
between	O
midazolam	B-Chemical
and	O
thiopentone	B-Chemical
had	O
no	O
apparent	O
clinical	O
consequences	O
.	O

Midazolam	B-Chemical
is	O
a	O
new	O
alternative	O
agent	O
for	O
induction	O
in	O
combination	O
anaesthesia	O
.	O

Cardiotoxic	B-Disease
and	O
possible	O
leukemogenic	O
effects	O
of	O
adriamycin	B-Chemical
in	O
nonhuman	O
primates	O
.	O

10	O
monkeys	O
(	O
macaques	O
)	O
received	O
adriamycin	B-Chemical
by	O
monthly	O
intravenous	O
injections	O
at	O
12	O
mg/m2	O
(	O
1	O
mg/kg	O
)	O
.	O

8	O
of	O
the	O
10	O
monkeys	O
developed	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
at	O
an	O
average	O
cumulative	O
adriamycin	B-Chemical
dose	O
(	O
310	O
mg/m2	O
)	O
well	O
below	O
that	O
considered	O
the	O
safe	O
upper	O
limit	O
(	O
550	O
mg/m2	O
)	O
in	O
man	O
.	O

Histologically	O
,	O
the	O
myocardial	B-Disease
lesions	I-Disease
resembled	O
those	O
found	O
in	O
human	O
anthracycline-induced	B-Chemical
cardiomyopathy	B-Disease
.	O

1	O
of	O
the	O
10	O
monkeys	O
developed	O
acute	B-Disease
myeloblastic	I-Disease
leukemia	I-Disease
after	O
receiving	O
324	O
mg/m2	O
of	O
adriamycin	B-Chemical
;	O
the	O
10th	O
monkey	O
is	O
alive	O
and	O
well	O
26	O
months	O
after	O
the	O
last	O
dose	O
of	O
drug	B-Drug
.	O

Our	O
results	O
suggest	O
that	O
adriamycin	B-Chemical
is	O
a	O
more	O
potent	O
cardiotoxin	O
in	O
monkeys	O
than	O
in	O
man	O
,	O
and	O
that	O
leukemia	B-Disease
may	O
be	O
a	O
consequence	O
of	O
prolonged	O
treatment	O
with	O
this	O
drug	B-Drug
.	O

Doxorubicin	B-Chemical
cardiomyopathy	B-Disease
in	O
children	O
with	O
left-sided	O
Wilms	B-Disease
tumor	I-Disease
.	O

Two	O
children	O
with	O
Wilms	B-Disease
tumor	I-Disease
of	O
the	O
left	O
kidney	O
experienced	O
severe	O
anthracycline	B-Chemical
cardiomyopathy	B-Disease
after	O
irradiation	O
to	O
the	O
tumor	B-Disease
bed	O
and	O
conventional	O
dosage	O
of	O
doxorubicin	B-Chemical
.	O

The	O
cardiomyopathy	B-Disease
is	O
attributed	O
1	O
)	O
to	O
the	O
fact	O
that	O
radiation	O
fields	O
for	O
left	O
Wilms	B-Disease
tumor	I-Disease
include	O
the	O
lower	O
portion	O
of	O
the	O
heart	O
and	O
2	O
)	O
to	O
the	O
interaction	O
of	O
doxorubicin	B-Chemical
and	O
irradiation	O
on	O
cardiac	O
muscle	O
.	O

It	O
is	O
recommended	O
that	O
doxorubicin	B-Chemical
dosage	O
be	O
sharply	O
restricted	O
in	O
children	O
with	O
Wilms	B-Disease
tumor	I-Disease
of	O
the	O
left	O
kidney	O
who	O
receive	O
postoperative	O
irradiation	O
.	O

Promotional	O
effects	O
of	O
testosterone	B-Chemical
and	O
dietary	O
fat	O
on	O
prostate	O
carcinogenesis	B-Disease
in	O
genetically	O
susceptible	O
rats	O
.	O

Germfree	O
(	O
GF	O
)	O
Lobund	O
strain	O
Wistar	O
(	O
LW	O
)	O
rats	O
,	O
fed	O
vegetable	O
diet	O
L-485	O
,	O
have	O
developed	O
prostate	B-Disease
adenocarcinomas	I-Disease
spontaneously	O
(	O
10	O
%	O
incidence	O
)	O
at	O
average	O
age	O
34	O
months	O
.	O

Conventional	O
LW	O
rats	O
,	O
implanted	O
with	O
testosterone	B-Chemical
at	O
age	O
4	O
months	O
,	O
developed	O
a	O
higher	O
incidence	O
of	O
prostate	B-Disease
cancer	I-Disease
after	O
an	O
average	O
interval	O
of	O
14	O
months	O
:	O
24	O
%	O
had	O
developed	O
gross	O
tumors	B-Disease
,	O
and	O
40	O
%	O
when	O
it	O
included	O
microscopic	O
tumors	B-Disease
.	O

Preliminary	O
results	O
indicate	O
that	O
testosterone-treated	B-Chemical
LW	O
rats	O
that	O
were	O
fed	O
the	O
same	O
diet	O
,	O
which	O
was	O
supplemented	O
with	O
corn	O
oil	O
up	O
to	O
20	O
%	O
fat	O
,	O
developed	O
prostate	B-Disease
cancer	I-Disease
after	O
intervals	O
of	O
6-12	O
months	O
.	O

Aged	O
GF	O
Sprague-Dawley	O
(	O
SD	O
)	O
rats	O
have	O
not	O
developed	O
prostate	B-Disease
cancer	I-Disease
spontaneously	O
.	O

Conventional	O
SD	O
rats	O
fed	O
diet	O
L-485	O
and	O
treated	O
with	O
testosterone	B-Chemical
developed	O
only	O
prostatitis	B-Disease
.	O

Experimental	O
designs	O
should	O
consider	O
genetic	O
susceptibility	O
as	O
a	O
basic	O
prerequisite	O
for	O
studies	O
on	O
experimental	O
prostate	B-Disease
cancer	I-Disease
.	O

Mitomycin	B-Chemical
C	I-Chemical
associated	O
hemolytic	B-Disease
uremic	I-Disease
syndrome	I-Disease
.	O

Mitomycin	B-Chemical
C	I-Chemical
associated	O
Hemolytic	B-Disease
Uremic	I-Disease
Syndrome	I-Disease
(	O
HUS	B-Disease
)	O
is	O
a	O
potentially	O
fatal	O
but	O
uncommon	O
condition	O
that	O
is	O
not	O
yet	O
widely	O
recognised	O
.	O

It	O
consists	O
of	O
microangiopathic	O
hemolytic	B-Disease
anemia	I-Disease
,	O
thrombocytopenia	B-Disease
and	O
progressive	O
renal	B-Disease
failure	I-Disease
associated	O
with	O
mitomycin	B-Chemical
C	I-Chemical
treatment	O
and	O
affects	O
about	O
10	O
%	O
of	O
patients	O
treated	O
with	O
this	O
agent	O
.	O

The	O
renal	B-Disease
failure	I-Disease
usually	O
develops	O
about	O
8-10	O
mth	O
after	O
start	O
of	O
mitomycin	B-Chemical
C	I-Chemical
treatment	O
and	O
the	O
mortality	O
is	O
approximately	O
60	O
%	O
from	O
renal	B-Disease
failure	I-Disease
or	O
pulmonary	B-Disease
edema	I-Disease
.	O

Renal	B-Disease
lesions	I-Disease
are	O
similar	O
to	O
those	O
seen	O
in	O
idiopathic	O
HUS	B-Disease
and	O
include	O
arteriolar	O
fibrin	O
thrombi	B-Disease
,	O
expanded	O
subendothelial	O
zones	O
in	O
glomerular	O
capillary	O
walls	O
,	O
ischemic	B-Disease
wrinkling	O
of	O
glomerular	O
basement	O
membranes	O
and	O
mesangiolysis	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
postulated	O
as	O
mitomycin	B-Chemical
C-induced	O
endothelial	O
cell	O
damage	O
.	O

We	O
describe	O
the	O
clinical	O
course	O
and	O
pathological	O
findings	O
in	O
a	O
65	O
yr-old	O
man	O
with	O
gastric	O
adenocarcinoma	O
who	O
developed	O
renal	O
failure	O
and	O
thrombocytopenia	O
while	O
on	O
treatment	O
with	O
mitomycin	B-Chemical
C	O
and	O
died	O
in	O
pulmonary	O
edema	O
.	O

Continuous	O
ambulatory	O
ECG	O
monitoring	O
during	O
fluorouracil	B-Chemical
therapy	O
:	O
a	O
prospective	O
study	O
.	O

Although	O
there	O
have	O
been	O
anecdotal	O
reports	O
of	O
cardiac	B-Disease
toxicity	I-Disease
associated	O
with	O
fluorouracil	B-Chemical
(	O
5-FU	B-Chemical
)	O
therapy	O
,	O
this	O
phenomenon	O
has	O
not	O
been	O
studied	O
in	O
a	O
systematic	O
fashion	O
.	O

We	O
prospectively	O
performed	O
continuous	O
ambulatory	O
ECG	O
monitoring	O
on	O
25	O
patients	O
undergoing	O
5-FU	B-Chemical
infusion	O
for	O
treatment	O
of	O
solid	O
tumors	B-Disease
in	O
order	O
to	O
assess	O
the	O
incidence	O
of	O
ischemic	B-Disease
ST	O
changes	O
.	O

Patients	O
were	O
monitored	O
for	O
23	O
+/-	O
4	O
hours	O
before	O
5-FU	B-Chemical
infusion	O
,	O
and	O
98	O
+/-	O
9	O
hours	O
during	O
5-FU	B-Chemical
infusion	O
.	O

Anginal	B-Disease
episodes	O
were	O
rare	O
:	O
only	O
one	O
patient	O
had	O
angina	B-Disease
(	O
during	O
5-FU	B-Chemical
infusion	O
)	O
.	O

However	O
,	O
asymptomatic	O
ST	O
changes	O
(	O
greater	O
than	O
or	O
equal	O
to	O
1	O
mm	O
ST	O
deviation	O
)	O
were	O
common	O
:	O
six	O
of	O
25	O
patients	O
(	O
24	O
%	O
)	O
had	O
ST	O
changes	O
before	O
5-FU	B-Chemical
infusion	O
v	O
17	O
(	O
68	O
%	O
)	O
during	O
5-FU	B-Chemical
infusion	O
(	O
P	O
less	O
than	O
.002	O
)	O
.	O

The	O
incidence	O
of	O
ischemic	B-Disease
episodes	O
per	O
patient	O
per	O
hour	O
was	O
0.05	O
+/-	O
0.02	O
prior	O
to	O
5-FU	B-Chemical
infusion	O
v	O
0.13	O
+/-	O
0.03	O
during	O
5-FU	B-Chemical
infusion	O
(	O
P	O
less	O
than	O
.001	O
)	O
;	O
the	O
duration	O
of	O
ECG	O
changes	O
was	O
0.6	O
+/-	O
0.3	O
minutes	O
per	O
patient	O
per	O
hour	O
before	O
5-FU	B-Chemical
v	O
1.9	O
+/-	O
0.5	O
minutes	O
per	O
patient	O
per	O
hour	O
during	O
5-FU	B-Chemical
(	O
P	O
less	O
than	O
.01	O
)	O
.	O

ECG	O
changes	O
were	O
more	O
common	O
among	O
patients	O
with	O
known	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O

There	O
were	O
two	O
cases	O
of	O
sudden	B-Disease
death	I-Disease
,	O
both	O
of	O
which	O
occurred	O
at	O
the	O
end	O
of	O
the	O
chemotherapy	O
course	O
.	O

We	O
conclude	O
that	O
5-FU	B-Chemical
infusion	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
silent	O
ST	O
segment	O
deviation	O
suggestive	O
of	O
ischemia	B-Disease
,	O
particularly	O
among	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O

The	O
mechanism	O
and	O
clinical	O
significance	O
of	O
these	O
ECG	O
changes	O
remain	O
to	O
be	O
determined	O
.	O

Lethal	O
anuria	B-Disease
complicating	O
high	O
dose	O
ifosfamide	B-Chemical
chemotherapy	O
in	O
a	O
breast	B-Disease
cancer	I-Disease
patient	O
with	O
an	O
impaired	B-Disease
renal	I-Disease
function	I-Disease
.	O

A	O
sixty-year-old	O
woman	O
with	O
advanced	O
breast	B-Disease
cancer	I-Disease
,	O
previously	O
treated	O
with	O
cisplatin	B-Chemical
,	O
developed	O
an	O
irreversible	O
lethal	O
renal	B-Disease
failure	I-Disease
with	O
anuria	B-Disease
,	O
the	O
day	O
after	O
5	O
g/m2	O
bolus	O
ifosfamide	B-Chemical
.	O

Postrenal	B-Disease
failure	I-Disease
was	O
excluded	O
by	O
echography	O
.	O

A	O
prerenal	B-Disease
component	O
could	O
have	O
contributed	O
to	O
renal	B-Disease
failure	O
because	O
of	O
a	O
transient	O
hypotension	B-Disease
,	O
due	O
to	O
an	O
increasing	O
ascitis	O
,	O
occurring	O
just	O
before	O
anuria	B-Disease
.	O

However	O
,	O
correction	O
of	O
the	O
hemodynamic	O
parameters	O
did	O
not	O
improve	O
renal	O
function	O
.	O

Ifosfamide	B-Chemical
is	O
a	O
known	O
nephrotoxic	B-Disease
drug	B-Drug
with	O
demonstrated	O
tubulopathies	B-Disease
.	O

We	O
strongly	O
suspect	O
that	O
this	O
lethal	O
anuria	B-Disease
was	O
mainly	O
due	O
to	O
ifosfamide	B-Chemical
,	O
occurring	O
in	O
a	O
patient	O
having	O
received	O
previous	O
cisplatin	B-Chemical
chemotherapy	O
and	O
with	O
poor	O
kidney	O
perfusion	O
due	O
to	O
transient	O
hypotension	B-Disease
.	O

We	O
recommend	O
careful	O
use	O
of	O
ifosfamide	B-Chemical
in	O
patients	O
pretreated	O
with	O
nephrotoxic	B-Disease
chemotherapy	O
and	O
inadequate	O
renal	O
perfusion	O
.	O

Central	O
vein	B-Disease
thrombosis	I-Disease
and	O
topical	O
dipivalyl	B-Chemical
epinephrine	I-Chemical
.	O

A	O
report	O
is	O
given	O
on	O
an	O
83-year-old	O
female	O
who	O
acquired	O
central	O
vein	B-Disease
thrombosis	I-Disease
in	O
her	O
seeing	O
eye	O
one	O
day	O
after	O
having	O
started	O
topical	O
medication	O
with	O
dipivalyl	B-Chemical
epinephrine	I-Chemical
for	O
advanced	O
glaucoma	B-Disease
discovered	O
in	O
the	O
other	O
eye	O
.	O

From	O
present	O
knowledge	O
about	O
the	O
effects	O
of	O
adrenergic	O
eye	O
drops	O
on	O
ocular	O
blood	O
circulation	O
,	O
it	O
is	O
difficult	O
to	O
suggest	O
an	O
association	O
between	O
the	O
two	O
events	O
,	O
which	O
may	O
be	O
coincidental	O
only	O
.	O

Amelioration	O
of	O
bendrofluazide-induced	B-Chemical
hypokalemia	B-Disease
by	O
timolol	B-Chemical
.	O

The	O
beta	O
adrenergic	O
blocking	O
drug	B-Drug
,	O
timolol	B-Chemical
,	O
tended	O
to	O
correct	O
the	O
hypokalemia	B-Disease
of	O
short-term	O
bendrofluazide	B-Chemical
treatment	O
in	O
6	O
healthy	O
male	O
subjects	O
and	O
although	O
the	O
effect	O
was	O
small	O
it	O
was	O
significant	O
.	O

Timolol	B-Chemical
also	O
reduced	O
the	O
rise	O
in	O
plasma	O
aldosterone	B-Chemical
and	O
urine	O
potassium	B-Chemical
excretion	O
following	O
bendrofluazide	B-Chemical
and	O
increased	O
the	O
urine	O
sodium/potassium	B-Chemical
ratio	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
shift	O
of	O
potassium	B-Chemical
from	O
the	O
intracellular	O
to	O
the	O
extracellular	O
space	O
.	O

A	O
cross-sectional	O
evaluation	O
of	O
the	O
effect	O
of	O
risperidone	B-Chemical
and	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
on	O
bone	O
mineral	O
density	O
in	O
boys	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
risperidone-induced	B-Chemical
hyperprolactinemia	B-Disease
on	O
trabecular	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
children	O
and	O
adolescents	O
.	O

METHOD	O
:	O
Medically	O
healthy	O
7-	O
to	O
17-year-old	O
males	O
chronically	O
treated	O
,	O
in	O
a	O
naturalistic	O
setting	O
,	O
with	O
risperidone	B-Chemical
were	O
recruited	O
for	O
this	O
cross-sectional	O
study	O
through	O
child	O
psychiatry	O
outpatient	O
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O

Anthropometric	O
measurements	O
and	O
laboratory	O
testing	O
were	O
conducted	O
.	O

The	O
clinical	O
diagnoses	O
were	O
based	O
on	O
chart	O
review	O
,	O
and	O
developmental	O
and	O
treatment	O
history	O
was	O
obtained	O
from	O
the	O
medical	O
record	O
.	O

Volumetric	O
BMD	O
of	O
the	O
ultradistal	O
radius	O
was	O
measured	O
using	O
peripheral	O
quantitative	O
computed	O
tomography	O
,	O
and	O
areal	O
BMD	O
of	O
the	O
lumbar	O
spine	O
was	O
estimated	O
using	O
dual-energy	O
x-ray	O
absorptiometry	O
.	O

RESULTS	O
:	O
Hyperprolactinemia	B-Disease
was	O
present	O
in	O
49	O
%	O
of	O
83	O
boys	O
(	O
n	O
=	O
41	O
)	O
treated	O
with	O
risperidone	B-Chemical
for	O
a	O
mean	O
of	O
2.9	O
years	O
.	O

Serum	O
testosterone	B-Chemical
concentration	O
increased	O
with	O
pubertal	O
status	O
but	O
was	O
not	O
affected	O
by	O
hyperprolactinemia	B-Disease
.	O

As	O
expected	O
,	O
bone	O
mineral	O
content	O
and	O
BMD	O
increased	O
with	O
sexual	O
maturity	O
.	O

After	O
adjusting	O
for	O
the	O
stage	O
of	O
sexual	O
development	O
and	O
height	O
and	O
BMI	O
z	O
scores	O
,	O
serum	O
prolactin	O
was	O
negatively	O
associated	O
with	O
trabecular	O
volumetric	O
BMD	O
at	O
the	O
ultradistal	O
radius	O
(	O
P	O
<	O
.03	O
)	O
.	O

Controlling	O
for	O
relevant	O
covariates	O
,	O
we	O
also	O
found	O
treatment	O
with	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
to	O
be	O
associated	O
with	O
lower	O
trabecular	O
BMD	O
at	O
the	O
radius	O
(	O
P	O
=	O
.03	O
)	O
and	O
BMD	O
z	O
score	O
at	O
the	O
lumbar	O
spine	O
(	O
P	O
<	O
.05	O
)	O
.	O

These	O
findings	O
became	O
more	O
marked	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
non-Hispanic	O
white	O
patients	O
.	O

Of	O
13	O
documented	O
fractures	B-Disease
,	O
3	O
occurred	O
after	O
risperidone	B-Chemical
and	O
SSRIs	O
were	O
started	O
,	O
and	O
none	O
occurred	O
in	O
patients	O
with	O
hyperprolactinemia	B-Disease
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
link	O
risperidone-induced	B-Chemical
hyperprolactinemia	B-Disease
and	O
SSRI	O
treatment	O
to	O
lower	O
BMD	O
in	O
children	O
and	O
adolescents	O
.	O

Future	O
research	O
should	O
evaluate	O
the	O
longitudinal	O
course	O
of	O
this	O
adverse	O
event	O
to	O
determine	O
its	O
temporal	O
stability	O
and	O
whether	O
a	O
higher	O
fracture	O
rate	O
ensues	O
.	O

Seizures	B-Disease
associated	O
with	O
levofloxacin	B-Chemical
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O

PURPOSE	O
:	O
We	O
present	O
a	O
case	O
of	O
a	O
patient	O
who	O
developed	O
seizures	B-Disease
shortly	O
after	O
initiating	O
treatment	O
with	O
levofloxacin	B-Chemical
and	O
to	O
discuss	O
the	O
potential	O
drug-drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
1A2	O
in	O
this	O
case	O
,	O
as	O
well	O
as	O
in	O
other	O
cases	O
,	O
of	O
levofloxacin-induced	B-Chemical
seizures	B-Disease
.	O

METHODS	O
:	O
Several	O
biomedical	O
databases	O
were	O
searched	O
including	O
MEDLINE	O
,	O
Cochrane	O
and	O
Ovid	O
.	O

The	O
main	O
search	O
terms	O
utilized	O
were	O
case	O
report	O
and	O
levofloxacin	B-Chemical
.	O

The	O
search	O
was	O
limited	O
to	O
studies	O
published	O
in	O
English	O
.	O

RESULTS	O
:	O
Six	O
cases	O
of	O
levofloxacin-induced	B-Chemical
seizures	B-Disease
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

Drug-drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
CYP1A2	B-Drug
by	O
levofloxacin	B-Chemical
are	O
likely	O
involved	O
in	O
the	O
clinical	O
outcome	O
of	O
these	O
cases	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	O
when	O
initiating	O
levofloxacin	B-Chemical
therapy	O
in	O
patients	O
taking	O
medications	O
with	O
epileptogenic	O
properties	O
that	O
are	O
CYP1A2	B-Drug
substrates	O
.	O

Mice	O
lacking	O
mPGES-1	O
are	O
resistant	O
to	O
lithium-induced	B-Chemical
polyuria	B-Disease
.	O

Cyclooxygenase-2	O
activity	O
is	O
required	O
for	O
the	O
development	O
of	O
lithium-induced	B-Chemical
polyuria	B-Disease
.	O

However	O
,	O
the	O
involvement	O
of	O
a	O
specific	O
,	O
terminal	O
prostaglandin	B-Chemical
(	O
PG	B-Chemical
)	O
isomerase	O
has	O
not	O
been	O
evaluated	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
lithium-induced	B-Chemical
polyuria	B-Disease
in	O
mice	O
deficient	O
in	O
microsomal	O
prostaglandin	B-Chemical
E	I-Chemical
synthase-1	O
(	O
mPGES-1	O
)	O
.	O

A	O
2-wk	O
administration	O
of	O
LiCl	B-Chemical
(	O
4	O
mmol.kg	O
(	O
-1	O
)	O
.day	O
(	O
-1	O
)	O
ip	O
)	O
in	O
mPGES-1	O
+/+	O
mice	O
led	O
to	O
a	O
marked	O
polyuria	B-Disease
with	O
hyposmotic	O
urine	O
.	O

This	O
was	O
associated	O
with	O
elevated	O
renal	O
mPGES-1	B-Chemical
protein	O
expression	O
and	O
increased	O
urine	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	O
excretion	O
.	O

In	O
contrast	O
,	O
mPGES-1	O
-/-	O
mice	O
were	O
largely	O
resistant	O
to	O
lithium-induced	B-Chemical
polyuria	B-Disease
and	O
a	O
urine	O
concentrating	O
defect	O
,	O
accompanied	O
by	O
nearly	O
complete	O
blockade	O
of	O
high	O
urine	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
and	O
cAMP	O
output	O
.	O

Immunoblotting	O
,	O
immunohistochemistry	O
,	O
and	O
quantitative	O
(	O
q	O
)	O
RT-PCR	O
consistently	O
detected	O
a	O
significant	O
decrease	O
in	O
aquaporin-2	O
(	O
AQP2	O
)	O
protein	O
expression	O
in	O
both	O
the	O
renal	O
cortex	O
and	O
medulla	O
of	O
lithium-treated	B-Chemical
+/+	O
mice	O
.	O

This	O
decrease	O
was	O
significantly	O
attenuated	O
in	O
the	O
-/-	O
mice	O
.	O

qRT-PCR	O
detected	O
similar	O
patterns	O
of	O
changes	O
in	O
AQP2	O
mRNA	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
.	O

Similarly	O
,	O
the	O
total	O
protein	O
abundance	O
of	O
the	O
Na-K-2Cl	B-Chemical
cotransporter	O
(	O
NKCC2	B-Chemical
)	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
of	O
the	O
+/+	O
mice	O
was	O
significantly	O
reduced	O
by	O
lithium	B-Drug
treatment	O
.	O

In	O
contrast	O
,	O
the	O
dowregulation	O
of	O
renal	O
medullary	O
NKCC2	O
expression	O
was	O
significantly	O
attenuated	O
in	O
the	O
-/-	O
mice	O
.	O

We	O
conclude	O
that	O
mPGES-1-derived	O
PGE	O
(	O
2	O
)	O
mediates	O
lithium-induced	O
polyuria	O
likely	O
via	O
inhibition	O
of	O
AQP2	O
and	O
NKCC2	O
expression	O
.	O

Identification	O
of	O
a	O
simple	O
and	O
sensitive	O
microplate	O
method	O
for	O
the	O
detection	O
of	O
oversulfated	O
chondroitin	B-Chemical
sulfate	I-Chemical
in	O
heparin	B-Chemical
products	O
.	O

Heparin	B-Chemical
is	O
a	O
commonly	O
implemented	O
anticoagulant	B-Drug
used	O
to	O
treat	O
critically	O
ill	O
patients	O
.	O

Recently	O
,	O
a	O
number	O
of	O
commercial	O
lots	O
of	O
heparin	B-Chemical
products	O
were	O
found	O
to	O
be	O
contaminated	O
with	O
an	O
oversulfated	O
chondroitin	B-Chemical
sulfate	I-Chemical
(	O
OSCS	O
)	O
derivative	O
that	O
could	O
elicit	O
a	O
hypotensive	B-Disease
response	O
in	O
pigs	O
following	O
a	O
single	O
high-dose	O
infusion	O
.	O

Using	O
both	O
contaminated	O
heparin	B-Chemical
products	O
and	O
the	O
synthetically	O
produced	O
derivative	O
,	O
we	O
showed	O
that	O
the	O
OSCS	O
produces	O
dose-dependent	O
hypotension	B-Disease
in	O
pigs	O
.	O

The	O
no	O
observed	O
effect	O
level	O
(	O
NOEL	O
)	O
for	O
this	O
contaminant	O
appears	O
to	O
be	O
approximately	O
1mg/kg	O
,	O
corresponding	O
to	O
a	O
contamination	O
level	O
of	O
approximately	O
3	O
%	O
.	O

We	O
also	O
demonstrated	O
that	O
OSCS	O
can	O
be	O
identified	O
in	O
heparin	B-Chemical
products	O
using	O
a	O
simple	O
,	O
inexpensive	O
,	O
commercially	O
available	O
heparin	B-Chemical
enzyme	O
immunoassay	O
(	O
EIA	O
)	O
kit	O
that	O
has	O
a	O
limit	O
of	O
detection	O
of	O
approximately	O
0.1	O
%	O
,	O
well	O
below	O
the	O
NOEL	O
.	O

This	O
kit	O
may	O
provide	O
a	O
useful	O
method	O
to	O
test	O
heparin	B-Chemical
products	O
for	O
contamination	O
with	O
oversulfated	O
GAG	O
derivatives	O
.	O

Doxorubicin	B-Chemical
cardiomyopathy-induced	B-Disease
inflammation	B-Disease
and	O
apoptosis	O
are	O
attenuated	O
by	O
gene	O
deletion	O
of	O
the	O
kinin	O
B1	O
receptor	O
.	O

Clinical	O
use	O
of	O
the	O
anthracycline	B-Chemical
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
is	O
limited	O
by	O
its	O
cardiotoxic	B-Disease
effects	O
,	O
which	O
are	O
attributed	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O

To	O
elucidate	O
the	O
possible	O
role	O
of	O
the	O
kinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
during	O
the	O
development	O
of	O
DOX	B-Chemical
cardiomyopathy	B-Disease
,	O
we	O
studied	O
B1R	O
knockout	O
mice	O
(	O
B1R	O
(	O
-/-	O
)	O
)	O
by	O
investigating	O
cardiac	O
inflammation	B-Disease
and	O
apoptosis	O
after	O
induction	O
of	O
DOX-induced	B-Chemical
cardiomyopathy	B-Disease
.	O

DOX	B-Chemical
control	O
mice	O
showed	O
cardiac	B-Disease
dysfunction	I-Disease
measured	O
by	O
pressure-volume	O
loops	O
in	O
vivo	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduced	O
activation	O
state	O
of	O
AKT	O
,	O
as	O
well	O
as	O
an	O
increased	O
bax/bcl2	O
ratio	O
in	O
Western	O
blots	O
,	O
indicating	O
cardiac	B-Disease
apoptosis	I-Disease
.	O

Furthermore	O
,	O
mRNA	O
levels	O
of	O
the	O
proinflammatory	O
cytokine	O
interleukin	O
6	O
were	O
increased	O
in	O
the	O
cardiac	O
tissue	O
.	O

In	O
DOX	B-Chemical
B1R	O
(	O
-/-	O
)	O
mice	O
,	O
cardiac	B-Disease
dysfunction	I-Disease
was	O
improved	O
compared	O
to	O
DOX	B-Chemical
control	O
mice	O
,	O
which	O
was	O
associated	O
with	O
normalization	O
of	O
the	O
bax/bcl-2	O
ratio	O
and	O
interleukin	O
6	O
,	O
as	O
well	O
as	O
AKT	O
activation	O
state	O
.	O

These	O
findings	O
suggest	O
that	O
B1R	O
is	O
detrimental	O
in	O
DOX	B-Chemical
cardiomyopathy	B-Disease
in	O
that	O
it	O
mediates	O
the	O
inflammatory	O
response	O
and	O
apoptosis	O
.	O

These	O
insights	O
might	O
have	O
useful	O
implications	O
for	O
future	O
studies	O
utilizing	O
B1R	O
antagonists	O
for	O
treatment	O
of	O
human	O
DOX	B-Chemical
cardiomyopathy	B-Disease
.	O

Hepatotoxicity	B-Disease
associated	O
with	O
sulfasalazine	B-Chemical
in	O
inflammatory	O
arthritis	B-Disease
:	O
A	O
case	O
series	O
from	O
a	O
local	O
surveillance	O
of	O
serious	O
adverse	O
events	O
.	O

BACKGROUND	O
:	O
Spontaneous	O
reporting	O
systems	O
for	O
adverse	O
drug	B-Drug
reactions	O
(	O
ADRs	O
)	O
are	O
handicapped	O
by	O
under-reporting	O
and	O
limited	O
detail	O
on	O
individual	O
cases	O
.	O

We	O
report	O
an	O
investigation	O
from	O
a	O
local	O
surveillance	O
for	O
serious	O
adverse	O
drug	B-Drug
reactions	O
associated	O
with	O
disease	O
modifying	O
anti-rheumatic	O
drugs	B-Drug
that	O
was	O
triggered	O
by	O
the	O
occurrence	O
of	O
liver	B-Disease
failure	I-Disease
in	O
two	O
of	O
our	O
patients	O
.	O

METHODS	O
:	O
Serious	O
ADR	O
reports	O
have	O
been	O
solicited	O
from	O
local	O
clinicians	O
by	O
regular	O
postcards	O
over	O
the	O
past	O
seven	O
years	O
.	O

Patients	O
'	O
,	O
who	O
had	O
hepatotoxicity	B-Disease
on	O
sulfasalazine	B-Chemical
and	O
met	O
a	O
definition	O
of	O
a	O
serious	O
ADR	O
,	O
were	O
identified	O
.	O

Two	O
clinicians	O
reviewed	O
structured	O
case	O
reports	O
and	O
assessed	O
causality	O
by	O
consensus	O
and	O
by	O
using	O
a	O
causality	O
assessment	O
instrument	O
.	O

The	O
likely	O
frequency	O
of	O
hepatotoxicity	B-Disease
with	O
sulfasalazine	B-Chemical
was	O
estimated	O
by	O
making	O
a	O
series	O
of	O
conservative	O
assumptions	O
.	O

RESULTS	O
:	O
Ten	O
cases	O
were	O
identified	O
:	O
eight	O
occurred	O
during	O
surveillance	O
.	O

Eight	O
patients	O
were	O
hospitalised	O
,	O
two	O
in	O
hepatic	B-Disease
failure	I-Disease
-	O
one	O
died	O
after	O
a	O
liver	O
transplant	O
.	O

All	O
but	O
one	O
event	O
occurred	O
within	O
6	O
weeks	O
of	O
treatment	O
.	O

Seven	O
patients	O
had	O
a	O
skin	B-Disease
rash	I-Disease
,	O
three	O
eosinophilia	B-Disease
and	O
one	O
interstitial	B-Disease
nephritis	I-Disease
.	O

Five	O
patients	O
were	O
of	O
Black	O
British	O
of	O
African	O
or	O
Caribbean	O
descent	O
.	O

Liver	O
enzymes	O
showed	O
a	O
hepatocellular	O
pattern	O
in	O
four	O
cases	O
and	O
a	O
mixed	O
pattern	O
in	O
six	O
.	O

Drug-related	O
hepatotoxicity	B-Disease
was	O
judged	O
probable	O
or	O
highly	O
probable	O
in	O
8	O
patients	O
.	O

The	O
likely	O
frequency	O
of	O
serious	O
hepatotoxicity	B-Disease
with	O
sulfasalazine	B-Chemical
was	O
estimated	O
at	O
0.4	O
%	O
of	O
treated	O
patients	O
.	O

CONCLUSION	O
:	O
Serious	O
hepatotoxicity	B-Disease
associated	O
with	O
sulfasalazine	B-Chemical
appears	O
to	O
be	O
under-appreciated	O
and	O
intensive	O
monitoring	O
and	O
vigilance	O
in	O
the	O
first	O
6	O
weeks	O
of	O
treatment	O
is	O
especially	O
important	O
.	O

An	O
evaluation	O
of	O
amikacin	B-Chemical
nephrotoxicity	B-Disease
in	O
the	O
hematology/oncology	O
population	O
.	O

Amikacin	B-Chemical
is	O
an	O
aminoglycoside	B-Chemical
commonly	O
used	O
to	O
provide	O
empirical	O
double	O
gram-negative	O
treatment	O
for	O
febrile	B-Disease
neutropenia	I-Disease
and	O
other	O
suspected	O
infections	B-Disease
.	O

Strategies	O
of	O
extended-interval	O
and	O
conventional	O
dosing	O
have	O
been	O
utilized	O
extensively	O
in	O
the	O
general	O
medical	O
population	O
;	O
however	O
,	O
data	O
are	O
lacking	O
to	O
support	O
a	O
dosing	O
strategy	O
in	O
the	O
hematology/oncology	O
population	O
.	O

To	O
evaluate	O
amikacin-associated	B-Chemical
nephrotoxicity	B-Disease
in	O
an	O
adult	O
hematology/oncology	O
population	O
,	O
a	O
prospective	O
,	O
randomized	O
,	O
open-label	O
trial	O
was	O
conducted	O
at	O
a	O
university-affiliated	O
medical	O
center	O
.	O

Forty	O
patients	O
with	O
a	O
diagnosis	O
consistent	O
with	O
a	O
hematologic/oncologic	B-Disease
disorder	I-Disease
that	O
required	O
treatment	O
with	O
an	O
aminoglycoside	O
were	O
randomized	O
to	O
either	O
conventional	O
or	O
extended-interval	O
amikacin	B-Drug
.	O

The	O
occurrence	O
of	O
nephrotoxicity	O
by	O
means	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	O
and	O
evaluation	O
of	O
efficacy	O
via	O
amikacin	B-Drug
serum	O
concentrations	O
with	O
respective	O
pathogens	O
were	O
assessed	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	O
was	O
similar	O
between	O
the	O
conventional	O
and	O
extended-interval	O
groups	O
,	O
at	O
10	O
%	O
and	O
5	O
%	O
,	O
respectively	O
(	O
P	O
=	O
1.00	O
)	O
.	O

Six	O
patients	O
in	O
the	O
conventional	O
group	O
had	O
a	O
positive	O
culture	O
,	O
compared	O
with	O
none	O
in	O
the	O
extended-interval	O
group	O
(	O
P	O
=	O
0.002	O
)	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	O
was	O
similar	O
between	O
the	O
two	O
dosing	O
regimens	O
,	O
but	O
the	O
distribution	O
of	O
risk	O
factors	O
was	O
variable	O
between	O
the	O
two	O
groups	O
.	O

Efficacy	O
could	O
not	O
be	O
assessed	O
.	O

Memory	O
function	O
and	O
serotonin	B-Chemical
transporter	O
promoter	B-Drug
gene	O
polymorphism	O
in	O
ecstasy	B-Chemical
(	O
MDMA	B-Chemical
)	O
users	O
.	O

Although	O
3,4-methylenedioxymethamphetamine	B-Chemical
(	O
MDMA	B-Chemical
or	O
ecstasy	B-Chemical
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	B-Chemical
(	O
5-HT	B-Chemical
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	O
,	O
little	O
is	O
known	O
about	O
the	O
long-term	O
consequences	O
of	O
MDMA-induced	B-Chemical
5-HT	B-Chemical
neurotoxic	B-Disease
lesions	I-Disease
on	O
functions	O
in	O
which	O
5-HT	B-Chemical
is	O
involved	O
,	O
such	O
as	O
cognitive	O
function	O
.	O

Because	O
5-HT	B-Chemical
transporters	O
play	O
a	O
key	O
element	O
in	O
the	O
regulation	O
of	O
synaptic	O
5-HT	B-Chemical
transmission	O
it	O
may	O
be	O
important	O
to	O
control	O
for	O
the	O
potential	O
covariance	O
effect	O
of	O
a	O
polymorphism	O
in	O
the	O
5-HT	B-Chemical
transporter	O
promoter	B-Drug
gene	O
region	O
(	O
5-HTTLPR	O
)	O
when	O
studying	O
the	O
effects	O
of	O
MDMA	B-Chemical
as	O
well	O
as	O
cognitive	O
functioning	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moderate	O
and	O
heavy	O
MDMA	B-Chemical
use	O
on	O
cognitive	O
function	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
long-term	O
abstention	O
from	O
MDMA	B-Chemical
,	O
in	O
subjects	O
genotyped	O
for	O
5-HTTLPR	O
.	O

A	O
second	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
these	O
effects	O
differ	O
for	O
females	O
and	O
males	O
.	O

Fifteen	O
moderate	O
MDMA	B-Chemical
users	O
(	O
<	O
55	O
lifetime	O
tablets	O
)	O
,	O
22	O
heavy	O
MDMA+	B-Chemical
users	O
(	O
>	O
55	O
lifetime	O
tablets	O
)	O
,	O
16	O
ex-MDMA+	B-Chemical
users	O
(	O
last	O
tablet	O
>	O
1	O
year	O
ago	O
)	O
and	O
13	O
controls	O
were	O
compared	O
on	O
a	O
battery	O
of	O
neuropsychological	O
tests	O
.	O

DNA	O
from	O
peripheral	O
nuclear	O
blood	O
cells	O
was	O
genotyped	O
for	O
5-HTTLPR	O
using	O
standard	O
polymerase	O
chain	O
reaction	O
methods.A	O
significant	O
group	O
effect	O
was	O
observed	O
only	O
on	O
memory	O
function	O
tasks	O
(	O
p	O
=	O
0.04	O
)	O
but	O
not	O
on	O
reaction	O
times	O
(	O
p	O
=	O
0.61	O
)	O
or	O
attention/executive	O
functioning	O
(	O
p	O
=	O
0.59	O
)	O
.	O

Heavy	O
and	O
ex-MDMA+	B-Chemical
users	O
performed	O
significantly	O
poorer	O
on	O
memory	B-Disease
tasks	O
than	O
controls	O
.	O

In	O
contrast	O
,	O
no	O
evidence	O
of	O
memory	B-Disease
impairment	O
was	O
observed	O
in	O
moderate	O
MDMA	B-Chemical
users	O
.	O

No	O
significant	O
effect	O
of	O
5-HTTLPR	O
or	O
gender	O
was	O
observed	O
.	O

While	O
the	O
use	O
of	O
MDMA	B-Chemical
in	O
quantities	O
that	O
may	O
be	O
considered	O
``	O
moderate	O
''	O
is	O
not	O
associated	O
with	O
impaired	B-Disease
memory	I-Disease
functioning	I-Disease
,	O
heavy	O
use	O
of	O
MDMA	B-Chemical
use	O
may	O
lead	B-Drug
to	O
long	O
lasting	O
memory	B-Disease
impairments	I-Disease
.	O

No	O
effect	O
of	O
5-HTTLPR	O
or	O
gender	O
on	O
memory	O
function	O
or	O
MDMA	B-Chemical
use	O
was	O
observed	O
.	O

Aging	O
process	O
of	O
epithelial	O
cells	O
of	O
the	O
rat	O
prostate	O
lateral	O
lobe	O
in	O
experimental	O
hyperprolactinemia	B-Disease
induced	O
by	O
haloperidol	B-Chemical
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
hyperprolactinemia	B-Disease
,	O
induced	O
by	O
haloperidol	B-Chemical
(	O
HAL	B-Chemical
)	O
on	O
age	O
related	O
morphology	O
and	O
function	O
changes	O
of	O
epithelial	O
cells	O
in	O
rat	O
prostate	O
lateral	O
lobe	O
.	O

The	O
study	O
was	O
performed	O
on	O
sexually	O
mature	O
male	O
rats	O
.	O

Serum	O
concentrations	O
of	O
prolactin	O
(	O
PRL	B-Chemical
)	O
and	O
testosterone	B-Chemical
(	O
T	B-Chemical
)	O
were	O
measured	O
.	O

Tissue	O
sections	O
were	O
evaluated	O
with	O
light	O
and	O
electron	O
microscopy	O
.	O

Immunohistochemical	O
reactions	O
for	O
Anti-Proliferating	O
Cell	O
Nuclear	O
Antigen	O
(	O
PCNA	O
)	O
were	O
performed	O
.	O

In	O
rats	O
of	O
the	O
experimental	O
group	O
,	O
the	O
mean	O
concentration	O
of	O
:	O
PRL	B-Chemical
was	O
more	O
than	O
twice	O
higher	O
,	O
whereas	O
T	B-Chemical
concentration	O
was	O
almost	O
twice	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O

Light	O
microscopy	O
visualized	O
the	O
following	O
:	O
hypertrophy	B-Disease
and	O
epithelium	O
hyperplasia	B-Disease
of	O
the	O
glandular	O
ducts	O
,	O
associated	O
with	O
increased	O
PCNA	O
expression	O
.	O

Electron	O
microscopy	O
revealed	O
changes	O
in	O
columnar	O
epithelial	O
cells	O
,	O
concerning	O
organelles	O
,	O
engaged	O
in	O
protein	O
synthesis	O
and	O
secretion	O
.	O

Does	O
supplemental	O
vitamin	B-Chemical
C	I-Chemical
increase	O
cardiovascular	B-Disease
disease	I-Disease
risk	O
in	O
women	O
with	O
diabetes	B-Disease
?	O
BACKGROUND	O
:	O
Vitamin	B-Chemical
C	I-Chemical
acts	O
as	O
a	O
potent	O
antioxidant	O
;	O
however	O
,	O
it	O
can	O
also	O
be	O
a	O
prooxidant	O
and	O
glycate	O
protein	O
under	O
certain	O
circumstances	O
in	O
vitro	O
.	O

These	O
observations	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
high	O
intake	O
of	O
vitamin	B-Chemical
C	I-Chemical
in	O
diabetic	B-Disease
persons	O
might	O
promote	O
atherosclerosis	B-Disease
.	O

OBJECTIVE	O
:	O
The	O
objective	O
was	O
to	O
examine	O
the	O
relation	O
between	O
vitamin	B-Chemical
C	I-Chemical
intake	O
and	O
mortality	O
from	O
cardiovascular	B-Disease
disease	I-Disease
.	O

DESIGN	O
:	O
We	O
studied	O
the	O
relation	O
between	O
vitamin	B-Chemical
C	I-Chemical
intake	O
and	O
mortality	O
from	O
total	O
cardiovascular	B-Disease
disease	I-Disease
(	O
n	O
=	O
281	O
)	O
,	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
(	O
n	O
=	O
175	O
)	O
,	O
and	O
stroke	B-Disease
(	O
n	O
=	O
57	O
)	O
in	O
1923	O
postmenopausal	O
women	O
who	O
reported	O
being	O
diabetic	B-Disease
at	O
baseline	O
.	O

Diet	O
was	O
assessed	O
with	O
a	O
food-frequency	O
questionnaire	O
at	O
baseline	O
,	O
and	O
subjects	O
initially	O
free	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
were	O
prospectively	O
followed	O
for	O
15	O
y	O
.	O

RESULTS	O
:	O
After	O
adjustment	O
for	O
cardiovascular	B-Disease
disease	I-Disease
risk	O
factors	O
,	O
type	O
of	O
diabetes	B-Disease
medication	O
used	O
,	O
duration	O
of	O
diabetes	B-Disease
,	O
and	O
intakes	O
of	O
folate	B-Chemical
,	O
vitamin	B-Chemical
E	I-Chemical
,	O
and	O
beta-carotene	B-Chemical
,	O
the	O
adjusted	O
relative	O
risks	O
of	O
total	O
cardiovascular	B-Disease
disease	I-Disease
mortality	O
were	O
1.0	O
,	O
0.97	O
,	O
1.11	O
,	O
1.47	O
,	O
and	O
1.84	O
(	O
P	O
for	O
trend	O
<	O
0.01	O
)	O
across	O
quintiles	O
of	O
total	O
vitamin	B-Chemical
C	I-Chemical
intake	O
from	O
food	O
and	O
supplements	O
.	O

Adjusted	O
relative	O
risks	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
were	O
1.0	O
,	O
0.81	O
,	O
0.99	O
,	O
1.26	O
,	O
and	O
1.91	O
(	O
P	O
for	O
trend	O
=	O
0.01	O
)	O
and	O
of	O
stroke	B-Disease
were	O
1.0	O
,	O
0.52	O
,	O
1.23	O
,	O
2.22	O
,	O
and	O
2.57	O
(	O
P	O
for	O
trend	O
<	O
0.01	O
)	O
.	O

When	O
dietary	O
and	O
supplemental	O
vitamin	B-Chemical
C	I-Chemical
were	O
analyzed	O
separately	O
,	O
only	O
supplemental	O
vitamin	B-Chemical
C	I-Chemical
showed	O
a	O
positive	O
association	O
with	O
mortality	O
endpoints	O
.	O

Vitamin	B-Chemical
C	I-Chemical
intake	O
was	O
unrelated	O
to	O
mortality	O
from	O
cardiovascular	B-Disease
disease	I-Disease
in	O
the	O
nondiabetic	O
subjects	O
at	O
baseline	O
.	O

CONCLUSION	O
:	O
A	O
high	O
vitamin	B-Chemical
C	I-Chemical
intake	O
from	O
supplements	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cardiovascular	B-Disease
disease	I-Disease
mortality	O
in	O
postmenopausal	O
women	O
with	O
diabetes	B-Disease
.	O

Absolute	O
and	O
attributable	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
on	O
combined	O
cyproterone	B-Chemical
acetate	I-Chemical
and	O
ethinylestradiol	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
achieve	O
absolute	O
risk	O
estimates	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
among	O
women	O
on	O
cyproterone	B-Chemical
acetate	I-Chemical
plus	O
ethinylestradiol	B-Chemical
(	O
CPA/EE	B-Chemical
)	O
,	O
and	O
among	O
women	O
on	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

METHODS	O
:	O
From	O
the	O
Danish	O
National	O
Register	O
of	O
Patients	O
(	O
NRP	O
)	O
,	O
1996	O
to	O
1998	O
,	O
the	O
records	O
of	O
1.1	O
million	O
Danish	O
women	O
,	O
ages	O
15	O
to	O
44	O
years	O
,	O
were	O
searched	O
for	O
evidence	O
of	O
VTE	O
.	O

COC	O
use	O
was	O
ascertained	O
through	O
mailed	O
questionnaires	O
.	O

Sales	O
statistics	O
of	O
COCs	O
and	O
CPA/EE	B-Chemical
were	O
provided	O
through	O
Danish	O
Drug	B-Drug
Statistics	O
.	O

RESULTS	O
:	O
During	O
the	O
time	O
frame	O
of	O
the	O
study	O
,	O
330	O
women	O
were	O
found	O
to	O
have	O
had	O
VTE	O
while	O
on	O
COCs	O
.	O

Of	O
these	O
women	O
,	O
67	O
were	O
on	O
levonorgestrel-containing	O
COCs	O
.	O

Eleven	O
were	O
on	O
CPA/EE	O
.	O

The	O
corresponding	O
absolute	O
risk	O
of	O
VTE	O
was	O
3.4	O
(	O
range	O
,	O
3.1-3.8	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
the	O
women	O
on	O
COCs	O
,	O
4.2	O
(	O
range	O
,	O
3.2-5.2	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
women	O
on	O
levonorgestrel-containing	O
COCs	O
,	O
and	O
3.1	O
(	O
range	O
,	O
1.3-4.9	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
the	O
women	O
on	O
CPA/EE	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
the	O
absolute	O
risk	O
of	O
VTE	O
among	O
Danish	O
women	O
on	O
COCs	O
is	O
similar	O
to	O
that	O
among	O
women	O
taking	O
CPA/EE	O
.	O

Effect	O
of	O
lindane	B-Chemical
on	O
hepatic	O
and	O
brain	O
cytochrome	O
P450s	O
and	O
influence	O
of	O
P450	O
modulation	O
in	O
lindane	B-Chemical
induced	O
neurotoxicity	B-Disease
.	O

Oral	O
administration	O
of	O
lindane	B-Chemical
(	O
2.5	O
,	O
5	O
,	O
10	O
and	O
15	O
mg/kg	O
,	O
body	O
weight	O
)	O
for	O
5	O
days	O
was	O
found	O
to	O
produce	O
a	O
dose-dependent	O
increase	O
in	O
the	O
activity	O
of	O
P450	O
dependent	O
7-ethoxyresorufin-O-deethylase	O
(	O
EROD	O
)	O
,	O
7-pentoxyresorufin-O-dealkylase	O
(	O
PROD	O
)	O
and	O
N-nitrosodimethylamine	B-Chemical
demethylase	O
(	O
NDMA-d	B-Chemical
)	O
in	O
rat	O
brain	O
and	O
liver	O
.	O

A	O
significant	O
increase	O
in	O
the	O
hepatic	O
and	O
brain	O
P450	O
monooxygenases	O
was	O
also	O
observed	O
when	O
the	O
duration	O
of	O
exposure	O
of	O
low	O
dose	O
(	O
2.5	O
mg/kg	O
)	O
of	O
lindane	B-Chemical
was	O
increased	O
from	O
5	O
days	O
to	O
15	O
or	O
21	O
days	O
.	O

As	O
observed	O
with	O
different	O
doses	O
,	O
the	O
magnitude	O
of	O
induction	O
in	O
the	O
activity	O
of	O
P450	O
monooxygenases	O
was	O
several	O
fold	O
higher	O
in	O
liver	O
microsomes	O
when	O
compared	O
with	O
the	O
brain	O
.	O

Western	O
blotting	O
studies	O
have	O
indicated	O
that	O
the	O
increase	O
in	O
the	O
P450	O
enzymes	O
could	O
be	O
due	O
to	O
the	O
increase	O
in	O
the	O
expression	O
of	O
P450	O
1A1/1A2	O
,	O
2B1/2B2	O
and	O
2E1	O
isoenzymes	O
.	O

In	O
vitro	O
studies	O
using	O
organic	O
inhibitors	O
specific	O
for	O
individual	O
P450	O
isoenzymes	O
and	O
antibody	O
inhibition	O
experiments	O
have	O
further	O
demonstrated	O
that	O
the	O
increase	O
in	O
the	O
activity	O
of	O
PROD	O
,	O
EROD	O
and	O
NDMA-d	B-Chemical
are	O
due	O
to	O
the	O
increase	O
in	O
the	O
levels	O
of	O
P450	O
2B1/2B2	O
,	O
1A1/1A2	O
and	O
2E1	O
isoenzymes	O
,	O
respectively	O
.	O

Induction	O
studies	O
have	O
further	O
shown	O
that	O
while	O
pretreatment	O
of	O
3-methylcholanthrene	B-Chemical
(	O
MC	B-Chemical
)	O
,	O
an	O
inducer	O
of	O
P4501A1/1A2	O
,	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
incidence	O
of	O
lindane	B-Chemical
induced	O
convulsions	B-Disease
,	O
pretreatment	O
with	O
phenobarbital	B-Chemical
(	O
PB	O
)	O
,	O
an	O
inducer	O
of	O
P450	O
2B1/2B2	O
or	O
ethanol	B-Chemical
,	O
an	O
inducer	O
of	O
P450	O
2E1	O
catalysed	O
reactions	O
,	O
significantly	O
increased	O
the	O
incidence	O
of	O
lindane	B-Chemical
induced	O
convulsions	B-Disease
.	O

Similarly	O
,	O
when	O
the	O
P450-mediated	O
metabolism	O
of	O
lindane	B-Chemical
was	O
blocked	O
by	O
cobalt	B-Chemical
chloride	I-Chemical
incidence	O
of	O
convulsions	B-Disease
was	O
increased	O
in	O
animals	O
treated	O
with	O
lindane	B-Chemical
indicating	O
that	O
lindane	B-Chemical
per	O
se	O
or	O
its	O
metabolites	O
formed	O
by	O
PB	O
or	O
ethanol	B-Chemical
inducible	O
P450	O
isoenzymes	O
are	O
involved	O
in	O
its	O
neurobehavioral	O
toxicity	B-Disease
.	O

Seizure	B-Disease
associated	O
with	O
sleep	B-Disease
deprivation	I-Disease
and	O
sustained-release	O
bupropion	B-Chemical
.	O

This	O
case	O
report	O
describes	O
a	O
generalized	O
seizure	B-Disease
associated	O
with	O
sustained-release	O
bupropion	B-Chemical
use	O
and	O
sleep	B-Disease
deprivation	I-Disease
.	O

The	O
subject	O
,	O
a	O
31-year-old	O
female	O
smoker	O
,	O
was	O
participating	O
in	O
a	O
clinical	O
trial	O
evaluating	O
an	O
investigational	O
medication	O
for	O
smoking	O
cessation	O
that	O
used	O
sustained-release	O
bupropion	B-Chemical
as	O
an	O
active	O
control	O
.	O

After	O
5	O
weeks	O
of	O
bupropion	B-Chemical
use	O
,	O
the	O
subject	O
experienced	O
a	O
generalized	O
tonic	O
clonic	O
seizure	B-Disease
after	O
staying	O
up	O
nearly	O
all	O
night	O
packing	O
and	O
moving	O
to	O
a	O
new	O
residence	O
.	O

The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
seizures	B-Disease
.	O

We	O
suggest	O
that	O
sleep	B-Disease
deprivation	I-Disease
may	O
add	O
to	O
the	O
risk	O
of	O
bupropion-associated	B-Chemical
seizures	B-Disease
.	O

Nephrotoxic	B-Disease
effects	O
in	O
high-risk	O
patients	O
undergoing	O
angiography	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
iodinated	O
contrast	O
medium	O
can	O
result	O
in	O
nephropathy	B-Disease
.	O

Whether	O
iso-osmolar	O
contrast	O
medium	O
is	O
less	O
nephrotoxic	B-Disease
than	O
low-osmolar	O
contrast	O
medium	O
in	O
high-risk	O
patients	O
is	O
uncertain	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
,	O
prospective	O
,	O
multicenter	O
study	O
comparing	O
the	O
nephrotoxic	B-Disease
effects	O
of	O
an	O
iso-osmolar	O
,	O
dimeric	O
,	O
nonionic	O
contrast	O
medium	O
,	O
iodixanol	B-Chemical
,	O
with	O
those	O
of	O
a	O
low-osmolar	O
,	O
nonionic	O
,	O
monomeric	O
contrast	O
medium	O
,	O
iohexol	B-Chemical
.	O

The	O
study	O
involved	O
129	O
patients	O
with	O
diabetes	B-Disease
with	O
serum	O
creatinine	B-Chemical
concentrations	O
of	O
1.5	O
to	O
3.5	O
mg	O
per	O
deciliter	O
who	O
underwent	O
coronary	O
or	O
aortofemoral	O
angiography	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
peak	O
increase	O
from	O
base	O
line	O
in	O
the	O
creatinine	B-Chemical
concentration	O
during	O
the	O
three	O
days	O
after	O
angiography	O
.	O

Other	O
end	O
points	O
were	O
an	O
increase	O
in	O
the	O
creatinine	B-Chemical
concentration	O
of	O
0.5	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
an	O
increase	O
of	O
1.0	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
and	O
a	O
change	O
in	O
the	O
creatinine	B-Chemical
concentration	O
from	O
day	O
0	O
to	O
day	O
7	O
.	O

RESULTS	O
:	O
The	O
creatinine	B-Chemical
concentration	O
increased	O
significantly	O
less	O
in	O
patients	O
who	O
received	O
iodixanol	B-Chemical
.	O

From	O
day	O
0	O
to	O
day	O
3	O
,	O
the	O
mean	O
peak	O
increase	O
in	O
creatinine	B-Chemical
was	O
0.13	O
mg	O
per	O
deciliter	O
in	O
the	O
iodixanol	B-Chemical
group	O
and	O
0.55	O
mg	O
per	O
deciliter	O
in	O
the	O
iohexol	B-Chemical
group	O
(	O
P=0.001	O
;	O
the	O
increase	O
with	O
iodixanol	B-Chemical
minus	O
the	O
increase	O
with	O
iohexol	B-Chemical
,	O
-0.42	O
mg	O
per	O
deciliter	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
-0.73	O
to	O
-0.22	O
]	O
)	O
.	O

Two	O
of	O
the	O
64	O
patients	O
in	O
the	O
iodixanol	B-Chemical
group	O
(	O
3	O
percent	O
)	O
had	O
an	O
increase	O
in	O
the	O
creatinine	B-Chemical
concentration	O
of	O
0.5	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
as	O
compared	O
with	O
17	O
of	O
the	O
65	O
patients	O
in	O
the	O
iohexol	B-Chemical
group	O
(	O
26	O
percent	O
)	O
(	O
P=0.002	O
;	O
odds	O
ratio	O
for	O
such	O
an	O
increase	O
in	O
the	O
iodixanol	B-Chemical
group	O
,	O
0.09	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
0.02	O
to	O
0.41	O
]	O
)	O
.	O

No	O
patient	O
receiving	O
iodixanol	B-Chemical
had	O
an	O
increase	O
of	O
1.0	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
but	O
10	O
patients	O
in	O
the	O
iohexol	B-Chemical
group	O
(	O
15	O
percent	O
)	O
did	O
.	O

The	O
mean	O
change	O
in	O
the	O
creatinine	B-Chemical
concentration	O
from	O
day	O
0	O
to	O
day	O
7	O
was	O
0.07	O
mg	O
per	O
deciliter	O
in	O
the	O
iodixanol	B-Chemical
group	O
and	O
0.24	O
mg	O
per	O
deciliter	O
in	O
the	O
iohexol	B-Chemical
group	O
(	O
P=0.003	O
;	O
value	O
in	O
the	O
iodixanol	B-Chemical
group	O
minus	O
the	O
value	O
in	O
the	O
iohexol	B-Chemical
group	O
,	O
-0.17	O
mg	O
per	O
deciliter	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
-0.34	O
to	O
-0.07	O
]	O
)	O
.	O

CONCLUSIONS	O
:	O
Nephropathy	B-Disease
induced	O
by	O
contrast	O
medium	O
may	O
be	O
less	O
likely	O
to	O
develop	O
in	O
high-risk	O
patients	O
when	O
iodixanol	B-Chemical
is	O
used	O
rather	O
than	O
a	O
low-osmolar	O
,	O
nonionic	O
contrast	O
medium	O
.	O

Experimental	O
cranial	O
pain	B-Disease
elicited	O
by	O
capsaicin	B-Chemical
:	O
a	O
PET	O
study	O
.	O

Using	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
it	O
was	O
shown	O
recently	O
that	O
in	O
migraine	B-Disease
without	O
aura	O
certain	O
areas	O
in	O
the	O
brain	O
stem	O
were	O
activated	O
during	O
the	O
headache	B-Disease
state	O
,	O
but	O
not	O
in	O
the	O
headache	B-Disease
free	O
interval	O
.	O

It	O
was	O
suggested	O
that	O
this	O
brain	O
stem	O
activation	O
is	O
inherent	O
to	O
the	O
migraine	B-Disease
attack	O
itself	O
and	O
represents	O
the	O
so	O
called	O
'migraine	B-Disease
generator	O
'	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
performed	O
an	O
experimental	O
pain	B-Disease
study	O
in	O
seven	O
healthy	O
volunteers	O
,	O
using	O
the	O
same	O
positioning	O
in	O
the	O
PET	O
scanner	O
as	O
in	O
the	O
migraine	B-Disease
patients	O
.	O

A	O
small	O
amount	O
of	O
capsaicin	B-Chemical
was	O
administered	O
subcutaneously	O
in	O
the	O
right	O
forehead	O
to	O
evoke	O
a	O
burning	O
painful	B-Disease
sensation	O
in	O
the	O
first	O
division	O
of	O
the	O
trigeminal	O
nerve	O
.	O

Increases	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
were	O
found	O
bilaterally	O
in	O
the	O
insula	O
,	O
in	O
the	O
anterior	O
cingulate	O
cortex	O
,	O
the	O
cavernous	O
sinus	O
and	O
the	O
cerebellum	O
.	O

Using	O
the	O
same	O
stereotactic	O
space	O
limits	O
as	O
in	O
the	O
above	O
mentioned	O
migraine	B-Disease
study	O
no	O
brain	O
stem	O
activation	O
was	O
found	O
in	O
the	O
acute	O
pain	B-Disease
state	O
compared	O
to	O
the	O
pain	B-Disease
free	O
state	O
.	O

The	O
increase	O
of	O
activation	O
in	O
the	O
region	O
of	O
the	O
cavernous	O
sinus	O
however	O
,	O
suggests	O
that	O
this	O
structure	O
is	O
more	O
likely	O
to	O
be	O
involved	O
in	O
trigeminal	O
transmitted	O
pain	B-Disease
as	O
such	O
,	O
rather	O
than	O
in	O
a	O
specific	O
type	O
of	O
headache	B-Disease
as	O
was	O
suggested	O
for	O
cluster	B-Disease
headache	I-Disease
.	O

Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
with	O
risperidone	B-Chemical
.	O

Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
dopamine	B-Chemical
D2	O
receptor	O
blockade	O
in	O
the	O
striatum	O
of	O
the	O
basal	O
ganglia	O
.	O

Risperidone	B-Chemical
,	O
a	O
benzisoxazole	B-Chemical
derivative	O
antipsychotic	O
,	O
has	O
high	O
serotonin	B-Chemical
5-HT2	O
receptor	O
blockade	O
and	O
dose-related	O
D2	O
receptor	O
blockade	O
.	O

The	O
high	O
ratio	O
is	O
believed	O
to	O
impart	O
the	O
low	O
frequency	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
with	O
risperidone	B-Chemical
at	O
low	O
dosages	O
.	O

With	O
this	O
low	O
frequency	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
,	O
it	O
was	O
thought	O
the	O
frequency	O
of	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
might	O
also	O
be	O
lowered	O
.	O

A	O
73-year-old	O
woman	O
developed	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
after	O
monotherapy	O
with	O
risperidone	B-Chemical
.	O

The	O
syndrome	O
reversed	O
after	O
discontinuing	O
risperidone	B-Chemical
and	O
starting	O
treatment	O
with	O
dantrolene	B-Chemical
and	O
bromocriptine	B-Chemical
.	O

It	O
appears	O
that	O
the	O
protection	O
from	O
extrapyramidal	O
side	O
effects	O
observed	O
with	O
risperidone	B-Chemical
does	O
not	O
ensure	O
protection	O
from	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
.	O

Hepatic	O
and	O
extrahepatic	O
angiotensinogen	O
gene	O
expression	O
in	O
rats	O
with	O
acute	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

Plasma	O
concentration	O
and	O
urine	O
excretion	O
of	O
the	O
renin-angiotensin	B-Chemical
system	O
proteins	O
are	O
altered	O
in	O
rats	O
with	O
nephrotic	B-Disease
syndrome	I-Disease
(	O
NS	B-Disease
)	O
.	O

In	O
this	O
work	O
the	O
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
levels	O
of	O
angiotensinogen	O
(	O
Ao	O
)	O
were	O
analyzed	O
with	O
the	O
slot-blot	O
hybridization	O
technique	O
in	O
liver	O
and	O
other	O
extrahepatic	O
tissues	O
:	O
kidney	O
,	O
heart	O
,	O
brain	O
,	O
and	O
adrenal	O
gland	O
from	O
control	O
,	O
nephrotic	B-Disease
,	O
and	O
pair-fed	O
(	O
PF	O
)	O
rats	O
.	O

NS	B-Disease
was	O
induced	O
by	O
a	O
single	O
injection	O
of	O
puromycin	B-Chemical
amino-nucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
.	O

Although	O
a	O
great	O
urinary	O
excretion	O
and	O
half-normal	O
plasma	O
levels	O
of	O
Ao	O
were	O
observed	O
on	O
day	O
6	O
after	O
PAN	B-Chemical
injection	O
,	O
when	O
NS	B-Disease
was	O
clearly	O
established	O
,	O
hepatic	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
.	O

Furthermore	O
,	O
the	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
in	O
any	O
of	O
the	O
extrahepatic	O
tissues	O
studied	O
on	O
day	O
6	O
,	O
nor	O
did	O
its	O
hepatic	O
levels	O
at	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
or	O
7	O
after	O
PAN	B-Chemical
injection	O
.	O

These	O
data	O
suggest	O
that	O
the	O
hepatic	O
and	O
extrahepatic	O
Ao	O
mRNA	O
levels	O
are	O
unaltered	O
during	O
the	O
development	O
of	O
the	O
acute	O
NS	B-Disease
induced	O
by	O
PAN	B-Chemical
.	O

Cyclophosphamide	B-Chemical
associated	O
bladder	B-Disease
cancer	I-Disease
--	O
a	O
highly	O
aggressive	O
disease	O
:	O
analysis	O
of	O
12	O
cases	O
.	O

PURPOSE	O
:	O
We	O
gained	O
knowledge	O
of	O
the	O
etiology	O
,	O
treatment	O
and	O
prevention	O
of	O
cyclophosphamide	B-Chemical
associated	O
urothelial	B-Disease
cancer	I-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
medical	O
records	O
of	O
6	O
men	O
and	O
6	O
women	O
(	O
mean	O
age	O
55	O
years	O
)	O
with	O
cyclophosphamide	B-Chemical
associated	O
bladder	B-Disease
cancer	I-Disease
were	O
reviewed	O
.	O

RESULTS	O
:	O
All	O
tumors	B-Disease
were	O
grade	O
3	O
or	O
4	O
transitional	O
cell	O
carcinoma	B-Disease
.	O

Of	O
the	O
5	O
patients	O
initially	O
treated	O
with	O
endoscopic	O
resection	O
alone	O
only	O
1	O
is	O
alive	O
without	O
disease	O
.	O

Of	O
the	O
6	O
patients	O
who	O
underwent	O
early	O
cystectomy	O
4	O
were	O
alive	O
at	O
24	O
to	O
111	O
months	O
.	O

The	O
remaining	O
patient	O
with	O
extensive	O
cancer	B-Disease
underwent	O
partial	O
cystectomy	O
for	O
palliation	O
and	O
died	O
3	O
months	O
later	O
.	O

CONCLUSIONS	O
:	O
Cyclophosphamide	B-Chemical
associated	O
bladder	B-Disease
tumor	I-Disease
is	O
an	O
aggressive	O
disease	O
.	O

However	O
,	O
long-term	O
survival	O
is	O
possible	O
when	O
radical	O
cystectomy	O
is	O
performed	O
for	O
bladder	B-Disease
tumors	I-Disease
with	O
any	O
sign	O
of	O
invasion	O
and	O
for	O
recurrent	O
high	O
grade	O
disease	O
,	O
even	O
when	O
noninvasive	O
.	O

Leg	B-Disease
and	I-Disease
back	I-Disease
pain	I-Disease
after	O
spinal	O
anaesthesia	O
involving	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
.	O

Fifty-four	O
patients	O
,	O
aged	O
27-90	O
years	O
,	O
who	O
were	O
given	O
lignocaine	B-Chemical
5	O
%	O
in	O
6.8	O
%	O
glucose	B-Chemical
solution	O
for	O
spinal	O
anaesthesia	O
were	O
studied	O
.	O

Thirteen	O
of	O
these	O
patients	O
experienced	O
pain	B-Disease
in	B-Disease
the	I-Disease
legs	I-Disease
and/or	I-Disease
back	I-Disease
after	O
recovery	O
from	O
anaesthesia	O
.	O

The	O
patients	O
affected	O
were	O
younger	O
(	O
p	O
<	O
0.05	O
)	O
and	O
the	O
site	O
of	O
the	O
dural	O
puncture	O
was	O
higher	O
(	O
p	O
<	O
0.01	O
)	O
than	O
those	O
individuals	O
without	O
pain	B-Disease
.	O

Five	O
of	O
the	O
13	O
patients	O
(	O
38	O
%	O
)	O
with	O
pain	B-Disease
and	O
seven	O
of	O
the	O
41	O
patients	O
(	O
17	O
%	O
)	O
without	O
pain	B-Disease
admitted	O
to	O
a	O
high	O
alcohol	B-Chemical
intake	O
,	O
which	O
might	O
be	O
a	O
contributing	O
factor	O
.	O

Leg	B-Disease
and/or	I-Disease
back	I-Disease
pain	I-Disease
is	O
associated	O
with	O
the	O
intrathecal	O
use	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
.	O

Acute	O
blood	O
pressure	O
elevations	O
with	O
caffeine	B-Chemical
in	O
men	O
with	O
borderline	O
systemic	O
hypertension	B-Disease
.	O

Whether	O
the	O
vasoconstrictive	O
actions	O
of	O
caffeine	B-Chemical
are	O
enhanced	O
in	O
hypertensive	B-Disease
persons	O
has	O
not	O
been	O
demonstrated	O
.	O

Thus	O
,	O
caffeine	B-Chemical
(	O
3.3	O
mg/kg	O
)	O
versus	O
placebo	O
was	O
tested	O
in	O
48	O
healthy	O
men	O
(	O
aged	O
20	O
to	O
35	O
years	O
)	O
selected	O
after	O
screening	O
on	O
2	O
separate	O
occasions	O
.	O

Borderline	O
hypertensive	B-Disease
men	O
(	O
n	O
=	O
24	O
)	O
were	O
selected	O
with	O
screening	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
of	O
140	O
to	O
160	O
mm	O
Hg	O
and/or	O
diastolic	O
BP	O
90	O
to	O
99	O
mm	O
Hg	O
.	O

Low-risk	O
controls	O
(	O
n	O
=	O
24	O
)	O
reported	O
no	O
parental	O
history	O
of	O
hypertension	B-Disease
and	O
had	O
screening	O
BP	O
<	O
130/85	O
mm	O
Hg	O
.	O

Participants	O
were	O
then	O
tested	O
on	O
2	O
occasions	O
after	O
12-hour	O
abstinence	O
from	O
caffeine	B-Chemical
in	O
each	O
of	O
2	O
protocols	O
;	O
this	O
required	O
a	O
total	O
of	O
4	O
laboratory	O
visits	O
.	O

Caffeine-induced	B-Chemical
changes	O
in	O
diastolic	O
BP	O
were	O
2	O
to	O
3	O
times	O
larger	O
in	O
borderline	O
subjects	O
than	O
in	O
controls	O
(	O
+8.4	O
vs	O
+3.8	O
mm	O
Hg	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
were	O
attributable	O
to	O
larger	O
changes	O
in	O
impedance-derived	O
measures	O
of	O
systemic	O
vascular	O
resistance	O
(	O
+135	O
vs	O
+45	O
dynes.s.cm-5	O
,	O
p	O
<	O
0.004	O
)	O
.	O

These	O
findings	O
were	O
consistent	O
and	O
reached	O
significance	O
in	O
both	O
protocols	O
.	O

The	O
percentage	O
of	O
borderline	O
subjects	O
in	O
whom	O
diastolic	O
BP	O
changes	O
exceeded	O
the	O
median	O
control	O
response	O
was	O
96	O
%	O
.	O

Consequently	O
,	O
whereas	O
all	O
participants	O
exhibited	O
normotensive	O
levels	O
during	O
the	O
resting	O
predrug	O
baseline	O
,	O
33	O
%	O
of	O
borderline	O
subjects	O
achieved	O
hypertensive	B-Disease
BP	O
levels	O
after	O
caffeine	B-Chemical
ingestion	O
.	O

Thus	O
,	O
in	O
borderline	O
hypertensive	B-Disease
men	O
,	O
exaggerated	O
responses	O
to	O
caffeine	B-Chemical
were	O
:	O
selective	O
for	O
diastolic	O
BP	O
,	O
consistent	O
with	O
greater	O
vasoconstriction	O
,	O
replicated	O
in	O
2	O
protocols	O
,	O
and	O
representative	O
of	O
nearly	O
all	O
borderline	O
hypertensives	B-Disease
.	O

We	O
suspect	O
that	O
the	O
potential	O
for	O
caffeine	B-Chemical
to	O
stabilize	O
high	O
resistance	O
states	O
in	O
susceptible	O
persons	O
suggests	O
that	O
its	O
use	O
may	O
facilitate	O
their	O
disease	O
progression	O
,	O
as	O
well	O
as	O
hinder	O
accurate	O
diagnosis	O
and	O
treatment	O
.	O

Hallucinations	B-Disease
and	O
ifosfamide-induced	B-Chemical
neurotoxicity	B-Disease
.	O

BACKGROUND	O
:	O
Hallucinations	B-Disease
as	O
a	O
symptom	O
of	O
central	O
neurotoxicity	B-Disease
are	O
a	O
known	O
but	O
poorly	O
described	O
side	O
effect	O
of	O
ifosfamide	B-Chemical
.	O

Most	O
cases	O
of	O
ifosfamide-induced	B-Chemical
hallucinations	B-Disease
have	O
been	O
reported	O
with	O
other	O
mental	O
status	O
changes	O
.	O

METHODS	O
:	O
The	O
authors	O
interviewed	O
six	O
persons	O
with	O
ifosfamide-induced	B-Chemical
hallucinations	B-Disease
in	O
the	O
presence	O
of	O
a	O
clear	O
sensorium	O
.	O

All	O
patients	O
were	O
receiving	O
high-dose	O
ifosfamide	B-Chemical
as	O
part	O
of	O
their	O
bone	O
marrow	O
transplant	O
procedure	O
.	O

RESULTS	O
:	O
Hallucinations	B-Disease
occurred	O
only	O
when	O
the	O
patient	O
's	O
eyes	O
were	O
closed	O
and	O
,	O
in	O
all	O
but	O
one	O
case	O
,	O
were	O
reported	O
as	O
disturbing	O
or	O
frightening	O
.	O

Underreporting	O
of	O
these	O
hallucinations	B-Disease
by	O
patients	O
is	O
likely	O
.	O

CONCLUSIONS	O
:	O
Hallucinations	B-Disease
may	O
be	O
the	O
sole	O
or	O
first	O
manifestation	O
of	O
neurotoxicity	B-Disease
.	O

The	O
incidence	O
may	O
be	O
dose	O
and	O
infusion-time	O
related	O
.	O

The	O
clinician	O
should	O
be	O
alerted	O
for	O
possible	O
ifosfamide-induced	B-Chemical
hallucinations	B-Disease
,	O
which	O
may	O
occur	O
without	O
other	O
signs	O
of	O
neurotoxicity	B-Disease
.	O

``	O
Eyes-closed	O
''	O
hallucinatory	B-Disease
experiences	O
appear	O
to	O
be	O
an	O
unusual	O
feature	O
of	O
this	O
presentation	O
.	O

Patients	O
anxious	O
about	O
this	O
experience	O
respond	O
well	O
to	O
support	O
and	O
education	O
about	O
this	O
occurrence	O
.	O

Optimal	O
pharmacologic	O
management	O
of	O
disturbed	O
patients	O
is	O
unclear	O
.	O

If	O
agitation	B-Disease
becomes	O
marked	O
,	O
high-potency	O
neuroleptics	O
(	O
i.e.	O
,	O
haloperidol	B-Chemical
)	O
may	O
be	O
effective	O
.	O

Chlorpropamide-induced	B-Chemical
optic	B-Disease
neuropathy	I-Disease
.	O

A	O
65-year-old	O
woman	O
with	O
adult-onset	B-Disease
diabetes	I-Disease
treated	O
with	O
chlorpropamide	B-Chemical
(	O
Diabenese	B-Chemical
)	O
had	O
a	O
toxic	B-Disease
optic	I-Disease
neuropathy	I-Disease
that	O
resolved	O
with	O
discontinuation	O
of	O
chlorpropamide	B-Chemical
therapy	O
.	O

Visual	B-Disease
loss	I-Disease
occurs	O
in	O
diabetics	B-Disease
for	O
a	O
variety	O
of	O
reasons	O
,	O
and	O
accurate	O
diagnosis	O
is	O
necessary	O
to	O
institute	O
appropriate	O
therapy	O
.	O

The	O
possibility	O
of	O
a	O
drug-induced	O
optic	B-Disease
neuropathy	I-Disease
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
visual	B-Disease
loss	I-Disease
in	O
diabetics	B-Disease
.	O

Levodopa-induced	B-Chemical
dyskinesia	B-Disease
and	O
thalamotomy	O
.	O

Levodopa-induced	B-Chemical
dyskinesia	B-Disease
of	O
the	O
limbs	O
in	O
thirteen	O
cases	O
of	O
Parkinsonism	B-Disease
,	O
which	O
was	O
choreic	O
,	O
ballistic	O
or	O
dystonic	B-Disease
in	O
type	O
,	O
was	O
alleviated	O
almost	O
completely	O
by	O
stereotaxic	O
surgery	O
using	O
a	O
microelectrode	O
technique	O
for	O
the	O
ventralis	O
oralis	O
anterior	O
and	O
posterior	O
nuclei	O
of	O
the	O
thalamus	O
,	O
but	O
much	O
less	O
by	O
the	O
ventralis	O
intermedius	O
nucleus	O
.	O

Control	O
of	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
by	O
thalamic	B-Disease
lesions	I-Disease
in	O
the	O
course	O
of	O
routine	O
treatment	O
of	O
Parkinsonism	B-Disease
is	O
discussed	O
.	O

Factors	O
associated	O
with	O
nephrotoxicity	B-Disease
and	O
clinical	O
outcome	O
in	O
patients	O
receiving	O
amikacin	B-Chemical
.	O

Data	O
from	O
60	O
patients	O
treated	O
with	O
amikacin	B-Chemical
were	O
analyzed	O
for	O
factors	O
associated	O
with	O
nephrotoxicity	B-Disease
.	O

In	O
42	O
of	O
these	O
patients	O
,	O
data	O
were	O
examined	O
for	O
factors	O
associated	O
with	O
clinical	O
outcome	O
.	O

Variables	O
evaluated	O
included	O
patient	O
weight	O
,	O
age	O
,	O
sex	O
,	O
serum	O
creatinine	B-Chemical
level	O
,	O
creatinine	B-Chemical
clearance	O
,	O
duration	O
of	O
therapy	O
,	O
total	O
dose	O
,	O
mean	O
daily	O
dose	O
,	O
organism	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
,	O
mean	O
peak	O
levels	O
,	O
mean	O
trough	O
levels	O
,	O
mean	O
area	O
under	O
the	O
serum	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
,	O
total	O
AUC	O
,	O
mean	O
AUC	O
greater	O
than	O
MIC	O
,	O
total	O
AUC	O
greater	O
than	O
MIC	O
,	O
mean	O
Schumacher	O
's	O
intensity	O
factor	O
(	O
IF	O
)	O
,	O
total	O
IF	O
,	O
In	O
(	O
mean	O
maximum	O
concentration	O
[	O
Cmax	O
]	O
/MIC	O
)	O
.	O

Model-dependent	O
pharmacokinetic	O
parameters	O
were	O
calculated	O
by	O
computer	O
based	O
on	O
a	O
one-compartment	O
model	O
.	O

When	O
the	O
parameters	O
were	O
examined	O
individually	O
,	O
duration	O
of	O
therapy	O
and	O
total	O
AUC	O
correlated	O
significantly	O
(	O
P	O
less	O
than	O
.05	O
)	O
with	O
nephrotoxicity	B-Disease
.	O

In	O
contrast	O
,	O
a	O
stepwise	O
discriminant	O
function	O
analysis	O
identified	O
only	O
duration	O
of	O
therapy	O
(	O
P	O
less	O
than	O
.001	O
)	O
as	O
an	O
important	O
factor	O
.	O

Based	O
on	O
this	O
model	O
and	O
on	O
Bayes	O
'	O
theorem	O
,	O
the	O
predictive	O
accuracy	O
of	O
identifying	O
``	O
nephrotoxic	B-Disease
''	O
patients	O
increased	O
from	O
0.17	O
to	O
0.39	O
.	O

When	O
examined	O
individually	O
,	O
mean	O
IF	O
,	O
MIC	O
,	O
total	O
dose	O
,	O
mean	O
daily	O
dose	O
,	O
and	O
ln	O
(	O
mean	O
Cmax/MIC	O
)	O
correlated	O
significantly	O
(	O
P	O
less	O
than	O
.05	O
)	O
with	O
cure	O
.	O

In	O
contrast	O
,	O
a	O
simultaneous	O
multivariable	O
analysis	O
identified	O
IF	O
,	O
MIC	O
,	O
and	O
total	O
dose	O
according	O
to	O
one	O
model	O
and	O
ln	O
(	O
mean	O
Cmax/MIC	O
)	O
according	O
to	O
a	O
second	O
statistical	O
model	O
of	O
parameters	O
selected	O
to	O
have	O
the	O
greatest	O
prospective	O
value	O
.	O

Based	O
on	O
Bayes	O
'	O
theorem	O
and	O
the	O
first	O
model	O
,	O
the	O
predictive	O
accuracy	O
of	O
identifying	O
patients	O
not	O
cured	O
increased	O
from	O
0.19	O
to	O
0.83	O
.	O

For	O
the	O
second	O
model	O
,	O
the	O
predictive	O
accuracy	O
increased	O
from	O
0.19	O
to	O
0.50	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Cardiac	O
transplantation	O
:	O
improved	O
quality	O
of	O
survival	O
with	O
a	O
modified	O
immunosuppressive	O
protocol	O
.	O

The	O
effects	O
on	O
renal	O
function	O
on	O
two	O
different	O
immunosuppressive	O
protocols	O
were	O
evaluated	O
retrospectively	O
in	O
two	O
subsequent	O
groups	O
of	O
heart	O
transplant	O
recipients	O
.	O

In	O
group	O
I	O
,	O
cyclosporine	B-Chemical
was	O
given	O
before	O
the	O
procedure	O
at	O
a	O
loading	O
dose	O
of	O
17.5	O
mg/kg	O
and	O
then	O
continued	O
after	O
the	O
procedure	O
to	O
keep	O
a	O
whole	O
blood	O
level	O
about	O
1000	O
ng/ml	O
.	O

In	O
group	O
II	O
,	O
cyclosporine	B-Chemical
was	O
started	O
only	O
after	O
the	O
procedure	O
at	O
a	O
lower	O
dosage	O
and	O
was	O
complemented	O
by	O
azathioprine	B-Chemical
,	O
which	O
was	O
used	O
for	O
the	O
first	O
postoperative	O
week	O
.	O

Group	O
II	O
showed	O
a	O
better	O
perioperative	O
renal	O
function	O
as	O
determined	O
by	O
serum	O
blood	O
urea	B-Chemical
nitrogen	I-Chemical
and	O
serum	O
creatinine	B-Chemical
levels	O
.	O

Group	O
II	O
also	O
showed	O
a	O
significant	O
decrease	O
of	O
chronic	O
nephrotoxicity	B-Disease
secondary	O
to	O
long-term	O
therapy	O
with	O
cyclosporine	B-Chemical
.	O

Despite	O
this	O
improvement	O
in	O
late	O
renal	O
function	O
,	O
group	O
II	O
still	O
shows	O
a	O
slow	O
rise	O
in	O
serum	O
creatinine	B-Chemical
.	O

We	O
think	O
that	O
even	O
these	O
lower	O
dosages	O
of	O
cyclosporine	B-Chemical
can	O
cause	O
chronic	O
nephrotoxicity	B-Disease
and	O
that	O
further	O
modification	O
of	O
the	O
immunosuppressive	O
regimen	O
is	O
required	O
to	O
completely	O
abolish	O
this	O
toxic	O
side	O
effect	O
.	O

Reversible	O
cholestasis	B-Disease
with	O
bile	B-Disease
duct	I-Disease
injury	I-Disease
following	O
azathioprine	B-Chemical
therapy	O
.	O

A	O
case	O
report	O
.	O

A	O
67-year-old	O
patient	O
,	O
with	O
primary	O
polymyositis	B-Disease
and	O
without	O
previous	O
evidence	O
of	O
liver	B-Disease
disease	I-Disease
,	O
developed	O
clinical	O
and	O
biochemical	O
features	O
of	O
severe	O
cholestasis	B-Disease
3	O
months	O
after	O
initiation	O
of	O
azathioprine	B-Chemical
therapy	O
.	O

Liver	O
biopsy	O
showed	O
cholestasis	B-Disease
with	O
both	O
cytological	O
and	O
architectural	O
alterations	O
of	O
interlobular	O
bile	O
ducts	O
.	O

Azathioprine	B-Chemical
withdrawal	O
resulted	O
after	O
7	O
weeks	O
in	O
the	O
resolution	O
of	O
clinical	O
and	O
biochemical	O
abnormalities	O
.	O

It	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
reversible	O
azathioprine-induced	B-Chemical
cholestasis	B-Disease
associated	O
with	O
histological	O
evidence	O
of	O
bile	B-Disease
duct	I-Disease
injury	I-Disease
.	O

Renal	O
function	O
and	O
hemodynamics	O
during	O
prolonged	O
isoflurane-induced	B-Chemical
hypotension	B-Disease
in	O
humans	O
.	O

The	O
effect	O
of	O
isoflurane-induced	B-Chemical
hypotension	B-Disease
on	O
glomerular	O
function	O
and	O
renal	O
blood	O
flow	O
was	O
investigated	O
in	O
20	O
human	O
subjects	O
.	O

Glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
effective	O
renal	O
plasma	O
flow	O
(	O
ERPF	O
)	O
were	O
measured	O
by	O
inulin	O
and	O
para-aminohippurate	B-Chemical
(	O
PAH	B-Chemical
)	O
clearance	O
,	O
respectively	O
.	O

Anesthesia	B-Drug
was	O
maintained	O
with	O
fentanyl	B-Chemical
,	O
nitrous	B-Chemical
oxide	I-Chemical
,	O
oxygen	B-Chemical
,	O
and	O
isoflurane	B-Chemical
.	O

Hypotension	B-Disease
was	O
induced	O
for	O
236.9	O
+/-	O
15.1	O
min	O
by	O
increasing	O
the	O
isoflurane	B-Chemical
inspired	O
concentration	O
to	O
maintain	O
a	O
mean	O
arterial	O
pressure	O
of	O
59.8	O
+/-	O
0.4	O
mmHg	O
.	O

GFR	O
and	O
ERPF	O
decreased	O
with	O
the	O
induction	O
of	O
anesthesia	B-Drug
but	O
not	O
significantly	O
more	O
during	O
hypotension	B-Disease
.	O

Postoperatively	O
,	O
ERPF	O
returned	O
to	O
preoperative	O
values	O
,	O
whereas	O
GFR	O
was	O
higher	O
than	O
preoperative	O
values	O
.	O

Renal	O
vascular	O
resistance	O
increased	O
during	O
anesthesia	B-Drug
but	O
decreased	O
when	O
hypotension	B-Disease
was	O
induced	O
,	O
allowing	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
.	O

We	O
conclude	O
that	O
renal	O
compensatory	O
mechanisms	O
are	O
preserved	O
during	O
isoflurane-induced	B-Chemical
hypotension	B-Disease
and	O
that	O
renal	O
function	O
and	O
hemodynamics	O
quickly	O
return	O
to	O
normal	O
when	O
normotension	O
is	O
resumed	O
.	O

Debrisoquine	B-Chemical
phenotype	O
and	O
the	O
pharmacokinetics	O
and	O
beta-2	O
receptor	O
pharmacodynamics	O
of	O
metoprolol	B-Chemical
and	O
its	O
enantiomers	O
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta-blocker	O
metoprolol	B-Chemical
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine/sparteine	B-Chemical
type	O
.	O

The	O
two	O
metabolic	O
phenotypes	O
,	O
extensive	O
(	O
EM	O
)	O
and	O
poor	O
metabolizers	O
(	O
PM	O
)	O
,	O
show	O
different	O
stereoselective	O
metabolism	O
,	O
resulting	O
in	O
apparently	O
higher	O
beta-1	O
adrenoceptor	O
antagonistic	O
potency	O
of	O
racemic	O
metoprolol	B-Drug
in	O
EMs	O
.	O

We	O
investigated	O
if	O
the	O
latter	O
also	O
applies	O
to	O
the	O
beta-2	O
adrenoceptor	O
antagonism	O
by	O
metoprolol	B-Drug
.	O

The	O
drug	B-Drug
effect	O
studied	O
was	O
the	O
antagonism	O
by	O
metoprolol	B-Drug
of	O
terbutaline-induced	O
hypokalemia	O
.	O

By	O
using	O
pharmacokinetic	O
pharmacodynamic	O
modeling	O
the	O
pharmacodynamics	O
of	O
racemic	O
metoprolol	B-Drug
and	O
the	O
active	O
S-isomer	O
,	O
were	O
quantitated	O
in	O
EMs	O
and	O
PMs	O
in	O
terms	O
of	O
IC50	O
values	O
,	O
representing	O
metoprolol	B-Drug
plasma	O
concentrations	O
resulting	O
in	O
half-maximum	O
receptor	O
occupancy	O
.	O

Six	O
EMs	O
received	O
0.5	O
mg	O
of	O
terbutaline	B-Drug
s.c.	O
on	O
two	O
different	O
occasions	O
:	O
1	O
)	O
1	O
hr	O
after	O
administration	O
of	O
a	O
placebo	O
and	O
2	O
)	O
1	O
hr	O
after	O
150	O
mg	O
of	O
metoprolol	B-Drug
p.o	O
.	O

Five	O
PMs	O
were	O
studied	O
according	O
to	O
the	O
same	O
protocol	O
,	O
except	O
for	O
a	O
higher	O
terbutaline	B-Drug
dose	O
(	O
0.75	O
mg	O
)	O
on	O
day	O
2	O
.	O

Blood	O
samples	O
for	O
the	O
analysis	O
of	O
plasma	O
potassium	B-Drug
,	O
terbutaline	B-Drug
,	O
metoprolol	B-Drug
(	O
racemic	O
,	O
R-	O
and	O
S-isomer	O
)	O
,	O
and	O
alpha-hydroxymetoprolol	O
concentrations	O
were	O
taken	O
at	O
regular	O
time	O
intervals	O
,	O
during	O
8	O
hr	O
after	O
metoprolol	B-Drug
.	O

In	O
PMs	O
,	O
metoprolol	B-Drug
increased	O
the	O
terbutaline	B-Drug
area	O
under	O
the	O
plasma	O
concentration	O
vs.	O
time	O
curve	O
(	O
+67	O
%	O
)	O
.	O

Higher	O
metoprolol/alpha-hydroxymetoprolol	O
ratios	O
in	O
PMs	O
were	O
predictive	O
for	O
higher	O
R-/S-isomer	O
ratios	O
of	O
unchanged	O
drug	B-Drug
.	O

There	O
was	O
a	O
difference	O
in	O
metoprolol	B-Drug
potency	O
with	O
higher	O
racemic	O
metoprolol	B-Drug
IC50	O
values	O
in	O
PMs	O
(	O
72	O
+/-	O
7	O
ng.ml-1	O
)	O
than	O
EMs	O
(	O
42	O
+/-	O
8	O
ng.ml-1	O
,	O
P	O
less	O
than	O
.001	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Cefotetan-induced	B-Chemical
immune	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Immune	O
hemolytic	B-Disease
anemia	I-Disease
due	O
to	O
a	O
drug-adsorption	O
mechanism	O
has	O
been	O
described	O
primarily	O
in	O
patients	O
receiving	O
penicillins	B-Chemical
and	O
first-generation	O
cephalosporins	B-Chemical
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
anemia	B-Disease
while	O
receiving	O
intravenous	O
cefotetan	B-Chemical
.	O

Cefotetan-dependent	B-Chemical
antibodies	O
were	O
detected	O
in	O
the	O
patient	O
's	O
serum	O
and	O
in	O
an	O
eluate	O
prepared	O
from	O
his	O
red	O
blood	O
cells	O
.	O

The	O
eluate	O
also	O
reacted	O
weakly	O
with	O
red	O
blood	O
cells	O
in	O
the	O
absence	O
of	O
cefotetan	B-Chemical
,	O
suggesting	O
the	O
concomitant	O
formation	O
of	O
warm-reactive	O
autoantibodies	O
.	O

These	O
observations	O
,	O
in	O
conjunction	O
with	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
extravascular	O
hemolysis	B-Disease
,	O
are	O
consistent	O
with	O
drug-induced	O
hemolytic	B-Disease
anemia	I-Disease
,	O
possibly	O
involving	O
both	O
drug-adsorption	O
and	O
autoantibody	O
formation	O
mechanisms	O
.	O

This	O
case	O
emphasizes	O
the	O
need	O
for	O
increased	O
awareness	O
of	O
hemolytic	O
reactions	O
to	O
all	O
cephalosporins	B-Chemical
.	O

Acute	B-Disease
renal	I-Disease
failure	I-Disease
subsequent	O
to	O
the	O
administration	O
of	O
rifampicin	B-Chemical
.	O

A	O
follow-up	O
study	O
of	O
cases	O
reported	O
earlier	O
.	O

A	O
clinical	O
presentation	O
is	O
made	O
of	O
a	O
2-3	O
year	O
follow-up	O
of	O
six	O
cases	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
that	O
have	O
been	O
reported	O
earlier	O
.	O

The	O
patients	O
had	O
developed	O
transient	O
renal	B-Disease
failure	I-Disease
after	O
the	O
intermittent	O
administration	O
of	O
rifampicin	B-Chemical
.	O

The	O
stage	O
of	O
olig-anuria	B-Disease
lasted	O
for	O
1-3	O
weeks	O
,	O
and	O
five	O
of	O
the	O
patients	O
were	O
treated	O
by	O
hemodialysis	O
.	O

Two	O
of	O
the	O
patients	O
died	O
due	O
to	O
unrelated	O
causes	O
during	O
the	O
follow-up	O
period	O
.	O

The	O
four	O
patients	O
re-examined	O
were	O
clinically	O
cured	O
.	O

Pathologic	O
findings	O
by	O
light	O
microscopy	O
and	O
immunofluorescence	O
at	O
biopsy	O
were	O
scarce	O
.	O

Nothing	O
abnormal	O
was	O
seen	O
by	O
electron	O
microscopy	O
in	O
two	O
of	O
the	O
cases	O
studied	O
.	O

Renal	O
function	O
was	O
normal	O
.	O

In	O
three	O
cases	O
the	O
excretion	O
at	O
131I-hippuran	O
renography	O
was	O
slightly	O
slowed	O
.	O

Although	O
in	O
the	O
acute	O
stage	O
the	O
renal	B-Disease
lesions	I-Disease
histologically	O
appeared	O
toxic	O
,	O
evidence	O
suggestive	O
of	O
an	O
immunological	O
mechanism	O
can	O
not	O
be	O
excluded	O
.	O

Type	B-Disease
B	I-Disease
hepatitis	I-Disease
after	O
needle-stick	O
exposure	O
:	O
prevention	O
with	O
hepatitis	B-Disease
B	I-Disease
immune	O
globulin	O
.	O

Final	O
report	O
of	O
the	O
Veterans	O
Administration	O
Cooperative	O
Study	O
.	O

Hepatitis	B-Disease
B	I-Disease
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
immune	O
serum	O
globulin	O
(	O
ISG	O
)	O
were	O
examined	O
in	O
a	O
randomized	O
,	O
double-blind	O
trial	O
to	O
assess	O
their	O
relative	O
efficacies	O
in	O
preventing	O
type	B-Disease
B	I-Disease
hepatitis	I-Disease
after	O
needle-stick	O
exposure	O
to	O
hepatitis	B-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBsAG	B-Chemical
)	O
-positive	O
donors	O
.	O

Clinical	O
hepatitis	B-Disease
developed	O
in	O
1.4	O
%	O
of	O
HBIG	O
and	O
in	O
5.9	O
%	O
of	O
ISG	O
recipients	O
(	O
P	O
=	O
0.016	O
)	O
,	O
and	O
seroconversion	O
(	O
anti-HBs	O
)	O
occurred	O
in	O
5.6	O
%	O
and	O
20.7	O
%	O
of	O
them	O
respectively	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

Mild	O
and	O
transient	O
side-effects	O
were	O
noted	O
in	O
3.0	O
%	O
of	O
ISG	O
and	O
in	O
3.2	O
%	O
of	O
HBIG	O
recipients	O
.	O

Available	O
donor	O
sera	O
were	O
examined	O
for	O
DNA	O
polymerase	O
(	O
DNAP	O
)	O
and	O
e	O
antigen	O
and	O
antibody	O
(	O
HBeAg	B-Chemical
;	O
anti-HBE	O
)	O
.	O

Both	O
DNAP	O
and	O
HBeAg	B-Chemical
showed	O
a	O
highly	O
statistically	O
significant	O
correlation	O
with	O
the	O
infectivity	O
of	O
HBsAg-positive	B-Chemical
donors	O
.	O

Hepatitis	B-Disease
B	I-Disease
immune	O
globulin	O
remained	O
significantly	O
superior	O
to	O
ISG	O
in	O
preventing	O
type	B-Disease
B	I-Disease
hepatitis	I-Disease
even	O
when	O
the	O
analysis	O
was	O
confined	O
to	O
these	O
two	O
high-risk	O
subgroups	O
.	O

The	O
efficacy	O
of	O
ISG	O
in	O
preventing	O
type	B-Disease
B	I-Disease
hepatitis	I-Disease
can	O
not	O
be	O
ascertained	O
because	O
a	O
true	O
placebo	O
group	O
was	O
not	O
included	O
.	O

Serotonin	B-Disease
syndrome	I-Disease
from	O
venlafaxine-tranylcypromine	B-Chemical
interaction	O
.	O

Excessive	O
stimulation	O
of	O
serotonin	B-Chemical
5HT1A	O
receptors	O
causes	O
a	O
syndrome	O
of	O
serotonin	B-Chemical
excess	O
that	O
consists	O
of	O
shivering	O
,	O
muscle	B-Disease
rigidity	I-Disease
,	O
salivation	B-Disease
,	O
confusion	B-Disease
,	O
agitation	B-Disease
and	O
hyperthermia	B-Disease
.	O

The	O
most	O
common	O
cause	O
of	O
this	O
syndrome	O
is	O
an	O
interaction	O
between	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(	O
MAOI	O
)	O
and	O
a	O
specific	O
serotonin	B-Chemical
reuptake	O
inhibitor	O
.	O

Venlafaxine	B-Chemical
is	O
a	O
new	O
antidepressant	O
agent	O
that	O
inhibits	O
the	O
reuptake	O
of	O
serotonin	B-Chemical
and	O
norepinephrine	B-Chemical
.	O

We	O
report	O
a	O
venlafaxine-MAOI	B-Chemical
interaction	O
that	O
resulted	O
in	O
the	O
serotonin	B-Disease
syndrome	I-Disease
in	O
a	O
23-y-old	O
male	O
who	O
was	O
taking	O
tranylcypromine	B-Chemical
for	O
depression	B-Disease
.	O

He	O
had	O
been	O
well	O
until	O
the	O
morning	O
of	O
presentation	O
when	O
he	O
took	O
1/2	O
tab	O
of	O
venlafaxine	B-Chemical
.	O

Within	O
2	O
h	O
he	O
became	O
confused	O
with	O
jerking	O
movements	O
of	O
his	O
extremities	O
,	O
tremors	B-Disease
and	O
rigidity	B-Disease
.	O

He	O
was	O
brought	O
directly	O
to	O
a	O
hospital	O
where	O
he	O
was	O
found	O
to	O
be	O
agitated	O
and	O
confused	O
with	O
shivering	O
,	O
myoclonic	B-Disease
jerks	I-Disease
,	O
rigidity	B-Disease
,	O
salivation	B-Disease
and	O
diaphoresis	O
.	O

His	O
pupils	O
were	O
7	O
mm	O
and	O
sluggishly	O
reactive	O
to	O
light	O
.	O

Vital	O
signs	O
were	O
:	O
blood	O
pressure	O
120/67	O
mm	O
Hg	O
,	O
heart	O
rate	O
127/min	O
,	O
respiratory	O
rate	O
28/min	O
,	O
and	O
temperature	O
97	O
F.	O
After	O
180	O
mg	O
of	O
diazepam	B-Chemical
i.v	O
.	O

he	O
remained	O
tremulous	O
with	O
muscle	B-Disease
rigidity	I-Disease
and	O
clenched	O
jaws	O
.	O

He	O
was	O
intubated	O
for	O
airway	O
protection	O
and	O
because	O
of	O
hypoventilation	B-Disease
,	O
and	O
was	O
paralyzed	B-Disease
to	O
control	O
muscle	B-Disease
rigidity	I-Disease
.	O

His	O
subsequent	O
course	O
was	O
remarkable	O
for	O
non-immune	O
thrombocytopenia	B-Disease
which	O
resolved	O
.	O

The	O
patient	O
's	O
maximal	O
temperature	O
was	O
101.2	O
F	O
and	O
his	O
CPK	O
remained	O
<	O
500	O
units/L	O
with	O
no	O
other	O
evidence	O
of	O
rhabdomyolysis	B-Disease
.	O

His	O
mental	O
status	O
normalized	O
and	O
he	O
was	O
transferred	O
to	O
a	O
psychiatry	O
ward	O
.	O

This	O
patient	O
survived	O
without	O
sequelae	O
due	O
to	O
the	O
aggressive	O
sedation	O
and	O
neuromuscular	O
paralysis	B-Disease
.	O

Effect	O
of	O
nondopaminergic	O
drugs	B-Drug
on	O
L-dopa-induced	B-Chemical
dyskinesias	B-Disease
in	O
MPTP-treated	B-Chemical
monkeys	O
.	O

A	O
group	O
of	O
four	O
monkeys	O
was	O
rendered	O
parkinsonian	B-Disease
with	O
the	O
toxin	B-Drug
MPTP	B-Chemical
.	O

They	O
were	O
then	O
treated	O
chronically	O
with	O
L-DOPA/benserazide	B-Chemical
50/12.5	O
mg/kg	O
given	O
orally	O
daily	O
for	O
2	O
months	O
.	O

This	O
dose	O
produced	O
a	O
striking	O
antiparkinsonian	O
effect	O
,	O
but	O
all	O
animals	O
manifested	O
dyskinesia	B-Disease
.	O

A	O
series	O
of	O
agents	O
acting	O
primarily	O
on	O
neurotransmitters	O
other	O
than	O
dopamine	B-Chemical
were	O
then	O
tested	O
in	O
combination	O
with	O
L-DOPA	B-Chemical
to	O
see	O
if	O
the	O
dyskinetic	B-Disease
movements	O
would	O
be	O
modified	O
.	O

Several	O
drugs	B-Drug
,	O
including	O
clonidine	B-Chemical
,	O
physostigmine	B-Chemical
,	O
methysergide	B-Chemical
,	O
5-MDOT	B-Chemical
,	O
propranolol	B-Chemical
,	O
and	O
MK-801	B-Chemical
,	O
markedly	O
reduced	O
the	O
dyskinetic	B-Disease
movements	O
but	O
at	O
the	O
cost	O
of	O
a	O
return	O
of	O
parkinsonian	B-Disease
symptomatology	O
.	O

However	O
,	O
yohimbine	B-Chemical
and	O
meperidine	B-Chemical
reduced	O
predominantly	O
the	O
dyskinetic	B-Disease
movements	O
.	O

Baclofen	B-Chemical
was	O
also	O
useful	O
in	O
one	O
monkey	O
against	O
a	O
more	O
dystonic	B-Disease
form	O
of	O
dyskinesia	B-Disease
.	O

Atropine	B-Chemical
converted	O
the	O
dystonic	B-Disease
movements	O
into	O
chorea	B-Disease
.	O

CCNU	B-Chemical
(	O
lomustine	B-Chemical
)	O
toxicity	B-Disease
in	O
dogs	O
:	O
a	O
retrospective	O
study	O
(	O
2002-07	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
incidence	O
of	O
haematological	B-Disease
,	I-Disease
renal	I-Disease
,	I-Disease
hepatic	I-Disease
and	I-Disease
gastrointestinal	I-Disease
toxicities	I-Disease
in	O
tumour-bearing	O
dogs	O
receiving	O
1-	O
(	O
2-chloroethyl	O
)	O
-3-cyclohexyl-1-nitrosourea	O
(	O
CCNU	B-Drug
)	O
.	O

DESIGN	O
:	O
The	O
medical	O
records	O
of	O
206	O
dogs	O
that	O
were	O
treated	O
with	O
CCNU	B-Drug
at	O
the	O
Melbourne	O
Veterinary	O
Specialist	O
Centre	O
between	O
February	O
2002	O
and	O
December	O
2007	O
were	O
retrospectively	O
evaluated	O
.	O

RESULTS	O
:	O
Of	O
the	O
206	O
dogs	O
treated	O
with	O
CCNU	B-Drug
,	O
185	O
met	O
the	O
inclusion	O
criteria	O
for	O
at	O
least	O
one	O
class	O
of	O
toxicity	O
.	O

CCNU	B-Drug
was	O
used	O
most	O
commonly	O
in	O
the	O
treatment	O
of	O
lymphoma	O
,	O
mast	O
cell	O
tumour	O
,	O
brain	O
tumour	O
,	O
histiocytic	O
tumours	O
and	O
epitheliotropic	O
lymphoma	O
.	O

Throughout	O
treatment	O
,	O
56.9	O
%	O
of	O
dogs	O
experienced	O
neutropenia	O
,	O
34.2	O
%	O
experienced	O
anaemia	O
and	O
14.2	O
%	O
experienced	O
thrombocytopenia	O
.	O

Gastrointestinal	O
toxicosis	O
was	O
detected	O
in	O
37.8	O
%	O
of	O
dogs	O
,	O
the	O
most	O
common	O
sign	O
of	O
which	O
was	O
vomiting	O
(	O
24.3	O
%	O
)	O
.	O

Potential	O
renal	O
toxicity	O
and	O
elevated	O
alanine	O
transaminase	O
(	O
ALT	O
)	O
concentration	O
were	O
reported	O
in	O
12.2	O
%	O
and	O
48.8	O
%	O
of	O
dogs	O
,	O
respectively	O
.	O

The	O
incidence	O
of	O
hepatic	O
failure	O
was	O
1.2	O
%	O
.	O

CONCLUSIONS	O
:	O
CCNU-associated	O
toxicity	O
in	O
dogs	O
is	O
common	O
,	O
but	O
is	O
usually	O
not	O
life	O
threatening	O
.	O

Neuroactive	O
steroids	B-Chemical
protect	O
against	O
pilocarpine-	B-Chemical
and	O
kainic	B-Chemical
acid-induced	O
limbic	O
seizures	O
and	O
status	O
epilepticus	O
in	O
mice	O
.	O

Several	O
structurally	O
related	O
metabolites	O
of	O
progesterone	B-Chemical
(	O
3	B-Chemical
alpha-hydroxy	I-Chemical
pregnane-20-ones	I-Chemical
)	O
and	O
deoxycorticosterone	B-Chemical
(	O
3	B-Chemical
alpha-hydroxy	I-Chemical
pregnane-21-diol-20-ones	I-Chemical
)	O
and	O
their	O
3	O
beta-epimers	O
were	O
evaluated	O
for	O
protective	O
activity	O
against	O
pilocarpine-	B-Chemical
,	O
kainic	B-Chemical
acid-	O
and	O
N-methyl-D-aspartate	O
(	O
NMDA	O
)	O
-induced	O
seizures	O
in	O
mice	O
.	O

Steroids	O
with	O
the	O
3-hydroxy	O
group	O
in	O
the	O
alpha-position	O
and	O
5-H	O
in	O
the	O
alpha-	O
or	O
beta-configurations	O
were	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine	B-Drug
(	O
416	O
mg/kg	O
,	O
s.c.	O
)	O
-induced	O
limbic	O
motor	O
seizures	O
and	O
status	O
epilepticus	O
(	O
ED50	O
values	O
,	O
7.0-18.7	O
mg/kg	O
,	O
i.p.	O
)	O
.	O

The	O
corresponding	O
epimers	O
with	O
the	O
3-hydroxy	O
group	O
in	O
the	O
beta-position	O
were	O
also	O
effective	O
but	O
less	O
potent	O
(	O
ED50	O
values	O
,	O
33.8-63.5	O
,	O
i.p.	O
)	O
.	O

Although	O
the	O
neuroactive	O
steroids	O
were	O
considerably	O
less	O
potent	O
than	O
the	O
benzodiazepine	O
clonazepam	B-Drug
in	O
protecting	O
against	O
pilocarpine	B-Drug
seizures	O
,	O
steroids	O
with	O
the	O
5	O
alpha,3	O
alpha-configuration	O
had	O
comparable	O
or	O
higher	O
protective	O
index	O
values	O
(	O
TD50	O
for	O
motor	O
impairment	O
divided	O
by	O
ED50	O
for	O
seizure	O
protection	O
)	O
than	O
clonazepam	B-Drug
,	O
indicating	O
that	O
some	O
neuroactive	O
steroids	O
may	O
have	O
lower	O
relative	O
toxicity	O
.	O

Steroids	O
with	O
the	O
5	O
alpha,3	O
alpha-	O
or	O
5	O
beta,3	O
alpha-configurations	O
also	O
produced	O
a	O
dose-dependent	O
delay	O
in	O
the	O
onset	O
of	O
limbic	O
seizures	O
induced	O
by	O
kainic	B-Chemical
acid	O
(	O
32	O
mg/kg	O
,	O
s.c.	O
)	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
the	O
seizures	O
.	O

However	O
,	O
when	O
a	O
second	O
dose	O
of	O
the	O
steroid	O
was	O
administered	O
1	O
hr	O
after	O
the	O
first	O
dose	O
,	O
complete	O
protection	O
from	O
the	O
kainic	O
acid-induced	O
limbic	O
seizures	O
and	O
status	O
epilepticus	O
was	O
obtained	O
.	O

The	O
steroids	O
also	O
caused	O
a	O
dose-dependent	O
delay	O
in	O
NMDA	O
(	O
257	O
mg/kg	O
,	O
s.c.	O
)	O
-induced	O
lethality	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
NMDA	O
seizures	O
or	O
lethality	O
.	O

We	O
conclude	O
that	O
neuroactive	O
steroids	O
are	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine-	O
and	O
kainic	O
acid-induced	O
seizures	O
and	O
status	O
epilepticus	O
in	O
mice	O
,	O
and	O
may	O
be	O
of	O
utility	O
in	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
status	O
epilepticus	O
in	O
humans	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
combination	O
N-butyl-deoxynojirimycin	B-Chemical
(	O
SC-48334	B-Chemical
)	O
and	O
zidovudine	B-Chemical
in	O
patients	O
with	O
HIV-1	B-Disease
infection	I-Disease
and	O
200-500	O
CD4	O
cells/mm3	O
.	O

We	O
conducted	O
a	O
double-blind	O
,	O
randomized	O
phase	O
II	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
activity	O
of	O
combination	O
therapy	O
with	O
N-butyl-deoxynojirimycin	B-Chemical
(	O
SC-48334	B-Chemical
)	O
(	O
an	O
alpha-glucosidase	O
I	O
inhibitor	O
)	O
and	O
zidovudine	B-Chemical
versus	O
zidovudine	B-Chemical
alone	O
.	O

Patients	O
with	O
200	O
to	O
500	O
CD4	O
cells/mm3	O
who	O
tolerated	O
<	O
or	O
=	O
12	O
weeks	O
of	O
prior	O
zidovudine	B-Chemical
therapy	O
received	O
SC-48334	B-Chemical
(	O
1000	O
mg	O
every	O
8	O
h	O
)	O
and	O
zidovudine	B-Chemical
(	O
100	O
mg	O
every	O
8	O
h	O
)	O
or	O
zidovudine	B-Chemical
and	O
placebo	O
.	O

Sixty	O
patients	O
received	O
combination	O
therapy	O
and	O
58	O
,	O
zidovudine	B-Chemical
and	O
placebo	O
.	O

Twenty-three	O
patients	O
(	O
38	O
%	O
)	O
and	O
15	O
(	O
26	O
%	O
)	O
,	O
in	O
the	O
combination	O
and	O
zidovudine	B-Chemical
groups	O
,	O
respectively	O
,	O
discontinued	O
therapy	O
(	O
p	O
=	O
0.15	O
)	O
.	O

The	O
mean	O
SC-48334	B-Chemical
steady-state	O
trough	O
level	O
(	O
4.04	O
+/-	O
0.99	O
micrograms/ml	O
)	O
was	O
below	O
the	O
in	O
vitro	O
inhibitory	O
concentration	O
for	O
human	O
immunodeficiency	B-Disease
virus	O
(	O
HIV	O
)	O
.	O

The	O
mean	O
increase	O
in	O
CD4	O
cells	O
at	O
week	O
4	O
was	O
73.8	O
cells/mm3	O
and	O
52.4	O
cells/mm3	O
for	O
the	O
combination	O
and	O
zidovudine	B-Chemical
groups	O
,	O
respectively	O
(	O
p	O
>	O
0.36	O
)	O
.	O

For	O
patients	O
with	O
prior	O
zidovudine	B-Chemical
therapy	O
,	O
the	O
mean	O
change	O
in	O
CD4	O
cells	O
in	O
the	O
combination	O
and	O
zidovudine	B-Chemical
groups	O
was	O
63.7	O
cells/mm3	O
and	O
4.9	O
cells/mm3	O
at	O
week	O
8	O
and	O
6.8	O
cells/mm3	O
and	O
-45.1	O
cells/mm3	O
at	O
week	O
16	O
,	O
respectively	O
.	O

The	O
number	O
of	O
patients	O
with	O
suppression	O
of	O
HIV	O
p24	O
antigenemia	O
in	O
the	O
combination	O
and	O
zidovudine	B-Chemical
groups	O
was	O
six	O
(	O
40	O
%	O
)	O
and	O
two	O
(	O
11	O
%	O
)	O
at	O
week	O
4	O
(	O
p	O
=	O
0.10	O
)	O
and	O
five	O
(	O
45	O
%	O
)	O
and	O
two	O
(	O
14	O
%	O
)	O
at	O
week	O
24	O
(	O
p	O
=	O
0.08	O
)	O
,	O
respectively	O
.	O

Diarrhea	B-Disease
,	O
flatulence	B-Disease
,	O
abdominal	B-Disease
pain	I-Disease
,	O
and	O
weight	B-Disease
loss	I-Disease
were	O
common	O
for	O
combination	O
recipients	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Recent	O
preclinical	O
and	O
clinical	O
studies	O
with	O
the	O
thymidylate	O
synthase	O
inhibitor	O
N10-propargyl-5,8-dideazafolic	B-Chemical
acid	I-Chemical
(	O
CB	B-Chemical
3717	I-Chemical
)	O
.	O

CB	B-Chemical
3717	I-Chemical
,	O
N10-propargyl-5,8-dideazafolic	B-Chemical
acid	I-Chemical
,	O
is	O
a	O
tight-binding	O
inhibitor	O
of	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
whose	O
cytotoxicity	B-Disease
is	O
mediated	O
solely	O
through	O
the	O
inhibition	O
of	O
this	O
enzyme	O
.	O

Recent	O
preclinical	O
studies	O
have	O
focused	O
on	O
the	O
intracellular	O
formation	O
of	O
CB	B-Chemical
3717	I-Chemical
polyglutamates	O
.	O

Following	O
a	O
12-hour	O
exposure	O
of	O
L1210	O
cells	O
to	O
50	O
microM	O
[	O
3H	O
]	O
CB	B-Chemical
3717	I-Chemical
,	O
30	O
%	O
of	O
the	O
extractable	O
radioactivity	O
could	O
be	O
accounted	O
for	O
as	O
CB	B-Chemical
3717	I-Chemical
tetra-	O
and	O
pentaglutamate	O
,	O
as	O
determined	O
by	O
high-pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analyses	O
.	O

As	O
inhibitors	O
of	O
isolated	O
L1210	O
TS	O
,	O
CB	B-Chemical
3717	I-Chemical
di-	O
,	O
tri-	O
,	O
tetra-	O
and	O
pentaglutamate	O
are	O
26-	O
,	O
87-	O
,	O
119-	O
and	O
114-fold	O
more	O
potent	O
than	O
CB	B-Chemical
3717	I-Chemical
,	O
respectively	O
,	O
and	O
their	O
formation	O
may	O
,	O
therefore	O
,	O
be	O
an	O
important	O
determinant	O
of	O
CB	O
3717	O
cytotoxicity	B-Disease
.	O

In	O
early	O
clinical	O
studies	O
with	O
CB	B-Chemical
3717	I-Chemical
,	O
activity	O
has	O
been	O
seen	O
in	O
breast	B-Disease
cancer	I-Disease
,	O
ovarian	B-Disease
cancer	I-Disease
,	O
hepatoma	B-Disease
,	O
and	O
mesothelioma	B-Disease
.	O

Toxicities	B-Disease
included	O
hepatotoxicity	B-Disease
,	O
malaise	B-Disease
,	O
and	O
dose-limiting	O
nephrotoxicity	B-Disease
.	O

This	O
latter	O
effect	O
is	O
thought	O
to	O
be	O
due	O
to	O
drug	B-Drug
precipitation	O
within	O
the	O
renal	O
tubule	O
as	O
a	O
result	O
of	O
the	O
poor	O
solubility	O
of	O
CB	B-Chemical
3717	I-Chemical
under	O
acidic	O
conditions	O
.	O

In	O
an	O
attempt	O
to	O
overcome	O
this	O
problem	O
,	O
a	O
clinical	O
trial	O
of	O
CB	B-Chemical
3717	I-Chemical
administered	O
with	O
alkaline	O
diuresis	O
is	O
under	O
way	O
.	O

Preliminary	O
results	O
at	O
400	O
and	O
500	O
mg/m2	O
suggest	O
that	O
a	O
reduction	O
in	O
nephrotoxicity	B-Disease
may	O
have	O
been	O
achieved	O
with	O
only	O
1	O
instance	O
of	O
renal	B-Disease
toxicity	I-Disease
in	O
10	O
patients	O
.	O

Hepatotoxicity	B-Disease
and	O
malaise	B-Disease
are	O
again	O
the	O
most	O
frequent	O
side	O
effects	O
.	O

Evidence	O
of	O
antitumor	O
activity	O
has	O
been	O
seen	O
in	O
3	O
patients	O
.	O

Pharmacokinetic	O
investigations	O
have	O
shown	O
that	O
alkaline	O
diuresis	O
does	O
not	O
alter	O
CB	B-Chemical
3717	I-Chemical
plasma	O
levels	O
or	O
urinary	O
excretion	O
and	O
that	O
satisfactory	O
urinary	O
alkalinization	O
can	O
be	O
readily	O
achieved	O
.	O

Ethopropazine	B-Chemical
and	O
benztropine	B-Chemical
in	O
neuroleptic-induced	O
parkinsonism	B-Disease
.	O

In	O
a	O
12-week	O
controlled	O
study	O
ethopropazine	B-Chemical
was	O
compared	O
to	O
benztropine	B-Chemical
in	O
the	O
treatment	O
of	O
parkinsonism	B-Disease
induced	O
by	O
fluphenazine	B-Chemical
enanthate	I-Chemical
in	O
60	O
schizophrenic	B-Disease
outpatients	O
.	O

Ethopropazine	B-Chemical
and	O
benztropine	B-Chemical
were	O
found	O
to	O
be	O
equally	O
effective	O
in	O
controlling	O
parkinsonian	B-Disease
symptoms	I-Disease
and	O
were	O
as	O
efficacious	O
as	O
procyclidine	B-Chemical
,	O
their	O
previous	O
antiparkinsonian	O
drug	B-Drug
.	O

However	O
,	O
benztropine	B-Chemical
treated	O
patients	O
had	O
a	O
significant	O
increase	O
in	O
tardive	B-Disease
dyskinesia	I-Disease
compared	O
to	O
their	O
condition	O
during	O
procyclindine	B-Chemical
treatment	O
,	O
and	O
significantly	O
more	O
anxiety	B-Disease
and	O
depression	B-Disease
than	O
ethopropazine	B-Chemical
treated	O
patients	O
.	O

This	O
suggests	O
that	O
benztropine	B-Chemical
is	O
not	O
the	O
anticholinergic	B-Drug
drug	B-Drug
of	O
choice	O
in	O
the	O
treatment	O
of	O
neuroleptic-induced	O
parkinsonian	B-Disease
symptoms	I-Disease
,	O
because	O
of	O
its	O
more	O
toxic	O
central	O
and	O
peripheral	O
atropinic	O
effect	O
.	O

Effect	O
of	O
alpha-tocopherol	B-Chemical
and	O
deferoxamine	B-Chemical
on	O
methamphetamine-induced	B-Chemical
neurotoxicity	B-Disease
.	O

Methamphetamine	B-Chemical
(	O
MA	B-Chemical
)	O
-induced	O
dopaminergic	B-Drug
neurotoxicity	B-Disease
is	O
believed	O
to	O
be	O
associated	O
with	O
the	O
increased	O
formation	O
of	O
free	O
radicals	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
alpha-tocopherol	B-Chemical
(	O
alpha-TC	B-Chemical
)	O
,	O
a	O
scavenger	O
of	O
reactive	O
oxygen	B-Chemical
species	O
,	O
and	O
deferoxamine	B-Chemical
(	O
DFO	B-Chemical
)	O
,	O
an	O
iron	B-Chemical
chelator	O
,	O
on	O
the	O
MA-induced	B-Chemical
neurotoxicity	B-Disease
.	O

Male	O
rats	O
were	O
treated	O
with	O
MA	B-Chemical
(	O
10	O
mg/kg	O
,	O
every	O
2	O
h	O
for	O
four	O
injections	O
)	O
.	O

The	O
rat	O
received	O
either	O
alpha-TC	B-Chemical
(	O
20	O
mg/kg	O
)	O
intraperitoneally	O
for	O
3	O
days	O
and	O
30	O
min	O
prior	O
to	O
MA	B-Chemical
administration	O
or	O
DFO	B-Chemical
(	O
50	O
mg/kg	O
)	O
subcutaneously	O
30	O
min	O
before	O
MA	B-Chemical
administration	O
.	O

The	O
concentrations	O
of	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
,	O
serotonin	B-Chemical
and	O
their	O
metabolites	O
decreased	O
significantly	O
after	O
MA	B-Chemical
administration	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
alpha-TC	B-Chemical
and	O
DFO	B-Chemical
pretreatment	O
.	O

alpha-TC	B-Chemical
and	O
DFO	B-Chemical
attenuated	O
the	O
MA-induced	B-Chemical
hyperthermia	B-Disease
as	O
well	O
as	O
the	O
alterations	O
in	O
the	O
locomotor	O
activity	O
.	O

The	O
level	O
of	O
lipid	O
peroxidation	O
was	O
higher	O
and	O
the	O
reduced	O
glutathione	B-Chemical
concentration	O
was	O
lower	O
in	O
the	O
MA-treated	B-Chemical
rats	O
.	O

These	O
changes	O
were	O
significantly	O
attenuated	O
by	O
alpha-TC	B-Chemical
and	O
DFO	B-Chemical
.	O

This	O
suggests	O
that	O
alpha-TC	B-Chemical
and	O
DFO	B-Chemical
ameliorate	O
the	O
MA-induced	B-Chemical
neuronal	B-Disease
damage	I-Disease
by	O
decreasing	O
the	O
level	O
of	O
oxidative	O
stress	O
.	O

Use	O
of	O
dexamethasone	B-Chemical
with	O
mesna	B-Chemical
for	O
the	O
prevention	O
of	O
ifosfamide-induced	B-Chemical
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

AIM	O
:	O
Hemorrhagic	B-Disease
cystitis	I-Disease
(	O
HC	O
)	O
is	O
a	O
limiting	O
side-effect	O
of	O
chemotherapy	O
with	O
ifosfamide	B-Drug
(	O
IFS	O
)	O
.	O

In	O
the	O
study	O
presented	O
here	O
,	O
we	O
investigated	O
the	O
use	O
of	O
dexamethasone	B-Drug
in	O
combination	O
with	O
mesna	O
for	O
the	O
prevention	O
of	O
IFS-induced	O
HC	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
(	O
150-200	O
g	O
;	O
6	O
rats	O
per	O
group	O
)	O
were	O
treated	O
with	O
saline	O
or	O
mesna	O
5	O
min	O
(	O
i.p	O
.	O

)	O
before	O
and	O
2	O
and	O
6	O
h	O
after	O
(	O
v.o	O
.	O

)	O
administration	O
of	O
IFS	O
.	O

One	O
,	O
two	O
or	O
three	O
doses	O
of	O
mesna	O
were	O
replaced	O
with	O
dexamethasone	B-Drug
alone	O
or	O
with	O
dexamethasone	B-Drug
plus	O
mesna	O
.	O

Cystitis	O
was	O
evaluated	O
24	O
h	O
after	O
its	O
induction	O
by	O
the	O
changes	O
in	O
bladder	O
wet	O
weight	O
and	O
by	O
macroscopic	O
and	O
microscopic	O
analysis	O
.	O

RESULTS	O
:	O
The	O
replacement	O
of	O
the	O
last	O
dose	O
or	O
the	O
last	O
two	O
doses	O
of	O
mesna	O
with	O
dexamethasone	B-Drug
reduced	O
the	O
increase	O
in	O
bladder	O
wet	O
weight	O
induced	O
by	O
IFS	O
by	O
84.79	O
%	O
and	O
89.13	O
%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
it	O
almost	O
abolished	O
the	O
macroscopic	O
and	O
microscopic	O
alterations	O
induced	O
by	O
IFS	O
.	O

Moreover	O
,	O
the	O
addition	O
of	O
dexamethasone	B-Drug
to	O
the	O
last	O
two	O
doses	O
of	O
mesna	O
was	O
more	O
efficient	O
than	O
three	O
doses	O
of	O
mesna	O
alone	O
when	O
evaluated	O
microscopically	O
.	O

CONCLUSION	O
:	O
Dexamethasone	B-Drug
in	O
combination	O
with	O
mesna	O
was	O
efficient	O
in	O
blocking	O
IFS-induced	O
HC	O
.	O

However	O
,	O
the	O
replacement	O
of	O
last	O
two	O
doses	O
of	O
mesna	O
with	O
saline	O
or	O
all	O
of	O
the	O
mesna	O
doses	O
with	O
dexamethasone	B-Drug
did	O
not	O
prevent	O
HC	O
.	O

Behavioral	O
effects	O
of	O
MK-801	B-Chemical
on	O
reserpine-treated	B-Chemical
mice	O
.	O

The	O
effects	O
of	O
dizocilpine	B-Chemical
(	O
MK-801	B-Chemical
)	O
,	O
a	O
noncompetitive	O
N-methyl-D-aspartate	B-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
antagonist	O
,	O
were	O
studied	O
on	O
dopamine-related	B-Chemical
behaviors	O
induced	O
by	O
reserpine	B-Chemical
treatments	O
.	O

This	O
study	O
focuses	O
on	O
behavioral	O
syndromes	O
that	O
may	O
used	O
as	O
models	O
for	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
,	O
or	O
tardive	B-Disease
dyskinesia	I-Disease
,	O
and	O
its	O
response	O
after	O
glutamatergic	O
blockage	O
.	O

Reserpine	B-Chemical
(	O
1	O
mg/kg	O
)	O
,	O
administered	O
once	O
every	O
other	O
day	O
for	O
4	O
days	O
,	O
produced	O
increases	O
in	O
orofacial	B-Disease
dyskinesia	I-Disease
,	O
tongue	O
protrusion	O
and	O
vacuous	O
chewing	O
in	O
mice	O
,	O
which	O
are	O
signs	O
indicative	O
of	O
tardive	B-Disease
dyskinesia	I-Disease
.	O

Reserpine	B-Chemical
also	O
produced	O
tremor	B-Disease
and	O
catalepsy	B-Disease
,	O
which	O
are	O
signs	O
suggestive	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

MK-801	B-Chemical
(	O
0.1	O
mg/kg	O
)	O
,	O
administered	O
30	O
min	O
before	O
the	O
observation	O
test	O
,	O
prevented	O
the	O
vacuous	O
chewing	O
movements	O
,	O
tongue	O
protrusions	O
and	O
catalepsy	B-Disease
induced	O
by	O
reserpine	B-Chemical
.	O

However	O
,	O
MK-801	B-Chemical
injection	O
produced	O
a	O
significant	O
increase	O
of	O
tremor	B-Disease
in	O
reserpine-treated	B-Chemical
mice	O
.	O

Reserpine	B-Chemical
(	O
1	O
mg/kg	O
)	O
,	O
administered	O
90	O
min	O
before	O
the	O
test	O
and	O
followed	O
by	O
apomophine	B-Chemical
injection	O
(	O
0.1	O
mg/kg	O
)	O
5	O
min	O
before	O
the	O
test	O
,	O
did	O
not	O
produce	O
oral	B-Disease
dyskinesia	I-Disease
in	O
mice	O
.	O

On	O
the	O
other	O
hand	O
,	O
reserpine	B-Chemical
induced	O
increases	O
in	O
tremor	B-Disease
and	O
catalepsy	B-Disease
compared	O
to	O
control	O
mice	O
.	O

MK-801	B-Chemical
(	O
0.1	O
mg/kg	O
)	O
administration	O
attenuated	O
the	O
catalepsy	B-Disease
and	O
tremor	B-Disease
induced	O
by	O
reserpine	B-Chemical
.	O

Pretreatment	O
with	O
reserpine	B-Chemical
(	O
1	O
mg/kg	O
)	O
24	O
h	O
before	O
the	O
observation	O
test	O
produced	O
increases	O
in	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusion	O
,	O
as	O
well	O
as	O
increases	O
in	O
tremor	B-Disease
and	O
catalepsy	B-Disease
,	O
whereas	O
MK-801	B-Chemical
(	O
0.1	O
mg/kg	O
)	O
injection	O
90	O
min	O
before	O
the	O
test	O
reversed	O
the	O
effects	O
of	O
reserpine	B-Chemical
.	O

These	O
results	O
show	O
that	O
reserpine	B-Chemical
produces	O
different	O
and	O
abnormal	B-Disease
movements	I-Disease
,	O
which	O
are	O
related	O
to	O
dose	O
and	O
schedule	O
employed	O
and	O
can	O
be	O
considered	O
as	O
parkinsonian-like	B-Disease
and	O
tardive	B-Disease
dsykinesia	I-Disease
signs	O
.	O

The	O
glutamatergic	O
blockage	O
produced	O
by	O
NMDA	B-Chemical
can	O
restore	O
these	O
signs	O
,	O
such	O
as	O
vacuous	O
chewing	O
movements	O
,	O
tongue	O
protrusions	O
,	O
catalepsy	B-Disease
and	O
tremor	B-Disease
according	O
to	O
the	O
employed	O
model	O
.	O

Effect	O
of	O
glyceryl	B-Chemical
trinitrate	I-Chemical
on	O
the	O
sphincter	B-Disease
of	I-Disease
Oddi	I-Disease
spasm	I-Disease
evoked	O
by	O
prostigmine-morphine	O
administration	O
.	O

OBJECTIVE	O
:	O
In	O
this	O
study	O
the	O
effect	O
of	O
glyceryl	B-Chemical
trinitrate	I-Chemical
on	O
the	O
prostigmine-morphine-induced	B-Chemical
sphincter	O
of	O
Oddi	O
spasm	O
was	O
evaluated	O
in	O
nine	O
female	O
patients	O
with	O
sphincter	O
of	O
Oddi	O
dyskinesia	O
.	O

METHOD	O
:	O
Sphincter	O
of	O
Oddi	O
spasm	O
was	O
induced	O
by	O
prostigmine-morphine	B-Chemical
administration	O
(	O
0.5	O
mg	O
prostigmine	O
intramuscularly	O
and	O
10	O
mg	O
morphine	B-Drug
subcutaneously	O
)	O
and	O
visualized	O
by	O
quantitative	O
hepatobiliary	O
scintigraphy	O
.	O

The	O
entire	O
procedure	O
was	O
repeated	O
during	O
glyceryl	O
trinitrate	O
infusion	O
(	O
Nitrolingual	O
1	O
microg/kg/min	O
for	O
120	O
min	O
)	O
.	O

RESULTS	O
:	O
Prostigmine-morphine	O
provocation	O
caused	O
significant	O
increases	O
in	O
the	O
time	O
to	O
peak	O
activity	O
(	O
Tmax	O
)	O
over	O
the	O
hepatic	O
hilum	O
(	O
HH	O
:	O
34.33	O
+/-	O
5.05	O
vs.	O
22.77	O
+/-	O
3.26	O
)	O
and	O
the	O
common	O
bile	O
duct	O
(	O
CBD	O
:	O
60.44	O
+/-	O
5.99	O
vs.	O
40.0	O
+/-	O
2.88	O
)	O
and	O
in	O
the	O
half-time	O
of	I-Disease
excretion	O
(	O
T1/2	B-Drug
)	O
over	O
the	O
liver	O
parenchyma	O
(	O
LP	O
:	O
120.04	O
+/-	O
16.01	O
vs.	O
27.37	O
+/-	O
2.19	O
)	O
,	O
HH	O
(	O
117.61	O
+/-	O
14.71	O
vs.	O
31.85	O
+/-	O
3.99	O
)	O
and	O
CBD	O
(	O
158.11	O
+/-	O
9.18	O
vs.	O
40.1	O
+/-	O
6.24	O
)	O
,	O
indicating	O
a	O
complete	O
spasm	I-Disease
at	O
the	O
level	O
of	I-Disease
the	O
sphincter	B-Disease
of	I-Chemical
Oddi	I-Chemical
.	O

Glyceryl	O
trinitrate	O
infusion	O
completely	O
normalized	O
the	O
prostigmine-morphine-induced	O
alterations	O
in	O
these	O
quantitative	O
parameters	O
(	O
TmaX	O
over	O
the	O
LP	O
:	O
11.33	O
+/-	O
1.13	O
;	O
over	O
the	O
HH	O
:	O
18.88	O
+/-	O
1.48	O
;	O
and	O
over	O
the	O
CBD	O
:	O
36.22	O
+/-	O
1.92	O
;	O
and	O
T1/2	B-Drug
over	O
the	O
LP	O
:	O
28.21	O
+/-	O
1.83	O
;	O
over	O
the	O
HH	O
:	O
33.42	O
+/-	O
3.10	O
;	O
and	O
over	O
the	O
CBD	O
:	O
41.66	O
+/-	O
6.33	O
)	O
,	O
suggesting	O
an	O
effective	O
sphincter-relaxing	B-Chemical
effect	O
of	I-Chemical
glyceryl	O
trinitrate	O
.	O

CONCLUSION	O
:	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
effectiveness	O
of	O
glyceryl	O
trinitrate	O
on	O
the	O
morphine-induced	B-Drug
sphincter	O
of	O
Oddi	O
spasm	B-Chemical
in	O
humans	O
.	O

Since	O
glyceryl	O
trinitrate	O
is	O
able	O
to	O
overcome	O
even	O
the	O
drastic	O
effect	O
of	I-Disease
morphine	B-Drug
,	O
it	O
might	O
be	O
of	I-Disease
relevance	O
in	O
the	O
treatment	O
of	I-Disease
sphincter	B-Disease
of	I-Chemical
Oddi	I-Chemical
dyskinesia	O
.	O

Effects	O
of	O
acute	O
steroid	B-Chemical
administration	O
on	O
ventilatory	O
and	O
peripheral	O
muscles	O
in	O
rats	O
.	O

Occasional	O
case	O
reports	O
have	O
shown	O
that	O
acute	O
myopathy	B-Disease
may	O
occur	O
in	O
patients	O
treated	O
with	O
massive	O
doses	O
of	O
corticosteroids	B-Chemical
.	O

The	O
mechanism	O
of	O
this	O
myopathy	B-Disease
is	O
poorly	O
understood	O
.	O

Therefore	O
,	O
60	O
male	O
rats	O
were	O
randomly	O
assigned	O
to	O
receive	O
daily	O
injection	O
of	O
saline	O
(	O
C	O
)	O
,	O
methylprednisolone	B-Chemical
(	O
M	B-Chemical
)	O
,	O
or	O
triamcinolone	B-Chemical
(	O
T	B-Chemical
)	O
80	O
mg/kg/d	O
for	O
5	O
d.	O
Nutritional	O
intake	I-Disease
,	O
measured	O
daily	O
in	O
15	O
animals	O
,	O
showed	O
a	O
significant	O
reduction	B-Disease
of	I-Disease
food	I-Disease
intake	O
in	O
the	O
steroid-treated	B-Chemical
groups	O
(	O
-50	O
and	O
-79	O
%	O
in	O
M	B-Chemical
and	O
T	B-Chemical
,	O
respectively	O
)	O
.	O

This	O
was	O
associated	O
with	O
a	O
similar	O
loss	B-Disease
in	I-Disease
body	I-Disease
weight	I-Disease
.	O

In	O
the	O
45	O
remaining	O
animals	O
,	O
diaphragm	O
contractility	O
and	O
histopathologic	O
features	O
of	O
several	O
muscles	O
were	O
studied	O
.	O

Weights	O
of	O
respiratory	O
and	O
peripheral	O
muscles	O
were	O
similarly	O
decreased	O
after	O
steroid	B-Chemical
treatment	O
.	O

Maximal	B-Chemical
twitches	O
of	O
the	O
diaphragm	O
were	O
lower	O
in	O
the	O
C	O
group	O
(	O
653	O
+/-	O
174	O
g/cm	O
(	O
2	O
)	O
)	O
than	O
in	O
the	O
M	O
group	O
(	O
837	O
+/-	O
171	O
g/cm	O
(	O
2	O
)	O
;	O
p	O
<	O
0.05	O
)	O
and	O
the	O
T	B-Chemical
group	O
(	O
765	O
+/-	O
145	O
g/cm	O
(	O
2	O
)	O
,	O
NS	O
)	O
.	O

Half-relaxation	O
time	O
was	O
prolonged	O
in	O
both	O
steroid	B-Chemical
groups	O
,	O
and	O
time	O
to	O
peak	O
tension	O
was	O
longer	O
with	O
M	B-Chemical
,	O
whereas	O
tetanic	B-Disease
tensions	O
were	O
similar	O
.	O

Steroid	B-Chemical
treatment	O
also	O
induced	O
a	O
leftward	O
shift	O
of	O
the	O
force-frequency	O
curve	O
at	O
25	O
and	O
50	O
Hz	O
when	O
compared	O
with	O
saline	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
.	O

ATPase	O
staining	O
of	O
the	O
diaphragm	O
,	O
scalenus	O
medius	O
,	O
and	O
gastrocnemius	O
showed	O
type	O
IIb	O
fiber	O
atrophy	B-Disease
in	O
the	O
steroid	B-Chemical
groups	O
and	O
also	O
diaphragmatic	O
type	O
IIa	O
atrophy	B-Disease
with	O
T	B-Chemical
,	O
whereas	O
histologic	O
examinations	O
revealed	O
a	O
normal	O
muscular	O
pattern	O
with	O
absence	O
of	O
necrosis	B-Disease
.	O

Finally	O
,	O
a	O
pair-fed	O
(	O
PF	O
)	O
study	O
,	O
performed	O
in	O
18	O
rats	O
(	O
C	O
,	O
T	B-Chemical
,	O
and	O
PF	O
)	O
,	O
showed	O
that	O
muscle	B-Disease
atrophy	I-Disease
was	O
considerably	O
less	O
pronounced	O
in	O
PF	O
animals	O
than	O
in	O
T-treated	B-Chemical
animals	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
short-term	O
treatment	O
with	O
massive	O
doses	O
of	O
steroids	B-Chemical
induced	O
severe	O
respiratory	O
and	O
limb	O
muscle	O
wasting	O
;	O
(	O
2	O
)	O
both	O
types	O
of	O
steroids	B-Chemical
induced	O
predominantly	O
type	O
IIb	O
atrophy	B-Disease
,	O
resulting	O
in	O
the	O
expected	O
alterations	O
in	O
diaphragm	O
contractile	O
properties	O
;	O
(	O
3	O
)	O
neither	O
steroid	B-Chemical
caused	O
muscle	O
necrosis	B-Disease
;	O
(	O
4	O
)	O
type	O
IIb	O
atrophy	B-Disease
was	O
not	O
caused	O
by	O
acute	O
nutritional	O
deprivation	O
alone	O
.	O

Refractory	O
cardiogenic	B-Disease
shock	I-Disease
and	O
complete	O
heart	B-Disease
block	I-Disease
after	O
verapamil	B-Chemical
SR	O
and	O
metoprolol	B-Chemical
treatment	O
.	O

A	O
case	O
report	O
.	O

A	O
seventy-eight-year-old	O
woman	O
presented	O
with	O
complete	O
heart	B-Disease
block	I-Disease
and	O
refractory	O
hypotension	B-Disease
two	O
days	O
after	O
a	O
therapeutic	O
dose	O
of	O
sustained-release	O
verapamil	B-Chemical
with	O
concomitant	O
use	O
of	O
metoprolol	B-Chemical
.	O

The	O
patient	O
continued	O
to	O
remain	O
hypotensive	B-Disease
with	O
complete	O
heart	B-Disease
block	I-Disease
,	O
even	O
with	O
multiple	O
uses	O
of	O
intravenous	O
atropine	B-Chemical
as	O
well	O
as	O
high	O
doses	O
of	O
pressor	O
agents	O
such	O
as	O
dopamine	B-Chemical
and	O
dobutamine	B-Chemical
.	O

However	O
,	O
shortly	O
after	O
the	O
use	O
of	O
intravenous	O
calcium	B-Chemical
chloride	I-Chemical
,	O
the	O
refractory	O
hypotension	B-Disease
and	O
complete	O
heart	B-Disease
block	I-Disease
resolved	O
.	O

A	O
phase	O
I	O
clinical	O
study	O
of	O
the	O
antipurine	B-Chemical
antifolate	O
lometrexol	B-Chemical
(	O
DDATHF	B-Chemical
)	O
given	O
with	O
oral	O
folic	B-Chemical
acid	I-Chemical
.	O

Lometrexol	B-Chemical
is	O
an	O
antifolate	O
which	O
inhibits	O
glycinamide	B-Chemical
ribonucleotide	I-Chemical
formyltransferase	O
(	O
GARFT	O
)	O
,	O
an	O
enzyme	O
essential	O
for	O
de	O
novo	O
purine	B-Chemical
synthesis	O
.	O

Extensive	O
experimental	O
and	O
limited	O
clinical	O
data	O
have	O
shown	O
that	O
lometrexol	B-Chemical
has	O
activity	O
against	O
tumours	B-Disease
which	O
are	O
refractory	O
to	O
other	O
drugs	B-Drug
,	O
notably	O
methotrexate	B-Chemical
.	O

However	O
,	O
the	O
initial	O
clinical	O
development	O
of	O
lometrexol	B-Chemical
was	O
curtailed	O
because	O
of	O
severe	O
and	O
cumulative	O
antiproliferative	O
toxicities	B-Disease
.	O

Preclinical	O
murine	O
studies	O
demonstrated	O
that	O
the	O
toxicity	B-Disease
of	O
lometrexol	B-Chemical
can	O
be	O
prevented	O
by	O
low	O
dose	O
folic	B-Chemical
acid	I-Chemical
administration	O
,	O
i.e	O
.	O

for	O
7	O
days	O
prior	O
to	O
and	O
7	O
days	O
following	O
a	O
single	O
bolus	O
dose	O
.	O

This	O
observation	O
prompted	O
a	O
Phase	O
I	O
clinical	O
study	O
of	O
lometrexol	B-Chemical
given	O
with	O
folic	B-Chemical
acid	I-Chemical
supplementation	O
which	O
has	O
confirmed	O
that	O
the	O
toxicity	B-Disease
of	O
lometrexol	B-Chemical
can	O
be	O
markedly	O
reduced	O
by	O
folic	B-Chemical
acid	I-Chemical
supplementation	O
.	O

Thrombocytopenia	B-Disease
and	O
mucositis	B-Disease
were	O
the	O
major	O
toxicities	B-Disease
.	O

There	O
was	O
no	O
clear	O
relationship	O
between	O
clinical	O
toxicity	B-Disease
and	O
the	O
extent	O
of	O
plasma	O
folate	B-Chemical
elevation	O
.	O

Associated	O
studies	O
demonstrated	O
that	O
lometrexol	B-Chemical
plasma	O
pharmacokinetics	O
were	O
not	O
altered	O
by	O
folic	B-Chemical
acid	I-Chemical
administration	O
indicating	O
that	O
supplementation	O
is	O
unlikely	O
to	O
reduce	O
toxicity	B-Disease
by	O
enhancing	O
lometrexol	B-Chemical
plasma	O
clearance	O
.	O

The	O
work	O
described	O
in	O
this	O
report	O
has	O
identified	O
for	O
the	O
first	O
time	O
a	O
clinically	O
acceptable	O
schedule	O
for	O
the	O
administration	O
of	O
a	O
GARFT	O
inhibitor	O
.	O

This	O
information	O
will	O
facilitate	O
the	O
future	O
evaluation	O
of	O
this	O
class	O
of	O
compounds	O
in	O
cancer	B-Disease
therapy	O
.	O

Involvement	O
of	O
the	O
mu-opiate	O
receptor	O
in	O
peripheral	O
analgesia	B-Disease
.	O

The	O
intradermal	O
injection	O
of	O
mu	O
(	O
morphine	B-Chemical
,	O
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol	B-Chemical
and	O
morphiceptin	B-Chemical
)	I-Chemical
,	O
kappa	O
(	I-Chemical
trans-3,4-dichloro-N-methyl-N	B-Chemical
[	I-Chemical
2-	I-Chemical
(	I-Chemical
1-pyrrolidinyl	I-Chemical
)	I-Chemical
cyclohexyl	I-Chemical
]	I-Chemical
benzeneactemide	O
)	O
and	O
delta	O
(	O
[	B-Chemical
D-Pen2.5	I-Chemical
]	I-Chemical
-enkephalin	O
and	O
[	B-Chemical
D-Ser2	I-Chemical
]	I-Chemical
-	I-Chemical
[	B-Chemical
Leu	I-Chemical
]	I-Chemical
enkephalin-Thr	I-Chemical
)	O
selective	O
opioid-agonists	O
,	O
by	O
themselves	O
,	O
did	O
not	O
significantly	O
affect	O
the	O
mechanical	O
nociceptive	O
threshold	O
in	O
the	O
hindpaw	O
of	O
the	O
rat	O
.	O

Intradermal	O
injection	O
of	O
mu	O
,	O
but	O
not	O
delta	O
or	O
kappa	O
opioid-agonists	O
,	O
however	O
,	O
produced	O
dose-dependent	O
inhibition	O
of	O
prostaglandin	B-Chemical
E2-induced	O
hyperalgesia	O
.	O

The	O
analgesic	O
effect	O
of	O
the	O
mu-agonist	O
morphine	B-Drug
was	O
dose-dependently	O
antagonized	O
by	O
naloxone	B-Drug
and	O
prevented	O
by	O
co-injection	O
of	O
pertussis	O
toxin	B-Drug
.	O

Morphine	B-Drug
did	O
not	O
,	O
however	O
,	O
alter	O
the	O
hyperalgesia	O
induced	O
by	O
8-bromo	O
cyclic	O
adenosine	B-Drug
monophosphate	O
.	O

We	O
conclude	O
that	O
the	O
analgesic	O
action	O
of	O
opioids	O
on	O
the	O
peripheral	O
terminals	O
of	O
primary	O
afferents	O
is	O
via	O
a	O
binding	O
site	O
with	O
characteristics	O
of	O
the	O
mu-opioid	O
receptor	O
and	O
that	O
this	O
action	O
is	O
mediated	O
by	O
inhibition	O
of	O
the	O
cyclic	O
adenosine	B-Drug
monophosphate	O
second	O
messenger	O
system	O
.	O

Adequate	O
timing	O
of	O
ribavirin	B-Chemical
reduction	O
in	O
patients	O
with	O
hemolysis	B-Disease
during	O
combination	O
therapy	O
of	O
interferon	B-Chemical
and	O
ribavirin	B-Chemical
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
.	O

BACKGROUND	O
:	O
Hemolytic	B-Disease
anemia	I-Disease
is	O
one	O
of	O
the	O
major	O
adverse	O
events	O
of	O
the	O
combination	O
therapy	O
of	O
interferon	B-Chemical
and	O
ribavirin	B-Chemical
.	O

Because	O
of	O
ribavirin-related	B-Chemical
hemolytic	B-Disease
anemia	I-Disease
,	O
dose	O
reduction	O
is	O
a	O
common	O
event	O
in	O
this	O
therapy	O
.	O

In	O
this	O
clinical	O
retrospective	O
cohort	O
study	O
we	O
have	O
examined	O
the	O
suitable	O
timing	O
of	O
ribavirin	B-Chemical
reduction	O
in	O
patients	O
with	O
hemolysis	B-Disease
during	O
combination	O
therapy	O
.	O

METHODS	O
:	O
Thirty-seven	O
of	O
160	O
patients	O
who	O
had	O
HCV-genotype	O
1b	O
,	O
had	O
high	O
virus	O
load	O
,	O
and	O
received	O
24-week	O
combination	O
therapy	O
developed	O
anemia	B-Disease
with	O
hemoglobin	O
level	O
<	O
10	O
g/dl	O
or	O
anemia-related	B-Disease
signs	O
during	O
therapy	O
.	O

After	O
that	O
,	O
these	O
37	O
patients	O
were	O
reduced	O
one	O
tablet	O
of	O
ribavirin	B-Chemical
(	O
200	O
mg	O
)	O
per	O
day	O
.	O

After	O
reduction	O
of	O
ribavirin	B-Chemical
,	O
27	O
of	O
37	O
patients	O
could	O
continue	O
combination	O
therapy	O
for	O
a	O
total	O
of	O
24	O
weeks	O
(	O
group	O
A	O
)	O
.	O

However	O
,	O
10	O
of	O
37	O
patients	O
with	O
reduction	O
of	O
ribavirin	B-Chemical
could	O
not	O
continue	O
combination	O
therapy	O
because	O
their	O
<	O
8.5	O
g/dl	O
hemoglobin	O
values	O
decreased	O
to	O
or	O
anemia-related	B-Disease
severe	O
side	O
effects	O
occurred	O
(	O
group	O
B	O
)	O
.	O

We	O
assessed	O
the	O
final	O
efficacy	O
and	O
safety	O
after	O
reduction	O
of	O
ribavirin	B-Chemical
in	O
groups	O
A	O
and	O
B	O
.	O

RESULTS	O
:	O
A	O
sustained	O
virological	O
response	O
(	O
SVR	O
)	O
was	O
29.6	O
%	O
(	O
8/27	O
)	O
in	O
group	O
A	O
and	O
10	O
%	O
(	O
1/10	O
)	O
in	O
group	O
B	O
,	O
respectively	O
.	O

A	O
34.4	O
%	O
(	O
12/27	O
)	O
of	O
SVR	O
+	O
biological	O
response	O
in	O
group	O
A	O
was	O
higher	O
than	O
10	O
%	O
(	O
1/10	O
)	O
in	O
group	O
B	O
(	O
P	O
=	O
0.051	O
)	O
,	O
with	O
slight	O
significance	O
.	O

With	O
respect	O
to	O
hemoglobin	O
level	O
at	O
the	O
time	O
of	O
ribavirin	B-Chemical
reduction	O
,	O
a	O
rate	O
of	O
continuation	O
of	O
therapy	O
in	O
patients	O
with	O
>	O
or	O
=10	O
g/dl	O
hemoglobin	O
was	O
higher	O
than	O
that	O
in	O
patients	O
with	O
<	O
10	O
g/dl	O
(	O
P	O
=	O
0.036	O
)	O
.	O

CONCLUSIONS	O
:	O
Reduction	O
of	O
ribavirin	B-Chemical
at	O
hemoglobin	O
level	O
>	O
or	O
=10	O
g/dl	O
is	O
suitable	O
in	O
terms	O
of	O
efficacy	O
and	O
side	O
effects	O
.	O

Increased	O
expression	O
and	O
apical	O
targeting	O
of	O
renal	O
ENaC	O
subunits	O
in	O
puromycin	B-Chemical
aminonucleoside-induced	O
nephrotic	O
syndrome	O
in	O
rats	O
.	O

Nephrotic	B-Disease
syndrome	I-Disease
is	O
often	O
accompanied	O
by	O
sodium	B-Chemical
retention	O
and	O
generalized	O
edema	B-Disease
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
decreased	O
renal	O
sodium	B-Chemical
excretion	O
remains	O
undefined	O
.	O

We	O
hypothesized	O
that	O
epithelial	O
Na	B-Chemical
channel	O
(	O
ENaC	O
)	O
subunit	O
dysregulation	O
may	O
be	O
responsible	O
for	O
the	O
increased	O
sodium	B-Chemical
retention	O
.	O

An	O
experimental	O
group	O
of	O
rats	O
was	O
treated	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
;	O
180	O
mg/kg	O
iv	O
)	O
,	O
whereas	O
the	O
control	O
group	O
received	O
only	O
vehicle	O
.	O

After	O
7	O
days	O
,	O
PAN	B-Chemical
treatment	O
induced	O
significant	O
proteinuria	B-Disease
,	O
hypoalbuminemia	B-Disease
,	O
decreased	O
urinary	O
sodium	B-Chemical
excretion	O
,	O
and	O
extensive	O
ascites	B-Disease
.	O

The	O
protein	O
abundance	O
of	O
alpha-ENaC	O
and	O
beta-ENaC	O
was	O
increased	O
in	O
the	O
inner	O
stripe	O
of	O
the	O
outer	O
medulla	O
(	O
ISOM	O
)	O
and	O
in	O
the	O
inner	O
medulla	O
(	O
IM	O
)	O
but	O
was	O
not	O
altered	O
in	O
the	O
cortex	O
.	O

gamma-ENaC	O
abundance	O
was	O
increased	O
in	O
the	O
cortex	O
,	O
ISOM	O
,	O
and	O
IM	O
.	O

Immunoperoxidase	O
brightfield-	O
and	O
laser-scanning	O
confocal	O
fluorescence	O
microscopy	O
demonstrated	O
increased	O
targeting	O
of	O
alpha-ENaC	O
,	O
beta-ENaC	O
,	O
and	O
gamma-ENaC	O
subunits	O
to	O
the	O
apical	O
plasma	O
membrane	O
in	O
the	O
distal	O
convoluted	O
tubule	O
(	O
DCT2	O
)	O
,	O
connecting	O
tubule	O
,	O
and	O
cortical	O
and	O
medullary	O
collecting	O
duct	O
segments	O
.	O

Immunoelectron	O
microscopy	O
further	O
revealed	O
an	O
increased	O
labeling	O
of	O
alpha-ENaC	O
in	O
the	O
apical	O
plasma	O
membrane	O
of	O
cortical	O
collecting	O
duct	O
principal	O
cells	O
of	O
PAN-treated	B-Chemical
rats	O
,	O
indicating	O
enhanced	O
apical	O
targeting	O
of	O
alpha-ENaC	B-Chemical
subunits	O
.	O

In	O
contrast	O
,	O
the	O
protein	O
abundances	O
of	O
Na	O
(	O
+	O
)	O
/H	B-Chemical
(	O
+	O
)	O
exchanger	O
type	O
3	O
(	O
NHE3	O
)	O
,	O
Na	B-Chemical
(	O
+	O
)	O
-K	B-Chemical
(	O
+	O
)	O
-2Cl	B-Chemical
(	O
-	O
)	O
cotransporter	O
(	O
BSC-1	O
)	O
,	O
and	O
thiazide-sensitive	B-Chemical
Na	B-Chemical
(	O
+	O
)	O
-Cl	B-Chemical
(	O
-	O
)	O
cotransporter	O
(	O
TSC	O
)	O
were	O
decreased	O
.	O

Moreover	O
,	O
the	O
abundance	O
of	O
the	O
alpha	O
(	O
1	O
)	O
-subunit	O
of	O
the	O
Na-K-ATPase	B-Chemical
was	O
decreased	O
in	O
the	O
cortex	O
and	O
ISOM	O
,	O
but	O
it	O
remained	O
unchanged	O
in	O
the	O
IM	O
.	O

In	O
conclusion	O
,	O
the	O
increased	O
or	O
sustained	O
expression	O
of	O
ENaC	O
subunits	O
combined	O
with	O
increased	O
apical	O
targeting	O
in	O
the	O
DCT2	O
,	O
connecting	O
tubule	O
,	O
and	O
collecting	O
duct	O
are	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
sodium	O
retention	O
associated	O
with	O
PAN-induced	O
nephrotic	O
syndrome	O
.	O

The	O
decreased	O
abundance	O
of	O
NHE3	O
,	O
BSC-1	O
,	O
TSC	O
,	O
and	O
Na-K-ATPase	B-Chemical
may	O
play	O
a	O
compensatory	O
role	O
to	O
promote	O
sodium	B-Chemical
excretion	O
.	O

Does	O
hormone	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	B-Disease
cancer	I-Disease
have	O
a	O
detrimental	B-Disease
effect	I-Disease
on	I-Disease
memory	I-Disease
and	I-Disease
cognition	I-Disease
?	O
A	O
pilot	O
study	O
.	O

This	O
pilot	O
study	O
examines	O
whether	O
hormone	O
therapy	O
for	O
breast	B-Disease
cancer	I-Disease
affects	O
cognition	O
.	O

Patients	O
participating	O
in	O
a	O
randomised	O
trial	O
of	O
anastrozole	B-Chemical
,	O
tamoxifen	B-Chemical
alone	O
or	O
combined	O
(	O
ATAC	O
)	O
(	O
n=94	O
)	O
and	O
a	O
group	O
of	O
women	O
without	O
breast	B-Disease
cancer	I-Disease
(	O
n=35	O
)	O
completed	O
a	O
battery	O
of	O
neuropsychological	O
measures	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
patients	O
were	O
impaired	O
on	O
a	O
processing	O
speed	O
task	O
(	O
p=0.032	O
)	O
and	O
on	O
a	O
measure	O
of	O
immediate	O
verbal	O
memory	O
(	O
p=0.026	O
)	O
after	O
controlling	O
for	O
the	O
use	O
of	O
hormone	O
replacement	O
therapy	O
in	O
both	O
groups	O
.	O

Patient	O
group	O
performance	O
was	O
not	O
significantly	O
related	O
to	O
length	O
of	O
treatment	O
or	O
measures	O
of	O
psychological	O
morbidity	O
.	O

The	O
results	O
showed	O
specific	O
impairments	O
in	O
processing	O
speed	O
and	O
verbal	O
memory	O
in	O
women	O
receiving	O
hormonal	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	B-Disease
cancer	I-Disease
.	O

Verbal	O
memory	O
may	O
be	O
especially	O
sensitive	O
to	O
changes	O
in	O
oestrogen	B-Chemical
levels	O
,	O
a	O
finding	O
commonly	O
reported	O
in	O
studies	O
of	O
hormone	O
replacement	O
therapy	O
in	O
healthy	O
women	O
.	O

In	O
view	O
of	O
the	O
increased	O
use	O
of	O
hormone	O
therapies	O
in	O
an	O
adjuvant	O
and	O
preventative	O
setting	O
their	O
impact	O
on	O
cognitive	O
functioning	O
should	O
be	O
investigated	O
more	O
thoroughly	O
.	O

Association	O
of	O
nitric	B-Chemical
oxide	I-Chemical
production	O
and	O
apoptosis	O
in	O
a	O
model	O
of	O
experimental	O
nephropathy	B-Disease
.	O

BACKGROUND	O
:	O
In	O
recent	O
studies	O
increased	O
amounts	O
of	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
and	O
apoptosis	O
have	O
been	O
implicated	O
in	O
various	O
pathological	O
conditions	O
in	O
the	O
kidney	O
.	O

We	O
have	O
studied	O
the	O
role	O
of	O
NO	B-Chemical
and	O
its	O
association	O
with	O
apoptosis	O
in	O
an	O
experimental	O
model	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
.	O

METHODS	O
:	O
The	O
alteration	O
in	O
the	O
NO	B-Chemical
pathway	O
was	O
assessed	O
by	O
measuring	O
nitrite	B-Chemical
levels	O
in	O
serum/urine	O
and	O
by	O
evaluating	O
the	O
changes	O
in	O
vascular	O
reactivity	O
of	O
the	O
isolated	O
perfused	O
rat	O
kidney	O
(	O
IPRK	O
)	O
system	O
.	O

Rats	O
were	O
stratified	O
into	O
control	O
groups	O
and	O
ADR-induced	B-Chemical
nephropathy	B-Disease
groups	O
.	O

These	O
two	O
groups	O
were	O
then	O
divided	O
into	O
:	O
group	O
1	O
,	O
animals	O
receiving	O
saline	O
;	O
and	O
group	O
2	O
,	O
animals	O
receiving	O
aminoguanidine	B-Chemical
(	O
AG	B-Chemical
)	O
which	O
is	O
a	O
specific	O
inhibitor	O
of	O
inducible-NO	B-Chemical
synthase	O
.	O

On	O
day	O
21	O
,	O
rats	O
were	O
sacrificed	O
after	O
obtaining	O
material	O
for	O
biochemical	O
analysis	O
.	O

RESULTS	O
:	O
Histopathological	O
examination	O
of	O
the	O
kidneys	O
of	O
rats	O
treated	O
with	O
ADR	B-Chemical
revealed	O
focal	O
areas	O
of	O
mesangial	B-Disease
proliferation	I-Disease
and	O
mild	O
tubulointerstitial	B-Disease
inflammation	I-Disease
.	O

They	O
also	O
had	O
significantly	O
higher	O
levels	O
of	O
proteinuria	B-Disease
compared	O
with	O
control	O
and	O
treatment	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Urine	O
nitrite	B-Chemical
levels	O
were	O
significantly	O
increased	O
in	O
the	O
ADR-nephropathy	B-Chemical
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
the	O
IPRK	O
phenylephrine	O
and	O
acetylcholine	O
related	O
responses	O
were	O
significantly	O
impaired	O
in	O
the	O
ADR-nephropathy	B-Disease
group	O
.	O

Apoptosis	O
was	O
not	O
detected	O
in	O
controls	O
.	O

However	O
,	O
in	O
the	O
ADR-nephropathy	O
group	O
,	O
numerous	O
apoptotic	O
cells	O
were	O
identified	O
in	O
the	O
tubulointerstitial	O
areas	O
.	O

Double	O
staining	O
revealed	O
numerous	O
interstitial	O
apoptotic	O
cells	O
to	O
stain	O
for	O
ED1	O
,	O
a	O
marker	O
for	O
monocytes/macrophages	O
.	O

Treatment	O
with	O
AG	O
prevented	O
the	O
impairment	O
of	O
renal	O
vascular	O
bed	O
responses	O
and	O
reduced	O
both	O
urine	O
nitrite	B-Drug
levels	O
and	O
apoptosis	O
to	O
control	O
levels	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
interactions	O
between	O
NO	O
and	O
apoptosis	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
the	O
ADR-induced	O
nephrosis	O
.	O

The	O
attenuating	O
effect	O
of	O
carteolol	B-Chemical
hydrochloride	I-Chemical
,	O
a	O
beta-adrenoceptor	O
antagonist	O
,	O
on	O
neuroleptic-induced	O
catalepsy	B-Disease
in	O
rats	O
.	O

It	O
is	O
known	O
that	O
beta-adrenoceptor	O
antagonists	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	B-Disease
,	O
one	O
of	O
the	O
extrapyramidal	O
side	O
effects	O
that	O
occur	O
during	O
neuroleptic	B-Drug
treatment	O
.	O

Neuroleptic-induced	O
catalepsy	B-Disease
,	O
a	O
model	O
of	O
neuroleptic-induced	O
extrapyramidal	O
side	O
effects	O
,	O
was	O
considered	O
suitable	O
as	O
a	O
model	O
for	O
predicting	O
neuroleptic-induced	O
akathisia	B-Disease
in	O
humans	O
,	O
although	O
neuroleptic-induced	O
catalepsy	B-Disease
was	O
not	O
considered	O
a	O
specific	O
test	O
for	O
neuroleptic-induced	O
akathisia	B-Disease
.	O

Therefore	O
,	O
the	O
effects	O
of	O
carteolol	B-Chemical
,	O
a	O
beta-adrenoceptor	O
antagonist	O
,	O
on	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
in	O
rats	O
were	O
behaviorally	O
studied	O
and	O
compared	O
with	O
those	O
of	O
propranolol	B-Chemical
and	O
biperiden	B-Chemical
,	O
a	O
muscarinic	O
receptor	O
antagonist	O
.	O

Carteolol	B-Chemical
,	O
as	O
well	O
as	O
propranolol	B-Chemical
and	O
biperiden	B-Chemical
,	O
inhibited	O
the	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
.	O

The	O
inhibitory	O
effect	O
of	O
carteolol	B-Chemical
was	O
almost	O
comparable	O
to	O
that	O
of	O
propranolol	B-Chemical
,	O
but	O
was	O
weaker	O
than	O
that	O
of	O
biperiden	B-Chemical
.	O

Carteolol	B-Chemical
did	O
not	O
evoke	O
postsynaptic	O
dopamine	B-Chemical
receptor-stimulating	O
behavioral	O
signs	O
such	O
as	O
stereotypy	O
and	O
hyperlocomotion	B-Disease
in	O
rats	O
.	O

Carteolol	B-Chemical
did	O
not	O
antagonize	O
the	O
inhibitory	O
effects	O
of	O
haloperidol	B-Chemical
on	O
apomorphine-induced	B-Chemical
stereotypy	O
and	O
locomotor	O
activity	O
in	O
rats	O
.	O

In	O
addition	O
,	O
carteolol	B-Chemical
did	O
not	O
evoke	O
5-HT1A	O
receptor-stimulating	O
behavioral	O
signs	O
such	O
as	O
flat	O
body	O
posture	O
and	O
forepaw	O
treading	O
and	O
did	O
not	O
inhibit	O
5-hydroxytryptophan-induced	B-Chemical
head	O
twitch	O
in	O
rats	O
.	O

Finally	O
,	O
carteolol	B-Chemical
did	O
not	O
inhibit	O
physostigmine-induced	B-Chemical
lethality	O
in	O
rats	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
carteolol	B-Chemical
improves	O
haloperidol-induced	B-Chemical
catalepsy	B-Disease
via	O
its	O
beta-adrenoceptor	O
antagonistic	O
activity	O
and	O
is	O
expected	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	B-Disease
without	O
attenuating	O
neuroleptic-induced	O
antipsychotic	O
effects	O
due	O
to	O
its	O
postsynaptic	O
dopamine	B-Chemical
receptor	O
antagonistic	O
activity	O
.	O

Penicillamine-induced	B-Chemical
rapidly	O
progressive	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

A	O
67-year-old	O
woman	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
presented	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
(	O
RPGN	B-Disease
)	O
after	O
5	O
months	O
of	O
D-penicillamine	B-Chemical
(	O
250	O
mg/day	O
)	O
treatment	O
.	O

Light	O
microscopy	O
study	O
showed	O
severe	O
glomerulonephritis	B-Disease
with	O
crescent	O
formation	O
in	O
60	O
%	O
of	O
the	O
glomeruli	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
in	O
the	O
wall	O
of	O
an	O
arteriole	O
.	O

Immunofluorescence	O
revealed	O
scanty	O
granular	O
IgG	O
,	O
IgA	O
and	O
C3	O
deposits	O
along	O
the	O
capillary	O
walls	O
and	O
mesangium	O
.	O

The	O
patient	O
was	O
treated	O
with	O
steroid	B-Chemical
pulse	O
,	O
plasmapheresis	O
,	O
cyclophosphamide	B-Chemical
and	O
antiplatelet	B-Chemical
agents	I-Chemical
.	O

A	O
complete	O
recovery	O
of	O
renal	O
function	O
was	O
achieved	O
in	O
a	O
few	O
weeks	O
.	O

This	O
new	O
case	O
of	O
RPGN	B-Disease
in	O
the	O
course	O
of	O
D-penicillamine	B-Chemical
treatment	O
emphasizes	O
the	O
need	O
for	O
frequent	O
monitoring	O
of	O
renal	O
function	O
and	O
evaluation	O
of	O
urinary	O
sediment	O
and	O
proteinuria	B-Disease
in	O
these	O
patients	O
.	O

The	O
prompt	O
discontinuation	O
of	O
D-penicillamine	B-Chemical
and	O
vigorous	O
treatment	O
measures	O
could	O
allow	O
for	O
a	O
good	O
prognosis	O
as	O
in	O
this	O
case	O
.	O

Nature	O
,	O
time	O
course	O
and	O
dose	O
dependence	O
of	O
zidovudine-related	B-Chemical
side	O
effects	O
:	O
results	O
from	O
the	O
Multicenter	O
Canadian	O
Azidothymidine	B-Chemical
Trial	O
.	O

To	O
characterize	O
the	O
nature	O
,	O
time	O
course	O
and	O
dose	O
dependency	O
of	O
zidovudine-related	B-Chemical
side	O
effects	O
,	O
we	O
undertook	O
a	O
multicenter	O
,	O
prospective	O
,	O
dose-range	O
finding	O
study	O
.	O

Our	O
study	O
group	O
consisted	O
of	O
74	O
HIV-positive	B-Disease
homosexual	O
men	O
belonging	O
to	O
groups	O
II	O
B	O
,	O
III	O
and	O
IV	O
C2	O
from	O
the	O
Centers	O
for	O
Disease	O
Control	O
(	O
CDC	O
)	O
classification	O
of	O
HIV	B-Disease
disease	O
.	O

Following	O
a	O
3-week	O
observation	O
period	O
,	O
volunteers	O
were	O
treated	O
with	O
zidovudine	B-Chemical
600	O
mg/day	O
for	O
18	O
weeks	O
,	O
900	O
mg/day	O
for	O
9	O
weeks	O
and	O
1200	O
mg/day	O
for	O
9	O
weeks	O
,	O
followed	O
by	O
a	O
washout	O
period	O
of	O
6	O
weeks	O
after	O
which	O
they	O
were	O
re-started	O
on	O
1200	O
mg/day	O
or	O
the	O
highest	O
tolerated	O
dose	O
at	O
8-hourly	O
intervals	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
4-hourly	O
or	O
8-hourly	O
regimens	O
within	O
CDC	O
groups	O
while	O
taking	O
600	O
and	O
1200	O
mg/day	O
.	O

Clinical	O
and	O
laboratory	O
evaluations	O
were	O
performed	O
at	O
3-week	O
intervals	O
.	O

Symptomatic	O
adverse	O
effects	O
were	O
present	O
in	O
96	O
%	O
of	O
subjects	O
,	O
most	O
commonly	O
nausea	B-Disease
(	O
64	O
%	O
)	O
,	O
fatigue	B-Disease
(	O
55	O
%	O
)	O
and	O
headache	B-Disease
(	O
49	O
%	O
)	O
.	O

These	O
were	O
generally	O
self-limited	O
,	O
reappearing	O
briefly	O
at	O
each	O
dose	O
increment	O
.	O

A	O
decrease	O
in	O
hemoglobin	O
occurred	O
shortly	O
after	O
initiation	O
of	O
therapy	O
.	O

This	O
was	O
not	O
dose	O
dependent	O
and	O
reversed	O
rapidly	O
upon	O
discontinuation	O
of	O
treatment	O
.	O

A	O
red	O
blood	O
cell	O
count	O
decrease	O
,	O
a	O
mean	O
cell	O
volume	O
increase	O
and	O
a	O
granulocyte	O
count	O
decrease	O
developed	O
early	O
in	O
a	O
dose-independent	O
fashion	O
,	O
reverting	O
at	O
least	O
partially	O
during	O
the	O
washout	O
phase	O
.	O

The	O
decrease	O
in	O
reticulocyte	O
count	O
was	O
dose	O
related	O
between	O
600	O
and	O
900	O
mg/day	O
with	O
no	O
further	O
change	O
when	O
the	O
dose	O
was	O
escalated	O
to	O
1200	O
mg/day	O
.	O

Bone	O
marrow	O
changes	O
occurred	O
rapidly	O
as	O
demonstrated	O
by	O
megaloblastosis	B-Disease
in	O
95	O
%	O
of	O
65	O
specimens	O
at	O
week	O
18	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Bilateral	B-Disease
optic	I-Disease
neuropathy	I-Disease
due	O
to	O
combined	O
ethambutol	B-Chemical
and	O
isoniazid	B-Chemical
treatment	O
.	O

The	O
case	O
of	O
a	O
40-year-old	O
patient	O
who	O
underwent	O
an	O
unsuccessful	O
cadaver	O
kidney	O
transplantation	O
and	O
was	O
treated	O
with	O
ethambutol	B-Chemical
and	O
isoniazid	B-Chemical
is	O
reported	O
.	O

A	O
bilateral	B-Disease
retrobulbar	I-Disease
neuropathy	I-Disease
with	O
an	O
unusual	O
central	O
bitemporal	O
hemianopic	O
scotoma	B-Disease
was	O
found	O
.	O

Ethambutol	B-Chemical
was	O
stopped	O
and	O
only	O
small	O
improvement	O
of	O
the	O
visual	O
acuity	O
followed	O
.	O

Isoniazid	B-Chemical
was	O
discontinued	O
later	O
,	O
followed	O
by	O
a	O
dramatic	O
improvement	O
in	O
the	O
visual	O
acuity	O
.	O

The	O
hazards	O
of	O
optic	O
nerve	O
toxicity	B-Disease
due	O
to	O
ethambutol	B-Chemical
are	O
known	O
.	O

We	O
emphasize	O
the	O
potential	O
danger	O
in	O
the	O
use	O
of	O
ethambutol	B-Chemical
and	O
isoniazid	B-Chemical
.	O

Progestational	O
agents	O
and	O
blood	B-Disease
coagulation	I-Disease
.	O

VII	O
.	O

Thromboembolic	B-Disease
and	O
other	O
complications	O
of	O
oral	B-Chemical
contraceptive	I-Chemical
therapy	O
in	O
relationship	O
to	O
pretreatment	O
levels	O
of	O
blood	B-Disease
coagulation	I-Disease
factors	O
:	O
summary	O
report	O
of	O
a	O
ten-year	O
study	O
.	O

During	O
a	O
ten-year	O
period	O
,	O
348	O
women	O
were	O
studied	O
for	O
a	O
total	O
of	O
5,877	O
patient	O
months	O
in	O
four	O
separate	O
studies	O
relating	O
oral	B-Chemical
contraceptives	I-Chemical
to	O
changes	O
in	O
hematologic	O
parameters	O
.	O

Significant	O
increases	O
in	O
certain	O
factors	O
of	O
the	O
blood	B-Disease
coagulation	I-Disease
and	O
fibrinolysin	O
systems	O
(	O
factors	O
I	O
,	O
II	O
,	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
and	O
plasminogen	O
)	O
were	O
observed	O
in	O
the	O
treated	O
groups	O
.	O

Severe	O
complications	O
developed	O
in	O
four	O
patients	O
.	O

All	O
four	O
had	O
an	O
abnormal	O
blood	B-Disease
coagulation	I-Disease
profile	O
,	O
suggesting	O
``	O
hypercoagulability	B-Disease
''	O
before	O
initiation	O
of	O
therapy	O
.	O

Some	O
of	O
these	O
findings	O
represented	O
the	O
most	O
extreme	O
abnormalities	O
seen	O
in	O
the	O
entire	O
group	O
of	O
patients	O
;	O
some	O
increased	O
further	O
during	O
therapy	O
.	O

One	O
of	O
these	O
patients	O
developed	O
a	O
myocardial	B-Disease
infarction	I-Disease
before	O
receiving	O
any	O
medication	O
,	O
shortly	O
after	O
the	O
base-line	O
values	O
were	O
obtained	O
.	O

One	O
patient	O
developed	O
retinopathy	B-Disease
19	O
months	O
after	O
she	O
began	O
therapy	O
,	O
and	O
another	O
developed	O
thrombophlebitis	B-Disease
after	O
27	O
months	O
of	O
therapy	O
.	O

The	O
fourth	O
patient	O
developed	O
thrombophlebitis	B-Disease
14	O
days	O
after	O
initiation	O
of	O
contraceptive	O
therapy	O
.	O

All	O
four	O
patients	O
were	O
of	O
the	O
A	O
or	O
AB	O
blood	O
group	O
.	O

Previous	O
studies	O
suggested	O
the	O
possiblility	O
of	O
increased	O
propensity	O
for	O
thromboembolic	B-Disease
episodes	I-Disease
in	O
patients	O
possessing	O
the	O
A	O
antigen	O
.	O

It	O
appears	O
from	O
these	O
data	O
that	O
hematologic	O
work-ups	O
may	O
be	O
useful	O
in	O
women	O
who	O
are	O
about	O
to	O
start	O
long-term	O
oral	B-Chemical
contraceptive	I-Chemical
therapy	O
.	O

Cardiac	B-Disease
arrest	I-Disease
in	O
a	O
child	O
with	O
cerebral	B-Disease
palsy	I-Disease
undergoing	O
sevoflurane	B-Chemical
induction	O
of	O
anesthesia	B-Drug
after	O
preoperative	O
clonidine	B-Chemical
.	O

Clonidine	B-Chemical
is	O
a	O
frequently	O
administered	O
alpha2-adrenergic	O
agonist	O
which	O
can	O
decrease	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
5-year-old	O
child	O
with	O
cerebral	B-Disease
palsy	I-Disease
and	O
seizure	B-Disease
disorder	I-Disease
,	O
receiving	O
clonidine	B-Chemical
for	O
restlessness	B-Disease
,	O
who	O
presented	O
for	O
placement	O
of	O
a	O
baclofen	B-Chemical
pump	O
.	O

Without	O
the	O
knowledge	O
of	O
the	O
medical	O
personnel	O
,	O
the	O
patient	O
's	O
mother	O
administered	O
three	O
doses	O
of	O
clonidine	B-Chemical
during	O
the	O
evening	O
before	O
and	O
morning	O
of	O
surgery	O
to	O
reduce	O
anxiety	B-Disease
.	O

During	O
induction	O
of	O
anesthesia	B-Drug
,	O
the	O
patient	O
developed	O
bradycardia	B-Disease
and	O
hypotension	B-Disease
requiring	O
cardiac	O
resuscitation	O
.	O

There	O
are	O
no	O
previous	O
reports	O
of	O
clonidine-associated	B-Chemical
cardiac	B-Disease
arrest	I-Disease
in	O
a	O
child	O
undergoing	O
induction	O
of	O
anesthesia	B-Drug
.	O

Effects	O
of	O
UMB24	B-Chemical
and	O
(	O
+/-	O
)	O
-SM	B-Chemical
21	I-Chemical
,	O
putative	O
sigma2-preferring	O
antagonists	O
,	O
on	O
behavioral	O
toxic	O
and	O
stimulant	O
effects	O
of	O
cocaine	B-Chemical
in	O
mice	O
.	O

Earlier	O
studies	O
have	O
demonstrated	O
that	O
antagonism	O
of	O
sigma1	O
receptors	O
attenuates	O
the	O
convulsive	B-Disease
,	O
lethal	O
,	O
locomotor	O
stimulatory	O
and	O
rewarding	O
actions	O
of	O
cocaine	B-Chemical
in	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
contribution	O
of	O
sigma2	O
receptors	O
is	O
unclear	O
because	O
experimental	O
tools	O
to	O
selectively	O
target	O
this	O
subtype	O
are	O
unavailable	O
.	O

To	O
begin	O
addressing	O
this	O
need	O
,	O
we	O
characterized	O
UMB24	B-Chemical
(	I-Chemical
1-	B-Chemical
(	I-Chemical
2-phenethyl	I-Chemical
)	I-Chemical
-4-	I-Chemical
(	I-Chemical
2-pyridyl	I-Chemical
)	I-Chemical
-piperazine	O
)	O
and	O
(	O
+/-	O
)	O
-SM	B-Chemical
21	I-Chemical
(	I-Chemical
3alpha-tropanyl-2-	B-Chemical
(	I-Chemical
4-chorophenoxy	I-Chemical
)	I-Chemical
butyrate	O
)	O
in	O
receptor	O
binding	O
and	O
behavioral	O
studies	O
.	O

Receptor	O
binding	O
studies	O
confirmed	O
that	O
UMB24	B-Chemical
and	O
(	O
+/-	O
)	O
-SM	B-Chemical
21	I-Chemical
display	O
preferential	O
affinity	O
for	O
sigma2	O
over	O
sigma1	O
receptors	O
.	O

In	O
behavioral	O
studies	O
,	O
pretreatment	O
of	O
Swiss	O
Webster	O
mice	O
with	O
UMB24	B-Chemical
or	O
(	O
+/-	O
)	O
-SM	B-Chemical
21	I-Chemical
significantly	O
attenuated	O
cocaine-induced	B-Chemical
convulsions	B-Disease
and	O
locomotor	O
activity	O
,	O
but	O
not	O
lethality	O
.	O

When	O
administered	O
alone	O
,	O
(	O
+/-	O
)	O
-SM	B-Chemical
21	I-Chemical
produced	O
no	O
significant	O
effects	O
compared	O
to	O
control	O
injections	O
of	O
saline	O
,	O
but	O
UMB24	B-Chemical
had	O
locomotor	O
depressant	O
actions	O
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
sigma2	O
receptor	O
antagonists	O
have	O
the	O
potential	O
to	O
attenuate	O
some	O
of	O
the	O
behavioral	O
effects	O
of	O
cocaine	B-Chemical
,	O
and	O
further	O
development	O
of	O
more	O
selective	O
,	O
high	O
affinity	O
ligands	O
are	O
warranted	O
.	O

Methimazole-induced	B-Chemical
cholestatic	B-Disease
jaundice	I-Disease
.	O

Methimazole	B-Chemical
is	O
a	O
widely	O
used	O
and	O
generally	O
well-tolerated	O
antithyroid	O
agent	O
.	O

A	O
43-year-old	O
woman	O
had	O
severe	O
jaundice	B-Disease
and	O
itching	B-Disease
1	O
month	O
after	O
receiving	O
methimazole	B-Chemical
(	O
10	O
mg	O
tid	O
)	O
and	O
propranolol	B-Chemical
(	O
20	O
mg	O
tid	O
)	O
for	O
treatment	O
of	O
hyperthyroidism	B-Disease
.	O

The	O
patient	O
continued	O
treatment	O
for	O
another	O
4	O
days	O
after	O
the	O
appearance	O
of	O
jaundice	B-Disease
until	O
she	O
finished	O
both	O
medications	O
.	O

When	O
seen	O
at	O
the	O
emergency	O
department	O
2	O
weeks	O
later	O
,	O
she	O
still	O
had	O
severe	O
icterus	B-Disease
,	O
pruritus	B-Disease
,	O
and	O
hyperbilirubinemia	B-Disease
,	O
formed	O
mainly	O
of	O
the	O
conjugated	O
fraction	O
.	O

Methimazole-induced	B-Chemical
cholestasis	B-Disease
was	O
diagnosed	O
,	O
and	O
propranolol	B-Chemical
therapy	O
was	O
resumed	O
.	O

Over	O
the	O
following	O
9	O
days	O
,	O
the	O
symptoms	O
improved	O
and	O
plasma	O
bilirubin	B-Chemical
levels	O
were	O
normal	O
after	O
12	O
weeks	O
without	O
methimazole	B-Chemical
.	O

In	O
rare	O
cases	O
within	O
the	O
first	O
few	O
weeks	O
of	O
therapy	O
,	O
this	O
drug	B-Drug
can	O
cause	O
severe	O
and	O
reversible	O
cholestatic	B-Disease
jaundice	I-Disease
.	O

Physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
this	O
adverse	O
effect	O
so	O
that	O
,	O
upon	O
occurrence	O
,	O
they	O
can	O
discontinue	O
methimazole	B-Chemical
therapy	O
and	O
avoid	O
unnecessary	O
invasive	O
procedures	O
.	O

Ciprofloxacin-induced	B-Chemical
acute	O
interstitial	B-Disease
nephritis	I-Disease
and	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
.	O

Ciprofloxacin	B-Chemical
has	O
been	O
associated	O
with	O
several	O
side	O
effects	O
including	O
interstitial	B-Disease
nephritis	I-Disease
and	O
hemolytic	B-Disease
anemia	I-Disease
.	O

The	O
combination	O
of	O
both	O
side	O
effects	O
is	O
extremely	O
rare	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
ciprofloxacin-induced	B-Chemical
interstitial	B-Disease
nephritis	I-Disease
and	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
.	O

Hemolytic	B-Disease
anemia	I-Disease
improved	O
after	O
stopping	O
the	O
drug	B-Drug
and	O
initiation	O
of	O
steroid	B-Chemical
therapy	O
.	O

Unfortunately	O
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
was	O
irreversible	O
and	O
the	O
patient	O
developed	O
end-stage	B-Disease
renal	I-Disease
disease	I-Disease
.	O

Contribution	O
of	O
sodium	B-Chemical
valproate	I-Chemical
to	O
the	O
syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
secretion	I-Disease
of	I-Disease
antidiuretic	I-Disease
hormone	I-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
62-year-old	O
man	O
who	O
was	O
administered	O
sodium	B-Chemical
valproate	I-Chemical
(	O
VPA	B-Chemical
)	O
and	O
who	O
subsequently	O
developed	O
the	O
syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
secretion	I-Disease
of	I-Disease
antidiuretic	I-Disease
hormone	I-Disease
(	O
SIADH	B-Disease
)	O
.	O

He	O
had	O
been	O
taking	O
VPA	B-Chemical
for	O
treatment	O
of	O
idiopathic	O
generalized	O
tonic-clonic	B-Disease
convulsions	I-Disease
since	O
he	O
was	O
56	O
years	O
old	O
.	O

After	O
substituting	O
VPA	B-Chemical
with	O
zonisamide	B-Chemical
,	O
the	O
serum	O
sodium	B-Chemical
level	O
returned	O
to	O
normal	O
.	O

We	O
consider	O
this	O
episode	O
of	O
SIADH	B-Disease
to	O
be	O
the	I-Disease
result	O
of	I-Disease
a	O
combination	O
of	I-Disease
factors	O
including	O
a	O
weakness	B-Disease
of	I-Disease
the	I-Disease
central	O
nervous	O
system	O
and	O
the	O
long-term	O
administration	O
of	O
VPA	B-Chemical
.	O

Vasopressin	B-Chemical
in	O
the	O
treatment	O
of	O
milrinone-induced	B-Chemical
hypotension	B-Disease
in	O
severe	O
heart	B-Disease
failure	I-Disease
.	O

The	O
use	O
of	O
phosphodiesterase	O
inhibitors	O
such	O
as	O
milrinone	B-Chemical
in	O
the	O
treatment	O
of	O
severe	O
heart	B-Disease
failure	I-Disease
is	O
frequently	O
restricted	O
because	O
they	O
cause	O
vasodilation	O
and	O
hypotension	B-Disease
.	O

In	O
patients	O
with	O
decompensated	O
heart	B-Disease
failure	I-Disease
with	O
hypotension	B-Disease
after	O
treatment	O
with	O
milrinone	B-Chemical
,	O
low	O
doses	O
of	O
vasopressin	B-Chemical
restored	O
blood	O
pressure	O
without	O
inhibiting	O
the	O
inotropic	O
effect	O
of	O
milrinone	B-Chemical
.	O

Halogenated	O
anesthetics	B-Drug
form	O
liver	O
adducts	O
and	O
antigens	O
that	O
cross-react	O
with	O
halothane-induced	B-Chemical
antibodies	O
.	O

Two	O
halogenated	O
anesthetics	B-Drug
,	O
enflurane	B-Chemical
and	O
isoflurane	B-Chemical
,	O
have	O
been	O
associated	O
with	O
an	O
allergic-type	O
hepatic	B-Disease
injury	I-Disease
both	O
alone	O
and	O
following	O
previous	O
exposure	O
to	O
halothane	B-Chemical
.	O

Halothane	B-Chemical
hepatitis	B-Disease
appears	O
to	O
involve	O
an	O
aberrant	O
immune	O
response	O
.	O

An	O
antibody	O
response	O
to	O
a	O
protein-bound	O
biotransformation	O
product	O
(	O
trifluoroacetyl	B-Chemical
adduct	O
)	O
has	O
been	O
detected	O
on	O
halothane	B-Chemical
hepatitis	B-Disease
patients	O
.	O

This	O
study	O
was	O
performed	O
to	O
determine	O
cross-reactivity	O
between	O
enflurane	B-Chemical
and	O
isoflurane	B-Chemical
with	O
the	O
hypersensitivity	B-Disease
induced	O
by	O
halothane	B-Chemical
.	O

The	O
subcellular	O
and	O
lobular	O
production	O
of	O
hepatic	O
neoantigens	O
recognized	O
by	O
halothane-induced	B-Chemical
antibodies	O
following	O
enflurane	B-Chemical
and	O
isoflurane	B-Chemical
,	O
and	O
the	O
biochemical	O
nature	O
of	O
these	O
neoantigens	O
was	O
investigated	O
in	O
two	O
animal	O
models	O
.	O

Enflurane	B-Chemical
administration	O
resulted	O
in	O
neoantigens	O
detected	O
in	O
both	O
the	O
microsomal	O
and	O
cytosolic	O
fraction	O
of	O
liver	O
homogenates	O
and	O
in	O
the	O
centrilobular	O
region	O
of	O
the	O
liver	O
.	O

In	O
the	O
same	O
liver	O
,	O
biochemical	O
analysis	O
detected	O
fluorinated	O
liver	O
adducts	O
that	O
were	O
up	O
to	O
20-fold	O
greater	O
in	O
guinea	O
pigs	O
than	O
in	O
rats	O
.	O

This	O
supports	O
and	O
extends	O
previous	O
evidence	O
for	O
a	O
mechanism	O
by	O
which	O
enflurane	B-Chemical
and/or	O
isoflurane	B-Chemical
could	O
produce	O
a	O
hypersensitivity	B-Disease
condition	O
similar	O
to	O
that	O
of	O
halothane	B-Chemical
hepatitis	B-Disease
either	O
alone	O
or	O
subsequent	O
to	O
halothane	B-Chemical
administration	O
.	O

The	O
guinea	O
pig	O
would	O
appear	O
to	O
be	O
a	O
useful	O
model	O
for	O
further	O
investigations	O
of	O
the	O
immunological	O
response	O
to	O
these	O
antigens	O
.	O

Induction	O
by	O
paracetamol	B-Chemical
of	O
bladder	B-Disease
and	I-Disease
liver	I-Disease
tumours	I-Disease
in	O
the	O
rat	O
.	O

Effects	O
on	O
hepatocyte	O
fine	O
structure	O
.	O

Groups	O
of	O
male	O
and	O
female	O
inbred	O
Leeds	O
strain	O
rats	O
were	O
fed	O
diets	O
containing	O
either	O
0.5	O
%	O
or	O
1.0	O
%	O
paracetamol	B-Chemical
by	O
weight	O
for	O
up	O
to	O
18	O
months	O
.	O

At	O
the	O
1.0	O
%	O
dosage	O
level	O
,	O
20	O
%	O
of	O
rats	O
of	O
both	O
sexes	O
developed	O
neoplastic	O
nodules	O
of	O
the	O
liver	O
,	O
a	O
statistically	O
significant	O
incidence	O
.	O

These	O
rats	O
also	O
showed	O
gross	O
enlargement	O
of	O
their	O
livers	O
and	O
an	O
increase	O
in	O
foci	O
of	O
cellular	O
alteration	O
,	O
the	O
latter	O
also	O
being	O
observed	O
in	O
the	O
low	O
dosage	O
male	O
rats	O
.	O

Papillomas	B-Disease
of	O
the	O
transitional	O
epithelium	O
of	O
the	O
bladder	O
developed	O
in	O
all	O
paracetamol-treated	B-Chemical
groups	O
,	O
and	O
three	O
rats	O
bore	O
bladder	B-Disease
carcinomas	I-Disease
.	O

However	O
,	O
significant	O
yields	O
of	O
bladder	B-Disease
tumours	I-Disease
were	O
only	O
obtained	O
from	O
low	O
dosage	O
females	O
and	O
high	O
dosage	O
males	O
.	O

Additionally	O
,	O
20	O
to	O
25	O
%	O
of	O
paracetamol-treated	B-Chemical
rats	O
developed	O
hyperplasia	B-Disease
of	O
the	O
bladder	B-Disease
epithelium	O
,	O
which	O
was	O
not	O
coincident	O
with	O
the	O
presence	O
of	O
bladder	B-Disease
calculi	O
.	O

A	O
low	O
yield	O
of	O
tumours	B-Disease
at	O
various	O
other	O
sites	O
also	O
arose	O
following	O
paracetamol	B-Chemical
feeding	O
.	O

An	O
electron	O
microscope	O
study	O
of	O
the	O
livers	O
of	O
paracetamol-treated	B-Chemical
rats	O
revealed	O
ultrastructural	O
changes	O
in	O
the	O
hepatocytes	O
that	O
resemble	O
those	O
that	O
result	O
from	O
exposure	O
to	O
a	O
variety	O
of	O
known	O
hepatocarcinogens	B-Disease
.	O

Rat	O
extraocular	O
muscle	O
regeneration	O
.	O

Repair	O
of	O
local	O
anesthetic-induced	O
damage	O
.	O

Local	O
anesthetics	B-Drug
that	O
are	O
commonly	O
used	O
in	O
ophthalmic	O
surgery	O
(	O
0.75	O
%	O
bupivacaine	B-Chemical
hydrochloride	I-Chemical
,	O
2.0	O
%	O
mepivacaine	B-Chemical
hydrochloride	I-Chemical
,	O
and	O
2.0	O
%	O
lidocaine	B-Chemical
hydrochloride	I-Chemical
plus	O
1:100,000	O
epinephrine	B-Chemical
)	O
were	O
injected	O
into	O
the	O
retrobulbar	O
area	O
of	O
rat	O
eyes	O
.	O

Controls	O
were	O
injected	O
with	O
physiological	O
saline	O
.	O

All	O
three	O
anesthetics	B-Drug
produced	O
massive	O
degeneration	I-Disease
of	O
the	O
extraocular	O
muscles	O
.	O

Muscle	B-Disease
degeneration	O
is	O
followed	O
by	O
regeneration	O
of	O
the	O
damaged	O
muscle	B-Disease
fibers	O
.	O

In	O
addition	O
to	O
muscle	B-Disease
damage	O
,	O
severe	O
damage	O
was	O
also	O
seen	O
in	O
harderian	O
glands	O
,	O
especially	O
after	O
exposure	O
to	O
mepivacaine	B-Chemical
and	O
lidocaine	B-Chemical
plus	O
epinephrine	B-Chemical
.	O

With	O
these	O
findings	O
in	O
rats	O
,	O
it	O
is	O
hypothesized	O
that	O
the	O
temporary	O
diplopia	B-Disease
sometimes	O
seen	O
in	O
patients	O
after	O
ophthalmic	O
surgery	O
might	O
be	O
due	O
to	O
anesthetic-induced	O
damage	O
to	O
the	O
extraocular	O
muscles	O
.	O

Reversal	O
of	O
neuroleptic-induced	O
catalepsy	B-Disease
by	O
novel	O
aryl-piperazine	B-Chemical
anxiolytic	O
drugs	B-Drug
.	O

The	O
novel	O
anxiolytic	O
drug	B-Drug
,	O
buspirone	B-Chemical
,	O
reverses	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
.	O

A	O
series	O
of	O
aryl-piperazine	B-Chemical
analogues	O
of	O
buspirone	B-Chemical
and	O
other	O
5-hydroxytryptaminergic	B-Chemical
agonists	I-Chemical
were	O
tested	O
for	O
their	O
ability	O
to	O
reverse	O
haloperidol	B-Chemical
induced	O
catalepsy	B-Disease
.	O

Those	O
drugs	B-Drug
with	O
strong	O
affinity	O
for	O
5-hydroxytryptamine1a	B-Chemical
receptors	O
were	O
able	O
to	O
reverse	O
catalepsy	B-Disease
.	O

Drugs	B-Drug
with	O
affinity	O
for	O
other	O
5-HT	B-Chemical
receptors	O
or	O
weak	O
affinity	O
were	O
ineffective	O
.	O

However	O
,	O
inhibition	O
of	O
postsynaptic	O
5-HT	B-Chemical
receptors	O
neither	O
inhibited	O
nor	O
potentiated	O
reversal	O
of	O
catalepsy	B-Disease
and	O
leaves	O
open	O
the	O
question	O
as	O
to	O
the	O
site	O
or	O
mechanism	O
for	O
this	O
effect	O
.	O

Diazepam	B-Chemical
facilitates	O
reflex	O
bradycardia	B-Disease
in	O
conscious	O
rats	O
.	O

The	O
effects	O
of	O
diazepam	B-Chemical
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
conscious	O
rats	O
.	O

Intravenous	O
administration	O
of	O
diazepam	B-Chemical
(	O
1-30	O
mg	O
kg-1	O
)	O
produced	O
a	O
dose-dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate	O
.	O

Also	O
,	O
reflex	O
bradycardia	B-Disease
was	O
produced	O
in	O
rats	O
by	O
intravenous	O
infusion	O
of	O
adrenaline	B-Chemical
(	O
1.25-2.5	O
micrograms	O
kg-1	O
)	O
.	O

Intravenous	O
pretreatment	O
of	O
the	O
rats	O
with	O
diazepam	B-Chemical
,	O
although	O
causing	O
no	O
change	O
in	O
the	O
adrenaline-induced	B-Chemical
pressor	O
effect	O
,	O
did	O
enhance	O
the	O
adrenaline-induced	B-Chemical
reflex	O
bradycardia	B-Disease
.	O

However	O
,	O
the	O
diazepam	B-Chemical
enhancement	O
of	O
adrenaline-induced	B-Chemical
reflex	O
bradycardia	B-Disease
was	O
antagonized	O
by	O
pretreatment	O
of	O
rats	O
with	O
an	O
intravenous	O
dose	O
of	O
picrotoxin	B-Chemical
(	O
an	O
agent	O
blocks	O
chloride	B-Chemical
channels	O
by	O
binding	O
to	O
sites	O
associated	O
with	O
the	O
benzodiazepine-GABA-chloride	B-Chemical
channel	O
macromolecular	O
complex	O
)	O
.	O

The	O
data	O
indicate	O
that	O
diazepam	B-Drug
acts	O
through	O
the	O
benzodiazepine-GABA-chloride	B-Chemical
channel	O
macromolecular	O
complex	O
within	O
the	O
central	O
nervous	O
system	O
to	O
facilitate	O
reflex	O
bradycardia	O
mediated	O
through	O
baroreceptor	O
reflexes	O
in	O
response	O
to	O
an	O
acute	O
increase	O
in	O
arterial	O
pressure	O
.	O

Chronic	O
carbamazepine	B-Chemical
inhibits	O
the	O
development	O
of	O
local	O
anesthetic	B-Drug
seizures	B-Disease
kindled	O
by	O
cocaine	B-Chemical
and	O
lidocaine	B-Chemical
.	O

The	O
effects	O
of	O
carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
treatment	O
on	O
local	O
anesthetic-kindled	O
seizures	B-Disease
and	O
lethality	O
were	O
evaluated	O
in	O
different	O
stages	O
of	O
the	O
kindling	O
process	O
and	O
under	O
different	O
methods	O
of	O
CBZ	B-Chemical
administration	O
.	O

Chronic	O
oral	O
CBZ	B-Chemical
inhibited	O
the	O
development	O
of	O
both	O
lidocaine-	B-Chemical
and	O
cocaine-induced	B-Chemical
seizures	B-Disease
,	O
but	O
had	O
little	O
effect	O
on	O
the	O
fully	O
developed	O
local	O
anesthetic	B-Drug
seizures	B-Disease
.	O

Chronic	O
CBZ	B-Chemical
also	O
decreased	O
the	O
incidence	O
of	O
seizure-related	B-Disease
mortality	O
in	O
the	O
cocaine-injected	B-Chemical
rats	O
.	O

Acute	O
CBZ	B-Chemical
over	O
a	O
range	O
of	O
doses	O
(	O
15-50	O
mg/kg	O
)	O
had	O
no	O
effect	O
on	O
completed	O
lidocaine-kindled	B-Chemical
or	O
acute	O
cocaine-induced	B-Chemical
seizures	B-Disease
.	O

Repeated	O
i.p	O
.	O

injection	O
of	O
CBZ	B-Chemical
(	O
15	O
mg/kg	O
)	O
also	O
was	O
without	O
effect	O
on	O
the	O
development	O
of	O
lidocaine-	B-Chemical
or	O
cocaine-kindled	B-Chemical
seizures	B-Disease
.	O

The	O
differential	O
effects	O
of	O
CBZ	B-Chemical
depending	O
upon	O
stage	O
of	O
seizure	B-Disease
development	O
suggest	O
that	O
distinct	O
mechanisms	O
underlie	O
the	O
development	O
versus	O
maintenance	O
of	O
local	O
anesthetic-kindled	O
seizures	B-Disease
.	O

The	O
effectiveness	O
of	O
chronic	O
but	O
not	O
repeated	O
,	O
intermittent	O
injections	O
of	O
CBZ	B-Chemical
suggests	O
that	O
different	O
biochemical	O
consequences	O
result	O
from	O
the	O
different	O
treatment	O
regimens	O
.	O

The	O
possible	O
utility	O
of	O
chronic	O
CBZ	B-Chemical
in	O
preventing	O
the	O
development	O
of	O
toxic	O
side	O
effects	O
in	O
human	O
cocaine	B-Chemical
users	O
is	O
suggested	O
by	O
these	O
data	O
,	O
but	O
remains	O
to	O
be	O
directly	O
evaluated	O
.	O

D-penicillamine	B-Chemical
in	O
the	O
treatment	O
of	O
localized	B-Disease
scleroderma	I-Disease
.	O

Localized	B-Disease
scleroderma	I-Disease
has	O
no	O
recognized	O
internal	O
organ	O
involvement	O
but	O
may	O
be	O
disfiguring	O
and	O
disabling	O
when	O
the	O
cutaneous	O
lesions	O
are	O
extensive	O
or	O
affect	O
children	O
.	O

There	O
is	O
no	O
accepted	O
or	O
proven	O
treatment	O
for	O
localized	B-Disease
scleroderma	I-Disease
.	O

Case	O
reports	O
of	O
11	O
patients	O
with	O
severe	O
,	O
extensive	O
localized	B-Disease
scleroderma	I-Disease
who	O
were	O
treated	O
with	O
D-penicillamine	B-Chemical
are	O
summarized	O
in	O
this	O
article	O
.	O

This	O
drug	B-Drug
was	O
judged	O
to	O
have	O
a	O
favorable	O
effect	O
on	O
the	O
disease	O
course	O
in	O
7	O
(	O
64	O
%	O
)	O
of	O
11	O
patients	O
.	O

Improvement	O
began	O
within	O
3	O
to	O
6	O
months	O
and	O
consisted	O
of	O
cessation	O
of	O
active	O
cutaneous	O
lesions	O
in	O
all	O
7	O
patients	O
,	O
skin	O
softening	O
in	O
5	O
,	O
and	O
more	O
normal	O
growth	O
of	O
the	O
affected	O
limb	O
in	O
2	O
of	O
3	O
children	O
.	O

Joint	O
stiffness	O
and	O
contractures	B-Disease
also	O
improved	O
.	O

The	O
dose	O
of	O
D-penicillamine	B-Chemical
associated	O
with	O
a	O
favorable	O
response	O
was	O
as	O
low	O
as	O
2	O
to	O
5	O
mg/kg	O
per	O
day	O
given	O
over	O
a	O
period	O
ranging	O
from	O
15	O
to	O
53	O
months	O
.	O

D-Penicillamine	B-Chemical
caused	O
nephrotic	B-Disease
syndrome	I-Disease
in	O
1	O
patient	O
and	O
milder	O
reversible	O
proteinuria	B-Disease
in	O
3	O
other	O
patients	O
;	O
none	O
developed	O
renal	B-Disease
insufficiency	I-Disease
.	O

These	O
data	O
suggest	O
that	O
D-penicillamine	B-Chemical
may	O
be	O
effective	O
in	O
severe	O
cases	O
of	O
localized	B-Disease
scleroderma	I-Disease
.	O

Preservation	O
of	O
renal	O
blood	O
flow	O
during	O
hypotension	B-Disease
induced	O
with	O
fenoldopam	B-Chemical
in	O
dogs	O
.	O

The	O
introduction	O
of	O
drugs	B-Drug
that	O
could	O
induce	O
hypotension	B-Disease
with	O
different	O
pharmacological	O
actions	O
would	O
be	O
advantageous	O
because	O
side	O
effects	O
unique	O
to	O
a	O
specific	O
drug	B-Drug
could	O
be	O
minimized	O
by	O
selecting	O
appropriate	O
therapy	O
.	O

Specific	O
dopamine-1	B-Chemical
,	O
(	O
DA1	B-Chemical
)	O
and	O
dopamine-2	B-Chemical
(	O
DA2	B-Chemical
)	O
receptor	O
agonists	O
are	O
now	O
under	O
clinical	O
investigation	O
.	O

Fenoldopam	B-Chemical
mesylate	I-Chemical
is	O
a	O
specific	O
DA1	O
receptor	O
agonist	O
that	O
lowers	O
blood	O
pressure	O
by	O
vasodilatation	O
.	O

The	O
hypothesis	O
that	O
fenoldopam	B-Chemical
could	O
be	O
used	O
to	O
induce	O
hypotension	B-Disease
and	O
preserve	O
blood	O
flow	O
to	O
the	O
kidney	O
was	O
tested	O
.	O

Systemic	O
aortic	O
blood	O
pressure	O
and	O
renal	O
blood	O
flow	O
were	O
measured	O
continuously	O
with	O
a	O
carotid	O
arterial	O
catheter	O
and	O
an	O
electromagnetic	O
flow	O
probe	O
respectively	O
,	O
in	O
order	O
to	O
compare	O
the	O
cardiovascular	O
and	O
renal	O
vascular	O
effects	O
of	O
fenoldopam	B-Chemical
and	O
sodium	B-Chemical
nitroprusside	B-Chemical
in	O
ten	O
dogs	O
under	O
halothane	B-Chemical
general	O
anaesthesia	O
.	O

Mean	O
arterial	O
pressure	O
was	O
decreased	O
30	O
+/-	O
8	O
per	O
cent	O
from	O
control	O
with	O
infusion	O
of	O
fenoldopam	B-Chemical
(	O
3.4	O
+/-	O
2.0	O
micrograms.kg-1.min-1	O
)	O
and	O
34	O
+/-	O
4	O
per	O
cent	O
with	O
infusion	O
of	O
sodium	B-Chemical
nitroprusside	B-Chemical
(	O
5.9	O
micrograms.kg-1.min-1	O
)	O
(	O
NS	O
)	O
.	O

Renal	O
blood	O
flow	O
(	O
RBF	O
)	O
increased	O
during	O
fenoldopam-induced	B-Chemical
hypotension	B-Disease
11	O
+/-	O
7	O
per	O
cent	O
and	O
decreased	O
21	O
+/-	O
8	O
per	O
cent	O
during	O
sodium	B-Chemical
nitroprusside-induced	B-Chemical
hypotension	B-Disease
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Sodium	O
nitroprusside	B-Chemical
is	O
a	O
non-selective	O
arteriolar	O
and	O
venous	O
vasodilator	O
that	O
can	O
produce	O
redistribution	O
of	O
blood	O
flow	O
away	O
from	O
the	O
kidney	O
during	O
induced	O
hypotension	B-Disease
.	O

Fenoldopam	B-Drug
is	O
a	O
selective	O
dopamine-1	B-Chemical
(	O
DA1	O
)	O
receptor	O
agonist	O
that	O
causes	O
vasodilatation	O
to	O
the	O
kidney	O
and	O
other	O
organs	O
with	O
DA1	O
receptors	O
and	O
preserves	O
blood	O
flow	O
to	O
the	O
kidney	O
during	O
induced	O
hypotension	B-Disease
.	O

Antiarrhythmic	B-Drug
effects	O
of	O
optical	O
isomers	O
of	O
cibenzoline	B-Chemical
on	O
canine	O
ventricular	B-Disease
arrhythmias	I-Disease
.	O

Antiarrhythmic	B-Drug
effects	O
of	O
(	O
+	O
)	O
-cibenzoline	B-Chemical
and	O
(	O
-	O
)	O
-cibenzoline	B-Chemical
were	O
examined	O
using	O
two	O
canine	O
ventricular	B-Disease
arrhythmia	I-Disease
models	O
.	O

Digitalis	B-Chemical
arrhythmia	B-Disease
,	O
which	O
is	O
suppressed	O
by	O
Na	B-Chemical
channel	O
blockers	O
,	O
was	O
induced	O
by	O
intermittent	O
intravenous	O
(	O
i.v	O
.	O

)	O
injection	O
of	O
ouabain	B-Chemical
in	O
pentobarbital-anesthetized	B-Chemical
dogs	O
.	O

Adrenaline	B-Disease
arrhythmia	I-Disease
,	O
which	O
is	O
suppressed	O
by	O
Ca	B-Chemical
channel	O
blockers	O
,	O
was	O
induced	O
by	O
adrenaline	B-Chemical
infusion	O
in	O
halothane-anesthetized	B-Chemical
dogs	O
.	O

Ten	O
and	O
5	O
mg/kg	O
i.v	O
.	O

(	O
+	O
)	O
-cibenzoline	B-Chemical
suppressed	O
digitalis-	B-Chemical
and	O
adrenaline-induced	B-Chemical
arrhythmias	B-Disease
,	O
respectively	O
.	O

The	O
minimum	O
effective	O
plasma	O
concentrations	O
of	O
(	O
+	O
)	O
-cibenzoline	B-Chemical
for	O
digitalis-	B-Chemical
and	O
adrenaline-induced	B-Chemical
arrhythmias	B-Disease
were	O
1.4	O
+/-	O
0.4	O
and	O
2.0	O
+/-	O
0.6	O
micrograms/ml	O
,	O
respectively	O
(	O
mean	O
+/-	O
SD	O
,	O
n	O
=	O
6	O
)	O
.	O

A	O
lower	O
dose	O
of	O
1	O
mg/kg	O
i.v	O
.	O

of	O
(	O
-	O
)	O
-cibenzoline	B-Chemical
suppressed	O
the	O
digitalis-induced	B-Chemical
arrhythmia	B-Disease
,	O
whereas	O
5	O
mg/kg	O
i.v	O
.	O

was	O
needed	O
to	O
suppress	O
adrenaline-induced	B-Chemical
arrhythmias	B-Disease
.	O

The	O
minimum	O
effective	O
plasma	O
concentrations	O
of	O
(	O
-	O
)	O
-cibenzoline	B-Chemical
for	O
digitalis-	B-Chemical
and	O
adrenaline-induced	B-Chemical
arrhythmia	B-Disease
were	O
0.06	O
+/-	O
0.04	O
and	O
0.7	O
+/-	O
0.1	O
micrograms/ml	O
,	O
respectively	O
(	O
mean	O
+/-	O
SD	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
stronger	O
antiarrhythmic	B-Drug
effect	O
of	O
(	O
-	O
)	O
-cibenzoline	B-Chemical
indicates	O
that	O
(	O
-	O
)	O
-isomer	O
may	O
have	O
an	O
effect	O
nearly	O
5-20	O
times	O
stronger	O
in	O
suppressing	O
Na	B-Chemical
channels	O
,	O
but	O
effects	O
of	O
both	O
drugs	B-Drug
on	O
Ca	B-Chemical
channels	O
may	O
be	O
almost	O
equipotent	O
.	O

Effect	O
of	O
Hibiscus	B-Chemical
rosa	I-Chemical
sinensis	I-Chemical
on	O
reserpine-induced	B-Chemical
neurobehavioral	O
and	O
biochemical	O
alterations	O
in	O
rats	O
.	O

Effect	O
of	O
methanolic	O
extract	O
of	O
Hibiscus	B-Chemical
rosa	I-Chemical
sinensis	I-Chemical
(	O
100-300	O
mg/kg	O
)	O
was	O
studied	O
on	O
reserpine-induced	B-Chemical
orofacial	O
dyskinesia	B-Disease
and	O
neurochemical	O
alterations	O
.	O

The	O
rats	O
were	O
treated	O
with	O
intraperitoneal	O
reserpine	B-Chemical
(	O
1	O
mg/kg	O
,	O
ip	O
)	O
for	O
3	O
days	O
every	O
other	O
day	O
.	O

On	O
day	O
5	O
,	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusions	O
were	O
counted	O
for	O
5	O
min	O
.	O

Reserpine	B-Chemical
treated	O
rats	O
significantly	O
developed	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusions	O
however	O
,	O
coadministration	O
of	O
Hibiscus	B-Chemical
rosa	I-Chemical
sinensis	I-Chemical
roots	O
extract	O
(	O
100	O
,	O
200	O
and	O
300	O
mg/kg	O
,	O
per	O
orally	O
)	O
attenuated	O
the	O
effects	O
.	O

Biochemical	O
analysis	O
of	O
brain	O
revealed	O
that	O
the	O
reserpine	B-Chemical
treatment	O
significantly	O
increased	O
lipid	O
peroxidation	O
and	O
decreased	O
levels	O
of	O
superoxide	B-Chemical
dismutase	O
(	O
SOD	O
)	O
,	O
catalase	O
(	O
CAT	O
)	O
and	O
glutathione	B-Chemical
reductase	O
(	O
GSH	O
)	O
,	O
an	O
index	O
of	O
oxidative	O
stress	O
process	O
.	O

Coadministration	O
of	O
extract	O
significantly	O
reduced	O
the	O
lipid	O
peroxidation	O
and	O
reversed	O
the	O
decrease	O
in	O
brain	O
SOD	O
,	O
CAT	O
and	O
GSH	O
levels	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
Hibiscus	B-Chemical
rosa	I-Chemical
sinensis	I-Chemical
had	O
a	O
protective	O
role	O
against	O
reserpine-induced	B-Chemical
orofacial	O
dyskinesia	B-Disease
and	O
oxidative	O
stress	O
.	O

Comparison	O
of	O
aqueous	O
and	O
gellan	O
ophthalmic	O
timolol	B-Chemical
with	O
placebo	O
on	O
the	O
24-hour	O
heart	O
rate	O
response	O
in	O
patients	O
on	O
treatment	O
for	O
glaucoma	B-Disease
.	O

PURPOSE	O
:	O
Topical	O
beta-blocker	O
treatment	O
is	O
routine	O
therapy	O
in	O
the	O
management	O
of	O
patients	O
with	O
glaucoma	B-Disease
.	O

Therapy	O
results	O
in	O
systemic	O
absorption	O
,	O
however	O
,	O
the	O
degree	O
of	O
reduction	O
of	O
resting	O
and	O
peak	O
heart	O
rate	O
has	O
not	O
been	O
quantified	O
.	O

DESIGN	O
:	O
This	O
trial	O
evaluated	O
the	O
effect	O
of	O
placebo	O
,	O
0.5	O
%	O
aqueous	O
timolol	B-Chemical
(	O
timolol	B-Chemical
solution	O
)	O
and	O
a	O
0.5	O
%	O
timolol	B-Chemical
suspension	O
that	O
forms	O
a	O
gel	O
on	O
application	O
to	O
the	O
conjunctiva	O
(	O
timolol	B-Chemical
gellan	O
)	O
on	O
the	O
24-hour	O
heart	O
rate	O
in	O
patients	O
currently	O
being	O
treated	O
for	O
glaucoma	B-Disease
to	O
quantify	O
the	O
reduction	O
in	O
mean	O
heart	O
rate	O
.	O

METHODS	O
:	O
Forty-three	O
Caucasian	O
patients	O
with	O
primary	O
open-angle	B-Disease
glaucoma	I-Disease
or	O
ocular	B-Disease
hypertension	I-Disease
with	O
a	O
mean	O
(	O
+/-SD	O
)	O
age	O
of	O
63	O
(	O
+/-8	O
)	O
years	O
were	O
randomized	O
and	O
crossed	O
over	O
in	O
a	O
double-masked	O
manner	O
to	O
14	O
days	O
of	O
treatment	O
with	O
placebo	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
timolol	B-Chemical
solution	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
or	O
timolol	B-Chemical
gellan	O
(	O
morning	O
in	O
both	O
eyes	O
with	O
placebo	O
in	O
the	O
evening	O
)	O
.	O

On	O
the	O
13th	O
day	O
of	O
each	O
period	O
,	O
heart	O
rate	O
was	O
recorded	O
continuously	O
during	O
a	O
typical	O
,	O
ambulant	O
24-hour	O
period	O
.	O

RESULTS	O
:	O
Both	O
timolol	B-Chemical
solution	O
and	O
timolol	B-Chemical
gellan	O
reduced	O
the	O
mean	O
24-hour	O
heart	O
rate	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
or	O
=	O
.001	O
)	O
,	O
and	O
this	O
reduction	O
was	O
most	O
pronounced	O
during	O
the	O
daytime	O
(	O
-7.5	O
%	O
change	O
in	O
mean	O
heart	O
rate	O
,	O
-5.7	O
beats/min	O
)	O
.	O

Timolol	B-Chemical
gellan	O
showed	O
a	O
numerically	O
but	O
not	O
significantly	O
smaller	O
reduction	O
in	O
24-hour	O
heart	O
rate	O
,	O
compared	O
with	O
timolol	B-Chemical
solution	O
.	O

During	O
the	O
night	O
,	O
the	O
mean	O
12-hour	O
heart	O
rate	O
on	O
placebo	O
and	O
timolol	B-Chemical
gellan	O
were	O
both	O
significantly	O
less	O
than	O
on	O
timolol	B-Chemical
solution	O
;	O
the	O
difference	O
between	O
solution	O
and	O
gellan	O
treatments	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
.01	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
timolol	B-Chemical
solution	O
and	O
timolol	B-Chemical
gellan	O
decrease	O
the	O
mean	O
24-hour	O
heart	O
rate	O
compared	O
with	O
placebo	O
.	O

This	O
response	O
was	O
most	O
pronounced	O
during	O
the	O
active	O
daytime	O
period	O
.	O

These	O
data	O
quantify	O
the	O
modest	O
bradycardia	B-Disease
associated	O
with	O
ophthalmic	O
beta-blocker	O
therapy	O
in	O
a	O
typical	O
patient	O
population	O
on	O
therapy	O
for	O
glaucoma	B-Disease
.	O

Although	O
exercise	O
performance	O
was	O
not	O
assessed	O
in	O
this	O
trial	O
,	O
reductions	O
of	O
this	O
magnitude	O
should	O
not	O
have	O
substantial	O
clinical	O
consequences	O
.	O

5	B-Chemical
flourouracil-induced	O
apical	O
ballooning	O
syndrome	O
:	O
a	O
case	O
report	O
.	O

The	O
apical	B-Disease
ballooning	I-Disease
syndrome	I-Disease
(	O
ABS	B-Disease
)	O
is	O
a	O
recently	O
described	O
stress-mediated	O
acute	B-Disease
cardiac	I-Disease
syndrome	I-Disease
characterized	O
by	O
transient	O
wall-motion	O
abnormalities	O
involving	O
the	O
apex	O
and	O
midventricle	O
with	O
hyperkinesis	B-Disease
of	O
the	O
basal	O
left	O
ventricular	O
(	O
LV	O
)	O
segments	O
without	O
obstructive	O
epicardial	B-Disease
coronary	I-Disease
disease	I-Disease
.	O

Cardiotoxicity	B-Disease
is	O
not	O
an	O
uncommon	O
adverse	O
effect	O
of	O
chemotherapeutic	O
agents	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
of	O
ABS	B-Disease
secondary	O
to	O
chemotherapeutic	O
agents	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
woman	O
who	O
developed	O
the	O
syndrome	O
after	O
chemotherapy	O
for	O
metastatic	O
cancer	B-Disease
.	O

A	O
79-year-old	O
woman	O
presented	O
with	O
typical	O
ischemic	B-Disease
chest	B-Disease
pain	I-Disease
,	O
elevated	O
cardiac	O
enzymes	O
with	O
significant	O
ST-segment	O
abnormalities	O
on	O
her	O
electrocardiogram	O
.	O

She	O
underwent	O
recent	O
chemotherapy	O
with	O
fluorouracil	B-Chemical
for	O
metastatic	O
colorectal	B-Disease
cancer	I-Disease
.	O

Echocardiography	O
revealed	O
a	O
wall-motion	O
abnormality	O
involving	O
the	O
apical	O
and	O
periapical	O
segments	O
which	O
appeared	O
akinetic	B-Disease
.	O

Coronary	O
angiography	O
revealed	O
no	O
obstructive	O
coronary	O
lesions	O
.	O

The	O
patient	O
was	O
stabilized	O
with	O
medical	O
therapy	O
.	O

Four	O
weeks	O
later	O
she	O
remained	O
completely	O
asymptomatic	O
.	O

Echocardiogram	O
revealed	O
a	O
normal	O
ejection	O
fraction	O
and	O
a	O
resolution	O
of	O
the	O
apical	O
akinesis	B-Disease
.	O

Pathogenetic	O
mechanisms	O
of	O
cardiac	B-Disease
complications	I-Disease
in	O
cancer	B-Disease
patients	O
undergoing	O
chemotherapy	O
include	O
coronary	B-Disease
vasospasm	I-Disease
,	O
endothelial	O
damage	O
and	O
consequent	O
thrombus	B-Disease
formation	O
.	O

In	O
our	O
patient	O
,	O
both	O
supraphysiologic	O
levels	O
of	O
plasma	O
catecholamines	B-Chemical
and	O
stress	O
related	O
neuropeptides	O
caused	O
by	O
cancer	B-Disease
diagnosis	O
as	O
well	O
as	O
chemotherapy	O
may	O
have	O
contributed	O
the	O
development	O
of	O
ABS	B-Disease
.	O

Reduction	O
of	O
pain	B-Disease
during	O
induction	O
with	O
target-controlled	O
propofol	B-Chemical
and	O
remifentanil	B-Chemical
.	O

BACKGROUND	O
:	O
Pain	B-Disease
on	O
injection	O
of	O
propofol	B-Chemical
is	O
unpleasant	O
.	O

We	O
hypothesized	O
that	O
propofol	B-Chemical
infusion	O
pain	B-Disease
might	O
be	O
prevented	O
by	O
infusing	O
remifentanil	B-Chemical
before	O
starting	O
the	O
propofol	B-Chemical
infusion	O
in	O
a	O
clinical	O
setting	O
where	O
target-controlled	O
infusions	O
(	O
TCI	O
)	O
of	O
both	O
drugs	B-Drug
were	O
used	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
was	O
performed	O
to	O
determine	O
the	O
effect-site	O
concentration	O
(	O
Ce	O
)	O
of	O
remifentanil	B-Chemical
to	O
prevent	O
the	O
pain	B-Disease
without	O
producing	O
complications	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
128	O
patients	O
undergoing	O
general	O
surgery	O
were	O
randomly	O
allocated	O
to	O
receive	O
normal	O
saline	O
(	O
control	O
)	O
or	O
remifentanil	B-Chemical
to	O
a	O
target	O
Ce	O
of	O
2	O
ng	O
ml	O
(	O
-1	O
)	O
(	O
R2	O
)	O
,	O
4	O
ng	O
ml	O
(	O
-1	O
)	O
(	O
R4	O
)	O
,	O
or	O
6	O
ng	O
ml	O
(	O
-1	O
)	O
(	O
R6	O
)	O
administered	O
via	O
TCI	O
.	O

After	O
the	O
target	O
Ce	O
was	O
achieved	O
,	O
the	O
infusion	O
of	O
propofol	B-Chemical
was	O
started	O
.	O

Remifentanil-related	B-Chemical
complications	O
were	O
assessed	O
during	O
the	O
remifentanil	B-Chemical
infusion	O
,	O
and	O
pain	B-Disease
caused	O
by	O
propofol	B-Chemical
was	O
evaluated	O
using	O
a	O
four-point	O
scale	O
during	O
the	O
propofol	B-Chemical
infusion	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
pain	B-Disease
was	O
significantly	O
lower	O
in	O
Groups	O
R4	O
and	O
R6	O
than	O
in	O
the	O
control	O
and	O
R2	O
groups	O
(	O
12/32	O
and	O
6/31	O
vs	O
26/31	O
and	O
25/32	O
,	O
respectively	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Pain	B-Disease
was	O
less	O
severe	O
in	O
Groups	O
R4	O
and	O
R6	O
than	O
in	O
the	O
control	O
and	O
R2	O
groups	O
(	O
P	O
<	O
0.001	O
)	O
.	O

However	O
,	O
both	O
incidence	O
and	O
severity	O
of	O
pain	B-Disease
were	O
not	O
different	O
between	O
Groups	O
R4	O
and	O
R6	O
.	O

No	O
significant	O
complications	O
were	O
observed	O
during	O
the	O
study	O
.	O

CONCLUSIONS	O
:	O
During	O
induction	O
of	O
anaesthesia	O
with	O
TCI	O
of	O
propofol	B-Chemical
and	O
remifentanil	B-Chemical
,	O
a	O
significant	O
reduction	O
in	O
propofol	B-Chemical
infusion	O
pain	B-Disease
was	O
achieved	O
without	O
significant	O
complications	O
by	O
prior	O
administration	O
of	O
remifentanil	B-Chemical
at	O
a	O
target	O
Ce	O
of	O
4	O
ng	O
ml	O
(	O
-1	O
)	O
.	O

Prenatal	O
exposure	O
to	O
fluoxetine	B-Chemical
induces	O
fetal	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
in	O
the	O
rat	O
.	O

RATIONALE	O
:	O
Fluoxetine	B-Chemical
is	O
a	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitor	O
antidepressant	O
widely	O
used	O
by	O
pregnant	O
women	O
.	O

Epidemiological	O
data	O
suggest	O
that	O
fluoxetine	B-Chemical
exposure	O
prenatally	O
increases	O
the	O
prevalence	O
of	O
persistent	O
pulmonary	B-Disease
hypertension	I-Disease
syndrome	I-Disease
of	O
the	O
newborn	O
.	O

The	O
mechanism	O
responsible	O
for	O
this	O
effect	O
is	O
unclear	O
and	O
paradoxical	O
,	O
considering	O
the	O
current	O
evidence	O
of	O
a	O
pulmonary	B-Disease
hypertension	I-Disease
protective	O
fluoxetine	B-Chemical
effect	O
in	O
adult	O
rodents	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
fluoxetine	B-Chemical
effect	O
on	O
fetal	O
rat	O
pulmonary	O
vascular	O
smooth	O
muscle	O
mechanical	O
properties	O
and	O
cell	O
proliferation	O
rate	O
.	O

METHODS	O
:	O
Pregnant	O
rats	O
were	O
treated	O
with	O
fluoxetine	B-Chemical
(	O
10	O
mg/kg	O
)	O
from	O
Day	O
11	O
through	O
Day	O
21	O
of	O
gestation	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Fetuses	O
were	O
delivered	O
by	O
cesarean	O
section	O
.	O

As	O
compared	O
with	O
controls	O
,	O
fluoxetine	B-Chemical
exposure	O
resulted	O
in	O
fetal	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
weight	O
ratio	O
of	O
the	O
right	O
ventricle	O
to	O
the	O
left	O
ventricle	O
plus	O
septum	O
(	O
P	O
=	O
0.02	O
)	O
and	O
by	O
an	O
increase	O
in	O
pulmonary	I-Chemical
arterial	O
medial	O
thickness	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Postnatal	O
mortality	O
was	O
increased	O
among	O
experimental	O
animals	O
,	O
and	O
arterial	O
oxygen	O
saturation	O
was	O
96	O
+/-	O
1	O
%	O
in	O
1-day-old	O
control	O
animals	O
and	O
significantly	O
lower	O
(	O
P	O
<	O
0.01	O
)	O
in	O
fluoxetine-exposed	O
pups	O
(	O
79	O
+/-	O
2	O
%	O
)	O
.	O

In	O
vitro	O
,	O
fluoxetine	B-Drug
induced	O
pulmonary	I-Chemical
arterial	O
muscle	O
contraction	O
in	O
fetal	B-Chemical
,	O
but	O
not	O
adult	O
,	O
animals	O
(	O
P	O
<	O
0.01	O
)	O
and	O
reduced	O
serotonin-induced	O
contraction	O
at	O
both	O
ages	O
(	O
P	O
<	O
0.01	O
)	O
.	O

After	O
in	O
utero	O
exposure	O
to	O
a	O
low	O
fluoxetine	B-Drug
concentration	O
the	O
pulmonary	B-Chemical
arterial	O
smooth	O
muscle	O
cell	O
proliferation	O
rate	O
was	O
significantly	O
increased	O
in	O
fetal	O
,	O
but	O
not	O
adult	O
,	O
cells	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
the	O
adult	O
,	O
fluoxetine	B-Drug
exposure	O
in	O
utero	O
induces	O
pulmonary	B-Chemical
hypertension	O
in	O
the	O
fetal	O
rat	O
as	O
a	O
result	O
of	O
a	O
developmentally	O
regulated	O
increase	O
in	O
pulmonary	O
vascular	O
smooth	O
muscle	O
proliferation	O
.	O

Syncope	B-Disease
and	O
QT	B-Disease
prolongation	I-Disease
among	O
patients	O
treated	O
with	O
methadone	B-Chemical
for	O
heroin	B-Chemical
dependence	O
in	O
the	O
city	O
of	O
Copenhagen	O
.	O

BACKGROUND	O
:	O
Methadone	B-Chemical
is	O
prescribed	O
to	O
heroin	B-Chemical
addicts	O
to	O
decrease	O
illicit	O
opioid	O
use	O
.	O

Prolongation	O
of	O
the	O
QT	O
interval	O
in	O
the	O
ECG	O
of	O
patients	O
with	O
torsade	B-Disease
de	B-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
has	O
been	O
reported	O
in	O
methadone	B-Chemical
users	O
.	O

As	O
heroin	B-Chemical
addicts	O
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	B-Drug
,	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	O
of	O
syncope	B-Disease
to	O
illicit	O
drug	B-Drug
use	O
and	O
thereby	O
underestimate	O
the	O
incidence	O
of	O
TdP	B-Disease
in	O
this	O
special	O
population	O
,	O
and	O
the	O
high	O
mortality	O
in	O
this	O
population	O
may	O
,	O
in	O
part	O
,	O
be	O
caused	O
by	O
the	O
proarrhythmic	O
effect	O
of	O
methadone	B-Chemical
.	O

METHODS	O
:	O
In	O
this	O
cross-sectional	O
study	O
interview	O
,	O
ECGs	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
a	O
population	O
of	O
adult	O
heroin	B-Chemical
addicts	O
treated	O
with	O
methadone	B-Chemical
or	O
buprenorphine	B-Chemical
on	O
a	O
daily	O
basis	O
.	O

Of	O
the	O
patients	O
at	O
the	O
Drug	B-Drug
Addiction	O
Service	O
in	O
the	O
municipal	O
of	O
Copenhagen	O
,	O
450	O
(	O
approximately	O
52	O
%	O
)	O
were	O
included	O
.	O

The	O
QT	O
interval	O
was	O
estimated	O
from	O
12	O
lead	B-Drug
ECGs	O
.	O

All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	O
of	O
syncope	B-Disease
.	O

The	O
association	O
between	O
opioid	O
dose	O
and	O
QT	O
,	O
and	O
methadone	B-Chemical
dose	O
and	O
reporting	O
of	O
syncope	B-Disease
was	O
assessed	O
using	O
multivariate	O
linear	O
regression	O
and	O
logistic	O
regression	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Methadone	B-Chemical
dose	O
was	O
associated	O
with	O
longer	O
QT	O
interval	O
of	O
0.140	O
ms/mg	O
(	O
p	O
=	O
0.002	O
)	O
.	O

No	O
association	O
between	O
buprenorphine	B-Chemical
and	O
QTc	O
was	O
found	O
.	O

Among	O
the	O
subjects	O
treated	O
with	O
methadone	B-Chemical
,	O
28	O
%	O
men	O
and	O
32	O
%	O
women	O
had	O
prolonged	B-Disease
QTc	I-Disease
interval	I-Disease
.	O

None	O
of	O
the	O
subjects	O
treated	O
with	O
buprenorphine	B-Chemical
had	O
QTc	O
interval	O
>	O
0.440	O
s	O
(	O
(	O
1/2	O
)	O
)	O
.	O

A	O
50	O
mg	O
higher	O
methadone	B-Chemical
dose	O
was	O
associated	O
with	O
a	O
1.2	O
(	O
95	O
%	O
CI	O
1.1	O
to	O
1.4	O
)	O
times	O
higher	O
odds	O
for	O
syncope	B-Disease
.	O

CONCLUSIONS	O
:	O
Methadone	B-Chemical
is	O
associated	O
with	O
QT	B-Disease
prolongation	I-Disease
and	O
higher	O
reporting	O
of	O
syncope	B-Disease
in	O
a	O
population	O
of	O
heroin	B-Chemical
addicts	O
.	O

Peripheral	B-Disease
neuropathy	I-Disease
caused	O
by	O
high-dose	O
cytosine	B-Chemical
arabinoside	I-Chemical
treatment	O
in	O
a	O
patient	O
with	O
acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
.	O

The	O
central	O
nervous	O
system	O
toxicity	B-Disease
of	O
high-dose	O
cytosine	B-Chemical
arabinoside	I-Chemical
is	O
well	O
recognized	O
,	O
but	O
the	O
toxicity	B-Disease
of	O
cytosine	B-Chemical
arabinoside	I-Chemical
in	O
the	O
peripheral	O
nervous	O
system	O
has	O
been	O
infrequently	O
reported	O
.	O

A	O
49-year-old	O
Japanese	O
man	O
was	O
diagnosed	O
with	O
acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
.	O

After	O
he	O
achieved	O
complete	O
remission	O
,	O
he	O
received	O
high-dose	O
cytosine	B-Chemical
arabinoside	I-Chemical
treatment	O
(	O
2	O
g/m2	O
twice	O
a	O
day	O
for	O
5	O
days	O
;	O
total	O
,	O
20	O
g/m2	O
)	O
as	O
consolidation	O
therapy	O
.	O

The	O
first	O
course	O
of	O
high-dose	O
cytosine	B-Chemical
arabinoside	I-Chemical
resulted	O
in	O
no	O
unusual	O
symptoms	O
,	O
but	O
on	O
day	O
21	O
of	O
the	O
second	O
course	O
of	O
treatment	O
,	O
the	O
patient	O
complained	O
of	O
numbness	B-Disease
in	O
his	O
right	O
foot	O
.	O

Electromyogram	O
and	O
nerve-conduction	O
studies	O
showed	O
peripheral	B-Disease
neuropathy	I-Disease
in	O
both	O
peroneal	O
nerves	O
.	O

This	O
neuropathy	B-Disease
was	O
gradually	O
resolving	O
;	O
however	O
,	O
after	O
the	O
patient	O
received	O
allogeneic	O
bone	O
marrow	O
transplantation	O
,	O
the	O
symptoms	O
worsened	O
,	O
with	O
the	O
development	O
of	O
graft-versus-host	B-Disease
disease	I-Disease
,	O
and	O
the	O
symptoms	O
subsequently	O
responded	O
to	O
methylprednisolone	B-Chemical
.	O

Although	O
the	O
mechanisms	O
of	O
peripheral	B-Disease
neuropathy	I-Disease
are	O
still	O
unclear	O
,	O
high-dose	O
cytosine	B-Chemical
arabinoside	I-Chemical
is	O
a	O
therapy	O
that	O
is	O
potentially	O
toxic	O
to	O
the	O
peripheral	O
nervous	O
system	O
,	O
and	O
auto/alloimmunity	O
may	O
play	O
an	O
important	O
role	O
in	O
these	O
mechanisms	O
.	O

Atorvastatin	B-Chemical
prevented	O
and	O
reversed	O
dexamethasone-induced	B-Chemical
hypertension	B-Disease
in	O
the	O
rat	O
.	O

To	O
assess	O
the	O
antioxidant	O
effects	O
of	O
atorvastatin	B-Chemical
(	O
atorva	B-Chemical
)	O
on	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
-induced	O
hypertension	B-Disease
,	O
60	O
male	O
Sprague-Dawley	O
rats	O
were	O
treated	O
with	O
atorva	B-Chemical
30	O
mg/kg/day	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dex	B-Chemical
increased	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
from	O
109	O
+/-	O
1.8	O
to	O
135	O
+/-	O
0.6	O
mmHg	O
and	O
plasma	O
superoxide	B-Chemical
(	O
5711	O
+/-	O
284.9	O
saline	O
,	O
7931	O
+/-	O
392.8	O
U/ml	O
dex	B-Chemical
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
this	O
prevention	O
study	O
,	O
SBP	O
in	O
the	O
atorva	B-Chemical
+	O
dex	B-Chemical
group	O
was	O
increased	O
from	O
115	O
+/-	O
0.4	O
to	O
124	O
+/-	O
1.5	O
mmHg	O
,	O
but	O
this	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
dex-only	B-Chemical
group	O
(	O
P	O
'	O
<	O
0.05	O
)	O
.	O

Atorva	B-Chemical
reversed	O
dex-induced	B-Chemical
hypertension	B-Disease
(	O
129	O
+/-	O
0.6	O
mmHg	O
,	O
vs.	O
135	O
+/-	O
0.6	O
mmHg	O
P	O
'	O
<	O
0.05	O
)	O
and	O
decreased	O
plasma	O
superoxide	B-Chemical
(	O
7931	O
+/-	O
392.8	O
dex	B-Chemical
,	O
1187	O
+/-	O
441.2	O
atorva	B-Chemical
+	O
dex	B-Chemical
,	O
P	O
<	O
0.0001	O
)	O
.	O

Plasma	O
nitrate/nitrite	B-Chemical
(	O
NOx	O
)	O
was	O
decreased	O
in	O
dex-treated	O
rats	O
compared	O
to	O
saline-treated	O
rats	O
(	O
11.2	O
+/-	O
1.08	O
microm	O
,	O
15.3	O
+/-	O
1.17	O
microm	O
,	O
respectively	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Atorva	O
affected	O
neither	O
plasma	O
NOx	O
nor	O
thymus	O
weight	O
.	O

Thus	O
,	O
atorvastatin	B-Drug
prevented	O
and	O
reversed	O
dexamethasone-induced	O
hypertension	O
in	O
the	O
rat	O
.	O

Two	O
prodrugs	O
of	O
potent	O
and	O
selective	O
GluR5	O
kainate	B-Chemical
receptor	O
antagonists	O
actives	O
in	O
three	O
animal	O
models	O
of	O
pain	B-Disease
.	O

Amino	O
acids	O
5	O
and	O
7	O
,	O
two	O
potent	O
and	O
selective	O
competitive	O
GluR5	O
KA	B-Chemical
receptor	O
antagonists	O
,	O
exhibited	O
high	O
GluR5	O
receptor	O
affinity	O
over	O
other	O
glutamate	B-Chemical
receptors	O
.	O

Their	O
ester	O
prodrugs	O
6	O
and	O
8	O
were	O
orally	O
active	O
in	O
three	O
models	O
of	O
pain	B-Disease
:	O
reversal	O
of	O
formalin-induced	B-Chemical
paw	O
licking	O
,	O
carrageenan-induced	B-Chemical
thermal	B-Disease
hyperalgesia	I-Disease
,	O
and	O
capsaicin-induced	B-Chemical
mechanical	B-Disease
hyperalgesia	I-Disease
.	O

Sirolimus	B-Chemical
and	O
mycophenolate	B-Chemical
mofetil	I-Chemical
for	O
calcineurin-free	O
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
.	O

Calcineurin	O
inhibitors	O
,	O
such	O
as	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
,	O
have	O
been	O
available	O
for	O
almost	O
20	O
years	O
.	O

Although	O
these	O
drugs	B-Drug
are	O
highly	O
effective	O
and	O
represent	O
the	O
mainstay	O
of	O
transplant	O
immunosuppression	O
,	O
they	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
nephrotoxicity	B-Disease
.	O

Acute	O
nephrotoxicity	B-Disease
,	O
which	O
occurs	O
in	O
the	O
early	O
period	O
after	O
transplantation	O
,	O
leads	O
to	O
a	O
higher	O
rate	O
of	O
dialysis	O
,	O
and	O
chronic	O
nephrotoxicity	B-Disease
may	O
eventually	O
result	O
in	O
graft	O
loss	O
.	O

Acute	O
and	O
chronic	O
nephrotoxicity	B-Disease
is	O
becoming	O
more	O
common	O
as	O
the	O
use	O
of	O
marginal	O
kidneys	O
for	O
transplantation	O
increases	O
.	O

Two	O
recently	O
available	O
immunosuppressive	O
agents	O
,	O
mycophenolate	B-Chemical
mofetil	I-Chemical
and	O
sirolimus	B-Chemical
(	O
rapamycin	B-Chemical
)	O
,	O
have	O
no	O
nephrotoxicity	B-Disease
.	O

The	O
use	O
of	O
these	O
drugs	B-Drug
in	O
combination	O
with	O
other	O
agents	O
has	O
led	O
to	O
the	O
development	O
of	O
new	O
paradigms	O
of	O
immunosuppressive	O
therapy	O
.	O

This	O
paper	O
reviews	O
the	O
results	O
of	O
clinical	O
trials	O
that	O
have	O
investigated	O
these	O
new	O
approaches	O
to	O
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
.	O

Erythropoietin	O
restores	O
the	O
anemia-induced	B-Disease
reduction	O
in	O
cyclophosphamide	B-Chemical
cytotoxicity	B-Disease
in	O
rat	O
tumors	B-Disease
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	O
of	O
anemia	B-Disease
prevention	O
by	O
recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
treatment	O
on	O
the	O
cytotoxicity	B-Disease
of	O
cyclophosphamide	B-Chemical
in	O
solid	O
experimental	O
tumors	B-Disease
.	O

Anemia	B-Disease
was	O
induced	O
using	O
a	O
single	O
dose	O
of	O
carboplatin	B-Chemical
(	O
50	O
mg/kg	O
i.v	O
.	O

)	O
resulting	O
in	O
a	O
long-lasting	O
reduction	O
(	O
30	O
%	O
)	O
of	O
the	O
hemoglobin	O
concentration	O
.	O

In	O
a	O
second	O
group	O
,	O
the	O
development	O
of	O
anemia	B-Disease
was	O
prevented	O
by	O
rHuEPO	O
(	O
1000	O
IU/kg	O
)	O
administered	O
s.c.	O
three	O
times/week	O
starting	O
7	O
days	O
before	O
carboplatin	B-Chemical
application	O
.	O

Four	O
days	O
after	O
carboplatin	B-Chemical
treatment	O
,	O
tumors	B-Disease
(	O
DS-sarcoma	B-Disease
of	O
the	O
rat	O
)	O
were	O
implanted	O
s.c.	O
onto	O
the	O
hind	O
food	O
dorsum	O
.	O

Neither	O
carboplatin	B-Chemical
nor	O
rHuEPO	O
treatment	O
influenced	O
tumor	B-Disease
growth	O
rate	O
per	O
se	O
.	O

When	O
tumors	B-Disease
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
cyclophosphamide	B-Chemical
(	O
60	O
mg/kg	O
i.p	O
.	O

)	O
5	O
days	O
after	O
implantation	O
,	O
a	O
growth	O
delay	O
with	O
a	O
subsequent	O
regrowth	O
of	O
the	O
tumors	B-Disease
was	O
observed	O
.	O

In	O
the	O
anemia	B-Disease
group	O
,	O
the	O
growth	O
delay	O
was	O
significantly	O
shorter	O
compared	O
with	O
nonanemic	O
controls	O
(	O
13.3	O
days	O
versus	O
8.6	O
days	O
)	O
.	O

In	O
the	O
group	O
where	O
anemia	B-Disease
was	O
prevented	O
by	O
rHuEPO	O
treatment	O
,	O
growth	O
delay	O
was	O
comparable	O
with	O
that	O
of	O
nonanemic	O
controls	O
(	O
13.3	O
days	O
)	O
.	O

These	O
results	O
suggest	O
that	O
chemotherapy-induced	O
anemia	B-Disease
reduces	O
cytotoxicity	B-Disease
of	O
cyclophosphamide	B-Chemical
in	O
tumors	B-Disease
,	O
whereas	O
correction	O
of	O
anemia	B-Disease
by	O
rHuEPO	O
treatment	O
(	O
epoetin	O
alpha	O
)	O
increases	O
the	O
sensitivity	O
,	O
probably	O
as	O
a	O
result	O
of	O
an	O
improved	O
oxygen	B-Chemical
supply	O
to	O
tumor	B-Disease
tissue	O
.	O

The	O
role	O
of	O
nitrergic	O
system	O
in	O
lidocaine-induced	B-Chemical
convulsion	B-Disease
in	O
the	O
mouse	O
.	O

The	O
effects	O
of	O
N-nitro-L-arginine-methyl	B-Chemical
ester	I-Chemical
(	O
L-NAME	B-Chemical
)	O
a	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
synthase	O
inhibitor	O
and	O
L-arginine	B-Chemical
,	O
a	O
NO	B-Chemical
precursor	O
,	O
were	O
investigated	O
on	O
lidocaine-induced	B-Chemical
convulsions	B-Disease
.	O

In	O
the	O
first	O
experiment	O
,	O
four	O
groups	O
of	O
mice	O
received	O
physiological	O
saline	O
(	O
0.9	O
%	O
)	O
,	O
L-arginine	B-Chemical
(	O
300	O
mg/kg	O
,	O
i.p	O
.	O

)	O
,	O
L-NAME	B-Chemical
(	O
100	O
mg/kg	O
,	O
i.p	O
.	O

)	O
and	O
diazepam	B-Chemical
(	O
2	O
mg/kg	O
)	O
,	O
respectively	O
.	O

Thirty	O
minutes	O
after	O
these	O
injections	O
,	O
all	O
mice	O
received	O
lidocaine	B-Chemical
(	O
50	O
mg/kg	O
,	O
i.p.	O
)	O
.	O

In	O
the	O
second	O
experiment	O
,	O
four	O
groups	O
of	O
mice	O
received	O
similar	O
treatment	O
in	O
the	O
first	O
experiment	O
,	O
and	O
30	O
min	O
after	O
these	O
injections	O
,	O
all	O
mice	O
received	O
a	O
higher	O
dose	O
of	O
lidocaine	B-Chemical
(	O
80	O
mg/kg	O
)	O
.	O

L-NAME	B-Chemical
(	O
100	O
mg/kg	O
,	O
i.p	O
.	O

)	O
and	O
diazepam	B-Chemical
(	O
2	O
mg/kg	O
)	O
significantly	O
decreased	O
the	O
incidence	O
of	O
lidocaine	B-Chemical
(	O
50	O
mg/kg	O
)	O
-induced	O
convulsions	B-Disease
.	O

In	O
contrast	O
,	O
the	O
L-arginine	B-Chemical
treatment	O
increased	O
the	O
incidence	O
of	O
lidocaine	B-Chemical
(	O
80	O
mg/kg	O
,	O
i.p	O
.	O

)	O
-induced	O
convulsions	B-Disease
significantly	O
.	O

These	O
results	O
may	O
suggest	O
that	O
NO	B-Chemical
is	O
a	O
proconvulsant	O
mediator	O
in	O
lidocaine-induced	B-Chemical
convulsions	B-Disease
.	O

Effect	O
of	O
intravenous	O
metoprolol	B-Chemical
or	O
intravenous	O
metoprolol	B-Chemical
plus	O
glucagon	B-Drug
on	O
dobutamine-induced	B-Chemical
myocardial	B-Disease
ischemia	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
effect	O
of	O
metoprolol	B-Chemical
on	O
dobutamine	B-Chemical
stress	O
testing	O
with	O
technetium-99m	B-Chemical
sestamibi	I-Chemical
single-photon	O
emission	O
computed	O
tomography	O
imaging	O
and	O
ST-segment	O
monitoring	O
,	O
and	O
to	O
assess	O
the	O
impact	O
of	O
intravenous	O
glucagon	B-Drug
on	O
metoprolol	B-Chemical
's	O
effects	O
.	O

DESIGN	O
:	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

SETTING	O
:	O
Community	O
hospital	O
.	O

PATIENTS	O
:	O
Twenty-two	O
patients	O
with	O
known	O
reversible	O
perfusion	O
defects	O
.	O

INTERVENTION	O
:	O
Patients	O
underwent	O
dobutamine	B-Chemical
stress	O
tests	O
per	O
standard	O
protocol	O
.	O

Before	O
dobutamine	B-Chemical
was	O
begun	O
,	O
no	O
therapy	O
was	O
given	O
during	O
the	O
first	O
visit	O
,	O
and	O
patients	O
were	O
randomized	O
on	O
subsequent	O
visits	O
to	O
receive	O
metoprolol	B-Chemical
or	O
metoprolol	B-Chemical
plus	O
glucagon	B-Drug
1	O
mg.	O
Metoprolol	B-Chemical
was	O
dosed	O
to	O
achieve	O
a	O
resting	O
predobutamine	B-Chemical
heart	O
rate	O
below	O
65	O
beats/minute	O
or	O
a	O
total	O
intravenous	O
dose	O
of	O
20	O
mg.	O
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Metoprolol	B-Chemical
reduced	O
maximum	O
heart	O
rate	O
31	O
%	O
,	O
summed	O
stress	O
scores	O
29	O
%	O
,	O
and	O
summed	O
difference	O
scores	O
43	O
%	O
versus	O
control	O
.	O

Metoprolol	B-Chemical
plus	O
glucagon	B-Drug
also	O
reduced	O
the	O
maximum	O
heart	O
rate	O
29	O
%	O
versus	O
control	O
.	O

Summed	O
stress	O
and	O
summed	O
difference	O
scores	O
were	O
not	O
significantly	O
reduced	O
,	O
although	O
they	O
were	O
18	O
%	O
and	O
30	O
%	O
lower	O
,	O
respectively	O
,	O
than	O
control	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
any	O
parameter	O
between	O
metoprolol	B-Chemical
and	O
metoprolol-glucagon	B-Chemical
.	O

CONCLUSION	O
:	O
During	O
dobutamine	B-Chemical
stress	O
testing	O
,	O
metoprolol	B-Chemical
attenuates	O
or	O
eliminates	O
evidence	O
of	O
myocardial	B-Disease
ischemia	I-Disease
.	O

Glucagon	B-Drug
1	O
mg	O
,	O
although	O
somewhat	O
effective	O
,	O
does	O
not	O
correct	O
this	O
effect	O
to	O
the	O
extent	O
that	O
it	O
can	O
be	O
administered	O
clinically	O
.	O

Prednisolone-induced	B-Chemical
muscle	B-Disease
dysfunction	I-Disease
is	O
caused	O
more	O
by	O
atrophy	B-Disease
than	O
by	O
altered	O
acetylcholine	B-Chemical
receptor	O
expression	O
.	O

Large	O
doses	O
of	O
glucocorticoids	O
can	O
alter	O
muscle	O
physiology	O
and	O
susceptibility	O
to	O
neuromuscular	O
blocking	O
drugs	B-Drug
by	O
mechanisms	O
not	O
clearly	O
understood	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
moderate	O
and	O
large	O
doses	O
of	O
prednisolone	B-Chemical
on	O
muscle	O
function	O
and	O
pharmacology	O
,	O
and	O
their	O
relationship	O
to	O
changes	O
in	O
muscle	O
size	O
and	O
acetylcholine	B-Chemical
receptor	O
(	O
AChR	O
)	O
expression	O
.	O

With	O
institutional	O
approval	O
,	O
35	O
Sprague-Dawley	O
rats	O
were	O
randomly	O
allocated	O
to	O
receive	O
daily	O
subcutaneous	O
doses	O
of	O
10	O
mg/kg	O
prednisolone	B-Chemical
(	O
P10	O
group	O
)	O
,	O
100	O
mg/kg	O
prednisolone	B-Chemical
(	O
P100	O
group	O
)	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
(	O
S	O
group	O
)	O
for	O
7	O
days	O
.	O

A	O
fourth	O
group	O
of	O
rats	O
was	O
pair	O
fed	O
(	O
food	O
restricted	O
)	O
with	O
the	O
P100	O
rats	O
for	O
7	O
days	O
(	O
FR	O
group	O
)	O
.	O

On	O
Day	O
8	O
,	O
the	O
nerve-evoked	O
peak	O
twitch	O
tensions	O
,	O
tetanic	B-Disease
tensions	O
,	O
and	O
fatigability	O
,	O
and	O
the	O
dose-response	O
curves	O
of	O
d-tubocurarine	B-Chemical
in	O
the	O
tibialis	O
cranialis	O
muscle	O
were	O
measured	O
in	O
vivo	O
and	O
related	O
to	O
muscle	O
mass	O
or	O
expression	O
of	O
AChRs	O
.	O

Rate	O
of	O
body	O
weight	O
gain	O
was	O
depressed	O
in	O
the	O
P100	O
,	O
FR	O
,	O
and	O
P10	O
groups	O
compared	O
with	O
the	O
S	O
group	O
.	O

Tibialis	O
muscle	O
mass	O
was	O
smaller	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
P10	O
or	O
S	O
groups	O
.	O

The	O
evoked	O
peak	O
twitch	O
and	O
tetanic	B-Disease
tensions	O
were	O
less	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
P10	O
or	O
S	O
groups	O
,	O
however	O
,	O
tension	O
per	O
milligram	O
of	O
muscle	O
mass	O
was	O
greater	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
S	O
group	O
.	O

The	O
50	O
%	O
effective	O
dose	O
of	O
d-tubocurarine	B-Chemical
(	O
microg/kg	O
)	O
in	O
the	O
tibialis	O
muscle	O
was	O
smaller	O
in	O
the	O
P10	O
(	O
33.6	O
+/-	O
5.4	O
)	O
than	O
in	O
the	O
S	O
(	O
61.9	O
+/-	O
5.0	O
)	O
or	O
the	O
P100	O
(	O
71.3	O
+/-	O
9.6	O
)	O
groups	O
.	O

AChR	O
expression	O
was	O
less	O
in	O
the	O
P10	O
group	O
than	O
in	O
the	O
S	O
group	O
.	O

The	O
evoked	O
tensions	O
correlated	O
with	O
muscle	O
mass	O
(	O
r	O
(	O
2	O
)	O
=	O
0.32	O
,	O
P	O
<	O
0.001	O
)	O
,	O
however	O
,	O
not	O
with	O
expression	O
of	O
AChR	O
.	O

The	O
50	O
%	O
effective	O
dose	O
of	O
d-tubocurarine	B-Chemical
did	O
not	O
correlate	O
with	O
muscle	O
mass	O
or	O
AChR	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
neuromuscular	B-Disease
dysfunction	I-Disease
after	O
prednisolone	B-Chemical
is	O
dose-dependent	O
,	O
and	O
derives	O
primarily	O
from	O
muscle	B-Disease
atrophy	I-Disease
and	O
derives	O
less	O
so	O
from	O
changes	O
in	O
AChR	O
expression	O
.	O

IMPLICATIONS	O
:	O
The	O
mechanisms	O
by	O
which	O
chronic	O
glucocorticoid	O
therapy	O
alters	O
neuromuscular	O
physiology	O
and	O
pharmacology	O
are	O
unclear	O
.	O

We	O
suggest	O
that	O
the	O
observed	O
effects	O
are	O
dose-dependent	O
and	O
derive	O
primarily	O
from	O
muscle	B-Disease
atrophy	I-Disease
and	O
derive	O
less	O
from	O
changes	O
in	O
acetylcholine	B-Chemical
receptor	O
expression	O
.	O

Rapid	O
reversal	O
of	O
life-threatening	O
diltiazem-induced	B-Chemical
tetany	B-Disease
with	O
calcium	B-Chemical
chloride	I-Chemical
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
tetany	B-Disease
with	O
sudden	O
respiratory	B-Disease
arrest	I-Disease
after	O
the	O
infusion	O
of	O
intravenous	O
diltiazem	B-Chemical
.	O

The	O
administration	O
of	O
calcium	B-Chemical
chloride	I-Chemical
rapidly	O
resolved	O
the	O
patient	O
's	O
tetany	B-Disease
with	O
prompt	O
recovery	O
of	O
respiratory	O
function	O
,	O
averting	O
the	O
need	O
for	O
more	O
aggressive	O
airway	O
management	O
and	O
ventilatory	O
support	O
.	O

The	O
emergency	O
physician	O
should	O
be	O
aware	O
that	O
life-threatening	O
tetany	B-Disease
may	O
accompany	O
the	O
administration	O
of	O
intravenous	O
diltiazem	B-Chemical
and	O
that	O
calcium	B-Chemical
chloride	I-Chemical
may	O
be	O
a	O
rapid	O
and	O
effective	O
remedy	O
.	O

Effects	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
on	O
hemostasis	O
in	O
patients	O
with	O
aneurysmal	B-Disease
subarachnoid	I-Disease
hemorrhage	I-Disease
.	O

Platelet	O
function	O
is	O
impaired	O
by	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
(	O
NSAIDs	O
)	O
with	O
prominent	O
anti-inflammatory	O
properties	O
.	O

Their	O
safety	O
in	O
patients	O
undergoing	O
intracranial	O
surgery	O
is	O
under	O
debate	O
.	O

Patients	O
with	O
aneurysmal	B-Disease
subarachnoid	I-Disease
hemorrhage	I-Disease
(	O
SAH	B-Disease
)	O
were	O
randomized	O
to	O
receive	O
either	O
ketoprofen	B-Chemical
,	O
100	O
mg	O
,	O
three	O
times	O
a	O
day	O
(	O
ketoprofen	B-Chemical
group	O
,	O
n	O
=	O
9	O
)	O
or	O
a	O
weak	O
NSAID	O
,	O
acetaminophen	B-Chemical
,	O
1	O
g	O
,	O
three	O
times	O
a	O
day	O
(	O
acetaminophen	B-Chemical
group	O
,	O
n	O
=	O
9	O
)	O
starting	O
immediately	O
after	O
the	O
diagnosis	O
of	O
aneurysmal	B-Disease
SAH	B-Disease
.	O

Treatment	O
was	O
continued	O
for	O
3	O
days	O
postoperatively	O
.	O

Test	O
blood	O
samples	O
were	O
taken	O
before	O
treatment	O
and	O
surgery	O
as	O
well	O
as	O
on	O
the	O
first	O
,	O
third	O
,	O
and	O
fifth	O
postoperative	O
mornings	O
.	O

Maximal	O
platelet	B-Disease
aggregation	I-Disease
induced	O
by	O
6	O
microM	O
of	O
adenosine	B-Chemical
diphosphate	I-Chemical
decreased	O
after	O
administration	O
of	O
ketoprofen	B-Chemical
.	O

Aggregation	O
was	O
lower	O
(	O
P	O
<	O
.05	O
)	O
in	O
the	O
ketoprofen	B-Chemical
group	O
than	O
in	O
the	O
acetaminophen	B-Chemical
group	O
just	O
before	O
surgery	O
and	O
on	O
the	O
third	O
postoperative	O
day	O
.	O

In	O
contrast	O
,	O
maximal	O
platelet	B-Disease
aggregation	I-Disease
increased	O
in	O
the	O
acetaminophen	B-Chemical
group	O
on	O
the	O
third	O
postoperative	O
day	O
as	O
compared	O
with	O
the	O
pretreatment	O
platelet	B-Disease
aggregation	I-Disease
results	O
(	O
P	O
<	O
.05	O
)	O
.	O

One	O
patient	O
in	O
the	O
ketoprofen	B-Chemical
group	O
developed	O
a	O
postoperative	O
intracranial	O
hematoma	B-Disease
.	O

Coagulation	O
(	O
prothrombin	O
time	O
[	O
PT	O
]	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
[	O
APPT	O
]	O
,	O
fibrinogen	B-Drug
concentration	O
,	O
and	O
antithrombin	O
III	O
[	O
AT	O
III	O
]	O
)	O
was	O
comparable	O
between	O
the	O
two	O
groups	O
.	O

Ketoprofen	B-Chemical
but	O
not	O
acetaminophen	B-Chemical
impaired	O
platelet	O
function	O
in	O
patients	O
with	O
SAH	B-Disease
.	O

If	O
ketoprofen	B-Chemical
is	O
used	O
before	O
surgery	O
on	O
cerebral	O
artery	B-Disease
aneurysms	I-Disease
,	O
it	O
may	O
pose	O
an	O
additional	O
risk	O
factor	O
for	O
hemorrhage	B-Disease
.	O

Value	O
of	O
methylprednisolone	B-Chemical
in	O
prevention	O
of	O
the	O
arthralgia-myalgia	B-Disease
syndrome	O
associated	O
with	O
the	O
total	O
dose	O
infusion	O
of	O
iron	B-Drug
dextran	B-Drug
:	O
a	O
double	O
blind	O
randomized	O
trial	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
total	O
dose	O
infusion	O
(	O
TDI	O
)	O
of	O
iron	B-Chemical
dextran	I-Chemical
has	O
been	O
well	O
documented	O
.	O

In	O
40	O
%	O
of	O
treated	O
patients	O
,	O
an	O
arthralgia-myalgia	B-Disease
syndrome	O
develops	O
.	O

The	O
purpose	O
of	O
this	O
randomized	O
,	O
double-blind	O
,	O
prospective	O
study	O
was	O
to	O
investigate	O
whether	O
intravenous	O
(	O
i.v	O
.	O

)	O
administration	O
of	O
methylprednisolone	B-Drug
(	O
MP	O
)	O
prevents	O
this	O
complication	O
.	O

Sixty-five	O
patients	O
,	O
34	O
women	O
and	O
31	O
men	O
,	O
ages	O
36	O
to	O
80	O
years	O
,	O
received	O
either	O
normal	O
saline	O
before	O
and	O
after	O
TDI	O
(	O
group	O
1	O
)	O
,	O
125	O
mg	O
i.v	O
.	O

MP	O
before	O
and	O
saline	O
after	O
TDI	O
(	O
group	O
2	O
)	O
,	O
or	O
125	O
mg	O
i.v	O
.	O

MP	O
before	O
and	O
after	O
TDI	O
(	O
group	O
3	O
)	O
.	O

Patients	O
were	O
observed	O
for	O
72	O
hours	O
and	O
reactions	O
were	O
recorded	O
and	O
graded	O
according	O
to	O
severity	O
.	O

Fifty-eight	O
percent	O
of	O
group	O
1	O
patients	O
,	O
33	O
%	O
of	O
group	O
2	O
,	O
and	O
26	O
%	O
of	O
group	O
3	O
had	O
reactions	O
to	O
TDI	O
.	O

The	O
severity	O
of	O
reactions	O
(	O
minimal	O
,	O
mild	O
,	O
and	O
moderate	O
,	O
respectively	O
)	O
was	O
as	O
follows	O
:	O
group	O
1	O
--	O
6	O
,	O
6	O
,	O
and	O
2	O
;	O
group	O
2	O
--	O
1	O
,	O
5	O
,	O
and	O
0	O
;	O
group	O
3	O
--	O
5	O
,	O
1	O
,	O
and	O
0	O
.	O

Data	O
were	O
analyzed	O
by	O
the	O
two-sided	O
Fisher	O
's	O
exact	O
test	O
using	O
95	O
%	O
confidence	O
intervals	O
with	O
the	O
approximation	O
of	O
Woolf	O
.	O

These	O
data	O
demonstrate	O
that	O
administration	O
of	O
MP	O
before	O
and	O
after	O
TDI	O
reduces	O
the	O
frequency	O
and	O
severity	O
of	O
the	O
arthralgia-myalgia	B-Disease
syndrome	O
.	O

We	O
conclude	O
that	O
125	O
mg	O
i.v	O
.	O

MP	O
should	O
be	O
given	O
routinely	O
before	O
and	O
after	O
TDI	O
of	O
iron	B-Drug
dextran	B-Drug
.	O

Long-term	O
effects	O
of	O
vincristine	B-Chemical
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Forty	O
patients	O
with	O
Non-Hodgkin	B-Disease
's	I-Disease
Lymphoma	I-Disease
treated	O
with	O
vincristine	B-Chemical
between	O
1984	O
and	O
1990	O
(	O
cumulative	O
dose	O
12	O
mg	O
in	O
18-24	O
weeks	O
)	O
were	O
investigated	O
in	O
order	O
to	O
evaluate	O
the	O
long	O
term	O
effects	O
of	O
vincristine	B-Chemical
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

The	O
patients	O
were	O
interviewed	O
with	O
emphasis	O
on	O
neuropathic	B-Disease
symptoms	I-Disease
.	O

Physical	O
and	O
quantitative	O
sensory	O
examination	O
with	O
determination	O
of	O
vibratory	O
perception	O
and	O
thermal	O
discrimination	O
thresholds	O
were	O
performed	O
,	O
four	O
to	O
77	O
months	O
(	O
median	O
34	O
months	O
)	O
after	O
vincristine	B-Chemical
treatment	O
.	O

Twenty-seven	O
patients	O
reported	O
neuropathic	B-Disease
symptoms	I-Disease
.	O

In	O
13	O
of	O
these	O
27	O
patients	O
symptoms	O
were	O
still	O
present	O
at	O
the	O
time	O
of	O
examination	O
.	O

In	O
these	O
patients	O
sensory	O
signs	O
and	O
symptoms	O
predominated	O
.	O

In	O
the	O
other	O
14	O
patients	O
symptoms	O
had	O
been	O
present	O
in	O
the	O
past	O
.	O

Symptoms	O
persisted	O
maximally	O
40	O
months	O
since	O
cessation	O
of	O
therapy	O
.	O

There	O
was	O
no	O
age	O
difference	O
between	O
patients	O
with	O
and	O
without	O
complaints	O
at	O
the	O
time	O
of	O
examination	O
.	O

Normal	O
reflexes	O
were	O
found	O
in	O
two	O
third	O
of	O
patients	O
.	O

Neuropathic	O
complaints	O
were	O
not	O
very	O
troublesome	O
on	O
the	O
long	O
term	O
.	O

It	O
is	O
concluded	O
that	O
with	O
the	O
above	O
mentioned	O
vincristine	B-Chemical
dose	O
schedule	O
signs	O
and	O
symptoms	O
of	O
vincristine	B-Chemical
neuropathy	B-Disease
are	O
reversible	O
for	O
a	O
great	O
deal	O
and	O
prognosis	O
is	O
fairly	O
good	O
.	O

A	O
case	O
of	O
polymyositis	B-Disease
in	O
a	O
patient	O
with	O
primary	B-Disease
biliary	I-Disease
cirrhosis	I-Disease
treated	O
with	O
D-penicillamine	B-Chemical
.	O

Although	O
D-penicillamine	B-Chemical
has	O
been	O
used	O
for	O
many	O
rheumatologic	B-Disease
diseases	I-Disease
,	O
toxicity	B-Disease
limits	O
its	O
usefulness	O
in	O
many	O
patients	O
.	O

Polymyositis/dermatomyositis	B-Disease
can	O
develop	O
as	O
one	O
of	O
the	O
autoimmune	O
complications	O
of	O
D-penicillamine	B-Drug
treatment	O
,	O
but	O
its	O
exact	O
pathogenesis	O
remains	O
unclear	O
.	O

We	O
report	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
,	O
who	O
developed	O
polymyositis	O
while	O
receiving	O
D-penicillamine	B-Drug
therapy	O
.	O

We	O
described	O
the	O
special	O
clinical	O
course	O
of	O
the	O
patient	O
.	O

Patients	O
receiving	O
D-penicillamine	B-Drug
therapy	O
should	O
be	O
followed	O
carefully	O
for	O
the	O
development	O
of	O
autoimmune	O
complications	O
like	O
polymyositis/dermatomyositis	B-Disease
.	O

Photodistributed	O
nifedipine-induced	B-Chemical
facial	O
telangiectasia	B-Disease
.	O

Five	O
months	O
after	O
starting	O
nifedipine	B-Chemical
(	O
Adalat	B-Chemical
)	O
,	O
two	O
patients	O
developed	O
photodistributed	O
facial	O
telangiectasia	B-Disease
,	O
which	O
became	O
more	O
noticeable	O
with	O
time	O
.	O

Neither	O
patient	O
complained	O
of	O
photosensitivity	O
or	O
flushing	B-Disease
.	O

Both	O
patients	O
reported	O
a	O
significant	O
cosmetic	O
improvement	O
after	O
discontinuing	O
the	O
drug	B-Drug
.	O

One	O
commenced	O
the	O
closely	O
related	O
drug	B-Drug
amlodipine	B-Chemical
3	O
years	O
later	O
,	O
with	O
recurrence	O
of	O
telangiectasia	B-Disease
.	O

The	O
photodistribution	O
of	O
the	O
telangiectasia	B-Disease
suggests	O
a	O
significant	O
drug/light	O
interaction	O
.	O

Nephrotoxicity	B-Disease
of	O
cyclosporin	B-Chemical
A	I-Chemical
and	O
FK506	B-Chemical
:	O
inhibition	O
of	O
calcineurin	O
phosphatase	O
.	O

Cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
;	O
50	O
mg/kg	O
)	O
and	O
Fujimycine	B-Chemical
(	O
FK506	B-Chemical
;	O
5	O
mg/kg	O
)	O
,	O
but	O
not	O
the	O
related	O
macrolide	B-Chemical
immunosuppressant	O
rapamycin	B-Chemical
(	O
5	O
mg/kg	O
)	O
,	O
caused	O
a	O
reduction	O
of	O
glomerular	O
filtration	O
rate	O
,	O
degenerative	O
changes	O
of	O
proximal	O
tubular	O
epithelium	O
,	O
and	O
hypertrophy	B-Disease
of	O
the	O
juxtaglomerular	O
apparatus	O
in	O
male	O
Wistar	O
rats	O
when	O
given	O
for	O
10	O
days	O
.	O

The	O
molecular	O
mechanisms	O
of	O
CsA	B-Chemical
and	O
FK506	B-Chemical
toxicity	B-Disease
were	O
investigated	O
.	O

Cyclophilin	O
A	O
and	O
FK506-binding	B-Chemical
protein	O
,	O
the	O
main	O
intracytoplasmic	O
receptors	O
for	O
CsA	B-Chemical
and	O
FK506	B-Chemical
,	O
respectively	O
,	O
were	O
each	O
detected	O
in	O
renal	O
tissue	O
extract	O
.	O

In	O
the	O
kidney	O
,	O
high	O
levels	O
of	O
immunoreactive	O
and	O
enzymatically	O
active	O
calcineurin	O
were	O
found	O
which	O
were	O
inhibited	O
by	O
the	O
immunosuppressants	O
CsA	B-Chemical
and	O
FK506	B-Chemical
,	O
but	O
not	O
by	O
rapamycin	B-Chemical
.	O

Finally	O
,	O
specific	O
immunophilin-drug-calcineurin	O
complexes	O
formed	O
only	O
in	O
the	O
presence	O
of	O
CsA	B-Chemical
and	O
FK506	B-Chemical
,	O
but	O
not	O
rapamycin	B-Chemical
.	O

These	O
results	O
suggest	O
that	O
the	O
nephrotoxic	B-Disease
effects	O
of	O
CsA	B-Chemical
and	O
FK506	B-Chemical
is	O
likely	O
mediated	O
through	O
binding	O
to	O
renal	O
immunophilin	O
and	O
inhibiting	O
calcineurin	O
phosphatase	O
.	O

Massive	O
cerebral	B-Disease
edema	I-Disease
associated	O
with	O
fulminant	O
hepatic	B-Disease
failure	I-Disease
in	O
acetaminophen	B-Chemical
overdose	B-Disease
:	O
possible	O
role	O
of	O
cranial	O
decompression	O
.	O

Cerebral	B-Disease
edema	I-Disease
may	O
complicate	O
the	O
course	O
of	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
.	O

Response	O
to	O
conventional	O
therapy	O
has	O
been	O
disappointing	O
.	O

We	O
present	O
a	O
patient	O
with	O
fatal	O
acetaminophen-induced	B-Chemical
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
,	O
with	O
signs	O
and	O
symptoms	O
of	O
cerebral	B-Disease
edema	I-Disease
,	O
unresponsive	O
to	O
conventional	O
medical	O
therapy	O
.	O

Cranial	O
decompression	O
was	O
carried	O
out	O
.	O

A	O
justification	O
of	O
the	O
need	O
for	O
further	O
evaluation	O
of	O
cranial	O
decompression	O
in	O
such	O
patients	O
is	O
presented	O
.	O

Gentamicin	B-Chemical
nephropathy	B-Disease
in	O
a	O
neonate	O
.	O

The	O
clinical	O
and	O
autopsy	O
findings	O
in	O
a	O
premature	O
baby	O
who	O
died	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
therapy	O
with	O
gentamicin	B-Chemical
(	O
5	O
mg/kg/day	O
)	O
and	O
penicillin	B-Chemical
are	O
presented	O
.	O

The	O
serum	O
gentamicin	B-Chemical
concentration	O
had	O
reached	O
toxic	O
levels	O
when	O
anuria	B-Disease
developed	O
.	O

Numerous	O
periodic	B-Chemical
acid	I-Chemical
Schiff	O
(	O
PAS	O
)	O
positive	O
,	O
diastase	O
resistant	O
cytoplasmic	O
inclusion	O
bodies	O
which	O
appeared	O
as	O
myelin	O
figures	O
in	O
cytosegresomes	O
under	O
the	O
electron	O
microscope	O
were	O
identified	O
in	O
the	O
proximal	O
convoluted	O
tubules	O
.	O

The	O
pathological	O
changes	O
induced	O
by	O
gentamicin	B-Chemical
in	O
the	O
human	O
neonatal	O
kidneys	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Anti-carcinogenic	B-Disease
action	O
of	O
phenobarbital	B-Chemical
given	O
simultaneously	O
with	O
diethylnitrosamine	B-Chemical
in	O
the	O
rat	O
.	O

The	O
present	O
work	O
has	O
been	O
planned	O
in	O
order	O
to	O
elucidate	O
the	O
effect	O
of	O
phenobarbital	B-Chemical
(	O
PB	B-Chemical
:	O
15	O
mg	O
per	O
rat	O
of	O
ingested	O
dose	O
)	O
on	O
carcinogenesis	B-Disease
when	O
it	O
is	O
administered	O
simultaneously	O
with	O
diethylnitrosamine	B-Chemical
(	O
DEN	B-Chemical
:	O
10	O
mg/kg/day	O
)	O
.	O

Wistar	O
rats	O
(	O
180	O
g	O
)	O
were	O
treated	O
by	O
DEN	B-Chemical
alone	O
or	O
by	O
DEN	B-Chemical
+	O
PB	B-Chemical
during	O
2	O
,	O
4	O
and	O
6	O
weeks	O
according	O
to	O
our	O
schedule	O
for	O
hepatocarcinogenesis	B-Disease
.	O

After	O
the	O
end	O
of	O
the	O
treatment	O
,	O
the	O
number	O
and	O
the	O
size	O
of	O
induced	O
PAS	O
positive	O
preneoplastic	B-Disease
foci	I-Disease
was	O
significantly	O
reduced	O
when	O
PB	B-Chemical
was	O
given	O
simultaneously	O
with	O
DEN	B-Chemical
for	O
4	O
and	O
6	O
weeks	O
.	O

The	O
mitotic	O
inhibition	O
and	O
the	O
production	O
of	O
micronuclei	O
normally	O
observed	O
after	O
partial	O
hepatectomy	O
in	O
DEN	B-Chemical
treated	O
rats	O
were	O
also	O
significantly	O
decreased	O
in	O
DEN	B-Chemical
+	O
PB	B-Chemical
treated	O
rats	O
.	O

When	O
the	O
treatment	O
last	O
only	O
2	O
weeks	O
,	O
the	O
presence	O
of	O
PB	B-Chemical
did	O
not	O
change	O
significantly	O
the	O
last	O
parameters	O
.	O

In	O
DEN	B-Chemical
+	O
PB	B-Chemical
treated	O
rats	O
,	O
the	O
survival	O
was	O
prolonged	O
and	O
the	O
tumor	B-Disease
incidence	O
decreased	O
as	O
compared	O
with	O
the	O
results	O
obtained	O
by	O
DEN	B-Chemical
alone	O
.	O

It	O
is	O
concluded	O
that	O
PB	B-Chemical
,	O
which	O
promotes	O
carcinogenesis	B-Disease
when	O
administered	O
after	O
the	O
DEN	B-Chemical
treatment	O
,	O
reduces	O
the	O
carcinogen	O
effect	O
when	O
given	O
simultaneously	O
with	O
DEN	B-Chemical
.	O

This	O
'anti-carcinogen	O
'	O
effect	O
acts	O
on	O
the	O
initiation	O
as	O
well	O
as	O
on	O
the	O
promotion	O
of	O
the	O
precancerous	B-Disease
lesions	I-Disease
.	O

Biochemical	O
investigations	O
are	O
in	O
progress	O
to	O
obtain	O
more	O
information	O
about	O
this	O
'paradoxical	O
'	O
PB	B-Chemical
effect	O
.	O

Post-operative	O
rigidity	B-Disease
after	O
fentanyl	B-Chemical
administration	O
.	O

A	O
case	O
of	O
thoraco-abdominal	O
rigidity	B-Disease
leading	O
to	O
respiratory	B-Disease
failure	I-Disease
is	O
described	O
in	O
the	O
post-operative	O
period	O
in	O
an	O
elderly	O
patient	O
who	O
received	O
a	O
moderate	O
dose	O
of	O
fentanyl	B-Chemical
.	O

This	O
was	O
successfully	O
reversed	O
by	O
naloxone	B-Chemical
.	O

The	O
mechanisms	O
possibly	O
implicated	O
in	O
this	O
accident	O
are	O
discussed	O
.	O

Postpartum	O
psychosis	B-Disease
induced	O
by	O
bromocriptine	B-Chemical
.	O

Two	O
multigravida	O
patients	O
with	O
no	O
prior	O
psychiatric	B-Disease
history	O
were	O
seen	O
with	O
postpartum	O
psychosis	B-Disease
,	O
having	O
received	O
bromocriptine	B-Chemical
for	O
inhibition	B-Disease
of	I-Disease
lactation	I-Disease
.	O

Bromocriptine	B-Chemical
given	O
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
psychosis	B-Disease
in	O
patients	O
receiving	O
the	O
drug	B-Drug
for	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

These	O
cases	O
demonstrate	O
that	O
bromocriptine	B-Chemical
may	O
cause	O
psychosis	B-Disease
even	O
when	O
given	O
in	O
low	O
doses	O
.	O

A	O
prospective	O
study	O
on	O
the	O
dose	O
dependency	O
of	O
cardiotoxicity	B-Disease
induced	O
by	O
mitomycin	B-Chemical
C	I-Chemical
.	O

Since	O
1975	O
mitomycin	B-Chemical
C	I-Chemical
(	O
MMC	B-Chemical
)	O
has	O
been	O
suggested	O
to	O
be	O
cardiotoxic	B-Disease
,	O
especially	O
when	O
combined	O
with	O
or	O
given	O
following	O
doxorubicin	B-Chemical
.	O

Data	O
on	O
dose	O
dependency	O
or	O
incidence	O
concerning	O
this	O
side	O
effect	O
were	O
not	O
known	O
.	O

We	O
have	O
initiated	O
a	O
prospective	O
study	O
to	O
obtain	O
some	O
more	O
data	O
on	O
these	O
subjects	O
.	O

Forty-four	O
MMC-treated	B-Chemical
patients	O
were	O
studied	O
,	O
37	O
of	O
them	O
could	O
be	O
evaluated	O
.	O

All	O
patients	O
were	O
studied	O
by	O
repeated	O
physical	O
examinations	O
,	O
chest	O
X-rays	O
,	O
electro-	O
and	O
echocardiography	O
and	O
radionuclide	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
EF	O
)	O
determinations	O
.	O

The	O
results	O
were	O
evaluated	O
per	O
cumulative	O
dose	O
level	O
.	O

One	O
of	O
the	O
patients	O
developed	O
cardiac	B-Disease
failure	I-Disease
after	O
30	O
mg	O
m-2	O
MMC	B-Chemical
and	O
only	O
150	O
mg	O
m-2	O
doxorubicin	B-Chemical
.	O

The	O
cardiac	B-Disease
failure	I-Disease
was	O
predicted	O
by	O
a	O
drop	O
in	O
EF	O
determined	O
during	O
a	O
cold	O
pressor	O
test	O
.	O

None	O
of	O
the	O
other	O
patients	O
developed	O
clinical	O
cardiotoxicity	B-Disease
,	O
nor	O
did	O
the	O
studied	O
parameters	O
change	O
.	O

The	O
literature	O
on	O
this	O
subject	O
was	O
also	O
reviewed	O
.	O

Based	O
on	O
the	O
combined	O
data	O
from	O
the	O
present	O
study	O
and	O
the	O
literature	O
,	O
we	O
suggest	O
that	O
MMC-related	B-Chemical
cardiotoxicity	B-Disease
is	O
dose	O
dependent	O
,	O
occurring	O
at	O
cumulative	O
dose	O
levels	O
of	O
30	O
mg	O
m-2	O
or	O
more	O
,	O
mainly	O
in	O
patients	O
also	O
(	O
previously	O
or	O
simultaneously	O
)	O
treated	O
with	O
doxorubicin	B-Chemical
.	O

The	O
incidence	O
is	O
likely	O
to	O
be	O
less	O
than	O
10	O
%	O
even	O
for	O
this	O
risk	O
group	O
.	O

Phlorizin-induced	B-Chemical
glycosuria	B-Disease
does	O
not	O
prevent	O
gentamicin	B-Chemical
nephrotoxicity	B-Disease
in	O
rats	O
.	O

Because	O
rats	O
with	O
streptozotocin-induced	B-Chemical
diabetes	B-Disease
mellitus	I-Disease
(	O
DM	B-Disease
)	O
have	O
a	O
high	O
solute	O
diuresis	O
(	O
glycosuria	B-Disease
of	O
10	O
to	O
12	O
g/day	O
)	O
,	O
we	O
have	O
suggested	O
that	O
this	O
may	O
in	O
part	O
be	O
responsible	O
for	O
their	O
resistance	O
to	O
gentamicin-induced	B-Chemical
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
ARF	B-Disease
)	O
.	O

The	O
protection	O
from	O
gentamicin	B-Chemical
nephrotoxicity	B-Disease
was	O
studied	O
in	O
non-diabetic	B-Disease
rats	O
with	O
chronic	O
solute	O
diuresis	O
induced	O
by	O
blockage	O
of	O
tubular	O
glucose	B-Chemical
reabsorption	O
with	O
phlorizin	B-Chemical
(	O
P	B-Chemical
)	O
.	O

DM	B-Disease
rats	O
with	O
mild	O
glycosuria	B-Disease
(	O
similar	O
in	O
degree	O
to	O
that	O
of	O
the	O
P	B-Chemical
treated	O
animals	O
)	O
were	O
also	O
studied	O
.	O

Unanesthetized	O
adult	O
female	O
,	O
Sprague-Dawley	O
rats	O
were	O
divided	O
in	O
four	O
groups	O
and	O
studied	O
for	O
15	O
days	O
.	O

Group	O
1	O
(	O
P	B-Chemical
alone	O
)	O
received	O
P	B-Chemical
,	O
360	O
mg/day	O
,	O
for	O
15	O
days	O
;	O
Group	O
II	O
(	O
P	B-Chemical
+	O
gentamicin	B-Chemical
)	O
;	O
Group	O
III	O
(	O
gentamicin	B-Chemical
alone	O
)	O
and	O
Group	O
IV	O
(	O
mild	O
DM	B-Disease
+	O
gentamicin	B-Chemical
)	O
.	O

Nephrotoxic	B-Disease
doses	O
(	O
40	O
mg/kg	O
body	O
wt/day	O
)	O
of	O
gentamicin	B-Chemical
were	O
injected	O
during	O
the	O
last	O
nine	O
days	O
of	O
study	O
to	O
the	O
animals	O
of	O
groups	O
II	O
to	O
IV	O
.	O

In	O
Group	O
I	O
,	O
P	B-Chemical
induced	O
a	O
moderate	O
and	O
stable	O
glycosuria	B-Disease
(	O
3.9	O
+/-	O
0.1	O
g/day	O
,	O
SE	O
)	O
,	O
and	O
no	O
functional	O
or	O
morphologic	O
evidence	O
of	O
renal	B-Disease
dysfunction	I-Disease
(	O
baseline	O
CCr	O
2.1	O
+/-	O
0.1	O
ml/min	O
,	O
undetectable	O
lysozymuria	O
)	O
or	O
damage	O
(	O
tubular	B-Disease
necrosis	I-Disease
score	O
[	O
maximum	O
4	O
]	O
,	O
zero	O
)	O
.	O

In	O
Group	O
II	O
,	O
P	B-Chemical
did	O
not	O
prevent	O
gentamicin-ARF	B-Chemical
(	O
maximal	O
decrease	O
in	O
CCr	O
at	O
day	O
9.89	O
%	O
,	O
P	O
less	O
than	O
0.001	O
;	O
peak	O
lysozymuria	O
,	O
1863	O
+/-	O
321	O
micrograms/day	O
;	O
and	O
tubular	O
necrosis	O
score	O
,	O
3.9	O
+/-	O
0.1	O
)	O
.	O

These	O
values	O
were	O
not	O
different	O
from	O
those	O
of	O
Group	O
III	O
:	O
maximal	O
decrease	O
in	O
CCr	O
73	O
%	O
(	O
P	O
less	O
than	O
0.001	O
)	O
;	O
lysozymuria	O
,	O
2147	O
+/-	O
701	O
micrograms/day	O
;	O
tubular	O
necrosis	O
score	O
,	O
3.8	O
+/-	O
0.1	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Tiapride	B-Chemical
in	O
levodopa-induced	B-Chemical
involuntary	B-Disease
movements	I-Disease
.	O

Tiapride	B-Chemical
,	O
a	O
substituted	O
benzamide	B-Chemical
derivative	O
closely	O
related	O
to	O
metoclopramide	B-Chemical
,	O
reduced	O
levodopa-induced	B-Chemical
peak	O
dose	O
involuntary	B-Disease
movements	I-Disease
in	O
16	O
patients	O
with	O
idiopathic	B-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
.	O

However	O
,	O
an	O
unacceptable	O
increase	O
in	O
disability	O
from	O
Parkinsonism	B-Disease
with	O
aggravation	O
of	O
end-of-dose	O
akinesia	B-Disease
led	O
to	O
its	O
cessation	O
in	O
14	O
patients	O
.	O

Tiapride	B-Chemical
had	O
no	O
effect	O
on	O
levodopa-induced	B-Chemical
early	O
morning	O
of	O
``	O
off-period	O
''	O
segmental	O
dystonia	B-Disease
.	O

These	O
results	O
fail	O
to	O
support	O
the	O
notion	O
that	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
are	O
caused	O
by	O
overstimulation	O
of	O
a	O
separate	O
group	O
of	O
dopamine	B-Chemical
receptors	O
.	O

Effects	O
of	O
the	O
hippocampal	O
deep	O
brain	O
stimulation	O
on	O
cortical	O
epileptic	B-Disease
discharges	O
in	O
penicillin	B-Chemical
-	O
induced	O
epilepsy	B-Disease
model	O
in	O
rats	O
.	O

AIM	O
:	O
Experimental	O
and	O
clinical	O
studies	O
have	O
revealed	O
that	O
hippocampal	O
DBS	O
can	O
control	O
epileptic	B-Disease
activity	O
,	O
but	O
the	O
mechanism	O
of	O
action	O
is	O
obscure	O
and	O
optimal	O
stimulation	O
parameters	O
are	O
not	O
clearly	O
defined	O
.	O

The	O
aim	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
high	O
frequency	O
hippocampal	O
stimulation	O
on	O
cortical	O
epileptic	B-Disease
activity	O
in	O
penicillin-induced	B-Chemical
epilepsy	B-Disease
model	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Twenty-five	O
Sprague-Dawley	O
rats	O
were	O
implanted	O
DBS	O
electrodes	O
.	O

In	O
group-1	O
(	O
n=10	O
)	O
hippocampal	O
DBS	O
was	O
off	O
and	O
in	O
the	O
group-2	O
(	O
n=10	O
)	O
hippocampal	O
DBS	O
was	O
on	O
(	O
185	O
Hz	O
,	O
0.5V	O
,	O
1V	O
,	O
2V	O
,	O
and	O
5V	O
for	O
60	O
sec	O
)	O
following	O
penicillin	B-Chemical
G	I-Chemical
injection	O
intracortically	O
.	O

In	O
the	O
control	O
group	O
hippocampal	O
DBS	O
was	O
on	O
following	O
8	O
l	O
saline	O
injection	O
intracortically	O
.	O

EEG	O
recordings	O
were	O
obtained	O
before	O
and	O
15	O
minutes	O
following	O
penicillin-G	B-Chemical
injection	O
,	O
and	O
at	O
10th	O
minutes	O
following	O
each	O
stimulus	O
for	O
analysis	O
in	O
terms	O
of	O
frequency	O
,	O
amplitude	O
,	O
and	O
power	O
spectrum	O
.	O

RESULTS	O
:	O
High	O
frequency	O
hippocampal	O
DBS	O
suppressed	O
the	O
acute	O
penicillin-induced	B-Chemical
cortical	O
epileptic	B-Disease
activity	O
independent	O
from	O
stimulus	O
intensity	O
.	O

In	O
the	O
control	O
group	O
,	O
hippocampal	O
stimulation	O
alone	O
lead	B-Drug
only	O
to	O
diffuse	O
slowing	O
of	O
cerebral	O
bioelectrical	O
activity	O
at	O
5V	O
stimulation	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
revealed	O
that	O
continuous	O
high	O
frequency	O
stimulation	O
of	O
the	O
hippocampus	O
suppressed	O
acute	O
cortical	O
epileptic	B-Disease
activity	O
effectively	O
without	O
causing	O
secondary	O
epileptic	B-Disease
discharges	O
.	O

These	O
results	O
are	O
important	O
in	O
terms	O
of	O
defining	O
the	O
optimal	O
parameters	O
of	O
hippocampal	O
DBS	O
in	O
patients	O
with	O
epilepsy	B-Disease
.	O

Neural	O
correlates	O
of	O
S-ketamine	B-Chemical
induced	O
psychosis	B-Disease
during	O
overt	O
continuous	O
verbal	O
fluency	O
.	O

The	O
glutamatergic	O
N-methyl-D-aspartate	B-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	B-Disease
.	O

Administered	O
to	O
healthy	O
volunteers	O
,	O
a	O
subanesthetic	O
dose	O
of	O
the	O
non-competitive	O
NMDA	B-Chemical
receptor	O
antagonist	O
ketamine	B-Chemical
leads	O
to	O
psychopathological	O
symptoms	O
similar	O
to	O
those	O
observed	O
in	O
schizophrenia	B-Disease
.	O

In	O
patients	O
with	O
schizophrenia	B-Disease
,	O
ketamine	B-Chemical
exacerbates	O
the	O
core	O
symptoms	O
of	O
illness	O
,	O
supporting	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	B-Disease
dysfunction	I-Disease
.	O

In	O
a	O
counterbalanced	O
,	O
placebo-controlled	O
,	O
double-blind	O
study	O
design	O
,	O
healthy	O
subjects	O
were	O
administered	O
a	O
continuous	O
subanesthetic	O
S-ketamine	B-Chemical
infusion	O
while	O
differences	O
in	O
BOLD	O
responses	O
measured	O
with	O
fMRI	O
were	O
detected	O
.	O

During	O
the	O
scanning	O
period	O
,	O
subjects	O
performed	O
continuous	O
overt	O
verbal	O
fluency	O
tasks	O
(	O
phonological	O
,	O
lexical	O
and	O
semantic	O
)	O
.	O

Ketamine-induced	B-Chemical
psychopathological	O
symptoms	O
were	O
assessed	O
with	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
.	O

Ketamine	B-Chemical
elicited	O
psychosis	B-Disease
like	O
psychopathology	O
.	O

Post-hoc	O
t-tests	O
revealed	O
significant	O
differences	O
between	O
placebo	O
and	O
ketamine	B-Chemical
for	O
the	O
amounts	O
of	O
words	O
generated	O
during	O
lexical	O
and	O
semantic	O
verbal	O
fluency	O
,	O
while	O
the	O
phonological	O
domain	O
remained	O
unaffected	O
.	O

Ketamine	B-Chemical
led	O
to	O
enhanced	O
cortical	O
activations	O
in	O
supramarginal	O
and	O
frontal	O
brain	O
regions	O
for	O
phonological	O
and	O
lexical	O
verbal	O
fluency	O
,	O
but	O
not	O
for	O
semantic	O
verbal	O
fluency	O
.	O

Ketamine	B-Chemical
induces	O
activation	O
changes	O
in	O
healthy	O
subjects	O
similar	O
to	O
those	O
observed	O
in	O
patients	O
with	O
schizophrenia	B-Disease
,	O
particularly	O
in	O
frontal	O
and	O
temporal	O
brain	O
regions	O
.	O

Our	O
results	O
provide	O
further	O
support	O
for	O
the	O
hypothesis	O
of	O
an	O
NMDA	B-Chemical
receptor	O
dysfunction	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	B-Disease
.	O

Dopamine	B-Chemical
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
methamphetamine-induced	B-Chemical
neurotoxicity	B-Disease
.	O

It	O
is	O
widely	O
believed	O
that	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
mediates	O
methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
-induced	O
toxicity	B-Disease
to	O
brain	O
dopaminergic	B-Drug
neurons	O
,	O
because	O
drugs	B-Drug
that	O
interfere	O
with	O
DA	B-Chemical
neurotransmission	O
decrease	O
toxicity	B-Disease
,	O
whereas	O
drugs	B-Drug
that	O
increase	O
DA	B-Chemical
neurotransmission	O
enhance	O
toxicity	B-Disease
.	O

However	O
,	O
temperature	O
effects	O
of	O
drugs	B-Drug
that	O
have	O
been	O
used	O
to	O
manipulate	O
brain	O
DA	B-Chemical
neurotransmission	O
confound	O
interpretation	O
of	O
the	O
data	O
.	O

Here	O
we	O
show	O
that	O
the	O
recently	O
reported	O
ability	O
of	O
L-dihydroxyphenylalanine	B-Chemical
to	O
reverse	O
the	O
protective	O
effect	O
of	O
alpha-methyl-para-tyrosine	B-Chemical
on	O
METH-induced	B-Chemical
DA	B-Chemical
neurotoxicity	B-Disease
is	O
also	O
confounded	O
by	O
drug	B-Drug
effects	O
on	O
body	O
temperature	O
.	O

Further	O
,	O
we	O
show	O
that	O
mice	O
genetically	O
engineered	O
to	O
be	O
deficient	O
in	O
brain	O
DA	B-Chemical
develop	O
METH	B-Chemical
neurotoxicity	B-Disease
,	O
as	O
long	O
as	O
the	O
thermic	O
effects	O
of	O
METH	B-Chemical
are	O
preserved	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
mice	O
genetically	O
engineered	O
to	O
have	O
unilateral	O
brain	O
DA	B-Chemical
deficits	O
develop	O
METH-induced	B-Chemical
dopaminergic	B-Disease
deficits	I-Disease
that	O
are	O
of	O
comparable	O
magnitude	O
on	O
both	O
sides	O
of	O
the	O
brain	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
demonstrate	O
that	O
DA	B-Chemical
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
METH-induced	B-Chemical
dopaminergic	B-Drug
neurotoxicity	B-Disease
and	O
suggest	O
that	O
mechanisms	O
independent	O
of	O
DA	B-Chemical
warrant	O
more	O
intense	O
investigation	O
.	O

Brainstem	B-Disease
dysgenesis	I-Disease
in	O
an	O
infant	O
prenatally	O
exposed	O
to	O
cocaine	B-Chemical
.	O

Many	O
authors	O
described	O
the	O
effects	O
on	O
the	O
fetus	O
of	O
maternal	O
cocaine	B-Disease
abuse	I-Disease
during	O
pregnancy	O
.	O

Vasoconstriction	O
appears	O
to	O
be	O
the	O
common	O
mechanism	O
of	O
action	O
leading	O
to	O
a	O
wide	O
range	O
of	O
fetal	B-Disease
anomalies	I-Disease
.	O

We	O
report	O
on	O
an	O
infant	O
with	O
multiple	B-Disease
cranial-nerve	I-Disease
involvement	I-Disease
attributable	O
to	O
brainstem	B-Disease
dysgenesis	I-Disease
,	O
born	O
to	O
a	O
cocaine-addicted	B-Disease
mother	O
.	O

The	O
protective	O
role	O
of	O
Nrf2	O
in	O
streptozotocin-induced	B-Chemical
diabetic	B-Disease
nephropathy	I-Disease
.	O

OBJECTIVE	O
:	O
Diabetic	B-Disease
nephropathy	I-Disease
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
renal	B-Disease
failure	I-Disease
,	O
which	O
is	O
accompanied	O
by	O
the	O
production	O
of	O
reactive	O
oxygen	B-Chemical
species	O
(	O
ROS	O
)	O
.	O

Nrf2	O
is	O
the	O
primary	O
transcription	O
factor	O
that	O
controls	O
the	O
antioxidant	O
response	O
essential	O
for	O
maintaining	O
cellular	O
redox	O
homeostasis	O
.	O

Here	O
,	O
we	O
report	O
our	O
findings	O
demonstrating	O
a	O
protective	O
role	O
of	O
Nrf2	O
against	O
diabetic	B-Disease
nephropathy	I-Disease
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
We	O
explore	O
the	O
protective	O
role	O
of	O
Nrf2	O
against	O
diabetic	B-Disease
nephropathy	I-Disease
using	O
human	O
kidney	O
biopsy	O
tissues	O
from	O
diabetic	B-Disease
nephropathy	I-Disease
patients	O
,	O
a	O
streptozotocin-induced	B-Chemical
diabetic	B-Disease
nephropathy	I-Disease
model	O
in	O
Nrf2	O
(	O
-/-	O
)	O
mice	O
,	O
and	O
cultured	O
human	O
mesangial	O
cells	O
.	O

RESULTS	O
:	O
The	O
glomeruli	O
of	O
human	O
diabetic	B-Disease
nephropathy	I-Disease
patients	O
were	O
under	O
oxidative	O
stress	O
and	O
had	O
elevated	O
Nrf2	O
levels	O
.	O

In	O
the	O
animal	O
study	O
,	O
Nrf2	O
was	O
demonstrated	O
to	O
be	O
crucial	O
in	O
ameliorating	O
streptozotocin-induced	B-Chemical
renal	B-Disease
damage	I-Disease
.	O

This	O
is	O
evident	O
by	O
Nrf2	O
(	O
-/-	O
)	O
mice	O
having	O
higher	O
ROS	O
production	O
and	O
suffering	O
from	O
greater	O
oxidative	O
DNA	O
damage	O
and	O
renal	B-Disease
injury	I-Disease
compared	O
with	O
Nrf2	O
(	O
+/+	O
)	O
mice	O
.	O

Mechanistic	O
studies	O
in	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
systems	O
showed	O
that	O
the	O
Nrf2-mediated	O
protection	O
against	O
diabetic	B-Disease
nephropathy	I-Disease
is	O
,	O
at	O
least	O
,	O
partially	O
through	O
inhibition	O
of	O
transforming	O
growth	O
factor-beta1	O
(	O
TGF-beta1	O
)	O
and	O
reduction	O
of	O
extracellular	O
matrix	O
production	O
.	O

In	O
human	O
renal	O
mesangial	O
cells	O
,	O
high	O
glucose	B-Chemical
induced	O
ROS	O
production	O
and	O
activated	O
expression	O
of	O
Nrf2	O
and	O
its	O
downstream	O
genes	O
.	O

Furthermore	O
,	O
activation	O
or	O
overexpression	O
of	O
Nrf2	O
inhibited	O
the	O
promoter	B-Drug
activity	O
of	O
TGF-beta1	O
in	O
a	O
dose-dependent	O
manner	O
,	O
whereas	O
knockdown	O
of	O
Nrf2	O
by	O
siRNA	O
enhanced	O
TGF-beta1	O
transcription	O
and	O
fibronectin	O
production	O
.	O

CONCLUSIONS	O
:	O
This	O
work	O
clearly	O
indicates	O
a	O
protective	O
role	O
of	O
Nrf2	O
in	O
diabetic	B-Disease
nephropathy	I-Disease
,	O
suggesting	O
that	O
dietary	O
or	O
therapeutic	O
activation	O
of	O
Nrf2	O
could	O
be	O
used	O
as	O
a	O
strategy	O
to	O
prevent	O
or	O
slow	O
down	O
the	O
progression	O
of	O
diabetic	B-Disease
nephropathy	I-Disease
.	O

High-dose	O
tranexamic	B-Chemical
Acid	I-Chemical
is	O
associated	O
with	O
nonischemic	O
clinical	O
seizures	B-Disease
in	O
cardiac	O
surgical	O
patients	O
.	O

BACKGROUND	O
:	O
In	O
2	O
separate	O
centers	O
,	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	B-Disease
seizures	B-Disease
from	O
1.3	O
%	O
to	O
3.8	O
%	O
in	O
patients	O
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O

These	O
events	O
were	O
temporally	O
coincident	O
with	O
the	O
initial	O
use	O
of	O
high-dose	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
TXA	B-Chemical
)	O
therapy	O
after	O
withdrawal	O
of	O
aprotinin	O
from	O
general	O
clinical	O
usage	O
.	O

The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	B-Chemical
usage	O
and	O
seizures	B-Disease
after	O
cardiac	O
surgery	O
.	O

METHODS	O
:	O
An	O
in-depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	O
who	O
developed	O
perioperative	O
seizures	B-Disease
.	O

Electroencephalographic	O
activity	O
was	O
recorded	O
in	O
11	O
of	O
these	O
patients	O
,	O
and	O
all	O
patients	O
had	O
a	O
formal	O
neurological	O
evaluation	O
and	O
brain	O
imaging	O
studies	O
.	O

RESULTS	O
:	O
Twenty-one	O
of	O
the	O
24	O
patients	O
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	B-Disease
ischemic	I-Disease
injury	I-Disease
,	O
but	O
seizures	B-Disease
were	O
likely	O
due	O
to	O
ischemic	B-Disease
brain	I-Disease
injury	I-Disease
in	O
3	O
patients	O
.	O

All	O
patients	O
with	O
seizures	B-Disease
did	O
not	O
have	O
permanent	O
neurological	B-Disease
abnormalities	I-Disease
.	O

All	O
24	O
patients	O
with	O
seizures	B-Disease
received	O
high	O
doses	O
of	O
TXA	B-Chemical
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg/kg	O
,	O
had	O
a	O
mean	O
age	O
of	O
69.9	O
years	O
,	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O

All	O
but	O
one	O
patient	O
were	O
managed	O
using	O
cardiopulmonary	O
bypass	O
.	O

No	O
evidence	O
of	O
brain	B-Disease
ischemic	I-Disease
,	O
metabolic	O
,	O
or	O
hyperthermia-induced	B-Disease
causes	O
for	O
their	O
seizures	B-Disease
was	O
apparent	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
use	O
of	O
high-dose	O
TXA	B-Chemical
in	O
older	O
patients	O
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
and	O
open-chamber	O
cardiac	O
surgery	O
is	O
associated	O
with	O
clinical	O
seizures	B-Disease
in	O
susceptible	O
patients	O
.	O

Recurrent	O
dysosmia	B-Disease
induced	O
by	O
pyrazinamide	B-Chemical
.	O

Pyrazinamide	B-Chemical
can	O
have	O
adverse	O
effects	O
such	O
as	O
hepatic	B-Disease
toxicity	I-Disease
,	O
hyperuricemia	B-Disease
or	O
digestive	O
disorders	O
.	O

In	O
rare	O
cases	O
,	O
alterations	O
in	O
taste	O
and	O
smell	O
function	O
have	O
been	O
reported	O
for	O
pyrazinamide	B-Chemical
when	O
combined	O
with	O
other	O
drugs	B-Drug
.	O

We	O
report	O
a	O
case	O
of	O
reversible	O
olfactory	B-Disease
disorder	I-Disease
related	O
to	O
pyrazinamide	B-Chemical
in	O
a	O
woman	O
,	O
with	O
a	O
positive	O
rechallenge	O
.	O

The	O
patient	O
presented	O
every	O
day	O
a	O
sensation	O
of	O
smelling	O
something	O
burning	O
15	O
min	O
after	O
drug	B-Drug
intake	O
.	O

Dysosmia	B-Disease
disappeared	O
completely	O
after	O
pyrazinamide	B-Chemical
withdrawal	O
and	O
recurred	O
after	O
its	O
rechallenge	O
.	O

The	O
case	O
was	O
reported	O
to	O
the	O
Tunisian	O
Centre	O
of	O
Pharmacovigilance	O
.	O

Longitudinal	O
assessment	O
of	O
air	O
conduction	O
audiograms	O
in	O
a	O
phase	O
III	O
clinical	O
trial	O
of	O
difluoromethylornithine	B-Chemical
and	O
sulindac	B-Chemical
for	O
prevention	O
of	O
sporadic	O
colorectal	B-Disease
adenomas	I-Disease
.	O

A	O
phase	O
III	O
clinical	O
trial	O
assessed	O
the	O
recurrence	O
of	O
adenomatous	B-Disease
polyps	I-Disease
after	O
treatment	O
for	O
36	O
months	O
with	O
difluoromethylornithine	B-Chemical
(	O
DFMO	B-Chemical
)	O
plus	O
sulindac	B-Chemical
or	O
matched	O
placebos	O
.	O

Temporary	O
hearing	B-Disease
loss	I-Disease
is	O
a	O
known	O
toxicity	B-Disease
of	O
treatment	O
with	O
DFMO	B-Chemical
,	O
thus	O
a	O
comprehensive	O
approach	O
was	O
developed	O
to	O
analyze	O
serial	O
air	O
conduction	O
audiograms	O
.	O

The	O
generalized	O
estimating	O
equation	O
method	O
estimated	O
the	O
mean	O
difference	O
between	O
treatment	O
arms	O
with	O
regard	O
to	O
change	O
in	O
air	O
conduction	O
pure	O
tone	O
thresholds	O
while	O
accounting	O
for	O
within-subject	O
correlation	O
due	O
to	O
repeated	O
measurements	O
at	O
frequencies	O
.	O

Based	O
on	O
290	O
subjects	O
,	O
there	O
was	O
an	O
average	O
difference	O
of	O
0.50	O
dB	O
between	O
subjects	O
treated	O
with	O
DFMO	B-Chemical
plus	O
sulindac	B-Chemical
compared	O
with	O
those	O
treated	O
with	O
placebo	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-0.64	O
to	O
1.63	O
dB	O
;	O
P	O
=	O
0.39	O
)	O
,	O
adjusted	O
for	O
baseline	O
values	O
,	O
age	O
,	O
and	O
frequencies	O
.	O

In	O
the	O
normal	O
speech	O
range	O
of	O
500	O
to	O
3,000	O
Hz	O
,	O
an	O
estimated	O
difference	O
of	O
0.99	O
dB	O
(	O
-0.17	O
to	O
2.14	O
dB	O
;	O
P	O
=	O
0.09	O
)	O
was	O
detected	O
.	O

Dose	O
intensity	O
did	O
not	O
add	O
information	O
to	O
models	O
.	O

There	O
were	O
14	O
of	O
151	O
(	O
9.3	O
%	O
)	O
in	O
the	O
DFMO	B-Chemical
plus	O
sulindac	B-Chemical
group	O
and	O
4	O
of	O
139	O
(	O
2.9	O
%	O
)	O
in	O
the	O
placebo	O
group	O
who	O
experienced	O
at	O
least	O
15	O
dB	O
hearing	O
reduction	O
from	O
baseline	O
in	O
2	O
or	O
more	O
consecutive	O
frequencies	O
across	O
the	O
entire	O
range	O
tested	O
(	O
P	O
=	O
0.02	O
)	O
.	O

Follow-up	O
air	O
conduction	O
done	O
at	O
least	O
6	O
months	O
after	O
end	O
of	O
treatment	O
showed	O
an	O
adjusted	O
mean	O
difference	O
in	O
hearing	O
thresholds	O
of	O
1.08	O
dB	O
(	O
-0.81	O
to	O
2.96	O
dB	O
;	O
P	O
=	O
0.26	O
)	O
between	O
treatment	O
arms	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
proportion	O
of	O
subjects	O
in	O
the	O
DFMO	B-Chemical
plus	O
sulindac	B-Chemical
group	O
who	O
experienced	O
clinically	O
significant	O
hearing	B-Disease
loss	I-Disease
compared	O
with	O
the	O
placebo	O
group	O
.	O

The	O
estimated	O
attributable	O
risk	O
of	O
ototoxicity	B-Disease
from	O
exposure	O
to	O
the	O
drug	B-Drug
is	O
8.4	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-2.0	O
%	O
to	O
18.8	O
%	O
;	O
P	O
=	O
0.12	O
)	O
.	O

There	O
is	O
a	O
<	O
2	O
dB	O
difference	O
in	O
mean	O
threshold	O
for	O
patients	O
treated	O
with	O
DFMO	B-Chemical
plus	O
sulindac	B-Chemical
compared	O
with	O
those	O
treated	O
with	O
placebo	O
.	O

Increased	O
mental	B-Disease
slowing	I-Disease
associated	O
with	O
the	O
APOE	O
epsilon4	O
allele	O
after	O
trihexyphenidyl	B-Chemical
oral	O
anticholinergic	B-Drug
challenge	O
in	O
healthy	O
elderly	O
.	O

OBJECTIVES	O
:	O
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
examine	O
the	O
relationship	O
between	O
APOE	O
epsilon4	O
and	O
subjective	O
effects	O
of	O
trihexyphenidyl	B-Chemical
on	O
measures	O
reflecting	O
sedation	O
and	O
confusion	B-Disease
and	O
to	O
investigate	O
the	O
relationship	O
between	O
trihexyphenidyl-induced	B-Chemical
subjective	O
effects	O
and	O
objective	O
memory	O
performance	O
.	O

METHODS	O
:	O
This	O
study	O
comprised	O
24	O
cognitively	O
intact	O
,	O
health	O
elderly	O
adults	O
(	O
12	O
APOE	O
epsilon4	O
carriers	O
)	O
at	O
an	O
outpatient	O
geriatric	O
psychiatry	O
research	O
clinic	O
.	O

This	O
was	O
a	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
three-way	O
,	O
crossover	O
experimental	O
design	O
.	O

All	O
participants	O
received	O
1.0	O
mg	O
or	O
2.0	O
mg	O
trihexyphenidyl	B-Chemical
or	O
placebo	O
administered	O
in	O
counterbalanced	O
sequences	O
over	O
a	O
period	O
of	O
three	O
consecutive	O
weeks	O
.	O

Bond	O
and	O
Lader	O
's	O
visual	O
analog	O
scales	O
and	O
alternate	O
versions	O
of	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
were	O
administered	O
in	O
a	O
repeated	O
measures	O
design	O
at	O
baseline	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
hours	O
postdrug	O
administration	O
.	O

RESULTS	O
:	O
A	O
2.0-mg	O
oral	O
dose	O
of	O
trihexyphenidyl	B-Chemical
resulted	O
in	O
increased	O
subjective	O
ratings	O
of	O
mental	B-Disease
slowness	I-Disease
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

Drug	B-Drug
effects	O
as	O
determined	O
by	O
difference	O
scores	O
between	O
2.0	O
mg	O
trihexyphenidyl	B-Chemical
and	O
placebo	O
on	O
ratings	O
of	O
mental	B-Disease
slowness	I-Disease
significantly	O
correlated	O
with	O
total	O
and	O
delayed	O
recall	O
on	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

However	O
,	O
no	O
significant	O
effects	O
were	O
found	O
with	O
other	O
visual	O
analog	O
scales	O
reflecting	O
subjective	O
sedation	O
and	O
clear-headedness	O
.	O

CONCLUSION	O
:	O
The	O
epsilon4	O
allele	O
in	O
healthy	O
elderly	O
was	O
associated	O
with	O
increased	O
subjective	O
mental	B-Disease
slowing	I-Disease
after	O
trihexyphenidyl	B-Chemical
anticholinergic	B-Drug
challenge	O
.	O

Behavioral	O
effects	O
of	O
pubertal	O
anabolic	O
androgenic	O
steroid	B-Chemical
exposure	O
in	O
male	O
rats	O
with	O
low	O
serotonin	B-Chemical
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactive	O
effects	O
of	O
chronic	O
anabolic	O
androgenic	O
steroid	B-Chemical
(	O
AAS	O
)	O
exposure	O
and	O
brain	O
serotonin	B-Chemical
(	O
5-hydroxytryptamine	B-Chemical
,	O
5-HT	B-Chemical
)	O
depletion	O
on	O
behavior	O
of	O
pubertal	O
male	O
rats	O
.	O

Serotonin	B-Chemical
was	O
depleted	O
beginning	O
on	O
postnatal	O
day	O
26	O
with	O
parachlorophenylalanine	B-Chemical
(	O
PCPA	B-Chemical
100	O
mg/kg	O
,	O
every	O
other	O
day	O
)	O
;	O
controls	O
received	O
saline	O
.	O

At	O
puberty	O
(	O
P40	O
)	O
,	O
half	O
the	O
PCPA-treated	B-Chemical
rats	O
and	O
half	O
the	O
saline-treated	O
rats	O
began	O
treatment	O
with	O
testosterone	B-Chemical
(	O
T	B-Chemical
,	O
5	O
mg/kg	O
,	O
5	O
days/week	O
)	O
.	O

Behavioral	O
measures	O
included	O
locomotion	O
,	O
irritability	B-Disease
,	O
copulation	O
,	O
partner	O
preference	O
,	O
and	O
aggression	B-Disease
.	O

Animals	O
were	O
tested	O
for	O
aggression	B-Disease
in	O
their	O
home	O
cage	O
,	O
both	O
with	O
and	O
without	O
physical	O
provocation	O
(	O
mild	O
tail	O
pinch	O
)	O
.	O

Brain	O
levels	O
of	O
5-HT	B-Chemical
and	O
its	O
metabolite	O
,	O
5-hydroxyindoleacetic	B-Chemical
acid	I-Chemical
(	O
5-HIAA	B-Chemical
)	O
,	O
were	O
determined	O
using	O
HPLC	O
.	O

PCPA	B-Chemical
significantly	O
and	O
substantially	O
depleted	O
5-HT	B-Chemical
and	O
5-HIAA	B-Chemical
in	O
all	O
brain	O
regions	O
examined	O
.	O

Chronic	O
T	B-Chemical
treatment	O
significantly	O
decreased	O
5-HT	B-Chemical
and	O
5-HIAA	B-Chemical
in	O
certain	O
brain	O
areas	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
PCPA	B-Chemical
.	O

Chronic	O
exposure	O
to	O
PCPA	B-Chemical
alone	O
significantly	O
decreased	O
locomotor	O
activity	O
and	O
increased	O
irritability	B-Disease
but	O
had	O
no	O
effect	O
on	O
sexual	O
behavior	O
,	O
partner	O
preference	O
,	O
or	O
aggression	B-Disease
.	O

T	B-Chemical
alone	O
had	O
no	O
effect	O
on	O
locomotion	O
,	O
irritability	B-Disease
,	O
or	O
sexual	O
behavior	O
but	O
increased	O
partner	O
preference	O
and	O
aggression	B-Disease
.	O

The	B-Chemical
most	O
striking	O
effect	O
of	O
combining	O
T+PCPA	B-Chemical
was	O
a	O
significant	O
increase	O
in	O
attack	O
frequency	O
as	O
well	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
latency	O
to	O
attack	O
,	O
particularly	O
following	O
physical	O
provocation	O
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	O
AAS	O
users	O
with	O
low	O
central	O
5-HT	B-Chemical
may	O
be	O
especially	O
prone	O
to	O
exhibit	O
aggressive	B-Disease
behavior	I-Disease
.	O

Intracavitary	O
chemotherapy	O
(	O
paclitaxel/carboplatin	B-Chemical
liquid	O
crystalline	O
cubic	O
phases	O
)	O
for	O
recurrent	O
glioblastoma	O
--	O
clinical	O
observations	O
.	O

Human	O
malignant	O
brain	B-Disease
tumors	I-Disease
have	O
a	O
poor	O
prognosis	O
in	O
spite	O
of	O
surgery	O
and	O
radiation	O
therapy	O
.	O

Cubic	O
phases	O
consist	O
of	O
curved	O
biocontinuous	O
lipid	O
bilayers	O
,	O
separating	O
two	O
congruent	O
networks	O
of	O
water	O
channels	O
.	O

Used	O
as	O
a	O
host	O
for	O
cytotoxic	O
drugs	B-Drug
,	O
the	O
gel-like	O
matrix	O
can	O
easily	O
be	O
applied	O
to	O
the	O
walls	O
of	O
a	O
surgical	O
resection	O
cavity	O
.	O

For	O
human	O
glioblastoma	B-Disease
recurrences	O
,	O
the	O
feasibility	O
,	O
safety	O
,	O
and	O
short-term	O
effects	O
of	O
a	O
surgical	O
intracavitary	O
application	O
of	O
paclitaxel	B-Chemical
and	O
carboplatin	B-Chemical
encapsulated	O
by	O
liquid	O
crystalline	O
cubic	O
phases	O
are	O
examined	O
in	O
a	O
pilot	O
study	O
.	O

A	O
total	O
of	O
12	O
patients	O
with	O
a	O
recurrence	O
of	O
a	O
glioblastoma	B-Disease
multiforme	O
underwent	O
re-resection	O
and	O
received	O
an	O
intracavitary	O
application	O
of	O
paclitaxel	B-Chemical
and	O
carboplatin	B-Chemical
cubic	O
phases	O
in	O
different	O
dosages	O
.	O

Six	O
of	O
the	O
patients	O
received	O
more	O
than	O
15	O
mg	O
paclitaxel	B-Chemical
and	O
suffered	O
from	O
moderate	O
to	O
severe	O
brain	B-Disease
edema	I-Disease
,	O
while	O
the	O
remaining	O
patients	O
received	O
only	O
a	O
total	O
of	O
15	O
mg	O
paclitaxel	B-Chemical
.	O

In	O
the	O
latter	O
group	O
,	O
brain	B-Disease
edema	I-Disease
was	O
markedly	O
reduced	O
and	O
dealt	O
medically	O
.	O

Intracavitary	O
chemotherapy	O
in	O
recurrent	O
glioblastoma	B-Disease
using	O
cubic	O
phases	O
is	O
feasible	O
and	O
safe	O
,	O
yet	O
the	O
clinical	O
benefit	O
remains	O
to	O
be	O
examined	O
in	O
a	O
clinical	O
phase	O
II	O
study	O
.	O

Methylphenidate-induced	B-Chemical
obsessive-compulsive	B-Disease
symptoms	I-Disease
in	O
an	O
elderly	O
man	O
.	O

An	O
82-year-old	O
man	O
with	O
treatment-resistant	B-Disease
depression	I-Disease
and	O
early	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
was	O
started	O
on	O
methylphenidate	B-Chemical
.	O

Significant	O
obsessive-compulsive	B-Disease
behavior	I-Disease
ensued	O
but	O
diminished	O
over	O
several	O
weeks	O
when	O
methylphenidate	B-Chemical
was	O
replaced	O
by	O
fluvoxamine	B-Chemical
.	O

The	O
patient	O
had	O
no	O
prior	O
psychiatric	B-Disease
history	O
,	O
but	O
he	O
had	O
a	O
sister	O
with	O
obsessive-compulsive	B-Disease
disorder	I-Disease
.	O

It	O
appears	O
that	O
methylphenidate	B-Chemical
precipitated	O
the	O
patient	O
's	O
pathological	O
behavior	O
.	O

Cardiac	B-Disease
arrest	I-Disease
after	O
intravenous	O
metoclopramide	B-Chemical
-	O
a	O
case	O
of	O
five	O
repeated	O
injections	O
of	O
metoclopramide	B-Chemical
causing	O
five	O
episodes	O
of	O
cardiac	B-Disease
arrest	I-Disease
.	O

We	O
describe	O
a	O
patient	O
where	O
intravenous	O
injection	O
of	O
metoclopramide	B-Chemical
was	O
immediately	O
followed	O
by	O
asystole	B-Disease
repeatedly	O
.	O

The	O
patient	O
received	O
metoclopramide	B-Chemical
10	O
mg	O
i.v	O
.	O

five	O
times	O
during	O
48	O
h.	O
After	O
interviewing	O
the	O
attending	O
nurses	O
and	O
reviewing	O
the	O
written	O
documentation	O
,	O
it	O
is	O
clear	O
that	O
every	O
administration	O
of	O
metoclopramide	B-Chemical
was	O
immediately	O
(	O
within	O
s	O
)	O
followed	O
by	O
asystole	B-Disease
.	O

The	O
asystole	B-Disease
lasted	O
15-30	O
s	O
on	O
four	O
occasions	O
,	O
on	O
one	O
occasion	O
it	O
lasted	O
2	O
min	O
.	O

The	O
patient	O
received	O
atropine	B-Chemical
0.5-1	O
mg	O
and	O
chest	O
compressions	O
,	O
before	O
sinus	O
rhythm	O
again	O
took	O
over	O
.	O

We	O
interpret	O
this	O
as	O
episodes	O
of	O
cardiac	B-Disease
arrest	I-Disease
caused	O
by	O
metoclopramide	B-Chemical
.	O

The	O
rapid	O
injection	O
via	O
the	O
central	O
venous	O
route	O
and	O
the	O
concomitant	O
tapering	O
of	O
dopamine	B-Chemical
infusion	O
might	O
have	O
contributed	O
in	O
precipitating	O
the	O
adverse	O
drug	B-Drug
reaction	O
.	O

Severe	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
associated	O
with	O
prophylactic	O
use	O
of	O
cefotetan	B-Chemical
in	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Second-	O
and	O
third-generation	O
cephalosporins	B-Chemical
,	O
especially	O
cefotetan	B-Chemical
,	O
are	O
increasingly	O
associated	O
with	O
severe	O
,	O
sometimes	O
fatal	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
.	O

We	O
noticed	O
that	O
10	O
of	O
our	O
35	O
cases	O
of	O
cefotetan-induced	B-Chemical
hemolytic	B-Disease
anemias	I-Disease
were	O
in	O
patients	O
who	O
had	O
received	O
cefotetan	B-Chemical
prophylactically	O
for	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Eight	O
of	O
these	O
cases	O
of	O
severe	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
are	O
described	O
.	O

Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
after	O
spinal	O
anaesthesia	O
with	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
:	O
a	O
review	O
of	O
six	O
cases	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
1993-1997	O
.	O

Six	O
cases	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
with	O
varying	O
severity	O
were	O
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
during	O
the	O
period	O
1993-1997	O
.	O

All	O
were	O
associated	O
with	O
spinal	O
anaesthesia	O
using	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
.	O

Five	O
cases	O
had	O
single-shot	O
spinal	O
anaesthesia	O
and	O
one	O
had	O
a	O
repeat	O
spinal	O
anaesthetic	O
due	O
to	O
inadequate	O
block	O
.	O

The	O
dose	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
administered	O
ranged	O
from	O
60	O
to	O
120	O
mg.	O
Three	O
of	O
the	O
cases	O
were	O
most	O
likely	O
caused	O
by	O
direct	O
neurotoxicity	B-Disease
of	O
hyperbaric	O
5	O
%	O
lignocaine	B-Chemical
.	O

In	O
the	O
other	O
3	O
cases	O
,	O
direct	O
neurotoxicity	B-Disease
was	O
also	O
probable	O
,	O
but	O
unfortunately	O
radiological	O
investigations	O
were	O
not	O
done	O
to	O
definitely	O
exclude	O
a	O
compressive	O
aetiology	O
.	O

All	O
cases	O
sustained	O
permanent	O
neurological	B-Disease
deficits	I-Disease
.	O

We	O
recommend	O
that	O
hyperbaric	O
lignocaine	B-Chemical
should	O
be	O
administered	O
in	O
concentrations	O
not	O
greater	O
than	O
2	O
%	O
and	O
at	O
a	O
total	O
dose	O
preferably	O
not	O
exceeding	O
60	O
mg	O
.	O

Cortical	O
motor	O
overactivation	O
in	O
parkinsonian	B-Disease
patients	O
with	O
L-dopa-induced	B-Chemical
peak-dose	O
dyskinesia	B-Disease
.	O

We	O
have	O
studied	O
the	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
changes	O
induced	O
by	O
the	O
execution	O
of	O
a	O
finger-to-thumb	O
opposition	O
motor	O
task	O
in	O
the	O
supplementary	O
and	O
primary	O
motor	O
cortex	O
of	O
two	O
groups	O
of	O
parkinsonian	B-Disease
patients	O
on	O
L-dopa	B-Chemical
medication	O
,	O
the	O
first	O
one	O
without	O
L-dopa	B-Chemical
induced	O
dyskinesia	B-Disease
(	O
n	O
=	O
23	O
)	O
and	O
the	O
other	O
with	O
moderate	O
peak-dose	O
dyskinesia	B-Disease
(	O
n	O
=	O
15	O
)	O
,	O
and	O
of	O
a	O
group	O
of	O
14	O
normal	O
subjects	O
.	O

Single	O
photon	O
emission	O
tomography	O
with	O
i.v	O
.	O

133Xe	O
was	O
used	O
to	O
measure	O
the	O
rCBF	O
changes	O
.	O

The	O
dyskinetic	B-Disease
parkinsonian	B-Disease
patients	O
exhibited	O
a	O
pattern	O
of	O
response	O
which	O
was	O
markedly	O
different	O
from	O
those	O
of	O
the	O
normal	O
subjects	O
and	O
non-dyskinetic	B-Disease
parkinsonian	B-Disease
patients	O
,	O
with	O
a	O
significant	O
overactivation	O
in	O
the	O
supplementary	O
motor	O
area	O
and	O
the	O
ipsi-	O
and	O
contralateral	O
primary	O
motor	O
areas	O
.	O

These	O
results	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
an	O
hyperkinetic	B-Disease
abnormal	B-Disease
involuntary	I-Disease
movement	I-Disease
,	O
like	O
L-dopa-induced	B-Chemical
peak	O
dose	O
dyskinesia	B-Disease
,	O
is	O
due	O
to	O
a	O
disinhibition	O
of	O
the	O
primary	O
and	O
associated	O
motor	O
cortex	O
secondary	O
to	O
an	O
excessive	O
outflow	O
of	O
the	O
pallidothalamocortical	O
motor	O
loop	O
.	O

Dexamethasone-induced	B-Chemical
ocular	B-Disease
hypertension	I-Disease
in	O
perfusion-cultured	O
human	O
eyes	O
.	O

PURPOSE	O
:	O
Glucocorticoid	O
administration	O
can	O
lead	B-Drug
to	O
the	O
development	O
of	O
ocular	B-Disease
hypertension	I-Disease
and	O
corticosteroid	B-Disease
glaucoma	I-Disease
in	O
a	O
subset	O
of	O
the	O
population	O
through	O
a	O
decrease	O
in	O
the	O
aqueous	O
humor	O
outflow	O
facility	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
glucocorticoid	O
treatment	O
can	O
directly	O
affect	O
the	O
outflow	O
facility	O
of	O
isolated	O
,	O
perfusion-cultured	O
human	O
eyes	O
.	O

METHODS	O
:	O
The	O
anterior	O
segments	O
of	O
human	O
donor	O
eyes	O
from	O
regional	O
eye	O
banks	O
were	O
placed	O
in	O
a	O
constant	O
flow	O
,	O
variable	O
pressure	O
perfusion	O
culture	O
system	O
.	O

Paired	O
eyes	O
were	O
perfused	O
in	O
serum-free	O
media	O
with	O
or	O
without	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	B-Chemical
for	O
12	O
days	O
.	O

Intraocular	O
pressure	O
was	O
monitored	O
daily	O
.	O

After	O
incubation	O
,	O
the	O
eyes	O
were	O
morphologically	O
characterized	O
by	O
light	O
microscopy	O
,	O
transmission	O
and	O
scanning	O
electron	O
microscopy	O
,	O
and	O
scanning	O
laser	O
confocal	O
microscopy	O
.	O

RESULTS	O
:	O
A	O
significant	O
increase	O
in	O
intraocular	O
pressure	O
developed	O
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	O
perfused	O
with	O
dexamethasone	B-Chemical
with	O
an	O
average	O
pressure	O
rise	O
of	O
17.5	O
+/-	O
3.8	O
mm	O
Hg	O
after	O
12	O
days	O
of	O
dexamethasone	B-Chemical
exposure	O
.	O

The	O
contralateral	O
control	O
eyes	O
,	O
which	O
did	O
not	O
receive	O
dexamethasone	B-Chemical
,	O
maintained	O
a	O
stable	O
intraocular	O
pressure	O
during	O
the	O
same	O
period	O
.	O

The	O
outflow	O
pathway	O
of	O
the	O
untreated	O
eyes	O
appeared	O
morphologically	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
dexamethasone-treated	B-Chemical
hypertensive	B-Disease
eyes	I-Disease
had	O
thickened	O
trabecular	O
beams	O
,	O
decreased	O
intertrabecular	O
spaces	O
,	O
thickened	O
juxtacanalicular	O
tissue	O
,	O
activated	O
trabecular	O
meshwork	O
cells	O
,	O
and	O
increased	O
amounts	O
of	O
amorphogranular	O
extracellular	O
material	O
,	O
especially	O
in	O
the	O
juxtacanalicular	O
tissue	O
and	O
beneath	O
the	O
endothelial	O
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O

The	O
dexamethasone-treated	B-Chemical
nonresponder	O
eyes	O
appeared	O
to	O
be	O
morphologically	O
similar	O
to	O
the	O
untreated	O
eyes	O
,	O
although	O
several	O
subtle	O
dexamethasone-induced	B-Chemical
morphologic	O
changes	O
were	O
evident	O
.	O

CONCLUSION	O
:	O
Dexamethasone	B-Chemical
treatment	O
of	O
isolated	O
,	O
perfusion-cultured	O
human	O
eyes	O
led	O
to	O
the	O
generation	O
of	O
ocular	B-Disease
hypertension	I-Disease
in	O
approximately	O
30	O
%	O
of	O
the	O
dexamethasone-treated	B-Chemical
eyes	O
.	O

Steroid	B-Chemical
treatment	O
resulted	O
in	O
morphologic	O
changes	O
in	O
the	O
trabecular	O
meshwork	O
similar	O
to	O
those	O
reported	O
for	O
corticosteroid	B-Disease
glaucoma	I-Disease
and	O
open	B-Disease
angle	I-Disease
glaucoma	I-Disease
.	O

This	O
system	O
may	O
provide	O
an	O
acute	O
model	O
in	O
which	O
to	O
study	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
steroid	B-Disease
glaucoma	I-Disease
and	O
primary	B-Disease
open	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O

Cognitive	B-Disease
deterioration	I-Disease
from	O
long-term	O
abuse	O
of	O
dextromethorphan	B-Chemical
:	O
a	O
case	O
report	O
.	O

Dextromethorphan	B-Chemical
(	O
DM	B-Chemical
)	O
,	O
the	O
dextrorotatory	O
isomer	O
of	O
3-hydroxy-N-methylmorphinan	B-Chemical
,	O
is	O
the	O
main	O
ingredient	O
in	O
a	O
number	O
of	O
widely	O
available	O
,	O
over-the-counter	O
antitussives	O
.	O

Initial	O
studies	O
(	O
Bornstein	O
1968	O
)	O
showed	O
that	O
it	O
possessed	O
no	O
respiratory	O
suppressant	O
effects	O
and	O
no	O
addiction	O
liability	O
.	O

Subsequently	O
,	O
however	O
,	O
several	O
articles	O
reporting	O
abuse	O
of	O
this	O
drug	B-Drug
have	O
appeared	O
in	O
the	O
literature	O
.	O

The	O
drug	B-Drug
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	B-Disease
,	O
restlessness	B-Disease
,	O
insomnia	B-Disease
,	O
ataxia	B-Disease
,	O
slurred	O
speech	O
and	O
nystagmus	B-Disease
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	B-Disease
behavior	I-Disease
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O

There	O
have	O
also	O
been	O
two	O
reported	O
fatalities	O
from	O
DM	B-Chemical
overdoses	O
(	O
Fleming	O
1986	O
)	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
describing	O
the	O
effects	O
of	O
chronic	O
abuse	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
cognitive	B-Disease
deterioration	I-Disease
resulting	O
from	O
prolonged	O
use	O
of	O
DM	B-Chemical
.	O

Long-term	O
lithium	B-Chemical
treatment	O
and	O
the	O
kidney	O
.	O

Interim	O
report	O
on	O
fifty	O
patients	O
.	O

This	O
is	O
a	O
report	O
on	O
the	O
first	O
part	O
of	O
our	O
study	O
of	O
the	O
effects	O
of	O
long-term	O
lithium	B-Chemical
treatment	O
on	O
the	O
kidney	O
.	O

Creatinine	B-Chemical
clearance	O
,	O
maximum	O
urinary	O
osmolality	O
and	O
24	O
hour	O
urine	O
volume	O
have	O
been	O
tested	O
in	O
50	O
affectively	O
ill	O
patients	O
who	O
have	O
been	O
on	O
long-term	O
lithium	B-Chemical
for	O
more	O
than	O
one	O
year	O
.	O

These	O
findings	O
have	O
been	O
compared	O
with	O
norms	O
and	O
with	O
values	O
of	O
the	O
same	O
tests	O
from	O
screening	O
prior	O
to	O
lithium	B-Chemical
,	O
available	O
for	O
most	O
of	O
our	O
patients	O
.	O

No	O
evidence	O
was	O
found	O
for	O
any	O
reduction	O
of	O
glomerular	O
filtration	O
during	O
lithium	B-Chemical
treatment	O
.	O

Low	O
clearance	O
values	O
found	O
in	O
several	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
their	O
age	O
and	O
their	O
pre-lithium	B-Chemical
values	O
.	O

Urinary	O
concentration	O
defect	O
appeared	O
frequent	O
but	O
the	O
extent	O
of	O
the	O
impairment	O
is	O
difficult	O
to	O
assess	O
because	O
of	O
the	O
uncertainty	O
about	O
the	O
norms	O
applicable	O
to	O
this	O
group	O
of	O
patients	O
.	O

The	O
concentration	O
defect	O
appeared	O
reversible	O
,	O
at	O
least	O
in	O
part	O
.	O

Polyuria	B-Disease
above	O
3	O
litres/24	O
hours	O
was	O
found	O
in	O
10	O
%	O
of	O
patients	O
.	O

An	O
attempt	O
is	O
made	O
to	O
draw	O
practical	O
conclusions	O
from	O
the	O
preliminary	O
findings	O
.	O

Complete	O
heart	B-Disease
block	I-Disease
following	O
a	O
single	O
dose	O
of	O
trazodone	B-Chemical
.	O

Forty	O
minutes	O
after	O
receiving	O
a	O
single	O
starting	O
dose	O
of	O
trazodone	B-Chemical
,	O
a	O
patient	O
developed	O
complete	O
heart	B-Disease
block	I-Disease
.	O

The	O
case	O
illustrates	O
that	O
,	O
despite	O
the	O
results	O
of	O
earlier	O
studies	O
,	O
trazodone	B-Chemical
's	O
effect	O
on	O
cardiac	O
conduction	O
may	O
be	O
severe	O
in	O
individuals	O
at	O
risk	O
for	O
conduction	O
delay	O
.	O

Quinidine	B-Chemical
phenylethylbarbiturate-induced	O
fulminant	O
hepatitis	O
in	O
a	O
pregnant	O
woman	O
.	O

A	O
case	O
report	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
19-year-old	O
Laotian	O
patient	O
affected	O
by	O
fulminant	O
hepatitis	B-Disease
during	O
the	O
third	O
trimester	O
of	O
her	O
pregnancy	O
after	O
a	O
1-month	O
administration	O
of	O
quinidine	B-Chemical
phenylethylbarbiturate	I-Chemical
.	O

After	O
delivery	O
,	O
the	O
patient	O
underwent	O
orthotopic	O
liver	O
transplantation	O
.	O

The	O
patient	O
was	O
in	O
good	O
condition	O
16	O
months	O
after	O
liver	O
transplantation	O
.	O

Quinidine	B-Chemical
itself	O
or	O
phenylethylbarbiturate	B-Chemical
may	O
be	O
responsible	O
for	O
fulminant	O
hepatitis	B-Disease
in	O
this	O
patient	O
.	O

The	O
epidemiology	O
of	O
the	O
acute	O
flank	B-Disease
pain	I-Disease
syndrome	O
from	O
suprofen	B-Chemical
.	O

Suprofen	B-Chemical
,	O
a	O
new	O
nonsteroidal	O
anti-inflammatory	O
drug	B-Drug
,	O
was	O
marketed	O
in	O
early	O
1986	O
as	O
an	O
analgesic	O
agent	O
.	O

Until	O
physicians	O
began	O
reporting	O
an	O
unusual	O
acute	O
flank	B-Disease
pain	I-Disease
syndrome	O
to	O
the	O
spontaneous	O
reporting	O
system	O
,	O
700,000	O
persons	O
used	O
the	O
drug	B-Drug
in	O
the	O
United	O
States	O
.	O

Through	O
August	O
1986	O
,	O
a	O
total	O
of	O
163	O
cases	O
of	O
this	O
syndrome	O
were	O
reported	O
.	O

To	O
elucidate	O
the	O
epidemiology	O
of	O
the	O
syndrome	O
,	O
a	O
case-control	O
study	O
was	O
performed	O
,	O
comparing	O
62	O
of	O
the	O
case	O
patients	O
who	O
had	O
been	O
reported	O
to	O
the	O
spontaneous	O
reporting	O
system	O
to	O
185	O
suprofen-exposed	B-Chemical
control	O
subjects	O
who	O
did	O
not	O
have	O
the	O
syndrome	O
.	O

Case	O
patients	O
were	O
more	O
likely	O
to	O
be	O
men	O
(	O
odds	O
ratio	O
,	O
3.8	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.2-12.1	O
)	O
,	O
suffer	O
from	O
hay	B-Disease
fever	I-Disease
and	O
asthma	B-Disease
(	O
odds	O
ratio	O
,	O
3.4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.0-11.9	O
)	O
;	O
to	O
participate	O
in	O
regular	O
exercise	O
(	O
odds	O
ratio	O
,	O
5.9	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.1-30.7	O
)	O
,	O
especially	O
in	O
the	O
use	O
of	O
Nautilus	O
equipment	O
(	O
p	O
=	O
0.02	O
)	O
;	O
and	O
to	O
use	O
alcohol	B-Chemical
(	O
odds	O
ratio	O
,	O
4.4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.1-17.5	O
)	O
.	O

Possible	O
risk	O
factors	O
included	O
young	O
age	O
,	O
concurrent	O
use	O
of	O
other	O
analgesic	O
agents	O
(	O
especially	O
ibuprofen	B-Chemical
)	O
,	O
preexisting	O
renal	B-Disease
disease	I-Disease
,	O
a	O
history	O
of	O
kidney	B-Disease
stones	I-Disease
,	O
a	O
history	O
of	O
gout	B-Disease
,	O
a	O
recent	O
increase	O
in	O
activity	O
,	O
a	O
recent	O
increase	O
in	O
sun	O
exposure	O
,	O
and	O
residence	O
in	O
the	O
Sunbelt	O
.	O

These	O
were	O
findings	O
that	O
were	O
suggestive	O
but	O
did	O
not	O
reach	O
conventional	O
statistical	O
significance	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
mechanism	O
for	O
this	O
unusual	O
syndrome	O
:	O
acute	O
diffuse	O
crystallization	O
of	O
uric	B-Chemical
acid	I-Chemical
in	O
renal	O
tubules	O
.	O

Hemolytic-uremic	B-Disease
syndrome	I-Disease
associated	O
with	O
ingestion	O
of	O
quinine	B-Chemical
.	O

Hemolytic-uremic	B-Disease
syndrome	I-Disease
following	O
quinine	B-Chemical
ingestion	O
is	O
a	O
newly	O
described	O
phenomenon	O
,	O
with	O
just	O
two	O
previous	O
descriptions	O
of	O
4	O
cases	O
in	O
the	O
literature	O
.	O

We	O
describe	O
a	O
5th	O
case	O
.	O

The	O
reaction	O
may	O
be	O
mediated	O
by	O
the	O
presence	O
of	O
antibodies	O
reactive	O
against	O
platelets	O
in	O
the	O
presence	O
of	O
quinine	B-Chemical
.	O

Treatment	O
has	O
included	O
use	O
of	O
plasma	O
exchange	O
,	O
prednisone	B-Chemical
,	O
aspirin	B-Chemical
,	O
and	O
dipyridamole	B-Chemical
.	O

The	O
patients	O
have	O
all	O
regained	O
some	O
degree	O
of	O
renal	O
function	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
pharmacological	O
treatment	O
or	O
spontaneous	O
resolution	O
is	O
responsible	O
for	O
the	O
improvement	O
.	O

Quinine-associated	B-Chemical
hemolytic-uremic	B-Disease
syndrome	I-Disease
probably	O
occurs	O
more	O
often	O
than	O
is	O
recognized	O
.	O

It	O
is	O
important	O
to	O
recognize	O
this	O
reaction	O
when	O
it	O
occurs	O
and	O
to	O
avoid	O
further	O
quinine	B-Chemical
exposure	O
,	O
since	O
the	O
reaction	O
seems	O
to	O
be	O
recurrent	O
.	O

Pyeloureteral	O
filling	O
defects	O
associated	O
with	O
systemic	O
anticoagulation	O
:	O
a	O
case	O
report	O
.	O

The	O
etiology	O
of	O
pyeloureteritis	B-Disease
cystica	I-Disease
has	O
long	O
been	O
attributed	O
to	O
chronic	O
infection	B-Disease
and	O
inflammation	B-Disease
.	O

A	O
case	O
is	O
presented	O
that	O
is	O
unique	O
in	O
that	O
the	O
acute	O
onset	O
and	O
the	O
rapid	O
resolution	O
of	O
pyeloureteral	O
filling	O
defects	O
in	O
this	O
patient	O
were	O
documented	O
by	O
radiography	O
.	O

There	O
is	O
no	O
evidence	O
of	O
antecedent	O
or	O
concurrent	O
infection	B-Disease
in	O
this	O
patient	O
.	O

The	O
disease	O
occurred	O
subsequent	O
to	O
the	O
initiation	O
of	O
heparin	B-Chemical
therapy	O
for	O
suspected	O
pelvic	O
thrombophlebitis	B-Disease
and	O
cleared	O
rapidly	O
subsequent	O
to	O
its	O
discontinuation	O
.	O

The	O
rate	O
of	O
resolution	O
of	O
the	O
radiographic	O
findings	O
may	O
be	O
helpful	O
in	O
distinguishing	O
between	O
true	O
pyeloureteritis	B-Disease
cystica	I-Disease
and	O
submucosal	B-Disease
hemorrhage	I-Disease
.	O

Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	O
liver	O
and	O
hepatoma	B-Disease
of	O
mice	O
induced	O
by	O
alpha-benzene	B-Chemical
hexachloride	I-Chemical
.	O

Peroxisomes	O
in	O
hepatomas	B-Disease
and	O
hyperplastic	O
preneoplastic	O
liver	B-Disease
lesions	I-Disease
induced	O
in	O
mice	O
by	O
500	O
ppm	O
alpha-benzene	B-Chemical
hexachloride	I-Chemical
were	O
examined	O
histochemically	O
and	O
electron	O
microscopically	O
.	O

Although	O
most	O
of	O
the	O
hepatomas	B-Disease
were	O
well-differentiated	O
tumors	B-Disease
and	O
contained	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
,	O
the	O
tumor	B-Disease
cells	O
did	O
not	O
respond	O
to	O
ethyl-alpha-p-chlorophenoxyisobutyrate	B-Chemical
with	O
proliferation	O
of	O
peroxisomes	O
.	O

At	O
the	O
16th	O
week	O
of	O
carcinogen	O
feeding	O
,	O
hyperplastic	O
nodules	O
appeared	O
and	O
advanced	O
to	O
further	O
stages	O
.	O

A	O
majority	O
of	O
the	O
nodules	O
showed	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
and	O
the	O
inductive	O
proliferation	O
of	O
peroxisomes	O
.	O

Within	O
the	O
nodules	O
,	O
foci	O
of	O
proliferation	O
of	O
the	O
cells	O
that	O
showed	O
no	O
inducibility	O
of	O
proliferation	O
of	O
peroxisomes	O
appeared	O
.	O

These	O
cells	O
proliferated	O
further	O
,	O
replacing	O
the	O
most	O
part	O
of	O
the	O
nodules	O
,	O
and	O
with	O
this	O
process	O
hepatomas	B-Disease
appeared	O
to	O
have	O
been	O
formed	O
.	O

No	O
abnormal	O
matrical	O
inclusions	O
of	O
peroxisomes	O
were	O
formed	O
in	O
the	O
cells	O
of	O
hyperplastic	O
nodules	O
by	O
ethyl-alpha-p-chlorophenoxyisobutyrate	B-Chemical
unlike	O
in	O
the	O
case	O
of	O
rats	O
.	O

Quinidine	B-Chemical
hepatitis	B-Disease
.	O

Long-term	O
administration	O
of	O
quinidine	B-Chemical
was	O
associated	O
with	O
persistent	O
elevation	O
of	O
serum	O
concentrations	O
of	O
SGOT	O
,	O
lactic	B-Chemical
acid	I-Chemical
dehydrogenase	O
,	O
and	O
alkaline	O
phosphatase	O
.	O

Liver	O
biopsy	O
showed	O
active	O
hepatitis	B-Disease
.	O

Discontinuance	O
of	O
quinidine	B-Chemical
therapy	O
led	O
to	O
normalization	O
of	O
liver	O
function	O
tests	O
.	O

A	O
challenge	O
dose	O
of	O
quinidine	B-Chemical
caused	O
clinical	O
symptoms	O
and	O
abrupt	O
elevation	O
of	O
SGOT	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
lactic	B-Chemical
acid	I-Chemical
dehydrogenase	O
values	O
.	O

We	O
concluded	O
that	O
this	O
patient	O
had	O
quinidine	B-Chemical
hepatotoxicity	B-Disease
and	O
believe	O
that	O
this	O
is	O
the	O
first	O
case	O
reported	O
with	O
liver	O
biopsy	O
documentation	O
.	O

This	O
report	O
also	O
suggests	O
that	O
,	O
even	O
after	O
long-term	O
administration	O
,	O
the	O
hepatic	B-Disease
toxicity	I-Disease
is	O
reversible	O
.	O

Cholesteryl	B-Chemical
hemisuccinate	I-Chemical
treatment	O
protects	O
rodents	O
from	O
the	O
toxic	O
effects	O
of	O
acetaminophen	B-Chemical
,	O
adriamycin	B-Chemical
,	O
carbon	B-Chemical
tetrachloride	I-Chemical
,	O
chloroform	B-Chemical
and	O
galactosamine	B-Chemical
.	O

In	O
addition	O
to	O
its	O
use	O
as	O
a	O
stabilizer/rigidifier	O
of	O
membranes	O
,	O
cholesteryl	B-Chemical
hemisuccinate	I-Chemical
,	O
tris	B-Chemical
salt	I-Chemical
(	O
CS	B-Chemical
)	O
administration	O
has	O
also	O
been	O
shown	O
to	O
protect	O
rats	O
from	O
the	O
hepatotoxic	B-Disease
effects	O
of	O
carbon	B-Chemical
tetrachloride	I-Chemical
(	O
CCl4	B-Chemical
)	O
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
mechanism	O
of	O
CS	B-Chemical
cytoprotection	O
,	O
we	O
examined	O
in	O
rats	O
and	O
mice	O
the	O
protective	O
abilities	O
of	O
CS	B-Chemical
and	O
the	O
non-hydrolyzable	O
ether	O
form	O
of	O
CS	B-Chemical
,	O
gamma-cholesteryloxybutyric	B-Chemical
acid	I-Chemical
,	O
tris	B-Chemical
salt	I-Chemical
(	O
CSE	B-Chemical
)	O
against	O
acetaminophen-	B-Chemical
,	O
adriamycin-	B-Chemical
,	O
carbon	B-Chemical
tetrachloride-	O
,	O
chloroform-	O
and	O
galactosamine-induced	O
toxicity	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrated	O
that	O
CS-mediated	O
protection	O
is	O
not	O
selective	O
for	O
a	O
particular	O
species	O
,	O
organ	O
system	O
or	O
toxic	O
chemical	O
.	O

A	O
24-h	O
pretreatment	O
of	O
both	O
rats	O
and	O
mice	O
with	O
a	O
single	O
dose	O
of	O
CS	O
(	O
100mg/kg	O
,	O
i.p	O
.	O

)	O
,	O
resulted	O
in	O
significant	O
protection	O
against	O
the	O
hepatotoxic	O
effects	O
of	O
CCl4	O
,	O
CHCl3	O
,	O
acetaminophen	B-Drug
and	O
galactosamine	O
and	O
against	O
the	O
lethal	O
(	O
and	O
presumably	O
cardiotoxic	O
)	O
effect	O
of	O
adriamycin	O
administration	O
.	O

Maximal	O
CS-mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

These	O
data	O
suggest	O
that	O
CS	O
intervenes	O
in	O
a	O
critical	O
cellular	O
event	O
that	O
is	O
an	O
important	O
common	O
pathway	O
to	O
toxic	O
cell	O
death	O
.	O

The	O
mechanism	O
of	O
CS	O
protection	O
does	O
not	O
appear	O
to	O
be	O
dependent	O
on	O
the	O
inhibition	O
of	O
chemical	O
bioactivation	O
to	O
a	O
toxic	O
reactive	O
intermediate	O
(	O
in	O
light	O
of	O
the	O
protection	O
observed	O
against	O
galactosamine	O
hepatotoxicity	O
)	O
.	O

However	O
,	O
based	O
on	O
the	O
data	O
presented	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
CS	O
administration	O
inhibits	O
chemical	O
bioactivation	O
.	O

Our	O
findings	O
do	O
suggest	O
that	O
CS-mediated	O
protection	O
is	O
dependent	O
on	O
the	O
action	O
of	O
the	O
intact	O
anionic	O
CS	O
molecule	O
(	O
non-hydrolyzable	O
CSE	O
was	O
as	O
protective	O
as	O
CS	O
)	O
,	O
whose	O
mechanism	O
has	O
yet	O
to	O
be	O
defined	O
.	O

DSMM	O
XI	O
study	O
:	O
dose	O
definition	O
for	O
intravenous	O
cyclophosphamide	B-Chemical
in	O
combination	O
with	O
bortezomib/dexamethasone	B-Chemical
for	O
remission	O
induction	O
in	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	O
.	O

A	O
clinical	O
trial	O
was	O
initiated	O
to	O
evaluate	O
the	O
recommended	O
dose	O
of	O
cyclophosphamide	B-Chemical
in	O
combination	O
with	O
bortezomib	B-Chemical
and	O
dexamethasone	B-Chemical
as	O
induction	O
treatment	O
before	O
stem	O
cell	O
transplantation	O
for	O
younger	O
patients	O
with	O
newly	O
diagnosed	O
multiple	B-Disease
myeloma	I-Disease
(	O
MM	B-Disease
)	O
.	O

Thirty	O
patients	O
were	O
treated	O
with	O
three	O
21-day	O
cycles	O
of	O
bortezomib	B-Chemical
1.3	O
mg/m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
plus	O
dexamethasone	B-Chemical
40	O
mg	O
on	O
the	O
day	O
of	O
bortezomib	B-Chemical
injection	O
and	O
the	O
day	O
after	O
plus	O
cyclophosphamide	B-Chemical
at	O
900	O
,	O
1,200	O
,	O
or	O
1,500	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
.	O

The	O
maximum	O
tolerated	O
dose	O
of	O
cyclophosphamide	B-Chemical
was	O
defined	O
as	O
900	O
mg/m	O
(	O
2	O
)	O
.	O

At	O
this	O
dose	O
level	O
,	O
92	O
%	O
of	O
patients	O
achieved	O
at	O
least	O
a	O
partial	O
response	O
.	O

The	O
overall	O
response	O
rate	O
[	O
complete	O
response	O
(	O
CR	O
)	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
]	O
across	O
all	O
dose	O
levels	O
was	O
77	O
%	O
,	O
with	O
a	O
10	O
%	O
CR	O
rate	O
.	O

No	O
patient	O
experienced	O
progressive	O
disease	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
were	O
hematological	B-Disease
and	I-Disease
gastrointestinal	I-Disease
toxicities	I-Disease
as	O
well	O
as	O
neuropathy	O
.	O

The	O
results	O
suggest	O
that	O
bortezomib	B-Drug
in	O
combination	O
with	O
cyclophosphamide	B-Drug
at	O
900	O
mg/m	O
(	O
2	O
)	O
and	O
dexamethasone	B-Drug
is	O
an	O
effective	O
induction	O
treatment	O
for	O
patients	O
with	O
newly	O
diagnosed	O
MM	O
that	O
warrants	O
further	O
investigation	O
.	O

Results	O
of	O
a	O
comparative	O
,	O
phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
assessment	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
fixed-dose	O
combination	O
of	O
telmisartan	B-Chemical
and	O
amlodipine	B-Chemical
versus	O
amlodipine	B-Chemical
monotherapy	O
in	O
Indian	O
adults	O
with	O
stage	O
II	O
hypertension	B-Disease
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
new	O
fixed-dose	O
combination	O
(	O
FDC	O
)	O
of	O
telmisartan	B-Chemical
40	O
mg	O
+	O
amlodipine	B-Chemical
5	O
mg	O
(	O
T+A	O
)	O
compared	O
with	O
amlodipine	B-Chemical
5-mg	O
monotherapy	O
(	O
A	O
)	O
in	O
adult	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	B-Disease
.	O

METHODS	O
:	O
This	O
comparative	O
,	O
Phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
was	O
conducted	O
in	O
Indian	O
patients	O
aged	O
18	O
to	O
65	O
years	O
with	O
established	O
stage	O
II	O
hypertension	B-Disease
.	O

Patients	O
were	O
treated	O
with	O
oral	O
FDC	O
of	O
T+A	O
or	O
A	O
QD	O
before	O
breakfast	O
for	O
12	O
weeks	O
;	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
heart	O
rate	O
were	O
measured	O
in	O
the	O
sitting	O
position	O
.	O

Primary	O
efficacy	O
end	O
points	O
were	O
reduction	O
in	O
clinical	O
systolic	O
BP	O
(	O
SBP	O
)	O
/	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
to	O
study	O
end	O
and	O
number	O
of	O
responders	O
(	O
ie	O
,	O
patients	O
who	O
achieved	O
target	O
SBP/	O
DBP	O
<	O
130/	O
<	O
80	O
mm	O
Hg	O
)	O
at	O
end	O
of	O
study	O
.	O

Tolerability	O
was	O
assessed	O
by	O
treatment-emergent	O
adverse	O
events	O
,	O
identified	O
using	O
physical	O
examination	O
,	O
laboratory	O
analysis	O
,	O
and	O
electrocardiography	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
210	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
;	O
203	O
patients	O
(	O
143	O
men	O
,	O
60	O
women	O
)	O
completed	O
the	O
study	O
while	O
7	O
were	O
lost	O
to	O
follow-up	O
(	O
4	O
patients	O
in	O
the	O
T+A	O
group	O
and	O
3	O
in	O
the	O
A	O
group	O
)	O
and	O
considered	O
with-drawn	O
.	O

At	O
study	O
end	O
,	O
statistically	O
significant	O
percentage	O
reductions	O
from	O
baseline	O
within	O
groups	O
and	O
between	O
groups	O
were	O
observed	O
in	O
SBP	O
(	O
T+A	O
[	O
-27.4	O
%	O
]	O
;	O
A	O
[	O
-16.6	O
%	O
]	O
)	O
and	O
DBP	O
(	O
T+A	O
[	O
-20.1	O
%	O
]	O
;	O
A	O
[	O
-13.3	O
%	O
]	O
)	O
(	O
all	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Response	O
rates	O
were	O
87.3	O
%	O
(	O
89/102	O
)	O
in	O
the	O
T+A	O
group	O
and	O
69.3	O
%	O
(	O
70/101	O
)	O
in	O
the	O
A	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
prevalences	O
of	O
adverse	O
events	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
treatment	O
groups	O
(	O
T+A	O
,	O
16.0	O
%	O
[	O
17/106	O
]	O
;	O
A	O
,	O
15.4	O
%	O
[	O
16/104	O
]	O
)	O
.	O

Peripheral	O
edema	B-Disease
was	O
reported	O
in	O
8.5	O
%	O
patients	O
(	O
9/106	O
)	O
in	O
the	O
T+A	O
group	O
compared	O
with	O
13.5	O
%	O
(	O
14/104	O
)	O
in	O
the	O
A	O
group	O
,	O
and	O
cough	B-Disease
was	O
reported	O
in	O
3.8	O
%	O
patients	O
(	O
4/106	O
)	O
in	O
the	O
T+A	O
group	O
and	O
1.0	O
%	O
(	O
1/104	O
)	O
patients	O
in	O
the	O
A	O
group	O
;	O
these	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
incidences	O
of	O
headache	B-Disease
,	O
dizziness	B-Disease
,	O
and	O
diarrhea	B-Disease
were	O
similar	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
:	O
Among	O
these	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	B-Disease
,	O
the	O
FDC	O
of	O
T+A	O
was	O
found	O
to	O
be	O
significantly	O
more	O
effective	O
,	O
with	O
regard	O
to	O
BP	O
reductions	O
,	O
than	O
A	O
,	O
and	O
both	O
treatments	O
were	O
well	O
tolerated	O
.	O

Cutaneous	B-Disease
leucocytoclastic	I-Disease
vasculitis	I-Disease
associated	O
with	O
oxacillin	B-Chemical
.	O

A	O
67-year-old	O
man	O
who	O
was	O
treated	O
with	O
oxacillin	B-Chemical
for	O
one	O
week	O
because	O
of	O
Staphylococcus	B-Disease
aureus	I-Disease
bacteremia	I-Disease
,	O
developed	O
renal	O
failure	O
and	O
diffuse	O
,	O
symmetric	O
,	O
palpable	O
purpuric	O
lesions	O
on	O
his	O
feet	O
.	O

Necrotic	O
blisters	O
were	O
noted	O
on	O
his	O
fingers	O
.	O

Skin	O
biopsies	O
showed	O
findings	O
diagnostic	O
of	O
leucocytoclastic	O
vasculitis	O
.	O

Oxacillin	B-Drug
was	O
discontinued	O
and	O
patient	O
was	O
treated	O
with	O
corticosteroids	O
.	O

The	O
rash	O
disappeared	O
after	O
three	O
weeks	O
and	O
renal	O
function	O
returned	O
to	O
normal	O
.	O

Leucocytoclastic	O
vasculitis	O
presents	O
as	O
palpable	O
purpura	O
of	O
the	O
lower	O
extremities	O
often	O
accompanied	O
by	O
abdominal	O
pain	O
,	O
arthralgia	O
,	O
and	O
renal	O
involvement	O
.	O

Etiologic	O
factors	O
or	O
associated	O
disorders	O
include	O
infections	O
,	O
medications	O
,	O
collagen	O
vascular	O
disease	O
and	O
neoplasia	O
.	O

However	O
,	O
in	O
half	O
of	O
the	O
cases	O
no	O
etiologic	O
factor	O
is	O
identified	O
.	O

Usually	O
it	O
is	O
a	O
self-limited	O
disorder	O
,	O
but	O
corticosteroid	B-Drug
therapy	O
may	O
be	O
needed	O
in	O
life-threatening	O
cases	O
since	O
early	O
treatment	O
with	O
corticosteroids	O
in	O
severe	O
cases	O
can	O
prevent	O
complications	O
.	O

Oxacillin	B-Drug
should	O
be	O
included	O
among	O
the	O
drugs	B-Drug
that	O
can	O
cause	O
leucocytoclastic	O
vasculitis	O
.	O

Naloxazone	B-Chemical
pretreatment	O
modifies	O
cardiorespiratory	O
,	O
temperature	O
,	O
and	O
behavioral	O
effects	O
of	O
morphine	B-Chemical
.	O

Behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
a	O
lethal	O
dose	O
of	O
morphine	B-Chemical
were	O
evaluated	O
in	O
rats	O
pretreated	O
with	O
saline	O
or	O
naloxazone	B-Chemical
,	O
an	O
antagonist	O
of	O
high-affinity	O
mu	O
1	O
opioid	O
receptors	O
.	O

Pretreatment	O
with	O
naloxazone	B-Chemical
significantly	O
blocked	O
morphine	B-Chemical
analgesia	B-Disease
,	O
catalepsy	B-Disease
and	O
hypothermia	B-Disease
at	O
a	O
dose	O
which	O
completely	O
eliminated	O
high-affinity	O
binding	O
in	O
brain	O
membranes	O
.	O

Moreover	O
,	O
naloxazone	B-Chemical
significantly	O
attenuated	O
the	O
morphine-induced	B-Chemical
hypotension	B-Disease
and	O
respiratory	B-Disease
depression	I-Disease
,	O
whereas	O
morphine-induced	B-Chemical
bradycardia	B-Disease
was	O
less	O
affected	O
.	O

Results	O
indicate	O
that	O
subpopulations	O
of	O
mu	O
receptors	O
may	O
mediate	O
selective	O
behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
morphine	B-Chemical
.	O

Dexrazoxane	B-Chemical
protects	O
against	O
myelosuppression	B-Disease
from	O
the	O
DNA	O
cleavage-enhancing	O
drugs	B-Drug
etoposide	B-Chemical
and	O
daunorubicin	B-Chemical
but	O
not	O
doxorubicin	B-Chemical
.	O

PURPOSE	O
:	O
The	O
anthracyclines	B-Chemical
daunorubicin	B-Chemical
and	O
doxorubicin	B-Chemical
and	O
the	O
epipodophyllotoxin	B-Chemical
etoposide	B-Chemical
are	O
potent	O
DNA	O
cleavage-enhancing	O
drugs	B-Drug
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	B-Disease
and	O
cardiac	B-Disease
toxicity	I-Disease
limit	O
their	O
use	O
.	O

Dexrazoxane	B-Chemical
(	O
ICRF-187	B-Chemical
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline-induced	B-Chemical
cardiotoxicity	B-Disease
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	B-Disease
toxicity	I-Disease
following	O
coadministration	O
of	O
dexrazoxane	B-Chemical
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	B-Drug
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	O
and	O
murine	O
blood	O
progenitor	O
cells	O
to	O
etoposide	B-Chemical
,	O
daunorubicin	B-Chemical
,	O
and	O
doxorubicin	B-Chemical
+/-	O
dexrazoxane	B-Chemical
was	O
determined	O
in	O
granulocyte-macrophage	O
colony	O
forming	O
assays	O
.	O

Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	O
were	O
treated	O
with	O
etoposide	B-Chemical
,	O
daunorubicin	B-Chemical
,	O
and	O
doxorubicin	B-Chemical
,	O
with	O
or	O
without	O
dexrazoxane	B-Chemical
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	B-Chemical
reduced	O
myelosuppression	B-Disease
and	O
weight	B-Disease
loss	I-Disease
from	O
daunorubicin	B-Chemical
and	O
etoposide	B-Chemical
in	O
mice	O
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	B-Chemical
neither	O
reduced	O
myelosuppression	B-Disease
,	O
weight	B-Disease
loss	I-Disease
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	B-Disease
from	O
doxorubicin	B-Chemical
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	B-Chemical
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	B-Chemical
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	B-Chemical
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	B-Chemical
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	B-Chemical
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	B-Disease
combining	O
dexrazoxane	B-Chemical
and	O
high	O
doses	O
of	O
etoposide	B-Chemical
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	B-Disease
toxicity	I-Disease
.	O

If	O
successful	O
,	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	O
chemotherapy	O
.	O

Effects	O
of	O
the	O
novel	O
compound	O
aniracetam	B-Chemical
(	O
Ro	B-Chemical
13-5057	I-Chemical
)	O
upon	O
impaired	B-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
in	O
rodents	O
.	O

The	O
effect	O
of	O
aniracetam	B-Chemical
(	O
Ro	B-Chemical
13-5057	I-Chemical
,	O
1-anisoyl-2-pyrrolidinone	B-Chemical
)	O
was	O
studied	O
on	O
various	O
forms	O
of	O
experimentally	O
impaired	B-Disease
cognitive	I-Disease
functions	I-Disease
(	O
learning	O
and	O
memory	O
)	O
in	O
rodents	O
and	O
produced	O
the	O
following	O
effects	O
:	O
(	O
1	O
)	O
almost	O
complete	O
prevention	O
of	O
the	O
incapacity	O
to	O
learn	O
a	O
discrete	O
escape	O
response	O
in	O
rats	O
exposed	O
to	O
sublethal	O
hypercapnia	B-Disease
immediately	O
before	O
the	O
acquisition	O
session	O
;	O
(	O
2	O
)	O
partial	O
(	O
rats	O
)	O
or	O
complete	O
(	O
mice	O
)	O
prevention	O
of	O
the	O
scopolamine-induced	B-Chemical
short-term	O
amnesia	B-Disease
for	O
a	O
passive	O
avoidance	O
task	O
;	O
(	O
3	O
)	O
complete	O
protection	O
against	O
amnesia	B-Disease
for	O
a	O
passive	O
avoidance	O
task	O
in	O
rats	O
submitted	O
to	O
electroconvulsive	O
shock	O
immediately	O
after	O
avoidance	O
acquisition	O
;	O
(	O
4	O
)	O
prevention	O
of	O
the	O
long-term	O
retention-	O
or	O
retrieval-deficit	O
for	O
a	O
passive	O
avoidance	O
task	O
induced	O
in	O
rats	O
and	O
mice	O
by	O
chloramphenicol	B-Chemical
or	O
cycloheximide	B-Chemical
administered	O
immediately	O
after	O
acquisition	O
;	O
(	O
5	O
)	O
reversal	O
,	O
when	O
administered	O
as	O
late	O
as	O
1	O
h	O
before	O
the	O
retention	O
test	O
,	O
of	O
the	O
deficit	O
in	O
retention	O
or	O
retrieval	O
of	O
a	O
passive	O
avoidance	O
task	O
induced	O
by	O
cycloheximide	B-Chemical
injected	O
2	O
days	O
previously	O
;	O
(	O
6	O
)	O
prevention	O
of	O
the	O
deficit	O
in	O
the	O
retrieval	O
of	O
an	O
active	O
avoidance	O
task	O
induced	O
in	O
mice	O
by	O
subconvulsant	O
electroshock	O
or	O
hypercapnia	B-Disease
applied	O
immediately	O
before	O
retrieval	O
testing	O
(	O
24	O
h	O
after	O
acquisition	O
)	O
.	O

These	O
improvements	O
or	O
normalizations	O
of	O
impaired	B-Disease
cognitive	I-Disease
functions	I-Disease
were	O
seen	O
at	O
oral	O
aniracetam	B-Chemical
doses	O
of	O
10-100	O
mg/kg	O
.	O

Generally	O
,	O
the	O
dose-response	O
curves	O
were	O
bell-shaped	O
.	O

The	O
mechanisms	O
underlying	O
the	O
activity	O
of	O
aniracetam	B-Chemical
and	O
its	O
'therapeutic	O
window	O
'	O
are	O
unknown	O
.	O

Piracetam	B-Chemical
,	O
another	O
pyrrolidinone	B-Chemical
derivative	O
was	O
used	O
for	O
comparison	O
.	O

It	O
was	O
active	O
only	O
in	O
six	O
of	O
nine	O
tests	O
and	O
had	O
about	O
one-tenth	O
the	O
potency	O
of	O
aniracetam	B-Chemical
.	O

The	O
results	O
indicate	O
that	O
aniracetam	B-Chemical
improves	O
cognitive	O
functions	O
which	O
are	O
impaired	O
by	O
different	O
procedure	O
and	O
in	O
different	O
phases	O
of	O
the	O
learning	O
and	O
memory	O
process	O
.	O

Nicotine	B-Chemical
potentiation	O
of	O
morphine-induced	B-Chemical
catalepsy	B-Disease
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
effects	O
of	O
nicotine	B-Chemical
on	O
catalepsy	B-Disease
induced	O
by	O
morphine	B-Chemical
in	O
mice	O
have	O
been	O
investigated	O
.	O

Morphine	B-Chemical
but	O
not	O
nicotine	B-Chemical
induced	O
a	O
dose-dependent	O
catalepsy	B-Disease
.	O

The	O
response	O
of	O
morphine	B-Chemical
was	O
potentiated	O
by	O
nicotine	B-Chemical
.	O

Intraperitoneal	O
administration	O
of	O
atropine	B-Chemical
,	O
naloxone	B-Chemical
,	O
mecamylamine	B-Chemical
,	O
and	O
hexamethonium	B-Chemical
to	O
mice	O
reduced	O
catalepsy	B-Disease
induced	O
by	O
a	O
combination	O
of	O
morphine	B-Chemical
with	O
nicotine	B-Chemical
.	O

Intracerebroventricular	O
injection	O
of	O
atropine	B-Chemical
,	O
hexamethonium	B-Chemical
,	O
and	O
naloxone	B-Chemical
also	O
decreased	O
catalepsy	B-Disease
induced	O
by	O
morphine	B-Chemical
plus	O
nicotine	B-Chemical
.	O

Intraperitoneal	O
administration	O
of	O
atropine	B-Chemical
,	O
but	O
not	O
intraperitoneal	O
or	O
intracerebroventricular	O
injection	O
of	O
hexamethonium	B-Chemical
,	O
decreased	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
morphine	B-Chemical
.	O

It	O
was	O
concluded	O
that	O
morphine	B-Chemical
catalepsy	B-Disease
can	O
be	O
elicited	O
by	O
opioid	O
and	O
cholinergic	O
receptors	O
,	O
and	O
the	O
potentiation	O
of	O
morphine	B-Chemical
induced	O
by	O
nicotine	B-Chemical
may	O
also	O
be	O
mediated	O
through	O
cholinergic	O
receptor	O
mechanisms	O
.	O

Reduced	O
cardiotoxicity	B-Disease
and	O
preserved	O
antitumor	O
efficacy	O
of	O
liposome-encapsulated	O
doxorubicin	B-Chemical
and	O
cyclophosphamide	B-Chemical
compared	O
with	O
conventional	O
doxorubicin	B-Chemical
and	O
cyclophosphamide	B-Chemical
in	O
a	O
randomized	O
,	O
multicenter	O
trial	O
of	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O

PURPOSE	O
:	O
To	O
determine	O
whether	O
Myocet	B-Chemical
(	O
liposome-encapsulated	O
doxorubicin	B-Chemical
;	O
The	O
Liposome	O
Company	O
,	O
Elan	O
Corporation	O
,	O
Princeton	O
,	O
NJ	O
)	O
in	O
combination	O
with	O
cyclophosphamide	B-Chemical
significantly	O
reduces	O
doxorubicin	B-Chemical
cardiotoxicity	B-Disease
while	O
providing	O
comparable	O
antitumor	O
efficacy	O
in	O
first-line	O
treatment	O
of	O
metastatic	O
breast	B-Disease
cancer	I-Disease
(	O
MBC	B-Disease
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Two	O
hundred	O
ninety-seven	O
patients	O
with	O
MBC	B-Disease
and	O
no	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
were	O
randomized	O
to	O
receive	O
either	O
60	O
mg/m	O
(	O
2	O
)	O
of	O
Myocet	B-Chemical
(	O
M	O
)	O
or	O
conventional	O
doxorubicin	B-Chemical
(	O
A	O
)	O
,	O
in	O
combination	O
with	O
600	O
mg/m	O
(	O
2	O
)	O
of	O
cyclophosphamide	B-Chemical
(	O
C	O
)	O
,	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	B-Disease
.	O

Cardiotoxicity	B-Disease
was	O
defined	O
by	O
reductions	O
in	O
left-ventricular	O
ejection	O
fraction	O
,	O
assessed	O
by	O
serial	O
multigated	O
radionuclide	O
angiography	O
scans	O
,	O
or	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
(	O
CHF	B-Disease
)	O
.	O

Antitumor	B-Disease
efficacy	O
was	O
assessed	O
by	O
objective	O
tumor	O
response	O
rates	O
(	O
World	O
Health	O
Organization	O
criteria	O
)	O
,	O
time	O
to	O
progression	O
,	O
and	O
survival	O
.	O

RESULTS	O
:	O
Six	O
percent	O
of	O
MC	O
patients	O
versus	O
21	O
%	O
(	O
including	O
five	O
cases	O
of	O
CHF	B-Disease
)	O
of	O
AC	O
patients	O
developed	O
cardiotoxicity	B-Disease
(	O
P	O
=.0002	O
)	O
.	O

Median	O
cumulative	O
doxorubicin	B-Chemical
dose	O
at	O
onset	O
was	O
more	O
than	O
2,220	O
mg/m	O
(	O
2	O
)	O
for	O
MC	O
versus	O
480	O
mg/m	O
(	O
2	O
)	O
for	O
AC	O
(	O
P	O
=.0001	O
,	O
hazard	O
ratio	O
,	O
5.04	O
)	O
.	O

MC	O
patients	O
also	O
experienced	O
less	O
grade	O
4	O
neutropenia	B-Disease
.	O

Antitumor	O
efficacy	O
of	O
MC	O
versus	O
AC	O
was	O
comparable	O
:	O
objective	O
response	O
rates	O
,	O
43	O
%	O
versus	O
43	O
%	O
;	O
median	O
time	O
to	O
progression	O
,	O
5.1	O
%	O
versus	O
5.5	O
months	O
;	O
median	O
time	O
to	O
treatment	O
failure	O
,	O
4.6	O
versus	O
4.4	O
months	O
;	O
and	O
median	O
survival	O
,	O
19	O
versus	O
16	O
months	O
.	O

CONCLUSION	O
:	O
Myocet	B-Chemical
improves	O
the	O
therapeutic	O
index	O
of	O
doxorubicin	B-Chemical
by	O
significantly	O
reducing	O
cardiotoxicity	B-Disease
and	O
grade	O
4	O
neutropenia	B-Disease
and	O
provides	O
comparable	O
antitumor	O
efficacy	O
,	O
when	O
used	O
in	O
combination	O
with	O
cyclophosphamide	B-Chemical
as	O
first-line	O
therapy	O
for	O
MBC	B-Disease
.	O

Protective	O
effect	O
of	O
a	O
specific	O
platelet-activating	O
factor	O
antagonist	O
,	O
BN	B-Chemical
52021	I-Chemical
,	O
on	O
bupivacaine-induced	B-Chemical
cardiovascular	B-Disease
impairments	I-Disease
in	O
rats	O
.	O

Administration	O
of	O
the	O
local	O
anaesthetic	O
bupivacaine	B-Chemical
(	I-Disease
1.5	O
or	O
2	O
mg/kg	O
,	O
i.v	O
.	O

)	I-Disease
to	O
rats	O
elicited	O
a	O
marked	O
decrease	B-Disease
of	I-Disease
mean	I-Disease
arterial	I-Disease
blood	I-Disease
pressure	I-Disease
(	I-Disease
MBP	I-Disease
)	I-Disease
and	I-Disease
heart	I-Disease
rate	I-Disease
(	I-Disease
HR	O
)	I-Chemical
leading	O
to	O
death	O
(	I-Chemical
in	O
67	O
%	O
or	O
90	O
%	O
of	I-Chemical
animals	O
respectively	O
)	I-Chemical
.	O

Intravenous	O
injection	O
of	I-Chemical
the	O
specific	O
platelet-activating	O
factor	O
(	I-Chemical
PAF	O
)	I-Chemical
antagonist	O
BN	O
52021	O
(	I-Chemical
10	O
mg/kg	O
)	I-Chemical
,	O
30	O
min	O
before	O
bupivacaine	O
administration	O
(	I-Chemical
2	O
mg/kg	O
i.v	O
.	O

)	I-Chemical
suppressed	O
both	O
the	O
decrease	B-Chemical
of	I-Chemical
MBP	O
and	O
HR	I-Chemical
.	O

In	O
contrast	O
,	O
doses	O
of	I-Chemical
1	O
mg/kg	O
BN	O
52021	O
given	O
30	O
min	O
before	O
or	O
10	O
mg/kg	O
administered	O
5	O
min	O
before	O
i.v	O
.	O

injection	O
of	I-Chemical
bupivacaine	O
were	O
ineffective	O
.	O

When	O
BN	B-Disease
52021	I-Disease
(	O
20	O
mg/kg	O
i.v	O
.	O

)	O
was	O
injected	O
immediately	O
after	O
bupivacaine	B-Chemical
(	O
2	O
mg/kg	O
)	O
,	O
a	O
partial	O
reversion	O
of	I-Chemical
the	O
decrease	B-Chemical
of	I-Chemical
MBP	I-Chemical
and	I-Chemical
HR	O
was	O
observed	O
,	O
whereas	O
the	O
dose	O
of	I-Chemical
10	O
mg/kg	O
was	O
ineffective	O
.	O

A	O
partial	O
recovery	O
of	I-Chemical
bupivacaine-induced	O
ECG	O
alterations	O
was	O
observed	O
after	O
pretreatment	O
of	I-Chemical
the	O
rats	O
with	O
BN	O
52021	O
.	O

Since	O
the	O
administration	O
of	I-Chemical
BN	O
52021	O
,	O
at	O
all	O
doses	O
studied	O
,	O
did	O
not	O
alter	O
MBP	O
and	O
HR	I-Chemical
at	O
the	O
doses	O
used	O
,	O
the	O
bulk	O
of	I-Chemical
these	O
results	O
clearly	O
demonstrate	O
a	O
protective	O
action	O
of	O
BN	B-Disease
52021	I-Disease
,	O
a	O
specific	O
antagonist	O
of	O
PAF	O
,	O
against	O
bupivacaine-induced	B-Chemical
cardiovascular	O
toxicity	O
.	O

Thus	O
,	O
consistent	O
with	O
its	O
direct	O
effect	O
on	O
heart	O
,	O
PAF	O
appears	O
to	O
be	O
implicated	O
in	O
bupivacaine-induced	O
cardiovascular	O
alterations	O
.	O

Benzylacyclouridine	B-Chemical
reverses	O
azidothymidine-induced	B-Chemical
marrow	B-Disease
suppression	I-Disease
without	O
impairment	O
of	O
anti-human	O
immunodeficiency	B-Disease
virus	O
activity	O
.	O

Increased	O
extracellular	O
concentrations	O
of	O
uridine	B-Chemical
(	O
Urd	B-Chemical
)	O
have	O
been	O
reported	O
to	O
reduce	O
,	O
in	O
vitro	O
,	O
azidothymidine	B-Chemical
(	O
AZT	B-Chemical
)	O
-induced	O
inhibition	O
of	O
human	O
granulocyte-macrophage	O
progenitor	O
cells	O
without	O
impairment	O
of	O
its	O
antihuman	O
immunodeficiency	B-Disease
virus	O
(	O
HIV	O
)	O
activity	O
.	O

Because	O
of	O
the	O
clinical	O
toxicities	B-Disease
associated	O
with	O
chronic	O
Urd	B-Chemical
administration	O
,	O
the	O
ability	O
of	O
benzylacyclouridine	B-Chemical
(	O
BAU	B-Chemical
)	O
to	O
effect	O
,	O
in	O
vivo	O
,	O
AZT-induced	B-Chemical
anemia	B-Disease
and	O
leukopenia	B-Disease
was	O
assessed	O
.	O

This	O
agent	O
inhibits	O
Urd	B-Chemical
catabolism	O
and	O
,	O
in	O
vivo	O
,	O
increases	O
the	O
plasma	O
concentration	O
of	O
Urd	B-Chemical
in	O
a	O
dose-dependent	O
manner	O
,	O
without	O
Urd-related	B-Chemical
toxicity	B-Disease
.	O

In	O
mice	O
rendered	O
anemic	B-Disease
and	O
leukopenic	B-Disease
by	O
the	O
administration	O
of	O
AZT	B-Chemical
for	O
28	O
days	O
in	O
drinking	O
water	O
(	O
1.5	O
mg/mL	O
)	O
,	O
the	O
continued	O
administration	O
of	O
AZT	B-Chemical
plus	O
daily	O
BAU	B-Chemical
(	O
300	O
mg/kg	O
,	O
orally	O
)	O
partially	O
reversed	O
AZT-induced	B-Chemical
anemia	B-Disease
and	O
leukopenia	B-Disease
(	O
P	O
less	O
than	O
.05	O
)	O
,	O
increased	O
peripheral	O
reticulocytes	O
(	O
to	O
4.9	O
%	O
,	O
P	O
less	O
than	O
.01	O
)	O
,	O
increased	O
cellularity	O
in	O
the	O
marrow	O
,	O
and	O
improved	O
megaloblastosis	B-Disease
.	O

When	O
coadministered	O
with	O
AZT	B-Chemical
from	O
the	O
onset	O
of	O
drug	B-Drug
administration	O
,	O
BAU	B-Chemical
reduced	O
AZT-induced	B-Chemical
marrow	B-Disease
toxicity	I-Disease
.	O

In	O
vitro	O
,	O
at	O
a	O
concentration	O
of	O
100	O
mumol/L	O
,	O
BAU	B-Chemical
possesses	O
minimal	O
anti-HIV	O
activity	O
and	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
AZT	B-Chemical
to	O
reverse	O
the	O
HIV-induced	O
cytopathic	O
effect	O
in	O
MT4	O
cells	O
.	O

The	O
clinical	O
and	O
biochemical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Cyclophosphamide-induced	B-Chemical
cystitis	B-Disease
in	O
freely-moving	O
conscious	O
rats	O
:	O
behavioral	O
approach	O
to	O
a	O
new	O
model	O
of	O
visceral	B-Disease
pain	I-Disease
.	O

PURPOSE	O
:	O
To	O
develop	O
a	O
model	O
of	O
visceral	B-Disease
pain	I-Disease
in	O
rats	O
using	O
a	O
behavioral	O
approach	O
.	O

Cyclophosphamide	B-Chemical
(	O
CP	B-Chemical
)	O
,	O
an	O
antitumoral	O
agent	O
known	O
to	O
produce	O
toxic	O
effects	O
on	O
the	O
bladder	O
wall	O
through	O
its	O
main	O
toxic	O
metabolite	O
acrolein	B-Chemical
,	O
was	O
used	O
to	O
induce	O
cystitis	B-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
CP	B-Chemical
was	O
administered	O
at	O
doses	O
of	O
50	O
,	O
100	O
and	O
200	O
mg./kg	O
.	O

i.p	O
.	O

to	O
male	O
rats	O
,	O
and	O
their	O
behavior	O
observed	O
and	O
scored	O
.	O

The	O
effects	O
of	O
morphine	B-Chemical
(	O
0.5	O
to	O
4	O
mg./kg	O
.	O

i.v	O
.	O

)	O
on	O
CP-induced	B-Chemical
behavioral	O
modifications	O
were	O
tested	O
administered	O
alone	O
and	O
after	O
naloxone	B-Chemical
(	O
1	O
mg./kg	O
.	O

s.c.	O
)	O
.	O

In	O
addition	O
,	O
90	O
minutes	O
after	O
CP	B-Chemical
injection	O
,	O
that	O
is	O
,	O
at	O
the	O
time	O
of	O
administration	O
of	O
morphine	B-Chemical
,	O
the	O
bladder	O
was	O
removed	O
in	O
some	O
rats	O
for	O
histological	O
examination	O
.	O

Finally	O
,	O
to	O
show	O
that	O
the	O
bladder	O
is	O
essential	O
for	O
the	O
CP-induced	B-Chemical
behavioral	O
modifications	O
,	O
female	O
rats	O
also	O
received	O
CP	B-Chemical
at	O
doses	O
of	O
200	O
mg./kg	O
.	O

i.p	O
.	O

and	O
of	O
20	O
mg.	O
by	O
the	O
intravesical	O
route	O
,	O
and	O
acrolein	B-Chemical
at	O
doses	O
of	O
0.5	O
mg.	O
by	O
the	O
intravesical	O
route	O
and	O
of	O
5	O
mg./kg	O
.	O

i.v	O
.	O

RESULTS	O
:	O
CP	B-Chemical
dose-relatedly	O
induced	O
marked	O
behavioral	O
modifications	O
in	O
male	O
rats	O
:	O
breathing	O
rate	O
decrease	O
,	O
closing	O
of	O
the	O
eyes	O
and	O
occurrence	O
of	O
specific	O
postures	O
.	O

Morphine	B-Chemical
dose-dependently	O
reversed	O
these	O
behavioral	B-Disease
disorders	I-Disease
.	O

A	O
dose	O
of	O
0.5	O
mg./kg	O
.	O

produced	O
a	O
reduction	O
of	O
almost	O
50	O
%	O
of	O
the	O
behavioral	O
score	O
induced	O
by	O
CP	B-Chemical
200	O
mg./kg	O
.	O

This	O
effect	O
was	O
completely	O
prevented	O
by	O
pretreatment	O
with	O
naloxone	B-Chemical
.	O

At	O
the	O
time	O
of	O
administration	O
of	O
morphine	B-Chemical
,	O
histological	O
modifications	O
of	O
the	O
bladder	O
wall	O
,	O
such	O
as	O
chorionic	O
and	O
muscle	O
layer	O
edema	B-Disease
,	O
were	O
observed	O
.	O

In	O
female	O
rats	O
,	O
CP	B-Chemical
200	O
mg./kg	O
.	O

i.p	O
.	O

produced	O
the	O
same	O
marked	O
behavioral	O
modifications	O
as	O
those	O
observed	O
in	O
male	O
rats	O
.	O

Administered	O
at	O
the	O
dose	O
of	O
20	O
mg.	O
intravesically	O
,	O
CP	B-Chemical
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
,	O
whereas	O
acrolein	B-Chemical
at	O
0.5	O
mg.	O
intravesically	O
induced	O
behavioral	O
modifications	O
identical	O
to	O
those	O
under	O
CP	B-Chemical
200	O
mg./kg	O
.	O

i.p.	O
,	O
with	O
the	O
same	O
maximal	O
levels	O
.	O

Conversely	O
,	O
acrolein	B-Chemical
5	O
mg./kg	O
.	O

i.v	O
.	O

did	O
not	O
produce	O
any	O
behavioral	O
effects	O
at	O
all	O
.	O

CONCLUSIONS	O
:	O
Overall	O
,	O
these	O
results	O
indicate	O
that	O
this	O
experimental	O
model	O
of	O
CP-induced	B-Chemical
cystitis	B-Disease
may	O
be	O
an	O
interesting	O
new	O
behavioral	O
model	O
of	O
inflammatory	O
visceral	B-Disease
pain	I-Disease
,	O
allowing	O
a	O
better	O
understanding	O
of	O
these	O
painful	B-Disease
syndromes	I-Disease
and	O
thus	O
a	O
better	O
therapeutic	O
approach	O
to	O
them	O
.	O

Hyperalgesia	B-Disease
and	O
myoclonus	B-Disease
in	O
terminal	O
cancer	B-Disease
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	B-Chemical
.	O

Eight	O
cancer	B-Disease
patients	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
treated	O
with	O
high	O
doses	O
of	O
intravenous	O
morphine	B-Chemical
developed	O
hyperalgesia	B-Disease
.	O

All	O
cases	O
were	O
retrospectively	O
sampled	O
from	O
three	O
different	O
hospitals	O
in	O
Copenhagen	O
.	O

Five	O
patients	O
developed	O
universal	O
hyperalgesia	B-Disease
and	O
hyperesthesia	B-Disease
which	O
in	O
2	O
cases	O
were	O
accompanied	O
by	O
myoclonus	B-Disease
.	O

In	O
3	O
patients	O
a	O
pre-existing	O
neuralgia	B-Disease
increased	O
to	O
excruciating	O
intensity	O
and	O
in	O
2	O
of	O
these	O
cases	O
myoclonus	B-Disease
occurred	O
simultaneously	O
.	O

Although	O
only	O
few	O
clinical	O
descriptions	O
of	O
the	O
relationship	O
between	O
hyperalgesia/myoclonus	B-Disease
and	O
high	O
doses	O
of	O
morphine	B-Drug
are	O
available	O
,	O
experimental	O
support	O
from	O
animal	O
studies	O
indicates	O
that	O
morphine	B-Drug
,	O
or	O
its	O
metabolites	O
,	O
plays	O
a	O
causative	O
role	O
for	O
the	O
observed	O
behavioural	O
syndrome	O
.	O

The	O
possible	O
mechanisms	O
are	O
discussed	O
and	O
treatment	O
proposals	O
given	O
suggesting	O
the	O
use	O
of	O
more	O
efficacious	O
opioids	O
with	O
less	O
excitatory	O
potency	O
in	O
these	O
situations	O
.	O

A	O
prospective	O
study	O
of	O
adverse	O
reactions	O
associated	O
with	O
vancomycin	B-Chemical
therapy	O
.	O

A	O
prospective	O
evaluation	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
vancomycin	B-Chemical
was	O
conducted	O
in	O
54	O
consecutive	O
patients	O
over	O
a	O
16-month	O
period	O
.	O

Vancomycin	B-Chemical
was	O
curative	O
in	O
95	O
%	O
of	O
43	O
patients	O
with	O
proven	O
infection	B-Disease
.	O

Drugs	B-Drug
were	O
ceased	O
in	O
six	O
patients	O
because	O
of	O
adverse	O
reactions	O
;	O
in	O
three	O
of	O
these	O
vancomycin	B-Chemical
was	O
considered	O
the	O
likely	O
cause	O
.	O

Reactions	O
included	O
thrombophlebitis	B-Disease
(	O
20	O
of	O
54	O
patients	O
)	O
,	O
rash	B-Disease
(	O
4	O
of	O
54	O
)	O
,	O
nephrotoxicity	B-Disease
(	O
4	O
of	O
50	O
)	O
,	O
proteinuria	B-Disease
(	O
1	O
of	O
50	O
)	O
and	O
ototoxicity	B-Disease
(	O
1	O
of	O
11	O
patients	O
tested	O
by	O
audiometry	O
)	O
.	O

Thrombophlebitis	B-Disease
occurred	O
only	O
with	O
infusion	O
through	O
peripheral	O
cannulae	O
;	O
nephrotoxicity	B-Disease
and	O
ototoxicity	B-Disease
were	O
confined	O
to	O
patients	O
receiving	O
an	O
aminoglycoside	B-Chemical
plus	O
vancomycin	B-Chemical
.	O

We	O
conclude	O
that	O
vancomycin	B-Chemical
,	O
administered	O
appropriately	O
,	O
constitutes	O
safe	O
,	O
effective	O
therapy	O
for	O
infections	B-Disease
caused	O
by	O
susceptible	O
bacteria	O
.	O

Blockade	O
of	O
both	O
D-1	O
and	O
D-2	O
dopamine	B-Chemical
receptors	O
may	O
induce	O
catalepsy	B-Disease
in	O
mice	O
.	O

1	O
.	O

The	O
catalepsy	B-Disease
induced	O
by	O
dopamine	B-Chemical
antagonists	O
has	O
been	O
tested	O
and	O
the	O
possible	O
dopamine	B-Chemical
subtypes	O
involved	O
in	O
catalepsy	B-Disease
was	O
determined	O
.	O

2	O
.	O

Dopamine	B-Chemical
antagonist	O
fluphenazine	B-Chemical
,	O
D-1	O
antagonist	O
SCH	B-Chemical
23390	I-Chemical
or	O
D-2	O
antagonist	O
sulpiride	B-Chemical
induced	O
catalepsy	B-Disease
.	O

The	O
effect	O
of	O
fluphenazine	B-Chemical
and	O
sulpiride	B-Chemical
was	O
dose-dependent	O
.	O

Combination	O
of	O
SCH	B-Chemical
23390	I-Chemical
with	O
sulpiride	B-Chemical
did	O
not	O
induce	O
catalepsy	B-Disease
potentiation	O
.	O

3	O
.	O

D-1	O
agonist	O
SKF	B-Chemical
38393	I-Chemical
or	O
D-2	O
agonist	O
quinpirole	B-Chemical
decreased	O
the	O
catalepsy	B-Disease
induced	O
by	O
fluphenazine	B-Chemical
,	O
SCH	B-Chemical
23390	I-Chemical
or	O
sulpiride	B-Chemical
.	O

4	O
.	O

Combination	O
of	O
SKF	B-Chemical
38393	I-Chemical
with	O
quinpirole	B-Chemical
did	O
not	O
cause	O
potentiated	O
inhibitory	O
effect	O
on	O
catalepsy	B-Disease
induced	O
by	O
dopamine	B-Chemical
antagonists	O
.	O

5	O
.	O

The	O
data	O
may	O
indicate	O
that	O
although	O
D-2	O
receptor	O
blockade	O
is	O
involved	O
in	O
catalepsy	B-Disease
,	O
the	O
D-1	O
receptor	O
may	O
plan	O
a	O
role	O
.	O

Dextran-etodolac	B-Chemical
conjugates	O
:	O
synthesis	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O

Etodolac	B-Chemical
(	O
E	B-Chemical
)	O
,	O
is	O
a	O
non-narcotic	O
analgesic	O
and	O
antiinflammatory	O
drug	B-Drug
.	O

A	O
biodegradable	O
polymer	O
dextran	B-Chemical
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac-dextran	B-Chemical
conjugates	O
(	O
ED	O
)	O
to	O
improve	O
its	O
aqueous	O
solubility	O
and	O
reduce	O
gastrointestinal	O
side	O
effects	O
.	O

An	O
activated	O
moiety	O
,	O
i.e	O
.	O

N-acylimidazole	O
derivative	O
of	O
etodolac	B-Drug
(	O
EAI	O
)	O
,	O
was	O
condensed	O
with	O
the	O
polysaccharide	O
polymer	O
dextran	B-Chemical
of	O
different	O
molecular	O
weights	O
(	O
40000	O
,	O
60000	O
,	O
110000	O
and	O
200000	O
)	O
.	O

IR	O
spectral	O
data	O
confirmed	O
formation	O
of	O
ester	O
bonding	O
in	O
the	O
conjugates	O
.	O

Etodolac	B-Drug
contents	O
were	O
evaluated	O
by	O
UV-spectrophotometric	O
analysis	O
.	O

The	O
molecular	O
weights	O
were	O
determined	O
by	O
measuring	O
viscosity	O
using	O
the	O
Mark-Howink-Sakurada	O
equation	O
.	O

In	O
vitro	O
hydrolysis	O
of	O
ED	O
was	O
done	O
in	O
aqueous	O
buffers	O
(	O
pH	O
1.2	O
,	O
7.4	O
,	O
9	O
)	O
and	O
in	O
80	O
%	O
(	O
v/v	O
)	O
human	O
plasma	O
(	O
pH	O
7.4	O
)	O
.	O

At	O
pH	O
9	O
,	O
a	O
higher	O
rate	O
of	O
etodolac	B-Drug
release	O
from	O
ED	O
was	O
observed	O
as	O
compared	O
to	O
aqueous	O
buffer	O
of	O
pH	O
7.4	O
and	O
80	O
%	O
human	O
plasma	O
(	O
pH	O
7.4	O
)	O
,	O
following	O
first-order	O
kinetics	O
.	O

In	O
vivo	O
investigations	O
were	O
performed	O
in	O
animals	O
.	O

Acute	O
analgesic	O
and	O
antiinflammatory	O
activities	O
were	O
ascertained	O
using	O
acetic	O
acid	O
induced	O
writhing	O
model	O
(	O
mice	O
)	O
and	O
carrageenan-induced	O
rat	O
paw	O
edema	O
model	O
,	O
respectively	O
.	O

In	O
comparison	O
to	O
control	O
,	O
E	O
and	O
ED1-ED4	O
showed	O
highly	O
significant	O
analgesic	O
and	O
antiinflammatory	O
activities	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Biological	O
evaluation	O
suggested	O
that	O
conjugates	O
(	O
ED1-ED4	O
)	O
retained	O
comparable	O
analgesic	O
and	O
antiinflammatory	O
activities	O
with	O
remarkably	O
reduced	O
ulcerogenicity	O
as	O
compared	O
to	O
their	O
parent	O
drug	B-Drug
--	O
etodolac	B-Drug
.	O

Hypersensitivity	B-Disease
myocarditis	B-Disease
complicating	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
heart	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
eosinophilic	B-Disease
myocarditis	I-Disease
complicating	O
hypertrophic	O
cardiomyopathy	O
.	O

The	O
47-year-old	O
female	O
patient	O
,	O
known	O
to	O
have	O
hypertrophic	O
cardiomyopathy	O
,	O
was	O
admitted	O
with	O
biventricular	O
failure	O
and	O
managed	O
aggressively	O
with	O
dobutamine	B-Drug
infusion	O
and	O
other	O
drugs	B-Drug
while	O
being	O
assessed	O
for	O
heart	O
transplantation	O
.	O

On	O
transthoracic	O
echocardiogram	O
,	O
she	O
had	O
moderate	O
left	O
ventricular	O
dysfunction	O
with	O
regional	O
variability	O
and	O
moderate	O
mitral	O
regurgitation	O
.	O

The	O
recipient	O
's	O
heart	O
showed	O
the	O
features	O
of	O
apical	O
hypertrophic	O
cardiomyopathy	O
and	O
myocarditis	O
with	O
abundant	O
eosinophils	O
.	O

Myocarditis	O
is	O
rare	O
and	O
eosinophilic	B-Chemical
myocarditis	B-Chemical
is	O
rarer	O
.	O

It	O
is	O
likely	O
that	O
the	O
hypersensitivity	O
(	O
eosinophilic	O
)	O
myocarditis	O
was	O
related	O
to	O
dobutamine	B-Drug
infusion	O
therapy	O
.	O

Eosinophilic	O
myocarditis	O
has	O
been	O
reported	O
with	O
an	O
incidence	O
of	O
2.4	O
%	O
to	O
7.2	O
%	O
in	O
explanted	O
hearts	O
and	O
may	O
be	O
related	O
to	O
multidrug	O
therapy	O
.	O

All-	B-Chemical
trans-retinoic	I-Chemical
acid-induced	O
erythema	O
nodosum	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O

Erythema	B-Disease
nodosum	I-Disease
associated	O
with	O
all-	B-Chemical
trans-retinoic	I-Chemical
acid	I-Chemical
(	O
ATRA	B-Chemical
)	O
for	O
acute	B-Disease
promyelocytic	I-Disease
leukemia	I-Disease
(	O
APL	B-Disease
)	O
is	O
very	O
rare	O
.	O

We	O
describe	O
four	O
patients	O
with	O
classic	O
APL	B-Disease
who	O
developed	O
erythema	B-Disease
nodosum	I-Disease
during	O
ATRA	B-Chemical
therapy	O
.	O

Fever	B-Disease
and	O
subsequent	O
multiple	O
painful	B-Disease
erythematous	B-Disease
nodules	I-Disease
over	O
extremities	O
developed	O
on	O
D11	O
,	O
D16	O
,	O
D17	O
,	O
and	O
D19	O
,	O
respectively	O
,	O
after	O
ATRA	B-Chemical
therapy	O
.	O

The	O
skin	O
biopsy	O
taken	O
from	O
each	O
patient	O
was	O
consistent	O
with	O
erythema	B-Disease
nodosum	I-Disease
.	O

All	O
patients	O
received	O
short	O
course	O
of	O
steroids	B-Chemical
.	O

Fever	B-Disease
subsided	O
rapidly	O
and	O
the	O
skin	O
lesions	O
regressed	O
completely	O
.	O

All	O
patients	O
achieved	O
complete	O
remission	O
without	O
withdrawal	O
of	O
ATRA	B-Chemical
.	O

ATRA	B-Chemical
seemed	O
to	O
be	O
the	O
most	O
possible	O
etiology	O
of	O
erythema	B-Disease
nodosum	I-Disease
in	O
our	O
patients	O
.	O

Short-term	O
use	O
of	O
steroid	B-Chemical
is	O
very	O
effective	O
in	O
ATRA-induced	B-Chemical
erythema	B-Disease
nodosum	I-Disease
.	O

Delayed-onset	O
heparin-induced	B-Chemical
thrombocytopenia	B-Disease
.	O

BACKGROUND	O
:	O
Heparin-induced	B-Chemical
thrombocytopenia	B-Disease
presents	O
5	O
to	O
12	O
days	O
after	O
heparin	B-Chemical
exposure	O
,	O
with	O
or	I-Disease
without	O
arterial	B-Disease
or	I-Disease
venous	I-Disease
thromboemboli	I-Chemical
.	O

Delayed	O
recognition	O
and	O
treatment	O
of	O
heparin-induced	B-Drug
thrombocytopenia	O
contribute	O
to	O
poor	O
patient	O
outcomes	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
and	O
increase	O
awareness	O
of	O
a	O
clinical	O
scenario	O
in	O
which	O
the	O
onset	O
or	O
manifestations	O
of	O
heparin-induced	B-Drug
thrombocytopenia	O
are	O
delayed	O
.	O

DESIGN	O
:	O
Retrospective	O
case	O
series	O
.	O

SETTING	O
:	O
Three	O
large	O
urban	O
hospitals	O
(	O
with	O
active	O
cardiovascular	O
surgery	O
programs	O
)	O
.	O

PATIENTS	O
:	O
14	O
patients	O
seen	O
over	O
a	O
3-year	O
period	O
in	O
whom	O
heparin-induced	B-Drug
thrombocytopenia	O
became	O
apparent	O
on	O
delayed	O
presentation	O
with	O
thromboembolic	O
complications	O
.	O

MEASUREMENTS	O
:	O
Platelet	O
counts	O
,	O
onset	O
of	O
objectively	O
determined	O
thromboembolism	O
,	O
results	O
of	O
heparin-induced	B-Drug
platelet	O
factor	O
4	O
antibody	O
tests	O
,	O
and	O
outcomes	O
.	O

RESULTS	O
:	O
Patients	O
went	O
home	O
after	O
hospitalizations	O
that	O
had	O
included	O
heparin	B-Drug
exposure	O
--	O
in	O
most	O
cases	O
,	O
with	O
no	O
thrombocytopenia	O
recognized	O
--	O
only	O
to	O
return	O
to	O
the	O
hospital	O
(	O
median	O
,	O
day	O
14	O
)	O
with	O
thromboembolic	O
complications	O
.	O

Thromboemboli	O
were	O
venous	O
(	O
12	O
patients	O
,	O
7	O
with	O
pulmonary	O
emboli	O
)	O
or	O
arterial	B-Chemical
(	O
4	O
patients	O
)	O
or	O
both	O
.	O

Platelet	O
counts	O
were	O
mildly	O
decreased	O
in	O
all	O
but	O
2	O
patients	O
on	O
second	O
presentation	O
.	O

On	O
readmission	O
,	O
11	O
patients	O
received	O
therapeutic	O
heparin	B-Drug
,	O
which	O
worsened	O
the	O
patients	O
'	O
clinical	O
condition	O
and	O
,	O
in	O
all	O
11	O
cases	O
,	O
decreased	O
the	O
platelet	O
count	O
(	O
mean	O
at	O
readmission	O
,	O
143	O
x	O
10	O
(	O
9	O
)	O
cells/L	O
;	O
mean	O
nadir	O
after	O
heparin	B-Drug
re-exposure	O
,	O
39	O
x	O
10	O
(	O
9	O
)	O
cells/L	O
)	O
.	O

Results	O
of	O
serologic	O
tests	O
for	O
heparin-induced	B-Drug
antibodies	O
were	O
positive	O
in	O
all	O
patients	O
.	O

Subsequent	O
treatments	O
included	O
alternative	O
anticoagulants	B-Drug
(	O
11	O
patients	O
)	O
,	O
thrombolytic	O
drugs	B-Drug
(	O
3	O
patients	O
)	O
,	O
inferior	O
vena	O
cava	O
filters	O
(	O
3	O
patients	O
)	O
and	O
,	O
eventually	O
,	O
warfarin	B-Drug
(	O
11	O
patients	O
)	O
.	O

Three	O
patients	O
died	O
.	O

CONCLUSIONS	O
:	O
Delayed-onset	O
heparin-induced	B-Drug
thrombocytopenia	O
is	O
increasingly	O
being	O
recognized	O
.	O

To	O
avoid	O
disastrous	O
outcomes	O
,	O
physicians	O
must	O
consider	O
heparin-induced	B-Drug
thrombocytopenia	O
whenever	O
a	O
recently	O
hospitalized	O
patient	O
returns	O
with	O
thromboembolism	O
;	O
therapy	O
with	O
alternative	O
anticoagulants	B-Drug
,	O
not	O
heparin	B-Drug
,	O
should	O
be	O
initiated	O
.	O

Valsartan	B-Chemical
,	O
a	O
new	O
angiotensin	B-Chemical
II	I-Chemical
antagonist	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	B-Disease
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
against	O
amlodipine	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	B-Drug
efficacy	O
of	O
a	O
new	O
angiotensin	B-Chemical
II	I-Chemical
antagonist	O
,	O
valsartan	B-Chemical
,	O
with	O
a	O
reference	O
therapy	O
,	O
amlodipine	B-Chemical
.	O

METHODS	O
:	O
One	O
hundred	O
sixty-eight	O
adult	O
outpatients	O
with	O
mild	O
to	O
moderate	O
hypertension	B-Disease
were	O
randomly	O
allocated	O
in	O
double-blind	O
fashion	O
and	O
equal	O
number	O
to	O
receive	O
80	O
mg	O
valsartan	B-Chemical
or	O
5	O
mg	O
amlodipine	B-Chemical
for	O
12	O
weeks	O
.	O

After	O
8	O
weeks	O
of	O
therapy	O
,	O
in	O
patients	O
whose	O
blood	O
pressure	O
remained	O
uncontrolled	O
,	O
5	O
mg	O
amlodipine	B-Chemical
was	O
added	O
to	O
the	O
initial	O
therapy	O
.	O

Patients	O
were	O
assessed	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
change	O
from	O
baseline	O
in	O
mean	O
sitting	O
diastolic	O
blood	O
pressure	O
at	O
8	O
weeks	O
.	O

Secondary	O
variables	O
included	O
change	O
in	O
sitting	O
systolic	O
blood	O
pressure	O
and	O
responder	O
rates	O
.	O

RESULTS	O
:	O
Both	O
valsartan	B-Chemical
and	O
amlodipine	B-Chemical
were	O
effective	O
at	O
lowering	O
blood	O
pressure	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

Similar	O
decreases	O
were	O
observed	O
in	O
both	O
groups	O
,	O
with	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
for	O
any	O
variable	O
analyzed	O
.	O

For	O
the	O
primary	O
variable	O
the	O
difference	O
was	O
0.5	O
mm	O
Hg	O
in	O
favor	O
of	O
valsartan	B-Chemical
(	O
p	O
=	O
0.68	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-2.7	O
to	O
1.7	O
)	O
.	O

Responder	O
rates	O
at	O
8	O
weeks	O
were	O
66.7	O
%	O
for	O
valsartan	B-Chemical
and	O
60.2	O
%	O
for	O
amlodipine	B-Chemical
(	O
p	O
=	O
0.39	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

The	O
incidence	O
of	O
drug-related	O
dependent	O
edema	B-Disease
was	O
somewhat	O
higher	O
in	O
the	O
amlodipine	B-Chemical
group	O
,	O
particularly	O
at	O
a	O
dose	O
of	O
10	O
mg	O
per	O
day	O
(	O
2.4	O
%	O
for	O
80	O
mg	O
valsartan	B-Chemical
;	O
3.6	O
%	O
for	O
5	O
mg	O
amlodipine	B-Chemical
;	O
0	O
%	O
for	O
valsartan	B-Chemical
plus	O
5	O
mg	O
amlodipine	B-Chemical
;	O
14.3	O
%	O
for	O
10	O
mg	O
amlodipine	B-Chemical
)	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
show	O
that	O
valsartan	B-Chemical
is	O
at	O
least	O
as	O
effective	O
as	O
amlodipine	B-Chemical
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	B-Disease
.	O

The	O
results	O
also	O
show	O
valsartan	B-Chemical
to	O
be	O
well	O
tolerated	O
and	O
suggest	O
that	O
it	O
is	O
not	O
associated	O
with	O
side	O
effects	O
characteristic	O
of	O
this	O
comparator	O
class	O
,	O
dihydropyridine	B-Chemical
calcium	B-Chemical
antagonists	O
.	O

KF17837	B-Chemical
:	O
a	O
novel	O
selective	O
adenosine	B-Chemical
A2A	O
receptor	O
antagonist	O
with	O
anticataleptic	O
activity	O
.	O

KF17837	B-Chemical
is	O
a	O
novel	O
selective	O
adenosine	B-Chemical
A2A	O
receptor	O
antagonist	O
.	O

Oral	O
administration	O
of	O
KF17837	B-Chemical
(	O
2.5	O
,	O
10.0	O
and	O
30.0	O
mg/kg	O
)	O
significantly	O
ameliorated	O
the	O
cataleptic	B-Disease
responses	O
induced	O
by	O
intracerebroventricular	O
administration	O
of	O
an	O
adenosine	B-Chemical
A2A	O
receptor	O
agonist	O
,	O
CGS	B-Chemical
21680	I-Chemical
(	O
10	O
micrograms	O
)	O
,	O
in	O
a	O
dose-dependent	O
manner	O
.	O

KF17837	B-Chemical
also	O
reduced	O
the	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
(	O
1	O
mg/kg	O
i.p	O
.	O

)	O
and	O
by	O
reserpine	B-Chemical
(	O
5	O
mg/kg	O
i.p.	O
)	O
.	O

These	O
anticataleptic	O
effects	O
were	O
exhibited	O
dose	O
dependently	O
at	O
doses	O
from	O
0.625	O
and	O
2.5	O
mg/kg	O
p.o.	O
,	O
respectively	O
.	O

Moreover	O
,	O
KF17837	B-Chemical
(	O
0.625	O
mg/kg	O
p.o	O
.	O

)	O
potentiated	O
the	O
anticataleptic	O
effects	O
of	O
a	O
subthreshold	O
dose	O
of	O
L-3,4-dihydroxyphenylalanine	B-Chemical
(	O
L-DOPA	B-Chemical
;	O
25	O
mg/kg	O
i.p	O
.	O

)	O
plus	O
benserazide	B-Chemical
(	O
6.25	O
mg/kg	O
i.p.	O
)	O
.	O

These	O
results	O
suggested	O
that	O
KF17837	B-Chemical
is	O
a	O
centrally	O
active	O
adenosine	B-Chemical
A2A	O
receptor	O
antagonist	O
and	O
that	O
the	O
dopaminergic	B-Drug
function	O
of	O
the	O
nigrostriatal	O
pathway	O
is	O
potentiated	O
by	O
adenosine	B-Chemical
A2A	O
receptor	O
antagonists	O
.	O

Furthermore	O
,	O
KF17837	B-Chemical
may	O
be	O
a	O
useful	O
drug	B-Drug
in	O
the	O
treatment	O
of	O
parkinsonism	B-Disease
.	O

Some	O
central	O
effects	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	B-Chemical
.	O

We	O
investigated	O
the	O
effect	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	B-Chemical
,	O
a	O
selective	O
serotonin	B-Chemical
uptake	O
inhibitor	O
,	O
on	O
behavioral	O
effects	O
of	O
dopaminomimetics	O
and	O
methoxamine	B-Chemical
and	O
on	O
the	O
animal	O
behavior	O
in	O
the	O
``	O
behavioral	O
despair	O
''	O
test	O
.	O

A	O
repeated	O
treatment	O
with	O
fluvoxamine	B-Chemical
(	O
twice	O
daily	O
for	O
14	O
days	O
)	O
potentiated	O
in	O
mice	O
and	O
in	O
rats	O
(	O
weaker	O
)	O
the	O
amphetamine-induced	B-Chemical
hyperactivity	B-Disease
.	O

The	O
hyperactivity	B-Disease
induced	O
by	O
nomifensine	B-Chemical
in	O
mice	O
remained	O
unaffected	O
by	O
fluvoxamine	B-Chemical
.	O

The	O
stimulation	O
of	O
locomotor	O
activity	O
by	O
intracerebroventricularly	O
administered	O
methoxamine	B-Chemical
was	O
not	O
affected	O
by	O
repeated	O
treatment	O
with	O
fluvoxamine	B-Chemical
.	O

Given	O
three	O
times	O
fluvoxamine	B-Chemical
had	O
no	O
effect	O
on	O
the	O
immobilization	O
time	O
in	O
the	O
``	O
behavioral	O
despair	O
''	O
test	O
in	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
fluvoxamine	B-Chemical
given	O
repeatedly	O
acts	O
differently	O
than	O
citalopram	B-Chemical
,	O
another	O
selective	O
serotonin	B-Chemical
uptake	O
inhibitor	O
,	O
and	O
differs	O
also	O
from	O
other	O
antidepressant	O
drugs	B-Drug
.	O

Severe	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
patient	O
on	O
amiodarone	B-Chemical
presenting	O
with	O
myxedemic	B-Disease
coma	I-Disease
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
myxedema	B-Disease
coma	I-Disease
secondary	O
to	O
amiodarone-induced	O
hypothyroidism	O
in	O
a	O
patient	O
with	O
severe	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

To	O
our	O
knowledge	O
and	O
after	O
reviewing	O
the	O
literature	O
there	O
is	O
one	O
case	O
report	O
of	O
myxedema	B-Chemical
coma	B-Chemical
during	O
long	O
term	O
amiodarone	B-Disease
therapy	O
.	O

Myxedema	O
coma	O
is	O
a	O
life	O
threatening	O
condition	O
that	O
carries	O
a	O
mortality	O
reaching	O
as	O
high	O
as	O
20	O
%	O
with	O
treatment	O
.	O

The	O
condition	O
is	O
treated	O
with	O
intravenous	O
thyroxine	B-Drug
(	O
T4	B-Drug
)	O
or	O
intravenous	O
tri-iodo-thyronine	O
(	O
T3	B-Drug
)	O
.	O

Patients	O
with	O
CHF	O
on	O
amiodarone	B-Drug
may	O
suffer	O
serious	O
morbidity	O
and	O
mortality	O
from	O
hypothyroidism	B-Chemical
,	O
and	O
thus	O
may	O
deserve	O
closer	O
follow	O
up	O
for	O
thyroid	B-Drug
stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
.	O

This	O
case	O
report	O
carries	O
an	O
important	O
clinical	O
application	O
given	O
the	O
frequent	O
usage	O
of	O
amiodarone	B-Drug
among	O
CHF	O
patients	O
.	O

The	O
myriad	O
clinical	O
presentation	O
of	O
myxedema	O
coma	O
and	O
its	O
serious	O
morbidity	O
and	O
mortality	O
stresses	O
the	O
need	O
to	O
suspect	O
this	O
clinical	O
syndrome	O
among	O
CHF	O
patients	O
presenting	O
with	O
hypotension	O
,	O
weakness	O
or	O
other	O
unexplained	O
symptoms	O
.	O

Fear-potentiated	O
startle	B-Disease
,	O
but	O
not	O
light-enhanced	O
startle	B-Disease
,	O
is	O
enhanced	O
by	O
anxiogenic	O
drugs	B-Drug
.	O

RATIONALE	O
AND	O
OBJECTIVES	O
:	O
The	O
light-enhanced	O
startle	B-Disease
paradigm	O
(	O
LES	O
)	O
is	O
suggested	O
to	O
model	O
anxiety	B-Disease
,	O
because	O
of	O
the	O
non-specific	O
cue	O
and	O
the	O
long-term	O
effect	O
.	O

In	O
contrast	O
,	O
the	O
fear-potentiated	O
startle	B-Disease
(	O
FPS	O
)	O
is	O
suggested	O
to	O
model	O
conditioned	O
fear	O
.	O

However	O
,	O
the	O
pharmacological	O
profiles	O
of	O
these	O
two	O
paradigms	O
are	O
very	O
similar	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
putative	O
anxiogenic	O
drugs	B-Drug
on	O
LES	O
and	O
FPS	O
and	O
aimed	O
at	O
determining	O
the	O
sensitivity	O
of	O
LES	O
for	O
anxiogenic	O
drugs	B-Drug
and	O
to	O
potentially	O
showing	O
a	O
pharmacological	O
differentiation	O
between	O
these	O
two	O
paradigms	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
received	O
each	O
dose	O
of	O
the	O
alpha	O
(	O
2	O
)	O
-adrenoceptor	O
antagonist	O
yohimbine	B-Chemical
(	O
0.25-1.0mg/kg	O
)	O
,	O
the	O
5-HT	B-Chemical
(	O
2C	O
)	O
receptor	O
agonist	O
m-chlorophenylpiperazine	B-Chemical
(	O
mCPP	B-Chemical
,	O
0.5-2.0mg/kg	O
)	O
or	O
the	O
GABA	B-Chemical
(	O
A	O
)	O
inverse	O
receptor	O
agonist	O
pentylenetetrazole	B-Chemical
(	O
PTZ	B-Chemical
,	O
3-30mg/kg	O
)	O
and	O
were	O
subsequently	O
tested	O
in	O
either	O
LES	O
or	O
FPS	O
.	O

RESULTS	O
:	O
None	O
of	O
the	O
drugs	B-Drug
enhanced	O
LES	O
,	O
whereas	O
mCPP	B-Chemical
increased	O
percentage	O
FPS	O
and	O
yohimbine	B-Chemical
increased	O
absolute	O
FPS	O
values	O
.	O

Furthermore	O
,	O
yohimbine	B-Chemical
increased	O
baseline	O
startle	B-Disease
amplitude	O
in	O
the	O
LES	O
,	O
while	O
mCPP	B-Chemical
suppressed	O
baseline	O
startle	B-Disease
in	O
both	O
the	O
LES	O
and	O
FPS	O
and	O
PTZ	B-Chemical
suppressed	O
baseline	O
startle	B-Disease
in	O
the	O
FPS	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
findings	O
in	O
the	O
FPS	O
paradigm	O
,	O
none	O
of	O
the	O
drugs	B-Drug
were	O
able	O
to	O
exacerbate	O
the	O
LES	O
response	O
.	O

Thus	O
,	O
a	O
clear	O
pharmacological	O
differentiation	O
was	O
found	O
between	O
LES	O
and	O
FPS	O
.	O

Proteinase	O
3-antineutrophil	O
cytoplasmic	O
antibody-	O
(	O
PR3-ANCA	O
)	O
positive	O
necrotizing	O
glomerulonephritis	B-Disease
after	O
restarting	O
sulphasalazine	B-Chemical
treatment	O
.	O

A	O
59-year-old	O
woman	O
with	O
ulcerative	B-Disease
colitis	I-Disease
developed	O
red	B-Disease
eyes	I-Disease
,	O
pleural	B-Disease
effusion	I-Disease
,	O
eosinophilia	B-Disease
and	O
urinary	B-Disease
abnormalities	I-Disease
after	O
restarting	O
of	O
sulphasalazine	B-Chemical
treatment	O
.	O

Light	O
microscopy	O
of	O
a	O
kidney	O
biopsy	O
revealed	O
segmental	B-Disease
necrotizing	I-Disease
glomerulonephritis	I-Disease
without	O
deposition	O
of	O
immunoglobulin	O
or	O
complement	O
.	O

Proteinase	O
3-antineutrophil	O
cytoplasmic	O
antibody	O
(	O
PR3-ANCA	O
)	O
titer	O
was	O
elevated	O
at	O
183	O
ELISA	O
units	O
(	O
EU	O
)	O
in	O
sera	O
(	O
normal	O
range	O
less	O
than	O
10	O
EU	O
)	O
,	O
myeloperoxidase-ANCA	O
was	O
negative	O
.	O

PR3-ANCA	O
titer	O
was	O
250	O
and	O
1,070	O
EU	O
in	O
pleural	B-Disease
effusions	I-Disease
on	O
right	O
and	O
left	O
side	O
,	O
respectively	O
.	O

Although	O
cessation	O
of	O
sulphasalazine	B-Chemical
treatment	O
resulted	O
in	O
improvements	O
in	O
fever	B-Disease
,	O
red	B-Disease
eyes	I-Disease
,	O
chest	B-Disease
pain	I-Disease
,	O
titer	O
of	O
C-reactive	O
protein	O
and	O
volume	O
of	O
the	O
pleural	B-Disease
effusions	I-Disease
,	O
we	O
initiated	O
steroid	B-Chemical
therapy	O
,	O
because	O
PR3-ANCA	O
titer	O
rose	O
to	O
320	O
EU	O
,	O
eosinophil	O
count	O
increased	O
to	O
1,100	O
cells/microl	O
,	O
and	O
the	O
pleural	B-Disease
effusion	I-Disease
remained	O
.	O

One	O
month	O
after	O
steroid	B-Chemical
therapy	O
,	O
the	O
pleural	B-Disease
effusion	I-Disease
disappeared	O
,	O
and	O
PR3-ANCA	O
titer	O
normalized	O
3	O
months	O
later	O
.	O

This	O
case	O
suggests	O
that	O
sulphasalazine	B-Chemical
can	O
induce	O
PR3-ANCA-positive	O
necrotizing	O
glomerulonephritis	B-Disease
.	O

Is	O
phenytoin	B-Chemical
administration	O
safe	O
in	O
a	O
hypothermic	B-Disease
child	O
?	O
A	O
male	O
neonate	O
with	O
a	O
Chiari	B-Disease
malformation	I-Disease
and	O
a	O
leaking	O
myelomeningocoele	O
underwent	O
ventriculoperitoneal	O
shunt	O
insertion	O
followed	O
by	O
repair	O
of	O
myelomeningocoele	O
.	O

During	O
anaesthesia	O
and	O
surgery	O
,	O
he	O
inadvertently	O
became	O
moderately	O
hypothermic	B-Disease
.	O

Intravenous	O
phenytoin	B-Chemical
was	O
administered	O
during	O
the	O
later	O
part	O
of	O
the	O
surgery	O
for	O
seizure	B-Disease
prophylaxis	O
.	O

Following	O
phenytoin	B-Chemical
administration	O
,	O
the	O
patient	O
developed	O
acute	O
severe	O
bradycardia	B-Disease
,	O
refractory	O
to	O
atropine	B-Chemical
and	O
adrenaline	B-Chemical
.	O

The	O
cardiac	O
depressant	O
actions	O
of	O
phenytoin	B-Chemical
and	O
hypothermia	B-Disease
can	O
be	O
additive	O
.	O

Administration	O
of	O
phenytoin	B-Chemical
in	O
the	O
presence	O
of	O
hypothermia	B-Disease
may	O
lead	B-Drug
to	O
an	O
adverse	O
cardiac	O
event	O
in	O
children	O
.	O

As	O
phenytoin	B-Chemical
is	O
a	O
commonly	O
used	O
drug	B-Drug
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
interaction	O
.	O

Amisulpride	B-Chemical
related	O
tic-like	B-Disease
symptoms	I-Disease
in	O
an	O
adolescent	O
schizophrenic	B-Disease
.	O

Tic	B-Disease
disorders	I-Disease
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	B-Chemical
,	O
olanzapine	B-Chemical
and	O
ziprasidone	B-Chemical
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic-like	B-Disease
symptoms	I-Disease
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	B-Chemical
or	O
clozapine	B-Chemical
.	O

We	O
present	O
a	O
15-year-old	O
girl	O
schizophrenic	B-Disease
who	O
developed	O
frequent	O
involuntary	B-Disease
eye-blinking	I-Disease
movements	I-Disease
after	O
5	O
months	O
of	O
amisulpride	B-Chemical
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic-like	B-Disease
symptoms	I-Disease
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	B-Chemical
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

However	O
,	O
her	O
psychosis	B-Disease
recurred	O
after	O
the	O
dose	O
reduction	O
.	O

We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	B-Chemical
.	O

She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O

No	O
more	O
tic-like	B-Disease
symptoms	I-Disease
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	O
suggests	O
that	O
tic-like	B-Disease
symptoms	I-Disease
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
such	O
as	O
quetiapine	B-Chemical
,	O
clozapine	B-Chemical
,	O
or	O
amisulpride	B-Chemical
.	O

Comparison	O
of	O
developmental	O
toxicology	O
of	O
aspirin	B-Chemical
(	O
acetylsalicylic	B-Chemical
acid	I-Chemical
)	O
in	O
rats	O
using	O
selected	O
dosing	O
paradigms	O
.	O

BACKGROUND	O
:	O
Analysis	O
of	O
the	O
literature	O
for	O
nonsteroidal	O
anti-inflammatory	O
drugs	B-Drug
(	O
NSAIDs	O
)	O
suggests	O
that	O
a	O
low	O
incidence	O
of	O
developmental	B-Disease
anomalies	I-Disease
occurs	O
in	O
rats	O
given	O
NSAIDs	O
on	O
specific	O
days	O
during	O
organogenesis	O
.	O

Aspirin	B-Chemical
(	O
acetylsalicylic	B-Chemical
acid	I-Chemical
[	O
ASA	B-Chemical
]	O
)	O
,	O
an	O
irreversible	O
cyclooxygenase	O
1	O
and	O
2	O
inhibitor	O
,	O
induces	O
developmental	B-Disease
anomalies	I-Disease
when	O
administered	O
to	O
Wistar	O
rats	O
on	O
gestational	O
day	O
(	O
GD	O
)	O
9	O
,	O
10	O
,	O
or	O
11	O
(	O
Kimmel	O
CA	O
,	O
Wilson	O
JG	O
,	O
Schumacher	O
HJ	O
.	O

Teratology	O
4:15-24	O
,	O
1971	O
)	O
.	O

There	O
are	O
no	O
published	O
ASA	B-Chemical
studies	O
using	O
the	O
multiple	O
dosing	O
paradigm	O
of	O
GDs	O
6	O
to	O
17	O
.	O

Objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
compare	O
results	O
between	O
Sprague-Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
strains	O
when	O
ASA	B-Chemical
is	O
administered	O
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	O
following	O
single	O
and	O
multiple	O
dosings	O
during	O
organogenesis	O
in	O
SD	O
rats	O
;	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
maternal	O
gastrointestinal	B-Disease
toxicity	I-Disease
confounds	O
the	O
detection	O
of	O
low	O
incidence	O
malformations	B-Disease
with	O
ASA	B-Chemical
when	O
a	O
multiple	O
dosing	O
paradigm	O
is	O
used	O
.	O

METHODS	O
:	O
ASA	B-Chemical
was	O
administered	O
as	O
a	O
single	O
dose	O
on	O
GD	O
9	O
(	O
0	O
,	O
250	O
,	O
500	O
,	O
or	O
625	O
mg/kg	O
)	O
,	O
10	O
(	O
0	O
,	O
500	O
,	O
625	O
,	O
or	O
750	O
mg/kg	O
)	O
,	O
or	O
11	O
(	O
0	O
,	O
500	O
,	O
750	O
,	O
or	O
1000	O
mg/kg	O
)	O
and	O
from	O
GD	O
6	O
to	O
GD	O
17	O
(	O
0	O
,	O
50	O
,	O
125	O
,	O
or	O
250	O
mg/kg	O
a	O
day	O
)	O
in	O
the	O
multiple	O
dose	O
study	O
to	O
SD	O
rats	O
.	O

Animals	O
were	O
killed	O
on	O
GD	O
21	O
,	O
and	O
fetuses	O
were	O
examined	O
viscerally	O
.	O

RESULTS	O
:	O
The	O
literature	O
evaluation	O
suggested	O
that	O
NSAIDs	O
induce	O
ventricular	B-Disease
septal	I-Disease
defects	I-Disease
(	O
VSDs	B-Disease
)	O
and	O
midline	B-Disease
defects	I-Disease
(	O
MDs	B-Disease
)	O
in	O
rats	O
and	O
diaphragmatic	B-Disease
hernia	I-Disease
(	O
DH	B-Disease
)	O
,	O
MDs	B-Disease
,	O
and	O
VSDs	B-Disease
in	O
rabbits	O
(	O
Cook	O
JC	O
et	O
al.	O
,	O
2003	O
)	O
;	O
hence	O
,	O
the	O
present	O
study	O
focused	O
on	O
these	O
malformations	B-Disease
,	O
even	O
though	O
ASA	B-Chemical
induces	O
several	O
other	O
low-incidence	O
malformations	B-Disease
.	O

In	O
single	O
dose	O
studies	O
,	O
DH	B-Disease
,	O
MD	B-Disease
,	O
and	O
VSD	B-Disease
were	O
induced	O
on	O
GDs	O
9	O
and	O
10	O
.	O

VSD	B-Disease
also	O
was	O
noted	O
following	O
treatment	O
on	O
GD	O
11	O
.	O

In	O
contrast	O
,	O
DH	B-Disease
and	O
MD	B-Disease
were	O
noted	O
in	O
the	O
multiple	O
dose	O
study	O
design	O
only	O
in	O
the	O
high-dose	O
group	O
,	O
and	O
VSD	B-Disease
was	O
noted	O
across	O
all	O
dose	O
groups	O
.	O

CONCLUSIONS	O
:	O
High	O
concordance	O
in	O
major	O
developmental	B-Disease
anomalies	I-Disease
between	O
Wistar	O
and	O
SD	O
rats	O
were	O
noted	O
with	O
the	O
exception	O
of	O
VSD	B-Disease
in	O
the	O
SD	O
rats	O
and	O
hydrocephalus	B-Disease
in	O
the	O
Wistar	O
rats	O
.	O

Variations	O
and	O
malformations	B-Disease
were	O
similar	O
when	O
ASA	B-Chemical
was	O
administered	O
as	O
a	O
single	O
dose	O
or	O
during	O
the	O
period	O
of	O
organogenesis	O
(	O
GDs	O
6	O
to	O
17	O
)	O
.	O

It	O
was	O
also	O
evident	O
that	O
,	O
by	O
titrating	O
the	O
dose	O
to	O
achieve	O
a	O
maximum	O
tolerated	O
dose	O
,	O
malformations	B-Disease
that	O
normally	O
occur	O
at	O
low	O
incidence	O
,	O
as	O
reported	O
from	O
previous	O
single	O
dose	O
studies	O
,	O
could	O
also	O
be	O
induced	O
with	O
ASA	B-Chemical
given	O
at	O
multiple	O
doses	O
.	O

Torsade	B-Disease
de	B-Disease
pointes	I-Disease
induced	O
by	O
metoclopramide	B-Chemical
in	O
an	O
elderly	O
woman	O
with	O
preexisting	O
complete	O
left	B-Disease
bundle	I-Disease
branch	I-Disease
block	I-Disease
.	O

There	O
is	O
a	O
growing	O
list	O
of	O
drugs	B-Drug
implicated	O
in	O
acquired	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
and	O
torsade	B-Disease
de	B-Disease
pointes	I-Disease
.	O

However	O
,	O
the	O
torsadogenic	O
potential	O
of	O
metoclopramide	B-Chemical
,	O
a	O
commonly	O
used	O
antiemetic	O
and	O
prokinetic	O
drug	B-Drug
,	O
has	O
not	O
been	O
reported	O
in	O
the	O
literature	O
,	O
despite	O
its	O
chemical	O
similarity	O
to	O
procainamide	B-Chemical
.	O

We	O
report	O
on	O
a	O
92-year-old	O
woman	O
with	O
preexisting	O
complete	O
left	B-Disease
bundle	I-Disease
branch	I-Disease
block	I-Disease
who	O
developed	O
torsade	B-Disease
de	B-Disease
pointes	I-Disease
after	O
intravenous	O
and	O
oral	O
administration	O
of	O
metoclopramide	B-Chemical
.	O

This	O
patient	O
also	O
developed	O
torsade	B-Disease
de	B-Disease
pointes	I-Disease
when	O
cisapride	B-Chemical
and	O
erythromycin	B-Chemical
were	O
given	O
simultaneously	O
.	O

These	O
two	O
episodes	O
were	O
suppressed	O
successfully	O
after	O
discontinuing	O
the	O
offending	O
drugs	B-Drug
and	O
administering	O
class	O
IB	O
drugs	B-Drug
.	O

This	O
is	O
the	O
first	O
documentation	O
that	O
metoclopramide	B-Chemical
provokes	O
torsade	B-Disease
de	B-Disease
pointes	I-Disease
clinically	O
.	O

Metoclopramide	B-Chemical
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
risk	O
of	O
torsade	B-Disease
de	B-Disease
pointes	I-Disease
.	O

Apomorphine	B-Chemical
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

Apomorphine	B-Chemical
was	O
the	O
first	O
dopaminergic	B-Drug
drug	B-Drug
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
by	O
subcutaneous	O
administration	O
of	O
apomorphine	B-Chemical
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	B-Chemical
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	B-Chemical
and	O
that	O
apomorphine	B-Chemical
rescue	O
injections	O
can	O
reliably	O
revert	O
off-periods	O
even	O
in	O
patients	O
with	O
complex	O
on-off	O
motor	O
swings	O
.	O

Continuous	O
subcutaneous	O
apomorphine	B-Chemical
infusions	O
can	O
reduce	O
daily	O
off-time	O
by	O
more	O
than	O
50	O
%	O
in	O
this	O
group	O
of	O
patients	O
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add-on	O
therapy	O
with	O
oral	O
dopamine	B-Chemical
agonists	O
or	O
COMT	O
inhibitors	O
.	O

Extended	O
follow-up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long-term	O
persistence	O
of	O
apomorphine	B-Chemical
efficacy	O
.	O

In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	B-Chemical
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	B-Chemical
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	B-Disease
complications	O
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	B-Chemical
treatment	O
in	O
fluctuating	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O

Fatal	O
excited	O
delirium	B-Disease
following	O
cocaine	B-Chemical
use	O
:	O
epidemiologic	O
findings	O
provide	O
new	O
evidence	O
for	O
mechanisms	O
of	O
cocaine	B-Chemical
toxicity	B-Disease
.	O

We	O
describe	O
an	O
outbreak	O
of	O
deaths	O
from	O
cocaine-induced	B-Chemical
excited	O
delirium	B-Disease
(	O
EDDs	B-Disease
)	O
in	O
Dade	O
County	O
,	O
Florida	O
between	O
1979	O
and	O
1990	O
.	O

From	O
a	O
registry	O
of	O
all	O
cocaine-related	B-Chemical
deaths	O
in	O
Dade	O
County	O
,	O
Florida	O
,	O
from	O
1969-1990	O
,	O
58	O
EDDs	B-Disease
were	O
compared	O
with	O
125	O
victims	O
of	O
accidental	O
cocaine	B-Chemical
overdose	B-Disease
without	O
excited	O
delirium	B-Disease
.	O

Compared	O
with	O
controls	O
,	O
EDDs	B-Disease
were	O
more	O
frequently	O
black	O
,	O
male	O
,	O
and	O
younger	O
.	O

They	O
were	O
less	O
likely	O
to	O
have	O
a	O
low	O
body	O
mass	O
index	O
,	O
and	O
more	O
likely	O
to	O
have	O
died	O
in	O
police	O
custody	O
,	O
to	O
have	O
received	O
medical	O
treatment	O
immediately	O
before	O
death	O
,	O
to	O
have	O
survived	O
for	O
a	O
longer	O
period	O
,	O
to	O
have	O
developed	O
hyperthermia	B-Disease
,	O
and	O
to	O
have	O
died	O
in	O
summer	O
months	O
.	O

EDDs	B-Disease
had	O
concentrations	O
of	O
cocaine	B-Chemical
and	O
benzoylecgonine	B-Chemical
in	O
autopsy	O
blood	O
that	O
were	O
similar	O
to	O
those	O
for	O
controls	O
.	O

The	O
epidemiologic	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
hypothesis	O
that	O
chronic	O
cocaine	B-Chemical
use	O
disrupts	O
dopaminergic	B-Drug
function	O
and	O
,	O
when	O
coupled	O
with	O
recent	O
cocaine	B-Chemical
use	O
,	O
may	O
precipitate	O
agitation	B-Disease
,	O
delirium	B-Disease
,	O
aberrant	O
thermoregulation	O
,	O
rhabdomyolysis	B-Disease
,	O
and	O
sudden	B-Disease
death	I-Disease
.	O

Heparin-induced	B-Chemical
thrombocytopenia	B-Disease
,	O
thrombosis	B-Disease
,	O
and	O
hemorrhage	B-Disease
.	O

Sixty-two	O
patients	O
with	O
a	O
heparin-induced	B-Chemical
thrombocytopenia	B-Disease
are	O
reported	O
.	O

Clinical	O
manifestations	O
of	O
this	O
disorder	O
include	O
hemorrhage	B-Disease
or	O
,	O
more	O
frequently	O
,	O
thromboembolic	B-Disease
events	O
in	O
patients	O
receiving	O
heparin	B-Chemical
.	O

Laboratory	B-Disease
testing	O
has	B-Disease
revealed	B-Disease
a	B-Disease
falling	O
platelet	O
count	O
,	O
increased	O
resistance	O
to	O
heparin	B-Chemical
,	O
and	O
aggregation	O
of	O
platelets	O
by	O
the	O
patient	O
's	O
plasma	O
when	O
heparin	B-Chemical
is	O
added	O
.	O

Immunologic	O
testing	O
has	O
demonstrated	O
the	O
presence	O
of	O
a	O
heparin-dependent	B-Chemical
platelet	O
membrane	O
antibody	O
.	O

The	O
20	O
deaths	O
,	O
52	O
hemorrhagic	B-Disease
and	I-Disease
thromboembolic	I-Disease
complications	I-Disease
,	O
and	O
21	O
surgical	O
procedures	O
to	O
manage	O
the	O
complications	I-Chemical
confirm	O
the	O
seriousness	O
of	O
the	O
disorder	O
.	O

Specific	O
risk	O
factors	O
have	O
not	O
been	O
identified	O
;	O
therefore	O
,	O
all	O
patients	O
receiving	O
heparin	B-Drug
should	O
be	O
monitored	O
.	O

If	O
the	O
platelet	O
count	O
falls	O
to	O
less	O
than	O
100,000/mm3	O
,	O
while	O
the	O
patient	O
is	O
receiving	O
heparin	B-Drug
,	O
platelet	O
aggregation	O
testing	O
,	O
using	O
the	O
patient	O
's	O
plasma	O
,	O
is	O
indicated	O
.	O

Management	O
consists	O
of	O
cessation	O
of	O
heparin	B-Drug
,	O
platelet	O
anti-aggregating	O
agents	O
,	O
and	O
alternate	O
forms	O
of	O
anticoagulation	O
when	O
indicated	O
.	O

Cardiac	B-Disease
toxicity	I-Disease
of	O
5-fluorouracil	B-Chemical
.	O

Report	O
of	O
a	O
case	O
of	O
spontaneous	O
angina	B-Disease
.	O

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
colon	B-Disease
carcinoma	I-Disease
and	O
liver	O
metastasis	B-Disease
who	O
presented	O
chest	B-Disease
pain	I-Disease
after	O
5-fluorouracil	B-Chemical
(	O
5-FU	B-Chemical
)	O
administration	O
.	O

Clinical	O
electrocardiographic	O
evolution	O
was	O
similar	O
to	O
that	O
observed	O
in	O
Prinzmetal	B-Disease
's	I-Disease
angina	I-Disease
,	O
and	O
chest	B-Disease
pain	I-Disease
promptly	O
resolved	O
with	O
nifedipine	B-Chemical
.	O

These	O
data	O
suggest	O
that	O
coronary	B-Disease
spasm	I-Disease
may	O
be	O
the	O
cause	O
of	O
cardiotoxicity	B-Disease
due	O
to	O
5-FU	B-Chemical
,	O
and	O
that	O
calcium	B-Chemical
antagonists	O
may	O
probably	O
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
5-FU	B-Chemical
cardiotoxicity	B-Disease
.	O

Toxicity	B-Disease
due	O
to	O
remission	O
inducing	O
drugs	B-Drug
in	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Association	O
with	O
HLA-B35	O
and	O
Cw4	O
antigens	O
.	O

Twenty-five	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
who	O
developed	O
toxicity	B-Disease
while	O
taking	O
remission	O
inducing	O
drugs	B-Drug
and	O
30	O
without	O
toxicity	B-Disease
were	O
studied	O
for	O
possible	O
associations	O
with	O
class	O
I	O
and	O
II	O
HLA	O
antigens	O
.	O

A	O
strong	O
association	O
has	O
been	O
found	O
between	O
nephritis	B-Disease
and	O
dermatitis	B-Disease
due	O
to	O
Tiopronin	B-Chemical
(	O
a	O
D-Penicillamine	B-Chemical
like	O
compound	O
)	O
and	O
class	O
I	O
antigens	O
B35-Cw4	O
,	O
and	O
between	O
dermatitis	B-Disease
due	O
to	O
gold	B-Chemical
thiosulphate	B-Chemical
and	O
B35	O
.	O

Compared	O
to	O
healthy	O
controls	O
a	O
lower	O
DR5	O
frequency	O
was	O
observed	O
in	O
patients	O
with	O
RA	B-Disease
except	O
for	O
the	O
Tiopronin	B-Chemical
related	O
nephritis	B-Disease
group	O
.	O

Transient	O
hemiparesis	B-Disease
:	O
a	O
rare	O
manifestation	O
of	O
diphenylhydantoin	B-Chemical
toxicity	B-Disease
.	O

Report	O
of	O
two	O
cases	O
.	O

Among	O
the	O
common	O
side	O
effects	O
of	O
diphenylhydantoin	B-Chemical
(	O
DPH	B-Chemical
)	O
overdose	B-Disease
,	O
the	O
most	O
frequently	O
encountered	O
neurological	O
signs	O
are	O
those	O
of	O
cerebellar	B-Disease
dysfunction	I-Disease
.	O

Very	O
rarely	O
,	O
the	O
toxic	O
neurological	O
manifestations	O
of	O
this	O
drug	B-Drug
are	O
of	O
cerebral	O
origin	O
.	O

Two	O
patients	O
are	O
presented	O
who	O
suffered	O
progressive	O
hemiparesis	B-Disease
due	O
to	O
DPH	B-Chemical
overdose	B-Disease
.	O

Both	O
had	O
brain	O
surgery	O
before	O
DPH	B-Chemical
treatment	O
.	O

It	O
is	O
assumed	O
that	O
patients	O
with	O
some	O
cerebral	B-Disease
damage	I-Disease
are	O
liable	O
to	O
manifest	O
DPH	B-Chemical
toxicity	B-Disease
as	O
focal	O
neurological	O
signs	O
.	O

Nerve	O
growth	O
factor	O
and	O
prostaglandins	B-Chemical
in	O
the	O
urine	O
of	O
female	O
patients	O
with	O
overactive	B-Disease
bladder	I-Disease
.	O

PURPOSE	O
:	O
NGF	O
and	O
PGs	B-Chemical
in	O
the	O
bladder	O
can	O
be	O
affected	O
by	O
pathological	O
changes	O
in	O
the	O
bladder	O
and	O
these	O
changes	O
can	O
be	O
detected	O
in	O
urine	O
.	O

We	O
investigated	O
changes	O
in	O
urinary	O
NGF	O
and	O
PGs	B-Chemical
in	O
women	O
with	O
OAB	B-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
study	O
groups	O
included	O
65	O
women	O
with	O
OAB	B-Disease
and	O
20	O
without	O
bladder	O
symptoms	O
who	O
served	O
as	O
controls	O
.	O

Evaluation	O
included	O
patient	O
history	O
,	O
urinalysis	O
,	O
a	O
voiding	O
diary	O
and	O
urodynamic	O
studies	O
.	O

Urine	O
samples	O
were	O
collected	O
.	O

NGF	O
,	O
PGE2	B-Chemical
,	O
PGF2alpha	B-Chemical
and	O
PGI2	B-Chemical
were	O
measured	O
using	O
enzyme-linked	O
immunosorbent	O
assay	O
and	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
correlations	O
between	O
urinary	O
NGF	O
and	O
PG	B-Chemical
,	O
and	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	B-Disease
were	O
examined	O
.	O

RESULTS	O
:	O
Urinary	O
NGF	O
,	O
PGE2	B-Chemical
and	O
PGF2alpha	B-Chemical
were	O
significantly	O
increased	O
in	O
patients	O
with	O
OAB	B-Disease
compared	O
with	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
urinary	O
PGI2	B-Chemical
was	O
not	O
different	O
between	O
controls	O
and	O
patients	O
with	O
OAB	B-Disease
.	O

In	O
patients	O
with	O
OAB	B-Disease
urinary	O
PGE2	B-Chemical
positively	O
correlated	O
with	O
volume	O
at	O
first	O
desire	O
to	O
void	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Urinary	O
NGF	O
,	O
PGF2alpha	B-Chemical
and	O
PGI2	B-Chemical
did	O
not	O
correlate	O
with	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	B-Disease
.	O

CONCLUSIONS	O
:	O
NGF	O
and	O
PGs	B-Chemical
have	O
important	O
roles	O
in	O
the	O
development	O
of	O
OAB	B-Disease
symptoms	O
in	O
female	O
patients	O
.	O

Urinary	O
levels	O
of	O
these	O
factors	O
may	O
be	O
used	O
as	O
markers	O
to	O
evaluate	O
OAB	B-Disease
symptoms	O
.	O

Acute	O
low	B-Disease
back	I-Disease
pain	I-Disease
during	O
intravenous	O
administration	O
of	O
amiodarone	B-Chemical
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Amiodarone	B-Chemical
represents	O
an	O
effective	O
antiarrhythmic	B-Drug
drug	B-Drug
for	O
cardioversion	O
of	O
recent-onset	O
atrial	B-Disease
fibrillation	I-Disease
(	O
AF	B-Disease
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent-onset	O
atrial	B-Disease
fibrillation	I-Disease
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B-Disease
back	I-Disease
pain	I-Disease
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	B-Chemical
loading	O
.	O

Notably	O
,	O
this	O
side	O
effect	O
has	O
not	O
been	O
ever	O
reported	O
in	O
the	O
medical	O
literature	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
since	O
prompt	O
termination	O
of	O
parenteral	O
administration	O
leads	O
to	O
complete	O
resolution	O
.	O

Postoperative	B-Disease
myalgia	I-Disease
after	O
succinylcholine	B-Chemical
:	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
.	O

A	O
common	O
side	O
effect	O
associated	O
with	O
succinylcholine	B-Chemical
is	O
postoperative	B-Disease
myalgia	I-Disease
.	O

The	O
pathogenesis	O
of	O
this	O
myalgia	B-Disease
is	O
still	O
unclear	O
;	O
inflammation	B-Disease
has	O
been	O
suggested	O
but	O
without	O
convincing	O
evidence	O
.	O

We	O
designed	O
the	O
present	O
study	O
to	O
investigate	O
whether	O
an	O
inflammatory	O
reaction	O
contributes	O
to	O
this	O
myalgia	B-Disease
.	O

The	O
incidence	O
and	O
severity	O
of	O
succinylcholine-associated	B-Chemical
myalgia	B-Disease
was	O
determined	O
in	O
64	O
patients	O
pretreated	O
with	O
saline	O
or	O
dexamethasone	B-Chemical
before	O
succinylcholine	B-Chemical
(	O
n	O
=	O
32	O
for	O
each	O
)	O
.	O

Incidence	O
and	O
severity	O
of	O
myalgia	B-Disease
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
15	O
patients	O
in	O
the	O
dexamethasone	B-Chemical
group	O
complained	O
of	O
myalgia	B-Disease
compared	O
with	O
18	O
patients	O
in	O
the	O
saline	O
group	O
,	O
and	O
severe	O
myalgia	B-Disease
was	O
reported	O
by	O
five	O
patients	O
and	O
three	O
patients	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O

At	O
48	O
h	O
after	O
surgery	O
,	O
12	O
patients	O
in	O
both	O
groups	O
still	O
suffered	O
from	O
myalgia	B-Disease
(	O
not	O
significant	O
)	O
.	O

In	O
addition	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
as	O
an	O
early	O
marker	O
of	O
inflammation	B-Disease
was	O
assessed	O
in	O
a	O
subgroup	O
of	O
10	O
patients	O
pretreated	O
with	O
saline	O
.	O

We	O
found	O
an	O
increase	O
of	O
IL-6	O
for	O
only	O
three	O
patients	O
,	O
but	O
only	O
one	O
patient	O
reported	O
myalgia	B-Disease
;	O
no	O
relationship	O
between	O
myalgia	B-Disease
and	O
the	O
increase	O
of	O
IL-6	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
of	O
succinylcholine-associated	B-Chemical
myalgia	B-Disease
.	O

IMPLICATIONS	O
:	O
Administration	O
of	O
dexamethasone	B-Chemical
before	O
succinylcholine	B-Chemical
was	O
not	O
effective	O
in	O
decreasing	O
the	O
incidence	O
or	O
the	O
severity	O
of	O
succinylcholine-induced	B-Chemical
postoperative	B-Disease
myalgia	I-Disease
.	O

Furthermore	O
,	O
there	O
was	O
no	O
significant	O
relationship	O
between	O
postoperative	B-Disease
myalgia	I-Disease
and	O
time	O
course	O
of	O
interleukin-6	O
concentrations	O
,	O
a	O
marker	O
of	O
inflammation	B-Disease
.	O

Pretreatment	O
with	O
dexamethasone	B-Chemical
is	O
not	O
justified	O
to	O
prevent	O
postoperative	B-Disease
myalgia	I-Disease
after	O
succinylcholine	B-Chemical
.	O

Levodopa-induced	B-Chemical
oromandibular	O
dystonia	B-Disease
in	O
progressive	B-Disease
supranuclear	I-Disease
palsy	I-Disease
.	O

Levodopa-induced	B-Chemical
dyskinesias	B-Disease
have	O
been	O
reported	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
and	O
multiple	B-Disease
system	I-Disease
atrophy	I-Disease
.	O

Cranial	O
dystonias	B-Disease
are	O
rare	O
in	O
patients	O
with	O
progressive	B-Disease
supranuclear	I-Disease
palsy	I-Disease
(	O
PSP	B-Disease
)	O
.	O

In	O
this	O
report	O
we	O
describe	O
an	O
unusual	O
case	O
of	O
reversible	O
levodopa-induced	B-Chemical
Oromandibular	B-Disease
dystonia	I-Disease
(	O
OMD	B-Disease
)	O
in	O
a	O
PSP	B-Disease
patient	O
to	O
highlight	O
the	O
importance	O
of	O
recognizing	O
this	O
drug	B-Drug
related	O
complication	O
in	O
the	O
management	O
of	O
PSP	B-Disease
,	O
and	O
discuss	O
the	O
possible	O
underlying	O
pathophysiology	O
.	O

Protective	O
effect	O
of	O
edaravone	B-Chemical
against	O
streptomycin-induced	B-Chemical
vestibulotoxicity	B-Disease
in	O
the	O
guinea	O
pig	O
.	O

This	O
study	O
investigated	O
alleviation	O
of	O
streptomycin-induced	B-Chemical
vestibulotoxicity	B-Disease
by	O
edaravone	B-Chemical
in	O
guinea	O
pigs	O
.	O

Edaravone	B-Chemical
,	O
a	O
free	O
radical	O
scavenger	O
,	O
has	O
potent	O
free	O
radical	O
quenching	O
action	O
and	O
is	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
cerebral	B-Disease
infarction	I-Disease
.	O

Streptomycin	B-Chemical
was	O
administered	O
to	O
the	O
inner	O
ear	O
by	O
osmotic	O
pump	O
for	O
24	O
h	O
,	O
and	O
edaravone	B-Chemical
(	O
n=8	O
)	O
or	O
saline	O
(	O
n=6	O
)	O
was	O
intraperitoneally	O
injected	O
once	O
a	O
day	O
for	O
7	O
days	O
.	O

We	O
observed	O
horizontal	O
vestibulo-ocular	O
reflex	O
as	O
a	O
marker	O
of	O
postoperative	O
vestibular	O
function	O
.	O

Animals	O
injected	O
with	O
saline	O
showed	O
statistically	O
smaller	O
gains	O
than	O
those	O
injected	O
with	O
edaravone	B-Chemical
.	O

These	O
results	O
suggest	O
that	O
edaravone	B-Chemical
suppresses	O
streptomycin-induced	B-Chemical
vestibulotoxicity	B-Disease
.	O

Ketamine	B-Chemical
in	O
war/tropical	O
surgery	O
(	O
a	O
final	O
tribute	O
to	O
the	O
racemic	O
mixture	O
)	O
.	O

A	O
technique	O
of	O
continuous	O
intravenous	O
anaesthesia	O
with	O
ketamine	B-Chemical
was	O
used	O
successfully	O
during	O
the	O
Somalia	O
civil	O
war	O
in	O
1994	O
and	O
in	O
north	O
Uganda	O
in	O
1999	O
for	O
64	O
operations	O
in	O
62	O
patients	O
,	O
aged	O
from	O
6	O
weeks	O
to	O
70	O
years	O
,	O
undergoing	O
limb	O
and	O
abdominal	O
surgery	O
including	O
caesarian	O
sections	O
and	O
interventions	O
in	O
neonates	O
.	O

Operations	O
lasting	O
up	O
to	O
2h	O
could	O
be	O
performed	O
in	O
the	O
absence	O
of	O
sophisticated	O
equipment	O
such	O
as	O
pulse	O
oximeters	O
or	O
ventilators	O
in	O
patients	O
on	O
spontaneous	O
ventilation	O
breathing	O
air/oxygen	B-Chemical
only	O
.	O

After	O
premedication	O
with	O
diazepam	B-Chemical
,	O
glycopyrrolate	B-Chemical
and	O
local	O
anaesthesia	O
,	O
and	O
induction	O
with	O
standard	O
doses	O
of	O
ketamine	B-Chemical
,	O
a	O
maintenance	O
dose	O
of	O
10-20	O
microg/kg/min	O
of	O
ketamine	B-Chemical
proved	O
safe	O
and	O
effective	O
.	O

Emphasis	O
was	O
placed	O
on	O
bedside	O
clinical	O
monitoring	O
,	O
relying	O
heavily	O
on	O
the	O
heart	O
rate	O
.	O

Diazepam	B-Chemical
,	O
unless	O
contraindicated	O
or	O
risky	O
,	O
remains	O
the	O
only	O
necessary	O
complementary	O
drug	B-Drug
to	O
ketamine	B-Chemical
as	O
it	O
buffers	O
its	O
cardiovascular	O
response	O
and	O
decreases	O
the	O
duration	O
and	O
intensity	O
of	O
operative	O
and	O
postoperative	O
hallucinations	B-Disease
.	O

Local	O
anaesthetic	O
blocks	O
were	O
useful	O
in	O
decreasing	O
the	O
requirement	O
for	O
postoperative	O
analgesia	B-Disease
.	O

An	O
antisialogue	O
was	O
usually	O
unnecessary	O
in	O
operations	O
lasting	O
up	O
to	O
2	O
h	O
,	O
glycopyrrolate	B-Chemical
being	O
the	O
best	O
choice	O
for	O
its	O
lowest	O
psychotropic	O
and	O
chronotropic	O
effects	O
,	O
especially	O
in	O
a	O
hot	O
climate	O
.	O

Experience	O
in	O
war/tropical	O
settings	O
suggests	O
this	O
technique	O
could	O
be	O
useful	O
in	O
civilian	O
contexts	O
such	O
as	O
outdoor	O
life-saving	O
emergency	O
surgery	O
or	O
in	O
mass	O
casualties	O
where	O
,	O
e.g	O
.	O

amputation	O
and	O
rapid	O
extrication	O
were	O
required	O
.	O

Steroid	B-Chemical
structure	O
and	O
pharmacological	O
properties	O
determine	O
the	O
anti-amnesic	B-Disease
effects	O
of	O
pregnenolone	B-Chemical
sulphate	I-Chemical
in	O
the	O
passive	O
avoidance	O
task	O
in	O
rats	O
.	O

Pregnenolone	B-Chemical
sulphate	I-Chemical
(	O
PREGS	B-Chemical
)	O
has	O
generated	O
interest	O
as	O
one	O
of	O
the	O
most	O
potent	O
memory-enhancing	O
neurosteroids	B-Chemical
to	O
be	O
examined	O
in	O
rodent	O
learning	O
studies	O
,	O
with	O
particular	O
importance	O
in	O
the	O
ageing	O
process	O
.	O

The	O
mechanism	O
by	O
which	O
this	O
endogenous	O
steroid	O
enhances	O
memory	O
formation	O
is	O
hypothesized	O
to	O
involve	O
actions	O
on	O
glutamatergic	O
and	O
GABAergic	O
systems	O
.	O

This	O
hypothesis	O
stems	O
from	O
findings	O
that	O
PREGS	B-Chemical
is	O
a	O
potent	O
positive	O
modulator	O
of	O
N-methyl-d-aspartate	B-Chemical
receptors	O
(	O
NMDARs	O
)	O
and	O
a	O
negative	O
modulator	O
of	O
gamma-aminobutyric	B-Chemical
acid	I-Chemical
(	O
A	O
)	O
receptors	O
(	O
GABA	B-Chemical
(	O
A	O
)	O
Rs	O
)	O
.	O

Moreover	O
,	O
PREGS	B-Chemical
is	O
able	O
to	O
reverse	O
the	O
amnesic-like	B-Disease
effects	O
of	O
NMDAR	O
and	O
GABA	B-Chemical
(	O
A	O
)	O
R	O
ligands	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
the	O
present	O
study	O
in	O
rats	O
examined	O
the	O
memory-altering	O
abilities	O
of	O
structural	O
analogs	O
of	O
PREGS	B-Chemical
,	O
which	O
differ	O
in	O
their	O
modulation	O
of	O
NMDAR	O
and/or	O
GABA	B-Chemical
(	O
A	O
)	O
R	O
function	O
.	O

The	O
analogs	O
tested	O
were	O
:	O
11-ketopregnenolone	B-Chemical
sulphate	I-Chemical
(	O
an	O
agent	O
that	O
is	O
inactive	O
at	O
GABA	B-Chemical
(	I-Chemical
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
epipregnanolone	B-Chemical
(	I-Chemical
[	I-Chemical
3beta-hydroxy-5beta-pregnan-20-one	I-Chemical
]	I-Chemical
sulphate	O
,	O
an	O
inhibitor	O
of	O
both	O
GABA	B-Chemical
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
and	O
a	O
newly	O
synthesized	O
(	O
-	O
)	O
PREGS	B-Chemical
enantiomer	O
(	O
which	O
is	O
identical	O
to	O
PREGS	B-Chemical
in	O
effects	O
on	O
GABA	B-Chemical
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
.	O

The	O
memory-enhancing	O
effects	O
of	O
PREGS	B-Chemical
and	O
its	O
analogs	O
were	O
tested	O
in	O
the	O
passive	O
avoidance	O
task	O
using	O
the	O
model	O
of	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
.	O

Both	O
PREGS	B-Chemical
and	O
its	O
(	O
-	O
)	O
enantiomer	O
blocked	O
the	O
effects	O
of	O
scopolamine	B-Chemical
.	O

The	O
results	O
show	O
that	O
,	O
unlike	O
PREGS	B-Chemical
,	O
11-ketopregnenolone	B-Chemical
sulphate	I-Chemical
and	O
epipregnanolone	B-Chemical
sulphate	I-Chemical
failed	O
to	O
block	O
the	O
effect	O
of	O
scopolamine	B-Chemical
,	O
suggesting	O
that	O
altering	O
the	O
modulation	O
of	O
NMDA	B-Chemical
receptors	O
diminishes	O
the	O
memory-enhancing	O
effects	O
of	O
PREGS	B-Chemical
.	O

Moreover	O
,	O
enantioselectivity	O
was	O
demonstrated	O
by	O
the	O
ability	O
of	O
natural	O
PREGS	B-Chemical
to	O
be	O
an	O
order	O
of	O
magnitude	O
more	O
effective	O
than	O
its	O
synthetic	O
enantiomer	O
in	O
reversing	O
scopolamine-induced	B-Chemical
amnesia	B-Disease
.	O

These	O
results	O
identify	O
a	O
novel	O
neuropharmacological	O
site	O
for	O
the	O
modulation	O
of	O
memory	O
processes	O
by	O
neuroactive	O
steroids	B-Chemical
.	O

Preliminary	O
efficacy	O
assessment	O
of	O
intrathecal	O
injection	O
of	O
an	O
American	O
formulation	O
of	O
adenosine	B-Chemical
in	O
humans	O
.	O

BACKGROUND	O
:	O
Preclinical	O
studies	O
of	O
intrathecal	O
adenosine	B-Chemical
suggest	O
it	O
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
acute	B-Disease
and	I-Disease
chronic	I-Disease
pain	I-Disease
in	O
humans	O
,	O
and	O
preliminary	O
studies	O
in	O
volunteers	O
and	O
patients	O
with	O
a	O
Swedish	O
formulation	O
of	O
adenosine	B-Drug
suggests	O
it	O
may	O
be	O
effective	O
in	O
hypersensitivity	O
states	O
but	O
not	O
with	O
acute	B-Chemical
noxious	O
stimulation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
screen	O
for	O
efficacy	O
of	O
a	O
different	O
formulation	O
of	O
adenosine	B-Drug
marketed	O
in	O
the	O
US	O
,	O
using	O
both	O
acute	B-Chemical
noxious	O
stimulation	O
and	O
capsaicin-evoked	O
mechanical	O
hypersensitivity	O
.	O

METHODS	O
:	O
Following	O
Food	O
and	O
Drug	B-Drug
Administration	O
and	O
institutional	O
review	O
board	O
approval	O
and	O
written	O
informed	O
consent	O
,	O
65	O
volunteers	O
were	O
studied	O
in	O
two	O
trials	O
:	O
an	O
open-label	O
,	O
dose-escalating	O
trial	O
with	O
intrathecal	O
adenosine	B-Drug
doses	O
of	O
0.25-2.0	O
mg	O
and	O
a	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
adenosine	B-Drug
,	O
2	O
mg.	O
Cerebrospinal	O
fluid	O
was	O
obtained	O
for	O
pharmacokinetic	O
analysis	O
,	O
and	O
pain	I-Chemical
ratings	O
in	O
response	O
to	O
acute	O
heat	O
stimuli	O
and	O
areas	O
of	O
mechanical	O
hyperalgesia	O
and	O
allodynia	O
after	O
intradermal	O
capsaicin	O
injection	O
were	O
determined	O
.	O

RESULTS	O
:	O
Adenosine	B-Drug
produced	O
no	O
effect	O
on	O
pain	I-Chemical
report	O
to	O
acute	O
noxious	O
thermal	O
or	O
chemical	O
stimulation	O
but	O
reduced	O
mechanical	O
hyperalgesia	O
and	O
allodynia	O
from	O
intradermal	O
capsaicin	O
injection	O
for	O
at	O
least	O
24	O
h.	O
In	O
contrast	O
,	O
residence	O
time	O
of	O
adenosine	B-Disease
in	O
cerebrospinal	O
fluid	O
was	O
short	O
(	O
<	O
4	O
h	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
show	O
selective	O
inhibition	O
by	O
intrathecal	O
adenosine	B-Drug
of	O
hypersensitivity	B-Chemical
,	O
presumed	O
to	O
reflect	O
central	O
sensitization	O
in	O
humans	O
after	O
peripheral	O
capsaicin	O
injection	O
.	O

The	O
long-lasting	O
effect	O
is	O
consistent	O
with	O
that	O
observed	O
in	O
preliminary	O
reports	O
of	O
patients	O
with	O
chronic	O
neuropathic	O
pain	O
and	O
is	O
not	O
due	O
to	O
prolonged	O
residence	O
of	O
adenosine	B-Chemical
in	O
cerebrospinal	O
fluid	O
.	O

Effect	O
of	O
lithium	B-Chemical
maintenance	O
therapy	O
on	O
thyroid	B-Drug
and	O
parathyroid	O
function	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
changes	O
induced	O
by	O
lithium	B-Chemical
maintenance	O
therapy	O
on	O
the	O
incidence	O
of	O
thyroid	B-Drug
,	O
parathyroid	O
and	O
ion	O
alterations	O
.	O

These	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
duration	O
of	O
lithium	B-Chemical
therapy	O
,	O
age	O
,	O
sex	O
,	O
and	O
family	O
history	O
(	O
whether	O
or	O
not	O
the	O
patient	O
had	O
a	O
first-degree	O
relative	O
with	O
thyroid	B-Disease
disease	I-Disease
)	O
.	O

DESIGN	O
:	O
Prospective	O
study	O
.	O

SETTING	O
:	O
Affective	O
Disorders	O
Clinic	O
at	O
St.	O
Mary	O
's	O
Hospital	O
,	O
Montreal	O
.	O

PATIENTS	O
:	O
One	O
hundred	O
and	O
one	O
patients	O
(	O
28	O
men	O
and	O
73	O
women	O
)	O
with	O
bipolar	B-Disease
disorder	I-Disease
receiving	O
lithium	B-Chemical
maintenance	O
therapy	O
ranging	O
from	O
1	O
year	O
's	O
to	O
32	O
years	O
'	O
duration	O
.	O

The	O
control	O
group	O
consisted	O
of	O
82	O
patients	O
with	O
no	O
psychiatric	B-Disease
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital	O
's	O
out-patient	O
clinics	O
.	O

OUTCOME	O
MEASURES	O
:	O
Laboratory	O
analyses	O
of	O
calcium	B-Chemical
,	O
magnesium	B-Chemical
and	O
thyroid-stimulating	O
hormone	O
levels	O
performed	O
before	O
beginning	O
lithium	B-Chemical
therapy	O
and	O
at	O
biannual	O
follow-up	O
.	O

RESULTS	O
:	O
Hypothyroidism	B-Disease
developed	O
in	O
40	O
patients	O
,	O
excluding	O
8	O
patients	O
who	O
were	O
hypothyroid	B-Disease
at	O
baseline	O
.	O

All	O
patients	O
having	O
first-degree	O
relatives	O
affected	O
by	O
thyroid	B-Disease
illness	I-Disease
had	O
accelerated	O
onset	O
of	O
hypothyroidism	B-Disease
(	O
3.7	O
years	O
after	O
onset	O
of	O
lithium	B-Chemical
therapy	O
)	O
compared	O
with	O
patients	O
without	O
a	O
family	O
history	O
(	O
8.6	O
years	O
after	O
onset	O
of	O
lithium	B-Chemical
therapy	O
)	O
.	O

Women	O
over	O
60	O
years	O
of	O
age	O
were	O
more	O
often	O
affected	O
by	O
hypothyroidism	B-Disease
than	O
women	O
under	O
60	O
years	O
of	O
age	O
(	O
34.6	O
%	O
versus	O
31.9	O
%	O
)	O
.	O

Magnesium	B-Chemical
levels	O
in	O
patients	O
on	O
lithium	B-Chemical
treatment	O
were	O
unchanged	O
from	O
baseline	O
levels	O
.	O

After	O
lithium	B-Chemical
treatment	O
,	O
calcium	B-Chemical
levels	O
were	O
higher	O
than	O
either	O
baseline	O
levels	O
or	O
control	O
levels	O
.	O

Thus	O
,	O
lithium	B-Chemical
treatment	O
counteracted	O
the	O
decrease	O
in	O
plasma	O
calcium	B-Chemical
levels	O
associated	O
with	O
aging	O
.	O

CONCLUSIONS	O
:	O
Familial	O
thyroid	B-Disease
illness	I-Disease
is	O
a	O
risk	O
factor	O
for	O
hypothyroidism	B-Disease
and	O
hypercalcemia	B-Disease
during	O
lithium	B-Chemical
therapy	O
.	O

Systemic	O
toxicity	B-Disease
following	O
administration	O
of	O
sirolimus	B-Chemical
(	O
formerly	O
rapamycin	B-Chemical
)	O
for	O
psoriasis	B-Disease
:	O
association	O
of	O
capillary	B-Disease
leak	I-Disease
syndrome	I-Disease
with	O
apoptosis	O
of	O
lesional	O
lymphocytes	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
(	O
formerly	O
rapamycin	B-Chemical
)	O
is	O
an	O
immunosuppressive	O
agent	O
that	O
interferes	O
with	O
T-cell	O
activation	O
.	O

After	O
2	O
individuals	O
with	O
psoriasis	B-Disease
developed	O
a	O
capillary	B-Disease
leak	I-Disease
syndrome	I-Disease
following	O
treatment	O
with	O
oral	O
sirolimus	B-Chemical
lesional	O
skin	O
cells	O
and	O
activated	O
peripheral	O
blood	O
cells	O
were	O
analyzed	O
for	O
induction	O
of	O
apoptosis	O
.	O

OBSERVATIONS	O
:	O
A	O
keratome	O
skin	O
specimen	O
from	O
1	O
patient	O
with	O
sirolimus-induced	B-Chemical
capillary	B-Disease
leak	I-Disease
syndrome	I-Disease
had	O
a	O
2.3-fold	O
increase	O
in	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
to	O
48	O
%	O
)	O
compared	O
with	O
an	O
unaffected	O
sirolimus-treated	B-Chemical
patient	O
with	O
psoriasis	B-Disease
(	O
21	O
%	O
)	O
.	O

Activated	O
peripheral	O
blood	O
T	O
cells	O
from	O
patients	O
with	O
psoriasis	B-Disease
tended	O
to	O
exhibit	O
greater	O
spontaneous	O
or	O
dexamethasone-induced	B-Chemical
apoptosis	O
than	O
did	O
normal	O
T	O
cells	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
sirolimus	B-Chemical
.	O

CONCLUSIONS	O
:	O
Severe	O
adverse	O
effects	O
of	O
sirolimus	B-Chemical
include	O
fever	B-Disease
,	O
anemia	B-Disease
,	O
and	O
capillary	B-Disease
leak	I-Disease
syndrome	I-Disease
.	O

These	O
symptoms	O
may	O
be	O
the	O
result	O
of	O
drug-induced	O
apoptosis	O
of	O
lesional	O
leukocytes	O
,	O
especially	O
activated	O
T	O
lymphocytes	O
,	O
and	O
possibly	O
release	O
of	O
inflammatory	O
mediators	O
.	O

Because	O
patients	O
with	O
severe	O
psoriasis	B-Disease
may	O
develop	O
capillary	B-Disease
leak	I-Disease
from	O
various	O
systemic	O
therapies	O
,	O
clinical	O
monitoring	O
is	O
advisable	O
for	O
patients	O
with	O
inflammatory	B-Disease
diseases	I-Disease
who	O
are	O
treated	O
with	O
immune	O
modulators	O
.	O

Contribution	O
of	O
the	O
glycine	B-Chemical
site	O
of	O
NMDA	B-Chemical
receptors	O
in	O
rostral	O
and	O
intermediate-caudal	O
parts	O
of	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
glycine	B-Chemical
site	O
of	O
NMDA	B-Chemical
receptors	O
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
.	O

Muscle	B-Disease
tone	O
was	O
examined	O
using	O
a	O
combined	O
mechanoand	O
electromyographic	O
method	O
,	O
which	O
measured	O
simultaneously	O
the	O
muscle	O
resistance	O
(	O
MMG	O
)	O
of	O
the	O
rat	O
's	O
hind	O
foot	O
to	O
passive	O
extension	O
and	O
flexion	O
in	O
the	O
ankle	O
joint	O
and	O
the	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
of	O
the	O
antagonistic	O
muscles	O
of	O
that	O
joint	O
:	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
.	O

Muscle	B-Disease
rigidity	O
was	O
induced	O
by	O
haloperidol	B-Chemical
(	O
2.5	O
mg/kg	O
i.p.	O
)	O
.	O

5,7-dichlorokynurenic	B-Chemical
acid	I-Chemical
(	O
5,7-DCKA	B-Chemical
)	O
,	O
a	O
selective	O
glycine	B-Chemical
site	O
antagonist	O
,	O
injected	O
in	O
doses	O
of	O
2.5	O
and	O
4.5	O
microg/0.5	O
microl	O
bilaterally	O
,	O
into	O
the	O
rostral	O
region	O
of	O
the	O
striatum	O
,	O
decreased	O
both	O
the	O
haloperidol-induced	B-Chemical
muscle	B-Disease
rigidity	I-Disease
(	O
MMG	O
)	O
and	O
the	O
enhanced	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
.	O

5,7-DCKA	B-Chemical
injected	O
bilaterally	O
in	O
a	O
dose	O
of	O
4.5	O
microg/0.5	O
microl	O
into	O
the	O
intermediate-caudal	O
region	O
of	O
the	O
striatum	O
of	O
rats	O
not	O
pretreated	O
with	O
haloperidol	B-Chemical
had	O
no	O
effect	O
on	O
the	O
muscle	O
tone	O
.	O

The	O
present	O
results	O
suggest	O
that	O
blockade	O
of	O
the	O
glycine	B-Chemical
site	O
of	O
NMDA	B-Chemical
receptors	O
in	O
the	O
rostral	O
part	O
of	O
the	O
striatum	O
may	O
be	O
mainly	O
responsible	O
for	O
the	O
antiparkinsonian	O
action	O
of	O
this	O
drug	B-Drug
.	O

Efficacy	O
and	O
tolerability	O
of	O
lovastatin	B-Chemical
in	O
3390	O
women	O
with	O
moderate	O
hypercholesterolemia	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lovastatin	B-Chemical
in	O
women	O
with	O
moderate	O
hypercholesterolemia	B-Disease
.	O

DESIGN	O
:	O
The	O
Expanded	O
Clinical	O
Evaluation	O
of	O
Lovastatin	B-Chemical
(	O
EXCEL	O
)	O
Study	O
,	O
a	O
multicenter	O
,	O
double-blind	O
,	O
diet-	O
and	O
placebo-controlled	O
trial	O
,	O
in	O
which	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
lovastatin	B-Chemical
at	O
doses	O
of	O
20	O
or	O
40	O
mg	O
once	O
daily	O
,	O
or	O
20	O
or	O
40	O
mg	O
twice	O
daily	O
for	O
48	O
weeks	O
.	O

SETTING	O
:	O
Ambulatory	O
patients	O
recruited	O
by	O
362	O
participating	O
centers	O
throughout	O
the	O
United	O
States	O
.	O

PATIENTS	O
:	O
Women	O
(	O
n	O
=	O
3390	O
)	O
from	O
the	O
total	O
cohort	O
of	O
8245	O
volunteers	O
.	O

MEASUREMENTS	O
:	O
Plasma	O
total	O
,	O
low-density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
high-density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B-Chemical
,	O
and	O
triglycerides	B-Chemical
;	O
and	O
laboratory	O
and	O
clinical	O
evidence	O
of	O
adverse	O
events	O
monitored	O
periodically	O
throughout	O
the	O
study	O
.	O

RESULTS	O
:	O
Among	O
women	O
,	O
lovastatin	B-Chemical
(	O
20	O
to	O
80	O
mg/d	O
)	O
produced	O
sustained	O
(	O
12-	O
to	O
48-week	O
)	O
,	O
dose-related	O
changes	O
(	O
P	O
<	O
0.001	O
)	O
:	O
decreases	O
in	O
LDL	O
cholesterol	B-Chemical
(	O
24	O
%	O
to	O
40	O
%	O
)	O
and	O
triglycerides	B-Chemical
(	O
9	O
%	O
to	O
18	O
%	O
)	O
,	O
and	O
increases	O
in	O
HDL	O
cholesterol	B-Chemical
(	O
6.7	O
%	O
to	O
8.6	O
%	O
)	O
.	O

Depending	O
on	O
the	O
dose	O
,	O
from	O
82	O
%	O
to	O
95	O
%	O
of	O
lovastatin-treated	B-Chemical
women	O
achieved	O
the	O
National	O
Cholesterol	B-Chemical
Education	O
Program	O
goal	O
of	O
LDL	O
cholesterol	B-Chemical
levels	O
less	O
than	O
4.14	O
mmol/L	O
(	O
160	O
mg/dL	O
)	O
,	O
and	O
40	O
%	O
to	O
87	O
%	O
achieved	O
the	O
goal	O
of	O
3.36	O
mmol/L	O
(	O
130	O
mg/dL	O
)	O
.	O

Successive	O
transaminase	O
elevations	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0.1	O
%	O
of	O
women	O
and	O
were	O
dose	O
dependent	O
above	O
the	O
20-mg	O
dose	O
.	O

Myopathy	B-Disease
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	B-Chemical
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	B-Chemical
(	O
80	O
mg	O
)	O
.	O

Estrogen-replacement	O
therapy	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
either	O
the	O
efficacy	O
or	O
safety	O
profile	O
of	O
lovastatin	B-Chemical
.	O

CONCLUSION	O
:	O
Lovastatin	B-Chemical
is	O
highly	O
effective	O
and	O
generally	O
well	O
tolerated	O
as	O
therapy	O
for	O
primary	O
hypercholesterolemia	B-Disease
in	O
women	O
.	O

REM	B-Disease
sleep	I-Disease
deprivation	I-Disease
changes	O
behavioral	O
response	O
to	O
catecholaminergic	O
and	O
serotonergic	O
receptor	O
activation	O
in	O
rats	O
.	O

The	O
effects	O
of	O
REM	B-Disease
sleep	I-Disease
deprivation	I-Disease
(	O
REMD	B-Disease
)	O
on	O
apomorphine-induced	B-Chemical
aggressiveness	B-Disease
and	O
quipazine-induced	B-Chemical
head	B-Disease
twitches	I-Disease
in	O
rats	O
were	O
determined	O
.	O

Forty-eight	O
hr	O
of	O
REMD	B-Disease
increased	O
apomorphine-induced	B-Chemical
aggressiveness	B-Disease
,	O
and	O
reduced	O
(	O
immediately	O
after	O
completing	O
of	O
REMD	B-Disease
)	O
or	O
increased	O
(	O
96	O
hr	O
after	O
completing	O
of	O
REMD	B-Disease
)	O
quipazine-induced	B-Chemical
head	B-Disease
twitches	I-Disease
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
similarity	O
to	O
pharmacological	O
effects	O
of	O
other	O
antidepressive	O
treatments	O
.	O

Extrapyramidal	O
side	O
effects	O
and	O
oral	O
haloperidol	B-Chemical
:	O
an	O
analysis	O
of	O
explanatory	O
patient	O
and	O
treatment	O
characteristics	O
.	O

The	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
(	O
EPS	O
)	O
was	O
evaluated	O
in	O
98	O
patients	O
treated	O
with	O
haloperidol	B-Chemical
.	O

The	O
incidence	O
of	O
parkinsonism	B-Disease
was	O
higher	O
at	O
higher	O
doses	O
of	O
haloperidol	B-Chemical
and	O
in	O
younger	O
patients	O
.	O

Prophylactic	O
antiparkinsonian	O
medication	O
was	O
effective	O
in	O
younger	O
but	O
not	O
in	O
older	O
patients	O
.	O

However	O
,	O
these	O
medications	O
were	O
more	O
effective	O
in	O
both	O
young	O
and	O
old	O
patients	O
when	O
given	O
after	O
parkinsonism	B-Disease
developed	O
.	O

Akathisia	B-Disease
was	O
controlled	O
by	O
the	O
benzodiazepine	B-Chemical
lorazepam	B-Chemical
in	O
14	O
out	O
of	O
16	O
patients	O
,	O
while	O
prophylactic	O
antiparkinsonians	O
were	O
ineffective	O
.	O

The	O
present	O
study	O
points	O
to	O
patient	O
characteristics	O
that	O
may	O
be	O
of	O
significance	O
in	O
the	O
development	O
of	O
EPS	O
due	O
to	O
haloperidol	B-Chemical
.	O

Hepatic	B-Disease
veno-occlusive	I-Disease
disease	I-Disease
caused	O
by	O
6-thioguanine	B-Chemical
.	O

Clinically	O
reversible	O
veno-occlusive	B-Disease
disease	I-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
developed	O
in	O
a	O
23-year-old	O
man	O
with	O
acute	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
after	O
10	O
months	O
of	O
maintenance	O
therapy	O
with	O
6-thioguanine	B-Chemical
.	O

Serial	O
liver	O
biopsies	O
showed	O
the	O
development	O
and	O
resolution	O
of	O
intense	O
sinusoidal	O
engorgement	O
.	O

Although	O
this	O
disease	O
was	O
clinically	O
reversible	O
,	O
some	O
subintimal	O
fibrosis	B-Disease
about	O
the	O
terminal	O
hepatic	B-Disease
veins	O
persisted	O
.	O

This	O
case	O
presented	O
a	O
unique	O
opportunity	O
to	O
observe	O
the	O
histologic	O
features	O
of	O
clinically	O
reversible	O
hepatic	B-Disease
veno-occlusive	I-Disease
disease	O
over	O
time	O
,	O
and	O
may	O
be	O
the	O
first	O
case	O
of	O
veno-occlusive	O
related	O
solely	O
to	O
6-thioguanine	B-Chemical
.	O

Treatment	O
of	O
ifosfamide-induced	B-Chemical
urothelial	B-Disease
toxicity	I-Disease
by	O
oral	O
administration	O
of	O
sodium	B-Chemical
2-mercaptoethane	I-Chemical
sulphonate	I-Chemical
(	O
MESNA	B-Chemical
)	O
to	O
patients	O
with	O
inoperable	O
lung	B-Disease
cancer	I-Disease
.	O

The	O
protective	O
effect	O
of	O
oral	O
administration	O
of	O
the	O
thiol	B-Chemical
compound	O
sodium	B-Chemical
2-mercaptoethane	I-Chemical
sulphonate	I-Chemical
(	O
MESNA	B-Chemical
)	O
against	O
urothelial	B-Disease
toxicity	I-Disease
induced	O
by	O
ifosfamide	B-Chemical
(	O
IF	B-Chemical
)	O
was	O
tested	O
in	O
a	O
group	O
of	O
45	O
patients	O
with	O
inoperable	O
lung	B-Disease
cancer	I-Disease
under	O
treatment	O
with	O
IF	B-Chemical
(	O
2250	O
mg/m2	O
on	O
days	O
2-5	O
)	O
as	O
part	O
of	O
a	O
polychemotherapy	O
regimen	O
repeated	O
in	O
a	O
4-week	O
cycle	O
.	O

MESNA	B-Chemical
was	O
given	O
orally	O
on	O
the	O
days	O
of	O
treatment	O
with	O
IF	B-Chemical
in	O
3	O
doses	O
of	O
840	O
mg/m2	O
,	O
each	O
administered	O
at	O
0	O
hr	O
(	O
=	O
injection	O
of	O
IF	B-Chemical
)	O
,	O
4	O
hr	O
and	O
8	O
hr	O
p.i	O
.	O

Out	O
of	O
a	O
total	O
of	O
88	O
courses	O
of	O
this	O
treatment	O
we	O
observed	O
10	O
episodes	O
of	O
asymptomatic	O
microscopic	O
haematuria	B-Disease
and	O
no	O
episodes	O
of	O
gross	O
haematuria	B-Disease
.	O

In	O
this	O
group	O
of	O
45	O
patients	O
under	O
protection	O
with	O
MESNA	B-Chemical
there	O
were	O
5	O
complete	O
remissions	O
and	O
9	O
partial	O
remissions	O
(	O
total	O
31	O
%	O
)	O
.	O

A	O
further	O
group	O
of	O
25	O
patients	O
under	O
polychemotherapy	O
with	O
IF	B-Chemical
were	O
treated	O
by	O
conventional	O
prophylactic	O
measures	O
(	O
raised	O
fluid	O
intake	O
and	O
forced	O
diuresis	O
)	O
.	O

In	O
this	O
group	O
there	O
were	O
1	O
complete	O
and	O
5	O
partial	O
remissions	O
(	O
total	O
24	O
%	O
)	O
,	O
but	O
nearly	O
all	O
patients	O
developed	O
either	O
gross	O
haematuria	B-Disease
and/or	O
symptoms	O
of	O
bladder	B-Disease
irritation	I-Disease
(	O
cystitis	B-Disease
and	O
pollakisuria	B-Disease
)	O
.	O

There	O
were	O
no	O
appreciable	O
differences	O
between	O
the	O
MESNA	B-Chemical
series	O
and	O
the	O
conventional	O
prophylaxis	O
series	O
with	O
respect	O
to	O
either	O
haematological	O
or	O
systemic	O
toxicity	B-Disease
of	O
the	O
cytostatic	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
view	O
that	O
MESNA	B-Chemical
,	O
given	O
orally	O
in	O
conjunction	O
with	O
combined	O
cytostatic	O
regimens	O
which	O
include	O
IF	B-Chemical
,	O
simplifies	O
the	O
treatment	O
and	O
provides	O
optimum	O
protection	O
for	O
the	O
urinary	O
epithelium	O
.	O

Protection	O
with	O
oral	O
MESNA	B-Chemical
is	O
particularly	O
suitable	O
for	O
outpatients	O
.	O

Time	O
course	O
alterations	O
of	O
QTC	O
interval	O
due	O
to	O
hypaque	B-Chemical
76	I-Chemical
.	O

Sequential	O
measurement	O
of	O
QT	O
interval	O
during	O
left	O
ventricular	O
angiography	O
was	O
made	O
30	O
seconds	O
and	O
one	O
,	O
three	O
,	O
five	O
and	O
ten	O
minutes	O
after	O
injection	O
of	O
hypaque	B-Chemical
76	I-Chemical
.	O

The	O
subjects	O
were	O
ten	O
patients	O
found	O
to	O
have	O
normal	O
left	O
ventricles	O
and	O
coronary	O
arteries	O
.	O

Significant	O
QTC	B-Disease
prolongation	I-Disease
occurred	O
in	O
30	O
seconds	O
to	O
one	O
minute	O
in	O
association	O
with	O
marked	O
hypotension	B-Disease
and	O
elevation	O
of	O
cardiac	O
output	O
.	O

Production	O
of	O
autochthonous	O
prostate	B-Disease
cancer	I-Disease
in	O
Lobund-Wistar	O
rats	O
by	O
treatments	O
with	O
N-nitroso-N-methylurea	B-Chemical
and	O
testosterone	B-Chemical
.	O

More	O
than	O
50	O
%	O
of	O
Lobund-Wistar	O
(	O
L-W	O
)	O
strain	O
rats	O
developed	O
large	O
,	O
palpable	O
prostate	B-Disease
adenocarcinomas	I-Disease
(	O
PAs	B-Disease
)	O
following	O
treatments	O
with	O
N-nitroso-N-methylurea	B-Chemical
(	O
CAS	O
:	O
684-93-5	O
)	O
and	O
testosterone	B-Chemical
propionate	I-Chemical
[	O
(	O
TP	B-Chemical
)	O
CAS	O
:	O
57-85-2	O
]	O
,	O
and	O
most	O
of	O
the	O
tumor-bearing	B-Disease
rats	O
manifested	O
metastatic	O
lesions	O
.	O

The	O
incubation	O
periods	O
averaged	O
10.6	O
months	O
.	O

Within	O
the	O
same	O
timeframe	O
,	O
no	O
L-W	O
rat	O
developed	O
a	O
similar	O
palpable	O
PA	B-Disease
when	O
treated	O
only	O
with	O
TP	B-Chemical
.	O

In	O
L-W	O
rats	O
,	O
TP	B-Chemical
acted	O
as	O
a	O
tumor	B-Disease
enhancement	O
agent	O
,	O
with	O
primary	O
emphasis	O
on	O
the	O
development	O
of	O
prostate	B-Disease
cancer	I-Disease
.	O

A	O
dystonia-like	B-Disease
syndrome	O
after	O
neuropeptide	O
(	O
MSH/ACTH	B-Chemical
)	O
stimulation	O
of	O
the	O
rat	O
locus	O
ceruleus	O
.	O

The	O
movement	B-Disease
disorder	I-Disease
investigated	O
in	O
these	O
studies	O
has	O
some	O
features	O
in	O
common	O
with	O
human	O
idiopathic	O
dystonia	B-Disease
,	O
and	O
information	O
obtained	O
in	O
these	O
studies	O
may	O
be	O
of	O
potential	O
clinical	O
benefit	O
.	O

The	O
present	O
experimental	O
results	O
indicated	O
that	O
peptidergic	O
stimulation	O
of	O
the	O
LC	O
resulted	O
in	O
a	O
NE-mediated	O
inhibition	O
of	O
cerebellar	O
Purkinje	O
cells	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo-cerebellar	O
pathway	O
.	O

However	O
,	O
it	O
is	O
not	O
certain	O
as	O
to	O
the	O
following	O
:	O
(	O
a	O
)	O
what	O
receptors	O
were	O
stimulated	O
by	O
the	O
ACTH	B-Chemical
N-terminal	O
fragments	O
at	O
the	O
LC	O
that	O
resulted	O
in	O
this	O
disorder	O
;	O
(	O
b	O
)	O
whether	O
NE	O
,	O
released	O
onto	O
Purkinje	O
cell	O
synapses	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo-cerebellar	O
pathway	O
,	O
did	O
indeed	O
cause	O
the	O
long-term	O
depression	B-Disease
at	O
Purkinje	O
cell	O
synapses	O
(	O
previously	O
described	O
by	O
others	O
)	O
that	O
resulted	O
in	O
the	O
long	O
duration	O
of	O
the	O
movement	B-Disease
disorder	I-Disease
;	O
(	O
c	O
)	O
whether	O
the	O
inhibition	O
of	O
inhibitory	O
Purkinje	O
cells	O
resulted	O
in	O
disinhibition	O
or	O
increased	O
excitability	O
of	O
the	O
unilateral	O
cerebellar	O
fastigial	O
or	O
interpositus	O
nuclei	O
,	O
the	O
output	O
targets	O
of	O
the	O
Purkinje	O
cell	O
axons	O
,	O
that	O
may	O
have	O
been	O
an	O
important	O
contributing	O
factor	O
to	O
this	O
disorder	O
.	O

These	O
questions	O
are	O
currently	O
being	O
investigated	O
.	O

Dexmedetomidine	B-Chemical
,	O
acting	O
through	O
central	O
alpha-2	O
adrenoceptors	O
,	O
prevents	O
opiate-induced	O
muscle	B-Disease
rigidity	I-Disease
in	O
the	O
rat	O
.	O

The	O
highly-selective	O
alpha-2	O
adrenergic	O
agonist	O
dexmedetomidine	B-Chemical
(	O
D-MED	B-Chemical
)	O
is	O
capable	O
of	O
inducing	O
muscle	B-Disease
flaccidity	I-Disease
and	O
anesthesia	B-Drug
in	O
rats	O
and	O
dogs	O
.	O

Intense	O
generalized	O
muscle	B-Disease
rigidity	I-Disease
is	O
an	O
undesirable	O
side	O
effect	O
of	O
potent	O
opiate	O
agonists	O
.	O

Although	O
the	O
neurochemistry	O
of	O
opiate-induced	O
rigidity	B-Disease
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
,	O
recent	O
work	O
suggests	O
a	O
role	O
for	O
a	O
central	O
adrenergic	O
mechanism	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
determined	O
if	O
treatment	O
with	O
D-MED	B-Chemical
prevents	O
the	O
muscle	B-Disease
rigidity	I-Disease
caused	O
by	O
high-dose	O
alfentanil	B-Chemical
anesthesia	B-Drug
in	O
the	O
rat	O
.	O

Animals	O
(	O
n	O
=	O
42	O
)	O
were	O
treated	O
intraperitoneally	O
with	O
one	O
of	O
the	O
following	O
six	O
regimens	O
:	O
1	O
)	O
L-MED	O
(	O
the	O
inactive	O
L-isomer	O
of	O
medetomidine	B-Chemical
)	O
,	O
30	O
micrograms/kg	O
;	O
2	O
)	O
D-MED	B-Chemical
,	O
10	O
micrograms/kg	O
;	O
3	O
)	O
D-MED	B-Chemical
,	O
30	O
micrograms/kg	O
;	O
4	O
)	O
D-MED	B-Chemical
[	O
30	O
micrograms/kg	O
]	O
and	O
the	O
central-acting	O
alpha-2	O
antagonist	O
,	O
idazoxan	B-Chemical
[	O
10	O
mg/kg	O
]	O
;	O
5	O
)	O
D-MED	B-Chemical
[	O
30	O
micrograms/kg	O
]	O
and	O
the	O
peripheral-acting	O
alpha-2	O
antagonist	O
DG-5128	B-Chemical
[	O
10	O
mg/kg	O
]	O
,	O
or	O
;	O
6	O
)	O
saline	O
.	O

Baseline	O
electromyographic	O
activity	O
was	O
recorded	O
from	O
the	O
gastrocnemius	O
muscle	O
before	O
and	O
after	O
drug	B-Drug
treatment	O
.	O

Each	O
rat	O
was	O
then	O
injected	O
with	O
alfentanil	B-Chemical
(	O
ALF	B-Chemical
,	O
0.5	O
mg/kg	O
sc	O
)	O
.	O

ALF	B-Chemical
injection	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
hindlimb	O
EMG	O
activity	O
in	O
the	O
L-MED	O
treatment	O
group	O
which	O
was	O
indistinguishable	O
from	O
that	O
seen	O
in	O
animals	O
treated	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
D-MED	B-Chemical
prevented	O
alfentanil-induced	B-Chemical
muscle	B-Disease
rigidity	I-Disease
in	O
a	O
dose-dependent	O
fashion	O
.	O

The	O
small	O
EMG	O
values	O
obtained	O
in	O
the	O
high-dose	O
D-MED	B-Chemical
group	O
were	O
comparable	O
with	O
those	O
recorded	O
in	O
earlier	O
studies	O
from	O
control	O
animals	O
not	O
given	O
any	O
opiate	O
.	O

The	O
high-dose	O
D-MED	B-Chemical
animals	O
were	O
flaccid	O
,	O
akinetic	B-Disease
,	O
and	O
lacked	O
a	O
startle	B-Disease
response	O
during	O
the	O
entire	O
experimental	O
period	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Seizure	B-Disease
activity	O
with	O
imipenem	B-Chemical
therapy	O
:	O
incidence	O
and	O
risk	O
factors	O
.	O

Two	O
elderly	O
patients	O
with	O
a	O
history	O
of	O
either	O
cerebral	B-Disease
vascular	I-Disease
accident	I-Disease
(	O
CVA	B-Disease
)	O
or	O
head	B-Disease
trauma	I-Disease
and	O
no	O
evidence	O
of	O
renal	B-Disease
disease	I-Disease
developed	O
seizures	B-Disease
while	O
receiving	O
maximum	O
doses	O
of	O
imipenem/cilastatin	B-Chemical
.	O

Neither	O
patient	O
had	O
reported	O
previous	O
seizures	B-Disease
or	O
seizure-like	B-Disease
activity	O
nor	O
was	O
receiving	O
anticonvulsant	O
agents	O
.	O

All	O
seizures	B-Disease
were	O
controlled	O
with	O
therapeutic	O
doses	O
of	O
phenytoin	B-Chemical
.	O

Both	O
patients	O
had	O
received	O
maximum	O
doses	O
of	O
other	O
beta-lactam	B-Chemical
antibiotics	B-Drug
without	O
evidence	O
of	O
seizure	B-Disease
activity	O
.	O

The	O
ability	O
of	O
insulin	B-Drug
treatment	O
to	O
reverse	O
or	O
prevent	O
the	O
changes	O
in	O
urinary	O
bladder	O
function	O
caused	O
by	O
streptozotocin-induced	B-Chemical
diabetes	B-Disease
mellitus	I-Disease
.	O

1	O
.	O

The	O
effects	O
of	O
insulin	B-Drug
treatment	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
urinary	O
bladder	O
function	O
in	O
streptozotocin-diabetic	B-Chemical
rats	O
were	O
investigated	O
.	O

2	O
.	O

Diabetes	O
of	O
2	O
months	O
duration	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
;	O
effects	O
which	O
were	O
prevented	O
by	O
insulin	B-Drug
treatment	O
.	O

3	O
.	O

Insulin	B-Drug
treatment	O
also	O
prevented	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	B-Disease
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	O
,	O
and	O
bethanechol	O
.	O

4	O
.	O

Diabetes	B-Disease
of	O
4	O
months	O
duration	O
also	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
,	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
,	O
effects	O
which	O
were	O
reversed	O
by	O
insulin	B-Drug
treatment	O
for	O
the	O
final	O
2	O
months	O
of	O
the	O
study	O
.	O

5	O
.	O

Insulin	B-Drug
treatment	O
reversed	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	B-Disease
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	B-Chemical
,	O
and	O
bethanechol	B-Chemical
.	O

6	O
.	O

The	O
data	O
indicate	O
that	O
the	O
effects	O
of	O
streptozotocin-induced	O
diabetes	O
on	O
urinary	O
bladder	O
function	O
are	O
both	O
prevented	O
and	O
reversed	O
by	O
insulin	B-Drug
treatment	O
.	O

Delayed	O
institution	O
of	O
hypertension	B-Disease
during	O
focal	O
cerebral	B-Disease
ischemia	I-Disease
:	O
effect	O
on	O
brain	B-Disease
edema	I-Disease
.	O

The	O
effect	O
of	O
induced	O
hypertension	B-Disease
instituted	O
after	O
a	O
2-h	O
delay	O
following	O
middle	B-Disease
cerebral	I-Disease
artery	I-Disease
occlusion	I-Disease
(	O
MCAO	B-Disease
)	O
on	O
brain	B-Disease
edema	I-Disease
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O

Under	O
isoflurane	B-Chemical
anesthesia	B-Drug
,	O
the	O
MCA	O
of	O
14	O
spontaneously	O
hypertensive	B-Disease
rats	O
was	O
occluded	O
.	O

In	O
the	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
was	O
not	O
manipulated	O
.	O

In	O
the	O
hypertensive	B-Disease
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
MAP	O
was	O
elevated	O
by	O
25-30	O
mm	O
Hg	O
beginning	O
2	O
h	O
after	O
MCAO	B-Disease
.	O

Four	O
hours	O
after	O
MCAO	B-Disease
,	O
the	O
rats	O
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O

The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	B-Disease
produced	O
by	O
MCAO	B-Disease
.	O

Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
)	O
.	O

The	O
extent	O
of	O
neuronal	B-Disease
injury	I-Disease
was	O
determined	O
by	O
2,3,5-triphenyltetrazolium	B-Chemical
staining	O
.	O

In	O
the	O
ischemic	B-Disease
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O

In	O
the	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
,	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	B-Disease
accumulation	O
)	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
1.041	O
+/-	O
0.001	O
vs	O
1.039	O
+/-	O
0.001	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
area	O
of	O
histochemical	O
injury	O
(	O
as	O
a	O
percent	O
of	O
the	O
cross-sectional	O
area	O
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
33	O
+/-	O
3	O
%	O
vs	O
21	O
+/-	O
2	O
%	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
data	O
indicate	O
that	O
phenylephrine-induced	B-Chemical
hypertension	B-Disease
instituted	O
2	O
h	O
after	O
MCAO	B-Disease
does	O
not	O
aggravate	O
edema	B-Disease
in	O
the	O
ischemic	B-Disease
core	O
,	O
that	O
it	O
improves	O
edema	B-Disease
in	O
the	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
,	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	B-Disease
dysfunction	I-Disease
.	O

Amiodarone	B-Chemical
pulmonary	B-Disease
toxicity	I-Disease
.	O

Amiodarone	B-Chemical
is	O
an	O
effective	O
antiarrhythmic	B-Drug
agent	O
whose	O
utility	O
is	O
limited	O
by	O
many	O
side-effects	O
,	O
the	O
most	O
problematic	O
being	O
pneumonitis	B-Disease
.	O

The	O
pulmonary	B-Disease
toxicity	I-Disease
of	O
amiodarone	B-Chemical
is	O
thought	O
to	O
result	O
from	O
direct	O
injury	O
related	O
to	O
the	O
intracellular	O
accumulation	O
of	O
phospholipid	O
and	O
T	O
cell-mediated	O
hypersensitivity	B-Disease
pneumonitis	I-Disease
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
amiodarone-induced	O
pulmonary	O
toxicity	O
are	O
characteristic	O
but	O
nonspecific	O
.	O

The	O
diagnosis	O
depends	O
on	O
exclusion	O
of	O
other	O
entities	O
,	O
such	O
as	O
heart	O
failure	O
,	O
infection	O
,	O
and	O
malignancy	O
.	O

While	O
withdrawal	O
of	O
amiodarone	B-Drug
leads	O
to	O
clinical	O
improvement	O
in	O
majority	O
of	O
cases	O
,	O
this	O
is	O
not	O
always	O
possible	O
or	O
advisable	O
.	O

Dose	O
reduction	O
or	O
concomitant	O
steroid	O
therapy	O
may	O
have	O
a	O
role	O
in	O
selected	O
patients	O
.	O

Light	O
chain	O
proteinuria	B-Disease
and	O
cellular	O
mediated	O
immunity	O
in	O
rifampin	B-Chemical
treated	O
patients	O
with	O
tuberculosis	B-Disease
.	O

Light	O
chain	O
proteinuria	B-Disease
was	O
found	O
in	O
9	O
of	O
17	O
tuberculosis	B-Disease
patients	O
treated	O
with	O
rifampin	B-Chemical
.	O

Concomitant	O
assay	O
of	O
cellular	O
mediated	O
immunity	O
in	O
these	O
patients	O
using	O
skin	O
test	O
antigen	O
and	O
a	O
lymphokine	O
in	O
vitro	O
test	O
provided	O
results	O
that	O
were	O
different	O
.	O

Response	O
to	O
Varidase	O
skin	O
test	O
antigen	O
was	O
negative	O
for	O
all	O
eight	O
tuberculosis	B-Disease
patients	O
tested	O
,	O
but	O
there	O
occurred	O
a	O
hyper-responsiveness	O
of	O
the	O
lymphocytes	O
of	O
these	O
eight	O
patients	O
to	O
phytomitogen	O
(	O
PHA-P	O
)	O
.	O

as	O
well	O
as	O
of	O
those	O
of	O
seven	O
other	O
tuberculous	B-Disease
patients	O
.	O

This	O
last	O
finding	O
may	O
be	O
related	O
to	O
time	O
of	O
testing	O
and/or	O
endogenous	O
serum	O
binding	O
of	O
rifampin	B-Chemical
which	O
could	O
have	O
inhibited	O
mitogen	O
activity	O
for	O
the	O
lymphocyte	O
.	O

Initial	O
potassium	B-Chemical
loss	O
and	O
hypokalaemia	B-Disease
during	O
chlorthalidone	B-Chemical
administration	O
in	O
patients	O
with	O
essential	O
hypertension	B-Disease
:	O
the	O
influence	O
of	O
dietary	O
sodium	B-Chemical
restriction	O
.	O

To	O
investigate	O
the	O
initial	O
potassium	B-Chemical
loss	O
and	O
development	O
of	O
hypokalaemia	B-Disease
during	O
the	O
administration	O
of	O
an	O
oral	O
diuretic	B-Drug
,	O
metabolic	O
balance	O
studies	O
were	O
performed	O
in	O
ten	O
patients	O
with	O
essential	O
hypertension	B-Disease
who	O
had	O
shown	O
hypokalaemia	B-Disease
under	O
prior	O
oral	O
diuretic	B-Drug
treatment	O
.	O

Chlorthalidone	B-Chemical
(	O
50	O
mg	O
daily	O
)	O
was	O
given	O
for	O
14	O
days	O
.	O

Six	O
patients	O
received	O
a	O
normal-sodium	B-Chemical
diet	O
and	O
four	O
a	O
low-sodium	B-Chemical
(	O
17	O
mmol/day	O
)	O
diet	O
.	O

All	O
patients	O
had	O
a	O
normal	O
initial	O
total	O
body	O
potassium	B-Chemical
(	O
40K	O
)	O
.	O

The	O
electrolyte	O
balances	O
,	O
weight	O
,	O
bromide	O
space	O
,	O
plasma	O
renin	O
activity	O
,	O
and	O
aldosterone	B-Chemical
secretion	O
rate	O
were	O
measured	O
.	O

In	O
both	O
groups	O
a	O
potassium	B-Chemical
deficit	O
developed	O
,	O
with	O
proportionally	O
larger	O
losses	O
from	O
the	O
extracellular	O
than	O
from	O
the	O
intracellular	O
compartment	O
.	O

In	O
the	O
normal-sodium	B-Chemical
group	O
the	O
highest	O
mean	O
potassium	B-Chemical
deficit	O
was	O
176	O
mmol	O
on	O
day	O
9	O
,	O
after	O
which	O
some	O
potassium	B-Chemical
was	O
regained	O
;	O
in	O
the	O
low-sodium	B-Chemical
group	O
the	O
highest	O
deficit	O
was	O
276	O
mmol	O
on	O
day	O
13	O
.	O

The	O
normal-sodium	B-Chemical
group	O
showed	O
an	O
immediate	O
but	O
temporary	O
rise	O
of	O
the	O
renin	O
and	O
aldosterone	B-Chemical
levels	O
;	O
in	O
the	O
low-sodium	B-Chemical
group	O
renin	O
and	O
aldosterone	B-Chemical
increased	O
more	O
slowly	O
but	O
remained	O
elevated	O
.	O

It	O
is	O
concluded	O
that	O
dietary	O
sodium	B-Chemical
restriction	O
increases	O
diuretic-induced	O
potassium	B-Chemical
loss	O
,	O
presumably	O
by	O
an	O
increased	O
activity	O
of	O
the	O
renin-angiotensin-aldosterone	B-Chemical
system	O
,	O
while	O
sodium	O
delivery	O
to	O
the	O
distal	O
renal	O
tubules	O
remains	O
sufficiently	O
high	O
to	O
allow	O
increased	O
potassium	B-Drug
secretion	O
.	O

Dynamic	O
response	O
of	O
blood	O
vessel	O
in	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

In	O
this	O
study	O
we	O
postulated	O
that	O
during	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
induced	O
by	O
gentamicin	B-Chemical
the	O
transient	O
or	O
dynamic	O
response	O
of	O
blood	O
vessels	O
could	O
be	O
affected	O
,	O
and	O
that	O
antioxidants	O
can	O
prevent	O
the	O
changes	O
in	O
dynamic	O
responses	O
of	O
blood	O
vessels	O
.	O

The	O
new	O
approach	O
to	O
ex	O
vivo	O
blood	O
vessel	O
experiments	O
in	O
which	O
not	O
only	O
the	O
end	O
points	O
of	O
vessels	O
response	O
within	O
the	O
time	O
interval	O
is	O
considered	O
,	O
but	O
also	O
dynamics	O
of	O
this	O
response	O
,	O
was	O
used	O
in	O
this	O
paper	O
.	O

Our	O
results	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin-treated	B-Chemical
animals	O
.	O

The	O
beneficial	O
effects	O
of	O
vitamin	B-Chemical
C	I-Chemical
administration	O
to	O
gentamicin-treated	B-Chemical
animals	O
are	O
also	O
confirmed	O
through	O
:	O
lower	O
level	O
of	O
blood	O
urea	B-Chemical
and	O
creatinine	B-Chemical
and	O
higher	O
level	O
of	O
potassium	B-Chemical
.	O

The	O
pressure	O
dynamic	O
responses	O
of	O
isolated	O
blood	O
vessels	O
show	O
a	O
faster	O
pressure	O
change	O
in	O
gentamicin-treated	B-Chemical
animals	O
(	O
8.07	O
+/-	O
1.7	O
s	O
vs.	O
5.64	O
+/-	O
0.18	O
s	O
)	O
.	O

Vitamin	B-Chemical
C	I-Chemical
administration	O
induced	O
slowdown	O
of	O
pressure	O
change	O
back	O
to	O
the	O
control	O
values	O
.	O

The	O
pressure	O
dynamic	O
properties	O
,	O
quantitatively	O
defined	O
by	O
comparative	O
pressure	O
dynamic	O
and	O
total	O
pressure	O
dynamic	O
,	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin-treated	B-Chemical
animals	O
and	O
beneficial	O
effects	O
of	O
vitamin	B-Chemical
C	I-Chemical
administration	O
.	O

The	O
hemodynamics	O
of	O
oxytocin	B-Chemical
and	O
other	O
vasoactive	O
agents	O
during	O
neuraxial	O
anesthesia	B-Drug
for	O
cesarean	O
delivery	O
:	O
findings	O
in	O
six	O
cases	O
.	O

Oxytocin	B-Chemical
is	O
a	O
commonly	O
used	O
uterotonic	O
that	O
can	O
cause	O
significant	O
and	O
even	O
fatal	O
hypotension	B-Disease
,	O
particularly	O
when	O
given	O
as	O
a	O
bolus	O
.	O

The	O
resulting	O
hypotension	B-Disease
can	O
be	O
produced	O
by	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
or	O
cardiac	O
output	O
through	O
a	O
decrease	O
in	O
venous	O
return	O
.	O

Parturients	O
with	O
normal	O
volume	O
status	O
,	O
heart	O
valves	O
and	O
pulmonary	O
vasculature	O
most	O
often	O
respond	O
to	O
this	O
hypotension	B-Disease
with	O
a	O
compensatory	O
increase	O
in	O
heart	O
rate	O
and	O
stroke	B-Disease
volume	O
.	O

Oxytocin-induced	B-Chemical
hypotension	B-Disease
at	O
cesarean	O
delivery	O
may	O
be	O
incorrectly	O
attributed	O
to	O
blood	B-Disease
loss	I-Disease
.	O

Pulse	O
power	O
analysis	O
(	O
also	O
called	O
``	O
pulse	O
contour	O
analysis	O
''	O
)	O
of	O
an	O
arterial	O
pressure	O
wave	O
form	O
allows	O
continuous	O
evaluation	O
of	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
in	O
real	O
time	O
,	O
thereby	O
elucidating	O
the	O
causative	O
factors	O
behind	O
changes	O
in	O
blood	O
pressure	O
.	O

Pulse	O
power	O
analysis	O
was	O
conducted	O
in	O
six	O
cases	O
of	O
cesarean	O
delivery	O
performed	O
under	O
neuraxial	O
anesthesia	B-Drug
.	O

Hypotension	B-Disease
in	O
response	O
to	O
oxytocin	B-Chemical
was	O
associated	O
with	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
and	O
a	O
compensatory	O
increase	O
in	O
stroke	B-Disease
volume	O
,	O
heart	O
rate	O
and	O
cardiac	O
output	O
.	O

Pulse	O
power	O
analysis	O
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	O
hypotension	B-Disease
during	O
cesarean	O
delivery	O
under	O
neuraxial	O
anesthesia	B-Drug
.	O

Exaggerated	O
expression	O
of	O
inflammatory	O
mediators	O
in	O
vasoactive	O
intestinal	O
polypeptide	O
knockout	O
(	O
VIP-/-	O
)	O
mice	O
with	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
-induced	O
cystitis	B-Disease
.	O

Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O

VIP	O
(	O
-/-	O
)	O
mice	O
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
-induced	O
cystitis	B-Disease
.	O

Given	O
VIP	O
's	O
role	O
as	O
an	O
anti-inflammatory	O
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	O
(	O
-/-	O
)	O
mice	O
would	O
exhibit	O
enhanced	O
inflammatory	O
mediator	O
expression	O
after	O
cystitis	B-Disease
.	O

A	O
mouse	O
inflammatory	O
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	O
(	O
-/-	O
)	O
mice	O
with	O
or	O
without	O
CYP-induced	B-Chemical
cystitis	B-Disease
(	O
150	O
mg/kg	O
;	O
i.p	O
.	O

;	O
48	O
h	O
)	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	O
(	O
-/-	O
)	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	O
(	O
-/-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	O
(	O
-/-	O
)	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
.	O

The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1.5-fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0.05	O
for	O
the	O
comparison	O
being	O
made	O
.	O

Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme-linked	O
immunoassays	O
including	O
IL-1beta	O
and	O
CXCL1	O
.	O

CYP	B-Chemical
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
increased	O
expression	O
of	O
CXCL1	O
and	O
IL-1beta	O
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	O
(	O
-/-	O
)	O
mice	O
,	O
but	O
expression	O
in	O
VIP	O
(	O
-/-	O
)	O
mice	O
with	O
CYP	B-Chemical
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
greater	O
(	O
4.2-	O
to	O
13-fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	B-Disease
(	O
3.6-	O
to	O
5-fold	O
increase	O
)	O
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP	O
(	O
-/-	O
)	O
mice	O
with	O
bladder	B-Disease
inflammation	O
,	O
inflammatory	O
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	B-Chemical
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	B-Disease
dysfunction	I-Disease
in	O
VIP	O
(	O
-/-	O
)	O
mice	O
with	O
bladder	B-Disease
inflammation	I-Disease
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O

Intraocular	O
pressure	O
in	O
patients	O
with	O
uveitis	B-Disease
treated	O
with	O
fluocinolone	B-Chemical
acetonide	I-Chemical
implants	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
the	O
incidence	O
and	O
management	O
of	O
elevated	B-Disease
intraocular	I-Disease
pressure	I-Disease
(	O
IOP	O
)	O
in	O
patients	O
with	O
uveitis	B-Disease
treated	O
with	O
the	O
fluocinolone	B-Chemical
acetonide	I-Chemical
(	O
FA	B-Chemical
)	O
intravitreal	O
implant	O
.	O

DESIGN	O
:	O
Pooled	O
data	O
from	O
3	O
multicenter	O
,	O
double-masked	O
,	O
randomized	O
,	O
controlled	O
,	O
phase	O
2b/3	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
0.59-mg	O
or	O
2.1-mg	O
FA	B-Chemical
intravitreal	O
implant	O
or	O
standard	O
therapy	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
During	O
the	O
3-year	O
follow-up	O
,	O
71.0	O
%	O
of	O
implanted	O
eyes	O
had	O
an	O
IOP	O
increase	O
of	O
10	O
mm	O
Hg	O
or	O
more	O
than	O
baseline	O
and	O
55.1	O
%	O
,	O
24.7	O
%	O
,	O
and	O
6.2	O
%	O
of	O
eyes	O
reached	O
an	O
IOP	O
of	O
30	O
mm	O
Hg	O
or	O
more	O
,	O
40	O
mm	O
Hg	O
or	O
more	O
,	O
and	O
50	O
mm	O
Hg	O
or	O
more	O
,	O
respectively	O
.	O

Topical	O
IOP-lowering	O
medication	O
was	O
administered	O
in	O
74.8	O
%	O
of	O
implanted	O
eyes	O
,	O
and	O
IOP-lowering	O
surgeries	O
,	O
most	O
of	O
which	O
were	O
trabeculectomies	O
(	O
76.2	O
%	O
)	O
,	O
were	O
performed	O
on	O
36.6	O
%	O
of	O
implanted	O
eyes	O
.	O

Intraocular	O
pressure-lowering	O
surgeries	O
were	O
considered	O
a	O
success	O
(	O
postoperative	O
IOP	O
of	O
6-21	O
mm	O
Hg	O
with	O
or	O
without	O
additional	O
IOP-lowering	O
medication	O
)	O
in	O
85.1	O
%	O
of	O
eyes	O
at	O
1	O
year	O
.	O

The	O
rate	O
of	O
hypotony	B-Disease
(	O
IOP	O
<	O
/=	O
5	O
mm	O
Hg	O
)	O
following	O
IOP-lowering	O
surgery	O
(	O
42.5	O
%	O
)	O
was	O
not	O
different	O
from	O
that	O
of	O
implanted	O
eyes	O
not	O
subjected	O
to	O
surgery	O
(	O
35.4	O
%	O
)	O
(	O
P	O
=	O
.09	O
)	O
.	O

CONCLUSION	O
:	O
Elevated	O
IOP	O
is	O
a	O
significant	O
complication	O
with	O
the	O
FA	O
intravitreal	O
implant	O
but	O
may	O
be	O
controlled	O
with	O
medication	O
and	O
surgery	O
.	O

Pallidal	O
stimulation	O
:	O
an	O
alternative	O
to	O
pallidotomy	O
?	O
A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O

Laitinen	O
's	O
procedure	O
improved	O
most	O
symptoms	O
in	O
drug-resistant	O
PD	B-Disease
,	O
which	O
engendered	O
wide	O
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O

Another	O
lesioning	O
procedure	O
,	O
ventrolateral	O
thalamotomy	O
,	O
has	O
become	O
a	O
powerful	O
alternative	O
to	O
stimulate	O
the	O
nucleus	O
ventralis	O
intermedius	O
,	O
producing	O
high	O
long-term	O
success	O
rates	O
and	O
low	O
morbidity	O
rates	O
.	O

Pallidal	O
stimulation	O
has	O
not	O
met	O
with	O
the	O
same	O
success	O
.	O

According	O
to	O
the	O
literature	O
pallidotomy	O
improves	O
the	O
``	O
on	O
''	O
symptoms	O
of	O
PD	B-Disease
,	O
such	O
as	O
dyskinesias	B-Disease
,	O
as	O
well	O
as	O
the	O
``	O
off	O
''	O
symptoms	O
,	O
such	O
as	O
rigidity	B-Disease
,	O
bradykinesia	B-Disease
,	O
and	O
on-off	O
fluctuations	O
.	O

Pallidal	O
stimulation	O
improves	O
bradykinesia	B-Disease
and	O
rigidity	B-Disease
to	O
a	O
minor	O
extent	O
;	O
however	O
,	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa-induced	B-Chemical
dyskinesias	B-Disease
.	O

Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper-	B-Disease
or	I-Disease
dyskinetic	I-Disease
upper	O
limbs	O
,	O
but	O
increases	O
the	O
``	O
freezing	O
''	O
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O

Considering	O
the	O
small	O
increase	O
in	O
the	O
patient	O
's	O
independence	O
,	O
the	O
high	O
costs	O
of	O
bilateral	O
implants	O
,	O
and	O
the	O
difficulty	O
most	O
patients	O
experience	O
in	O
handling	O
the	O
devices	O
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
bilateral	O
pallidal	O
stimulation	O
is	O
a	O
real	O
alternative	O
to	O
pallidotomy	O
.	O

Case	O
report	O
:	O
Dexatrim	B-Chemical
(	O
Phenylpropanolamine	B-Chemical
)	O
as	O
a	O
cause	O
of	O
myocardial	B-Disease
infarction	I-Disease
.	O

Phenylpropanolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
is	O
a	O
sympathetic	O
amine	B-Chemical
used	O
in	O
over-the-counter	O
cold	O
remedies	O
and	O
weight-control	O
preparations	O
worldwide	O
.	O

Its	O
use	O
has	O
been	O
associated	O
with	O
hypertensive	B-Disease
episodes	O
and	O
hemorrhagic	B-Disease
strokes	I-Disease
in	O
younger	O
women	O
.	O

Several	O
reports	O
have	O
linked	O
the	O
abuse	O
of	O
PPA	O
with	O
myocardial	O
injury	O
,	O
especially	O
when	O
overdose	O
is	O
involved	O
.	O

We	O
report	O
here	O
the	O
first	O
case	O
of	O
Dexatrim	O
(	O
PPA	O
)	O
-induced	O
myocardial	O
injury	O
in	O
a	O
young	O
woman	O
who	O
was	O
using	O
it	O
at	O
recommended	O
doses	O
for	O
weight	O
control	O
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
7	O
other	O
cases	O
of	O
PPA	O
related	O
myocardial	O
injury	O
that	O
have	O
been	O
reported	O
so	O
far	O
.	O

Physicians	O
and	O
patients	O
should	O
be	O
alert	O
to	O
the	O
potential	O
cardiac	O
risk	O
associated	O
with	O
the	O
use	O
of	O
PPA	O
,	O
even	O
at	O
doses	O
generally	O
considered	O
to	O
be	O
safe	O
.	O

Risperidone-associated	B-Chemical
,	O
benign	O
transient	O
visual	B-Disease
disturbances	I-Disease
in	O
schizophrenic	B-Disease
patients	O
with	O
a	O
past	O
history	O
of	O
LSD	B-Chemical
abuse	O
.	O

Two	O
schizophrenic	B-Disease
patients	O
,	O
who	O
had	O
a	O
prior	O
history	O
of	O
LSD	B-Chemical
abuse	O
and	O
who	O
had	O
previously	O
developed	O
EPS	B-Disease
with	O
classic	O
antipsychotics	O
,	O
were	O
successfully	O
treated	O
with	O
risperidone	B-Chemical
.	O

They	O
both	O
reported	O
short	O
episodes	O
of	O
transient	O
visual	B-Disease
disturbances	I-Disease
,	O
which	O
appeared	O
immediately	O
after	O
starting	O
treatment	O
with	O
risperidone	B-Chemical
.	O

This	O
imagery	O
resembled	O
visual	B-Disease
disturbances	I-Disease
previously	O
experienced	O
as	O
``	O
flashbacks	O
''	O
related	O
to	O
prior	O
LSD	B-Chemical
consumption	O
.	O

Risperidone	B-Chemical
administration	O
was	O
continued	O
and	O
the	O
visual	B-Disease
disturbances	I-Disease
gradually	O
wore	O
off	O
.	O

During	O
a	O
six-month	O
follow-up	O
period	O
,	O
there	O
was	O
no	O
recurrence	O
of	O
visual	B-Disease
disturbances	I-Disease
.	O

This	O
phenomenon	O
may	O
be	O
interpreted	O
as	O
a	O
benign	O
,	O
short-term	O
and	O
self-limiting	O
side	O
effect	O
which	O
does	O
not	O
contraindicate	O
the	O
use	O
of	O
risperidone	B-Chemical
or	O
interfere	O
with	O
treatment	O
.	O

Conclusions	O
based	O
on	O
two	O
case	O
reports	O
should	O
be	O
taken	O
with	O
appropriate	O
caution	O
.	O

Activation	O
of	O
poly	B-Chemical
(	I-Chemical
ADP-ribose	I-Chemical
)	I-Chemical
polymerase	O
contributes	O
to	O
development	O
of	O
doxorubicin-induced	B-Chemical
heart	B-Disease
failure	I-Disease
.	O

Activation	O
of	O
the	O
nuclear	O
enzyme	O
poly	B-Chemical
(	I-Chemical
ADP-ribose	I-Chemical
)	I-Chemical
polymerase	O
(	O
PARP	O
)	O
by	O
oxidant-mediated	O
DNA	O
damage	O
is	O
an	O
important	O
pathway	O
of	O
cell	O
dysfunction	O
and	O
tissue	O
injury	O
in	O
conditions	O
associated	O
with	O
oxidative	O
stress	O
.	O

Increased	O
oxidative	O
stress	O
is	O
a	O
major	O
factor	O
implicated	O
in	O
the	O
cardiotoxicity	B-Disease
of	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
,	O
a	O
widely	O
used	O
antitumor	O
anthracycline	B-Chemical
antibiotic	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
activation	O
of	O
PARP	O
may	O
contribute	O
to	O
the	O
DOX-induced	B-Chemical
cardiotoxicity	B-Disease
.	O

Using	O
a	O
dual	O
approach	O
of	O
PARP-1	O
suppression	O
,	O
by	O
genetic	O
deletion	O
or	O
pharmacological	O
inhibition	O
with	O
the	O
phenanthridinone	O
PARP	O
inhibitor	O
PJ34	B-Chemical
,	O
we	O
now	O
demonstrate	O
the	O
role	O
of	O
PARP	O
in	O
the	O
development	O
of	O
cardiac	B-Disease
dysfunction	I-Disease
induced	O
by	O
DOX	B-Chemical
.	O

PARP-1+/+	O
and	O
PARP-1-/-	O
mice	O
received	O
a	O
single	O
injection	O
of	O
DOX	B-Chemical
(	O
25	O
mg/kg	O
i.p	O
)	O
.	O

Five	O
days	O
after	O
DOX	B-Chemical
administration	O
,	O
left	O
ventricular	O
performance	O
was	O
significantly	O
depressed	O
in	O
PARP-1+/+	O
mice	O
,	O
but	O
only	O
to	O
a	O
smaller	O
extent	O
in	O
PARP-1-/-	O
ones	O
.	O

Similar	O
experiments	O
were	O
conducted	O
in	O
BALB/c	O
mice	O
treated	O
with	O
PJ34	B-Chemical
or	O
vehicle	O
.	O

Treatment	O
with	O
a	O
PJ34	B-Chemical
significantly	O
improved	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
increased	O
the	O
survival	O
of	O
the	O
animals	O
.	O

In	O
addition	O
PJ34	B-Chemical
significantly	O
reduced	O
the	O
DOX-induced	B-Chemical
increase	O
in	O
the	O
serum	O
lactate	B-Chemical
dehydrogenase	O
and	O
creatine	B-Chemical
kinase	O
activities	O
but	O
not	O
metalloproteinase	O
activation	O
in	O
the	O
heart	O
.	O

Thus	O
,	O
PARP	O
activation	O
contributes	O
to	O
the	O
cardiotoxicity	B-Disease
of	O
DOX	B-Chemical
.	O

PARP	O
inhibitors	O
may	O
exert	O
protective	O
effects	O
against	O
the	O
development	O
of	O
severe	O
cardiac	B-Disease
complications	I-Disease
associated	O
with	O
the	O
DOX	B-Chemical
treatment	O
.	O

Fluconazole-induced	B-Chemical
torsade	B-Disease
de	B-Disease
pointes	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
present	O
a	O
case	O
of	O
fluconazole-associated	B-Chemical
torsade	B-Disease
de	B-Disease
pointes	I-Disease
(	O
TDP	B-Disease
)	O
and	O
discuss	O
fluconazole	B-Chemical
's	O
role	O
in	O
causing	O
TDP	B-Disease
.	O

CASE	O
SUMMARY	O
:	O
A	O
68-year-old	O
white	O
woman	O
with	O
Candida	O
glabrata	O
isolated	O
from	O
a	O
presacral	O
abscess	O
developed	O
TDP	B-Disease
eight	O
days	O
after	O
commencing	O
oral	O
fluconazole	B-Chemical
The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
TDP	B-Disease
,	O
including	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
cardiomyopathy	B-Disease
,	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
and	O
electrolyte	O
abnormalities	O
There	O
was	O
a	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
fluconazole	B-Chemical
and	O
TDP	B-Disease
.	O

The	O
TDP	B-Disease
resolved	O
when	O
fluconazole	B-Chemical
was	O
discontinued	O
;	O
however	O
,	O
the	O
patient	O
continued	O
to	O
have	O
premature	B-Disease
ventricular	I-Disease
contractions	I-Disease
and	O
nonsustained	O
ventricular	B-Disease
tachycardia	I-Disease
(	O
NSVT	B-Disease
)	O
until	O
six	O
days	O
after	O
drug	B-Drug
cessation	O
DISCUSSION	O
:	O
Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
use	O
of	O
fluconazole	B-Chemical
and	O
the	O
development	O
of	O
TDP	B-Disease
.	O

The	O
possible	O
mechanism	O
is	O
depression	B-Disease
of	O
rapidly	O
activating	O
delayed	O
rectifier	O
potassium	B-Chemical
currents	O
.	O

In	O
our	O
patient	O
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	O
that	O
could	O
explain	O
QT	B-Disease
prolongation	I-Disease
or	O
TDP	B-Disease
The	O
complete	O
disappearance	O
of	O
NSVT	B-Disease
and	O
premature	B-Disease
ventricular	I-Disease
contractions	I-Disease
followed	O
by	O
normalization	O
of	O
QT	O
interval	O
after	O
the	O
drug	B-Drug
was	O
stopped	O
strongly	O
suggests	O
fluconazole	B-Chemical
as	O
the	O
etiology	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	B-Chemical
,	O
even	O
at	O
low	O
doses	O
,	O
may	O
cause	O
prolongation	B-Disease
of	I-Disease
the	I-Disease
QT	I-Disease
interval	I-Disease
,	O
leading	O
to	O
TDP	B-Disease
.	O

Serial	O
electrocardiographic	O
monitoring	O
may	O
be	O
considered	O
when	O
fluconazole	B-Chemical
is	O
administered	O
in	O
patients	O
who	O
are	O
at	O
risk	O
for	O
ventricular	B-Disease
arrhythmias	I-Disease
.	O

High-dose	O
methylprednisolone	B-Chemical
may	O
do	O
more	O
harm	O
for	O
spinal	B-Disease
cord	I-Disease
injury	I-Disease
.	O

Because	O
of	O
the	O
National	O
Acute	O
Spinal	B-Disease
Cord	I-Disease
Injury	I-Disease
Studies	O
(	O
NASCIS	O
)	O
,	O
high-dose	O
methylprednisolone	B-Chemical
became	O
the	O
standard	O
of	O
care	O
for	O
the	O
acute	O
spinal	B-Disease
cord	I-Disease
injury	I-Disease
.	O

In	O
the	O
NASCIS	O
,	O
there	O
was	O
no	O
mention	O
regarding	O
the	O
possibility	O
of	O
acute	O
corticosteroid	B-Chemical
myopathy	B-Disease
that	O
high-dose	O
methylprednisolone	B-Chemical
may	O
cause	O
.	O

The	O
dosage	O
of	O
methylprednisolone	B-Chemical
recommended	O
by	O
the	O
NASCIS	O
3	O
is	O
the	O
highest	O
dose	O
of	O
steroids	B-Chemical
ever	O
being	O
used	O
during	O
a	O
2-day	O
period	O
for	O
any	O
clinical	O
condition	O
.	O

We	O
hypothesize	O
that	O
it	O
may	O
cause	O
some	O
damage	B-Disease
to	I-Disease
the	I-Disease
muscle	I-Disease
of	O
spinal	B-Disease
cord	I-Disease
injury	I-Disease
patients	O
.	O

Further	O
,	O
steroid	B-Chemical
myopathy	B-Disease
recovers	O
naturally	O
and	O
the	O
neurological	O
improvement	O
shown	O
in	O
the	O
NASCIS	O
may	O
be	O
just	O
a	O
recording	O
of	O
this	O
natural	O
motor	O
recovery	O
from	O
the	O
steroid	B-Chemical
myopathy	B-Disease
,	O
instead	O
of	O
any	O
protection	O
that	O
methylprednisolone	B-Chemical
offers	O
to	O
the	O
spinal	B-Disease
cord	I-Disease
injury	I-Disease
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
discussion	O
considering	O
the	O
possibility	O
that	O
the	O
methylprednisolone	B-Chemical
recommended	O
by	O
NASCIS	O
may	O
cause	O
acute	O
corticosteroid	B-Chemical
myopathy	B-Disease
.	O

Probing	O
peripheral	O
and	O
central	O
cholinergic	O
system	O
responses	O
.	O

OBJECTIVE	O
:	O
The	O
pharmacological	O
response	O
to	O
drugs	B-Drug
that	O
act	O
on	O
the	O
cholinergic	O
system	O
of	O
the	O
iris	O
has	O
been	O
used	O
to	O
predict	O
deficits	O
in	O
central	O
cholinergic	O
functioning	O
due	O
to	O
diseases	O
such	O
as	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
,	O
yet	O
correlations	O
between	O
central	O
and	O
peripheral	O
responses	O
have	O
not	O
been	O
properly	O
studied	O
.	O

This	O
study	O
assessed	O
the	O
effect	O
of	O
normal	O
aging	O
on	O
(	O
1	O
)	O
the	O
tropicamide-induced	B-Chemical
increase	O
in	O
pupil	O
diameter	O
,	O
and	O
(	O
2	O
)	O
the	O
reversal	O
of	O
this	O
effect	O
with	O
pilocarpine	B-Chemical
.	O

Scopolamine	B-Chemical
was	O
used	O
as	O
a	O
positive	O
control	O
to	O
detect	O
age-dependent	O
changes	O
in	O
central	O
cholinergic	O
functioning	O
in	O
the	O
elderly	O
.	O

DESIGN	O
:	O
Randomized	O
double-blind	O
controlled	O
trial	O
.	O

PARTICIPANTS	O
:	O
Ten	O
healthy	O
elderly	O
(	O
mean	O
age	O
70	O
)	O
and	O
9	O
young	O
(	O
mean	O
age	O
33	O
)	O
volunteers	O
.	O

INTERVENTIONS	O
:	O
Pupil	O
diameter	O
was	O
monitored	O
using	O
a	O
computerized	O
infrared	O
pupillometer	O
over	O
4	O
hours	O
.	O

The	O
study	O
involved	O
4	O
sessions	O
.	O

In	O
1	O
session	O
,	O
tropicamide	B-Chemical
(	O
20	O
microL	O
,	O
0.01	O
%	O
)	O
was	O
administered	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

In	O
another	O
session	O
,	O
tropicamide	B-Chemical
(	O
20	O
microL	O
,	O
0.01	O
%	O
)	O
was	O
administered	O
to	O
both	O
eyes	O
,	O
followed	O
23	O
minutes	O
later	O
by	O
the	O
application	O
of	O
pilocarpine	B-Chemical
(	O
20	O
microL	O
,	O
0.1	O
%	O
)	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

All	O
eye	O
drops	O
were	O
given	O
in	O
a	O
randomized	O
order	O
.	O

In	O
2	O
separate	O
sessions	O
,	O
a	O
single	O
dose	O
of	O
scopolamine	B-Chemical
(	O
0.5	O
mg	O
,	O
intravenously	O
)	O
or	O
placebo	O
was	O
administered	O
,	O
and	O
the	O
effects	O
on	O
word	O
recall	O
were	O
measured	O
using	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
over	O
2	O
hours	O
.	O

OUTCOME	O
MEASURES	O
:	O
Pupil	O
size	O
at	O
time	O
points	O
after	O
administration	O
of	O
tropicamide	B-Chemical
and	O
pilocarpine	B-Chemical
;	O
scopolamine-induced	B-Chemical
impairment	B-Disease
in	I-Disease
word	I-Disease
recall	I-Disease
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
elderly	O
and	O
young	O
volunteers	O
in	O
pupillary	O
response	O
to	O
tropicamide	B-Chemical
at	O
any	O
time	O
point	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
elderly	O
group	O
had	O
a	O
significantly	O
greater	O
pilocarpine-induced	B-Chemical
net	O
decrease	O
in	O
pupil	O
size	O
85	O
,	O
125	O
,	O
165	O
and	O
215	O
minutes	O
after	O
administration	O
,	O
compared	O
with	O
the	O
young	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Compared	O
with	O
the	O
young	O
group	O
,	O
the	O
elderly	O
group	O
had	O
greater	O
scopolamine-induced	B-Chemical
impairment	B-Disease
in	I-Disease
word	I-Disease
recall	I-Disease
60	O
,	O
90	O
and	O
120	O
minutes	O
after	O
administration	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
is	O
an	O
age-related	O
pupillary	O
response	O
to	O
pilocarpine	B-Chemical
that	O
is	O
not	O
found	O
with	O
tropicamide	B-Chemical
.	O

Thus	O
,	O
pilocarpine	B-Chemical
may	O
be	O
useful	O
to	O
assess	O
variations	O
in	O
central	O
cholinergic	O
function	O
in	O
elderly	O
patients	O
.	O

Acetazolamide-induced	B-Chemical
Gerstmann	B-Disease
syndrome	I-Disease
.	O

Acute	O
confusion	B-Disease
induced	O
by	O
acetazolamide	B-Chemical
is	O
a	O
well	O
known	O
adverse	O
drug	B-Drug
reaction	O
in	O
patients	O
with	O
renal	B-Disease
impairment	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
acetazolamide-induced	B-Chemical
Gerstmann	B-Disease
syndrome	I-Disease
in	O
a	O
patient	O
with	O
normal	O
renal	O
function	O
,	O
to	O
highlight	O
predisposing	O
factors	O
that	O
are	O
frequently	O
overlooked	O
.	O

Hypomania-like	B-Disease
syndrome	O
induced	O
by	O
olanzapine	B-Chemical
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
a	O
diagnosis	O
of	O
a	O
not	O
otherwise	O
specified	O
psychotic	B-Disease
disorder	I-Disease
(	O
DSM-IV	O
)	O
who	O
developed	O
hypomania	B-Disease
shortly	O
after	O
the	O
introduction	O
of	O
olanzapine	B-Chemical
treatment	O
.	O

Neutrophil	O
superoxide	B-Chemical
and	O
hydrogen	B-Chemical
peroxide	I-Chemical
production	O
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
.	O

Defects	O
in	O
superoxide	B-Chemical
and	O
hydrogen	B-Chemical
peroxide	I-Chemical
production	O
may	O
be	O
implicated	O
in	O
the	O
high	O
incidence	O
of	O
bacterial	B-Disease
infections	I-Disease
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
ALF	B-Disease
)	O
.	O

In	O
the	O
present	O
study	O
,	O
oxygen	B-Chemical
radical	O
production	O
in	O
patients	O
with	O
ALF	B-Disease
due	O
to	O
paracetamol	B-Chemical
overdose	B-Disease
was	O
compared	O
with	O
that	O
of	O
healthy	O
volunteers	O
.	O

Neutrophils	O
from	O
14	O
ALF	B-Disease
patients	O
were	O
stimulated	O
via	O
the	O
complement	O
receptors	O
using	O
zymosan	O
opsonized	O
with	O
ALF	B-Disease
or	O
control	O
serum	O
.	O

Superoxide	B-Chemical
and	O
hydrogen	B-Chemical
peroxide	I-Chemical
production	O
by	O
ALF	B-Disease
neutrophils	O
stimulated	O
with	O
zymosan	O
opsonized	O
with	O
ALF	B-Disease
serum	O
was	O
significantly	O
reduced	O
compared	O
with	O
the	O
control	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O

This	O
defect	O
persisted	O
when	O
zymosan	O
opsonized	O
by	O
control	O
serum	O
was	O
used	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Superoxide	B-Chemical
and	O
hydrogen	B-Chemical
peroxide	I-Chemical
production	O
in	O
neutrophils	O
stimulated	O
with	O
formyl-methionyl-leucyl-phenylalanine	B-Chemical
(	O
fMLP	B-Chemical
)	O
from	O
a	O
further	O
18	O
ALF	B-Disease
patients	O
was	O
unaffected	O
compared	O
with	O
control	O
neutrophils	O
.	O

Serum	O
C3	O
complement	O
levels	O
were	O
significantly	O
reduced	O
in	O
ALF	B-Disease
patients	O
compared	O
with	O
control	O
subjects	O
(	O
P	O
<	O
0.0005	O
)	O
.	O

These	O
results	O
demonstrate	O
a	O
neutrophil	O
defect	O
in	O
ALF	B-Disease
due	O
to	O
paracetamol	B-Chemical
overdose	B-Disease
,	O
that	O
is	O
complement	O
dependent	O
but	O
independent	O
of	O
serum	O
complement	O
,	O
possibly	O
connected	O
to	O
the	O
complement	O
receptor	O
.	O

Absence	O
of	O
effect	O
of	O
sertraline	B-Chemical
on	O
time-based	O
sensitization	O
of	O
cognitive	B-Disease
impairment	I-Disease
with	O
haloperidol	B-Chemical
.	O

This	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
study	O
evaluated	O
the	O
effects	O
of	O
haloperidol	B-Chemical
alone	O
and	O
haloperidol	B-Chemical
plus	O
sertraline	B-Chemical
on	O
cognitive	O
and	O
psychomotor	O
function	O
in	O
24	O
healthy	O
male	O
subjects	O
.	O

METHOD	O
:	O
All	O
subjects	O
received	O
placebo	O
on	O
Day	O
1	O
and	O
haloperidol	B-Chemical
2	O
mg	O
on	O
Days	O
2	O
and	O
25	O
.	O

From	O
Days	O
9	O
to	O
25	O
,	O
subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
sertraline	B-Chemical
(	O
12	O
subjects	O
)	O
or	O
placebo	O
(	O
12	O
subjects	O
)	O
;	O
the	O
sertraline	B-Chemical
dose	O
was	O
titrated	O
from	O
50	O
to	O
200	O
mg/day	O
from	O
Days	O
9	O
to	O
16	O
,	O
and	O
remained	O
at	O
200	O
mg/day	O
for	O
the	O
final	O
10	O
days	O
of	I-Disease
the	O
drug	B-Drug
administration	O
period	O
.	O

Cognitive	O
function	I-Disease
testing	O
was	O
performed	O
before	O
dosing	O
and	O
over	O
a	O
24-hour	O
period	O
after	O
dosing	O
on	O
Days	O
1	O
,	O
2	O
,	O
and	O
25	O
.	O

RESULTS	O
:	O
Impairment	B-Disease
of	I-Disease
cognitive	O
function	O
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	B-Chemical
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

When	O
single-dose	O
haloperidol	B-Chemical
was	O
given	O
again	O
25	O
days	O
later	O
,	O
greater	O
impairment	O
with	O
earlier	O
onset	O
was	O
noted	O
in	O
several	O
tests	O
in	O
both	O
treatment	O
groups	O
,	O
suggesting	O
enhancement	O
of	O
this	O
effect	O
.	O

There	O
was	O
no	O
indication	O
that	O
sertraline	B-Chemical
exacerbated	O
the	O
impairment	O
produced	O
by	O
haloperidol	B-Chemical
since	O
an	O
equivalent	O
effect	O
also	O
occurred	O
in	O
the	O
placebo	O
group	O
.	O

Three	O
subjects	O
(	O
2	O
on	O
sertraline	B-Chemical
and	O
1	O
on	O
placebo	O
)	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

Ten	O
subjects	O
in	O
each	O
group	O
reported	O
side	O
effects	O
related	O
to	O
treatment	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
sertraline	B-Chemical
and	O
of	O
placebo	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Haloperidol	B-Chemical
produced	O
a	O
clear	O
profile	O
of	O
cognitive	B-Disease
impairment	I-Disease
that	O
was	O
not	O
worsened	O
by	O
concomitant	O
sertraline	B-Chemical
administration	O
.	O

Ciprofloxacin-induced	B-Chemical
nephrotoxicity	B-Disease
in	O
patients	O
with	O
cancer	B-Disease
.	O

Nephrotoxicity	B-Disease
associated	O
with	O
ciprofloxacin	B-Chemical
is	O
uncommon	O
.	O

Five	O
patients	O
with	O
cancer	B-Disease
who	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
that	O
followed	O
treatment	O
with	O
ciprofloxacin	B-Chemical
are	O
described	O
and	O
an	O
additional	O
15	O
cases	O
reported	O
in	O
the	O
literature	O
are	O
reviewed	O
.	O

Other	O
than	O
elevation	O
of	O
serum	O
creatinine	B-Chemical
levels	O
,	O
characteristic	O
clinical	O
manifestations	O
and	O
abnormal	O
laboratory	O
findings	O
are	O
not	O
frequently	O
present	O
.	O

Allergic	O
interstitial	B-Disease
nephritis	I-Disease
is	O
believed	O
to	O
be	O
the	O
underlying	O
pathological-process	O
.	O

Definitive	O
diagnosis	O
requires	O
performance	O
of	O
renal	O
biopsy	O
,	O
although	O
this	O
is	O
not	O
always	O
feasible	O
.	O

An	O
improvement	O
in	O
renal	O
function	O
that	O
followed	O
the	O
discontinuation	O
of	O
the	O
offending	O
antibiotic	O
supports	O
the	O
presumptive	O
diagnosis	O
of	O
ciprofloxacin-induced	B-Chemical
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Case	O
report	O
:	O
pentamidine	B-Chemical
and	O
polymorphic	O
ventricular	B-Disease
tachycardia	I-Disease
revisited	O
.	O

Pentamidine	B-Chemical
isethionate	I-Chemical
has	O
been	O
associated	O
with	O
ventricular	B-Disease
tachyarrhythmias	I-Disease
,	O
including	O
torsade	B-Disease
de	B-Disease
pointes	I-Disease
.	O

This	O
article	O
reports	O
two	O
cases	O
of	O
this	O
complication	O
and	O
reviews	O
all	O
reported	O
cases	O
to	O
date	O
.	O

Pentamidine-induced	B-Chemical
torsade	B-Disease
de	B-Disease
pointes	I-Disease
may	O
be	O
related	O
to	O
serum	O
magnesium	B-Chemical
levels	O
and	O
hypomagnesemia	B-Disease
may	O
synergistically	O
induce	O
torsade	O
.	O

Torsade	B-Disease
de	B-Disease
pointes	I-Disease
occurred	O
after	O
an	O
average	O
of	O
10	O
days	O
of	O
treatment	O
with	O
pentamidine	B-Chemical
.	O

In	O
these	O
patients	O
,	O
no	O
other	O
acute	O
side	O
effects	O
of	O
pentamidine	B-Chemical
were	O
observed	O
.	O

Torsade	B-Disease
de	B-Disease
pointes	I-Disease
can	O
be	O
treated	O
when	O
recognized	O
early	O
,	O
possibly	O
without	O
discontinuation	O
of	O
pentamidine	B-Chemical
.	O

When	O
QTc	B-Disease
interval	I-Disease
prolongation	I-Disease
is	O
observed	O
,	O
early	O
magnesium	B-Chemical
supplementation	O
is	O
advocated	O
.	O

Time	O
dependence	O
of	O
plasma	O
malondialdehyde	B-Chemical
,	O
oxypurines	B-Chemical
,	O
and	O
nucleosides	B-Chemical
during	O
incomplete	O
cerebral	B-Disease
ischemia	I-Disease
in	O
the	O
rat	O
.	O

Incomplete	O
cerebral	B-Disease
ischemia	I-Disease
(	O
30	O
min	O
)	O
was	O
induced	O
in	O
the	O
rat	O
by	O
bilaterally	O
clamping	O
the	O
common	O
carotid	O
arteries	O
.	O

Peripheral	O
venous	O
blood	O
samples	O
were	O
withdrawn	O
from	O
the	O
femoral	O
vein	O
four	O
times	O
(	O
once	O
every	O
5	O
min	O
)	O
before	O
ischemia	B-Disease
(	O
0	O
time	O
)	O
and	O
5	O
,	O
15	O
,	O
and	O
30	O
min	O
after	O
ischemia	B-Disease
.	O

Plasma	O
extracts	O
were	O
analyzed	O
by	O
a	O
highly	O
sensitive	O
high-performance	O
liquid	O
chromatographic	O
method	O
for	O
the	O
direct	O
determination	O
of	O
malondialdehyde	B-Chemical
,	O
oxypurines	B-Chemical
,	O
and	O
nucleosides	B-Chemical
.	O

During	O
ischemia	B-Disease
,	O
a	O
time-dependent	O
increase	O
of	O
plasma	O
oxypurines	B-Chemical
and	O
nucleosides	B-Chemical
was	O
observed	O
.	O

Plasma	O
malondialdehyde	B-Chemical
,	O
which	O
was	O
present	O
in	O
minimal	O
amount	O
at	O
zero	O
time	O
(	O
0.058	O
mumol/liter	O
plasma	O
;	O
SD	O
0.015	O
)	O
,	O
increased	O
after	O
5	O
min	O
of	O
ischemia	B-Disease
,	O
resulting	O
in	O
a	O
fivefold	O
increase	O
after	O
30	O
min	O
of	O
carotid	O
occlusion	O
(	O
0.298	O
mumol/liter	O
plasma	O
;	O
SD	O
0.078	O
)	O
.	O

Increased	O
plasma	O
malondialdehyde	B-Chemical
was	O
also	O
recorded	O
in	O
two	O
other	O
groups	O
of	O
animals	O
subjected	O
to	O
the	O
same	O
experimental	O
model	O
,	O
one	O
receiving	O
20	O
mg/kg	O
b.w	O
.	O

of	O
the	O
cyclooxygenase	O
inhibitor	O
acetylsalicylate	B-Chemical
intravenously	O
immediately	O
before	O
ischemia	B-Disease
,	O
the	O
other	O
receiving	O
650	O
micrograms/kg	O
b.w	O
.	O

of	O
the	O
hypotensive	B-Disease
drug	B-Drug
nitroprusside	B-Chemical
at	O
a	O
flow	O
rate	O
of	O
103	O
microliters/min	O
intravenously	O
during	O
ischemia	B-Disease
,	O
although	O
in	O
this	O
latter	O
group	O
malondialdehyde	B-Chemical
was	O
significantly	O
higher	O
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
determination	O
of	O
malondialdehyde	B-Chemical
,	O
oxypurines	B-Chemical
,	O
and	O
nucleosides	B-Chemical
in	O
peripheral	O
blood	O
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	O
alterations	O
of	O
tissues	O
occurring	O
during	O
ischemic	B-Disease
phenomena	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Cholinergic	O
toxicity	B-Disease
resulting	O
from	O
ocular	O
instillation	O
of	O
echothiophate	B-Chemical
iodide	I-Chemical
eye	O
drops	O
.	O

A	O
patient	O
developed	O
a	O
severe	O
cholinergic	O
syndrome	O
from	O
the	O
use	O
of	O
echothiophate	B-Chemical
iodide	I-Chemical
ophthalmic	O
drops	O
,	O
presented	O
with	O
profound	O
muscle	B-Disease
weakness	I-Disease
and	O
was	O
initially	O
given	O
the	O
diagnosis	O
of	O
myasthenia	B-Disease
gravis	I-Disease
.	O

Red	O
blood	O
cell	O
and	O
serum	O
cholinesterase	O
levels	O
were	O
severely	O
depressed	O
and	O
symptoms	O
resolved	O
spontaneously	O
following	O
discontinuation	O
of	O
the	O
eye	O
drops	O
.	O

Acute	B-Disease
renal	I-Disease
failure	I-Disease
in	O
high	O
dose	O
carboplatin	B-Chemical
chemotherapy	O
.	O

Carboplatin	B-Chemical
has	O
been	O
reported	O
to	O
cause	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
when	O
administered	O
in	O
high	O
doses	O
to	O
adult	O
patients	O
.	O

We	O
report	O
a	O
4	O
1/2-year-old	O
girl	O
who	O
was	O
treated	O
with	O
high-dose	O
carboplatin	B-Chemical
for	O
metastatic	O
parameningeal	O
embryonal	B-Disease
rhabdomyosarcoma	I-Disease
.	O

Acute	B-Disease
renal	I-Disease
failure	I-Disease
developed	O
followed	O
by	O
a	O
slow	O
partial	O
recovery	O
of	O
renal	O
function	O
.	O

Possible	O
contributing	O
factors	O
are	O
discussed	O
.	O

Endometrial	B-Disease
carcinoma	I-Disease
after	O
Hodgkin	B-Disease
disease	I-Disease
in	O
childhood	O
.	O

A	O
34-year-old	O
patient	O
developed	O
metastic	O
endometrial	B-Disease
carcinoma	I-Disease
after	O
Hodgkin	B-Disease
disease	I-Disease
in	O
childhood	O
.	O

She	O
had	O
ovarian	B-Disease
failure	I-Disease
after	O
abdominal	O
irradiation	O
and	O
chemotherapy	O
for	O
Hodgkin	B-Disease
disease	I-Disease
,	O
and	O
received	O
exogenous	O
estrogens	B-Chemical
,	O
a	O
treatment	O
implicated	O
in	O
the	O
development	O
of	O
endometrial	B-Disease
cancer	I-Disease
in	O
menopausal	O
women	O
.	O

Young	O
women	O
on	O
replacement	O
estrogens	B-Chemical
for	O
ovarian	B-Disease
failure	I-Disease
after	O
cancer	B-Disease
therapy	O
may	O
also	O
have	O
increased	O
risk	O
of	O
endometrial	B-Disease
carcinoma	I-Disease
and	O
should	O
be	O
examined	O
periodically	O
.	O

Induction	O
of	O
the	O
obstructive	B-Disease
sleep	I-Disease
apnea	I-Disease
syndrome	I-Disease
in	O
a	O
woman	O
by	O
exogenous	O
androgen	B-Chemical
administration	O
.	O

We	O
documented	O
airway	O
occlusion	O
during	O
sleep	I-Disease
and	O
an	O
abnormally	O
high	O
supraglottic	O
resistance	O
while	O
awake	O
in	O
a	O
54-yr-old	O
woman	O
who	O
had	O
developed	O
physical	O
changes	O
and	O
the	O
syndrome	B-Disease
of	I-Disease
obstructive	I-Disease
sleep	I-Disease
apnea	O
while	O
being	O
administered	O
exogenous	O
androgens	B-Chemical
.	O

When	O
the	O
androgens	B-Chemical
were	O
withdrawn	O
,	O
the	O
patient	O
's	O
physical	O
changes	O
,	O
symptoms	O
,	O
sleep	O
study	O
,	O
and	O
supraglottic	O
resistance	O
all	O
returned	O
to	O
normal	O
.	O

A	O
rechallenge	O
with	O
androgen	B-Chemical
produced	O
symptoms	O
of	O
obstructive	B-Disease
sleep	I-Disease
apnea	I-Disease
that	O
abated	O
upon	O
withdrawal	O
of	O
the	O
hormone	O
.	O

Previous	O
reports	O
have	O
favored	O
a	O
role	O
of	O
androgens	B-Chemical
in	O
the	O
pathogenesis	O
of	O
sleep	B-Disease
apnea	I-Disease
.	O

Our	O
report	O
provides	O
direct	O
evidence	O
for	O
this	O
role	O
.	O

Structural	O
and	O
functional	O
measurements	O
indicate	O
that	O
androgens	B-Chemical
exert	O
a	O
permissive	O
or	O
necessary	O
action	O
on	O
the	O
structural	O
configuration	O
of	O
the	O
oropharynx	O
that	O
predisposes	O
to	O
obstruction	O
during	O
sleep	I-Disease
.	O

Development	O
of	O
the	O
obstructive	B-Disease
sleep	I-Disease
apnea	I-Disease
syndrome	O
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	B-Chemical
therapy	O
.	O

Effect	O
of	O
captopril	B-Chemical
on	O
pre-existing	O
and	O
aminonucleoside-induced	B-Chemical
proteinuria	B-Disease
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
.	O

Proteinuria	B-Disease
is	O
a	O
side	O
effect	O
of	O
captopril	B-Chemical
treatment	O
in	O
hypertensive	B-Disease
patients	O
.	O

The	O
possibility	O
of	O
reproducing	O
the	O
same	O
renal	B-Disease
abnormality	I-Disease
with	O
captopril	B-Chemical
was	O
examined	O
in	O
SHR	O
.	O

Oral	O
administration	O
of	O
captopril	B-Chemical
at	O
100	O
mg/kg	O
for	O
14	O
days	O
failed	O
to	O
aggravate	O
proteinuria	B-Disease
pre-existing	O
in	O
SHR	O
.	O

Also	O
,	O
captopril	B-Chemical
treatment	O
failed	O
to	O
potentiate	O
or	O
facilitate	O
development	O
of	O
massive	O
proteinuria	B-Disease
invoked	O
by	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
in	O
SHR	O
.	O

Captopril	B-Chemical
had	O
little	O
or	O
no	O
demonstrable	O
effects	O
on	O
serum	O
electrolyte	O
concentrations	O
,	O
excretion	O
of	O
urine	O
,	O
sodium	B-Chemical
and	O
potassium	B-Chemical
,	O
endogenous	O
creatinine	B-Chemical
clearance	O
,	O
body	O
weight	O
,	O
and	O
food	O
and	O
water	O
consumption	O
.	O

However	O
,	O
ketone	B-Chemical
bodies	O
were	O
consistently	O
present	O
in	O
urine	O
and	O
several	O
lethalities	O
occurred	O
during	O
multiple	O
dosing	O
of	O
captopril	B-Chemical
in	O
SHR	O
.	O

Epileptogenic	O
properties	O
of	O
enflurane	B-Chemical
and	O
their	O
clinical	O
interpretation	O
.	O

Three	O
cases	O
of	O
EEG	O
changes	O
induced	O
by	O
single	O
exposure	O
to	O
enflurane	B-Chemical
anesthesia	B-Drug
are	O
reported	O
.	O

In	O
one	O
patient	O
,	O
enflurane	B-Chemical
administered	O
during	O
a	O
donor	O
nephrectomy	O
resulted	O
in	O
unexpected	O
partial	O
motor	O
seizures	B-Disease
.	O

Until	O
the	O
cause	O
of	O
the	O
seizures	B-Disease
was	O
correctly	O
identified	O
,	O
the	O
patient	O
was	O
inappropriately	O
treated	O
with	O
anticonvulsants	O
.	O

Two	O
other	O
patients	O
suffered	O
from	O
partial	O
,	O
complex	O
and	O
generalized	O
seizures	B-Disease
uncontrolled	O
by	O
medication	O
.	O

Epileptic	B-Disease
foci	O
delineated	O
and	O
activated	O
by	O
enflurane	B-Chemical
were	O
surgically	O
ablated	O
and	O
the	O
patients	O
are	O
now	O
seizure-free	B-Disease
.	O

Previous	O
exposures	O
to	O
enflurane	B-Chemical
have	O
to	O
be	O
disclosed	O
to	O
avoid	O
mistakes	O
in	O
clinical	O
interpretation	O
of	O
the	O
EEG	O
.	O

On	O
the	O
other	O
hand	O
,	O
enflurane	B-Chemical
may	O
prove	O
to	O
be	O
a	O
safe	O
fast	O
acting	O
activator	O
of	O
epileptic	B-Disease
foci	O
during	O
corticography	O
or	O
depth	O
electrode	O
intraoperative	O
recordings	O
.	O

Reversible	O
cerebral	B-Disease
lesions	I-Disease
associated	O
with	O
tiazofurin	B-Chemical
usage	O
:	O
MR	O
demonstration	O
.	O

Tiazofurin	B-Chemical
is	O
an	O
experimental	O
chemotherapeutic	O
agent	O
currently	O
undergoing	O
clinical	O
evaluation	O
.	O

We	O
report	O
our	O
results	O
with	O
magnetic	O
resonance	O
(	O
MR	O
)	O
in	O
demonstrating	O
reversible	O
cerebral	B-Disease
abnormalities	I-Disease
concurrent	O
with	O
the	O
use	O
of	O
this	O
drug	B-Drug
.	O

The	O
abnormalities	O
on	O
MR	O
were	O
correlated	O
with	O
findings	O
on	O
CT	O
as	O
well	O
as	O
with	O
cerebral	O
angiography	O
.	O

The	O
utility	O
of	O
MR	O
in	O
the	O
evaluation	O
of	O
patients	O
receiving	O
this	O
new	O
agent	O
is	O
illustrated	O
.	O

Antagonism	O
of	O
diazepam-induced	B-Chemical
sedative	O
effects	O
by	O
Ro15-1788	B-Chemical
in	O
patients	O
after	O
surgery	O
under	O
lumbar	O
epidural	O
block	O
.	O

A	O
double-blind	O
placebo-controlled	O
investigation	O
of	O
efficacy	O
and	O
safety	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
Ro15-1788	B-Chemical
and	O
a	O
placebo	O
in	O
reversing	O
diazepam-induced	B-Chemical
effects	O
after	O
surgery	O
under	O
epidural	O
block	O
,	O
and	O
to	O
evaluate	O
the	O
local	O
tolerance	O
and	O
general	O
safety	O
of	O
Ro15-1788	B-Chemical
.	O

Fifty-seven	O
patients	O
were	O
sedated	O
with	O
diazepam	B-Chemical
for	O
surgery	O
under	O
epidural	O
anaesthesia	O
.	O

Antagonism	O
of	O
diazepam-induced	B-Chemical
effects	O
by	O
Ro15-1788	B-Chemical
was	O
investigated	O
postoperatively	O
in	O
a	O
double-blind	O
placebo-controlled	O
trial	O
.	O

The	O
patient	O
's	O
subjective	O
assessment	O
of	O
mood	O
rating	O
,	O
an	O
objective	O
test	O
of	O
performance	O
,	O
a	O
test	O
for	O
amnesia	B-Disease
,	O
and	O
vital	O
signs	O
were	O
recorded	O
for	O
up	O
to	O
300	O
min	O
after	O
administration	O
of	O
the	O
trial	O
drug	B-Drug
.	O

No	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
for	O
mood	O
rating	O
,	O
amnesia	B-Disease
,	O
or	O
vital	O
signs	O
.	O

The	O
Ro15-1788	B-Chemical
group	O
showed	O
a	O
significant	O
improvement	O
in	O
the	O
performance	O
test	O
up	O
to	O
120	O
min	O
after	O
administration	O
of	O
the	O
drug	B-Drug
.	O

There	O
was	O
no	O
evidence	O
of	O
reaction	O
at	O
the	O
injection	O
site	O
.	O

Enhanced	O
stimulus-induced	O
neurotransmitter	O
overflow	O
in	O
epinephrine-induced	B-Chemical
hypertensive	B-Disease
rats	O
is	O
not	O
mediated	O
by	O
prejunctional	O
beta-adrenoceptor	O
activation	O
.	O

The	O
present	O
study	O
examines	O
the	O
effect	O
of	O
6-day	O
epinephrine	B-Chemical
treatment	O
(	O
100	O
micrograms/kg	O
per	O
h	O
,	O
s.c.	O
)	O
on	O
stimulus-induced	O
(	O
1	O
Hz	O
)	O
endogenous	O
neurotransmitter	O
overflow	O
from	O
the	O
isolated	O
perfused	O
kidney	O
of	O
vehicle-	O
and	O
epinephrine-treated	B-Chemical
rats	O
.	O

Renal	O
catecholamine	B-Chemical
stores	O
and	O
stimulus-induced	O
overflow	O
in	O
the	O
vehicle-treated	O
group	O
consisted	O
of	O
norepinephrine	B-Chemical
only	O
.	O

However	O
,	O
epinephrine	B-Chemical
treatment	O
resulted	O
in	O
the	O
incorporation	O
of	O
epinephrine	B-Chemical
into	O
renal	O
catecholamine	B-Chemical
stores	O
such	O
that	O
approximately	O
40	O
%	O
of	O
the	O
catecholamine	B-Chemical
present	O
was	O
epinephrine	B-Chemical
while	O
the	O
norepinephrine	B-Chemical
content	O
was	O
reduced	O
by	O
a	O
similar	O
degree	O
.	O

Total	O
tissue	O
catecholamine	B-Chemical
content	O
of	O
the	O
kidney	O
on	O
a	O
molar	O
basis	O
was	O
unchanged	O
.	O

Stimulus-induced	O
fractional	O
overflow	O
of	O
neurotransmitter	O
from	O
the	O
epinephrine-treated	B-Chemical
kidneys	O
was	O
approximately	O
twice	O
normal	O
and	O
consisted	O
of	O
both	O
norepinephrine	B-Chemical
and	O
epinephrine	B-Chemical
in	O
proportions	O
similar	O
to	O
those	O
found	O
in	O
the	O
kidney	O
.	O

This	O
difference	O
in	O
fractional	O
overflow	O
between	O
groups	O
was	O
not	O
affected	O
by	O
neuronal	O
and	O
extraneuronal	O
uptake	O
blockade	O
.	O

Propranolol	B-Chemical
had	O
no	O
effect	O
on	O
stimulus-induced	O
overflow	O
in	O
either	O
group	O
.	O

Phentolamine	B-Chemical
increased	O
stimulus-induced	O
overflow	O
in	O
both	O
groups	O
although	O
the	O
increment	O
in	O
overflow	O
was	O
greater	O
in	O
the	O
epinephrine-treated	B-Chemical
group	O
.	O

In	O
conclusion	O
,	O
chronic	O
epinephrine	B-Chemical
treatment	O
results	O
in	O
enhanced	O
fractional	O
neurotransmitter	O
overflow	O
.	O

However	O
,	O
neither	O
alterations	O
in	O
prejunctional	O
beta-adrenoceptor	O
influences	O
nor	O
alterations	O
in	O
neuronal	O
and	O
extraneuronal	O
uptake	O
mechanisms	O
appear	O
to	O
be	O
responsible	O
for	O
this	O
alteration	O
.	O

Furthermore	O
,	O
data	O
obtained	O
with	O
phentolamine	B-Chemical
alone	O
do	O
not	O
suggest	O
alpha-adrenoceptor	O
desensitization	O
as	O
the	O
cause	O
of	O
the	O
enhanced	O
neurotransmitter	O
overflow	O
after	O
epinephrine	B-Chemical
treatment	O
.	O

Ocular	O
manifestations	O
of	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
.	O

We	O
followed	O
210	O
cases	O
of	O
juvenile	B-Disease
rheumatoid	I-Disease
arthritis	I-Disease
closely	O
for	O
eleven	O
years	O
.	O

Thirty-six	O
of	O
the	O
210	O
patients	O
(	O
17.2	O
%	O
)	O
developed	O
iridocyclitis	B-Disease
.	O

Iridocyclitis	B-Disease
was	O
seen	O
most	O
frequently	O
in	O
young	O
female	O
patients	O
(	O
0	O
to	O
4	O
years	O
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	O
of	O
the	O
arthritis	B-Disease
.	O

However	O
,	O
30	O
%	O
of	O
the	O
patients	O
developed	O
uveitis	B-Disease
after	O
16	O
years	O
of	O
age	O
.	O

Although	O
61	O
%	O
of	O
patients	O
had	O
a	O
noncontributory	O
ocular	O
history	O
on	O
entry	O
,	O
42	O
%	O
had	O
active	O
uveitis	B-Disease
on	O
entry	O
.	O

Our	O
approach	O
was	O
effective	O
in	O
detecting	O
uveitis	B-Disease
in	O
new	O
cases	O
and	O
exacerbations	O
of	O
uveitis	B-Disease
in	O
established	O
cases	O
.	O

Forty-four	O
percent	O
of	O
patients	O
with	O
uveitis	B-Disease
had	O
one	O
or	O
more	O
identifiable	O
signs	O
or	O
symptoms	O
,	O
such	O
as	O
red	O
eye	O
,	O
ocular	B-Disease
pain	I-Disease
,	O
decreased	B-Disease
visual	I-Disease
acuity	I-Disease
,	O
or	O
photophobia	B-Disease
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O

Even	O
after	O
early	O
detection	O
and	O
prompt	O
treatment	O
,	O
41	O
%	O
of	O
cases	O
of	O
uveitis	B-Disease
did	O
not	O
respond	O
to	O
more	O
than	O
six	O
months	O
of	O
intensive	O
topical	O
treatment	O
with	O
corticosteroids	B-Chemical
and	O
mydriatics	O
.	O

Despite	O
this	O
,	O
there	O
was	O
a	O
dramatic	O
decrease	O
in	O
the	O
50	O
%	O
incidence	O
of	O
blinding	O
complications	O
of	O
uveitis	B-Disease
cited	O
in	O
earlier	O
studies	O
.	O

Cataract	B-Disease
and	O
band	B-Disease
keratopathy	I-Disease
occurred	O
in	O
only	O
22	O
and	O
13	O
%	O
of	O
our	O
group	O
,	O
respectively	O
.	O

We	O
used	O
chloroquine	B-Chemical
or	O
hydroxychloroquine	B-Chemical
in	O
173	O
of	O
210	O
cases	O
and	O
found	O
only	O
one	O
case	O
of	O
chorioretinopathy	B-Disease
attributable	O
to	O
these	O
drugs	B-Drug
.	O

Systemically	O
administered	O
corticosteroids	B-Chemical
were	O
used	O
in	O
75	O
of	O
210	O
cases	O
;	O
a	O
significant	O
number	O
of	O
posterior	O
subcapsular	O
cataracts	B-Disease
was	O
found	O
.	O

Typical	O
keratoconjunctivitis	B-Disease
sicca	O
developed	O
in	O
three	O
of	O
the	O
uveitis	B-Disease
cases	O
.	O

This	O
association	O
with	O
uveitis	B-Disease
and	O
JRA	O
was	O
not	O
noted	O
previously	O
.	O

Surgical	O
treatment	O
of	O
cataracts	B-Disease
,	O
band	B-Disease
keratopathy	I-Disease
,	O
and	O
glaucoma	B-Disease
achieved	O
uniformly	O
discouraging	O
results	O
.	O

Water	B-Disease
intoxication	I-Disease
associated	O
with	O
oxytocin	B-Chemical
administration	O
during	O
saline-induced	O
abortion	B-Disease
.	O

Four	O
cases	O
of	O
water	B-Disease
intoxication	I-Disease
in	O
connection	O
with	O
oxytocin	B-Chemical
administration	O
during	O
saline-induced	O
abortions	B-Disease
are	O
described	O
.	O

The	O
mechanism	O
of	O
water	B-Disease
intoxication	I-Disease
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	O
.	O

Oxytocin	B-Chemical
administration	O
during	O
midtrimester-induced	O
abortions	B-Disease
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	O
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	O
of	O
water	B-Disease
intoxication	I-Disease
and	O
instructed	O
to	O
watch	O
the	O
diuresis	O
and	O
report	O
such	O
early	O
signs	O
of	O
the	O
syndrome	O
as	O
asthenia	B-Disease
,	O
muscular	O
irritability	B-Disease
,	O
or	O
headaches	B-Disease
.	O

The	O
oxytocin	B-Chemical
should	O
be	O
given	O
only	O
in	O
Ringers	O
lactate	B-Chemical
or	O
,	O
alternately	O
,	O
in	O
Ringers	O
lactate	B-Chemical
and	O
a	O
5	O
per	O
cent	O
dextrose	B-Chemical
and	O
water	O
solutions	O
.	O

The	O
urinary	O
output	O
should	O
be	O
monitored	O
and	O
the	O
oxytocin	B-Chemical
administration	O
discontinued	O
and	O
the	O
serum	O
electrolytes	O
checked	O
if	O
the	O
urinary	O
output	O
decreases	O
.	O

The	O
oxytocin	B-Chemical
should	O
not	O
be	O
administered	O
in	O
excess	O
of	O
36	O
hours	O
.	O

If	O
the	O
patient	O
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	B-Chemical
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	O
in	O
order	O
to	O
perform	O
electrolyte	O
determinations	O
and	O
correct	O
any	O
electrolyte	O
imbalance	O
.	O

